PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Evan, T; Wang, VMY; Behrens, A				Evan, Theodore; Wang, Victoria Min-Yi; Behrens, Axel			The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; EMT-ACTIVATOR ZEB1; TUMOR-CELLS; METABOLISM; PLASTICITY; SUBTYPES; METASTASIS; MARKER; GROWTH	Intratumour heterogeneity (ITH) has become an important focus of cancer research in recent years. ITH describes the cellular variation that enables tumour evolution, including tumour progression, metastasis and resistance to treatment. The selection and expansion of genetically distinct treatment-resistant cancer cell clones provides one explanation for treatment failure. However, tumour cell variation need not be genetically encoded. In pancreatic ductal adenocarcinoma (PDAC) in particular, the complex tumour microenvironment as well as crosstalk between tumour and stromal cells result in exceptionally variable tumour cell phenotypes that are also highly adaptable. In this review we discuss four different types of phenotypic heterogeneity within PDAC, from morphological to metabolic heterogeneity. We suggest that these different types of ITH are not independent, but, rather, can inform one another. Lastly, we highlight recent findings that suggest how therapeutic efforts may halt PDAC progression by constraining cellular heterogeneity.	[Evan, Theodore; Behrens, Axel] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, Canc Stem Cell Lab, London SW3 6JB, England; [Wang, Victoria Min-Yi] CRUK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Behrens, Axel] Imperial Coll London, Dept Surg & Canc, London SW7 2AZ, England; [Behrens, Axel] Imperial Coll London, CRUK Convergence Sci Ctr, London SW7 2AZ, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Beatson Institute; Imperial College London; Imperial College London	Behrens, A (corresponding author), Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, Canc Stem Cell Lab, London SW3 6JB, England.; Wang, VMY (corresponding author), CRUK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland.; Behrens, A (corresponding author), Imperial Coll London, Dept Surg & Canc, London SW7 2AZ, England.; Behrens, A (corresponding author), Imperial Coll London, CRUK Convergence Sci Ctr, London SW7 2AZ, England.	vmy.wang@mail.utoronto.ca; axel.behrens@icr.ac.uk		Wang, Victoria/0000-0002-2657-6118	Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research [CTR-Q5-Y2]; CRUK Accelerator Award [C422/A23614]; Sir Henry Wellcome Postdoctoral Fellowship [221607/Z/20/Z]	Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research; CRUK Accelerator Award; Sir Henry Wellcome Postdoctoral Fellowship	We would like to thank Dr. Catherine Cremona for her editing of this review. This work was supported by the Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research (CTR-Q5-Y2). TE was supported by a doctoral clinical fellowship from a CRUK Accelerator Award (C422/A23614). VW was supported by a Sir Henry Wellcome Postdoctoral Fellowship (221607/Z/20/Z).	Abrego J, 2017, CANCER LETT, V400, P37, DOI 10.1016/j.canlet.2017.04.029; Aiello NM, 2019, J EXP MED, V216, P1016, DOI 10.1084/jem.20181827; Aiello NM, 2018, DEV CELL, V45, P681, DOI 10.1016/j.devcel.2018.05.027; Aiello NM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12819; Andricovich J, 2018, CANCER CELL, V33, P512, DOI 10.1016/j.ccell.2018.02.003; Baek G, 2014, CELL REP, V9, P2233, DOI 10.1016/j.celrep.2014.11.025; Bailey JM, 2014, GASTROENTEROLOGY, V146, P245, DOI 10.1053/j.gastro.2013.09.050; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Ball CR, 2017, EMBO MOL MED, V9, P918, DOI 10.15252/emmm.201607354; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Biancur DE, 2018, BBA-REV CANCER, V1870, P67, DOI 10.1016/j.bbcan.2018.04.011; Biancur DE, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15965; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bott AJ, 2019, CELL REP, V29, P1287, DOI 10.1016/j.celrep.2019.09.056; Boudreau A, 2016, NAT CHEM BIOL, V12, P779, DOI 10.1038/nchembio.2143; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; Brunton H, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107625; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Carstens JL, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108990; Chan-Seng-Yue M, 2020, NAT GENET, V52, P231, DOI 10.1038/s41588-019-0566-9; Chang Q, 2011, CANCER RES, V71, P3110, DOI 10.1158/0008-5472.CAN-10-4049; Chiou SH, 2017, CANCER DISCOV, V7, P1184, DOI 10.1158/2159-8290.CD-17-0250; Collisson EA, 2019, NAT REV GASTRO HEPAT, V16, P207, DOI 10.1038/s41575-019-0109-y; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Daemen A, 2015, P NATL ACAD SCI USA, V112, pE4410, DOI 10.1073/pnas.1501605112; Dawson MA, 2017, SCIENCE, V355, P1147, DOI 10.1126/science.aam7304; Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713; Dosch JS, 2015, CANCER RES, V75, P4582, DOI 10.1158/0008-5472.CAN-14-2793; Dovmark TH, 2017, ONCOGENE, V36, P4538, DOI 10.1038/onc.2017.71; Encarnacion-Rosado J, 2021, NAT REV GASTRO HEPAT, V18, P482, DOI 10.1038/s41575-021-00431-7; Fox RG, 2016, NATURE, V534, P407, DOI 10.1038/nature17988; Galvan JA, 2015, BRIT J CANCER, V112, P1944, DOI 10.1038/bjc.2015.177; Genovese G, 2017, NATURE, V542, P362, DOI 10.1038/nature21064; Gorunova L, 1998, GENE CHROMOSOME CANC, V23, P81, DOI 10.1002/(SICI)1098-2264(199810)23:2<81::AID-GCC1>3.0.CO;2-0; Grabocka E, 2016, CELL, V167, P1803, DOI 10.1016/j.cell.2016.11.035; Guillaumond F, 2013, P NATL ACAD SCI USA, V110, P3919, DOI 10.1073/pnas.1219555110; Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayashi A, 2020, NAT CANCER, V1, P59, DOI 10.1038/s43018-019-0010-1; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hermann PC, 2018, SEMIN CANCER BIOL, V53, P223, DOI 10.1016/j.semcancer.2018.08.007; Hosein AN, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129212; Huang JJ, 2021, GASTROENTEROLOGY, V160, P744, DOI 10.1053/j.gastro.2020.10.007; Juiz NA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00246; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Karasinska JM, 2020, CLIN CANCER RES, V26, P135, DOI 10.1158/1078-0432.CCR-19-1543; Kim MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020636; Komar G, 2009, CLIN CANCER RES, V15, P5511, DOI 10.1158/1078-0432.CCR-09-0414; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kumar S, 2019, CELL METAB, V30, P201, DOI 10.1016/j.cmet.2019.04.003; LaMonte G, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-23; Lan LX, 2022, NATURE, V607, P163, DOI 10.1038/s41586-022-04888-7; Laplane L, 2016, CANC STEM CELLS PHIL; Laplane L, 2019, ELIFE, V8, DOI 10.7554/eLife.46563; Lee SW, 2019, DEV CELL, V50, P381, DOI 10.1016/j.devcel.2019.05.043; Lehmann W, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10498; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Liang C, 2020, GUT, V69, P888, DOI 10.1136/gutjnl-2018-317163; Ligorio M, 2019, CELL, V178, P160, DOI 10.1016/j.cell.2019.05.012; Lomberk G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04383-6; Lytle NK, 2019, CELL, V177, P572, DOI 10.1016/j.cell.2019.03.010; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Martinelli P, 2017, GUT, V66, P1665, DOI 10.1136/gutjnl-2015-311256; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Maruno T, 2021, ELIFE, V10, DOI 10.7554/eLife.55117; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Miranda-Lorenzo I, 2014, NAT METHODS, V11, P1161, DOI [10.1038/NMETH.3112, 10.1038/nmeth.3112]; Miyabayashi K, 2020, CANCER DISCOV, V10, P1566, DOI 10.1158/2159-8290.CD-20-0133; Moffitt RA, 2015, NAT GENET, V47, P1168, DOI 10.1038/ng.3398; Mueller S, 2018, NATURE, V554, P62, DOI 10.1038/nature25459; Neesse A, 2019, GUT, V68, P159, DOI 10.1136/gutjnl-2018-316451; Neoptolemos JP, 2018, NAT REV GASTRO HEPAT, V15, P332, DOI 10.1038/s41575-018-0005-x; Nicolle R, 2017, CELL REP, V21, P2458, DOI 10.1016/j.celrep.2017.11.003; Nollmann FI, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8080281; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Ozturk H, 2022, DEV CELL, V57, P1331, DOI 10.1016/j.devcel.2022.04.014; Parker SJ, 2020, CANCER DISCOV, V10, P1018, DOI 10.1158/2159-8290.CD-19-0959; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Patnaik S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00588; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Pourshams A, 2019, LANCET GASTROENTEROL, V4, P934, DOI 10.1016/S2468-1253(19)30347-4; Quinton RJ, 2021, NATURE, V590, P492, DOI 10.1038/s41586-020-03133-3; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Reichert M, 2018, DEV CELL, V45, P696, DOI 10.1016/j.devcel.2018.05.025; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Rice AJ, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.54; Roe JS, 2017, CELL, V170, P875, DOI 10.1016/j.cell.2017.07.007; Roerink SF, 2018, NATURE, V556, P457, DOI 10.1038/s41586-018-0024-3; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Seino T, 2018, CELL STEM CELL, V22, P454, DOI 10.1016/j.stem.2017.12.009; Seth S, 2019, CELL REP, V26, P1518, DOI 10.1016/j.celrep.2019.01.048; Sharick JT, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00553; Shi JJ, 2019, CANCER LETT, V453, P158, DOI 10.1016/j.canlet.2019.03.051; Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Simeonov KP, 2021, CANCER CELL, V39, P1150, DOI 10.1016/j.ccell.2021.05.005; Singh SK, 2003, CANCER RES, V63, P5821; Skrypek N, 2017, TRENDS GENET, V33, P943, DOI 10.1016/j.tig.2017.08.004; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y; Still ER, 2017, BRIT J CANCER, V116, P1375, DOI 10.1038/bjc.2017.113; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Tiriac H, 2018, CANCER DISCOV, V8, P1112, DOI 10.1158/2159-8290.CD-18-0349; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Viale A, 2015, CANCER RES, V75, P3687, DOI 10.1158/0008-5472.CAN-15-0491; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Walsh AJ, 2016, PANCREAS, V45, P863, DOI 10.1097/MPA.0000000000000543; Walsh AJ, 2014, CANCER RES, V74, P5184, DOI 10.1158/0008-5472.CAN-14-0663; Wang VMY, 2019, NAT CELL BIOL, V21, P1425, DOI 10.1038/s41556-019-0407-1; Wang WJ, 2019, GUT, V68, P1245, DOI 10.1136/gutjnl-2017-315541; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Waters AM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031435; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yang LF, 2017, ANNU REV BIOMED ENG, V19, P163, DOI 10.1146/annurev-bioeng-071516-044546; Yang MC, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0449-3; Ye JW, 2019, J PHARM ANAL, V9, P217, DOI 10.1016/j.jpha.2019.05.004; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yoo HC, 2020, CELL METAB, V31, P267, DOI 10.1016/j.cmet.2019.11.020; Zhao XH, 2019, WORLD J GASTROENTERO, V25, P138, DOI 10.3748/wjg.v25.i1.138; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	132	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4686	4695		10.1038/s41388-022-02448-x	http://dx.doi.org/10.1038/s41388-022-02448-x		SEP 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36088504	Green Published, hybrid			2022-12-28	WOS:000852353400001
J	Pan, D; Yang, WW; Zeng, Y; Qin, HK; Xu, YT; Gui, YP; Fan, XS; Tian, G; Wu, YJ; Sun, HP; Ye, YT; Yang, SH; Zhou, JY; Guo, QL; Zhao, L				Pan, Di; Yang, Wanwan; Zeng, Yao; Qin, Hongkun; Xu, Yuting; Gui, Yanping; Fan, Xiangshan; Tian, Geng; Wu, Yujia; Sun, Haopeng; Ye, Yuting; Yang, Shihe; Zhou, Jieying; Guo, Qinglong; Zhao, Li			AKR1C3 regulated by NRF2/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma	ONCOGENE			English	Article							KETO REDUCTASE 1C3	Aldo-keto reductase family 1 member C3 (AKR1C3) serves as a contributor to numerous kinds of tumors, and its expression is elevated in patients with hepatocellular carcinoma (HCC). However, the biological function of AKR1C3 in HCC remains unclear. Here we investigated the role of AKR1C3 in liver carcinogenesis using in vitro and in vivo models. We determined that AKR1C3 is frequently increased in HCC tissues with poor prognosis. Genetically manipulated cells with AKR1C3 construction were examined to highlight the pro-tumoral growth of both wild-type AKR1C3 and mutant in vitro and in vivo. We observed promising treatment effects of AKR1C3 shRNA by intratumoral injection in mice. Mechanically, we demonstrated that the transcription factor heterodimer NRF2/MAFG was able to bind directly to AKR1C3 promoter to activate its transcription. Further, AKR1C3 stabilized PARP1 by decreasing its ubiquitination, which resulted in HCC cell proliferation and low sensitivity of Cisplatin. Moreover, we discovered that the tumorigenic role of AKR1C3 was non-catalytic dependent and the NRF2/MAFG-AKR1C3-PARP1 axis might be one of the important proliferation pathways in HCC. In conclusion, blockage of AKR1C3 expression provides potential therapeutic benefits against HCC.	[Pan, Di; Yang, Wanwan; Zeng, Yao; Qin, Hongkun; Xu, Yuting; Gui, Yanping; Tian, Geng; Wu, Yujia; Ye, Yuting; Yang, Shihe; Guo, Qinglong; Zhao, Li] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Dept Physiol, Nanjing 211198, Jiangsu, Peoples R China; [Pan, Di] Guizhou Med Univ, Sch Pharmaceut Sci, Key Lab Optimal Utilizat Nat Med Resources, Guiyang 550025, Guizhou, Peoples R China; [Fan, Xiangshan] Nanjing Univ, Sch Med, Dept Pathol, Nanjing Drum Tower Hosp, Nanjing 210000, Jiangsu, Peoples R China; [Sun, Haopeng] China Pharmaceut Univ, Dept Pharm, Nanjing 211198, Jiangsu, Peoples R China; [Zhou, Jieying] Florida Int Univ, Dept Chem & Biochem, Miami, FL 33199 USA; [Guo, Qinglong] China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Jiangsu, Peoples R China	China Pharmaceutical University; Guizhou Medical University; Nanjing University; China Pharmaceutical University; State University System of Florida; Florida International University; China Pharmaceutical University	Guo, QL; Zhao, L (corresponding author), China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Dept Physiol, Nanjing 211198, Jiangsu, Peoples R China.; Guo, QL (corresponding author), China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Jiangsu, Peoples R China.	anticancer_drug@163.com; zhaoli@cpu.edu.cn	yang, wanwan/GZM-4650-2022	Tian, Geng/0000-0001-6320-6346; fan, xiangshan/0000-0003-4552-5858; wu, wu yu jia/0000-0001-9542-273X	Key Program of the National Science Foundation of China [81830105]; National Science Foundation of China [81773774]	Key Program of the National Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Key Program of the National Science Foundation of China (81830105); the program of the National Science Foundation of China (81773774).	Bortolozzi R, 2018, BRIT J CANCER, V118, P985, DOI 10.1038/s41416-018-0014-0; Cao CG, 2020, J MED CHEM, V63, P11012, DOI 10.1021/acs.jmedchem.0c00821; Chaudhuri AR, 2017, NAT REV MOL CELL BIO, V18, P610, DOI 10.1038/nrm.2017.53; Curtin NJ, 2020, NAT REV DRUG DISCOV, V19, P711, DOI 10.1038/s41573-020-0076-6; Dong QZ, 2019, CANCER RES, V79, P819, DOI 10.1158/0008-5472.CAN-18-1273; Feng M, 2020, INNOVATION-AMSTERDAM, V1, DOI 10.1016/j.xinn.2020.100032; Gatti M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107985; Hirotsu Y, 2012, NUCLEIC ACIDS RES, V40, P10228, DOI 10.1093/nar/gks827; Hu ZH, 2021, ONCOGENE, V40, P647, DOI 10.1038/s41388-020-01551-1; Jackson VJ, 2012, ACTA CRYSTALLOGR F, V68, P409, DOI 10.1107/S1744309112009049; Katsuoka F, 2016, GENE, V586, P197, DOI 10.1016/j.gene.2016.03.058; Kim SY, 2021, ONCOGENE, V40, P4652, DOI 10.1038/s41388-021-01875-6; Ko HL, 2011, HEPATOLOGY, V54, P1190, DOI 10.1002/hep.24502; Rizner TL, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2019.104446; Liu Y, 2020, J MED CHEM, V63, P11305, DOI 10.1021/acs.jmedchem.9b02138; Llovet JM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00240-3; Mantel A, 2012, J INVEST DERMATOL, V132, P1103, DOI 10.1038/jid.2011.412; Matsunaga T, 2020, CHEM-BIOL INTERACT, V332, DOI 10.1016/j.cbi.2020.109295; Noordermeer SM, 2019, TRENDS CELL BIOL, V29, P820, DOI 10.1016/j.tcb.2019.07.008; Penning TM, 2019, ENDOCR REV, V40, P447, DOI 10.1210/er.2018-00089; Penning TM, 2019, MOL CELL ENDOCRINOL, V489, P82, DOI 10.1016/j.mce.2018.07.002; Penning TM, 2017, EXPERT OPIN THER PAT, V27, P1329, DOI 10.1080/13543776.2017.1379503; Penning TM, 2015, CHEM-BIOL INTERACT, V234, P236, DOI 10.1016/j.cbi.2014.09.024; Powell K, 2015, CLIN CANCER RES, V21, P2569, DOI 10.1158/1078-0432.CCR-14-2352; Rheinbay E, 2020, NATURE, V578, P102, DOI 10.1038/s41586-020-1965-x; Ricciotti E, 2021, CANCER RES, V81, P3751, DOI 10.1158/0008-5472.CAN-21-0758; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Vallim TQD, 2015, CELL METAB, V21, P298, DOI 10.1016/j.cmet.2015.01.007; Velica P, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-121; Vera-Puente O, 2018, TRANSL RES, V200, P1, DOI 10.1016/j.trsl.2018.06.005; Wu T, 2014, FREE RADICAL BIO MED, V67, P69, DOI 10.1016/j.freeradbiomed.2013.10.806; Xie L, 2013, CANCER GENE THER, V20, P260, DOI 10.1038/cgt.2013.15; Zeng CM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00119; Zhang L, 2019, NUCLEIC ACIDS RES, V47, P8502, DOI 10.1093/nar/gkz545; Zhao QY, 2019, CHEM COMMUN, V55, P369, DOI 10.1039/c8cc07813k; Zhao SF, 2019, ONCOL LETT, V18, P4515, DOI 10.3892/ol.2019.10802; Zhou QQ, 2021, CANCER RES, V81, P1361, DOI 10.1158/0008-5472.CAN-20-2480	37	1	1	9	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3846	3858		10.1038/s41388-022-02379-7	http://dx.doi.org/10.1038/s41388-022-02379-7		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35773412				2022-12-28	WOS:000819316500001
J	Kumarasamy, V; Nambiar, R; Wang, JX; Rosenheck, H; Witkiewicz, AK; Knudsen, ES				Kumarasamy, Vishnu; Nambiar, Ram; Wang, Jianxin; Rosenheck, Hanna; Witkiewicz, Agnieszka K.; Knudsen, Erik S.			RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models	ONCOGENE			English	Article							ESTROGEN-RECEPTOR; RETINOBLASTOMA PROTEIN; POSTMENOPAUSAL WOMEN; CDK4/6 INHIBITION; MECHANISMS; PATHWAYS; CELLS; PI3K	The management of metastatic estrogen receptor (ER) positive HER2 negative breast cancer (ER+) has improved; however, therapeutic resistance and disease progression emerges in majority of cases. Using unbiased approaches, as expected PI3K and MTOR inhibitors emerge as potent inhibitors to delay proliferation of ER+ models harboring PIK3CA mutations. However, the cytostatic efficacy of these drugs is hindered due to marginal impact on the expression of cyclin D1. Different combination approaches involving the inhibition of ER pathway or cell cycle result in durable growth arrest via RB activation and subsequent inhibition of CDK2 activity. However, cell cycle alterations due to RB loss or ectopic CDK4/cyclin D1 activation yields resistance to these cytostatic combination treatments. To define means to counter resistance to targeted therapies imparted with RB loss; complementary drug screens were performed with RB-deleted isogenic cell lines. In this setting, RB loss renders ER+ breast cancer models more vulnerable to drugs that target DNA replication and mitosis. Pairwise combinations using these classes of drugs defines greater selectivity for RB deficiency. The combination of AURK and WEE1 inhibitors, yields synergistic cell death selectively in RB-deleted ER+ breast cancer cells via apoptosis and yields profound disease control in vivo. Through unbiased efforts the XIAP/CIAP inhibitor birinapant was identified as a novel RB-selective agent. Birinapant further enhances the cytotoxic effect of chemotherapies and targeted therapies used in the treatment of ER+ breast cancer models selectively in the RB-deficient setting. Using organoid culture and xenograft models, we demonstrate the highly selective use of birinapant based combinations for the treatment of RB-deficient tumors. Together, these data illustrate the critical role of RB-pathway in response to many agents used to treat ER+ breast cancer, whilst informing new therapeutic approaches that could be deployed against resistant disease.	[Kumarasamy, Vishnu; Nambiar, Ram; Wang, Jianxin; Rosenheck, Hanna; Witkiewicz, Agnieszka K.; Knudsen, Erik S.] Roswell Park Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Knudsen, ES (corresponding author), Roswell Park Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.	Erik.Knudsen@roswellpark.org			National Cancer Institute (NCI)	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank all members of the laboratory group and colleagues in the discussion and preparation of the manuscript. We thank Emily Schultz for acquiring the patient information and the genetic characteristics of the tumor tissues. Dr. Steven Pruitt provided the lentiviral vector for CDK2 sensor. Drug screening was performed through Small Molecule Screening facility at RoswellPark Cancer Center. We would like to thank Dr. Sandra Sexton, Facility director of Laboratory Animal Resources at Roswell Park for assisting us with xenografts. The research was supported by a grant to AKW and ESK from National Cancer Institute (NCI).	Ahmad A, 2019, ADV EXP MED BIOL, V1152, P1, DOI 10.1007/978-3-030-20301-6_1; Andre F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904; Arnedos M, 2018, ANN ONCOL, V29, P1755, DOI 10.1093/annonc/mdy202; Asghar US, 2022, JCO PRECIS ONCOL, V6, DOI 10.1200/PO.21.00002; Bertucci F, 2019, NATURE, V569, P560, DOI 10.1038/s41586-019-1056-z; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; Condon SM, 2014, J MED CHEM, V57, P3666, DOI 10.1021/jm500176w; Condorelli R, 2018, ANN ONCOL, V29, P640, DOI 10.1093/annonc/mdx784; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dean JL, 2012, J BIOL CHEM, V287, P29075, DOI 10.1074/jbc.M112.365494; Desmedt C, 2006, CELL CYCLE, V5, P2198, DOI 10.4161/cc.5.19.3254; Dickler MN, 2017, CLIN CANCER RES, V23, P5218, DOI 10.1158/1078-0432.CCR-17-0754; Dickson MA, 2014, CLIN CANCER RES, V20, P3379, DOI 10.1158/1078-0432.CCR-13-1551; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Dowsett M, 2013, J CLIN ONCOL, V31, P2783, DOI 10.1200/JCO.2012.46.1558; Elkabets M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005747; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Franco J, 2016, CELL REP, V14, P979, DOI 10.1016/j.celrep.2015.12.094; Gong XQ, 2019, CANCER DISCOV, V9, P248, DOI 10.1158/2159-8290.CD-18-0469; Guarducci C, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523-018-0092-4; Howell A, 2008, BEST PRACT RES CL EN, V22, P615, DOI 10.1016/j.beem.2008.09.002; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; Knudsen Erik S, 2020, Am Soc Clin Oncol Educ Book, V40, P115, DOI 10.1200/EDBK_281085; Knudsen ES, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0873-9; Knudsen ES, 2019, TRENDS CANCER, V5, P308, DOI 10.1016/j.trecan.2019.03.005; Knudsen ES, 2019, ONCOGENE, V38, P3355, DOI 10.1038/s41388-018-0650-0; Knudsen ES, 2018, GUT, V67, P508, DOI 10.1136/gutjnl-2016-313133; Kumarasamy V, 2021, CANCER RES, V81, P1347, DOI 10.1158/0008-5472.CAN-20-2275; Kumarasamy V, 2020, ONCOGENE, V39, P1831, DOI 10.1038/s41388-019-1102-1; Lalaoui N, 2020, CELL DEATH DIFFER, V27, P2768, DOI 10.1038/s41418-020-0541-0; Lee JW, 2019, CLIN CANCER RES, V25, P3430, DOI 10.1158/1078-0432.CCR-18-0440; Li ZQ, 2018, CANCER CELL, V34, P893, DOI 10.1016/j.ccell.2018.11.006; Manna Subrata, 2016, Sign Transduct Insights, V5, P1; McKeage K, 2004, DRUGS, V64, P633, DOI 10.2165/00003495-200464060-00009; Michaloglou C, 2018, MOL CANCER THER, V17, P908, DOI 10.1158/1535-7163.MCT-17-0537; Mills JN, 2018, CURR OPIN PHARMACOL, V41, P59, DOI 10.1016/j.coph.2018.04.009; Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; O'Leary B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03215-x; Oser MG, 2019, CANCER DISCOV, V9, P230, DOI 10.1158/2159-8290.CD-18-0389; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Presti D, 2019, CANCERS, V11, DOI 10.3390/cancers11091242; Provenzano A, 2013, EXPERT REV ANTICANC, V13, P143, DOI [10.1586/ERA.12.173, 10.1586/era.12.173]; Pu MY, 2020, BREAST CANCER RES TR, V179, P197, DOI 10.1007/s10549-019-05446-y; Rawlinson R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-483; Rubin SM, 2013, TRENDS BIOCHEM SCI, V38, P12, DOI 10.1016/j.tibs.2012.10.007; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Thu KL, 2018, CELL CYCLE, V17, P1871, DOI 10.1080/15384101.2018.1502567; Turner NC, 2018, NEW ENGL J MED, V379, P1926, DOI 10.1056/NEJMoa1810527; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Wander SA, 2020, CANCER DISCOV, V10, P1174, DOI 10.1158/2159-8290.CD-19-1390; Webster JD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00365; Weigelt B, 2011, ONCOGENE, V30, P3222, DOI 10.1038/onc.2011.42; Witkiewicz AK, 2018, CELL REP, V22, P1185, DOI 10.1016/j.celrep.2018.01.022; Yardley DA, 2013, ADV THER, V30, P870, DOI 10.1007/s12325-013-0060-1; Yue G, 2017, SCI REP-UK, V7, DOI 10.1038/srep45411; Zanudo JGT, 2021, CANCER RES, V81, P4603, DOI 10.1158/0008-5472.CAN-21-1208	60	1	1	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3524	3538		10.1038/s41388-022-02362-2	http://dx.doi.org/10.1038/s41388-022-02362-2		JUN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35676324				2022-12-28	WOS:000807963600001
J	Pan, X; Li, X; Sun, J; Xiong, ZY; Hu, HY; Ning, SW; Zhi, H				Pan, Xu; Li, Xin; Sun, Jie; Xiong, Zhiying; Hu, Haoyu; Ning, Shangwei; Zhi, Hui			Enhancer methylation dynamics drive core transcriptional regulatory circuitry in pan-cancer	ONCOGENE			English	Article							DNA METHYLATION; GENE-EXPRESSION; LANDSCAPES; REVEALS	Accumulating evidence has demonstrated that enhancer methylation has strong and dynamic regulatory effects on gene expression. Some transcription factors (TFs) can auto- and cross-regulate in a feed-forward manner, and cooperate with their enhancers to form core transcriptional regulatory circuitries (CRCs). However, the elaborated regulatory mechanism between enhancer methylation and CRC remains the tip of the iceberg. Here, we revealed that DNA methylation could drive the tissue-specific enhancer basal transcription and target gene expression in human cancers. By integrating methylome, transcriptome, and 3D genomic data, we identified enhancer methylation triplets (enhancer methylation-enhancer transcription-target gene expression) and dissected potential regulatory patterns within them. Moreover, we observed that cancer-specific core TFs regulated by enhancers were able to shape their enhancer methylation forming the enhancer methylation-driven CRCs (emCRCs). Further parsing of clinical implications showed rewired emCRCs could serve as druggable targets and prognostic risk markers. In summary, the integrative analysis of enhancer methylation regulome would facilitate portraying the cancer epigenomics landscape and developing the epigenetic anti-cancer approaches.	[Pan, Xu; Li, Xin; Sun, Jie; Xiong, Zhiying; Hu, Haoyu; Ning, Shangwei; Zhi, Hui] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China; [Li, Xin] Cent South Univ, Xiangya Hosp, Hunan Engn Res Ctr Skin Hlth & Dis, Hunan Key Lab Skin Canc & Psoriasis,Dept Dermatol, Changsha 410008, Hunan, Peoples R China	Harbin Medical University; Central South University	Ning, SW; Zhi, H (corresponding author), Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China.	ningsw@ems.hrbmu.edu.cn; zhihui@ems.hrbmu.edu.cn		Zhi, Hui/0000-0001-9103-8642	Natural Science Foundation of Heilongjiang Province, China [LH2020C05]; National Natural Science Foundation of China [32170674, 32070672]	Natural Science Foundation of Heilongjiang Province, China(Natural Science Foundation of Heilongjiang Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Natural Science Foundation of Heilongjiang Province, China [LH2020C05]; the National Natural Science Foundation of China [32170674 and 32070672].	Aguilo F, 2016, CELL REP, V14, P479, DOI 10.1016/j.celrep.2015.12.043; Baek SJ, 2016, ONCOTARGET, V7, P25620, DOI 10.18632/oncotarget.8239; Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335; Barnett KR, 2020, MOL CELL, V77, P1350, DOI 10.1016/j.molcel.2020.01.004; Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; Bell RE, 2016, GENOME RES, V26, P601, DOI 10.1101/gr.197194.115; Benner C, 2015, P NATL ACAD SCI USA, V112, P12776, DOI 10.1073/pnas.1512995112; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chakravarty D, 2017, JCO PRECIS ONCOL, V1; Chen H, 2018, CELL, V173, P386, DOI 10.1016/j.cell.2018.03.027; Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143; Davis CA, 2018, NUCLEIC ACIDS RES, V46, pD794, DOI 10.1093/nar/gkx1081; Decaesteker B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06699-9; Domcke S, 2015, NATURE, V528, P575, DOI 10.1038/nature16462; Feldmann A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003994; Gutierrez-Arcelus M, 2013, ELIFE, V2, DOI 10.7554/eLife.00523; Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hatzi K, 2013, CELL REP, V4, P578, DOI 10.1016/j.celrep.2013.06.016; Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018; Hegde AN, 2019, LEARN MEMORY, V26, P307, DOI 10.1101/lm.048769.118; Home P, 2012, P NATL ACAD SCI USA, V109, P7362, DOI 10.1073/pnas.1201595109; Kent LN, 2016, J CLIN INVEST, V126, P2955, DOI 10.1172/JCI85506; Kim S, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2016.140; Li J, 2015, CANCER RES, V75, P3728, DOI 10.1158/0008-5472.CAN-15-0273; Mei SL, 2017, CANCER RES, V77, pE19, DOI 10.1158/0008-5472.CAN-17-0327; Miao YF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02113-y; Moore JE, 2020, NATURE, V583, P699, DOI 10.1038/s41586-020-2493-4; Niculescu RS, 2006, J MACH LEARN RES, V7, P1357; Paralkar VR, 2016, MOL CELL, V62, P104, DOI 10.1016/j.molcel.2016.02.029; Petell CJ, 2016, NUCLEIC ACIDS RES, V44, P7605, DOI 10.1093/nar/gkw426; Priness I, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-111; Qian MX, 2017, GENOME RES, V27, P185, DOI 10.1101/gr.209163.116; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Saint-Andre V, 2016, GENOME RES, V26, P385, DOI 10.1101/gr.197590.115; Sanda T, 2012, CANCER CELL, V22, P209, DOI 10.1016/j.ccr.2012.06.007; Sato N, 2006, BIOCHEM BIOPH RES CO, V344, P845, DOI 10.1016/j.bbrc.2006.04.007; Schadt EE, 2005, NAT GENET, V37, P710, DOI 10.1038/ng1589; Schuijers J, 2018, CELL REP, V23, P349, DOI 10.1016/j.celrep.2018.03.056; Sladky VC, 2020, DEV CELL, V52, P335, DOI 10.1016/j.devcel.2019.12.016; Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1; Song YL, 2019, MOL CELL, V75, P905, DOI 10.1016/j.molcel.2019.06.045; Steuer R, 2002, BIOINFORMATICS, V18, pS231, DOI 10.1093/bioinformatics/18.suppl_2.S231; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki T, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0169-6; Symmons O, 2014, GENOME RES, V24, P390, DOI 10.1101/gr.163519.113; Tong Y, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1442-0; Tsamardinos I, 2010, LECT NOTES ARTIF INT, V6323, P322, DOI 10.1007/978-3-642-15939-8_21; Vanzan L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23630-x; Chung VY, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0506-3; Wagenmakers EJ, 2004, PSYCHON B REV, V11, P192, DOI 10.3758/BF03206482; Wiench M, 2011, EMBO J, V30, P3028, DOI 10.1038/emboj.2011.210; Xiong L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08245-z; Xu QH, 2016, MODERN PATHOL, V29, P546, DOI 10.1038/modpathol.2016.60; Yao LJ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0668-3; Zhang Y, 2016, NAT GENET, V48, P1003, DOI 10.1038/ng.3635; Zhao Y, 2016, CELL REP, V15, P599, DOI 10.1016/j.celrep.2016.03.038; ZHOU YY, 2019, NAT COMMUN, V10, DOI [10.1038/S41467-019-09234-6, DOI 10.1038/s41587-020-0546-8, DOI 10.1038/S41467-019-09234-6]; Zhu H, 2016, NAT REV GENET, V17, P551, DOI 10.1038/nrg.2016.83	61	1	1	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3474	3484		10.1038/s41388-022-02359-x	http://dx.doi.org/10.1038/s41388-022-02359-x		JUN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35655092				2022-12-28	WOS:000805097900001
J	Sun, FF; Wang, XP; Hu, J; Liu, JM; Wang, X; Jia, WQ; Yu, ZY; Gao, L; Dou, BK; Zhao, R; Feng, TT; Wang, XL; Zhang, WB; Liu, H; Liu, KH; Shao, Y; Dong, XS; Han, B				Sun, Feifei; Wang, Xinpei; Hu, Jing; Liu, Junmei; Wang, Xin; Jia, Wenqiao; Yu, Zeyuan; Gao, Lin; Dou, Baokai; Zhao, Ru; Feng, Tingting; Wang, Xueli; Zhang, Wenbo; Liu, Hui; Liu, Kaihua; Shao, Yang; Dong, Xuesen; Han, Bo			RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway	ONCOGENE			English	Article							ANDROGEN-RECEPTOR; CANCER; PONTIN; COMPLEX; REPTIN; IDENTIFICATION; EXPRESSION; MECHANISM; COFACTOR; ATPASES	Although enzalutamide improves the overall survival of patients with metastatic prostate cancers, enzalutamide resistance (ENZR) will be inevitably developed. Emerging evidence support that alternative oncogenic pathways may bypass the androgen receptor (AR) signaling to promote ENZR progression, however, the underpinning mechanisms remain poorly defined. Here, we report that the expression of RuvB like AAA ATPase 1 (RUVBL1) is upregulated in ENZR cells and xenograft models and prostate tumors in patients. Enzalutamide increases RUVBL1 accumulation in the cytoplasm, which in turn enhances the recruitment of CRAF proto-oncogene serine/threonine kinase protein to plexin A1 (PLXNA1) and the subsequent activation of the downstream MAPK pathway. Co-overexpression of RUVBL1 and PLXNA1 defines a subgroup of prostate cancer (PCa) patients with a poor prognosis. Furthermore, pharmacological inhibition of RUVBL1 by CB-6644 suppresses ENZR cell proliferation and xenograft growth and allows re-sensitization of ENZR cells and xenografts to enzalutamide, indicating that RUVBL1 may act to substitute the AR signaling to promote cancer cell survival and ENZR development. Together, these findings may lead to the identification of RUVBL1 as a potential therapeutic target for ENZR tumors.	[Sun, Feifei; Wang, Xinpei; Wang, Xin; Yu, Zeyuan; Gao, Lin; Zhao, Ru; Feng, Tingting; Zhang, Wenbo; Han, Bo] Shandong Univ, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China; [Sun, Feifei; Wang, Xinpei; Wang, Xin; Yu, Zeyuan; Gao, Lin; Zhao, Ru; Feng, Tingting; Zhang, Wenbo; Han, Bo] Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Hu, Jing; Liu, Hui; Han, Bo] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Peoples R China; [Liu, Junmei] Sch Basic Med Sci, Dept Biochem & Mol Biol, Jinan 250012, Peoples R China; [Jia, Wenqiao] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Hlth Management Ctr, Jinan 250012, Peoples R China; [Dou, Baokai] Shandong First Med Univ, Dept Pharm, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China; [Wang, Xueli] Binzhou City Cent Hosp, Dept Pathol, Binzhou, Peoples R China; [Liu, Kaihua; Shao, Yang] Nanjing Geneseeq Technol Inc, Nanjing, Jiangsu, Peoples R China; [Dong, Xuesen] Vancouver Gen Hosp, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; [Dong, Xuesen] Univ British Columbia, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada	Shandong University; Shandong University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Geneseeq Technology Inc.; University of British Columbia; University of British Columbia	Han, B (corresponding author), Shandong Univ, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China.; Han, B (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Shandong, Peoples R China.; Han, B (corresponding author), Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Peoples R China.; Dong, XS (corresponding author), Vancouver Gen Hosp, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada.; Dong, XS (corresponding author), Univ British Columbia, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada.	xdong@prostatecentre.com; boh@sdu.edu.cn		Wang, Xin/0000-0003-1973-754X; Wang, Xinpei/0000-0002-2304-1580	Joint Research Fund of Natural Science, Shandong Province [ZR2019LZL014]; National Natural Science Foundation of China [81972416, 82172818]; Major Science and Technology Innovation Project of Shandong Province [2018CXGC1210]; National Key Research and Development Program of China [2018YFC0114703]; Fundamental Research Funds of Shandong University [2018JC016]	Joint Research Fund of Natural Science, Shandong Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Science and Technology Innovation Project of Shandong Province; National Key Research and Development Program of China; Fundamental Research Funds of Shandong University	This work was supported by the Joint Research Fund of Natural Science, Shandong Province (ZR2019LZL014), National Natural Science Foundation of China (Grant No. 81972416, 82172818), Major Science and Technology Innovation Project of Shandong Province (2018CXGC1210), the National Key Research and Development Program of China (2018YFC0114703), and The Fundamental Research Funds of Shandong University (2018JC016).	Advani SJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9154; Aramayo RJ, 2018, NAT STRUCT MOL BIOL, V25, P37, DOI 10.1038/s41594-017-0003-7; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Assimon VA, 2019, ACS CHEM BIOL, V14, P236, DOI 10.1021/acschembio.8b00904; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Bizarro J, 2014, J CELL BIOL, V207, P463, DOI 10.1083/jcb.201404160; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chen JA, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0947-9; Clarke TL, 2017, MOL CELL, V65, P900, DOI 10.1016/j.molcel.2017.01.019; Dauden MI, 2021, CURR OPIN STRUC BIOL, V67, P78, DOI 10.1016/j.sbi.2020.08.010; Fan WJ, 2017, BBA-GEN SUBJECTS, V1861, P1788, DOI 10.1016/j.bbagen.2017.03.016; Gao L, 2021, CANCER RES, V81, P1026, DOI 10.1158/0008-5472.CAN-20-1965; Guo H, 2018, BIOCHEM BIOPH RES CO, V498, P932, DOI 10.1016/j.bbrc.2018.03.084; Hu J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1222-z; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huber O, 2008, CANCER RES, V68, P6873, DOI 10.1158/0008-5472.CAN-08-0547; Izumi N, 2012, CANCER SCI, V103, P50, DOI 10.1111/j.1349-7006.2011.02112.x; Lauscher JC, 2007, HUM PATHOL, V38, P978, DOI 10.1016/j.humpath.2007.01.005; Li SZ, 2019, CANCER RES, V79, P2580, DOI 10.1158/0008-5472.CAN-18-2812; Mao YQ, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00058; Mello T, 2020, INT J CANCER, V146, P3410, DOI 10.1002/ijc.32787; Mostaghel EA, 2019, CLIN CANCER RES, V25, P426, DOI 10.1158/1078-0432.CCR-18-1431; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Qi M, 2018, ONCOGENE, V37, P1075, DOI 10.1038/onc.2017.380; Ren SC, 2018, EUR UROL, V73, P322, DOI 10.1016/j.eururo.2017.08.027; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Runge JS, 2018, G3-GENES GENOM GENET, V8, P1095, DOI 10.1534/g3.117.300504; Taniuchi K, 2014, INT J ONCOL, V44, P1945, DOI 10.3892/ijo.2014.2380; Tellman TV, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22063218; Thomas C, 2013, MOL CANCER THER, V12, P2342, DOI 10.1158/1535-7163.MCT-13-0032; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Venteicher AS, 2008, CELL, V132, P945, DOI 10.1016/j.cell.2008.01.019; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; Wang L, 2013, PROSTATE CANCER P D, V16, P301, DOI 10.1038/pcan.2013.25; Wang L, 2017, CANCER RES, V77, P5755, DOI 10.1158/0008-5472.CAN-17-0150; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yenerall P, 2020, CELL CHEM BIOL, V27, P105, DOI 10.1016/j.chembiol.2019.12.005; Yuan XS, 2016, TUMOR BIOL, V37, P16015, DOI 10.1007/s13277-016-5452-9; Zhang A, 2015, CELL REP, V13, P209, DOI 10.1016/j.celrep.2015.08.069; Zhang JX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23025-y; Zhang XX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138820; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111	44	1	1	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3239	3250		10.1038/s41388-022-02332-8	http://dx.doi.org/10.1038/s41388-022-02332-8		MAY 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35508542				2022-12-28	WOS:000790621800002
J	Copello, VA; Burnstein, KL				Copello, Valeria A.; Burnstein, Kerry L.			The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor	ONCOGENE			English	Article							PROTEOMIC ANALYSIS; VARIANT	Prostate cancer that recurs following androgen-deprivation therapy is termed castration-resistant, which is incurable and is marked by reactivation of androgen receptor (AR) signaling. KIF20A, a kinesin with unique structural features, is overexpressed in human castration-resistant prostate cancer (CRPC) compared to androgen-dependent PC and benign tissue. KIF20A has well-described roles in mitotic processes, but it has a less characterized function in vesicle fission and trafficking within Golgi-driven secretory pathways. Stable expression of KIF20A in androgen-dependent PC cells promoted progression to CRPC through the activation of AR signaling in vitro and in vivo. KIF20A expression resulted in the secretion of autocrine factors in the conditioned media that activated AR and caused castration-resistant proliferation of naive androgen-dependent cells. Pharmacologic disruption of vesicle biogenesis blocked KIF20A-driven castration-resistant proliferation of androgen-dependent PC. KIF20A depletion or treatment with the KIF20A-specific inhibitor, paprotrain, reduced CRPC. These data are the first to establish KIF20A as a driver of CRPC progression through AR activation and as a promising therapeutic target against CRPC.	[Copello, Valeria A.] Sheila & David Fuente Grad Program Canc Biol, Miami, FL USA; [Copello, Valeria A.; Burnstein, Kerry L.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; [Copello, Valeria A.; Burnstein, Kerry L.] Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami	Burnstein, KL (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.; Burnstein, KL (corresponding author), Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.	kburnstein@med.miami.edu		Copello, Valeria/0000-0002-7035-4467	National Cancer Institute (NCI) Cancer Center Support Grant (CCSG) [P30-CA240139]; VA Merit Review [1I01BX002773]; Mike Slive Foundation; Sylvester Comprehensive Cancer Center	National Cancer Institute (NCI) Cancer Center Support Grant (CCSG); VA Merit Review(US Department of Veterans Affairs); Mike Slive Foundation; Sylvester Comprehensive Cancer Center	We thank Dr. Deukwoo Kwon (University of Miami) for assistance with statistical analyses, and the Cancer Modeling Shared Resource (Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine), which is supported by the National Cancer Institute (NCI) Cancer Center Support Grant (CCSG) P30-CA240139, for the immunohistochemistry assistance. We thank Drs. M. Julia Martinez and Nahuel Peinetti for helpful comments on the manuscript. This work was supported by VA Merit Review 1I01BX002773 (to KLB), the Mike Slive Foundation (to KLB), and Developmental Funds from the Sylvester Comprehensive Cancer Center (to KLB).	Adriaans IE, 2020, CURR BIOL, V30, P2628, DOI 10.1016/j.cub.2020.04.081; Archer M, 2020, CANCERS, V12, DOI 10.3390/cancers12102984; Aryee MJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005211; Atherton J, 2017, ELIFE, V6, DOI 10.7554/eLife.27793; Auchus RJ, 2020, ANNU REV MED, V71, P33, DOI 10.1146/annurev-med-051418-060357; Catalano M, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1703244; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang KH, 2011, P NATL ACAD SCI USA, V108, P13728, DOI 10.1073/pnas.1107898108; Crowe AR, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3465; Dalela Deepansh, 2016, Rev Urol, V18, P1; Desai K, 2021, ENDOCR REV, V42, P354, DOI 10.1210/endrev/bnab002; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Einstein DJ, 2019, CURR OPIN ONCOL, V31, P175, DOI 10.1097/CCO.0000000000000520; Fernandes RC, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108585; Gaglani S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810131; Galligan JT, 2015, J PROTEOME RES, V14, P953, DOI 10.1021/pr501005v; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Gregory CW, 2001, CANCER RES, V61, P2892; Hizir MS, 2014, ACS APPL MATER INTER, V6, P14772, DOI 10.1021/am504190a; Hu LL, 2021, ONCOGENE, V40, P6479, DOI 10.1038/s41388-021-02026-7; Imai K, 2011, BRIT J CANCER, V104, P300, DOI 10.1038/sj.bjc.6606052; Kaur SP, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88519-7; Labriere C, 2016, BIOORGAN MED CHEM, V24, P721, DOI 10.1016/j.bmc.2015.12.042; Landini G, 2021, BIOINFORMATICS, V37, P1485, DOI 10.1093/bioinformatics/btaa847; Li YW, 2020, EXP CELL RES, V395, DOI 10.1016/j.yexcr.2020.112212; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Ma TF, 2021, CANCER LETT, V504, P37, DOI 10.1016/j.canlet.2020.12.037; Magani F, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20188202; Magani F, 2017, MOL CANCER RES, V15, P1469, DOI 10.1158/1541-7786.MCR-17-0280; Miserey-Lenkei S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01266-0; Nakamura M, 2020, INT J ONCOL, V57, P277, DOI 10.3892/ijo.2020.5060; Rayford W, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02140-y; Ren XH, 2020, AGING-US, V12, P25878, DOI 10.18632/aging.202153; Ridge SM, 2018, INT J CANCER, V142, P2056, DOI 10.1002/ijc.31226; Roggero CM, 2021, ONCOGENE, V40, P1106, DOI 10.1038/s41388-020-01585-5; Ross-Adams H, 2015, EBIOMEDICINE, V2, P1133, DOI 10.1016/j.ebiom.2015.07.017; Saito K, 2017, J NEURO-ONCOL, V132, P63, DOI 10.1007/s11060-016-2360-1; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tcherniuk S, 2010, ANGEW CHEM INT EDIT, V49, P8228, DOI 10.1002/anie.201003254; Terada Y, 2003, J CELL BIOL, V162, P757, DOI 10.1083/jcb.200305048; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang YA, 2020, ONCOGENE, V39, P7225, DOI 10.1038/s41388-020-01496-5; Wu JR, 2010, PHARM STAT, V9, P46, DOI 10.1002/pst.369; Zhang Z, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/4782730	46	2	2	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2824	2832		10.1038/s41388-022-02307-9	http://dx.doi.org/10.1038/s41388-022-02307-9		APR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35418689	Green Accepted			2022-12-28	WOS:000783468200001
J	Guo, P; Chen, Q; Peng, KS; Xie, JY; Liu, JJ; Ren, WJ; Tong, ZW; Li, M; Xu, JM; Zhang, YY; Yu, CD; Mo, PL				Guo, Peng; Chen, Qiang; Peng, Kesong; Xie, Jianyuan; Liu, Junjia; Ren, Wenjing; Tong, Zhangwei; Li, Ming; Xu, Jianming; Zhang, Yongyou; Yu, Chundong; Mo, Pingli			Nuclear receptor coactivator SRC-1 promotes colorectal cancer progression through enhancing GLI2-mediated Hedgehog signaling	ONCOGENE			English	Article							COREGULATORS; INHIBITION; GENE; TIF2; METASTASIS; DISRUPTION; EXPRESSION; PROTEINS; SURVIVAL; PATHWAY	Overexpression of nuclear coactivator steroid receptor coactivator 1 (SRC-1) and aberrant activation of the Hedgehog (Hh) signaling pathway are associated with various tumorigenesis; however, the significance of SRC-1 in colorectal cancer (CRC) and its contribution to the activation of Hh signaling are unclear. Here, we identified a conserved Hh signaling signature positively correlated with SRC-1 expression in CRC based on TCGA database; SRC-1 deficiency significantly inhibited the proliferation, survival, migration, invasion, and tumorigenesis of both human and mouse CRC cells, and SRC-1 knockout significantly suppressed azoxymethane/dextran sodium sulfate (AOM/DSS)-induced CRC in mice. Mechanistically, SRC-1 promoted the expression of GLI family zinc finger 2 (GLI2), a major downstream transcription factor of Hh pathway, and cooperated with GLI2 to enhance multiple Hh-regulated oncogene expression, including Cyclin D1, Bcl-2, and Slug. Pharmacological blockages of SRC-1 and Hh signaling retarded CRC progression in human CRC cell xenograft mouse model. Together, our studies uncover an SRC-1/GLI2-regulated Hh signaling looping axis that promotes CRC tumorigenesis, offering an attractive strategy for CRC treatment.	[Guo, Peng; Chen, Qiang; Peng, Kesong; Xie, Jianyuan; Liu, Junjia; Ren, Wenjing; Tong, Zhangwei; Li, Ming; Zhang, Yongyou; Yu, Chundong; Mo, Pingli] Xiamen Univ, Innovat Ctr Cell Signaling Network, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China; [Peng, Kesong] Fudan Univ, Sch Basic Med Sci, Dept Cellular & Genet Med, Shanghai 200433, Peoples R China; [Liu, Junjia; Zhang, Yongyou] Xiamen Univ, Res Ctr Mol Diagnost, Sch Life Sci, Natl Inst Data Sci Hlth & Med Engn,Minist Educ, Xiamen 361102, Fujian, Peoples R China; [Xu, Jianming] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Xiamen University; Fudan University; Xiamen University; Baylor College of Medicine	Zhang, YY; Yu, CD; Mo, PL (corresponding author), Xiamen Univ, Innovat Ctr Cell Signaling Network, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China.; Zhang, YY (corresponding author), Xiamen Univ, Res Ctr Mol Diagnost, Sch Life Sci, Natl Inst Data Sci Hlth & Med Engn,Minist Educ, Xiamen 361102, Fujian, Peoples R China.	yongyouzhang@xmu.edu.cn; cdyu@xmu.edu.cn; mop@xmu.edu.cn		Li, Ming/0000-0002-9700-1282; zhang, yongyou/0000-0003-2413-9106; Peng, Kesong/0000-0001-9035-3421; Xu, Jianming/0000-0002-8208-9162	National Natural Science Foundation of China [81970485, 81772942, 81772539]; Fundamental Research Funds for the Central Universities [20720180048]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We would like to thank Shiwen Luo (Nanchang University) for providing GLI2 expression plasmid and Hedgehog signaling reporter 8xGLI. We also thank Dr. Mingxia Zhu for technical support. This work was supported by the National Natural Science Foundation of China (Nos. 81970485 and 81772942 to Chundong Yu, and No. 81772539 to Yongyou Zhang), and the Fundamental Research Funds for the Central Universities (No. 20720180048 to Yongyou Zhang).	Berlin J, 2013, CLIN CANCER RES, V19, P258, DOI 10.1158/1078-0432.CCR-12-1800; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719; Chen Q, 2022, ONCOGENE, V41, P1421, DOI 10.1038/s41388-021-02173-x; Datta A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26811-w; Dlugosz A, 2012, NAT REV DRUG DISCOV, V11, P437, DOI 10.1038/nrd3753; Du K, 2018, GASTROENTEROLOGY, V154, P1465, DOI 10.1053/j.gastro.2017.12.022; Duteil D, 2010, CELL METAB, V12, P496, DOI 10.1016/j.cmet.2010.09.016; Fattahi S, 2018, J CELL PHYSIOL, V233, P5726, DOI 10.1002/jcp.26506; Giudici M, 2016, HANDB EXP PHARMACOL, V233, P95, DOI 10.1007/164_2015_5; Hsia EY, 2010, ADV DRUG DELIVER REV, V62, P1227, DOI 10.1016/j.addr.2010.09.016; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Jain S, 2017, ONCOTARGETS THER, V10, DOI 10.2147/OTT.S130910; Kangwan N, 2016, ONCOTARGET, V7, P7667, DOI 10.18632/oncotarget.6765; Kato S, 2011, TRENDS BIOCHEM SCI, V36, P272, DOI 10.1016/j.tibs.2011.01.001; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lin JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25684-3; Lonard DM, 2012, NAT REV ENDOCRINOL, V8, P598, DOI 10.1038/nrendo.2012.100; Louet JF, 2010, CELL METAB, V12, P606, DOI 10.1016/j.cmet.2010.11.009; Madison BB, 2005, DEVELOPMENT, V132, P279, DOI 10.1242/dev.01576; Mark M, 2004, P NATL ACAD SCI USA, V101, P4453, DOI 10.1073/pnas.0400234101; Meerson A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2938-1; Mo P, 2015, ONCOGENE, V34, P3935, DOI 10.1038/onc.2014.324; Myers E, 2005, CLIN CANCER RES, V11, P2111, DOI 10.1158/1078-0432.CCR-04-1192; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223; Papadopoulos V, 2016, CLIN COLORECTAL CANC, V15, P116, DOI 10.1016/j.clcc.2016.02.010; Peng KS, 2020, ONCOGENE, V39, P7076, DOI 10.1038/s41388-020-01483-w; Peng KS, 2019, GASTROENTEROLOGY, V156, P1112, DOI 10.1053/j.gastro.2018.11.036; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Qin L, 2014, CANCER RES, V74, P3477, DOI 10.1158/0008-5472.CAN-13-2639; Qin L, 2011, CANCER RES, V71, P1742, DOI 10.1158/0008-5472.CAN-10-3453; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Raleigh DR, 2018, J CLIN INVEST, V128, P120, DOI 10.1172/JCI92710; Russo L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17088-5; Sang YZ, 2018, CANCER RES, V78, P1792, DOI 10.1158/0008-5472.CAN-17-2774; Sari IN, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110208; Seba V, 2021, POLYMERS-BASEL, V13, DOI 10.3390/polym13162611; Tong ZW, 2015, J BIOL CHEM, V290, P18596, DOI 10.1074/jbc.M115.640490; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Walsh CA, 2014, CANCER RES, V74, P2533, DOI 10.1158/0008-5472.CAN-13-2133; Walsh CA, 2012, INT J BIOL SCI, V8, P470, DOI 10.7150/ijbs.4125; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Wang Y, 2014, CANCER RES, V74, P1506, DOI 10.1158/0008-5472.CAN-13-2939; Wang Y, 2011, MOL ENDOCRINOL, V25, P2041, DOI 10.1210/me.2011-1222; Xin MH, 2018, MED RES REV, V38, P870, DOI 10.1002/med.21482; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; Zeng X, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082279; Zhao C, 2017, SCIENCE, V356, DOI 10.1126/science.aal3485; Zhuo MH, 2020, ONCOGENE, V39, P3336, DOI 10.1038/s41388-020-1219-2	55	1	1	8	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2846	2859		10.1038/s41388-022-02308-8	http://dx.doi.org/10.1038/s41388-022-02308-8		APR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35418691				2022-12-28	WOS:000783468200006
J	Iida, T; Mizutani, Y; Esaki, N; Ponik, SM; Burkel, BM; Weng, L; Kuwata, K; Masamune, A; Ishihara, S; Haga, H; Kataoka, K; Mii, S; Shiraki, Y; Ishikawa, T; Ohno, E; Kawashima, H; Hirooka, Y; Fujishiro, M; Takahashi, M; Enomoto, A				Iida, Tadashi; Mizutani, Yasuyuki; Esaki, Nobutoshi; Ponik, Suzanne M.; Burkel, Brian M.; Weng, Liang; Kuwata, Keiko; Masamune, Atsushi; Ishihara, Seiichiro; Haga, Hisashi; Kataoka, Kunio; Mii, Shinji; Shiraki, Yukihiro; Ishikawa, Takuya; Ohno, Eizaburo; Kawashima, Hiroki; Hirooka, Yoshiki; Fujishiro, Mitsuhiro; Takahashi, Masahide; Enomoto, Atsushi			Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics	ONCOGENE			English	Article							CARCINOMA-ASSOCIATED FIBROBLASTS; DUCTAL ADENOCARCINOMA; TUMOR; MYOFIBROBLASTS; AM80; IMMUNOSUPPRESSION; INHIBITION; FIBROSIS; FAMILY; ROLES	Previous therapeutic attempts to deplete cancer-associated fibroblasts (CAFs) or inhibit their proliferation in pancreatic ductal adenocarcinoma (PDAC) were not successful in mice or patients. Thus, CAFs may be tumor suppressive or heterogeneous, with distinct cancer-restraining and -promoting CAFs (rCAFs and pCAFs, respectively). Here, we showed that induced expression of the glycosylphosphatidylinositol-anchored protein Meflin, a rCAF-specific marker, in CAFs by genetic and pharmacological approaches improved the chemosensitivity of mouse PDAC. A chemical library screen identified Am80, a synthetic, nonnatural retinoid, as a reagent that effectively induced Meflin expression in CAFs. Am80 administration improved the sensitivity of PDAC to chemotherapeutics, accompanied by increases in tumor vessel area and intratumoral drug delivery. Mechanistically, Meflin was involved in the suppression of tissue stiffening by interacting with lysyl oxidase to inhibit its collagen crosslinking activity. These data suggested that modulation of CAF heterogeneity may represent a strategy for PDAC treatment.	[Iida, Tadashi; Mizutani, Yasuyuki; Esaki, Nobutoshi; Kataoka, Kunio; Mii, Shinji; Shiraki, Yukihiro; Enomoto, Atsushi] Nagoya Univ, Dept Pathol, Grad Sch Med, Nagoya, Aichi, Japan; [Iida, Tadashi; Mizutani, Yasuyuki; Kataoka, Kunio; Ishikawa, Takuya; Ohno, Eizaburo; Kawashima, Hiroki; Fujishiro, Mitsuhiro] Nagoya Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Nagoya, Aichi, Japan; [Ponik, Suzanne M.; Burkel, Brian M.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI USA; [Weng, Liang] Cent South Univ, Xiangya Hosp, Xiangya Canc Ctr, Dept Oncol, Changsha, Peoples R China; [Kuwata, Keiko] Nagoya Univ, Inst Transformat Biomol, Nagoya, Japan; [Masamune, Atsushi] Tohoku Univ, Div Gastroenterol, Grad Sch Med, Sendai, Miyagi, Japan; [Ishihara, Seiichiro; Haga, Hisashi] Hokkaido Univ, Fac Adv Life Sci, Sapporo, Hokkaido, Japan; [Kawashima, Hiroki] Nagoya Univ Hosp, Dept Endoscopy, Nagoya, Aichi, Japan; [Hirooka, Yoshiki] Fujita Hlth Univ, Dept Gastroenterol & Hepatol, Toyoake, Aichi, Japan; [Takahashi, Masahide] Fujita Hlth Univ, Int Ctr Cell & Gene Therapy, Toyoake, Aichi, Japan; [Takahashi, Masahide] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan	Nagoya University; Nagoya University; University of Wisconsin System; University of Wisconsin Madison; Central South University; Nagoya University; Tohoku University; Hokkaido University; Nagoya University; Fujita Health University; Fujita Health University; University of Tokyo	Enomoto, A (corresponding author), Nagoya Univ, Dept Pathol, Grad Sch Med, Nagoya, Aichi, Japan.	enomoto@iar.nagoya-u.ac.jp	Mii, Shinji/I-7480-2014; Shiraki, Yukihiro/AIA-7918-2022	Mii, Shinji/0000-0001-8266-3235; Shiraki, Yukihiro/0000-0003-3666-0556	Ministry of Education, Culture, Sports, Science and Technology of Japan [18H02638, 20H03467]; Nagoya University Hospital Funding for Clinical Research; MED-CREST (Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology) [JP20gm0810007h0105, JP20gm1210009s0102]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from AMED [JP20cm0106377h0001, JP21cm0106704h0002]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Nagoya University Hospital Funding for Clinical Research; MED-CREST (Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology); Project for Cancer Research and Therapeutic Evolution (P-CREATE) from AMED	We thank David Tuveson (Cold Spring Harbor Laboratory) and Chang-il Hwang (UC Davis College of Biological Sciences) for providing the mouse PDAC cell line mT5; Kohji Kusano (ID Pharma Co., Ltd.) for generating recombinant Sendai virus; Shuzo Watanabe, Kaoru Shimada (RaQualia Pharma Inc.), and Hisao Ekimoto (TMRC Co., Ltd) for helpful discussions on Am80; Kentaro Taki (Nagoya University) for help with mass spectrometry; and Kozo Uchiyama and Kaori Ushida (Nagoya University) for technical assistance. This work was supported by a Grant-in-Aid for Scientific Research (B) (grant nos. 18H02638 to AE and 20H03467 to MT) commissioned by the Ministry of Education, Culture, Sports, Science and Technology of Japan; Nagoya University Hospital Funding for Clinical Research (to AE); AMED-CREST (Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology; grant nos. JP20gm0810007h0105 and JP20gm1210009s0102 to AE); and the Project for Cancer Research and Therapeutic Evolution (P-CREATE) from AMED (grant nos. JP20cm0106377h0001 to AE and JP21cm0106704h0002 to YM).	Apte MV, 2004, PANCREAS, V29, P179, DOI 10.1097/00006676-200410000-00002; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Bhattacharjee S, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146987; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen Y, 2021, CANCER CELL, V39, P548, DOI 10.1016/j.ccell.2021.02.007; Chronopoulos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12630; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Gieniec KA, 2019, BRIT J CANCER, V121, P293, DOI 10.1038/s41416-019-0509-3; Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118; Hara A, 2021, GENES CELLS, V26, P495, DOI 10.1111/gtc.12855; Hara A, 2019, CIRC RES, V125, P414, DOI 10.1161/CIRCRESAHA.119.314806; HASHIMOTO Y, 1990, BIOCHEM BIOPH RES CO, V166, P1300, DOI 10.1016/0006-291X(90)91007-F; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Ishii G, 2016, ADV DRUG DELIVER REV, V99, P186, DOI 10.1016/j.addr.2015.07.007; Kagechika H, 2002, CURR MED CHEM, V9, P591, DOI 10.2174/0929867024606975; KAGECHIKA H, 1984, CHEM PHARM BULL, V32, P4209; Klemann C, 2009, AM J PATHOL, V174, P2234, DOI 10.2353/ajpath.2009.081084; Kobayashi H, 2021, GASTROENTEROLOGY, V160, P1224, DOI 10.1053/j.gastro.2020.11.011; Kobayashi H, 2019, NAT REV GASTRO HEPAT, V16, P282, DOI 10.1038/s41575-019-0115-0; Kocher HM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18636-w; Le Calve B, 2016, ONCOTARGET, V7, P32100, DOI 10.18632/oncotarget.8527; Lee JJ, 2014, P NATL ACAD SCI USA, V111, pE3091, DOI 10.1073/pnas.1411679111; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Maeda K, 2016, SCI REP-UK, V6, DOI 10.1038/srep22288; Mezawa Y, 2016, CELL TISSUE RES, V365, P675, DOI 10.1007/s00441-016-2471-1; Miyai Y, 2020, CANCER SCI, V111, P1047, DOI 10.1111/cas.14346; Mizutani Y, 2019, CANCER RES, V79, P5367, DOI 10.1158/0008-5472.CAN-19-0454; Nagathihalli NS, 2016, ONCOTARGET, V7, P65982, DOI 10.18632/oncotarget.11786; Neesse A, 2019, GUT, V68, P159, DOI 10.1136/gutjnl-2018-316451; Neuzillet C, 2019, J PATHOL, V248, P51, DOI 10.1002/path.5224; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pure E, 2018, ONCOGENE, V37, P4343, DOI 10.1038/s41388-018-0275-3; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Sanda T, 2005, LEUKEMIA, V19, P901, DOI 10.1038/sj.leu.2403754; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shi Y, 2019, NATURE, V569, P131, DOI 10.1038/s41586-019-1130-6; Takahashi M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.749924; Tebben PJ, 2016, ENDOCR REV, V37, P521, DOI 10.1210/er.2016-1070; Tobita T, 1997, BLOOD, V90, P967, DOI 10.1182/blood.V90.3.967.967_967_973; Waghray M, 2016, CANCER DISCOV, V6, P886, DOI 10.1158/2159-8290.CD-15-0947; Xu JZ, 2020, EMBO J, V39, DOI 10.15252/embj.2019103255; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Zhang DX, 2018, CANCER RES, V78, P1700, DOI 10.1158/0008-5472.CAN-17-1366; Zhang K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07638-4	51	5	5	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2764	2777		10.1038/s41388-022-02288-9	http://dx.doi.org/10.1038/s41388-022-02288-9		APR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35414659				2022-12-28	WOS:000781960100001
J	Baker, K; O'Donnell, C; Bendix, M; Keogh, S; Byrne, J; O'Riordain, M; Neary, P; Houston, A; Brint, E				Baker, Kevin; O'Donnell, Charlotte; Bendix, Maura; Keogh, Samuel; Byrne, James; O'Riordain, Michael; Neary, Peter; Houston, Aileen; Brint, Elizabeth			IL-36 signalling enhances a pro-tumorigenic phenotype in colon cancer cells with cancer cell growth restricted by administration of the IL-36R antagonist	ONCOGENE			English	Article							ULCERATIVE-COLITIS; EXPRESSION; INTERLEUKIN-36; RECEPTOR; FAMILY; ROLES	The IL-36 cytokines are a recently described subset of the IL-1 family of cytokines, shown to play a role in the pathogenesis of intestinal diseases such as Inflammatory Bowel Disease (IBD). Given the link between IBD and colitis -associated cancer, as well as the involvement of other IL-1 family members in intestinal tumorigenesis, the aim of this work was to investigate whether IL-36 cytokines play a role in the pathogenesis of colon cancer. Whilst research to date has focused on the role of IL-36 family members in augmenting the immune response to induce tumour rejection, very little remains known about IL-36R signalling in tumour cells in this context. In this study we demonstrate that expression of IL-36 family member mRNA and protein are significantly increased in colorectal cancer tissue compared to adjacent non-tumour. In vitro assays showed stimulation of colon cancer cell lines with IL-36R agonists resulted in the activation of the pro-tumorigenic phenotypes of increased cellular migration, invasion and proliferation in both 2D and 3D models. In addition, the IL-36 cytokines induced strong expression of pro-inflammatory chemokines in both human and murine cell lines. Intraperitoneal injection of IL-36Ra significantly reduced tumour burden using the subcutaneous CT26 tumour model in syngeneic Balb/mice, and this was associated with a decrease in Ki-67 expression by tumour cells in the IL-36Ra- treated group relative to untreated, suggesting the inhibition of the pro-proliferative signalling of IL-36 agonists resulted in the decreased tumour size. Moreover, colon cancer cells lacking the IL-36R also showed reduced tumour growth and reduced Ki-67 expression in vivo. Taken together, this data suggests that targeting IL-36R signalling may be a useful targeted therapy for colorectal cancer patients with IL-36R(+) tumour cells.	[Baker, Kevin; Bendix, Maura; Keogh, Samuel; Byrne, James; Brint, Elizabeth] Univ Coll Cork, Dept Pathol, Cork, Ireland; [Baker, Kevin; Houston, Aileen; Brint, Elizabeth] Univ Coll Cork, APC Microbiome Ireland, Cork, Ireland; [O'Donnell, Charlotte; Houston, Aileen] Univ Coll Cork, Dept Med, Cork, Ireland; [Bendix, Maura] Univ Coll Cork, Canc Res UCC, Cork, Ireland; [O'Riordain, Michael] Mercy Univ Hosp, Cork, Ireland; [Neary, Peter] Waterford Univ Hosp, Waterford, Ireland	University College Cork; University College Cork; University College Cork; University College Cork; University College Cork	Brint, E (corresponding author), Univ Coll Cork, Dept Pathol, Cork, Ireland.; Brint, E (corresponding author), Univ Coll Cork, APC Microbiome Ireland, Cork, Ireland.	e.brint@ucc.ie		Houston, Aileen/0000-0003-1362-5256; Bendix, Maura/0000-0001-8883-2677; Brint, Elizabeth/0000-0001-9214-149X	Government of Ireland [GOIPG/2018/2974]; IReL Consortium	Government of Ireland; IReL Consortium	This work was funded by a grant from the Government of Ireland postgraduate scholarship scheme GOIPG/2018/2974. Open Access funding provided by the IReL Consortium.	Aldinucci D, 2020, CANCERS, V12, DOI 10.3390/cancers12071765; Baker KJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01197; Bassoy EY, 2018, IMMUNOL REV, V281, P169, DOI 10.1111/imr.12610; Byrne J, 2021, CELL MOL LIFE SCI, V78, P6215, DOI 10.1007/s00018-021-03909-4; Chun E, 2015, CELL REP, V12, P244, DOI 10.1016/j.celrep.2015.06.024; Diaz-Maroto NG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094960; Ding LP, 2018, ONCOTARGET, V9, P2895, DOI 10.18632/oncotarget.22814; Dunn E, 2001, TRENDS IMMUNOL, V22, P533, DOI 10.1016/S1471-4906(01)02034-8; Duronio Robert J, 2013, Cold Spring Harb Perspect Biol, V5, pa008904, DOI 10.1101/cshperspect.a008904; Fernandes P, 2014, J IMMUNOL, V193, P6103, DOI 10.4049/jimmunol.1303083; Fonseca-Camarillo G, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5140691; Frick VO, 2016, WORLD J GASTROENTERO, V22, P833, DOI 10.3748/wjg.v22.i2.833; Gabay C, 2015, J LEUKOCYTE BIOL, V97, P645, DOI 10.1189/jlb.3RI1014-495R; Gelfo V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176009; Holen I, 2016, ONCOTARGET, V7, P75571, DOI 10.18632/oncotarget.12289; Ko HBM, 2015, MODERN PATHOL, V28, P1584, DOI 10.1038/modpathol.2015.111; Kobelt D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00980; Le Rolle AF, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0555-4; Leon G, 2021, INFLAMM BOWEL DIS, V27, P440, DOI 10.1093/ibd/izaa232; Liu Q, 2020, INT J BIOL SCI, V16, P1023, DOI 10.7150/ijbs.40535; Mao DL, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819883633; McCombs JE, 2021, AM J RESP CELL MOL, V64, P153, DOI 10.1165/rcmb.2020-0461ED; Medina-Contreras O, 2016, J IMMUNOL, V196, P34, DOI 10.4049/jimmunol.1501312; Najdaghi S, 2020, CYTOKINE, V135, DOI 10.1016/j.cyto.2020.155205; Nishida A, 2016, INFLAMM BOWEL DIS, V22, P303, DOI 10.1097/MIB.0000000000000654; O'Donnell C, 2016, BRIT J CANCER, V114, P37, DOI 10.1038/bjc.2015.433; Pijuan J, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00107; Qu QX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00634; Queen D, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00317; Ridker PM, 2017, LANCET, V390, P1833, DOI 10.1016/S0140-6736(17)32247-X; Russell SE, 2016, MUCOSAL IMMUNOL, V9, P1193, DOI 10.1038/mi.2015.134; Swindell WR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00080; Uppala R, 2021, CELL MOL IMMUNOL, V18, P307, DOI 10.1038/s41423-020-0519-3; Wang D, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0701-2; Wang XF, 2015, CANCER CELL, V28, P296, DOI 10.1016/j.ccell.2015.07.014; Weinstein AM, 2019, CANCER IMMUNOL IMMUN, V68, P109, DOI 10.1007/s00262-018-2259-0; Weinstein AM, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1322238; Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z; Yang W, ADV SCI, V2022; Yashiro M, 2014, WORLD J GASTROENTERO, V20, P16389, DOI 10.3748/wjg.v20.i44.16389; Zhao X, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01803	41	1	1	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2672	2684		10.1038/s41388-022-02281-2	http://dx.doi.org/10.1038/s41388-022-02281-2		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35365751	Green Published, hybrid			2022-12-28	WOS:000777275200001
J	Lee, WK; Zhu, XG; Park, S; Zhu, YJ; Zhao, L; Meltzer, P; Cheng, SY				Lee, Woo Kyung; Zhu, Xuguang; Park, Sunmi; Zhu, Yuelin Jack; Zhao, Li; Meltzer, Paul; Cheng, Sheue-Yann			Regulation of cancer stem cell activity by thyroid hormone receptor beta	ONCOGENE			English	Article							TR-BETA; EXPRESSION; CARCINOMA; GENE; MUTATION; IDENTIFICATION; TUMORIGENESIS; ASSOCIATION; INHIBITION; PATHWAY	Increasing numbers of cancer stem cell markers have been recently identified. It is not known, however, whether a member of the nuclear receptor superfamily, thyroid hormone receptor beta (TR beta), can function to regulate cancer stem cell (CSC) activity. Using anaplastic thyroid cancer cells (ATC) as a model, we highlight the role of TR beta in CSC activity. ATC is one of the most aggressive solid cancers in humans and is resistant to currently available therapeutics. Recent studies provide evidence that CSC activity underlies aggressiveness and therapeutic resistance of ATC. Here we show that TR beta inhibits CSC activity by suppressing tumor-sphere formation of human ATC cells and their tumor-initiating capacity. TR beta suppresses the expression of CSC regulators, including ALDH, KLF2, SOX2, b-catenin, and ABCG2, in ATC cell-induced xenograft tumors. Single-cell transcriptomic analysis shows that TR beta reduces CSC population in ATC-induced xenograft tumors. Analysis of The Cancer Genome Atlas (TCGA) database demonstrates that the inhibition of CSC capacity by TR beta contributes to favorable clinical outcomes in human cancer. Our studies show that TR beta is a newly identified transcription regulator that acts to suppress CSC activity and that TR beta could be considered as a molecular target for therapeutic intervention of ATC.	[Lee, Woo Kyung; Zhu, Xuguang; Park, Sunmi; Zhao, Li; Cheng, Sheue-Yann] NCI, Lab Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Zhu, Yuelin Jack; Meltzer, Paul] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cheng, SY (corresponding author), NCI, Lab Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	chengs@mail.nih.gov	Doolittle, Woo Kyung Lee/CAJ-0252-2022	Doolittle, Woo Kyung Lee/0000-0002-6737-3173	Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health	Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research is supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ando S, 2001, J CLIN ENDOCR METAB, V86, P5572, DOI 10.1210/jc.86.11.5572; Aranda A, 2009, TRENDS ENDOCRIN MET, V20, P318, DOI 10.1016/j.tem.2009.03.011; Ayob AZ, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0426-4; Bolf EL, 2020, MOL CANCER RES, V18, P1443, DOI 10.1158/1541-7786.MCR-20-0282; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Carr FE, 2016, ENDOCRINOLOGY, V157, P3278, DOI 10.1210/en.2015-2046; Enomoto K, 2017, J CLIN ENDOCR METAB, V102, P2268, DOI 10.1210/jc.2016-3771; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Guigon CJ, 2011, ONCOGENE, V30, P3381, DOI 10.1038/onc.2011.50; Haghpanah V, 2016, LIFE SCI, V146, P34, DOI 10.1016/j.lfs.2015.12.057; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Iwasaki Y, 2010, ANN SURG ONCOL, V17, P2222, DOI 10.1245/s10434-010-0956-9; Jazdzewski K, 2011, J CLIN ENDOCR METAB, V96, pE546, DOI 10.1210/jc.2010-1594; Jean E, 2011, J CELL MOL MED, V15, P119, DOI 10.1111/j.1582-4934.2009.00942.x; Jerzak KJ, 2018, BREAST CANCER RES TR, V171, P709, DOI 10.1007/s10549-018-4844-5; Joseph B, 2007, J CLIN ENDOCR METAB, V92, P4766, DOI 10.1210/jc.2007-0812; Kim WG, 2014, THYROID, V24, P260, DOI 10.1089/thy.2013.0054; Kim WG, 2013, BBA-GEN SUBJECTS, V1830, P3928, DOI 10.1016/j.bbagen.2012.04.002; Kim WG, 2013, ENDOCRINOLOGY, V154, P25, DOI 10.1210/en.2012-1728; Lee CH, 2016, ONCOTARGET, V7, P1215, DOI 10.18632/oncotarget.6261; Lee WK., 2021, J CANC METASTASIS TR, V7, P27; Lee WK, 2020, ENDOCR-RELAT CANCER, V27, P209, DOI 10.1530/ERC-19-0482; Lee WK, 2019, EUR J ENDOCRINOL, V181, P139, DOI 10.1530/EJE-18-1025; Lee WK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102867; Li W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065095; Li Z, 2002, CANCER RES, V62, P1939; Lopez-Mateo I, 2020, THYROID, V30, P116, DOI 10.1089/thy.2019.0175; Mabbott NA, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-632; Marlow LA, 2010, J CLIN ENDOCR METAB, V95, P5338, DOI 10.1210/jc.2010-1421; Molinaro E, 2017, NAT REV ENDOCRINOL, V13, P644, DOI 10.1038/nrendo.2017.76; Park JW, 2013, AM J CANCER RES, V3, P302; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Ravi N, 2020, CANCERS, V12, DOI 10.3390/cancers12030680; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Silva JM, 2002, ONCOGENE, V21, P4307, DOI 10.1038/sj.onc.1205534; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smallridge RC, 2012, THYROID, V22, P1104, DOI 10.1089/thy.2012.0302; Smallridge RC, 2012, J CLIN ENDOCR METAB, V97, P2566, DOI 10.1210/jc.2012-1314; Subbiah V, 2018, J CLIN ONCOL, V36, P7, DOI 10.1200/JCO.2017.73.6785; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Tiedje V, 2018, ENDOCR-RELAT CANCER, V25, pR153, DOI 10.1530/ERC-17-0435; Tuttle RM, 2017, THYROID, V27, P751, DOI 10.1089/thy.2017.0102	45	1	1	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2315	2325		10.1038/s41388-022-02242-9	http://dx.doi.org/10.1038/s41388-022-02242-9		MAR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35256781	Green Accepted			2022-12-28	WOS:000765674100004
J	Zhang, YJ; Dho, SE; Othman, K; Simpson, CD; Lapierre, J; Bondoc, A; McGlade, CJ				Zhang, Yangjing; Dho, Sascha E.; Othman, Kamal; Simpson, Craig D.; Lapierre, Jessica; Bondoc, Andrew; McGlade, C. Jane			Numb exon 9 inclusion regulates Integrin beta 5 surface expression and promotes breast cancer metastasis	ONCOGENE			English	Article							FATE DETERMINANT NUMB; CELL FATE; ISOFORMS; DIFFERENTIATION; IDENTIFICATION; INVOLVEMENT; ENDOCYTOSIS; PROGRESSION; ATTACHMENT; SUPPRESSOR	The endocytic adaptor protein Numb acts as a tumor suppressor through downregulation of oncogenic pathways in multiple cancer types. The identification of splicing alterations giving rise to changes in Numb protein isoform expression indicate that Numb also has tumor promoting activity, though the underlying mechanisms are unknown. Here we report that NUMB exon 9 inclusion, which results in production of a protein isoform with an additional 49 amino acids, is a feature of multiple cancer types including all subtypes of breast cancer and correlates with worse progression-free survival. Specific deletion of exon 9-included Numb isoforms (Exon9in) from breast cancer cells reduced cell growth and prevents spontaneous lung metastasis in a mouse model. Quantitative proteome profiling showed that loss of Exon9in causes downregulation of membrane receptors and adhesion molecules, as well as proteins involved in extracellular matrix organization and the epithelial-mesenchymal transition (EMT) state. In addition, exon 9 deletion caused remodeling of the endocytic network, decreased ITG beta 5 surface localization, cell spreading on vitronectin and downstream signaling to ERK and SRC. Together these observations suggest that Exon9in isoform expression disrupts the endocytic trafficking functions of Numb, resulting in increased surface expression of ITG beta 5 as well as other plasma membrane proteins to promote cell adhesion, EMT, and tumor metastasis.	[Zhang, Yangjing; Othman, Kamal; McGlade, C. Jane] Univ Toronto, Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada; [Zhang, Yangjing; Dho, Sascha E.; Othman, Kamal; Lapierre, Jessica; Bondoc, Andrew; McGlade, C. Jane] Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Dho, Sascha E.; Lapierre, Jessica; Bondoc, Andrew; McGlade, C. Jane] Program Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Simpson, Craig D.] Hosp Sick Children, SPARC BioCtr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	McGlade, CJ (corresponding author), Univ Toronto, Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.; McGlade, CJ (corresponding author), Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.; McGlade, CJ (corresponding author), Program Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jmcglade@sickkids.ca		Zhang, Yangjing/0000-0003-3762-0767	Canadian Institutes of Health Research [FRN 106507]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The authors thank the following: Michael Reedijk and Qiang Shen for assistance with mouse xenograft experiments, SPARC Molecular Analysis for TMT mass spectrometry, Amanda Luck for mouse colony maintenance and caliper measurements, Nesrin Sabha for help with IHC staining, and Kim Lau and Paul Paroutis (The Imaging Facility, The Hospital for Sick Children) for their assistance with TIRF microscopy and imaging analysis. This work was supported with funds from the Canadian Institutes of Health Research to CJM (FRN 106507).	Bani-Yaghoub M, 2007, DEV DYNAM, V236, P696, DOI 10.1002/dvdy.21072; Baschieri F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06367-y; Bechara EG, 2013, MOL CELL, V52, P720, DOI 10.1016/j.molcel.2013.11.010; Bianchi-Smiraglia A, 2013, ONCOGENE, V32, P3049, DOI 10.1038/onc.2012.320; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Chaudhuri O, 2014, NAT MATER, V13, P970, DOI [10.1038/nmat4009, 10.1038/NMAT4009]; Chen HZ, 2009, PATHOBIOLOGY, V76, P149, DOI 10.1159/000209393; Cheng C, 2020, AM J PHYSIOL-GASTR L, V318, pG841, DOI 10.1152/ajpgi.00178.2019; Colaluca IN, 2008, NATURE, V451, P76, DOI 10.1038/nature06412; Colaluca IN, 2018, J CELL BIOL, V217, P745, DOI 10.1083/jcb.201709092; Cullen PJ, 2018, NAT REV MOL CELL BIO, V19, P679, DOI 10.1038/s41580-018-0053-7; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Dooley CM, 2003, J NEUROBIOL, V54, P313, DOI 10.1002/neu.10176; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Ke H, 2018, P NATL ACAD SCI USA, V115, pE3426, DOI 10.1073/pnas.1714573115; Khan I, 2021, BRIT J CANCER, V124, P66, DOI 10.1038/s41416-020-01179-8; Kim KK, 2013, J CELL BIOL, V200, P443, DOI 10.1083/jcb.201206146; Koike S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09617-9; Krieger JR, 2019, J PROTEOME RES, V18, P2346, DOI 10.1021/acs.jproteome.9b00082; Krieger JR, 2015, PROTEOMICS, V15, P434, DOI 10.1002/pmic.201400232; Krieger JR, 2013, MOL CELL PROTEOMICS, V12, P499, DOI 10.1074/mcp.M112.020768; Lajoie P, 2010, INT REV CEL MOL BIO, V282, P135, DOI 10.1016/S1937-6448(10)82003-9; Lamaze C, 2015, BIOMED J, V38, P367, DOI 10.4103/2319-4170.164229; Lau KM, 2011, EXP CELL RES, V317, P539, DOI 10.1016/j.yexcr.2010.12.005; Leyton-Puig D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16068; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Lock JG, 2018, NAT CELL BIOL, V20, P1290, DOI 10.1038/s41556-018-0220-2; Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116; Lu YY, 2015, HEPATOLOGY, V62, P1122, DOI 10.1002/hep.27923; McGill MA, 2009, J BIOL CHEM, V284, P26427, DOI 10.1074/jbc.M109.014845; Misquitta-Ali CM, 2011, MOL CELL BIOL, V31, P138, DOI 10.1128/MCB.00709-10; Moran TB, 2011, MOL ENDOCRINOL, V25, P117, DOI 10.1210/me.2010-0248; Moreno-Layseca P, 2019, NAT CELL BIOL, V21, P122, DOI 10.1038/s41556-018-0223-z; Nishimura T, 2007, DEV CELL, V13, P15, DOI 10.1016/j.devcel.2007.05.003; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Peden AA, 2004, J CELL BIOL, V164, P1065, DOI 10.1083/jcb.200311064; Rajendran D, 2016, ONCOGENE, V35, P5202, DOI 10.1038/onc.2016.69; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9; Ricono JM, 2009, CANCER RES, V69, P1383, DOI 10.1158/0008-5472.CAN-08-3612; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Sanchez E, 2019, J BIOL CHEM, V294, P3012, DOI 10.1074/jbc.RA118.005532; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Smith CA, 2004, MOL BIOL CELL, V15, P3698, DOI 10.1091/mbc.E04-01-0026; Song W, 2017, ONCOGENE, V36, P5620, DOI 10.1038/onc.2017.170; Sun LX, 2018, ONCOGENE, V37, P3698, DOI 10.1038/s41388-018-0202-7; TAFTAF R, NAT COMMUN, V2021, P12; Toriya M, 2006, DEV NEUROSCI-BASEL, V28, P142, DOI 10.1159/000090760; Tosoni D, 2015, J CELL BIOL, V211, P845, DOI 10.1083/jcb.201505037; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Verdi JM, 1999, P NATL ACAD SCI USA, V96, P10472, DOI 10.1073/pnas.96.18.10472; Wang ZZ, 2009, EMBO J, V28, P2360, DOI 10.1038/emboj.2009.190; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; Wei R, 2019, J MOL CELL BIOL, V11, P994, DOI 10.1093/jmcb/mjz003; Welinder C, 2011, J PROTEOME RES, V10, P1416, DOI 10.1021/pr1011476; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; Yamaguchi H, 2009, CANCER RES, V69, P8594, DOI 10.1158/0008-5472.CAN-09-2305; Zecchini S, 2011, EMBO MOL MED, V3, P480, DOI 10.1002/emmm.201100152; Zhang SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094974; Zhang Y, 2016, FASEB J, V30, P3474, DOI 10.1096/fj.201600387R; Zheng KL, 2015, INT J CLIN EXP PATHO, V8, P6181; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289; Zuidema A, 2018, J CELL SCI, V131, DOI 10.1242/jcs.221317	68	2	2	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2079	2094		10.1038/s41388-022-02225-w	http://dx.doi.org/10.1038/s41388-022-02225-w		FEB 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35181737				2022-12-28	WOS:000757709600001
J	Liao, CG; Liang, XH; Ke, Y; Yao, L; Liu, M; Liu, ZK; He, L; Guo, YX; Bian, HJ; Chen, ZN; Kong, LM				Liao, Cheng-Gong; Liang, Xiao-Hua; Ke, Yuan; Yao, Li; Liu, Man; Liu, Ze-Kun; He, Lin; Guo, Yi-Xiao; Bian, Huijie; Chen, Zhi-Nan; Kong, Ling-Min			Active demethylation upregulates CD147 expression promoting non-small cell lung cancer invasion and metastasis	ONCOGENE			English	Article							TARGETED DNA DEMETHYLATION; 5-HYDROXYMETHYLCYTOSINE SIGNATURES; BONE METASTASIS; POOR-PROGNOSIS; 5-METHYLCYTOSINE; HYPOMETHYLATION; PROLIFERATION; RECRUITMENT; METHYLATION; MECHANISMS	Non-small cell lung cancer (NSCLC) is a fatal disease, and its metastatic process is poorly understood. Although aberrant methylation is involved in tumor progression, the mechanisms underlying dynamic DNA methylation remain to be elucidated. It is significant to study the molecular mechanism of NSCLC metastasis and identify new biomarkers for NSCLC early diagnosis. Here, we performed MeDIP-seq and hMeDIP-seq analyses to detect the genes regulated by dynamic DNA methylation. Comparison of the 5mC and 5hmC sites revealed that the CD147 gene underwent active demethylation in NSCLC tissues compared with normal tissues, and this demethylation upregulated CD147 expression. Significantly high levels of CD147 expression and low levels of promoter methylation were observed in NSCLC tissues. Then, we identified the CD147 promoter as a target of KLF6, MeCP2, and DNMT3A. Treatment of cells with TGF-beta triggered active demethylation involving loss of KLF6/MeCP2/DNMT3A and recruitment of Sp1, Tet1, TDG, and SMAD2/3 transcription complexes. A dCas9-SunTag-DNMAT3A-sgCD147-targeted methylation system was constructed to reverse CD147 expression. The targeted methylation system downregulated CD147 expression and inhibited NSCLC proliferation and metastasis in vitro and in vivo. Accordingly, we used cfDNA to detect the levels of CD147 methylation in NSCLC tissues and found that the CD147 methylation levels exhibited an inverse relationship with tumor size, lymphatic metastasis, and TNM stage. In conclusion, this study clarified the mechanism of active demethylation of CD147 and suggested that the targeted methylation of CD147 could inhibit NSCLC invasion and metastasis, providing a highly promising therapeutic target for NSCLC.	[Liao, Cheng-Gong; Ke, Yuan] Fourth Mil Med Univ, Tangdu Hosp, Dept Oncol, Xian 710038, Peoples R China; [Liang, Xiao-Hua] Fourth Mil Med Univ, Tangdu Hosp, Dept Thorac Surg, Xian 710038, Peoples R China; [Yao, Li] Northwest Univ, Dept Pathol, Xian 3 Hosp, Affiliated Hosp, Xian 710018, Peoples R China; [Liu, Man; Liu, Ze-Kun; He, Lin; Guo, Yi-Xiao; Bian, Huijie; Chen, Zhi-Nan; Kong, Ling-Min] Fourth Mil Med Univ, Natl Translat Sci Ctr Mol Med, Dept Cell Biol, Xian 710032, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Northwest University Xi'an; Air Force Military Medical University	Bian, HJ; Chen, ZN; Kong, LM (corresponding author), Fourth Mil Med Univ, Natl Translat Sci Ctr Mol Med, Dept Cell Biol, Xian 710032, Peoples R China.	hjbian@fmmu.edu.cn; znchen@fmmu.edu.cn; konglingmin81@163.com		Chen, Zhi-Nan/0000-0001-5512-4623; Cheng-Gong, Liao/0000-0002-7624-0196	Basic Research Plan of Natural Science in Shaanxi Province [2020JM-326]; National Natural Science Foundation of China [8217111294]; Social Talent Fund Supporting Scheme of Tangdu Hospital [2021SHRC001]; National Key Research [2018YFA0109000]; Development Program of China [2019YFC1316303]	Basic Research Plan of Natural Science in Shaanxi Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Social Talent Fund Supporting Scheme of Tangdu Hospital; National Key Research; Development Program of China	This study was supported by grants from the Basic Research Plan of Natural Science in Shaanxi Province (2020JM-326), the National Natural Science Foundation of China (8217111294), the Social Talent Fund Supporting Scheme of Tangdu Hospital (2021SHRC001), the National Key Research (2018YFA0109000) and the Development Program of China (2019YFC1316303).	Anton T, 2017, NUCLEUS-PHILA, V8, P279, DOI 10.1080/19491034.2017.1292194; CHEN Z-N, 1992, Zhonghua Zhongliu Zazhi, V14, P9; Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020; Duruisseaux M, 2018, SEMIN CANCER BIOL, V51, P116, DOI 10.1016/j.semcancer.2017.09.005; Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI 10.2217/EPI.09.33; Escudero L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19175-0; Fei F, 2014, ANN SURG ONCOL, V21, P4359, DOI 10.1245/s10434-014-3816-1; Ge JP, 2016, SCI REP-UK, V6, DOI 10.1038/srep19366; Goulet CR, 2021, ADV EXP MED BIOL, V1270, P89, DOI 10.1007/978-3-030-47189-7_6; Guler GD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18965-w; Hashimoto H, 2012, NUCLEIC ACIDS RES, V40, P4841, DOI 10.1093/nar/gks155; Hassan HM, 2017, CELL REP, V19, P1685, DOI 10.1016/j.celrep.2017.05.007; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hervouet E, 2009, EPIGENETICS-US, V4, P487, DOI 10.4161/epi.4.7.9883; Huang YH, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1248-5; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Jeschke J, 2017, J CLIN INVEST, V127, P3090, DOI 10.1172/JCI91095; Jin L, 2012, CELL RES, V22, P1356, DOI 10.1038/cr.2012.90; Kidder BL, 2011, NAT IMMUNOL, V12, P918, DOI 10.1038/ni.2117; Kim BN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67325-7; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Kohli RM, 2013, NATURE, V502, P472, DOI 10.1038/nature12750; Kong LM, 2016, ONCOTARGET, V7, P27975, DOI 10.18632/oncotarget.8564; Kong LM, 2014, CANCER RES, V74, P3764, DOI 10.1158/0008-5472.CAN-13-3555; Kong LM, 2011, J CELL MOL MED, V15, P1415, DOI 10.1111/j.1582-4934.2010.01124.x; Ku XM, 2007, SCAND J IMMUNOL, V65, P435, DOI 10.1111/j.1365-3083.2007.01930.x; Li HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep16552; Li WS, 2017, CELL RES, V27, P1243, DOI 10.1038/cr.2017.121; Li Y, 2009, HISTOPATHOLOGY, V54, P677, DOI 10.1111/j.1365-2559.2009.03280.x; Liao CG, 2011, MOL CELL BIOL, V31, P2591, DOI 10.1128/MCB.05160-11; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maeder ML, 2013, NAT BIOTECHNOL, V31, P1137, DOI 10.1038/nbt.2726; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Moreira EA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12861; Morita S, 2016, NAT BIOTECHNOL, V34, P1060, DOI 10.1038/nbt.3658; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; O'Leary K, 2018, CURR CANCER DRUG TAR, V18, P89, DOI 10.2174/1568009617666170203162556; Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641; Pflueger C, 2018, GENOME RES, V28, P1193, DOI 10.1101/gr.233049.117; Porteus MH, 2005, NAT BIOTECHNOL, V23, P967, DOI 10.1038/nbt1125; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song CX, 2017, CELL RES, V27, P1231, DOI 10.1038/cr.2017.106; Stevens LE., 2018, JOVE-J VIS EXP, V136, P56650; Strauss A, 2013, MOL PLANT, V6, P1384, DOI 10.1093/mp/sst075; Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027; Tseng HC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18444-2; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7; Wang H, 2017, FUTURE ONCOL, V13, P695, DOI 10.2217/fon-2016-0237; Wang K, 2021, CELL METAB, V33, P160, DOI 10.1016/j.cmet.2020.12.010; Wang Q, 2019, CANCER LETT, V448, P132, DOI 10.1016/j.canlet.2019.01.040; Wang SJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01647-2; Warton K, 2016, ENDOCR-RELAT CANCER, V23, pR157, DOI 10.1530/ERC-15-0369; Wu H, 2011, GENE DEV, V25, P2436, DOI 10.1101/gad.179184.111; Wu J, 2016, ONCOGENE, V35, P5468, DOI 10.1038/onc.2016.89; Wu J, 2011, ONCOGENE, V30, P4410, DOI 10.1038/onc.2011.149; Zhang JN, 2020, INT J GEN MED, V13, P1115, DOI 10.2147/IJGM.S279023; Zhang RY, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00233	57	4	4	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1780	1794		10.1038/s41388-022-02213-0	http://dx.doi.org/10.1038/s41388-022-02213-0		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35132181	hybrid, Green Published			2022-12-28	WOS:000752288100001
J	Lin, JG; Xia, LZ; Oyang, LD; Liang, JX; Tan, SM; Wu, NY; Yi, P; Pan, Q; Rao, S; Han, YQ; Tang, YY; Su, M; Luo, X; Yang, YQ; Chen, XH; Yang, LX; Zhou, YJ; Liao, QJ				Lin, Jinguan; Xia, Longzheng; Oyang, Linda; Liang, Jiaxin; Tan, Shiming; Wu, Nayiyuan; Yi, Pin; Pan, Qing; Rao, Shan; Han, Yaqian; Tang, Yanyan; Su, Min; Luo, Xia; Yang, Yiqing; Chen, Xiaohui; Yang, Lixia; Zhou, Yujuan; Liao, Qianjin			The POU2F1-ALDOA axis promotes the proliferation and chemoresistance of colon cancer cells by enhancing glycolysis and the pentose phosphate pathway activity	ONCOGENE			English	Article							BREAST-CANCER; RESISTANCE; OXALIPLATIN; APOPTOSIS; TRANSCRIPTION; ALDOLASE; INSIGHTS	Cancer metabolic reprogramming enhances its malignant behaviors and drug resistance, which is regulated by POU domain transcription factors. This study explored the effect of POU domain class 2 transcription factor 1 (POU2F1) on metabolic reprogramming in colon cancer. The POU2F1 expression was analyzed in GEO dataset, TCGA cohorts and human colon cancer tissues by bioinformatics and immunohistochemistry. The effects of altered POU2F1 expression on proliferation, glucose metabolism and oxaliplatin sensitivity of colon cancer cells were tested. The impacts of POU2F1 on aldolase A (ALDOA) expression and malignant behaviors of colon cancer cells were examined. We found that up-regulated POU2F1 expression was associated with worse prognosis and oxaliplatin resistance in colon cancer. POU2F1 enhanced the proliferation, aerobic glycolysis and the pentose phosphate pathway (PPP) activity, but reduced oxidative stress and apoptosis in colon cancer cells, dependent on up-regulating ALDOA expression. Mechanistically, POU2F1 directly bound to the ALDOA promoter to enhance the ALDOA promoter activity in colon cancer cells. Moreover, activation of the POU2F1-ALDOA axis decreased the sensitivity to oxaliplatin in colon cancer cells. These data indicate that the POU2F1-ALDOA axis promotes the progression and oxaliplatin resistance by enhancing metabolic reprogramming in colon cancer. Our findings suggest that the POU2F1-ALDOA axis may be new therapeutic targets to overcome oxaliplatin resistance in colon cancer.	[Lin, Jinguan; Xia, Longzheng; Oyang, Linda; Liang, Jiaxin; Tan, Shiming; Wu, Nayiyuan; Yi, Pin; Pan, Qing; Rao, Shan; Han, Yaqian; Tang, Yanyan; Su, Min; Luo, Xia; Yang, Yiqing; Chen, Xiaohui; Yang, Lixia; Zhou, Yujuan; Liao, Qianjin] Cent South Univ, Hunan Canc Hosp, Hunan Key Lab Canc Metab, Changsha 410013, Hunan, Peoples R China; [Lin, Jinguan; Xia, Longzheng; Oyang, Linda; Liang, Jiaxin; Tan, Shiming; Wu, Nayiyuan; Yi, Pin; Pan, Qing; Rao, Shan; Han, Yaqian; Tang, Yanyan; Su, Min; Luo, Xia; Yang, Yiqing; Chen, Xiaohui; Yang, Lixia; Zhou, Yujuan; Liao, Qianjin] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha 410013, Hunan, Peoples R China; [Yi, Pin; Pan, Qing] Univ South China, Hengyang 421001, Hunan, Peoples R China; [Zhou, Yujuan; Liao, Qianjin] Hunan Key Lab Translat Radiat Oncol, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China	Central South University; Central South University; University of South China	Zhou, YJ; Liao, QJ (corresponding author), Cent South Univ, Hunan Canc Hosp, Hunan Key Lab Canc Metab, Changsha 410013, Hunan, Peoples R China.; Zhou, YJ; Liao, QJ (corresponding author), Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha 410013, Hunan, Peoples R China.; Zhou, YJ; Liao, QJ (corresponding author), Hunan Key Lab Translat Radiat Oncol, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	yujany_zhou@163.com; march-on@126.com			National Natural Science Foundation of China [82173142, 81972636, 81872281, 81772842]; Natural Science Foundation of Hunan Province [2020JJ5336, 2019JJ40175, 2019JJ40183, 2018JJ1013]; Research Project of Health Commission of Hunan Province [202203034978, 202109031837, 20201020]; China Hunan Provincial Science and Technology Department [2018SK7005]; Ascend Foundation of National Cancer Center [NCC2018b68]; Hunan Cancer Hospital Climb Plan [ZX2020001-3, YF2020002]; Fundamental Research Funds for the Central Universities of Central South University [2019zzts832, 2019zzts833]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Research Project of Health Commission of Hunan Province; China Hunan Provincial Science and Technology Department; Ascend Foundation of National Cancer Center; Hunan Cancer Hospital Climb Plan; Fundamental Research Funds for the Central Universities of Central South University	This work was supported in part by grants from the following sources: the National Natural Science Foundation of China (82173142, 81972636, 81872281, 81772842), the Natural Science Foundation of Hunan Province (2020JJ5336, 2019JJ40175, 2019JJ40183, 2018JJ1013), the Research Project of Health Commission of Hunan Province (202203034978, 202109031837, 20201020), China Hunan Provincial Science and Technology Department (2018SK7005), Ascend Foundation of National Cancer Center (NCC2018b68), and Supported By Hunan Cancer Hospital Climb Plan (ZX2020001-3, YF2020002) and By the Fundamental Research Funds for the Central Universities of Central South University (2019zzts832, 2019zzts833).	Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Benson AB, 2018, J NATL COMPR CANC NE, V16, P359, DOI 10.6004/jnccn.2018.0021; Bidkhori G, 2018, P NATL ACAD SCI USA, V115, pE11874, DOI 10.1073/pnas.1807305115; Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532; Bu PC, 2018, CELL METAB, V27, P1249, DOI 10.1016/j.cmet.2018.04.003; Cao PH, 2019, INT J BIOL SCI, V15, P1676, DOI 10.7150/ijbs.35265; Chen Q, 2020, LEUKEMIA, V34, P2736, DOI 10.1038/s41375-020-0801-5; Cheng CY, 2018, BIOMED PHARMACOTHER, V108, P194, DOI 10.1016/j.biopha.2018.09.031; Costanzo P, 1999, FEBS LETT, V454, P61, DOI 10.1016/S0014-5793(99)00775-9; Dai Ling, 2018, Cancer Manag Res, V10, P1799, DOI 10.2147/CMAR.S157925; Fan JJ, 2017, GENET MOL RES, V16, DOI 10.4238/gmr16039234; Fionda C, 2019, CANCERS, V11, DOI 10.3390/cancers11060810; Gold DA, 2014, MOL BIOL EVOL, V31, P3136, DOI 10.1093/molbev/msu243; Herbert K, 2019, GENE DEV, V33, P310, DOI 10.1101/gad.314633.118; Jiang ZH, 2018, J CELL MOL MED, V22, P4377, DOI 10.1111/jcmm.13732; Kawai K, 2017, INT J ONCOL, V50, P525, DOI 10.3892/ijo.2016.3814; Kondaveeti Y, 2015, CANCER LETT, V364, P44, DOI 10.1016/j.canlet.2015.04.025; Kuo CC, 2019, THERANOSTICS, V9, P2526, DOI 10.7150/thno.32915; Li QG, 2016, MOL CANCER RES, V14, P830, DOI 10.1158/1541-7786.MCR-16-0032; Lopez-Bertoni H, 2020, CANCER RES, V80, P1644, DOI 10.1158/0008-5472.CAN-19-1624; Maddox J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003048; Mou JJ, 2018, BIOMED PHARMACOTHER, V103, P729, DOI 10.1016/j.biopha.2018.04.099; Ortmayr K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09695-9; Pages F, 2020, ANN ONCOL, V31, P921, DOI 10.1016/j.annonc.2020.03.310; Pankratova EV, 1998, FEBS LETT, V426, P81, DOI 10.1016/S0014-5793(98)00316-0; Park JS, 2020, NATURE, V578, P621, DOI 10.1038/s41586-020-1998-1; Petr MA, 2020, TRENDS CELL BIOL, V30, P117, DOI 10.1016/j.tcb.2019.12.001; Pierce CJ, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00247-1; Ramanathan B, 2005, CANCER RES, V65, P8455, DOI 10.1158/0008-5472.CAN-05-1162; Sau A, 2018, ACS APPL MATER INTER, V10, P4582, DOI 10.1021/acsami.7b18837; Schworer S, 2019, CELL METAB, V29, P576, DOI 10.1016/j.cmet.2019.01.015; Shakya A, 2009, NAT CELL BIOL, V11, P320, DOI 10.1038/ncb1840; Sharpe DJ, 2014, ONCOTARGET, V5, P8803, DOI 10.18632/oncotarget.2492; Tantin D, 2013, DEVELOPMENT, V140, P2857, DOI 10.1242/dev.095927; Tharp ME, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14055-8; Vazquez-Arreguin K, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007687; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wazir U, 2019, CANCER GENOM PROTEOM, V16, P121, DOI 10.21873/cgp.20117; Wu D, 2020, BIOCHEM BIOPH RES CO, V533, P533, DOI 10.1016/j.bbrc.2020.09.003; Yu JW, 2019, MED SCI MONITOR, V25, P1204, DOI 10.12659/MSM.912109; Yu LL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14437-3; Zheng PL, 2018, CELL RES, V28, P833, DOI 10.1038/s41422-018-0065-z; Zhu HY, 2017, AM J CANCER RES, V7, P1665	43	4	5	7	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1024	1039		10.1038/s41388-021-02148-y	http://dx.doi.org/10.1038/s41388-021-02148-y		JAN 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34997215	Green Published, hybrid			2022-12-28	WOS:000740148300001
J	Zhang, YJ; Zhang, YX; Ai, B; Gong, JJ; Li, YC; Yu, SY; Cai, XY; Zhang, L				Zhang, Yujie; Zhang, Yuxin; Ai, Bo; Gong, Juejun; Li, Yichen; Yu, Shiying; Cai, Xiuyu; Zhang, Li			GTF2E2 is a novel biomarker for recurrence after surgery and promotes progression of esophageal squamous cell carcinoma via miR-139-5p/GTF2E2/FUS axis	ONCOGENE			English	Article							TRANSCRIPTION; EXPRESSION; TFIIE; MUTATIONS; MICRORNAS; COMPLEX	Esophageal squamous cell carcinoma (ESCC) is one of the most lethal gastrointestinal malignancies with high mortality. Recurrence develops within only a few years after curative resection and perioperative adjuvant therapy in 30-50% of these patients. Therefore, it is essential to identify postoperative recurrence biomarkers to facilitate selecting the following surveillance and therapeutic strategies. The general transcription factor IIE subunit beta (GTF2E2) is crucial for physiological and pathological functions, but its roles in the aggression and recurrence of ESCC remain ambiguous. In this study, we found that GTF2E2 was highly expressed in ESCC samples, and elevated GTF2E2 expression predicted early recurrence after surgery for ESCC patients. High expression of GTF2E2 associated with more aggressive clinic features and poor prognosis. GTF2E2 promoted the proliferation and mobility of ESCC cells in vitro and in vivo. We further revealed that miR-139-5p repressed GTF2E2 expression by downregulating its mRNA through binding with Argonaute 2 (Ago2). Rescue assays suggested that miR-139-5p affected GTF2E2-mediated ESCC progression. Moreover, GTF2E2 positively interacted with FUS promoter and regulated FUS expression, and the phenotype changes caused by GTF2E2 manipulation were recovered by rescuing FUS expression in ESCC cells. Additionally, we demonstrated that GTF2E2 promotes ESCC cells progression via activation of the AKT/ERK/mTOR pathway. In conclusion, GTF2E2 may serve as a novel biomarker for recurrence after surgery and a potential therapeutic target for ESCC patients, and it promotes ESCC progression via miR-139-5p/GTF2E2/FUS axis.	[Zhang, Yujie; Gong, Juejun; Li, Yichen; Yu, Shiying; Zhang, Li] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Zhang, Yuxin] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Ai, Bo] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Thorac Surg Ctr, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Cai, Xiuyu] Sun Yet Sen Univ, Collaborat Innovat Ctr Canc Med, Dept VIP Inpatient, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; State Key Lab Oncology South China; Sun Yat Sen University	Yu, SY; Zhang, L (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.; Cai, XY (corresponding author), Sun Yet Sen Univ, Collaborat Innovat Ctr Canc Med, Dept VIP Inpatient, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.	syyu_qh@163.com; caixy_84@outlook.com; luzigang@163.com	yuxin, Zhang/GNH-2283-2022	zhang, yujie/0000-0002-9109-3171; Cai, Xiuyu/0000-0002-5251-9272	National Science Foundation of China [81572934, 82172825]; Chinese Society of Clinical Oncology Foundation [Y-BMS2019070]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Society of Clinical Oncology Foundation	This work was supported by the National Science Foundation of China (No. 81572934, 82172825) and Chinese Society of Clinical Oncology Foundation (No. Y-BMS2019070).	Baiu Ioana, 2020, JAMA, V324, P1580, DOI 10.1001/jama.2020.2101; Bakir B, 2020, TRENDS CELL BIOL, V30, P764, DOI 10.1016/j.tcb.2020.07.003; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bi GS, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01878-z; Borggreve AS, 2018, ANN NY ACAD SCI, V1434, P192, DOI 10.1111/nyas.13677; Compe E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10131-1; Davies AR, 2014, J SURG ONCOL, V109, P459, DOI 10.1002/jso.23511; Dhar SK, 2014, ANTIOXID REDOX SIGN, V20, P1550, DOI 10.1089/ars.2012.4984; Ding ZY, 2014, HEPATOLOGY, V60, P1620, DOI 10.1002/hep.27273; Du F, 2020, THERANOSTICS, V10, P7335, DOI 10.7150/thno.45971; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Dziuba N, 2012, AIDS RES HUM RETROV, V28, P1329, DOI 10.1089/aid.2011.0358; Elkayam E, 2012, CELL, V150, P100, DOI 10.1016/j.cell.2012.05.017; Feng Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2028-9; Gao L, 2019, CELL DEATH DIS, V10, DOI [10.1038/s41419-019-1971, 10.1038/s41419-019-1971-9]; Hamai Y, 2018, WORLD J SURG, V42, P2190, DOI 10.1007/s00268-017-4430-8; Hua SN, 2018, ONCOGENE, V37, P1624, DOI 10.1038/s41388-017-0057-3; Jiao WP, 2019, DIGEST LIVER DIS, V51, P149, DOI 10.1016/j.dld.2018.07.017; Kakeji Y, 2021, ESOPHAGUS-TOKYO, V18, P25, DOI 10.1007/s10388-020-00782-1; Kuschal C, 2016, AM J HUM GENET, V98, P627, DOI 10.1016/j.ajhg.2016.02.008; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Liu R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077068; Liu SX, 2021, J CELL PHYSIOL, V236, P79, DOI 10.1002/jcp.29481; LoRusso PM, 2016, J CLIN ONCOL, V34, P3803, DOI 10.1200/JCO.2014.59.0018; Lu TX, 2018, J ALLERGY CLIN IMMUN, V141, P1202, DOI 10.1016/j.jaci.2017.08.034; Mariette C, 2003, CANCER-AM CANCER SOC, V97, P1616, DOI 10.1002/cncr.11228; Miwa K, 2016, J MOL BIOL, V428, P4258, DOI 10.1016/j.jmb.2016.09.008; Montero-Conde C, 2020, INT J CANCER, V146, P521, DOI 10.1002/ijc.32622; Ni WJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6622-0; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Roskoski R, 2019, PHARMACOL RES, V142, P151, DOI 10.1016/j.phrs.2019.01.039; Schirle NT, 2014, SCIENCE, V346, P608, DOI 10.1126/science.1258040; Tang S, 2021, CANCER IMAGING, V21, DOI 10.1186/s40644-021-00407-5; Thei AF, 2019, AM J HUM GENET, V105, P434, DOI 10.1016/j.ajhg.2019.06.017; Theil AF, 2017, HUM MOL GENET, V26, P4689, DOI 10.1093/hmg/ddx351; Wang ZJ, 2020, J ONCOL, V2020, DOI 10.1155/2020/8813800; Wei WQ, 2020, LANCET ONCOL, V21, pE342, DOI 10.1016/S1470-2045(20)30073-5; Wen J, 2021, ANN SURG, V273, P523, DOI 10.1097/SLA.0000000000003369; Wu Q, 2020, CANCER BIOL THER, V21, P17, DOI 10.1080/15384047.2019.1647050; Yang H, 2018, J CLIN ONCOL, V36, P2796, DOI 10.1200/JCO.2018.79.1483; Yang LW, 2020, WORLD NEUROSURG, V138, pE492, DOI 10.1016/j.wneu.2020.02.159; Yang M, 2013, ONCOL REP, V29, P169, DOI 10.3892/or.2012.2105; Yang S, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00981-4; Yang YM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00323-3; Zhu ZJ, 2011, ANN THORAC SURG, V91, P1502, DOI 10.1016/j.athoracsur.2011.01.007	46	0	0	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					782	796		10.1038/s41388-021-02122-8	http://dx.doi.org/10.1038/s41388-021-02122-8		DEC 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34853466	hybrid, Green Published			2022-12-28	WOS:000724661100001
J	Yi, BZ; Wang, SB; Wang, XR; Liu, ZC; Zhang, C; Li, M; Gao, S; Wei, S; Bae, S; Stringer-Reasor, E; Wang, LZ; Liu, RH				Yi, Baozhu; Wang, Shuaibin; Wang, Xinran; Liu, Zhichao; Zhang, Chao; Li, Ming; Gao, Song; Wei, Shi; Bae, Sejong; Stringer-Reasor, Erica; Wang, Lizhong; Liu, Runhua			CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer	ONCOGENE			English	Article							TRANSCRIPTIONAL REPRESSOR HBP1; BETA-CATENIN; INVASION; PATHWAY; FOXP3; EXPRESSION; MICRORNAS; MIR-3662; THERAPY; COMPLEX	MicroRNA-3662 (miR-3662) is minimally expressed in normal human tissues but is highly expressed in all types of cancers, including breast cancer. As determined with The Cancer Genome Atlas dataset, miR-3662 expression is higher in triple-negative breast cancers (TNBCs) and African American breast cancers than in other breast cancer types. However, the functional role of miR-3662 remains a topic of debate. Here, we found that inhibition or knockout of endogenous, mature miR-3662 in TNBC cells suppresses proliferation and migration in vitro and tumor growth and metastasis in vivo. Functional analysis revealed that, for TNBC cells, knockout of miR-3662 reduces the activation of Wnt/beta-catenin signaling. Furthermore, using CRISPR-mediated miR-3662 activation and repression, dual-luciferase assays, and miRNA/mRNA immunoprecipitation assays, we established that HMG-box transcription factor 1 (HBP-1), a Wnt/beta-catenin signaling inhibitor, is a target of miR-3662 and is most likely responsible for miR-3662-mediated TNBC cell proliferation. Our results suggest that miR-3662 has an oncogenic function in tumor progression and metastasis via an miR-3662-HBP1 axis, regulating the Wnt /beta-catenin signaling pathway in TNBC cells. Since miR-3662 expression occurs a tumor-specific manner, it is a promising biomarker and therapeutic target for patients who have TNBCs with dysregulation of miR-3662, especially African Americans.	[Yi, Baozhu; Wang, Shuaibin; Wang, Xinran; Liu, Zhichao; Zhang, Chao; Li, Ming; Gao, Song; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA; [Wei, Shi; Bae, Sejong; Stringer-Reasor, Erica; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA; [Wei, Shi] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Bae, Sejong; Stringer-Reasor, Erica] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Wang, LZ; Liu, RH (corresponding author), Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.; Wang, LZ; Liu, RH (corresponding author), Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA.	lwang12@uab.edu; runhua@uab.edu		LI, Ming/0000-0002-4198-8807; bae, sejong/0000-0001-9982-3223	National Cancer Institute [CA223077, CA238273, CA242917]; Breast Cancer Research Foundation of Alabama	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation of Alabama	We thank Dr. Donald Hill for editorial assistance in preparing this manuscript. This work was supported by grants from the National Cancer Institute (CA223077, CA238273 and CA242917 for R. Liu) and the Breast Cancer Research Foundation of Alabama (L. Wang). Results are based, in part, upon data generated by TCGA Research Network: http://cancergenome.nih.gov/.	Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048; Berasi SP, 2004, MOL CELL BIOL, V24, P3011, DOI 10.1128/MCB.24.7.3011-3024.2004; Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543; Bollaert E, 2019, CELL MOL LIFE SCI, V76, P1529, DOI 10.1007/s00018-019-03012-9; Caparica R, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000504; Chen ZQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0616-8; Cicekdal MB, 2021, BRIT J NUTR, V125, P1, DOI 10.1017/S0007114519002757; Cittelly DM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-317; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Gao S, 2017, ONCOTARGET, V8, P41451, DOI 10.18632/oncotarget.17816; Gao YC, 2016, NAT METHODS, V13, P1043, DOI [10.1038/NMETH.4042, 10.1038/nmeth.4042]; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Hansen TB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010961; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu RH, 2015, CANCER RES, V75, P1714, DOI 10.1158/0008-5472.CAN-14-2109; Liu RH, 2015, CANCER RES, V75, P1703, DOI 10.1158/0008-5472.CAN-14-2108; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maharry SE, 2016, CANCER DISCOV, V6, P1036, DOI 10.1158/2159-8290.CD-16-0023; O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402; Powrozek T, 2017, J CANCER RES CLIN, V143, P1941, DOI 10.1007/s00432-017-2444-0; Powrozek T, 2015, TRANSL RES, V166, P315, DOI 10.1016/j.trsl.2015.05.009; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Shi YX, 2017, MED SCI MONITOR, V23, P2042, DOI 10.12659/MSM.901191; Shih HH, 2001, MOL CELL BIOL, V21, P5723, DOI 10.1128/MCB.21.17.5723-5732.2001; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tang J, 2012, INT J MOL SCI, V13, P13414, DOI 10.3390/ijms131013414; van Schooneveld E, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0526-y; Wang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6909; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Wang M, 2020, MOL CANCER RES, V18, P943, DOI 10.1158/1541-7786.MCR-19-1033; Wang YC, 2019, ONCOGENE, V38, P4820, DOI 10.1038/s41388-019-0760-3; Xiu M, 2003, MOL CELL BIOL, V23, P8890, DOI 10.1128/MCB.23.23.8890-8901.2003; Xu JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117097; Xu SH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11406; Ye J, 2020, NEOPLASMA, V67, P773, DOI 10.4149/neo_2020_190730N689; Yee AS, 2004, GENE, V336, P1, DOI 10.1016/j.gene.2004.04.004; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang GX, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0858-x; Zhang W, 2016, CLIN CANCER RES, V22, P2545, DOI 10.1158/1078-0432.CCR-15-1927; Zhu L, 2019, CANCER MANAG RES, V11, P5845, DOI 10.2147/CMAR.S200540	48	2	2	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					268	279		10.1038/s41388-021-02089-6	http://dx.doi.org/10.1038/s41388-021-02089-6		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34728806	Green Accepted			2022-12-28	WOS:000713936100001
J	Yu, SY; Zang, WC; Qiu, YC; Liao, LM; Zheng, XF				Yu, Shuyu; Zang, Weicheng; Qiu, Yuchong; Liao, Liming; Zheng, Xiaofeng			Deubiquitinase OTUB2 exacerbates the progression of colorectal cancer by promoting PKM2 activity and glycolysis	ONCOGENE			English	Article							KINASE; GROWTH; DEGRADATION; SUPPRESS; PATHWAY; PARKIN; SWITCH	Aberrant regulation of ubiquitination often leads to metabolic reprogramming in tumor cells. However, the underlying mechanisms are not fully understood. Here we demonstrate that OTUB2, an OTU deubiquitinase, is upregulated in colorectal cancer (CRC) and exacerbates the progression of CRC through modulating the aerobic glycolysis. Mechanistically, OTUB2 directly interacts with pyruvate kinase M2 (PKM2) and inhibits its ubiquitination by blocking the interaction between PKM2 and its ubiquitin E3 ligase Parkin, thereby enhancing PKM2 activity and promoting glycolysis. In response to glucose starvation stress, the effect of OTUB2 on PKM2 is enhanced, which confers metabolic advantage to CRC cells. Moreover, OTUB2 depletion reduces glucose consumption, lactate production, and cellular ATP production. OTUB2-knockout CRC cells exhibit attenuated proliferation and migration, as well as an elevated level of apoptosis and increased sensitivity to chemotherapy drugs. Furthermore, in vivo assays show that knockout of OTUB2 inhibits tumor growth in mice. Taken together, these findings reveal the critical role of OTUB2 in the regulation of glycolysis and illustrate the molecular mechanism underlying its role as a negative regulator of PKM2 ubiquitination in CRC, establishing a bridge between OTUB2-regulated PKM2 ubiquitination and altered metabolic patterns in CRC and suggesting that OTUB2 is a promising target for CRC treatment.	[Yu, Shuyu; Zang, Weicheng; Qiu, Yuchong; Liao, Liming; Zheng, Xiaofeng] Peking Univ, Sch Life Sci, State Key Lab Prot & Plant Gene Res, Beijing, Peoples R China; [Yu, Shuyu; Zang, Weicheng; Qiu, Yuchong; Liao, Liming; Zheng, Xiaofeng] Peking Univ, Sch Life Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China	Peking University; Peking University	Zheng, XF (corresponding author), Peking Univ, Sch Life Sci, State Key Lab Prot & Plant Gene Res, Beijing, Peoples R China.; Zheng, XF (corresponding author), Peking Univ, Sch Life Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China.	xiaofengz@pku.edu.cn			National Natural Science Foundation of China [81730080, 82130081]; Beijing Natural Science Foundation [5212008]; National Key Research and Development Program of China [2016YFC1302401]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); National Key Research and Development Program of China	This work was supported by the National Natural Science Foundation of China (grant nos. 81730080 and 82130081), Beijing Natural Science Foundation (5212008), and the National Key Research and Development Program of China (grant no. 2016YFC1302401). We sincerely thank Prof. Lingqiang Zhang for providing human deubiquitinase OTU subfamily plasmids, Prof. Wensheng Wei for providing the CRISPR/Cas9 related plasmids, Prof. Jianguo Ji for providing HT-29 cell line, Prof. Dajun Deng for providing CCD-18Co cell line, Prof. Binghui Li for providing FHC cell line, and Prof. Zhijie Chang for providing NCM460 and DLD-1 cell lines. We thank the National Center for Protein Sciences at Peking University, particularly Guilan Li, Jia Luo, Yinghua Guo, Liying Du and Hongxia Lv for technical help. We also appreciate the assistance of Dong Liu, Xiaochen Li and Liqin Fu from the Core Facilities of Life Sciences at Peking University for their assistance with the protein MS analysis work and microscopic imaging.	Beck A, 2013, DIABETOLOGIA, V56, P1317, DOI 10.1007/s00125-013-2889-x; Bhardwaj A, 2016, P NATL ACAD SCI USA, V113, pE538, DOI 10.1073/pnas.1520045113; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai JL, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01324; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Choi HS, 2020, CANCERS, V12, DOI 10.3390/cancers12061548; Clague MJ, 2019, NAT REV MOL CELL BIO, V20, P338, DOI 10.1038/s41580-019-0099-1; Dang CV, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.297pe75; Das Gupta K, 2020, CELL REP, V30, P2712, DOI 10.1016/j.celrep.2020.02.007; Dayton TL, 2016, EMBO REP, V17, P1721, DOI 10.15252/embr.201643300; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Diefenbacher ME, 2014, J CLIN INVEST, V124, P3407, DOI 10.1172/JCI73733; Feng YL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2278-6; FITZMAURICE C, 2018, J CLIN ONCOL, V36; Gu ZL, 2020, KAOHSIUNG J MED SCI, V36, P399, DOI 10.1002/kjm2.12187; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; HAN C, 2016, NAT COMMUN, V7; Harper JW, 2018, NAT REV MOL CELL BIO, V19, P93, DOI 10.1038/nrm.2017.129; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hou PP, 2020, MOL CELL, V78, P1192, DOI 10.1016/j.molcel.2020.05.004; Iansante V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8882; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Jin X, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.21; Johmura Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep31194; Kato K, 2014, MOL CELL, V53, P617, DOI 10.1016/j.molcel.2014.01.030; Kim SR, 2015, INT J ONCOL, V46, P2116, DOI 10.3892/ijo.2015.2901; Kwasna D, 2018, MOL CELL, V70, P150, DOI 10.1016/j.molcel.2018.02.023; Lee HJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10374-y; Lee SB, 2019, NAT CELL BIOL, V21, P940, DOI 10.1038/s41556-019-0356-8; Li J, 2019, THERANOSTICS, V9, P179, DOI 10.7150/thno.29545; Li S, 2010, J BIOL CHEM, V285, P4291, DOI 10.1074/jbc.M109.074971; Li XY, 2018, BIOCHEM BIOPH RES CO, V505, P113, DOI 10.1016/j.bbrc.2018.09.071; Liang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12431; Lim KS, 2018, MOL CELL, V72, P925, DOI 10.1016/j.molcel.2018.10.045; Liu FB, 2017, NAT CELL BIOL, V19, P1358, DOI 10.1038/ncb3630; Liu J, 2020, J CLIN INVEST, V130, P3253, DOI 10.1172/JCI132876; Liu K, 2016, J BIOL CHEM, V291, P10307, DOI 10.1074/jbc.M115.703066; Lv L, 2013, MOL CELL, V52, P340, DOI 10.1016/j.molcel.2013.09.004; Ma YF, 2019, CANCER MANAG RES, V11, P13, DOI 10.2147/CMAR.S184781; Macintyre AN, 2011, MOL CELL, V42, P713, DOI 10.1016/j.molcel.2011.06.003; Novellasdemunt L, 2017, CELL REP, V21, P612, DOI 10.1016/j.celrep.2017.09.072; Ordureau A, 2020, MOL CELL, V77, P1124, DOI 10.1016/j.molcel.2019.11.013; Park SH, 2016, CANCER RES, V76, P3802, DOI 10.1158/0008-5472.CAN-15-2498; Qi HL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1271-9; Shang Y, 2017, ONCOGENE, V36, P4191, DOI 10.1038/onc.2017.31; Singh JP, 2020, ONCOGENE, V39, P560, DOI 10.1038/s41388-019-0975-3; Sobol A, 2017, MOL CANCER RES, V15, P117, DOI 10.1158/1541-7786.MCR-16-0281-T; Spoden GA, 2009, J CELL BIOCHEM, V107, P293, DOI 10.1002/jcb.22125; Viana R, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858-015-0053-6; Wang B, 2017, NATURE, V545, P365, DOI 10.1038/nature22344; Wang Y, 2017, P NATL ACAD SCI USA, V114, P13732, DOI 10.1073/pnas.1704145115; Xing C, 2016, CANCER RES, V76, P83, DOI 10.1158/0008-5472.CAN-14-3595; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yoshino S, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.19; Yuan L, 2015, NAT CELL BIOL, V17, P1169, DOI 10.1038/ncb3218; Yuan P, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8450606; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030	60	7	8	8	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					46	56		10.1038/s41388-021-02071-2	http://dx.doi.org/10.1038/s41388-021-02071-2		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34671086				2022-12-28	WOS:000709271000001
J	Cao, CH; Ling, H; Han, K; Lu, XP; Cai, MY; Cao, JH; Zhou, J; Xiang, ZC; Chen, JW; Li, S; Lin, JL; Duan, JL; Luo, J; Fang, YJ; Pan, ZZ; Liang, L; Wang, F; Xie, D; Wang, FW				Cao, Chen-Hui; Ling, Han; Han, Kai; Lu, Xiao-Peng; Cai, Mu-Yan; Cao, Jing-Hua; Zhou, Jie; Xiang, Zhi-Cheng; Chen, Jie-Wei; Li, Si; Lin, Jin-Long; Duan, Jin-Ling; Luo, Jie; Fang, Yu-Jing; Pan, Zhi-Zhong; Liang, Li; Wang, Feng; Xie, Dan; Wang, Feng-Wei			PPIP5K2 promotes colorectal carcinoma pathogenesis through facilitating DNA homologous recombination repair	ONCOGENE			English	Article							NUCLEAR EXPORT; C-ABL; PROTEIN; PHOSPHORYLATION; CANCER; PATHWAYS; COMPLEX; HEALTH; CELLS; AKT	Colorectal carcinoma (CRC) is the second most deadly cancer worldwide. Therapies that take advantage of DNA repair defects have been explored in various tumors but not yet systematically in CRC. Here, we found that Diphosphoinositol Pentakisphosphate Kinase 2 (PPIP5K2), an inositol pyrophosphate kinase, was highly expressed in CRC and associated with a poor prognosis of CRC patients. In vitro and in vivo functional studies demonstrated that PPIP5K2 could promote the proliferation and migration ability of CRC cells independent of its inositol pyrophosphate kinase activity. Mechanically, S1006 dephosphorylation of PPIP5K2 could accelerate its dissociation with 14-3-3 in the cytoplasm, resulting in more nuclear distribution. Moreover, DNA damage treatments such as doxorubicin (DOX) or irradiation (IR) could induce nuclear translocation of PPIP5K2, which subsequently promoted homologous recombination (HR) repair by binding and recruiting RPA70 to the DNA damage site as a novel scaffold protein. Importantly, we verified that S1006 dephosphorylation of PPIP5K2 could significantly enhance the DNA repair ability of CRC cells through a series of DNA repair phenotype assays. In conclusion, PPIP5K2 is critical for enhancing the survival of CRC cells via facilitating DNA HR repair. Our findings revealed an unrecognized biological function and mechanism model of PPIP5K2 dependent on S1006 phosphorylation and provided a potential therapeutic target for CRC patients.	[Cao, Chen-Hui; Ling, Han; Han, Kai; Cai, Mu-Yan; Cao, Jing-Hua; Zhou, Jie; Xiang, Zhi-Cheng; Chen, Jie-Wei; Li, Si; Lin, Jin-Long; Duan, Jin-Ling; Luo, Jie; Fang, Yu-Jing; Pan, Zhi-Zhong; Wang, Feng; Xie, Dan; Wang, Feng-Wei] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510060, Peoples R China; [Han, Kai; Fang, Yu-Jing; Pan, Zhi-Zhong] Sun Yat Sen Univ, Dept Colorectal Surg, Ctr Canc, Guangzhou 510060, Peoples R China; [Lu, Xiao-Peng] Shenzhen Univ, Sch Med, Dept Biochem & Mol Biol, Guangdong Key Lab Genome Instabil & Human Dis Pre, Shenzhen 518055, Peoples R China; [Cai, Mu-Yan; Chen, Jie-Wei; Xie, Dan] Sun Yat Sen Univ, Dept Pathol, Ctr Canc, Guangzhou 510060, Peoples R China; [Liang, Li] Southern Med Univ, Dept Pathol, Guangzhou 510060, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Shenzhen University; Sun Yat Sen University; Southern Medical University - China	Xie, D; Wang, FW (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510060, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ, Dept Pathol, Ctr Canc, Guangzhou 510060, Peoples R China.	xiedan@sysucc.org.cn; wangfengw@sysucc.org.cn		Cao, Chenhui/0000-0002-8119-0613	National Key R&D Program of China [2017YFC1309000]; National Natural Science Foundation of China [81972227, 81730072, 82072608, 81872001, 82002467]; Natural Science Foundation of Guangdong [2020A151501021, 2020A1515011020]; Guangzhou Science and Technology Plan Projects [201904020044]; China Postdoctoral Science Foundation [2020M672999]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Plan Projects; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from the National Key R&D Program of China [grant number 2017YFC1309000]; the National Natural Science Foundation of China [grant numbers 81972227, 81730072, 82072608, 81872001, and 82002467]; the Natural Science Foundation of Guangdong [grant numbers 2020A151501021 and 2020A1515011020]; the Guangzhou Science and Technology Plan Projects [grant number 201904020044] and the China Postdoctoral Science Foundation (2020M672999).	Aghazadeh Y, 2016, DRUG DISCOV TODAY, V21, P278, DOI 10.1016/j.drudis.2015.09.012; Ashworth A, 2018, NAT REV CLIN ONCOL, V15, P564, DOI 10.1038/s41571-018-0055-6; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bhat KP, 2018, NAT STRUCT MOL BIOL, V25, P446, DOI 10.1038/s41594-018-0075-z; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai MY, 2020, CELL REP, V30, P2402, DOI 10.1016/j.celrep.2020.01.052; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chakraborty A, 2018, BIOL REV, V93, P1203, DOI 10.1111/brv.12392; Chen Huarong, 2017, Oncotarget, V8, P95054, DOI 10.18632/oncotarget.10982; Cremolini C, 2015, NAT REV CLIN ONCOL, V12, P607, DOI 10.1038/nrclinonc.2015.129; Fanning E, 2006, NUCLEIC ACIDS RES, V34, P4126, DOI 10.1093/nar/gkl550; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gao SS, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba7822; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Gu CF, 2017, P NATL ACAD SCI USA, V114, P11968, DOI 10.1073/pnas.1702370114; Han K, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01184-8; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Hou ZY, 2010, CANCER RES, V70, P4385, DOI 10.1158/0008-5472.CAN-10-0070; Jadav RS, 2016, CELL SIGNAL, V28, P1124, DOI 10.1016/j.cellsig.2016.04.011; Khaled ML, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55866-5; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Liu HP, 2018, NATURE, V563, P131, DOI 10.1038/s41586-018-0629-6; Liu J, 2010, NAT STRUCT MOL BIOL, V17, P1260, DOI 10.1038/nsmb.1904; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; Machkalyan Gayane, 2016, J Mol Signal, V11, P4, DOI 10.5334/1750-2187-11-4; Marechal A, 2015, CELL RES, V25, P9, DOI 10.1038/cr.2014.147; Moon S, 2017, EMBO REP, V18, P61, DOI 10.15252/embr.201642683; Morrison BH, 2002, ONCOGENE, V21, P1882, DOI 10.1038/sj.onc.1205265; Nihira K, 2008, ONCOGENE, V27, P7285, DOI 10.1038/onc.2008.334; Pendergast AM, 2005, NAT CELL BIOL, V7, P213, DOI 10.1038/ncb0305-213; Pohlmann J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004586; Pulloor NK, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003981; Randall Thomas A., 2020, Advances in Biological Regulation, V75, P100674, DOI 10.1016/j.jbior.2019.100674; Romanova LY, 2004, ONCOGENE, V23, P9025, DOI 10.1038/sj.onc.1207982; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Thota SG, 2015, J BIOSCIENCES, V40, P593, DOI 10.1007/s12038-015-9549-x; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Wang HC, 2014, CHEM BIOL, V21, P689, DOI 10.1016/j.chembiol.2014.03.009; Wang HC, 2012, NAT CHEM BIOL, V8, P111, DOI 10.1038/nchembio.733; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang QY, 2017, P NATL ACAD SCI USA, V114, pE6054, DOI 10.1073/pnas.1700694114; Yong ST, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860-015-0063-7; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yousaf RW, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007297	48	1	1	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6680	6691		10.1038/s41388-021-02052-5	http://dx.doi.org/10.1038/s41388-021-02052-5		OCT 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34645979				2022-12-28	WOS:000706949900002
J	Zheng, DD; Cao, M; Zuo, SY; Xia, X; Zhi, CC; Lin, YB; Deng, ST; Yuan, XQ				Zheng, Dandan; Cao, Meng; Zuo, Siyu; Xia, Xin; Zhi, Chunchun; Lin, Yanbing; Deng, Sitong; Yuan, Xiaoqin			RANBP1 promotes colorectal cancer progression by regulating pre-miRNA nuclear export via a positive feedback loop with YAP	ONCOGENE			English	Article							MICRORNA BIOGENESIS; PATHWAY; COMPLEX; STEP	Colorectal cancer (CRC) is among the top five most common malignant tumors worldwide and has a high mortality rate. Identification of the mechanism of CRC and potential therapeutic targets is critical for improving survival. In the present study, we observed high expression of RAN binding protein 1 (RANBP1) in CRC tissues. Upregulated RANBP1 expression was strongly associated with TNM stages and was an independent risk factor for poor prognosis. In vitro and in vivo functional experiments demonstrated that RANBP1 promoted the proliferation and invasion of CRC cells and inhibited the apoptosis of CRC cells. Low RANBP1 expression reduced the expression levels of hsa-miR-18a, hsa-miR-183, and hsa-miR-106 microRNAs (miRNAs) by inhibiting the nucleoplasmic transport of precursor miRNAs (pre-miRNAs), thereby promoting the accumulation of the latter in the nucleus and reducing the expression of mature miRNAs. Further experiments and bioinformatic analyses demonstrated that RANBP1 promoted the expression of YAP by regulating miRNAs and the Hippo pathway. We also found that YAP acted as a transcriptional cofactor to activate RANBP1 transcription in combination with TEAD4 transcription factor. Thus, RANBP1 further promoted the progression of CRC by forming a positive feedback loop with YAP. Our results revealed the biological role and mechanism of RANBP1 in CRC for the first time, suggesting that RANBP1 can be used as a diagnostic molecule and a potential therapeutic target in CRC.	[Zheng, Dandan; Zuo, Siyu; Xia, Xin; Lin, Yanbing; Deng, Sitong; Yuan, Xiaoqin] Nanjing Med Univ, Dept Anat Histol & Embryol, Nanjing 211166, Peoples R China; [Cao, Meng] Nanjing Univ, Dept Gen Surg, Nanjing Drum Tower Hosp, Affiliated Hosp,Med Sch, Nanjing 210008, Peoples R China; [Zuo, Siyu] Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Sch Med, Hangzhou 310003, Peoples R China; [Zhi, Chunchun] Nanjing Univ, Nanjing Jinling Hosp, Dept Pathol, Sch Med, Nanjing 210002, Peoples R China; [Yuan, Xiaoqin] Nanjing Med Univ, Key Lab Aging & Dis, Nanjing 211166, Peoples R China	Nanjing Medical University; Nanjing University; Zhejiang University; Nanjing University; Nanjing Medical University	Yuan, XQ (corresponding author), Nanjing Med Univ, Dept Anat Histol & Embryol, Nanjing 211166, Peoples R China.; Yuan, XQ (corresponding author), Nanjing Med Univ, Key Lab Aging & Dis, Nanjing 211166, Peoples R China.	yuanxq@njmu.edu.cn			National Natural Science Foundation of China [81972288]; General Project of the Natural Science Foundation of Jiangsu Province [BK20191353]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); General Project of the Natural Science Foundation of Jiangsu Province	This work was supported by the National Natural Science Foundation of China (no. 81972288) and the General Project of the Natural Science Foundation of Jiangsu Province (no. BK20191353).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Dattilo V, 2017, SCI REP-UK, V7, DOI 10.1038/srep45361; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Kalab P, 2008, J CELL SCI, V121, P1577, DOI 10.1242/jcs.005959; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kim VN, 2004, TRENDS CELL BIOL, V14, P156, DOI 10.1016/j.tcb.2004.02.006; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Muralidhar B, 2011, J PATHOL, V224, P496, DOI 10.1002/path.2898; Nicoli S, 2010, NATURE, V464, P1196, DOI 10.1038/nature08889; Oh D, 2016, P NATL ACAD SCI USA, V113, P8729, DOI 10.1073/pnas.1607498113; Rensen WM, 2009, ONCOGENE, V28, P1748, DOI 10.1038/onc.2009.24; Shigeyasu K, 2017, CLIN CANCER RES, V23, P1312, DOI 10.1158/1078-0432.CCR-16-1023; Shu GS, 2012, PATHOL RES PRACT, V208, P392, DOI 10.1016/j.prp.2012.05.001; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Wagh PK, 2015, J PATHOL, V236, P41, DOI 10.1002/path.4500; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Zhang L, 2015, CURR BIOL, V25, P296, DOI 10.1016/j.cub.2014.11.054; Zhang QM, 2017, AM J CANCER RES, V7, P935; Zhou QW, 2019, CANCER SCI, V110, P1194, DOI 10.1111/cas.13951	37	3	3	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					930	942		10.1038/s41388-021-02036-5	http://dx.doi.org/10.1038/s41388-021-02036-5		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34615998				2022-12-28	WOS:000705759400003
J	Sh, Y; Zhang, XL; Yang, ZM; Dong, JR; Wang, YZ; Zhou, Y; Li, XJ; Guo, CX; Hu, ZY				Sh, Yuan; Zhang, Xiuli; Yang, Zhimin; Dong, Jierong; Wang, Yuanzhuo; Zhou, Ying; Li, Xuejie; Guo, Caixia; Hu, Zhiyuan			CaSee: A lightning transfer-learning model directly used to discriminate cancer/normal cells from scRNA-seq	ONCOGENE			English	Article							MAP	Single-cell RNA sequencing (scRNA-seq) is one of the most efficient technologies for human tumor research. However, data analysis is still faced with technical challenges, especially the difficulty in efficiently and accurately discriminating cancer/normal cells in the scRNA-seq expression matrix. If we can address these challenges, we can have a deeper understanding of the intratumoral and intertumoral heterogeneity. In this study, we developed a cancer/normal cell discrimination pipeline called pan-Cancer Seeker (CaSee) devoted to scRNA-seq expression matrix, which is based on the traditional high-quality pan-cancer bulk sequencing data using transfer learning. CaSee is the first tool directly used to discriminate cancer/normal cells in the scRNA-seq expression matrix, with much wider application fields and higher efficiency than copy number variation (CNV) method which requires corresponding reference cells. CaSee is user-friendly and can adapt to a variety of data sources, including but not limited to scRNA tissue sequencing data, scRNA cell line sequencing data, scRNA xenograft cell sequencing data and scRNA circulating tumor cell sequencing data. It is compatible with mainstream sequencing technology platforms, 10x Genomics Chromium, Smart-seq2, and Microwell-seq. Here, CaSee pipeline exhibited excellent performance in the multicenter data evaluation of 11 retrospective cohorts and one independent dataset, with an average discrimination accuracy of 96.69%. In general, the development of a deep-learning based, pan-cancer cell discrimination model, CaSee, to distinguish cancer cells from normal cells will be compelling to researchers working in the genomics, cancer, and single-cell fields.	[Sh, Yuan; Yang, Zhimin; Zhou, Ying; Li, Xuejie; Hu, Zhiyuan] Fujian Med Univ, Sch Basic Med Sci, Fujian Prov Key Lab Brain Aging & Neurodegenerat, Fuzhou 350108, Fujian, Peoples R China; [Sh, Yuan; Zhang, Xiuli; Yang, Zhimin; Dong, Jierong; Wang, Yuanzhuo; Hu, Zhiyuan] Natl Ctr Nanosci & Technol China, CAS Ctr Excellence Nanosci, CAS Key Lab Standardizat & Measurement Nanotechno, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China; [Guo, Caixia] China Natl Ctr Bioinformat, Beijing, Peoples R China; [Guo, Caixia] Chinese Acad Sci, Beijing Inst Genom, Key Lab Genom & Precis Med, Beijing, Peoples R China; [Hu, Zhiyuan] Univ Chinese Acad Sci, Sch Nanosci & Technol, Sino Danish Coll, Beijing 100049, Peoples R China; [Hu, Zhiyuan] Wuhan Inst Technol, Sch Chem Engn & Pharm, Wuhan 430205, Peoples R China	Fujian Medical University; Chinese Academy of Sciences; National Center for Nanoscience & Technology - China; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Wuhan Institute of Technology	Sh, Y; Zhang, XL; Hu, ZY (corresponding author), Fujian Med Univ, Sch Basic Med Sci, Fujian Prov Key Lab Brain Aging & Neurodegenerat, Fuzhou 350108, Fujian, Peoples R China.; Sh, Y; Zhang, XL; Hu, ZY (corresponding author), Natl Ctr Nanosci & Technol China, CAS Ctr Excellence Nanosci, CAS Key Lab Standardizat & Measurement Nanotechno, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.; Hu, ZY (corresponding author), Univ Chinese Acad Sci, Sch Nanosci & Technol, Sino Danish Coll, Beijing 100049, Peoples R China.; Hu, ZY (corresponding author), Wuhan Inst Technol, Sch Chem Engn & Pharm, Wuhan 430205, Peoples R China.	yuansh3354@163.com; zhangxl2020@nanoctr.cn; huzy@nanoctr.cn		Sh, yuan/0000-0002-6028-0185; Zhang, Xiuli/0000-0002-5694-0101; zm, yang/0000-0002-7527-2313; Hu, Zhiyuan/0000-0003-2212-0268	China Postdoctoral Science Foundation [2021M690806]; Beijing Natural Science Foundation Haidian original innovation joint fund [L202023]; National Natural Science Foundation of China [32027801, 31870992, 21775031]; Strategic Priority Research Program of Chinese Academy of Sciences [XDB36000000, XDB38010400]; CAS-JSPS [GJHZ2094]; Research Foundation for Advanced Talents of Fujian Medical University [XRCZX2017020, XRCZX2019005]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Beijing Natural Science Foundation Haidian original innovation joint fund(Beijing Natural Science Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Strategic Priority Research Program of Chinese Academy of Sciences(Chinese Academy of Sciences); CAS-JSPS; Research Foundation for Advanced Talents of Fujian Medical University	This work was supported by the China Postdoctoral Science Foundation (2021M690806), Beijing Natural Science Foundation Haidian original innovation joint fund (L202023), the National Natural Science Foundation of China (32027801, 31870992, 21775031), the Strategic Priority Research Program of Chinese Academy of Sciences (Grant No. XDB36000000, XDB38010400), CAS-JSPS (Grant No. GJHZ2094), Research Foundation for Advanced Talents of Fujian Medical University (XRCZX2017020, XRCZX2019005). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. We thank Dr.Jianming Zeng(University of Macau), and all the members of his bioinformatics team, biotrainee, for generously sharing their experience and codes. We also thank Prof. Xiaopei Shen (Fujian Medical University) and his teammate, Hao Fu, Haibo Zhu, Guanghao Liu, Mengyao Wang, et al. for generously help, discussion, and advice about CaSee pipeline.	Andreatta M, 2021, COMPUT STRUCT BIOTEC, V19, P3796, DOI 10.1016/j.csbj.2021.06.043; Bassez A, 2021, NAT MED, V27, P820, DOI 10.1038/s41591-021-01323-8; Bell CC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10652-9; Bischoff P, 2021, ONCOGENE, V40, P6748, DOI 10.1038/s41388-021-02054-3; Gao RL, 2021, NAT BIOTECHNOL, V39, P599, DOI 10.1038/s41587-020-00795-2; Han XP, 2020, NATURE, V581, P303, DOI 10.1038/s41586-020-2157-4; Hao Yuhan, 2021, Cell, V184, P3573, DOI 10.1016/j.cell.2021.04.048; He Y, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02083-3; Hu J, 2020, NAT MACH INTELL, V2, P607, DOI 10.1038/s42256-020-00233-7; Hu LS, 2017, P NATL ACAD SCI USA, V114, pE3964, DOI 10.1073/pnas.1617816114; Kharchenko PV, 2014, NAT METHODS, V11, P740, DOI [10.1038/NMETH.2967, 10.1038/nmeth.2967]; Kim N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16164-1; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Krizhevsky A., P 25 INT C NEUR INF, P1097; Lee HO, 2020, NAT GENET, V52, P594, DOI 10.1038/s41588-020-0636-z; Maynard A, 2020, CELL, V182, P1232, DOI 10.1016/j.cell.2020.07.017; Nguyen QH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04334-1; Oh DY, 2020, CELL, V181, P1612, DOI 10.1016/j.cell.2020.05.017; Oren Y, 2021, NATURE, V596, P576, DOI 10.1038/s41586-021-03796-6; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Qiao K, ACCURATE RECONSTRUCT, P14; Qiu YPL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20167-3; Rambow F, 2018, CELL, V174, P843, DOI 10.1016/j.cell.2018.06.025; Roels J, 2020, NAT IMMUNOL, V21, P1280, DOI 10.1038/s41590-020-0747-9; Sabour S., 2017, ARXIV; Shao X, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkab775; Taylor AM, 2018, CANCER CELL, V33, P676, DOI 10.1016/j.ccell.2018.03.007; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Wagner J, 2019, CELL, V177, P1330, DOI 10.1016/j.cell.2019.03.005; Wang LF, 2020, NAT MACH INTELL, V2, P693, DOI 10.1038/s42256-020-00244-4; Xi E, 2017, ARXIV; Yamada H, 2019, ACS CENTRAL SCI, V5, P1717, DOI 10.1021/acscentsci.9b00804; Yuan HT, 2019, NUCLEIC ACIDS RES, V47, pD900, DOI 10.1093/nar/gky939; Zarrei M, 2015, NAT REV GENET, V16, P172, DOI 10.1038/nrg3871; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900; Zhou Y, 2020, CANCER CELL, V38, P818, DOI 10.1016/j.ccell.2020.09.015; Zhu RC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23087-y	39	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4866	4876		10.1038/s41388-022-02478-5	http://dx.doi.org/10.1038/s41388-022-02478-5		OCT 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36192479	Green Submitted			2022-12-28	WOS:000865226400001
J	Tan, QL; Liu, ZQ; Gao, XB; Wang, YB; Qiu, XF; Chen, JH; Liang, LC; Guo, HQ; Huang, SS; Wu, DL; Zhou, B; Hu, RG; Li, ZF				Tan, Qilong; Liu, Ziqun; Gao, Xiaobo; Wang, Yibo; Qiu, Xuefeng; Chen, Jiahui; Liang, Liuchun; Guo, Hongqian; Huang, Shengsong; Wu, Denglong; Zhou, Bing; Hu, Ronggui; Li, Zhenfei			Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors	ONCOGENE			English	Article							UBIQUITIN-PROTEIN LIGASE; PROSTATE-CANCER; ANDROGEN-RECEPTOR; E6-ASSOCIATED PROTEIN; E6-AP; ENZALUTAMIDE; RESISTANCE; COACTIVATOR; EXPRESSION; MUTATIONS	Strategies to degrade steroid receptors and their alternative splicing isoforms are critical for disease management. Here we report that celastrol recruited the ubiquitin ligase UBE3A and degraded androgen receptor (AR), AR-v7, and glucocorticoid receptor (GR) to suppress prostate cancer development. UBE3A was not an optimal endogenous AR ubiquitin ligase in mice and patients, but celastrol promoted the interaction between UBE3A and AR. Multiple domains of AR, including the DNA binding domain (DBD), were implicated into the UBE3A-AR interaction. Sharing a conserved DBD, GR, AR-v7, and other steroid receptors were recognized and degraded by UBE3A after celastrol treatment. Thus, celastrol suppressed prostate cancer cell proliferation more potently than enzalutamide. Modifying the carboxyl group of celastrol improved its anti-tumor activity. Together, our findings revealed that celastrol might be a potential molecular glue to enhance the interaction between UBE3A and steroid receptors to degrade multiple steroid receptors and splicing isoforms in prostate cancer, paving a way for further drug optimization and disease treatment.	[Tan, Qilong; Liu, Ziqun; Chen, Jiahui; Li, Zhenfei] Univ Chinese Acad Sci, State Key Lab Cell Biol, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol,Chinese Acad Sc, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Gao, Xiaobo] Fudan Univ, State Key Lab Med Neurobiol, Inst Translat Brain Res, Shanghai 200032, Peoples R China; [Gao, Xiaobo] Fudan Univ, MOE Frontiers Ctr Brain Sci, Shanghai 200032, Peoples R China; [Hu, Ronggui] Univ Chinese Acad Sci, Chinese Acad Sci, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol,State Key Lab M, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Wang, Yibo; Liang, Liuchun; Zhou, Bing] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China; [Wang, Yibo; Zhou, Bing] Univ Chinese Acad Sci, Sch Pharmaceut Sci & Technol, Hangzhou Inst Adv Study, Hangzhou 310024, Peoples R China; [Qiu, Xuefeng; Guo, Hongqian] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Dept Urol, Nanjing 210008, Peoples R China; [Huang, Shengsong; Wu, Denglong] Tongji Univ, Tongji Hosp, Sch Med, Dept Urol, Shanghai 200065, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Fudan University; Fudan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Nanjing University; Tongji University	Li, ZF (corresponding author), Univ Chinese Acad Sci, State Key Lab Cell Biol, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol,Chinese Acad Sc, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Hu, RG (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol,State Key Lab M, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Zhou, B (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China.; Zhou, B (corresponding author), Univ Chinese Acad Sci, Sch Pharmaceut Sci & Technol, Hangzhou Inst Adv Study, Hangzhou 310024, Peoples R China.	zhoubing@simm.ac.cn; coryhu@sibcb.ac.cn; zhenfei.li@sibcb.ac.cn	Li, Zhenfei/AAU-1097-2020	Li, Zhenfei/0000-0001-6520-431X; wang, yibo/0000-0002-6952-2582	National Key R&D Program of China [2018YFA0508200, 2019YFA0802103]; National Natural Science Foundation of China [92157101, 81973166, 91753207, 91853128, 81525019]; Department of Science and Technology of Zhejiang Province [2021C03104]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science and Technology of Zhejiang Province	We thank the staff members (Zhuo Yang, et al) of the chemical biology core facility, the high-performance computing service platform, and the bioinformatics core in Shanghai Institute of Biochemistry and Cell Biology (SIBCB), mass spectrometry staff members of the National Facility for Protein in Shanghai (NFPS), and the Zhangjiang Lab and staff members (Pengyu Wang, et al.) of Bio-Med Big Data Center /Shanghai Institute of Nutrition and Health (SINH) for providing technical support and assistance in data collection and analysis. This work was supported by funding from the National Key R&D Program of China (2018YFA0508200 to ZL; 2019YFA0802103 and 2018YFA0508200 to RH), National Natural Science Foundation of China (92157101 to ZL; 81973166, 91753207 to BZ; 91853128, 81525019 to RH). RH was also supported by funding from Department of Science and Technology of Zhejiang Province (Proj. No. 2021C03104).	Alyamani M, 2017, CELL CHEM BIOL, V24, P825, DOI 10.1016/j.chembiol.2017.05.020; [Anonymous], 2020, Cancer Discov, V10, P1084, DOI 10.1158/2159-8290.CD-NB2020-054; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Birch SE, 2014, ANN ONCOL, V25, P2392, DOI 10.1093/annonc/mdu454; Chadli A, 2010, J BIOL CHEM, V285, P4224, DOI 10.1074/jbc.M109.081018; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Efstathiou E, 2015, EUR UROL, V67, P53, DOI 10.1016/j.eururo.2014.05.005; Fang MM, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.681295; Furr BJA, 1996, EUR UROL, V29, P83; Gao XH, 2005, ENDOCRINOLOGY, V146, P1707, DOI 10.1210/en.2004-1198; Groner AC, 2017, J CLIN INVEST, V127, P1126, DOI 10.1172/JCI88885; Han X, 2019, J MED CHEM, V62, P941, DOI 10.1021/acs.jmedchem.8b01631; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hou ZM, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100561; Hou ZM, 2021, CANCER LETT, V516, P1, DOI 10.1016/j.canlet.2021.04.010; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Jones JO, 2009, ACS CHEM BIOL, V4, P199, DOI 10.1021/cb900024z; Khan OY, 2006, MOL ENDOCRINOL, V20, P544, DOI 10.1210/me.2005-0110; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kregel S, 2020, NEOPLASIA, V22, P111, DOI 10.1016/j.neo.2019.12.003; Lee JH, 2006, BIOCHEM PHARMACOL, V72, P1311, DOI 10.1016/j.bcp.2006.08.014; Li HF, 2014, J MED CHEM, V57, P6458, DOI 10.1021/jm500802j; Li JN, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe8226; Lim HY, 2021, CANCER LETT, V521, P252, DOI 10.1016/j.canlet.2021.08.030; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Mei ZJ, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100608; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Park JH, 2002, AM J PATHOL, V161, P727, DOI 10.1016/S0002-9440(10)64228-9; Ponnusamy S, 2019, CLIN CANCER RES, V25, P6764, DOI 10.1158/1078-0432.CCR-19-1458; Ramamoorthy Sivapriya, 2008, Nucl Recept Signal, V6, pe006, DOI 10.1621/nrs.06006; Salminen A, 2010, BIOCHEM BIOPH RES CO, V394, P439, DOI 10.1016/j.bbrc.2010.03.050; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schneekloth AR, 2008, BIOORG MED CHEM LETT, V18, P5904, DOI 10.1016/j.bmcl.2008.07.114; Seo HR, 2011, CHEM-BIOL INTERACT, V193, P34, DOI 10.1016/j.cbi.2011.04.009; Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101; Shi JF, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.558741; Smith CL, 2002, MOL CELL BIOL, V22, P525, DOI 10.1128/MCB.22.2.525-535.2002; Takwale AD, 2020, EUR J MED CHEM, V208, DOI 10.1016/j.ejmech.2020.112769; Tata JR, 2002, NAT REV MOL CELL BIO, V3, P702, DOI 10.1038/nrm914; Toure M, 2016, ANGEW CHEM INT EDIT, V55, P1966, DOI 10.1002/anie.201507978; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Xu XX, 2018, CELL RES, V28, P48, DOI 10.1038/cr.2017.132; Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529; Yang ZM, 2007, NAT MED, V13, P348, DOI 10.1038/nm1547; Zhao LJ, 2020, NEOPLASIA, V22, P522, DOI 10.1016/j.neo.2020.07.002; Zhou YQ, 2017, MOL BIOSYST, V13, P83, DOI 10.1039/c6mb00691d	51	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4754	4767		10.1038/s41388-022-02467-8	http://dx.doi.org/10.1038/s41388-022-02467-8		SEP 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36109631				2022-12-28	WOS:000854052300001
J	Winkler, R; Magdefrau, AS; Piskor, EM; Kleemann, M; Beyer, M; Linke, K; Hansen, L; Schaffer, AM; Hoffmann, ME; Poepsel, S; Heyd, F; Beli, P; Moroy, T; Mahboobi, S; Kramer, OH; Kosan, C				Winkler, Rene; Magdefrau, Ann-Sophie; Piskor, Eva-Maria; Kleemann, Markus; Beyer, Mandy; Linke, Kevin; Hansen, Lisa; Schaffer, Anna-Maria; Hoffmann, Marina E.; Poepsel, Simon; Heyd, Florian; Beli, Petra; Moroy, Tarik; Mahboobi, Siavosh; Kramer, Oliver H.; Kosan, Christian			Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition	ONCOGENE			English	Article							UBIQUITIN-MEDIATED PROTEOLYSIS; C-MYC; DOWN-REGULATION; HDAC6; CANCER; TUBULIN; ACETYLATION; EXPRESSION; LINES; NOXA	Overexpression of MYC is a genuine cancer driver in lymphomas and related to poor prognosis. However, therapeutic targeting of the transcription factor MYC remains challenging. Here, we show that inhibition of the histone deacetylase 6 (HDAC6) using the HDAC6 inhibitor Marbostat-100 (M-100) reduces oncogenic MYC levels and prevents lymphomagenesis in a mouse model of MYC-induced aggressive B-cell lymphoma. M-100 specifically alters protein-protein interactions by switching the acetylation state of HDAC6 substrates, such as tubulin. Tubulin facilitates nuclear import of MYC, and MYC-dependent B-cell lymphoma cells rely on continuous import of MYC due to its high turn-over. Acetylation of tubulin impairs this mechanism and enables proteasomal degradation of MYC. M-100 targets almost exclusively B-cell lymphoma cells with high levels of MYC whereas non-tumor cells are not affected. M-100 induces massive apoptosis in human and murine MYC-overexpressing B-cell lymphoma cells. We identified the heat-shock protein DNAJA3 as an interactor of tubulin in an acetylation-dependent manner and overexpression of DNAJA3 resulted in a pronounced degradation of MYC. We propose a mechanism by which DNAJA3 associates with hyperacetylated tubulin in the cytoplasm to control MYC turnover. Taken together, our data demonstrate a beneficial role of HDAC6 inhibition in MYC-dependent B-cell lymphoma.	[Winkler, Rene; Magdefrau, Ann-Sophie; Piskor, Eva-Maria; Kleemann, Markus; Linke, Kevin; Hansen, Lisa; Schaffer, Anna-Maria; Kosan, Christian] Friedrich Schiller Univ, Ctr Mol Biomed CMB, Dept Biochem, D-07745 Jena, Germany; [Beyer, Mandy; Kramer, Oliver H.] Univ Med Ctr Mainz, Inst Toxicol, D-55131 Mainz, Germany; [Hoffmann, Marina E.; Beli, Petra] Inst Mol Biol IMB, D-55128 Mainz, Germany; [Poepsel, Simon] Univ Cologne, Fac Med, Ctr Mol Med Cologne CMMC, D-50931 Cologne, Germany; [Poepsel, Simon] Univ Cologne, Univ Hosp, D-50931 Cologne, Germany; [Poepsel, Simon] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50931 Cologne, Germany; [Heyd, Florian] Free Univ Berlin, Inst Chem & Biochem, Lab RNA Biochem, D-14195 Berlin, Germany; [Moroy, Tarik] Inst Rech Clin Montreal IRCM, Montreal, PQ H2W 1R7, Canada; [Mahboobi, Siavosh] Univ Regensburg, Inst Pharm, Dept Pharmaceut Med Chem 1, D-93040 Regensburg, Germany; [Winkler, Rene] Josep Carreras Leukaemia Res Inst IJC, Campus ICO Germans Trias & Pujol, Badalona 08916, Spain	Friedrich Schiller University of Jena; Johannes Gutenberg University of Mainz; Institute of Molecular Biology (IMB); University of Cologne; University of Cologne; University of Cologne; Free University of Berlin; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Regensburg; Catalan Institute of Oncology; Institut de Recerca Contra la Leucemia Josep Carreras (IJC)	Kosan, C (corresponding author), Friedrich Schiller Univ, Ctr Mol Biomed CMB, Dept Biochem, D-07745 Jena, Germany.	christian.kosan@uni-jena.de	Winkler, René/ABB-4629-2020	Winkler, René/0000-0002-7570-0242	Carl Zeiss Foundation; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [GRK 1715]; Landesgraduiertenstipendium (Friedrich Schiller University Jena); DFG [393547839-SFB 1361, GRK 2291/9-1, 427404172]; Projekt DEAL	Carl Zeiss Foundation; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); Landesgraduiertenstipendium (Friedrich Schiller University Jena); DFG(German Research Foundation (DFG)); Projekt DEAL	RW was supported by a scholarship from the Carl Zeiss Foundation. CK received funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), GRK 1715. E-MP was supported by a Landesgraduiertenstipendium (Friedrich Schiller University Jena). Work done in the group of OHK was done by MB and is funded by DFG, Project-ID 393547839-SFB 1361 and DFG, GRK 2291/9-1, project number 427404172. Open Access funding enabled and organized by Projekt DEAL.	ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Amengual JE, 2021, ONCOLOGIST, V26, DOI 10.1002/onco.13673; Amengual JE, 2017, CLIN CANCER RES, V23, P3084, DOI 10.1158/1078-0432.CCR-16-2022; Amengual JE, 2015, CLIN CANCER RES, V21, P4663, DOI 10.1158/1078-0432.CCR-14-3068; Aukema SM, 2014, HAEMATOLOGICA, V99, P726, DOI 10.3324/haematol.2013.091827; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basso K, 2015, NAT REV IMMUNOL, V15, P172, DOI 10.1038/nri3814; Bemark M, 2000, ONCOGENE, V19, P3404, DOI 10.1038/sj.onc.1203686; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Beyer M, 2019, CANCERS, V11, DOI 10.3390/cancers11101436; Chen CY, 2013, CANCER RES, V73, P4009, DOI 10.1158/0008-5472.CAN-12-4066; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Croxford JL, 2013, BLOOD, V121, P2512, DOI 10.1182/blood-2012-08-449025; Deng WH, 2018, TRANSL ONCOL, V11, P1147, DOI 10.1016/j.tranon.2018.07.007; Depetter Y, 2019, INT J CANCER, V145, P735, DOI 10.1002/ijc.32169; Fernandez-Serrano M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010253; Gupta M, 2012, BLOOD, V120, P4400, DOI 10.1182/blood-2012-05-428466; Heidelberger JB, 2018, EMBO REP, V19, DOI 10.15252/embr.201744754; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Inoue S, 2013, GENE DEV, V27, P1101, DOI 10.1101/gad.214577.113; Joshi G, 2020, CANCERS, V12, DOI 10.3390/cancers12103009; Karpova MB, 2005, LEUKEMIA, V19, P159, DOI 10.1038/sj.leu.2403534; Kleo K, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5537-0; Koh CM, 2015, NATURE, V523, P96, DOI 10.1038/nature14351; Lechner S, 2022, NAT CHEM BIOL; Leonhardt M, 2018, EUR J MED CHEM, V152, P329, DOI 10.1016/j.ejmech.2018.04.046; Lorenzin F, 2016, ELIFE, V5, DOI 10.7554/eLife.15161; Lu B, 2006, J BIOL CHEM, V281, P13150, DOI 10.1074/jbc.M509179200; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Miyake Y, 2016, NAT CHEM BIOL, V12, P748, DOI 10.1038/nchembio.2140; Nakamura M, 1996, INT IMMUNOL, V8, P193, DOI 10.1093/intimm/8.2.193; Nebbioso A, 2017, CLIN CANCER RES, V23, P2542, DOI 10.1158/1078-0432.CCR-15-2388; New M, 2012, MOL ONCOL, V6, P637, DOI 10.1016/j.molonc.2012.09.003; Niklinski J, 2000, MOL CELL BIOL, V20, P5276, DOI 10.1128/MCB.20.14.5276-5284.2000; PHILIP I, 1984, J NATL CANCER I, V73, P835; Poole CJ, 2017, GENES-BASEL, V8, DOI 10.3390/genes8050142; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Rempel RE, 2014, MOL CANCER THER, V13, P3219, DOI 10.1158/1535-7163.MCT-13-0044; Ross J, 2021, EUR J MED CHEM, V213, DOI 10.1016/j.ejmech.2020.113137; Ross J, 2019, CANCER RES, V79, P4184, DOI 10.1158/0008-5472.CAN-18-3038; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schafer C, 2017, CELL SIGNAL, V29, P218, DOI 10.1016/j.cellsig.2016.11.002; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schuster C, 2011, BLOOD, V118, P4635, DOI 10.1182/blood-2010-10-313098; Sellmer A, 2018, J MED CHEM, V61, P3454, DOI 10.1021/acs.jmedchem.7b01593; Shin DY, 2015, CANCER LETT, V364, P89, DOI 10.1016/j.canlet.2015.03.016; Sterrenberg JN, 2011, CANCER LETT, V312, P129, DOI 10.1016/j.canlet.2011.08.019; Stojanovic N, 2017, ONCOGENE, V36, P1804, DOI 10.1038/onc.2016.344; Stubbs MC, 2015, CLIN CANCER RES, V21, P2348, DOI 10.1158/1078-0432.CCR-14-1290; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Thompson JW, 2014, J BIOL CHEM, V289, P28942, DOI 10.1074/jbc.M114.573352; Trabucco SE, 2015, CLIN CANCER RES, V21, P113, DOI 10.1158/1078-0432.CCR-13-3346; Wachholz V, 2022, ARCH TOXICOL, V96, P177, DOI 10.1007/s00204-021-03174-1; Winkler R, 2017, METHODS MOL BIOL, V1510, P93, DOI 10.1007/978-1-4939-6527-4_7; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763	60	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4560	4572		10.1038/s41388-022-02450-3	http://dx.doi.org/10.1038/s41388-022-02450-3		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36068335	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000850425100003
J	Niu, XD; Yang, Y; Ren, YM; Zhou, ST; Mao, Q; Wang, Y				Niu, Xiaodong; Yang, Yuan; Ren, Yanming; Zhou, Shengtao; Mao, Qing; Wang, Yuan			Crosstalk between m(6)A regulators and mRNA during cancer progression	ONCOGENE			English	Review							METHYLTRANSFERASE METTL3 PROMOTES; STEM-LIKE CELLS; NUCLEAR-RNA; HEPATOCELLULAR-CARCINOMA; M6A MODIFICATION; GENE-EXPRESSION; BREAST-CANCER; SELF-RENEWAL; N-6-METHYLADENOSINE; N6-METHYLADENOSINE	m(6)A modification, the most abundant and widespread RNA modification, is present and involved in the occurrence and development of various cancers. To date, most studies have mainly focused on the roles of a single m(6)A regulator (writer/eraser/reader) in various cancers, but cumulative evidence shows that aberrant m(6)A regulators and m(6)A levels exert dual effects (promoting and/or inhibiting roles) in cancer progression. Recently, studies have investigated the direct interactions between different m(6)A regulators (writer/eraser and reader) and mRNAs in a variety of cancers. In this review, we summarize the functions of m(6)A regulators and their roles in various types of cancers. We further propose the possible crosstalk mechanisms (Writer-m(6)A-Reader-mRNA axis and Eraser-m(6)A-Reader-mRNA axis) between different m(6)A regulators and mRNAs during cancer progression. We also discuss the clinical potential of m(6)A regulator-targeting strategies.	[Niu, Xiaodong; Yang, Yuan; Ren, Yanming; Mao, Qing; Wang, Yuan] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Peoples R China; [Niu, Xiaodong; Yang, Yuan; Ren, Yanming; Mao, Qing; Wang, Yuan] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China; [Niu, Xiaodong; Yang, Yuan; Ren, Yanming; Mao, Qing; Wang, Yuan] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China; [Zhou, Shengtao] Sichuan Univ, West China Hosp 2, State Key Lab Biotherapy, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University	Mao, Q; Wang, Y (corresponding author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Peoples R China.; Mao, Q; Wang, Y (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China.; Mao, Q; Wang, Y (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China.	qingmao2000@163.com; wangyuan@scu.edu.cn		Niu, Xiaodong/0000-0003-4750-812X; Wang, Yuan/0000-0002-6324-6134; Zhou, Shengtao/0000-0001-8322-5536	National Natural Science Foundation of China [81902532, 82072773]; China Postdoctoral Science Foundation [2022M712255]; National Key Research and Development Program of China; Stem Cell and Translational Research [2017YFA0106500]; Distinguished Young Scientists Program of Sichuan Province [2019JDJQ0029]; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYYC20019]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Key Research and Development Program of China; Stem Cell and Translational Research; Distinguished Young Scientists Program of Sichuan Province; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University	This work was supported by the National Natural Science Foundation of China (81902532 to YY and 82072773 to QM), the fellowship of China Postdoctoral Science Foundation (2022M712255 to XDN), the National Key Research and Development Program of China, Stem Cell and Translational Research (2017YFA0106500 to YW), the Distinguished Young Scientists Program of Sichuan Province (2019JDJQ0029 to YW), and the 1 center dot 3 center dot 5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYYC20019 to YW).	ADAMS JM, 1975, NATURE, V255, P28, DOI 10.1038/255028a0; Alarcon CR, 2015, CELL, V162, P1299, DOI 10.1016/j.cell.2015.08.011; Baquero-Perez B, 2019, ELIFE, V8, DOI 10.7554/eLife.47261; BEEMON K, 1977, J MOL BIOL, V113, P165, DOI 10.1016/0022-2836(77)90047-X; Blanco S, 2016, NATURE, V534, P335, DOI 10.1038/nature18282; Brown JA, 2016, P NATL ACAD SCI USA, V113, P14013, DOI 10.1073/pnas.1614759113; Cai XL, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00703-w; Chai RC, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01124-z; Chen F, 2021, CANCER RES, V81, P2847, DOI 10.1158/0008-5472.CAN-20-3779; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Chen SJ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28913-5; Chen WW, 2020, EUR REV MED PHARMACO, V24, P4263, DOI 10.26355/eurrev_202004_21006; Chen XX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01220-7; Chen YB, 2021, THERANOSTICS, V11, P7640, DOI 10.7150/thno.61178; Cheng C, 2021, MOL THER-NUCL ACIDS, V23, P487, DOI 10.1016/j.omtn.2020.12.001; Cheng MS, 2019, ONCOGENE, V38, P3667, DOI 10.1038/s41388-019-0683-z; Choe J, 2018, NATURE, V561, P556, DOI 10.1038/s41586-018-0538-8; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; DESROSIERS R, 1974, P NATL ACAD SCI USA, V71, P3971, DOI 10.1073/pnas.71.10.3971; Dixit D, 2021, CANCER DISCOV, V11, P480, DOI 10.1158/2159-8290.CD-20-0331; Dominissini D, 2016, NATURE, V530, P441, DOI 10.1038/nature16998; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Dong SH, 2021, CANCER COMMUN, V41, P538, DOI 10.1002/cac2.12161; Fan ZY, 2021, J CELL MOL MED, V25, P10197, DOI 10.1111/jcmm.16957; Fan ZY, 2021, BIOCHEM BIOPH RES CO, V546, P169, DOI 10.1016/j.bbrc.2021.01.085; Frye M, 2018, SCIENCE, V361, P1346, DOI 10.1126/science.aau1646; Fukumoto T, 2019, CANCER RES, V79, P2812, DOI 10.1158/0008-5472.CAN-18-3592; Gkatza NA, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000297; Guimaraes-Teixeira C, 2021, J PERS MED, V11, DOI 10.3390/jpm11100996; Gutschner T, 2014, HEPATOLOGY, V59, P1900, DOI 10.1002/hep.26997; Han ST, 2021, THERANOSTICS, V11, P8464, DOI 10.7150/thno.60028; He HB, 2019, BIOCHEM BIOPH RES CO, V517, P581, DOI 10.1016/j.bbrc.2019.07.058; He J, 2021, MOL THER, V29, P1821, DOI 10.1016/j.ymthe.2021.01.019; Hsu PJ, 2017, CELL RES, V27, P1115, DOI 10.1038/cr.2017.99; Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006; Huang Y, 2015, NUCLEIC ACIDS RES, V43, P373, DOI 10.1093/nar/gku1276; Huo FC, 2021, ONCOGENE, V40, P2968, DOI 10.1038/s41388-021-01753-1; Iaiza A, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01159-6; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Jiang XL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00450-x; Jin D, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01161-1; Jin D, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0830-6; Jin H, 2019, EBIOMEDICINE, V47, P195, DOI 10.1016/j.ebiom.2019.07.068; Jin M, 2021, CANCER LETT, V518, P214, DOI 10.1016/j.canlet.2021.07.022; Kasowitz SD, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007412; Lee Y, 2020, TRENDS GENET, V36, P177, DOI 10.1016/j.tig.2019.12.007; Li EJ, 2022, ELIFE, V11, DOI 10.7554/eLife.75231; Li FX, 2019, CANCER RES, V79, P5785, DOI 10.1158/0008-5472.CAN-18-2868; Li H, 2021, MOL THER-NUCL ACIDS, V24, P25, DOI 10.1016/j.omtn.2021.02.001; Li JF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01267-6; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Li XY, 2016, NAT CHEM BIOL, V12, P311, DOI [10.1038/NCHEMBIO.2040, 10.1038/nchembio.2040]; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Lin ZY, 2020, EMBO J, V39, DOI 10.15252/embj.2019103181; Liu J, 2018, NAT CELL BIOL, V20, P1074, DOI 10.1038/s41556-018-0174-4; Liu L, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.778; Liu X, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04950-2; Liu ZC, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01398-4; Lv DM, 2022, ONCOGENE, V41, P1727, DOI 10.1038/s41388-022-02214-z; Ma HG, 2021, AGING-US, V13, P22332, DOI 10.18632/aging.203541; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Ma S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0805-7; Meyer KD, 2015, CELL, V163, P999, DOI 10.1016/j.cell.2015.10.012; Tran NV, 2019, NUCLEIC ACIDS RES, V47, P7719, DOI 10.1093/nar/gkz619; Nombela P, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01263-w; Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Qing Y, 2021, MOL CELL, V81, P922, DOI 10.1016/j.molcel.2020.12.026; Qiu XY, 2021, CANCER RES, V81, P4778, DOI 10.1158/0008-5472.CAN-21-0468; Roundtree IA, 2017, ELIFE, V6, DOI 10.7554/eLife.31311; Roundtree IA, 2017, CELL, V169, P1187, DOI 10.1016/j.cell.2017.05.045; Ruan DY, 2021, ONCOGENE, V40, P5168, DOI 10.1038/s41388-021-01916-0; Shen C, 2020, CELL STEM CELL, V27, P64, DOI 10.1016/j.stem.2020.04.009; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Singh B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159072; Song P, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00444-9; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Tan Z, 2022, ONCOGENE, V41, P2860, DOI 10.1038/s41388-022-02306-w; Tang XD, 2019, ONCOL LETT, V17, P2473, DOI 10.3892/ol.2018.9873; Tassinari V, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02271-9; Tian JB, 2020, GUT, V69, P2180, DOI 10.1136/gutjnl-2019-320179; Tsuchiya K, 2022, CANCER GENE THER, DOI 10.1038/s41417-022-00451-8; Uddin MB, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01356-0; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wan WJ, 2022, MOL CANCER, V21, DOI 10.1186/s12943-021-01447-y; Wang F, 2021, ONCOGENE, V40, P3885, DOI 10.1038/s41388-021-01820-7; Wang P, 2016, MOL CELL, V63, P306, DOI 10.1016/j.molcel.2016.05.041; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang SY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0847-4; Wang S, 2021, CANCER SCI, V112, P3243, DOI 10.1111/cas.15011; Wang W, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23501-5; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01415-6; Wang X, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01871-4; Wei JC, 2020, J CELL MOL MED, V24, P11366, DOI 10.1111/jcmm.15738; Wen J, 2018, MOL CELL, V69, P1028, DOI 10.1016/j.molcel.2018.02.015; Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016; Wu GW, 2021, EMBO REP, V22, DOI 10.15252/embr.202051519; Wu HY, 2021, ACTA BIOCH BIOPH SIN, V53, P304, DOI 10.1093/abbs/gmaa170; Wu R, 2019, CELL RES, V29, P23, DOI 10.1038/s41422-018-0113-8; Xiang S, 2020, AM J TRANSL RES, V12, P1789; Xiao P, 2021, MOL CANCER RES, V19, P726, DOI 10.1158/1541-7786.MCR-20-0541; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Xie F, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01359-x; Xie JP, 2021, J BUON, V26, P444; Xiong J, 2022, MOL CELL, V82, P1660, DOI 10.1016/j.molcel.2022.02.033; Xu AS, 2022, MOL THER, V30, P1104, DOI 10.1016/j.ymthe.2021.12.012; Xu HF, 2020, THERANOSTICS, V10, P5671, DOI 10.7150/thno.42539; Xu QC, 2022, ONCOGENE, V41, P1622, DOI 10.1038/s41388-022-02185-1; Xu YF, 2021, CANCER LETT, V522, P142, DOI 10.1016/j.canlet.2021.08.027; Yan F, 2018, CELL RES, V28, P1062, DOI 10.1038/s41422-018-0097-4; Yang F, 2019, ONCOGENE, V38, P4755, DOI 10.1038/s41388-019-0755-0; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Yang X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1146-4; Yang XY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03739-z; Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8; Yang ZC, 2022, EBIOMEDICINE, V80, DOI 10.1016/j.ebiom.2022.104019; Yang Z, 2020, AGING-US, V12, P24967, DOI 10.18632/aging.103767; Yang Z, 2021, CANCER GENE THER, V28, P141, DOI 10.1038/s41417-020-0193-8; Yang ZZ, 2021, P NATL ACAD SCI USA, V118, DOI [10.1073/pnas.2025948118|1of8, 10.1073/pnas.2025948118]; Ye MF, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.12049; Yin HL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21514-8; Yu XF, 2022, MINERVA MED, V113, P309, DOI 10.23736/S0026-4806.20.06653-7; Yuan Y, 2020, J CANCER, V11, P3588, DOI 10.7150/jca.42338; Yuan Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03315-x; Yue B, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1065-4; Yue YA, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0019-0; Zaccara S, 2020, CELL, V181, P1582, DOI 10.1016/j.cell.2020.05.012; Zhang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01170-0; Zhang DH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03793-7; Zhang LL, 2022, BRIT J CANCER, V127, P30, DOI 10.1038/s41416-022-01757-y; Zhang L, 2021, THERANOSTICS, V11, P1100, DOI 10.7150/thno.49345; Zhang RN, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0229-9; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1116-x; Zhao B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09060-w; Zhao W, 2020, MOL THER-NUCL ACIDS, V20, P1, DOI 10.1016/j.omtn.2020.01.033; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006; Zhou B, 2021, HEPATOLOGY, V73, P91, DOI 10.1002/hep.31220; Zhou D, 2021, MOL ONCOL, V15, P2172, DOI 10.1002/1878-0261.12898; Zhou ZJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01216-3; Zhu PP, 2021, ONCOGENE, V40, P1609, DOI 10.1038/s41388-020-01638-9; Zhu Y, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04817-6	149	0	0	14	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4407	4419		10.1038/s41388-022-02441-4	http://dx.doi.org/10.1038/s41388-022-02441-4		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	36008465				2022-12-28	WOS:000844588600003
J	Wan, HX; Gao, NN; Lu, W; Lu, C; Chen, J; Wang, YM; Dong, H				Wan, Hanxing; Gao, Nannan; Lu, Wei; Lu, Cheng; Chen, Jun; Wang, Yimin; Dong, Hui			NCX1 coupled with TRPC1 to promote gastric cancer via Ca2+/AKT/beta-catenin pathway	ONCOGENE			English	Article							CALCIUM-SENSING RECEPTOR; NA+/CA2+ EXCHANGER 1; EXPRESSION	Plasma membrane Na+/Ca2+ exchanger 1 (NCX1) is a bidirectional ion transporter to operate in Ca2+ entry or exit modes, and TRPC1 is Ca2+-permeable channel. Both NCX1 and TRPC1 play critical roles in maintaining cytosolic free Ca2+ ([Ca2+](cyt)) homeostasis in mammalian cells. Although either TRPC1 channel or Ca2+ entry mode of NCX1 is implicated in some tumorigenesis, it has not been explored if a coordination of NCX1 and TRPC1 involves in the pathogenesis of H. pylori-associated human gastric cancer (GC). Here we found the protein expression of NCX1 was significantly enhanced in human GC specimens, which correlated with tumor progression and poor survival in GC patients. TRPC1 and NCX1 were parallelly enhanced, co-localized and bound in human GC cells. By a functional coupling, TRPC1 drives NCX1 to the Ca2+ entry mode, raising [Ca2+](cyt) in GC cells. Moreover, CaCl2, H. pylori and their virulence factors all enhanced expressions and activities of NCX1 and TRPC1, and evoked aberrant Ca2+ entry to promote proliferation, migration, and invasion of GC cells through AKT/beta-catenin pathway. Tumor growth and metastasis also depended on the enhanced expression of NCX1 in subcutaneously xenografted GC mouse model. Overall, our findings indicate that TRPC1/NCX1 coupling may promote H. pylori-associated GC through the Ca2+/AKT/beta-catenin pathway. Since the Ca2+ exit mode and the Ca2+ entry mode of NCX1 play different roles under mostly physiological and pathological conditions respectively, targeting TRPC1/NCX1 coupling could be a novel strategy for selectively blocking Ca2+ entry mode to potentially treat digestive cancer with less side effect.	[Wan, Hanxing; Lu, Wei; Dong, Hui] Qingdao Univ, Sch Pharm, Dept Pharmacol, Med Coll, 1 Ningde Rd, Qingdao 266073, Peoples R China; [Wan, Hanxing; Gao, Nannan; Lu, Cheng; Chen, Jun] Army Med Univ, Xingiao Hosp, Dept Gastroenterol, Chongqing 400037, Peoples R China; [Wang, Yimin] First Hosp Qinhuangdao, Dept Gen Surg, Qinhuangdao, Hebei, Peoples R China; [Dong, Hui] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA	Qingdao University; Army Medical University; University of California System; University of California San Diego	Dong, H (corresponding author), Qingdao Univ, Sch Pharm, Dept Pharmacol, Med Coll, 1 Ningde Rd, Qingdao 266073, Peoples R China.; Dong, H (corresponding author), Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.	h2dong@ucsd.edu		Gao, Nannan/0000-0003-1306-6749	National Natural Science Foundation of China [81972328, 81873544, 82103591]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	These studies were supported by research grants from the National Natural Science Foundation of China (No. 81972328 to HXW, No. 81873544 to HD, and No. 82103591 to NNG).	Berridge MJ, 2016, PHYSIOL REV, V96, P1261, DOI 10.1152/physrev.00006.2016; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Cai R, 2009, INT J CANCER, V125, P2281, DOI 10.1002/ijc.24551; Chen JL, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a035113; Chovancova B, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10091257; Davis FM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036923; Dong H, 2005, AM J PHYSIOL-GASTR L, V288, pG457, DOI 10.1152/ajpgi.00381.2004; DONG H, 2010, AM J PHYSIOL-CELL PH, V299; Dong H, 2019, ACTA PHYSIOL, V225, DOI 10.1111/apha.13223; du Sert NP, 2020, BRIT J PHARMACOL, V177, P3617, DOI 10.1111/bph.15193; Elzamzamy OM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020388; Fujimoto Y, 2016, J PHARMACOL SCI, V132, P181, DOI 10.1016/j.jphs.2016.10.003; Gao NN, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01707-7; Ge PB, 2018, CELL BIOL INT, V42, P975, DOI 10.1002/cbin.10963; Ghanayem BI, 1987, GASTROENTEROLOGY, V92, P106, DOI 10.1016/0016-5085(87)90845-6; Harper AGS, 2016, ADV EXP MED BIOL, V898, P67, DOI 10.1007/978-3-319-26974-0_4; Hu HJ, 2019, BRIT J PHARMACOL, V176, P2691, DOI 10.1111/bph.14692; Iimuro M, 2013, ANTICANCER RES, V33, P3667; Joshi Smita S, 2021, CA Cancer J Clin, V71, P264, DOI 10.3322/caac.21657; Kemeny LV, 2013, AM J PHYSIOL-GASTR L, V305, pG552, DOI 10.1152/ajpgi.00394.2012; Li H, 2018, J CELL BIOCHEM, V119, P9997, DOI 10.1002/jcb.27329; LIU Z, 2022, INT J MOL SCI, V23; Long Y, 2013, ACTA PHARMACOL SIN, V34, P691, DOI 10.1038/aps.2013.4; Mahdi SHA, 2015, ARCH BIOCHEM BIOPHYS, V583, P18, DOI 10.1016/j.abb.2015.07.008; Marchi S, 2020, MOL CELL, V78, P1055, DOI 10.1016/j.molcel.2020.04.017; Martinotti S, 2020, METHODS MOL BIOL, V2109, P225, DOI 10.1007/7651_2019_259; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Monteith GR, 2017, NAT REV CANCER, V17, P367, DOI 10.1038/nrc.2017.18; Ottolia M, 2013, ADV EXP MED BIOL, V961, P49, DOI 10.1007/978-1-4614-4756-6_5; Patergnani S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218323; Rodrigues T, 2019, BIOCHEM PHARMACOL, V163, P357, DOI 10.1016/j.bcp.2019.02.032; Seo JH, 2011, GASTROENTEROLOGY, V141, P2064, DOI 10.1053/j.gastro.2011.08.048; Takenoue T, 2000, ANN ONCOL, V11, P273, DOI 10.1023/A:1008337913456; Tang B, 2019, ONCOGENE, V38, P3946, DOI 10.1038/s41388-019-0709-6; Tang B, 2016, CANCER LETT, V377, P44, DOI 10.1016/j.canlet.2016.04.027; TATSUTA M, 1990, CANCER RES, V50, P2095; Timmons JA, 2012, J GASTROINTEST SURG, V16, P1397, DOI 10.1007/s11605-012-1876-8; Wan HX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02562-x; Wang F, 2022, ONCOGENE, V41, P246, DOI 10.1038/s41388-021-02078-9; Wang HN, 2019, ONCOGENE, V38, P1489, DOI 10.1038/s41388-018-0532-5; Wen JX, 2016, ONCOTARGET, V7, P63816, DOI 10.18632/oncotarget.11695; Wessler S, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0171-4; Wong JH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12648-1; Xie R, 2017, CANCER RES, V77, P6499, DOI 10.1158/0008-5472.CAN-17-0360; Xu JY, 2018, CANCER RES, V78, P2564, DOI 10.1158/0008-5472.CAN-17-2061; Xu JY, 2016, CARCINOGENESIS, V37, P290, DOI 10.1093/carcin/bgw004; Zhang FL, 2021, BRIT J PHARMACOL, V178, P346, DOI 10.1111/bph.15287; Zhang FL, 2019, BRIT J PHARMACOL, V176, P1700, DOI 10.1111/bph.14640; Zhang ZY, 2020, BIOCHEM BIOPH RES CO, V529, P85, DOI 10.1016/j.bbrc.2020.05.181; Zhao JK, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0629-4	50	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2022	41	35					4169	4182		10.1038/s41388-022-02412-9	http://dx.doi.org/10.1038/s41388-022-02412-9		JUL 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4A3US	35882979	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000830346700001
J	Bellenghi, M; Talarico, G; Botti, L; Puglisi, R; Tabolacci, C; Portararo, P; Piva, A; Pontecorvi, G; Care, A; Colombo, MP; Mattia, G; Sangaletti, S				Bellenghi, Maria; Talarico, Giovanna; Botti, Laura; Puglisi, Rossella; Tabolacci, Claudio; Portararo, Paola; Piva, Annamaria; Pontecorvi, Giada; Care, Alessandra; Colombo, Mario P.; Mattia, Gianfranco; Sangaletti, Sabina			SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX; SUPPRESSOR-CELLS; BREAST-CANCER; MESENCHYMAL TRANSITION; BONE-MARROW; REGULATORS; FIBROSIS	Dysregulated fatty acid metabolism interacts with oncogenic signals, thereby worsening tumor aggressiveness. The stearoyl-CoA desaturating enzymes, SCD1 and SCD5, convert of saturated fatty acids to monounsaturated fatty acids. While SCD1 is frequently overexpressed in tumor cells and has been widely studied, SCD5 has both limited expression and poor characterization. Here we evaluated, in vitro and in vivo, the effects of SCD5 overexpression in a metastatic clone of 4T1. The results showed SCD5-driven reprogramming of fatty acid metabolism, involving desaturation of stearic acid to oleic acid, which eventually blocked SPARC secretion. The latter event reduced the aggressiveness of the 4T1 subclone by decreasing the ECM deposition and reverting the Epithelial to Mesenchymal Transition (EMT) status. Variation of the fatty acid profile by SCD5-gene transduction or the direct administration oleic acid reduces the immune suppressive activity of myeloid cells and promoting granulocytic myeloid-derived suppressor cell maturation, eventually favoring T-cell activation. The less immunosuppressive microenvironment generated by SCD5 overexpression was enhanced in Sparc-KO mice, indicating that both extracellular and endogenous SPARC additively regulate myeloid cell-suppressive activities. Overall, our data sheds light on exploring the oleic acid-dependent inhibition of SPARC secretion as a possible mechanism to reduce breast cancer malignancy.	[Bellenghi, Maria; Puglisi, Rossella; Pontecorvi, Giada; Care, Alessandra; Mattia, Gianfranco] Ist Super Sanita, Ctr Gender Specif Med, Rome, Italy; [Talarico, Giovanna; Botti, Laura; Portararo, Paola; Piva, Annamaria; Colombo, Mario P.; Sangaletti, Sabina] Fdn IRCCS Ist Nazl Tumori, Dept Res, Mol Immunol Unit, Milan, Italy; [Tabolacci, Claudio] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy	Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto Superiore di Sanita (ISS)	Mattia, G (corresponding author), Ist Super Sanita, Ctr Gender Specif Med, Rome, Italy.; Sangaletti, S (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Res, Mol Immunol Unit, Milan, Italy.	gianfranco.mattia@iss.it; sabina.sangaletti@istitutotumori.mi.it	Tabolacci, Claudio/U-4194-2017; Colombo, Mario P./V-7166-2017	Tabolacci, Claudio/0000-0001-5001-285X; Colombo, Mario P./0000-0003-0042-7955	AIRC IG [22204, 24363, 18815]; FIRC-AIRC fellowship "Fabrizio Ansuini" [22474]; FIRC-AIRC fellowship "Giorgio Boglio' [22460]; Fondazione Umberto Veronesi	AIRC IG(Fondazione AIRC per la ricerca sul cancro); FIRC-AIRC fellowship "Fabrizio Ansuini"; FIRC-AIRC fellowship "Giorgio Boglio'; Fondazione Umberto Veronesi(Fondazione Umberto Veronesi)	This work was supported by AIRC IG no. 22204 to SS, IG no. 24363 to MPC and IG no 18815 to AC. MB was partially supported by the FIRC-AIRC fellowship "Fabrizio Ansuini" n. 22474, GT was supported by the FIRC-AIRC fellowship "Giorgio Boglio' no. 22460, and CT by Fondazione Umberto Veronesi, which we gratefully acknowledge.	Al-Khami AA, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1344804; Al-Khami AA, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1200771; Angelucci Cristiana, 2018, Oncotarget, V9, P24364, DOI 10.18632/oncotarget.25273; Bellenghi M, 2015, J PATHOL, V236, P315, DOI 10.1002/path.4535; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chiodoni C, 2017, J LEUKOCYTE BIOL, V102, P287, DOI 10.1189/jlb.3MR1016-447R; Clark AM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.676135; Craven KE, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83913-7; Donati K, 2017, CANCER GROWTH METAST, V10, DOI 10.1177/1179064417738513; Engebraaten O, 2013, AM J PATHOL, V183, P1064, DOI 10.1016/j.ajpath.2013.05.033; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Harusato A, 2019, CANCER IMMUNOL RES, V7, P544, DOI 10.1158/2326-6066.CIR-18-0444; Hawila E, 2017, CELL REP, V21, P2212, DOI 10.1016/j.celrep.2017.10.104; He MW, 2015, SCI REP-UK, V5, DOI 10.1038/srep11298; Holder AM, 2013, BREAST CANCER RES TR, V137, P319, DOI 10.1007/s10549-012-2354-4; Hossain F, 2015, CANCER IMMUNOL RES, V3, P1236, DOI 10.1158/2326-6066.CIR-15-0036; Li HC, 2020, THERANOSTICS, V10, P7053, DOI 10.7150/thno.41388; Lope V, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103132; Martinek N, 2008, J CELL SCI, V121, P1671, DOI 10.1242/jcs.021931; Masjedi A, 2018, BIOMED PHARMACOTHER, V108, P1415, DOI 10.1016/j.biopha.2018.09.177; Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008-5472.CAN-07-1882; Ojala PJ, 2007, J LEUKOCYTE BIOL, V82, P1501, DOI 10.1189/jlb.0507292; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Pelekanou V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00301; Poltavets V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00431; Puglisi Rossella, 2018, Oncotarget, V9, P7567, DOI 10.18632/oncotarget.24085; Rodriguez PC, 2005, J EXP MED, V202, P931, DOI 10.1084/jem.20050715; Sangaletti S, 2003, J EXP MED, V198, P1475, DOI 10.1084/jem.20030202; Sangaletti S, 2008, CANCER RES, V68, P9050, DOI 10.1158/0008-5472.CAN-08-1327; Sangaletti S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01369; Sangaletti S, 2016, CELL REP, V17, P233, DOI 10.1016/j.celrep.2016.08.075; Sangaletti S, 2011, AM J PATHOL, V179, P3000, DOI 10.1016/j.ajpath.2011.08.027; Strauss L, 2015, CANCER CELL, V28, P253, DOI 10.1016/j.ccell.2015.07.006; Tzanakakis G, 2018, DEV DYNAM, V247, P368, DOI 10.1002/dvdy.24557; Veglia F, 2019, NATURE, V569, P73, DOI 10.1038/s41586-019-1118-2; Wong SLI, 2017, BRIT J PHARMACOL, V174, P3, DOI 10.1111/bph.13653; Zhu AJ, 2016, ONCOTARGET, V7, P76628, DOI 10.18632/oncotarget.10532	40	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2022	41	34					4055	4065		10.1038/s41388-022-02401-y	http://dx.doi.org/10.1038/s41388-022-02401-y		JUL 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3W0LE	35851846				2022-12-28	WOS:000826844200002
J	Horiguchi, H; Kadomatsu, T; Yumoto, S; Masuda, T; Miyata, K; Yamamura, S; Sato, M; Morinaga, J; Ohtsuki, S; Baba, H; Moroishi, T; Oike, Y				Horiguchi, Haruki; Kadomatsu, Tsuyoshi; Yumoto, Shinsei; Masuda, Takeshi; Miyata, Keishi; Yamamura, Shuji; Sato, Michio; Morinaga, Jun; Ohtsuki, Sumio; Baba, Hideo; Moroishi, Toshiro; Oike, Yuichi			Tumor cell-derived ANGPTL2 promotes beta-catenin-driven intestinal tumorigenesis	ONCOGENE			English	Article							ANGIOPOIETIN-LIKE PROTEIN-2; CANCER CELLS; OB-CADHERIN; STEM-CELLS; EXPRESSION; WNT; MUTATIONS; COLON; GENE; PROLIFERATION	Uncontrolled proliferation of intestinal epithelial cells caused by mutations in genes of the WNT/beta-catenin pathway is associated with development of intestinal cancers. We previously reported that intestinal stromal cell-derived angiopoietin-like protein 2 (ANGPTL2) controls epithelial regeneration and intestinal immune responses. However, the role of tumor cell-derived ANGPTL2 in intestinal tumorigenesis remained unclear. Here, we show that tumor cell-derived ANGPTL2 promotes beta-catenin-driven intestinal tumorigenesis. ANGPTL2 deficiency suppressed intestinal tumor development in an experimental mouse model of sporadic colon cancer. We also found that increased ANGPTL2 expression in colorectal cancer (CRC) cells augments beta-catenin pathway signaling and promotes tumor cell proliferation. Relevant to mechanism, our findings suggest that tumor cell-derived ANGPTL2 upregulates expression of OB-cadherin, which then interacts with beta-catenin, blocking destruction complex-independent proteasomal degradation of beta-catenin proteins. Moreover, our observations support a model whereby ANGPTL2-induced OB-cadherin expression in CRC cells is accompanied by decreased cell surface integrin alpha 5 beta 1 expression. These findings overall provide novel insight into mechanisms of beta-catenin-driven intestinal tumorigenesis.	[Horiguchi, Haruki; Kadomatsu, Tsuyoshi; Yumoto, Shinsei; Miyata, Keishi; Yamamura, Shuji; Sato, Michio; Morinaga, Jun; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Kumamoto 8608556, Japan; [Horiguchi, Haruki; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Dept Aging & Geriatr Med, Kumamoto 8608556, Japan; [Kadomatsu, Tsuyoshi; Miyata, Keishi; Moroishi, Toshiro; Oike, Yuichi] Kumamoto Univ, Ctr Metab Regulat Hlth Aging CMHA, Grad Sch Med Sci, Kumamoto 8608556, Japan; [Yumoto, Shinsei; Baba, Hideo] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto 8608556, Japan; [Masuda, Takeshi; Ohtsuki, Sumio] Kumamoto Univ, Fac Life Sci, Dept Pharmaceut Microbiol, Kumamoto 8608556, Japan; [Moroishi, Toshiro] Kumamoto Univ, Fac Life Sci, Dept Cell Signaling & Metab Med, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University	Kadomatsu, T; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Kumamoto 8608556, Japan.; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Aging & Geriatr Med, Kumamoto 8608556, Japan.; Kadomatsu, T; Oike, Y (corresponding author), Kumamoto Univ, Ctr Metab Regulat Hlth Aging CMHA, Grad Sch Med Sci, Kumamoto 8608556, Japan.	tkado@gpo.kumamoto-u.ac.jp; oike@gpo.kumamoto-u.ac.jp	Ohtsuki, Sumio/S-4360-2016; Miyata, Keishi/HGF-1876-2022	Ohtsuki, Sumio/0000-0003-4634-7133; Miyata, Keishi/0000-0003-0336-1859; SATO, MICHIO/0000-0001-9339-1642	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [21K07101, 21K15508]; Takeda Science Foundation; Tasaki Memorial Research Grant	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Takeda Science Foundation(Takeda Science Foundation (TSF)); Tasaki Memorial Research Grant	We thank Kiyoka Tabu, Noriko Shirai, and Sayomi Iwaki for technical assistance. This work was supported by the Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (grant 21K07101 to TK and grant 21K15508 to HH), the Takeda Science Foundation (HH, TK), and Tasaki Memorial Research Grant for 2021 (HH).	Aoi J, 2011, CANCER RES, V71, P7502, DOI 10.1158/0008-5472.CAN-11-1758; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Cheng J, 2019, BMC EVOL BIOL, V19, DOI 10.1186/s12862-019-1477-1; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; Endo M, 2012, CANCER RES, V72, P1784, DOI 10.1158/0008-5472.CAN-11-3878; Feltes CM, 2002, CANCER RES, V62, P6688; Halbleib JM, 2007, MOL BIOL CELL, V18, P4261, DOI 10.1091/mbc.E07-04-0308; Hato T, 2008, TRENDS CARDIOVAS MED, V18, P6, DOI 10.1016/j.tcm.2007.10.003; HOFFMANN I, 1995, DEV BIOL, V169, P337, DOI 10.1006/dbio.1995.1148; Horiguchi H, 2021, ONCOGENE, V40, P55, DOI 10.1038/s41388-020-01505-7; Horiguchi H, 2019, GENE DEV, V33, P1641, DOI 10.1101/gad.329417.119; Horiguchi H, 2017, EMBO J, V36, P409, DOI 10.15252/embj.201695690; Horiguchi H, 2014, CANCER SCI, V105, P1550, DOI 10.1111/cas.12554; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Kadomatsu T, 2014, TRENDS ENDOCRIN MET, V25, P245, DOI 10.1016/j.tem.2014.03.012; Kaur H, 2012, MOL CANCER RES, V10, P293, DOI 10.1158/1541-7786.MCR-11-0457; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koshida S, 2005, DEV CELL, V8, P587, DOI 10.1016/j.devcel.2005.03.006; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Kumawat K, 2014, EXPERT OPIN THER TAR, V18, P1023, DOI 10.1517/14728222.2014.934813; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Masuda T, 2015, SCI REP-UK, V5, DOI 10.1038/srep09170; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427; Motokawa I, 2016, AM J PHYSIOL-LUNG C, V311, pL704, DOI 10.1152/ajplung.00005.2016; Munro SB, 1995, EXP MOL PATHOL, V62, P118, DOI 10.1006/exmp.1995.1013; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Odagiri H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004612; Oike Y, 2003, P NATL ACAD SCI USA, V100, P9494, DOI 10.1073/pnas.1531901100; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Osumi H, 2020, CANCER SCI, V111, P1241, DOI 10.1111/cas.14337; Oudhoff MJ, 2016, DEV CELL, V37, P47, DOI 10.1016/j.devcel.2016.03.002; Pishvaian MJ, 1999, CANCER RES, V59, P947; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Satriyo PB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020148; Shibata T, 1996, CANCER LETT, V99, P147, DOI 10.1016/0304-3835(95)04047-1; Starchenko A, 2017, MOL BIOL CELL, V28, P1288, DOI 10.1091/mbc.E16-12-0852; Su YY, 2008, MOL CELL, V32, P652, DOI 10.1016/j.molcel.2008.10.023; Tabata M, 2009, CELL METAB, V10, P178, DOI 10.1016/j.cmet.2009.08.003; Takahashi M, 1998, CANCER RES, V58, P42; Tomita K, 2000, CANCER RES, V60, P3650; van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhui QQ, 2018, ONCOL LETT, V15, P1417, DOI 10.3892/ol.2017.7458	50	1	1	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					4028	4041		10.1038/s41388-022-02405-8	http://dx.doi.org/10.1038/s41388-022-02405-8		JUL 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35831580				2022-12-28	WOS:000824241600001
J	Liu, YQ; Luo, M; Shi, Y; Guo, Y; Zhang, H; Yang, KD; Li, TR; Yang, LQ; Liu, TT; Huang, B; Liu, Q; He, ZC; Zhang, XN; Wang, WY; Wang, S; Zeng, H; Niu, Q; Zhang, X; Cui, YH; Zhang, ZR; Bian, XW; Ping, YF				Liu, Yu-Qi; Luo, Min; Shi, Yu; Guo, Ying; Zhang, Hua; Yang, Kai-Di; Li, Tian-Ran; Yang, Liu-Qing; Liu, Ting-Ting; Huang, Bo; Liu, Qing; He, Zhi-Cheng; Zhang, Xiao-Ning; Wang, Wen-Ying; Wang, Shuai; Zeng, Hui; Niu, Qin; Zhang, Xia; Cui, You-Hong; Zhang, Zhi-Ren; Bian, Xiu-Wu; Ping, Yi-Fang			Dicer deficiency impairs proliferation but potentiates anti-tumoral effect of macrophages in glioblastoma	ONCOGENE			English	Article							MICRORNA; GLIOMA; INVASIVENESS; POLARIZATION	Glioblastoma is a lethal primary brain tumor with abundant immune-suppressive glioblastoma-associated macrophage (GAM) infiltration. Skewing immune suppressive GAMs towards an immune-activating phenotype represents a promising immunotherapeutic strategy against glioblastoma. Herein, we reported that genetic deletion of miRNA-processing enzyme Dicer in macrophages inhibited the growth of GL261 murine glioblastoma xenografts and prolonged survival of tumor-bearing mice. Single cell RNA sequencing (scRNA-seq) of the tumor-infiltrating immune cells revealed that Dicer deletion in macrophages reduced the proportion of cell-cycling GAM cluster and reprogramed the remaining GAMs towards a proinflammatory activation state (enhanced phagocytotic and IFN-producing signature). Dicer-deficient GAMs showed reduced level of cyclin-dependent kinases (CDK1 and CDK2) and increased expression of CDK inhibitor p27 Kip1, thus manifesting impaired proliferation. Dicer knockout enhanced phagocytotic activity of GAMs to eliminate GL261 tumor cells. Increased proinflammatory GAM clusters in macrophage Dicer-deficient mice actively interacted with tumor-infiltrating T cells and NK cells through TNF paracrine signaling to create a pro-inflammatory immune microenvironment for tumor cell elimination. Our work identifies the role of Dicer deletion in macrophages in generating an immune-activating microenvironment, which could be further developed as a potential immunotherapeutic strategy against glioblastoma.	[Liu, Yu-Qi; Luo, Min; Shi, Yu; Guo, Ying; Zhang, Hua; Yang, Kai-Di; Li, Tian-Ran; Yang, Liu-Qing; Liu, Qing; He, Zhi-Cheng; Zhang, Xiao-Ning; Wang, Wen-Ying; Wang, Shuai; Zeng, Hui; Niu, Qin; Zhang, Xia; Cui, You-Hong; Bian, Xiu-Wu; Ping, Yi-Fang] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Inst Pathol, Chongqing 400038, Peoples R China; [Liu, Yu-Qi; Luo, Min; Shi, Yu; Guo, Ying; Zhang, Hua; Yang, Kai-Di; Li, Tian-Ran; Yang, Liu-Qing; Liu, Qing; He, Zhi-Cheng; Zhang, Xiao-Ning; Wang, Wen-Ying; Wang, Shuai; Zeng, Hui; Niu, Qin; Zhang, Xia; Cui, You-Hong; Bian, Xiu-Wu; Ping, Yi-Fang] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China; [Liu, Yu-Qi; Luo, Min; Shi, Yu; Guo, Ying; Zhang, Hua; Yang, Kai-Di; Li, Tian-Ran; Yang, Liu-Qing; Liu, Qing; He, Zhi-Cheng; Zhang, Xiao-Ning; Wang, Wen-Ying; Wang, Shuai; Zeng, Hui; Niu, Qin; Zhang, Xia; Cui, You-Hong; Bian, Xiu-Wu; Ping, Yi-Fang] Minist Educ China, Key Lab Tumor Immunopathol, Chongqing 400038, Peoples R China; [Liu, Yu-Qi] Third Mil Med Univ, Army Med Univ, Xingiao Hosp, Army Hosp 953,Shigatse Branch, Shigatse 857000, Peoples R China; [Liu, Ting-Ting; Huang, Bo; Zhang, Zhi-Ren] Third Mil Med Univ, Army Med Univ, Inst Immunol, Chongqing 400038, Peoples R China	Army Medical University; Army Medical University; Ministry of Education, China; Army Medical University; Army Medical University	Bian, XW; Ping, YF (corresponding author), Third Mil Med Univ, Army Med Univ, Southwest Hosp, Inst Pathol, Chongqing 400038, Peoples R China.; Bian, XW; Ping, YF (corresponding author), Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China.; Bian, XW; Ping, YF (corresponding author), Minist Educ China, Key Lab Tumor Immunopathol, Chongqing 400038, Peoples R China.; Zhang, ZR (corresponding author), Third Mil Med Univ, Army Med Univ, Inst Immunol, Chongqing 400038, Peoples R China.	zhangzhiren@tmmu.edu.cn; bianxiuwu@263.net; pingyifang@126.com	Zhang, Xia/B-8152-2008; liu, ting/GZM-3326-2022	Zhang, Xia/0000-0002-9040-1486; liuqing, yang/0000-0002-9727-8580; Liu, Yuqi/0000-0002-5247-2152	National Natural Science Foundation of China [81821003, 81702940, 81922056]; National Key Research and Development Program of China [2016YFA0502201]; Science and Technology Innovation Project of Chongqing Science and Technology Commission, China [cstc2021yszx-jcyj0003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Science and Technology Innovation Project of Chongqing Science and Technology Commission, China	This research was supported by the National Natural Science Foundation of China under Grants [Nos. 81821003, 81702940 and 81922056], the National Key Research and Development Program of China (2016YFA0502201), and Science and Technology Innovation Project of Chongqing Science and Technology Commission, China (No. cstc2021yszx-jcyj0003).	Antonios JP, 2017, NEURO-ONCOLOGY, V19, P796, DOI 10.1093/neuonc/now287; Antunes ARP, 2021, NAT NEUROSCI, V24, P595, DOI 10.1038/s41593-020-00789-y; Baer C, 2016, NAT CELL BIOL, V18, P790, DOI 10.1038/ncb3371; Canfran-Duque A, 2017, EMBO MOL MED, V9, P1244, DOI 10.15252/emmm.201607492; Chen ZH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01004; Cho YK, 2019, MOL METAB, V29, P86, DOI 10.1016/j.molmet.2019.08.015; Cloughesy TF, 2019, NAT MED, V25, P477, DOI 10.1038/s41591-018-0337-7; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Dupont G, 2019, CLIN ANAT, V32, P117, DOI 10.1002/ca.23308; Feng MY, 2019, NAT REV CANCER, V19, P568, DOI 10.1038/s41568-019-0183-z; Frederico SC, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.672508; Gholamin S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf2968; Grabowski MM, 2021, J NEURO-ONCOL, V151, P3, DOI 10.1007/s11060-020-03483-y; Gross TJ, 2014, J BIOL CHEM, V289, P12823, DOI 10.1074/jbc.M114.565473; Gutmann DH, 2019, NEURON, V104, P442, DOI 10.1016/j.neuron.2019.08.028; Horwitz SM, 2018, BLOOD, V131, P888, DOI 10.1182/blood-2017-08-802470; Jackson CM, 2019, NAT IMMUNOL, V20, P1100, DOI 10.1038/s41590-019-0433-y; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Ma PF, 2017, J HEPATOL, V67, P770, DOI 10.1016/j.jhep.2017.05.022; Mathsyaraja H, 2015, ONCOGENE, V34, P3651, DOI 10.1038/onc.2014.294; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Ostrom QT, 2018, JAMA ONCOL, V4, P1254, DOI 10.1001/jamaoncol.2018.1789; Perry JR, 2017, NEW ENGL J MED, V376, P1027, DOI 10.1056/NEJMoa1611977; Piao Y, 2016, NEURO-ONCOLOGY, V18, P1230, DOI 10.1093/neuonc/now030; Prosniak M, 2013, CLIN CANCER RES, V19, P3776, DOI 10.1158/1078-0432.CCR-12-1940; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Romani M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00464; Ruckerl D, 2012, BLOOD, V120, P2307, DOI 10.1182/blood-2012-02-408252; Schalper KA, 2019, NAT MED, V25, P470, DOI 10.1038/s41591-018-0339-5; Shen C, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006259; Shi Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aah6816; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Spigel DR, 2021, ANN ONCOL, V32, P631, DOI 10.1016/j.annonc.2021.01.071; Szulzewsky F, 2018, NEURO-ONCOLOGY, V20, P355, DOI 10.1093/neuonc/nox165; von Roemeling CA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15129-8; Wang X, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1085-3; Wei YY, 2018, CIRCULATION, V138, P2007, DOI 10.1161/CIRCULATIONAHA.117.031589; Weiss T, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb2311; Wu KY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01731; Xie F, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0892-z; Xun QJ, 2020, CURR MED CHEM, V27, P3944, DOI 10.2174/1573394715666190618121649; Zhang J, 2012, CARCINOGENESIS, V33, P312, DOI 10.1093/carcin/bgr289	42	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3791	3803		10.1038/s41388-022-02393-9	http://dx.doi.org/10.1038/s41388-022-02393-9		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35764885				2022-12-28	WOS:000817826700001
J	Ueshima, S; Fang, J				Ueshima, Shuhei; Fang, Jia			Histone H3K9 methyltransferase SETDB1 augments invadopodia formation to promote tumor metastasis	ONCOGENE			English	Article							DNA METHYLATION; MESENCHYMAL TRANSITION; LUNG-CANCER; E-CADHERIN; FOXA2; PROGRESSION; EXPRESSION; ESET; TRANSCRIPTION; SUPPRESSOR	Non-small cell lung cancer (NSCLC) is one of leading causes of cancer-related mortality worldwide, which harbors various accumulated genetic and epigenetic abnormalities. Histone methyltransferase SETDB1 is a pivotal epigenetic regulator whose focal amplification and upregulation are commonly detected in NSCLC. However, molecular mechanisms underlying the pro-oncogenic function of SETDB1 remain poorly characterized. Here, we demonstrate that SETDB1 augments the migration and invasion capabilities of NSCLC cells by reinforcing invadopodia formation and mediated ECM degradation. At the molecular level, SETDB1 suppresses the expression of FOXA2, a crucial tumor and metastasis suppressor via coordinated epigenetic mechanisms - SETDB1 not only catalyzes histone H3K9 methylation on FOXA2 genomic locus, but also recruits DNMT3A to regulate DNA methylation on CpG island. Consequently, depletion of Setdb1 in murine lung adenocarcinoma cells completely abolished their full and spontaneous metastatic capabilities in mouse xenograft models. These findings together establish the pro-metastasis activity of SETDB1 in NSCLC and elucidate the underlying cellular and molecular mechanisms.	[Ueshima, Shuhei; Fang, Jia] Roswell Park Comprehens Canc Ctr, Dept Pharmacol Therapeut, Buffalo, NY 14263 USA		Fang, J (corresponding author), Roswell Park Comprehens Canc Ctr, Dept Pharmacol Therapeut, Buffalo, NY 14263 USA.	Jia.Fang@RoswellPark.org		Fang, Jia/0000-0001-8583-1652	NIH [CA172774]; Roswell Park Alliance Foundation; RPCCC; NCI center grant [P30CA016056]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Roswell Park Alliance Foundation; RPCCC; NCI center grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Tyler Jacks for murine lung adenocarcinoma cell lines, Dr. Shengyu Yang for technical assistance with invadopodia assays, Dr. David Goodrich for constructive discussion and suggestions and support from Roswell Park Comprehensive Cancer Center (RPCCC) Shared Resources, including BIOINFO, GSR, TISR, and LASR. This project was supported, in part, by grants from the NIH (CA172774) and Roswell Park Alliance Foundation (all to JF), and by RPCCC and NCI center grant P30CA016056.	Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Basseres DS, 2012, LUNG CANCER, V77, P31, DOI 10.1016/j.lungcan.2012.01.011; Bowden ET, 2006, EXP CELL RES, V312, P1240, DOI 10.1016/j.yexcr.2005.12.012; Bowden ET, 2001, METHOD CELL BIOL, V63, P613; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Cruz-Tapias P, 2019, CANCERS, V11, DOI 10.3390/cancers11081134; Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004; Duruisseaux M, 2018, SEMIN CANCER BIOL, V51, P116, DOI 10.1016/j.semcancer.2017.09.005; Eckert MA, 2017, J CELL SCI, V130, P2036, DOI 10.1242/jcs.198200; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Fei Q, 2015, GENOME RES, V25, P1325, DOI 10.1101/gr.177576.114; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fukuda K, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060596; Gauchier M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3673; Griffin GK, 2021, NATURE, V595, P309, DOI 10.1038/s41586-021-03520-4; Guler GD, 2017, CANCER CELL, V32, P221, DOI 10.1016/j.ccell.2017.07.002; Halmos B, 2004, CANCER RES, V64, P4137, DOI 10.1158/0008-5472.CAN-03-4052; Halpern KB, 2014, J BIOL CHEM, V289, P23882, DOI 10.1074/jbc.M114.573469; Hawkins AG, 2019, NEOPLASIA, V21, P1063, DOI 10.1016/j.neo.2019.08.007; Holemon H, 2007, BIOTECHNIQUES, V43, P683, DOI 10.2144/000112597; Juznic L, 2021, GUT, V70, P485, DOI 10.1136/gutjnl-2020-321339; Kang YK, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.573515; Kokura K, 2010, EMBO J, V29, P3673, DOI 10.1038/emboj.2010.239; Lafuente-Sanchis A, 2016, CLIN TRANSL ONCOL, V18, P798, DOI 10.1007/s12094-015-1440-6; Lee T, 2016, J PATHOL TRANSL MED, V50, P197, DOI 10.4132/jptm.2016.03.09; Leung D, 2014, P NATL ACAD SCI USA, V111, P6690, DOI 10.1073/pnas.1322273111; Li CMC, 2015, GENE DEV, V29, P1850, DOI 10.1101/gad.267393.115; Li CMC, 2013, GENE DEV, V27, P1557, DOI 10.1101/gad.222745.113; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Liu JH, 2018, CANCER MANAG RES, V10, P391, DOI 10.2147/CMAR.S150552; Lowy CM, 2015, CELL ADHES MIGR, V9, P112, DOI 10.1080/19336918.2015.1008331; Mozzetta C, 2015, NAT REV MOL CELL BIO, V16, P499, DOI 10.1038/nrm4029; Naciri I, 2019, NUCLEIC ACIDS RES, V47, P3407, DOI 10.1093/nar/gkz080; Nyren-Erickson EK, 2013, BBA-GEN SUBJECTS, V1830, P4445, DOI 10.1016/j.bbagen.2013.05.011; Pelaez R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181579; Rodriguez-Paredes M, 2014, ONCOGENE, V33, P2807, DOI 10.1038/onc.2013.239; Saini P, 2018, J CELL SCI, V131, DOI 10.1242/jcs.203661; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smallwood A, 2007, GENE DEV, V21, P1169, DOI 10.1101/gad.1536807; Strepkos D, 2021, CANCER RES, V81, P525, DOI 10.1158/0008-5472.CAN-20-2906; Sun LD, 2016, CELL MOL LIFE SCI, V73, P4493, DOI 10.1007/s00018-016-2303-1; Takikita S, 2016, J IMMUNOL, V197, P2269, DOI 10.4049/jimmunol.1502486; Tang YN, 2011, CELL RES, V21, P316, DOI 10.1038/cr.2010.126; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Wang BL, 2018, EXP THER MED, V16, P133, DOI 10.3892/etm.2018.6157; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Wu PC, 2014, CANCER RES, V74, P7333, DOI 10.1158/0008-5472.CAN-13-3572; Yuan P, 2009, GENE DEV, V23, P2507, DOI 10.1101/gad.1831909; Zhang SM, 2021, NATURE, V598, P682, DOI 10.1038/s41586-021-03994-2; Zhang Z, 2015, CANCER LETT, V361, P240, DOI 10.1016/j.canlet.2015.03.008	51	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3370	3380		10.1038/s41388-022-02345-3	http://dx.doi.org/10.1038/s41388-022-02345-3		MAY 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35546351				2022-12-28	WOS:000793636100001
J	Bertolini, I; Perego, M; Ghosh, JC; Kossenkov, AV; Altieri, DC				Bertolini, Irene; Perego, Michela; Ghosh, Jagadish C.; Kossenkov, Andrew, V; Altieri, Dario C.			NF kappa B activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment	ONCOGENE			English	Article							INTEGRIN	Small extracellular vesicles (sEV) contribute to the crosstalk between tumor cells and stroma, but the underlying signals are elusive. Here, we show that sEV generated by breast cancer cells in hypoxic (sEV(HYP)), but not normoxic (sEV(NORM)) conditions activate NF kappa B in recipient normal mammary epithelial cells. This increases the production and release of inflammatory cytokines, promotes mitochondrial dynamics leading to heightened cell motility and disrupts 3D mammary acini architecture with aberrant cell proliferation, reduced apoptosis and EMT. Mechanistically, Integrin-Linked Kinase packaged in sEV(HYP) via HIF1 alpha is sufficient to activate NF kappa B in the normal mammary epithelium, in vivo. Therefore, sEV(HYP) activation of NF kappa B drives multiple oncogenic steps of inflammation, mitochondrial dynamics, and mammary gland morphogenesis in a breast cancer microenvironment.	[Bertolini, Irene; Perego, Michela; Ghosh, Jagadish C.; Altieri, Dario C.] Wistar Inst Anat & Biol, Immunol Microenvironm & Metastasis Program, Philadelphia, PA 19104 USA; [Kossenkov, Andrew, V] Wistar Inst Anat & Biol, Bioinformat Shared Resource, Philadelphia, PA 19104 USA; [Kossenkov, Andrew, V] Wistar Inst Anat & Biol, Gene Express & Regulat Program, Philadelphia, PA 19104 USA	The Wistar Institute; The Wistar Institute; The Wistar Institute	Altieri, DC (corresponding author), Wistar Inst Anat & Biol, Immunol Microenvironm & Metastasis Program, Philadelphia, PA 19104 USA.	daltieri@wistar.org		ALTIERI, DARIO C/0000-0002-0617-3469	National Institutes of Health (NIH) [P01 CA140043, R35 CA220446, R50 CA211199]; Mary Kay Foundation	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary Kay Foundation	We thank James Hayden and Frederick Keeney of the Wistar Imaging Core Shared Resource for assistance with time-lapse videomicroscopy and Sudheer Mulugu of the Electron Microscopy Resource Lab, Perelman School of Medicine, University of Pennsylvania for cryo-electron microscopy. This work was supported by National Institutes of Health (NIH) grants P01 CA140043, R35 CA220446 (D.C.A.), R50 CA211199 (A.V.K.) and an award from the Mary Kay Foundation (D.C.A.).	Baram T, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.614468; Bertolini I, 2020, DEV CELL, V55, P163, DOI 10.1016/j.devcel.2020.07.014; Caino MC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13730; Chen F, 2019, NAT CELL BIOL, V21, P498, DOI 10.1038/s41556-019-0299-0; Curtius K, 2018, NAT REV CANCER, V18, P19, DOI 10.1038/nrc.2017.102; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Jaiswal R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00125; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Lucien F, 2019, BIOCHEM SOC T, V47, P273, DOI 10.1042/BST20180253; Ma YF, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.606906; Marar C, 2021, NAT IMMUNOL, V22, P560, DOI 10.1038/s41590-021-00899-0; Sansone P, 2017, P NATL ACAD SCI USA, V114, pE9066, DOI 10.1073/pnas.1704862114; Singh A, 2016, MOL CANCER RES, V14, P1136, DOI 10.1158/1541-7786.MCR-16-0058; Sung BH, 2021, DEV CELL, V56, P1861, DOI 10.1016/j.devcel.2021.03.020; Sung BH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15747-2; Vaynberg J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06906-7; You SX, 2019, P NATL ACAD SCI USA, V116, P24012, DOI 10.1073/pnas.1909243116; Zhao LJ, 2021, EMBO REP, V22, DOI 10.15252/embr.202050922	18	4	4	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2520	2525		10.1038/s41388-022-02280-3	http://dx.doi.org/10.1038/s41388-022-02280-3		MAR 2022	6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35354906	Green Accepted			2022-12-28	WOS:000775854600002
J	Chen, TC; Yao, CY; Chen, YR; Yuan, CT; Lin, CC; Hsu, YC; Chuang, PH; Kao, CJ; Li, YH; Hou, HA; Chou, WC; Tien, HF				Chen, Tsung-Chih; Yao, Chi-Yuan; Chen, Yu-Ren; Yuan, Chang-Tsu; Lin, Chien-Chin; Hsu, Yueh-Chwen; Chuang, Po-Han; Kao, Chein-Jun; Li, Yi-Hung; Hou, Hsin-An; Chou, Wen-Chien; Tien, Hwei-Fang			Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; NETWORKS; ATM	The pathogenesis of acute leukemia involves interaction among genetic alterations. Mutations of IDH1/2 and PHF6 are common and co-exist in some patients of hematopoietic malignancies, but their cooperative effects remain unexplored. In this study, we addressed the question by characterizing the hematopoietic phenotypes of mice harboring neither, Phf6 knockout, Idh2 R172K, or combined mutations. We found that the combined Phf6(KO)Idh2(R172K) mice showed biased hematopoietic differentiation toward myeloid lineages and reduced long-term hematopoietic stem cells. They rapidly developed neoplasms of myeloid and lymphoid lineages, with much shorter survival compared with single mutated and wild-type mice. The marrow and spleen cells of the combined mutated mice produced a drastically increased amount of 2-hydroxyglutarate compared with mice harboring Idh2 R172K. Single-cell RNA sequencing revealed distinct patterns of transcriptome of the hematopoietic stem/progenitor cells from the combined mutated mice, including aberrant expression of metabolic enzymes, increased expression of several oncogenes, and impairment of DNA repairs, as confirmed by the enhanced gamma H2AX expression in the marrow and spleen cells. We conclude that Idh2 and Phf6 mutations are synergistic in leukemogenesis, at least through overproduction of 2-hydroxyglutarate and impairment of DNA repairs.	[Chen, Tsung-Chih] Taichung Vet Gen Hosp, Dept Internal Med, Div Hematol Med Oncol, Taichung, Taiwan; [Chen, Tsung-Chih; Yao, Chi-Yuan; Yuan, Chang-Tsu; Lin, Chien-Chin; Chuang, Po-Han] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Yao, Chi-Yuan; Chen, Yu-Ren; Lin, Chien-Chin; Hsu, Yueh-Chwen; Chuang, Po-Han; Kao, Chein-Jun; Chou, Wen-Chien] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Yuan, Chang-Tsu; Chou, Wen-Chien] Natl Taiwan Univ, Dept Pathol, Canc Ctr, Taipei, Taiwan; [Yuan, Chang-Tsu] Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan; [Li, Yi-Hung] Chinese Culture Univ, Dept Anim Sci, Taipei, Taiwan; [Hou, Hsin-An; Tien, Hwei-Fang] Natl Taiwan Univ Hosp, Dept Internal Med, Div Hematol, Taipei, Taiwan	Taichung Veterans General Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Chinese Culture University; National Taiwan University; National Taiwan University Hospital	Chou, WC (corresponding author), Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan.; Chou, WC (corresponding author), Natl Taiwan Univ, Dept Pathol, Canc Ctr, Taipei, Taiwan.	wchou@ntu.edu.tw		Yuan, Chang-Tsu/0000-0003-1438-9187; LIN, CHIEN-CHIN/0000-0001-7160-2285; CHOU, WEN-CHIEN/0000-0003-2967-698X	Ministry of Science and Technology of Taiwan [MOST 106-2314-B-002-224-MY3, MOST 106-2314-B-002-152-, MOST 107-2314-B-075A-010-, MOST 108-2314-B-075A-007-, MOST 109-2314-B-002 -221-, MOST 109-2314-B-075A-008-MY2]; Ministry of Health and Welfare [MOHW109-TDU-B-211-134009];  [TCVGH-1093702B];  [TCVGH-1103701B]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan); ; 	We thank the technical services provided by the Transgenic Mouse Model Core Facility of the National Core Facility Program for Biotechnology, Ministry of Science and Technology, the Animal Resources Laboratory of National Taiwan University Centers of Genomic and Precision Medicine, the Metabolomics Core Laboratory of National Taiwan University Center of Genomic Medicine, and the National Center for Genome Medicine. We thank the technical help from the Genomics Core Facility of the Institute of Molecular Biology, Academia Sinica. We would like to acknowledge the service provided by the Flow Cytometric Analyzing and Sorting Core Facilities at National Taiwan University Hospital and First Core Laboratory of National Taiwan University College of Medicine. The study was supported by research grants including TCVGH-1093702B, TCVGH-1103701B, Ministry of Science and Technology of Taiwan (MOST 106-2314-B-002-224-MY3, MOST 106-2314-B-002-152-, MOST 107-2314-B-075A-010-, MOST 108-2314-B-075A-007-, MOST 109-2314-B-002 -221- and MOST 109-2314-B-075A-008-MY2-), and Ministry of Health and Welfare (MOHW109-TDU-B-211-134009).	Abelson S, 2018, NATURE, V559, P400, DOI 10.1038/s41586-018-0317-6; Amson R, 2012, NAT MED, V18, P91, DOI 10.1038/nm.2546; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bommer UA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071632; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Chan SM, 2015, NAT MED, V21, P178, DOI 10.1038/nm.3788; Chen C, 2013, GENE DEV, V27, P1974, DOI 10.1101/gad.226613.113; Corces-Zimmerman MR, 2014, P NATL ACAD SCI USA, V111, P2548, DOI 10.1073/pnas.1324297111; Dahlin JS, 2018, BLOOD, V131, pE1, DOI 10.1182/blood-2017-12-821413; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; de Rooij JDE, 2016, BRIT J HAEMATOL, V175, P967, DOI 10.1111/bjh.13891; Dekker LJM, 2020, FASEB J, V34, P3646, DOI 10.1096/fj.201902352R; Desai P, 2018, NAT MED, V24, P1015, DOI 10.1038/s41591-018-0081-z; Duan L, 2019, CANCER BIOL THER, V20, P252, DOI 10.1080/15384047.2018.1523858; Gan LH, 2020, CELL REP, V30, P3717, DOI 10.1016/j.celrep.2020.02.085; Holmfeldt L, 2010, PEDIATR BLOOD CANCER, V55, P595, DOI 10.1002/pbc.22661; Hsu YC, 2019, BLOOD ADV, V3, P2355, DOI 10.1182/bloodadvances.2019000391; Inoue S, 2016, CANCER CELL, V30, P337, DOI 10.1016/j.ccell.2016.05.018; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Lemonnier F, 2016, P NATL ACAD SCI USA, V113, P15084, DOI 10.1073/pnas.1617929114; Lin CC, 2014, AM J HEMATOL, V89, P137, DOI 10.1002/ajh.23596; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McRae HM, 2019, BLOOD, V133, P1729, DOI 10.1182/blood-2018-07-860726; Miyagi S, 2019, BLOOD, V133, P2495, DOI 10.1182/blood.2019000468; Molenaar RJ, 2018, ONCOGENE, V37, P1949, DOI 10.1038/s41388-017-0077-z; Mori T, 2016, LEUKEMIA, V30, P2270, DOI 10.1038/leu.2016.212; Nestorowa S, 2016, BLOOD, V128, pE20, DOI 10.1182/blood-2016-05-716480; Notta F, 2016, SCIENCE, V351, P139, DOI 10.1126/science.aab2116; Oh S, 2020, NUCLEIC ACIDS RES, V48, P9037, DOI 10.1093/nar/gkaa626; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Pellin D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10291-0; Psaila B, 2020, MOL CELL, V78, P477, DOI 10.1016/j.molcel.2020.04.008; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038; Soto-Feliciano YM, 2017, GENE DEV, V31, P973, DOI 10.1101/gad.295857.117; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Van Vlierberghe P, 2011, LEUKEMIA, V25, P130, DOI 10.1038/leu.2010.247; Van Vlierberghe P, 2010, NAT GENET, V42, P338, DOI 10.1038/ng.542; Wang JD, 2013, J BIOL CHEM, V288, P3174, DOI 10.1074/jbc.M112.414839; Wang P, 2015, CELL REP, V13, P2353, DOI 10.1016/j.celrep.2015.11.029; Wang Q, 2011, HAEMATOL-HEMATOL J, V96, P1808, DOI 10.3324/haematol.2011.043083; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Warmerdam DO, 2020, EMBO REP, V21, DOI 10.15252/embr.201948460; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wendorff AA, 2019, CANCER DISCOV, V9, P436, DOI 10.1158/2159-8290.CD-18-1005; Xia D, 2017, LEUKEMIA LYMPHOMA, V58, P2208, DOI 10.1080/10428194.2017.1287358; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Ye D, 2018, TRENDS CANCER, V4, P151, DOI 10.1016/j.trecan.2017.12.005; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang H, 2013, CANCER CELL, V24, P575, DOI 10.1016/j.ccr.2013.09.018; Zhang XT, 2020, BLOOD, V135, P845, DOI 10.1182/blood.2019003330; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; Zhou C, 2017, LEUKEMIA, V31, P1196, DOI 10.1038/leu.2016.329	56	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1576	1588		10.1038/s41388-022-02193-1	http://dx.doi.org/10.1038/s41388-022-02193-1		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35091680				2022-12-28	WOS:000749073300002
J	Melnyk, JE; Steri, V; Nguyen, HG; Hwang, YC; Gordan, JD; Hann, B; Feng, FY; Shokat, KM				Melnyk, James E.; Steri, Veronica; Nguyen, Hao G.; Hwang, Y. Christina; Gordan, John D.; Hann, Byron; Feng, Felix Y.; Shokat, Kevan M.			Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKC beta 1	ONCOGENE			English	Article							ANDROGEN-RECEPTOR; ENZALUTAMIDE RESISTANCE; DOWN-REGULATION; VARIANTS; ENZASTAURIN; EXPRESSION; DOMAIN; PHOSPHORYLATION; OLIGONUCLEOTIDE; ANTIANDROGEN	The androgen receptor (AR) is a central driver of aggressive prostate cancer. After initial treatment with androgen receptor signaling inhibitors (ARSi), reactivation of AR signaling leads to resistance. Alternative splicing of AR mRNA yields the AR-V7 splice variant, which is currently an undruggable mechanism of ARSi resistance: AR-V7 lacks a ligand binding domain, where hormones and anti-androgen antagonists act, but still activates AR signaling. We reveal PKC beta as a druggable regulator of transcription and splicing at the AR genomic locus. We identify a clinical PKC beta inhibitor in combination with an FDA-approved anti-androgen as an approach for repressing AR genomic locus expression, including expression of AR-V7, while antagonizing full-length AR. PKC beta inhibition reduces total AR gene expression, thus reducing AR-V7 protein levels and sensitizing prostate cancer cells to current anti-androgen therapies. We demonstrate that this combination may be a viable therapeutic strategy for AR-V7-positive prostate cancer.	[Melnyk, James E.; Shokat, Kevan M.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Steri, Veronica; Nguyen, Hao G.; Hwang, Y. Christina; Gordan, John D.; Hann, Byron; Feng, Felix Y.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA; [Steri, Veronica; Hann, Byron] Univ Calif San Francisco, Preclin Therapeut Core, San Francisco, CA 94158 USA; [Nguyen, Hao G.; Feng, Felix Y.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA; [Hwang, Y. Christina; Gordan, John D.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA; [Hwang, Y. Christina; Gordan, John D.] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94158 USA; [Feng, Felix Y.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; [Feng, Felix Y.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Shokat, Kevan M.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Shokat, KM (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.; Shokat, KM (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	Kevan.shokat@ucsf.edu		Melnyk, James/0000-0003-1915-8089	NIH [1F32CA236347-01, R01 CA227025, 1R01CA221969-01, 1R01CA244550]; PCF YI; Burroughs Wellcome Fund Career Award; Benioff Initiative for Prostate Cancer Research; Howard Hughes Medical Institute; Samuel Waxman Cancer Research Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PCF YI; Burroughs Wellcome Fund Career Award(Burroughs Wellcome Fund); Benioff Initiative for Prostate Cancer Research; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Samuel Waxman Cancer Research Foundation	We thank Davide Ruggero, the UCSF Preclinical Therapeutics Core and the UCSF/Gladstone Institutes Thermo Fisher Scientific Proteomics Facility for research assistance and discussion. We thank Amy Crossan, Shizong A. Dai, Douglas Wassarman, and Jack Stevenson for critical reading of this paper. Portions of Fig. 1A and Fig. 6A were created with BioRender.com. This work is supported by NIH grant 1F32CA236347-01 (to J.E.M.); PCF YI and Challenge grants (to H.G.N.); Burroughs Wellcome Fund Career Award (to J.D. G.); NIH R01 CA227025 and the Benioff Initiative for Prostate Cancer Research (to F.Y.F.), the Howard Hughes Medical Institute, Samuel Waxman Cancer Research Foundation, NIH 1R01CA221969-01 and NIH 1R01CA244550 (to K.M.S.).	An SA, 2018, EBIOMEDICINE, V36, P553, DOI 10.1016/j.ebiom.2018.09.005; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Armstrong CM, 2019, ASIAN J UROL, V6, P42, DOI 10.1016/j.ajur.2018.07.003; Bain DL, 2007, ANNU REV PHYSIOL, V69, P201, DOI 10.1146/annurev.physiol.69.031905.160308; Beretta GL, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00369; Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016; Bianchini D, 2013, BRIT J CANCER, V109, P2579, DOI 10.1038/bjc.2013.619; Cai CM, 2014, CELL REP, V9, P1618, DOI 10.1016/j.celrep.2014.11.008; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Carabet LA, 2019, MOLECULES, V24, DOI 10.3390/molecules24040763; Choi M, 2014, BIOINFORMATICS, V30, P2524, DOI 10.1093/bioinformatics/btu305; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; De Mol E, 2016, ACS CHEM BIOL, V11, P2499, DOI 10.1021/acschembio.6b00182; De Velasco MA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122688; Dreicer R, 2013, INVEST NEW DRUG, V31, P1044, DOI 10.1007/s10637-013-9940-0; Dreicer R, 2011, INVEST NEW DRUG, V29, P1441, DOI 10.1007/s10637-010-9428-0; Gao S, 2016, CELL REP, V17, P966, DOI 10.1016/j.celrep.2016.09.064; Graff JR, 2005, CANCER RES, V65, P7462, DOI 10.1158/0008-5472.CAN-05-0071; Han D, 2019, CANCER RES, V79, P5260, DOI 10.1158/0008-5472.CAN-19-0815; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; HUANG FL, 1989, J BIOL CHEM, V264, P4238; Hwang DJ, 2019, J MED CHEM, V62, P491, DOI 10.1021/acs.jmedchem.8b00973; Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162; Khurana N, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9010068; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Kwegyir-Afful AK, 2015, ONCOTARGET, V6, P27440, DOI 10.18632/oncotarget.4578; Lehar J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100116; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Li HF, 2014, J MED CHEM, V57, P6458, DOI 10.1021/jm500802j; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Loberg RD, 2006, UROL ONCOL-SEMIN ORI, V24, P161, DOI 10.1016/j.urolonc.2005.11.005; Makkonen H, 2011, MOL CELL ENDOCRINOL, V331, P57, DOI 10.1016/j.mce.2010.08.008; Maurer U, 2014, J CELL SCI, V127, P1369, DOI 10.1242/jcs.138057; Melnyk JE, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2020.115712; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2003, EMBO J, V22, P270, DOI 10.1093/emboj/cdg023; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Myung JK, 2013, J CLIN INVEST, V123, P2948, DOI 10.1172/JCI66398; Newton AC, 2010, AM J PHYSIOL-ENDOC M, V298, pE395, DOI 10.1152/ajpendo.00477.2009; Podar K, 2007, BLOOD, V109, P1669, DOI 10.1182/blood-2006-08-042747; Ponnusamy S, 2019, CLIN CANCER RES, V25, P6764, DOI 10.1158/1078-0432.CCR-19-1458; Prekovic S, 2016, MOL CANCER THER, V15, P1702, DOI 10.1158/1535-7163.MCT-15-0892; Putney James W, 2012, Adv Biol Regul, V52, P152; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Saha SK, 2016, CANCER DISCOV, V6, P727, DOI 10.1158/2159-8290.CD-15-1442; Salami J, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0105-8; Scher Howard I, 2016, JAMA Oncol, V2, P1441, DOI 10.1001/jamaoncol.2016.1828; Schilling B, 2012, MOL CELL PROTEOMICS, V11, P202, DOI 10.1074/mcp.M112.017707; Shiota M, 2014, CLIN CANCER RES, V20, P951, DOI 10.1158/1078-0432.CCR-13-1809; Thorne CA, 2015, NAT CHEM BIOL, V11, P58, DOI 10.1038/nchembio.1690; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Velez MVL, 2019, ONCOGENE, V38, P3696, DOI 10.1038/s41388-019-0696-7; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Xiao LB, 2018, CANCER RES, V78, P5731, DOI 10.1158/0008-5472.CAN-18-0941; Yadav B, 2015, COMPUT STRUCT BIOTEC, V13, P504, DOI 10.1016/j.csbj.2015.09.001; Yang ZY, 2020, MOL CANCER THER, V19, P75, DOI 10.1158/1535-7163.MCT-19-0489; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Zhang XW, 2017, MOL THER, V25, P79, DOI 10.1016/j.ymthe.2016.10.017	68	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1536	1549		10.1038/s41388-022-02179-z	http://dx.doi.org/10.1038/s41388-022-02179-z		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35087237	Green Published, hybrid			2022-12-28	WOS:000749068200001
J	Madrazo, E; Gonzalez-Novo, R; Ortiz-Placin, C; de Lacoba, MG; Gonzalez-Murillo, A; Ramirez, M; Redondo-Munoz, J				Madrazo, Elena; Gonzalez-Novo, Raquel; Ortiz-Placin, Candido; Garcia de Lacoba, Mario; Gonzalez-Murillo, Africa; Ramirez, Manuel; Redondo-Munoz, Javier			Fast H3K9 methylation promoted by CXCL12 contributes to nuclear changes and invasiveness of T-acute lymphoblastic leukemia cells	ONCOGENE			English	Article							MIGRATION; KINASE; CXCR4; INFILTRATION; CHROMATIN; PATHOGENESIS; PHOSPHORYLATION; DEFORMATION; STRATEGIES; ORIGINS	T-acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that comprises the accumulation of malignant T-cells. Despite current therapies, failure to conventional treatments and relapse are frequent in children with T-ALL. It is known that the chemokine CXCL12 modulates leukemia survival and dissemination; however, our understanding of molecular mechanisms used by T-ALL cells to infiltrate and respond to leukemia cells-microenvironment interactions is still vague. In the present study, we showed that CXCL12 promoted H3K9 methylation in cell lines and primary T-ALL cells within minutes. We thus identified that CXCL12-mediated H3K9 methylation affected the global chromatin configuration and the nuclear mechanics of T-ALL cells. Importantly, we characterized changes in the genomic profile of T-ALL cells associated with rapid CXCL12 stimulation. We showed that blocking CXCR4 and protein kinase C (PKC) impaired the H3K9 methylation induced by CXCL12 in T-ALL cells. Finally, blocking H3K9 methyltransferases reduced the efficiency of T-ALL cells to deform their nuclei, migrate across confined spaces, and home to spleen and bone marrow in vivo models. Together, our data show novel functions for CXL12 as a master regulator of nuclear deformability and epigenetic changes in T-ALL cells, and its potential as a promising pharmacological target against T-ALL dissemination.	[Madrazo, Elena; Gonzalez-Novo, Raquel; Ortiz-Placin, Candido; Redondo-Munoz, Javier] Ctr Invest Biol Margarita Salas CIB Margarita Sal, Dept Mol Med, Madrid, Spain; [Garcia de Lacoba, Mario] Ctr Invest Biol Margarita Salas CIB Margarita Sal, Bioinformat & Biostat Unit, Madrid, Spain; [Gonzalez-Murillo, Africa; Ramirez, Manuel] Hosp Univ Nino Jesus, Dept Paediat Haematol & Oncol, Madrid, Spain; [Gonzalez-Murillo, Africa; Ramirez, Manuel] Hlth Res Inst La Princesa, Madrid, Spain		Redondo-Munoz, J (corresponding author), Ctr Invest Biol Margarita Salas CIB Margarita Sal, Dept Mol Med, Madrid, Spain.	Javier.redondo@cib.csic.es	; Gonzalez, Africa/M-3426-2014	Gonzalez-Novo, Raquel/0000-0002-3796-2751; Redondo-Munoz, Javier/0000-0003-0607-2171; Ortiz Placin, Candido/0000-0003-0529-4047; Gonzalez, Africa/0000-0001-7747-1204	FPI Scholarship 2018 (Ministerio de Ciencia e Innovacion/MICINN); FPI Scholarship 2018 (Agencia Estatal de Investigacion/AEI); FPI Scholarship 2018 (Fondo Europeo de Desarrollo Regional/FEDER); undergraduate fellowship "Beca de Introduccion a la Investigacion" (Asociacion Espanola Contra el Cancer); Asociacion Pablo Ugarte; Gilead Sciences International Scholar in Hematology/Oncology (Gilead); 2020 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation); Ministerio de Ciencia e Innovacion/MICINN [SAF2017-86327-R]; Agencia Estatal de Investigacion/AEI [SAF2017-86327-R]; Fondo Europeo de Desarrollo Regional/FEDER [SAF2017-86327-R]	FPI Scholarship 2018 (Ministerio de Ciencia e Innovacion/MICINN); FPI Scholarship 2018 (Agencia Estatal de Investigacion/AEI); FPI Scholarship 2018 (Fondo Europeo de Desarrollo Regional/FEDER); undergraduate fellowship "Beca de Introduccion a la Investigacion" (Asociacion Espanola Contra el Cancer); Asociacion Pablo Ugarte; Gilead Sciences International Scholar in Hematology/Oncology (Gilead); 2020 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation); Ministerio de Ciencia e Innovacion/MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Agencia Estatal de Investigacion/AEI; Fondo Europeo de Desarrollo Regional/FEDER(European CommissionSpanish Government)	The authors thank the Microscopy Unit and the Flow Cytometry Core Unit of Instituto de Investigacion Biosanitaria Gregorio Maranon (IiSGM) for assistance with confocal, videomicroscopy and flow cytometry analyses. The UCM-Genomic CAI Unit for their assistance with the microarray experiments. We thank Dr. Ignacio Casal, Joaquin Teixido, Alicia Garcia-Arroyo and Maria Montoya for insightful and critical comments. This research was supported by a FPI Scholarship 2018 (Ministerio de Ciencia e Innovacion/MICINN, Agencia Estatal de Investigacion/AEI y Fondo Europeo de Desarrollo Regional/FEDER) to R. G.N.; an undergraduate fellowship "Beca de Introduccion a la Investigacion" (Asociacion Espanola Contra el Cancer) to C.O.P.; and by grants from Asociacion Pablo Ugarte to M.R., Gilead Sciences International Scholar in Hematology/Oncology (Gilead), 2020 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation) and SAF2017-86327-R (Ministerio de Ciencia e Innovacion/MICINN, Agencia Estatal de Investigacion/AEI y Fondo Europeo de Desarrollo Regional/FEDER) to J.R.M.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Almamun M, 2015, EPIGENETICS-US, V10, P882, DOI 10.1080/15592294.2015.1078050; Alsadeq A, 2017, HAEMATOLOGICA, V102, P346, DOI 10.3324/haematol.2016.147744; Altman A, 2016, ANNU REV IMMUNOL, V34, P511, DOI 10.1146/annurev-immunol-041015-055347; Apaolaza I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00555-y; Bao Y, 2019, ONCOGENE, V38, P881, DOI 10.1038/s41388-018-0452-4; Barbieri F, 2016, EXPERT OPIN DRUG DIS, V11, P1093, DOI 10.1080/17460441.2016.1233176; Bendall LJ, 2005, CANCER RES, V65, P3290, DOI 10.1158/0008-5472.CAN-04-3402; Bradstock KF, 2000, LEUKEMIA, V14, P882, DOI 10.1038/sj.leu.2401729; Cancilla D, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01672; Cannon JL, 2017, ONCOTARGET, V8, P84626, DOI 10.18632/oncotarget.21394; Melo RDC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085926; Crazzolara R, 2001, BRIT J HAEMATOL, V115, P545, DOI 10.1046/j.1365-2141.2001.03164.x; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Edens LJ, 2017, MOL BIOL CELL, V28, P1389, DOI 10.1091/mbc.E16-11-0786; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Friedl P, 2011, CURR OPIN CELL BIOL, V23, P55, DOI 10.1016/j.ceb.2010.10.015; Frishman-Levy L, 2017, BRIT J HAEMATOL, V176, P157, DOI 10.1111/bjh.14411; Gerlitz G, 2010, J CELL SCI, V123, P2207, DOI 10.1242/jcs.058271; Gomez AM, 2015, BLOOD CELL MOL DIS, V55, P220, DOI 10.1016/j.bcmd.2015.07.001; Guinamard R, 1999, J EXP MED, V189, P1461, DOI 10.1084/jem.189.9.1461; Hong ZX, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01060-y; Irianto J, 2017, BIOPHYS J, V112, P446, DOI 10.1016/j.bpj.2016.09.047; Isham CR, 2007, BLOOD, V109, P2579, DOI 10.1182/blood-2006-07-027326; Jost TR, 2016, J LEUKOCYTE BIOL, V99, P1077, DOI 10.1189/jlb.5MA0915-394R; Jung HJ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.15; Kato I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027042; Kidiyoor GR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18580-9; Konopleva MY, 2011, J CLIN ONCOL, V29, P591, DOI 10.1200/JCO.2010.31.0904; Kuang SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061807; Lai YS, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.37; Le Berre M, 2012, INTEGR BIOL-UK, V4, P1406, DOI 10.1039/c2ib20056b; Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood-2008-12-196618; Lu CW, 2020, CANCER LETT, V476, P87, DOI 10.1016/j.canlet.2020.02.004; Madrazo E, 2018, CANCERS, V10, DOI 10.3390/cancers10090325; Makhija E, 2016, P NATL ACAD SCI USA, V113, pE32, DOI 10.1073/pnas.1513189113; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nava MM, 2020, CELL, V181, P800, DOI 10.1016/j.cell.2020.03.052; Pajerowski JD, 2007, P NATL ACAD SCI USA, V104, P15619, DOI 10.1073/pnas.0702576104; Passaro D, 2015, CANCER CELL, V27, P769, DOI 10.1016/j.ccell.2015.05.003; Perim AD, 2015, CELL MOL LIFE SCI, V72, P1715, DOI 10.1007/s00018-014-1830-x; Petit I, 2005, J CLIN INVEST, V115, P168, DOI 10.1172/JCI200521773; Pfeifer CR, 2019, ADV EXP MED BIOL, V1146, P117, DOI 10.1007/978-3-030-17593-1_8; Pfeifer CR, 2018, MOL BIOL CELL, V29, P1948, DOI 10.1091/mbc.E18-02-0079; Pitt LA, 2015, CANCER CELL, V27, P755, DOI 10.1016/j.ccell.2015.05.002; Poli A, 2018, FASEB J, V32, P681, DOI 10.1096/fj.201700690R; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Pui CH, 2007, NAT REV DRUG DISCOV, V6, P149, DOI 10.1038/nrd2240; Randhawa S, 2016, BRIT J HAEMATOL, V174, P425, DOI 10.1111/bjh.14075; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Redondo-Munoz J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00156; Schumann K, 2010, IMMUNITY, V32, P703, DOI 10.1016/j.immuni.2010.04.017; Scupoli MT, 2008, HAEMATOLOGICA, V93, P524, DOI 10.3324/haematol.12098; Sison EAR, 2015, ONCOTARGET, V6, P30902, DOI 10.18632/oncotarget.5094; Song ZY, 2019, ONCOGENE, V38, P1560, DOI 10.1038/s41388-018-0519-2; Stephens AD, 2019, CURR OPIN CELL BIOL, V58, P76, DOI 10.1016/j.ceb.2019.02.006; Stephens AD, 2017, MOL BIOL CELL, V28, P1984, DOI 10.1091/mbc.E16-09-0653; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Vadillo E, 2018, BLOOD REV, V32, P36, DOI 10.1016/j.blre.2017.08.006; Vargas P, 2014, JOVE-J VIS EXP, DOI 10.3791/51099; Velazquez-Avila M, 2019, LEUKEMIA, V33, P1337, DOI 10.1038/s41375-018-0333-4; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Wei SY, 2014, J MOL CELL BIOL, V6, P458, DOI 10.1093/jmcb/mju050; Yokoyama M, 2017, ONCOTARGET, V8, P21315, DOI 10.18632/oncotarget.15528; Zhang XH, 2016, NUCLEIC ACIDS RES, V44, P3031, DOI 10.1093/nar/gkv1348	66	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1324	1336		10.1038/s41388-021-02168-8	http://dx.doi.org/10.1038/s41388-021-02168-8		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	34999734	Green Published			2022-12-28	WOS:000740423700002
J	Kan, TT; Zhang, SP; Zhou, ST; Zhang, Y; Zhao, Y; Gao, YH; Zhang, T; Gao, F; Wang, X; Zhao, LJ; Yang, MS				Kan, Tongtong; Zhang, Shupeng; Zhou, Shengtao; Zhang, Ya; Zhao, Yun; Gao, Yinghua; Zhang, Tao; Gao, Feng; Wang, Xin; Zhao, Linjie; Yang, Mengsu			Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence	ONCOGENE			English	Article							GENE-EXPRESSION PROFILES; STEM-CELLS; HETEROGENEITY; MECHANISMS; GROWTH; PROGRESSION; RESISTANCE; CYR61	Epithelial ovarian cancers (EOCs) are sensitive to chemotherapy but will ultimately relapse and develop drug resistance. The origin of EOC recurrence has been elusive due to intra-tumor heterogeneity. Here we performed single-cell RNA sequencing (scRNA-seq) in 13,369 cells from primary, untreated peritoneal metastasis, and relapse tumors. We used time-resolved analysis to chart the developmental sequence of cells from the metastatic tumors, then traced the earliest replanting cells back to the primary tumors. We discovered seven distinct subpopulations in primary tumors where the CYR61(+) "stress" subpopulation was identified as the relapse-initiators. Furthermore, a subpopulation of RGS5(+) cancer-associated fibroblasts (CAFs) was found to strongly support tumor metastasis. The combined CYR61/RGS5 expression scores significantly correlated with the relapse-free-survival of EOC patients and can be used as predictors of EOC recurrence. Our study provides insights into the mechanism of EOC recurrence and presents CYR61(+) relapse-initiating cells as potential therapeutic targets to prevent EOC relapse.	[Kan, Tongtong; Gao, Feng; Wang, Xin; Yang, Mengsu] City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China; [Kan, Tongtong] Beijing Inst Basic Med Sci, Beijing, Peoples R China; [Zhang, Shupeng; Zhang, Ya; Gao, Yinghua] Shandong First Med Univ, Affiliated Hosp 2, Dept Pathol, Tai An, Shandong, Peoples R China; [Zhou, Shengtao; Zhao, Linjie] Sichuan Univ, West China Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ,Dept Obstet & Gynecol,West China Hosp, Chengdu, Peoples R China; [Zhou, Shengtao; Zhao, Linjie] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr, State Key Lab Biotherapy, Chengdu, Peoples R China; [Zhao, Yun] Taian Tumor Prevent & Treatment Hosp, Dept Pathol, Tai An, Shandong, Peoples R China; [Zhang, Tao] Shandong Univ, Sch Publ Hlth, Dept Biostat, Jinan, Peoples R China; [Yang, Mengsu] City Univ Hong Kong, Shenzhen Res Inst, Key Lab Biochip Technol, Shenzhen, Peoples R China	City University of Hong Kong; Academy of Military Medical Sciences - China; Shandong First Medical University & Shandong Academy of Medical Sciences; Sichuan University; Sichuan University; Shandong University; City University of Hong Kong	Kan, TT; Yang, MS (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China.; Kan, TT (corresponding author), Beijing Inst Basic Med Sci, Beijing, Peoples R China.; Yang, MS (corresponding author), City Univ Hong Kong, Shenzhen Res Inst, Key Lab Biochip Technol, Shenzhen, Peoples R China.	tongtongkan@hotmail.com; bhmyang@cityu.edu.hk		Wang, Xin/0000-0002-5122-2418; Zhou, Shengtao/0000-0001-8322-5536; Gao, Feng/0000-0002-0500-5527	General Research Fund [CityU_11319516]; Research Impact Fund of Hong Kong Research Grant Council [R1020-18F]; Guangdong Frontier and Key Technology Development Fund of Guangdong Province, PR China [2017B020226001]; Knowledge Innovation Program of Shenzhen Municipality, PR China [JCYJ20170818095453642, JCYJ20180307123759162]	General Research Fund; Research Impact Fund of Hong Kong Research Grant Council; Guangdong Frontier and Key Technology Development Fund of Guangdong Province, PR China; Knowledge Innovation Program of Shenzhen Municipality, PR China	We thank Dr Junhai Wang from Taian Tumor Prevention and Treatment Hospital for assistance with IHC. This work was supported by grants from the General Research Fund (CityU_11319516) and the Research Impact Fund (R1020-18F) of Hong Kong Research Grant Council, the Guangdong Frontier and Key Technology Development Fund (2017B020226001) of Guangdong Province, PR China, and the Knowledge Innovation Program (JCYJ20170818095453642 and JCYJ20180307123759162) of Shenzhen Municipality, PR China.	Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Corrado G, 2017, EXPERT REV ANTICANC, V17, P1147, DOI 10.1080/14737140.2017.1398088; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; Dan S, 2002, CANCER RES, V62, P1139; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Gery S, 2005, CLIN CANCER RES, V11, P7243, DOI 10.1158/1078-0432.CCR-05-0231; Goveia J, 2020, CANCER CELL, V37, P21, DOI 10.1016/j.ccell.2019.12.001; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hellinger JW, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01074; Hennessy BT, 2009, LANCET, V374, P1371, DOI 10.1016/S0140-6736(09)61338-6; Hoang-Minh LB, 2018, EMBO J, V37, DOI 10.15252/embj.201798772; Hyun HB, 2018, MOLECULES, V23, DOI 10.3390/molecules23020209; Kan TT, 2020, ONCOGENE, V39, P4227, DOI 10.1038/s41388-020-1288-2; Khalique L, 2007, J PATHOL, V211, P286, DOI 10.1002/path.2112; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Klein CA, 2011, CURR OPIN GENET DEV, V21, P42, DOI 10.1016/j.gde.2010.10.011; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3; Li XP, 2018, EXP THER MED, V16, P730, DOI 10.3892/etm.2018.6274; Lin JPA, 2012, CANCER IMMUNOL IMMUN, V61, P677, DOI 10.1007/s00262-011-1135-y; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Maity G, 2019, MOL CANCER THER, V18, P788, DOI 10.1158/1535-7163.MCT-18-0899; Martz CA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.aaa1877; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Pantel Klaus, 2014, Bonekey Rep, V3, P584, DOI 10.1038/bonekey.2014.79; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Tirosh I, 2016, NATURE, V539, P309, DOI 10.1038/nature20123; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Vasey PA, 2003, BRIT J CANCER, V89, pS23, DOI 10.1038/sj.bjc.6601497; Vladoiu MC, 2019, NATURE, V572, P67, DOI 10.1038/s41586-019-1158-7; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Zembutsu H, 2002, CANCER RES, V62, P518; Zhang YQ, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.057; Zlobec I, 2007, J CLIN PATHOL, V60, P1112, DOI 10.1136/jcp.2006.044537	50	6	6	7	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					895	906		10.1038/s41388-021-02139-z	http://dx.doi.org/10.1038/s41388-021-02139-z		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34992217				2022-12-28	WOS:000739823800001
J	Page, EC; Heatley, SL; Eadie, LN; McClure, BJ; de Bock, CE; Omari, S; Yeung, DT; Hughes, TP; Thomas, PQ; White, DL				Page, Elyse C.; Heatley, Susan L.; Eadie, Laura N.; McClure, Barbara J.; de Bock, Charles E.; Omari, Sofia; Yeung, David T.; Hughes, Timothy P.; Thomas, Paul Q.; White, Deborah L.			HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; MURINE XENOGRAFT MODELS; CHILDREN; TRANSCRIPTION; INHIBITION; PI3K/MTOR; TRANSFORMATION; ACTIVATION; EXPRESSION; MUTATIONS	The genetic basis of the predisposition for Down Syndrome (DS) patients to develop cytokine receptor-like factor 2 rearranged (CRLF2r) acute lymphoblastic leukemia (ALL) is currently unknown. Genes located on chromosome 21 and expressed in hematopoietic cells are likely candidates for investigation of CRLF2r DS-ALL pathogenesis. We explored the high-mobility group nucleosome-binding protein 1 (HMGN1), located in the DS critical region, in an inducible CRISPR/Cas9 knockout (KO) xenograft model to assess the effect of HMGN1 loss of function on the leukemic burden. We demonstrated HMGN1 KO-mitigated leukemic phenotypes including hepatosplenomegaly, thrombocytopenia, and anemia, commonly observed in leukemia patients, and significantly increased survival in vivo. HMGN1 overexpression in murine stem cells and Ba/F3 cells in vitro, in combination with P2RY8-CRLF2, resulted in cytokine-independent transformation and upregulation of cell signaling pathways associated with leukemic development. Finally, in vitro screening demonstrated successful targeting of P2RY8-CRLF2 and HMGN1 co-expressing cell lines and patient samples with fedratinib (JAK2 inhibitor), and GSK-J4 (demethylase inhibitor) in combination. Together, these data provide critical insight into the development and persistence of CRLF2r DS-ALL and identify HMGN1 as a potential therapeutic target to improve outcomes and reduce toxicity in this high-risk cohort of young patients.	[Page, Elyse C.; Heatley, Susan L.; Eadie, Laura N.; McClure, Barbara J.; Yeung, David T.; Hughes, Timothy P.; White, Deborah L.] South Australian Hlth & Med Res Inst, Canc Program, Precis Med Theme, Adelaide, SA, Australia; [Page, Elyse C.; White, Deborah L.] Univ Adelaide, Fac Sci, Adelaide, SA, Australia; [Heatley, Susan L.; Eadie, Laura N.; McClure, Barbara J.; Yeung, David T.; Hughes, Timothy P.; Thomas, Paul Q.; White, Deborah L.] Univ Adelaide, Discipline Med, Adelaide, SA, Australia; [Page, Elyse C.; White, Deborah L.] Australian & New Zealand Childrens Haematol Oncol, Sydney, NSW, Australia; [de Bock, Charles E.; Omari, Sofia] UNSW Sydney, Lowy Canc Res Ctr, Childrens Canc Inst, Sydney, NSW, Australia; [de Bock, Charles E.; Omari, Sofia] UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Yeung, David T.; Hughes, Timothy P.; White, Deborah L.] Australasian Leukaemia & Lymphoma Grp, Melbourne, Vic, Australia; [Yeung, David T.; Hughes, Timothy P.] Royal Adelaide Hosp, Dept Haematol, Adelaide, SA, Australia; [Yeung, David T.; Hughes, Timothy P.] SA Pathol, Adelaide, SA, Australia; [Yeung, David T.] Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA, Australia; [Thomas, Paul Q.] South Australian Hlth & Med Res Inst, Gene Editing Program, Precis Med Theme, Adelaide, SA, Australia; [White, Deborah L.] Australian Genom Hlth Alliance AGHA, Sydney, NSW, Australia	South Australian Health & Medical Research Institute (SAHMRI); University of Adelaide; University of Adelaide; Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; Royal Adelaide Hospital; SA Pathology; University of South Australia; South Australian Health & Medical Research Institute (SAHMRI)	White, DL (corresponding author), South Australian Hlth & Med Res Inst, Canc Program, Precis Med Theme, Adelaide, SA, Australia.; White, DL (corresponding author), Univ Adelaide, Fac Sci, Adelaide, SA, Australia.; White, DL (corresponding author), Univ Adelaide, Discipline Med, Adelaide, SA, Australia.; White, DL (corresponding author), Australian & New Zealand Childrens Haematol Oncol, Sydney, NSW, Australia.; White, DL (corresponding author), Australasian Leukaemia & Lymphoma Grp, Melbourne, Vic, Australia.; White, DL (corresponding author), Australian Genom Hlth Alliance AGHA, Sydney, NSW, Australia.	Deborah.white@sahmri.com	Heatley, Susan/AGP-2179-2022; de Bock, Charles/H-7699-2019	de Bock, Charles/0000-0001-5182-8535; Heatley, Susan/0000-0001-7497-6477; White, Deborah/0000-0003-4844-333X; McClure, Barbara/0000-0002-5201-4127; Omari, Sofia/0000-0003-0345-5601	Detmold Hoopman Group; Australian Cancer Research Foundation; Australian Government through the Zero Childhood Cancer Program; NHMRC; Beat Cancer; RTP University of Adelaide scholarship	Detmold Hoopman Group; Australian Cancer Research Foundation; Australian Government through the Zero Childhood Cancer Program; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Beat Cancer; RTP University of Adelaide scholarship	Flow cytometry analysis and cell sorting were performed at the South Australian Health Medical Research Institute (SAHMRI) in the ACRF Cellular Imaging and Cytometry Core Facility. The Facility is generously supported by the Detmold Hoopman Group, Australian Cancer Research Foundation, and the Australian Government through the Zero Childhood Cancer Program. Animal models were performed in the Bioresources Core Facility at SAHMRI and we would like to acknowledge the technical support provided. The authors acknowledge the facilities and scientific and technical assistance of the National Imaging Facility, a National Collaborative Research Infrastructure Strategy (NCRIS) capability, at the Preclinical Imaging and Research Laboratories/Bioresources, South Australian Health and Medical Research Institute. This study has been performed as partial fulfillment of the requirement for a Ph.D. degree from the University of Adelaide Faculty of Sciences for E.C.P. Funding for this study was provided by NHMRC, Beat Cancer, and L.F.A. E.C.P. was supported by an RTP University of Adelaide scholarship.	Adikusuma F, 2018, NATURE, V560, pE8, DOI 10.1038/s41586-018-0380-z; Antonarakis SE, 2017, NAT REV GENET, V18, P147, DOI 10.1038/nrg.2016.154; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Buitenkamp TD, 2012, LEUKEMIA, V26, P2204, DOI 10.1038/leu.2012.84; Buitenkamp TD, 2014, BLOOD, V123, P70, DOI 10.1182/blood-2013-06-509463; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P431, DOI 10.1016/S0968-0004(01)01855-2; Cabal-Hierro L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15221-z; Caruso C, 2019, CANCER DISCOV, V9, P1332, DOI 10.1158/2159-8290.CD-NB2019-102; Catez F, 2002, EMBO REP, V3, P760, DOI 10.1093/embo-reports/kvf156; Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113; Den Boer ML, 2009, LANCET ONCOL, V10, P125, DOI 10.1016/S1470-2045(08)70339-5; Figueroa ME, 2013, J CLIN INVEST, V123, P3099, DOI 10.1172/JCI66203; Ghosh S, 2009, AM J MED GENET A, V149A, P1415, DOI 10.1002/ajmg.a.32932; Gozgit JM, 2008, J BIOL CHEM, V283, P32334, DOI 10.1074/jbc.M803813200; Hama A, 2008, BRIT J HAEMATOL, V140, P552, DOI 10.1111/j.1365-2141.2007.06971.x; Heerema NA, 2007, GENE CHROMOSOME CANC, V46, P684, DOI 10.1002/gcc.20451; Hertzberg L, 2010, BLOOD, V115, P1006, DOI 10.1182/blood-2009-08-235408; Hurtz C, 2020, J CLIN INVEST, V130, P3637, DOI 10.1172/JCI134424; Izraeli S, 2014, BLOOD, V123, P35, DOI 10.1182/blood-2013-07-453480; Lane AA, 2014, NAT GENET, V46, P618, DOI 10.1038/ng.2949; Lee P, 2016, LEUKEMIA, V30, P1816, DOI 10.1038/leu.2016.164; Li Q, 2018, ONCOL LETT, V15, P4517, DOI 10.3892/ol.2018.7898; Li WP, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0761-2; Li YN, 2018, J CANCER RES CLIN, V144, P1065, DOI 10.1007/s00432-018-2631-7; Lim JH, 2004, MOL CELL, V15, P573, DOI 10.1016/j.molcel.2004.08.006; Maude SL, 2015, BLOOD, V125, P1759, DOI 10.1182/blood-2014-06-580480; Meyr F, 2013, BRIT J HAEMATOL, V162, P98, DOI 10.1111/bjh.12348; Mowery CT, 2018, CELL REP, V25, P1898, DOI 10.1016/j.celrep.2018.10.061; Mullally A, 2020, BLOOD ADV, V4, P1792, DOI 10.1182/bloodadvances.2019000954; Mullighan CG, 2009, NAT GENET, V41, P1243, DOI 10.1038/ng.469; Mullighan CG, 2009, P NATL ACAD SCI USA, V106, P9414, DOI 10.1073/pnas.0811761106; Page EC, 2018, CANCER LETT, V432, P69, DOI 10.1016/j.canlet.2018.05.045; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Roberts I, 2014, BRIT J HAEMATOL, V167, P587, DOI 10.1111/bjh.13096; Roberts KG, 2014, NEW ENGL J MED, V371, P1005, DOI 10.1056/NEJMoa1403088; Rochman M, 2011, NUCLEIC ACIDS RES, V39, P4076, DOI 10.1093/nar/gkq1343; Russell LJ, 2009, BLOOD, V114, P2688, DOI 10.1182/blood-2009-03-208397; Sandhofer N, 2015, LEUKEMIA, V29, P828, DOI 10.1038/leu.2014.305; Tasian SK, 2017, BLOOD, V129, P177, DOI 10.1182/blood-2016-05-707653; Tasian SK, 2012, BLOOD, V120, P833, DOI 10.1182/blood-2011-12-389932; Tasian Sarah K., 2011, Critical Reviews in Oncogenesis, V16, P13; Vesely C, 2017, LEUKEMIA, V31, P1491, DOI 10.1038/leu.2016.365; Whitlock JA, 2006, BRIT J HAEMATOL, V135, P595, DOI 10.1111/j.1365-2141.2006.06337.x; Yoda A, 2010, P NATL ACAD SCI USA, V107, P252, DOI 10.1073/pnas.0911726107; Zhu N, 2007, MOL CELL BIOL, V27, P8859, DOI 10.1128/MCB.01724-07	45	2	2	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					797	808		10.1038/s41388-021-02126-4	http://dx.doi.org/10.1038/s41388-021-02126-4		DEC 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34857887				2022-12-28	WOS:000725389500001
J	Ruiz-Torres, SJ; Bourn, JR; Benight, NM; Hunt, BG; Lester, C; Waltz, SE				Ruiz-Torres, Sasha J.; Bourn, Jennifer R.; Benight, Nancy M.; Hunt, Brian G.; Lester, Carissa; Waltz, Susan E.			Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; STIMULATING PROTEIN; IFN-GAMMA; PERITONEAL-MACROPHAGES; TUMOR-GROWTH; ACTIVATION; EXPRESSION; CELLS; IL-12; INHIBITION	Tumor associated macrophages (TAMs) play a major role in regulating mammary tumor growth and in directing the responses of tumor infiltrating leukocytes in the microenvironment. However, macrophage-specific mechanisms regulating the interactions of macrophages with tumor cells and other leukocytes that support tumor progression have not been extensively studied. In this study, we show that the activation of the RON receptor tyrosine kinase signaling pathway specifically in macrophages supports breast cancer growth and metastasis. Using clinically relevant murine models of breast cancer, we demonstrate that loss of macrophage RON expression results in decreases in mammary tumor cell proliferation, survival, cancer stem cell self-renewal, and metastasis. Macrophage RON signaling modulates these phenotypes via direct effects on the tumor proper and indirectly by regulating leukocyte recruitment including macrophages, T-cells, and B-cells in the mammary tumor microenvironment. We further show that macrophage RON expression regulates the macrophage secretome including IL-35 and other immunosuppressive factors. Overall, our studies implicate activation of RON signaling in macrophages as a key player in supporting a thriving mammary pro-tumor microenvironment through novel mechanisms including the augmentation of tumor cell properties through IL-35.	[Ruiz-Torres, Sasha J.; Bourn, Jennifer R.; Benight, Nancy M.; Hunt, Brian G.; Lester, Carissa; Waltz, Susan E.] Univ Cincinnati, Dept Canc Biol, Coll Med, Cincinnati, OH 45267 USA; [Waltz, Susan E.] Cincinnati Vet Affairs Med Ctr, Res Serv, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Waltz, SE (corresponding author), Univ Cincinnati, Dept Canc Biol, Coll Med, Cincinnati, OH 45267 USA.; Waltz, SE (corresponding author), Cincinnati Vet Affairs Med Ctr, Res Serv, Cincinnati, OH 45267 USA.	susan.waltz@uc.edu		Bourn, Jennifer/0000-0002-0902-2850; Waltz, Susan/0000-0003-3572-4642; Hunt, Brian/0000-0003-4155-730X	US Department of Veterans Affairs [1IOBX000803]; National Institutes of Health [R01 CA239697, T32 CA117846, F31 CA228373]; National Institutes of Diabetes & Digestive & Kidney Diseases [P30 DK078392]	US Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Diabetes & Digestive & Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank Vidjaya L. Premkumar, Lennox Brooks, Rebekah Karns, James Davis, and Madison Nashu for their technical and bioinformatic assistance. US Department of Veterans Affairs research grant 1IOBX000803 (SEW); National Institutes of Health grants R01 CA239697 (SEW), T32 CA117846 (SEW, SJRT, NMB, JRB), F31 CA228373 (BGH, SEW), and National Institutes of Diabetes & Digestive & Kidney Diseases grant P30 DK078392.	Benight NM, 2015, ONCOTARGET, V6, P17445, DOI 10.18632/oncotarget.3641; Benight NM, 2012, EXPERT OPIN THER TAR, V16, P921, DOI 10.1517/14728222.2012.710200; Brunelleschi S, 2001, BRIT J PHARMACOL, V134, P1285, DOI 10.1038/sj.bjp.0704356; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Chen YQ, 1998, J IMMUNOL, V161, P4950; Choi JJ, 2015, CLIN REV ALLERG IMMU, V49, P327, DOI 10.1007/s12016-015-8468-9; Dambuza IM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00838-4; De Nardo D, 2018, METHODS MOL BIOL, V1784, P35, DOI 10.1007/978-1-4939-7837-3_4; Eyob H, 2013, CANCER DISCOV, V3, P751, DOI 10.1158/2159-8290.CD-12-0480; Goodridge HS, 2003, IMMUNOLOGY, V109, P415, DOI 10.1046/j.1365-2567.2003.01689.x; Gurusamy D, 2013, CANCER RES, V73, P1752, DOI 10.1158/0008-5472.CAN-12-2474; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hunt BG, 2020, BREAST CANCER RES TR, V181, P529, DOI 10.1007/s10549-020-05653-y; Ito Y, 2010, J CLIN INVEST, V120, P1981, DOI 10.1172/JCI39650; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; Jadus MR, 1996, BLOOD, V87, P5232, DOI 10.1182/blood.V87.12.5232.bloodjournal87125232; Kollet JI, 2006, MOL IMMUNOL, V43, P623, DOI 10.1016/j.molimm.2005.04.004; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Kourko O, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00969; Kulkarni RM, 2014, HEPATOB PANCREAT DIS, V13, P281, DOI 10.1016/S1499-3872(14)60254-X; KULKARNI RM, 2014, AM J PHYSIOL-GASTR L, V306; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; Lee CC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06268-0; Lindsten T, 2017, INT J ONCOL, V51, P104, DOI 10.3892/ijo.2017.3996; Liu JG, 2004, J BIOL CHEM, V279, P55609, DOI 10.1074/jbc.M406565200; McClaine RJ, 2010, NEOPLASIA, V12, P650, DOI 10.1593/neo.10476; Morrison AC, 2004, J IMMUNOL, V172, P1825, DOI 10.4049/jimmunol.172.3.1825; Morrison AC, 2002, J IMMUNOL, V168, P853, DOI 10.4049/jimmunol.168.2.853; Nanney LB, 1998, J INVEST DERMATOL, V111, P573, DOI 10.1046/j.1523-1747.1998.00332.x; Nikolaidis NM, 2011, INNATE IMMUN-LONDON, V17, P499, DOI 10.1177/1753425910383725; Nikolaidis NM, 2010, SHOCK, V33, P197, DOI 10.1097/SHK.0b013e3181ae8155; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Pylayeva-Gupta Y, 2016, CLIN CANCER RES, V22, P4973, DOI 10.1158/1078-0432.CCR-16-0743; Ray M, 2010, J IMMUNOL, V185, P7309, DOI 10.4049/jimmunol.1000095; Ruiz-Torres SJ, 2017, ONCOTARGET, V8, P58918, DOI 10.18632/oncotarget.19441; Sainz B, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9012369; Sawant DV, 2015, J INTERF CYTOK RES, V35, P499, DOI 10.1089/jir.2015.0015; Sharda DR, 2011, J IMMUNOL, V187, P2181, DOI 10.4049/jimmunol.1003460; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Singh Saroj, 2017, Biochim Open, V4, P8, DOI 10.1016/j.biopen.2016.11.002; Stuart WD, 2011, HEPATOLOGY, V53, P1618, DOI 10.1002/hep.24239; Sullivan C, 2020, MOL CANCER RES, V18, P1244, DOI 10.1158/1541-7786.MCR-20-0060; Vignali DAA, 2012, NAT IMMUNOL, V13, P722, DOI 10.1038/ni.2366; Wagh PK, 2008, ADV CANCER RES, V100, P1, DOI 10.1016/S0065-230X(08)00001-8; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI11881; WANG MH, 1994, J BIOL CHEM, V269, P14027; Wellenstein MD, 2018, IMMUNITY, V48, P399, DOI 10.1016/j.immuni.2018.03.004; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; Wilson CB, 2008, J IMMUNOL, V181, P2303, DOI 10.4049/jimmunol.181.4.2303; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	50	3	3	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					321	333		10.1038/s41388-021-02091-y	http://dx.doi.org/10.1038/s41388-021-02091-y		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34743208	Green Accepted			2022-12-28	WOS:000715015000002
J	Polosukhina, D; Singh, K; Asim, M; Barry, DP; Allaman, MM; Hardbower, DM; Piazuelo, MB; Washington, MK; Gobert, AP; Wilson, KT; Coburn, LA				Polosukhina, Dina; Singh, Kshipra; Asim, Mohammad; Barry, Daniel P.; Allaman, Margaret M.; Hardbower, Dana M.; Piazuelo, M. Blanca; Washington, M. Kay; Gobert, Alain P.; Wilson, Keith T.; Coburn, Lori A.			CCL11 exacerbates colitis and inflammation-associated colon tumorigenesis	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CCR3; ULCERATIVE-COLITIS; BOWEL-DISEASE; COLORECTAL-CANCER; EOTAXIN-1; SERUM	CCL11, also known as eotaxin-1, is described as an eosinophil chemoattractant, which has been implicated in allergic and Th2 inflammatory diseases. We have reported that CCL11 is significantly increased in the serum of inflammatory bowel disease (IBD) patients, colonic eosinophils are increased and correlate with tissue CCL11 levels in ulcerative colitis patients, and CCL11 is increased in dextran sulfate sodium (DSS)-induced murine colitis. Here, we show that CCL11 is involved in the pathogenesis of DSS-induced colitis and in colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC). Ccl11(-/-) mice exposed to DSS then allowed to recover had significantly less body weight loss and a decrease in histologic injury versus wild-type (WT) mice. In the AOM-DSS model, Ccl11(-/-) mice exhibited decreased colonic tumor number and burden, histologic injury, and colonic eosinophil infiltration versus WT mice. Ccl11 is expressed by both colonic epithelial and lamina propria immune cells. Studies in bone marrow chimera mice revealed that hematopoietic- and epithelial-cell-derived CCL11 were both important for tumorigenesis in the AOM-DSS model. These findings indicate that CCL11 is important in the regulation of colitis and associated carcinogenesis and thus anti-CCL11 antibodies may be useful for treatment and cancer chemoprevention in IBD.	[Polosukhina, Dina; Singh, Kshipra; Asim, Mohammad; Barry, Daniel P.; Allaman, Margaret M.; Hardbower, Dana M.; Piazuelo, M. Blanca; Gobert, Alain P.; Wilson, Keith T.; Coburn, Lori A.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA; [Hardbower, Dana M.; Washington, M. Kay; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Piazuelo, M. Blanca; Gobert, Alain P.; Wilson, Keith T.; Coburn, Lori A.] Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA; [Wilson, Keith T.; Coburn, Lori A.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA; [Coburn, Lori A.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Coburn, LA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA.; Coburn, LA (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA.; Coburn, LA (corresponding author), Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.; Coburn, LA (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	lori.coburn@vumc.org	Allaman, Margaret/GNO-9854-2022; /B-5647-2008	Coburn, Lori/0000-0003-3249-9806; Wilson, Keith/0000-0003-4421-1830; /0000-0002-3972-3914	NIH training grant [5T32DK007673]; Vanderbilt Physician Scientist Development Award; Veterans Affairs Career Development Award [1IK2BX002126]; Veterans Affairs Merit Award [1I01BX004366]; National Institutes of Health (NIH) [R01DK128200, R01CA190612, P01CA116087, P01CA028842]; Veterans Affairs Merit Review [I01CX002171]; Crohn's and Colitis Foundation Senior Research Award [703003]; Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer [T32GM008554, F31DK10715]; NIH (Vanderbilt Digestive Disease Research Center) [P30DK058404]; NCI/NIH Cancer Center Support Grant [P30CA068485]; Vanderbilt Mouse Metabolic Phenotyping Center [U24DK059637]	NIH training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt Physician Scientist Development Award; Veterans Affairs Career Development Award; Veterans Affairs Merit Award(US Department of Veterans Affairs); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit Review(US Department of Veterans Affairs); Crohn's and Colitis Foundation Senior Research Award; Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer; NIH (Vanderbilt Digestive Disease Research Center)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI/NIH Cancer Center Support Grant; Vanderbilt Mouse Metabolic Phenotyping Center	LAC was supported by NIH training grant 5T32DK007673, a Vanderbilt Physician Scientist Development Award, a Veterans Affairs Career Development Award 1IK2BX002126, and a Veterans Affairs Merit Award 1I01BX004366. This work was also funded by National Institutes of Health (NIH) grants R01DK128200, R01CA190612, P01CA116087, and P01CA028842 (KTW), Veterans Affairs Merit Review grant I01CX002171 (KTW), Crohn's and Colitis Foundation Senior Research Award 703003 (KTW), the Thomas F. Frist Sr. Endowment (KTW), and the Vanderbilt Center for Mucosal Inflammation and Cancer (KTW). DMH was supported by T32GM008554 and F31DK10715. Additional support was provided by the Tissue Morphology Subcore of NIH Grant P30DK058404 (Vanderbilt Digestive Disease Research Center). The Translational Pathology Shared Resource was supported by NCI/NIH Cancer Center Support Grant P30CA068485 and the Vanderbilt Mouse Metabolic Phenotyping Center Grant U24DK059637.	Adar T, 2016, DIGEST DIS SCI, V61, P1915, DOI 10.1007/s10620-016-4047-z; Adar T, 2014, CLIN IMMUNOL, V153, P199, DOI 10.1016/j.clim.2014.04.012; Agarwal M, 2013, PROSTATE, V73, P573, DOI 10.1002/pros.22597; Ahrens R, 2008, J IMMUNOL, V181, P7390, DOI 10.4049/jimmunol.181.10.7390; Barrett CW, 2011, CANCER RES, V71, P1302, DOI 10.1158/0008-5472.CAN-10-3317; Beaugerie L, 2015, NEW ENGL J MED, V372, P1441, DOI 10.1056/NEJMra1403718; Chandrasekar B, 2013, J INFECT DIS, V207, P1556, DOI 10.1093/infdis/jit067; Coburn LA, 2019, ONCOGENE, V38, P1067, DOI 10.1038/s41388-018-0492-9; Coburn LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082300; Dahlhamer JM, 2016, MMWR-MORBID MORTAL W, V65, P1166, DOI 10.15585/mmwr.mm6542a3; Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Ferhat M, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.455; Forbes E, 2004, J IMMUNOL, V172, P5664, DOI 10.4049/jimmunol.172.9.5664; Gobert AP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01242; Hardbower DM, 2017, ONCOGENE, V36, P3807, DOI 10.1038/onc.2017.23; Heidegger I, 2015, PROSTATE, V75, P1904, DOI 10.1002/pros.23086; Hol J, 2010, J LEUKOCYTE BIOL, V87, P501, DOI 10.1189/jlb.0809532; Kaiko GE, 2008, IMMUNOLOGY, V123, P326, DOI 10.1111/j.1365-2567.2007.02719.x; Karki R, 2019, NAT REV CANCER, V19, P197, DOI 10.1038/s41568-019-0123-y; Komura T, 2018, CAN J GASTROENTEROL, V2018, DOI 10.1155/2018/7436205; Levina V, 2009, CLIN CANCER RES, V15, P2647, DOI 10.1158/1078-0432.CCR-08-2024; Manousou P, 2010, CLIN EXP IMMUNOL, V162, P337, DOI 10.1111/j.1365-2249.2010.04248.x; Masterson JC, 2015, GUT, V64, P1236, DOI 10.1136/gutjnl-2014-306998; Olen O, 2020, LANCET, V395, P123, DOI 10.1016/S0140-6736(19)32545-0; Popivanova BK, 2009, CANCER RES, V69, P7884, DOI 10.1158/0008-5472.CAN-09-1451; Quante M, 2013, GASTROENTEROLOGY, V145, P63, DOI 10.1053/j.gastro.2013.03.052; Reichman H, 2019, CANCER IMMUNOL RES, V7, P388, DOI 10.1158/2326-6066.CIR-18-0494; Rmali KA, 2007, COLORECTAL DIS, V9, P3, DOI 10.1111/j.1463-1318.2006.01089.x; SARTOR RB, 1994, GASTROENTEROLOGY, V106, P533, DOI 10.1016/0016-5085(94)90614-9; Scoville EA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39232-z; Singh K, 2011, J BIOL CHEM, V286, P3839, DOI 10.1074/jbc.M110.176719; Vieira AT, 2009, AM J PATHOL, V175, P2382, DOI 10.2353/ajpath.2009.090093; Wagsater Dick, 2007, World J Surg Oncol, V5, P84, DOI 10.1186/1477-7819-5-84; Zimmerman NP, 2008, INFLAMM BOWEL DIS, V14, P1000, DOI 10.1002/ibd.20480	36	7	7	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6540	6546		10.1038/s41388-021-02046-3	http://dx.doi.org/10.1038/s41388-021-02046-3		OCT 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34625710	Green Accepted			2022-12-28	WOS:000705760400004
J	Roukens, MG; Frederiks, CL; Seinstra, D; Braccioli, L; Khalil, AA; Pals, C; De Neck, S; Bornes, L; Beerling, E; Mokry, M; de Bruin, A; Westendorp, B; van Rheenen, J; Coffer, PJ				Roukens, M. Guy; Frederiks, Cynthia L.; Seinstra, Danielle; Braccioli, Luca; Khalil, Antoine A.; Pals, Cornelieke; De Neck, Simon; Bornes, Laura; Beerling, Evelyne; Mokry, Michal; de Bruin, Alain; Westendorp, Bart; van Rheenen, Jacco; Coffer, Paul J.			Regulation of a progenitor gene program by SOX4 is essential for mammary tumor proliferation	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER METASTASIS; ENRICHMENT ANALYSIS; EXPRESSION; REVEALS; CELLS; COLONIZATION; POPULATION; PLASTICITY; REQUIRES	In breast cancer the transcription factor SOX4 has been shown to be associated with poor survival, increased tumor size and metastasis formation. This has mostly been attributed to the ability of SOX4 to regulate Epithelial-to-Mesenchymal-Transition (EMT). However, SOX4 regulates target gene transcription in a context-dependent manner that is determined by the cellular and epigenetic state. In this study we have investigated the loss of SOX4 in mammary tumor development utilizing organoids derived from a PyMT genetic mouse model of breast cancer. Using CRISPR/Cas9 to abrogate SOX4 expression, we found that SOX4 is required for inhibiting differentiation by regulating a subset of genes that are highly activated in fetal mammary stem cells (fMaSC). In this way, SOX4 re-activates an oncogenic transcriptional program that is regulated in many progenitor cell-types during embryonic development. SOX4-knockout organoids are characterized by the presence of more differentiated cells that exhibit luminal or basal gene expression patterns, but lower expression of cell cycle genes. In agreement, primary tumor growth and metastatic outgrowth in the lungs are impaired in SOX4(KO) tumors. Finally, SOX4(KO) tumors show a severe loss in competitive capacity to grow out compared to SOX4-proficient cells in primary tumors. Our study identifies a novel role for SOX4 in maintaining mammary tumors in an undifferentiated and proliferative state. Therapeutic manipulation of SOX4 function could provide a novel strategy for cancer differentiation therapy, which would promote differentiation and inhibit cycling of tumor cells.	[Roukens, M. Guy; Frederiks, Cynthia L.; Braccioli, Luca; Pals, Cornelieke; Coffer, Paul J.] Univ Med Ctr Utrecht, Regenerat Med Ctr Utrecht, Utrecht, Netherlands; [Roukens, M. Guy; Frederiks, Cynthia L.; Braccioli, Luca; Khalil, Antoine A.; Pals, Cornelieke; Coffer, Paul J.] Univ Med Ctr Utrecht, Ctr Mol Med Utrecht, Utrecht, Netherlands; [Seinstra, Danielle; Bornes, Laura; Beerling, Evelyne; van Rheenen, Jacco] Netherlands Canc Inst, Oncode Inst, Dept Mol Pathol, Amsterdam, Netherlands; [De Neck, Simon; de Bruin, Alain; Westendorp, Bart] Univ Utrecht, Fac Vet Med, Dept Biomol Hlth Sci, Utrecht, Netherlands; [De Neck, Simon; de Bruin, Alain] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands; [Mokry, Michal] Univ Med Ctr Utrecht, Lab Expt Cardiol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute; Utrecht University; University of Groningen; Utrecht University; Utrecht University Medical Center	Roukens, MG; Coffer, PJ (corresponding author), Univ Med Ctr Utrecht, Regenerat Med Ctr Utrecht, Utrecht, Netherlands.; Roukens, MG; Coffer, PJ (corresponding author), Univ Med Ctr Utrecht, Ctr Mol Med Utrecht, Utrecht, Netherlands.	m.g.roukens2@umcutrecht.nl; pcoffer@umcutrecht.nl		Khalil, Antoine A./0000-0003-3469-0778; Westendorp, Bart/0000-0003-1043-3638; Roukens, Guy/0000-0002-4270-8678; Mokry, Michal/0000-0002-5298-4852; de Bruin, Alain/0000-0001-8579-2649; Bornes, Laura/0000-0001-9721-1223				Aiello NM, 2016, DIS MODEL MECH, V9, P105, DOI 10.1242/dmm.023184; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034; Bornes L, 2019, CELL REP, V29, P2565, DOI 10.1016/j.celrep.2019.10.107; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Braccioli L, 2018, STEM CELL RES, V33, P110, DOI 10.1016/j.scr.2018.10.005; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dravis C, 2018, CANCER CELL, V34, P466, DOI 10.1016/j.ccell.2018.08.001; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Elso CM, 2004, GENES IMMUN, V5, P93, DOI 10.1038/sj.gene.6364042; Foronda M, 2014, CELL REP, V8, P486, DOI 10.1016/j.celrep.2014.06.031; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giraddi RR, 2018, CELL REP, V24, P1653, DOI 10.1016/j.celrep.2018.07.025; Gracz AD, 2018, GASTROENTEROLOGY, V155, P1508, DOI 10.1053/j.gastro.2018.07.023; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Pfefferle AD, 2015, BREAST CANCER RES TR, V149, P425, DOI 10.1007/s10549-014-3262-6; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081; Spike BT, 2012, CELL STEM CELL, V10, P183, DOI 10.1016/j.stem.2011.12.018; Stankic M, 2013, CELL REP, V5, P1228, DOI 10.1016/j.celrep.2013.11.014; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Vervoort SJ, 2013, ONCOGENE, V32, P3397, DOI 10.1038/onc.2012.506; Vervoort SJ, 2018, ELIFE, V7, DOI 10.7554/eLife.27706; Vervoort SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053238; Wahl GM, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0012-z; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Zhang H., 2014, BLOOD, V124, P1577, DOI DOI 10.1182/BLOOD.V124.21.1577.1577; Zhang H, 2013, CANCER CELL, V24, P575, DOI 10.1016/j.ccr.2013.09.018; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045	44	4	4	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6343	6353		10.1038/s41388-021-02004-z	http://dx.doi.org/10.1038/s41388-021-02004-z		SEP 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34584219	Green Published, hybrid			2022-12-28	WOS:000701638300002
J	Unlu, B; Kocaturk, B; Rondon, AMR; Lewis, CS; Swier, N; van den Akker, RFP; Krijgsman, D; Noordhoek, I; Blok, EJ; Bogdanov, VY; Ruf, W; Kuppen, PJK; Versteeg, HH				Unlu, Betul; Kocaturk, Begum; Rondon, Araci M. R.; Lewis, Clayton S.; Swier, Nathalie; van den Akker, Rob F. P.; Krijgsman, Danielle; Noordhoek, Iris; Blok, Erik J.; Bogdanov, Vladimir Y.; Ruf, Wolfram; Kuppen, Peter J. K.; Versteeg, Henri H.			Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer	ONCOGENE			English	Article							FACTOR EXPRESSION; CELLS; PROGNOSIS; CARCINOMA; EMT; COAGULATION; MECHANISMS; TRANSITION; INSIGHTS; THERAPY	Tissue Factor (TF) is the initiator of blood coagulation but also functions as a signal transduction receptor. TF expression in breast cancer is associated with higher tumor grade, metastasis and poor survival. The role of TF signaling on the early phases of metastasis has never been addressed. Here, we show an association between TF expression and metastasis as well as cancer stemness in 574 breast cancer patients. In preclinical models, blockade of TF signaling inhibited metastasis tenfold independent of primary tumor growth. TF blockade caused a reduction in epithelial-to-mesenchymal-transition, cancer stemness and expression of the pro-metastatic markers Slug and SOX9 in several breast cancer cell lines and in ex vivo cultured tumor cells. Mechanistically, TF forms a complex with beta 1-integrin leading to inactivation of beta 1-integrin. Inhibition of TF signaling induces a shift in TF-binding from alpha 3 beta 1-integrin to alpha 6 beta 4 and dictates FAK recruitment, leading to reduced epithelial-to-mesenchymal-transition and tumor cell differentiation. In conclusion, TF signaling inhibition leads to reduced pro-metastatic transcriptional programs, and a subsequent integrin beta 1 and beta 4-dependent reduction in metastasic dissemination.	[Unlu, Betul; Kocaturk, Begum; Rondon, Araci M. R.; Swier, Nathalie; van den Akker, Rob F. P.; Versteeg, Henri H.] Leiden Univ, Dept Internal Med, Einthoven Lab Expt Vasc Med, Med Ctr, Leiden, Netherlands; [Lewis, Clayton S.; Bogdanov, Vladimir Y.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Hematol Oncol, Cincinnati, OH USA; [Krijgsman, Danielle; Noordhoek, Iris; Blok, Erik J.; Kuppen, Peter J. K.] Leiden Univ, Dept Surg, Med Ctr, Leiden, Netherlands; [Ruf, Wolfram] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA USA; [Ruf, Wolfram] Johannes Gutenberg Univ Mainz, Ctr Thrombosis & Hemostasis, Med Ctr, Mainz, Germany	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University System of Ohio; University of Cincinnati; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Scripps Research Institute; Johannes Gutenberg University of Mainz	Versteeg, HH (corresponding author), Leiden Univ, Dept Internal Med, Einthoven Lab Expt Vasc Med, Med Ctr, Leiden, Netherlands.	h.h.versteeg@lumc.nl	; Unlu, Betul/L-2048-2018	Rondon, Araci M R/0000-0002-2703-8805; Unlu, Betul/0000-0001-5587-4176	Dutch Cancer Society [UL 2015-7594]; Netherlands Organization for Scientific Research [VIDI 91710329]; Worldwide Cancer Research [15-1186]; NIH/NCI [R01CA190717]	Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Worldwide Cancer Research; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Dutch Cancer Society (UL 2015-7594), The Netherlands Organization for Scientific Research (VIDI 91710329) and Worldwide Cancer Research (15-1186). VYB and CSL are partially supported by the NIH/NCI (grant R01CA190717).	Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103; Beaver CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089834; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Bierie B, 2017, P NATL ACAD SCI USA, V114, pE2337, DOI 10.1073/pnas.1618298114; Chen QK, 2013, DIFFERENTIATION, V86, P126, DOI 10.1016/j.diff.2013.03.003; DeSantis CE, 2017, CA-CANCER J CLIN, V67, P439, DOI 10.3322/caac.21412; Dorfleutner A, 2004, MOL BIOL CELL, V15, P4416, DOI 10.1091/mbc.E03-09-0640; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Garg M, 2017, WORLD J STEM CELLS, V9, P118, DOI 10.4252/wjsc.v9.i8.118; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Horton MA, 1997, INT J BIOCHEM CELL B, V29, P721, DOI 10.1016/S1357-2725(96)00155-0; Ishiwata T, 2016, PATHOL INT, V66, P601, DOI 10.1111/pin.12447; Jessani N, 2004, P NATL ACAD SCI USA, V101, P13756, DOI 10.1073/pnas.0404727101; Kim KJ, 2017, J CLIN MED, V6, DOI 10.3390/jcm6030032; Kocaturk B, 2013, J THROMB HAEMOST, V11, P285, DOI 10.1111/jth.12222; Kocaturk B, 2015, JOVE-J VIS EXP, DOI 10.3791/51967; Kocaturk B, 2013, P NATL ACAD SCI USA, V110, P11517, DOI 10.1073/pnas.1307100110; Kotiyal S, 2014, BIOCHEM BIOPH RES CO, V453, P112, DOI 10.1016/j.bbrc.2014.09.069; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Levy S, 2005, PHYSIOLOGY, V20, P218, DOI 10.1152/physiol.00015.2005; Magnus N, 2014, P NATL ACAD SCI USA, V111, P3544, DOI 10.1073/pnas.1314118111; Marwali MR, 2003, BLOOD, V102, P215, DOI 10.1182/blood-2002-10-3195; Nistico P, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0459-x; Nitori N, 2005, CLIN CANCER RES, V11, P2531, DOI 10.1158/1078-0432.CCR-04-0866; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Palumbo JS, 2007, BLOOD, V110, P133, DOI 10.1182/blood-2007-01-065995; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Paula AD, 2017, ANTICANCER RES, V37, P2173, DOI 10.21873/anticanres.11552; Richards JO, 2016, CANCER IMMUNOL IMMUN, V65, P1325, DOI 10.1007/s00262-016-1885-7; Rothmeier AS, 2018, BLOOD, V131, P674, DOI 10.1182/blood-2017-02-768218; Ryden L, 2010, INT J CANCER, V126, P2330, DOI 10.1002/ijc.24921; Sawada M, 1999, BRIT J CANCER, V79, P472, DOI 10.1038/sj.bjc.6690073; Schaffner F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061071; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seto S, 2000, CANCER, V88, P295, DOI 10.1002/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U; Shaker H, 2017, ONCOTARGET, V8, P25915, DOI 10.18632/oncotarget.13928; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; STURM U, 1992, VIRCHOWS ARCH A, V421, P79, DOI 10.1007/BF01607039; Teplyakov A, 2017, CELL SIGNAL, V36, P139, DOI 10.1016/j.cellsig.2017.05.004; Ueno T, 2000, BRIT J CANCER, V83, P164; Unlu B, 2017, THROMB RES, V156, P1, DOI 10.1016/j.thromres.2017.05.028; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; van den Berg YW, 2012, BLOOD, V119, P924, DOI 10.1182/blood-2011-06-317685; van Nes JGH, 2011, BREAST CANCER RES TR, V125, P671, DOI 10.1007/s10549-010-0854-7; Versteeg HH, 2008, BLOOD, V111, P190, DOI 10.1182/blood-2007-07-101048; Yamashita H, 2007, J SURG ONCOL, V95, P324, DOI 10.1002/jso.20680; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zhang XS, 2017, ONCOTARGET, V8, P59086, DOI 10.18632/oncotarget.19175	51	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5176	5185		10.1038/s41388-022-02511-7	http://dx.doi.org/10.1038/s41388-022-02511-7		OCT 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271029	Bronze			2022-12-28	WOS:000870984500003
J	Wang, XY; Liu, Y; Han, AN; Tang, CX; Xu, R; Feng, LY; Yang, Y; Chen, LY; Lin, ZH				Wang, Xinyue; Liu, Ying; Han, Anna; Tang, Chunxiao; Xu, Ran; Feng, Linyuan; Yang, Yang; Chen, Liyan; Lin, Zhenhua			The NQO1/p53/SREBP1 axis promotes hepatocellular carcinoma progression and metastasis by regulating Snail stability	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; LIPID-METABOLISM; NQO1; CELLS	Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide, and its abnormal metabolism affects the survival and prognosis of patients. Recent studies have found that NAD(P)H quinone oxidoreductase-1 (NQO1) played an important role in tumor metabolism and malignant progression. However, the molecular mechanisms by which NQO1 regulates lipid metabolism during HCC progression remain unclear. In this study, bioinformatics analysis and immunohistochemical results showed that NQO1 was highly expressed in HCC tissues and its high expression was closely related to the poor prognosis of HCC patients. Overexpression of NQO1 promoted the cell proliferation, epithelial-to-mesenchymal transition (EMT) process, and angiogenesis of HCC cells. Luciferase reporter assay further revealed that NQO1/p53 could induce the transcriptional activity of SREBP1, consequently regulating HCC progression through lipid anabolism. In addition, Snail protein was stabilized by NQO1/p53/SREBP1 axis and triggered the EMT process, and participated in the regulatory role of NQO1/p53/SREBP1 axis in HCC. Together, these data indicated that NQO1/SREBP1 axis promoted the progression and metastasis of HCC, and might be a potential therapeutic target for HCC.	[Wang, Xinyue; Liu, Ying; Han, Anna; Tang, Chunxiao; Xu, Ran; Feng, Linyuan; Yang, Yang; Chen, Liyan; Lin, Zhenhua] Yanbian Univ, Key Lab Pathobiol, State Ethn Affairs Commiss, Yanji 133000, Peoples R China; [Wang, Xinyue; Feng, Linyuan; Yang, Yang; Lin, Zhenhua] Yanbian Univ, Affiliated Hosp, Cent Lab, Yanji 133000, Peoples R China	Yanbian University; Yanbian University	Lin, ZH (corresponding author), Yanbian Univ, Key Lab Pathobiol, State Ethn Affairs Commiss, Yanji 133000, Peoples R China.; Lin, ZH (corresponding author), Yanbian Univ, Affiliated Hosp, Cent Lab, Yanji 133000, Peoples R China.	zhlin720@ybu.edu.cn		Wang, Xinyue/0000-0002-8634-9590	Projects of Science and Technology Department of Jilin Province [210101207, 202002021JC]; National Natural Science Foundation of China [31760313]; Fund of Tumen River Scholar Project	Projects of Science and Technology Department of Jilin Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fund of Tumen River Scholar Project	This research was supported by the Projects of Science and Technology Department of Jilin Province (No.210101207, No.202002021JC), the National Natural Science Foundation of China (No.31760313), the Fund of Tumen River Scholar Project.	Patino-Morales CC, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101320; Cheng CM, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0301-4; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Deng ZQ, 2020, AUTOPHAGY, V16, P917, DOI 10.1080/15548627.2019.1644076; Dimri M, 2020, HEPATOLOGY, V71, P549, DOI 10.1002/hep.30818; Duan FF, 2018, J HEPATOL, V68, P1191, DOI 10.1016/j.jhep.2018.02.003; Fagerholm R, 2008, NAT GENET, V40, P844, DOI 10.1038/ng.155; Guo DL, 2014, CURR PHARM DESIGN, V20, P2619, DOI 10.2174/13816128113199990486; Han JB, 2015, NATURE, V524, P243, DOI 10.1038/nature14557; Karlsson MC, 2017, MOL ONCOL, V11, P781, DOI 10.1002/1878-0261.12092; Katikireddy KR, 2018, FREE RADICAL BIO MED, V116, P19, DOI 10.1016/j.freeradbiomed.2017.12.036; Kim J, 2019, CANCER CELL, V35, P191, DOI 10.1016/j.ccell.2018.12.012; Kumar DP, 2019, HEPATOLOGY, V69, P1520, DOI 10.1002/hep.30346; Lajin B, 2013, BRIT J CANCER, V109, P1325, DOI 10.1038/bjc.2013.357; Lewis AM, 2017, MOL CARCINOGEN, V56, P1825, DOI 10.1002/mc.20199; Lin LJ, 2017, HUM PATHOL, V69, P31, DOI 10.1016/j.humpath.2017.09.002; Liu J, 2019, J MOL CELL BIOL, V11, P284, DOI 10.1093/jmcb/mjy070; Liu J, 2020, HEPATOLOGY, V71, P1262, DOI 10.1002/hep.30917; Llovet JM, 2021, NAT REV GASTRO HEPAT, V18, P293, DOI 10.1038/s41575-020-00395-0; Long MT, 2022, GASTROENTEROLOGY; Luo SL, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9146528; Lyu JF, 2018, INT J BIOL SCI, V14, P1175, DOI 10.7150/ijbs.26011; Ma Y, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-414; Maan M, 2018, BIOCHEM BIOPH RES CO, V504, P582, DOI 10.1016/j.bbrc.2018.02.097; Oh ET, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13593; Pang MF, 2016, ONCOGENE, V35, P748, DOI 10.1038/onc.2015.133; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pasquier J, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02244-9; Piscaglia F, 2016, HEPATOLOGY, V63, P827, DOI 10.1002/hep.28368; Rohrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89; Santos PM, 2019, CANCER IMMUNOL RES, V7, P1001, DOI 10.1158/2326-6066.CIR-18-0513; Satriano L, 2019, NAT REV GASTRO HEPAT, V16, P748, DOI 10.1038/s41575-019-0217-8; Shimokawa M, 2020, CANCER SCI, V111, P1228, DOI 10.1111/cas.14320; Singal AG, 2020, J HEPATOL, V72, P250, DOI 10.1016/j.jhep.2019.08.025; Wang CC, 2018, HEPATOLOGY, V68, P1833, DOI 10.1002/hep.30030; Wang RQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2252-3; Wang XY, 2020, CANCER SCI, V111, P4061, DOI 10.1111/cas.14562; Wu XS, 2018, J MED CHEM, V61, P11280, DOI 10.1021/acs.jmedchem.8b01424; Xing R, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.783236; Xu DQ, 2020, NATURE, V580, P530, DOI 10.1038/s41586-020-2183-2; Yang Y, 2019, CANCER LETT, V453, P170, DOI 10.1016/j.canlet.2019.03.054; Yang Y, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-14; Yin F, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.49; Zhang KJ, 2018, J MED CHEM, V61, P6983, DOI [10.1021/acsjmedchem.8b00124, 10.1021/acs.jmedchem.8b00124]; Zhang N, 2019, CELL DEATH DIFFER, V26, P843, DOI 10.1038/s41418-018-0158-8; Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1156-5; Zhao WX, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.747282	47	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5107	5120		10.1038/s41388-022-02477-6	http://dx.doi.org/10.1038/s41388-022-02477-6		OCT 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36253445				2022-12-28	WOS:000868969900002
J	Doolittle, WKL; Park, S; Lee, SG; Jeong, S; Lee, G; Ryu, D; Schoonjans, K; Auwerx, J; Lee, J; Jo, YS				Doolittle, Woo Kyung Lee; Park, Sunmi; Lee, Seul Gi; Jeong, Seonhyang; Lee, Gibbeum; Ryu, Dongryeol; Schoonjans, Kristina; Auwerx, Johan; Lee, Jandee; Jo, Young Suk			Non-genomic activation of the AKT-mTOR pathway by the mitochondrial stress response in thyroid cancer	ONCOGENE			English	Article							GENE-EXPRESSION; METABOLISM; PHOSPHORYLATION; PERSPECTIVE; SURVIVAL; WARBURG; PROTEOSTASIS; SUPPRESSION; HOMEOSTASIS; RESISTANCE	Cancer progression is associated with metabolic reprogramming and causes significant intracellular stress; however, the mechanisms that link cellular stress and growth signalling are not fully understood. Here, we identified a mechanism that couples the mitochondrial stress response (MSR) with tumour progression. We demonstrated that the MSR is activated in a significant proportion of human thyroid cancers via the upregulation of heat shock protein D family members and the mitokine, growth differentiation factor 15. Our study also revealed that MSR triggered AKT/S6K signalling by activating mTORC2 via activating transcription factor 4/sestrin 2 activation whilst promoting leucine transporter and nutrient-induced mTORC1 activation. Importantly, we found that an increase in (mt)DNA played an essential role in MSR-induced mTOR activation and that crosstalk between MYC and MSR potentiated mTOR activation. Together, these findings suggest that the MSR could be a predictive marker for aggressive human thyroid cancer as well as a useful therapeutic target.	[Doolittle, Woo Kyung Lee] NCI, Lab Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Park, Sunmi; Jeong, Seonhyang; Jo, Young Suk] Yonsei Univ, Dept Internal Med, Open NBI Convergence Technol Res Lab, Coll Med, Seoul 03722, South Korea; [Lee, Seul Gi] Eulji Univ, Dept Surg, Sch Med, Daejeon 34824, South Korea; [Lee, Gibbeum; Lee, Jandee] Yonsei Univ, Severance Hosp, Yonsei Canc Ctr, Dept Surg,Coll Med,Open NBI Convergence Technol R, Seoul 03722, South Korea; [Ryu, Dongryeol] Sungkyunkwan Univ, Dept Mol Cell Biol, Lab Mol & Integrat Biol, Sch Med, Suwon 16419, South Korea; [Schoonjans, Kristina] Ecole Polytech Fed Lausanne, Lab Metab Signaling, CH-1015 Lausanne, Switzerland; [Auwerx, Johan] Ecole Polytech Fed Lausanne, Lab Integrat Syst Physiol, CH-1015 Lausanne, Switzerland; [Doolittle, Woo Kyung Lee] Case Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Dept Med, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yonsei University; Yonsei University Health System; Eulji University; Yonsei University; Yonsei University Health System; Sungkyunkwan University (SKKU); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Case Western Reserve University; University Hospitals of Cleveland	Jo, YS (corresponding author), Yonsei Univ, Dept Internal Med, Open NBI Convergence Technol Res Lab, Coll Med, Seoul 03722, South Korea.; Lee, J (corresponding author), Yonsei Univ, Severance Hosp, Yonsei Canc Ctr, Dept Surg,Coll Med,Open NBI Convergence Technol R, Seoul 03722, South Korea.	jandee@yuhs.ac; joys@yuhs.ac	Doolittle, Woo Kyung Lee/CAJ-0252-2022	Doolittle, Woo Kyung Lee/0000-0002-6737-3173; Jo, Young Suk/0000-0001-9926-8389; Ryu, Dongryeol/0000-0001-5905-6760; Lee, Jandee/0000-0003-4090-0049; Schoonjans, Kristina/0000-0003-1247-4265	National Research Foundation of Korea grant - Korean government [NRF-2018R1A2B6004179, NRF-2021R1H1A2012035, NRF-2020R1A2C1006047, NRF-2020R1I1A1A01069524]; National Research Foundation of Korea GRL grant [NRF-2017K1A1A2013124]; Ecole Polytechnique Federale de Lausanne; European Research Council [ERC-AdG-787702]; Swiss Cancer Research [KFS-4226-08-2017]; Swiss National Science Foundation, Sinergia [CRSII3_160798]	National Research Foundation of Korea grant - Korean government(National Research Foundation of Korea); National Research Foundation of Korea GRL grant; Ecole Polytechnique Federale de Lausanne; European Research Council(European Research Council (ERC)European Commission); Swiss Cancer Research; Swiss National Science Foundation, Sinergia(Swiss National Science Foundation (SNSF))	We received funding from the National Research Foundation of Korea grant, funded by the Korean government NRF-2018R1A2B6004179 and NRF-2021R1H1A2012035 (YSJ); NRF-2020R1A2C1006047 (JL); NRF-2020R1I1A1A01069524 (SP); National Research Foundation of Korea GRL grant NRF-2017K1A1A2013124 (JA); Ecole Polytechnique Federale de Lausanne (JA and KS); European Research Council ERC-AdG-787702 (JA); Swiss Cancer Research KFS-4226-08-2017 (KS); and Swiss National Science Foundation, Sinergia CRSII3_160798 (KS).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bao XT, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03505-1; Budanov AV, 2002, ONCOGENE, V21, P6017, DOI 10.1038/sj.onc.1205877; Byun JK, 2017, CELL REP, V20, P586, DOI 10.1016/j.celrep.2017.06.066; Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004; Chandel NS, 2015, CELL METAB, V22, P204, DOI 10.1016/j.cmet.2015.05.013; Chantranupong L, 2014, CELL REP, V9, P1, DOI 10.1016/j.celrep.2014.09.014; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; D'Amico D, 2017, TRENDS BIOCHEM SCI, V42, P712, DOI 10.1016/j.tibs.2017.05.002; Ding L, 2018, CELL, V173, P305, DOI 10.1016/j.cell.2018.03.033; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Garaeva AA, 2016, CELL CYCLE, V15, P64, DOI 10.1080/15384101.2015.1120929; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Houtkooper RH, 2013, NATURE, V497, P451, DOI 10.1038/nature12188; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Ishida S, 2013, P NATL ACAD SCI USA, V110, P19507, DOI 10.1073/pnas.1318431110; Johnson SC, 2013, SCIENCE, V342, P1524, DOI 10.1126/science.1244360; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Knippler CM, 2019, ENDOCR-RELAT CANCER, V26, P699, DOI 10.1530/ERC-19-0188; Kowalsky AH, 2020, J BIOL CHEM, V295, P1769, DOI 10.1074/jbc.RA119.010857; Lee MH, 2011, J CLIN ENDOCR METAB, V96, pE19, DOI 10.1210/jc.2010-1071; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martinez-Reyes I, 2012, BIOCHEM J, V444, P249, DOI 10.1042/BJ20111829; Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025; Matilainen O, 2017, TRENDS CELL BIOL, V27, P453, DOI 10.1016/j.tcb.2017.02.004; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; Moullan N, 2015, CELL REP, V10, P1681, DOI 10.1016/j.celrep.2015.02.034; Nacarelli T, 2015, EXP GERONTOL, V68, P66, DOI 10.1016/j.exger.2014.11.004; Nargund AM, 2012, SCIENCE, V337, P587, DOI 10.1126/science.1223560; O'Malley J, 2020, TRENDS CANCER, V6, P688, DOI 10.1016/j.trecan.2020.04.009; Park HW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5233; Parmigiani A, 2014, CELL REP, V9, P1281, DOI 10.1016/j.celrep.2014.10.019; Peng M, 2015, HUM MOL GENET, V24, P4829, DOI 10.1093/hmg/ddv207; Peng M, 2014, CELL, V159, P122, DOI 10.1016/j.cell.2014.08.038; Peng XX, 2018, CELL REP, V23, P255, DOI 10.1016/j.celrep.2018.03.077; Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155; Quiros PM, 2017, J CELL BIOL, V216, P2027, DOI 10.1083/jcb.201702058; Quiros PM, 2016, NAT REV MOL CELL BIO, V17, P213, DOI 10.1038/nrm.2016.23; Ringel MD, 2001, CANCER RES, V61, P6105; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saxton RA, 2016, SCIENCE, V351, P53, DOI 10.1126/science.aad2087; Steffen KK, 2016, CELL METAB, V23, P1004, DOI 10.1016/j.cmet.2016.05.013; Taylor AM, 2018, CANCER CELL, V33, P676, DOI 10.1016/j.ccell.2018.03.007; Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; WARBURG O, 1956, SCIENCE, V124, P269; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Ye JB, 2015, GENE DEV, V29, P2331, DOI 10.1101/gad.269324.115; Yi HS, 2018, J MOL ENDOCRINOL, V61, pR91, DOI 10.1530/JME-18-0005; Yoneda T, 2004, J CELL SCI, V117, P4055, DOI 10.1242/jcs.01275; Yu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-y; Yu M, 2007, TOXICOL LETT, V170, P83, DOI 10.1016/j.toxlet.2007.02.013; Zaugg K, 2011, GENE DEV, V25, P1041, DOI 10.1101/gad.1987211; Zhang J, 2008, J BIOL CHEM, V283, P35375, DOI 10.1074/jbc.M806480200; Zheng XD, 2016, ELIFE, V5, DOI 10.7554/eLife.13378; Zhou Q, 2015, TOXICOL SCI, V143, P81, DOI 10.1093/toxsci/kfu211	70	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4893	4904		10.1038/s41388-022-02484-7	http://dx.doi.org/10.1038/s41388-022-02484-7		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36195659				2022-12-28	WOS:000864233500001
J	Ogden, S; Carys, K; Ahmed, I; Bruce, J; Sharrocks, AD				Ogden, Samuel; Carys, Kashmala; Ahmed, Ibrahim; Bruce, Jason; Sharrocks, Andrew D.			Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition	ONCOGENE			English	Article							CANCER-CELLS; ESOPHAGEAL; TRASTUZUMAB; DRIVES; COMBINATION; PLASTICITY; LAPATINIB; GENES; ALPHA; WOMEN	Oesophageal adenocarcinoma (OAC) patients show poor survival rates and there are few targeted molecular therapies available. However, components of the receptor tyrosine kinase (RTK) driven pathways are commonly mutated in OAC, typified by high frequency amplifications of the RTK ERBB2. ERBB2 can be therapeutically targeted, but this has limited clinical benefit due to the acquisition of drug resistance. Here we examined how OAC cells adapt to ERBB2 inhibition as they transition to a drug resistant state. ERBB2 inhibition triggers widespread remodelling of the accessible chromatin landscape and the underlying gene regulatory networks. The transcriptional regulators HNF4A and PPARGC1A play a key role in this network rewiring. Initially, inhibition of cell cycle associated gene expression programmes is observed, with compensatory increases in the programmes driving changes in metabolic activity. Both PPARGC1A and HNF4A are required for the acquisition of resistance to ERBB2 inhibition and PPARGC1A is instrumental in promoting a switch to dependency on oxidative phosphorylation. Our work therefore reveals the molecular pathways that support the acquisition of a resistant state and points to potential new therapeutic strategies to combat cellular adaptation and ensuing drug resistance.	[Ogden, Samuel; Carys, Kashmala; Ahmed, Ibrahim; Bruce, Jason; Sharrocks, Andrew D.] Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England	University of Manchester	Sharrocks, AD (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	andrew.d.sharrocks@manchester.ac.uk		Bruce, Jason/0000-0002-4503-1981	Wellcome Trust [103857/Z/14/Z, 102171/Z/13/Z]	Wellcome Trust(Wellcome Trust)	We thank Guanhua Yan for excellent technical assistance, Connor Rogerson for advice and help with RNA-seq data processing and staff in the Bioinformatics, Genomic Technologies and Flow cytometry core facilities. Rebecca Fitzgerald for providing the OAC organoid. We also thank Nicoletta Bobola, Tim Somervaille and Shen-Hsi Yang for critical appraisal of the manuscript. This work was funded by grants from the Wellcome Trust (103857/Z/14/Z and 102171/Z/13/Z).	Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59; Bang YJ, 2010, LANCET, V376, P1302; Bell CC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10652-9; Bi MJ, 2020, NAT CELL BIOL, V22, P701, DOI 10.1038/s41556-020-0514-z; Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Boumahdi S, 2020, NAT REV DRUG DISCOV, V19, P39, DOI 10.1038/s41573-019-0044-1; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Britton E, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006879; Brunton H, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107625; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Charos AE, 2012, GENOME RES, V22, P1668, DOI 10.1101/gr.127761.111; Chen L, 2020, GUT, V69, P630, DOI 10.1136/gutjnl-2019-318325; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Coleman HG, 2018, GASTROENTEROLOGY, V154, P390, DOI 10.1053/j.gastro.2017.07.046; Corces MR, 2018, SCIENCE, V362, P420, DOI 10.1126/science.aav1898; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; De Vitto H, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0081-6; Deblois G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12156; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Flavahan WA, 2019, NATURE, V575, P229, DOI 10.1038/s41586-019-1668-3; Frankell AM, 2019, NAT GENET, V51, P506, DOI 10.1038/s41588-018-0331-5; Hammerlindl H, 2018, J CELL COMMUN SIGNAL, V12, P133, DOI 10.1007/s12079-017-0435-1; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hecht JR, 2016, J CLIN ONCOL, V34, P443, DOI 10.1200/JCO.2015.62.6598; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Janjigian YY, 2018, CANCER DISCOV, V8, P49, DOI 10.1158/2159-8290.CD-17-0787; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Keld R, 2011, BRIT J CANCER, V105, P124, DOI 10.1038/bjc.2011.187; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Kim J, 2014, J CLIN INVEST, V124, P5145, DOI 10.1172/JCI75200; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li XD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05190-9; Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liau BB, 2017, CELL STEM CELL, V20, P233, DOI 10.1016/j.stem.2016.11.003; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Ma S, 2021, CANCER RES, V81, P1216, DOI 10.1158/0008-5472.CAN-20-0652; Maag JLV, 2017, MOL CANCER RES, V15, P1558, DOI 10.1158/1541-7786.MCR-17-0332; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Pan J, 2020, CANCER RES, V80, P2722, DOI 10.1158/0008-5472.CAN-20-0390; Peters Y, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0086-z; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Ramirez M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10690; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rogerson C, 2020, ELIFE, V9, DOI 10.7554/eLife.57189; Rogerson C, 2019, GENOME RES, V29, P723, DOI 10.1101/gr.243345.118; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shen SS, 2020, CELL, V183, P860, DOI 10.1016/j.cell.2020.10.027; Somerville TDD, 2018, CELL REP, V25, P1741, DOI 10.1016/j.celrep.2018.10.051; Stachler MD, 2018, GASTROENTEROLOGY, V155, P156, DOI 10.1053/j.gastro.2018.03.047; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang DS, 2019, GUT, V68, P1152, DOI 10.1136/gutjnl-2018-316522; Weaver JMJ, 2014, NAT GENET, V46, P837, DOI 10.1038/ng.3013; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yen K, 2017, CANCER DISCOV, V7, P478, DOI 10.1158/2159-8290.CD-16-1034; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zeng Y, 2018, PHARM BIOL, V56, P393, DOI 10.1080/13880209.2018.1493610; Zhang YR, 2020, CANCER RES, V80, P30, DOI 10.1158/0008-5472.CAN-19-1389; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; ZHOU YY, 2019, NAT COMMUN, V10, DOI [10.1038/S41467-019-09234-6, DOI 10.1038/s41587-020-0546-8, DOI 10.1038/S41467-019-09234-6]	72	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2022	41	43					4808	4822		10.1038/s41388-022-02465-w	http://dx.doi.org/10.1038/s41388-022-02465-w		SEP 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M4RI	36153371	hybrid, Green Published			2022-12-28	WOS:000857812100001
J	Zhao, LY; Zhang, X; Zhou, YF; Fu, KL; Lau, HCH; Chun, TWY; Cheung, AHK; Coker, OO; Wei, H; Wu, WKK; Wong, SH; Sung, JJY; To, KF; Yu, J				Zhao, Liuyang; Zhang, Xiang; Zhou, Yunfei; Fu, Kaili; Lau, Harry Cheuk-Hay; Chun, Tommy Wai-Yiu; Cheung, Alvin Ho-Kwan; Coker, Olabisi Oluwabukola; Wei, Hong; Wu, William Ka-Kei; Wong, Sunny Hei; Sung, Joseph Jao-Yiu; To, Ka Fai; Yu, Jun			Parvimonas micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients	ONCOGENE			English	Article							GUT MICROBIOTA; CELLS	Large-scale fecal shotgun metagenomic sequencing revealed the high abundance of Parvimonas micra in colorectal cancer (CRC) patients. We investigated the role and clinical significance of P. micra in colorectal tumorigenesis. The abundance of P. micra was examined in 309 fecal samples and 165 colon biopsy tissues of CRC patients and healthy subjects. P. micra was significantly enriched in fecal samples from 128 CRC patients compared to 181 healthy subjects (P < 0.0001); and in colon tissue biopsies from 52 CRC patients compared to 61 healthy subjects (P < 0.0001). Multivariate analysis showed that P. micra is an independent risk factor of poor survival in CRC patients (Hazard Ratio: 1.93). P. micra strain was isolated from feces of a CRC patient. Apc(min/+) mice gavaged with P. micra showed significantly higher tumor burden and tumor load (both P < 0.01). Consistently, gavage of P. micra significantly promoted colonocyte proliferation in conventional mice, which was further confirmed by germ-free mice. P. micra colonization up-regulated genes involved in cell proliferation, stemness, angiogenesis and invasiveness/metastasis; and enhanced Th17 cells infiltration and expression of Th17 cells-secreted cytokines (Il-17, Il-22, and Il-23) in the colon of Apc(min/+), conventional and germ-free mice. P. micra-conditioned medium significantly promoted the differentiation of CD4(+) T cells to Th17 cells (IL-17(+)CD4(+) phenotype) and enhanced the oncogenic Wnt signaling pathway. In conclusion, P. micra promoted colorectal tumorigenesis in mice by inducing colonocyte proliferation and altering Th17 immune response. P. micra may act as a prognostic biomarker for poor survival of CRC patients.	[Zhao, Liuyang; Zhang, Xiang; Zhou, Yunfei; Fu, Kaili; Lau, Harry Cheuk-Hay; Chun, Tommy Wai-Yiu; Coker, Olabisi Oluwabukola; Wu, William Ka-Kei; Wong, Sunny Hei; Sung, Joseph Jao-Yiu; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,Inst Digest Dis,State Key La, Hong Kong, Peoples R China; [Zhao, Liuyang; Cheung, Alvin Ho-Kwan; To, Ka Fai] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; [Wei, Hong] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Precis Med, Guangzhou, Peoples R China; [Wu, William Ka-Kei] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Sun Yat Sen University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,Inst Digest Dis,State Key La, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	wu, william/HII-5817-2022; Lau, Harry Cheuk Hay/X-3413-2019; Wu, William K.K./A-3277-2009	Lau, Harry Cheuk Hay/0000-0003-3581-2909; Wu, William K.K./0000-0002-5662-5240	National Key R&D Program of China [2020YFA0509200/2020YFA0509203]; RGC-Research Impact Fund Hong Kong [R4032-21F]; RGC-GRF Hong Kong [14163817]; Vice-Chancellor's Discretionary Fund CUHK; CUHK direct grant	National Key R&D Program of China; RGC-Research Impact Fund Hong Kong; RGC-GRF Hong Kong(Hong Kong Research Grants Council); Vice-Chancellor's Discretionary Fund CUHK; CUHK direct grant(Chinese University of Hong Kong)	This project was supported by National Key R&D Program of China (2020YFA0509200/2020YFA0509203); RGC-Research Impact Fund Hong Kong (R4032-21F); RGC-GRF Hong Kong (14163817); Vice-Chancellor's Discretionary Fund CUHK and CUHK direct grant.	Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Dai ZW, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0451-2; Flemer B, 2018, GUT, V67, P1454, DOI 10.1136/gutjnl-2017-314814; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535; Irrazabal T, 2014, MOL CELL, V54, P309, DOI 10.1016/j.molcel.2014.03.039; Koeth LM, 2004, J ANTIMICROB CHEMOTH, V53, P1039, DOI 10.1093/jac/dkh248; Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007; La Vecchia S, 2020, SEMIN CELL DEV BIOL, V98, P63, DOI 10.1016/j.semcdb.2019.05.018; Li BL, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368-018-0043-9; Li Q, 2021, GASTROENTEROLOGY, V160, P1179, DOI 10.1053/j.gastro.2020.09.003; Loftus M, 2021, BMC MICROBIOL, V21, DOI 10.1186/s12866-021-02153-x; Long XH, 2019, NAT MICROBIOL, V4, P2319, DOI 10.1038/s41564-019-0541-3; Louis P, 2014, NAT REV MICROBIOL, V12, P661, DOI 10.1038/nrmicro3344; Nakatsu G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9727; Park SY, 2021, CANCERS, V13, DOI 10.3390/cancers13092124; Purcell RV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11237-6; Segata N, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r42; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sillanpaa J, 2008, FEMS MICROBIOL LETT, V289, P104, DOI 10.1111/j.1574-6968.2008.01378.x; Tsoi H, 2017, GASTROENTEROLOGY, V152, P1419, DOI 10.1053/j.gastro.2017.01.009; VANDALEN PJ, 1993, INT J SYST BACTERIOL, V43, P787, DOI 10.1099/00207713-43-4-787; Wagner A, 2021, CELL, V184, P4168, DOI 10.1016/j.cell.2021.05.045; Wong SH, 2019, NAT REV GASTRO HEPAT, V16, P690, DOI 10.1038/s41575-019-0209-8; Wong SH, 2017, GASTROENTEROLOGY, V153, P1621, DOI 10.1053/j.gastro.2017.08.022; Wong SH, 2017, GUT, V66, P1441, DOI 10.1136/gutjnl-2016-312766; Xu J, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.11967; Yachida S, 2019, NAT MED, V25, P968, DOI 10.1038/s41591-019-0458-7; Yu J, 2017, GUT, V66, P70, DOI 10.1136/gutjnl-2015-309800; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zheng DP, 2020, CELL RES, V30, P492, DOI 10.1038/s41422-020-0332-7	31	1	1	9	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2022	41	36					4200	4210		10.1038/s41388-022-02395-7	http://dx.doi.org/10.1038/s41388-022-02395-7		JUL 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4G5OH	35882981	Green Published, hybrid			2022-12-28	WOS:000830346600001
J	Zeng, ZC; Xu, SW; Wang, FF; Peng, X; Zhang, WN; Zhan, YZ; Ding, YQ; Liu, ZG; Liang, L				Zeng, Zhicheng; Xu, Shaowan; Wang, Feifei; Peng, Xin; Zhang, Wanning; Zhan, Yizhi; Ding, Yanqing; Liu, Ziguang; Liang, Li			HAO1-mediated oxalate metabolism promotes lung pre-metastatic niche formation by inducing neutrophil extracellular traps	ONCOGENE			English	Article							GLYCOLATE OXIDASE; MOUSE MODEL; RECOGNITION; ACTIVATION; CELLS; RNAS	Metabolic reprogramming has been shown to be involved in cancer-induced pre-metastatic niche (PMN) formation, but the underlying mechanisms have been insufficiently explored. Here, we showed that hydroxyacid oxidase 1 (HAO1), a rate-limiting enzyme of oxalate synthesis, was upregulated in the alveolar epithelial cells of mice bearing metastatic breast cancer cells at the pre-metastatic stage, leading to oxalate accumulation in lung tissue. Lung oxalate accumulation induced neutrophil extracellular trap (NET) formation by activating NADPH oxidase, which facilitated the formation of pre-metastatic niche. In addition, lung oxalate accumulation promoted the proliferation of metastatic cancer cells by activating the MAPK signaling pathway. Pharmacologic inhibition of HAO1 could effectively suppress the lung oxalate accumulation induced by primary cancer, consequently dampening lung metastasis of breast cancer. Breast cancer cells induced HAO1 expression and oxalate accumulation in alveolar epithelial cells by activating TLR3-IRF3 signaling. Collectively, these findings underscore the role of HAO1-mediated oxalate metabolism in cancer-induced lung PMN formation and metastasis. HAO1 could be an appealing therapeutic target for preventing lung metastasis of cancer.	[Zeng, Zhicheng; Liu, Ziguang] Southern Med Univ, Peoples Hosp Shunde Foshan 1, Shunde Hosp, Dept Pathol, Foshan, Guangdong, Peoples R China; [Zeng, Zhicheng; Xu, Shaowan; Wang, Feifei; Peng, Xin; Zhang, Wanning; Zhan, Yizhi; Ding, Yanqing; Liang, Li] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Peoples R China; [Zeng, Zhicheng; Xu, Shaowan; Wang, Feifei; Peng, Xin; Zhang, Wanning; Zhan, Yizhi; Ding, Yanqing; Liang, Li] Southern Med Univ, Basic Med Coll, Guangzhou 510515, Peoples R China; [Zeng, Zhicheng; Xu, Shaowan; Wang, Feifei; Peng, Xin; Zhang, Wanning; Zhan, Yizhi; Ding, Yanqing; Liang, Li] Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Liang, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Peoples R China.; Liang, L (corresponding author), Southern Med Univ, Basic Med Coll, Guangzhou 510515, Peoples R China.; Liang, L (corresponding author), Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China.	lli@smu.edu.cn			National Key R&D Program of China [2017YFC1309002]; National Natural Science Foundation of China [81672821, 81472313, 81773101, 81903002, 82003059]; China Postdoctoral Science Foundation [2019M652963, 2020M682624]; Cancer Research UK [A3655]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Cancer Research UK(Cancer Research UK)	This work was supported by the National Key R&D Program of China (2017YFC1309002), National Natural Science Foundation of China (81672821, 81472313, 81773101, 81903002, 82003059), China Postdoctoral Science Foundation (2019M652963, 2020M682624), Cancer Research UK grant A3655.	Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Baker PRS, 2004, AM J PHYSIOL-CELL PH, V287, pC1359, DOI 10.1152/ajpcell.00238.2004; Bourhis JM, 2009, ACTA CRYSTALLOGR F, V65, P1246, DOI 10.1107/S1744309109041670; Castellaro AM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1747-2; Cools-Lartigue J, 2013, J CLIN INVEST, V123, P3446, DOI 10.1172/JCI67484; Dutta C, 2016, MOL THER, V24, P770, DOI 10.1038/mt.2016.4; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Forte G, 2012, J IMMUNOL, V188, P5357, DOI 10.4049/jimmunol.1103811; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Jablonska J, 2017, ONCOTARGET, V8, P112132, DOI 10.18632/oncotarget.22792; Jorch SK, 2017, NAT MED, V23, P279, DOI 10.1038/nm.4294; Joshi S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/462361; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Lee W, 2019, AGING-US, V11, P6624, DOI 10.18632/aging.102258; Liebow A, 2017, J AM SOC NEPHROL, V28, P494, DOI 10.1681/ASN.2016030338; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Martin-Higueras C, 2016, MOL THER, V24, P719, DOI 10.1038/mt.2015.224; Milara J, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0179-5; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Robertson DS, 2011, CLIN CHEM LAB MED, V49, P1405, DOI 10.1515/CCLM.2011.238; Schnedler N, 2011, J HEPATOL, V54, P513, DOI 10.1016/j.jhep.2010.07.036; Simoes RV, 2015, NEOPLASIA, V17, P671, DOI 10.1016/j.neo.2015.08.005; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Tavora B, 2020, NATURE, V586, P299, DOI 10.1038/s41586-020-2774-y; Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001; Tsuji H, 2016, WORLD J UROL, V34, P89, DOI 10.1007/s00345-015-1563-y; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Whitsett JA, 2015, NAT IMMUNOL, V16, P27, DOI 10.1038/ni.3045; Wu ZM, 2015, CELL STEM CELL, V17, P47, DOI 10.1016/j.stem.2015.05.016; Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6; Yang XY, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.703640; Yuan JM, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00949-4; Zabaleta N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07827-1; Zeng ZC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07810-w; Zhu JN, 2019, FREE RADICAL BIO MED, V134, P9, DOI 10.1016/j.freeradbiomed.2018.12.033	37	1	1	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2022	41	29					3719	3731		10.1038/s41388-022-02248-3	http://dx.doi.org/10.1038/s41388-022-02248-3		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y6YE	35739335	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000814926700001
J	Moser, R; Gurley, KE; Nikolova, O; Qin, GR; Joshi, R; Mendez, E; Shmulevich, I; Ashley, A; Grandori, C; Kemp, CJ				Moser, Russell; Gurley, Kay E.; Nikolova, Olga; Qin, Guangrong; Joshi, Rashmi; Mendez, Eduardo; Shmulevich, Ilya; Ashley, Amanda; Grandori, Carla; Kemp, Christopher J.			Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; TUMOR-FORMATION; ONCOGENIC RAS; MALIGNANT PROGRESSION; THERAPEUTIC TARGETS; SKIN TUMORS; CANCER; MICE; PROMOTION; GROWTH	The oncogene Ras and the tumor suppressor gene p53 are frequently co-mutated in human cancer and mutations in Ras and p53 can cooperate to generate a more malignant cell state. To discover novel druggable targets for cancers carrying co-mutations in Ras and p53, we performed arrayed, kinome focused siRNA and oncology drug phenotypic screening utilizing a set of syngeneic Ras mutant squamous cell carcinoma (SCC) cell lines that also carried co-mutations in selected p53 pathway genes. These cell lines were derived from SCCs from carcinogen-treated inbred mice which harbored germline deletions or mutations in Trp53, p19(Arf), Atm, or Prkdc. Both siRNA and drug phenotypic screening converge to implicate the phosphoinositol kinases, receptor tyrosine kinases, MAP kinases, as well as cell cycle and DNA damage response genes as targetable dependencies in SCC. Differences in functional kinome profiles between Ras mutant cell lines reflect incomplete penetrance of Ras synthetic lethal kinases and indicate that co-mutations cause a rewiring of survival pathways in Ras mutant tumors. This study describes the functional kinomic landscape of Ras/p53 mutant chemically-induced squamous cell carcinoma in both the baseline unperturbed state and following DNA damage and nominates candidate therapeutic targets, including the Nek4 kinase, for further development.	[Moser, Russell; Gurley, Kay E.; Kemp, Christopher J.] Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA; [Nikolova, Olga] Oregon Hlth & Sci Univ, Div Oncol Sci, Portland, OR 97201 USA; [Qin, Guangrong; Shmulevich, Ilya] Inst Syst Biol, Seattle, WA USA; [Joshi, Rashmi; Ashley, Amanda] New Mexico State Univ, Las Cruces, NM 88003 USA; [Mendez, Eduardo; Grandori, Carla] SEngine Precis Med, Seattle, WA USA	Fred Hutchinson Cancer Center; Oregon Health & Science University; Institute for Systems Biology (ISB); New Mexico State University	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA.	cjkemp@fhcrc.org			NCI [U01 CA176303, U01 CA217883, U54 CA132381, R01 CA214428, R01 CA215647, 2P30CA015704]; ACS [123653-RSG-13-066]; Hartwell Fund	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS(American Cancer Society); Hartwell Fund	This work was supported by The Hartwell Fund, NCI U01 CA176303, U01 CA217883, U54 CA132381, R01 CA214428, R01 CA215647, 2P30CA015704, and ACS 123653-RSG-13-066. We acknowledge technical assistance from Slobodan Beronja in generating normal mouse keratinocytes and the use of data from the NCI's Cancer Target Discovery and Development Network, The Cancer Genome Atlas, and The Cell Line Encyclopedia.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Adhikari H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05692-6; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Bai YF, 2004, CANCER RES, V64, P8808, DOI 10.1158/0008-5472.CAN-04-3143; Bailey SL, 2008, MOL CANCER RES, V6, P1185, DOI 10.1158/1541-7786.MCR-07-2009; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Pavan ICB, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030507; Birmingham A, 2009, NAT METHODS, V6, P569, DOI 10.1038/nmeth.1351; Burke JE, 2018, MOL CELL, V71, P653, DOI 10.1016/j.molcel.2018.08.005; BURNS PA, 1991, ONCOGENE, V6, P2363; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Choi SY, 2015, BBA-MOL CELL BIOL L, V1851, P711, DOI 10.1016/j.bbalip.2015.01.009; Costa-Cabral S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149099; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; Dahlhoff M, 2017, J INVEST DERMATOL, V137, P921, DOI 10.1016/j.jid.2016.11.023; Dahlhoff M, 2015, MOL ONCOL, V9, P1825, DOI 10.1016/j.molonc.2015.06.007; Ding NH, 2018, J CELL MOL MED, V22, P5877, DOI 10.1111/jcmm.13857; Dlugosz AA, 1997, CANCER RES, V57, P3180; Doles J, 2010, CANCER RES, V70, P1033, DOI 10.1158/0008-5472.CAN-09-2113; Ehrenreiter K, 2009, CANCER CELL, V16, P149, DOI 10.1016/j.ccr.2009.06.008; Eyers PA, 2017, TRENDS CELL BIOL, V27, P284, DOI 10.1016/j.tcb.2016.11.002; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Fry AM, 2012, J CELL SCI, V125, P4423, DOI 10.1242/jcs.111195; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hahn WC, 2021, CELL, V184, P1142, DOI 10.1016/j.cell.2021.02.020; Hara T, 2005, CANCER RES, V65, P7356, DOI 10.1158/0008-5472.CAN-04-4241; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Jameson KL, 2013, NAT MED, V19, P626, DOI 10.1038/nm.3165; KEITH WN, 1990, CANCER RES, V50, P6841; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kemp CJ, 1999, CARCINOGENESIS, V20, P2051, DOI 10.1093/carcin/20.11.2051; Kemp CJ, 2014, MOUSE MODELS CANC LA, P5160; Kiessling MK, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3042-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Martin TD, 2017, CELL REP, V20, P427, DOI 10.1016/j.celrep.2017.06.061; McCreery MQ, 2015, NAT MED, V21, P1514, DOI 10.1038/nm.3979; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; Mendez E, 2018, CLIN CANCER RES, V24, P2740, DOI 10.1158/1078-0432.CCR-17-3796; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Moniz L, 2011, CELL DIV, V6, DOI 10.1186/1747-1028-6-18; Moore AR, 2020, NAT REV DRUG DISCOV, V19, P533, DOI 10.1038/s41573-020-0068-6; Moser R, 2014, CLIN CANCER RES, V20, P4274, DOI 10.1158/1078-0432.CCR-13-2858; Nassar D, 2015, NAT MED, V21, P946, DOI 10.1038/nm.3878; Nguyen CL, 2012, MOL CELL BIOL, V32, P3963, DOI 10.1128/MCB.00436-12; Nowak Jonathan A., 2009, V482, P215, DOI 10.1007/978-1-59745-060-7_14; Park SJ, 2016, ONCOTARGET, V7, P65957, DOI 10.18632/oncotarget.11781; Parker PJ, 2021, NAT REV CANCER, V21, P51, DOI 10.1038/s41568-020-00310-4; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Prior IA, 2020, CANCER RES, V80, P2969, DOI 10.1158/0008-5472.CAN-19-3682; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Ryan CJ, 2018, TRENDS CANCER, V4, P671, DOI 10.1016/j.trecan.2018.08.003; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schneider G, 2017, NAT REV CANCER, V17, P239, DOI 10.1038/nrc.2017.5; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Sterneck E, 2006, ONCOGENE, V25, P1272, DOI 10.1038/sj.onc.1209144; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Tsunoda N, 2009, CANCER SCI, V100, P111, DOI 10.1111/j.1349-7006.2008.01007.x; Weinberg F, 2017, EBIOMEDICINE, V20, P79, DOI 10.1016/j.ebiom.2017.04.015; Xu C, 2018, CLIN CANCER RES, V24, P2828, DOI 10.1158/1078-0432.CCR-17-1339; Yadav V, 2011, MOL CARCINOGEN, V50, P346, DOI 10.1002/mc.20716; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	79	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3355	3369		10.1038/s41388-022-02330-w	http://dx.doi.org/10.1038/s41388-022-02330-w		MAY 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35538224				2022-12-28	WOS:000793037400002
J	Peng, W; Shi, S; Zhong, JC; Liang, HH; Hou, JB; Hu, XS; Wang, F; Zhang, JY; Geng, SJ; Sun, XC; Zhong, D; Cui, HJ				Peng, Wen; Shi, Shuang; Zhong, Jiacheng; Liang, Hanghua; Hou, Jianbin; Hu, Xiaosong; Wang, Feng; Zhang, Jiayi; Geng, Shengjun; Sun, Xiaochuan; Zhong, Dong; Cui, Hongjuan			CBX3 accelerates the malignant progression of glioblastoma multiforme by stabilizing EGFR expression	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; LUNG ADENOCARCINOMA; CANCER PROGRESSION; TUMOR-SUPPRESSOR; HISTONE H3; LYSINE 9; PARKIN; P53; PROLIFERATION; GENE	CBX3, also known as HP1 gamma, is a major isoform of heterochromatin protein 1, whose deregulation has been reported to promote the development of human cancers. However, the molecular mechanism of CBX3 in glioblastoma multiforme (GBM) are unclear. Our study reported the identification of CBX3 as a potential therapeutic target for GBM. Briefly, we found that, CBX3 is significantly upregulated in GBM and reduces patient survival. In addition, functional assays demonstrated that CBX3 significantly promote the proliferation, invasion and tumorigenesis of GBM cells in vitro and in vivo. Mechanistically, Erlotinib, a small molecule targeting epidermal growth factor receptor (EGFR) tyrosine kinase, was used to demonstrate that CBX3 direct the malignant progression of GBM are EGFR dependent. Previous studies have shown that PARK2(Parkin) and STUB1(Carboxy Terminus of Hsp70-Interacting Protein) are EGFR-specific E3 ligases. Notably, we verified that CBX3 directly suppressed PARK2 and STUB1 at the transcriptional level through its CD domain to reduce the ubiquitination of EGFR. Moreover, the CSD domain of CBX3 interacted with PARK2 and regulated its ubiquitination to further reduce its protein level. Collectively, these results revealed an unknown mechanism underlying the pathogenesis of GBM and confirmed that CBX3 is a promising therapeutic target.	[Peng, Wen; Liang, Hanghua; Hou, Jianbin; Hu, Xiaosong; Wang, Feng; Zhang, Jiayi; Geng, Shengjun; Cui, Hongjuan] Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China; [Peng, Wen; Liang, Hanghua; Hou, Jianbin; Hu, Xiaosong; Wang, Feng; Zhang, Jiayi; Geng, Shengjun; Cui, Hongjuan] Southwest Univ, Med Res Inst, Canc Ctr, Chongqing 400716, Peoples R China; [Shi, Shuang; Zhong, Jiacheng; Sun, Xiaochuan; Zhong, Dong] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China	Southwest University - China; Southwest University - China; Chongqing Medical University	Cui, HJ (corresponding author), Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China.; Cui, HJ (corresponding author), Southwest Univ, Med Res Inst, Canc Ctr, Chongqing 400716, Peoples R China.; Zhong, D (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	zhongdongdp@sina.com; hcui@swu.edu.cn	Hu, Xiao/GQI-0007-2022	Hu, Xiao/0000-0003-1128-4099	Natural Science Foundation of Chongqing [cstc2019jcyj-zdxmX0033]; Chongqing Doctoral Research and Innovation Project [CYB21131]	Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing); Chongqing Doctoral Research and Innovation Project	This research was supported by the Natural Science Foundation of Chongqing (cstc2019jcyj-zdxmX0033) and Chongqing Doctoral Research and Innovation Project (CYB21131).	Akaike Y, 2015, ONCOGENE, V34, P3463, DOI 10.1038/onc.2014.278; Alam H, 2018, CANCER RES, V78, P3834, DOI 10.1158/0008-5472.CAN-17-3571; Aldape K, 2015, ACTA NEUROPATHOL, V129, P829, DOI 10.1007/s00401-015-1432-1; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bhuripanyo K, 2018, SCI ADV, V4, DOI 10.1126/sciadv.1701393; Brandes AA, 2008, CLIN CANCER RES, V14, P957, DOI 10.1158/1078-0432.CCR-07-1810; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cai HP, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03247-6; Caillier M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015507; Chakravarti A, 2013, INT J RADIAT ONCOL, V85, P1206, DOI 10.1016/j.ijrobp.2012.10.008; Chang SC, 2018, ASIA-PAC J CLIN ONCO, V14, pe283, DOI 10.1111/ajco.12820; Chen CY, 2013, CANCER RES, V73, P4009, DOI 10.1158/0008-5472.CAN-12-4066; Chen LY, 2018, BIOCHEM BIOPH RES CO, V500, P691, DOI 10.1016/j.bbrc.2018.04.137; Choi Jae Duk, 2013, Genomics & Informatics, V11, P164, DOI 10.5808/GI.2013.11.4.164; da Costa CA, 2009, NAT CELL BIOL, V11, P1370, DOI 10.1038/ncb1981; Dialynas GK, 2008, MUTAT RES-FUND MOL M, V647, P13, DOI 10.1016/j.mrfmmm.2008.09.007; England B, 2013, TUMOR BIOL, V34, P2063, DOI 10.1007/s13277-013-0871-3; Eskilsson E, 2018, NEURO-ONCOLOGY, V20, P743, DOI 10.1093/neuonc/nox191; Furnari FB, 2015, NAT REV CANCER, V15, P302, DOI 10.1038/nrc3918; Gao FQ, 2020, GENE, V726, DOI 10.1016/j.gene.2019.144196; Guimaraes DP, 2002, BIOCHIMIE, V84, P83, DOI 10.1016/S0300-9084(01)01356-6; Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535-7163.MCT-11-0048; Hou J, 2017, ONCOGENE, V36, P1134, DOI 10.1038/onc.2016.280; Karpel-Massler G, 2009, MOL CANCER RES, V7, P1000, DOI 10.1158/1541-7786.MCR-08-0479; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li Q, 2021, TRANSL LUNG CANCER R, V10, P936, DOI 10.21037/tlcr-21-147; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lim M, 2018, NAT REV CLIN ONCOL, V15, P422, DOI 10.1038/s41571-018-0003-5; Lin DC, 2015, CANCER RES, V75, P1815, DOI 10.1158/0008-5472.CAN-14-1433; Liu M, 2015, CANCER RES, V75, P4593, DOI 10.1158/0008-5472.CAN-14-3735; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Maugeri G, 2015, INT J ONCOL, V47, P1282, DOI 10.3892/ijo.2015.3105; Okorokov AL, 2009, CURR OPIN STRUC BIOL, V19, P197, DOI 10.1016/j.sbi.2009.02.003; Osuka S, 2017, J CLIN INVEST, V127, P415, DOI 10.1172/JCI89587; Reardon DA, 2014, NEURO-ONCOLOGY, V16, pviii7, DOI 10.1093/neuonc/nou232; Roth P, 2014, NEURO-ONCOLOGY, V16, pviii14, DOI 10.1093/neuonc/nou222; Shao GB, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0784-2; Sridharan R, 2013, NAT CELL BIOL, V15, P872, DOI 10.1038/ncb2768; Stathias V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07659-z; Sunico CR, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-29; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Viotti J, 2014, ONCOGENE, V33, P1764, DOI 10.1038/onc.2013.124; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang FM, 2021, MOL NEUROBIOL, V58, P3362, DOI 10.1007/s12035-021-02337-6; Wang SQ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1930-3; Wang TX, 2014, ONCOTARGET, V5, P1969, DOI 10.18632/oncotarget.1890; Weisz L, 2007, ONCOGENE, V26, P2202, DOI 10.1038/sj.onc.1210294; Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8; Wong SC, 2021, NUTRIENTS, V13, DOI 10.3390/nu13030950; Xuan F, 2016, NEURO-ONCOLOGY, V18, P819, DOI 10.1093/neuonc/nov281; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yeo CWS, 2012, CANCER RES, V72, P2543, DOI 10.1158/0008-5472.CAN-11-3060; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhang Y, 2018, CANCERS, V10, DOI 10.3390/cancers10090297; Zhao SP, 2019, J NEURO-ONCOL, V145, P35, DOI 10.1007/s11060-019-03286-w; Zhao YZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0137-7; Zhong XP, 2019, AGING-US, V11, P5483, DOI 10.18632/aging.102132	58	3	3	10	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3051	3063		10.1038/s41388-022-02296-9	http://dx.doi.org/10.1038/s41388-022-02296-9		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35459780				2022-12-28	WOS:000787474100005
J	Kidger, AM; Saville, MK; Rushworth, LK; Davidson, J; Stellzig, J; Ono, M; Kuebelsbeck, LA; Janssen, KP; Holzmann, B; Morton, JP; Sansom, OJ; Caunt, CJ; Keyse, SM				Kidger, Andrew M.; Saville, Mark K.; Rushworth, Linda K.; Davidson, Jane; Stellzig, Julia; Ono, Motoharu; Kuebelsbeck, Ludwig A.; Janssen, Klaus-Peter; Holzmann, Bernhard; Morton, Jennifer P.; Sansom, Owen J.; Caunt, Christopher J.; Keyse, Stephen M.			Suppression of mutant Kirsten-RAS (KRAS(G12D))-driven pancreatic carcinogenesis by dual-specificity MAP kinase phosphatases 5 and 6	ONCOGENE			English	Article							DOWN-REGULATION; POTENTIAL-ROLE; GROWTH-FACTORS; K-RAS; CANCER; DUSP6; PROGRESSION; PROTEIN; PROLIFERATION; DUSP6/MKP-3	The cytoplasmic phosphatase DUSP6 and its nuclear counterpart DUSP5 are negative regulators of RAS/ERK signalling. Here we use deletion of either Dusp5 or Dusp6 to explore the roles of these phosphatases in a murine model of KRAS(G12D)-driven pancreatic cancer. By 56-days, loss of either DUSP5 or DUSP6 causes a significant increase in KRAS(G12D)-driven pancreatic hyperplasia. This is accompanied by increased pancreatic acinar to ductal metaplasia (ADM) and the development of pre-neoplastic pancreatic intraepithelial neoplasia (PanINs). In contrast, by 100-days, pancreatic hyperplasia is reversed with significant atrophy of pancreatic tissue and weight loss observed in animals lacking either DUSP5 or DUSP6. On further ageing, Dusp6(-/-) mice display accelerated development of metastatic pancreatic ductal adenocarcinoma (PDAC), while in Dusp5(-/-) animals, although PDAC development is increased this process is attenuated by atrophy of pancreatic acinar tissue and severe weight loss in some animals before cancer could progress. Our data suggest that despite a common target in the ERK MAP kinase, DUSP5 and DUSP6 play partially non-redundant roles in suppressing oncogenic KRAS(G12D) signalling, thus retarding both tumour initiation and progression. Our data suggest that loss of either DUSP5 or DUSP6, as observed in certain human tumours, including the pancreas, could promote carcinogenesis.	[Kidger, Andrew M.; Saville, Mark K.; Rushworth, Linda K.; Davidson, Jane; Stellzig, Julia; Ono, Motoharu; Keyse, Stephen M.] Univ Dundee, Jacqui Wood Canc Ctr, Sch Med, Div Cellular & Syst Med,Stress Response Lab, Dundee DD1 9SY, Scotland; [Kuebelsbeck, Ludwig A.; Janssen, Klaus-Peter; Holzmann, Bernhard] Tech Univ Munich, Sch Med, Dept Surg, Klinikum Rechts Isar, Munich, Germany; [Morton, Jennifer P.; Sansom, Owen J.] Inst Canc Sci, Garscube Estate,Switchback Rd, Glasgow G61 1QH, Lanark, Scotland; [Morton, Jennifer P.; Sansom, Owen J.] CRUK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland; [Caunt, Christopher J.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of Dundee; Technical University of Munich; University of Glasgow; Beatson Institute; University of Bath	Keyse, SM (corresponding author), Univ Dundee, Jacqui Wood Canc Ctr, Sch Med, Div Cellular & Syst Med,Stress Response Lab, Dundee DD1 9SY, Scotland.	s.m.keyse@dundee.ac.uk		Kubelsbeck, Ludwig/0000-0002-2888-6558; Sansom, Owen J./0000-0001-9540-3010	Cancer Research UK [C8227/A12053, A25142, A17196, A21139, A29996, A25233]; MRC Research Grant [MR/N020790/1]; Dundee Cancer Centre Studentship; Deutsche Krebshilfe e.V. (German Cancer Aid) [111822]; German Research Council (DFG) through collaborative Research Centre 1321 [SFB1321]	Cancer Research UK(Cancer Research UK); MRC Research Grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Dundee Cancer Centre Studentship; Deutsche Krebshilfe e.V. (German Cancer Aid)(Deutsche Krebshilfe); German Research Council (DFG) through collaborative Research Centre 1321(German Research Foundation (DFG))	We would like to thank the staff of the Biological Resources Unit (Ninewells Hospital) and The Biological Services Unit (CRUK Beatson Institute, Glasgow) for animal husbandry and technical assistance. Tayside Tissue Bank (Mairi Lennie and Sharon King) for tissue sectioning and slide scanning. Richard Odle (Babraham Institute, Cambridge) for IHC scoring. Catherine Winchester (CRUK Beatson Institute, Glasgow) for critical reading of the manuscript, Ian Rosewell, Linda Groom, David Williams and Susanne Van Schelven for technical assistance during the early stages of this project. SMK was supported by a Cancer Research UK Programme Grant (C8227/A12053), an MRC Research Grant (MR/N020790/1 to SMK and CJC) and a Dundee Cancer Centre Studentship (to AMK), JPM and OJS are supported by Cancer Research UK (A25142, A17196, A21139, A29996 and A25233). BH and K-PJ are supported by grant 111822 from Deutsche Krebshilfe e.V. (German Cancer Aid) and LAK is supported by the German Research Council (DFG) through collaborative Research Centre 1321 (SFB1321). We dedicate this manuscript to the memory of our friend and colleague CJC.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Beaudry K, 2019, J CELL PHYSIOL, V234, P6731, DOI 10.1002/jcp.27420; Belo J, 2013, STEM CELLS DEV, V22, P2935, DOI 10.1089/scd.2013.0106; Buffet C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184861; Cai C, 2015, INT J CLIN EXP MED, V8, P4186; Caunt CJ, 2013, FEBS J, V280, P489, DOI 10.1111/j.1742-4658.2012.08716.x; Cheung EC, 2020, CANCER CELL, V37, P168, DOI 10.1016/j.ccell.2019.12.012; Collisson EA, 2012, CANCER DISCOV, V2, P685, DOI 10.1158/2159-8290.CD-11-0347; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Ekerot M, 2008, BIOCHEM J, V412, P287, DOI 10.1042/BJ20071512; Furukawa T, 2005, MODERN PATHOL, V18, P1034, DOI 10.1038/modpathol.3800383; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Guerra C, 2013, MOL ONCOL, V7, P232, DOI 10.1016/j.molonc.2013.02.002; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Harris NLE, 2017, ONCOGENE, V36, P4288, DOI 10.1038/onc.2017.63; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Holmes DA, 2015, EMBO J, V34, P218, DOI 10.15252/embj.201489456; Holzenberger M, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.21.e92; Karlsson M, 2004, J BIOL CHEM, V279, P41882, DOI 10.1074/jbc.M406720200; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kidger AM, 2017, P NATL ACAD SCI USA, V114, pE317, DOI 10.1073/pnas.1614684114; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Kucharska A, 2009, CELL SIGNAL, V21, P1794, DOI 10.1016/j.cellsig.2009.07.015; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Maillet M, 2008, J BIOL CHEM, V283, P31246, DOI 10.1074/jbc.M806085200; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Means AL, 2005, DEVELOPMENT, V132, P3767, DOI 10.1242/dev.01925; Messina S, 2011, ONCOGENE, V30, P3813, DOI 10.1038/onc.2011.99; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Nagdas S, 2019, CELL REP, V28, P1845, DOI 10.1016/j.celrep.2019.07.031; Okudela K, 2009, AM J PATHOL, V175, P867, DOI 10.2353/ajpath.2009.080489; Packer LM, 2009, PIGM CELL MELANOMA R, V22, P785, DOI 10.1111/j.1755-148X.2009.00618.x; Rushworth LK, 2014, P NATL ACAD SCI USA, V111, P18267, DOI 10.1073/pnas.1420159112; Seternes OM, 2019, BBA-MOL CELL RES, V1866, P124, DOI 10.1016/j.bbamcr.2018.09.002; Shin SH, 2013, AM J PATHOL, V182, P1275, DOI 10.1016/j.ajpath.2013.01.004; Shojaee S, 2015, CANCER CELL, V28, P114, DOI 10.1016/j.ccell.2015.05.008; Togel L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20176-9; Tonnetti L, 2008, CANCER RES, V68, P5648, DOI 10.1158/0008-5472.CAN-07-5850; Tuveson DA, 2005, COLD SH Q B, V70, P65, DOI 10.1101/sqb.2005.70.040; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130; von Figura G, 2014, NAT CELL BIOL, V16, P255, DOI 10.1038/ncb2916; Wittig-Blaich S, 2017, ONCOTARGET, V8, P23760, DOI 10.18632/oncotarget.15863; Wojtukiewicz MZ, 2001, THROMB HAEMOSTASIS, V86, P1416; Xu SH, 2005, J HUM GENET, V50, P159, DOI 10.1007/s10038-005-0235-y; Xue A, 2008, PANCREAS, V36, P160, DOI 10.1097/MPA.0b013e31815750f0; Yan XB, 2016, AM J CANCER RES, V6, P2323; Zhou HM, 2001, CANCER RES, V61, P970	56	1	1	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2811	2823		10.1038/s41388-022-02302-0	http://dx.doi.org/10.1038/s41388-022-02302-0		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35418690	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000783468200005
J	Sun, R; Lei, C; Chen, L; He, LQ; Guo, HX; Zhang, X; Feng, WK; Yan, J; McClain, CJ; Deng, ZB				Sun, Rui; Lei, Chao; Chen, Liang; He, Liqing; Guo, Haixun; Zhang, Xiang; Feng, Wenke; Yan, Jun; McClain, Craig J.; Deng, Zhongbin			Alcohol-driven metabolic reprogramming promotes development of ROR gamma t-deficient thymic lymphoma	ONCOGENE			English	Article							C-MYC; GLUTAMINE-METABOLISM; MTOR; INHIBITION; EXPRESSION; PROTEIN; DIFFERENTIATION; REQUIREMENT; ADAPTATION; GLYCOLYSIS	ROR gamma t is a master regulator of Th17 cells. Despite evidence linking ROR gamma t deficiency/inhibition with metastatic thymic T cell lymphomas, the role of ROR gamma t in lymphoma metabolism is unknown. Chronic alcohol consumption plays a causal role in many human cancers. The risk of T cell lymphoma remains unclear in humans with alcohol use disorders (AUD) after chronic ROR gamma t inhibition. Here we demonstrated that alcohol consumption accelerates ROR gamma t deficiency-induced lymphomagenesis. Loss of ROR gamma t signaling in the thymus promotes aerobic glycolysis and glutaminolysis and increases allocation of glutamine carbon into lipids. Importantly, alcohol consumption results in a shift from aerobic glycolysis to glutaminolysis. Both ROR gamma t deficiency- and alcohol-induced metabolic alterations are mediated by c-Myc, as silencing of c-Myc decreases the effects of alcohol consumption and ROR gamma t deficiency on glutaminolysis, biosynthesis, and tumor growth in vivo. The ethanol-mediated c-Myc activation coupled with increased glutaminolysis underscore the critical role of ROR gamma t-Myc signaling and translation in lymphoma.	[Sun, Rui; Lei, Chao; Chen, Liang; Yan, Jun; Deng, Zhongbin] Univ Louisville, Dept Surg, Div Immunotherapy, Louisville, KY 40292 USA; [Sun, Rui] Huazhong Univ Sci & Technol, Wuhan Hosp 4, Puai Hosp, Tongji Med Coll,Dept Oncol, Wuhan 430033, Peoples R China; [Sun, Rui; Lei, Chao; Chen, Liang; Yan, Jun; Deng, Zhongbin] Univ Louisville, Brown Canc Ctr, Louisville, KY 40292 USA; [He, Liqing; Zhang, Xiang] Univ Louisville, Dept Chem, Louisville, KY 40292 USA; [Guo, Haixun] Univ Louisville, Dept Radiol, Louisville, KY 40292 USA; [Zhang, Xiang; Feng, Wenke; McClain, Craig J.; Deng, Zhongbin] Univ Louisville, Alcohol Res Ctr, Louisville, KY 40292 USA; [Zhang, Xiang; Feng, Wenke; McClain, Craig J.; Deng, Zhongbin] Univ Louisville, Hepatobiol & Toxicol Ctr, Louisville, KY 40292 USA; [Feng, Wenke; McClain, Craig J.] Univ Louisville, Dept Med, Louisville, KY 40292 USA; [McClain, Craig J.] Robley Rex VA Med Ctr, Louisville, KY USA	University of Louisville; Huazhong University of Science & Technology; University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Louisville	Deng, ZB (corresponding author), Univ Louisville, Dept Surg, Div Immunotherapy, Louisville, KY 40292 USA.; Deng, ZB (corresponding author), Univ Louisville, Brown Canc Ctr, Louisville, KY 40292 USA.; Deng, ZB (corresponding author), Univ Louisville, Alcohol Res Ctr, Louisville, KY 40292 USA.; Deng, ZB (corresponding author), Univ Louisville, Hepatobiol & Toxicol Ctr, Louisville, KY 40292 USA.	z0deng01@louisville.edu	Yan, Jun/A-8988-2008; Guo, Haixun/GYR-1920-2022; Lei, Chao/AFK-3169-2022	Guo, Haixun/0000-0002-9702-5444; Lei, Chao/0000-0002-5220-086X	NIH [R21AA025724, R21AI128206, R21AI159194, R01 DK115406, P50AA024337, P20GM113226]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the NIH R21AA025724, R21AI128206, R21AI159194 and R01 DK115406 (ZD), and NIH P50AA024337, P20GM113226, (CJM). We thank Dr. J. Ainsworth for editorial assistance.	Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Choi WM, 2019, CELL METAB, V30, P877, DOI 10.1016/j.cmet.2019.08.001; Chu SH, 2021, HEPATOLOGY, V73, P952, DOI 10.1002/hep.31321; Comerford SA, 2014, CELL, V159, P1591, DOI 10.1016/j.cell.2014.11.020; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Evangelisti C, 2011, LEUKEMIA, V25, P781, DOI 10.1038/leu.2011.20; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gao YH, 2019, GUT, V68, P1311, DOI 10.1136/gutjnl-2018-316221; Gu Y, 2017, CANCER CELL, V32, P115, DOI 10.1016/j.ccell.2017.06.001; Guntermann C, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91127; Guo YX, 2016, CELL REP, V17, P3206, DOI 10.1016/j.celrep.2016.11.073; He YW, 2000, J IMMUNOL, V164, P5668, DOI 10.4049/jimmunol.164.11.5668; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jun S, 2021, CELL METAB, V33, P1777, DOI 10.1016/j.cmet.2021.07.016; Kalaitzidis D, 2012, CELL STEM CELL, V11, P429, DOI 10.1016/j.stem.2012.06.009; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kishton RJ, 2016, CELL METAB, V23, P649, DOI 10.1016/j.cmet.2016.03.008; Kurebayashi S, 2000, P NATL ACAD SCI USA, V97, P10132, DOI 10.1073/pnas.97.18.10132; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Liljevald M, 2016, AUTOIMMUN REV, V15, P1062, DOI 10.1016/j.autrev.2016.07.036; Ma HY, 2020, J HEPATOL, V72, P946, DOI 10.1016/j.jhep.2019.12.016; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Mak TW, 2017, IMMUNITY, V46, P675, DOI 10.1016/j.immuni.2017.03.019; Nevzorova YA, 2016, J HEPATOL, V64, P628, DOI 10.1016/j.jhep.2015.11.005; Odera JO, 2020, BIOCHEM J, V477, P3075, DOI 10.1042/BCJ20200452; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pollizzi KN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121710; Ramstead AG, 2020, CELL REP, V30, P2889, DOI 10.1016/j.celrep.2020.02.042; Scheepstra M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9833; Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shao T, 2018, J HEPATOL, V69, P886, DOI 10.1016/j.jhep.2018.05.021; Siler SQ, 1998, AM J PHYSIOL-ENDOC M, V275, pE897, DOI 10.1152/ajpendo.1998.275.5.E897; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369; Ueda E, 2002, CANCER RES, V62, P901; Waickman AT, 2012, IMMUNOL REV, V249, P43, DOI 10.1111/j.1600-065X.2012.01152.x; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xiao S, 2014, IMMUNITY, V40, P477, DOI 10.1016/j.immuni.2014.04.004; Yang K, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aas9818; Zakhari S, 2007, HEPATOLOGY, V46, P2032, DOI 10.1002/hep.22010	46	0	0	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2287	2302		10.1038/s41388-022-02257-2	http://dx.doi.org/10.1038/s41388-022-02257-2		MAR 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35246617	Green Accepted			2022-12-28	WOS:000764592500001
J	Llobet, SG; Bhattacharya, A; Everts, M; van der Vegt, B; Fehrmann, RSN; van Vugt, MATM; Kok, K				Llobet, Sergi Guerrero; Bhattacharya, Arkajyoti; Everts, Marieke; van der Vegt, Bert; Fehrmann, Rudolf S. N.; van Vugt, Marcel A. T. M.; Kok, Klaas			An mRNA expression-based signature for oncogene-induced replication-stress	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; OVARIAN-CANCER; GENOMIC INSTABILITY; INDUCED SENESCENCE; NAT10; CELLS; ACETYLATION; ACTIVATION; RESISTANT; BARRIER	Oncogene-induced replication stress characterizes many aggressive cancers. Several treatments are being developed that target replication stress, however, identification of tumors with high levels of replication stress remains challenging. We describe a gene expression signature of oncogene-induced replication stress. A panel of triple-negative breast cancer (TNBC) and non-transformed cell lines were engineered to overexpress CDC25A, CCNE1 or MYC, which resulted in slower replication kinetics. RNA sequencing analysis revealed a set of 52 commonly upregulated genes. In parallel, mRNA expression analysis of patient-derived tumor samples (TCGA, n = 10,592) also revealed differential gene expression in tumors with amplification of oncogenes that trigger replication stress (CDC25A, CCNE1, MYC, CCND1, MYB, MOS, KRAS, ERBB2, and E2F1). Upon integration, we identified a six-gene signature of oncogene-induced replication stress (NAT10, DDX27, ZNF48, C8ORF33, MOCS3, and MPP6). Immunohistochemical analysis of NAT10 in breast cancer samples (n = 330) showed strong correlation with expression of phospho-RPA (R = 0.451, p = 1.82 x 10(-20)) and gamma H2AX (R = 0.304, p = 2.95 x 10(-9)). Finally, we applied our oncogene-induced replication stress signature to patient samples from TCGA (n = 8,862) and GEO (n = 13,912) to define the levels of replication stress across 27 tumor subtypes, identifying diffuse large B cell lymphoma, ovarian cancer, TNBC and colorectal carcinoma as cancer subtypes with high levels of oncogene-induced replication stress.	[Llobet, Sergi Guerrero; Bhattacharya, Arkajyoti; Everts, Marieke; Fehrmann, Rudolf S. N.; van Vugt, Marcel A. T. M.] Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands; [Kok, Klaas] Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [van der Vegt, Bert] Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	van Vugt, MATM (corresponding author), Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands.	m.vugt@umcg.nl	van der Vegt, Bert/G-5887-2014; Fehrmann, Rudolf/E-2551-2011	van der Vegt, Bert/0000-0002-2613-1506; van Vugt, Marcel/0000-0002-3202-4678; Guerrero Llobet, Sergi/0000-0003-2776-8610; Bhattacharya, Arkajyoti/0000-0003-1479-0739; Fehrmann, Rudolf/0000-0002-7516-315X	Netherlands Organization for Scientific Research (NWO-VIDI) [917.13334]; Netherlands Organization for Scientific Research (NWO-VENI) [916-16025]; Dutch Cancer Society [RUG 2013-5960, 11352]; European Research Council (ERC)	Netherlands Organization for Scientific Research (NWO-VIDI)(Netherlands Organization for Scientific Research (NWO)); Netherlands Organization for Scientific Research (NWO-VENI)(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding); European Research Council (ERC)(European Research Council (ERC)European Commission)	We thank members of the Medical Oncology laboratory for fruitful discussions. This work was financially supported by grant from the Netherlands Organization for Scientific Research (NWO-VIDI #917.13334 to M.A.T.M.v.V. and NWO-VENI #916-16025 to R.S.N.F.), the Dutch Cancer Society (RUG 2013-5960 to R.S.N.F and #11352 to M.A.T.M.v.V.) and from the European Research Council (ERC-Consolidator grant "TENSION" to M.A.T.M.v.V.).	Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159-8290.CD-11-0320; Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Arango D, 2018, CELL, V175, P1872, DOI 10.1016/j.cell.2018.10.030; Aziz K, 2019, GASTROENTEROLOGY, V157, P210, DOI 10.1053/j.gastro.2019.03.016; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Carlos AR, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3697; Chen X, 2018, CLIN CANCER RES, V24, P6594, DOI 10.1158/1078-0432.CCR-18-1446; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de Jong MRW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193098; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dominissini D, 2018, CELL, V175, P1725, DOI 10.1016/j.cell.2018.11.037; Espana-Agusti J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02245-1; Farshidfar F, 2017, CELL REP, V18, P2780, DOI 10.1016/j.celrep.2017.02.033; Ferrao PT, 2012, ONCOGENE, V31, P1661, DOI 10.1038/onc.2011.358; Gadhikar MA, 2018, CANCER RES, V78, P781, DOI 10.1158/0008-5472.CAN-17-2802; Gerlinger M, 2010, BRIT J CANCER, V103, P1139, DOI 10.1038/sj.bjc.6605912; Llobet SG, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-00181-w; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Heijink AM, 2015, P NATL ACAD SCI USA, V112, P15160, DOI 10.1073/pnas.1505283112; Inoue S, 2016, CANCER CELL, V30, P337, DOI 10.1016/j.ccell.2016.05.018; Italiano A, 2018, ANN ONCOL, V29, P1304, DOI 10.1093/annonc/mdy076; Joseph NM, 2019, J PATHOL, V248, P164, DOI 10.1002/path.5243; Kanu N, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1042-9; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kok YP, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00270-2; Konstantinopoulos PA, 2020, LANCET ONCOL, V21, P957, DOI 10.1016/S1470-2045(20)30180-7; Leijen S, 2016, J CLIN ONCOL, V34, P4354, DOI 10.1200/JCO.2016.67.5942; Liu HY, 2020, NUCLEIC ACIDS RES, V48, P3638, DOI 10.1093/nar/gkaa130; Liu XF, 2016, EMBO REP, V17, P349, DOI 10.15252/embr.201540505; Lopez-Contreras AJ, 2012, J EXP MED, V209, P455, DOI 10.1084/jem.20112147; Calzetta NL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc8257; Macheret M, 2018, NATURE, V555, P112, DOI 10.1038/nature25507; Maya-Mendoza A, 2015, MOL ONCOL, V9, P601, DOI 10.1016/j.molonc.2014.11.001; Neelsen KJ, 2013, J CELL BIOL, V200, P699, DOI 10.1083/jcb.201212058; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Pillay N, 2019, CANCER CELL, V35, P519, DOI 10.1016/j.ccell.2019.02.004; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Reddy A, 2017, CELL, V171, P481, DOI 10.1016/j.cell.2017.09.027; Shen Q, 2009, EXP CELL RES, V315, P1653, DOI 10.1016/j.yexcr.2009.03.007; Shimura T, 2013, CELL CYCLE, V12, P773, DOI 10.4161/cc.23719; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Urzua-Traslavina CG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21671-w; Wengner AM, 2020, MOL CANCER THER, V19, P26, DOI 10.1158/1535-7163.MCT-19-0019; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Young LA, 2019, CANCER RES, V79, P3762, DOI 10.1158/0008-5472.CAN-18-2480; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897	50	3	3	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1216	1224		10.1038/s41388-021-02162-0	http://dx.doi.org/10.1038/s41388-021-02162-0		JAN 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35091678	Green Submitted, Green Accepted			2022-12-28	WOS:000749073200001
J	Yi, Y; Li, YQ; Li, C; Wu, LX; Zhao, DY; Li, FX; Fazli, LD; Wang, R; Wang, L; Dong, XS; Zhao, W; Chen, KF; Cao, Q				Yi, Yang; Li, Yanqiang; Li, Chao; Wu, Longxiang; Zhao, Dongyu; Li, Fuxi; Fazli, Ladan; Wang, Rui; Wang, Long; Dong, Xuesen; Zhao, Wei; Chen, Kaifu; Cao, Qi			Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE EZH2; GENE-EXPRESSION; PROTEIN EZH2; POLYCOMB; RECEPTOR; PROGRESSION; PACKAGE; GROWTH; CELLS	Cell division cycle-associated 8 (CDCA8) is a component of chromosomal passenger complex (CPC) that participates in mitotic regulation. Although cancer-related CDCA8 hyperactivation has been widely observed, its molecular mechanism remains elusive. Here, we report that CDCA8 overexpression maintains tumorigenicity and is associated with poor clinical outcome in patients with prostate cancer (PCa). Notably, enhancer of zeste homolog 2 (EZH2) is identified to be responsible for CDCA8 activation in PCa. Genome-wide assays revealed that EZH2-induced H3K27 trimethylation represses let-7b expression and thus protects the let-7b-targeting CDCA8 transcripts. More importantly, EZH2 facilitates the self-activation of E2F1 by recruiting E2F1 to its own promoter region in a methylation-independent manner. The high level of E2F1 further promotes transcription of CDCA8 along with the other CPC subunits. Taken together, our study suggests that EZH2-mediated cell cycle regulation in PCa relies on both its methyltransferase and non-methyltransferase activities.	[Yi, Yang; Li, Chao; Wu, Longxiang; Wang, Rui; Cao, Qi] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA; [Yi, Yang; Li, Chao; Cao, Qi] Houston Methodist Res Inst, Ctr Inflammat & Epigenet, Houston, TX 77030 USA; [Li, Yanqiang; Zhao, Dongyu; Chen, Kaifu] Boston Childrens Hosp, Dept Cardiol, Basic & Translat Res Div, Boston, MA 02115 USA; [Li, Yanqiang; Zhao, Dongyu; Chen, Kaifu] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Li, Chao; Wang, Long] Cent South Univ, Xiangya Hosp 3, Dept Urol, Changsha 410013, Peoples R China; [Wu, Longxiang] Cent South Univ, Dept Urol, Xiangya Hosp, Changsha 410008, Peoples R China; [Li, Fuxi; Zhao, Wei] Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Guangzhou 510080, Peoples R China; [Fazli, Ladan; Dong, Xuesen] Vancouver Gen Hosp, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; [Fazli, Ladan; Dong, Xuesen] Univ British Columbia, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada; [Chen, Kaifu] Dana Farber Harvard Canc Ctr, Prostate Canc Program, 450 Brookline Ave,BP332A, Boston, MA 02215 USA; [Cao, Qi] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Central South University; Central South University; Sun Yat Sen University; University of British Columbia; University of British Columbia; Harvard University; Dana-Farber Cancer Institute; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Cao, Q (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA.; Cao, Q (corresponding author), Houston Methodist Res Inst, Ctr Inflammat & Epigenet, Houston, TX 77030 USA.; Chen, KF (corresponding author), Boston Childrens Hosp, Dept Cardiol, Basic & Translat Res Div, Boston, MA 02115 USA.; Chen, KF (corresponding author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.; Chen, KF (corresponding author), Dana Farber Harvard Canc Ctr, Prostate Canc Program, 450 Brookline Ave,BP332A, Boston, MA 02215 USA.; Cao, Q (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.	kaifu.chen@childrens.harvard.edu; qi.cao@northwestern.edu	Dong, Xuesen/AGF-9228-2022; Cao, Qi/A-5517-2010	Yi, Yang/0000-0002-1958-7249; Cao, Qi/0000-0002-5140-3681; Dong, Xuesen/0000-0002-3115-3371	American Cancer Society [RSG-15-192-01]; Northwestern University; Northwestern University, U.S. Department of Defense [W81XWH-17-1-0357, W81XWH-19-1-0563, W81XWH-20-1-0504]; NIH/NCI [R01CA208257, R01CA256741]; Prostate SPORE [P50CA180995]; Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital	American Cancer Society(American Cancer Society); Northwestern University; Northwestern University, U.S. Department of Defense; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Prostate SPORE; Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital	This work was supported by American Cancer Society (RSG-15-192-01) and a startup funding provided by the Northwestern University. Part of effort for QC was supported by Northwestern University, U.S. Department of Defense (W81XWH-17-1-0357, W81XWH-19-1-0563 and W81XWH-20-1-0504), NIH/NCI (R01CA208257, R01CA256741 and Prostate SPORE P50CA180995 Development Research Program) and Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Asenjo HG, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay4768; Ben-Salem S, 2021, ENDOCR-RELAT CANCER, V28, pR141, DOI 10.1530/ERC-20-0517; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Chen KF, 2013, GENOME RES, V23, P341, DOI 10.1101/gr.142067.112; Chirshev E, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0240-y; Chun JN, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2019.188336; Dai C, 2015, J BIOL CHEM, V290, P22423, DOI 10.1074/jbc.M115.642710; Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043; Fillmore CM, 2015, NATURE, V520, P239, DOI 10.1038/nature14122; Gao X, 2020, PEERJ, V8, DOI 10.7717/peerj.9078; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433; Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008-5472.CAN-10-1933; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hernandez J, 2004, CANCER-AM CANCER SOC, V101, P894, DOI 10.1002/cncr.20480; Huang HY, 2020, NUCLEIC ACIDS RES, V48, pD148, DOI 10.1093/nar/gkz896; Ishak CA, 2016, MOL CELL, V64, P1074, DOI 10.1016/j.molcel.2016.10.021; Jeon T, 2021, CANCERS, V13, DOI 10.3390/cancers13051055; Kim J, 2018, CELL REP, V25, P2808, DOI 10.1016/j.celrep.2018.11.035; Kong DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033729; Koyen AE, 2020, ONCOGENE, V39, P4798, DOI 10.1038/s41388-020-1332-2; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Liu T, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.608393; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705; Park SH, 2021, ONCOGENE, V40, P5788, DOI 10.1038/s41388-021-01982-4; Park SH, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe2261; Qi Gonghua, 2021, Am J Cancer Res, V11, P389; Rastgoo N, 2018, LEUKEMIA, V32, P2471, DOI 10.1038/s41375-018-0140-y; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Sullivan M, 2007, NAT REV MOL CELL BIO, V8, P894, DOI 10.1038/nrm2276; Tabbal H, 2019, BRIT J CANCER, V121, P384, DOI 10.1038/s41416-019-0538-y; Tang C, 2021, BIOL REPROD, V105, P267, DOI 10.1093/biolre/ioab062; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48; Xie N, 2015, INT J CANCER, V136, pE27, DOI 10.1002/ijc.29147; Xu H, 2016, MOL CANCER RES, V14, P163, DOI 10.1158/1541-7786.MCR-15-0313; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang Q, 2019, ACM T INTEL SYST TEC, V10, DOI 10.1145/3298981; Yi Y, 2021, NAT CELL BIOL, V23, P341, DOI 10.1038/s41556-021-00653-6; Yin HL, 2020, THERANOSTICS, V10, P8494, DOI 10.7150/thno.44849; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu Y, 2015, PROSTATE, V75, P1043, DOI 10.1002/pros.22988; Zhao DY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18913-8; Zhuang CB, 2016, INT J ONCOL, V48, P1195, DOI 10.3892/ijo.2016.3336	54	1	1	5	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1610	1621		10.1038/s41388-022-02208-x	http://dx.doi.org/10.1038/s41388-022-02208-x		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35094010				2022-12-28	WOS:000750486500001
J	Zigrossi, A; Hong, LK; Ekyalongo, RC; Cruz-Alvarez, C; Gornick, E; Diamond, AM; Kastrati, I				Zigrossi, Alexandra; Hong, Lenny K.; Ekyalongo, Roudy C.; Cruz-Alvarez, Cindy; Gornick, Emily; Diamond, Alan M.; Kastrati, Irida			SELENOF is a new tumor suppressor in breast cancer	ONCOGENE			English	Article							15-KDA SELENOPROTEIN; SEP15; PROTEIN; ROLES	Epidemiological evidence has indicated an inverse association between selenium status and various types of cancer, including breast cancer. Selenoproteins are the primary mediators of selenium effects in human health. We have previously reported loss of heterozygosity in breast tumor samples of the gene for one of the selenoproteins, SELENOF. The function of SELENOF remains unclear and whether SELENOF levels impact breast cancer risk or outcome is unknown. The mining of breast cancer patient databases revealed that SELENOF mRNA is significantly lower in late-stage tumor samples and lower levels of SELENOF also predict poor patient outcome from breast cancer. Genetically manipulating SELENOF in human breast cancer cells or in the murine mammary gland by overexpression, silencing or knockout impacted cell viability by affecting both proliferation and cell death. Restoring SELENOF can attenuate a number of aggressive cancer phenotypes in breast cancer cells, including clonogenic survival, and enhance the response to drugs or radiation used in breast cancer therapy. Importantly, enhancing SELENOF expression reduced in vivo tumor growth in a murine xenograft model of breast cancer. These data indicate that SELENOF is a new tumor suppressor in breast cancer.	[Zigrossi, Alexandra; Ekyalongo, Roudy C.; Cruz-Alvarez, Cindy; Gornick, Emily; Kastrati, Irida] Loyola Univ Chicago, Dept Canc Biol, Maywood, IL 60153 USA; [Hong, Lenny K.; Diamond, Alan M.] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA	Loyola University Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kastrati, I (corresponding author), Loyola Univ Chicago, Dept Canc Biol, Maywood, IL 60153 USA.	ikastrati@luc.edu		Kastrati, Irida/0000-0002-8086-1411	LUC funds; Office of the Assistant Secretary of Defense for Health Affairs through the Prostate Cancer Research Program [W81XWH-17-PCRP-HDRA]	LUC funds; Office of the Assistant Secretary of Defense for Health Affairs through the Prostate Cancer Research Program	This work was supported by LUC funds to IK and by the Office of the Assistant Secretary of Defense for Health Affairs through the Prostate Cancer Research Program under Award No. W81XWH-17-PCRP-HDRA to AMD. These funding sources had no involvement in the data presented here.	Apostolou S, 2004, ONCOGENE, V23, P5032, DOI 10.1038/sj.onc.1207683; Ekoue DN, 2018, PROSTATE, V78, P279, DOI 10.1002/pros.23471; El-Bayoumy K, 1991, ROLE SELENIUM CANC P; Gladyshev VN, 2016, J BIOL CHEM, V291, P24036, DOI 10.1074/jbc.M116.756155; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hatfield DL, 2014, TRENDS BIOCHEM SCI, V39, P112, DOI 10.1016/j.tibs.2013.12.007; Hetz C, 2020, NAT REV MOL CELL BIO, V21, P421, DOI 10.1038/s41580-020-0250-z; Hong LK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222112040; Hu YJ, 2001, CANCER RES, V61, P2307; Hudson TS, 2012, CARCINOGENESIS, V33, P1225, DOI 10.1093/carcin/bgs129; Irons R, 2010, CANCER PREV RES, V3, P630, DOI 10.1158/1940-6207.CAPR-10-0003; Kasaikina MV, 2011, J BIOL CHEM, V286, P33203, DOI 10.1074/jbc.M111.259218; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; Kumaraswamy E, 2002, METHOD ENZYMOL, V347, P187; Labunskyy VM, 2007, IUBMB LIFE, V59, P1, DOI 10.1080/15216540601126694; Labunskyy VM, 2014, PHYSIOL REV, V94, P739, DOI 10.1152/physrev.00039.2013; Labunskyy VM, 2009, BIOCHEMISTRY-US, V48, P8458, DOI 10.1021/bi900717p; Penney KL, 2010, CANCER PREV RES, V3, P604, DOI 10.1158/1940-6207.CAPR-09-0216; Schomburg L, 2009, BBA-GEN SUBJECTS, V1790, P1453, DOI 10.1016/j.bbagen.2009.03.015; SCHRAUZER GN, 1977, BIOINORG CHEM, V7, P23, DOI 10.1016/S0006-3061(00)80126-X; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Stadtman TC, 2000, ANN NY ACAD SCI, V899, P399, DOI 10.1111/j.1749-6632.2000.tb06203.x; Tsuji PA, 2011, NUTRIENTS, V3, P805, DOI 10.3390/nu3090805; Xun PC, 2011, ENVIRON RES, V111, P514, DOI 10.1016/j.envres.2011.01.016; Yim SH, 2018, CELL REP, V23, P1387, DOI 10.1016/j.celrep.2018.04.009; Zhang Y, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050383	28	3	3	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1263	1268		10.1038/s41388-021-02158-w	http://dx.doi.org/10.1038/s41388-021-02158-w		JAN 2022	6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35082382				2022-12-28	WOS:000749084700002
J	Chiavarina, B; Ronca, R; Otaka, Y; Sutton, RB; Rezzola, S; Yokobori, T; Chiodelli, P; Souche, R; Pourquier, D; Maraver, A; Faa, G; Khellaf, L; Turtoi, E; Oyama, T; Gofflot, S; Bellahcene, A; Detry, O; Delvenne, P; Castronovo, V; Nishiyama, M; Turtoi, A				Chiavarina, Barbara; Ronca, Roberto; Otaka, Yukihiro; Sutton, Roger Bryan; Rezzola, Sara; Yokobori, Takehiko; Chiodelli, Paola; Souche, Regis; Pourquier, Didier; Maraver, Antonio; Faa, Gavino; Khellaf, Lakhdar; Turtoi, Evgenia; Oyama, Tetsunari; Gofflot, Stephanie; Bellahcene, Akeila; Detry, Olivier; Delvenne, Philippe; Castronovo, Vincent; Nishiyama, Masahiko; Turtoi, Andrei			Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma	ONCOGENE			English	Article							CANCER-ASSOCIATED FIBROBLASTS; SARCOMA-VIRUS; CELLS; HETEROGENEITY; EXPRESSION; SORAFENIB; INHIBITOR; TARGETS; PROTEIN; VEGF	Cancer-associated fibroblasts (CAF) are important constituents of the tumor microenvironment (TME) and are major drivers of tumorigenesis. Yet, therapies aiming at eliminating CAF have failed to cure patients. This setback has raised questions regarding whether CAF exclusively favour cancer progression, or if they may also assume tumor-suppressor functions. In the present study, we used proteomics and single cell RNA-sequencing analysis to examine the CAF landscape in hepatocellular carcinoma (HCC). We thereby unveil three major CAF populations in HCC, one of which specifically expressing the prolargin protein. This CAF subpopulation (further termed as CAF_Port) shared a strong transcriptomic signature with portal liver fibroblasts. We further show that CAF_Port deposit prolargin in the TME and that its levels are lower in tumors as compared to the peritumoral region. Mechanistically, aggressive cancer cells degraded prolargin using matrix metalloprotease activity. Survival analysis of 188 patients revealed that high prolargin protein levels correlate with good patient outcome (HR = 0.37; p = 0.01). In vivo, co-injection of cancer cells with fibroblasts silenced for prolargin, led to faster tumor development (5-fold; p = 0.01), mainly due to stronger angiogenesis. Using protein-protein interaction study and structural modelling, we further demonstrate that prolargin binds and inhibits the activity of several pro-agiogenic proteins, including hepatocyte and fibroblast growth factors. In conclusion, prolargin is angiogenesis modulator and CAF-derived tumor suppressor in HCC. Stabilizing prolargin levels in the CAF_Port subpopulation may revert their tumor-antagonizing properties, warranting exploration in further pre-clinical studies.	[Chiavarina, Barbara; Souche, Regis; Pourquier, Didier; Turtoi, Evgenia; Turtoi, Andrei] INSERM, Tumor Microenvironm & Resistance Treatment Lab, Inst Rech Cancerol Montpellier, U1194, Montpellier, France; [Chiavarina, Barbara; Souche, Regis; Maraver, Antonio; Turtoi, Evgenia; Turtoi, Andrei] Univ Montpellier, Montpellier, France; [Chiavarina, Barbara; Souche, Regis; Pourquier, Didier; Maraver, Antonio; Khellaf, Lakhdar; Turtoi, Evgenia; Turtoi, Andrei] Inst Reg Canc Montpellier ICM Val dAurelle, Montpellier, France; [Ronca, Roberto; Rezzola, Sara; Chiodelli, Paola] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Otaka, Yukihiro; Nishiyama, Masahiko] Gunma Univ, Dept Mol Pharmacol & Oncol, Grad Sch Med, Gunma, Japan; [Otaka, Yukihiro; Yokobori, Takehiko; Nishiyama, Masahiko; Turtoi, Andrei] Gunma Univ Initiat Adv Res GIAR, Gunma, Japan; [Sutton, Roger Bryan] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Physiol & Mol Biophys, Lubbock, TX 79430 USA; [Yokobori, Takehiko] Gunma Univ Maebashi, Grad Sch Med, Dept Gen Surg Sci, Gunma, Japan; [Maraver, Antonio] INSERM, Oncogen Pathways Lung Canc Lab, Inst Rech Cancerol Montpellier, U1194, Montpellier, France; [Faa, Gavino] Univ Cagliari, Univ Hosp San Giovanni Dio AOU Cagliari, Dept Pathol, Cagliari, Italy; [Oyama, Tetsunari] Gunma Univ, Grad Sch Med, Dept Diagnost Pathol, Maebashi, Gumma, Japan; [Gofflot, Stephanie] Univ Liege, BIOTHEQUE, Liege, Belgium; [Bellahcene, Akeila; Castronovo, Vincent] Univ Liege, Metastasis Res Lab, GIGA Canc, Liege, Belgium; [Detry, Olivier] Univ Liege, Univ Hosp, Dept Abdominal Surg, Liege, Belgium; [Delvenne, Philippe] Univ Liege, Univ Hosp, Dept Pathol, Liege, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); University of Brescia; Gunma University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Cagliari; Gunma University; University of Liege; University of Liege; University of Liege; University of Liege	Chiavarina, B; Turtoi, A (corresponding author), INSERM, Tumor Microenvironm & Resistance Treatment Lab, Inst Rech Cancerol Montpellier, U1194, Montpellier, France.; Chiavarina, B; Turtoi, A (corresponding author), Univ Montpellier, Montpellier, France.; Chiavarina, B; Turtoi, A (corresponding author), Inst Reg Canc Montpellier ICM Val dAurelle, Montpellier, France.; Turtoi, A (corresponding author), Gunma Univ Initiat Adv Res GIAR, Gunma, Japan.	barbara.chiavarina@inserm.fr; andrei.turtoi@inserm.fr	Detry, Olivier/I-9333-2019; Ronca, Roberto/AAC-6470-2022	Detry, Olivier/0000-0002-9436-6673; Ronca, Roberto/0000-0001-8979-7068; Chiavarina, Barbara/0000-0003-1444-174X; Turtoi, Andrei/0000-0003-3813-6635; Maraver, Antonio/0000-0002-5527-5680; Otaka, Yukihiro/0000-0002-9162-7188	University of Liege; National Fund for Scientific Research (FNRS); Gunma University (GIAR Research Program for Omics-Based Medical Science); Fondation de France grant [00078461]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [MFAG 18459, 23151]; Fondazione Umberto Veronesi fellowship; LabEx MabImprove Starting Grant; Fondation Contre le Cancer	University of Liege(University of Liege); National Fund for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS); Gunma University (GIAR Research Program for Omics-Based Medical Science); Fondation de France grant; Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Umberto Veronesi fellowship(Fondazione Umberto Veronesi); LabEx MabImprove Starting Grant; Fondation Contre le Cancer	The authors acknowledge the experimental support of Naima Maloujahmoum (Metastasis Research Laboratory, University of Liege), Susumu Rokudai (Department of Molecular Pharmacology and Oncology, Gunma University), and Tadashi Handa (Pathology Dept. Gunma University). The authors are particularly thankful to Arnaud Blomme (Metastasis Research Laboratory, University of Liege) and Touko Hirano (Laboratory for Analytical Instruments, Gunma University Graduate School of Medicine) for the help concerning the MS analysis of patient material. The authors thank the Small Animal Imaging Platform of Montpellier (IPAM, http://www.ipam.cnrs.fr/) for the help with animal experiments. AT is thankful to Jacques Colinge (Bioinformatics and Systems Biology group, IRCM, Montpellier) for his R teachings and to Peter Friedl (The University of Texas MD Anderson Cancer Center, Houston, Texas, USA) for the helpful discussions. This work was supported with grants from the University of Liege, National Fund for Scientific Research (FNRS), Gunma University (GIAR Research Program for Omics-Based Medical Science). BC is supported by a Fondation de France grant (No. 00078461). RR is supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), grant number MFAG 18459 and IG 2019 -ID. 23151; SR is supported by Fondazione Umberto Veronesi fellowship. AT is a senior research fellow of the French National Institute of Health and Medical Research (INSERM) and is supported by LabEx MabImprove Starting Grant. OD is supported by a grant from the "Fondation Contre le Cancer". No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the paper.	Adnane L, 2006, METHOD ENZYMOL, V407, P597, DOI 10.1016/S0076-6879(05)07047-3; Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Cabello-Aguilar S, 2020, NUCLEIC ACIDS RES, V48, DOI 10.1093/nar/gkaa183; Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719; Chang PH, 2012, CANCER RES, V72, P4652, DOI 10.1158/0008-5472.CAN-12-0877; Chiavarina B, 2017, CURR MED CHEM, V24, P2846, DOI 10.2174/0929867324666170428104311; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; DeFilippis RA, 2012, CANCER DISCOV, V2, P826, DOI 10.1158/2159-8290.CD-12-0107; Dobie R, 2019, CELL REP, V29, P1832, DOI 10.1016/j.celrep.2019.10.024; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fields GB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01278; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Guo DJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03032-0; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Ma LC, 2019, CANCER CELL, V36, P418, DOI 10.1016/j.ccell.2019.08.007; Maris P, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001871; Morse MA, 2019, CLIN CANCER RES, V25, P912, DOI 10.1158/1078-0432.CCR-18-1254; Neill T, 2012, AM J PATHOL, V181, P380, DOI 10.1016/j.ajpath.2012.04.029; Nwosu ZC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0872-6; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Orimo A, 2007, CANCER BIOL THER, V6, P618, DOI 10.4161/cbt.6.4.4255; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ramisch S, 2014, P NATL ACAD SCI USA, V111, P17875, DOI 10.1073/pnas.1413638111; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ronca R, 2018, CURR OPIN ONCOL, V30, P45, DOI 10.1097/CCO.0000000000000420; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Turtoi A, 2011, J PROTEOME RES, V10, P3160, DOI 10.1021/pr200212r; Turtoi A, 2011, AM J PATHOL, V178, P12, DOI 10.1016/j.ajpath.2010.08.004; Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559; Waltregny D, 1998, J NATL CANCER I, V90, P1000, DOI 10.1093/jnci/90.13.1000; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535-7163.MCT-17-0646	45	2	2	5	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1410	1420		10.1038/s41388-021-02171-z	http://dx.doi.org/10.1038/s41388-021-02171-z		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35031773				2022-12-28	WOS:000742613600003
J	James, NE; Woodman, M; Ribeiro, JR				James, Nicole E.; Woodman, Morgan; Ribeiro, Jennifer R.			Prognostic immunologic signatures in epithelial ovarian cancer	ONCOGENE			English	Review							GENE-EXPRESSION; T-CELLS; CHEMOTHERAPY; SURVIVAL; MICROENVIRONMENT; CARCINOMA; BRCA1	Epithelial Ovarian Cancer (EOC) is a deadly gynecologic malignancy in which patients frequently develop recurrent disease following initial platinum-taxane chemotherapy. Analogous to many other cancer subtypes, EOC clinical trials have centered upon immunotherapeutic approaches, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies in EOC patients have been low, evidence suggests that ovarian tumors are immunogenic and that immune-related genomic profiles can serve as prognostic markers. This review will discuss recent advances in the development of immune-based prognostic signatures in EOC that predict patient clinical outcomes, as well as emphasize specific research areas that need to be addressed to drive this field forward.	[James, Nicole E.; Woodman, Morgan; Ribeiro, Jennifer R.] Women & Infants Hosp Rhode Isl, Program Womens Oncol, Dept Obstet & Gynecol, Providence, RI 02905 USA; [James, Nicole E.; Ribeiro, Jennifer R.] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA	Women & Infants Hospital Rhode Island; Brown University	Ribeiro, JR (corresponding author), Women & Infants Hosp Rhode Isl, Program Womens Oncol, Dept Obstet & Gynecol, Providence, RI 02905 USA.; Ribeiro, JR (corresponding author), Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA.	Jrribeiro@wihri.org		Ribeiro, Jennifer/0000-0002-1685-8568				Bohm S, 2016, CLIN CANCER RES, V22, P3025, DOI 10.1158/1078-0432.CCR-15-2657; Brunekreeft KL, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1760705; Cao TF, 2021, J OVARIAN RES, V14, DOI 10.1186/s13048-021-00766-4; Chang CC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113311; Chang L, 2019, THERANOSTICS, V9, P4130, DOI 10.7150/thno.34692; Chifman J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2948-z; Clarke B, 2009, MODERN PATHOL, V22, P393, DOI 10.1038/modpathol.2008.191; Cortez AJ, 2018, CANCER CHEMOTH PHARM, V81, P17, DOI 10.1007/s00280-017-3501-8; Ding Q, 2020, AGING-US, V12, P4879, DOI 10.18632/aging.102914; Farkkila A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15315-8; Foukakis T, 2018, BRIT J CANCER, V118, P480, DOI 10.1038/bjc.2017.446; Guo QY, 2015, SCI REP-UK, V5, DOI 10.1038/srep17683; Hamanishi J, 2015, J CLIN ONCOL, V33, P4015, DOI 10.1200/JCO.2015.62.3397; Hao DP, 2018, CLIN CANCER RES, V24, P3560, DOI 10.1158/1078-0432.CCR-17-3862; Harwood FC, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar3938; Honkala AT, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03139; James NE, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.622182; James NE, 2020, CANCERS, V12, DOI 10.3390/cancers12082150; Jimenez-Sanchez A, 2020, NAT GENET, V52, P582, DOI 10.1038/s41588-020-0630-5; Jones WD, 2020, CANCERS, V12, DOI 10.3390/cancers12030620; Khadirnaikar S, 2020, CANCER REP-US, V3, DOI 10.1002/cnr2.1166; Korsunsky I, 2017, J INVEST MED, V65, P1068, DOI 10.1136/jim-2017-000457; Koti M, 2015, BRIT J CANCER, V112, P1215, DOI 10.1038/bjc.2015.81; Li H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86294-z; Liu GY, 2012, PHARMACOGENOMICS, V13, P1523, DOI [10.2217/PGS.12.137, 10.2217/pgs.12.137]; Liu J, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201431; Liu SY, 2020, ONCOTARGETS THER, V13, P6037, DOI 10.2147/OTT.S256708; Lu XF, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12979; Mairinger F, 2019, CANCER MANAG RES, V11, P9571, DOI 10.2147/CMAR.S219872; Mesnage SJL, 2017, ANN ONCOL, V28, P651, DOI 10.1093/annonc/mdw625; Mlynska A, 2019, ONCOL REP, V41, P1238, DOI 10.3892/or.2018.6886; Nixon AB, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0799-2; Olivier M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194781; Radestad E, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1535730; Ray M, 2019, GENE CHROMOSOME CANC, V58, P34, DOI 10.1002/gcc.22688; Rossi L, 2017, ONCOTARGET, V8, P12389, DOI 10.18632/oncotarget.13310; Shen SP, 2019, EBIOMEDICINE, V40, P318, DOI 10.1016/j.ebiom.2018.12.054; Siamakpour-Reihani S, 2020, GYNECOL ONCOL, V156, P662, DOI 10.1016/j.ygyno.2019.12.019; Talluri B, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090360; Vankerckhoven A, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101076; Weberpals JI, 2021, CANCER MED-US, V10, P3045, DOI 10.1002/cam4.3831; Wei Y., 2020, PEERJ, V8; Wu Y, 2020, AGING-US, V12, P11398, DOI 10.18632/aging.103199; Yan SB, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07695-3; Zhang B, 2021, J CELL MOL MED, V25, P2918, DOI 10.1111/jcmm.16327; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhang LY, 2019, ONCOTARGETS THER, V12, P7005, DOI 10.2147/OTT.S200191	47	4	4	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1389	1396		10.1038/s41388-022-02181-5	http://dx.doi.org/10.1038/s41388-022-02181-5		JAN 2022	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35031772				2022-12-28	WOS:000742613600001
J	Smalling, RV; Bechard, ME; Duryea, J; Kingsley, PJ; Roberts, ER; Marnett, LJ; Bilbao, D; Stauffer, SR; McDonald, OG				Smalling, Rana, V; Bechard, Matthew E.; Duryea, Jeff; Kingsley, Philip J.; Roberts, Evan R.; Marnett, Lawrence J.; Bilbao, Daniel; Stauffer, Shaun R.; McDonald, Oliver G.			Aminopyridine analogs selectively target metastatic pancreatic cancer	ONCOGENE			English	Article							DISTANT METASTASIS; 6-AMINONICOTINAMIDE; HETEROGENEITY; ADENOCARCINOMA; METABOLISM; CELLS	Metastatic outgrowth is supported by metabolic adaptations that may differ from the primary tumor of origin. However, it is unknown if such adaptations are therapeutically actionable. Here we report a novel aminopyridine compound that targets a unique Phosphogluconate Dehydrogenase (PGD)-dependent metabolic adaptation in distant metastases from pancreatic cancer patients. Compared to structurally similar analogs, 6-aminopicolamine (6AP) potently and selectively reversed PGD-dependent metastatic properties, including intrinsic tumorigenic capacity, excess glucose consumption, and global histone hyperacetylation. 6AP acted as a water-soluble prodrug that was converted into intracellular bioactive metabolites that inhibited PGD in vitro, and 6AP monotherapy demonstrated anti-metastatic efficacy with minimal toxicity in vivo. Collectively, these studies identify 6AP and possibly other 6-aminopyridines as well-tolerated prodrugs with selectivity for metastatic pancreatic cancers. If unique metabolic adaptations are a common feature of metastatic or otherwise aggressive human malignancies, then such dependencies could provide a largely untapped pool of druggable targets for patients with advanced cancers.	[Smalling, Rana, V; Bechard, Matthew E.; McDonald, Oliver G.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; [Duryea, Jeff; Roberts, Evan R.; Bilbao, Daniel; McDonald, Oliver G.] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol & Lab Med, Miller Sch Med, Miami, FL 33136 USA; [Kingsley, Philip J.; Marnett, Lawrence J.] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN USA; [Stauffer, Shaun R.] Vanderbilt Univ, Dept Pharmacol, Med Ctr, Nashville, TN USA; [Stauffer, Shaun R.] Cleveland Clin, Ctr Therapeut Discovery, Cleveland, OH USA	Vanderbilt University; University of Miami; Vanderbilt University; Vanderbilt University; Cleveland Clinic Foundation	McDonald, OG (corresponding author), Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA.; McDonald, OG (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol & Lab Med, Miller Sch Med, Miami, FL 33136 USA.	ogm443@miami.edu		McDonald, Oliver/0000-0002-6602-7535; Kingsley, Philip/0000-0002-5470-4340	National Institutes of Health [R01 CA222594, 5P30 DK058404]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institutes of Health grants R01 CA222594 (OGM) and 5P30 DK058404 (OGM).	Balachandran VP, 2019, GASTROENTEROLOGY, V156, P2056, DOI 10.1053/j.gastro.2018.12.038; Bechard ME, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17839-5; Bechard ME, 2018, ONCOGENE, V37, P5248, DOI 10.1038/s41388-018-0346-5; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Daneshmandi S, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108831; DIETRICH LS, 1958, J BIOL CHEM, V233, P964; Embuscado EE, 2005, CANCER BIOL THER, V4, P548, DOI 10.4161/cbt.4.5.1663; Fendt SM, 2020, CANCER DISCOV, V10, P1797, DOI 10.1158/2159-8290.CD-20-0844; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Hayashi A, 2021, NAT REV GASTRO HEPAT, V18, P469, DOI 10.1038/s41575-021-00463-z; HERKEN H, 1976, N-S ARCH PHARMACOL, V293, P245, DOI 10.1007/BF00507347; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Iacobuzio-Donahue CA, 2020, NAT CANCER, V1, P3, DOI 10.1038/s43018-019-0002-1; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; JOHNSON WJ, 1955, SCIENCE, V122, P834, DOI 10.1126/science.122.3174.834; Ju HQ, 2016, CANCER LETT, V379, P1, DOI 10.1016/j.canlet.2016.05.024; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; KOHLER E, 1970, FEBS LETT, V6, P225, DOI 10.1016/0014-5793(70)80063-1; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McDonald OG, 2020, MOL CELL ONCOL, V7, DOI 10.1080/23723556.2020.1825910; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Recouvreux MV, 2020, J EXP MED, V217, DOI 10.1084/jem.20200388; Reiter JG, 2018, SCIENCE, V361, P1033, DOI 10.1126/science.aat7171; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Roe JS, 2017, CELL, V170, P875, DOI 10.1016/j.cell.2017.07.007; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Soares Kevin C, 2014, J Vis Exp, P51677, DOI 10.3791/51677; Storz P, 2020, GASTROENTEROLOGY, V158, P2072, DOI 10.1053/j.gastro.2020.02.059; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Walker DL, 1999, BIOCHEM PHARMACOL, V58, P1057, DOI 10.1016/S0006-2952(99)00179-3; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yoshida T, 2020, BIOCHEM BIOPH RES CO, V522, P633, DOI 10.1016/j.bbrc.2019.11.130	40	1	1	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1518	1525		10.1038/s41388-022-02183-3	http://dx.doi.org/10.1038/s41388-022-02183-3		JAN 2022	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35031771	Green Accepted			2022-12-28	WOS:000742613600002
J	Liu, XQ; Shao, XR; Liu, Y; Dong, ZX; Chan, SH; Shi, YY; Chen, SN; Qi, L; Zhong, L; Yu, Y; Lv, T; Yang, PF; Li, LY; Wang, XB; Zhang, XD; Li, X; Zhao, WX; Sehgal, L; Li, M; Zhang, XD				Liu, Xue-Qi; Shao, Xin-Rong; Liu, Ye; Dong, Zhao-Xia; Chan, Sze-Hoi; Shi, Yuan-Yuan; Chen, Shu-Na; Qi, Lin; Zhong, Li; Yu, Yue; Lv, Ting; Yang, Peng-Fei; Li, Li-Yan; Wang, Xiao-Bin; Zhang, Xu-Dong; Li, Xin; Zhao, Wenxue; Sehgal, Lalit; Li, Miao; Zhang, Xing-Ding			Tight junction protein 1 promotes vasculature remodeling via regulating USP2/TWIST1 in bladder cancer	ONCOGENE			English	Article							TUMOR ANGIOGENESIS; MESENCHYMAL TRANSITION; VASCULOGENIC MIMICRY; BREAST-CANCER; GROWTH; MACROPHAGES; METASTASIS; TWIST1; PHOSPHORYLATION; MODEL	Bladder cancer (BLCA) is the most common malignant tumor of the urinary system and is characterized by high metastatic rates and poor prognosis. The expression of tight junction protein 1 (TJP1) is associated with bladder cancer invasion; however, the mechanism by which TJP1 affects vasculature remodeling remains unknown. In this study, we found that TJP1 expression correlated with tumor angiogenesis and poor overall survival in clinical samples. Furthermore, TJP1 overexpression promoted tumor angiogenesis in BLCA cells and stimulated recruitment of macrophages to tumors by upregulating CCL2 expression. Mechanistically, TJP1 interacted with TWIST1 and enhanced the transcriptional activity of CCL2. The impairment of tumor angiogenesis caused by knockdown of TJP1 was dramatically rescued by overexpression of TWIST1. Furthermore, TJP1 recruited USP2, which deubiquitinated TWIST1, thereby protecting TWIST1 from proteasome-mediated protein degradation. In conclusion, our results suggest that TJP1 controls angiogenesis in BLCA via TWIST1-dependent regulation of CCL2. We demonstrate that TJP1 functions as a scaffold for the interaction between USP2 and TWIST1 and this may provide potential therapeutic targets in bladder cancer.	[Liu, Xue-Qi; Shao, Xin-Rong; Dong, Zhao-Xia; Chan, Sze-Hoi; Shi, Yuan-Yuan; Chen, Shu-Na; Qi, Lin; Yu, Yue; Li, Li-Yan; Zhang, Xu-Dong; Li, Xin; Zhao, Wenxue; Zhang, Xing-Ding] Sun Yat Sen Univ, Mol Canc Res Ctr, Sch Med, Shenzhen Campus Sun Yat Sen Univ, Shenzhen, Peoples R China; [Liu, Ye; Lv, Ting; Yang, Peng-Fei] Sun Yat Sen Univ, Dept Pathol, Affiliated Hosp 5, Zhuhai, Peoples R China; [Zhong, Li] Sun Yat Sen Univ, Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Wang, Xiao-Bin] China Med Univ, Ctr Reprod Med, Androl Sect, Shengjing Hosp, Shenyang, Peoples R China; [Sehgal, Lalit] Ohio State Univ, Dept Internal Med, Div Hematol, Comprehens Canc Ctr, Columbus, OH USA; [Li, Miao] Shenzhen Univ, Shenzhen Second Peoples Hosp, Affiliated Hosp 1, Shenzhen, Peoples R China; [Li, Miao] Shenzhen Univ, Sch Biomed Engn, Guangdong Key Lab Biomed Measurements & Ultrasoun, Hlth Sci Ctr, Shenzhen, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; China Medical University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Second People's Hospital of Shenzhen; Shenzhen University; Shenzhen University	Zhang, XD (corresponding author), Sun Yat Sen Univ, Mol Canc Res Ctr, Sch Med, Shenzhen Campus Sun Yat Sen Univ, Shenzhen, Peoples R China.; Li, M (corresponding author), Shenzhen Univ, Shenzhen Second Peoples Hosp, Affiliated Hosp 1, Shenzhen, Peoples R China.	limiao27@mail.sysu.edu.cn; zhangxd39@mail.sysu.edu.cn	; Li, Xin/A-4137-2011	Liu, Xueqi/0000-0002-8295-032X; Zhong, Li/0000-0002-1646-2862; Li, Xin/0000-0001-8328-4894; Yang, Pengfei/0000-0001-5266-2311	National Natural Science Foundation of China [81970191, 32170789, 3210050130]; Guangdong Natural Science Foundation of China [2018A0303130090]; Shenzhen Science and Technology Innovation Commission, China [JCYJ20190807160209294, JCYJ20190807160813467]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation of China(National Natural Science Foundation of Guangdong Province); Shenzhen Science and Technology Innovation Commission, China	We thank Prof. Kang (Sun Yat-sen University Cancer Center) for kindly providing T24 and 5637 bladder cancer cells and the faculty (Fifth Affiliated Hospital of Sun Yat-sen University) for collecting the clinical samples. This work was supported in part by the National Natural Science Foundation of China (grant no. 81970191; 32170789; 3210050130); supported by Guangdong Natural Science Foundation of China (grant no. 2018A0303130090); supported by Shenzhen Science and Technology Innovation Commission, China (JCYJ20190807160209294, JCYJ20190807160813467).	Anghelina M, 2004, STEM CELLS DEV, V13, P665, DOI 10.1089/scd.2004.13.665; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Bauer H, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/402593; Beutel O, 2019, CELL, V179, P923, DOI 10.1016/j.cell.2019.10.011; Black PC, 2007, CANCER METAST REV, V26, P623, DOI 10.1007/s10555-007-9084-9; de Iongh RU, 2005, CELLS TISSUES ORGANS, V179, P43, DOI 10.1159/000084508; Dhanasekaran R, 2020, ELIFE, V9, DOI 10.7554/eLife.50731; Flamme I, 1997, J CELL PHYSIOL, V173, P206, DOI 10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C; He JB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1512-6; HENRY N, 1983, FEBS LETT, V161, P243, DOI 10.1016/0014-5793(83)81017-5; Hsu YL, 2017, ONCOGENE, V36, P4929, DOI 10.1038/onc.2017.105; Hu L, 2008, CANCER RES, V68, P4296, DOI 10.1158/0008-5472.CAN-08-0067; Koga M, 2008, BIOCHEM BIOPH RES CO, V365, P279, DOI 10.1016/j.bbrc.2007.10.182; Laakkonen JP, 2017, ANGIOGENESIS, V20, P109, DOI 10.1007/s10456-016-9532-7; Lee KW, 2015, CANCER RES, V75, P73, DOI 10.1158/0008-5472.CAN-14-0350; Lesage J, 2017, FASEB J, V31, P1678, DOI 10.1096/fj.201600890R; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li CW, 2016, CANCER RES, V76, P1451, DOI 10.1158/0008-5472.CAN-15-1941; Li FT, 2020, CANCERS, V12, DOI 10.3390/cancers12061582; Li TL, 2018, ONCOL LETT, V16, P687, DOI 10.3892/ol.2018.8733; Liu XW, 2016, AM J PATHOL, V186, P2486, DOI 10.1016/j.ajpath.2016.04.018; Low-Marchelli JM, 2013, CANCER RES, V73, P662, DOI 10.1158/0008-5472.CAN-12-0653; Martin TA, 2002, J CELL PHYSIOL, V192, P268, DOI 10.1002/jcp.10133; Meng J, 2019, ONCOGENE, V38, P228, DOI 10.1038/s41388-018-0428-4; Naito S, 2016, EUR UROL, V70, P506, DOI 10.1016/j.eururo.2016.03.053; Neufeld G, 2006, CANCER METAST REV, V25, P373, DOI 10.1007/s10555-006-9011-5; Ponce M. Lourdes, 2009, V467, P183, DOI 10.1007/978-1-59745-241-0_10; Rao Q, 2016, ONCOTARGET, V7, P7842, DOI 10.18632/oncotarget.5467; Ribatti D, 2007, CANCER LETT, V248, P18, DOI 10.1016/j.canlet.2006.06.007; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Roberts CM, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3169-9; Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031; Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9; Sun T, 2011, HEPATOLOGY, V54, P1690, DOI 10.1002/hep.24543; Tornavaca O, 2015, J CELL BIOL, V208, P821, DOI 10.1083/jcb.201404140; Tran LD, 2021, NAT REV CANCER, V21, P104, DOI 10.1038/s41568-020-00313-1; Tsai KW, 2018, ANTICANCER RES, V38, P4607, DOI 10.21873/anticanres.12765; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang SY, 2012, BREAST CANCER RES TR, V133, P1037, DOI 10.1007/s10549-011-1902-7; Wang XS, 2015, FEBS J, V282, P4376, DOI 10.1111/febs.13502; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Witjes JA, 2014, EUR UROL, V65, P778, DOI 10.1016/j.eururo.2013.11.046; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang WH, 2016, ONCOGENE, V35, P2287, DOI 10.1038/onc.2015.291; Yang Z, 2020, CANCER LETT, V473, P118, DOI 10.1016/j.canlet.2019.12.018; Zhao YJ, 2015, ONCOLOGIST, V20, P660, DOI 10.1634/theoncologist.2014-0465; Zhao ZX, 2017, ONCOTARGET, V8, P20380, DOI 10.18632/oncotarget.14608; Zhou L, 2016, ONCOTARGET, V7, P76214, DOI 10.18632/oncotarget.12775	49	4	4	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					502	514		10.1038/s41388-021-02112-w	http://dx.doi.org/10.1038/s41388-021-02112-w		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34782718				2022-12-28	WOS:000718778400002
J	Zheng, YL; Wu, JJ; Deng, R; Lin, CS; Huang, YH; Yang, X; Wang, CH; Yang, MM; He, YF; Lu, JB; Su, XD; Yan, Q; Zhu, YH; Guan, XY; Li, Y; Yun, JP				Zheng, Yinli; Wu, Jinjun; Deng, Ru; Lin, Censhan; Huang, Yuhua; Yang, Xia; Wang, Chunhua; Yang, Mingming; He, Yangfan; Lu, Jiabin; Su, Xiaodong; Yan, Qian; Zhu, Yinghui; Guan, Xinyuan; Li, Yan; Yun, Jingping			G3BP2 regulated by the lncRNA LINC01554 facilitates esophageal squamous cell carcinoma metastasis through stabilizing HDGF transcript	ONCOGENE			English	Article							RNA-BINDING PROTEINS; HEPATOCELLULAR-CARCINOMA; CANCER; EXPRESSION; INVASION; LINK	Metastasis is the leading cause of death of patients with esophageal squamous cell carcinoma (ESCC). Although an increasing number of studies have demonstrated the involvement of G3BP2 in several human cancers, how G3BP2 interacts with long noncoding RNAs and regulates mRNA transcripts in mediating ESCC metastasis remains unclear. In this study, we uncovered that G3BP2 was upregulated in ESCC. Further analysis revealed that upregulation of G3BP2 was significantly correlated with lymph node metastasis, depth of tumor invasion and unfavorable outcomes in ESCC patients. Both in vitro and in vivo functional assays demonstrated that G3BP2 dramatically enhanced ESCC cell migration and invasion. Mechanistically, LINC01554 maintained the high G3BP2 expression in ESCC by protecting G3BP2 from degradation through ubiquitination and the interaction domains within LINC01554 and G3BP2 were identified. In addition, RNA-seq revealed that HDGF was regulated by G3BP2. G3BP2 bound to HDGF mRNA transcript to stabilize its expression. Ectopic expression of HDGF effectively abolished the G3BP2 depletion-mediated inhibitory effect on tumor cell migration. Intriguingly, introduction of compound C108 which can inhibit G3BP2 remarkedly suppressed ESCC cell metastasis in vitro and in vivo. Collectively, this study describes a newly discovered regulatory axis, LINC01554/G3BP2/HDGF, that facilitates ESCC metastasis and will provide novel therapeutic strategies for ESCC.	[Zheng, Yinli; Deng, Ru; Lin, Censhan; Huang, Yuhua; Yang, Xia; Wang, Chunhua; Yang, Mingming; He, Yangfan; Lu, Jiabin; Su, Xiaodong; Zhu, Yinghui; Guan, Xinyuan; Li, Yan; Yun, Jingping] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Peoples R China; [Zheng, Yinli; Deng, Ru; Lin, Censhan; Huang, Yuhua; Yang, Xia; Wang, Chunhua; Yang, Mingming; He, Yangfan; Lu, Jiabin; Yun, Jingping] Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou 510060, Peoples R China; [Wu, Jinjun] Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Joint Lab Translat Canc Res Chinese Med, Minist Educ Peoples Republ China, Guangzhou 510006, Peoples R China; [Su, Xiaodong] Sun Yat Sen Univ, Dept Thorac Surg, Canc Ctr, Guangzhou 510060, Peoples R China; [Yan, Qian] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Inst Gastroenterol, Dept Colorectal Surg,Guangdong Prov Key Lab Color, Guangzhou 510000, Peoples R China; [Guan, Xinyuan] Univ Hong Kong, Dept Clin Oncol, State Key Lab Liver Res, Hong Kong 852, Peoples R China; [Guan, Xinyuan] Univ Hong Kong, Dept Clin Oncol, Shenzhen Hosp, Shenzhen 518053, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Guangzhou University of Chinese Medicine; Ministry of Education, China; Sun Yat Sen University; Sun Yat Sen University; University of Hong Kong; University of Hong Kong	Li, Y; Yun, JP (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Peoples R China.; Yun, JP (corresponding author), Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou 510060, Peoples R China.	liy6@mail.sysu.edu.cn; yunjp@sysucc.org.cn			National Natural Science Foundation of Guangdong Province [2018B030311005]; National Natural Science Foundation of China [82003056, 82072611, 82072604]; Guangdong Basic and Applied Basic Research Foundation [2019A1515110054]; China Postdoctoral Science Foundation [2019M663307]; Young Talent Teachers Plan of Sun Yat-sen University [20YKPY183]	National Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Young Talent Teachers Plan of Sun Yat-sen University	This study was supported by The National Natural Science Foundation of Guangdong Province (No.2018B030311005), The National Natural Science Foundation of China (No.82003056, 82072611, 82072604), Guangdong Basic and Applied Basic Research Foundation (No. 2019A1515110054), China Postdoctoral Science Foundation (No. 2019M663307), and Young Talent Teachers Plan of Sun Yat-sen University (No.20YKPY183).	Alam U, 2019, BBA-MOL CELL RES, V1866, P360, DOI 10.1016/j.bbamcr.2018.09.001; Ashikari D, 2017, ONCOGENE, V36, P6272, DOI 10.1038/onc.2017.225; Azad TD, 2020, GASTROENTEROLOGY, V158, P494, DOI 10.1053/j.gastro.2019.10.039; Bao CH, 2014, FUTURE ONCOL, V10, P2675, DOI 10.2217/fon.14.194; Bikkavilli RK, 2011, J CELL SCI, V124, P2310, DOI 10.1242/jcs.084046; Chen XX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00650-0; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fu QF, 2017, CLIN CANCER RES, V23, P6336, DOI 10.1158/1078-0432.CCR-16-2813; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Gao Y, 2013, HUM GENET, V132, P649, DOI 10.1007/s00439-013-1276-5; Gupta N, 2017, P NATL ACAD SCI USA, V114, P1033, DOI 10.1073/pnas.1525387114; Hao QY, 2020, EUR REV MED PHARMACO, V24, P12667, DOI 10.26355/eurrev_202012_24164; Heijink AM, 2019, CELL REP, V28, P2345, DOI 10.1016/j.celrep.2019.07.070; Hu XT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1095-y; Hubner JM, 2019, NEURO-ONCOLOGY, V21, P878, DOI 10.1093/neuonc/noz058; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Lin CH, 2020, CANCERS, V12, DOI 10.3390/cancers12092690; Lin YW, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6229-5; Liu HW, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01241-2; Liu X, 2017, GASTROENTEROLOGY, V153, P166, DOI 10.1053/j.gastro.2017.03.033; Matsuki H, 2013, GENES CELLS, V18, P135, DOI 10.1111/gtc.12023; Noh JH, 2018, WIRES RNA, V9, DOI 10.1002/wrna.1471; Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shih TC, 2012, J HEPATOL, V57, P584, DOI 10.1016/j.jhep.2012.04.031; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Takayama KI, 2018, MOL CANCER RES, V16, P846, DOI 10.1158/1541-7786.MCR-17-0471; Taniuchi K, 2011, MOL CANCER RES, V9, P856, DOI 10.1158/1541-7786.MCR-10-0574; Tian H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18929-0; Valiente-Echeverria F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5819; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0; Wei SC, 2015, NAT CELL BIOL, V17, P678, DOI 10.1038/ncb3157; Yang Y, 2021, ONCOGENE, V40, P731, DOI 10.1038/s41388-020-01485-8; Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556-019-0311-8; Yuan YH, 2009, CIRC RES, V105, P1177, DOI 10.1161/CIRCRESAHA.109.204669; Zeng HM, 2018, LANCET GLOB HEALTH, V6, pE555, DOI 10.1016/S2214-109X(18)30127-X; Zheng YL, 2019, THERANOSTICS, V9, P796, DOI 10.7150/thno.28992; Zuo XL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0839-x	40	4	4	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					515	526		10.1038/s41388-021-02073-0	http://dx.doi.org/10.1038/s41388-021-02073-0		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34782720	hybrid, Green Published			2022-12-28	WOS:000718778400005
J	Shin, DH; Kim, SH; Choi, M; Bae, YK; Han, C; Choi, BK; Kim, SS; Han, JY				Shin, Dong Hoon; Kim, Sun Ha; Choi, Minyoung; Bae, Young-Ki; Han, Chungyong; Choi, Beom K.; Kim, Sang Soo; Han, Ji-Youn			Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1	ONCOGENE			English	Article							FACTOR RECEPTOR; EGF RECEPTOR; RAS; ADAM17; CHEMOTHERAPY; ACTIVATION; PHYSIOLOGY; PATHWAYS; GENETICS; CLEAVAGE	We previously found the SLC3A2-NRG1 (S-N) fusion gene in a lung adenocarcinoma specimen without known driver mutations and validated this in 59 invasive mucinous adenocarcinoma (IMA) samples. Interestingly, KRAS mutation coexisted (62.5%) in 10 out of 16 NRG1 fusions. In this study, we examined the role of mutant KRAS in regulating the S-N fusion protein in KRAS mutant (H358) and wild-type (Calu-3) cells. KRAS mutation-mediated increase in MEK1/2 and ERK1/2 activity enhanced disintegrin and metalloproteinase (ADAM)17 activity, which increased the shedding of NRG1 from the S-N fusion protein. The cleavage of NRG1 also increased the phosphorylation of ERBB2-ERBB3 heterocomplex receptors and their downstream signalling pathways, including PI3K/Akt/mTOR, even under activated KRAS mutation signalling. The concurrence of S-N fusion and KRAS mutation synergistically increased cell proliferation, colony formation, tumour growth, and the cells' resistance to EGFR kinase inhibitors more than KRAS mutation alone. Targeted inhibition of MEK1/2, and ADAM17 significantly induced apoptosis singly and when combined with each mutation singly or with chemotherapy in both the concurrent KRAS mutant and S-N fusion xenograft and lung orthotopic models. Taken together, this is the first study to report that KRAS mutation increased NRG1 cleavage from the S-N fusion protein through ADAM17, thereby enhancing the Ras/Raf/MEK/ERK and ERBB/PI3K/Akt/mTOR pathways. Moreover, the coexistence of KRAS mutant and S-N fusion in lung tumours renders them vulnerable to MEK1/2 and/or ADAM17 inhibitors, at least in part, due to their dependency on the strong positive loop between KRAS mutation and S-N fusion.	[Shin, Dong Hoon; Kim, Sun Ha; Choi, Minyoung; Bae, Young-Ki; Han, Chungyong; Choi, Beom K.; Kim, Sang Soo; Han, Ji-Youn] Res Inst, Goyang S, South Korea; [Shin, Dong Hoon; Kim, Sun Ha] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Canc Biomed Sci, Goyang Si, Gyeonggi Do, South Korea	National Cancer Center - Korea (NCC)	Shin, DH; Han, JY (corresponding author), Res Inst, Goyang S, South Korea.; Shin, DH (corresponding author), Natl Canc Ctr, Grad Sch Canc Sci & Policy, Canc Biomed Sci, Goyang Si, Gyeonggi Do, South Korea.	dhshin@ncc.re.kr; jymama@ncc.re.kr			National Cancer Centre [NCC-2010070, 2110340]; National Research Fund [NRF-2021R1F1A1062721]	National Cancer Centre; National Research Fund(Luxembourg National Research Fund)	This work was supported by grants (NCC-2010070 and 2110340) funded by the National Cancer Centre, and NRF-2021R1F1A1062721 funded by the National Research Fund.	Ambrogio C, 2017, ONCOGENE, V36, P2309, DOI 10.1038/onc.2016.385; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Baumgart A, 2010, CANCER RES, V70, P5368, DOI 10.1158/0008-5472.CAN-09-3763; BOS JL, 1989, CANCER RES, V49, P4682; Burdett S, 2014, LANCET, V383, P1561, DOI 10.1016/S0140-6736(13)62159-5; Chang JC, 2021, CLIN CANCER RES, V27, P4066, DOI 10.1158/1078-0432.CCR-21-0423; Chen JC, 2016, PHYSIOL REV, V96, P1025, DOI 10.1152/physrev.00030.2015; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Cisowski J, 2016, ONCOGENE, V35, P1328, DOI 10.1038/onc.2015.186; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Fridman JS, 2007, CLIN CANCER RES, V13, P1892, DOI 10.1158/1078-0432.CCR-06-2116; Greulich Heidi, 2010, Genes Cancer, V1, P1200, DOI 10.1177/1947601911407324; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hames ML, 2016, LUNG CANCER, V92, P29, DOI 10.1016/j.lungcan.2015.11.004; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Janssens E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052915; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jonna S, 2019, CLIN CANCER RES, V25, P4966, DOI 10.1158/1078-0432.CCR-19-0160; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kamb A, 2003, MOL BIOL CELL, V14, P2201, DOI 10.1091/mbc.E02-11-0732; Karreth FA, 2009, CURR OPIN GENET DEV, V19, P4, DOI 10.1016/j.gde.2008.12.006; Kim BM, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8275256; Kim TM, 2015, J THORAC ONCOL, V10, P1736, DOI 10.1097/JTO.0000000000000688; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Kwan JC, 2009, J MED CHEM, V52, P5732, DOI 10.1021/jm9009394; Ma SQ, 2021, ONCOGENE, V40, P2596, DOI 10.1038/s41388-021-01734-4; Ni SS, 2013, TUMOR BIOL, V34, P1813, DOI 10.1007/s13277-013-0721-3; Saad MI, 2019, CANCERS, V11, DOI 10.3390/cancers11091218; Saad MI, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809976; Sharma A, 2016, CLIN CANCER RES, V22, P4428, DOI 10.1158/1078-0432.CCR-15-2449; Sharma SV, 2010, BIOCHEM PHARMACOL, V80, P666, DOI 10.1016/j.bcp.2010.03.001; Shin DH, 2018, MOL CANCER THER, V17, P2024, DOI 10.1158/1535-7163.MCT-17-1178; Shin DH, 2016, ONCOTARGET, V7, P69450, DOI 10.18632/oncotarget.11913; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270; Unni AM, 2015, ELIFE, V4, DOI 10.7554/eLife.06907; Van Schaeybroeck S, 2011, CANCER RES, V71, P1071, DOI 10.1158/0008-5472.CAN-10-0714; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Wong MCS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14513-7; Xu PL, 2010, MOL CELL, V37, P551, DOI 10.1016/j.molcel.2010.01.034; Ying HQ, 2016, GENE DEV, V30, P355, DOI 10.1101/gad.275776.115; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Zheng ZY, 2020, CANCER CELL, V37, P387, DOI 10.1016/j.ccell.2020.02.003; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024; Zunke F, 2017, BBA-MOL CELL RES, V1864, P2059, DOI 10.1016/j.bbamcr.2017.07.001	48	4	4	4	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					280	292		10.1038/s41388-021-02097-6	http://dx.doi.org/10.1038/s41388-021-02097-6		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34743207				2022-12-28	WOS:000715015000001
J	Chen, XY; Chen, HT; Yao, HH; Zhao, K; Zhang, Y; He, D; Zhu, YX; Cheng, YX; Liu, R; Xu, RS; Cao, K				Chen, Xingyu; Chen, Haotian; Yao, Honghui; Zhao, Kai; Zhang, Yao; He, Dong; Zhu, Yuxing; Cheng, YaXin; Liu, Rui; Xu, Runshi; Cao, Ke			Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer	ONCOGENE			English	Article							CELL-DEATH; BLOCKADE	The latest research confirms that cytotoxic lymphocytes rely on pyroptosis to kill tumor cells, suggesting that pyroptosis plays a vital role in immune response. However, the influence of pyroptosis on tumor microenvironment (TME) remodeling and immunotherapy is still unclear. We analyzed the variations in the expression of 28 pyroptosis-related molecules in pan-cancer tissues and normal tissues and the influence of genome changes. We investigated 2,214 bladder cancer samples and determined that there are three pyroptosis phenotypes in bladder cancer, and there are significant differences in cell infiltration characteristics in different pyroptosis phenotypes. Phenotypes with high expression of pyroptosis-related molecules are "hot tumors" with better immune function. We used a principal component analysis to measure the level of pyroptosis in patients with PyroScore, and confirmed that the PyroScore can predict the prognosis of bladder cancer patients, the sensitivity of the immune phenotype to chemotherapy, and the response to immunotherapy. Patients with a high PyroScore are more sensitive to chemotherapeutics such as cisplatin and gemcitabine, and have a better prognosis (HR = 0.7; 95%CI = 0.51-0.97, P = 0.041). Our study suggests a significant correlation between the expression imbalance of pyroptosis-related molecules and genome variation in various cancers and suggests pyroptosis plays an important role in modeling the TME. Evaluating pyroptosis modification patterns contributes to enhancing our understanding of TME infiltration and can guide more effective immunotherapy strategies.	[Chen, Xingyu; Chen, Haotian; Zhang, Yao; Zhu, Yuxing; Cheng, YaXin; Liu, Rui; Cao, Ke] Cent South Univ, Dept Oncol, Xiangya Hosp 3, 283 Tongzipo Rd, Changsha 410013, Peoples R China; [Yao, Honghui] Karolinska Inst, Dept Learning Informat Management & Eth, Solna, Sweden; [Zhao, Kai] Cent South Univ, Dept Hematol, Xiangya Hosp 3, Changsha 410013, Peoples R China; [Zhao, Kai] Cent South Univ, Key Lab Nonresolving Inflammat & Canc Hunan Prov, Xiangya Hosp 3, Changsha 410013, Peoples R China; [He, Dong] Hunan Univ Chinese Med, Dept Respirat, Peoples Hosp Hunan Prov 2, Changsha 410000, Peoples R China; [Xu, Runshi] Hunan Prov Hunan Univ Chinese Med, Changsha 410000, Peoples R China	Central South University; Karolinska Institutet; Central South University; Central South University; Hunan University of Chinese Medicine	Cao, K (corresponding author), Cent South Univ, Dept Oncol, Xiangya Hosp 3, 283 Tongzipo Rd, Changsha 410013, Peoples R China.	csucaoke@163.com	Xu, Runshi/AEI-9782-2022		National Natural Science Foundation of China [81874137]; science and technology innovation Program of Hunan Province [2020RC4011]; Outstanding Youth Foundation of Hunan Province [2018JJ1047]; Hunan Province Science and Technology Talent Promotion Project [2019TJ-Q10]; Young Scholars of "Furong Scholar Program" in Hunan Province; Wisdom Accumulation and Talent Cultivation Project of the Third xiangya hosipital of Central South University [BJ202001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); science and technology innovation Program of Hunan Province; Outstanding Youth Foundation of Hunan Province; Hunan Province Science and Technology Talent Promotion Project; Young Scholars of "Furong Scholar Program" in Hunan Province; Wisdom Accumulation and Talent Cultivation Project of the Third xiangya hosipital of Central South University	This work was supported by the National Natural Science Foundation of China (81874137), the science and technology innovation Program of Hunan Province (2020RC4011), the Outstanding Youth Foundation of Hunan Province (2018JJ1047), the Hunan Province Science and Technology Talent Promotion Project (2019TJ-Q10), Young Scholars of "Furong Scholar Program" in Hunan Province, and the Wisdom Accumulation and Talent Cultivation Project of the Third xiangya hosipital of Central South University (BJ202001).	An H, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03454-9; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; BECHT E, 2016, GENOME BIOL; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Bode C, 2021, EUR J IMMUNOL, V51, P1686, DOI 10.1002/eji.202048810; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Broz P, 2020, NAT REV IMMUNOL, V20, P143, DOI 10.1038/s41577-019-0228-2; Chen XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672158; Cristescu R, 2019, SCIENCE, V363, DOI 10.1126/science.aax1384; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Decout A, 2021, NAT REV IMMUNOL, V21, P548, DOI 10.1038/s41577-021-00524-z; Finotello Francesca, 2019, Genome Med, V11, P34, DOI 10.1186/s13073-019-0638-6; Hou JW, 2020, NAT CELL BIOL, V22, P1264, DOI 10.1038/s41556-020-0575-z; Jiang MX, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00349-0; Kamoun A, 2020, EUR UROL, V77, P420, DOI 10.1016/j.eururo.2019.09.006; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Marin-Acevedo JA, 2019, MAYO CLIN PROC, V94, P1321, DOI 10.1016/j.mayocp.2019.03.012; Pitt JM, 2016, ANN ONCOL, V27, P1482, DOI 10.1093/annonc/mdw168; Qin XM, 2020, J PHYS CHEM A, V124, P10066, DOI 10.1021/acs.jpca.0c06019; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rosenbaum SR, 2021, CANCER DISCOV, V11, P266, DOI 10.1158/2159-8290.CD-20-0805; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Roupret M, 2021, EUR UROL, V79, P62, DOI 10.1016/j.eururo.2020.05.042; Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7; SHEN X, 2021, CELL DEATH DIS, V12; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Van Opdenbosch N, 2019, IMMUNITY, V50, P1352, DOI 10.1016/j.immuni.2019.05.020; Wang QY, 2020, NATURE, V579, P421, DOI 10.1038/s41586-020-2079-1; Xi GM, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105713; Xiao Y, 2019, CLIN CANCER RES, V25, P5002, DOI 10.1158/1078-0432.CCR-18-3524; Zhang ZB, 2020, NATURE, V579, P415, DOI 10.1038/s41586-020-2071-9; Zheng M, 2020, CELL, V181, P674, DOI 10.1016/j.cell.2020.03.040; Zhou ZW, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100872	35	26	26	12	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6381	6393		10.1038/s41388-021-02024-9	http://dx.doi.org/10.1038/s41388-021-02024-9		SEP 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34588621				2022-12-28	WOS:000701380400001
J	Lee, CS; Siprashvili, Z; Mah, A; Bencomo, T; Elcavage, LE; Che, YL; Shenoy, RM; Aasi, SZ; Khavari, PA				Lee, Carolyn S.; Siprashvili, Zurab; Mah, Angela; Bencomo, Tomas; Elcavage, Lara E.; Che, Yonglu; Shenoy, Rajani M.; Aasi, Sumaira Z.; Khavari, Paul A.			Mutant collagen COL11A1 enhances cancerous invasion	ONCOGENE			English	Article							MATRIX METALLOPROTEINASES; SKIN-CANCER; MUTATIONS; GENE; SUBSTITUTION; PROGRESSION; METASTASIS; CARCINOMAS; NEOPLASIA; DIAGNOSIS	Collagens are the most abundant proteins in the body and comprise the basement membranes and stroma through which cancerous invasion occurs; however, a pro-neoplastic function for mutant collagens is undefined. Here we identify COL11A1 mutations in 66 of 100 cutaneous squamous cell carcinomas (cSCCs), the second most common U.S. cancer, concentrated in a triple helical region known to produce trans-dominant collagens. Analysis of COL11A1 and other collagen genes found that they are mutated across common epithelial malignancies. Knockout of mutant COL11A1 impairs cSCC tumorigenesis in vivo. Compared to otherwise genetically identical COL11A1 wild-type tissue, gene-edited mutant COL11A1 skin is characterized by induction of beta 1 integrin targets and accelerated neoplastic invasion. In mosaic tissue, mutant COL11A1 cells enhanced invasion by neighboring wild-type cells. These results suggest that specific collagens are commonly mutated in cancer and that mutant collagens may accelerate this process.	[Lee, Carolyn S.; Siprashvili, Zurab; Mah, Angela; Bencomo, Tomas; Elcavage, Lara E.; Che, Yonglu; Shenoy, Rajani M.; Aasi, Sumaira Z.; Khavari, Paul A.] Stanford Univ, Stanford Program Epithelial Biol, Stanford, CA 94305 USA; [Lee, Carolyn S.; Khavari, Paul A.] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA; [Lee, Carolyn S.; Khavari, Paul A.] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA	Stanford University; Stanford Cancer Institute; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Lee, CS; Khavari, PA (corresponding author), Stanford Univ, Stanford Program Epithelial Biol, Stanford, CA 94305 USA.; Lee, CS; Khavari, PA (corresponding author), Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA.; Lee, CS; Khavari, PA (corresponding author), Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA.	carilee@stanford.edu; khavari@stanford.edu		Elcavage, Lara/0000-0003-1457-2109; Bencomo, Tomas/0000-0001-6048-8843; Lee, Carolyn/0000-0002-6511-3757				Annunen S, 1999, AM J HUM GENET, V65, P974, DOI 10.1086/302585; Bak RO, 2018, NAT PROTOC, V13, P358, DOI 10.1038/nprot.2017.143; Bak RO, 2017, ELIFE, V6, DOI 10.7554/eLife.27873.001; Benjamin D S. T., 2019, BIORXIV, DOI [10.1101/861054, DOI 10.1101/861054, 10.1101/861054v1]; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Cathcart J, 2015, GENES DIS, V2, P26, DOI 10.1016/j.gendis.2014.12.002; Chen Y, 2021, CANCER CELL, V39, P548, DOI 10.1016/j.ccell.2021.02.007; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; Chong IW, 2006, ONCOL REP, V16, P981; Cooper J, 2019, CANCER CELL, V35, P347, DOI 10.1016/j.ccell.2019.01.007; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Durinck S, 2011, CANCER DISCOV, V1, P137, DOI 10.1158/2159-8290.CD-11-0028; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Fritsch A, 2009, J BIOL CHEM, V284, P30248, DOI 10.1074/jbc.M109.045294; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Hammami-Hauasli N, 1998, J BIOL CHEM, V273, P19228, DOI 10.1074/jbc.273.30.19228; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; Hida M, 2014, IN VITRO CELL DEV-AN, V50, P358, DOI 10.1007/s11626-013-9692-3; Jameson KL, 2013, NAT MED, V19, P626, DOI 10.1038/nm.3165; Jia DY, 2016, CANCER LETT, V382, P203, DOI 10.1016/j.canlet.2016.09.001; Karia PS, 2013, J AM ACAD DERMATOL, V68, P957, DOI 10.1016/j.jaad.2012.11.037; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim JS, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn566; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; Labun K, 2019, NUCLEIC ACIDS RES, V47, pW171, DOI 10.1093/nar/gkz365; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Lee CS, 2018, J INVEST DERMATOL, V138, P1445, DOI 10.1016/j.jid.2018.01.003; Lee CS, 2014, NAT GENET, V46, P1060, DOI 10.1038/ng.3091; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; MARINKOVICH MP, 1993, DEV DYNAM, V197, P255, DOI 10.1002/aja.1001970404; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; McLean WHI, 2011, HUM MOL GENET, V20, pR189, DOI 10.1093/hmg/ddr379; Pickering CR, 2014, CLIN CANCER RES, V20, P6582, DOI 10.1158/1078-0432.CCR-14-1768; Que SKT, 2018, J AM ACAD DERMATOL, V78, P237, DOI 10.1016/j.jaad.2017.08.059; Raglow Z, 2015, CANCER LETT, V357, P448, DOI 10.1016/j.canlet.2014.12.011; Reuter JA, 2009, CANCER CELL, V15, P477, DOI 10.1016/j.ccr.2009.04.002; Ricard-Blum S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004978; Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339; Ridky TW, 2010, NAT MED, V16, P1450, DOI 10.1038/nm.2265; Rogers HW, 2015, JAMA DERMATOL, V151, P1081, DOI 10.1001/jamadermatol.2015.1187; Shen LH, 2016, ONCOL REP, V36, P877, DOI 10.3892/or.2016.4869; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sorushanova A, 2019, ADV MATER, V31, DOI 10.1002/adma.201801651; South AP, 2014, J INVEST DERMATOL, V134, P2630, DOI 10.1038/jid.2014.154; Stuelten CH, 2018, NAT REV CANCER, V18, P296, DOI 10.1038/nrc.2018.15; Supp DM, 2019, CELL TRANSPLANT, V28, P1242, DOI 10.1177/0963689719857657; Tarpey PS, 2013, NAT GENET, V45, P923, DOI 10.1038/ng.2668; UITTO J, 1994, J INVEST DERMATOL, V103, pS39, DOI 10.1111/1523-1747.ep12398967; Stormo Gary D, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1110s43, 10.1002/0471250953.bi1201s43]; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; Wang NJ, 2011, P NATL ACAD SCI USA, V108, P17761, DOI 10.1073/pnas.1114669108; Wu YH, 2014, ONCOGENE, V33, P3432, DOI 10.1038/onc.2013.307; Zhang JY, 2007, CANCER RES, V67, P3827, DOI 10.1158/0008-5472.CAN-06-4017	55	5	5	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6299	6307		10.1038/s41388-021-02013-y	http://dx.doi.org/10.1038/s41388-021-02013-y		SEP 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34584216	Green Published, hybrid			2022-12-28	WOS:000701638300001
J	Maiques-Diaz, A; Nicosia, L; Basma, NJ; Romero-Camarero, I; Camera, F; Spencer, GJ; Amaral, FMR; Simeoni, F; Wingelhofer, B; Williamson, AJK; Pierce, A; Whetton, AD; Somervaille, TCP				Maiques-Diaz, Alba; Nicosia, Luciano; Basma, Naseer J.; Romero-Camarero, Isabel; Camera, Francesco; Spencer, Gary J.; Amaral, Fabio M. R.; Simeoni, Fabrizio; Wingelhofer, Bettina; Williamson, Andrew J. K.; Pierce, Andrew; Whetton, Anthony D.; Somervaille, Tim C. P.			HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block	ONCOGENE			English	Article							TRANS-RETINOIC ACID; SNAG DOMAIN; DEMETHYLASE; INHIBITION; COREST; DEACETYLASE; COMPLEX; MLL; PROLIFERATION; NEUTROPENIA	Pharmacologic inhibition of LSD1 induces molecular and morphologic differentiation of blast cells in acute myeloid leukemia (AML) patients harboring MLL gene translocations. In addition to its demethylase activity, LSD1 has a critical scaffolding function at genomic sites occupied by the SNAG domain transcription repressor GFI1. Importantly, inhibitors block both enzymatic and scaffolding activities, in the latter case by disrupting the protein:protein interaction of GFI1 with LSD1. To explore the wider consequences of LSD1 inhibition on the LSD1 protein complex we applied mass spectrometry technologies. We discovered that the interaction of the HMG-box protein HMG20B with LSD1 was also disrupted by LSD1 inhibition. Downstream investigations revealed that HMG20B is co-located on chromatin with GFI1 and LSD1 genome-wide; the strongest HMG20B binding co-locates with the strongest GFI1 and LSD1 binding. Functional assays demonstrated that HMG20B depletion induces leukemia cell differentiation and further revealed that HMG20B is required for the transcription repressor activity of GFI1 through stabilizing LSD1 on chromatin at GFI1 binding sites. Interaction of HMG20B with LSD1 is through its coiled-coil domain. Thus, HMG20B is a critical component of the GFI1:LSD1 transcription repressor complex which contributes to leukemia cell differentiation block.	[Maiques-Diaz, Alba; Nicosia, Luciano; Basma, Naseer J.; Romero-Camarero, Isabel; Camera, Francesco; Spencer, Gary J.; Amaral, Fabio M. R.; Simeoni, Fabrizio; Wingelhofer, Bettina; Somervaille, Tim C. P.] Univ Manchester, Canc Res UK Manchester Inst, Leukaemia Biol Lab, Manchester Canc Res Ctr Bldg,555 Wilmslow Rd, Manchester M20 4GJ, Lancs, England; [Williamson, Andrew J. K.; Pierce, Andrew; Whetton, Anthony D.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Wolfson Mol Imaging Ctr, Stem Cell & Leukaemia Prote Lab, 27 Palatine Rd, Manchester M20 3LJ, Lancs, England; [Pierce, Andrew] Fron Heulog Bangor Univ, Coll Human Sci, Sch Med & Hlth Sci, Bangor LL57 2TH, Gwynedd, Wales; [Whetton, Anthony D.] Univ Surrey, Sch Vet Med, VSM Bldg, Guildford GU2 7AL, Surrey, England; [Whetton, Anthony D.] Univ Surrey, Sch Biosci & Med, VSM Bldg, Guildford GU2 7AL, Surrey, England	Cancer Research UK; University of Manchester; University of Manchester; University of Surrey; University of Surrey	Somervaille, TCP (corresponding author), Univ Manchester, Canc Res UK Manchester Inst, Leukaemia Biol Lab, Manchester Canc Res Ctr Bldg,555 Wilmslow Rd, Manchester M20 4GJ, Lancs, England.	tim.somervaille@cruk.manchester.ac.uk		Nicosia, Luciano/0000-0003-3016-931X; Romero-Camarero, Isabel/0000-0002-2859-7641; Simeoni, Fabrizio/0000-0002-5543-6413; Maiques-Diaz, Alba/0000-0002-3365-3775	Cancer Research UK [C5759/A20971, C5759/A27412]; Kay Kendall Leukaemia Fund Junior Research Fellowship [KKL1185]; Blood Cancer UK [13005, 19007]; Imago Biosciences; Leukaemia UK [2020/JGF/005]	Cancer Research UK(Cancer Research UK); Kay Kendall Leukaemia Fund Junior Research Fellowship; Blood Cancer UK; Imago Biosciences; Leukaemia UK	This work was supported by Cancer Research UK grant numbers C5759/A20971 and C5759/A27412 (AM-D, LN, FC, IR-C, GJS, BW, FMRA, FS, TCPS); a Kay Kendall Leukaemia Fund Junior Research Fellowship (KKL1185) (to IR-C); Blood Cancer UK grant numbers 13005 and 19007 (to AP, AJKW, ADW); an educational grant from Imago Biosciences (to NJB); and Leukaemia UK grant number 2020/JGF/005 (to BW). We are grateful to Jeff Barry, Wolfgang Breitwieser, Gillian Newton, Duncan Smith, John Weightman for technical support; and to Andrew Porter for pre-submission review of the manuscript. Cancer Research UK grant numbers C5759/A20971 and C5759/A27412; Kay Kendall Leukaemia Fund Junior Research Fellowship KKL1185; Blood Cancer UK grant numbers 13005 and 19007; Leukaemia UK grant number 2020/JGF/005.	Barth J, 2019, LEUKEMIA, V33, P1411, DOI 10.1038/s41375-018-0375-7; Carmichael CL, 2020, BLOOD, V136, P957, DOI 10.1182/blood.2019002548; Deb G, 2020, LEUKEMIA, V34, P1266, DOI 10.1038/s41375-019-0659-6; Esteghamat F, 2011, HAEMATOL-HEMATOL J, V96, P1252, DOI 10.3324/haematol.2011.045211; Fiskus W, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00487-3; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Ishikawa Y, 2017, MOL CANCER THER, V16, P273, DOI 10.1158/1535-7163.MCT-16-0471; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; Lee C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08269-5; Leiendecker L, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012525; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Maiques-Diaz A, 2018, CELL REP, V22, P3641, DOI 10.1016/j.celrep.2018.03.012; Maiques-Diaz A, 2016, EPIGENOMICS-UK, V8, P1103, DOI 10.2217/epi-2016-0009; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Marneth AE, 2018, HAEMATOLOGICA, V103, pE395, DOI 10.3324/haematol.2017.180844; McClellan D, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00020-19; McGrath JP, 2016, CANCER RES, V76, P1975, DOI 10.1158/0008-5472.CAN-15-2333; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Moroy T, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00824; Nicosia L, 2022, ONCOGENE, V41, P878, DOI 10.1038/s41388-021-02123-7; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Pettit K, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123244; Ravasio R, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax2746; Rivero S, 2015, ONCOGENE, V34, P5264, DOI 10.1038/onc.2014.446; Salamero O, 2020, J CLIN ONCOL, V38, P4260, DOI 10.1200/JCO.19.03250; Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Song Y, 2020, CELL REP, V30, P2699, DOI 10.1016/j.celrep.2020.01.091; Sumoy L, 2000, CYTOGENET CELL GENET, V88, P62, DOI 10.1159/000015486; Takagi S, 2017, CANCER RES, V77, P4652, DOI 10.1158/0008-5472.CAN-16-3502; Tayari MM, 2021, CLIN CANCER RES, V27, P1893, DOI 10.1158/1078-0432.CCR-20-4054; van Bergen MGJM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01027; Wass M, 2021, LEUKEMIA, V35, P701, DOI 10.1038/s41375-020-0892-z; Welcker JE, 2013, DEVELOPMENT, V140, P4947, DOI 10.1242/dev.097642; Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805; Wynder C, 2005, NAT CELL BIOL, V7, P1113, DOI 10.1038/ncb1312; Yamamoto Ryusuke, 2018, Oncotarget, V9, P21007, DOI 10.18632/oncotarget.24774; Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	47	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4841	4854		10.1038/s41388-022-02471-y	http://dx.doi.org/10.1038/s41388-022-02471-y		SEP 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36171271	hybrid, Green Published			2022-12-28	WOS:000861196200001
J	Komatsu, M; Ichikawa, H; Chiwaki, F; Sakamoto, H; Komatsuzaki, R; Asaumi, M; Tsunoyama, K; Fukagawa, T; Matsushita, H; Boku, N; Matsusaki, K; Takeshita, F; Yoshida, T; Sasaki, H				Komatsu, Masayuki; Ichikawa, Hitoshi; Chiwaki, Fumiko; Sakamoto, Hiromi; Komatsuzaki, Rie; Asaumi, Makoto; Tsunoyama, Kazuhisa; Fukagawa, Takeo; Matsushita, Hiromichi; Boku, Narikazu; Matsusaki, Keisuke; Takeshita, Fumitaka; Yoshida, Teruhiko; Sasaki, Hiroki			ARHGAP-RhoA signaling provokes homotypic adhesion-triggered cell death of metastasized diffuse-type gastric cancer	ONCOGENE			English	Article							LIQUID-CHROMATOGRAPHY; STEM-CELLS; PROTEOMICS; MUTATIONS; CARCINOMA; SURVIVAL; ENTOSIS; ROLES; GAIN	Genetic alteration of Rho GTPase-activating proteins (ARHGAP) and GTPase RhoA is a hallmark of diffuse-type gastric cancer and elucidating its biological significance is critical to comprehensively understanding this malignancy. Here, we report that gene fusions of ARHGAP6/ARHGAP26 are frequent genetic events in peritoneally-metastasized gastric and pancreatic cancer. From the malignant ascites of patients, we established gastric cancer cell lines that spontaneously gain hotspot RHOA mutations or four different ARHGAP6/ARHGAP26 fusions. These alterations critically downregulate RhoA-ROCK-MLC2 signaling, which elicits cell death. Omics and functional analyses revealed that the downstream signaling initiates actin stress fibers and reinforces intercellular junctions via several types of catenin. E-cadherin-centered homotypic adhesion followed by lysosomal membrane permeabilization is a pivotal mechanism in cell death. These findings support the tumor-suppressive nature of ARHGAP-RhoA signaling and might indicate a new avenue of drug discovery against this refractory cancer.	[Komatsu, Masayuki; Chiwaki, Fumiko; Takeshita, Fumitaka; Sasaki, Hiroki] Natl Canc Ctr, Dept Translat Oncol, Res Inst, Tokyo, Japan; [Ichikawa, Hitoshi; Sakamoto, Hiromi] Natl Canc Ctr, Dept Clin Genom, Tokyo, Japan; [Komatsuzaki, Rie] Natl Canc Ctr, Div Canc Therapeut, Tokyo, Japan; [Asaumi, Makoto; Tsunoyama, Kazuhisa] Astellas Pharma Inc, Adv Informat & Analyt, Ibaraki, Japan; [Fukagawa, Takeo] Teikyo Univ, Dept Surg, Sch Med, Tokyo, Japan; [Matsushita, Hiromichi] Natl Canc Ctr, Dept Lab Med, Tokyo, Japan; [Boku, Narikazu] Natl Canc Ctr, Div Gastrointestinal Med Oncol, Tokyo, Japan; [Matsusaki, Keisuke] Kanamecho Hosp, Ascites Treatment Ctr, Tokyo, Japan; [Yoshida, Teruhiko] Natl Canc Ctr, Genet Med & Serv, Tokyo, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Astellas Pharmaceuticals; Teikyo University; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan	Komatsu, M; Sasaki, H (corresponding author), Natl Canc Ctr, Dept Translat Oncol, Res Inst, Tokyo, Japan.	makomats@ncc.go.jp; hksasaki@ncc.go.jp		Komatsu, Masayuki/0000-0003-1180-1746; Chiwaki, Fumiko/0000-0002-0914-9157; Ichikawa, Hitoshi/0000-0003-0142-2240; Boku, Narikazu/0000-0002-1438-707X	National Institute of Biomedical Innovation [ID10-41]; National Cancer Center Research and Development Fund [28-A-11, 29-A-2, 2020-J-2]; AMED (Japan Agency for Medical Research and Development) [JP20ck0106519]; Astellas Pharma, Inc [CH27066]	National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); National Cancer Center Research and Development Fund(National Cancer Center - Japan); AMED (Japan Agency for Medical Research and Development)(Japan Agency for Medical Research and Development (AMED)); Astellas Pharma, Inc(Astellas Pharmaceuticals)	This research was supported by the National Institute of Biomedical Innovation (Program ID10-41), by the National Cancer Center Research and Development Fund (28-A-11, 29-A-2, and 2020-J-2), by AMED (Japan Agency for Medical Research and Development, JP20ck0106519), and by Astellas Pharma, Inc (CH27066). We thank H. Nikki March, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.	Abe Y, 2020, THERANOSTICS, V10, P2115, DOI 10.7150/thno.37623; Alduaij W, 2011, BLOOD, V117, P4519, DOI 10.1182/blood-2010-07-296913; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bros M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070733; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Chiba H, 2008, BBA-BIOMEMBRANES, V1778, P588, DOI 10.1016/j.bbamem.2007.08.017; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; DUARTE I, 1981, HUM PATHOL, V12, P237, DOI 10.1016/S0046-8177(81)80124-4; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Fukagawa T, 2010, WORLD J SURG, V34, P563, DOI 10.1007/s00268-009-0355-1; Hamann JC, 2017, CELL REP, V20, P201, DOI 10.1016/j.celrep.2017.06.037; Han MKL, 2017, NAT CELL BIOL, V19, P14, DOI 10.1038/ncb3457; Hodge RG, 2020, CRIT REV BIOCHEM MOL, V55, P386, DOI 10.1080/10409238.2020.1810622; Ivanov A, 2009, J CLIN INVEST, V119, P2143, DOI 10.1172/JCI37884; Japanese Gastric Cancer Association Registration Committee, 2006, Gastric Cancer, V9, P51; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kumeta M, 2018, GENES CELLS, V23, P715, DOI 10.1111/gtc.12603; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Leverrier Y, 2001, NAT CELL BIOL, V3, pE91, DOI 10.1038/35070151; Loh CY, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101118; Lu M, 2014, MOL CELL, V54, P987, DOI 10.1016/j.molcel.2014.04.029; Ma Z, 2007, J CELL BIOL, V179, P23, DOI 10.1083/jcb.200706097; MacDonald Justin A., 2018, Cardiovascular & Hematological Disorders - Drug Targets, V18, P4, DOI 10.2174/1871529X18666180326120638; Maeda M, 2016, GASTRIC CANCER, V19, P326, DOI 10.1007/s10120-015-0525-9; Mendonsa AM, 2018, ONCOGENE, V37, P4769, DOI 10.1038/s41388-018-0304-2; Mimori K, 2008, CLIN CANCER RES, V14, P2609, DOI 10.1158/1078-0432.CCR-07-4354; Nakayama I, 2019, CANCER SCI, V110, P1352, DOI 10.1111/cas.13967; Negishi A, 2009, CANCER SCI, V100, P514, DOI 10.1111/j.1349-7006.2008.01055.x; Ono M, 2006, MOL CELL PROTEOMICS, V5, P1338, DOI 10.1074/mcp.T500039-MCP200; Petrova YI, 2016, MOL BIOL CELL, V27, P3233, DOI 10.1091/mbc.E16-01-0058; Polkowski W, 1999, ANN SURG ONCOL, V6, P290, DOI 10.1007/s10434-999-0290-2; Qiu MZ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-58; Ratheesh A, 2012, NAT REV MOL CELL BIO, V13, P673, DOI 10.1038/nrm3431; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Shim HJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66637-y; Shu Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04907-0; Song HN, 2016, J THORAC ONCOL, V11, pE45, DOI 10.1016/j.jtho.2015.12.093; Sun Q, 2014, CELL RES, V24, P1288, DOI 10.1038/cr.2014.137; Svensmark JH, 2019, ONCOGENE, V38, P7447, DOI 10.1038/s41388-019-0963-7; Tanaka Atsushi, 2018, Oncotarget, V9, P29336, DOI 10.18632/oncotarget.25464; Tanaka Y, 2021, NAT CANCER, V2, P962, DOI 10.1038/s43018-021-00240-6; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; Ushiku T, 2016, GASTRIC CANCER, V19, P403, DOI 10.1007/s10120-015-0493-0; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310; Xu XF, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0847-5; Yang H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06747-4; Yang HHN, 2018, CELL STEM CELL, V23, P882, DOI 10.1016/j.stem.2018.09.016; Yao F, 2015, CELL REP, V12, P272, DOI 10.1016/j.celrep.2015.06.020; Zhang HS, 2020, CANCER DISCOV, V10, P288, DOI 10.1158/2159-8290.CD-19-0811; Zhang WH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01214; Zheng HC, 2008, VIRCHOWS ARCH, V452, P525, DOI 10.1007/s00428-007-0572-7	58	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2022	41	43					4779	4794		10.1038/s41388-022-02469-6	http://dx.doi.org/10.1038/s41388-022-02469-6		SEP 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M4RI	36127398				2022-12-28	WOS:000855639800002
J	Shen, XJ; Kong, S; Ma, S; Shen, L; Zheng, M; Qin, SY; Qi, J; Wang, QH; Cui, XP; Ju, SQ				Shen, Xianjuan; Kong, Shan; Ma, Shuo; Shen, Lei; Zheng, Ming; Qin, Shiyi; Qi, Jing; Wang, Qiuhong; Cui, Xiaopeng; Ju, Shaoqing			Hsa_circ_0000437 promotes pathogenesis of gastric cancer and lymph node metastasis	ONCOGENE			English	Article							SRSF3 REPRESSES; CIRCULAR RNA; BIOMARKER; PROTEIN; CELLS	Cellular communication between gastric cancer (GC) cells with different metastatic potentials and microenvironments and resultant cancer progression is not fully understood. Circular RNAs (circRNAs) and exosomal circRNAs are known to play extremely important regulatory roles in GC occurrence and progression. Here, we revealed significant differences in coronin-like actin-binding protein 1C (CORO1C) derived circRNA hsa_circ_0000437 between GC and para-cancer tissues. Hsa_circ_0000437 regulated GC cell proliferation, invasion, migration and apoptosis by targeting Ser/Arg-rich splicing factor 3 (SRSF3) and inhibiting programmed cell death 4 (PDCD4). The ectopic expression of hsa_circ_0000437 dramatically promoted tumor growth in nude mice in vivo. Furthermore, both gain-of-function and loss-of-function experiments demonstrated that hsa_circ_0000437 promoted human lymphatic endothelial cells (HLECs) invasion, migration, and tube formation in vitro and also promoted lymphangiogenesis and lymph node metastasis (LNM) in popliteal LNM model in vivo, when it was enriched in GC-secreted exosomes and transferred into HLECs. Mechanistically, exosomal hsa_circ_0000437 induced LNM via HSPA2-ERK signaling pathway independent of VEGF-C. Clinical data showed that exosomal hsa_circ_0000437 was enriched in the serum of GC patients, which was associated with LNM. In summary, these findings highlight the potential role of hsa_circ_0000437 as an outcome biomarker in GC patients with LNM, which may provide a novel target for GC therapy.	[Shen, Xianjuan; Kong, Shan; Ma, Shuo; Shen, Lei; Zheng, Ming; Qin, Shiyi; Ju, Shaoqing] Nantong Univ, Lab Med Ctr, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China; [Shen, Xianjuan; Qi, Jing] Nantong Univ, Res Ctr Clin Med, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China; [Wang, Qiuhong] Nantong Univ, Dept Clin Lab, Nantong Maternal & Child Hlth Care Hosp, Nantong 226018, Jiangsu, Peoples R China; [Cui, Xiaopeng] Nantong Univ, Dept Gen Surg, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China	Nantong University; Nantong University; Nantong University; Nantong University	Ju, SQ (corresponding author), Nantong Univ, Lab Med Ctr, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.; Cui, XP (corresponding author), Nantong Univ, Dept Gen Surg, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.	cuixiaopeng2000@163.com; jsq814@hotmail.com			National Natural Science Foundation of China [81871720, 82072363]; Nantong Science and Technology Project [MS12021002]; Nantong Commission of Health [MB2021061]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Nantong Science and Technology Project; Nantong Commission of Health	This work was supported by the National Natural Science Foundation of China (Nos. 81871720, 82072363), Nantong Science and Technology Project (MS12021002). The project of Nantong Commission of Health (MB2021061).	Cao LX, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.10.16; Cao YZ, 2021, GENE, V767, DOI 10.1016/j.gene.2020.145182; Chai PW, 2018, NUCLEIC ACIDS RES, V46, P6041, DOI 10.1093/nar/gky366; Chen LL, 2020, NAT REV MOL CELL BIO, V21, P475, DOI 10.1038/s41580-020-0243-y; Cheng X, 2019, FEBS OPEN BIO, V9, P1097, DOI 10.1002/2211-5463.12639; Deng Y, 2015, ARTERIOSCL THROM VAS, V35, P421, DOI 10.1161/ATVBAHA.114.304881; Feng W, 2019, CLIN CHIM ACTA, V496, P125, DOI 10.1016/j.cca.2019.07.003; Guo X, 2021, CLIN TRANSL ONCOL, V23, P1020, DOI 10.1007/s12094-020-02485-6; Huang AQ, 2020, THERANOSTICS, V10, P3503, DOI 10.7150/thno.42174; Huang XX, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0969-3; Ishii M, 2019, MOL CELL BIOCHEM, V455, P185, DOI 10.1007/s11010-018-3481-y; Jung HY, 2015, CLIN CANCER RES, V21, P962, DOI 10.1158/1078-0432.CCR-13-3173; Ke H, 2018, P NATL ACAD SCI USA, V115, pE3426, DOI 10.1073/pnas.1714573115; Kim J, 2014, CELL DEATH DIFFER, V21, P481, DOI 10.1038/cdd.2013.171; Kok VC, 2020, INT J NANOMED, V15, P8019, DOI 10.2147/IJN.S272378; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Kuranaga Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103012; Lei B, 2019, INT J MED SCI, V16, P292, DOI 10.7150/ijms.28047; Lei M, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1135-7; Liang YK, 2021, MOL THER-NUCL ACIDS, V23, P355, DOI 10.1016/j.omtn.2020.11.012; Lim JP, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3187-7; Liu LP, 2015, GUT, V64, P26, DOI 10.1136/gutjnl-2013-306388; Liu Y, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01358-w; Ma S, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04158-w; Ma S, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-020-01701-1; Maeng YS, 2016, ONCOGENE, V35, P196, DOI 10.1038/onc.2015.73; Mu GC, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1098-6; Park SK, 2016, BIOCHEM BIOPH RES CO, V470, P431, DOI 10.1016/j.bbrc.2016.01.019; Rong DW, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0958-6; Schwager S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00308; Shi XF, 2020, MOL THER-NUCL ACIDS, V19, P384, DOI 10.1016/j.omtn.2019.11.023; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Song X, 2019, CANCER RES, V79, P5288, DOI 10.1158/0008-5472.CAN-19-1504; Wang G, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01964-2; Wang M, 2020, MOL THER-NUCL ACIDS, V21, P367, DOI 10.1016/j.omtn.2020.06.008; Wang ZX, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.682594; Wu P, 2021, HISTOL HISTOPATHOL, V36, P447, DOI 10.14670/HH-18-305; Wu YY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01215-4; Xu LF, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9612425; Zang JK, 2020, J NEUROSCI RES, V98, P87, DOI 10.1002/jnr.24356; Zhang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1015-1; Zhang QG, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1125-9; Zhu YJ, 2019, THERANOSTICS, V9, P3526, DOI 10.7150/thno.32796; Zhu YX, 2020, ONCOGENE, V39, P6071, DOI 10.1038/s41388-020-01421-w	44	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4724	4735		10.1038/s41388-022-02449-w	http://dx.doi.org/10.1038/s41388-022-02449-w		SEP 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36109630				2022-12-28	WOS:000854052400002
J	Boisteau, E; Posseme, C; Di Modugno, F; Edeline, J; Coulouarn, C; Hrstka, R; Martisova, A; Delom, F; Treton, X; Eriksson, LA; Chevet, E; Lievre, A; Ogier-Denis, E				Boisteau, Emeric; Posseme, Celine; Di Modugno, Federico; Edeline, Julien; Coulouarn, Cedric; Hrstka, Roman; Martisova, Andrea; Delom, Frederic; Treton, Xavier; Eriksson, Leif A.; Chevet, Eric; Lievre, Astrid; Ogier-Denis, Eric			Anterior gradient proteins in gastrointestinal cancers: from cell biology to pathophysiology	ONCOGENE			English	Review							ADENOCARCINOMA-ASSOCIATED GENE; DISULFIDE-ISOMERASE; COLORECTAL-CANCER; PANCREATIC-CANCER; DIFFERENTIAL EXPRESSION; THIOREDOXIN SUPERFAMILY; PROGNOSTIC-FACTOR; GASTRIC-CANCER; PDI FAMILY; AGR2 GENE	Most of the organs of the digestive tract comprise secretory epithelia that require specialized molecular machines to achieve their functions. As such anterior gradient (AGR) proteins, which comprise AGR1, AGR2, and AGR3, belong to the protein disulfide isomerase family, and are involved in secretory and transmembrane protein biogenesis in the endoplasmic reticulum. They are generally expressed in epithelial cells with high levels in most of the digestive tract epithelia. To date, the vast majority of the reports concern AGR2, which has been shown to exhibit various subcellular localizations and exert pro-oncogenic functions. AGR2 overexpression has recently been associated with a poor prognosis in digestive cancers. AGR2 is also involved in epithelial homeostasis. Its deletion in mice results in severe diffuse gut inflammation, whereas in inflammatory bowel diseases, the secretion of AGR2 in the extracellular milieu participates in the reshaping of the cellular microenvironment. AGR2 thus plays a key role in inflammation and oncogenesis and may represent a therapeutic target of interest. In this review, we summarize the already known roles and mechanisms of action of the AGR family proteins in digestive diseases, their expression in the healthy digestive tract, and in digestive oncology. At last, we discuss the potential diagnostic and therapeutic implications underlying the biology of AGR proteins.	[Boisteau, Emeric; Posseme, Celine; Di Modugno, Federico; Edeline, Julien; Coulouarn, Cedric; Chevet, Eric; Lievre, Astrid; Ogier-Denis, Eric] Univ Rennes, INSERM U1242, Rennes, France; [Boisteau, Emeric; Lievre, Astrid] Univ Rennes, Univ Hosp Pontchaillou, Dept Gastroenterol, Rennes, France; [Posseme, Celine; Di Modugno, Federico; Edeline, Julien; Chevet, Eric; Ogier-Denis, Eric] Ctr Lutte Canc Eugene Marquis, Rennes, France; [Hrstka, Roman; Martisova, Andrea] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, Brno, Czech Republic; [Martisova, Andrea] Masaryk Univ, Fac Sci, Natl Ctr Biomol Res, Brno, Czech Republic; [Delom, Frederic] Univ Bordeaux, INSERM U1312, Bordeaux, France; [Treton, Xavier] Univ Paris, AP HP, Clichy, France; [Eriksson, Leif A.] Univ Gothenburg, Dept Chem & Mol Biol, Gothenburg, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; CHU Rennes; Universite de Rennes; UNICANCER; Centre Eugene Marquis; Masaryk Memorial Cancer Institute; Masaryk University Brno; UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Gothenburg	Chevet, E; Lievre, A; Ogier-Denis, E (corresponding author), Univ Rennes, INSERM U1242, Rennes, France.; Lievre, A (corresponding author), Univ Rennes, Univ Hosp Pontchaillou, Dept Gastroenterol, Rennes, France.; Chevet, E; Ogier-Denis, E (corresponding author), Ctr Lutte Canc Eugene Marquis, Rennes, France.	eric.chevet@inserm.fr; astrid.lievre@chu-rennes.fr; eric.ogier-denis@inserm.fr	Edeline, Julien/F-6852-2013	Edeline, Julien/0000-0002-8289-7741; Eriksson, Leif A./0000-0001-5654-3109; Di Modugno, Federico/0000-0001-8201-7997; Martisova, Andrea/0000-0002-0081-0498	INCa [PRT-K20-136]; INCa (PLBIO); La Ligue Contre le Cancer Gironde; Site de recherche integree sur le cancer de Bordeaux (SIRIC Brio); Swedish research council [2019-3684]; Swedish Cancer Foundation [21-1447 Pj]; ministry of health	INCa(Institut National du Cancer (INCA) France); INCa (PLBIO); La Ligue Contre le Cancer Gironde; Site de recherche integree sur le cancer de Bordeaux (SIRIC Brio); Swedish research council(Swedish Research CouncilEuropean Commission); Swedish Cancer Foundation; ministry of health	We thank the Immuno-histopathology platform H2P2 for their expertise and work (https://histopathologie.univ-rennes1.fr/) and Raphael Pineau for his technical help. This work was funded by grants from INCa (PRT-K20-136) to CC and JE, INCa (PLBIO) to EC, La Ligue Contre le Cancer to EO-D and AL and from La Ligue Contre le Cancer Gironde and from the Site de recherche integree sur le cancer de Bordeaux (SIRIC Brio) to FD. LAE acknowledges funding from the Swedish research council (grant no 2019-3684) and the Swedish Cancer Foundation (grant no 21-1447 Pj). EB was funded by an "annee-recherche" grant from the ministry of health.	Aberger F, 1998, MECH DEVELOP, V72, P115, DOI 10.1016/S0925-4773(98)00021-5; Adam PJ, 2003, J BIOL CHEM, V278, P6482, DOI 10.1074/jbc.M210184200; Al-Shaibi AA, 2021, CELL MOL GASTROENTER, V12, P1809, DOI 10.1016/j.jcmgh.2021.07.001; Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; [Anonymous], 2020, CBIOPORTAL CANC GEN; Arshavsky-Graham Sofia, 2021, ACS Meas Sci Au, V1, P82, DOI 10.1021/acsmeasuresciau.1c00019; Arumugam T, 2015, MOL CANCER THER, V14, P941, DOI 10.1158/1535-7163.MCT-14-0470; Bai ZG, 2011, INT J ONCOL, V38, P375, DOI 10.3892/ijo.2010.873; Barraclough DL, 2009, AM J PATHOL, V175, P1848, DOI 10.2353/ajpath.2009.090246; Bergstrom JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104186; Bialobrzeska W, 2021, BIOSENSORS-BASEL, V11, DOI 10.3390/bios11060184; Bonser LR, 2015, AM J RESP CELL MOL, V53, P536, DOI 10.1165/rcmb.2014-0318OC; Bouchalova P, 2022, MOL CELL PROTEOMICS, V21, DOI 10.1016/j.mcpro.2021.100188; Bradley L, 1996, DEVELOPMENT, V122, P2739; Brychtova V, 2014, EXP MOL PATHOL, V96, P375, DOI 10.1016/j.yexmp.2014.04.002; Brychtova V, 2014, PANCREAS, V43, P75, DOI 10.1097/MPA.0b013e3182a63bc3; cbioportal, CBIOPORTAL CANC GENO; Cernocka H, 2021, BIOELECTROCHEMISTRY, V140, DOI 10.1016/j.bioelechem.2021.107808; Chen SY, 2017, ONCOTARGET, V8, P41690, DOI 10.18632/oncotarget.16677; Chevet E, 2013, ONCOGENE, V32, P2499, DOI 10.1038/onc.2012.346; Chi JY, 2020, CELL SIGNAL, V65, DOI 10.1016/j.cellsig.2019.109419; Clarke DJ, 2016, BBA-PROTEINS PROTEOM, V1864, P551, DOI 10.1016/j.bbapap.2016.02.011; Delom F, 2020, AM J PHYSIOL-CELL PH, V318, pC40, DOI 10.1152/ajpcell.00532.2018; depmap, DEPMAP DAT EXPL; DiMaio MA, 2012, HUM PATHOL, V43, P1799, DOI 10.1016/j.humpath.2012.03.019; Dong AW, 2011, J BIOL CHEM, V286, P18301, DOI 10.1074/jbc.M110.215707; Dumartin L, 2017, ONCOGENE, V36, P3094, DOI 10.1038/onc.2016.459; Dumartin L, 2011, CANCER RES, V71, P7091, DOI 10.1158/0008-5472.CAN-11-1367; Fessart D, 2021, BIORXIV, DOI [10.1101/2021.09.07.459258v1, DOI 10.1101/2021.09.07.459258V1]; Fessart D, 2022, OPEN BIOL, V12, DOI DOI 10.1098/RSOB.220068; Fessart D, 2016, ELIFE, V5, DOI 10.7554/eLife.13887; Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740; Fomenko DE, 2002, PROTEIN SCI, V11, P2285, DOI 10.1110/ps.0218302; Camarillo GF, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/9238970; Gray TA, 2014, MOL BIOSYST, V10, P1409, DOI 10.1039/c4mb00113c; Gray TA, 2012, J IMMUNOL METHODS, V378, P20, DOI 10.1016/j.jim.2012.01.013; Guo H, 2017, ONCOGENE, V36, P5098, DOI 10.1038/onc.2017.132; Guo H, 2016, BIOCHEM BIOPH RES CO, V475, P57, DOI 10.1016/j.bbrc.2016.05.033; Gupta A, 2013, J BIOL CHEM, V288, P4321, DOI 10.1074/jbc.M112.433086; Gupta A, 2012, J BIOL CHEM, V287, P4773, DOI 10.1074/jbc.M111.301531; Hatahet F, 2009, ANTIOXID REDOX SIGN, V11, P2807, DOI [10.1089/ars.2009.2466, 10.1089/ARS.2009.2466]; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Honore B, 2000, FEBS LETT, V466, P11, DOI 10.1016/S0014-5793(99)01780-9; Hrstka R, 2016, MOL ONCOL, V10, P652, DOI 10.1016/j.molonc.2015.12.003; Ivanova AS, 2015, SCI REP-UK, V5, DOI 10.1038/srep08123; Ivanova AS, 2013, SCI REP-UK, V3, DOI 10.1038/srep01279; Jach D, 2021, AM J CANCER RES, V11, P5249; Jeon Y, 2022, HEPATOLOGY, DOI 10.1002/hep.32397; Jeong W, 2008, J BIOL CHEM, V283, P25557, DOI 10.1074/jbc.M803804200; Jess T, 2013, CLIN GASTROENTEROL H, V11, P43, DOI 10.1016/j.cgh.2012.09.026; Jessop CE, 2009, J CELL SCI, V122, P4287, DOI 10.1242/jcs.059154; Jia MQ, 2018, BBA-MOL BASIS DIS, V1864, P1622, DOI 10.1016/j.bbadis.2018.01.021; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Kim HS, 2011, ONCOL REP, V25, P717, DOI 10.3892/or.2010.1126; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; Kozlov G, 2010, FEBS J, V277, P3924, DOI 10.1111/j.1742-4658.2010.07793.x; Lamichane BD, 2019, BIOCHEM BIOPH RES CO, V515, P600, DOI 10.1016/j.bbrc.2019.05.154; Lee DH, 2011, MOL CELLS, V31, P563, DOI 10.1007/s10059-011-1053-z; Lee HJ, 2012, EXP MOL MED, V44, P60, DOI 10.3858/emm.2012.44.1.006; Lemaire SD, 2004, PHOTOSYNTH RES, V82, P203, DOI 10.1007/s11120-004-1091-x; Lepreux S, 2011, LIVER INT, V31, P322, DOI 10.1111/j.1478-3231.2010.02438.x; Li J, 2019, EXP CELL RES, V385, DOI 10.1016/j.yexcr.2019.111644; Liu ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103910; Ma SR, 2015, ONCOTARGET, V6, P8807, DOI 10.18632/oncotarget.3556; Maattanen P, 2010, SEMIN CELL DEV BIOL, V21, P500, DOI 10.1016/j.semcdb.2010.03.006; Makawita S, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-404; Maslon MM, 2010, J MOL BIOL, V404, P418, DOI 10.1016/j.jmb.2010.09.035; Matsuo Y, 2022, ANTIOXID REDOX SIGN, V36, P984, DOI 10.1089/ars.2021.0187; Matsusaki M, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2019.04.003; Maurel M, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810120; microvesicles, VESICLEPEDIA GENE SU; Mizuuchi Y, 2015, LAB INVEST, V95, P193, DOI 10.1038/labinvest.2014.138; Mohtar MA, 2018, MOL CELL PROTEOMICS, V17, P737, DOI 10.1074/mcp.RA118.000573; Moidu NA, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05000; Nancarrow DJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022513; ncbi, CALU CALUMENIN HOMO; ncbi, RCN1 RET 1; Negi H, 2019, CANCER LETT, V449, P125, DOI 10.1016/j.canlet.2019.01.025; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Norris AM, 2013, ONCOGENE, V32, P3867, DOI 10.1038/onc.2012.394; Obacz J, 2015, EUR J CELL BIOL, V94, P139, DOI 10.1016/j.ejcb.2015.01.002; Oka OBV, 2019, EMBO J, V38, DOI 10.15252/embj.2018100990; Oka OBV, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2122657119; Olen O, 2020, LANCET GASTROENTEROL, V5, P475, DOI 10.1016/S2468-1253(20)30005-4; Park SW, 2009, P NATL ACAD SCI USA, V106, P6950, DOI 10.1073/pnas.0808722106; Patel P, 2013, J MOL BIOL, V425, P929, DOI 10.1016/j.jmb.2012.12.009; Pelaseyed T, 2014, IMMUNOL REV, V260, P8, DOI 10.1111/imr.12182; Petek E, 2000, CYTOGENET CELL GENET, V89, P141, DOI 10.1159/000015594; Pizzi M, 2012, HUM PATHOL, V43, P1839, DOI 10.1016/j.humpath.2012.01.004; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; proteinatlas, AGR3 PROTEIN EXPRESS; proteinatlas, AGR2 PROT EXPR SUMM; proteinatlas, TXNDC12 PROTEIN EXPR; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; Raykhel I, 2007, J CELL BIOL, V179, P1193, DOI 10.1083/jcb.200705180; Riener MO, 2014, EUR J CANCER, V50, P1722, DOI 10.1016/j.ejca.2014.04.012; Riener MO, 2009, HISTOL HISTOPATHOL, V24, P1121, DOI 10.14670/HH-24.1121; Schroeder BW, 2012, AM J RESP CELL MOL, V47, P178, DOI 10.1165/rcmb.2011-0421OC; Shih LJ, 2007, GENE EXPR PATTERNS, V7, P452, DOI 10.1016/j.modgep.2006.11.003; Sicari D, 2021, EMBO REP, V22, DOI 10.15252/embr.202051412; Simon EP, 2015, P NATL ACAD SCI USA, V112, pE5916, DOI 10.1073/pnas.1424894112; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Tian SB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15757-z; Tian SB, 2018, EXP CELL RES, V364, P198, DOI 10.1016/j.yexcr.2018.02.004; Tiemann K, 2019, ONCOGENE, V38, P3003, DOI 10.1038/s41388-018-0638-9; Tsuji T, 2015, CANCER RES, V75, P356, DOI 10.1158/0008-5472.CAN-14-1693; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Valladares-Ayerbes M, 2012, INT J MOL SCI, V13, P4367, DOI 10.3390/ijms13044367; Nguyen VD, 2018, ACTA CRYSTALLOGR F, V74, P425, DOI 10.1107/S2053230X18009093; Vanderlaag KE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2586; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Vivekanandan P, 2009, HUM PATHOL, V40, P293, DOI 10.1016/j.humpath.2008.08.003; Worfolk JC, 2019, ANTIOXID REDOX SIGN, V31, P1117, DOI 10.1089/ars.2018.7647; Wu J, 2015, ONCOTARGET, V6, P11794, DOI 10.18632/oncotarget.3649; Ye XL, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6483860; Yosudjai J, 2018, BIOMED PHARMACOTHER, V107, P109, DOI 10.1016/j.biopha.2018.07.154; Yuan KF, 2020, CELL DEATH DIFFER, V27, P1355, DOI 10.1038/s41418-019-0421-7; Zhang J, 2016, ONCOL LETT, V11, P2075, DOI 10.3892/ol.2016.4160; Zhao F, 2010, DEV BIOL, V338, P268, DOI 10.1016/j.ydbio.2009.12.008; Zheng W, 2006, GENES IMMUN, V7, P11, DOI 10.1038/sj.gene.6364263	120	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4673	4685		10.1038/s41388-022-02452-1	http://dx.doi.org/10.1038/s41388-022-02452-1		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36068336				2022-12-28	WOS:000850425100001
J	Wang, J; Li, JJ; Yin, LJ; Pu, TJ; Wei, J; Karthikeyan, V; Lin, TP; Gao, AC; Wu, BJ				Wang, Jing; Li, Jingjing; Yin, Lijuan; Pu, Tianjie; Wei, Jing; Karthikeyan, Varsha; Lin, Tzu-Ping; Gao, Allen C.; Wu, Boyang Jason			Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CELL-LINE; RECEPTOR; STAT3; DIFFERENTIATION; TYROSINE; PROTEIN; TRANSCRIPTION; ASSOCIATION; EXPRESSION	Neuroendocrine prostate cancer (NEPC), a lethal subset of prostate cancer, is characterized by loss of AR signaling and resulting resistance to AR-targeted therapy during neuroendocrine transdifferentiation, for which the molecular mechanisms remain unclear. Here, we report that neuropilin 2 (NRP2) is upregulated in both de novo and therapy-induced NEPC, which induces neuroendocrine markers, neuroendocrine cell morphology, and NEPC cell aggressive behavior. NRP2 silencing restricted NEPC tumor xenograft growth. Mechanistically, NRP2 engages in reciprocal crosstalk with AR, where NRP2 is transcriptionally inhibited by AR, and in turn suppresses AR signaling by downregulating the AR transcriptional program and confers resistance to enzalutamide. Moreover, NRP2 physically interacts with VEGFR2 through the intracellular SEA domain to activate STAT3 phosphorylation and subsequently SOX2, thus driving NEPC differentiation and growth. Collectively, these results characterize NRP2 as a driver of NEPC and suggest NRP2 as a potential therapeutic target in NEPC.	[Wang, Jing; Li, Jingjing; Pu, Tianjie; Wei, Jing; Wu, Boyang Jason] Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Spokane, WA 99202 USA; [Yin, Lijuan] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Uro Oncol Res Program, Los Angeles, CA 90048 USA; [Karthikeyan, Varsha] Washington State Univ, Coll Pharm & Pharmaceut Sci, Summer Undergrad Res Fellowship Program, Spokane, WA 99202 USA; [Karthikeyan, Varsha] Oregon State Univ, Coll Sci, Sch Life Sci, Dept Integrat Biol, Corvallis, OR 97331 USA; [Lin, Tzu-Ping] Taipei Vet Gen Hosp, Dept Urol, Taipei 11217, Taiwan; [Lin, Tzu-Ping] Natl Yang Ming Chiao Tung Univ, Sch Med, Dept Urol, Taipei 11221, Taiwan; [Lin, Tzu-Ping] Natl Yang Ming Chiao Tung Univ, Shu Tien Urol Res Ctr, Taipei 11221, Taiwan; [Gao, Allen C.] Univ Calif Davis, Dept Urol Surg, Sacramento, CA 95817 USA; [Li, Jingjing] Shanghai Jiao Tong Univ, Sch Pharm, Lab Regener, Shanghai 200240, Peoples R China; [Yin, Lijuan] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu 610041, Sichuan, Peoples R China	Washington State University; Cedars Sinai Medical Center; Washington State University; Oregon State University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; University of California System; University of California Davis; Shanghai Jiao Tong University; Sichuan University	Wu, BJ (corresponding author), Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Spokane, WA 99202 USA.	boyang.wu@wsu.edu		Karthikeyan, Varsha/0000-0003-3196-8850; Li, Jingjing/0000-0002-0661-5642	Department of Defense Prostate Cancer Research Program [W81XWH-19-1-0279]; NIH/NCI [R37CA233658]; WSU	Department of Defense Prostate Cancer Research Program(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); WSU	This work was supported by the Department of Defense Prostate Cancer Research Program grant W81XWH-19-1-0279, NIH/NCI grant R37CA233658, and WSU startup funding to B.J.W. We thank Yidi Xu (Washington State University) for providing technical assistance, Mahul Amin (Cedars-Sinai Medical Center) for providing NEPC clinical samples, and Gary Mawyer for editorial assistance.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Aparicio A, 2011, CANCER DISCOV, V1, P466, DOI 10.1158/2159-8290.CD-11-0259; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2014, CLIN CANCER RES, V20, P2846, DOI 10.1158/1078-0432.CCR-13-3309; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Bland T, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2020.101970; Borkowetz A, 2020, INT J CANCER, V146, P2619, DOI 10.1002/ijc.32679; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai HB, 1999, J NEUROSCI, V19, P6519; Chen SY, 2019, AM J CLIN EXP UROL, V7, P327; Davies AH, 2018, NAT REV UROL, V15, P271, DOI 10.1038/nrurol.2018.22; Dutta S, 2022, ONCOGENE, V41, P3747, DOI 10.1038/s41388-022-02382-y; Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538; Favier B, 2006, BLOOD, V108, P1243, DOI 10.1182/blood-2005-11-4447; Foshay KM, 2008, STEM CELLS DEV, V17, P269, DOI 10.1089/scd.2007.0098; Gerhauser C, 2018, CANCER CELL, V34, P996, DOI 10.1016/j.ccell.2018.10.016; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Goel HL, 2012, CANCER DISCOV, V2, P906, DOI 10.1158/2159-8290.CD-12-0085; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gray MJ, 2008, J NATL CANCER I, V100, P109, DOI 10.1093/jnci/djm279; Gritsina G, 2019, ASIAN J ANDROL, V21, P215, DOI 10.4103/aja.aja_19_19; Hahn D, 2000, J UROLOGY, V164, P506, DOI 10.1016/S0022-5347(05)67414-9; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huss WJ, 2004, PROSTATE, V60, P91, DOI 10.1002/pros.20032; Jackson MW, 2002, CANCER RES, V62, P854; Kaushal V, 2005, CLIN CANCER RES, V11, P584; Khoury A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13753-7; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; Lajoie BR, 2015, METHODS, V72, P65, DOI 10.1016/j.ymeth.2014.10.031; Liu YZ, 2019, SCI TRANSL MED, V11, DOI [10.1126/scitranslmed.aaw4993, 10.1126/scitranslmed.aax9364]; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Neufeld G, 2002, ADV EXP MED BIOL, V515, P81; Polavaram NS, 2021, BONE RES, V9, DOI 10.1038/s41413-021-00136-2; Potiron VA, 2007, CANCER RES, V67, P8708, DOI 10.1158/0008-5472.CAN-06-3612; Prahst C, 2008, J BIOL CHEM, V283, P25110, DOI 10.1074/jbc.C800137200; Ren SC, 2018, EUR UROL, V73, P322, DOI 10.1016/j.eururo.2017.08.027; Ren XM, 2010, ACS MED CHEM LETT, V1, P454, DOI 10.1021/ml100146z; Rizzolio S, 2011, CURR MED CHEM, V18, P3563, DOI 10.2174/092986711796642544; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Sulpice E, 2008, BLOOD, V111, P2036, DOI 10.1182/blood-2007-04-084269; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Taberlay PC, 2016, GENOME RES, V26, P719, DOI 10.1101/gr.201517.115; Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383; Tam KJ, 2017, ONCOTARGET, V8, P9617, DOI 10.18632/oncotarget.14168; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tolomeo M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020603; Tsai HK, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3729-z; Tse BWC, 2017, ONCOGENE, V36, P3417, DOI 10.1038/onc.2016.482; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Wang HT, 2014, J CLIN ONCOL, V32, P3383, DOI 10.1200/JCO.2013.54.3553; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu X, 2017, ASIAN J ANDROL, V19, P686, DOI 10.4103/1008-682X.191518; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257; Zhu H, 2018, THERANOSTICS, V8, P676, DOI 10.7150/thno.21463	58	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4307	4317		10.1038/s41388-022-02437-0	http://dx.doi.org/10.1038/s41388-022-02437-0		AUG 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35986103				2022-12-28	WOS:000843252700001
J	Fukuoka, T; Moriwaki, K; Takamatsu, S; Kondo, J; Tanaka-Okamoto, M; Tomioka, A; Semba, M; Komazawa-Sakon, S; Kamada, Y; Kaji, H; Miyamoto, Y; Inoue, M; Bessho, K; Miyoshi, Y; Ozono, K; Nakano, H; Miyoshi, E				Fukuoka, Tomoya; Moriwaki, Kenta; Takamatsu, Shinji; Kondo, Jumpei; Tanaka-Okamoto, Miki; Tomioka, Azusa; Semba, Manami; Komazawa-Sakon, Sachiko; Kamada, Yoshihiro; Kaji, Hiroyuki; Miyamoto, Yasuhide; Inoue, Masahiro; Bessho, Kazuhiko; Miyoshi, Yoko; Ozono, Keiichi; Nakano, Hiroyasu; Miyoshi, Eiji			Lewis glycosphingolipids as critical determinants of TRAIL sensitivity in cancer cells	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; LIPID RAFTS; RECEPTOR; NECROSIS; FUCOSYLATION; EXPRESSION; APOPTOSIS; ACTIVATION; COMPLEX; GLYCOSYLATION	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cancer cell death and contributes to tumor rejection by cytotoxic lymphocytes in cancer immunosurveillance and immunotherapy. TRAIL and TRAIL receptor agonists have garnered wide popularity as promising agents for cancer therapy. We previously demonstrated that the loss of fucosylation in cancer cells impairs TRAIL sensitivity; however, the precise structures of the fucosylated glycans that regulate TRAIL sensitivity and their carrier molecules remain elusive. Herein, we observed that Lewis glycans among various fucosylated glycans positively regulate TRAIL-induced cell death. Specifically, Lewis glycans on lacto/neolacto glycosphingolipids, but not glycoproteins including TRAIL receptors, enhanced TRAIL-induced formation of the cytosolic caspase 8 complex, without affecting the formation of the membranous receptor complex. Furthermore, type I Lewis glycan expression in colon cancer cell lines and patient-derived cancer organoids was positively correlated with TRAIL sensitivity. These findings provide novel insights into the regulatory mechanism of TRAIL-induced cell death and facilitate the identification of novel predictive biomarkers for TRAIL-related cancer therapies in future.	[Fukuoka, Tomoya; Takamatsu, Shinji; Kondo, Jumpei; Kamada, Yoshihiro; Miyoshi, Eiji] Osaka Univ, Grad Sch Med, Dept Mol Biochem & Clin Invest, Suita, Osaka 5650871, Japan; [Fukuoka, Tomoya; Bessho, Kazuhiko; Miyoshi, Yoko; Ozono, Keiichi] Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka 5650871, Japan; [Moriwaki, Kenta; Semba, Manami; Komazawa-Sakon, Sachiko; Nakano, Hiroyasu] Toho Univ, Sch Med, Dept Biochem, Ota Ku, Tokyo 1438540, Japan; [Kondo, Jumpei; Inoue, Masahiro] Kyoto Univ, Grad Sch Med, Dept Clin Bioresource Res & Dev, Sakyou Ku, Kyoto 6068501, Japan; [Tanaka-Okamoto, Miki; Miyamoto, Yasuhide] Osaka Int Canc Inst, Dept Mol Biol, Chuo Ku, Osaka 5418567, Japan; [Tomioka, Azusa; Kaji, Hiroyuki] Natl Inst Adv Ind Sci & Technol, Cellular & Mol Biotechnol Res Inst, Mol & Cellular Glycoprote Res Grp, Tsukuba, Ibaraki 3058565, Japan; [Semba, Manami] Tokyo Univ Sci, Fac Adv Engn, Dept Biol Sci & Technol, Katsushika Ku, Tokyo 1258585, Japan; [Kamada, Yoshihiro] Osaka Univ, Grad Sch Med, Dept Adv Metab Hepatol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST); Tokyo University of Science; Osaka University	Miyoshi, E (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Biochem & Clin Invest, Suita, Osaka 5650871, Japan.; Moriwaki, K (corresponding author), Toho Univ, Sch Med, Dept Biochem, Ota Ku, Tokyo 1438540, Japan.	kenta.moriwaki@med.toho-u.ac.jp; emiyoshi@sahs.med.osaka-u.ac.jp	; Kaji, Hiroyuki/L-7122-2018	Moriwaki, Kenta/0000-0002-8724-4715; TAKAMATSU, Shinji/0000-0003-1996-7740; Kaji, Hiroyuki/0000-0002-0910-9999	Japan Society for the Promotion of Science [16H06945, 19K07399]; Takeda Science Foundation; GSK Japan Research Grant; Japan Agency for Medical Research and Development [JP20ae0101042, JP20gm1210002]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF)); GSK Japan Research Grant; Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	This study was supported by the Japan Society for the Promotion of Science (KM: 16H06945 and 19K07399), the Takeda Science Foundation (KM), GSK Japan Research Grant 2020 (KM), and the Japan Agency for Medical Research and Development (JP20ae0101042 to KM and JP20gm1210002 to HN).	Akazawa Y, 2009, GASTROENTEROLOGY, V136, P2365, DOI 10.1053/j.gastro.2009.02.071; Deng D, 2020, TRENDS CANCER, V6, P989, DOI 10.1016/j.trecan.2020.06.006; Dickens LS, 2012, MOL CELL, V47, P291, DOI 10.1016/j.molcel.2012.05.004; Dufour F, 2017, CELL DEATH DIFFER, V24, P500, DOI 10.1038/cdd.2016.150; Dufva O, 2020, BLOOD, V135, P597, DOI 10.1182/blood.2019002121; Fox JL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20806-9; Henry CM, 2017, MOL CELL, V65, P715, DOI 10.1016/j.molcel.2017.01.022; Holdener BC, 2019, CURR OPIN STRUC BIOL, V56, P78, DOI 10.1016/j.sbi.2018.12.005; Jiang YL, 2020, FASEB J, V34, P11786, DOI 10.1096/fj.201900053RR; Jin ZY, 2006, MOL CELL BIOL, V26, P8136, DOI 10.1128/MCB.00257-06; Kohlhaas SL, 2007, J BIOL CHEM, V282, P12831, DOI 10.1074/jbc.M700438200; Kondo J, 2011, P NATL ACAD SCI USA, V108, P6235, DOI 10.1073/pnas.1015938108; Lafont E, 2018, TRENDS BIOCHEM SCI, V43, P44, DOI 10.1016/j.tibs.2017.11.002; Lafont E, 2017, EMBO J, V36, P1147, DOI 10.15252/embj.201695699; Lavrik IN, 2008, J BIOL CHEM, V283, P26401, DOI 10.1074/jbc.M800823200; Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81; Lemoine J, 2021, CLIN CANCER RES, V27, P6298, DOI 10.1158/1078-0432.CCR-21-1559; Linderoth E, 2013, J BIOL CHEM, V288, P32922, DOI 10.1074/jbc.M113.481507; Liu C, 2020, INT J ONCOL, V56, P900, DOI 10.3892/ijo.2020.4989; Ma B, 2006, GLYCOBIOLOGY, V16, p158R, DOI 10.1093/glycob/cwl040; Marconi M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.389; Miyoshi E, 2008, J BIOCHEM, V143, P725, DOI 10.1093/jb/mvn011; Moriwaki K, 2007, GLYCOBIOLOGY, V17, P1311, DOI 10.1093/glycob/cwm094; Moriwaki K, 2013, GENE DEV, V27, P1640, DOI 10.1101/gad.223321.113; Moriwaki K, 2011, J BIOL CHEM, V286, P43123, DOI 10.1074/jbc.M111.262741; Moriwaki K, 2009, GASTROENTEROLOGY, V137, P188, DOI 10.1053/j.gastro.2009.04.002; Nakayama K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070298; Noda K, 2003, CANCER RES, V63, P6282; Ouyang W, 2013, INT J ONCOL, V42, P699, DOI 10.3892/ijo.2012.1748; Pan LQ, 2019, CELL, V176, P1477, DOI 10.1016/j.cell.2019.02.001; Seko A, 2008, J BIOL CHEM, V283, P33094, DOI 10.1074/jbc.M806933200; Singh N, 2020, CANCER DISCOV, V10, P552, DOI 10.1158/2159-8290.CD-19-0813; Song JJ, 2010, CELL SIGNAL, V22, P553, DOI 10.1016/j.cellsig.2009.11.012; Stern HM, 2010, CLIN CANCER RES, V16, P1587, DOI 10.1158/1078-0432.CCR-09-3108; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Togayachi A, 2010, P NATL ACAD SCI USA, V107, P11900, DOI 10.1073/pnas.0914298107; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; YAGO K, 1993, CANCER RES, V53, P5559; Zhang BJ, 2019, FEBS J, V286, P555, DOI 10.1111/febs.14742	40	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4385	4396		10.1038/s41388-022-02434-3	http://dx.doi.org/10.1038/s41388-022-02434-3		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35970887				2022-12-28	WOS:000840610900001
J	Ratze, MAK; Koorman, T; Sijnesael, T; Bassey-Archibong, B; van de Ven, R; Enserink, L; Visser, D; Jaksani, S; Viciano, I; Bakker, ERM; Richard, F; Tutt, A; O'Leary, L; Fitzpatrick, A; Roca-Cusachs, P; van Diest, PJ; Desmedt, C; Daniel, JM; Isacke, CM; Derksen, PWB				Ratze, Max A. K.; Koorman, Thijs; Sijnesael, Thijmen; Bassey-Archibong, Blessing; van de Ven, Robert; Enserink, Lotte; Visser, Daan; Jaksani, Sridevi; Viciano, Ignacio; Bakker, Elvira R. M.; Richard, Francois; Tutt, Andrew; O'Leary, Lynda; Fitzpatrick, Amanda; Roca-Cusachs, Pere; van Diest, Paul J.; Desmedt, Christine; Daniel, Juliet M.; Isacke, Clare M.; Derksen, Patrick W. B.			Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; ANOIKIS RESISTANCE; GENE-EXPRESSION; CARCINOMA; ID2; GROWTH; D1; PROLIFERATION; DIFFERENTIATION; REPRESSION	Invasive lobular breast carcinoma (ILC) is characterized by proliferative indolence and long-term latency relapses. This study aimed to identify how disseminating ILC cells control the balance between quiescence and cell cycle re-entry. In the absence of anchorage, ILC cells undergo a sustained cell cycle arrest in G0/G1 while maintaining viability. From the genes that are upregulated in anchorage independent ILC cells, we selected Inhibitor of DNA binding 2 (Id2), a mediator of cell cycle progression. Using loss-of-function experiments, we demonstrate that Id2 is essential for anchorage independent survival (anoikis resistance) in vitro and lung colonization in mice. Importantly, we find that under anchorage independent conditions, E-cadherin loss promotes expression of Id2 in multiple mouse and (organotypic) human models of ILC, an event that is caused by a direct p120-catenin/Kaiso-dependent transcriptional de-repression of the canonical Kaiso binding sequence TCCTGCNA. Conversely, stable inducible restoration of E-cadherin expression in the ILC cell line SUM44PE inhibits Id2 expression and anoikis resistance. We show evidence that Id2 accumulates in the cytosol, where it induces a sustained and CDK4/6-dependent G0/G1 cell cycle arrest through interaction with hypo-phosphorylated Rb. Finally, we find that Id2 is indeed enriched in ILC when compared to other breast cancers, and confirm cytosolic Id2 protein expression in primary ILC samples. In sum, we have linked mutational inactivation of E-cadherin to direct inhibition of cell cycle progression. Our work indicates that loss of E-cadherin and subsequent expression of Id2 drive indolence and dissemination of ILC. As such, E-cadherin and Id2 are promising candidates to stratify low and intermediate grade invasive breast cancers for the use of clinical cell cycle intervention drugs.	[Ratze, Max A. K.; Koorman, Thijs; Sijnesael, Thijmen; van de Ven, Robert; Enserink, Lotte; Visser, Daan; Jaksani, Sridevi; Bakker, Elvira R. M.; van Diest, Paul J.; Derksen, Patrick W. B.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Bassey-Archibong, Blessing; Daniel, Juliet M.] McMaster Univ, Dept Biol, Hamilton, ON, Canada; [Viciano, Ignacio; Roca-Cusachs, Pere] Barcelona Inst Technol BIST, Inst Bioengn Catalonia IBEC, Barcelona, Spain; [Richard, Francois; Desmedt, Christine] Katholieke Univ Leuven, Lab Translat Breast Canc Res, Leuven, Belgium; [Tutt, Andrew] Kings Coll London, Breast Canc Now Res Unit, London, England; [Tutt, Andrew; O'Leary, Lynda; Fitzpatrick, Amanda; Isacke, Clare M.] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England	Utrecht University; Utrecht University Medical Center; McMaster University; Barcelona Institute of Science & Technology; Institut de Bioenginyeria de Catalunya; University of Barcelona; KU Leuven; University of London; King's College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Derksen, PWB (corresponding author), Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands.	p.w.b.derksen@umcutrecht.nl	; Derksen, Patrick/C-6643-2008; Desmedt, Christine/P-7438-2017	Tutt, Andrew/0000-0001-8715-2901; Sijnesael, Thijmen/0000-0003-2248-9786; Derksen, Patrick/0000-0003-0732-7762; Isacke, Clare/0000-0002-9222-3345; Koorman, Thijs/0000-0002-6064-3353; Desmedt, Christine/0000-0002-5223-5579	NHS; St Thomas' NHS Foundation Trust and King's College London; Royal Marsden NHS Foundation Trust; Canadian Breast Cancer Foundation; Juravinski Hospital and Cancer Center Foundation; Schlumberger Faculty for the Future Fellowship; Breast Cancer Now [2018NovPCC1297]; NC3Rs [NC/P001262/1]; Medical Research Council Clinical Research Training Fellowship; Netherlands Organization for Scientific Research [NWO/ZonMW-VIDI 016.096.318]; Dutch Cancer Society [KWF-UU-2011-5230, KWF-UU-2014-7201, KWF-UU-2016-10456]; Pfizer; European Union [731957, CA19138]; COST (European Cooperation in Science and Technology)	NHS; St Thomas' NHS Foundation Trust and King's College London; Royal Marsden NHS Foundation Trust(Royal Society of New ZealandMarsden Fund (NZ)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Juravinski Hospital and Cancer Center Foundation; Schlumberger Faculty for the Future Fellowship(Schlumberger); Breast Cancer Now; NC3Rs(UK Research & Innovation (UKRI)National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs)); Medical Research Council Clinical Research Training Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding); Pfizer(Pfizer); European Union(European Commission); COST (European Cooperation in Science and Technology)(European Cooperation in Science and Technology (COST))	We thank Jonathan R. Keller (National Cancer Institute, Frederick, MA, USA) for the Id2 reporter, and Livio Kleij and Nikki Kolsters for technical support. Members from the De Bruin and Daniel laboratories are acknowledged for input and fruitful discussions. We thank the UMC Utrecht Cell Microscopy Center for imaging support. Rebecca Marlow and Eleanor Knight (BCN Organoid Facility) for their advice on the ILC PDO generation and Angela Clifford (KCL) in her role as BTBC trial coordinator. We acknowledge NHS funding to the NIHR Biomedical Research Centres at both Guy's and St Thomas' NHS Foundation Trust and King's College London, and the Royal Marsden NHS Foundation Trust and the Canadian Breast Cancer Foundation, the Juravinski Hospital and Cancer Center Foundation (JHCCF). BIB-A was partly supported by a Schlumberger Faculty for the Future Fellowship. We received financial support by Breast Cancer Now (CTR-Q4-Y3), NC3Rs (NC/P001262/1) (CMI/AT) and a Medical Research Council Clinical Research Training Fellowship (AF), grants from the Netherlands Organization for Scientific Research (NWO/ZonMW-VIDI 016.096.318), the Dutch Cancer Society (KWF-UU-2011-5230, KWF-UU-2014-7201 and KWF-UU-2016-10456), Breast Cancer Now (2018NovPCC1297) which is supported by funding from Pfizer, and the European Union's Horizon 2020 FET Proactive program under the grant agreement No. 731957 (MECHANO-CONTROL). This publication is based upon work from COST action LOBSTERPOT (CA19138), supported by COST (European Cooperation in Science and Technology).	Annunziato S, 2016, GENE DEV, V30, P1470, DOI 10.1101/gad.279190.116; Arpino G, 2004, BREAST CANCER RES, V6, pR149, DOI 10.1186/bcr767; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Boelens MC, 2016, CELL REP, V16, P2087, DOI 10.1016/j.celrep.2016.07.059; Booij TH, 2016, J BIOMOL SCREEN, V21, P912, DOI 10.1177/1087057116657269; Bruner HC, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029330; Christgen M, 2021, CANCERS, V13, DOI 10.3390/cancers13153695; Christgen M, 2016, PATHOL RES PRACT, V212, P583, DOI 10.1016/j.prp.2016.05.002; Coma S, 2010, CANCER RES, V70, P3823, DOI 10.1158/0008-5472.CAN-09-3048; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Derksen PWB, 2011, DIS MODEL MECH, V4, P347, DOI 10.1242/dmm.006395; Desmedt C, 2017, SEMIN CANCER BIOL, V44, P98, DOI 10.1016/j.semcancer.2017.03.007; Di Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109688; Engel J, 2003, EUR J CANCER, V39, P1794, DOI 10.1016/S0959-8049(03)00422-2; Engelstaedter Verena, 2011, Arch Gynecol Obstet, V283 Suppl 1, P93, DOI 10.1007/s00404-011-1843-8; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gainer SM, 2012, J SURG RES, V177, P93, DOI 10.1016/j.jss.2012.03.014; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gray MJ, 2008, ONCOGENE, V27, P7192, DOI 10.1038/onc.2008.356; Guiu S, 2014, CRIT REV ONCOL HEMAT, V92, P235, DOI 10.1016/j.critrevonc.2014.07.003; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Hornsveld M, 2016, CELL DEATH DIFFER, V23, P1483, DOI 10.1038/cdd.2016.33; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jares P, 1997, J PATHOL, V182, P160; Johnson J, 2016, ONCOGENE, V35, P4829, DOI 10.1038/onc.2016.32; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kijewska M, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-018-1093-9; Kim NS, 2011, MOL CELL BIOL, V31, P4775, DOI 10.1128/MCB.05646-11; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korhonen T, 2013, BREAST, V22, P1119, DOI 10.1016/j.breast.2013.06.001; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Li HJ, 2010, BLOOD, V116, P1060, DOI 10.1182/blood-2009-11-255075; Liu Y, 2019, BREAST CANCER RES TR, V175, P77, DOI 10.1007/s10549-018-05126-3; Mandoli A, 2014, GENOM DATA, V2, P170, DOI 10.1016/j.gdata.2014.06.014; Manning AL, 2012, NAT REV CANCER, V12, P220, DOI 10.1038/nrc3216; Mathieu MC, 2004, EUR J CANCER, V40, P342, DOI 10.1016/j.ejca.2003.08.015; Meng WX, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002899; Meng YG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-75; Metzger O, 2013, ANN ONCOL, V24, P377, DOI 10.1093/annonc/mds280; Michaut M, 2016, SCI REP-UK, V6, DOI 10.1038/srep18517; NEWSTEAD GM, 1992, RADIOLOGY, V184, P623, DOI 10.1148/radiology.184.3.1324506; O'Brien N, 2018, MOL CANCER THER, V17, P897, DOI 10.1158/1535-7163.MCT-17-0290; Oyama T, 1998, CANCER RES, V58, P2876; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Pestalozzi BC, 2008, J CLIN ONCOL, V26, P3006, DOI 10.1200/JCO.2007.14.9336; Pierre CC, 2015, BBA-GENE REGUL MECH, V1849, P1432, DOI 10.1016/j.bbagrm.2015.10.018; Pinto Proenca Rita, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2017-223542; Rollin J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004158; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Sandercock AM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0415-0; Schackmann RCJ, 2013, CANCER RES, V73, P4937, DOI 10.1158/0008-5472.CAN-13-0180; Schackmann RCJ, 2011, J CLIN INVEST, V121, P3176, DOI 10.1172/JCI41695; Shapiro GI, 2000, CELL BIOCHEM BIOPHYS, V33, P189, DOI 10.1385/CBB:33:2:189; Suzuki Keiko, 2010, BMC Res Notes, V3, P294, DOI 10.1186/1756-0500-3-294; Teo K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33525-5; Tobin NP, 2012, HUM PATHOL, V43, P2053, DOI 10.1016/j.humpath.2012.02.015; Troyanovsky RB, 2003, MOL CELL BIOL, V23, P7965, DOI 10.1128/MCB.23.22.7965-7972.2003; van de Ven RAH, 2015, DIS MODEL MECH, V8, P373, DOI 10.1242/dmm.018648; vanDiest PJ, 1997, AM J PATHOL, V150, P705; Vlug EJ, 2013, CELL ONCOL, V36, P375, DOI 10.1007/s13402-013-0143-7; Wazir U, 2013, ANTICANCER RES, V33, P2179; Zhou JD, 2017, ONCOTARGET, V8, P91979, DOI 10.18632/oncotarget.20559	67	3	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2932	2944		10.1038/s41388-022-02314-w	http://dx.doi.org/10.1038/s41388-022-02314-w		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35437308	Green Published, hybrid			2022-12-28	WOS:000784068300002
J	Aschtgen, MS; Fragkoulis, K; Sanz, G; Normark, S; Selivanova, G; Henriques-Normark, B; Peuget, S				Aschtgen, Marie-Stephanie; Fragkoulis, Konstantinos; Sanz, Gema; Normark, Staffan; Selivanova, Galina; Henriques-Normark, Birgitta; Peuget, Sylvain			Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization	ONCOGENE			English	Article							PYOGENIC LIVER-ABSCESS; HELICOBACTER-PYLORI; COLORECTAL-CANCER; GENE; ACTIVATION; PROMOTES; TARGETS; MICROBIOTA; MODEL; RAS	Increasing evidence highlights the role of bacteria in the physiopathology of cancer. However, the underlying molecular mechanisms remains poorly understood. Several cancer-associated bacteria have been shown to produce toxins which interfere with the host defense against tumorigenesis. Here, we show that lipopolysaccharides from Klebsiella pneumoniae and other Enterobacteria strongly inhibit the host tumor suppressor p53 pathway through a novel mechanism of p53 regulation. We found that lipopolysaccharides destabilize TP53 mRNA through a TLR4-NF-kappa B-mediated inhibition of the RNA-binding factor Wig-1. Importantly, we show that K. pneumoniae disables two major tumor barriers, oncogene-induced DNA damage signaling and senescence, by impairing p53 transcriptional activity upon DNA damage and oncogenic stress. Furthermore, we found an inverse correlation between the levels of TLR4 and p53 mutation in colorectal tumors. Hence, our data suggest that the repression of p53 by Enterobacteria via TLR4 alleviates the selection pressure for p53 oncogenic mutations and shapes the genomic evolution of cancer.	[Aschtgen, Marie-Stephanie; Fragkoulis, Konstantinos; Sanz, Gema; Normark, Staffan; Selivanova, Galina; Henriques-Normark, Birgitta; Peuget, Sylvain] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden; [Normark, Staffan; Henriques-Normark, Birgitta] Karolinska Univ Hosp, Clin Microbiol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Aschtgen, MS; Peuget, S (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden.	marie-stephanie.aschtgen@ki.se; sylvain.peuget@ki.se	Peuget, Sylvain/AAB-4730-2022	aschtgen, marie-stephanie/0000-0003-2413-8226; Peuget, Sylvain/0000-0002-3315-1935; Selivanova, Galina/0000-0002-8698-4332	Swedish Research Council; Swedish Cancer Society; Knut and Alice Wallenberg Foundation; Swedish foundation for Strategic Research; Karolinska Institute; EMBO	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Swedish foundation for Strategic Research(Swedish Foundation for Strategic Research); Karolinska Institute(Karolinska Institutet); EMBO(European Molecular Biology Organization (EMBO))	We thank all our colleagues for sharing precious reagents and material with us, especially Dr. Yunn-Hwen Gan (National University of Singapore), Dr. Gary Huffnagle (University of Michigan) and Mr. Alexandros Petropoulos (Karolinska Institute) for bacteria strains, and Prof. Klas Wiman (Karolinska Institute) for Wig-1 antibody. We thank Ms. Aleksandra Boikova and Mr. Riccardo Bevilacqua for technical support. This study was supported by the Swedish Research Council, the Swedish Cancer Society, Knut and Alice Wallenberg Foundation, the Swedish foundation for Strategic Research and the Karolinska Institute. MSA was supported by a short-term fellowship from EMBO.	Ak P, 2010, FASEB J, V24, P3643, DOI 10.1096/fj.10-160549; Arandkar S, 2018, P NATL ACAD SCI USA, V115, P6410, DOI 10.1073/pnas.1719076115; Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820; Berezow AB, 2009, MICROB PATHOGENESIS, V47, P68, DOI 10.1016/j.micpath.2009.04.015; Bergounioux J, 2012, CELL HOST MICROBE, V11, P240, DOI 10.1016/j.chom.2012.01.013; Bersani C, 2014, ONCOGENE, V33, P4407, DOI 10.1038/onc.2013.594; Bersani C, 2016, ONCOTARGET, V7, P1895, DOI 10.18632/oncotarget.6557; Bieging-Rolett KT, 2020, MOL CELL, V80, P452, DOI 10.1016/j.molcel.2020.10.022; Brennan CA, 2019, NAT REV MICROBIOL, V17, P156, DOI 10.1038/s41579-018-0129-6; Burns DM, 2008, GENE DEV, V22, P3449, DOI 10.1101/gad.1697808; Buti L, 2011, P NATL ACAD SCI USA, V108, P9238, DOI 10.1073/pnas.1106200108; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan W, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm163; Chen J, 2010, GENE DEV, V24, P2146, DOI 10.1101/gad.1968910; Costa L, 2020, GUT, V69, P1582, DOI 10.1136/gutjnl-2019-318640; Cuevas-Ramos G, 2010, P NATL ACAD SCI USA, V107, P11537, DOI 10.1073/pnas.1001261107; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; de Waal GM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65324-2; Diaz-Munoz MD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00454-2; Ewels PA, 2020, NAT BIOTECHNOL, V38, P276, DOI 10.1038/s41587-020-0439-x; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ge ZM, 2007, CELL MICROBIOL, V9, P2070, DOI 10.1111/j.1462-5822.2007.00939.x; Gonzalez E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6201; Greathouse KL, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1501-6; Gudkov AV, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026161; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Haronikova L, 2019, NUCLEIC ACIDS RES, V47, P3257, DOI 10.1093/nar/gkz124; He XY, 2015, CELL REP, V13, P888, DOI 10.1016/j.celrep.2015.09.045; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; HORNICK DB, 1995, INFECT IMMUN, V63, P2026, DOI 10.1128/IAI.63.5.2026-2032.1995; Horvat A, 2018, ONCOGENE, V37, P5054, DOI 10.1038/s41388-018-0343-8; Huang Tzu-Wen, 2014, BMC Res Notes, V7, P13, DOI 10.1186/1756-0500-7-13; Huang WK, 2012, COLORECTAL DIS, V14, pe794, DOI 10.1111/j.1463-1318.2012.03174.x; Janic A, 2018, NAT MED, V24, P947, DOI 10.1038/s41591-018-0043-5; Jeong SW, 2012, J GASTROEN HEPATOL, V27, P248, DOI 10.1111/j.1440-1746.2011.06851.x; Jimenez N, 2009, J BACTERIOL, V191, P2228, DOI 10.1128/JB.01395-08; Joruiz SM, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026039; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Lam MMC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05114-7; Lan Y, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22838; Lee IR, 2016, SCI REP-UK, V6, DOI 10.1038/srep29316; Lee YK, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00587-18; Levine AJ, 2020, NAT REV CANCER, V20, P471, DOI 10.1038/s41568-020-0262-1; Liu G, 2009, J IMMUNOL, V182, P5063, DOI 10.4049/jimmunol.0803526; Madenspacher JH, 2013, J EXP MED, V210, P891, DOI 10.1084/jem.20121674; Mei QX, 2018, PANCREATOLOGY, V18, P438, DOI 10.1016/j.pan.2018.03.005; Menendez D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001360; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Nguyen HCB, 2020, NATURE, V584, P286, DOI 10.1038/s41586-020-2576-2; Niu GL, 2005, MOL CELL BIOL, V25, P7432, DOI 10.1128/MCB.25.17.7432-7440.2005; Pai AA, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006338; Procopio MG, 2015, NAT CELL BIOL, V17, P1193, DOI 10.1038/ncb3228; Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9; Reimand J, 2016, NUCLEIC ACIDS RES, V44, pW83, DOI 10.1093/nar/gkw199; Rivas C, 2010, VIRUSES-BASEL, V2, P298, DOI 10.3390/v2010298; Sepich-Poore GD, 2021, SCIENCE, V371, P1331, DOI 10.1126/science.abc4552; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Siegl C, 2015, NAT REV MICROBIOL, V13, P741, DOI 10.1038/nrmicro3537; Tornesello ML, 2018, CANCERS, V10, DOI 10.3390/cancers10070213; Vilborg A, 2009, P NATL ACAD SCI USA, V106, P15756, DOI 10.1073/pnas.0900862106; Wang SL, 2006, CANCER RES, V66, P6982, DOI 10.1158/0008-5472.CAN-06-0511; Wang TT, 2012, ISME J, V6, P320, DOI 10.1038/ismej.2011.109; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Wei JX, 2010, GASTROENTEROLOGY, V139, P1333, DOI 10.1053/j.gastro.2010.06.018; Wirbel J, 2019, NAT MED, V25, P679, DOI 10.1038/s41591-019-0406-6; Wu N, 2013, MICROB ECOL, V66, P462, DOI 10.1007/s00248-013-0245-9; Zella D, 2018, P NATL ACAD SCI USA, V115, pE12005, DOI 10.1073/pnas.1815660115; Zhang MQZ, 2018, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00323	76	0	0	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2173	2186		10.1038/s41388-022-02238-5	http://dx.doi.org/10.1038/s41388-022-02238-5		FEB 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35197571	Green Published, hybrid			2022-12-28	WOS:000760099800002
J	Wu, SQ; Guo, BB; Zhang, LY; Zhu, X; Zhao, PP; Deng, JQ; Zheng, J; Li, F; Wang, YR; Zhang, SH; Zhang, Z; Lu, JC; Zhou, YF				Wu, Siqi; Guo, Binbin; Zhang, Liyuan; Zhu, Xun; Zhao, Peipei; Deng, Jieqiong; Zheng, Jian; Li, Fang; Wang, Yirong; Zhang, Shenghua; Zhang, Zheng; Lu, Jiachun; Zhou, Yifeng			A micropeptide XBP1SBM encoded by lncRNA promotes angiogenesis and metastasis of TNBC via XBP1s pathway	ONCOGENE			English	Article							NEGATIVE BREAST-CANCER; PROTEIN; METABOLISM; EXPRESSION	Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with a poor prognosis. To date, the mechanism of TNBC's aggressive phenotype is still unclear. Based on metabolome analysis, we found that glutamine (Gln) metabolism plays a key role in the difference between TNBC and non-TNBC. We identified a 21-amino-acid survival-associated micropeptide XBP1SBM, encoded by the lncRNA MLLT4-AS1, which was upregulated in TNBC tissues and Gln-deprived TNBC cell lines. We showed that XBP1SBM expression was upregulated by Gln-deprivation-induced XBP1s transcriptional promotion, and in turn retained XBP1s in the nuclear to enhance the expression of VEGF. Using human endothelial cells, mouse xenograft models and mouse spontaneous BC models, we found that XBP1SBM improved Gln levels and promoted angiogenesis and metastasis in TNBC. Our study showed that a TNBC-specific nutrient deficiency adaption results in aggressive TNBC, and this mechanism provides a novel potential prognostic biomarker and therapeutic target in TNBC.	[Wu, Siqi; Guo, Binbin; Deng, Jieqiong; Li, Fang; Wang, Yirong; Zhang, Shenghua; Zhang, Zheng; Zhou, Yifeng] Soochow Univ, Dept Genet, Med Coll, Suzhou 215123, Peoples R China; [Zhang, Liyuan; Zhao, Peipei] Soochow Univ, Dept Radiotherapy & Oncol, Affiliated Hosp 2, San Xiang Rd 1055, Suzhou 215004, Peoples R China; [Zhu, Xun] Soochow Univ, Dept Gen Surg, Affiliated Hosp 2, San Xiang Rd 1055, Suzhou 215004, Peoples R China; [Zheng, Jian; Zhou, Yifeng] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Zheng, Jian; Zhou, Yifeng] Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China; [Lu, Jiachun] Guangzhou Med Univ, Affiliated Hosp 1, Sch Publ Hlth, Inst Chem Carcinogenesis, Guangzhou 510182, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; State Key Lab Oncology South China; Sun Yat Sen University; Guangzhou Medical University	Zhou, YF (corresponding author), Soochow Univ, Dept Genet, Med Coll, Suzhou 215123, Peoples R China.; Zhou, YF (corresponding author), Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Zhou, YF (corresponding author), Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China.	zhouyifeng@suda.edu.cn	Wu, Siqi/GVT-6711-2022; zhang, zheng/HCH-9684-2022	Wu, Siqi/0000-0002-5051-2923; Zheng, Jian/0000-0001-9831-7038	National Scientific Foundation of China [82103263, 81772544, 81972649]; National Science Fund for Distinguished Young Scholars [82125027]; Program for Guangdong Introducing Innovative and Entrepreneurial Teams [2017ZT07S096]	National Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Program for Guangdong Introducing Innovative and Entrepreneurial Teams	This work was supported by The National Scientific Foundation of China grants 82103263, 81772544 and 81972649; The National Science Fund for Distinguished Young Scholars 82125027; Program for Guangdong Introducing Innovative and Entrepreneurial Teams (2017ZT07S096).	Anderson DM, 2015, CELL, V160, P595, DOI 10.1016/j.cell.2015.01.009; Bielenberg DR, 2015, CANCER J, V21, P267, DOI 10.1097/PPO.0000000000000138; Brown M, 2008, CANCER-AM CANCER SOC, V112, P737, DOI 10.1002/cncr.23243; Budczies J, 2015, INT J CANCER, V136, P1619, DOI 10.1002/ijc.29152; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008; Chasse H, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw907; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Choi SW, 2019, BRIEF BIOINFORM, V20, P1853, DOI 10.1093/bib/bby055; Davies MPA, 2008, INT J CANCER, V123, P85, DOI 10.1002/ijc.23479; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Guo BB, 2020, EMBO J, V39, DOI 10.15252/embj.2019102190; Guttman M, 2013, CELL, V154, P240, DOI 10.1016/j.cell.2013.06.009; Hetz C, 2011, PHYSIOL REV, V91, P1219, DOI 10.1152/physrev.00001.2011; Hu R, 2015, MOL CELL BIOL, V35, P379, DOI 10.1128/MCB.00847-14; Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015; Jiang YZ, 2019, CANCER CELL, V35, P428, DOI 10.1016/j.ccell.2019.02.001; Karaayvaz M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06052-0; Kaser A, 2010, CELL RES, V20, P506, DOI 10.1038/cr.2010.61; Kim RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep39342; Kung HN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002229; Li F, 2019, INT J CANCER, V145, P927, DOI 10.1002/ijc.32166; Li HY, 2015, CELL SIGNAL, V27, P82, DOI 10.1016/j.cellsig.2014.09.018; Li W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0949-7; Li W, 2017, J BIOL CHEM, V292, P5801, DOI 10.1074/jbc.M116.758508; Li W, 2014, GASTROENTEROLOGY, V146, P1714, DOI 10.1053/j.gastro.2014.03.002; Liu L, 2019, NAT CELL BIOL, V21, P328, DOI 10.1038/s41556-019-0285-6; Loayza-Puch F, 2016, NATURE, V530, P490, DOI 10.1038/nature16982; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Mayers JR, 2015, TRENDS BIOCHEM SCI, V40, P130, DOI 10.1016/j.tibs.2015.01.004; Mohammed RAA, 2011, MODERN PATHOL, V24, P774, DOI 10.1038/modpathol.2011.4; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Shanware NP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5900; Tajan M, 2018, CELL METAB, V28, P721, DOI 10.1016/j.cmet.2018.07.005; Tian J, 2018, BRIT J CANCER, V119, P1495, DOI 10.1038/s41416-018-0287-3; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Wang YR, 2020, J EXP MED, V217, DOI 10.1084/jem.20190950; Wang YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08033-9; White E, 2013, GENE DEV, V27, P2065, DOI 10.1101/gad.228122.113; Wu H, 2015, ONCOGENE, V34, P4723, DOI 10.1038/onc.2014.400; Yoshida H, 2006, J CELL BIOL, V172, P565, DOI 10.1083/jcb.200508145; Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151	42	3	3	10	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2163	2172		10.1038/s41388-022-02229-6	http://dx.doi.org/10.1038/s41388-022-02229-6		FEB 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35197570				2022-12-28	WOS:000760099800001
J	Tsuboyama, N; Wang, R; Szczepanski, AP; Chen, HH; Zhao, ZB; Shi, L; Wang, L				Tsuboyama, Natsumi; Wang, Ru; Szczepanski, Aileen Patricia; Chen, Huanhuan; Zhao, Zibo; Shi, Lei; Wang, Lu			Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer	ONCOGENE			English	Article							BRCA1-ASSOCIATED PROTEIN-1; UVEAL MELANOMA; BAP1; MUTATIONS; ASSOCIATION; GAIN	Small cell lung cancer (SCLC) is an aggressive disease, with patients diagnosed with either early-stage, limited stage, or extensive stage of SCLC tumor progression. Discovering and targeting the functional biomarkers for SCLC will be crucial in understanding the molecular basis underlying SCLC tumorigenesis to better assist in improving clinical treatment. Emerging studies have demonstrated that dysregulations in BAP1 histone H2A deubiquitinase complex are collectively associated with pathogenesis in human SCLC. Here, we investigated the function of the oncogenic BAP1/ASXL3/BRD4 epigenetic axis in SCLC by developing a next-generation BAP1 inhibitor, iBAP-II, and focusing on the epigenetic balance established between BAP1 and non-canonical PRC1 complexes in regulating SCLC-specific transcriptional programming. We further demonstrated that pharmacologic inhibition of BAP1's catalytic activity disrupted BAP1/ASXL3/BRD4 epigenetic axis by inducing protein degradation of the ASXL3 scaffold protein, which bridges BRD4 and BAP1 at active enhancers. Furthermore, treatment of iBAP-II represses neuroendocrine lineage-specific ASCL1/MYCL/E2F signaling in SCLC cell lines, and dramatically inhibits SCLC cell viability and tumor growth in vivo. In summary, this study has provided mechanistic insight into the oncogenic function of BAP1 in SCLC and highlighted the potential of targeting BAP1's activity as a novel SCLC therapy.	[Tsuboyama, Natsumi; Szczepanski, Aileen Patricia; Zhao, Zibo; Wang, Lu] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA; [Tsuboyama, Natsumi; Szczepanski, Aileen Patricia; Zhao, Zibo; Wang, Lu] Northwestern Univ, Feinberg Sch Med, Simpson Querrey Ctr Epigenet, Chicago, IL 60611 USA; [Wang, Ru; Chen, Huanhuan; Shi, Lei] China Pharmaceut Univ, Dept Med Chem, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; China Pharmaceutical University	Wang, L (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA.; Wang, L (corresponding author), Northwestern Univ, Feinberg Sch Med, Simpson Querrey Ctr Epigenet, Chicago, IL 60611 USA.; Shi, L (corresponding author), China Pharmaceut Univ, Dept Med Chem, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China.	shilei@cpu.edu.cn; lu.wang1@northwestern.edu	Zhao, Zibo/GWQ-3444-2022	, Aileen/0000-0002-4133-0634; Tsuboyama, Natsumi/0000-0002-8620-3479; Wang, Lu/0000-0003-0441-0747				Asada S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05085-9; Balasubramani A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8307; Baymaz HI, 2014, PROTEOMICS, V14, P2179, DOI 10.1002/pmic.201400013; Bononi A, 2017, NATURE, V546, P549, DOI 10.1038/nature22798; Borromeo MD, 2016, CELL REP, V16, P1259, DOI 10.1016/j.celrep.2016.06.081; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Campagne A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08255-x; Carbone M, 2020, CANCER DISCOV, V10, P1103, DOI 10.1158/2159-8290.CD-19-1220; Carbone M, 2020, NAT REV CANCER, V20, P533, DOI 10.1038/s41568-020-0265-y; Conway E, 2021, MOL CELL, V81, P3526, DOI 10.1016/j.molcel.2021.06.020; De I, 2019, STRUCTURE, V27, P528, DOI 10.1016/j.str.2018.11.013; Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711; Dobrinic P, 2021, NAT STRUCT MOL BIOL, V28, P811, DOI 10.1038/s41594-021-00661-y; Gardner EE, 2017, CANCER CELL, V31, P286, DOI 10.1016/j.ccell.2017.01.006; Gazdar AF, 2017, NAT REV CANCER, V17, P725, DOI 10.1038/nrc.2017.87; Guo Y, 2018, LEUKEMIA, V32, P1834, DOI 10.1038/s41375-018-0126-9; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; He M, 2019, SCIENCE, V364, P283, DOI 10.1126/science.aav4902; Jiang LY, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005895; Kalirai H, 2014, BRIT J CANCER, V111, P1373, DOI 10.1038/bjc.2014.417; Khan P, 2022, SEMIN CANCER BIOL, V83, P57, DOI 10.1016/j.semcancer.2020.11.006; Kim DW, 2016, GENE DEV, V30, P1289, DOI 10.1101/gad.279307.116; Krushkal J, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00876-8; Lee HS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6128; Machida YJ, 2009, J BIOL CHEM, V284, P34179, DOI 10.1074/jbc.M109.046755; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08; Novelli F, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2111946118; Okino Y, 2015, J BIOL CHEM, V290, P1580, DOI 10.1074/jbc.M114.609834; Piunti A, 2021, NAT REV MOL CELL BIO, V22, P326, DOI 10.1038/s41580-021-00341-1; Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554; Qin JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9471; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Ruan HB, 2012, CELL METAB, V16, P226, DOI 10.1016/j.cmet.2012.07.006; Rudin CM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00235-0; Scheuermann JC, 2010, NATURE, V465, P243, DOI 10.1038/nature08966; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Srivastava A, 2016, HUM MOL GENET, V25, P597, DOI 10.1093/hmg/ddv499; Stanton BZ, 2017, NAT GENET, V49, P282, DOI 10.1038/ng.3735; Szczepanski AP, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00760-3; Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029; van Essen TH, 2014, BRIT J OPHTHALMOL, V98, P1738, DOI 10.1136/bjophthalmol-2014-305047; Wang L, 2021, NAT CANCER, V2, P515, DOI 10.1038/s43018-021-00199-4; Yang H, 2018, BLOOD, V131, P328, DOI 10.1182/blood-2017-06-789669; Yu L, 2018, GENE DEV, V32, P1537, DOI 10.1101/gad.318436.118; Zhao ZB, 2021, CANCER RES, V81, P4696, DOI 10.1158/0008-5472.CAN-21-1114	46	3	3	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2152	2162		10.1038/s41388-022-02240-x	http://dx.doi.org/10.1038/s41388-022-02240-x		FEB 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35194152	hybrid, Green Published			2022-12-28	WOS:000759404700003
J	Liao, YD; Huang, JM; Liu, P; Zhang, CY; Liu, JX; Xia, M; Shang, CL; Ooi, SY; Chen, YL; Qin, SH; Du, QQ; Liu, TY; Xu, MM; Zou, QJ; Zhou, YJ; Huang, H; Pan, YW; Wang, W; Yao, SZ				Liao, Yuandong; Huang, Jiaming; Liu, Pan; Zhang, Chunyu; Liu, Junxiu; Xia, Meng; Shang, Chunliang; Ooi, Shiyin; Chen, Yili; Qin, Shuhang; Du, Qiqiao; Liu, Tianyu; Xu, Manman; Zou, Qiaojian; Zhou, Yijia; Huang, Hua; Pan, Yuwen; Wang, Wei; Yao, Shuzhong			Downregulation of LNMAS orchestrates partial EMT and immune escape from macrophage phagocytosis to promote lymph node metastasis of cervical cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH; MECHANISMS; EXPRESSION; RATIO	Epithelial-mesenchymal transition (EMT) is an essential step to drive the metastatic cascade to lymph nodes (LNs) in cervical cancer cells. However, few of them metastasize successfully partially due to increased susceptibility to immunosurveillance conferred by EMT. The precise mechanisms of cancer cells orchestrate EMT and immune evasion remain largely unexplored. In this study, we identified a lncRNA termed lymph node metastasis associated suppressor (LNMAS), which was downregulated in LN-positive cervical cancer patients and correlated with LN metastasis and prognosis. Functionally, LNMAS suppressed cervical cancer cells metastasis in vitro and in vivo. Mechanistically, LNMAS exerts its metastasis suppressive activity by competitively interacting with HMGB1 and abrogating the chromatin accessibility of TWIST1 and STC1, inhibiting TWIST1-mediated partial EMT and STC1-dependent immune escape from macrophage phagocytosis. We further demonstrated that the CpG sites in the promoter region of LNMAS was hypermethylated and contributed to the downregulation of LNMAS. Taken together, our results reveal the essential role of LNMAS in the LN metastasis of cervical cancer and provide mechanistic insights into the regulation of LNMAS in EMT and immune evasion.	[Liao, Yuandong; Huang, Jiaming; Liu, Pan; Zhang, Chunyu; Liu, Junxiu; Xia, Meng; Ooi, Shiyin; Chen, Yili; Qin, Shuhang; Du, Qiqiao; Liu, Tianyu; Xu, Manman; Zou, Qiaojian; Zhou, Yijia; Huang, Hua; Pan, Yuwen; Wang, Wei; Yao, Shuzhong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Guangzhou 510080, Guangdong, Peoples R China; [Shang, Chunliang] Peking Univ Third Hosp, Dept Obstet & Gynecol, Beijing 100191, Peoples R China	Sun Yat Sen University; Peking University	Wang, W; Yao, SZ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Guangzhou 510080, Guangdong, Peoples R China.	wangw245@mail.sysu.edu.cn; yaoshuzh@mail.sysu.edu.cn	Zhang, Chun-yu/HDP-5776-2022	Yao, Shuzhong/0000-0002-5145-5705	National Natural Science Foundation of China [81874102, 82072874, 81902627]; Guangzhou Science and Technology Programme [202002020043]; Sun Yat-sen University Clinical Research Foundation of 5010 Project [2017006]; Natural Science Foundation of Guangdong Province [2017A030313509]; Guangdong Basic and Applied Basic Research Foundation [2021A1515011776]; First Affiliated Hospital of Sun Yat-sen University Undergraduate Teaching Reform Research Project [31911130-200437]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Programme; Sun Yat-sen University Clinical Research Foundation of 5010 Project; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Basic and Applied Basic Research Foundation; First Affiliated Hospital of Sun Yat-sen University Undergraduate Teaching Reform Research Project	This work was supported by the National Natural Science Foundation of China (No. 81874102, 82072874 to SZY; 81902627 to JMH), Guangzhou Science and Technology Programme (No. 202002020043 to SZY), Sun Yat-sen University Clinical Research Foundation of 5010 Project (No. 2017006 to SZY), Natural Science Foundation of Guangdong Province (No. 2017A030313509 to WW), Guangdong Basic and Applied Basic Research Foundation (No. 2021A1515011776 to WW) and the First Affiliated Hospital of Sun Yat-sen University Undergraduate Teaching Reform Research Project (No. 31911130-200437 to WW).	Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Aiello NM, 2019, J EXP MED, V216, P1016, DOI 10.1084/jem.20181827; Athie A, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201908078; Barkal AA, 2019, NATURE, V572, P392, DOI 10.1038/s41586-019-1456-0; Battistelli C, 2021, CANCER RES, V81, P103, DOI 10.1158/0008-5472.CAN-20-1764; Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808; Berger AC, 2018, CANCER CELL, V33, P690, DOI 10.1016/j.ccell.2018.03.014; Bhatla N, 2018, INT J GYNECOL OBSTET, V143, P22, DOI 10.1002/ijgo.12611; Blair RH, 2016, J MOL BIOL, V428, P4060, DOI 10.1016/j.jmb.2016.08.018; Brabletz S, 2021, EMBO J, V40, DOI 10.15252/embj.2021108647; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen Y, 2013, INT J GYNECOL CANCER, V23, P157, DOI 10.1097/IGC.0b013e3182778bcf; Chockley PJ, 2018, J CLIN INVEST, V128, P1384, DOI 10.1172/JCI97611; Chu Ci, 2012, J Vis Exp, DOI 10.3791/3912; Dong WH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00340; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Fan JY, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0705-2; Feng MY, 2019, NAT REV CANCER, V19, P568, DOI 10.1038/s41568-019-0183-z; Fleming ND, 2015, GYNECOL ONCOL, V136, P48, DOI 10.1016/j.ygyno.2014.11.010; Garner H, 2020, NAT REV IMMUNOL, V20, P483, DOI 10.1038/s41577-019-0271-z; Guo FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053989; Huang D, 2018, NAT IMMUNOL, V19, P1112, DOI 10.1038/s41590-018-0207-y; Huang JM, 2018, ONCOL LETT, V15, P5584, DOI 10.3892/ol.2018.8037; Iurlaro M, 2021, NAT GENET, V53, P279, DOI 10.1038/s41588-020-00768-w; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Karaman S, 2014, J CLIN INVEST, V124, P922, DOI 10.1172/JCI71606; Klein M, 1999, J ENDOCRINOL, V161, P41, DOI 10.1677/joe.0.1610041; Kong DG, 2021, ONCOGENE, V40, P964, DOI 10.1038/s41388-020-01539-x; Kozlova AL, 2018, MOL BIOL+, V52, P637, DOI 10.1134/S0026893318050096; Lee CK, 2019, SCIENCE, V363, P644, DOI 10.1126/science.aav0173; Lepique AP, 2009, CLIN CANCER RES, V15, P4391, DOI 10.1158/1078-0432.CCR-09-0489; LIN H, CANCER CELL, V2021; Liu F, 2018, ONCOGENE, V37, P2394, DOI 10.1038/s41388-017-0119-6; Liu JQ, 2020, LIFE SCI, V241, DOI 10.1016/j.lfs.2019.117134; Liu XS, 2016, CELL, V167, P233, DOI 10.1016/j.cell.2016.08.056; Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110; Lv DJ, 2019, THERANOSTICS, V9, P5166, DOI 10.7150/thno.33972; Mikheeva SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-194; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Mohme M, 2017, NAT REV CLIN ONCOL, V14, P155, DOI 10.1038/nrclinonc.2016.144; Noman MZ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1345415; Noordhuis MG, 2011, CLIN CANCER RES, V17, P1317, DOI 10.1158/1078-0432.CCR-10-2320; Oki S, 2018, EMBO REP, V19, DOI 10.15252/embr.201846255; Pan X, 2021, CANCER BIOTHER RADIO, V36, P501, DOI 10.1089/cbr.2019.3344; Quan YS, 2018, BIOCHEM BIOPH RES CO, V497, P527, DOI 10.1016/j.bbrc.2018.02.072; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shang CL, 2018, CANCER RES, V78, P877, DOI 10.1158/0008-5472.CAN-17-2356; Shibata K, 2008, ANN ONCOL, V19, P81, DOI 10.1093/annonc/mdm344; Sikic BI, 2019, J CLIN ONCOL, V37, P946, DOI 10.1200/JCO.18.02018; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vojta A, 2016, NUCLEIC ACIDS RES, V44, P5615, DOI 10.1093/nar/gkw159; Wang JB, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00444; Winkle M, 2021, NAT REV DRUG DISCOV, V20, P629, DOI 10.1038/s41573-021-00219-z; Wu N, 2021, CELL DEATH DIFFER, V28, P219, DOI 10.1038/s41418-020-0596-y; Wu YM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1014-2; Xia M., 2020, CELL DEATH DIS, V11; Xu LL, 2021, ONCOGENE, V40, P3578, DOI 10.1038/s41388-021-01760-2; Xu XX, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.9; Yu BY, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01575; Zeng YT, 2019, ONCOGENE, V38, P6940, DOI 10.1038/s41388-019-0906-3; Zhang CY, 2020, THERANOSTICS, V10, P6561, DOI 10.7150/thno.44868; Zhu CY, 2020, EUR REV MED PHARMACO, V24, P2321, DOI 10.26355/eurrev_202003_20498	63	3	3	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1931	1943		10.1038/s41388-022-02202-3	http://dx.doi.org/10.1038/s41388-022-02202-3		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35152264	hybrid, Green Published			2022-12-28	WOS:000754368500001
J	Cho, HC; Huang, YL; Hung, JT; Hung, TH; Cheng, KC; Liu, YH; Kuo, MW; Wang, SH; Yu, AL; Yu, J				Cho, Huan-Chieh; Huang, Yenlin; Hung, Jung-Tung; Hung, Tsai-Hsien; Cheng, Kai-Chun; Liu, Yun-Hen; Kuo, Ming-Wei; Wang, Sheng-Hung; Yu, Alice L.; Yu, John			Puf-A promotes cancer progression by interacting with nucleophosmin in nucleolus	ONCOGENE			English	Article							CELL-CYCLE; TRANSCRIPTION FACTOR; RIBOSOME BIOGENESIS; BINDING-SITE; LUNG-CANCER; P53; TARGET; EXPRESSION; PROLIFERATION; RECOGNITION	Previously, we identified Puf-A as a novel member of Puf-family RNA-binding proteins; however, its biological functions remain obscure. Analysis of tumor samples of non-small cell lung cancer (NSCLC) showed that high Puf-A expression correlated with high histology grade and abnormal p53 status. Kaplan-Meier curve for overall survival revealed high expression of Puf-A to predict poor prognosis in stage I NSCLC. Among patients with colorectal cancer, high Puf-A expression also showed an adverse impact on overall survival. In lung cancer cell lines, downregulation of p53 increased Puf-A expression, and upregulation of p53 dampened its expression. However, luciferase reporter assays indicated that PUF-A locus harbored the p53-response element, but regulated Puf-A transcription indirectly. In vivo suppression of p53 in CCSP-rtTA/TetO-Cre/LSL-Kras(G12D)/p53(flox/flox) conditional mutant mice accelerated the progression of the Kras(G12D)-driven lung cancer, along with enhanced expression of Puf-A. Importantly, intranasal delivery of shPuf-A to the inducible Kras(G12D)/p53(flox/flox) mice suppressed tumor progression. Puf-A silencing led to marked decreases in the 80S ribosomes, along with decrease in S6 and L5 in the cytoplasm and accumulation in the nucleolus. Based on immunofluorescence staining and immunoprecipitation studies, Puf-A interacted with NPM1 in nucleolus. Puf-A silencing resulted in NPM1 translocation from nucleolus to nucleoplasm and this disruption of NPM1 localization was reversed by a rescue experiment. Mechanistically, Puf-A silencing altered NPM1 localization, leading to the retention of ribosomal proteins in nucleolus and diminished ribosome biogenesis, followed by cell-cycle arrest/cell death. Puf-A is a potential theranostic target for cancer therapy and an important player in cancer progression.	[Cho, Huan-Chieh; Huang, Yenlin; Hung, Jung-Tung; Hung, Tsai-Hsien; Cheng, Kai-Chun; Kuo, Ming-Wei; Wang, Sheng-Hung; Yu, Alice L.; Yu, John] Chang Gung Mem Hosp Linkou, Inst Stem Cell & Translat Canc Res, Taoyuan, Taiwan; [Huang, Yenlin] Chang Gung Mem Hosp Linkou, Dept Anat Pathol, Taoyuan, Taiwan; [Liu, Yun-Hen] Chang Gung Mem Hosp Linkou, Dept Surg, Taoyuan, Taiwan; [Yu, Alice L.] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Yu, Alice L.] Univ Calif San Diego, Med Ctr, Dept Pediat, San Diego, CA 92103 USA; [Yu, John] Acad Sinica, Inst Cellular & Organism Biol, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Academia Sinica - Taiwan; University of California System; University of California San Diego; Academia Sinica - Taiwan	Yu, J (corresponding author), Chang Gung Mem Hosp Linkou, Inst Stem Cell & Translat Canc Res, Taoyuan, Taiwan.	johnyu@gate.sinica.edu.tw		Yu, John/0000-0002-3237-4272	Ministry of Science and Technology of Taiwan [MOST 106-3114-B-182A-001, MOST 107-2321-B-182A-005, MOST 108-2321-B-182A-004, MOST 109-2321-B-182A-005]; CGMH at Linkou of Taiwan [CMRPG3H1342, OMRPG3C0047-OMRPG3C0048, CMRPG3J0311-CMRPG3J0313]; CGMH fellowship	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); CGMH at Linkou of Taiwan; CGMH fellowship	This work was supported by Ministry of Science and Technology of Taiwan (MOST 106-3114-B-182A-001, MOST 107-2321-B-182A-005, MOST 108-2321-B-182A-004, and MOST 109-2321-B-182A-005); and CGMH at Linkou of Taiwan (CMRPG3H1342, OMRPG3C0047-OMRPG3C0048 to JY and CMRPG3J0311-CMRPG3J0313 to JTH). HCC is a recipient of CGMH fellowship.	Ando K, 2017, J CELL BIOL, V216, P1795, DOI 10.1083/jcb.201608095; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Bursac S, 2014, BBA-MOL BASIS DIS, V1842, P817, DOI 10.1016/j.bbadis.2013.08.014; Chang HY, 2011, CANCER RES, V71, P1126, DOI 10.1158/0008-5472.CAN-10-1831; Chen SY, 2018, J DRUG TARGET, V26, P27, DOI 10.1080/1061186X.2017.1332066; Cho HC, 2011, CANCER RES, V71, P7250, DOI 10.1158/0008-5472.CAN-11-0903; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Dez C, 2004, CURR OPIN MICROBIOL, V7, P631, DOI 10.1016/j.mib.2004.10.007; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fan CC, 2013, TUMOR BIOL, V34, P2557, DOI 10.1007/s13277-013-0801-4; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fischer M, 2016, CELL CYCLE, V15, P2852, DOI 10.1080/15384101.2016.1205393; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P164, DOI 10.1093/nar/gkv927; Fischer M, 2015, ONCOTARGET, V6, P41402, DOI 10.18632/oncotarget.6356; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Golomb L, 2014, FEBS LETT, V588, P2571, DOI 10.1016/j.febslet.2014.04.014; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Iqbal Nida, 2014, Mol Biol Int, V2014, P852748, DOI 10.1155/2014/852748; Ishibashi H, 2003, J CLIN ENDOCR METAB, V88, P2309, DOI 10.1210/jc.2002-021353; Jordan JJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000104; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kiankhooy A, 2014, ANN THORAC SURG, V98, P1175, DOI 10.1016/j.athoracsur.2014.05.061; Kreft L, 2017, NUCLEIC ACIDS RES, V45, pW490, DOI 10.1093/nar/gkx376; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuo MW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004980; Li SH, 2017, J ORAL PATHOL MED, V46, P175, DOI 10.1111/jop.12482; Li ZL, 2008, P NATL ACAD SCI USA, V105, P18794, DOI 10.1073/pnas.0806879105; Li ZH, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000213; Lindstrom MS, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/195209; Liu GY, 2017, J CELL BIOCHEM, V118, P4697, DOI 10.1002/jcb.26135; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Mitrea DM, 2016, ELIFE, V5, DOI 10.7554/eLife.13571; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Ponkratova D., 2020, BIOL B REV, V10, P266; Qiu C, 2014, P NATL ACAD SCI USA, V111, P18554, DOI 10.1073/pnas.1407634112; Rosorius O, 2000, J BIOL CHEM, V275, P12061, DOI 10.1074/jbc.275.16.12061; Sawazaki H, 2017, WORLD J UROL, V35, P1081, DOI 10.1007/s00345-016-1977-1; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; Sinn HP, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3111-1; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stepinski D, 2018, HISTOCHEM CELL BIOL, V150, P607, DOI 10.1007/s00418-018-1706-5; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang XQ, 2002, CELL, V110, P501, DOI 10.1016/S0092-8674(02)00873-5; Xie DY, 2014, ONCOL REP, V32, P2517, DOI 10.3892/or.2014.3538; Xie M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13280; Zhu CQ, 2014, TRANSL LUNG CANCER R, V3, P149, DOI 10.3978/j.issn.2218-6751.2014.06.09	51	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1155	1165		10.1038/s41388-021-02138-0	http://dx.doi.org/10.1038/s41388-021-02138-0		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	34999733	hybrid, Green Published			2022-12-28	WOS:000740423400001
J	DiNatale, A; Kaur, R; Qian, C; Zhang, JY; Marchioli, M; Ipe, D; Castelli, M; McNair, CM; Kumar, G; Meucci, O; Fatatis, A				DiNatale, Anthony; Kaur, Ramanpreet; Qian, Chen; Zhang, Jieyi; Marchioli, Michael; Ipe, Darin; Castelli, Maria; McNair, Chris M.; Kumar, Gaurav; Meucci, Olimpia; Fatatis, Alessandro			Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to chemotherapy	ONCOGENE			English	Article							FRACTALKINE RECEPTOR CX(3)CR1; STEM-CELLS; CHEMOKINE CX3CL1; TUMOR-CELLS; ADHESION; BONE; PLASTICITY; MIGRATION; SALL4; PLURIPOTENCY	Metastasis-initiating cells (MICs) display stem cell-like features, cause metastatic recurrences and defy chemotherapy, which leads to patients' demise. Here we show that prostate and breast cancer patients harbor contingents of tumor cells with high expression of CX3CR1, OCT4a (POU5F1), and NANOG. Impairing CX3CR1 expression or signaling hampered the formation of tumor spheroids by cell lines from which we isolated small subsets co-expressing CX3CR1 and stemness-related markers, similarly to patients' tumors. These rare CX3CR1(High) cells show transcriptomic profiles enriched in pathways that regulate pluripotency and endowed with metastasis-initiating behavior in murine models. Cancer cells lacking these features (CX3CR1(Low)) were capable of re-acquiring CX3CR1-associated features over time, implying that MICs can continuously emerge from non-stem cancer cells. CX3CR1 expression also conferred resistance to docetaxel, and prolonged treatment with docetaxel selected CX3CR1(High) phenotypes with de-enriched transcriptomic profiles for apoptotic pathways. These findings nominate CX3CR1 as a novel marker of stem-like tumor cells and provide conceptual ground for future development of approaches targeting CX3CR1 signaling and (re)expression as therapeutic means to prevent or contain metastasis initiation.	[DiNatale, Anthony; Kaur, Ramanpreet; Qian, Chen; Zhang, Jieyi; Marchioli, Michael; Ipe, Darin; Castelli, Maria; Meucci, Olimpia; Fatatis, Alessandro] Drexel Univ, Coll Med, Dept Pharmacol & Physiol, Philadelphia, PA 19102 USA; [McNair, Chris M.; Kumar, Gaurav] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [McNair, Chris M.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Canc Informat, Philadelphia, PA 19107 USA; [Meucci, Olimpia] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Program Immune Cell Regulat & Targeting, Philadelphia, PA 19107 USA; [Fatatis, Alessandro] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Program Translat & Cellular Oncol, Philadelphia, PA 19107 USA; [Kaur, Ramanpreet] Champ Oncol, 1330 Piccard Dr, Rockville, MD 20850 USA; [Qian, Chen] Cedars Sinai, Samuel Oschin Canc Ctr, Los Angeles, CA 90048 USA; [Castelli, Maria] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	Drexel University; Jefferson University; Jefferson University; Jefferson University; Jefferson University; Cedars Sinai Medical Center; University of Pennsylvania; Pennsylvania Medicine	Fatatis, A (corresponding author), Drexel Univ, Coll Med, Dept Pharmacol & Physiol, Philadelphia, PA 19102 USA.; Fatatis, A (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Program Translat & Cellular Oncol, Philadelphia, PA 19107 USA.	af39@drexel.edu	Qian, Chen/GWV-0990-2022	DiNatale, Anthony/0000-0003-3221-7506; Meucci, Olimpia/0000-0001-8333-4804	NCI [R01-CA202929]; DoD [BC150659]; Wallace H. Coulter Foundation; Pennsylvania Breast Cancer Coalition; Breast Cancer Alliance; Sidney Kimmel Cancer Center (SKCC) Support Grant [5P30CA056036-21]	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DoD(United States Department of Defense); Wallace H. Coulter Foundation; Pennsylvania Breast Cancer Coalition; Breast Cancer Alliance; Sidney Kimmel Cancer Center (SKCC) Support Grant	This work was supported by NCI grant R01-CA202929 (AF and OM), DoD grant BC150659 (AF), Wallace H. Coulter Foundation (AF and OM), Pennsylvania Breast Cancer Coalition (AF), Exceptional Project Grant from Breast Cancer Alliance (AF), and the Sidney Kimmel Cancer Center (SKCC) Support Grant 5P30CA056036-21 (AF). We would like to thank: Dr. Meenhard Herlyn (Wistar Institute, Philadelphia, PA) and Dr. Edward Hartsough (Pharmacology and Physiology, Drexel University College of Medicine) for providing the WM793 and 1205Lu human melanoma cell lines; Dr. Edward Hartsough (Pharmacology and Physiology, Drexel University College of Medicine) and Dr. Josep Domingo-Domenech (Cancer Biology, SKCC at Thomas Jefferson University) for helpful discussions; Dr. Paolo Fortina, Professor of Cancer Biology and Director of the Cancer Genomics and Translational Research/Pathology core services at SKCC for consultation and advice with RNA Sequencing; Ms. Shannon Cremin (Translational Research Project Manager), Ms. Danielle Wentworth (Biorepository Manager) and the SKCC Biorepository of Thomas Jefferson University for providing the human specimens used in this study. The authors are also grateful to Dr. Bradley Nash (Director, Office of Scientific Communications, Department of Pharmacology and Physiology, Drexel University College of Medicine) for critically reading and editing the manuscript.	Agarwal N, 2014, ANN ONCOL, V25, P1700, DOI 10.1093/annonc/mdu038; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Annett S, 2018, PHARMACOL THERAPEUT, V187, P13, DOI 10.1016/j.pharmthera.2018.02.001; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bendas Gerd, 2012, Int J Cell Biol, V2012, P676731, DOI 10.1155/2012/676731; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Cabrera MC, 2015, WORLD J STEM CELLS, V7, P27, DOI 10.4252/wjsc.v7.i1.27; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Celia-Terrassa T, 2018, NAT CELL BIOL, V20, P868, DOI 10.1038/s41556-018-0145-9; Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chandrakesan P, 2016, J Carcinog Mutagen, V7; Chen W, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1740936; Cheung TH, 2013, NAT REV MOL CELL BIO, V14, P329, DOI 10.1038/nrm3591; Chimento A, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00807; Do DV, 2013, GENE DEV, V27, P1378, DOI 10.1101/gad.221176.113; Das PK, 2020, STEM CELL REV REP, V16, P397, DOI 10.1007/s12015-019-09942-y; Dillekas H, 2019, CANCER MED-US, V8, P5574, DOI 10.1002/cam4.2474; Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005; Er EE, 2018, NAT CELL BIOL, V20, P966, DOI 10.1038/s41556-018-0138-8; Erreni M, 2010, EUR J CANCER, V46, P3383, DOI 10.1016/j.ejca.2010.07.022; Esposito M, 2014, PHARMACOL THERAPEUT, V141, P222, DOI 10.1016/j.pharmthera.2013.10.006; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Francescone R, 2021, CANCER DISCOV, V11, P446, DOI 10.1158/2159-8290.CD-20-0775; Ganesh K, 2021, NAT MED, V27, P34, DOI 10.1038/s41591-020-01195-4; Gassenmaier M, 2013, STEM CELLS, V31, P1467, DOI 10.1002/stem.1407; Geng Y, 2012, ANN BIOMED ENG, V40, P790, DOI 10.1007/s10439-011-0463-6; Gravina GL, 2015, PROSTATE, V75, P1227, DOI 10.1002/pros.23007; Gu GY, 2007, CANCER RES, V67, P4807, DOI 10.1158/0008-5472.CAN-06-4608; Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Huang LY, 2017, BIOCHEM BIOPH RES CO, V493, P1510, DOI 10.1016/j.bbrc.2017.10.006; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Igntiadis M, 2008, EUR J CANCER, V44, P2726, DOI 10.1016/j.ejca.2008.09.033; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Jamieson WL, 2008, CANCER RES, V68, P1715, DOI 10.1158/0008-5472.CAN-07-1315; Jamieson-Gladney WL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3016; JavanMoghadam-Kamrani S, 2008, CELL CYCLE, V7, P2434, DOI 10.4161/cc.6364; Jiao XM, 2019, CANCER RES, V79, P4801, DOI 10.1158/0008-5472.CAN-19-1167; Kakinuma T, 2006, J LEUKOCYTE BIOL, V79, P639, DOI 10.1189/jlb.1105633; Karatas OF, 2016, PROSTATE, V76, P434, DOI 10.1002/pros.23137; Kato H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046576; Kim J, 2016, ONCOGENE, V35, P1334, DOI 10.1038/onc.2015.205; Kim M, 2012, MOL CANCER RES, V10, P11, DOI 10.1158/1541-7786.MCR-11-0256; Kim SY, 2013, CELL SIGNAL, V25, P961, DOI 10.1016/j.cellsig.2013.01.007; King KM, 2009, CURR ONCOL, V16, P149; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; LaFave LM, 2012, TRENDS PHARMACOL SCI, V33, P574, DOI 10.1016/j.tips.2012.08.005; Lee SJ, 2006, AM J PHYSIOL-HEART C, V291, pH2836, DOI 10.1152/ajpheart.00113.2006; Li WZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14364-2; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu AF, 2013, CHIN J CANCER, V32, P483, DOI 10.5732/cjc.012.10282; Liu Y, 2021, CLIN TRANSL ONCOL, V23, P378, DOI 10.1007/s12094-020-02431-6; Locatelli M, 2010, EUR CYTOKINE NETW, V21, P27, DOI 10.1684/ecn.2009.0184; Lombardo Y, 2015, JOVE-J VIS EXP, DOI 10.3791/52671; Main HG, 2017, ONCOGENE, V36, P3025, DOI 10.1038/onc.2016.456; Mandegar MA, 2016, CELL STEM CELL, V18, P541, DOI 10.1016/j.stem.2016.01.022; Mantovani A, 2010, CYTOKINE GROWTH F R, V21, P27, DOI 10.1016/j.cytogfr.2009.11.007; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Micalizzi DS, 2017, GENE DEV, V31, P1827, DOI 10.1101/gad.305805.117; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Morein D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00952; Mukherjee D, 2013, AM J CANCER RES, V3, P46; Obenauf AC, 2015, TRENDS CANCER, V1, P76, DOI 10.1016/j.trecan.2015.07.009; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Palmeri Laura, 2008, Ther Clin Risk Manag, V4, P1047; Pasello M, 2020, SEMIN CANCER BIOL, V60, P57, DOI 10.1016/j.semcancer.2019.10.004; Pein M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15188-x; Putzer BM, 2017, ADV DRUG DELIVER REV, V120, P89, DOI 10.1016/j.addr.2017.07.013; Qian C, 2018, MOL CANCER RES, V16, P1844, DOI 10.1158/1541-7786.MCR-18-0302; Quayle LA, 2018, CLIN EXP METASTAS, V35, P831, DOI 10.1007/s10585-018-9946-2; Qureshi-Baig K, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0602-2; Ramsey DM, 2013, BIOORG MED CHEM LETT, V23, P20, DOI 10.1016/j.bmcl.2012.10.138; Rao S, 2010, BIOL BLOOD MARROW TR, V16, pS187, DOI 10.1016/j.bbmt.2009.12.111; Riethdorf S, 2008, INT J CANCER, V123, P1991, DOI 10.1002/ijc.23825; Riihimaki M, 2018, CANCER MED-US, V7, P5534, DOI 10.1002/cam4.1697; Shahriari K, 2017, ONCOGENE, V36, P2846, DOI 10.1038/onc.2016.436; Shen F, 2016, MOL CANCER RES, V14, P518, DOI 10.1158/1541-7786.MCR-16-0013; Shen Y, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw023; Shi GL, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt39; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; Singh SK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19643-0; Stojic L, 2018, NUCLEIC ACIDS RES, V46, P5950, DOI 10.1093/nar/gky437; Tatetsu H, 2016, GENE, V584, P111, DOI 10.1016/j.gene.2016.02.019; Thankamony AP, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00079; Tsubooka N, 2009, GENES CELLS, V14, P683, DOI 10.1111/j.1365-2443.2009.01301.x; Wada A, 2015, ONCOL REP, V33, P2935, DOI 10.3892/or.2015.3941; Walcher L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01280; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Wang YJ, 2015, AM J PHYSIOL-CELL PH, V309, pC709, DOI 10.1152/ajpcell.00212.2015; Weber MR, 2016, THROMB RES, V140, pS27, DOI 10.1016/S0049-3848(16)30095-0; Worrede A, 2019, PHARMACOL THERAPEUT, V199, P117, DOI 10.1016/j.pharmthera.2019.03.007; Yang JC, 2018, BIOMARK RES, V6, DOI 10.1186/s40364-017-0115-6; Yang JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010766; Yang JC, 2008, P NATL ACAD SCI USA, V105, P19756, DOI 10.1073/pnas.0809321105; Yang XP, 2007, CIRC RES, V101, P1001, DOI 10.1161/CIRCRESAHA.107.160812; Yao X, 2014, UROL ONCOL-SEMIN ORI, V32, P162, DOI 10.1016/j.urolonc.2012.12.006; Yuan S, 2019, CANCER DISCOV, V9, P837, DOI 10.1158/2159-8290.CD-19-0015; Zhang WJ, 2021, CELL, V184, P2471, DOI 10.1016/j.cell.2021.03.011; Zhao Wenxiu, 2017, Cancer Transl Med, V3, P87, DOI 10.4103/ctm.ctm_69_16; Zhao Y, 2018, SEMIN CANCER BIOL, V53, P139, DOI 10.1016/j.semcancer.2018.08.002; Zheng DQ, 1999, CANCER RES, V59, P1655	114	0	0	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1337	1351		10.1038/s41388-021-02174-w	http://dx.doi.org/10.1038/s41388-021-02174-w		JAN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	34999735	Green Accepted			2022-12-28	WOS:000740423700003
J	He, ZS; Khatib, AM; Creemers, JWM				He, Zongsheng; Khatib, Abdel-Majid; Creemers, John W. M.			The proprotein convertase furin in cancer: more than an oncogene	ONCOGENE			English	Review							TUMOR-NECROSIS-FACTOR; TRANS-GOLGI NETWORK; ENDOPROTEOLYTIC CLEAVAGE; SELECTIVE-INHIBITION; PROCESSING ENZYME; IMMUNE EVASION; FACTOR-ALPHA; E-CADHERIN; IN-VITRO; T-CELLS	Furin is the first discovered proprotein convertase member and is present in almost all mammalian cells. Therefore, by regulating the maturation of a wide range of proproteins, Furin expression and/or activity is involved in various physiological and pathophysiological processes ranging from embryonic development to carcinogenesis. Since many of these protein precursors are involved in initiating and maintaining the hallmarks of cancer, Furin has been proposed as a potential target for treating several human cancers. In contrast, other studies have revealed that some types of cancer do not benefit from Furin inhibition. Therefore, understanding the heterogeneous functions of Furin in cancer will provide important insights into the design of effective strategies targeting Furin in cancer treatment. Here, we present recent advances in understanding how Furin expression and activity are regulated in cancer cells and their influences on the activity of Furin substrates in carcinogenesis. Furthermore, we discuss how Furin represses tumorigenic properties of several cancer cells and why Furin inhibition leads to aggressive phenotypes in other tumors. Finally, we summarize the clinical applications of Furin inhibition in treating human cancers.	[He, Zongsheng] Army Med Univ, Daping Hosp, Dept Gastroenterol, Chongqing, Peoples R China; [He, Zongsheng; Creemers, John W. M.] Katholieke Univ Leuven, Lab Biochem Neuroendocrinol, Dept Human Genet, Leuven, Belgium; [Khatib, Abdel-Majid] INSERM, LAMC, UMR 1029, Allee Geoffroy St Hilaire, Pessac, France; [Khatib, Abdel-Majid] Inst Bergoinie, Bordeaux, France	Army Medical University; KU Leuven; Institut National de la Sante et de la Recherche Medicale (Inserm)	Creemers, JWM (corresponding author), Katholieke Univ Leuven, Lab Biochem Neuroendocrinol, Dept Human Genet, Leuven, Belgium.; Khatib, AM (corresponding author), INSERM, LAMC, UMR 1029, Allee Geoffroy St Hilaire, Pessac, France.; Khatib, AM (corresponding author), Inst Bergoinie, Bordeaux, France.	majid.khatib@inserm.fr; john.creemers@kuleuven.be		He, Zongsheng/0000-0003-2499-8402; Creemers, John/0000-0003-2518-9295	FWO Vlaanderen [G.0738.15]	FWO Vlaanderen(FWO)	We would like to thank Sandra McElroy for proofreading manuscript. We acknowledge grant support from FWO Vlaanderen (Grant no. G.0738.15) to JC.	Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; Al Rifai O, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.690681; Bassi DE, 2017, MOL CARCINOGEN, V56, P1182, DOI 10.1002/mc.22550; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; Baumgart A, 2015, ONCOGENE, V34, P578, DOI 10.1038/onc.2013.592; Bergeron E, 2003, BIOCHEM J, V373, P475, DOI 10.1042/BJ20021630; Bernasconi-Elias P, 2016, ONCOGENE, V35, P6077, DOI 10.1038/onc.2016.133; Bertrand F, 2015, CANCER RES, V75, P2619, DOI 10.1158/0008-5472.CAN-14-2524; Bilbao D, 2014, EMBO MOL MED, V6, P1423, DOI 10.15252/emmm.201303376; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blanchette F, 2001, J CELL PHYSIOL, V188, P264, DOI 10.1002/jcp.1116; Bommireddy R, 2007, TRENDS MOL MED, V13, P492, DOI 10.1016/j.molmed.2007.08.005; Brouwers B, 2021, DIABETES, V70, P492, DOI 10.2337/db20-0474; Cao J, 2005, J BIOL CHEM, V280, P10974, DOI 10.1074/jbc.M412370200; Casazza A, 2012, EMBO MOL MED, V4, P234, DOI 10.1002/emmm.201100205; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang LY, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1040215; Chen WJ, 2016, NAT REV IMMUNOL, V16, P723, DOI 10.1038/nri.2016.112; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Christensen C, 2005, CANCER RES, V65, P6167, DOI 10.1158/0008-5472.CAN-04-4309; Coppola I, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126344; Cordova ZM, 2016, ONCOTARGET, V7, P54392, DOI 10.18632/oncotarget.11106; Couture F, 2015, EXPERT OPIN THER PAT, V25, P379, DOI 10.1517/13543776.2014.1000303; Creemers JWM, 2008, FRONT BIOSCI-LANDMRK, V13, P4960, DOI 10.2741/3055; D'Anjou F, 2011, TRANSL ONCOL, V4, P157, DOI 10.1593/tlo.10295; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Declercq J, 2017, EUR J CELL BIOL, V96, P432, DOI 10.1016/j.ejcb.2017.03.010; Declercq J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/321276; Declercq J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/148651; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Derynck R, 2021, NAT REV CLIN ONCOL, V18, P9, DOI 10.1038/s41571-020-0403-1; Doci CL, 2015, CANCER RES, V75, P2937, DOI 10.1158/0008-5472.CAN-14-3121; Duguay SJ, 1998, J BIOL CHEM, V273, P18443, DOI 10.1074/jbc.273.29.18443; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Duval S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02893-0; Essalmani R, 2011, J BIOL CHEM, V286, P4257, DOI 10.1074/jbc.M110.192104; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Fu J, 2015, MOL CARCINOGEN, V54, P698, DOI 10.1002/mc.22131; Garancher A, 2020, NAT NEUROSCI, V23, P842, DOI 10.1038/s41593-020-0628-4; Ghisoli M, 2017, J PEDIAT HEMATOL ONC, V39, pE183, DOI 10.1097/MPH.0000000000000822; Ghisoli M, 2016, MOL THER, V24, P1478, DOI 10.1038/mt.2016.86; Ghisoli M, 2015, MOL THER, V23, P1103, DOI 10.1038/mt.2015.43; Ginefra P, 2018, CELL REP, V22, P2176, DOI 10.1016/j.celrep.2018.02.005; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hartley G, 2017, CANCER IMMUNOL IMMUN, V66, P523, DOI 10.1007/s00262-017-1955-5; Hasegawa-Minato J, 2018, ONCOTARGET, V9, P3483, DOI 10.18632/oncotarget.23322; He ZS, 2020, CANCERS, V12, DOI 10.3390/cancers12092686; He ZS, 2020, CANCER LETT, V484, P40, DOI 10.1016/j.canlet.2020.05.001; He ZS, 2020, ONCOGENE, V39, P3571, DOI 10.1038/s41388-020-1238-z; Huang YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040738; Huo X, 2021, ONCOTARGETS THER, V14, P809, DOI 10.2147/OTT.S276553; Jaaks P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161396; Jin WJ, 2005, J BIOL CHEM, V280, P36551, DOI 10.1074/jbc.M502264200; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kara I, 2015, J BIOL CHEM, V290, P2812, DOI 10.1074/jbc.M114.592543; Kearney CJ, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar3451; Khatib AM, 2016, ONCOTARGET, V7, P12102, DOI 10.18632/oncotarget.7728; Khatib AM, 2005, AM J PATHOL, V167, P749, DOI 10.1016/S0002-9440(10)62048-2; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Khatib AM, 1999, CANCER RES, V59, P1356; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; Klein-Szanto AJ, 2017, BIOCHEM PHARMACOL, V140, P8, DOI 10.1016/j.bcp.2017.04.027; Kusmartsev S, 2006, CANCER IMMUNOL IMMUN, V55, P237, DOI 10.1007/s00262-005-0048-z; Lapierre M, 2007, CANCER RES, V67, P9030, DOI 10.1158/0008-5472.CAN-07-0807; Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lehmann M, 1996, BIOCHEM J, V317, P803, DOI 10.1042/bj3170803; Lei RX, 2009, HEPATOLOGY, V50, P763, DOI 10.1002/hep.23062; Levesque C, 2012, J MED CHEM, V55, P10501, DOI 10.1021/jm3011178; Liefers-Visser JAL, 2017, CANCER TREAT REV, V60, P90, DOI 10.1016/j.ctrv.2017.08.012; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Louagie E, 2008, P NATL ACAD SCI USA, V105, P12319, DOI 10.1073/pnas.0800340105; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Ma J, 2017, EUR J CELL BIOL, V96, P457, DOI 10.1016/j.ejcb.2017.06.001; Maret D, 2012, NEOPLASIA, V14, P880, DOI 10.1593/neo.121250; Maret D, 2010, NEOPLASIA, V12, P1066, DOI 10.1593/neo.10954; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; McColl BK, 2007, FASEB J, V21, P1088, DOI 10.1096/fj.06-7060com; McMahon S, 2006, J BIOL CHEM, V281, P24171, DOI 10.1074/jbc.M604507200; Mesnard D, 2011, GENE DEV, V25, P1871, DOI 10.1101/gad.16738711; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Mumblat Y, 2015, CANCER RES, V75, P2177, DOI 10.1158/0008-5472.CAN-14-2464; Nemunaitis J, 2014, ONCOLOGY-BASEL, V87, P21, DOI 10.1159/000360993; Oh J, 2016, GYNECOL ONCOL, V143, P504, DOI 10.1016/j.ygyno.2016.09.018; Paleyanda RK, 1997, J BIOL CHEM, V272, P15270, DOI 10.1074/jbc.272.24.15270; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Parker MW, 2010, BIOCHEMISTRY-US, V49, P4068, DOI 10.1021/bi100327r; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Pesu M, 2008, NATURE, V455, P246, DOI 10.1038/nature07210; Plaimauer B, 2001, BIOCHEM J, V354, P689, DOI 10.1042/0264-6021:3540689; Posthaus H, 1998, FEBS LETT, V438, P306, DOI 10.1016/S0014-5793(98)01330-1; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Ramirez C, 2019, NATURE, V576, P477, DOI 10.1038/s41586-019-1831-x; Rocconi RP, 2020, J CLIN ONCOL, V38; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; Roebroek AJM, 2004, J BIOL CHEM, V279, P53442, DOI 10.1074/jbc.M407152200; Rose M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.667850; Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002; Sarkar FH, 2007, MINI-REV MED CHEM, V7, P599; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Scamuffa N, 2008, J CLIN INVEST, V118, P352, DOI 10.1172/JCI32040; Scamuffa N, 2014, CARCINOGENESIS, V35, P528, DOI 10.1093/carcin/bgt345; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Senzer N, 2012, MOL THER, V20, P679, DOI 10.1038/mt.2011.269; Shakya M, 2021, ENDOCR REV, V42, P259, DOI 10.1210/endrev/bnaa033; Shiryaev SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054290; Siegfried G, 2005, ONCOGENE, V24, P6925, DOI 10.1038/sj.onc.1208838; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Siegfried G, 2003, CANCER RES, V63, P1458; Siegfried G, 2020, CANCER LETT, V473, P50, DOI 10.1016/j.canlet.2019.12.027; Soulet F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.129070; Srour N, 2003, FEBS LETT, V554, P275, DOI 10.1016/S0014-5793(03)01159-1; Sugano Y, 2003, ONCOGENE, V22, P2309, DOI 10.1038/sj.onc.1206305; Susan-Resiga D, 2011, J BIOL CHEM, V286, P22785, DOI 10.1074/jbc.M111.233577; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Tian S, 2011, INT J MOL SCI, V12, P1060, DOI 10.3390/ijms12021060; Tome M, 2019, CANCER RES, V79, P5008, DOI 10.1158/0008-5472.CAN-19-0086; Turpeinen H, 2011, ATHEROSCLEROSIS, V219, P799, DOI 10.1016/j.atherosclerosis.2011.08.011; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Uhlen M, 2019, SCIENCE, V366, P1471, DOI 10.1126/science.aax9198; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vahatupa M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1245266; van der Veeken J, 2016, CELL, V166, P977, DOI 10.1016/j.cell.2016.07.006; VANDEVEN WJM, 1991, ENZYME, V45, P257, DOI 10.1159/000468900; Varshavsky A, 2008, CANCER RES, V68, P6922, DOI 10.1158/0008-5472.CAN-07-5408; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; Yakala GK, 2019, ARTERIOSCL THROM VAS, V39, P387, DOI 10.1161/ATVBAHA.118.311903; Yu WN, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00989; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang YZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0796-y; Zhang YL, 2017, INT J ONCOL, V50, P1352, DOI 10.3892/ijo.2017.3896; Zhao XD, 2017, CANCER RES, V77, P817, DOI 10.1158/0008-5472.CAN-16-2379; Zhao XQ, 2012, J CLIN INVEST, V122, P4094, DOI 10.1172/JCI64115; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; Zhou BL, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.648402; Zhu JJ, 2012, BIOCHEM J, V448, P73, DOI 10.1042/BJ20120537	144	6	6	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1252	1262		10.1038/s41388-021-02175-9	http://dx.doi.org/10.1038/s41388-021-02175-9		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	34997216				2022-12-28	WOS:000740148500002
J	Sun, LZ; Xi, SY; Zhou, ZD; Zhang, FF; Hu, PC; Cui, YZ; Wu, SS; Wang, Y; Wu, SY; Wang, YC; Du, YY; Zheng, JY; Yang, H; Chen, M; Yan, Q; Yu, DD; Shi, CR; Zhang, Y; Xie, D; Guan, XY; Li, Y				Sun, Liangzhan; Xi, Shaoyan; Zhou, Zhengdong; Zhang, Feifei; Hu, Pengchao; Cui, Yuzhu; Wu, Shasha; Wang, Ying; Wu, Shayi; Wang, Yanchen; Du, Yuyang; Zheng, Jingyi; Yang, Hui; Chen, Miao; Yan, Qian; Yu, Dandan; Shi, Chaoran; Zhang, Yu; Xie, Dan; Guan, Xin-Yuan; Li, Yan			Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor	ONCOGENE			English	Article							INITIATION-FACTOR; PATHWAY; KINASE; ACTIVATION; EIF4E	Hyperactivation of RAS/MAPK signaling is commonly observed in hepatocellular carcinoma (HCC). Gain-of-function mutations of canonical RAS genes, however, are rarely detected and it remains unclear how the activity of this pathway is turned on during hepatocarcinogenesis. We performed a comprehensive analysis of RAS superfamily genetic alterations across ten subfamilies, 152 members in 377 HCC patients from the Cancer Genome Atlas database. RIT1 (Ras-like without CAAX 1) was the most frequently altered RAS member amplified in 13% of the HCC cohort. Both genomic amplification and CREB-mediated transcriptional activation contributed to the elevated RIT1 expression, and its overexpression correlated with RAS/MAPK activation and poor prognosis. Then, we found that RIT1-induced angiogenesis via the MEK/ERK/EIF4E/HIF1-alpha/VEGFA axis. MAP3K11 and MAP3K12, in addition to CRAF, could mediate this process by binding to RIT1. Moreover, RIT1 increased the phosphorylation of p38 MAPK and AKT to promote cell survival under reactive oxygen species stress. Based on this mechanistic understanding, we treated RIT1-overexpressing HCC with combined regimen sorafenib plus AKT inhibitor, and achieved enhanced antitumor effects in vivo. Our study reveals RAS "orphan" member RIT1 as the most common genetic alteration of RAS family in HCC and combination of sorafenib with AKT inhibitor might be a promising treatment strategy for RIT1-overexpressing HCC.	[Sun, Liangzhan; Zhou, Zhengdong; Hu, Pengchao; Wu, Shasha; Wang, Yanchen; Du, Yuyang; Zheng, Jingyi; Yang, Hui; Yu, Dandan; Li, Yan] Southern Univ Sci & Technol, Sch Life Sci, Dept Biol, Shenzhen, Peoples R China; [Sun, Liangzhan; Zhang, Feifei; Cui, Yuzhu; Wu, Shayi; Chen, Miao; Yan, Qian; Yu, Dandan; Shi, Chaoran; Zhang, Yu; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China; [Sun, Liangzhan; Yan, Qian; Yu, Dandan; Guan, Xin-Yuan] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China; [Xi, Shaoyan] Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou, Peoples R China; [Xi, Shaoyan; Wang, Ying; Xie, Dan; Guan, Xin-Yuan] Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Xi, Shaoyan; Wang, Ying; Xie, Dan; Guan, Xin-Yuan] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China; [Wang, Ying] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, Guangzhou, Peoples R China; [Guan, Xin-Yuan] Univ Hong Kong, Shenzhen Hosp, Shenzhen, Peoples R China	Southern University of Science & Technology; University of Hong Kong; University of Hong Kong; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; University of Hong Kong	Li, Y (corresponding author), Southern Univ Sci & Technol, Sch Life Sci, Dept Biol, Shenzhen, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China.; Guan, XY (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, Shenzhen Hosp, Shenzhen, Peoples R China.	xyguan@hku.hk; liy33@sustech.edu			National Natural Science Foundation of China [82073127]; Shenzhen Fundamental Research Programs [JCYJ20190809145215160]; Shenzhen Science and Technology Innovation Commission [KYTDPT20181011104005, KQTD2018041118502879]; Guangdong Innovative Research Team Fund [2016ZT06S172]; Hong Kong Research Grant Council [17143716, C7065-18GF, C7026-18GF, T12-704/16-R]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Fundamental Research Programs; Shenzhen Science and Technology Innovation Commission; Guangdong Innovative Research Team Fund; Hong Kong Research Grant Council(Hong Kong Research Grants Council)	This work was supported by the National Natural Science Foundation of China (82073127), Shenzhen Fundamental Research Programs (JCYJ20190809145215160), Shenzhen Science and Technology Innovation Commission (KYTDPT20181011104005 and KQTD2018041118502879), and Guangdong Innovative Research Team Fund (No. 2016ZT06S172). Hong Kong Research Grant Council grants including GRF (17143716), Collaborative Research Funds (C7065-18GF and C7026-18GF) and Theme-based Research Scheme (T12-704/16-R).	Al-Salama ZT, 2019, DRUGS, V79, P665, DOI 10.1007/s40265-019-01116-x; Aoki Y, 2013, AM J HUM GENET, V93, P173, DOI 10.1016/j.ajhg.2013.05.021; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Cai WK, 2011, MOL BIOL CELL, V22, P3231, DOI 10.1091/mbc.E11-05-0400; Calcagni G, 2017, INT J CARDIOL, V245, P92, DOI 10.1016/j.ijcard.2017.07.068; Cao J, 2014, BIOCHEM PHARMACOL, V89, P20, DOI 10.1016/j.bcp.2013.12.002; Castel P, 2019, SCIENCE, V363, P1226, DOI 10.1126/science.aav1444; Chadee DN, 2013, CAN J PHYSIOL PHARM, V91, P268, DOI 10.1139/cjpp-2012-0258; Delire B, 2015, EUR J CLIN INVEST, V45, P609, DOI 10.1111/eci.12441; Fang JH, 2018, HEPATOLOGY, V68, P1459, DOI 10.1002/hep.29920; Fang ZH, 2016, J BIOL CHEM, V291, P15641, DOI 10.1074/jbc.M116.714196; Feng YF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0979-x; Grabocka E, 2014, CANCER CELL, V25, P243, DOI 10.1016/j.ccr.2014.01.005; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; Harrison SMW, 2005, DEV DYNAM, V232, P817, DOI 10.1002/dvdy.20346; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Huang YWA, 2017, CELL, V168, P427, DOI 10.1016/j.cell.2016.12.044; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Li Jin-Tian, 2003, Ai Zheng, V22, P695; Li N, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3478305; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Roth GS, 2017, MOL CANCER THER, V16, P2157, DOI 10.1158/1535-7163.MCT-16-0602-T; Ryan MB, 2018, NAT REV CLIN ONCOL, V15, P709, DOI 10.1038/s41571-018-0105-0; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Shi GX, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.384248; Shi GX, 2005, MOL CELL BIOL, V25, P830, DOI 10.1128/MCB.25.2.830-846.2005; Shveygert M, 2010, MOL CELL BIOL, V30, P5160, DOI 10.1128/MCB.00448-10; Song Z, 2019, CANCER LETT, V460, P96, DOI 10.1016/j.canlet.2019.06.016; Taketomi A, 2013, SURG TODAY, V43, P289, DOI 10.1007/s00595-012-0462-8; Waters AM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031435; Xu FJ, 2015, INT J CLIN EXP PATHO, V8, P10315; Zhang PP, 2019, CANCER LETT, V442, P53, DOI 10.1016/j.canlet.2018.10.035	35	1	2	4	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					732	744		10.1038/s41388-021-02130-8	http://dx.doi.org/10.1038/s41388-021-02130-8		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34845378				2022-12-28	WOS:000723571700001
J	Bui, T; Gu, Y; Ancot, F; Sanguin-Gendreau, V; Zuo, DM; Muller, WJ				Bui, Tung; Gu, Yu; Ancot, Frederic; Sanguin-Gendreau, Virginie; Zuo, Dongmei; Muller, William J.			Emergence of beta 1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvironment	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX; MOUSE MODEL; PROGRESSION; DISRUPTION; KINASE	The molecular and cellular mechanisms underlying mammary tumour dormancy and cancer recurrence are unclear and remain to be elucidated. Here, we report that mammary epithelial-specific disruption of beta 1 integrin in a murine model of Luminal B human breast cancer drastically impairs tumour growth with proliferation block, apoptosis induction and cellular senescence. beta 1 integrin-deficient dormant lesions show activation of the tumour suppressor p53, and tumours that circumvent dormancy possess p53 mutation analogous to those in human disease. We further demonstrate that mammary epithelial deletion of p53 in beta 1 integrin-deficient mice fully rescues tumour dormancy and bypasses cellular senescence. Additionally, recurrent beta 1 integrin-deficient tumours exhibit fibrosis with increased cancer-associated fibroblast infiltration and extracellular matrix deposition, absent in fast-growing beta 1 integrin/p53-deficient lesions. Taken together, these observations argue that beta 1 integrin modulates p53-dependent cellular senescence resulting in tumour dormancy and that pro-tumourigenic stromal cues and intrinsic genetic mutation are required for dormancy exit.	[Bui, Tung; Gu, Yu; Ancot, Frederic; Sanguin-Gendreau, Virginie; Zuo, Dongmei; Muller, William J.] McGill Univ, Rosalind & Morris Goodman Canc Inst, Montreal, PQ H3A 1A3, Canada; [Bui, Tung; Gu, Yu; Muller, William J.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Muller, William J.] McGill Univ, Fac Med, Montreal, PQ H3G 2M1, Canada	McGill University; McGill University; McGill University	Muller, WJ (corresponding author), McGill Univ, Rosalind & Morris Goodman Canc Inst, Montreal, PQ H3A 1A3, Canada.; Muller, WJ (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.; Muller, WJ (corresponding author), McGill Univ, Fac Med, Montreal, PQ H3G 2M1, Canada.	william.muller@mcgill.ca			Cedars Cancer Institute Fellowship; McGill Integrated Cancer Research Training Programme award; CURE Foundation Fellowship in Breast Cancer Research; Canderel Graduate Studentship Award; Canada Research Chair in Molecular Oncology; CIHR Foundation; CCSRI innovation programmes	Cedars Cancer Institute Fellowship; McGill Integrated Cancer Research Training Programme award; CURE Foundation Fellowship in Breast Cancer Research; Canderel Graduate Studentship Award; Canada Research Chair in Molecular Oncology(Canada Research Chairs); CIHR Foundation(Canadian Institutes of Health Research (CIHR)); CCSRI innovation programmes	We thank Alain Sarabia Pacis, Goodman Cancer Institute Bionformatics Core, Canadian Tumour for Computational Genomics (C3G), McGill University for bioinformatic analyses of RNA-seq and scRNA-seq data, Dr. Erika Wee and the Advanced BioImaging Facility, McGill University for analysis using Imaris software, Cleber Silveira Moraes from GCI Histology Core, Cynthia Lavoie for monitoring mouse cohort and Mitra Cowen from GCI Transgenic Core. We are also grateful to Dr. Stephen Dilworth for supplying PyV mT antibodies. TB is supported by the Cedars Cancer Institute Fellowship and McGill Integrated Cancer Research Training Programme award. YG is supported by the CURE Foundation Fellowship in Breast Cancer Research and the Canderel Graduate Studentship Award. WJM is supported by Canada Research Chair in Molecular Oncology and grants from CIHR Foundation and CCSRI innovation programmes.	Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; Barkan D, 2010, EUR J CANCER, V46, P1181, DOI 10.1016/j.ejca.2010.02.027; Bartoschek M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07582-3; Bui T, 2019, CELL REP, V29, P589, DOI 10.1016/j.celrep.2019.09.004; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Faget DV, 2019, NAT REV CANCER, V19, P439, DOI 10.1038/s41568-019-0156-2; Graus-Porta D, 2001, NEURON, V31, P367, DOI 10.1016/S0896-6273(01)00374-9; Grochova D, 2008, ONCOGENE, V27, P1243, DOI 10.1038/sj.onc.1210748; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Hamidi H, 2019, NAT REV CANCER, V19, P179, DOI 10.1038/s41568-019-0112-1; Ilic D, 1998, J CELL BIOL, V143, P547; Jones LM, 2016, CANCER RES, V76, P1416, DOI 10.1158/0008-5472.CAN-15-2770; Jones MC, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0227; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kren A, 2007, EMBO J, V26, P2832, DOI 10.1038/sj.emboj.7601738; Lahlou H, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3131; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; Marino S, 2000, GENE DEV, V14, P994; Martin MD, 2008, CANCER RES, V68, P6251, DOI 10.1158/0008-5472.CAN-08-0537; McConnell JC, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0664-2; Moreno-Layseca P, 2014, MATRIX BIOL, V34, P144, DOI 10.1016/j.matbio.2013.10.011; Murnyak B, 2016, ONCOTARGET, V7, P64910, DOI 10.18632/oncotarget.11912; Pelaez R, 2019, CANCERS, V11, DOI 10.3390/cancers11050615; Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568-020-0263-0; Pontier SM, 2010, ONCOGENE, V29, P3374, DOI 10.1038/onc.2010.86; Pontier SM, 2008, APMIS, V116, P677, DOI 10.1111/j.1600-0463.2008.01026.x; Rao T, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3603; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Smith HW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10681-4; Triana-Martinez F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020346; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Winkler J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18794-x; Zerdoumi Y, 2017, HUM MOL GENET, V26, P2591, DOI 10.1093/hmg/ddx106	35	2	2	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					527	537		10.1038/s41388-021-02107-7	http://dx.doi.org/10.1038/s41388-021-02107-7		NOV 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34782719	hybrid, Green Published			2022-12-28	WOS:000718778400004
J	Raab, M; Matthess, Y; Raab, CA; Gutfreund, N; Dotsch, V; Becker, S; Sanhaji, M; Strebhardt, K				Raab, Monika; Matthess, Yves; Raab, Christopher A.; Gutfreund, Niklas; Doetsch, Volker; Becker, Sven; Sanhaji, Mourad; Strebhardt, Klaus			A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1	ONCOGENE			English	Article							POLO-LIKE KINASE-1; AURORA-A; STRUCTURAL BASIS; CANCER; PHOSPHORYLATION; EXPRESSION; CELLS; DEGRADATION; CHECKPOINT; VOLASERTIB	Polo-like kinase 1 (PLK1) is a crucial regulator of cell cycle progression. It is established that the activation of PLK1 depends on the coordinated action of Aurora-A and Bora. Nevertheless, very little is known about the spatiotemporal regulation of PLK1 during G2, specifically, the mechanisms that keep cytoplasmic PLK1 inactive until shortly before mitosis onset. Here, we describe PLK1 dimerization as a new mechanism that controls PLK1 activation. During the early G2 phase, Bora supports transient PLK1 dimerization, thus fine-tuning the timely regulated activation of PLK1 and modulating its nuclear entry. At late G2, the phosphorylation of T210 by Aurora-A triggers dimer dissociation and generates active PLK1 monomers that support entry into mitosis. Interfering with this critical PLK1 dimer/monomer switch prevents the association of PLK1 with importins, limiting its nuclear shuttling, and causes nuclear PLK1 mislocalization during the G2-M transition. Our results suggest a novel conformational space for the design of a new generation of PLK1 inhibitors.	[Raab, Monika; Matthess, Yves; Raab, Christopher A.; Becker, Sven; Sanhaji, Mourad; Strebhardt, Klaus] Goethe Univ, Med Sch, Dept Gynecol, Frankfurt, Germany; [Gutfreund, Niklas; Doetsch, Volker] Goethe Univ, Inst Viophys Chem, Max von Laue Str 9, D-60438 Frankfurt, Germany; [Gutfreund, Niklas; Doetsch, Volker] Goethe Univ, Ctr Biomol Magnet Resonance, Max von Laue Str 9, D-60438 Frankfurt, Germany; [Strebhardt, Klaus] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ)	Sanhaji, M; Strebhardt, K (corresponding author), Goethe Univ, Med Sch, Dept Gynecol, Frankfurt, Germany.; Strebhardt, K (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.	mourad.sanhaji@kgu.de; strebhardt@em.uni-frankfurt.de		Sanhaji, Mourad/0000-0001-8202-0694; Strebhardt, Klaus/0000-0003-2173-9763	Deutsche Forschungsgemeinschaft; Messer Stiftung; Deutsche Krebshilfe; German Cancer Consortium (DKTK), Heidelberg; Verein zur Forderung der Wissenschaft; Pravention and Therapie von Kehlkopfkrebs e.V; Projekt DEAL	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Messer Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); German Cancer Consortium (DKTK), Heidelberg; Verein zur Forderung der Wissenschaft; Pravention and Therapie von Kehlkopfkrebs e.V; Projekt DEAL	This work was supported by grants from the Deutsche Forschungsgemeinschaft (M. Raab), Messer Stiftung, Deutsche Krebshilfe, German Cancer Consortium (DKTK), Heidelberg and Verein zur Forderung der Wissenschaft, Pravention and Therapie von Kehlkopfkrebs e.V. Open Access funding enabled and organized by Projekt DEAL.	Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Asteriti IA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00283; Barbosa J, 2020, EMBO J, V39, DOI 10.15252/embj.2018100789; Baxter M, 2020, CHEMMEDCHEM, V15, P1058, DOI 10.1002/cmdc.202000137; Bruinsma W, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00132; Bruinsma W, 2012, TRENDS BIOCHEM SCI, V37, P534, DOI 10.1016/j.tibs.2012.09.005; Byrne DP, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aax2713; Chan EHY, 2008, CHROMOSOMA, V117, P457, DOI 10.1007/s00412-008-0165-5; de Carcer G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05429-5; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Gheghiani L, 2017, CELL REP, V19, P2060, DOI 10.1016/j.celrep.2017.05.031; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Gutteridge REA, 2016, MOL CANCER THER, V15, P1427, DOI 10.1158/1535-7163.MCT-15-0897; Joukov V, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar4195; Joukov V, 2014, MOL CELL, V55, P578, DOI 10.1016/j.molcel.2014.06.016; Kachaner D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01876-8; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lee MS, 2009, BBA-MOL CELL RES, V1793, P1571, DOI 10.1016/j.bbamcr.2009.07.005; Li HC, 2010, EMBO J, V29, P2953, DOI 10.1038/emboj.2010.174; Lim DC, 2020, MOL CELL ONCOL, V7, DOI 10.1080/23723556.2020.1832419; Lossl P, 2016, ACS CENTRAL SCI, V2, P445, DOI 10.1021/acscentsci.6b00053; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Macville M, 1999, CANCER RES, V59, P141; Matthess Y, 2010, MOL CELL BIOL, V30, P5726, DOI 10.1128/MCB.00731-10; Meng L, 2015, MOL CELL BIOL, V35, P2626, DOI 10.1128/MCB.00068-15; Meunier S, 2016, TRENDS CELL BIOL, V26, P80, DOI 10.1016/j.tcb.2015.09.001; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Park CH, 2015, J BIOL CHEM, V290, P8569, DOI 10.1074/jbc.M114.623546; Pitzius S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1936-z; Pujade-Lauraine E, 2016, J CLIN ONCOL, V34, P706, DOI 10.1200/JCO.2015.62.1474; Qi FF, 2018, CELL REP, V24, P546, DOI 10.1016/j.celrep.2018.06.087; Raab M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45627-9; Raab M, 2018, ACS CHEM BIOL, V13, P1921, DOI 10.1021/acschembio.7b01078; Rapley J, 2005, MOL CELL BIOL, V25, P1309, DOI 10.1128/MCB.25.4.1309-1324.2005; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Seki A, 2008, J CELL BIOL, V181, P65, DOI 10.1083/jcb.200712027; Sells TB, 2015, ACS MED CHEM LETT, V6, P630, DOI 10.1021/ml500409n; Seo YH, 2009, P NATL ACAD SCI USA, V106, P16163, DOI 10.1073/pnas.0903015106; Singh P, 2021, MOL CELL, V81, P67, DOI 10.1016/j.molcel.2020.10.040; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Song XH, 2020, FASEB J, V34, P4348, DOI 10.1096/fj.201902007R; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Strebhardt K, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1485539; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Taniguchi E, 2002, J BIOL CHEM, V277, P48884, DOI 10.1074/jbc.M206307200; Tsuchiya Y, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101318; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Wilhelm T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11584-0; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xu J, 2013, NAT STRUCT MOL BIOL, V20, P1047, DOI 10.1038/nsmb.2623; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhu K, 2016, STRUCTURE, V24, P1110, DOI 10.1016/j.str.2016.04.012; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	62	2	2	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					372	386		10.1038/s41388-021-02094-9	http://dx.doi.org/10.1038/s41388-021-02094-9		NOV 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34759346	Green Published, hybrid			2022-12-28	WOS:000716867900001
J	Ingram, K; Samson, SC; Zewdu, R; Zitnay, RG; Snyder, EL; Mendoza, MC				Ingram, Kelley; Samson, Shiela C.; Zewdu, Rediet; Zitnay, Rebecca G.; Snyder, Eric L.; Mendoza, Michelle C.			NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity	ONCOGENE			English	Article							KINASE PHOSPHATASES; ADENOCARCINOMA; EXPRESSION; CLASSIFICATION; SUPPRESSION; ACTIVATION; INITIATION; KRAS(G12D); COOPERATE; DRIVEN	The RAS -> RAF -> MEK -> ERK pathway is hyperactivated in the majority of human lung adenocarcinoma (LUAD). However, the initial activating mutations induce homeostatic feedback mechanisms that limit ERK activity. How ERK activation reaches the tumor-promoting levels that overcome the feedback and drive malignant progression is unclear. We show here that the lung lineage transcription factor NKX2-1 suppresses ERK activity. In human tissue samples and cell lines, xenografts, and genetic mouse models, NKX2-1 induces the ERK phosphatase DUSP6, which inactivates ERK. In tumor cells from late-stage LUAD with silenced NKX2-1, re-introduction of NKX2-1 induces DUSP6 and inhibits tumor growth and metastasis. We show that DUSP6 is necessary for NKX2-1-mediated inhibition of tumor progression in vivo and that DUSP6 expression is sufficient to inhibit RAS-driven LUAD. Our results indicate that NKX2-1 silencing, and thereby DUSP6 downregulation, is a mechanism by which early LUAD can unleash ERK hyperactivation for tumor progression.	[Ingram, Kelley; Samson, Shiela C.; Snyder, Eric L.; Mendoza, Michelle C.] Univ Utah, Dept Ontol Sci, Salt Lake City, UT 84112 USA; [Ingram, Kelley; Samson, Shiela C.; Zewdu, Rediet; Zitnay, Rebecca G.; Snyder, Eric L.; Mendoza, Michelle C.] Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Zewdu, Rediet; Snyder, Eric L.] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; [Zitnay, Rebecca G.; Mendoza, Michelle C.] Univ Utah, Dept Biomed Engn, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Mendoza, MC (corresponding author), Univ Utah, Dept Ontol Sci, Salt Lake City, UT 84112 USA.; Mendoza, MC (corresponding author), Huntsman Canc Inst, Salt Lake City, UT 84112 USA.; Mendoza, MC (corresponding author), Univ Utah, Dept Biomed Engn, Salt Lake City, UT 84112 USA.	Michelle.Mendoza@hci.utah.edu		Mendoza, Michelle/0000-0002-6490-1794; Snyder, Eric/0000-0003-3591-3195	University of Utah Flow Cytometry Facility; American Cancer Society [RSG CSM130435]; V Scholar Award; Burroughs Wellcome Fund; American Lung Association Research Grant;  [K01CA168850];  [R21CA215891];  [5P30CA042014-24];  [1S10RR026802-01];  [R01CA212415];  [R01CA240317]	University of Utah Flow Cytometry Facility; American Cancer Society(American Cancer Society); V Scholar Award; Burroughs Wellcome Fund(Burroughs Wellcome Fund); American Lung Association Research Grant; ; ; ; ; ; 	Thanks to Dr. Stephen Keyse for the gift of the DUSP6 promoter constructs and Dr. Doug Mackay for H2B-mCherry-N2. Thanks to Keith Carney for the development of software for automated cell migration tracking. Flow cytometry was supported by the University of Utah Flow Cytometry Facility and funding from 5P30CA042014-24 and 1S10RR026802-01. Thanks to the University of Utah Cell Imaging Core and the Huntsman Cancer Institute Preclinical Research Resource. M.C.M was supported by K01CA168850, R21CA215891, an American Lung Association Research Grant, American Cancer Society RSG CSM130435, and V Scholar Award. E.L.S. was supported by a Career Award for Medical Scientists from the Burroughs Wellcome Fund, a V Scholar Award, and R01CA212415 and R01CA240317.	Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Camolotto SA, 2018, ELIFE, V7, DOI 10.7554/eLife.38579; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096; Cicchini M, 2017, CELL REP, V18, P1958, DOI 10.1016/j.celrep.2017.01.069; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Davies AE, 2020, CELL SYST, V11, P161, DOI 10.1016/j.cels.2020.07.004; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ding W, 2003, GENE, V322, P175, DOI 10.1016/j.gene.2003.09.004; Ekerot M, 2008, BIOCHEM J, V412, P287, DOI 10.1042/BJ20071512; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Gilbert-Ross M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90487; Gillies TE, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20209518; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hrustanovic G, 2015, NAT MED, V21, P1038, DOI 10.1038/nm.3930; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kong XJ, 2017, NATURE, V550, P270, DOI 10.1038/nature24037; Li CMC, 2015, GENE DEV, V29, P1850, DOI 10.1101/gad.267393.115; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Marjanovic ND, 2020, CANCER CELL, V38, P229, DOI 10.1016/j.ccell.2020.06.012; Minoo P, 2007, MOL CELL BIOL, V27, P2155, DOI 10.1128/MCB.01133-06; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nieto P, 2017, NATURE, V548, P239, DOI 10.1038/nature23297; Noguchi M, 2010, CANCER METAST REV, V29, P15, DOI 10.1007/s10555-010-9210-y; Nunes-Xavier C, 2011, ANTI-CANCER AGENT ME, V11, P109, DOI 10.2174/187152011794941190; Okudela K, 2009, AM J PATHOL, V175, P867, DOI 10.2353/ajpath.2009.080489; Premsrirut PK, 2011, CELL, V145, P145, DOI 10.1016/j.cell.2011.03.012; Russell PA, 2011, J THORAC ONCOL, V6, P1496, DOI 10.1097/JTO.0b013e318221f701; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Trejo CL, 2012, CANCER RES, V72, P3048, DOI 10.1158/0008-5472.CAN-11-3649; Unni AM, 2018, ELIFE, V7, DOI 10.7554/eLife.33718; Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644; Watanabe H, 2013, GENE DEV, V27, P197, DOI 10.1101/gad.203208.112; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Yatabe Y, 2005, AM J SURG PATHOL, V29, P633, DOI 10.1097/01.pas.0000157935.28066.35; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232; Zewdu R, 2021, ELIFE, V10, DOI 10.7554/eLife.66788	43	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					293	300		10.1038/s41388-021-02076-x	http://dx.doi.org/10.1038/s41388-021-02076-x		OCT 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34689179	Green Accepted, Green Submitted			2022-12-28	WOS:000710613600002
J	Amin, P; Awal, S; Vigneron, S; Roque, S; Mechali, F; Labbe, JC; Lorca, T; Castro, A				Amin, Priya; Awal, Sushil; Vigneron, Suzanne; Roque, Sylvain; Mechali, Francisca; Labbe, Jean Claude; Lorca, Thierry; Castro, Anna			PP2A-B55: substrates and regulators in the control of cellular functions	ONCOGENE			English	Review							PROTEIN PHOSPHATASE 2A; GREATWALL KINASE; TUMOR-SUPPRESSOR; SUBUNIT INTERACTION; MITOTIC EXIT; T-ANTIGEN; PHOSPHORYLATION; DEPHOSPHORYLATION; CANCER; B55-ALPHA	PP2A is a major serine/threonine phosphatase class involved in the regulation of cell signaling through the removal of protein phosphorylation. This class of phosphatases is comprised of different heterotrimeric complexes displaying distinct substrate specificities. The present review will focus on one specific heterocomplex, the phosphatase PP2A-B55. Herein, we will report the direct substrates of this phosphatase identified to date, and its impact on different cell signaling cascades. We will additionally describe its negative regulation by its inhibitors Arpp19 and ENSA and their upstream kinase Greatwall. Finally, we will describe the essential molecular features defining PP2A-B55 substrate specificity that confer the correct temporal pattern of substrate dephosphorylation. The main objective of this review is to provide the reader with a unique source compiling all the knowledge of this particular holoenzyme that has evolved as a key enzyme for cell homeostasis and cancer development.	[Amin, Priya; Awal, Sushil; Vigneron, Suzanne; Roque, Sylvain; Mechali, Francisca; Labbe, Jean Claude; Lorca, Thierry; Castro, Anna] Univ Montpellier, Ctr Rech Biol Cellulaire Montpellier CRBM, CNRS UMR 5237, 1919 Route Mende, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Lorca, T; Castro, A (corresponding author), Univ Montpellier, Ctr Rech Biol Cellulaire Montpellier CRBM, CNRS UMR 5237, 1919 Route Mende, F-34293 Montpellier 5, France.	thierry.lorca@crbm.cnrs.fr; anna.castro@crbm.cnrs.fr	CASTRO, ANNA/F-4350-2010	CASTRO, ANNA/0000-0002-3655-1352; Lorca, Thierry/0000-0003-2007-8924	Agence National de la Recherche [ANR-18CE13-0013, ANR-18-CE13-0018-01]; La Ligue Nationale Contre le Cancer; Fondation ARC [PJA 20181207931]; LABEX EpiGenMed [ANR-10-LABEX-12-01]	Agence National de la Recherche(French National Research Agency (ANR)); La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Fondation ARC; LABEX EpiGenMed	This work was supported by the Agence National de la Recherche (KiPARPP, ANR-18CE13-0013 and REPLIGREAT, ANR-18-CE13-0018-01), La Ligue Nationale Contre le Cancer (Equipe Labellisee, EL2019 CASTRO), the Fondation ARC (PJA 20181207931), and the LABEX EpiGenMed (ANR-10-LABEX-12-01). PA is a Fondation pour la Recherche Medicale (FRM) fellow. SA and SR are LABEX EpiGenMed fellows.	Alvarez-Fernandez M, 2013, P NATL ACAD SCI USA, V110, P17374, DOI 10.1073/pnas.1310745110; Alvarez-Fernandez M, 2011, J BIOL CHEM, V286, P33029, DOI 10.1074/jbc.M111.253724; Andrade EC, 2017, J NEUROSCI, V37, P2709, DOI 10.1523/JNEUROSCI.4559-15.2017; Batut J, 2008, DEVELOPMENT, V135, P2927, DOI 10.1242/dev.020842; Bollen M, 2010, TRENDS BIOCHEM SCI, V35, P450, DOI 10.1016/j.tibs.2010.03.002; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Castilho PV, 2009, MOL BIOL CELL, V20, P4777, DOI 10.1091/mbc.E09-07-0643; Charrasse S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00339-4; Chen S, 2008, J BIOL CHEM, V283, P10513, DOI 10.1074/jbc.M709852200; Cheng Y, 2011, CANCER GENET-NY, V204, P375, DOI 10.1016/j.cancergen.2011.05.002; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Cundell MJ, 2016, J CELL BIOL, V214, P539, DOI 10.1083/jcb.201606033; Cundell MJ, 2013, MOL CELL, V52, P393, DOI 10.1016/j.molcel.2013.09.005; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Di Conza G, 2017, CELL REP, V18, P1699, DOI 10.1016/j.celrep.2017.01.051; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Diril MK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006310; Dupre A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4318; Eichhorn PJA, 2007, PLOS GENET, V3, P2381, DOI 10.1371/journal.pgen.0030218; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Foster David A, 2010, Genes Cancer, V1, P1124, DOI 10.1177/1947601910392989; Fritz A, 2006, J BIOL CHEM, V281, P6236, DOI 10.1074/jbc.M509249200; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; Fujiwara N, 2016, J BIOL CHEM, V291, P10858, DOI 10.1074/jbc.M115.704908; Gharbi-Ayachi A, 2010, SCIENCE, V330, P1673, DOI 10.1126/science.1197048; Godfrey M, 2017, MOL CELL, V65, P393, DOI 10.1016/j.molcel.2016.12.018; Gong YP, 2018, AM J CANCER RES, V8, P1030; Hached K, 2019, J CELL BIOL, V218, P541, DOI 10.1083/jcb.201708105; Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002; Hegarat N, 2020, EMBO J, V39, DOI 10.15252/embj.2020104419; Heim A, 2015, EMBO REP, V16, P1501, DOI 10.15252/embr.201540876; Hein AL, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0172-9; Hein JB, 2017, NAT CELL BIOL, V19, P1433, DOI 10.1038/ncb3634; Heroes E, 2013, FEBS J, V280, P584, DOI 10.1111/j.1742-4658.2012.08547.x; Hertz EPT, 2016, MOL CELL, V63, P686, DOI 10.1016/j.molcel.2016.06.024; Hoermann B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17334-x; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hutter LH, 2017, CELL CYCLE, V16, P1885, DOI 10.1080/15384101.2017.1371885; Jayadeva G, 2010, J BIOL CHEM, V285, P29863, DOI 10.1074/jbc.M110.162354; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Kalev P, 2012, CANCER RES, V72, P6414, DOI 10.1158/0008-5472.CAN-12-1667; Kamada Y, 2012, INT J HEMATOL, V96, P492, DOI 10.1007/s12185-012-1171-1; Kamenz J, 2021, CURR BIOL, V31, P794, DOI 10.1016/j.cub.2020.11.058; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Kruse T, 2020, EMBO J, V39, DOI 10.15252/embj.2019103695; Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200; Kurimchak A, 2013, MOL CELL BIOL, V33, P3330, DOI 10.1128/MCB.00082-13; Labbe JC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23657-0; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Lipina C, 2016, TRENDS ENDOCRIN MET, V27, P868, DOI 10.1016/j.tem.2016.08.005; Longin S, 2007, J BIOL CHEM, V282, P26971, DOI 10.1074/jbc.M704059200; Lu MR, 2015, SCI REP-UK, V5, DOI 10.1038/srep08735; Ma S, 2016, J CELL SCI, V129, P1329, DOI 10.1242/jcs.178855; Ma SH, 2019, ANNU REV BIOCHEM, V88, P577, DOI 10.1146/annurev-biochem-013118-111829; Margolis SS, 2006, CELL, V127, P759, DOI 10.1016/j.cell.2006.10.035; Mazhar S, 2019, BBA-MOL CELL RES, V1866, P51, DOI 10.1016/j.bbamcr.2018.08.020; McCloy RA, 2015, MOL CELL PROTEOMICS, V14, P2194, DOI 10.1074/mcp.M114.046938; Mehsen H, 2018, J CELL BIOL, V217, P4106, DOI 10.1083/jcb.201804018; Merrill RA, 2013, FEBS J, V280, P662, DOI 10.1111/j.1742-4658.2012.08631.x; Mochida S, 2016, CURR BIOL, V26, P3361, DOI 10.1016/j.cub.2016.10.022; Mochida S, 2014, FEBS J, V281, P1159, DOI 10.1111/febs.12685; Mochida S, 2010, SCIENCE, V330, P1670, DOI 10.1126/science.1195689; Mochida S, 2009, EMBO J, V28, P2777, DOI 10.1038/emboj.2009.238; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Mosca L, 2013, AM J HEMATOL, V88, P16, DOI 10.1002/ajh.23339; Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466; Murphy AK, 2014, J CELL BIOL, V206, P493, DOI 10.1083/jcb.201404111; Nasa I, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aba7823; NISHIMURA M, 1995, J BIOL CHEM, V270, P26341, DOI 10.1074/jbc.270.44.26341; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Paroni G, 2008, MOL BIOL CELL, V19, P655, DOI 10.1091/mbc.E07-06-0623; Pomerening JR, 2003, NAT CELL BIOL, V5, P346, DOI 10.1038/ncb954; Porter IM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3677; Rata S, 2018, CURR BIOL, V28, P3824, DOI 10.1016/j.cub.2018.09.059; Reid MA, 2013, MOL CELL, V50, P200, DOI 10.1016/j.molcel.2013.02.008; Reilly PT, 2014, BIOESSAYS, V36, P1062, DOI 10.1002/bies.201400058; Ren DP, 2017, J BIOL CHEM, V292, P10026, DOI 10.1074/jbc.M117.778233; Ricotta D, 2008, J BIOL CHEM, V283, P5510, DOI 10.1074/jbc.M707166200; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Ruvolo PP, 2011, LEUKEMIA, V25, P1711, DOI 10.1038/leu.2011.146; Ruvolo PP, 2016, BBA CLIN, V6, P87, DOI 10.1016/j.bbacli.2016.08.002; Ruvolo PP, 2014, BBA-MOL CELL RES, V1843, P1969, DOI 10.1016/j.bbamcr.2014.05.006; Sha W, 2003, P NATL ACAD SCI USA, V100, P975, DOI 10.1073/pnas.0235349100; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Skoczylas C, 2004, CELL CYCLE, V3, P606; Tan J, 2010, CANCER CELL, V18, P459, DOI 10.1016/j.ccr.2010.10.021; Tan YM, 2014, CANCER RES, V74, P2006, DOI 10.1158/0008-5472.CAN-13-1263; Tavernier N, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21922-w; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Vigneron S, 2018, DEV CELL, V45, P637, DOI 10.1016/j.devcel.2018.05.005; Vigneron S, 2009, EMBO J, V28, P2786, DOI 10.1038/emboj.2009.228; Voets E, 2010, CELL CYCLE, V9, P3591, DOI 10.4161/cc.9.17.12832; Wang FF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21040-6; Wang J, 2017, EMBO REP, V18, P437, DOI 10.15252/embr.201642788; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Wang XR, 2016, STRUCTURE, V24, P2174, DOI 10.1016/j.str.2016.09.010; Wei YJ, 2015, ELIFE, V4, DOI 10.7554/eLife.05289; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Williams BC, 2014, ELIFE, V3, DOI 10.7554/eLife.01695; Wirth M, 2013, SEMIN CANCER BIOL, V23, P301, DOI 10.1016/j.semcancer.2013.05.007; Wong PM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9048; Wong QWL, 2010, CLIN CANCER RES, V16, P867, DOI 10.1158/1078-0432.CCR-09-1840; Wu CG, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.27; Xie FF, 2020, CANCER BIOTHER RADIO, V35, P129, DOI 10.1089/cbr.2019.2960; Xing Y, 2006, CELL, V127, P341, DOI 10.1016/j.cell.2006.09.025; Xu YH, 2008, MOL CELL, V31, P873, DOI 10.1016/j.molcel.2008.08.006; Ye HF, 2020, CANCER MANAG RES, V12, P419, DOI 10.2147/CMAR.S228429; Yeong FM, 2003, CURR BIOL, V13, P2058, DOI 10.1016/j.cub.2003.10.032; Yu JT, 2004, J CELL BIOL, V164, P487, DOI 10.1083/JCB.200310059; Zhang W, 2009, J BIOL CHEM, V284, P22649, DOI 10.1074/jbc.M109.013698	117	6	6	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					1	14		10.1038/s41388-021-02068-x	http://dx.doi.org/10.1038/s41388-021-02068-x		OCT 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34686773				2022-12-28	WOS:000710056600001
J	Pelaz, SG; Tabernero, A				Pelaz, Sara G.; Tabernero, Arantxa			Src: coordinating metabolism in cancer	ONCOGENE			English	Review							ROUS-SARCOMA-VIRUS; DEPENDENT TYROSINE PHOSPHORYLATION; C-SRC; FAMILY KINASES; GLUCOSE-TRANSPORTER; GROWTH-FACTOR; OXIDATIVE-PHOSPHORYLATION; ONCOGENIC PROPERTIES; PHOSPHATASE-ACTIVITY; MEDIATED ACTIVATION	Metabolism must be tightly regulated to fulfil the dynamic requirements of cancer cells during proliferation, migration, stemness and differentiation. Src is a node of several signals involved in many of these biological processes, and it is also an important regulator of cell metabolism. Glucose uptake, glycolysis, the pentose-phosphate pathway and oxidative phosphorylation are among the metabolic pathways that can be regulated by Src. Therefore, this oncoprotein is in an excellent position to coordinate and finely tune cell metabolism to fuel the different cancer cell activities. Here, we provide an up-to-date summary of recent progress made in determining the role of Src in glucose metabolism as well as the link of this role with cancer cell metabolic plasticity and tumour progression. We also discuss the opportunities and challenges facing this field.	[Pelaz, Sara G.; Tabernero, Arantxa] Univ Salamanca, Inst Neurociencias Castilla & Leon INCYL, Dept Bioquim & Biol Mol, Inst Invest Biomed Salamanca IBSAL, Calle Pintor Fernando Gallego 1, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Tabernero, A (corresponding author), Univ Salamanca, Inst Neurociencias Castilla & Leon INCYL, Dept Bioquim & Biol Mol, Inst Invest Biomed Salamanca IBSAL, Calle Pintor Fernando Gallego 1, Salamanca 37007, Spain.	ataber@usal.es	G. Pelaz, Sara/AAO-3028-2020; Tabernero, Arantxa/K-5950-2014	G. Pelaz, Sara/0000-0001-6908-3172; Tabernero, Arantxa/0000-0001-6302-6134	FEDER [PID2021-128549OB-I00, RTI2018099873-B-I00, SA125P20]; Junta de Castilla y Leon; European Social Fund	FEDER(European Commission); Junta de Castilla y Leon(Junta de Castilla y Leon); European Social Fund(European Social Fund (ESF))	This study was funded by Spanish Ministerio de Ciencia e Innovacion, FEDER RTI2018099873-B-I00, FEDER PID2021-128549OB-I00 and Junta de Castilla y Leon, FEDER SA125P20. SGP was a fellowship recipient from the Junta de Castilla y Leon and the European Social Fund.	Alcala S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207437; Alessandro M, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101639; Almaguel FA, 2021, FRONT GENET, V11, DOI 10.3389/fgene.2020.614726; Ancey PB, 2018, FEBS J, V285, P2926, DOI 10.1111/febs.14577; Arachiche A, 2008, J BIOL CHEM, V283, P24406, DOI 10.1074/jbc.M709217200; Augereau O, 2005, CELL MOL LIFE SCI, V62, P1478, DOI 10.1007/s00018-005-5005-7; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; BOSCA L, 1986, BIOCHEM J, V236, P595, DOI 10.1042/bj2360595; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burkhardt AL, 2001, CURR PROTOC IMMUNOL; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Cardone L, 2004, MOL CELL BIOL, V24, P4613, DOI 10.1128/MCB.24.11.4613-4626.2004; Valle-Casuso JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032448; Carruthers A, 2009, AM J PHYSIOL-ENDOC M, V297, pE836, DOI 10.1152/ajpendo.00496.2009; Chatelain EH, 2011, CELL MOL LIFE SCI, V68, P2603, DOI 10.1007/s00018-010-0573-6; Chen G, 2014, MOL CELL, V54, P362, DOI 10.1016/j.molcel.2014.02.034; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Chueh AC, 2021, ONCOGENE, V40, P3015, DOI 10.1038/s41388-021-01755-z; Ci SS, 2020, FASEB J, V34, P10443, DOI 10.1096/fj.201902904RR; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Colell A, 2009, CELL DEATH DIFFER, V16, P1573, DOI 10.1038/cdd.2009.137; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Cori CF, 1925, J BIOL CHEM, V64, P11; Cori CF., 1928, J CANC RES, V12, P301; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; DeLalio LJ, 2019, J BIOL CHEM, V294, P6940, DOI 10.1074/jbc.RA118.006982; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Diaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795; Djeungoue-Petga MA, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2134-8; EIGENBRODT E, 1983, EMBO J, V2, P1565, DOI 10.1002/j.1460-2075.1983.tb01625.x; Eigenbrodt E, 1998, CELL GROWTH ONCOGENE, P15; Eskilsson E, 2016, NEURO-ONCOLOGY, V18, P1644, DOI 10.1093/neuonc/now113; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Gangoso E, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.560; GLOSSMANN H, 1981, MOL CELL ENDOCRINOL, V23, P49, DOI 10.1016/0303-7207(81)90116-7; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gonzalez-Sanchez A, 2016, ONCOTARGET, V7, P49819, DOI 10.18632/oncotarget.10454; Guedouari H, 2021, MITOCHONDRION, V57, P257, DOI 10.1016/j.mito.2020.12.012; Guedouari Hala, 2020, Cell Physiol Biochem, V54, P517, DOI 10.33594/000000237; Gupte RS, 2007, J CARD FAIL, V13, P497, DOI 10.1016/j.cardfail.2007.04.003; Gupte RS, 2009, FREE RADICAL BIO MED, V47, P219, DOI 10.1016/j.freeradbiomed.2009.01.028; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; Hebert-Chatelain E, 2012, BBA-BIOENERGETICS, V1817, P718, DOI 10.1016/j.bbabio.2012.01.014; Heppner DE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06790-1; Higuchi M, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108876; Hu H, 2016, CELL, V164, P433, DOI 10.1016/j.cell.2015.12.042; Hua TNM, 2019, EBIOMEDICINE, V41, P134, DOI 10.1016/j.ebiom.2019.02.015; Hunter CA, 2020, CELL SIGNAL, V72, DOI 10.1016/j.cellsig.2020.109651; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jain S, 2015, CANCER RES, V75, P4863, DOI 10.1158/0008-5472.CAN-14-2345; Jaraiz-Rodriguez M, 2020, NEURO-ONCOLOGY, V22, P493, DOI 10.1093/neuonc/noz243; Jaraiz-Rodriguez M, 2017, STEM CELL REP, V9, P451, DOI 10.1016/j.stemcr.2017.06.007; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Jin L, 2017, ONCOGENE, V36, P3797, DOI 10.1038/onc.2017.6; Jin Y, 2016, ONCOTARGET, V7, P25113, DOI 10.18632/oncotarget.7159; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; Kemble DJ, 2009, P NATL ACAD SCI USA, V106, P5070, DOI 10.1073/pnas.0806117106; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Lee JH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29142-x; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Li J, 2017, CANCER RES, V77, pE51, DOI 10.1158/0008-5472.CAN-17-0369; Liang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12431; Lin YC, 2012, NEOPLASIA, V14, P463, DOI 10.1596/neo.12300; Liu CJ, 2016, J BIOL CHEM, V291, P15540, DOI 10.1074/jbc.M115.712976; Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422; Liu RL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08921-8; Liu ST, 2014, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00416; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Luttrell DK, 2004, ONCOGENE, V23, P7969, DOI 10.1038/sj.onc.1208162; Ma HH, 2021, ONCOGENE, V40, P2567, DOI 10.1038/s41388-021-01673-0; Ma HH, 2020, CELL REP, V30, P4235, DOI 10.1016/j.celrep.2020.03.005; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Magaway C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121584; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; MARCHAND MJ, 1992, BIOCHEM J, V285, P413, DOI 10.1042/bj2850413; Martellucci S, 2020, CANCERS, V12, DOI 10.3390/cancers12061448; MARTIN GS, 1970, NATURE, V227, P1021, DOI 10.1038/2271021a0; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MARTIN GS, 1971, P NATL ACAD SCI USA, V68, P2739, DOI 10.1073/pnas.68.11.2739; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; Mayoral-Varo V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235850; Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098; Muir A, 2018, SCIENCE, V360, P962, DOI 10.1126/science.aar5986; Ogura M, 2012, BIOCHEM J, V447, P281, DOI 10.1042/BJ20120509; OKADA M, 1991, J BIOL CHEM, V266, P24249; Okada M, 2012, INT J BIOL SCI, V8, P1385, DOI 10.7150/ijbs.5141; Pal R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06844-4; Palikaras K, 2018, NAT CELL BIOL, V20, P1013, DOI 10.1038/s41556-018-0176-2; Pan S, 2009, ARTERIOSCL THROM VAS, V29, P895, DOI 10.1161/ATVBAHA.109.184812; Park JH, 2016, CELL REP, V14, P2154, DOI 10.1016/j.celrep.2016.02.004; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Pelaz SG, 2021, CANCERS, V13, DOI 10.3390/cancers13174262; Pelaz SG, 2020, EBIOMEDICINE, V62, DOI 10.1016/j.ebiom.2020.103134; Place AT, 2011, MOL PHARMACOL, V80, P665, DOI 10.1124/mol.111.073957; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; PRESEK P, 1988, FEBS LETT, V242, P194, DOI 10.1016/0014-5793(88)81014-7; R Development Core Team, 2009, R LANG ENV STAT COMP; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Reynolds AB, 2014, ONCOGENE, V33, P4537, DOI 10.1038/onc.2013.416; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; SALTER DW, 1982, P NATL ACAD SCI-BIOL, V79, P1540, DOI 10.1073/pnas.79.5.1540; Salvi M, 2004, CELL MOL LIFE SCI, V61, P2393, DOI 10.1007/s00018-004-4211-z; Salvi M, 2002, BBA-MOL CELL RES, V1589, P181, DOI 10.1016/S0167-4889(02)00174-X; Sato H, 2016, J DIABETES INVEST, V7, P171, DOI 10.1111/jdi.12407; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44; Shupnik MA, 2004, ONCOGENE, V23, P7979, DOI 10.1038/sj.onc.1208076; Sigismund S, 2018, MOL ONCOL, V12, P3, DOI 10.1002/1878-0261.12155; Simpson IA, 2008, AM J PHYSIOL-ENDOC M, V295, pE242, DOI 10.1152/ajpendo.90388.2008; Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73; Smolinski MP, 2018, J MED CHEM, V61, P4704, DOI 10.1021/acs.jmedchem.8b00164; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Song LT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19694-w; Sorgen PL, 2004, J BIOL CHEM, V279, P54695, DOI 10.1074/jbc.M409552200; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Temps C, 2021, CANCER RES, V81, P5438, DOI 10.1158/0008-5472.CAN-21-0613; Thakur R, 2015, SCI REP-UK, V5, DOI 10.1038/srep10194; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Thorens B, 2010, AM J PHYSIOL-ENDOC M, V298, pE141, DOI 10.1152/ajpendo.00712.2009; Tian Q, 2020, ONCOGENE, V39, P3980, DOI 10.1038/s41388-020-1262-z; Tisdale EJ, 2007, TRAFFIC, V8, P733, DOI 10.1111/j.1600-0854.2007.00569.x; Valle S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18954-z; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; WARBURG OTTO, 1926, KLIN WOCHENSCHR, V5, P829, DOI 10.1007/BF01726240; Xie YB, 2019, MOL MED REP, V19, P783, DOI 10.3892/mmr.2018.9713; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zang QS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043424; Zhang F, 2006, AM J PHYSIOL-CELL PH, V291, pC466, DOI 10.1152/ajpcell.00418.2005; Zhang J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13732; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; Zhou ZF, 2018, CANCER RES, V78, P2248, DOI 10.1158/0008-5472.CAN-17-2726; Zhu S, 2007, CANCER RES, V67, P10129, DOI 10.1158/0008-5472.CAN-06-4338	147	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4917	4928		10.1038/s41388-022-02487-4	http://dx.doi.org/10.1038/s41388-022-02487-4		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36217026	Green Published, hybrid			2022-12-28	WOS:000865701400001
J	Srivastava, S; Jiang, J; Misra, J; Seim, G; Staschke, KA; Zhong, MH; Zhou, L; Liu, Y; Chen, C; Dave, U; Kapur, R; Batra, S; Zhang, C; Zhou, JH; Fan, J; Wek, RC; Zhang, J				Srivastava, Sankalpip; Jiang, Jie; Misra, Jagannath; Seim, Gretchen; Staschke, Kirk A.; Zhong, Minghua; Zhou, Leonardo; Liu, Yu; Chen, Chong; Dave, Utpal; Kapur, Reuben; Batra, Sandeep; Zhang, Chi; Zhou, Jiehao; Fan, Jing; Wek, Ronald C.; Zhang, Ji			Asparagine bioavailability regulates the translation of MYC oncogene	ONCOGENE			English	Article							C-MYC; GLUTAMINE; METABOLISM; DEPRIVATION; SUPPRESSION; ADAPTATION	Amino acid restriction has recently emerged as a compelling strategy to inhibit tumor growth. Recent work suggests that amino acids can regulate cellular signaling in addition to their role as biosynthetic substrates. Using lymphoid cancer cells as a model, we found that asparagine depletion acutely reduces the expression of c-MYC protein without changing its mRNA expression. Furthermore, asparagine depletion inhibits the translation of MYC mRNA without altering the rate of MYC protein degradation. Of interest, the inhibitory effect on MYC mRNA translation during asparagine depletion is not due to the activation of the general controlled nonderepressible 2 (GCN2) pathway and is not a consequence of the inhibition of global protein synthesis. In addition, both the 5' and 3' untranslated regions (UTRs) of MYC mRNA are not required for this inhibitory effect. Finally, using a MYC-driven mouse B cell lymphoma model, we found that shRNA inhibition of asparagine synthetase (ASNS) or pharmacological inhibition of asparagine production can significantly reduce the MYC protein expression and tumor growth when environmental asparagine becomes limiting. Since MYC is a critical oncogene, our results uncover a molecular connection between MYC mRNA translation and asparagine bioavailability and shed light on a potential to target MYC oncogene post-transcriptionally through asparagine restriction.	[Srivastava, Sankalpip; Jiang, Jie; Zhong, Minghua; Zhou, Leonardo; Kapur, Reuben; Zhang, Ji] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Srivastava, Sankalpip; Misra, Jagannath; Staschke, Kirk A.; Wek, Ronald C.; Zhang, Ji] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Seim, Gretchen] Univ Wisconsin Madison, Morgridge Inst Res, Madison, WI 53715 USA; [Seim, Gretchen] Univ Wisconsin Madison, Dept Nutr Sci, Madison, WI 53715 USA; [Chen, Chong] Sichuan Univ, West China Hosp, Dept Hematol, State Key Lab Biotherapy, Chengdu 610000, Sichuan, Peoples R China; [Chen, Chong] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu 610000, Sichuan, Peoples R China; [Dave, Utpal] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Batra, Sandeep] Indiana Univ Hlth, Riley Hosp Children, Indianapolis, IN 46202 USA; [Zhang, Chi] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Zhou, Jiehao] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Wisconsin System; University of Wisconsin Madison; The Morgridge Institute for Research, Inc.; University of Wisconsin System; University of Wisconsin Madison; Sichuan University; Sichuan University; Indiana University System; Indiana University Bloomington; Indiana University System; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Zhang, J (corresponding author), Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.; Zhang, J (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	jzh1@iu.edu	Misra, Jagannath/AAW-8774-2021; Staschke, Kirk/HGC-5664-2022	Staschke, Kirk/0000-0001-8722-9585; Chen, Chong/0000-0002-6787-0495; Dave, Utpal/0000-0002-9416-1686	NIH/NCI [CA244625]; American Society of Hematologyand the Riley Children Foundation; NIH/NIGMS [GM136331]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Society of Hematologyand the Riley Children Foundation; NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH/NCI CA244625, the American Society of Hematologyand the Riley Children Foundation. RCW is supported by NIH/NIGMS GM136331 and isa member of the advisory board of HiberCell, Inc.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Anthony TG, 2004, J BIOL CHEM, V279, P36553, DOI 10.1074/jbc.M404559200; Averous J, 2016, SCI REP-UK, V6, DOI 10.1038/srep27698; Avramis VI, 2012, ANTICANCER RES, V32, P2423; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; BROOME JD, 1961, NATURE, V191, P1114, DOI 10.1038/1911114a0; Clasquin Michelle F, 2012, Curr Protoc Bioinformatics, VChapter 14, DOI 10.1002/0471250953.bi1411s37; Concordet JP, 2018, NUCLEIC ACIDS RES, V46, pW242, DOI 10.1093/nar/gky354; Csibi A, 2014, CURR BIOL, V24, P2274, DOI 10.1016/j.cub.2014.08.007; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang Chi V, 2010, Genes Cancer, V1, P526; Dejure FR, 2017, EMBO J, V36, P1854, DOI 10.15252/embj.201796662; Delgado M Dolores, 2010, Genes Cancer, V1, P605, DOI 10.1177/1947601910377495; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Deng LF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15573-6; Farrell AS, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014365; Fine BM, 2005, CANCER RES, V65, P291; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gonzalez A, 2017, EMBO J, V36, P397, DOI 10.15252/embj.201696010; Halbrook CJ, 2020, BIORXIV, DOI [10.1101/2020.05.15.098368v1.full, DOI 10.1101/2020.05.15.098368V1.FULL]; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Jiang J, 2021, METABOLITES, V11, DOI 10.3390/metabo11060402; Jiang J, 2019, J BIOL CHEM, V294, P18674, DOI 10.1074/jbc.RA119.010447; Krall AS, 2021, CELL METAB, V33, P1013, DOI 10.1016/j.cmet.2021.02.001; Krall AS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11457; Layer JH, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00652-19; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Melamud E, 2010, ANAL CHEM, V82, P9818, DOI 10.1021/ac1021166; Meng DL, 2020, J BIOL CHEM, V295, P2890, DOI 10.1074/jbc.AC119.011578; Misra J, 2021, NUCLEIC ACIDS RES, V49, P5726, DOI 10.1093/nar/gkab362; Nakamura A, 2018, P NATL ACAD SCI USA, V115, pE7776, DOI 10.1073/pnas.1805523115; Pathria G, 2019, NAT CELL BIOL, V21, P1590, DOI 10.1038/s41556-019-0415-1; Pavlova NN, 2018, CELL METAB, V27, P428, DOI 10.1016/j.cmet.2017.12.006; Pelossof R, 2017, NAT BIOTECHNOL, V35, P350, DOI 10.1038/nbt.3807; Pernicova I, 2014, NAT REV ENDOCRINOL, V10, P143, DOI 10.1038/nrendo.2013.256; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.05033; Sidrauski C, 2013, ELIFE, V2, DOI 10.7554/eLife.00498; Stine ZE, 2022, NAT REV DRUG DISCOV, V21, P141, DOI 10.1038/s41573-021-00339-6; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Sullivan LB, 2018, NAT CELL BIOL, V20, P782, DOI 10.1038/s41556-018-0125-0; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wilson GJ, 2013, AM J PHYSIOL-ENDOC M, V305, pE1124, DOI 10.1152/ajpendo.00080.2013; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wolfe AL, 2014, NATURE, V513, P65, DOI 10.1038/nature13485; Wu J, 2021, NAT CELL BIOL, V23, DOI 10.1038/s41556-020-00615-4; Ye JB, 2015, GENE DEV, V29, P2331, DOI 10.1101/gad.269324.115; Yue M, 2017, CELL REP, V21, P3819, DOI 10.1016/j.celrep.2017.12.002; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099	54	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4855	4865		10.1038/s41388-022-02474-9	http://dx.doi.org/10.1038/s41388-022-02474-9		OCT 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36182969	Green Accepted			2022-12-28	WOS:000862526800003
J	Ligumsky, H; Merenbakh-Lamin, K; Keren-Khadmy, N; Wolf, I; Rubinek, T				Ligumsky, Hagai; Merenbakh-Lamin, Keren; Keren-Khadmy, Noa; Wolf, Ido; Rubinek, Tami			The role of alpha-klotho in human cancer: molecular and clinical aspects	ONCOGENE			English	Review							NF-KAPPA-B; CELL LUNG-CANCER; TUMOR-SUPPRESSOR; OVARIAN-CANCER; BREAST-CANCER; EXPRESSION; GROWTH; INFLAMMATION; GENE; IDENTIFICATION	Klotho is a well-established longevity hormone. Its most prominent function is the regulation of phosphate homeostasis. However, klotho possesses multiple pleiotropic activities, including inhibition of major signaling pathways, reducing oxidative stress and suppressing inflammation. These activities are tightly associated with cancer, and klotho was discovered as a universal tumor suppressor. We review here novel molecular aspects of klotho activity in cancer, focusing on its structure-function relationships and clinical aspects regarding its expression, blood levels, clinical risk, and prognostic value in the clinical setting. In addition, the potential benefit of klotho treatment combined with chemotherapy, biological therapy, or immunotherapy, are discussed. Finally, as klotho was shown in preclinical models to inhibit cancer development and growth, we discuss various approaches to developing klotho-based therapies.	[Ligumsky, Hagai; Merenbakh-Lamin, Keren; Keren-Khadmy, Noa; Wolf, Ido; Rubinek, Tami] Tel Aviv Sourasky Med Ctr, Oncol Div, Tel Aviv, Israel; [Ligumsky, Hagai; Wolf, Ido; Rubinek, Tami] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Rubinek, T (corresponding author), Tel Aviv Sourasky Med Ctr, Oncol Div, Tel Aviv, Israel.; Rubinek, T (corresponding author), Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.	tamarru@tlvmc.gov.il			Tova and Sami Sagol Foundation	Tova and Sami Sagol Foundation	The research leading to this work has received funding supported by Tova and Sami Sagol Foundation.	Abramovitz L, 2011, CLIN CANCER RES, V17, P4254, DOI 10.1158/1078-0432.CCR-10-2749; Allaoui R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13050; Rubinstein TA, 2021, CANCERS, V13, DOI 10.3390/cancers13246297; Arbour KC, 2018, J CLIN ONCOL, V36, P2872, DOI 10.1200/JCO.2018.79.0006; Brownstein CA, 2008, P NATL ACAD SCI USA, V105, P3455, DOI 10.1073/pnas.0712361105; Camilli TC, 2011, PIGM CELL MELANOMA R, V24, P175, DOI 10.1111/j.1755-148X.2010.00792.x; Cha SK, 2008, P NATL ACAD SCI USA, V105, P9805, DOI 10.1073/pnas.0803223105; Chakravarthy A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06654-8; Chang B, 2012, ONCOL REP, V28, P1022, DOI 10.3892/or.2012.1865; Chen B, 2018, J CANCER, V9, P1248, DOI 10.7150/jca.23967; Chen B, 2012, CANCER BIOL THER, V13, P1221, DOI 10.4161/cbt.21420; Chen B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-99; Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104; Chen CD, 2020, FASEB J, V34, P7234, DOI 10.1096/fj.202000171R; Chen CD, 2018, J MOL NEUROSCI, V64, P175, DOI 10.1007/s12031-017-1011-0; Chen GZ, 2018, NATURE, V553, P461, DOI 10.1038/nature25451; Chen JL, 2018, HYPERTENSION, V71, P877, DOI 10.1161/HYPERTENSIONAHA.117.10560; Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005; Dalton GD, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00323; Delcroix V, 2018, CANCERS, V10, DOI 10.3390/cancers10110439; Doi S, 2011, J BIOL CHEM, V286, P8655, DOI 10.1074/jbc.M110.174037; Drakaki A, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1824645; Fakhar M, 2022, ARCH BIOCHEM BIOPHYS, V719, DOI 10.1016/j.abb.2022.109171; Gigante M, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001917; Guo Y, 2018, BBA-MOL BASIS DIS, V1864, P238, DOI 10.1016/j.bbadis.2017.09.029; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heijboer AC, 2013, NEPHROL DIAL TRANSPL, V28, P2283, DOI 10.1093/ndt/gft236; Hui HP, 2017, ONCOTARGET, V8, P15663, DOI 10.18632/oncotarget.14933; Imura A, 2007, SCIENCE, V316, P1615, DOI 10.1126/science.1135901; Jiang B, 2014, CANCER INVEST, V32, P218, DOI 10.3109/07357907.2014.905586; Jorge LB, 2019, AM J PHYSIOL-RENAL, V316, pF438, DOI 10.1152/ajprenal.00625.2017; Kartolo A, 2021, J IMMUNOTHER, V44, P167, DOI 10.1097/CJI.0000000000000360; King GD, 2012, AGE, V34, P1405, DOI 10.1007/s11357-011-9315-4; King GD, 2012, BIOCHEM J, V441, P453, DOI 10.1042/BJ20101909; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lee J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-109; Li QG, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0241-2; Li XX, 2014, INT J ONCOL, V45, P611, DOI 10.3892/ijo.2014.2430; Ligumsky H, 2015, MOL CANCER RES, V13, P1398, DOI 10.1158/1541-7786.MCR-15-0141; Liu C, 2015, INT J CLIN EXP PATHO, V8, P7446; Liu F, 2011, NAT CELL BIOL, V13, P254, DOI 10.1038/ncb2167; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Lojkin I, 2015, CANCER LETT, V362, P149, DOI 10.1016/j.canlet.2015.03.035; Lu L, 2008, CANCER INVEST, V26, P185, DOI 10.1080/07357900701638343; Madathil SV, 2014, AM J PATHOL, V184, P827, DOI 10.1016/j.ajpath.2013.11.016; Mao XQ, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01428-1; Masso A, 2018, MOL PSYCHIATR, V23, DOI 10.1038/mp.2017.211; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Mazzotta C, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1233-0; Okada S, 2000, INT IMMUNOL, V12, P861, DOI 10.1093/intimm/12.6.861; Pako J, 2020, PATHOL ONCOL RES, V26, P233, DOI 10.1007/s12253-018-0441-5; Pan J, 2011, TUMOR BIOL, V32, P729, DOI 10.1007/s13277-011-0174-5; Pawlikowski M, 2019, ENDOKRYNOL POL, V70, P237, DOI 10.5603/EP.a2019.0004; Peshes-Yeloz N, 2019, WORLD NEUROSURG, V130, pE324, DOI 10.1016/j.wneu.2019.06.082; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rassy E, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920907504; Rubinek T, 2016, VITAM HORM, V101, P197, DOI 10.1016/bs.vh.2016.03.001; Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4; Rubinstein TA, 2019, ONCOGENE, V38, P794, DOI 10.1038/s41388-018-0489-4; Scott SC, 2018, J THORAC ONCOL, V13, P1771, DOI 10.1016/j.jtho.2018.06.004; Shimada T, 2004, CIRCULATION, V110, P1148, DOI 10.1161/01.CIR.0000139854.74847.99; Shmulevich R, 2020, ONCOGENE, V39, P4636, DOI 10.1038/s41388-020-1313-5; Shu GS, 2013, CELL ONCOL, V36, P121, DOI 10.1007/s13402-012-0118-0; Sun HD, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0717-0; Suvannasankha A, 2015, ONCOTARGET, V6, P19647, DOI 10.18632/oncotarget.3794; Takegahara K, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12679; Tang X, 2016, DIS ESOPHAGUS, V29, P207, DOI 10.1111/dote.12289; Tang XW, 2016, LAB INVEST, V96, P197, DOI 10.1038/labinvest.2015.86; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Tohyama O, 2004, J BIOL CHEM, V279, P9777, DOI 10.1074/jbc.M312392200; Usuda J, 2011, LUNG CANCER, V74, P332, DOI 10.1016/j.lungcan.2011.03.004; Usuda J, 2011, LUNG CANCER, V72, P355, DOI 10.1016/j.lungcan.2010.10.008; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Wang LJ, 2011, AM J CANCER RES, V1, P111; Wang XL, 2011, ONCOL REP, V25, P1465, DOI 10.3892/or.2011.1178; Witkowski JM, 2007, J IMMUNOL, V178, P771, DOI 10.4049/jimmunol.178.2.771; Wolf I, 2010, ONCOGENE, V29, P26, DOI 10.1038/onc.2009.301; Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292; Wu Q, 2021, CANCER MANAG RES, V13, P4791, DOI 10.2147/CMAR.S295086; Wu XL, 2008, J BIOL CHEM, V283, P33304, DOI 10.1074/jbc.M803319200; Xie BA, 2016, ONCOTARGET, V7, P80765, DOI 10.18632/oncotarget.12623; Xie BA, 2013, HUM PATHOL, V44, P795, DOI 10.1016/j.humpath.2012.07.023; Xie B, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-18; Yan YL, 2017, MOL MED REP, V15, P1777, DOI 10.3892/mmr.2017.6172; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963; Yuan Q, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28096-z; Zhou XX, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0391-5; Zhou YM, 2017, PHARMAZIE, V72, P227, DOI 10.1691/ph.2017.6867; Zhu WS, 2019, AGING-US, V11, P5246, DOI 10.18632/aging.102121; Zhu Y, 2013, CANCER SCI, V104, P663, DOI 10.1111/cas.12134; Zhu Y, 2019, CANCER MANAG RES, V11, P1383, DOI 10.2147/CMAR.S188415	93	1	1	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4487	4497		10.1038/s41388-022-02440-5	http://dx.doi.org/10.1038/s41388-022-02440-5		AUG 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36038662				2022-12-28	WOS:000847262000003
J	Hu, XS; Liu, RC; Hou, JB; Peng, W; Wan, SC; Xu, MH; Li, YS; Zhang, GH; Zhai, X; Liang, P; Cui, HJ				Hu, Xiaosong; Liu, Ruochen; Hou, Jianbing; Peng, Wen; Wan, Sicheng; Xu, Minghao; Li, Yongsen; Zhang, Guanghui; Zhai, Xuan; Liang, Ping; Cui, Hongjuan			SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation	ONCOGENE			English	Article							N-MYC; THERAPEUTIC TARGET; DNA-BINDING; GENE; EXPRESSION; COMPLEX; PROTEIN; STABILIZATION; PROLIFERATION; AMPLIFICATION	SMARCE1 gene, encoding a core subunit of SWI/SNF chromatin remodeling complex, is situated on chromosome 17q21-ter region that is frequently gained in neuroblastoma. However, its role in the tumorigenesis remains unknown. Here, we showed that high expression of SMARCE1 was associated with poor prognosis of patients with neuroblastoma, especially those with MYCN amplification. Knockdown of SMARCE1 reduced proliferation, colony formation, and tumorigenicity of neuroblastoma cells. Mechanistically, SMARCE1 directly interacted with MYCN, which was necessary for MYCN-mediated transcriptional activation of downstream target genes including PLK1, ODC1, and E2F2. Overexpression of PLK1, ODC1 or E2F2 significantly reversed the inhibiting effect of SMARCE1 knockdown on the proliferation, colony formation, and tumorigenicity of MYCN-amplified neuroblastoma cells. Moreover, we revealed that MYCN directly regulated SMARCE1 transcription through binding to a non-canonical E-box of SMARCE1 promoter, thus enhancing SMARCE1-MYCN cooperativity. These findings establish SMARCE1 is a critical oncogenic factor in neuroblastoma and provide a new potential target for treatment of neuroblastoma with 17q21-ter gain and MYCN amplification.	[Hu, Xiaosong; Liu, Ruochen; Hou, Jianbing; Peng, Wen; Wan, Sicheng; Xu, Minghao; Li, Yongsen; Zhang, Guanghui; Cui, Hongjuan] Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China; [Hu, Xiaosong; Liu, Ruochen; Hou, Jianbing; Peng, Wen; Wan, Sicheng; Xu, Minghao; Li, Yongsen; Zhang, Guanghui; Cui, Hongjuan] Southwest Univ, Canc Ctr, Med Res Inst, Chongqing 400716, Peoples R China; [Zhai, Xuan; Liang, Ping] Chongqing Med Univ, Childrens Hosp, Dept Neurosurg, Chongqing 400014, Peoples R China; [Zhai, Xuan; Liang, Ping] Chongqing Key Lab Pediat, Chongqing 400010, Peoples R China	Southwest University - China; Southwest University - China; Chongqing Medical University	Cui, HJ (corresponding author), Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China.; Cui, HJ (corresponding author), Southwest Univ, Canc Ctr, Med Res Inst, Chongqing 400716, Peoples R China.; Liang, P (corresponding author), Chongqing Med Univ, Childrens Hosp, Dept Neurosurg, Chongqing 400014, Peoples R China.; Liang, P (corresponding author), Chongqing Key Lab Pediat, Chongqing 400010, Peoples R China.	pingliangnet@163.com; hcui@swu.edu.cn	Zhang, Guanghui/HHS-1240-2022	Zhang, Guanghui/0000-0002-6289-4965; Xu, Minghao/0000-0003-0535-8231	Natural Science Foundation of Chongqing [cstc2019jcyj-zdxmX0033, cstc2022ycjh-bgzxm0145]; pilot program of Southwest University [SWU-XDZD22006]	Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing); pilot program of Southwest University	This research was supported by the Natural Science Foundation of Chongqing (cstc2019jcyj-zdxmX0033, cstc2022ycjh-bgzxm0145), the pilot program of Southwest University (SWU-XDZD22006).	Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Amente S, 2015, ONCOTARGET, V6, P14572, DOI 10.18632/oncotarget.3990; Amente S, 2011, NUCLEIC ACIDS RES, V39, P9498, DOI 10.1093/nar/gkr638; Baluapuri A, 2020, NAT REV MOL CELL BIO, V21, P255, DOI 10.1038/s41580-020-0215-2; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bell E, 2010, CANCER LETT, V293, P144, DOI 10.1016/j.canlet.2010.01.015; Bell JL, 2015, J CLIN ONCOL, V33, P1285, DOI 10.1200/JCO.2014.55.9880; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bourdeaut F, 2009, J PATHOL, V219, P463, DOI 10.1002/path.2614; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Burkhart CA, 2003, J NATL CANCER I, V95, P1394, DOI 10.1093/jnci/djg045; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Clapier CR, 2017, NAT REV MOL CELL BIO, V18, P407, DOI 10.1038/nrm.2017.26; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; Davis CA, 2018, NUCLEIC ACIDS RES, V46, pD794, DOI 10.1093/nar/gkx1081; DIAS P, 1990, INT J CANCER, V45, P593, DOI 10.1002/ijc.2910450403; Duffy DJ, 2018, GENE REP, V12, P187, DOI 10.1016/j.genrep.2018.06.018; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fetahu IS, 2021, CANCER METAST REV, V40, P173, DOI 10.1007/s10555-020-09946-y; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Heo Y, 2020, BIOCHEM BIOPH RES CO, V533, P919, DOI 10.1016/j.bbrc.2020.09.094; Hogarty MD, 2008, CANCER RES, V68, P9735, DOI 10.1158/0008-5472.CAN-07-6866; Hou J, 2017, ONCOGENE, V36, P1134, DOI 10.1038/onc.2016.280; Hu XS, 2022, BIOCHEM BIOPH RES CO, V599, P148, DOI 10.1016/j.bbrc.2022.01.124; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Hui ABY, 2001, LAB INVEST, V81, P717, DOI 10.1038/labinvest.3780280; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Krstic A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.612518; Kumar P, 2020, SEMIN CANCER BIOL, V67, P105, DOI 10.1016/j.semcancer.2019.06.016; Lee TH, 2009, NAT CELL BIOL, V11, P97, DOI 10.1038/ncb1818; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; Li YS, 2021, MEDCOMM, V2, P467, DOI 10.1002/mco2.73; Mao L, 2011, CANCER RES, V71, P4314, DOI 10.1158/0008-5472.CAN-11-0051; Mastronikolis N, 2019, J BUON, V24, P2242; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Monclair T, 2009, J CLIN ONCOL, V27, P298, DOI 10.1200/JCO.2008.16.6876; Nagy Z, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22143-x; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Nakayama RT, 2017, NAT GENET, V49, P1613, DOI 10.1038/ng.3958; NISEN PD, 1986, CANCER RES, V46, P6217; O'Neill S, 2001, GENE CHROMOSOME CANC, V30, P87, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1055>3.0.CO;2-J; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Peng W, 2022, ONCOGENE, V41, P3051, DOI 10.1038/s41388-022-02296-9; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Rust K, 2018, EMBO J, V37, DOI 10.15252/embj.201798659; Sethuraman A, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0738-9; Sokol ES, 2017, P NATL ACAD SCI USA, V114, P4153, DOI 10.1073/pnas.1703931114; Sun JR, 2018, J INVEST DERMATOL, V138, P1795, DOI 10.1016/j.jid.2018.02.028; Tonelli R, 2005, MOL CANCER THER, V4, P779, DOI 10.1158/1535-7163.MCT-04-0213; Tsukiyama T, 2002, NAT REV MOL CELL BIO, V3, P422, DOI 10.1038/nrm828; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wan M, 2009, EUR J IMMUNOL, V39, P580, DOI 10.1002/eji.200838909; Wattler F, 1999, GENOMICS, V60, P172, DOI 10.1006/geno.1999.5913; Wei JC, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00176; WENZEL A, 1995, EUR J CANCER, V31A, P516, DOI 10.1016/0959-8049(95)00060-V; Wong M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11132-w; Wong M, 2017, CANCER RES, V77, P2522, DOI 10.1158/0008-5472.CAN-16-1663; Xiao DB, 2016, MOL CELL, V64, P493, DOI 10.1016/j.molcel.2016.09.016; Yang R, 2020, ONCOGENE, V39, P2975, DOI 10.1038/s41388-020-1199-2; Zafar AT, 2021, MED RES REV, V41, P961, DOI 10.1002/med.21750; Zeid R, 2018, NAT GENET, V50, P515, DOI 10.1038/s41588-018-0044-9; Zhang K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1086-8; Zhang WW, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0581-9	74	2	2	9	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4295	4306		10.1038/s41388-022-02428-1	http://dx.doi.org/10.1038/s41388-022-02428-1		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35978151				2022-12-28	WOS:000843817400001
J	Balinth, S; Fisher, ML; Hwangbo, Y; Wu, CZ; Ballon, C; Sun, XQ; Mills, AA				Balinth, Seamus; Fisher, Matthew L.; Hwangbo, Yon; Wu, Caizhi; Ballon, Carlos; Sun, Xueqin; Mills, Alea A.			EZH2 regulates a SETDB1/Delta Np63 alpha axis via RUNX3 to drive a cancer stem cell phenotype in squamous cell carcinoma	ONCOGENE			English	Article							P53 HOMOLOG; EXPRESSION; P63; PROLIFERATION; MELANOMA; PROMOTER; ENHANCER; TARGETS; GENE; HEAD	Enhancer of zeste homolog 2 (EZH2) and SET domain bifurcated 1 (SETDB1, also known as ESET) are oncogenic methyltransferases implicated in a number of human cancers. These enzymes typically function as epigenetic repressors of target genes by methylating histone H3 K27 and H3-K9 residues, respectively. Here, we show that EZH2 and SETDB1 are essential to proliferation in 3 SCC cell lines, HSC-5, FaDu, and Cal33. Additionally, we find both of these proteins highly expressed in an aggressive stem-like SCC sub-population. Depletion of either EZH2 or SETDB1 disrupts these stem-like cells and their associated phenotypes of spheroid formation, invasion, and tumor growth. We show that SETDB1 regulates this SCC stem cell phenotype through cooperation with Delta Np63 alpha, an oncogenic isoform of the p53-related transcription factor p63. Furthermore, EZH2 is upstream of both SETDB1 and Delta Np63 alpha, activating these targets via repression of the tumor suppressor RUNX3. We show that targeting this pathway with inhibitors of EZH2 results in activation of RUNX3 and repression of both SETDB1 and Delta Np63 alpha, antagonizing the SCC cancer stem cell phenotype. This work highlights a novel pathway that drives an aggressive cancer stem cell phenotype and demonstrates a means of pharmacological intervention.	[Balinth, Seamus; Fisher, Matthew L.; Hwangbo, Yon; Wu, Caizhi; Ballon, Carlos; Sun, Xueqin; Mills, Alea A.] Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA; [Balinth, Seamus] SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Mills, AA (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	mills@cshl.edu		Balinth, Seamus/0000-0003-2926-7051	Office of the Director, National Institutes of Health [5P30CA045508, CA247400, CA225134, R01CA190997, R21OD018332]; Cold Spring Harbor Laboratory; Northwell Health Affiliation	Office of the Director, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cold Spring Harbor Laboratory; Northwell Health Affiliation	This work was supported by the Office of the Director, National Institutes of Health through award numbers 5P30CA045508 (Cancer Center Support Grant), CA247400 (to SB), CA225134 (to MLF), as well as R01CA190997 and R21OD018332 (to AAM). This project was also supported through the Cold Spring Harbor Laboratory and Northwell Health Affiliation.	Antonini D, 2006, MOL CELL BIOL, V26, P3308, DOI 10.1128/MCB.26.8.3308-3318.2006; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Bacciu A, 2004, CLIN OTOLARYNGOL, V29, P545, DOI 10.1111/j.1365-2273.2004.00851.x; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Bailey TL, 2015, NUCLEIC ACIDS RES, V43, pW39, DOI 10.1093/nar/gkv416; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; Date Y, 2020, MOL CELLS, V43, P176, DOI 10.14348/molcells.2019.0285; Deng HY, 2017, EUR J CARDIO-THORAC, V51, P421, DOI 10.1093/ejcts/ezw315; Dragu DL, 2015, WORLD J STEM CELLS, V7, P1185, DOI 10.4252/wjsc.v7.i9.1185; Fisher ML, 2021, CANCER RES, V81, P6246, DOI 10.1158/0008-5472.CAN-21-0707; Fisher ML, 2020, J CELL SCI, V133, DOI 10.1242/jcs.228015; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Gao F, 2009, J CANCER RES CLIN, V135, P739, DOI 10.1007/s00432-008-0508-x; Jian Z, 2017, J INVEST DERMATOL, V137, P31, DOI 10.1016/j.jid.2016.07.033; Jiang LM, 2022, CANCERS, V14, DOI 10.3390/cancers14020415; Johnson N, 2001, J Dent Educ, V65, P328; Kaidar-Person O, 2018, DRUG RESIST UPDATE, V40, P13, DOI 10.1016/j.drup.2018.09.001; Kanumuri R, 2021, ONCOGENE, V40, P5327, DOI 10.1038/s41388-021-01927-x; Karanth AV, 2017, EXPERT OPIN THER TAR, V21, P319, DOI 10.1080/14728222.2017.1279604; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009; Kikuchi K, 2017, JPN DENT SCI REV, V53, P95, DOI 10.1016/j.jdsr.2017.01.002; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136; Kudo Y, 2011, J CELL BIOCHEM, V112, P387, DOI 10.1002/jcb.22967; Kumar A, 2016, ONCOGENE, V35, P4857, DOI 10.1038/onc.2016.18; Lee SH, 2019, TUBERC RESPIR DIS, V82, P179, DOI 10.4046/trd.2018.0068; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Lin CW, 2015, ONCOTARGET, V6, P8434, DOI 10.18632/oncotarget.3020; Liu-Smith F, 2017, ADV EXP MED BIOL, V996, P27, DOI 10.1007/978-3-319-56017-5_3; Lu B, 2018, CANCER CELL, V34, P970, DOI 10.1016/j.ccell.2018.10.015; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Oshimori N, 2020, CANCER SCI, V111, P3985, DOI 10.1111/cas.14639; Otani S, 2022, ONCOGENE, V41, P683, DOI 10.1038/s41388-021-02120-w; Paver EC, 2020, PATHOLOGY, V52, P179, DOI 10.1016/j.pathol.2019.10.008; Petitjean A, 2008, CARCINOGENESIS, V29, P273, DOI 10.1093/carcin/bgm258; Regina C, 2016, ONCOTARGET, V7, P28836, DOI 10.18632/oncotarget.7089; Romano RA, 2006, J INVEST DERMATOL, V126, P1469, DOI 10.1038/sj.jid.5700297; Selvarajan V, 2017, LEUKEMIA, V31, P2219, DOI 10.1038/leu.2017.40; Shi JW, 2015, NAT BIOTECHNOL, V33, P661, DOI 10.1038/nbt.3235; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Soares E, 2018, CELL MOL LIFE SCI, V75, P1179, DOI 10.1007/s00018-017-2701-z; Somerville TDD, 2018, CELL REP, V25, P1741, DOI 10.1016/j.celrep.2018.10.051; Su JL, 2016, CELL BIOCHEM FUNCT, V34, P597, DOI 10.1002/cbf.3233; Sugiura H, 2008, ONCOL REP, V19, P713; Tagliamento M, 2018, EXPERT OPIN PHARMACO, V19, P2055, DOI 10.1080/14656566.2018.1540591; Tsusaka T, 2019, EMBO REP, V20, DOI 10.15252/embr.201948297; Xiao ZH, 2020, ONCOL REP, V43, P1289, DOI 10.3892/or.2020.7508; Yan W, 2011, AM J CANCER RES, V1, P275; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhao MH, 2019, INT J ONCOL, V55, P1165, DOI 10.3892/ijo.2019.4880	55	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2022	41	35					4130	4144		10.1038/s41388-022-02417-4	http://dx.doi.org/10.1038/s41388-022-02417-4		JUL 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4A3US	35864175				2022-12-28	WOS:000828442600002
J	Zhao, Y; Sun, HF; Zhao, YY; Liu, QQ; Liu, Y; Hou, YF; Jin, W				Zhao, Yang; Sun, Hefen; Zhao, Yuanyuan; Liu, Qiqi; Liu, Yang; Hou, Yifeng; Jin, Wei			NSrp70 suppresses metastasis in triple-negative breast cancer by modulating Numb/T beta R1/EMT axis	ONCOGENE			English	Article							SPECKLE-RELATED PROTEIN; ISOFORM; EXPRESSION; NUMB; ABERRANT	Alternative splicing of mRNA precursors allows cancer cells to create different protein isoforms that promote growth and survival. Compared to normal cells, cancer cells frequently exhibit a higher diversity of their transcriptomes. A comprehensive understanding of splicing regulation is required to correct the splicing alterations for the future precision oncology. A quantitative proteomic screen was performed to identify the regulators associated the metastasis in triple-negative breast cancer. Multiple in vitro and in vivo functional analyses were used to study the effects of NSrp70 on breast cancer metastasis. Next, transcriptomic sequencing (RNA-seq) and alternative splicing bioinformatics analysis was applied to screen the potential targets of NSrp70. Moreover, in vitro splicing assays, RNA pull-down, and RNA immunoprecipitation assay were used to confirm the specific binding between NSrp70 and downstream target genes. Furthermore, the prognostic value of NSrp70 was analyzed in a cohort of patients by performing IHC. We uncovered NSrp70 as a novel suppressor of breast cancer metastasis. We discovered that NSrp70 inhibited the skipped exon alternative splicing of NUMB, promoted the degradation of transforming growth factor receptor 1 through lysosome pathway, and regulated TGF beta/SMAD-mediated epithelial-mesenchymal transition phenotype in breast cancer cells. Furthermore, high NSrp70 expression correlated with a better prognosis in breast cancer patients. Our findings revealed that splicing regulator NSrp70 serves as a metastasis suppressor.	[Zhao, Yang; Sun, Hefen; Zhao, Yuanyuan; Liu, Qiqi; Liu, Yang; Hou, Yifeng; Jin, Wei] Fudan Univ, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Zhao, Yang; Sun, Hefen; Zhao, Yuanyuan; Liu, Qiqi; Hou, Yifeng; Jin, Wei] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Sun, HF; Jin, W (corresponding author), Fudan Univ, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Sun, HF; Jin, W (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.	sunhefen2006@163.com; jinwei@fudan.edu.cn	ZHAO, YUAN/HCI-5831-2022; jin, wei/M-4717-2018	jin, wei/0000-0001-8263-571X	National Natural Science Foundation of China [81972727]; Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai [2017BR028]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai	This work was supported by a grant from National Natural Science Foundation of China (81972727) and the Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai (2017BR028). We gratefully acknowledge the help of professor Igor Vladimirovich Reshetov (I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation) for the support of clinical statistical analysis.	Bell MV, 1998, MOL CELL BIOL, V18, P5930, DOI 10.1128/MCB.18.10.5930; Cheng CH, 2006, GENE DEV, V20, P1715, DOI 10.1101/gad.1430906; Choi DB, 2014, LEUKEMIA RES, V38, P1252, DOI 10.1016/j.leukres.2014.08.001; Cooper TA, 2005, METHODS, V37, P331, DOI 10.1016/j.ymeth.2005.07.015; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Erb U, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-29; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Imamura T, 2012, BREAST CANCER-TOKYO, V19, P118, DOI 10.1007/s12282-011-0321-2; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Kandachar V, 2012, CURR OPIN CELL BIOL, V24, P534, DOI 10.1016/j.ceb.2012.06.006; Katz Y, 2010, NAT METHODS, V7, P1009, DOI 10.1038/NMETH.1528; Kim CH, 2016, J BIOL CHEM, V291, P6169, DOI 10.1074/jbc.M115.689414; Kim YD, 2011, NUCLEIC ACIDS RES, V39, P4300, DOI 10.1093/nar/gkq1267; Ladomery Michael, 2013, Int J Cell Biol, V2013, P463786, DOI 10.1155/2013/463786; Lee SH, 2016, BIOCHEM BIOPH RES CO, V479, P238, DOI 10.1016/j.bbrc.2016.09.051; Lee SCW, 2016, NAT MED, V22, P976, DOI 10.1038/nm.4165; Lee Y, 2015, ANNU REV BIOCHEM, V84, P291, DOI 10.1146/annurev-biochem-060614-034316; Li N, 2000, BJU INT, V85, P514, DOI 10.1046/j.1464-410x.2000.00483.x; Loh TJ, 2014, ONCOL REP, V31, P273, DOI 10.3892/or.2013.2812; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Misquitta-Ali CM, 2011, MOL CELL BIOL, V31, P138, DOI 10.1128/MCB.00709-10; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pece S, 2011, BBA-REV CANCER, V1815, P26, DOI 10.1016/j.bbcan.2010.10.001; Read A, 2018, ENDOCR-RELAT CANCER, V25, pR467, DOI 10.1530/ERC-18-0068; Reithmeier A, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3616-7; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Spector DL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a000646; Stoss O, 1999, BRAIN RES PROTOC, V4, P383, DOI 10.1016/S1385-299X(99)00043-4; Sun HY, 2017, BIOCHEM BIOPH RES CO, V491, P780, DOI 10.1016/j.bbrc.2017.07.084; Sun HF, 2019, CANCER LETT, V440, P189, DOI 10.1016/j.canlet.2018.10.018; Townley-Tilson WHD, 2006, RNA, V12, P1853, DOI 10.1261/rna.76006; Tripathi V, 2012, MOL BIOL CELL, V23, P3694, DOI 10.1091/mbc.E12-03-0206; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang ZZ, 2010, CELL ADHES MIGR, V4, P176, DOI 10.4161/cam.4.2.10690; Xiao XY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-151; Xie J, 2015, NEUROSCIENCE, V310, P723, DOI 10.1016/j.neuroscience.2015.10.012; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zheng YZ, 2014, BREAST CANCER RES TR, V145, P349, DOI 10.1007/s10549-014-2967-x; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289	42	1	1	4	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3409	3422		10.1038/s41388-022-02349-z	http://dx.doi.org/10.1038/s41388-022-02349-z		MAY 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35568738	Green Submitted			2022-12-28	WOS:000795517600001
J	Sala, M; Allain, N; Moreau, M; Jabouille, A; Henriet, E; Abou-Hammoud, A; Uguen, A; Di-Tommaso, S; Dourthe, C; Raymond, AA; Dupuy, JW; Gerard, E; Dugot-Senant, N; Rousseau, B; Merlio, JP; Pham-Ledart, A; Vergier, B; Tartare-Deckert, S; Moreau, V; Saltel, F				Sala, Margaux; Allain, Nathalie; Moreau, Melanie; Jabouille, Arnaud; Henriet, Elodie; Abou-Hammoud, Aya; Uguen, Arnaud; Di-Tommaso, Sylvaine; Dourthe, Cyril; Raymond, Anne-Aurelie; Dupuy, Jean-William; Gerard, Emilie; Dugot-Senant, Nathalie; Rousseau, Benoit; Merlio, Jean-Phillipe; Pham-Ledart, Anne; Vergier, Beatrice; Tartare-Deckert, Sophie; Moreau, Violaine; Saltel, Frederic			Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation	ONCOGENE			English	Article							DOWN-REGULATION; DDR1; INHIBITION; METASTASIS; ACTIVATION; MUTATIONS; DISCOVERY; FAMILY; CANCER; GENE	Combined therapy with anti-BRAF plus anti-MEK is currently used as first-line treatment of patients with metastatic melanomas harboring the somatic BRAF V600E mutation. However, the main issue with targeted therapy is the acquisition of tumor cell resistance. In a majority of resistant melanoma cells, the resistant process consists in epithelial-to-mesenchymal transition (EMT). This process called phenotype switching makes melanoma cells more invasive. Its signature is characterized by MITF low, AXL high, and actin cytoskeleton reorganization through RhoA activation. In parallel of this phenotype switching phase, the resistant cells exhibit an anarchic cell proliferation due to hyper-activation of the MAP kinase pathway. We show that a majority of human melanoma overexpress discoidin domain receptor 2 (DDR2) after treatment. The same result was found in resistant cell lines presenting phenotype switching compared to the corresponding sensitive cell lines. We demonstrate that DDR2 inhibition induces a decrease in AXL expression and reduces stress fiber formation in resistant melanoma cell lines. In this phenotype switching context, we report that DDR2 control cell and tumor proliferation through the MAP kinase pathway in resistant cells in vitro and in vivo. Therefore, inhibition of DDR2 could be a new and promising strategy for countering this resistance mechanism.	[Sala, Margaux; Allain, Nathalie; Moreau, Melanie; Jabouille, Arnaud; Henriet, Elodie; Abou-Hammoud, Aya; Uguen, Arnaud; Di-Tommaso, Sylvaine; Dourthe, Cyril; Raymond, Anne-Aurelie; Moreau, Violaine; Saltel, Frederic] BoRdeaux Inst OnCol, BRIC, UMR1312, INSERM, 146 Rue Leo Saignat, F-33076 Bordeaux, France; [Sala, Margaux; Allain, Nathalie; Moreau, Melanie; Jabouille, Arnaud; Henriet, Elodie; Abou-Hammoud, Aya; Di-Tommaso, Sylvaine; Dourthe, Cyril; Raymond, Anne-Aurelie; Moreau, Violaine; Saltel, Frederic] Bordeaux Univ, 146 Rue Leo Saignat, F-33076 Bordeaux, France; [Uguen, Arnaud] Brest Univ Hosp Ctr, Dept Pathol, F-29200 Brest, France; [Di-Tommaso, Sylvaine; Dourthe, Cyril; Raymond, Anne-Aurelie; Saltel, Frederic] UMS 005, Oncoprot, F-33076 Bordeaux, France; [Dupuy, Jean-William] Bordeaux Univ, Plateforme Proteome, F-33000 Bordeaux, France; [Gerard, Emilie] Bordeaux Univ Hosp, Dermatol Dept, 1 Ave Jean Burguet, F-33000 Bordeaux, France; [Dugot-Senant, Nathalie] Histol Plateforme, UMS 005, F-33076 Bordeaux, France; [Rousseau, Benoit] Bordeaux Univ, Common Anim Housing Serv, F-33076 Bordeaux, France; [Merlio, Jean-Phillipe; Pham-Ledart, Anne; Vergier, Beatrice] Bordeaux Res Translat Oncol, Cutaneous Lymphoma Oncogenesis, BaRITOn, INSERM,UMR1053,Team 3, 146 Rue Leo Saignat, F-33076 Bordeaux, France; [Merlio, Jean-Phillipe; Pham-Ledart, Anne; Vergier, Beatrice] Bordeaux Univ Hosp, Tumor Bank & Tumor Biol Lab, Ave Magellan, F-33604 Pessac, France; [Tartare-Deckert, Sophie] Univ Cote dAzur, C3M, INSERM, F-06204 Nice, France; [Henriet, Elodie] Johns Hopkins Univ, Sch Med, Ewalds Lab, Dept Cell Biol, Baltimore, MD USA; [Abou-Hammoud, Aya] Bordeaux Univ, MFP, UMR 5234, 146 Rue Leo Saignat, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Brest; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Johns Hopkins University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Saltel, F (corresponding author), BoRdeaux Inst OnCol, BRIC, UMR1312, INSERM, 146 Rue Leo Saignat, F-33076 Bordeaux, France.; Saltel, F (corresponding author), Bordeaux Univ, 146 Rue Leo Saignat, F-33076 Bordeaux, France.; Saltel, F (corresponding author), UMS 005, Oncoprot, F-33076 Bordeaux, France.	frederic.saltel@inserm.fr	JABOUILLE, Arnaud/ABC-5823-2020; TARTARE-DECKERT, Sophie/P-6057-2015; Dupuy, Jean-William JWD/F-5335-2012	JABOUILLE, Arnaud/0000-0002-2281-430X; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Dupuy, Jean-William JWD/0000-0002-2448-4797; Moreau, Violaine/0000-0002-4513-7022; Sala, Margaux/0000-0003-3483-361X; saltel, frederic/0000-0002-0724-9680	Inca (PLBIO Inca) [PLBIO15-135]; SIRIC BRIO 2; Fondation de France; FRM, equipe labellisee [DEQ20180839586]; French ministere superieur de l'enseignement et de la recherche	Inca (PLBIO Inca); SIRIC BRIO 2; Fondation de France(Fondation de France); FRM, equipe labellisee; French ministere superieur de l'enseignement et de la recherche	This work is supported by Inca (PLBIO Inca, PLBIO15-135), SIRIC BRIO 2, Fondation de France, FRM, equipe labellisee (grant number DEQ20180839586). Margaux Sala is financed by a PhD grant from the French ministere superieur de l'enseignement et de la recherche.	Ambrogio C, 2016, NAT MED, V22, P270, DOI 10.1038/nm.4041; Arozarena I, 2019, NAT REV CANCER, V19, P377, DOI 10.1038/s41568-019-0154-4; Ascierto PA, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-85; Badiola I, 2011, ONCOL REP, V26, P971, DOI 10.3892/or.2011.1356; Basile KJ, 2014, PIGM CELL MELANOMA R, V27, P479, DOI 10.1111/pcmr.12218; Das S, 2006, CANCER RES, V66, P8123, DOI 10.1158/0008-5472.CAN-06-1215; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Day E, 2008, EUR J PHARMACOL, V599, P44, DOI 10.1016/j.ejphar.2008.10.014; de Moura CR, 2019, PIGM CELL MELANOMA R, V32, P697, DOI 10.1111/pcmr.12809; Deutsch EW, 2020, NUCLEIC ACIDS RES, V48, pD1145, DOI 10.1093/nar/gkz984; Du ZF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0782-4; El Azreq MA, 2016, ONCOTARGET, V7, P44975, DOI 10.18632/oncotarget.10455; Gao MS, 2013, J MED CHEM, V56, P3281, DOI 10.1021/jm301824k; Girard CA, 2020, CANCER RES, V80, P1927, DOI 10.1158/0008-5472.CAN-19-2914; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Grither WR, 2018, P NATL ACAD SCI USA, V115, pE7786, DOI 10.1073/pnas.1805020115; Grither WR, 2018, ONCOGENE, V37, P1714, DOI 10.1038/s41388-017-0043-9; Hammerman PS, 2011, CANCER DISCOV, V1, P78, DOI 10.1158/2159-8274.CD-11-0005; Hartman ML, 2015, CELL MOL LIFE SCI, V72, P1249, DOI 10.1007/s00018-014-1791-0; Hedberg ML, 2016, J CLIN INVEST, V126, P169, DOI 10.1172/JCI82066; Henriet E, 2018, CELL ADHES MIGR, V12, P363, DOI 10.1080/19336918.2018.1465156; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Juin A, 2014, J CELL BIOL, V207, P517, DOI 10.1083/jcb.201404079; Juin A, 2012, MOL BIOL CELL, V23, P297, DOI 10.1091/mbc.E11-07-0594; Keating GM, 2017, DRUGS, V77, P85, DOI 10.1007/s40265-016-0677-x; Kim HG, 2013, ACS CHEM BIOL, V8, P2145, DOI 10.1021/cb400430t; Korshunov VA, 2012, CLIN SCI, V122, P361, DOI 10.1042/CS20110411; Kurashige J, 2016, SCI REP-UK, V6, DOI 10.1038/srep22371; Larkin JMG, 2015, J CLIN ONCOL, V33; Leitinger B, 2003, J BIOL CHEM, V278, P16761, DOI 10.1074/jbc.M301370200; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Misek SA, 2020, ONCOGENE, V39, P1466, DOI 10.1038/s41388-019-1074-1; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Park JW, 2015, J CANCER RES CLIN, V141, P1973, DOI 10.1007/s00432-015-1967-5; Rammal H, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00055; Ren TT, 2014, J PATHOL, V234, P526, DOI 10.1002/path.4415; Ren TT, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0397-3; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Sullivan RJ, 2013, EUR J CANCER, V49, P1297, DOI 10.1016/j.ejca.2012.11.019; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Valiathan RR, 2012, CANCER METAST REV, V31, P295, DOI 10.1007/s10555-012-9346-z; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wagenaar TR, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12171; Wang LQ, 2018, CELL, V173, P1413, DOI 10.1016/j.cell.2018.04.012; Wang YG, 2016, DIGEST DIS SCI, V61, P2272, DOI 10.1007/s10620-016-4116-3; Xie BH, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0218-6	52	0	0	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2571	2586		10.1038/s41388-022-02266-1	http://dx.doi.org/10.1038/s41388-022-02266-1		MAR 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35322197				2022-12-28	WOS:000772273600002
J	Kwon, J; Choi, H; Ware, AD; Morillo, BC; Wang, HY; Bouker, KB; Lu, XB; Waldman, T; Han, C				Kwon, Juntae; Choi, Hyeongjwa; Ware, Anna D.; Morillo, Bernadette Cecilia; Wang, Haiyang; Bouker, Kerrie B.; Lu, Xiongbin; Waldman, Todd; Han, Cecil			USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model	ONCOGENE			English	Article							SURFACE EPITHELIUM; CANCER; AUTOPHAGY; ORIGIN; PTEN; P53; PACLITAXEL; PATHWAY; BIOLOGY; CELLS	Epithelial ovarian cancer is the most lethal gynecologic malignancy and one of the most common causes of cancer mortality among women worldwide. Ubiquitin-Specific Peptidase 13 (USP13) gene copy is strongly amplified in human epithelial ovarian cancer, and high USP13 expression is correlated with poor survival outcomes. Yet, its pathological contribution to ovarian tumorigenesis remains unknown. We crossed a conditional Usp13 overexpressing knock-in mouse with a conditional knockout of Trp53 and Pten mouse and generated a novel ovarian cancer genetically engineered mouse model (GEMM), which closely recapitulates the genetic changes driving ovarian cancer in humans. Overexpression of USP13 with deletion of Trp53 and Pten in murine ovarian surface epithelium accelerated ovarian tumorigenesis and led to decreased survival in mice. Notably, USP13 greatly enhanced peritoneal metastasis of ovarian tumors with frequent development of hemorrhagic ascites. The primary and metastatic tumors exhibited morphology and clinical behavior similar to human high-grade serous ovarian cancer. Co-inhibition of USP13 and AKT significantly decreased the viability of the primary murine ovarian cancer cells isolated from the GEMM. USP13 also increased the tumorigenic and metastatic abilities of primary murine ovarian cancer cells in a syngeneic mouse study. These findings suggest a critical role of USP13 in ovarian cancer development and reveal USP13 as a potential therapeutic target for ovarian cancer.	[Kwon, Juntae; Choi, Hyeongjwa; Ware, Anna D.; Wang, Haiyang; Waldman, Todd; Han, Cecil] Georgetown Univ, Dept Oncol, Sch Med, Washington, DC 20007 USA; [Morillo, Bernadette Cecilia; Waldman, Todd] Georgetown Univ, Biochem & Mol Biol, Sch Med, Washington, DC 20007 USA; [Bouker, Kerrie B.; Waldman, Todd; Han, Cecil] Georgetown Univ, Lombardi Comprehens Canc Ctr, Sch Med, Washington, DC 20007 USA; [Lu, Xiongbin] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Georgetown University; Georgetown University; Georgetown University; Indiana University System; Indiana University Bloomington	Han, C (corresponding author), Georgetown Univ, Dept Oncol, Sch Med, Washington, DC 20007 USA.; Han, C (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Sch Med, Washington, DC 20007 USA.	ch1182@georgetown.edu		Kwon, Juntae/0000-0002-5439-3239	Rivkin Center Foundation [616749]; Mary Kay Foundation [05-19]; American Cancer Society [RSG-21120-01-TBE]; National Institutes of Health [R01CA222251]	Rivkin Center Foundation; Mary Kay Foundation; American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants to C.H. from the Rivkin Center Foundation (#616749), the Mary Kay Foundation (#05-19), the American Cancer Society (RSG-21120-01-TBE, Grant DOI #: doi.org/10.53354/pc.gr.151096), and to X.L. from the National Institutes of Health (R01CA222251).	Al Habyan S, 2018, ONCOGENE, V37, P5127, DOI 10.1038/s41388-018-0317-x; ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Auersperg N, 2008, GYNECOL ONCOL, V110, P452, DOI 10.1016/j.ygyno.2008.05.031; Auersperg N, 2013, GYNECOL ONCOL, V130, P246, DOI 10.1016/j.ygyno.2013.03.021; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bobbs AS, 2015, CANCER GROWTH METAST, P29, DOI 10.4137/CGM.S21221; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Coscia F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12645; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Dobbin ZC, 2013, INT J MOL SCI, V14, P8213, DOI 10.3390/ijms14048213; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252; Han C., 2016, NAT COMMUN, V7; Hanrahan AJ, 2012, CANCER DISCOV, V2, P56, DOI 10.1158/2159-8290.CD-11-0170; Hao DP, 2017, CLIN CANCER RES, V23, P7400, DOI 10.1158/1078-0432.CCR-17-0638; Karnezis AN, 2017, NAT REV CANCER, V17, P65, DOI 10.1038/nrc.2016.113; Kim J, 2018, CANCERS, V10; Kim O, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008808; Klotz DM, 2017, ARCH GYNECOL OBSTET, V296, P1055, DOI 10.1007/s00404-017-4529-z; Kobel M, 2010, INT J GYNECOL PATHOL, V29, P203, DOI 10.1097/PGP.0b013e3181c042b6; Kroeger PT, 2017, CURR OPIN OBSTET GYN, V29, P26, DOI 10.1097/GCO.0000000000000340; Labidi-Galy SI, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00962-1; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lawrenson K, 2019, CELL REP, V29, P3726, DOI 10.1016/j.celrep.2019.10.122; Lheureux S, 2019, CA-CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559; Li Y., 2017, NAT COMMUN, V8; Lisio MA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040952; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Lo Riso P, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00786-7; Macintyre G, 2018, NAT GENET, V50, P1262, DOI 10.1038/s41588-018-0179-8; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mehra Karishma, 2011, Front Biosci (Elite Ed), V3, P625, DOI 10.2741/e275; Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396; Moss NM, 2009, CANCER RES, V69, P7121, DOI 10.1158/0008-5472.CAN-08-4151; Motohara T, 2019, ONCOGENE, V38, P2885, DOI 10.1038/s41388-018-0637-x; Nagy A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84787-5; Otsuka I, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094409; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Perets R, 2016, CANCER RES, V76, P10, DOI 10.1158/0008-5472.CAN-15-1382; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Reyes-Turcu FE, 2006, CELL, V124, P1197, DOI 10.1016/j.cell.2006.02.038; Sandercock J, 2002, BRIT J CANCER, V87, P815, DOI 10.1038/sj.bjc.6600567; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stuckelberger S, 2018, J PATHOL, V245, P129, DOI 10.1002/path.5065; Sun H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15534; Szabova L, 2012, CANCER RES, V72, P4141, DOI 10.1158/0008-5472.CAN-11-3834; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Wu R, 2016, J PATHOL, V240, P341, DOI 10.1002/path.4783; Xing DY, 2005, P NATL ACAD SCI USA, V102, P6936, DOI 10.1073/pnas.0502256102; Zhai YL, 2017, J PATHOL, V243, P16, DOI 10.1002/path.4927; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhang L, 2016, ONCOGENE, V35, P5010, DOI 10.1038/onc.2016.53; Zhang SZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02693-9; Zhang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13116-2; Zhao XS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1421	67	3	3	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1974	1985		10.1038/s41388-022-02224-x	http://dx.doi.org/10.1038/s41388-022-02224-x		FEB 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35173307	Green Published, hybrid			2022-12-28	WOS:000756457400002
J	Guerra, E; Relli, V; Ceci, M; Tripaldi, R; Simeone, P; Aloisi, AL; Pantalone, L; La Sorda, R; Lattanzio, R; Sacchetti, A; Havas, K; Guarnieri, S; Vergara, D; Fournier, I; Salzet, M; Tinari, N; Piantelli, M; Trerotola, M; Alberti, S				Guerra, Emanuela; Relli, Valeria; Ceci, Martina; Tripaldi, Romina; Simeone, Pasquale; Aloisi, Anna Laura; Pantalone, Ludovica; La Sorda, Rossana; Lattanzio, Rossano; Sacchetti, Andrea; Havas, Kristina; Guarnieri, Simone; Vergara, Daniele; Fournier, Isabelle; Salzet, Michel; Tinari, Nicola; Piantelli, Mauro; Trerotola, Marco; Alberti, Saverio			Trop-2, Na+/K+ ATPase, CD9, PKC alpha, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion	ONCOGENE			English	Article							PROTEIN-KINASE-C; E-CADHERIN; TETRASPANIN CD9; CELL-ADHESION; PH DOMAINS; TUMOR; BINDING; OUABAIN; METASTASIS; CLEAVAGE	Trop-2 is a transmembrane signal transducer that is overexpressed in most human cancers, and drives malignant progression. To gain knowledge on the higher-order molecular mechanisms that drive Trop-2 signaling, we applied next-generation sequencing, proteomics, and high-resolution microscopy to models and primary cases of human colorectal cancer (CRC). We had previously shown that Trop-2 induces a Ca2+ signal. We reveal here that Trop-2 binds the cell membrane Na+/K+-ATPase, and that clustering of Trop-2 induces an intracellular Ca2+ rise followed by membrane translocation of PKC alpha, which in turn phosphorylates the Trop-2 cytoplasmic tail. This feed-forward signaling is promoted by the binding of Trop-2 to the PKC alpha membrane-anchor CD9. CRISPR-based inactivation of CD9 in CRC cells shows that CD9 is required by Trop-2 for recruiting PKC alpha and cofilin-1 to the cell membrane. This induces malignant progression through proteolytic cleavage of E-cadherin, remodeling of the beta-actin cytoskeleton, and activation of Akt and ERK. The interaction between Trop-2 and CD9 was validated in vivo in murine models of CRC growth and invasion. Overexpression of the components of this Trop-2-driven super-complex significantly worsened disease-free and overall survival of CRC patients, supporting a pivotal relevance in CRC malignant progression. Our findings demonstrate a previously unsuspected layer of cancer growth regulation, which is dormant in normal tissues, and is activated by Trop-2 in cancer cells.	[Guerra, Emanuela; Relli, Valeria; Ceci, Martina; Tripaldi, Romina; Simeone, Pasquale; Aloisi, Anna Laura; Pantalone, Ludovica; La Sorda, Rossana; Lattanzio, Rossano; Sacchetti, Andrea; Havas, Kristina; Piantelli, Mauro; Trerotola, Marco; Alberti, Saverio] Univ G DAnnunzio, Ctr Adv Studies & Technol CAST, Lab Canc Pathol, Chieti, Italy; [Guerra, Emanuela; Tinari, Nicola; Piantelli, Mauro; Trerotola, Marco] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy; [Lattanzio, Rossano] Univ G DAnnunzio, Dept Innovat Technol Med & Dent, Chieti, Italy; [Guarnieri, Simone] Univ G DAnnunzio, Ctr Adv Studies & Technol CAST, Lab Cell Physiol, Chieti, Italy; [Guarnieri, Simone] Univ G DAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy; [Vergara, Daniele] Univ Salento, Dept Biol & Environm Sci & Technol, Lecce, Italy; [Fournier, Isabelle; Salzet, Michel] Univ Lille 1, INSERM, U1192, Lab Proteom Reponse Inflammatoire Spectrometrie M, Cite Sci, Villeneuve Dascq, France; [Alberti, Saverio] Univ Messina, Dept Biomed Sci, Unit Med Genet, Messina, Italy; [Simeone, Pasquale] Univ G DAnnunzio, Dept Med & Aging Sci, Chieti, Italy; [Simeone, Pasquale] Univ G DAnnunzio, Ctr Adv Studies & Technol CAST, Lab Cytomorphol, Chieti, Italy; [Sacchetti, Andrea] Erasmus MC, Josephine Nefkens Inst, Rotterdam, Netherlands; [Havas, Kristina] FIRC Inst Mol Oncol IFOM, Milan, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; University of Salento; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; University of Messina; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Erasmus University Rotterdam; Erasmus MC; IFOM - FIRC Institute of Molecular Oncology	Trerotola, M; Alberti, S (corresponding author), Univ G DAnnunzio, Ctr Adv Studies & Technol CAST, Lab Canc Pathol, Chieti, Italy.; Trerotola, M (corresponding author), Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy.; Alberti, S (corresponding author), Univ Messina, Dept Biomed Sci, Unit Med Genet, Messina, Italy.	marco.trerotola@unich.it; salberti@unime.it	Vergara, Daniele/K-3831-2014; Alberti, Saverio/M-4511-2014; Salzet, Michel/A-7675-2011; Simeone, Pasquale/K-7549-2016	Vergara, Daniele/0000-0002-2396-7674; Alberti, Saverio/0000-0002-4647-6042; Salzet, Michel/0000-0003-4318-0817; Simeone, Pasquale/0000-0003-4430-480X; Ceci, Martina/0000-0002-4550-8823; Guerra, Emanuela/0000-0002-7091-8621	Italian Ministry of Health [RicOncol RF-EMR-2006-361866]; Italian Ministry of Development-FESR; Region Abruzzo (POR FESR 2007-2013: Activity 1.1.1 line B) [C78C14000100005]; Oncoxx Biotech, Italy; Marie Curie Transfer of Knowledge Fellowship-EC VI Framework Program [014541]; Programma Per Giovani Ricercatori "Rita Levi Montalcini", Italian Ministry of University and Research [PGR12I7N1Z];  [SSI000651];  [1083/2006];  [1828/2006]	Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of Development-FESR; Region Abruzzo (POR FESR 2007-2013: Activity 1.1.1 line B); Oncoxx Biotech, Italy; Marie Curie Transfer of Knowledge Fellowship-EC VI Framework Program; Programma Per Giovani Ricercatori "Rita Levi Montalcini", Italian Ministry of University and Research; ; ; 	Italian Ministry of Health (RicOncol RF-EMR-2006-361866), Italian Ministry of Development-FESR 2016-2018. SSI000651, art. 69 Reg. (CE) n. 1083/2006 and Reg. (CE) n. 1828/2006, Region Abruzzo (POR FESR 2007-2013: Activity 1.1.1 line B) C78C14000100005, Oncoxx Biotech, Italy and Marie Curie Transfer of Knowledge Fellowship-EC VI Framework Program (Contract 014541) to SA. Programma Per Giovani Ricercatori "Rita Levi Montalcini", Italian Ministry of University and Research (Grant PGR12I7N1Z) to MT. EG is an inventor in patents WO201687651 and WO201784763, and a partner in Mediterranea Theranostic Srl. MT is an inventor in patent WO201784763. SA is an inventor in patents WO201089782, WO201687651, and WO201784763, and is founder and CEO of Oncoxx Biotech Srl and Mediterranea Theranostic Srl. VR was an employee of Oncoxx Biotech Srl. PS is an inventor in a patent application under consideration (EP3546948).	Agesen TH, 2012, GUT, V61, P1560, DOI 10.1136/gutjnl-2011-301179; Alberti S, 1999, PROTEINS, V35, P360; Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; ALBERTI S, 1992, HYBRIDOMA, V11, P539, DOI 10.1089/hyb.1992.11.539; Ambrogi F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096993; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Bahmad HF, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00347; Bardia A, 2019, NEW ENGL J MED, V380, P741, DOI 10.1056/NEJMoa1814213; BASU A, 1995, INT J CANCER, V62, P472, DOI 10.1002/ijc.2910620419; Cabantous S, 2013, SCI REP-UK, V3, DOI 10.1038/srep02854; Chen DD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-716; Choi CK, 2008, NAT CELL BIOL, V10, P1039, DOI 10.1038/ncb1763; Ciccarelli FD, 2000, HUM MOL GENET, V9, P1001, DOI 10.1093/hmg/9.6.1001; Di Baldassarre A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30537-z; El Sewedy T, 1998, INT J CANCER, V75, P324, DOI 10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.3.CO;2-5; Farah CA, 2012, ADV EXP MED BIOL, V740, P663, DOI 10.1007/978-94-007-2888-2_29; FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520; Freeley M, 2011, CELL SIGNAL, V23, P753, DOI 10.1016/j.cellsig.2010.10.013; Guerra E, 2013, ONCOGENE, V32, P1594, DOI 10.1038/onc.2012.151; Guerra E, 2008, CANCER RES, V68, P8113, DOI 10.1158/0008-5472.CAN-07-6135; Guerra E, 2021, NEOPLASIA, V23, P898, DOI 10.1016/j.neo.2021.07.002; Guerra E, 2016, CLIN CANCER RES, V22, P4197, DOI 10.1158/1078-0432.CCR-15-1701; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Hoshino A, 2020, CELL, V182, P1044, DOI 10.1016/j.cell.2020.07.009; Jiang XP, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2019.118574; Krishn SR, 2019, MATRIX BIOL, V77, P41, DOI 10.1016/j.matbio.2018.08.004; Larre I, 2010, P NATL ACAD SCI USA, V107, P11387, DOI 10.1073/pnas.1000500107; Liang M, 2007, J BIOL CHEM, V282, P10585, DOI 10.1074/jbc.M609181200; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Matchkov VV, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00179; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; Mori Y, 2019, J BIOL CHEM, V294, P11513, DOI 10.1074/jbc.RA119.008084; MORIKAWA K, 1988, CANCER RES, V48, P6863; Murayama Y, 2008, J CELL PHYSIOL, V216, P135, DOI 10.1002/jcp.21384; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Ninsontia C, 2014, ANTICANCER RES, V34, P5495; Powner D, 2011, BIOCHEM SOC T, V39, P563, DOI 10.1042/BST0390563; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Ripani E, 1998, INT J CANCER, V76, P671; Saczko-Brack D, 2016, P NATL ACAD SCI USA, V113, pE8387, DOI 10.1073/pnas.1612719113; Sakuma M, 2012, MOL BIOL CELL, V23, P3707, DOI 10.1091/mbc.E12-01-0053; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041; Shen JJ, 2020, ACTA PHARMACOL SIN, V41, P110, DOI 10.1038/s41401-019-0290-0; Spratley SJ, 2011, J BIOL CHEM, V286, P34254, DOI 10.1074/jbc.M111.259424; Stoyanova T, 2012, GENE DEV, V26, P2271, DOI 10.1101/gad.196451.112; Sveen A, 2011, GENOME MED, V3, DOI 10.1186/gm248; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; Thomas A, 2019, CLIN CANCER RES, V25, P6581, DOI 10.1158/1078-0432.CCR-19-1089; Tian J, 2006, MOL BIOL CELL, V17, P317, DOI 10.1091/mbc.E05-08-0735; Tian J, 2008, PHYSIOLOGY, V23, P205, DOI 10.1152/physiol.00008.2008; Tian J, 2009, J BIOL CHEM, V284, P14921, DOI 10.1074/jbc.M808355200; Trerotola M, 2013, ONCOGENE, V32, P222, DOI 10.1038/onc.2012.36; Trerotola M, 2021, NEOPLASIA, V23, P415, DOI 10.1016/j.neo.2021.03.006; Trerotola M, 2015, ONCOTARGET, V6, P14318, DOI 10.18632/oncotarget.3960; Trerotola M, 2013, CANCER RES, V73, P3155, DOI 10.1158/0008-5472.CAN-12-3266; Trerotola M, 2012, J CELL PHYSIOL, V227, P3670, DOI 10.1002/jcp.24074; Van Rheenen J, 2007, J CELL BIOL, V179, P1247, DOI 10.1083/jcb.200706206; Wang HX, 2011, J CELL SCI, V124, P2702, DOI 10.1242/jcs.085449; Wanger TM, 2015, CELL SIGNAL, V27, P1325, DOI 10.1016/j.cellsig.2015.03.017; Watanabe T, 2007, MOL BIOL CELL, V18, P605, DOI 10.1091/mbc.E06-07-0590; Zanna P, 2007, CANCER-AM CANCER SOC, V110, P452, DOI 10.1002/cncr.22785; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	66	3	3	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1795	1808		10.1038/s41388-022-02220-1	http://dx.doi.org/10.1038/s41388-022-02220-1		FEB 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35132180	Green Published			2022-12-28	WOS:000752288100002
J	Biondini, M; Kiepas, A; El-Houjeiri, L; Nis, MGA; Hsu, BE; Fortier, AM; Morin, G; Martina, JA; Sirois, I; Aguilar-Mahecha, A; Gruosso, T; McGuirk, S; Rose, AAN; Tokat, UM; Johnson, RM; Sahin, O; Bareke, E; St-Pierre, J; Park, M; Basik, M; Majewski, J; Puertollano, R; Pause, A; Huang, SD; Keler, T; Siegel, PM				Biondini, Marco; Kiepas, Alex; El-Houjeiri, Leeanna; Nis, Matthew G. An; Hsu, Brian E.; Fortier, Anne-Marie; Morin, Genevieve; Martina, Jose A.; Sirois, Isabelle; Aguilar-Mahecha, Adriana; Gruosso, Tina; McGuirk, Shawn; Rose, April A. N.; Tokat, Unal M.; Johnson, Radia M.; Sahin, Ozgur; Bareke, Eric; St-Pierre, Julie; Park, Morag; Basik, Mark; Majewski, Jacek; Puertollano, Rosa; Pause, Arnim; Huang, Sidong; Keler, Tibor; Siegel, Peter M.			HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin	ONCOGENE			English	Article							ANTIBODY-DRUG CONJUGATE; GLYCOPROTEIN NONMETASTATIC B; PHASE-II; TFEB; AUTOPHAGY; MELANOMA; PATHWAY; FLCN; RECRUITMENT; MECHANISMS	Transmembrane glycoprotein NMB (GPNMB) is a prognostic marker of poor outcome in patients with triple-negative breast cancer (TNBC). Glembatumumab Vedotin, an antibody drug conjugate targeting GPNMB, exhibits variable efficacy against GPNMB-positive metastatic TNBC as a single agent. We show that GPNMB levels increase in response to standard-of-care and experimental therapies for multiple breast cancer subtypes. While these therapeutic stressors induce GPNMB expression through differential engagement of the MiTF family of transcription factors, not all are capable of increasing GPNMB cell-surface localization required for Glembatumumab Vedotin inhibition. Using a FACS-based genetic screen, we discovered that suppression of heat shock protein 90 (HSP90) concomitantly increases GPNMB expression and cell-surface localization. Mechanistically, HSP90 inhibition resulted in lysosomal dispersion towards the cell periphery and fusion with the plasma membrane, which delivers GPNMB to the cell surface. Finally, treatment with HSP90 inhibitors sensitizes breast cancers to Glembatumumab Vedotin in vivo, suggesting that combination of HSP90 inhibitors and Glembatumumab Vedotin may be a viable treatment strategy for patients with metastatic TNBC.	[Biondini, Marco; Kiepas, Alex; El-Houjeiri, Leeanna; Nis, Matthew G. An; Hsu, Brian E.; Fortier, Anne-Marie; Morin, Genevieve; Gruosso, Tina; McGuirk, Shawn; Park, Morag; Pause, Arnim; Huang, Sidong; Siegel, Peter M.] McGill Univ, Goodman Canc Res Inst, Montreal, PQ, Canada; [Biondini, Marco; Nis, Matthew G. An; Hsu, Brian E.; Park, Morag; Pause, Arnim; Siegel, Peter M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Kiepas, Alex; McGuirk, Shawn] McGill Univ, Dept Physiol, Montreal, PQ, Canada; [El-Houjeiri, Leeanna; Fortier, Anne-Marie; Morin, Genevieve; Gruosso, Tina; Park, Morag; Huang, Sidong; Siegel, Peter M.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Martina, Jose A.; Puertollano, Rosa] NHLBI, Cell & Dev Biol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA; [Sirois, Isabelle; Aguilar-Mahecha, Adriana; Basik, Mark] Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Lady Davis Inst Med Res, Montreal, PQ, Canada; [Rose, April A. N.; Basik, Mark] McGill Univ, Dept Oncol & Surg, Montreal, PQ, Canada; [Tokat, Unal M.] Bilkent Univ, Dept Mol Biol & Genet, Ankara, Turkey; [Johnson, Radia M.] Genentech Inc, 1 DNA Way South, San Francisco, CA USA; [Sahin, Ozgur] Univ South Carolina, Dept Drug Discovery & Biomed Sci, Columbia, SC 29208 USA; [Bareke, Eric; Majewski, Jacek] McGill Univ, Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Bareke, Eric; Majewski, Jacek] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [St-Pierre, Julie] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [St-Pierre, Julie] Univ Ottawa, Ottawa Inst Syst Biol, Ottawa, ON, Canada; [Keler, Tibor] Celldex Therapeut, Hampton, NJ USA	McGill University; McGill University; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Lady Davis Institute; McGill University; McGill University; Ihsan Dogramaci Bilkent University; Roche Holding; Genentech; University of South Carolina System; University of South Carolina Columbia; McGill University; McGill University; University of Ottawa; University of Ottawa	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Res Inst, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.	peter.siegel@mcgill.ca	Johnson, Radia/GYV-4663-2022; St-Pierre, Julie/AGB-3651-2022; Aguilar, Adriana/GRF-2369-2022; Kiepas, Alex/GVS-8491-2022; Tokat, Ünal Metin/ABA-6061-2020	Johnson, Radia/0000-0002-9755-9307; St-Pierre, Julie/0000-0002-2815-7099; Tokat, Ünal Metin/0000-0003-0026-368X; Kiepas, Alexander/0000-0001-8169-3897	Fonds de recherche du Quebec-Sante (FRQS) post-doctoral fellowship; Canadian Institutes of Health Research [PJT-153327]	Fonds de recherche du Quebec-Sante (FRQS) post-doctoral fellowship; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We acknowledge technical assistance from the McGill GCRC Histology core facility for routine histological services. We acknowledge McGill Life Science Complex Advanced BioImaging Facility (ABIF) for technical assistance in acquisition/analysis of images. We acknowledge McGill Platform for Cellular Perturbation (MPCP) for providing the shRNAs libraries and technical assistance with screnning process and analysis. We acknowledge McGill Life Science Complex Cell Vision Core for technical assistance in acquisition/analysis of flow cytometry data. We acknowledge Genome Quebec and McGill University for support of the Q-CROC-03 trial. We acknowledge Dr. Alana Welm for providing us with HCI-010 PDX tumor model. We thank members of the Siegel laboratory, all collaborators and Dr. Ursini-Siegel for thoughtful discussions and critical reading of the paper. MB was the recipient of a Fonds de recherche du Quebec-Sante (FRQS) post-doctoral fellowship. PMS is a William Dawson Scholar of McGill University. This work was supported by an operating grant from the Canadian Institutes of Health Research to PMS (PJT-153327).	Agarraberes FA, 2001, J CELL SCI, V114, P2491; Bandyopadhyay U, 2008, MOL CELL BIOL, V28, P5747, DOI 10.1128/MCB.02070-07; Bekki H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1830-8; Bendell J, 2014, J CLIN ONCOL, V32, P3619, DOI 10.1200/JCO.2013.52.5683; Bergin Alice R T, 2019, F1000Res, V8, DOI 10.12688/f1000research.18888.1; Boshuizen J, 2020, MOL CELL, V78, P1002, DOI 10.1016/j.molcel.2020.05.031; Butler LM, 2015, MOL CANCER RES, V13, P1445, DOI 10.1158/1541-7786.MCR-15-0234; Chen C, 2018, CANCER RES, V78, P6424, DOI 10.1158/0008-5472.CAN-18-0599; Cheng Y, 2017, MOLECULES, V22, DOI 10.3390/molecules22101551; Dai CK, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0525; Damaskos C, 2019, ANTICANCER RES, V39, P5285, DOI 10.21873/anticanres.13722; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; El-Houjeiri L, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI144871; Giulino-Roth L, 2017, MOL CANCER THER, V16, P1779, DOI 10.1158/1535-7163.MCT-16-0848; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hoffmann RM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1395127; Hong SB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015793; Jansson KH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35417-0; Jing JP, 2012, MOL CANCER THER, V11, P720, DOI 10.1158/1535-7163.MCT-11-0505; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Jongsma MLM, 2016, CELL, V166, P152, DOI 10.1016/j.cell.2016.05.078; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Kong T, 2020, CANCER RES, V80, P444, DOI 10.1158/0008-5472.CAN-19-1108; Kopp LM, 2019, EUR J CANCER, V121, P177, DOI 10.1016/j.ejca.2019.08.015; Lauwers E, 2018, MOL CELL, V71, P689, DOI 10.1016/j.molcel.2018.07.016; Le Borgne R, 2001, J CELL SCI, V114, P2831; Li B, 2010, FASEB J, V24, P4767, DOI 10.1096/fj.10-154757; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Liu H, 2018, CANCER DISCOV, V8, P354, DOI 10.1158/2159-8290.CD-17-0679; Martina JA, 2017, TRANSCR-AUSTIN, V8, P48, DOI 10.1080/21541264.2016.1264353; Martina JA, 2016, EMBO J, V35, P479, DOI 10.15252/embj.201593428; Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754; Martina JA, 2013, J CELL BIOL, V200, P475, DOI 10.1083/jcb.201209135; Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653; McGuirk Shawn, 2021, Elife, V10, DOI 10.7554/eLife.65150; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Noda Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11828-3; Nytko KJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69619-2; Ott PA, 2019, CANCER-AM CANCER SOC, V125, P1113, DOI 10.1002/cncr.31892; Park S, 2019, BIOMOL THER, V27, P423, DOI 10.4062/biomolther.2019.051; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Petit CS, 2013, J CELL BIOL, V202, P1107, DOI 10.1083/jcb.201307084; Pick E, 2007, CANCER RES, V67, P2932, DOI 10.1158/0008-5472.CAN-06-4511; Pogenberg V, 2012, GENE DEV, V26, P2647, DOI 10.1101/gad.198192.112; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Pu J, 2016, J CELL SCI, V129, P4329, DOI 10.1242/jcs.196287; Puertollano R, 2018, EMBO J, V37, DOI 10.15252/embj.201798804; Qian XZ, 2008, MOL ONCOL, V2, P81, DOI 10.1016/j.molonc.2008.02.002; Raben N, 2016, ANNU REV CELL DEV BI, V32, P255, DOI 10.1146/annurev-cellbio-111315-125407; Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790; Rose AAN, 2017, PHARMACOL THERAPEUT, V179, P127, DOI 10.1016/j.pharmthera.2017.05.010; Rose AAN, 2016, CLIN CANCER RES, V22, P6088, DOI 10.1158/1078-0432.CCR-16-1192; Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078-0432.CCR-09-1611; Schmidt LS, 2018, GENE, V640, P28, DOI 10.1016/j.gene.2017.09.044; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Sirois I, 2019, MOL CANCER RES, V17, P2492, DOI 10.1158/1541-7786.MCR-19-0264; Slade L, 2017, MOL CANCER RES, V15, P1637, DOI 10.1158/1541-7786.MCR-17-0320; Starling GP, 2016, EMBO REP, V17, P823, DOI 10.15252/embr.201541382; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Tanaka M, 2017, CANCER RES, V77, P897, DOI 10.1158/0008-5472.CAN-16-2486; Tse KF, 2006, CLIN CANCER RES, V12, P1373, DOI 10.1158/1078-0432.CCR-05-2018; Vahdat LT, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-P6-20-01; van der Lienden MJC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010066; Vega-Rubin-de-Celis S, 2017, AUTOPHAGY, V13, P464, DOI 10.1080/15548627.2016.1271514; Wada S, 2016, GENE DEV, V30, P2551, DOI 10.1101/gad.287953.116; Wang H, 2016, MOL CLIN ONCOL, V5, P326, DOI 10.3892/mco.2016.963; Wang Y, 2015, CHEM COMMUN, V51, P1410, DOI 10.1039/c4cc07284g; Woodford MR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12037; Yang ZJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09181-2; Yardley DA, 2015, J CLIN ONCOL, V33, P1609, DOI 10.1200/JCO.2014.56.2959; Zhitomirsky B, 2015, ONCOTARGET, V6, P1143, DOI 10.18632/oncotarget.2732	76	2	2	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1701	1717		10.1038/s41388-022-02206-z	http://dx.doi.org/10.1038/s41388-022-02206-z		FEB 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35110681				2022-12-28	WOS:000749991500001
J	Fidyt, K; Pastorczak, A; Cyran, J; Crump, NT; Goral, A; Madzio, J; Muchowicz, A; Poprzeczko, M; Domka, K; Komorowski, L; Winiarska, M; Harman, JR; Siudakowska, K; Graczyk-Jarzynka, A; Patkowska, E; Lech-Maranda, E; Mlynarski, W; Golab, J; Milne, TA; Firczuk, M				Fidyt, Klaudyna; Pastorczak, Agata; Cyran, Julia; Crump, Nicholas T.; Goral, Agnieszka; Madzio, Joanna; Muchowicz, Angelika; Poprzeczko, Martyna; Domka, Krzysztof; Komorowski, Lukasz; Winiarska, Magdalena; Harman, Joe R.; Siudakowska, Karolina; Graczyk-Jarzynka, Agnieszka; Patkowska, Elzbieta; Lech-Maranda, Ewa; Mlynarski, Wojciech; Golab, Jakub; Milne, Thomas A.; Firczuk, Malgorzata			Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax	ONCOGENE			English	Article							H3K79 METHYLATION; FUSION PROTEINS; BCL-2; INHIBITOR; AURANOFIN; APOPTOSIS; MCL-1; THIOREDOXIN; UBIQUITINATION; TRANSCRIPTION	The prognosis for B-cell precursor acute lymphoblastic leukemia patients with Mixed-Lineage Leukemia (MLL) gene rearrangements (MLLr BCP-ALL) is still extremely poor. Inhibition of anti-apoptotic protein BCL-2 with venetoclax emerged as a promising strategy for this subtype of BCP-ALL, however, lack of sufficient responses in preclinical models and the possibility of developing resistance exclude using venetoclax as monotherapy. Herein, we aimed to uncover potential mechanisms responsible for limited venetoclax activity in MLLr BCP-ALL and to identify drugs that could be used in combination therapy. Using RNA-seq, we observed that long-term exposure to venetoclax in vivo in a patient-derived xenograft model leads to downregulation of several tumor protein 53 (TP53)-related genes. Interestingly, auranofin, a thioredoxin reductase inhibitor, sensitized MLLr BCP-ALL to venetoclax in various in vitro and in vivo models, independently of the p53 pathway functionality. Synergistic activity of these drugs resulted from auranofin-mediated upregulation of NOXA pro-apoptotic protein and potent induction of apoptotic cell death. More specifically, we observed that auranofin orchestrates upregulation of the NOXA-encoding gene Phorbol-12-Myristate-13-Acetate-Induced Protein 1 (PMAIP1) associated with chromatin remodeling and increased transcriptional accessibility. Altogether, these results present an efficacious drug combination that could be considered for the treatment of MLLr BCP-ALL patients, including those with TP53 mutations.	[Fidyt, Klaudyna; Cyran, Julia; Goral, Agnieszka; Muchowicz, Angelika; Poprzeczko, Martyna; Domka, Krzysztof; Komorowski, Lukasz; Winiarska, Magdalena; Siudakowska, Karolina; Graczyk-Jarzynka, Agnieszka; Golab, Jakub; Firczuk, Malgorzata] Med Univ Warsaw, Dept Immunol, Warsaw, Poland; [Fidyt, Klaudyna; Komorowski, Lukasz] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland; [Pastorczak, Agata; Madzio, Joanna; Mlynarski, Wojciech] Med Univ Lodz, Dept Pediat Oncol & Hematol, Lodz, Poland; [Crump, Nicholas T.; Harman, Joe R.; Milne, Thomas A.] Univ Oxford, Med Res Council Mol Haematol Unit, Oxford, England; [Poprzeczko, Martyna; Domka, Krzysztof; Winiarska, Magdalena; Graczyk-Jarzynka, Agnieszka] Polish Acad Sci, Mossakowski Med Res Inst, Warsaw, Poland; [Patkowska, Elzbieta; Lech-Maranda, Ewa] Inst Hematol & Transfus Med, Dept Hematol, Warsaw, Poland	Medical University of Warsaw; Medical University of Warsaw; Medical University Lodz; University of Oxford; Polish Academy of Sciences; Mossakowski Medical Research Institute of the Polish Academy of Sciences	Firczuk, M (corresponding author), Med Univ Warsaw, Dept Immunol, Warsaw, Poland.	mfirczuk@wum.edu.pl	Madzio, Joanna/ABC-5122-2020; Patkowska, Elżbieta/AAD-3938-2020; Muchowicz, Angelika/J-7494-2012; Golab, Jakub/K-6974-2013	Madzio, Joanna/0000-0003-0766-0194; Patkowska, Elżbieta/0000-0001-8691-4310; Goral, Agnieszka/0000-0002-7324-9718; Pastorczak, Agata/0000-0003-3089-6947; Fidyt, Klaudyna/0000-0003-0568-4950; Crump, Nicholas/0000-0001-9610-6763; Janowska (Poprzeczko), Martyna/0000-0002-8703-5614; Komorowski, Lukasz Wit/0000-0002-7646-1968; Winiarska, Magdalena/0000-0001-5605-3329; Muchowicz, Angelika/0000-0003-4707-1722; Mlynarski, Wojciech/0000-0003-2714-5851; Golab, Jakub/0000-0002-2830-5100	National Science Centre (Poland) [2015/18/E/NZ5/00723, 2018/31/N/NZ5/01438, 2019/32/T/NZ5/00241]; Ministry of Education and Science (Poland) [013/RID/2018/19]; Medical Research Council (MRC, UK) Molecular Haematology Unit (MHU) grant [MC_UU_00016/6]; Engineering and Physical Sciences Research Council (EPSRC) [2119788, EP/R513295/1]	National Science Centre (Poland)(National Science Centre, Poland); Ministry of Education and Science (Poland)(Ministry of Science and Higher Education, Poland); Medical Research Council (MRC, UK) Molecular Haematology Unit (MHU) grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council (EPSRC)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by the National Science Centre (Poland) grants: 2015/18/E/NZ5/00723 (MF), 2018/31/N/NZ5/01438 (KF), 2019/32/T/NZ5/00241 (KF), and by the Ministry of Education and Science (Poland) within "Regional Initiative of Excellence" program 013/RID/2018/19 (JG), project budget 12 000 000 PLN. TAM, NTC, and JRH are supported by Medical Research Council (MRC, UK) Molecular Haematology Unit (MHU) grant MC_UU_00016/6 and Engineering and Physical Sciences Research Council (EPSRC) Doctoral Training Program grant project reference 2119788 and EP/R513295/1. We gratefully acknowledge Prof Meinrad Busslinger who kindly provided GFP+ OP9 cells for the co-culture studies. We would also like to acknowledge methodological support in co-culture studies and PDXs generation provided by the researchers from Newcastle University, Prof Olaf Heidenreich (currently Princess Maxima Center, Utrecht, the Netherlands), Dr Deepali Pal, and Dr Helen Blair. We thank for the technical support provided by Elzbieta Gutkowska, Ewa Chmiel, Ewa Pieta, Magdalena Dlugolecka from the Department of Immunology at Medical University of Warsaw. We would also like to thank all patients, their parents and staff from Central Clinical Hospital of the Medical University of Lodz, and from the Institute of Hematology and Transfusion Medicine in Warsaw. We also acknowledge Dr Maksymilian Bielecki from SWPS University of Social Sciences and Humanities for advising in statistical analyses.	Agirre X, 2003, MOL CARCINOGEN, V38, P201, DOI 10.1002/mc.10159; Alford SE, 2015, CANCER RES, V75, P1366, DOI 10.1158/0008-5472.CAN-14-1849; Anderson MA, 2016, BLOOD, V127, P3215, DOI 10.1182/blood-2016-01-688796; Benito JM, 2015, CELL REP, V13, P2715, DOI 10.1016/j.celrep.2015.12.003; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bhatt S, 2020, CANCER CELL, V38, P872, DOI 10.1016/j.ccell.2020.10.010; Biswas D, 2011, P NATL ACAD SCI USA, V108, P15751, DOI 10.1073/pnas.1111498108; Bohler S, 2021, HAEMATOLOGICA, V106, P3136, DOI 10.3324/haematol.2020.252130; Chen HC, 2015, NAT CELL BIOL, V17, P1270, DOI 10.1038/ncb3236; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cox AG, 2008, BIOCHEM PHARMACOL, V76, P1097, DOI 10.1016/j.bcp.2008.08.021; Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104; Deregowska A, 2020, GENES-BASEL, V11, DOI 10.3390/genes11101145; Diaz-Flores E, 2019, CANCER RES, V79, P2339, DOI 10.1158/0008-5472.CAN-18-0236; Fidyt K, 2019, MOL ONCOL, V13, P1180, DOI 10.1002/1878-0261.12476; Fischer U, 2015, NAT GENET, V47, P1020, DOI 10.1038/ng.3362; Frismantas V, 2017, BLOOD, V129, pE26, DOI 10.1182/blood-2016-09-738070; Gibson CJ, 2015, CLIN CANCER RES, V21, P5021, DOI 10.1158/1078-0432.CCR-15-0364; Gomez-Bougie P, 2011, BIOCHEM BIOPH RES CO, V413, P460, DOI 10.1016/j.bbrc.2011.08.118; Herling CD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03170-7; Jain P, 2020, AM J HEMATOL, V95, P623, DOI 10.1002/ajh.25796; Jin S, 2020, CLIN CANCER RES, V26, P3371, DOI 10.1158/1078-0432.CCR-19-1900; Khaw SL, 2016, BLOOD, V128, P1382, DOI 10.1182/blood-2016-03-707414; Leonard JT, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1583.1583; Li BS, 2020, BLOOD, V135, P41, DOI 10.1182/blood.2019002220; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Liu NN, 2014, ONCOTARGET, V5, P5453, DOI 10.18632/oncotarget.2113; Lukashchuk N, 2007, MOL CELL BIOL, V27, P8284, DOI 10.1128/MCB.00050-07; Maji S, 2018, ADV CANCER RES, V137, P37, DOI 10.1016/bs.acr.2017.11.001; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Milne TA, 2005, CANCER RES, V65, P11367, DOI 10.1158/0008-5472.CAN-05-1041; MIYASHITA T, 1992, CANCER RES, V52, P5407; Moujalled DM, 2020, BLOOD ADV, V4, P2762, DOI 10.1182/bloodadvances.2019001416; Moujalled DM, 2019, LEUKEMIA, V33, P905, DOI 10.1038/s41375-018-0261-3; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Nechiporuk T, 2019, CANCER DISCOV, V9, P910, DOI 10.1158/2159-8290.CD-19-0125; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Pal D, 2016, LEUKEMIA, V30, P1691, DOI 10.1038/leu.2016.79; Pang XM, 2014, J BIOL CHEM, V289, P17802, DOI 10.1074/jbc.M114.548172; Pollyea DA, 2021, AM J HEMATOL, V96, P208, DOI 10.1002/ajh.26039; Radenkovic F, 2017, BIOCHEM PHARMACOL, V146, P42, DOI 10.1016/j.bcp.2017.09.009; Ramsey HE, 2018, CANCER DISCOV, V8, P1566, DOI 10.1158/2159-8290.CD-18-0140; Richmond J, 2015, CLIN CANCER RES, V21, P1395, DOI 10.1158/1078-0432.CCR-14-2300; Rigobello MP, 2005, FREE RADICAL RES, V39, P687, DOI 10.1080/10715760500135391; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Scherr M, 2019, LEUKEMIA, V33, P1313, DOI 10.1038/s41375-018-0315-6; Seyfried F, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1801-0; Seyfried F, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1081.1081; Stengel A, 2014, BLOOD, V124, P251, DOI 10.1182/blood-2014-02-558833; Thijssen R, 2021, BLOOD, V137, P2721, DOI 10.1182/blood.2020010167; Trino S, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00491; Wang J, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0259-8; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yokoyama A, 2010, CANCER CELL, V17, P198, DOI 10.1016/j.ccr.2009.12.040; Zeisig DT, 2005, ONCOGENE, V24, P5525, DOI 10.1038/sj.onc.1208699	58	2	2	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1600	1609		10.1038/s41388-022-02196-y	http://dx.doi.org/10.1038/s41388-022-02196-y		JAN 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35091682	hybrid, Green Published			2022-12-28	WOS:000749073300001
J	Steiner, S; Seleznik, GM; Reding, T; Stopic, M; Lenggenhager, D; ten Buren, E; Eshmuminov, D; Endhardt, K; Hagedorn, C; Heidenblut, AM; Bratus-Neuenschwander, A; Grossmann, J; Trachsel, C; Jabbar, KS; Hahn, SA; vom Berg, J; Graf, R; Gupta, A				Steiner, Sabrina; Seleznik, Gitta M.; Reding, Theresia; Stopic, Matea; Lenggenhager, Daniela; ten Buren, Emiel; Eshmuminov, Dilmurodjon; Endhardt, Katharina; Hagedorn, Catherine; Heidenblut, Anna M.; Bratus-Neuenschwander, Anna; Grossmann, Jonas; Trachsel, Christian; Jabbar, Karolina S.; Hahn, Stephan A.; vom Berg, Johannes; Graf, Rolf; Gupta, Anurag			De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer	ONCOGENE			English	Article							1 INDUCES SENESCENCE; TUMOR-SUPPRESSOR; BIOLOGY; INHIBITION; ACTIVATION; HEDGEHOG; MARKERS	Molecular events occurring in stepwise progression from pre-malignant lesions (pancreatic intraepithelial neoplasia; PanIN) to the development of pancreatic ductal adenocarcinoma (PDAC) are poorly understood. Thus, characterization of early PanIN lesions may reveal markers that can help in diagnosing PDAC at an early stage and allow understanding the pathology of the disease. We performed the molecular and histological assessment of patient-derived PanINs, tumor tissues and pancreas from mouse models with PDAC (KC mice that harbor K-RAS mutation in pancreatic tissue), where we noted marked upregulation of gastrokine (GKN) proteins. To further understand the role of gastrokine proteins in PDAC development, GKN-deficient KC mice were developed by intercrossing gastrokine-deficient mice with KC mice. Panc-02 (pancreatic cancer cells of mouse origin) were genetically modified to express GKN1 for further in vitro and in vivo analysis. Our results show that gastrokine proteins were absent in healthy pancreas and invasive cancer, while its expression was prominent in low-grade PanINs. We could detect these proteins in pancreatic juice and serum of KC mice. Furthermore, accelerated PanIN and tumor development were noted in gastrokine deficient KC mice. Loss of gastrokine 1 protein delayed apoptosis during carcinogenesis leading to the development of desmoplastic stroma while loss of gastrokine 2 increased the proliferation rate in precursor lesions. In summary, we identified gastrokine proteins in early pancreatic precursor lesions, where gastrokine proteins delay pancreatic carcinogenesis.	[Steiner, Sabrina; Seleznik, Gitta M.; Reding, Theresia; Stopic, Matea; Eshmuminov, Dilmurodjon; Hagedorn, Catherine; Graf, Rolf; Gupta, Anurag] Univ Hosp Zurich, Visceral & Transplantat Surg, CH-8091 Zurich, Switzerland; [Lenggenhager, Daniela; Endhardt, Katharina] Univ Hosp Zurich, Dept Pathol & Mol Pathol, CH-8091 Zurich, Switzerland; [Lenggenhager, Daniela; Endhardt, Katharina] Univ Zurich, CH-8091 Zurich, Switzerland; [ten Buren, Emiel; vom Berg, Johannes] Univ Zurich, Inst Lab Anim Sci, CH-8952 Schlieren, Switzerland; [Heidenblut, Anna M.; Hahn, Stephan A.] Ruhr Univ Bochum, Fac Med, Dept Mol GI Oncol, D-44780 Bochum, Germany; [Bratus-Neuenschwander, Anna; Grossmann, Jonas; Trachsel, Christian] Univ Zurich, ETH, Funct Genom Ctr Zurich, CH-8093 Zurich, Switzerland; [Jabbar, Karolina S.] Univ Gothenburg, Dept Med Biochem, S-40530 Gothenburg, Sweden	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; Ruhr University Bochum; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Gothenburg	Graf, R; Gupta, A (corresponding author), Univ Hosp Zurich, Visceral & Transplantat Surg, CH-8091 Zurich, Switzerland.	Rolf.graf@usz.ch; Anurag.Gupta@usz.ch	Hahn, Stephan/E-3880-2010	Hahn, Stephan/0000-0003-0855-9741; Gupta, Anurag/0000-0001-6850-3489; vom Berg, Johannes/0000-0002-4086-1564; Lenggenhager, Daniela/0000-0002-5382-9854; Steiner, Sabrina/0000-0002-1562-2430	Vontobel Stiftung Zurich; Edoardo R., Giovanni, Giuseppe und Chiarina Sassella-Stiftung; Swiss National Science Foundation (SNF) [310030_166645]	Vontobel Stiftung Zurich; Edoardo R., Giovanni, Giuseppe und Chiarina Sassella-Stiftung; Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF))	For the excellent support with microarray and proteomics analysis, we would like to acknowledge Lennart Opitz and Nathalie Selevsek from the Functional Genomics Centre Zurich (FGCZ). For the technical support with histology samples, we would like to thank Dr. Ursula Suss, Pia Fuchs, Andrea Garcete, and Ines Kleiber. For the outstanding service, we would like to acknowledge the animal care taker team of the University Hospital Zurich (BZL) and University of Zurich (LASC). We also thank Ms. Noelle Bayyoud for proofreading/English editing of the manuscript. This work was supported by grants from Vontobel Stiftung Zurich (R.G.) and Edoardo R., Giovanni, Giuseppe und Chiarina Sassella-Stiftung (A.G.) and by a grant by the Swiss National Science Foundation (SNF GRANT number: 310030_166645).	Algul H, 2007, INT J CANCER, V121, P1410, DOI 10.1002/ijc.22779; Bernadotte A, 2016, AGING-US, V8, P3, DOI 10.18632/aging.100871; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cicenas J, 2017, CANCERS, V9, DOI 10.3390/cancers9050042; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collisson EA, 2019, NAT REV GASTRO HEPAT, V16, P207, DOI 10.1038/s41575-019-0109-y; Distler M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/474905; Fahlbusch FB, 2013, PLACENTA, V34, P1027, DOI 10.1016/j.placenta.2013.08.005; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hutchings D, 2018, AM J SURG PATHOL, V42, P1556, DOI 10.1097/PAS.0000000000001148; Jabbar KS, 2018, J CLIN ONCOL, V36, P367, DOI 10.1200/JCO.2017.73.7288; Lee JJ, 2014, P NATL ACAD SCI USA, V111, pE3091, DOI 10.1073/pnas.1411679111; MATSUZAWA K, 1992, HUM PATHOL, V23, P925, DOI 10.1016/0046-8177(92)90407-T; Menheniott TR, 2016, J CLIN INVEST, V126, P1383, DOI 10.1172/JCI82655; Menheniott TR, 2013, AM J PHYSIOL-GASTR L, V304, pG109, DOI 10.1152/ajpgi.00374.2012; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Murphy SJ, 2013, GASTROENTEROLOGY, V145, P1098, DOI 10.1053/j.gastro.2013.07.049; Nollmann FI, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8080281; Notta F, 2017, GUT, V66, P2170, DOI 10.1136/gutjnl-2016-313317; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Ray K, 2017, NAT REV GASTRO HEPAT, V14, P504, DOI 10.1038/nrgastro.2017.111; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Sah RP, 2013, GASTROENTEROLOGY, V144, P1076, DOI 10.1053/j.gastro.2013.01.041; Seleznik GM, 2012, GASTROENTEROLOGY, V143, P1361, DOI 10.1053/j.gastro.2012.07.112; SESSA F, 1990, GASTROENTEROLOGY, V98, P1655, DOI 10.1016/0016-5085(90)91104-E; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Toback FG, 2003, AM J PHYSIOL-GASTR L, V285, pG344, DOI 10.1152/ajpgi.00455.2002; Xing R, 2012, GUT, V61, P43, DOI 10.1136/gut.2010.230623; Xu ZH, 2010, AM J PATHOL, V177, P2585, DOI 10.2353/ajpath.2010.090899; Yan GR, 2011, PROTEOMICS, V11, P3657, DOI 10.1002/pmic.201100215; Yoon JH, 2017, GASTRIC CANCER, V20, P274, DOI 10.1007/s10120-016-0617-1; Yoon JH, 2014, ONCOTARGET, V5, P11695, DOI 10.18632/oncotarget.2586; Yoon JH, 2011, J CANCER RES CLIN, V137, P1697, DOI 10.1007/s00432-011-1051-8	36	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1507	1517		10.1038/s41388-022-02182-4	http://dx.doi.org/10.1038/s41388-022-02182-4		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35082384	Green Published, hybrid			2022-12-28	WOS:000749084600001
J	Alhayyani, S; McLeod, L; West, AC; Balic, JJ; Hodges, C; Yu, L; Smith, JA; Prodanovic, Z; Bozinovski, S; Kumar, B; Ruwanpura, SM; Saad, MI; Jenkins, BJ				Alhayyani, Sultan; McLeod, Louise; West, Alison C.; Balic, Jesse J.; Hodges, Christopher; Yu, Liang; Smith, Julian A.; Prodanovic, Zdenka; Bozinovski, Steven; Kumar, Beena; Ruwanpura, Saleela M.; Saad, Mohamed I.; Jenkins, Brendan J.			Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer	ONCOGENE			English	Article							K-RAS MUTATIONS; MITOCHONDRIAL STAT3; SIGNAL TRANSDUCER; EPITHELIAL-CELLS; ACTIVATION; EXPRESSION; MYC; TRANSCRIPTION; RECEPTOR; TYROSINE	The oncogenic potential of the latent transcription factor signal transducer and activator of transcription (STAT)3 in many human cancers, including lung cancer, has been largely attributed to its nuclear activity as a tyrosine-phosphorylated (pY(705) site) transcription factor. By contrast, an alternate mitochondrial pool of serine phosphorylated (pS(727) site) STAT3 has been shown to promote tumourigenesis by regulating metabolic processes, although this has been reported in only a restricted number of mutant RAS-addicted neoplasms. Therefore, the involvement of STAT3 serine phosphorylation in the pathogenesis of most cancer types, including mutant KRAS lung adenocarcinoma (LAC), is unknown. Here, we demonstrate that LAC is suppressed in oncogenic Kras(G12D)-driven mouse models engineered for pS(727)-STAT3 deficiency. The proliferative potential of the transformed Kras(G12D) lung epithelium, and mutant KRAS human LAC cells, was significantly reduced upon pS(727)-STAT3 deficiency. Notably, we uncover the multifaceted capacity of constitutive pS(727)-STAT3 to metabolically reprogramme LAC cells towards a hyper-proliferative state by regulating nuclear and mitochondrial (mt) gene transcription, the latter via the mtDNA transcription factor, TFAM. Collectively, our findings reveal an obligate requirement for the transcriptional activity of pS(727)-STAT3 in mutant KRAS-driven LAC with potential to guide future therapeutic targeting approaches.	[Alhayyani, Sultan; McLeod, Louise; West, Alison C.; Balic, Jesse J.; Hodges, Christopher; Yu, Liang; Ruwanpura, Saleela M.; Saad, Mohamed I.; Jenkins, Brendan J.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia; [Alhayyani, Sultan; McLeod, Louise; West, Alison C.; Balic, Jesse J.; Hodges, Christopher; Yu, Liang; Ruwanpura, Saleela M.; Saad, Mohamed I.; Jenkins, Brendan J.] Monash Univ, Sch Clin Sci, Dept Mol & Translat Sci, Clayton, Vic 3168, Australia; [Alhayyani, Sultan] King Abdulaziz Univ, Coll Arts & Sci, Dept Chem, Rabigh, Saudi Arabia; [Smith, Julian A.] Monash Univ, Sch Clin Sci, Dept Surg, Monash Hlth, Clayton, Vic 3168, Australia; [Smith, Julian A.] Monash Hlth, Dept Cardiothorac Surg, Clayton, Vic 3168, Australia; [Prodanovic, Zdenka] Monash Hlth, Monash Biobank, Clayton, Vic 3168, Australia; [Bozinovski, Steven] RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic 3082, Australia; [Kumar, Beena] Monash Hlth, Dept Anat Pathol, Clayton, Vic 3168, Australia	Hudson Institute of Medical Research; Monash University; King Abdulaziz University; Monash University; Royal Melbourne Institute of Technology (RMIT)	Jenkins, BJ (corresponding author), Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia.; Jenkins, BJ (corresponding author), Monash Univ, Sch Clin Sci, Dept Mol & Translat Sci, Clayton, Vic 3168, Australia.	brendan.jenkins@hudson.org.au	Alhayyani/AAR-7025-2020	Saad, Mohamed I./0000-0002-4855-2360; Bozinovski, Steven/0000-0001-6533-8641; McLeod, Louise/0000-0002-7595-6432	National Health and Medical Research Council (NHMRC) of Australia; Cancer Council Victoria Postdoctoral Fellowship by the Victorian Government of Australia; Department of Chemistry, College of Sciences and Arts, King Abdulaziz University, Rabigh, Saudi Arabia; NHMRC Senior Medical Research Fellowship; Cancer Council Victoria Postdoctoral Fellowship	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria Postdoctoral Fellowship by the Victorian Government of Australia; Department of Chemistry, College of Sciences and Arts, King Abdulaziz University, Rabigh, Saudi Arabia; NHMRC Senior Medical Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria Postdoctoral Fellowship(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	We are deeply grateful to D. Gough and S. Fernando (Hudson Institute of Medical Research, Melbourne, Australia) for expert technical assistance and proofreading of the manuscript, as well as A. Vais (Monash Histology Platform, Melbourne, Australia) for immunofluorescence expertise. This work was supported by a research grant awarded by the National Health and Medical Research Council (NHMRC) of Australia to BJJ, as well as the Operational Infrastructure Support Programme by the Victorian Government of Australia. MIS is supported by a Cancer Council Victoria Postdoctoral Fellowship. SA was sponsored by the Department of Chemistry, College of Sciences and Arts, King Abdulaziz University, Rabigh, Saudi Arabia. BJJ is supported by a NHMRC Senior Medical Research Fellowship.	Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Balic JJ, 2019, CANCER RES, V79, P5272, DOI 10.1158/0008-5472.CAN-19-0974; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Brooks GD, 2016, CANCER RES, V76, P866, DOI 10.1158/0008-5472.CAN-15-2388; Caetano MS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07042-y; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; D'Amico S, 2018, GENE DEV, V32, P1175, DOI 10.1101/gad.311852.118; Dragoj M, 2015, TUMOR BIOL, V36, P8773, DOI 10.1007/s13277-015-3620-y; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Dutta P, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6649-2; Garama DJ, 2016, CYTOKINE, V87, P20, DOI 10.1016/j.cyto.2016.05.019; Garassino MC, 2011, ANN ONCOL, V22, P235, DOI 10.1093/annonc/mdq680; Gough DJ, 2014, BLOOD, V124, P2252, DOI 10.1182/blood-2013-02-484196; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Grabner B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7285; Han YH, 2008, ONCOL REP, V20, P689, DOI 10.3892/or_00000061; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirahara K, 2015, IMMUNITY, V42, P877, DOI 10.1016/j.immuni.2015.04.014; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Ji H, 2006, ONCOGENE, V25, P2105, DOI 10.1038/sj.onc.1209237; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kim HS, 2010, CANCER-AM CANCER SOC, V116, P676, DOI 10.1002/cncr.24748; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li Y, 2007, CANCER RES, V67, P8494, DOI 10.1158/0008-5472.CAN-07-0647; Liou GY, 2016, CELL REP, V14, P2325, DOI 10.1016/j.celrep.2016.02.029; Liu YD, 2019, INT J CANCER, V144, P3056, DOI 10.1002/ijc.32060; Macias E, 2014, J INVEST DERMATOL, V134, P1971, DOI 10.1038/jid.2014.68; Mao YQ, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00058; Marson VJ, 2004, HISTOPATHOLOGY, V45, P125, DOI 10.1111/j.1365-2559.2004.01893.x; McClelland MR, 2007, AM J RESP CELL MOL, V36, P343, DOI 10.1165/rcmb.2006-0311OC; Meissl K, 2017, CYTOKINE, V89, P12, DOI 10.1016/j.cyto.2015.11.011; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Nagao A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020238; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Noonan KL, 2015, J THORAC ONCOL, V10, P1523, DOI 10.1097/JTO.0000000000000667; Oft M, 2014, CANCER IMMUNOL RES, V2, P194, DOI 10.1158/2326-6066.CIR-13-0214; Poli V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00121; Roman M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0789-x; Ruwanpura SM, 2011, AM J RESP CELL MOL, V45, P720, DOI 10.1165/rcmb.2010-0462OC; Saad MI, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809976; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tong MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182282; Tran PT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002125; Walser Tonya, 2008, Proc Am Thorac Soc, V5, P811, DOI 10.1513/pats.200809-100TH; Wang XC, 2016, ONCOTARGETS THER, V9, P5461, DOI 10.2147/OTT.S94745; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Weng MT, 2013, PROTEIN CELL, V4, P807, DOI 10.1007/s13238-013-3056-3; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; Wong MCS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14513-7; Yang Q, 2012, EXP MOL PATHOL, V93, P227, DOI 10.1016/j.yexmp.2012.04.009; Yu CH, 2015, AM J PHYSIOL-GASTR L, V309, pG146, DOI 10.1152/ajpgi.00462.2014; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yu L, 2018, CLIN CANCER RES, V24, P1459, DOI 10.1158/1078-0432.CCR-17-2485; Zhou J, 2015, ONCOGENE, V34, P3804, DOI 10.1038/onc.2014.318; Zhu SG, 2014, BLOOD, V124, P403, DOI 10.1182/blood-2013-05-499707; Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646; Zouein FA, 2013, HYPERTENS RES, V36, P496, DOI 10.1038/hr.2012.223	71	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					809	823		10.1038/s41388-021-02134-4	http://dx.doi.org/10.1038/s41388-021-02134-4		DEC 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34857889				2022-12-28	WOS:000725388800002
J	Kuiken, HJ; Dhakal, S; Selfors, LM; Friend, CM; Zhang, T; Callari, M; Schackmann, RCJ; Gray, GK; Crowdis, J; Bhang, HEC; Baslan, T; Stegmeier, F; Gygi, SP; Caldas, C; Brugge, JS				Kuiken, Hendrik J.; Dhakal, Sabin; Selfors, Laura M.; Friend, Chandler M.; Zhang, Tian; Callari, Maurizio; Schackmann, Ron C. J.; Gray, G. Kenneth; Crowdis, Jett; Bhang, Hyo-Eun C.; Baslan, Timour; Stegmeier, Frank; Gygi, Steven P.; Caldas, Carlos; Brugge, Joan S.			Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts	ONCOGENE			English	Article							TUMOR HETEROGENEITY; CANCER; EVOLUTION; CELLS; METASTASIS; XENOGRAFTS; MEDICINE; METAGENE; ACID	Intratumoral heterogeneity has been described for various tumor types and models of human cancer, and can have profound effects on tumor progression and drug resistance. This study describes an in-depth analysis of molecular and functional heterogeneity among subclonal populations (SCPs) derived from a single triple-negative breast cancer cell line, including copy number analysis, whole-exome and RNA sequencing, proteome analysis, and barcode analysis of clonal dynamics, as well as functional assays. The SCPs were found to have multiple unique genetic alterations and displayed significant variation in anchorage independent growth and tumor forming ability. Analyses of clonal dynamics in SCP mixtures using DNA barcode technology revealed selection for distinct clonal populations in different in vitro and in vivo environmental contexts, demonstrating that in vitro propagation of cancer cell lines using different culture conditions can contribute to the establishment of unique strains. These analyses also revealed strong enrichment of a single SCP during the development of xenograft tumors in immune-compromised mice. This SCP displayed attenuated interferon signaling in vivo and reduced sensitivity to the antiproliferative effects of type I interferons. Reduction in interferon signaling was found to provide a selective advantage within the xenograft microenvironment specifically. In concordance with the previously described role of interferon signaling as tumor suppressor, these findings suggest that similar selective pressures may be operative in human cancer and patient-derived xenograft models.	[Kuiken, Hendrik J.; Dhakal, Sabin; Selfors, Laura M.; Friend, Chandler M.; Zhang, Tian; Schackmann, Ron C. J.; Gray, G. Kenneth; Crowdis, Jett; Gygi, Steven P.; Brugge, Joan S.] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA; [Kuiken, Hendrik J.; Dhakal, Sabin; Selfors, Laura M.; Friend, Chandler M.; Schackmann, Ron C. J.; Gray, G. Kenneth; Crowdis, Jett; Brugge, Joan S.] Ludwig Ctr Harvard, Boston, MA 02115 USA; [Callari, Maurizio; Caldas, Carlos] Univ Cambridge, Li Ka Shing Ctr, Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England; [Bhang, Hyo-Eun C.; Stegmeier, Frank] Novartis Inst Biomed Res, Dept Oncol, Cambridge, MA 02139 USA; [Baslan, Timour] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Kuiken, Hendrik J.] Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; [Dhakal, Sabin] Inzen Therapeut, Cambridge, MA 02142 USA; [Schackmann, Ron C. J.] Merus, NL-3584 CM Utrecht, Netherlands; [Crowdis, Jett] Broad Inst, Cambridge, MA 02142 USA; [Bhang, Hyo-Eun C.] Civetta Therapeut, Cambridge, MA 02142 USA; [Stegmeier, Frank] KSQ Therapeut Inc, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Novartis; Memorial Sloan Kettering Cancer Center; Netherlands Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Brugge, JS (corresponding author), Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA.; Brugge, JS (corresponding author), Ludwig Ctr Harvard, Boston, MA 02115 USA.	Joan_Brugge@hms.harvard.edu		SELFORS, LAURA/0000-0002-1317-7353	NIH [PPG P01CA080111]; Breast Cancer Research Foundation [BCRF-19-021]; Ludwig Center at Harvard	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; Ludwig Center at Harvard	We are grateful to Angie Martinez-Gakidis for scientific editing, the ICCB-Longwood Screening Facility at Harvard Medical School for providing support and access to instruments, and the BioPolymers Facility at Harvard Medical School and Bauer Core Facility at Harvard University for providing support with next-generation sequencing. This work was supported by grants from the NIH (PPG P01CA080111), the Breast Cancer Research Foundation (BCRF-19-021), and the Ludwig Center at Harvard.	Agelopoulos K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-78; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bakhoum SF, 2018, CELL, V174, P1347, DOI 10.1016/j.cell.2018.08.027; Baslan T, 2020, ELIFE, V9, DOI 10.7554/eLife.51480; Baslan T, 2017, NAT REV CANCER, V17, P557, DOI 10.1038/nrc.2017.58; Ben-David U, 2018, NATURE, V560, P325, DOI 10.1038/s41586-018-0409-3; Ben-David U, 2017, NAT GENET, V49, P1567, DOI 10.1038/ng.3967; Bhang HEC, 2015, NAT MED, V21, P440, DOI 10.1038/nm.3841; Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041; Byrne AT, 2017, NAT REV CANCER, V17, P254, DOI 10.1038/nrc.2016.140; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; Callari M, 2016, CLIN CANCER RES, V22, P337, DOI 10.1158/1078-0432.CCR-15-0757; Callari M, 2014, MOL ONCOL, V8, P1278, DOI 10.1016/j.molonc.2014.04.010; Cantor JR, 2017, CELL, V169, P258, DOI 10.1016/j.cell.2017.03.023; Cassidy JW, 2015, CANCER RES, V75, P2963, DOI 10.1158/0008-5472.CAN-15-0727; Chung W, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15081; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Echeverria GV, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07406-4; Eirew P, 2015, NATURE, V518, P422, DOI 10.1038/nature13952; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; Gao RL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00244-w; Gao RL, 2016, NAT GENET, V48, P1119, DOI 10.1038/ng.3641; Georgopoulou D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22303-z; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grigoriadis A, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-619; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003; Karaayvaz M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06052-0; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Laks E, 2019, CELL, V179, P1207, DOI 10.1016/j.cell.2019.10.026; Li WZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14364-2; Lim B, 2020, CANCER CELL, V37, P456, DOI 10.1016/j.ccell.2020.03.008; Liu YS, 2019, NAT BIOTECHNOL, V37, P314, DOI 10.1038/s41587-019-0037-y; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marusyk A, 2020, CANCER CELL, V37, P471, DOI 10.1016/j.ccell.2020.03.007; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Merino D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08595-2; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Naffar-Abu Amara S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19584-1; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Nolan-Stevaux O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067316; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Olive JF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198790; Paludan SR, 2019, NAT REV IMMUNOL, V19, P141, DOI 10.1038/s41577-018-0117-0; Post AEM, 2018, CLIN CANCER RES, V24, P3397, DOI 10.1158/1078-0432.CCR-17-2551; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27; Saleiro D, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.101299; Sato K, 2019, CANCER GENOM PROTEOM, V16, P21, DOI 10.21873/cgp.20109; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1; Tabassum DP, 2015, NAT REV CANCER, V15, P473, DOI 10.1038/nrc3971; Waclaw B, 2015, NATURE, V525, P261, DOI 10.1038/nature14971; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600; WEBER H, 1987, EMBO J, V6, P591, DOI 10.1002/j.1460-2075.1987.tb04795.x; Woo XY, 2021, NAT GENET, V53, DOI 10.1038/s41588-020-00750-6; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Zardavas D, 2015, NAT REV CLIN ONCOL, V12, P381, DOI 10.1038/nrclinonc.2015.73; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	71	2	2	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					112	124		10.1038/s41388-021-02075-y	http://dx.doi.org/10.1038/s41388-021-02075-y		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34703030	Green Accepted			2022-12-28	WOS:000711362100001
J	Zhang, JN; Zhang, L; Nie, J; Lin, Y; Li, Y; Xu, W; Zhao, JY; Zhao, SM; Wang, CJ				Zhang, Jianong; Zhang, Liang; Nie, Ji; Lin, Yan; Li, Yao; Xu, Wei; Zhao, Jian-Yuan; Zhao, Shi-Min; Wang, Chenji			Calcineurin inactivation inhibits pyruvate dehydrogenase complex activity and induces the Warburg effect	ONCOGENE			English	Article							PHOSPHATASE; PHOSPHORYLATION; PROMOTES; BINDING; PROTEIN; KINASE; OVEREXPRESSION; CYCLOSPORINE; DEFICIENCY; ACTIVATION	Calcineurin is a calcium- and calmodulin-dependent serine/threonine protein phosphatase that connects the Ca2+-dependent signalling to multiple cellular responses. Calcineurin inhibitors (CNIs) have been widely used to suppress immune response in allograft patients. However, CNIs significantly increase cancer incidence in transplant recipients compared with the general population. Accumulating evidence suggests that CNIs may promote the malignant transformation of cancer cells in addition to its role in immunosuppression, but the underlying mechanisms remain poorly understood. Here, we show that calcineurin interacts with pyruvate dehydrogenase complex (PDC), a mitochondrial gatekeeper enzyme that connects two key metabolic pathways of cells, glycolysis and the tricarboxylic acid cycle. Mitochondrial-localized calcineurin dephosphorylates PDHA1 at Ser232, Ser293 and Ser300, and thus enhances PDC enzymatic activity, remodels cellular glycolysis and oxidative phosphorylation, and suppresses cancer cell proliferation. Hypoxia attenuates mitochondrial translocation of calcineurin to promote PDC inactivation. Moreover, CNIs promote metabolic remodelling and the Warburg effect by blocking calcineurin-mediated PDC activation in cancer cells. Our findings indicate that calcineurin is a critical regulator of mitochondrial metabolism and suggest that CNIs may promote tumorigenesis through inhibition of the calcineurin-PDC pathway.	[Zhang, Jianong; Zhang, Liang; Nie, Ji; Lin, Yan; Li, Yao; Zhao, Shi-Min; Wang, Chenji] Fudan Univ, Key Lab Reprod Regulat NPFPC, State Key Lab Genet Engn,SIPPR,IRD,Sch Life Sci, MOE Engn Res Ctr Gene Technol,Obstet & Gynecol Ho, Shanghai 200438, Peoples R China; [Xu, Wei] Fudan Univ, Shanghai Peoples Hosp 5, Shanghai 200032, Peoples R China; [Xu, Wei] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China; [Zhao, Jian-Yuan] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200438, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Zhao, SM; Wang, CJ (corresponding author), Fudan Univ, Key Lab Reprod Regulat NPFPC, State Key Lab Genet Engn,SIPPR,IRD,Sch Life Sci, MOE Engn Res Ctr Gene Technol,Obstet & Gynecol Ho, Shanghai 200438, Peoples R China.	zhaosm@fudan.edu.cn; chenjiwang@fudan.edu.cn		wang, chenji/0000-0002-5752-6439; Zhao, Jian-Yuan/0000-0001-9861-0330	National Science Foundation of China [91957125, 81972396, 31330023, 3182100, 291753207, 31930062, 81722021, 81771627, 31521003, 31671483, 31871432]; Shanghai Rising-Star Program [18QA1400300]; National Key R&D Program of China [2018YFA0800300, 2019YFA0801900, 2018YFA0801300, 2018YFC1004700]; Science and Technology Municipal Commission of Shanghai, China [16JC1405301]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Rising-Star Program; National Key R&D Program of China; Science and Technology Municipal Commission of Shanghai, China	This work was supported by grants from the National Science Foundation of China (No. 91957125, 81972396 to CJW, No. 31330023, 3182100, 291753207, 31930062 to SMZ; No. 81722021, 81771627, 31521003 to JYZ; No. 31671483, 31871432 to WX), Shanghai Rising-Star Program (No. 18QA1400300 to WX), National Key R&D Program of China (No. 2018YFA0800300 to SMZ; 2019YFA0801900 to JYZ; 2018YFA0801300, 2018YFC1004700 to WX); Science and Technology Municipal Commission of Shanghai, China (No. 16JC1405301 to SMZ).	Basu A, 2008, CANCER RES, V68, P5689, DOI 10.1158/0008-5472.CAN-07-6603; Basu A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023919; Cereghetti GM, 2010, CELL DEATH DIFFER, V17, P1785, DOI 10.1038/cdd.2010.61; Charni-Natan Meital, 2020, STAR Protoc, V1, P100086, DOI 10.1016/j.xpro.2020.100086; Chen GL, 1996, J BIOL CHEM, V271, P28064, DOI 10.1074/jbc.271.45.28064; Datta D, 2009, CANCER RES, V69, P8902, DOI 10.1158/0008-5472.CAN-09-1404; Dougherty MK, 2009, MOL CELL, V34, P652, DOI 10.1016/j.molcel.2009.06.001; Duan LL, 2010, P NATL ACAD SCI USA, V107, P22314, DOI 10.1073/pnas.1016630108; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Fan J, 2014, J BIOL CHEM, V289, P26533, DOI 10.1074/jbc.M114.593970; Fan J, 2014, MOL CELL, V53, P534, DOI 10.1016/j.molcel.2013.12.026; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; Golias T, 2019, INT J CANCER, V144, P674, DOI 10.1002/ijc.31812; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Han WN, 2012, CANCER PREV RES, V5, P1155, DOI 10.1158/1940-6207.CAPR-12-0185-T; Han Z, 2008, J BIOL CHEM, V283, P237, DOI 10.1074/jbc.M704748200; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Karpova T, 2003, BBA-PROTEINS PROTEOM, V1652, P126, DOI 10.1016/j.bbapap.2003.08.010; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kinoshita E, 2006, MOL CELL PROTEOMICS, V5, P749, DOI 10.1074/mcp.T500024-MCP200; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kung L, 2000, TRANSPLANTATION, V70, P327, DOI 10.1097/00007890-200007270-00017; Li B, 2013, CLIN CANCER RES, V19, P5835, DOI 10.1158/1078-0432.CCR-12-3629; Li HM, 2011, TRENDS CELL BIOL, V21, P91, DOI 10.1016/j.tcb.2010.09.011; Liu LL, 2005, MOL BIOL REP, V32, P41, DOI 10.1007/s11033-004-4250-4; Maj MC, 2006, MOL CELL ENDOCRINOL, V249, P1, DOI 10.1016/j.mce.2006.02.003; Maluccio M, 2003, TRANSPLANTATION, V76, P597, DOI 10.1097/01.TP.0000081399.75231.3B; McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200; Medina DL, 2015, NAT CELL BIOL, V17, P288, DOI 10.1038/ncb3114; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; MURAMATSU T, 1992, BIOCHEM BIOPH RES CO, V188, P265, DOI 10.1016/0006-291X(92)92379-C; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Park J, 2013, MOL CELL, V50, P919, DOI 10.1016/j.molcel.2013.06.001; Patel MS, 2014, J BIOL CHEM, V289, P16615, DOI 10.1074/jbc.R114.563148; Pfluger PT, 2015, CELL METAB, V22, P838, DOI 10.1016/j.cmet.2015.08.022; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Shan CL, 2014, J BIOL CHEM, V289, P21413, DOI 10.1074/jbc.M114.581124; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Sutendra G, 2014, CELL, V158, P84, DOI 10.1016/j.cell.2014.04.046; Ume AC, 2020, PHOTODERMATOL PHOTO, V36, P433, DOI 10.1111/phpp.12600; Yu XK, 2008, STRUCTURE, V16, P104, DOI 10.1016/j.str.2007.10.024	45	1	1	5	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6692	6702		10.1038/s41388-021-02065-0	http://dx.doi.org/10.1038/s41388-021-02065-0		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34667275				2022-12-28	WOS:000708806900002
J	Ye, ZPP; Ai, XL; Zhao, LJ; Fei, F; Wang, P; Zhou, ST				Ye, Zengpanpan; Ai, Xiaolin; Zhao, Linjie; Fei, Fan; Wang, Ping; Zhou, Shengtao			Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics	ONCOGENE			English	Review							TUMOR-ASSOCIATED MACROPHAGES; REGULATORY T-CELLS; SUPPRESSOR-CELLS; DENDRITIC CELLS; BRAIN-TUMORS; GLIOMA MICROENVIRONMENT; SURVIVAL ADVANTAGE; RESIDENT MICROGLIA; LYMPHOCYTE RATIO; DOWN-REGULATION	Glioblastoma (GBM) is the most common and malignant type of intracranial tumors with poor prognosis. Accumulating evidence suggests that phenotypic alterations of infiltrating myeloid cells in the tumor microenvironment are important for GBM progression. Conventional tumor immunotherapy commonly targets T-cells, while innate immunity as a therapeutic target is an emerging field. Targeting infiltrating myeloid cells that induce immune suppression in the TME provides a novel direction to improve the prognosis of patients with GBM. The factors released by tumor cells recruit myeloid cells into tumor bed and reprogram infiltrating myeloid cells into immunostimulatory/immunosuppressive phenotypes. Reciprocally, infiltrating myeloid cells, especially microglia/macrophages, regulate GBM progression and affect therapeutic efficacy. Herein, we revisited biological characteristics and functions of infiltrating myeloid cells and discussed the recent advances in immunotherapies targeting infiltrating myeloid cells in GBM. With an evolving understanding of the complex interactions between infiltrating myeloid cells and tumor cells in the tumor microenvironment, we will expand novel immunotherapeutic regimens targeting infiltrating myeloid cells in GBM treatment and improve the outcomes of GBM patients.	[Ye, Zengpanpan; Ai, Xiaolin; Wang, Ping; Zhou, Shengtao] Sichuan Univ, West China Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Dept Obstet & Gynecol,Minist Educ, Chengdu, Peoples R China; [Ye, Zengpanpan; Ai, Xiaolin; Wang, Ping; Zhou, Shengtao] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Peoples R China; [Zhao, Linjie] Univ Calif San Diego, Dept Med, Div Regenerat Med, La Jolla, CA 92103 USA; [Fei, Fan] Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Neurosurg, 32 West Second Sect,First Ring Rd, Chengdu 610072, Sichuan, Peoples R China; [Fei, Fan] Univ Elect Sci & Technol China, Sch Med, 32 West Second Sect,First Ring Rd, Chengdu 610072, Sichuan, Peoples R China	Sichuan University; Sichuan University; University of California System; University of California San Diego; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; University of Electronic Science & Technology of China	Wang, P; Zhou, ST (corresponding author), Sichuan Univ, West China Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Dept Obstet & Gynecol,Minist Educ, Chengdu, Peoples R China.; Wang, P; Zhou, ST (corresponding author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Peoples R China.; Fei, F (corresponding author), Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Neurosurg, 32 West Second Sect,First Ring Rd, Chengdu 610072, Sichuan, Peoples R China.; Fei, F (corresponding author), Univ Elect Sci & Technol China, Sch Med, 32 West Second Sect,First Ring Rd, Chengdu 610072, Sichuan, Peoples R China.	917597029@qq.com; wangping_886@126.com; taotaovip2005@163.com		Fei, Fan/0000-0003-4437-3186; Zhou, Shengtao/0000-0001-8322-5536	National Natural Science Foundation of China [81822034, 81821002]; National Key Research and Development Program of China [2017YFA0106800, 2018YFA0109200]; Sichuan Science-Technology International Cooperation Project [2019YFH0144]; Sichuan Science-Technology Key Research and Development Program [2021YFS0015]; West China Second Hospital, Sichuan University [KS021, K1907]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Sichuan Science-Technology International Cooperation Project; Sichuan Science-Technology Key Research and Development Program; West China Second Hospital, Sichuan University	This work was supported by grants from National Natural Science Foundation of China (grant # 81822034 and grant # 81821002), National Key Research and Development Program of China (2017YFA0106800 and 2018YFA0109200), Sichuan Science-Technology International Cooperation Project (grant #2019YFH0144), Sichuan Science-Technology Key Research and Development Program (grant #2021YFS0015), Direct Scientific Research Grants from West China Second Hospital, Sichuan University (grant #KS021 and #K1907).	Adrover JM, 2016, TRENDS IMMUNOL, V37, P334, DOI 10.1016/j.it.2016.03.005; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Akasaki Y, 2004, J IMMUNOL, V173, P4352, DOI 10.4049/jimmunol.173.7.4352; Alban TJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01191; Alban TJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122264; Albulescu R, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/979748; Alfaro C, 2016, CLIN CANCER RES, V22, P3924, DOI 10.1158/1078-0432.CCR-15-2463; An ZY, 2018, CANCER RES, V78, P6785, DOI 10.1158/0008-5472.CAN-17-3551; Antunes ARP, 2020, ELIFE, V9, DOI 10.7554/eLife.52176; Aslan K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14642-0; Aspord C, 2013, CANCER IMMUNOL RES, V1, P402, DOI 10.1158/2326-6066.CIR-13-0114-T; Bah I, 2018, CELL IMMUNOL, V332, P32, DOI 10.1016/j.cellimm.2018.07.003; Bambury RM, 2013, J NEURO-ONCOL, V114, P149, DOI 10.1007/s11060-013-1164-9; Batich KA, 2017, CLIN CANCER RES, V23, P1898, DOI 10.1158/1078-0432.CCR-16-2057; Bayik D, 2020, CANCER DISCOV, V10, P1210, DOI 10.1158/2159-8290.CD-19-1355; Bertaut A, 2016, ONCOTARGET, V7, P70948, DOI 10.18632/oncotarget.10898; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Brandenburg S, 2016, ACTA NEUROPATHOL, V131, P365, DOI 10.1007/s00401-015-1529-6; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245; da Fonseca ACC, 2014, J NEUROIMMUNOL, V274, P71, DOI 10.1016/j.jneuroim.2014.06.021; Castro BA, 2017, ONCOGENE, V36, P3749, DOI 10.1038/onc.2017.1; Chabot V, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0848-2; Chae M, 2015, NEURO-ONCOLOGY, V17, P978, DOI 10.1093/neuonc/nou343; Chai EQ, 2019, CANCER MANAG RES, V11, P7307, DOI 10.2147/CMAR.S210545; Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Chen PW, 2019, CANCER CELL, V35, P868, DOI 10.1016/j.ccell.2019.05.003; Chen XB, 2014, CANCER RES, V74, P7285, DOI 10.1158/0008-5472.CAN-14-1240; Chen ZH, 2019, P NATL ACAD SCI USA, V116, P14254, DOI 10.1073/pnas.1902366116; Chen ZH, 2017, CANCER RES, V77, P2266, DOI 10.1158/0008-5472.CAN-16-2310; Chio CC, 2001, BRIT J CANCER, V85, P1185, DOI 10.1054/bjoc.2001.2055; Cho HR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47438-4; Chonan M, 2015, NEURO-ONCOLOGY, V17, P1453, DOI 10.1093/neuonc/nov090; Cimino PJ, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0443-7; Condamine T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8943; Cui X, 2018, BIOMATERIALS, V161, P164, DOI 10.1016/j.biomaterials.2018.01.053; Delwar ZM, 2018, CANCER RES, V78, P718, DOI 10.1158/0008-5472.CAN-17-0599; Dey M, 2015, J IMMUNOL, V195, P367, DOI 10.4049/jimmunol.1401607; Dubinski D, 2016, NEURO-ONCOLOGY, V18, P807, DOI 10.1093/neuonc/nov280; Dumitru CA, 2013, SEMIN CANCER BIOL, V23, P141, DOI 10.1016/j.semcancer.2013.02.005; Fan YF, 2008, J CEREBR BLOOD F MET, V28, P90, DOI 10.1038/sj.jcbfm.9600509; Fiore A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07654-4; Friebel E, 2020, CELL, V181, P1626, DOI 10.1016/j.cell.2020.04.055; Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297; Gabrusiewicz K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85841; Galani V, 2017, J INTERF CYTOK RES, V37, P139, DOI 10.1089/jir.2016.0094; Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031; Ghoochani A, 2016, ONCOGENE, V35, P6246, DOI 10.1038/onc.2016.160; Gielen PR, 2016, NEURO-ONCOLOGY, V18, P1253, DOI 10.1093/neuonc/now034; Ginhoux F, 2016, IMMUNITY, V44, P439, DOI 10.1016/j.immuni.2016.02.024; Gousias K, 2013, J NEUROIMMUNOL, V264, P84, DOI 10.1016/j.jneuroim.2013.09.001; Guneykaya D, 2018, CELL REP, V24, P2773, DOI 10.1016/j.celrep.2018.08.001; Guo XF, 2018, ONCOGENE, V37, P4239, DOI 10.1038/s41388-018-0261-9; Hanamsagar R, 2017, GLIA, V65, P1504, DOI 10.1002/glia.23176; Hu CE, 2011, SCAND J GASTROENTERO, V46, P156, DOI 10.3109/00365521.2010.516450; Hu JM, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abc2511; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Huang YJ, 2017, J CLIN INVEST, V127, P1826, DOI 10.1172/JCI86443; Inoges S, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1202-z; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Jung Y, 2018, CELL PHYSIOL BIOCHEM, V48, P1332, DOI 10.1159/000492092; Kamran N, 2018, CLIN IMMUNOL, V189, P34, DOI 10.1016/j.clim.2016.10.008; Kamran N, 2017, MOL THER, V25, P232, DOI 10.1016/j.ymthe.2016.10.003; Kees T, 2012, NEURO-ONCOLOGY, V14, P64, DOI 10.1093/neuonc/nor182; Klemm F, 2020, CELL, V181, P1643, DOI 10.1016/j.cell.2020.05.007; Kloepper J, 2016, P NATL ACAD SCI USA, V113, P4476, DOI 10.1073/pnas.1525360113; Kodama L, 2019, TRENDS MOL MED, V25, P741, DOI 10.1016/j.molmed.2019.05.001; Kwon HS, 2020, TRANSL NEURODEGENER, V9, DOI 10.1186/s40035-020-00221-2; Lamano JB, 2019, CLIN CANCER RES, V25, P3643, DOI 10.1158/1078-0432.CCR-18-2402; Laoui D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13720; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Lee-Chang C, 2019, CANCER IMMUNOL RES, V7, P1928, DOI 10.1158/2326-6066.CIR-19-0240; Lehrer S, 2019, CLIN NEUROL NEUROSUR, V177, P63, DOI 10.1016/j.clineuro.2018.12.021; Li HQ, 2009, J IMMUNOL, V182, P240, DOI 10.4049/jimmunol.182.1.240; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Liang H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15015; Liang J, 2014, CLIN CANCER RES, V20, P187, DOI 10.1158/1078-0432.CCR-13-1279; Liau LM, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1507-6; Liau LM., 2000, NEUROSURG FOCUS, V9, P8; Lin H, 2018, J CLIN INVEST, V128, P1708, DOI 10.1172/JCI120803; Liu CY, 2010, J CANCER RES CLIN, V136, P35, DOI 10.1007/s00432-009-0634-0; Lu-Emerson C, 2013, NEURO-ONCOLOGY, V15, P1079, DOI 10.1093/neuonc/not082; Manda-Handzlik A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121477; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Mao YM, 2014, CLIN CANCER RES, V20, P4096, DOI 10.1158/1078-0432.CCR-14-0635; Marie JC, 2006, IMMUNITY, V25, P441, DOI 10.1016/j.immuni.2006.07.012; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; Mason M, 2017, J NEURO-ONCOL, V132, P463, DOI 10.1007/s11060-017-2395-y; Massara M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01349; Mattila S, 2009, NEUROPATHOLOGY, V29, P156, DOI 10.1111/j.1440-1789.2008.00963.x; Megjugorac NJ, 2004, J LEUKOCYTE BIOL, V75, P504, DOI 10.1189/jlb.0603291; Meng XQ, 2019, EBIOMEDICINE, V41, P185, DOI 10.1016/j.ebiom.2019.01.067; Mitchell DA, 2015, NATURE, V519, P366, DOI 10.1038/nature14320; Muller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1362-4; Muraoka D, 2019, J CLIN INVEST, V129, P1278, DOI 10.1172/JCI97642; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Osterberg N, 2016, NEURO-ONCOLOGY, V18, P939, DOI 10.1093/neuonc/now005; Ott M, 2020, CLIN CANCER RES, V26, P4983, DOI 10.1158/1078-0432.CCR-19-4092; Otvos B, 2016, STEM CELLS, V34, P2026, DOI 10.1002/stem.2393; Pallotta MT, 2011, NAT IMMUNOL, V12, P870, DOI 10.1038/ni.2077; Park JE, 2019, ONCOGENE, V38, P5158, DOI 10.1038/s41388-019-0782-x; Peereboom DM, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130748; Pinton L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0536-x; Polajeva J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025222; Poli A, 2013, ONCOTARGET, V4, P1527, DOI 10.18632/oncotarget.1291; Poon CC, 2017, BRAIN, V140, P1548, DOI 10.1093/brain/aww355; Powell DR, 2016, TRENDS IMMUNOL, V37, P41, DOI 10.1016/j.it.2015.11.008; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Qian MY, 2020, ONCOGENE, V39, P428, DOI 10.1038/s41388-019-0996-y; Raber PL, 2014, INT J CANCER, V134, P2853, DOI 10.1002/ijc.28622; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Raychaudhuri B, 2015, J NEURO-ONCOL, V122, P293, DOI 10.1007/s11060-015-1720-6; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Reap EA, 2018, CANCER RES, V78, P256, DOI 10.1158/0008-5472.CAN-17-0469; Ribechini E, 2017, BLOOD ADV, V1, P947, DOI 10.1182/bloodadvances.2017006858; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rodriguez PC, 2004, CANCER RES, V64, P5839, DOI 10.1158/0008-5472.CAN-04-0465; Roesch S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020436; Roy A, 2015, ONCOTARGET, V6, P23647, DOI 10.18632/oncotarget.4640; Sade-Feldman M, 2013, IMMUNITY, V38, P541, DOI 10.1016/j.immuni.2013.02.007; Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006; Schernberg A, 2018, CLIN TRANSL RAD ONCO, V10, P47, DOI 10.1016/j.ctro.2018.04.002; Scholz A, 2016, EMBO MOL MED, V8, P39, DOI 10.15252/emmm.201505505; Schwarz JM, 2012, J NEUROCHEM, V120, P948, DOI 10.1111/j.1471-4159.2011.07630.x; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Shoji T, 2016, NEURO-ONCOLOGY, V18, P1120, DOI 10.1093/neuonc/now023; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sielska M, 2013, J PATHOL, V230, P310, DOI 10.1002/path.4192; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; Sippel TR, 2011, CLIN CANCER RES, V17, P6992, DOI 10.1158/1078-0432.CCR-11-1107; Soderberg SS, 2009, ANN NY ACAD SCI, V1176, P55, DOI 10.1111/j.1749-6632.2009.04569.x; Song LH, 2019, J CELL BIOCHEM, V120, P19518, DOI 10.1002/jcb.29259; Sorensen MD, 2018, NEUROPATH APPL NEURO, V44, P185, DOI 10.1111/nan.12428; Spiller KL, 2014, BIOMATERIALS, V35, P4477, DOI 10.1016/j.biomaterials.2014.02.012; Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718; Takeda A, 2018, GLIA, V66, P2366, DOI 10.1002/glia.23475; Takenaka MC, 2019, NAT NEUROSCI, V22, P729, DOI 10.1038/s41593-019-0370-y; Tan AC, 2020, CA-CANCER J CLIN, V70, P299, DOI 10.3322/caac.21613; Tao WW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16827-z; Tel J, 2014, TRENDS IMMUNOL, V35, P38, DOI 10.1016/j.it.2013.10.007; Thaci B, 2014, CANCER GENE THER, V21, P38, DOI 10.1038/cgt.2013.81; Thion MS, 2018, CELL, V172, P500, DOI 10.1016/j.cell.2017.11.042; Thomas RP, 2019, CLIN CANCER RES, V25, P6948, DOI 10.1158/1078-0432.CCR-19-1421; Tomaszewski W, 2019, CLIN CANCER RES, V25, P4202, DOI 10.1158/1078-0432.CCR-18-1627; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Ugolini A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138581; Vakilian A, 2017, NEUROCHEM INT, V103, P1, DOI 10.1016/j.neuint.2016.12.013; Van Acker HH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00658; Villa A, 2018, CELL REP, V23, P3501, DOI 10.1016/j.celrep.2018.05.048; Wainwright DA, 2012, CLIN CANCER RES, V18, P6110, DOI 10.1158/1078-0432.CCR-12-2130; Wang JL, 2017, EXP CELL RES, V360, P66, DOI 10.1016/j.yexcr.2017.07.031; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Wang QR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03050-0; Wang SC, 2012, LAB INVEST, V92, P151, DOI 10.1038/labinvest.2011.128; Wang ZL, 2019, CNS NEUROSCI THER, V25, P876, DOI 10.1111/cns.13120; Wei J, 2019, J CLIN INVEST, V129, P137, DOI 10.1172/JCI121266; Wen PY, 2019, CLIN CANCER RES, V25, P5799, DOI 10.1158/1078-0432.CCR-19-0261; Wildes TJ, 2018, CLIN CANCER RES, V24, P3955, DOI 10.1158/1078-0432.CCR-17-3061; Wu J, 2018, NEURO-ONCOLOGY, V20, P92, DOI 10.1093/neuonc/nox111; WU M, 2018, NAT COMMUN, V9; Xue JW, 2017, NAT NANOTECHNOL, V12, P692, DOI [10.1038/nnano.2017.54, 10.1038/NNANO.2017.54]; Yan J, 2021, CANCER LETT, V506, P83, DOI 10.1016/j.canlet.2021.02.021; Yan J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08770-5; Yee PP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19193-y; Yin JL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16789-2; Zeiner PS, 2019, BRAIN PATHOL, V29, P513, DOI 10.1111/bpa.12690; Zhang DC, 2015, NATURE, V525, P528, DOI 10.1038/nature15367; Zhang J, 2012, CARCINOGENESIS, V33, P312, DOI 10.1093/carcin/bgr289; Zhang P, 2019, P NATL ACAD SCI USA, V116, P23714, DOI 10.1073/pnas.1906346116; Zhang YJ, 2018, MOL CELL, V71, P201, DOI 10.1016/j.molcel.2018.06.023; Zhang ZP, 2020, CANCER IMMUNOL RES, V8, P966, DOI 10.1158/2326-6066.CIR-19-0759; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090; Zhu C, 2017, ONCOGENE, V36, P5356, DOI 10.1038/onc.2017.145	177	5	5	3	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6059	6070		10.1038/s41388-021-02010-1	http://dx.doi.org/10.1038/s41388-021-02010-1		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34556813				2022-12-28	WOS:000698556400001
J	Peng, HY; Nerreter, T; Mestermann, K; Wachter, J; Chang, J; Hudecek, M; Rader, C				Peng, Haiyong; Nerreter, Thomas; Mestermann, Katrin; Wachter, Jakob; Chang, Jing; Hudecek, Michael; Rader, Christoph			ROR1-targeting switchable CAR-T cells for cancer therapy	ONCOGENE			English	Article							ANTIBODY-LIKE IMMUNORECEPTORS; CHIMERIC ANTIGEN RECEPTORS; AFFINITY; ROR1; TARGET; ACTIVATION; EXPRESSION; DESIGN; DOMAIN; RECRUITMENT	The success of chimeric antigen receptor T cell (CAR-T) therapy in the treatment of hematologic malignancies has prompted the development of numerous CAR-T technologies, including switchable CAR-T (sCAR-T) systems that combine a universal CAR-T with bispecific adapter proteins. Owing to their controllability and versatility, sCAR-Ts have received considerable attention. To explore the therapeutic utility of sCAR-Ts targeting the receptor tyrosine kinase ROR1, which is expressed in hematologic and solid malignancies, and to identify bispecific adaptor proteins that efficiently mediate universal CAR-T engagement, a panel of switches based on ROR1-targeting Fabs with different epitopes and affinities was compared in in vitro and in vivo models of ROR1-expressing cancers. For switches targeting overlapping or identical epitopes, potency correlated with affinity. Surprisingly, however, we identified a switch targeting a unique epitope with low affinity but mediating potent and selective antitumor activity in vitro and in vivo. Converted to a conventional CAR-T, the same anti-ROR1 mAb (324) outperformed a clinically investigated conventional CAR-T that is based on an anti-ROR1 mAb (R12) with similar to 200-fold higher affinity. Thus, demonstrating therapeutic utility on their own, sCAR-Ts also facilitate higher throughput screening for the identification of conventional CAR-T candidates for preclinical and clinical studies.	[Peng, Haiyong; Chang, Jing; Rader, Christoph] Univ Florida, Dept Immunol & Microbiol, UF Scripps Biomed Res, Jupiter, FL 33458 USA; [Nerreter, Thomas; Mestermann, Katrin; Wachter, Jakob; Hudecek, Michael] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Oberclurrbacher Str 6, D-97080 Wurzburg, Germany	State University System of Florida; University of Florida; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg	Peng, HY; Rader, C (corresponding author), Univ Florida, Dept Immunol & Microbiol, UF Scripps Biomed Res, Jupiter, FL 33458 USA.	h.peng@ufl.edu; c.rader@ufl.edu		peng, haiyong/0000-0003-0312-1337; Rader, Christoph/0000-0001-9955-3454	National Institutes of Health (NIH) [R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961, R21 CA263240]; Klorfine Foundation	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Klorfine Foundation	CR acknowledges support by National Institutes of Health (NIH) grants R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961, and R21 CA263240, and by the Klorfine Foundation.	Acevedo-Rocha CG, 2015, SCI REP-UK, V5, DOI 10.1038/srep10654; Arndt C, 2020, CANCERS, V12, DOI 10.3390/cancers12051302; Balakrishnan A, 2017, CLIN CANCER RES, V23, P3061, DOI 10.1158/1078-0432.CCR-16-2083; Baskar S, 2008, CLIN CANCER RES, V14, P396, DOI 10.1158/1078-0432.CCR-07-1823; Benmebarek MR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061283; Berger C, 2015, CANCER IMMUNOL RES, V3, P206, DOI 10.1158/2326-6066.CIR-14-0163; Cao Y, 2016, ANGEW CHEM INT EDIT, V55, P7520, DOI 10.1002/anie.201601902; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chmielewski M, 2004, J IMMUNOL, V173, P7647, DOI 10.4049/jimmunol.173.12.7647; Cho JH, 2018, CELL, V173, P1426, DOI 10.1016/j.cell.2018.03.038; Choi MY, 2018, CELL STEM CELL, V22, P951, DOI 10.1016/j.stem.2018.05.018; Dana H, 2021, ACTA PHARM SIN B, V11, P1129, DOI 10.1016/j.apsb.2020.10.020; Darowski D, 2019, MABS-AUSTIN, V11, P621, DOI 10.1080/19420862.2019.1596511; Dave H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052655; Depil S, 2020, NAT REV DRUG DISCOV, V19, P185, DOI 10.1038/s41573-019-0051-2; Feins S, 2019, AM J HEMATOL, V94, pS3, DOI 10.1002/ajh.25418; Ghorashian S, 2019, NAT MED, V25, P1408, DOI 10.1038/s41591-019-0549-5; Goydel RS, 2020, J BIOL CHEM, V295, P5995, DOI 10.1074/jbc.RA120.012791; Greenman R, 2021, MOL CANCER THER, V20, P872, DOI 10.1158/1535-7163.MCT-19-1109; Hojjat-Farsangi M, 2014, SEMIN CANCER BIOL, V29, P21, DOI 10.1016/j.semcancer.2014.07.005; Hombach AA, 2007, J IMMUNOL, V178, P4650, DOI 10.4049/jimmunol.178.7.4650; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Hoyos V, 2010, LEUKEMIA, V24, P1160, DOI 10.1038/leu.2010.75; Hudecek M, 2015, CANCER IMMUNOL RES, V3, P125, DOI 10.1158/2326-6066.CIR-14-0127; Hudecek M, 2013, CLIN CANCER RES, V19, P3153, DOI 10.1158/1078-0432.CCR-13-0330; Hudecek M, 2010, BLOOD, V116, P4532, DOI 10.1182/blood-2010-05-283309; Jayaraman J, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102931; Jensen MC, 2015, CURR OPIN IMMUNOL, V33, P9, DOI 10.1016/j.coi.2015.01.002; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kamrani A, 2019, EXPERT OPIN THER TAR, V23, P447, DOI 10.1080/14728222.2019.1602608; Labanieh L, 2022, CELL, V185, P1745, DOI 10.1016/j.cell.2022.03.041; Larson RC, 2021, NAT REV CANCER, V21, P145, DOI 10.1038/s41568-020-00323-z; Lee YG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10565-7; Lindner SE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz3223; Liu XJ, 2015, CANCER RES, V75, P3596, DOI 10.1158/0008-5472.CAN-15-0159; Menck K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010142; Minutolo NG, 2020, J AM CHEM SOC, V142, P6554, DOI 10.1021/jacs.9b11622; Minutolo NG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00176; Moreno-Cortes E, 2021, CRIT REV ONCOL HEMAT, V159, DOI 10.1016/j.critrevonc.2021.103239; Nerreter T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10948-w; Peng Haiyong, 2021, Antib Ther, V4, P222, DOI 10.1093/abt/tbab023; Peng H, 2017, J MOL BIOL, V429, P2954, DOI 10.1016/j.jmb.2017.08.003; Picanco-Castro V, 2020, METHODS MOL BIOL, V2086, P1, DOI 10.1007/978-1-0716-0146-4_1; Qi JP, 2020, ANGEW CHEM INT EDIT, V59, P12178, DOI 10.1002/anie.202005432; Qi JP, 2018, P NATL ACAD SCI USA, V115, pE5467, DOI 10.1073/pnas.1719905115; Raj D, 2019, GUT, V68, P1052, DOI 10.1136/gutjnl-2018-316595; Rennert P, 2019, BLOOD, V134, DOI 10.1182/blood-2019-130654; Rodgers DT, 2016, P NATL ACAD SCI USA, V113, pE459, DOI 10.1073/pnas.1524155113; Rydzek J, 2019, MOL THER, V27, P287, DOI 10.1016/j.ymthe.2018.11.015; Sahillioglu AC, 2022, CURR OPIN IMMUNOL, V74, P190, DOI 10.1016/j.coi.2021.07.002; Schmid DA, 2010, J IMMUNOL, V184, P4936, DOI 10.4049/jimmunol.1000173; Shabani M, 2015, EXPERT OPIN THER TAR, V19, P941, DOI 10.1517/14728222.2015.1025753; Srivastava S, 2021, CANCER CELL, V39, P193, DOI 10.1016/j.ccell.2020.11.005; Srivastava S, 2019, CANCER CELL, V35, P489, DOI 10.1016/j.ccell.2019.02.003; Townsend MH, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0817-0; Viaud S, 2018, P NATL ACAD SCI USA, V115, pE10898, DOI 10.1073/pnas.1810060115; Wang M.L., 2022, NEJM EVID, V1, pEVIDoa2100001, DOI [10.1056/EVIDoa2100001, DOI 10.1056/EVIDOA2100001]; Wang XL, 2011, BLOOD, V118, P1255, DOI 10.1182/blood-2011-02-337360; Wu CY, 2015, SCIENCE, V350, DOI 10.1126/science.aab4077; Yam PY, 2002, MOL THER, V5, P479, DOI 10.1006/mthe.2002.0558; Yang JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021018; Zahnd C, 2004, J BIOL CHEM, V279, P18870, DOI 10.1074/jbc.M309169200; Zhao YM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.680834	63	1	1	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2022	41	34					4104	4114		10.1038/s41388-022-02416-5	http://dx.doi.org/10.1038/s41388-022-02416-5			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3W0LE	35859167				2022-12-28	WOS:000842046700005
J	Lu, XY; Wang, J; Wang, W; Lu, CF; Qu, TY; He, XZ; Liu, XY; Guo, RH; Zhang, EB				Lu, Xiyi; Wang, Jing; Wang, Wei; Lu, Chenfei; Qu, Tianyu; He, Xuezhi; Liu, Xinyin; Guo, Renhua; Zhang, Erbao			Copy number amplification and SP1-activated lncRNA MELTF-AS1 regulates tumorigenesis by driving phase separation of YBX1 to activate ANXA8 in non-small cell lung cancer	ONCOGENE			English	Article							BOX BINDING-PROTEIN; NONCODING RNAS; EXPRESSION; TRANSCRIPTION; PROGRESSION; PROMOTES; YB-1; SP1; METASTASIS; RESISTANCE	Long non-coding RNAs (lncRNAs) are reported to play key roles in tumorigenesis. However, the mechanisms underlying lncRNA-mediated regulation of RNA-binding protein phase separation in tumorigenesis have not been completely elucidated. In this study, an oncogenic lncRNA MELTF-AS1 was identified using systematic data analysis, screening, and verification. MELTF-AS1 was markedly upregulated in non-small cell lung cancer (NSCLC). High MELTF-AS1 levels were associated with advanced tumor-node-metastasis stage (TNM), high tumor size, and decreased survival time. Functionally, MELTF-AS1 regulated cell proliferation and metastasis in vitro and in vivo. RNA sequencing analysis revealed that MELTF-AS1 knockdown specifically modulated genes associated with cell proliferation, apoptosis, and migration. Mechanistically, at the genome level, copy number amplification promoted MELTF-AS1 expression. At the transcriptional level, the transcription factor SP1 directly activated MELTF-AS1 transcription by binding to its promoter. Furthermore, MELTF-AS1 could directly bind and drive the phase separation of YBX1, which was an RNA-binding protein and involved in tumorigenesis, thus activating ANXA8 transcription and promoting tumorigenesis of NSCLC. Aberrant activation of ANXA8 and promotion of tumorigenesis have been found in a variety of tumors. These novel findings demonstrated the critical role of MELTF-AS1-driven phase separation-mediated transcriptional regulation and provided a potential novel diagnostic and therapeutic target for NSCLC.	[Lu, Xiyi; Qu, Tianyu; Liu, Xinyin; Guo, Renhua] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Wang, Jing; He, Xuezhi] Nanjing Med Univ, Res Ctr Bone & Stem Cells, Dept Anat Histol & Embryol, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Wang, Wei] Nanjing Med Univ, Dept Thorac Surg, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Lu, Chenfei] Yangzhou Univ, Dept Clin Med, Med Coll, Yangzhou, Jiangsu, Peoples R China; [Zhang, Erbao] Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Epidemiol, Nanjing 211166, Peoples R China; [Zhang, Erbao] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Yangzhou University; Nanjing Medical University; Nanjing Medical University	Guo, RH (corresponding author), Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.; Zhang, EB (corresponding author), Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Epidemiol, Nanjing 211166, Peoples R China.; Zhang, EB (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.	rhguo@njmu.edu.cn; erbaozhang@njmu.edu.cn		zhang, erbao/0000-0002-5752-7976; Qu, Tianyu/0000-0002-4242-0615; Lu, Xiyi/0000-0003-2204-2052; Guo, Renhua/0000-0003-4475-8617	National Natural Science Foundation of China [82172992, 81972188, 82103133]; Natural Science Foundation of Jiangsu Province [BK20211253, BK20210973]; China Postdoctoral Science Foundation [2020M671395]; Medical Important Talents [ZDRCA2016024]; Program for Innovative Research Team of Nanjing Medical University [JX102GSP201727]; Wu Jie-ping Foundation [320.6799.15032]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Medical Important Talents; Program for Innovative Research Team of Nanjing Medical University; Wu Jie-ping Foundation	This work was supported by the National Natural Science Foundation of China [82172992, 81972188 and 82103133], Natural Science Foundation of Jiangsu Province [BK20211253 and BK20210973], China Postdoctoral Science Foundation (2020M671395), the Medical Important Talents [ZDRCA2016024], the Program for Innovative Research Team of Nanjing Medical University [JX102GSP201727], and the Wu Jie-ping Foundation [320.6799.15032].	Alberti S, 2019, ANNU REV GENET, V53, P171, DOI 10.1146/annurev-genet-112618-043527; Banani SF, 2017, NAT REV MOL CELL BIO, V18, P285, DOI 10.1038/nrm.2017.7; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Boija A, 2021, CANCER CELL, V39, P174, DOI 10.1016/j.ccell.2020.12.003; Boija A, 2018, CELL, V175, P1842, DOI 10.1016/j.cell.2018.10.042; Camps C, 2009, CLIN LUNG CANCER, V10, P83, DOI 10.3816/CLC.2009.n.010; Chen ZR, 2016, J CLIN INVEST, V126, P2267, DOI 10.1172/JCI85250; Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Flippot R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08363-6; Goodarzi H, 2015, CELL, V161, P790, DOI 10.1016/j.cell.2015.02.053; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Hata H, 2014, MOL CARCINOGEN, V53, P181, DOI 10.1002/mc.21961; Imada K, 2013, CLIN CANCER RES, V19, P4638, DOI 10.1158/1078-0432.CCR-12-3705; Jiang S, 2020, ELIFE, V9, DOI 10.7554/eLife.60264; Jungert K, 2007, CANCER RES, V67, P1563, DOI 10.1158/0008-5472.CAN-06-1670; Kosnopfel C, 2014, EUR J CELL BIOL, V93, P61, DOI 10.1016/j.ejcb.2013.11.007; La-Touche S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146740; Li CL, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12632; Li D, 2017, HEPATOLOGY, V65, P1612, DOI 10.1002/hep.29010; Li J, 2015, CANCER RES, V75, P3728, DOI 10.1158/0008-5472.CAN-15-0273; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008; Lin M, 2006, ONCOGENE, V25, P1424, DOI 10.1038/sj.onc.1209166; Liu K, 2019, EUR REV MED PHARMACO, V23, P5884, DOI 10.26355/eurrev_201907_18333; Liu XY, 2019, MOL THER-NUCL ACIDS, V16, P155, DOI 10.1016/j.omtn.2019.02.010; Liu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep14082; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Munschauer M, 2018, NATURE, V561, P132, DOI 10.1038/s41586-018-0453-z; Petrelli NJ, 2009, J CLIN ONCOL, V27, P6052, DOI 10.1200/JCO.2009.26.6171; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Ricciotti RW, 2017, CANCER GENET-NY, V218, P69, DOI 10.1016/j.cancergen.2017.09.005; Roden C, 2021, NAT REV MOL CELL BIO, V22, P183, DOI 10.1038/s41580-020-0264-6; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; SARKAR A, 1994, BLOOD, V84, P279; SCHIMKE RT, 1990, CANCER CELL-MON REV, V2, P149; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Song J, 2007, CLIN CANCER RES, V13, P6842, DOI 10.1158/1078-0432.CCR-07-0569; Stein T, 2005, CLIN CANCER RES, V11, P6872, DOI 10.1158/1078-0432.CCR-05-0547; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wei YP, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109890; Wierstra I, 2008, BIOCHEM BIOPH RES CO, V372, P1, DOI 10.1016/j.bbrc.2008.03.074; Wu M, 2021, SCIENCE, V373, P547, DOI 10.1126/science.abf6582; Yan XD, 2010, CANCER RES, V70, P1616, DOI 10.1158/0008-5472.CAN-09-3215; Yang F, 2017, CANCER RES, V77, P5543, DOI 10.1158/0008-5472.CAN-17-1375; Yin DD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0836-7; Yu XX, 2005, HEPATOLOGY, V42, P362, DOI 10.1002/hep.20783; Zhang EB, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1523-0; Zhang EB, 2017, NUCLEIC ACIDS RES, V45, P3086, DOI 10.1093/nar/gkw1247	55	4	4	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3222	3238		10.1038/s41388-022-02292-z	http://dx.doi.org/10.1038/s41388-022-02292-z		MAY 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35508543				2022-12-28	WOS:000790621800003
J	Shirakihara, T; Yamaguchi, H; Kondo, T; Yashiro, M; Sakai, R				Shirakihara, Takuya; Yamaguchi, Hideki; Kondo, Tadashi; Yashiro, Masakazu; Sakai, Ryuichi			Transferrin receptor 1 promotes the fibroblast growth factor receptor-mediated oncogenic potential of diffused-type gastric cancer	ONCOGENE			English	Article							FGF RECEPTORS; CELL-LINES; K-SAM; PHOSPHORYLATION; CARCINOMA; SEQUENCE; MET; EXPRESSION; INHIBITOR; BINDING	Diffuse-type gastric cancer (DGC) is a highly invasive subtype of gastric adenocarcinoma that frequently exhibits scattered peritoneal metastasis. Previous studies have shown that the genes of receptor tyrosine kinases (RTKs), such as fibroblast growth factor receptor 2 (FGFR2) or Met, are amplified in some DGC cell lines, leading to the constitutive activation of corresponding RTKs. In these cell lines, the survival of cancer cells appears to be dependent on the activation of RTKs. To gain novel insights into the downstream signaling pathways of RTKs specific to DGC, phosphotyrosine-containing proteins associated with activated FGFR2 were purified through two sequential rounds of immunoprecipitation from the lysates of two DGC cell lines. As a result, transferrin receptor 1 (TfR1) was identified as the binding partner of FGFR2. Biochemical analysis confirmed that TfR1 protein binds to FGFR2 and is phosphorylated at tyrosine 20 (Tyr20) in an FGFR2 kinase activity-dependent manner. The knockdown of TfR1 and treatment with an inhibitor of FGFR2 caused significant impairment in iron uptake and suppression of cellular proliferation in vitro. Moreover, the suppression of expression levels of TfR1 in the DGC cells significantly reduced their tumorigenicity and potency of peritoneal dissemination. It was indicated that TfR1, when phosphorylated by the binding partner FGFR2 in DGC cells, promotes proliferation and tumorigenicity of these cancer cells. These results suggest that the control of TfR1 function may serve as a therapeutic target in DGC with activated FGFR2.	[Shirakihara, Takuya; Sakai, Ryuichi] Kitasato Univ, Sch Med, Dept Biochem, Sagamihara, Kanagawa, Japan; [Yamaguchi, Hideki] Sasaki Fdn, Sasaki Inst, Dept Canc Cell Res, Tokyo, Japan; [Kondo, Tadashi] Natl Canc Ctr, Div Rare Canc Res, Tokyo, Japan; [Yashiro, Masakazu] Osaka City Univ, Grad Sch Med, Mol Oncol & Therapeut, Osaka, Japan	Kitasato University; National Cancer Center - Japan; Osaka Metropolitan University	Sakai, R (corresponding author), Kitasato Univ, Sch Med, Dept Biochem, Sagamihara, Kanagawa, Japan.	rsakai@kitasato-u.ac.jp		Sakai, Ryuichi/0000-0001-6833-1103; Shirakihara, Takuya/0000-0002-6222-0143; Yamaguchi, Hideki/0000-0003-2125-9655	JSPS KAKENHI [JP17K08648, JP18K07242, JP21K07105]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr. Kazuyoshi Yanagihara (National Cancer Center, Japan) for providing 44As3 and 58As9 cell lines. This work was supported by JSPS KAKENHI Grants Numbers JP17K08648, JP18K07242, and JP21K07105.	Aisen P, 2004, INT J BIOCHEM CELL B, V36, P2137, DOI 10.1016/j.biocel.2004.02.007; Bottcher RT, 2004, NAT CELL BIOL, V6, P38, DOI 10.1038/ncb1082; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010; Daniels TR, 2012, BBA-GEN SUBJECTS, V1820, P291, DOI 10.1016/j.bbagen.2011.07.016; Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362; FAULK WP, 1980, LANCET, V2, P390; GALBRAITH GMP, 1980, CELL IMMUNOL, V49, P215, DOI 10.1016/0008-8749(80)90072-6; GATTER KC, 1983, J CLIN PATHOL, V36, P539, DOI 10.1136/jcp.36.5.539; Hattori Y, 1996, CLIN CANCER RES, V2, P1373; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Jabara HH, 2016, NAT GENET, V48, P74, DOI 10.1038/ng.3465; Jian JL, 2011, J BIOL CHEM, V286, P35708, DOI 10.1074/jbc.M111.271585; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kawabata H, 2001, BLOOD, V98, P2714, DOI 10.1182/blood.V98.9.2714; Kovalenko D, 2003, J BIOL CHEM, V278, P14087, DOI 10.1074/jbc.C200606200; Kuang YB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1528-y; Kumar N, 2007, PLOS COMPUT BIOL, V3, P35, DOI 10.1371/journal.pcbi.0030004; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Liu YJ, 2014, BRIT J CANCER, V110, P1169, DOI 10.1038/bjc.2014.61; Mattiuzzi C, 2019, J EPIDEMIOL GLOB HEA, V9, P217, DOI 10.2991/jegh.k.191008.001; Nakamura K, 2006, GASTROENTEROLOGY, V131, P1530, DOI 10.1053/j.gastro.2006.08.030; NAKATANI H, 1990, JPN J CANCER RES, V81, P707, DOI 10.1111/j.1349-7006.1990.tb02631.x; NECKERS LM, 1986, CANCER INVEST, V4, P461, DOI 10.3109/07357908609017524; Porebska N, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010007; Qiu H, 2009, CANCER SCI, V100, P181, DOI 10.1111/j.1349-7006.2008.01004.x; Shen Y, 2018, AM J CANCER RES, V8, P916; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; TAETLE R, 1986, CANCER RES, V46, P1759; Torti SV, 2020, CANCER RES, V80, P5435, DOI 10.1158/0008-5472.CAN-20-2017; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Xue X, 2016, CELL METAB, V24, P447, DOI 10.1016/j.cmet.2016.07.015; Yamaguchi H, 2014, CANCER SCI, V105, P528, DOI 10.1111/cas.12387; Yanagihara K, 2005, CANCER SCI, V96, P323, DOI 10.1111/j.1349-7006.2005.00054.x; Yashiro M, 1996, CLIN EXP METASTAS, V14, P43, DOI 10.1007/BF00157685	45	2	2	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2587	2596		10.1038/s41388-022-02270-5	http://dx.doi.org/10.1038/s41388-022-02270-5		MAR 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35338344				2022-12-28	WOS:000780349900001
J	Zhao, D; Zheng, SL; Wang, XW; Liu, H; Zhao, KM; Li, L; Hu, Y				Zhao, Dong; Zheng, Shanliang; Wang, Xingwen; Liu, Hao; Zhao, Kunming; Li, Li; Hu, Ying			iASPP is essential for HIF-1 alpha stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; HYPOXIA-INDUCIBLE FACTORS; UP-REGULATION; EXPRESSION; RESISTANCE; CELLS; HIF-1; P53; REPRESSION; HIF1-ALPHA	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) plays central roles in the hypoxia response. It is highly expressed in multiple cancers, but not always correlated with hypoxia. Mutation of the von Hippel-Lindau (VHL) gene, which encodes an E3 ligase, contributes to the constructive activation of HIF-1 alpha in specific tumor types, as exemplified by renal cell carcinoma; but how VHL wild-type tumors acquire this ability is not completely understood. Here, we found that the oncogene iASPP (inhibitor of apoptosis-simulating protein of p53) plays essential roles in such a context. Genetic inhibition of iASPP reduced tumor growth, accompanied by impaired angiogenesis, increased areas of tumor necrosis, and reduced glycolysis that was HIF-1 alpha-dependent. These abilities of iASPP were validated by in vitro assays. Mechanistically, iASPP directly binds VHL at its beta domain, a region also involved in HIF-1 alpha binding, therefore blocking VHL's binding and the subsequent degradation of HIF-1 alpha protein under normoxia. iASPP levels correlate with HIF-1 alpha protein and vascular endothelial growth factor (VEGF) and the glucose transporter protein type 1(GLUT1), representative HIF-1 alpha target genes, in human colon cancer tissues. Furthermore, inhibition of iASPP expression synergizes with low toxic dose of the HIF-1 alpha inhibitor YC-1 to inhibit HIF-1 alpha expression and tumor growth. Our findings suggest that iASPP contributes to HIF-1 alpha activation in cancers, and that iASPP-mediated HIF-1 alpha stabilization has potential as a therapeutic approach against cancer.	[Zhao, Dong; Zheng, Shanliang; Wang, Xingwen; Liu, Hao; Zhao, Kunming; Hu, Ying] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Heilongjiang, Peoples R China; [Li, Li] Harbin Med Univ, Affiliated Hosp 3, Harbin 150040, Heilongjiang, Peoples R China	Harbin Institute of Technology; Harbin Medical University	Hu, Y (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Heilongjiang, Peoples R China.	huying@hit.edu.cn		Zhao, Dong/0000-0001-7214-6947	National Natural Science Foundation of China [82025027, 31871389, 31741084, 32000517]; China Postdoctoral Science Foundation [2020M680045, 2021T140161]; Nature Science Foundation of Heilongjiang Province [YQ2021C024]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Nature Science Foundation of Heilongjiang Province(Natural Science Foundation of Heilongjiang Province)	This work was funded by the National Natural Science Foundation of China (No. 82025027, 31871389, 31741084, 32000517), China Postdoctoral Science Foundation (No. 2020M680045 and 2021T140161), and the Nature Science Foundation of Heilongjiang Province (No. YQ2021C024).	Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029; Buckley DL, 2012, J AM CHEM SOC, V134, P4465, DOI 10.1021/ja209924v; Cai Y, 2012, APOPTOSIS, V17, P777, DOI 10.1007/s10495-012-0728-z; de Heer EC, 2020, J CLIN INVEST, V130, P5074, DOI 10.1172/JCI137552; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; De Saedeleer CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046571; Domene C, 2012, PROTEINS, V80, P733, DOI 10.1002/prot.23230; Du SC., 2019, CANCER CELL INT, V19; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Gao K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0561-6; Ge WJ, 2017, CANCER CELL, V32, P561, DOI 10.1016/j.ccell.2017.09.008; Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055; Ghosh AK, 2009, BLOOD, V113, P5568, DOI 10.1182/blood-2008-10-185686; Hoefflin R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17873-3; Hu Y, 2015, ONCOTARGET, V6, P42478, DOI 10.18632/oncotarget.6478; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jia YJ, 2014, FASEB J, V28, P2816, DOI 10.1096/fj.13-244632; Jiang LL, 2011, CLIN CANCER RES, V17, P6924, DOI 10.1158/1078-0432.CCR-11-0588; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kim JW, 2015, ANN SURG ONCOL, V22, P662, DOI 10.1245/s10434-014-4003-0; Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10347; Krzywinska E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01599-w; Kuczynski EA, 2019, NAT REV CLIN ONCOL, V16, P469, DOI 10.1038/s41571-019-0181-9; Kwon SJ, 2005, CLIN CANCER RES, V11, P7607, DOI 10.1158/1078-0432.CCR-05-0981; LaGory EL, 2016, NAT CELL BIOL, V18, P356, DOI 10.1038/ncb3330; Lang JY, 2019, ACS NANO, V13, P2176, DOI 10.1021/acsnano.8b08823; Lee P, 2020, NAT REV MOL CELL BIO, V21, P268, DOI 10.1038/s41580-020-0227-y; Lee YH, 2015, CLIN CANCER RES, V21, P1438, DOI 10.1158/1078-0432.CCR-14-1979; Li HY, 2020, J BIOL CHEM, V295, P4049, DOI 10.1074/jbc.RA119.011411; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Lu B, 2010, GASTROENTEROLOGY, V139, P2183, DOI 10.1053/j.gastro.2010.06.049; Lu M, 2016, CANCER CELL, V30, P822, DOI 10.1016/j.ccell.2016.09.019; Lu M, 2013, CANCER CELL, V23, P618, DOI 10.1016/j.ccr.2013.03.013; Luu VD, 2009, CLIN CANCER RES, V15, P3297, DOI 10.1158/1078-0432.CCR-08-2779; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Martinez-Reyes I, 2021, NAT REV CANCER, V21, P669, DOI 10.1038/s41568-021-00378-6; Mastrogiannaki M, 2009, J CLIN INVEST, V119, P1159, DOI 10.1172/JCI38499; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Merlo A, 2017, ONCOTARGET, V8, P1, DOI 10.18632/oncotarget.14265; Pandolfi S, 2015, CELL DEATH DIFFER, V22, P2006, DOI 10.1038/cdd.2015.56; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; Trigiante G, 2006, NAT REV CANCER, V6, P217, DOI 10.1038/nrc1818; Triner D, 2016, J CLIN INVEST, V126, P3689, DOI 10.1172/JCI84430; Xiong Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0520-6; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhao WH, 2013, INT J MOL MED, V32, P101, DOI 10.3892/ijmm.2013.1365; Zhong H, 1999, CANCER RES, V59, P5830	55	2	2	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1944	1958		10.1038/s41388-022-02234-9	http://dx.doi.org/10.1038/s41388-022-02234-9		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35169254				2022-12-28	WOS:000755405100001
J	Chen, B; Xu, F; Gao, Y; Hu, GS; Zhu, KL; Lu, HY; Xu, A; Chen, SP; Wu, LJ; Zhao, GP				Chen, Bin; Xu, Feng; Gao, Yang; Hu, Guanshuo; Zhu, Kaili; Lu, Huayi; Xu, An; Chen, Shaopeng; Wu, Lijun; Zhao, Guoping			DNA damage-induced translocation of mitochondrial factor HIGD1A into the nucleus regulates homologous recombination and radio/chemo-sensitivity	ONCOGENE			English	Article							STRAND BREAK REPAIR; PROTEIN-A RPA; REPLICATION; RAD51; IDENTIFICATION; INHIBITORS; DYNAMICS; SITES; SSDNA	HIGD1A is an important mitochondrial protein recently shown to have a novel nuclear localization under severe stress. However, whether this protein is also associated with the DNA damage response has rarely been studied. Here, we reported that DSBs-induced the translocation of mitochondrial HIGD1A to the nucleus is dependent on nuclear pore complex (NPCs), which finally promotes HR and radio/chemo-resistance. Importantly, NUP93 and HIGD1A physically interact and the interaction domain with NUP93 is located at residues 46-60 of HIGD1A. Chromatin-enriched HIGD1A can then directly interact with RPA. During the early stages of HR, HIGD1A promotes the loading of RPA to DSBs and activates the DNA damage-dependent chromatin association of RAD9-RAD1-HUS1 complex (9-1-1), which stimulates the ATR-Chk1-dependent G2/M DNA damage checkpoint. After facilitating RPA-ssDNA binding, HIGD1A in turn inhibits abnormal persistence of RPA1 foci by promoting ubiquitination of RPA1 and inducing its eventual proteasomal degradation. In addition, we have identified clinical drug Preveon associated with the HIGD1A-NUP93 interaction domain using a virtual screening approach. This compound directly interacted with HIGD1A, which was verified by NMR, and then inhibited HIGD1A translocation. Collectively, we demonstrate a novel role for HIGD1A in DSBs and provide rationale for using HIGD1A inhibitors as cancer therapeutics.	[Chen, Bin; Xu, Feng; Gao, Yang; Hu, Guanshuo; Zhu, Kaili; Xu, An; Chen, Shaopeng; Wu, Lijun; Zhao, Guoping] Chinese Acad Sci, High Magnet Field Lab, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Anhui, Peoples R China; [Chen, Bin; Xu, Feng; Gao, Yang; Hu, Guanshuo; Zhu, Kaili; Xu, An; Chen, Shaopeng; Wu, Lijun; Zhao, Guoping] Chinese Acad Sci, Hefei Inst Phys Sci, Anhui Prov Key Lab Environm Toxicol & Pollut Cont, Hefei 230031, Anhui, Peoples R China; [Chen, Bin; Xu, Feng; Gao, Yang; Hu, Guanshuo; Zhu, Kaili] Univ Sci & Technol China, Hefei 230026, Anhui, Peoples R China; [Lu, Huayi] Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, USTC, Hefei 230001, Anhui, Peoples R China; [Wu, Lijun] Anhui Univ, Inst Phys Sci, Informat Mat & Intelligent Sensing Lab Anhui Prov, Hefei 230601, Anhui, Peoples R China	Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui University; Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS	Zhao, GP (corresponding author), Chinese Acad Sci, High Magnet Field Lab, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Anhui, Peoples R China.	gpz@ipp.ac.cn		Zhao, Guoping/0000-0002-4691-3257	National Science Fund for Excellent Young Scholars [12122510]; National Natural Science Foundation of China [32171240, 11835014, 31870845]; HFIPS Director's Fund [YZJJZX202014]; CAS Pioneer Hundred Talents Program	National Science Fund for Excellent Young Scholars; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); HFIPS Director's Fund; CAS Pioneer Hundred Talents Program	This work was supported by the National Science Fund for Excellent Young Scholars (12122510), the National Natural Science Foundation of China (32171240, 11835014, and 31870845), the HFIPS Director's Fund (Grant No. YZJJZX202014) and the CAS Pioneer Hundred Talents Program (GZ).	Ameri K, 2015, CELL REP, V10, P891, DOI 10.1016/j.celrep.2015.01.020; Ameri K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062758; An HJ, 2013, P NATL ACAD SCI USA, V110, P13014, DOI 10.1073/pnas.1307170110; Basu A, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/201367; Brandsma Inger, 2012, Genome Integr, V3, P9, DOI 10.1186/2041-9414-3-9; Cheng ZH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02823-0; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Chuderland D, 2008, MOL CELL, V31, P850, DOI 10.1016/j.molcel.2008.08.007; Ci SS, 2020, FASEB J, V34, P10443, DOI 10.1096/fj.201902904RR; Damasceno JD, 2016, MOL MICROBIOL, V101, P1054, DOI 10.1111/mmi.13441; Dudas A, 2004, MUTAT RES-REV MUTAT, V566, P131, DOI 10.1016/j.mrrev.2003.07.001; Dueva Rositsa, 2020, NAR Cancer, V2, pzcaa022, DOI 10.1093/narcan/zcaa022; Hayashi H, 2012, FASEB J, V26, P2306, DOI 10.1096/fj.11-196063; Hayashi T, 2015, P NATL ACAD SCI USA, V112, P1553, DOI 10.1073/pnas.1419767112; Hsu DW, 2011, J CELL SCI, V124, P1655, DOI 10.1242/jcs.081471; Inano S, 2017, MOL CELL, V66, P622, DOI 10.1016/j.molcel.2017.04.022; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Klammt C, 2012, NAT METHODS, V9, P834, DOI [10.1038/NMETH.2033, 10.1038/nmeth.2033]; Kosova AA, 2017, BIOCHEMISTRY-MOSCOW+, V82, P643, DOI 10.1134/S0006297917060013; Lans H, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-4; Li T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6051262; Liu C, 2013, INT J MOL SCI, V14, P14225, DOI 10.3390/ijms140714225; Ma CJ, 2017, NUCLEIC ACIDS RES, V45, P749, DOI 10.1093/nar/gkw1125; Mohr D, 2009, EMBO J, V28, P2541, DOI 10.1038/emboj.2009.200; Nagao T, 2020, FASEB J, V34, P1859, DOI 10.1096/fj.201800389R; Nuss JE, 2005, BIOCHEMISTRY-US, V44, P8428, DOI 10.1021/bi0480584; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Pantano C, 2006, ANTIOXID REDOX SIGN, V8, P1791, DOI 10.1089/ars.2006.8.1791; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Pokhrel N, 2017, NUCLEIC ACIDS RES, V45, P9413, DOI 10.1093/nar/gkx598; Qian W, 2012, J CELL SCI, V125, P5745, DOI 10.1242/jcs.109769; Raynard S, 2008, GENE DEV, V22, P2903, DOI 10.1101/gad.1742408; Saldivar JC, 2017, NAT REV MOL CELL BIO, V18, P783, DOI 10.1038/nrm.2017.116; Shaughnessy DT, 2014, ENVIRON HEALTH PERSP, V122, P1271, DOI 10.1289/ehp.1408418; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Tang JB, 2010, MOL CANCER RES, V8, P67, DOI 10.1158/1541-7786.MCR-09-0411; Timon-Gomez A, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107607; Wassing IE, 2021, SEMIN CELL DEV BIOL, V113, P38, DOI 10.1016/j.semcdb.2020.08.010; WOZNIAK AJ, 1984, CANCER RES, V44, P626; Xu LM, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101604; Yang QY, 2017, P NATL ACAD SCI USA, V114, pE6054, DOI 10.1073/pnas.1700694114; Ying WH, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/691251; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zou Y, 2006, J CELL PHYSIOL, V208, P267, DOI 10.1002/jcp.20622	45	2	2	45	94	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1918	1930		10.1038/s41388-022-02226-9	http://dx.doi.org/10.1038/s41388-022-02226-9		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35152263				2022-12-28	WOS:000754368500002
J	Mazzu, YZ; Liao, YR; Nandakumar, S; Jehane, LE; Koche, RP; Rajanala, SH; Li, RF; Zhao, HY; Gerke, TA; Chakraborty, G; Lee, GSM; Nanjangud, GJ; Gopalan, A; Chen, Y; Kantoff, PW				Mazzu, Ying Z.; Liao, Yu-Rou; Nandakumar, Subhiksha; Jehane, Lina E.; Koche, Richard P.; Rajanala, Sai Harisha; Li, Ruifang; Zhao, HuiYong; Gerke, Travis A.; Chakraborty, Goutam; Lee, Gwo-Shu Mary; Nanjangud, Gouri J.; Gopalan, Anuradha; Chen, Yu; Kantoff, Philip W.			Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer	ONCOGENE			English	Article							ANDROGEN DEPRIVATION; RECEPTOR; TRANSCRIPTION; EXPRESSION; RESISTANCE; JAB1/CSN5; REVEALS; PATHWAY; JAB1	Chromosome 8q gain is associated with poor clinical outcomes in prostate cancer, but the underlying biological mechanisms remain to be clarified. CSN5, a putative androgen receptor (AR) partner that is located on chromosome 8q, is the key subunit of the COP9 signalosome, which deactivates ubiquitin ligases. Deregulation of CSN5 could affect diverse cellular functions that contribute to tumor development, but there has been no comprehensive study of its function in prostate cancer. The clinical significance of CSN5 amplification/overexpression was evaluated in 16 prostate cancer clinical cohorts. Its oncogenic activity was assessed by genetic and pharmacologic perturbations of CSN5 activity in prostate cancer cell lines. The molecular mechanisms of CSN5 function were assessed, as was the efficacy of the CSN5 inhibitor CSN5i-3 in vitro and in vivo. Finally, the transcription cofactor activity of CSN5 in prostate cancer cells was determined. The prognostic significance of CSN5 amplification and overexpression in prostate cancer was independent of MYC amplification. Inhibition of CSN5 inhibited its oncogenic function by targeting AR signaling, DNA repair, multiple oncogenic pathways, and spliceosome regulation. Furthermore, inhibition of CSN5 repressed metabolic pathways, including oxidative phosphorylation and glycolysis in AR-negative prostate cancer cells. Targeting CSN5 with CSN5i-3 showed potent antitumor activity in vitro and in vivo. Importantly, CSN5i-3 synergizes with PARP inhibitors to inhibit prostate cancer cell growth. CSN5 functions as a transcription cofactor to cooperate with multiple transcription factors in prostate cancer. Inhibiting CSN5 strongly attenuates prostate cancer progression and could enhance PARP inhibition efficacy in the treatment of prostate cancer.	[Mazzu, Ying Z.; Liao, Yu-Rou; Jehane, Lina E.; Rajanala, Sai Harisha; Chakraborty, Goutam; Chen, Yu; Kantoff, Philip W.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Nandakumar, Subhiksha] Mem Sloan Kettering Canc Ctr, Ctr Mol Oncol, 1275 York Ave, New York, NY 10021 USA; [Koche, Richard P.; Li, Ruifang] Mem Sloan Kettering Canc Ctr, Epigenet Innovat Lab, Ctr Epigenet Res, New York, NY 10065 USA; [Zhao, HuiYong] Mem Sloan Kettering Canc Ctr, Antitumor Assessment Core Facil, 1275 York Ave, New York, NY 10021 USA; [Gerke, Travis A.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Lee, Gwo-Shu Mary] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; [Nanjangud, Gouri J.] Mem Sloan Kettering Canc Ctr, Mol Cytogenet Core Facil, 1275 York Ave, New York, NY 10021 USA; [Gopalan, Anuradha] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Chen, Yu] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; H Lee Moffitt Cancer Center & Research Institute; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Mazzu, YZ; Kantoff, PW (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.	yingzmazzu@gmail.com; kantoffp@outlook.com		Mazzu, Ying/0000-0003-0265-6970	Department of Defense Prostate Cancer Research Program Translational Science Award [W81XWH-20-1-0114]; NIH/NCI Cancer Center Support Grant [P30 CA008748]	Department of Defense Prostate Cancer Research Program Translational Science Award(United States Department of Defense); NIH/NCI Cancer Center Support Grant	This research was funded by a Department of Defense Prostate Cancer Research Program Translational Science Award (W81XWH-20-1-0114 to P.W. Kantoff) and in part through the NIH/NCI Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748). We acknowledge that Eva Altmann from Novartis Institutes for BioMedical Research (Switzerland) kindly provided CSN5i-3 for the study; Lorelei A. Mucci from the Department of Epidemiology, Harvard T.H. Chan School of Public Health (Boston, Massachusetts) kindly provided information on the PHS/HPFS cohorts. We thank Margaret McPartland for editing and members of the Kantoff laboratory for help and discussion. This research was funded by a Department of Defense Prostate Cancer Research Program Translational Science Award (W81XWH-20-1-0114 to P.W. Kantoff) and in part through the NIH/NCI Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748).	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Adler AS, 2008, CANCER RES, V68, P506, DOI 10.1158/0008-5472.CAN-07-3060; Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Altomare DA, 2012, CURR MED CHEM, V19, P3748; Armenia J, 2019, NAT GENET, V51, P1194, DOI 10.1038/s41588-019-0451-6; Azad AA, 2015, EUR UROL, V67, P23, DOI 10.1016/j.eururo.2014.06.045; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Caggiano C, 2019, NUCLEIC ACIDS RES, V47, P6160, DOI 10.1093/nar/gkz344; Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Civenni G, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00385; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Danielpour D, 2019, BIOCHEM BIOPH RES CO, V518, P374, DOI 10.1016/j.bbrc.2019.08.066; Devlies W, 2021, CANCERS, V13, DOI 10.3390/cancers13040915; El Marabti E, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00080; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guo Z, 2019, GENE, V687, P219, DOI 10.1016/j.gene.2018.11.061; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hwang JH, 2019, CELL REP, V29, P2355, DOI 10.1016/j.celrep.2019.10.068; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; Kaya-Okur HS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09982-5; Liu GH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00135; Loriot Y, 2013, ANN ONCOL, V24, P1807, DOI 10.1093/annonc/mdt136; Lu RQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12044; Macoska JA, 2000, UROLOGY, V55, P776, DOI 10.1016/S0090-4295(00)00468-4; Mazzu YZ, 2019, CLIN CANCER RES, V25, P4480, DOI 10.1158/1078-0432.CCR-18-4046; Mullard A, 2020, NAT REV DRUG DISCOV, V19, P435, DOI 10.1038/d41573-020-00107-y; Nielsen T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-177; Nishimoto A, 2020, BIOCHEM BIOPH RES CO, V533, P548, DOI 10.1016/j.bbrc.2020.09.007; Pan YB, 2014, CANCER BIOL THER, V15, P256, DOI 10.4161/cbt.27823; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Phillips JW, 2020, P NATL ACAD SCI USA, V117, P5269, DOI 10.1073/pnas.1915975117; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sankpal UT, 2011, MED CHEM, V7, P518; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun Q, 2009, MOL ENDOCRINOL, V23, P2038, DOI 10.1210/me.2009-0092; Sveen A, 2016, ONCOGENE, V35, P2413, DOI 10.1038/onc.2015.318; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; You SY, 2016, CANCER RES, V76, P4948, DOI 10.1158/0008-5472.CAN-16-0902; Zhang D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16649-z; Zhao SG, 2017, JAMA ONCOL, V3, P1663, DOI 10.1001/jamaoncol.2017.0751; Zhou XC, 2020, NEOPLASIA, V22, P192, DOI 10.1016/j.neo.2020.02.002	50	0	0	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					671	682		10.1038/s41388-021-02118-4	http://dx.doi.org/10.1038/s41388-021-02118-4		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34802033	Green Accepted			2022-12-28	WOS:000720700200001
J	Shin, Y; Kim, S; Ghate, NB; Rhie, SK; An, W				Shin, Yonghwan; Kim, Sungmin; Ghate, Nikhil B.; Rhie, Suhn K.; An, Woojin			MMP-9 drives the melanomagenic transcription program through histone H3 tail proteolysis	ONCOGENE			English	Article							MATRIX METALLOPROTEINASES; MUTATIONS; INHIBITION; GENE; BRAF; PROGRESSION; CLEAVAGE; TRIGGERS; BIOLOGY; EZH2	Melanoma is a type of skin cancer that develops in pigment-producing melanocytes and often spreads to other parts of the body. Aberrant gene expression has been considered as a crucial step for increasing the risk of melanomagenesis, but how chromatin reorganization contributes to this pathogenic process is still not well understood. Here we report that matrix metalloproteinase 9 (MMP-9) localizes to the nucleus of melanoma cells and potentiates gene expression by proteolytically clipping the histone H3 N-terminal tail (H3NT). From genome-wide studies, we discovered that growth-regulatory genes are selectively targeted and activated by MMP-9-dependent H3NT proteolysis in melanoma cells. MMP-9 cooperates functionally with p300/CBP because MMP-9 cleaves H3NT in a manner that is dependent on p300/CBP-mediated acetylation of H3K18. The functional significance of MMP-9-dependent H3NT proteolysis is further underscored by the fact that RNAi knockdown and small-molecule inhibition of MMP-9 and p300/CBP impede melanomagenic gene expression and melanoma tumor growth. Together, our data establish new functions and mechanisms for nuclear MMP-9 in promoting melanomagenesis and demonstrate how MMP-9-dependent H3NT proteolysis can be exploited to prevent and treat melanoma skin cancer.	[Shin, Yonghwan; Kim, Sungmin; Ghate, Nikhil B.; Rhie, Suhn K.; An, Woojin] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Med, Los Angeles, CA 90033 USA	University of Southern California	An, W (corresponding author), Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Med, Los Angeles, CA 90033 USA.	woojinan@usc.edu		Rhie, Suhn/0000-0002-5522-5296; Kim, Sungmin/0000-0001-5873-6430	NIH [AR073233, P30CA014089]; National Cancer Institute	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant AR073233 awarded to WA. The study was also partly supported by award number P30CA014089 from the National Cancer Institute.	Agrawal A, 2008, CHEMMEDCHEM, V3, P812, DOI 10.1002/cmdc.200700290; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Boissy RE, 1997, PIGM CELL RES, V10, P12, DOI 10.1111/j.1600-0749.1997.tb00461.x; Bruschi F, 2013, PATHOGENS, V2, P105, DOI 10.3390/pathogens2010105; Chen HX, 2014, J INVEST DERMATOL, V134, P2080, DOI 10.1038/jid.2014.161; Daura E, 2021, NEUROBIOL DIS, V156, DOI 10.1016/j.nbd.2021.105418; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ding L, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00417-z; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dong JL, 2003, CANCER RES, V63, P3883; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Faiao-Flores F, 2019, CLIN CANCER RES, V25, P5686, DOI 10.1158/1078-0432.CCR-18-3382; Ferrari KJ, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkaa1228; Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955; Fu CH, 2020, MOL MED REP, V21, P1421, DOI 10.3892/mmr.2020.10950; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Guarneri C, 2017, ONCOL REP, V37, P737, DOI 10.3892/or.2017.5362; Hoffmann F, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-0818-7; Kim E, 2019, CANCER RES, V79, P2649, DOI 10.1158/0008-5472.CAN-18-2331; Kim JM, 2018, ONCOGENE, V37, P5749, DOI 10.1038/s41388-018-0356-3; Kim K, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0193-1; Kim K, 2016, GENE DEV, V30, P208, DOI 10.1101/gad.268714.115; Kim K, 2013, MOL CELL, V52, P459, DOI 10.1016/j.molcel.2013.09.017; Klein T, 2011, AMINO ACIDS, V41, P271, DOI 10.1007/s00726-010-0689-x; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; Lue JK, 2019, CLIN CANCER RES, V25, P5271, DOI 10.1158/1078-0432.CCR-18-3989; Mahmoud F, 2016, CANCER BIOL THER, V17, P579, DOI 10.1080/15384047.2016.1167291; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Napoli S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051151; Papazafiropoulou A, 2009, HIPPOKRATIA, V13, P76; Rangaswami H, 2007, ONCOL REP, V18, P909; Rice JC, 2021, EPIGENET CHROMATIN, V14, DOI 10.1186/s13072-021-00398-4; Santos MCLG, 2004, J ORAL REHABIL, V31, P660, DOI 10.1111/j.1365-2842.2004.01297.x; Shen J, 2017, EMBO REP, V18, P2131, DOI 10.15252/embr.201743892; Shin Y, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0270-0; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Vargova Viola, 2012, Exp Suppl, V103, P1, DOI 10.1007/978-3-0348-0364-9_1; Wang R, 2018, MOL CANCER THER, V17, P2543, DOI 10.1158/1535-7163.MCT-18-0511; Wilmott JS, 2015, MODERN PATHOL, V28, P884, DOI 10.1038/modpathol.2015.34; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003; Zhao XB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023409; Zhou SH, 2021, AGEING RES REV, V69, DOI 10.1016/j.arr.2021.101349	46	3	3	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					560	570		10.1038/s41388-021-02109-5	http://dx.doi.org/10.1038/s41388-021-02109-5		NOV 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785776				2022-12-28	WOS:000719277200005
J	Leon, F; Seshacharyulu, P; Nimmakayala, RK; Chugh, S; Karmakar, S; Nallasamy, P; Vengoji, R; Rachagani, S; Cox, JL; Mallya, K; Batra, SK; Ponnusamy, MP				Leon, Frank; Seshacharyulu, Parthasarathy; Nimmakayala, Rama K.; Chugh, Seema; Karmakar, Saswati; Nallasamy, Palanisamy; Vengoji, Raghupathy; Rachagani, Satyanarayana; Cox, Jesse L.; Mallya, Kavita; Batra, Surinder K.; Ponnusamy, Moorthy P.			Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer	ONCOGENE			English	Article							SELF-RENEWAL; CELLS; BREAST; TUMORIGENICITY; PROGRESSION; EXPRESSION; RESISTANCE; INITIATION; NANOG	Aberrant protein glycosylation has been shown to have a significant contribution in aggressive cancer, including pancreatic cancer (PC). Emerging evidence has implicated the involvement of cancer stem cells (CSCs) in PC aggressiveness; however, the contribution of glycosylation on self-renewal properties and maintenance of CSC is understudied. Here, using several in vitro and in vivo models lacking C1GALT1 expression, we identified the role of aberrant O-glycosylation in stemness properties and aggressive PC metastasis. A loss in C1GALT1 was found to result in the truncation of O-glycosylation on several glycoproteins with an enrichment of Tn carbohydrate antigen. Mapping of Tn-bearing glycoproteins in C1GALT1 KO cells identified significant Tn enrichment on CSC glycoprotein CD44. Notably, a loss of C1GALT1 in PC cells was found to enhance CSC features (side population-SP, ALDH1+, and tumorspheres) and self-renewal markers NANOG, SOX9, and KLF4. Furthermore, a loss of CD44 in existing C1GALT1 KO cells decreased NANOG expression and CSC features. We determined that O-glycosylation of CD44 activates ERK/NF-kB signaling, which results in increased NANOG expression in PC cells that facilitated the alteration of CSC features, suggesting that NANOG is essential for PC stemness. Finally, we identified that loss of C1GALT1 expression was found to augment tumorigenic and metastatic potential, while an additional loss of CD44 in these cells reversed the effects. Overall, our results identified that truncation of O-glycans on CD44 increases NANOG activation that mediates increased CSC activation.	[Leon, Frank; Seshacharyulu, Parthasarathy; Nimmakayala, Rama K.; Chugh, Seema; Karmakar, Saswati; Nallasamy, Palanisamy; Vengoji, Raghupathy; Rachagani, Satyanarayana; Mallya, Kavita; Batra, Surinder K.; Ponnusamy, Moorthy P.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Cox, Jesse L.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Batra, Surinder K.; Ponnusamy, Moorthy P.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Batra, Surinder K.; Ponnusamy, Moorthy P.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK; Ponnusamy, MP (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Batra, SK; Ponnusamy, MP (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.; Batra, SK; Ponnusamy, MP (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu; mpalanim@unmc.edu	Nimmakayala, Rama Krishna/CAG-5670-2022; Seshacharyulu, Parthasarathy/AGL-7648-2022; Nallasamy, Palanisamy/AAH-7727-2021	Nimmakayala, Rama Krishna/0000-0003-4637-4828; Seshacharyulu, Parthasarathy/0000-0002-2348-3901; Nallasamy, Palanisamy/0000-0001-8962-2487	National Institutes of Health [R01 CA210637, R01 CA206444, P01 CA217798, U01 CA200466, U01 CA210240]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Craig Semerad, Victoria B. Smith, and Samantha Wall of the Flow Cytometry Research Facility, University of Nebraska Medical Center, for assisting with flow cytometry. We thank Janice A. Taylor and James R. Talaska of the Advanced Microscopy Core Facility at the University of Nebraska Medical Center for assisting with confocal microscopy. Further, we thank Dr. Vikas Kumar and Dr. Dragana Lagundin, of the Mass Spectrometry and Proteomics Core Facility at the University of Nebraska Medical Center, for assisting with proteomics. Lastly, we thank Corinn E. Grabow for assistance in technical support. We were supported primarily by the following grants from the National Institutes of Health R01 CA210637, R01 CA206444, P01 CA217798, U01 CA200466, and U01 CA210240. The authors/work in this article were supported, in parts, by the following grants from the National Institutes of Health (R01 CA210637, R01 CA206444, P01 CA217798, U01 CA200466, and U01 CA210240).	Abel EV, 2013, GASTROENTEROLOGY, V144, P1241, DOI 10.1053/j.gastro.2013.01.072; Alison MR, 2011, J PATHOL, V223, P147, DOI 10.1002/path.2793; Barkeer S, 2018, NEOPLASIA, V20, P813, DOI 10.1016/j.neo.2018.06.001; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Chia J, 2016, BBA-GEN SUBJECTS, V1860, P1623, DOI 10.1016/j.bbagen.2016.03.008; Chugh S, 2018, GASTROENTEROLOGY, V155, P1608, DOI 10.1053/j.gastro.2018.08.007; Chugh S, 2016, BRIT J CANCER, V114, P1376, DOI 10.1038/bjc.2016.116; Cummings RD, 2019, GLYCOCONJUGATE J, V36, P241, DOI 10.1007/s10719-019-09876-0; de Beca FF, 2013, J CLIN PATHOL, V66, P187, DOI 10.1136/jclinpath-2012-201169; Dorsett KA, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0574-5; Es-haghi M, 2016, TUMOR BIOL, V37, P1559, DOI 10.1007/s13277-015-4690-6; Fang RP, 2020, ONCOGENE, V39, P2290, DOI 10.1038/s41388-019-1146-2; Feitelson MA, 2015, SEMIN CANCER BIOL, V35, pS25, DOI 10.1016/j.semcancer.2015.02.006; Freitas D, 2019, EBIOMEDICINE, V40, P349, DOI 10.1016/j.ebiom.2019.01.017; Ghantous A, 2013, DRUG DISCOV TODAY, V18, P894, DOI 10.1016/j.drudis.2013.05.005; Gill DJ, 2013, P NATL ACAD SCI USA, V110, pE3152, DOI 10.1073/pnas.1305269110; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gupta R, 2020, BRIT J CANCER, V122, P1661, DOI 10.1038/s41416-020-0772-3; Ju TZ, 2011, ANGEW CHEM INT EDIT, V50, P1770, DOI 10.1002/anie.201002313; Kaltschmidt C, 2019, CANCERS, V11, DOI 10.3390/cancers11050655; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li WZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14364-2; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Mimeault M, 2014, CANCER EPIDEM BIOMAR, V23, P234, DOI 10.1158/1055-9965.EPI-13-0785; Nimmakayala RK, 2019, BBA-REV CANCER, V1871, P50, DOI 10.1016/j.bbcan.2018.10.006; Nimmakayala RK, 2018, GASTROENTEROLOGY, V155, P892, DOI 10.1053/j.gastro.2018.05.041; Radhakrishnan P, 2014, P NATL ACAD SCI USA, V111, pE4066, DOI 10.1073/pnas.1406619111; Remmers N, 2013, CLIN CANCER RES, V19, P1981, DOI 10.1158/1078-0432.CCR-12-2662; Rinkenbaugh AL, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020016; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Schultz MJ, 2016, CANCER RES, V76, P3978, DOI 10.1158/0008-5472.CAN-15-2834; Scott E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061389; Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79; Stowell SR, 2015, ANNU REV PATHOL-MECH, V10, P473, DOI 10.1146/annurev-pathol-012414-040438; Thomas D, 2019, J CELL MOL MED, V23, P6885, DOI 10.1111/jcmm.14572; Trinchera M, 2017, BIOLOGY-BASEL, V6, DOI 10.3390/biology6010016; Vaz AP, 2014, BRIT J CANCER, V111, P486, DOI 10.1038/bjc.2014.152; Vaz AP, 2016, ONCOTARGET, V7, P3307, DOI 10.18632/oncotarget.6580; Wang L, 2018, METHODS MOL BIOL, V1692, P31, DOI 10.1007/978-1-4939-7401-6_3; Zakaria N, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00166; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	42	3	3	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					57	71		10.1038/s41388-021-02047-2	http://dx.doi.org/10.1038/s41388-021-02047-2		OCT 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34675409	Green Accepted			2022-12-28	WOS:000709687900002
J	Bolado-Carrancio, A; Lee, M; Ewing, A; Muir, M; Macleod, KG; Gallagher, WM; Nguyen, LK; Carragher, NO; Semple, CA; Brunton, VG; Caswell, PT; von Kriegsheim, A				Bolado-Carrancio, Alfonso; Lee, Martin; Ewing, Ailith; Muir, Morwenna; Macleod, Kenneth G.; Gallagher, William M.; Nguyen, Lan K.; Carragher, Neil O.; Semple, Colin A.; Brunton, Valerie G.; Caswell, Patrick T.; von Kriegsheim, Alex			ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling	ONCOGENE			English	Article							UBIQUITIN-LIKE PROTEIN; ISG15 CONJUGATION; EARLY ENDOSOMES; 15-KDA PROTEIN; CELL-MIGRATION; IN-VITRO; CANCER; EXPRESSION; ACTIVATION; UBP43	ISG15 is an ubiquitin-like modifier that is associated with reduced survival rates in breast cancer patients. The mechanism by which ISG15 achieves this however remains elusive. We demonstrate that modification of Rab GDP-Dissociation Inhibitor Beta (GDI2) by ISG15 (ISGylation) alters endocytic recycling of the EGF receptor (EGFR) in non-interferon stimulated cells using CRISPR-knock out models for ISGylation. By regulating EGFR trafficking, ISGylation enhances EGFR recycling and sustains Akt-signalling. We further show that Akt signalling positively correlates with levels of ISG15 and its E2-ligase in basal breast cancer cohorts, confirming the link between ISGylation and Akt signalling in human tumours. Persistent and enhanced Akt activation explains the more aggressive tumour behaviour observed in human breast cancers. We show that ISGylation can act as a driver of tumour progression rather than merely being a bystander.	[Bolado-Carrancio, Alfonso; Lee, Martin; Muir, Morwenna; Macleod, Kenneth G.; Carragher, Neil O.; Brunton, Valerie G.; von Kriegsheim, Alex] Univ Edinburgh, Inst Genet & Canc, Edinburgh Canc Res Ctr, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland; [Ewing, Ailith] Univ Edinburgh, Inst Genet & Canc, MRC Human Genet Unit, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland; [Gallagher, William M.] Univ Coll Dublin, UCD Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin D4, Ireland; [Nguyen, Lan K.] Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia; [Caswell, Patrick T.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Wellcome Trust Ctr Cell Matrix Res, Fac Biol Med & Hlth,Sch Biol Sci, Manchester, Lancs, England	University of Edinburgh; University of Edinburgh; University College Dublin; Monash University; University of Manchester	von Kriegsheim, A (corresponding author), Univ Edinburgh, Inst Genet & Canc, Edinburgh Canc Res Ctr, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland.	alex.vonkriegsheim@IGMM.ed.ac.uk	MacLeod, Kenneth/GWU-8940-2022; Lee, Martin/K-8682-2015	Lee, Martin/0000-0001-6529-5784; Bolado-Carrancio, Alfonso/0000-0003-2330-7489	Breast Cancer NOW [2013NovPR183]; Cancer Research UK (CRUK) [C157/A255140, C157/A24837]; Wellcome Trust [208402/Z/17/Z, 203128/A/16/Z]; MRC [MC_UU_00007/16, MR/R009376/1]; Worldwide Cancer Research [14-1226]; Australia's Victorian Cancer Agency [MCRF18026]; BREAST-PREDICT (CCRC13GAL); Science Foundation Ireland [15/IA/3104]	Breast Cancer NOW; Cancer Research UK (CRUK)(Cancer Research UK); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Worldwide Cancer Research; Australia's Victorian Cancer Agency; BREAST-PREDICT (CCRC13GAL); Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	We thank Ana Herrero for help with the cellular fractionation method, Breast Cancer NOW (2013NovPR183), Cancer Research UK. Cancer Research UK (CRUK Edinburgh Centre C157/A255140 & C157/A24837), Wellcome Trust (Multiuser Equipment Grant, 208402/Z/17/Z & Centre for Cell-Matrix Research 203128/A/16/Z), MRC (core funding to the MRC Human Genetics Unit MRC grant MC_UU_00007/16 & MR/R009376/1), Worldwide Cancer Research (14-1226), Australia's Victorian Cancer Agency (MCRF18026), BREAST-PREDICT (CCRC13GAL) and Science Foundation Ireland (15/IA/3104) for funding.	Andersen JB, 2006, BRIT J CANCER, V94, P1465, DOI 10.1038/sj.bjc.6603099; Ankney JA, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0530-7; Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Burks J, 2014, ONCOGENE, V33, P794, DOI 10.1038/onc.2012.633; Burks J, 2015, ONCOTARGET, V6, P7221, DOI 10.18632/oncotarget.3372; Butti R, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0797-x; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Cerikan B, 2016, DEV CELL, V39, P28, DOI 10.1016/j.devcel.2016.08.020; Creighton CJ, 2007, ONCOGENE, V26, P4648, DOI 10.1038/sj.onc.1210245; DCunha J, 1996, J IMMUNOL, V157, P4100; de Graauw M, 2014, ONCOGENE, V33, P2610, DOI 10.1038/onc.2013.219; Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123; Desai SD, 2012, EXP BIOL MED, V237, P38, DOI 10.1258/ebm.2011.011236; Farrell J, 2014, J PROTEOME RES, V13, P2874, DOI 10.1021/pr5000285; Frittoli E, 2014, J CELL BIOL, V206, P307, DOI 10.1083/jcb.201403127; Giannakopoulos NV, 2005, BIOCHEM BIOPH RES CO, V336, P496, DOI 10.1016/j.bbrc.2005.08.132; Gilbert PM, 2001, J BIOL CHEM, V276, P8014, DOI 10.1074/jbc.M008845200; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hermann M, 2017, TRENDS IMMUNOL, V38, P79, DOI 10.1016/j.it.2016.11.001; Huang YF, 2014, CELL CYCLE, V13, P2200, DOI 10.4161/cc.29209; Jeon YJ, 2009, EMBO REP, V10, P374, DOI 10.1038/embor.2009.23; Kiessling A, 2009, ONCOGENE, V28, P2606, DOI 10.1038/onc.2009.115; KNIGHT E, 1991, J IMMUNOL, V146, P2280; KORANT BD, 1984, J BIOL CHEM, V259, P4835; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Li C, 2014, ONCOTARGET, V5, P8429, DOI 10.18632/oncotarget.2316; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Luan P, 2000, TRAFFIC, V1, P270, DOI 10.1034/j.1600-0854.2000.010309.x; Mackenzie KJ, 2017, NATURE, V548, P461, DOI 10.1038/nature23449; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Malakhova O, 2002, J BIOL CHEM, V277, P14703, DOI 10.1074/jbc.M111527200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; Malakhova OA, 2006, EMBO J, V25, P2358, DOI 10.1038/sj.emboj.7601149; Masuda H, 2012, BREAST CANCER RES TR, V136, P331, DOI 10.1007/s10549-012-2289-9; Morales DJ, 2013, J MOL BIOL, V425, P4995, DOI 10.1016/j.jmb.2013.09.041; Mustachio LM, 2017, ONCOTARGET, V8, P3, DOI 10.18632/oncotarget.13914; Nabet BY, 2017, CELL, V170, P352, DOI 10.1016/j.cell.2017.06.031; Nishimura Y, 2015, INT J ONCOL, V46, P1721, DOI 10.3892/ijo.2015.2871; Padovan E, 2002, CANCER RES, V62, P3453; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354; Shin J, 2016, CANCER SCI, V107, P828, DOI 10.1111/cas.12935; Shisheva A, 1999, BIOCHEMISTRY-US, V38, P11711, DOI 10.1021/bi990200r; Sivan G, 2016, J VIROL, V90, P8891, DOI 10.1128/JVI.01114-16; Sooryanarain H, 2017, J VIROL, V91, DOI 10.1128/JVI.00621-17; Takeuchi T, 2005, J BIOCHEM, V138, P711, DOI 10.1093/jb/mvi172; Talvinen K, 2006, ANTICANCER RES, V26, P4745; Turriziani Benedetta, 2014, Biology (Basel), V3, P320, DOI 10.3390/biology3020320; Villarreal DO, 2015, MOL THER, V23, P1653, DOI 10.1038/mt.2015.120; Villarroya-Beltri C, 2017, J CELL SCI, V130, P2961, DOI 10.1242/jcs.205468; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Yang PS, 2011, CANCER SCI, V102, P2172, DOI 10.1111/j.1349-7006.2011.02089.x; Yanguez E, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003632; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhang YF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13393-x; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102	64	4	4	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6235	6247		10.1038/s41388-021-02017-8	http://dx.doi.org/10.1038/s41388-021-02017-8		SEP 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34556814	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000698556400003
J	Blazquez, R; Chuang, HN; Wenske, B; Trigueros, L; Wlochowitz, D; Liguori, R; Ferrazzi, F; Regen, T; Proescholdt, MA; Rohde, V; Riemenschneider, MJ; Stadelmann, C; Bleckmann, A; Beissbarth, T; van Rossum, D; Hanisch, UK; Pukrop, T				Blazquez, Raquel; Chuang, Han-Ning; Wenske, Britta; Trigueros, Laura; Wlochowitz, Darius; Liguori, Renato; Ferrazzi, Fulvia; Regen, Tommy; Proescholdt, Martin A.; Rohde, Veit; Riemenschneider, Markus J.; Stadelmann, Christine; Bleckmann, Annalen; Beissbarth, Tim; van Rossum, Denise; Hanisch, Uwe K.; Pukrop, Tobias			Intralesional TLR4 agonist treatment strengthens the organ defense against colonizing cancer cells in the brain	ONCOGENE			English	Article							BREAST-CANCER; NITRIC-OXIDE; PROMOTES; RECEPTOR; METASTASIS; MICROENVIRONMENT; INTERFACE; TISSUE; GENE	Brain metastasis in breast cancer remains difficult to treat and its incidence is increasing. Therefore, the development of new therapies is of utmost clinical relevance. Recently, toll-like receptor (TLR) 4 was correlated with IL6 expression and poor prognosis in 1 215 breast cancer primaries. In contrast, we demonstrated that TLR4 stimulation reduces microglia-assisted breast cancer cell invasion. However, the expression, prognostic value, or therapeutic potential of TLR signaling in breast cancer brain metastasis have not been investigated. We thus tested the prognostic value of various TLRs in two brain-metastasis gene sets. Furthermore, we investigated different TLR agonists, as well as MyD88 and TRIF-deficient microenvironments in organotypic brain-slice ex vivo co-cultures and in vivo colonization experiments. These experiments underline the ambiguous roles of TLR4, its adapter MyD88, and the target nitric oxide (NO) during brain colonization. Moreover, analysis of the gene expression datasets of breast cancer brain metastasis patients revealed associations of TLR1 and IL6 with poor overall survival. Finally, our finding that a single LPS application at the onset of colonization shapes the later microglia/macrophage reaction at the macro-metastasis brain-parenchyma interface (MMPI) and reduces metastatic infiltration into the brain parenchyma may prove useful in immunotherapeutic considerations.	[Blazquez, Raquel; Trigueros, Laura; Pukrop, Tobias] Univ Hosp Regensburg, Dept Internal Med 3, Hematol & Med Oncol, D-93053 Regensburg, Germany; [Blazquez, Raquel; Chuang, Han-Ning; Wenske, Britta; Bleckmann, Annalen; Pukrop, Tobias] Univ Med Ctr Gottingen, Dept Hematol & Med Oncol, D-37075 Gottingen, Germany; [Wlochowitz, Darius; Beissbarth, Tim] Georg August Univ, Univ Med Ctr Gottingen, Inst Med Bioinformat, D-37075 Gottingen, Germany; [Liguori, Renato; Ferrazzi, Fulvia] Friedrich Alexander Univ Erlangen Nurnberg, Inst Pathol, D-91054 Erlangen, Germany; [Liguori, Renato; Ferrazzi, Fulvia] Friedrich Alexander Univ Erlangen Nurnberg, Dept Nephropathol, Inst Pathol, D-91054 Erlangen, Germany; [Regen, Tommy; Stadelmann, Christine; van Rossum, Denise; Hanisch, Uwe K.] Univ Med Ctr Gottingen, Inst Neuropathol, D-37075 Gottingen, Germany; [Regen, Tommy] Johannes Gutenberg Univ Mainz, Univ Med Ctr, D-55131 Mainz, Germany; [Proescholdt, Martin A.] Univ Hosp Regensburg, Dept Neurosurg, D-93053 Regensburg, Germany; [Rohde, Veit] Univ Med Ctr Gottingen, Dept Neurosurg, D-37075 Gottingen, Germany; [Riemenschneider, Markus J.] Univ Hosp Regensburg, Dept Neuropathol, D-93053 Regensburg, Germany; [Bleckmann, Annalen] Univ Hosp Munster, Dept Med Hematol Oncol & Pneumol A, D-48149 Munster, Germany; [van Rossum, Denise] Sartorius Canada Inc, Oakville, ON L6M 2V9, Canada; [Pukrop, Tobias] Fraunhofer Inst Toxicol & Expt Med, Div Personalized Tumor Therapy, D-93053 Regensburg, Germany	University of Regensburg; University of Gottingen; University of Gottingen; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Gottingen; Johannes Gutenberg University of Mainz; University of Regensburg; University of Gottingen; University of Regensburg; University of Munster; Fraunhofer Gesellschaft	Pukrop, T (corresponding author), Univ Hosp Regensburg, Dept Internal Med 3, Hematol & Med Oncol, D-93053 Regensburg, Germany.; Pukrop, T (corresponding author), Univ Med Ctr Gottingen, Dept Hematol & Med Oncol, D-37075 Gottingen, Germany.; Pukrop, T (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Div Personalized Tumor Therapy, D-93053 Regensburg, Germany.	tobias.pukrop@ukr.de		Liguori, Renato/0000-0002-5704-9409	Deutsche Forschungsgemeinschaft [DFG PU 355/4-1, FOR2127 (PU 355/5-1), SFB/TRR 305/1]; German Federal Ministry of Education and Research (BMBF) [0316173C, 031L0024]; DFG [INST 89/506-1 FUGG]; Projekt DEAL	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); DFG(German Research Foundation (DFG)); Projekt DEAL	This work was supported by the Deutsche Forschungsgemeinschaft projects DFG PU 355/4-1, FOR2127 (PU 355/5-1) and SFB/TRR 305/1 (B03 and Z01); and the German Federal Ministry of Education and Research (BMBF) projects e:Bio MetastaSys on the platform Medical Systems (0316173C) and e:Med MyPathSem (031L0024). The FV3000 confocal microscope was also funded by a grant (INST 89/506-1 FUGG, 91b GG) from the DFG. Open Access funding enabled and organized by Projekt DEAL.	Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Bhatia S, 2019, CLIN CANCER RES, V25, P1185, DOI 10.1158/1078-0432.CCR-18-0469; Blazquez R, 2020, SEMIN CANCER BIOL, V60, P324, DOI 10.1016/j.semcancer.2019.10.012; Blazquez R, 2018, GLIA, V66, P2438, DOI 10.1002/glia.23485; Blazquez R, 2017, METHODS MOL BIOL, V1612, P213, DOI 10.1007/978-1-4939-7021-6_16; Cheng HW, 2014, CANCER LETT, V353, P1, DOI 10.1016/j.canlet.2014.07.014; Chuang HN, 2013, JOVE-J VIS EXP, DOI 10.3791/50881; Chuang HN, 2013, GLIA, V61, P1331, DOI 10.1002/glia.22518; COLEY WB, 1991, CLIN ORTHOP RELAT R, P3; Cosgrove N, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-27987-5; Drexler SK, 2010, INT J BIOCHEM CELL B, V42, P506, DOI 10.1016/j.biocel.2009.10.009; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Nunez NG, 2012, CANCER RES, V72, P592, DOI 10.1158/0008-5472.CAN-11-0534; Hajal C, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg8139; Heinecke JL, 2014, P NATL ACAD SCI USA, V111, P6323, DOI 10.1073/pnas.1401799111; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Hu F, 2015, NEURO-ONCOLOGY, V17, P200, DOI 10.1093/neuonc/nou324; Jang GY, 2020, EXP MOL MED, V52, P1926, DOI 10.1038/s12276-020-00540-4; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Klemm F, 2011, CARCINOGENESIS, V32, P434, DOI 10.1093/carcin/bgq269; Kudo Y, 2019, ANN ONCOL, V30, P1521, DOI 10.1093/annonc/mdz207; Lechner M, 2005, SEMIN CANCER BIOL, V15, P277, DOI 10.1016/j.semcancer.2005.04.004; Lee CH, 2010, J IMMUNOTHER, V33, P73, DOI 10.1097/CJI.0b013e3181b7a0a4; Lee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847; Li YPD, 2019, CANCER IMMUNOL IMMUN, V68, P1501, DOI 10.1007/s00262-019-02384-y; Lin XL, 2015, J CLIN ONCOL, V33, P3475, DOI 10.1200/JCO.2015.60.9503; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; Pukrop T, 2010, GLIA, V58, P1477, DOI 10.1002/glia.21022; Regen T, 2011, BRAIN BEHAV IMMUN, V25, P957, DOI 10.1016/j.bbi.2010.10.009; Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27; Rostami R, 2016, J NEURO-ONCOL, V127, P407, DOI 10.1007/s11060-016-2075-3; Sanmarco LM, 2021, J EXP MED, V218, DOI 10.1084/jem.20202715; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schulz M, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101178; Shi SX, 2020, MOL MED REP, V21, P786, DOI 10.3892/mmr.2019.10853; Siam L, 2015, ONCOTARGET, V6, P29254, DOI 10.18632/oncotarget.4201; Somaiah N, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.11006; Steeg PS, 2011, NAT REV CANCER, V11, P352, DOI 10.1038/nrc3053; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tehranian C, 2022, NEURO-ONCOLOGY, V24, P213, DOI 10.1093/neuonc/noab159; Tumurkhuu G, 2010, CELL IMMUNOL, V261, P122, DOI 10.1016/j.cellimm.2009.11.009; Weiss JM, 2010, J EXP MED, V207, P2455, DOI 10.1084/jem.20100670; Werner-Klein M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18701-4; Yu LX, 2010, HEPATOLOGY, V52, P1322, DOI 10.1002/hep.23845	45	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					5008	5019		10.1038/s41388-022-02496-3	http://dx.doi.org/10.1038/s41388-022-02496-3		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36224342	hybrid, Green Published			2022-12-28	WOS:000866316700002
J	Kang, S; Wang, LX; Xu, L; Wang, RQ; Kang, QZ; Gao, XF; Yu, L				Kang, Synat; Wang, Lixin; Xu, Lu; Wang, Ruiqi; Kang, Qingzheng; Gao, Xuefeng; Yu, Li			Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype	ONCOGENE			English	Article							CANCER-TESTIS ANTIGEN; ACUTE MYELOID-LEUKEMIA; DNA METHYLTRANSFERASE; EPIGENETIC MODULATION; EXPRESSION; METHYLATION; LYMPHOCYTES; INDUCTION; IMMUNOTHERAPY; AZACITIDINE	NY-ESO-1 is a well-known cancer-testis antigen (CTA) with re-expression in numerous cancer types, but its expression is suppressed in myeloid leukemia cells. Patients with acute myeloid leukemia (AML) receiving decitabine (DAC) exhibit induced expression of NY-ESO-1 in blasts; thus, we investigated the effects of NY-ESO-1-specific TCR-engineered T (TCR-T) cells combined with DAC against AML. NY-ESO-1-specific TCR-T cells could efficiently eliminate AML cell lines (including U937, HL60, and Kasumi-1cells) and primary AML blasts in vitro by targeting the DAC-induced NY-ESO-1 expression. Moreover, the incubation of T cells with DAC during TCR transduction (designated as dTCR-T cells) could further enhance the anti-leukemia efficacy of TCR-T cells and increase the generation of memory-like phenotype. The combination of DAC with NY-ESO-1-specific dTCR-T cells showed a superior anti-tumor efficacy in vivo and prolonged the survival of an AML xenograft mouse model, with three out of five mice showing complete elimination of AML cells over 90 days. This outcome was correlated with enhanced expressions of IFN-gamma and TNF-alpha, and an increased proportion of central memory T cells (CD45RO(+)CD62L(+) and CD45RO(+)CCR7(+)). Taken together, these data provide preclinical evidence for the combined use of DAC and NY-ESO-1-specific dTCR-T cells for the treatment of AML.	[Kang, Synat; Wang, Lixin; Xu, Lu; Kang, Qingzheng; Gao, Xuefeng; Yu, Li] Shenzhen Univ, Clin Med Acad, Dept Hematol & Oncol,Int Canc Ctr,Hlth Sci Ctr, Gen Hosp,Shenzhen Key Lab Precis Med Hematol Mali, Shenzhen 518000, Guangdong, Peoples R China; [Wang, Ruiqi] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China; [Gao, Xuefeng] Shenzhen Univ, Cent Lab, Shenzhen Key Lab Precis Med Hematol Malignancies, Gen Hosp, Shenzhen 518000, Guangdong, Peoples R China	Shenzhen University; Nankai University; Shenzhen University	Gao, XF; Yu, L (corresponding author), Shenzhen Univ, Clin Med Acad, Dept Hematol & Oncol,Int Canc Ctr,Hlth Sci Ctr, Gen Hosp,Shenzhen Key Lab Precis Med Hematol Mali, Shenzhen 518000, Guangdong, Peoples R China.; Gao, XF (corresponding author), Shenzhen Univ, Cent Lab, Shenzhen Key Lab Precis Med Hematol Malignancies, Gen Hosp, Shenzhen 518000, Guangdong, Peoples R China.	xfgao@szu.edu.cn; yuli@szu.edu.cn	kang, synat/GRO-6634-2022	kang, synat/0000-0001-6898-5289; Gao, Xuefeng/0000-0002-1904-392X	Chinese National Major Project for New Drug Innovation [2019ZX09201002003]; National Natural Science Foundation of China [82030076, 82070161, 81970151, 81670162, 81870134, 81900474]; Shenzhen Science and Technology Foundation [JCYJ20190808163601776, JCYJ20200109113810154]; Shenzhen Key Laboratory Foundation [ZDSYS20200811143757022]; Sanming Project of Medicine in Shenzhen [SZSM202111004]; Stability support project in colleges and universities of Shenzhen Science and technology innovation Commission [20200830182623001]; Shenzhen Peacock Talent Programs Research Start-up Grant [827000644]; Natural Science Foundation of Shenzhen University General Hospital [SUGH2019QD012]	Chinese National Major Project for New Drug Innovation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Foundation; Shenzhen Key Laboratory Foundation; Sanming Project of Medicine in Shenzhen; Stability support project in colleges and universities of Shenzhen Science and technology innovation Commission; Shenzhen Peacock Talent Programs Research Start-up Grant; Natural Science Foundation of Shenzhen University General Hospital	This work was supported by grants Chinese National Major Project for New Drug Innovation (2019ZX09201002003), National Natural Science Foundation of China (82030076, 82070161, 81970151, 81670162, 81870134 and 81900474), Shenzhen Science and Technology Foundation (JCYJ20190808163601776, JCYJ20200109113810154), Shenzhen Key Laboratory Foundation (ZDSYS20200811143757022), Sanming Project of Medicine in Shenzhen (SZSM202111004), Stability support project in colleges and universities of Shenzhen Science and technology innovation Commission (20200830182623001), Shenzhen Peacock Talent Programs Research Start-up Grant (827000644 to XG), and Natural Science Foundation of Shenzhen University General Hospital (SUGH2019QD012).	Acheampong DO, 2018, BIOMED PHARMACOTHER, V97, P225, DOI 10.1016/j.biopha.2017.10.100; Almstedt M, 2010, LEUKEMIA RES, V34, P899, DOI 10.1016/j.leukres.2010.02.004; Arai Y, 2015, BLOOD, V126, P415, DOI 10.1182/blood-2015-04-642652; Atanackovic D, 2011, AM J HEMATOL, V86, P918, DOI 10.1002/ajh.22141; Raneros AB, 2015, GENES IMMUN, V16, P71, DOI 10.1038/gene.2014.58; Bethune MT, 2018, P NATL ACAD SCI USA, V115, pE10702, DOI 10.1073/pnas.1810653115; Caballero OL, 2009, CANCER SCI, V100, P2014, DOI 10.1111/j.1349-7006.2009.01303.x; Cany J, 2018, BLOOD, V131, P202, DOI 10.1182/blood-2017-06-790204; Cer?n-Maldonado R., 2015, REV MED HOSP GEN MEX, V78, P78; Chapuis AG, 2019, NAT MED, V25, P1064, DOI 10.1038/s41591-019-0472-9; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Chou J, 2012, J IMMUNOTHER, V35, P131, DOI 10.1097/CJI.0b013e31824300c7; Dubovsky JA, 2007, PROSTATE, V67, P1781, DOI 10.1002/pros.20665; Elegheert J, 2018, NAT PROTOC, V13, P2991, DOI 10.1038/s41596-018-0075-9; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Fry TJ, 2018, NAT MED, V24, P20, DOI 10.1038/nm.4441; Goodyear O, 2010, BLOOD, V116, P1908, DOI 10.1182/blood-2009-11-249474; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Griffiths EA, 2018, CLIN CANCER RES, V24, P1019, DOI 10.1158/1078-0432.CCR-17-1792; Jahn L, 2016, ONCOTARGET, V7, P77021, DOI 10.18632/oncotarget.12778; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Jungbluth AA, 2001, INT J CANCER, V92, P856, DOI 10.1002/ijc.1282; Kang S, 2019, FRONT MED-PRC, V13, P69, DOI 10.1007/s11684-018-0677-1; Klar AS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139221; Leonard SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087475; Lim SH, 1999, BRIT J CANCER, V81, P1162, DOI 10.1038/sj.bjc.6690824; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Mardiana S, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00697; McCormack E, 2013, CANCER IMMUNOL IMMUN, V62, P773, DOI 10.1007/s00262-012-1384-4; Natsume A, 2008, INT J CANCER, V122, P2542, DOI 10.1002/ijc.23407; Negrotto S, 2012, LEUKEMIA, V26, P244, DOI 10.1038/leu.2011.207; Odunsi K, 2014, CANCER IMMUNOL RES, V2, P37, DOI 10.1158/2326-6066.CIR-13-0126; Rapoport AP, 2015, NAT MED, V21, P914, DOI 10.1038/nm.3910; Robbins PF, 2008, J IMMUNOL, V180, P6116, DOI 10.4049/jimmunol.180.9.6116; Robbins PF, 2015, CLIN CANCER RES, V21, P1019, DOI 10.1158/1078-0432.CCR-14-2708; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Rohner A, 2007, LEUKEMIA RES, V31, P1393, DOI 10.1016/j.leukres.2007.02.020; Srivastava P., 2015, BLOOD, V126, P2873, DOI [10.1182/blood.V126.23.2873.2873, DOI 10.1182/BLOOD.V126.23.2873.2873]; Srivastava P, 2016, ONCOTARGET, V7, P12840, DOI 10.18632/oncotarget.7326; Srivastava P, 2015, EPIGENETICS-US, V10, P237, DOI 10.1080/15592294.2015.1017198; Stadtmauer EA, 2019, BLOOD ADV, V3, P2022, DOI 10.1182/bloodadvances.2019000194; Storb R, 2013, J CLIN ONCOL, V31, P1530, DOI 10.1200/JCO.2012.45.0247; Tawara I, 2017, BLOOD, V130, P1985, DOI 10.1182/blood-2017-06-791202; Topfer K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/918471; Toor AA, 2012, BRIT J HAEMATOL, V158, P700, DOI 10.1111/j.1365-2141.2012.09225.x; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; Wakamatsu M, 2019, BLOOD ADV, V3, P105, DOI 10.1182/bloodadvances.2018025643; Walter RB, 2020, BLOOD REV, V44, DOI 10.1016/j.blre.2020.100679; Wang BH, 2021, HEMATOLOGY, V26, P371, DOI 10.1080/16078454.2021.1921434; Wang Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20696-x; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Woloszynska-Read A, 2008, CLIN CANCER RES, V14, P3283, DOI 10.1158/1078-0432.CCR-07-5279; Xia Y, 2018, ONCOL LETT, V16, P6998, DOI 10.3892/ol.2018.9534; Xu Y, 2016, J CLIN INVEST, V126, P35, DOI 10.1172/JCI85631; Xu Y, 2014, BLOOD, V123, P3750, DOI 10.1182/blood-2014-01-552174; Yao YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070522; You LS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01787; Zeiser R, 2019, BLOOD, V133, P1290, DOI 10.1182/blood-2018-10-846824; Zhang YK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-018-0720-y; Zhou JH, 2013, MOL MED REP, V8, P1549, DOI 10.3892/mmr.2013.1659	62	0	0	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4696	4708		10.1038/s41388-022-02455-y	http://dx.doi.org/10.1038/s41388-022-02455-y		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36097193	hybrid, Green Published			2022-12-28	WOS:000852927100001
J	Kortum, B; Radhakrishnan, H; Zincke, F; Sachse, C; Burock, S; Keilholz, U; Dahlmann, M; Walther, W; Dittmar, G; Kobelt, D; Stein, U				Kortuem, Benedikt; Radhakrishnan, Harikrishnan; Zincke, Fabian; Sachse, Christoph; Burock, Susen; Keilholz, Ulrich; Dahlmann, Mathias; Walther, Wolfgang; Dittmar, Gunnar; Kobelt, Dennis; Stein, Ulrike			Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-beta-catenin-S100A4 axis of metastasis	ONCOGENE			English	Article							COLORECTAL-CANCER PATIENTS; BETA-CATENIN; COLON-CANCER; PROGNOSTIC VALUE; STEM-CELLS; S100A4; MACC1; PHOSPHORYLATION; TRANSCRIPTS; PROGRESSION	Colorectal cancer (CRC) is the second-most common malignant disease worldwide, and metastasis is the main culprit of CRC-related death. Metachronous metastases remain to be an unpredictable, unpreventable, and fatal complication, and tracing the molecular chain of events that lead to metastasis would provide mechanistically linked biomarkers for the maintenance of remission in CRC patients after curative treatment. We hypothesized, that Metastasis-associated in colorectal cancer-1 (MACC1) induces a secretory phenotype to enforce metastasis in a paracrine manner, and found, that the cell-free culture medium of MACC1-expressing CRC cells induces migration. Stable isotope labeling by amino acids in cell culture mass spectrometry (SILAC-MS) of the medium revealed, that S100A4 is significantly enriched in the MACC1-specific secretome. Remarkably, both biomarkers correlate in expression data of independent cohorts as well as within CRC tumor sections. Furthermore, combined elevated transcript levels of the metastasis genes MACC1 and S100A4 in primary tumors and in blood plasma robustly identifies CRC patients at high risk for poor metastasis-free (MFS) and overall survival (OS). Mechanistically, MACC1 strengthens the interaction of beta-catenin with TCF4, thus inducing S100A4 synthesis transcriptionally, resulting in elevated secretion to enforce cell motility and metastasis. In cell motility assays, S100A4 was indispensable for MACC1-induced migration, as shown via knock-out and pharmacological inhibition of S100A4. The direct transcriptional and functional relationship of MACC1 and S100A4 was probed by combined targeting with repositioned drugs. In fact, the MACC1-beta-catenin-S100A4 axis by statins (MACC1) and niclosamide (S100A4) synergized in inhibiting cancer cell motility in vitro and metastasis in vivo. The MACC1-beta-catenin-S100A4 signaling axis is causal for CRC metastasis. Selectively repositioned drugs synergize in restricting MACC1/S100A4-driven metastasis with cross-entity potential.	[Kortuem, Benedikt; Radhakrishnan, Harikrishnan; Zincke, Fabian; Dahlmann, Mathias; Walther, Wolfgang; Kobelt, Dennis; Stein, Ulrike] Charite Univ Med Berlin, Expt & Clin Res Ctr, Berlin, Germany; [Kortuem, Benedikt; Radhakrishnan, Harikrishnan; Zincke, Fabian; Dahlmann, Mathias; Walther, Wolfgang; Dittmar, Gunnar; Kobelt, Dennis; Stein, Ulrike] Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany; [Zincke, Fabian; Dahlmann, Mathias; Kobelt, Dennis; Stein, Ulrike] German Canc Consortium DKTK, Heidelberg, Germany; [Sachse, Christoph] NMI TT Pharmaserv, Berlin, Germany; [Burock, Susen; Keilholz, Ulrich] Charite, Ctr Charite Comprehens Canc Ctr 10, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stein, U (corresponding author), Charite Univ Med Berlin, Expt & Clin Res Ctr, Berlin, Germany.; Stein, U (corresponding author), Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany.; Stein, U (corresponding author), German Canc Consortium DKTK, Heidelberg, Germany.	ustein@mdc-berlin.de	Radhakrishnan, Harikrishnan/GWZ-6616-2022	Radhakrishnan, Harikrishnan/0000-0002-5435-4520; Kortum, Benedikt/0000-0003-3734-6665	Projekt DEAL	Projekt DEAL	Open Access funding enabled and organized by Projekt DEAL.	Arlt F, 2009, INT J BIOCHEM CELL B, V41, P2356, DOI 10.1016/j.biocel.2009.08.001; Becker M, 2002, BRIT J CANCER, V87, P1328, DOI 10.1038/sj.bjc.6600573; Belot N, 2002, BBA-PROTEINS PROTEOM, V1600, P74, DOI 10.1016/S1570-9639(02)00447-8; Borgquist S, 2019, BMC CANCER, V19, DOI 10.1186/s12885-018-5263-z; Budczies J, 2020, SEMIN CANCER BIOL, V60, P365, DOI 10.1016/j.semcancer.2019.08.010; Burock S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4197-9; Burock S, 2015, WORLD J GASTROENTERO, V21, P333, DOI 10.3748/wjg.v21.i1.333; Chowdhury MKH, 2016, BIOCHEM J, V473, P1247, DOI 10.1042/BCJ20160121; Dahlmann M, 2016, CANCERS, V8, DOI 10.3390/cancers8060059; Dahlmann M, 2015, METHODS MOL BIOL, V1317, P153, DOI 10.1007/978-1-4939-2727-2_10; Dahlmann M, 2014, ONCOTARGET, V5, P3220, DOI 10.18632/oncotarget.1908; Dammann K, 2015, CANCER PREV RES, V8, P1093, DOI 10.1158/1940-6207.CAPR-15-0205-T; Di Veroli GY, 2016, BIOINFORMATICS, V32, P2866, DOI 10.1093/bioinformatics/btw230; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Fang L, 2016, CANCER RES, V76, P891, DOI 10.1158/0008-5472.CAN-15-1519; Fei F, 2017, ONCOTARGET, V8, P73219, DOI 10.18632/oncotarget.18016; Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-13; Garrett SC, 2008, BIOCHEMISTRY-US, V47, P986, DOI 10.1021/bi7021624; Gohlke BO, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.726; Grum-Schwensen B, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1034-2; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Handeli S, 2008, MOL CANCER THER, V7, P521, DOI 10.1158/1535-7163.MCT-07-2063; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Ilm K, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0316-2; IMBASTARI F, CELL MOL LIFE SCI, V2021; Jiang W, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02041-2; Juneja M, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2000784; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Kobelt D, 2021, ONCOGENE, V40, P5286, DOI 10.1038/s41388-021-01917-z; Kobelt D, 2021, METHODS MOL BIOL, V2294, P133, DOI 10.1007/978-1-0716-1350-4_9; Kobelt D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00980; Kopczynska EK, 2016, WSPOLCZESNA ONKOL, V20, P273, DOI 10.5114/wo.2016.61846; Koulis C, 2020, CANCERS, V12, DOI 10.3390/cancers12040812; Lee G, 2010, GASTROENTEROLOGY, V139, P869, DOI 10.1053/j.gastro.2010.05.037; Lemos C, 2016, CLIN CANCER RES, V22, P2812, DOI 10.1158/1078-0432.CCR-15-1425; Li ZH, 2006, CANCER RES, V66, P5173, DOI 10.1158/0008-5472.CAN-05-3087; Link T, 2019, MOL ONCOL, V13, P1268, DOI 10.1002/1878-0261.12484; Malashkevich VN, 2010, P NATL ACAD SCI USA, V107, P8605, DOI 10.1073/pnas.0913660107; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; Nielsen SF, 2012, NEW ENGL J MED, V367, P1792, DOI 10.1056/NEJMoa1201735; Novac N, 2013, TRENDS PHARMACOL SCI, V34, P267, DOI 10.1016/j.tips.2013.03.004; Ormanns S, 2014, ONCOTARGET, V5, P2999, DOI 10.18632/oncotarget.1626; Park MH, 2012, BIOCHEM BIOPH RES CO, V419, P543, DOI 10.1016/j.bbrc.2012.02.056; Pita-Fernandez S, 2015, ANN ONCOL, V26, P644, DOI 10.1093/annonc/mdu543; Radhakrishnan H, 2018, CANCER METAST REV, V37, P805, DOI 10.1007/s10555-018-9771-8; Rohr UP, 2017, ANN ONCOL, V28, P1869, DOI 10.1093/annonc/mdx207; Sack U, 2011, JNCI-J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190; Schubert-Fritschle G, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00234; Schutte M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14262; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Stein U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049249; Stein U, 2011, J MOL DIAGN, V13, P189, DOI 10.1016/j.jmoldx.2010.10.002; Stein U, 2010, J MOL MED, V88, P11, DOI 10.1007/s00109-009-0537-1; Stein U, 2009, CELL CYCLE, V8, P2467, DOI 10.4161/cc.8.15.9018; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Trochet D, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02045-y; Tsuji S, 2012, BRIT J CANCER, V106, P126, DOI 10.1038/bjc.2011.505; Tsukamoto S, 2011, CLIN CANCER RES, V17, P2444, DOI 10.1158/1078-0432.CCR-10-2884; Weidle UH, 2015, CLIN EXP METASTAS, V32, P623, DOI 10.1007/s10585-015-9732-3; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304	62	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4446	4458		10.1038/s41388-022-02407-6	http://dx.doi.org/10.1038/s41388-022-02407-6		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	36008464	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000844588600002
J	Meng, XQ; Peng, JX; Xie, XS; Yu, FH; Wang, WC; Pan, QH; Jin, HL; Huang, XL; Yu, HY; Li, SR; Feng, DY; Liu, QX; Fang, LK; Lee, MH				Meng, Xiangqi; Peng, Jingxuan; Xie, Xiaoshan; Yu, Fenghai; Wang, Wencong; Pan, Qihao; Jin, Huilin; Huang, Xiaoling; Yu, Hongyan; Li, Shengrong; Feng, Dianying; Liu, Qingxin; Fang, Lekun; Lee, Mong-Hong			Roles of lncRNA LVBU in regulating urea cycle/polyamine synthesis axis to promote colorectal carcinoma progression	ONCOGENE			English	Article							THERAPEUTIC TARGET; BCL6; HIF-1-ALPHA; IMMUNITY; HYPOXIA	Altered expression of Urea Cycle (UC) enzymes occurs in many tumors, resulting a metabolic hallmark termed as UC dysregulation. Polyamines are synthesized from ornithine, and polyamine synthetic genes are elevated in various tumors. However, the underlying deregulations of UC/ polyamine synthesis in cancer remain elusive. Here, we characterized a hypoxia-induced lncRNA LVBU (lncRNA regulation via BCL6/urea cycle) that is highly expressed in colorectal cancer (CRC) and correlates with poor cancer prognosis. Increased LVBU expression promoted CRC cells proliferation, foci formation and tumorigenesis. Further, LVBU regulates urea cycle and polyamine synthesis through BCL6, a negative regulator of p53. Mechanistically, overexpression of LVBU competitively bound miR-10a/miR-34c to protect BCL6 from miR-10a/34c-mediated degradation, which in turn allows BCL6 to block p53-mediated suppression of genes (arginase1 ARG1, ornithine transcarbamylase OTC, ornithine decarboxylase 1 ODC1) involved in UC/polyamine synthesis. Significantly, ODC1 inhibitor attenuated the growth of patient derived xenografts (PDX) that sustain high LVBU levels. Taken together, elevated LVBU can regulate BCL6-p53 signaling axis for systemic UC/polyamine synthesis reprogramming and confers a predilection toward CRC development. Our data demonstrates that further drug development and clinical evaluation of inhibiting UC/polyamine synthesis are warranted for CRC patients with high expression of LVBU.	[Meng, Xiangqi; Peng, Jingxuan; Xie, Xiaoshan; Yu, Fenghai; Wang, Wencong; Pan, Qihao; Jin, Huilin; Huang, Xiaoling; Feng, Dianying; Liu, Qingxin; Fang, Lekun; Lee, Mong-Hong] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou 510655, Peoples R China; [Meng, Xiangqi; Peng, Jingxuan; Xie, Xiaoshan; Yu, Fenghai; Wang, Wencong; Pan, Qihao; Jin, Huilin; Huang, Xiaoling; Feng, Dianying; Liu, Qingxin; Fang, Lekun; Lee, Mong-Hong] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Res Inst Gastroenterol, Guangzhou 510655, Peoples R China; [Yu, Hongyan] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, Dept Clin Biol Resource Bank, Guangzhou 510623, Peoples R China; [Li, Shengrong] Chengdu Univ Tradit Chinese Med, Pharm Coll, Chengdu 611137, Peoples R China; [Fang, Lekun] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510655, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; Chengdu University of Traditional Chinese Medicine; Sun Yat Sen University	Meng, XQ; Fang, LK; Lee, MH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou 510655, Peoples R China.; Meng, XQ; Fang, LK; Lee, MH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Res Inst Gastroenterol, Guangzhou 510655, Peoples R China.; Fang, LK (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510655, Peoples R China.	mengxq3@mail.sysu.edu.cn; fanglk3@mail.sysu.edu.cn; limh33@mail.sysu.edu.cn		Meng, Xiangqi/0000-0002-6407-6122	National Key R&D Program of China [2020YFA0803300]; National Natural Science Foundation of China [81630072, 81702533]; Natural Science Foundation of Guangdong Province [2019A1515010099, 2021A1515012081]; Shenzhen Municipal Government of China [KQTD20170810160226082]; Fundamental Research Funds for the Central Universities [19ykpy07]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Shenzhen Municipal Government of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	The authors would like to thank Xinhai Zhu for performing LC-MS/MS analysis, Xiangli Li, Junyan Feng and Manqi Meng for their technical help and Lishuo Shi for statistical analysis. This work was supported by the National Key R&D Program of China (2020YFA0803300), the National Natural Science Foundation of China (81630072 and 81702533), the Natural Science Foundation of Guangdong Province (2019A1515010099 and 2021A1515012081), Shenzhen Municipal Government of China (KQTD20170810160226082), and the Fundamental Research Funds for the Central Universities (19ykpy07).	Agostini M, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0247-6; Bachmann AS, 2018, J BIOL CHEM, V293, P18757, DOI 10.1074/jbc.TM118.003336; Bassiri H, 2015, TRANSL PEDIATR, V4, P226, DOI 10.3978/j.issn.2224-4336.2015.04.06; Bhandari V, 2019, NAT GENET, V51, P308, DOI 10.1038/s41588-018-0318-2; Byrne AT, 2017, NAT REV CANCER, V17, P254, DOI 10.1038/nrc.2016.140; Cardenas MG, 2017, CLIN CANCER RES, V23, P885, DOI 10.1158/1078-0432.CCR-16-2071; Cardenas MG, 2016, J CLIN INVEST, V126, P3351, DOI 10.1172/JCI85795; Casero RA, 2018, NAT REV CANCER, V18, P681, DOI 10.1038/s41568-018-0050-3; Choi HH, 2020, ADV SCI, V7, DOI 10.1002/advs.202000681; Colgan SP, 2020, ANNU REV IMMUNOL, V38, P341, DOI 10.1146/annurev-immunol-100819-121537; Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1; Dragomir MP, 2020, GUT, V69, P748, DOI 10.1136/gutjnl-2019-318279; Fan Q, 2016, PROTEIN CELL, V7, P899, DOI 10.1007/s13238-016-0316-z; Gonzalez FJ, 2018, NAT REV ENDOCRINOL, V15, P21, DOI 10.1038/s41574-018-0096-z; He W, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0014-1; Hilton LK, 2019, BLOOD, V134, P1528, DOI 10.1182/blood.2019002600; Hogarty MD, 2008, CANCER RES, V68, P9735, DOI 10.1158/0008-5472.CAN-07-6866; Kerres N, 2017, CELL REP, V20, P2860, DOI 10.1016/j.celrep.2017.08.081; Keshet R, 2018, NAT REV CANCER, V18, P634, DOI 10.1038/s41568-018-0054-z; Kocarnik JM, 2015, GASTROENTEROL REP, V3, P269, DOI 10.1093/gastro/gov046; Lee JS, 2018, CELL, V174, P1559, DOI 10.1016/j.cell.2018.07.019; Lee P, 2020, NAT REV MOL CELL BIO, V21, P268, DOI 10.1038/s41580-020-0227-y; Leeman-Neill RJ, 2018, EXPERT OPIN THER TAR, V22, P143, DOI 10.1080/14728222.2018.1420782; Li L, 2019, NATURE, V567, P253, DOI 10.1038/s41586-019-0996-7; Phan L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8530; Lucien F, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15884; Matsumoto S, 2019, J HUM GENET, V64, P833, DOI 10.1038/s10038-019-0614-4; Miska J, 2019, CELL REP, V27, P226, DOI 10.1016/j.celrep.2019.03.029; Rabinovich S, 2015, NATURE, V527, P379, DOI 10.1038/nature15529; Seiffert M, 2020, HAEMATOLOGICA, V105, P856, DOI 10.3324/haematol.2019.246330; Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551; Slabicki M, 2020, NATURE, V588, P164, DOI 10.1038/s41586-020-2925-1; Sun NH, 2020, CELL MOL BIOL LETT, V25, DOI 10.1186/s11658-020-00210-3; Sveen A, 2020, NAT REV CLIN ONCOL, V17, P11, DOI 10.1038/s41571-019-0241-1; Taylor CT, 2017, NAT REV IMMUNOL, V17, P774, DOI 10.1038/nri.2017.103; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Wang H, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0680-1; Welponer H, 2020, J CANCER, V11, P1446, DOI 10.7150/jca.33831; Willson JA, 2022, BLOOD, V139, P281, DOI 10.1182/blood.2021011010; Xiong SW, 2019, ONCOL REP, V42, P1635, DOI 10.3892/or.2019.7280; Xu L, 2017, P NATL ACAD SCI USA, V114, P3981, DOI 10.1073/pnas.1609758114; Zheng YL, 2019, THERANOSTICS, V9, P796, DOI 10.7150/thno.28992; Zou SM, 2018, GASTROENTEROL REP, V6, P1, DOI 10.1093/gastro/gox031	43	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2022	41	36					4231	4243		10.1038/s41388-022-02413-8	http://dx.doi.org/10.1038/s41388-022-02413-8		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4G5OH	35906392	hybrid, Green Published			2022-12-28	WOS:000832824600001
J	Thirusangu, P; Ray, U; Bhattacharya, SS; Oien, DB; Jin, L; Staub, J; Kannan, N; Molina, JR; Shridhar, V				Thirusangu, Prabhu; Ray, Upasana; Bhattacharya, Sayantani Sarkar; Oien, Derek B.; Jin, Ling; Staub, Julie; Kannan, Nagarajan; Molina, Julian R.; Shridhar, Viji			PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma	ONCOGENE			English	Article							RESISTANCE PROTEIN BCRP/ABCG2; EXPRESSION	PFKFB3 (6-phosphofructo-2-kinase) is the rate-limiting enzyme of glycolysis and is overexpressed in several human cancers that are associated with poor prognosis. High PFKFB3 expression in cancer stem cells promotes glycolysis and survival in the tumor microenvironment. Inhibition of PFKFB3 by the glycolytic inhibitor PFK158 and by shRNA stable knockdown in small cell lung carcinoma (SCLC) cell lines inhibited glycolysis, proliferation, spheroid formation, and the expression of cancer stem cell markers CD133, Aldh1, CD44, Sox2, and ABCG2. These factors are also associated with chemotherapy resistance. We found that PFK158 treatment and PFKFB3 knockdown enhanced the ABCG2-interacting drugs doxorubicin, etoposide, and 5-fluorouracil in reducing cell viability under conditions of enriched cancer stem cells (CSC). Additionally, PFKFB3 inhibition attenuated the invasion/migration of SCLC cells by downregulating YAP/TAZ signaling while increasing pLATS1 via activation of pMST1 and NF2 and by reducing the mesenchymal protein expression. PFKFB3 knockdown and PFK158 treatment in a H1048 SCLC cancer stem cell-enriched mouse xenograft model showed significant reduction in tumor growth and weight with reduced expression of cancer stem cell markers, ABCG2, and YAP/TAZ. Our findings identify that PFKFB3 is a novel target to regulate cancer stem cells and its associated therapeutic resistance markers YAP/TAZ and ABCG2 in SCLC models.	[Thirusangu, Prabhu; Ray, Upasana; Bhattacharya, Sayantani Sarkar; Oien, Derek B.; Jin, Ling; Staub, Julie; Shridhar, Viji] Mayo Clin, Dept Expt Pathol & Med, Rochester, MN 55905 USA; [Kannan, Nagarajan] Mayo Clin, Ctr Regenerat Med, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN USA; [Molina, Julian R.] Mayo Clin, Dept Med Oncol, Rochester, MN USA; [Oien, Derek B.] AstraZeneca, Oncol R&D, Boston, MA USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; AstraZeneca	Shridhar, V (corresponding author), Mayo Clin, Dept Expt Pathol & Med, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Oien, Derek B/ABF-3114-2021; Sarkar Bhattacharya, Sayantani/AAG-6222-2020	Oien, Derek B/0000-0002-0730-5654; Sarkar Bhattacharya, Sayantani/0000-0001-8971-7566; Ray, Upasana/0000-0002-9804-6888	Department of Defense (DOD) [W81XWH-18-1-0504]; Department of Experimental Pathology and Laboratory, Mayo Clinic, United States	Department of Defense (DOD)(United States Department of Defense); Department of Experimental Pathology and Laboratory, Mayo Clinic, United States	This work was supported by grant from the Department of Defense (DOD) (W81XWH-18-1-0504) to V.S., Department of Experimental Pathology and Laboratory, Mayo Clinic, United States.	Altan M, 2015, CANCER J, V21, P425, DOI 10.1097/PPO.0000000000000148; Ashrafian H, 2006, LANCET, V367, P618, DOI 10.1016/S0140-6736(06)68228-7; Atsumi T, 2002, CANCER RES, V62, P5881; Avin BRV, 2014, EUR J MED CHEM, V75, P211, DOI 10.1016/j.ejmech.2014.01.050; Begicevic RR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112362; Bhattacharya SS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1916-3; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; Codony-Servat J, 2016, TRANSL LUNG CANCER R, V5, P16, DOI 10.3978/j.issn.2218-6751.2016.01.01; Dai YY, 2017, ONCOTARGET, V8, P4096, DOI 10.18632/oncotarget.13686; Fan FQ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2304; Gatti L, 2009, MINI-REV MED CHEM, V9, P1102, DOI 10.2174/138955709788922656; Gong J, 2018, J ONCOL PRACT, V14, P359, DOI 10.1200/JOP.18.00204; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Jung D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20531-w; Klameth L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05562-z; LeBlanc L, 2021, CELL MOL LIFE SCI, V78, P4201, DOI 10.1007/s00018-021-03781-2; Li HM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0481-1; Lu L, 2017, ONCOTARGET, V8, P62793, DOI 10.18632/oncotarget.19513; MacDonagh L, 2016, CANCER LETT, V372, P147, DOI [10.1016/j.canlet.2016,01.012, 10.1016/j.canlet.2016.01.012]; Mao QC, 2015, AAPS J, V17, P65, DOI 10.1208/s12248-014-9668-6; Matak D, 2017, CYTOTECHNOLOGY, V69, P565, DOI 10.1007/s10616-016-0063-2; Minchenko OH, 2014, WORLD J GASTROENTERO, V20, P13705, DOI 10.3748/wjg.v20.i38.13705; Mondal S, 2019, INT J CANCER, V144, P178, DOI 10.1002/ijc.31868; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nakanishi T, 2012, CHIN J CANCER, V31, P73, DOI 10.5732/cjc.011.10320; Natarajan K, 2012, BIOCHEM PHARMACOL, V83, P1084, DOI 10.1016/j.bcp.2012.01.002; Noguchi K, 2009, ADV DRUG DELIVER REV, V61, P26, DOI 10.1016/j.addr.2008.07.003; Park JH, 2018, MOL CELLS, V41, P83, DOI 10.14348/molcells.2018.2242; Plouffe SW, 2016, MOL CELL, V64, P993, DOI 10.1016/j.molcel.2016.10.034; Qin A, 2018, J ONCOL PRACT, V14, P369, DOI 10.1200/JOP.18.00278; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Song J, 2018, ONCOL LETT, V16, P3949, DOI 10.3892/ol.2018.9141; Thirusangu P, 2020, CHRONIC LUNG DIS PAT, P129; Thirusangu P, 2021, CANCERS, V13, DOI 10.3390/cancers13092004; Thirusangu P, 2017, ANGIOGENESIS, V20, P55, DOI 10.1007/s10456-016-9528-3; Thirusangu P, 2017, BIOCHEM PHARMACOL, V125, P26, DOI 10.1016/j.bcp.2016.11.009; Verma S, 2019, P NATL ACAD SCI USA, V116, P7363, DOI 10.1073/pnas.1822155116; Vinci M, 2015, JOVE-J VIS EXP, DOI 10.3791/52686; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warren JSA, 2018, CANCERS, V10, DOI 10.3390/cancers10040115; Xiao YN, 2021, ONCOGENE, V40, P1409, DOI 10.1038/s41388-020-01621-4; Yadav UP, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01010; Yamaguchi H, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00928; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Yuan JH, 2009, CANCER CHEMOTH PHARM, V63, P1103, DOI 10.1007/s00280-008-0838-z; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhu X, 2020, WORLD J STEM CELLS, V12, P448, DOI 10.4252/wjsc.v12.i6.448	50	2	2	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					4003	4017		10.1038/s41388-022-02391-x	http://dx.doi.org/10.1038/s41388-022-02391-x		JUL 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35804016	Green Published, hybrid			2022-12-28	WOS:000824972000002
J	Meijer, TG; Nguyen, L; Van Hoeck, A; Sieuwerts, AM; Verkaik, NS; Ladan, MM; Ruigrok-Ritstier, K; van Deurzen, CHM; van de Werken, HJG; Lips, EH; Linn, SC; Memari, Y; Davies, H; Nik-Zainal, S; Kanaar, R; Martens, JWM; Cuppen, E; Jager, A; van Gent, DC				Meijer, Titia G.; Nguyen, Luan; Van Hoeck, Arne; Sieuwerts, Anieta M.; Verkaik, Nicole S.; Ladan, Marjolijn M.; Ruigrok-Ritstier, Kirsten; van Deurzen, Carolien H. M.; van de Werken, Harmen J. G.; Lips, Esther H.; Linn, Sabine C.; Memari, Yasin; Davies, Helen; Nik-Zainal, Serena; Kanaar, Roland; Martens, John W. M.; Cuppen, Edwin; Jager, Agnes; van Gent, Dik C.			Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests	ONCOGENE			English	Article							BREAST-CANCER; OLAPARIB; CHEMOTHERAPY; ASSOCIATION; LANDSCAPE; BENEFIT	Germline BRCA1/2 mutation status is predictive for response to Poly-[ADP-Ribose]-Polymerase (PARP) inhibitors in breast cancer (BC) patients. However, non-germline BRCA1/2 mutated and homologous recombination repair deficient (HRD) tumors are likely also PARP-inhibitor sensitive. Clinical validity and utility of various HRD biomarkers are under investigation. The REpair CAPacity (RECAP) test is a functional method to select HRD tumors based on their inability to form RAD51 foci. We investigated whether this functional test defines a similar group of HRD tumors as DNA-based tests. An HRD enriched cohort (n = 71; 52 primary and 19 metastatic BCs) selected based on the RECAP test (26 RECAP-HRD; 37%), was subjected to DNA-based HRD tests (i.e., Classifier of HOmologous Recombination Deficiency (CHORD) and BRCA1/2-like classifier). Whole genome sequencing (WGS) was carried out for 38 primary and 19 metastatic BCs. The RECAP test identified all bi-allelic BRCA deficient samples (n = 15) in this cohort. RECAP status partially correlated with DNA-based HRD test outcomes (70% concordance for both RECAP-CHORD and RECAP-BRCA1/2-like classifier). RECAP selected additional samples unable to form RAD51 foci, suggesting that this functional assay identified deficiencies in other DNA repair genes, which could also result in PARP-inhibitor sensitivity. Direct comparison of these HRD tests in clinical trials will be required to evaluate the optimal predictive test for clinical decision making.	[Meijer, Titia G.; Verkaik, Nicole S.; Ladan, Marjolijn M.; Kanaar, Roland; van Gent, Dik C.] Erasmus MC, Erasmus MC Canc Inst, Dept Mol Genet, Rotterdam, Netherlands; [Meijer, Titia G.; van Deurzen, Carolien H. M.; Kanaar, Roland; van Gent, Dik C.] Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands; [Meijer, Titia G.; Nguyen, Luan; Van Hoeck, Arne; Verkaik, Nicole S.; Ladan, Marjolijn M.; Cuppen, Edwin] Oncode Inst, Utrecht, Netherlands; [Nguyen, Luan; Van Hoeck, Arne; Cuppen, Edwin] Univ Med Ctr Utrecht, Dept Mol Genet, Utrecht, Netherlands; [Sieuwerts, Anieta M.; Ruigrok-Ritstier, Kirsten; Martens, John W. M.; Jager, Agnes] Erasmus MC, Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands; [van de Werken, Harmen J. G.] Erasmus MC, Canc Computat Biol Ctr, Erasmus MC Canc Inst, Rotterdam, Netherlands; [van de Werken, Harmen J. G.] Erasmus MC, Erasmus MC Canc Inst, Dept Urol, Rotterdam, Netherlands; [van de Werken, Harmen J. G.] Erasmus MC, Erasmus MC Canc Inst, Dept Immunol, Rotterdam, Netherlands; [Lips, Esther H.; Linn, Sabine C.] Netherlands Canc Inst, Dept Mol Pathol, Amsterdam, Netherlands; [Linn, Sabine C.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; [Linn, Sabine C.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Memari, Yasin; Davies, Helen; Nik-Zainal, Serena] Univ Cambridge, Acad Dept Med Genet, Cambridge Biomed Campus, Cambridge, England; [Memari, Yasin; Davies, Helen; Nik-Zainal, Serena] Univ Cambridge, MRC Canc Unit, Cambridge Biomed Campus, Cambridge, England; [Cuppen, Edwin] Hartwig Med Fdn, Sci Pk, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center; University of Cambridge; University of Cambridge	Meijer, TG (corresponding author), Erasmus MC, Erasmus MC Canc Inst, Dept Mol Genet, Rotterdam, Netherlands.; Meijer, TG (corresponding author), Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands.; Meijer, TG (corresponding author), Oncode Inst, Utrecht, Netherlands.	t.meijer@erasmusmc.nl	Werken, Harmen van de/G-8979-2013; Nguyen, Luan/GYA-2927-2022	Werken, Harmen van de/0000-0002-9794-1477; Lips, Esther/0000-0003-3488-4935; van Gent, Dik C./0000-0003-1473-8148	Dutch Cancer Society [EMCR 2014-7048, EMCR 2008-4045]; Dutch Cancer Society; Netherlands Organization for Scientific Research (NWO)	Dutch Cancer Society(KWF Kankerbestrijding); Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	DCvG, AJ, and RK have received funding from the Dutch Cancer Society (Alpe d'Huzes grant number EMCR 2014-7048 and grant number EMCR 2008-4045). This work is part of the Oncode Institute which is partly financed by the Dutch Cancer Society and was funded by the gravitation program CancerGenomiCs.nl from the Netherlands Organization for Scientific Research (NWO).	Angus L, 2019, NAT GENET, V51, P1450, DOI 10.1038/s41588-019-0507-7; [Anonymous], BIORXIV, DOI 10.1101/781013; Chopra N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16142-7; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Eikesdal HP, 2021, ANN ONCOL, V32, P240, DOI 10.1016/j.annonc.2020.11.009; Ettl J, 2018, ANN ONCOL, V29, P1939, DOI 10.1093/annonc/mdy257; Goncalves A, 2020, CANCERS, V12, DOI 10.3390/cancers12061378; Joosse SA, 2012, BREAST CANCER RES TR, V132, P379, DOI 10.1007/s10549-010-1016-7; Joosse SA, 2009, BREAST CANCER RES TR, V116, P479, DOI 10.1007/s10549-008-0117-z; Knijnenburg TA, 2018, CELL REP, V23, P239, DOI 10.1016/j.celrep.2018.03.076; Ladan MM, 2021, CANCERS, V13, DOI 10.3390/cancers13051004; LI A, 2019, NPJ BREAST CANCER, V5; Lips EH, 2011, ANN ONCOL, V22, P870, DOI 10.1093/annonc/mdq468; Litton JK, 2018, NEW ENGL J MED, V379, P753, DOI 10.1056/NEJMoa1802905; LITTON JK, 2020, J CLIN ONCOL, V38; Llop-Guevara A, 2021, ANN ONCOL, V32, P1590, DOI 10.1016/j.annonc.2021.09.003; Loibl S, 2018, ANN ONCOL, V29, P2341, DOI 10.1093/annonc/mdy460; Mayer EL, 2020, ANN ONCOL, V31, P1518, DOI 10.1016/j.annonc.2020.08.2064; Meijer TG, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00268; Meijer TG, 2018, CLIN CANCER RES, V24, P6277, DOI 10.1158/1078-0432.CCR-18-0063; Naipal KAT, 2014, CLIN CANCER RES, V20, P4816, DOI 10.1158/1078-0432.CCR-14-0571; Nguyen L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19406-4; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Nones K, 2019, ANN ONCOL, V30, P1071, DOI 10.1093/annonc/mdz132; Pilie PG, 2019, CLIN CANCER RES, V25, P3759, DOI 10.1158/1078-0432.CCR-18-0968; Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y; Robson ME, 2019, ANN ONCOL, V30, P558, DOI 10.1093/annonc/mdz012; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Schouten PC, 2016, INT J CANCER, V139, P882, DOI 10.1002/ijc.30078; Schouten PC, 2015, MOL ONCOL, V9, P1274, DOI 10.1016/j.molonc.2015.03.002; Schouten PC, 2013, BREAST CANCER RES TR, V139, P317, DOI 10.1007/s10549-013-2558-2; Schwartz LH, 2016, EUR J CANCER, V62, P132, DOI 10.1016/j.ejca.2016.03.081; Severson TM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0861-2; Sharma P, 2018, ANN ONCOL, V29, P654, DOI 10.1093/annonc/mdx821; Shimelis H, 2017, CANCER RES, V77, P2789, DOI 10.1158/0008-5472.CAN-16-2568; Staaf J, 2019, NAT MED, V25, P1526, DOI 10.1038/s41591-019-0582-4; Stronach EA, 2018, MOL CANCER RES, V16, P1103, DOI 10.1158/1541-7786.MCR-18-0034; Tudini E, 2018, BREAST CANCER RES TR, V172, P497, DOI 10.1007/s10549-018-4903-y; Tutt A, 2018, NAT MED, V24, P628, DOI 10.1038/s41591-018-0009-7; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Vollebergh MA, 2011, ANN ONCOL, V22, P1561, DOI 10.1093/annonc/mdq624	41	2	2	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3498	3506		10.1038/s41388-022-02363-1	http://dx.doi.org/10.1038/s41388-022-02363-1		JUN 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35662281	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000805724700002
J	Hamad, SH; Montgomery, SA; Simon, JM; Bowman, BM; Spainhower, KB; Murphy, RM; Knudsen, ES; Fenton, SE; Randell, SH; Holt, JR; Hayes, DN; Witkiewicz, AK; Oliver, TG; Ben Major, M; Weissman, BE				Hamad, Samera H.; Montgomery, Stephanie A.; Simon, Jeremy M.; Bowman, Brittany M.; Spainhower, Kyle B.; Murphy, Ryan M.; Knudsen, Erik S.; Fenton, Suzanne E.; Randell, Scott H.; Holt, Jeremiah R.; Hayes, D. Neil; Witkiewicz, Agnieszka K.; Oliver, Trudy G.; Ben Major, M.; Weissman, Bernard E.			TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice	ONCOGENE			English	Article							KEAP1-NRF2 PATHWAY; 3Q AMPLIFICATION; MUTATIONS; CARCINOMA; NRF2; INACTIVATION; ACTIVATION; MECHANISMS; GENES; P63	Studies have shown that Nrf2(E79Q/+) is one of the most common mutations found in human tumors. To elucidate how this genetic change contributes to lung cancer, we compared lung tumor development in a genetically-engineered mouse model (GEMM) with dual Trp53/p16 loss, the most common mutations found in human lung tumors, in the presence or absence of Nrf2(E79Q/+). Trp53/p16-deficient mice developed combined-small cell lung cancer (C-SCLC), a mixture of pure-SCLC (P-SCLC) and large cell neuroendocrine carcinoma. Mice possessing the LSL-Nrf2(E79Q) mutation showed no difference in the incidence or latency of C-SCLC compared with Nrf2(+/+) mice. However, these tumors did not express NRF2 despite Cre-induced recombination of the LSL-Nrf2(E79Q) allele. Trp53/p16-deficient mice also developed P-SCLC, where activation of the NRF2(E79Q) mutation associated with a higher incidence of this tumor type. All C-SCLCs and P-SCLCs were positive for NE-markers, NKX1-2 (a lung cancer marker) and negative for P63 (a squamous cell marker), while only P-SCLC expressed NRF2 by immunohistochemistry. Analysis of a consensus NRF2 pathway signature in human NE+-lung tumors showed variable activation of NRF2 signaling. Our study characterizes the first GEMM that develops C-SCLC, a poorly-studied human cancer and implicates a role for NRF2 activation in SCLC development.	[Hamad, Samera H.; Montgomery, Stephanie A.; Simon, Jeremy M.; Bowman, Brittany M.; Ben Major, M.; Weissman, Bernard E.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Montgomery, Stephanie A.; Weissman, Bernard E.] Univ N Carolina, Dept Pathol & Lab Med, Sch Med, Chapel Hill, NC 27515 USA; [Simon, Jeremy M.] Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27515 USA; [Simon, Jeremy M.] Univ N Carolina, UNC Neurosci Ctr, Sch Med, Chapel Hill, NC 27515 USA; [Spainhower, Kyle B.; Oliver, Trudy G.] Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT USA; [Murphy, Ryan M.] Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27515 USA; [Knudsen, Erik S.; Witkiewicz, Agnieszka K.] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA; [Fenton, Suzanne E.] NIEHS, Div Natl Toxicol Program, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Randell, Scott H.] Univ N Carolina, Sch Med, Marsico Lung Inst, Chapel Hill, NC 27515 USA; [Holt, Jeremiah R.; Hayes, D. Neil] Univ Tennessee, Hlth Sci Ctr Canc Res, Dept Med, Div Hematol & Oncol, Memphis, TN USA; [Ben Major, M.] Univ N Carolina, Dept Cell Biol & Physiol, Sch Med, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Utah System of Higher Education; University of Utah; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Tennessee System; University of Tennessee Health Science Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Ben Major, M; Weissman, BE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.; Weissman, BE (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Sch Med, Chapel Hill, NC 27515 USA.; Ben Major, M (corresponding author), Univ N Carolina, Dept Cell Biol & Physiol, Sch Med, Chapel Hill, NC 27515 USA.	bmajor@wustl.edu; weissman@med.unc.edu	, Pathology Services Core/CEZ-2246-2022	Holt, Jeremiah/0000-0002-5201-5015	National Institutes of Environmental and Health Sciences [T32ES007126]; Golberg; National Cancer Institute [CA216051]; UNC Lineberger Clinical/Translational Research Award;  [5R01CA244841-02];  [5U01CA231844-04];  [5U24CA213274-05]	National Institutes of Environmental and Health Sciences; Golberg; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UNC Lineberger Clinical/Translational Research Award; ; ; 	This study was supported by a grant from the National Institutes of Environmental and Health Sciences (T32ES007126) (S.H.H), a Golberg Postdoctoral Fellow (S.H.H.), a grant from the National Cancer Institute (CA216051) (B.E.W, M.B.M.) and by grants 5R01CA244841-02, 5U01CA231844-04, and 5U24CA213274-05 (T.G.O.). These studies were also supported in part by a UNC Lineberger Clinical/Translational Research Award.	Alcala N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11276-9; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bowman BM, 2020, J PATHOL, V252, P125, DOI 10.1002/path.5504; Bryan HK, 2013, BIOCHEM PHARMACOL, V85, P705, DOI 10.1016/j.bcp.2012.11.016; Cancer Genome Atlas Research N, 2014, NATURE, V511, P50, DOI [10.1038/nature133851:CAS:528:DC%2BC2cXht1ChurnI, DOI 10.1038/NATURE133851:CAS:528:DC%2BC2CXHT1CHURNI]; Cescon DW, 2015, CLIN CANCER RES, V21, P2499, DOI 10.1158/1078-0432.CCR-14-2206; Cloer EW, 2019, CANCER RES, V79, P889, DOI 10.1158/0008-5472.CAN-18-2723; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Demirhan O, 2010, CANCER EPIDEMIOL, V34, P472, DOI 10.1016/j.canep.2010.03.018; Desai A, 2016, CANCER BIOL MED, V13, P77, DOI 10.28092/j.issn.2095-3941.2016.0008; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Engel NW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166690; Fernandez-Cuesta L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4518; Gabriel AAG, 2020, GIGASCIENCE, V9, DOI 10.1093/gigascience/giaa112; George J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03099-x; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Hamad Samera H, 2017, Tob Regul Sci, V3, P459, DOI 10.18001/TRS.3.4.7; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Ireland AS, 2020, CANCER CELL, V38, P60, DOI 10.1016/j.ccell.2020.05.001; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001; Kazanets A, 2016, BBA-REV CANCER, V1865, P275, DOI 10.1016/j.bbcan.2016.04.001; Kerins MJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31281-0; Kim JH, 2017, ONCOTARGET, V8, P48248, DOI 10.18632/oncotarget.17594; Kodama T, 2014, MOL CANCER THER, V13, P2910, DOI 10.1158/1535-7163.MCT-14-0274; KOIKE K, 1990, J VIROL, V64, P3988, DOI 10.1128/JVI.64.8.3988-3991.1990; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Laddha SV, 2019, CANCER RES, V79, P4339, DOI 10.1158/0008-5472.CAN-19-0214; Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003; Leversha MA, 2003, J PATHOL, V200, P610, DOI 10.1002/path.1374; Li SY, 2016, J THORAC ONCOL, V11, P2129, DOI 10.1016/j.jtho.2016.08.142; Lubet R, 2005, EXP LUNG RES, V31, P117, DOI 10.1080/01902140490495499; Lubojemska A, 2016, VET COMP ONCOL, V14, pE70, DOI 10.1111/vco.12102; Maronpot RR, 1999, PATHOLOGY MOUSE REFE; Massion PP, 2003, CANCER RES, V63, P7113; McCaughan F, 2010, AM J RESP CRIT CARE, V182, P83, DOI 10.1164/rccm.201001-0005OC; McFadden DG, 2014, CELL, V156, P1298, DOI 10.1016/j.cell.2014.02.031; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005; Mukhopadhyay S, 2011, AM J SURG PATHOL, V35, P15, DOI 10.1097/PAS.0b013e3182036d05; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Park KS, 2011, CELL CYCLE, V10, P2806, DOI 10.4161/cc.10.16.17012; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Perez-Moreno P, 2012, CLIN CANCER RES, V18, P2443, DOI 10.1158/1078-0432.CCR-11-2370; Qian J, 2008, J THORAC ONCOL, V3, P212, DOI 10.1097/JTO.0b013e3181663544; Rekhtman N, 2012, CLIN CANCER RES, V18, P1167, DOI 10.1158/1078-0432.CCR-11-2109; Reznik GK, 1994, IARC PUBL, P30524; Romero R, 2017, NAT MED, V23, P1362, DOI 10.1038/nm.4407; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Schaffer BE, 2010, CANCER RES, V70, P3877, DOI 10.1158/0008-5472.CAN-09-4228; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Siegel Rebecca L, 2019, CA Cancer J Clin, V69, P7, DOI 10.3322/caac.21551; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Snow AN, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-30; Society AC, 2019, CANC FACTS FIGURES 2; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Sonkin D, 2019, LUNG CANCER MANAG, V8, DOI 10.2217/lmt-2019-0005; Sutherland KD, 2011, CANCER CELL, V19, P754, DOI 10.1016/j.ccr.2011.04.019; Swanton C, 2016, NEW ENGL J MED, V374, P1864, DOI 10.1056/NEJMra1504688; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Travis WD, 2014, PATHOLOGE, V35, P188, DOI 10.1007/s00292-014-1974-3; Travis William D, 2009, Eur J Cancer, V45 Suppl 1, P251, DOI 10.1016/S0959-8049(09)70040-1; WAALKES MP, 1987, CANCER RES, V47, P2445; Wang SH, 2019, MAYO CLIN PROC, V94, P1599, DOI 10.1016/j.mayocp.2019.01.034; Wu MX, 2003, AM J CLIN PATHOL, V119, P696, DOI 10.1309/XCP6EWPB3BMRKA; Yamano S, 2016, CANCER SCI, V107, P123, DOI 10.1111/cas.12855; Zheng M, 2016, SURG ONCOL CLIN N AM, V25, P447, DOI 10.1016/j.soc.2016.02.003; Zhu Yanliang, 2008, Zhongguo Fei Ai Za Zhi, V11, P681, DOI 10.3779/j.issn.1009-3419.2008.05.009	69	1	1	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3423	3432		10.1038/s41388-022-02348-0	http://dx.doi.org/10.1038/s41388-022-02348-0		MAY 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35577980	Green Submitted			2022-12-28	WOS:000796348100001
J	Aponte, E; Lafitte, M; Sirvent, A; Simon, V; Barbery, M; Fourgous, E; Maffei, M; Armand, F; Hamelin, R; Pannequin, J; Fort, P; Pons, M; Roche, S; Boublik, Y				Aponte, Emilie; Lafitte, Marie; Sirvent, Audrey; Simon, Valerie; Barbery, Maud; Fourgous, Elise; Maffei, Mariano; Armand, Florence; Hamelin, Romain; Pannequin, Julie; Fort, Philippe; Pons, Miquel; Roche, Serge; Boublik, Yvan			Regulation of Src tumor activity by its N-terminal intrinsically disordered region	ONCOGENE			English	Article							TYROSINE KINASES; UNIQUE DOMAIN; FAMILY; CELL; PHOSPHORYLATION; DIMERIZATION; REQUIREMENT; SEQUENCE; REVEALS; BINDING	The membrane-anchored Src tyrosine kinase is involved in numerous pathways and its deregulation is involved in human cancer. Our knowledge on Src regulation relies on crystallography, which revealed intramolecular interactions to control active Src conformations. However, Src contains a N-terminal intrinsically disordered unique domain (UD) whose function remains unclear. Using NMR, we reported that UD forms an intramolecular fuzzy complex involving a conserved region with lipid-binding capacity named Unique Lipid-Binding Region (ULBR), which could modulate Src membrane anchoring. Here we show that the ULBR is essential for Src's oncogenic capacity. ULBR inactive mutations inhibited Src transforming activity in NIH3T3 cells and in human colon cancer cells. It also reduced Src-induced tumor development in nude mice. An intact ULBR was required for MAPK signaling without affecting Src kinase activity nor sub-cellular localization. Phospho-proteomic analyses revealed that, while not impacting on the global tyrosine phospho-proteome in colon cancer cells, this region modulates phosphorylation of specific membrane-localized tyrosine kinases needed for Src oncogenic signaling, including EPHA2 and Fyn. Collectively, this study reveals an important role of this intrinsically disordered region in malignant cell transformation and suggests a novel layer of Src regulation by this unique region via membrane substrate phosphorylation.	[Aponte, Emilie; Lafitte, Marie; Sirvent, Audrey; Simon, Valerie; Barbery, Maud; Fourgous, Elise; Fort, Philippe; Roche, Serge; Boublik, Yvan] Univ Montpellier, CNRS, CRBM, F-34000 Montpellier, France; [Aponte, Emilie; Lafitte, Marie; Sirvent, Audrey; Simon, Valerie; Barbery, Maud; Fourgous, Elise; Roche, Serge; Boublik, Yvan] Univ Montpellier, CNRS, CRBM, Equipe Labellisee Ligue Canc, F-34000 Montpellier, France; [Maffei, Mariano; Pons, Miquel] Univ Barcelona, Dept Inorgan & Organ Chem, Biomol NMR Lab, Baldiri Reixac 10-12, Barcelona 08028, Spain; [Maffei, Mariano] Evvivax Srl, Via Castel Romano 100, I-00128 Rome, Italy; [Armand, Florence; Hamelin, Romain] Ecole Polytech Fed Lausanne EPFL, Sch Life Sci, Prote Core Facil, CH-1015 Lausanne, Switzerland; [Pannequin, Julie; Roche, Serge] Univ Montpellier, CNRS, IGF, F-34000 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Barcelona; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Roche, S (corresponding author), Univ Montpellier, CNRS, CRBM, F-34000 Montpellier, France.; Roche, S (corresponding author), Univ Montpellier, CNRS, CRBM, Equipe Labellisee Ligue Canc, F-34000 Montpellier, France.; Pons, M (corresponding author), Univ Barcelona, Dept Inorgan & Organ Chem, Biomol NMR Lab, Baldiri Reixac 10-12, Barcelona 08028, Spain.; Roche, S (corresponding author), Univ Montpellier, CNRS, IGF, F-34000 Montpellier, France.	mpons@ub.edu; serge.roche@crbm.cnrs.fr	Maffei, Mariano/AAD-3508-2021	roche, serge/0000-0003-3413-3859; Maffei, Mariano/0000-0003-0909-4886	Fundacio Marato de TV3; Spanish Ministry of Science and Innovation [PID2019-104914RB-I00]; La Ligue Nationale Contre le Cancer (LNCC); Montpellier SIRIC Grant [INCa-DGOS-Inserm 6045]; ANR; CNRS; University of Montpellier; SIRIC Montpellier Cancer Grant [INCa_Inserm_DGOS_12553]; Fondation pour la Recherche Medicale (FRM); Fondation de France; european regional development foundation; occitanian region (FEDER-FSE 2014-2020 Languedoc Roussillon)	Fundacio Marato de TV3; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); La Ligue Nationale Contre le Cancer (LNCC); Montpellier SIRIC Grant; ANR(French National Research Agency (ANR)); CNRS(Centre National de la Recherche Scientifique (CNRS)); University of Montpellier; SIRIC Montpellier Cancer Grant; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Fondation de France(Fondation de France); european regional development foundation; occitanian region (FEDER-FSE 2014-2020 Languedoc Roussillon)	We thank the Montpellier RIO Imaging and RHEM platforms for imaging and immunohistochemistry analyses, and the Proteomic Core Platform of EPFL for proteomic analyses. This work was supported by Fundacio Marato de TV3, Spanish Ministry of Science and Innovation (project PID2019-104914RB-I00), La Ligue Nationale Contre le Cancer (LNCC), Montpellier SIRIC Grant "INCa-DGOS-Inserm 6045", ANR, CNRS, and the University of Montpellier. RHEM facility supported by SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553, the european regional development foundation and the occitanian region (FEDER-FSE 2014-2020 Languedoc Roussillon), IBiSA and Ligue contre le cancer for processing our animal tissues and histology technics. ML is supported by the Fondation pour la Recherche Medicale (FRM) and the Fondation de France. SR is an INSERM investigator.	Amata I, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00181; Amata I, 2013, CHEMBIOCHEM, V14, P1820, DOI 10.1002/cbic.201300139; Arbesu M, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00039; Arbesu M, 2017, STRUCTURE, V25, P630, DOI 10.1016/j.str.2017.02.011; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; Eide CA, 2019, CANCER CELL, V36, P431, DOI 10.1016/j.ccell.2019.08.004; Fuxreiter M, 2012, MOL BIOSYST, V8, P168, DOI 10.1039/c1mb05234a; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Jeitany M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201707918; Kashiwagi K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16872-7; Kato G, 2019, ENEURO, V6, DOI 10.1523/ENEURO.0418-18.2019; Katoh Kazutaka, 2013, Mol Biol Evol, V30, P772, DOI 10.1093/molbev/mst010; Kerjouan A, 2021, J CELL SCI, V134, DOI 10.1242/jcs.254599; Kim PW, 2003, SCIENCE, V301, P1725, DOI 10.1126/science.1085643; Le Roux AL, 2019, ISCIENCE, V12, P194, DOI 10.1016/j.isci.2019.01.010; Le Roux AL, 2016, CHEMISTRYSELECT, V1, P642, DOI 10.1002/slct.201600117; Le Roux AL, 2016, COLLOID SURFACE B, V138, P17, DOI 10.1016/j.colsurfb.2015.11.013; Lecointre C, 2018, STRUCTURE, V26, P545, DOI 10.1016/j.str.2018.01.017; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Maffei M, 2015, STRUCTURE, V23, P893, DOI 10.1016/j.str.2015.03.009; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Naudin C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4159; Perez Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep01295; Perez Y, 2009, J MOL BIOL, V391, P136, DOI 10.1016/j.jmb.2009.06.018; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sirvent A, 2010, ONCOGENE, V29, P1303, DOI 10.1038/onc.2009.450; Sirvent A, 2020, CANCERS, V12, DOI 10.3390/cancers12082014; Sirvent A, 2012, MOL CELL PROTEOMICS, V11, P1937, DOI 10.1074/mcp.M112.018168; Sirvent A, 2012, AM J CANCER RES, V2, P357; Spassov DS, 2018, CELL REP, V25, P449, DOI 10.1016/j.celrep.2018.09.035; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Teixeira JMC, 2018, MOLECULES, V23, DOI 10.3390/molecules23112731; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Veracini L, 2006, J CELL SCI, V119, P2921, DOI 10.1242/jcs.03015; Wright PE, 2015, NAT REV MOL CELL BIO, V16, P18, DOI 10.1038/nrm3920; Yang ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	42	2	2	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					960	970		10.1038/s41388-021-02092-x	http://dx.doi.org/10.1038/s41388-021-02092-x		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34999732	Green Submitted, hybrid, Green Published			2022-12-28	WOS:000740423400002
J	Wu, Q; Liu, FF; Ge, MM; Laster, KV; Wei, LX; Du, RJ; Jiang, M; Zhang, J; Zhi, YF; Jin, GG; Zhao, SM; Kim, DJ; Dong, ZG; Liu, KD				Wu, Qiong; Liu, Fangfang; Ge, Mengmeng; Laster, Kyle Vaughn; Wei, Lixiao; Du, Ruijuan; Jiang, Ming; Zhang, Jing; Zhi, Yafei; Jin, Guoguo; Zhao, Simin; Kim, Dong Joon; Dong, Zigang; Liu, Kangdong			BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression	ONCOGENE			English	Article							GENOMIC LANDSCAPE; GENE-EXPRESSION; TARGETING MYCN; P73 ISOFORMS; CANCER; OVEREXPRESSION; TRANSCRIPTION; INHIBITION; P53; SENSITIVITY	The low survival rate of esophageal squamous cell carcinoma patients is primarily attributed to technical limitations and a lack of insight regarding the molecular mechanisms contributing to its progression. Alterations in epigenetic modulators are critical to cancer development and prognosis. BRD4, a chromatin reader protein, plays an essential role in regulating oncogene expression. Here, we investigated the contributing role of BRD4 and its related mechanisms in the context of ESCC tumor progression. Our observations showed that BRD4 transcript and protein expression levels are significantly increased in ESCC patient tissues. Genetic or pharmacological inhibition of BRD4 suppressed ESCC cell proliferation in vitro and in vivo. Proteomic and transcriptomic analyses were subsequently used to deduce the potential targets of BRD4. Mechanistic studies showed that RCC2 is a downstream target of BRD4. Inhibition of either BRD4 or RCC2 resulted in decreased ESCC cell proliferation. The BRD4-TP73 interaction facilitated the binding of BRD4 complex to the promoter region of RCC2, and subsequently modulated RCC2 transcription. Furthermore, targeting BRD4 with inhibitors significantly decreased tumor volume in ESCC PDX models, indicating that BRD4 expression may contribute to tumor progression. Collectively, these findings suggest that BRD4 inhibition could be a promising strategy to treat ESCC by downregulating RCC2.	[Wu, Qiong; Liu, Fangfang; Du, Ruijuan; Zhang, Jing; Zhi, Yafei; Kim, Dong Joon; Dong, Zigang; Liu, Kangdong] Zhengzhou Univ, Sch Basic Med Sci, Pathophysiol Dept, Zhengzhou 450000, Peoples R China; [Wu, Qiong; Liu, Fangfang; Ge, Mengmeng; Laster, Kyle Vaughn; Wei, Lixiao; Du, Ruijuan; Jiang, Ming; Zhang, Jing; Zhi, Yafei; Jin, Guoguo; Zhao, Simin; Kim, Dong Joon; Dong, Zigang; Liu, Kangdong] China US Henan Hormel Canc Inst, Zhengzhou 450000, Peoples R China; [Jin, Guoguo] Henan Luoyang Orthoped Hosp, Zhengzhou 450000, Henan, Peoples R China; [Zhao, Simin] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450000, Henan, Peoples R China; [Dong, Zigang; Liu, Kangdong] State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450000, Henan, Peoples R China; [Dong, Zigang; Liu, Kangdong] Zhengzhou Univ, Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou 450000, Henan, Peoples R China; [Liu, Kangdong] Canc Chemoprevent Int Collaborat Lab, Zhengzhou 450000, Henan, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University	Kim, DJ; Dong, ZG; Liu, KD (corresponding author), Zhengzhou Univ, Sch Basic Med Sci, Pathophysiol Dept, Zhengzhou 450000, Peoples R China.; Kim, DJ; Dong, ZG; Liu, KD (corresponding author), China US Henan Hormel Canc Inst, Zhengzhou 450000, Peoples R China.; Dong, ZG; Liu, KD (corresponding author), State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450000, Henan, Peoples R China.; Dong, ZG; Liu, KD (corresponding author), Zhengzhou Univ, Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou 450000, Henan, Peoples R China.; Liu, KD (corresponding author), Canc Chemoprevent Int Collaborat Lab, Zhengzhou 450000, Henan, Peoples R China.	djkim@hci-cn.org; zgdong@hci-cn.org; kdliu@zzu.edu.cn			National Natural Science Foundations of China [81872335]; National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, China [2018ZX09711002]; Central Plains Science and Technology Innovation Leading Talents (KL)	National Natural Science Foundations of China(National Natural Science Foundation of China (NSFC)); National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, China; Central Plains Science and Technology Innovation Leading Talents (KL)	This research was funded by the National Natural Science Foundations of China (Grant no. 81872335), National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, China (No. 2018ZX09711002) and Central Plains Science and Technology Innovation Leading Talents (KL). We thank all members of our team for critical input and suggestions.	Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruun J, 2015, CLIN CANCER RES, V21, P3759, DOI 10.1158/1078-0432.CCR-14-3294; Calderon-Aparicio A, 2020, MOL CANCER RES, V18, P1660, DOI 10.1158/1541-7786.MCR-19-1152; Cao W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13797-9; Carrasco G, 2010, CLIN CANCER RES, V16, P3253, DOI 10.1158/1078-0432.CCR-09-2491; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen QM, 2020, HUM CELL, V33, P709, DOI 10.1007/s13577-020-00353-7; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Dominguez G, 2001, BREAST CANCER RES TR, V66, P183, DOI 10.1023/A:1010624717311; Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0915-9; Dullo I, 2015, NAT CELL BIOL, V17, P511, DOI 10.1038/ncb3130; Dutton SJ, 2014, LANCET ONCOL, V15, P894, DOI 10.1016/S1470-2045(14)70024-5; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Faivre EJ, 2020, NATURE, V578, P306, DOI 10.1038/s41586-020-1930-8; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Fontanals-Cirera B, 2017, MOL CELL, V68, P731, DOI 10.1016/j.molcel.2017.11.004; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Henssen A, 2016, CLIN CANCER RES, V22, P2470, DOI 10.1158/1078-0432.CCR-15-1449; Hu N, 2016, CANCER RES, V76, P1714, DOI 10.1158/0008-5472.CAN-15-0338; Hu N, 2009, CANCER RES, V69, P5908, DOI 10.1158/0008-5472.CAN-08-4622; Hu XM, 2014, J BIOL CHEM, V289, P23154, DOI 10.1074/jbc.M114.570812; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jiang YA, 2016, ONCOL REP, V35, P785, DOI 10.3892/or.2015.4459; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Li L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05231-3; Lin DC, 2018, GASTROENTEROLOGY, V154, P374, DOI 10.1053/j.gastro.2017.06.066; Liu KD, 2013, CANCER RES, V73, P2181, DOI 10.1158/0008-5472.CAN-12-3408; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Matsuo M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-15; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Mirguet O, 2013, J MED CHEM, V56, P7501, DOI 10.1021/jm401088k; Mollinari C, 2003, DEV CELL, V5, P295, DOI 10.1016/S1534-5807(03)00205-3; Nagarajan S, 2017, NUCLEIC ACIDS RES, V45, P3130, DOI 10.1093/nar/gkw1276; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; Novak U, 2001, ANN ONCOL, V12, P981, DOI 10.1023/A:1011153206003; Nozaki M, 2001, BRAIN PATHOL, V11, P296; Padmanabhan A, 2020, CIRCULATION, V142, P2338, DOI 10.1161/CIRCULATIONAHA.120.047753; Pang B, 2017, CLIN CANCER RES, V23, P5598, DOI 10.1158/1078-0432.CCR-16-2909; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Sawada G, 2016, GASTROENTEROLOGY, V150, P1171, DOI 10.1053/j.gastro.2016.01.035; Shah MA, 2015, J CLIN ONCOL, V33, P1760, DOI 10.1200/JCO.2014.60.1799; Sharif T, 2019, CLIN CANCER RES, V25, P2001, DOI 10.1158/1078-0432.CCR-17-3177; Siu KT, 2017, LEUKEMIA, V31, P1760, DOI 10.1038/leu.2016.355; Smyth EC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.48; Soldevilla B, 2011, CLIN CANCER RES, V17, P6029, DOI 10.1158/1078-0432.CCR-10-2388; Song C, 2018, ONCOGENE, V37, P8, DOI 10.1038/onc.2017.306; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Su H, 2011, CLIN CANCER RES, V17, P2955, DOI 10.1158/1078-0432.CCR-10-2724; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Thrumurthy SG, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4373; Tomkova K, 2004, CANCER RES, V64, P6390, DOI 10.1158/0008-5472.CAN-04-2176; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004; Yang H, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06901-6; Yu H, 2019, BIOCHEM BIOPH RES CO, V516, P999, DOI 10.1016/j.bbrc.2019.06.097; Zaika AI, 1999, CANCER RES, V59, P3257; Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591-018-0158-8; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	65	3	3	7	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					347	360		10.1038/s41388-021-02099-4	http://dx.doi.org/10.1038/s41388-021-02099-4		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34750516				2022-12-28	WOS:000715670800003
J	Wang, F; Zhang, JY; Tang, HY; Pang, Y; Ke, XX; Peng, W; Chen, ST; Abbas, MN; Dong, Z; Cui, ZB; Cui, HJ				Wang, Feng; Zhang, Jiayi; Tang, Houyi; Pang, Yi; Ke, Xiaoxue; Peng, Wen; Chen, Shitong; Abbas, Muhammad Nadeem; Dong, Zhen; Cui, Zhaobo; Cui, Hongjuan			Nup54-induced CARM1 nuclear importation promotes gastric cancer cell proliferation and tumorigenesis through transcriptional activation and methylation of Notch2	ONCOGENE			English	Article							ARGININE METHYLATION; GLYCOSYLATION; PHOSPHORYLATION; COACTIVATOR; METABOLISM; MASTERMIND; REGULATOR; GROWTH; P63	Gastric cancer (GC) has the fifth highest incidence globally, but its molecular mechanisms are not well understood. Here, we report that coactivator-associated arginine methyltransferase 1 (CARM1) is specifically highly expressed in gastric cancer and that its overexpression correlates with poor prognosis in patients with gastric cancer. Nucleoporin 54 (Nup54) was identified as a CARM1-interacting protein that promoted CARM1 nuclear importation. In the nucleus, CARM1 cooperates with transcriptional factor EB (TFEB) to activate Notch2 transcription by inducing H3R17me2 of the Notch2 promoter but not H3R26me2. Additionally, the Notch2 intracellular domain (N2ICD) was identified as a CARM1 substrate. Methylation of N2ICD at R1786, R1838, and R2047 by CARM1 enhanced the binding between N2ICD and mastermind-like protein 1 (MAML1) and increased gastric cancer cell proliferation in vitro and tumor formation in vivo. Our findings reveal a molecular mechanism linking CARM1-mediated transcriptional activation of the Notch2 signaling pathway to Notch2 methylation in gastric cancer progression.	[Wang, Feng; Zhang, Jiayi; Tang, Houyi; Ke, Xiaoxue; Peng, Wen; Chen, Shitong; Abbas, Muhammad Nadeem; Dong, Zhen; Cui, Hongjuan] Southwest Univ, Inst Sericulture & Syst Biol, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China; [Wang, Feng; Zhang, Jiayi; Tang, Houyi; Ke, Xiaoxue; Peng, Wen; Chen, Shitong; Abbas, Muhammad Nadeem; Dong, Zhen; Cui, Hongjuan] Southwest Univ, Canc Ctr, Med Res Inst, Chongqing 400716, Peoples R China; [Pang, Yi] Chongqing Three Gorges Med Coll, Chongqing Engn Res Ctr Antitumor Nat Drugs, Chongqing 404120, Peoples R China; [Cui, Zhaobo] Harrison Int Peace Hosp, Dept Intens Care Unit, Hengshui 053000, Hebei, Peoples R China	Southwest University - China; Southwest University - China	Cui, HJ (corresponding author), Southwest Univ, Inst Sericulture & Syst Biol, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China.; Cui, HJ (corresponding author), Southwest Univ, Canc Ctr, Med Res Inst, Chongqing 400716, Peoples R China.; Cui, ZB (corresponding author), Harrison Int Peace Hosp, Dept Intens Care Unit, Hengshui 053000, Hebei, Peoples R China.	zhaobocui2014@sina.com; hcui@swu.edu.cn		Dong, Zhen/0000-0003-3108-0245	China Postdoctoral Science Foundation [2021M692679]; Chongqing Postdoctoral Research Institute [7820100607]; National Key Research, and Development Program of China [2016YFC1302204, 2017YFC308600]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Chongqing Postdoctoral Research Institute; National Key Research, and Development Program of China	This study was supported by the fellowship of China Postdoctoral Science Foundation (2021M692679), the special support from Chongqing Postdoctoral Research Institute (7820100607), the National Key Research, and Development Program of China (No.2016YFC1302204 and 2017YFC308600). We thank GEPIA 2 database (http://gepia2.cancer-pku.cn/#survival), TIMER 2.0 database (http://timer.cistrome.org/), Oncomine database (https://www.oncomine.org/resource/login.html) for initial data analysis. We are grateful to PMeS (http://bioinfo.ncu.edu.cn/inquiries_PMeS.aspx) for the prediction of protein methylation sites. Technical support of confocal microscopy from Lei Zhang is greatly appreciated.	Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426; Andersen P, 2012, TRENDS CELL BIOL, V22, P257, DOI 10.1016/j.tcb.2012.02.003; Asakawa H, 2018, METHODS MOL BIOL, V1721, P105, DOI 10.1007/978-1-4939-7546-4_10; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Blanc RS, 2017, MOL CELL, V65, P8, DOI 10.1016/j.molcel.2016.11.003; Borlido J, 2018, EMBO REP, V19, P3, DOI 10.15252/embr.201745497; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheng DH, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800117; Chug H, 2015, SCIENCE, V350, P106, DOI 10.1126/science.aac7420; Demitrack ES, 2017, CELL MOL GASTROENTER, V3, P323, DOI 10.1016/j.jcmgh.2017.01.012; Deng Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1082-z; El Messaoudi S, 2006, P NATL ACAD SCI USA, V103, P13351, DOI 10.1073/pnas.0605692103; Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Gao WW, 2018, MOL CELL, V70, P340, DOI 10.1016/j.molcel.2018.03.006; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Hazawa M, 2018, EMBO REP, V19, P73, DOI 10.15252/embr.201744523; Hunter GL, 2020, ADV EXP MED BIOL, V1227, P51, DOI 10.1007/978-3-030-36422-9_4; Jeong GY, 2021, CANCER RES, V81, P77, DOI 10.1158/0008-5472.CAN-20-0360; Karakashev S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03031-3; Kawabe YI, 2012, CELL STEM CELL, V11, P333, DOI 10.1016/j.stem.2012.07.001; Kim YR, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-197; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kunnimalaiyaan S, 2015, HPB, V17, P770, DOI 10.1111/hpb.12442; Larsen SC, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf7329; Lim R, 2019, SCIENCE, V364, P188, DOI 10.1126/science.aat0778; Liu FB, 2017, NAT CELL BIOL, V19, P1358, DOI 10.1038/ncb3630; Liu JW, 2020, EMBO REP, V21, DOI 10.15252/embr.201948597; Penton AL, 2012, SEMIN CELL DEV BIOL, V23, P450, DOI 10.1016/j.semcdb.2012.01.010; Rodriguez-Bravo V, 2018, CELL, V174, P1200, DOI 10.1016/j.cell.2018.07.015; Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014; Shishkova E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15571; Takeuchi H, 2014, BIOCHEM BIOPH RES CO, V453, P235, DOI 10.1016/j.bbrc.2014.05.115; Takeuchi H, 2010, SEMIN CELL DEV BIOL, V21, P638, DOI 10.1016/j.semcdb.2010.03.003; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Thandapani P, 2013, MOL CELL, V50, P613, DOI 10.1016/j.molcel.2013.05.021; Torres-Padilla ME, 2007, NATURE, V445, P214, DOI 10.1038/nature05458; Wang F, 2017, ONCOTARGET, V8, P57187, DOI 10.18632/oncotarget.19231; Wang L, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500463; Wang L, 2016, CANCER CELL, V30, P179, DOI 10.1016/j.ccell.2016.06.013; Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007; Wang XM, 2014, AM J PHYSIOL-RENAL, V306, pF205, DOI 10.1152/ajprenal.90005.2013; Wang YP, 2016, MOL CELL, V64, P673, DOI 10.1016/j.molcel.2016.09.028; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu Q, 2009, STEM CELLS, V27, P2637, DOI 10.1002/stem.131; Xiu MX, 2019, AM J CANCER RES, V9, P837; Yadav N, 2008, EMBO REP, V9, P193, DOI 10.1038/sj.embor.7401151; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Zhang DK, 2017, ONCOTARGET, V8, P80956, DOI 10.18632/oncotarget.20898; Zhong XY, 2018, CELL REP, V24, P3207, DOI 10.1016/j.celrep.2018.08.066; Zhou MH, 2014, ONCOL LETT, V8, P959, DOI 10.3892/ol.2014.2263	52	2	2	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					246	259		10.1038/s41388-021-02078-9	http://dx.doi.org/10.1038/s41388-021-02078-9		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34725461				2022-12-28	WOS:000713567000001
J	Liu, WL; Li, HZ; Aerbajinai, W; Botos, I; Rodgers, GP				Liu, Wenli; Li, Hongzhen; Aerbajinai, Wulin; Botos, Istvan; Rodgers, Griffin P.			OLFM4-RET fusion is an oncogenic driver in small intestine adenocarcinoma	ONCOGENE			English	Article							TYROSINE KINASE; AUTOPHOSPHORYLATION SITES; PAPILLARY CARCINOMAS; RET PROTOONCOGENE; RET/PTC1 ONCOGENE; EXPRESSION; IDENTIFICATION; HGC-1; ACTIVATION; APOPTOSIS	Small intestine adenocarcinoma is a rare intestinal malignancy with distinct clinical, pathological, and molecular characteristics. Recently, a fusion of the intestinal stem-cell marker olfactomedin 4 (OLFM4) and the proto-oncogene RET has been identified in a small intestine adenocarcinoma patient. Here we investigated the biological effects of OLFM4-RET fusion and whether it can initiate tumorigenesis in small intestine. OLFM4 expression was found to be frequently lost or reduced in human small intestine adenocarcinoma, and its downregulation correlated with high tumor grade and advanced tumor stage. Expression of OLFM4-RET fusion-induced cellular transformation in HEK293 cells and blocked RET-induced inhibition of colony growth in HuTu 80 small intestine adenocarcinoma cells. Further, expression of OLFM4-RET activated the RAS-RAF-MAPK and STAT3 cell signaling pathways in both HEK293 cells and HuTu 80 cells. OLFM4-RET expression in HEK293 cells upregulated multiple families of genes related to carcinogenesis, cancer progression, and metastasis. Targeted expression of OLFM4-RET in the small intestine led to the development of hyperplasia, adenoma, or adenocarcinoma in transgenic mice. Our study suggests that OLFM4-RET is an oncogenic driver of small intestine tumorigenesis. Therefore, the small intestine adenocarcinoma patients with OLFM4-RET fusion may benefit from treatment with RET kinase inhibitor.	[Liu, Wenli; Li, Hongzhen; Aerbajinai, Wulin; Rodgers, Griffin P.] NHLBI, Mol & Clin Hematol Branch, Bldg 10, Bethesda, MD 20892 USA; [Botos, Istvan] NIDDK, Lab Mol Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Rodgers, GP (corresponding author), NHLBI, Mol & Clin Hematol Branch, Bldg 10, Bethesda, MD 20892 USA.	griffinr@extra.niddk.nih.gov		Rodgers, Griffin/0000-0002-4710-0012				Ballerini P, 2012, LEUKEMIA, V26, P2384, DOI 10.1038/leu.2012.109; Blaker H, 2004, SCAND J GASTROENTERO, V39, P748, DOI 10.1080/00365520410005847; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Canibano C, 2007, EMBO J, V26, P2015, DOI 10.1038/sj.emboj.7601636; Eblen ST, 2018, ADV CANCER RES, V138, P99, DOI 10.1016/bs.acr.2018.02.004; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hwang JH, 2003, MOL ENDOCRINOL, V17, P1155, DOI 10.1210/me.2002-0401; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Ju YS, 2012, GENOME RES, V22, P436, DOI 10.1101/gr.133645.111; Kawamoto Y, 2004, J BIOL CHEM, V279, P14213, DOI 10.1074/jbc.M312600200; Knowles PP, 2006, J BIOL CHEM, V281, P33577, DOI 10.1074/jbc.M605604200; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Kollara A, 2001, BREAST CANCER RES TR, V67, P245, DOI 10.1023/A:1017938608460; Le Rolle AF, 2015, ONCOTARGET, V6, P28929, DOI 10.18632/oncotarget.4325; Leone V, 2010, ONCOGENE, V29, P4341, DOI 10.1038/onc.2010.179; Levy DE, 2006, P NATL ACAD SCI USA, V103, P10151, DOI 10.1073/pnas.0604042103; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Liu W, 2007, HISTOPATHOLOGY, V51, P157, DOI 10.1111/j.1365-2559.2007.02763.x; Liu W, 2016, ONCOGENE, V35, P5237, DOI 10.1038/onc.2016.58; Liu WL, 2008, CLIN CANCER RES, V14, P1041, DOI 10.1158/1078-0432.CCR-07-4125; Liu WL, 2006, EXP CELL RES, V312, P1785, DOI 10.1016/j.yexcr.2006.02.011; Liu WL, 2016, CANCER METAST REV, V35, P201, DOI 10.1007/s10555-016-9624-2; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Luo Y, 2013, ONCOGENE, V32, P2037, DOI 10.1038/onc.2012.225; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142; Perea D, 2017, EMBO J, V36, P3029, DOI 10.15252/embj.201696247; Powell DJ, 1998, CANCER RES, V58, P5523; Raghav K, 2013, NAT REV CLIN ONCOL, V10, P534, DOI 10.1038/nrclinonc.2013.132; Reeser JW, 2017, J MOL DIAGN, V19, P682, DOI 10.1016/j.jmoldx.2017.05.006; Resemann HK, 2014, MOL CELL ENDOCRINOL, V382, P603, DOI 10.1016/j.mce.2013.06.029; Santoro M, 1996, ONCOGENE, V12, P1821; Santoro Massimo, 2013, Cold Spring Harb Perspect Biol, V5, pa009233, DOI 10.1101/cshperspect.a009233; Sariola H, 2003, J CELL SCI, V116, P3855, DOI 10.1242/jcs.00786; Sasselli V, 2012, DEV BIOL, V366, P64, DOI 10.1016/j.ydbio.2012.01.012; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; Tallini G, 2001, ADV ANAT PATHOL, V8, P345, DOI 10.1097/00125480-200111000-00005; Van der Flier LG, 2009, GASTROENTEROLOGY, V137, P15, DOI 10.1053/j.gastro.2009.05.035; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Zhang JC, 2002, GENE, V283, P83, DOI 10.1016/S0378-1119(01)00763-6	43	2	2	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					72	82		10.1038/s41388-021-02072-1	http://dx.doi.org/10.1038/s41388-021-02072-1		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34675408				2022-12-28	WOS:000709687900001
J	Komura, K; Inamoto, T; Tsujino, T; Matsui, Y; Konuma, T; Nishimura, K; Uchimoto, T; Tsutsumi, T; Matsunaga, T; Maenosono, R; Yoshikawa, Y; Taniguchi, K; Tanaka, T; Uehara, H; Hirata, K; Hirano, H; Nomi, H; Hirose, Y; Ono, F; Azuma, H				Komura, Kazumasa; Inamoto, Teruo; Tsujino, Takuya; Matsui, Yusuke; Konuma, Tsuyoshi; Nishimura, Kazuki; Uchimoto, Taizo; Tsutsumi, Takeshi; Matsunaga, Tomohisa; Maenosono, Ryoichi; Yoshikawa, Yuki; Taniguchi, Kohei; Tanaka, Tomohito; Uehara, Hirofumi; Hirata, Koichi; Hirano, Hajime; Nomi, Hayahito; Hirose, Yoshinobu; Ono, Fumihito; Azuma, Haruhito			Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents	ONCOGENE			English	Article							FOXM1/BUB1B SIGNALING PATHWAY; CELL-LINE; BUBR1; ATM; BLADDER; TRANSCRIPTION; INHIBITOR; PLATFORM; REGIONS; APC/C	There has been accumulating evidence for the clinical benefit of chemoradiation therapy (CRT), whereas mechanisms in CRT-recurrent clones derived from the primary tumor are still elusive. Herein, we identified an aberrant BUB1B/BUBR1 expression in CRT-recurrent clones in bladder cancer (BC) by comprehensive proteomic analysis. CRT-recurrent BC cells exhibited a cell-cycle-independent upregulation of BUB1B/BUBR1 expression rendering an enhanced DNA repair activity in response to DNA double-strand breaks (DSBs). With DNA repair analyses employing the CRISPR/cas9 system, we revealed that cells with aberrant BUB1B/BUBR1 expression dominantly exploit mutagenic nonhomologous end joining (NHEJ). We further found that phosphorylated ATM interacts with BUB1B/BUBR1 after ionizing radiation (IR) treatment, and the resistance to DSBs by increased BUB1B/BUBR1 depends on the functional ATM. In vivo, tumor growth of CRT-resistant T24R cells was abrogated by ATM inhibition using AZD0156. A dataset analysis identified FOXM1 as a putative BUB1B/BUBR1-targeting transcription factor causing its increased expression. These data collectively suggest a redundant role of BUB1B/BUBR1 underlying mutagenic NHEJ in an ATM-dependent manner, aside from the canonical activity of BUB1B/BUBR1 on the G2/M checkpoint, and offer novel clues to overcome CRT resistance.	[Komura, Kazumasa; Inamoto, Teruo; Nishimura, Kazuki; Uchimoto, Taizo; Matsunaga, Tomohisa; Maenosono, Ryoichi; Yoshikawa, Yuki; Uehara, Hirofumi; Hirano, Hajime; Nomi, Hayahito; Azuma, Haruhito] Osaka Med & Pharmaceut Univ, Dept Urol, Osaka 5698686, Japan; [Komura, Kazumasa; Taniguchi, Kohei; Tanaka, Tomohito; Ono, Fumihito] Osaka Med & Pharmaceut Univ, Translat Res Program, Osaka 5698686, Japan; [Tsujino, Takuya; Tsutsumi, Takeshi] Harvard Med Sch, Brigham & Womens Hosp, Dept Surg, Div Urol, Boston, MA 02115 USA; [Matsui, Yusuke] Nagoya Univ, Dept Integrated Hlth Sci, Biomed & Hlth Informat Unit, Grad Sch Med, Nagoya, Aichi 4618673, Japan; [Matsui, Yusuke] Nagoya Univ, Inst Glycocore Res iGCORE, Nagoya, Aichi 4618673, Japan; [Konuma, Tsuyoshi] Yokohama City Univ, Grad Sch Med Life Sci, Yokohama, Kanagawa 2300045, Japan; [Hirata, Koichi; Hirose, Yoshinobu] Osaka Med & Pharmaceut Univ, Dept Pathol, Osaka 5698686, Japan; [Ono, Fumihito] Osaka Med & Pharmaceut Univ, Dept Physiol, Osaka 5698686, Japan	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Nagoya University; Nagoya University; Yokohama City University	Komura, K (corresponding author), Osaka Med & Pharmaceut Univ, Dept Urol, Osaka 5698686, Japan.; Komura, K (corresponding author), Osaka Med & Pharmaceut Univ, Translat Res Program, Osaka 5698686, Japan.	kazumasa.komura@ompu.ac.jp	Hirose, Yoshinobu/AAW-9079-2020	Hirose, Yoshinobu/0000-0002-3860-0293; Konuma, Tsuyoshi/0000-0002-4412-2849; Nishimura, Kazuki/0000-0002-2878-7664	Japan Society for the Promotion of Science: JSPS [21H03070, 19K18624, 17K16821, 16K11033, 16K11034]; Uehara Memorial Foundation; NOVARTIS Foundation (Japan) for the Promotion of Science; Japan Research Foundation for Clinical Pharmacology; Yamaguchi Endocrine Disease Research Foundation; Takeda Science Foundation; Young Research Grant of Japanese Urological Association (JUA)	Japan Society for the Promotion of Science: JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Uehara Memorial Foundation(Uehara Memorial Foundation); NOVARTIS Foundation (Japan) for the Promotion of Science(Novartis); Japan Research Foundation for Clinical Pharmacology; Yamaguchi Endocrine Disease Research Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Young Research Grant of Japanese Urological Association (JUA)	This work was partially supported by the Grant-in-Aid No. 21H03070, 19K18624, 17K16821, 16K11033, and 16K11034 (Japan Society for the Promotion of Science: JSPS), the Uehara Memorial Foundation, the NOVARTIS Foundation (Japan) for the Promotion of Science, Japan Research Foundation for Clinical Pharmacology, Yamaguchi Endocrine Disease Research Foundation, the Takeda Science Foundation, and Young Research Grant of Japanese Urological Association (JUA).	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Balmus G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07729-2; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bergom C, 2019, INT J RADIAT ONCOL, V105, P698, DOI 10.1016/j.ijrobp.2019.07.026; Betermier M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004086; Bolanos-Garcia VM, 2011, TRENDS BIOCHEM SCI, V36, P141, DOI 10.1016/j.tibs.2010.08.004; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chai N, 2018, BIOCHEM BIOPH RES CO, V500, P924, DOI 10.1016/j.bbrc.2018.04.201; Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48; Chao WCH, 2012, NATURE, V484, P208, DOI 10.1038/nature10896; Davenport JW, 1999, GENOMICS, V55, P113, DOI 10.1006/geno.1998.5629; Degorce SL, 2016, J MED CHEM, V59, P6281, DOI 10.1021/acs.jmedchem.6b00519; DINNEY CPN, 1995, J UROLOGY, V154, P1532, DOI 10.1016/S0022-5347(01)66923-4; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Fang Y, 2006, ONCOGENE, V25, P3598, DOI 10.1038/sj.onc.1209392; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gertz J, 2013, MOL CELL, V52, P25, DOI 10.1016/j.molcel.2013.08.037; Guo T, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1518-x; Jette NR, 2019, BRIT J CANCER, V121, P600, DOI 10.1038/s41416-019-0565-8; Kapanidou M, 2015, TRENDS MOL MED, V21, P364, DOI 10.1016/j.molmed.2015.04.003; Karess RE, 2013, INT REV CEL MOL BIO, V306, P223, DOI 10.1016/B978-0-12-407694-5.00006-7; Kato-Inui T, 2018, NUCLEIC ACIDS RES, V46, P4677, DOI 10.1093/nar/gky264; Kirmitzoglou I, 2015, BIOINFORMATICS, V31, P2208, DOI 10.1093/bioinformatics/btv115; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Lara-Gonzalez P, 2011, J CELL SCI, V124, P4332, DOI 10.1242/jcs.094763; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lee JS, 2010, J CLIN ONCOL, V28, P2660, DOI 10.1200/JCO.2009.25.0977; Ma Q, 2017, ONCOL REP, V38, P3367, DOI 10.3892/or.2017.6032; Mcree AJ, 2011, FUTURE ONCOL, V7, P409, DOI [10.2217/FON.11.7, 10.2217/fon.11.7]; Miyaoka Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep23549; MORITA T, 1995, UROL RES, V23, P143, DOI 10.1007/BF00389565; Myslinski E, 2007, NUCLEIC ACIDS RES, V35, P3453, DOI 10.1093/nar/gkm239; Randon G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39525-3; Riches LC, 2020, MOL CANCER THER, V19, P13, DOI 10.1158/1535-7163.MCT-18-1394; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rodgers K, 2016, J CELL PHYSIOL, V231, P15, DOI 10.1002/jcp.25053; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Sanders DA, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0696-z; Sanders DA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r6; Shen MJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1161-8; Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Thompson R, 2015, MOL CELL, V58, P767, DOI 10.1016/j.molcel.2015.03.034; Traven A, 2005, BIOESSAYS, V27, P397, DOI 10.1002/bies.20204; Wan XL, 2012, CANCER RES, V72, P5889, DOI 10.1158/0008-5472.CAN-12-1991; Wang C, 2017, TRANSL ONCOL, V10, P190, DOI 10.1016/j.tranon.2017.01.007; Weston VJ, 2010, BLOOD, V116, P4578, DOI 10.1182/blood-2010-01-265769; Zuiverloon TCM, 2018, BLADDER CANCER, V4, P169, DOI 10.3233/BLC-180167	51	5	5	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6210	6222		10.1038/s41388-021-02021-y	http://dx.doi.org/10.1038/s41388-021-02021-y		SEP 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34545188	Green Published, hybrid			2022-12-28	WOS:000698130400002
J	Di Giulio, S; Colicchia, V; Pastorino, F; Pedretti, F; Fabretti, F; di Robilant, VN; Ramponi, V; Scafetta, G; Moretti, M; Licursi, V; Belardinilli, F; Peruzzi, G; Infante, P; Goffredo, BM; Coppa, A; Canettieri, G; Bartolazzi, A; Ponzoni, M; Giannini, G; Petroni, M				Di Giulio, Stefano; Colicchia, Valeria; Pastorino, Fabio; Pedretti, Flaminia; Fabretti, Francesca; di Robilant, Vittoria Nicolis; Ramponi, Valentina; Scafetta, Giorgia; Moretti, Marta; Licursi, Valerio; Belardinilli, Francesca; Peruzzi, Giovanna; Infante, Paola; Goffredo, Bianca Maria; Coppa, Anna; Canettieri, Gianluca; Bartolazzi, Armando; Ponzoni, Mirco; Giannini, Giuseppe; Petroni, Marialaura			A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors	ONCOGENE			English	Article							N-MYC; HUMAN NEUROBLASTOMA; REPLICATION STRESS; EXPRESSION; CELLS; PROGRESSION; SENSITIVITY; DELETION; ONCOGENE; HMGI(Y)	MYCN drives aggressive behavior and refractoriness to chemotherapy, in several tumors. Since MYCN inactivation in clinical settings is not achievable, alternative vulnerabilities of MYCN-driven tumors need to be explored to identify more effective and less toxic therapies. We previously demonstrated that PARP inhibitors enhance MYCN-induced replication stress and promote mitotic catastrophe, counteracted by CHK1. Here, we showed that PARP and CHK1 inhibitors synergized to induce death in neuroblastoma cells and in primary cultures of SHH-dependent medulloblastoma, their combination being more effective in MYCN amplified and MYCN overexpressing cells compared to MYCN non-amplified cells. Although the MYCN amplified IMR-32 cell line carrying the p.Val2716Ala ATM mutation showed the highest sensitivity to the drug combination, this was not related to ATM status, as indicated by CRISPR/Cas9-based correction of the mutation. Suboptimal doses of the CHK1 inhibitor MK-8776 plus the PARP inhibitor olaparib led to a MYCN-dependent accumulation of DNA damage and cell death in vitro and significantly reduced the growth of four in vivo models of MYCN-driven tumors, without major toxicities. Our data highlight the combination of PARP and CHK1 inhibitors as a new potential chemo-free strategy to treat MYCN-driven tumors, which might be promptly translated into clinical trials.	[Di Giulio, Stefano; Colicchia, Valeria; Pedretti, Flaminia; Fabretti, Francesca; di Robilant, Vittoria Nicolis; Ramponi, Valentina; Belardinilli, Francesca; Canettieri, Gianluca; Giannini, Giuseppe; Petroni, Marialaura] Univ Roma La Sapienza, Dept Mol Med, I-00161 Rome, Italy; [Pastorino, Fabio; Ponzoni, Mirco] IRCCS Ist Giannina Gaslini, Lab Expt Therapies Oncol, I-16147 Genoa, Italy; [Scafetta, Giorgia; Bartolazzi, Armando] St Andrea Univ Hosp, Pathol Res Lab, I-00189 Rome, Italy; [Moretti, Marta; Coppa, Anna] Univ Roma La Sapienza, Dept Expt Med, I-00161 Rome, Italy; [Licursi, Valerio] Univ Roma La Sapienza, Dept Biol & Biotechnol Charles Darwin, I-00185 Rome, Italy; [Peruzzi, Giovanna; Infante, Paola] Fdn Ist Italiano Tecnol IIT, Ctr Life Nano & Neuro Sci, Rome, Italy; [Goffredo, Bianca Maria] Osped Pediat Bambino Gesu, Metab Pathol Lab, I-00165 Rome, Italy; [Canettieri, Gianluca; Giannini, Giuseppe] Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy; [Colicchia, Valeria] Univ Tor Vergata, Dept Biol, I-00173 Rome, Italy; [Pedretti, Flaminia] Vail dHebron Inst Oncol VHIO, Vail dHebron Res Inst VHIR, Expt Therapeut Grp, Barcelona, Spain; [Ramponi, Valentina] Barcelona Inst Sci & Technol BIST, Inst Res Biomed IRB Barcelona, Cellular Plast & Dis Grp, Barcelona 08028, Spain	Sapienza University Rome; University of Genoa; IRCCS Istituto Giannina Gaslini; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Sapienza University Rome; Sapienza University Rome; Istituto Italiano di Tecnologia - IIT; IRCCS Bambino Gesu; Fondazione Cenci Bolognetti; University of Rome Tor Vergata; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Vall d'Hebron Institut d'Oncologia (VHIO); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona	Giannini, G (corresponding author), Univ Roma La Sapienza, Dept Mol Med, I-00161 Rome, Italy.; Giannini, G (corresponding author), Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy.	giuseppe.giannini@uniroma1.it	Scafetta, Giorgia/AAB-9787-2022; Giannini, Giuseppe/B-5672-2013	Peruzzi, Giovanna/0000-0002-6517-9107; Giannini, Giuseppe/0000-0003-0299-4056; Belardinilli, Francesca/0000-0003-4966-7044; Infante, Paola/0000-0003-0682-3916; CANETTIERI, Gianluca/0000-0001-6694-2613	Italian Ministry of Education, Universities and Research-Dipartimenti di Eccellenza [L. 232/2016]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG17734, IG24329]; Italian Ministry of University and Research, PRIN projects; Istituto Pasteur-Fondazione Cenci Bolognetti; fondi Ricerca Ateneo La Sapienza; AIRC [IG17575]; AFM-Telethon grant [21025]; PhD Programme in Tecnologie Biomediche in Medicina Clinica, University La Sapienza; Fondazione Umberto Veronesi	Italian Ministry of Education, Universities and Research-Dipartimenti di Eccellenza(Ministry of Education, Universities and Research (MIUR)); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research, PRIN projects; Istituto Pasteur-Fondazione Cenci Bolognetti(Istituto Pasteur Italia Fondazione Cenci Bolognetti); fondi Ricerca Ateneo La Sapienza; AIRC(Fondazione AIRC per la ricerca sul cancro); AFM-Telethon grant; PhD Programme in Tecnologie Biomediche in Medicina Clinica, University La Sapienza; Fondazione Umberto Veronesi(Fondazione Umberto Veronesi)	We are grateful to Michele Cilli and Laura Emionite for technical supports in the animal facility and Antonio Daga for the luciferase transfection of IMR-32 cells. We are also grateful to Simone De Panfilis (CLN2S@Sapienza Imaging Facility of the Istituto Italiano di Tecnologia, Rome, Italy) for the acquisition of confocal microscopy data. This work was supported by: Italian Ministry of Education, Universities and Research-Dipartimenti di Eccellenza-L. 232/2016; Associazione Italiana per la Ricerca sul Cancro (AIRC) grant IG17734 and IG24329, Italian Ministry of University and Research, PRIN projects, Istituto Pasteur-Fondazione Cenci Bolognetti and fondi Ricerca Ateneo La Sapienza (to GG); AIRC grant IG17575, AFM-Telethon grant #21025, and Istituto Pasteur-Fondazione Cenci Bolognetti (to GC). FF and FB were recipients of fellowships from the PhD Programme in Tecnologie Biomediche in Medicina Clinica, University La Sapienza and Fondazione Umberto Veronesi, respectively.	Althoff K, 2015, ONCOGENE, V34, P3357, DOI 10.1038/onc.2014.269; Bendell JC, 2020, INVEST NEW DRUG, V38, P1145, DOI 10.1007/s10637-019-00873-6; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cash T, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.29065; Chayka O, 2015, J BIOL CHEM, V290, P2198, DOI 10.1074/jbc.M114.624056; Chesler L, 2011, SEMIN CANCER BIOL, V21, P245, DOI 10.1016/j.semcancer.2011.09.011; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Colicchia V, 2017, ONCOGENE, V36, P4682, DOI 10.1038/onc.2017.40; Cossu I, 2015, BIOMATERIALS, V68, P89, DOI 10.1016/j.biomaterials.2015.07.054; Daud AI, 2015, J CLIN ONCOL, V33, P1060, DOI 10.1200/JCO.2014.57.5027; Demuth I, 2011, NEUROGENETICS, V12, P273, DOI 10.1007/s10048-011-0299-0; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng FY, 2015, MOL CELL, V58, P925, DOI 10.1016/j.molcel.2015.04.016; Forment JV, 2018, PHARMACOL THERAPEUT, V188, P155, DOI 10.1016/j.pharmthera.2018.03.005; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Giannini G, 1999, CANCER RES, V59, P2484; Giannini G, 2000, BRIT J CANCER, V83, P1503, DOI 10.1054/bjoc.2000.1494; Gu L, 2015, EBIOMEDICINE, V2, P1923, DOI 10.1016/j.ebiom.2015.11.016; Hatton BA, 2006, CANCER RES, V66, P8655, DOI 10.1158/0008-5472.CAN-06-1621; Hou HG, 2015, INT J CANCER, V136, P1688, DOI 10.1002/ijc.29132; Judware R, 1995, ONCOGENE, V11, P2599; Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095; Lee EK, 2019, TRENDS CANCER, V5, P524, DOI 10.1016/j.trecan.2019.06.004; Lowery CD, 2019, CLIN CANCER RES, V25, P2278, DOI 10.1158/1078-0432.CCR-18-2728; Lowery CD, 2017, CLIN CANCER RES, V23, P4354, DOI 10.1158/1078-0432.CCR-16-2876; Lupo B, 2014, BBA-REV CANCER, V1846, P201, DOI 10.1016/j.bbcan.2014.07.004; Lutz W, 1996, ONCOGENE, V13, P803; Mandriota SJ, 2015, ONCOTARGET, V6, P18558, DOI 10.18632/oncotarget.4061; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Olsen RR, 2017, ONCOGENE, V36, P5075, DOI 10.1038/onc.2017.128; Paquet D, 2016, NATURE, V533, P125, DOI 10.1038/nature17664; Pastorino F, 2003, CANCER RES, V63, P7400; Petroni M, 2016, CELL DEATH DIFFER, V23, P197, DOI 10.1038/cdd.2015.81; Petroni M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56057-y; Petroni M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0924-z; Petroni M, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1079673; Petroni M, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00141; Petroni M, 2011, MOL CANCER RES, V9, P67, DOI 10.1158/1541-7786.MCR-10-0227; Rickman DS, 2018, CANCER DISCOV, V8, P150, DOI 10.1158/2159-8290.CD-17-0273; Rundle S, 2017, CANCERS, V9, DOI 10.3390/cancers9050041; Russell MR, 2013, CANCER RES, V73, P776, DOI 10.1158/0008-5472.CAN-12-2669; Sanmartin E, 2017, CLIN CANCER RES, V23, P6875, DOI 10.1158/1078-0432.CCR-17-0593; Scott SP, 2002, P NATL ACAD SCI USA, V99, P925, DOI 10.1073/pnas.012329699; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Southgate HED, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00371; Swartling FJ, 2010, GENE DEV, V24, P1059, DOI 10.1101/gad.1907510; Takagi M, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1409-7; Takagi M, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/.inci/djx062; Ubhi T, 2019, CANCER RES, V79, P1730, DOI 10.1158/0008-5472.CAN-18-3631; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Wehler T, 2017, LUNG CANCER, V108, P212, DOI 10.1016/j.lungcan.2017.03.001; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Whitfield JR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00010; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yap Timothy A, 2019, Am Soc Clin Oncol Educ Book, V39, P185, DOI 10.1200/EDBK_238473	57	7	7	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6143	6152		10.1038/s41388-021-02003-0	http://dx.doi.org/10.1038/s41388-021-02003-0		SEP 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34508175	hybrid, Green Published			2022-12-28	WOS:000694774500002
J	Wang, CX; Long, QL; Fu, Q; Xu, QX; Fu, D; Li, Y; Gao, LB; Guo, JM; Zhang, XL; Lam, EWF; Campisi, J; Sun, Y				Wang, Changxu; Long, Qilai; Fu, Qiang; Xu, Qixia; Fu, Da; Li, Yan; Gao, Libin; Guo, Jianming; Zhang, Xiaoling; Lam, Eric W-F; Campisi, Judith; Sun, Yu			Targeting epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistance	ONCOGENE			English	Article							SENESCENCE; CANCER; PATHWAY; EGFR; AMPHIREGULIN; PANITUMUMAB; TRIAL	The tumor microenvironment (TME) represents a milieu enabling cancer cells to develop malignant properties, while concerted interactions between cancer and stromal cells frequently shape an "activated/reprogramed" niche to accelerate pathological progression. Here we report that a soluble factor epiregulin (EREG) is produced by senescent stromal cells, which non-cell-autonomously develop the senescence-associated secretory phenotype (SASP) upon DNA damage. Genotoxicity triggers EREG expression by engaging NF-kappa B and C/EBP, a process supported by elevated chromatin accessibility and increased histone acetylation. Stromal EREG reprograms the expression profile of recipient neoplastic cells in a paracrine manner, causing upregulation of MARCHF4, a membrane-bound E3 ubiquitin ligase involved in malignant progression, specifically drug resistance. A combinational strategy that empowers EREG-specific targeting in treatment-damaged TME significantly promotes cancer therapeutic efficacy in preclinical trials, achieving response indices superior to those of solely targeting cancer cells. In clinical oncology, EREG is expressed in tumor stroma and handily measurable in circulating blood of cancer patients post-chemotherapy. This study establishes EREG as both a targetable SASP factor and a new noninvasive biomarker of treatment-damaged TME, thus disclosing its substantial value in translational medicine. [GRAPHICS] .	[Wang, Changxu; Xu, Qixia; Li, Yan; Gao, Libin; Sun, Yu] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai 200031, Peoples R China; [Long, Qilai; Guo, Jianming] Fudan Univ, Zhongshan Hosp, Dept Urol, Shanghai 200032, Peoples R China; [Fu, Qiang; Sun, Yu] Binzhou Med Univ, Inst Aging Med, Dept Pharmacol, Yantai 264003, Shandong, Peoples R China; [Fu, Da] Tongji Univ, Shanghai Peoples Hosp 10, Cent Lab Med Res, Sch Med, Shanghai 200072, Peoples R China; [Zhang, Xiaoling] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Orthoped Surg, Sch Med, Shanghai 200092, Peoples R China; [Lam, Eric W-F] Imperial Coll London, Dept Surg & Canc, London W12 0NN, England; [Campisi, Judith] Buck Inst Res Aging, Novato, CA 94945 USA; [Campisi, Judith] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; [Sun, Yu] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Sun, Yu] Univ Washington, VAPSHCS, Seattle, WA 98195 USA	Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; University of Chinese Academy of Sciences, CAS; Fudan University; Binzhou Medical University; Tongji University; Shanghai Jiao Tong University; Imperial College London; Buck Institute for Research on Aging; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Sun, Y (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai 200031, Peoples R China.; Sun, Y (corresponding author), Binzhou Med Univ, Inst Aging Med, Dept Pharmacol, Yantai 264003, Shandong, Peoples R China.; Sun, Y (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.; Sun, Y (corresponding author), Univ Washington, VAPSHCS, Seattle, WA 98195 USA.	sunyu@sibs.ac.cn	; fu, qiang/O-7262-2014	Lam, Eric/0000-0003-1274-3576; fu, qiang/0000-0002-6932-7103	National Key Research and Development Program of China [2020YFC2002800, 2016YFC1302400]; National Natural Science Foundation of China (NSFC) [81472709, 31671425, 31871380, 82130045]; Strategic Priority Research Program of Chinese Academy of Sciences [XDB39010500]; Anti-Aging Collaborative Program of SINH and BY-HEALTH [C01201911260006, C01202112160005]; Joint Fund Program of Natural Science Foundation of Shandong Province [ZR202108130049, ZR2021LSW021]; University and Locality Collaborative Development Program of Yantai [2019XDRHXMRC08, 2020XDRHXMXK02, 2021XDHZ082]; U.S. DoD PCRP [PC111703]; National Natural Science Foundation of China [81370730, 81571512]; Yantai Double Hundred Program	National Key Research and Development Program of China; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Strategic Priority Research Program of Chinese Academy of Sciences(Chinese Academy of Sciences); Anti-Aging Collaborative Program of SINH and BY-HEALTH; Joint Fund Program of Natural Science Foundation of Shandong Province; University and Locality Collaborative Development Program of Yantai; U.S. DoD PCRP; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Yantai Double Hundred Program	We are grateful to members of Sun laboratory for reagents, comments and other contributions to this project. We appreciate Ge Zhang for technical assistance of bioinformatics profiling of epigenetic datasets. The work was supported by grants from National Key Research and Development Program of China (2020YFC2002800, 2016YFC1302400), National Natural Science Foundation of China (NSFC) (81472709, 31671425, 31871380, 82130045) to YS, the Strategic Priority Research Program of Chinese Academy of Sciences (XDB39010500) to YS, Anti-Aging Collaborative Program of SINH and BY-HEALTH (C01201911260006 and C01202112160005) to YS, Joint Fund Program of Natural Science Foundation of Shandong Province (ZR202108130049 and ZR2021LSW021), the University and Locality Collaborative Development Program of Yantai (2019XDRHXMRC08 and 2020XDRHXMXK02) to YS, and the U.S. DoD PCRP (Idea Development Award PC111703) to YS; National Natural Science Foundation of China (81370730, 81571512), the University and Locality Collaborative Development Program of Yantai (2021XDHZ082) and Yantai Double Hundred Program to QF.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Apweiler R, 2010, NUCLEIC ACIDS RES, V38, pD142, DOI 10.1093/nar/gkp846; Babon JJ, 2019, BIOCHEM J, V476, P2869, DOI 10.1042/BCJ20190577; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Birch J, 2020, GENE DEV, V34, P1565, DOI 10.1101/gad.343129.120; Bruyere C, 2014, J INORG BIOCHEM, V141, P144, DOI 10.1016/j.jinorgbio.2014.08.015; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06860-4; Cho MC, 2008, BIOCHEM BIOPH RES CO, V377, P832, DOI 10.1016/j.bbrc.2008.10.053; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Costa VM, 2020, ARCH TOXICOL, V94, P4067, DOI 10.1007/s00204-020-02874-4; D'Alterio C, 2020, SEMIN CANCER BIOL, V60, P351, DOI 10.1016/j.semcancer.2019.08.019; Das T, 2021, DRUG RESIST UPDATE, V55, DOI 10.1016/j.drup.2021.100754; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Di Nicolantonio F, 2021, NAT REV CLIN ONCOL, V18, P506, DOI 10.1038/s41571-021-00495-z; Dueck AC, 2020, JAMA ONCOL, V6, DOI 10.1001/jamaoncol.2019.3332; El-Hashim AZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09349-0; Fedchenko N, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0221-9; Fitsiou E, 2022, SEMIN CANCER BIOL, V81, P5, DOI 10.1016/j.semcancer.2021.03.021; Flanagan KC, 2018, ONCOTARGET, V9, P21, DOI 10.18632/oncotarget.22940; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69; Gao L, 2018, PATHOL RES PRACT, V214, P732, DOI 10.1016/j.prp.2018.03.002; Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005; He MJ, 2019, ONCOGENE, V38, P5551, DOI 10.1038/s41388-019-0817-3; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hernandez-Segura A, 2017, CURR BIOL, V27, P2652, DOI 10.1016/j.cub.2017.07.033; Hollis A, 2012, CHEMBIOCHEM, V13, P302, DOI 10.1002/cbic.201100652; Job S, 2019, CANCERS, V11, DOI 10.3390/cancers11060795; Kamide D, 2016, CANCER SCI, V107, P666, DOI 10.1111/cas.12914; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Kohsaka S, 2014, NEURO-ONCOLOGY, V16, P960, DOI 10.1093/neuonc/not315; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Li SQ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.634097; Lim JJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9141343; Liu PY, 2021, NAT CELL BIOL, V23, P355, DOI 10.1038/s41556-021-00656-3; Liu SL, 2020, THERANOSTICS, V10, P10589, DOI 10.7150/thno.47176; Ma SQ, 2021, ONCOGENE, V40, P2596, DOI 10.1038/s41388-021-01734-4; Maglott D, 2011, NUCLEIC ACIDS RES, V39, pD52, DOI 10.1093/nar/gkq1237; Mancini M, 2018, EMBO MOL MED, V10, P294, DOI 10.15252/emmm.201708076; Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748; Parry AJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04283-9; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892; Qu X, 2016, ONCOGENE, V35, P6403, DOI 10.1038/onc.2016.170; Qu YD, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0992-4; Riese DJ, 2014, SEMIN CELL DEV BIOL, V28, P49, DOI 10.1016/j.semcdb.2014.03.005; Rodier F, 2011, J CELL SCI, V124, P68, DOI 10.1242/jcs.071340; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Ruscetti M, 2020, CELL, V181, P424, DOI 10.1016/j.cell.2020.03.008; Seligmann JF, 2020, ANN ONCOL, V31, P1021, DOI 10.1016/j.annonc.2020.04.476; Sen P, 2019, MOL CELL, V73, P684, DOI 10.1016/j.molcel.2019.01.021; Song SL, 2020, TRENDS BIOCHEM SCI, V45, P578, DOI 10.1016/j.tibs.2020.03.008; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Strimpakos A, 2013, CLIN COLORECTAL CANC, V12, P267, DOI 10.1016/j.clcc.2013.07.001; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Sun Y, 2016, CANCER LETT, V380, P205, DOI 10.1016/j.canlet.2015.07.044; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Torring N, 2005, PROSTATE, V64, P1, DOI 10.1002/pros.20214; Wang YJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1277-x; Watanabe T, 2010, EUR J CANCER, V46, P2119, DOI 10.1016/j.ejca.2010.04.019; Westendorp F, 2021, ONCOGENE, V40, P1628, DOI 10.1038/s41388-020-01633-0; Wiley CD, 2017, AGING CELL, V16, P1043, DOI 10.1111/acel.12632; Williams CJM, 2021, CLIN CANCER RES, V27, P3422, DOI 10.1158/1078-0432.CCR-21-0120; Wilson KJ, 2009, PHARMACOL THERAPEUT, V122, P1, DOI 10.1016/j.pharmthera.2008.11.008; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xia QY, 2019, PATHOL RES PRACT, V215, P873, DOI 10.1016/j.prp.2019.01.030; Yang JL, 2014, CANCER CHEMOTH PHARM, V74, P637, DOI 10.1007/s00280-014-2523-8; Zhang BY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04010-4	72	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4941	4959		10.1038/s41388-022-02476-7	http://dx.doi.org/10.1038/s41388-022-02476-7		OCT 2022	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36202915	Green Submitted, hybrid, Green Published			2022-12-28	WOS:000864553300001
J	Wang, XH; Brea, L; Lu, XD; Gritsina, G; Park, SH; Xie, WQ; Zhao, JC; Yu, JD				Wang, Xiaohai; Brea, Lourdes; Lu, Xiaodong; Gritsina, Galina; Park, Su H.; Xie, Wanqing; Zhao, Jonathan C.; Yu, Jindan			FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A	ONCOGENE			English	Article							RESISTANT PROSTATE-CANCER; BIOCHEMICAL FAILURE; TUMOR HYPOXIA; RADIOTHERAPY; PROGRESSION; CCL2	Intratumoral hypoxia is associated with castration-resistant prostate cancer (CRPC), a lethal disease. FOXA1 is an epithelial transcription factor that is down-regulated in CRPC. We have previously reported that FOXA1 loss induces epithelial-mesenchymal transition (EMT) and cell motility through elevated TGF beta signaling. However, whether FOXA1 directly regulates hypoxia pathways of CRPC tumors has not been previously studied. Here we report that FOXA1 down-regulation induces hypoxia transcriptional programs, and FOXA1 level is negatively correlated with hypoxia markers in clinical prostate cancer (PCa) samples. Mechanistically, FOXA1 directly binds to an intragenic enhancer of HIF1A to inhibit its expression, and HIF1A, in turn, is critical in mediating FOXA1 loss-induced hypoxia gene expression. Further, we identify CCL2, a chemokine ligand that modulates tumor microenvironment and promotes cancer progression, as a crucial target of the FOXA1-HIF1A axis. We found that FOXA1 loss leads to immunosuppressive macrophage infiltration and increased cell invasion, dependent on HIF1A expression. Critically, therapeutic targeting of HIF1A-CCL2 using pharmacological inhibitors abolishes FOXA1 loss-induced macrophage infiltration and PCa cell invasion. In summary, our study reveals an essential role of FOXA1 in controlling the hypoxic tumor microenvironment and establishes the HIF1A-CCL2 axis as one mechanism of FOXA1 loss-induced CRPC progression.	[Wang, Xiaohai; Brea, Lourdes; Lu, Xiaodong; Gritsina, Galina; Park, Su H.; Xie, Wanqing; Zhao, Jonathan C.; Yu, Jindan] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA; [Wang, Xiaohai] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China; [Yu, Jindan] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Yu, Jindan] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Shanghai Jiao Tong University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine	Yu, JD (corresponding author), Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA.; Yu, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.; Yu, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu		Brea, Lourdes/0000-0001-9727-7185; Lu, xiaodong/0000-0003-4731-0762; Gritsina, Galina/0000-0002-3404-7961	NIH [P50CA180995, R50CA211271]; Prostate Cancer Foundation [2017CHAL2008]; NIH/NCI [T32 CA009560]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the NIH prostate SPORE P50CA180995 (to JY), NIH R50CA211271 (to JCZ), and Prostate Cancer Foundation 2017CHAL2008 (to JY, JCZ). LB, SHP, and GG were supported in part by NIH/NCI training grant T32 CA009560.	Brahimi-Horn MC, 2005, INT REV CYTOL, V242, P157; Fraga A, 2015, CLIN GENITOURIN CANC, V13, P295, DOI 10.1016/j.clgc.2015.03.006; Fumagalli D, 2016, ANN ONCOL, V27, P1860, DOI 10.1093/annonc/mdw286; Geng H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07411-7; Guo HY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08133-6; Gupta K, 2017, TRANSL CANCER RES, V6, pS104, DOI 10.21037/tcr.2017.01.20; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He YD, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI147025; Henze AT, 2016, J CLIN INVEST, V126, P3672, DOI 10.1172/JCI84427; Jin HJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4972; Jin HJ, 2013, CANCER RES, V73, P3725, DOI 10.1158/0008-5472.CAN-12-3468; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kim J, 2017, ONCOGENE, V36, P4072, DOI 10.1038/onc.2017.50; Korbecki J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165647; Kupelian PA, 2006, UROLOGY, V68, P593, DOI 10.1016/j.urology.2006.03.075; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lee GT, 2018, BRIT J CANCER, V118, P670, DOI 10.1038/bjc.2017.451; Li N, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060799; Lim SY, 2016, ONCOTARGET, V7, P28697, DOI 10.18632/oncotarget.7376; Lin YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0760-3; Litwin MS, 2017, JAMA-J AM MED ASSOC, V317, P2532, DOI 10.1001/jama.2017.7248; Liu YW, 2014, NAT MED, V20, P272, DOI 10.1038/nm.3485; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506; Lo CH, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00247; Loberg RD, 2007, NEOPLASIA, V9, P556, DOI 10.1593/neo.07307; Milosevic M, 2012, CLIN CANCER RES, V18, P2108, DOI 10.1158/1078-0432.CCR-11-2711; Mimeault M, 2013, J CELL MOL MED, V17, P30, DOI 10.1111/jcmm.12004; Narita T, 2009, NEURO-ONCOLOGY, V11, P946; Nguyen HM, 2017, PROSTATE, V77, P654, DOI 10.1002/pros.23313; Noman MZ, 2015, AM J PHYSIOL-CELL PH, V309, pC569, DOI 10.1152/ajpcell.00207.2015; Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008; Phatnani HP, 2006, GENE DEV, V20, P2922, DOI 10.1101/gad.1477006; Ranasinghe WKB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054251; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551; Song B, 2019, J CLIN INVEST, V129, P569, DOI 10.1172/JCI122367; Su WJ, 2019, CANCER CELL, V36, P139, DOI 10.1016/j.ccell.2019.06.009; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tran MGB, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06890-6; Tsai YC, 2018, BBA-MOL BASIS DIS, V1864, P1717, DOI 10.1016/j.bbadis.2018.02.016; Tucci M, 2018, ONCOTARGETS THER, V11, P7353, DOI 10.2147/OTT.S153764; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; Vergis R, 2008, LANCET ONCOL, V9, P342, DOI 10.1016/S1470-2045(08)70076-7; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang KL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15396-5; Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009; Zhong H, 2004, CANCER DETECT PREV, V28, P88, DOI 10.1016/j.cdp.2003.12.009	50	1	1	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4259	4270		10.1038/s41388-022-02423-6	http://dx.doi.org/10.1038/s41388-022-02423-6		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35931888				2022-12-28	WOS:000836492100001
J	Constantin, TA; Greenland, KK; Varela-Carver, A; Bevan, CL				Constantin, Theodora A.; Greenland, Kyle K.; Varela-Carver, Anabel; Bevan, Charlotte L.			Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer	ONCOGENE			English	Review							NUCLEOTIDE EXCISION-REPAIR; INHIBITOR BAY 1251152; P-TEFB; ANDROGEN RECEPTOR; PRECLINICAL MODELS; SERINE PHOSPHORYLATION; PREINITIATION COMPLEX; SELECTIVE INHIBITOR; COVALENT INHIBITOR; ANTITUMOR-ACTIVITY	Transcriptional deregulation has emerged as a hallmark of several cancer types. In metastatic castration-resistant prostate cancer, a stage in which systemic androgen deprivation therapies fail to show clinical benefit, transcriptional addiction to the androgen receptor is maintained in most patients. This has led to increased efforts to find novel therapies that prevent oncogenic transactivation of the androgen receptor. In this context, a group of druggable protein kinases, known as transcription associated cyclin-dependent kinases (tCDKs), show great potential as therapeutic targets. Despite initial reservations about targeting tCDKs due to their ubiquitous and prerequisite nature, preclinical studies showed that selectively inhibiting such kinases could provide sufficient therapeutic window to exert antitumour effects in the absence of systemic toxicity. As a result, several highly specific inhibitors are currently being trialled in solid tumours, including prostate cancer. This article summarises the roles of tCDKs in regulating gene transcription and highlights rationales for their targeting in prostate cancer. It provides an overview of the most recent developments in this therapeutic area, including the most recent clinical advances, and discusses the utility of tCDK inhibitors in combination with established cancer agents.	[Constantin, Theodora A.; Greenland, Kyle K.; Varela-Carver, Anabel; Bevan, Charlotte L.] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Imperial Ctr Translat & Expt Med, London, England	Imperial College London	Bevan, CL (corresponding author), Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Imperial Ctr Translat & Expt Med, London, England.	charlotte.bevan@imperial.ac.uk	; Bevan, Charlotte/K-2276-2012	Greenland, Kyle/0000-0003-3887-4160; Bevan, Charlotte/0000-0002-7533-0552; Constantin, Theodora Alexandra/0000-0003-2132-5165	Medical Research Council Doctoral Training Partnership [MR/N014103/1]; Imperial President's PhD Scholarship	Medical Research Council Doctoral Training Partnership(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Imperial President's PhD Scholarship	This work was supported by the Medical Research Council Doctoral Training Partnership (TAC and KKG) (grant number MR/N014103/1) and the Imperial President's PhD Scholarship (TAC).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Ali S, 2009, CANCER RES, V69, P6208, DOI 10.1158/0008-5472.CAN-09-0301; Araujo SJ, 2000, GENE DEV, V14, P349; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Barlaam B, 2020, J MED CHEM, V63, P15564, DOI 10.1021/acs.jmedchem.0c01754; Bose P, 2013, EXPERT OPIN INV DRUG, V22, P723, DOI 10.1517/13543784.2013.789859; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Byrne M, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-117257; Chen MQ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111413; Chen XR, 2020, NPJ PRECIS ONCOL, V4, DOI 10.1038/s41698-020-00137-0; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; Cidado J, 2020, CLIN CANCER RES, V26, P922, DOI 10.1158/1078-0432.CCR-19-1853; Clarke PA, 2016, ELIFE, V5, DOI 10.7554/eLife.20722; Coin F, 2008, MOL CELL, V31, P9, DOI 10.1016/j.molcel.2008.04.024; Daniels D., 2013, J PROTEOM BIOINFORM, V2, P004, DOI DOI 10.4172/JPB.S2-004; Diamond JR, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.2507; Dubbury SJ, 2018, NATURE, V564, P141, DOI 10.1038/s41586-018-0758-y; Durbin AD, 2018, NAT GENET, V50, P1240, DOI 10.1038/s41588-018-0191-z; Ebmeier CC, 2017, CELL REP, V20, P1173, DOI 10.1016/j.celrep.2017.07.021; Egloff S, 2018, TRANSCR-AUSTIN, V9, P95, DOI 10.1080/21541264.2017.1344346; Egloff S, 2012, RNA BIOL, V9, P1033, DOI 10.4161/rna.21166; Eick D, 2013, CHEM REV, V113, P8456, DOI 10.1021/cr400071f; Fisher RP, 2019, TRANSCR-AUSTIN, V10, P47, DOI 10.1080/21541264.2018.1553483; Gajduskova P, 2020, NAT STRUCT MOL BIOL, DOI 10.1038/s41594-020-0406-8; Gordon V, 2010, MOL ENDOCRINOL, V24, P2267, DOI 10.1210/me.2010-0238; Greber BJ, 2019, ELIFE, V8, DOI 10.7554/eLife.44771; Greenleaf AL, 2019, TRANSCR-AUSTIN, V10, P91, DOI 10.1080/21541264.2018.1535211; Guarducci C, 2019, P 2018 SAN ANTONIO B, pPD712; Guen VJ, 2013, P NATL ACAD SCI USA, V110, P19525, DOI 10.1073/pnas.1306814110; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Henry SH, 2021, ANN ONCOL, V32, pS364, DOI 10.1016/j.annonc.2021.08.291; Hsin JP, 2012, GENE DEV, V26, P2119, DOI 10.1101/gad.200303.112; Hsin JP, 2011, SCIENCE, V334, P683, DOI 10.1126/science.1206034; Hu SH, 2019, CANCER RES, V79, P3479, DOI 10.1158/0008-5472.CAN-19-0119; Jaeger MG, 2020, NAT GENET, V52, P719, DOI 10.1038/s41588-020-0635-0; Jiang BS, 2021, EUR J MED CHEM, V221, DOI 10.1016/j.ejmech.2021.113481; Jiang BS, 2021, NAT CHEM BIOL, V17, P675, DOI 10.1038/s41589-021-00765-y; Johannessen LH, 2019, P AACR NCI EORTC INT, pC091; Kalan S, 2017, CELL REP, V21, P467, DOI 10.1016/j.celrep.2017.09.056; Kasten M, 2001, ONCOGENE, V20, P1832, DOI 10.1038/sj.onc.1204295; Kokic G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10745-5; Krajewska M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09703-y; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Laitem C, 2015, NAT STRUCT MOL BIOL, V22, P396, DOI 10.1038/nsmb.3000; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Lei HQ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04027-6; Li YC, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd4484; Liang K, 2015, MOL CELL BIOL, V35, P928, DOI 10.1128/MCB.01426-14; Liu XM, 2017, NUCLEIC ACIDS RES, V45, P3738, DOI 10.1093/nar/gkw1291; Loyer P, 2008, J BIOL CHEM, V283, P7721, DOI 10.1074/jbc.M708188200; Lucking U, 2017, CHEMMEDCHEM, V12, P1776, DOI 10.1002/cmdc.201700447; Luedtke DA, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0112-3; Luse DS, 2013, BBA-GENE REGUL MECH, V1829, P63, DOI 10.1016/j.bbagrm.2012.08.010; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Marineau JJ, 2022, J MED CHEM, V65, P1458, DOI 10.1021/acs.jmedchem.1c01171; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Mbonye U, 2018, J BIOL CHEM, V293, P10009, DOI 10.1074/jbc.RA117.001347; McCalmont H, 2020, BLOOD ADV, V4, P296, DOI 10.1182/bloodadvances.2019000586; McDermott MSJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030638; McLaughlin RP, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1161-9; Minzel W, 2018, CELL, V175, P171, DOI 10.1016/j.cell.2018.07.045; Moreno V, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.7538; Nagaraja S, 2017, CANCER CELL, V31, P635, DOI 10.1016/j.ccell.2017.03.011; Nakamura Akito, 2018, Oncotarget, V9, P13474, DOI 10.18632/oncotarget.24414; Nam RK, 2007, BRIT J CANCER, V97, P1690, DOI 10.1038/sj.bjc.6604054; Narita T, 2017, BLOOD, V130, P1114, DOI 10.1182/blood-2016-09-741983; Nilson KA, 2015, MOL CELL, V59, P576, DOI 10.1016/j.molcel.2015.06.032; Olson CM, 2019, CELL CHEM BIOL, V26, P792, DOI 10.1016/j.chembiol.2019.02.012; Patel H, 2018, MOL CANCER THER, V17, P1156, DOI 10.1158/1535-7163.MCT-16-0847; Pelish HE, 2015, NATURE, V526, P273, DOI 10.1038/nature14904; Perales R, 2009, MOL CELL, V36, P178, DOI 10.1016/j.molcel.2009.09.018; Phillips DC, 2020, LEUKEMIA, V34, P1646, DOI 10.1038/s41375-019-0652-0; Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Ponguta LA, 2008, J BIOL CHEM, V283, P20989, DOI 10.1074/jbc.M802392200; Poss ZC, 2016, CELL REP, V15, P436, DOI 10.1016/j.celrep.2016.03.030; Quereda V, 2019, CANCER CELL, V36, P545, DOI 10.1016/j.ccell.2019.09.004; Rasool RU, 2019, CANCER DISCOV, V9, P1538, DOI 10.1158/2159-8290.CD-19-0189; Richters A, 2021, CELL CHEM BIOL, V28, P134, DOI 10.1016/j.chembiol.2020.10.001; Rimel JK, 2020, GENE DEV, V34, P1452, DOI 10.1101/gad.341545.120; Rusan M, 2018, CANCER DISCOV, V8, P59, DOI 10.1158/2159-8290.CD-17-0461; Rzymski T, 2017, ONCOTARGET, V8, P33779, DOI 10.18632/oncotarget.16810; Sanso M, 2016, GENE DEV, V30, P117, DOI 10.1101/gad.269589.115; Sanso M, 2013, TRANSCR-AUSTIN, V4, P146, DOI 10.4161/trns.25146; Satyam LK, 2020, EUR J CANCER, V138, pS47; Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010; Soutourina J, 2018, NAT REV MOL CELL BIO, V19, P262, DOI 10.1038/nrm.2017.115; Sun BW, 2020, ONCOGENE, V39, P50, DOI 10.1038/s41388-019-0953-9; Tien JF, 2017, NUCLEIC ACIDS RES, V45, P6698, DOI 10.1093/nar/gkx187; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; Vos SM, 2018, NATURE, V560, P601, DOI 10.1038/s41586-018-0442-2; Wei Y, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01301-7; West TA, 2014, EUR J CANCER, V50, P1916, DOI 10.1016/j.ejca.2014.04.004; Wong KH, 2014, MOL CELL, V54, P601, DOI 10.1016/j.molcel.2014.03.024; Yamada T, 2006, MOL CELL, V21, P227, DOI 10.1016/j.molcel.2005.11.024; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zhang HH, 2018, CELL, V175, P1244, DOI 10.1016/j.cell.2018.09.051; Zhang H, 2020, CANCER CELL, V37, P37, DOI 10.1016/j.ccell.2019.11.003; Zhang TH, 2016, NAT CHEM BIOL, V12, P876, DOI 10.1038/nchembio.2166; Zhang ZF, 2017, MOL CANCER THER, V16, P1739, DOI 10.1158/1535-7163.MCT-17-0078; Zong HL, 2007, MOL CELL BIOL, V27, P7125, DOI 10.1128/MCB.01753-06	104	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3303	3315		10.1038/s41388-022-02347-1	http://dx.doi.org/10.1038/s41388-022-02347-1		MAY 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35568739	Green Published, hybrid			2022-12-28	WOS:000795517600002
J	Simond, AM; Bui, T; Zuo, DM; Sanguin-Gendreau, V; Rao, T; Phillips, WA; Cardiff, RD; Muller, WJ				Simond, Alexandra M.; Bui, Tung; Zuo, Dongmei; Sanguin-Gendreau, Virginie; Rao, Trisha; Phillips, Wayne A.; Cardiff, Robert D.; Muller, William J.			Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PIK3CA MUTATIONS; PHOSPHOINOSITIDE 3-KINASE; TUMORIGENESIS; AMPLIFICATION; ONCOGENE; PROTEIN; IMPACT; ROLES; GENE	p110 alpha is a catalytic subunit of phosphoinositide 3-kinase (PI3K), a major downstream effector of receptor tyrosine kinase ErbB2, that is amplified and overexpressed in 20-30% of breast cancers, 40% of which have an activating mutation in p110 alpha. Despite the high frequency of PIK3CA gain-of-function mutations, their prognostic value is controversial. Here, we employ a knock-in transgenic strategy to restrict the expression of an activated form of ErbB2 and p110 alpha kinase domain mutation (p110 alpha(HR)) in the mammary epithelium. Physiological levels of transgene expression under the control of their endogenous promoters did not result in a major synergistic effect. However, tumors arising in ErbB2/p110 alpha(HR) bi-genic strain metastasized to the lung with significantly reduced capacity compared to tumors expressing ErbB2 alone. The reduced metastasis was further associated with retention of the myoepithelial layer reminiscent of ductal carcinoma in situ (DCIS), a non-invasive stage of human breast cancer. Molecular and biochemical analyses revealed that these poorly metastatic tumors exhibited a significant decrease in phospho-myosin light chain 2 (MLC2) associated with cellular contractility and migration. Examination of human samples for MLC2 activity revealed a progressive increase in cellular contractility between non-invasive DCIS and invasive ductal carcinoma. Collectively, these data argue that p110 alpha(HR) mutation attenuates metastatic behavior in the context of ErbB2-driven breast cancer.	[Simond, Alexandra M.; Bui, Tung; Zuo, Dongmei; Sanguin-Gendreau, Virginie; Rao, Trisha; Muller, William J.] McGill Univ, Rosalind & Morris Goodman Canc Res Inst, Montreal, PQ, Canada; [Simond, Alexandra M.; Bui, Tung; Muller, William J.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Phillips, Wayne A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Phillips, Wayne A.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Cardiff, Robert D.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; [Muller, William J.] McGill Univ, Fac Med, Montreal, PQ, Canada	McGill University; McGill University; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of California System; University of California Davis; McGill University	Muller, WJ (corresponding author), McGill Univ, Rosalind & Morris Goodman Canc Res Inst, Montreal, PQ, Canada.; Muller, WJ (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.; Muller, WJ (corresponding author), McGill Univ, Fac Med, Montreal, PQ, Canada.	william.muller@mcgill.ca	Phillips, Wayne/H-8070-2013	Phillips, Wayne/0000-0002-7961-638X	Canada Research Councils Chair in Molecular Oncology [950-2310-33]; Canadian Institutes of Health Research [CIHR-FDN-148373]	Canada Research Councils Chair in Molecular Oncology; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by a Canada Research Councils Chair in Molecular Oncology (950-2310-33), and a Foundation award from the Canadian Institutes of Health Research (CIHR-FDN-148373) (all to W.J.M.).	Adams JR, 2011, CANCER RES, V71, P2706, DOI 10.1158/0008-5472.CAN-10-0738; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Barbareschi M, 2007, CLIN CANCER RES, V13, P6064, DOI 10.1158/1078-0432.CCR-07-0266; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Cizkova M, 2013, BRIT J CANCER, V108, P1807, DOI 10.1038/bjc.2013.164; Cizkova M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3113; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DAVIES BR, 1993, ONCOGENE, V8, P999; Dumont AG, 2012, CHIN J CANCER, V31, P327, DOI 10.5732/cjc.012.10032; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Kalinsky K, 2009, CLIN CANCER RES, V15, P5049, DOI 10.1158/1078-0432.CCR-09-0632; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kinross KM, 2012, J CLIN INVEST, V122, P553, DOI 10.1172/JCI59309; Koren S, 2013, FEBS J, V280, P2758, DOI 10.1111/febs.12175; Li YR, 2016, ONCOTARGET, V7, P46785, DOI 10.18632/oncotarget.8800; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Pandey PR, 2010, FRONT BIOSCI-LANDMRK, V15, P226, DOI 10.2741/3617; Shimoi T, 2018, CANCER SCI, V109, P2558, DOI 10.1111/cas.13696; Simond AM, 2020, ADV CANCER RES, V147, P189, DOI 10.1016/bs.acr.2020.04.004; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244	31	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3445	3451		10.1038/s41388-022-02323-9	http://dx.doi.org/10.1038/s41388-022-02323-9		MAY 2022	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35538223				2022-12-28	WOS:000793037400001
J	Kim, JY; Cho, TM; Park, JM; Park, S; Park, M; Dal Nam, K; Ko, D; Seo, J; Kim, S; Jung, E; Farrand, L; Nguyen, CT; Hoang, VH; La, MT; Ann, J; Nam, G; Park, HJ; Lee, J; Kim, YJ; Seo, JH				Kim, Ji Young; Cho, Tae-Min; Park, Jung Min; Park, Soeun; Park, Minsu; Dal Nam, Kee; Ko, Dongmi; Seo, Juyeon; Kim, Seongjae; Jung, Eunsun; Farrand, Lee; Nguyen, Cong-Truong; Hoang, Van-Hai; La, Minh Thanh; Ann, Jihyae; Nam, Gibeom; Park, Hyun-Ju; Lee, Jeewoo; Kim, Yoon-Jae; Seo, Jae Hong			A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response	ONCOGENE			English	Article							MATRIX METALLOPROTEINASE-2; STEM-CELLS; PROTEINS; EXPRESSION; HSP90-ALPHA; CHAPERONES; INVASION; GROWTH; PHASE; ALDH1	Despite recent advances, there remains a significant unmet need for the development of new targeted therapies for triple-negative breast cancer (TNBC). Although the heat shock protein HSP90 is a promising target, previous inhibitors have had issues during development including undesirable induction of the heat shock response (HSR) and off-target effects leading to toxicity. SL-145 is a novel, rationally-designed C-terminal HSP90 inhibitor that induces apoptosis in TNBC cells via the suppression of oncogenic AKT, MEK/ERK, and JAK2/STAT3 signaling and does not trigger the HSR, in contrast to other inhibitors. In an orthotopic allograft model incorporating breast cancer stem cell-enriched TNBC tumors, SL-145 potently suppressed tumor growth, angiogenesis, and metastases concomitant with dysregulation of the JAK2/STAT3 signaling pathway. Our findings highlight the potential of SL-145 in suppressing metastatic TNBC independent of the HSR.	[Kim, Ji Young; Cho, Tae-Min; Park, Jung Min; Park, Soeun; Park, Minsu; Dal Nam, Kee; Ko, Dongmi; Seo, Juyeon; Kim, Seongjae; Jung, Eunsun; Kim, Yoon-Jae; Seo, Jae Hong] Korea Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul 02841, South Korea; [Kim, Ji Young; Cho, Tae-Min; Dal Nam, Kee; Jung, Eunsun; Kim, Yoon-Jae; Seo, Jae Hong] Korea Univ, Guro Hosp, Dept Biomed Res Ctr, Seoul 08308, South Korea; [Cho, Tae-Min; Park, Jung Min; Park, Soeun; Park, Minsu; Ko, Dongmi; Seo, Juyeon; Kim, Seongjae; Jung, Eunsun; Kim, Yoon-Jae; Seo, Jae Hong] Korea Univ, Coll Med, Brain Korea 21 Program Biomed Sci, Seoul 02841, South Korea; [Farrand, Lee] Univ Adelaide, Fac Hlth & Med Sci, Adelaide Med Sch, Adelaide, SA 5000, Australia; [Nguyen, Cong-Truong; Hoang, Van-Hai; La, Minh Thanh; Ann, Jihyae; Lee, Jeewoo] Seoul Natl Univ, Coll Pharm, Lab Med Chem, Seoul 08826, South Korea; [Nam, Gibeom; Park, Hyun-Ju] Sungkyunkwan Univ, Sch Pharm, Suwon 16419, Gyeonggi Do, South Korea	Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine); University of Adelaide; Seoul National University (SNU); Sungkyunkwan University (SKKU)	Kim, YJ; Seo, JH (corresponding author), Korea Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul 02841, South Korea.; Kim, YJ; Seo, JH (corresponding author), Korea Univ, Guro Hosp, Dept Biomed Res Ctr, Seoul 08308, South Korea.; Kim, YJ; Seo, JH (corresponding author), Korea Univ, Coll Med, Brain Korea 21 Program Biomed Sci, Seoul 02841, South Korea.; Lee, J (corresponding author), Seoul Natl Univ, Coll Pharm, Lab Med Chem, Seoul 08826, South Korea.	jeewoo@snu.ac.kr; natureyj@nate.com; cancer@korea.ac.kr		Nguyen, Cong Truong/0000-0001-8142-4187; jeong, eunseon/0000-0002-5900-6138	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HA17C0053, HR20C0021]; National Research Foundation (NRF) - Korean government (MSIT) [2019M3E5D1A01068998, 2021R1A2C2009723, 2021R1I1A1A01045588]; Brain Korea (BK) 21 Plus Program	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea; National Research Foundation (NRF) - Korean government (MSIT)(National Research Foundation of Korea); Brain Korea (BK) 21 Plus Program	This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HA17C0053, HR20C0021), the National Research Foundation (NRF) funded by the Korean government (MSIT) (Grant number: 2019M3E5D1A01068998, 2021R1A2C2009723, 2021R1I1A1A01045588), and was supported by the Brain Korea (BK) 21 Plus Program.	Ayub A, 2015, BIOMED PHARMACOTHER, V75, P40, DOI 10.1016/j.biopha.2015.08.031; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Bocchini Claire E, 2014, JAKSTAT, V3, pe970459, DOI 10.4161/21623988.2014.970459; Bradley E, 2012, STEM CELLS, V30, P1624, DOI 10.1002/stem.1143; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Cho TM, 2019, CANCER LETT, V447, P141, DOI 10.1016/j.canlet.2019.01.029; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Frezzato F, 2019, INT J CANCER, V145, P3089, DOI 10.1002/ijc.32383; Garcia-Carbonero R, 2013, LANCET ONCOL, V14, pE358, DOI 10.1016/S1470-2045(13)70169-4; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Jhaveri K, 2012, BBA-MOL CELL RES, V1823, P742, DOI 10.1016/j.bbamcr.2011.10.008; Kalimutho M, 2015, TRENDS PHARMACOL SCI, V36, P822, DOI 10.1016/j.tips.2015.08.009; Khan MA, 2019, DRUG DISCOV TODAY, V24, P2181, DOI 10.1016/j.drudis.2019.09.001; Kummar S, 2010, EUR J CANCER, V46, P340, DOI 10.1016/j.ejca.2009.10.026; Lambert AW, 2021, NAT REV CANCER, V21, P325, DOI 10.1038/s41568-021-00332-6; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Merdad A, 2014, ANTICANCER RES, V34, P1355; Metz JT, 2010, CURR OPIN CHEM BIOL, V14, P498, DOI 10.1016/j.cbpa.2010.06.166; Neckers L, 2018, CELL STRESS CHAPERON, V23, P467, DOI 10.1007/s12192-018-0877-2; Oh E, 2018, INT J CANCER, V143, P1978, DOI 10.1002/ijc.31585; Pacey S, 2011, CLIN CANCER RES, V17, P1561, DOI 10.1158/1078-0432.CCR-10-1927; Park JM, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01283-6; Park SY, 2019, CANCERS, V11, DOI 10.3390/cancers11070965; Peon A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04264-w; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Qin JJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1206-z; Rao MS, 2019, FRONT BIG DATA, V2, DOI 10.3389/fdata.2019.00025; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Sauvage F, 2017, J CONTROL RELEASE, V248, P133, DOI 10.1016/j.jconrel.2017.01.013; Schopf FH, 2017, NAT REV MOL CELL BIO, V18, P345, DOI 10.1038/nrm.2017.20; Solit DB, 2007, CLIN CANCER RES, V13, P1775, DOI 10.1158/1078-0432.CCR-06-1863; Song XM, 2010, J BIOL CHEM, V285, P40039, DOI 10.1074/jbc.M110.181941; Subramanian C, 2020, MOL ONCOL, V14, P2058, DOI 10.1002/1878-0261.12686; Thakur R, 2015, SCI REP-UK, V5, DOI 10.1038/srep10194; Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887; Wagner AJ, 2016, EUR J CANCER, V61, P94, DOI 10.1016/j.ejca.2016.03.076; Wang XX, 2014, INT J ONCOL, V45, P18, DOI 10.3892/ijo.2014.2399; Wang Y, 2015, CHEM COMMUN, V51, P1410, DOI 10.1039/c4cc07284g; Wu JM, 2017, TRENDS PHARMACOL SCI, V38, P226, DOI 10.1016/j.tips.2016.11.009; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383	45	2	2	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3289	3297		10.1038/s41388-022-02269-y	http://dx.doi.org/10.1038/s41388-022-02269-y		MAY 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35501463	Green Published, hybrid			2022-12-28	WOS:000789736500002
J	Li, XK; Chen, HC; Zhang, LZ; Chen, L; Wei, W; Gao, SG; Xue, Q; Li, Y; Wang, B; Li, JG; Gao, YS; Lin, YL				Li, Xingkai; Chen, Hengchi; Zhang, Lizhen; Chen, Li; Wei, Wei; Gao, Shugeng; Xue, Qi; Li, Yue; Wang, Bing; Li, Jiagen; Gao, Yushun; Lin, Yanliang			27-hydroxycholesterol linked high cholesterol diet to lung adenocarcinoma metastasis	ONCOGENE			English	Article							CANCER; 25-HYDROXYCHOLESTEROL; LIPIDS	Dietary cholesterol has been implicated to promote lung cancer. Lung adenocarcinoma (LAC) is a main type of lung cancer, whereas the functional mechanism of cholesterol in LAC remained largely unknown. In the present study, we evidenced that cholesterol promoted cell proliferation and invasion of LAC in vitro as well as LAC metastasis in vivo. Cyp27A1 knockdown reduced the cholesterol-induced LAC cells proliferation and invasion. In contrast, Cyp7B1 knockdown enhanced the effect of cholesterol on LAC cells proliferation and invasion. Furthermore, Cyp27A1 deficiency remarkably reduced high cholesterol-induced LAC metastasis in vivo. Mechanism investigation demonstrated that exposure of LAC cells to 27-hydroxycholesterol induced the phosphorylation of AKT and NF kappa B p65, and promoted the expression of peptidylprolyl isomerase B (PPIB), especially in the coculture with THP1-derived macrophage. Meanwhile, 27-hydroxycholesterol induced the secretion of FGF2 and IL-6, which contributed to the expression of snail and vimentin. Luciferase report assay and ChIP assay confirmed that NF kappa B p65 controlled the transcription of PPIB. Inhibiting NF kappa B p65 activation reduced PPIB expression. PPIB inhibition reduced 27-hydroxycholesterol-induced expression of snail and vimentin. These results indicated that 27-hydroxycholesterol linked high cholesterol and LAC metastasis by regulating NF kappa B/PPIB axis and the secretion of FGF2 and IL-6.	[Li, Xingkai; Chen, Hengchi; Gao, Shugeng; Xue, Qi; Wang, Bing; Li, Jiagen; Gao, Yushun] Chinese Acad Med Sci & Peking Union Med Coll, Dept Thorac Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China; [Zhang, Lizhen; Lin, Yanliang] Shandong First Med Univ, Dept Cent Lab, Shandong Prov Hosp, Jinan, Peoples R China; [Chen, Li; Lin, Yanliang] Shandong Univ, Dept Cent Lab, Shandong Prov Hosp, Jinan, Peoples R China; [Wei, Wei] Shandong Prov Ecoenvironm Monitoring Ctr, Jinan, Peoples R China; [Li, Yue] Peking Univ Third Hosp, Dept Anesthesiol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Peking University	Gao, YS (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Dept Thorac Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China.; Lin, YL (corresponding author), Shandong First Med Univ, Dept Cent Lab, Shandong Prov Hosp, Jinan, Peoples R China.; Lin, YL (corresponding author), Shandong Univ, Dept Cent Lab, Shandong Prov Hosp, Jinan, Peoples R China.	1027david@sohu.com; yanlianglin@aliyun.com			National Natural Science Foundation of China [81572272, 81972177]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (Grant No. 81572272; 81972177).	Baek AE, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00910-z; Cagno V, 2017, REDOX BIOL, V12, P522, DOI 10.1016/j.redox.2017.03.016; CARPENTER KLH, 1995, BBA-LIPID LIPID MET, V1256, P141, DOI 10.1016/0005-2760(94)00247-V; Chen L, 2017, BIOCHEM BIOPH RES CO, V484, P857, DOI 10.1016/j.bbrc.2017.02.003; Choi TG, 2018, J PATHOL, V246, P115, DOI 10.1002/path.5107; De Stefani E, 2002, LUNG CANCER-J IASLC, V35, P43, DOI 10.1016/S0169-5002(01)00281-1; Hiramitsu S, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00470; Kurimoto R, 2016, INT J ONCOL, V48, P1825, DOI 10.3892/ijo.2016.3419; Lin XJ, 2018, NUTRIENTS, V10, DOI 10.3390/nu10020185; Lin XJ, 2017, J CLIN LIPIDOL, V11, P1073, DOI 10.1016/j.jacl.2017.05.004; Llaverias G, 2010, AM J PATHOL, V177, P3180, DOI 10.2353/ajpath.2010.100568; Ma JB, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.281; Nelson ER, 2018, MOL CELL ENDOCRINOL, V466, P73, DOI 10.1016/j.mce.2017.09.021; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; Raza S, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0422-x; Rossin D, 2019, FREE RADICAL BIO MED, V136, P35, DOI 10.1016/j.freeradbiomed.2019.03.020; SHEKELLE RB, 1991, AM J EPIDEMIOL, V134, P480, DOI 10.1093/oxfordjournals.aje.a116119; Wang JS, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0705-9; Williams PD, 2011, NEOPLASIA, V13, P1122, DOI 10.1593/neo.111398; Wu Q, 2013, CELL REP, V5, P637, DOI 10.1016/j.celrep.2013.10.006; Wu YF, 2015, BIOCHEM BIOPH RES CO, V457, P614, DOI 10.1016/j.bbrc.2015.01.035; Yang ZZ, 2017, EBIOMEDICINE, V19, P49, DOI 10.1016/j.ebiom.2017.04.017; Zhang YW, 2017, INT J CANCER, V140, P1645, DOI 10.1002/ijc.30581; Zhao ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095884	24	2	2	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2685	2695		10.1038/s41388-022-02285-y	http://dx.doi.org/10.1038/s41388-022-02285-y		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35379924	Green Published, hybrid			2022-12-28	WOS:000778745900001
J	Komatsu, M; Nakamura, K; Takeda, T; Chiwaki, F; Banno, K; Aoki, D; Takeshita, F; Sasaki, H				Komatsu, Masayuki; Nakamura, Kanako; Takeda, Takashi; Chiwaki, Fumiko; Banno, Kouji; Aoki, Daisuke; Takeshita, Fumitaka; Sasaki, Hiroki			Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; MESENCHYMAL TRANSITION; ACQUIRED-RESISTANCE; TYROSINE KINASE; LUNG-CANCER; INHIBITOR; THERAPY; HEAD; NECK; OVEREXPRESSION	Oncogenic signalling confers tumour-progression advantages; thus, its pharmacological blockade is the best strategy for cancer chemotherapy. However, drug resistance and heterogeneous dependency of tumour hamper their therapeutic potential, suggesting the necessity for a new ubiquitous modality based on evading drug resistance. Here, we proposed a denovoaddiction to oncogenic signalling (Dead-On) concept, wherein specific blockade of target molecules forces cancer cells to develop dependency on an oncogenic signalling. In cervical squamous cell carcinoma cells, Aurora A/B dual blockade elicited rapid addiction to EGFR-Erk signalling, and its pharmacological/genetic inhibition synergistically enhanced anti-cancer activities in vitro, in vivo, and in a patient-derived organoid model. The signal activation was independent of EGFR genetic status, it was triggered by receptor accumulation on the plasma membrane via Rab11-mediated endocytic recycling machinery. These findings support our novel Dead-On concept which may lead to drug discovery as well as expand the adaptation of approved targeted drugs.	[Komatsu, Masayuki; Chiwaki, Fumiko; Takeshita, Fumitaka; Sasaki, Hiroki] Natl Canc Ctr, Dept Translat Oncol, Tokyo, Japan; [Nakamura, Kanako; Takeda, Takashi; Banno, Kouji; Aoki, Daisuke] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan	National Cancer Center - Japan; Keio University	Komatsu, M; Sasaki, H (corresponding author), Natl Canc Ctr, Dept Translat Oncol, Tokyo, Japan.	makomats@ncc.go.jp; hksasaki@ncc.go.jp	Takeda, Takashi/AAB-1391-2019	Takeda, Takashi/0000-0001-6686-5742; Chiwaki, Fumiko/0000-0002-0914-9157; Komatsu, Masayuki/0000-0003-1180-1746; BANNO, KOUJI/0000-0003-2610-2833	Pfizer [WO195177]; National Cancer Center Research and Development Fund [28-A-11, 29-A-2]	Pfizer(Pfizer); National Cancer Center Research and Development Fund(National Cancer Center - Japan)	This work was supported by Pfizer Investigator-Initiated Research (WO195177) Program and by the National Cancer Center Research and Development Fund (28-A-11, 29-A-2). We would like to thank Editage (www.editage.com) for English language editing.	Arjonen A, 2012, TRAFFIC, V13, P610, DOI 10.1111/j.1600-0854.2012.01327.x; Astsaturov I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001083; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Barsouk A., 2019, MED SCI, V7, P1; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carlton JG, 2012, SCIENCE, V336, P220, DOI 10.1126/science.1217180; Carvajal RD, 2006, CLIN CANCER RES, V12, P6869, DOI 10.1158/1078-0432.CCR-06-1405; Chung BM, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-84; Cortot AB, 2013, CANCER RES, V73, P834, DOI 10.1158/0008-5472.CAN-12-2066; Crafton SM, 2016, CLIN THER, V38, P449, DOI 10.1016/j.clinthera.2016.02.007; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Dotto GP, 2016, CANCER CELL, V29, P622, DOI 10.1016/j.ccell.2016.04.004; Elkabets M, 2015, CANCER CELL, V27, P533, DOI 10.1016/j.ccell.2015.03.010; Flaherty KT, 2020, JNCI-J NATL CANCER I, V112, DOI 10.1093/jnci/djz245; Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460; Fukuoka S, 2017, ONCOTARGET, V8, P11020, DOI 10.18632/oncotarget.14209; Gabrielli B, 2015, MOL CANCER THER, V14, P2753, DOI 10.1158/1535-7163.MCT-15-0506; Gao ML, 2012, EMBO MOL MED, V4, P776, DOI 10.1002/emmm.201100944; Giles KM, 2013, MOL CANCER THER, V12, P2541, DOI 10.1158/1535-7163.MCT-13-0170; Goh LK, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017459; Gonzalez-Loyola A, 2015, MOL CELL BIOL, V35, P3566, DOI 10.1128/MCB.01286-14; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hehnly H, 2014, DEV CELL, V28, P497, DOI 10.1016/j.devcel.2014.01.014; Hochegger H, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120185; Huang XF, 2008, BLOOD, V111, P2854, DOI 10.1182/blood-2007-07-099325; Jani JP, 2010, MOL CANCER THER, V9, P883, DOI 10.1158/1535-7163.MCT-09-0915; Jonker CTH, 2020, J CELL SCI, V133, DOI 10.1242/jcs.231225; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Kollareddy M, 2012, INVEST NEW DRUG, V30, P2411, DOI 10.1007/s10637-012-9798-6; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Li LK, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aam7479; Lim SM, 2018, CANCER TREAT REV, V65, P1, DOI 10.1016/j.ctrv.2018.02.006; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Lin G, 2015, ONCOL LETT, V10, P901, DOI 10.3892/ol.2015.3277; Lin L, 2019, CANCERS, V11, DOI 10.3390/cancers11081156; Lou K, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw9450; Lowenberg B, 2011, BLOOD, V118, P6030, DOI 10.1182/blood-2011-07-366930; Madshus IH, 2009, J CELL SCI, V122, P3433, DOI 10.1242/jcs.050260; McLornan DP, 2014, NEW ENGL J MED, V371, P1725, DOI 10.1056/NEJMra1407390; Mehra Ranee, 2008, Clin Adv Hematol Oncol, V6, P742; Melichar B, 2015, LANCET ONCOL, V16, P395, DOI 10.1016/S1470-2045(15)70051-3; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Schilder RJ, 2009, INT J GYNECOL CANCER, V19, P929, DOI 10.1111/IGC.0b013e3181a83467; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shah KN, 2019, NAT MED, V25, P111, DOI 10.1038/s41591-018-0264-7; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Song HN, 2016, J THORAC ONCOL, V11, pE45, DOI 10.1016/j.jtho.2015.12.093; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Thalappilly S, 2010, ONCOGENE, V29, P2528, DOI 10.1038/onc.2010.1; Thomas R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00800; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; Tsuruo T, 2003, CANCER SCI, V94, P15, DOI 10.1111/j.1349-7006.2003.tb01345.x; Twu NF, 2009, EUR J OBSTET GYN R B, V142, P57, DOI 10.1016/j.ejogrb.2008.09.012; Vojnic M, 2019, J THORAC ONCOL, V14, P802, DOI 10.1016/j.jtho.2018.12.038; Vora C, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2018-000462; Wan XB, 2008, CARCINOGENESIS, V29, P1930, DOI 10.1093/carcin/bgn176; Wang SH, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0268-z; Wong GS, 2018, NAT MED, V24, P968, DOI 10.1038/s41591-018-0022-x; Xia ZB, 2013, MOL CANCER RES, V11, P1101, DOI 10.1158/1541-7786.MCR-13-0044	65	0	0	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2326	2339		10.1038/s41388-022-02256-3	http://dx.doi.org/10.1038/s41388-022-02256-3		MAR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35250028				2022-12-28	WOS:000765203000001
J	Lv, B; Pan, YD; Hou, DS; Chen, P; Zhang, J; Chu, YW; Li, MQ; Zeng, Y; Yang, DQ; Liu, J				Lv, Bin; Pan, Yida; Hou, Daisen; Chen, Ping; Zhang, Jun; Chu, Yiwei; Li, Mingqi; Zeng, Yan; Yang, Dongqin; Liu, Jie			RNF4 silencing induces cell growth arrest and DNA damage by promoting nuclear targeting of p62 in hepatocellular carcinoma	ONCOGENE			English	Article							E3 UBIQUITIN LIGASE; OXIDATIVE STRESS; HEPATITIS-B; AUTOPHAGY; CANCER; SUMO; PROTEIN; P62/SQSTM1; REPAIR; ANGIOGENESIS	Hepatocellular carcinoma (HCC) is one of the largest causes of cancer-related deaths worldwide owing to the limitation of effective treatment options. The ubiquitin-proteasome system has been rapidly recognized as a frequent target of deregulation leading to cancers. Enhanced DNA damage response (DDR) promotes HCC growth and prevents chemosensitivity, and ubiquitin E3 ligases are key modulators in DDR. Therefore, a better understanding of how E3 ligases regulate cell growth and DNA damage may provide novel insights in understanding the oncogenic mechanism and improving the efficacy of DNA damage therapeutic agents. Here, we performed a high-content RNAi screening targeting 52 DDR-related E3 ligases in HCC and found that ring finger protein 4 (RNF4) was essential for HCC growth. RNF4 was highly expressed in HCC tissues, and the expression levels of RNF4 were associated with poor outcomes. RNF4 silencing significantly suppressed the cell growth, and subsequently induced G2/M arrest and apoptosis of HCC cells in vitro; RNF4 silencing also demonstrated the tumor-suppressive efficacy on HCC in vivo. Moreover, RNF4 silencing increased DNA damage, and rendered HCC cells more sensitive to DNA damage drugs and radiation. We found RNF4 functionally interacts with p62, and mechanistic analyses indicated that RNF4 silencing triggered the nuclear enrichment of p62. Moreover, the p62 nuclear targeting was required for increased DNA damage and growth suppression mediated by RNF4 silencing. Thus, our findings suggest RNF4 is essential for HCC proliferation via preventing nuclear translocation of p62. RNF4 silencing promotes DNA damage and may serve as a novel strategy to suppress cell growth and increase the sensitivity of DNA damage therapeutic agents in HCC.	[Lv, Bin; Pan, Yida; Zhang, Jun; Yang, Dongqin; Liu, Jie] Fudan Univ, Huashan Hosp, Dept Digest Dis, 12 Middle Wulumuqi Rd, Shanghai, Peoples R China; [Hou, Daisen; Chen, Ping; Liu, Jie] Fudan Univ, Sch Basic Med Sci, Inst Biomed Sci, 130 Dongan Rd, Shanghai, Peoples R China; [Hou, Daisen; Chen, Ping; Chu, Yiwei; Liu, Jie] Fudan Univ, Sch Basic Med Sci, Dept Immunol, 130 Dongan Rd, Shanghai, Peoples R China; [Li, Mingqi] Univ Tennessee, Ctr Canc Res, Hlth Sci Ctr, Memphis, TN 38163 USA; [Zeng, Yan] Jilin Agr Univ, Coll Vet Med, 2888 Xincheng St, Changchun, Peoples R China	Fudan University; Fudan University; Fudan University; University of Tennessee System; University of Tennessee Health Science Center; Jilin Agricultural University	Yang, DQ; Liu, J (corresponding author), Fudan Univ, Huashan Hosp, Dept Digest Dis, 12 Middle Wulumuqi Rd, Shanghai, Peoples R China.; Liu, J (corresponding author), Fudan Univ, Sch Basic Med Sci, Inst Biomed Sci, 130 Dongan Rd, Shanghai, Peoples R China.; Liu, J (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Immunol, 130 Dongan Rd, Shanghai, Peoples R China.	kobesakura@fudan.edu.cn; jieliu@fudan.edu.cn			National Natural Science Foundation Grant of China [81770579, 81830080, 81861168038, 81970506, 81800477]	National Natural Science Foundation Grant of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation Grant of China [81770579, 81830080, 81861168038, 81970506, 81800477]. The authors thank Ying Zhao for p62 WT, p62 Delta UBA, p62 Delta PB1, p62 Delta NES and p62 Delta NLS plasmids. The authors thank Dr. Zhaohui Wu and Dr. Mingfang Lv for revising our manuscript. The authors thank Mengxiao Ge for replenishing our experimental data.	Al-Hakim AK, 2008, BIOCHEM J, V411, P249, DOI 10.1042/BJ20080067; Balogh J, 2016, J HEPATOCELL CARCINO, V3, P41, DOI 10.2147/JHC.S61146; Bartolini D, 2018, TRANSL RES, V193, P54, DOI 10.1016/j.trsl.2017.11.007; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Brinkmann K, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00098; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Clausen TH, 2010, AUTOPHAGY, V6, P330, DOI 10.4161/auto.6.3.11226; Collins GA, 2017, CELL, V169, P792, DOI 10.1016/j.cell.2017.04.023; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; Denk H, 2019, EXPERT OPIN THER TAR, V23, P393, DOI 10.1080/14728222.2019.1601703; Erpapazoglou Zoi, 2014, Cells, V3, P1027, DOI 10.3390/cells3041027; Fang JH, 2011, HEPATOLOGY, V54, P1729, DOI 10.1002/hep.24577; Feng YC, 2017, AUTOPHAGY, V13, P995, DOI 10.1080/15548627.2017.1317427; Fryrear KA, 2012, BLOOD, V119, P1173, DOI 10.1182/blood-2011-06-358564; Gartner A, 2014, MOL CELL, V55, P1, DOI 10.1016/j.molcel.2014.06.022; Galanty Y, 2012, GENE DEV, V26, P1179, DOI 10.1101/gad.188284.112; Goto Y, 2017, MUTAT RES-FUND MOL M, V803, P76, DOI 10.1016/j.mrfmmm.2017.07.007; Groocock LM, 2014, EMBO REP, V15, P601, DOI 10.1002/embr.201338369; Hao ZL, 2015, FRONT BIOSCI-LANDMRK, V20, P474, DOI 10.2741/4320; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Jung YS, 2012, FEBS LETT, V586, P1397, DOI 10.1016/j.febslet.2012.03.052; Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540; Lin XL, 2013, DNA CELL BIOL, V32, P220, DOI 10.1089/dna.2012.1915; Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Pankiv S, 2010, J BIOL CHEM, V285, P5941, DOI 10.1074/jbc.M109.039925; Saito T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12030; Sanchez-Martin P, 2018, J CELL SCI, V131, DOI 10.1242/jcs.222836; Sang YZ, 2015, ONCOTARGET, V6, P42590, DOI 10.18632/oncotarget.6052; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; Sriramachandran AM, 2014, BBA-MOL CELL RES, V1843, P75, DOI 10.1016/j.bbamcr.2013.08.022; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Su YT, 2013, MOL CELL BIOL, V33, P1546, DOI 10.1128/MCB.01146-12; Sun L, 2008, J INT MED RES, V36, P1015, DOI 10.1177/147323000803600519; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; Taniguchi K, 2016, FEBS LETT, V590, P2375, DOI 10.1002/1873-3468.12301; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Uckelmann M, 2017, DNA REPAIR, V56, P92, DOI 10.1016/j.dnarep.2017.06.011; Vyas R, 2013, CELL DEATH DIFFER, V20, P490, DOI 10.1038/cdd.2012.145; Wang GC, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00005; Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027; Xiang X, 2017, CANCER MED-US, V6, P2357, DOI 10.1002/cam4.1176; Yang D, 2013, CELL DEATH DIFFER, V20, P235, DOI 10.1038/cdd.2012.113; Yang DQ, 2019, EBIOMEDICINE, V47, P114, DOI 10.1016/j.ebiom.2019.08.068; Yang DQ, 2012, AUTOPHAGY, V8, P1856, DOI 10.4161/auto.22024; Yi T, 2008, CANCER RES, V68, P1843, DOI 10.1158/0008-5472.CAN-07-5944; Zhao XM, 2018, RADIAT RES, V190, P385, DOI 10.1667/RR14981.1	47	0	0	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2275	2286		10.1038/s41388-022-02247-4	http://dx.doi.org/10.1038/s41388-022-02247-4		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35236966				2022-12-28	WOS:000763262700002
J	Srinivas, US; Tay, NSC; Jaynes, P; Anbuselvan, A; Ramachandran, GK; Wardyn, JD; Hoppe, MM; Hoang, PM; Peng, YF; Lim, S; Lee, MY; Peethala, PC; An, O; Shendre, A; Tan, BWQ; Jemimah, S; Lakshmanan, M; Hu, LY; Jakhar, R; Sachaphibulkij, K; Lim, LHK; Pervaiz, S; Crasta, K; Yang, H; Tan, P; Liang, C; Ho, LN; Khanchandani, V; Kappei, D; Yong, WP; Tan, DSP; Bordi, M; Campello, S; Tam, WL; Frezza, C; Jeyasekharan, AD				Srinivas, Upadhyayula S.; Tay, Norbert S. C.; Jaynes, Patrick; Anbuselvan, Akshaya; Ramachandran, Gokula K.; Wardyn, Joanna D.; Hoppe, Michal M.; Hoang, Phuong Mai; Peng, Yanfen; Lim, Sherlly; Lee, May Yin; Peethala, Praveen C.; An, Omer; Shendre, Akshay; Tan, Bryce W. Q.; Jemimah, Sherlyn; Lakshmanan, Manikandan; Hu, Longyu; Jakhar, Rekha; Sachaphibulkij, Karishma; Lim, Lina H. K.; Pervaiz, Shazib; Crasta, Karen; Yang, Henry; Tan, Patrick; Liang, Chao; Ho, Lena; Khanchandani, Vartika; Kappei, Dennis; Yong, Wei Peng; Tan, David S. P.; Bordi, Matteo; Campello, Silvia; Tam, Wai Leong; Frezza, Christian; Jeyasekharan, Anand D.			PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production	ONCOGENE			English	Article							POLO-LIKE KINASE-1; CLEAR-CELL; SWI/SNF COMPLEXES; TUMOR PROGRESSION; BI 6727; EXPRESSION; CANCER; DNA; PHOSPHORYLATION; TARGET	Inhibitors of the mitotic kinase PLK1 yield objective responses in a subset of refractory cancers. However, PLK1 overexpression in cancer does not correlate with drug sensitivity, and the clinical development of PLK1 inhibitors has been hampered by the lack of patient selection marker. Using a high-throughput chemical screen, we discovered that cells deficient for the tumor suppressor ARID1A are highly sensitive to PLK1 inhibition. Interestingly this sensitivity was unrelated to canonical functions of PLK1 in mediating G2/M cell cycle transition. Instead, a whole-genome CRISPR screen revealed PLK1 inhibitor sensitivity in ARID1A deficient cells to be dependent on the mitochondrial translation machinery. We find that ARID1A knock-out (KO) cells have an unusual mitochondrial phenotype with aberrant biogenesis, increased oxygen consumption/expression of oxidative phosphorylation genes, but without increased ATP production. Using expansion microscopy and biochemical fractionation, we see that a subset of PLK1 localizes to the mitochondria in interphase cells. Inhibition of PLK1 in ARID1A KO cells further uncouples oxygen consumption from ATP production, with subsequent membrane depolarization and apoptosis. Knockdown of specific subunits of the mitochondrial ribosome reverses PLK1-inhibitor induced apoptosis in ARID1A deficient cells, confirming specificity of the phenotype. Together, these findings highlight a novel interphase role for PLK1 in maintaining mitochondrial fitness under metabolic stress, and a strategy for therapeutic use of PLK1 inhibitors. To translate these findings, we describe a quantitative microscopy assay for assessment of ARID1A protein loss, which could offer a novel patient selection strategy for the clinical development of PLK1 inhibitors in cancer.	[Srinivas, Upadhyayula S.; Tay, Norbert S. C.; Jaynes, Patrick; Anbuselvan, Akshaya; Ramachandran, Gokula K.; Wardyn, Joanna D.; Hoppe, Michal M.; Hoang, Phuong Mai; Peng, Yanfen; Lim, Sherlly; Peethala, Praveen C.; An, Omer; Shendre, Akshay; Tan, Bryce W. Q.; Jemimah, Sherlyn; Yang, Henry; Khanchandani, Vartika; Kappei, Dennis; Yong, Wei Peng; Tan, David S. P.; Tam, Wai Leong; Jeyasekharan, Anand D.] Natl Univ Singapore NUS, Canc Sci Inst Singapore, Singapore, Singapore; [Lee, May Yin; Tan, Patrick; Tam, Wai Leong] ASTAR, Genome Inst Singapore GIS, Singapore, Singapore; [Lakshmanan, Manikandan] ASTAR, Inst Mol & Cell Biol IMCB, Singapore, Singapore; [Hu, Longyu; Tan, Patrick] Duke NUS Med Sch, Canc & Stem Cell Biol, Singapore, Singapore; [Jakhar, Rekha; Sachaphibulkij, Karishma; Lim, Lina H. K.; Pervaiz, Shazib; Crasta, Karen] Natl Univ Singapore NUS, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Jakhar, Rekha; Crasta, Karen] Natl Univ Hlth Syst NUHS, Ctr Hlth Longev, Singapore, Singapore; [Liang, Chao; Ho, Lena] Duke NUS Med Sch, Cardiovasc & Metab Disorders, Singapore, Singapore; [Kappei, Dennis; Tam, Wai Leong] Natl Univ Singapore NUS, Yong Loo Lin Sch Med, Dept Biochem, Singapore, Singapore; [Kappei, Dennis; Jeyasekharan, Anand D.] Natl Univ Singapore NUS, NUS Ctr Canc Res N2CR, Yong Loo Lin Sch Med, Singapore, Singapore; [Yong, Wei Peng; Tan, David S. P.; Jeyasekharan, Anand D.] Natl Univ Hosp NUH, Natl Univ Canc Inst Singapore NCIS, Singapore, Singapore; [Bordi, Matteo; Campello, Silvia] Univ Roma Tor Vergata, Dept Biol, Rome, Italy; [Frezza, Christian] Univ Cambridge, MRC Canc Unit, Cambridge, England	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; University of Rome Tor Vergata; University of Cambridge	Jeyasekharan, AD (corresponding author), Natl Univ Singapore NUS, Canc Sci Inst Singapore, Singapore, Singapore.; Jeyasekharan, AD (corresponding author), Natl Univ Singapore NUS, NUS Ctr Canc Res N2CR, Yong Loo Lin Sch Med, Singapore, Singapore.; Jeyasekharan, AD (corresponding author), Natl Univ Hosp NUH, Natl Univ Canc Inst Singapore NCIS, Singapore, Singapore.	csiadj@nus.edu.sg	Tan, David/HIR-2214-2022; Lee, May Yin/AAB-3450-2021	Lee, May Yin/0000-0003-2366-9463; Peng, Yanfen/0000-0003-1753-8547; Hoppe, Michal Marek/0000-0002-0364-6080; Tam, Wai Leong/0000-0003-2365-5264; Jemimah, Sherlyn/0000-0003-1974-5064; Tay, Norbert/0000-0002-4960-9250	Singapore Ministry of Health's National Medical Research Council Transition Award [NMRC/TA/0052/2016]; Cancer Science Institute of Singapore; National University of Singapore, through the National Research Foundation Singapore; Singapore Ministry of Education under its Research Centers of Excellence initiative; Singapore Ministry of Health's National Medical Research Council [NMRC/CIRG/1400/2014]	Singapore Ministry of Health's National Medical Research Council Transition Award(Ministry of Health-SingaporeNational Medical Research Council, Singapore); Cancer Science Institute of Singapore; National University of Singapore, through the National Research Foundation Singapore; Singapore Ministry of Education under its Research Centers of Excellence initiative(Ministry of Education, Singapore); Singapore Ministry of Health's National Medical Research Council(National Medical Research Council, Singapore)	ADJ is supported by the Singapore Ministry of Health's National Medical Research Council Transition Award (NMRC/TA/0052/2016). Work in ADJ's and the Kappei laboratory is also funded by the Cancer Science Institute of Singapore, National University of Singapore, through the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centers of Excellence initiative. Part of this work was funded through a collaborative grant between ADJ and DSPT from the Singapore Ministry of Health's National Medical Research Council (NMRC/CIRG/1400/2014).	ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Ashizawa M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43293-5; Ayhan A, 2012, INT J GYNECOL CANCER, V22, P1310, DOI 10.1097/IGC.0b013e31826b5dcc; Bertolin G, 2018, ELIFE, V7, DOI 10.7554/eLife.38111; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Bruinsma W, 2012, TRENDS BIOCHEM SCI, V37, P534, DOI 10.1016/j.tibs.2012.09.005; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Croucher PJP, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.AM2020-2019; Deribe YL, 2018, NAT MED, V24, P1047, DOI 10.1038/s41591-018-0019-5; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Dykhuizen EC, 2013, NATURE, V497, P624, DOI 10.1038/nature12146; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Elsayed I, 2019, FUTURE MED CHEM, V11, P1383, DOI 10.4155/fmc-2019-0084; Fukumoto T, 2019, CANCER RES, V79, P5482, DOI 10.1158/0008-5472.CAN-19-1302; Gorlick R, 2014, PEDIATR BLOOD CANCER, V61, P158, DOI 10.1002/pbc.24616; Gutteridge REA, 2017, CANCER LETT, V394, P13, DOI 10.1016/j.canlet.2017.02.013; Gutteridge REA, 2016, MOL CANCER THER, V15, P1427, DOI 10.1158/1535-7163.MCT-15-0897; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Hoppe MM, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202013366; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Joukov V, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar4195; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Koc EC, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00183; Li ZG, 2014, MOL CELL BIOL, V34, P3642, DOI 10.1128/MCB.00814-14; Liu CR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09813-7; Liu WC, 2011, P NATL ACAD SCI USA, V108, P12920, DOI 10.1073/pnas.1107332108; Liu XQ, 2015, TRANSL ONCOL, V8, P185, DOI 10.1016/j.tranon.2015.03.010; Liu ZX, 2017, TRANSL ONCOL, V10, P22, DOI 10.1016/j.tranon.2016.10.003; Ma XY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01647-5; Mao TL, 2013, AM J SURG PATHOL, V37, P1342, DOI 10.1097/PAS.0b013e3182889dc3; Matsumoto T, 2009, P NATL ACAD SCI USA, V106, P14542, DOI 10.1073/pnas.0904229106; Mennuni M, 2022, EMBO REP, V23, DOI 10.15252/embr.202153054; Miller RE, 2016, MOL CANCER THER, V15, P1472, DOI 10.1158/1535-7163.MCT-15-0554; Nickerson JA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00049; Ogiwara H, 2019, CANCER CELL, V35, P177, DOI 10.1016/j.ccell.2018.12.009; Perez-Riverol Y, 2022, NUCLEIC ACIDS RES, V50, pD543, DOI 10.1093/nar/gkab1038; Popov LD, 2020, J CELL MOL MED, V24, P4892, DOI 10.1111/jcmm.15194; Richter U, 2015, J CELL BIOL, V211, P373, DOI 10.1083/jcb.201504062; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Savas S, 2018, CRIT REV ONCOL HEMAT, V123, P114, DOI 10.1016/j.critrevonc.2018.01.009; Sharon D, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax2863; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Tillberg PW, 2016, NAT BIOTECHNOL, V34, P987, DOI 10.1038/nbt.3625; Tolstorukov MY, 2013, P NATL ACAD SCI USA, V110, P10165, DOI 10.1073/pnas.1302209110; Trizzino M, 2018, CELL REP, V23, P3933, DOI 10.1016/j.celrep.2018.05.097; Valente AJ, 2017, ACTA HISTOCHEM, V119, P315, DOI 10.1016/j.acthis.2017.03.001; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wardyn JD., 2021, CURR PROTOC, V1, P286; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wu CJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05694-4; Wu JN, 2013, CANCER DISCOV, V3, P35, DOI 10.1158/2159-8290.CD-12-0361; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Yamamoto S, 2012, MODERN PATHOL, V25, P615, DOI 10.1038/modpathol.2011.189; Yao CH, 2019, ELIFE, V8, DOI 10.7554/eLife.41351; Yim H, 2013, ANTI-CANCER DRUG, V24, P999, DOI 10.1097/CAD.0000000000000007; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	60	3	3	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1986	2002		10.1038/s41388-022-02219-8	http://dx.doi.org/10.1038/s41388-022-02219-8		MAR 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35236967				2022-12-28	WOS:000763262700001
J	Zhang, YH; Mohibi, S; Vasilatis, DM; Chen, MY; Zhang, J; Chen, XB				Zhang, Yanhong; Mohibi, Shakur; Vasilatis, Demitria M.; Chen, Mingyi; Zhang, Jin; Chen, Xinbin			Ferredoxin reductase and p53 are necessary for lipid homeostasis and tumor suppression through the ABCA1-SREBP pathway	ONCOGENE			English	Article							LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL-METABOLISM; ADRENODOXIN REDUCTASE; STEROID HYDROXYLASE; ELECTRON-TRANSFER; PROSTATE-CANCER; TRANSGENIC MICE; NILE RED; GENE; BINDING	p53 is known to modulate metabolism and FDXR is required for steroidogenesis. Given that FDXR is a target/regulator of p53, the FDXR-p53 axis may play a unique role in lipid metabolism. Here, we found that expression of ABCA1, a cholesterol-efflux pump, was suppressed by loss of FDXR and/or p53, leading to activation of master lipogenic regulators SREBP1/2. Accordingly, lipid droplets, cholesterol, and triglycerides were increased by loss of FDXR or p53, which were further increased by loss of both FDXR and p53. To explore the biological significance of the FDXR-p53 axis, we generated a cohort of mice deficient in Fdxr and/or Trp53. We found that Fdxr(+/-), Trp53(+/-), and Fdxr(+/-);Trp53(+/-) mice had a short life span and were prone to spontaneous tumors and liver steatosis. Moreover, the levels of serum cholesterol and triglycerides were significantly increased in Fdxr(+/-) and Trp53(+/-) mice, which were further increased in Fdxr(+/-);Trp53(+/-) mice. Interestingly, loss of Fdxr but not p53 led to accumulation of serum low-density lipoprotein. Together, our findings reveal that the FDXR-p53 axis plays a critical role in lipid homeostasis and tumor suppression.	[Zhang, Yanhong; Mohibi, Shakur; Vasilatis, Demitria M.; Zhang, Jin; Chen, Xinbin] Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, Davis, CA 95616 USA; [Zhang, Yanhong; Mohibi, Shakur; Vasilatis, Demitria M.; Zhang, Jin; Chen, Xinbin] Univ Calif Davis, Sch Med, Comparat Oncol Lab, Davis, CA 95616 USA; [Chen, Mingyi] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Texas System; University of Texas Southwestern Medical Center Dallas	Zhang, J; Chen, XB (corresponding author), Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, Davis, CA 95616 USA.; Zhang, J; Chen, XB (corresponding author), Univ Calif Davis, Sch Med, Comparat Oncol Lab, Davis, CA 95616 USA.	jinzhang@ucdavis.edu; xbchen@ucdavis.edu		zhang, jin/0000-0002-6835-920X; chen, xinbin/0000-0002-4582-6506; Mohibi, Shakur/0000-0001-5539-0841	NIH [CA224433, CA250338]; UCD Cancer Center Core Support Grant [CA093373]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UCD Cancer Center Core Support Grant	This work is supported in part by NIH grant CA224433 and CA250338 and by UCD Cancer Center Core Support Grant CA093373.	Assaily W, 2011, MOL CELL, V44, P491, DOI 10.1016/j.molcel.2011.08.038; Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; DESSI S, 1994, CANCER, V73, P253, DOI 10.1002/1097-0142(19940115)73:2<253::AID-CNCR2820730204>3.0.CO;2-F; DESSI S, 1992, BRIT J CANCER, V66, P787, DOI 10.1038/bjc.1992.361; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Funauchi Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep16497; Genicot G, 2005, THERIOGENOLOGY, V63, P1181, DOI 10.1016/j.theriogenology.2004.06.006; Graziani SR, 2002, GYNECOL ONCOL, V85, P493, DOI 10.1006/gyno.2002.6654; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; Guo DL, 2014, CURR PHARM DESIGN, V20, P2619, DOI 10.2174/13816128113199990486; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; Hinson DD, 1997, J LIPID RES, V38, P2216; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Huang WC, 2012, MOL CANCER RES, V10, P133, DOI 10.1158/1541-7786.MCR-11-0206; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Ki DH, 2007, INT J CANCER, V121, P2005, DOI 10.1002/ijc.22975; KIMURA T, 1967, J BIOL CHEM, V242, P485; Kolanjiappan K, 2003, CLIN BIOCHEM, V36, P61, DOI 10.1016/S0009-9120(02)00421-6; Kubicka S, 1997, HEPATOLOGY, V25, P867, DOI 10.1002/hep.510250414; Lacroix M, 2020, MOL METAB, V33, P2, DOI 10.1016/j.molmet.2019.10.002; Lane-Donovan C, 2014, NEURON, V83, P771, DOI 10.1016/j.neuron.2014.08.005; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Liu Y, 2014, P NATL ACAD SCI USA, V111, pE2414, DOI 10.1073/pnas.1315605111; Lochner M, 2015, TRENDS IMMUNOL, V36, P81, DOI 10.1016/j.it.2014.12.005; Ma WZ, 2007, J BIOENERG BIOMEMBR, V39, P243, DOI 10.1007/s10863-007-9083-0; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Michihara A, 2001, BIOL PHARM BULL, V24, P1231, DOI 10.1248/bpb.24.1231; Miller WL, 2011, J LIPID RES, V52, P2111, DOI 10.1194/jlr.R016675; Moon SH, 2019, CELL, V176, P564, DOI 10.1016/j.cell.2018.11.011; Moustafa MA, 2004, CANCER SCI, V95, P530, DOI 10.1111/j.1349-7006.2004.tb03244.x; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; Osborne TF, 2009, GENE DEV, V23, P2578, DOI 10.1101/gad.1854309; Parrales A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122074; Paul A, 2017, AM J HUM GENET, V101, P630, DOI 10.1016/j.ajhg.2017.09.007; Peng YY, 2017, HUM MOL GENET, V26, P4937, DOI 10.1093/hmg/ddx377; Rudling M, 1996, BBA-LIPID LIPID MET, V1299, P75, DOI 10.1016/0005-2760(95)00195-6; Sanchez-Macedo N, 2013, CELL DEATH DIFFER, V20, P659, DOI 10.1038/cdd.2012.168; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Schaffner C P, 1981, Prog Clin Biol Res, V75A, P279; Schimanski S, 2010, HORM METAB RES, V42, P102, DOI 10.1055/s-0029-1241859; Shao W, 2012, CELL METAB, V16, P414, DOI 10.1016/j.cmet.2012.09.002; Sheftel AD, 2010, P NATL ACAD SCI USA, V107, P11775, DOI 10.1073/pnas.1004250107; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Simabuco Fernando M, 2018, Oncotarget, V9, P23780, DOI 10.18632/oncotarget.25267; Stenton SL, 2021, HUM MUTAT, V42, P310, DOI 10.1002/humu.24160; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Tatidis L, 2002, BIOCHEM PHARMACOL, V63, P2169, DOI 10.1016/S0006-2952(02)01018-3; Veldurthy V, 2016, VITAM HORM, V100, P137, DOI 10.1016/bs.vh.2015.10.005; Vickery LE, 1997, STEROIDS, V62, P124, DOI 10.1016/S0039-128X(96)00170-5; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wang XW, 2013, J MOL CELL BIOL, V5, P147, DOI 10.1093/jmcb/mjs064; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335; Yahagi N, 2003, J BIOL CHEM, V278, P25395, DOI 10.1074/jbc.M302364200; Yamauchi Y, 2015, J BIOL CHEM, V290, P23464, DOI 10.1074/jbc.M115.662668; Yang HJ, 2017, P NATL ACAD SCI USA, V114, P11500, DOI 10.1073/pnas.1711814114; Yoshioka Y, 2000, NMR BIOMED, V13, P377, DOI 10.1002/1099-1492(200011)13:7<377::AID-NBM658>3.0.CO;2-E; Zhang J, 2020, J PATHOL, V251, P284, DOI 10.1002/path.5451; Zhang J, 2018, CANCER RES, V78, P1511, DOI 10.1158/0008-5472.CAN-17-2457; Zhang J, 2014, P NATL ACAD SCI USA, V111, P18637, DOI 10.1073/pnas.1415607112; Zhang YH, 2017, GENE DEV, V31, P1243, DOI 10.1101/gad.299388.117; Zhou S, 2003, MUTAGENESIS, V18, P287, DOI 10.1093/mutage/18.3.287; Zollner A, 2008, FEBS J, V275, P799, DOI 10.1111/j.1742-4658.2008.06253.x	68	3	3	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1718	1726		10.1038/s41388-021-02100-0	http://dx.doi.org/10.1038/s41388-021-02100-0		FEB 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35121827	Green Published, hybrid			2022-12-28	WOS:000751251500001
J	Hua, Z; Wei, RF; Guo, MJ; Lin, ZG; Yu, XC; Li, XY; Gu, CY; Yang, Y				Hua, Zhen; Wei, Rongfang; Guo, Mengjie; Lin, Zigen; Yu, Xichao; Li, Xinying; Gu, Chunyan; Yang, Ye			YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis	ONCOGENE			English	Article							MOLECULAR CLASSIFICATION; PROTEASOME INHIBITORS; CANCER; HETEROGENEITY; STAT5; MEK	Multiple myeloma (MM) is still incurable partially due to lacking effective therapeutic targets. Aberrant N6-methyladenosine (m6A) RNA modification plays a vital role in many cancers, however few researches are executed in MM. We first screened the m6A-related genes in MM patient cohorts and correlated these genes with patient outcomes. We found that YTHDF2, a well-recognized m6A reader, was increased in MM patients and associated with poor outcomes. Decreased YTHDF2 expression hampered MM cell proliferation in vitro and in vivo, while enforced YTHDF2 expression reversed those effects. The analyses of m6A-RIP-seq and RIP-PCR indicated that STAT5A was the downstream target of YTHDF2, which was binding to the m6A modification site of STAT5A to promote its mRNA degradation. ChIP-seq and PCR assays revealed that STAT5A suppressed MM cell proliferation by occupying the transcription site of MAP2K2 to decrease ERK phosphorylation. In addition, we confirmed that YTHDF2 mediated the unphosphorylated form of STAT5A to inhibit the expression of MAP2K2/p-ERK. In conclusion, our study highlights that YTHDF2/STAT5A/MAP2K2/p-ERK axis plays a key role in MM proliferation and targeting YTHDF2 may be a promising therapeutic strategy.	[Hua, Zhen; Guo, Mengjie; Gu, Chunyan] Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Nanjing, Peoples R China; [Hua, Zhen; Wei, Rongfang; Guo, Mengjie; Lin, Zigen; Yu, Xichao; Li, Xinying; Gu, Chunyan; Yang, Ye] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Nanjing, Peoples R China	Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine	Gu, CY (corresponding author), Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Nanjing, Peoples R China.; Gu, CY; Yang, Y (corresponding author), Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Nanjing, Peoples R China.	guchunyan@njucm.edu.cn; yangye876@sina.com	li, xin/HHS-9461-2022; Lang, Ming/HIK-0758-2022; yang, yang/GWB-9426-2022; YANG, YE/F-4987-2015	Gu, Chunyan/0000-0001-7408-8840; Li, Xinying/0000-0002-1162-2556; Hua, Zoe/0000-0002-7672-2929; YANG, YE/0000-0003-0228-5102; Xichao, YU/0000-0003-2694-1389; Lin, Zigen/0000-0001-7323-4279; Wei, Rongfang/0000-0002-7654-7251	National Natural Science Foundation of China [81970196, 82073885, 82003832]; Natural Science Foundation of Jiangsu Province [BK20200097]; Jiangsu Postgraduate Research and Practice Innovation Program [KYCX21_1769]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Jiangsu Postgraduate Research and Practice Innovation Program; Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine)	This work was supported by National Natural Science Foundation of China 81970196 (to CG), 82073885 (to YY), 82003832 (to MG); Natural Science Foundation of Jiangsu Province BK20200097 (to CG); Jiangsu Postgraduate Research and Practice Innovation Program KYCX21_1769 (to RW); A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine).	Bach C, 2019, ONCOL RES TREAT, V42, P123; Bai H, 2021, CURR RES TRANSL MED, V69, DOI 10.1016/j.retram.2021.103288; Bakhoum SF, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a029611; Bianchi G, 2014, CA-CANCER J CLIN, V64, P422, DOI 10.3322/caac.21252; Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997; Brioli A, 2014, BRIT J HAEMATOL, V165, P441, DOI 10.1111/bjh.12805; Brown S, 2021, CL LYMPH MYELOM LEUK, V21, P154, DOI 10.1016/j.clml.2020.11.019; Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood-2009-12-261032; Cardona-Benavides IJ, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020336; Chang YZ, 2021, CANCER LETT, V511, P36, DOI 10.1016/j.canlet.2021.04.020; Chen B, 2019, MOL BIOL REP, V46, P2567, DOI 10.1007/s11033-019-04655-4; Chen Y, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01207-4; CIMINO G, 1990, BRIT J HAEMATOL, V75, P373, DOI 10.1111/j.1365-2141.1990.tb04351.x; Cui XC, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12768; Dimopoulos K, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.29; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626; du Pont SR, 2017, J CLIN ONCOL, V35, P963, DOI 10.1200/JCO.2016.70.6705; Furigo IC, 2018, BRAIN STRUCT FUNCT, V223, P2229, DOI 10.1007/s00429-018-1627-z; Gu CY, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01380-0; He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9; Heuck CJ, 2016, LEUKEMIA, V30, P976, DOI 10.1038/leu.2015.208; Hu BB, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1099-7; Hu XY, 2013, P NATL ACAD SCI USA, V110, P10213, DOI 10.1073/pnas.1221243110; Huang T, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2235-4; Jiang FJ, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01066-6; Kimura A, 2010, J BIOL CHEM, V285, P32704, DOI 10.1074/jbc.M110.141804; Lauta VM, 2003, CANCER, V97, P2440, DOI 10.1002/cncr.11072; Li WX, 2008, TRENDS CELL BIOL, V18, P545, DOI 10.1016/j.tcb.2008.08.008; Li ZR, 2018, CELL RES, V28, P904, DOI 10.1038/s41422-018-0072-0; Liao W, 2013, IMMUNITY, V38, P13, DOI 10.1016/j.immuni.2013.01.004; Liu Y, 2021, CELL METAB, V33, P1221, DOI 10.1016/j.cmet.2021.04.001; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Manasanch EE, 2017, NAT REV CLIN ONCOL, V14, P417, DOI [10.1038/nrclinonc.2016.206, 10.1007/s12079-011-0121-7]; McClure JJ, 2018, ADV CANCER RES, V138, P183, DOI 10.1016/bs.acr.2018.02.006; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Neuse CJ, 2020, LEUKEMIA, V34, P2887, DOI 10.1038/s41375-020-0921-y; Neuzillet C, 2014, PHARMACOL THERAPEUT, V141, P160, DOI 10.1016/j.pharmthera.2013.10.001; Peng Y, 2020, LIFE SCI, V249, DOI 10.1016/j.lfs.2020.117503; Rajkumar SV, 2016, AM J HEMATOL, V91, P720, DOI 10.1002/ajh.24402; Rajkumar SV, 2009, CURR PROB CANCER, V33, P7, DOI 10.1016/j.currproblcancer.2009.01.001; Rani A, 2016, J INTERF CYTOK RES, V36, P226, DOI 10.1089/jir.2015.0054; Ri M, 2016, INT J HEMATOL, V104, P273, DOI 10.1007/s12185-016-2016-0; Rollig C, 2015, LANCET, V385, P2197, DOI 10.1016/S0140-6736(14)60493-1; Shen XT, 2020, CANCER BIOL MED, V17, P937, DOI 10.20892/j.issn.2095-3941.2020.0402; Shen XD, 2021, FRONT GENET, V11, DOI 10.3389/fgene.2020.592042; Sheng H, 2020, CARCINOGENESIS, V41, P541, DOI 10.1093/carcin/bgz152; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song P, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01244-z; Song S, 2021, ONCOGENE, V40, P5393, DOI 10.1038/s41388-021-01939-7; Sonneveld P, 2016, BLOOD, V127, P2955, DOI 10.1182/blood-2016-01-631200; Sun T, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108613; Surbek M, 2021, CYTOKINE, V139, DOI 10.1016/j.cyto.2020.155392; Tang XZ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00746-6; Teras LR, 2016, CA-CANCER J CLIN, V66, P443, DOI 10.3322/caac.21357; van Nieuwenhuijzen N, 2018, CANCER RES, V78, P2449, DOI 10.1158/0008-5472.CAN-17-3115; Wang TY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01204-7; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wei RF, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01501; Wu CJ, 2020, CANCERS, V12, DOI 10.3390/cancers12010024; Xu J, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.36; Xu Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.561703; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458; Zhang L, 2021, RNA BIOL, V18, P1265, DOI 10.1080/15476286.2020.1841458; Zhao ZJ, 2018, ACTA PHARM SIN B, V8, P539, DOI 10.1016/j.apsb.2018.03.001; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006; Zhu HL, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.714267; Zhuang JL, 2019, BLOOD, V133, P1572, DOI 10.1182/blood-2018-06-859686	68	5	5	5	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1482	1491		10.1038/s41388-022-02191-3	http://dx.doi.org/10.1038/s41388-022-02191-3		JAN 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35075244				2022-12-28	WOS:000746328800002
J	Kwon, OJ; Zhang, BY; Jia, DY; Zhang, L; Wei, X; Zhou, ZC; Liu, DL; Huynh, KT; Zhang, K; Zhang, YQ; Labhart, P; Sboner, A; Barbieri, C; Haffner, MC; Creighton, CJ; Xin, L				Kwon, Oh-Joon; Zhang, Boyu; Jia, Deyong; Zhang, Li; Wei, Xing; Zhou, Zhicheng; Liu, Deli; Khoi Trung Huynh; Zhang, Kai; Zhang, Yiqun; Labhart, Paul; Sboner, Andrea; Barbieri, Chris; Haffner, Michael C.; Creighton, Chad J.; Xin, Li			Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130	ONCOGENE			English	Article							TO-LUMINAL DIFFERENTIATION; ANDROGEN-RECEPTOR; ACCELERATES INITIATION; CHRONIC INFLAMMATION; GENE-EXPRESSION; MOUSE MODEL; CANCER; HYPERPLASIA; TISSUE; PROGRESSION	Macrophages are increased in human benign prostatic hyperplasia and prostate cancer. We generate a Pb-Csf1 mouse model with prostate-specific overexpression of macrophage colony-stimulating factor (M-Csf/Csf1). Csf1 overexpression promotes immune cell infiltration into the prostate, modulates the macrophage polarity in a lobe-specific manner, and induces senescence and low-grade prostatic intraepithelial neoplasia (PIN). The Pb-Csf1 prostate luminal cells exhibit increased stem cell features and undergo an epithelial-to-mesenchymal transition. Human prostate cancer patients with high CSF-1 expression display similar transcriptional alterations with the Pb-Csf1 model. P53 knockout alleviates senescence but fails to progress PIN lesions. Ablating epithelial Gp130 but not Il1r1 substantially blocks PIN lesion formation. The androgen receptor (AR) is downregulated in Pb-Csf1 mice. ChIP-Seq analysis reveals altered AR binding in 2482 genes although there is no significant widespread change in global AR transcriptional activity. Collectively, our study demonstrates that increased macrophage infiltration causes PIN formation but fails to transform prostate cells.	[Kwon, Oh-Joon; Jia, Deyong; Zhang, Li; Wei, Xing; Zhou, Zhicheng; Zhang, Kai; Xin, Li] Univ Washington, Dept Urol, Seattle, WA 98109 USA; [Zhang, Boyu] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Liu, Deli; Sboner, Andrea; Barbieri, Chris] Weill Cornell Med, Sandra & Edward Meyer Canc Ctr, New York, NY USA; [Liu, Deli; Sboner, Andrea; Barbieri, Chris] Weill Cornell Med, Dept Urol, New York, NY USA; [Khoi Trung Huynh] Univ Washington, Dept Biol, Seattle, WA 98109 USA; [Zhang, Yiqun; Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Labhart, Paul] Act Motif, San Diego, CA USA; [Haffner, Michael C.] Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98109 USA; [Xin, Li] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Baylor College of Medicine; Cornell University; Cornell University; University of Washington; University of Washington Seattle; Baylor College of Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Xin, L (corresponding author), Univ Washington, Dept Urol, Seattle, WA 98109 USA.; Xin, L (corresponding author), Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA.	xin18@uw.edu	Jia, Deyong/GSJ-0327-2022; Jia, Deyong/GQP-9611-2022; Zhang, YiQun/HCI-2427-2022	Jia, Deyong/0000-0003-2034-0363; Kwon, Oh-Joon/0000-0001-9067-0240; Zhang, Yiqun/0000-0001-5058-5623	 [R01CA190378];  [R01DK092202];  [R01DK107436]	; ; 	We thank Dr. Fen Wang for the ARR2PB-Cre mice, Dr. Rodger McEver for the Gp130fl/fl mice, and Dr. Richard Stanley for the mouse Csf-1 cDNA. This work is supported by R01CA190378, R01DK092202 and R01DK107436 (L.X.).	Barron DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013751; Becerra-Diaz M, 2018, J IMMUNOL, V201, P2923, DOI 10.4049/jimmunol.1800352; Birbach A, 2011, NEOPLASIA, V13, P692, DOI 10.1593/neo.11524; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chen TS, 2000, CANCER RES, V60, P2132; Cioni B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18313-y; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Debelec-Butuner B, 2014, MOL CARCINOGEN, V53, P85, DOI 10.1002/mc.21948; Dennis LK, 2002, UROLOGY, V60, P78, DOI 10.1016/S0090-4295(02)01637-0; Elkahwaji JE, 2007, PROSTATE, V67, P14, DOI 10.1002/pros.20445; Endo Y, 2007, ONCOGENE, V26, P5587, DOI 10.1038/sj.onc.1210344; Fong L, 1997, J IMMUNOL, V159, P3113; Graham TR, 2010, BREAST CANCER RES TR, V123, P139, DOI 10.1007/s10549-009-0623-7; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gurel B, 2014, CANCER EPIDEM BIOMAR, V23, P847, DOI 10.1158/1055-9965.EPI-13-1126; Haverkamp JM, 2011, PROSTATE, V71, P1139, DOI 10.1002/pros.21327; Hewitt SC, 2012, MOL ENDOCRINOL, V26, P887, DOI 10.1210/me.2011-1311; Hmadcha A, 1999, J EXP MED, V190, P1595, DOI 10.1084/jem.190.11.1595; Husaini Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043833; Ide H, 2002, P NATL ACAD SCI USA, V99, P14404, DOI 10.1073/pnas.222537099; Jin RJ, 2008, CANCER RES, V68, P6762, DOI 10.1158/0008-5472.CAN-08-0107; Kazma R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051680; Khalili M, 2010, AM J PATHOL, V176, P2259, DOI 10.2353/ajpath.2010.080747; Kirma N, 2004, CANCER RES, V64, P4162, DOI 10.1158/0008-5472.CAN-03-2971; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Kumar V, 2017, CANCER CELL, V32, P654, DOI 10.1016/j.ccell.2017.10.005; Kwon OJ, 2016, STEM CELL RES, V16, P682, DOI 10.1016/j.scr.2016.04.009; Kwon OJ, 2014, P NATL ACAD SCI USA, V111, pE592, DOI 10.1073/pnas.1318157111; Leach DA, 2017, MOL CELL ENDOCRINOL, V439, P261, DOI 10.1016/j.mce.2016.09.010; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lissbrant IF, 2000, INT J ONCOL, V17, P445; Liu G, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0386-7; Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656; Maggio M, 2005, J Endocrinol Invest, V28, P116; Maggio M, 2006, J ANDROL, V27, P725, DOI 10.2164/jandrol.106.000141; Malinen M, 2017, NUCLEIC ACIDS RES, V45, P619, DOI 10.1093/nar/gkw855; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; ORMANDY CJ, 1992, INT J CANCER, V50, P777, DOI 10.1002/ijc.2910500519; Park JH, 2002, AM J PATHOL, V161, P727, DOI 10.1016/S0002-9440(10)64228-9; Platz EA, 2017, CANCER EPIDEM BIOMAR, V26, P1549, DOI 10.1158/1055-9965.EPI-17-0503; Schlomm T, 2016, EUR UROL, V69, P1157, DOI 10.1016/j.eururo.2016.02.024; Shinohara DB, 2013, PROSTATE, V73, P1007, DOI 10.1002/pros.22648; Simons BW, 2015, J PATHOL, V235, P478, DOI 10.1002/path.4472; Sorrentino C, 2011, CLIN CANCER RES, V17, P1571, DOI 10.1158/1078-0432.CCR-10-2804; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Stanley ER, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a021857; Strobel O, 2007, GASTROENTEROLOGY, V133, P1999, DOI 10.1053/j.gastro.2007.09.009; Traish A, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120549; Valdez JM, 2012, CELL STEM CELL, V11, P676, DOI 10.1016/j.stem.2012.07.003; Vignozzi L, 2012, J ENDOCRINOL, V214, P31, DOI 10.1530/JOE-12-0142; Vignozzi L, 2012, J ENDOCRINOL, V212, P71, DOI 10.1530/JOE-11-0289; Wang XH, 2012, J BIOL CHEM, V287, P18376, DOI 10.1074/jbc.M112.355164; Wang ZW, 2017, J PATHOL, V243, P457, DOI 10.1002/path.4985; Zhang BY, 2016, MOL CELL, V63, P976, DOI 10.1016/j.molcel.2016.07.025; Zhang LY, 2009, AM J PATHOL, V175, P489, DOI 10.2353/ajpath.2009.080727; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	60	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1309	1323		10.1038/s41388-021-02169-7	http://dx.doi.org/10.1038/s41388-021-02169-7		JAN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	34999736	Green Accepted			2022-12-28	WOS:000740423700001
J	Hu, MN; Bao, RX; Lin, M; Han, XR; Ai, YJ; Gao, Y; Guan, KL; Xiong, Y; Yuan, HX				Hu, Mengnan; Bao, Ruoxuan; Lin, Miao; Han, Xiao-Ran; Ai, Ying-Jie; Gao, Yun; Guan, Kun-Liang; Xiong, Yue; Yuan, Hai-Xin			ALK fusion promotes metabolic reprogramming of cancer cells by transcriptionally upregulating PFKFB3	ONCOGENE			English	Article							ANAPLASTIC LYMPHOMA KINASE; 6-PHOSPHOFRUCTO-2-KINASE PFKFB3; TYROSINE KINASE; PROTEIN-KINASE; GROWTH-FACTOR; GLYCOLYSIS; IDENTIFICATION; INHIBITION; MECHANISMS; STRATEGY	Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase of the insulin receptor kinase subfamily, is activated in multiple cancer types through translocation or overexpression. Although several generations of ALK tyrosine kinase inhibitors (TKIs) have been developed for clinic use, drug resistance remains a major challenge. In this study, by quantitative proteomic approach, we identified the glycolytic regulatory enzyme, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), as a new target of ALK. Expression of PFKFB3 is highly dependent on ALK activity in ALK(+) anaplastic large cell lymphoma and non-small-cell lung cancer (NSCLC) cells. Notably, ALK and PFKFB3 expressions exhibit significant correlation in clinic ALK(+) NSCLC samples. We further demonstrated that ALK promotes PFKFB3 transcription through the downstream transcription factor STAT3. Upregulation of PFKFB3 by ALK is important for high glycolysis level as well as oncogenic activity of ALK(+) lymphoma cells. Finally, targeting PFKFB3 by its inhibitor can overcome drug resistance in cells bearing TKI-resistant mutants of ALK. Collectively, our studies reveal a novel ALK-STAT3-PFKFB3 axis to promote cell proliferation and tumorigenesis, providing an alternative strategy for the treatment of ALK-positive tumors.	[Hu, Mengnan; Bao, Ruoxuan; Gao, Yun; Yuan, Hai-Xin] Fudan Univ, Peoples Hosp Shanghai 5, Shanghai, Peoples R China; [Hu, Mengnan; Bao, Ruoxuan; Gao, Yun; Yuan, Hai-Xin] Fudan Univ, Mol & Cell Biol Lab, Inst Biomed Sci, Shanghai, Peoples R China; [Lin, Miao] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai, Peoples R China; [Lin, Miao] Fudan Univ, Zhongshan Hosp Xiamen, Dept Thorac Surg, Xiamen, Peoples R China; [Han, Xiao-Ran] Cullgen Shanghai Inc, Pu Dong New Area, 230 Chuan Hong Rd, Shanghai, Peoples R China; [Ai, Ying-Jie] Fudan Univ, Zhongshan Hosp, Dept Gastroenterol & Hepatol, Shanghai, Peoples R China; [Guan, Kun-Liang] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Guan, Kun-Liang] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Xiong, Yue] Cullgen Inc, 12671 High Bluff Dr, San Diego, CA 92130 USA; [Yuan, Hai-Xin] Chongqing Med Univ, Ctr Novel Target & Therapeut Intervent, Chongqing, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego; Chongqing Medical University	Yuan, HX (corresponding author), Fudan Univ, Peoples Hosp Shanghai 5, Shanghai, Peoples R China.; Yuan, HX (corresponding author), Fudan Univ, Mol & Cell Biol Lab, Inst Biomed Sci, Shanghai, Peoples R China.; Yuan, HX (corresponding author), Chongqing Med Univ, Ctr Novel Target & Therapeut Intervent, Chongqing, Peoples R China.	yuanhaixin@fudan.edu.cn		Yuan, Hai-Xin/0000-0002-1624-3934	NSFC [82172595, 81773190]; National Key Research and Development Project of China [2018YFA0800304]; Supporting Program of Health Commission of Fujian Province for junior talents [2021GGB03]; Shanghai Pujiang Program [2020PJD009]; Innovative Research Team of High-level Local University in Shanghai	NSFC(National Natural Science Foundation of China (NSFC)); National Key Research and Development Project of China; Supporting Program of Health Commission of Fujian Province for junior talents; Shanghai Pujiang Program(Shanghai Pujiang Program); Innovative Research Team of High-level Local University in Shanghai	We thank Xian Chen and Ling Xie (UNC) for their aid with mass spectrometry analysis, and Jian Jin (Mount Sinai) and Jing Liu (Cullgen Inc.) for providing ALK degrader compound. We appreciate Hongbin Ji and Zhen Qin (SIBCB, CAS) for their help in the analysis of ALK mutant tumors. We also thank Kuirong Luo (Zhongshan Hospital, Fudan University) for the help with the interpretation of IHC results. This work was supported by the NSFC grants (No. 82172595 and 81773190 to H-XY), the National Key Research and Development Project of China (No. 2018YFA0800304 to H-XY), Supporting Program of Health Commission of Fujian Province for junior talents (2021GGB03 to ML) and Shanghai Pujiang Program (2020PJD009 to ML). H-XY is also supported by the Innovative Research Team of High-level Local University in Shanghai.	Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; Ambrogio C, 2005, BLOOD, V106, P3907, DOI 10.1182/blood-2005-03-1204; Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006; Chaft JE, 2012, MOL CANCER THER, V11, P485, DOI 10.1158/1535-7163.MCT-11-0692; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535-7163.MCT-07-0482; Clem BF, 2013, MOL CANCER THER, V12, P1461, DOI 10.1158/1535-7163.MCT-13-0097; De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037; Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231; Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473; Fontana D, 2015, CANCER MED-US, V4, P953, DOI 10.1002/cam4.413; Gainor JF, 2013, J CLIN ONCOL, V31, P3987, DOI 10.1200/JCO.2012.45.2029; Gustafsson NMS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06287-x; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hrustanovic G, 2015, NAT MED, V21, P1038, DOI 10.1038/nm.3930; Li FL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02950-5; Lovly CM, 2014, NAT MED, V20, P1027, DOI 10.1038/nm.3667; Ma Y, 2016, ONCOGENE, V35, P6132, DOI 10.1038/onc.2016.150; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; McDonnell SRP, 2013, BLOOD, V122, P958, DOI 10.1182/blood-2013-01-482026; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; Mosse YP, 2009, CLIN CANCER RES, V15, P5609, DOI 10.1158/1078-0432.CCR-08-2762; Normant E, 2011, ONCOGENE, V30, P2581, DOI 10.1038/onc.2010.625; Olsen TK, 2015, NEURO-ONCOLOGY, V17, P1365, DOI 10.1093/neuonc/nov039; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8; Schoors S, 2014, CELL METAB, V19, P37, DOI 10.1016/j.cmet.2013.11.008; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Touriol Christian, 2000, Blood, V95, P3204; Tudzarova S, 2011, P NATL ACAD SCI USA, V108, P5278, DOI 10.1073/pnas.1102247108; US Food and Drug Administration, 2016, US; Wang YH, 2020, EUR J MED CHEM, V203, DOI 10.1016/j.ejmech.2020.112612; Wasik MA, 2009, SEMIN ONCOL, V36, pS27, DOI 10.1053/j.seminoncol.2009.02.007; Yalcin A, 2009, J BIOL CHEM, V284, P24223, DOI 10.1074/jbc.M109.016816; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003; Yamamoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4480; Zhang CW, 2018, EUR J MED CHEM, V151, P304, DOI 10.1016/j.ejmech.2018.03.071	44	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4547	4559		10.1038/s41388-022-02453-0	http://dx.doi.org/10.1038/s41388-022-02453-0		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36064579				2022-12-28	WOS:000849997400001
J	Zhan, Y; Qiao, W; Yi, BL; Yang, XY; Li, MM; Sun, L; Ji, L; Su, P; Wang, X; Zhang, FR; Zhang, R; Gao, MJ; Zhao, WJ; Song, YC				Zhan, Ying; Qiao, Wei; Yi, Bolong; Yang, Xinyu; Li, Miaomiao; Sun, Lu; Ji, Lian; Su, Peng; Wang, Xin; Zhang, Furong; Zhang, Rui; Gao, Mingjun; Zhao, Wujun; Song, Yichen			Dual role of pseudogene TMEM198B in promoting lipid metabolism and immune escape of glioma cells	ONCOGENE			English	Article							ATP CITRATE LYASE; TUMOR PROGRESSION; PROLIFERATION; DIFFERENTIATION; ACTIVATION; MIGRATION; INVASION	Dysregulation of pseudogenes, enhancement of fatty acid synthesis and formation of immunosuppressive microenvironment are important factors that promote the malignant progression of glioma. It is of great significance to search for the molecular mechanism of interaction between the three and then perform targeted interference for improving the treatment of glioma. In this study, we found that pseudogene transmembrane protein 198B (TMEM198B) was highly expressed in glioma tissues and cell lines, and it could promote malignant progression of glioma by regulating lipid metabolism reprogramming and remodeling immune microenvironment. Applying the experimental methods of gene interference, lipidomics and immunology, we further confirmed that TMEM198B promoted PLAG1 like zinc finger 2 (PLAGL2) expression by mediating tri-methylation of histone H3 on lysine 4 (H3K4me3) of PLAGL2 through binding to SET domain containing 1B (SETD1B). Increased PLAGL2 could transcriptional activate ATP citrate lyase (ACLY) and ELOVL fatty acid elongase 6 (ELOVL6) expression, and then influenced the biological behaviors of glioma cells via enhancing the de novo lipogenesis and fatty acid acyl chain elongation. At the same time, TMEM198B promoted macrophages lipid accumulation and intensification of fatty acid oxidation (FAO) through glioma-derived exosomes (GDEs), further induced macrophages to M2 polarization, which subsequently facilitated immune escape of glioma cells. In conclusion, our present study clarifies that the TMEM198B/PLAGL2/ACLY/ELOVL6 pathway conducts crucial regulatory effects on the malignant progression of glioma, which provides novel targets and new ideas for molecular targeted therapy and immunotherapy of glioma.	[Zhan, Ying; Qiao, Wei; Sun, Lu; Wang, Xin] China Med Univ, Dept Ultrasound, Shengjing Hosp, Shenyang 110004, Peoples R China; [Yi, Bolong; Yang, Xinyu; Li, Miaomiao; Zhang, Furong; Zhang, Rui; Gao, Mingjun; Zhao, Wujun; Song, Yichen] China Med Univ, Dept Neurosurg, Shengjing Hosp, Shenyang 110004, Peoples R China; [Yi, Bolong; Yang, Xinyu; Li, Miaomiao; Zhang, Furong; Zhang, Rui; Gao, Mingjun; Zhao, Wujun; Song, Yichen] Liaoning Clin Med Res Ctr Nervous Syst Dis, Shenyang 110004, Peoples R China; [Yi, Bolong; Yang, Xinyu; Li, Miaomiao; Zhang, Furong; Zhang, Rui; Gao, Mingjun; Zhao, Wujun; Song, Yichen] Key Lab Neurooncol Liaoning Prov, Shenyang 110004, Peoples R China; [Ji, Lian; Su, Peng] China Med Univ, Med Res Ctr, Liaoning Key Lab Res & Applicat Anim Models Envir, Shengjing Hosp, Shenyang 110004, Peoples R China	China Medical University; China Medical University; China Medical University	Song, YC (corresponding author), China Med Univ, Dept Neurosurg, Shengjing Hosp, Shenyang 110004, Peoples R China.; Song, YC (corresponding author), Liaoning Clin Med Res Ctr Nervous Syst Dis, Shenyang 110004, Peoples R China.; Song, YC (corresponding author), Key Lab Neurooncol Liaoning Prov, Shenyang 110004, Peoples R China.	songyc@sj-hospital.org			Natural Science Foundation of China [81571686, 81571868, 81372682]; Natural Science Foundation of Liaoning Province [2020-MS-170]; Outstanding Scientific Research Talent Plan of Shengjing hospital [2020M0322]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Liaoning Province(Natural Science Foundation of Liaoning Province); Outstanding Scientific Research Talent Plan of Shengjing hospital	This work is supported by grants from the Natural Science Foundation of China (81571686, 81571868 and 81372682), Natural Science Foundation of Liaoning Province (2020-MS-170) and Outstanding Scientific Research Talent Plan of Shengjing hospital (NO.2020M0322).	Beckner ME, 2010, INT J CANCER, V126, P2282, DOI 10.1002/ijc.24918; Broekman ML, 2018, NAT REV NEUROL, V14, P482, DOI 10.1038/s41582-018-0025-8; Chen X, 2020, THERANOSTICS, V10, P1479, DOI 10.7150/thno.40659; Cheng J, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01189-3; Chi KC, 2019, MOL NEUROBIOL, V56, P4589, DOI 10.1007/s12035-018-1392-2; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Dong WW, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.411; Geng F, 2016, CLIN CANCER RES, V22, P5337, DOI 10.1158/1078-0432.CCR-15-2973; Gimple RC, 2019, CANCER DISCOV, V9, P1248, DOI 10.1158/2159-8290.CD-19-0061; Guo XF, 2018, ONCOGENE, V37, P4239, DOI 10.1038/s41388-018-0261-9; Han W, 2018, ONCOGENE, V37, P710, DOI 10.1038/onc.2017.385; Hu WW, 2021, HEPATOLOGY, V73, P674, DOI 10.1002/hep.31293; Icard P, 2020, CANCER LETT, V471, P125, DOI 10.1016/j.canlet.2019.12.010; Jakobsson A, 2006, PROG LIPID RES, V45, P237, DOI 10.1016/j.plipres.2006.01.004; Jiang L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02927; Koufaris C, 2016, ONCOGENE, V35, P2766, DOI 10.1038/onc.2015.333; Kumagai S, 2020, IMMUNITY, V53, P187, DOI 10.1016/j.immuni.2020.06.016; Kumari R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12194-6; Kwon M, 2020, NUCLEIC ACIDS RES, V48, P5442, DOI 10.1093/nar/gkaa317; Liao KM, 2020, CANCER LETT, V490, P111, DOI 10.1016/j.canlet.2020.07.012; Lim M, 2018, NAT REV CLIN ONCOL, V15, P422, DOI 10.1038/s41571-018-0003-5; Lin H, 2017, NEURO-ONCOLOGY, V19, P43, DOI 10.1093/neuonc/now128; Lindner P, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2340-4; Luo Q, 2020, CANCER SCI, V111, P4000, DOI 10.1111/cas.14616; Marien E, 2016, ONCOTARGET, V7, P12582, DOI 10.18632/oncotarget.7179; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Muir K, 2013, CANCER RES, V73, P4722, DOI 10.1158/0008-5472.CAN-12-3797; Muranaka H, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.51; Qian MY, 2020, ONCOGENE, V39, P428, DOI 10.1038/s41388-019-0996-y; Redd PS, 2017, CANCER RES, V77, P2834, DOI 10.1158/0008-5472.CAN-16-2238; Shergalis A, 2018, PHARMACOL REV, V70, P412, DOI 10.1124/pr.117.014944; Song YC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1200-5; Song YC, 2014, EXP CELL RES, V324, P54, DOI 10.1016/j.yexcr.2014.03.009; Strickland M, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00043; Su P, 2020, CANCER RES, V80, P1438, DOI 10.1158/0008-5472.CAN-19-2994; Sun M, 2017, MOL THER, V25, P739, DOI 10.1016/j.ymthe.2016.12.018; Wang M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03042-3; Wang SB, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2345-z; Wu H, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910698; Wu L, 2021, THERANOSTICS, V11, P700, DOI 10.7150/thno.47800; Xi SY, 2021, ONCOGENE, V40, P4453, DOI 10.1038/s41388-021-01854-x; Yin XZ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108278; Zheng HW, 2010, CANCER CELL, V17, P497, DOI 10.1016/j.ccr.2010.03.020; Zong ZQ, 2019, J CELL MOL MED, V23, P5048, DOI 10.1111/jcmm.14362	44	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4512	4523		10.1038/s41388-022-02445-0	http://dx.doi.org/10.1038/s41388-022-02445-0		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36038663				2022-12-28	WOS:000847262000001
J	Strocchi, S; Reggiani, F; Gobbi, G; Ciarrocchi, A; Sancisi, V				Strocchi, Silvia; Reggiani, Francesca; Gobbi, Giulia; Ciarrocchi, Alessia; Sancisi, Valentina			The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation	ONCOGENE			English	Review							RNA-POLYMERASE-II; PROLINE-HYDROXYLATION; NITRIC-OXIDE; TRANSCRIPTIONAL ACTIVITY; BREAST TUMORIGENESIS; PROTEIN STABILITY; DOMAIN PROTEIN-2; DIRECT BINDING; LARGE SUBUNIT; GROWTH-FACTOR	EGLN1, EGLN2 and EGLN3 are proline hydroxylase whose main function is the regulation of the HIF factors. They work as oxygen sensors and are the main responsible of HIF alpha subunits degradation in normoxia. Being their activity strictly oxygen-dependent, when oxygen tension lowers, their control on HIF alpha is released, leading to activation of systemic and cellular response to hypoxia. However, EGLN family members activity is not limited to HIF modulation, but it includes the regulation of essential mechanisms for cell survival, cell cycle metabolism, proliferation and transcription. This is due to their reported hydroxylase activity on a number of non-HIF targets and sometimes to hydroxylase-independent functions. For these reasons, EGLN enzymes appear fundamental for development and progression of different cancer types, playing either a tumor-suppressive or a tumor-promoting role, according to EGLN isoform and to tumor context. Notably, EGLN1, the most studied isoform, has been shown to have also a central role in tumor micro-environment modulation, mediating CAF activation and impairing HIF1 alpha -related angiogenesis, thus covering an important function in cancer metastasis promotion. Considering the recent knowledge acquired on EGLNs, the possibility to target these enzymes for cancer treatment is emerging. However, due to their multifaceted and controversial roles in different cancer types, the use of EGLN inhibitors as anti-cancer drugs should be carefully evaluated in each context.	[Strocchi, Silvia; Reggiani, Francesca; Gobbi, Giulia; Ciarrocchi, Alessia; Sancisi, Valentina] Azienda USL IRCCS Reggio Emilia, Lab Translat Res, Reggio Emilia, Italy		Sancisi, V (corresponding author), Azienda USL IRCCS Reggio Emilia, Lab Translat Res, Reggio Emilia, Italy.	valentina.sancisi@ausl.re.it	REGGIANI, FRANCESCA/K-1082-2018; Sancisi, Valentina/H-6701-2018	REGGIANI, FRANCESCA/0000-0002-4090-8908; Sancisi, Valentina/0000-0003-4357-1228	AIRC under IG 2021 [26377]; Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2020 - Fondi 5 per Mille 2018; Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2019 - Fondi 5 per Mille 2017; Fondazione Umberto Veronesi (FUV); Italian Ministry of Health - Ricerca Corrente Annual Program 2023	AIRC under IG 2021(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2020 - Fondi 5 per Mille 2018; Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2019 - Fondi 5 per Mille 2017; Fondazione Umberto Veronesi (FUV)(Fondazione Umberto Veronesi); Italian Ministry of Health - Ricerca Corrente Annual Program 2023	The research leading to this work has received funding from AIRC under IG 2021 - ID. 26377 project - P.I. Sancisi Valentina. Valentina Sancisi is funded by the Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2020 - Fondi 5 per Mille 2018. Giulia Gobbi is funded by the Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2019 - Fondi 5 per Mille 2017. Francesca Reggiani is supported by Fondazione Umberto Veronesi (FUV). This study was partially supported by Italian Ministry of Health - Ricerca Corrente Annual Program 2023.	Akizawa T, 2019, AM J NEPHROL, V49, P271, DOI 10.1159/000499111; Andersen S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023847; Apanovich N, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.615787; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Barratt J, 2021, NEPHROL DIAL TRANSPL, V36, P1616, DOI 10.1093/ndt/gfab191; Berchner-Pfannschmidt U, 2007, J BIOL CHEM, V282, P1788, DOI 10.1074/jbc.M607065200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bordoli MR, 2011, ONCOGENE, V30, P548, DOI 10.1038/onc.2010.433; Briggs KJ, 2016, CELL, V166, P126, DOI 10.1016/j.cell.2016.05.042; Bryant JD, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00647-17; Bur H, 2018, ANTICANCER RES, V38, P329, DOI 10.21873/anticanres.12226; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; Chan MC, 2016, J BIOL CHEM, V291, P20661, DOI 10.1074/jbc.M116.749291; Chen F, 2019, NAT CELL BIOL, V21, P498, DOI 10.1038/s41556-019-0299-0; Chen N, 2011, CELL RES, V21, P983, DOI 10.1038/cr.2011.66; Chen SF, 2011, MOL CELL BIOCHEM, V358, P257, DOI 10.1007/s11010-011-0976-1; Choueiri TK, 2020, NAT MED, V26, P1519, DOI 10.1038/s41591-020-1093-z; Chowdhury R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12673; Cockmann ME, 2019, ELIFE, V8, DOI 10.7554/eLife.46490; Couvelard A, 2008, CLIN CANCER RES, V14, P6634, DOI 10.1158/1078-0432.CCR-07-5258; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; D'Hulst G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13889-6; de Oliveira RL, 2012, CANCER CELL, V22, P263, DOI 10.1016/j.ccr.2012.06.028; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Deschoemaeker S, 2015, EMBO MOL MED, V7, P1350, DOI 10.15252/emmm.201505492; Dey A, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz8534; Di Conza G, 2017, CELL REP, V18, P2836, DOI 10.1016/j.celrep.2017.02.081; Di Conza G, 2017, CELL REP, V18, P1699, DOI 10.1016/j.celrep.2017.01.051; Dopeso H, 2018, CANCER RES, V78, P1805, DOI 10.1158/0008-5472.CAN-17-1346; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erber L, 2019, MOL CELL PROTEOMICS, V18, P1772, DOI 10.1074/mcp.RA119.001535; Erez N, 2003, CANCER RES, V63, P8777; Fitzpatrick SF, 2016, BIOCHEM BIOPH RES CO, V474, P579, DOI 10.1016/j.bbrc.2016.04.085; Foxler DE, 2012, NAT CELL BIOL, V14, P201, DOI 10.1038/ncb2424; Fujimoto TN, 2019, CANCER RES, V79, P2327, DOI 10.1158/0008-5472.CAN-18-1785; Garvalov BK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6577; German NJ, 2016, MOL CELL, V63, P1006, DOI 10.1016/j.molcel.2016.08.014; Giatromanolaki A, 2008, CANCER LETT, V262, P87, DOI 10.1016/j.canlet.2007.11.041; Guan D, 2021, J INORG BIOCHEM, V218, DOI 10.1016/j.jinorgbio.2021.111413; Guo JP, 2016, SCIENCE, V353, P929, DOI 10.1126/science.aad5755; Guo JQ, 2020, ARTIF CELL NANOMED B, V48, P37, DOI 10.1080/21691401.2019.1699806; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Heindryckx F, 2012, J HEPATOL, V57, P61, DOI 10.1016/j.jhep.2012.02.021; Hogel H, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0410-5; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2017, MOL CELL, V66, P772, DOI 10.1016/j.molcel.2017.06.002; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jokilehto T, 2006, CLIN CANCER RES, V12, P1080, DOI 10.1158/1078-0432.CCR-05-2022; Jokilehto T, 2010, J CELL MOL MED, V14, P758, DOI 10.1111/j.1582-4934.2010.01030.x; Jokilehto T, 2010, EXP CELL RES, V316, P1169, DOI 10.1016/j.yexcr.2010.02.012; Jubb AM, 2004, J CLIN PATHOL, V57, P504, DOI 10.1136/jcp.2003.012963; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Klotzsche-von Ameln A, 2012, CANCER BIOL THER, V13, DOI 10.4161/cbt.13.4.18830; Klotzsche-von Ameln A, 2011, CANCER RES, V71, P3306, DOI 10.1158/0008-5472.CAN-10-3838; Koivunen P, 2007, J BIOL CHEM, V282, P30544, DOI 10.1074/jbc.M704988200; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Koren A, 2021, CANCERS, V13, DOI 10.3390/cancers13102309; Kozlova N, 2019, CANCER RES, V79, P4042, DOI 10.1158/0008-5472.CAN-18-3852; Kozlova N, 2017, ONCOTARGET, V8, P9885, DOI 10.18632/oncotarget.14241; Kuchnio A, 2015, CELL REP, V12, P992, DOI 10.1016/j.celrep.2015.07.010; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lee G, 2016, SCI REP-UK, V6, DOI 10.1038/srep18928; Lee SH, 2014, ONCOGENE, V33, P1458, DOI 10.1038/onc.2013.76; Lee SB, 2020, MOL CELL, V79, P376, DOI 10.1016/j.molcel.2020.06.021; Leinonen H, 2019, NEUROPHARMACOLOGY, V153, P63, DOI 10.1016/j.neuropharm.2019.04.023; Leinonen H, 2016, HUM MOL GENET, V25, P3810, DOI 10.1093/hmg/ddw228; Li Z, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000179; Li ZQ, 2019, CLIN CANCER RES, V25, P5947, DOI 10.1158/1078-0432.CCR-18-4145; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Liu XJ, 2020, MOL CELL, V77, P1294, DOI 10.1016/j.molcel.2020.01.009; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Luukkaa M, 2009, INT J RADIAT BIOL, V85, P900, DOI [10.3109/09553000903074104, 10.1080/09553000903074104]; Ma MY, 2017, ONCOTARGET, V8, P12983, DOI 10.18632/oncotarget.14677; Madsen CD, 2015, EMBO REP, V16, P1394, DOI 10.15252/embr.201540107; Maher ER, 2013, SEMIN CANCER BIOL, V23, P10, DOI 10.1016/j.semcancer.2012.06.003; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Miikkulainen P, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0167-y; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Moser SC, 2013, DEV CELL, V26, P381, DOI 10.1016/j.devcel.2013.06.014; Naba A, 2014, ELIFE, V3, DOI 10.7554/eLife.01308; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Nunez-O'Mara A, 2015, J CELL SCI, V128, P40, DOI 10.1242/jcs.151514; Oh ET, 2016, SCI REP-UK, V6, DOI 10.1038/srep27382; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ortmann B, 2016, J CELL SCI, V129, P191, DOI 10.1242/jcs.179911; Oughtred R, 2021, PROTEIN SCI, V30, P187, DOI 10.1002/pro.3978; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Peurala E, 2012, BREAST CANCER RES TR, V133, P179, DOI 10.1007/s10549-011-1750-5; Price C, 2019, CANCER RES, V79, P2564, DOI 10.1158/0008-5472.CAN-18-2674; Ramani MKV, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2021.166912; Rawluszko AA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-526; Reggiani F, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01357-z; Rodriguez J, 2018, CELL REP, V24, P1316, DOI 10.1016/j.celrep.2018.06.108; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shi M, 2021, CANCER LETT, V496, P144, DOI 10.1016/j.canlet.2020.10.011; Song DS, 2013, J BIOL CHEM, V288, P9662, DOI 10.1074/jbc.M112.440552; Steinhoff A, 2009, BIOCHEM BIOPH RES CO, V387, P705, DOI 10.1016/j.bbrc.2009.07.090; Su Y, 2010, BRIT J CANCER, V103, P1571, DOI 10.1038/sj.bjc.6605936; Su Y, 2012, CANCER-AM CANCER SOC, V118, P960, DOI 10.1002/cncr.26344; Takada M, 2017, ONCOTARGET, V8, P6787, DOI 10.18632/oncotarget.14290; Takeda K, 2007, CIRCULATION, V116, P774, DOI 10.1161/CIRCULATIONAHA.107.701516; Takeda K, 2006, MOL CELL BIOL, V26, P8336, DOI 10.1128/MCB.00425-06; Tanaka T, 2015, J GASTROENTEROL, V50, P975, DOI 10.1007/s00535-014-1030-3; Tanaka T, 2014, J CANCER RES CLIN, V140, P503, DOI 10.1007/s00432-014-1593-7; Tennant DA, 2009, ONCOGENE, V28, P4009, DOI 10.1038/onc.2009.250; To KKW, 2005, J BIOL CHEM, V280, P38102, DOI 10.1074/jbc.M504342200; Tseng CW, 2018, CANCER RES, V78, P2799, DOI 10.1158/0008-5472.CAN-17-2906; Ullah K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17376-0; Vidimar V, 2019, CANCER LETT, V440, P145, DOI 10.1016/j.canlet.2018.09.029; Wang L, 2020, LIFE SCI, V242, DOI 10.1016/j.lfs.2019.117167; Xiang JF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0367-6; Xie GF, 2012, EXP BIOL MED, V237, P860, DOI 10.1258/ebm.2012.011331; Xie X, 2014, CANCER GENET-NY, V207, P188, DOI 10.1016/j.cancergen.2014.04.008; Xu YM, 2019, J BIOL CHEM, V294, P9949, DOI 10.1074/jbc.RA118.007181; Yi Y, 2010, CLIN CANCER RES, V16, P5142, DOI 10.1158/1078-0432.CCR-09-3416; Zacharias NM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062849; Zhang J, 2015, EMBO J, V34, P2953, DOI 10.15252/embj.201591437; Zhang LL, 2017, CANCER LETT, V390, P11, DOI 10.1016/j.canlet.2017.01.003; Zhang Q, 2009, CANCER CELL, V16, P413, DOI 10.1016/j.ccr.2009.09.029; Zheng F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21535-3; Zheng XN, 2014, GENE DEV, V28, P1429, DOI 10.1101/gad.242131.114; Zurlo G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13168-4	127	2	2	9	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2022	41	29					3665	3679		10.1038/s41388-022-02378-8	http://dx.doi.org/10.1038/s41388-022-02378-8		JUN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y6YE	35705735				2022-12-28	WOS:000811468900001
J	Wang, XH; Zhang, LH; Chan, FKL; Ji, JF; Yu, J; Liang, JQ				Wang, Xiaohong; Zhang, Lianhai; Chan, Francis K. L.; Ji, Jiafu; Yu, Jun; Liang, Jessie Qiaoyi			Gamma-glutamyltransferase 7 suppresses gastric cancer by cooperating with RAB7 to induce mitophagy	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; EPIGENETIC ALTERATIONS; AUTOPHAGY; GROWTH	We identified gamma-glutamyltransferase 7 (GGT7) to be frequently downregulated in gastric cancer, but its role remains unknown. Here we elucidated the clinical significance, functional roles, and molecular mechanism of GGT7 in gastric cancer. GGT7 was downregulated by promoter methylation and restored by demethylation treatment in gastric cancer cells. GGT7 methylation inversely correlated with mRNA expression in gastric tumors (n = 221; r = -0.686, P < 0.0001). High-expression of GGT7 in adjacent non-tumor tissues was significantly associated with favorable survival in gastric cancer patients (n = 138; P = 0.009), and was an independent prognostic factor by multivariate Cox regression (HR = 0.381, P < 0.05). GGT7 significantly inhibited gastric cancer cell growth, G1-S transition, and migration and invasion abilities. GGT7 also significantly attenuated the growth of subcutaneous xenograft tumors and reduced metastasis to the lung in nude mice. The mitophagy regulator RAB7 was identified as a direct downstream co-player of GGT7 by co-immunoprecipitation followed by mass spectrometry. Growth suppression effect of GGT7 was at least partly dependent on RAB7 by rescue experiments. GGT7 induced autophagy as shown by electron microscopy and confirmed by the increased LC3B and decreased p62. GGT7 recruited RAB7 by direct binding and drove RAB7 to translocate from nucleus to cytoplasm, subsequently mediating mitophagy by increasing mitophagy mediators/inducers. GGT7 inhibited intracellular ROS, which was associated with increased mitophagy, and subsequently suppressed MAPK signaling. Collectively, GGT7 plays a pivotal tumor-suppressing role in gastric cancer by directly binding with RAB7 to induce mitophagy and inhibit ROS and MAPK cascades. GGT7 is an independent prognostic factor for gastric cancer patients.	[Wang, Xiaohong; Chan, Francis K. L.; Yu, Jun; Liang, Jessie Qiaoyi] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China; [Wang, Xiaohong; Chan, Francis K. L.; Yu, Jun; Liang, Jessie Qiaoyi] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Dept Med & Therapeut State, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Hong Kong, Peoples R China; [Wang, Xiaohong; Zhang, Lianhai; Ji, Jiafu] Peking Univ, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst, Beijing, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University	Yu, J; Liang, JQ (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J; Liang, JQ (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Dept Med & Therapeut State, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Hong Kong, Peoples R China.; Ji, JF (corresponding author), Peking Univ, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst, Beijing, Peoples R China.	jijiafu@hsc.pku.edu.cn; junyu@cuhk.edu.hk; JessieQY@cuhk.edu.hk	Liang, Qiaoyi Jessie/G-9612-2019; Chan, Francis K. L./F-4851-2010; Jun, Yu/D-8569-2015	Liang, Qiaoyi Jessie/0000-0001-8496-3442; Chan, Francis K. L./0000-0001-7388-2436; JI, JIAFU/0000-0001-6878-5543; Jun, Yu/0000-0001-5008-2153	RGC-GRF Hong Kong [C7065-18GF]; National Nature and Science Foundation of China [81773000]	RGC-GRF Hong Kong(Hong Kong Research Grants Council); National Nature and Science Foundation of China(National Natural Science Foundation of China (NSFC))	The project was supported by the RGC-GRF Hong Kong (14116418), National Nature and Science Foundation of China (81773000), RGC-GRF Hong Kong (C7065-18GF), and Vice-Chancellor's Discretionary Fund CUHK.	Alonso-Curbelo D, 2015, ONCOTARGET, V6, P11848, DOI 10.18632/oncotarget.4055; Alonso-Curbelo D, 2014, CANCER CELL, V26, P61, DOI 10.1016/j.ccr.2014.04.030; Bloemberg D, 2019, AM J PHYSIOL-CELL PH, V317, pC111, DOI 10.1152/ajpcell.00261.2018; Bui TT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1232-y; Camargo MC, 2014, GUT, V63, P236, DOI 10.1136/gutjnl-2013-304531; Carroll B, 2013, DEV CELL, V25, P15, DOI 10.1016/j.devcel.2013.03.005; Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Guerra F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5030034; Heisterkamp N, 2008, HUM GENET, V123, P321, DOI 10.1007/s00439-008-0487-7; Ho CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11111775; Jimenez-Orgaz A, 2018, EMBO J, V37, P235, DOI 10.15252/embj.201797128; Kongara S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00171; Li X, 2016, ONCOGENE, V35, P2453, DOI 10.1038/onc.2015.300; Liang QY, 2014, GASTROENTEROLOGY, V147, P1350, DOI 10.1053/j.gastro.2014.08.036; Lim JS, 2004, FREE RADICAL BIO MED, V37, P1018, DOI 10.1016/j.freeradbiomed.2004.06.032; Magnelli L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082893; Otani K, 2013, EXPERT REV MOL DIAGN, V13, P445, DOI [10.1586/ERM.13.32, 10.1586/erm.13.32]; Qian HR, 2016, ONCOTARGET, V7, P17641, DOI 10.18632/oncotarget.7508; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Wang KN, 2016, GUT, V65, P1619, DOI 10.1136/gutjnl-2015-309276; Yamano K, 2014, ELIFE, V3, DOI 10.7554/eLife.01612; Yang XZ, 2016, ONCOGENE, V35, P5699, DOI 10.1038/onc.2016.81; Yu J, 2017, ONCOGENE, V36, P182, DOI 10.1038/onc.2016.187; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zhang M, 2009, BIOSCIENCE REP, V29, P193, DOI 10.1042/BSR20090032; Zhao T, 2017, J BIOL CHEM, V292, P19198, DOI 10.1074/jbc.M116.773093	28	0	0	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3485	3497		10.1038/s41388-022-02339-1	http://dx.doi.org/10.1038/s41388-022-02339-1		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35662282				2022-12-28	WOS:000805724700001
J	Chen, J; Li, ZQ; Jia, X; Song, WF; Wu, H; Zhu, H; Xuan, ZF; Du, YH; Zhu, XX; Song, GY; Dong, HJ; Bian, SC; Wang, S; Zhao, YC; Xie, HY; Zheng, SS; Song, PH				Chen, Jian; Li, Zequn; Jia, Xing; Song, Wenfeng; Wu, Hao; Zhu, Hai; Xuan, Zefeng; Du, Yehui; Zhu, Xingxin; Song, Guangyuan; Dong, Haijiang; Bian, Suchen; Wang, Shuo; Zhao, Yongchao; Xie, Haiyang; Zheng, Shusen; Song, Penghong			Targeting anillin inhibits tumorigenesis and tumor growth in hepatocellular carcinoma via impairing cytokinesis fidelity	ONCOGENE			English	Article							ANLN; CANCER; PLAYS; RHOA	Targeting cytokinesis can suppress tumor growth by blocking cell division and promoting apoptosis. We aimed to characterize key cytokinesis regulator in hepatocellular carcinoma (HCC) progression, providing insights into identifying promising HCC therapeutic targets. The unbiased bioinformatic screening identified Anillin actin binding protein (ANLN) as a critical cytokinesis regulator involved in HCC development. Functional assay demonstrated that knockdown of ANLN inhibited HCC growth by inducing cytokinesis failure and DNA damage, leading to multinucleation and mitotic catastrophe. Mechanistically, ANLN acts as a scaffold to strengthen interaction between RACGAP1 and PLK1. ANLN promotes PLK1-mediated RACGAP1 phosphorylation and RhoA activation to ensure cytokinesis fidelity. To explore the function of ANLN in HCC tumorigenesis, we hydrodynamically transfected c-Myc and NRAS plasmids into Anln(+/+), Anln(+/-), and Anln(-/-) mice through tail vein injection. Hepatic Anln ablation significantly impaired c-Myc/NRAS-driven hepatocarcinogenesis. Moreover, enhanced hepatic polyploidization was observed in Anln ablation mice, manifesting as increasing proportion of cellular and nuclear polyploidy. Clinically, ANLN is upregulated in human HCC tissues and high level of ANLN is correlated with poor patients' prognosis. Additionally, the proportion of cellular polyploidy decreases during HCC progression and ANLN level is significantly correlated with cellular polyploidy proportion in human HCC samples. In conclusion, ANLN is identified as a key cytokinesis regulator contributing to HCC initiation and progression. Our findings revealed a novel mechanism of ANLN in the regulation of cytokinesis to promote HCC tumorigenesis and growth, suggesting targeting ANLN to inhibit cytokinesis may be a promising therapeutic strategy for HCC.	[Chen, Jian; Li, Zequn; Jia, Xing; Song, Wenfeng; Wu, Hao; Zhu, Hai; Zhu, Xingxin; Song, Guangyuan; Dong, Haijiang; Bian, Suchen; Wang, Shuo; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Zhejiang Univ, Affiliated Hosp 1, Dept Surg, Div Hepatobiliary & Pancreat Surg,Sch Med, Hangzhou, Peoples R China; [Chen, Jian; Li, Zequn; Jia, Xing; Song, Wenfeng; Wu, Hao; Zhu, Hai; Zhu, Xingxin; Song, Guangyuan; Dong, Haijiang; Bian, Suchen; Zhao, Yongchao; Xie, Haiyang; Zheng, Shusen; Song, Penghong] NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Peoples R China; [Chen, Jian; Li, Zequn; Jia, Xing; Song, Wenfeng; Wu, Hao; Zhu, Hai; Zhu, Xingxin; Song, Guangyuan; Dong, Haijiang; Bian, Suchen; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Chinese Acad Med Sci 2019RU019, Res Unit Collaborat Diag & Treatment Hepatobiliar, Key Lab Diag & Treatment Organ Transplantat, Hangzhou, Peoples R China; [Chen, Jian; Li, Zequn; Jia, Xing; Song, Wenfeng; Wu, Hao; Zhu, Hai; Zhu, Xingxin; Song, Guangyuan; Dong, Haijiang; Bian, Suchen; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Res Ctr Diag & Treatment Hepatobiliary Dis, Key Lab Organ Transplantat, Hangzhou, Zhejiang, Peoples R China; [Xuan, Zefeng] Zhejiang Univ, Affiliated Hosp 1, Div Breast Surg, Sch Med, Hangzhou, Peoples R China; [Du, Yehui] Zhejiang Univ, Affiliated Hosp 1, Div Thyroid Surg, Sch Med, Hangzhou, Peoples R China; [Zhao, Yongchao] Zhejiang Univ, Inst Translat Med, Sch Med, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University	Zheng, SS; Song, PH (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Dept Surg, Div Hepatobiliary & Pancreat Surg,Sch Med, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), Chinese Acad Med Sci 2019RU019, Res Unit Collaborat Diag & Treatment Hepatobiliar, Key Lab Diag & Treatment Organ Transplantat, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), Res Ctr Diag & Treatment Hepatobiliary Dis, Key Lab Organ Transplantat, Hangzhou, Zhejiang, Peoples R China.	shusenzheng@zju.edu.cn; songpenghong@zju.edu.cn			Key Research and Development Plan of Zhejiang Province [2019C03050]; National Natural Science Foundation of China [81870434, 82070652]; Innovative Research Groups of National Natural Science Foundation of China [81721091]	Key Research and Development Plan of Zhejiang Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovative Research Groups of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the grants from the Key Research and Development Plan of Zhejiang Province (No. 2020C04003), the National Natural Science Foundation of China (No. 81870434 and No. 82070652), the Innovative Research Groups of National Natural Science Foundation of China (No. 81721091) and the Key Research and Development Plan of Zhejiang Province (No. 2019C03050).	Basant A, 2018, CURR BIOL, V28, pR570, DOI 10.1016/j.cub.2018.03.045; Budnar S, 2019, DEV CELL, V49, P894, DOI 10.1016/j.devcel.2019.04.031; Burkard ME, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000111; Chaikovsky AC, 2021, NATURE, V592, P794, DOI 10.1038/s41586-021-03474-7; Chen J, 2021, BIOCHEM PHARMACOL, V188, DOI 10.1016/j.bcp.2021.114494; Chen J, 2021, ONCOGENE, V40, P163, DOI 10.1038/s41388-020-01522-6; Donne R, 2020, NAT REV GASTRO HEPAT, V17, P391, DOI 10.1038/s41575-020-0284-x; Duncan AW, 2010, NATURE, V467, P707, DOI 10.1038/nature09414; Gentric G, 2014, AM J PATHOL, V184, P322, DOI 10.1016/j.ajpath.2013.06.035; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Lens SMA, 2019, NAT REV CANCER, V19, P32, DOI 10.1038/s41568-018-0084-6; Li Z, 2019, HEPATOB PANCREAT DIS, V18, P303, DOI 10.1016/j.hbpd.2019.05.013; Lian YF, 2018, AGING-US, V10, P1884, DOI 10.18632/aging.101510; Lin Heng, 2021, Nat Commun, V12, P645, DOI 10.1038/s41467-020-20572-8; Lulli M, 2021, CANCER RES, V81, P2861, DOI 10.1158/0008-5472.CAN-20-3134; Ma H, 2022, HEPATOLOGY, DOI 10.1002/hep.32335; Maiani E, 2021, NATURE, V592, P799, DOI 10.1038/s41586-021-03422-5; Matsumoto T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-20916-y; Pallavicini G, 2018, CANCER RES, V78, P4599, DOI 10.1158/0008-5472.CAN-17-4060; Piekny AJ, 2010, SEMIN CELL DEV BIOL, V21, P881, DOI 10.1016/j.semcdb.2010.08.002; Qiao YT, 2021, EXP BIOL MED, V246, P1343, DOI 10.1177/15353702211008380; Rebouissou S, 2020, J HEPATOL, V72, P215, DOI 10.1016/j.jhep.2019.08.017; Sarveazad A, 2019, J RES MED SCI, V24, DOI 10.4103/jrms.JRMS_1017_18; Simoneschi D, 2021, NATURE, V592, P789, DOI 10.1038/s41586-021-03445-y; Su KC, 2011, DEV CELL, V21, P1104, DOI 10.1016/j.devcel.2011.11.003; Suzuki C, 2005, CANCER RES, V65, P11314, DOI 10.1158/0008-5472.CAN-05-1507; Tuan NM, 2020, CANCERS, V12, DOI 10.3390/cancers12061600; Wang AB, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1340-7; Wilkinson PD, 2019, HEPATOLOGY, V69, P1242, DOI 10.1002/hep.30286; Wolfe BA, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000110; Xu M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1020-4; Yang XM, 2018, GASTROENTEROLOGY, V155, P1233, DOI 10.1053/j.gastro.2018.07.010; Zhang L, 2010, CURR BIOL, V20, pR135, DOI 10.1016/j.cub.2009.12.017; Zhang SY, 2018, GASTROENTEROLOGY, V154, P1421, DOI 10.1053/j.gastro.2017.12.013; Zhang SY, 2018, DEV CELL, V44, P447, DOI 10.1016/j.devcel.2018.01.010; Zhao WM, 2005, P NATL ACAD SCI USA, V102, P13158, DOI 10.1073/pnas.0504145102; Zhou WB, 2015, MOL CELL BIOCHEM, V398, P11, DOI 10.1007/s11010-014-2200-6	38	1	1	4	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3118	3130		10.1038/s41388-022-02274-1	http://dx.doi.org/10.1038/s41388-022-02274-1		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35477750				2022-12-28	WOS:000794881300001
J	Lim, JS; Lee, KW; Ko, KP; Jeong, SI; Ryu, BK; Lee, MG; Chi, SG				Lim, Ji-Sun; Lee, Kyung-Woo; Ko, Kyung-Phil; Jeong, Seong-In; Ryu, Byung-Kyu; Lee, Min-Goo; Chi, Sung-Gil			XAF1 destabilizes estrogen receptor alpha through the assembly of a BRCA1-mediated destruction complex and promotes estrogen-induced apoptosis	ONCOGENE			English	Article							XIAP-ASSOCIATED FACTOR-1; ESTRADIOL-INDUCED APOPTOSIS; BREAST-CANCER; LIGASE ACTIVITY; EXPRESSION; BRCA1; IDENTIFICATION; GENE; GROWTH; SWITCH	X-linked inhibitor of apoptosis-associated factor 1 (XAF1) is a pro-apoptotic tumor suppressor that is frequently inactivated in multiple human cancers. However, its candidacy as a suppressor in the pathogenesis of breast cancer remains undefined. Here, we report that XAF1 acts as a molecular switch in estrogen (E2)-mediated cell-fate decisions favoring apoptosis over cell proliferation. XAF1 promoter hypermethylation is observed predominantly in estrogen receptor alpha (ER alpha)-positive versus ER alpha-negative tumor cells and associated with attenuated apoptotic response to E2. XAF1 is activated by E2 through a G protein-coupled estrogen receptor-mediated non-genomic pathway and induces ER alpha degradation and apoptosis while it is repressed by ER alpha for E2 stimulation of cell proliferation. The XAF1-ER alpha mutual antagonism dictates the outcomes of E2 signaling and its alteration is linked to the development of E2-resistant tumors. Mechanistically, XAF1 destabilizes ER alpha through the assembly of breast cancer-associated gene 1 (BRCA1)-mediated destruction complex. XAF1 interacts with ER alpha and BRCA1 via the zinc finger (ZF) domains 5/6 and 4, respectively, and the mutants lacking either of these domains fail to drive ER alpha ubiquitination and apoptosis. E2-induced regression of XAF1(+/+) tumors is abolished by XAF1 depletion while XAF1(-/-) tumors recover E2 response by XAF1 restoration. XAF1 and ER alpha expression show an inverse correlation in primary breast tumors, and XAF1 expression is associated with the overall survival of patients with ER alpha-positive but not ER alpha-negative cancer. Together, this study uncovers an important role for the XAF1-ER alpha antagonism as a linchpin to govern E2-mediated cell-fate decisions, illuminating the mechanistic consequence of XAF1 alteration in breast tumorigenesis.	[Lim, Ji-Sun; Lee, Kyung-Woo; Ko, Kyung-Phil; Jeong, Seong-In; Ryu, Byung-Kyu; Lee, Min-Goo; Chi, Sung-Gil] Korea Univ, Coll Life Sci & Technol, Dept Life Sci, Seoul 02841, South Korea; [Ryu, Byung-Kyu] Korea Univ, Sch Med, Dept Neurosurg, Seoul 02841, South Korea	Korea University; Korea University; Korea University Medicine (KU Medicine)	Chi, SG (corresponding author), Korea Univ, Coll Life Sci & Technol, Dept Life Sci, Seoul 02841, South Korea.	chi6302@korea.ac.kr			National Cancer Center [HA17C0034]; National Research Foundation of Korea [NRF-2021R1A2B03002487]; Korea University Grant, Republic of Korea [K2006781]	National Cancer Center; National Research Foundation of Korea(National Research Foundation of Korea); Korea University Grant, Republic of Korea	This work was supported in part by the National Cancer Center (HA17C0034, SGC), the National Research Foundation of Korea (NRF-2021R1A2B03002487, SGC), and Korea University Grant (K2006781, SGC), Republic of Korea.	Acconcia F, 2017, MOL CELL ENDOCRINOL, V457, P3, DOI 10.1016/j.mce.2016.10.033; Altiok N, 2007, BREAST CANCER RES TR, V105, P247, DOI 10.1007/s10549-006-9451-1; Altiok N, 2011, ONCOL LETT, V2, P1281, DOI 10.3892/ol.2011.385; Bennink HJTC, 2017, MATURITAS, V95, P11, DOI 10.1016/j.maturitas.2016.10.010; Burns KA, 2012, ARCH TOXICOL, V86, P1491, DOI 10.1007/s00204-012-0868-5; Byun DS, 2003, CANCER RES, V63, P7068; Carmeci C, 1997, GENOMICS, V45, P607, DOI 10.1006/geno.1997.4972; Carroll JS, 2016, EUR J ENDOCRINOL, V175, pR41, DOI 10.1530/EJE-16-0124; Chi D, 2019, P NATL ACAD SCI USA, V116, P11437, DOI 10.1073/pnas.1819155116; Chung SK, 2007, GASTROENTEROLOGY, V132, P2459, DOI 10.1053/j.gastro.2007.04.024; Deng Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57819-9; Dizin E, 2010, INT J BIOCHEM CELL B, V42, P693, DOI 10.1016/j.biocel.2009.12.025; Eakin CM, 2007, P NATL ACAD SCI USA, V104, P5794, DOI 10.1073/pnas.0610887104; Ellis MJ, 2009, JAMA-J AM MED ASSOC, V302, P774, DOI 10.1001/jama.2009.1204; Fan SJ, 2002, CANCER RES, V62, P141; Fang XL, 2006, INT J CANCER, V118, P2485, DOI 10.1002/ijc.21636; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Han J, 2013, CELL DEATH DIFFER, V20, P1055, DOI 10.1038/cdd.2013.33; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Jeong SI, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0867-4; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kota K, 2017, CUREUS, V9, DOI 10.7759/cureus.1434; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Leclercq G, 2006, CURR CANCER DRUG TAR, V6, P39, DOI 10.2174/156800906775471716; Lee MG, 2006, ONCOGENE, V25, P5807, DOI 10.1038/sj.onc.1209867; Lee MG, 2014, P NATL ACAD SCI USA, V111, P15532, DOI 10.1073/pnas.1411746111; Lewis JS, 2005, JNCI-J NATL CANCER I, V97, P1746, DOI 10.1093/jnci/dji400; Lewis-Wambi JS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2255; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Micali OC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-52; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Osborne CK, 2001, CLIN CANCER RES, V7, p4338S; Pedram A, 2002, J BIOL CHEM, V277, P50768, DOI 10.1074/jbc.M210106200; Rahman Syed Azizur, 2019, Asian Pac J Cancer Prev, V20, P1901, DOI 10.31557/APJCP.2019.20.6.1901; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Seval Y, 2006, J CLIN ENDOCR METAB, V91, P2349, DOI 10.1210/jc.2005-2132; Shin CH, 2017, P NATL ACAD SCI USA, V114, P5683, DOI 10.1073/pnas.1700861114; Sun M, 2012, MOL ENDOCRINOL, V26, P736, DOI 10.1210/me.2011-1158; Sun PH, 2011, CANCER LETT, V310, P170, DOI 10.1016/j.canlet.2011.06.037; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Tu SP, 2010, CANCER-AM CANCER SOC, V116, P1252, DOI 10.1002/cncr.24814; Wang J, 2009, CARCINOGENESIS, V30, P1507, DOI 10.1093/carcin/bgp155; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xia Y, 2006, MOL CELL BIOCHEM, V286, P67, DOI 10.1007/s11010-005-9094-2; Zhou W, 2014, NAT REV CANCER, V14, P26, DOI 10.1038/nrc3622; Zhu LM, 2014, ONCOTARGET, V5, P5403, DOI 10.18632/oncotarget.2114	51	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2897	2908		10.1038/s41388-022-02315-9	http://dx.doi.org/10.1038/s41388-022-02315-9		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35430604				2022-12-28	WOS:000782888200002
J	Lu, CW; Yang, DF; Klement, JD; Colson, YL; Oberlies, NH; Pearce, CJ; Colby, AH; Grinstaff, MW; Liu, ZQ; Shi, HD; Ding, HF; Liu, KB				Lu, Chunwan; Yang, Dafeng; Klement, John D.; Colson, Yolonda L.; Oberlies, Nicholas H.; Pearce, Cedric J.; Colby, Aaron H.; Grinstaff, Mark W.; Liu, Zhuoqi; Shi, Huidong; Ding, Han-Fei; Liu, Kebin			H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth	ONCOGENE			English	Article							OXIDATIVE STRESS; LACTATE-DEHYDROGENASE; CELL-CYCLE; CANCER; METABOLISM; APOPTOSIS; INHIBITION; ACTIVATION; G9A; METHYLATION	The role of glucose-6-phosphate dehydrogenase (G6PD) in human cancer is incompletely understood. In a metabolite screening, we observed that inhibition of H3K9 methylation suppressed aerobic glycolysis and enhances the PPP in human mesothelioma cells. Genome-wide screening identified G6PD as an H3K9me3 target gene whose expression is correlated with increased tumor cell apoptosis. Inhibition of aerobic glycolysis enzyme LDHA and G6PD had no significant effects on tumor cell survival. Ablation of G6PD had no significant effect on human mesothelioma and colon carcinoma xenograft growth in athymic mice. However, activation of G6PD with the G6PD-selective activator AG1 induced tumor cell death. AG1 increased tumor cell ROS production and the resultant extrinsic and intrinsic death pathways, mitochondrial processes, and unfolded protein response in tumor cells. Consistent with increased tumor cell death in vitro, AG1 suppressed human mesothelioma xenograft growth in a dose-dependent manner in vivo. Furthermore, AG1 treatment significantly increased tumor-bearing mouse survival in an intra-peritoneum xenograft athymic mouse model. Therefore, in human mesothelioma and colon carcinoma, G6PD is not essential for tumor growth. G6PD acts as a metabolic checkpoint to control metabolic flux towards the PPP to promote tumor cell apoptosis, and its expression is repressed by its promotor H3K9me3 deposition.	[Lu, Chunwan] Tianjin Univ, Sch Life Sci, Tianjin 300072, Peoples R China; [Lu, Chunwan; Yang, Dafeng; Klement, John D.; Liu, Kebin] Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Yang, Dafeng; Klement, John D.; Liu, Zhuoqi; Shi, Huidong; Ding, Han-Fei; Liu, Kebin] Med Coll Georgia, Georgia Canc Ctr, Augusta, GA 30912 USA; [Yang, Dafeng; Klement, John D.; Liu, Kebin] Charlie Norwood VA Med Ctr, Augusta, GA 30904 USA; [Colson, Yolonda L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Div Thorac Surg, Boston, MA 02114 USA; [Oberlies, Nicholas H.] Univ North Carolina Greensboro, Dept Chem & Biochem, Greensboro, NC 27402 USA; [Pearce, Cedric J.] Mycosynthetix Inc, Hillsborough, NC 27278 USA; [Colby, Aaron H.; Grinstaff, Mark W.] Ion Pharmaceut, Brookline, MA 02445 USA; [Colby, Aaron H.; Grinstaff, Mark W.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Tianjin University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Harvard Medical School; Massachusetts General Hospital; University of North Carolina; University of North Carolina Greensboro; Boston University	Lu, CW (corresponding author), Tianjin Univ, Sch Life Sci, Tianjin 300072, Peoples R China.; Lu, CW (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	Chunwanlu@tju.edu.cn	Oberlies, Nicholas/D-8162-2011; Grinstaff, Mark/U-2829-2017	Oberlies, Nicholas/0000-0002-0354-8464; Grinstaff, Mark/0000-0002-5453-3668; Ding, Han-Fei/0000-0001-5702-3439; Shi, Huidong/0000-0003-1137-3390	National Cancer Institute [R01 CA227433, R01CA133085, P01 CA125066, R01CA190429, R01CA236890, F30CA236436]; US Department of Veterans Affairs Award [CX001364]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US Department of Veterans Affairs Award(US Department of Veterans Affairs)	We thank Dr. Roni Bollag at the Georgia Cancer Center Biorepository for providing the human mesothelioma specimen and for pathological analysis. We also thank Dr. Natasha Savage for tumor specimen analysis and Dr. Kimya Jones for immunohistochemical analysis of tumor specimen. This work was supported by the National Cancer Institute grants R01 CA227433 (to MWG, YLC, NHO, KL), R01CA133085 (to KL), P01 CA125066 (to NHO), R01CA190429, and R01CA236890 (to H-FD), F30CA236436 (to JDK), and the US Department of Veterans Affairs Award CX001364 (to KL).	Abbosh PH, 2006, CANCER RES, V66, P5582, DOI 10.1158/0008-5472.CAN-05-3575; Aggarwal BB, 2012, BLOOD, V119, P651, DOI 10.1182/blood-2011-04-325225; Amrine CSM, 2018, J IND MICROBIOL BIOT, V45, P1053, DOI 10.1007/s10295-018-2083-8; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Chen L, 2019, NAT METAB, V1, P404, DOI 10.1038/s42255-019-0043-x; Cui WY, 2021, CANCER TREAT REV, V100, DOI 10.1016/j.ctrv.2021.102265; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Dick TP, 2015, MOL CELL, V59, P519, DOI 10.1016/j.molcel.2015.08.002; Ding H., 2021, SCI ADV, V7, P1; Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004; Fiehn O, 2008, PLANT J, V53, P691, DOI 10.1111/j.1365-313X.2007.03387.x; Figueroa M, 2012, J ANTIBIOT, V65, P559, DOI 10.1038/ja.2012.69; Fritsch L, 2010, MOL CELL, V37, P46, DOI 10.1016/j.molcel.2009.12.017; Ge TX, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00365; Ghergurovich JM, 2020, CANCER RES, V80, P3820, DOI 10.1158/0008-5472.CAN-19-2486; Ghergurovich JM, 2020, NAT CHEM BIOL, V16, P731, DOI 10.1038/s41589-020-0533-x; Gu Y., 2014, CELL DEATH DIS, V5; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hotta K, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000461; Hwang S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06447-z; Iurlaro R, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00479-16; Jian SL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.192; Koo SJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00202; Kowalik MA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00087; Kuehne A, 2015, MOL CELL, V59, P359, DOI 10.1016/j.molcel.2015.06.017; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Lemoine J, 2021, CLIN CANCER RES, V27, P6298, DOI 10.1158/1078-0432.CCR-21-1559; Li W, 2021, NAT METAB, V3, P75, DOI 10.1038/s42255-020-00330-2; Liu B, 2019, ACS CHEM NEUROSCI, V10, P2332, DOI 10.1021/acschemneuro.8b00644; Lu CW, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-003543; Lu CW, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002624; Lu CW, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001365; Lu CW, 2020, CANCER LETT, V476, P87, DOI 10.1016/j.canlet.2020.02.004; Lu CW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw283; Matei D, 2020, CANCER RES, V80, P3775, DOI 10.1158/0008-5472.CAN-19-3837; McCambridge AJ, 2018, J THORAC ONCOL, V13, P606, DOI 10.1016/j.jtho.2018.02.021; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Menon DR, 2020, THERANOSTICS, V10, P6261, DOI 10.7150/thno.42523; Monteiro-Reis S, 2020, CANCERS, V12, DOI 10.3390/cancers12051066; Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005; Muller MM, 2016, NAT CHEM BIOL, V12, P188, DOI [10.1038/NCHEMBIO.2008, 10.1038/nchembio.2008]; Nagashio R, 2019, BBA-PROTEINS PROTEOM, V1867, P38, DOI 10.1016/j.bbapap.2018.05.005; Nakajima EC, 2022, CLIN CANCER RES, V28, P446, DOI 10.1158/1078-0432.CCR-21-1466; Nakamura M, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001679; Nicetto D, 2019, SCIENCE, V363, P294, DOI 10.1126/science.aau0583; Olcina MM, 2016, ONCOGENE, V35, P793, DOI 10.1038/onc.2015.134; Oshima N, 2020, CELL REP, V30, P1798, DOI 10.1016/j.celrep.2020.01.039; Paschall AV, 2015, GENOM DATA, V5, P189, DOI 10.1016/j.gdata.2015.05.043; Paschall AV, 2015, J IMMUNOL, V195, P1868, DOI 10.4049/jimmunol.1402243; Pathria G, 2018, EMBO J, V37, DOI 10.15252/embj.201899735; Pinton G, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.678447; Raub AG, 2019, CHEMMEDCHEM, V14, P1321, DOI 10.1002/cmdc.201900341; Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Salvi A, 2020, MOL CANCER THER, V19, P89, DOI 10.1158/1535-7163.MCT-19-0205; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Stomper J., 2021, CLIN EPIGENETICS, P13; Tu DZ, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1659-1; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Williams D, 2019, CLIN EXP METASTAS, V36, P211, DOI 10.1007/s10585-019-09967-0; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Wu SR, 2018, CANCER RES, V78, P4549, DOI 10.1158/0008-5472.CAN-17-4047; Yeung C, 2019, CANCER RES, V79, P5060, DOI 10.1158/0008-5472.CAN-19-0217; Zhang XM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.85	66	1	1	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2651	2662		10.1038/s41388-022-02283-0	http://dx.doi.org/10.1038/s41388-022-02283-0		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35351997	Green Accepted			2022-12-28	WOS:000774697300001
J	Ji, XY; Chen, XP; Zhang, BX; Xie, M; Zhang, TY; Luo, XY; Liu, DF; Feng, YY; Wang, YJ; Sun, MY; Li, CX; Huang, WJ; Xia, LM				Ji, Xiaoyu; Chen, Xiaoping; Zhang, Bixiang; Xie, Meng; Zhang, Tongyue; Luo, Xiangyuan; Liu, Danfei; Feng, Yangyang; Wang, Yijun; Sun, Mengyu; Li, Congxin; Huang, Wenjie; Xia, Limin			T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1	ONCOGENE			English	Article							PREDICTS POOR-PROGNOSIS; THERAPEUTIC TARGET; CELL-MIGRATION; CANCER; GENE; EXPRESSION; TBX3; DOWNSTREAM; INHIBITION; RESISTANCE	The effect of targeted therapy for metastatic hepatocellular carcinoma (HCC) is still unsatisfactory. Exploring the underlying mechanism of HCC metastasis is favorable to provide new therapeutic strategies. T-box (TBX) transcription factor family genes, which are crucial regulators in embryo and organ development, are vital for regulating tumor initiation, growth and metastasis. Here we explored the role of TBX19 in HCC metastasis, which is one of the most upregulated TBX family genes in human HCC tissues. TBX19 expression was markedly upregulated in HCC tissues and elevated TBX19 expression predicted poor prognosis. Overexpression of TBX19 enhanced HCC metastasis through upregulating epidermal growth factor receptor (EGFR) and Rac family small GTPase 1 (RAC1) expression. Downregulation of EGFR and RAC1 inhibited TBX19-mediated HCC metastasis, while upregulation of EGFR and RAC1 restored inhibition of HCC metastasis mediated by TBX19 knockdown. Furthermore, epidermal growth factor (EGF)/EGFR signaling upregulated TBX19 expression via the extracellular signal-regulated kinase (ERK)/nuclear factor (NF)-kB axis. Besides, the combined application of EGFR inhibitor Erlotinib and RAC1 inhibitor NSC23766 markedly inhibited TBX19-mediated HCC metastasis. In HCC cohorts, TBX19 expression was positively associated with EGFR and RAC1 expression. Patients with positive coexpression of TBX19/EGFR or TBX19/RAC1 displayed the poorest prognosis. In conclusion, EGF/EGFR signaling upregulated TBX19 expression via ERK/NF-kB pathway and TBX19 fostered HCC metastasis by enhancing EGFR and RAC1 expression, which formed an EGF-TBX19-EGFR positive feedback loop. Targeting this signaling pathway may offer a potential therapeutic strategy to efficiently restrain TBX19-mediated HCC metastasis.	[Ji, Xiaoyu; Xie, Meng; Zhang, Tongyue; Luo, Xiangyuan; Liu, Danfei; Feng, Yangyang; Wang, Yijun; Sun, Mengyu; Li, Congxin; Xia, Limin] Huazhong Univ Sci & Technol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Dept Gastroenterol,Hubei Key Lab HepatoPancreato, Wuhan 430030, Hubei, Peoples R China; [Chen, Xiaoping; Zhang, Bixiang; Huang, Wenjie] Huazhong Univ Sci & Technol, Hepat Surg Ctr,Hubei Key Lab HepatoPancreatobilia, Tongji Med Coll,Clin Med Res Ctr Hepat Surg Hubei, Tongji Hosp,Key Lab Organ Transplantat,Minist Edu, Wuhan 430030, Hubei, Peoples R China; [Chen, Xiaoping; Zhang, Bixiang; Huang, Wenjie] Huazhong Univ Sci & Technol, Hepat Surg Ctr,Hubei Key Lab HepatoPancreatobilia, Tongji Med Coll,Clin Med Res Ctr Hepat Surg Hubei, Tongji Hosp,Key Lab Organ Transplantat,Minist Pub, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Dept Gastroenterol,Hubei Key Lab HepatoPancreato, Wuhan 430030, Hubei, Peoples R China.; Huang, WJ (corresponding author), Huazhong Univ Sci & Technol, Hepat Surg Ctr,Hubei Key Lab HepatoPancreatobilia, Tongji Med Coll,Clin Med Res Ctr Hepat Surg Hubei, Tongji Hosp,Key Lab Organ Transplantat,Minist Edu, Wuhan 430030, Hubei, Peoples R China.; Huang, WJ (corresponding author), Huazhong Univ Sci & Technol, Hepat Surg Ctr,Hubei Key Lab HepatoPancreatobilia, Tongji Med Coll,Clin Med Res Ctr Hepat Surg Hubei, Tongji Hosp,Key Lab Organ Transplantat,Minist Pub, Wuhan 430030, Hubei, Peoples R China.	huangwenjie@tjh.tjmu.edu.cn; xialimin@tjh.tjmu.edu.cn	Wang, Yijun/GXW-1763-2022	Huang, Wenjie/0000-0003-3182-8516; Danfei, Liu/0000-0002-2298-5520; Zhang, Bixiang/0000-0002-1609-7260	National Natural Science Foundation of China [81871911, 81972237, 81772623]; National Key Research and Development Program of China [2018YFC1312103]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China	Research was supported by grants from the National Natural Science Foundation of China No. 81871911 (WH), No. 81972237 (LX), No. 81772623 (LX), and National Key Research and Development Program of China 2018YFC1312103 (LX).	Abrahams A, 2010, IUBMB LIFE, V62, P92, DOI 10.1002/iub.275; Ando J, 2017, FUKUSHIMA J MED SCI, V63, P141, DOI 10.5387/fms.2017-08; Bayo J, 2021, GUT, V70, P1362, DOI 10.1136/gutjnl-2020-321454; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Buckley AF, 2008, AM J CLIN PATHOL, V129, P245, DOI 10.1309/WF10QAAED3PP93BH; Cannon AC, 2020, TRENDS CANCER, V6, P478, DOI 10.1016/j.trecan.2020.02.021; Cao XB, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-42; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang FY, 2016, ONCOL LETT, V12, P4305, DOI 10.3892/ol.2016.5296; Chen J, 2020, HEPATOLOGY, V71, P1712, DOI 10.1002/hep.30951; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Conlon FL, 2002, GENOME BIOL, V3; Cui J, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.616173; Dong L, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0025-6; Dong XB, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.590898; Feng XG, 2018, ONCOL RES, V26, P959, DOI 10.3727/096504017X15145624664031; Finn RS, 2021, HEPATOLOGY, V73, P150, DOI 10.1002/hep.31306; Furuse J, 2008, CRIT REV ONCOL HEMAT, V67, P8, DOI 10.1016/j.critrevonc.2008.02.009; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gastonguay AJ, 2012, CANCER BIOL THER, V13, P647, DOI 10.4161/cbt.20082; Gordan JD, 2020, J CLIN ONCOL, V38, P4317, DOI 10.1200/JCO.20.02672; Gudino V, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22531-3; He Q, 2021, HEPATOLOGY, V74, P3174, DOI 10.1002/hep.32062; He Q, 2020, ONCOGENE, V39, P7279, DOI 10.1038/s41388-020-01500-y; Hu WW, 2021, HEPATOLOGY, V73, P674, DOI 10.1002/hep.31293; Huang PX, 2014, J CELL MOL MED, V18, P218, DOI 10.1111/jcmm.12153; Kaneto N, 2014, CANCER SCI, V105, P788, DOI 10.1111/cas.12425; Kang L, 2020, AM J TRANSL RES, V12, P7870; Karachaliou N, 2019, EXPERT REV RESP MED, V13, P1019, DOI 10.1080/17476348.2019.1656068; Koinis F, 2020, CANCERS, V12, DOI 10.3390/cancers12010244; Komposch K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010030; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Li DX, 2020, THERANOSTICS, V10, P3749, DOI 10.7150/thno.42596; Liang BY, 2021, J HEPATOL, V75, P120, DOI 10.1016/j.jhep.2021.01.044; Liang JX, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.674426; Liu JX, 2001, P NATL ACAD SCI USA, V98, P8674, DOI 10.1073/pnas.141234898; Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240; Liu XY, 2019, EXP THER MED, V17, P723, DOI 10.3892/etm.2018.7028; Liu ZY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1412-8; Liu ZC, 2018, J CELL BIOCHEM, V119, P4170, DOI 10.1002/jcb.26625; London M, 2020, CELL BIOL INT, V44, P1267, DOI 10.1002/cbin.11340; Lowery FJ, 2012, CANCER METAST REV, V31, P479, DOI 10.1007/s10555-012-9380-x; Papaioannou VE, 2014, DEVELOPMENT, V141, P3819, DOI 10.1242/dev.104471; Renard CA, 2007, CANCER RES, V67, P901, DOI 10.1158/0008-5472.CAN-06-2344; Roselli M, 2012, CLIN CANCER RES, V18, P3868, DOI 10.1158/1078-0432.CCR-11-3211; Sigismund S, 2018, MOL ONCOL, V12, P3, DOI 10.1002/1878-0261.12155; Tang ML, 2021, CANCER RES, V81, P3835, DOI 10.1158/0008-5472.CAN-21-0436; Thomas MB, 2007, CANCER-AM CANCER SOC, V110, P1059, DOI 10.1002/cncr.22886; Wang N, 2019, THYROID, V29, P378, DOI 10.1089/thy.2018.0312; Wansleben S, 2014, BBA-REV CANCER, V1846, P380, DOI 10.1016/j.bbcan.2014.08.004; Xu MJ, 2017, CANCER METAST REV, V36, P463, DOI 10.1007/s10555-017-9687-8; Yoneda N, 2011, LAB INVEST, V91, P262, DOI 10.1038/labinvest.2010.161; Yu J, 2010, ONCOGENE, V29, P6464, DOI 10.1038/onc.2010.370; Zhang J, 2016, SAUDI MED J, V37, P1184, DOI 10.15537/smj.2016.11.16267; Zhangyuan GY, 2020, ONCOGENE, V39, P1213, DOI 10.1038/s41388-019-1052-7; Zhao ST, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0820-6; Zhou K, 2018, LAB INVEST, V98, P989, DOI 10.1038/s41374-018-0071-2; Zhou QQ, 2020, ONCOGENE, V39, P2140, DOI 10.1038/s41388-019-1131-9; Zhu G, 2015, ONCOGENE, V34, P5971, DOI 10.1038/onc.2015.45; Zhu YJ, 2017, ACTA PHARMACOL SIN, V38, P614, DOI 10.1038/aps.2017.5; Zong MJ, 2011, INT J MOL SCI, V12, P4953, DOI 10.3390/ijms12084953	61	3	3	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2225	2238		10.1038/s41388-022-02249-2	http://dx.doi.org/10.1038/s41388-022-02249-2		FEB 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35217793				2022-12-28	WOS:000761868000001
J	Gu, X; Zhuang, A; Yu, J; Chai, PW; Jia, RB; Ruan, J				Gu, Xiang; Zhuang, Ai; Yu, Jie; Chai, Peiwei; Jia, Renbing; Ruan, Jing			Phase separation drives tumor pathogenesis and evolution: all roads lead to Rome	ONCOGENE			English	Review							RNA-POLYMERASE-II; SUPER-ENHANCERS; CELL IDENTITY; CANCER; TRANSCRIPTION; PML; GRANULES; COMPLEX; BINDING; FUS	Cells coordinate numerous biochemical reactions in space and time, depending on the subdivision of the intracellular space into functional compartments. Compelling evidence has demonstrated that phase separation induces the formation of membrane-less compartments to partition intracellular substances in a strictly regulated manner and participates in various biological processes. Based on the strong association of cancer with the dysregulation of intracellular physiological processes and the occurrence of phase separation in cancer-associated condensates, phase separation undoubtedly plays a significant role in tumorigenesis. In this review, we summarize the drivers and functions of phase separation, elaborate on the roles of phase separation in tumor pathogenesis and evolution, and propose substantial research and therapeutic prospects for phase separation in cancer.	[Gu, Xiang; Zhuang, Ai; Yu, Jie; Chai, Peiwei; Jia, Renbing; Ruan, Jing] Shanghai Jiao Tong Univ, Ninth Peoples Hosp, Dept Ophthalmol, Sch Med, Shanghai 20025, Peoples R China; [Gu, Xiang; Zhuang, Ai; Yu, Jie; Chai, Peiwei; Jia, Renbing; Ruan, Jing] Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai 20025, Peoples R China	Shanghai Jiao Tong University	Chai, PW; Jia, RB; Ruan, J (corresponding author), Shanghai Jiao Tong Univ, Ninth Peoples Hosp, Dept Ophthalmol, Sch Med, Shanghai 20025, Peoples R China.; Chai, PW; Jia, RB; Ruan, J (corresponding author), Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai 20025, Peoples R China.	chaipeiwei123@sjtu.edu.cn; renbingjia@sjtu.edu.cn; drjruan@163.com	Ruan, Jing/GON-6485-2022	Ruan, Jing/0000-0001-8728-4568	National Key Research and Development Plan [2017YFE0196300]; National Natural Science Foundation of China [81772875, 81972530, 82073889, U1932135]; Science and Technology Commission of Shanghai Municipality [SHDC2020CR1009A, 20DZ2270800, 19JC1410200]; Fund for Excellent Young Scholars of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine [JYYQ001]	National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Fund for Excellent Young Scholars of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine	This work was supported by the National Key Research and Development Plan (2017YFE0196300), the National Natural Science Foundation of China (81772875, 81972530, 82073889 and U1932135), Science and Technology Commission of Shanghai Municipality (SHDC2020CR1009A, 20DZ2270800 and 19JC1410200), Fund for Excellent Young Scholars of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (JYYQ001).	Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306; Abu Ahmad Y, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092374; Adjei AA, 2005, J CLIN ONCOL, V23, P5386, DOI 10.1200/JCO.2005.23.648; Altmeyer M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9088; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bergeron-Sandoval LP, 2016, CELL, V165, P1067, DOI 10.1016/j.cell.2016.05.026; Bienz M, 2020, CELL, V182, P799, DOI 10.1016/j.cell.2020.07.037; Boeynaems S, 2018, TRENDS CELL BIOL, V28, P420, DOI 10.1016/j.tcb.2018.02.004; Boija A, 2021, CANCER CELL, V39, P174, DOI 10.1016/j.ccell.2020.12.003; Boija A, 2018, CELL, V175, P1842, DOI 10.1016/j.cell.2018.10.042; Bouchard JJ, 2018, MOL CELL, V72, P19, DOI 10.1016/j.molcel.2018.08.027; Boulay G, 2017, CELL, V171, P163, DOI 10.1016/j.cell.2017.07.036; Boysen G, 2015, ELIFE, V4, DOI 10.7554/eLife.09207; Brangwynne CP, 2009, SCIENCE, V324, P1729, DOI 10.1126/science.1172046; Bulger M, 2011, CELL, V144, P327, DOI 10.1016/j.cell.2011.01.024; Burke KA, 2015, MOL CELL, V60, P231, DOI 10.1016/j.molcel.2015.09.006; Cai DF, 2019, NAT CELL BIOL, V21, P1578, DOI 10.1038/s41556-019-0433-z; Carabet LA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010120; Case LB, 2019, SCIENCE, V363, P1093, DOI 10.1126/science.aau6313; Caslini C, 2019, ONCOGENE, V38, P6599, DOI 10.1038/s41388-019-0897-0; Chang HR, 2018, MUTAT RES-FUND MOL M, V809, P99, DOI 10.1016/j.mrfmmm.2017.05.002; Chen D, 2020, DEV CELL, V55, P588, DOI 10.1016/j.devcel.2020.10.010; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; de The H, 2017, CANCER CELL, V32, P552, DOI 10.1016/j.ccell.2017.10.002; De Vitis M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020606; di Masi A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.115; Du MJ, 2018, SCIENCE, V361, P704, DOI 10.1126/science.aat1022; Feric M, 2013, NAT CELL BIOL, V15, P1253, DOI 10.1038/ncb2830; Frottin F, 2019, SCIENCE, V365, P342, DOI 10.1126/science.aaw9157; Fu Y, 2020, NAT CHEM BIOL, V16, P955, DOI 10.1038/s41589-020-0524-y; Fujioka Y, 2020, NATURE, V578, P301, DOI 10.1038/s41586-020-1977-6; Gan WJ, 2015, MOL CELL, V59, P917, DOI 10.1016/j.molcel.2015.07.026; Gao P, 2013, CELL, V153, P1094, DOI 10.1016/j.cell.2013.04.046; Gao YF, 2019, CELL RES, V29, P767, DOI 10.1038/s41422-019-0210-3; Gibson BA, 2019, CELL, V179, P470, DOI 10.1016/j.cell.2019.08.037; Guo YE, 2019, NATURE, V572, P543, DOI 10.1038/s41586-019-1464-0; Gupta R, 2020, ONCOGENE, V39, P7093, DOI 10.1038/s41388-020-01490-x; Harlen KM, 2017, NAT REV MOL CELL BIO, V18, P263, DOI 10.1038/nrm.2017.10; Henninger JE, 2021, CELL, V184, P207, DOI 10.1016/j.cell.2020.11.030; Hnisz D, 2017, CELL, V169, P13, DOI 10.1016/j.cell.2017.02.007; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hofweber M, 2018, CELL, V173, P706, DOI 10.1016/j.cell.2018.03.004; Hu J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13347; Hyman AA, 2014, ANNU REV CELL DEV BI, V30, P39, DOI 10.1146/annurev-cellbio-100913-013325; Hyman AA, 2012, SCIENCE, V337, P1047, DOI 10.1126/science.1223728; Iconaru LI, 2015, SCI REP-UK, V5, DOI 10.1038/srep15686; Jeggo PA, 2016, NAT REV CANCER, V16, P35, DOI 10.1038/nrc.2015.4; Jia WL, 2020, NUCLEIC ACIDS RES, V48, pW415, DOI 10.1093/nar/gkaa371; Jiang H, 2013, NAT STRUCT MOL BIOL, V20, P1156, DOI 10.1038/nsmb.2656; Jin L, 2017, ONCOGENE, V36, P3797, DOI 10.1038/onc.2017.6; Kedersha N, 2013, TRENDS BIOCHEM SCI, V38, P494, DOI 10.1016/j.tibs.2013.07.004; Kilic S, 2019, EMBO J, V38, DOI 10.15252/embj.2018101379; Kim TH, 2019, SCIENCE, V365, P825, DOI 10.1126/science.aax4240; Klein IA, 2020, SCIENCE, V368, P1386, DOI 10.1126/science.aaz4427; Kwon I, 2013, CELL, V155, P1049, DOI 10.1016/j.cell.2013.10.033; Kwon JE, 2006, J BIOL CHEM, V281, P12664, DOI 10.1074/jbc.M600204200; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Li W, 2020, NAT CELL BIOL, V22, P960, DOI 10.1038/s41556-020-0550-8; Lu HS, 2018, NATURE, V558, P318, DOI 10.1038/s41586-018-0174-3; Lu Y, 2020, NAT CELL BIOL, V22, DOI 10.1038/s41556-020-0485-0; Mastrocola AS, 2013, J BIOL CHEM, V288, P24731, DOI 10.1074/jbc.M113.497974; Mateju D, 2020, CELL, V183, P1801, DOI 10.1016/j.cell.2020.11.010; Mirza-Aghazadeh-Attari M, 2019, DNA REPAIR, V73, P110, DOI 10.1016/j.dnarep.2018.11.008; Mitrea DM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03255-3; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Oshidari R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14546-z; Pak CW, 2016, MOL CELL, V63, P72, DOI 10.1016/j.molcel.2016.05.042; Pan J, 2015, ONCOGENE, V34, P3957, DOI 10.1038/onc.2014.327; Plys AJ, 2019, GENE DEV, V33, P799, DOI 10.1101/gad.326488.119; Potts PR, 2007, NAT STRUCT MOL BIOL, V14, P581, DOI 10.1038/nsmb1259; Ries RJ, 2019, NATURE, V571, P424, DOI 10.1038/s41586-019-1374-1; Ryan JJ, 2019, J BIOL CHEM, V294, P11286, DOI 10.1074/jbc.RA119.009494; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; Saito M, 2019, NAT CHEM BIOL, V15, P51, DOI 10.1038/s41589-018-0180-7; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sanulli S, 2019, NATURE, V575, P390, DOI 10.1038/s41586-019-1669-2; Seton-Rogers Sarah, 2018, Nat Rev Cancer, V18, P667, DOI 10.1038/s41568-018-0066-8; Shima Y, 2008, MOL CELL BIOL, V28, P7126, DOI 10.1128/MCB.00897-08; Shin Y, 2017, SCIENCE, V357, DOI 10.1126/science.aaf4382; Shrinivas K, 2019, MOL CELL, V75, P549, DOI 10.1016/j.molcel.2019.07.009; Somasekharan SP, 2015, J CELL BIOL, V208, P913, DOI 10.1083/jcb.201411047; Song YZ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1124-x; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Su XL, 2016, SCIENCE, V352, P595, DOI 10.1126/science.aad9964; Sun DX, 2018, CELL RES, V28, P405, DOI 10.1038/s41422-018-0017-7; Tatavosian R, 2019, J BIOL CHEM, V294, P1451, DOI 10.1074/jbc.RA118.006620; Tsai WC, 2016, J BIOL CHEM, V291, P22671, DOI 10.1074/jbc.M116.739573; Tsang B, 2019, P NATL ACAD SCI USA, V116, P4218, DOI 10.1073/pnas.1814385116; Varadi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139731; Vernon RM, 2018, ELIFE, V7, DOI 10.7554/eLife.31486; Wang JH, 2020, PROTEIN CELL, V11, P304, DOI 10.1007/s13238-019-00660-2; Wang L, 2019, MOL CELL, V76, P646, DOI 10.1016/j.molcel.2019.08.019; Wang RJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe5708; Wangeline MA, 2017, ANNU REV CELL DEV BI, V33, P467, DOI 10.1146/annurev-cellbio-111315-125036; Weber SC, 2015, CURR BIOL, V25, P641, DOI 10.1016/j.cub.2015.01.012; Wheeler RJ, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0193; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Wu H, 2016, CELL, V165, P1055, DOI 10.1016/j.cell.2016.05.004; Xia SY, 2021, PROTEIN CELL, V12, P680, DOI 10.1007/s13238-021-00839-6; Xie W, 2013, SCIENCE, V341, P245, DOI 10.1126/science.1236254; Yamasaki A, 2020, MOL CELL, V77, P1163, DOI 10.1016/j.molcel.2019.12.026; Yamazaki T, 2018, MOL CELL, V70, P1038, DOI 10.1016/j.molcel.2018.05.019; Yasuda S, 2020, NATURE, V578, P296, DOI 10.1038/s41586-020-1982-9; Yu M, 2021, MOL CELL, V81, P1216, DOI 10.1016/j.molcel.2021.01.010; Zaborowska J, 2016, NAT STRUCT MOL BIOL, V23, P771, DOI 10.1038/nsmb.3285; Zamaraev AV, 2017, TRENDS CELL BIOL, V27, P322, DOI 10.1016/j.tcb.2017.01.003; Zhang GM, 2018, CELL, V174, P1492, DOI 10.1016/j.cell.2018.08.006; Zhang H, 2020, SCI CHINA LIFE SCI, V63, P953, DOI 10.1007/s11427-020-1702-x; Zhang HY, 2020, MOL BIOL CELL, V31, P2048, DOI 10.1091/mbc.E19-10-0589; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhou W, 2021, MOL CELL, V81, P739, DOI 10.1016/j.molcel.2021.01.024; Zhu GY, 2021, CELL RES, V31, P1028, DOI 10.1038/s41422-021-00504-x; Zhu GY, 2020, CELL, V183, P490, DOI 10.1016/j.cell.2020.09.002	116	1	1	6	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1527	1535		10.1038/s41388-022-02195-z	http://dx.doi.org/10.1038/s41388-022-02195-z		FEB 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35132182				2022-12-28	WOS:000752287800001
J	Wang, ZB; Liu, YQ; Peng, L; Till, B; Liao, YW; Yuan, SM; Yan, X; Chen, L; Fu, Q; Qin, ZH				Wang, Zibing; Liu, Yuqing; Peng, Ling; Till, Brian; Liao, Yuwei; Yuan, Shumin; Yan, Xiang; Chen, Lin; Fu, Qiang; Qin, Zhihai			Role of fibrosarcoma-induced CD11b(+) myeloid cells and tumor necrosis factor-alpha in B cell responses	ONCOGENE			English	Article							TRANS-RETINOIC ACID; SUPPRESSOR-CELLS; T-CELLS; DIFFERENTIATION; IMMUNOTHERAPY; LYMPHOCYTES; POPULATION; ACTIVATION; LINEAGE	The role of B cells in the anti-tumor immune response remains controversial. An increase in the number of B cells in the peripheral blood of some tumor patients has been associated with poor immunotherapy efficacy. However, the mechanism leading to the generation of these cells is not well-described. Using a fibrosarcoma model, we show that intraperitoneal administration of a xenogeneic antigen in tumor-bearing mice evokes large increases in antigen-specific serum immunoglobulin formation compared to tumor-naive mice. An inability of tumor-bearing mice to induce enhanced antibody production after myeloid cell depletion suggests the antibody responses are CD11b(+) myeloid cell-dependent. In vitro, CD11b(+) myeloid cells promoted B cell proliferation, activation, and survival. High levels of tumor necrosis factor (TNF)-alpha were produced by CD11b(+) cells, and TNF-alpha blockade inhibited B cell responses. CD11b(+) cells appear to be important promoters of B cell responses and targeting B cells may increase the efficacy of immunotherapy in tumor-bearing hosts.	[Wang, Zibing; Yuan, Shumin] Zhengzhou Univ, Dept Immunotherapy, Affiliated Canc Hosp, Zhengzhou, Peoples R China; [Wang, Zibing; Yuan, Shumin; Fu, Qiang] Henan Canc Hosp, Zhengzhou, Peoples R China; [Liu, Yuqing] Xinxiang Med Coll, Dept Oncol, Affiliated Hosp 3, Xinxiang, Henan, Peoples R China; [Peng, Ling] Zhejiang Prov Peoples Hosp, Dept Resp Dis, Hangzhou, Peoples R China; [Till, Brian] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA; [Liao, Yuwei] Yangjiang Peoples Hosp, Yangjiang Key Lab Resp Dis, Yangjiang, Peoples R China; [Yan, Xiang] Chinese Peoples Liberat Army Gen Hosp, Med Oncol Dept, Beijing, Peoples R China; [Chen, Lin] Guangzhou Med Univ, GZMU GIBH Sch Life Sci, Guangzhou, Peoples R China; [Fu, Qiang] Zhengzhou Univ, Dept Gen Surg, Affiliated Canc Hosp, Zhengzhou, Peoples R China; [Qin, Zhihai] Chinese Acad Sci, Inst Biophys, Key Lab Prot & Peptide Pharmaceut, Beijing, Peoples R China	Zhengzhou University; Zhengzhou University; Xinxiang Medical University; Zhejiang Provincial People's Hospital; Fred Hutchinson Cancer Center; Chinese People's Liberation Army General Hospital; Guangzhou Medical University; Zhengzhou University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, ZB (corresponding author), Zhengzhou Univ, Dept Immunotherapy, Affiliated Canc Hosp, Zhengzhou, Peoples R China.; Wang, ZB (corresponding author), Henan Canc Hosp, Zhengzhou, Peoples R China.	zlyywzb2118@zzu.edu.cn	yan, Xiang/ABI-1846-2020	yan, Xiang/0000-0002-3683-474X	National Natural Science Foundation of China [81972690, 81000914]; Medical Science and Technology Research Project of Health Commission of Henan Province [2018010033]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science and Technology Research Project of Health Commission of Henan Province	This work was supported by the National Natural Science Foundation of China (Grant No. 81972690 and 81000914) and Medical Science and Technology Research Project of Health Commission of Henan Province (2018010033). The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.	Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Bauer R, 2018, CANCER RES, V78, P3220, DOI 10.1158/0008-5472.CAN-17-3415; Bodogai M, 2015, CANCER RES, V75, P3456, DOI 10.1158/0008-5472.CAN-14-3077; BURDIN N, 1995, J IMMUNOL, V154, P2533; Cani PD, 2018, NAT REV GASTRO HEPAT, V15, P671, DOI 10.1038/s41575-018-0025-6; Cook MB, 2019, GUT, V68, P960, DOI 10.1136/gutjnl-2018-316678; Dawson HD, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-27; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Forster M, 2017, J LEUKOCYTE BIOL, V101, P643, DOI 10.1189/jlb.1AB0415-177RR; Fridman WH, 2021, J EXP MED, V218, DOI 10.1084/jem.20200851; Grover A, 2021, CANCER DISCOV, V11, P2693, DOI 10.1158/2159-8290.CD-21-0764; Gu Y, 2019, NAT MED, V25, P312, DOI 10.1038/s41591-018-0309-y; Holmgaard RB, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1151595; Hutchins AP, 2015, SCI REP-UK, V5, DOI 10.1038/srep09100; Iwata M, 2003, INT IMMUNOL, V15, P1017, DOI 10.1093/intimm/dxg101; Jaufmann J, 2020, EUR J IMMUNOL, V50, P33, DOI 10.1002/eji.201948240; Jordan MB, 2004, SCIENCE, V304, P1808, DOI 10.1126/science.1089926; Knier B, 2018, NAT IMMUNOL, V19, P1341, DOI 10.1038/s41590-018-0237-5; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Lamichhane P, 2017, CANCER RES, V77, P6667, DOI 10.1158/0008-5472.CAN-17-0740; Lechner A, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1535293; Lee-Chang C, 2019, CANCER IMMUNOL RES, V7, P1928, DOI 10.1158/2326-6066.CIR-19-0240; Long AH, 2016, CANCER IMMUNOL RES, V4, P869, DOI 10.1158/2326-6066.CIR-15-0230; Lv ZW, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1747688; Ma YF, 2013, J IMMUNOL, V190, P5588, DOI 10.4049/jimmunol.1203216; Medoff BD, 2009, J IMMUNOL, V182, P623, DOI 10.4049/jimmunol.182.1.623; Minguet S, 2008, EUR J IMMUNOL, V38, P2475, DOI 10.1002/eji.200738094; Montes CL, 2006, EUR J IMMUNOL, V36, P1474, DOI 10.1002/eji.200535537; Montinaro A, 2018, IMMUNITY, V48, P481, DOI 10.1016/j.immuni.2018.03.011; Morikawa K, 2005, INT IMMUNOPHARMACOL, V5, P1830, DOI 10.1016/j.intimp.2005.06.002; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Qin ZH, 1998, NAT MED, V4, P627, DOI 10.1038/nm0598-627; Rastad Jessica L, 2018, Immunohorizons, V2, P87, DOI 10.4049/immunohorizons.1700066; Schmid T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01471; Shen M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1413520; Somasundaram R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00452-4; Spiotto MT, 2003, P NATL ACAD SCI USA, V100, P5425, DOI 10.1073/pnas.0930140100; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Tang A, 2016, INT J CANCER, V139, P1358, DOI 10.1002/ijc.30169; Tang CHA, 2018, CANCER IMMUNOL RES, V6, P696, DOI 10.1158/2326-6066.CIR-17-0582; Tobin RP, 2018, INT IMMUNOPHARMACOL, V63, P282, DOI 10.1016/j.intimp.2018.08.007; Tokunaga R, 2019, CANCER TREAT REV, V73, P10, DOI 10.1016/j.ctrv.2018.12.001; Vasilevsky S, 2008, J IMMUNOL, V181, P1787, DOI 10.4049/jimmunol.181.3.1787; Waffarn EE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9991; Wang SS, 2019, CELL MOL IMMUNOL, V16, P6, DOI 10.1038/s41423-018-0027-x; Wang ZB, 2016, ONCOTARGET, V7, P4760, DOI 10.18632/oncotarget.6734; Wang ZB, 2010, J IMMUNOTHER, V33, P167, DOI 10.1097/CJI.0b013e3181bed2ba; Wu WC, 2019, CANCER IMMUNOL RES, V7, P1605, DOI 10.1158/2326-6066.CIR-18-0902; Xu X, 2017, CELL MOL IMMUNOL, V14, P597, DOI 10.1038/cmi.2015.103; Yuan SM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.563622; Yuan SM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.563653; Zhao XQ, 2012, J CLIN INVEST, V122, P4094, DOI 10.1172/JCI64115	55	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1434	1444		10.1038/s41388-022-02187-z	http://dx.doi.org/10.1038/s41388-022-02187-z		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35034094				2022-12-28	WOS:000742809900001
J	Fjaestad, KY; Romer, AMA; Goitea, V; Johansen, AZ; Thorseth, ML; Carretta, M; Engelholm, LH; Grontved, L; Junker, N; Madsen, DH				Fjaestad, Klaire Yixin; Romer, Anne Mette Askehoj; Goitea, Victor; Johansen, Astrid Zedlitz; Thorseth, Marie-Louise; Carretta, Marco; Engelholm, Lars Henning; Grontved, Lars; Junker, Niels; Madsen, Daniel Hargbol			Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment	ONCOGENE			English	Article							NERVOUS-SYSTEM; OPEN-LABEL; PROPRANOLOL; CELLS; PEMBROLIZUMAB; COMBINATION; MANAGEMENT; SUPPRESSES; PHENOTYPE; MORTALITY	The development of immune checkpoint inhibitors (ICI) marks an important breakthrough of cancer therapies in the past years. However, only a limited fraction of patients benefit from such treatments, prompting the search for immune modulating agents that can improve the therapeutic efficacy. The nonselective beta blocker, propranolol, which for decades has been prescribed for the treatment of cardiovascular conditions, has recently been used successfully to treat metastatic angiosarcoma. These results have led to an orphan drug designation by the European Medicines Agency for the treatment of soft tissue sarcomas. The anti-tumor effects of propranolol are suggested to involve the reduction of cancer cell proliferation as well as angiogenesis. Here, we show that oral administration of propranolol delays tumor progression of MCA205 fibrosarcoma model and MC38 colon cancer model and increases the survival rate of tumor bearing mice. Propranolol works by reducing tumor angiogenesis and facilitating an anti-tumoral microenvironment with increased T cell infiltration and reduced infiltration of myeloid-derived suppressor cells (MDSCs). Using T cell deficient mice, we demonstrate that the full anti-tumor effect of propranolol requires the presence of T cells. Flow cytometry-based analysis and RNA sequencing of FACS-sorted cells show that propranolol treatment leads to an upregulation of PD-L1 on tumor associated macrophages (TAMs) and changes in their chemokine expression profile. Lastly, we observe that the co-administration of propranolol significantly enhances the efficacy of anti-CTLA4 therapy. Our results identify propranolol as an immune modulating agent, which can improve immune checkpoint inhibitor therapies in soft tissue sarcoma patients and potentially in other cancers.	[Fjaestad, Klaire Yixin; Romer, Anne Mette Askehoj; Johansen, Astrid Zedlitz; Thorseth, Marie-Louise; Carretta, Marco; Madsen, Daniel Hargbol] Copenhagen Univ Hosp Herlev & Gentofte, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, Herlev, Denmark; [Fjaestad, Klaire Yixin; Thorseth, Marie-Louise; Madsen, Daniel Hargbol] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark; [Romer, Anne Mette Askehoj] Roskilde Univ, Dept Sci & Environm, Roskilde, Denmark; [Goitea, Victor; Grontved, Lars] Univ Southern Denmark, Dept Biochem & Mol Biol, Odense, Denmark; [Engelholm, Lars Henning] Univ Copenhagen, Biotech Res & Innovat Ctr, Finsen Lab, Copenhagen, Denmark; [Junker, Niels] Copenhagen Univ Hosp Herlev & Gentofte, Dept Oncol, Herlev, Denmark	University of Copenhagen; Roskilde University; University of Southern Denmark; University of Copenhagen	Madsen, DH (corresponding author), Copenhagen Univ Hosp Herlev & Gentofte, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, Herlev, Denmark.; Madsen, DH (corresponding author), Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark.	daniel.hargboel.madsen@regionh.dk	Johansen, Astrid/CAF-7679-2022	Askehoj Romer, Anne Mette/0000-0002-5408-7020; Madsen, Daniel Hargboel/0000-0002-3183-6201; Fjaestad, Klaire Yixin/0000-0002-0141-6898; Grontved, Lars/0000-0002-6735-8483; Thorseth, Marie-Louise/0000-0001-7978-5549; Engelholm, Lars/0000-0002-6616-1232; Goitea, Victor/0000-0002-1564-4111; CARRETTA, MARCO/0000-0002-8135-7188	Lundbeck Foundation [R307-2018-3326]; Danish Cancer Society [R231-A14035, R231-A13832]; Independent Research Fund Denmark; department of Oncology, Herlev Hospital	Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); Independent Research Fund Denmark; department of Oncology, Herlev Hospital	This work was supported by the Lundbeck Foundation (R307-2018-3326) (to DHM), Danish Cancer Society (R231-A14035 and R231-A13832 (to DHM and LHE)), the Independent Research Fund Denmark (to LG), and department of Oncology, Herlev Hospital.	Agac D, 2018, BRAIN BEHAV IMMUN, V74, P176, DOI 10.1016/j.bbi.2018.09.004; Amaya Clarissa N, 2018, Oncoscience, V5, P109, DOI 10.18632/oncoscience.413; Awad RM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01977; Baghba R, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0530-4; Bai RL, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00209-0; Banavali S, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.499; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Barnes TA, 2017, BRIT J CANCER, V117, P451, DOI 10.1038/bjc.2017.220; Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422; Barton AL, 2015, J PEDIATR-US, V166, P115, DOI 10.1016/j.jpeds.2014.08.067; Brohee L, 2015, ONCOTARGET, V6, P11264, DOI 10.18632/oncotarget.3595; Bucsek MJ, 2017, CANCER RES, V77, P5639, DOI 10.1158/0008-5472.CAN-17-0546; Casali PG, 2014, ANN ONCOL, V25, P102, DOI 10.1093/annonc/mdu254; Chandran S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00787; Cole SW, 2015, NAT REV CANCER, V15, P563, DOI 10.1038/nrc3978; D'Angelo SP, 2018, LANCET ONCOL, V19, P416, DOI 10.1016/S1470-2045(18)30006-8; Daher C, 2019, CANCER IMMUNOL RES, V7, P1849, DOI 10.1158/2326-6066.CIR-18-0833; Eng JWL, 2014, CANCER IMMUNOL IMMUN, V63, P1115, DOI 10.1007/s00262-014-1617-9; Enot DP, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1462431; Fares Charlene M, 2019, Am Soc Clin Oncol Educ Book, V39, P147, DOI 10.1200/EDBK_240837; Field CS, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1376154; Gandhi S, 2021, CLIN CANCER RES, V27, P87, DOI 10.1158/1078-0432.CCR-20-2381; Hoang NT, 2018, CANCER MANAG RES, V10, P1089, DOI 10.2147/CMAR.S159641; Hou AH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00783; Idos GE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60255-4; Jin MZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00280-x; Jurberg AD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01440; Kamiya A, 2019, NAT NEUROSCI, V22, P1289, DOI 10.1038/s41593-019-0430-3; Kokolus KM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1405205; Liu YT, 2020, CLIN CANCER RES, V26, P970, DOI [10.1158/1078-0432.CCR-19-1040z, 10.1158/1078-0432.CCR-19-1040]; Magnon C, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.975643; Makale MT, 2017, BIOCYBERN BIOMED ENG, V37, P443, DOI 10.1016/j.bbe.2017.05.001; Mohammadpour H, 2019, J CLIN INVEST, V129, P5537, DOI 10.1172/JCI129502; Mravec B, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217958; Nagaraja AS, 2013, J CLIN INVEST, V123, P558, DOI 10.1172/JCI67887; Neophytou CM, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00899; Pantziarka Pan, 2018, Ecancermedicalscience, V12, ped82, DOI 10.3332/ecancer.2018.ed82; Pantziarka P, 2016, ECANCERMEDICALSCIENC, V10, DOI 10.3332/ecancer.2016.680; Pasquier E, 2016, EBIOMEDICINE, V6, P87, DOI 10.1016/j.ebiom.2016.02.026; Pedersen L, 2016, CELL METAB, V23, P554, DOI 10.1016/j.cmet.2016.01.011; Peranzoni E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01590; Qiao GX, 2019, CANCER IMMUNOL IMMUN, V68, P11, DOI 10.1007/s00262-018-2243-8; Rains Steven L, 2017, Oncoscience, V4, P95, DOI 10.18632/oncoscience.357; Srinivasan AV, 2019, ANN INDIAN ACAD NEUR, V22, P21, DOI 10.4103/aian.AIAN_201_18; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; Vaddepally RK, 2020, CANCERS, V12, DOI 10.3390/cancers12030738; Wagner Michael J, 2018, J Exp Pharmacol, V10, P51, DOI 10.2147/JEP.S146211; Wesolowski R, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-10; Wieduwild E, 2020, J EXP MED, V217, DOI 10.1084/jem.20190554; Wood Laura S, 2020, JCO Oncol Pract, V16, p15s, DOI 10.1200/JOP.19.00647; Zhong SL, 2016, EUR J CANCER PREV, V25, P440, DOI 10.1097/CEJ.0000000000000192; Zhou L, 2016, J IMMUNOL, V196, P3460, DOI 10.4049/jimmunol.1501677	52	8	8	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1364	1375		10.1038/s41388-021-02170-0	http://dx.doi.org/10.1038/s41388-021-02170-0		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35017664	Green Published, hybrid			2022-12-28	WOS:000741240600002
J	Frey, P; Devisme, A; Rose, K; Schrempp, M; Freihen, V; Andrieux, G; Boerries, M; Hecht, A				Frey, Patrick; Devisme, Antoine; Rose, Katja; Schrempp, Monika; Freihen, Vivien; Andrieux, Geoffroy; Boerries, Melanie; Hecht, Andreas			SMAD4 mutations do not preclude epithelial-mesenchymal transition in colorectal cancer	ONCOGENE			English	Article							CONSENSUS MOLECULAR SUBTYPES; EPHB3 TUMOR-SUPPRESSOR; SNAIL TRANSCRIPTION; EXPRESSION; GENE; PROGRESSION	Transforming growth factor beta (TGF beta) superfamily signaling is a prime inducer of epithelial-mesenchymal transitions (EMT) that foster cancer cell invasion and metastasis, a major cause of cancer-related deaths. Yet, TGF beta signaling is frequently inactivated in human tumor entities including colorectal cancer (CRC) and pancreatic adenocarcinoma (PAAD) with a high proportion of mutations incapacitating SMAD4, which codes for a transcription factor (TF) central to canonical TGF beta and bone morphogenetic protein (BMP) signaling. Beyond its role in initiating EMT, SMAD4 was reported to crucially contribute to subsequent gene regulatory events during EMT execution. It is therefore widely assumed that SMAD4-mutant (SMAD4(mut)) cancer cells are unable to undergo EMT. Here, we scrutinized this notion and probed for potential SMAD4-independent EMT execution using SMAD4(mut) CRC cell lines. We show that SMAD4(mut) cells exhibit morphological changes, become invasive, and regulate EMT marker genes upon induction of the EMT-TF SNAIL1. Furthermore, SNAIL1-induced EMT in SMAD4(mut) cells was found to be entirely independent of TGF beta/BMP receptor activity. Global assessment of the SNAIL1-dependent transcriptome confirmed the manifestation of an EMT gene regulatory program in SMAD4(mut) cells highly related to established EMT signatures. Finally, analyses of human tumor transcriptomes showed that SMAD4 mutations are not underrepresented in mesenchymal tumor samples and that expression patterns of EMT-associated genes are similar in SMAD4(mut) and SMAD4 wild-type (SMAD4(wt)) cases. Altogether, our findings suggest that alternative TFs take over the gene regulatory functions of SMAD4 downstream of EMT-TFs, arguing for considerable plasticity of gene regulatory networks operating in EMT execution. Further, they establish that EMT is not categorically precluded in SMAD4(mut) tumors, which is relevant for their diagnostic and therapeutic evaluation.	[Frey, Patrick; Rose, Katja; Schrempp, Monika; Freihen, Vivien; Hecht, Andreas] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany; [Frey, Patrick; Hecht, Andreas] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Freiburg, Germany; [Frey, Patrick; Devisme, Antoine; Hecht, Andreas] Univ Freiburg, Fac Biol, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] Univ Freiburg, Fac Med, Med Ctr, Inst Med Bioinformat & Syst Med, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] German Canc Consortium DKTK, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] German Canc Res Ctr, Heidelberg, Germany; [Hecht, Andreas] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Hecht, A (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, Fac Biol, Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany.	andreas.hecht@mol-med.uni-freiburg.de			Excellence Initiative of the German Research Foundation [GSC-4]; Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg; Deutsche Forschungsgemeinschaft (DFG) [CRC-850]; German Federal Ministry of Education and Research by MIRACUM within the Medical Informatics Funding Scheme [FKZ 01ZZ1801B]; DFG [CRC-1479, 441891347-S1, CRC-1160, CRC-1453, 431984000-S1, TRR167]	Excellence Initiative of the German Research Foundation(German Research Foundation (DFG)); Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Federal Ministry of Education and Research by MIRACUM within the Medical Informatics Funding Scheme; DFG(German Research Foundation (DFG))	The authors wish to thank the team at the Lighthouse Core Facility Freiburg, Germany for cell sorting assistance, M. Bewerunge-Hudler and her team from the Genomics and Proteomics Core Facility at the German Cancer Research Center (DKFZ), Heidelberg, Germany for their microarray services, and all members of the Hecht laboratory for critical reading of the manuscript. The results shown here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.This study was supported in part by the Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School) and in part by the Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg. Additional financial support was obtained from the Deutsche Forschungsgemeinschaft (DFG) (CRC-850 subprojects B5 to AH; C9 and Z1 to MB). MB received further funding from the German Federal Ministry of Education and Research by MIRACUM within the Medical Informatics Funding Scheme (FKZ 01ZZ1801B), and from the DFG within the following consortia: CRC-1479 (Project ID: 441891347-S1), CRC-1160 (Project Z02), CRC-1453 (Project ID 431984000-S1), and TRR167 (Project Z01).	Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Beyes S, 2019, ONCOGENE, V38, P6647, DOI 10.1038/s41388-019-0905-4; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Cook DP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16066-2; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eide PW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16747-x; Feldker N, 2020, EMBO J, V39, DOI 10.15252/embj.2019103209; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Freihen V, 2020, INT J CANCER, V146, P2229, DOI 10.1002/ijc.32644; Frey P, 2020, CANCERS, V12, DOI 10.3390/cancers12041019; Groger CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051136; Guerrero-Martinez JA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19877-5; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Haeussler M, 2019, NUCLEIC ACIDS RES, V47, pD853, DOI 10.1093/nar/gky1095; Hayashi Y, 2011, CANCER SCI, V102, P1228, DOI 10.1111/j.1349-7006.2011.01910.x; Herwig R, 2016, NAT PROTOC, V11, P1889, DOI 10.1038/nprot.2016.117; Inamoto S, 2016, CLIN CANCER RES, V22, P492, DOI 10.1158/1078-0432.CCR-15-0726; Jagle S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007109; Jagle S, 2014, P NATL ACAD SCI USA, V111, P4886, DOI 10.1073/pnas.1314523111; Ji Q, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1119-y; Khan FM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00268-2; Kolmykov S, 2021, NUCLEIC ACIDS RES, V49, pD104, DOI 10.1093/nar/gkaa1057; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Linnekamp JF, 2018, CELL DEATH DIFFER, V25, P616, DOI 10.1038/s41418-017-0011-5; Ma CQ, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0212-5; Ma ZQ, 2018, SEMIN CANCER BIOL, V50, P21, DOI 10.1016/j.semcancer.2018.02.004; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; McFaline-Figueroa JL, 2019, NAT GENET, V51, P1389, DOI 10.1038/s41588-019-0489-5; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Mei Z, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4298-5; Meyer-Schaller N, 2019, DEV CELL, V48, P539, DOI 10.1016/j.devcel.2018.12.023; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pires BRB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169622; Ramirez D, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00054; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ronsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395; Stanisavljevic J, 2011, J CELL SCI, V124, P4159, DOI 10.1242/jcs.078824; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Voorneveld PW, 2014, GASTROENTEROLOGY, V147, P196, DOI 10.1053/j.gastro.2014.03.052; Wang GH, 2018, PATHOL RES PRACT, V214, P1362, DOI 10.1016/j.prp.2018.06.018; Wang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056664; Wang Y, 2021, LAB INVEST, V101, P463, DOI 10.1038/s41374-020-00517-x; Wendt Michael K, 2014, JAKSTAT, V3, pe28975, DOI 10.4161/jkst.28975; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Wu WS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18101-7; Yan P, 2016, CLIN CANCER RES, V22, P3037, DOI 10.1158/1078-0432.CCR-15-0939; Zhang B, 2014, BRIT J CANCER, V110, P946, DOI 10.1038/bjc.2013.789; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304; Zhang YE, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022129; Zhang Y, 2019, BIOMED PHARMACOTHER, V110, P400, DOI 10.1016/j.biopha.2018.11.112	64	1	1	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					824	837		10.1038/s41388-021-02128-2	http://dx.doi.org/10.1038/s41388-021-02128-2		DEC 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34857888	hybrid, Green Published			2022-12-28	WOS:000725388800001
J	Otani, S; Date, Y; Ueno, T; Ito, T; Kajikawa, S; Omori, K; Taniuchi, I; Umeda, M; Komori, T; Toguchida, J; Ito, K				Otani, Shohei; Date, Yuki; Ueno, Tomoya; Ito, Tomoko; Kajikawa, Shuhei; Omori, Keisuke; Taniuchi, Ichiro; Umeda, Masahiro; Komori, Toshihisa; Toguchida, Junya; Ito, Kosei			Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma	ONCOGENE			English	Article							C-MYC; TRANSCRIPTIONAL REGULATION; TUMOR-SUPPRESSOR; P53 LOSS; CANCER; CELLS; EXPRESSION; REPRESSION; FAMILY; INACTIVATION	Osteosarcoma (OS) in human patients is characterized by genetic alteration of TP53. Osteoprogenitor-specific p53-deleted mice (OS mice) have been widely used to study the process of osteosarcomagenesis. However, the molecular mechanisms responsible for the development of OS upon p53 inactivation remain largely unknown. In this study, we detected prominent RUNX3/Runx3 expression in human and mouse p53-deficient OS. Myc was aberrantly upregulated by Runx3 via mR1, a consensus Runx site in the Myc promoter, in a manner dependent on p53 deficiency. Reduction of the Myc level by disruption of mR1 or Runx3 knockdown decreased the tumorigenicity of p53-deficient OS cells and effectively suppressed OS development in OS mice. Furthermore, Runx inhibitors exerted therapeutic effects on OS mice. Together, these results show that p53 deficiency promotes osteosarcomagenesis in human and mouse by allowing Runx3 to induce oncogenic Myc expression.	[Otani, Shohei; Date, Yuki; Ueno, Tomoya; Ito, Tomoko; Omori, Keisuke; Ito, Kosei] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Bone Biol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan; [Otani, Shohei; Omori, Keisuke; Umeda, Masahiro] Nagasaki Univ, Grad Sch Biomed Sci, Dept Clin Oral Oncol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan; [Date, Yuki] Japan Soc Promot Sci, Chiyoda Ku, 5-3-1 Kojimachi, Tokyo 1020083, Japan; [Kajikawa, Shuhei] Okayama Univ Sci, Dept Vet Med, Fac Vet Med, 1-3 Ikoinooka, Imabari, Ehime 7948555, Japan; [Taniuchi, Ichiro] RIKEN Ctr Integrat Med Sci, Lab Transcript Regulat, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan; [Komori, Toshihisa] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan; [Toguchida, Junya] Kyoto Univ, Inst Frontier Life & Med Sci, Sakyo Ku, Shogoin Kawahara Cho, Kyoto 6068507, Japan; [Toguchida, Junya] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan	Nagasaki University; Nagasaki University; Japan Society for the Promotion of Science; Okayama University of Science; RIKEN; Nagasaki University; Kyoto University; Kyoto University	Ito, K (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Bone Biol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	itok@nagasaki-u.ac.jp		Otani, Shohei/0000-0001-5474-2243	KAKENHI/Japan Society for the Promotion of Science (JSPS) [26290040, 18H02972, 19K22724]; JSPS Research Fellowship for Young Scientists [18J20543]; Funding Program for Next Generation World-Leading Researchers [LS097]	KAKENHI/Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); JSPS Research Fellowship for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Funding Program for Next Generation World-Leading Researchers(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank G. Huang for critical advice on the study; A. Berns and F. W. Alt for providing the p53 and Myc flox mouse lines, respectively; T. Kishino for generating genome-edited mouse lines; and all members of the Biomedical Research Center, Nagasaki University for maintaining mouse lines. This work was supported by KAKENHI/Japan Society for the Promotion of Science (JSPS) grants 26290040 (KI), 18H02972 (KI), and 19K22724 (KI); by the Funding Program for Next Generation World-Leading Researchers LS097 (KI); and by the JSPS Research Fellowship for Young Scientists 18J20543 (YD).	Bauer O, 2015, MOL CELL BIOL, V35, P1097, DOI 10.1128/MCB.01106-14; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Bledsoe KL, 2014, J CELL PHYSIOL, V229, P2049, DOI 10.1002/jcp.24663; Bonev B, 2017, CELL, V171, P557, DOI 10.1016/j.cell.2017.09.043; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Bougeard G, 2015, J CLIN ONCOL, V33, P2345, DOI 10.1200/JCO.2014.59.5728; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; Bushweller JH, 2019, NAT REV CANCER, V19, P611, DOI 10.1038/s41568-019-0196-7; Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Cho SW, 2018, CELL, V173, P1398, DOI 10.1016/j.cell.2018.03.068; Chuang LSH, 2017, ADV EXP MED BIOL, V962, P299, DOI 10.1007/978-981-10-3233-2_19; Chuang LSH, 2013, INT J CANCER, V132, P1260, DOI 10.1002/ijc.27964; Cunningham L, 2012, P NATL ACAD SCI USA, V109, P14592, DOI 10.1073/pnas.1200037109; Date Y, 2020, MOL CELLS, V43, P176, DOI 10.14348/molcells.2019.0285; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; He YL, 2015, STEM CELLS, V33, P1304, DOI 10.1002/stem.1925; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hosoi H, 2021, GENE, V774, DOI 10.1016/j.gene.2021.145421; Illendula A, 2016, EBIOMEDICINE, V8, P117, DOI 10.1016/j.ebiom.2016.04.032; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lancho O, 2018, TRENDS CANCER, V4, P810, DOI 10.1016/j.trecan.2018.10.003; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745; Morita K, 2017, J CLIN INVEST, V127, P2815, DOI 10.1172/JCI91788; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Naoe Y, 2007, J EXP MED, V204, P1749, DOI 10.1084/jem.20062456; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; PORTER DE, 1992, J BONE JOINT SURG BR, V74, P883; Pulikkan JA, 2018, CELL, V174, P172, DOI 10.1016/j.cell.2018.05.048; Qin X, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009169; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Sabapathy K, 2018, NAT REV CLIN ONCOL, V15, P13, DOI 10.1038/nrclinonc.2017.151; Shin MH, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005884; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; van der Deen M, 2012, J BIOL CHEM, V287, P4503, DOI 10.1074/jbc.M111.287771; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Whittle MC, 2015, CELL, V161, P1345, DOI 10.1016/j.cell.2015.04.048; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Yamada C, 2010, J BIOL CHEM, V285, P16693, DOI 10.1074/jbc.M109.055525	54	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					683	691		10.1038/s41388-021-02120-w	http://dx.doi.org/10.1038/s41388-021-02120-w		NOV 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34803166				2022-12-28	WOS:000720812600001
J	Wu, XN; Seraia, E; Hatch, SB; Wan, X; Ebner, DV; Aroldi, F; Jiang, YY; Ryan, AJ; Bogenrieder, T; Weyer-Czernilofsky, U; Rieunier, G; Macaulay, VM				Wu, Xiaoning; Seraia, Elena; Hatch, Stephanie B.; Wan, Xiao; Ebner, Daniel V.; Aroldi, Francesca; Jiang, Yanyan; Ryan, Anderson J.; Bogenrieder, Thomas; Weyer-Czernilofsky, Ulrike; Rieunier, Guillaume; Macaulay, Valentine M.			CHK1 inhibition exacerbates replication stress induced by IGF blockade	ONCOGENE			English	Article							DNA-DAMAGING AGENTS; BREAST-CANCER; H2AX PHOSPHORYLATION; CELLS; CHECKPOINT; EFFICACY; MK-8776; REPAIR; ATR; RADIOSENSITIVITY	We recently reported that genetic or pharmacological inhibition of insulin-like growth factor receptor (IGF-1R) slows DNA replication and induces replication stress by downregulating the regulatory subunit RRM2 of ribonucleotide reductase, perturbing deoxynucleotide triphosphate (dNTP) supply. Aiming to exploit this effect in therapy we performed a compound screen in five breast cancer cell lines with IGF neutralising antibody xentuzumab. Inhibitor of checkpoint kinase CHK1 was identified as a top screen hit. Co-inhibition of IGF and CHK1 caused synergistic suppression of cell viability, cell survival and tumour growth in 2D cell culture, 3D spheroid cultures and in vivo. Investigating the mechanism of synthetic lethality, we reveal that CHK1 inhibition in IGF-1R depleted or inhibited cells further downregulated RRM2, reduced dNTP supply and profoundly delayed replication fork progression. These effects resulted in significant accumulation of unreplicated single-stranded DNA and increased cell death, indicative of replication catastrophe. Similar phenotypes were induced by IGF:WEE1 co-inhibition, also via exacerbation of RRM2 downregulation. Exogenous RRM2 expression rescued hallmarks of replication stress induced by co-inhibiting IGF with CHK1 or WEE1, identifying RRM2 as a critical target of the functional IGF:CHK1 and IGF:WEE1 interactions. These data identify novel therapeutic vulnerabilities and may inform future trials of IGF inhibitory drugs.	[Wu, Xiaoning; Aroldi, Francesca] Univ Oxford, Dept Oncol, Oxford, England; [Seraia, Elena; Hatch, Stephanie B.; Wan, Xiao; Ebner, Daniel V.] Univ Oxford, Target Discovery Inst, Oxford, England; [Jiang, Yanyan; Ryan, Anderson J.] Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Oxford, England; [Bogenrieder, Thomas; Weyer-Czernilofsky, Ulrike] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; [Bogenrieder, Thomas] CO Fdn Recherches Med, AMAL Therapeut, CH-1205 Geneva, Switzerland; [Bogenrieder, Thomas] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Dept Urol, Munich, Germany; [Macaulay, Valentine M.] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England; [Rieunier, Guillaume] Immunocore Ltd, Abingdon, Oxon, England	University of Oxford; University of Oxford; University of Oxford; Boehringer Ingelheim; University of Munich; University of Oxford	Macaulay, VM (corresponding author), Univ Oxford, Nuffield Dept Surg Sci, Oxford, England.; Rieunier, G (corresponding author), Immunocore Ltd, Abingdon, Oxon, England.	guillaume.rieunier@immunocore.com; valentine.macaulay@nds.ox.ac.uk	RYAN, Anderson/ACG-0319-2022	RYAN, Anderson/0000-0001-6241-7969; Jiang, Yanyan/0000-0001-6014-811X; Wu, Xiaoning/0000-0002-8279-1517; Ebner, Daniel/0000-0002-6495-7026; Hatch, Stephanie/0000-0002-7401-9279	Breast Cancer Now [2014NovPR364]; Cancer Research UK [C476/A27060]; Oxfordshire Health Services Research Committee [1326]; NIHR Oxford Biomedical Research Centre; Harrington Discovery Institute	Breast Cancer Now; Cancer Research UK(Cancer Research UK); Oxfordshire Health Services Research Committee; NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Harrington Discovery Institute	We acknowledge the assistance and expertise provided by Rhodri Wilson and Graham Brown from the Microscopy core facility, Department of Oncology, University of Oxford. We thank Dr Anthony Kong for MCF7, ZR-75-1, T47D, and HCC1143 breast cancer cell lines, Prof. Adrian Harris for HeLa cells and Michael Sanderson (ex-Boehringer Ingelheim, now Merck) for the generous supply of BI885578. This study was supported by Breast Cancer Now (grant 2014NovPR364 to VMM), Cancer Research UK (grant C476/A27060 to VMM and GR), Oxfordshire Health Services Research Committee (grant 1326 to FA) and support to VMM from the NIHR Oxford Biomedical Research Centre and the Harrington Discovery Institute. We are grateful to Andrew Blackford, Tim Humphrey and Ian Mills for comments on the paper.	Amin O, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1803-y; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Booth L, 2018, CANCER BIOL THER, V19, P786, DOI 10.1080/15384047.2018.1472189; Borowiec AS, 2011, BBA-MOL CELL RES, V1813, P723, DOI 10.1016/j.bbamcr.2011.01.025; Brideau C, 2003, J BIOMOL SCREEN, V8, P634, DOI 10.1177/1087057103258285; Buisson R, 2015, MOL CELL, V59, P1011, DOI 10.1016/j.molcel.2015.07.029; Chitnis MM, 2014, ONCOGENE, V33, P5262, DOI 10.1038/onc.2013.460; Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Conti C, 2007, MOL BIOL CELL, V18, P3059, DOI 10.1091/mbc.E06-08-0689; Cosaceanu D, 2007, ONCOGENE, V26, P2423, DOI 10.1038/sj.onc.1210037; Creighton CJ, 2008, J CLIN ONCOL, V26, P4078, DOI 10.1200/JCO.2007.13.4429; Dai Y, 2013, MOL CANCER THER, V12, P878, DOI 10.1158/1535-7163.MCT-12-0902; de Bono J, 2020, BRIT J CANCER, V122, P1324, DOI 10.1038/s41416-020-0774-1; ELLWART JW, 1990, CYTOMETRY, V11, P239, DOI 10.1002/cyto.990110204; Ferte C, 2013, MOL CANCER THER, V12, P1213, DOI 10.1158/1535-7163.MCT-12-1067; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Friedbichler K, 2014, MOL CANCER THER, V13, P399, DOI 10.1158/1535-7163.MCT-13-0598; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Gonzalez Besteiro MA, 2019, EMBO J, V38, DOI 10.15252/embj.2018101284; Hamelers IHL, 2002, J BIOL CHEM, V277, P47645, DOI 10.1074/jbc.M208727200; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Hill SJ, 2014, MOL CELL BIOL, V34, P3828, DOI 10.1128/MCB.01646-13; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Kasahara K, 2010, EMBO J, V29, P2802, DOI 10.1038/emboj.2010.157; Koppenhafer SL, 2020, MOL CANCER RES, V18, P91, DOI 10.1158/1541-7786.MCR-19-0585; Landoni JC, 2018, BIOL METHODS PROTOC, V3; Lodhia KA, 2015, INT J CANCER, V136, P2961, DOI 10.1002/ijc.29327; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Ma XB, 2019, BREAST CANCER RES TR, V176, P109, DOI 10.1007/s10549-019-05189-w; Mathews CK, 2015, NAT REV CANCER, V15, P528, DOI 10.1038/nrc3981; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; Mladenova V, 2008, Z NATURFORSCH C, V63, P289; Moeglin E, 2019, CANCERS, V11, DOI 10.3390/cancers11030355; Moiseeva T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01401-x; Montano R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-604; Nath S, 2016, PHARMACOL THERAPEUT, V163, P94, DOI 10.1016/j.pharmthera.2016.03.013; O'Flanagan CH, 2016, ONCOTARGET, V7, P56826, DOI 10.18632/oncotarget.10862; Parsels LA, 2018, CELL CYCLE, V17, P1076, DOI 10.1080/15384101.2018.1475827; Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015; Rafiei S, 2020, CANCER RES, V80, P2094, DOI 10.1158/0008-5472.CAN-19-3126; Riesterer O, 2011, INT J RADIAT ONCOL, V79, P1179, DOI 10.1016/j.ijrobp.2010.10.003; Rieunier G, 2021, CANCER RES, V81, P2128, DOI 10.1158/0008-5472.CAN-20-2860; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sanderson MP, 2015, MOL CANCER THER, V14, P2762, DOI 10.1158/1535-7163.MCT-15-0539; Sanjiv K, 2016, CELL REP, V17, P3407, DOI 10.1016/j.celrep.2016.12.031; Sant Shilpa, 2017, Drug Discov Today Technol, V23, P27, DOI 10.1016/j.ddtec.2017.03.002; Schmid P, 2021, BREAST CANCER RES, V23, DOI 10.1186/s13058-020-01382-8; Sen T, 2019, J THORAC ONCOL, V14, P2152, DOI 10.1016/j.jtho.2019.08.009; Solier S, 2009, MOL CELL BIOL, V29, P68, DOI 10.1128/MCB.00581-08; Speroni J, 2012, P NATL ACAD SCI USA, V109, P7344, DOI 10.1073/pnas.1116345109; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Toledo L, 2017, MOL CELL, V66, P735, DOI 10.1016/j.molcel.2017.05.001; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Turney BW, 2012, RADIOTHER ONCOL, V103, P402, DOI 10.1016/j.radonc.2012.03.009; Vesela E, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7010019; Wang C, 2017, TRANSL ONCOL, V10, P190, DOI 10.1016/j.tranon.2017.01.007; Webster JA, 2017, LEUKEMIA RES, V61, P108, DOI 10.1016/j.leukres.2017.09.005; Yamaguchi R, 2015, FEBS LETT, V589, P4097, DOI 10.1016/j.febslet.2015.11.009; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhang YW, 2009, J BIOL CHEM, V284, P18085, DOI 10.1074/jbc.M109.003020; Zhou ZR, 2017, ACTA PHARMACOL SIN, V38, P513, DOI 10.1038/aps.2016.136	66	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					476	488		10.1038/s41388-021-02080-1	http://dx.doi.org/10.1038/s41388-021-02080-1		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34773074	Green Submitted, hybrid, Green Published			2022-12-28	WOS:000717915200003
J	Mirzakhani, K; Kallenbach, J; Rasa, SMM; Ribaudo, F; Ungelenk, M; Ehsani, M; Gong, WR; Gassler, N; Leeder, M; Grimm, MO; Neri, F; Baniahmad, A				Mirzakhani, Kimia; Kallenbach, Julia; Rasa, Seyed Mohammad Mahdi; Ribaudo, Federico; Ungelenk, Martin; Ehsani, Marzieh; Gong, Wenrong; Gassler, Nikolaus; Leeder, Mirjam; Grimm, Marc-Oliver; Neri, Francesco; Baniahmad, Aria			The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; THERAPY BAT; RECEPTOR; RATIONALE; TESTOSTERONE; ACTIVATION; APOPTOSIS; PATHWAY; KINASE	The bipolar androgen therapy (BAT) to treat prostate cancer (PCa) includes cycles of supraphysiological androgen levels (SAL) under androgen-deprivation therapy (ADT). We showed previously that SAL induces cellular senescence in androgen-sensitive PCa cells and in ex vivo-treated patient PCa tumor samples. Here, we analyzed the underlying molecular pathway and reveal that SAL induces cellular senescence in both, castration-sensitive (CSPC) LNCaP and castration-resistant PCa (CRPC) C4-2 cells through the cell cycle inhibitor p15(INK4b) and increased phosphorylation of AKT. Treatment with the AKT inhibitor (AKTi) potently inhibited SAL-induced expression of p15(INK4b) and cellular senescence in both cell lines. Proximity-ligation assays (PLA) combined with high-resolution laser-scanning microscopy indicate that SAL promotes interaction of endogenous androgen receptor (AR) with AKT in the cytoplasm as well as in the nucleus detectable after three days. Transcriptome sequencing (RNA-seq) comparing the SAL-induced transcriptomes of LNCaP with C4-2 cells as well as with AKTi-treated cell transcriptomes revealed landscapes for cell senescence. Interestingly, one of the identified genes is the lncRNASAT1. SAL treatment of native patient tumor samples ex vivo upregulates lncRNASAT1. In PCa tumor tissues, lncRNASAT1 is downregulated compared with nontumor tissues of the same patients. Knockdown indicates that the lncRNASAT1 is crucial for SAL-induced cancer-cell senescence as an upstream factor for pAKT and for p15(INK4b). Further, knockdown of lncRNASAT1 enhances cell proliferation by SAL, suggesting that lncRNASAT1 serves as a tumor suppressor at SAL. Interestingly, immunoprecipitation of AR detected lncRNASAT1 as an AR-interacting partner that regulates AR target-gene expression. Similarly, RNA-ChIP experiments revealed the interaction of AR with lncRNASAT1 on chromatin. Thus, we identified a novel AR-lncRNASAT1-AKT-p15(INK4b) signaling axis to mediate SAL-induced cellular senescence.	[Mirzakhani, Kimia; Kallenbach, Julia; Ribaudo, Federico; Ungelenk, Martin; Ehsani, Marzieh; Leeder, Mirjam; Baniahmad, Aria] Jena Univ Hosp, Inst Human Genet, Jena, Germany; [Rasa, Seyed Mohammad Mahdi; Neri, Francesco] Leibniz Inst Aging, Jena, Germany; [Gong, Wenrong] Hubei Univ Arts & Sci, Med Coll, Xiangyang, Peoples R China; [Gassler, Nikolaus] Jena Univ Hosp, Inst Forens Med, Sect Pathol, Jena, Germany; [Grimm, Marc-Oliver] Jena Univ Hosp, Dept Adult & Pediat Urol, Jena, Germany; [Gong, Wenrong] SCW Medicath LTD, Shenzhen, Peoples R China	Friedrich Schiller University of Jena; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Hubei University of Arts & Science; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Baniahmad, A (corresponding author), Jena Univ Hosp, Inst Human Genet, Jena, Germany.	aria.baniahmad@med.uni-jena.de	Neri, Francesco/A-3321-2014	Neri, Francesco/0000-0003-3903-1974	German Academic Exchange Service (DAAD); German Cancer Aid	German Academic Exchange Service (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); German Cancer Aid(Deutsche Krebshilfe)	This work was supported by the German Academic Exchange Service (DAAD) to K.M. and M.E. and the German Cancer Aid to A.B.	Calabrese EJ, 2001, CRIT REV TOXICOL, V31, P517, DOI 10.1080/20014091111794; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chuu CP, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-63; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Coa LL, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181312; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Deng Q, 2017, CELL PHYSIOL BIOCHEM, V43, P223, DOI 10.1159/000480343; Denmeade SR, 2010, PROSTATE, V70, P1600, DOI 10.1002/pros.21196; Denmeade SR, 2018, CLIN ADV HEMATOL ONC, V16, P408; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Esmaeili M, 2016, J MOL MED, V94, P1167, DOI 10.1007/s00109-016-1440-1; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Handa RJ, 2008, HORM BEHAV, V53, P741, DOI 10.1016/j.yhbeh.2007.09.012; Hessenkemper W, 2014, MOL ENDOCRINOL, V28, P1831, DOI 10.1210/me.2014-1170; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; Isaacs JT, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.10.32; Isaacs JT, 2017, CELL CYCLE, V16, P1639, DOI 10.1080/15384101.2017.1360645; Isaacs JT, 2012, PROSTATE, V72, P1491, DOI 10.1002/pros.22504; Kikani CK, 2005, J CELL BIOCHEM, V96, P1157, DOI 10.1002/jcb.20651; Lasher RA, 2012, J TISSUE ENG, V3, DOI 10.1177/2041731412455354; Leibowitz RL, 2010, BJU INT, V105, P1397, DOI 10.1111/j.1464-410X.2009.08980.x; Leung JK, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00002; Liao RS, 2013, TRANSL ANDROL UROL, V2, P187, DOI 10.3978/j.issn.2223-4683.2013.09.07; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Martelli AM, 2012, BBA-MOL CELL RES, V1823, P2168, DOI 10.1016/j.bbamcr.2012.08.017; Mearini L, 2013, WORLD J UROL, V31, P247, DOI 10.1007/s00345-011-0793-x; Mirochnik Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031052; Moehren U, 2008, FASEB J, V22, P1258, DOI 10.1096/fj.07-9360com; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Prehn RT, 1999, CANCER RES, V59, P4161; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Roediger J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-214; Rosner M, 2012, METHODS MOL BIOL, V821, P105, DOI 10.1007/978-1-61779-430-8_8; Schweizer MT, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010563; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Stattin P, 2004, INT J CANCER, V108, P418, DOI 10.1002/ijc.11572; Teply BA, 2018, LANCET ONCOL, V19, P76, DOI 10.1016/S1470-2045(17)30906-3; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; Wang Y, 2007, CURR CANCER DRUG TAR, V7, P591, DOI 10.2174/156800907781662248; Xu YH, 2019, CANCER LETT, V464, P37, DOI 10.1016/j.canlet.2019.08.010; Yang Q, 2019, GENE, V716, DOI 10.1016/j.gene.2019.144010	44	6	6	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					943	959		10.1038/s41388-021-02060-5	http://dx.doi.org/10.1038/s41388-021-02060-5		OCT 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34667276	Green Published, hybrid			2022-12-28	WOS:000708806900004
J	Tong, JS; Tan, X; Risnik, D; Gao, M; Song, XP; Ermine, K; Shen, LF; Wang, SM; Yu, J; Zhang, L				Tong, Jingshan; Tan, Xiao; Risnik, Denise; Gao, Man; Song, Xiangping; Ermine, Kaylee; Shen, Liangfang; Wang, Shaomeng; Yu, Jian; Zhang, Lin			BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade	ONCOGENE			English	Article							BROMODOMAIN INHIBITORS; INDUCED APOPTOSIS; RECEPTOR 5; EXPRESSION; RESISTANCE; BRD4; STABILIZATION; SENSITIVITY; MECHANISMS; TUMORS	Bromodomain and extra-terminal domain (BET) family proteins are epigenetic readers that play a critical role in oncogenesis by controlling the expression of oncogenes such as c-Myc. Targeting BET family proteins has recently emerged as a promising anticancer strategy. However, the molecular mechanisms by which cancer cells respond to BET inhibition are not well understood. In this study, we found that inducing the degradation of BET proteins by the proteolysis targeting chimeras (PROTAC) approach potently suppressed the growth of colorectal cancer (CRC) including patient-derived tumors. Mechanistically, BET degradation transcriptionally activates Death Receptor 5 (DR5) to trigger immunogenic cell death (ICD) in CRC cells. Enhanced DR5 induction further sensitizes CRC cells with a mutation in Speckle-type POZ protein (SPOP). Furthermore, DR5 is indispensable for a striking antitumor effect of combining BET degradation and anti-PD-1 antibody, which was well tolerated in mice and almost eradicated syngeneic tumors. Our results demonstrate that BET degradation triggers DR5-mediated ICD to potently suppress CRC and potentiate immune checkpoint blockade. These results provide a rationale, mechanistic insights, and potential biomarkers for developing a precision CRC therapy by inducing BET protein degradation.	[Tong, Jingshan; Tan, Xiao; Risnik, Denise; Gao, Man; Song, Xiangping; Ermine, Kaylee; Yu, Jian; Zhang, Lin] UPMC Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Tong, Jingshan; Tan, Xiao; Risnik, Denise; Song, Xiangping; Ermine, Kaylee; Zhang, Lin] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15213 USA; [Tan, Xiao; Shen, Liangfang] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China; [Gao, Man; Yu, Jian] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA; [Song, Xiangping] Cent South Univ, Xiangya Hosp, Dept Gastrointestinal Surg, Changsha 410008, Hunan, Peoples R China; [Wang, Shaomeng] Univ Michigan, Dept Internal Med, Sch Med, Ann Arbor, MI 48109 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Central South University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Central South University; University of Michigan System; University of Michigan	Zhang, L (corresponding author), UPMC Hillman Canc Ctr, Pittsburgh, PA 15213 USA.; Zhang, L (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Tong, Jingshan/0000-0003-1640-5769; Ermine, Kaylee/0000-0002-0870-7129; Risnik, Denise/0000-0001-8843-7968	U.S. National Institutes of Health [R01CA203028, R01CA217141, R01CA236271, R01CA247231, R01CA248112, R01CA215758, U19AI068021, R01CA215481, T32GM133332, P30CA047904]	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank our lab members for discussion and critical reading. This work was supported by the U.S. National Institutes of Health grants (R01CA203028, R01CA217141, R01CA236271, R01CA247231, and R01CA248112 to LZ; R01CA215758 to SW; U19AI068021 and R01CA215481 to JY; T32GM133332 to KE). This project used the Hillman Cancer Center Animal Facility, Cytometry Facility, and Tissue and Research Pathology Services, which are supported in part by P30CA047904.	An SA, 2018, EBIOMEDICINE, V36, P553, DOI 10.1016/j.ebiom.2018.09.005; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bai LC, 2017, CANCER RES, V77, P2476, DOI 10.1158/0008-5472.CAN-16-2622; Bhola PD, 2016, MOL CELL, V61, P695, DOI 10.1016/j.molcel.2016.02.019; Bolden JE, 2014, CELL REP, V8, P1919, DOI 10.1016/j.celrep.2014.08.025; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chen DS, 2014, CLIN CANCER RES, V20, P3472, DOI 10.1158/1078-0432.CCR-13-2944; Chu E, 2012, CLIN COLORECTAL CANC, V11, P1, DOI 10.1016/j.clcc.2011.05.005; Conery AR, 2016, CANCER RES, V76, P1313, DOI 10.1158/0008-5472.CAN-15-1458; Dai XP, 2017, NAT MED, V23, DOI 10.1038/nm.4378; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633; Gadd MS, 2017, NAT CHEM BIOL, V13, P514, DOI [10.1038/nchembio.2329, 10.1038/NCHEMBIO.2329]; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Germano G, 2017, NATURE, V552, P116, DOI 10.1038/nature24673; Han B, 2015, ONCOTARGET, V6, P17532, DOI 10.18632/oncotarget.3947; He K, 2016, ONCOGENE, V35, P148, DOI 10.1038/onc.2015.79; Hogg SJ, 2017, CELL REP, V18, P2162, DOI 10.1016/j.celrep.2017.02.011; Hu Y, 2015, INT J MOL SCI, V16, P1928, DOI 10.3390/ijms16011928; Janouskova H, 2017, NAT MED, V23, P1046, DOI 10.1038/nm.4372; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee DU, 2016, TOXICOL APPL PHARM, V300, P47, DOI 10.1016/j.taap.2016.03.013; Leibowitz B, 2014, P NATL ACAD SCI USA, V111, P16520, DOI 10.1073/pnas.1415178111; Li J, 2015, CANCER RES, V75, P508, DOI 10.1158/0008-5472.CAN-14-1215; Li XY, 2017, ONCOTARGET, V8, P9280, DOI 10.18632/oncotarget.14063; Lin JJ, 2016, TRENDS CANCER, V2, P350, DOI 10.1016/j.trecan.2016.05.010; Lu J, 2015, CHEM BIOL, V22, P755, DOI 10.1016/j.chembiol.2015.05.009; Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312; McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265; Oh YT, 2012, J BIOL CHEM, V287, P257, DOI 10.1074/jbc.M111.304006; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Pozzi C, 2016, NAT MED, V22, P624, DOI 10.1038/nm.4078; Selby MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161779; Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159-8290.CD-17-0605; Tan X, 2019, CANCER RES, V79, P1191, DOI 10.1158/0008-5472.CAN-18-3223; Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61; Togel L, 2016, MOL CANCER THER, V15, P1217, DOI 10.1158/1535-7163.MCT-15-0724; Tong JS, 2018, CANCER RES, V78, P4704, DOI 10.1158/0008-5472.CAN-18-0399; Tong JS, 2017, CANCER RES, V77, P2512, DOI 10.1158/0008-5472.CAN-16-3242; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wang YJ, 2018, GENES DIS, V5, P194, DOI 10.1016/j.gendis.2018.05.003; Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yao WL, 2015, ONCOTARGET, V6, P34669, DOI 10.18632/oncotarget.5785; Zengerle M, 2015, ACS CHEM BIOL, V10, P1770, DOI 10.1021/acschembio.5b00216; Zhang PZ, 2017, NAT MED, V23, P1055, DOI 10.1038/nm.4379; Zhou B, 2018, J MED CHEM, V61, P462, DOI 10.1021/acs.jmedchem.6b01816; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032	56	5	5	5	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6566	6578		10.1038/s41388-021-02041-8	http://dx.doi.org/10.1038/s41388-021-02041-8		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34615996	Green Accepted			2022-12-28	WOS:000705759400004
J	Lee, SO; Lou, W; Hou, M; Onate, SA; Gao, AC				Lee, Soo Ok; Lou, Wei; Hou, Min; Onate, Sergio A.; Gao, Allen C.			Editorial Expression of Concern: Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway	ONCOGENE			English	Editorial Material							GROWTH					allen.gao@roswellpark.org						DeMiguel F, 2002, PROSTATE, V52, P123, DOI 10.1002/pros.10110; Lee SO, 2003, CLIN CANCER RES, V9, P370; Lee SO, 2003, ONCOGENE, V22, P7981, DOI 10.1038/sj.onc.1206735	3	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6547	6547		10.1038/s41388-021-02034-7	http://dx.doi.org/10.1038/s41388-021-02034-7		OCT 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34599276	Bronze			2022-12-28	WOS:000702648500001
J	Lebedev, T; Vagapova, E; Spirin, P; Rubtsov, P; Astashkova, O; Mikheeva, A; Sorokin, M; Vladimirova, U; Suntsova, M; Konovalov, D; Roumiantsev, A; Stocking, C; Buzdin, A; Prassolov, V				Lebedev, Timofey; Vagapova, Elmira; Spirin, Pavel; Rubtsov, Petr; Astashkova, Olga; Mikheeva, Alesya; Sorokin, Maxim; Vladimirova, Uliana; Suntsova, Maria; Konovalov, Dmitry; Roumiantsev, Alexander; Stocking, Carol; Buzdin, Anton; Prassolov, Vladimir			Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes	ONCOGENE			English	Article							GENE-EXPRESSION; IMATINIB MESYLATE; ERYTHROPOIETIN; CELLS; RECEPTOR; CLASSIFICATION; ACTIVATION; PATHWAYS; FREQUENT; MYCN	Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-risk NB, but their efficacy is likely impaired by the cancer cells' ability to adapt to these drugs through the employment of alternative signaling pathways. Based on the expression of 48 growth factor-related genes in 1189 NB tumors, we have developed a model for NB patient survival prediction. This model discriminates between stage 4 NB tumors with favorable outcomes (>80% overall survival) and very poor outcomes (<10%) independently from MYCN-amplification status. Using signaling pathway analysis and gene set enrichment methods in 60 NB patients with known therapy response, we identified signaling pathways, including EPO, NGF, and HGF, upregulated in patients with no or partial response. In a therapeutic setting, we showed that among six selected growth factors, EPO, and NGF showed the most pronounced protective effects in vitro against several promising anti-NB multikinase inhibitors: imatinib, dasatinib, crizotinib, cabozantinib, and axitinib. Mechanistically kinase inhibitors potentiated NB cells to stronger ERK activation by EPO and NGF. The protective action of these growth factors strongly correlated with ERK activation and was ERK-dependent. ERK inhibitors combined with anticancer drugs, especially with dasatinib, showed a synergistic effect on NB cell death. Consideration of growth factor signaling activity benefits NB outcome prediction and tailoring therapy regimens to treat NB.	[Lebedev, Timofey; Vagapova, Elmira; Spirin, Pavel; Rubtsov, Petr; Astashkova, Olga; Mikheeva, Alesya; Prassolov, Vladimir] Russian Acad Sci, Engelhardt Inst Mol Biol, Dept Canc Cell Biol, Moscow, Russia; [Lebedev, Timofey; Vagapova, Elmira; Spirin, Pavel; Prassolov, Vladimir] Russian Acad Sci, Engelhardt Inst Mol Biol, Ctr Precis Genome Editing & Genet Technol Biomed, Moscow, Russia; [Astashkova, Olga; Mikheeva, Alesya; Buzdin, Anton] Natl Res Univ, Moscow Inst Phys & Technol, Moscow, Moscow Region, Russia; [Sorokin, Maxim; Buzdin, Anton] Shemyakin Ovchinnikov Inst Bioorgan Chem, Grp Genom Regulat Cell Signaling Syst, Moscow, Russia; [Sorokin, Maxim; Buzdin, Anton] OmicsWay Corp, Dept Bioinformat & Mol Networks, Walnut, CA USA; [Sorokin, Maxim; Vladimirova, Uliana; Suntsova, Maria; Buzdin, Anton] Sechenov First Moscow State Med Univ, Inst Personalized Med, Moscow, Russia; [Konovalov, Dmitry; Roumiantsev, Alexander] D Rogachyov Fed Res Ctr Pediat Hematol Oncol & Im, Moscow, Russia; [Stocking, Carol] Univ Med Ctr Hamburg Eppendorf UKE, Res Dept Cell & Gene Therapy, Dept Stem Cell Transplantat, Hamburg, Germany; [Stocking, Carol] Heinrich Pette Inst, Leibniz Inst Expt Virol, Hamburg, Germany	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Moscow Institute of Physics & Technology; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Sechenov First Moscow State Medical University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute	Lebedev, T (corresponding author), Russian Acad Sci, Engelhardt Inst Mol Biol, Dept Canc Cell Biol, Moscow, Russia.; Lebedev, T (corresponding author), Russian Acad Sci, Engelhardt Inst Mol Biol, Ctr Precis Genome Editing & Genet Technol Biomed, Moscow, Russia.	lebedevtd@gmail.com	Lebedev, Timofey/ABG-3319-2021; Suntsova, Maria/O-2056-2013; Sorokin, Maksim I/P-1459-2017; Mikheeva, Alesya/ABB-9826-2021	Suntsova, Maria/0000-0002-0280-4446; Sorokin, Maksim I/0000-0001-7685-3446; Khabusheva, Elmira/0000-0002-2680-9356; Spirin, Pavel/0000-0002-0610-5079	RSF [19-74-00120]; RFBR [20-34-70119]; Ministry of Science and Higher Education of the Russian Federation [075-15-2019-1660]; Russian Foundation for Basic Research [19-29-01108]	RSF(Russian Science Foundation (RSF)); RFBR(Russian Foundation for Basic Research (RFBR)); Ministry of Science and Higher Education of the Russian Federation; Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR))	We thank Boris Fehse and Kristoffer Riecken (University Medical Center HamburgEppendorf, Hamburg, Germany) for providing LeGO packaging vectors. The creation and analysis of ERK-KTR cells were performed within the work funded by RSF project no. 19-74-00120. Cell viability measurement and drug-induced expression changes were supported by was funded by RFBR project no. 20-34-70119. The creation of cell lines with EPOR knockdown and automated microscopy work were supported by grant 075-15-2019-1660 from the Ministry of Science and Higher Education of the Russian Federation. Transcriptome analysis was financed by the Russian Foundation for Basic Research grant 19-29-01108.	Aikin TJ, 2020, ELIFE, V9, DOI 10.7554/eLife.60541; Andreotti AH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002287; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Borisov N, 2020, METHODS MOL BIOL, V2063, P189, DOI 10.1007/978-1-0716-0138-9_15; Calafiore L, 2013, ANN ONCOL, V24, P1406, DOI 10.1093/annonc/mds648; Cangelosi D, 2020, CANCERS, V12, DOI 10.3390/cancers12092343; Chen ZH, 2017, ONCOTARGET, V8, P104090, DOI 10.18632/oncotarget.22011; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Daudigeos-Dubus E, 2017, INT J ONCOL, V50, P203, DOI 10.3892/ijo.2016.3792; Eggert A, 2000, KLIN PADIATR, V212, P200, DOI 10.1055/s-2000-9677; Eleveld TF, 2015, NAT GENET, V47, P864, DOI 10.1038/ng.3333; Foster JH, 2021, CLIN CANCER RES, V27, P3543, DOI 10.1158/1078-0432.CCR-20-4224; Goedhart J, 2021, MOL BIOL CELL, V32, P470, DOI 10.1091/mbc.E20-09-0583; Hartlieb SA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21247-8; He J, 2017, TRANSL ONCOL, V10, P936, DOI 10.1016/j.tranon.2017.09.008; Hirano I, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00105; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; James Melville, 2020, Arxiv, DOI arXiv:1802.03426; Vazquez-Mellado MJ, 2015, LIFE SCI, V137, P142, DOI 10.1016/j.lfs.2015.07.022; Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Korja M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-57; Lebedev TD, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01046; Lord SJ, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202001064; McInnes L., 2017, J OPEN SOURCE SOFTW, V2, P205, DOI 10.21105/joss.00205; Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468; Mlakar V, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0686-8; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Morandi F, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1468953; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Petrov I, 2017, ONCOTARGET, V8, P83768, DOI 10.18632/oncotarget.19662; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Rajbhandari P, 2018, CANCER DISCOV, V8, P582, DOI 10.1158/2159-8290.CD-16-0861; Regot S, 2014, CELL, V157, P1724, DOI 10.1016/j.cell.2014.04.039; Sartelet H, 2007, CANCER-AM CANCER SOC, V110, P1096, DOI 10.1002/cncr.22879; Scala S, 1996, CANCER RES, V56, P3737; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shohet J, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1863; Sokol E, 2019, CHILDREN-BASEL, V6, DOI 10.3390/children6020027; Spirin PV, 2014, LEUKEMIA, V28, P2222, DOI 10.1038/leu.2014.130; Stolze I, 2002, BLOOD, V100, P2623, DOI 10.1182/blood-2001-12-0169; Su ZQ, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0523-y; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Todaro M, 2013, CANCER RES, V73, P6393, DOI 10.1158/0008-5472.CAN-13-0248; Uccini S, 2005, CLIN CANCER RES, V11, P380; Vagapova ER, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90701-w; Valentijn LJ, 2015, NAT GENET, V47, P1411, DOI 10.1038/ng.3438; Vitali R, 2009, INT J CANCER, V125, P2547, DOI 10.1002/ijc.24606; Wang C, 2014, NAT BIOTECHNOL, V32, P926, DOI 10.1038/nbt.3001; Wang K, 2011, NATURE, V469, P216, DOI 10.1038/nature09609; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Zhu SZ, 2012, CANCER CELL, V21, P362, DOI 10.1016/j.ccr.2012.02.010	59	8	8	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6258	6272		10.1038/s41388-021-02018-7	http://dx.doi.org/10.1038/s41388-021-02018-7		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34556815	hybrid, Green Published			2022-12-28	WOS:000698556400004
J	Liu, ZD; Sang, XL; Wang, M; Liu, YC; Liu, J; Wang, XF; Liu, PX; Cheng, HL				Liu, Zundong; Sang, Xiaolin; Wang, Min; Liu, Yichao; Liu, Jiao; Wang, Xuefei; Liu, Pixu; Cheng, Hailing			Melatonin potentiates the cytotoxic effect of Neratinib in HER2(+) breast cancer through promoting endocytosis and lysosomal degradation of HER2	ONCOGENE			English	Article							IRREVERSIBLE INHIBITOR; HSP90; GROWTH; ERBB2; IDENTIFICATION; CHEMOTHERAPY; TRAFFICKING; COMBINATION; ACTIVATION; RESISTANCE	Complete blockade of the HER2 protein itself and HER signaling network is critical to achieving effective HER2-targeted therapies. Despite the success of HER2-targeted therapies, the diseases will relapse in a significant fraction of patients with HER2(+) breast cancers. How to improve the therapeutic efficacy of existing HER2-targeted agents remains an unmet clinical need. Here, we uncover a role of Melatonin in diminishing HER2-mediated signaling by destruction of HER2 protein. Mechanistically, Melatonin treatment attenuated the protective effect of the HSP90 chaperone complex on its client protein HER2, triggering ubiquitylation and subsequent endocytic lysosomal degradation of HER2. The inhibitory effect of Melatonin on HER2 signaling substantially enhanced the cytotoxic effects of the pan-HER inhibitor Neratinib in HER2(+) breast cancer cells. Lastly, we demonstrate that dual inhibition of HER2 by combined use of Melatonin and Neratinib effectively blocked the growth of HER2(+) breast tumor xenografts in vivo. Our findings shed light on the potential use of Melatonin in a novel dual HER2 blockade strategy for HER2(+) breast cancer treatment.	[Liu, Zundong; Sang, Xiaolin; Wang, Min; Liu, Yichao; Liu, Jiao; Wang, Xuefei; Cheng, Hailing] Dalian Med Univ, Inst Canc, Hosp 2, Dalian, Liaoning, Peoples R China; [Liu, Pixu] Dalian Med Univ, Inst Canc Stem Cell, Hosp 2, Dalian, Liaoning, Peoples R China	Dalian Medical University; Dalian Medical University	Cheng, HL (corresponding author), Dalian Med Univ, Inst Canc, Hosp 2, Dalian, Liaoning, Peoples R China.; Liu, PX (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Hosp 2, Dalian, Liaoning, Peoples R China.	pixu_liu@163.com; hailingcheng_dmu@163.com		Sang, Xiaolin/0000-0001-8154-2853	Dalian Key Laboratory of Molecular Targeted Cancer Therapy; Molecular Biology Laboratory of National Administration of Traditional Chinese Medicine (Class III); National Natural Science Foundation of China [81672575, 81874111, 81972482]; Liaoning Provincial Key Research and Development Program [2020JH2/10300049]; Liaoning Revitalization Talents Program [XLYC2002043]; Dalian Leading Talents Fund [203598]; Liaoning Provincial Climbing Scholars Supporting Program of China; Scientific Research Fund of Liaoning Provincial Department of Education [LZ2020006, LZ2020069]; Science and Technology Innovation Fund of Dalian Department of Science and Technology [2020JJ27SN079, 2021JJ12SN39]	Dalian Key Laboratory of Molecular Targeted Cancer Therapy; Molecular Biology Laboratory of National Administration of Traditional Chinese Medicine (Class III); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Liaoning Provincial Key Research and Development Program; Liaoning Revitalization Talents Program; Dalian Leading Talents Fund; Liaoning Provincial Climbing Scholars Supporting Program of China; Scientific Research Fund of Liaoning Provincial Department of Education; Science and Technology Innovation Fund of Dalian Department of Science and Technology	We acknowledge the support of the Dalian Key Laboratory of Molecular Targeted Cancer Therapy and the Molecular Biology Laboratory of National Administration of Traditional Chinese Medicine (Class III). This work was supported by the National Natural Science Foundation of China (Nos. 81672575 and 81874111 to HC; No. 81972482 to PL), the Liaoning Provincial Key Research and Development Program (No. 2020JH2/10300049 to PL), Liaoning Revitalization Talents Program (XLYC2002043 to PL), Dalian Leading Talents Fund (203598 to PL), the Liaoning Provincial Climbing Scholars Supporting Program of China (HC and PL), the Scientific Research Fund of Liaoning Provincial Department of Education (LZ2020006 to PL; LZ2020069 to XS), and Science and Technology Innovation Fund of Dalian Department of Science and Technology (2020JJ27SN079 to HC, 2021JJ12SN39 to PL.).	Andersen LPH, 2016, CLIN DRUG INVEST, V36, P169, DOI 10.1007/s40261-015-0368-5; Anisimov VN, 2010, CELL CYCLE, V9, P188, DOI 10.4161/cc.9.1.10407; Anisimov VN, 2003, INT J CANCER, V103, P300, DOI 10.1002/ijc.10827; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Ashton JC, 2015, CANCER RES, V75, P2400, DOI 10.1158/0008-5472.CAN-14-3763; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Breslin S, 2017, BRIT J CANCER, V116, P620, DOI 10.1038/bjc.2016.445; Burstein HJ, 2010, J CLIN ONCOL, V28, P1301, DOI 10.1200/JCO.2009.25.8707; Chung SS, 2014, INT J ONCOL, V44, P403, DOI 10.3892/ijo.2013.2195; Clague MJ, 2012, DEV CELL, V23, P457, DOI 10.1016/j.devcel.2012.08.011; Clague MJ, 2010, CELL, V143, P682, DOI 10.1016/j.cell.2010.11.012; Chuffa LGD, 2017, CARCINOGENESIS, V38, P945, DOI 10.1093/carcin/bgx054; Deeks ED, 2017, DRUGS, V77, P1695, DOI 10.1007/s40265-017-0811-4; Ding JL, 2019, CANCER LETT, V440, P54, DOI 10.1016/j.canlet.2018.09.030; Dodda BR, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00525; Galano A, 2018, MOLECULES, V23, DOI 10.3390/molecules23030530; Gingras I, 2017, NAT REV CLIN ONCOL, V14, P669, DOI 10.1038/nrclinonc.2017.96; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Goutsouliak K, 2020, NAT REV CLIN ONCOL, V17, P233, DOI 10.1038/s41571-019-0299-9; Hallett ST, 2017, CELL REP, V21, P1386, DOI 10.1016/j.celrep.2017.10.042; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hendriks BS, 2003, CANCER RES, V63, P1130; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Karakas B, 2018, BBA-MOL CELL RES, V1865, P1073, DOI 10.1016/j.bbamcr.2018.05.002; Kong XY, 2020, TRENDS ENDOCRIN MET, V31, P859, DOI 10.1016/j.tem.2020.08.001; Li BT, 2020, CANCER DISCOV, V10, P674, DOI 10.1158/2159-8290.CD-20-0215; Li Y, 2017, ONCOTARGET, V8, P39896, DOI 10.18632/oncotarget.16379; Lissoni P, 1999, EUR J CANCER, V35, P1688, DOI 10.1016/S0959-8049(99)00159-8; Malow BA, 2021, J AM ACAD CHILD PSY, V60, P252, DOI 10.1016/j.jaac.2019.12.007; Mao LL, 2016, MOL CANCER RES, V14, P1159, DOI 10.1158/1541-7786.MCR-16-0158; Mao LL, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2794; Marx C, 2010, CANCER RES, V70, P3709, DOI 10.1158/0008-5472.CAN-09-3768; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Oh DY, 2020, NAT REV CLIN ONCOL, V17, P33, DOI 10.1038/s41571-019-0268-3; Pariente R, 2016, J PINEAL RES, V60, P55, DOI 10.1111/jpi.12288; Pedersen NM, 2008, MOL CANCER RES, V6, P491, DOI 10.1158/1541-7786.MCR-07-0191; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Rabindran SK, 2004, CANCER RES, V64, P3958, DOI 10.1158/0008-5472.CAN-03-2868; Ren YL, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00426-y; Sang XL, 2021, CANCER LETT, V518, P82, DOI 10.1016/j.canlet.2021.06.011; Shevtsov M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215284; Sletten TL, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002587; Sookprasert A, 2014, ANTICANCER RES, V34, P7327; Strous GJ, 1999, J CELL SCI, V112, P1417; Talib WH, 2018, MOLECULES, V23, DOI 10.3390/molecules23030518; Huynh TK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194812; Tikhomirov O, 2003, CANCER RES, V63, P39; Wang JN, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0069-2; Wang M, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101225; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wissner A, 2003, J MED CHEM, V46, P49, DOI 10.1021/jm020241c; Wissner A, 2008, ARCH PHARM, V341, P465, DOI 10.1002/ardp.200800009; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; Xia WL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3480; Xu WP, 2005, NAT STRUCT MOL BIOL, V12, P120, DOI 10.1038/nsmb885; Yi JY, 2019, EBIOMEDICINE, V43, P225, DOI 10.1016/j.ebiom.2019.03.027; Zhang J, 2020, AGING-US, V12, P5423, DOI 10.18632/aging.102968; Zhang JR, 2020, CELL DEATH DIFFER, V27, P2710, DOI 10.1038/s41418-020-0538-8; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhang YQ, 2016, CANCER LETT, V382, P176, DOI 10.1016/j.canlet.2016.08.026	61	6	6	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6273	6283		10.1038/s41388-021-02015-w	http://dx.doi.org/10.1038/s41388-021-02015-w		SEP 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34556812	Green Published, hybrid			2022-12-28	WOS:000698556400002
J	Dieter, SM; Lovecchio, D; Pataskar, A; Zowada, MK; Korner, PR; Khalizieva, A; van Tellingen, O; Jager, D; Glimm, H; Agami, R				Dieter, Sebastian M.; Lovecchio, Domenica; Pataskar, Abhijeet; Zowada, Martina K.; Korner, Pierre-Rene; Khalizieva, Anna; van Tellingen, Olaf; Jaeger, Dirk; Glimm, Hanno; Agami, Reuven			Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors	ONCOGENE			English	Article							BRAF(V600E) INHIBITION; MOLECULAR-CLONING; CANCER-CELLS; COLON-CANCER; KAPPA-B; GROWTH; RESISTANCE; HIPPO; YAP; YAP/TAZ	Accumulating evidence identifies non-genetic mechanisms substantially contributing to drug resistance in cancer patients. Preclinical and clinical data implicate the transcriptional co-activators YAP1 and its paralog TAZ in resistance to multiple targeted therapies, highlighting the strong need for therapeutic strategies overcoming YAP1/TAZ-mediated resistance across tumor entities. Here, we show particularly high YAP1/TAZ activity in MITFlow/AXL(high) melanomas characterized by resistance to MAPK pathway inhibition and broad receptor tyrosine kinase activity. To uncover genetic dependencies of melanoma cells with high YAP1/TAZ activity, we used a genome-wide CRISPR/Cas9 functional screen and identified SLC35B2, the 3 '-phosphoadenosine-5 '-phosphosulfate transporter of the Golgi apparatus, as an essential gene for YAP1/TAZ-driven drug resistance. SLC35B2 expression correlates with tumor progression, and its loss decreases heparan sulfate expression, reduces receptor tyrosine kinase activity, and sensitizes resistant melanoma cells to BRAF inhibition in vitro and in vivo. Thus, targeting heparan sulfation via SLC35B2 represents a novel approach for breaking receptor tyrosine kinase-mediated resistance to MAPK pathway inhibitors.	[Dieter, Sebastian M.; Lovecchio, Domenica; Pataskar, Abhijeet; Korner, Pierre-Rene; Khalizieva, Anna; Agami, Reuven] Netherlands Canc Inst, Oncode Inst, Div Oncogen, Amsterdam, Netherlands; [Dieter, Sebastian M.; Zowada, Martina K.] Natl Ctr Tumor Dis NCT, Translat Funct Canc Genom, Heidelberg & German Canc Res Ctr DKFZ, Heidelberg, Germany; [Dieter, Sebastian M.; Glimm, Hanno] Heidelberg Univ Hosp, Dept Med Oncol, Dept Med Oncol, Natl Ctr Tumor Dis NCT, Heidelberg, Germany; [Dieter, Sebastian M.; Jaeger, Dirk; Glimm, Hanno] Dresden & German Canc Res Ctr DKFZ, Dept Translat Med Oncol, Natl Ctr Tumor Dis NCT, Dresden, Germany; [van Tellingen, Olaf] Netherlands Canc Inst, Div Pharmacol, Amsterdam, Netherlands; [Jaeger, Dirk; Glimm, Hanno] German Canc Consortium DKTK, Heidelberg, Germany; [Glimm, Hanno] Tech Univ Dresden, Natl Ctr Tumor Dis NCT, Ctr Personalized Oncol, Dresden & Univ Hosp Carl Gustav Carus Dresden, Dresden, Germany; [Glimm, Hanno] German Canc Consortium DKTK, Dresden, Germany; [Agami, Reuven] Rotterdam Univ, Erasmus MC, Rotterdam, Netherlands	Netherlands Cancer Institute; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Netherlands Cancer Institute; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Helmholtz Association; German Cancer Research Center (DKFZ); Erasmus University Rotterdam; Erasmus MC	Dieter, SM; Agami, R (corresponding author), Netherlands Canc Inst, Oncode Inst, Div Oncogen, Amsterdam, Netherlands.; Dieter, SM (corresponding author), Natl Ctr Tumor Dis NCT, Translat Funct Canc Genom, Heidelberg & German Canc Res Ctr DKFZ, Heidelberg, Germany.; Dieter, SM (corresponding author), Heidelberg Univ Hosp, Dept Med Oncol, Dept Med Oncol, Natl Ctr Tumor Dis NCT, Heidelberg, Germany.; Dieter, SM (corresponding author), Dresden & German Canc Res Ctr DKFZ, Dept Translat Med Oncol, Natl Ctr Tumor Dis NCT, Dresden, Germany.; Agami, R (corresponding author), Rotterdam Univ, Erasmus MC, Rotterdam, Netherlands.	s.dieter@nki.nl; r.agami@nki.nl	agami, reuven/GOG-8289-2022	Dieter, Sebastian/0000-0003-1324-7638; Agami, Reuven/0000-0002-2848-2473; Zowada, Martina/0000-0002-4231-1021				Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Akervall J, 2014, EUR J CANCER, V50, P570, DOI 10.1016/j.ejca.2013.11.007; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Biehs B, 2018, NATURE, V562, P429, DOI 10.1038/s41586-018-0596-y; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Cecchi F, 2012, CANCER CELL, V22, P250, DOI 10.1016/j.ccr.2012.06.029; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; D'Arienzo A, 2019, ORTHOP RES REV, V11, P199, DOI 10.2147/ORR.S183979; Dieter SM, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109394; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; Gao HX, 2019, VIROLOGY, V529, P91, DOI 10.1016/j.virol.2019.01.019; Germain N, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9120474; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Hangauer MJ, 2017, NATURE, V551, P247, DOI 10.1038/nature24297; Hinata K, 2003, ONCOGENE, V22, P1955, DOI 10.1038/sj.onc.1206198; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Janostiak R, 2019, ISCIENCE, V16, P453, DOI 10.1016/j.isci.2019.06.001; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; Kamiyama S, 2006, J BIOL CHEM, V281, P10945, DOI 10.1074/jbc.M508991200; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim MH, 2016, EMBO J, V35, P462, DOI 10.15252/embj.201592081; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Korkmaz G, 2016, NAT BIOTECHNOL, V34, P192, DOI 10.1038/nbt.3450; Kurppa KJ, 2020, CANCER CELL, V37, P104, DOI 10.1016/j.ccell.2019.12.006; Lamar JM, 2019, J BIOL CHEM, V294, P2302, DOI 10.1074/jbc.RA118.004364; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li L, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02272-8; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lin L, 2015, NAT REV DRUG DISCOV, V14, P543, DOI 10.1038/nrd4626; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Miao BC, 2015, CANCER DISCOV, V5, P274, DOI 10.1158/2159-8290.CD-14-0295; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Mundhenke C, 2002, AM J PATHOL, V160, P185, DOI 10.1016/S0002-9440(10)64362-3; Nguyen CDK, 2019, TRENDS CANCER, V5, P283, DOI 10.1016/j.trecan.2019.02.010; Ohkawa Y, 2021, MOL CANCER RES, V19, P150, DOI 10.1158/1541-7786.MCR-20-0420; Park RJ, 2017, NAT GENET, V49, P193, DOI 10.1038/ng.3741; Pham TH, 2021, CANCER DISCOV, V11, P778, DOI 10.1158/2159-8290.CD-20-0706; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Reijmers RM, 2010, BLOOD, V115, P601, DOI 10.1182/blood-2009-02-204396; Salgia R, 2018, TRENDS CANCER, V4, P110, DOI 10.1016/j.trecan.2018.01.001; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Thamamongood T, 2020, J VIROL, V94, DOI 10.1128/JVI.00752-20; TheUniProtConsortium, 2017, Nucleic Acids Res, V45, pD158, DOI 10.1093/nar/gkw1099; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wang JY, 2017, INT J ONCOL, V50, P345, DOI 10.3892/ijo.2016.3811; Wang Tim, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot090803; Wang YM, 2018, CELL REP, V25, P1304, DOI 10.1016/j.celrep.2018.10.001; Weiss RJ, 2017, ORG BIOMOL CHEM, V15, P5656, DOI 10.1039/c7ob01058c; Winter J, 2016, BIOINFORMATICS, V32, P632, DOI 10.1093/bioinformatics/btv617; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; Yang YS, 2015, MOLECULES, V20, P2138, DOI 10.3390/molecules20022138; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang XM, 2020, ONCOGENE, V39, P5267, DOI 10.1038/s41388-020-1362-9; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	76	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3953	3968		10.1038/s41388-022-02400-z	http://dx.doi.org/10.1038/s41388-022-02400-z		JUL 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35798875	Green Published, hybrid			2022-12-28	WOS:000821721300006
J	Ma, XL; Zhu, KY; Chen, YD; Tang, WG; Xie, SH; Zheng, H; Tong, Y; Wang, YC; Ren, N; Guo, L; Lu, RQ				Ma, Xiao-Lu; Zhu, Ke-Yu; Chen, Yue-Da; Tang, Wei-Guo; Xie, Su-Hong; Zheng, Hui; Tong, Ying; Wang, Yan-Chun; Ren, Ning; Guo, Lin; Lu, Ren-Quan			Identification of a novel Calpain-2-SRC feed-back loop as necessity for beta-Catenin accumulation and signaling activation in hepatocellular carcinoma	ONCOGENE			English	Article							PROTEINS; PATHWAY; BINDING; CAPN2; SRC	Rapid progression is the major cause of the poor prognosis of hepatocellular carcinoma (HCC); however, the underlying mechanism remained unclear. Here, we found Calpain-2 (CAPN2), a well-established protease that accelerates tumor progression in several malignancies, is overexpressed in HCC and acts as an independent predictor for poor outcomes. Furthermore, CAPN2 promoted the proliferation and invasion of HCC, and showed a positive correlation with the levels of invasion-related markers. Mechanistically, a novel CAPN2-SRC positive regulatory loop was identified upstream of beta-catenin to prevent its ubiquitination and degradation, and subsequently promoted HCC progression: CAPN2 could proteolyze PTP1B to form a truncation of approximately 42 kDa with increased phosphatase activity, resulting in reduced SRC Y530 phosphorylation and increased SRC kinase activity; meanwhile, CAPN2 itself was a bone fide substrate of SRC that was primarily phosphorylated at Y625 by SRC and exhibited increased proteolysis activity upon phosphorylation. Interestingly, the CAPN2-SRC loop could not only restrain most of cytoplasmic beta-catenin degradation by inhibiting GSK3 beta pathway, but also prevented TRIM33-induced nuclear beta-catenin degradation even in beta-catenin-mutant cells. Present study identified a CAPN2-SRC positive loop responsible for intracellular beta-catenin accumulation and signaling activation, and targeting CAPN2 protease activity might be a promising approach for preventing HCC progression.	[Ma, Xiao-Lu; Zhu, Ke-Yu; Xie, Su-Hong; Zheng, Hui; Tong, Ying; Wang, Yan-Chun; Guo, Lin; Lu, Ren-Quan] Fudan Univ, Shanghai Canc Ctr, Dept Clin Lab, Shanghai 200032, Peoples R China; [Ma, Xiao-Lu; Zhu, Ke-Yu; Xie, Su-Hong; Zheng, Hui; Tong, Ying; Wang, Yan-Chun; Guo, Lin; Lu, Ren-Quan] Fudan Univ, Shanghai Med Sch, Dept Oncol, Shanghai 200032, Peoples R China; [Chen, Yue-Da] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Xiamen Branch, Shanghai 200032, Peoples R China; [Tang, Wei-Guo; Ren, Ning] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai 200032, Peoples R China; [Tang, Wei-Guo; Ren, Ning] Fudan Univ, Minhang Hosp, Dept Hepatobiliary & Pancreat Surg, Shanghai 201100, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University	Guo, L; Lu, RQ (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Clin Lab, Shanghai 200032, Peoples R China.; Guo, L; Lu, RQ (corresponding author), Fudan Univ, Shanghai Med Sch, Dept Oncol, Shanghai 200032, Peoples R China.; Ren, N (corresponding author), Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai 200032, Peoples R China.; Ren, N (corresponding author), Fudan Univ, Minhang Hosp, Dept Hepatobiliary & Pancreat Surg, Shanghai 201100, Peoples R China.	ren.ning@zs-hospital.sh.cn; guolin500@hotmail.com; renquanlu@fudan.edu.cn	wang, yixuan/GXW-2866-2022; Wang, Yijun/GXW-1763-2022; wang, yi/GVT-8516-2022; Wang, Yixuan/GZK-6559-2022; Wang, Yin/HCI-9352-2022; Wang, Yu/GZL-9655-2022	chen, yueda/0000-0002-0642-5312	National Natural Science Foundation of China [81772774, 82072876, 81772808, 81472672, 82002618, 81800190]; Program of scientific and technological innovation action plan, Shanghai Municipal Commission of science and technology [20XD1434200, 20Y11903500]; Shanghai International Science and Technology Collaboration Program [18410721900]; Shanghai Sailing Program [20YF1407900]; Shanghai Natural Science Foundation; Shanghai Municipal Commission of science and technology [19ZR1410300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of scientific and technological innovation action plan, Shanghai Municipal Commission of science and technology; Shanghai International Science and Technology Collaboration Program; Shanghai Sailing Program; Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); Shanghai Municipal Commission of science and technology	LR-Q was sponsored by National Natural Science Foundation of China (81772774, 82072876); Program of scientific and technological innovation action plan, Shanghai Municipal Commission of science and technology (20XD1434200, 20Y11903500). GL was sponsored by National Natural Science Foundation of China (81772808). RN was sponsored by the Shanghai International Science and Technology Collaboration Program (18410721900), and the National Natural Science Foundation of China (81472672). MX-L was sponsored by Shanghai Sailing Program (20YF1407900); National Natural Science Foundation of China (82002618). WY-C was sponsored by National Natural Science Foundation of China (81800190). ZH was sponsored by Shanghai Natural Science Foundation, Shanghai Municipal Commission of science and technology (19ZR1410300).	Ahn JC, 2021, HEPATOLOGY, V73, P422, DOI 10.1002/hep.31165; Baudry M, 2016, TRENDS NEUROSCI, V39, P235, DOI 10.1016/j.tins.2016.01.007; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Caruso S, 2019, GASTROENTEROLOGY, V157, P760, DOI 10.1053/j.gastro.2019.05.001; Chitalia VC, 2008, NAT CELL BIOL, V10, P1208, DOI 10.1038/ncb1781; Cortesio CL, 2008, J CELL BIOL, V180, P957, DOI 10.1083/jcb.200708048; Dong ZR, 2020, HEPATOLOGY, V72, P923, DOI 10.1002/hep.31076; Finn RS, 2021, HEPATOLOGY, V73, P150, DOI 10.1002/hep.31306; Gao Q, 2019, CELL, V179, P561, DOI 10.1016/j.cell.2019.08.052; Hu B, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.233; Jiang Y, 2019, NATURE, V567, P257, DOI 10.1038/s41586-019-0987-8; Kong FH, 2021, THERANOSTICS, V11, P5464, DOI 10.7150/thno.54822; Lee TKW, 2021, NAT REV GASTRO HEPAT, DOI 10.1038/s41575-021-00508-3; Lee WJ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03575-1; Leung HW, 2021, CANCER RES, V81, P3229, DOI 10.1158/0008-5472.CAN-21-0184; Lin JT, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118659; Liu L, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12588; Liu QH, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-020-01021-x; Liu Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0595-0; Lyle CL, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050498; Moro L, 2020, NAT CELL BIOL, V22, P1130, DOI 10.1038/s41556-020-0560-6; Ngan E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15059; Perugorria MJ, 2019, NAT REV GASTRO HEPAT, V16, P121, DOI 10.1038/s41575-018-0075-9; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Shao HS, 2006, MOL CELL BIOL, V26, P5481, DOI 10.1128/MCB.02243-05; Shen CP, 2012, PROTEOMICS, V12, P1917, DOI 10.1002/pmic.201200027; Song YZ, 2020, SEMIN CANCER BIOL, V67, P43, DOI 10.1016/j.semcancer.2020.02.001; Storr SJ, 2012, ANN ONCOL, V23, P2289, DOI 10.1093/annonc/mds176; Sun YF, 2013, HEPATOLOGY, V57, P1458, DOI 10.1002/hep.26151; Tai WT, 2016, HEPATOLOGY, V63, P1528, DOI 10.1002/hep.28478; Wang CW, 2020, GENOM PROTEOM BIOINF, V18, P72, DOI 10.1016/j.gpb.2020.01.001; Xie XQ, 2020, MOL THER-ONCOLYTICS, V17, P320, DOI 10.1016/j.omto.2020.04.003; Xu FK, 2019, INT J BIOL SCI, V15, P127, DOI 10.7150/ijbs.28834; Xue JF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7156; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017; Zhang YX, 2020, J CELL MOL MED, V24, P9125, DOI 10.1111/jcmm.15549; Zhu XD, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0794-6	38	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3554	3569		10.1038/s41388-022-02367-x	http://dx.doi.org/10.1038/s41388-022-02367-x		JUN 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35697802				2022-12-28	WOS:000810359900001
J	Gallardo, A; Molina, A; Asenjo, HG; Lopez-Onieva, L; Martorell-Marugan, J; Espinosa-Martinez, M; Grinan-Lison, C; Alvarez-Perez, JC; Cara, FE; Navarro-Marchal, SA; Carmona-Saez, P; Medina, PP; Marchal, JA; Granados-Principal, S; Sanchez-Pozo, A; Landeira, D				Gallardo, Amador; Molina, Aldara; Asenjo, Helena G.; Lopez-Onieva, Lourdes; Martorell-Marugan, Jordi; Espinosa-Martinez, Mencia; Grinan-Lison, Carmen; Carlos Alvarez-Perez, Juan; Cara, Francisca E.; Navarro-Marchal, Saul A.; Carmona-Saez, Pedro; Medina, Pedro P.; Antonio Marchal, Juan; Granados-Principal, Sergio; Sanchez-Pozo, Antonio; Landeira, David			EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization	ONCOGENE			English	Article							E-CADHERIN; POLYCOMB; TRANSCRIPTION; INHIBITION; EXPRESSION; REPRESSION; GENES; MUTATIONS; SUZ12	Reversible transition between the epithelial and mesenchymal states are key aspects of carcinoma cell dissemination and the metastatic disease, and thus, characterizing the molecular basis of the epithelial to mesenchymal transition (EMT) is crucial to find druggable targets and more effective therapeutic approaches in cancer. Emerging studies suggest that epigenetic regulators might endorse cancer cells with the cell plasticity required to conduct dynamic changes in cell state during EMT. However, epigenetic mechanisms involved remain mostly unknown. Polycomb Repressive Complexes (PRCs) proteins are well-established epigenetic regulators of development and stem cell differentiation, but their role in different cancer systems is inconsistent and sometimes paradoxical. In this study, we have analysed the role of the PRC2 protein EZH2 in lung carcinoma cells. We found that besides its described role in CDKN2A-dependent cell proliferation, EZH2 upholds the epithelial state of cancer cells by repressing the transcription of hundreds of mesenchymal genes. Chemical inhibition or genetic removal of EZH2 promotes the residence of cancer cells in the mesenchymal state during reversible epithelial-mesenchymal transition. In fitting, analysis of human patient samples and tumour xenograft models indicate that EZH2 is required to efficiently repress mesenchymal genes and facilitate tumour colonization in vivo. Overall, this study discloses a novel role of PRC2 as a master regulator of EMT in carcinoma cells. This finding has important implications for the design of therapies based on EZH2 inhibitors in human cancer patients.	[Gallardo, Amador; Molina, Aldara; Asenjo, Helena G.; Lopez-Onieva, Lourdes; Martorell-Marugan, Jordi; Espinosa-Martinez, Mencia; Grinan-Lison, Carmen; Carlos Alvarez-Perez, Juan; Cara, Francisca E.; Carmona-Saez, Pedro; Medina, Pedro P.; Granados-Principal, Sergio; Sanchez-Pozo, Antonio; Landeira, David] Ctr Genom & Oncol Res GENYO, Ave Ilustrac 114, Granada 18016, Spain; [Gallardo, Amador; Molina, Aldara; Asenjo, Helena G.; Espinosa-Martinez, Mencia; Granados-Principal, Sergio; Sanchez-Pozo, Antonio; Landeira, David] Univ Granada, Fac Pharm, Dept Biochem & Mol Biol 2, Granada, Spain; [Gallardo, Amador; Molina, Aldara; Asenjo, Helena G.; Lopez-Onieva, Lourdes; Espinosa-Martinez, Mencia; Grinan-Lison, Carmen; Carlos Alvarez-Perez, Juan; Navarro-Marchal, Saul A.; Medina, Pedro P.; Antonio Marchal, Juan; Granados-Principal, Sergio; Landeira, David] Inst Invest Biosanitaria Ibs GRANADA, Granada, Spain; [Lopez-Onieva, Lourdes; Carlos Alvarez-Perez, Juan; Medina, Pedro P.] Univ Granada, Fac Sci, Dept Biochem & Mol Biol 1, Granada, Spain; [Martorell-Marugan, Jordi; Carmona-Saez, Pedro] Univ Granada, Fac Sci, Dept Stat, Granada, Spain; [Martorell-Marugan, Jordi] Fdn Bruno Kessler, Data Sci Hlth Res Unit, Trento, Italy; [Grinan-Lison, Carmen] Complejo Hosp Jaen, UGC Oncol Med, Jaen 23007, Spain; [Navarro-Marchal, Saul A.] Univ Granada, Fac Sci, Dept Appl Phys, Granada 18071, Spain; [Navarro-Marchal, Saul A.; Antonio Marchal, Juan] Univ Granada, Ctr Biomed Res CIBM, Biopathol & Regenerat Med Inst IBIMER, Granada 18016, Spain; [Navarro-Marchal, Saul A.; Antonio Marchal, Juan] Univ Granada, Excellence Res Unit Modelling Nat MNat, Granada 18016, Spain; [Navarro-Marchal, Saul A.] Univ Edinburgh, Inst Genet & Canc, Canc Res UK Edinburgh Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; [Antonio Marchal, Juan] Univ Granada, Sch Med, Dept Human Anat & Embryol, Granada, Spain	University of Granada; Instituto de Investigacion Biosanitaria IBS Granada; University of Granada; University of Granada; Fondazione Bruno Kessler; Complejo Hospitalario de Jaen; University of Granada; University of Granada; University of Granada; University of Edinburgh; University of Granada	Landeira, D (corresponding author), Ctr Genom & Oncol Res GENYO, Ave Ilustrac 114, Granada 18016, Spain.; Landeira, D (corresponding author), Univ Granada, Fac Pharm, Dept Biochem & Mol Biol 2, Granada, Spain.; Landeira, D (corresponding author), Inst Invest Biosanitaria Ibs GRANADA, Granada, Spain.	davidlandeira@ugr.es	Landeira, David/ADY-5662-2022; Granados-Principal, Sergio/B-4987-2014; Martorell-Marugan, Jordi/M-5996-2019; Landeira, David/F-5001-2018; Navarro, Saul Abenhamar/B-7425-2016; Lopez Onieva, Lourdes/A-6475-2019; medina, pedro p./D-1688-2013	Granados-Principal, Sergio/0000-0001-8773-9489; Martorell-Marugan, Jordi/0000-0002-5186-0735; Landeira, David/0000-0002-3267-454X; Navarro, Saul Abenhamar/0000-0003-3508-6396; Lopez Onieva, Lourdes/0000-0001-5509-3804; medina, pedro p./0000-0002-7834-7093	Consejeria de Salud y Familias, Junta de Andalucia [RH-0139-2020]; Instituto de Salud Carlos III [CP19/00029, PI15/00336, PI19/01533]; MCIN/AEI/FEDER "Una manera de hacer Europa" [RTI2018.101309B-C22]; Chair "Doctors Galera-Requena in cancer stem cell research"; Ministerio de Ciencia e Innovacion [PID2020-119032RB-I00]; FEDER/Junta de Andalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades [P20_00335, B-CTS-40-UGR20]; Spanish ministry of science and innovation [PID2019-108108-100, EUR2021-122005]; Andalusian regional government [PC-0246-2017, PIER-0211-2019, PY20_00681]; University of Granada [A-BIO-6-UGR20]	Consejeria de Salud y Familias, Junta de Andalucia(Junta de Andalucia); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); MCIN/AEI/FEDER "Una manera de hacer Europa"; Chair "Doctors Galera-Requena in cancer stem cell research"; Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); FEDER/Junta de Andalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades; Spanish ministry of science and innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Andalusian regional government; University of Granada	CGL was funded by the Consejeria de Salud y Familias, Junta de Andalucia (RH-0139-2020) and SG-P is funded by Instituto de Salud Carlos III (CP19/00029, PI15/00336, PI19/01533). JAM is supported by RTI2018.101309B-C22 funded by MCIN/AEI/10.13039/501100011033/FEDER "Una manera de hacer Europa" and by the Chair "Doctors Galera-Requena in cancer stem cell research". PCS is funded by Ministerio de Ciencia e Innovacion (grant PID2020-119032RB-I00) and FEDER/Junta de Andalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades (grants P20_00335 and B-CTS-40-UGR20). The Landeira lab is supported by the Spanish ministry of science and innovation (PID2019-108108-100, EUR2021-122005), the Andalusian regional government (PC-0246-2017, PIER-0211-2019, PY20_00681) and the University of Granada (A-BIO-6-UGR20) grants.	Asenjo HG, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay4768; Awla D, 2012, J LEUKOCYTE BIOL, V91, P711, DOI 10.1189/jlb.0811443; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Fillmore CM, 2015, NATURE, V520, P239, DOI 10.1038/nature14122; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Fursova NA, 2019, MOL CELL, V74, P1020, DOI 10.1016/j.molcel.2019.03.024; Gallardo A, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.201900535; Gonzalez-Gonzalez A, 2018, CLIN CANCER RES, V24, P5697, DOI 10.1158/1078-0432.CCR-17-3125; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hardavella G, 2016, TRANSL LUNG CANCER R, V5, P272, DOI 10.21037/tlcr.2016.02.01; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Horibata S, 2015, JOVE-J VIS EXP, DOI 10.3791/52727; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Koppens M, 2016, ONCOGENE, V35, P1341, DOI 10.1038/onc.2015.195; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Landeira D, 2015, CELL REP, V12, P573, DOI 10.1016/j.celrep.2015.06.060; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Marasca F, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201700137; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007; Pattabiraman DR, 2016, SCIENCE, V351, P1042, DOI 10.1126/science.aad3680; Piunti A, 2021, NAT REV MOL CELL BIO, V22, P326, DOI 10.1038/s41580-021-00341-1; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Schuettengruber B, 2017, CELL, V171, P34, DOI 10.1016/j.cell.2017.08.002; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Serresi M, 2018, J EXP MED, V215, P3115, DOI 10.1084/jem.20180801; Serresi M, 2016, CANCER CELL, V29, P17, DOI 10.1016/j.ccell.2015.12.006; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tarazona S, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv711; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	57	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3611	3624		10.1038/s41388-022-02375-x	http://dx.doi.org/10.1038/s41388-022-02375-x		JUN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35680984				2022-12-28	WOS:000808419000002
J	Bernstock, JD; Kang, KD; Klinger, NV; Olsen, HE; Gary, S; Totsch, SK; Ghajar-Rahimi, G; Segar, D; Thompson, EM; Darley-Usmar, V; Mott, BT; Peruzzotti-Jametti, L; Friedman, GK				Bernstock, Joshua D.; Kang, Kyung-Don; Klinger, Neil, V; Olsen, Hannah E.; Gary, Sam; Totsch, Stacie K.; Ghajar-Rahimi, Gelare; Segar, David; Thompson, Eric M.; Darley-Usmar, Victor; Mott, Bryan T.; Peruzzotti-Jametti, Luca; Friedman, Gregory K.			Targeting oncometabolism to maximize immunotherapy in malignant brain tumors	ONCOGENE			English	Review							CENTRAL-NERVOUS-SYSTEM; REGULATORY T-CELLS; ADJUVANT TEMOZOLOMIDE; EMERGING HALLMARKS; GLIOBLASTOMA CELLS; IMMUNE RESISTANCE; POLY-ICLC; IN-VIVO; GLUCOSE; METABOLISM	Brain tumors result in significant morbidity and mortality in both children and adults. Recent data indicate that immunotherapies may offer a survival benefit after standard of care has failed for malignant brain tumors. Modest results from several late phase clinical trials, however, underscore the need for more refined, comprehensive strategies that incorporate new mechanistic and pharmacologic knowledge. Recently, oncometabolism has emerged as an adjunct modality for combinatorial treatment approaches necessitated by the aggressive, refractory nature of high-grade glioma and other progressive malignant brain tumors. Manipulation of metabolic processes in cancer and immune cells that comprise the tumor microenvironment through controlled targeting of oncogenic pathways may be utilized to maximize the efficacy of immunotherapy and improve patient outcomes. Herein, we summarize preclinical and early phase clinical trial research of oncometabolism-based therapeutics that may augment immunotherapy by exploiting the biochemical and genetic underpinnings of brain tumors. We also examine metabolic pathways related to immune cells that target tumor cells, termed "tumor immunometabolism". Specifically, we focus on glycolysis and altered glucose metabolism, including glucose transporters, hexokinase, pyruvate dehydrogenase, and lactate dehydrogenase, glutamine, and we discuss targeting arginase, adenosine, and indoleamine 2,3-dioxygenase, and toll-like receptors. Lastly, we summarize future directions targeting metabolism in combination with emerging therapies such as oncolytic virotherapy, vaccines, and chimeric antigen receptor T cells.	[Bernstock, Joshua D.; Klinger, Neil, V; Olsen, Hannah E.; Segar, David] Brigham & Womens Hosp, Harvard Med Sch, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA; [Kang, Kyung-Don; Totsch, Stacie K.; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA; [Gary, Sam; Ghajar-Rahimi, Gelare] Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL USA; [Thompson, Eric M.] Duke Univ, Dept Neurosurg, Durham, NC USA; [Darley-Usmar, Victor] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Mott, Bryan T.] Wake Forest Baptist Med Ctr, Dept Neurosurg, Winston Salem, NC USA; [Peruzzotti-Jametti, Luca] Univ Cambridge, Dept Clin Neurosci, Cambridge, England	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Duke University; University of Alabama System; University of Alabama Birmingham; Wake Forest University; Wake Forest Baptist Medical Center; University of Cambridge	Bernstock, JD (corresponding author), Brigham & Womens Hosp, Harvard Med Sch, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.; Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA.	jbernstock@partners.org; gfriedman@peds.uab.edu		Bernstock, Joshua/0000-0002-7814-3867; Ghajar-Rahimi, Gelare/0000-0001-5089-7176; Friedman, Gregory/0000-0002-6653-7420	U.S. Food and Drug Administration [R01FD005379, R01FD006368]; Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Andrew McDonough B+ Foundation; Cannonball Kids' cancer Foundation; FISM-Fondazione Italiana Sclerosi Multipla-cod [2017/B/5]; "5 per mille" public funding; Wellcome Trust CRCD Fellowship [RG G105713]; Addenbrooke's Charitable Trust [RG 97519]; Department of Defense [CA171067]; Musella Foundation for Brain Tumor Research and Information; Pediatric Brain Tumor Foundation	U.S. Food and Drug Administration; Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Andrew McDonough B+ Foundation; Cannonball Kids' cancer Foundation; FISM-Fondazione Italiana Sclerosi Multipla-cod(Fondazione Italiana Sclerosi Multipla (FISM)); "5 per mille" public funding; Wellcome Trust CRCD Fellowship(Wellcome Trust); Addenbrooke's Charitable Trust; Department of Defense(United States Department of Defense); Musella Foundation for Brain Tumor Research and Information; Pediatric Brain Tumor Foundation	GKF is supported by grants from the U.S. Food and Drug Administration (R01FD005379 and R01FD006368), the Rally Foundation for Childhood Cancer Research, Hyundai Hope on Wheels, Andrew McDonough B+ Foundation, and Cannonball Kids' cancer Foundation. LP-J has been supported by a senior research fellowship FISM-Fondazione Italiana Sclerosi Multipla-cod. 2017/B/5 and financed or co financed with the "5 per mille" public funding, a Wellcome Trust CRCD Fellowship (RG G105713), and the Addenbrooke's Charitable Trust (RG 97519). EMT is supported by the Department of Defense (CA171067), The Musella Foundation for Brain Tumor Research and Information, and the Pediatric Brain Tumor Foundation. We thank Adam A. Dmytriw for reviewing the manuscript.	Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; Bavaresco L, 2008, MOL CELL BIOCHEM, V319, P61, DOI 10.1007/s11010-008-9877-3; Bernstock JD, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1678921; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Bullen JW, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf0583; Bunse L, 2018, NAT MED, V24, P1192, DOI 10.1038/s41591-018-0095-6; Cascone T, 2018, CELL METAB, V27, P977, DOI 10.1016/j.cmet.2018.02.024; Certo M, 2021, NAT REV IMMUNOL, V21, P151, DOI 10.1038/s41577-020-0406-2; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Cohen KJ, 2011, NEURO-ONCOLOGY, V13, P317, DOI 10.1093/neuonc/noq191; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Cosset E, 2017, CANCER CELL, V32, P856, DOI 10.1016/j.ccell.2017.10.016; Crane CA, 2014, P NATL ACAD SCI USA, V111, P12823, DOI 10.1073/pnas.1413933111; Dang L, 2010, NATURE, V465, P966, DOI 10.1038/nature09132; DANIELE S, 2015, SCI REP-UK, V5; De Waele J, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1407899; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Flavahan WA, 2013, NAT NEUROSCI, V16, P1373, DOI 10.1038/nn.3510; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Friedman GK, 2021, NEW ENGL J MED, V384, P1613, DOI 10.1056/NEJMoa2024947; Galluzzi L, 2014, METHOD ENZYMOL, V542, pXIX, DOI 10.1016/B978-0-12-416618-9.10000-7; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031; Gielen PR, 2016, NEURO-ONCOLOGY, V18, P1253, DOI 10.1093/neuonc/now034; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Grzywa TM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00938; GUPTA S, 2017, CANCER RES, V77; Hanihara M, 2016, J NEUROSURG, V124, P1594, DOI 10.3171/2015.5.JNS141901; Hermans D, 2020, P NATL ACAD SCI USA, V117, P6047, DOI 10.1073/pnas.1920413117; Hill BG, 2020, BIOL CHEM, V401, P3, DOI 10.1515/hsz-2019-0268; Huang L, 2018, CELL MOL IMMUNOL, V15, P428, DOI 10.1038/cmi.2018.4; Jiang J, 2019, CANCERS, V11, DOI 10.3390/cancers11060804; Kareva I, 2013, CANCER RES, V73, P2737, DOI 10.1158/0008-5472.CAN-12-3696; Kathagen-Buhmann A, 2016, NEURO-ONCOLOGY, V18, P1219, DOI 10.1093/neuonc/now024; Kawalekar OU, 2016, IMMUNITY, V44, P380, DOI 10.1016/j.immuni.2016.01.021; Kees T, 2012, NEURO-ONCOLOGY, V14, P64, DOI 10.1093/neuonc/nor182; Kohanbash G, 2017, J CLIN INVEST, V127, P1425, DOI 10.1172/JCI90644; Krzak G, 2021, TRENDS IMMUNOL, V42, P45, DOI 10.1016/j.it.2020.11.004; Kuang R, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.88815; Kyi C, 2018, CLIN CANCER RES, V24, P4937, DOI 10.1158/1078-0432.CCR-17-1866; Le Calve B, 2010, NEOPLASIA, V12, P727, DOI 10.1593/neo.10526; Libby CJ, 2018, ACS CHEM BIOL, V13, P2048, DOI 10.1021/acschembio.8b00251; Libby CJ, 2018, BBA-REV CANCER, V1869, P175, DOI 10.1016/j.bbcan.2018.01.004; Lin H, 2017, NEURO-ONCOLOGY, V19, P43, DOI 10.1093/neuonc/now128; Liu FK, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-019-1085-6; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; McBrayer SK, 2018, CELL, V175, P101, DOI 10.1016/j.cell.2018.08.038; Mehta MM, 2018, CANCER METAB, V6, DOI 10.1186/s40170-018-0184-5; Mellinghoff I, 2018, NEURO-ONCOLOGY, V20, P234; Metz R, 2012, ONCOIMMUNOLOGY, V1, P1460, DOI 10.4161/onci.21716; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Mitsuka K, 2013, NEUROSURGERY, V72, P1031, DOI 10.1227/NEU.0b013e31828cf945; Moesta AK, 2020, NAT REV IMMUNOL, V20, P739, DOI 10.1038/s41577-020-0376-4; Moon YW, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0094-9; Mooney J, 2019, WORLD NEUROSURG, V129, P90, DOI 10.1016/j.wneu.2019.05.205; Muller S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98791; Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002; Nayak L, 2021, CLIN CANCER RES, V27, P1048, DOI 10.1158/1078-0432.CCR-20-2500; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Ohta A, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00304; Olsen Hannah E, 2021, Neurooncol Adv, V3, pvdab027, DOI 10.1093/noajnl/vdab027; Oshima N, 2020, CELL REP, V30, P1798, DOI 10.1016/j.celrep.2020.01.039; Ostrom Quinn T, 2019, Neuro Oncol, V21, pv1, DOI 10.1093/neuonc/noz150; Ott M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134386; PAPADOPOULOS KP, 2017, J CLIN ONCOL, V35; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; PEREZ RP, 2017, J CLIN ONCOL, V35; Pollack IF, 2016, NEURO-ONCOLOGY, V18, P1157, DOI 10.1093/neuonc/now026; Rai G, 2020, J MED CHEM, V63, P10984, DOI 10.1021/acs.jmedchem.0c00916; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Reardon DA, 2020, JAMA ONCOL, V6, P1003, DOI 10.1001/jamaoncol.2020.1024; Reinfeld BI, 2021, NATURE, V593, P282, DOI 10.1038/s41586-021-03442-1; Rogers TW, 2018, J NEURO-ONCOL, V137, P181, DOI 10.1007/s11060-017-2710-7; Rosenfeld MR, 2010, NEURO-ONCOLOGY, V12, P1071, DOI 10.1093/neuonc/noq071; Sanzey M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123544; Sciacovelli M, 2017, CELL DEATH DIFFER, V24, P1, DOI 10.1038/cdd.2016.137; Shen H, 2015, MOL CANCER THER, V14, P1794, DOI 10.1158/1535-7163.MCT-15-0247; Sheth S, 2014, INT J MOL SCI, V15, P2024, DOI 10.3390/ijms15022024; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Siu L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001095; Steggerda SM, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0308-4; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tejera Dalissa, 2020, CNS Oncol, V9, pCNS62, DOI 10.2217/cns-2020-0014; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Totsch SK, 2019, ONCOGENE, V38, P6159, DOI 10.1038/s41388-019-0870-y; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Velpula KK, 2017, ONCOTARGET, V8, P35639, DOI 10.18632/oncotarget.16767; Wainwright DA, 2012, CLIN CANCER RES, V18, P6110, DOI 10.1158/1078-0432.CCR-12-2130; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Wicks RT, 2015, NEURO-ONCOLOGY, V17, P70, DOI 10.1093/neuonc/nou143; Wu JY, 2020, MOL CELL, V77, P213, DOI 10.1016/j.molcel.2019.10.023; Xu S, 2013, NEURO-ONCOLOGY, V15, P1160, DOI 10.1093/neuonc/not067; Yan A, 2019, J NEUROSCI, V39, P4387, DOI 10.1523/JNEUROSCI.1118-18.2019; Yuen Carlen A, 2016, CNS Oncol, V5, P101, DOI 10.2217/cns-2015-0006; Zappasodi R, 2021, NATURE, V591, P652, DOI 10.1038/s41586-021-03326-4; Zhai LJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01185; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; Zhou WH, 2019, CANCERS, V11, DOI 10.3390/cancers11091231; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	105	3	3	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2663	2671		10.1038/s41388-022-02312-y	http://dx.doi.org/10.1038/s41388-022-02312-y		APR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35430605	Green Accepted			2022-12-28	WOS:000782888200001
J	Zhang, X; Zheng, SY; Hu, CH; Li, GL; Lin, HC; Xia, RP; Ye, YC; He, RH; Li, ZH; Lin, Q; Chen, RF; Zhou, QB				Zhang, Xiang; Zheng, Shangyou; Hu, Chonghui; Li, Guolin; Lin, Hongcao; Xia, Renpeng; Ye, Yuancheng; He, Rihua; Li, Zhihua; Lin, Qing; Chen, Rufu; Zhou, Quanbo			Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair	ONCOGENE			English	Article							CISPLATIN RESISTANCE; TUMOR; CHEMORESISTANCE; CELLS; CHEMOTHERAPY; INHIBITION; EXPRESSION; PATHWAY; END	The tumor stroma of pancreatic ductal adenocarcinoma (PDAC) is characterized by an abundant and heterogeneous population of cancer-associated fibroblasts (CAFs), which are critically involved in chemoresistance. However, the underlying mechanism of CAFs in chemoresistance is unclear. Here, we show that CAF(R), a CAF subset derived from platinum-resistant PDAC patients, assumes an iCAF phenotype and produces more IL8 than CAF(S) isolated from platinum-sensitive PDAC patients. CAF(R)-derived IL8 promotes oxaliplatin chemoresistance in PDAC. Based on long noncoding RNA (lncRNA) profiling in tumor cells incubated with CAF-CM, we found that UPK1A-AS1, whose expression is directly induced by IL8/NF-kappa B signaling, functions as a chemoresistance-promoting lncRNA and is critical for active IL8-induced oxaliplatin resistance. Impressively, blocking the activation of UPK1A-AS1 expression increases the oxaliplatin sensitivity of tumor cells in vivo. Mechanistically, UPK1A-AS1 strengthens the interaction between Ku70 and Ku80 to facilitate nonhomologous end joining (NHEJ), thereby enhancing DNA double-strand break (DSB) repair. Clinically, UPK1A-AS1 expression is positively correlated with IL8 expression, a poor chemotherapeutic response and a shorter progression-free survival (PFS) time in advanced PDAC patients. Collectively, our study reveals a lncRNA-mediated mechanism of CAF-derived paracrine IL8-dependent oxaliplatin resistance and highlights UPK1A-AS1 as a potential therapeutic target.	[Zhang, Xiang; Li, Zhihua; Zhou, Quanbo] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China; [Zhang, Xiang; Zhou, Quanbo] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pancreatobiliary Surg, Guangzhou 510120, Guangdong, Peoples R China; [Zheng, Shangyou; Hu, Chonghui; Xia, Renpeng; Ye, Yuancheng; He, Rihua; Lin, Qing; Chen, Rufu] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Pancreas Ctr, Dept Gen Surg, Guangzhou 510080, Guangdong, Peoples R China; [Zheng, Shangyou; Ye, Yuancheng; Lin, Qing; Chen, Rufu] Southern Med Univ, Sch Clin Med 2, Guangzhou 510515, Guangdong, Peoples R China; [Hu, Chonghui; Chen, Rufu] Guangdong Cardiovasc Inst, Guangzhou 510080, Guangdong, Peoples R China; [Li, Guolin] Sun Yat Sen Univ, Dept Hepatobiliary Pancreat & Splen Surg, Affiliated Hosp 6, Guangzhou 510655, Guangdong, Peoples R China; [Lin, Hongcao] Sun Yat Sen Univ, Gen Surg Shenshan Med Ctr, Mem Hosp, Shanwei 516600, Guangdong, Peoples R China; [Xia, Renpeng] Hunan Childrens Hosp, Dept Neonatal Gen Surg, Changsha 410007, Hunan, Peoples R China; [Li, Zhihua] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, Guangzhou 510120, Guangdong, Peoples R China; [Lin, Qing; Chen, Rufu] South China Univ Technol, Sch Med, Guangzhou 510006, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; South China University of Technology	Zhou, QB (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China.; Zhou, QB (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pancreatobiliary Surg, Guangzhou 510120, Guangdong, Peoples R China.; Lin, Q; Chen, RF (corresponding author), Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Pancreas Ctr, Dept Gen Surg, Guangzhou 510080, Guangdong, Peoples R China.; Lin, Q; Chen, RF (corresponding author), Southern Med Univ, Sch Clin Med 2, Guangzhou 510515, Guangdong, Peoples R China.; Chen, RF (corresponding author), Guangdong Cardiovasc Inst, Guangzhou 510080, Guangdong, Peoples R China.; Lin, Q; Chen, RF (corresponding author), South China Univ Technol, Sch Med, Guangzhou 510006, Guangdong, Peoples R China.	gzhorse@163.com; chenrufu@mail.sysu.edu; zhouqbo@mail.sysu.edu.cn		Zhang, Xiang/0000-0002-7144-1933	National Natural Science Foundation of China [82073149, 81871945, 82072639]; Guangdong Science and Technology Department [2020B1212060018]; National Key R&D Program of China [2017YFC1308600]; Special Fund of "Dengfeng Plan" of Guangdong Provincial People's Hospital, China [KJ012019509, DFJH2020027]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Science and Technology Department; National Key R&D Program of China; Special Fund of "Dengfeng Plan" of Guangdong Provincial People's Hospital, China	This study was supported by grants from the National Natural Science Foundation of China (grant number 82073149, 81871945, 82072639), the Guangdong Science and Technology Department (grant number 2021A1515011089), and the National Key R&D Program of China (grant number 2017YFC1308600), the Special Fund of "Dengfeng Plan" of Guangdong Provincial People's Hospital, China (KJ012019509, DFJH2020027), the Guangdong Science and Technology Department (grant number 2020B1212060018).	Biffi G, 2021, PHYSIOL REV, V101, P147, DOI 10.1152/physrev.00048.2019; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Byun Y, 2020, MOL CELLS, V43, P975, DOI 10.14348/molcells.2020.0126; Causse SZ, 2019, ONCOGENE, V38, P2767, DOI 10.1038/s41388-018-0616-2; Ding J, 2020, HEPATOLOGY, V72, P1666, DOI 10.1002/hep.31195; Dominguez CX, 2020, CANCER DISCOV, V10, P232, DOI 10.1158/2159-8290.CD-19-0644; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Fan LL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2405-4; Fell VL, 2015, MUTAT RES-REV MUTAT, V763, P15, DOI 10.1016/j.mrrev.2014.06.002; Feng HR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03111-7; Golan T, 2014, BRIT J CANCER, V111, P1132, DOI 10.1038/bjc.2014.418; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Grossberg AJ, 2020, CA-CANCER J CLIN, V70, P375, DOI 10.3322/caac.21626; Diaz-Maroto NG, 2019, CLIN CANCER RES, V25, P4466, DOI 10.1158/1078-0432.CCR-18-3957; Guo XF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01196-4; Haemmig S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw1868; Ham IH, 2021, CANCERS, V13, DOI 10.3390/cancers13051172; Hato SV, 2014, CLIN CANCER RES, V20, P2831, DOI 10.1158/1078-0432.CCR-13-3141; Hirata E, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026781; Ho WJ, 2020, NAT REV CLIN ONCOL, V17, P527, DOI 10.1038/s41571-020-0363-5; Hosein AN, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129212; Hustinx SR, 2005, CANCER BIOL THER, V4, P83, DOI 10.4161/cbt.4.1.1380; Kobayashi H, 2019, NAT REV GASTRO HEPAT, V16, P282, DOI 10.1038/s41575-019-0115-0; Li BR, 2021, ONCOGENE, V40, P4686, DOI 10.1038/s41388-021-01870-x; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Melisi D, 2011, JNCI-J NATL CANCER I, V103, P1190, DOI 10.1093/jnci/djr243; Milosevic V, 2020, INT J CANCER, V146, P192, DOI 10.1002/ijc.32419; Moffitt RA, 2015, NAT GENET, V47, P1168, DOI 10.1038/ng.3398; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Ohuchida K, 2004, CANCER RES, V64, P3215, DOI 10.1158/0008-5472.CAN-03-2464; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Park W, 2021, JAMA-J AM MED ASSOC, V326, P851, DOI 10.1001/jama.2021.13027; Reiss KA, 2021, J CLIN ONCOL, V39, P2497, DOI 10.1200/JCO.21.00003; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Srivastava M, 2012, CELL, V151, P1474, DOI 10.1016/j.cell.2012.11.054; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Su D, 2020, THERANOSTICS, V10, P5029, DOI 10.7150/thno.42440; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Thakur B, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0636-8; Thapar R, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkaa1233; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Unfried JP, 2021, CANCER RES, V81, P4910, DOI 10.1158/0008-5472.CAN-21-0463; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang BS, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01684-x; Wang D, 2020, CELL DEATH DIFFER, V27, P3337, DOI 10.1038/s41418-020-0581-5; Wang W., 2021, NAT COMMUN, V12; Wang WM, 2016, CELL, V165, P1092, DOI 10.1016/j.cell.2016.04.009; Wattenberg MM, 2020, BRIT J CANCER, V122, P333, DOI 10.1038/s41416-019-0582-7; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Wei LS, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03574-2; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xie WK, 2022, SEMIN CANCER BIOL, V83, P303, DOI 10.1016/j.semcancer.2020.11.004; Yin F, 2020, ONCOTARGETS THER, V13, P2689, DOI 10.2147/OTT.S234924; Zhai J, 2019, CANCER LETT, V454, P37, DOI 10.1016/j.canlet.2019.04.002; Zhang DY, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01748-y; Zhao BL, 2020, NAT REV MOL CELL BIO, V21, P765, DOI 10.1038/s41580-020-00297-8; Zhu YX, 2020, CELL MOL GASTROENTER, V10, P811, DOI 10.1016/j.jcmgh.2020.06.009	60	4	4	5	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2372	2389		10.1038/s41388-022-02253-6	http://dx.doi.org/10.1038/s41388-022-02253-6		MAR 2022	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35264742	Green Published, hybrid			2022-12-28	WOS:000766524200001
J	Teoh, PJ; An, O; Chung, TH; Vaiyapuri, T; Raju, A; Hoppe, MM; Toh, SHM; Wang, W; Chan, MC; Fullwood, MJ; Jeyasekharan, AD; Tergaonkar, V; Chen, LL; Yang, H; Chng, WJ				Teoh, Phaik Ju; An, Omer; Chung, Tae-Hoon; Vaiyapuri, Thamil; Raju, Anandhkumar; Hoppe, Michal M.; Toh, Sabrina H. M.; Wang, Wilson; Chan, Ming Chun; Fullwood, Melissa J.; Jeyasekharan, Anand D.; Tergaonkar, Vinay; Chen, Leilei; Yang, Henry; Chng, Wee Joo			p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain)	ONCOGENE			English	Article							CHECKPOINT KINASE INHIBITOR; DNA-REPAIR; PLASMA-CELLS; DEXAMETHASONE; AZD7762; CANCER; DAMAGE; LENALIDOMIDE; CARFILZOMIB; MECHANISMS	Recurrent cytogenetic abnormalities are the main hallmark of multiple myeloma (MM) and patients having 2 or more high-risk prognostic events are associated with extremely poor outcome. 17p13(del) and 1q21(gain) are critical and independent high-risk cytogenetic markers, however, the biological significance underlying the poor outcome in MM patients having co-occurrence of both these chromosomal aberrations has never been interrogated. Herein, we identified that patients harbouring concomitant 17p13(del) with 1q21(gain) demonstrated the worst prognosis as compared to patients with single- (either 17p13(del) or 1q21(gain)) and with no chromosomal events (WT for both chromosomal loci); and they are highly enriched for genomic instability (GI) signature. We discovered that the GI feature in the patients with concomitant 17p13(del)-1q21(gain) was recapitulating the biological properties of myeloma cells with co-existing p53-deficiency and NEIL1 mRNA-hyper-editing (associated with chromosome 17p and 1q, respectively) that have inherent DNA damage response (DDR) and persistent activation of Chk1 pathway. Importantly, this became a vulnerable point for therapeutic targeting whereby the cells with this co-abnormalities demonstrated hyper-sensitivity to siRNA- and pharmacological-mediated-Chk1 inhibition, as observed at both the in vitro and in vivo levels. Mechanistically, this was attributable to the synthetic lethal relationship between p53-NEIL1-Chk1 abnormalities. The Chk1 inhibitor (AZD7762) tested showed good synergism with standard-of-care myeloma drugs, velcade and melphalan, thus further reinforcing the translational potential of this therapeutic approach. In summary, combination of NEIL1-p53 abnormalities with an ensuing Chk1 activation could serve as an Achilles heel and predispose MM cells with co-existing 1q21(gain) and 17p13(del) to therapeutic vulnerability for Chk1 inhibition.	[Teoh, Phaik Ju; Jeyasekharan, Anand D.; Chng, Wee Joo] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore; [Teoh, Phaik Ju; An, Omer; Chung, Tae-Hoon; Hoppe, Michal M.; Toh, Sabrina H. M.; Fullwood, Melissa J.; Jeyasekharan, Anand D.; Chen, Leilei; Yang, Henry; Chng, Wee Joo] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Vaiyapuri, Thamil; Raju, Anandhkumar; Tergaonkar, Vinay] ASTAR, Inst Mol & Cell Biol IMCB, Singapore, Singapore; [Wang, Wilson; Chan, Ming Chun] Natl Univ Singapore Hosp, Dept Orthopaed Surg, Singapore, Singapore; [Wang, Wilson; Chan, Ming Chun] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Orthopaed Surg, Singapore, Singapore; [Jeyasekharan, Anand D.; Chng, Wee Joo] Natl Univ Canc Inst, Singapore, Singapore; [Jeyasekharan, Anand D.; Chng, Wee Joo] Natl Univ Hlth Syst, Dept Haematol Oncol, Natl Univ Canc Inst Singapore, Singapore, Singapore	National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore	Teoh, PJ (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.; Teoh, PJ (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.	mdctpju@nus.edu.sg	wang, wilson/GYD-5657-2022	Teoh, Phaik Ju/0000-0001-8350-1641; Hoppe, Michal Marek/0000-0002-0364-6080	Ministry of Education of Singapore [MOE2019-T2-1-083]; NMRC OF-YIRG grant [NMRC/OFYIRG/032/201700]	Ministry of Education of Singapore(Ministry of Education, Singapore); NMRC OF-YIRG grant	This study was funded by Tier 2 grant provided by the Ministry of Education of Singapore (MOE2019-T2-1-083) and NMRC OF-YIRG grant (NMRC/OFYIRG/032/201700). We would like to thank Pamela Chng for helping out with tissue culture and functional assays, Y.F. Goh, J.Q. Thng and W.N. Fam for helping with the processing and isolation of normal CD138 + plasma cells from healthy volunteers' samples and M.Y. Koh for assisting in lentivirus work.	Agnelli L, 2013, EXPERT OPIN BIOL TH, V13, pS55, DOI 10.1517/14712598.2013.793305; Avet-Loiseau H, 2010, J CLIN ONCOL, V28, P4630, DOI 10.1200/JCO.2010.28.3945; Herrero AB, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00098; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Bolli N, 2018, LEUKEMIA, V32, P2604, DOI 10.1038/s41375-018-0037-9; Boyd KD, 2012, LEUKEMIA, V26, P349, DOI 10.1038/leu.2011.204; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Chang H, 2011, LEUKEMIA RES, V35, P95, DOI 10.1016/j.leukres.2010.05.002; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Chng WJ, 2011, LEUKEMIA, V25, P1026, DOI 10.1038/leu.2011.53; Chung TH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066361; Cottini F, 2015, CANCER DISCOV, V5, P972, DOI 10.1158/2159-8290.CD-14-0943; Dimopoulos MA, 2010, LEUKEMIA, V24, P1769, DOI 10.1038/leu.2010.175; Eischen CM, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026096; Fonseca R, 2009, LEUKEMIA, V23, P2210, DOI 10.1038/leu.2009.174; Gkotzamanidou M, 2016, BLOOD, V128, P1214, DOI 10.1182/blood-2016-01-691618; Gourzones-Dmitriev C, 2013, CELL CYCLE, V12, P2760, DOI 10.4161/cc.25951; Gu CY, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01380-0; Hao SY, 2021, MODERN PATHOL, V34, P327, DOI 10.1038/s41379-020-00669-7; Hayden PJ, 2007, HUM MOL GENET, V16, P3117, DOI 10.1093/hmg/ddm273; Herrero AB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122003; Herrero AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121581; Jakubowiak AJ, 2013, LEUKEMIA, V27, P2351, DOI 10.1038/leu.2013.152; Janz S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00424; Kawasumi M, 2014, CANCER RES, V74, P7534, DOI 10.1158/0008-5472.CAN-14-2650; Kumar SK, 2019, CANCER J, V25, P59, DOI 10.1097/PPO.0000000000000353; Landau HJ, 2012, MOL CANCER THER, V11, P1781, DOI 10.1158/1535-7163.MCT-11-0949; Lazzari E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01890-w; Ma ZK, 2012, MOL MED REP, V6, P897, DOI 10.3892/mmr.2012.999; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Neri P, 2013, EXPERT OPIN BIOL TH, V13, pS69, DOI 10.1517/14712598.2013.814637; Neri P, 2011, BLOOD, V118, P6368, DOI 10.1182/blood-2011-06-363911; Qiu ZJ, 2018, RADIOTHER ONCOL, V126, P450, DOI 10.1016/j.radonc.2017.09.043; Ray A, 2016, BRIT J HAEMATOL, V174, P397, DOI 10.1111/bjh.14065; Rundle S, 2017, CANCERS, V9, DOI 10.3390/cancers9050041; Schmidt TM, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00474-8; Shah V, 2018, LEUKEMIA, V32, P102, DOI 10.1038/leu.2017.179; Shammas MA, 2009, BLOOD, V113, P2290, DOI 10.1182/blood-2007-05-089193; Sonneveld P, 2016, HAEMATOLOGICA, V101, P396, DOI 10.3324/haematol.2015.129189; Sousa MML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055493; Stewart AK, 2015, NEW ENGL J MED, V372, P142, DOI 10.1056/NEJMoa1411321; Tembhare P, 2012, LEUKEMIA LYMPHOMA, V53, P721, DOI 10.3109/10428194.2011.623257; Teoh PJ, 2021, LEUKEMIA, V35, P346, DOI 10.1038/s41375-020-01076-2; Teoh PJ, 2020, HAEMATOLOGICA, V105, P1391, DOI 10.3324/haematol.2019.221176; Teoh PJ, 2018, BLOOD, V132, P1304, DOI 10.1182/blood-2018-02-832576; Walker BA, 2019, LEUKEMIA, V33, P159, DOI 10.1038/s41375-018-0196-8; Yan, 2014, LEUKEMIA, V14, P102; Yang CG, 2009, CHEMBIOCHEM, V10, P417, DOI 10.1002/cbic.200800580; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492	51	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2106	2121		10.1038/s41388-022-02227-8	http://dx.doi.org/10.1038/s41388-022-02227-8		FEB 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35190641				2022-12-28	WOS:000758960300001
J	Wu, HZ; Ding, XY; Hu, XY; Zhao, Q; Chen, QC; Sun, T; Li, YL; Guo, H; Li, M; Gao, ZM; Yao, WF; Zhao, L; Li, K; Wei, MJ				Wu, Huizhe; Ding, Xiangyu; Hu, Xiaoyun; Zhao, Qing; Chen, Qiuchen; Sun, Tong; Li, Yalun; Guo, Hao; Li, Meng; Gao, Ziming; Yao, Weifan; Zhao, Lin; Li, Kai; Wei, Minjie			LINC01021 maintains tumorigenicity by enhancing N6-methyladenosine reader IMP2 dependent stabilization of MSX1 and JARID2: implication in colorectal cancer	ONCOGENE			English	Article							RNA-BINDING PROTEINS; M(6)A MODIFICATION; MESSENGER-RNA; NONCODING RNAS; METHYLATION; CROSSTALK; ROLES	Insulin-like growth factor-2 mRNA-binding protein 2 (IGF2BP2, also known as IMP2), a novel class III N6-methyladenosine (m(6)A) reader, has recently gained attention due to its critical functions in recognizing and stabilizing m(6)A modified oncogenic transcripts. However, whether and how long non-coding RNAs (lncRNAs) facilitate IMP2's role as m(6)A "reader" remains elusive, particularly in colorectal cancer (CRC). Here, we demonstrated that oncogenic LINC021 specifically bound with the m(6)A "reader" IMP2 protein and enhanced the mRNA stability of MSX1 and JARID2 in an m(6)A regulatory manner during CRC tumorigenesis and pathogenesis. Specifically, a remarkable upregulation of LINC021 was confirmed in CRC cell lines and clinical tissues (n = 130). High level of LINC021acted as an independent prognostic predictor for CRC clinical outcomes. Functional assays demonstrated that LINC021 exerted its functions as an oncogene to aggravate CRC malignant phenotypes including enhanced cell proliferation, colony formation, migration capabilities, and reduced cell apoptosis. Mechanistically, LINC021 directly recognized IMP2 protein, the latter enhanced the mRNA stability of transcripts such as MSX1 and JARID2 by recognizing their m(6)A-modified element RGGAC. Thus, these findings uncovered an essential LINC021/IMP2/MSX1 and JARID2 signaling axis in CRC tumorigenesis, which provided profound insights into our understanding of m(6)A modification regulated by lncRNA in CRC initiation and progression and shed light on the targeting of this axis for CRC treatment.	[Wu, Huizhe; Ding, Xiangyu; Hu, Xiaoyun; Zhao, Qing; Chen, Qiuchen; Sun, Tong; Guo, Hao; Li, Meng; Yao, Weifan; Zhao, Lin; Wei, Minjie] China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang 110122, Peoples R China; [Wu, Huizhe; Ding, Xiangyu; Hu, Xiaoyun; Zhao, Qing; Chen, Qiuchen; Sun, Tong; Guo, Hao; Li, Meng; Yao, Weifan; Zhao, Lin; Wei, Minjie] China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang 110122, Peoples R China; [Wu, Huizhe; Ding, Xiangyu; Hu, Xiaoyun; Zhao, Qing; Chen, Qiuchen; Sun, Tong; Guo, Hao; Li, Meng; Yao, Weifan; Zhao, Lin; Wei, Minjie] China Med Univ, Liaoning Canc Immune Peptide Drug Engn Technol Re, Shenyang 110122, Peoples R China; [Wu, Huizhe; Ding, Xiangyu; Hu, Xiaoyun; Zhao, Qing; Chen, Qiuchen; Sun, Tong; Guo, Hao; Li, Meng; Yao, Weifan; Zhao, Lin; Wei, Minjie] China Med Univ, Ctr Key Lab Precis Diag & Treatment Gastrointesti, Minist Educ, Shenyang 110122, Peoples R China; [Li, Yalun] China Med Univ, Affiliated Hosp 1, Dept Anorectal Surg, Shenyang 110001, Peoples R China; [Gao, Ziming; Li, Kai] China Med Univ, Affiliated Hosp 1, Dept Surg Oncol & Gen Surg, Minist Educ,Key Lab Precis Diag & Treatment Gastr, Shenyang 110001, Peoples R China; [Wei, Minjie] Liaoning Med Diag & Treatment Ctr, Shenyang, Peoples R China	China Medical University; China Medical University; China Medical University; China Medical University; China Medical University; China Medical University	Wei, MJ (corresponding author), China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang 110122, Peoples R China.; Wei, MJ (corresponding author), China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang 110122, Peoples R China.; Wei, MJ (corresponding author), China Med Univ, Liaoning Canc Immune Peptide Drug Engn Technol Re, Shenyang 110122, Peoples R China.; Wei, MJ (corresponding author), China Med Univ, Ctr Key Lab Precis Diag & Treatment Gastrointesti, Minist Educ, Shenyang 110122, Peoples R China.; Li, K (corresponding author), China Med Univ, Affiliated Hosp 1, Dept Surg Oncol & Gen Surg, Minist Educ,Key Lab Precis Diag & Treatment Gastr, Shenyang 110001, Peoples R China.; Wei, MJ (corresponding author), Liaoning Med Diag & Treatment Ctr, Shenyang, Peoples R China.	cmu_likai@163.com; mjwei@cmu.edu.cn	Hu, Xiao/GQI-0007-2022	Hu, Xiao/0000-0003-1128-4099	National Natural Science Foundation of China [81872905, 82073884]; Science and Technology Innovative Foundation for Young and Middle-aged Scientists of Shenyang City [RC200382]; Shenyang High Level Talent Innovation and Entrepreneurship Team [2019-SYRCCY-B-01]; Major Special S&T Projects in Liaoning Province [2019JH1/10300005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Innovative Foundation for Young and Middle-aged Scientists of Shenyang City; Shenyang High Level Talent Innovation and Entrepreneurship Team; Major Special S&T Projects in Liaoning Province	This work was supported by grants from the National Natural Science Foundation of China (81872905, 82073884), Science and Technology Innovative Foundation for Young and Middle-aged Scientists of Shenyang City (RC200382), Shenyang High Level Talent Innovation and Entrepreneurship Team (2019-SYRCCY-B-01), and Major Special S&T Projects in Liaoning Province [2019JH1/10300005].	Adhikari A, 2019, J BIOL CHEM, V294, P19451, DOI 10.1074/jbc.RA119.010060; Ban YY, 2020, MOL ONCOL, V14, P1282, DOI 10.1002/1878-0261.12676; Chatterji P, 2018, TRENDS MOL MED, V24, P490, DOI 10.1016/j.molmed.2018.03.008; Dai FS, 2020, MOL THER-NUCL ACIDS, V22, P62, DOI 10.1016/j.omtn.2020.08.004; Degrauwe N, 2016, GENE DEV, V30, P2459, DOI 10.1101/gad.287540.116; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; Ferre F, 2016, BRIEF BIOINFORM, V17, P106, DOI 10.1093/bib/bbv031; Francescangeli F, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122936; He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9; Heppt MV, 2018, J INVEST DERMATOL, V138, P141, DOI 10.1016/j.jid.2017.05.038; Hou PF, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01857-2; Hu XG, 2020, CELL DEATH DIFFER, V27, P1782, DOI 10.1038/s41418-019-0461-z; Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Hunten S, 2015, MOL CELL PROTEOMICS, V14, P2609, DOI 10.1074/mcp.M115.050237; Khan RIN, 2021, GENOMICS, V113, P2860, DOI 10.1016/j.ygeno.2021.06.013; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Liu HM, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02833-y; Lu SX, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01204-0; Ma S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0805-7; Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197; Meyer J, 2019, CLIN GASTROENTEROL H, V17, P1448, DOI 10.1016/j.cgh.2018.07.031; Muller S, 2019, NUCLEIC ACIDS RES, V47, P375, DOI 10.1093/nar/gky1012; Ni W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1079-y; Qu F, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.645823; Roignant JY, 2017, TRENDS GENET, V33, P380, DOI 10.1016/j.tig.2017.04.003; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Tong JY, 2018, FRONT MED-PRC, V12, P481, DOI 10.1007/s11684-018-0654-8; Wang LY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225758; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang TY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01204-7; Wang YL, 2020, THERANOSTICS, V10, P9407, DOI 10.7150/thno.48520; Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0; Xiang Y, 2017, NATURE, V543, P573, DOI 10.1038/nature21671; Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8; Yi YC, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01233-2; Zaccara S, 2020, CELL, V181, P1582, DOI 10.1016/j.cell.2020.05.012; Zhang J., 2020, CELL DEATH DIS, V11; Zhang YH, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01706-8; Zhao W, 2020, MOL THER-NUCL ACIDS, V19, P405, DOI 10.1016/j.omtn.2019.11.022; Zhao YC, 2021, THERANOSTICS, V11, P4549, DOI 10.7150/thno.54967; Zhou B, 2021, CANCER LETT, V497, P89, DOI 10.1016/j.canlet.2020.10.002; Zhou DJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16777-6; Zhou ZJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01216-3; Zhu PP, 2021, ONCOGENE, V40, P1609, DOI 10.1038/s41388-020-01638-9	46	3	3	5	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1959	1973		10.1038/s41388-022-02189-x	http://dx.doi.org/10.1038/s41388-022-02189-x		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35173309				2022-12-28	WOS:000756457400001
J	Hong, SY; Lu, YC; Hsiao, SH; Kao, YR; Lee, MH; Lin, YP; Wang, CY; Wu, CW				Hong, Shiao-Ya; Lu, Yi-Chun; Hsiao, Shih-Hsin; Kao, Yu-Rung; Lee, Meng-Hsuan; Lin, Yi-Ping; Wang, Cheng-Yi; Wu, Cheng-Wen			Stabilization of AURKA by the E3 ubiquitin ligase CBLC in lung adenocarcinoma	ONCOGENE			English	Article							AURORA-A KINASE; FAMILY; GROWTH	CBL family proteins (CBL, CBLB and CBLC in mammals) are E3 ubiquitin ligases of protein tyrosine kinases. CBL mediates the lysosomal degradation of activated EGFR through K63-linked ubiquitination, while CBLC has an oncogenic function by positively regulating EGFR activation through K6 and K11-linked ubiquitination in EGFR mutant lung adenocarcinoma (LAD). Here, we used immunoprecipitation and mass spectrometry to study the CBLC interactome, and found that CBLC is also involved in cell cycle regulation by stabilizing Aurora kinase A (AURKA). CBLC interacted with the kinase domain of AURKA and positively regulated the stability of AURKA by conjugating monoubiquitination and K11/K63-linked polyubiquitination, which are protective from degrading K11/K48 polyubiquitination. CBLC depletion markedly decreased the half-life of AURKA in cycloheximide-treated LAD cells. When LAD cells were synchronized with double thymidine block at the G1/S boundary and then released into mitotic arrest, CBLC depletion delayed the accumulation and activation of AURKA and prevented cancer cells from entering mitosis. CBLC deficiency significantly delayed cell cycle progression, reduced the mitotic population, and increased apoptosis of LAD cells. Targeting CBLC inhibited tumor growth of LAD cells and enhanced their sensitivity to paclitaxel in xenograft models. Immunohistochemical staining of the tissue microarray also revealed a positive correlation between the expression of CBLC and AURKA in normal and LAD tissues, further supporting the positive regulation of AURKA expression by CBLC. In summary, these findings indicate that the oncogenic E3 ligase CBLC plays a role in mitotic entry by stabilizing AURKA via ubiquitination in LAD. This work demonstrates that targeting CBLC combined with paclitaxel might be a potential option for the treatment of LAD patients who have no available targeted therapies.	[Hong, Shiao-Ya; Lu, Yi-Chun] Cardinal Tien Hosp, Med Res Ctr, New Taipei, Taiwan; [Hong, Shiao-Ya; Kao, Yu-Rung; Wu, Cheng-Wen] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Hsiao, Shih-Hsin] Taipei Med Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Lee, Meng-Hsuan; Lin, Yi-Ping] Natl Yang Ming Chiao Tung Univ, Inst Microbiol & Immunol, Taipei, Taiwan; [Wang, Cheng-Yi] Cardinal Tien Hosp, Dept Internal Med, New Taipei, Taiwan; [Wang, Cheng-Yi] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan; [Wu, Cheng-Wen] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan	Academia Sinica - Taiwan; Taipei Medical University; Taipei Medical University Hospital; National Yang Ming Chiao Tung University; Fu Jen Catholic University; National Yang Ming Chiao Tung University	Wu, CW (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.; Wang, CY (corresponding author), Cardinal Tien Hosp, Dept Internal Med, New Taipei, Taiwan.; Wang, CY (corresponding author), Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan.; Wu, CW (corresponding author), Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan.	cywang@mospital.com; chengwenwu@nycu.edu.tw		Hong, Shiao-Ya/0000-0003-4302-1509; Wang, Cheng-Yi/0000-0001-7426-0743	Ministry of Science and Technology of Taiwan [MOST 109-2314-B-567-001-MY2, MOST 110-2314-B-567-004, MOST 109-2320-B-A49-001]; Cardinal Tien Hospital [CTH 110A-2207, CTH 110A-NDMC-2227]; Academia Sinica [AS-CFII-108-115, AS-CFII-108-113]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Cardinal Tien Hospital; Academia Sinica(Academia Sinica - Taiwan)	This work was supported by the Ministry of Science and Technology of Taiwan (MOST 109-2314-B-567-001-MY2 and MOST 110-2314-B-567-004 to SYH, MOST 109-2320-B-A49-001 to CWW) and Cardinal Tien Hospital (CTH 110A-2207 to SYH and CTH 110A-NDMC-2227 to CYW). We also thank the core facilities of IBMS, funded by Academia Sinica Core Facility and Innovative Instrument Projects (AS-CFII-108-115, AS-CFII-108-113).	Abdelbaki A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.243071; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bassermann F, 2014, BBA-MOL CELL RES, V1843, P150, DOI 10.1016/j.bbamcr.2013.02.028; Bertolin G, 2020, CELL MOL LIFE SCI, V77, P1031, DOI 10.1007/s00018-019-03310-2; Caracciolo D, 2020, INT J CANCER, V147, P2658, DOI 10.1002/ijc.33038; Cowley DO, 2009, MOL CELL BIOL, V29, P1059, DOI 10.1128/MCB.01062-08; Du RJ, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01305-3; Frankum J, 2015, ONCOTARGET, V6, P10746, DOI 10.18632/oncotarget.3628; Galetta D, 2020, CANCERS, P12; Genova C, 2020, EXPERT REV RESP MED, V14, P367, DOI 10.1080/17476348.2020.1714441; Gilberto S, 2017, J CELL BIOL, V216, P2259, DOI 10.1083/jcb.201703170; Griffiths EK, 2003, MOL CELL BIOL, V23, P7708, DOI 10.1128/MCB.23.21.7708-7718.2003; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hirst J, 2017, AGING-US, V9, P1945, DOI 10.18632/aging.101291; Hong SY, 2018, CANCER RES, V78, P4984, DOI 10.1158/0008-5472.CAN-17-3858; Hsu FF, 2017, ONCOGENE, V36, P6805, DOI 10.1038/onc.2017.294; Ke YW, 2003, CELL RES, V13, P69, DOI 10.1038/sj.cr.7290152; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Kim B, 2007, CANCER RES, V67, P7431, DOI 10.1158/0008-5472.CAN-07-0003; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Lee WY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138789; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin XR, 2020, AM J CANCER RES, V10, P2705; Lindon C, 2016, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00307; Lu LY, 2008, J BIOL CHEM, V283, P31785, DOI 10.1074/jbc.M805880200; Moghe S, 2012, BIOL OPEN, V1, P82, DOI 10.1242/bio.2011018; Mou PK, 2021, EXP MOL MED, V53, P835, DOI 10.1038/s12276-021-00635-6; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Reiter R, 2006, CLIN CANCER RES, V12, P5136, DOI 10.1158/1078-0432.CCR-05-1650; Sadowski M, 2012, IUBMB LIFE, V64, P136, DOI 10.1002/iub.589; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; Teixeira LK, 2013, ANNU REV BIOCHEM, V82, P387, DOI 10.1146/annurev-biochem-060410-105307; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Do TV, 2017, ONCOTARGET, V8, P50376, DOI 10.18632/oncotarget.18970; Willems E, 2018, CELL DIV, V13, DOI 10.1186/s13008-018-0040-6; Yan M, 2016, MED RES REV, V36, P1036, DOI 10.1002/med.21399; Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358	42	2	2	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1907	1917		10.1038/s41388-022-02180-6	http://dx.doi.org/10.1038/s41388-022-02180-6		FEB 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35149839				2022-12-28	WOS:000754149000001
J	Journo, S; Goldberg, AK; Sokol, ES; Zinger, L; Pasmanik-Chor, M; Sarvin, B; Simkin, D; Fuchs, S; Shlomi, T; Wolf, I; Rubinek, T				Journo, Shani; Goldberg, Anat Klein; Sokol, Ethan S.; Zinger, Lotem; Pasmanik-Chor, Metsada; Sarvin, Boris; Simkin, Dor; Fuchs, Sivan; Shlomi, Tomer; Wolf, Ido; Rubinek, Tami			Genomic alterations drive metastases formation in pancreatic ductal adenocarcinoma cancer: deciphering the role of CDKN2A and CDKN2B in mediating liver tropism	ONCOGENE			English	Article							KINASE-4 INHIBITOR GENE; GLUTAMINE-METABOLISM; SOMATIC MUTATIONS; DELETIONS; AMMONIA	Metastases are often the direct cause of death from pancreatic ductal adenocarcinoma (PDAC). The role of genomic alterations (GA) in mediating tropism and metastasis formation by PDAC cells is currently unknown. We aimed to identify GAs predisposing colonization of PDAC cells to the liver and decipher mechanisms enabling this process. In order to reveal specific genes, we studied the frequency of GA in 8,880 local and 7,983 metastatic PDAC samples. We observed differential pattern of GA in the local tumor and specific metastatic sites, with liver metastases characterized by deletion of CDKN2A/B (encoding p16/p15, respectively). The role of CDKN2A/B in promoting liver metastasis was evidenced by enhanced tumorigenic phenotype of p15/p16-deleted PDAC cells when exposed to hepatocytes conditioned media. The liver is characterized by high-ammonia low-glutamine environment and transcriptomic assays indicated unique adaptation of PDAC cells to these conditions, including regulation of genes leading to reduced glutaminolysis, like overexpression of GLUL and reduction in GLS2. Furthermore, metabolic assays indicated an increase in glutamate derived from [U-C-13]-glucose in p15/p16-deleted cells. Importantly, these cells thrived under high ammonia condition. These data suggest a unique role for genomic alterations in mediating tropism of PDAC. Among these alterations, p15/16 deletion was identified as a promoter of liver metastases. Further studies indicated a unique role for p15/16 in regulating glutaminolysis. These findings reveal vulnerabilities in PDAC cells, which may pave the way for the development of novel therapeutic strategies aiming at the prevention of liver metastases formation.	[Journo, Shani; Goldberg, Anat Klein; Zinger, Lotem; Simkin, Dor; Fuchs, Sivan; Wolf, Ido; Rubinek, Tami] Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel; [Journo, Shani; Zinger, Lotem; Wolf, Ido; Rubinek, Tami] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Sokol, Ethan S.] Fdn Med Inc, Cambridge, MA 02141 USA; [Pasmanik-Chor, Metsada] Tel Aviv Univ, Fac Life Sci, Bioinformat Unit, Tel Aviv, Israel; [Sarvin, Boris; Shlomi, Tomer] Technion, Fac Comp Sci, Haifa, Israel; [Sarvin, Boris; Shlomi, Tomer] Technion, Fac Biol, Haifa, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Foundation Medicine; Tel Aviv University; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Wolf, I; Rubinek, T (corresponding author), Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel.; Wolf, I; Rubinek, T (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	wolf-i@inter.net.il; rubinekt@gmail.com			Israel Science Foundation [1320/14]; Israel Cancer Association [20160053]; Margaret Stultz foundation for Pancreatic Cancer Research; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; TASMC excellence fund	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Margaret Stultz foundation for Pancreatic Cancer Research; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; TASMC excellence fund	This work was financially supported by the Israel Science Foundation to I.W. (grant no. 1320/14); the Israel Cancer Association to I.W. (grant no. 20160053); The Margaret Stultz foundation for Pancreatic Cancer Research, the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; and TASMC excellence fund. The funding sources had no implications on the study design, collections, analysis, and interpretation of data or writing the manuscript. Israel Cancer Association, ISF, Pancreatic Cancer Foundation	Boldes T, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07005-x; Bott AJ, 2019, CELL REP, V29, P1287, DOI 10.1016/j.celrep.2019.09.056; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Cluntun AA, 2017, TRENDS CANCER, V3, P169, DOI 10.1016/j.trecan.2017.01.005; Connor AA, 2019, CANCER CELL, V35, P267, DOI 10.1016/j.ccell.2018.12.010; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; Edwards Mina, 2013, Methods Mol Biol, V987, P283, DOI 10.1007/978-1-62703-321-3_24; Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Haussinger D, 2007, FRONT BIOSCI-LANDMRK, V12, P371, DOI 10.2741/2070; Hao Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13934; Hatting M, 2018, ANN NY ACAD SCI, V1411, P21, DOI 10.1111/nyas.13435; Haussinger D, 2001, J NUTR, V131, p2509S, DOI 10.1093/jn/131.9.2509S; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Kent OA, 2016, MOL CANCER RES, V14, P267, DOI 10.1158/1541-7786.MCR-15-0456; Kietzmann T, 1997, BIOCHEM J, V321, P17, DOI 10.1042/bj3210017; Kim GW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041701; Kumar A, 2018, BIOCHEM BIOPH RES CO, V500, P731, DOI 10.1016/j.bbrc.2018.04.144; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Melamud E, 2010, ANAL CHEM, V82, P9818, DOI 10.1021/ac1021166; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Pokorny AMJ, 2018, INTERN MED J, V48, P637, DOI 10.1111/imj.13810; Reiter JG, 2018, SCIENCE, V361, P1033, DOI 10.1126/science.aat7171; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4; Spinelli JB, 2017, SCIENCE, V358, P941, DOI 10.1126/science.aam9305; Tanaka M, 2019, BRIT J SURG, V106, P1590, DOI 10.1002/bjs.11295; Walker V, 2014, ADV CLIN CHEM, V67, P73, DOI 10.1016/bs.acc.2014.09.002; Watford M, 2000, J NUTR, V130, p983S, DOI 10.1093/jn/130.4.983S; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Yachida S, 2012, CLIN CANCER RES, V18, P6339, DOI 10.1158/1078-0432.CCR-12-1215; Yang LF, 2014, MOL SYST BIOL, V10, DOI 10.1002/msb.20134892; Yu T, 2018, BIOMED PHARMACOTHER, V108, P1162, DOI 10.1016/j.biopha.2018.09.132; Yuan LQ, 2015, ENDOCR-RELAT CANCER, V22, P577, DOI 10.1530/ERC-15-0192; Zinger L, 2019, CLIN CANCER RES, V25, P2900, DOI 10.1158/1078-0432.CCR-18-1505	43	1	1	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1468	1481		10.1038/s41388-022-02184-2	http://dx.doi.org/10.1038/s41388-022-02184-2		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35064215				2022-12-28	WOS:000745402900001
J	Han, WT; Liu, MY; Han, D; Li, MQ; Toure, AA; Wang, ZF; Besschetnova, A; Patalano, S; Macoska, JA; Gao, S; He, HH; Cai, CM				Han, Wanting; Liu, Mingyu; Han, Dong; Li, Muqing; Toure, Anthia A.; Wang, Zifeng; Besschetnova, Anna; Patalano, Susan; Macoska, Jill A.; Gao, Shuai; He, Housheng Hansen; Cai, Changmeng			RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition	ONCOGENE			English	Article							NEUROENDOCRINE PHENOTYPE; LINEAGE PLASTICITY; INCREASED SURVIVAL; MECHANISMS; PHOSPHORYLATION; DIFFERENTIATION; DEMETHYLATION; METASTASIS; EXPRESSION; GENOMICS	Genomic loss of RB1 is a common alteration in castration-resistant prostate cancer (CRPC) and is associated with poor patient outcomes. RB1 loss is also a critical event that promotes the neuroendocrine transdifferentiation of prostate cancer (PCa) induced by the androgen receptor (AR) signaling inhibition (ARSi). The loss of Rb protein disrupts the Rb-E2F repressor complex and thus hyperactivates E2F transcription activators. While the impact of Rb inactivation on PCa progression and linage plasticity has been previously studied, there is a pressing need to fully understand underlying mechanisms and identify vulnerabilities that can be therapeutically targeted in Rb-deficient CRPC. Using an integrated cistromic and transcriptomic analysis, we have characterized Rb activities in multiple CRPC models by identifying Rb-directly regulated genes and revealed that Rb has distinct binding sites and targets in CRPC with different genomic backgrounds. Significantly, we show that E2F1 chromatin binding and transcription activity in Rb-deficient CRPC are highly dependent on LSD1/KDM1A, and that Rb inactivation sensitizes CRPC tumor to the LSD1 inhibitor treatment. These results provide new molecular insights into Rb activity in PCa progression and suggest that targeting LSD1 activity with small molecule inhibitors may be a potential treatment strategy to treat Rb-deficient CRPC.	[Han, Wanting; Liu, Mingyu; Han, Dong; Li, Muqing; Toure, Anthia A.; Wang, Zifeng; Besschetnova, Anna; Patalano, Susan; Macoska, Jill A.; Gao, Shuai; Cai, Changmeng] Univ Massachusetts, Ctr Personalized Canc Therapy, Boston, MA 02125 USA; [Han, Wanting; Liu, Mingyu; Li, Muqing; Toure, Anthia A.; Wang, Zifeng; Besschetnova, Anna; Patalano, Susan; Macoska, Jill A.; Gao, Shuai; Cai, Changmeng] Univ Massachusetts, Dept Biol, Boston, MA 02125 USA; [He, Housheng Hansen] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [He, Housheng Hansen] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada	University of Massachusetts System; University of Massachusetts Boston; University of Massachusetts System; University of Massachusetts Boston; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Cai, CM (corresponding author), Univ Massachusetts, Ctr Personalized Canc Therapy, Boston, MA 02125 USA.; Cai, CM (corresponding author), Univ Massachusetts, Dept Biol, Boston, MA 02125 USA.	changmeng.cai@umb.edu	Han, Wanting/GQA-5728-2022; Han, Wanting/AEX-5349-2022	Han, Wanting/0000-0002-2173-3647; Besschetnova, Anna/0000-0003-3623-1997; Gao, Shuai/0000-0002-7304-8801; Macoska, Jill/0000-0001-8471-2221; Han, Dong/0000-0002-6224-855X	NIH [R00 CA166507, R01 CA211350, U54 CA156734]; DOD [W81XWH-16-1-0445, W81XWH-19-1-0361, W81XWH-21-1-0267, W81XWH-19-1-0777]; CIHR [142246, 152863, 152864, 159567]; Terry Fox Frontiers Program [1090 P3]; Integrative Biosciences Program at the University of Massachusetts Boston; CSM (College of Science and Mathematics) Dean's Doctoral Research Fellowship from the University of Massachusetts Boston	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); CIHR(Canadian Institutes of Health Research (CIHR)); Terry Fox Frontiers Program; Integrative Biosciences Program at the University of Massachusetts Boston; CSM (College of Science and Mathematics) Dean's Doctoral Research Fellowship from the University of Massachusetts Boston	This work is supported by grants from NIH (R00 CA166507 and R01 CA211350 to CC, U54 CA156734 to JAM), DOD (W81XWH-16-1-0445, W81XWH-19-1-0361, and W81XWH-21-1-0267 to CC, W81XWH-19-1-0777 to SG), CIHR (142246, 152863, 152864, and 159567 to HHH), and Terry Fox Frontiers Program Project Grants (1090 P3 to HHH). MLiu was supported by the graduate fellowship from the Integrative Biosciences Program at the University of Massachusetts Boston. WH and ZW were supported by CSM (College of Science and Mathematics) Dean's Doctoral Research Fellowship from the University of Massachusetts Boston. HHH holds Joey and Toby Tanenbaum Brazilian Ball Chair in Prostate Cancer.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Beltran H, 2019, CLIN CANCER RES, V25, P6916, DOI 10.1158/1078-0432.CCR-19-1423; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Berger A, 2019, J CLIN INVEST, V129, P3924, DOI 10.1172/JCI127961; Cai CM, 2014, CELL REP, V9, P1618, DOI 10.1016/j.celrep.2014.11.008; Chen WS, 2019, CLIN CANCER RES, V25, P4290, DOI 10.1158/1078-0432.CCR-19-0404; Cho HS, 2011, CANCER RES, V71, P655, DOI 10.1158/0008-5472.CAN-10-2446; Coleman DJ, 2020, NEOPLASIA, V22, P253, DOI 10.1016/j.neo.2020.04.002; Conteduca V, 2019, EUR J CANCER, V121, P7, DOI 10.1016/j.ejca.2019.08.011; Danza G, 2012, MOL CANCER RES, V10, P230, DOI 10.1158/1541-7786.MCR-11-0296; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; Fang Y, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0811-9; Gao S, 2020, NAT GENET, V52, P1011, DOI 10.1038/s41588-020-0681-7; Gao S, 2019, CELL RES, V29, P770, DOI 10.1038/s41422-019-0203-2; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo HY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08133-6; He Y, 2018, ONCOGENE, V37, P534, DOI 10.1038/onc.2017.353; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Korenchuk S, 2001, IN VIVO, V15, P163; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Laurent B, 2015, MOL CELL, V57, P957, DOI 10.1016/j.molcel.2015.01.010; Lin TP, 2016, ONCOTARGET, V7, P26137, DOI 10.18632/oncotarget.8433; Mandigo AC, 2021, CANCER DISCOV, V11, P2334, DOI 10.1158/2159-8290.CD-20-1114; Mateo J, 2020, J CLIN INVEST, V130, P1743, DOI [10.1172/JCI132031, 10.1172/JCl132031]; McNair C, 2018, J CLIN INVEST, V128, P341, DOI 10.1172/JCI93566; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Nyquist MD, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107669; Pfitzenmaier J, 2003, J BONE MINER RES, V18, P1882, DOI 10.1359/jbmr.2003.18.10.1882; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rubin MA, 2020, MOL CELL, V80, P562, DOI 10.1016/j.molcel.2020.10.033; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sehrawat A, 2018, P NATL ACAD SCI USA, V115, pE4179, DOI 10.1073/pnas.1719168115; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Yuan HR, 2020, CANCER CELL, V38, P350, DOI 10.1016/j.ccell.2020.05.022; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhang XT, 2015, CLIN CANCER RES, V21, P4698, DOI 10.1158/1078-0432.CCR-15-0157; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao Y, 2019, EMBO J, V38, DOI 10.15252/embj.201899599	51	3	3	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					852	864		10.1038/s41388-021-02135-3	http://dx.doi.org/10.1038/s41388-021-02135-3		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34975152	Green Accepted			2022-12-28	WOS:000737109100001
J	Li, MJ; Rao, XP; Cui, Y; Zhang, L; Li, X; Wang, BY; Zheng, YJ; Teng, LS; Zhou, TH; Zhuo, W				Li, Mengjie; Rao, Xianping; Cui, Yun; Zhang, Lu; Li, Xiang; Wang, Boya; Zheng, Yijun; Teng, Lisong; Zhou, Tianhua; Zhuo, Wei			The keratin 17/YAP/IL6 axis contributes to E-cadherin loss and aggressiveness of diffuse gastric cancer	ONCOGENE			English	Article							HIPPO PATHWAY; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; YAP; MUTATIONS; ACTIVATION; CARCINOMA; GROWTH; CDH1; RHOA	DGC is a particular aggressive malignancy with poor prognosis. Recent omics studies characterized DGC with CDH1/E-cadherin loss and EMT-signatures. However, the underlying mechanisms for maintaining the aggressive behavior and molecular features of DGC remain unclear. Here, we find that intermediate filaments KRT17 is significantly lower in DGC tissues than that in intestinal gastric cancer tissues and associated with poor prognosis of DGC. We demonstrate that downregulation of KRT17 induces E-cadherin loss, EMT changes, and metastasis behaviors of GC cells. Mechanistically, the loss of intermediate filaments KRT17 induces reorganization of cytoskeleton, further activates YAP signaling, and increases IL6 expression, which contributes to the enhanced metastasis ability of GC cells. Together, these results indicate that KRT17/YAP/IL6 axis contributes to maintaining E-cadherin loss, EMT feature, and metastasis of DGC, providing a new insight into the role of aberrant intermediate filaments in DGC malignancy.	[Li, Mengjie; Rao, Xianping; Cui, Yun; Zhang, Lu; Li, Xiang; Zheng, Yijun; Zhou, Tianhua; Zhuo, Wei] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Cell Biol, Sch Med, Hangzhou, Peoples R China; [Li, Mengjie; Rao, Xianping; Cui, Yun; Zhang, Lu; Li, Xiang; Zheng, Yijun; Zhou, Tianhua; Zhuo, Wei] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gastroenterol, Sch Med, Hangzhou, Peoples R China; [Li, Mengjie; Rao, Xianping; Cui, Yun; Zhang, Lu; Li, Xiang; Zheng, Yijun; Teng, Lisong; Zhou, Tianhua; Zhuo, Wei] Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China; [Li, Mengjie; Rao, Xianping; Cui, Yun; Zhang, Lu; Li, Xiang; Wang, Boya; Zhou, Tianhua; Zhuo, Wei] Zhejiang Univ, Inst Gastroenterol, Hangzhou, Peoples R China; [Wang, Boya] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Pharm, Sch Med, Hangzhou, Peoples R China; [Zheng, Yijun; Teng, Lisong] Zhejiang Univ, Affiliated Hosp 1, Dept Surg Oncol, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China; [Zhou, Tianhua] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; University of Toronto	Zhou, TH; Zhuo, W (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Cell Biol, Sch Med, Hangzhou, Peoples R China.; Zhou, TH; Zhuo, W (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gastroenterol, Sch Med, Hangzhou, Peoples R China.; Zhou, TH; Zhuo, W (corresponding author), Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China.; Zhou, TH; Zhuo, W (corresponding author), Zhejiang Univ, Inst Gastroenterol, Hangzhou, Peoples R China.; Zhou, TH (corresponding author), Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.	tzhou@zju.edu.cn; wzhuo@zju.edu.cn	zhou, tianhua/K-4908-2013; li, mengjie/GRS-3931-2022	zhou, tianhua/0000-0002-1791-2124; Zhuo, Wei/0000-0002-8251-4210; Zheng, Yijun/0000-0002-5064-8935	National Natural Science Foundation of China [31771540, 81972276, 82173040, 91740205, 31620103911]; Natural Scientific Foundation of Zhejiang Province, China [LYY19H310011]; Fundamental Research Funds for the Central Universities [2021QNA7004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Scientific Foundation of Zhejiang Province, China(Natural Science Foundation of Zhejiang Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank Hai Song for providing pcDNA3.1-YAP plasmid. This work was supported by the National Natural Science Foundation of China (31771540, 81972276, 82173040, 91740205, 31620103911), Natural Scientific Foundation of Zhejiang Province, China (LYY19H310011), Fundamental Research Funds for the Central Universities (2021QNA7004).	Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; BECKER KF, 1994, CANCER RES, V54, P3845; Benham-Pyle BW, 2015, SCIENCE, V348, P1024, DOI 10.1126/science.aaa4559; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chivu-Economescu M, 2017, GASTRIC CANCER, V20, P948, DOI 10.1007/s10120-017-0712-y; Chivu-Economescu M, 2010, HEPATO-GASTROENTEROL, V57, P1453; Cho SY, 2017, GASTROENTEROLOGY, V153, P536, DOI 10.1053/j.gastro.2017.05.012; Choi W, 2018, CANCER RES, V78, P3306, DOI 10.1158/0008-5472.CAN-17-3487; Coccolini F, 2013, WORLD J GASTROENTERO, V19, P6979, DOI 10.3748/wjg.v19.i41.6979; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Corso G, 2013, J CLIN ONCOL, V31, P868, DOI 10.1200/JCO.2012.44.4612; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Eliazer S, 2019, CELL STEM CELL, V25, P654, DOI 10.1016/j.stem.2019.08.007; Enzo E, 2015, EMBO J, V34, P1349, DOI 10.15252/embj.201490379; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Fitzgerald RC, 2010, J MED GENET, V47, P436, DOI 10.1136/jmg.2009.074237; Ge S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03121-2; Ham IH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0972-8; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Henson DE, 2004, ARCH PATHOL LAB MED, V128, P765; Hobbs RP, 2016, ONCOGENE, V35, P5653, DOI 10.1038/onc.2016.102; Hu H, 2018, J CANCER, V9, P346, DOI 10.7150/jca.19838; Huang CH, 2020, INT J CANCER, V146, P1937, DOI 10.1002/ijc.32609; Ide M, 2012, ANN SURG ONCOL, V19, P3506, DOI 10.1245/s10434-012-2437-9; Jiao S, 2018, J EXP MED, V215, P699, DOI 10.1084/jem.20171116; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Khanom R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161163; Kim HJ, 2015, BIOMOL THER, V23, P301, DOI 10.4062/biomolther.2015.032; Kim T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10186; Kurokawa I, 2011, EXP DERMATOL, V20, P217, DOI 10.1111/j.1600-0625.2009.01006.x; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee JY, 2017, GUT LIVER, V11, P807, DOI 10.5009/gnl17033; Lee JH, 2018, ANN SURG, V267, P105, DOI 10.1097/SLA.0000000000002040; Lee KH, 2013, ANTICANCER RES, V33, P3765; Li D, 2020, CANCER MANAG RES, V12, P2087, DOI 10.2147/CMAR.S243129; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lim HYG, 2020, NATURE, V585, P404, DOI 10.1038/s41586-020-2647-4; Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639; Liu Z, 2020, J PROTEOMICS, V211, DOI 10.1016/j.jprot.2019.103557; Mahmud N, 2015, J CLIN ONCOL, V33, pE19, DOI 10.1200/JCO.2013.49.1159; Mo JS, 2015, NAT CELL BIOL, V17, P500, DOI 10.1038/ncb3111; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Mun DG, 2019, CANCER CELL, V35, P111, DOI 10.1016/j.ccell.2018.12.003; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Oliveira C, 2015, LANCET ONCOL, V16, pE60, DOI 10.1016/S1470-2045(14)71016-2; Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013; Park J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10729-5; Park YH, 2016, NAT IMMUNOL, V17, P914, DOI 10.1038/ni.3457; PROBY CM, 1993, AM J PATHOL, V143, P1667; Qi Yi-Jun, 2020, PLoS Biol, V18, pe3000825, DOI 10.1371/journal.pbio.3000825; Quinn JJ, 2021, SCIENCE, V371, P909, DOI 10.1126/science.abc1944; Reddy BVVG, 2013, DEV CELL, V24, P459, DOI 10.1016/j.devcel.2013.01.020; Robinson BS, 2010, CURR BIOL, V20, P582, DOI 10.1016/j.cub.2010.03.019; Rodriguez-Boulan E, 2014, NAT REV MOL CELL BIO, V15, P225, DOI 10.1038/nrm3775; Shen B, 2013, CELL RES, V23, P720, DOI 10.1038/cr.2013.46; Shimada S, 2012, GUT, V61, P344, DOI 10.1136/gutjnl-2011-300050; Shintani Y, 2016, J THORAC ONCOL, V11, P1482, DOI 10.1016/j.jtho.2016.05.025; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Tang Y, 2020, CANCER CELL, V38, P115, DOI 10.1016/j.ccell.2020.05.019; van der Post RS, 2015, J MED GENET, V52, P361, DOI 10.1136/jmedgenet-2015-103094; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang YB, 2018, CIRCULATION, V138, P48, DOI 10.1161/CIRCULATIONAHA.117.032398; Wang Z, 2019, CANCER MANAG RES, V11, P7485, DOI 10.2147/CMAR.S218926; Wang ZY, 2014, P NATL ACAD SCI USA, V111, pE89, DOI 10.1073/pnas.1319190110; Weng YS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0988-0; Xu X, 2015, INT J ONCOL, V46, P2479, DOI 10.3892/ijo.2015.2966; Yang N, 2020, THERANOSTICS, V10, P5790, DOI 10.7150/thno.44789; Yimlamai D, 2014, CELL, V157, P1324, DOI 10.1016/j.cell.2014.03.060; Yoon C, 2016, CLIN CANCER RES, V22, P971, DOI 10.1158/1078-0432.CCR-15-1356; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yue T, 2012, DEV CELL, V22, P255, DOI 10.1016/j.devcel.2011.12.011; Zhang HS, 2020, CANCER DISCOV, V10, P288, DOI 10.1158/2159-8290.CD-19-0811; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhou X, 2015, J CLIN INVEST, V125, P2123, DOI 10.1172/JCI79573	80	7	7	5	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					770	781		10.1038/s41388-021-02119-3	http://dx.doi.org/10.1038/s41388-021-02119-3		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34845376				2022-12-28	WOS:000723571700005
J	Kong, Y; Zhang, YT; Wang, HL; Kan, WJ; Guo, HR; Liu, Y; Zang, Y; Li, J				Kong, Ya; Zhang, Yutian; Wang, Hanlin; Kan, Weijuan; Guo, Haoran; Liu, Yun; Zang, Yi; Li, Jia			Inner nuclear membrane protein TMEM201 promotes breast cancer metastasis by positive regulating TGF beta signaling	ONCOGENE			English	Article							INTEGRAL PROTEIN; MAN1; REVEALS; LAMINA; SAMP1	Emerging evidence shows the association between nuclear envelope and tumor progression, however, the functional contributions of specific constituents of the nuclear envelope remain largely unclear. We found that the expression level of transmembrane protein 201 (TMEM201), an integral inner nuclear membrane protein of unknown function, was significantly elevated in invasive breast cancer and predicted poor breast cancer prognosis. We showed that TMEM201, as a positive modulator, was both necessary and sufficient to regulate the migration and invasion of breast cancer cells in vitro and in vivo. Mechanistically, RNA-sequencing analysis and validation showed that TMEM201 deficiency inhibited epithelial-to-mesenchymal transition and transforming growth factor-beta signaling. Finally, we showed that TMEM201 physically interacted with SMAD2/3 and was required for the phosphorylation of SMAD2/3, nuclear translocation and transcriptional activation of the TGF beta. Thus, we demonstrated that specific inner nuclear membrane component mediated signal-dependent transcriptional effects to control breast cancer metastasis.	[Kong, Ya; Zhang, Yutian; Wang, Hanlin; Kan, Weijuan; Guo, Haoran; Zang, Yi; Li, Jia] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China; [Kong, Ya; Zhang, Yutian; Guo, Haoran; Zang, Yi; Li, Jia] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Wang, Hanlin] Fudan Univ, Dept Pharmacol, Shanghai 201203, Peoples R China; [Liu, Yun] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Drug Screening, 24 Tong Jia Xiang St, Nanjing 210009, Peoples R China; [Zang, Yi; Li, Jia] UCAS, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou, Peoples R China; [Li, Jia] Pilot Natl Lab Marine Sci & Technol Qingdao, Open Studio Druggabil Res Marine Nat Prod, Qingdao 266237, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Fudan University; China Pharmaceutical University; Qingdao National Laboratory for Marine Science & Technology	Zang, Y; Li, J (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China.; Zang, Y; Li, J (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Zang, Y; Li, J (corresponding author), UCAS, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou, Peoples R China.; Li, J (corresponding author), Pilot Natl Lab Marine Sci & Technol Qingdao, Open Studio Druggabil Res Marine Nat Prod, Qingdao 266237, Peoples R China.	yzang@simm.ac.cn; jli@simm.ac.cn	Li, Jia/F-9116-2011	Wang, Hanlin/0000-0003-0443-4378	National Natural Science Foundation of China [31871414, 81971265]; Science and Technology Commission of Shanghai Municipality [19JC1416300]; Shanghai Institute of Materia Medica [SIMM2004KF-01]; Shanghai Municipal Human Resources and Social Security Bureau [Y91204R]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Institute of Materia Medica; Shanghai Municipal Human Resources and Social Security Bureau	This work is supported by the National Natural Science Foundation of China (Grant 31871414, 81971265), Science and Technology Commission of Shanghai Municipality (19JC1416300), Shanghai Institute of Materia Medica (SIMM2004KF-01), Shanghai Municipal Human Resources and Social Security Bureau (Y91204R).	Bell ES, 2016, EUR J CELL BIOL, V95, P449, DOI 10.1016/j.ejcb.2016.06.007; Bengtsson L, 2007, FEBS J, V274, P1374, DOI 10.1111/j.1742-4658.2007.05696.x; Borrego-Pinto J, 2012, J CELL SCI, V125, P1099, DOI 10.1242/jcs.087049; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buch C, 2009, J CELL SCI, V122, P2100, DOI 10.1242/jcs.047373; Chow KH, 2012, NAT REV CANCER, V12, P196, DOI 10.1038/nrc3219; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de las Heras JI, 2013, SEMIN CANCER BIOL, V23, P125, DOI 10.1016/j.semcancer.2012.01.008; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Goldberg M, 1998, MOL CELL BIOL, V18, P4315, DOI 10.1128/MCB.18.7.4315; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Hetzer MW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000539; Kao KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-143; Karlsson G, 2005, PHYSIOL GENOMICS, V21, P396, DOI 10.1152/physiolgenomics.00303.2004; Korfali N, 2012, NUCLEUS-PHILA, V3, P552, DOI 10.4161/nucl.22257; Korfali N, 2010, MOL CELL PROTEOMICS, V9, P2571, DOI 10.1074/mcp.M110.002915; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lin F, 2005, HUM MOL GENET, V14, P437, DOI 10.1093/hmg/ddi040; Liu C, 2019, ONCOTARGETS THER, V12, P3817, DOI 10.2147/OTT.S179870; Lu T, 2016, BIOCHEM BIOPH RES CO, V478, P1189, DOI 10.1016/j.bbrc.2016.08.093; Mansharamani M, 2005, J BIOL CHEM, V280, P13863, DOI 10.1074/jbc.M413020200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5070063; Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475; Osada SI, 2003, DEVELOPMENT, V130, P1783, DOI 10.1242/dev.00401; Pan D, 2005, J BIOL CHEM, V280, P15992, DOI 10.1074/jbc.M411234200; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Raju GP, 2003, J BIOL CHEM, V278, P428, DOI 10.1074/jbc.M210505200; Reis-Sobreiro M, 2018, CANCER RES, V78, P6086, DOI 10.1158/0008-5472.CAN-18-0608; Rodriguez-Bravo V, 2018, CELL, V174, P1200, DOI 10.1016/j.cell.2018.07.015; Schaffer BE, 2015, CELL METAB, V22, P907, DOI 10.1016/j.cmet.2015.09.009; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Schirmer EC, 2007, EXP CELL RES, V313, P2167, DOI 10.1016/j.yexcr.2007.03.012; Schreiber KH, 2013, CELL, V152, P1365, DOI 10.1016/j.cell.2013.02.015; Shi JL, 2019, AM J TRANSL RES, V11, P393; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Vijayaraghavan B, 2018, BBA-BIOMEMBRANES, V1860, P1326, DOI 10.1016/j.bbamem.2018.03.001; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wilkie GS, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.003129; Wolff AC, 2018, ARCH PATHOL LAB MED, V142, P1364, DOI [10.5858/arpa.2018-0902-SA, 10.1200/JCO.2018.77.8738]; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Zhou HJ, 2013, J PROTEOME RES, V12, P260, DOI 10.1021/pr300630k	45	4	4	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					647	656		10.1038/s41388-021-02098-5	http://dx.doi.org/10.1038/s41388-021-02098-5		NOV 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34799661				2022-12-28	WOS:000720611600002
J	Yin, L; Zeng, YJ; Zeng, RY; Chen, YH; Wang, TL; Rodabaugh, KJ; Yu, F; Natarajan, A; Karpf, AR; Dong, JX				Yin, Ling; Zeng, Yongji; Zeng, Renya; Chen, Yuanhong; Wang, Tian-Li; Rodabaugh, Kerry J.; Yu, Fang; Natarajan, Amarnath; Karpf, Adam R.; Dong, Jixin			Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR FUNCTION; PHOSPHATASE-ACTIVITY; PKR; PHOSPHORYLATION; EXPRESSION; INHIBITOR; APOPTOSIS; STRESS; MOTILITY; MITOSIS	Anti-tubulin agents, such as paclitaxel, have been used extensively for treatment of several types of cancer, including ovarian, lung, breast, and pancreatic cancers. Despite their wide use in cancer treatment, however, patient response is highly variable and drug resistance remains a major clinical issue. Protein kinase RNA-activated (PKR) plays a critical role in immune response to viral infection. We identified PKR as a phospho-protein in response to anti-tubulin agents and this phosphorylation occurs independent of its own kinase activity. PKR is phosphorylated by cyclin-dependent kinase 1 (CDK1) during anti-tubulin treatment and unperturbed mitosis and that PKR regulates mitotic progression in a phosphorylation-dependent manner. Furthermore, inactivation of PKR confers resistance to paclitaxel in ovarian and breast cancer cells in vitro and in vivo. PKR expression levels and activity are decreased in chemotherapeutic recurrent ovarian cancer patients. Mechanistically, our findings suggest that PKR controls paclitaxel chemosensitivity through repressing Bcl2 expression. Pharmacological inhibition of Bcl2 with FDA-approved agent venetoclax overcomes paclitaxel resistance in preclinical animal models of ovarian cancer. Our results suggest that PKR is a critical determinant of paclitaxel cytotoxicity and that PKR-Bcl2 axis as a potential therapeutic target for the treatment of recurrent drug-resistant ovarian tumors.	[Yin, Ling; Zeng, Yongji; Zeng, Renya; Chen, Yuanhong; Natarajan, Amarnath; Karpf, Adam R.; Dong, Jixin] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Wang, Tian-Li] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Wang, Tian-Li] Johns Hopkins Med Inst, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Rodabaugh, Kerry J.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Dept Gynecol Oncol, Omaha, NE 68198 USA; [Yu, Fang] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA; [Yin, Ling] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China	University of Nebraska System; University of Nebraska Medical Center; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; State Key Lab Oncology South China; Sun Yat Sen University	Dong, JX (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	dongj@unmc.edu	Yin, Ling/AAD-8990-2022	Yin, Ling/0000-0003-1606-2620; Natarajan, Amarnath/0000-0001-5067-0203; Karpf, Adam/0000-0002-0866-0666	National Institutes of Health (NIH) [P30 GM106397]; Fred & Pamela Buffett Cancer Center Support [P30 CA036727]; NIH [P30 GM106397, R01 GM109066]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fred & Pamela Buffett Cancer Center Support; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are very grateful to Dr. Michael Seiden for the SKOV3/SKOV3-Taxol resistant cell lines [43]. All fluorescence images were acquired by Zeiss LSM 710 or LSM 800 confocal microscopes at the Advanced Microscopy Core at the University of Nebraska Medical Center. The core is supported in part by grant P30 GM106397 from the National Institutes of Health (NIH). Research in the Dong laboratory is supported by Fred & Pamela Buffett Cancer Center Support Grant (P30 CA036727), grants P30 GM106397 and R01 GM109066 from the NIH. We also thank Dr. Joyce Solheim for critical reading and comments on the manuscript.	Garcia MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023887; Barage S, 2017, J MOL GRAPH MODEL, V75, P322, DOI 10.1016/j.jmgm.2017.06.009; Barille-Nion S, 2012, ANTICANCER RES, V32, P4225; Basu S, 1997, CANCER RES, V57, P943; Beretta L, 1996, ONCOGENE, V12, P1593; Blalock WL, 2009, J CELL PHYSIOL, V221, P232, DOI 10.1002/jcp.21848; Cang SD, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0224-3; Carvalho BM, 2013, OBESITY, V21, P2452, DOI 10.1002/oby.20410; Chen XC, 2016, J BIOL CHEM, V291, P14761, DOI 10.1074/jbc.M116.722751; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Darini C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10138-8; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006; Dzananovic E, 2018, BIOTECHNOL GENET ENG, V34, P33, DOI 10.1080/02648725.2018.1467151; Eichhorn JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.360; Garcia MA, 2006, MICROBIOL MOL BIOL R, V70, P1032, DOI 10.1128/MMBR.00027-06; Garcia-Ortega MB, 2017, EXPERT REV MOL MED, V19, DOI 10.1017/erm.2017.11; Gascoigne KE, 2009, J CELL SCI, V122, P2579, DOI 10.1242/jcs.039719; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; Harley ME, 2010, EMBO J, V29, P2407, DOI 10.1038/emboj.2010.112; He Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024855; Henriques AC, 2019, CANCER LETT, V440, P64, DOI 10.1016/j.canlet.2018.10.005; Hu CW, 2015, ONCOL RES, V22, P159, DOI 10.3727/096504015X14298122915628; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kim Y, 2014, GENE DEV, V28, P1310, DOI 10.1101/gad.242644.114; Lamendola DE, 2003, CANCER RES, V63, P2200; Lee ES, 2007, FEBS LETT, V581, P4325, DOI 10.1016/j.febslet.2007.08.001; Lee YS, 2020, WIRES RNA, V11, DOI 10.1002/wrna.1558; Li XL, 2017, ELIFE, V6, DOI 10.7554/eLife.27301; Marchal JA, 2014, FASEB J, V28, P1965, DOI 10.1096/fj.13-248294; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001; Natarajan A, 2004, J MED CHEM, V47, P1882, DOI 10.1021/jm0499716; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Peidis P, 2011, CELL DEATH DIFFER, V18, P145, DOI 10.1038/cdd.2010.76; Pyo CW, 2008, BIOCHEM BIOPH RES CO, V377, P1001, DOI 10.1016/j.bbrc.2008.10.103; Roh MS, 2005, PATHOL INT, V55, P688, DOI 10.1111/j.1440-1827.2005.01892.x; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Ruvolo VR, 2008, J BIOL CHEM, V283, P35474, DOI 10.1074/jbc.M800951200; Schmidt S, 2019, NAT CELL BIOL, V21, P1413, DOI 10.1038/s41556-019-0408-0; Shimada A, 1998, CANCER RES, V58, P4434; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Stauffer S, 2019, J CELL SCI, V132, DOI 10.1242/jcs.236000; Stauffer S, 2017, CELL SIGNAL, V39, P74, DOI 10.1016/j.cellsig.2017.08.001; Tang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11526-0; Terrano DT, 2010, MOL CELL BIOL, V30, P640, DOI 10.1128/MCB.00882-09; Tronel C, 2014, NEUROCHEM INT, V64, P73, DOI 10.1016/j.neuint.2013.10.012; Wang YH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19598; Wang Z, 2018, CELL SIGNAL, V52, P137, DOI 10.1016/j.cellsig.2018.09.007; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Xiao JL, 2016, MED SCI MONITOR, V22, P5074, DOI 10.12659/MSM.898139; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Yang SP, 2013, CANCER RES, V73, P6722, DOI 10.1158/0008-5472.CAN-13-2049; Yoon CH, 2009, P NATL ACAD SCI USA, V106, P7852, DOI 10.1073/pnas.0812148106; Yu Y, 2015, CANCER CELL, V28, P82, DOI 10.1016/j.ccell.2015.05.009; Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15; Zhang L, 2012, J BIOL CHEM, V287, P34069, DOI 10.1074/jbc.M112.385518; Zhou JL, 2018, P NATL ACAD SCI USA, V115, pE6760, DOI 10.1073/pnas.1800621115	61	0	0	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6772	6785		10.1038/s41388-021-02117-5	http://dx.doi.org/10.1038/s41388-021-02117-5		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34799660	Green Accepted			2022-12-28	WOS:000720611600001
J	Wu, D; Tan, H; Su, WJ; Cheng, DM; Wang, GW; Wang, J; Ma, DA; Dong, GM; Sun, PQ				Wu, Dan; Tan, Hua; Su, Weijun; Cheng, Dongmei; Wang, Guanwen; Wang, Juan; Ma, Ding A.; Dong, George M.; Sun, Peiqing			MZF1 mediates oncogene-induced senescence by promoting the transcription of p16(INK4A)	ONCOGENE			English	Article							CELLULAR SENESCENCE; TUMOR-SUPPRESSOR; CANCER; EXPRESSION; RAS; CHROMATIN; CHD7; P53; OVEREXPRESSION; RETINOBLASTOMA	Oncogene induced senescence is a tumor suppressing defense mechanism, in which the cell cycle-dependent protein kinase (CDK) inhibitor p16(INK4A) (encoded by the CDKN2A gene) plays a key role. We previously reported that a transcriptional co-activator chromodomain helicase DNA binding protein 7 (CHD7) mediates oncogenic ras-induced senescence by inducing transcription of the p16(INK4A) gene. In the current study, we identified myeloid zinc finger 1 (MZF1) as the transcriptional factor that recruits CHD7 to the p16(INK4A) promoter, where it mediates oncogenic ras-induced p16(INK4A) transcription and senescence through CHD7, in primary human cells from multiple origins. Moreover, the expression of MZF1 is induced by oncogenic ras in senescent cells through the c-Jun and Ets1 transcriptional factors upon their activation by the Ras-Raf-1-MEK-ERK signaling pathway. In non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma (PAAD) where activating ras mutations occur frequently, reduced MZF1 expression is observed in tumors, as compared to corresponding normal tissues, and correlates with poor patient survival. Analysis of single cell RNA-sequencing data from PAAD patients revealed that among the tumor cells with normal RB expression levels, those with reduced levels of MZF1 are more likely to express lower p16(INK4A) levels. These findings have identified novel signaling components in the pathway that mediates induction of the p16(INK4A) tumor suppressor and the senescence response, and suggested that MZF1 is a potential tumor suppressor in at least some cancer types, the loss of which contributes to the inactivation of the p16(INK4A)/RB pathway and disruption of senescence in tumor cells with intact RB.	[Wu, Dan; Cheng, Dongmei; Wang, Guanwen; Wang, Juan; Ma, Ding A.; Dong, George M.; Sun, Peiqing] Wake Forest Baptist Med Ctr, Comprehens Canc Ctr, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA; [Tan, Hua] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA; [Su, Weijun; Wang, Guanwen; Wang, Juan] Nankai Univ Sch Med, Tianjin, Peoples R China	Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Health Science Center Houston	Sun, PQ (corresponding author), Wake Forest Baptist Med Ctr, Comprehens Canc Ctr, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	psun@wakehealth.edu		Sun, Peiqing/0000-0003-2255-6504	NIH/NCI [CA131231, CA172115, P30CA012197]; Anderson Oncology Research Professorship	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Anderson Oncology Research Professorship	We thank the Cell Engineering and Cellular Imaging Shared Resources of WFBCCC. This study was supported by NIH/NCI grants CA131231, CA172115 and P30CA012197 (PS). PS is supported by the Anderson Oncology Research Professorship.	Bajpai R, 2010, NATURE, V463, P958, DOI 10.1038/nature08733; Bastide K, 2009, LUNG CANCER, V63, P348, DOI 10.1016/j.lungcan.2008.06.007; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brix DM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010223; Brix DM, 2019, ONCOGENE, V38, P3170, DOI 10.1038/s41388-018-0653-x; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen Y, 2015, ONCOGENE, V34, P3839, DOI 10.1038/onc.2014.310; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Coppe JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Deng Y, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/868131; di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071; Dublin EA, 1998, INT J CANCER, V79, P71, DOI 10.1002/(SICI)1097-0215(19980220)79:1<71::AID-IJC14>3.0.CO;2-K; Eguchi T, 2015, J CELL BIOCHEM, V116, P2146, DOI 10.1002/jcb.25203; Eguchi T, 2019, CANCERS, V11, DOI 10.3390/cancers11060792; Engelen E, 2011, NAT GENET, V43, P607, DOI 10.1038/ng.825; Feng WJ, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00309; Feng WJ, 2013, CELL STEM CELL, V13, P62, DOI 10.1016/j.stem.2013.05.002; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005; Gorgoulis VG, 1998, AM J PATHOL, V153, P1749, DOI 10.1016/S0002-9440(10)65690-8; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hellmich C, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00230; Hernandez-Segura A, 2017, CURR BIOL, V27, P2652, DOI 10.1016/j.cub.2017.07.033; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; Hsieh YH, 2006, BIOCHEM BIOPH RES CO, V339, P217, DOI 10.1016/j.bbrc.2005.11.015; Hsieh YH, 2007, CHINESE J PHYSIOL, V50, P9; Iwasaki O, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13604-5; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; Kanojia D, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax2879; Kotake Y, 2015, ANTICANCER RES, V35, P4397; Krizhanovsky V, 2008, COLD SH Q B, V73, P513, DOI 10.1101/sqb.2008.73.048; Kwong J, 2013, MOL CELL BIOL, V33, P3780, DOI 10.1128/MCB.00784-13; LaPak KM, 2014, MOL CANCER RES, V12, P167, DOI 10.1158/1541-7786.MCR-13-0350; Lee JH, 2017, INT J ONCOL, V50, P272, DOI 10.3892/ijo.2016.3793; Lee S, 2019, BMB REP, V52, P35, DOI 10.5483/BMBRep.2019.52.1.294; Lee S, 2019, NAT CELL BIOL, V21, P94, DOI 10.1038/s41556-018-0249-2; Li GQ, 2017, CELL PHYSIOL BIOCHEM, V44, P1242, DOI 10.1159/000485454; Li JJ, 2021, CANCER RES, V81, P114, DOI 10.1158/0008-5472.CAN-20-2270; Li WB, 2015, MOL CELL, V59, P188, DOI 10.1016/j.molcel.2015.06.002; Liu XP, 2015, ONCOTARGET, V6, P7930, DOI 10.18632/oncotarget.3181; Liu XL, 2018, ACTA PHARMACOL SIN, V39, P1553, DOI 10.1038/aps.2017.198; Murai K, 1997, GENES CELLS, V2, P581, DOI 10.1046/j.1365-2443.1997.1430341.x; Ohtani N, 2012, EXP DERMATOL, V21, P1, DOI 10.1111/j.1600-0625.2012.01493.x; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Peterson MJ, 2000, GENE, V254, P105, DOI 10.1016/S0378-1119(00)00281-X; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; Roman M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0789-x; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Scaglioni PP, 2012, EMBO MOL MED, V4, P594, DOI 10.1002/emmm.201200233; Schnetz MP, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001023; Schnetz MP, 2009, GENOME RES, V19, P590, DOI 10.1101/gr.086983.108; Schosserer M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00278; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Su WJ, 2018, ONCOGENE, V37, P5618, DOI 10.1038/s41388-018-0358-1; Sun LY, 2018, GENES-BASEL, V9, DOI 10.3390/genes9040211; Tsai LH, 2015, ONCOGENE, V34, P1641, DOI 10.1038/onc.2014.118; Tsai SJ, 2012, BIOCHEM BIOPH RES CO, V425, P462, DOI 10.1016/j.bbrc.2012.07.125; Tvingsholm SA, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0014-6; Ulianov SV, 2016, GENOME RES, V26, P70, DOI 10.1101/gr.196006.115; Vishwamitra D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0324-2; Waters AM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031435; Yokoyama Y, 2015, CELL CYCLE, V14, P2160, DOI 10.1080/15384101.2015.1049778; Zhang SL, 2019, J BIOL CHEM, V294, P16756, DOI 10.1074/jbc.RA119.009779; Zhang Y, 2014, BIOCHEM BIOPH RES CO, V453, P172, DOI 10.1016/j.bbrc.2014.09.092; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	71	2	2	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					414	426		10.1038/s41388-021-02110-y	http://dx.doi.org/10.1038/s41388-021-02110-y		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34773072	Green Accepted			2022-12-28	WOS:000717915200001
J	Berditchevski, F; Fennell, E; Murray, PG				Berditchevski, Fedor; Fennell, Eanna; Murray, Paul G.			Calcium-dependent signalling in B-cell lymphomas	ONCOGENE			English	Review							EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; NF-KAPPA-B; BRUTONS TYROSINE KINASE; PKC-BETA; DOWN-REGULATION; BURKITT-LYMPHOMA; C-BETA; EXPRESSION; SURVIVAL	Induced waves of calcium fluxes initiate multiple signalling pathways that play an important role in the differentiation and maturation of B-cells. Finely tuned transient Ca+2 fluxes from the endoplasmic reticulum in response to B-cell receptor (BCR) or chemokine receptor activation are followed by more sustained calcium influxes from the extracellular environment and contribute to the mechanisms responsible for the proliferation of B-cells, their migration within lymphoid organs and their differentiation. Dysregulation of these well-balanced mechanisms in B-cell lymphomas results in uncontrolled cell proliferation and resistance to apoptosis. Consequently, several cytotoxic drugs (and anti-proliferative compounds) used in standard chemotherapy regimens for the treatment of people with lymphoma target calcium-dependent pathways. Furthermore, similar to 10% of lymphoma associated mutations are found in genes with functions in calcium-dependent signalling, including those affecting B-cell receptor signalling pathways. In this review, we provide an overview of the Ca2+-dependent signalling network and outline the contribution of its key components to B cell lymphomagenesis. We also consider how the oncogenic Epstein-Barr virus, which is causally linked to the pathogenesis of a number of B-cell lymphomas, can modify Ca2+-dependent signalling.	[Berditchevski, Fedor] Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England; [Fennell, Eanna; Murray, Paul G.] Univ Limerick, Hlth Res Inst, Limerick V94 T9PX, Ireland; [Murray, Paul G.] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Limerick; University of Birmingham	Berditchevski, F (corresponding author), Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England.; Murray, PG (corresponding author), Univ Limerick, Hlth Res Inst, Limerick V94 T9PX, Ireland.; Murray, PG (corresponding author), Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, W Midlands, England.	f.berditchevski@bham.ac.uk; P.G.Murray@bham.ac.uk		Berditchevski, Fedor/0000-0003-0911-834X; Fennell, Eanna/0000-0002-1280-3439	Wellcome Trust [202708/Z/16/A]; European Regional Development Fund Project [ENOCH: CZ.02.1.01/0.0/0.0/16_019/0000868]	Wellcome Trust(Wellcome TrustEuropean Commission); European Regional Development Fund Project	The work was funded by the Seeding Discovery award from the Wellcome Trust [202708/Z/16/A] and a European Regional Development Fund Project (ENOCH: CZ.02.1.01/0.0/0.0/16_019/0000868). Figures were created with BioRender.com.	Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Azar AA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70191-y; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Ben Dhiab M, 2015, CELL ONCOL, V38, P453, DOI 10.1007/s13402-015-0242-8; Blair D, 2012, BIOCHEM J, V448, P165, DOI 10.1042/BJ20121225; Borgstrom A, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020229; Chen J, 2004, NAT IMMUNOL, V5, P651, DOI 10.1038/ni1072; Chen LF, 2008, BLOOD, V111, P2230, DOI 10.1182/blood-2007-07-100115; Chen WP, 1999, J IMMUNOL, V163, P2483; Chen YQ, 2021, IMMUNOL RES, V69, P8, DOI 10.1007/s12026-021-09177-5; Cheng CY, 2018, CANCER MED-US, V7, P380, DOI 10.1002/cam4.1276; Chuang SS, 2007, AM J CLIN PATHOL, V128, P558, DOI 10.1309/EQJR3D3V0CCQGP04; Conacci-Sorrell M, 2014, GENE DEV, V28, P689, DOI 10.1101/gad.231894.113; Conacci-Sorrell M, 2011, CELL CYCLE, V10, P604, DOI 10.4161/cc.10.4.14794; Creamer TP, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00636-4; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; de Porto AP, 2019, MOL MED, V25, DOI 10.1186/s10020-018-0069-7; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; Dellis O, 2011, J BIOL CHEM, V286, P18583, DOI 10.1074/jbc.M111.222257; Diaz F, 2000, CELL CALCIUM, V27, P315, DOI 10.1054/ceca.2000.0126; Dong XQ, 2019, CELL SIGNAL, V53, P68, DOI 10.1016/j.cellsig.2018.09.012; Engelke M, 2007, IMMUNOL REV, V218, P235, DOI 10.1111/j.1600-065X.2007.00539.x; Espinosa I, 2006, ANN HEMATOL, V85, P597, DOI 10.1007/s00277-006-0144-y; Fish K, 2020, P NATL ACAD SCI USA, V117, P26318, DOI 10.1073/pnas.2007946117; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Frazzi R, 2017, LEUKEMIA RES, V57, P89, DOI 10.1016/j.leukres.2017.02.012; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Gauchy AC, 2020, HEMATOL ONCOL, V38, P326, DOI 10.1002/hon.2735; Gayle S, 2017, BLOOD, V129, P1768, DOI 10.1182/blood-2016-09-736892; Giachelia M, 2014, J MOL DIAGN, V16, P467, DOI 10.1016/j.jmoldx.2014.03.003; Hans CP, 2005, MODERN PATHOL, V18, P1377, DOI 10.1038/modpathol.3800434; Havranek O, 2017, BLOOD, V130, P995, DOI 10.1182/blood-2016-10-747303; He XF, 2020, EXP HEMATOL, V86, P21, DOI 10.1016/j.exphem.2020.05.001; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hobeika E, 2015, J MOL MED, V93, P143, DOI 10.1007/s00109-015-1252-8; Jones RJ, 2007, INT J CANCER, V121, P1274, DOI 10.1002/ijc.22839; Jung HJ, 2012, BLOOD, V119, P2568, DOI 10.1182/blood-2011-09-377598; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Kapoor I, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2158-0; Khadra N, 2011, P NATL ACAD SCI USA, V108, P19072, DOI 10.1073/pnas.1116946108; Kim CW, 2021, LIFE SCI, V277, DOI 10.1016/j.lfs.2021.119607; Kim JE, 2014, MOL CELL BIOL, V34, P325, DOI 10.1128/MCB.00912-13; Kim J, 2012, J IMMUNOL, V188, P182, DOI 10.4049/jimmunol.1102297; Kondo E, 2003, EUR J IMMUNOL, V33, P1, DOI 10.1002/immu.200390000; Kosowicz JG, 2017, J VIROL, V91, DOI 10.1128/JVI.00747-17; Kristensen LS, 2014, ONCOTARGET, V5, P9798, DOI 10.18632/oncotarget.2394; Krysiak K, 2017, BLOOD, V129, P473, DOI 10.1182/blood-2016-07-729954; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Latour S, 2019, CANCERS, V11, DOI 10.3390/cancers11030291; Latour S, 2018, CANCERS, V10, DOI 10.3390/cancers10110402; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Li SY, 2007, BIOL DIRECT, V2, DOI 10.1186/1745-6150-2-8; Linley A, 2015, BLOOD, V126, P1902, DOI 10.1182/blood-2015-04-640805; Loo SK, 2017, HISTOPATHOLOGY, V71, P98, DOI 10.1111/his.13204; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Mahtani T, 2019, IMMUNOL REV, V291, P104, DOI 10.1111/imr.12770; Mao J, 2020, CLIN CHIM ACTA, V510, P741, DOI 10.1016/j.cca.2020.09.011; Marafiot T, 2005, BRIT J HAEMATOL, V128, P333, DOI 10.1111/j.1365-2141.2004.05313.x; Marshall MJE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01245; Maxwell SA, 2011, LEUKEMIA LYMPHOMA, V52, P849, DOI 10.3109/10428194.2010.551793; Medyouf H, 2008, CELL CYCLE, V7, P297, DOI 10.4161/cc.7.3.5357; Merchant M, 2001, VIROLOGY, V291, P46, DOI 10.1006/viro.2001.1187; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Montresor Alessio, 2018, Oncotarget, V9, P35123, DOI 10.18632/oncotarget.26212; Mukhopadhyay S, 2001, FEBS LETT, V505, P37, DOI 10.1016/S0014-5793(01)02765-X; MURRAY PG, 1992, J PATHOL, V166, P1, DOI 10.1002/path.1711660102; Nakashima M, 2018, BIOL CELL, V110, P109, DOI 10.1111/boc.201800002; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Numaga T, 2010, J CELL SCI, V123, P927, DOI 10.1242/jcs.061051; Oellerich T, 2011, EMBO J, V30, P3620, DOI 10.1038/emboj.2011.251; Ok CY, 2013, BLOOD, V122, P328, DOI 10.1182/blood-2013-03-489708; Ondrisova L, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.591577; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Pfeifhofer C, 2006, J IMMUNOL, V176, P6004, DOI 10.4049/jimmunol.176.10.6004; Polouliakh N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004189; Portis T, 2004, ONCOGENE, V23, P8619, DOI 10.1038/sj.onc.1207905; Portis T, 2003, BLOOD, V102, P4166, DOI 10.1182/blood-2003-04-1018; Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043; Romero-Masters JC, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008365; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Ruiz-Vela A, 2001, J EXP MED, V194, P247, DOI 10.1084/jem.194.3.247; Saijo K, 2003, ANN NY ACAD SCI, V987, P125, DOI 10.1111/j.1749-6632.2003.tb06040.x; SATO S, 1995, P NATL ACAD SCI USA, V92, P11558, DOI 10.1073/pnas.92.25.11558; Schaadt E, 2005, J GEN VIROL, V86, P551, DOI 10.1099/vir.0.80440-0; Schain F, 2008, INT J CANCER, V123, P2285, DOI 10.1002/ijc.23781; Schain F, 2008, CLIN LYMPHOMA MYELOM, V8, P340, DOI 10.3816/CLM.2008.n.049; Scott DW, 2014, NAT REV CANCER, V14, P517, DOI 10.1038/nrc3774; Seifert M, 2019, METHODS MOL BIOL, V1956, P1, DOI 10.1007/978-1-4939-9151-8_1; Shair KHY, 2007, PLOS PATHOG, V3, P1669, DOI 10.1371/journal.ppat.0030166; Shirakawa AK, 2010, CELL MOL IMMUNOL, V7, P428, DOI 10.1038/cmi.2010.46; Sicari D, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111347; Singh K, 2016, MUTAT RES-REV MUTAT, V769, P1, DOI [10.1016/j.mrrev.2016.06.001, 10.1016/j.md.2017.03.001]; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Su TT, 2002, NAT IMMUNOL, V3, P780, DOI 10.1038/ni823; Tao L, 2013, ELIFE, V2, DOI 10.7554/eLife.00518; Taylor CW, 2017, CELL CALCIUM, V63, P48, DOI 10.1016/j.ceca.2016.10.005; Taylor J, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1734326; ten Hacken E, 2017, CANCER CELL, V32, P716, DOI 10.1016/j.ccell.2017.10.015; Vacher P, 2015, J IMMUNOL, V195, P2207, DOI 10.4049/jimmunol.1402942; Vallet N, 2020, ANN HEMATOL, V99, P229, DOI 10.1007/s00277-019-03890-w; Varela-Lopez A, 2019, FOOD CHEM TOXICOL, V134, DOI 10.1016/j.fct.2019.110834; Varghese E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20123017; Venkataraman C, 2006, IMMUNOL LETT, V105, P83, DOI 10.1016/j.imlet.2006.01.006; Vockerodt M, 2008, J PATHOL, V216, P83, DOI 10.1002/path.2384; Vockerodt M, 2013, J PATHOL, V230, P399, DOI 10.1002/path.4198; Wang L, 2021, CHINESE MED J-PEKING, V134, P253, DOI 10.1097/CM9.0000000000001294; Wang L, 2013, ONCOL REP, V30, P2427, DOI 10.3892/or.2013.2729; Weniger MA, 2021, LEUKEMIA, V35, P968, DOI 10.1038/s41375-021-01204-6; Wist M, 2020, J BIOL CHEM, V295, P5717, DOI 10.1074/jbc.RA119.011946; Xue C, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01518-y; Young LS, 2016, NAT REV CANCER, V16, P789, DOI 10.1038/nrc.2016.92; Young RM, 2015, P NATL ACAD SCI USA, V112, P13447, DOI 10.1073/pnas.1514944112; Zhang JY, 2019, CLIN CANCER RES, V25, P4168, DOI 10.1158/1078-0432.CCR-18-2146; Zhang LW, 2004, VIROLOGY, V323, P141, DOI 10.1016/j.virol.2004.03.007; Zhu DM, 2000, CLIN CANCER RES, V6, P2456	119	0	0	6	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6321	6328		10.1038/s41388-021-02025-8	http://dx.doi.org/10.1038/s41388-021-02025-8		OCT 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34625709	Green Published, hybrid			2022-12-28	WOS:000705760400002
J	Moskovich, D; Finkelshtein, Y; Alfandari, A; Rosemarin, A; Lifschytz, T; Weisz, A; Mondal, S; Ungati, H; Katzav, A; Kidron, D; Mugesh, G; Ellis, M; Lerer, B; Ashur-Fabian, O				Moskovich, Dotan; Finkelshtein, Yael; Alfandari, Adi; Rosemarin, Amit; Lifschytz, Tzuri; Weisz, Avivit; Mondal, Santanu; Ungati, Harinarayana; Katzav, Aviva; Kidron, Debora; Mugesh, Govindasamy; Ellis, Martin; Lerer, Bernard; Ashur-Fabian, Osnat			Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment	ONCOGENE			English	Article							IODOTHYRONINE DEIODINASE MIMICS; THYROID-HORMONE-RECEPTOR; TYPE-3 DEIODINASE; MEDICINAL CHEMISTRY; KINASE INHIBITOR; GENE-EXPRESSION; PROLIFERATION; TRANSCRIPTION; MAPK; DIFFERENTIATION	The enzyme iodothyronine deiodinase type 3 (DIO3) contributes to cancer proliferation by inactivating the tumor-suppressive actions of thyroid hormone (T3). We recently established DIO3 involvement in the progression of high-grade serous ovarian cancer (HGSOC). Here we provide a link between high DIO3 expression and lower survival in patients, similar to common disease markers such as Ki67, PAX8, CA-125, and CCNE1. These observations suggest that DIO3 is a logical target for inhibition. Using a DIO3 mimic, we developed original DIO3 inhibitors that contain a core of dibromomaleic anhydride (DBRMD) as scaffold. Two compounds, PBENZ-DBRMD and ITYR-DBRMD, demonstrated attenuated cell counts, induction in apoptosis, and a reduction in cell proliferation in DIO3-positive HGSOC cells (OVCAR3 and KURAMOCHI), but not in DIO3-negative normal ovary cells (CHOK1) and OVCAR3 depleted for DIO3 or its substrate, T3. Potent tumor inhibition with a high safety profile was further established in HGSOC xenograft model, with no effect in DIO3-depleted tumors. The antitumor effects are mediated by downregulation in an array of pro-cancerous proteins, the majority of which known to be repressed by T3. To conclude, using small molecules that specifically target the DIO3 enzyme we present a new treatment paradigm for ovarian cancer and potentially other DIO3-dependent malignancies.	[Moskovich, Dotan; Finkelshtein, Yael; Alfandari, Adi; Ellis, Martin; Ashur-Fabian, Osnat] Meir Med Ctr, Hematol Inst, Translat Oncol Lab, Kefar Sava, Israel; [Moskovich, Dotan; Finkelshtein, Yael; Alfandari, Adi; Ellis, Martin; Ashur-Fabian, Osnat] Meir Med Ctr, Blood Bank, Kefar Sava, Israel; [Moskovich, Dotan; Finkelshtein, Yael; Alfandari, Adi; Ashur-Fabian, Osnat] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel; [Lifschytz, Tzuri; Lerer, Bernard] Hadassah Hebrew Univ, Med Ctr, Biol Psychiat Lab, Jerusalem, Israel; [Weisz, Avivit; Katzav, Aviva; Kidron, Debora] Meir Med Ctr, Dept Pathol, Kefar Sava, Israel; [Mondal, Santanu; Ungati, Harinarayana; Mugesh, Govindasamy] Indian Inst Sci, Dept Inorgan & Phys Chem, Bangalore, Karnataka, India; [Ellis, Martin] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Hadassah University Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Indian Institute of Science (IISC) - Bangalore; Tel Aviv University; Sackler Faculty of Medicine	Ashur-Fabian, O (corresponding author), Meir Med Ctr, Hematol Inst, Translat Oncol Lab, Kefar Sava, Israel.; Ashur-Fabian, O (corresponding author), Meir Med Ctr, Blood Bank, Kefar Sava, Israel.; Ashur-Fabian, O (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel.	osnataf@gmail.com	Mondal, Santanu/L-9157-2015	Mondal, Santanu/0000-0002-7399-8364	Israel Innovation Authority, Nofar Program for Applied Research in Academia, Ministry of Economics [59435]	Israel Innovation Authority, Nofar Program for Applied Research in Academia, Ministry of Economics	The work of DM was done in partial fulfillment of the requirements for a PhD degree from the Sackler Faculty of Medicine, Tel Aviv University, Israel. OA-F and BL received support from the Israel Innovation Authority, Nofar Program for Applied Research in Academia, Ministry of Economics (Project 59435).	Bargonetti J, 2019, J MOL CELL BIOL, V11, P605, DOI 10.1093/jmcb/mjz067; Catalano V, 2016, CANCER RES, V76, P1237, DOI 10.1158/0008-5472.CAN-15-1542; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Cohen K, 2011, MOL CANCER RES, V9, P1385, DOI 10.1158/1541-7786.MCR-11-0187; Cole AJ., 2016, SCI REP-UK, V6, P1, DOI [10.1038/s41598-016-0001-8, DOI 10.1038/S41598-016-0001-8]; Contreras-Jurado C, 2016, SCI REP-UK, V6, DOI 10.1038/srep30990; Dentice M, 2007, P NATL ACAD SCI USA, V104, P14466, DOI 10.1073/pnas.0706754104; Dentice M, 2013, EXPERT OPIN THER TAR, V17, P1369, DOI 10.1517/14728222.2013.833189; Dentice M, 2012, GASTROENTEROLOGY, V143, P1037, DOI 10.1053/j.gastro.2012.06.042; Dhillon S, 2021, DRUGS, V81, P283, DOI 10.1007/s40265-020-01464-z; Di Girolamo D, 2016, J CLIN INVEST, V126, P2308, DOI 10.1172/JCI84465; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Flores-Morales A, 2002, MOL ENDOCRINOL, V16, P1257, DOI 10.1210/me.16.6.1257; Gagne R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-341; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Ghannam-Shahbari D, 2018, ONCOGENE, V37, P2213, DOI 10.1038/s41388-017-0040-z; Goemann IM, 2018, ENDOCR-RELAT CANCER, V25, pR625, DOI 10.1530/ERC-18-0097; Goemann IM, 2017, ENDOCR-RELAT CANCER, V24, pR367, DOI 10.1530/ERC-17-0192; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Hernandes MZ, 2010, CURR DRUG TARGETS, V11, P303, DOI 10.2174/138945010790711996; Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075; Lheureux S, 2019, LANCET, V393, P1240, DOI 10.1016/S0140-6736(18)32552-2; Luongo C, 2019, NAT REV ENDOCRINOL, V15, P479, DOI 10.1038/s41574-019-0218-2; Manna D, 2012, J AM CHEM SOC, V134, P4269, DOI 10.1021/ja210478k; Manna D, 2011, J AM CHEM SOC, V133, P9980, DOI 10.1021/ja201657s; Manna D, 2010, ANGEW CHEM INT EDIT, V49, P9246, DOI 10.1002/anie.201005235; Mondal S, 2016, ORG BIOMOL CHEM, V14, P9490, DOI 10.1039/c6ob01375a; Moskovich D, 2021, CANCER LETT, V501, P224, DOI 10.1016/j.canlet.2020.11.011; Nappi A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137175; Nappi A, 2021, ENDOCRINOLOGY, V162, DOI 10.1210/endocr/bqab016; Perez-Juste G, 2000, J BIOL CHEM, V275, P1307, DOI 10.1074/jbc.275.2.1307; Perez-Juste G, 1999, J BIOL CHEM, V274, P5026, DOI 10.1074/jbc.274.8.5026; Porlan E, 2008, ONCOGENE, V27, P2795, DOI 10.1038/sj.onc.1210936; Punchihewa C, 2012, J BIOL CHEM, V287, P14289, DOI 10.1074/jbc.M112.353201; Raja K, 2015, ANGEW CHEM INT EDIT, V54, P7674, DOI 10.1002/anie.201502762; Renko K, 2015, THYROID, V25, P962, DOI 10.1089/thy.2015.0058; Romitti M, 2016, ENDOCR-RELAT CANCER, V23, P135, DOI 10.1530/ERC-15-0162; Schweizer U, 2014, P NATL ACAD SCI USA, V111, P10526, DOI 10.1073/pnas.1323873111; Shinderman-Maman E, 2016, ONCOGENE, V35, P1977, DOI 10.1038/onc.2015.262; SIEGEL R, 2021 CA CANC J CLIN, V71, P33; Simpkins F, 2018, CLIN CANCER RES, V24, P4874, DOI 10.1158/1078-0432.CCR-17-3697; Smith BD, 2019, CANCER CELL, V35, P738, DOI 10.1016/j.ccell.2019.04.006; Steegborn C, 2020, EXP CLIN ENDOCR DIAB, V128, P375, DOI 10.1055/a-1022-9916; SUAREZ J, 2010, AM J PHYSIOL-CELL PH, V299; Voth AR, 2007, CURR TOP MED CHEM, V7, P1336; Nguyen VHL, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0596-z; Wasik R, 2010, J PHYS CHEM B, V114, P10601, DOI 10.1021/jp102848y; Wilcken R, 2013, J MED CHEM, V56, P1363, DOI 10.1021/jm3012068; YAGINUMA Y, 1992, CANCER RES, V52, P4196	49	3	3	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6248	6257		10.1038/s41388-021-02020-z	http://dx.doi.org/10.1038/s41388-021-02020-z		SEP 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34556811				2022-12-28	WOS:000698556400005
J	Heltemes-Harris, LM; Hubbard, GK; LaRue, RS; Munro, SA; Yang, RD; Henzler, CM; Starr, TK; Sarver, AL; Kornblau, SM; Farrar, MA				Heltemes-Harris, Lynn M.; Hubbard, Gregory K.; LaRue, Rebecca S.; Munro, Sarah A.; Yang, Rendong; Henzler, Christine M.; Starr, Timothy K.; Sarver, Aaron L.; Kornblau, Steven M.; Farrar, Michael A.			Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia	ONCOGENE			English	Article							STAT5 ACTIVATION; LYMPHOBLASTIC-LEUKEMIA; KAPPA-B; CBL-B; DIFFERENTIATION; GENE; TRANSFORMATION; RESISTANCE; DELETION; FAILURE	The transcription factors PAX5, IKZF1, and EBF1 are frequently mutated in B cell acute lymphoblastic leukemia (B-ALL). We demonstrate that compound heterozygous loss of multiple genes critical for B and T cell development drives transformation, including Pax5(+/-)xEbf1(+/-), Pax5(+/-)xikzf1(+/-), and Ebf1(+/-)xlkzf1(+/-) mice for B-ALL, or Tcf7(+/-)xlkzf1(+/-) mice for T-ALL. To identify genetic defects that cooperate with Pax5 and Ebf1 compound heterozygosity to initiate leukemia, we performed a Sleeping Beauty (SB) transposon screen that identified cooperating partners including gain-of-function mutations in Stat5b (similar to 65%) and Jak7 (similar to 68%), or loss-of-function mutations in Cblb (61%) and Myb (32%). These findings underscore the role of JAK/STAT5B signaling in B cell transformation and demonstrate roles for loss-of-function mutations in Cblb and Myb in transformation. RNA-Seq studies demonstrated upregulation of a PDK1>SGK3>MYC pathway; treatment of Pax5(+/-)xEbf1(+/- )leukemia cells with PDK1 inhibitors blocked proliferation in vitro. In addition, we identified a conserved transcriptional gene signature between human and murine leukemias characterized by upregulation of myeloid genes, most notably involving the GM-CSF pathway, that resemble a B cell/myeloid mixed-lineage leukemia. Thus, our findings identify multiple mechanisms that cooperate with defects in B cell transcription factors to generate either progenitor B cell or mixed B/myeloid-like leukemias.	[Heltemes-Harris, Lynn M.; Hubbard, Gregory K.; Farrar, Michael A.] Univ Minnesota, Ctr Immunol, Minneapolis, MN 55455 USA; [Heltemes-Harris, Lynn M.; Hubbard, Gregory K.; Starr, Timothy K.; Sarver, Aaron L.; Farrar, Michael A.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA; [Heltemes-Harris, Lynn M.; Hubbard, Gregory K.; Farrar, Michael A.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [LaRue, Rebecca S.; Munro, Sarah A.; Yang, Rendong; Henzler, Christine M.] Univ Minnesota, Minnesota Supercomp Inst, Minneapolis, MN 55455 USA; [Starr, Timothy K.] Univ Minnesota, Dept Obstet Gynecol & Womens Hlth, Minneapolis, MN 55455 USA; [Kornblau, Steven M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Yang, Rendong] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; UTMD Anderson Cancer Center; University of Minnesota System	Farrar, MA (corresponding author), Univ Minnesota, Ctr Immunol, Minneapolis, MN 55455 USA.; Farrar, MA (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.; Farrar, MA (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.	farra005@umn.edu	; yang, rendong/I-5552-2014	Starr, Timothy/0000-0002-6308-3451; yang, rendong/0000-0002-9512-2240; Heltemes Harris, Lynn/0000-0002-2668-8005; Kornblau, Steven/0000-0002-5990-9548; Farrar, Michael/0000-0002-5569-0366	Cancer Research Institute Investigator award; Leukemia and Lymphoma Society Scholar award; UMN Masonic Cancer center; NIH [RO1 CA232317]; Randy Shaver Cancer Research and Community Fund; Masonic Cancer Center; NCI [CA211249]; Masonic Cancer Center Support Grant [CA077598]; CPRIT MIRA RP [160693]; NIH/NCI [P50 CA100632-09]; NIH NCI [R21 CA216652]	Cancer Research Institute Investigator award; Leukemia and Lymphoma Society Scholar award(Leukemia and Lymphoma Society); UMN Masonic Cancer center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Randy Shaver Cancer Research and Community Fund; Masonic Cancer Center; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Masonic Cancer Center Support Grant; CPRIT MIRA RP; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank A. Rost, for technical assistance with mouse breeding; the University of Minnesota's Supercomputing Institute for providing computing and bioinformatic resources; Dr. Meinrad Busslinger (Pax5+/-), Dr. Rudolf Grosschedl (Ebf1-/-), Dr. Peter Johnson (Cebpa-/-), Dr. Andrew Wells (Ikzf1-/-) and Dr. David Largaespada (Rosa26LSLSB11T2/OncxRosa26LSL-SB11) for providing the indicated mouse strains. The results published here are in part based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative, phs000218, managed by the NCI. This work was supported by a Cancer Research Institute Investigator award, a Leukemia and Lymphoma Society Scholar award, funding from the UMN Masonic Cancer center and grants from the NIH (RO1 CA232317) to MAF. TKS was supported by grants from the Randy Shaver Cancer Research and Community Fund, NIH NCI (R21 CA216652), and the Masonic Cancer Center. ALS was supported by NCI (CA211249) and Masonic Cancer Center Support Grant (CA077598). SMK was supported by CPRIT MIRA RP 160693 and NIH/NCI P50 CA100632-09.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Badger-Brown KM, 2013, LEUKEMIA, V27, P1146, DOI 10.1038/leu.2012.331; Beckmann PJ, 2019, CANCER RES, V79, P905, DOI 10.1158/0008-5472.CAN-18-1261; Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen F, 2007, CANCER RES, V67, P11093, DOI 10.1158/0008-5472.CAN-07-1576; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Churchman ML, 2018, CANCER CELL, V33, P937, DOI 10.1016/j.ccell.2018.03.021; Dupuy AJ, 2009, CANCER RES, V69, P8150, DOI 10.1158/0008-5472.CAN-09-1135; Fahl SP, 2009, J IMMUNOL, V183, P5582, DOI 10.4049/jimmunol.0901187; Goetz CA, 2004, J IMMUNOL, V172, P4770, DOI 10.4049/jimmunol.172.8.4770; Heath V, 2004, BLOOD, V104, P1639, DOI 10.1182/blood-2003-11-3963; Heltemes-Harris LM, 2016, ONCOGENE, V35, P3454, DOI 10.1038/onc.2015.405; Heltemes-Harris LM, 2011, J EXP MED, V208, P1135, DOI 10.1084/jem.20101947; Katerndahl CDS, 2017, NAT IMMUNOL, V18, P694, DOI 10.1038/ni.3716; Kollmann S, 2019, LEUKEMIA, V33, P1583, DOI 10.1038/s41375-018-0369-5; Kornblau SM, 2009, BLOOD, V113, P154, DOI 10.1182/blood-2007-10-119438; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Mullighan CG, 2014, HEMATOL-AM SOC HEMAT, P174, DOI 10.1182/asheducation-2014.1.174; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732; Oliveros J.C., 2007, VENNY INTERACTIVE TO; Papathanasiou P, 2003, IMMUNITY, V19, P131, DOI 10.1016/S1074-7613(03)00168-7; Prasad MAJ, 2015, BLOOD, V125, P4052, DOI 10.1182/blood-2014-12-617282; Roberts KG, 2014, NEW ENGL J MED, V371, P1005, DOI 10.1056/NEJMoa1403088; Sarver AL, 2021, LAB INVEST, V101, P701, DOI 10.1038/s41374-021-00573-x; Scott MC, 2018, CANCER RES, V78, P326, DOI 10.1158/0008-5472.CAN-17-0576; Shah S, 2013, NAT GENET, V45, P1226, DOI 10.1038/ng.2754; Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595; Temiz NA, 2016, GENOME RES, V26, P119, DOI 10.1101/gr.188649.114; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; van der Weyden L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1586-1; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Xiao X, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2617-2; Zhou JJ, 2021, NAT IMMUNOL, V22, P460, DOI 10.1038/s41590-021-00888-3	43	3	3	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6166	6179		10.1038/s41388-021-02012-z	http://dx.doi.org/10.1038/s41388-021-02012-z		SEP 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34535769	Green Accepted, Green Submitted			2022-12-28	WOS:000696766300001
J	Harrod, A; Lai, CF; Goldsbrough, I; Simmons, GM; Oppermans, N; Santos, DB; Gyorffy, B; Allsopp, RC; Toghill, BJ; Balachandran, K; Lawson, M; Morrow, CJ; Surakala, M; Carnevalli, LS; Zhang, P; Guttery, DS; Shaw, JA; Coombes, RC; Buluwela, L; Ali, S				Harrod, Alison; Lai, Chun-Fui; Goldsbrough, Isabella; Simmons, Georgia M.; Oppermans, Natasha; Santos, Daniela B.; Gyorffy, Balazs; Allsopp, Rebecca C.; Toghill, Bradley J.; Balachandran, Kirsty; Lawson, Mandy; Morrow, Christopher J.; Surakala, Manasa; Carnevalli, Larissa S.; Zhang, Pei; Guttery, David S.; Shaw, Jacqueline A.; Coombes, R. Charles; Buluwela, Lakjaya; Ali, Simak			Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer	ONCOGENE			English	Article							LIGAND-BINDING DOMAIN; ACQUIRED ENDOCRINE RESISTANCE; ACTIVATING ESR1 MUTATIONS; ALPHA MUTATIONS; THERAPEUTIC VULNERABILITIES; AROMATASE INHIBITORS; CELLS; ANTAGONISM; LANDSCAPE; STABILITY	Mutations in the estrogen receptor (ESR1) gene are common in ER-positive breast cancer patients who progress on endocrine therapies. Most mutations localise to just three residues at, or near, the C-terminal helix 12 of the hormone binding domain, at leucine-536, tyrosine-537 and aspartate-538. To investigate these mutations, we have used CRISPR-Cas9 mediated genome engineering to generate a comprehensive set of isogenic mutant breast cancer cell lines. Our results confirm that L536R, Y537C, Y537N, Y537S and D538G mutations confer estrogen-independent growth in breast cancer cells. Growth assays show mutation-specific reductions in sensitivities to drugs representing three classes of clinical anti-estrogens. These differential mutation- and drug-selectivity profiles have implications for treatment choices following clinical emergence of ER mutations. Our results further suggest that mutant expression levels may be determinants of the degree of resistance to some anti-estrogens. Differential gene expression analysis demonstrates up-regulation of estrogen-responsive genes, as expected, but also reveals that enrichment for interferon-regulated gene expression is a common feature of all mutations. Finally, a new gene signature developed from the gene expression profiles in ER mutant cells predicts clinical response in breast cancer patients with ER mutations.	[Harrod, Alison; Lai, Chun-Fui; Goldsbrough, Isabella; Simmons, Georgia M.; Oppermans, Natasha; Santos, Daniela B.; Balachandran, Kirsty; Coombes, R. Charles; Buluwela, Lakjaya; Ali, Simak] Imperial Coll London, Dept Surg & Canc, London W12 0NN, England; [Gyorffy, Balazs] Semmelweis Univ, Dept Bioinformat, H-1094 Budapest, Hungary; [Gyorffy, Balazs] TTK Canc Biomarker Res Grp, H-1117 Budapest, Hungary; [Allsopp, Rebecca C.; Toghill, Bradley J.; Guttery, David S.; Shaw, Jacqueline A.] Univ Leicester, Leicester Canc Res Ctr, Dept Genet & Genome Biol, Leicester Royal Infirm, Robert Kilpatrick Clin Sci Bldg, Leicester LE2 7LX, Leics, England; [Lawson, Mandy; Morrow, Christopher J.; Surakala, Manasa; Carnevalli, Larissa S.; Zhang, Pei] AstraZeneca, Early Oncol R&D, Biomed Campus,1 Francis Crick Ave, Cambridge CB2 0AA, England; [Harrod, Alison] Inst Canc Res, Fulham Rd, London SW3 6JB, England	Imperial College London; Semmelweis University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; University of Leicester; AstraZeneca; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Buluwela, L; Ali, S (corresponding author), Imperial Coll London, Dept Surg & Canc, London W12 0NN, England.	l.buluwela@imperial.ac.uk; simak.ali@imperial.ac.uk	; Ali, Simak/M-6912-2018	Coombes, Raoul Charles/0000-0002-4811-1100; Carnevalli, Larissa/0000-0001-7432-0195; Ali, Simak/0000-0002-1320-0816; Harrod, Alison/0000-0002-3977-2791	Cancer Research UK Imperial Centre; Medical Research Council [MR/P016413/1, MR/P018521/1]; Breast Cancer Now [2014MayPR234]; Cancer Research UK [C37/A18784]; Ministry for Innovation and Technology in Hungary [2020-1.1.6-JoVO-2021-00013, 2020-4.1.1.-TKP2020]; Imperial Experimental Cancer Medicine Centre; Imperial NIHR Biomedical Research Centre	Cancer Research UK Imperial Centre; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breast Cancer Now; Cancer Research UK(Cancer Research UK); Ministry for Innovation and Technology in Hungary; Imperial Experimental Cancer Medicine Centre; Imperial NIHR Biomedical Research Centre(National Institute for Health Research (NIHR))	We thank Dr Jun Liang (Genentech) for GDC-0810. AH was supported by a Ph.D. studentship from the Cancer Research UK Imperial Centre. IG and KB were supported by a Medical Research Council Industrial CASE studentship (MR/P016413/1) and clinical research training fellowship (MR/P018521/1), respectively. CFL was supported by Breast Cancer Now (2014MayPR234) and Cancer Research UK (C37/A18784). BG was supported by the 2020-1.1.6-JoVO-2021-00013 and 2020-4.1.1.-TKP2020 grants of the Ministry for Innovation and Technology in Hungary. Additional support was provided by the Imperial Experimental Cancer Medicine Centre and the Imperial NIHR Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Abe O, 2005, LANCET, V366, P2087; Anders S, 2012, GENOME RES, V22, P2008, DOI 10.1101/gr.133744.111; Andreano KJ, 2020, MOL CANCER THER, V19, P1395, DOI 10.1158/1535-7163.MCT-19-1148; Arnesen S, 2021, CANCER RES, V81, P539, DOI 10.1158/0008-5472.CAN-20-1171; Bahreini A, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0851-4; Baird R, 2021, CANCER RES, V81; Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-293; Barrangou R, 2016, NAT BIOTECHNOL, V34, P933, DOI 10.1038/nbt.3659; Bidard FC, 2022, J CLIN ONCOL, V40, P3246, DOI 10.1200/JCO.22.00338; Bottcher R, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku289; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Carlson KE, 1997, BIOCHEMISTRY-US, V36, P14897, DOI 10.1021/bi971746l; Chumsri S, 2011, J STEROID BIOCHEM, V125, P13, DOI 10.1016/j.jsbmb.2011.02.001; Coombes RC, 2019, CLIN CANCER RES, V25, P4255, DOI 10.1158/1078-0432.CCR-18-3663; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dahlgren M, 2021, JNCI CANCER SPECT, V5, DOI 10.1093/jncics/pkab028; Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1; Eng FCS, 1997, MOL CELL BIOL, V17, P4644, DOI 10.1128/MCB.17.8.4644; Fanning Sean W, 2016, Elife, V5, DOI 10.7554/eLife.12792; Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Gates LA, 2018, ONCOGENE, V37, P4581, DOI 10.1038/s41388-018-0284-2; Gelsomino L, 2018, CANCER LETT, V428, P12, DOI 10.1016/j.canlet.2018.04.023; Gu GW, 2021, ONCOGENE, V40, P997, DOI 10.1038/s41388-020-01563-x; HACKENBERG R, 1992, J STEROID BIOCHEM, V43, P599, DOI 10.1016/0960-0760(92)90284-P; Harrod A, 2017, ONCOGENE, V36, P2286, DOI 10.1038/onc.2016.382; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Herzog SK, 2022, BRIT J CANCER, V126, P174, DOI 10.1038/s41416-021-01564-x; Hickey TE, 2021, NAT MED, V27, P310, DOI 10.1038/s41591-020-01168-7; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Jia SH, 2018, ONCOLOGY-BASEL, V94, P176, DOI 10.1159/000485510; Kalinsky K, 2021, J CLIN ONCOL, V39, P100, DOI 10.1200/JCO.20.03040; Katzenellenbogen JA, 2018, NAT REV CANCER, V18, P377, DOI 10.1038/s41568-018-0001-z; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lanczky A, 2021, J MED INTERNET RES, V23, DOI 10.2196/27633; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920; Mao CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep34753; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Nettles KW, 2008, NAT CHEM BIOL, V4, P241, DOI 10.1038/nchembio.76; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; O'Leary B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03215-x; Oesterreich S, 2013, NAT GENET, V45, P1415, DOI 10.1038/ng.2831; Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Pearce ST, 2003, J BIOL CHEM, V278, P7630, DOI 10.1074/jbc.M211129200; Pleasance E, 2020, NAT CANCER, V1, P452, DOI 10.1038/s43018-020-0050-6; Puyang XL, 2018, CANCER DISCOV, V8, P1176, DOI 10.1158/2159-8290.CD-17-1229; Razavi P, 2018, CANCER CELL, V34, P427, DOI 10.1016/j.ccell.2018.08.008; Rinaldi J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231999; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Sava GP, 2020, ONCOGENE, V39, P651, DOI 10.1038/s41388-019-1008-y; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schurch NJ, 2016, RNA, V22, P839, DOI 10.1261/rna.053959.115; Shaw JA, 2017, CLIN CANCER RES, V23, P88, DOI 10.1158/1078-0432.CCR-16-0825; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spoerke JM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11579; STOVER EP, 1987, ENDOCRINOLOGY, V120, P2597, DOI 10.1210/endo-120-6-2597; Toy W, 2017, CANCER DISCOV, V7, P277, DOI 10.1158/2159-8290.CD-15-1523; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Williams MM, 2021, CANCER RES, V81, P732, DOI 10.1158/0008-5472.CAN-20-1200; Yu LQ, 2019, CANCER LETT, V442, P373, DOI 10.1016/j.canlet.2018.10.041; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhao CQ, 2003, J BIOL CHEM, V278, P27278, DOI 10.1074/jbc.M303840200	73	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4905	4915		10.1038/s41388-022-02483-8	http://dx.doi.org/10.1038/s41388-022-02483-8		OCT 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36198774	Green Published, hybrid			2022-12-28	WOS:000864316200001
J	Ipsen, MB; Sorensen, EMG; Thomsen, EA; Weiss, S; Haldrup, J; Dalby, A; Palmfeldt, J; Bross, P; Rasmussen, M; Fredsoe, J; Klingenberg, S; Jochumsen, MR; Bouchelouche, K; Ulhoi, BP; Borre, M; Mikkelsen, JG; Sorensen, KD				Ipsen, Malene Blond; Sorensen, Ea Marie Givskov; Thomsen, Emil Aagaard; Weiss, Simone; Haldrup, Jakob; Dalby, Anders; Palmfeldt, Johan; Bross, Peter; Rasmussen, Martin; Fredsoe, Jacob; Klingenberg, Soren; Jochumsen, Mads R.; Bouchelouche, Kirsten; Ulhoi, Benedicte Parm; Borre, Michael; Mikkelsen, Jacob Giehm; Sorensen, Karina Dalsgaard			A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer	ONCOGENE			English	Article							CELL-FREE DNA; POLY(ADP-RIBOSE); REPAIR; ACTIVATION; AUTOPHAGY; OLAPARIB	DNA repair gene mutations are frequent in castration-resistant prostate cancer (CRPC), suggesting eligibility for poly(ADP-ribose) polymerase inhibitor (PARPi) treatment. However, therapy resistance is a major clinical challenge and genes contributing to PARPi resistance are poorly understood. Using a genome-wide CRISPR-Cas9 knockout screen, this study aimed at identifying genes involved in PARPi resistance in CRPC. Based on the screen, we identified PARP1, and six novel candidates associated with olaparib resistance upon knockout. For validation, we generated multiple knockout populations/clones per gene in C4 and/or LNCaP CRPC cells, which confirmed that loss of PARP1, ARH3, YWHAE, or UBR5 caused olaparib resistance. PARP1 or ARH3 knockout caused cross-resistance to other PARPis (veliparib and niraparib). Furthermore, PARP1 or ARH3 knockout led to reduced autophagy, while pharmacological induction of autophagy partially reverted their PARPi resistant phenotype. Tumor RNA sequencing of 126 prostate cancer patients identified low ARH3 expression as an independent predictor of recurrence. Our results advance the understanding of PARPi response by identifying four novel genes that contribute to PARPi sensitivity in CRPC and suggest a new model of PARPi resistance through decreased autophagy.	[Ipsen, Malene Blond; Sorensen, Ea Marie Givskov; Weiss, Simone; Haldrup, Jakob; Rasmussen, Martin; Fredsoe, Jacob; Klingenberg, Soren; Sorensen, Karina Dalsgaard] Aarhus Univ Hosp, Dept Mol Med, Aarhus, Denmark; [Ipsen, Malene Blond; Sorensen, Ea Marie Givskov; Weiss, Simone; Haldrup, Jakob; Palmfeldt, Johan; Bross, Peter; Rasmussen, Martin; Fredsoe, Jacob; Klingenberg, Soren; Jochumsen, Mads R.; Bouchelouche, Kirsten; Borre, Michael; Sorensen, Karina Dalsgaard] Aarhus Univ, Dept Clin Med, Aarhus, Denmark; [Thomsen, Emil Aagaard; Haldrup, Jakob; Mikkelsen, Jacob Giehm] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Dalby, Anders] Teitur Troph, Aarhus, Denmark; [Palmfeldt, Johan; Bross, Peter] Aarhus Univ Hosp, Res Unit Mol Med, Aarhus, Denmark; [Klingenberg, Soren; Jochumsen, Mads R.; Bouchelouche, Kirsten] Aarhus Univ Hosp, Dept Nucl Med, Aarhus, Denmark; [Klingenberg, Soren; Jochumsen, Mads R.; Bouchelouche, Kirsten] Aarhus Univ Hosp, PET Ctr, Aarhus, Denmark; [Ulhoi, Benedicte Parm] Aarhus Univ Hosp, Dept Pathol, Aarhus, Denmark; [Borre, Michael] Aarhus Univ Hosp, Dept Urol, Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University	Sorensen, KD (corresponding author), Aarhus Univ Hosp, Dept Mol Med, Aarhus, Denmark.; Sorensen, KD (corresponding author), Aarhus Univ, Dept Clin Med, Aarhus, Denmark.	kdso@clin.au.dk	Rasmussen, Martin/GRY-5664-2022; Thomsen, Emil Aagaard/ABB-9850-2021; Bross, Peter/B-7219-2013	Rasmussen, Martin/0000-0001-9077-7857; Thomsen, Emil Aagaard/0000-0002-2685-7745; Jochumsen, Mads Ryo/0000-0002-7676-2322; Klingenberg, Soren/0000-0003-4308-2950; Sorensen, Karina Dalsgaard/0000-0002-4902-5490; Fredsoe, Jacob/0000-0002-7319-2467; Mikkelsen, Jacob Giehm/0000-0002-1322-3209; Palmfeldt, Johan/0000-0001-5585-639X; Bross, Peter/0000-0001-9526-8525	Novo Nordisk Foundation; Aase & Ejnar Danielsens Fond; Fabrikant Einar Willumsens Mindelegat; Tomrermester Jorgen Holm & Hustru Elisa F. Hansens Mindelegat; Direktor Emil C. Hertz og Hustru Inge Hertz Fond; Graduate School of Health (Aarhus University); Beckett Fonden (MBI); NEYE Fonden; Helge Peetz & Verner Peetz & Hustru Vilma Peetz Fond	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Aase & Ejnar Danielsens Fond; Fabrikant Einar Willumsens Mindelegat; Tomrermester Jorgen Holm & Hustru Elisa F. Hansens Mindelegat; Direktor Emil C. Hertz og Hustru Inge Hertz Fond; Graduate School of Health (Aarhus University); Beckett Fonden (MBI); NEYE Fonden; Helge Peetz & Verner Peetz & Hustru Vilma Peetz Fond	This work was supported by grants from The Novo Nordisk Foundation (KDS), Aase & Ejnar Danielsens Fond (MBI), Fabrikant Einar Willumsens Mindelegat (MBI), Tomrermester Jorgen Holm & Hustru Elisa F. Hansens Mindelegat (MBI), Direktor Emil C. Hertz og Hustru Inge Hertz Fond (MBI), Graduate School of Health (Aarhus University; MBI), Helge Peetz & Verner Peetz & Hustru Vilma Peetz Fond (MBI), Beckett Fonden (MBI), and NEYE Fonden (MBI). The Danish Cancer Biobank is acknowledged for providing patient samples and information on handling and storage.	Abida W, 2017, JCO PRECIS ONCOL, V2017, DOI [DOI 10.1200/PO.17.00029, 10.1200/PO.17.00029, 10.1200/po.17.00029]; Arun B, 2015, INT J ONCOL, V47, P262, DOI 10.3892/ijo.2015.3003; Cahuzac M, 2022, COMMUN BIOL, V5, DOI 10.1038/s42003-022-03210-5; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen X, 2019, BIOCHEM BIOPH RES CO, V508, P620, DOI 10.1016/j.bbrc.2018.11.062; Cornford P, 2021, EUR UROL, V79, P263, DOI 10.1016/j.eururo.2020.09.046; de Bono J, 2020, NEW ENGL J MED, V382, P2091, DOI 10.1056/NEJMoa1911440; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Eliopoulos AG, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00204; FDA, 2021, FDA APPR OL HRR GEN; Formentini L, 2009, J BIOL CHEM, V284, P17668, DOI 10.1074/jbc.M109.002931; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Gogola E, 2018, CANCER CELL, V33, P1078, DOI 10.1016/j.ccell.2018.05.008; Goodall J, 2017, CANCER DISCOV, V7, P1006, DOI 10.1158/2159-8290.CD-17-0261; Hazan I, 2019, CELL REP, V29, P560, DOI 10.1016/j.celrep.2019.09.001; He YJ, 2018, NATURE, V563, P522, DOI 10.1038/s41586-018-0670-5; Hopkins TA, 2015, MOL CANCER RES, V13, P1465, DOI 10.1158/1541-7786.MCR-15-0191-T; Hussain M, 2020, NEW ENGL J MED, V383, P2345, DOI 10.1056/NEJMoa2022485; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Kolde R, 2012, BIOINFORMATICS, V28, P573, DOI 10.1093/bioinformatics/btr709; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lee JS, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092013; Li CYG, 2019, CELL REP, V26, P1333, DOI 10.1016/j.celrep.2019.01.013; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Niere M, 2008, MOL CELL BIOL, V28, P814, DOI 10.1128/MCB.01766-07; Pennington KL, 2018, ONCOGENE, V37, P5587, DOI 10.1038/s41388-018-0348-3; Pettitt SJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03917-2; Quigley D, 2017, CANCER DISCOV, V7, P999, DOI 10.1158/2159-8290.CD-17-0146; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rath S, 2021, NUCLEIC ACIDS RES, V49, pD1541, DOI 10.1093/nar/gkaa1011; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ryo LB, 2019, METHODS MOL BIOL, V1961, P93, DOI 10.1007/978-1-4939-9170-9_7; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Steensel V, TIDE TRACKING INDELS; Tai S, 2012, MOL CANCER THER, V11, P1320, DOI 10.1158/1535-7163.MCT-11-0954; Tukachinsky H, 2021, CLIN CANCER RES, V27, P3094, DOI 10.1158/1078-0432.CCR-20-4805; Valabrega G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084203; Velimezi G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04649-z; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Zhang MQ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60849-y	45	0	0	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4271	4281		10.1038/s41388-022-02427-2	http://dx.doi.org/10.1038/s41388-022-02427-2		AUG 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35933519				2022-12-28	WOS:000836761200001
J	Gao, M; Qi, ZJ; Deng, M; Huang, HY; Xu, ZJ; Guo, GJ; Jing, JJ; Huang, XF; Xu, M; Kloeber, JA; Liu, SJ; Huang, JZ; Lou, ZK; Han, JX				Gao, Ming; Qi, Zijuan; Deng, Min; Huang, Hongyang; Xu, Zhijie; Guo, Guijie; Jing, Jiajun; Huang, Xiaofeng; Xu, Ming; Kloeber, Jake A.; Liu, Sijin; Huang, Jinzhou; Lou, Zhenkun; Han, Jinxiang			The deubiquitinase USP7 regulates oxidative stress through stabilization of HO-1	ONCOGENE			English	Article							HEME OXYGENASE-1; ARSENIC TOXICITY; UBIQUITINATION; USP7/HAUSP; ACTIVATION; MECHANISMS; CANCER; NRF2; P53	Heme oxygenase-1 (HO-1) is an inducible heme degradation enzyme that plays a cytoprotective role against various oxidative and inflammatory stresses. However, it has also been shown to exert an important role in cancer progression through a variety of mechanisms. Although transcription factors such as Nrf2 are involved in HO-1 regulation, the posttranslational modifications of HO-1 after oxidative insults and the underlying mechanisms remain unexplored. Here, we screened and identified that the deubiquitinase USP7 plays a key role in the control of redox homeostasis through promoting HO-1 deubiquitination and stabilization in hepatocytes. We used low-dose arsenic as a stress model which does not affect the transcriptional level of HO-1, and found that the interaction between USP7 and HO-1 is increased after arsenic exposure, leading to enhanced HO-1 expression and attenuated oxidative damages. Furthermore, HO-1 protein is ubiquitinated at K243 and subjected to degradation under resting conditions; whereas when after arsenic exposure, USP7 itself can be ubiquitinated at K476, thereafter promoting the binding between USP7 and HO-1, finally leading to enhanced HO-1 deubiquitination and protein accumulation. Moreover, depletion of USP7 and HO-1 inhibit liver tumor growth in vivo, and USP7 positively correlates with HO-1 protein level in clinical human hepatocellular carcinoma (HCC) specimens. In summary, our findings reveal a critical role of USP7 as a HO-1 deubiquitinating enzyme in the regulation of oxidative stresses, and suggest that USP7 inhibitor might be a potential therapeutic agent for treating HO-1 overexpressed liver cancers.	[Gao, Ming; Jing, Jiajun; Huang, Xiaofeng; Xu, Ming; Liu, Sijin] Chinese Acad Sci, Res Ctr Ecoenvironm Sci, State Key Lab Environm Chem & Ecotoxicol, Beijing 100085, Peoples R China; [Gao, Ming; Jing, Jiajun; Huang, Xiaofeng; Xu, Ming; Liu, Sijin] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Qi, Zijuan; Han, Jinxiang] Shandong First Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Jinan 250014, Shandong, Peoples R China; [Deng, Min] Chinese Acad Med Sci, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Deng, Min] Chinese Acad Med Sci, Dept Radiat Oncol, Beijing 100021, Peoples R China; [Huang, Hongyang] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong 999077, Peoples R China; [Xu, Zhijie] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Dept Pathol, Changsha 410008, Hunan, Peoples R China; [Guo, Guijie; Kloeber, Jake A.; Huang, Jinzhou; Lou, Zhenkun] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA; [Kloeber, Jake A.] Mayo Clin, Mayo Clin Med Scientist Training Program, Rochester, MN 55905 USA	Chinese Academy of Sciences; Research Center for Eco-Environmental Sciences (RCEES); Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Shandong First Medical University & Shandong Academy of Medical Sciences; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; University of Hong Kong; Central South University; Mayo Clinic; Mayo Clinic	Han, JX (corresponding author), Shandong First Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Jinan 250014, Shandong, Peoples R China.; Huang, JZ; Lou, ZK (corresponding author), Mayo Clin, Dept Oncol, Rochester, MN 55905 USA.	huang.jinzhou@mayo.edu; lou.zhenkun@mayo.edu; jxhan9888@aliyun.com		Kloeber, Jake/0000-0002-6646-564X; Huang, Hongyang/0000-0002-5138-7781	National Natural Science Foundation of China [22076212]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDPB2004]; Science Fund for Creative Research Groups of the National Natural Science Foundation of China [22021003]; Youth Innovation Promotion Association of CAS [2021040]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); Science Fund for Creative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association of CAS	This research was supported by National Natural Science Foundation of China (Grant no. 22076212), Strategic Priority Research Program of the Chinese Academy of Sciences (XDPB2004), Science Fund for Creative Research Groups of the National Natural Science Foundation of China (22021003) and Youth Innovation Promotion Association of CAS (2021040).	Abiko Y, 2010, J TOXICOL SCI, V35, P419, DOI 10.2131/jts.35.419; Alam J, 2007, AM J RESP CELL MOL, V36, P166, DOI 10.1165/rcmb.2006-0340TR; Deng L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0107-0; Fernandez-Montalvan A, 2007, FEBS J, V274, P4256, DOI 10.1111/j.1742-4658.2007.05952.x; Ferrandiz ML, 2008, CURR PHARM DESIGN, V14, P473, DOI 10.2174/138161208783597399; Gallo LH, 2017, CELL CYCLE, V16, P634, DOI 10.1080/15384101.2017.1288326; Gao M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19202-0; Han JJW, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100732; Hsu FF, 2017, ONCOGENE, V36, P6805, DOI 10.1038/onc.2017.294; Hubaux R, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-20; Hughes MF, 2002, TOXICOL LETT, V133, P1, DOI 10.1016/S0378-4274(02)00084-X; Jomova K, 2011, J APPL TOXICOL, V31, P95, DOI 10.1002/jat.1649; Kashiwaba S, 2015, CELL REP, V13, P2072, DOI 10.1016/j.celrep.2015.11.014; Khoronenkova SV, 2012, MOL CELL, V45, P801, DOI 10.1016/j.molcel.2012.01.021; Khoronenkova SV, 2011, NUCLEIC ACIDS RES, V39, P2604, DOI 10.1093/nar/gkq1210; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kumagai Y, 2007, ANNU REV PHARMACOL, V47, P243, DOI 10.1146/annurev.pharmtox.47.120505.105144; Lee G, 2016, BIOCHEM BIOPH RES CO, V470, P181, DOI 10.1016/j.bbrc.2016.01.021; Lee JG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2532; Li CY, 2020, J HAZARD MATER, V395, DOI 10.1016/j.jhazmat.2020.122588; Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0; Hoang KNL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.658315; Morotti A, 2014, LEUKEMIA, V28, P1326, DOI 10.1038/leu.2013.370; Nininahazwe L, 2021, DRUG DISCOV TODAY, V26, P490, DOI 10.1016/j.drudis.2020.10.028; Nitti M, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6020029; Popovic D, 2014, NAT MED, V20, P1242, DOI 10.1038/nm.3739; Pozhidaeva A, 2019, DNA REPAIR, V76, P30, DOI 10.1016/j.dnarep.2019.02.005; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Song J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1007-9; Soza-Ried C, 2019, CRIT REV ONCOL HEMAT, V139, P128, DOI 10.1016/j.critrevonc.2019.01.012; Srisook K, 2005, ANTIOXID REDOX SIGN, V7, P1674, DOI 10.1089/ars.2005.7.1674; Sun TS, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01262-x; Tan JQ, 2020, BIOTECHNOL LETT, V42, P2453, DOI 10.1007/s10529-020-02982-2; Toro A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010035; Waalkes MP, 2004, TOXICOL APPL PHARM, V198, P377, DOI 10.1016/j.taap.2003.10.028; Wang ZR, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00427; Was H, 2010, CURR DRUG TARGETS, V11, P1551, DOI 10.2174/1389450111009011551; Yi GF, 2020, FOOD FUNCT, V11, P2725, DOI 10.1039/c9fo01466g; Zhou J, 2018, MED CHEM, V14, P3, DOI 10.2174/1573406413666171020115539; Zhou Y, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.67; Zhu CP, 2014, SCI REP-UK, V4, DOI 10.1038/srep05029; Zou CX, 2016, ONCOL REP, V36, P2715, DOI 10.3892/or.2016.5056	42	0	0	8	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					4018	4027		10.1038/s41388-022-02403-w	http://dx.doi.org/10.1038/s41388-022-02403-w		JUL 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35821281				2022-12-28	WOS:000823350200001
J	Buschhaus, JM; Rajendran, S; Humphries, BA; Cutter, AC; Muniz, AJ; Ciavattone, NG; Buschhaus, AM; Caneque, T; Nwosu, ZC; Sahoo, D; Bevoor, AS; Shah, YM; Lyssiotis, CA; Ghosh, P; Wicha, MS; Rodriguez, R; Luker, GD				Buschhaus, Johanna M.; Rajendran, Shrila; Humphries, Brock A.; Cutter, Alyssa C.; Muniz, Ayse J.; Ciavattone, Nicholas G.; Buschhaus, Alexander M.; Caneque, Tatiana; Nwosu, Zeribe C.; Sahoo, Debashis; Bevoor, Avinash S.; Shah, Yatrik M.; Lyssiotis, Costas A.; Ghosh, Pradipta; Wicha, Max S.; Rodriguez, Raphael; Luker, Gary D.			Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer	ONCOGENE			English	Article							ENDOCRINE RESISTANCE; DOWN-REGULATION; SALINOMYCIN; SENSITIVITY; INHIBITION; EXPRESSION; TUMORS	Patients with estrogen receptor-positive (ER+) breast cancer, the most common subtype, remain at risk for lethal metastatic disease years after diagnosis. Recurrence arises partly because tumor cells in bone marrow become resistant to estrogen-targeted therapy. Here, we utilized a co-culture model of bone marrow mesenchymal stem cells (MSCs) and ER+ breast cancer cells to recapitulate interactions of cancer cells in bone marrow niches. ER+ breast cancer cells in direct contact with MSCs acquire cancer stem-like (CSC) phenotypes with increased resistance to standard antiestrogenic drugs. We confirmed that co-culture with MSCs increased labile iron in breast cancer cells, a phenotype associated with CSCs and disease progression. Clinically approved iron chelators and in-house lysosomal iron-targeting compounds restored sensitivity to antiestrogenic therapy. These findings establish iron modulation as a mechanism to reverse MSC-induced drug resistance and suggest iron modulation in combination with estrogen-targeted therapy as a promising, translatable strategy to treat ER+ breast cancer.	[Buschhaus, Johanna M.; Luker, Gary D.] Univ Michigan, Dept Biomed Engn, 2200 Bonisteel, Ann Arbor, MI 48109 USA; [Buschhaus, Johanna M.; Rajendran, Shrila; Humphries, Brock A.; Cutter, Alyssa C.; Ciavattone, Nicholas G.; Buschhaus, Alexander M.; Bevoor, Avinash S.; Luker, Gary D.] Univ Michigan, Ctr Mol Imaging, Dept Radiol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA; [Muniz, Ayse J.] Univ Michigan, Macromol Sci & Engn & Biointerfaces Inst, Ann Arbor, MI 48109 USA; [Caneque, Tatiana; Rodriguez, Raphael] PSL Res Univ, Inst Curie, Chem Biol Canc Lab, CNRS UMR 3666,INSERM U1143, Paris, France; [Nwosu, Zeribe C.; Shah, Yatrik M.; Lyssiotis, Costas A.] Univ Michigan, Med Sch, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Sahoo, Debashis] Univ Calif San Diego, Pediat & Comp Sci & Engn, La Jolla, CA 92093 USA; [Shah, Yatrik M.] Univ Michigan, Med Sch, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA; [Shah, Yatrik M.] Univ Michigan, Med Sch, Rogel Canc Ctr, Ann Arbor, MI 48109 USA; [Lyssiotis, Costas A.] Univ Michigan, Med Sch, Dept Internal Med, Ann Arbor, MI 48109 USA; [Ghosh, Pradipta] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Ghosh, Pradipta] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Wicha, Max S.] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA; [Luker, Gary D.] Univ Michigan, Dept Microbiol & Immunol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; University of Michigan System; University of Michigan; University of California System; University of California San Diego; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Luker, GD (corresponding author), Univ Michigan, Dept Biomed Engn, 2200 Bonisteel, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Ctr Mol Imaging, Dept Radiol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Dept Microbiol & Immunol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	gluker@med.umich.edu		Nwosu, Zeribe/0000-0003-1641-2045; luker, gary/0000-0001-6832-2581; Caneque, Tatiana/0000-0002-1110-0643	University of Michigan Rogel Cancer Center through National Institutes of Health [P30CA046592]; NIH [R01CA100768, R01CA238042, R01GM138385, R01CA148828, R01CA245546, R01DK095201, R01CA248160, R35CA197585, R01CA2449310, U01CA210152, R01CA238023, R33CA225549, R50CA221807, R37CA222563]; Breast Cancer Research Foundation [BCRF-18-173]; European Research Council under the European Union [647973]; Foundation Charles Defforey-Institut de France; Ligue Contre le Cancer Equipe Labellisee; National Science Foundation Graduate Research Fellowship [DGE 1256260]; American Cancer Society -Michigan Cancer Research Fund Postdoctoral Fellowship [PF-18-236-01-CCG]; Michigan Postdoctoral Pioneer Program at the University of Michigan Medical School	University of Michigan Rogel Cancer Center through National Institutes of Health; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; European Research Council under the European Union(European Research Council (ERC)); Foundation Charles Defforey-Institut de France; Ligue Contre le Cancer Equipe Labellisee; National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF)); American Cancer Society -Michigan Cancer Research Fund Postdoctoral Fellowship(American Cancer Society); Michigan Postdoctoral Pioneer Program at the University of Michigan Medical School	We acknowledge support to the University of Michigan Rogel Cancer Center through National Institutes of Health grant P30CA046592 for flow cytometry and animal imaging studies. The authors acknowledge funding from NIH grants R01CA100768, R01CA238042, R01GM138385, R01CA148828, R01CA245546, R01DK095201, R01CA248160, R35CA197585, R01CA2449310, U01CA210152, R01CA238023, R33CA225549, R50CA221807, and R37CA222563 and funding from the Breast Cancer Research Foundation grant BCRF-18-173. RR lab is funded by the European Research Council under the European Union's Horizon 2020 research and innovation programme grant agreement No 647973 (R.R.), the Foundation Charles Defforey-Institut de France, and Ligue Contre le Cancer Equipe Labellisee. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE 1256260 (JMB and AJM). BAH, Ph.D., was supported by an American Cancer Society -Michigan Cancer Research Fund Postdoctoral Fellowship, PF-18-236-01-CCG. ZCN is supported by the Michigan Postdoctoral Pioneer Program at the University of Michigan Medical School.	Adamo A, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.584232; Amanatullah DF, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0910-x; Blanchette-Farra N, 2018, ONCOGENE, V37, P4013, DOI 10.1038/s41388-018-0243-y; Brown RAM, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00476; Buschhaus JM, TARGETING DISSEMINAT; Buschhaus JM, 2018, METHODS MOL BIOL, V1686, P201, DOI 10.1007/978-1-4939-7371-2_15; Bystrom LM, 2014, ANTIOXID REDOX SIGN, V20, P1917, DOI 10.1089/ars.2012.5014; Cavnar SP, 2016, TOMOGRAPHY, V2, P146, DOI 10.18383/j.tom.2016.00157; Chanvorachote P, 2016, AM J PHYSIOL-CELL PH, V310, pC728, DOI 10.1152/ajpcell.00322.2015; Chen Dar-Ren, 2014, Biomed Res Int, V2014, P532161, DOI 10.1155/2014/532161; Chirillo R, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00698; Colacino JA, 2018, STEM CELL REP, V10, P1596, DOI 10.1016/j.stemcr.2018.03.001; Eckley SS, 2019, TOMOGRAPHY, V5, P346, DOI 10.18383/j.tom.2019.00019; El Hout M, 2018, SEMIN CANCER BIOL, V53, P125, DOI 10.1016/j.semcancer.2018.07.009; Forciniti S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062257; Ge SX, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2486-6; Goto W, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07673-9; Graham N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041121; Houthuijzen J, 2012, BRIT J CANCER, V106, P1901, DOI 10.1038/bjc.2012.201; Hu JJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep17426; Huang J, 2017, BREAST CANCER RES TR, V161, P229, DOI 10.1007/s10549-016-4052-0; Huczynski A, 2012, BIOORG MED CHEM LETT, V22, P7146, DOI 10.1016/j.bmcl.2012.09.068; Humphries BA, 2019, MOL CANCER RES, V17, P1142, DOI 10.1158/1541-7786.MCR-18-0836; Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Katsura Y, 2019, CANCERS, V11, DOI 10.3390/cancers11020177; Katzenellenbogen JA, 2018, NAT REV CANCER, V18, P377, DOI 10.1038/s41568-018-0001-z; Kucerova L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-535; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Leimberg MJ, 2008, J CELL BIOCHEM, V103, P1211, DOI 10.1002/jcb.21499; Liang W, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.626812; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Luo M, 2018, CELL METAB, V28, P69, DOI 10.1016/j.cmet.2018.06.006; Luo M, 2015, CURR PHARM DESIGN, V21, P1301, DOI 10.2174/1381612821666141211120604; Magnani L, 2013, P NATL ACAD SCI USA, V110, pE1490, DOI 10.1073/pnas.1219992110; Mody K, 2019, INVEST NEW DRUG, V37, P684, DOI 10.1007/s10637-018-0703-9; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muller S, 2020, NAT CHEM, V12, P929, DOI 10.1038/s41557-020-0513-5; Muluhngwi P, 2015, ENDOCR-RELAT CANCER, V22, pR279, DOI 10.1530/ERC-15-0355; Oren B, 2016, J PATHOL, V239, P274, DOI 10.1002/path.4724; Pantel Klaus, 2014, Bonekey Rep, V3, P584, DOI 10.1038/bonekey.2014.79; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Patel SA, 2011, ONCOL REV, V5, P93, DOI 10.1007/s12156-010-0071-y; Plava J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0960-z; Pogribny IP, 2013, INT J ONCOL, V42, P1822, DOI 10.3892/ijo.2013.1855; Raggi C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17804-1; Ray P, 2015, ONCOGENE, V34, P2043, DOI 10.1038/onc.2014.157; Recalcati S, 2019, FREE RADICAL BIO MED, V133, P216, DOI 10.1016/j.freeradbiomed.2018.07.015; Rodriguez R, 2022, MOL CELL, V82, P728, DOI 10.1016/j.molcel.2021.12.001; Saeki I, 2016, WORLD J GASTROENTERO, V22, P8967, DOI 10.3748/wjg.v22.i40.8967; Sarmiento-Castro A, 2020, STEM CELL REP, V15, P307, DOI 10.1016/j.stemcr.2020.06.020; Savci-Heijink CD, 2015, BREAST CANCER RES TR, V150, P547, DOI 10.1007/s10549-015-3352-0; Schonberg DL, 2015, CANCER CELL, V28, P441, DOI 10.1016/j.ccell.2015.09.002; Shi Z, 2012, BREAST CANCER RES TR, V135, P737, DOI 10.1007/s10549-012-2196-0; Shiozawa Y, 2011, CLIN CANCER RES, V17, P5553, DOI 10.1158/1078-0432.CCR-10-2505; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Mai TT, 2017, NAT CHEM, V9, P1025, DOI [10.1038/NCHEM.2778, 10.1038/nchem.2778]; Tury S, 2018, J PATHOL, V246, P103, DOI 10.1002/path.5104; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Yeh WL, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0630-2; Yousef GM, 2004, BRIT J CANCER, V90, P167, DOI 10.1038/sj.bjc.6601451	61	1	1	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2022	41	29					3705	3718		10.1038/s41388-022-02385-9	http://dx.doi.org/10.1038/s41388-022-02385-9		JUN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y6YE	35732800				2022-12-28	WOS:000814460500001
J	Jiang, Y; Zhao, JS; Xu, JK; Zhang, HY; Zhou, JP; Li, H; Zhang, GQ; Xu, K; Jing, ZT				Jiang, Yang; Zhao, Junshuang; Xu, Jinkun; Zhang, Haiying; Zhou, Jinpeng; Li, Hao; Zhang, Guoqing; Xu, Kai; Jing, Zhitao			Glioblastoma-associated microglia-derived exosomal circKIF18A promotes angiogenesis by targeting FOXC2	ONCOGENE			English	Article							ENDOTHELIAL-CELLS; GLIOMAS; EXPRESSION; INDUCTION; RNA	Glioblastoma multiforme (GBM) is the most lethal primary tumor with active neovascularization in the central nervous system. Studying the novel molecular mechanisms of GBM angiogenesis is very important. The glioblastoma-associated microglia (GAM) M2 polarization was constructed, and microglia-derived exosomes (MDEs) were isolated to co-culture with human brain microvessel endothelial cells (hBMECs). CircRNA sequence and molecular biological experiments were used to detect the expression levels and regulation functions among circKIF18A, FOXC2, ITGB3, CXCR4, DLL4 and the PI3K/AKT signaling. The functional effects of silencing or overexpression of these molecules were evaluated in hBMECs viability, invasion, and tube formation in vitro and tumorigenicity in vivo. M2 microglia polarization is positively correlated with microvessels' density in GBM patients. M2 GAM can promote the angiogenesis of GBM via transporting exosomal circKIF18A into hBMECs. Mechanistically, circKIF18A can bind to, maintain the stability and nuclear translocation of FOXC2 in hBMECs. Furtherly, as a transcription factor, FOXC2 can directly bind to the promoter of ITGB3, CXCR4, and DLL4 and upregulate their expressions. Besides, FOXC2 can also activate the PI3K/AKT signaling and promote the angiogenesis of GBM. Our study identified a novel molecular mechanism for M2 GAM-derived exosomal circKIF18A participating in GBM angiogenesis via targeting FOXC2. This may provide a novel treatment target to improve the outcomes for anti-angiogenic therapies in GBM.	[Jiang, Yang] Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, Sch Med, Shanghai 200072, Peoples R China; [Zhao, Junshuang; Xu, Jinkun; Zhou, Jinpeng; Li, Hao; Zhang, Guoqing; Xu, Kai; Jing, Zhitao] China Med Univ, Hosp 1, Dept Neurosurg, 155 North Nanjing St, Shenyang 110001, Peoples R China; [Zhang, Haiying] Liaoning Univ Tradit Chinese Med, Int Educ Coll, 79 Chongshan East Rd, Shenyang 110042, Peoples R China	Tongji University; China Medical University; Liaoning University of Traditional Chinese Medicine	Jing, ZT (corresponding author), China Med Univ, Hosp 1, Dept Neurosurg, 155 North Nanjing St, Shenyang 110001, Peoples R China.	jingzhitao@hotmail.com			National Natural Science Foundation of China [82072794, 82004423]; Major Disease Prevention and Control Technology Action Plan of China [2018ZX-07S-006]; Natural Science Foundation of Liaoning province [2021-MS-207]; Social Development Program from Shenyang Science and Technology Bureau, China [20-205-4-075]; Shanghai Sailing Program [21YF1449900]; Shanghai Post-doctoral Excellence Program [2021336]; China Postdoctoral Science Foundation [267285]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Disease Prevention and Control Technology Action Plan of China; Natural Science Foundation of Liaoning province(Natural Science Foundation of Liaoning Province); Social Development Program from Shenyang Science and Technology Bureau, China; Shanghai Sailing Program; Shanghai Post-doctoral Excellence Program; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (Nos. 82072794, 82004423), the Major Disease Prevention and Control Technology Action Plan of China (2018ZX-07S-006), the Natural Science Foundation of Liaoning province (2021-MS-207), the Social Development Program from Shenyang Science and Technology Bureau, China (20-205-4-075), Shanghai Sailing Program (No. 21YF1449900), Shanghai Post-doctoral Excellence Program (No. 2021336) and China Postdoctoral Science Foundation (No. 267285).	Bydoun M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32433-y; Cheng N, 2021, BIOCHEM PHARMACOL, V183, DOI 10.1016/j.bcp.2020.114354; Cui X, 2018, BIOMATERIALS, V161, P164, DOI 10.1016/j.biomaterials.2018.01.053; Ding CY, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01942-6; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Han YG, 2021, AGING-US, V13, P13287, DOI 10.18632/aging.203013; Hayashi H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002401; Hayashi H, 2008, BIOCHEM BIOPH RES CO, V367, P584, DOI 10.1016/j.bbrc.2007.12.183; Hayashi H, 2009, CELL ADHES MIGR, V3, P24, DOI 10.4161/cam.3.1.7252; He ZW, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1065-7; Huang XY, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-1529-9; Jian XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1134-8; Jiang Y, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01691-y; Jiang Y, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102651; Jiang Y, 2019, EBIOMEDICINE, V48, P36, DOI 10.1016/j.ebiom.2019.09.037; Jiang Y, 2018, EBIOMEDICINE, V37, P78, DOI 10.1016/j.ebiom.2018.10.053; Li WH, 2013, ONCOL RES, V21, P111, DOI 10.3727/096504013X13814233062171; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li ZZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1371-0; Liu XB, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01625-8; Ma X, 2017, AM J TRANSL RES, V9, P5012; Nie JH, 2019, NON-CODING RNA, V5, DOI 10.3390/ncrna5020036; Peterson TE, 2016, P NATL ACAD SCI USA, V113, P4470, DOI 10.1073/pnas.1525349113; Plate KH, 2012, ACTA NEUROPATHOL, V124, P763, DOI 10.1007/s00401-012-1066-5; Sahebjam S, 2020, NEURO-ONCOLOGY; Sorensen MD, 2018, NEUROPATH APPL NEURO, V44, P185, DOI 10.1111/nan.12428; Sun SF, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01779-5; Tu JJ, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12929; Wang M, 2020, MOL THER-NUCL ACIDS, V21, P367, DOI 10.1016/j.omtn.2020.06.008; Wang T, 2018, CLIN CHIM ACTA, V479, P84, DOI 10.1016/j.cca.2018.01.019; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Wang ZF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1181-4; Yang YH, 2021, MOL THER, V29, P1226, DOI 10.1016/j.ymthe.2020.11.024; Yin JL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16789-2; You WL, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-199; Zhan GW, 2018, NAT COMMUN, V9, DOI [10.1038/s41467-018-06269-z, 10.1038/s41467-017-02251-3]	36	0	0	8	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3461	3473		10.1038/s41388-022-02360-4	http://dx.doi.org/10.1038/s41388-022-02360-4		MAY 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35637250				2022-12-28	WOS:000802880500002
J	Xia, ZC; Kon, N; Gu, AP; Tavana, O; Gu, W				Xia, Zhangchuan; Kon, Ning; Gu, Alyssa P.; Tavana, Omid; Gu, Wei			Deciphering the acetylation code of p53 in transcription regulation and tumor suppression	ONCOGENE			English	Review							CREB-BINDING PROTEIN; CELL-CYCLE ARREST; DNA-BINDING; P300/CBP-ASSOCIATED FACTOR; TRANSACTIVATION DOMAIN; FUNCTIONAL-ANALYSIS; COMPLEX-FORMATION; TERNARY COMPLEX; GENE-EXPRESSION; EMERGING ROLES	Although it is well-established that p53-mediated tumor suppression mainly acts through its ability in transcriptional regulation, the molecular mechanisms of this regulation are not completely understood. Among a number of regulatory modes, acetylation of p53 attracts great interests. p53 was one of the first non-histone proteins found to be functionally regulated by acetylation and deacetylation, and subsequent work has established that reversible acetylation is a general mechanism for regulation of non-histone proteins. Unlike other types of posttranslational modifications occurred during stress responses, the role of p53 acetylation has been recently validated in vivo by using the knock-in mice with both acetylation-defective and acetylation-mimicking p53 mutants. Here, we review the role of acetylation in p53-mediated activities, with a focus on which specific acetylation sites are critical for p53-dependent transcription regulation during tumor suppression and how acetylation of p53 recruits specific "readers" to execute its promoter-specific regulation of different targets. We also discuss the role of p53 acetylation in differentially regulating its classic activities in cell cycle arrest, senescence and apoptosis as well as newly identified unconventional functions such as cell metabolism and ferroptosis.	[Xia, Zhangchuan; Kon, Ning; Gu, Alyssa P.; Tavana, Omid; Gu, Wei] Columbia Univ, Vagelos Coll Phys & Surg, Inst Canc Genet, 1130 Nicholas Ave, New York, NY 10032 USA; [Xia, Zhangchuan; Kon, Ning; Gu, Alyssa P.; Tavana, Omid; Gu, Wei] Columbia Univ, Vagelos Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, 1130 Nicholas Ave, New York, NY 10032 USA; [Gu, Wei] Columbia Univ, Vagelos Coll Phys & Surg, Dept Pathol & Cell Biol, 1130 Nicholas Ave, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Gu, W (corresponding author), Columbia Univ, Vagelos Coll Phys & Surg, Inst Canc Genet, 1130 Nicholas Ave, New York, NY 10032 USA.; Gu, W (corresponding author), Columbia Univ, Vagelos Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, 1130 Nicholas Ave, New York, NY 10032 USA.; Gu, W (corresponding author), Columbia Univ, Vagelos Coll Phys & Surg, Dept Pathol & Cell Biol, 1130 Nicholas Ave, New York, NY 10032 USA.	wg8@cumc.columbia.edu	Xia, Zhangchuan/AAO-3890-2020	Xia, Zhangchuan/0000-0002-1176-0027; Gu, Wei/0000-0002-1480-2368	National Cancer Institute of the National Institutes of Health [R35CA253059, RO1CA258390, R01CA254970]	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute of the National Institutes of Health under Award R35CA253059, RO1CA258390 and R01CA254970 to WG. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Abida WM, 2007, J BIOL CHEM, V282, P1797, DOI 10.1074/jbc.M609001200; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Amodio N, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0606-4; Assi M, 2017, AM J PHYSIOL-REG I, V313, pR646, DOI 10.1152/ajpregu.00247.2017; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Badgley MA, 2020, SCIENCE, V368, P85, DOI 10.1126/science.aaw9872; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Barnoud T, 2021, ONCOGENE, V40, P4281, DOI 10.1038/s41388-021-01852-z; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Boutelle AM, 2021, TRENDS CELL BIOL, V31, P298, DOI 10.1016/j.tcb.2020.12.011; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Buschmann T, 2000, CANCER RES, V60, P896; Cai WJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13608-1; Campaner S, 2011, MOL CELL, V43, P681, DOI 10.1016/j.molcel.2011.08.007; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chaudhary R, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1410; Chehab NH, 2000, GENE DEV, V14, P278; Chen Ruibing, 2021, Nucleic Acids Res, V49, P4199, DOI 10.1093/nar/gkab222; Cheung EC, 2020, CANCER CELL, V37, P168, DOI 10.1016/j.ccell.2019.12.012; Cheung EC, 2013, DEV CELL, V25, P463, DOI 10.1016/j.devcel.2013.05.001; Cheung EC, 2012, P NATL ACAD SCI USA, V109, P20491, DOI 10.1073/pnas.1206530109; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Chu B, 2019, NAT CELL BIOL, V21, P579, DOI 10.1038/s41556-019-0305-6; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Ferreon JC, 2009, P NATL ACAD SCI USA, V106, P6591, DOI 10.1073/pnas.0811023106; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fujisawa T, 2017, NAT REV MOL CELL BIO, V18, P246, DOI 10.1038/nrm.2016.143; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamard PJ, 2013, GENE DEV, V27, P1868, DOI 10.1101/gad.224386.113; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Ivanov GS, 2007, MOL CELL BIOL, V27, P6756, DOI 10.1128/MCB.00460-07; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jenkins LMM, 2009, BIOCHEMISTRY-US, V48, P1244, DOI 10.1021/bi801716h; Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115; Jiang L, 2015, CELL CYCLE, V14, P2881, DOI 10.1080/15384101.2015.1068479; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Jiang LR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2445-9; Jiang MC, 2019, AM J CANCER RES, V9, P1354; Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710; Joubel A, 2009, MOL CELL PROTEOMICS, V8, P1167, DOI 10.1074/mcp.M800487-MCP200; Juillard F, 2020, P NATL ACAD SCI USA, V117, P22443, DOI 10.1073/pnas.2004809117; Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/NCHEMBIO.2238, 10.1038/nchembio.2238]; Kaiser AM, 2018, CELL DEATH DIFFER, V25, P93, DOI 10.1038/cdd.2017.171; Kar S, 2002, J BIOL CHEM, V277, P15579, DOI 10.1074/jbc.M106915200; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kon Ning, 2021, Oncoscience, V8, P58, DOI 10.18632/oncoscience.534; Kon N, 2021, GENE DEV, V35, DOI 10.1101/gad.348236.121; Kon N, 2021, CANCER RES, V81, P935, DOI 10.1158/0008-5472.CAN-20-1804; Kon Ning, 2018, Oncotarget, V9, P7282, DOI 10.18632/oncotarget.23837; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lee CW, 2010, P NATL ACAD SCI USA, V107, P19290, DOI 10.1073/pnas.1013078107; Lehnertz B, 2011, MOL CELL, V43, P673, DOI 10.1016/j.molcel.2011.08.006; Leu JIJ, 2019, P NATL ACAD SCI USA, V116, P8390, DOI 10.1073/pnas.1821277116; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; Li AG, 2007, MOL CELL, V28, P408, DOI 10.1016/j.molcel.2007.09.006; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Li TY, 2016, ONCOTARGET, V7, P11838, DOI 10.18632/oncotarget.7864; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Li XZ, 2009, MOL CELL, V36, P290, DOI 10.1016/j.molcel.2009.07.031; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin T, 2019, INT J BIOL SCI, V15, P1287, DOI 10.7150/ijbs.33218; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y., 2022, CELL DEATH DIFFER; Liu Yanqing, 2022, Semin Cancer Biol, V85, P4, DOI 10.1016/j.semcancer.2021.03.010; Liu YQ, 2019, J MOL CELL BIOL, V11, P564, DOI 10.1093/jmcb/mjz060; LUNA RMD, 1995, NATURE, V378, P203; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Ma XY, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1881-x; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Mello SS, 2018, CURR OPIN CELL BIOL, V51, P65, DOI 10.1016/j.ceb.2017.11.005; Naidu SR, 2012, CELL CYCLE, V11, P2717, DOI 10.4161/cc.21091; Narita T, 2019, NAT REV MOL CELL BIO, V20, P156, DOI 10.1038/s41580-018-0081-3; Nitsch S, 2021, EMBO REP, V22, DOI 10.15252/embr.202152774; Ou Y, 2016, P NATL ACAD SCI USA, V113, pE6806, DOI 10.1073/pnas.1607152113; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Puca R, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-85; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Reed SM, 2015, CANCERS, V7, P30, DOI 10.3390/cancers7010030; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Rokudai S, 2013, P NATL ACAD SCI USA, V110, P3895, DOI 10.1073/pnas.1300490110; Rokudai S, 2009, J BIOL CHEM, V284, P237, DOI 10.1074/jbc.M805101200; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Scolnick DM, 1997, CANCER RES, V57, P3693; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Simeonova I, 2013, CELL REP, V3, P2046, DOI 10.1016/j.celrep.2013.05.028; Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017; Statello L, 2021, NAT REV MOL CELL BIO, V22, P159, DOI 10.1038/s41580-021-00330-4; STERNER R, 1979, J BIOL CHEM, V254, P1577; Stockwell BR, 2020, TRENDS CELL BIOL, V30, P478, DOI 10.1016/j.tcb.2020.02.009; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Teufel DP, 2009, ONCOGENE, V28, P2112, DOI 10.1038/onc.2009.71; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Verdin E, 2015, NAT REV MOL CELL BIO, V16, P258, DOI 10.1038/nrm3931; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang DL, 2017, NUCLEUS-PHILA, V8, P360, DOI 10.1080/19491034.2017.1313939; Wang DL, 2016, NATURE, V538, P118, DOI 10.1038/nature19759; Wang SJ, 2016, CELL REP, V17, P366, DOI 10.1016/j.celrep.2016.09.022; Wang YH, 2003, J BIOL CHEM, V278, P25568, DOI 10.1074/jbc.M212574200; Wen J, 2021, J MOL CELL BIOL, V13, P774, DOI 10.1093/jmcb/mjab047; Wu SY, 2009, EMBO J, V28, P1246, DOI 10.1038/emboj.2009.83; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yang X, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abi6684; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang A, 2014, J MOL CELL BIOL, V6, P181, DOI 10.1093/jmcb/mju013; Zhang YH, 2017, GENE DEV, V31, P1243, DOI 10.1101/gad.299388.117	131	6	6	10	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3039	3050		10.1038/s41388-022-02331-9	http://dx.doi.org/10.1038/s41388-022-02331-9		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35487975	Green Accepted			2022-12-28	WOS:000788990000002
J	Tsai, YT; Li, CY; Huang, YH; Chang, TS; Lin, CY; Chuang, CH; Wang, CY; Anuraga, G; Chang, TH; Shih, TC; Lin, ZY; Chen, YL; Chung, I; Lee, KH; Chang, CC; Sung, SY; Yang, KH; Tsui, WL; Yap, CV; Wu, MH				Tsai, Yao-Tsung; Li, Chih-Yi; Huang, Yen-Hua; Chang, Te-Sheng; Lin, Chung-Yen; Chuang, Chia-Hsien; Wang, Chih-Yang; Anuraga, Gangga; Chang, Tzu-Hao; Shih, Tsung-Chieh; Lin, Zu-Yau; Chen, Yuh-Ling; Chung, Ivy; Lee, Kuen-Haur; Chang, Che-Chang; Sung, Shian-Ying; Yang, Kai-Huei; Tsui, Wan-Lin; Yap, Chee-Voon; Wu, Ming-Heng			Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts	ONCOGENE			English	Article							FACTOR RECEPTOR 1; DISINTEGRIN; SORAFENIB	Most cases of hepatocellular carcinoma (HCC) arise with the fibrotic microenvironment where hepatic stellate cells (HSCs) and carcinoma-associated fibroblasts (CAFs) are critical components in HCC progression. Therefore, CAF normalization could be a feasible therapy for HCC. Galectin-1 (Gal-1), a beta-galactoside-binding lectin, is critical for HSC activation and liver fibrosis. However, few studies has evaluated the pathological role of Gal-1 in HCC stroma and its role in hepatic CAF is unclear. Here we showed that Gal-1 mainly expressed in HCC stroma, but not cancer cells. High expression of Gal-1 is correlated with CAF markers and poor prognoses of HCC patients. In co-culture systems, targeting Gal-1 in CAFs or HSCs, using small hairpin (sh)RNAs or an therapeutic inhibitor (LLS30), downregulated plasminogen activator inhibitor-2 (PAI-2) production which suppressed cancer stem-like cell properties and invasion ability of HCC in a paracrine manner. The Gal-1-targeting effect was mediated by increased a disintegrin and metalloprotease 17 (ADAM17)-dependent TNF-receptor 1 (TNFR1) shedding/cleavage which inhibited the TNF-alpha -> JNK -> c-Jun/ATF2 signaling axis of pro-inflammatory gene transcription. Silencing Gal-1 in CAFs inhibited CAF-augmented HCC progression and reprogrammed the CAF-mediated inflammatory responses in a co-injection xenograft model. Taken together, the findings uncover a crucial role of Gal-1 in CAFs that orchestrates an inflammatory CSC niche supporting HCC progression and demonstrate that targeting Gal-1 could be a potential therapy for fibrosis-related HCC.	[Tsai, Yao-Tsung; Li, Chih-Yi; Chang, Che-Chang; Sung, Shian-Ying; Yang, Kai-Huei; Tsui, Wan-Lin; Yap, Chee-Voon; Wu, Ming-Heng] Taipei Med Univ, Int PhD Program Translat Sci, Taipei, Taiwan; [Tsai, Yao-Tsung; Li, Chih-Yi; Huang, Yen-Hua; Chang, Che-Chang; Sung, Shian-Ying; Yang, Kai-Huei; Tsui, Wan-Lin; Yap, Chee-Voon; Wu, Ming-Heng] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Translat Med, Taipei, Taiwan; [Huang, Yen-Hua] Taipei Med Univ, Dept Biochem & Mol Cell Biol, Taipei, Taiwan; [Huang, Yen-Hua] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan; [Huang, Yen-Hua; Wu, Ming-Heng] Taipei Med Univ, Ctr Cell Therapy & Regenerat Med, Taipei, Taiwan; [Chang, Te-Sheng] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Chang, Te-Sheng] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Chiayi, Taiwan; [Lin, Chung-Yen; Chuang, Chia-Hsien] Acad Sinica, Inst Informat Sci, Taipei, Taiwan; [Wang, Chih-Yang; Anuraga, Gangga; Lee, Kuen-Haur] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Chang, Tzu-Hao] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Biomed Informat, Taipei, Taiwan; [Shih, Tsung-Chieh] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Lin, Zu-Yau] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan; [Lin, Zu-Yau] Kaohsiung Med Univ, Coll Med, Sch Med, Fac Internal Med, Kaohsiung, Taiwan; [Chen, Yuh-Ling] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan, Taiwan; [Chung, Ivy] Univ Malaya, Fac Med, Canc Res Inst, Kuala Lumpur 50603, Malaysia; [Chung, Ivy] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia; [Wu, Ming-Heng] TMU Res Ctr Canc Translat Med, Taipei, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Chang Gung University; Chang Gung Memorial Hospital; Academia Sinica - Taiwan; Taipei Medical University; Taipei Medical University; University of California System; University of California Davis; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; National Cheng Kung University; Universiti Malaya; Universiti Malaya	Wu, MH (corresponding author), Taipei Med Univ, Int PhD Program Translat Sci, Taipei, Taiwan.; Wu, MH (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Translat Med, Taipei, Taiwan.; Wu, MH (corresponding author), Taipei Med Univ, Ctr Cell Therapy & Regenerat Med, Taipei, Taiwan.; Wu, MH (corresponding author), TMU Res Ctr Canc Translat Med, Taipei, Taiwan.	mhwu1015@tmu.edu.tw	Wang, Chihyang/ADO-2306-2022; Anuraga, Gangga/AAE-8623-2021; Chung, Ivy/C-3804-2012	Wang, Chihyang/0000-0002-4137-5074; Anuraga, Gangga/0000-0002-0902-3968; Chuang, Chia-Hsien/0000-0002-3639-4684; Huang, Yen-Hua/0000-0001-6020-9998	Chang Gung Memorial Hospital (Chiayi, Taiwan); "TMU Research Center of Cancer Translational Medicine" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan	Chang Gung Memorial Hospital (Chiayi, Taiwan)(Chang Gung Memorial Hospital); "TMU Research Center of Cancer Translational Medicine" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan	We thank the National RNAi Core Facility at Academia Sinica, Taiwan for providing shRNA reagents and related services. We thank the Image and Bioinformatics Core Facility of Taipei Medical University for confocal microscopy and the microarray analysis. Human samples were from the Human Tumor Tissue Bank, Chang Gung Memorial Hospital (Chiayi, Taiwan). This work was financially supported by the "TMU Research Center of Cancer Translational Medicine" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.	Abolarinwa BA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184624; Bernot D, 2011, J CELL SCI, V124, P1224, DOI 10.1242/jcs.079889; Biffi G, 2021, PHYSIOL REV, V101, P147, DOI 10.1152/physrev.00048.2019; Boulaftali Y, 2013, ARTERIOSCL THROM VAS, V33, P1647, DOI 10.1161/ATVBAHA.113.301494; Castello-Cros R, 2011, CELL CYCLE, V10, P2021, DOI 10.4161/cc.10.12.16002; Chen PC, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.625943; Chen ZY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01286; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Cousin JM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091566; Deng M, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005548; Dominguez CX, 2020, CANCER DISCOV, V10, P232, DOI 10.1158/2159-8290.CD-19-0644; Donisi C, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.601240; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Gao Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0448-6; Izaguirre G, 2019, BIOCHEMISTRY-US, V58, P1679, DOI 10.1021/acs.biochem.8b01295; Lei T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22135-w; Leung Z, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1402-x; Lin ZY, 2012, BIOMED PHARMACOTHER, V66, P525, DOI 10.1016/j.biopha.2012.02.001; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Lockett AD, 2013, AM J RESP CELL MOL, V49, P143, DOI 10.1165/rcmb.2012-0515OC; Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Martinez-Bosch N, 2020, ADV EXP MED BIOL, V1259, P17, DOI 10.1007/978-3-030-43093-1_2; Monteran L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01835; Ngo MHT, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041931; Nurmik M, 2020, INT J CANCER, V146, P895, DOI 10.1002/ijc.32193; Potikha T, 2019, FASEB J, V33, P7995, DOI 10.1096/fj.201900017R; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Sakimoto T, 2009, INVEST OPHTH VIS SCI, V50, P4618, DOI 10.1167/iovs.08-2669; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shih TC, 2018, CLIN CANCER RES, V24, P4319, DOI 10.1158/1078-0432.CCR-18-0157; Spano D, 2010, MOL MED, V16, P102, DOI 10.2119/molmed.2009.00119; Tarrats N, 2011, HEPATOLOGY, V54, P319, DOI 10.1002/hep.24388; Toegel S, 2016, J IMMUNOL, V196, P1910, DOI 10.4049/jimmunol.1501165; Wu H, 2012, J GASTROEN HEPATOL, V27, P1312, DOI 10.1111/j.1440-1746.2012.07130.x; Wu MH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11212-1; Yeh CC, 2015, MOL CELL PROTEOMICS, V14, P1527, DOI 10.1074/mcp.M114.046417; Zhang PF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.324	40	2	2	4	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					3011	3023		10.1038/s41388-022-02309-7	http://dx.doi.org/10.1038/s41388-022-02309-7		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35459781				2022-12-28	WOS:000787474100003
J	Garcia-Dominguez, DJ; Hajji, N; Lopez-Alemany, R; Sanchez-Molina, S; Figuerola-Bou, E; Civanto, FJM; Rello-Varona, S; Andres-Leon, E; Benito, A; Keun, HC; Mora, J; Tirado, OM; de Alava, E; Hontecillas-Prieto, L				Garcia-Dominguez, Daniel J.; Hajji, Nabil; Lopez-Alemany, Roser; Sanchez-Molina, Sara; Figuerola-Bou, Elisabet; Civanto, Francisco J. Moron; Rello-Varona, Santiago; Andres-Leon, Eduardo; Benito, Adrian; Keun, Hector C.; Mora, Jaume; Tirado, Oscar M.; de Alava, Enrique; Hontecillas-Prieto, Lourdes			Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1	ONCOGENE			English	Article							CANCER METASTASIS; SIALIDASE NEU1; METHYLATION; AUTOPHAGY; CELLS; OVEREXPRESSION; PROLIFERATION; APOPTOSIS; INVASION; MIMICRY	Ewing sarcoma (EWS) is an aggressive bone and soft tissue tumor with high susceptibility to metastasize. The underlying molecular mechanisms leading to EWS metastases remain poorly understood. Epigenetic changes have been implicated in EWS tumor growth and progression. Linking epigenetics and metastases may provide insight into novel molecular targets in EWS and improve its treatment. Here, we evaluated the effects of a selective G9a histone methyltransferase inhibitor (BIX01294) on EWS metastatic process. Our results showed that overexpression of G9a in tumors from EWS patients correlates with poor prognosis. Moreover, we observe a significantly higher expression of G9a in metastatic EWS tumor as compared to either primary or recurrent tumor. Using functional assays, we demonstrate that pharmacological G9a inhibition using BIX01294 disrupts several metastatic steps in vitro, such as migration, invasion, adhesion, colony formation and vasculogenic mimicry. Moreover, BIX01294 reduces tumor growth and metastases in two spontaneous metastases mouse models. We further identified the sialidase NEU1 as a direct target and effector of G9a in the metastatic process in EWS. NEU1 overexpression impairs migration, invasion and clonogenic capacity of EWS cell lines. Overall, G9a inhibition impairs metastases in vitro and in vivo through the overexpression of NEU1. G9a has strong potential as a prognostic marker and may be a promising therapeutic target for EWS patients.	[Garcia-Dominguez, Daniel J.; Civanto, Francisco J. Moron; de Alava, Enrique; Hontecillas-Prieto, Lourdes] Hosp Univ Virgen del Rocio, Inst Biomed Seville IBiS, CSIC, CIBERONC, Seville, Spain; [Hajji, Nabil] Imperial Coll London, Div Brain Sci, London, England; [Sanchez-Molina, Sara; Figuerola-Bou, Elisabet; Mora, Jaume] Hosp St Joan de Deu, Dev Tumour Biol Lab, Barcelona, Spain; [Andres-Leon, Eduardo] Consejo Super Invest Cient IPBLN CSIC, Bioinformat Unit, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain; [Benito, Adrian; Keun, Hector C.] Imperial Coll London, Div Canc, Canc Metab & Syst Toxicol Grp, London, England; [de Alava, Enrique] Univ Seville, Pathol Unit, Univ Virgen del Rocio, CIBERONC,CSIC, Seville, Spain; [de Alava, Enrique] Univ Seville, Sch Med, Dept Normal & Pathol Cytol & Histol, Seville 41009, Spain; [Garcia-Dominguez, Daniel J.; Hontecillas-Prieto, Lourdes] Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, Virgen Macarena Univ Hosp, Seville, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Imperial College London; University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Imperial College London; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; University of Sevilla; Hospital Universitario Virgen Macarena; University of Sevilla	Garcia-Dominguez, DJ; de Alava, E; Hontecillas-Prieto, L (corresponding author), Hosp Univ Virgen del Rocio, Inst Biomed Seville IBiS, CSIC, CIBERONC, Seville, Spain.; Garcia-Dominguez, DJ; Hontecillas-Prieto, L (corresponding author), Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, Virgen Macarena Univ Hosp, Seville, Spain.	dgarcia-ibis@us.es; enrique.alava.sspa@juntadeandalucia.es; lhontecillas-ibis@us.es	de Alava, Enrique/GOH-0368-2022; Andrés-León., Eduardo/K-8944-2014; Rello-Varona, Santi/A-4882-2009; Sanchez-Molina, Sara/B-2148-2017	de Alava, Enrique/0000-0001-8400-046X; Andrés-León., Eduardo/0000-0002-0621-9914; Figuerola-Bou, Elisabet/0000-0002-6839-9586; Rello-Varona, Santi/0000-0002-7500-5522; Sanchez-Molina, Sara/0000-0002-1430-131X; Hajji, Nabil/0000-0002-0695-920X	Asociacion Espanola Contra el Cancer" (AECC); Ministry of Economy and Competitiveness of Spain-FEDER (CIBERONC) [PI2000003, RD06/0020/0059]; CIBERONC [CB16/12/00361]; Consejeria de Salud de la Junta de Andalucia [PI-0013-2018]; Asociacion Alba Perez lucha contra el cancer infantil"; Catalan Agency for the Management of University and Research Grants [AGAUR 2017 SGR 332]	Asociacion Espanola Contra el Cancer" (AECC); Ministry of Economy and Competitiveness of Spain-FEDER (CIBERONC); CIBERONC; Consejeria de Salud de la Junta de Andalucia(Junta de Andalucia); Asociacion Alba Perez lucha contra el cancer infantil"; Catalan Agency for the Management of University and Research Grants	Research in the EDA and OMT labs are supported by "Asociacion Espanola Contra el Cancer" (AECC). EDA lab is also supported by the Ministry of Economy and Competitiveness of Spain-FEDER (CIBERONC, PI2000003, RD06/0020/0059). DGD and LHP are supported by CIBERONC (CB16/12/00361)S. LHP is funded by the Consejeria de Salud de la Junta de Andalucia (PI-0013-2018). SRV is supported by "Asociacion Alba Perez lucha contra el cancer infantil". The OMT lab is supported by the Catalan Agency for the Management of University and Research Grants (AGAUR 2017 SGR 332).	Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Bergin CJ, 2021, ONCOGENE, V40, P1191, DOI 10.1038/s41388-020-01591-7; Boulias K, 2004, NUCLEIC ACIDS RES, V32, P6096, DOI 10.1093/nar/gkh947; Casciello F, 2017, P NATL ACAD SCI USA, V114, P7077, DOI 10.1073/pnas.1618706114; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Chen RJ, 2017, ONCOTARGET, V8, P62081, DOI 10.18632/oncotarget.19060; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; Dang NN, 2020, AGING-US, V12, P2393, DOI 10.18632/aging.102750; de Nigris F, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115605; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Garcia-Dominguez DJ, 2021, ONCOGENE, V40, P5843, DOI 10.1038/s41388-021-01974-4; Garcia-Dominguez Daniel Jose, 2018, Oncotarget, V9, P31397, DOI 10.18632/oncotarget.25829; Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256; Gilmour AM, 2013, CELL SIGNAL, V25, P2587, DOI 10.1016/j.cellsig.2013.08.008; Grunewald TGP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0003-x; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hontecillas-Prieto L, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.578011; Hou GJ, 2016, ONCOTARGET, V7, P64957, DOI 10.18632/oncotarget.11778; Hu L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0322-6; Kim K, 2018, BIOCHEM BIOPH RES CO, V496, P758, DOI 10.1016/j.bbrc.2018.01.074; Kim Y, 2013, AUTOPHAGY, V9, P2126, DOI 10.4161/auto.26308; Kramer JM, 2016, BIOCHEM CELL BIOL, V94, P26, DOI 10.1139/bcb-2015-0017; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Li F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138390; Li XL, 2018, SPRINGERBRIEF MATH, P1, DOI 10.1007/978-3-319-89617-5_1; Liao HY, 2018, ONCOTARGETS THER, V11, P6947, DOI 10.2147/OTT.S172190; Lopez-Alemany R, 2021, METHODS MOL BIOL, V2226, P201, DOI 10.1007/978-1-0716-1020-6_16; Mabe NW, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108341; Mackintosh C, 2012, ONCOGENE, V31, P1287, DOI 10.1038/onc.2011.317; Oh SY, 2015, MOL CELLS, V38, P528, DOI 10.14348/molcells.2015.0026; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Pang ALY, 2014, ONCOL LETT, V7, P1819, DOI 10.3892/ol.2014.2034; Papait R, 2017, CIRCULATION, V136, P1233, DOI 10.1161/CIRCULATIONAHA.117.028561; Qin J, 2018, ONCOL LETT, V15, P8611, DOI 10.3892/ol.2018.8446; Ren AS, 2015, BIOCHEM BIOPH RES CO, V459, P10, DOI 10.1016/j.bbrc.2015.01.068; Ren LR, 2016, MOL CELL BIOCHEM, V411, P213, DOI 10.1007/s11010-015-2583-z; Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44; Segovia C, 2019, NAT MED, V25, P1073, DOI 10.1038/s41591-019-0499-y; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Uemura T, 2009, ONCOGENE, V28, P1218, DOI 10.1038/onc.2008.471; van der Schaft DWJ, 2005, CANCER RES, V65, P11520, DOI 10.1158/0008-5472.CAN-05-2468; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wei L, 2017, J HEPATOL, V67, P758, DOI 10.1016/j.jhep.2017.05.015; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Yin C, 2019, FASEB J, V33, P14036, DOI 10.1096/fj.201900233RR; Yokoyama M, 2017, ONCOTARGET, V8, P21315, DOI 10.18632/oncotarget.15528	51	3	3	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2638	2650		10.1038/s41388-022-02279-w	http://dx.doi.org/10.1038/s41388-022-02279-w		MAR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35354905	Green Published, hybrid			2022-12-28	WOS:000775854600001
J	Nan, G; Zhao, SH; Wang, T; Chao, D; Tian, RF; Wang, WJ; Fu, X; Lin, P; Guo, T; Wang, B; Sun, XX; Chen, X; Chen, ZN; Wang, SJ; Cui, HY				Nan, Gang; Zhao, Shu-Hua; Wang, Ting; Chao, Dong; Tian, Ruo-Fei; Wang, Wen-Jing; Fu, Xin; Lin, Peng; Guo, Ting; Wang, Bin; Sun, Xiu-Xuan; Chen, Xi; Chen, Zhi-Nan; Wang, Shi-Jie; Cui, Hong-Yong			CD147 supports paclitaxel resistance via interacting with RanBP1	ONCOGENE			English	Article							OVARIAN-CANCER CELLS; TAXOL RESISTANCE; BETA; INHIBITION; APOPTOSIS; MUTATIONS; CHEMOSENSITIVITY; HAB18G/CD147; MECHANISMS; EXPRESSION	Though the great success of paclitaxel, the variable response of patients to the drug limits its clinical utility and the precise mechanisms underlying the variable response to paclitaxel remain largely unknown. This study aims to verify the role and the underlying mechanisms of CD147 in paclitaxel resistance. Immunostaining was used to analyze human non-small-cell lung cancer (NSCLC) and ovarian cancer tissues. RNA-sequencing was used to identify downstream effectors. Annexin V-FITC/propidium iodide and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining were used to detect apoptosis. Co-immunoprecipitation (Co-IP), fluorescence resonance energy transfer (FRET) and surface plasmon resonance (SPR) were performed to determine protein interactions. Fluorescence recovery after photobleaching (FRAP) was performed to measure the speed of microtubule turnover. Xenograft tumor model was established to evaluate sensitivity of cancer cells to paclitaxel in vivo. In vitro and in vivo assays showed that silencing CD147 sensitized the cancer cells to paclitaxel treatment. CD147 protected cancer cells from paclitaxel-induced caspase-3 mediated apoptosis regardless of p53 status. Truncation analysis showed that the intracellular domain of CD147 (CD147(ICD)) was indispensable for CD147-regulated sensitivity to paclitaxel. Via screening the interacting proteins of CD147(ICD), Ran binding protein 1 (RanBP1) was identified to interact with CD147(ICD) via its C-terminal tail. Furthermore, we showed that RanBP1 mediated CD147-regulated microtubule stability and dynamics as well as response to paclitaxel treatment. These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant.	[Nan, Gang; Tian, Ruo-Fei; Wang, Wen-Jing; Fu, Xin; Lin, Peng; Guo, Ting; Wang, Bin; Sun, Xiu-Xuan; Chen, Zhi-Nan; Wang, Shi-Jie; Cui, Hong-Yong] Fourth Mil Med Univ, Natl Translat Sci Ctr Mol Med, Xian 710032, Peoples R China; [Nan, Gang; Tian, Ruo-Fei; Wang, Wen-Jing; Fu, Xin; Lin, Peng; Guo, Ting; Wang, Bin; Sun, Xiu-Xuan; Chen, Zhi-Nan; Wang, Shi-Jie; Cui, Hong-Yong] Fourth Mil Med Univ, Dept Cell Biol, Xian 710032, Peoples R China; [Zhao, Shu-Hua] Fourth Mil Med Univ, Xijing Hosp, Dept Obstet & Gynecol, Xian 710032, Peoples R China; [Wang, Ting] Fourth Mil Med Univ, Dept Biochem & Mol Biol, Xian 710032, Peoples R China; [Chao, Dong] 940th Hosp Joint Logist Support Force Chinese Peo, Dept Thorac Surg, Lanzhou 730050, Peoples R China; [Chen, Xi] Northwest Univ, Coll Chem & Mat Sci, Xian 710127, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Northwest University Xi'an	Chen, ZN; Wang, SJ; Cui, HY (corresponding author), Fourth Mil Med Univ, Natl Translat Sci Ctr Mol Med, Xian 710032, Peoples R China.; Chen, ZN; Wang, SJ; Cui, HY (corresponding author), Fourth Mil Med Univ, Dept Cell Biol, Xian 710032, Peoples R China.	znchen@fmmu.edu.cn; kola_519@163.com; cui-hongyong@163.com		Chen, Zhi-Nan/0000-0001-5512-4623	National Key Research and Development Program of China [2018YFA0109000]; National Postdoctoral Program for Innovative Talents [BX20180376]; State Key Laboratory of Cancer Biology [CBSKL2019ZZ16]; Discipline Promotion Foundation of Xijing Hospital [XJZT18MJ92]; Natural Science Foundation of Shaanxi Province [2020SF-252]; Basic Research Plan of Natural Science in Shaanxi Province [2020JM-326]; National Natural Science Foundation of China [31601127, 82103360, 82173244]	National Key Research and Development Program of China; National Postdoctoral Program for Innovative Talents; State Key Laboratory of Cancer Biology; Discipline Promotion Foundation of Xijing Hospital; Natural Science Foundation of Shaanxi Province(Natural Science Foundation of Shaanxi Province); Basic Research Plan of Natural Science in Shaanxi Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Key Research and Development Program of China (2018YFA0109000), the National Postdoctoral Program for Innovative Talents (BX20180376), the State Key Laboratory of Cancer Biology (CBSKL2019ZZ16), the Discipline Promotion Foundation of Xijing Hospital (XJZT18MJ92), the Natural Science Foundation of Shaanxi Province (2020SF-252), the Basic Research Plan of Natural Science in Shaanxi Province (2020JM-326) and the National Natural Science Foundation of China (31601127, 82103360 and 82173244). We thank Ms Rui-Rui Yao and Ms. Wen Wen for paraffin section, Ms Tian-Jiao Zhang for mouse model establishment.	Als AB, 2007, CLIN CANCER RES, V13, P4407, DOI 10.1158/1078-0432.CCR-07-0109; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Cavazza T, 2016, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00082; Chen YK, 2009, CANCER LETT, V278, P113, DOI 10.1016/j.canlet.2009.01.004; Cui HY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00677-2; Cui HY, 2016, ONCOTARGET, V7, P5613, DOI 10.18632/oncotarget.6723; Dasso M, 2002, CURR BIOL, V12, pR502, DOI 10.1016/S0960-9822(02)00970-3; Fan XY, 2019, AM J TRANSL RES, V11, P3543; Fruehauf J P, 1994, Contrib Gynecol Obstet, V19, P39; Gao J, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0920-9; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Gonzalez-Garay ML, 1999, J BIOL CHEM, V274, P23875, DOI 10.1074/jbc.274.34.23875; Gou XC, 2009, CANCER SCI, V100, P837, DOI 10.1111/j.1349-7006.2009.01113.x; Gulluni F, 2017, CANCER CELL, V32, P444, DOI 10.1016/j.ccell.2017.09.002; He LF, 2001, MOL CANCER THER, V1, P3; Hu Yun, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P192, DOI 10.3969/j.issn.1672-7347.2011.03.002; Inoue S, 2001, Hum Cell, V14, P211; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Kanakkanthara A, 2013, CANCER TREAT REV, V39, P161, DOI 10.1016/j.ctrv.2012.07.005; Kang MJ, 2013, PROTEOMICS, V13, P1714, DOI 10.1002/pmic.201200511; Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803; Kuang YH, 2008, J PROTEOME RES, V7, P4784, DOI 10.1021/pr800355b; Kuang YH, 2009, CANCER LETT, V276, P189, DOI 10.1016/j.canlet.2008.11.010; Li Y, 2009, HISTOPATHOLOGY, V54, P677, DOI 10.1111/j.1365-2559.2009.03280.x; Liang Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102496; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Milross CG, 1996, JNCI-J NATL CANCER I, V88, P1308, DOI 10.1093/jnci/88.18.1308; Muramatsu T, 2016, J BIOCHEM, V159, P481, DOI 10.1093/jb/mvv127; Nami B, 2018, CANCERS, V10, DOI 10.3390/cancers10080274; Newman JR, 2008, ARCH OTOLARYNGOL, V134, P1218, DOI 10.1001/archotol.134.11.1218; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang J, 2012, CELL DEATH DIFFER, V19, P1779, DOI 10.1038/cdd.2012.60; Wang SJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01647-2; Wu B, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.251; Xu J, 2007, HEPATOLOGY, V45, P269, DOI 10.1002/hep.21465; Yau KC, 2020, CELL CYCLE, V19, P1899, DOI 10.1080/15384101.2020.1782036; Yin SH, 2007, MOL CANCER THER, V6, P2798, DOI 10.1158/1535-7163.MCT-06-0791; Yin SH, 2012, PHARM RES-DORDR, V29, P2994, DOI 10.1007/s11095-012-0794-5; Yin SH, 2010, MOL CANCER THER, V9, P327, DOI 10.1158/1535-7163.MCT-09-0674; Yong YL, 2019, J PATHOL, V249, P255, DOI 10.1002/path.5316; Yu Y, 2015, CANCER CELL, V28, P82, DOI 10.1016/j.ccell.2015.05.009; Zheng YY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02811-7; Zou W, 2007, CANCER LETT, V248, P211, DOI 10.1016/j.canlet.2006.07.005	47	1	1	5	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					983	996		10.1038/s41388-021-02143-3	http://dx.doi.org/10.1038/s41388-021-02143-3		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34974521	hybrid, Green Published			2022-12-28	WOS:000736941300002
J	Yan, H; Yu, CC; Fine, SA; Youssof, AL; Yang, YR; Yan, J; Karg, DC; Cheung, EC; Friedman, RA; Ying, HQ; Chen, EI; Luo, J; Miao, Y; Qiu, WL; Su, GH				Yan, Han; Yu, Chih-Chieh; Fine, Stuart A.; Youssof, Ayman Lee; Yang, Ye-Ran; Yan, Jun; Karg, Dillon C.; Cheung, Edwin C.; Friedman, Richard A.; Ying, Haoqiang; Chen, Emily, I; Luo, Ji; Miao, Yi; Qiu, Wanglong; Su, Gloria H.			Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1	ONCOGENE			English	Article							MUTANT K-RAS; HIPPO PATHWAY; IMBALANCE; TAZ; SPECIFICITY; MUTATIONS; CONVERGE; ROLES	Human pancreatic ductal adenocarcinoma (PDAC) harboring one KRAS mutant allele often displays increasing genomic loss of the remaining wild-type (WT) allele (known as LOH at KRAS) as tumors progress to metastasis, yet the molecular ramification of this WT allelic loss is unknown. In this study, we showed that the restoration of WT KRAS expression in human PDAC cell lines with LOH at KRAS significantly attenuated the malignancy of PDAC cells both in vitro and in vivo, demonstrating a tumor-suppressive role of the WT KRAS allele. Through RNA-Seq, we identified the HIPPO signaling pathway to be positively regulated by WT KRAS in PDAC cells. In accordance with this observation, PDAC cells with LOH at KRAS exhibited increased nuclear localization and activation of transcriptional co-activator YAP1. Mechanistically, we discovered that WT KRAS expression sequestered YAP1 from the nucleus, through enhanced 14-3-3zeta interaction with phosphorylated YAP1 at S127. Consistently, expression of a constitutively-active YAP1 mutant in PDAC cells bypassed the growth inhibitory effects of WT KRAS. In patient samples, we found that the YAP1-activation genes were significantly upregulated in tumors with LOH at KRAS, and YAP1 nuclear localization predicted poor survival for PDAC patients. Collectively, our results reveal that the WT allelic loss leads to functional activation of YAP1 and enhanced tumor malignancy, which explains the selection advantage of the tumor cells with LOH at KRAS during pancreatic cancer clonal evolution and progression to metastasis, and should be taken into consideration in future therapeutic strategies targeting KRAS.	[Yan, Han; Yu, Chih-Chieh; Yang, Ye-Ran; Qiu, Wanglong; Su, Gloria H.] Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, New York, NY 10027 USA; [Yan, Han; Yu, Chih-Chieh; Fine, Stuart A.; Youssof, Ayman Lee; Karg, Dillon C.; Cheung, Edwin C.; Friedman, Richard A.; Chen, Emily, I; Qiu, Wanglong; Su, Gloria H.] Columbia Univ, Irving Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA; [Yan, Han; Miao, Yi] Nanjing Med Univ, Pancreas Ctr, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Yan, Han; Miao, Yi] Nanjing Med Univ, Dept Gen Surg, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Yan, Jun] Tianjin First Ctr Hosp, Dept Pathol, Tianjin, TJ, Peoples R China; [Friedman, Richard A.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Biomed Informat Shared Resource, Irving Med Ctr, New York, NY USA; [Friedman, Richard A.] Columbia Univ, Dept Biomed Informat, Biomed Informat Shared Resource, Irving Med Ctr, New York, NY USA; [Ying, Haoqiang] Univ Texas MD Anderson Canc Ctr, Mol & Cellular Oncol Dept, Houston, TX 77030 USA; [Chen, Emily, I] Columbia Univ, Dept Pharmacol, Irving Med Ctr, New York, NY USA; [Luo, Ji] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA; [Su, Gloria H.] Columbia Univ, Dept Otolaryngol & Head & Neck Surg, Irving Med Ctr, New York, NY 10027 USA; [Su, Gloria H.] Columbia Univ, Pancreas Ctr, Irving Med Ctr, New York, NY 10027 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Nanjing Medical University; Nanjing Medical University; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; University of Texas System; UTMD Anderson Cancer Center; Columbia University; NewYork-Presbyterian Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Su, GH (corresponding author), Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, New York, NY 10027 USA.; Su, GH (corresponding author), Columbia Univ, Irving Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA.; Su, GH (corresponding author), Columbia Univ, Dept Otolaryngol & Head & Neck Surg, Irving Med Ctr, New York, NY 10027 USA.; Su, GH (corresponding author), Columbia Univ, Pancreas Ctr, Irving Med Ctr, New York, NY 10027 USA.	gs2157@columbia.edu		Ying, Haoqiang/0000-0003-0616-2310; Fine, Stuart/0000-0003-1213-1799; Yu, Chih-Chieh/0000-0002-6828-1764; Yang, Yeran/0000-0003-2189-2207; Yan, Han/0000-0002-2041-3115	NIH/NCI [R01 CA217207, R01 CA178445]; NIH [P30CA013696]; CUIMC Irving Drug Discovery Pilot Award [HICCC_FY21IDD01]; China Scholarship Council; Morgan Stanley Children's Hospital-Beijing Children's Hospital Program; NCI-ICBP (Integrative Cancer Biology Program) Summer Research Program	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CUIMC Irving Drug Discovery Pilot Award; China Scholarship Council(China Scholarship Council); Morgan Stanley Children's Hospital-Beijing Children's Hospital Program; NCI-ICBP (Integrative Cancer Biology Program) Summer Research Program	This study was supported by NIH/NCI R01 CA178445, NIH/NCI R01 CA217207, CUIMC Irving Drug Discovery Pilot Award (HICCC_FY21IDD01), and NIH P30CA013696 for the HICCC. HYan was supported by the China Scholarship Council for research at the CUIMC. YY was supported by the Morgan Stanley Children's Hospital-Beijing Children's Hospital Program. DCK was supported by the NCI-ICBP (Integrative Cancer Biology Program) Summer Research Program.	Ahsan S., 2017, CURR PROTOC BIOINFOR, V57, p7.15.1, DOI 10.1002/cpbi.24; Alexa A, 2006, BIOINFORMATICS, V22, P1600, DOI 10.1093/bioinformatics/btl140; Ambrogio C, 2018, CELL, V172, P857, DOI 10.1016/j.cell.2017.12.020; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Avruch J, 2009, J BIOL CHEM, V284, P11001, DOI 10.1074/jbc.R800073200; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Chiosea SI, 2011, MODERN PATHOL, V24, P1571, DOI 10.1038/modpathol.2011.109; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EVERITT B, 1980, QUAL QUANT, V14, P75, DOI 10.1007/BF00154794; Gibson-Corley KN, 2013, VET PATHOL, V50, P1007, DOI 10.1177/0300985813485099; Grabocka E, 2014, CANCER CELL, V25, P243, DOI 10.1016/j.ccr.2014.01.005; Gruber R, 2016, GASTROENTEROLOGY, V151, P526, DOI 10.1053/j.gastro.2016.05.006; Hart SN, 2013, J COMPUT BIOL, V20, P970, DOI 10.1089/cmb.2012.0283; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hong X, 2014, EMBO J, V33, P2447, DOI 10.15252/embj.201489385; Hosseini P., 2010, BMC RES NOTES, V3; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025; Krasinskas AM, 2013, MODERN PATHOL, V26, P1346, DOI 10.1038/modpathol.2013.71; Lampson BL, 2013, CURR BIOL, V23, P70, DOI 10.1016/j.cub.2012.11.031; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liu RJ, 2015, NUCLEIC ACIDS RES, V43, pE97, DOI 10.1093/nar/gkv412; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Malapelle U, 2015, J CLIN PATHOL, V68, P265, DOI 10.1136/jclinpath-2014-202761; Matallanas D, 2011, MOL CELL, V44, P893, DOI 10.1016/j.molcel.2011.10.016; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Modrek B, 2009, MOL CANCER RES, V7, P1244, DOI 10.1158/1541-7786.MCR-08-0532; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Mueller S, 2018, NATURE, V554, P62, DOI 10.1038/nature25459; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Qiu WL, 2011, ONCOTARGET, V2, P862; R Core Team, 2015, R LANGUAGE ENV STAT; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Romano D, 2013, MOL CELL BIOL, V33, P1859, DOI 10.1128/MCB.01414-12; Allende MTS, 2017, PANCREAS, V46, P913, DOI 10.1097/MPA.0000000000000867; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simon R, 2002, GENET EPIDEMIOL, V23, P21, DOI 10.1002/gepi.202; Singh A, 2005, FASEB J, V19, P161, DOI 10.1096/fj.04-2584hyp; Soh J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007464; Staffas A, 2015, LEUKEMIA, V29, P1032, DOI 10.1038/leu.2014.315; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Sun TAN, 2021, GENES DIS, V8, P241, DOI 10.1016/j.gendis.2020.05.004; To MD, 2013, ONCOGENE, V32, P4028, DOI 10.1038/onc.2012.404; To MD, 2008, NAT GENET, V40, P1240, DOI 10.1038/ng.211; Tu B, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130811; Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130; Volodko N, 2014, FEBS LETT, V588, P2671, DOI 10.1016/j.febslet.2014.02.041; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Yan H, 2019, CANCER LETT, V442, P333, DOI 10.1016/j.canlet.2018.11.007; Young A, 2013, CANCER DISCOV, V3, P112, DOI 10.1158/2159-8290.CD-12-0231; Yu CC, 2017, CANCER LETT, V384, P86, DOI 10.1016/j.canlet.2016.10.013; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhou BY, 2016, SEMIN CELL DEV BIOL, V58, P60, DOI 10.1016/j.semcdb.2016.07.012	65	3	3	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6759	6771		10.1038/s41388-021-02040-9	http://dx.doi.org/10.1038/s41388-021-02040-9		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34663879	Green Accepted			2022-12-28	WOS:000708355700004
J	Hu, LL; Chen, X; Narwade, N; Lim, MGL; Chen, ZK; Tennakoon, C; Guan, PY; Chan, UI; Zhao, ZXL; Deng, MK; Xu, XL; Sung, WK; Cheung, E				Hu, Lingling; Chen, Xin; Narwade, Nitin; Lim, Michelle Gek Liang; Chen, Zikai; Tennakoon, Chandana; Guan, Peiyong; Chan, Un In; Zhao, Zuxianglan; Deng, Mokan; Xu, Xiaoling; Sung, Wing-Kin; Cheung, Edwin			Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression	ONCOGENE			English	Article							GENE-EXPRESSION; AUTOPHAGY; DEGRADATION; RECRUITMENT; POPULATIONS; APOPTOSIS; NETWORKS; PROGRAM; GROWTH	Androgen receptor (AR) plays a central role in driving prostate cancer (PCa) progression. How AR promotes this process is still not completely clear. Herein, we used single-cell transcriptome analysis to reconstruct the transcriptional network of AR in PCa. Our work shows AR directly regulates a set of signature genes in the ER-to-Golgi protein vesicle-mediated transport pathway. The expression of these genes is required for maximum androgen-dependent ER-to-Golgi trafficking, cell growth, and survival. Our analyses also reveal the signature genes are associated with PCa progression and prognosis. Moreover, we find inhibition of the ER-to-Golgi transport process with a small molecule enhanced antiandrogen-mediated tumor suppression of hormone-sensitive and insensitive PCa. Finally, we demonstrate AR collaborates with CREB3L2 in mediating ER-to-Golgi trafficking in PCa. In summary, our findings uncover a critical role for dysregulation of ER-to-Golgi trafficking expression and function in PCa progression, provide detailed mechanistic insights for how AR tightly controls this process, and highlight the prospect of targeting the ER-to-Golgi pathway as a therapeutic strategy for advanced PCa.	[Hu, Lingling; Narwade, Nitin; Chan, Un In; Zhao, Zuxianglan; Deng, Mokan; Xu, Xiaoling; Cheung, Edwin] Univ Macau, Canc Ctr, Taipa, Macao, Peoples R China; [Hu, Lingling; Narwade, Nitin; Chan, Un In; Zhao, Zuxianglan; Deng, Mokan; Xu, Xiaoling; Cheung, Edwin] Univ Macau, Ctr Precis Med Res & Training, Taipa, Macao, Peoples R China; [Hu, Lingling; Narwade, Nitin; Chan, Un In; Deng, Mokan; Xu, Xiaoling; Cheung, Edwin] Univ Macau, Frontier Sci Ctr Precis Oncol, Minist Educ, Taipa, Macao, Peoples R China; [Hu, Lingling; Chen, Xin; Narwade, Nitin; Chen, Zikai; Chan, Un In; Zhao, Zuxianglan; Deng, Mokan; Xu, Xiaoling; Cheung, Edwin] Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China; [Chen, Xin] Guangdong Univ Technol, Sch Automat, Guangdong Key Lab LoT Informat Technol, Guangzhou 510006, Guangdong, Peoples R China; [Lim, Michelle Gek Liang; Tennakoon, Chandana; Guan, Peiyong; Sung, Wing-Kin] Genome Inst Singapore, Singapore 138672, Singapore; [Sung, Wing-Kin] Natl Univ Singapore, Sch Comp, Singapore 117417, Singapore; [Chen, Zikai] Hanshan Normal Univ, Chaozhou 521041, Guangdong, Peoples R China	University of Macau; University of Macau; University of Macau; University of Macau; Guangdong University of Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; Hanshan Normal University	Cheung, E (corresponding author), Univ Macau, Canc Ctr, Taipa, Macao, Peoples R China.; Cheung, E (corresponding author), Univ Macau, Ctr Precis Med Res & Training, Taipa, Macao, Peoples R China.; Cheung, E (corresponding author), Univ Macau, Frontier Sci Ctr Precis Oncol, Minist Educ, Taipa, Macao, Peoples R China.; Cheung, E (corresponding author), Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China.; Sung, WK (corresponding author), Genome Inst Singapore, Singapore 138672, Singapore.; Sung, WK (corresponding author), Natl Univ Singapore, Sch Comp, Singapore 117417, Singapore.	ksung@gis.a-star.edu.sg; echeung@um.edu.mo	hu, ling/GWC-1104-2022; Guan, Peiyong/A-3715-2015	NARWADE, NITIN/0000-0002-1368-307X; Guan, Peiyong/0000-0001-9958-0137	National Science Foundation of China [62003094]; University of Macau [MYRG2018-00033-FHS, MYRG2020-00100-FHS]; Macau Science and Technology Development Fund [102/2015/A3, 0137/2020/A3, 0011/2019/AKP]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); University of Macau; Macau Science and Technology Development Fund	We are grateful for financial support from the National Science Foundation of China (Grant No. 62003094) to X.C., the University of Macau (MYRG2018-00033-FHS and MYRG2020-00100-FHS) and the Macau Science and Technology Development Fund (102/2015/A3, 0137/2020/A3, and 0011/2019/AKP) to E.C.	Alberts B., 2008, MOL BIOL CEL, V5th ed.; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Arakel EC, 2018, J CELL SCI, V131, DOI 10.1242/jcs.209890; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Blessing AM, 2017, AUTOPHAGY, V13, P506, DOI 10.1080/15548627.2016.1268300; Boncompain G, 2012, NAT METHODS, V9, P493, DOI [10.1038/NMETH.1928, 10.1038/nmeth.1928]; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030; Chapman JR, 1999, BJU INT, V83, P703; Chng KR, 2013, CANCER LETT, V340, P254, DOI 10.1016/j.canlet.2012.11.009; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Cho U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162623; David JM, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030022; Davis JE, 2016, ONCOTARGET, V7, P39834, DOI 10.18632/oncotarget.9405; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Der E, 2019, NAT IMMUNOL, V20, P915, DOI 10.1038/s41590-019-0386-1; Enge M, 2017, CELL, V171, P321, DOI 10.1016/j.cell.2017.09.004; Feng Q, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00858; Fong KW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07475-5; Gao S, 2016, CELL REP, V17, P966, DOI 10.1016/j.celrep.2016.09.064; Gomez-Navarro N, 2016, CURR BIOL, V26, pR54, DOI 10.1016/j.cub.2015.12.017; Gonthier K, 2019, J STEROID BIOCHEM, V191, DOI 10.1016/j.jsbmb.2019.04.016; Guan Y, 2020, J HEPATOL, V72, P746, DOI 10.1016/j.jhep.2019.11.007; He YD, 2018, NUCLEIC ACIDS RES, V46, P1895, DOI 10.1093/nar/gkx1306; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Howley BV, 2018, ONCOGENE, V37, P1308, DOI 10.1038/s41388-017-0023-0; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Ishikawa T, 2017, J CELL BIOL, V216, P1761, DOI 10.1083/jcb.201609100; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Iwamoto H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125982; Jensen D, 2011, J CELL SCI, V124, P1, DOI 10.1242/jcs.069773; Jeong YT, 2018, ELIFE, V7, DOI 10.7554/eLife.42253; Jing JC, 2019, INT J BIOL SCI, V15, P2419, DOI 10.7150/ijbs.37008; Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim TH, 2017, SCI REP-UK, V7, DOI 10.1038/srep45300; Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008-5472.CAN-05-1809; La Manno G, 2016, CELL, V167, P566, DOI 10.1016/j.cell.2016.09.027; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee JH, 2017, CELL, V170, P1149, DOI 10.1016/j.cell.2017.07.028; Linja MJ, 2001, CANCER RES, V61, P3550; Lonergan Peter E, 2011, J Carcinog, V10, P20, DOI 10.4103/1477-3163.83937; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mediavilla-Varela M, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-68; Mills IG, 2014, NAT REV CANCER, V14, P187, DOI 10.1038/nrc3678; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Mordente JA, 1998, J UROLOGY, V159, P275, DOI 10.1016/S0022-5347(01)64081-3; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; Nauseef JT, 2011, NAT REV UROL, V8, P428, DOI 10.1038/nrurol.2011.85; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Niu TK, 2005, MOL BIOL CELL, V16, P1213, DOI 10.1091/mbc.E04-07-0599; Paek SM, 2018, MAR DRUGS, V16, DOI 10.3390/md16040133; Parolia A, 2019, NATURE, V571, P413, DOI 10.1038/s41586-019-1347-4; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Rajamahanty S, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-5; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Reck-Peterson SL, 2018, NAT REV MOL CELL BIO, V19, P382, DOI 10.1038/s41580-018-0004-3; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; Saito A, 2009, NAT CELL BIOL, V11, P1197, DOI 10.1038/ncb1962; Sampieri L, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00123; Scharaw S, 2016, J CELL BIOL, V215, P543, DOI 10.1083/jcb.201601090; Sheng X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08152-3; Sheng X, 2015, EMBO MOL MED, V7, P788, DOI 10.15252/emmm.201404509; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sung YY, 2014, ENDOCR-RELAT CANCER, V21, pR1, DOI 10.1530/ERC-13-0326; Swinnen JV, 2004, J STEROID BIOCHEM, V92, P273, DOI 10.1016/j.jsbmb.2004.10.013; Sztul E, 2009, FEBS LETT, V583, P3770, DOI 10.1016/j.febslet.2009.10.083; Takeda DY, 2018, CELL, V174, P422, DOI 10.1016/j.cell.2018.05.037; Tan PY, 2012, MOL CELL BIOL, V32, P399, DOI 10.1128/MCB.05958-11; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Tomoishi S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08703-6; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Webber MM, 1995, CLIN CANCER RES, V1, P1089; Wise GJ, 2000, J UROLOGY, V164, P722, DOI 10.1016/S0022-5347(05)67289-8; Wu DY, 2014, NUCLEIC ACIDS RES, V42, P3607, DOI 10.1093/nar/gkt1382; Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zeisel A, 2018, CELL, V174, P999, DOI 10.1016/j.cell.2018.06.021; Zhang JB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0571-4; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhang Z, 2018, MED SCI MONITOR, V24, P8190, DOI 10.12659/MSM.912643; Zhao SG, 2019, JNCI-J NATL CANCER I, V111, P301, DOI 10.1093/jnci/djy141; ZHOU YY, 2019, NAT COMMUN, V10, DOI [10.1038/S41467-019-09234-6, DOI 10.1038/s41587-020-0546-8, DOI 10.1038/S41467-019-09234-6]; Zhu DT, 2018, CELL REP, V25, P2285, DOI 10.1016/j.celrep.2018.10.093; Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237	93	2	2	8	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6479	6493		10.1038/s41388-021-02026-7	http://dx.doi.org/10.1038/s41388-021-02026-7		OCT 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34611310				2022-12-28	WOS:000703836100003
J	Labanca, E; Bizzotto, J; Sanchis, P; Anselmino, N; Yang, J; Shepherd, PDA; Paez, A; Antico-Arciuch, V; Lage-Vickers, S; Hoang, AG; Tang, XM; Raso, MG; Titus, M; Efstathiou, E; Cotignola, J; Araujo, J; Logothetis, C; Vazquez, E; Navone, N; Gueron, G				Labanca, Estefania; Bizzotto, Juan; Sanchis, Pablo; Anselmino, Nicolas; Yang, Jun; Shepherd, Peter D. A.; Paez, Alejandra; Antico-Arciuch, Valeria; Lage-Vickers, Sofia; Hoang, Anh G.; Tang, Ximing; Raso, Maria Gabriela; Titus, Mark; Efstathiou, Eleni; Cotignola, Javier; Araujo, John; Logothetis, Christopher; Vazquez, Elba; Navone, Nora; Gueron, Geraldine			Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel	ONCOGENE			English	Article							METABOLISM; PATHWAY; BODIES; DISCOVERY; RESPONSES; REVEALS; ENZYME; ATLAS	Prostate cancer (PCa) that progresses after androgen deprivation therapy (ADT) remains incurable. The underlying mechanisms that account for the ultimate emergence of resistance to ADT, progressing to castrate-resistant prostate cancer (CRPC), include those that reactivate androgen receptor (AR), or those that are entirely independent or cooperate with androgen signaling to underlie PCa progression. The intricacy of metabolic pathways associated with PCa progression spurred us to develop a metabolism-centric analysis to assess the metabolic shift occurring in PCa that progresses with low AR expression. We used PCa patient-derived xenografts (PDXs) to assess the metabolic changes after castration of tumor-bearing mice and subsequently confirmed main findings in human donor tumor that progressed after ADT. We found that relapsed tumors had a significant increase in fatty acids and ketone body (KB) content compared with baseline. We confirmed that critical ketolytic enzymes (ACAT1, OXCT1, BDH1) were dysregulated after castrate-resistant progression. Further, these enzymes are increased in the human donor tissue after progressing to ADT. In an in silico approach, increased ACAT1, OXCT1, BDH1 expression was also observed for a subset of PCa patients that relapsed with low AR and ERG (ETS-related gene) expression. Further, expression of these factors was also associated with decreased time to biochemical relapse and decreased progression-free survival. Our studies reveal the key metabolites fueling castration resistant progression in the context of a partial or complete loss of AR dependence.	[Labanca, Estefania; Anselmino, Nicolas; Yang, Jun; Shepherd, Peter D. A.; Hoang, Anh G.; Titus, Mark; Efstathiou, Eleni; Araujo, John; Logothetis, Christopher; Navone, Nora] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Labanca, Estefania; Anselmino, Nicolas; Yang, Jun; Shepherd, Peter D. A.; Hoang, Anh G.; Titus, Mark; Efstathiou, Eleni; Araujo, John; Logothetis, Christopher; Navone, Nora] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Houston, TX 77030 USA; [Bizzotto, Juan; Sanchis, Pablo; Paez, Alejandra; Antico-Arciuch, Valeria; Lage-Vickers, Sofia; Cotignola, Javier; Vazquez, Elba; Gueron, Geraldine] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Lab Inflamac & Canc, Buenos Aires, DF, Argentina; [Bizzotto, Juan; Sanchis, Pablo; Paez, Alejandra; Antico-Arciuch, Valeria; Lage-Vickers, Sofia; Cotignola, Javier; Vazquez, Elba; Gueron, Geraldine] Univ Buenos Aires, CONICET, Inst Quim Biol, Fac Ciencias Exactas & Nat IQUIBIC, Buenos Aires, DF, Argentina; [Paez, Alejandra] Univ Buenos Aires, Inst Oncol Angel H Roffo, Unidad Transferencia Genet, Buenos Aires, DF, Argentina; [Tang, Ximing; Raso, Maria Gabriela] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires; University of Texas System; UTMD Anderson Cancer Center	Navone, N (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.; Navone, N (corresponding author), Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Houston, TX 77030 USA.; Vazquez, E; Gueron, G (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Lab Inflamac & Canc, Buenos Aires, DF, Argentina.; Vazquez, E; Gueron, G (corresponding author), Univ Buenos Aires, CONICET, Inst Quim Biol, Fac Ciencias Exactas & Nat IQUIBIC, Buenos Aires, DF, Argentina.	elba@qb.fcen.uba.ar; nnavone@mdanderson.org; ggueron@gmail.com	Bizzotto, Juan Antonio/AAZ-9350-2021	Bizzotto, Juan Antonio/0000-0002-7844-2162; Sanchis, Pablo Antonio/0000-0002-0243-8036; Anselmino, Nicolas/0000-0002-6482-2623; Paez, Alejandra/0000-0002-7715-7458; Labanca, Estefania/0000-0003-3201-7790				Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Abida W, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00029; Allen BG, 2013, CLIN CANCER RES, V19, P3905, DOI 10.1158/1078-0432.CCR-12-0287; Blighe K., 2018, ENHANCEDVOLCANO PUBL; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Chriett S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36941-9; DeHaven CD, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758-2946-2-9; Devic S, 2016, J CANCER, V7, P817, DOI 10.7150/jca.14274; Efstathiou E, 2015, EUR UROL, V67, P53, DOI 10.1016/j.eururo.2014.05.005; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Faria Michelle, 2018, Oncotarget, V9, P36273, DOI 10.18632/oncotarget.26345; Garcia-Bermudez J, 2016, MOL CELL, V64, P856, DOI 10.1016/j.molcel.2016.11.023; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Goveia J, 2016, EMBO MOL MED, V8, P1134, DOI 10.15252/emmm.201606798; Hakimi AA, 2016, CANCER CELL, V29, P104, DOI 10.1016/j.ccell.2015.12.004; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang D, 2016, CELL RES, V26, P1112, DOI 10.1038/cr.2016.109; Jaworski DM, 2016, J CELL BIOCHEM, V117, P574, DOI 10.1002/jcb.25305; Kassambara A., 2021, RSTATIX PIPE FRIENDL; Klement Rainer J, 2016, BMC Res Notes, V9, P143, DOI 10.1186/s13104-016-1959-9; Kolde Raivo, 2019, CRAN; Labanca E, 2020, ENDOCR-RELAT CANCER, V27, pR255, DOI 10.1530/ERC-19-0472; Li LK, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005070; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Lima AR, 2016, TRANSL ONCOL, V9, P357, DOI 10.1016/j.tranon.2016.05.004; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014; Martinez-Outschoorn UE, 2012, CELL CYCLE, V11, P3956, DOI 10.4161/cc.22136; Mierziak J, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11030402; Morscher RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129802; Nagarajan A, 2016, TRENDS CANCER, V2, P365, DOI 10.1016/j.trecan.2016.06.002; Navone NM, 2018, PROSTATE, V78, P1262, DOI 10.1002/pros.23701; Newman JC, 2014, TRENDS ENDOCRIN MET, V25, P42, DOI 10.1016/j.tem.2013.09.002; Palanisamy N, 2020, CLIN CANCER RES, V26, P4933, DOI 10.1158/1078-0432.CCR-20-0479; Poff AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065522; Puchalska P, 2017, CELL METAB, V25, P262, DOI 10.1016/j.cmet.2016.12.022; Rodrigues LM, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0166-z; Ross-Adams H, 2015, EBIOMEDICINE, V2, P1133, DOI 10.1016/j.ebiom.2015.07.017; Roychowdhury S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003161; Salameh A, 2015, P NATL ACAD SCI USA, V112, P8403, DOI 10.1073/pnas.1507882112; Saraon P, 2014, PROSTATE, V74, P372, DOI 10.1002/pros.22758; Saraon P, 2013, MOL CELL PROTEOMICS, V12, P1589, DOI 10.1074/mcp.M112.023887; Shukla SK, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-18; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; THUMELIN S, 1993, BIOCHEM J, V292, P493, DOI 10.1042/bj2920493; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Tzelepi V, 2012, CLIN CANCER RES, V18, P666, DOI 10.1158/1078-0432.CCR-11-1867; Varkaris A, 2016, CLIN CANCER RES, V22, P107, DOI 10.1158/1078-0432.CCR-15-0235; Vazquez ES., 2017, INT J SCI RES, V6, P614; Wan XH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009332; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yang J, 2001, CANCER RES, V61, P5652; Yoshii Y, 2015, CANCER LETT, V356, P211, DOI 10.1016/j.canlet.2014.02.019; Zhang DJ, 2011, AM J PHYSIOL-ENDOC M, V300, pE287, DOI 10.1152/ajpendo.00308.2010; Zhang J, 2018, J LIPID RES, V59, P625, DOI 10.1194/jlr.M082040; Zhang S, 2017, LIFE SCI, V183, P110, DOI 10.1016/j.lfs.2017.07.003; Zhang W, 2018, CLIN CANCER RES, V24, P696, DOI 10.1158/1078-0432.CCR-17-1872; Zhang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06177-2	64	5	5	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6284	6298		10.1038/s41388-021-02008-9	http://dx.doi.org/10.1038/s41388-021-02008-9		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34584218	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000701638300004
J	Zhang, XD; Hu, FY; Zhu, BW; Jiao, XL; Li, Y; Wu, S; Ren, GL; Li, JZ; Xie, QP; Pan, YF; Li, HY; Zhao, LL				Zhang, Xiaodong; Hu, Fangyu; Zhu, Baiwang; Jiao, Xueli; Li, Yun; Wu, Shuang; Ren, Ganglin; Li, Jizhen; Xie, Qipeng; Pan, Yifei; Li, Hongyan; Zhao, Lingling			Downregulation of TEX11 promotes S-Phase progression and proliferation in colorectal cancer cells through the FOXO3a/COP1/c-Jun/p21 axis	ONCOGENE			English	Article							C-JUN; TRANSCRIPTIONAL REGULATION; CYCLE; GENE; AZOOSPERMIA	Colorectal cancer (CRC) is the most common digestive tract malignancy, attributing to approximately 9.4% of global cancer-related deaths. However, the pathogenesis of CRC is poorly understood. The testis-expressed 11 (TEX11) gene is located on the X chromosome and is required for spermatogenesis, and is reported might serve as a biomarker for early onset CRC according to database analysis. However, the role played by TEX11 in cancer progression remains to be investigated. In this study, we show that TEX11 expression is significantly downregulated in CRC cell lines and clinical CRC tissue samples, and TEX11 expression correlates with poor prognosis in CRC patients. We further demonstrate that TEX11 can significantly inhibit the proliferative capacity of CRC cells in vitro and in vivo. Mechanistically, we demonstrate that TEX11 promotes transcription of COP1 by upregulating FOXO3a expression. This enhanced COP1 expression subsequently accelerates the degradation of the negative transcriptional regulator c-Jun, which, in turn, enhances p21 transcription inhibiting CRC cell cycle progression and proliferation. Overall, our findings suggest that TEX11 may be a valuable therapeutic target for the treatment of CRC.	[Zhang, Xiaodong; Zhu, Baiwang; Pan, Yifei] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325035, Zhejiang, Peoples R China; [Hu, Fangyu; Jiao, Xueli; Li, Yun; Wu, Shuang; Ren, Ganglin; Li, Hongyan; Zhao, Lingling] Wenzhou Med Univ, Sch Lab Med & Life Sci, Zhejiang Prov Key Lab Med Genet, Key Lab Lab Med,Minist Educ, Wenzhou 325035, Zhejiang, Peoples R China; [Li, Jizhen; Xie, Qipeng] Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou 325027, Zhejiang, Peoples R China; [Li, Jizhen; Xie, Qipeng] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Zhejiang, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University	Pan, YF (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325035, Zhejiang, Peoples R China.; Li, HY; Zhao, LL (corresponding author), Wenzhou Med Univ, Sch Lab Med & Life Sci, Zhejiang Prov Key Lab Med Genet, Key Lab Lab Med,Minist Educ, Wenzhou 325035, Zhejiang, Peoples R China.	13506641535@139.com; hylee666@163.com; zhaolingling@wmu.edu.cn			Key Project of Science and Technology Innovation Team of Zhejiang Province [2013TD10]; Key Discipline of Zhejiang Province in Medical Technology; Wenzhou Science & Technology Bureau [Y20180857]; Wenzhou Medical University [89219018]	Key Project of Science and Technology Innovation Team of Zhejiang Province; Key Discipline of Zhejiang Province in Medical Technology; Wenzhou Science & Technology Bureau; Wenzhou Medical University	Bioinformatics results described here are based on data from the TCGA research network (http://cancergenome.nih.gov/).We thank all participants, specimen donors, and research groups who participated in the creation of the TCGA CRC cancer dataset. This work was partially supported by the Key Project of Science and Technology Innovation Team of Zhejiang Province (2013TD10), Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A), Wenzhou Science & Technology Bureau (Y20180857), and Wenzhou Medical University (89219018).	Akgul O, 2014, WORLD J GASTROENTERO, V20, P6113, DOI 10.3748/wjg.v20.i20.6113; Blanchard JM, 2000, BIOCHEM PHARMACOL, V60, P1179, DOI 10.1016/S0006-2952(00)00384-1; Boeding JRE, 2018, INT J COLORECTAL DIS, V33, P1393, DOI 10.1007/s00384-018-3132-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chacko L, 2015, DIGEST DIS SCI, V60, P698, DOI 10.1007/s10620-014-3452-4; Chen FJ, 2022, NEOPLASIA, V24, P22, DOI 10.1016/j.neo.2021.11.014; Cheng JM, 2015, J BIOL REG HOMEOS AG, V29, P85; Csizmok V, 2018, STRUCTURE, V26, P28, DOI 10.1016/j.str.2017.11.003; Dapper AL, 2019, EVOLUTION, V73, P2368, DOI 10.1111/evo.13850; de Moraes GN, 2016, CURR DRUG TARGETS, V17, P164, DOI 10.2174/1389450115666141122211549; El-Deiry WS, 2016, CANCER RES, V76, P5189, DOI 10.1158/0008-5472.CAN-16-2055; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Fasano C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091110; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Gao BX, 2006, J BIOL CHEM, V281, P29711, DOI 10.1074/jbc.M604596200; Garcia R, 2008, Z NATURFORSCH C, V63, P17; Gausman V, 2020, CLIN GASTROENTEROL H, V18, P2752, DOI 10.1016/j.cgh.2019.10.009; Guiraldelli MF, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007381; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; Hume S, 2020, NUCLEIC ACIDS RES, V48, P12483, DOI 10.1093/nar/gkaa1002; Jin HL, 2018, MOL THER-NUCL ACIDS, V11, P312, DOI 10.1016/j.omtn.2018.03.003; Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008; Koo JH, 2010, J GASTROEN HEPATOL, V25, P33, DOI 10.1111/j.1440-1746.2009.05992.x; Li HY, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.602; Liu Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0856-3; Lukashev AN, 2016, BIOCHEMISTRY-MOSCOW+, V81, P700, DOI 10.1134/S0006297916070063; Luo TC, 2013, MOL BIOL REP, V40, P6561, DOI 10.1007/s11033-013-2694-0; Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Migliorini D, 2011, J CLIN INVEST, V121, P1329, DOI 10.1172/JCI45784; Nho Richard Seonghun, 2014, World J Biol Chem, V5, P346, DOI 10.4331/wjbc.v5.i3.346; Ray AL, 2020, BRIT J CANCER, V123, P624, DOI 10.1038/s41416-020-0913-8; Shamloo B, 2019, CANCERS, V11, DOI 10.3390/cancers11081178; Song YZ, 2020, SEMIN CANCER BIOL, V67, P43, DOI 10.1016/j.semcancer.2020.02.001; Tuttelmann F, 2018, MED GENET-BERLIN, V30, P12, DOI 10.1007/s11825-018-0181-7; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wang Feng, 2015, Intrinsically Disord Proteins, V3, pe1056906, DOI 10.1080/21690707.2015.1056906; Wang Y, 2019, ADV EXP MED BIOL, V1206, P527, DOI 10.1007/978-981-15-0602-4_25; Wang ZB, 2005, CELL BIOL INT, V29, P489, DOI 10.1016/j.cellbi.2005.04.001; Watanabe M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13122502; Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z; Yang F, 2015, EMBO MOL MED, V7, P1198, DOI 10.15252/emmm.201404967; Yatsenko AN, 2015, NEW ENGL J MED, V372, P2097, DOI 10.1056/NEJMoa1406192; Zhang YQ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-30342-3; Zheng K, 2010, J ANDROL, V31, P79, DOI 10.2164/jandrol.109.008193	45	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5133	5145		10.1038/s41388-022-02490-9	http://dx.doi.org/10.1038/s41388-022-02490-9		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36258021				2022-12-28	WOS:000869591700002
J	Muller, GA; Asthana, A; Rubin, SM				Mueller, Gerd A.; Asthana, Anushweta; Rubin, Seth M.			Structure and function of MuvB complexes	ONCOGENE			English	Review							CELL-CYCLE PROGRESSION; B-MYB; DREAM COMPLEX; TRANSCRIPTION FACTOR; GENE-EXPRESSION; HISTONE METHYLATION; POCKET PROTEINS; TERMINAL DOMAIN; DROSOPHILA MYB; G2/M GENES	Proper progression through the cell-division cycle is critical to normal development and homeostasis and is necessarily misregulated in cancer. The key to cell-cycle regulation is the control of two waves of transcription that occur at the onset of DNA replication (S phase) and mitosis (M phase). MuvB complexes play a central role in the regulation of these genes. When cells are not actively dividing, the MuvB complex DREAM represses G1/S and G2/M genes. Remarkably, MuvB also forms activator complexes together with the oncogenic transcription factors B-MYB and FOXM1 that are required for the expression of the mitotic genes in G2/M. Despite this essential role in the control of cell division and the relationship to cancer, it has been unclear how MuvB complexes inhibit and stimulate gene expression. Here we review recent discoveries of MuvB structure and molecular interactions, including with nucleosomes and other chromatin-binding proteins, which have led to the first mechanistic models for the biochemical function of MuvB complexes.	[Mueller, Gerd A.; Asthana, Anushweta; Rubin, Seth M.] Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Muller, GA; Rubin, SM (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	gemuelle@ucsc.edu; srubin@ucsc.edu	Müller, Gerd Armin/AAO-6714-2021; Müller, Gerd Armin/GYU-9447-2022	Müller, Gerd Armin/0000-0002-4967-2487; Müller, Gerd Armin/0000-0002-4967-2487; Rubin, Seth/0000-0002-1670-4147; Asthana, Anushweta/0000-0001-6112-6668	National Institutes of Health [R01GM124148, R01GM127707, R01CA228413]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Research in the authors' laboratory is funded by grants from the National Institutes of Health (R01GM124148, R01GM127707, and R01CA228413 to S.M.R.). Figures 1 and 3 were created with BioRender.com.	Adams MK, 2020, MOL CELL PROTEOMICS, V19, DOI 10.1074/mcp.RA120.002078; Andrejka L, 2011, P NATL ACAD SCI USA, V108, P17438, DOI 10.1073/pnas.1111855108; Asthana A, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28094-1; Bainor AJ, 2018, CELL REP, V25, P2797, DOI 10.1016/j.celrep.2018.11.024; Barger CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11020251; Beall EL, 2007, GENE DEV, V21, P904, DOI 10.1101/gad.1516607; Beall EL, 2004, GENE DEV, V18, P1667, DOI 10.1101/gad.1206604; Beshiri ML, 2012, P NATL ACAD SCI USA, V109, P18499, DOI 10.1073/pnas.1216724109; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Blanchard DP, 2014, P NATL ACAD SCI USA, V111, pE4234, DOI 10.1073/pnas.1416321111; Boichuk S, 2013, CANCER RES, V73, P5120, DOI 10.1158/0008-5472.CAN-13-0579; Branigan TB, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108808; Calvisi DF, 2011, HEPATOLOGY, V53, P1226, DOI 10.1002/hep.24174; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Chen BR, 2021, ELIFE, V10, DOI 10.7554/eLife.68466; Chen X, 2013, MOL CELL BIOL, V33, P227, DOI 10.1128/MCB.00881-12; Cheng MH, 2017, BIOL OPEN, V6, P967, DOI 10.1242/bio.025825; Ciciro Y, 2021, ONCOGENESIS, V10, DOI 10.1038/s41389-021-00309-y; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Colino-Sanguino Y, 2022, TRENDS GENET, V38, P273, DOI 10.1016/j.tig.2021.10.003; DeBruhl H, 2013, MOL CELL BIOL, V33, P1809, DOI 10.1128/MCB.01401-12; Dick FA, 2018, NAT REV CANCER, V18, P442, DOI 10.1038/s41568-018-0008-5; Down CF, 2012, BBA-GENE REGUL MECH, V1819, P855, DOI 10.1016/j.bbagrm.2012.03.008; Duan L., 2022, SCI REP-UK, V12; Duffy MJ, 2022, SEMIN CANCER BIOL, V79, P58, DOI 10.1016/j.semcancer.2020.07.005; Dyson NJ, 2016, GENE DEV, V30, P1492, DOI 10.1101/gad.282145.116; Eisinger-Mathason TSK, 2015, P NATL ACAD SCI USA, V112, pE3402, DOI 10.1073/pnas.1420005112; Enrico TP, 2021, ELIFE, V10, DOI [10.7554/eLife.70691, 10.7554/eLife.70691.sa0, 10.7554/eLife.70691.sa1, 10.7554/eLife.70691.sa2]; Esterlechner J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062882; Fera D, 2012, CHEM BIOL, V19, P518, DOI 10.1016/j.chembiol.2012.03.007; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fischer M, 2017, CRIT REV BIOCHEM MOL, V52, P638, DOI 10.1080/10409238.2017.1360836; Fischer M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02831-9; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Forristal C, 2014, MOL CELL BIOL, V34, P2221, DOI 10.1128/MCB.01523-13; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Gartel AL, 2017, CANCER RES, V77, P3135, DOI 10.1158/0008-5472.CAN-16-3566; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Goetsch PD, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007088; Grant GD, 2013, MOL BIOL CELL, V24, P3634, DOI 10.1091/mbc.E13-05-0264; Grundl M, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008818; Guiley KZ, 2018, P NATL ACAD SCI USA, V115, P10016, DOI 10.1073/pnas.1808136115; Guiley KZ, 2015, GENE DEV, V29, P961, DOI 10.1101/gad.257568.114; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harrison MM, 2006, P NATL ACAD SCI USA, V103, P16782, DOI 10.1073/pnas.0608461103; Hsu J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10901-x; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iltzsche F, 2017, ONCOGENE, V36, P110, DOI 10.1038/onc.2016.181; Iness AN, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.637193; Iness AN, 2019, ONCOGENE, V38, P1080, DOI 10.1038/s41388-018-0490-y; Jiang JQ, 2007, DEVELOPMENT, V134, P1549, DOI 10.1242/dev.000521; Joaquin M, 2002, ONCOGENE, V21, P7923, DOI 10.1038/sj.onc.1206001; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Kim MJ, 2021, MOL CELL, V81, P1698, DOI 10.1016/j.molcel.2021.02.001; Knight AS, 2009, ONCOGENE, V28, P1737, DOI 10.1038/onc.2009.22; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Korenjak M, 2014, NUCLEIC ACIDS RES, V42, P8939, DOI 10.1093/nar/gku609; Kurimchak A, 2012, GENE, V499, P1, DOI 10.1016/j.gene.2012.02.015; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Latorre I, 2015, GENE DEV, V29, P495, DOI 10.1101/gad.255810.114; Lewis PW, 2012, MOL CELL BIOL, V32, P3218, DOI 10.1128/MCB.00432-12; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Liban TJ, 2016, J MOL BIOL, V428, P3960, DOI 10.1016/j.jmb.2016.08.017; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Lu R, 2013, TRENDS BIOCHEM SCI, V38, P546, DOI 10.1016/j.tibs.2013.08.002; MacDonald J, 2017, MOL CANCER RES, V15, P371, DOI 10.1158/1541-7786.MCR-16-0323-T; Mages CFS, 2017, ELIFE, V6, DOI 10.7554/eLife.26876; Marceau AH, 2019, ELIFE, V8, DOI 10.7554/eLife.46131; Marceau AH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12301; Matsuo T, 2012, CELL CYCLE, V11, P3227, DOI 10.4161/cc.21569; Morgan D. O., 2007, CELL CYCLE PRINCIPLE; Muller GA, 2017, ONCOTARGET, V8, P97736, DOI 10.18632/oncotarget.10888; Muller GA, 2014, NUCLEIC ACIDS RES, V42, P10331, DOI 10.1093/nar/gku696; Muller GA, 2012, NUCLEIC ACIDS RES, V40, P1561, DOI 10.1093/nar/gkr793; Nilsson MB, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz4589; Oji A, 2020, BIOL REPROD, V102, P975, DOI 10.1093/biolre/ioaa002; Oka O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052906; Okumura F, 2016, MOL CELL BIOL, V36, P1803, DOI 10.1128/MCB.00067-16; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Patel AJ, 2019, P NATL ACAD SCI USA, V116, P21715, DOI 10.1073/pnas.1912858116; Pattschull G, 2019, CELL REP, V27, P3533, DOI 10.1016/j.celrep.2019.05.071; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Rashid NN, 2011, J GEN VIROL, V92, P2620, DOI 10.1099/vir.0.035352-0; Reichert N, 2010, MOL CELL BIOL, V30, P2896, DOI 10.1128/MCB.00028-10; Roberts MS, 2020, CANCER RES, V80, P1693, DOI 10.1158/0008-5472.CAN-19-3466; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Rushton JJ, 2001, BLOOD CELL MOL DIS, V27, P459, DOI 10.1006/bcmd.2001.0405; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sahni JM, 2017, CANCER RES, V77, P5395, DOI 10.1158/0008-5472.CAN-17-1571; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sanders DA, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0696-z; Schade AE, 2019, NUCLEIC ACIDS RES, V47, P11197, DOI 10.1093/nar/gkz961; Schade AE, 2019, ONCOGENE, V38, P4962, DOI 10.1038/s41388-019-0767-9; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Schmit F, 2009, FEBS J, V276, P5703, DOI 10.1111/j.1742-4658.2009.07261.x; Schmitges FW, 2011, MOL CELL, V42, P330, DOI 10.1016/j.molcel.2011.03.025; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 2000, CANCER RES, V60, P3689; Song JJ, 2008, GENE DEV, V22, P1313, DOI 10.1101/gad.1653308; Tabuchi TM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002074; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Uxa S, 2019, NUCLEIC ACIDS RES, V47, P9087, DOI 10.1093/nar/gkz635; van Oevelen C, 2008, MOL CELL, V32, P359, DOI 10.1016/j.molcel.2008.10.015; Vorster PJ, 2020, BIOL OPEN, V9, DOI 10.1242/bio.051508; Wang C, 2022, J BIOL CHEM, V298; Wang XX, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00609-16; Wei T, 2019, ONCOGENE, V38, P5541, DOI 10.1038/s41388-019-0801-y; Wen H, 2008, GENE DEV, V22, P601, DOI 10.1101/gad.1626308; Werwein E, 2019, NUCLEIC ACIDS RES, V47, P103, DOI 10.1093/nar/gky935; White-Cooper H, 2000, DEVELOPMENT, V127, P5463; Wiseman EF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0339-8; Wolter P, 2017, ONCOTARGET, V8, P11160, DOI 10.18632/oncotarget.14466; Xu C, 2011, PROTEIN CELL, V2, P202, DOI 10.1007/s13238-011-1018-1; Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	120	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2909	2919		10.1038/s41388-022-02321-x	http://dx.doi.org/10.1038/s41388-022-02321-x		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35468940	Green Accepted			2022-12-28	WOS:000787133300001
J	Jiao, DY; Chen, YJ; Wang, YL; Sun, HR; Shi, Q; Zhang, L; Zhao, XY; Liu, YJ; He, HY; Lv, ZH; Liu, C; Zhang, PZ; Gao, K; Huang, Y; Li, Y; Li, L; Wang, CJ				Jiao, Dongyue; Chen, Yingji; Wang, Yalan; Sun, Huiru; Shi, Qing; Zhang, Liang; Zhao, Xiaying; Liu, Yajuan; He, Huiying; Lv, Zeheng; Liu, Chuan; Zhang, Pingzhao; Gao, Kun; Huang, Yan; Li, Yao; Li, Liang; Wang, Chenji			DCAF12 promotes apoptosis and inhibits NF-kappa B activation by acting as an endogenous antagonist of IAPs	ONCOGENE			English	Article							STRUCTURAL BASIS; CASPASE INHIBITORS; SERINE-PROTEASE; CELL-DEATH; XIAP; IDENTIFICATION; FAMILY; REAPER; GROWTH; GENE	Members of the Inhibitor of Apoptosis Protein (IAP) family are essential for cell survival and appear to neutralize the cell death machinery by binding pro-apoptotic caspases. dcaf12 was recently identified as an apoptosis regulator in Drosophila. However, the underlying molecular mechanisms are unknown. Here we revealed that human DCAF12 homolog binds multiple IAPs, including XIAP, cIAP1, cIAP2, and BRUCE, through recognition of BIR domains in IAPs. The pro-apoptotic function of DCAF12 is dependent on its capacity to bind IAPs. In response to apoptotic stimuli, DCAF12 translocates from the nucleus to the cytoplasm, where it blocks the interaction between XIAP and pro-apoptotic caspases to facilitate caspase activation and apoptosis execution. Similarly, DCAF12 suppresses NF-kappa B activation in an IAP binding-dependent manner. Moreover, DCAF12 acts as a tumor suppressor to restrict the malignant phenotypes of cancer cells. Together, our results suggest that DCAF12 is an evolutionarily conserved IAP antagonist.	[Jiao, Dongyue; Chen, Yingji; Wang, Yalan; Sun, Huiru; Shi, Qing; Zhang, Liang; Zhao, Xiaying; Liu, Yajuan; He, Huiying; Huang, Yan; Li, Yao; Wang, Chenji] Fudan Univ, Shanghai Stomatol Hosp, Shanghai 200438, Peoples R China; [Jiao, Dongyue; Chen, Yingji; Wang, Yalan; Sun, Huiru; Shi, Qing; Zhang, Liang; Zhao, Xiaying; Liu, Yajuan; He, Huiying; Huang, Yan; Li, Yao; Wang, Chenji] Fudan Univ, MOE Engn Res Ctr Gene Technol, Shanghai Engn Res Ctr Ind Microorg, Sch Stomatol,Sch Life Sci,State Key Lab Genet Eng, Shanghai 200438, Peoples R China; [Lv, Zeheng; Gao, Kun] Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Dept Clin Lab, Shanghai 200092, Peoples R China; [Liu, Chuan; Li, Liang] Zibo Cent Hosp, Dept Thyroid & Breast Surg, Zibo 255036, Peoples R China; [Zhang, Pingzhao] Fudan Univ, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Zhang, Pingzhao] Fudan Univ, Dept Pathol, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Tongji University; Fudan University; Fudan University	Wang, CJ (corresponding author), Fudan Univ, Shanghai Stomatol Hosp, Shanghai 200438, Peoples R China.; Wang, CJ (corresponding author), Fudan Univ, MOE Engn Res Ctr Gene Technol, Shanghai Engn Res Ctr Ind Microorg, Sch Stomatol,Sch Life Sci,State Key Lab Genet Eng, Shanghai 200438, Peoples R China.; Li, L (corresponding author), Zibo Cent Hosp, Dept Thyroid & Breast Surg, Zibo 255036, Peoples R China.	liliangzb@sina.com; chenjiwang@fudan.edu.cn			National Natural Science Foundation of China [91957125, 81972396, 81672558, 91954106, 81872109, 81872260, 81572768]; Natural Science Foundation of Shanghai [22ZR1449200, 22ZR1406600]; Natural Science Foundation of Shandong Province [ZR2021MH212]; Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University [SKLGE-2111]; Science and Technology Research Program of Shanghai [9DZ2282100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University; Science and Technology Research Program of Shanghai	We thank Dr. Mikihiko Naito for providing BRUCE cDNAs. This work was in part supported by the National Natural Science Foundation of China (No. 91957125, 81972396, 81672558 to CW; No. 91954106, 81872109 to KG.; No. 81872260, 81572768 to PZ) the Natural Science Foundation of Shanghai (No. 22ZR1449200 to KG; 22ZR1406600 to CW), the Natural Science Foundation of Shandong Province (No. ZR2021MH212 to LL), the Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University (No. SKLGE-2111 to KG), the Science and Technology Research Program of Shanghai (No. 9DZ2282100).	BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Cho YS, 2020, GENE DEV, V34, P53, DOI 10.1101/gad.333146.119; Damgaard RB, 2013, EMBO MOL MED, V5, P1278, DOI 10.1002/emmm.201303090; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dubrez-Daloz L, 2008, CELL CYCLE, V7, P1036, DOI 10.4161/cc.7.8.5783; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Gao K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0561-6; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hao YY, 2004, NAT CELL BIOL, V6, P849, DOI 10.1038/ncb1159; Hu XY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1200-y; Huang YH, 2003, J BIOL CHEM, V278, P49517, DOI 10.1074/jbc.M310061200; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Hwangbo DS, 2016, DEV BIOL, V413, P50, DOI 10.1016/j.ydbio.2016.03.003; Jackson S, 2009, TRENDS BIOCHEM SCI, V34, P562, DOI 10.1016/j.tibs.2009.07.002; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kalkavan H, 2018, CELL DEATH DIFFER, V25, P46, DOI 10.1038/cdd.2017.179; Kim K, 2013, MOL CELL, V52, P459, DOI 10.1016/j.molcel.2013.09.017; Koren I, 2018, CELL, V173, P1622, DOI 10.1016/j.cell.2018.04.028; Kumar S, 2020, PHARMACOL THERAPEUT, V214, DOI 10.1016/j.pharmthera.2020.107610; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Lu M, 2007, MOL CELL, V26, P689, DOI 10.1016/j.molcel.2007.05.006; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Patron LA, 2019, J CELL BIOL, V218, P993, DOI 10.1083/jcb.201805099; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Ravichandran R, 2019, EMBO REP, V20, DOI 10.15252/embr.201847352; Richter B W, 2000, Sci STKE, V2000, ppe1, DOI 10.1126/stke.2000.44.pe1; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Varfolomeev E, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001878; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2001, GENOME BIOL, V2; Wajant H, 2011, FEBS J, V278, P862, DOI 10.1111/j.1742-4658.2011.08015.x; Wang XX, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00609-16; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Zheng C, 2010, MOL CELL, V38, P101, DOI 10.1016/j.molcel.2010.03.009	45	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					3000	3010		10.1038/s41388-022-02319-5	http://dx.doi.org/10.1038/s41388-022-02319-5		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35459779				2022-12-28	WOS:000787474100002
J	Koorman, T; Jansen, KA; Khalil, A; Haughton, PD; Visser, D; Ratze, MAK; Haakma, WE; Sakalauskaite, G; van Diest, PJ; de Rooij, J; Derksen, PWB				Koorman, Thijs; Jansen, Karin A.; Khalil, Antoine; Haughton, Peter D.; Visser, Daan; Ratze, Max A. K.; Haakma, Wisse E.; Sakalauskaite, Gabriele; van Diest, Paul J.; de Rooij, Johan; Derksen, Patrick W. B.			Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment	ONCOGENE			English	Article							LYSYL OXIDASE; MOLECULAR ROLE; 2 LOXL2; METASTASIS; STIFFNESS; LOCALIZATION; TRANSMISSION; PROTEOLYSIS; REPRESSION; MIGRATION	The tumor micro-environment often contains stiff and irregular-bundled collagen fibers that are used by tumor cells to disseminate. It is still unclear how and to what extent, extracellular matrix (ECM) stiffness versus ECM bundle size and alignment dictate cancer cell invasion. Here, we have uncoupled Collagen-I bundling from stiffness by introducing inter-collagen crosslinks, combined with temperature induced aggregation of collagen bundling. Using organotypic models from mouse invasive ductal and invasive lobular breast cancers, we show that increased collagen bundling in 3D induces a generic increase in breast cancer invasion that is independent of migration mode. However, systemic collagen stiffening using advanced glycation end product (AGE) crosslinking prevents collective invasion, while leaving single cell invasion unaffected. Collective invasion into collagen matrices by ductal breast cancer cells depends on Lysyl oxidase-like 3 (Loxl3), a factor produced by tumor cells that reinforces local collagen stiffness. Finally, we present clinical evidence that collectively invading cancer cells at the invasive front of ductal breast carcinoma upregulate LOXL3. By uncoupling the mechanical, chemical, and structural cues that control invasion of breast cancer in three dimensions, our data reveal that spatial control over stiffness and bundling underlie collective dissemination of ductal-type breast cancers.	[Koorman, Thijs; Jansen, Karin A.; Haughton, Peter D.; Visser, Daan; Ratze, Max A. K.; Haakma, Wisse E.; Sakalauskaite, Gabriele; van Diest, Paul J.; Derksen, Patrick W. B.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Khalil, Antoine; de Rooij, Johan] Univ Med Ctr Utrecht, Ctr Mol Med, Mol Canc Res, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Derksen, PWB (corresponding author), Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands.; de Rooij, J (corresponding author), Univ Med Ctr Utrecht, Ctr Mol Med, Mol Canc Res, Utrecht, Netherlands.	J.deRooij-3@umcutrecht.nl; p.w.b.derksen@umcutrecht.nl	; Derksen, Patrick/C-6643-2008	de rooij, johan/0000-0001-6101-7875; Haakma, Wisse/0000-0002-1362-4790; Khalil, Antoine A./0000-0003-3469-0778; Koorman, Thijs/0000-0002-6064-3353; Derksen, Patrick/0000-0003-0732-7762	Netherlands Organization for Scientific Research [NWO-TOP 02007]; Dutch Cancer Society [KWF-2017-10456]; European Union [731957]; COST (European Cooperation in Science and Technology) [CA19138]	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding); European Union(European Commission); COST (European Cooperation in Science and Technology)(European Cooperation in Science and Technology (COST))	The authors thank Tina Vermonden and Mies van Steenbergen for help with and use of the rheometer, and Holger Rehmann and Richard van Schaik for purifying the GFP-CNA35 probe. We are indebted to Federica Burla for sharing the pore size determining program in Python, and Nico Jansen for help with rewriting the collagen alignment program to an ImageJ plugin. Lilian Sluimer and Jeroen Vermeulen are thanked for their help on quality control and statistics of the clinical datasets, and the Tissue Facility (Pathology Department UMCU) for immunohistochemistry on tissue sections. We are also grateful to Nalan Liv and Tineke Veenendaal for electron microscopy. We thank Jacco van Rheenen for the parental PyMT organoids and Martijn Gloerich for comments and conceptual input. This work was financially supported by grants from The Netherlands Organization for Scientific Research (NWO-TOP 02007), Dutch Cancer Society grants (KWF-2017-10456), and the European Union's Horizon 2020 FET Proactive program under the grant agreement No. 731957 (MECHANO-CONTROL). This article is also based upon work from COST Action (CA19138), supported by COST (European Cooperation in Science and Technology).	Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; Ahmad S, 2018, SEMIN CANCER BIOL, V49, P44, DOI 10.1016/j.semcancer.2017.07.001; Ahmadzadeh H, 2017, P NATL ACAD SCI USA, V114, pE1617, DOI 10.1073/pnas.1617037114; Baker AM, 2013, ONCOGENE, V32, P1863, DOI 10.1038/onc.2012.202; Balcioglu HE, 2016, SCI REP-UK, V6, DOI 10.1038/srep22580; Blank MAB, 2017, ULTRASOUND MED BIOL, V43, P387, DOI 10.1016/j.ultrasmedbio.2016.09.002; Canesin G, 2015, ONCOGENE, V34, P951, DOI 10.1038/onc.2014.23; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chiue H, 2015, BIOCHEM BIOPH RES CO, V461, P445, DOI 10.1016/j.bbrc.2015.04.011; Christgen M, 2016, PATHOL RES PRACT, V212, P583, DOI 10.1016/j.prp.2016.05.002; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Cuevas EP, 2014, BIOL OPEN, V3, P129, DOI 10.1242/bio.20146841; Derksen PWB, 2011, DIS MODEL MECH, V4, P347, DOI 10.1242/dmm.006395; Drifka CR, 2016, ONCOTARGET, V7, P76197, DOI 10.18632/oncotarget.12772; Dupont S, 2016, EXP CELL RES, V343, P42, DOI 10.1016/j.yexcr.2015.10.034; Ewald AJ, 2012, J CELL SCI, V125, P2638, DOI 10.1242/jcs.096875; Fan HJ, 2020, GENE DEV, V34, P1359, DOI 10.1101/gad.339796.120; Feldker N, 2020, EMBO J, V39, DOI 10.15252/embj.2019103209; Fiorino S, 2018, FUTURE ONCOL, V14, P1601, DOI 10.2217/fon-2017-0510; Hynes RO., 2012, COLD SPRING HARB PER, V4, pA004903, DOI [10.1101/cshperspect.a004903, DOI 10.1101/CSHPERSPECT.A004903]; Jansen KA, 2018, BIOPHYS J, V114, P2665, DOI 10.1016/j.bpj.2018.04.043; Kai F, 2019, DEV CELL, V49, P332, DOI 10.1016/j.devcel.2019.03.026; Keating M, 2017, ACTA BIOMATER, V57, P304, DOI 10.1016/j.actbio.2017.05.008; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kraft-Sheleg O, 2016, DEV CELL, V36, P550, DOI 10.1016/j.devcel.2016.02.009; Krajina BA, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe1969; Kushner MH, 2020, EMBO REP, V21, DOI 10.15252/embr.201948741; Laurentino TD, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143587; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lopez JI, 2011, INTEGR BIOL-UK, V3, P910, DOI 10.1039/c1ib00043h; Ma XY, 2013, BIOPHYS J, V104, P1410, DOI 10.1016/j.bpj.2013.02.017; Millanes-Romero A, 2013, MOL CELL, V52, P746, DOI 10.1016/j.molcel.2013.10.015; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Salvador F, 2017, CANCER RES, V77, P5846, DOI 10.1158/0008-5472.CAN-16-3152; Schackmann RCJ, 2011, J CLIN INVEST, V121, P3176, DOI 10.1172/JCI41695; Sflomos G, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202013180; Sharma A, 2016, PHYS REV E, V94, DOI 10.1103/PhysRevE.94.042407; Staneva R, 2018, MOL BIOL CELL, V29, P2979, DOI 10.1091/mbc.E18-01-0068; Tasdemir N, 2018, CANCER RES, V78, P6209, DOI 10.1158/0008-5472.CAN-18-1416; Vallet SD, 2019, ESSAYS BIOCHEM, V63, P349, DOI 10.1042/EBC20180050; van de Ven RAH, 2015, DIS MODEL MECH, V8, P373, DOI 10.1242/dmm.018648; Vlug E, 2014, ARCH IMMUNOL THER EX, V62, P7, DOI 10.1007/s00005-013-0251-0; Vlug EJ, 2013, CELL ONCOL, V36, P375, DOI 10.1007/s13402-013-0143-7; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Wang HL, 2014, BIOPHYS J, V107, P2592, DOI 10.1016/j.bpj.2014.09.044; Weiler SME, 2020, CANCER LETT, V473, P164, DOI 10.1016/j.canlet.2019.12.044; Wolf K, 2013, J CELL BIOL, V201, P1069, DOI 10.1083/jcb.201210152; Wrenn ED, 2020, CELL, V183, P395, DOI 10.1016/j.cell.2020.08.045; Yang YL, 2009, BIOPHYS J, V97, P2051, DOI 10.1016/j.bpj.2009.07.035; Zemke NR, 2019, GENE DEV, V33, P828, DOI 10.1101/gad.324814.119	56	12	12	12	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2458	2469		10.1038/s41388-022-02258-1	http://dx.doi.org/10.1038/s41388-022-02258-1		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35292774	hybrid, Green Published			2022-12-28	WOS:000769296900001
J	Rong, ZX; Zhang, L; Li, Z; Xiao, Z; Duan, YM; Ren, XX; Zi, YY; Gao, J; Mu, Y; Guan, YD; Cao, Z; Wang, XT; Pei, Q; Zeng, Y; Fan, Q; Zeng, ZM; Ou, DM; He, J; Nie, YJ; Tan, R; Weng, L; Li, YH; Xiang, R; Deng, YZ; Sun, LQ				Rong, Zhuoxian; Zhang, Lu; Li, Zhi; Xiao, Zhi; Duan, Yumei; Ren, Xinxin; Zi, Yuyuan; Gao, Jie; Mu, Yun; Guan, Yidi; Cao, Zhen; Wang, Xitao; Pei, Qian; Zeng, Yu; Fan, Qi; Zeng, Zimei; Ou, Danmin; He, Jiang; Nie, Yingjie; Tan, Rong; Weng, Liang; Li, Yuhao; Xiang, Rong; Deng, Yuezhen; Sun, Lunquan			SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/beta-catenin signaling	ONCOGENE			English	Article							INDUCIBLE KINASE 2; WNT; HETEROGENEITY; CELLS; TUMORIGENESIS; EXPRESSION; ROLES	Breast cancer stem cells (BCSCs) are the main drivers of recurrence and metastasis. However, commonly used drugs rarely target BCSCs. Via screenings, we found that Salt-inducible kinase 2 (SIK2) participated in breast cancer (BC) stemness maintenance and zebrafish embryos development. SIK2 was upregulated in recurrence samples. Knockdown of SIK2 expression reduced the proportion of BCSCs and the tumor initiation of BC cells. Mechanistically, SIK2, phosphorylated by CK1 alpha, directly phosphorylated LRP6 in a SIK2 kinase activity-dependent manner, leading to Wnt/beta-catenin signaling pathway activation. ARN-3236 and HG-9-91-01, inhibitors of SIK2, inhibited LRP6 phosphorylation and beta-catenin accumulation and disturbed stemness maintenance. In addition, the SIK2-activated Wnt/beta-catenin signaling led to induction of IDH1 expression, causing metabolic reprogramming in BC cells. These findings demonstrate a novel mechanism whereby Wnt/beta-catenin signaling pathway is regulated by different kinases in response to metabolic requirement of CSCs, and suggest that SIK2 inhibition may potentially be a strategy for eliminating BCSCs.	[Rong, Zhuoxian; Zhang, Lu; Li, Zhi; Ren, Xinxin; Zi, Yuyuan; Gao, Jie; Mu, Yun; Guan, Yidi; Cao, Zhen; Wang, Xitao; Pei, Qian; Zeng, Yu; Fan, Qi; Zeng, Zimei; Ou, Danmin; He, Jiang; Tan, Rong; Weng, Liang; Deng, Yuezhen; Sun, Lunquan] Cent South Univ, Xiangya Hosp, Xiangya Canc Ctr, Changsha 410008, Peoples R China; [Rong, Zhuoxian; Zhang, Lu; Li, Zhi; Ren, Xinxin; Zi, Yuyuan; Gao, Jie; Mu, Yun; Guan, Yidi; Cao, Zhen; Wang, Xitao; Pei, Qian; Zeng, Yu; Fan, Qi; Zeng, Zimei; Ou, Danmin; He, Jiang; Tan, Rong; Weng, Liang; Deng, Yuezhen; Sun, Lunquan] Lab Mol Radiat Oncol Hunan Prov, Changsha 410008, Peoples R China; [Rong, Zhuoxian; Li, Zhi; He, Jiang; Tan, Rong; Weng, Liang; Deng, Yuezhen; Sun, Lunquan] Natl Clin Res Ctr Gerontol, Inst Gerontol Canc Res, Changsha 410008, Peoples R China; [Rong, Zhuoxian; Li, Zhi; Tan, Rong; Weng, Liang; Deng, Yuezhen; Sun, Lunquan] Hunan Int Sci & Technol Collaborat Base Precis Me, Changsha 410008, Peoples R China; [Rong, Zhuoxian; Li, Zhi; Tan, Rong; Weng, Liang; Deng, Yuezhen; Sun, Lunquan] Cent South Univ, Xiangya Hosp, Ctr Mol Imaging, Changsha 410008, Peoples R China; [Xiao, Zhi] Cent South Univ, Xiangya Hosp, Dept Breast Surg, Changsha 410008, Peoples R China; [Duan, Yumei] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Peoples R China; [Nie, Yingjie] Guizhou Prov Peoples Hosp, NHC Key Lab Pulm Immune Related Dis, Guiyang 550000, Peoples R China; [Li, Yuhao; Xiang, Rong] Nankai Univ, Coll Med, 94 Weijin Rd, Tianjin 300071, Peoples R China	Central South University; Central South University; Central South University; Central South University; Nankai University	Deng, YZ; Sun, LQ (corresponding author), Cent South Univ, Xiangya Hosp, Xiangya Canc Ctr, Changsha 410008, Peoples R China.; Deng, YZ; Sun, LQ (corresponding author), Lab Mol Radiat Oncol Hunan Prov, Changsha 410008, Peoples R China.; Deng, YZ; Sun, LQ (corresponding author), Natl Clin Res Ctr Gerontol, Inst Gerontol Canc Res, Changsha 410008, Peoples R China.; Deng, YZ; Sun, LQ (corresponding author), Hunan Int Sci & Technol Collaborat Base Precis Me, Changsha 410008, Peoples R China.; Deng, YZ; Sun, LQ (corresponding author), Cent South Univ, Xiangya Hosp, Ctr Mol Imaging, Changsha 410008, Peoples R China.	yuezhendeng@csu.edu.cn; lunquansun@csu.edu.cn	xiao, zhi/HHS-0189-2022		National Natural Science Foundation of China [81874200, 82030087, 82103675, 82172980, 82060308]; Hunan Provincial Science and Technology Department [2018RS3028, 2021JJ0039]; Guizhou Science and Technology Immunology and infection Platform [2018-5706, 2017-5724]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Science and Technology Department; Guizhou Science and Technology Immunology and infection Platform	This work was supported partly by National Natural Science Foundation of China (81874200, 82030087, 82103675, 82172980, and 82060308), Fund 2018RS3028, and 2021JJ0039 from Hunan Provincial Science and Technology Department and Guizhou Science and Technology Immunology and infection Platform (2018-5706 and 2017-5724).	Acebron SP, 2016, TRENDS CELL BIOL, V26, P956, DOI 10.1016/j.tcb.2016.07.009; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Almeida LL, 2018, STEM CELL REP, V11, P1040, DOI 10.1016/j.stemcr.2018.09.008; Angeloni V, 2015, SEMIN CANCER BIOL, V31, P43, DOI 10.1016/j.semcancer.2014.08.004; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Cai SJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0337-z; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen JX, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1076-1; Cheng R, 2016, DIABETES, V65, P3730, DOI 10.2337/db16-0426; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Dittmer J, 2018, SEMIN CANCER BIOL, V53, P59, DOI 10.1016/j.semcancer.2018.07.007; El-Sahli S, 2019, CANCERS, V11, DOI 10.3390/cancers11070904; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hiraga T, 2016, INT J CANCER, V138, P1698, DOI 10.1002/ijc.29921; Jackson HW, 2020, NATURE, V578, P615, DOI 10.1038/s41586-019-1876-x; Jalalirad M, 2021, ONCOGENE, V40, P2509, DOI 10.1038/s41388-021-01711-x; Kim SE, 2013, SCIENCE, V340, P867, DOI 10.1126/science.1232389; Krug K, 2020, CELL, V183, P1436, DOI 10.1016/j.cell.2020.10.036; Lanczky A, 2021, J MED INTERNET RES, V23, DOI 10.2196/27633; Liu B., 2021, J TRANSL MED, V19, P1; Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107; Liu W, 2006, EMBO J, V25, P1646, DOI 10.1038/sj.emboj.7601057; Maxfield KE, 2016, MOL CELL BIOL, V36, P3048, DOI 10.1128/MCB.00380-16; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Miller-Kleinhenz J, 2018, BIOMATERIALS, V152, P47, DOI 10.1016/j.biomaterials.2017.10.035; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Ou DM, 2020, CANCER BIOL MED, V17, P328, DOI 10.20892/j.issn.2095-3941.2019.0229; Raisch J, 2019, CANCERS, V11, DOI 10.3390/cancers11081162; Ren XX, 2022, CANCER RES, V82, P60, DOI 10.1158/0008-5472.CAN-21-1020; Sakamoto K, 2018, TRENDS ENDOCRIN MET, V29, P828, DOI 10.1016/j.tem.2018.09.007; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Vitale I, 2021, NAT MED, V27, P212, DOI 10.1038/s41591-021-01233-9; Waitkus MS, 2018, CANCER CELL, V34, P186, DOI 10.1016/j.ccell.2018.04.011; Xie JR, 2022, CANCER RES, V82, P872, DOI 10.1158/0008-5472.CAN-21-2187; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang ZN, 2016, SCI REP-UK, V6, DOI 10.1038/srep23317; Zhou JH, 2017, CLIN CANCER RES, V23, P1945, DOI 10.1158/1078-0432.CCR-16-1562; Zohrap Neslihan, 2018, Oncotarget, V9, P21876, DOI 10.18632/oncotarget.25082	43	2	2	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2390	2403		10.1038/s41388-022-02259-0	http://dx.doi.org/10.1038/s41388-022-02259-0		MAR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35277657				2022-12-28	WOS:000767708400001
J	Roetman, JJ; Apostolova, MKI; Philip, M				Roetman, Jessica J.; Apostolova, Minna K., I; Philip, Mary			Viral and cellular oncogenes promote immune evasion	ONCOGENE			English	Review							EPSTEIN-BARR-VIRUS; MHC CLASS-I; TUMOR-SUPPRESSOR GENES; HEPATITIS-B-VIRUS; ANTIGEN PRESENTATION; ACQUIRED-RESISTANCE; HODGKIN LYMPHOMA; CANCER-CELLS; EXPRESSION; PROTEIN	Thirteen percent of cancers worldwide are associated with viral infections. While many human oncogenic viruses are widely endemic, very few infected individuals develop cancer. This raises the question why oncogenic viruses encode viral oncogenes if they can replicate and spread between human hosts without causing cancer. Interestingly, viral infection triggers innate immune signaling pathways that in turn activate tumor suppressors such as p53, suggesting that tumor suppressors may have evolved not primarily to prevent cancer, but to thwart viral infection. Here, we summarize and compare several major immune evasion strategies used by viral and non-viral cancers, with a focus on oncogenes that play dual roles in promoting tumorigenicity and immune evasion. By highlighting important and illustrative examples of how oncogenic viruses evade the immune system, we aim to shed light on how non-viral cancers avoid immune detection. Further study and understanding of how viral and non-viral oncogenes impact immune function could lead to improved strategies to combine molecular therapies targeting oncoproteins in combination with immunomodulators.	[Roetman, Jessica J.; Philip, Mary] Vanderbilt Univ, Program Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Apostolova, Minna K., I] Vanderbilt Univ, Dept Biochem & Chem Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Philip, Mary] Vanderbilt Univ, Med Ctr, Div Hematol & Oncol, Dept Med, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Philip, M (corresponding author), Vanderbilt Univ, Program Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.; Philip, M (corresponding author), Vanderbilt Univ, Med Ctr, Div Hematol & Oncol, Dept Med, Nashville, TN 37235 USA.	mary.philip@vumc.org		Apostolova, Minna/0000-0003-3382-7082	V Foundation [P30DK058404, 50CA098131]; Serodino Adventure Allee Fund	V Foundation; Serodino Adventure Allee Fund	This work was supported by funding from the V Foundation, P30DK058404, 50CA098131, and the Serodino Adventure Allee Fund.	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Alcocer-Gonzalez JM, 2006, VIRAL IMMUNOL, V19, P481, DOI 10.1089/vim.2006.19.481; Anastasiadou E, 2019, LEUKEMIA, V33, P132, DOI 10.1038/s41375-018-0178-x; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Bermudez-Morales VH, 2011, MOL MED REP, V4, P369, DOI 10.3892/mmr.2011.429; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Bradley SD, 2015, CANCER IMMUNOL RES, V3, P602, DOI 10.1158/2326-6066.CIR-15-0030; Brea EJ, 2016, CANCER IMMUNOL RES, V4, P936, DOI 10.1158/2326-6066.CIR-16-0177; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chang HC, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-015-0242-3; Chang Y, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0264; Chin EN, 2020, SCIENCE, V369, P993, DOI 10.1126/science.abb4255; Clark DN, 2015, FUTURE VIROL, V10, P283, DOI 10.2217/FVL.14.113; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Cornel AM, 2020, CANCERS, V12, DOI 10.3390/cancers12071760; Corrales L, 2017, CELL RES, V27, P96, DOI 10.1038/cr.2016.149; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367; Croft NP, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000490; de Martel C, 2020, LANCET GLOB HEALTH, V8, pE180, DOI 10.1016/S2214-109X(19)30488-7; de Queiroz NMGP, 2019, MOL CANCER RES, V17, P974, DOI 10.1158/1541-7786.MCR-18-0504; del Campo AB, 2014, INT J CANCER, V134, P102, DOI 10.1002/ijc.28338; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; Forloni M, 2010, CANCER RES, V70, P916, DOI 10.1158/0008-5472.CAN-09-2582; Gaglia MM, 2018, CURR OPIN VIROL, V32, P48, DOI 10.1016/j.coviro.2018.09.003; Galluzzi L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000337; Gettinger S, 2017, CANCER DISCOV, V7, P1420, DOI 10.1158/2159-8290.CD-17-0593; Green DR, 2009, NAT REV IMMUNOL, V9, P353, DOI 10.1038/nri2545; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Griguolo G, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0548-6; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hannesdottir L, 2013, EUR J IMMUNOL, V43, P2718, DOI 10.1002/eji.201242505; Hansen TH, 2009, NAT REV IMMUNOL, V9, P503, DOI 10.1038/nri2575; Harding SM, 2017, NATURE, V548, P466, DOI 10.1038/nature23470; Hasim A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044952; Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x; Hislop AD, 2007, J EXP MED, V204, P1863, DOI 10.1084/jem.20070256; Hoare M, 2016, NAT CELL BIOL, V18, P979, DOI 10.1038/ncb3397; Inoue M, 2012, ONCOIMMUNOLOGY, V1, P1104, DOI 10.4161/onci.21056; Jiao L, 2020, J GENE MED, V22, DOI 10.1002/jgm.3148; Kansara M, 2013, J CLIN INVEST, V123, P5351, DOI 10.1172/JCI70559; Khan G, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037505; Kontomanolis EN, 2020, ANTICANCER RES, V40, P6009, DOI 10.21873/anticanres.14622; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Krump NA, 2018, NAT REV MICROBIOL, V16, P684, DOI 10.1038/s41579-018-0064-6; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Lau L, 2015, SCIENCE, V350, P568, DOI 10.1126/science.aab3291; Le Naour J, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1777624; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Li P, 2019, J IMMUNOL, V202, P3065, DOI 10.4049/jimmunol.1801199; Liu YH, 2015, J VIROL, V89, P2287, DOI 10.1128/JVI.02760-14; Lu WJ, 2006, CELL DEATH DIFFER, V13, P909, DOI 10.1038/sj.cdd.4401922; Ma Z, 2016, CELL HOST MICROBE, V19, P150, DOI 10.1016/j.chom.2016.01.010; Mandai M, 2016, CLIN CANCER RES, V22, P2329, DOI 10.1158/1078-0432.CCR-16-0224; Marcus A, 2018, IMMUNITY, V49, P754, DOI 10.1016/j.immuni.2018.09.016; Markosyan N, 2019, J CLIN INVEST, V129, P3594, DOI 10.1172/JCI127755; McCormick C, 2005, SCIENCE, V307, P739, DOI 10.1126/science.1105779; Menendez D, 2013, CURR OPIN ONCOL, V25, P85, DOI 10.1097/CCO.0b013e32835b6386; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Mogensen TH, 2001, MICROBIOL MOL BIOL R, V65, P131, DOI 10.1128/MMBR.65.1.131-150.2001; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Moore PS, 2010, NAT REV CANCER, V10, P878, DOI 10.1038/nrc2961; Muhr LSA, 2017, INT J CANCER, V141, P2498, DOI 10.1002/ijc.31017; Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99; Nakayama A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211358; Ng KW, 2018, TRENDS IMMUNOL, V39, P44, DOI 10.1016/j.it.2017.07.013; Pan BS, 2020, SCIENCE, V369, P935, DOI 10.1126/science.aba6098; Pandey Nitesh Vinodbhai, 2020, VirusDisease, V31, P1, DOI 10.1007/s13337-019-00563-0; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Pedersen MH, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1305531; Petrazzuolo A, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03997-x; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Philip M, 2022, NAT REV IMMUNOL, V22, P209, DOI 10.1038/s41577-021-00574-3; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Rivas C, 2010, VIRUSES-BASEL, V2, P298, DOI 10.3390/v2010298; Roemer MGM, 2016, J CLIN ONCOL, V34, P2690, DOI 10.1200/JCO.2016.66.4482; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Sapkota B, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22890; Schietinger A, 2016, IMMUNITY, V45, P389, DOI 10.1016/j.immuni.2016.07.011; Schneider JW, 2017, AM J CLIN DERMATOL, V18, P529, DOI 10.1007/s40257-017-0270-4; Schoenfeld AJ, 2020, CANCER CELL, V37, P443, DOI 10.1016/j.ccell.2020.03.017; Shaikh MH, 2019, MICROB PATHOGENESIS, V132, P162, DOI 10.1016/j.micpath.2019.05.004; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Stanley M, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0268; Strong MJ, 2015, J VIROL, V89, P10110, DOI 10.1128/JVI.01110-15; Sugiyama E, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aav3937; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tanaka Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002521; Taura M, 2012, MOL CELL BIOL, V32, P1581, DOI 10.1128/MCB.06454-11; Toso A, 2014, CELL REP, V9, P75, DOI 10.1016/j.celrep.2014.08.044; Tsurumi T, 2005, REV MED VIROL, V15, P3, DOI 10.1002/rmv.441; Uzhachenko RV, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108944; Wang X, 2015, CELL SIGNAL, V27, P443, DOI 10.1016/j.cellsig.2014.12.003; Wang YJ, 2018, GENES DIS, V5, P194, DOI 10.1016/j.gendis.2018.05.003; Wang ZL, 2015, CANCER IMMUNOL IMMUN, V64, P1057, DOI 10.1007/s00262-015-1713-5; Wienand K, 2019, BLOOD ADV, V3, P4065, DOI 10.1182/bloodadvances.2019001012; Willimsky G, 2005, NATURE, V437, P141, DOI 10.1038/nature03954; Wu SY, 2019, NAT CELL BIOL, V21, P1027, DOI 10.1038/s41556-019-0352-z; Xia TL, 2016, CANCER RES, V76, P6747, DOI 10.1158/0008-5472.CAN-16-1404; Xia TL, 2016, CELL REP, V14, P282, DOI 10.1016/j.celrep.2015.12.029; Yang CA, 2017, ONCOLOGY-BASEL, V92, P115, DOI 10.1159/000452281; Young LS, 2016, NAT REV CANCER, V16, P789, DOI 10.1038/nrc.2016.92; Yum S, 2020, CELL RES, V30, P639, DOI 10.1038/s41422-020-0346-1; Zhou QJ, 2015, J BIOL CHEM, V290, P14729, DOI 10.1074/jbc.M114.633065; Zimber-Strobl U, 1999, CURR TOP MICROBIOL, V246, P315; Zuo JM, 2011, J VIROL, V85, P1604, DOI 10.1128/JVI.01608-10; Zuo JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000255; zur Hausen H, 2009, VIROLOGY, V392, P1, DOI 10.1016/j.virol.2009.06.001	112	0	0	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					921	929		10.1038/s41388-021-02145-1	http://dx.doi.org/10.1038/s41388-021-02145-1		JAN 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	35022539	Green Accepted			2022-12-28	WOS:000741853200001
J	Huang, HW; Chen, CY; Huang, YH; Yeh, CT; Wang, CS; Chang, CC; Lin, KH				Huang, Hsiang-Wei; Chen, Ching-Ying; Huang, Ya-Hui; Yeh, Chau-Ting; Wang, Chia-Siu; Chang, Cheng-Chih; Lin, Kwang-Huei			CMAHP promotes metastasis by reducing ubiquitination of Snail and inducing angiogenesis via GM-CSF overexpression in gastric cancer	ONCOGENE			English	Article							NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA METASTASIS; ACETYLNEURAMINIC ACID HYDROXYLASE; CELL-MIGRATION; GLYCOLYLNEURAMINIC ACID; GROWTH-FACTOR; HISTONE H1; INFLAMMATION; PATHWAY; PROGRESSION	Pseudogenes are generally considered "junk" DNA or "genomic fossils" generated during the evolution process that lack biological activity. However, accumulating reports indicate that pseudogenes have biological functions critical for cancer development. Experiments from the current study showed marked overexpression of the cytidine monophospho-N-acetylneuraminic acid hydroxylase pseudogene (CMAHP) in gastric cancer, which was associated with poor overall survival. However, the mechanisms underlying the activity of CMAHP in tumor development are largely unknown. Gene Set Enrichment Analysis (GSEA) revealed that CMAHP-correlated genes are significantly involved in epithelial-mesenchymal transition (EMT) and angiogenesis. Functional studies further confirmed that CMAHP mediates metastasis and angiogenesis in vitro and in vivo. Furthermore, CMAHP promoted cancer cell migration, invasion, and metastasis through Snail overexpression, which decreased ubiquitination mediated by NF-kappa B signaling. Angiogenesis is known to be induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulation. CMAHP increased GM-CSF transactivation via promoting direct binding of c-Jun to the -1981/-1975 region of the GM-CSF promoter. Notably, CMAHP interacts with Histone H1.4 promoting histone acetylation to enhance c-Jun and RelA (p65) expression. Our collective findings provide novel evidence that CMAHP contributes to tumor progression and modulates metastasis and angiogenesis in gastric cancer.	[Huang, Hsiang-Wei; Chen, Ching-Ying; Lin, Kwang-Huei] Chang Gung Univ, Coll Med, Dept Biochem, Taoyuan, Taiwan; [Huang, Hsiang-Wei; Chen, Ching-Ying; Lin, Kwang-Huei] Chang Gung Univ, Coll Med, Dept Biomed Sci, Taoyuan, Taiwan; [Huang, Ya-Hui; Yeh, Chau-Ting; Lin, Kwang-Huei] Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan; [Wang, Chia-Siu; Chang, Cheng-Chih] Chang Gung Mem Hosp Chia Yi, Dept Gen Surg, Chiayi, Taiwan; [Lin, Kwang-Huei] Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan	Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology	Lin, KH (corresponding author), Chang Gung Univ, Coll Med, Dept Biochem, Taoyuan, Taiwan.; Lin, KH (corresponding author), Chang Gung Univ, Coll Med, Dept Biomed Sci, Taoyuan, Taiwan.; Lin, KH (corresponding author), Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan.; Lin, KH (corresponding author), Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan.	khlin@mail.cgu.edu.tw		Lin, Kwang-Huei/0000-0002-5649-2222; Huang, Hsiang-Wei/0000-0001-5590-7695	Chang Gung Memorial Hospital, Taoyuan, Taiwan [CMRPD1H0631, CMRPD1H0632, CMRPD1H0633, CMRPG6K0031, CMRPG6K0032, CMRPG6K0033]; Ministry of Science and Technology of the Republic of China [MOST 106-2314-B182A-130-to CSW]; Chang Gung Memorial Hospital, Taoyuan, Taiwan	Chang Gung Memorial Hospital, Taoyuan, Taiwan(Chang Gung Memorial Hospital); Ministry of Science and Technology of the Republic of China(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital, Taoyuan, Taiwan(Chang Gung Memorial Hospital)	This research was funded by grants from Chang Gung Memorial Hospital, Taoyuan, Taiwan (CMRPD1H0631, CMRPD1H0632, CMRPD1H0633 to KHL; CMRPG6K0031, CMRPG6K0032, CMRPG6K0033 to CCC, and CSW) and from the Ministry of Science and Technology of the Republic of China (MOST 106-2314-B182A-130-to CSW). And The APC was funded by Chang Gung Memorial Hospital, Taoyuan, Taiwan.	Bardor M, 2005, J BIOL CHEM, V280, P4228, DOI 10.1074/jbc.M412040200; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Becher B, 2016, IMMUNITY, V45, P963, DOI 10.1016/j.immuni.2016.10.026; Bull C, 2018, CANCER RES, V78, P3574, DOI 10.1158/0008-5472.CAN-17-3376; Cao F, 2020, GENOMICS, V112, P694, DOI 10.1016/j.ygeno.2019.05.002; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen CY, 2019, THERANOSTICS, V9, P2361, DOI 10.7150/thno.29628; Chen ZH, 2014, CELL REP, V8, P2003, DOI 10.1016/j.celrep.2014.08.008; Chou HH, 2002, P NATL ACAD SCI USA, V99, P11736, DOI 10.1073/pnas.182257399; Feng HT, 2017, CELL ADHES MIGR, V11, P464, DOI 10.1080/19336918.2016.1259058; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hao FJ, 2020, J CELL MOL MED, V24, P11779, DOI 10.1111/jcmm.15790; He WJ, 2020, ONCOTARGETS THER, V13, P11059, DOI 10.2147/OTT.S235643; Hedlund M, 2008, P NATL ACAD SCI USA, V105, P18936, DOI 10.1073/pnas.0803943105; Heerboth S, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0048-3; Henderson V, 2015, CELL ADHES MIGR, V9, P255, DOI 10.1080/19336918.2015.1013383; Hergeth SP, 2015, EMBO REP, V16, P1439, DOI 10.15252/embr.201540749; Hirayama M, 2016, INT IMMUNOL, V28, P319, DOI 10.1093/intimm/dxw027; Hsieh HL, 2019, WORLD J GASTRO ONCOL, V11, P686, DOI 10.4251/wjgo.v11.i9.686; Hu XL, 2018, CANCERS, V10, DOI 10.3390/cancers10080256; Huang HW, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010067; Jaatinen T, 2006, STEM CELLS, V24, P631, DOI 10.1634/stemcells.2005-0185; Jin L, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101036; Joo YY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45537-w; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kang CL, 2019, THERANOSTICS, V9, P4421, DOI 10.7150/thno.32854; Khanna S, 2018, CLIN CANCER RES, V24, P2859, DOI 10.1158/1078-0432.CCR-17-3757; Lin YH, 2021, ONCOGENE, V40, P4675, DOI 10.1038/s41388-021-01905-3; Lin YH, 2018, HEPATOLOGY, V67, P188, DOI 10.1002/hep.29462; Lotfi N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01265; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Newton R, 2010, BIOCHEM J, V427, P113, DOI 10.1042/BJ20091038; Nystedt J, 2010, STEM CELLS, V28, P258, DOI 10.1002/stem.250; Samraj AN, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00033; Skrzypek K, 2020, CANCERS, V12, DOI 10.3390/cancers12010209; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9; Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Takahashi T, 2014, J VIROL, V88, P8445, DOI 10.1128/JVI.00716-14; Tang DF, 2017, MED SCI MONIT BASIC, V23, P141, DOI 10.12659/MSMBR.903910; Tawara Ken, 2011, Cancer Manag Res, V3, P177, DOI 10.2147/CMR.S18101; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje; Wang H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19540-z; Wang TT, 2017, GUT, V66, P1900, DOI 10.1136/gutjnl-2016-313075; Wang Y, 2014, CANCER RES, V74, P716, DOI 10.1158/0008-5472.CAN-13-1459; Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yu B, 2016, NUCLEUS-PHILA, V7, P155, DOI 10.1080/19491034.2016.1179408; Yusufova N, 2021, NATURE, V589, P299, DOI 10.1038/s41586-020-3017-y; Zhang XY, 2017, ONCOL LETT, V13, P543, DOI 10.3892/ol.2016.5506; Zhang YM, 2020, CELL CYCLE, V19, P142, DOI 10.1080/15384101.2019.1699753; Zhang YH, 2019, CELL DEATH DIFFER, V26, P565, DOI 10.1038/s41418-018-0147-y; Zhang ZL, 2003, GENOME RES, V13, P2541, DOI 10.1101/gr.1429003; Zheng LF, 2015, BREAST CANCER RES TR, V150, P105, DOI 10.1007/s10549-015-3298-2	56	6	6	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					159	172		10.1038/s41388-021-02087-8	http://dx.doi.org/10.1038/s41388-021-02087-8		OCT 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34716430				2022-12-28	WOS:000712720900002
J	Rasheed, SAK; Subramanyan, LV; Lim, WK; Udayappan, UK; Wang, M; Casey, PJ				Rasheed, Suhail Ahmed Kabeer; Subramanyan, Lalitha Vaishnavi; Lim, Wei Kiang; Udayappan, Udhaya Kumari; Wang, Mei; Casey, Patrick J.			The emerging roles of G alpha 12/13 proteins on the hallmarks of cancer in solid tumors	ONCOGENE			English	Review							HETEROTRIMERIC G-PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; EMBRYONAL CARCINOMA-CELLS; COUPLED RECEPTORS; GEP ONCOGENE; G ALPHA(12); STEM-CELLS; COOPERATIVE TRANSFORMATION; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY	G12 proteins comprise a subfamily of G-alpha subunits of heterotrimeric GTP-binding proteins (G proteins) that link specific cell surface G protein-coupled receptors (GPCRs) to downstream signaling molecules and play important roles in human physiology. The G12 subfamily contains two family members: G alpha 12 and G alpha 13 (encoded by the GNA12 and GNA13 genes, respectively) and, as with all G proteins, their activity is regulated by their ability to bind to guanine nucleotides. Increased expression of both G alpha 12 and G alpha 13, and their enhanced signaling, has been associated with tumorigenesis and tumor progression of multiple cancer types over the past decade. Despite these strong associations, G alpha 12/13 proteins are underappreciated in the field of cancer. As our understanding of G protein involvement in oncogenic signaling has evolved, it has become clear that G alpha 12/13 signaling is pleotropic and activates specific downstream effectors in different tumor types. Further, the expression of G alpha 12/13 proteins is regulated through a series of transcriptional and post-transcriptional mechanisms, several of which are frequently deregulated in cancer. With the ever-increasing understanding of tumorigenic processes driven by G alpha 12/13 proteins, it is becoming clear that targeting G alpha 12/13 signaling in a context-specific manner could provide a new strategy to improve therapeutic outcomes in a number of solid tumors. In this review, we detail how G alpha 12/13 proteins, which were first discovered as proto-oncogenes, are now known to drive several "classical" hallmarks, and also play important roles in the "emerging" hallmarks, of cancer.	[Rasheed, Suhail Ahmed Kabeer; Subramanyan, Lalitha Vaishnavi; Lim, Wei Kiang; Udayappan, Udhaya Kumari; Wang, Mei; Casey, Patrick J.] Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Casey, Patrick J.] Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Durham, NC 27710 USA	National University of Singapore; Duke University	Casey, PJ (corresponding author), Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore.; Casey, PJ (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Durham, NC 27710 USA.	patrick.casey@duke.edu		Casey, Patrick/0000-0002-7366-9309; Wang, Mei/0000-0001-6887-6840; Rasheed, Suhail Ahmed Kabeer/0000-0002-7674-7560	Ministry of Education, Singapore [MOE2018-T2-1-147]	Ministry of Education, Singapore(Ministry of Education, Singapore)	We thank Ministry of Education, Singapore (PI: Patrick Casey; MOE2018-T2-1-147) for funding some of the work described in the manuscript. We declare that the authors do not have any conflict of interest.	Akhurst RJ, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022301; Alfaro C, 2017, CANCER TREAT REV, V60, P24, DOI 10.1016/j.ctrv.2017.08.004; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Annala S, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau5948; Arang N, 2020, FEBS LETT, V594, P4201, DOI 10.1002/1873-3468.14017; Baillie R, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00112; Bartolome RA, 2008, CANCER RES, V68, P8221, DOI 10.1158/0008-5472.CAN-08-0561; Bian D, 2006, ONCOGENE, V25, P2234, DOI 10.1038/sj.onc.1209261; Buch TRH, 2014, ADV BIOSCI BIOTECHNO, V05, P73, DOI DOI 10.1007/JHEP09(2014)006; Cai H, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-31; Carloni V, 2013, ONCOGENE, V32, P2649, DOI 10.1038/onc.2012.268; Cerchio R, 2020, GPCRS: STRUCTURE, FUNCTION, AND DRUG DISCOVERY, P463, DOI 10.1016/B978-0-12-816228-6.00022-2; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chang Q, 2014, SEMIN IMMUNOL, V26, P48, DOI 10.1016/j.smim.2014.01.007; Chen QY, 2016, ONCOTARGET, V7, P18247, DOI 10.18632/oncotarget.7570; Chiang CW, 2014, J HIGH ENERGY PHYS, DOI [10.1007/JHEP09(2014)006, 10.1186/1750-2187-9-6]; De Francesco EM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122713; Dermott JM, 1999, ONCOGENE, V18, P7185, DOI 10.1038/sj.onc.1203345; Dobashi A, 2016, J CLIN EXP HEMATOP, V56, P71; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Dougan M, 2009, ANNU REV IMMUNOL, V27, P83, DOI 10.1146/annurev.immunol.021908.132544; Fouad YA, 2017, AM J CANCER RES, V7, P1016; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fu XD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002790; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Gan CP, 2014, ONCOTARGET, V5, P9626, DOI 10.18632/oncotarget.2437; Gantulga D, 2008, J BIOCHEM, V144, P693, DOI 10.1093/jb/mvn123; Gentzler R, 2016, IMMUNOTHERAPY-UK, V8, P583, DOI 10.2217/imt-2015-0029; Giretti MS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002238; Ha Ji Hee, 2015, Genes Cancer, V6, P356; Ha JH, 2014, CELL SIGNAL, V26, P122, DOI 10.1016/j.cellsig.2013.08.012; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178; Heide T, 2019, J PATHOL, V248, P230, DOI 10.1002/path.5250; Hsu JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04313-6; Hu YQ, 2015, ONCOL REP, V34, P2507, DOI 10.3892/or.2015.4209; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Jhun BS, 2018, J PHYSIOL-LONDON, V596, P827, DOI 10.1113/JP275418; Jian SL., 2013, PLOS ONE, V8, P1, DOI DOI 10.1016/j.cell.2008.03.027; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Joshi S, 2015, INT J CANCER, V137, P1503, DOI 10.1002/ijc.29506; Juneja J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026085; Juneja J, 2009, BRIT J PHARMACOL, V158, P32, DOI 10.1111/j.1476-5381.2009.00180.x; Jung HS, 2014, CELL SIGNAL, V26, P1456, DOI 10.1016/j.cellsig.2014.02.022; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kim ES, 2010, BREAST CANCER RES TR, V124, P49, DOI 10.1007/s10549-009-0697-2; Koundouros N, 2020, BRIT J CANCER, V122, P4, DOI 10.1038/s41416-019-0650-z; Kozasa T, 2011, J BIOCHEM, V150, P357, DOI 10.1093/jb/mvr105; Krawetz R, 2006, EXP CELL RES, V312, P3224, DOI 10.1016/j.yexcr.2006.06.016; Krawetz R, 2009, BIOCHEM CELL BIOL, V87, P567, DOI [10.1139/o09-014, 10.1139/O09-014]; Kumar RN, 2006, ONCOGENE, V25, P899, DOI 10.1038/sj.onc.1209132; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Lee SJ, 2009, ONCOGENE, V28, P1230, DOI 10.1038/onc.2008.488; Lee SY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0577-4; Li HL, 2019, CANCER BIOL MED, V16, P79, DOI 10.20892/j.issn.2095-3941.2018.0170; Lim WK, 2019, J BIOL CHEM, V294, P18192, DOI 10.1074/jbc.RA119.010018; Liu SC, 2009, CANCER RES, V69, P6122, DOI 10.1158/0008-5472.CAN-08-3435; Liu WJ, 2017, GENE, V626, P275, DOI 10.1016/j.gene.2017.05.040; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mariggio S, 2006, CELL SIGNAL, V18, P2200, DOI 10.1016/j.cellsig.2006.05.003; Mastop M, 2018, PLOS ONE, V13, P1, DOI DOI 10.1158/2159-8290.CD-15-0224; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Morin RD, 2013, BLOOD, V122, P1256, DOI 10.1182/blood-2013-02-483727; Mu GG, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0081-6; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; Mutlu M, 2016, SCI REP-UK, V6, DOI 10.1038/srep32541; O'Hayre M, 2014, CURR OPIN CELL BIOL, V27, P126, DOI 10.1016/j.ceb.2014.01.005; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299; Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Prud'homme GJ, 2012, CURR PHARM DESIGN, V18, P2838; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Radhika V, 2005, ONCOGENE, V24, P4597, DOI 10.1038/sj.onc.1208665; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Rasheed SAK, 2018, ONCOGENE, V37, P1340, DOI 10.1038/s41388-017-0038-6; Rasheed SAK, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0337-x; Rasheed SAK, 2013, J BIOL CHEM, V288, P7986, DOI 10.1074/jbc.M112.437749; Rives ML, 2018, MOL PHARMACOL, V93, P581, DOI 10.1124/mol.117.111369; Rohrer DK, 1998, PHYSIOL REV, V78, P35, DOI 10.1152/physrev.1998.78.1.35; Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh JK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3436; Sivaraj KK, 2013, DEV CELL, V25, P427, DOI 10.1016/j.devcel.2013.04.008; Solomon H, 2011, J PATHOL, V225, P475, DOI 10.1002/path.2988; Song YD, 2009, CLIN CANCER RES, V15, P492, DOI 10.1158/1078-0432.CCR-08-1945; Sonnenburg DW, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0692-z; Stark MS, 2016, ONCOTARGET, V7, P49677, DOI 10.18632/oncotarget.10109; Stecky RC, 2020, CELL SIGNAL, V72, DOI 10.1016/j.cellsig.2020.109653; Sutkeviciute I, 2020, J BIOL CHEM, V295, P11626, DOI 10.1074/jbc.REV120.009348; Suzuki N, 2009, NEUROSIGNALS, V17, P55, DOI 10.1159/000186690; Syrovatkina V, 2019, PROTEIN SCI, V28, P305, DOI 10.1002/pro.3531; Teo CR, 2016, CELL SIGNAL, V28, P1479, DOI 10.1016/j.cellsig.2016.07.001; Thiery JP, 2013, CANCER CELL, V23, P272, DOI 10.1016/j.ccr.2013.03.004; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Tripathi P, 2012, INT J BIOCHEM CELL B, V44, P1852, DOI 10.1016/j.biocel.2012.06.025; Turm H, 2010, J BIOL CHEM, V285, P15137, DOI 10.1074/jbc.M109.072843; Udayappan UK, 2017, MOLECULES, V22, DOI 10.3390/molecules22040612; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Ward Y, 2011, CANCER RES, V71, P7301, DOI 10.1158/0008-5472.CAN-11-2381; Worzfeld T, 2008, TRENDS PHARMACOL SCI, V29, P582, DOI 10.1016/j.tips.2008.08.002; Wu V, 2019, J BIOL CHEM, V294, P11062, DOI 10.1074/jbc.REV119.005601; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Xu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep35948; Yagi H, 2016, ONCOGENE, V35, P4471, DOI 10.1038/onc.2015.505; Yagi H, 2019, FASEB J, V33, P13683, DOI 10.1096/fj.201901278R; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yan M, 2015, J MOL SIGNAL, V10, P1; Yang YM, 2015, ONCOGENE, V34, P2910, DOI 10.1038/onc.2014.218; Yang YM, 2015, ONCOTARGET, V6, P19055, DOI 10.18632/oncotarget.3957; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yuan JZ, 2006, CELL SIGNAL, V18, P1051, DOI 10.1016/j.cellsig.2005.08.017; Zhang HH, 2013, INT J CLIN EXP PATHO, V6, P1734; Zhang JX, 2014, ANN ONCOL, V25, P2196, DOI 10.1093/annonc/mdu439; Zhang JX, 2016, ONCOTARGET, V7, P4414, DOI 10.18632/oncotarget.6780; Zhang YH, 1996, ONCOGENE, V12, P2377; Zhang ZQ, 2018, CANCER MED-US, V7, P5611, DOI 10.1002/cam4.1783	130	4	4	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					147	158		10.1038/s41388-021-02069-w	http://dx.doi.org/10.1038/s41388-021-02069-w		OCT 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34689178	hybrid, Green Published			2022-12-28	WOS:000710613600001
J	Alam, SK; Zhang, YC; Wang, L; Zhu, Z; Hernandez, CE; Zhou, YL; Yang, N; Lei, J; Chen, XY; Zeng, L; Klein, MA; Hoeppner, LH				Alam, Sk. Kayum; Zhang, Yongchang; Wang, Li; Zhu, Zhu; Hernandez, Christina E.; Zhou, Yuling; Yang, Nong; Lei, Jian; Chen, Xiaoyan; Zeng, Liang; Klein, Mark A.; Hoeppner, Luke H.			DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; MEDIATES TRASTUZUMAB RESISTANCE; TYROSINE KINASE INHIBITORS; T-DARPP; ACQUIRED-RESISTANCE; CANCER CELLS; GEFITINIB; MUTATIONS; MEHD7945A; DOPAMINE	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-refractory lung adenocarcinoma (LUAD) progression is a major clinical problem. New approaches to predict and prevent acquired resistance to EGFR TKIs are urgently needed. Here, we show that dopamine and cyclic AMP-regulated phosphoprotein, Mr 32000 (DARPP-32) physically recruits ERBB3 (HER3) to EGFR to mediate switching from EGFR homodimers to EGFR:ERBB3 heterodimers to bypass EGFR TKI-mediated inhibition by potentiating ERBB3-dependent activation of oncogenic signaling. In paired LUAD patient-derived specimens before and after EGFR TKI-refractory disease progression, we reveal that DARPP-32 and kinase-activated EGFR and ERBB3 proteins are overexpressed upon acquired resistance. In mice, DARPP-32 ablation sensitizes gefitinib-resistant xenografts to EGFR TKIs, while DARPP-32 overexpression increases gefitinib-refractory LUAD progression in gefitinib-sensitive lung tumors. We introduce a DARPP-32-mediated, ERBB3-dependent mechanism the LUAD cells use to evade EGFR TKI-induced cell death, potentially paving the way for the development of therapies to better combat therapy-refractory LUAD progression.	[Alam, Sk. Kayum; Wang, Li; Zhu, Zhu; Hernandez, Christina E.; Hoeppner, Luke H.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Zhang, Yongchang; Zhou, Yuling; Yang, Nong; Zeng, Liang] Cent South Univ, Affiliated Canc Hosp, Hunan Canc Hosp,Dept Med Oncol, Lung Canc & Gastrointestinal Unit,Xiangya Sch Med, Changsha, Peoples R China; [Lei, Jian; Chen, Xiaoyan] Cent South Univ, Affiliated Canc Hosp, Hunan Canc Hosp, Dept Pathol,Xiangya Sch Med, Changsha, Peoples R China; [Klein, Mark A.] Minneapolis Vet Affairs Healthcare Syst, Hematol Oncol Sect, Minneapolis, MN USA; [Klein, Mark A.] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA; [Klein, Mark A.; Hoeppner, Luke H.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA	University of Minnesota System; Central South University; Central South University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Alam, SK; Hoeppner, LH (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Hoeppner, LH (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.	skalam@umn.edu; hoepp005@umn.edu	Wang, Li/AAM-2454-2021; ALAM, SK KAYUM/ABA-3659-2020	Wang, Li/0000-0002-8969-7427; ALAM, SK KAYUM/0000-0001-5342-4542; Hoeppner, Luke/0000-0003-3948-4244; Zhang, Yongchang/0000-0002-6829-7176	Elsa U. Pardee Foundation; American Cancer Society [129819-IRG-16-189-58-IRG81]; Hormel Foundation; Fifth District Eagles Cancer Telethon Postdoctoral Fellowship Award; Department of Veterans Affairs (Veterans Health Administration)	Elsa U. Pardee Foundation; American Cancer Society(American Cancer Society); Hormel Foundation; Fifth District Eagles Cancer Telethon Postdoctoral Fellowship Award; Department of Veterans Affairs (Veterans Health Administration)(US Department of Veterans Affairs)	This work was supported by The Elsa U. Pardee Foundation, Institutional Research Grant #129819-IRG-16-189-58-IRG81 from the American Cancer Society, and The Hormel Foundation (to L.H.H.) as well as the Fifth District Eagles Cancer Telethon Postdoctoral Fellowship Award (to S.K.A.). This material is based partially upon work supported by the Department of Veterans Affairs (specifically, the Veterans Health Administration). M.A.K. is an employee of the Minneapolis VA Healthcare System.	Alam SK, 2020, BRIT J CANCER, V123, P819, DOI 10.1038/s41416-020-0923-6; Alam SK, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0050-6; [Anonymous], 2021, Cancer Discov, V11, pOF6, DOI 10.1158/2159-8290.CD-NB2021-0340; Avanes A, 2019, BIOCHEM PHARMACOL, V160, P71, DOI 10.1016/j.bcp.2018.12.008; Balz LM, 2012, J PATHOL, V227, P234, DOI 10.1002/path.3991; Beckler A, 2003, CANCER, V98, P1547, DOI 10.1002/cncr.11654; Belkhiri A, 2005, CANCER RES, V65, P6583, DOI 10.1158/0008-5472.CAN-05-1433; Belkhiri A, 2008, CLIN CANCER RES, V14, P4564, DOI 10.1158/1078-0432.CCR-08-0121; Belkhiri A, 2008, CANCER RES, V68, P395, DOI 10.1158/0008-5472.CAN-07-1580; Belkhiri A, 2016, ONCOTARGET, V7, P17631, DOI 10.18632/oncotarget.7268; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Chen Z, 2016, GUT, V65, P925, DOI 10.1136/gutjnl-2014-308416; Christenson JL, 2015, ONCOTARGET, V6, P33134, DOI 10.18632/oncotarget.5311; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Cortot AB, 2014, EUR RESPIR REV, V23, P356, DOI 10.1183/09059180.00004614; El-Rifai W, 2002, CANCER RES, V62, P4061; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Fayette J, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00232; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; Hamel S, 2010, BREAST CANCER RES TR, V120, P47, DOI 10.1007/s10549-009-0364-7; Han SW, 2005, INT J CANCER, V113, P109, DOI 10.1002/ijc.20550; Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; Hoeppner LH, 2015, MOL ONCOL, V9, P270, DOI 10.1016/j.molonc.2014.08.008; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hong J, 2012, CANCER RES, V72, P4504, DOI 10.1158/0008-5472.CAN-12-1119; Huang S, 2013, CANCER RES, V73, P824, DOI 10.1158/0008-5472.CAN-12-1611; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Juchum M, 2015, DRUG RESIST UPDATE, V20, P12, DOI 10.1016/j.drup.2015.05.002; Jura N, 2009, P NATL ACAD SCI USA, V106, P21608, DOI 10.1073/pnas.0912101106; Juric D, 2015, CLIN CANCER RES, V21, P2462, DOI 10.1158/1078-0432.CCR-14-2412; Kumagai Shogo, 2021, Nat Rev Cancer, V21, P181, DOI 10.1038/s41568-020-00322-0; Lee CK, 2015, J CLIN ONCOL, V33, P1958, DOI 10.1200/JCO.2014.58.1736; Lemmon MA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020768; Lenz G, 2018, CLIN CANCER RES, V24, P1216, DOI 10.1158/1078-0432.CCR-17-0824; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Li CR, 2015, MOL CANCER THER, V14, P2049, DOI 10.1158/1535-7163.MCT-15-0155; Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6; Liu Q, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0793-1; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; McKnight BN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27454-6; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Momand J, 2017, FEBS OPEN BIO, V7, P1328, DOI 10.1002/2211-5463.12269; Mukherjee K, 2010, SURGERY, V148, P354, DOI 10.1016/j.surg.2010.05.011; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Offin M, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00126; Ono M, 2004, MOL CANCER THER, V3, P465; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Reck M, 2017, NEW ENGL J MED, V377, P849, DOI 10.1056/NEJMra1703413; Roberts TC, 2020, NAT REV DRUG DISCOV, V19, P673, DOI 10.1038/s41573-020-0075-7; Roper N, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100007; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Saba NF, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00031; Salvesen GS, 2002, CELL DEATH DIFFER, V9, P3, DOI 10.1038/sj.cdd.4400963; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shih Andrew J, 2011, Cancers (Basel), V3, P1195, DOI 10.3390/cancers3011195; Sidaway P, 2020, NAT REV CLIN ONCOL, V17, P336, DOI 10.1038/s41571-020-0366-2; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Skoulidis F, 2019, NAT REV CANCER, V19, P495, DOI 10.1038/s41568-019-0179-8; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Song XL, 2015, CANCER RES, V75, P1035, DOI 10.1158/0008-5472.CAN-13-1625; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; Tiwari A, 2020, GASTROENTEROLOGY, V159, P1882, DOI 10.1053/j.gastro.2020.07.046; Tomasello C, 2018, CRIT REV ONCOL HEMAT, V123, P149, DOI 10.1016/j.critrevonc.2018.01.013; Tumbrink HL, 2021, ONCOGENE, V40, P1, DOI 10.1038/s41388-020-01510-w; Vangamudi B, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-32; Vangamudi B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-240; WALAAS SI, 1983, J NEUROSCI, V3, P291; Wang DD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128360; Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2; Wang MSJ, 2005, INT J CLIN PRACT, V59, P58, DOI 10.1111/j.1742-1241.2004.00305.x; Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xia WL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3480; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980; Zhang X, 2021, CANCER RES, V81, P3051, DOI 10.1158/0008-5472.CAN-20-2435; Zhou Q, 2012, BRIT J PHARMACOL, V166, P1756, DOI 10.1111/j.1476-5381.2012.01875.x; Zhu SM, 2020, CANCER LETT, V491, P87, DOI 10.1016/j.canlet.2020.07.014; Zhu SM, 2019, ONCOGENE, V38, P5805, DOI 10.1038/s41388-019-0843-1; Zhu SM, 2017, GUT, V66, P802, DOI 10.1136/gutjnl-2016-312141; Zhu SM, 2011, GASTROENTEROLOGY, V141, P1738, DOI 10.1053/j.gastro.2011.06.070	94	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					83	98		10.1038/s41388-021-02028-5	http://dx.doi.org/10.1038/s41388-021-02028-5		OCT 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34675407	Green Submitted, hybrid, Green Published			2022-12-28	WOS:000709687900003
J	Garcia-Valverde, A; Rosell, J; Sayols, S; Gomez-Peregrina, D; Pilco-Janeta, DF; Olivares-Rivas, I; de Alava, E; Maurel, J; Rubio-Casadevall, J; Esteve, A; Gut, M; Valverde, C; Barretina, J; Carles, J; Demetri, GD; Fletcher, JA; Arribas, J; Serrano, C				Garcia-Valverde, Alfonso; Rosell, Jordi; Sayols, Sergi; Gomez-Peregrina, David; Pilco-Janeta, Daniel F.; Olivares-Rivas, Ivan; de Alava, Enrique; Maurel, Joan; Rubio-Casadevall, Jordi; Esteve, Anna; Gut, Marta; Valverde, Claudia; Barretina, Jordi; Carles, Joan; Demetri, George D.; Fletcher, Jonathan A.; Arribas, Joaquin; Serrano, Cesar			E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor	ONCOGENE			English	Article							IMATINIB MESYLATE; KINASE INHIBITOR; MECHANISMS; SURVIVAL; FBXO32; FOXO3A; TUMORIGENESIS; QUIESCENCE; SUPPRESSOR; MUTATIONS	KIT/PDGFRA oncogenic tyrosine kinase signaling is the central oncogenic event in most gastrointestinal stromal tumors (GIST), which are human malignant mesenchymal neoplasms that often feature myogenic differentiation. Although targeted inhibition of KIT/PDGFRA provides substantial clinical benefit, GIST cells adapt to KIT/PDGFRA driver suppression and eventually develop resistance. The specific molecular events leading to adaptive resistance in GIST remain unclear. By using clinically representative in vitro and in vivo GIST models and GIST patients' samples, we found that the E3 ubiquitin ligase Atrogin-1 (FBXO32)-the main effector of muscular atrophy in cachexia-resulted in the most critical gene derepressed in response to KIT inhibition, regardless the type of KIT primary or secondary mutation. Atrogin-1 in GISTs is transcriptionally controlled by the KIT-FOXO3a axis, thus indicating overlap with Atrogin-1 regulation mechanisms in nonneoplastic muscle cells. Further, Atrogin-1 overexpression was a GIST-cell-specific pro-survival mechanism that enabled the adaptation to KIT-targeted inhibition by apoptosis evasion through cell quiescence. Buttressed on these findings, we established in vitro and in vivo the preclinical proof-of-concept for co-targeting KIT and the ubiquitin pathway to maximize the therapeutic response to first-line imatinib treatment.	[Garcia-Valverde, Alfonso; Rosell, Jordi; Gomez-Peregrina, David; Pilco-Janeta, Daniel F.; Olivares-Rivas, Ivan; Serrano, Cesar] Vall Hebron Inst Oncol VHIO, Sarcoma Translat Res Lab, Barcelona, Spain; [Sayols, Sergi] Inst Mol Biol, Mainz, Germany; [Pilco-Janeta, Daniel F.; Fletcher, Jonathan A.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Pilco-Janeta, Daniel F.; Demetri, George D.; Fletcher, Jonathan A.] Harvard Med Sch, Boston, MA 02115 USA; [de Alava, Enrique] Univ Seville, CIBERONC, CSIC, Virgen Rocio Univ Hosp,Inst Biomed Sevilla IBiS, Seville, Spain; [de Alava, Enrique] Univ Seville, Sch Med, Dept Normal & Pathol Cytol & Histol, Seville, Spain; [Maurel, Joan] Univ Barcelona, IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Hosp Clin Barcelona,Med Oncol Dept, Barcelona, Spain; [Rubio-Casadevall, Jordi] Inst Catala Oncoi, Med Oncol Serv, Girona, Spain; [Esteve, Anna; Gut, Marta] Barcelona Inst Sci & Technol BIST, Ctr Genom Regulat, CNAG CRG, Barcelona, Spain; [Esteve, Anna; Gut, Marta] Univ Pompeu Fabra UPF, Barcelona, Spain; [Valverde, Claudia; Carles, Joan; Serrano, Cesar] Vail Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain; [Barretina, Jordi] Inst Catala Oncoi, Inst Invest Ciencies Salut Germans Trias & Pujol, Badalona, Spain; [Demetri, George D.] Dana Farber Canc Inst, Sarcoma & Bone Canc Treatment Ctr, Boston, MA 02115 USA; [Demetri, George D.] Harvard Med Sch, Ludwig Ctr Harvard, Boston, MA 02115 USA; [Arribas, Joaquin] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain; [Arribas, Joaquin] Vail Hebron Inst Oncol VHIO, Growth Factors Lab, Barcelona, Spain; [Arribas, Joaquin] CIBERONC, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); Institute of Molecular Biology (IMB); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; University of Sevilla; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Hospital Universitari Vall d'Hebron; Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol (IGTP); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; ICREA; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC	Serrano, C (corresponding author), Vall Hebron Inst Oncol VHIO, Sarcoma Translat Res Lab, Barcelona, Spain.; Serrano, C (corresponding author), Vail Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain.	cserrano@vhio.net	de Alava, Enrique/GOH-0368-2022; Esteve-Codina, Anna/M-9614-2015	de Alava, Enrique/0000-0001-8400-046X; Esteve-Codina, Anna/0000-0003-0361-2873; Rubio-Casadevall, Jordi/0000-0002-3516-6970; Sayols, Sergi/0000-0002-3877-4170; Pilco-Janeta, Daniel Fernando/0000-0003-3640-0498	2014 SARC International Career Development Award (SARC Sarcoma Spore) [1U54CA168512-01]; Fundacion Mari Paz Jimenez Casado; FERO Foundation; Spanish Society of Medical Oncology (SEOM); PERIS [SLT006/17/221]; ISCIII [PI16/01371, PI19/01271, FI20/00275, PT17/0009/0019]; FEDER	2014 SARC International Career Development Award (SARC Sarcoma Spore); Fundacion Mari Paz Jimenez Casado; FERO Foundation; Spanish Society of Medical Oncology (SEOM); PERIS; ISCIII(Instituto de Salud Carlos III); FEDER(European Commission)	This project was funded by the 2014 SARC International Career Development Award (SARC Sarcoma Spore 1U54CA168512-01), Fundacion Mari Paz Jimenez Casado, FERO Foundation, Spanish Society of Medical Oncology (SEOM), PERIS SLT006/17/221, ISCIII PI16/01371 and PI19/01271, all to C.S. ISCIII FI20/00275 (to DG-P), and a Ph.D. fellowship from the National Secretary for Higher Education, Science, Technology and Innovation of Ecuador (SENESCYT) (to DFP-J). AE-C is funded by ISCIII PT17/0009/0019 and co-funded by FEDER. We thank the Cellex Foundation for providing facilities and equipment.	Bardia A, 2020, ONCOLOGIST, V25, pE160, DOI 10.1634/theoncologist.2019-0297; Bauer S, 2007, ONCOGENE, V26, P7560, DOI 10.1038/sj.onc.1210558; Boichuk S, 2013, CANCER RES, V73, P5120, DOI 10.1158/0008-5472.CAN-13-0579; Bosbach B, 2017, P NATL ACAD SCI USA, V114, pE8448, DOI 10.1073/pnas.1711449114; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chi P, 2010, NATURE, V467, P849, DOI 10.1038/nature09409; Chou JL, 2010, LAB INVEST, V90, P414, DOI 10.1038/labinvest.2009.138; Ciarapica R, 2014, ONCOGENE, V33, P4173, DOI 10.1038/onc.2013.471; Cohen NA, 2015, CANCER RES, V75, P2061, DOI 10.1158/0008-5472.CAN-14-2564; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri George D, 2010, J Natl Compr Canc Netw, V8 Suppl 2, pS1; Dolly SO, 2016, CLIN CANCER RES, V22, P2874, DOI 10.1158/1078-0432.CCR-15-2225; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Frolov A, 2003, MOL CANCER THER, V2, P699; Garcia-Valverde A, 2020, MOL CANCER THER, V19, P1289, DOI 10.1158/1535-7163.MCT-19-1069; Garner AP, 2014, CLIN CANCER RES, V20, P5745, DOI 10.1158/1078-0432.CCR-14-1397; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Grunewald S, 2021, CANCER DISCOV, V11, P108, DOI 10.1158/2159-8290.CD-20-0487; Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461; Hemming ML, 2018, P NATL ACAD SCI USA, V115, pE5746, DOI 10.1073/pnas.1802079115; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hyer ML, 2018, NAT MED, V24, P186, DOI 10.1038/nm.4474; Jin JP, 2007, NATURE, V447, P1135, DOI 10.1038/nature05902; Lagirand-Cantaloube J, 2008, EMBO J, V27, P1266, DOI 10.1038/emboj.2008.52; Li F, 2015, CANCER DISCOV, V5, P438, DOI 10.1158/2159-8290.CD-14-0763; Liegl B, 2008, J PATHOL, V216, P64, DOI 10.1002/path.2382; Liu Y, 2008, CANCER RES, V68, P9015, DOI 10.1158/0008-5472.CAN-08-1935; Maurel J, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569-016-0050-6; Pascual-Reguant L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05912-z; Ran LL, 2018, CANCER DISCOV, V8, P234, DOI 10.1158/2159-8290.CD-17-0468; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Serrano C, 2020, CLIN CANCER RES, V26, P5078, DOI 10.1158/1078-0432.CCR-20-1706; Serrano C, 2019, CLIN CANCER RES, V25, P7287, DOI 10.1158/1078-0432.CCR-19-2150; Serrano C, 2019, BRIT J CANCER, V120, P612, DOI 10.1038/s41416-019-0389-6; Skurk C, 2005, J BIOL CHEM, V280, P20814, DOI 10.1074/jbc.M500528200; Taylor BS, 2011, NAT REV CANCER, V11, P541, DOI 10.1038/nrc3087; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Vitiello GA, 2019, J CLIN INVEST, V129, P1863, DOI 10.1172/JCI124108; Wang D, 2012, ANN SURG ONCOL, V19, P1074, DOI 10.1245/s10434-011-2190-5; Wang YX, 2014, NAT GENET, V46, P601, DOI 10.1038/ng.2974; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Zhou H, 2017, ONCOGENE, V36, P3312, DOI 10.1038/onc.2016.479; Zhu MJ, 2007, ONCOGENE, V26, P6386, DOI 10.1038/sj.onc.1210464	50	1	1	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6614	6626		10.1038/s41388-021-02049-0	http://dx.doi.org/10.1038/s41388-021-02049-0		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34621020				2022-12-28	WOS:000704524600001
J	Mohanty, S; Mohapatra, P; Shriwas, O; Ansari, SA; Priyadarshini, M; Priyadarsini, S; Rath, R; Sultania, M; Das Majumdar, SK; Swain, RK; Dash, R				Mohanty, Sibasish; Mohapatra, Pallavi; Shriwas, Omprakash; Ansari, Shamima Azma; Priyadarshini, Manashi; Priyadarsini, Swatismita; Rath, Rachna; Sultania, Mahesh; Das Majumdar, Saroj Kumar; Swain, Rajeeb K.; Dash, Rupesh			CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis	ONCOGENE			English	Article							LESTAURTINIB CEP701; P53; PHOSPHORYLATION; INHIBITOR; CANCER; MDM2	Cisplatin, 5FU and docetaxel (TPF) are the most common chemotherapy regimen used for advanced OSCC. However, many cancer patients experience relapse, continued tumor growth, and spread due to drug resistance, which leads to treatment failure and metastatic disease. Here, using a CRISPR/Cas9 based kinome knockout screening, Misshapen-like kinase 1 (MINK1) is identified as an important mediator of 5FU resistance in OSCC. Analysis of clinical samples demonstrated significantly higher MINK1 expression in the tumor tissues of chemotherapy non-responders as compared to chemotherapy responders. The nude mice and zebrafish xenograft experiments indicate that knocking out MINK1 restores 5FU mediated cell death in chemoresistant OSCC. An antibody based phosphorylation array screen revealed MINK1 as a negative regulator of p53. Mechanistically, MINK1 modulates AKT phosphorylation at Ser473, which enables p-MDM2 (Ser 166) mediated degradation of p53. We also identified lestaurtinib as a potent inhibitor of MINK1 kinase activity. The patient derived TPF resistant cell based xenograft data suggest that lestaurtinib restores 5FU sensitivity and facilitates a significant reduction of tumor burden. Overall, our study suggests that MINK1 is a major driver of 5FU resistance in OSCC. The novel combination of MINK1 inhibitor lestaurtinib and 5FU needs further clinical investigation in advanced OSCC.	[Mohanty, Sibasish; Mohapatra, Pallavi; Shriwas, Omprakash; Ansari, Shamima Azma; Priyadarshini, Manashi; Priyadarsini, Swatismita; Swain, Rajeeb K.; Dash, Rupesh] Inst Life Sci, Bhubaneswar 751023, Odisha, India; [Mohanty, Sibasish; Mohapatra, Pallavi; Ansari, Shamima Azma] Reg Ctr Biotechnol, Faridabad, India; [Priyadarshini, Manashi] KIIT Univ, KIIT Sch Biotechnol, Bhubaneswar, India; [Rath, Rachna] SCB Dent Coll Hosp, Dept Oral & Maxillofacial Pathol, Cuttack 753007, Odisha, India; [Sultania, Mahesh] All India Inst Med Sci, Dept Surg Oncol, Bhubaneswar 751019, Odisha, India; [Das Majumdar, Saroj Kumar] All India Inst Med Sci, Dept Radiotherapy, Bhubaneswar 751019, Odisha, India	Department of Biotechnology (DBT) India; Institute of Life Sciences India (ILS); Department of Biotechnology (DBT) India; Regional Centre for Biotechnology; Kalinga Institute of Industrial Technology (KIIT); Srirama Chandra Bhanja Medical College & Hospital; All India Institute of Medical Sciences (AIIMS) Bhubaneswar; All India Institute of Medical Sciences (AIIMS) Bhubaneswar	Dash, R (corresponding author), Inst Life Sci, Bhubaneswar 751023, Odisha, India.	rupeshdash@ils.res.in			ICMR [5/13/9/2019-NCD-III]; Institute of Life Sciences, Bhubaneswar intramural; DBT [BT/INF/22/SP28293/2018]	ICMR(Indian Council of Medical Research (ICMR)); Institute of Life Sciences, Bhubaneswar intramural; DBT(Department of Biotechnology (DBT) India)	This work is supported by ICMR (5/13/9/2019-NCD-III), Institute of Life Sciences, Bhubaneswar intramural support and DBT BT/INF/22/SP28293/2018 (for imaging facility).	[Anonymous], 2020, Nat Rev Dis Primers, V6, P93, DOI 10.1038/s41572-020-00233-2; Chaturvedi A, 2020, HEAD NECK PATHOL, V14, P616, DOI 10.1007/s12105-019-01082-6; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Daulat AM, 2016, DEV CELL, V37, P311, DOI 10.1016/j.devcel.2016.04.011; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gross S, 2015, J CLIN INVEST, V125, P1780, DOI 10.1172/JCI76094; Hexner EO, 2008, BLOOD, V111, P5663, DOI 10.1182/blood-2007-04-083402; Jin LT, 2018, CANCER CELL, V34, P315, DOI 10.1016/j.ccell.2018.06.012; John LSS, 2000, CANCER GENE THER, V7, P749, DOI 10.1038/sj.cgt.7700166; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Knapper S, 2006, BLOOD, V108, P3262, DOI 10.1182/blood-2006-04-015560; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Leroy B, 2014, HUM MUTAT, V35, P756, DOI 10.1002/humu.22556; Maclaine NJ, 2009, AGING-US, V1, P490, DOI 10.18632/aging.100047; Maji S, 2019, CARCINOGENESIS, V40, P173, DOI 10.1093/carcin/bgy135; Maji S, 2018, ADV CANCER RES, V137, P37, DOI 10.1016/bs.acr.2017.11.001; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Moll UM, 2003, MOL CANCER RES, V1, P1001; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shabbir M, 2010, EXPERT OPIN INV DRUG, V19, P427, DOI 10.1517/13543781003598862; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Vishak S, 2015, INDIAN J MED PAEDIAT, V36, P148, DOI 10.4103/0971-5851.166716; YEUDALL WA, 1995, ORAL ONCOL, V31B, P136, DOI 10.1016/0964-1955(94)00030-8; Yogosawa S, 2018, CANCER SCI, V109, P3376, DOI 10.1111/cas.13792	25	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4929	4940		10.1038/s41388-022-02475-8	http://dx.doi.org/10.1038/s41388-022-02475-8		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36182968	Green Published, hybrid			2022-12-28	WOS:000862526800002
J	Liu, W; Shen, DX; Ju, LA; Zhang, RJ; Du, WZ; Jin, W; Xiong, KP; Wang, G; Qian, KY; Zhang, Y; Xiao, Y; Wang, XH				Liu, Wei; Shen, Dexin; Ju, Lingao; Zhang, Renjie; Du, Wenzhi; Jin, Wan; Xiong, Kangping; Wang, Gang; Qian, Kaiyu; Zhang, Yi; Xiao, Yu; Wang, Xinghuan			MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3	ONCOGENE			English	Article							CELL-CYCLE; B-MYB; TARGET; FOXM1	The transcription factor MYB proto-oncogene like 2 (MYBL2) is critical in regulating gene expression and tumorigenesis. However, the biological function of MYBL2 in bladder cancer (BLCA) remains to be elucidated. Here, we first revealed that MYBL2 was elevated in BLCA tissues and significantly correlated with clinicopathological parameters and cancer-specific survival in BLCA patients. Phenotypic assays showed that MYBL2 deficiency suppressed the proliferation and migration of BLCA cells in vitro and in vivo, whereas MYBL2 overexpression contributed to the opposite phenotype. Mechanistically, MYBL2 could bind to the promoter of its downstream target gene cell division cycle-associated protein 3 (CDCA3) and transactivate it, which in turn promoted the malignant phenotype of BLCA cells. Further investigations revealed that MYBL2 interacted with forkhead box M1 (FOXM1) to co-regulate the transcription of CDCA3. In addition, MYBL2/FOXM1 and CDCA3 might activate Wnt/beta-catenin signaling, thereby promoting the malignant phenotype of BLCA cells. In conclusion, the current study identifies MYBL2 as an oncogene in BLCA. MYBL2 can accelerate the proliferation and metastasis of BLCA through the transactivation of CDCA3.	[Liu, Wei; Shen, Dexin; Zhang, Renjie; Du, Wenzhi; Xiong, Kangping; Qian, Kaiyu; Xiao, Yu; Wang, Xinghuan] Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China; [Ju, Lingao; Jin, Wan; Wang, Gang; Qian, Kaiyu; Xiao, Yu; Wang, Xinghuan] Wuhan Univ, Dept Biol Repositories, Zhongnan Hosp, Wuhan, Peoples R China; [Jin, Wan; Zhang, Yi] Euler Technol, ZGC Life Sci Pk, Beijing, Peoples R China; [Zhang, Yi] Peking Univ, Ctr Quantitat Biol, Sch Life Sci, Beijing, Peoples R China; [Wang, Xinghuan] Chinese Acad Med Sci, Wuhan Res Ctr Infect Dis & Canc, Wuhan, Peoples R China	Wuhan University; Wuhan University; Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College	Xiao, Y; Wang, XH (corresponding author), Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China.; Xiao, Y; Wang, XH (corresponding author), Wuhan Univ, Dept Biol Repositories, Zhongnan Hosp, Wuhan, Peoples R China.; Zhang, Y (corresponding author), Euler Technol, ZGC Life Sci Pk, Beijing, Peoples R China.; Zhang, Y (corresponding author), Peking Univ, Ctr Quantitat Biol, Sch Life Sci, Beijing, Peoples R China.; Wang, XH (corresponding author), Chinese Acad Med Sci, Wuhan Res Ctr Infect Dis & Canc, Wuhan, Peoples R China.	zy@eulertechnology.com; yu.xiao@whu.edu.cn; wangxinghuan@whu.edu.cn		Liu, Wei/0000-0002-7908-8476; Qian, Kaiyu/0000-0003-4153-1265; Zhang, Yi/0000-0001-5388-1276	National Natural Science Foundation of China [82172985, 81772730]; Improvement Project for Theranostic Ability on Difficulty Miscellaneous Disease (Tumor) from National Health Commission of China [ZLYNXM202006]; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2020-PT320-004]; Research Fund of Zhongnan Hospital of Wuhan University [ZNJC201915, SWYBK00-03, 413100049, PTXM2020024]; Science and Technology Department of Hubei Province Key Project [2022EJD001, YYXKNL2022001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Improvement Project for Theranostic Ability on Difficulty Miscellaneous Disease (Tumor) from National Health Commission of China; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences; Research Fund of Zhongnan Hospital of Wuhan University; Science and Technology Department of Hubei Province Key Project	The excellent technical assistance of Ms. Yayun Fang and Ms. Danni Shan are gratefully acknowledged. Part of the analysis was performed on the High Performance Computing Platform of the Center for Life Science (Peking University). The study was funded by National Natural Science Foundation of China (82172985 and 81772730), Improvement Project for Theranostic Ability on Difficulty Miscellaneous Disease (Tumor) from National Health Commission of China (ZLYNXM202006), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2020-PT320-004), Research Fund of Zhongnan Hospital of Wuhan University (ZNJC201915, SWYBK00-03, 413100049, and PTXM2020024), Science and Technology Department of Hubei Province Key Project (2022EJD001 and YYXKNL2022001).	[Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Bayley R, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188407; Bian J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092125; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao R, 2018, CANCER LETT, V414, P278, DOI 10.1016/j.canlet.2017.11.015; Chen G, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.2994; Choi BR, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107540; Ciciro Y, 2021, ONCOGENESIS, V10, DOI 10.1038/s41389-021-00309-y; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Gong AH, 2012, CANCER RES, V72, P5658, DOI 10.1158/0008-5472.CAN-12-0953; Guiley KZ, 2018, P NATL ACAD SCI USA, V115, P10016, DOI 10.1073/pnas.1808136115; Han J, 2021, TRANSL CANCER RES, V10, P4076, DOI 10.21037/tcr-21-175; He S, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110851; Heinrichs S, 2013, ELIFE, V2, DOI 10.7554/eLife.00825; Hou XY, 2020, EXPERT REV ANTICANC, V20, P1107, DOI 10.1080/14737140.2020.1838280; Iness AN, 2019, ONCOGENE, V38, P1080, DOI 10.1038/s41388-018-0490-y; Li MS, 2019, AGING-US, V11, P10626, DOI 10.18632/aging.102481; Li QJ, 2021, THERANOSTICS, V11, P5794, DOI 10.7150/thno.56604; Liu Q, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03969-1; Okumura F, 2016, MOL CELL BIOL, V36, P1803, DOI 10.1128/MCB.00067-16; Pan CW, 2016, ONCOTARGET, V7, P35119, DOI 10.18632/oncotarget.9046; Ramirez JG, 2021, CANCERS, V13, DOI 10.3390/cancers13194980; Rimar KJ, 2017, CANCER-AM CANCER SOC, V123, P1912, DOI 10.1002/cncr.30631; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Salik B, 2020, CANCER CELL, V38, P263, DOI 10.1016/j.ccell.2020.05.014; Shen DX, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01969-x; Sheng Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14590-9; Wang ZW, 2010, CANCER TREAT REV, V36, P151, DOI 10.1016/j.ctrv.2009.11.006; Xie HY, 2021, J CELL MOL MED, V25, P1958, DOI 10.1111/jcmm.15948; Xiong YC, 2020, MOL CELL BIOCHEM, V468, P185, DOI 10.1007/s11010-020-03721-x; Xue YJ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-200; Xueling GE, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-33; Yu RJ, 2017, PATHOL RES PRACT, V213, P964, DOI 10.1016/j.prp.2017.04.024; Zhang X, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0573-6	36	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4606	4617		10.1038/s41388-022-02456-x	http://dx.doi.org/10.1038/s41388-022-02456-x		SEP 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36071275				2022-12-28	WOS:000850752600001
J	Kudaravalli, S; den Hollander, P; Mani, SA				Kudaravalli, Sriya; den Hollander, Petra; Mani, Sendurai A.			Role of p38 MAP kinase in cancer stem cells and metastasis	ONCOGENE			English	Review							ACTIVATED PROTEIN-KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; ALDEHYDE DEHYDROGENASE 1; BREAST-CANCER; DRUG-RESISTANCE; TUMOR-GROWTH; INHIBITION; PLAYS; BONE; EXPRESSION	Therapeutic resistance and metastatic progression are responsible for the majority of cancer mortalities. In particular, the development of resistance is a significant barrier to the efficacy of cancer treatments such as chemotherapy, radiotherapy, targeted therapies, and immunotherapies. Cancer stem cells (CSCs) underlie treatment resistance and metastasis. p38 mitogen-activated protein kinase (p38 MAPK) is downstream of several CSC-specific signaling pathways, and it plays an important role in CSC development and maintenance and contributes to metastasis and chemoresistance. Therefore, the development of therapeutic approaches targeting p38 can sensitize tumors to chemotherapy and prevent metastatic progression.	[Kudaravalli, Sriya; den Hollander, Petra; Mani, Sendurai A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Kudaravalli, Sriya] Rice Univ, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Rice University	Mani, SA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.	smani@mdanderson.org	Mani, Sendurai/A-7244-2009	Mani, Sendurai/0000-0002-5918-4276	CPRIT [RP160710/RP170172]; NIH/NCI [R01CA200970/2R01CA155243]; NSF [PHY-1935762]; Bowes Foundation; MD Anderson Cancer Center Support Grant [CA016672]	CPRIT; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NSF(National Science Foundation (NSF)); Bowes Foundation; MD Anderson Cancer Center Support Grant	This research was awarded to SAM and supported by CPRIT (RP160710/RP170172), NIH/NCI (R01CA200970/2R01CA155243), the NSF (PHY-1935762), the Bowes Foundation and in part by the MD Anderson Cancer Center Support Grant CA016672 (MRP to SAM).	Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3; Afify SM, 2019, CANCERS, V11, DOI 10.3390/cancers11030345; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Antoon JW, 2013, INT J ONCOL, V42, P1139, DOI 10.3892/ijo.2013.1814; Bakewell SJ, 2003, P NATL ACAD SCI USA, V100, P14205, DOI 10.1073/pnas.2234372100; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; Barriere G, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-114; Boothello RS, 2019, MOL CANCER THER, V18, P51, DOI 10.1158/1535-7163.MCT-18-0104; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Canovas B, 2018, CANCER CELL, V33, P1094, DOI 10.1016/j.ccell.2018.04.010; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; Cervenka I, 2011, MOL CELL BIOL, V31, P179, DOI 10.1128/MCB.00550-10; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chen W, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1740936; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076; De Chiara G, 2006, J BIOL CHEM, V281, P21353, DOI 10.1074/jbc.M511052200; Barrantes IDB, 2011, P NATL ACAD SCI USA, V108, P12764, DOI 10.1073/pnas.1015013108; Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711; Deng KY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0126-x; Desgrosellier JS, 2014, DEV CELL, V30, P295, DOI 10.1016/j.devcel.2014.06.005; Du BW, 2016, MOLECULES, V21, DOI 10.3390/molecules21070965; El Amrani M, 2019, MOL CARCINOGEN, V58, P1985, DOI 10.1002/mc.23090; Escos A, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00031; Fang Y, 2017, ONCOTARGET, V8, P26702, DOI 10.18632/oncotarget.15804; Felding-Habermann B, 2001, HAEMOSTASIS, V31, P55; Grun D, 2018, ONCOGENE, V37, P4711, DOI 10.1038/s41388-018-0290-4; Gui Ting, 2012, J Signal Transduct, V2012, P289243, DOI 10.1155/2012/289243; Guo XL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-375; Gyorffy B, 2021, COMPUT STRUCT BIOTEC, V19, P4101, DOI 10.1016/j.csbj.2021.07.014; Haq R, 2002, CANCER RES, V62, P5076; Hara J, 2014, ONCOL REP, V31, P589, DOI 10.3892/or.2013.2876; Hayakawa M, 2017, J BIOL CHEM, V292, P1762, DOI 10.1074/jbc.M116.764548; He D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054181; He YL, 2018, J CELL BIOL, V217, P315, DOI 10.1083/jcb.201701049; Hiratsuka S, 2011, P NATL ACAD SCI USA, V108, P302, DOI 10.1073/pnas.1016917108; Hirose Y, 2003, MOL CELL BIOL, V23, P8306, DOI 10.1128/MCB.23.22.8306-8315.2003; Hollander PD., 2019, CANCER RES, V79, P4669; Hosotani Ryo, 2002, Pancreas, V25, pe30, DOI 10.1097/00006676-200208000-00021; IKAWA M, 1983, J BIOL CHEM, V258, P6282; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kalli M, 2022, MOL CANCER RES, V20, P485, DOI 10.1158/1541-7786.MCR-21-0266; Kasimir-Bauer S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3099; Keely SJ, 2003, AM J PHYSIOL-CELL PH, V284, pC339, DOI 10.1152/ajpcell.00144.2002; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Kren A, 2007, EMBO J, V26, P2832, DOI 10.1038/sj.emboj.7601738; Kucuksayan H., 2017, TUMOR BIOL, V39, DOI DOI 10.1177/1010428317706212; Kumar D, 2016, J INVEST DERMATOL, V136, P2462, DOI 10.1016/j.jid.2016.07.024; Kurosu T, 2005, APOPTOSIS, V10, P1111, DOI 10.1007/s10495-005-3372-z; Lathia J, 2020, ONCOLOGIST, V25, P123, DOI 10.1634/theoncologist.2019-0517; Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118; Lin SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049605; Lin Y, 2016, ORAL ONCOL, V60, P81, DOI 10.1016/j.oraloncology.2016.06.010; Llopis A, 2012, CELL CYCLE, V11, P3627, DOI 10.4161/cc.21917; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2011.439, 10.1038/onc.2012.147]; Loret N, 2019, CANCERS, V11, DOI 10.3390/cancers11060838; Lu HQ, 2018, CANCER RES, V78, P4191, DOI 10.1158/0008-5472.CAN-18-0270; Mak VCY, 2021, NEOPLASIA, V23, P718, DOI 10.1016/j.neo.2021.05.009; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Mansoori B, 2017, ADV PHARM BULL, V7, P339, DOI 10.15171/apb.2017.041; Marengo B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.118; Martinez-Limon A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061913; Mathews LA, 2011, CANCER METAST REV, V30, P185, DOI 10.1007/s10555-011-9277-0; McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Munne PM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27220-9; Osz A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96340-5; Paillas S, 2011, CANCER RES, V71, P1041, DOI 10.1158/0008-5472.CAN-10-2726; Paranjape AN, 2016, ONCOGENE, V35, P5963, DOI 10.1038/onc.2015.498; Patel NJ, 2016, ONCOTARGET, V7, P84608, DOI 10.18632/oncotarget.12358; Pereira L, 2013, EMBO MOL MED, V5, P1759, DOI 10.1002/emmm.201302732; Pokhrel RH, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01420-9; Pradella D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0579-2; Prieto-Vila M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122574; Qi XT, 2019, ACTA PHARMACOL SIN, V40, P546, DOI 10.1038/s41401-018-0050-6; Qi XM, 2015, STEM CELLS, V33, P2738, DOI 10.1002/stem.2068; Raha D, 2014, CANCER RES, V74, P3579, DOI 10.1158/0008-5472.CAN-13-3456; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Roy S, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0062-6; Roy S, 2018, J ORAL PATHOL MED, V47, P492, DOI 10.1111/jop.12707; Saha RN, 2007, J IMMUNOL, V179, P7101, DOI 10.4049/jimmunol.179.10.7101; Sahu V, 2019, CANCER RES TREAT, V51, P313, DOI 10.4143/crt.2018.105; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Seyfried Thomas N., 2013, Critical Reviews in Oncogenesis, V18, P43; Singh SK, 2003, CANCER RES, V63, P5821; Soeda A, 2017, ONCOTARGET, V8, P33316, DOI 10.18632/oncotarget.16741; Su XM, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145296; Takayama S, 2005, ANTICANCER RES, V25, P79; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Tan W, 2014, MOL MED REP, V10, P3275, DOI 10.3892/mmr.2014.2598; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Tang J, 2018, CANCER MED-US, V7, P3965, DOI 10.1002/cam4.1640; Thomas ML., 2014, CHEMOTHERAPY, V3, P10; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Vergote I, 2020, GYNECOL ONCOL, V156, P23, DOI 10.1016/j.ygyno.2019.11.006; Warr N, 2012, DEV CELL, V23, P1020, DOI 10.1016/j.devcel.2012.09.016; Werden SJ, 2016, ONCOGENE, V35, P5977, DOI 10.1038/onc.2016.203; Xiang T, 2015, ONCOGENE, V34, P165, DOI 10.1038/onc.2013.537; Xie CF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1052-z; Xie Y, 2014, MOL MED REP, V10, P2346, DOI 10.3892/mmr.2014.2490; Xiong Y, 2007, J BIOL CHEM, V282, P4975, DOI 10.1074/jbc.M606742200; Xu M, 2018, BBA-MOL BASIS DIS, V1864, P3605, DOI 10.1016/j.bbadis.2018.08.024; Xu M, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0532-4; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang SY, 2011, INT J ONCOL, V38, P1695, DOI 10.3892/ijo.2011.982; Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058915; Yu ZR, 2012, INT J BIOCHEM CELL B, V44, P2144, DOI 10.1016/j.biocel.2012.08.022; Yu-Lee LY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54566-4; Yuan B, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242809; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	122	6	6	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3177	3185		10.1038/s41388-022-02329-3	http://dx.doi.org/10.1038/s41388-022-02329-3		APR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35501462	hybrid, Green Published			2022-12-28	WOS:000789736600002
J	Liu, Z; Li, JH; Ding, Y; Ma, M; Chen, J; Lei, W; Li, L; Yao, YY; Yu, X; Zhong, M; Liao, Q; Fang, WD; Fan, LW; Huang, CY; Zhong, HG; Wen, Q; Fang, Z; Chen, JY; Huang, SS; Xiong, JP; Xiang, XJ; Deng, J				Liu, Zhen; Li, Junhe; Ding, Yun; Ma, Mei; Chen, Jun; Lei, Wan; Li, Li; Yao, Yangyang; Yu, Xin; Zhong, Min; Liao, Quan; Fang, Weidan; Fan, Linwei; Huang, Chunye; Zhong, Hongguang; Wen, Qin; Fang, Zi; Chen, Jingyi; Huang, Shanshan; Xiong, Jianpin; Xiang, Xiaojun; Deng, Jun			USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer	ONCOGENE			English	Article							HIPPO PATHWAY; GROWTH; CHEMORESISTANCE; PROLIFERATION; MECHANISMS; LATS	The importance of the Hippo-Yes-associated protein 1 (YAP1) pathway in gastric carcinogenesis and metastasis has attracted considerable research attention; however, the regulatory network of YAP1 in gastric cancer (GC) is not completely understood. In this study, ubiquitin-specific peptidase 49 (USP49) was identified as a novel deubiquitinase of YAP1, knockdown of USP49 inhibited the proliferation, metastasis, chemoresistance, and peritoneal metastasis of GC cells. Overexpression of USP49 showed opposing biological effects. Moreover, USP49 was transcriptionally activated by the YAP1/TEAD4 complex, which formed a positive feedback loop with YAP1 to promote the malignant progression of GC cells. Finally, we collected tissue samples and clinical follow-up information from 482 GC patients. The results showed that USP49 expression was high in GC cells and positively correlated with the expression of YAP1 and its target genes, connective tissue growth factor (CTGF) and cysteine-rich angiogenic inducer 61 (CYR61). Survival and Cox regression analysis showed that high USP49 expression was associated with poor prognosis and was an independent prognostic factor. Moreover, patients with high USP49 and YAP1 expression had extremely short overall survival. The findings of this study reveal that the aberrant activation of the USP49/YAP1 positive feedback loop plays a critical role in the malignant progression of GC, thus providing potential novel prognostic factors and therapeutic targets for GC.	[Liu, Zhen; Li, Junhe; Ding, Yun; Ma, Mei; Chen, Jun; Lei, Wan; Li, Li; Yao, Yangyang; Yu, Xin; Zhong, Min; Liao, Quan; Fang, Weidan; Fan, Linwei; Huang, Chunye; Zhong, Hongguang; Wen, Qin; Fang, Zi; Chen, Jingyi; Huang, Shanshan; Xiong, Jianpin; Xiang, Xiaojun; Deng, Jun] Nanchang Univ, Dept Oncol, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China; [Liu, Zhen; Ding, Yun; Ma, Mei; Yu, Xin; Zhong, Min; Liao, Quan; Fang, Weidan; Fan, Linwei; Fang, Zi] Jiangxi Key Lab Individual Canc Therapy, 17 Yongwai St, Nanchang 330006, Jiangxi, Peoples R China	Nanchang University	Huang, SS; Xiong, JP (corresponding author), Nanchang Univ, Dept Oncol, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.	923834857@qq.com; Jpxiong0630@outlook.com; xjxiang_nc@ncu.edu.cn; dengjun19871106@ncu.edu.cn			JiangXi Province General Projects [20202BBGL73036]; National Natural Science Foundation of China [81760432, 8216100370]; Key Laboratory Fund of Jiangxi Province [20202BCD42011]; Jiangxi Provincial Outstanding Young Talents projects [2019BCB23020]; Science and Technology Department of Jiangxi Province [20202BBGL73055, 20202BAB216028]; Jiangxi Provincial Young Talents projects [20204BCJ23016]; Jiangxi Provincial Outstanding Youth projects [2018ACB21037]; CSCO-Bayer Cancer Research Fund [Y-bayer202001/zb-0007]; Department of Health of Jiangxi Province Projects [2019A058]	JiangXi Province General Projects; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Laboratory Fund of Jiangxi Province; Jiangxi Provincial Outstanding Young Talents projects; Science and Technology Department of Jiangxi Province; Jiangxi Provincial Young Talents projects; Jiangxi Provincial Outstanding Youth projects; CSCO-Bayer Cancer Research Fund; Department of Health of Jiangxi Province Projects	This work was supported by JiangXi Province General Projects (grant 20202BBGL73036), the National Natural Science Foundation of China (grant 81760432), Key Laboratory Fund of Jiangxi Province (grant number: 20202BCD42011), Jiangxi Provincial Outstanding Young Talents projects (grant 2019BCB23020), the Science and Technology Department of Jiangxi Province (grant 20202BBGL73055), Jiangxi Provincial Young Talents projects (grant 20204BCJ23016), the National Natural Science Foundation of China (grant 8216100370), Jiangxi Provincial Outstanding Youth projects (grant 2018ACB21037), the CSCO-Bayer Cancer Research Fund (grant Y-bayer202001/zb-0007), the Science and Technology Department of Jiangxi Province (grant 20202BAB216028), and the Department of Health of Jiangxi Province Projects (grant 2019A058).	Ajani JA, 2021, GUT, V70, P55, DOI 10.1136/gutjnl-2019-319748; An LW, 2020, J EXP MED, V217, DOI 10.1084/jem.20191817; D'Arcy P, 2014, CLIN CANCER RES, V20, P3908, DOI 10.1158/1078-0432.CCR-14-0568; Deng J, 2016, ONCOTARGET, V7, P10037, DOI 10.18632/oncotarget.7048; Fang ZL, 2018, ELIFE, V7, DOI 10.7554/eLife.31275; Harrigan JA, 2018, NAT REV DRUG DISCOV, V17, P57, DOI 10.1038/nrd.2017.152; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Huang SS, 2020, J CELL MOL MED, V24, P11133, DOI 10.1111/jcmm.15613; Jiao S, 2018, J EXP MED, V215, P699, DOI 10.1084/jem.20171116; Kategaya L, 2017, NATURE, V550, P534, DOI 10.1038/nature24006; Li L, 2018, GENE, V641, P240, DOI 10.1016/j.gene.2017.09.071; Liu Z, 2018, BIOCHEM BIOPH RES CO, V505, P843, DOI 10.1016/j.bbrc.2018.09.191; Liu Z, 2018, BIOCHEM BIOPH RES CO, V503, P2370, DOI 10.1016/j.bbrc.2018.06.163; Luo KT, 2017, EMBO J, V36, P1434, DOI 10.15252/embj.201695669; Ma XJ, 2017, P NATL ACAD SCI USA, V114, P1934, DOI 10.1073/pnas.1621359114; Marti P, 2015, HEPATOLOGY, V62, P1497, DOI 10.1002/hep.27992; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Mevissen TET, 2017, ANNU REV BIOCHEM, V86, P159, DOI 10.1146/annurev-biochem-061516-044916; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Pan BQ, 2020, PROTEIN CELL, V11, P138, DOI 10.1007/s13238-019-00674-w; Pan T, 2019, ELIFE, V8, DOI 10.7554/eLife.48318; Qian WL, 2020, ONCOGENE, V39, P6802, DOI 10.1038/s41388-020-01471-0; Shah MA, 2015, J CLIN ONCOL, V33, P1760, DOI 10.1200/JCO.2014.60.1799; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Sun TS, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01262-x; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Tang Y, 2020, CANCER CELL, V38, P115, DOI 10.1016/j.ccell.2020.05.019; Togasaki K, 2021, GASTROENTEROLOGY, V160, P823, DOI 10.1053/j.gastro.2020.10.047; Toloczko A, 2017, CANCER RES, V77, P4921, DOI 10.1158/0008-5472.CAN-16-3413; Tu RF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0475-3; Yang LB, 2020, MOL CELL BIOCHEM, V474, P263, DOI 10.1007/s11010-020-03850-3; Yao F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04620-y; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030; Zhang Z, 2013, GENE DEV, V27, P1581, DOI 10.1101/gad.211037.112; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhou ZA, 2020, CANCER RES, V80, P2550, DOI 10.1158/0008-5472.CAN-19-3718; Zhu H, 2020, CANCER RES, V80, P2204, DOI 10.1158/0008-5472.CAN-19-2388; Zhu LL, 2020, GENE, V742, DOI 10.1016/j.gene.2020.144556; Zhu WJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.698751; Zhuang YY, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00494-0	42	1	1	7	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2555	2570		10.1038/s41388-022-02267-0	http://dx.doi.org/10.1038/s41388-022-02267-0		MAR 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35318441				2022-12-28	WOS:000771890400001
J	Tu, JJ; Fang, YL; Han, DF; Tan, XW; Xu, Z; Jiang, HF; Wang, XM; Hong, WM; Wei, W				Tu, Jiajie; Fang, Yilong; Han, Dafei; Tan, Xuewen; Xu, Zhen; Jiang, Haifeng; Wang, Xinming; Hong, Wenming; Wei, Wei			MicroRNA-22 represses glioma development via activation of macrophage-mediated innate and adaptive immune responses	ONCOGENE			English	Article							STEM-CELLS; OSTEOGENIC DIFFERENTIATION; PROLIFERATION; INVASION; INHIBITION; TEMOZOLOMIDE; SENSITIVITY; RECEPTOR; HEALTH	Macrophage-mediated tumor cell phagocytosis and subsequent neoantigen presentation are critical for generating anti-tumor immunity. This study aimed to uncover the potential clinical value and molecular mechanisms of miRNA-22 (miR-22) in tumor cell phagocytosis via macrophages and more efficient T cell priming. We found that miR-22 expression was markedly downregulated in primary macrophages from glioma tissue samples compared to adjacent tissues. miR-22-overexpressing macrophages inhibited glioma cell proliferation and migration, respectively. miR-22 upregulation stimulated the phagocytic ability of macrophages, enhanced tumor cell phagocytosis, antigen presentation, and efficient T cell priming. Additionally, our data revealed that miR-22-overexpressing macrophages inhibited glioma formation in vivo, HDAC6 was a target, and NF-kappa B signaling was a pathway closely associated with miR-22 in tumor-associated macrophages (TAMs) of glioma. Our findings revealed the essential roles of miR-22 in tumor cell phagocytosis by macrophages and more efficient T cell priming, facilitating further research on phagocytic regulation to enhance the response to tumor immunotherapy.	[Tu, Jiajie; Fang, Yilong; Han, Dafei; Tan, Xuewen; Xu, Zhen; Jiang, Haifeng; Wei, Wei] Anhui Med Univ, Inst Clin Pharmacol, Key Lab Antiinflammatory & Immune Med, Minist Educ,Anhui Collaborat Innovat Ctr Antiinfl, Hefei, Peoples R China; [Wang, Xinming; Hong, Wenming] Anhui Med Univ, Affiliated Hosp 1, Dept Neurosurg, Hefei, Peoples R China	Anhui Medical University; Anhui Medical University	Wei, W (corresponding author), Anhui Med Univ, Inst Clin Pharmacol, Key Lab Antiinflammatory & Immune Med, Minist Educ,Anhui Collaborat Innovat Ctr Antiinfl, Hefei, Peoples R China.; Hong, WM (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Neurosurg, Hefei, Peoples R China.	524594636@qq.com; wwei@ahmu.edu.cn	wei, wei/HHR-8613-2022	hong, wenming/0000-0002-1143-8046	National Natural Science Foundation of China [31900616, 81673444, 82003795]; project of improvement of the scientific ability of Anhui Medical University [2020xkjT009]; Natural Science Foundation of Anhui Province for young scholars [1908085QH379]; Open Fund of Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, P.R. China, Anhui Medical University [KFJJ-2021-01]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); project of improvement of the scientific ability of Anhui Medical University; Natural Science Foundation of Anhui Province for young scholars; Open Fund of Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, P.R. China, Anhui Medical University	This study was supported by the National Natural Science Foundation of China (31900616, 81673444, 82003795), The project of improvement of the scientific ability of Anhui Medical University (2020xkjT009), Natural Science Foundation of Anhui Province for young scholars (1908085QH379) and The Open Fund of Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, P.R. China, Anhui Medical University (KFJJ-2021-01).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chang SJ, 2009, MOL BIOL REP, V36, P2165, DOI 10.1007/s11033-008-9430-1; Chen HC, 2016, TUMOR BIOL, V37, P6761, DOI 10.1007/s13277-015-4575-8; Domingues P, 2016, BRAIN BEHAV IMMUN, V53, P1, DOI 10.1016/j.bbi.2015.07.019; Guerriero JL, 2019, INT REV CEL MOL BIO, V342, P73, DOI 10.1016/bs.ircmb.2018.07.001; Guo YW, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00125; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Heimberger AB, 2003, CLIN CANCER RES, V9, P4247; Hu T, 2020, NEUROSCI LETT, V728, DOI 10.1016/j.neulet.2020.134896; Huang S, 2012, STEM CELLS DEV, V21, P2531, DOI 10.1089/scd.2012.0014; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Josephs Debra H, 2015, Front Biosci (Elite Ed), V7, P293; Kim GW, 2019, ANTICANCER RES, V39, P6731, DOI 10.21873/anticanres.13888; Knox T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42237-3; Kramer OH, 2014, TRENDS PHARMACOL SCI, V35, P501, DOI 10.1016/j.tips.2014.08.001; Krutzik SR, 2005, NAT MED, V11, P653, DOI 10.1038/nm1246; Kurynina AV, 2018, BIOCHEMISTRY-MOSCOW+, V83, P200, DOI 10.1134/S0006297918030021; Li S, 2018, ONCOGENE, V37, P884, DOI 10.1038/onc.2017.381; Lorenzi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046928; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lu W, 2015, NAT IMMUNOL, V16, P1185, DOI 10.1038/ni.3292; Medler TR, 2016, MOL CANCER RES, V14, P994, DOI 10.1158/1541-7786.MCR-16-0109; Park SJ, 2014, CANCER LETT, V354, P97, DOI 10.1016/j.canlet.2014.07.041; Pei XF, 2018, PATHOL RES PRACT, V214, P1095, DOI 10.1016/j.prp.2018.04.009; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Salmi Marko, 2017, Duodecim, V133, P829; Seidel C, 2015, EPIGENOMICS-UK, V7, P103, DOI [10.2217/EPI.14.69, 10.2217/epi.14.69]; Shen C, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006259; Sin WC, 2016, ONCOGENE, V35, P1504, DOI 10.1038/onc.2015.210; von Roemeling CA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15129-8; Wan SF, 2016, ONCOTARGET, V7, P76667, DOI 10.18632/oncotarget.12395; Wang B, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110395; Wang ZH, 2016, CANCER LETT, V379, P134, DOI 10.1016/j.canlet.2016.06.001; Wang ZH, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0765-5; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wong MLH, 2009, J CLIN NEUROSCI, V16, P1119, DOI 10.1016/j.jocn.2009.02.009; Wongjampa W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206644; Yan GQ, 2017, J CELL BIOCHEM, V118, P1653, DOI 10.1002/jcb.25931; Yang Q, 2019, ACM T INTEL SYST TEC, V10, DOI 10.1145/3298981; Yang W, 2018, CANCER LETT, V415, P164, DOI 10.1016/j.canlet.2017.12.005; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Zhang K, 2017, EUR REV MED PHARMACO, V21, P3598; Zhang L, 2020, EUR REV MED PHARMACO, V24, P571, DOI 10.26355/eurrev_202001_20033; Zhang X, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0133-8; Zhang YQ, 2020, J BUON, V25, P491; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090	46	3	3	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2444	2457		10.1038/s41388-022-02236-7	http://dx.doi.org/10.1038/s41388-022-02236-7		MAR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35279703				2022-12-28	WOS:000767909000002
J	Jin, Y; Pan, YM; Zheng, S; Liu, Y; Xu, J; Peng, YZ; Zhang, ZM; Wang, YD; Xiong, YL; Xu, L; Mu, KY; Chen, SW; Zheng, F; Yuan, Y; Fu, J				Jin, Ying; Pan, Yamu; Zheng, Shuang; Liu, Yao; Xu, Jie; Peng, Yazhi; Zhang, Zemei; Wang, Yadong; Xiong, Yulian; Xu, Lei; Mu, Kaiyu; Chen, Suwen; Zheng, Fei; Yuan, Ye; Fu, Jian			Inactivation of EGLN3 hydroxylase facilitates Erk3 degradation via autophagy and impedes lung cancer growth	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; NF-KAPPA-B; PROLYL HYDROXYLASE; INDEPENDENT INHIBITION; PYRUVATE-KINASE; PROMOTES; HYPOXIA; PHD3; HIF; DIFFERENTIATION	EGLN3 is critically important for growth of various cancers including lung cancer. However, virtually nothing is known about the role and mechanism for EGLN3 hydroxylase activity in cancers. EGLN3 catalyzes the hydroxylation of extracellular signal-regulated kinase 3 (Erk3), a potent driver of cancers. The role and mechanism for EGLN3-induced stabilization of Erk3 remain to be defined. Here, we show that Erk3 interacts with heat shock cognate protein of 70 kDa (HSC70) and lysosome-associated membrane protein type 2 A (LAMP2A), two core components of chaperone-mediated autophagy (CMA). As a consequence, Erk3 is degraded by the CMA-lysosome pathway. EGLN3-catalyzed hydroxylation antagonizes CMA-dependent destruction of Erk3. Mechanistically, hydroxylation blunts the interaction of Erk3 with LAMP2A, thereby blocking lysosomal decay of Erk3. EGLN3 inactivation inhibits macrophage migration, efferocytosis, and M2 polarization. Studies using EGLN3 catalytically inactive knock-in mice indicate that inactivation of EGLN3 hydroxylase in host cells ameliorates LLC cancer growth through reprogramming the tumor microenvironment (TME). Adoptive transfer of macrophages with inactivated EGLN3 restrains tumor growth by mounting anti-tumor immunity and restricting angiogenesis. Administration of EGLN3 hydroxylase pharmacologic inhibitor to mice bearing LLC carcinoma impedes cancer growth by targeting the TME. LLC cells harboring inactivated EGLN3 exhibit reduced tumor burden via mitigating immunosuppressive milieu and inducing cancer senescence. This study provides novel insights into the role of CMA in regulating Erk3 stability and the mechanism behind EGLN3-enhanced stability of Erk3. This work demonstrates that inactivation of EGLN3 in malignant and stromal cells suppresses tumor by orchestrating reciprocal interplays between cancer cells and the TME. This work sheds new light on the role and mechanism for EGLN3 catalytic activity in regulating cancer growth. Manipulating EGLN3 activity holds promise for cancer treatment.	[Jin, Ying; Pan, Yamu; Zheng, Shuang; Liu, Yao; Xu, Jie; Peng, Yazhi; Zhang, Zemei; Wang, Yadong; Xiong, Yulian; Xu, Lei; Mu, Kaiyu; Chen, Suwen; Zheng, Fei; Yuan, Ye; Fu, Jian] Hubei Univ Med, Lab Inflammat & Vasc Biol, Inst Clin Med, Renmin Hosp, Shiyan, Hubei, Peoples R China; [Jin, Ying; Pan, Yamu; Zheng, Shuang; Liu, Yao; Xu, Jie; Peng, Yazhi; Zhang, Zemei; Wang, Yadong; Xiong, Yulian; Xu, Lei; Mu, Kaiyu; Chen, Suwen; Zheng, Fei; Yuan, Ye; Fu, Jian] Hubei Univ Med, Dept Cardiol, Renmin Hosp, Shiyan, Hubei, Peoples R China; [Jin, Ying; Fu, Jian] Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14627 USA; [Jin, Ying; Fu, Jian] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14627 USA; [Zheng, Shuang] Hubei Univ Med, Renmin Hosp, Dept Ultrasound, Shiyan, Hubei, Peoples R China; [Zhang, Zemei] Jinzhou Med Univ, Grad Sch, Jinzhou, Liaoning, Peoples R China	Hubei University of Medicine; Hubei University of Medicine; University of Rochester; University of Rochester; Hubei University of Medicine; Jinzhou Medical University	Jin, Y; Fu, J (corresponding author), Hubei Univ Med, Lab Inflammat & Vasc Biol, Inst Clin Med, Renmin Hosp, Shiyan, Hubei, Peoples R China.; Jin, Y; Fu, J (corresponding author), Hubei Univ Med, Dept Cardiol, Renmin Hosp, Shiyan, Hubei, Peoples R China.; Jin, Y; Fu, J (corresponding author), Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14627 USA.; Jin, Y; Fu, J (corresponding author), Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14627 USA.	jdyj0001@163.com; jianfu0326@163.com		Jin, Ying/0000-0002-8811-2204	National Natural Science Foundation of China [81872381]; Health Commission of Hubei Province Scientific Research Projects [WJ2019Z003, WJ2019M047]; Hubei University of Medicine; Hubei University of Medicine Renmin Hospital	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Health Commission of Hubei Province Scientific Research Projects; Hubei University of Medicine; Hubei University of Medicine Renmin Hospital	This work was funded by grants from the National Natural Science Foundation of China (81872381) and from the Health Commission of Hubei Province Scientific Research Projects (WJ2019Z003 and WJ2019M047) to Fu and Jin. This work was also supported by startup funds from the Hubei University of Medicine and the Hubei University of Medicine Renmin Hospital to Fu and Jin.	Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bogucka K, 2021, CANCER GENE THER, V28, P359, DOI 10.1038/s41417-020-00245-w; Carey KL, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108371; Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007; Cassetta L, 2018, NAT REV DRUG DISCOV, V17, P887, DOI 10.1038/nrd.2018.169; Cerezo-Wallis D, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1073-3; Chen SW, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015513; Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245; Conway EM, 2016, AM J RESP CRIT CARE, V193, P116, DOI 10.1164/rccm.201508-1545CI; Cortes M, 2017, EMBO J, V36, P3336, DOI 10.15252/embj.201797345; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Dopeso H, 2018, CANCER RES, V78, P1805, DOI 10.1158/0008-5472.CAN-17-1346; Elkhadragy L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114044; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Ferreira JV, 2013, AUTOPHAGY, V9, P1349, DOI 10.4161/auto.25190; Franklin RA, 2016, TRENDS CANCER, V2, P20, DOI 10.1016/j.trecan.2015.11.004; Fu J, 2003, J BIOL CHEM, V278, P52660, DOI 10.1074/jbc.M308036200; Fu J, 2007, J BIOL CHEM, V282, P12410, DOI 10.1074/jbc.M608748200; Fu J, 2016, CELL SIGNAL, V28, P72, DOI 10.1016/j.cellsig.2015.11.011; Fu J, 2013, MOL CELL BIOL, V33, P3050, DOI 10.1128/MCB.00273-13; Fu J, 2010, J BIOL CHEM, V285, P8927, DOI 10.1074/jbc.M109.078600; German NJ, 2016, MOL CELL, V63, P1006, DOI 10.1016/j.molcel.2016.08.014; Gonda TA, 2020, CANCER RES, V80, P4754, DOI 10.1158/0008-5472.CAN-20-0285; Gonzalez-Rodriguez P, 2021, AUTOPHAGY, V17, P1259, DOI 10.1080/15548627.2020.1816664; Gregory CD, 2011, J PATHOL, V223, P177, DOI 10.1002/path.2792; He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015; Henze AT, 2016, J CLIN INVEST, V126, P3672, DOI 10.1172/JCI84427; Henze AT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6582; Hogel H, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0410-5; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kaushik S, 2018, NAT REV MOL CELL BIO, V19, P365, DOI 10.1038/s41580-018-0001-6; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Long WW, 2012, J CLIN INVEST, V122, P1869, DOI 10.1172/JCI61492; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Miikkulainen P, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0167-y; Rodriguez J, 2018, CELL REP, V24, P1316, DOI 10.1016/j.celrep.2018.06.108; Rodriguez J, 2016, CELL REP, V14, P2745, DOI 10.1016/j.celrep.2016.02.043; Roy S, 2018, CANCER RES, V78, P5600, DOI 10.1158/0008-5472.CAN-18-0562; Schodel J, 2019, NAT REV NEPHROL, V15, P641, DOI 10.1038/s41581-019-0182-z; Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720; Sounni NE, 2013, CLIN CHEM, V59, P85, DOI 10.1373/clinchem.2012.185363; Tan BH, 2018, CANCER RES, V78, P4929, DOI 10.1158/0008-5472.CAN-18-0152; Valkenburg KC, 2018, NAT REV CLIN ONCOL, V15, P366, DOI 10.1038/s41571-018-0007-1; Wang Wei, 2018, Cancer Cell, V34, P757, DOI 10.1016/j.ccell.2018.10.006; Wang W, 2014, J CELL PHYSIOL, V229, P1529, DOI 10.1002/jcp.24596; Wang YS, 2020, EMBO REP, V21, DOI 10.15252/embr.201948335; Xie L, 2012, J CLIN INVEST, V122, P2827, DOI 10.1172/JCI62374; Xu YM, 2019, J BIOL CHEM, V294, P9949, DOI 10.1074/jbc.RA118.007181; Xue J, 2010, GASTROENTEROLOGY, V138, P606, DOI 10.1053/j.gastro.2009.09.049; Yang M, 2018, CANCER RES, V78, P5492, DOI 10.1158/0008-5472.CAN-18-1367	55	4	4	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1752	1766		10.1038/s41388-022-02203-2	http://dx.doi.org/10.1038/s41388-022-02203-2		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35124697	hybrid, Green Published			2022-12-28	WOS:000751597800001
J	Zhang, YF; Li, Q; Huang, PQ; Su, T; Jiang, SH; Hu, LP; Zhang, XL; Sun, Y; Pan, H; Yang, XM; Li, J; Gai, YZ; Zhu, L; Yao, LL; Li, DX; Sun, YW; Zhang, ZG; Liu, DJ; Zhang, YL; Nie, HZ				Zhang, Yi-Fan; Li, Qing; Huang, Pei-Qi; Su, Tong; Jiang, Shu-Heng; Hu, Li-Peng; Zhang, Xue-Li; Sun, Yue; Pan, Hong; Yang, Xiao-Mei; Li, Jun; Gai, Yan-Zhi; Zhu, Lei; Yao, Lin-Li; Li, Dong-Xue; Sun, Yong-Wei; Zhang, Zhi-Gang; Liu, De-Jun; Zhang, Yan-Li; Nie, Hui-Zhen			A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							PROTEIN; TUMOR; INHIBITOR	Pancreatic ductal adenocarcinoma (PDAC), cancer with a high mortality rate and the highest rate of KRAS mutation, reportedly internalizes proteins via macropinocytosis to adapt to low amino acid levels in the tumor microenvironment. Here, we aimed to identify a key regulator of macropinocytosis for the survival of tumor cells in a low amino acid environment in PDAC. FYVE, RhoGEF, and PH domain-containing protein 6 (FGD6) were identified as key regulators of macropinocytosis. FGD6 promoted PDAC cell proliferation, macropinocytosis, and tumor growth both in vitro and in vivo. The macropinocytosis level was decreased with FGD6 knockdown in PDAC cell lines. Moreover, FGD6 promoted macropinocytosis by participating in the trans-Golgi network and enhancing the membrane localization of growth factor receptors, especially the TGF-beta receptor. TGF-beta enhanced macropinocytosis in PDAC cells. Additionally, YAP nuclear translocation induced by a low amino acid tumor environment initiated FGD6 expression by coactivation with YY1. Clinical data analysis based on TCGA and GEO datasets showed that FGD6 expression was upregulated in PDAC tissue, and high FGD6 expression was correlated with poor prognosis in patients with PDAC. In tumor tissue from Kras(G12D/+)/Trp53(R172H/-)/Pdx1-Cre (KPC) mice, FGD6 expression escalated during PDAC development. Our results uncover a previously unappreciated mechanism of macropinocytosis in PDAC. Strategies to target FGD6 and growth factors membrane localization might be developed for the treatment of PDAC.	[Zhang, Yi-Fan; Li, Qing; Huang, Pei-Qi; Jiang, Shu-Heng; Hu, Li-Peng; Zhang, Xue-Li; Sun, Yue; Pan, Hong; Yang, Xiao-Mei; Li, Jun; Gai, Yan-Zhi; Zhu, Lei; Yao, Lin-Li; Li, Dong-Xue; Zhang, Zhi-Gang; Zhang, Yan-Li; Nie, Hui-Zhen] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai 200240, Peoples R China; [Su, Tong] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Shanghai Key Lab Gynecol & Oncol,Dept Gynecol & O, Shanghai 200127, Peoples R China; [Sun, Yong-Wei; Liu, De-Jun] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Biliary Pancreat Surg, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, YL; Nie, HZ (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai 200240, Peoples R China.; Liu, DJ (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Biliary Pancreat Surg, Shanghai 200127, Peoples R China.	Liudejun@renji.com; ylzhang@shsci.org; hznie@shsci.org		Zhang, Xueli/0000-0001-8306-0639; Hu, Lipeng/0000-0002-5941-3825	National Natural Science Foundation of China [81672837, 81872242, 82002485]; Natural Science Foundation of Shanghai [21ZR1461400, 19ZR1452500]; Shanghai Municipal Health Commission [202040104]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Shanghai Municipal Health Commission	This study was supported by the National Natural Science Foundation of China (81672837, to H.-Z. Nie; 81872242, to Y.-L. Zhang; 82002485, to Q.Li), the Natural Science Foundation of Shanghai (21ZR1461400, to H.-Z. Nie; 19ZR1452500 to X.-M. Yang), Shanghai Municipal Health Commission (202040104, to Y.-L. Zhang).	Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Boncompain G, 2012, NAT METHODS, V9, P493, DOI [10.1038/NMETH.1928, 10.1038/nmeth.1928]; Commisso C, 2014, NAT PROTOC, V9, P182, DOI 10.1038/nprot.2014.004; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Davidson SM, 2017, NAT MED, V23, P235, DOI 10.1038/nm.4256; Donaldson JG, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0148; Edwards DN, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan4667; Egorov MV, 2009, MOL BIOL CELL, V20, P2413, DOI 10.1091/mbc.E08-11-1136; Eitzen G, 2019, BIOCHEM CELL BIOL, V97, P257, DOI 10.1139/bcb-2018-0185; Ferreira APA, 2018, TRENDS CELL BIOL, V28, P188, DOI 10.1016/j.tcb.2017.11.004; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Hassan Z, 2018, BRIT J CANCER, V118, P366, DOI 10.1038/bjc.2017.421; Hong L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02818-x; Hong L, 2013, J BIOL CHEM, V288, P8531, DOI 10.1074/jbc.M112.435941; Hoxha S, 2020, CANCER RES, V80, P2512, DOI 10.1158/0008-5472.CAN-19-2415; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; King B, 2020, GENE DEV, V34, P1345, DOI 10.1101/gad.340661.120; Koo JH, 2018, CELL METAB, V28, P196, DOI 10.1016/j.cmet.2018.07.010; Lee SW, 2019, DEV CELL, V50, P381, DOI 10.1016/j.devcel.2019.05.043; Lee SW, 2019, METHODS MOL BIOL, V1882, P171, DOI 10.1007/978-1-4939-8879-2_16; Lim JP, 2011, IMMUNOL CELL BIOL, V89, P836, DOI 10.1038/icb.2011.20; Luo K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022137; Marques PE, 2017, CELL, V169, P766, DOI 10.1016/j.cell.2017.04.031; Moffitt RA, 2015, NAT GENET, V47, P1168, DOI 10.1038/ng.3398; Mossmann D, 2018, NAT REV CANCER, V18, P744, DOI 10.1038/s41568-018-0074-8; Nakazawa MS, 2016, NAT REV CANCER, V16, P663, DOI 10.1038/nrc.2016.84; Nofal M, 2017, MOL CELL, V67, P936, DOI 10.1016/j.molcel.2017.08.011; Palm W, 2017, P NATL ACAD SCI USA, V114, pE8628, DOI 10.1073/pnas.1712726114; Palm W, 2017, NATURE, V546, P234, DOI 10.1038/nature22379; Palm W, 2015, CELL, V162, P259, DOI 10.1016/j.cell.2015.06.017; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rashidian J, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005735; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Steenblock C, 2014, J BIOL CHEM, V289, P18347, DOI 10.1074/jbc.M113.504894; Swanson JA, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0157; Syed V, 2016, J CELL BIOCHEM, V117, P1279, DOI 10.1002/jcb.25496; Tu B, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130811; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; Wolfgang CL, 2013, CA-CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190; Yang CS, 2018, EMBO REP, V19, DOI 10.15252/embr.201643577; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017; Zhang Y-F, 2019, TARGETING TUMOR MICR, V8, P4; Zhang YL, 2018, CANCER RES, V78, P2305, DOI 10.1158/0008-5472.CAN-17-2867	45	0	0	9	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1203	1215		10.1038/s41388-021-02159-9	http://dx.doi.org/10.1038/s41388-021-02159-9		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35082383				2022-12-28	WOS:000749084700001
J	Laut, AK; Dorneburg, C; Furstberger, A; Barth, TFE; Kestler, HA; Debatin, KM; Beltinger, C				Laut, Astrid K.; Dorneburg, Carmen; Furstberger, Axel; Barth, Thomas F. E.; Kestler, Hans A.; Debatin, Klaus-Michael; Beltinger, Christian			CHD5 inhibits metastasis of neuroblastoma	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; MOLECULAR ANALYSIS; BINDING-PROTEIN; DISTAL 1P; DELETION; REGION; EXPRESSION; INVASION; LOCI; MECHANISMS	CHD5, a tumor suppressor at 1p36, is frequently lost or silenced in poor prognosis neuroblastoma (NB) and many adult cancers. The role of CHD5 in metastasis is unknown. We confirm that low expression of CHD5 is associated with stage 4 NB. Forced expression of CHD5 in NB cell lines with 1p loss inhibited key aspects of the metastatic cascade in vitro: anchorage-independent growth, migration, and invasion. In vivo, formation of bone marrow and liver metastases developing from intravenously injected NB cells was delayed and decreased by forced CHD5 expression. Genome-wide mRNA sequencing revealed reduction of genes and gene sets associated with metastasis when CHD5 was overexpressed. Known metastasis-suppressing genes preferentially upregulated in CHD5-overexpressing NB cells included PLCL1. In patient NB, low expression of PLCL1was associated with metastatic disease and poor survival. Knockdown of PLCL1 and of p53 in IMR5 NB cells overexpressing CHD5 reversed CHD5-induced inhibition of invasion and migration in vitro. In summary, CHD5 is a metastasis suppressor in NB.	[Laut, Astrid K.; Dorneburg, Carmen; Beltinger, Christian] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Sect Expt Pediat Oncol, Ulm, Germany; [Furstberger, Axel; Kestler, Hans A.] Ulm Univ, Inst Med Syst Biol, Ulm, Germany; [Barth, Thomas F. E.] Univ Med Ctr Ulm, Dept Pathol, Ulm, Germany; [Debatin, Klaus-Michael] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany	Ulm University; Ulm University; Ulm University; Ulm University	Beltinger, C (corresponding author), Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Sect Expt Pediat Oncol, Ulm, Germany.	Christian.Beltinger@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Kestler, Hans A./D-5799-2012	Debatin, Klaus-Michael/0000-0002-8397-1886; Kestler, Hans A./0000-0002-4759-5254	Deutsche Forschungsgemeinschaft [GRK2254]; DFG	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG(German Research Foundation (DFG))	The excellent technical assistance of Nicole Heymann, Helgard Knauss and Alix Otto is greatly appreciated. This work was supported by a grant of the Deutsche Forschungsgemeinschaft to CB (Project B1 within the GRK2254). AL was a member of the International Graduate School in Molecular Medicine, Ulm, that is funded by the DFG.	Ara T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555-006-9028-9; Asano S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05908-7; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bhoopathi P, 2019, ONCOGENE, V38, P6781, DOI 10.1038/s41388-019-0920-5; Botzer LE, 2016, BRIT J CANCER, V114, P759, DOI 10.1038/bjc.2016.26; Byrne FL, 2014, ONCOGENE, V33, P882, DOI 10.1038/onc.2013.11; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Chen DD, 2020, NEOPLASIA, V22, P231, DOI 10.1016/j.neo.2020.04.001; CHENG NC, 1995, ONCOGENE, V10, P291; Chou RH, 2012, ONCOL REP, V27, P238, DOI 10.3892/or.2011.1497; Delloye-Bourgeois C, 2017, CANCER CELL, V32, P427, DOI 10.1016/j.ccell.2017.09.006; Dorneburg C, 2018, CLIN CANCER RES, V24, P5772, DOI 10.1158/1078-0432.CCR-17-2578; Egan CM, 2013, DEV CELL, V26, P223, DOI 10.1016/j.devcel.2013.07.008; Fabian J, 2016, ONCOTARGET, V7, P66344, DOI 10.18632/oncotarget.11662; Fife CM, 2017, ONCOGENE, V36, P501, DOI 10.1038/onc.2016.220; Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176; Garcia I, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-277; GEHRING M, 1995, CANCER RES, V55, P5366; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Kolla Venkatadri, 2014, Cancer Res, V74, P652, DOI 10.1158/0008-5472.CAN-13-3056; Kolla V, 2015, BIOCHEM J, V468, P345, DOI 10.1042/BJ20150030; Koyama H, 2012, CLIN CANCER RES, V18, P1588, DOI 10.1158/1078-0432.CCR-11-2644; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Maetani Y, 2021, BIOCHEM BIOPH RES CO, V552, P106, DOI 10.1016/j.bbrc.2021.03.045; Maris John M, 2010, N Engl J Med, V362, P2202, DOI 10.1056/NEJMra0804577; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; MARTINSSON T, 1995, CANCER RES, V55, P5681; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Naraparaju K, 2016, ONCOTARGET, V7, P15977, DOI 10.18632/oncotarget.7434; Okawa ER, 2008, ONCOGENE, V27, P803, DOI 10.1038/sj.onc.1210675; Paul S, 2013, CELL REP, V3, P92, DOI 10.1016/j.celrep.2012.12.009; Quan JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108066; Quan JH, 2014, J BIOL CHEM, V289, P20717, DOI 10.1074/jbc.M114.568568; Seong BKA, 2017, CANCER RES, V77, P696, DOI 10.1158/0008-5472.CAN-16-1502; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306; White PS, 1997, EUR J CANCER, V33, P1957, DOI 10.1016/S0959-8049(97)00311-0; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Wu PY, 2019, CANCER RES, V79, P5550, DOI 10.1158/0008-5472.CAN-18-3272; Xiang X, 2015, CANCER LETT, V359, P187, DOI 10.1016/j.canlet.2015.01.008; Xie CR, 2015, ONCOTARGET, V6, P40940, DOI 10.18632/oncotarget.5724; Zhu SZ, 2017, CANCER CELL, V32, P310, DOI 10.1016/j.ccell.2017.08.002	45	4	4	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					622	633		10.1038/s41388-021-02081-0	http://dx.doi.org/10.1038/s41388-021-02081-0		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34789839	hybrid, Green Published			2022-12-28	WOS:000719713800001
J	Jiang, CC; Marsland, M; Wang, YF; Dowdell, A; Eden, E; Gao, FF; Faulkner, S; Jobling, P; Li, X; Liu, LH; He, ZY; Hondermarck, H				Jiang, Chen Chen; Marsland, Mark; Wang, Yufang; Dowdell, Amiee; Eden, Edward; Gao, Fangfang; Faulkner, Sam; Jobling, Phillip; Li, Xiang; Liu, Lihua; He, Zhangyu; Hondermarck, Hubert			Tumor innervation is triggered by endoplasmic reticulum stress	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; GENE; CANCER; MICROENVIRONMENT; EXPRESSION; SURVIVAL	Nerve infiltration in the tumor microenvironment is emerging as a promoter of cancer progression that could be targeted in therapies, but the mechanisms initiating tumor innervation remain to be elucidated. Here we report that endoplasmic reticulum (ER) stress in cancer cells is transmitted to neuronal cells, resulting in neurite outgrowth and tumor innervation. In vitro, the induction of ER stress in various human cancer cells resulted in the synthesis and release of the precursor for brain-derived neurotrophic factor (proBDNF) through a mechanism dependent on the transcription factor X-box binding protein 1 (XBP1). Cancer cell-released proBDNF was found to mediate the transmission of ER stress to neurons, resulting in the stimulation of neurite outgrowth. Next-generation sequencing indicated the increased expression of the Egl-9 family hypoxia inducible factor 3 (EGLN3) that was mediated by c-MYC and necessary to neurite outgrowth induced by proBDNF. In orthotopic tumor xenograft, ER stress stimulated XBP1 and proBDNF expression as well as tumor innervation. Anti-proBDNF antibody inhibited both tumor innervation and cancer progression induced by ER stress. Interestingly, the chemotherapeutic drug 5-Fluorouracil (5-FU) was found to induce ER stress and tumor innervation, and this effect was inhibited by anti-proBDNF antibody. Finally, in human tumors, cancer tissues with nerve infiltration expressed high XBP1 and proBDNF while EGLN3 was upregulated in infiltrated nerves. This study reveals that ER stress participates in tumor innervation through the release of proBDNF and that targeting this pathway could be used in future therapies.	[Jiang, Chen Chen; Marsland, Mark; Dowdell, Amiee; Eden, Edward; Gao, Fangfang; Faulkner, Sam; Jobling, Phillip; Li, Xiang; Hondermarck, Hubert] Univ Newcastle, Sch Biomed Sci & Pharm, Canc Neurobiol Grp, Callaghan, NSW 2308, Australia; [Jiang, Chen Chen; Marsland, Mark; Dowdell, Amiee; Eden, Edward; Gao, Fangfang; Faulkner, Sam; Jobling, Phillip; Li, Xiang; Hondermarck, Hubert] Hunter Med Res Inst, New Lambton, NSW 2305, Australia; [Jiang, Chen Chen] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Wang, Yufang; Liu, Lihua; He, Zhangyu] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China; [Gao, Fangfang] Zhengzhou Univ, Affiliated Hosp 1, Dept Radiotherapy, Zhengzhou 450000, Henan, Peoples R China	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; Sichuan University; Zhengzhou University	Hondermarck, H (corresponding author), Univ Newcastle, Sch Biomed Sci & Pharm, Canc Neurobiol Grp, Callaghan, NSW 2308, Australia.; Hondermarck, H (corresponding author), Hunter Med Res Inst, New Lambton, NSW 2305, Australia.	hubert.hondermarck@newcastle.edu.au		Faulkner, Sam/0000-0002-4732-8252; Li, Xiang/0000-0003-1199-7152	University of Newcastle (Australia); Hunter Cancer Research Alliance; Hunter Medical Research Institute; Maitland Cancer Appeal Committee (NSW Australia)	University of Newcastle (Australia); Hunter Cancer Research Alliance; Hunter Medical Research Institute; Maitland Cancer Appeal Committee (NSW Australia)	Y This work was supported by the University of Newcastle (Australia), the Hunter Cancer Research Alliance, the Hunter Medical Research Institute, and the Maitland Cancer Appeal Committee (NSW Australia). We thank Kristen McEwan for excellent technical contribution. We also thank Kathryn Leaney from Cancer Voice NSW for her excellent consumer contribution.	Allen JK, 2018, CANCER RES, V78, P3233, DOI 10.1158/0008-5472.CAN-16-1701; Bai YY, 2016, NEUROPSYCHOPHARMACOL, V41, P2882, DOI 10.1038/npp.2016.100; Cao ZY, 2014, ONCOL LETT, V7, P1260, DOI 10.3892/ol.2014.1856; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Demir IE, 2020, CANCER CELL, V38, P11, DOI 10.1016/j.ccell.2020.05.023; Evans JP, 2019, LAB ANIM-UK, V53, P598, DOI 10.1177/0023677219826165; Faulkner S, 2019, CANCER DISCOV, V9, P702, DOI 10.1158/2159-8290.CD-18-1398; Griffin N, 2020, AM J PATHOL, V190, P1921, DOI 10.1016/j.ajpath.2020.05.012; Guo ST, 2016, ONCOGENE, V35, P3049, DOI 10.1038/onc.2015.361; Haberberger RV, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00184; Hayakawa Y, 2017, CANCER CELL, V31, P21, DOI 10.1016/j.ccell.2016.11.005; Hayashi A, 2007, J BIOL CHEM, V282, P34525, DOI 10.1074/jbc.M704300200; Henze AT, 2010, CANCER RES, V70, P357, DOI 10.1158/0008-5472.CAN-09-1876; Hetz C, 2020, NAT REV MOL CELL BIO, V21, P421, DOI 10.1038/s41580-020-0250-z; Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kamiya A, 2019, NAT NEUROSCI, V22, P1289, DOI 10.1038/s41593-019-0430-3; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; Kim JK, 2016, ENVIRON TOXICOL PHAR, V44, P128, DOI 10.1016/j.etap.2016.05.005; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; LUNDBERG LM, 1988, HISTOCHEMISTRY, V90, P9, DOI 10.1007/BF00495700; Maclean KN, 2012, J BIOL CHEM, V287, P31994, DOI 10.1074/jbc.M112.355172; Maertens GN, 2006, J CELL SCI, V119, P2563, DOI 10.1242/jcs.02995; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Monje M, 2020, CELL, V181, P219, DOI 10.1016/j.cell.2020.03.034; Murao N, 2017, J BIOCHEM, V162, P155, DOI 10.1093/jb/mvx047; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Peterson SC, 2015, CELL STEM CELL, V16, P400, DOI 10.1016/j.stem.2015.02.006; Pundavela J, 2015, MOL ONCOL, V9, P1626, DOI 10.1016/j.molonc.2015.05.001; Renz BW, 2018, CANCER DISCOV, V8, P1458, DOI 10.1158/2159-8290.CD-18-0046; Renz BW, 2018, CANCER CELL, V33, P75, DOI 10.1016/j.ccell.2017.11.007; Saloman JL, 2016, P NATL ACAD SCI USA, V113, P3078, DOI 10.1073/pnas.1512603113; Sheng X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08152-3; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007; Valdes P, 2014, P NATL ACAD SCI USA, V111, P6804, DOI 10.1073/pnas.1321845111; Vanhecke E, 2011, CLIN CANCER RES, V17, P1741, DOI 10.1158/1078-0432.CCR-10-1890; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wiatrak B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040958; Xie H, 2018, J CLIN INVEST, V128, P1300, DOI 10.1172/JCI95864; Yin XY, 2001, ONCOGENE, V20, P2908, DOI 10.1038/sj.onc.1204417; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569	44	0	0	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					586	599		10.1038/s41388-021-02108-6	http://dx.doi.org/10.1038/s41388-021-02108-6		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785777				2022-12-28	WOS:000719277200001
J	Jin, X; Zhang, B; Zhang, H; Yu, HX				Jin, Xin; Zhang, Bin; Zhang, Hao; Yu, Haixin			Smoking-associated upregulation of CBX3 suppresses ARHGAP24 expression to activate Rac1 signaling and promote tumor progression in lung adenocarcinoma	ONCOGENE			English	Article							PANCREATIC-CANCER; RHO-GTPASES; METHYLATION; RESISTANCE; CELLS; BRD4	Although tobacco smoking is a risk factor for lung adenocarcinoma (LUAD), the mechanisms by which tobacco smoking induces LUAD development remain elusive. Histone methylation levels in human bronchial epithelial cells have been reported to increase after exposure to cigarettes. In this study, we explored the mechanisms regulating histone methylation in LUAD in response to smoking. We found that the histone H3K9 methylation reader CBX3 was upregulated in current smokers with LUAD, and that CBX3 overexpression promoted LUAD progression. Functional enrichment analyses revealed that CBX3 regulated the activation of Rho GTPases in LUAD. We also found that by forming a complex with TRIM28, TRIM24, and RBBP4, CBX3 repressed the expression of ARHGAP24 and increased the amount of active Rac1 in LUAD cells. Collectively, these results suggest that smoking associated upregulation of CBX3 promotes LUAD progression by activating the ARHGAP24/Rac1 pathway. Hence, the CBX3/ARHGAP24/Rac1 axis may represent a promising therapeutic target in smoking-induced LUAD.	[Jin, Xin] Cent South Univ, Xiangya Hosp 2, Dept Urol, Changsha 410011, Hunan, Peoples R China; [Jin, Xin] Cent South Univ, Urooncol Inst, Changsha 410011, Hunan, Peoples R China; [Zhang, Bin; Yu, Haixin] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China; [Zhang, Hao] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha 410011, Hunan, Peoples R China	Central South University; Central South University; Huazhong University of Science & Technology; Central South University	Yu, HX (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China.; Zhang, H (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha 410011, Hunan, Peoples R China.	zhanghao7106@csu.edu.cn; haixin.y@outlook.com		Yu, Haixin/0000-0002-0245-2102; Jin, Xin/0000-0001-6461-6005	Chinese National Natural Science Foundation [82073321]	Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the Chinese National Natural Science Foundation Grant No. 82073321 (XJ).	Abe K, 2011, BIOL REPROD, V85, P1013, DOI 10.1095/biolreprod.111.091512; Alam H, 2018, CANCER RES, V78, P3834, DOI 10.1158/0008-5472.CAN-17-3571; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Bot C, 2017, J CELL SCI, V130, P1134, DOI 10.1242/jcs.197236; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai HP, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03247-6; Chang C, 2018, ONCOGENE, V37, P415, DOI 10.1038/onc.2017.332; Cho EJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091037; Fong KW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07475-5; Glancy E, 2021, CURR OPIN STRUC BIOL, V67, P135, DOI 10.1016/j.sbi.2020.10.017; Gray JL, 2020, ANGEW CHEM INT EDIT, V59, P6342, DOI 10.1002/anie.201900585; Haga Raquel B, 2016, Small GTPases, V7, P207; He X, 2017, INT J CHRONIC OBSTR, V12, P3245, DOI 10.2147/COPD.S144881; He ZS, 2021, J CELL PHYSIOL, V236, P107, DOI 10.1002/jcp.29631; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Huang CY, 2017, GENE DEV, V31, P241, DOI 10.1101/gad.292169.116; Itsumi M, 2013, J MOL ENDOCRINOL, V50, P401, DOI 10.1530/JME-13-0024; Jin X, 2017, CANCER RES, V77, P4328, DOI 10.1158/0008-5472.CAN-16-3143; Jin X, 2017, J BIOL CHEM, V292, P6269, DOI 10.1074/jbc.M116.764407; Johan MZ, 2019, BIOCHEM SOC T, V47, P101, DOI 10.1042/BST20180334; Kang NX, 2015, INT IMMUNOPHARMACOL, V24, P95, DOI 10.1016/j.intimp.2014.10.029; Kaur G, 2019, ARCH TOXICOL, V93, P2715, DOI 10.1007/s00204-019-02562-y; Li H, 2015, LUNG CANCER, V88, P1, DOI 10.1016/j.lungcan.2015.01.017; Lin HX, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/2412741; Liu HL, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-5000; Maeda T, 2018, CANCER RES, V78, P205, DOI 10.1158/0008-5472.CAN-17-1636; Nakamura F, 2013, BIOCHEM J, V453, P17, DOI 10.1042/BJ20130290; Oyama K, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0187-z; Porazinski S, 2020, ADV EXP MED BIOL, V1223, P99, DOI 10.1007/978-3-030-35582-1_6; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Saini V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041401; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Singh PB, 2010, RUSS J GENET+, V46, P1257, DOI 10.1134/S1022795410100297; Stueve TR, 2017, HUM MOL GENET, V26, P3014, DOI 10.1093/hmg/ddx188; Sundar IK, 2014, J PROTEOME RES, V13, P982, DOI 10.1021/pr400998n; Svensmark JH, 2019, ONCOGENE, V38, P7447, DOI 10.1038/s41388-019-0963-7; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Yang C, 2020, AM J CANCER RES, V10, P523; Yang JZ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1107-y; Yu HX, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00872-y; Zaidan NZ, 2020, NUCLEIC ACIDS RES, V48, P12660, DOI 10.1093/nar/gkaa1091; Zhang B, 2021, MOL ONCOL, V15, P3062, DOI 10.1002/1878-0261.12955; Zhang Y, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0292-4; Zhong XP, 2019, AGING-US, V11, P5483, DOI 10.18632/aging.102132	45	4	4	4	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					538	549		10.1038/s41388-021-02114-8	http://dx.doi.org/10.1038/s41388-021-02114-8		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785774	hybrid, Green Published			2022-12-28	WOS:000719277200003
J	Zhang, Z; Liu, RY; Wang, YF; Wang, Y; Shuai, YJ; Ke, CW; Jin, R; Wang, XD; Luo, JT				Zhang, Ze; Liu, Ruoyan; Wang, Yafei; Wang, Yun; Shuai, Yanjie; Ke, Chuangwu; Jin, Rui; Wang, Xudong; Luo, Jingtao			Phosphorylation of MICAL2 by ARG promotes head and neck cancer tumorigenesis by regulating skeletal rearrangement	ONCOGENE			English	Article							CELL-MIGRATION; ACTIN; INVASION; KINASES; METASTASIS; TRANSITION; CCG-1423; FAMILY; GROWTH	The actin cytoskeletal architecture provides the structural underpinnings for crucial cellular behaviors. In cancer cells, changes in the actin cytoskeleton may serve as prerequisites for proliferation, invasion, and metastatic dissemination. However, the underlying mechanisms remain largely unknown. Here, we show that MICAL2, which is increased in head and neck squamous cell carcinoma (HNSCC) and inversely associated with patient survival, promotes HNSCC growth, invasion, and migration. MICAL2 serves as a flavoprotein monooxygenase and directly induces actin filament depolymerization by specifically oxidizing the methionine 44 and 47 residues of F-actin. The kinase ARG interacts with MICAL2 and augments MICAL2-mediated actin disassembly. Direct phosphorylation assay and mass spectrometry confirmed that ARG phosphorylates MICAL2 at Tyr445, Tyr463, and Tyr488. Substitution of the Tyr445 or Tyr463 residue of purified recombinant MICAL2-redox with phenylalanine (generating a non-phosphorylatable mutant) abolishes the enhanced MICAL2-mediated F-actin disassembly induced by ARG. Consistently, ectopic expression of non-phosphorylatable MICAL2 mutants (MICAL2(Y445F) and MICAL2(Y463F), not MICAL2(Y488F)) failed to ameliorate HNSCC cell growth, whereas expression of wild-type MICAL2 or MICAL2(Y488F) rescued the impaired proliferation induced by MICAL2 knockdown. Moreover, CCG-1423, an inhibitor of MICAL2, was shown to inhibit HNSCC cell proliferation, invasion, and migration. Taken together, our findings indicate that phosphorylation of MICAL2 at Tyr445 and Tyr463 by ARG mediates F-actin disassembly and promotes HNSCC progression.	[Zhang, Ze; Wang, Yafei; Wang, Yun; Shuai, Yanjie; Ke, Chuangwu; Jin, Rui; Wang, Xudong; Luo, Jingtao] Tianjin Med Univ Canc Inst & Hosp, Dept Maxillofacial & Otorhinolaryngol Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Zhang, Ze; Wang, Yafei; Wang, Yun; Shuai, Yanjie; Ke, Chuangwu; Jin, Rui; Wang, Xudong; Luo, Jingtao] Tianjin Med Univ Canc Inst & Hosp, Dept Head & Neck Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Zhang, Ze; Liu, Ruoyan; Wang, Yafei; Wang, Yun; Shuai, Yanjie; Ke, Chuangwu; Jin, Rui; Wang, Xudong; Luo, Jingtao] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Zhang, Ze; Liu, Ruoyan; Wang, Yafei; Wang, Yun; Shuai, Yanjie; Ke, Chuangwu; Jin, Rui; Wang, Xudong; Luo, Jingtao] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China; [Liu, Ruoyan] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Gynecol Oncol, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Luo, JT (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Maxillofacial & Otorhinolaryngol Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China.; Luo, JT (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Head & Neck Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China.; Luo, JT (corresponding author), Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.; Luo, JT (corresponding author), Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.	jluo@tmu.edu.cn			Natural Science Foundation of China [81902757, 82073006, 82002757]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Our sincere appreciation goes out to Professor Ren and Dr. Zhu of the State Key Laboratory of Plant Physiology and Biochemistry of China Agricultural University, for providing technical guidance. We thank the TCGA project for its valuable contributions to HNSCC research. This study was supported by the Natural Science Foundation of China (nos. 81902757, 82073006, and 82002757).	Alto LT, 2018, CURR BIOL, V28, pR538, DOI 10.1016/j.cub.2018.01.025; [Anonymous], 2020, Nat Rev Dis Primers, V6, P93, DOI 10.1038/s41572-020-00233-2; Ashida S, 2006, CLIN CANCER RES, V12, P2767, DOI 10.1158/1078-0432.CCR-05-1995; Barravecchia I, 2019, BBA-MOL BASIS DIS, V1865, P2111, DOI 10.1016/j.bbadis.2019.04.008; Beuchle D, 2007, MECH DEVELOP, V124, P390, DOI 10.1016/j.mod.2007.01.006; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Brandt DT, 2009, NAT CELL BIOL, V11, P557, DOI 10.1038/ncb1862; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Colicelli J, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3139re6; Evelyn CR, 2007, MOL CANCER THER, V6, P2249, DOI 10.1158/1535-7163.MCT-06-0782; Fremont S, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms14528; Gau D, 2017, ANGIOGENESIS, V20, P663, DOI 10.1007/s10456-017-9560-y; Giridharan SSP, 2012, J CELL SCI, V125, P614, DOI 10.1242/jcs.089367; Greuber EK, 2013, NAT REV CANCER, V13, P559, DOI 10.1038/nrc3563; Grintsevich EE, 2016, NAT CELL BIOL, V18, P876, DOI 10.1038/ncb3390; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayes KE, 2013, ONCOGENE, V32, P4766, DOI 10.1038/onc.2012.513; Hellweg R, 2018, HORM CANCER-US, V9, P326, DOI 10.1007/s12672-018-0337-6; Hung RJ, 2011, SCIENCE, V334, P1710, DOI 10.1126/science.1211956; Hung RJ, 2010, NATURE, V463, P823, DOI 10.1038/nature08724; IKKAI T, 1966, SCIENCE, V152, P1756, DOI 10.1126/science.152.3730.1756; Kobayashi M, 2019, INVEST OPHTH VIS SCI, V60, P528, DOI 10.1167/iovs.18-25678; Kunda P, 2009, TRENDS CELL BIOL, V19, P174, DOI 10.1016/j.tcb.2009.01.006; Li CF, 2019, NAT CELL BIOL, V21, P251, DOI 10.1038/s41556-018-0268-z; Liu L, 2018, BBA-MOL BASIS DIS, V1864, P3109, DOI 10.1016/j.bbadis.2018.05.026; Lundquist MR, 2014, CELL, V156, P563, DOI 10.1016/j.cell.2013.12.035; Mariotti S, 2016, ONCOTARGET, V7, P1808, DOI 10.18632/oncotarget.6577; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Mouneimne G, 2012, CANCER CELL, V22, P615, DOI 10.1016/j.ccr.2012.09.027; Orr BO, 2017, NATURE, V550, P109, DOI 10.1038/nature24017; Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; Shaul YD, 2014, CELL, V158, P1094, DOI 10.1016/j.cell.2014.07.032; Sutherland JD, 1999, CURR OPIN CELL BIOL, V11, P142, DOI 10.1016/S0955-0674(99)80018-0; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Wang J, 2015, TRENDS CANCER, V1, P110, DOI 10.1016/j.trecan.2015.07.004; Wang Y, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12920; Wu H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17943-5; Wu H, 2016, PROTEIN EXPRES PURIF, V127, P116, DOI 10.1016/j.pep.2016.05.008; Ye GT, 2017, THERANOSTICS, V7, P3338, DOI 10.7150/thno.20512; Yoon J, 2017, DEV CELL, V42, P117, DOI 10.1016/j.devcel.2017.06.007; Zhang Z, 2020, BRIT J CANCER, V122, P82, DOI 10.1038/s41416-019-0637-9; Zhang Z, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00434; Zhou WL, 2020, CANCER LETT, V483, P75, DOI 10.1016/j.canlet.2020.04.019	47	2	2	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					334	346		10.1038/s41388-021-02101-z	http://dx.doi.org/10.1038/s41388-021-02101-z		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34750518				2022-12-28	WOS:000715670800001
J	Liu, R; Gou, DM; Xiang, J; Pan, XM; Gao, QZ; Zhou, P; Liu, Y; Hu, J; Wang, K; Tang, N				Liu, Rui; Gou, Dongmei; Xiang, Jin; Pan, Xuanming; Gao, Qingzhu; Zhou, Peng; Liu, Yi; Hu, Jie; Wang, Kai; Tang, Ni			O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis	ONCOGENE			English	Article							CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; TIP60 HISTONE ACETYLTRANSFERASE; GROWTH-FACTOR; CANCER; ACETYLATION; EXPRESSION; LINKS; MYC; GLYCOSYLATION; TUMORIGENESIS	Aberrant glucose metabolism and elevated O-linked beta-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC). Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation. However, whether PCK1 deficiency and hyper O-GlcNAcylation can induce HCC metastasis is largely unknown. Here, gain- and loss-of-function studies demonstrate that PCK1 suppresses HCC metastasis in vitro and in vivo. Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells. Mechanistically, PCK1 depletion suppressed KAT5 ubiquitination by increasing its O-GlcNAcylation, thereby stabilizing KAT5. KAT5 O-GlcNAcylation epigenetically activates TWIST1 expression via histone H4 acetylation, and enhances MMP9 and MMP14 expression via c-Myc acetylation, thus promoting epithelial-mesenchymal transition (EMT) in HCC. In addition, targeting HBP-mediated O-GlcNAcylation of KAT5 inhibits lung metastasis of HCC in hepatospecific Pck1-deletion mice. Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.	[Liu, Rui; Gou, Dongmei; Xiang, Jin; Pan, Xuanming; Gao, Qingzhu; Zhou, Peng; Liu, Yi; Hu, Jie; Wang, Kai; Tang, Ni] Chongqing Med Univ, Affiliated Hosp 2, Key Lab Mol Biol Infect Dis, Minist Educ,Inst Viral Hepatitis,Dept Infect Dis, Chongqing 400010, Peoples R China	Chongqing Medical University	Wang, K; Tang, N (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Key Lab Mol Biol Infect Dis, Minist Educ,Inst Viral Hepatitis,Dept Infect Dis, Chongqing 400010, Peoples R China.	wangkai@cqmu.edu.cn; nitang@cqmu.edu.cn	Wang, Kai/U-3552-2019	Wang, Kai/0000-0002-0137-1247; Xiang, Jin/0000-0002-3890-5556	National Natural Science Foundation of China [82073251, 82072286, 81872270]; Natural Science Foundation Project of Chongqing [cstc2018jcyjAX0254, cstc2019jscx-dxwtBX0019, cstc2019jcyj-msxmX0587]; Talent Development Program of CQMU for Postgraduate [BJRC201913]; Kuanren talents program of the second affiliated hospital of Chongqing Medical University; Science and Technology Research Program of Chongqing Municipal Education Commission [KJZD-M202000401, KJQN201900429]; Scientific Research Innovation Project for Postgraduate in Chongqing [CYB21196]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation Project of Chongqing(Natural Science Foundation of Chongqing); Talent Development Program of CQMU for Postgraduate; Kuanren talents program of the second affiliated hospital of Chongqing Medical University; Science and Technology Research Program of Chongqing Municipal Education Commission; Scientific Research Innovation Project for Postgraduate in Chongqing	We would like to thank Dr. T.-C He (University of Chicago, USA) for providing the pAdEasy system. We are grateful to Prof. Ding Xue (Tsinghua University, China) for supplying the CRISPR/Cas9 system. We also thank Prof. Bing Sun (Shanghai Institute of Biochemistry and Cell Biology, China) for providing the pLL3.7 vector. This work was supported by the National Natural Science Foundation of China [grant no. 82073251, 82072286, and 81872270]; the Natural Science Foundation Project of Chongqing [cstc2018jcyjAX0254, cstc2019jscx-dxwtBX0019, and cstc2019jcyj-msxmX0587]; the Talent Development Program of CQMU for Postgraduate [grant no. BJRC201913], the Kuanren talents program of the second affiliated hospital of Chongqing Medical University, the Science and Technology Research Program of Chongqing Municipal Education Commission (KJZD-M202000401, KJQN201900429), and the Scientific Research Innovation Project for Postgraduate in Chongqing (grant no. CYB21196).	Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bian XL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14420; Brauns-Schubert P, 2018, EMBO REP, V19, P244, DOI 10.15252/embr.201744311; Charvet C, 2011, MOL CELL, V42, P584, DOI 10.1016/j.molcel.2011.03.033; Col E, 2005, EMBO J, V24, P2634, DOI 10.1038/sj.emboj.7600734; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Ezponda T, 2013, ONCOGENE, V32, P2882, DOI 10.1038/onc.2012.297; Feng J, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01629-4; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Gao SS, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba7822; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Ghobashi AH, 2018, J APPL GENET, V59, P161, DOI 10.1007/s13353-018-0432-y; Grasmann G, 2019, BBA-REV CANCER, V1872, P24, DOI 10.1016/j.bbcan.2019.05.006; Halkidou K, 2004, NUCLEIC ACIDS RES, V32, P1654, DOI 10.1093/nar/gkh296; Han CF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01654-6; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hirata H, 2016, CANCER RES, V76, P3265, DOI 10.1158/0008-5472.CAN-15-2601; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Jiang MZ, 2019, THERANOSTICS, V9, P5359, DOI 10.7150/thno.34024; Jiang MZ, 2019, ONCOGENE, V38, P301, DOI 10.1038/s41388-018-0435-5; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kwan SY, 2020, HEPATOLOGY, V71, P275, DOI 10.1002/hep.30807; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Lemercier C, 2003, J BIOL CHEM, V278, P4713, DOI 10.1074/jbc.M211811200; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Li Y, 2015, CANCER RES, V75, P1191, DOI 10.1158/0008-5472.CAN-14-2615; Liang YJ, 2015, CANCER RES, V75, P3672, DOI 10.1158/0008-5472.CAN-15-0930; Lin SY, 2012, SCIENCE, V336, P477, DOI 10.1126/science.1217032; Liu GM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1165-x; Liu MX, 2018, ONCOGENE, V37, P1637, DOI 10.1038/s41388-017-0070-6; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Ma RH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3508; Montal ED, 2015, MOL CELL, V60, P571, DOI 10.1016/j.molcel.2015.09.025; Nagel AK, 2015, ADV CANCER RES, V126, P137, DOI 10.1016/bs.acr.2014.12.003; Park SY, 2010, EMBO J, V29, P3787, DOI 10.1038/emboj.2010.254; Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x; Shay G, 2015, MATRIX BIOL, V44-46, P200, DOI 10.1016/j.matbio.2015.01.019; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Song ZM, 2020, P NATL ACAD SCI USA, V117, P21568, DOI 10.1073/pnas.1922330117; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tan M, 2019, MOL ONCOL, V13, P757, DOI 10.1002/1878-0261.12425; Tuo L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1029-y; Vieira P, 2017, MOL GENET METAB, V120, P337, DOI 10.1016/j.ymgme.2017.02.003; Wang LT, 2019, ONCOGENE, V38, P518, DOI 10.1038/s41388-018-0457-z; Wei X, 2019, ENDOCR-RELAT CANCER, V26, P141, DOI 10.1530/ERC-18-0193; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Xiang J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI144703; Yamaguchi N, 2019, ELIFE, V8, DOI 10.7554/eLife.52135; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yoshiji H, 2004, HEPATOLOGY, V39, P1517, DOI 10.1002/hep.20218; Zachara NE, 2004, BBA-GEN SUBJECTS, V1673, P13, DOI 10.1016/j.bbagen.2004.03.016; Zhu GZ, 2016, GLYCOBIOLOGY, V26, P820, DOI 10.1093/glycob/cww025; Zhu QQ, 2012, MED ONCOL, V29, P985, DOI 10.1007/s12032-011-9912-1; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	59	2	2	5	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6707	6719		10.1038/s41388-021-02058-z	http://dx.doi.org/10.1038/s41388-021-02058-z		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34650217	Green Published, hybrid			2022-12-28	WOS:000707295500001
J	Garcia-Rendueles, AR; Chenlo, M; Oroz-Gonjar, F; Solomou, A; Mistry, A; Barry, S; Gaston-Massuet, C; Garcia-Lavandeira, M; Perez-Romero, S; Suarez-Farina, M; Pradilla-Dieste, A; Dieguez, C; Mehlen, P; Korbonits, M; Alvarez, CV				Garcia-Rendueles, Angela R.; Chenlo, Miguel; Oroz-Gonjar, Fernando; Solomou, Antonia; Mistry, Anisha; Barry, Sayka; Gaston-Massuet, Carles; Garcia-Lavandeira, Montserrat; Perez-Romero, Sihara; Suarez-Farina, Maria; Pradilla-Dieste, Alberto; Dieguez, Carlos; Mehlen, Patrick; Korbonits, Marta; Alvarez, Clara, V			RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas	ONCOGENE			English	Article							RECEPTOR-INTERACTING-PROTEIN; PITUITARY-ADENOMA PREDISPOSITION; GENE-EXPRESSION; GROWTH-HORMONE; IN-SITU; MUTATIONS; CELLS; GH; APOPTOSIS; PATHWAY	It is unclear how loss-of-function germline mutations in the widely-expressed co-chaperone AIP, result in young-onset growth hormone secreting pituitary tumours. The RET receptor, uniquely co-expressed in somatotrophs with PIT1, induces apoptosis when unliganded, while RET supports cell survival when it is bound to its ligand. We demonstrate that at the plasma membrane, AIP is required to form a complex with monomeric-intracellular-RET, caspase-3 and PKC delta resulting in PIT1/CDKN2A-ARF/p53-apoptosis pathway activation. AIP-deficiency blocks RET/caspase-3/PKC delta activation preventing PIT1 accumulation and apoptosis. The presence or lack of the inhibitory effect on RET-induced apoptosis separated pathogenic AIP variants from non-pathogenic ones. We used virogenomics in neonatal rats to demonstrate the effect of mutant AIP protein on the RET apoptotic pathway in vivo. In adult male rats altered AIP induces elevated IGF-1 and gigantism, with pituitary hyperplasia through blocking the RET-apoptotic pathway. In females, pituitary hyperplasia is induced but IGF-1 rise and gigantism are blunted by puberty. Somatotroph adenomas from pituitary-specific Aip-knockout mice overexpress the RET-ligand GDNF, therefore, upregulating the survival pathway. Somatotroph adenomas from patients with or without AIP mutation abundantly express GDNF, but AIP-mutated tissues have less CDKN2A-ARF expression. Our findings explain the tissue-specific mechanism of AIP-induced somatotrophinomas and provide a previously unknown tumorigenic mechanism, opening treatment avenues for AIP-related tumours.	[Garcia-Rendueles, Angela R.; Chenlo, Miguel; Oroz-Gonjar, Fernando; Garcia-Lavandeira, Montserrat; Perez-Romero, Sihara; Suarez-Farina, Maria; Pradilla-Dieste, Alberto; Dieguez, Carlos; Alvarez, Clara, V] Univ Santiago de Compostela USC, Ctr Invest Med Mol & Enfermedades Cron CIMUS, Neoplasia & Endocrine Differentiat POL5, Santiago De Compostela, Spain; [Solomou, Antonia; Mistry, Anisha; Barry, Sayka; Gaston-Massuet, Carles; Korbonits, Marta] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Dept Endocrinol, London, England; [Mehlen, Patrick] Univ Lyon, Ctr Leon Berard, Patrick Mehlen Apoptosis Canc & Dev Lab Equipe La, INSERM U1052 CNRS UMR5286,LabEx DEVweCAN,Inst PLA, F-69008 Lyon, France	Universidade de Santiago de Compostela; University of London; Queen Mary University London; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Alvarez, CV (corresponding author), Univ Santiago de Compostela USC, Ctr Invest Med Mol & Enfermedades Cron CIMUS, Neoplasia & Endocrine Differentiat POL5, Santiago De Compostela, Spain.; Korbonits, M (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Dept Endocrinol, London, England.	m.korbonits@qmul.ac.uk; clara.alvarez@usc.es	Alvarez, Clara V/AAN-4173-2020	Garcia Lavandeira, Montserrat/0000-0001-9208-2418; Chenlo, Miguel Angel/0000-0002-1802-0021; Alvarez, Clara V/0000-0003-1500-4058; dieguez, carlos/0000-0002-0919-4337	Medical Research Council UK [MR/M018539/1/010550]; Agencia Estatal de Investigacion (AEI, Spain); European FEDER funds [PID2019-110437RB-I00]; Xunta de Galicia (Centro singular de investigacion de Galicia accreditation 2019-2022); European Union (European Regional Development Fund -ERDF)	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Agencia Estatal de Investigacion (AEI, Spain); European FEDER funds(European Commission); Xunta de Galicia (Centro singular de investigacion de Galicia accreditation 2019-2022); European Union (European Regional Development Fund -ERDF)	This work was supported by Medical Research Council UK MR/M018539/1/010550 QM project to MK (PI) and CVA, and by Agencia Estatal de Investigacion (AEI, Spain) with the participation of European FEDER funds PID2019-110437RB-I00 project to CVA. This work has received financial support from the Xunta de Galicia (Centro singular de investigacion de Galicia accreditation 2019-2022) and the European Union (European Regional Development Fund -ERDF).	Aflorei ED, 2018, J MED GENET, V55, P522, DOI 10.1136/jmedgenet-2017-105191; Andoniadou CL, 2013, CELL STEM CELL, V13, P433, DOI 10.1016/j.stem.2013.07.004; Awad S, 2018, END ABSTR, V59, pP127; Barry S, 2019, ONCOGENE, V38, P5381, DOI 10.1038/s41388-019-0779-5; Beckers A, 2013, ENDOCR REV, V34, P239, DOI 10.1210/er.2012-1013; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bizzi MF, 2018, MOL CELL ENDOCRINOL, V476, P103, DOI 10.1016/j.mce.2018.04.014; Bogner EM, 2020, INT J CANCER, V147, P3523, DOI 10.1002/ijc.33268; Bolger GB, 2016, ENDOCR-RELAT CANCER, V23, P419, DOI 10.1530/ERC-15-0205; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Cai F, 2013, EUR J ENDOCRINOL, V169, P867, DOI 10.1530/EJE-13-0442; Caimari, 2019, END ABSTR, V65; Canibano C, 2007, EMBO J, V26, P2015, DOI 10.1038/sj.emboj.7601636; Carty DM, 2021, PITUITARY, V24, P48, DOI 10.1007/s11102-020-01085-5; Cazabat L, 2012, J CLIN ENDOCR METAB, V97, pE663, DOI 10.1210/jc.2011-2291; Chen BJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01704-z; Chenlo M, 2019, EBIOMEDICINE, V43, P537, DOI 10.1016/j.ebiom.2019.04.007; Colao A, 2011, ENDOCR REV, V32, P247, DOI 10.1210/er.2010-0002; Costantini F, 2010, ORGANOGENESIS, V6, P252, DOI 10.4161/org.6.4.12680; Denes J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117107; Diaz-Rodriguez E, 2012, ONCOGENE, V31, P2824, DOI 10.1038/onc.2011.458; Diaz-Rodriguez E, 2014, ENDOCRINOLOGY, V155, P4329, DOI 10.1210/en.2014-1034; Formosa R, 2017, HORM CANCER-US, V8, P174, DOI 10.1007/s12672-017-0288-3; Fredriksson S, 2002, NAT BIOTECHNOL, V20, P473, DOI 10.1038/nbt0502-473; Gadelha MR, 2019, ENDOCR REV, V40, P268, DOI 10.1210/er.2018-00115; Garcia A, 2001, MOL ENDOCRINOL, V15, P1484, DOI 10.1210/me.15.9.1484; Garcia-Lavandeira M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004815; Garcia-Lavandeira M, 2015, NEUROENDOCRINOLOGY, V101, P175, DOI 10.1159/000375502; Garcia-Rendueles AR, 2017, ONCOGENE, V36, P652, DOI 10.1038/onc.2016.233; Gaston-Massuet C, 2008, DEV BIOL, V324, P322, DOI 10.1016/j.ydbio.2008.08.008; Gillam MP, 2017, J ENDOCR SOC, V1, P78, DOI 10.1210/js.2016-1004; Giustina A, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz096; Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235; Gremeaux L, 2012, STEM CELLS DEV, V21, P801, DOI 10.1089/scd.2011.0496; Guillou A, 2011, ENDOCRINOLOGY, V152, P515, DOI 10.1210/en.2010-0673; Hernandez-Ramirez Laura C, 2018, Oncotarget, V9, P9177, DOI 10.18632/oncotarget.24183; Hernandez-Ramirez LC, 2016, J CLIN ENDOCR METAB, V101, P3144, DOI 10.1210/jc.2016-1307; Hernandez-Ramirez LC, 2015, J CLIN ENDOCR METAB, V100, pE1242, DOI 10.1210/jc.2015-1869; Holden Paul, 2009, BMC Res Notes, V2, P243, DOI 10.1186/1756-0500-2-243; Hollingshead BD, 2004, J BIOL CHEM, V279, P45652, DOI 10.1074/jbc.M407840200; Igreja S, 2010, HUM MUTAT, V31, P950, DOI 10.1002/humu.21292; Iwata T, 2007, CLIN ENDOCRINOL, V66, P499, DOI 10.1111/j.1365-2265.2007.02758.x; Japon MA, 2002, J CLIN ENDOCR METAB, V87, P1879, DOI 10.1210/jc.87.4.1879; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P1117, DOI 10.1177/42.8.8027530; Jayakody SA, 2012, J CLIN INVEST, V122, P3635, DOI 10.1172/JCI64311; Jones TR, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-482; Kasuki L, 2012, ENDOCR-RELAT CANCER, V19, pL25, DOI 10.1530/ERC-12-0020; Korbonits, 2017, END ABSTR, V50; Lecoq AL, 2016, J ENDOCRINOL, V231, P59, DOI 10.1530/JOE-16-0190; Leontiou CA, 2008, J CLIN ENDOCR METAB, V93, P2390, DOI 10.1210/jc.2007-2611; Li JC, 2018, NUCLEIC ACIDS RES, V46, P7793, DOI 10.1093/nar/gky678; Lin BC, 2007, J BIOL CHEM, V282, P35924, DOI 10.1074/jbc.M705471200; Marques P, 2020, J CLIN ENDOCR METAB, V105, pE2247, DOI 10.1210/clinem/dgaa040; Martin-Rodriguez JF, 2015, SCI REP-UK, V5, DOI 10.1038/srep16298; Melin AD, 2005, J MAMMAL, V86, P1042, DOI 10.1644/1545-1542(2005)86[1042:MPGETI]2.0.CO;2; Morgan RML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053339; Negulescu AM, 2018, FEBS J, V285, P3909, DOI 10.1111/febs.14507; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Raitila A, 2010, AM J PATHOL, V177, P1969, DOI 10.2353/ajpath.2010.100138; Ramirez-Yanez GO, 2005, EUR J ORTHODONT, V27, P494, DOI 10.1093/ejo/cji028; Reyland ME, 2007, BIOCHEM SOC T, V35, P1001, DOI 10.1042/BST0351001; Ritvonen E, 2017, EUR J ENDOCRINOL, V176, P243, DOI 10.1530/EJE-16-0620; Rizzoti K, 2013, CELL STEM CELL, V13, P419, DOI 10.1016/j.stem.2013.07.006; Rostomyan L, 2015, ENDOCR-RELAT CANCER, V22, P745, DOI 10.1530/ERC-15-0320; Salzer E, 2013, BLOOD, V121, P3112, DOI 10.1182/blood-2012-10-460741; SASAKI F, 1988, ENDOCRINOLOGY, V122, P1622, DOI 10.1210/endo-122-4-1622; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Solloso A, 2008, J CELL PHYSIOL, V215, P140, DOI 10.1002/jcp.21295; Sun DJ, 2019, CELL REP, V27, P1461, DOI 10.1016/j.celrep.2019.04.014; Tuominen I, 2015, ONCOGENE, V34, P1174, DOI 10.1038/onc.2014.50; Urbano AG, 2000, ENDOCRINOLOGY, V141, P1893, DOI 10.1210/en.141.5.1893; Vargiolu M, 2009, J CLIN ENDOCR METAB, V94, P2571, DOI 10.1210/jc.2008-1980; Vierimaa O, 2006, SCIENCE, V312, P1228, DOI 10.1126/science.1126100; Villa C, 2011, ENDOCR-RELAT CANCER, V18, P347, DOI 10.1530/ERC-11-0059; Wang J, 2004, J ENDOCRINOL, V180, P247, DOI 10.1677/joe.0.1800247; Xekouki P, 2013, ENDOCR-RELAT CANCER, V20, pL11, DOI 10.1530/ERC-13-0218; Yamashita M, 2006, VIROLOGY, V344, P88, DOI 10.1016/j.virol.2005.09.012; Zatelli MC, 2013, PITUITARY, V16, P238, DOI 10.1007/s11102-012-0409-5; Zorn JA, 2012, J BIOL CHEM, V287, P33781, DOI 10.1074/jbc.M112.386128	80	3	3	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6354	6368		10.1038/s41388-021-02009-8	http://dx.doi.org/10.1038/s41388-021-02009-8		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34588620	Green Published, hybrid			2022-12-28	WOS:000701380400003
J	Vafaizadeh, V; Buechel, D; Rubinstein, N; Kalathur, RKR; Bazzani, L; Saxena, M; Valenta, T; Hausmann, G; Cantu, C; Basler, K; Christofori, G				Vafaizadeh, Vida; Buechel, David; Rubinstein, Natalia; Kalathur, Ravi K. R.; Bazzani, Lorenzo; Saxena, Meera; Valenta, Tomas; Hausmann, George; Cantu, Claudio; Basler, Konrad; Christofori, Gerhard			The interactions of Bcl9/Bcl9L with beta-catenin and Pygopus promote breast cancer growth, invasion, and metastasis	ONCOGENE			English	Article							EXPRESSION; CELLS; GENE; INACTIVATION; TRANSITION; ONCOGENE; DELETION; BCL9-2; MODEL; B9L	Canonical Wnt/beta-catenin signaling is an established regulator of cellular state and its critical contributions to tumor initiation, malignant tumor progression and metastasis formation have been demonstrated in various cancer types. Here, we investigated how the binding of beta-catenin to the transcriptional coactivators B-cell CLL/lymphoma 9 (Bcl9) and Bcl9-Like (Bcl9L) affected mammary gland carcinogenesis in the MMTV-PyMT transgenic mouse model of metastatic breast cancer. Conditional knockout of both Bcl9 and Bcl9L resulted into tumor cell death. In contrast, disrupting the interaction of Bcl9/Bcl9L with beta-catenin, either by deletion of their HD2 domains or by a point mutation in the N-terminal domain of beta-catenin (D164A), diminished primary tumor growth and tumor cell proliferation and reduced tumor cell invasion and lung metastasis. In comparison, the disruption of HD1 domain-mediated binding of Bcl9/Bcl9L to Pygopus had only moderate effects. Interestingly, interfering with the beta-catenin-Bcl9/Bcl9L-Pygo chain of adapters only partially impaired the transcriptional response of mammary tumor cells to Wnt3a and TGF beta treatments. Together, the results indicate that Bcl9/Bcl9L modulate but are not critically required for canonical Wnt signaling in its contribution to breast cancer growth and malignant progression, a notion consistent with the "just-right" hypothesis of Wnt-driven tumor progression.	[Vafaizadeh, Vida; Buechel, David; Kalathur, Ravi K. R.; Bazzani, Lorenzo; Saxena, Meera; Christofori, Gerhard] Univ Basel, Dept Biomed, Basel, Switzerland; [Rubinstein, Natalia] Univ Buenos Aires, Inst Biociencias Biotecnol & Biol Traslac, Dept Fisiol Biol Mol & Celular, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina; [Kalathur, Ravi K. R.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Bazzani, Lorenzo] Univ Siena, Dept Life Sci, Siena, Italy; [Valenta, Tomas; Hausmann, George; Basler, Konrad] Univ Zurich, Dept Mol Life Sci, Zurich, Switzerland; [Cantu, Claudio] Linkoping Univ, Wallenberg Ctr Mol Med, Linkoping, Sweden; [Cantu, Claudio] Linkoping Univ, Fac Med & Hlth Sci, Dept Biomed & Clin Sci, Div Mol Med & Virol, Linkoping, Sweden	University of Basel; University of Buenos Aires; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Siena; University of Zurich; Linkoping University; Linkoping University	Vafaizadeh, V; Christofori, G (corresponding author), Univ Basel, Dept Biomed, Basel, Switzerland.	vidavafaizadeh@gmail.com; gerhard.christofori@unibas.ch		Rubinstein, Natalia/0000-0002-5690-1516; Hausmann, George/0000-0002-2146-6665; Cantu, Claudio/0000-0003-1547-5415; Vafaizadeh, Vida/0000-0002-0875-6246	SystemsX.ch MTD project MetastasiX [2014/268]; Swiss National Science Foundation [310030B_163471]; Swiss National Science Foundation Sinergia [CRSII3_136274]; Knut and Alice Wallenberg Foundation; Cancerfonden [CAN 2018/542]; Universitat Basel (Universitatsbibliothek Basel)	SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss National Science Foundation Sinergia(Swiss National Science Foundation (SNSF)); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Cancerfonden(Swedish Cancer Society); Universitat Basel (Universitatsbibliothek Basel)	We acknowledge funding for this work by the SystemsX.ch MTD project MetastasiX (2014/268), a project grant by the Swiss National Science Foundation (310030B_163471), and the Swiss National Science Foundation Sinergia grant CRSII3_136274. CC is a WCMM fellow supported by the Knut and Alice Wallenberg Foundation and by Cancerfonden (CAN 2018/542). Open Access funding provided by Universitat Basel (Universitatsbibliothek Basel).	Andrews PGP, 2018, CELL REP, V23, P1516, DOI 10.1016/j.celrep.2018.04.020; Borrelli C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21591-9; Brault V, 2001, DEVELOPMENT, V128, P1253; Cantu C, 2018, GENE DEV, V32, P1443, DOI 10.1101/gad.315531.118; Cantu C, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4598; Cantu C, 2014, GENE DEV, V28, P1879, DOI 10.1101/gad.246140.114; Chaffer CL, 2007, CELLS TISSUES ORGANS, V185, P7, DOI 10.1159/000101298; de la Roche M, 2014, CANCER RES, V74, P1495, DOI 10.1158/0008-5472.CAN-13-2682; Deka J, 2010, CANCER RES, V70, P6619, DOI 10.1158/0008-5472.CAN-10-0148; Derynck R, 2019, DEV CELL, V49, P313, DOI 10.1016/j.devcel.2019.04.026; El-Hage P, 2015, MOL CANCER RES, V13, P902, DOI 10.1158/1541-7786.MCR-14-0180; Elsarraj HS, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-0157-z; Elsarraj HS, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0630-z; Feng M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau5240; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Gay DM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08586-3; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; He X, 2006, CELL, V127, P40, DOI 10.1016/j.cell.2006.09.016; Herr P, 2012, TRENDS MOL MED, V18, P483, DOI 10.1016/j.molmed.2012.06.008; Jia W, 2011, MOL CANCER RES, V9, P1732, DOI 10.1158/1541-7786.MCR-11-0245; Jiang M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13842-7; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katoh M, 2018, INT J MOL MED, V42, P713, DOI 10.3892/ijmm.2018.3689; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Li J, 2013, CELL REP, V5, P1650, DOI 10.1016/j.celrep.2013.11.037; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07193-w; Luna JM, 2017, MOL CELL, V67, P400, DOI 10.1016/j.molcel.2017.06.025; Mani M, 2009, CANCER RES, V69, P7577, DOI 10.1158/0008-5472.CAN-09-0773; Meyer-Schaller N, 2019, DEV CELL, V48, P539, DOI 10.1016/j.devcel.2018.12.023; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Mieszczanek J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08164-z; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Moor AE, 2015, EBIOMEDICINE, V2, P1932, DOI 10.1016/j.ebiom.2015.10.030; Moses H, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003277; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Parker DS, 2002, DEVELOPMENT, V129, P2565; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Sannino G, 2016, ONCOTARGET, V7, P73725, DOI 10.18632/oncotarget.12455; Saxena M, 2020, CANCER RES, V80, P3631, DOI 10.1158/0008-5472.CAN-19-2910; Saxena M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30640-1; Shang ZS, 2019, J BIOL CHEM, V294, P9844, DOI 10.1074/jbc.RA119.007655; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Toya H, 2007, CANCER SCI, V98, P484, DOI 10.1111/j.1349-7006.2007.00430.x; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Valenta T, 2011, GENE DEV, V25, P2631, DOI 10.1101/gad.181289.111; van Schie EH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00025; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Waldmeier L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048651; Xie Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054507; Xu WQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07978-z; Yang C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.356; Yang G, 2020, NANOTECHNOLOGY, V31, DOI 10.1088/1361-6528/ab5a03; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Zatula N, 2014, ONCOTARGET, V5, P6770, DOI 10.18632/oncotarget.2252; Zhang Y, 2018, LIFE SCI, V208, P284, DOI 10.1016/j.lfs.2018.07.023; Zimmerli D, 2020, ELIFE, V9, DOI 10.7554/eLife.58123	58	4	4	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6195	6209		10.1038/s41388-021-02016-9	http://dx.doi.org/10.1038/s41388-021-02016-9		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34545187	Green Published, hybrid			2022-12-28	WOS:000698130400001
J	Gao, YF; Jiang, M; Guo, FQ; Liu, XJ; Zhang, Q; Yang, S; Yeung, YT; Yang, R; Wang, KK; Wu, Q; Zhang, DD; Zhang, CJ; Laster, KV; Ge, MM; Nie, WN; Liu, KD; Dong, ZG				Gao, Yunfeng; Jiang, Ming; Guo, Fangqin; Liu, Xuejiao; Zhang, Qi; Yang, Sen; Yeung, Yiu To; Yang, Ran; Wang, Keke; Wu, Qiong; Zhang, Dandan; Zhang, Chengjuan; Laster, Kyle Vaughn; Ge, Mengmeng; Nie, Wenna; Liu, Kangdong; Dong, Zigang			A novel lncRNA MTAR1 promotes cancer development through IGF2BPs mediated post-transcriptional regulation of c-MYC	ONCOGENE			English	Article							MESSENGER-RNA STABILITY; LIQUID PHASE-SEPARATION; LONG NONCODING RNA; ONCOGENE; CONTRIBUTES; GROWTH	Abnormal translation of the MYC proto-oncogene is a hallmark of the initiation and maintenance of tumorigenesis. However, the molecular mechanism underlying increased MYC protein levels in certain cancer types without a corresponding increase in MYC mRNA levels is unclear. Here, we identified a novel lncRNA, MTAR1, which is critical for post-transcriptional regulation of MYC-induced tumorigenesis. MTAR1 is essential for recruiting IGF2BPs into PABP1-mediated liquid-liquid phase separation (LLPS) complexes and facilitates IGF2BPs-mediated MYC mRNA translation. MTAR1 enhanced binding between IGF2BPs and PABP1, thereby promoting MYC mRNA stability and increased MYC mRNA translation. In summary, MTAR1 is a novel MYC-related lncRNA that contributes to tumor progression by enhancing MYC translation through mediating PABP1/IGF2BPs liquid-liquid phase separation.	[Gao, Yunfeng; Jiang, Ming; Guo, Fangqin; Liu, Xuejiao; Zhang, Qi; Yang, Sen; Yang, Ran; Wang, Keke; Wu, Qiong; Zhang, Dandan; Laster, Kyle Vaughn; Ge, Mengmeng; Nie, Wenna; Liu, Kangdong; Dong, Zigang] China US Henan Hormel Canc Inst, Zhengzhou 450000, Peoples R China; [Liu, Xuejiao; Wu, Qiong; Liu, Kangdong; Dong, Zigang] Zhengzhou Univ, Sch Basic Med Sci, Pathophysiol Dept, AMS, Zhengzhou 450000, Peoples R China; [Yeung, Yiu To] Univ Edinburgh, Ctr Reprod Hlth, Queens Med Res Inst, Med Res Council MRC, Edinburgh EH16 4TJ, Midlothian, Scotland; [Zhang, Chengjuan] Henan Canc Hosp, Dept Mol Pathol Cent Biorepository, Zhengzhou 450000, Peoples R China; [Liu, Kangdong; Dong, Zigang] Canc Chemoprevent Int Collaborat Lab, Zhengzhou 450000, Peoples R China; [Liu, Kangdong; Dong, Zigang] State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450000, Peoples R China	Zhengzhou University; University of Edinburgh; Zhengzhou University	Liu, KD; Dong, ZG (corresponding author), China US Henan Hormel Canc Inst, Zhengzhou 450000, Peoples R China.; Liu, KD; Dong, ZG (corresponding author), Zhengzhou Univ, Sch Basic Med Sci, Pathophysiol Dept, AMS, Zhengzhou 450000, Peoples R China.; Liu, KD; Dong, ZG (corresponding author), Canc Chemoprevent Int Collaborat Lab, Zhengzhou 450000, Peoples R China.; Liu, KD; Dong, ZG (corresponding author), State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450000, Peoples R China.	kdliu@hci-cn.org; zgdong@hci-cn.org	Jiang, Ming/GSE-4312-2022	Jiang, Ming/0000-0001-6794-3116	National Natural Science Foundations of China [81872335, 81802875, 81972639]; Project of Science and Technology of the Henan Province for Tackling Key Problems [182102310128]	National Natural Science Foundations of China(National Natural Science Foundation of China (NSFC)); Project of Science and Technology of the Henan Province for Tackling Key Problems	This research is supported by the National Natural Science Foundations of China (No. 81802876), the Project of Science and Technology of the Henan Province for Tackling Key Problems (182102310128) and the National Natural Science Foundations of China (Nos. 81872335, 81802875, 81972639).	Aguzzi A, 2016, TRENDS CELL BIOL, V26, P547, DOI 10.1016/j.tcb.2016.03.004; Bachireddy P, 2012, CLIN EXP IMMUNOL, V167, P188, DOI 10.1111/j.1365-2249.2011.04514.x; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Bolha L, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/7243968; Borzi C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2003-5; Brangwynne CP, 2009, SCIENCE, V324, P1729, DOI 10.1126/science.1172046; Bridges MC, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202009045; Cai DF, 2019, NAT CELL BIOL, V21, P1578, DOI 10.1038/s41556-019-0433-z; Cao JG, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/4217259; Casey SC, 2018, BLOOD, V131, P2007, DOI 10.1182/blood-2017-11-742577; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Emst C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00168; Esposito M, 2021, NAT CELL BIOL, V23, P257, DOI 10.1038/s41556-021-00641-w; Fox AH, 2018, TRENDS BIOCHEM SCI, V43, P124, DOI 10.1016/j.tibs.2017.12.001; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Guo CJ, 2020, CELL, V181, P621, DOI 10.1016/j.cell.2020.03.006; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Hunecke D, 2012, J PATHOL, V228, P520, DOI 10.1002/path.4059; Hyman AA, 2014, ANNU REV CELL DEV BI, V30, P39, DOI 10.1146/annurev-cellbio-100913-013325; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Labun K, 2019, NUCLEIC ACIDS RES, V47, pW171, DOI 10.1093/nar/gkz365; Lian Y, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317715804; Liu Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102621; Lu Y, 2020, NAT CELL BIOL, V22, DOI 10.1038/s41556-020-0485-0; Marderosian M, 2006, ONCOGENE, V25, P6277, DOI 10.1038/sj.onc.1209645; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Patel GP, 2005, NUCLEIC ACIDS RES, V33, P7074, DOI 10.1093/nar/gki1014; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sauvageau M, 2019, ADV EXP MED BIOL, V1203, P285, DOI 10.1007/978-3-030-31434-7_10; Tsang B, 2020, CELL, V183, P1742, DOI 10.1016/j.cell.2020.11.050; Wang JY, 2018, CANCER LETT, V419, P64, DOI 10.1016/j.canlet.2018.01.051; Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556-019-0311-8; Yu YF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2149; Zaslavsky BY, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090473; Zhang H, 2020, SCI CHINA LIFE SCI, V63, P953, DOI 10.1007/s11427-020-1702-x; Zhang K, 2020, MOL CANCER RES, V18, P612, DOI 10.1158/1541-7786.MCR-19-0805; Zhou HX, 2018, TRENDS BIOCHEM SCI, V43, P499, DOI 10.1016/j.tibs.2018.03.007; Zhou W, 2021, MOL CELL, V81, P739, DOI 10.1016/j.molcel.2021.01.024; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	46	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4736	4753		10.1038/s41388-022-02464-x	http://dx.doi.org/10.1038/s41388-022-02464-x		SEP 2022	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36109629				2022-12-28	WOS:000854052400001
J	Vulin, M; Jehanno, C; Sethi, A; Correia, AL; Obradovic, MMS; Couto, JP; Coissieux, MM; Diepenbruck, M; Preca, BT; Volkmann, K; Maur, PAD; Schmidt, A; Munst, S; Sauteur, L; Kloc, M; Palafox, M; Britschgi, A; Unterreiner, V; Galuba, O; Claerr, I; Lopez-Romero, S; Galli, GG; Baeschlin, D; Okamoto, R; Soysal, SD; Mechera, R; Weber, WP; Radimerski, T; Bentires-Alj, M				Vulin, Milica; Jehanno, Charly; Sethi, Atul; Correia, Ana Luisa; Obradovic, Milan M. S.; Couto, Joana Pinto; Coissieux, Marie-May; Diepenbruck, Maren; Preca, Bogdan-Tiberius; Volkmann, Katrin; Maur, Priska Auf Der; Schmidt, Alexander; Munst, Simone; Sauteur, Loic; Kloc, Michal; Palafox, Marta; Britschgi, Adrian; Unterreiner, Vincent; Galuba, Olaf; Claerr, Isabelle; Lopez-Romero, Sandra; Galli, Giorgio G.; Baeschlin, Daniel; Okamoto, Ryoko; Soysal, Savas D.; Mechera, Robert; Weber, Walter P.; Radimerski, Thomas; Bentires-Alj, Mohamed			A high-throughput drug screen reveals means to differentiate triple-negative breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; HISTONE DEACETYLASE INHIBITOR; MAMMARY-GLAND DEVELOPMENT; STEM-CELL; GENE-EXPRESSION; ER; ACTIVATION; TRANSCRIPTION; MULTIPOTENCY; REACTIVATION	Plasticity delineates cancer subtypes with more or less favourable outcomes. In breast cancer, the subtype triple-negative lacks expression of major differentiation markers, e.g., estrogen receptor alpha (ER alpha), and its high cellular plasticity results in greater aggressiveness and poorer prognosis than other subtypes. Whether plasticity itself represents a potential vulnerability of cancer cells is not clear. However, we show here that cancer cell plasticity can be exploited to differentiate triple-negative breast cancer (TNBC). Using a high-throughput imaging-based reporter drug screen with 9 501 compounds, we have identified three polo-like kinase 1 (PLK1) inhibitors as major inducers of ER alpha protein expression and downstream activity in TNBC cells. PLK1 inhibition upregulates a cell differentiation program characterized by increased DNA damage, mitotic arrest, and ultimately cell death. Furthermore, cells surviving PLK1 inhibition have decreased tumorigenic potential, and targeting PLK1 in already established tumours reduces tumour growth both in cell line- and patient-derived xenograft models. In addition, the upregulation of genes upon PLK1 inhibition correlates with their expression in normal breast tissue and with better overall survival in breast cancer patients. Our results indicate that differentiation therapy based on PLK1 inhibition is a potential alternative strategy to treat TNBC.	[Vulin, Milica; Jehanno, Charly; Sethi, Atul; Correia, Ana Luisa; Obradovic, Milan M. S.; Couto, Joana Pinto; Coissieux, Marie-May; Diepenbruck, Maren; Preca, Bogdan-Tiberius; Volkmann, Katrin; Maur, Priska Auf Der; Sauteur, Loic; Kloc, Michal; Palafox, Marta; Okamoto, Ryoko; Bentires-Alj, Mohamed] Univ Basel, Univ Hosp Basel, Dept Biomed, Dept Surg, Basel, Switzerland; [Vulin, Milica; Sethi, Atul; Correia, Ana Luisa; Obradovic, Milan M. S.; Couto, Joana Pinto; Coissieux, Marie-May; Britschgi, Adrian; Okamoto, Ryoko; Bentires-Alj, Mohamed] Friedrich Miescher Inst Biomed Res, Basel, Switzerland; [Sethi, Atul; Kloc, Michal] Swiss Inst Bioinformat, Basel, Switzerland; [Schmidt, Alexander] Univ Basel, Biozentrum, Prote Core Facil, Basel, Switzerland; [Munst, Simone] Univ Basel, Univ Hosp Basel, Inst Pathol & Med Genet, Basel, Switzerland; [Unterreiner, Vincent; Galuba, Olaf; Claerr, Isabelle; Lopez-Romero, Sandra; Galli, Giorgio G.; Baeschlin, Daniel; Radimerski, Thomas] Novartis Inst Biomed Res, Basel, Switzerland; [Soysal, Savas D.; Mechera, Robert; Weber, Walter P.] Univ Basel, Univ Hosp Basel, Dept Surg, Basel, Switzerland; [Soysal, Savas D.; Mechera, Robert; Weber, Walter P.] Univ Basel, Univ Hosp Basel, Breast Canc Ctr, Basel, Switzerland	University of Basel; Friedrich Miescher Institute for Biomedical Research; Swiss Institute of Bioinformatics; University of Basel; University of Basel; Novartis; University of Basel; University of Basel	Bentires-Alj, M (corresponding author), Univ Basel, Univ Hosp Basel, Dept Biomed, Dept Surg, Basel, Switzerland.; Bentires-Alj, M (corresponding author), Friedrich Miescher Inst Biomed Res, Basel, Switzerland.	m.bentires-alj@unibas.ch		Correia, Ana Luisa/0000-0003-2414-0131; Coissieux, Marie-May/0000-0001-5017-5253; Vulin, Milica/0000-0002-7686-5102	University of Basel	University of Basel	Open access funding provided by University of Basel.	Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Ahrne E, 2016, J PROTEOME RES, V15, P2537, DOI 10.1021/acs.jproteome.6b00066; Archey WB, 2002, ONCOGENE, V21, P7034, DOI 10.1038/sj.onc.1205844; Arozarena I, 2019, NAT REV CANCER, V19, P377, DOI 10.1038/s41568-019-0154-4; Bahreini A, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0851-4; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bayliss J, 2007, CLIN CANCER RES, V13, P7029, DOI 10.1158/1078-0432.CCR-07-0587; Berto M, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800055; Boumahdi S, 2020, NAT REV DRUG DISCOV, V19, P39, DOI 10.1038/s41573-019-0044-1; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023; Canham SM, 2020, CELL CHEM BIOL, V27, P1124, DOI 10.1016/j.chembiol.2020.07.004; Cascio S, 2007, J BIOL CHEM, V282, P3498, DOI 10.1074/jbc.M606244200; Chi D, 2019, P NATL ACAD SCI USA, V116, P11437, DOI 10.1073/pnas.1819155116; Clarke RB, 1997, CANCER RES, V57, P4987; Clevers H, 2018, ANNU REV BIOCHEM, V87, P1015, DOI 10.1146/annurev-biochem-062917-012341; Cottu P, 2012, BREAST CANCER RES TR, V133, P595, DOI 10.1007/s10549-011-1815-5; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de Carcer G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05429-5; de The H, 2018, NAT REV CANCER, V18, P117, DOI 10.1038/nrc.2017.103; de The H, 2010, NAT REV CANCER, V10, P775, DOI 10.1038/nrc2943; Dekoninck S, 2019, NAT CELL BIOL, V21, P18, DOI 10.1038/s41556-018-0237-6; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Di Cosimo S, 2020, LANCET, V396, P1046, DOI 10.1016/S0140-6736(20)31962-0; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; Ding Y, 2011, CANCER RES, V71, P5225, DOI 10.1158/0008-5472.CAN-11-0076; Du J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035957; Duss S, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1734; Ershov D, 2022, NAT METHODS, V19, P829, DOI 10.1038/s41592-022-01507-1; Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x; Farcas AM, 2021, ENDOCRINOLOGY, V162, DOI 10.1210/endocr/bqaa224; FERGUSON AT, 1995, CANCER RES, V55, P2279; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011; Hait NC, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.16; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Howlader N, 2018, CANCER EPIDEM BIOMAR, V27, P619, DOI 10.1158/1055-9965.EPI-17-0627; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Ishay-Ronen D, 2019, CANCER CELL, V35, P17, DOI 10.1016/j.ccell.2018.12.002; Jehanno C., 2022, TRENDS CELL BIOL, VS0962-8924, P00079, DOI [10.1016/j.tcb.2022.03.007, DOI 10.1016/J.TCB.2022.03.007]; Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koren S, 2015, NATURE, V525, P114, DOI 10.1038/nature14669; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lapidus RG, 1998, CANCER RES, V58, P2515; Levin-Allerhand JA, 2003, CONTEMP TOP LAB ANIM, V42, P33; Li JY, 2020, CANCER RES, V80, P4037, DOI 10.1158/0008-5472.CAN-20-1420; Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708; Lu LY, 2008, MOL CELL BIOL, V28, P6870, DOI 10.1128/MCB.00392-08; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; Molinuevo R, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202001063; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023; Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369; Restall C, 2009, INT J CANCER, V125, P483, DOI 10.1002/ijc.24350; Risom T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05729-w; Santos MA, 2014, NATURE, V514, P107, DOI 10.1038/nature13483; Sanz-Gomez N, 2020, CELL DEATH DIFFER, V27, P2451, DOI 10.1038/s41418-020-0515-2; Sappok A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-8; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmidt U, 2018, LECT NOTES COMPUT SC, V11071, P265, DOI 10.1007/978-3-030-00934-2_30; Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; Siersbaek R, 2018, GENE DEV, V32, P1141, DOI 10.1101/gad.316646.118; Slepicka PF, 2021, SEMIN CELL DEV BIOL, V114, P93, DOI 10.1016/j.semcdb.2020.09.014; Tanos T, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3166; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; Varga J, 2017, NAT CELL BIOL, V19, P1133, DOI 10.1038/ncb3611; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wahl GM, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0012-z; Wang JW, 2012, CELL, V148, P1001, DOI 10.1016/j.cell.2012.01.040; Wang YX, 2011, PROTEOMICS, V11, P2019, DOI 10.1002/pmic.201000722; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890; Yuan S, 2019, CANCER DISCOV, V9, P837, DOI 10.1158/2159-8290.CD-19-0015; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x; Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549; ZHOU YY, 2019, NAT COMMUN, V10, DOI [10.1038/S41467-019-09234-6, DOI 10.1038/s41587-020-0546-8, DOI 10.1038/S41467-019-09234-6]; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	82	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4459	4473		10.1038/s41388-022-02429-0	http://dx.doi.org/10.1038/s41388-022-02429-0		AUG 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	36008466	Green Published, hybrid			2022-12-28	WOS:000844588600001
J	Liu, C; Wang, JL; Zheng, YJ; Zhu, Y; Zhou, ZH; Liu, ZY; Lin, CD; Wan, YY; Wen, YT; Liu, CY; Yuan, MY; Zeng, YARA; Yan, ZJ; Ge, GX; Chen, JF				Liu, Cui; Wang, JunLei; Zheng, YaJuan; Zhu, Yue; Zhou, ZhengHang; Liu, ZhaoYuan; Lin, ChangDong; Wan, YaoYing; Wen, YaTing; Liu, ChunYe; Yuan, MengYa; Zeng, Yi Arial; Yan, ZhanJun; Ge, GaoXiang; Chen, JianFeng			Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin alpha v beta 3	ONCOGENE			English	Article							ASPARAGINYL ENDOPEPTIDASE; ALPHA(V)BETA(3) INTEGRIN; THERAPEUTIC TARGETS; MAMMALIAN LEGUMAIN; BONE METASTASIS; OUTSIDE-IN; EXPRESSION; ACTIVATION; PROSTATE; PATHWAYS	Tumor metastasis is the leading cause of cancer-associated mortality. Unfortunately, the underlying mechanism of metastasis is poorly understood. Expression of legumain (LGMN), an endo-lysosomal cysteine protease, positively correlates with breast cancer metastatic progression and poor prognosis. Here, we report that LGMN is secreted in the zymogen form by motile breast cancer cells. Through binding to cell surface integrin alpha v beta 3 via an RGD motif, the autocrine pro-LGMN activates FAK-Src-RhoA signaling in cancer cells and promotes cancer cell migration and invasion independent of LGMN protease activity. Either silencing LGMN expression or mutationally abolishing pro-LGMN-alpha v beta 3 interaction significantly inhibits cancer cell migration and invasion in vitro and breast cancer metastasis in vivo. Finally, we developed a monoclonal antibody against LGMN RGD motif, which blocks pro-LGMN-alpha v beta 3 binding, and effectively suppresses cancer cell migration and invasion in vitro and breast cancer metastasis in vivo. Thus, disruption of pro-LGMN-integrin alpha v beta 3 interaction may be a potentially promising strategy for treating breast cancer metastasis.	[Liu, Cui; Wang, JunLei; Zheng, YaJuan; Zhu, Yue; Liu, ZhaoYuan; Wan, YaoYing; Wen, YaTing; Liu, ChunYe; Yuan, MengYa; Zeng, Yi Arial; Ge, GaoXiang; Chen, JianFeng] Chinese Acad Sci, State Key Lab Cell Biol, Shanghai Inst Biochem & Cell Biol, Ctr Excellence Mol Cell Sci,Univ Chinese Acad Sci, Shanghai 200031, Peoples R China; [Zhou, ZhengHang; Zeng, Yi Arial; Ge, GaoXiang; Chen, JianFeng] Univ Chinese Acad Sci, Sch Life Sci, Hangzhou Inst Adv Study, Key Lab Syst Hlth Sci Zhejiang Prov, Hangzhou 310024, Peoples R China; [Lin, ChangDong] Tongji Univ, Sch Life Sci & Technol, Orthopaed Dept,Tongji Hosp, Minist Educ,Key Lab Spine & Spinal Cord Injury Re, Shanghai 200092, Peoples R China; [Yan, ZhanJun] Soochow Univ, Suzhou Peoples Hosp 9, Dept Orthoped, Suzhou 215000, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Tongji University; Soochow University - China	Ge, GX; Chen, JF (corresponding author), Chinese Acad Sci, State Key Lab Cell Biol, Shanghai Inst Biochem & Cell Biol, Ctr Excellence Mol Cell Sci,Univ Chinese Acad Sci, Shanghai 200031, Peoples R China.; Ge, GX; Chen, JF (corresponding author), Univ Chinese Acad Sci, Sch Life Sci, Hangzhou Inst Adv Study, Key Lab Syst Hlth Sci Zhejiang Prov, Hangzhou 310024, Peoples R China.; Yan, ZJ (corresponding author), Soochow Univ, Suzhou Peoples Hosp 9, Dept Orthoped, Suzhou 215000, Peoples R China.	yanzhanjun2010@163.com; gxge@sibcb.ac.cn; jfchen@sibcb.ac.cn			National Key Research and Development Program of China [2020YFA0509102, 2020YFA0803203]; National Natural Science Foundation of China [31970702, 32030024, 31830112, 31525016, 32070789]; Program of Shanghai Academic Research Leader [19XD1404200]; National Ten Thousand Talents Program; SA-SIBS scholarship program	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of Shanghai Academic Research Leader; National Ten Thousand Talents Program; SA-SIBS scholarship program	This work was supported by grants from National Key Research and Development Program of China (2020YFA0509102 to J.F.C., 2020YFA0803203 to G.X.G.), National Natural Science Foundation of China (31970702 to C.D.L., 32030024, 31830112, 31525016 to J.F.C., 32070789 to G.X.G.). Program of Shanghai Academic Research Leader (19XD1404200), National Ten Thousand Talents Program. The authors gratefully acknowledge the support of SA-SIBS scholarship program.	Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Braulke T, 2009, BBA-MOL CELL RES, V1793, P605, DOI 10.1016/j.bbamcr.2008.10.016; Briggs JJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-17; Brooks SA, 2010, ACTA HISTOCHEM, V112, P3, DOI 10.1016/j.acthis.2008.11.022; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Carreiras F, 1996, GYNECOL ONCOL, V62, P260, DOI 10.1006/gyno.1996.0225; Chen JM, 2001, BIOL CHEM, V382, P777, DOI 10.1515/BC.2001.093; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Cooper J, 2019, CANCER CELL, V35, P347, DOI 10.1016/j.ccell.2019.01.007; Dall E, 2016, BIOCHIMIE, V122, P126, DOI 10.1016/j.biochi.2015.09.022; Dall E, 2013, P NATL ACAD SCI USA, V110, P10940, DOI 10.1073/pnas.1300686110; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; Futakuchi M, 2016, ADV DRUG DELIVER REV, V99, P206, DOI 10.1016/j.addr.2015.11.017; Gawenda J, 2007, BREAST CANCER RES TR, V102, P1, DOI 10.1007/s10549-006-9311-z; Gehler S, 2013, CRIT REV EUKAR GENE, V23, P139, DOI 10.1615/CritRevEukarGeneExpr.2013006647; Guo PT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073090; Haeger A, 2020, J EXP MED, V217, DOI 10.1084/jem.20181184; Haugen MH, 2015, EUR J CANCER, V51, P9, DOI 10.1016/j.ejca.2014.10.020; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Karagiannis GS, 2014, MOL ONCOL, V8, P178, DOI 10.1016/j.molonc.2013.10.008; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Liao D, 2011, NANOMED-NANOTECHNOL, V7, P665, DOI 10.1016/j.nano.2011.03.001; Lin YY, 2013, CANCER SCI, V104, P1217, DOI 10.1111/cas.12202; Liu Y, 2012, MOL PHARMACEUT, V9, P168, DOI 10.1021/mp200434n; Lu L, 2016, J BIOL CHEM, V291, P10363, DOI 10.1074/jbc.M116.717694; Maire V, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0063712, 10.1371/journal.pone.0077372]; Maire V, 2013, CANCER RES, V73, P813, DOI 10.1158/0008-5472.CAN-12-2633; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Maubant S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122333; McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429; Meng F, 2015, ONCOL RES, V23, P7, DOI 10.3727/096504015X14410238486649; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Murthy RV, 2005, CLIN CANCER RES, V11, P2293, DOI 10.1158/1078-0432.CCR-04-1642; Nagalla S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r34; Nakashima Y, 2013, CANCER SCI, V104, P1718, DOI 10.1111/cas.12286; Natali PG, 1997, CANCER RES, V57, P1554; Ohno Y, 2013, WORLD J UROL, V31, P359, DOI 10.1007/s00345-012-0977-z; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qi Q, 2017, J MED CHEM, V60, P7244, DOI 10.1021/acs.jmedchem.7b00228; Richardson AM, 2018, CLIN CANCER RES, V24, P420, DOI 10.1158/1078-0432.CCR-17-1776; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Sepulveda FE, 2009, IMMUNITY, V31, P737, DOI 10.1016/j.immuni.2009.09.013; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Upheber S, 2015, CELL SIGNAL, V27, P652, DOI 10.1016/j.cellsig.2014.11.028; van der Horst G, 2011, NEOPLASIA, V13, P516, DOI 10.1593/neo.11122; Mercedes SVA, 2021, NAT REV CANCER, V21, P592, DOI 10.1038/s41568-021-00376-8; Wang LN, 2012, J CELL BIOCHEM, V113, P2679, DOI 10.1002/jcb.24143; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Westcott JM, 2015, J CLIN INVEST, V125, P1927, DOI 10.1172/JCI77767; Wu WY, 2006, CANCER RES, V66, P970, DOI 10.1158/0008-5472.CAN-05-2591; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang CX, 2019, ONCOGENE, V38, P7113, DOI 10.1038/s41388-019-0899-y; Zeltz C, 2020, SEMIN CANCER BIOL, V62, P166, DOI 10.1016/j.semcancer.2019.08.004; Zhao LX, 2014, CELL RES, V24, P344, DOI 10.1038/cr.2014.4; Zhu JQ, 2007, BLOOD, V110, P2475, DOI 10.1182/blood-2007-03-080077	59	0	0	9	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2022	41	34					4091	4103		10.1038/s41388-022-02409-4	http://dx.doi.org/10.1038/s41388-022-02409-4		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3W0LE	35854065				2022-12-28	WOS:000827369300001
J	You, A; Wei,; Yuan, HF; Gu, LK; Zhou, J; Deng, DJ				You, Abin; Tian, Wei; Yuan, Hongfan; Gu, Liankun; Zhou, Jing; Deng, Dajun			TTC22 promotes m6A-mediated WTAP expression and colon cancer metastasis in an RPL4 binding-dependent pattern	ONCOGENE			English	Article							MESSENGER-RNA METHYLATION; GENE-EXPRESSION; PROTEIN L4; M(6)A; N-6-METHYLADENOSINE; COMPLEX	WTAP, an essential component of the RNA N-6-methyladenosine (m6A) modification complex, guides METLL3-METLL14 heteroduplexes to target RNAs in the nuclear speckles of mammalian cells. Here, we show that TTC22 is widely coexpressed with WTAP and FTO in many human tissues by mining Genotype-Tissue Expression (GTEx) datasets. Our results indicate that the direct interaction of TTC22 with 60S ribosomal protein L4 (RPL4) promotes the binding of WTAP mRNA to RPL4, enhances the stability and translation efficiency of WTAP mRNA, and consequently increases the level of WTAP protein. Also, WTAP mRNA itself is an m6A target and YTHDF1 is characterized as an essential m6A binding protein interacting with m6A-modified WTAP mRNA. TTC22 triggers a positive feedback loop between WTAP expression and WTAP mRNA m6A modification, leading to an increased m6A level in total RNA. The knockdown of RPL4, WTAP, or YTHDF1 expression diminishes the TTC22-induced increase in the m6A level of total RNA. Thus, TTC22 caused dramatic expression changes in genes related to metabolic pathways, ribosomal biogenesis, the RNA spliceosome, and microorganism infections. Importantly, TTC22 upregulates the expression of SNAI1 by increasing m6A level and thus promotes lung metastases of colon cancer cells in mice. In conclusion, our study showed that TTC22 upregulates WTAP and SNAI1 expression, which contributes to TTC22-induced colon cancer metastasis.	[You, Abin; Tian, Wei; Yuan, Hongfan; Gu, Liankun; Zhou, Jing; Deng, Dajun] Peking Univ Canc Hosp & Inst, Div Etiol, Key Lab Carcinogenesis & Translat Res MOE Beijing, Beijing 100142, Peoples R China; [You, Abin] Xiamen Univ, Affiliated Hosp 1, Xiamen Key Lab Antitumor Drug Transformat Res, Dept Med Oncol, Xiamen 361003, Fujian, Peoples R China; [Deng, Dajun] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 211166, Peoples R China	Xiamen University; Nanjing Medical University	Wei,; Deng, DJ (corresponding author), Peking Univ Canc Hosp & Inst, Div Etiol, Key Lab Carcinogenesis & Translat Res MOE Beijing, Beijing 100142, Peoples R China.; Deng, DJ (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 211166, Peoples R China.	tianwei@bjmu.edu.cn; dengdajun@bjmu.edu.cn	Deng, Dajun/D-4605-2009	Deng, Dajun/0000-0001-5161-5943	National Natural Science Foundation of China [81372592]; Beijing Hospitals Authority' Mission Plan [SML20191101]; Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation; Fundamental Research Funds for the Central Universities [BMU2020PY005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Hospitals Authority' Mission Plan; Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by grants from the National Natural Science Foundation of China (81372592) and from Beijing Hospitals Authority' Mission Plan (SML20191101) to DD and by a grant from the Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation and the Fundamental Research Funds for the Central Universities (BMU2020PY005) to WT. An Open access license has not been selected.	Agarwala SD, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002732; Capalbo L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12507-9; Chung DD, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107696; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Frye M, 2018, SCIENCE, V361, P1346, DOI 10.1126/science.aau1646; Geula S, 2015, SCIENCE, V347, P1002, DOI 10.1126/science.1261417; He X, 2016, ONCOTARGET, V7, P16217, DOI 10.18632/oncotarget.7479; Horiuchi K, 2013, J BIOL CHEM, V288, P33292, DOI 10.1074/jbc.M113.500397; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Li A, 2017, CELL RES, V27, P444, DOI 10.1038/cr.2017.10; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Ma WR, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01150-4; McFadden MJ, 2021, TRENDS BIOCHEM SCI, V46, P366, DOI 10.1016/j.tibs.2020.11.008; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Miao CG, 2015, IMMUNOL LETT, V166, P45, DOI 10.1016/j.imlet.2015.05.011; Niu Yamei, 2013, Genomics Proteomics & Bioinformatics, V11, P8, DOI 10.1016/j.gpb.2012.12.002; Panneerdoss S, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar8263; Pillet B, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005565; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Pringle Eric S, 2019, Curr Protoc Mol Biol, V125, pe79, DOI 10.1002/cpmb.79; Schwartz S, 2014, CELL REP, V8, P284, DOI 10.1016/j.celrep.2014.05.048; Shen B, 2013, CELL RES, V23, P720, DOI 10.1038/cr.2013.46; Shen CL, 2016, P NATL ACAD SCI USA, V113, P2229, DOI 10.1073/pnas.1525444113; Shi YL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12801-6; Soerensen M, 2019, BIOGERONTOLOGY, V20, P627, DOI 10.1007/s10522-019-09818-1; Sorci M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0843-z; Stransky N, 2015, NATURE, V528, P84, DOI 10.1038/nature15736; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tian W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0925-y; Wang X, 2017, RNA BIOL, V14, P300, DOI 10.1080/15476286.2017.1282025; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Xiang MY, 2020, EPIGENOMICS-UK, V12, P801, DOI 10.2217/epi-2019-0358; Yang YCT, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1273-2; Zeytuni N, 2012, STRUCTURE, V20, P397, DOI 10.1016/j.str.2012.01.006; Zhao B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09060-w; Zhao BXS, 2017, NAT REV MOL CELL BIO, V18, P31, DOI 10.1038/nrm.2016.132; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015	43	1	1	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3925	3938		10.1038/s41388-022-02402-x	http://dx.doi.org/10.1038/s41388-022-02402-x		JUL 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35798874	Green Submitted			2022-12-28	WOS:000821721300003
J	Xu, H; Jin, J; Chen, Y; Wu, GQ; Zhu, H; Wang, Q; Wang, J; Li, SG; Grigore, FN; Ma, J; Chen, CC; Lan, Q; Li, M				Xu, Hui; Jin, Jing; Chen, Ying; Wu, Guoqing; Zhu, Hua; Wang, Qing; Wang, Ji; Li, Shenggang; Grigore, Florina-Nicoleta; Ma, Jun; Chen, Clark C.; Lan, Qing; Li, Ming			GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair	ONCOGENE			English	Article							CENTRAL-NERVOUS-SYSTEM; BREAST-CANCER; STING PATHWAY; NRF2; INFLAMMATION; ACTIVATION; PROTEINS; ADAPTER; HEALTH; GLIOMA	Glioblastoma is the most common malignant brain cancer with dismal survival and prognosis. Temozolomide (TMZ) is a first-line chemotherapeutic agent for glioblastoma, but the emergence of drug resistance limits its anti-tumor activity. We previously discovered that the interferon inducible guanylate binding protein 3 (GBP3) is highly elevated and promotes tumorigenicity of glioblastoma. Here, we show that TMZ treatment significantly upregulates the expression of GBP3 and stimulator of interferon genes (STING), both of which increase TMZ-induced DNA damage repair and reduce cell apoptosis of glioblastoma cells. Mechanistically, relying on its N-terminal GTPase domain, GBP3 physically interacts with STING to stabilize STING protein levels, which in turn induces expression of p62 (Sequestosome 1), nuclear factor erythroid 2 like 2 (NFE2L2, NRF2), and O6-methlyguanine-DNA-methyltransferase (MGMT), leading to the resistance to TMZ treatment. Reducing GBP3 levels by RNA interference in glioblastoma cells markedly increases the sensitivity to TMZ treatment in vitro and in murine glioblastoma models. Clinically, GBP3 expression is high and positively correlated with STING, NRF2, p62, and MGMT expression in human glioblastoma tumors, and is associated with poor outcomes. These findings provide novel insight into TMZ resistance and suggest that GBP3 may represent a novel potential target for the treatment of glioblastoma.	[Xu, Hui; Jin, Jing; Chen, Ying; Wu, Guoqing; Wang, Qing; Wang, Ji; Li, Shenggang; Lan, Qing] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou 215004, Jiangsu, Peoples R China; [Xu, Hui; Lan, Qing] Soochow Univ, Inst Neurosci, Jiangsu Key Lab Neuropsychiat Dis, Suzhou 215004, Jiangsu, Peoples R China; [Zhu, Hua] China Med Univ, Hosp 1, Dept Pediat, Shenyang 110122, Liaoning, Peoples R China; [Grigore, Florina-Nicoleta; Ma, Jun; Chen, Clark C.; Li, Ming] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA	Soochow University - China; Soochow University - China; China Medical University; University of Minnesota System; University of Minnesota Twin Cities	Lan, Q (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou 215004, Jiangsu, Peoples R China.; Lan, Q (corresponding author), Soochow Univ, Inst Neurosci, Jiangsu Key Lab Neuropsychiat Dis, Suzhou 215004, Jiangsu, Peoples R China.; Li, M (corresponding author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.	szlq006@163.com; m2li@umn.edu	Ma, Jun/ADU-1664-2022	Ma, Jun/0000-0003-0427-8205	National Natural Science Foundation of China [81572480]; Priority Academic Program Development of Jiangsu Higher Education Institutions; Key Laboratory of Minimally Invasive Neurosurgery of Suzhou [SZ2021262]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions; Key Laboratory of Minimally Invasive Neurosurgery of Suzhou	This work was supported by grants from the National Natural Science Foundation of China (81572480), the Priority Academic Program Development of Jiangsu Higher Education Institutions, and the Key Laboratory of Minimally Invasive Neurosurgery of Suzhou (SZ2021262).	Cheng LF, 2020, INT J ONCOL, V57, P858, DOI 10.3892/ijo.2020.5086; Cheng ZL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0198-7; Cong ZX, 2014, J NEURO-ONCOL, V116, P41, DOI 10.1007/s11060-013-1260-x; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Deng DN, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1004-x; Duan ZF, 2006, CANCER CHEMOTH PHARM, V57, P25, DOI 10.1007/s00280-005-0026-3; Dunphy G, 2018, MOL CELL, V71, P745, DOI 10.1016/j.molcel.2018.07.034; Fukumoto M, 2014, CANCER SCI, V105, P1351, DOI 10.1111/cas.12489; Godoy P, 2014, BREAST CANCER-TOKYO, V21, P491, DOI 10.1007/s12282-012-0404-8; Guimaraes DP, 2009, INT J CANCER, V124, P272, DOI 10.1002/ijc.23944; Hombach-Klonisch S, 2018, PHARMACOL THERAPEUT, V184, P13, DOI 10.1016/j.pharmthera.2017.10.017; Kitange GJ, 2009, NEURO-ONCOLOGY, V11, P281, DOI 10.1215/15228517-2008-090; Kwon J, 2020, CANCER DISCOV, V10, P26, DOI 10.1158/2159-8290.CD-19-0761; Li M, 2017, ONCOTARGET, V8, P55319, DOI 10.18632/oncotarget.19429; Li M, 2011, J EXP MED, V208, P2657, DOI 10.1084/jem.20111102; Li T, 2018, J EXP MED, V215, P1287, DOI 10.1084/jem.20180139; Liu JH, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01641-8; Liu YX, 2007, P NATL ACAD SCI USA, V104, P5205, DOI 10.1073/pnas.0700898104; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Ma LN, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0517-y; Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030; Nordmann A, 2012, FASEB J, V26, P1290, DOI 10.1096/fj.11-189886; Ostrom Quinn T, 2019, Neuro Oncol, V21, pv1, DOI 10.1093/neuonc/noz150; Paranjpe A, 2016, J BIOMED RES, V30, P393, DOI 10.7555/JBR.30.20160040; Pilla-Moffett D, 2016, J MOL BIOL, V428, P3495, DOI 10.1016/j.jmb.2016.04.032; Polonen P, 2019, ONCOGENE, V38, P7473, DOI 10.1038/s41388-019-0956-6; Prabakaran T, 2018, EMBO J, V37, DOI 10.15252/embj.201797858; Quintero M, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3726-2; Rocha CRR, 2016, ONCOTARGET, V7, P48081, DOI 10.18632/oncotarget.10129; Reislander T, 2020, MOL CELL, V80, P21, DOI 10.1016/j.molcel.2020.07.026; Ryoo IG, 2018, REDOX BIOL, V17, P246, DOI 10.1016/j.redox.2018.04.015; Singh A, 2016, ACS CHEM BIOL, V11, P3214, DOI 10.1021/acschembio.6b00651; Storozynsky Q, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228877; Tretina K, 2019, J EXP MED, V216, P482, DOI 10.1084/jem.20182031; Vashi N, 2021, TRENDS BIOCHEM SCI, V46, P446, DOI 10.1016/j.tibs.2020.12.010; Wang J, 2020, J CELL BIOCHEM, V121, P1250, DOI 10.1002/jcb.29358; Wu JF, 2019, BIOCHEM BIOPH RES CO, V518, P698, DOI 10.1016/j.bbrc.2019.08.113; Xia TL, 2016, CELL REP, V14, P282, DOI 10.1016/j.celrep.2015.12.029; Xu H, 2018, BIOCHEM BIOPH RES CO, V495, P446, DOI 10.1016/j.bbrc.2017.11.050; Yu SY, 2020, ONCOGENE, V39, P5042, DOI 10.1038/s41388-020-1348-7; Yu XT, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03492-3; Zhang Q, 2019, CELL DEATH DIFFER, V26, P2300, DOI 10.1038/s41418-019-0303-z; Zhao J, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01494; Zheng JY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01250-1	44	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3876	3885		10.1038/s41388-022-02397-5	http://dx.doi.org/10.1038/s41388-022-02397-5		JUL 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35780181				2022-12-28	WOS:000819907600003
J	Yang, YS; Jia, XZ; Lu, QY; Cai, SL; Huang, XT; Yang, SH; Wood, C; Wang, YH; Zhou, JJ; Chen, YD; Yang, JS; Yang, WJ				Yang, Yao-Shun; Jia, Xi-Zheng; Lu, Qian-Yun; Cai, Sun-Li; Huang, Xue-Ting; Yang, Shu-Hua; Wood, Chris; Wang, Yue-Hong; Zhou, Jiao-Jiao; Chen, Yi-Ding; Yang, Jin-Shu; Yang, Wei-Jun			Exosomal DEK removes chemoradiotherapy resistance by triggering quiescence exit of breast cancer stem cells	ONCOGENE			English	Article							PREDICTS POOR-PROGNOSIS; PROTEIN; ONCOPROTEIN; GENE; DNA; OVEREXPRESSION; CHROMATIN; HETEROGENEITY; EXPRESSION; INHIBITOR	Tumor therapeutics often target the primary tumor bulk but fail to eradicate therapy-resistant cancer stem cells (CSCs) in quiescent state. These can then become activated to initiate recurrence and/or metastasis beyond therapy. Here, we identified and isolated chemoradiotherapy-resistant CSCs in quiescent state with high capacity of tumor-initiation and tumorsphere formation from three types of breast tumors in mice. Experiments of knockdown and rescue revealed DEK, a nuclear protein, as essential for CSC activation. Exogenous DEK was then used to trigger quiescence exit of CSCs. ChIP-seq and ATAC-seq showed that DEK directly binds to chromatin, facilitating its genome-wide accessibility. The resulting epigenetic events upregulate the expression of cellular activation-related genes including MYC targets, whereas cellular quiescence-related genes including the p53 signaling pathway are silenced. However, twinned with DEK-induced activation, formerly resistant CSCs were then destroyed by chemotherapy in vitro. In mice, traditional chemoradiotherapy concurrent with the injection of DEK-containing exosomes resulted in eradication of primary tumors together with formerly resistant CSCs without recurrence or metastasis. Our findings advance knowledge of the mechanism of quiescent CSC activation and may provide novel clinical opportunities for removal of quiescence-linked therapy resistance.	[Yang, Yao-Shun; Jia, Xi-Zheng; Lu, Qian-Yun; Cai, Sun-Li; Huang, Xue-Ting; Yang, Shu-Hua; Wood, Chris; Yang, Jin-Shu; Yang, Wei-Jun] Zhejiang Univ, Coll Life Sci, MOE Lab Biosyst Homeostasis & Protect, Hangzhou 310058, Peoples R China; [Wang, Yue-Hong] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Resp Med, Hangzhou, Peoples R China; [Zhou, Jiao-Jiao; Chen, Yi-Ding] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Surg Oncol, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Yang, WJ (corresponding author), Zhejiang Univ, Coll Life Sci, MOE Lab Biosyst Homeostasis & Protect, Hangzhou 310058, Peoples R China.	w_jyang@zju.edu.cn	Huang, Xueting/HGT-9440-2022	Huang, Xueting/0000-0001-7893-168X; Jia, Xi-Zheng/0000-0002-6656-0997; Wood, Christopher/0000-0002-5517-9496; Cai, Sunli/0000-0003-3784-7048; Yang, Shuhua/0000-0002-1125-8088	National Major Research and Development Project [2016YFA0101201]; National Natural Science Foundation of China [31730084]	National Major Research and Development Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Major Research and Development Project (2016YFA0101201) and the National Natural Science Foundation of China (Project No. 31730084).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bajaj J, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201911053; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Boichuk S, 2013, CANCER RES, V73, P5120, DOI 10.1158/0008-5472.CAN-13-0579; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Capitano ML, 2019, J CLIN INVEST, V129, P2555, DOI 10.1172/JCI127460; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Dai L, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00453-16; Damen MPF, 2021, FEBS J, V288, P6286, DOI 10.1111/febs.15626; Ewton DZ, 2011, MOL CANCER THER, V10, P2104, DOI 10.1158/1535-7163.MCT-11-0498; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hacker KE, 2018, NEOPLASIA, V20, P1209, DOI 10.1016/j.neo.2018.10.005; Hidayat M, 2019, BOSNIAN J BASIC MED, V19, P355, DOI 10.17305/bjbms.2019.4227; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Hu HG, 2007, BIOCHEM BIOPH RES CO, V358, P1008, DOI 10.1016/j.bbrc.2007.05.019; Hua Y, 2009, SCI CHINA SER C, V52, P637, DOI 10.1007/s11427-009-0088-2; Jia WH, 2019, BIOCHEM J, V476, P1753, DOI 10.1042/BCJ20190169; Johnsen KB, 2014, BBA-REV CANCER, V1846, P75, DOI 10.1016/j.bbcan.2014.04.005; Kavanaugh GM, 2011, NUCLEIC ACIDS RES, V39, P7465, DOI 10.1093/nar/gkr454; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Khoo WH, 2019, BLOOD, V134, P30, DOI 10.1182/blood.2018880930; Koleva RI, 2012, BLOOD, V119, P4878, DOI 10.1182/blood-2011-10-383083; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu SP, 2012, PATHOL INT, V62, P176, DOI 10.1111/j.1440-1827.2011.02775.x; Marusyk A, 2020, CANCER CELL, V37, P471, DOI 10.1016/j.ccell.2020.03.007; Mor-Vaknin N, 2006, MOL CELL BIOL, V26, P9484, DOI 10.1128/MCB.01030-06; Najafi M, 2019, LIFE SCI, V234, DOI 10.1016/j.lfs.2019.116781; Piao JJ, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-67; Recasens A, 2019, TRENDS PHARMACOL SCI, V40, P128, DOI 10.1016/j.tips.2018.12.004; Saha AK, 2013, P NATL ACAD SCI USA, V110, P6847, DOI 10.1073/pnas.1220751110; Saito Y, 2010, NAT BIOTECHNOL, V28, P275, DOI 10.1038/nbt.1607; Sanden C, 2015, LEUKEMIA, V29, P1632, DOI 10.1038/leu.2015.72; Sanden C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-215; Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442; Sistigu A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02166; Steinbichler TB, 2018, SEMIN CANCER BIOL, V53, P156, DOI 10.1016/j.semcancer.2018.11.006; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun J, 2017, ONCOL REP, V37, P857, DOI 10.3892/or.2016.5302; Teng Y, 2018, CURR CANCER DRUG TAR, V18, P256, DOI 10.2174/1568009617666170522094730; Vinnedge LMP, 2015, ONCOGENE, V34, P2325, DOI 10.1038/onc.2014.173; Waldmann T, 2004, GENE, V343, P1, DOI 10.1016/j.gene.2004.08.029; Waldmann T, 2002, J BIOL CHEM, V277, P24988, DOI 10.1074/jbc.M204045200; Wang XY, 2014, INT J CLIN EXP PATHO, V7, P5016; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Ye S, 2019, CANCER RES, V79, P4729, DOI 10.1158/0008-5472.CAN-19-1084; Yi HC, 2015, MOL MED REP, V11, P1318, DOI 10.3892/mmr.2014.2781; Zeng X., 2021, PHARM RES-DORDR, V163	52	1	1	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2624	2637		10.1038/s41388-022-02278-x	http://dx.doi.org/10.1038/s41388-022-02278-x		MAR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35351996				2022-12-28	WOS:000774697100001
J	Song, HJ; Wang, JQ; Wang, XJ; Yuan, BL; Li, D; Hu, AP; Guo, YH; Cai, S; Jin, SK; Zhou, Y; Li, QL; Chen, G; Gao, HY; Zheng, LD; Tong, QS				Song, Huajie; Wang, Jianqun; Wang, Xiaojing; Yuan, Boling; Li, Dan; Hu, Anpei; Guo, Yanhua; Cai, Shuang; Jin, Shikai; Zhou, Yi; Li, Qilan; Chen, Guo; Gao, Haiyang; Zheng, Liduan; Tong, Qiangsong			HNF4A-AS1-encoded small peptide promotes self-renewal and aggressiveness of neuroblastoma stem cells via eEF1A1-repressed SMAD4 transactivation	ONCOGENE			English	Article							SENESCENCE; PROGRESSION; ACTIVATION; PROTEIN; CLASSIFICATION; IDENTIFICATION; STRATEGIES	Cancer stem cells play crucial roles in tumorigenesis and aggressiveness, while regulatory mechanisms in neuroblastoma (NB), a pediatric extracranial malignancy with highest incidence, are still unknown. Herein, a small 51-amino acid peptide (sPEP1) encoded by hepatocyte nuclear factor 4 alpha antisense RNA 1 (HNF4A-AS1) was identified in tumor tissues and cells, which facilitated self-renewal and aggressiveness of NB stem cells. MiRNA-409-5p interacted with HNF4A-AS1 to facilitate sPEP1 translation via recruiting eukaryotic translation initiation factor 3 subunit G, while sPEP1 repressed serum deprivation-induced senescence and promoted sphere formation, growth, or metastasis of NB stem cells. Mechanistically, sPEP1 directly interacted with eukaryotic translation elongation factor 1 alpha 1 (eEF1A1) to facilitate its binding to SMAD family member 4 (SMAD4), resulting in repression of SMAD4 transactivation and transcriptional upregulation of stem cell genes associated with tumor progression. Rescue experiments revealed that sPEP1 exerted oncogenic roles via facilitating physical interaction between eEF1A1 and SMAD4. Notably, knockdown of sPEP1 significantly repressed the self-renewal and metastasis of NB stem cells in vivo. High sPEP1 or eEF1A1 levels in clinical NB tissues were linked to poor patients' survival. These findings suggest that HNF4A-AS1-encoded sPEP1 promotes self-renewal and aggressive features of NB stem cells by eEF1A1-repressed SMAD4 transactivation.	[Song, Huajie; Wang, Jianqun; Yuan, Boling; Li, Dan; Hu, Anpei; Guo, Yanhua; Jin, Shikai; Li, Qilan; Chen, Guo; Tong, Qiangsong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pediat Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Wang, Xiaojing] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Geriatr, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Cai, Shuang; Zhou, Yi; Zheng, Liduan] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Gao, Haiyang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Zheng, Liduan; Tong, Qiangsong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Clin Ctr Human Genom Res, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pediat Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.; Zheng, LD (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.; Zheng, LD; Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Clin Ctr Human Genom Res, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.	ld_zheng@hotmail.com; qs_tong@hotmail.com			National Natural Science Foundation of China [81773094, 81772967, 81874085, 81874066, 81802925, 81903011, 81903008, 82072801, 82173316]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We are grateful for Dr. Ralf Janknecht for providing vectors. This work was granted by the National Natural Science Foundation of China (81773094, 81772967, 81874085, 81874066, 81802925, 81903011, 81903008, 82072801, 82173316).	Abbas W, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00075; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Balko JM, 2013, CANCER RES, V73, P6346, DOI 10.1158/0008-5472.CAN-13-1385; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Chiba T, 2010, HEPATOLOGY, V52, P1111, DOI 10.1002/hep.23793; Choi, 2019, SCI REP-UK, V9; Choi SW, 2019, BRIEF BIOINFORM, V20, P1853, DOI 10.1093/bib/bby055; Edmonds BT, 1996, J CELL SCI, V109, P2705; Fang EH, 2020, THERANOSTICS, V10, P1555, DOI 10.7150/thno.37383; Fang EH, 2019, ADV SCI, V6, DOI 10.1002/advs.201900581; Fujimaki K, 2019, P NATL ACAD SCI USA, V116, P22624, DOI 10.1073/pnas.1915905116; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hansford LM, 2007, CANCER RES, V67, P11234, DOI 10.1158/0008-5472.CAN-07-0718; Hernandez AL, 2019, MOL CARCINOGEN, V58, P1648, DOI 10.1002/mc.23049; Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015; Johnsson A, 2000, BRIT J CANCER, V83, P1047, DOI 10.1054/bjoc.2000.1420; Kojima K, 2007, CANCER RES, V67, P8121, DOI 10.1158/0008-5472.CAN-06-4167; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Li, 2018, NAT COMMUN, V9; Li D, 2018, CANCER RES, V78, P1169, DOI 10.1158/0008-5472.CAN-17-2295; Li HH, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910835; Li XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15909; Lindemann C, 2017, BIOL CHEM, V398, P687, DOI 10.1515/hsz-2017-0104; Magny EG, 2013, SCIENCE, V341, P1116, DOI 10.1126/science.1238802; Matsumoto A, 2017, NATURE, V541, P228, DOI 10.1038/nature21034; Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167; Mishra AK, 2007, P NATL ACAD SCI USA, V104, P13930, DOI 10.1073/pnas.0704915104; Nottrott S, 2006, NAT STRUCT MOL BIOL, V13, P1108, DOI 10.1038/nsmb1173; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Pandian V, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0002-8; Pauli A, 2014, SCIENCE, V343, P746, DOI 10.1126/science.1248636; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Pringle Eric S, 2019, Curr Protoc Mol Biol, V125, pe79, DOI 10.1002/cpmb.79; Rennie W, 2014, NUCLEIC ACIDS RES, V42, pW114, DOI 10.1093/nar/gku376; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Slavoff SA, 2013, NAT CHEM BIOL, V9, P59, DOI [10.1038/NCHEMBIO.1120, 10.1038/nchembio.1120]; Song HJ, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00857-7; Takenobu H, 2011, ONCOGENE, V30, P97, DOI 10.1038/onc.2010.383; Tan H, 2019, EBIOMEDICINE, V43, P82, DOI 10.1016/j.ebiom.2019.03.082; Thomas SK, 2004, J BIOL CHEM, V279, P27994, DOI 10.1074/jbc.M312663200; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vera M, 2014, ELIFE, V3, DOI 10.7554/eLife.03164; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wang, 2020, J EXP MED, V217, pe20190950; Wu P, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1147-3; Yang G, 2010, INT J BIOL SCI, V6, P1; Yu CC, 2011, J ONCOL, V2011, DOI 10.1155/2011/609259; Zhao X, 2016, ONCOGENE, V35, P3565, DOI 10.1038/onc.2015.422; Zhao X, 2020, MOL THER, V28, P946, DOI 10.1016/j.ymthe.2019.12.013; Zhao X, 2018, MOL THER, V26, P755, DOI 10.1016/j.ymthe.2017.12.017	50	2	2	5	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2505	2519		10.1038/s41388-022-02271-4	http://dx.doi.org/10.1038/s41388-022-02271-4		MAR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35318442				2022-12-28	WOS:000771890400002
J	Bharathy, N; Cleary, MM; Kim, JA; Nagamori, K; Crawford, KA; Wang, E; Saha, D; Settelmeyer, TP; Purohit, R; Skopelitis, D; Chang, K; Doran, JA; Kirschbaum, CW; Bharathy, S; Crews, DW; Randolph, ME; Karnezis, AN; Hudson-Price, L; Dhawan, J; Michalek, JE; Ciulli, A; Vakoc, CR; Keller, C				Bharathy, Narendra; Cleary, Megan M.; Kim, Jin-Ah; Nagamori, Kiyo; Crawford, Kenneth A.; Wang, Eric; Saha, Debarya; Settelmeyer, Teagan P.; Purohit, Reshma; Skopelitis, Damianos; Chang, Kenneth; Doran, Jessica A.; Kirschbaum, C. Ward; Bharathy, Suriya; Crews, Davis W.; Randolph, Matthew E.; Karnezis, Anthony N.; Hudson-Price, Lisa; Dhawan, Jyotsna; Michalek, Joel E.; Ciulli, Alessio; Vakoc, Christopher R.; Keller, Charles			SMARCA4 biology in alveolar rhabdomyosarcoma	ONCOGENE			English	Article							SMALL-CELL CARCINOMA; METASTATIC RHABDOMYOSARCOMA; SWI/SNF COMPLEXES; GENETIC LANDSCAPE; MUTATIONS; OVARY; BROMODOMAIN; CHILDREN; OUTCOMES; SARCOMA	Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and phenocopies a muscle precursor that fails to undergo terminal differentiation. The alveolar subtype (ARMS) has the poorest prognosis and represents the greatest unmet medical need for RMS. Emerging evidence supports the role of epigenetic dysregulation in RMS. Here we show that SMARCA4/BRG1, an ATP-dependent chromatin remodeling enzyme of the SWI/SNF complex, is prominently expressed in primary tumors from ARMS patients and cell cultures. Our validation studies for a CRISPR screen of 400 epigenetic targets identified SMARCA4 as a unique factor for long-term (but not short-term) tumor cell survival in ARMS. A SMARCA4/SMARCA2 protein degrader (ACBI-1) demonstrated similar long-term tumor cell dependence in vitro and in vivo. These results credential SMARCA4 as a tumor cell dependency factor and a therapeutic target in ARMS.	[Bharathy, Narendra; Cleary, Megan M.; Kim, Jin-Ah; Nagamori, Kiyo; Crawford, Kenneth A.; Saha, Debarya; Settelmeyer, Teagan P.; Purohit, Reshma; Doran, Jessica A.; Kirschbaum, C. Ward; Bharathy, Suriya; Crews, Davis W.; Randolph, Matthew E.; Hudson-Price, Lisa; Keller, Charles] Childrens Canc Therapy Dev Inst, Beaverton, OR 97005 USA; [Wang, Eric; Skopelitis, Damianos; Chang, Kenneth; Vakoc, Christopher R.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Saha, Debarya; Dhawan, Jyotsna] CSIR CCMB, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India; [Karnezis, Anthony N.] Univ Calif C Davis Med Ctr, Sacramento, CA 95817 USA; [Karnezis, Anthony N.] British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada; [Michalek, Joel E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Ciulli, Alessio] Univ Dundee, Sch Life Sci, Div Biol Chem & Drug Discovery, Dundee, Scotland; [Bharathy, Narendra] Univ Penn, Perelman Sch Med, Gene Therapy Program, Philadelphia, PA 19104 USA	Cold Spring Harbor Laboratory; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); British Columbia Cancer Agency; University of Texas System; University of Texas Health San Antonio; University of Dundee; University of Pennsylvania; Pennsylvania Medicine	Keller, C (corresponding author), Childrens Canc Therapy Dev Inst, Beaverton, OR 97005 USA.; Ciulli, A (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Drug Discovery, Dundee, Scotland.	a.ciulli@dundee.ac.uk; charles@cc-tdi.org		Nagamori, Kiyo/0000-0002-7891-3534; Keller, Charles/0000-0003-2505-7487	Braver Stronger Smarter Foundation; Maddie's Promise Foundation; NIH [R01CA189299, R01CA258720]; Boehringer Ingelheim; Pershing Square Sohn Cancer Research Alliance, Northwell Health Translational Research Award; Christina Renna Foundation; Clark Gillies Foundation; Friends of T.J. Foundation; Michelle Paternoster Foundation; National Cancer Institute [CA2455859]; Department of Biotechnology (DBT), Govt. of India; Indo-U.S. Science and Technology Forum (IUSSTF)	Braver Stronger Smarter Foundation; Maddie's Promise Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Boehringer Ingelheim(Boehringer Ingelheim); Pershing Square Sohn Cancer Research Alliance, Northwell Health Translational Research Award(Pershing Square Sohn Cancer Research Alliance); Christina Renna Foundation; Clark Gillies Foundation; Friends of T.J. Foundation; Michelle Paternoster Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Biotechnology (DBT), Govt. of India(Department of Biotechnology (DBT) India); Indo-U.S. Science and Technology Forum (IUSSTF)	We thank Dr. Manfred Kogl for generously providing vectors LMH-SMARCA2 and LMH-PBRM1. This study was funded by Braver Stronger Smarter Foundation, Maddie's Promise Foundation and by NIH grants R01CA189299 & R01CA258720. The ACBI-1 PROTAC degrader was developed with funding support to the Ciulli Laboratory by Boehringer Ingelheim. CRV was supported by the Pershing Square Sohn Cancer Research Alliance, Northwell Health Translational Research Award, The Christina Renna Foundation, The Clark Gillies Foundation, The Friends of T.J. Foundation, The Michelle Paternoster Foundation, and a grant from National Cancer Institute (CA2455859). DS was supported by the Indo-U.S. GETin program from Department of Biotechnology (DBT), Govt. of India and Indo-U.S. Science and Technology Forum (IUSSTF).	Abraham J, 2014, GENE DEV, V28, P1578, DOI 10.1101/gad.238733.114; Albini S, 2010, EXP CELL RES, V316, P3073, DOI 10.1016/j.yexcr.2010.05.023; Bell EH, 2016, CLIN CANCER RES, V22, P2396, DOI 10.1158/1078-0432.CCR-15-1468; Bharathy N, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aau7632; Bharathy N, 2016, J PATHOL, V240, P269, DOI 10.1002/path.4773; Blandford MC, 2006, PEDIATR BLOOD CANCER, V46, P329, DOI 10.1002/pbc.20466; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Chan-Penebre E, 2017, MOL CANCER THER, V16, P850, DOI 10.1158/1535-7163.MCT-16-0678; Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223; Dagher R, 1999, Oncologist, V4, P34; Farnaby W, 2019, NAT CHEM BIOL, V15, P672, DOI 10.1038/s41589-019-0294-6; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Karnezis AN, 2016, J PATHOL, V238, P389, DOI 10.1002/path.4633; Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Malempati S, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.10556; Malempati S, 2012, PEDIATR BLOOD CANCER, V59, P5, DOI 10.1002/pbc.24118; McBride MJ, 2018, J PATHOL, V244, P638, DOI 10.1002/path.5042; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Michel BC, 2018, NAT CELL BIOL, V20, P1410, DOI 10.1038/s41556-018-0221-1; Ohkawa Y, 2006, EMBO J, V25, P490, DOI 10.1038/sj.emboj.7600943; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Rudzinski ER, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26645; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Shi JW, 2015, NAT BIOTECHNOL, V33, P661, DOI 10.1038/nbt.3235; Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113; Vangamudi B, 2015, CANCER RES, V75, P3865, DOI 10.1158/0008-5472.CAN-14-3798; Wexler LH, 1997, J PEDIATR-US, V131, P508; Williams BA, 2004, J PEDIAT HEMATOL ONC, V26, P243, DOI 10.1097/00043426-200404000-00006; Willis MS, 2012, CIRC RES, V111, pE111, DOI 10.1161/CIRCRESAHA.112.265587; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931	36	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1647	1656		10.1038/s41388-022-02205-0	http://dx.doi.org/10.1038/s41388-022-02205-0		JAN 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35094009	Green Submitted			2022-12-28	WOS:000750486500002
J	Cannistraci, A; Hascoet, P; Ali, A; Mundra, P; Clarke, NW; Pavet, V; Marais, R				Cannistraci, A.; Hascoet, P.; Ali, A.; Mundra, P.; Clarke, N. W.; Pavet, V; Marais, R.			MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer	ONCOGENE			English	Article							RADICAL PROSTATECTOMY; ANDROGEN RECEPTOR; CELL-GROWTH; IN-VITRO; EXPRESSION; TOMOGRAPHY; PLASTICITY; BIOMARKERS; MICRORNAS; SURVIVAL	Prostate cancer (PCa) is the fifth leading cause of cancer related deaths worldwide, in part due to a lack of molecular stratification tools that can distinguish primary tumours that will remain indolent from those that will metastasise. Amongst potential molecular biomarkers, microRNAs (miRs) have attracted particular interest because of their high stability in body fluids and fixed tissues. These small non-coding RNAs modulate several physiological and pathological processes, including cancer progression. Herein we explore the prognostic potential and the functional role of miRs in localised PCa and their relation to nodal metastasis. We define a 7-miR signature that is associated with poor survival independently of age, Gleason score, pathological T state, N stage and surgical margin status and that is also prognostic for disease-free survival in patients with intermediate-risk localised disease. Within our 7-miR signature, we show that miR-378a-3p (hereafter miR-378a) levels are low in primary tumours compared to benign prostate tissue, and also lower in Gleason score 8-9 compared to Gleason 6-7 PCa. We demonstrate that miR-378a impairs glucose metabolism and reduces proliferation in PCa cells through independent mechanisms, and we identify glucose transporter 1 (GLUT1) messenger RNA as a direct target of miR-378a. We show that GLUT1 inhibition hampers glycolysis, leading to cell death. Our data provides a rational for a new PCa stratification strategy based on miR expression, and it reveals that miR-378a and GLUT1 are potential therapeutic targets in highly aggressive glycolytic PCa.	[Cannistraci, A.; Hascoet, P.; Mundra, P.; Pavet, V; Marais, R.] Univ Manchester, Canc Res UK Manchester Inst, Mol Oncol Grp, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England; [Ali, A.; Clarke, N. W.] Univ Manchester, Genitourinary Canc Res Grp, Manchester Canc Res Ctr, Div Canc Sci, 555 Wilmslow Rd, Manchester M20 4GJ, Lancs, England; [Ali, A.; Clarke, N. W.] Univ Manchester, FASTMAN Prostate Canc Ctr Excellence, Manchester Canc Res Ctr, Div Canc Sci, 555 Wilmslow Rd, Manchester M20 4GJ, Lancs, England; [Clarke, N. W.] Christie NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, Lancs, England	Cancer Research UK; University of Manchester; University of Manchester; University of Manchester; Christie NHS Foundation Trust	Pavet, V; Marais, R (corresponding author), Univ Manchester, Canc Res UK Manchester Inst, Mol Oncol Grp, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.	valeria.pavet@cruk.manchester.ac.uk; richard.marais@cruk.manchester.ac.uk		Pavet, Valeria/0000-0002-4472-6503	Cancer Research UK [C5759/A27412, C5759/A20971]; Prostate Cancer UK [CE013_2-004]	Cancer Research UK(Cancer Research UK); Prostate Cancer UK	We thank the CRUK Manchester Institute core facilities, particularly Duncan Smith (Biological Mass Spectrometry), Steve Bagley and Kang Zeng (Visualisation, Irradiation & Analysis), Wolfgang Breitwieser and Sudhakar Sahoo (Molecular Biology and Computational Biology Support). We also thank Pedro Oliveira and Maximiliano Portal for helpful discussions, Ashwin Sachdeva for constructive comments on the manuscript and Nathalie Dhomen for initial administration of the project. The results published here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.This work was supported by a core grant from Cancer Research UK to the Cancer Research UK Manchester Institute (C5759/A27412 and C5759/A20971) to RM, and Prostate Cancer UK (CE013_2-004) to RM and NWC.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Ancey PB, 2018, FEBS J, V285, P2926, DOI 10.1111/febs.14577; Arisan ED, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9030052; Bantscheff M, 2012, ANAL BIOANAL CHEM, V404, P939, DOI 10.1007/s00216-012-6203-4; Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006; Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y; Bonci D, 2016, ONCOGENE, V35, P1180, DOI 10.1038/onc.2015.176; Boorjian SA, 2007, J UROLOGY, V178, P864, DOI 10.1016/j.juro.2007.05.048; Boudreau A, 2016, NAT CHEM BIOL, V12, P779, DOI 10.1038/nchembio.2143; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Briganti A, 2009, EUR UROL, V55, P261, DOI 10.1016/j.eururo.2008.09.043; Carrer M, 2012, P NATL ACAD SCI USA, V109, P15330, DOI 10.1073/pnas.1207605109; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen QG, 2016, TUMOR BIOL, V37, P2095, DOI 10.1007/s13277-015-3996-8; Chen S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0376-5; Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757; Choi SYC, 2016, CLIN CANCER RES, V22, P2721, DOI 10.1158/1078-0432.CCR-15-1624; Cooper CS, 2015, NAT GENET, V47, P367, DOI 10.1038/ng.3221; Coppola V, 2013, ONCOGENE, V32, P1843, DOI 10.1038/onc.2012.194; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; de Padua MC, 2017, ONCOTARGET, V8, P87623, DOI 10.18632/oncotarget.21007; Ding NX, 2018, INT J MOL MED, V42, P381, DOI 10.3892/ijmm.2018.3639; Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008; Erber J, 2019, CANCER RES, V79, P4855, DOI 10.1158/0008-5472.CAN-18-3959; Fox JJ, 2018, JAMA ONCOL, V4, P217, DOI 10.1001/jamaoncol.2017.3588; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Guo XB, 2019, ONCOL REP, V42, P1957, DOI 10.3892/or.2019.7283; Hatziapostolou M, 2013, TRENDS ENDOCRIN MET, V24, P361, DOI 10.1016/j.tem.2013.03.002; James ND, 2016, JAMA ONCOL, V2, P348, DOI 10.1001/jamaoncol.2015.4350; Jans J, 2010, UROLOGY, V75, P786, DOI 10.1016/j.urology.2009.08.024; Kane CJ, 2017, EUR UROL FOCUS, V3, P487, DOI 10.1016/j.euf.2016.10.010; Kawaguchi M, 2016, BIOCHEM BIOPH RES CO, V474, P188, DOI 10.1016/j.bbrc.2016.04.098; Lan HY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/125094; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Liu W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6684; Liu Y, 2012, MOL CANCER THER, V11, P1672, DOI 10.1158/1535-7163.MCT-12-0131; Machado IF, 2020, CELL MOL LIFE SCI, V77, P1947, DOI 10.1007/s00018-019-03375-z; McGuirk S, 2020, TRENDS CANCER, V6, P49, DOI 10.1016/j.trecan.2019.11.009; Meirelles GSP, 2010, CLIN CANCER RES, V16, P6093, DOI 10.1158/1078-0432.CCR-10-1357; Menendez JA, 2012, CELL CYCLE, V11, P2782, DOI 10.4161/cc.20948; Meziou S, 2020, PROSTATE CANCER P D, V23, P441, DOI 10.1038/s41391-020-0202-x; Mishra S, 2014, ONCOGENE, V33, P4097, DOI 10.1038/onc.2013.374; Pertega-Gomes N, 2015, J PATHOL, V236, P517, DOI 10.1002/path.4547; Preisser F, 2020, EUR UROL ONCOL, V3, P270, DOI 10.1016/j.euo.2020.03.002; Ramani R, 2017, BIOMARK INSIGHTS, V12, P1, DOI 10.1177/1177271917702895; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Rickman DS, 2017, NAT MED, V23, P664, DOI 10.1038/nm.4341; Seto AG, 2018, BRIT J HAEMATOL, V183, P428, DOI 10.1111/bjh.15547; Shibuya K, 2015, ONCOTARGET, V6, P651, DOI 10.18632/oncotarget.2892; Shiratori R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55296-3; Siebeneicher H, 2016, CHEMMEDCHEM, V11, P2261, DOI 10.1002/cmdc.201600276; Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017; Stewart GD, 2008, ONCOL REP, V20, P1561, DOI 10.3892/or_00000180; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thomson DW, 2011, NUCLEIC ACIDS RES, V39, P6845, DOI 10.1093/nar/gkr330; van Zandwijk N, 2017, LANCET ONCOL, V18, P1386, DOI 10.1016/S1470-2045(17)30621-6; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Velazquez-Torres G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02851-7; Wani S, 2014, BIORXIV, DOI [10.1101/005439, DOI 10.1101/005439]; Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047; Xi Xiaochen, 2017, Non-Coding RNA, V3, P9, DOI 10.3390/ncrna3010009; Zhang YF, 2020, J AMB INTEL HUM COMP, V11, P4239, DOI 10.1007/s12652-020-01704-w; Ziegler A, 2012, HUM GENET, V131, P1627, DOI 10.1007/s00439-012-1188-9	65	4	4	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1445	1455		10.1038/s41388-022-02178-0	http://dx.doi.org/10.1038/s41388-022-02178-0		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35039635	Green Published, hybrid			2022-12-28	WOS:000743421700001
J	Liu, YL; Ma, L; Hua, FL; Min, ZH; Zhan, YX; Zhang, W; Yao, JX				Liu, Yonglei; Ma, Li; Hua, Fanli; Min, Zhihui; Zhan, Yanxia; Zhang, Wei; Yao, Junxia			Exosomal circCARM1 from spheroids reprograms cell metabolism by regulating PFKFB2 in breast cancer	ONCOGENE			English	Article							STEM-CELLS; CIRCULAR RNA	Cancer stem cells (CSC) are the major obstacle for cancer therapy in clinic. Exosomes are one type of vesicles that containing circular RNA (circRNAs) involved in cell-cell communication. However, the roles of breast CSC (BCSC) exosomes are still unclear, and the purpose of the study was to investigate breast cancer cell metabolism reprogramming by circRNAs from BCSC exosomes. The circRNA array was performed in the exosomes secreted from spheroids of MDA-231 cells. circCARM1 was higher in BCSC exosomes than it in the parent breast cancer cells. Further investigation demonstrated that BCSC exosomes circCARM1 played an important role in breast cancer cell glycolysis by miR-1252-5p/PFKFB2. In a conclusion, BCSC exosome-derived circCARM1 played an important role in breast cancer cell glycolysis by sponging miR-1252-5p which regulated PFKFB2 expression.	[Liu, Yonglei; Ma, Li] Fudan Univ, Zhongshan Hosp, Med Res Ctr, Qingpu Branch, Shanghai, Peoples R China; [Hua, Fanli] Fudan Univ, Zhongshan Hosp, ChinaDept Hematol, Qingpu Branch, Shanghai, Peoples R China; [Min, Zhihui; Zhang, Wei] Fudan Univ, Zhongshan Hosp, Inst Clin Sci, Shanghai, Peoples R China; [Zhan, Yanxia] Fudan Univ, Zhongshan Hosp, Dept Pathol, Qingpu Branch, Shanghai, Peoples R China; [Yao, Junxia] Fudan Univ, Zhongshan Hosp, Dept Hematol, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University	Liu, YL (corresponding author), Fudan Univ, Zhongshan Hosp, Med Res Ctr, Qingpu Branch, Shanghai, Peoples R China.	yongleiliu@yeah.net			Shanghai Municipal Health Commission [202140454]; Shanghai Science and Technology Committee [19140901000]; National Natural Science Foundation of China [81502571]	Shanghai Municipal Health Commission; Shanghai Science and Technology Committee(Shanghai Science & Technology Committee); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by Shanghai Municipal Health Commission (No: 202140454), Shanghai Science and Technology Committee (No: 19140901000), and National Natural Science Foundation of China (No: 81502571).	Al-Sowayan BS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00384; Chung IM, 2020, CLIN CHIM ACTA, V500, P226, DOI 10.1016/j.cca.2019.10.022; Clara JA, 2020, NAT REV CLIN ONCOL, V17, P204, DOI 10.1038/s41571-019-0293-2; Clayton SM, 2020, STEM CELLS DEV, V29, P327, DOI 10.1089/scd.2019.0197; El-Sahli S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239125; Fanale D, 2018, ADV EXP MED BIOL, V1087, P109, DOI 10.1007/978-981-13-1426-1_9; Gabrusiewicz K, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412909; Hardin H, 2018, LAB INVEST, V98, P1133, DOI 10.1038/s41374-018-0065-0; Hou J, 2018, CLIN TRANSL ONCOL, V20, P1109, DOI 10.1007/s12094-018-1839-y; Houles T, 2018, CANCER RES, V78, P2191, DOI 10.1158/0008-5472.CAN-17-2215; Hwang WL, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0699-4; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kristensen LS, 2018, ONCOGENE, V37, P555, DOI 10.1038/onc.2017.361; Li J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0822-3; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; de Andres JL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00966-3; Ozcan SC, 2020, MOL CELL BIOCHEM, V470, P115, DOI 10.1007/s11010-020-03751-5; Palacios-Ferrer JL, 2021, MOL ONCOL, V15, P407, DOI 10.1002/1878-0261.12823; Sharma A, 2018, INT J CANCER, V142, P1086, DOI 10.1002/ijc.31089; Taurin S, 2020, NEOPLASIA, V22, P663, DOI 10.1016/j.neo.2020.09.009; Wang L, 2020, J CELL MOL MED, V24, P6324, DOI 10.1111/jcmm.15274; Wang L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0997-z; Wang YX, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1041-z; Yang LQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0110-5; Yang ZY, 2020, CELL ONCOL, V43, P123, DOI 10.1007/s13402-019-00476-6; Yu T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0776-8; Zeng XB, 2021, PHARMACOL RES, V163, DOI 10.1016/j.phrs.2020.105320; Zhao SJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0419-y	28	4	4	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2012	2025		10.1038/s41388-021-02061-4	http://dx.doi.org/10.1038/s41388-021-02061-4		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35027669				2022-12-28	WOS:000742332100001
J	Yu, CN; Luo, D; Yu, J; Zhang, M; Zheng, XB; Xu, GC; Wang, JX; Wang, HL; Xu, YF; Jiang, K; Xu, J; Ma, XL; Jing, J; Shi, HB				Yu, Chune; Luo, Dan; Yu, Jing; Zhang, Min; Zheng, Xiaobo; Xu, Guangchao; Wang, Jiaxin; Wang, Huiling; Xu, Yufei; Jiang, Ke; Xu, Jie; Ma, Xuelei; Jing, Jing; Shi, Hubing			Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer	ONCOGENE			English	Article							LUNG; BRAF; ACTIVATION; TRAMETINIB; MUTATIONS	Targeting the KRAS pathway is a promising but challenging approach for colorectal cancer therapy. Despite showing potent efficacy in BRAF-mutated melanoma, MEK inhibitors appeared to be tolerated by colorectal cancer cells due to their intrinsic compensatory signaling. Here, we performed genome-wide CRISPR/Cas9 screening in the presence of MEK inhibitor to identify genes that are synthetically lethal with MEK inhibition in CRC models harboring KRAS mutations. Several genes were identified as potential functional drivers, which were significantly enriched in the GRB7-mediated RTK pathway. Loss-of-function and gain-of-function assays validated that GRB7 potently rendered CRC cells primary resistance to MEK inhibitors through the RTK pathway. Mass spectrum analysis of GRB7 immunoprecipitates revealed that PLK1 was the predominant interacting kinase of GRB7. Inhibition of PLK1 suppressed downstream signaling of RTK, including FAK, STAT3, AKT, and 4EBP1. The combination of PLK1 and MEK inhibitors synergistically inhibited CRC cell proliferation and induced apoptosis in vitro and in vivo. In conclusion, we identified GRB7-PLK1 as a pivotal axis mediating RTKs, resulting in MEK inhibitor tolerance. PLK1 is therefore a promising target for synergizing MEK inhibitors in the clinical treatment of CRC patients harboring KRAS mutations.	[Yu, Chune; Yu, Jing; Zhang, Min; Zheng, Xiaobo; Wang, Jiaxin; Wang, Huiling; Xu, Yufei; Jing, Jing; Shi, Hubing] Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Lab Integrat Med,State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Yu, Chune; Yu, Jing; Zhang, Min; Zheng, Xiaobo; Wang, Jiaxin; Wang, Huiling; Xu, Yufei; Jing, Jing; Shi, Hubing] Collaborat Innovat Ctr, Chengdu 610041, Sichuan, Peoples R China; [Luo, Dan] Chengdu Med Coll, Sch Basic Med Sci, Dept Immunol, Chengdu 610500, Sichuan, Peoples R China; [Xu, Guangchao] Zunyi Med Univ, Dept Plast Surg, Affiliated Hosp, Zunyi 563000, Guizhou, Peoples R China; [Jiang, Ke] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Head & Neck, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510000, Peoples R China; [Xu, Jie] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China; [Ma, Xuelei] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy,State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Chengdu Medical College; Zunyi Medical University; State Key Lab Oncology South China; Sun Yat Sen University; Shanghai Jiao Tong University; Sichuan University	Jing, J; Shi, HB (corresponding author), Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Lab Integrat Med,State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Jing, J; Shi, HB (corresponding author), Collaborat Innovat Ctr, Chengdu 610041, Sichuan, Peoples R China.	jj_zcy@vip.163.com; shihb@scu.edu.cn	yu, jing/GZL-0747-2022	yu, chune/0000-0002-5625-2843; Shi, Hubing/0000-0002-2926-3440; Xu, Guangchao/0000-0002-3806-2245	National Natural Science Foundation of China [81773752, 81902793, 81803574, 82172634, 31801143]; National Key Research and Development Program of China [2016YFC0906000, 2016YFC0906003]; Key Program of the Science and Technology Bureau of Sichuan [2021YFSY0007]; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYYC20013]; Western Medical Talent Training and Disciplinary Development Fund from Hengrui Pharma; China Postdoctoral Science Foundation [2019M653430]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Key Program of the Science and Technology Bureau of Sichuan; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University; Western Medical Talent Training and Disciplinary Development Fund from Hengrui Pharma; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We are also grateful to Li Chai and Yan Wang (Core Facility of West China Hospital) for their technical assistance. This work was funded by the National Natural Science Foundation of China (Nos. 81773752, 81902793, 81803574, 82172634, 31801143), the National Key Research and Development Program of China (No. 2016YFC0906000 [2016YFC0906003]), Key Program of the Science and Technology Bureau of Sichuan (No. 2021YFSY0007), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (No. ZYYC20013), Western Medical Talent Training and Disciplinary Development Fund from Hengrui Pharma, and China Postdoctoral Science Foundation (2019M653430).	Amodio V, 2020, CANCER DISCOV, V10, P1129, DOI 10.1158/2159-8290.CD-20-0187; Ascierto PA, 2013, LANCET ONCOL, V14, P249, DOI 10.1016/S1470-2045(13)70024-X; Babagana M, 2020, MOL CARCINOGEN, V59, P5, DOI 10.1002/mc.23123; Chan DW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052578; Chu PY, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050435; Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Fedele C, 2018, CANCER DISCOV, V8, P1237, DOI 10.1158/2159-8290.CD-18-0444; Fiala O, 2016, TUMOR BIOL, V37, P6823, DOI 10.1007/s13277-015-4523-7; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239; Housden BE, 2016, NAT BIOTECHNOL, V34, P621, DOI 10.1038/nbt.3599; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Kirouac DC, 2017, NPJ SYST BIOL APPL, V3, DOI 10.1038/s41540-017-0016-1; Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377; Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033; Li XL, 2019, CANCER RES, V79, P5088, DOI 10.1158/0008-5472.CAN-19-0325; Liang JB, 2020, CANCER RES, V80, P510, DOI 10.1158/0008-5472.CAN-18-3374; Liu YH, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0285-6; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947; Moore AR, 2020, NAT REV DRUG DISCOV, V19, P533, DOI 10.1038/s41573-020-0068-6; Neumann J, 2009, PATHOL RES PRACT, V205, P858, DOI 10.1016/j.prp.2009.07.010; Peng X, 2020, SOFT MATTER, V16, P54, DOI 10.1039/c9sm01847f; Ryan MB, 2020, CLIN CANCER RES, V26, P1633, DOI 10.1158/1078-0432.CCR-19-3523; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sparano JA, 2011, CLIN CANCER RES, V17, P7194, DOI 10.1158/1078-0432.CCR-10-3357; Sudhan DR, 2020, CANCER CELL, V37, P183, DOI 10.1016/j.ccell.2019.12.013; Sulahian R, 2019, CELL REP, V29, P118, DOI 10.1016/j.celrep.2019.08.090; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Sustic T, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0600-z; Sveen A, 2020, NAT REV CLIN ONCOL, V17, P11, DOI 10.1038/s41571-019-0241-1; Szlachta K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06676-2; Tsai NP, 2010, J CELL BIOL, V188, P325, DOI 10.1083/jcb.200910083; Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032; Wang YJ, 2010, CLIN CANCER RES, V16, P2529, DOI 10.1158/1078-0432.CCR-10-0018; Wei L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12606-7; Ye JW, 2019, J PHARM ANAL, V9, P217, DOI 10.1016/j.jpha.2019.05.004; Yu Chune, 2020, Mol Biomed, V1, P12, DOI 10.1186/s43556-020-00013-0; Yu CE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00990	45	11	11	6	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					191	203		10.1038/s41388-021-02077-w	http://dx.doi.org/10.1038/s41388-021-02077-w		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34718347	Green Published, hybrid			2022-12-28	WOS:000712941800002
J	Wang, Q; Wu, LH; Cao, RX; Gao, J; Chai, DM; Qin, YZ; Ma, L; Wu, SW; Tao, YS; Ma, J; Wang, ZW				Wang, Qi; Wu, Linhui; Cao, Ruoxue; Gao, Jing; Chai, Damin; Qin, Yanzi; Ma, Li; Wu, Shiwu; Tao, Yisheng; Ma, Jia; Wang, Zhi-wei			Fbxo45 promotes the malignant development of esophageal squamous cell carcinoma by targeting GGNBP2 for ubiquitination and degradation	ONCOGENE			English	Article							F-BOX PROTEINS; TUMOR-SUPPRESSOR; LIGASE COMPLEX; MESENCHYMAL TRANSITION; PROLIFERATION; EXPRESSION; INVASION; SYSTEM; GROWTH; ROLES	Esophageal squamous cell carcinoma (ESCC) is one of the most common and deadly cancers. Fbxo45, a substrate recognition subunit of E3 ligase, is critically involved in tumorigenesis and tumor progression. However, the function of Fbxo45 and the underlying mechanisms have not been elucidated in ESCC. We used cellular and molecular methods to explore the molecular basis of Fbxo45-mediated ESCC development. We found that ectopic overexpression of Fbxo45 promoted the growth of Kyse-150, Kyse30 and ECA-109 cells and inhibited the apoptosis. Moreover, overexpression of Fbxo45 promoted the migration and invasion of ESCC cells. Consistently, knockdown of Fbxo45 exhibited the opposite effects on ESCC cells. Mechanistically, we observed that Fbxo45 binds to GGNBP2 via its SPRY domain and targets GGNBP2 for ubiquitination and degradation. GGNBP2 overexpression exhibited anticancer activity in ESCC cells. Furthermore, Fbxo45 exerted its functions by regulating GGNBP2 stability in ESCC cells. Notably, overexpression of Fbxo45 facilitated tumor growth in mice. Strikingly, Fbxo45 was highly expressed in ESCC tissues, and GGNBP2 had a lower expression in ESCC specimens. High expression of Fbxo45 and low expression of GGNBP2 were associated with poor prognosis in ESCC patients. Fbxo45 was negatively correlated with GGNBP2 expression in ESCC tissues. Therefore, Fbxo45 serves as an oncoprotein to promote ESCC tumorigenesis by targeting the stability of the tumor suppressor GGNBP2 in ESCC.	[Wang, Qi; Gao, Jing; Chai, Damin; Qin, Yanzi; Ma, Li; Wu, Shiwu; Tao, Yisheng] Bengbu Med Coll, Dept Pathol, Affiliated Hosp 1, Bengbu 233030, Anhui, Peoples R China; [Wang, Qi; Gao, Jing; Chai, Damin; Qin, Yanzi; Ma, Li; Wu, Shiwu; Tao, Yisheng] Bengbu Med Coll, Dept Pathol, Bengbu 233030, Anhui, Peoples R China; [Wu, Linhui; Cao, Ruoxue; Ma, Jia; Wang, Zhi-wei] Bengbu Med Coll, Sch Lab Med, Dept Biochem & Mol Biol, Key Lab Canc Res & Clin Lab Diag, Bengbu 233030, Anhui, Peoples R China; [Wang, Zhi-wei] Wenzhou Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Wenzhou 325027, Zhejiang, Peoples R China	Bengbu Medical College; Bengbu Medical College; Bengbu Medical College; Wenzhou Medical University	Tao, YS (corresponding author), Bengbu Med Coll, Dept Pathol, Affiliated Hosp 1, Bengbu 233030, Anhui, Peoples R China.; Tao, YS (corresponding author), Bengbu Med Coll, Dept Pathol, Bengbu 233030, Anhui, Peoples R China.; Ma, J; Wang, ZW (corresponding author), Bengbu Med Coll, Sch Lab Med, Dept Biochem & Mol Biol, Key Lab Canc Res & Clin Lab Diag, Bengbu 233030, Anhui, Peoples R China.; Wang, ZW (corresponding author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Wenzhou 325027, Zhejiang, Peoples R China.	taoyishengbbyxy@163.com; majiamj10@126.com; zhiweichina@126.com						Abshire CF, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.55; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen X, 2014, CELL DEATH DIFFER, V21, P1535, DOI 10.1038/cdd.2014.92; Cheng LL, 2020, DIAGN PATHOL, V15, DOI 10.1186/s13000-020-00929-9; Ciechanover A, 2017, BEST PRACT RES CL HA, V30, P341, DOI 10.1016/j.beha.2017.09.001; Cino EA, 2016, J PHYS CHEM B, V120, P1060, DOI 10.1021/acs.jpcb.5b11565; Gao M, 2005, MOL CELL, V19, P581, DOI 10.1016/j.molcel.2005.08.017; Glynn RW, 2010, CANCER TREAT REV, V36, P224, DOI 10.1016/j.ctrv.2009.12.007; Gong J, 2016, INT J ONCOL, V48, P886, DOI 10.3892/ijo.2016.3325; Gong J, 2015, INT J ONCOL, V47, P43, DOI 10.3892/ijo.2015.2983; Gong J, 2014, INT J ONCOL, V45, P2199, DOI 10.3892/ijo.2014.2684; Guan R, 2012, MOL CELL BIOCHEM, V365, P211, DOI 10.1007/s11010-012-1262-6; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Kim HY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03757-x; Kogure N, 2017, ANTICANCER RES, V37, P191, DOI 10.21873/anticanres.11305; Lan ZJ, 2016, BREAST CANCER RES TR, V158, P263, DOI 10.1007/s10549-016-3880-2; Levin AM, 2008, CANCER RES, V68, P6492, DOI 10.1158/0008-5472.CAN-08-0348; Li SQ, 2016, BIOL REPROD, V94, DOI 10.1095/biolreprod.115.136358; Lin M, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0291-2; Lin M, 2019, CANCER LETT, V466, P61, DOI 10.1016/j.canlet.2019.09.008; Liu JJ, 2019, BREAST CANCER RES TR, V174, P65, DOI 10.1007/s10549-018-5052-z; MacGurn JA, 2012, ANNU REV BIOCHEM, V81, P231, DOI 10.1146/annurev-biochem-060210-093619; Malhotra GK, 2017, J SURG ONCOL, V115, P564, DOI 10.1002/jso.24592; Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Peschiaroli A, 2009, ONCOGENE, V28, P3157, DOI 10.1038/onc.2009.177; Pickens A, 2003, ANN THORAC SURG, V76, pS1367, DOI 10.1016/S0003-4975(03)01202-5; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Richter KT, 2020, CELL DEATH DIFFER, V27, P758, DOI 10.1038/s41418-019-0385-7; Saiga T, 2009, MOL CELL BIOL, V29, P3529, DOI 10.1128/MCB.00364-09; Salat D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130288; Tada H, 2010, J BIOL CHEM, V285, P3840, DOI 10.1074/jbc.M109.046284; Tang XF, 2019, GENET TEST MOL BIOMA, V23, P791, DOI 10.1089/gtmb.2019.0129; Wang K, 2018, J CANCER RES CLIN, V144, P1509, DOI 10.1007/s00432-018-2653-1; Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700; Wu LH, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04675-2; Wu YM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1014-2; Xia J, 2014, CURR PHARM DESIGN, V20, P5348, DOI 10.2174/1381612820666140128215756; Xia J, 2012, CURR DRUG TARGETS, V13, P1750, DOI 10.2174/138945012804545597; Xu M, 2015, ONCOTARGET, V6, P979, DOI 10.18632/oncotarget.2825; Xu YC, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00689-5; Yang Q, 2014, BRIT J CANCER, V110, P1958, DOI 10.1038/bjc.2014.136; Yin FQ, 2014, ONCOL REP, V32, P362, DOI 10.3892/or.2014.3175; Yoshida K, 2005, ONCOL REP, V14, P531; Zhan A, 2017, ONCOL RES, V25, P831, DOI 10.3727/096504016X14816726393937; Zheng NN, 2016, BBA-REV CANCER, V1866, P12, DOI 10.1016/j.bbcan.2016.05.001; Zhu ZH, 2017, GYNECOL ONCOL, V147, P418, DOI 10.1016/j.ygyno.2017.08.025	49	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2022	41	43					4795	4807		10.1038/s41388-022-02468-7	http://dx.doi.org/10.1038/s41388-022-02468-7		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M4RI	36127399				2022-12-28	WOS:000855639800001
J	Li, M; Xu, H; Qi, YH; Pan, ZW; Li, BY; Gao, ZJ; Zhao, RR; Xue, H; Li, G				Li, Ming; Xu, Hao; Qi, Yanhua; Pan, Ziwen; Li, Boyan; Gao, Zijie; Zhao, Rongrong; Xue, Hao; Li, Gang			Tumor-derived exosomes deliver the tumor suppressor miR-3591-3p to induce M2 macrophage polarization and promote glioma progression	ONCOGENE			English	Article							IMMUNITY; BRAIN; CELLS	Exosomes can selectively secrete harmful metabolic substances from cells to maintain cellular homeostasis, and complex crosstalk occurs between exosomes and tumor-associated macrophages (TAMs) in the glioma immune microenvironment. However, the precise mechanisms by which these exosome-encapsulated cargos create an immunosuppressive microenvironment remain unclear. Herein, we investigated the effect of glioma-derived exosomes (GDEs) on macrophage polarization and glioma progression. We performed sequencing analysis of cerebrospinal fluid (CSF) and tumor tissues from glioma patients to identify functional microRNAs (miRNAs). High levels of miR-3591-3p were found in CSF and GDEs but not in normal brain tissue or glial cells. Functionally, GDEs and miR-3591-3p significantly induced M2 macrophage polarization and increased the secretion of IL10 and TGF beta 1, which in turn promoted glioma invasion and migration. Moreover, miR-3591-3p overexpression in glioma cell lines resulted in G2/M arrest and markedly increased apoptosis. Mechanistically, miR-3591-3p can directly target CBLB and MAPK1 in macrophages and glioma cells, respectively, and further activate the JAK2/PI3K/AKT/mTOR, JAK2/STAT3, and MAPK signaling pathways. In vivo experiments confirmed that macrophages lentivirally transduced with miR-3591-3p can significantly promote glioma progression. Thus, our study demonstrates that tumor-suppressive miR-3591-3p in glioma cells can be secreted via exosomes and target TAMs to induce the formation of an immunosuppressive microenvironment. Collectively, these findings provide new insights into the role of glioma exosomal miRNAs in mediating the establishment of an immunosuppressive tumor microenvironment and show that miR-3591-3p may be a valuable biomarker and that blocking the encapsulation of miR-3591-3p into exosomes may become a novel immunotherapeutic strategy for glioma.	[Li, Ming; Xu, Hao; Qi, Yanhua; Pan, Ziwen; Li, Boyan; Gao, Zijie; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurosurg, Jinan 250012, Shandong, Peoples R China; [Li, Ming; Xu, Hao; Qi, Yanhua; Pan, Ziwen; Li, Boyan; Gao, Zijie; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Univ, Inst Brain & Braininspired Sci, Jinan 250012, Shandong, Peoples R China; [Li, Ming; Xu, Hao; Qi, Yanhua; Pan, Ziwen; Li, Boyan; Gao, Zijie; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Key Lab Brain Funct Remodeling, Jinan 250012, Shandong, Peoples R China; [Li, Ming] Qingdao Univ, Affiliated Taian City Cent Hosp, Dept Neurosurg, Tai An 271000, Shandong, Peoples R China; [Xu, Hao] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Neurosurg, Yantai 264000, Shandong, Peoples R China	Shandong University; Shandong University; Qingdao University; Qingdao University	Xue, H; Li, G (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurosurg, Jinan 250012, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Univ, Inst Brain & Braininspired Sci, Jinan 250012, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Key Lab Brain Funct Remodeling, Jinan 250012, Shandong, Peoples R China.	xuehao@sdu.edu.cn; dr.ligang@sdu.edu.cn			National Natural Science Foundation of China [82273195, 81874083, 82072776, 82273286, 82072775, 82203419]; Natural Science Foundation of Shandong Province of China [ZR2019BH057, ZR2020QH174, ZR2021LSW025]; Jinan Science and Technology Bureau of Shandong Province [2021GXRC029]; Key clinical Research project of Clinical Research Center of Shandong University [2020SDUCRCA011]; Taishan Pandeng Scholar Program of Shandong Province [tspd20210322]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province of China(Natural Science Foundation of Shandong Province); Jinan Science and Technology Bureau of Shandong Province; Key clinical Research project of Clinical Research Center of Shandong University; Taishan Pandeng Scholar Program of Shandong Province	We are grateful to the surgeons, physicians, and patients who participated in our studies. We thank the Novogene Co. Ltd and Tianjin Novogene Bioinformatics Technology Co., Ltd for miRNA and mRNA Sequencing technical development and support. This work was supported by grants from the National Natural Science Foundation of China (Nos. 82273195; 81874083; 82072776; 82273286; 82072775; 82203419), Natural Science Foundation of Shandong Province of China (Nos. ZR2019BH057; ZR2020QH174; ZR2021LSW025), the Jinan Science and Technology Bureau of Shandong Province (2021GXRC029), Key clinical Research project of Clinical Research Center of Shandong University (2020SDUCRCA011) and Taishan Pandeng Scholar Program of Shandong Province (No. tspd20210322).	Aldape K, 2019, NAT REV CLIN ONCOL, V16, P509, DOI 10.1038/s41571-019-0177-5; Anderson NR, 2021, CANCER RES, V81, P1201, DOI 10.1158/0008-5472.CAN-20-2990; Antunes ARP, 2021, NAT NEUROSCI, V24, P595, DOI 10.1038/s41593-020-00789-y; Barthel L, 2022, CANCER METAST REV, V41, P53, DOI 10.1007/s10555-021-09997-9; Chen CY, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01511-1; Chen DG, 2021, THERANOSTICS, V11, P1016, DOI 10.7150/thno.51777; Chen PW, 2019, CANCER CELL, V35, P868, DOI 10.1016/j.ccell.2019.05.003; Cheng J, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01189-3; Dapash M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092257; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Guo X, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001975; He GP, 2022, MOL CANCER, V21, DOI 10.1186/s12943-021-01440-5; Hoshino A, 2020, CELL, V182, P1044, DOI 10.1016/j.cell.2020.07.009; Hosseini R, 2022, MOL CANCER, V21, DOI 10.1186/s12943-021-01492-7; Iguchi Y, 2016, BRAIN, V139, P3187, DOI 10.1093/brain/aww237; Janjua TI, 2021, ADV DRUG DELIVER REV, V171, P108, DOI 10.1016/j.addr.2021.01.012; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kang M, 2021, ADV MATER, V33, DOI 10.1002/adma.202103258; Lavoie H, 2020, NAT REV MOL CELL BIO, V21, P607, DOI 10.1038/s41580-020-0255-7; Li X, 2020, J EXP MED, V217, DOI 10.1084/jem.20191537; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00299-9; Liu TQ, 2022, ONCOIMMUNOLOGY, V11, DOI 10.1080/2162402X.2022.2031499; Lv KS, 2017, GENE DEV, V31, P1007, DOI 10.1101/gad.297135.117; Ma FY, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003217; Miller KD, 2021, CA-CANCER J CLIN, V71, P381, DOI 10.3322/caac.21693; Morrissey SM, 2021, CELL METAB, V33, P2040, DOI 10.1016/j.cmet.2021.09.002; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Nguyen TTT, 2021, J EXP MED, V218, DOI 10.1084/jem.20202477; O'Brien K, 2020, NAT REV MOL CELL BIO, V21, P585, DOI 10.1038/s41580-020-0251-y; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Pan ZW, 2022, MOL CANCER, V21, DOI 10.1186/s12943-021-01485-6; Qiu W, 2021, MOL THER, V29, P3449, DOI 10.1016/j.ymthe.2021.06.023; TAKAHASHI A, 2017, NAT COMMUN, V8, DOI [10.1038/ncomms15287, DOI 10.1038/NCOMMS15287]; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Tzetzo SL, 2021, CANCER CELL, V39, P734, DOI 10.1016/j.ccell.2021.03.002; Vignard V, 2020, CANCER IMMUNOL RES, V8, P255, DOI 10.1158/2326-6066.CIR-19-0522; Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691; Wang YJ, 2021, CANCER CELL, V39, P1375, DOI 10.1016/j.ccell.2021.07.023; Wang Z, 2020, J CELL PHYSIOL, V235, P2825, DOI 10.1002/jcp.29188; Xia YQ, 2020, ADV MATER, V32, DOI 10.1002/adma.202002054; Xu JY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03664-1; Yan SJ, 2021, FEBS J, V288, P6174, DOI 10.1111/febs.15726; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang ZP, 2020, CANCER IMMUNOL RES, V8, P966, DOI 10.1158/2326-6066.CIR-19-0759; Zhou HH, 2021, MOL THER, V29, P3465, DOI 10.1016/j.ymthe.2021.06.019	46	0	0	15	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4618	4632		10.1038/s41388-022-02457-w	http://dx.doi.org/10.1038/s41388-022-02457-w		SEP 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36085418	hybrid, Green Published			2022-12-28	WOS:000852095400001
J	D'Agosto, S; Pezzini, F; Veghini, L; Delfino, P; Fiorini, C; Tane, GDT; Del Curatolo, A; Vicentini, C; Ferrari, G; Pasini, D; Andreani, S; Lupo, F; Fiorini, E; Lorenzon, G; Lawlor, RT; Rusev, B; Malinova, A; Luchini, C; Milella, M; Sereni, E; Pea, A; Bassi, C; Bailey, P; Scarpa, A; Bria, E; Corbo, V				D'Agosto, Sabrina; Pezzini, Francesco; Veghini, Lisa; Delfino, Pietro; Fiorini, Claudia; Tane, Gael D. Temgue; Del Curatolo, Anais; Vicentini, Caterina; Ferrari, Giorgia; Pasini, Davide; Andreani, Silvia; Lupo, Francesca; Fiorini, Elena; Lorenzon, Giulia; Lawlor, Rita T.; Rusev, Borislav; Malinova, Antonia; Luchini, Claudio; Milella, Michele; Sereni, Elisabetta; Pea, Antonio; Bassi, Claudio; Bailey, Peter; Scarpa, Aldo; Bria, Emilio; Corbo, Vincenzo			Loss of FGFR4 promotes the malignant phenotype of PDAC	ONCOGENE			English	Article							SET ENRICHMENT ANALYSIS; PANCREATIC-CANCER; CELL IDENTITY; GROWTH; ACTIVATION; INHIBITOR; SUBTYPES	Transcriptomic analyses of pancreatic ductal adenocarcinoma (PDAC) have identified two major epithelial subtypes with distinct biology and clinical behaviours. Here, we aimed to clarify the role of FGFR1 and FGFR4 in the definition of aggressive PDAC phenotypes. We found that the expression of FGFR4 is exclusively detected in epithelial cells, significantly elevated in the classical PDAC subtype, and associates with better outcomes. In highly aggressive basal-like/squamous PDAC, reduced FGFR4 expression aligns with hypermethylation of the gene and lower levels of histone marks associated with active transcription in its regulatory regions. Conversely, FGFR1 has more promiscuous expression in both normal and malignant pancreatic tissues and is strongly associated with the EMT phenotype but not with the basal-like cell lineage. Regardless of the genetic background, the increased proliferation of FGFR4-depleted PDAC cells correlates with hyperactivation of the mTORC1 pathway both in vitro and in vivo. Downregulation of FGFR4 in classical cell lines invariably leads to the enrichment of basal-like/squamous gene programs and is associated with either partial or full switch of phenotype. In sum, we show that endogenous levels of FGFR4 limit the malignant phenotype of PDAC cells. Finally, we propose FGFR4 as a valuable marker for the stratification of PDAC patients.	[D'Agosto, Sabrina; Pezzini, Francesco; Veghini, Lisa; Delfino, Pietro; Fiorini, Claudia; Tane, Gael D. Temgue; Ferrari, Giorgia; Pasini, Davide; Andreani, Silvia; Lupo, Francesca; Fiorini, Elena; Lorenzon, Giulia; Malinova, Antonia; Luchini, Claudio; Scarpa, Aldo; Corbo, Vincenzo] Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, Verona, Italy; [Del Curatolo, Anais; Vicentini, Caterina; Lawlor, Rita T.; Rusev, Borislav; Scarpa, Aldo; Corbo, Vincenzo] Univ & Hosp Trust Verona, ARC Net Res Ctr, Verona, Italy; [Milella, Michele] Univ & Hosp Trust Verona, Dept Med, Sect Oncol, Verona, Italy; [Sereni, Elisabetta; Pea, Antonio; Bassi, Claudio] Univ & Hosp Trust Verona, Pancreas Inst, Dept Surg, Verona, Italy; [Bailey, Peter] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Bailey, Peter] Canc Res UK Beatson Inst, Glasgow, Lanark, Scotland; [Bailey, Peter] Heidelberg Univ, Dept Gen Surg, Heidelberg, Germany; [Bria, Emilio] Fdn Policlin Univ Agostino Gemelli IRCCS, Comprehens Canc Ctr, Rome, Italy; [Bria, Emilio] Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Sect Med Oncol, Rome, Italy; [D'Agosto, Sabrina] Human Technopole, Milan, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Glasgow; Beatson Institute; Ruprecht Karls University Heidelberg; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Human Technopole	Corbo, V (corresponding author), Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, Verona, Italy.; Corbo, V (corresponding author), Univ & Hosp Trust Verona, ARC Net Res Ctr, Verona, Italy.	vincenzo.corbo@univr.it		Malinova, Antonia/0000-0003-0325-501X; Pasini, Davide/0000-0002-8270-7143	Associazione Italiana Ricerca sul Cancro (AIRC) [18178]; EU (MSCA project PRECODE) [861196]; National Cancer Institute (NCI) [HHSN26100008]; AIRC [IG20583, 24043, 19404, 20872, 25286]; Universita Cattolica del Sacro Cuore (UCSC); AIRC 5x1000 [12182]; Fondazione Nadia Valsecchi Onlus; Ontario Institute for Cancer Research through Government of Ontario	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); EU (MSCA project PRECODE); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AIRC(Fondazione AIRC per la ricerca sul cancro); Universita Cattolica del Sacro Cuore (UCSC); AIRC 5x1000(Fondazione AIRC per la ricerca sul cancro); Fondazione Nadia Valsecchi Onlus; Ontario Institute for Cancer Research through Government of Ontario	We gratefully acknowledge the Centro Piattaforme Tecnologiche (CPT - University of Verona, Verona, Italy) for granting access to the genomic facility of University of Verona. In addition, we acknowledge the assistance provided by Serena Pedron, Valerio Crestani, Claudia Parolini, e Paola Perfetti for the execution of immunohistochemical staining. VC is supported by Associazione Italiana Ricerca sul Cancro (AIRC; Grant No. 18178). VC is also supported by the EU (MSCA project PRECODE, grant No: 861196) and the National Cancer Institute (NCI, HHSN26100008). EB is supported by the AIRC (Grant No. IG20583), and by Institutional funds of Universita Cattolica del Sacro Cuore (UCSC-project D1). AS is supported by AIRC 5x1000, grant n 12182. SDa is supported by AIRC (24043). CF was supported for by the Fondazione Umberto Veronesi. AdC was supported by AIRC (19404, 20872). PD is supported by Fondazione Nadia Valsecchi Onlus. EF is supported by AIRC (25286). This study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario. The funding agencies had no role in the collection, analysis, and interpretation of data or in the writing of the paper.	Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Aguirre AJ, 2018, CANCER DISCOV, V8, P1096, DOI 10.1158/2159-8290.CD-18-0275; Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Andricovich J, 2018, CANCER CELL, V33, P512, DOI 10.1016/j.ccell.2018.02.003; Aung KL, 2018, CLIN CANCER RES, V24, P1344, DOI 10.1158/1078-0432.CCR-17-2994; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Balli D, 2017, CLIN CANCER RES, V23, P3129, DOI 10.1158/1078-0432.CCR-16-2128; Bhushan A, 2001, DEVELOPMENT, V128, P5109; Brunton H, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107625; Chan-Seng-Yue M, 2020, NAT GENET, V52, P231, DOI 10.1038/s41588-019-0566-9; Collisson EA, 2019, NAT REV GASTRO HEPAT, V16, P207, DOI 10.1038/s41575-019-0109-y; Diaferia GR, 2016, EMBO J, V35, P595, DOI 10.15252/embj.201592404; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Dreyer SB, 2021, GASTROENTEROLOGY, V160, P362, DOI 10.1053/j.gastro.2020.09.043; Elghazi L, 2002, P NATL ACAD SCI USA, V99, P3884, DOI 10.1073/pnas.062321799; Frattini V, 2018, NATURE, V553, P222, DOI 10.1038/nature25171; Goncalves CA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23295-6; Grun D, 2016, CELL STEM CELL, V19, P266, DOI 10.1016/j.stem.2016.05.010; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hagel M, 2015, CANCER DISCOV, V5, P424, DOI 10.1158/2159-8290.CD-14-1029; Hayashi A, 2020, NAT CANCER, V1, P59, DOI 10.1038/s43018-019-0010-1; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; Kalisz M, 2020, EMBO J, V39, DOI 10.15252/embj.2019102808; Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377; Kloesch B, 2022, GUT, V71, P766, DOI 10.1136/gutjnl-2020-321397; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lin W, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00776-9; Martinelli P, 2017, GUT, V66, P1665, DOI 10.1136/gutjnl-2015-311256; Meyers N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62106-8; Michl P, 2021, UNITED EUR GASTROENT, V9, P860, DOI 10.1002/ueg2.12123; Moffitt RA, 2015, NAT GENET, V47, P1168, DOI 10.1038/ng.3398; Motoda N, 2011, INT J ONCOL, V38, P133, DOI 10.3892/ijo_00000832; Muraro MJ, 2016, CELL SYST, V3, P385, DOI 10.1016/j.cels.2016.09.002; Neben CL, 2019, DEV BIOL, V447, P71, DOI 10.1016/j.ydbio.2017.10.017; Nicolle R, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102858; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Porter RL, 2019, P NATL ACAD SCI USA, V116, P26835, DOI 10.1073/pnas.1914915116; Rahib L, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.4708; Raoof S, 2019, ONCOGENE, V38, P6399, DOI 10.1038/s41388-019-0887-2; Sasaki N, 2020, CANCERS, V12, DOI 10.3390/cancers12102976; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Segerstolpe A, 2016, CELL METAB, V24, P593, DOI 10.1016/j.cmet.2016.08.020; Shah P, 2013, CELL, V153, P1589, DOI 10.1016/j.cell.2013.05.049; Somerville TDD, 2020, P NATL ACAD SCI USA, V117, P11471, DOI 10.1073/pnas.1921484117; Somerville TDD, 2018, CELL REP, V25, P1741, DOI 10.1016/j.celrep.2018.10.051; Steele NG, 2020, NAT CANCER, V1, P1097, DOI 10.1038/s43018-020-00121-4; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Ulaganathan VK, 2015, NATURE, V528, P570, DOI 10.1038/nature16449	53	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4371	4384		10.1038/s41388-022-02432-5	http://dx.doi.org/10.1038/s41388-022-02432-5		AUG 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35963908	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000840288700001
J	Zhang, MX; Wang, JL; Mo, CQ; Mao, XP; Feng, ZH; Li, JY; Lin, HS; Song, HD; Xu, QH; Wang, YH; Lu, J; Wei, JH; Han, H; Chen, W; Mao, HP; Luo, JH; Chen, ZH				Zhang, Ming-xiao; Wang, Jia-li; Mo, Cheng-qiang; Mao, Xiao-peng; Feng, Zi-hao; Li, Jia-ying; Lin, Hai-shan; Song, Hong-de; Xu, Quan-hui; Wang, Ying-han; Lu, Jun; Wei, Jin-huan; Han, Hui; Chen, Wei; Mao, Hai-ping; Luo, Jun-hang; Chen, Zhen-hua			CircME1 promotes aerobic glycolysis and sunitinib resistance of clear cell renal cell carcinoma through cis-regulation of ME1	ONCOGENE			English	Article							CANCER PROGRESSION; CONTRIBUTES; METASTASIS; MYC	Circular RNAs (circRNAs) play critical roles in clear cell renal cell carcinoma (ccRCC). However, their involvement in sunitinib resistance remains largely unknown. Herein, we identified a novel circRNA, named circME1, which contributes to sunitinib resistance development in ccRCC. CircME1 also promoted proliferation, migration, and invasion of ccRCC cells. Further mechanism analysis showed that circME1 interacted with U1 snRNP at the promoter of its parental gene ME1, thereby upregulating the expression of ME1, enhancing aerobic glycolysis of ccRCC, and promoting its malignant phenotype. Furthermore, ME1 specific inhibitor could effectively repress the oncogenic functions of circME1. Taken together, our study demonstrates that the circME1/ME1 pathway is involved in ccRCC progression and sunitinib resistance development, which may be exploited for anticancer therapy.	[Zhang, Ming-xiao; Mo, Cheng-qiang; Mao, Xiao-peng; Feng, Zi-hao; Li, Jia-ying; Lin, Hai-shan; Song, Hong-de; Xu, Quan-hui; Wang, Ying-han; Lu, Jun; Wei, Jin-huan; Chen, Wei; Luo, Jun-hang; Chen, Zhen-hua] Sun Yat sen Univ, Affiliated Hosp 1, Dept Urol, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China; [Wang, Jia-li; Mao, Hai-ping] Sun Yat sen Univ, Affiliated Hosp 1, Dept Nephrol, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China; [Han, Hui] Sun Yat sen Univ, Ctr Canc, Dept Urol, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China; [Luo, Jun-hang] Sun Yat sen Univ, Affiliated Hosp 1, Inst Precis Med, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Luo, JH; Chen, ZH (corresponding author), Sun Yat sen Univ, Affiliated Hosp 1, Dept Urol, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China.; Mao, HP (corresponding author), Sun Yat sen Univ, Affiliated Hosp 1, Dept Nephrol, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China.; Luo, JH (corresponding author), Sun Yat sen Univ, Affiliated Hosp 1, Inst Precis Med, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China.	maohp@mail.sysu.edu.cn; luojunh@mail.sysu.edu.cn; chenzhh75@mail.sysu.edu.cn			National Natural Science Foundation of China [81902576, 81725016, 81872094, 82002684]; Natural Science Foundation of Guangdong Province, China [2017B020227004, 2017A030313538]; China Postdoctoral Science Foundation [2020M683082]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (Nos. 81902576, 81725016, 81872094 and 82002684), the Natural Science Foundation of Guangdong Province, China (2017B020227004 and 2017A030313538), and China Postdoctoral Science Foundation Funded Project (No. 2020M683082).	Adelaiye-Ogala R, 2017, CANCER RES, V77, P6651, DOI 10.1158/0008-5472.CAN-17-0899; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Cao SB, 2019, ONCOGENE, V38, P7060, DOI 10.1038/s41388-019-0947-7; Chen Q, 2020, CANCER LETT, V469, P68, DOI 10.1016/j.canlet.2019.10.017; Chen RX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12651-2; Chen X, 2018, CLIN CANCER RES, V24, P6319, DOI 10.1158/1078-0432.CCR-18-1270; Chow LQM, 2007, J CLIN ONCOL, V25, P884, DOI 10.1200/JCO.2006.06.3602; Conn VM, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.53; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Escudier B, 2007, DRUGS, V67, P1257, DOI 10.2165/00003495-200767090-00002; Frank I, 2003, J UROLOGY, V170, P2225, DOI 10.1097/01.ju.0000095541.10333.a7; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; He JH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1120-1; He RF, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0614-1; Li JF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01225-2; Li Q, 2019, HEPATOLOGY, V70, P1298, DOI 10.1002/hep.30671; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liang WC, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1685-4; Liang YK, 2021, MOL THER-NUCL ACIDS, V23, P355, DOI 10.1016/j.omtn.2020.11.012; Liao RC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35106-y; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Ljungberg B, 2019, EUR UROL, V75, P799, DOI 10.1016/j.eururo.2019.02.011; Lu YX, 2018, CANCER RES, V78, P1972, DOI 10.1158/0008-5472.CAN-17-3155; Molina AM, 2014, EUR J CANCER, V50, P351, DOI 10.1016/j.ejca.2013.08.021; Nakashima C, 2018, CANCER SCI, V109, P2036, DOI 10.1111/cas.13594; Oudard S, 2007, ANN ONCOL, V18, P25, DOI 10.1093/annonc/mdm411; Pascale RM, 2020, CANCERS, V12, DOI 10.3390/cancers12102819; Patop IL, 2018, CURR OPIN GENET DEV, V48, P121, DOI 10.1016/j.gde.2017.11.007; Pisarsky L, 2016, CELL REP, V15, P1161, DOI 10.1016/j.celrep.2016.04.028; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Ruan HL, 2020, ONCOGENE, V39, P6113, DOI 10.1038/s41388-020-01409-6; Wang XH, 2021, MOL THER-NUCL ACIDS, V26, P122, DOI 10.1016/j.omtn.2021.07.003; Weng HQ, 2021, MOL THER-NUCL ACIDS, V23, P811, DOI 10.1016/j.omtn.2020.12.019; Will CL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003707; Yang Z, 2019, ONCOGENE, V38, P2516, DOI 10.1038/s41388-018-0602-8; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Yu T, 2021, MOL THER-NUCL ACIDS, V26, P649, DOI 10.1016/j.omtn.2021.08.029; Zhang ML, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06862-2; Zhu YH, 2020, MOL CELL, V77, P138, DOI 10.1016/j.molcel.2019.10.015	39	2	2	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					3979	3990		10.1038/s41388-022-02386-8	http://dx.doi.org/10.1038/s41388-022-02386-8		JUL 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35798876	Green Published			2022-12-28	WOS:000821721300001
J	Zeng, YJ; Yin, L; Zhou, JL; Zeng, RY; Xiao, Y; Black, AR; Hu, T; Singh, PK; Yin, F; Batra, SK; Yu, F; Chen, YH; Dong, JX				Zeng, Yongji; Yin, Ling; Zhou, Jiuli; Zeng, Renya; Xiao, Yi; Black, Adrian R.; Hu, Tuo; Singh, Pankaj K.; Yin, Feng; Batra, Surinder K.; Yu, Fang; Chen, Yuanhong; Dong, Jixin			MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; HIPPO PATHWAY; MITOTIC PHOSPHORYLATION; NAB-PACLITAXEL; SIZE-CONTROL; MITOSIS; KINASE; GROWTH; GEMCITABINE; HOMEOSTASIS	Despite paclitaxel's wide use in cancer treatment, patient response rate is still low and drug resistance is a major clinical obstacle. Through a Phos-tag-based kinome-wide screen, we identified MARK2 as a critical regulator for paclitaxel chemosensitivity in PDAC. We show that MARK2 is phosphorylated by CDK1 in response to antitubulin chemotherapeutics and in unperturbed mitosis. Phosphorylation is essential for MARK2 in regulating mitotic progression and paclitaxel cytotoxicity in PDAC cells. Mechanistically, our findings also suggest that MARK2 controls paclitaxel chemosensitivity by regulating class IIa HDACs. MARK2 directly phosphorylates HDAC4 specifically during antitubulin treatment. Phosphorylated HDAC4 promotes YAP activation and controls expression of YAP target genes induced by paclitaxel. Importantly, combination of HDAC inhibition and paclitaxel overcomes chemoresistance in organoid culture and preclinical PDAC animal models. The expression levels of MARK2, HDACs, and YAP are upregulated and positively correlated in PDAC patients. Inhibition of MARK2 or class IIa HDACs potentiates paclitaxel cytotoxicity by inducing mitotic abnormalities in PDAC cells. Together, our findings identify the MARK2-HDAC axis as a druggable target for overcoming chemoresistance in PDAC.	[Zeng, Yongji; Yin, Ling; Zhou, Jiuli; Zeng, Renya; Xiao, Yi; Black, Adrian R.; Hu, Tuo; Singh, Pankaj K.; Chen, Yuanhong; Dong, Jixin] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Yin, Feng] Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO USA; [Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA; [Yu, Fang] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE USA; [Zhou, Jiuli] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China	University of Nebraska System; University of Nebraska Medical Center; University of Missouri System; University of Missouri Columbia; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Tongji University	Dong, JX (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	dongj@unmc.edu	Hu, Tuo/HDM-3005-2022; Yin, Ling/AAD-8990-2022	Hu, Tuo/0000-0001-7069-1466; Yin, Ling/0000-0003-1606-2620; Zeng, Yongji/0000-0002-1184-1900; Singh, Pankaj/0000-0001-8903-0131; Batra, Surinder K./0000-0001-9470-9317	Fred & Pamela Buffett Cancer Center Support Grant [P30 CA036727]; National Institutes of Health (NIH) [R01 GM109066]	Fred & Pamela Buffett Cancer Center Support Grant; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr. Xiao-long Yang (Queens University) for the TetO-shCDK1 HeLa cell line. All fluorescence images were acquired by a Zeiss LSM 800 microscope and processed with accompanying software at the Advanced Microscopy Core at the University of Nebraska Medical Center. Research in the Dong laboratory is supported by Fred & Pamela Buffett Cancer Center Support Grant (P30 CA036727) and R01 GM109066 from the the National Institutes of Health (NIH). We are very grateful to Dr. Joyce Solheim for critical reading and comments on the paper.	Adamska Aleksandra, 2018, Advances in Biological Regulation, V68, P77, DOI 10.1016/j.jbior.2017.11.007; Ahrari S, 2017, ARCH BIOCHEM BIOPHYS, V630, P66, DOI 10.1016/j.abb.2017.07.002; Arash EH, 2017, EMBO REP, V18, P420, DOI 10.15252/embr.201642455; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; Beghini A, 2003, ONCOGENE, V22, P2581, DOI 10.1038/sj.onc.1206336; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Chen XC, 2016, CELL SIGNAL, V28, P1826, DOI 10.1016/j.cellsig.2016.08.013; Chen XC, 2016, J BIOL CHEM, V291, P14761, DOI 10.1074/jbc.M116.722751; Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775; Dequiedt F, 2006, MOL CELL BIOL, V26, P7086, DOI 10.1128/MCB.00231-06; Dietrich CS, 2010, GYNECOL ONCOL, V116, P126, DOI 10.1016/j.ygyno.2009.09.039; Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dowdy SC, 2006, MOL CANCER THER, V5, P2767, DOI 10.1158/1535-7163.MCT-06-0209; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Duong-Ly Krisna C, 2013, Curr Protoc Pharmacol, VChapter 2, DOI 10.1002/0471141755.ph0209s60; Fu V, 2017, CURR OPIN CELL BIOL, V49, P99, DOI 10.1016/j.ceb.2017.12.012; Goodwin JM, 2014, MOL CELL, V55, P436, DOI 10.1016/j.molcel.2014.06.021; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Henriques AC, 2019, CANCER LETT, V440, P64, DOI 10.1016/j.canlet.2018.10.005; Hessmann E, 2017, GUT, V66, P168, DOI 10.1136/gutjnl-2016-312539; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Huang HL, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001620; Hubaux R, 2015, INT J CANCER, V137, P2072, DOI 10.1002/ijc.29577; Jackson JR, 2007, NAT REV CANCER, V7, P107, DOI 10.1038/nrc2049; Janssen A, 2011, ONCOGENE, V30, P2799, DOI 10.1038/onc.2011.30; Jenardhanan P, 2014, MOL BIOSYST, V10, P1845, DOI 10.1039/c3mb70591a; Kato T, 2001, NEOPLASIA, V3, P4, DOI 10.1038/sj.neo.7900132; Kiyokawa N, 1997, J BIOL CHEM, V272, P18656, DOI 10.1074/jbc.272.30.18656; Koutsounas I, 2013, WORLD J GASTROENTERO, V19, P1173, DOI 10.3748/wjg.v19.i8.1173; Kwan J, 2016, GENE DEV, V30, P2696, DOI 10.1101/gad.284539.116; Lee KM, 2005, LAB INVEST, V85, P1003, DOI 10.1038/labinvest.3700298; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Ma A, 2001, MOL BIOL CELL, V12, P1; Ma WW, 2013, CLIN CANCER RES, V19, P5572, DOI 10.1158/1078-0432.CCR-13-1356; Magnani I, 2011, ANAL CELL PATHOL, V34, P319, DOI [10.1155/2011/206756, 10.3233/ACP-2011-0031]; Maugeri-Sacca M, 2018, PHARMACOL THERAPEUT, V186, P60, DOI 10.1016/j.pharmthera.2017.12.011; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723; Natalia MA., 2018, CELLS MICRORNA, V7, P54, DOI [10.2174/2211536606666171024160244, DOI 10.2174/2211536606666171024160244]; Ni X, 2015, ONCOL LETT, V9, P515, DOI 10.3892/ol.2014.2714; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Pardo OE, 2016, EMBO REP, V17, P570, DOI 10.15252/embr.201540970; Qiu Wanglong, 2013, Methods Mol Biol, V980, P215, DOI 10.1007/978-1-62703-287-2_11; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; Roche J, 2016, EUR J MED CHEM, V121, P451, DOI 10.1016/j.ejmech.2016.05.047; Sarantis P, 2020, WORLD J GASTRO ONCOL, V12, DOI 10.4251/wjgo.v12.i2.173; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sild M, 2019, MOL PSYCHIATR, V24, P1425, DOI 10.1038/s41380-019-0366-8; Sinn M, 2017, J CLIN ONCOL, V35, P3330, DOI 10.1200/JCO.2017.72.6463; Stauffer S, 2019, J CELL SCI, V132, DOI 10.1242/jcs.236000; Stauffer S, 2017, CELL SIGNAL, V39, P74, DOI 10.1016/j.cellsig.2017.08.001; Suraweera A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00092; Tang EI, 2013, J ENDOCRINOL, V217, pR13, DOI 10.1530/JOE-12-0586; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Tsai HC, 2014, BBA-MOL CELL RES, V1843, P846, DOI 10.1016/j.bbamcr.2014.01.007; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Von Hoff DD, 2011, J CLIN ONCOL, V29, P4548, DOI 10.1200/JCO.2011.36.5742; Wanek J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103128; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.328; Wang Z, 2018, CELL SIGNAL, V52, P137, DOI 10.1016/j.cellsig.2018.09.007; Wang ZK, 2014, EPIGENOMICS-UK, V6, P139, DOI 10.2217/epi.13.73; Weaver BA, 2014, MOL BIOL CELL, V25, P2677, DOI 10.1091/mbc.E14-04-0916; Woodring PJ, 2005, J BIOL CHEM, V280, P10318, DOI 10.1074/jbc.M410658200; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Yang CPH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081733; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zasadil LM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007965; Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15; Zhang L, 2012, J BIOL CHEM, V287, P34069, DOI 10.1074/jbc.M112.385518; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao YL, 2015, ONCOTARGET, V6, P21906, DOI 10.18632/oncotarget.4259; Zhou JL, 2018, P NATL ACAD SCI USA, V115, pE6760, DOI 10.1073/pnas.1800621115	79	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3859	3875		10.1038/s41388-022-02399-3	http://dx.doi.org/10.1038/s41388-022-02399-3		JUL 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35780183	Green Submitted			2022-12-28	WOS:000819907600002
J	Li, YJ; Yang, Q; Chen, H; Yang, XT; Han, JR; Yao, XJ; Wei, XJ; Si, JY; Yao, HL; Liu, HL; Wan, LX; Yang, HS; Wang, YM; Bao, DK				Li, Yujia; Yang, Qi; Chen, Hui; Yang, Xiaotian; Han, Jingru; Yao, Xiaojuan; Wei, Xiajie; Si, Jiaoyang; Yao, Huanling; Liu, Hongliang; Wan, Lixin; Yang, Hushan; Wang, Yanming; Bao, Dengke			TFAM downregulation promotes autophagy and ESCC survival through mtDNA stress-mediated STING pathway	ONCOGENE			English	Article								The dynamics of mitochondrial biogenesis regulation is critical in maintaining cellular homeostasis for immune regulation and tumor prevention. Here, we report that mitochondrial biogenesis disruption through TFAM reduction significantly impairs mitochondrial function, induces autophagy, and promotes esophageal squamous cell carcinoma (ESCC) growth. We found that TFAM protein reduction promotes mitochondrial DNA (mtDNA) release into the cytosol, induces cytosolic mtDNA stress, subsequently activates the cGAS-STING signaling pathway, thereby stimulating autophagy and ESCC growth. STING depletion or mtDNA degradation by DNase I abrogates mtDNA stress response, attenuates autophagy, and decreases the growth of TFAM depleted cells. In addition, autophagy inhibitor also ameliorates mitochondrial dysfunction-induced activation of the cGAS-STING signaling pathway and ESCC growth. In conclusion, our results indicate that mtDNA stress induced by mitochondria biogenesis perturbation activates the cGAS-STING pathway and autophagy to promote ESCC growth, revealing an underappreciated therapeutic strategy for ESCC. [GRAPHICS] .	[Li, Yujia; Yang, Qi; Chen, Hui; Yang, Xiaotian; Han, Jingru; Yao, Xiaojuan; Wei, Xiajie; Si, Jiaoyang; Liu, Hongliang; Bao, Dengke] Henan Univ, Sch Pharm, Lab Canc Biomarkers & Liquid Biopsy, Kaifeng 475004, Henan, Peoples R China; [Li, Yujia; Yang, Qi; Yao, Huanling; Wang, Yanming] Henan Univ, Sch Life Sci, Kaifeng 475004, Henan, Peoples R China; [Wan, Lixin; Bao, Dengke] Henan Univ, Nanyang Cent Hosp, Nanyang 473000, Henan, Peoples R China; [Yang, Hushan] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19107 USA	Henan University; Henan University; Henan University; Jefferson University	Bao, DK (corresponding author), Henan Univ, Sch Pharm, Lab Canc Biomarkers & Liquid Biopsy, Kaifeng 475004, Henan, Peoples R China.; Wang, YM (corresponding author), Henan Univ, Sch Life Sci, Kaifeng 475004, Henan, Peoples R China.; Bao, DK (corresponding author), Henan Univ, Nanyang Cent Hosp, Nanyang 473000, Henan, Peoples R China.; Yang, HS (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19107 USA.	hushan.yang@jefferson.edu; yanmingwang@henu.edu.cn; bdkmydy12004@126.com	wan, li/GRY-7634-2022		China Postdoctoral Science Foundation [2020M682286, 2021T140180]; Young Core Instructor of Henan [2021GGJS027]; Henan University	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Young Core Instructor of Henan; Henan University	Project funded by China Postdoctoral Science Foundation (NO. 2020M682286, 2021T140180) to DB, the Young Core Instructor of Henan (NO. 2021GGJS027) to DB. Thanks for startup fund from Henan University to YW and DB.		0	0	0	9	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3735	3746		10.1038/s41388-022-02365-z	http://dx.doi.org/10.1038/s41388-022-02365-z		JUN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35750756				2022-12-28	WOS:000815475400001
J	Ma, SJ; Dong, ZZ; Huang, YF; Liu, JY; Zhang, JT				Ma, Shijie; Dong, Zizheng; Huang, Yanfei; Liu, Jing-Yuan; Zhang, Jian-Ting			eIF3a regulation of mTOR signaling and translational control via HuR in cellular response to DNA damage	ONCOGENE			English	Article							RIBONUCLEOTIDE REDUCTASE M2; SMALL-MOLECULE INHIBITORS; INITIATION-FACTOR 3; BIOCHEMICAL-CHARACTERIZATION; PROTEIN-SYNTHESIS; MAMMALIAN TARGET; OVARIAN-CANCER; RAPAMYCIN TOR; ENTRY SITE; COMPLEX 1	eIF3a (eukaryotic translation initiation factor 3a), a subunit of the eIF3 complex, has been suggested to play a regulatory role in protein synthesis and in cellular response to DNA-damaging treatments. S6K1 is an effector and a mediator of mTOR complex 1 (mTORC1) in regulating protein synthesis and integrating diverse signals into control of cell growth and response to stress. Here, we show that eIF3a regulates S6K1 activity by inhibiting mTORC1 kinase via regulating Raptor synthesis. The regulation of Raptor synthesis is via eIF3a interaction with HuR (human antigen R) and binding of the eIF3a-HuR complex to the 5MODIFIER LETTER PRIME-UTR of Raptor mRNA. Furthermore, mTORC1 may mediate eIF3a function in cellular response to cisplatin by regulating synthesis of NER proteins and NER activity. Taken together, we conclude that the mTOR signaling pathway may also be regulated by translational control and mediate eIF3a regulation of cancer cell response to cisplatin by regulating NER protein synthesis.	[Ma, Shijie; Dong, Zizheng; Zhang, Jian-Ting] Univ Toledo, Coll Med & Life Sci, Dept Cell & Canc Biol, 2801 W Bancroft St, Toledo, OH 43606 USA; [Huang, Yanfei; Liu, Jing-Yuan] Univ Toledo, Coll Med & Life Sci, Dept Med, 2801 W Bancroft St, Toledo, OH 43606 USA	University System of Ohio; University of Toledo; University System of Ohio; University of Toledo	Zhang, JT (corresponding author), Univ Toledo, Coll Med & Life Sci, Dept Cell & Canc Biol, 2801 W Bancroft St, Toledo, OH 43606 USA.	jianting.zhang@utoledo.edu	huang, yan/GWM-4747-2022		NIH [R01 CA211904]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by the NIH grant R01 CA211904.	Ahn B, 2004, MOL CELLS, V18, P249; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Babichev Y, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0814-z; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chen J, 2021, BIOCHEM PHARMACOL, V190, DOI 10.1016/j.bcp.2021.114616; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; Dong ZZ, 2020, BIOCHEM J, V477, P1939, DOI 10.1042/BCJ20200025; Dong ZZ, 2013, J BIOL CHEM, V288, P27951, DOI 10.1074/jbc.M113.483164; Dong ZZ, 2005, NUCLEIC ACIDS RES, V33, P2715, DOI 10.1093/nar/gki569; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; Dunlop EA, 2009, CELL SIGNAL, V21, P827, DOI 10.1016/j.cellsig.2009.01.012; Espeillac C, 2011, J CLIN INVEST, V121, P2821, DOI 10.1172/JCI44203; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Foster KG, 2010, J BIOL CHEM, V285, P80, DOI 10.1074/jbc.M109.029637; Grunwald V, 2002, CANCER RES, V62, P6141; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Gwinn DM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009197; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Huang W, 2016, ONCOGENE, V35, P783, DOI 10.1038/onc.2015.215; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kocalis HE, 2014, MOL METAB, V3, P394, DOI 10.1016/j.molmet.2014.01.014; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Kwak D, 2012, J BIOL CHEM, V287, P18398, DOI 10.1074/jbc.M111.326538; Liu RY, 2011, ONCOGENE, V30, P4814, DOI 10.1038/onc.2011.189; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; Nassim R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065257; Neher TM, 2010, ACS CHEM BIOL, V5, P953, DOI 10.1021/cb1000444; Neher TM, 2010, BIOCHEMISTRY-US, V49, P669, DOI 10.1021/bi901575h; Nouspikel T, 2009, CELL MOL LIFE SCI, V66, P994, DOI 10.1007/s00018-009-8737-y; Peery R, 2020, J MED CHEM, V63, P7243, DOI 10.1021/acs.jmedchem.0c00475; Peng DJ, 2010, BIOCHEM BIOPH RES CO, V394, P600, DOI 10.1016/j.bbrc.2010.03.029; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Qi J, 2014, ONCOGENE, V33, P4156, DOI 10.1038/onc.2013.397; Qiao YW, 2002, MUTAT RES-FUND MOL M, V509, P165, DOI 10.1016/S0027-5107(02)00219-1; Ramirez-Valle F, 2010, MOL CELL BIOL, V30, P3151, DOI 10.1128/MCB.00322-09; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Stronach EA, 2011, NEOPLASIA, V13, P1069, DOI 10.1593/neo.111032; Su B, 2011, CRIT REV BIOCHEM MOL, V46, P527, DOI 10.3109/10409238.2011.618113; Tumia R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00753; Vandamme T, 2016, BRIT J CANCER, V114, P650, DOI 10.1038/bjc.2016.25; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wagner S, 2016, NUCLEIC ACIDS RES, V44, P10772, DOI 10.1093/nar/gkw972; Wagner S, 2014, MOL CELL BIOL, V34, P3041, DOI 10.1128/MCB.00663-14; Wei F, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-81; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yin JY, 2018, CANCER LETT, V412, P81, DOI 10.1016/j.canlet.2017.09.055; Yin JY, 2013, CARCINOGENESIS, V34, P1224, DOI 10.1093/carcin/bgt052; Yin JY, 2011, CLIN CANCER RES, V17, P4600, DOI 10.1158/1078-0432.CCR-10-2591; Yin JY, 2011, BIOSCIENCE REP, V31, P1, DOI 10.1042/BSR20100077; Yuan HX, 2016, CELL RES, V26, P267, DOI 10.1038/cr.2016.10; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	63	2	2	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2431	2443		10.1038/s41388-022-02262-5	http://dx.doi.org/10.1038/s41388-022-02262-5		MAR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35279705	Green Accepted			2022-12-28	WOS:000767909000003
J	Howley, BV; Mohanty, B; Dalton, A; Grelet, S; Karam, J; Dincman, T; Howe, PH				Howley, Breege, V; Mohanty, Bidyut; Dalton, Annamarie; Grelet, Simon; Karam, Joseph; Dincman, Toros; Howe, Philip H.			The ubiquitin E3 ligase ARIH1 regulates hnRNP E1 protein stability, EMT and breast cancer progression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MESSENGER-RNA; TGF-BETA; PCBP 1; TRANSLATION; METASTASIS; EXPRESSION; PARKIN; SWITCH; HHARI	The epithelial to mesenchymal transition (EMT), a process that is aberrantly activated in cancer and facilitates metastasis to distant organs, requires coordinated transcriptional and post-transcriptional control of gene expression. The tumor-suppressive RNA binding protein, hnRNP-E1, regulates splicing and translation of EMT-associated transcripts and it is thought that it plays a major role in the control of epithelial cell plasticity during cancer progression. We have utilized yeast 2 hybrid screening to identify novel hnRNP-E1 interactors that play a role in regulating hnRNP-E1; this approach led to the identification of the E3 ubiquitin ligase ARIH1. Here, we demonstrate that hnRNP-E1 protein stability is increased upon ARIH1 silencing, whereas, overexpression of ARIH1 leads to a reduction in hnRNP-E1. Reduced ubiquitination of hnRNP-E1 detected in ARIH1 knockdown (KD) cells compared to control suggests a role for ARIH1 in hnRNP-E1 degradation. The identification of hnRNP-E1 as a candidate substrate of ARIH1 led to the characterization of a novel function for this ubiquitin ligase in EMT induction and cancer progression. We demonstrate a delayed induction of EMT and reduced invasion in mammary epithelial cells silenced for ARIH1. Conversely, ARIH1 overexpression promoted EMT induction and invasion. ARIH1 silencing in breast cancer cells significantly attenuated cancer cell stemness in vitro and tumor formation in vivo. Finally, we utilized miniTurboID proximity labeling to identify novel ARIH1 interactors that may contribute to ARIH1's function in EMT induction and cancer progression.	[Howley, Breege, V; Mohanty, Bidyut; Dalton, Annamarie; Grelet, Simon; Karam, Joseph; Howe, Philip H.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Grelet, Simon] Univ S Alabama, Mitchell Canc Inst, Dept Biochem & Mol Biol, Mobile, AL USA; [Dincman, Toros] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA; [Howe, Philip H.] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; University of South Alabama; Medical University of South Carolina; Medical University of South Carolina	Howe, PH (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.; Howe, PH (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.	howep@musc.edu		Karam, Joseph/0000-0002-4536-7362; Howe, Philip/0000-0002-1358-1313	National Cancer Institute [CA154663]; DOD BCRP [BC170301, W81XWH-18-1-0003]; NIH [5KL2TR001452]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD BCRP(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by CA154663 from the National Cancer Institute to PHH, DOD BCRP BC170301 under Award No. W81XWH-18-1-0003 to ACD, and NIH 5KL2TR001452 to TD. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. This study used the services of the Cell & Molecular Imaging Shared Resource of MUSC, the Biorepository & Tissue Analysis Shared Resource, and the Gene Targeting and Knockout Shared Resource at MUSC. We would like to thank members of the Howe lab and Dr. Shaun Olsen for providing helpful feedback during the preparation of this manuscript.	Abudayyeh OO, 2016, SCIENCE, V353, DOI 10.1126/science.aaf5573; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Calderwood DA, 2003, NAT CELL BIOL, V5, P694, DOI 10.1038/ncb0803-694; Cao L, 2017, CANCER LETT, V403, P246, DOI 10.1016/j.canlet.2017.06.021; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Chen Q, 2021, CELL MOL LIFE SCI, V78, P949, DOI 10.1007/s00018-020-03544-5; Elmehdawi F, 2013, EXP CELL RES, V319, P161, DOI 10.1016/j.yexcr.2012.10.002; Feng YY, 2004, NAT CELL BIOL, V6, P1034, DOI 10.1038/ncb1104-1034; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grelet S, 2017, NAT CELL BIOL, V19, P1105, DOI 10.1038/ncb3595; Harvey SE, 2018, RNA, V24, P1326, DOI 10.1261/rna.066712.118; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Howley BV, 2016, ONCOGENE, V35, P1725, DOI 10.1038/onc.2015.238; Howley BV, 2019, CYTOKINE, V118, P19, DOI 10.1016/j.cyto.2017.12.032; Howley BV, 2018, ONCOGENE, V37, P1308, DOI 10.1038/s41388-017-0023-0; Huang LX, 2017, CANCER SCI, V108, P1985, DOI 10.1111/cas.13338; Hussey GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052624; Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003; James P, 1996, GENETICS, V144, P1425; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kelsall IR, 2013, EMBO J, V32, P2848, DOI 10.1038/emboj.2013.209; Ko TY, 2019, FASEB J, V33, P7143, DOI 10.1096/fj.201801534RR; Lee IH, 2014, ONCOGENE, V33, P4675, DOI 10.1038/onc.2014.69; LeFave CV, 2011, EMBO J, V30, P4084, DOI 10.1038/emboj.2011.259; Li F, 2019, EBIOMEDICINE, V45, P208, DOI 10.1016/j.ebiom.2019.06.017; Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Meng Q, 2007, P NATL ACAD SCI USA, V104, P5866, DOI 10.1073/pnas.0701065104; Okumura F, 2007, GENE DEV, V21, P255, DOI 10.1101/gad.1521607; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Schnoor M, 2018, TRENDS CELL BIOL, V28, P79, DOI 10.1016/j.tcb.2017.10.009; Scott DC, 2016, CELL, V166, P1198, DOI 10.1016/j.cell.2016.07.027; Shinriki S, 2018, J PATHOL, V244, P367, DOI 10.1002/path.5019; Sohn M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32796-2; Tan KL, 2018, DEV CELL, V45, P226, DOI 10.1016/j.devcel.2018.03.020; Tripathi V, 2016, MOL CELL, V64, P549, DOI 10.1016/j.molcel.2016.09.013; Villa E, 2017, CELL REP, V20, P2846, DOI 10.1016/j.celrep.2017.08.087; von Stechow L, 2015, MOL CELL BIOL, V35, P1254, DOI 10.1128/MCB.01152-14; Wang HH, 2010, CANCER CELL, V18, P52, DOI 10.1016/j.ccr.2010.04.028; Woosley AN, 2019, ONCOGENE, V38, P3794, DOI 10.1038/s41388-019-0703-z; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Zhang MP, 2017, AM J TRANSL RES, V9, P708; Zhang MP, 2016, AM J TRANSL RES, V8, P3567; Zhang ZZ, 2015, MOL CANCER THER, V14, P1162, DOI 10.1158/1535-7163.MCT-14-0695; Zihni C, 2016, NAT REV MOL CELL BIO, V17, P564, DOI 10.1038/nrm.2016.80	49	6	6	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1679	1690		10.1038/s41388-022-02199-9	http://dx.doi.org/10.1038/s41388-022-02199-9		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35102251	hybrid, Green Published			2022-12-28	WOS:000750409400003
J	Meinhardt, AL; Munkhbaatar, E; Hockendorf, U; Dietzen, M; Dechant, M; Anton, M; Jacob, A; Steiger, K; Weichert, W; Brcic, L; McGranahan, N; Branca, C; Kaufmann, T; Dengler, MA; Jost, PJ				Meinhardt, Anna-Lena; Munkhbaatar, Enkhtsetseg; Hockendorf, Ulrike; Dietzen, Michelle; Dechant, Marta; Anton, Martina; Jacob, Anne; Steiger, Katja; Weichert, Wilko; Brcic, Luka; McGranahan, Nicholas; Branca, Caterina; Kaufmann, Thomas; Dengler, Michael A.; Jost, Philipp J.			The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner	ONCOGENE			English	Article							APOPTOSIS; CELLS; PROLIFERATION; EXPRESSION; MUTATIONS; ENABLES; BAX	A variety of cancer entities are driven by KRAS mutations, which remain difficult to target clinically. Survival pathways, such as resistance to cell death, may represent a promising treatment approach in KRAS mutated cancers. Based on the frequently observed genomic deletions of BCL-2-related ovarian killer (BOK) in cancer patients, we explored the function of BOK in a mutant Kras(G12D)-driven murine model of lung cancer. Using Kras(G12D/+)Bok(-/-) mice, we observed an overall tumor-promoting function of BOK in vivo. Specifically, loss of BOK reduced proliferation both in cell lines in vitro as well as in Kras(G12D)-driven tumor lesions in vivo. During tumor development in vivo, loss of BOK resulted in a lower tumor burden, with fewer, smaller, and less advanced tumors. Using Kras(G12D/+)Tp53(Delta/Delta)Bok(-/-) mice, we identified that this phenotype was entirely dependent on the presence of functional p53. Furthermore, analysis of a human dataset of untreated early-stage lung tumors did not identify any common deletion of the BOK locus, independently of the TP53 status or the histopathological classification. Taken together our data indicate that BOK supports tumor progression in Kras-driven lung cancer.	[Meinhardt, Anna-Lena; Munkhbaatar, Enkhtsetseg; Hockendorf, Ulrike; Dechant, Marta; Branca, Caterina; Jost, Philipp J.] Tech Univ Munich, TUM Sch Med, Dept Med 3, Klinikum Rechts Isar, Munich, Germany; [Dietzen, Michelle; McGranahan, Nicholas] UCL, Canc Inst, Canc Res UK Lung Canc Ctr Excellence, Paul OGorman Bldg, London, England; [Dietzen, Michelle; McGranahan, Nicholas] UCL, Canc Inst, Canc Genome Evolut Res Grp, London, England; [Dietzen, Michelle] Francis Crick Inst, Canc Evolut & Genome Instabil Lab, London, England; [Anton, Martina] Tech Univ Munich, Sch Med, Inst Mol Immunol & Expt Oncol, Munich, Germany; [Jacob, Anne; Steiger, Katja; Weichert, Wilko] Tech Univ Munich, Inst Pathol, Munich, Germany; [Steiger, Katja; Weichert, Wilko; Jost, Philipp J.] German Canc Consortium DKTK, Partner Site Munich, Munich, Germany; [Brcic, Luka] Med Univ Graz, Diagnost & Res Inst Pathol, Diagnost & Res Ctr Mol BioMed, Graz, Austria; [Kaufmann, Thomas] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Dengler, Michael A.; Jost, Philipp J.] Med Univ Graz, Dept Med, Div Clin Oncol, Graz, Austria; [Meinhardt, Anna-Lena] Rutgers New Jersey Med Sch, Dept Med, Newark, NJ USA; [Munkhbaatar, Enkhtsetseg] Tech Univ Munich, Sch Med, Dept Surg, Munich, Germany	Technical University of Munich; Cancer Research UK; University of London; University College London; University of London; University College London; Francis Crick Institute; Technical University of Munich; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Medical University of Graz; University of Bern; Medical University of Graz; Rutgers State University New Brunswick; Rutgers State University Medical Center; Technical University of Munich	Jost, PJ (corresponding author), Tech Univ Munich, TUM Sch Med, Dept Med 3, Klinikum Rechts Isar, Munich, Germany.; Jost, PJ (corresponding author), German Canc Consortium DKTK, Partner Site Munich, Munich, Germany.; Dengler, MA; Jost, PJ (corresponding author), Med Univ Graz, Dept Med, Div Clin Oncol, Graz, Austria.	michael.dengler@medunigraz.at; philipp.jost@medunigraz.at	Dengler, Michael/AFR-3509-2022; Jost, Philipp J./S-4962-2016	Jost, Philipp J./0000-0003-2454-0362; Anton, Martina/0000-0001-5290-5213; Kaufmann, Thomas/0000-0001-9906-874X; Hockendorf, Ulrike/0000-0002-8218-3343; Dietzen, Michelle/0000-0002-6853-7563; Brcic, Luka/0000-0002-9098-8416; Steiger, Katja/0000-0002-7269-5433; Dengler, Michael/0000-0002-1693-1761	Deutsche Krebshilfe for AM (Doktorandenstipendium) [112066]; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [FOR 2036, SFB 1335, 360372040]; German Consortium for Translational Cancer Research (DKTK); Swiss National Science Foundation [31003A_173006]; Wellcome Trust; Royal Society [211179/Z/18/Z]; Cancer Research UK Lung Cancer Center of Excellence; NIHR BRC at University College London Hospitals; Rosetrees	Deutsche Krebshilfe for AM (Doktorandenstipendium)(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); German Consortium for Translational Cancer Research (DKTK); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Wellcome Trust(Wellcome Trust); Royal Society(Royal Society of London); Cancer Research UK Lung Cancer Center of Excellence; NIHR BRC at University College London Hospitals; Rosetrees(Rosetrees Trust)	We thank the members of the TRACERx consortium for participating in this study. The authors thank Bettina Flasch for excellent technical assistance. Grant support by Deutsche Krebshilfe for AM (Doktorandenstipendium 112066); the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation - FOR 2036, SFB 1335 (Project-ID 360372040)), German Consortium for Translational Cancer Research (DKTK) to KS and PJJ; Support by the Swiss National Science Foundation (project grant #31003A_173006) to TK; NM is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (Grant Number 211179/Z/18/Z), and also receives funding from Cancer Research UK Lung Cancer Center of Excellence, Rosetrees, and the NIHR BRC at University College London Hospitals.	Alenzi FQB, 2004, BRIT J BIOMED SCI, V61, P99, DOI 10.1080/09674845.2004.11732652; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brock CK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09010-6; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Carpio MA, 2015, P NATL ACAD SCI USA, V112, P7201, DOI 10.1073/pnas.1421063112; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Echeverry N, 2013, CELL DEATH DIFFER, V20, P785, DOI 10.1038/cdd.2013.10; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Ichim G, 2016, NAT REV CANCER, V16, P539, DOI 10.1038/nrc.2016.58; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Janic A, 2018, NAT MED, V24, P947, DOI 10.1038/s41591-018-0043-5; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Ke F, 2012, CELL DEATH DIFFER, V19, P915, DOI 10.1038/cdd.2011.210; Ke FFS, 2018, CELL, V173, P1217, DOI 10.1016/j.cell.2018.04.036; Lieschke E, 2019, J MOL CELL BIOL, V11, P212, DOI 10.1093/jmcb/mjy077; Llambi F, 2016, CELL, V165, P421, DOI 10.1016/j.cell.2016.02.026; Marino S, 2000, GENE DEV, V14, P994; Moravcikova E, 2017, INT J CANCER, V141, P2050, DOI 10.1002/ijc.30906; Munkhbaatar E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18372-1; Naim S, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.574338; Rabachini T, 2018, CELL DEATH DIFFER, V25, P706, DOI 10.1038/s41418-017-0008-0; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ray JE, 2010, CELL DEATH DIFFER, V17, P846, DOI 10.1038/cdd.2009.167; Srivastava R, 2019, P NATL ACAD SCI USA, V116, P15469, DOI 10.1073/pnas.1904523116; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Zhang F, 2019, MED SCI MONITOR, V25, P5356, DOI 10.12659/MSM.913706; Zheng JH, 2018, CELL REP, V23, P2083, DOI 10.1016/j.celrep.2018.04.060	33	1	1	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1376	1382		10.1038/s41388-021-02161-1	http://dx.doi.org/10.1038/s41388-021-02161-1		JAN 2022	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35091677	hybrid, Green Published			2022-12-28	WOS:000749073200002
J	Nicosia, L; Boffo, FL; Ceccacci, E; Conforti, F; Pallavicini, I; Bedin, F; Ravasio, R; Massignani, E; Somervaille, TCP; Minucci, S; Bonaldi, T				Nicosia, Luciano; Boffo, Francesca Ludovica; Ceccacci, Elena; Conforti, Fabio; Pallavicini, Isabella; Bedin, Fabio; Ravasio, Roberto; Massignani, Enrico; Somervaille, Tim C. P.; Minucci, Saverio; Bonaldi, Tiziana			Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML	ONCOGENE			English	Article							DEMETHYLASE; GENE	The histone demethylase LSD1 is over-expressed in hematological tumors and has emerged as a promising target for anticancer treatment, so that several LSD1 inhibitors are under development and testing, in preclinical and clinical settings. However, the complete understanding of their complex mechanism of action is still unreached. Here, we unraveled a novel mode of action of the LSD1 inhibitors MC2580 and DDP-38003, showing that they can induce differentiation of AML cells through the downregulation of the chromatin protein GSE1. Analysis of the phenotypic effects of GSE1 depletion in NB4 cells showed a strong decrease of cell viability in vitro and of tumor growth in vivo. Mechanistically, we found that a set of genes associated with immune response and cytokine-signaling pathways are upregulated by LSD1 inhibitors through GSE1-protein reduction and that LSD1 and GSE1 colocalize at promoters of a subset of these genes at the basal state, enforcing their transcriptional silencing. Moreover, we show that LSD1 inhibitors lead to the reduced binding of GSE1 to these promoters, activating transcriptional programs that trigger myeloid differentiation. Our study offers new insights into GSE1 as a novel therapeutic target for AML.	[Nicosia, Luciano; Boffo, Francesca Ludovica; Ceccacci, Elena; Conforti, Fabio; Pallavicini, Isabella; Bedin, Fabio; Ravasio, Roberto; Massignani, Enrico; Minucci, Saverio; Bonaldi, Tiziana] European Inst Oncol IRCCS, Dept Expt Oncol, IEO, I-20139 Milan, Italy; [Nicosia, Luciano; Somervaille, Tim C. P.] Univ Manchester, ItalyLeukaemia Biol Lab, Canc Res UK Manchester Inst, Oglesby Canc Res Ctr Bldg, Manchester M20 4GJ, Lancs, England; [Minucci, Saverio] Univ Milan, Dept Biosci, I-20133 Milan, Italy; [Bonaldi, Tiziana] Univ Milan, Dept Oncol & Haematooncol, I-20133 Milan, Italy	IRCCS European Institute of Oncology (IEO); Cancer Research UK; University of Manchester; University of Milan; University of Milan	Bonaldi, T (corresponding author), European Inst Oncol IRCCS, Dept Expt Oncol, IEO, I-20139 Milan, Italy.; Bonaldi, T (corresponding author), Univ Milan, Dept Oncol & Haematooncol, I-20133 Milan, Italy.	tiziana.bonaldi@ieo.it	Ravasio, Roberto/AAP-8901-2020	Ravasio, Roberto/0000-0002-3144-0514; Ceccacci, Elena/0000-0002-2285-8994; Nicosia, Luciano/0000-0003-3016-931X; Somervaille, Tim/0000-0002-9188-4379	Italian Association for Cancer Research [15741]; EPIC-XS - Horizon 2020 programme of the European Union [823839]; European Institute of Oncology Foundation (FIEO); Italian Foundation for Cancer Research (FIRC); Italian Association for Cancer Research (AIRC) [24944]; Cancer Research UK [C5759/A20971]	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); EPIC-XS - Horizon 2020 programme of the European Union; European Institute of Oncology Foundation (FIEO); Italian Foundation for Cancer Research (FIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Cancer Research UK(Cancer Research UK)	T.B. research activity is supported by grants from the Italian Association for Cancer Research (grant#15741) and by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union; L.N. was supported by a Fellowship of the European Institute of Oncology Foundation (FIEO) and was a PhD student within the European School of Molecular Medicine (SEMM); E.M. is supported by a fellowship of the Italian Foundation for Cancer Research (FIRC) and is a PhD student within the European School of Molecular Medicine (SEMM); S.M. is supported by the Italian Association for Cancer Research (AIRC, grant#24944); T.S. is supported by Cancer Research UK grant number C5759/A20971.	Abdel-Aziz AK, 2020, HAEMATOLOGICA, V105, P2105, DOI 10.3324/haematol.2019.224501; Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002; Bamodu OA, 2021, CANCERS, V13, DOI 10.3390/cancers13163959; Binda C, 2010, J AM CHEM SOC, V132, P6827, DOI 10.1021/ja101557k; Blagosklonny MV, 2003, SEMIN CANCER BIOL, V13, P97, DOI 10.1016/S1044-579X(02)00127-X; Blecher-Gonen R, 2013, NAT PROTOC, V8, P539, DOI 10.1038/nprot.2013.023; Carnesecchi J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188871; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chai P, 2016, BIOCHEM BIOPH RES CO, V471, P123, DOI 10.1016/j.bbrc.2016.01.168; Chao A, 2017, ONCOTARGET, V8, P74434, DOI 10.18632/oncotarget.20158; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen YW, 2012, CRIT REV EUKAR GENE, V22, P53, DOI 10.1615/CritRevEukarGeneExpr.v22.i1.40; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; Ding KS, 2018, J BIOL CHEM, V293, P3949, DOI 10.1074/jbc.RA117.001103; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Duan YC, 2017, EUR J MED CHEM, V140, P392, DOI 10.1016/j.ejmech.2017.09.038; Fang JW, 2017, ONCOTARGET, V8, P85085, DOI 10.18632/oncotarget.18564; Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; Huang M, 2019, CELL STEM CELL, V25, P433, DOI 10.1016/j.stem.2019.05.013; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Ishikawa Y, 2017, MOL CANCER THER, V16, P273, DOI 10.1158/1535-7163.MCT-16-0471; Kim SA, 2020, MOL CELL, V78, P903, DOI 10.1016/j.molcel.2020.04.019; Lan HY, 2019, P NATL ACAD SCI USA, V116, P12311, DOI 10.1073/pnas.1902012116; Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lanneau D, 2007, PRION, V1, P53, DOI 10.4161/pri.1.1.4059; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li Y, 2019, CANCER LETT, V454, P179, DOI 10.1016/j.canlet.2019.03.052; Liang XQ, 2013, BIOTECHNIQUES, V55, P267, DOI 10.2144/000114101; Lillico R, 2016, FUTURE MED CHEM, V8, P879, DOI 10.4155/fmc-2016-0021; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lokken AA, 2012, CANCER CELL, V21, P451, DOI 10.1016/j.ccr.2012.03.027; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maiques-Diaz A, 2018, CELL REP, V22, P3641, DOI 10.1016/j.celrep.2018.03.012; McClellan D, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00020-19; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Mihailovich M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9725; Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Perillo B, 2020, EXP MOL MED, V52, P1936, DOI 10.1038/s12276-020-00542-2; Ravasio R, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax2746; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sehrawat A, 2018, P NATL ACAD SCI USA, V115, pE4179, DOI 10.1073/pnas.1719168115; Seiler CY, 2014, NUCLEIC ACIDS RES, V42, pD1253, DOI 10.1093/nar/gkt1060; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Song P, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00444-9; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tyner JW, 2018, NATURE, V562, P526, DOI 10.1038/s41586-018-0623-z; Vianello P, 2016, J MED CHEM, V59, P1501, DOI 10.1021/acs.jmedchem.5b01209; Wang J, 2017, NUCLEIC ACIDS RES, V45, pW130, DOI 10.1093/nar/gkx356; Wang WB, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8834923; Wang XM, 2006, PHYSIOLOGY, V21, P362, DOI 10.1152/physiol.00024.2006; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wiemann S, 2016, NAT METHODS, V13, P191, DOI 10.1038/nmeth.3776; Yamamoto Ryusuke, 2018, Oncotarget, V9, P21007, DOI 10.18632/oncotarget.24774; Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145; Zhang XF, 2018, NAT PROTOC, V13, P530, DOI 10.1038/nprot.2017.147; Zhang XL, 2019, DRUG DES DEV THER, V13, P3037, DOI 10.2147/DDDT.S209219; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao ZK, 2013, TUMOR BIOL, V34, P173, DOI 10.1007/s13277-012-0525-x; Zheng YC, 2016, EPIGENOMICS-UK, V8, P651, DOI 10.2217/epi-2015-0002; Zheng YC, 2015, MED RES REV, V35, P1032, DOI 10.1002/med.21350; Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237	72	5	5	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					878	894		10.1038/s41388-021-02123-7	http://dx.doi.org/10.1038/s41388-021-02123-7		DEC 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34862459	Green Published, hybrid			2022-12-28	WOS:000725939000002
J	Zhang, BY; Zhang, MP; Yang, YJ; Li, Q; Yu, JP; Zhu, SM; Niu, YJ; Shang, ZQ				Zhang, Boya; Zhang, Mingpeng; Yang, Yanjie; Li, Qi; Yu, Jianpeng; Zhu, Shimiao; Niu, Yuanjie; Shang, Zhiqun			Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC	ONCOGENE			English	Article							RESISTANT PROSTATE-CANCER; ANDROGEN-RECEPTOR; PROTEASOMAL DEGRADATION; SPLICE VARIANTS; NONCODING RNA; PROGRESSION; MECHANISMS; EXPRESSION; THERAPY; GROWTH	Castration-resistant prostate cancer (CRPC) is a highly malignant type of advanced cancer resistant to androgen deprivation therapy. One of the important mechanisms for the development of CRPC is the persistent imbalanced regulation of AR and AR splice variants (AR/AR-Vs). In this study, we reported KDM4A-AS1, a recently discovered lncRNA, as a tumor promoter that was significantly increased in CRPC cell lines and cancer tissues. Depletion of KDM4A-AS1 significantly reduced cell viability, proliferation, migration in vitro, and tumor growth in vivo. We found that by binding to the NTD domain, KDM4A-AS1 enhances the stability of USP14-AR/AR-Vs complex, and promoted AR/AR-Vs deubiquitination to protect it from MDM2-mediated ubiquitin-proteasome degradation. Moreover, KDM4A-AS1 was found to enhance CRPC drug resistance to enzalutamide by repressing AR/AR-Vs degradation; antisense oligonucleotide drugs targeting KDM4A-AS1 significantly reduced the growth of tumors with enzalutamide resistance. Taken together, our results indicated that KDM4A-AS1 played an important role in the progression of CRPC and enzalutamide resistance by regulating AR/AR-Vs deubiquitination; targeting KDM4A-AS1 has broad clinical application potential.	[Zhang, Boya; Zhang, Mingpeng; Yang, Yanjie; Li, Qi; Yu, Jianpeng; Zhu, Shimiao; Niu, Yuanjie; Shang, Zhiqun] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Tianjin 300211, Peoples R China	Tianjin Medical University	Shang, ZQ (corresponding author), Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Tianjin 300211, Peoples R China.	zhiqun_shang@tmu.edu.cn	zhang, boya/GRO-7325-2022; shang, zhiqun/N-9995-2015	shang, zhiqun/0000-0001-8263-707X	National Natural Science Foundation of China [81872100, 81772756]; Natural Science Foundation of Tianjin [18PTLCSY00030, 19JCYBJC24900]; Tianjin Research Innovation Project for Postgraduate Students	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin); Tianjin Research Innovation Project for Postgraduate Students	This work was supported by National Natural Science Foundation of China (grants 81872100 and 81772756), Natural Science Foundation of Tianjin (18PTLCSY00030 and 19JCYBJC24900), and Tianjin Research Innovation Project for Postgraduate Students.	Bartonicek N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0530-6; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Davey Rachel A, 2016, Clin Biochem Rev, V37, P3; Geng C, 2014, CANCER RES, V74, P5631, DOI 10.1158/0008-5472.CAN-14-0476; Grillone K, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01622-x; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Kim TD, 2016, J CLIN INVEST, V126, P706, DOI 10.1172/JCI78132; Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kwegyir-Afful AK, 2015, ONCOTARGET, V6, P27440, DOI 10.18632/oncotarget.4578; Li B, 2014, PROSTATE, V74, P421, DOI 10.1002/pros.22763; Li YA, 2015, ONCOTARGET, V6, P33743, DOI 10.18632/oncotarget.5608; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li ZW, 2017, CELL DEATH DIFFER, V24, P59, DOI 10.1038/cdd.2016.95; Liao YN, 2018, ONCOGENE, V37, P1896, DOI 10.1038/s41388-017-0069-z; Liao YN, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.477; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Liu CF, 2019, MOL CANCER THER, V18, P1875, DOI 10.1158/1535-7163.MCT-18-1322; Liu CF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07178-x; Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296; Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Muppirala UK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-489; Ni W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1079-y; Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Sarkar S, 2014, ONCOGENE, V33, P26, DOI 10.1038/onc.2012.561; Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136; Shang ZQ, 2019, NUCLEIC ACIDS RES, V47, P4211, DOI 10.1093/nar/gkz108; Shipley WU, 2017, NEW ENGL J MED, V376, P417, DOI 10.1056/NEJMoa1607529; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Yang R, 2019, ONCOGENE, V38, P7133, DOI 10.1038/s41388-019-0909-0; Yin Y, 2017, CANCER RES, V77, P4745, DOI 10.1158/0008-5472.CAN-17-0164; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Yoshida T, 2005, CANCER RES, V65, P9611, DOI 10.1158/0008-5472.CAN-05-0817; Zhang A, 2015, CELL REP, V13, P209, DOI 10.1016/j.celrep.2015.08.069; Zhang H, 2015, CANCER RES, V75, P2363, DOI 10.1158/0008-5472.CAN-14-2928	49	5	5	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					387	399		10.1038/s41388-021-02103-x	http://dx.doi.org/10.1038/s41388-021-02103-x		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34759344	Green Published, hybrid			2022-12-28	WOS:000716867900002
J	Gorka, J; Marona, P; Kwapisz, O; Waligorska, A; Pospiech, E; Dobrucki, JW; Rys, J; Jura, J; Miekus, K				Gorka, Judyta; Marona, Paulina; Kwapisz, Oliwia; Waligorska, Agnieszka; Pospiech, Ewelina; Dobrucki, Jurek W.; Rys, Janusz; Jura, Jolanta; Miekus, Katarzyna			MCPIP1 inhibits Wnt/beta-catenin signaling pathway activity and modulates epithelial-mesenchymal transition during clear cell renal cell carcinoma progression by targeting miRNAs	ONCOGENE			English	Article							BETA-CATENIN; DECREASED EXPRESSION; E-CADHERIN; KAPPA-B; PROMOTES; PROTEIN; DEGRADATION; MICRORNA; PHOSPHORYLATION; INFLAMMATION	Epithelial-mesenchymal transition (EMT) refers to the acquisition of mesenchymal properties in cells participating in tumor progression. One hallmark of EMT is the increased level of active beta-catenin, which can trigger the transcription of Wnt-specific genes responsible for the control of cell fate. We investigated how Monocyte Chemotactic Protein-1-Induced Protein-1 (MCPIP1), a negative regulator of inflammatory processes, affects EMT in a clear cell renal cell carcinoma (ccRCC) cell line, patient tumor tissues and a xenotransplant model. We showed that MCPIP1 degrades miRNAs via its RNase activity and thus protects the mRNA transcripts of negative regulators of the Wnt/beta-catenin pathway from degradation, which in turn prevents EMT. Mechanistically, the loss of MCPIP1 RNase activity led to the upregulation of miRNA-519a-3p, miRNA-519b-3p, and miRNA-520c-3p, which inhibited the expression of Wnt pathway inhibitors (SFRP4, KREMEN1, CXXC4, CSNK1A1 and ZNFR3). Thus, the level of active nuclear beta-catenin was increased, leading to increased levels of EMT inducers (SNAI1, SNAI2, ZEB1 and TWIST) and, consequently, decreased expression of E-cadherin, increased expression of mesenchymal markers, and acquisition of the mesenchymal phenotype. This study revealed that MCPIP1 may act as a tumor suppressor that prevents EMT by stabilizing Wnt inhibitors and decreasing the levels of active beta-catenin and EMT inducers.	[Gorka, Judyta; Marona, Paulina; Kwapisz, Oliwia; Jura, Jolanta; Miekus, Katarzyna] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Gen Biochem, Gronostajowa 7, PL-30387 Krakow, Poland; [Waligorska, Agnieszka; Dobrucki, Jurek W.] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Cell Biophys, Gronostajowa 7, PL-30387 Krakow, Poland; [Pospiech, Ewelina] Jagiellonian Univ, Malopolska Ctr Biotechnol, Human Genome Variat Res Grp, Gronostajowa 7A, PL-30387 Krakow, Poland; [Rys, Janusz] Maria Sklodowska Curie Mem Inst Oncol, Ctr Oncol, Dept Tumor Pathol, Cracow Branch, Garncarska 11, PL-31115 Krakow, Poland	Jagiellonian University; Jagiellonian University; Jagiellonian University; Maria Sklodowska-Curie National Research Institute of Oncology	Miekus, K (corresponding author), Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Gen Biochem, Gronostajowa 7, PL-30387 Krakow, Poland.	katarzyna.miekus@uj.edu.pl	Górka, Judyta/GLU-4157-2022	Górka, Judyta/0000-0002-1298-329X; Miekus, Katarzyna/0000-0002-2716-203X	National Science Centre [2015/19/B/NZ5/01405, 2017/26/E/NZ5/00691]; KNOW [BMN 1/2017, BMN 1/2018]	National Science Centre(National Science Centre, Poland); KNOW	This work was supported in part by research grants from the National Science Centre nos. 2015/19/B/NZ5/01405 and 2017/26/E/NZ5/00691 (to KM) and KNOW BMN 1/2017 and BMN 1/2018 (to JG).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boratyn E, 2016, J CELL BIOCHEM, V117, P694, DOI 10.1002/jcb.25354; CHEN F, 2021, CELL DEATH DIS, V12; Choi H, 2010, CANCER RES, V70, P10101, DOI 10.1158/0008-5472.CAN-10-0505; Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345; Dobosz E, 2016, J INNATE IMMUN, V8, P564, DOI 10.1159/000448038; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Gorka J, 2020, EUR J PHARMACOL, V888, DOI 10.1016/j.ejphar.2020.173591; Heerboth S, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0048-3; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hsu RJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047649; Iwasaki H, 2011, NAT IMMUNOL, V12, P1167, DOI 10.1038/ni.2137; Kojima T, 2009, ONCOGENE, V28, P297, DOI 10.1038/onc.2008.391; Kruck S, 2013, INT J MOL SCI, V14, P10944, DOI 10.3390/ijms140610944; Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4; Li M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032152; Ligeza J, 2017, ANGIOGENESIS, V20, P325, DOI 10.1007/s10456-017-9540-2; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lu WB, 2016, CANCER RES, V76, P1429, DOI 10.1158/0008-5472.CAN-15-1115; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Marona P, 2017, CANCER RES, V77, P4905, DOI 10.1158/0008-5472.CAN-16-3190; Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Mino T, 2015, CELL, V161, P1058, DOI 10.1016/j.cell.2015.04.029; Mizgalska D, 2009, FEBS J, V276, P7386, DOI 10.1111/j.1742-4658.2009.07452.x; Mlcochova H, 2016, SCI REP-UK, V6, DOI 10.1038/srep31852; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orsulic S, 1999, J CELL SCI, V112, P1237; Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393; Reczko M, 2012, BIOINFORMATICS, V28, P771, DOI 10.1093/bioinformatics/bts043; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Shang S, 2017, ONCOTARGET, V8, P33972, DOI 10.18632/oncotarget.15687; Simon-Friedt BR, 2015, BIOL TRACE ELEM RES, V166, P66, DOI 10.1007/s12011-015-0339-y; Skalniak A, 2014, ONCOL REP, V31, P2385, DOI 10.3892/or.2014.3076; Skalniak L, 2013, FEBS J, V280, P2665, DOI 10.1111/febs.12264; Skalniak L, 2009, FEBS J, V276, P5892, DOI 10.1111/j.1742-4658.2009.07273.x; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Suzuki HI, 2011, MOL CELL, V44, P424, DOI 10.1016/j.molcel.2011.09.012; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Uehata T, 2013, BBA-GENE REGUL MECH, V1829, P708, DOI 10.1016/j.bbagrm.2013.03.001; Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Vlad-Fiegen A, 2012, FEBS OPEN BIO, V2, P26, DOI 10.1016/j.fob.2012.02.004; Xu JW, 2012, NUCLEIC ACIDS RES, V40, P6957, DOI 10.1093/nar/gks359; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027	53	6	6	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6720	6735		10.1038/s41388-021-02062-3	http://dx.doi.org/10.1038/s41388-021-02062-3		OCT 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34657130	Green Published, hybrid			2022-12-28	WOS:000707687400002
J	Li, ZL; He, YX; Li, YJ; Li, J; Zhao, HZ; Song, GB; Miyagishi, M; Wu, SR; Kasim, V				Li, Zhuolin; He, Yuxin; Li, Yanjun; Li, Juan; Zhao, Hezhao; Song, Guanbing; Miyagishi, Makoto; Wu, Shourong; Kasim, Vivi			NeuroD1 promotes tumor cell proliferation and tumorigenesis by directly activating the pentose phosphate pathway in colorectal carcinoma	ONCOGENE			English	Article							CANCER; GENE; TRANSCRIPTION; METABOLISM; EXPRESSION; CONTRIBUTE; MIGRATION; RECEPTOR; DIFFERENTIATION; CHROMATIN	Tumor metabolic reprogramming ensures that cancerous cells obtain sufficient building blocks, energy, and antioxidants to sustain rapid growth and for coping with oxidative stress. Neurogenic differentiation factor 1 (NeuroD1) is upregulated in various types of tumors; however, its involvement in tumor cell metabolic reprogramming remains unclear. In this study, we report that NeuroD1 is positively correlated with glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the pentose phosphate pathway (PPP), in colorectal cancer cells. In addition, the regulation of G6PD by NeuroD1 alters tumor cell metabolism by stimulating the PPP, leading to enhanced production of nucleotides and NADPH. These, in turn, promote DNA and lipid biosynthesis in tumor cells, while decreasing intracellular levels of reactive oxygen species. Mechanistically, we showed that NeuroD1 binds directly to the G6PD promoter to activate G6PD transcription. Consequently, tumor cell proliferation and colony formation are enhanced, leading to increased tumorigenic potential in vitro and in vivo. These findings reveal a novel function of NeuroD1 as a regulator of G6PD, whereby its oncogenic activity is linked to tumor cell metabolic reprogramming and regulation of the PPP. Furthermore, NeuroD1 represents a potential target for metabolism-based anti-tumor therapeutic strategies.	[Li, Zhuolin; He, Yuxin; Li, Yanjun; Li, Juan; Song, Guanbing; Wu, Shourong; Kasim, Vivi] Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China; [Li, Zhuolin; He, Yuxin; Li, Yanjun; Li, Juan; Wu, Shourong; Kasim, Vivi] Chongqing Univ, Coll Bioengn, Project Lab Biomech & Tissue Repair 111, Chongqing 400044, Peoples R China; [Zhao, Hezhao] Chongqing Univ, Chongqing Univ Canc Hosp, Dept Gastrointestinal Surg, Chongqing 400030, Peoples R China; [Miyagishi, Makoto] Natl Inst Adv Ind Sci & Technol, Biomed Res Inst, Mol Composite Med Res Grp, Tsukuba, Ibaraki, Japan; [Wu, Shourong; Kasim, Vivi] Chongqing Univ, Chongqing Univ Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis &, Chongqing 400030, Peoples R China	Chongqing University; Chongqing University; Chongqing University; National Institute of Advanced Industrial Science & Technology (AIST); Chongqing University	Wu, SR; Kasim, V (corresponding author), Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China.; Wu, SR; Kasim, V (corresponding author), Chongqing Univ, Coll Bioengn, Project Lab Biomech & Tissue Repair 111, Chongqing 400044, Peoples R China.; Wu, SR; Kasim, V (corresponding author), Chongqing Univ, Chongqing Univ Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis &, Chongqing 400030, Peoples R China.	shourongwu@cqu.edu.cn; vivikasim@cqu.edu.cn	Song, Guanbin/AFL-8473-2022	Wu, Shourong/0000-0001-9650-5465; Kasim, Vivi/0000-0001-9182-8230	National Natural Science Foundation of China [11832008, 31871367, 81872273]; Natural Science Foundation of Chongqing [cstc2018jcyjAX0411, cstc2018jcyjAX0374]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing)	We thank Dr. Bert Vogelstein (School of Medicine, Johns Hopkins University) for kindly providing wild-type and p53-null HCT116<SUP>p53null</SUP> cell lines. This work was supported by grants from the National Natural Science Foundation of China (11832008, 31871367, and 81872273); and the Natural Science Foundation of Chongqing (cstc2018jcyjAX0411 and cstc2018jcyjAX0374).	Almeida AS, 2018, REDOX BIOL, V17, P338, DOI 10.1016/j.redox.2018.05.004; Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Borromeo MD, 2016, CELL REP, V16, P1259, DOI 10.1016/j.celrep.2016.06.081; Boulay G, 2017, CANCER DISCOV, V7, P288, DOI 10.1158/2159-8290.CD-16-0844; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen L, 2019, NAT METAB, V1, P404, DOI 10.1038/s42255-019-0043-x; Cheng J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15819-3; Cheng Y, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107782; Cindolo L, 2007, EUR UROL, V52, P1365, DOI 10.1016/j.eururo.2006.11.030; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Enya M, 2008, HUM MUTAT, V29, pE271, DOI 10.1002/humu.20865; Gay CM, 2021, CANCER CELL, V39, P346, DOI 10.1016/j.ccell.2020.12.014; Giles ED, 2012, CANCER RES, V72, P6490, DOI 10.1158/0008-5472.CAN-12-1653; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang P, 2011, CANCER RES, V71, P2938, DOI 10.1158/0008-5472.CAN-10-3524; Ireland AS, 2020, CANCER CELL, V38, P60, DOI 10.1016/j.ccell.2020.05.001; Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172; Kim JW, 2002, MOL ENDOCRINOL, V16, P1097, DOI 10.1210/me.16.5.1097; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Ku HC, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00556; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lei K, 2020, CANCER SCI, V111, P175, DOI 10.1111/cas.14233; Li QD, 2019, CELL METAB, V30, P157, DOI 10.1016/j.cmet.2019.05.009; Liu CL, 2020, MOL CELL ENDOCRINOL, V499, DOI 10.1016/j.mce.2019.110595; Liu YH, 2016, J NEURO-ONCOL, V126, P455, DOI 10.1007/s11060-015-2003-y; Lu FJ, 2015, CANCER SCI, V106, P390, DOI 10.1111/cas.12628; Ma XY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01647-5; Marsich E, 2003, BIOCHEM J, V376, P707, DOI 10.1042/BJ20031021; Martin CC, 2003, BIOCHEM J, V371, P675, DOI 10.1042/BJ20021585; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Moates JM, 2003, DIABETES, V52, P403, DOI 10.2337/diabetes.52.2.403; Osborne JK, 2014, MOL BIOL CELL, V25, P1782, DOI 10.1091/mbc.E13-06-0316; Osborne JK, 2013, P NATL ACAD SCI USA, V110, P6524, DOI 10.1073/pnas.1303932110; Owonikoko TK, 2021, J THORAC ONCOL, V16, P464, DOI 10.1016/j.jtho.2020.11.006; Pan N, 2009, CELL TISSUE RES, V337, P407, DOI 10.1007/s00441-009-0826-6; Pang ZPP, 2011, NATURE, V476, P220, DOI 10.1038/nature10202; Park AK, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5742-x; Pataskar A, 2016, EMBO J, V35, P24, DOI 10.15252/embj.201591206; Patra KC, 2014, TRENDS BIOCHEM SCI, V39, P347, DOI 10.1016/j.tibs.2014.06.005; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Reina-Campos M, 2019, CANCER CELL, V36, P218, DOI 10.1016/j.ccell.2019.07.010; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Santana-Codina N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07472-8; Shan CL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1756-1; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Tang JY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11447-8; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Wang JJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03201-6; Wang M, 2018, CLIN TRANSL ONCOL, V20, P906, DOI 10.1007/s12094-017-1805-0; Wang Y, 2014, CELL BIOCHEM BIOPHYS, V69, P487, DOI 10.1007/s12013-014-9822-x; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wu SR, 2018, CANCER RES, V78, P4549, DOI 10.1158/0008-5472.CAN-17-4047; Xu H, 2021, ONCOGENE, V40, P1555, DOI 10.1038/s41388-020-01587-3; Yang HC, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091055	59	5	5	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6736	6747		10.1038/s41388-021-02063-2	http://dx.doi.org/10.1038/s41388-021-02063-2		OCT 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34657129				2022-12-28	WOS:000707687400001
J	Wang, SY; Wong, CC; Zhang, YQ; Huang, JZ; Li, CG; Zhai, JN; Wang, GP; Wei, H; Zhang, XJ; He, HH; Yu, J				Wang, Shiyan; Wong, Chi Chun; Zhang, Yanquan; Huang, Junzhe; Li, Chuangen; Zhai, Jianning; Wang, Guoping; Wei, Hong; Zhang, Xueji; He, Housheng Hansen; Yu, Jun			ZNF545 loss promotes ribosome biogenesis and protein translation to initiate colorectal tumorigenesis in mice	ONCOGENE			English	Article							RNA-POLYMERASE-I; NUCLEOLAR TRANSCRIPTION; BINDING	Ribosome biogenesis plays a pivotal role in tumorigenesis by supporting robust protein translation. We investigate the functional and molecular mechanism of Zinc finger protein 545 (ZNF545), a transcriptional repressor for ribosomal RNA (rRNA), in colorectal cancer (CRC). ZNF545 was silenced in CRC compared to adjacent normal tissues (P < 0.0001), implying a tumor-suppressive role. Colon-specific Znf545 knockout in mice accelerated CRC in Apc(Min/+) and azoxymethane/dextran sulfate sodium-induced CRC. Mechanistically, we demonstrated that ZNF545 uses its two zinc finger clusters to bind to minimal rDNA promoter, where it assembled transcriptional repressor complex by interacting with KAP1. Znf545 deletion in mouse embryonic fibroblasts not only increased rRNA transcription rate and the nucleolar size and number but also altered the nucleolar composition and architecture with an increased number of fibrillar centers surrounded by net-like dense fibrillar components. Consequently, Znf545 deletion promoted the gene expression of translation machinery, protein translation, and cell growth. Consistent with its tumor-suppressive role, ZNF545 overexpression in CRC cells induced growth arrest and apoptosis. Finally, administration of rRNA synthesis inhibitor, CX-5461, inhibited CRC development in Znf545(Delta/Delta)Apc(Min/+) mice. In conclusion, ZNF545 suppresses CRC through repressing rRNA transcription and protein translation. Targeting rRNA biosynthesis in ZNF545-silenced tumors is a potential therapeutic strategy for CRC.	[Wang, Shiyan; Wong, Chi Chun; Zhang, Yanquan; Huang, Junzhe; Li, Chuangen; Zhai, Jianning; Wang, Guoping; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China; [Wang, Shiyan; Wong, Chi Chun; Zhang, Yanquan; Huang, Junzhe; Li, Chuangen; Zhai, Jianning; Wang, Guoping; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China; [Wei, Hong] Sun Yat Sen Univ, Affiliated Hosp 1, Precis Med Inst, Guangzhou, Peoples R China; [Zhang, Xueji] Shenzhen Univ, Hlth Sci Ctr, Sch Biomed Engn, Shenzhen, Peoples R China; [He, Housheng Hansen] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Biophys, Toronto, ON, Canada	Chinese University of Hong Kong; Chinese University of Hong Kong; Sun Yat Sen University; Shenzhen University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	zhang, xueji/ABE-6497-2020; zhai, jianning/GSD-4306-2022	zhang, xueji/0000-0002-0035-3821; zhai, jianning/0000-0002-8780-492X; he, housheng hansen/0000-0003-2898-3363; Wong, Chi Chun/0000-0003-1362-3541	National Key R&D Program of China [2020YFA0509200/2020YFA0509203]; RGC-CRF Hong Kong [C4039-19G, C7065-18GF]; RGC-GRF Hong Kong [14163817, 14110819]; Vice-Chancellor's Discretionary Fund CUHK	National Key R&D Program of China; RGC-CRF Hong Kong; RGC-GRF Hong Kong(Hong Kong Research Grants Council); Vice-Chancellor's Discretionary Fund CUHK	This study was supported by National Key R&D Program of China (No. 2020YFA0509200/2020YFA0509203); RGC-CRF Hong Kong (C4039-19G, C7065-18GF); RGC-GRF Hong Kong (14163817, 14110819); Vice-Chancellor's Discretionary Fund CUHK.	Bruno PM, 2020, P NATL ACAD SCI USA, V117, P4053, DOI 10.1073/pnas.1921649117; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Cheng YD, 2012, MOL CANCER RES, V10, P925, DOI 10.1158/1541-7786.MCR-11-0594; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; Goodfellow S. J., 2013, SUBCELL BIOCH, V61, P211, DOI DOI 10.1007/978-94-007-4525-4_10); Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; Helleboid PY, 2019, EMBO J, V38, DOI 10.15252/embj.2018101220; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Khot A, 2019, CANCER DISCOV, V9, P1036, DOI 10.1158/2159-8290.CD-18-1455; Klug A, 2010, Q REV BIOPHYS, V43, P1, DOI 10.1017/S0033583510000089; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; Lupo A, 2013, CURR GENOMICS, V14, P268, DOI 10.2174/13892029113149990002; McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Orsolic I, 2016, SEMIN CANCER BIOL, V37-38, P36, DOI 10.1016/j.semcancer.2015.12.004; Popp MW, 2016, CELL, V165, P1319, DOI 10.1016/j.cell.2016.05.053; Quin JE, 2014, BBA-MOL BASIS DIS, V1842, P802, DOI 10.1016/j.bbadis.2013.12.009; Sanij E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16393-4; Scott MS, 2010, NUCLEIC ACIDS RES, V38, P7388, DOI 10.1093/nar/gkq653; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; Srivastava R, 2016, MICROBIOL MOL BIOL R, V80, P545, DOI 10.1128/MMBR.00005-16; Torrano V, 2006, J CELL SCI, V119, P1746, DOI 10.1242/jcs.02890; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Wang SY, 2020, CLIN CANCER RES, V26, P746, DOI 10.1158/1078-0432.CCR-19-1611; Wang SY, 2019, CANCER RES, V79, P4086, DOI 10.1158/0008-5472.CAN-18-3614; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; Weeks SE, 2019, CELL MOL LIFE SCI, V76, P4511, DOI 10.1007/s00018-019-03231-0; Xu H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14432; Yang P, 2017, TRENDS GENET, V33, P871, DOI 10.1016/j.tig.2017.08.006; Zeng W, 2010, EPIGENETICS-US, V5, P287, DOI 10.4161/epi.5.4.11683	38	6	6	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6590	6600		10.1038/s41388-021-01938-8	http://dx.doi.org/10.1038/s41388-021-01938-8		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34615997	Green Published, hybrid			2022-12-28	WOS:000705759400002
J	Gillen, SL; Waldron, JA; Bushell, M				Gillen, Sarah L.; Waldron, Joseph A.; Bushell, Martin			Codon optimality in cancer	ONCOGENE			English	Review							POLYMERASE-III TRANSCRIPTION; TRANSFER-RNA MODIFICATION; 3' UNTRANSLATED REGIONS; GENE-EXPRESSION; TRANSLATION EFFICIENCY; IN-VIVO; ALTERNATIVE POLYADENYLATION; MESSENGER-RNAS; BREAST-CANCER; TUMOR-GROWTH	A key characteristic of cancer cells is their increased proliferative capacity, which requires elevated levels of protein synthesis. The process of protein synthesis involves the translation of codons within the mRNA coding sequence into a string of amino acids to form a polypeptide chain. As most amino acids are encoded by multiple codons, the nucleotide sequence of a coding region can vary dramatically without altering the polypeptide sequence of the encoded protein. Although mutations that do not alter the final amino acid sequence are often thought of as silent/synonymous, these can still have dramatic effects on protein output. Because each codon has a distinct translation elongation rate and can differentially impact mRNA stability, each codon has a different degree of 'optimality' for protein synthesis. Recent data demonstrates that the codon preference of a transcriptome matches the abundance of tRNAs within the cell and that this supply and demand between tRNAs and mRNAs varies between different cell types. The largest observed distinction is between mRNAs encoding proteins associated with proliferation or differentiation. Nevertheless, precisely how codon optimality and tRNA expression levels regulate cell fate decisions and their role in malignancy is not fully understood. This review describes the current mechanistic understanding on codon optimality, its role in malignancy and discusses the potential to target codon optimality therapeutically in the context of cancer.	[Gillen, Sarah L.; Waldron, Joseph A.; Bushell, Martin] Canc Res UK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland; [Bushell, Martin] Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland	Beatson Institute; University of Glasgow	Gillen, SL; Bushell, M (corresponding author), Canc Res UK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.; Bushell, M (corresponding author), Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland.	slg76@cam.ac.uk; martin.bushell@glasgow.ac.uk		Gillen, Sarah/0000-0002-0192-864X	Cancer Research UK (CRUK) [A29252] Funding Source: Medline; Medical Research Council [MC_UP_A600_1024, MC_EX_G0902052] Funding Source: Medline	Cancer Research UK (CRUK)(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aharon-Hefetz N, 2020, ELIFE, V9, DOI 10.7554/eLife.58461; Bazzini AA, 2016, EMBO J, V35, P2087, DOI 10.15252/embj.201694699; Begley U, 2013, EMBO MOL MED, V5, P366, DOI 10.1002/emmm.201201161; Behrens A, 2021, MOL CELL, V81, P1802, DOI 10.1016/j.molcel.2021.01.028; Benisty H, 2020, P NATL ACAD SCI USA, V117, P30848, DOI 10.1073/pnas.2016119117; Bhat M, 2015, NAT REV DRUG DISCOV, V14, P261, DOI 10.1038/nrd4505; Bin YN, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0926-4; Boel G, 2016, NATURE, V529, P358, DOI 10.1038/nature16509; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bornelov S, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1726-z; Brule CE, 2017, TRENDS GENET, V33, P283, DOI 10.1016/j.tig.2017.02.001; Buhr F, 2016, MOL CELL, V61, P341, DOI 10.1016/j.molcel.2016.01.008; Burow DA, 2018, CELL REP, V24, P1704, DOI 10.1016/j.celrep.2018.07.039; Buschauer R, 2020, SCIENCE, V368, P281, DOI 10.1126/science.aay6912; Carneiro RL, 2019, NUCLEIC ACIDS RES, V47, P2216, DOI 10.1093/nar/gkz033; Chan PP, 2016, NUCLEIC ACIDS RES, V44, pD184, DOI 10.1093/nar/gkv1309; Chen Y, 2014, MOL CELL, V54, P737, DOI 10.1016/j.molcel.2014.03.034; Clarke CJ, 2016, CURR BIOL, V26, P755, DOI 10.1016/j.cub.2016.01.045; Collart MA, 2020, NUCLEIC ACIDS RES, V48, P1043, DOI 10.1093/nar/gkz763; Courel M, 2019, ELIFE, V8, DOI 10.7554/eLife.49708; Cozen AE, 2015, NAT METHODS, V12, P879, DOI [10.1038/NMETH.3508, 10.1038/nmeth.3508]; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Delaunay S, 2016, J EXP MED, V213, P2503, DOI 10.1084/jem.20160397; Deng WJ, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005706; Dhindsa RS, 2020, AM J HUM GENET, V107, P83, DOI 10.1016/j.ajhg.2020.05.011; Dittmar KA, 2006, PLOS GENET, V2, P2107, DOI 10.1371/journal.pgen.0020221; Dong C, 2016, BIOCHEM BIOPH RES CO, V476, P340, DOI 10.1016/j.bbrc.2016.05.124; dos Reis M, 2004, NUCLEIC ACIDS RES, V32, P5036, DOI 10.1093/nar/gkh834; Evans ME, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx514; Fan SQ, 2009, CANCER BIOL THER, V8, P1463, DOI 10.4161/cbt.8.15.8960; Forrest ME, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228730; Frenkel-Morgenstern M, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.3; Frumkin I, 2018, P NATL ACAD SCI USA, V115, pE4940, DOI 10.1073/pnas.1719375115; Fu JJ, 2018, J BIOL CHEM, V293, P17929, DOI 10.1074/jbc.RA118.004908; Fu YG, 2011, GENOME RES, V21, P741, DOI 10.1101/gr.115295.110; Torres AG, 2014, FEBS LETT, V588, P4279, DOI 10.1016/j.febslet.2014.09.025; Gamble CE, 2016, CELL, V166, P679, DOI 10.1016/j.cell.2016.05.070; Gao NL, 2021, GENOM PROTEOM BIOINF, V19, P949, DOI 10.1016/j.gpb.2021.03.002; Gingold H, 2014, CELL, V158, P1281, DOI 10.1016/j.cell.2014.08.011; Gingold H, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.14; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Goodarzi H, 2016, CELL, V165, P1416, DOI 10.1016/j.cell.2016.05.046; Gorochowski TE, 2015, NUCLEIC ACIDS RES, V43, P3022, DOI 10.1093/nar/gkv199; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grewal SS, 2015, BBA-GENE REGUL MECH, V1849, P898, DOI 10.1016/j.bbagrm.2014.12.005; Griseri P, 2014, WORLD J CLIN ONCOL, V5, P323, DOI 10.5306/wjco.v5.i3.323; Gruber AR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6465; Guimaraes JC, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1943-5; Hanson G, 2018, NAT REV MOL CELL BIO, V19, P20, DOI 10.1038/nrm.2017.91; Harigaya Y, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3749-8; He Q, 2020, CELL DEATH DIS, V11, P1; Hernandez-Alias X, 2021, MOL SYST BIOL, V17, DOI 10.15252/msb.202010097; Hia FB, 2019, EMBO REP, V20, DOI 10.15252/embr.201948220; Hinnebusch AG, 2016, SCIENCE, V352, P1413, DOI 10.1126/science.aad9868; Hoffman Y, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005879; Ingolia NT, 2012, NAT PROTOC, V7, P1534, DOI 10.1038/nprot.2012.086; Ji Z, 2009, P NATL ACAD SCI USA, V106, P7028, DOI 10.1073/pnas.0900028106; Kantidakis T, 2010, P NATL ACAD SCI USA, V107, P11823, DOI 10.1073/pnas.1005188107; Komar AA, 2016, HUM MOL GENET, V25, pR77, DOI 10.1093/hmg/ddw207; Ladang A, 2015, J EXP MED, V212, P2057, DOI 10.1084/jem.20142288; Lambert M, 2018, MOLECULES, V23, DOI 10.3390/molecules23061479; Lampson BL, 2013, CURR BIOL, V23, P70, DOI 10.1016/j.cub.2012.11.031; Lee LJ, 2021, TRENDS CANCER, V7, P134, DOI 10.1016/j.trecan.2020.09.005; Leppek K, 2018, NAT REV MOL CELL BIO, V19, P158, DOI 10.1038/nrm.2017.103; Lewinson, RNA BIOL, V2021; Li QS, 2021, BMC GASTROENTEROL, V21, DOI 10.1186/s12876-020-01553-z; Li YK, 2012, CANCER BIOL THER, V13, P272, DOI 10.4161/cbt.18923; Liu Y, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00642-6; Lorent J, 2019, EMBO J, V38, DOI 10.15252/embj.2018101323; Lu LG, 2018, CANCER INVEST, V36, P246, DOI 10.1080/07357907.2018.1466896; Mahlab S, 2012, RNA, V18, P640, DOI 10.1261/rna.030775.111; Makhtar WRW, 2017, ONCOGENE, V36, P6640, DOI 10.1038/onc.2017.273; Mauger DM, 2019, P NATL ACAD SCI USA, V116, P24075, DOI 10.1073/pnas.1908052116; Medina-Munoz SG, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-020-02251-5; Mishima Y, 2016, MOL CELL, V61, P874, DOI 10.1016/j.molcel.2016.02.027; Modelska A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.542; Najafabadi HS, 2009, NUCLEIC ACIDS RES, V37, P7014, DOI 10.1093/nar/gkp792; Novoa EM, 2019, MOL BIOL EVOL, V36, P2328, DOI 10.1093/molbev/msz124; Parmley JL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000548; Pavon-Eternod M, 2009, NUCLEIC ACIDS RES, V37, P7268, DOI 10.1093/nar/gkp787; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Perron G, 2018, CELL REP, V23, P1639, DOI 10.1016/j.celrep.2018.04.031; Pershing NLK, 2015, J CLIN INVEST, V125, P222, DOI 10.1172/JCI77627; Pinkard O, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17879-x; Plotkin JB, 2004, P NATL ACAD SCI USA, V101, P12588, DOI 10.1073/pnas.0404957101; Plotkin JB, 2011, NAT REV GENET, V12, P32, DOI 10.1038/nrg2899; Presnyak V, 2015, CELL, V160, P1111, DOI 10.1016/j.cell.2015.02.029; Radhakrishnan A, 2016, CELL, V167, P122, DOI 10.1016/j.cell.2016.08.053; Ranjan N, 2016, TRANSLATION, V4, DOI 10.1080/21690731.2016.1143076; Rapino F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22254-5; Rapino F, 2018, NATURE, V558, P605, DOI 10.1038/s41586-018-0243-7; Rapino F, 2017, TRENDS CANCER, V3, P249, DOI 10.1016/j.trecan.2017.02.004; Rocha EPC, 2004, GENOME RES, V14, P2279, DOI 10.1101/gr.2896904; Rouya C, 2014, RNA, V20, P1398, DOI 10.1261/rna.045302.114; Rubio CA, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0476-1; Rudolph KLM, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006024; Rudorf S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134994; Rudorf S, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003909; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Schuster SL, 2019, TRENDS CANCER, V5, P245, DOI 10.1016/j.trecan.2019.02.011; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Schwanhausser B, 2009, PROTEOMICS, V9, P205, DOI 10.1002/pmic.200800275; Sharma Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10489-2; SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P5125, DOI 10.1093/nar/14.13.5125; Silvera D, 2009, NAT CELL BIOL, V11, P903, DOI 10.1038/ncb1900; Sommerkamp P, 2021, TRENDS MOL MED, V27, P660, DOI 10.1016/j.molmed.2021.04.006; Supek F, 2014, CELL, V156, P1324, DOI 10.1016/j.cell.2014.01.051; Tesina P, 2020, EMBO J, V39, DOI 10.15252/embj.2019103365; Torrent M, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat6409; Trosemeier JH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43857-5; Vaklavas C, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00158; Waldman YY, 2010, NUCLEIC ACIDS RES, V38, P2964, DOI 10.1093/nar/gkq009; Walsh IM, 2020, P NATL ACAD SCI USA, V117, P3528, DOI 10.1073/pnas.1907126117; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Webster MW, 2018, MOL CELL, V70, P1089, DOI 10.1016/j.molcel.2018.05.033; Weinberg DE, 2016, CELL REP, V14, P1787, DOI 10.1016/j.celrep.2016.01.043; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; Wolfe AL, 2014, NATURE, V513, P65, DOI 10.1038/nature13485; Wu QS, 2019, ELIFE, V8, DOI 10.7554/eLife.45396; Wu XD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160463; Xu HY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44457-z; Xu SQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09235-5; Xu Y, 2013, NATURE, V495, P116, DOI 10.1038/nature11942; Yi J, 2017, ONCOTARGET, V8, P20751, DOI 10.18632/oncotarget.10612; Yu CH, 2015, MOL CELL, V59, P744, DOI 10.1016/j.molcel.2015.07.018; Zhang Z, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0239-8; Zhao FZ, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022590118; Zhao F, 2017, NUCLEIC ACIDS RES, V45, P8484, DOI 10.1093/nar/gkx501; Zhou M, 2013, NATURE, V495, P111, DOI 10.1038/nature11833; Zhou ZP, 2016, P NATL ACAD SCI USA, V113, pE6117, DOI 10.1073/pnas.1606724113; Zou Q, 2019, THERANOSTICS, V9, P4141, DOI 10.7150/thno.35033	134	4	4	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6309	6320		10.1038/s41388-021-02022-x	http://dx.doi.org/10.1038/s41388-021-02022-x		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34584217	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000701638300005
J	Lee, LM; Christodoulou, EG; Shyamsunder, P; Chen, BJ; Lee, KL; Fung, TK; So, CWE; Wong, GC; Petretto, E; Rackham, OJL; Ong, ST				Lee, Lin Ming; Christodoulou, Eleni G.; Shyamsunder, Pavithra; Chen, Bei Jun; Lee, Kian Leong; Fung, Tsz Kan; So, Chi Wai Eric; Wong, Gee Chuan; Petretto, Enrico; Rackham, Owen J. L.; Tiong Ong, S.			A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify (R)	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PLURIPOTENT STEM-CELLS; GENOME-WIDE ANALYSIS; TRANS-RETINOIC ACID; SELF-RENEWAL; CHIP-SEQ; EXPRESSION; ALPHA; PML; TRANSCRIPTION	Acute myeloid leukaemia (AML) is a rapidly fatal blood cancer that is characterised by the accumulation of immature myeloid cells in the blood and bone marrow as a result of blocked differentiation. Methods which identify master transcriptional regulators of AML subtype-specific leukaemia cell states and their combinations could be critical for discovering novel differentiation-inducing therapies. In this proof-of-concept study, we demonstrate a novel utility of the Mogrify (R) algorithm in identifying combinations of transcription factors (TFs) and drugs, which recapitulate granulocytic differentiation of the NB4 acute promyelocytic leukaemia (APL) cell line, using two different approaches. In the first approach, Connectivity Map (CMAP) analysis of these TFs and their target networks outperformed standard approaches, retrieving ATRA as the top hit. We identify dimaprit and mebendazole as a drug combination which induces myeloid differentiation. In the second approach, we show that genetic manipulation of specific Mogrify (R)-identified TFs (MYC and IRF1) leads to co-operative induction of APL differentiation, as does pharmacological targeting of these TFs using currently available compounds. We also show that loss of IRF1 blunts ATRA-mediated differentiation, and that MYC represses IRF1 expression through recruitment of PML-RARa, the driver fusion oncoprotein in APL, to the IRF1 promoter. Finally, we demonstrate that these drug combinations can also induce differentiation of primary patient-derived APL cells, and highlight the potential of targeting MYC and IRF1 in high-risk APL. Thus, these results suggest that Mogrify (R) could be used for drug discovery or repositioning in leukaemia differentiation therapy for other subtypes of leukaemia or cancers.	[Lee, Lin Ming; Shyamsunder, Pavithra; Lee, Kian Leong; Tiong Ong, S.] Duke NUS Med Sch, Programme Canc & Stem Cell Biol, Singapore, Singapore; [Christodoulou, Eleni G.; Chen, Bei Jun; Petretto, Enrico; Rackham, Owen J. L.] Duke NUS Med Sch, Ctr Computat Biol, Singapore, Singapore; [Christodoulou, Eleni G.; Chen, Bei Jun; Petretto, Enrico; Rackham, Owen J. L.] Duke NUS Med Sch, Programme Cardiovasc & Metab Disorders, Singapore, Singapore; [Fung, Tsz Kan; So, Chi Wai Eric] Kings Coll London, Comprehens Canc Ctr, London, England; [Fung, Tsz Kan; So, Chi Wai Eric] Kings Coll Hosp London, Dept Haematol Med, London, England; [Wong, Gee Chuan; Tiong Ong, S.] Singapore Gen Hosp, Dept Haematol, Singapore, Singapore; [Petretto, Enrico] Imperial Coll London, MRC London Inst Med Sci LMC, Fac Med, London, England; [Petretto, Enrico] China Pharmaceut Univ CPU, Inst Big Data & Artificial Intelligence Med, Sch Sci, Nanjing, Peoples R China; [Rackham, Owen J. L.] Univ Southampton, Sch Biol Sci, Southampton SO17 1BJ, England; [Tiong Ong, S.] Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore; [Tiong Ong, S.] Duke Univ, Dept Med, Med Ctr, Durham, NC USA	National University of Singapore; National University of Singapore; National University of Singapore; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; Singapore General Hospital; Imperial College London; University of Southampton; National Cancer Centre Singapore (NCCS); Duke University	Ong, ST (corresponding author), Duke NUS Med Sch, Programme Canc & Stem Cell Biol, Singapore, Singapore.; Petretto, E; Rackham, OJL (corresponding author), Duke NUS Med Sch, Ctr Computat Biol, Singapore, Singapore.; Petretto, E; Rackham, OJL (corresponding author), Duke NUS Med Sch, Programme Cardiovasc & Metab Disorders, Singapore, Singapore.; Ong, ST (corresponding author), Singapore Gen Hosp, Dept Haematol, Singapore, Singapore.; Petretto, E (corresponding author), Imperial Coll London, MRC London Inst Med Sci LMC, Fac Med, London, England.; Petretto, E (corresponding author), China Pharmaceut Univ CPU, Inst Big Data & Artificial Intelligence Med, Sch Sci, Nanjing, Peoples R China.; Rackham, OJL (corresponding author), Univ Southampton, Sch Biol Sci, Southampton SO17 1BJ, England.; Ong, ST (corresponding author), Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore.; Ong, ST (corresponding author), Duke Univ, Dept Med, Med Ctr, Durham, NC USA.	enrico.petretto@duke-nus.edu.sg; owen.rackham@duke-nus.edu.sg; sintiong.ong@duke-nus.edu.sg		Lee, Lin Ming/0000-0001-6229-3679	National Medical Research Council (NMRC) of Singapore [MOH-000059/MOH-CSASI18may-0002, NMRC/CIRG/1429/2015]; NMRC YIRG [NMRC/OFYIRG/0022/2016]; Singapore National Research Foundation grant [NRF-CRP20-2017-0002]	National Medical Research Council (NMRC) of Singapore(National Medical Research Council, Singapore); NMRC YIRG; Singapore National Research Foundation grant(National Research Foundation, Singapore)	The authors would like to acknowledge Dr. Sonia P. Chothani for providing the RNA-Seq data analysis pipeline, the ssCMAP developer, Dr. Shu-Dong Zhang, for helpful discussion on the algorithm's internal calculations, the Duke-NUS Genome Biology Facility (DGBF) for RNA, ChIP-and ATAC-sequencing services, as well as Dr. Gee Chuan Wong/Bryan Y.W. Teo, SGH Department of Haematology for providing primary APL samples. This work was funded by the National Medical Research Council (NMRC) of Singapore (MOH-000059/MOH-CSASI18may-0002) and NMRC/CIRG/1429/2015 to STO). OJLR is supported by NMRC YIRG (NMRC/OFYIRG/0022/2016) and by a Singapore National Research Foundation grant [NRF-CRP20-2017-0002].	Assi SA, 2019, NAT GENET, V51, P151, DOI 10.1038/s41588-018-0270-1; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Brodsky A, 1998, EUR J PHARMACOL, V350, P121, DOI 10.1016/S0014-2999(98)00227-1; Cao ZD, 2021, MOL CELL, V81, P3604, DOI 10.1016/j.molcel.2021.07.018; Chao MP, 2017, CELL STEM CELL, V20, P329, DOI 10.1016/j.stem.2016.11.018; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; Coccia EM, 2001, BIOCHEM J, V360, P285, DOI 10.1042/0264-6021:3600285; Corces MR, 2016, NAT GENET, V48, P1193, DOI 10.1038/ng.3646; de The H, 2018, NAT REV CANCER, V18, P117, DOI 10.1038/nrc.2017.103; de The H, 2017, CANCER CELL, V32, P552, DOI 10.1016/j.ccell.2017.10.002; dos Santos GA, 2013, J EXP MED, V210, P2793, DOI 10.1084/jem.20131121; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Fiedler K, 2012, AM J BLOOD RES, V2, P57; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Fujiwara T, 2009, MOL CELL, V36, P667, DOI 10.1016/j.molcel.2009.11.001; Gao TS, 2016, BIOINFORMATICS, V32, P3543, DOI 10.1093/bioinformatics/btw495; Gonda TJ, 2015, NAT REV CANCER, V15, P686, DOI 10.1038/nrc4018; Hu MH, 2018, J MED CHEM, V61, P2447, DOI 10.1021/acs.jmedchem.7b01697; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; KALINYAK KA, 1985, LIFE SCI, V36, P1909, DOI 10.1016/0024-3205(85)90439-4; Khwaja A, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.10; Kotini AG, 2017, CELL STEM CELL, V20, P315, DOI 10.1016/j.stem.2017.01.009; Kuhn M, 2012, NUCLEIC ACIDS RES, V40, pD876, DOI 10.1093/nar/gkr1011; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lan X, 2012, NUCLEIC ACIDS RES, V40, P7690, DOI 10.1093/nar/gks501; Leon J, 2009, CELL CYCLE, V8, P1148, DOI 10.4161/cc.8.8.8126; Li YL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53290-3; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin XJ, 2021, CLIN CANCER RES, V27, P3683, DOI 10.1158/1078-0432.CCR-20-4375; Liu QY, 2015, MOL PHARMACOL, V88, P469, DOI 10.1124/mol.115.097915; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lourenco C, 2021, NAT REV CANCER, V21, P579, DOI 10.1038/s41568-021-00367-9; Lucena-Araujo AR, 2019, BLOOD, V132, P951, DOI 10.1182/blood.2019000239; McClellan JS, 2015, P NATL ACAD SCI USA, V112, P4074, DOI 10.1073/pnas.1413383112; McNamara S, 2008, MOL CELL BIOL, V28, P2066, DOI 10.1128/MCB.01576-07; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Michalska A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01135; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Ng KP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205254; Nichol JN, 2016, CELL REP, V14, P2938, DOI 10.1016/j.celrep.2016.02.074; Norsworthy KJ, 2016, CURR OPIN HEMATOL, V23, P127, DOI 10.1097/MOH.0000000000000215; Padmanabhan A, 2013, J BIOL CHEM, V288, P14158, DOI 10.1074/jbc.M112.432377; Pan XN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105381; Pantziarka P, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.443; Park SM, 2019, CELL STEM CELL, V24, P153, DOI 10.1016/j.stem.2018.10.016; Paul F, 2016, CELL, V164, P325, DOI 10.1016/j.cell.2015.12.046; Prunier C, 2015, CELL REP, V10, P883, DOI 10.1016/j.celrep.2015.01.024; Quenech'Du N, 1998, LEUKEMIA, V12, P1829, DOI 10.1038/sj.leu.2401171; Rackham OJL, 2016, NAT GENET, V48, P331, DOI 10.1038/ng.3487; Ravandi F, 2009, J CLIN ONCOL, V27, P504, DOI 10.1200/JCO.2008.18.6130; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sapio L, 2017, J CELL PHYSIOL, V232, P922, DOI 10.1002/jcp.25650; SAWUTZ DG, 1984, J PHARMACOL EXP THER, V231, P1; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shayo C, 1997, MOL PHARMACOL, V51, P983, DOI 10.1124/mol.51.6.983; Shi LH, 2011, GENE, V487, P21, DOI 10.1016/j.gene.2011.07.004; Shyamsunder P, 2019, BLOOD, V133, P2507, DOI 10.1182/blood.2018886077; Si JL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-92; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tan Y, 2021, BLOOD, V137, P1503, DOI 10.1182/blood.2020005698; Testa U, 2004, LEUKEMIA, V18, P1864, DOI 10.1038/sj.leu.2403472; Testa U, 2016, ANN HEMATOL, V95, P673, DOI 10.1007/s00277-016-2622-1; Vicente C, 2012, CRIT REV ONCOL HEMAT, V82, P1, DOI 10.1016/j.critrevonc.2011.04.007; Walf-Vorderwulbecke V, 2018, LEUKEMIA, V32, P882, DOI 10.1038/leu.2017.317; Wang E, 2021, CELL STEM CELL, V28, P718, DOI 10.1016/j.stem.2020.12.005; Wang KK, 2010, CANCER CELL, V17, P186, DOI 10.1016/j.ccr.2009.12.045; Wang P., 2020, GENOME BIOL, V21; Yang LJ, 2003, J MOL DIAGN, V5, P212, DOI 10.1016/S1525-1578(10)60476-X; Yun HY, 2021, NAT GENET, V53, P1443, DOI 10.1038/s41588-021-00925-9; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhang L, 2020, BLOOD, V135, P1133, DOI 10.1182/blood.2019001863; Zhang SD, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-258; Zhao Q, 2004, LEUKEMIA, V18, P285, DOI 10.1038/sj.leu.2403226; Zheng PZ, 2005, P NATL ACAD SCI USA, V102, P7653, DOI 10.1073/pnas.0502825102	79	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5160	5175		10.1038/s41388-022-02505-5	http://dx.doi.org/10.1038/s41388-022-02505-5		OCT 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271030	Bronze			2022-12-28	WOS:000870984500001
J	Li, ZW; Li, BH; Yu, HY; Wang, PF; Wang, WW; Hou, PF; Li, ML; Chu, SF; Zheng, JN; Mao, LJ; Bai, J				Li, Zhongwei; Li, Bingheng; Yu, Haiyuan; Wang, Pengfei; Wang, Wenwen; Hou, Pingfu; Li, Minle; Chu, Sufang; Zheng, Junnian; Mao, Lijun; Bai, Jin			DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability	ONCOGENE			English	Article							METHYLATION; DEGRADATION	A plethora of studies have shown that both DNMT1 and EZH2 have great effects on the progression of a variety of cancers. However, it remains unclear whether the expression profiles of these two epigenetic enzymes are molecularly intertwined in prostate cancer (PC), especially in castration-resistant prostate cancer (CRPC). Here, we found that DNMT1 is highly expressed and facilitates PC cell proliferation and migration. Importantly, we demonstrate that the abrogation of DNMT1 expression can induce the decreased expression of EZH2, resulting in the less aggressive capacity of PC cells. Mechanistically, we discovered that DNMT1 promotes PC tumorigenesis and metastasis by inhibiting TRAF6 transcriptional expression and subsequent TRAF6-mediated EZH2 ubiquitination. Finally, we confirmed that there is a negative correlation between DNMT1 and TRAF6 expression and a positive correlation between DNMT1 and EZH2 expression in PC patients. In this study, we first disclose that there is a direct crosstalk between DNA methyltransferase DNMT1 expression and histone methyltransferase EZH2 expression in tumorigenesis and cancer metastasis in vitro and in vivo. Our results also show that targeting DNMT1 with its inhibitor decitabine (an FDA-approved drug) is an appealing treatment strategy for CRPC patients through epigenetic suppression of both DNMT1-mediated DNA methylation and EZH2-modulated histone methylation.	[Li, Zhongwei; Li, Bingheng; Yu, Haiyuan; Wang, Pengfei; Wang, Wenwen; Hou, Pingfu; Li, Minle; Chu, Sufang; Zheng, Junnian; Mao, Lijun; Bai, Jin] Xuzhou Med Univ, Canc Inst, Xuzhou, Jiangsu, Peoples R China; [Li, Zhongwei; Hou, Pingfu; Li, Minle; Zheng, Junnian; Bai, Jin] Xuzhou Med Univ, Affiliated Hosp, Ctr Clin Oncol, Xuzhou, Jiangsu, Peoples R China; [Li, Zhongwei; Hou, Pingfu; Li, Minle; Zheng, Junnian; Bai, Jin] Xuzhou Med Univ, Canc Inst, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou, Jiangsu, Peoples R China; [Mao, Lijun] Xuzhou Med Univ, Affiliated Hosp, Dept Urinary Surg, Xuzhou, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical University	Zheng, JN; Mao, LJ; Bai, J (corresponding author), Xuzhou Med Univ, Canc Inst, Xuzhou, Jiangsu, Peoples R China.; Zheng, JN; Bai, J (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Ctr Clin Oncol, Xuzhou, Jiangsu, Peoples R China.; Zheng, JN; Bai, J (corresponding author), Xuzhou Med Univ, Canc Inst, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou, Jiangsu, Peoples R China.; Mao, LJ (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Dept Urinary Surg, Xuzhou, Jiangsu, Peoples R China.	jnzheng@xzhmu.edu.cn; mljmlj05@126.com; bj@xzhmu.edu.cn		Zheng, Junnian/0000-0003-0208-6410	National Natural Science Foundation of China [82173060, 82072649]; Outstanding Youth Foundation of Jiangsu Province [BK20200046]; National Postdoctoral Research Funds of China [2019M651971, 2021T140577]; Postgraduate Research & Practice Innovation Program of Jiangsu [KYCX21_2689]; Jiangsu Provincial Key Medical Discipline; Project of Invigorating Health Care through Science, Technology and Education [ZDXKA2016014]; Qinglan Project of Jiangsu	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Outstanding Youth Foundation of Jiangsu Province; National Postdoctoral Research Funds of China; Postgraduate Research & Practice Innovation Program of Jiangsu; Jiangsu Provincial Key Medical Discipline; Project of Invigorating Health Care through Science, Technology and Education; Qinglan Project of Jiangsu	This work was supported by grants from the National Natural Science Foundation of China (82173060 and 82072649), the Outstanding Youth Foundation of Jiangsu Province (BK20200046), the National Postdoctoral Research Funds of China (2019M651971 and 2021T140577), the Postgraduate Research & Practice Innovation Program of Jiangsu (KYCX21_2689), the Jiangsu Provincial Key Medical Discipline, the Project of Invigorating Health Care through Science, Technology and Education (NO. ZDXKA2016014) and the Qinglan Project of Jiangsu.	Agarwal S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-99; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Bai J, 2019, P NATL ACAD SCI USA, V116, P11754, DOI 10.1073/pnas.1820990116; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Chen XT, 2021, CANCER LETT, V508, P115, DOI 10.1016/j.canlet.2021.03.023; Dhillon S, 2020, DRUGS, V80, P1373, DOI 10.1007/s40265-020-01389-7; DiNardo CD, 2019, BLOOD, V133, P7, DOI 10.1182/blood-2018-08-868752; Garcia-Manero G, 2020, BLOOD, V136, P674, DOI 10.1182/blood.2019004143; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Klutstein M, 2016, CANCER RES, V76, P3446, DOI 10.1158/0008-5472.CAN-15-3278; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li Z, 2016, CELL DEATH DIFFER, V23, P583, DOI 10.1038/cdd.2015.125; Li ZW, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04381-5; Li ZW, 2020, BIOCHEM BIOPH RES CO, V533, P679, DOI 10.1016/j.bbrc.2020.10.037; Li ZW, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00505-0; Li ZW, 2020, CELL DEATH DIFFER, V27, P3226, DOI 10.1038/s41418-020-00615-9; Li ZW, 2017, ONCOTARGET, V8, P67329, DOI 10.18632/oncotarget.18622; Liu H, 2020, CELL DEATH DIFFER, V27, P966, DOI 10.1038/s41418-019-0389-3; Lyko F, 2018, NAT REV GENET, V19, P81, DOI 10.1038/nrg.2017.80; Mao LJ, 2021, J CANCER, V12, P1846, DOI 10.7150/jca.46868; Montesinos P, 2021, LEUKEMIA, V35, P62, DOI 10.1038/s41375-020-0773-5; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Teo MY, 2019, ANNU REV MED, V70, P479, DOI 10.1146/annurev-med-051517-011947; Tzelepi V, 2020, PATHOLOGY, V52, P218, DOI 10.1016/j.pathol.2019.10.006; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wong KK, 2021, SEMIN CANCER BIOL, V72, P198, DOI 10.1016/j.semcancer.2020.05.010; Yu J, 2018, J CLIN INVEST, V128, P2376, DOI 10.1172/JCI97924; Zhu AP, 2021, CARCINOGENESIS, V42, P220, DOI 10.1093/carcin/bgaa088	28	2	2	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					3991	4002		10.1038/s41388-022-02404-9	http://dx.doi.org/10.1038/s41388-022-02404-9		JUL 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35804015				2022-12-28	WOS:000824972000001
J	Oh, KS; Nam, AR; Bang, JH; Seo, HR; Kim, JM; Yoon, J; Kim, TY; Oh, D				Oh, Kyoung-Seok; Nam, Ah-Rong; Bang, Ju-Hee; Seo, Hye-Rim; Kim, Jae-Min; Yoon, Jeesun; Kim, Tae-Yong; Oh, Do-Youn			A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION; ADP-RIBOSYLATION; MECHANISM; PATHWAY; REPAIR; CELLS	Despite its clinical efficacy in HER2-positive cancers, resistance to trastuzumab inevitably occurs. The DNA damage response (DDR) pathway is essential for maintaining genomic stability and cell survival. However, the role of the DDR pathway in HER2-positive tumors and trastuzumab resistance remains elusive. In this study, we verified that increased PARP1 expression in trastuzumab-resistant (TR) cells, owing to its augmented stability by escape from proteasomal degradation, confers tolerability to trastuzumab-induced DNA damage. Interruption of PARP1 in TR cells restrains its cellular growth, while simultaneously activating ATM to retain its genome stability. Dual inhibition of PARP and ATM induces synthetic lethality in TR cells by favoring the toxic NHEJ pathway instead of the HRR pathway. Our results highlight the potential of clinical development of DDR-targeting strategies for trastuzumab-resistant HER2-positive cancer patients.	[Oh, Kyoung-Seok; Nam, Ah-Rong; Bang, Ju-Hee; Seo, Hye-Rim; Kim, Jae-Min; Kim, Tae-Yong; Oh, Do-Youn] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul 03080, South Korea; [Seo, Hye-Rim; Kim, Jae-Min; Oh, Do-Youn] Seoul Natl Univ, Grad Sch, Integrated Major Innovat Med Sci, Seoul 03080, South Korea; [Yoon, Jeesun; Kim, Tae-Yong; Oh, Do-Youn] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 03080, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Oh, D (corresponding author), Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul 03080, South Korea.; Oh, D (corresponding author), Seoul Natl Univ, Grad Sch, Integrated Major Innovat Med Sci, Seoul 03080, South Korea.; Oh, D (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Seoul 03080, South Korea.	ohdoyoun@snu.ac.kr			SNUH research fund [03-2019-0220]; National Research Foundation of Korea (NRF) - Korea government (MSIT) [2021R1A2C2007430]; 3rd AstraZeneca-KHIDI (Korea Health Industry Development Institute) oncology research program [06-2016-2920]; Institute of Smart Healthcare Innovative Medical Sciences, a Brain Korea 21 four program, Seoul National University	SNUH research fund; National Research Foundation of Korea (NRF) - Korea government (MSIT)(National Research Foundation of KoreaMinistry of Science, ICT & Future Planning, Republic of KoreaMinistry of Science & ICT (MSIT), Republic of Korea); 3rd AstraZeneca-KHIDI (Korea Health Industry Development Institute) oncology research program; Institute of Smart Healthcare Innovative Medical Sciences, a Brain Korea 21 four program, Seoul National University	This research was supported by the SNUH research fund (Grant No. 03-2019-0220) and the Institute of Smart Healthcare Innovative Medical Sciences, a Brain Korea 21 four program, Seoul National University, and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (Grant No. 2021R1A2C2007430). This research was also supported by 3rd AstraZeneca-KHIDI (Korea Health Industry Development Institute) oncology research program (Grant No. 06-2016-2920).	Balmus G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07729-2; Boone JJM, 2009, MOL CANCER THER, V8, P3015, DOI 10.1158/1535-7163.MCT-09-0219; Britton S, 2020, NUCLEIC ACIDS RES, V48, P9710, DOI 10.1093/nar/gkaa723; Caron MC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10741-9; Chaudhuri AR, 2017, NAT REV MOL CELL BIO, V18, P610, DOI 10.1038/nrm.2017.53; Ekman S, 2019, ANN ONCOL, V30, P353, DOI 10.1093/annonc/mdz043; Gatti M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107985; Gibbs-Seymour I, 2016, MOL CELL, V62, P432, DOI 10.1016/j.molcel.2016.03.008; Haince JF, 2008, J BIOL CHEM, V283, P1197, DOI 10.1074/jbc.M706734200; Haince JF, 2007, J BIOL CHEM, V282, P16441, DOI 10.1074/jbc.M608406200; Hu YD, 2014, CANCER DISCOV, V4, P1430, DOI 10.1158/2159-8290.CD-13-0891; Jin MH, 2017, MOL CANCER THER, V16, P1145, DOI 10.1158/1535-7163.MCT-16-0669; Jin MH, 2021, GASTRIC CANCER, V24, P1003, DOI 10.1007/s10120-021-01176-7; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; Lae M, 2010, ANN ONCOL, V21, P815, DOI 10.1093/annonc/mdp488; Lanczky A, 2021, J MED INTERNET RES, V23, DOI 10.2196/27633; Li M, 2013, GENE DEV, V27, P1752, DOI 10.1101/gad.226357.113; Lubennikova E, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e12562; Mak JPY, 2020, MOL CANCER THER, V19, P123, DOI 10.1158/1535-7163.MCT-19-0474; Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5; Nam AR, 2016, ONCOTARGET, V7, P58007, DOI 10.18632/oncotarget.11157; Nowsheen S, 2012, CANCER RES, V72, P4796, DOI 10.1158/0008-5472.CAN-12-1287; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Oh DY, 2020, NAT REV CLIN ONCOL, V17, P33, DOI 10.1038/s41571-019-0268-3; Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108; Pilie PG, 2019, CLIN CANCER RES, V25, P3759, DOI 10.1158/1078-0432.CCR-18-0968; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Pohlmann PR, 2009, CLIN CANCER RES, V15, P7479, DOI 10.1158/1078-0432.CCR-09-0636; Qian H, 2020, J CELL MOL MED, V24, P4600, DOI 10.1111/jcmm.15121; Riches LC, 2020, MOL CANCER THER, V19, P13, DOI 10.1158/1535-7163.MCT-18-1394; Siena S, 2018, ANN ONCOL, V29, P1108, DOI 10.1093/annonc/mdy100; Smeenk G, 2013, J CELL SCI, V126, P889, DOI 10.1242/jcs.109413; Suskiewicz MJ, 2020, NATURE, V579, P598, DOI 10.1038/s41586-020-2013-6; Valabrega G, 2007, ANN ONCOL, V18, P977, DOI 10.1093/annonc/mdl475; Wielgos ME, 2018, MOL CANCER THER, V17, P921, DOI 10.1158/1535-7163.MCT-17-0302; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yarlagadda B, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0091-4; Yazinski SA, 2017, GENE DEV, V31, P318, DOI 10.1101/gad.290957.116	38	1	1	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3939	3952		10.1038/s41388-022-02384-w	http://dx.doi.org/10.1038/s41388-022-02384-w		JUL 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35798878				2022-12-28	WOS:000821721300007
J	Tarantino, D; Walker, C; Weekes, D; Pemberton, H; Davidson, K; Torga, G; Frankum, J; Mendes-Pereira, AM; Prince, C; Ferro, R; Brough, R; Pettitt, SJ; Lord, CJ; Grigoriadis, A; Tutt, ANJ				Tarantino, Dalia; Walker, Callum; Weekes, Daniel; Pemberton, Helen; Davidson, Kathryn; Torga, Gonzalo; Frankum, Jessica; Mendes-Pereira, Ana M.; Prince, Cynthia; Ferro, Riccardo; Brough, Rachel; Pettitt, Stephen J.; Lord, Christopher J.; Grigoriadis, Anita; Tutt, Andrew N. J.			Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance	ONCOGENE			English	Article							DNA-POLYMERASES; BREAST-CANCER; EXPRESSION; INHIBITOR; MUTATIONS; BRCANESS; TUMORS	HORMAD1 expression is usually restricted to germline cells, but it becomes mis-expressed in epithelial cells in similar to 60% of triple-negative breast cancers (TNBCs), where it is associated with elevated genomic instability (1). HORMAD1 expression in TNBC is bimodal with HORMAD1-positive TNBC representing a biologically distinct disease group. Identification of HORMAD1-driven genetic dependencies may uncover novel therapies for this disease group. To study HORMAD1-driven genetic dependencies, we generated a SUM159 cell line model with doxycycline-inducible HORMAD1 that replicated genomic instability phenotypes seen in HORMAD1-positive TNBC (1). Using small interfering RNA screens, we identified candidate genes whose depletion selectively inhibited the cellular growth of HORMAD1-expressing cells. We validated five genes (ATR, BRIP1, POLH, TDP1 and XRCC1), depletion of which led to reduced cellular growth or clonogenic survival in cells expressing HORMAD1. In addition to the translesion synthesis (TLS) polymerase POLH, we identified a HORMAD1-driven dependency upon additional TLS polymerases, namely POLK, REV1, REV3L and REV7. Our data confirms that out-of-context somatic expression of HORMAD1 can lead to genomic instability and reveals that HORMAD1 expression induces dependencies upon replication stress tolerance pathways, such as translesion synthesis. Our data also suggest that HORMAD1 expression could be a patient selection biomarker for agents targeting replication stress.	[Tarantino, Dalia; Weekes, Daniel; Mendes-Pereira, Ana M.; Prince, Cynthia; Ferro, Riccardo; Grigoriadis, Anita; Tutt, Andrew N. J.] Kings Coll London, Breast Canc Now Res Unit, London, England; [Tarantino, Dalia; Weekes, Daniel; Mendes-Pereira, Ana M.; Prince, Cynthia; Ferro, Riccardo; Grigoriadis, Anita; Tutt, Andrew N. J.] Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, Kings Hlth Partners AHSC, London, England; [Walker, Callum; Weekes, Daniel; Pemberton, Helen; Davidson, Kathryn; Torga, Gonzalo; Frankum, Jessica; Brough, Rachel; Pettitt, Stephen J.; Lord, Christopher J.; Tutt, Andrew N. J.] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England; [Pemberton, Helen; Frankum, Jessica; Brough, Rachel; Pettitt, Stephen J.; Lord, Christopher J.] Inst Canc Res, CRUK Gene Funct Lab, London, England	University of London; King's College London; King's Health Partners; University of London; King's College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Tutt, ANJ (corresponding author), Kings Coll London, Breast Canc Now Res Unit, London, England.; Tutt, ANJ (corresponding author), Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, Kings Hlth Partners AHSC, London, England.; Tutt, ANJ (corresponding author), Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England.	Andrew.Tutt@icr.ac.uk		Torga, Gonzalo/0000-0002-6401-5127; Tutt, Andrew/0000-0001-8715-2901; Grigoriadis, Anita/0000-0003-3434-201X	Programme Grants from Breast Cancer Now; Cancer Research UK; National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; NIHR Royal Marsden Hospital Biomedical Research Centre	Programme Grants from Breast Cancer Now; Cancer Research UK(Cancer Research UK); National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; NIHR Royal Marsden Hospital Biomedical Research Centre	This work was funded by Programme Grants from Breast Cancer Now as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre and by funding from Cancer Research UK, the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and the NIHR Royal Marsden Hospital Biomedical Research Centre to Prof. Andrew Tutt. We thank King's College London Genomic Core Facility for supporting the RT-qPCR data acquisition and analysis. We thank the Nikon Imaging Centre (KCL) for access to and assistance with the microscope facilities. We thank Sorapun Utting, Melanie Ferrao and Caroline Carey for technical and administrative assistance. We thank Dr. Rebecca Marlow for providing training in immunofluorescence image processing. We thank Dr. Tencho Tenev for providing assistance with the design and optimisation of the CRISPR-Cas9 based gene editing experiments. We thank Dr. Olivia Rossanese and the Cancer Therapeutics Unit (ICR) for kindly providing laboratory space for conducting part of the experimental work.	Bradbury A, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2019.107450; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Campbell J, 2016, CELL REP, V14, P2490, DOI 10.1016/j.celrep.2016.02.023; Campeau PM, 2008, HUM GENET, V124, P31, DOI 10.1007/s00439-008-0529-1; Chen B, 2019, CANCER MANAG RES, V11, P179, DOI 10.2147/CMAR.S187151; Daniel K, 2011, NAT CELL BIOL, V13, P599, DOI 10.1038/ncb2213; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gao YZ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33601-w; Il'ina IV, 2020, MOLECULES, V25, DOI 10.3390/molecules25153496; Jones SE, 2017, CANCER RES, V77, P7014, DOI 10.1158/0008-5472.CAN-17-2056; Ketkar A, 2019, ACS CHEM BIOL, V14, P1337, DOI 10.1021/acschembio.9b00304; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Liu K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2736-1; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Lord CJ, 2008, DNA REPAIR, V7, P2010, DOI 10.1016/j.dnarep.2008.08.014; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Menolfi D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07798-3; Nichols BA, 2018, CANCER RES, V78, P6196, DOI 10.1158/0008-5472.CAN-18-1377; Pommier Y, 2014, DNA REPAIR, V19, P114, DOI 10.1016/j.dnarep.2014.03.020; Rakha EA, 2008, HUM PATHOL, V39, P857, DOI 10.1016/j.humpath.2007.10.011; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Ryan CJ, 2018, TRENDS CANCER, V4, P671, DOI 10.1016/j.trecan.2018.08.003; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Sale JE, 2012, NAT REV MOL CELL BIO, V13, P141, DOI 10.1038/nrm3289; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Temprine K, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aau1453; Tonzi P, 2018, ELIFE, V7, DOI 10.7554/eLife.41426; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Tutt ANJ, 2021, NEW ENGL J MED, V384, P2394, DOI 10.1056/NEJMoa2105215; Wang Xian, 2018, Oncotarget, V9, P30115, DOI 10.18632/oncotarget.25728; Watkins J, 2015, CANCER DISCOV, V5, P488, DOI 10.1158/2159-8290.CD-14-1092; Wojtaszek JL, 2019, CELL, V178, P152, DOI 10.1016/j.cell.2019.05.028; Yamanaka K, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006842; Yang W, 2018, ANNU REV BIOCHEM, V87, P239, DOI 10.1146/annurev-biochem-062917-012405; Zafar MK, 2018, BIOCHEMISTRY-US, V57, P1262, DOI 10.1021/acs.biochem.7b01176; Zhang J, 2016, GENES-BASEL, V7, DOI 10.3390/genes7080051	40	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3969	3977		10.1038/s41388-022-02369-9	http://dx.doi.org/10.1038/s41388-022-02369-9		JUN 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35768547	hybrid, Green Published			2022-12-28	WOS:000818607200001
J	Kerr, A; Baxter, RC				Kerr, Aidan; Baxter, Robert C.			Noncoding RNA actions through IGFs and IGF binding proteins in cancer	ONCOGENE			English	Review							DOWN-REGULATION; PROMOTES PROLIFERATION; CLINICAL-SIGNIFICANCE; CELL-PROLIFERATION; BLADDER-CANCER; MESSENGER-RNAS; EMERGING ROLE; EXPRESSION; INVASION; PROGRESSION	The insulin-like growth factors (IGFs) and their regulatory proteins-IGF receptors and binding proteins-are strongly implicated in cancer progression and modulate cell survival and proliferation, migration, angiogenesis and metastasis. By regulating the bioavailability of the type-1 IGF receptor (IGF1R) ligands, IGF-1 and IGF-2, the IGF binding proteins (IGFBP-1 to -6) play essential roles in cancer progression. IGFBPs also influence cell communications through pathways that are independent of IGF1R activation. Noncoding RNAs (ncRNAs), which encompass a variety of RNA types including microRNAs (miRNAs) and long-noncoding RNAs (lncRNAs), have roles in multiple oncogenic pathways, but their many points of intersection with IGF axis functions remain to be fully explored. This review examines the functional interactions of miRNAs and lncRNAs with IGFs and their binding proteins in cancer, and reveals how the IGF axis may mediate ncRNA actions that promote or suppress cancer. A better understanding of the links between ncRNA and IGF pathways may suggest new avenues for prognosis and therapeutic intervention in cancer. Further, by exploring examples of intersecting ncRNA-IGF pathways in non-cancer conditions, it is proposed that new opportunities for future discovery in cancer control may be generated.	[Kerr, Aidan; Baxter, Robert C.] Univ Sydney, Royal North Shore Hosp, Fac Med & Hlth, Kolling Inst, Sydney, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Kerr, A; Baxter, RC (corresponding author), Univ Sydney, Royal North Shore Hosp, Fac Med & Hlth, Kolling Inst, Sydney, NSW 2065, Australia.	aidan.kerr1998@gmail.com; robert.baxter@sydney.edu.au			CAUL	CAUL	Open Access funding enabled and organized by CAUL and its Member Institutions.	An LF, 2020, ANTI-CANCER DRUG, V31, P473, DOI 10.1097/CAD.0000000000000888; Annunziata M, 2011, ACTA DIABETOL, V48, P1, DOI 10.1007/s00592-010-0227-z; Bai R, 2019, MOL CARCINOGEN, V58, P2254, DOI 10.1002/mc.23113; Baxter RC, 2014, NAT REV CANCER, V14, P329, DOI 10.1038/nrc3720; Beckwith H, 2015, MOL ENDOCRINOL, V29, P1549, DOI 10.1210/me.2015-1157; Brown J, 2009, VITAM HORM, V80, P699, DOI 10.1016/S0083-6729(08)00625-0; Cai HM, 2019, INT J CLIN EXP PATHO, V12, P2496; Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224; Cantile M, 2021, CANCERS, V13, DOI 10.3390/cancers13030570; Chai ZH, 2020, BIOL RES, V53, DOI 10.1186/s40659-020-00280-9; Chang YS, 2002, CLIN CANCER RES, V8, P3796; Chen BQ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121638; Chen C, 2021, CANCER LETT, V518, P169, DOI 10.1016/j.canlet.2021.07.005; Chen H, 2018, ONCOL LETT, V15, P6361, DOI 10.3892/ol.2018.8174; Chen PH, 2016, NEUROPHARMACOLOGY, V110, P362, DOI 10.1016/j.neuropharm.2016.07.038; Chen ZH, 2020, LIFE SCI, V243, DOI 10.1016/j.lfs.2020.117288; Chirshev E, 2021, CANCERS, V13, DOI 10.3390/cancers13184617; Chuang ST, 2008, J UROLOGY, V179, P445, DOI 10.1016/j.juro.2007.09.106; Coe EA, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008501; Cox OT, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00106; Cuciniello R, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02193-1; de Silva HC, 2019, CELL MOL LIFE SCI, V76, P2015, DOI 10.1007/s00018-019-03033-4; DiStefano JK, 2018, METHODS MOL BIOL, V1706, P91, DOI 10.1007/978-1-4939-7471-9_6; Fan Chuannan, 2019, Oncotarget, V10, P4192, DOI 10.18632/oncotarget.24115; Ferreira HJ, 2018, CANCER METAST REV, V37, P55, DOI 10.1007/s10555-017-9715-8; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Fukuhisa H, 2019, J HUM GENET, V64, P521, DOI 10.1038/s10038-019-0584-6; Gao LL, 2019, EBIOMEDICINE, V41, P395, DOI 10.1016/j.ebiom.2019.02.034; Gao ZH, 2002, J CLIN ENDOCR METAB, V87, P1170, DOI 10.1210/jc.87.3.1170; Ghaforui-Fard S, 2019, J CELL PHYSIOL, V234, P17100, DOI 10.1002/jcp.28464; Gil N, 2020, NAT REV GENET, V21, P102, DOI 10.1038/s41576-019-0184-5; Gleeson LM, 2001, J CLIN ENDOCR METAB, V86, P2484, DOI 10.1210/jc.86.6.2484; Goto K, 2016, ONCOGENE, V35, P3598, DOI 10.1038/onc.2015.445; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Hakuno F, 2018, J MOL ENDOCRINOL, V61, pT69, DOI 10.1530/JME-17-0311; Han N, 2020, AM J PHYSIOL-ENDOC M, V318, pE723, DOI 10.1152/ajpendo.00555.2018; Han S, 2014, BRIT J CANCER, V111, P1400, DOI 10.1038/bjc.2014.435; Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4; Hong DVS, 2020, BRIT J CANCER, V122, P1630, DOI 10.1038/s41416-020-0802-1; Hu JH, 2016, FETAL PEDIATR PATHOL, V35, P287, DOI 10.1080/15513815.2016.1178360; Huang Y, 2021, IUBMB LIFE, V73, P118, DOI 10.1002/iub.2409; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Ivkovic TC, 2017, CANCER LETT, V407, P113, DOI 10.1016/j.canlet.2017.04.007; Ji YT, 2020, PLACENTA, V101, P185, DOI 10.1016/j.placenta.2020.09.015; Katayama H, 2017, SCI REP-UK, V7, DOI 10.1038/srep44498; Khodadadi-Jamayran Alireza, 2018, Oncotarget, V9, P12868, DOI 10.18632/oncotarget.24403; Khordadmehr M, 2019, J CELL PHYSIOL, V234, P16861, DOI 10.1002/jcp.28368; Kozomara A, 2019, NUCLEIC ACIDS RES, V47, pD155, DOI 10.1093/nar/gky1141; Kumar AS, 2018, RNA BIOL, V15, P320, DOI 10.1080/15476286.2017.1338240; Lecerf C, 2019, CELL MOL LIFE SCI, V76, P4673, DOI 10.1007/s00018-019-03240-z; Lee CC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173890; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Li CJ, 2020, INT J BIOL SCI, V16, P2271, DOI 10.7150/ijbs.46986; Li GQ, 2019, PATHOL RES PRACT, V215, P34, DOI 10.1016/j.prp.2018.10.008; Li SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150418; Li T, 2020, CANCER LETT, V477, P19, DOI 10.1016/j.canlet.2020.02.036; Li X, 2015, ONCOGENE, V34, P1619, DOI 10.1038/onc.2014.98; Li XY, 2020, AM J TRANSL RES, V12, P6314; Lin MZ, 2014, ONCOGENE, V33, P85, DOI 10.1038/onc.2012.538; Liu Hongyu, 2018, Onco Targets Ther, V11, P7197, DOI 10.2147/OTT.S175467; Liu JW, 2019, DIGEST DIS SCI, V64, P1523, DOI 10.1007/s10620-018-5424-6; Liu LY, 2015, BIOCHEM BIOPH RES CO, V457, P621, DOI 10.1016/j.bbrc.2015.01.037; Liu SJ, 2021, NAT REV CANCER, V21, P446, DOI 10.1038/s41568-021-00353-1; Liu XN, 2020, AM J PHYSIOL-ENDOC M, V319, pE34, DOI 10.1152/ajpendo.00528.2019; Long ZS, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01557-5; Lorenzatti G, 2011, J CELL SCI, V124, P1752, DOI 10.1242/jcs.084194; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; McDonald KL, 2007, J NEUROPATH EXP NEUR, V66, P405, DOI 10.1097/nen.0b013e31804567d7; Medley JC, 2021, WIRES RNA, V12, DOI 10.1002/wrna.1627; Mercer TR, 2022, TRENDS PHARMACOL SCI, V43, P269, DOI 10.1016/j.tips.2022.01.008; Morchikh M, 2017, MOL CELL, V67, P387, DOI 10.1016/j.molcel.2017.06.020; Niinuma T, 2017, ONCOL LETT, V14, P5703, DOI 10.3892/ol.2017.6911; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Osher E, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080895; Paul P, 2018, J CELL PHYSIOL, V233, P2007, DOI 10.1002/jcp.25854; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Poloznikov AA, 2019, B EXP BIOL MED+, V166, P641, DOI 10.1007/s10517-019-04409-z; Qi L, 2018, BIOMED PHARMACOTHER, V103, P1507, DOI 10.1016/j.biopha.2018.04.053; Qu SP, 2019, EUR REV MED PHARMACO, V23, P4850, DOI 10.26355/eurrev_201906_18072; Santosh V, 2010, CANCER EPIDEM BIOMAR, V19, P1399, DOI 10.1158/1055-9965.EPI-09-1213; Sehgal K, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143945; Seligson DB, 2013, HORM CANCER-US, V4, P12, DOI 10.1007/s12672-012-0124-8; Shen P, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-020-01705-x; Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017; Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9; Sun Y, 2019, J CELL BIOCHEM, V120, P19406, DOI 10.1002/jcb.29055; Tan YL, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820909125; Thin KZ, 2019, CLIN CHIM ACTA, V494, P38, DOI 10.1016/j.cca.2019.03.002; Tong L, 2021, ADV CLIN EXP MED, V30, P661, DOI 10.17219/acem/134833; Wa QD, 2018, ONCOL REP, V39, P81, DOI 10.3892/or.2017.6096; Wang HH, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694316; Wang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096472; Wang XY, 2020, BIOCHEM BIOPH RES CO, V531, P573, DOI 10.1016/j.bbrc.2020.08.008; Wu XG, 2020, LIFE SCI, V243, DOI 10.1016/j.lfs.2020.117287; Yan L, 2018, J CELL BIOCHEM, V119, P3989, DOI 10.1002/jcb.26553; Yang BY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0722-8; Yang CH, 2014, J BIOL CHEM, V289, P25079, DOI 10.1074/jbc.M114.593863; Yang DK, 2020, CANCER MED-US, V9, P700, DOI 10.1002/cam4.2650; Yin L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02785-3; Yu GQ, 2017, ONCOL REP, V37, P1123, DOI 10.3892/or.2016.5326; ZeinElAbdeen YA, 2022, J MAMMARY GLAND BIOL, V27, P79, DOI 10.1007/s10911-022-09511-z; Zhan JF, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12692; Zhang NN, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.1012; Zhang Q, 2020, J CELL MOL MED, V24, P8236, DOI 10.1111/jcmm.15499; Zhang T, 2019, ONCOL REP, V41, P279, DOI 10.3892/or.2018.6840; Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211; Zheng F, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0146-6; Zhou N, 2018, ONCOL REP, V40, P2710, DOI 10.3892/or.2018.6640; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	109	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3385	3393		10.1038/s41388-022-02353-3	http://dx.doi.org/10.1038/s41388-022-02353-3		MAY 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35597813	hybrid, Green Published			2022-12-28	WOS:000798470300001
J	Ehsani, M; Bartsch, S; Rasa, SMM; Dittmann, J; Pungsrinont, T; Neubert, L; Huettner, SS; Kotolloshi, R; Schindler, K; Ahmad, A; Mosig, AS; Adam, L; Ori, A; Neri, F; Berndt, A; Grimm, MO; Baniahmad, A				Ehsani, Marzieh; Bartsch, Sophie; Rasa, Seyed Mohammad Mahdi; Dittmann, Jessica; Pungsrinont, Thanakorn; Neubert, Laura; Huettner, Soeren S.; Kotolloshi, Roland; Schindler, Katrin; Ahmad, Aya; Mosig, Alexander S.; Adam, Lisa; Ori, Alessandro; Neri, Francesco; Berndt, Alexander; Grimm, Marc-Oliver; Baniahmad, Aria			The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR INTEGRIN ALPHA(V)BETA(3); MICROVESSEL DENSITY; CELLULAR SENESCENCE; PROGNOSTIC VALUE; RECEPTOR; EXPRESSION; ANTAGONIST; VEGF; SURVIVAL	Castration-resistant prostate cancer (CRPC) is an aggressive lethal form of prostate cancer (PCa). Atraric acid (AA) not only inhibits the wild-type androgen receptor (AR) but also those AR mutants that confer therapy resistance to other clinically used AR antagonists, indicating a different mode of AR antagonism. AA induces cellular senescence and inhibits CRPC tumour growth in in vivo xenograft mouse model associated with reduced neo-angiogenesis suggesting the repression of intratumoural neo-angiogenesis by AA. In line with this, the secretome of CRPC cells mediates neo-angiogenesis in an androgen-dependent manner, which is counteracted by AA. This was confirmed by two in vitro models using primary human endothelial cells. Transcriptome sequencing revealed upregulated angiogenic pathways by androgen, being however VEGF-independent, and pointing to the pro-angiogenic factor angiopoietin 2 (ANGPT2) as a key driver of neo-angiogenesis induced by androgens and repressed by AA. In agreement with this, AA treatment of native patient-derived PCa tumour samples ex vivo inhibits ANGPT2 expression. Mechanistically, in addition to AA, immune-depletion of ANGPT2 from secretome or blocking ANGPT2-receptors inhibits androgen-induced angiogenesis. Taken together, we reveal a VEGF-independent ANGPT2-mediated angiogenic pathway that is inhibited by AA leading to repression of androgen-regulated neo-angiogenesis.	[Ehsani, Marzieh; Bartsch, Sophie; Dittmann, Jessica; Pungsrinont, Thanakorn; Neubert, Laura; Huettner, Soeren S.; Kotolloshi, Roland; Schindler, Katrin; Ahmad, Aya; Baniahmad, Aria] Jena Univ Hosp, Inst Human Genet, D-07740 Jena, Germany; [Rasa, Seyed Mohammad Mahdi; Adam, Lisa; Ori, Alessandro; Neri, Francesco] Leibniz Inst Aging, D-07745 Jena, Germany; [Mosig, Alexander S.] Jena Univ, Inst Biochem 2, D-07740 Jena, Germany; [Berndt, Alexander] Jena Univ Hosp, Inst Pathol, D-07740 Jena, Germany; [Grimm, Marc-Oliver] Jena Univ Hosp, Dept Adult & Pediat Urol, D-07740 Jena, Germany	Friedrich Schiller University of Jena; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Baniahmad, A (corresponding author), Jena Univ Hosp, Inst Human Genet, D-07740 Jena, Germany.	aria.baniahmad@med.uni-jena.de		Huttner, Soren/0000-0002-5054-0027	German Cancer Aid [70113814]; German Academic Exchange Service (DAAD) [91606773, 91644032]; Projekt DEAL	German Cancer Aid(Deutsche Krebshilfe); German Academic Exchange Service (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); Projekt DEAL	This work was supported by the German Cancer Aid (No. 70113814) to AB, the German Academic Exchange Service (DAAD) to ME (91606773), TP (91644032). Open Access funding enabled and organized by Projekt DEAL.	Albert JM, 2006, INT J RADIAT ONCOL, V65, P1536, DOI 10.1016/j.ijrobp.2006.04.036; Aparicio A, 2011, NAT REV UROL, V8, P562, DOI 10.1038/nrurol.2011.107; Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001; Bono AV, 2002, PROSTATE CANCER P D, V5, P123, DOI 10.1038/sj.pcan.4500572; Borre M, 1998, BRIT J CANCER, V78, P940, DOI 10.1038/bjc.1998.605; Breslin S, 2013, DRUG DISCOV TODAY, V18, P240, DOI 10.1016/j.drudis.2012.10.003; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02; Duque José Luis Ferreira, 2006, Clinics, V61, P401, DOI 10.1590/S1807-59322006000500006; Ehsani M, 2021, CANCERS, V13, DOI 10.3390/cancers13071534; Esmaeili M, 2016, J MOL MED, V94, P1167, DOI 10.1007/s00109-016-1440-1; Esmaeili M, 2016, J MOL CELL BIOL, V8, P207, DOI 10.1093/jmcb/mjw007; Felcht M, 2012, J CLIN INVEST, V122, P1991, DOI 10.1172/JCI58832; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685; Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Fromont G, 2005, INT J CANCER, V114, P174, DOI 10.1002/ijc.20704; Garcia J, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102017; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Gyftopoulos K, 2011, UROL INT, V87, P464, DOI 10.1159/000329289; Handa RJ, 2008, HORM BEHAV, V53, P741, DOI 10.1016/j.yhbeh.2007.09.012; He F, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181259; Helfrich I, 2009, CLIN CANCER RES, V15, P1384, DOI 10.1158/1078-0432.CCR-08-1615; Hessenkemper W, 2014, MOL ENDOCRINOL, V28, P1831, DOI 10.1210/me.2014-1170; Imanishi Y, 2007, CANCER RES, V67, P4254, DOI 10.1158/0008-5472.CAN-06-4100; Jia J, 2019, INT J ONCOL, V55, P157, DOI 10.3892/ijo.2019.4797; Johansen JA, 2007, J NEUROENDOCRINOL, V19, P823, DOI 10.1111/j.1365-2826.2007.01592.x; Khalili P, 2006, MOL CANCER THER, V5, P2271, DOI 10.1158/1535-7163.MCT-06-0100; Kim I, 2000, ONCOGENE, V19, P4549, DOI 10.1038/sj.onc.1203800; Korff T, 2004, 3 DIMENTIONAL IN VIT; Lecce L, 2014, MOL ENDOCRINOL, V28, P1487, DOI 10.1210/me.2013-1405; Li ZH, 2019, CHIN J NAT MEDICINES, V17, P241, DOI 10.1016/S1875-5364(19)30028-7; Liu ZQ, 2015, INT J CLIN EXP MED, V8, P2289; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; March B, 2020, NAT REV UROL, V17, P119, DOI 10.1038/s41585-019-0274-3; Max R, 1997, INT J CANCER, V71, P320, DOI 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.3.CO;2-3; Melegh Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112676; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morrissey C, 2010, PROSTATE, V70, P1799, DOI 10.1002/pros.21216; Mosaad EO, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18050-1; Nordby Y, 2015, PROSTATE, V75, P1682, DOI 10.1002/pros.23048; Papaioannou M, 2009, J CELL MOL MED, V13, P2210, DOI 10.1111/j.1582-4934.2008.00426.x; Pari AAA, 2020, CANCER RES, V80, P2586, DOI 10.1158/0008-5472.CAN-19-2660; Park JH, 2007, CHEST, V132, P200, DOI 10.1378/chest.06-2915; Perner S, 2015, ONCOTARGET, V6, P35542, DOI 10.18632/oncotarget.4689; Place RF, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-37; Raclaw KA, 2008, PROSTATE, V68, P1696, DOI 10.1002/pros.20844; Rigamonti N, 2014, CELL REP, V8, P696, DOI 10.1016/j.celrep.2014.06.059; Roediger J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-214; Roell D, 2019, J STEROID BIOCHEM, V188, P59, DOI 10.1016/j.jsbmb.2018.12.005; Schleich S, 2006, PLANTA MED, V72, P547, DOI 10.1055/s-2006-941472; Scholz A, 2015, ANN NY ACAD SCI, V1347, P45, DOI 10.1111/nyas.12726; Semenas J, 2013, DRUG DES DEV THER, V7, P875, DOI 10.2147/DDDT.S45703; Sfiligoi C, 2003, INT J CANCER, V103, P466, DOI 10.1002/ijc.10851; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Stoeltzing O, 2003, INT J CANCER, V104, P496, DOI 10.1002/ijc.10958; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sui AL, 2018, MED SCI MONITOR, V24, P5860, DOI 10.12659/MSM.907446; Taplin ME, 1999, CANCER RES, V59, P2511; ten Hagen TLM, 2013, INT J CANCER, V132, P2694, DOI 10.1002/ijc.27940; Wang K, 2012, ASIAN PAC J CANCER P, V13, P5665, DOI 10.7314/APJCP.2012.13.11.5665; Xuan ZX, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0992-4; Yu XL, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020457; Yuan HT, 2009, MOL CELL BIOL, V29, P2011, DOI 10.1128/MCB.01472-08	66	1	1	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3263	3277		10.1038/s41388-022-02333-7	http://dx.doi.org/10.1038/s41388-022-02333-7		MAY 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35513564	hybrid, Green Published			2022-12-28	WOS:000791081400001
J	Kim, Y; Ko, JY; Lee, SB; Oh, S; Park, JW; Kang, HG; Kim, DH; Chung, D; Lim, S; Kong, H; Kim, J; Yoo, KH; Han, W; Chun, KH; Park, JH				Kim, Yesol; Ko, Je Yeong; Lee, Soo-Been; Oh, Sumin; Park, Jee Won; Kang, Hyeok-Gu; Kim, Da-Hyun; Chung, Daeun; Lim, Sera; Kong, Hyunkyung; Kim, Jongmin; Yoo, Kyung Hyun; Han, Wonshik; Chun, Kyung-Hee; Park, Jong Hoon			Reduced miR-371b-5p expression drives tumor progression via CSDE1/RAC1 regulation in triple-negative breast cancer	ONCOGENE			English	Article							RNA-BINDING PROTEIN; COLD-SHOCK DOMAINS; NEOADJUVANT CHEMOTHERAPY; CELL-MIGRATION; MICRORNAS; SURVIVAL; UNR	Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer; however, specific prognostic biomarkers have not yet been developed. In this study, we identified dysregulated microRNAs (miRNAs) in TNBC by profiling miRNA and mRNA expression. In patients with TNBC, miR-371b-5p expression was reduced, and miR-371b-5p overexpression significantly mitigated TNBC cell growth, migration, and invasion. In addition, we found that expression of cold shock domain-containing protein E1 (CSDE1), a direct target gene of miR-371b-5p, was upregulated in TNBC cells, and inhibition of CSDE1 expression alleviated TNBC cell growth by regulating RAC1 transcription. Mechanistically, CSDE1, phosphorylated C-terminal domain (p-CTD) of RNA polymerase II (RNAPII), and CDK7 form a complex, and downregulation of CSDE1 leads to weak interaction between RNAPII p-CTD and CDK7, resulting in a decrease in RNAPII p-CTD expression to reduce RAC1 transcript levels in CSDE1-deficient TNBC cells. Our data demonstrate that miR-371b-5p is a tumor-suppressive miRNA that regulates the CSDE1/Rac1 axis and could be a potential prognostic biomarker for TNBC.	[Kim, Yesol; Ko, Je Yeong; Lee, Soo-Been; Oh, Sumin; Park, Jee Won; Chung, Daeun; Lim, Sera; Kong, Hyunkyung; Kim, Jongmin; Yoo, Kyung Hyun; Park, Jong Hoon] Sookmyung Womens Univ, Dept Biol Sci, Seoul, South Korea; [Kang, Hyeok-Gu; Kim, Da-Hyun; Chun, Kyung-Hee] Yonsei Univ, Grad Sch Med Sci, Dept Biochem & Mol Biol, Brain Korea 21 Project,Coll Med, Seoul, South Korea; [Han, Wonshik] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea; [Han, Wonshik] Seoul Natl Univ, Dept Surg, Coll Med, Seoul, South Korea; [Park, Jong Hoon] Sookmyung Womens Univ, Res Inst Womens Hlth, Seoul, South Korea	Sookmyung Women's University; Yonsei University; Yonsei University Health System; Seoul National University (SNU); Seoul National University (SNU); Sookmyung Women's University	Park, JH (corresponding author), Sookmyung Womens Univ, Dept Biol Sci, Seoul, South Korea.; Chun, KH (corresponding author), Yonsei Univ, Grad Sch Med Sci, Dept Biochem & Mol Biol, Brain Korea 21 Project,Coll Med, Seoul, South Korea.	KHCHUN@yuhs.ac; parkjh@sookmyung.ac.kr		Chun, Kyung-Hee/0000-0002-9867-7321	National Research Foundation of Korea (NRF) - Korean government (MSIT) [2019R1A2B5B03069738, 2016R1A5A1011974]	National Research Foundation of Korea (NRF) - Korean government (MSIT)(National Research Foundation of Korea)	This study was supported by grant from the National Research Foundation of Korea (NRF) funded by the Korean government (MSIT) (2019R1A2B5B03069738 and 2016R1A5A1011974).	Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043; Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Berrada N, 2010, ANN ONCOL, V21, P30, DOI 10.1093/annonc/mdq279; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Blows FM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000279; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Dormoy-Raclet V, 2007, ONCOGENE, V26, P2595, DOI 10.1038/sj.onc.1210068; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Goroncy Alexander K., 2010, Journal of Structural and Functional Genomics, V11, P181, DOI 10.1007/s10969-010-9081-z; Guo AX, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-019-0496-2; Huang CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076421; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Khoshnaw SM, 2009, J CLIN PATHOL, V62, P422, DOI 10.1136/jcp.2008.060681; King CE, 2011, CANCER RES, V71, P4260, DOI 10.1158/0008-5472.CAN-10-4637; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Li CH, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1210-4; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Martinez-Useros J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040560; Masuda H, 2013, CLIN CANCER RES, V19, P5533, DOI 10.1158/1078-0432.CCR-13-0799; Mishra PJ, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-19; Mitchell SF, 2014, MOL CELL, V54, P547, DOI 10.1016/j.molcel.2014.04.033; Moore KS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20518-7; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Steffen A, 2013, J CELL SCI, V126, P4572, DOI 10.1242/jcs.118232; Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359; Vo DT, 2012, AM J PATHOL, V181, P1762, DOI 10.1016/j.ajpath.2012.07.031; Wang YB, 2015, CELL, V163, P174, DOI 10.1016/j.cell.2015.08.063; Wurth L, 2016, CANCER CELL, V30, P694, DOI 10.1016/j.ccell.2016.10.004; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhou Q, 2012, ANNU REV BIOCHEM, V81, P119, DOI 10.1146/annurev-biochem-052610-095910	37	2	2	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3151	3161		10.1038/s41388-022-02326-6	http://dx.doi.org/10.1038/s41388-022-02326-6		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35490208	hybrid, Green Published			2022-12-28	WOS:000789076800001
J	Odeniyide, P; Yohe, ME; Pollard, K; Vaseva, AV; Calizo, A; Zhang, L; Rodriguez, FJ; Gross, JM; Allen, AN; Wan, XL; Somwar, R; Schreck, KC; Kessler, L; Wang, JW; Pratilas, CA				Odeniyide, Patience; Yohe, Marielle E.; Pollard, Kai; Vaseva, Angelina V.; Calizo, Ana; Zhang, Lindy; Rodriguez, Fausto J.; Gross, John M.; Allen, Amy N.; Wan, Xiaolin; Somwar, Romel; Schreck, Karisa C.; Kessler, Linda; Wang, Jiawan; Pratilas, Christine A.			Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma	ONCOGENE			English	Article							PHASE-II TRIAL; FARNESYLTRANSFERASE INHIBITOR TIPIFARNIB; ACUTE MYELOGENOUS LEUKEMIA; METASTATIC BREAST-CANCER; TRANSFERASE INHIBITOR; MEMBRANE ASSOCIATION; ONCOLOGY-GROUP; SOLID TUMORS; RAS; CHILDREN	Activating RAS mutations are found in a subset of fusion-negative rhabdomyosarcoma (RMS), and therapeutic strategies to directly target RAS in these tumors have been investigated, without clinical success to date. A potential strategy to inhibit oncogenic RAS activity is the disruption of RAS prenylation, an obligate step for RAS membrane localization and effector pathway signaling, through inhibition of farnesyltransferase (FTase). Of the major RAS family members, HRAS is uniquely dependent on FTase for prenylation, whereas NRAS and KRAS can utilize geranylgeranyl transferase as a bypass prenylation mechanism. Tumors driven by oncogenic HRAS may therefore be uniquely sensitive to FTase inhibition. To investigate the mutation-specific effects of FTase inhibition in RMS we utilized tipifarnib, a potent and selective FTase inhibitor, in in vitro and in vivo models of RMS genomically characterized for RAS mutation status. Tipifarnib reduced HRAS processing, and plasma membrane localization leading to decreased GTP-bound HRAS and decreased signaling through RAS effector pathways. In HRAS-mutant cell lines, tipifarnib reduced two-dimensional and three-dimensional cell growth, and in vivo treatment with tipifarnib resulted in tumor growth inhibition exclusively in HRAS-mutant RMS xenografts. Our data suggest that small molecule inhibition of FTase is active in HRAS-driven RMS and may represent an effective therapeutic strategy for a genomically-defined subset of RMS patients.	[Odeniyide, Patience; Pollard, Kai; Calizo, Ana; Zhang, Lindy; Allen, Amy N.; Wang, Jiawan; Pratilas, Christine A.] Johns Hopkins Univ, Sch Med, Dept Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA; [Yohe, Marielle E.; Wan, Xiaolin] NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; [Vaseva, Angelina V.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Rodriguez, Fausto J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Lab Med & Pathol, Los Angeles, CA 90095 USA; [Rodriguez, Fausto J.; Gross, John M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Somwar, Romel] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Schreck, Karisa C.; Pratilas, Christine A.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Schreck, Karisa C.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Kessler, Linda] Kura Oncol, San Diego, CA USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Pratilas, CA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA.; Pratilas, CA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.	cpratil1@jhmi.edu		Wang, Jiawan/0000-0002-2137-1826; Calizo, Ana/0000-0002-2581-6378; Odeniyide, Patience/0000-0002-9783-1657; Rodriguez, Fausto/0000-0001-8662-1219	Kura Oncology [NIH T32CA060441]; SKCCC Cancer Center Core Support [NIH P30 CA006973]; Memorial Sloan Kettering Cancer Center Support Grant [P30 CA008748]; Childhood Solid Tumor Network	Kura Oncology; SKCCC Cancer Center Core Support; Memorial Sloan Kettering Cancer Center Support Grant; Childhood Solid Tumor Network	This work has been funded by a grant from Kura Oncology (to CAP), the NIH T32CA060441 Pediatric Oncology Fellowship Training grant (to PO), the SKCCC Cancer Center Core Support (NIH P30 CA006973) and the Memorial Sloan Kettering Cancer Center Support Grant (P30 CA008748, RS). Cell line SJRHB000026_X1 was graciously provided by the Childhood Solid Tumor Network. Immunostaining was performed at the Oncology Tissue Services Core of Johns Hopkins University.	Alonso-Alonso R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63434-5; [Anonymous], 2021, CANCER DISCOV, V11; Arndt CAS, 2009, J CLIN ONCOL, V27, P5182, DOI 10.1200/JCO.2009.22.3768; Baba TT, 2008, J MUSCLE RES CELL M, V29, P127, DOI 10.1007/s10974-008-9146-9; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; Berzat AC, 2006, METHOD ENZYMOL, V407, P575, DOI 10.1016/S0076-6879(05)07046-1; BOS JL, 1989, CANCER RES, V49, P4682; Burnett AK, 2012, BRIT J HAEMATOL, V158, P519, DOI 10.1111/j.1365-2141.2012.09165.x; Case M, 2008, CANCER RES, V68, P6803, DOI 10.1158/0008-5472.CAN-08-0101; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Cloughesy TF, 2006, J CLIN ONCOL, V24, P3651, DOI 10.1200/JCO.2006.06.2323; Contente Sara, 2011, Genes Cancer, V2, P166, DOI 10.1177/1947601911405042; Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dalin MG, 2016, CLIN CANCER RES, V22, P4623, DOI 10.1158/1078-0432.CCR-16-0637; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; Ding HS, 2014, HAEMATOLOGICA, V99, P60, DOI 10.3324/haematol.2013.087734; Ding HS, 2011, BLOOD, V118, DOI 10.1182/blood-2011-02-334870; End DW, 2001, CANCER RES, V61, P131; Fedele C, 2018, CANCER DISCOV, V8, P1237, DOI 10.1158/2159-8290.CD-18-0444; Gervais R, 2005, ANN ONCOL, V16, P90, DOI 10.1093/annonc/mdi018; Gilardi M, 2020, MOL CANCER THER, V19, P1784, DOI 10.1158/1535-7163.MCT-19-0958; Haas-Kogan DA, 2011, NEURO-ONCOLOGY, V13, P298, DOI 10.1093/neuonc/noq202; Hanna GJ, 2020, CANCER-AM CANCER SOC, V126, P3972, DOI 10.1002/cncr.33036; Harousseau JL, 2009, BLOOD, V114, P1166, DOI 10.1182/blood-2009-01-198093; Hillig RC, 2019, P NATL ACAD SCI USA, V116, P2551, DOI 10.1073/pnas.1812963116; Ho A, 2018, MOL CANCER THER, V17, DOI 10.1158/1535-7163.TARG-17-LB-A10; Ho A, 2019, MOL CANCER THER, V18, DOI 10.1158/1535-7163.TARG-19-PR08; Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Karp JE, 2008, CLIN CANCER RES, V14, P3077, DOI 10.1158/1078-0432.CCR-07-4743; Kazi A, 2019, CLIN CANCER RES, V25, P5984, DOI 10.1158/1078-0432.CCR-18-3399; Kurzrock R, 2003, BLOOD, V102, P4527, DOI 10.1182/blood-2002-11-3359; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lee HW, 2020, CLIN CANCER RES, V26, P5113, DOI 10.1158/1078-0432.CCR-20-1246; Lee HW, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00741-6; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Li T, 2009, ANN ONCOL, V20, P642, DOI 10.1093/annonc/mdn689; Li TH, 2012, BREAST CANCER RES TR, V134, P345, DOI 10.1007/s10549-012-2071-z; Liu ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16135-6; Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223; Rao S, 2004, J CLIN ONCOL, V22, P3950, DOI 10.1200/JCO.2004.10.037; Raponi M, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-56; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Sasaki AT, 2009, METHODS MOL BIOL, V571, P333, DOI 10.1007/978-1-60761-198-1_23; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Shern JF, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.10515; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Sparano JA, 2009, CLIN CANCER RES, V15, P2942, DOI 10.1158/1078-0432.CCR-08-2658; Stalnecker CA, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay6013; Stewart E, 2017, NATURE, V549, P96, DOI 10.1038/nature23647; Stieglitz E, 2015, PEDIATR BLOOD CANCER, V62, P629, DOI 10.1002/pbc.25342; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tanaka T, 2017, J CELL PHYSIOL, V232, P192, DOI 10.1002/jcp.25411; Untch BR, 2018, CANCER RES, V78, P4642, DOI 10.1158/0008-5472.CAN-17-1925; Van Cutsem E, 2004, J CLIN ONCOL, V22, P1430, DOI 10.1200/JCO.2004.10.112; Wang JY, 2017, MEDCHEMCOMM, V8, P841, DOI 10.1039/c7md00030h; Weigel BJ, 2016, J CLIN ONCOL, V34, P117, DOI 10.1200/JCO.2015.63.4048; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Widemann BC, 2006, J CLIN ONCOL, V24, P507, DOI 10.1200/JCO.2005.03.8638; Widemann BC, 2014, NEURO-ONCOLOGY, V16, P707, DOI 10.1093/neuonc/nou004; Widemann BC, 2011, PEDIATR BLOOD CANCER, V56, P226, DOI 10.1002/pbc.22775; Wong GS, 2018, NAT MED, V24, P968, DOI 10.1038/s41591-018-0022-x; Wurzer G, 2001, J CELL BIOCHEM, P1; Zujewski J, 2000, J CLIN ONCOL, V18, P927, DOI 10.1200/JCO.2000.18.4.927	69	2	2	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2973	2983		10.1038/s41388-022-02305-x	http://dx.doi.org/10.1038/s41388-022-02305-x		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35459782	hybrid, Green Published			2022-12-28	WOS:000787474100004
J	Bramhecha, YM; Guerard, KP; Audet-Walsh, E; Rouzbeh, S; Kassem, O; Pernet, E; Scarlata, E; Hamel, L; Brimo, F; Divangahi, M; Aprikian, AG; Chevalier, S; Giguere, V; Lapointe, J				Bramhecha, Yogesh M.; Guerard, Karl-Philippe; Audet-Walsh, Etienne; Rouzbeh, Shaghayegh; Kassem, Ola; Pernet, Erwan; Scarlata, Eleonora; Hamel, Lucie; Brimo, Fadi; Divangahi, Maziar; Aprikian, Armen G.; Chevalier, Simone; Giguere, Vincent; Lapointe, Jacques			Fatty acid oxidation enzyme Delta 3, Delta 2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients	ONCOGENE			English	Article							BETA-OXIDATION; METABOLISM; PATHWAY; COA	Prostate cancer (PCa) metastases are highly enriched with genomic alterations including a gain at the 16p13.3 locus, recently shown to be associated with disease progression and poor clinical outcome. ECI1, residing at the 16p13.3 gain region, encodes Delta 3, Delta 2-Enoyl-CoA Delta Isomerase 1 (ECI1), a key mitochondrial fatty acid beta-oxidation enzyme. Although deregulated mitochondrial fatty acid beta-oxidation is known to drive PCa pathogenesis, the role of ECI1 in PCa is still unknown. We investigated the impacts of ECI1 on PCa phenotype in vitro and in vivo by modulating its expression in cell lines and assessed the clinical implications of its expression in human prostate tissue samples. In vitro, ECI1 overexpression increased PCa cell growth while ECI1 deficiency reduced its growth. ECI1 also enhanced colony formation, cell motility, and maximal mitochondrial respiratory capacity. In vivo, PCa cells stably overexpressing ECI1 injected orthotopically in nude mice formed larger prostate tumors with higher number of metastases. Immunohistochemistry analysis of the human tissue microarray representing 332 radical prostatectomy cases revealed a stronger ECI1 staining in prostate tumors compared to corresponding benign tissues. ECI1 expression varied amongst tumors and was higher in cases with 16p13.3 gain, high Gleason grade, and advanced tumor stage. ECI1 overexpression was a strong independent predictor of biochemical recurrence after adjusting for known clinicopathologic parameters (hazard ratio: 3.65, P < 0.001) or the established CAPRA-S score (hazard ratio: 3.95, P < 0.001). ECI1 overexpression was also associated with significant increased risk of distant metastasis and reduced overall survival. Overall, this study demonstrates the functional capacity of ECI1 in PCa progression and highlights the clinical implication of ECI1 as a potential target for the management of PCa.	[Bramhecha, Yogesh M.; Guerard, Karl-Philippe; Rouzbeh, Shaghayegh; Kassem, Ola; Scarlata, Eleonora; Hamel, Lucie; Aprikian, Armen G.; Chevalier, Simone; Lapointe, Jacques] McGill Univ, Div Urol, Dept Surg, Montreal, PQ, Canada; [Bramhecha, Yogesh M.; Guerard, Karl-Philippe; Audet-Walsh, Etienne; Rouzbeh, Shaghayegh; Kassem, Ola; Pernet, Erwan; Scarlata, Eleonora; Hamel, Lucie; Brimo, Fadi; Divangahi, Maziar; Aprikian, Armen G.; Chevalier, Simone; Giguere, Vincent; Lapointe, Jacques] McGill Univ, Hlth Ctr, Res Inst, Montreal, PQ, Canada; [Bramhecha, Yogesh M.; Kassem, Ola; Chevalier, Simone; Lapointe, Jacques] McGill Univ, Div Expt Med, Montreal, PQ, Canada; [Audet-Walsh, Etienne; Giguere, Vincent] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Pernet, Erwan; Divangahi, Maziar] McGill Univ, Dept Med, Meakins Christie Labs, Montreal, PQ, Canada; [Bramhecha, Yogesh M.] IMV Inc, Dartmouth, NS, Canada; [Audet-Walsh, Etienne] Univ Laval, Ctr Rech, CHU Quebec, Quebec City, PQ, Canada	McGill University; McGill University; McGill University; McGill University; McGill University; Laval University	Lapointe, J (corresponding author), McGill Univ, Div Urol, Dept Surg, Montreal, PQ, Canada.; Lapointe, J (corresponding author), McGill Univ, Hlth Ctr, Res Inst, Montreal, PQ, Canada.; Lapointe, J (corresponding author), McGill Univ, Div Expt Med, Montreal, PQ, Canada.	Jacques.lapointe@mcgill.ca			US Department of Defense (DoD) [W81XWH-11-1-0638]; Prostate Cancer Canada [D2019-2192]; Fonds de Recherche du Quebec-Sante (FRQS, Chercheur boursier); Canadian Institutes of Health Research (CIHR) Foundation; CIHR System Biology and McGill Division of Urology studentships; 100 Days Across Canada Urology Studentship Program on Prostate Cancer	US Department of Defense (DoD)(United States Department of Defense); Prostate Cancer Canada; Fonds de Recherche du Quebec-Sante (FRQS, Chercheur boursier); Canadian Institutes of Health Research (CIHR) Foundation(Canadian Institutes of Health Research (CIHR)); CIHR System Biology and McGill Division of Urology studentships(Canadian Institutes of Health Research (CIHR)); 100 Days Across Canada Urology Studentship Program on Prostate Cancer	US Department of Defense (DoD, W81XWH-11-1-0638), Prostate Cancer Canada (D2019-2192), the Fonds de Recherche du Quebec-Sante (FRQS, Chercheur boursier) to JL. Canadian Institutes of Health Research (CIHR) Foundation Grant to VG, CIHR System Biology and McGill Division of Urology studentships to YB, and 100 Days Across Canada Urology Studentship Program on Prostate Cancer to OK.	AASMUNDSTAD TA, 1992, J CLIN PATHOL, V45, P125, DOI 10.1136/jcp.45.2.125; Audet-Walsh E, 2017, GENE DEV, V31, P1228, DOI 10.1101/gad.299958.117; Audet-Walsh E, 2017, CANCER RES, V77, P378, DOI 10.1158/0008-5472.CAN-16-1204; Bramhecha YM, 2019, MODERN PATHOL, V32, P128, DOI 10.1038/s41379-018-0107-6; Bramhecha YM, 2018, MOL CANCER RES, V16, P115, DOI 10.1158/1541-7786.MCR-17-0270; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Cai QY, 2013, PROSTATE, V73, P842, DOI 10.1002/pros.22630; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Choucair K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-543; Choucair KA, 2012, TRANSL ONCOL, V5, P453, DOI 10.1593/tlo.12286; De Schrijver E, 2003, CANCER RES, V63, P3799; Deep G, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071061; Dueregger A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135704; Flaig TW, 2017, ONCOTARGET, V8, P56051, DOI 10.18632/oncotarget.17359; Gurvitz A, 1999, BIOCHEM J, V344, P903, DOI 10.1042/0264-6021:3440903; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Higgins LH, 2009, BBA-BIOENERGETICS, V1787, P1433, DOI 10.1016/j.bbabio.2009.06.003; Houten SM, 2010, J INHERIT METAB DIS, V33, P469, DOI 10.1007/s10545-010-9061-2; Itkonen HM, 2017, ONCOTARGET, V8, P38264, DOI 10.18632/oncotarget.16123; Janssen U, 2002, J BIOL CHEM, V277, P19579, DOI 10.1074/jbc.M110993200; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Joshi M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101115; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lapointe J, 2008, AM J SURG PATHOL, V32, P205, DOI 10.1097/PAS.0b013e318124a865; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Lee SH, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/854502; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; McDonnell E, 2016, CELL REP, V17, P1463, DOI 10.1016/j.celrep.2016.10.012; McShane LM, 2005, NAT CLIN PRACT ONCOL, V2, P416, DOI 10.1038/ncponc0252; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Oliva CR, 2010, J BIOL CHEM, V285, P39759, DOI 10.1074/jbc.M110.147504; Park JH, 2016, CELL REP, V14, P2154, DOI 10.1016/j.celrep.2016.02.004; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pfleger J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.202; Poluri RTK, 2021, ENDOCR-RELAT CANCER, V28, P257, DOI 10.1530/ERC-20-0504; Poluri RTK, 2019, DATA BRIEF, V25, DOI 10.1016/j.dib.2019.104372; Pougovkina O, 2014, HUM MOL GENET, V23, P3513, DOI 10.1093/hmg/ddu059; Punnen S, 2014, EUR UROL, V65, P1171, DOI 10.1016/j.eururo.2013.03.058; Qian J, 2015, P NATL ACAD SCI USA, V112, P3469, DOI 10.1073/pnas.1421975112; Qu Q, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.132; Rasmussen AL, 2011, J VIROL, V85, P11646, DOI 10.1128/JVI.05605-11; Rogers GW., 2014, CURR PROTOC TOXICOL, V60, p25 3 1, DOI 10.1002/0471140856.tx2503s60; Schlaepfer IR, 2014, MOL CANCER THER, V13, P2361, DOI 10.1158/1535-7163.MCT-14-0183; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Teh JT, 2019, MOL CANCER THER, V18, P693, DOI 10.1158/1535-7163.MCT-18-0766; Tuomela JM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-81; van Weeghel M, 2012, FASEB J, V26, P4316, DOI 10.1096/fj.12-206326; Wang SY, 2018, J BIOL CHEM, V293, P6544, DOI 10.1074/jbc.RA117.001323; WARBURG O, 1956, SCIENCE, V124, P269; Wong BW, 2017, NATURE, V542, P49, DOI 10.1038/nature21028; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Zadra G, 2019, P NATL ACAD SCI USA, V116, P631, DOI 10.1073/pnas.1808834116; Zadra G, 2013, BBA-MOL CELL BIOL L, V1831, P1518, DOI 10.1016/j.bbalip.2013.03.010; Zhang DY, 2002, J BIOL CHEM, V277, P9127, DOI 10.1074/jbc.M112228200	55	2	2	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2798	2810		10.1038/s41388-022-02276-z	http://dx.doi.org/10.1038/s41388-022-02276-z		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35411033				2022-12-28	WOS:000780668900004
J	Liu, R; Yang, GX; Bao, M; Zhou, ZM; Mao, XY; Liu, WJ; Jiang, XY; Zhu, D; Ren, XL; Huang, J; Chen, CS				Liu, Rong; Yang, Guangxi; Bao, Min; Zhou, Zhongmei; Mao, Xiaoyun; Liu, Wenjing; Jiang, Xiaoyan; Zhu, Di; Ren, Xinle; Huang, Jian; Chen, Ceshi			STAMBPL1 promotes breast cancer cell resistance to cisplatin partially by stabilizing MKP-1 expression	ONCOGENE			English	Article							PROTEIN-KINASE PHOSPHATASE-1; TUMORIGENESIS; ERK	Dual-specificity mitogen-activated protein kinase phosphatase-1 (MKP-1/DUSP1/CL-100) has been documented to promote breast cancer cell survival and chemoresistance. MKP-1 is an unstable protein that is ubiquitinated and degraded via the ubiquitin-proteasome system. However, it is not clear how MKP-1 protein stability is regulated in breast cancer. In this study, we performed a genome-wide siRNA library screen of deubiquitinases (DUBs) and identified STAMBPL1 as an MKP-1 DUB in breast cancer cells. STAMBPL1 interacts with MKP-1 and stabilizes MKP-1 via deubiquitination. Both STAMBPL1 and MKP-1 depletion sensitize breast cancer cells to cisplatin in vitro and in vivo, and ectopic overexpression of MKP-1 partially rescues STAMBPL1 depletion-induced cisplatin sensitivity. Furthermore, STAMBPL1 and MKP-1 depletion increased breast cancer sensitivity to cisplatin by increasing the phosphorylation and activation of c-Jun N-terminal protein kinase (JNK). Collectively, our findings not only identify STAMBPL1 as an MKP-1 DUB but also reveal a critical mechanism that regulates MKP-1 expression in breast cancer. Our findings indicate that the STAMBPL1/MKP-1 axis represents a potential therapeutic target in breast cancer.	[Liu, Rong; Yang, Guangxi; Bao, Min; Zhou, Zhongmei; Liu, Wenjing; Jiang, Xiaoyan; Chen, Ceshi] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Chinese Acad Sci & Yunnan Prov, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China; [Liu, Rong] Peking Univ First Hosp, Translat Canc Res Ctr, Beijing 100034, Peoples R China; [Bao, Min] Soochow Univ, Coll Pharmaceut Sci, Dept Pharmacol, Suzhou 215000, Peoples R China; [Mao, Xiaoyun] China Med Univ, Dept Breast Surg, Affiliated Hosp 1, Shenyang 110000, Peoples R China; [Zhu, Di; Ren, Xinle; Huang, Jian] Guangdong Med Univ, Affiliated Hosp, Ctr Pathol Diag & Res, Dept Pathol, Zhanjiang 524000, Peoples R China; [Chen, Ceshi] Chinese Acad Sci, Kunming Inst Zool, KIZ CUHK Joint Lab Bioresources & Mol Res Common, Kunming 650223, Yunnan, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Soochow University - China; China Medical University; Guangdong Medical University; Chinese Academy of Sciences; Kunming Institute of Zoology	Liu, R; Chen, CS (corresponding author), Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Chinese Acad Sci & Yunnan Prov, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China.; Liu, R (corresponding author), Peking Univ First Hosp, Translat Canc Res Ctr, Beijing 100034, Peoples R China.; Huang, J (corresponding author), Guangdong Med Univ, Affiliated Hosp, Ctr Pathol Diag & Res, Dept Pathol, Zhanjiang 524000, Peoples R China.; Chen, CS (corresponding author), Chinese Acad Sci, Kunming Inst Zool, KIZ CUHK Joint Lab Bioresources & Mol Res Common, Kunming 650223, Yunnan, Peoples R China.	liurong@pkufh.com; 18665763598@163.com; chenc@mail.kiz.ac.cn		Chen, Ceshi/0000-0001-6398-3516; Liu, Rong/0000-0001-6123-9152	National Key Research and Development Program of China [2020YFA0112300, 2018YFC2000400]; National Natural Science Foundation of China [81772847, 82073270, U1502222, 81572610, 81830087, U2102203]; Shortage of Talent of Project in Guangdong Province, China [4YF16002G]; Project of Innovative Research Team of Yunnan Province [2019HC005]; Yunnan Fundamental Research Projects [202001AW070018, 202101AS070050]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shortage of Talent of Project in Guangdong Province, China; Project of Innovative Research Team of Yunnan Province; Yunnan Fundamental Research Projects	This work was supported by the National Key Research and Development Program of China [2020YFA0112300 and 2018YFC2000400 to CC], National Natural Science Foundation of China [81772847, 82073270 and U1502222 to RL; 81572610 to JH; 81830087 and U2102203 to CC], a Shortage of Talent of Project in Guangdong Province, China [4YF16002G], Project of Innovative Research Team of Yunnan Province [2019HC005] and Yunnan Fundamental Research Projects (202001AW070018 and 202101AS070050).	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Chen X, 2019, CANCER LETT, V456, P49, DOI 10.1016/j.canlet.2019.04.020; D'Arcy P, 2015, PHARMACOL THERAPEUT, V147, P32, DOI 10.1016/j.pharmthera.2014.11.002; Deng L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0107-0; Eckstein N, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-91; Fang J, 2018, ONCOL LETT, V16, P1869, DOI 10.3892/ol.2018.8822; Guo F, 2020, CELL DEATH DIFFER, V27, P1938, DOI 10.1038/s41418-019-0473-8; Hill DP, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6278-9; Jamdade VS, 2015, BRIT J PHARMACOL, V172, P4228, DOI 10.1111/bph.13211; Kang YS, 2016, BIOCHEM BIOPH RES CO, V478, P403, DOI 10.1016/j.bbrc.2016.07.035; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lavorgna A, 2012, J VIROL, V86, P3357, DOI 10.1128/JVI.06456-11; Liao Q, 2003, GASTROENTEROLOGY, V124, P1830, DOI 10.1016/S0016-5085(03)00398-6; Lin YW, 2006, J BIOL CHEM, V281, P915, DOI 10.1074/jbc.M508720200; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Liu F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084982; Liu R, 2020, INT J BIOL SCI, V16, P611, DOI 10.7150/ijbs.39491; Liu R, 2016, THERANOSTICS, V6, P533, DOI 10.7150/thno.14315; Liu R, 2009, J BIOL CHEM, V284, P16791, DOI 10.1074/jbc.M808919200; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Lornejad-Schafer MR, 2005, CELL PHYSIOL BIOCHEM, V16, P193, DOI 10.1159/000089845; Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61; Petrelli F, 2016, BREAST CANCER RES TR, V160, P425, DOI 10.1007/s10549-016-4025-3; Qin JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9471; Rincon R, 2016, MOL CANCER THER, V15, P2780, DOI 10.1158/1535-7163.MCT-15-0920; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Sato Y, 2008, NATURE, V455, P358, DOI 10.1038/nature07254; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Shahriyar SA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103280; Shen JL, 2016, CANCER MED-US, V5, P2061, DOI 10.1002/cam4.772; Vicent S, 2004, CLIN CANCER RES, V10, P3639, DOI 10.1158/1078-0432.CCR-03-0771; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Wang J, 2007, CANCER RES, V67, P11933, DOI 10.1158/0008-5472.CAN-07-5185; Wang ZQ, 2006, CANCER RES, V66, P8870, DOI 10.1158/0008-5472.CAN-06-1280; Woo SM, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120838; Yu DJ, 2019, ONCOL LETT, V18, P4421, DOI 10.3892/ol.2019.10789; Zhao Q, 2006, J EXP MED, V203, P131, DOI 10.1084/jem.20051794	42	0	0	7	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2265	2274		10.1038/s41388-022-02252-7	http://dx.doi.org/10.1038/s41388-022-02252-7		MAR 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35236965				2022-12-28	WOS:000763262700003
J	Baumer, N; Tiemann, J; Scheller, A; Meyer, T; Wittmann, L; Suburu, MEG; Greune, L; Peipp, M; Kellmann, N; Gumnior, A; Brand, C; Hartmann, W; Rossig, C; Muller-Tidow, C; Neri, D; Strassert, CA; Ruter, C; Dersch, P; Lenz, G; Koeffler, HP; Berdel, WE; Baumer, S				Baeumer, Nicole; Tiemann, Jessica; Scheller, Annika; Meyer, Theresa; Wittmann, Lisa; Suburu, Matias Ezequiel Gutierrez; Greune, Lilo; Peipp, Matthias; Kellmann, Neele; Gumnior, Annika; Brand, Caroline; Hartmann, Wolfgang; Rossig, Claudia; Muller-Tidow, Carsten; Neri, Dario; Strassert, Cristian A.; Rueter, Christian; Dersch, Petra; Lenz, Georg; Koeffler, H. Phillip; Berdel, Wolfgang E.; Baeumer, Sebastian			Targeted siRNA nanocarrier: a platform technology for cancer treatment	ONCOGENE			English	Article							SMALL INTERFERING RNAS; PROTAMINE; DELIVERY; AGGREGATION; RESISTANCE; DRUGS	The small arginine-rich protein protamine condenses complete genomic DNA into the sperm head. Here, we applied its high RNA binding capacity for spontaneous electrostatic assembly of therapeutic nanoparticles decorated with tumour-cell-specific antibodies for efficiently targeting siRNA. Fluorescence microscopy and DLS measurements of these nanocarriers revealed the formation of a vesicular architecture that requires presence of antibody-protamine, defined excess of free SMCC-protamine, and anionic siRNA to form. Only these complex nanoparticles were efficient in the treatment of non-small-cell lung cancer (NSCLC) xenograft models, when the oncogene KRAS was targeted via EGFR-mediated delivery. To show general applicability, we used the modular platform for IGF1R-positive Ewing sarcomas. Anti-IGR1R-antibodies were integrated into an antibody-protamine nanoparticle with an siRNA specifically against the oncogenic translocation product EWS/FLI1. Using these nanoparticles, EWS/FLI1 knockdown blocked in vitro and in vivo growth of Ewing sarcoma cells. We conclude that these antibody-protamine-siRNA nanocarriers provide a novel platform technology to specifically target different cell types and yet undruggable targets in cancer therapy by RNAi.	[Baeumer, Nicole; Tiemann, Jessica; Scheller, Annika; Wittmann, Lisa; Kellmann, Neele; Gumnior, Annika; Brand, Caroline; Lenz, Georg; Berdel, Wolfgang E.; Baeumer, Sebastian] Univ Munster, Dept Med A, Hematol Oncol, Munster, Germany; [Meyer, Theresa; Greune, Lilo; Rueter, Christian; Dersch, Petra] Univ Munster, Ctr Mol Biol Inflammat ZMBE, Inst Infectiol, Munster, Germany; [Suburu, Matias Ezequiel Gutierrez; Strassert, Cristian A.] Univ Munster, Inst Inorgan & Analyt Chem, Munster, Germany; [Peipp, Matthias] Univ Kiel, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany; [Hartmann, Wolfgang] Univ Munster, Gerhard Domagk Inst Pathol, Munster, Germany; [Rossig, Claudia] Univ Childrens Hosp Munster, Dept Pediat Hematol & Oncol, Munster, Germany; [Muller-Tidow, Carsten] Heidelberg Univ, Dept Med 5, Heidelberg, Germany; [Neri, Dario] Swiss Fed Inst Technol, Inst Pharmaceut Sci, Zurich, Switzerland; [Koeffler, H. Phillip] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA	University of Munster; University of Munster; University of Munster; University of Kiel; University of Munster; University of Munster; Ruprecht Karls University Heidelberg; Swiss Federal Institutes of Technology Domain; ETH Zurich; Cedars Sinai Medical Center; University of California System; University of California Los Angeles	Baumer, S (corresponding author), Univ Munster, Dept Med A, Hematol Oncol, Munster, Germany.	baumers@uni-muenster.de	Baeumer, Sebastian/GYU-0544-2022; Peipp, Matthias/A-8775-2013	Meyer, Theresa/0000-0001-7748-9084; Tiemann, Jessica/0000-0002-1804-0348; Gutierrez Suburu, Matias Ezequiel/0000-0002-9133-3614	Deutsche Krebshilfe [70112282]; Wilhelm Sander-Stiftung [2014.054.1, 2017.071.1]; Innovative Medical Research of the University of Munster Medical School [111418, 211502, 121314, 111501, 121802]; Cedars-Sinai Cancer (CSC) Developmental Funds; Deutsche Forschungsgemeinschaft [6103/3-1, DFG CRC1009B03, DFG EXC1003]; Interdisciplinary Centre for Clinical Research (IZKF Munster) [Bau2/009/19]; Sanford Burnham Prebys (SBP) Cancer Center	Deutsche Krebshilfe(Deutsche Krebshilfe); Wilhelm Sander-Stiftung; Innovative Medical Research of the University of Munster Medical School; Cedars-Sinai Cancer (CSC) Developmental Funds; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Interdisciplinary Centre for Clinical Research (IZKF Munster); Sanford Burnham Prebys (SBP) Cancer Center	We thank Annette Westermann and Mara Apel for excellent technical support. This study was funded by Deutsche Krebshilfe (No. 70112282, NB and SB), Wilhelm Sander-Stiftung (2014.054.1 and 2017.071.1, WEB and SB), Innovative Medical Research of the University of Munster Medical School (111418, SB; 211502, SB; 121314, NB; 111501 and 121802, SB and NB), Sanford Burnham Prebys (SBP) Cancer Center and Cedars-Sinai Cancer (CSC) Developmental Funds to HPK, and Deutsche Forschungsgemeinschaft (DFG EXC1003, WEB and GL; 6103/3-1, SB; DFG CRC1009B03, CR). SB and NB gratefully acknowledge the Interdisciplinary Centre for Clinical Research (IZKF Munster, Bau2/009/19).	Baumer N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200163; Baumer N, 2016, NAT PROTOC, V11, P22, DOI 10.1038/nprot.2015.137; Baumer S, 2015, CLIN CANCER RES, V21, P1383, DOI 10.1158/1078-0432.CCR-13-2017; Balhorn R, 2000, MOL REPROD DEV, V56, P230, DOI 10.1002/(SICI)1098-2795(200006)56:2+<230::AID-MRD3>3.3.CO;2-M; Carr JA, 1999, J CARDIOVASC SURG, V40, P659; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Delgado D, 2011, EUR J PHARM BIOPHARM, V79, P495, DOI 10.1016/j.ejpb.2011.06.005; Dohjima T, 2003, MOL THER, V7, P811, DOI 10.1016/S1525-0016(03)00101-1; Dolgin E, 2020, NAT BIOTECHNOL, V38, P385, DOI 10.1038/s41587-020-0481-8; Doody JF, 2007, MOL CANCER THER, V6, P2642, DOI 10.1158/1535-7163.MCT-06-0506; Einstein A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/andp.19053220806; HED J, 1987, J IMMUNOL METHODS, V101, P119, DOI 10.1016/0022-1759(87)90224-9; Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864; Mochizuki T, 1998, ANESTH ANALG, V87, P781, DOI 10.1097/00000539-199810000-00008; Naing A, 2012, CLIN CANCER RES, V18, P2625, DOI 10.1158/1078-0432.CCR-12-0061; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; ROSSMANN P, 1982, VIRCHOWS ARCH B, V40, P81, DOI 10.1007/BF02932853; Rotow J, 2017, NAT REV CANCER, V17, P637, DOI 10.1038/nrc.2017.84; SMULL CE, 1962, J BACTERIOL, V84, P1035, DOI 10.1128/JB.84.5.1035-1040.1962; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Vasimalai N, 2013, J MATER CHEM B, V1, P5620, DOI 10.1039/c3tb20991a; Wang MN, 2021, NAT MED, V27, P1345, DOI 10.1038/s41591-021-01450-2; Yoo H, 2015, ARCH PHARM RES, V38, P129, DOI 10.1007/s12272-014-0359-8	23	1	1	8	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2210	2224		10.1038/s41388-022-02241-w	http://dx.doi.org/10.1038/s41388-022-02241-w		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35220407	Green Published, hybrid			2022-12-28	WOS:000761831800001
J	Zhang, T; Wang, Y; Li, Q; Lin, LY; Xu, CL; Xue, YQ; Hu, MY; Shi, YF; Wang, Y				Zhang, Tao; Wang, Yu; Li, Qing; Lin, Liangyu; Xu, Chunliang; Xue, Yueqing; Hu, Mingyuan; Shi, Yufang; Wang, Ying			Mesenchymal stromal cells equipped by IFN alpha empower T cells with potent anti-tumor immunity	ONCOGENE			English	Article							I INTERFERON; DENDRITIC CELLS; TUMOR-METASTASIS; PD-1 BLOCKADE; RESPONSES; MELANOMA; CXCR3; EXPRESSION; INSIGHTS; GENES	Cancer treatments have been revolutionized by the emergence of immune checkpoint blockade therapies. However, only a minority of patients with various tumor types have benefited from such treatments. New strategies focusing on the immune contexture of the tumor tissue microenvironment hold great promises. Here, we created IFN alpha-overexpressing mesenchymal stromal cells (IFN alpha-MSCs). Upon direct injection into tumors, we found that these cells are powerful in eliminating several types of tumors. Interestingly, the intra-tumoral injection of IFN alpha-MSCs could also induce specific anti-tumor effects on distant tumors. These IFN alpha-MSCs promoted tumor cells to produce CXCL10, which in turn potentiates the infiltration of CD8(+) T cells in the tumor site. Furthermore, IFN alpha-MSCs enhanced the expression of granzyme B (GZMB) in CD8(+) T cells and invigorated their cytotoxicity in a Stat3-dependent manner. Genetic ablation of Stat3 in CD8(+) T cells impaired the effect of IFN alpha-MSCs on GZMB expression. Importantly, the combination of IFN alpha-MSCs and PD-L1 blockade induced an even stronger anti-tumor immunity. Therefore, IFN alpha-MSCs represent a novel tumor immunotherapy strategy, especially when combined with PD-L1 blockade.	[Zhang, Tao; Wang, Yu; Li, Qing; Lin, Liangyu; Xu, Chunliang; Xue, Yueqing; Hu, Mingyuan; Shi, Yufang; Wang, Ying] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai 200031, Peoples R China; [Shi, Yufang] Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Soochow Univ Med Coll,Affiliated Hosp 3, Suzhou 215123, Jiangsu, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; University of Chinese Academy of Sciences, CAS; Soochow University - China	Shi, YF; Wang, Y (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai 200031, Peoples R China.; Shi, YF (corresponding author), Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Soochow Univ Med Coll,Affiliated Hosp 3, Suzhou 215123, Jiangsu, Peoples R China.	yufangshi@sibs.ac.cn; yingwang@sibs.ac.cn	Shi, Yufang/AAE-4431-2020	Shi, Yufang/0000-0001-8964-319X; wang, ying/0000-0002-2571-9367; Wang, Yu/0000-0002-7309-7304; Xu, Chunliang/0000-0002-4514-8477; Liangyu, Lin/0000-0003-4312-8955; shi, yu fang/0000-0001-9716-2126	National Key R&D Program of China [2018YFA0107500]; Scientific Innovation Project of the Chinese Academy of Sciences [XDA16020403]; National Natural Science Foundation of China [32070872, 31961133024, 31771641, 81571612, 31771581, 81861138015]; Soochow University; Department of Science and Technology of Jiangsu Province research fund [BE2016671]	National Key R&D Program of China; Scientific Innovation Project of the Chinese Academy of Sciences; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Soochow University; Department of Science and Technology of Jiangsu Province research fund	The study was supported by grants from the National Key R&D Program of China (2018YFA0107500), the Scientific Innovation Project of the Chinese Academy of Sciences (XDA16020403), the National Natural Science Foundation of China (32070872, 31961133024, 31771641, 81571612, 31771581 and 81861138015), a start-up fund from Soochow University, and the Department of Science and Technology of Jiangsu Province research fund (BE2016671).	Aref S, 2020, MOL THER, V28, P1043, DOI 10.1016/j.ymthe.2020.01.027; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bald T, 2014, CANCER DISCOV, V4, P674, DOI 10.1158/2159-8290.CD-13-0458; Bazhin AV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02129; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bracarda S, 2010, EUR J CANCER, V46, P284, DOI 10.1016/j.ejca.2009.10.013; Burnette BC, 2011, CANCER RES, V71, P2488, DOI 10.1158/0008-5472.CAN-10-2820; Cauwels A, 2018, CANCER RES, V78, P463, DOI 10.1158/0008-5472.CAN-17-1980; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Chheda ZS, 2016, J IMMUNOL, V197, P2016, DOI 10.4049/jimmunol.1502376; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Delaunay T, 2020, J THORAC ONCOL, V15, P827, DOI 10.1016/j.jtho.2019.12.128; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; Doron H, 2019, CELL REP, V28, P1785, DOI 10.1016/j.celrep.2019.07.033; Fend L, 2017, CANCER RES, V77, P4146, DOI 10.1158/0008-5472.CAN-16-2165; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Guo J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219829; Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Ji RR, 2012, CANCER IMMUNOL IMMUN, V61, P1019, DOI 10.1007/s00262-011-1172-6; Kather JN, 2018, ELIFE, V7, DOI 10.7554/eLife.36967; Kawada K, 2004, CANCER RES, V64, P4010, DOI 10.1158/0008-5472.CAN-03-1757; Liang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06890-y; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Mohty M, 2003, J IMMUNOL, V171, P3385, DOI 10.4049/jimmunol.171.7.3385; Montoya M, 2002, BLOOD, V99, P3263, DOI 10.1182/blood.V99.9.3263; Muller E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02520; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Paolini R, 2015, CYTOKINE GROWTH F R, V26, P113, DOI 10.1016/j.cytogfr.2014.11.003; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Robb RJ, 2011, BLOOD, V118, P3399, DOI 10.1182/blood-2010-12-325746; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193; Shou P, 2016, ONCOGENE, V35, P5953, DOI 10.1038/onc.2016.128; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tecchio C, 2004, BLOOD, V103, P3837, DOI 10.1182/blood-2003-08-2806; Tsuchiya N, 2019, CELL REP, V29, P162, DOI 10.1016/j.celrep.2019.08.086; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wightman SC, 2015, BRIT J CANCER, V113, P327, DOI 10.1038/bjc.2015.193; Xu C, 2014, ONCOGENE, V33, P5047, DOI 10.1038/onc.2013.458; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Yeruva S, 2008, INT J COLORECTAL DIS, V23, P305, DOI 10.1007/s00384-007-0396-6; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	57	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1866	1881		10.1038/s41388-022-02201-4	http://dx.doi.org/10.1038/s41388-022-02201-4		FEB 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35145233	hybrid, Green Published			2022-12-28	WOS:000754012300002
J	Zou, HL; Luo, J; Guo, YB; Liu, YH; Wang, Y; Deng, L; Li, P				Zou, Hailin; Luo, Juan; Guo, Yibo; Liu, Yuhong; Wang, Yun; Deng, Liang; Li, Peng			RNA-binding protein complex LIN28/MSI2 enhances cancer stem cell-like properties by modulating Hippo-YAP1 signaling and independently of Let-7	ONCOGENE			English	Article							BREAST-CANCER; EXPRESSION; PATHWAY; TAZ; MICRORNA; LIN28A; YAP; TRANSFORMATION; PROLIFERATION; PLURIPOTENCY	The RNA binding protein LIN28 directly modulates the stability and translation of target mRNAs independently of Let-7; however, the key downstream targets of LIN28 in this process are largely unknown. Here, we revealed that Hippo signaling effector YAP1 functioned as a key downstream regulator of LIN28 to modulate the cancer stem cell (CSC)-like properties and tumor progressions in triple negative breast cancer (TNBC). LIN28 was overexpressed in BC tissues and cell lines, and significantly correlated with poorer overall survivals in patients. Ectopic LIN28 expression enhanced, while knockdown of LIN28A inhibited the CSC-like properties, cell growth and invasive phenotypes of TNBC cells in vitro and in vivo. Transcriptome analysis demonstrated LIN28 overexpression significantly induced the expressions of YAP1 downstream genes, while reduced the transcripts of YAP1 upstream kinases, such as MST1/2 and LATS1/2, and knockdown of LIN28A exhibited the opposite effects. Furthermore, constitutive activation of YAP1 in LIN28 knockdown TNBC cells could rescue the cell growth and invasive phenotypes in vitro and in vivo. Mechanistically, instead of the dependence of Let-7, LIN28 recruited RNA binding protein MSI2 in a manner dependent on the LIN28 CSD domain and MSI2 RRM domain, to directly induce the mRNA decay of YAP1 upstream kinases, leading to the inhibition of Hippo pathway and activation of YAP1, which eventually gave rise to increased CSC populations, enhanced tumor cell growth and invasive phenotypes. Accordingly, co-upregulations of LIN28 and MSI2 in TNBC tissues were strongly associated with YAP1 protein level and tumor malignance. Taken together, our findings unravel a novel LIN28/MSI2-YAP1 regulatory axis to induce the CSC-like properties, tumor growth and metastasis, independently of Let-7, which may serve as a potential therapeutic strategy for the treatment of a subset of TNBC with LIN28 overexpression.	[Zou, Hailin; Luo, Juan; Guo, Yibo; Wang, Yun; Li, Peng] Sun Yat Sen Univ, Sci Res Ctr, Affiliated Hosp 7, Shenzhen 518107, Guangdong, Peoples R China; [Liu, Yuhong; Deng, Liang] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Gen Surg, Shenzhen 518107, Guangdong, Peoples R China; [Li, Peng] Sun Yat Sen Univ, Affiliated Hosp 7, Guangdong Prov Key Lab Digest Canc Res, 628 Zhenyuan Rd, Shenzhen 518107, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, P (corresponding author), Sun Yat Sen Univ, Sci Res Ctr, Affiliated Hosp 7, Shenzhen 518107, Guangdong, Peoples R China.; Li, P (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Guangdong Prov Key Lab Digest Canc Res, 628 Zhenyuan Rd, Shenzhen 518107, Guangdong, Peoples R China.	lipeng56@mail.sysu.edu.cn	Deng, Liang/GXH-6710-2022	Li, Peng/0000-0001-7226-4214	Shenzhen Science and Technology Innovation Commission [JCYJ20210324120409026]; Guangdong Basic and Applied Basic Research Foundation [2019A1515110285]; National Natural Science Foundation of China [32000679, 82072901]; Fundamental Research Funds for the Central Universities [20ykzd02]; Guangdong Provincial Key Laboratory of Digestive Cancer Research [2021B1212040006]	Shenzhen Science and Technology Innovation Commission; Guangdong Basic and Applied Basic Research Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Guangdong Provincial Key Laboratory of Digestive Cancer Research	This work was supported by Shenzhen Science and Technology Innovation Commission (JCYJ20210324120409026 to PL), Guangdong Basic and Applied Basic Research Foundation (Grant No. 2021A1515111052 to JL), National Natural Science Foundation of China (Grant No. 32000679 and 82072901 to PL), the Fundamental Research Funds for the Central Universities (Grant No. 20ykzd02 to PL), Guangdong Basic and Applied Basic Research Foundation (Grant No. 2019A1515110285 to PL), and the Guangdong Provincial Key Laboratory of Digestive Cancer Research (No. 2021B1212040006).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ali MA, 2021, CRIT REV ONCOL HEMAT, V157, DOI 10.1016/j.critrevonc.2020.103197; Balzeau J, 2017, FRONT GENET, V8, P1, DOI 10.3389/fgene.2017.00031; Balzer E, 2010, DEVELOPMENT, V137, P891, DOI 10.1242/dev.042895; Beachy SH, 2012, BLOOD, V120, P1048, DOI 10.1182/blood-2012-01-401760; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Borah A, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.35; Choi YM, 2017, ONCOGENE, V36, P2802, DOI 10.1038/onc.2016.441; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Farzaneh M, 2017, CELL REPROGRAM, V19, P289, DOI 10.1089/cell.2017.0015; Feng C, 2012, CELL CYCLE, V11, P2486, DOI 10.4161/cc.20893; Giatromanolaki A, 2011, MED ONCOL, V28, P745, DOI 10.1007/s12032-010-9530-3; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Jin JY, 2011, NUCLEIC ACIDS RES, V39, P3724, DOI 10.1093/nar/gkq1350; Kang MH, 2017, ONCOGENE, V36, P1745, DOI 10.1038/onc.2016.327; Kim T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10186; King CE, 2011, ONCOGENE, V30, P4185, DOI 10.1038/onc.2011.131; Kudinov AE, 2017, CLIN CANCER RES, V23, P2143, DOI 10.1158/1078-0432.CCR-16-2728; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li MX, 2019, ORAL ONCOL, V98, P92, DOI 10.1016/j.oraloncology.2019.09.024; Li P, 2016, GENE DEV, V30, P798, DOI 10.1101/gad.274951.115; Luo J, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/6674283; Maugeri-Sacca M, 2016, CRIT REV ONCOL HEMAT, V99, P115, DOI 10.1016/j.critrevonc.2015.12.004; Mo HN, 2021, FRONT MED-PRC, V15, P1, DOI 10.1007/s11684-020-0741-5; Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436; Moss EG, 2003, DEV BIOL, V258, P432, DOI 10.1016/S0012-1606(03)00126-X; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Park JH, 2018, MOL CELLS, V41, P83, DOI 10.14348/molcells.2018.2242; Peng F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.438; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Qiu CH, 2010, NUCLEIC ACIDS RES, V38, P1240, DOI 10.1093/nar/gkp1071; Reggiani F, 2021, TRENDS BIOCHEM SCI, V46, P154, DOI 10.1016/j.tibs.2020.08.012; Shyh-Chang N, 2013, CELL STEM CELL, V12, P395, DOI 10.1016/j.stem.2013.03.005; Thompson BJ, 2020, BIOESSAYS, V42, DOI 10.1002/bies.201900162; Tu HC, 2015, GENE DEV, V29, P1074, DOI 10.1101/gad.256693.114; Vadla B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002588; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang LF, 2018, CELL REP, V23, P3091, DOI 10.1016/j.celrep.2018.04.116; Wang LF, 2017, CELL REP, V18, P2664, DOI 10.1016/j.celrep.2017.02.044; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Wu ZM, 2021, TRENDS BIOCHEM SCI, V46, P51, DOI 10.1016/j.tibs.2020.08.008; Xu BS, 2009, RNA, V15, P357, DOI 10.1261/rna.1368009; Yang HY, 2020, MED ONCOL, V37, DOI 10.1007/s12032-020-01384-8; Yang J, 2015, MOL CELL BIOL, V35, P3225, DOI 10.1128/MCB.00426-15; Zeng YX, 2016, MOL CELL, V61, P153, DOI 10.1016/j.molcel.2015.11.020; Zhang K, 2015, BIOCHEMISTRY-US, V54, P6555, DOI 10.1021/acs.biochem.5b01014; Zhang R, 2022, SEMIN CANCER BIOL, V82, P11, DOI 10.1016/j.semcancer.2021.03.008; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhou JB, 2013, INT J BIOCHEM CELL B, V45, P973, DOI 10.1016/j.biocel.2013.02.006	52	5	5	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1657	1672		10.1038/s41388-022-02198-w	http://dx.doi.org/10.1038/s41388-022-02198-w		JAN 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35102250	hybrid, Green Published			2022-12-28	WOS:000750409400001
J	Mo, J; Moye, SL; McKay, RM; Le, LQ				Mo, Juan; Moye, Stefanie L.; McKay, Renee M.; Le, Lu Q.			Neurofibromin and suppression of tumorigenesis: beyond the GAP	ONCOGENE			English	Review							GENE-PRODUCT NEUROFIBROMIN; NF1 TUMOR-SUPPRESSOR; NERVE SHEATH TUMORS; EPITHELIAL-MESENCHYMAL TRANSITION; GENOTYPE-PHENOTYPE CORRELATION; SMALL-MOLECULE INHIBITORS; STEM-CELL PROLIFERATION; TYPE-1 GENE; SCHWANN-CELLS; PLEXIFORM NEUROFIBROMAS	Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disease and one of the most common inherited tumor predisposition syndromes, affecting 1 in 3000 individuals worldwide. The NF1 gene encodes neurofibromin, a large protein with RAS GTP-ase activating (RAS-GAP) activity, and loss of NF1 results in increased RAS signaling. Neurofibromin contains many other domains, and there is considerable evidence that these domains play a role in some manifestations of NF1. Investigating the role of these domains as well as the various signaling pathways that neurofibromin regulates and interacts with will provide a better understanding of how neurofibromin acts to suppress tumor development and potentially open new therapeutic avenues. In this review, we discuss what is known about the structure of neurofibromin, its interactions with other proteins and signaling pathways, its role in development and differentiation, and its function as a tumor suppressor. Finally, we discuss the latest research on potential therapeutics for neurofibromin-deficient neoplasms.	[Mo, Juan; Moye, Stefanie L.; McKay, Renee M.; Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, ODonnell Brain Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, ODonnell Brain Inst, Dallas, TX 75390 USA.	lu.le@utsouthwestern.edu		Le, Lu/0000-0003-2817-5382; McKay, Renee/0000-0001-5976-1996	US Department of Defense [W81XWH1910687]; Burroughs Wellcome Fund; National Cancer Institute of the NIH [R01 CA166593]; Developmental and Hyperactive RAS Tumor SPORE [U54 CA196519]; Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	US Department of Defense(United States Department of Defense); Burroughs Wellcome Fund(Burroughs Wellcome Fund); National Cancer Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Developmental and Hyperactive RAS Tumor SPORE; Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	JM is the recipient of the Early Investigator Research Award from the US Department of Defense (W81XWH1910687). LQL held a Career Award for Medical Scientists from the Burroughs Wellcome Fund and is the Thomas L. Shield, M.D. endowed Professor in Dermatology. He is supported by funding from the US Department of Defense, the National Cancer Institute of the NIH (R01 CA166593) and the Developmental and Hyperactive RAS Tumor SPORE (U54 CA196519); the Neurofibromatosis Therapeutic Acceleration Program; the NF1 Research Consortium Fund; and the Giorgio Foundation.	Afridi SK, 2015, AM J MED GENET A, V167, P2282, DOI 10.1002/ajmg.a.37186; Amano M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008704; Amirnasr A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59789-4; Anastasaki C, 2020, STEM CELL REP, V14, P541, DOI 10.1016/j.stemcr.2020.03.007; Anastasaki C, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00115; Anastasaki C, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000192; Anastasaki C, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000169; Anastasaki C, 2015, HUM MOL GENET, V24, P3518, DOI 10.1093/hmg/ddv103; ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; Antony-Debre I, 2017, J CLIN INVEST, V127, P4297, DOI 10.1172/JCI92504; Aras S, 2017, BRIT J CANCER, V117, P1583, DOI 10.1038/bjc.2017.356; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; Arima Y, 2010, EXP DERMATOL, V19, pE136, DOI 10.1111/j.1600-0625.2009.01017.x; Arkin MR, 2014, CHEM BIOL, V21, P1102, DOI 10.1016/j.chembiol.2014.09.001; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Arthur LL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14112; Arun V, 2013, FEBS LETT, V587, P1466, DOI 10.1016/j.febslet.2013.03.035; Arun V, 2013, J NEUROSCI RES, V91, P494, DOI 10.1002/jnr.23189; Assunto A, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1223-1; Atak ZK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038463; Bai RY, 2019, GENE THER, V26, P277, DOI 10.1038/s41434-019-0080-9; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Baralle FE, 2017, NAT REV MOL CELL BIO, V18, P437, DOI 10.1038/nrm.2017.27; Barron VA, 2012, BIOSCIENCE REP, V32, P131, DOI 10.1042/BSR20110060; Bausch B, 2007, J CLIN ENDOCR METAB, V92, P2784, DOI 10.1210/jc.2006-2833; Bayik D, 2021, NAT REV CANCER, V21, P526, DOI 10.1038/s41568-021-00366-w; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015; Bellampalli SS, 2019, PAIN, V160, P1007, DOI 10.1097/j.pain.0000000000001486; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bertucci F, 2019, NATURE, V569, P560, DOI 10.1038/s41586-019-1056-z; Biayna J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83152-w; Bodempudi V, 2009, MOL CELL BIOL, V29, P3964, DOI 10.1128/MCB.01153-08; Bolcekova A, 2013, NEOPLASMA, V60, P655, DOI 10.4149/neo_2013_084; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; Boregowda RK, 2016, ONCOTARGET, V7, P29689, DOI 10.18632/oncotarget.8822; Boudry-Labis E, 2013, AM J HEMATOL, V88, P306, DOI 10.1002/ajh.23403; Boyanapalli M, 2006, BIOCHEM BIOPH RES CO, V340, P1200, DOI 10.1016/j.bbrc.2005.12.129; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Brems H, 2007, NAT GENET, V39, P1120, DOI 10.1038/ng2113; Brosseau JP, 2020, BRIT J CANCER, V123, P178, DOI 10.1038/s41416-020-0903-x; Brosseau JP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07452-y; Brown JA, 2010, J NEUROSCI, V30, P5579, DOI 10.1523/JNEUROSCI.3994-09.2010; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Buono FD, 2019, J PAIN RES, V12, P2555, DOI 10.2147/JPR.S209540; Caravagna G, 2018, NAT METHODS, V15, P707, DOI 10.1038/s41592-018-0108-x; Cehajic-Kapetanovic J, 2020, NAT MED, V26, P354, DOI 10.1038/s41591-020-0763-1; Cerezo M, 2018, NAT MED, V24, P1877, DOI 10.1038/s41591-018-0217-1; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chai GL, 2010, CANCER SCI, V101, P1997, DOI 10.1111/j.1349-7006.2010.01616.x; Chan EM, 2019, NATURE, V568, P551, DOI 10.1038/s41586-019-1102-x; Chen A, 2020, TRENDS MOL MED, V26, P508, DOI 10.1016/j.molmed.2020.01.004; Chen Y, 2021, NAT REV CLIN ONCOL, V18, P792, DOI 10.1038/s41571-021-00546-5; Chen YH, 2015, GENE DEV, V29, P1677, DOI 10.1101/gad.261677.115; Chen ZG, 2019, CANCER DISCOV, V9, P114, DOI 10.1158/2159-8290.CD-18-0151; Chen ZG, 2014, CANCER CELL, V26, P695, DOI 10.1016/j.ccell.2014.09.009; Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073; Choi K, 2017, SCI REP-UK, V7, DOI 10.1038/srep43315; Cooke SL, 2010, ONCOGENE, V29, P4905, DOI 10.1038/onc.2010.245; Costa RM, 2001, NAT GENET, V27, P399, DOI 10.1038/86898; Cui Y, 2019, HUM MUTAT, V40, P187, DOI 10.1002/humu.23681; Cui YJ, 2008, CELL, V135, P549, DOI 10.1016/j.cell.2008.09.060; D'Angelo I, 2006, EMBO REP, V7, P174, DOI 10.1038/sj.embor.7400602; Daginakatte GC, 2007, HUM MOL GENET, V16, P1098, DOI 10.1093/hmg/ddm059; Dang I, 2011, NEUROCHEM RES, V36, P1697, DOI 10.1007/s11064-011-0433-2; Dasgupta B, 2005, J NEUROSCI, V25, P5584, DOI 10.1523/JNEUROSCI.4693-04.2005; Dasgupta B, 2005, CANCER RES, V65, P2755, DOI 10.1158/0008-5472.CAN-04-4058; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; De Schepper S, 2008, J INVEST DERMATOL, V128, P1050, DOI 10.1038/sj.jid.5701095; De Schepper S, 2006, J INVEST DERMATOL, V126, P653, DOI 10.1038/sj.jid.5700087; Della Corte CM, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0776-2; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Delpu Y, 2013, INT J MOL SCI, V14, P15029, DOI 10.3390/ijms140715029; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943; Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672; Dunzendorfer-Matt T, 2016, P NATL ACAD SCI USA, V113, P7497, DOI 10.1073/pnas.1607298113; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Faden DL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170348; Fadhlullah SFB, 2019, ONCOGENE, V38, P5367, DOI 10.1038/s41388-019-0809-3; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Farschtschi S, 2016, CANCER IMMUNOL IMMUN, V65, P1113, DOI 10.1007/s00262-016-1871-0; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Fisher MJ, 2021, NAT MED, V27, P165, DOI 10.1038/s41591-020-01193-6; Fisher MJ, 2018, AM J MED GENET A, V176, P1258, DOI 10.1002/ajmg.a.38675; Fletcher JS, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.98601; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Fotouhi N, 2005, CURR TOP MED CHEM, V5, P159, DOI 10.2174/1568026053507705; Friedman JM, 2022, GENEREVIEWS, P1993; Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254; Furukawa K, 2003, SURG TODAY, V33, P323, DOI 10.1007/s005950300074; Geist RT, 1996, NEUROSCI LETT, V211, P85, DOI 10.1016/0304-3940(96)12730-0; Genovese P, 2014, NATURE, V510, P235, DOI 10.1038/nature13420; Ghadimi MP, 2012, MOL CANCER THER, V11, P1758, DOI 10.1158/1535-7163.MCT-12-0015; Gong M, 2012, NEURO-ONCOLOGY, V14, P1007, DOI 10.1093/neuonc/nos124; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gorringe KL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011408; Gouzi JY, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002281; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; Gross AM, 2020, NEW ENGL J MED, V382, P1430, DOI 10.1056/NEJMoa1912735; Guo HF, 2000, NATURE, V403, P895, DOI 10.1038/35002593; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1995, CELL GROWTH DIFFER, V6, P315; GUTMANN DH, 1993, HUM MOL GENET, V2, P989; Haferlach C, 2012, LEUKEMIA, V26, P834, DOI 10.1038/leu.2011.296; Hall A, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau8389; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hiatt K, 2004, AM J PATHOL, V164, P1471, DOI 10.1016/S0002-9440(10)63233-6; Hinman MN, 2014, MOL CELL BIOL, V34, P2188, DOI 10.1128/MCB.00019-14; Hirata Y, 2016, J BIOL CHEM, V291, P3124, DOI 10.1074/jbc.M115.703710; Ho IS, 2007, J NEUROSCI, V27, P6852, DOI 10.1523/JNEUROSCI.0933-07.2007; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Holzel M, 2010, CELL, V142, P218, DOI 10.1016/j.cell.2010.06.004; Hsueh YP, 2001, J NEUROSCI, V21, P3764, DOI 10.1523/JNEUROSCI.21-11-03764.2001; Huang A, 2020, NAT REV DRUG DISCOV, V19, P23, DOI 10.1038/s41573-019-0046-z; Hutter S, 2016, HUM GENET, V135, P469, DOI 10.1007/s00439-016-1646-x; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Ismat FA, 2006, J CLIN INVEST, V116, P2378, DOI 10.1172/JCI28341; Itani S, 2012, J CANCER RES CLIN, V138, P1501, DOI 10.1007/s00432-012-1223-1; Izawa I, 1996, FEBS LETT, V382, P53, DOI 10.1016/0014-5793(96)00137-8; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jecrois ES, 2021, DEV CELL, V56, P2871, DOI 10.1016/j.devcel.2021.08.004; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335; Jones DL, 2008, NAT REV MOL CELL BIO, V9, P11, DOI 10.1038/nrm2319; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones RE, 2017, ONCOTARGET, V8, P40132, DOI 10.18632/oncotarget.16981; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kaufmann D, 2002, BIOCHEM BIOPH RES CO, V294, P496, DOI 10.1016/S0006-291X(02)00501-6; Kehrer-Sawatzki H, 2017, HUM GENET, V136, P349, DOI 10.1007/s00439-017-1766-y; Kim HA, 2001, J NEUROSCI, V21, P1110; Kluwe L, 1999, GENE CHROMOSOME CANC, V24, P283, DOI 10.1002/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koczkowska M, 2020, HUM MUTAT, V41, P299, DOI 10.1002/humu.23929; Koczkowska M, 2019, GENET MED, V21, P867, DOI 10.1038/s41436-018-0269-0; Koczkowska M, 2018, AM J HUM GENET, V102, P69, DOI 10.1016/j.ajhg.2017.12.001; Koliou X, 2016, J NEUROCHEM, V136, P78, DOI 10.1111/jnc.13401; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Larizza L, 2009, CURR MOL MED, V9, P634, DOI 10.2174/156652409788488801; Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261; Le LQ, 2011, CANCER RES, V71, P4686, DOI 10.1158/0008-5472.CAN-10-4577; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Lee K, 2017, NAT BIOMED ENG, V1, P889, DOI 10.1038/s41551-017-0137-2; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Li CJ, 2001, DEV BRAIN RES, V130, P231, DOI 10.1016/S0165-3806(01)00190-0; Liao CP, 2018, J CLIN INVEST, V128, P2848, DOI 10.1172/JCI99424; Lin YL, 2007, J CELL BIOL, V177, P829, DOI 10.1083/jcb.200608121; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Liu JY, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01901; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Luo G, 2014, CELL CYCLE, V13, P2780, DOI 10.4161/15384101.2015.945870; Mamcarz E, 2019, NEW ENGL J MED, V380, P1525, DOI 10.1056/NEJMoa1815408; Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; Marjanovic ND, 2013, CLIN CHEM, V59, P168, DOI 10.1373/clinchem.2012.184655; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Mautner VF, 2003, NEURORADIOLOGY, V45, P618, DOI 10.1007/s00234-003-0964-6; Melloni G, 2019, CANCERS, V11, DOI 10.3390/cancers11121838; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Mo J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139807; Mohammad HP, 2019, NAT MED, V25, P403, DOI 10.1038/s41591-019-0376-8; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Moutal A, 2017, PAIN, V158, P2203, DOI 10.1097/j.pain.0000000000001026; Murthy V, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007765; Nadim WD, 2016, P NATL ACAD SCI USA, V113, P12310, DOI 10.1073/pnas.1600914113; Nevedomskaya E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051359; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Opocher G, 2010, BEST PRACT RES CL EN, V24, P943, DOI 10.1016/j.beem.2010.05.001; Ozawa T, 2005, J BIOL CHEM, V280, P39524, DOI 10.1074/jbc.M503707200; Pacot L, 2021, CANCERS, V13, DOI 10.3390/cancers13122963; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Paria N, 2014, J BONE MINER RES, V29, P2636, DOI 10.1002/jbmr.2298; Parkin B, 2010, CLIN CANCER RES, V16, P4135, DOI 10.1158/1078-0432.CCR-09-2639; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pasmant E, 2009, J MED GENET, V46, P425, DOI 10.1136/jmg.2008.065243; Patrakitkomjorn S, 2008, J BIOL CHEM, V283, P9399, DOI 10.1074/jbc.M708206200; Patwardhan PP, 2014, CLIN CANCER RES, V20, P3146, DOI 10.1158/1078-0432.CCR-13-2576; Pawlak M, 2012, CURR TOP MED CHEM, V12, P486, DOI 10.2174/156802612799436641; Pearson A, 2020, CLIN CANCER RES, V26, P608, DOI 10.1158/1078-0432.CCR-18-4044; Pemov A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-194; Perrin GQ, 2019, BLOOD, V133, P407, DOI 10.1182/blood-2018-07-820720; Peta C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112348; Philpott C, 2017, HUM GENOMICS, V11, DOI 10.1186/s40246-017-0109-3; Pinna V, 2015, EUR J HUM GENET, V23, P1068, DOI 10.1038/ejhg.2014.243; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Presneau N, 2013, BRIT J CANCER, V108, P964, DOI 10.1038/bjc.2012.518; Prunier C, 2017, ONCOTARGET, V8, P41749, DOI 10.18632/oncotarget.16978; Qureshy Zoya, 2020, J Cancer Metastasis Treat, V6; Rakhra K, 2010, CANCER CELL, V18, P485, DOI 10.1016/j.ccr.2010.10.002; Rao UNM, 1997, HUM PATHOL, V28, P1066, DOI 10.1016/S0046-8177(97)90060-5; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Rischin A, 2019, RHEUMATOLOGY, V58, P1111, DOI 10.1093/rheumatology/kez012; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Rodriguez FJ, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0792-5; Rojnueangnit K, 2015, HUM MUTAT, V36, P1052, DOI 10.1002/humu.22832; Ross JS, 2014, MODERN PATHOL, V27, P271, DOI 10.1038/modpathol.2013.135; Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8; Sanchez-Ortiz E, 2014, GENE DEV, V28, P2407, DOI 10.1101/gad.246603.114; Sangha N, 2008, NEOPLASIA, V10, P1362, DOI 10.1593/neo.08784; Santoro C, 2015, EUR J HUM GENET, V23, P1460, DOI 10.1038/ejhg.2015.93; Scadden DT, 2014, CELL, V157, P41, DOI 10.1016/j.cell.2014.02.013; Scala M, 2021, CANCERS, V13, DOI 10.3390/cancers13081879; Sell S, 2010, AM J PATHOL, V176, P2584, DOI 10.2353/ajpath.2010.091064; Semenova G, 2017, BIOCHIMIE, V135, P1, DOI 10.1016/j.biochi.2017.01.001; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Serra G, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0718-7; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shapira S, 2007, CELL DEATH DIFFER, V14, P895, DOI 10.1038/sj.cdd.4402057; Sharif S, 2011, J MED GENET, V48, P256, DOI 10.1136/jmg.2010.081760; Sherekar M, 2020, J BIOL CHEM, V295, P1105, DOI 10.1074/jbc.RA119.010934; Shukla V, 2008, MUTAT RES-FUND MOL M, V637, P1, DOI 10.1016/j.mrfmmm.2007.07.012; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smith BA, 2015, P NATL ACAD SCI USA, V112, pE6544, DOI 10.1073/pnas.1518007112; Steinmann K, 2009, J INVEST DERMATOL, V129, P615, DOI 10.1038/jid.2008.274; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Stowe IB, 2012, GENE DEV, V26, P1421, DOI 10.1101/gad.190876.112; Subramanian S, 2010, J PATHOL, V220, P58, DOI 10.1002/path.2633; Summers MA, 2015, J MUSCULOSKEL NEURON, V15, P161; Tabata MM, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136262; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; Thomas SL, 2006, BIOCHEM BIOPH RES CO, V348, P971, DOI 10.1016/j.bbrc.2006.07.159; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; Trauger JW, 1996, NATURE, V382, P559, DOI 10.1038/382559a0; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Upadhyaya M, 2007, AM J HUM GENET, V80, P140, DOI 10.1086/510781; Vallee B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047283; Vandenbroucke I, 2004, FEBS LETT, V560, P98, DOI 10.1016/S0014-5793(04)00078-X; Vandenbroucke I, 2002, FEBS LETT, V522, P71, DOI 10.1016/S0014-5793(02)02887-9; Volta M, 2010, BIOCHEM BIOPH RES CO, V391, P1216, DOI 10.1016/j.bbrc.2009.12.043; Walker JA, 2018, EXPERT OPIN THER TAR, V22, P419, DOI 10.1080/14728222.2018.1465931; Walker James A, 2014, Rare Dis, V2, pe28341, DOI 10.4161/rdis.28341; Wang HF, 2011, J CLIN INVEST, V121, P4820, DOI 10.1172/JCI45677; Wang JW, 2021, CANCER RES, V81, P747, DOI 10.1158/0008-5472.CAN-20-1992; Wang S, 2014, P NATL ACAD SCI USA, V111, P4251, DOI 10.1073/pnas.1322198111; Wang WX, 2011, HUM MOL GENET, V20, P3910, DOI 10.1093/hmg/ddr310; Warrington NM, 2010, CANCER RES, V70, P5717, DOI 10.1158/0008-5472.CAN-09-3769; Wegscheid ML, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109315; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Weiss B, 2015, NEURO-ONCOLOGY, V17, P596, DOI 10.1093/neuonc/nou235; Weiss B, 2014, PEDIATR BLOOD CANCER, V61, P982, DOI 10.1002/pbc.24873; Weiss JB, 2017, BEHAV BRAIN RES, V332, P337, DOI 10.1016/j.bbr.2017.06.024; Welander J, 2012, HUM MOL GENET, V21, P5406, DOI 10.1093/hmg/dds402; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Widemann Brigitte C., 2019, Sarcoma, V2019, P7656747, DOI 10.1155/2019/7656747; Wiesner T, 2015, AM J SURG PATHOL, V39, P1357, DOI 10.1097/PAS.0000000000000451; Williams KB, 2020, GENES-BASEL, V11, DOI 10.3390/genes11050477; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433; Wolman MA, 2014, CELL REP, V8, P1265, DOI 10.1016/j.celrep.2014.07.054; Wolters PL, 2015, AM J MED GENET A, V167, P2103, DOI 10.1002/ajmg.a.37123; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Wu LMN, 2018, CANCER CELL, V33, P292, DOI 10.1016/j.ccell.2018.01.005; Xie KQ, 2016, CURR BIOL, V26, P2992, DOI 10.1016/j.cub.2016.09.010; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Xu M, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00270; Xu YC, 2019, NAT MED, V25, P301, DOI 10.1038/s41591-018-0321-2; Yan WP, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107909; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Yang FC, 2006, HUM MOL GENET, V15, P2421, DOI 10.1093/hmg/ddl165; Yang JL, 2011, CLIN CANCER RES, V17, P7563, DOI 10.1158/1078-0432.CCR-11-1707; Yang K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2703-x; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yunoue S, 2003, J BIOL CHEM, V278, P26958, DOI 10.1074/jbc.M209413200; Zheng ZY, 2020, CANCER CELL, V37, P387, DOI 10.1016/j.ccell.2020.02.003; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	286	1	1	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1235	1251		10.1038/s41388-021-02156-y	http://dx.doi.org/10.1038/s41388-021-02156-y		JAN 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35066574	Green Accepted			2022-12-28	WOS:000745605800001
J	Takagane, K; Umakoshi, M; Itoh, G; Kuriyama, S; Goto, A; Tanaka, M				Takagane, Kurara; Umakoshi, Michinobu; Itoh, Go; Kuriyama, Sei; Goto, Akiteru; Tanaka, Masamitsu			SKAP2 suppresses inflammation-mediated tumorigenesis by regulating SHP-1 and SHP-2	ONCOGENE			English	Article							TYROSINE-PHOSPHATASE; CYTOKINE PRODUCTION; KAPPA-B; RECEPTOR; SHPS-1; TOLL-LIKE-RECEPTOR-4; PHOSPHORYLATION; INTERFERON; MECHANISMS; INDUCTION	Inflammatory bowel diseases, like ulcerative colitis and Crohn's disease are frequently accompanied by colorectal cancers. However, the mechanisms underlying colitis-associated cancers are not fully understood. Src Kinase Associated Phosphoprotein 2 (SKAP2), a substrate of Src family kinases, is highly expressed in macrophages. Here, we examined the effects of SKAP2 on inflammatory responses in a mouse model of tumorigenesis with colitis induced by azoxymethane/dextran sulfate sodium. SKAP2 knockout increased the severity of colitis and tumorigenesis, as well as lipopolysaccharide (LPS) induced acute inflammation. SKAP2 attenuated inflammatory signaling in macrophages induced by uptake of cancer cell-derived exosomes. SKAP2(-/-) mice were characterized by the activation of NF-kappa B signaling and the upregulation and release of cytokines including TNF alpha, IL-1 beta, IL-6, CXCL-9/-10/-13, and sICAM1; SKAP2 overexpression attenuated NF-kappa B activation. Mechanistically, SKAP2 formed a complex with the SHP-1 tyrosine phosphatase via association with the Sirp alpha transmembrane receptor. SKAP2 also physically associated with the TIR domain of MyD88, TIRAP, and TRAM, adaptors of toll-like receptor 4 (TLR4). SKAP2-mediated recruitment of the Sirp alpha/SHP-1 complex to TLR4 attenuated inflammatory responses, whereas direct interaction of SKAP2 with SHP-2 decreased SHP-2 activation. SHP-2 is required for efficient NF-kappa B activation and suppresses the TRAM/TRIF-INF beta pathway; therefore, SKAP2-mediated SHP-2 inhibition affected two signaling axes from TLR4. The present findings indicate that SKAP2 prevents excess inflammation by inhibiting the TLR4-NF-kappa B pathway, and it activates the TLR4-IFN beta pathway through SHP-1 and SHP-2, thereby suppressing inflammation-mediated tumorigenesis.	[Takagane, Kurara; Itoh, Go; Kuriyama, Sei; Tanaka, Masamitsu] Akita Univ, Dept Mol Med & Biochem, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan; [Takagane, Kurara] Akita Univ, Tech Div, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan; [Umakoshi, Michinobu; Goto, Akiteru] Akita Univ, Dept Cellular & Organ Pathol, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan	Akita University; Akita University; Akita University	Tanaka, M (corresponding author), Akita Univ, Dept Mol Med & Biochem, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan.	mastanak@med.akita-u.ac.jp		Tanaka, Masamitsu/0000-0002-4823-9737; Kuriyama, Sei/0000-0002-5502-7177	JSPS KAKENHI [19H03495, 19K07681, 21K07090, 20H01094, 19K07454]; Takeda Science Foundation; Princess Takamatsu Cancer Research Fund [19-25123]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Princess Takamatsu Cancer Research Fund	This work was supported by JSPS KAKENHI grants (19H03495 to M. Tanaka, 19K07681 to G. Itoh, 21K07090 to S. Kuriyama, 20H01094 to K. Takagane, and 19K07454 to A. Goto), the Takeda Science Foundation grants (to M. Tanaka and G. Itoh), and a Research Grant from the Princess Takamatsu Cancer Research Fund (19-25123 to M. Tanaka).	Alenghat FJ, 2012, J CELL SCI, V125, P5535, DOI 10.1242/jcs.111260; An HZ, 2006, IMMUNITY, V25, P919, DOI 10.1016/j.immuni.2006.10.014; Antwi-Baffour SS, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0174-7; Barichello T, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/371465; Boras M, 2017, J EXP MED, V214, P851, DOI 10.1084/jem.20160647; Bourette RP, 2005, CELL SIGNAL, V17, P941, DOI 10.1016/j.cellsig.2004.11.009; Bretz NP, 2013, J BIOL CHEM, V288, P36691, DOI 10.1074/jbc.M113.512806; Bui TM, 2020, J LEUKOCYTE BIOL, V108, P787, DOI 10.1002/JLB.2MR0220-549R; Buwitt-Beckmann U, 2005, EUR J IMMUNOL, V35, P282, DOI 10.1002/eji.200424955; Chattopadhyay S, 2014, CYTOKINE GROWTH F R, V25, P533, DOI 10.1016/j.cytogfr.2014.06.002; Chaudhary A, 2007, IMMUNOL CELL BIOL, V85, P249, DOI 10.1038/sj.icb7100030; Chen R., 2012, BIO-PROTOCOL, V2; Chow A, 2014, SCI REP-UK, V4, DOI 10.1038/srep05750; Ciardiello C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020175; CORRIN B, 1980, J CLIN PATHOL, V33, P891, DOI 10.1136/jcp.33.9.891; Feng JR, 2019, ADV EXP MED BIOL, V1111, P19, DOI 10.1007/5584_2018_236; Floyel T, 2021, DIABETES, V70, P464, DOI 10.2337/db20-0092; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Fukata M, 2009, INFLAMM BOWEL DIS, V15, P997, DOI 10.1002/ibd.20880; Hoogland ICM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0332-6; Jakopin Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174265; Kagan JC, 2008, NAT IMMUNOL, V9, P361, DOI 10.1038/ni1569; Khaled AR, 1998, CELL IMMUNOL, V185, P49, DOI 10.1006/cimm.1998.1272; Kim EJ, 2013, INFLAMM RES, V62, P377, DOI 10.1007/s00011-013-0589-0; Kuzmich NN, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040034; Li P, 2019, BIOCHEM BIOPH RES CO, V508, P169, DOI 10.1016/j.bbrc.2018.11.074; Lu RZ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002597; Marongiu L, 2019, J LEUKOCYTE BIOL, V106, P147, DOI 10.1002/JLB.3MIR1218-483RR; Massa PT, 1998, J INTERF CYTOK RES, V18, P499, DOI 10.1089/jir.1998.18.499; Medvedev AE, 2007, J BIOL CHEM, V282, P16042, DOI 10.1074/jbc.M606781200; Miyake A, 2008, GENES CELLS, V13, P209, DOI 10.1111/j.1365-2443.2007.01161.x; Nguyen GT, 2020, ELIFE, V9, DOI 10.7554/eLife.56656; Niogret C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02468; Oshima K, 2002, FEBS LETT, V519, P1, DOI 10.1016/S0014-5793(02)02703-5; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Paschon V, 2016, MOL NEUROBIOL, V53, P2016, DOI 10.1007/s12035-015-9142-1; Pashenkov MV, 2019, J LEUKOCYTE BIOL, V105, P669, DOI 10.1002/JLB.2RU0718-290R; Qian ZR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/649161; Ramachandran IR, 2011, J IMMUNOL, V186, P3934, DOI 10.4049/jimmunol.1001675; Reinhold A, 2009, J LEUKOCYTE BIOL, V86, P61, DOI [10.1189/JLB.0608344, 10.1189/jlb.0608344]; Rosadini CV, 2017, CURR OPIN IMMUNOL, V44, P14, DOI 10.1016/j.coi.2016.10.005; Rosso M, 2011, CRIT REV IMMUNOL, V31, P379, DOI 10.1615/CritRevImmunol.v31.i5.20; Shaban L, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008576; Shi L, 2020, WORLD J GASTROENTERO, V26, DOI 10.3748/wjg.v26.i39.5983; Shimamura S, 2013, J BIOL CHEM, V288, P1171, DOI 10.1074/jbc.M112.386722; Snider AJ, 2016, METHODS MOL BIOL, V1438, P245, DOI 10.1007/978-1-4939-3661-8_14; Steinbichler TB, 2017, SEMIN CANCER BIOL, V44, P170, DOI 10.1016/j.semcancer.2017.02.006; Swanson KD, 2008, MOL CELL, V32, P564, DOI 10.1016/j.molcel.2008.09.022; Tanaka M, 2016, CANCER RES, V76, P358, DOI 10.1158/0008-5472.CAN-15-1879; Timms JF, 1999, CURR BIOL, V9, P927, DOI 10.1016/S0960-9822(99)80401-1; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5; van Heel DA, 2005, LANCET, V365, P1794, DOI 10.1016/S0140-6736(05)66582-8; Waldner MJ, 2015, CELL MOL GASTROENTER, V1, P6, DOI 10.1016/j.jcmgh.2014.11.006; Yashiro M, 2014, WORLD J GASTROENTERO, V20, P16389, DOI 10.3748/wjg.v20.i44.16389; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Zhang X, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0898-6	57	1	1	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1087	1099		10.1038/s41388-021-02153-1	http://dx.doi.org/10.1038/s41388-021-02153-1		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35034964				2022-12-28	WOS:000743007800002
J	Chen, Q; Zhuang, SQ; Hong, YL; Yang, LT; Guo, P; Mo, PL; Peng, KS; Li, WG; Xiao, NM; Yu, CD				Chen, Qiang; Zhuang, Shuqing; Hong, Yilin; Yang, Lingtao; Guo, Peng; Mo, Pingli; Peng, Kesong; Li, Wengang; Xiao, Nengming; Yu, Chundong			Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling	ONCOGENE			English	Article							IFN-GAMMA; MECHANISMS; PROGRESSION; PATHWAY	Programmed death-ligand 1 (PD-L1) is an important immunosuppressive molecule highly expressed on the surface of cancer cells. IFN gamma triggered cancer cell immunosuppression against CD8(+) T cell surveillance via up-regulation of PD-L1. Histone demethylase JMJD2D promotes colorectal cancer (CRC) progression; however, the role of JMJD2D in cancer immune escape is unknown. Here, we report that both PD-L1 and JMJD2D are frequently overexpressed in human CRC specimens with a significant positive correlation. Genetic ablation of JMJD2D in CRC cells attenuated the expression of PD-L1 and stalled tumor growth in mice, accompanied by the elevated number and effector function of tumor infiltrating CD8(+) T cells. Mechanistically, JMJD2D coactivated SP-1 to promote the expression of IFNGR1, which elevated STAT3-IRF1 signaling and promoted PD-L1 expression. Again, JMJD2D is a major coactivator for STAT3-IRF1 axis to enhance PD-L1 transcription in a demethylation activity dependent manner. Furthermore, pharmacological inhibition of JMJD2D conduced to improve the anti-tumor efficacy of PD-L1 antibody as demonstrated by slower tumor growth and higher infiltration and function of CD8(+) T cells in the combination of JMJD2D inhibitor 5-c-8HQ and PD-L1 antibody group compared with monotherapy with either agent. These results demonstrate that JMJD2D promotes CRC immune escape by enhancing PD-L1 expression to inhibit the activation and tumor infiltration of CD8(+) T cells; targeting JMJD2D has the potential role in promoting the efficacy of anti-PD-1/PD-L1 immunotherapy.	[Chen, Qiang; Zhuang, Shuqing; Hong, Yilin; Yang, Lingtao; Guo, Peng; Mo, Pingli; Xiao, Nengming; Yu, Chundong] Xiamen Univ, Innovat Ctr Cell Biol, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China; [Peng, Kesong] Fudan Univ, Sch Basic Med Sci, Dept Cellular & Genet Med, Shanghai, Peoples R China; [Li, Wengang] Xiamen Univ, Canc Res Ctr, Sch Med, Xiamen, Peoples R China; [Li, Wengang] Xiamen Univ, Xiangan Hosp, Res Ctr Retroperitoneal Tumor Comm Oncol Soc, Chinese Med Assoc,Sch Med, Xiamen, Peoples R China	Xiamen University; Fudan University; Xiamen University; Xiamen University	Xiao, NM; Yu, CD (corresponding author), Xiamen Univ, Innovat Ctr Cell Biol, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China.; Peng, KS (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Cellular & Genet Med, Shanghai, Peoples R China.; Li, WG (corresponding author), Xiamen Univ, Canc Res Ctr, Sch Med, Xiamen, Peoples R China.; Li, WG (corresponding author), Xiamen Univ, Xiangan Hosp, Res Ctr Retroperitoneal Tumor Comm Oncol Soc, Chinese Med Assoc,Sch Med, Xiamen, Peoples R China.	kesongpeng@fudan.edu.cn; lwgang@xmu.edu.cn; nengming@xmu.edu.cn; cdyu@xmu.edu.cn		Peng, Kesong/0000-0001-9035-3421	National Natural Science Foundation of China [81970485, 81772942, 31570883, 81972223]; Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University [PM20180917008]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University	This work was supported by the National Natural Science Foundation of China (No. 81970485 and No. 81772942 to Chundong Yu, No. 31570883 to Nengming Xiao, No. 81972223 to Wengang Li); Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University (No. PM20180917008 to Wengang Li).	Abiko K, 2015, BRIT J CANCER, V112, P1501, DOI 10.1038/bjc.2015.101; Canedo P, 2008, GUT, V57, P1504, DOI 10.1136/gut.2007.143578; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Cha JH, 2019, MOL CELL, V76, P359, DOI 10.1016/j.molcel.2019.09.030; Chen CG, 2012, AM J PATHOL, V180, P661, DOI 10.1016/j.ajpath.2011.10.040; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Deng SY, 2019, MOL CANCER THER, V18, P900, DOI 10.1158/1535-7163.MCT-18-1068; Doi T, 2017, ONCOL REP, V37, P1545, DOI 10.3892/or.2017.5399; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Du LY, 2020, J EXP MED, V217, DOI 10.1084/jem.20191115; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Guo R, 2019, CANCER SCI, V110, P1665, DOI 10.1111/cas.13989; Hogg SJ, 2017, CELL REP, V18, P2162, DOI 10.1016/j.celrep.2017.02.011; Kim EY, 2017, LUNG CANCER, V110, P63, DOI 10.1016/j.lungcan.2017.06.006; Lee HT, 2019, MOLECULES, V24, DOI 10.3390/molecules24061190; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Lin CF, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0317-0; Lu CW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw283; Luo N, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1438106; Mimura K, 2018, CANCER SCI, V109, P43, DOI 10.1111/cas.13424; Peng KS, 2020, ONCOGENE, V39, P7076, DOI 10.1038/s41388-020-01483-w; Peng KS, 2019, GASTROENTEROLOGY, V156, P1112, DOI 10.1053/j.gastro.2018.11.036; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Sheng Q, 2020, CLIN EXP IMMUNOL, V200, P45, DOI 10.1111/cei.13406; Singh S, 2020, NAT CELL BIOL, V22, P591, DOI 10.1038/s41556-020-0495-y; Sun L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0988-9; Tannenbaum CS, 2000, SEMIN CANCER BIOL, V10, P113, DOI 10.1006/scbi.2000.0314; Tong ZW, 2015, J BIOL CHEM, V290, P18596, DOI 10.1074/jbc.M115.640490; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Walter MR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.606489; Wang Y, 2018, CELL CYCLE, V17, P1457, DOI 10.1080/15384101.2018.1489177; Wang YH, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0346-6; Woods DM, 2015, CANCER IMMUNOL RES, V3, P1375, DOI 10.1158/2326-6066.CIR-15-0077-T; Xiao G, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0784-9; Zhao YT, 2019, BIOCHEM BIOPH RES CO, V517, P201, DOI 10.1016/j.bbrc.2019.07.039; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032; Zhuo MH, 2020, ONCOGENE, V39, P3336, DOI 10.1038/s41388-020-1219-2; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007	39	3	3	8	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1421	1433		10.1038/s41388-021-02173-x	http://dx.doi.org/10.1038/s41388-021-02173-x		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35027670				2022-12-28	WOS:000742332000001
J	Chen, J; Hou, SF; Tang, FJ; Liu, DS; Chen, ZZ; Zhang, HL; Wang, SH				Chen, Jia; Hou, Shu-Fen; Tang, Feng-Jie; Liu, Dai-Song; Chen, Zi-Zi; Zhang, Hong-Lian; Wang, Shao-Hua			HOTAIR/Sp1/miR-199a critically regulates cancer stemness and malignant progression of cutaneous squamous cell carcinoma	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; DNA METHYLATION; EXPRESSION; HOTAIR; CD44; IDENTIFICATION; PROLIFERATION; SP1	The long non-coding RNA (lncRNA), HOX antisense intergenic RNA (HOTAIR) is a well-characterized oncogene in multiple human cancers, but not in cutaneous squamous cell carcinoma (CSCC). In this study, we focused on investigating the potential role of HOTAIR in stemness of CSCC. By measuring its expression using RT-qPCR in CSCC vs. normal tissues, as well as in CSCC cell lines A431 or SCC13, A431- or SCC13-derived CSCC stem cells (CSCSCs), and normal skin fibroblasts (HSFs), we detected higher expression of HOTAIR in CSCC than in normal tissues, in recurrent than in non-recurrent CSCC tissues, in CSCCs and CSCSCs than in HSFs, and particularly, in CSCSCs than in CSCCs. Kaplan-Meier analysis suggested that higher expression of HOTAIR was positively correlated with worse overall survival of CSCC patients. Functional assays on colony formation, EdU incorporation, sphere formation, western blot on stem-cell biomarkers, and in vivo models showed that HOTAIR was essential in maintaining multiple stem cell phenotypes of CSCSCs in vitro and in vivo xenograft growth as well as metastasis. Mechanistically, HOTAIR directly interacted with and up-regulated Sp1. Sp1 then induced DNMT1-mediated promoter methylation and direct transcriptional repression of miR-199a-5p. Targeting Sp1 or DNMT1 further boosted the in vivo anti-tumor and anti-metastasis activities of targeting HOTAIR. In conclusion, HOTAIR, by up-regulating Sp1 and targeting miR-199a, promotes stemness and progression of CSCC. Targeting HOTAIR, Sp1 or the underlying mechanisms may thus benefit CSCC treatment.	[Chen, Jia; Hou, Shu-Fen; Tang, Feng-Jie; Liu, Dai-Song; Chen, Zi-Zi; Zhang, Hong-Lian; Wang, Shao-Hua] Cent South Univ, Dept Plast Surg, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China	Central South University	Wang, SH (corresponding author), Cent South Univ, Dept Plast Surg, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.	shaahww789@163.com			"perfect medical run-up" talent engineering project of The Third Xiangya Hospital of Central South University [JY201719]	"perfect medical run-up" talent engineering project of The Third Xiangya Hospital of Central South University	We would like to give our sincere gratitude to the reviewers for their constructive comments. This work was supported by the "perfect medical run-up" talent engineering project of The Third Xiangya Hospital of Central South University (Project Number: JY201719).	Alves CP, 2013, STEM CELLS, V31, P2827, DOI 10.1002/stem.1547; Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148; Bhat Shakil Ahmad, 2016, Noncoding RNA Res, V1, P43, DOI 10.1016/j.ncrna.2016.11.002; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Borena BM, 2014, CELL PHYSIOL BIOCHEM, V34, P1291, DOI 10.1159/000366338; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Burton KA, 2016, AM J CLIN DERMATOL, V17, P491, DOI 10.1007/s40257-016-0207-3; Chen BF, 2014, SCI REP-UK, V4, DOI 10.1038/srep06413; Chen BF, 2014, EPIGENETICS-US, V9, P119, DOI 10.4161/epi.25799; Deng J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170860; Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1; Dou J, 2016, AM J TRANSL RES, V8, P98; Gao SM, 2018, EXP HEMATOL, V67, P32, DOI 10.1016/j.exphem.2018.08.005; He J, 2019, TOXICOL APPL PHARM, V378, DOI 10.1016/j.taap.2019.114606; Hervouet E, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0450-y; Jian Z, 2017, J INVEST DERMATOL, V137, P31, DOI 10.1016/j.jid.2016.07.033; Jin YL, 2020, EUR J PHARMACOL, V878, DOI 10.1016/j.ejphar.2020.173105; Kim BK, 2015, J DERMATOL SCI, V79, P137, DOI 10.1016/j.jdermsci.2015.05.005; Kishikawa S, 2002, EUR J BIOCHEM, V269, P2961, DOI 10.1046/j.1432-1033.2002.02972.x; Koh SP, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02257; Kokko LL, 2011, ORAL ONCOL, V47, P510, DOI 10.1016/j.oraloncology.2011.03.026; Li JP, 2016, TUMOR BIOL, V37, P13287, DOI 10.1007/s13277-016-5244-2; Li XG, 2017, J CANCER RES CLIN, V143, P2189, DOI 10.1007/s00432-017-2478-3; Li Y, 2019, J ONCOL, V2019, DOI 10.1155/2019/5613417; Lin RK, 2010, CANCER RES, V70, P5807, DOI 10.1158/0008-5472.CAN-09-4161; Liu JM, 2013, INT J ONCOL, V42, P453, DOI 10.3892/ijo.2012.1720; Liu Y, 2020, REPROD SCI, V27, P110, DOI 10.1007/s43032-019-00016-5; Lu MY, 2017, ONCOTARGET, V8, P98542, DOI 10.18632/oncotarget.21614; Lu RH, 2020, CELL CYCLE, V19, P1, DOI 10.1080/15384101.2019.1689482; Nagano O, 2004, CANCER SCI, V95, P930, DOI 10.1111/j.1349-7006.2004.tb03179.x; Najafi M, 2019, J CELL PHYSIOL, V234, P8381, DOI 10.1002/jcp.27740; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Olivero C, 2019, METHODS MOL BIOL, V1879, P415, DOI 10.1007/7651_2018_134; PRIETO VG, 1995, AM J DERMATOPATH, V17, P447, DOI 10.1097/00000372-199510000-00003; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Sand M, 2016, EPIGENOMICS-UK, V8, P501, DOI 10.2217/epi-2015-0012; Senbanjo LT, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00018; Shen J, 2015, GASTROENT RES PRACT, V2015, DOI 10.1155/2015/230642; Song Y, 2019, INT J ONCOL, V54, P77, DOI 10.3892/ijo.2018.4625; Tang Q, 2018, CELL PHYSIOL BIOCHEM, V47, P893, DOI 10.1159/000490131; Wang SH, 2014, INT J CLIN EXP PATHO, V7, P7131; Wang SH, 2016, ONCOL LETT, V12, P97, DOI 10.3892/ol.2016.4602; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Wang YJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00158; Wu JJ, 2019, J ETHNOPHARMACOL, V237, P128, DOI 10.1016/j.jep.2019.03.027; Yu GJ, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0992-x; Zhang CY, 2019, ARTIF CELL NANOMED B, V47, P4110, DOI 10.1080/21691401.2019.1683566	47	6	6	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					99	111		10.1038/s41388-021-02014-x	http://dx.doi.org/10.1038/s41388-021-02014-x		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34697449				2022-12-28	WOS:000710873200001
J	Peng, X; Na, RS; Zhou, WT; Meng, XL; Yang, YH; Amini, S; Song, LW				Peng, Xiao; Na, Risi; Zhou, Wenting; Meng, Xiaole; Yang, Yunhai; Amini, Shohreh; Song, Liwei			Nuclear translocation of Gasdermin D sensitizes colorectal cancer to chemotherapy in a pyroptosis-independent manner	ONCOGENE			English	Article							KI-67 LABELING INDEX; OLAPARIB MONOTHERAPY; TARGETED THERAPY; GASTRIC-CANCER; OVARIAN-CANCER; CELL-SURVIVAL; DNA; HETEROGENEITY; COMBINATION; EXPRESSION	Gasdermin D (GSDMD) has recently been identified as a cytoplasmic effector protein that plays a central role in pyroptosis of immune cells. However, GSDMD is a universally expressed protein, and its function beyond pyroptosis, especially in cancer cells, has not been well characterized. Here, we report that predominant localization of GSDMD in the nucleoplasm in vivo indicates favorable clinical outcomes in colorectal cancer, while a lack of nuclear localization of GSDMD is associated with poor outcomes. Nuclear GSDMD, rather than cytoplasmic GSDMD, inhibits cell growth and promotes apoptosis in colorectal cancer. Hypoxia in the tumor microenvironment accounts for mild or moderate nuclear translocation of GSDMD in vivo. Under the stimulation of chemotherapy drugs, nuclear GSDMD promotes apoptosis via regulation of its subcellular distribution rather than pyroptosis-related cleavage. After nuclear translocation, GSDMD interacts with PARP-1 to dramatically inhibit its DNA damage repair-related function by functioning like the PARP inhibitor olaparib, thus forming a "hypoxia/chemotherapy-GSDMD nuclear translocation-PARP-1 blockade-DNA damage and apoptosis" axis. This study redefines the pyroptosis-independent function of GSDMD and suggests that the subcellular localization of GSDMD may serve as a molecular indicator of clinical outcomes and a promising therapeutic target in colorectal cancer.	[Peng, Xiao; Amini, Shohreh] Temple Univ, Dept Biol, BioLife Bldg,1900 North 12th St, Philadelphia, PA 19122 USA; [Na, Risi; Zhou, Wenting; Meng, Xiaole] Xiamen Univ, Xiangan Hosp, Sch Med, Dept Gen Surg, 2000 Xiangan East Rd, Xiamen 361102, Peoples R China; [Yang, Yunhai; Song, Liwei] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Oncol Surg, Sch Med, 241 West Huaihai Rd, Shanghai 200030, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Xiamen University; Shanghai Jiao Tong University	Amini, S (corresponding author), Temple Univ, Dept Biol, BioLife Bldg,1900 North 12th St, Philadelphia, PA 19122 USA.; Yang, YH; Song, LW (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Oncol Surg, Sch Med, 241 West Huaihai Rd, Shanghai 200030, Peoples R China.	yangyunhai_oncobio@shchest.org; shohreh.amini@temple.edu; songliwei_chest@shchest.org		XL, Meng/0000-0002-6388-9084	National Natural Science Foundation of China [NSFC82002427, NSFC 30801132]; Shanghai Chest Hospital Outstanding Talent Cultivation Project [2018YNZYB03]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Chest Hospital Outstanding Talent Cultivation Project	We thank Professor Feng Shao (National Institute of Biological Science) for the kind gift of the PCS2-Flag-tagged GSDMD plasmid. This project was supported by the National Natural Science Foundation of China (NSFC82002427, NSFC 30801132) and the Shanghai Chest Hospital Outstanding Talent Cultivation Project (2018YNZYB03).	Basourakos SP, 2017, CURR MED CHEM, V24, P1586, DOI 10.2174/0929867323666161214114948; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Cagatay T, 2018, CURR OPIN CELL BIOL, V52, P30, DOI 10.1016/j.ceb.2018.01.006; Cheng SB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2162-4; Cheung-Ong K, 2013, CHEM BIOL, V20, P648, DOI 10.1016/j.chembiol.2013.04.007; Gao JW, 2018, ONCOL REP, V40, P1971, DOI 10.3892/or.2018.6634; Gutting T, 2019, SEMIN CANCER BIOL, V55, P78, DOI 10.1016/j.semcancer.2018.04.003; Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530; He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Jakobsen JN, 2013, LUNG CANCER, V79, P1, DOI 10.1016/j.lungcan.2012.10.008; Jans DA, 2019, CURR OPIN CELL BIOL, V58, P50, DOI 10.1016/j.ceb.2019.01.001; Jia H, 2017, ONCOGENE, V36, P2655, DOI 10.1038/onc.2016.418; Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Karmakar M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16043-9; Kather JN, 2018, SEMIN CANCER BIOL, V52, P189, DOI 10.1016/j.semcancer.2018.02.010; Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Khanova E, 2018, HEPATOLOGY, V67, P1737, DOI 10.1002/hep.29645; Kim G, 2015, CLIN CANCER RES, V21, P4257, DOI 10.1158/1078-0432.CCR-15-0887; Kim HJ, 2017, NEURON, V96, P285, DOI 10.1016/j.neuron.2017.07.029; Komiyama H, 2010, GENES GENET SYST, V85, P75, DOI 10.1266/ggs.85.75; Kumareswaran R, 2012, J CELL SCI, V125, P189, DOI 10.1242/jcs.092262; Lane RJ, 2018, FUTURE ONCOL, V14, P647, DOI 10.2217/fon-2017-0546; Langelier MF, 2013, CURR OPIN STRUC BIOL, V23, P134, DOI 10.1016/j.sbi.2013.01.003; Linnekamp JF, 2015, CANCER RES, V75, P245, DOI 10.1158/0008-5472.CAN-14-2240; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Martin JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a027094; Mathew C, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01171; Matulonis UA, 2016, ANN ONCOL, V27, P1013, DOI 10.1093/annonc/mdw133; McKenzie BA, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01902-5; Pascal JM, 2018, DNA REPAIR, V71, P177, DOI 10.1016/j.dnarep.2018.08.022; Peddareddigari VG, 2010, CANCER MICROENVIRON, V3, P149, DOI 10.1007/s12307-010-0038-3; Petrova V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0011-9; Pyo JS, 2016, INT J BIOL MARKER, V31, pE204, DOI 10.5301/jbm.5000183; Rogers C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14128; Rothkamm K, 2015, ENVIRON MOL MUTAGEN, V56, P491, DOI 10.1002/em.21944; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Saeki N, 2007, ONCOGENE, V26, P6488, DOI 10.1038/sj.onc.1210475; Saeki N, 2009, GENE CHROMOSOME CANC, V48, P261, DOI 10.1002/gcc.20636; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; SMITH AE, 1985, PROC R SOC SER B-BIO, V226, P43, DOI 10.1098/rspb.1985.0078; Wang WJ, 2018, J DIGEST DIS, V19, P74, DOI 10.1111/1751-2980.12576; Wang YJ, 2019, DNA REPAIR, V81, DOI 10.1016/j.dnarep.2019.102651; Wang YB, 2018, BIOCHEM BIOPH RES CO, V495, P1418, DOI 10.1016/j.bbrc.2017.11.156; Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393; Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098; Xu B, 2018, J HEPATOL, V68, P773, DOI 10.1016/j.jhep.2017.11.040; Xu KW, 2015, ONCOTARGETS THER, V8, P3047, DOI 10.2147/OTT.S89154; Zhai ZH, 2017, SEMIN CELL DEV BIOL, V64, P107, DOI 10.1016/j.semcdb.2016.08.033; Zhang ZB, 2020, NATURE, V579, P415, DOI 10.1038/s41586-020-2071-9; Zhou ZW, 2020, SCIENCE, V368, P965, DOI 10.1126/science.aaz7548	55	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5092	5106		10.1038/s41388-022-02503-7	http://dx.doi.org/10.1038/s41388-022-02503-7		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36245058				2022-12-28	WOS:000868470400001
J	Lazaratos, AM; Annis, MG; Siegel, PM				Lazaratos, Anna-Maria; Annis, Matthew G.; Siegel, Peter M.			GPNMB: a potent inducer of immunosuppression in cancer	ONCOGENE			English	Review							ANTIBODY-DRUG CONJUGATE; MELANOMA PROTEIN-B; GLEMBATUMUMAB VEDOTIN; DC-HIL; THERAPEUTIC TARGET; NEGATIVE REGULATOR; DENDRITIC CELLS; PHASE I/II; TUMOR; GLYCOPROTEIN	The immune system is comprised of both innate and adaptive immune cells, which, in the context of cancer, collectively function to eliminate tumor cells. However, tumors can actively sculpt the immune landscape to favor the establishment of an immunosuppressive microenvironment, which promotes tumor growth and progression to metastatic disease. Glycoprotein-NMB (GPNMB) is a transmembrane glycoprotein that is overexpressed in a variety of cancers. It can promote primary tumor growth and metastasis, and GPNMB expression correlates with poor prognosis and shorter recurrence-free survival in patients. There is growing evidence supporting an immunosuppressive role for GPNMB in the context of malignancy. This review provides a description of the emerging roles of GPNMB as an inducer of immunosuppression, with a particular focus on its role in mediating cancer progression by restraining pro-inflammatory innate and adaptive immune responses.	[Lazaratos, Anna-Maria; Annis, Matthew G.; Siegel, Peter M.] McGill Univ, Goodman Canc Inst, Montreal, PQ, Canada; [Annis, Matthew G.; Siegel, Peter M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Siegel, Peter M.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Siegel, Peter M.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada; [Siegel, Peter M.] McGill Univ, Dept Oncol, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Inst, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Oncol, Montreal, PQ, Canada.	peter.siegel@mcgill.ca		Lazaratos, Anna-Maria/0000-0003-4923-7159	Canadian Institutes of Health Research [CIHR PJT-153327]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We thank members of the Siegel laboratory for thoughtful discussions and critical reading of the manuscript. Work referenced from the author's laboratory was supported by a Project grant to PMS from the Canadian Institutes of Health Research (CIHR PJT-153327). PMS is a McGill University William Dawson Scholar. Figures created with BioRender.com.	Abe H, 2007, BIOCHEM BIOPH RES CO, V356, P610, DOI 10.1016/j.bbrc.2007.03.035; Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Akiyoshi H, 2010, J IMMUNOL, V184, P3554, DOI 10.4049/jimmunol.0903250; Anderson MG, 2005, P NATL ACAD SCI USA, V102, P4566, DOI 10.1073/pnas.0407357102; Aponte PM, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/5619472; Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808; Bendell J, 2014, J CLIN ONCOL, V32, P3619, DOI 10.1200/JCO.2013.52.5683; Biondini M, 2022, ONCOGENE, V41, P1701, DOI 10.1038/s41388-022-02206-z; Biswas KB, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61931-1; Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460; Burris HA, 2017, J CLIN ONCOL, V35, P2028, DOI 10.1200/JCO.2016.70.1508; Cao LY, 2016, J INVEST DERMATOL, V136, P1801, DOI 10.1016/j.jid.2016.02.816; Chen C, 2018, CANCER RES, V78, P6424, DOI 10.1158/0008-5472.CAN-18-0599; Chung JS, 2007, J IMMUNOL, V179, P5778, DOI 10.4049/jimmunol.179.9.5778; Chung JS, 2007, BLOOD, V109, P4320, DOI 10.1182/blood-2006-11-053769; Chung JS, 2020, CLIN CANCER RES, V26, P1449, DOI 10.1158/1078-0432.CCR-19-2360; Chung JS, 2014, J INVEST DERMATOL, V134, P2784, DOI 10.1038/jid.2014.254; Chung JS, 2014, J IMMUNOL, V192, P2576, DOI 10.4049/jimmunol.1301857; Chung JS, 2013, IMMUNOLOGY, V138, P173, DOI 10.1111/imm.12027; Chung JS, 2011, EUR J IMMUNOL, V41, P1794, DOI 10.1002/eji.201041233; Chung JS, 2009, EUR J IMMUNOL, V39, P965, DOI 10.1002/eji.200838990; Emerson DA, 2018, BIODRUGS, V32, P221, DOI 10.1007/s40259-018-0277-2; Feng X, 2020, ONCOL LETT, V20, P2356, DOI 10.3892/ol.2020.11787; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Ganesh K, 2021, NAT MED, V27, P34, DOI 10.1038/s41591-020-01195-4; Gutknecht M, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0099-5; Hasanov M, 2020, CANCERS, V12, DOI 10.3390/cancers12082270; Hu XF, 2013, J CELL BIOCHEM, V114, P2729, DOI 10.1002/jcb.24621; Huang JJ, 2012, BRAIN BEHAV, V2, P85, DOI 10.1002/brb3.39; Kalbasi Anusha, 2020, Nat Rev Immunol, V20, P25, DOI 10.1038/s41577-019-0218-4; Katayama A, 2015, SCI REP-UK, V5, DOI 10.1038/srep16920; Khan S, 2021, J THORAC ONCOL, V16, pS131, DOI 10.1016/j.jtocrr.2021.100166; Kitano S, 2014, CANCER IMMUNOL RES, V2, P812, DOI 10.1158/2326-6066.CIR-14-0013; Knodler A, 2009, LEUKEMIA, V23, P535, DOI 10.1038/leu.2008.301; Kobayashi M, 2019, CLIN CANCER RES, V25, P828, DOI 10.1158/1078-0432.CCR-18-0330; Kopp LM, 2019, EUR J CANCER, V121, P177, DOI 10.1016/j.ejca.2019.08.015; Kumagai K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143413; Lai YS, 2019, J CELL MOL MED, V23, P1257, DOI 10.1111/jcmm.14027; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Li B, 2010, FASEB J, V24, P4767, DOI 10.1096/fj.10-154757; Li XF, 2019, P NATL ACAD SCI USA, V116, P3678, DOI 10.1073/pnas.1817652116; Liguori M, 2021, CELL MOL IMMUNOL, V18, P711, DOI 10.1038/s41423-020-0501-0; Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676; Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8; Maric G, 2013, ONCOTARGETS THER, V6, P839, DOI 10.2147/OTT.S44906; Martin K, 2014, CANCER IMMUNOL IMMUN, V63, P925, DOI 10.1007/s00262-014-1565-4; Modi S, 2020, NEW ENGL J MED, V382, P610, DOI 10.1056/NEJMoa1914510; Muller P, 2014, CANCER IMMUNOL RES, V2, P741, DOI 10.1158/2326-6066.CIR-13-0198; Nakano Y, 2014, NEUROSCIENCE, V277, P123, DOI 10.1016/j.neuroscience.2014.06.065; Neal ML, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1100-1; O'Donnell JS, 2019, NAT REV CLIN ONCOL, V16, P151, DOI 10.1038/s41571-018-0142-8; O'Donnell JS, 2017, CANCER TREAT REV, V52, P71, DOI 10.1016/j.ctrv.2016.11.007; Okita Yukari, 2018, Oncotarget, V9, P37289, DOI 10.18632/oncotarget.26472; Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7; Ono Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep23241; Ott PA, 2019, CANCER-AM CANCER SOC, V125, P1113, DOI 10.1002/cncr.31892; Ott PA, 2014, J CLIN ONCOL, V32, P3659, DOI 10.1200/JCO.2013.54.8115; Palisoc PJ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.814533; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Petroni G, 2022, NAT REV DRUG DISCOV, V21, P440, DOI 10.1038/s41573-022-00415-5; Pollack VA, 2007, CANCER CHEMOTH PHARM, V60, P423, DOI 10.1007/s00280-007-0490-z; Prabata A, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101232; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Ramachandran P, 2012, P NATL ACAD SCI USA, V109, pE3186, DOI 10.1073/pnas.1119964109; Ramani V, 2022, J INVEST DERMATOL, V142, P1372, DOI 10.1016/j.jid.2021.10.004; Ramani V, 2018, J INVEST DERMATOL, V138, P2443, DOI 10.1016/j.jid.2018.05.012; Ren FF, 2020, J CELL PHYSIOL, V235, P2738, DOI 10.1002/jcp.29177; Ripoll VM, 2007, J IMMUNOL, V178, P6557, DOI 10.4049/jimmunol.178.10.6557; Rose AAN, 2017, PHARMACOL THERAPEUT, V179, P127, DOI 10.1016/j.pharmthera.2017.05.010; Rose AAN, 2016, CLIN CANCER RES, V22, P6088, DOI 10.1158/1078-0432.CCR-16-1192; Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093; Saade M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.674739; Sasaki F, 2015, MOL MED REP, V12, P7503, DOI 10.3892/mmr.2015.4408; Schwarzbich MA, 2012, CANCER IMMUNOL IMMUN, V61, P193, DOI 10.1007/s00262-011-1096-1; Seligson JM, 2021, ANN PHARMACOTHER, V55, P921, DOI 10.1177/1060028020966548; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Song R, 2019, INFLAMMATION, V42, P1170, DOI 10.1007/s10753-019-00977-4; Sugimura K, 2015, J SURG ONCOL, V111, P752, DOI 10.1002/jso.23881; Szulzewsky F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116644; Tanaka H, 2012, SCI REP-UK, V2, DOI 10.1038/srep00573; Tomihari M, 2010, CANCER RES, V70, P5778, DOI 10.1158/0008-5472.CAN-09-2538; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tsou PS, 2020, FASEB J, V34, P8810, DOI 10.1096/fj.202000651; Turaj AH, 2017, CANCER CELL, V32, P777, DOI 10.1016/j.ccell.2017.11.001; Turrentine J, 2014, J INVEST DERMATOL, V134, P2839, DOI 10.1038/jid.2014.248; Voorwerk L, 2019, NAT MED, V25, P920, DOI 10.1038/s41591-019-0432-4; Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614; Xu XQ, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108199; Yamashita Y, 1999, J IMMUNOL, V162, P5940; Yardley DA, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.tps1110; Yardley DA, 2015, J CLIN ONCOL, V33, P1609, DOI 10.1200/JCO.2014.56.2959; Yu B, 2018, J INVEST DERMATOL, V138, P219, DOI 10.1016/j.jid.2017.08.034; Yu B, 2016, J CELL BIOCHEM, V117, P1511, DOI 10.1002/jcb.25394; Zhang HF, 2022, TISSUE CELL, V74, DOI 10.1016/j.tice.2021.101683; Zhao SL, 2022, APPL BIONICS BIOMECH, V2022, DOI 10.1155/2022/1790104; Zhou LT, 2017, CELL IMMUNOL, V316, P53, DOI 10.1016/j.cellimm.2017.03.006; Zhou XH, 2005, J BIOL CHEM, V280, P31240, DOI 10.1074/jbc.M502641200; Zhuo H, 2016, PHARMAZIE, V71, P555, DOI 10.1691/ph.2016.6683	99	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4573	4590		10.1038/s41388-022-02443-2	http://dx.doi.org/10.1038/s41388-022-02443-2		SEP 2022	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36050467				2022-12-28	WOS:000849283200001
J	Dong, PP; Cai, ZQ; Li, BF; Zhu, YQ; Chan, AKY; Chiang, MWL; Au, CH; Sung, WK; Cheung, TT; Lo, CM; Man, K; Lee, NP				Dong, Pingping; Cai, Ziqing; Li, Bingfeng; Zhu, Yueqin; Chan, Alice K. Y.; Chiang, Michael W. L.; Au, Chun Hang; Sung, Wing Kin; Cheung, Tan To; Lo, Chung Mau; Man, Kwan; Lee, Nikki P.			HFE promotes mitotic cell division through recruitment of cytokinetic abscission machinery in hepatocellular carcinoma	ONCOGENE			English	Article								HFE (Hemochromatosis) is a conventional iron level regulator and its loss of function due to gene mutations increases the risk of cancers including hepatocellular carcinoma (HCC). Likewise, studies focusing on HFE overexpression in cancers are all limited to linking up these events as a consequence of iron level deregulation. No study has explored any iron unrelated role of HFE in cancers. Here, we first reported HFE as an oncogene in HCC and its undescribed function on promoting abscission in cytokinesis during mitotic cell division, independent of its iron-regulating ability. Clinical analyses revealed HFE upregulation in tumors linking to large tumor size and poor prognosis. Functionally and mechanistically, HFE promoted cytokinetic abscission via facilitating ESCRT abscission machinery recruitment to the abscission site through signaling a novel HFE/ALK3/Smads/LIF/Hippo/YAP/YY1/KIF13A axis. Pharmacological blockage of HFE signaling axis impeded tumor phenotypes in vitro and in vivo. Our data on HFE-driven HCC unveiled a new mechanism utilized by cancer cells to propel rapid cell division. This study also laid the groundwork for tumor intolerable therapeutics development given the high cytokinetic dependency of cancer cells and their vulnerability to cytokinetic blockage.	[Dong, Pingping; Cai, Ziqing; Li, Bingfeng; Zhu, Yueqin; Cheung, Tan To; Lo, Chung Mau; Man, Kwan; Lee, Nikki P.] Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China; [Dong, Pingping] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Radiat Oncol, Hangzhou, Peoples R China; [Chan, Alice K. Y.; Chiang, Michael W. L.] City Univ Hong Kong, Dept Chem, Hong Kong, Peoples R China; [Chan, Alice K. Y.] Po Leung Kuk Tong Nai Kan Jr Secondary Coll, Hong Kong, Peoples R China; [Au, Chun Hang; Sung, Wing Kin] Hong Kong Genome Inst, Hong Kong, Peoples R China; [Sung, Wing Kin] Natl Univ Singapore, Sch Comp, Singapore, Singapore; [Sung, Wing Kin] Genome Inst Singapore, Computat & Syst Biol, Singapore, Singapore; [Lee, Nikki P.] Adv Biomed Instrumentat Ctr, Hong Kong Sci Pk, Hong Kong, Peoples R China	University of Hong Kong; Zhejiang University; City University of Hong Kong; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Man, K; Lee, NP (corresponding author), Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China.; Lee, NP (corresponding author), Adv Biomed Instrumentat Ctr, Hong Kong Sci Pk, Hong Kong, Peoples R China.	kwanman@hku.hk; nikkilee@hku.hk		Chiang, Michael W. L./0000-0001-7661-5560; Sung, Wing-Kin/0000-0001-7806-7086	Theme-based Research Scheme of the Research Grants Council, Hong Kong [T42-103/16-N, T12-703/19-R]; Health@InnoHK program of the Innovation and Technology Commission of the Hong Kong SAR Government	Theme-based Research Scheme of the Research Grants Council, Hong Kong; Health@InnoHK program of the Innovation and Technology Commission of the Hong Kong SAR Government	This study was financially supported by Theme-based Research Scheme (T42-103/16-N and T12-703/19-R) of the Research Grants Council, Hong Kong and the Health@InnoHK program of the Innovation and Technology Commission of the Hong Kong SAR Government.	Barton JC, 2015, GENE, V574, P179, DOI 10.1016/j.gene.2015.10.009; Bui DA, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaa9227; D'Avino PP, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a015834; Dong FY, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108856; Donne R, 2020, NAT REV GASTRO HEPAT, V17, P391, DOI 10.1038/s41575-020-0284-x; Fan YH, 2021, INT J ONCOL, V58, DOI 10.3892/ijo.2021.5205; Fededa JP, 2012, NAT CELL BIOL, V14, P440, DOI 10.1038/ncb2482; Feder J N, 2003, J Hepatol, V38, P704; Henriques AC, 2019, CANCER LETT, V440, P64, DOI 10.1016/j.canlet.2018.10.005; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Hoxha S, 2020, CANCER RES, V80, P2512, DOI 10.1158/0008-5472.CAN-19-2415; Josson S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068366; Lenarduzzi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074075; Lens SMA, 2019, NAT REV CANCER, V19, P32, DOI 10.1038/s41568-018-0084-6; Liu XR, 2018, CANCER SCI, V109, P3450, DOI 10.1111/cas.13794; Lu MQ, 2018, IUBMB LIFE, V70, P328, DOI 10.1002/iub.1726; Maugeri-Sacca M, 2018, PHARMACOL THERAPEUT, V186, P60, DOI 10.1016/j.pharmthera.2017.12.011; Muckenthaler MU, 2017, CELL, V168, P344, DOI 10.1016/j.cell.2016.12.034; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Poli M, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00086; Reuben A, 2017, IMMUN INFLAMM DIS, V5, P218, DOI 10.1002/iid3.158; Sagona AP, 2010, NAT CELL BIOL, V12, P362, DOI 10.1038/ncb2036; Shen HY, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106222; Sun XT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1987-1; Tang H, 2019, DIGEST LIVER DIS, V51, P1314, DOI 10.1016/j.dld.2019.02.012; Totaro A, 2018, NAT CELL BIOL, V20, P888, DOI 10.1038/s41556-018-0142-z; Verheul TCJ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.592164; Wang MT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11044-9; Weston Cody, 2014, Transl Oncogenomics, V6, P1, DOI 10.4137/TOG.S19064; Xing TH, 2018, EXP THER MED, V15, P4932, DOI 10.3892/etm.2018.6075; Xu HD, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.23; Yang T, 2013, CANCER SCI, V104, P552, DOI 10.1111/cas.12128; Yang XM, 2018, GASTROENTEROLOGY, V155, P1233, DOI 10.1053/j.gastro.2018.07.010; Zhang SY, 2018, GASTROENTEROLOGY, V154, P1421, DOI 10.1053/j.gastro.2017.12.013	34	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2022	41	36					4185	4199		10.1038/s41388-022-02419-2	http://dx.doi.org/10.1038/s41388-022-02419-2		JUL 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4G5OH	35882980				2022-12-28	WOS:000830346700002
J	More, A; Ito, I; Haridas, V; Chowdhury, S; Gu, Y; Dickson, P; Fowlkes, N; Shen, JP				More, Aditya; Ito, Ichiaki; Haridas, Valsala; Chowdhury, Saikat; Gu, Yue; Dickson, Princess; Fowlkes, Natalie; Shen, John Paul			Oncogene addiction to GNAS in GNAS(R201) mutant tumors	ONCOGENE			English	Article							BETA-CATENIN; G-PROTEIN; ACTIVATING MUTATION; SIGNALING PATHWAY; FREQUENT EVENT; WNT; PHOSPHORYLATION; EXPRESSION; LOCUS	The GNAS(R201) gain-of-function mutation is the single most frequent cancer-causing mutation across all heterotrimeric G proteins, driving oncogenesis in various low-grade/benign gastrointestinal and pancreatic tumors. In this study, we investigated the role of GNAS and its product G alpha s in tumor progression using peritoneal models of colorectal cancer (CRC). GNAS was knocked out in multiple CRC cell lines harboring GNAS(R201C/H) mutations (KM12, SNU175, SKCO1), leading to decreased cell-growth in 2D and 3D organoid models. Nude mice were peritoneally injected with GNAS-knockout KM12 cells, leading to a decrease in tumor growth and drastically improved survival at 7 weeks. Supporting these findings, GNAS overexpression in LS174T cells led to increased cell-growth in 2D and 3D organoid models, and increased tumor growth in PDX mouse models. GNAS knockout decreased levels of cyclic AMP in KM12 cells, and molecular profiling identified phosphorylation of beta-catenin and activation of its targets as critical downstream effects of mutant GNAS signaling. Supporting these findings, chemical inhibition of both PKA and beta-catenin reduced growth of GNAS mutant organoids. Our findings demonstrate oncogene addiction to GNAS in peritoneal models of GNAS(R201C/H) tumors, which signal through the cAMP/PKA and Wnt/beta-catenin pathways. Thus, GNAS and its downstream mediators are promising therapeutic targets for GNAS mutant tumors.	[More, Aditya; Ito, Ichiaki; Haridas, Valsala; Chowdhury, Saikat; Gu, Yue; Dickson, Princess; Shen, John Paul] MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA; [Fowlkes, Natalie] MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Shen, JP (corresponding author), MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA.	jshen8@mdanderson.org		More, Aditya/0000-0003-4511-4733; Shen, John Paul/0000-0003-4588-2775; Gu, Yue/0000-0002-9642-0338	National Cancer Institute [L30 CA171000, K22 CA234406]; Cancer Center Support Grant [CA16672]; Cancer Prevention & Research Institute of Texas [RR180035]; Col. Daniel Connelly Memorial Fund; NCI [CA16672, CA016672, R50CA221675]; Khalifa Bin Zayed Al Nahyan Foundation	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support Grant; Cancer Prevention & Research Institute of Texas; Col. Daniel Connelly Memorial Fund; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Khalifa Bin Zayed Al Nahyan Foundation	This work was supported by the National Cancer Institute (L30 CA171000 and K22 CA234406 to JPS, and the Cancer Center Support Grant (P30 CA016672), the Cancer Prevention & Research Institute of Texas (RR180035 to JPS, JPS is a CPRIT Scholar in Cancer Research), and the Col. Daniel Connelly Memorial Fund. We thank the following core facilities at MD Anderson Cancer Center for their services used in this study: Reverse Phase Protein Array Core (Supported by NCI grant #CA16672 and #R50CA221675), Advanced Technology Genomics Core (Supported by NCI Grant CA016672(ATGC)), Biospecimen Extraction Facility for sample processing and DNA/RNA/protein extraction, and Small Animal Imaging Facility (Supported by the Cancer Center Support Grant CA16672) for in vivo live imaging. In addition, data generated by TCGA Research Network: https://www.cancer.gov/tcga was used in this publication. We also acknowledge Dr Kenna Shaw and data integration and clinical team members from the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, supported by the Khalifa Bin Zayed Al Nahyan Foundation, for building and maintaining the MOCLIP database.	Almeida MQ, 2011, MOL CELL ENDOCRINOL, V336, P162, DOI 10.1016/j.mce.2010.11.018; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Ang CSP, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.17.00302; Arang N, 2020, FEBS LETT, V594, P4201, DOI 10.1002/1873-3468.14017; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Coles GL, 2020, CANCER CELL, V38, P129, DOI 10.1016/j.ccell.2020.05.003; Conway T, 2012, BIOINFORMATICS, V28, pI172, DOI 10.1093/bioinformatics/bts236; Dai SA, 2020, BIORXIV; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Faias S, 2020, WORLD J GASTRO ONCOL, V12, P1056, DOI 10.4251/wjgo.v12.i9.1056; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garcia-Murillas I, 2014, ONCOGENE, V33, P2478, DOI 10.1038/onc.2013.202; Goh G, 2014, NAT GENET, V46, P613, DOI 10.1038/ng.2956; Gueorguiev M, 2009, PITUITARY, V12, P245, DOI 10.1007/s11102-008-0147-x; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Hosoda W, 2015, VIRCHOWS ARCH, V466, P665, DOI 10.1007/s00428-015-1751-6; Hu Q, 2018, CELL, V173, P1254, DOI 10.1016/j.cell.2018.03.018; Ideno N, 2018, GASTROENTEROLOGY, V155, P1593, DOI 10.1053/j.gastro.2018.08.006; Innamorati G, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4133-z; Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276-020-0380-6; Khan M, 2018, CLIN COLORECTAL CANC, V17, pE699, DOI 10.1016/j.clcc.2018.07.005; Khan SK, 2018, P NATL ACAD SCI USA, V115, pE418, DOI 10.1073/pnas.1714313114; Kimbrel EA, 2009, MOL IMAGING, V8, P140, DOI 10.2310/7290.2009.00007; Komatsu H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087875; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin YL, 2020, J CANCER RES CLIN, V146, P2179, DOI 10.1007/s00432-020-03321-8; Lochner A, 2006, CARDIOVASC DRUG REV, V24, P261, DOI 10.1111/j.1527-3466.2006.00261.x; Nishikawa G, 2013, BRIT J CANCER, V108, P951, DOI 10.1038/bjc.2013.47; Nomura R, 2014, HUM PATHOL, V45, P2488, DOI 10.1016/j.humpath.2014.08.016; O'Hayre M, 2014, CURR OPIN CELL BIOL, V27, P126, DOI 10.1016/j.ceb.2014.01.005; Onken MD, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100403; Parsons MJ, 2021, CANCER DISCOV, V11, P2413, DOI 10.1158/2159-8290.CD-21-0190; Patel A, 2015, J CLIN ONCOL, V33; Patra KC, 2018, NAT CELL BIOL, V20, P811, DOI 10.1038/s41556-018-0122-3; Raghav K, 2020, BRIT J CANCER, V123, P1262, DOI 10.1038/s41416-020-1015-3; Regard JB, 2011, P NATL ACAD SCI USA, V108, P20101, DOI 10.1073/pnas.1114656108; Ritterhouse LL, 2017, MODERN PATHOL, V30, P1720, DOI 10.1038/modpathol.2017.88; Rosciglione S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5556; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Sassone-Corsi P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011148; Sastre-Perona Ana, 2012, Front Endocrinol (Lausanne), V3, P31, DOI 10.3389/fendo.2012.00031; Schatoff EM, 2017, CURR COLORECT CANC R, V13, P101, DOI 10.1007/s11888-017-0354-9; Stein MK, 2020, J SURG ONCOL, V121, P1320, DOI 10.1002/jso.25899; Stein MK, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.498; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Tischler G, 2014, SOURCE CODE BIOL MED, V9, DOI 10.1186/1751-0473-9-13; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06464-y; Weinstein LS, 2004, ENDOCRINOLOGY, V145, P5459, DOI 10.1210/en.2004-0865; Wilson CH, 2010, ONCOGENE, V29, P4567, DOI 10.1038/onc.2010.202; Yang IS, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2852-6; Zhang HY, 2020, EXP HEMATOL ONCOL, V9, DOI 10.1186/s40164-020-00191-1	59	1	1	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2022	41	35					4159	4168		10.1038/s41388-022-02388-6	http://dx.doi.org/10.1038/s41388-022-02388-6		JUL 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4A3US	35879396				2022-12-28	WOS:000829736900001
J	Wang, WH; Meng, YY; Chen, YX; Yu, YH; Wang, H; Yang, S; Sun, W				Wang, Wenhao; Meng, Yingying; Chen, Yaxin; Yu, Yanhong; Wang, Hang; Yang, Shuang; Sun, Wei			A comprehensive analysis of LMO2 pathogenic regulatory profile during T-lineage development and leukemic transformation	ONCOGENE			English	Article							GENE-THERAPY; BREAST-CANCER; CELL LEUKEMIA; EXPRESSION; PROTEIN; BINDING; LEUKEMOGENESIS; TRANSLOCATIONS; IDENTIFICATION; ONCOGENE	LMO2 is a well-known leukemic proto-oncogene, its ectopic expression in T-lineage specifically initiates malignant transformation of immature T cells and ultimately causes the onset of acute T-lymphocytic leukemia (T-ALL) in both mouse models and human patients. In this study, we systematically explored the LMO2 performance on the profiles of transcriptome, DNA-binding and protein interactions during T-lineage development in the pre-leukemic stage. Our data indicated that large-scale transcriptional dysregulation caused by LMO2 primarily occurred in DN3 thymocytes, characterized by enriched upregulation of the target genes of typical LMO2 complex, RUNX, ETS and STATs, and ectopic LMO2 primarily targeted to RUNX motifs along with intensive interaction with RUNX1 and H3K4 methyltransferase component ASH2L in this stage. However, binding of LMO2 on specific motifs was largely reduced in the following DP and SP stages, along with gradually disappeared LMO2-RUNX1 and LMO2-ASH2L interactions and less alteration of certain transcriptional factor profiles. Moreover, LMO2 showed relatively less influence on cellular behavior of DN3 thymocyte whereas displayed more prominent effects in DP and SP stages, including promoting Notch signaling and cell cycles. These findings provide a high-resolution landscape of the pathogenic role of LMO2 during T-lineage development in molecular level, and may benefit further clinical investigations for LMO2-associated T-lineage malignancies.	[Wang, Wenhao; Meng, Yingying; Chen, Yaxin; Yu, Yanhong; Wang, Hang; Yang, Shuang; Sun, Wei] Nankai Univ, Sch Med, Tianjin, Peoples R China	Nankai University	Sun, W (corresponding author), Nankai Univ, Sch Med, Tianjin, Peoples R China.	sunweibio@nankai.edu.cn	Yu, Yan/GYV-4514-2022	Wang, Wenhao/0000-0001-9777-2143	National Natural Science Foundation of China General Programs [81772976]	National Natural Science Foundation of China General Programs(National Natural Science Foundation of China (NSFC))	This work is supported by the National Natural Science Foundation of China General Programs (No. 81772976).	BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Chambers J, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150062; Cubedo E, 2012, BLOOD, V119, P5478, DOI 10.1182/blood-2012-01-403154; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Fujimoto T, 2007, EMBO J, V26, P2361, DOI 10.1038/sj.emboj.7601675; Gao P, 2020, GENE DEV, V34, P950, DOI 10.1101/gad.338202.120; Gao TS, 2016, BIOINFORMATICS, V32, P3543, DOI 10.1093/bioinformatics/btw495; Goode DK, 2016, DEV CELL, V36, P572, DOI 10.1016/j.devcel.2016.01.024; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hosokawa H, 2018, IMMUNITY, V48, P1119, DOI 10.1016/j.immuni.2018.04.024; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; LARSON RC, 1994, ONCOGENE, V9, P3675; Liu Y, 2017, ONCOTARGET, V8, P9513, DOI 10.18632/oncotarget.13434; Liu Y, 2017, MED SCI MONITOR, V23, P695, DOI 10.12659/MSM.903261; Liu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep36050; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Malumbres R, 2011, HAEMATOL-HEMATOL J, V96, P980, DOI 10.3324/haematol.2011.040568; Mao SF, 1999, MOL CELL BIOL, V19, P3635; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; McCormack MP, 2003, MOL CELL BIOL, V23, P9003, DOI 10.1128/MCB.23.24.9003-9013.2003; Natkunam Y, 2008, J CLIN ONCOL, V26, P447, DOI 10.1200/JCO.2007.13.0690; Natkunam Y, 2007, BLOOD, V109, P1636, DOI 10.1182/blood-2006-08-039024; Palii CG, 2011, EMBO J, V30, P494, DOI 10.1038/emboj.2010.342; Parvin S, 2019, CANCER CELL, V36, P237, DOI 10.1016/j.ccell.2019.07.007; Pike-Overzet K, 2007, LEUKEMIA, V21, P754, DOI 10.1038/sj.leu.2404563; Rothenberg EV, 2007, IMMUNITY, V26, P690, DOI 10.1016/j.immuni.2007.06.005; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Shin B, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2019655118; Smith S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085883; Sun W, 2010, EUR J HAEMATOL, V85, P508, DOI 10.1111/j.1600-0609.2010.01519.x; Sun W, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-22; Wang WH, 2020, MED SCI MONIT BASIC, V26, DOI 10.12659/MSMBR.924421; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wu C, 2018, BBA-MOL BASIS DIS, V1864, P2511, DOI 10.1016/j.bbadis.2018.05.013; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	38	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2022	41	34					4079	4090		10.1038/s41388-022-02414-7	http://dx.doi.org/10.1038/s41388-022-02414-7		JUL 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3W0LE	35851847				2022-12-28	WOS:000826844200001
J	Zhang, TZ; Wang, Z; Liu, MH; Liu, L; Yang, X; Zhang, Y; Bie, JT; Li, YT; Ren, MM; Song, C; Wang, WG; Tan, HY; Luo, JY				Zhang, Tianzhuo; Wang, Zhe; Liu, Minghui; Liu, Lu; Yang, Xin; Zhang, Yu; Bie, Juntao; Li, Yutong; Ren, Mengmeng; Song, Chen; Wang, Wengong; Tan, Hongyu; Luo, Jianyuan			Acetylation dependent translocation of EWSR1 regulates CHK2 alternative splicing in response to DNA damage	ONCOGENE			English	Article							EWINGS-SARCOMA PROTEIN; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; BIOCHEMICAL-PROPERTIES; KINASE; GENE; ATM; EWS-FLI1; CANCER; DOMAIN	Ewing sarcoma breakpoint region 1 (EWSR1) is a member of FET (FUS/EWSR1/TAF15) RNA-binding family of proteins. The Ewing sarcoma oncoprotein EWS-FLI1 has been extensively studied, while much less is known about EWSR1 itself, especially the potential role of EWSR1 in response to DNA damage. Here, we found that UV irradiation induces acetylation of EWSR1, which is required for its nucleoli translocation. We identified K423, K432, K438, K640, and K643 as the major acetylation sites, p300/CBP and HDAC3/HDAC10 as the major acetyltransferases and deacetylases, respectively. Mechanically, UV-induced EWSR1 acetylation repressed its interaction with spliceosomal component U1C, which caused abnormal splicing of CHK2, suppressing the activity of CHK2 in response to UV irradiation. Taken together, our findings uncover acetylation as a novel regulatory modification of EWSR1, and is essential for its function in DNA damage response.	[Zhang, Tianzhuo; Wang, Zhe; Liu, Minghui; Liu, Lu; Yang, Xin; Zhang, Yu; Bie, Juntao; Li, Yutong; Ren, Mengmeng; Song, Chen; Luo, Jianyuan] Peking Univ, Ctr Med Genet, Dept Med Genet, Hlth Sci Ctr, Beijing 100191, Peoples R China; [Zhang, Tianzhuo; Wang, Wengong; Luo, Jianyuan] Peking Univ, Dept Biochem & Biophys, Beijing Key Lab Prot Posttranslat Modificat & Cel, Hlth Sci Ctr, Beijing 100191, Peoples R China; [Tan, Hongyu] Peking Univ, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Dept Anesthesiol,Canc Hosp & Inst, Beijing 100142, Peoples R China	Peking University; Peking University; Peking University	Luo, JY (corresponding author), Peking Univ, Ctr Med Genet, Dept Med Genet, Hlth Sci Ctr, Beijing 100191, Peoples R China.; Luo, JY (corresponding author), Peking Univ, Dept Biochem & Biophys, Beijing Key Lab Prot Posttranslat Modificat & Cel, Hlth Sci Ctr, Beijing 100191, Peoples R China.; Tan, HY (corresponding author), Peking Univ, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Dept Anesthesiol,Canc Hosp & Inst, Beijing 100142, Peoples R China.	maggitan@yeah.net; luojianyuan@bjmu.edu.cn		Yang, Xin/0000-0003-0222-5839	National Natural Science Foundation of China [81874147, 82172959]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from National Natural Science Foundation of China (81874147, 82172959). We thank core facility at Peking University Health Science Center for experiment help.	Alex D, 2005, NUCLEIC ACIDS RES, V33, P1323, DOI 10.1093/nar/gki270; Araya N, 2005, BIOCHEM BIOPH RES CO, V329, P653, DOI 10.1016/j.bbrc.2005.02.018; Bachmaier R, 2009, ONCOGENE, V28, P1280, DOI 10.1038/onc.2008.484; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Berge EO, 2010, BBA-MOL CELL RES, V1803, P386, DOI 10.1016/j.bbamcr.2010.01.005; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Da Costa IC, 2020, ESSAYS BIOCHEM, V64, P737, DOI 10.1042/EBC20190095; Das S, 2013, FEBS LETT, V587, P417, DOI 10.1016/j.febslet.2013.01.035; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Du HS, 2002, NATURE, V419, P86, DOI 10.1038/nature00947; Dutertre M, 2010, NAT STRUCT MOL BIOL, V17, P1358, DOI 10.1038/nsmb.1912; Dutto I, 2018, CELL MOL LIFE SCI, V75, P1325, DOI 10.1007/s00018-017-2717-4; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Grunewald TGP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0003-x; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Han CJ, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abj8357; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; Hurov KE, 2010, GENE DEV, V24, P1939, DOI 10.1101/gad.1934210; Kim J, 1999, P NATL ACAD SCI USA, V96, P14300, DOI 10.1073/pnas.96.25.14300; Kim J, 2000, FEBS LETT, V474, P121, DOI 10.1016/S0014-5793(00)01590-8; Kim JD, 2008, INT J MOL MED, V22, P309, DOI 10.3892/ijmm_00000024; Klevernic IV, 2009, BIOCHEM J, V418, P625, DOI 10.1042/BJ20082097; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Lee SG, 2020, EMBO REP, V21, DOI 10.15252/embr.201948676; Li HJ, 2007, J CLIN INVEST, V117, P1314, DOI 10.1172/JCI31222; Li K, 2008, J BIOL CHEM, V283, P7590, DOI 10.1074/jbc.M709707200; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Munoz MJ, 2009, CELL, V137, P708, DOI 10.1016/j.cell.2009.03.010; Mustofa MK, 2020, ENVIRON MOL MUTAGEN, V61, P730, DOI 10.1002/em.22397; Muto Y, 2004, J MOL BIOL, V341, P185, DOI 10.1016/j.jmb.2004.04.078; Paronetto MP, 2011, MOL CELL, V43, P353, DOI 10.1016/j.molcel.2011.05.035; Paronetto Maria Paola, 2013, Int J Cell Biol, V2013, P642853, DOI 10.1155/2013/642853; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Ren XL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2640-8; Rosel TD, 2011, EMBO J, V30, P1965, DOI 10.1038/emboj.2011.106; Schwartz JC, 2015, ANNU REV BIOCHEM, V84, P355, DOI 10.1146/annurev-biochem-060614-034325; Shandilya J, 2009, MOL CELL BIOL, V29, P5115, DOI 10.1128/MCB.01969-08; Spahn L, 2002, CANCER RES, V62, P4583; Srivastava A, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.600682; Staalesen V, 2004, ONCOGENE, V23, P8535, DOI 10.1038/sj.onc.1207928; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Takahama K, 2011, FEBS J, V278, P988, DOI 10.1111/j.1742-4658.2011.08020.x; Tanoue Y, 2018, J INVEST DERMATOL, V138, P2550, DOI 10.1016/j.jid.2018.05.015; Zannini L, 2014, J MOL CELL BIOL, V6, P442, DOI 10.1093/jmcb/mju045	51	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2022	41	29					3694	3704		10.1038/s41388-022-02383-x	http://dx.doi.org/10.1038/s41388-022-02383-x		JUN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y6YE	35732801				2022-12-28	WOS:000814460500002
J	Li, YY; Yang, J; Zhang, QQ; Xu, SQ; Sun, W; Ge, SF; Xu, XW; Jager, MJ; Jia, RB; Zhang, JM; Fan, XQ				Li, Yongyun; Yang, Jie; Zhang, Qianqian; Xu, Shiqiong; Sun, Wei; Ge, Shengfang; Xu, Xiaowei; Jager, Martine J.; Jia, Renbing; Zhang, Jianming; Fan, Xianqun			Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma	ONCOGENE			English	Article							BREAST-CANCER METASTASIS; REPRESSES E-CADHERIN; OXIDATIVE STRESS; OCULAR MELANOMA; DRUG ELESCLOMOL; PHASE-I; INHIBITION; SLUG; ESTABLISHMENT; EXPRESSION	Unlike cutaneous melanoma, uveal melanoma (UM) is characterized by mutations in GNAQ and GNA11 and remains a fatal disease because there is essentially no effective targeted therapy or immunotherapy available. We report the discovery of the copper ionophore elesclomol as a GNAQ/11-specific UM inhibitor. Elesclomol was identified in a differential cytotoxicity screen of an in-house tool compound library, and its in vivo pharmacological efficacy was further confirmed in zebrafish and mouse UM models. Mechanistically, elesclomol transports copper to mitochondria and produces a large amount of reactive oxygen species (ROS) as Cu(II) is reduced to Cu(I) in GNAQ/11-mutant UM cells, which selectively activates LATS1 kinase in the Hippo signaling pathway and consequently promotes YAP phosphorylation and inhibits its nuclear accumulation. The inactivation of YAP downregulates the expression of SNAI2, which in turn suppresses the migration of UM cells. These findings were cross validated by our clinical observation that YAP activation was found specifically in UM samples with a GNAQ/11 mutation. Furthermore, addition of binimetinib, a MEK inhibitor, to elesclomol increased its synthetic lethality to GNAQ/11-mutant UM cells, thereby overriding drug resistance. This effect was confirmed in an orthotopic xenograft model and in a patient-derived xenograft model of UM. These studies reveal a novel mechanistic basis for repurposing elesclomol by showing that copper homeostasis is a GNAQ/11-specific vulnerability in UM. Elesclomol may provide a new therapeutic path for selectively targeting malignant GNAQ/11-mutant UM.	[Li, Yongyun; Yang, Jie; Xu, Shiqiong; Ge, Shengfang; Jia, Renbing; Fan, Xianqun] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China; [Li, Yongyun; Yang, Jie; Xu, Shiqiong; Ge, Shengfang; Jia, Renbing; Fan, Xianqun] Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai, Peoples R China; [Zhang, Qianqian; Sun, Wei; Zhang, Jianming] Shanghai Jiao Tong Univ, Ruijin Hosp, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China; [Xu, Xiaowei] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; [Jager, Martine J.] Leiden Univ, Dept Ophthalmol, Med Ctr, Leiden, Netherlands	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Jiao Tong University; University of Pennsylvania; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jia, RB; Fan, XQ (corresponding author), Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China.; Jia, RB; Fan, XQ (corresponding author), Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai, Peoples R China.; Zhang, JM (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China.	renbingjia@sjtu.edu.cn; jzuc@shsmu.edu.cn; fanxq@sjtu.edu.cn	Jager, Martine/AAR-3525-2020	Jager, Martine/0000-0003-2261-3820; Zhang, Jianming/0000-0001-6326-3906	National Natural Science Foundation of China [82073889]; Science and Technology Commission of Shanghai [20DZ2270800]; Shanghai Municipal Science and Technology Major Project [19JC1410200]; National Facility for Translational Medicine (Shanghai) [TMSZ2020-206]; Innovative Research Team of High-level Local Universities in Shanghai [SHSMU-ZDCX20210900]; State Key Laboratory of Medical Genomics	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Municipal Science and Technology Major Project; National Facility for Translational Medicine (Shanghai); Innovative Research Team of High-level Local Universities in Shanghai; State Key Laboratory of Medical Genomics	This research was supported by the National Natural Science Foundation of China (grant 82073889), the Science and Technology Commission of Shanghai (20DZ2270800), the Shanghai Municipal Science and Technology Major Project (19JC1410200), the National Facility for Translational Medicine (Shanghai) (TMSZ2020-206), the Innovative Research Team of High-level Local Universities in Shanghai (SHSMU-ZDCX20210900), and startup funding of State Key Laboratory of Medical Genomics to JZ. We thank Drs. David E. Fisher and Xu Wu (Massachusetts General Hospital), Yantao Chen, and Yunqi Li (Shanghai Jiao Tong University) for review of this work and discussions on various topics relating to this project.	Albayrak G, 2019, J CELL BIOCHEM, V120, P10564, DOI 10.1002/jcb.28342; Ambrosini G, 2013, MOL CANCER THER, V12, P768, DOI 10.1158/1535-7163.MCT-12-1020; Amirouchene-Angelozzi N, 2014, MOL ONCOL, V8, P1508, DOI 10.1016/j.molonc.2014.06.004; Asnaghi L, 2015, MOL VIS, V21, P919; Aubert L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17549-y; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Berkenblit A, 2007, CLIN CANCER RES, V13, P584, DOI 10.1158/1078-0432.CCR-06-0964; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brady DC, 2014, NATURE, V509, P492, DOI 10.1038/nature13180; Brouwer NJ, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.4.3; Campbell AP, 2018, NAT REV DRUG DISCOV, V17, P789, DOI 10.1038/nrd.2018.135; Carlson BA, 1996, CANCER RES, V56, P2973; Chen PW, 1997, CLIN EXP METASTAS, V15, P509, DOI 10.1023/A:1018479011340; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; DEWAARDSIEBINGA I, 1995, INT J CANCER, V62, P155, DOI 10.1002/ijc.2910620208; Fan HJ, 2020, GENE DEV, V34, P1359, DOI 10.1101/gad.339796.120; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Gunst JD, 2019, J VIRUS ERAD, V5, P133; Hajra KM, 2002, CANCER RES, V62, P1613; Harrington BS, 2020, CANCERS, V12, DOI 10.3390/cancers12061645; Harris IS, 2020, TRENDS CELL BIOL, V30, P440, DOI 10.1016/j.tcb.2020.03.002; Hasinoff BB, 2015, BIOCHEM PHARMACOL, V93, P266, DOI 10.1016/j.bcp.2014.12.008; Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002; Hedley D, 2016, LEUKEMIA LYMPHOMA, V57, P2437, DOI 10.3109/10428194.2016.1138293; Khoja L, 2019, ANN ONCOL, V30, P1370, DOI 10.1093/annonc/mdz176; Kirshner JR, 2008, MOL CANCER THER, V7, P2319, DOI 10.1158/1535-7163.MCT-08-0298; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979; KSANDER BR, 1991, INVEST OPHTH VIS SCI, V32, P3198; Li WY, 2020, GENE DEV, V34, P1310, DOI 10.1101/gad.339804.120; Li YY, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920965852; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Luyten GPM, 1996, INT J CANCER, V66, P380, DOI 10.1002/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Monk BJ, 2018, GYNECOL ONCOL, V151, P422, DOI 10.1016/j.ygyno.2018.10.001; Nagai M, 2012, FREE RADICAL BIO MED, V52, P2142, DOI 10.1016/j.freeradbiomed.2012.03.017; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; O'Day S, 2009, J CLIN ONCOL, V27, P5452, DOI 10.1200/JCO.2008.17.1579; O'Day SJ, 2013, J CLIN ONCOL, V31, P1211, DOI 10.1200/JCO.2012.44.5585; Onken MD, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao6852; Parry D, 2010, MOL CANCER THER, V9, P2344, DOI 10.1158/1535-7163.MCT-10-0324; Populoa H, 2010, MELANOMA RES, V20, P107, DOI 10.1097/CMR.0b013e32832ccd09; Qu Y, 2010, BREAST CANCER RES TR, V121, P311, DOI 10.1007/s10549-009-0470-6; Schrage R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10156; Seftor EA, 2002, CLIN EXP METASTAS, V19, P233, DOI 10.1023/A:1015591624171; Shanbhag V, 2019, P NATL ACAD SCI USA, V116, P6836, DOI 10.1073/pnas.1817473116; Shields CL, 2009, CLIN DERMATOL, V27, P122, DOI 10.1016/j.clindermatol.2008.09.010; Shimada K, 2018, CELL CHEM BIOL, V25, P585, DOI 10.1016/j.chembiol.2018.02.010; Shoushtari AN, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9511; Singh AD, 2003, OPHTHALMOLOGY, V110, P956, DOI 10.1016/S0161-6420(03)00078-2; Smit KN, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100800; Steeb T, 2018, EUR J CANCER, V103, P41, DOI 10.1016/j.ejca.2018.08.005; Tardito S, 2011, J AM CHEM SOC, V133, P6235, DOI 10.1021/ja109413c; Tripathi MK, 2005, J BIOL CHEM, V280, P17163, DOI 10.1074/jbc.M501375200; Tsvetkov P, 2019, NAT CHEM BIOL, V15, P681, DOI 10.1038/s41589-019-0291-9; van der Ent W, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15202; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Wang W, 2019, FASEB J, V33, P7180, DOI 10.1096/fj.201801635R; White SM, 2019, DEV CELL, V49, P425, DOI 10.1016/j.devcel.2019.04.014; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Zhang ZH, 2020, LEUKEMIA, V34, P380, DOI 10.1038/s41375-019-0566-x	63	0	0	16	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3539	3553		10.1038/s41388-022-02364-0	http://dx.doi.org/10.1038/s41388-022-02364-0		JUN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35697803				2022-12-28	WOS:000810359900002
J	Zhang, YX; Wu, JZ; Fu, Y; Yu, RR; Su, HC; Zheng, QS; Wu, H; Zhou, SQ; Wang, K; Zhao, J; Shen, SS; Xu, GF; Wang, L; Yan, C; Zou, XP; Lv, Y; Zhang, S				Zhang, Yixuan; Wu, Jianzhuang; Fu, Yao; Yu, Ranran; Su, Haochen; Zheng, Qisi; Wu, Hao; Zhou, Siqi; Wang, Kun; Zhao, Jing; Shen, Shanshan; Xu, Guifang; Wang, Lei; Yan, Chao; Zou, Xiaoping; Lv, Ying; Zhang, Shu			Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE STRESS; MODIFIED-FOLFIRINOX; INDUCED APOPTOSIS; INCREASING ROS; ER STRESS; MITOCHONDRIA; AUTOPHAGY; INHIBITION; METABOLISM	Pancreatic cancer (PC) is a fatal disease with poor survival and limited therapeutic strategies. In this study, we identified Hesperadin as a potent anti-cancer compound against PC, from a high-throughput screening of a commercial chemical library associated with cell death. Hesperadin induced potent growth inhibition in PC cell lines and patient-derived tumor organoids in a dose- and time-dependent manner, with IC50 values in the nanomolar range. Cellular studies showed that Hesperadin caused mitochondria damage in PC cells, resulting in reactive oxygen species production, ER stress and apoptotic cell death. Transcriptomic analysis using RNA-sequencing data identified GADD45A as a potential target of Hesperadin. Mechanistic studies showed that Hesperadin could increase GADD45A expression in PC cells via ATF4, leading to apoptosis. Moreover, immunohistochemical staining of 92 PC patient samples demonstrated the correlation between ATF4 and GADD45A expression. PC xenograft studies demonstrated that Hesperadin could effectively inhibit the growth of PC cells in vivo. Together, these findings suggest that Hesperadin is a novel drug candidate for PC.	[Zhang, Yixuan; Wu, Hao; Zhao, Jing; Shen, Shanshan; Xu, Guifang; Wang, Lei; Zou, Xiaoping; Lv, Ying; Zhang, Shu] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Gastroenterol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China; [Zhang, Yixuan; Wu, Jianzhuang; Su, Haochen; Wu, Hao; Zhou, Siqi; Wang, Kun; Zhao, Jing; Shen, Shanshan; Xu, Guifang; Wang, Lei; Yan, Chao; Zou, Xiaoping; Lv, Ying; Zhang, Shu] Nanjing Univ, Inst Pancreatol, Nanjing, Peoples R China; [Wu, Jianzhuang; Yu, Ranran; Yan, Chao] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing, Peoples R China; [Fu, Yao] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Pathol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China; [Su, Haochen] Nanjing Med Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Dept Gastroenterol, Nanjing, Peoples R China; [Zheng, Qisi] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Clin Lab, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China; [Zhou, Siqi] Jiangsu Univ, Affiliated Hosp, Nanjing Drum Tower Hosp, Dept Gastroenterol, Nanjing, Peoples R China; [Wang, Kun] Xuzhou Med Univ, Affiliated Hosp, Nanjing Drum Tower Hosp, Dept Gastroenterol, Nanjing, Peoples R China	Nanjing University; Nanjing University; Nanjing University; Nanjing University; Nanjing Medical University; Nanjing University; Nanjing University; Jiangsu University; Nanjing University; Nanjing University; Xuzhou Medical University	Zou, XP; Lv, Y; Zhang, S (corresponding author), Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Gastroenterol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.; Zou, XP; Lv, Y; Zhang, S (corresponding author), Nanjing Univ, Inst Pancreatol, Nanjing, Peoples R China.	zouxp@nju.edu.cn; lvying@njglyy.com; zhangsgastro@nju.edu.cn		Fu, Yao/0000-0001-9864-1030	National Natural Science Foundation of China [81802396, 82072652]; Natural Science Foundation of Jiangsu Province [SBK2019022491, BK20180117]; General Project of Nanjing Medical Science and Technology Development Project [YKK17077]; Nanjing Science and Technology Development Plan Project [201715023]; Nanjing Medical Science and Technology Development Key Project [ZKX18022]; Nanjing Science and technology project [201911038]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); General Project of Nanjing Medical Science and Technology Development Project; Nanjing Science and Technology Development Plan Project; Nanjing Medical Science and Technology Development Key Project; Nanjing Science and technology project	This work was supported by the National Natural Science Foundation of China (81802396 and 82072652), Natural Science Foundation of Jiangsu Province (SBK2019022491 and BK20180117), General Project of Nanjing Medical Science and Technology Development Project (YKK17077), Nanjing Science and Technology Development Plan Project (201715023), Nanjing Medical Science and Technology Development Key Project (ZKX18022), and Nanjing Science and technology project (201911038).	Aggarwal V, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110735; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen WQ, 2016, REDOX BIOL, V10, P78, DOI 10.1016/j.redox.2016.09.006; Chen X, 2021, NAT REV CANCER, V21, P71, DOI 10.1038/s41568-020-00312-2; Chen X, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.11.019; Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046; Chiu HY, 2020, ANTIOXID REDOX SIGN, V32, P309, DOI 10.1089/ars.2019.7898; Chuang KC, 2020, J DERMATOL SCI, V98, P152, DOI 10.1016/j.jdermsci.2020.03.009; Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004; DU J, 2021, CELL DEATH DIS, V12; Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Guo XY, 2020, NATURE, V579, P427, DOI 10.1038/s41586-020-2078-2; Harris IS, 2020, TRENDS CELL BIOL, V30, P440, DOI 10.1016/j.tcb.2020.03.002; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hu YL, 2019, ONCOGENE, V38, P731, DOI 10.1038/s41388-018-0478-7; Indo HP, 2007, MITOCHONDRION, V7, P106, DOI 10.1016/j.mito.2006.11.026; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Li W, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0805-4; Li X, 2017, CANCER LETT, V406, P22, DOI 10.1016/j.canlet.2017.07.012; Li X, 2018, INT J BIOL SCI, V14, P1291, DOI 10.7150/ijbs.26776; Lin YN, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109249; Liu CY, 2020, ENVIRON TOXICOL, V35, P1100, DOI 10.1002/tox.22946; Liu S, 2017, REDOX BIOL, V13, P528, DOI 10.1016/j.redox.2017.06.007; Missiroli S, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102943; Moore Alexandra, 2019, JAMA, V322, P1426, DOI 10.1001/jama.2019.14699; Nano M, 2019, CURR BIOL, V29, P3937, DOI 10.1016/j.cub.2019.09.041; Neoptolemos JP, 2018, NAT REV GASTRO HEPAT, V15, P332, DOI 10.1038/s41575-018-0005-x; Perillo B, 2020, EXP MOL MED, V52, P192, DOI 10.1038/s12276-020-0384-2; Rodic S, 2018, INT J CANCER, V142, P440, DOI 10.1002/ijc.31069; Sasaki K, 2020, BIOSCIENCE REP, V40; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Silva JM, 2009, NEUROBIOL DIS, V34, P357, DOI 10.1016/j.nbd.2009.02.005; Su MQ, 2018, INT J ONCOL, V53, P750, DOI 10.3892/ijo.2018.4402; Tempero MA, 2019, J NATL COMPR CANC NE, V17, P603, DOI 10.6004/jnccn.2019.5007; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Verfaillie T, 2012, CELL DEATH DIFFER, V19, P1880, DOI 10.1038/cdd.2012.74; Verfaillie T, 2013, CANCER LETT, V332, P249, DOI 10.1016/j.canlet.2010.07.016; Wang ZQ, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0367-7; Westrate LM, 2015, ANNU REV BIOCHEM, V84, P791, DOI 10.1146/annurev-biochem-072711-163501; Xiong WP, 2016, MOL CANCER THER, V15, P412, DOI 10.1158/1535-7163.MCT-15-0703; Yang LX, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02807-0; Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151; Zhou SQ, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0218-z; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	47	0	0	6	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3394	3408		10.1038/s41388-022-02328-4	http://dx.doi.org/10.1038/s41388-022-02328-4		MAY 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35551503				2022-12-28	WOS:000794082100002
J	Li, DX; Yu, XF; Kottur, J; Gong, WD; Zhang, Z; Storey, AJ; Tsai, YH; Uryu, H; Shen, YD; Byrum, SD; Edmondson, RD; Mackintosh, SG; Cai, L; Liu, ZJ; Aggarwal, AK; Tackett, AJ; Liu, J; Jin, J; Wang, GG				Li, Dongxu; Yu, Xufen; Kottur, Jithesh; Gong, Weida; Zhang, Zhao; Storey, Aaron J.; Tsai, Yi-Hsuan; Uryu, Hidetaka; Shen, Yudao; Byrum, Stephanie D.; Edmondson, Rick D.; Mackintosh, Samuel G.; Cai, Ling; Liu, Zhijie; Aggarwal, Aneel K.; Tackett, Alan J.; Liu, Jing; Jin, Jian; Wang, Gang Greg			Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic	ONCOGENE			English	Article							PROTEIN 5 WDR5; ENZYMATIC-ACTIVITY; STRUCTURAL BASIS; HIGH-AFFINITY; MLL1; DEGRADATION; COMPLEX; RECOGNITION; EXPRESSION; CANCER	WD repeat domain 5 (WDR5), an integral component of the MLL/KMT2A lysine methyltransferase complex, is critically involved in oncogenesis and represents an attractive onco-target. Inhibitors targeting protein-protein interactions (PPIs) between WDR5 and its binding partners, however, do not inhibit all of WDR5-mediated oncogenic functions and exert rather limited antitumor effects. Here, we report a cereblon (CRBN)-recruiting proteolysis targeting chimera (PROTAC) of WDR5, MS40, which selectively degrades WDR5 and the well-established neo-substrates of immunomodulatory drugs (IMiDs):CRBN, the Ikaros zinc finger (IKZF) transcription factors IKZF1 and IKZF3. MS40-induced WDR5 degradation caused disassociation of the MLL/KMT2A complex off chromatin, resulting in decreased H3K4me2. Transcriptomic profiling revealed that targets of both WDR5 and IMiDs:CRBN were significantly repressed by treatment of MS40. In MLL-rearranged leukemias, which exhibit IKZF1 high expression and dependency, co-suppression of WDR5 and Ikaros by MS40 is superior in suppressing oncogenesis to the WDR5 PPI inhibitor, to MS40's non-PROTAC analog controls (MS40N1 and MS40N2, which do not bind CRBN and WDR5, respectively), and to a matched VHL-based WDR5 PROTAC (MS169, which degrades WDR5 but not Ikaros). MS40 suppressed the growth of primary leukemia patient cells in vitro and patient-derived xenografts in vivo. Thus, dual degradation of WDR5 and Ikaros is a promising anti-cancer strategy.	[Li, Dongxu; Gong, Weida; Tsai, Yi-Hsuan; Uryu, Hidetaka; Cai, Ling; Wang, Gang Greg] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Li, Dongxu; Uryu, Hidetaka; Wang, Gang Greg] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27515 USA; [Yu, Xufen; Kottur, Jithesh; Shen, Yudao; Liu, Jing; Jin, Jian] Icahn Sch Med Mt Sinai, Mt Sinai Ctr Therapeut Discovery, New York, NY 10029 USA; [Yu, Xufen; Kottur, Jithesh; Shen, Yudao; Aggarwal, Aneel K.; Liu, Jing; Jin, Jian] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pharmacol Sci, New York, NY 10029 USA; [Yu, Xufen; Kottur, Jithesh; Shen, Yudao; Aggarwal, Aneel K.; Liu, Jing; Jin, Jian] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA; [Zhang, Zhao; Liu, Zhijie] Univ Texas Hlth Sci Ctr San Antonio, Mays Canc Ctr, Dept Mol Med, San Antonio, TX USA; [Storey, Aaron J.; Byrum, Stephanie D.; Edmondson, Rick D.; Mackintosh, Samuel G.; Tackett, Alan J.] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR USA; [Cai, Ling] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [Wang, Gang Greg] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Health San Antonio; University of Arkansas System; University of Arkansas Medical Sciences; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wang, GG (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.; Wang, GG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27515 USA.; Jin, J (corresponding author), Icahn Sch Med Mt Sinai, Mt Sinai Ctr Therapeut Discovery, New York, NY 10029 USA.; Jin, J (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pharmacol Sci, New York, NY 10029 USA.; Jin, J (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA.; Wang, GG (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA.	jian.jin@mssm.edu; greg_wang@med.unc.edu	; Wang, G Greg/L-6666-2014	Kottur, Jithesh/0000-0002-8075-3883; Wang, G Greg/0000-0002-7210-9940; YU, XUFEN/0000-0001-7794-7890	US National Institutes of Health [R01GM122749, P30CA196521, R01CA211336, R01CA215284, R01CA268384, R35GM131780, R24GM137786, P20GM121293, R01CA236209, P20GM103429]; NIH/Office of the Director Grant [S10OD018445, R01GM137009, U54 CA217297/PRJ001]; Icahn School of Medicine at Mount Sinai; Gabrielle's Angel Foundation for Cancer Research; When Everyone Survives (WES) Leukemia Research Foundation; UNC Lineberger Cancer Center UCRF Stimulus Initiative Grants; National Institutes of Health SIG grants [1S10OD025132, 1S10OD028504]; UNC Lineberger Comprehensive Cancer Center Core Support Grant [P30CA016086]	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/Office of the Director Grant; Icahn School of Medicine at Mount Sinai; Gabrielle's Angel Foundation for Cancer Research; When Everyone Survives (WES) Leukemia Research Foundation; UNC Lineberger Cancer Center UCRF Stimulus Initiative Grants; National Institutes of Health SIG grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UNC Lineberger Comprehensive Cancer Center Core Support Grant	We graciously thank Drs. J Bradner, W Kaelin, Y Dou, H Wen, X Shi, and H Jiang for providing reagents and cells used in the study and the Wang and Jin Laboratory members for helpful discussion and technical support. This work was supported in part by the US National Institutes of Health grants R01GM122749 (to JJ), P30CA196521 (to JJ), R01CA211336 (to GGW), R01CA215284 (to GGW), R01CA268384 (to JJ and GGW), R35GM131780 (to AKA), R24GM137786 (to AJT), P20GM121293 (to AJT), R01CA236209 (to AJT), P20GM103429 (to AJT), an NIH/Office of the Director Grant S10OD018445 (to SGM), R01GM137009 (to ZL), U54 CA217297/PRJ001 (to ZL), endowed professorships from the Icahn School of Medicine at Mount Sinai (to JJ and AKA), and grants/awards from Gabrielle's Angel Foundation for Cancer Research (to GGW), When Everyone Survives (WES) Leukemia Research Foundation (to GGW) and UNC Lineberger Cancer Center UCRF Stimulus Initiative Grants (to GGW and LC). G.G.W. is an American Cancer Society Research Scholar, a Leukemia and Lymphoma Society Scholar, and an American Society of Hematology Scholar in Basic Science. This work utilized the NMR Spectrometer Systems at Mount Sinai acquired with funding from National Institutes of Health SIG grants 1S10OD025132 and 1S10OD028504. We thank UNC's facilities, including Highthroughput Sequencing Facility (HTSF), Bioinformatics Core, Tissue Culture Facility, Animal Studies Core, and UNC Tissue Procurement Facility, for their professional assistance in this work. The cores affiliated with the UNC Cancer Center are supported in part by the UNC Lineberger Comprehensive Cancer Center Core Support Grant P30CA016086.	Ahn JH, 2021, NATURE, V595, P591, DOI 10.1038/s41586-021-03662-5; Aho ER, 2019, CELL REP, V26, P2916, DOI 10.1016/j.celrep.2019.02.047; Akuffo AA, 2018, J BIOL CHEM, V293, P6187, DOI 10.1074/jbc.M117.816868; Alicea-Velazquez NL, 2016, J BIOL CHEM, V291, P22357, DOI 10.1074/jbc.M116.752626; An J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15398; Bolshan Y, 2013, ACS MED CHEM LETT, V4, P353, DOI 10.1021/ml300467n; Cai L, 2018, MOL CELL, V72, P341, DOI 10.1016/j.molcel.2018.08.029; Cao F, 2014, MOL CELL, V53, P247, DOI 10.1016/j.molcel.2013.12.001; Carugo A, 2016, CELL REP, V16, P133, DOI 10.1016/j.celrep.2016.05.063; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Ciceri P, 2014, NAT CHEM BIOL, V10, P305, DOI 10.1038/nchembio.1471; Dale B, 2021, NAT REV CANCER, V21, P638, DOI 10.1038/s41568-021-00365-x; Dawson MA, 2017, SCIENCE, V355, P1147, DOI 10.1126/science.aam7304; Dharmarajan V, 2012, J BIOL CHEM, V287, P27275, DOI 10.1074/jbc.M112.364125; Dobrovolsky D, 2019, BLOOD, V133, P952, DOI 10.1182/blood-2018-07-862953; Dolle A, 2021, J MED CHEM, V64, P10682, DOI 10.1021/acs.jmedchem.1c00146; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Egan B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166438; Fan HT, 2020, NAT GENET, V52, P1384, DOI 10.1038/s41588-020-00729-3; Gadd MS, 2017, NAT CHEM BIOL, V13, P514, DOI [10.1038/nchembio.2329, 10.1038/NCHEMBIO.2329]; Ge Z, 2016, ONCOTARGET, V7, P37740, DOI 10.18632/oncotarget.9312; Getlik M, 2016, J MED CHEM, V59, P2478, DOI 10.1021/acs.jmedchem.5b01630; Grebien F, 2015, NAT CHEM BIOL, V11, P571, DOI [10.1038/nchembio.1859, 10.1038/NCHEMBIO.1859]; Guarnaccia AD, 2018, J CLIN MED, V7, DOI 10.3390/jcm7020021; Ishoey M, 2018, ACS CHEM BIOL, V13, P553, DOI 10.1021/acschembio.7b00969; Jin J, 2019, WD40 REPEAT DOMAIN PROTEIN 5 (WDR5) DEGRADATION/DISRUPTION COMPOUNDS AND METHODS OF USE, Patent No. [WO2019246570, 2019246570]; Karatas H, 2017, J MED CHEM, V60, P4818, DOI 10.1021/acs.jmedchem.6b01796; Karatas H, 2013, J AM CHEM SOC, V135, P669, DOI 10.1021/ja306028q; Kronke J, 2015, NATURE, V523, P183, DOI 10.1038/nature14610; Lai AC, 2017, NAT REV DRUG DISCOV, V16, P101, DOI 10.1038/nrd.2016.211; Li DD, 2016, EUR J MED CHEM, V124, P480, DOI 10.1016/j.ejmech.2016.08.036; Li JX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21293-2; Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Lu R, 2016, CANCER CELL, V30, P92, DOI 10.1016/j.ccell.2016.05.008; Macdonald JD, 2019, J MED CHEM, V62, P11232, DOI 10.1021/acs.jmedchem.9b01411; Matyskiela ME, 2016, NATURE, V535, P252, DOI 10.1038/nature18611; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; MORI T, 2018, SCI REP-UK, V8; Odho Z, 2010, J BIOL CHEM, V285, P32967, DOI 10.1074/jbc.M110.159921; Park I, 2021, CANCERS, V13, DOI 10.3390/cancers13205084; Patel A, 2008, J BIOL CHEM, V283, P32162, DOI 10.1074/jbc.M806317200; Patel A, 2008, J BIOL CHEM, V283, P32158, DOI 10.1074/jbc.C800164200; Patel A, 2011, J BIOL CHEM, V286, P3359, DOI 10.1074/jbc.M110.174524; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Ren ZH, 2019, BLOOD, V134, P1176, DOI 10.1182/blood.2019000578; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Romanelli A, 2020, ACS MED CHEM LETT, V11, P977, DOI 10.1021/acsmedchemlett.0c00014; Schapira M, 2019, NAT REV DRUG DISCOV, V18, P949, DOI 10.1038/s41573-019-0047-y; Senisterra G, 2013, BIOCHEM J, V449, P151, DOI 10.1042/BJ20121280; Simon SC, 2020, J MED CHEM, V63, P4315, DOI 10.1021/acs.jmedchem.0c00224; Steward MM, 2006, NAT STRUCT MOL BIOL, V13, P852, DOI 10.1038/nsmb1131; Sun YT, 2015, CANCER RES, V75, P5143, DOI 10.1158/0008-5472.CAN-15-0423; Thomas LR, 2015, MOL CELL, V58, P440, DOI 10.1016/j.molcel.2015.02.028; Tian J, 2020, J MED CHEM, V63, P656, DOI 10.1021/acs.jmedchem.9b01608; Townsend EC, 2016, CANCER CELL, V29, P574, DOI 10.1016/j.ccell.2016.03.008; Trievel RC, 2009, NAT STRUCT MOL BIOL, V16, P678, DOI 10.1038/nsmb0709-678; Wang F, 2018, J MED CHEM, V61, P5623, DOI 10.1021/acs.jmedchem.8b00375; Xia RL, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.788440; Xu BW, 2015, BLOOD, V125, P346, DOI 10.1182/blood-2014-06-581082; Xu J, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.8; YU X, 2021, SCI TRANSL MED, V13; Zhao S, 2021, NAT REV CANCER, V21, P413, DOI 10.1038/s41568-021-00357-x; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	64	3	3	13	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3328	3340		10.1038/s41388-022-02340-8	http://dx.doi.org/10.1038/s41388-022-02340-8		MAY 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35525905	Green Accepted			2022-12-28	WOS:000791911500001
J	Koppenhafer, SL; Goss, KL; Voigt, E; Croushore, E; Terry, WW; Ostergaard, J; Gordon, PM; Gordon, DJ				Koppenhafer, Stacia L.; Goss, Kelli L.; Voigt, Ellen; Croushore, Emma; Terry, William W.; Ostergaard, Jason; Gordon, Peter M.; Gordon, David J.			Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in ewing sarcoma	ONCOGENE			English	Article							LOOP-HELIX PROTEIN; MYELOID-LEUKEMIA; FUSION PROTEINS; UP-REGULATION; STEM-CELLS; DIFFERENTIATION; TARGET; INITIATION; FAMILY; OVEREXPRESSION	Sarcomas are difficult to treat and the therapy, even when effective, is associated with long-term and life-threatening side effects. In addition, the treatment regimens for many sarcomas, including Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma, are relatively unchanged over the past two decades, indicating a critical lack of progress. Although differentiation-based therapies are used for the treatment of some cancers, the application of this approach to sarcomas has proven challenging. Here, using a CRISPR-mediated gene knockout approach, we show that Inhibitor of DNA Binding 2 (ID2) is a critical regulator of developmental-related genes and tumor growth in vitro and in vivo in Ewing sarcoma tumors. We also identified that homoharringtonine, which is an inhibitor of protein translation and FDA-approved for the treatment of leukemia, decreases the level of the ID2 protein and significantly reduces tumor growth and prolongs mouse survival in an Ewing sarcoma xenograft model. Furthermore, in addition to targeting ID2, homoharringtonine also reduces the protein levels of ID1 and ID3, which are additional members of the ID family of proteins with well-described roles in tumorigenesis, in multiple types of cancer. Overall, these results provide insight into developmental regulation in Ewing sarcoma tumors and identify a novel, therapeutic approach to target the ID family of proteins using an FDA-approved drug.	[Koppenhafer, Stacia L.; Goss, Kelli L.; Croushore, Emma; Terry, William W.; Gordon, David J.] Univ Iowa, Div Pediat Hematol Oncol, Dept Pediat, Iowa City, IA 52242 USA; [Voigt, Ellen] Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA; [Ostergaard, Jason; Gordon, Peter M.] Univ Minnesota, Div Pediat Hematol Oncol, Dept Pediat, Minneapolis, MN 55455 USA	University of Iowa; University of Iowa; University of Minnesota System; University of Minnesota Twin Cities	Gordon, DJ (corresponding author), Univ Iowa, Div Pediat Hematol Oncol, Dept Pediat, Iowa City, IA 52242 USA.	david-j-gordon@uiowa.edu		Gordon, David/0000-0003-1830-4371; Croushore, Emma/0000-0002-8029-9289	University of Iowa Dance Marathon Award; Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant; Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation; Aiming for a Cure; NIH [R37-CA217910]; NCI [P30CA086862]; University of Iowa Carver College of Medicine; Holden Comprehensive Cancer Center (NCI) [P30CA086862]	University of Iowa Dance Marathon Award; Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant; Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation; Aiming for a Cure; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Iowa Carver College of Medicine; Holden Comprehensive Cancer Center (NCI)	We would like to acknowledge Henry Keen for assistance with the analysis of the RNAseq data. DJG is supported by a University of Iowa Dance Marathon Award, a Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant, Sammy's Superheroes, The Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation, Aiming for a Cure, and NIH Grant R37-CA217910. This work was also supported by a grant (P30CA086862) from the NCI, administered through the Holden Comprehensive Cancer Center at The University of Iowa. The authors would like to acknowledge use of the University of Iowa Flow Cytometry Facility and the DNA sequencing facility (Genomics Division of the Iowa Institute of Human Genetics) which are supported, in part, by the University of Iowa Carver College of Medicine and the Holden Comprehensive Cancer Center (NCI P30CA086862).	Bae WJ, 2017, BRIT J CANCER, V117, P1810, DOI 10.1038/bjc.2017.373; Bajikar SS, 2017, DEV CELL, V43, P418, DOI 10.1016/j.devcel.2017.10.027; Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Behjati S, 2021, CANCER DISCOV, V11, P542, DOI 10.1158/2159-8290.CD-20-0926; Bell BA, 2001, MED PEDIATR ONCOL, V37, P103, DOI 10.1002/mpo.1177; BENEZRA R, 1990, ANN NY ACAD SCI, V599, P1, DOI 10.1111/j.1749-6632.1990.tb42359.x; Benezra R, 2001, BBA-REV CANCER, V1551, pF39, DOI 10.1016/S0304-419X(01)00028-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Chen XX, 2019, FRONT MED-PRC, V13, P378, DOI 10.1007/s11684-018-0658-4; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Ehrlich M, 2017, P NATL ACAD SCI USA, V114, pE2243, DOI 10.1073/pnas.1614412114; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Gordon DJ, 2016, ONCOGENE, V35, P3092, DOI 10.1038/onc.2015.368; Goss KL, 2021, ONCOGENE, V40, P564, DOI 10.1038/s41388-020-01552-0; Goss KL, 2017, ONCOTARGET, V8, P87016, DOI 10.18632/oncotarget.18776; Goss KL, 2016, ONCOTARGET, V7, P63003, DOI 10.18632/oncotarget.11416; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Hao L, 2016, BIOCHEM BIOPH RES CO, V470, P643, DOI 10.1016/j.bbrc.2016.01.090; Howard TP, 2020, CLIN CANCER RES, V26, P4995, DOI 10.1158/1078-0432.CCR-19-2717; Huang YH, 2020, CANCER DISCOV, V10, P142, DOI 10.1158/2159-8290.CD-19-0529; Hwang DH, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-117; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Islam MS, 2009, NEUROCHEM INT, V54, P192, DOI 10.1016/j.neuint.2008.10.011; Jen Y, 1996, DEV DYNAM, V207, P235; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jin J, 2013, LANCET ONCOL, V14, P599, DOI 10.1016/S1470-2045(13)70152-9; Keenan AB, 2019, NUCLEIC ACIDS RES, V47, pW212, DOI 10.1093/nar/gkz446; Khoury JD, 2005, ADV ANAT PATHOL, V12, P212, DOI 10.1097/01.pap.0000175114.55541.52; Koppenhafer SL, 2018, MOL CANCER THER, V17, P2676, DOI 10.1158/1535-7163.MCT-18-0260; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lachmann A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03751-6; Lam SSY, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf3735; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lasorella A, 2002, CANCER RES, V62, P301; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638; Leacock SW, 2012, DIS MODEL MECH, V5, P95, DOI 10.1242/dmm.007401; Lee J, 2006, BLOOD, V107, P2686, DOI 10.1182/blood-2005-07-2798; Lessnick SL, 2012, ANNU REV PATHOL-MECH, V7, P145, DOI 10.1146/annurev-pathol-011110-130237; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Maire CL, 2010, STEM CELLS, V28, P1611, DOI 10.1002/stem.480; Maire CL, 2009, J NEUROSCI RES, V87, P3438, DOI 10.1002/jnr.22194; Meng J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2327-1; Merritt N, 2021, ELIFE, V10, DOI 10.7554/eLife.62857; Mistry H, 2013, MOL CANCER THER, V12, P2651, DOI 10.1158/1535-7163.MCT-13-0103-T; Nair R, 2014, MOL THER, V22, P1407, DOI 10.1038/mt.2014.83; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Ohmura S, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01393-9; Park HR, 2006, TUMORI, V92, P236, DOI 10.1177/030089160609200309; Patel AV, 2016, EBIOMEDICINE, V9, P110, DOI 10.1016/j.ebiom.2016.06.007; Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Potikyan G, 2008, LAB INVEST, V88, P1291, DOI 10.1038/labinvest.2008.99; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Riggi N, 2009, EXPERT REV ANTICANC, V9, P1025, DOI 10.1586/ERA.09.81; Roschger C, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-016-0161-y; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sachdeva R, 2019, CANCER RES, V79, P4057, DOI 10.1158/0008-5472.CAN-18-1357; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Schwentner R, 2017, ONCOTARGET, V8, P10980, DOI 10.18632/oncotarget.14091; Sole A, 2021, CANCER RES, V81, P4994, DOI 10.1158/0008-5472.CAN-20-3837; Svoboda LK, 2014, EPIGENETICS-US, V9, P1613, DOI 10.4161/15592294.2014.988048; Szu J, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.659601; Tam WF, 2008, BLOOD, V112, P1981, DOI 10.1182/blood-2007-07-103010; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Torchia EC, 2003, CANCER RES, V63, P3464; Toretsky JA, 2006, CANCER RES, V66, P5574, DOI 10.1158/0008-5472.CAN-05-3293; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Veerasamy M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051842; Venneti S, 2011, AM J SURG PATHOL, V35, P1463, DOI 10.1097/PAS.0b013e318224d2cd; von Levetzow C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019305; Wang L, 2015, BLOOD, V126, P640, DOI 10.1182/blood-2015-03-635532; Waters T, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07668-6; Williams SA, 2011, CELL, V146, P917, DOI 10.1016/j.cell.2011.07.040; Winer ES, 2018, ONCOL THER, V6, P9, DOI 10.1007/s40487-018-0058-6; Wojnarowicz PM, 2021, NPJ BREAST CANCER, V7, DOI 10.1038/s41523-021-00266-0; Wojnarowicz PM, 2019, CELL REP, V29, P62, DOI 10.1016/j.celrep.2019.08.073; Zhang CX, 2020, CANCER-AM CANCER SOC, V126, P344, DOI 10.1002/cncr.32534; Zhao GS, 2019, AM J TRANSL RES, V11, P2117; Zhao ZX, 2020, INT J MED SCI, V17, P995, DOI 10.7150/ijms.42805; Zhao ZY, 2015, TUMOR BIOL, V36, P4189, DOI 10.1007/s13277-015-3055-5; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	93	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2873	2884		10.1038/s41388-022-02310-0	http://dx.doi.org/10.1038/s41388-022-02310-0		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35422476	Green Accepted			2022-12-28	WOS:000782543300002
J	Lin, HY; Ko, CJ; Lo, TY; Wu, SR; Lan, SW; Huang, CA; Lin, YC; Lin, HH; Tu, HF; Lee, CF; Hsiao, PW; Huang, HP; Chen, MJ; Chang, KH; Lee, MS				Lin, Hsin-Ying; Ko, Chun-Jung; Lo, Tzu-Yu; Wu, Shang-Ru; Lan, Shao-Wei; Huang, Chen-An; Lin, Yi-Chin; Lin, Hsin-Hsien; Tu, Hsin-Fang; Lee, Cheng-Fan; Hsiao, Pei-Wen; Huang, Hsiang-Po; Chen, Mei-Jou; Chang, Kai-Hsiung; Lee, Ming-Shyue			Matriptase-2/NR4A3 axis switches TGF-beta action toward suppression of prostate cancer cell invasion, tumor growth, and metastasis	ONCOGENE			English	Article							SERINE-PROTEASE MATRIPTASE-2; UROKINASE PLASMINOGEN-ACTIVATOR; ORPHAN NUCLEAR RECEPTORS; BREAST-CANCER; IN-VITRO; IRON; TMPRSS6; SMAD2; EXPRESSION; PROGNOSIS	Dysregulation of pericellular proteolysis is strongly implicated in cancer metastasis through alteration of cell invasion and the microenvironment. Matriptase-2 (MT-2) is a membrane-anchored serine protease which can suppress prostate cancer (PCa) cell invasion. In this study, we showed that MT-2 was down-regulated in PCa and could suppress PCa cell motility, tumor growth, and metastasis. Using microarray and biochemical analysis, we found that MT-2 shifted TGF-beta action towards its tumor suppressor function by repressing epithelial-to-mesenchymal transition (EMT) and promoting Smad2 phosphorylation and nuclear accumulation to upregulate two TGF-beta 1 downstream effectors (p21 and PAI-1), culminating in hindrance of PCa cell motility and malignant growth. Mechanistically, MT-2 could dramatically up-regulate the expression of nuclear receptor NR4A3 via iron metabolism in PCa cells. MT-2-induced NR4A3 further coactivated Smad2 to activate p21 and PAI-1 expression. In addition, NR4A3 functioned as a suppressor of PCa and mediated MT-2 signaling to inhibit PCa tumorigenesis and metastasis. These results together indicate that NR4A3 sustains MT-2 signaling to suppress PCa cell invasion, tumor growth, and metastasis, and serves as a contextual factor for the TGF-beta/Smad2 signaling pathway in favor of tumor suppression via promoting p21 and PAI-1 expression.	[Lin, Hsin-Ying; Ko, Chun-Jung; Lo, Tzu-Yu; Wu, Shang-Ru; Lan, Shao-Wei; Huang, Chen-An; Lin, Yi-Chin; Lin, Hsin-Hsien; Tu, Hsin-Fang; Lee, Cheng-Fan; Lee, Ming-Shyue] Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, Taipei, Taiwan; [Hsiao, Pei-Wen] Acad Sinica, Agr Biotechnol Res Ctr, Taipei, Taiwan; [Huang, Hsiang-Po] Natl Taiwan Univ, Coll Med, Grad Inst Med Genom & Prote, Taipei, Taiwan; [Chen, Mei-Jou] Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan; [Chang, Kai-Hsiung] Natl Hlth Res Inst, Inst Cellular & Syst Med, Miaoli, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Health Research Institutes - Taiwan	Lee, MS (corresponding author), Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, Taipei, Taiwan.	mslee2006@ntu.edu.tw	Tu, Hsin-Fang/HGA-9284-2022	CHEN, MEI-JOU/0000-0002-2305-1105; Ko, Chun-Jung/0000-0001-6565-7060	National Health Research Institutes grants [NHRI-EX106-10401BI, NHRI-EX109-10725BI]; Ministry of Science and Technology grants [MOST 104-2320-B-002-044-MY3, MOST 105-2911-I-002-521, MOST 106-2320-B-002-046-MY3, MOST 108-2320-B-002-024-MY3, MOST 110-2320-B-002-067-MY3]; National Taiwan University grants [NTU105R89612, NTU107L890504, NTU110L893503]; NTUH Grant [UN110-029]	National Health Research Institutes grants; Ministry of Science and Technology grants; National Taiwan University grants; NTUH Grant	We appreciate the service of the First Core Laboratory of National Taiwan University College of Medicine. We thank the Laboratory Animal Core Facility (ABRC, Academia Sinica) for their services and Ms. Miranda Loney (Editor, ABRC) for critical suggestions for editing this article. This study was supported by National Health Research Institutes grants NHRI-EX106-10401BI and NHRI-EX109-10725BI, Ministry of Science and Technology grants MOST 104-2320-B-002-044-MY3, MOST 105-2911-I-002-521, MOST 106-2320-B-002-046-MY3 and MOST 108-2320-B-002-024-MY3, MOST 110-2320-B-002-067-MY3, National Taiwan University grants NTU105R89612, NTU107L890504 and NTU110L893503 to M.S. Lee, and NTUH Grant UN110-029 to M.J. Chen and M.S. Lee.	Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Bohm L, 2013, J CANCER RES CLIN, V139, P1221, DOI 10.1007/s00432-013-1428-y; Buck A, 2006, MOL CANCER RES, V4, P861, DOI 10.1158/1541-7786.MCR-06-0081; Cheng MF, 2017, APPL IMMUNOHISTO M M, V25, P481, DOI 10.1097/PAI.0000000000000324; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Deutsch AJA, 2017, CANCER RES, V77, P2375, DOI 10.1158/0008-5472.CAN-16-2320; Dong-Le Bourhis X, 1998, BRIT J CANCER, V77, P396, DOI 10.1038/bjc.1998.63; Duffy MJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0428-4; Duffy MJ, 2004, CURR PHARM DESIGN, V10, P39, DOI 10.2174/1381612043453559; Fedorova O, 2019, ONCOGENE, V38, P2108, DOI 10.1038/s41388-018-0566-8; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Folgueras AR, 2008, BLOOD, V112, P2539, DOI 10.1182/blood-2008-04-149773; Graham CH, 1997, PLACENTA, V18, P137, DOI 10.1016/S0143-4004(97)90085-0; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Heldin CH, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022053; Huynh LK, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110743; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kwaan HC, 2013, SEMIN THROMB HEMOST, V39, P382, DOI 10.1055/s-0033-1338127; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Mullican SE, 2007, NAT MED, V13, P730, DOI 10.1038/nm1579; Palumbo-Zerr K, 2015, NAT MED, V21, P150, DOI 10.1038/nm.3777; Parr C, 2007, CLIN CANCER RES, V13, P3568, DOI 10.1158/1078-0432.CCR-06-2357; Perttu MC, 2006, PROSTATE CANCER P D, V9, P185, DOI 10.1038/sj.pcan.4500871; Petersen M, 2010, ONCOGENE, V29, P1351, DOI 10.1038/onc.2009.426; Ramsay AJ, 2008, FRONT BIOSCI-LANDMRK, V13, P569, DOI 10.2741/2702; Ranhotra HS, 2015, J RECEPT SIG TRANSD, V35, P184, DOI 10.3109/10799893.2014.948555; Riggins GJ, 1997, CANCER RES, V57, P2578; Rodriguez-Calvo R, 2017, EXPERT OPIN THER TAR, V21, P291, DOI 10.1080/14728222.2017.1279146; Safe S, 2014, MOL ENDOCRINOL, V28, P157, DOI 10.1210/me.2013-1291; Sanchez M, 2011, BLOOD, V118, pE168, DOI 10.1182/blood-2011-04-343541; Sanders AJ, 2008, J CELL PHYSIOL, V216, P780, DOI 10.1002/jcp.21460; Santibanez JF, 2006, FEBS LETT, V580, P5385, DOI 10.1016/j.febslet.2006.09.003; Sevenich L, 2014, GENE DEV, V28, P2331, DOI 10.1101/gad.250647.114; Silvestri L, 2008, CELL METAB, V8, P502, DOI 10.1016/j.cmet.2008.09.012; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Tu WH, 2003, NEOPLASIA, V5, P267, DOI 10.1016/S1476-5586(03)80058-1; Tuhkanen H, 2013, INT J CANCER, V133, P2334, DOI 10.1002/ijc.28254; Vela D, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.273; Wang GC, 2018, GENE DEV, V32, P1105, DOI 10.1101/gad.315739.118; Webb SL, 2012, ONCOL REP, V28, P1491, DOI 10.3892/or.2012.1945; Xu J, 2015, CANCER CELL, V27, P177, DOI 10.1016/j.ccell.2014.11.025; Yeh CM, 2016, SCI REP-UK, V6, DOI 10.1038/srep31690; Yeh HW, 2019, CANCER RES, V79, P3797, DOI 10.1158/0008-5472.CAN-18-2019; Yeh HW, 2018, NAT CELL BIOL, V20, P479, DOI 10.1038/s41556-018-0062-y; Ying Z, 2017, J CLIN INVEST, V127, P1725, DOI 10.1172/JCI90439; Zhao XG, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1705-z	51	0	0	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2833	2845		10.1038/s41388-022-02303-z	http://dx.doi.org/10.1038/s41388-022-02303-z		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35418692				2022-12-28	WOS:000783468200003
J	Xu, LM; Zhang, J; Ma, Y; Yuan, YJ; Yu, H; Wang, J; Cao, XC; Zhu, L; Wang, P				Xu, Li-Ming; Zhang, Jiao; Ma, Yue; Yuan, Ya-Jing; Yu, Hao; Wang, Jun; Cao, Xu-Chen; Zhu, Li; Wang, Ping			MicroRNA-135 inhibits initiation of epithelial-mesenchymal transition in breast cancer by targeting ZNF217 and promoting m6A modification of NANOG	ONCOGENE			English	Article							CELL-PROLIFERATION; STEM-CELLS; TRANSCRIPTION; BIOMARKER; ONCOGENE	MicroRNAs play significant roles in various malignancies, with breast cancer (BC) being no exception. Consequently, we explored the functional mechanism of miR-135 in the progression of BC. In total, 55 pairs of BC and matched adjacent normal tissues were clinically collected from patients, followed by quantification of miR-135 and zinc finger protein 217 (ZNF217) expression patterns in BC tissues and cells. Accordingly, high ZNF217 expression and low miR-135 expression levels were identified in BC tissues and cells. Subsequently, the expressions of miR-135 and ZNF217 were altered to evaluate their effects on BC cell migration, invasion and EMT initiation. It was found that when ZNF217 was silenced or miR-135 was elevated, BC cell malignant behaviors were significantly inhibited, which was reproduced in nude mice for in vivo evidence. Furthermore, dual-luciferase reporter gene assay revealed the presence of direct binding between miR-135 and ZNF217. Subsequent co-immunoprecipitation, methylated-RNA binding protein immunoprecipitation and photoactivatable ribonucleoside enhanced-crosslinking and immunoprecipitation assays further revealed that ZNF217 could upregulate NANOG by reducing N6-methyladenosine levels via methyltransferase-like 13 (METTL3). Collectively, our findings highlighted the role of the miR-135/ZNF217/METTL3/NANOG axis in the progression of BC, emphasizing potential therapeutic targets ZNF217 silencing and miR-135 upregulation in preventing or treating BC.	[Xu, Li-Ming; Yu, Hao; Wang, Jun; Zhu, Li; Wang, Ping] Tianjin Med Univ, Minist Educ,Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc,Key Lab Breast Canc Preven, Dept Radiotherapy,Tianjins Clin Res Ctr Canc,Key, Tianjin 300060, Peoples R China; [Xu, Li-Ming; Wang, Jun] Tianjin Med Univ, Dept Radiotherapy, Canc Hosp, Airport Hosp, Tianjin 300308, Peoples R China; [Zhang, Jiao; Ma, Yue; Cao, Xu-Chen] Tianjin Med Univ, Minist Educ,Tianjins Clin Res Ctr Canc,Key Lab Br, Dept Breast Canc 1,Key Lab Canc Prevent & Therapy, Tianjin Med Univ Canc Inst & Hosp,Natl Clin Res C, Tianjin 300060, Peoples R China; [Zhang, Jiao] Zhengzhou Univ, Henan Breast Canc Ctr, Dept Breast Dis, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China; [Zhang, Jiao] Henan Canc Hosp, Zhengzhou 450008, Peoples R China; [Yuan, Ya-Jing] Tianjin Med Univ Canc Inst & Hosp, Dept Anesthesia, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Tianjins Clin Res, Tianjin 300060, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Zhengzhou University; Zhengzhou University; Tianjin Medical University	Zhu, L; Wang, P (corresponding author), Tianjin Med Univ, Minist Educ,Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc,Key Lab Breast Canc Preven, Dept Radiotherapy,Tianjins Clin Res Ctr Canc,Key, Tianjin 300060, Peoples R China.; Cao, XC (corresponding author), Tianjin Med Univ, Minist Educ,Tianjins Clin Res Ctr Canc,Key Lab Br, Dept Breast Canc 1,Key Lab Canc Prevent & Therapy, Tianjin Med Univ Canc Inst & Hosp,Natl Clin Res C, Tianjin 300060, Peoples R China.	xlm19821223@126.com; zhuli@tjmuch.com; wangping@tjmuch.com			National Natural Science Foundation of China [81502656, 81501140]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (No. 81502656 and No. 81501140).	Aguilo F, 2015, CELL STEM CELL, V17, P689, DOI 10.1016/j.stem.2015.09.005; Akram M, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0140-9; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P1; Ayuk SM, 2016, J PHOTOCH PHOTOBIO B, V161, P368, DOI 10.1016/j.jphotobiol.2016.05.027; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; Bellanger A, 2017, J PATHOL, V242, P73, DOI 10.1002/path.4882; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cohen PA, 2015, ONCOTARGET, V6, P41566, DOI 10.18632/oncotarget.5893; Gibadulinova A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124299; Goh JN, 2016, BIOL REV, V91, P409, DOI 10.1111/brv.12176; Hamam R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.440; Horne HN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23733-4; Hu C, 2016, J DRUG TARGET, V24, P422, DOI 10.3109/1061186X.2015.1082567; Jiang DQ, 2019, INT J MOL MED, V43, P1623, DOI 10.3892/ijmm.2019.4081; Jiang XK, 2016, ONCOTARGET, V7, P84893, DOI 10.18632/oncotarget.12753; Suarez-Sanchez FJ, 2021, CANCERS, V13, DOI 10.3390/cancers13030395; Kocak A, 2020, AM J PATHOL, V190, P1643, DOI 10.1016/j.ajpath.2020.04.015; Li F, 2020, MOL THER-NUCL ACIDS, V22, P456, DOI 10.1016/j.omtn.2020.09.008; Li ZW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116170; Lin CH, 2018, ONCOTARGETS THER, V11, P5419, DOI 10.2147/OTT.S164575; Littlepage LE, 2012, CANCER DISCOV, V2, P638, DOI 10.1158/2159-8290.CD-12-0093; McGuire A, 2015, CANCER METAST REV, V34, P145, DOI 10.1007/s10555-015-9551-7; Qin S, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160247; Qiu Y, 2018, ONCOL REP, V39, P138, DOI 10.3892/or.2017.6081; Rezaei M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3367; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Smith BN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104987; Sun YS, 2017, INT J BIOL SCI, V13, P1387, DOI 10.7150/ijbs.21635; Taipaleenmaki H, 2015, CANCER RES, V75, P1433, DOI 10.1158/0008-5472.CAN-14-1026; Vendrell JA, 2012, CANCER RES, V72, P3593, DOI 10.1158/0008-5472.CAN-11-3095; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang L, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10030457; Wang XW, 2020, BREAST CANCER-TOKYO, V27, P765, DOI 10.1007/s12282-020-01075-2; Yamada Y, 2013, CANCER SCI, V104, P304, DOI 10.1111/cas.12072; Yang DD, 2018, NUCLEIC ACIDS RES, V46, P3906, DOI 10.1093/nar/gky130; Yang Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08759-0; Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017; Zhang CZ, 2016, ONCOTARGET, V7, P64527, DOI 10.18632/oncotarget.11743; Zhao M, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317691682	40	2	2	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1742	1751		10.1038/s41388-022-02211-2	http://dx.doi.org/10.1038/s41388-022-02211-2		FEB 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35121826				2022-12-28	WOS:000751251500002
J	Han, AN; Chua, V; Baqai, U; Purwin, TJ; Bechtel, N; Hunter, E; Tiago, M; Seifert, E; Speicher, DW; Schug, ZT; Harbour, JW; Aplin, AE				Han, Anna; Chua, Vivian; Baqai, Usman; Purwin, Timothy J.; Bechtel, Nelisa; Hunter, Emily; Tiago, Manoela; Seifert, Erin; Speicher, David W.; Schug, Zachary T.; Harbour, J. William; Aplin, Andrew E.			Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma	ONCOGENE			English	Article							TCA CYCLE; METABOLISM; GENE; PHOSPHORYLATION; VALIDATION; EXPRESSION; UTILITY; KRAS	Effective therapeutic options are still lacking for uveal melanoma (UM) patients who develop metastasis. Metastatic traits of UM are linked to BRCA1-associated protein 1 (BAP1) mutations. Cell metabolism is re-programmed in UM with BAP1 mutant UM, but the underlying mechanisms and opportunities for therapeutic intervention remain unclear. BAP1 mutant UM tumors have an elevated glycolytic gene expression signature, with increased expression of pyruvate dehydrogenase (PDH) complex and PDH kinase (PDHK1). Furthermore, BAP1 mutant UM cells showed higher levels of phosphorylated PDHK1 and PDH that was associated with an upregulated glycolytic profile compared to BAP1 wild-type UM cells. Suppressing PDHK1-PDH phosphorylation decreased glycolytic capacity and cell growth, and induced cell cycle arrest of BAP1 mutant UM cells. Our results suggest that PDHK1-PDH phosphorylation is a causative factor of glycolytic phenotypes found in BAP1 mutant UM and propose a therapeutic opportunity for BAP1 mutant UM patients.	[Han, Anna; Chua, Vivian; Baqai, Usman; Purwin, Timothy J.; Bechtel, Nelisa; Hunter, Emily; Tiago, Manoela; Aplin, Andrew E.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Han, Anna] Jeonbuk Natl Univ, Dept Food Sci & Human Nutr, Jeonju 54896, Jeollabuk Do, South Korea; [Seifert, Erin] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; [Speicher, David W.] Wistar Inst Anat & Biol, Prote & Metabol Facil, Philadelphia, PA 19104 USA; [Speicher, David W.; Schug, Zachary T.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; [Harbour, J. William] Univ Miami, Sylvester Comprehens Canc Ctr, Bascom Palmer Eye Inst, Miami, FL 33146 USA; [Harbour, J. William] Univ Miami, Interdisciplinary Stem Cell Inst, Miller Sch Med, Miami, FL 33146 USA; [Harbour, J. William] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dept Ophthalmol, Dallas, TX 75390 USA; [Aplin, Andrew E.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jeonbuk National University; Jeonbuk National University Hospital; Jefferson University; The Wistar Institute; The Wistar Institute; Bascom Palmer Eye Institute; University of Miami; University of Miami; University of Texas System; University of Texas Southwestern Medical Center Dallas; Jefferson University	Aplin, AE (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA.	Andrew.Aplin@Jefferson.edu		Schug, Zachary/0000-0003-4197-8227; Purwin, Timothy/0000-0002-7053-8039	Cancer Center Support Grant [5P30CA056036-17]; National Institutes of Health (NIH)/National Cancer Institute (NCI) [R01 CA196278, R01 CA253977, P01 CA114046]; Melanoma Research Alliance team science award [559058]; American Association for Cancer Research (AACR)/Ocular Melanoma Foundation (OMF);  [P30CA010815];  [P01CA140043];  [S10OD023586]	Cancer Center Support Grant; National Institutes of Health (NIH)/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Melanoma Research Alliance team science award; American Association for Cancer Research (AACR)/Ocular Melanoma Foundation (OMF); ; ; 	The Cancer Center Support Grant 5P30CA056036-17 to the SKCC supported the Microscopy Shared Resource facility. We thank Dr. Bruce Ksander (Schepens Eye Research Institute, Boston, MA), Dr. Martine Jager (Leiden University, Leiden, The Netherlands), and Dr. Sergio Roman-Roman (Institute Curie, Paris, France) for cell lines. We are grateful to Dr. Michael Durante (University of Miami Miller School of Medicine, Miami, FL) for his help with single-cell RNA-Seq data and Dr. Hsin-Yao Tang (The Wistar Institute, Philadelphia, PA) for metabolomic analyses. This work was supported by National Institutes of Health (NIH)/National Cancer Institute (NCI) grants R01 CA196278, R01 CA253977, and P01 CA114046 to AEA. This work also was supported by a Melanoma Research Alliance team science award (#559058) to AEA and JWH. The Wistar Proteomics and Metabolomics Facility was supported by P30CA010815, P01CA140043, and S10OD023586. Further support was from the American Association for Cancer Research (AACR)/Ocular Melanoma Foundation (OMF) awarded to AH.	Agarwal E, 2019, J BIOL CHEM, V294, P10407, DOI 10.1074/jbc.AC119.008656; Amirouchene-Angelozzi N, 2014, MOL ONCOL, V8, P1508, DOI 10.1016/j.molonc.2014.06.004; Attrill H, 2019, DATABASE-OXFORD, DOI 10.1093/database/baz007; Baughman JM, 2016, CELL REP, V16, P583, DOI 10.1016/j.celrep.2016.05.096; Bononi A, 2017, CELL DEATH DIFFER, V24, P1694, DOI 10.1038/cdd.2017.95; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cai Z, 2020, MOL CELL, V80, P263, DOI 10.1016/j.molcel.2020.09.018; Carbone M, 2020, CANCER DISCOV, V10, P1103, DOI 10.1158/2159-8290.CD-19-1220; Carvajal RD, 2018, J CLIN ONCOL, V36, P1232, DOI 10.1200/JCO.2017.74.1090; Chattopadhyay C, 2019, INVEST OPHTH VIS SCI, V60, P4187, DOI 10.1167/iovs.19-28082; Chen CY, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00338; Cheng HY, 2017, MOL CANCER THER, V16, P516, DOI 10.1158/1535-7163.MCT-16-0552; Chua V, 2022, PIGM CELL MELANOMA R, V35, P78, DOI 10.1111/pcmr.13007; Chua V, 2021, CLIN CANCER RES, V27, P28, DOI 10.1158/1078-0432.CCR-20-2536; Chua V, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809081; Chua V, 2018, CURR OPIN ONCOL, V30, P134, DOI 10.1097/CCO.0000000000000425; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Di Nunno V, 2019, FUTURE ONCOL, V15, P2151, DOI 10.2217/fon-2018-0915; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Durante MA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14256-1; Eldredge-Hindy H, 2016, AM J CLIN ONCOL-CANC, V39, P189, DOI 10.1097/COC.0000000000000033; Field MG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02428-w; Forma E, 2014, CELL MOL BIOL LETT, V19, P438, DOI 10.2478/s11658-014-0204-6; Han A, 2021, TRENDS CANCER, V7, P671, DOI 10.1016/j.trecan.2021.05.005; Han A, 2021, CANCER RES, V81, P2807, DOI 10.1158/0008-5472.CAN-20-3430; Han AN, 2021, ONCOGENE, V40, P618, DOI 10.1038/s41388-020-01554-y; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hebert L, 2017, ONCOTARGET, V8, P72513, DOI 10.18632/oncotarget.19872; Heppt MV, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0800-0; Hutton JE, 2016, MOL CELL PROTEOMICS, V15, P2924, DOI 10.1074/mcp.M116.058925; Johansson PA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16276-8; Kalirai H, 2014, BRIT J CANCER, V111, P1373, DOI 10.1038/bjc.2014.417; Karlsson J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15606-0; Kennedy BE, 2019, CANCER RES, V79, P3824, DOI 10.1158/0008-5472.CAN-18-2414; Krantz BA, 2017, CLIN OPHTHALMOL, V11, P279, DOI 10.2147/OPTH.S89591; Kreuzaler P, 2020, MOL METAB, V33, P83, DOI 10.1016/j.molmet.2019.08.021; Lapadula D, 2019, MOL CANCER RES, V17, P963, DOI 10.1158/1541-7786.MCR-18-0574; Li J, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aaz8240; Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Meir T, 2007, INVEST OPHTH VIS SCI, V48, P4890, DOI 10.1167/iovs.07-0215; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nguyen GK, 2018, RADIOLOGY, V287, P884, DOI 10.1148/radiol.2018171504; Nie H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13601-8; Pascual G, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032920; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Ruan HB, 2012, CELL METAB, V16, P226, DOI 10.1016/j.cmet.2012.07.006; Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564; Nanda CS, 2020, BRIT J CANCER, V122, P136, DOI 10.1038/s41416-019-0663-7; Shain AH, 2019, NAT GENET, V51, P1123, DOI 10.1038/s41588-019-0440-9; Singh Arun D, 2005, Ophthalmol Clin North Am, V18, P75, DOI 10.1016/j.ohc.2004.07.002; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Wang A, 2016, J CLIN PATHOL, V69, P750, DOI 10.1136/jclinpath-2016-203866; Wei QY, 2020, ONCOGENE, V39, P6139, DOI 10.1038/s41388-020-01432-7; Zachar Z, 2011, J MOL MED, V89, P1137, DOI 10.1007/s00109-011-0785-8; Zhang S, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-10; Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325; Zhang YL, 2018, NAT CELL BIOL, V20, P1181, DOI 10.1038/s41556-018-0178-0	64	1	1	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1129	1139		10.1038/s41388-021-02154-0	http://dx.doi.org/10.1038/s41388-021-02154-0		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35046531	Green Accepted			2022-12-28	WOS:000744391200001
J	Singh, AP; Luo, HC; Matur, M; Eshelman, MA; Hamamoto, K; Sharma, A; Lesperance, J; Huang, SM				Singh, Ajeet P.; Luo, Huacheng; Matur, Meghana; Eshelman, Melanie A.; Hamamoto, Karina; Sharma, Arati; Lesperance, Julia; Huang, Suming			A coordinated function of lncRNA HOTTIP and miRNA-196b underpinning leukemogenesis by targeting FAS signaling	ONCOGENE			English	Article							NONCODING RNA; MICRORNA; TRANSCRIPTION; HOX; APOPTOSIS; CHROMATIN; LEUKEMIA; ELEMENTS; BINDING	MicroRNAs (miRNAs) may modulate more than 60% of human coding genes and act as negative regulators, whereas long noncoding RNAs (lncRNAs) regulate gene expression on multiple levels by interacting with chromatin, functional proteins, and RNAs such as mRNAs and microRNAs. However, the crosstalk between HOTTIP lncRNA and miRNAs in leukemogenesis remains elusive. Using combined integrated analyses of global miRNA expression profiling and state-of-the-art genomic analyses of chromatin such as ChIRP-seq (HOTTIP binding in genomewide), ChIP-seq, and ATAC-seq, we found that some miRNA genes are directly controlled by HOTTIP. Specifically, the HOX cluster miRNAs (miR-196a, miR-196b, miR-10a, and miR-10b), located cis and trans, were most dramatically regulated and significantly decreased in HOTTIP-/- AML cells. HOTTIP bound to the miR-196b promoter and HOTTIP deletion reduced chromatin accessibility and enrichment of active histone modifications at HOX cluster-associated miRNAs in AML cells, whereas reactivation of HOTTIP restored miR gene expression and chromatin accessibility in the CTCF-boundary-attenuated AML cells. Inactivation of HOTTIP or miR-196b promotes apoptosis by altering the chromatin signature at the FAS promoter and increasing FAS expression. Transplantation of miR-196b knockdown MOLM13 cells in NSG mice increased overall survival of mice compared to wild-type cells transplanted into mice. Thus, HOTTIP remodels the chromatin architecture around miRNAs to promote their transcription and consequently represses tumor suppressors and promotes leukemogenesis.	[Singh, Ajeet P.; Luo, Huacheng; Matur, Meghana; Eshelman, Melanie A.; Hamamoto, Karina; Lesperance, Julia; Huang, Suming] Penn State Univ, Dept Pediat, Coll Med, Div Pediat Hematol Oncol, Hershey, PA 17033 USA; [Singh, Ajeet P.] Penn State Univ, Dept Biochem & Mol Biol, Coll Med, Hershey, PA 17033 USA; [Singh, Ajeet P.] NCI, Thorac Surg Branch, NIH, Bethesda, MD 20892 USA; [Luo, Huacheng; Sharma, Arati; Huang, Suming] Penn State Univ, Coll Med, Penn State Canc Inst, Hershey, PA 17033 USA; [Sharma, Arati] Penn State Univ, Dept Med, Div Hematol & Oncol, Coll Med, Hershey, PA 17033 USA; [Sharma, Arati] Penn State Univ, Dept Pharmacol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Singh, AP; Luo, HC; Huang, SM (corresponding author), Penn State Univ, Dept Pediat, Coll Med, Div Pediat Hematol Oncol, Hershey, PA 17033 USA.; Singh, AP (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Coll Med, Hershey, PA 17033 USA.; Singh, AP (corresponding author), NCI, Thorac Surg Branch, NIH, Bethesda, MD 20892 USA.; Luo, HC; Huang, SM (corresponding author), Penn State Univ, Coll Med, Penn State Canc Inst, Hershey, PA 17033 USA.	ajeet.singh@nih.gov; hluo1@pennstatehealth.psu.edu; shuang4@pennstatehealth.psu.edu	Singh, Ajeet/N-8092-2017	Singh, Ajeet/0000-0002-0318-2167; Eshelman, Melanie/0000-0002-3814-5286	National Institutes of Health [R01DK110108, R01CA204044, R01HL141950]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful to the Penn State College of Medicine Genome Science Facility for illumine sequencing core and the Flow Cytometry & Cell Sorting Core. We are grateful for helpful discussions from Dr. Yi Qiu (Penn State College of Medicine). We thank Dr. Sachin Singh (Center for Cellular and Molecular Biology, India) for helping the data analysis from the TCGA dataset. This work was supported by the grants from National Institutes of Health (S.H., R01DK110108, R01CA204044, and R01HL141950).	Basta JM, 2020, DEV BIOL, V464, P176, DOI 10.1016/j.ydbio.2020.05.008; Chou CH, 2018, NUCLEIC ACIDS RES, V46, pD296, DOI 10.1093/nar/gkx1067; Collins CT, 2016, CURR OPIN HEMATOL, V23, P354, DOI 10.1097/MOH.0000000000000245; de Boer J, 2013, LEUKEMIA, V27, P1224, DOI 10.1038/leu.2013.78; De Kumar B, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501402; Denans N, 2015, ELIFE, V4, DOI 10.7554/eLife.04379; Dey BK, 2014, TRANSCR-AUSTIN, V5, DOI 10.4161/21541272.2014.944014; Dykes IM, 2017, GENOM PROTEOM BIOINF, V15, P177, DOI 10.1016/j.gpb.2016.12.005; Fernandes JCR, 2019, NON-CODING RNA, V5, DOI 10.3390/ncrna5010017; Furio-Tari P, 2016, NUCLEIC ACIDS RES, V44, pW176, DOI 10.1093/nar/gkw443; Garzon R, 2006, P NATL ACAD SCI USA, V103, P5078, DOI 10.1073/pnas.0600587103; Grossi E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14623-3; He RZ, 2019, GENES DIS, V6, P6, DOI 10.1016/j.gendis.2019.01.003; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965; Lambert M, 2019, CANCERS, V11, DOI 10.3390/cancers11060837; Li ZJ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1681; Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Luo HC, 2019, CANCER CELL, V36, P645, DOI 10.1016/j.ccell.2019.10.011; Luo HC, 2018, BLOOD, V132, P837, DOI 10.1182/blood-2017-11-814319; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Mo JS, 2015, ONCOTARGET, V6, P2843, DOI 10.18632/oncotarget.3066; Neijts R, 2016, GENE DEV, V30, P1937, DOI 10.1101/gad.285767.116; Qiu Yi, 2021, Blood, V138, P2327, DOI 10.1182/blood.2021011992; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rodrigues AR, 2017, P NATL ACAD SCI USA, V114, P3139, DOI 10.1073/pnas.1620767114; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Schep AN, 2017, NAT METHODS, V14, P975, DOI [10.1038/NMETH.4401, 10.1038/nmeth.4401]; Singh AP, 2020, CELL MOL GASTROENTER, V9, P447, DOI 10.1016/j.jcmgh.2019.11.001; Singh AP, 2016, MOL CELL BIOL, V36, P1990, DOI 10.1128/MCB.01101-15; Singh AP, 2017, ONCOTARGET, V8, P54925, DOI 10.18632/oncotarget.18976; Singh AP, 2014, NUCLEIC ACIDS RES, V42, P2958, DOI 10.1093/nar/gkt1232; Stadthagen G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003913; Takacs-Vellai K, 2007, DEV BIOL, V302, P661, DOI 10.1016/j.ydbio.2006.09.049; Tan YL, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-12; Wallace JA, 2017, BLOOD, V130, P1290, DOI 10.1182/blood-2016-10-697698; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Weiss FU, 2009, GASTROENTEROLOGY, V137, P2136, DOI 10.1053/j.gastro.2009.08.065; Yamamura S, 2018, CELL MOL LIFE SCI, V75, P467, DOI 10.1007/s00018-017-2626-6; Yendamuri S, 2009, LEUKEMIA, V23, P1257, DOI 10.1038/leu.2008.382	42	3	3	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					718	731		10.1038/s41388-021-02127-3	http://dx.doi.org/10.1038/s41388-021-02127-3		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34845377	Green Accepted, Green Submitted			2022-12-28	WOS:000723571700004
J	Ma, L; Lin, Y; Sun, SW; Xu, J; Yu, T; Chen, WL; Zhang, LH; Guo, YC; Wang, YW; Chen, T; Wei, JF; Zhu, LJ				Ma, Ling; Lin, Yu; Sun, Shan-Wen; Xu, Jun; Yu, Ting; Chen, Wen-Long; Zhang, Liang-Hui; Guo, Yu-Chen; Wang, Yi-Wen; Chen, Tao; Wei, Ji-Fu; Zhu, Ling-Jun			KIAA1429 is a potential prognostic marker in colorectal cancer by promoting the proliferation via downregulating WEE1 expression in an m6A-independent manner	ONCOGENE			English	Article							BUTYRATE; CARCINOMA	N6-methyladenosine (m6A), the most abundant mRNA modification in mammals, is involved in the metabolism of mRNA. KIAA1429 is regarded as the largest m6A methyltransferase and plays an important role in m6A modification. However, the prognostic value and function of KIAA1429 in colorectal cancer (CRC) are unclear. Quantitative real-time PCR and immunohistochemical assays were performed to evaluate the expression of KIAA1429 in CRC tissues. Kaplan-Meier survival curves and log-rank tests were used to assess the association between KIAA1429 expression and the prognosis of patients with CRC. CCK-8 assays, colony formation assays, cell cycle assays, and xenograft experiments were performed to investigate the effect of KIAA1429 on cell proliferation. RNA immunoprecipitation, methylated RNA immunoprecipitation assays, and RNA stability assays were conducted to explore the underlying mechanism. KIAA1429 was significantly upregulated in CRC tissues compared with adjacent normal tissues. Patients with higher expression of KIAA1429 had shorter overall survival than those with lower expression. Functionally, KIAA1429 promoted CRC cell proliferation in vitro and in vivo. Mechanistically, KIAA1429 negatively regulated the expression of WEE1 by decreasing its stability in an m6A-independent manner by binding to the third segment in the 3 '-UTR of WEE1 mRNA. Moreover, butyrate decreased the expression of KIAA1429 by downregulating the level of the transcription factor NF kappa B1. Our findings indicated that KIAA1429 plays an oncogenic role in CRC cells by inhibiting the expression of WEE1 in an m6A-independent manner and is associated with poor survival in CRC patients. These results suggested that KIAA1429 might be a potential prognostic marker for CRC.	[Ma, Ling; Lin, Yu; Sun, Shan-Wen; Xu, Jun; Yu, Ting; Zhang, Liang-Hui; Guo, Yu-Chen; Zhu, Ling-Jun] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Peoples R China; [Chen, Wen-Long; Wang, Yi-Wen; Chen, Tao] Nanjing Med Univ, Dept Colorectal Surg, Affiliated Hosp 1, Nanjing, Peoples R China; [Wei, Ji-Fu] Nanjing Med Univ, Res Div Clin Pharmacol, Affiliated Hosp 1, Nanjing, Peoples R China; [Wei, Ji-Fu] Nanjing Med Univ, Dept Pharm, Jiangsu Canc Hosp, Nanjing 210009, Peoples R China; [Wei, Ji-Fu] Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 210009, Peoples R China; [Wei, Ji-Fu] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 210009, Peoples R China; [Zhu, Ling-Jun] Nanjing Med Univ, Dept Oncol, Sir Run Run Hosp, Nanjing, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Zhu, LJ (corresponding author), Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Peoples R China.; Chen, T (corresponding author), Nanjing Med Univ, Dept Colorectal Surg, Affiliated Hosp 1, Nanjing, Peoples R China.; Wei, JF (corresponding author), Nanjing Med Univ, Res Div Clin Pharmacol, Affiliated Hosp 1, Nanjing, Peoples R China.; Wei, JF (corresponding author), Nanjing Med Univ, Dept Pharm, Jiangsu Canc Hosp, Nanjing 210009, Peoples R China.; Wei, JF (corresponding author), Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 210009, Peoples R China.; Wei, JF (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 210009, Peoples R China.; Zhu, LJ (corresponding author), Nanjing Med Univ, Dept Oncol, Sir Run Run Hosp, Nanjing, Peoples R China.	ct55979@163.com; weijifu@njmu.edu.cn; zhulingjun@njmu.edu.cn		Zhu, Lingjun/0000-0001-8033-1528; Ma, Ling/0000-0002-2960-1956	Natural Science Foundation of Jiangsu Province [BK20201495]; Jiangsu Province's Key Provincial Talents Program [ZDRCA2016089]; National Natural Science Foundation of China [82102981]	Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Jiangsu Province's Key Provincial Talents Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from Natural Science Foundation of Jiangsu Province (BK20201495), Jiangsu Province's Key Provincial Talents Program (ZDRCA2016089), and the National Natural Science Foundation of China (No. 82102981).	Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; Bai Y, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00332; Barros-Silva D, 2020, CANCERS, V12, DOI 10.3390/cancers12040771; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Chen XX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01220-7; Chen XX, 2020, MOL THER, V28, P599, DOI 10.1016/j.ymthe.2019.11.016; Chen YH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1053-8; Cheng XY, 2019, ONCOTARGETS THER, V12, P3421, DOI 10.2147/OTT.S180954; Dominguez-Kelly R, 2011, J CELL BIOL, V194, P567, DOI 10.1083/jcb.201101047; Encarnacao JC, 2015, CANCER METAST REV, V34, P465, DOI 10.1007/s10555-015-9578-9; Ge XC, 2017, ONCOL LETT, V13, P4341, DOI 10.3892/ol.2017.5984; Goncalves P, 2013, CURR DRUG METAB, V14, P994; Lan T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1106-z; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Li YS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1066-3; Liu Y, 2016, FOOD FUNCT, V7, P3772, DOI [10.1039/c6fo00856a, 10.1039/C6FO00856A]; Miao R, 2020, J CELL PHYSIOL, V235, P7420, DOI 10.1002/jcp.29645; Ni W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1079-y; Nishizawa Yujiro, 2018, Oncotarget, V9, P7476, DOI 10.18632/oncotarget.23554; Pan YT, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0590-8; Patel M, 2018, TRANSL RES, V197, P43, DOI 10.1016/j.trsl.2018.02.002; Peng W, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1408-4; Qian JY, 2019, ONCOGENE, V38, P6123, DOI 10.1038/s41388-019-0861-z; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Schwartz S, 2014, CELL REP, V8, P284, DOI 10.1016/j.celrep.2014.05.048; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; van der Geest LGM, 2015, CLIN EXP METASTAS, V32, P457, DOI 10.1007/s10585-015-9719-0; Wang JJ, 2017, BRIT J PHARMACOL, V174, P3811, DOI 10.1111/bph.13976; Wang XY, 2019, CELL RES, V29, P167, DOI 10.1038/s41422-018-0127-2; Wang XY, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01283-y; Wang YF, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0957-7; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Wu XQ, 2018, J CANCER, V9, P2510, DOI 10.7150/jca.25324; Yang PP, 2020, PATHOL ONCOL RES, V26, P1615, DOI 10.1007/s12253-019-00737-7; Yue B, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1065-4; Yue YA, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0019-0; Zhu W, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01868-1; Zhu W, 2020, J CELL MOL MED, V24, P3521, DOI 10.1111/jcmm.15042	39	7	7	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					692	703		10.1038/s41388-021-02066-z	http://dx.doi.org/10.1038/s41388-021-02066-z		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34819634				2022-12-28	WOS:000722084500001
J	Tapmeier, TT; Howell, JH; Zhao, L; Papiez, BW; Schnabel, JA; Muschel, RJ; Gal, A				Tapmeier, Thomas T.; Howell, Jake H.; Zhao, Lei; Papiez, Bartlomiej W.; Schnabel, Julia A.; Muschel, Ruth J.; Gal, Annamaria			Evolving polarisation of infiltrating and alveolar macrophages in the lung during metastatic progression of melanoma suggests CCR1 as a therapeutic target	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; BREAST-CANCER; IN-VIVO; PROGNOSTIC-SIGNIFICANCE; INTERNATIONAL UNION; PANCREATIC-CANCER; SERUM-LEVELS; CHEMOKINE; PROMOTES; SURVIVAL	Metastatic tumour progression is facilitated by tumour associated macrophages (TAMs) that enforce pro-tumour mechanisms and suppress immunity. In pulmonary metastases, it is unclear whether TAMs comprise tissue resident or infiltrating, recruited macrophages; and the different expression patterns of these TAMs are not well established. Using the mouse melanoma B16F10 model of experimental pulmonary metastasis, we show that infiltrating macrophages (IM) change their gene expression from an early pro-inflammatory to a later tumour promoting profile as the lesions grow. In contrast, resident alveolar macrophages (AM) maintain expression of crucial pro-inflammatory/anti-tumour genes with time. During metastatic growth, the pool of macrophages, which initially contains mainly alveolar macrophages, increasingly consists of infiltrating macrophages potentially facilitating metastasis progression. Blocking chemokine receptor mediated macrophage infiltration in the lung revealed a prominent role for CCR2 in Ly6C(+) pro-inflammatory monocyte/macrophage recruitment during metastasis progression, while inhibition of CCR2 signalling led to increased metastatic colony burden. CCR1 blockade, in contrast, suppressed late phase pro-tumour MR(+)Ly6C(-) monocyte/macrophage infiltration accompanied by expansion of the alveolar macrophage compartment and accumulation of NK cells, leading to reduced metastatic burden. These data indicate that IM has greater plasticity and higher phenotypic responsiveness to tumour challenge than AM. A considerable difference is also confirmed between CCR1 and CCR2 with regard to the recruited IM subsets, with CCR1 presenting a potential therapeutic target in pulmonary metastasis from melanoma.	[Tapmeier, Thomas T.; Muschel, Ruth J.; Gal, Annamaria] Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Dept Oncol, Oxford OX3 7DQ, England; [Tapmeier, Thomas T.] Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; [Tapmeier, Thomas T.] Hudson Inst Med Res, Ritchie Ctr, Clayton, Vic 3168, Australia; [Howell, Jake H.; Gal, Annamaria] Univ Brighton, Sch Appl Sci, Brighton BN2 4GJ, E Sussex, England; [Zhao, Lei] Shandong First Med Univ, Shandong Canc Hosp & Inst, Shandong Canc Hosp, Jinan 250117, Peoples R China; [Papiez, Bartlomiej W.] Big Data Inst, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford OX3 7LF, England; [Schnabel, Julia A.] Kings Coll London, Sch Biomed Imaging & Imaging Sci, London SE1 7EU, England; [Schnabel, Julia A.] Helmholtz Ctr Munich, German Ctr Environm Hlth, D-85764 Neuherberg, Germany; [Schnabel, Julia A.] Tech Univ Munich, Fac Informat, D-85748 Garching, Germany; [Schnabel, Julia A.] Tech Univ Munich, Inst Adv Study, D-85748 Garching, Germany	University of Oxford; Monash University; Hudson Institute of Medical Research; University of Brighton; Shandong First Medical University & Shandong Academy of Medical Sciences; University of London; King's College London; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technical University of Munich	Tapmeier, TT; Gal, A (corresponding author), Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Dept Oncol, Oxford OX3 7DQ, England.; Tapmeier, TT (corresponding author), Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia.; Tapmeier, TT (corresponding author), Hudson Inst Med Res, Ritchie Ctr, Clayton, Vic 3168, Australia.; Gal, A (corresponding author), Univ Brighton, Sch Appl Sci, Brighton BN2 4GJ, E Sussex, England.	Thomas.Tapmeier@monash.edu; A.Gal@brighton.ac.uk		Gal, Annamaria/0000-0001-8171-1389	Cancer Research UK [C5255/A15935]; Medical Research Council [MC_PC_12004]; National Natural Science Fund of China [81272375]; School of Applied Sciences, University of Brighton	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Natural Science Fund of China(National Natural Science Foundation of China (NSFC)); School of Applied Sciences, University of Brighton	We thank David M. Higgins for helping with the characterisation of macrophage compartments in the mouse lung and Sally A. Hill for providing the necessary platforms for animal experiments. We also thank Sabira Yameen for her help with immunohistochemistry. This work was funded by grants to RJM from Cancer Research UK (C5255/A15935) and the Medical Research Council (MC_PC_12004); LZ received support from the National Natural Science Fund of China (No. 81272375), and AG from the Output Enhancement Fund by the School of Applied Sciences, University of Brighton. Publications costs were supported by the Open Access Fund from the School of Applied Sciences, University of Brighton.	Amat M, 2006, BRIT J PHARMACOL, V149, P666, DOI 10.1038/sj.bjp.0706912; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Argyle D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02629; Bachelerie F, 2014, PHARMACOL REV, V66, P1, DOI 10.1124/pr.113.007724; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Bercovici N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01563; Biswas SK, 2013, SEMIN IMMUNOPATHOL, V35, P585, DOI 10.1007/s00281-013-0367-7; Bonapace L, 2014, NATURE, V515, DOI 10.1038/nature13862; Cai YH, 2014, J IMMUNOL, V192, P2821, DOI 10.4049/jimmunol.1302269; Chen HJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02887; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Chun E, 2015, CELL REP, V12, P244, DOI 10.1016/j.celrep.2015.06.024; Cornforth AN, 2009, J CLIN IMMUNOL, V29, P657, DOI 10.1007/s10875-009-9299-3; Dairaghi DJ, 2012, BLOOD, V120, P1449, DOI 10.1182/blood-2011-10-384784; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Gazzaniga S, 2007, J INVEST DERMATOL, V127, P2031, DOI 10.1038/sj.jid.5700827; Grossman JG, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1470729; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004; Higgins DM, 2008, J IMMUNOL, V180, P4892, DOI 10.4049/jimmunol.180.7.4892; Huang YK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11788-4; Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342; Jones KI, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809342; Kitagawa K, 2004, AM J PATHOL, V165, P237, DOI 10.1016/S0002-9440(10)63292-0; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Kitamura T, 2010, P NATL ACAD SCI USA, V107, P13063, DOI 10.1073/pnas.1002372107; Kratofil RM, 2017, ARTERIOSCL THROM VAS, V37, P35, DOI 10.1161/ATVBAHA.116.308198; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Liegeois M, 2018, CELL IMMUNOL, V330, P91, DOI 10.1016/j.cellimm.2018.02.001; Lim SY, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23187; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin SS, 2012, CANCER SCI, V103, P904, DOI 10.1111/j.1349-7006.2012.02259.x; Liu YY, 2018, PEERJ, V6, DOI 10.7717/peerj.4928; Lucotti S, 2019, J CLIN INVEST, V129, P1845, DOI 10.1172/JCI121985; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Miao M, 2020, EXPERT OPIN DRUG MET, V16, P11, DOI 10.1080/17425255.2020.1711884; Mitsi E, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0777-0; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Nosaka T, 2018, J IMMUNOL, V200, P1839, DOI 10.4049/jimmunol.1700544; Nywening TM, 2016, LANCET ONCOL, V17, P651, DOI 10.1016/S1470-2045(16)00078-4; Peiser L, 2000, INFECT IMMUN, V68, P1953, DOI 10.1128/IAI.68.4.1953-1963.2000; Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989; Pienta KJ, 2013, INVEST NEW DRUG, V31, P760, DOI 10.1007/s10637-012-9869-8; Poeta VM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00379; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Qian BZ, 2015, J EXP MED, V212, P1433, DOI 10.1084/jem.20141555; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Rosi S, 2005, NEUROSCIENCE, V134, P671, DOI 10.1016/j.neuroscience.2005.04.029; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Sadeghi M, 2015, BRIT J CANCER, V113, P756, DOI 10.1038/bjc.2015.227; Samaniego R, 2014, J LEUKOCYTE BIOL, V95, P797, DOI 10.1189/jlb.0613345; Sanford DE, 2013, CLIN CANCER RES, V19, P3404, DOI 10.1158/1078-0432.CCR-13-0525; Sasaki S, 2016, CANCER LETT, V378, P23, DOI 10.1016/j.canlet.2016.05.005; Sceneay J, 2012, CANCER RES, V72, P3906, DOI 10.1158/0008-5472.CAN-11-3873; Schmall A, 2015, AM J RESP CRIT CARE, V191, P437, DOI 10.1164/rccm.201406-1137OC; Schyns J, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5160794; Sharma SK, 2015, J IMMUNOL, V194, P5529, DOI 10.4049/jimmunol.1403215; Stanley ER, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a021857; Strachan DC, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26968; Svensson S, 2015, CLIN CANCER RES, V21, P3794, DOI 10.1158/1078-0432.CCR-15-0204; Vela M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00012; Velasco-Velazquez M, 2012, CANCER RES, V72, P3839, DOI 10.1158/0008-5472.CAN-11-3917; Weide B, 2015, CANCER IMMUNOL IMMUN, V64, P1075, DOI 10.1007/s00262-015-1714-4; Yang M, 2018, CANCER RES, V78, P5492, DOI 10.1158/0008-5472.CAN-18-1367; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578; Yuan X, 2017, GYNECOL ONCOL, V147, P181, DOI 10.1016/j.ygyno.2017.07.007; Zaynagetdinov R, 2013, AM J RESP CELL MOL, V49, P180, DOI 10.1165/rcmb.2012-0366MA; Zhang J, 2010, CYTOKINE GROWTH F R, V21, P41, DOI 10.1016/j.cytogfr.2009.11.009; Zhao XX, 2017, ONCOTARGET, V8, P30576, DOI 10.18632/oncotarget.15736	76	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					5032	5045		10.1038/s41388-022-02488-3	http://dx.doi.org/10.1038/s41388-022-02488-3		OCT 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36241867	hybrid, Green Published			2022-12-28	WOS:000873991500001
J	Wei, LY; Wang, WT; Yao, JX; Cui, ZY; Xu, ZH; Ding, HQ; Wu, XJ; Wang, DH; Luo, J; Ke, ZJ				Wei, Luyao; Wang, Wantao; Yao, Junxia; Cui, Zhengyu; Xu, Zihang; Ding, Hanqing; Wu, Xiaojun; Wang, Deheng; Luo, Jia; Ke, Zun-Ji			PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation	ONCOGENE			English	Article							RNA-BINDING PROTEIN; MOLECULAR PORTRAITS; THERAPEUTIC TARGET; EXPRESSION; KINASE; UBC9; GENE; PKR; GTPASES; SUMO	Most basal-like breast cancers (BLBCs) are triple-negative breast cancers (TNBCs), which is associated with high malignancy, high rate of recurrence and distant metastasis, and poor prognosis among all types of breast cancer. However, there are currently no effective therapies for BLBC. Furthermore, chemoresistance limits the therapeutic options for BLBC treatment. In this study, we screen out protein activator of the interferon-induced protein kinase (PACT) as an essential gene in BLBC metastasis. We find that high PACT expression level was associated with poor prognosis among BLBC patients. In vivo and in vitro investigations indicated that PACT could regulate BLBC metastasis by interacting with SUMO-conjugating enzyme Ubc9 to stimulate the SUMOylation and thus consequently the activation of Rac1. BLBC patients receiving chemotherapy presents poorer prognosis with PACT high expression, and PACT disruption sensitizes experimental mammary tumor metastases to chemotherapy, thus providing insights to consider PACT as a potential therapeutic target to overcome acquired chemoresistance in BLBC.	[Wei, Luyao; Wang, Wantao; Ding, Hanqing; Wang, Deheng; Ke, Zun-Ji] Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Dept Biochem, Shanghai Key Lab Hlth Identificat & Assessment, 1200 Cailun Rd, Shanghai 201203, Peoples R China; [Yao, Junxia] Fudan Univ, Dept Pathol, Qingpu Branch, Zhongshan Hosp, 1158 Gongyuan Rd, Shanghai 201700, Peoples R China; [Cui, Zhengyu] Tongji Univ, Shanghai East Hosp, Dept Internal Med Tradit Chinese Med, Sch Med, Shanghai 200120, PR, Peoples R China; [Xu, Zihang] Shanghai Univ Tradit Chinese Med, Sch Basic Med Sci, Dept Internal Class Med, 1200 Cailun Rd, Shanghai 201203, Peoples R China; [Wu, Xiaojun] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, Shanghai Key Lab Compound Chinese Med, 1200 Cailun Rd, Shanghai 201203, PR, Peoples R China; [Luo, Jia] Univ Iowa, Dept Pathol, Carver Coll Med, 51 Newton Rd, Iowa City, IA 52242 USA	Shanghai University of Traditional Chinese Medicine; Fudan University; Tongji University; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; University of Iowa	Ke, ZJ (corresponding author), Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Dept Biochem, Shanghai Key Lab Hlth Identificat & Assessment, 1200 Cailun Rd, Shanghai 201203, Peoples R China.	kezunji@shutcm.edu.cn	Ke, Zun-Ji/E-4822-2010	Ke, Zun-Ji/0000-0003-4038-2456	National Natural Science Foundation of China [31701217, 31570921]; Shanghai Key Laboratory of Health Identification and Assessment [13DZ2261000]; Shanghai Municipal Commission of Health and Family Planning [201540206]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Key Laboratory of Health Identification and Assessment; Shanghai Municipal Commission of Health and Family Planning	This research was supported by the National Natural Science Foundation of China (31701217 to LW, and 31570921 to ZJK), Shanghai Key Laboratory of Health Identification and Assessment (13DZ2261000), Shanghai Municipal Commission of Health and Family Planning (201540206 to ZJK).	Garcia MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023887; Bennett RL, 2008, MECH DEVELOP, V125, P777, DOI 10.1016/j.mod.2008.06.009; Bennett RL, 2006, BLOOD, V108, P821, DOI 10.1182/blood-2005-11-006817; Bennett RL, 2012, CELL CYCLE, V11, P407, DOI 10.4161/cc.11.2.18999; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bristow JM, 2009, J CELL SCI, V122, P4535, DOI 10.1242/jcs.053728; Cannon AC, 2020, TRENDS CANCER, V6, P478, DOI 10.1016/j.trecan.2020.02.021; Castillo-Lluva S, 2010, NAT CELL BIOL, V12, P1078, DOI 10.1038/ncb2112; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Chiosea S, 2008, BIOMARK INSIGHTS, V3, P253; DepMap Broad, 2021, DEPMAP 21Q3 PUBL FIG; Dickerman BK, 2015, FEBS J, V282, P4766, DOI 10.1111/febs.13533; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Dokmanovic M, 2009, MOL CANCER THER, V8, P1557, DOI 10.1158/1535-7163.MCT-09-0140; Dunnebier T, 2010, BREAST CANCER RES TR, V121, P185, DOI 10.1007/s10549-009-0530-y; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hisamatsu T, 2019, MOL CANCER THER, V18, P162, DOI 10.1158/1535-7163.MCT-17-1050; Ho CW, 2011, J BIOL CHEM, V286, P21826, DOI 10.1074/jbc.M111.234914; Huang X, 2002, BIOCHEM J, V366, P175, DOI 10.1042/BJ20020204; Jiang YZ, 2019, CANCER CELL, V35, P428, DOI 10.1016/j.ccell.2019.02.001; Jin X, 2020, NATURE, V588, P331, DOI 10.1038/s41586-020-2969-2; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Li H, 2013, ONCOL REP, V29, P1588, DOI 10.3892/or.2013.2268; Li QJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15308-7; Liu Y, 2017, MOL THER, V25, P666, DOI 10.1016/j.ymthe.2016.12.021; Lorente M, 2019, J CELL SCI, V132, DOI 10.1242/jcs.234120; Mack NA, 2011, CELL CYCLE, V10, P1571, DOI 10.4161/cc.10.10.15612; Marei Hadir, 2017, Small GTPases, V8, P139, DOI 10.1080/21541248.2016.1211398; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Mullany LE, 2016, BMC MED GENOMICS, V9, DOI 10.1186/s12920-016-0181-x; Pan YL, 2004, BIOCHEM BIOPH RES CO, V315, P686, DOI 10.1016/j.bbrc.2004.01.108; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Peidis P, 2011, CELL DEATH DIFFER, V18, P145, DOI 10.1038/cdd.2010.76; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Peters GA, 2009, P NATL ACAD SCI USA, V106, P10696, DOI 10.1073/pnas.0900735106; Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Reijnders MRF, 2017, AM J HUM GENET, V101, P466, DOI 10.1016/j.ajhg.2017.08.007; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rios AC, 2019, CANCER CELL, V35, P618, DOI 10.1016/j.ccell.2019.02.010; Rowe TM, 2006, P NATL ACAD SCI USA, V103, P5823, DOI 10.1073/pnas.0601287103; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Schwartz S, 2016, GENETICS, V203, P1249, DOI 10.1534/genetics.115.183194; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Su YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034250; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Svensmark JH, 2019, ONCOGENE, V38, P7447, DOI 10.1038/s41388-019-0963-7; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Xu J, 2016, Int J Chronic Dis Ther, V2, P31; YONG Y, 2015, SCI REP-UK, V5; Yoon C, 2017, MOL CANCER RES, V15, P1106, DOI 10.1158/1541-7786.MCR-17-0053; Yoon CH, 2009, P NATL ACAD SCI USA, V106, P7852, DOI 10.1073/pnas.0812148106	60	1	1	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4282	4294		10.1038/s41388-022-02431-6	http://dx.doi.org/10.1038/s41388-022-02431-6		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35974143				2022-12-28	WOS:000841092200001
J	Morales-Valencia, J; Lau, L; Marti-Nin, T; Ozerdem, U; David, G				Morales-Valencia, Jorge; Lau, Lena; Marti-Nin, Teresa; Ozerdem, Ugur; David, Gregory			Therapy-induced senescence promotes breast cancer cells plasticity by inducing Lipocalin-2 expression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CELLULAR SENESCENCE; GROWTH; FIBROBLASTS; RESISTANCE; MECHANISMS; INVASION; IRON	The acquisition of novel detrimental cellular properties following exposure to cytotoxic drugs leads to aggressive and metastatic tumors that often translates into an incurable disease. While the bulk of the primary tumor is eliminated upon exposure to chemotherapeutic treatment, residual cancer cells and non-transformed cells within the host can engage a stable cell cycle exit program named senescence. Senescent cells secrete a distinct set of pro-inflammatory factors, collectively termed the senescence-associated secretory phenotype (SASP). Upon exposure to the SASP, cancer cells undergo cellular plasticity resulting in increased proliferation, migration and epithelial-to-mesenchymal transition. The molecular mechanisms by which the SASP regulates these pro-tumorigenic features are poorly understood. Here, we report that breast cancer cells exposed to the SASP strongly upregulate Lipocalin-2 (LCN2). Furthermore, we demonstrate that LCN2 is critical for SASP-induced increased migration in breast cancer cells, and its inactivation potentiates the response to chemotherapeutic treatment in mouse models of breast cancer. Finally, we show that neoadjuvant chemotherapy treatment leads to LCN2 upregulation in residual human breast tumors, and correlates with worse overall survival. These findings provide the foundation for targeting LCN2 as an adjuvant therapeutic approach to prevent the emergence of aggressive tumors following chemotherapy.	[Morales-Valencia, Jorge; Lau, Lena; Marti-Nin, Teresa; David, Gregory] NYU, Dept Biochem & Mol Pharmacol, Langone Med Ctr, New York, NY 10016 USA; [Morales-Valencia, Jorge; David, Gregory] NYU Langone Hlth, NYU Langone Perlmutter Canc Ctr, New York, NY 10016 USA; [Ozerdem, Ugur] NYU, NYU Langone Hlth, Dept Pathol, Sch Med, New York, NY 10016 USA; [David, Gregory] NYU, NYU Langone Hlth, Dept Urol, Sch Med, New York, NY 10016 USA	New York University; NYU Langone Medical Center; NYU Langone Medical Center; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center	David, G (corresponding author), NYU, Dept Biochem & Mol Pharmacol, Langone Med Ctr, New York, NY 10016 USA.; David, G (corresponding author), NYU Langone Hlth, NYU Langone Perlmutter Canc Ctr, New York, NY 10016 USA.; David, G (corresponding author), NYU, NYU Langone Hlth, Dept Urol, Sch Med, New York, NY 10016 USA.	gregory.david@nyulangone.org		David, Gregory/0000-0002-1849-3232	NIH/NCI [CA246416]; NYS DoH [C36617GG]; NYSTEM Institutional Training Grant [C322560GG]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NYS DoH; NYSTEM Institutional Training Grant	The authors sincerely thank all members of the David lab for helpful discussions during the preparation of this manuscript. We wish to acknowledge the NYU Genome Technology Center for help with RNA sequencing (RNA-seq). We thank Dr. Richard Possemato (NYU School of Medicine), Dr. Eva Hernando (NYU School of Medicine), Dr. Thales Papagiannakopoulos (NYU School of Medicine), Dr. Benjamin Neel (NYU School of Medicine), and Dr. Judith Campisi (Buck Institute for Research on Aging) as well as members of their labs for the generous gift or reagents and plasmids and for helpful discussions. This work was funded by NIH/NCI (CA246416) [GD], NYS DoH (C36617GG) [GD] and the NYSTEM Institutional Training Grant (C322560GG) [JMV].	Asaoka M, 2020, BREAST CANCER-BASIC, V14, DOI 10.1177/1178223420980377; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Canino C, 2012, ONCOGENE, V31, P3148, DOI 10.1038/onc.2011.485; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Chi Y, 2020, SCIENCE, V369, P276, DOI 10.1126/science.aaz2193; Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000; Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Duy C, 2021, CANCER DISCOV, V11, P1542, DOI 10.1158/2159-8290.CD-20-1375; Espinoza-Sanchez Nancy Adriana, 2018, Oncotarget, V9, P26679, DOI 10.18632/oncotarget.25465; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Hu CX, 2018, ONCOTARGETS THER, V11, P8099, DOI 10.2147/OTT.S181223; Jung M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020273; Karabicici M, 2021, MOL ONCOL, V15, P2185, DOI 10.1002/1878-0261.12916; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; La Manna G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089497; Laberge RM, 2012, CANCER MICROENVIRON, V5, P39, DOI 10.1007/s12307-011-0069-4; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lau L, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00586-18; Leng XH, 2009, CANCER RES, V69, P8579, DOI 10.1158/0008-5472.CAN-09-1934; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167; Moirangthem A, 2016, SCI REP-UK, V6, DOI 10.1038/srep21903; Ortiz-Montero P, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0172-3; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]; Poli V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03264-2; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Saxena M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.61; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; Shi H, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-83; Tong ZM, 2008, CANCER RES, V68, P6100, DOI 10.1158/0008-5472.CAN-08-0540; van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193; Villodre ES, 2021, MOL ONCOL, V15, P2752, DOI 10.1002/1878-0261.13074; Xiao X, 2017, ANNU REV NUTR, V37, P103, DOI 10.1146/annurev-nutr-071816-064559; Xu HX, 2015, ONCOTARGETS THER, V8, P3783, DOI 10.2147/OTT.S95470; Yang J, 2009, CELL CYCLE, V8, P2347, DOI 10.4161/cc.8.15.9224; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Yedjou CG, 2019, ADV EXP MED BIOL, V1152, P31, DOI 10.1007/978-3-030-20301-6_3; Young ARJ, 2009, EMBO REP, V10, P228, DOI 10.1038/embor.2009.22; Zhang N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020849; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257	46	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4361	4370		10.1038/s41388-022-02433-4	http://dx.doi.org/10.1038/s41388-022-02433-4		AUG 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35953598	Green Submitted			2022-12-28	WOS:000839543400001
J	Gu, YY; Gao, HY; Zhang, H; John, A; Zhu, XJ; Shivaram, S; Yu, J; Weinshilboum, RM; Wang, LW				Gu, Yayun; Gao, Huanyao; Zhang, Huan; John, August; Zhu, Xiujuan; Shivaram, Suganti; Yu, Jia; Weinshilboum, Richard M.; Wang, Liewei			TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer	ONCOGENE			English	Article							UBIQUITIN LIGASE SMURF2; FACTOR RECEPTOR; ACTIVATION; MECHANISMS; PATHWAY	The HER2 receptor modulates downstream signaling by forming homodimers and heterodimers with other members of the HER family. For patients with HER2-positive breast cancer, Trastuzumab, an anti-HER2 monoclonal antibody as first-line therapy has shown significant survival benefits. However, the development of acquired resistance to Trastuzumab continues to be a significant obstacle. TNF receptor-associated factor 4 (TRAF4) upregulation was discovered to be associated with a worse clinical outcome. Here we identified TRAF4 overexpression as one of the putative mechanisms for HER2-positive breast cancer cells to maintain HER2 signaling during Trastuzumab treatment, while TRAF4 knockdown reduced HER2 stability and improved Trastuzumab sensitivity. Mechanistically, TRAF4 regulates HER2 level through its impact on SMAD specific E3 ubiquitin protein ligase protein 2 (SMURF2). The development of a membrane-associated protein complex containing HER2, TRAF4, and SMURF2 has been observed. SMURF2 bound to the HER2 cytoplasmic domain, and directly ubiquitinated it leading to HER2 degradation, whereas TRAF4 stabilized HER2 by degrading SMURF2 and inhibiting the binding of SMURF2 to HER2. Moreover, downregulation of TRAF4 has decreased the AKT/mTOR signaling. In conclusion, we discovered a new HER2 signaling regulation that involves the TRAF4-SMURF2 complex, a possible mechanism that might contribute to anti-HER2 resistance, making TRAF4 a viable target for treating HER2 + breast cancer.	[Gu, Yayun; Gao, Huanyao; Zhang, Huan; John, August; Zhu, Xiujuan; Shivaram, Suganti; Yu, Jia; Weinshilboum, Richard M.; Wang, Liewei] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Div Clin Pharmacol, Rochester, MN 55905 USA	Mayo Clinic	Wang, LW (corresponding author), Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Div Clin Pharmacol, Rochester, MN 55905 USA.	Wang.Liewei@mayo.edu		John, August/0000-0003-4615-9474	Breast Cancer Research Foundation (BCRF); Eisenberg Foundation; Nan Sawyer Breast Cancer Fund; Mayo Clinic Breast Cancer Specialized Program of Research Excellence [P50CA116201]	Breast Cancer Research Foundation (BCRF); Eisenberg Foundation; Nan Sawyer Breast Cancer Fund; Mayo Clinic Breast Cancer Specialized Program of Research Excellence	This work was supported by the Breast Cancer Research Foundation (BCRF), The Eisenberg Foundation, The Nan Sawyer Breast Cancer Fund, P50CA116201(Mayo Clinic Breast Cancer Specialized Program of Research Excellence).	Abell AN, 2005, J BIOL CHEM, V280, P35793, DOI 10.1074/jbc.C500260200; Ahmad A, 2019, ADV EXP MED BIOL, V1152, P217, DOI 10.1007/978-3-030-20301-6_10; Ahmad S, 2014, SCI REP-UK, V4, DOI 10.1038/srep04483; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Boughey JC, 2021, CLIN CANCER RES, V27, P4696, DOI 10.1158/1078-0432.CCR-21-0641; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Cai G, 2018, P NATL ACAD SCI USA, V115, P11531, DOI 10.1073/pnas.1809599115; Chandarlapaty S, 2012, CLIN CANCER RES, V18, P6784, DOI 10.1158/1078-0432.CCR-12-1785; Chandhoke AS, 2016, CELL DEATH DIFFER, V23, P876, DOI 10.1038/cdd.2015.152; Emanuelli A, 2019, CANCERS, V11, DOI 10.3390/cancers11040556; Exman P, 2021, CLIN ADV HEMATOL ONC, V19, P40; Fennell LM, 2018, FEBS J, V285, P2746, DOI 10.1111/febs.14478; Fu L, 2020, SEMIN CANCER BIOL, V67, P102, DOI 10.1016/j.semcancer.2019.12.023; Gijsen M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000563; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Hendriks BS, 2005, J BIOL CHEM, V280, P6157, DOI 10.1074/jbc.M410491200; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Klupp F, 2019, CANCER MANAG RES, V11, P1795, DOI 10.2147/CMAR.S178111; Koganti P, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00295; Kreutzfeldt J, 2020, AM J CANCER RES, V10, P1045; Kumagai Shogo, 2021, Nat Rev Cancer, V21, P181, DOI 10.1038/s41568-020-00322-0; Lazaro G, 2013, ENDOCR-RELAT CANCER, V20, P691, DOI 10.1530/ERC-13-0019; Li JT, 2019, CELL DEATH DIFFER, V26, P2652, DOI 10.1038/s41418-019-0328-3; Li S, 2010, MOL CELL BIOCHEM, V338, P11, DOI 10.1007/s11010-009-0315-y; Li YH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00603-7; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Moustakas A, 2013, MOL CELL, V51, P555, DOI 10.1016/j.molcel.2013.08.034; Nami B, 2018, CANCERS, V10, DOI 10.3390/cancers10100342; O'Brien NA, 2014, CLIN CANCER RES, V20, P3507, DOI 10.1158/1078-0432.CCR-13-2769; Oh DY, 2020, NAT REV CLIN ONCOL, V17, P33, DOI 10.1038/s41571-019-0268-3; Park HH, 2021, ARCH PHARM RES, V44, P475, DOI 10.1007/s12272-021-01330-w; Park J, 2020, ARCH PHARM RES, V43, P1144, DOI 10.1007/s12272-020-01281-8; Pohlmann PR, 2009, CLIN CANCER RES, V15, P7479, DOI 10.1158/1078-0432.CCR-09-0636; Ray D, 2011, NEOPLASIA, V13, P570, DOI 10.1593/neo.11632; Ray P, 2020, J BIOL CHEM, V295, P12661, DOI 10.1074/jbc.RA120.013519; Ren HY, 2020, BREAST CANCER RES TR, V183, P275, DOI 10.1007/s10549-020-05789-x; Ren YL, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00426-y; Roskoski R, 2019, PHARMACOL RES, V139, P395, DOI 10.1016/j.phrs.2018.11.014; Rousseau Adrien, 2011, Cancers (Basel), V3, P2734, DOI 10.3390/cancers3022734; Sajjad N, 2019, INT J BIOCHEM CELL B, V115, DOI 10.1016/j.biocel.2019.105589; Sawyers CL, 2019, CELL, V179, P8, DOI 10.1016/j.cell.2019.08.027; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Singh R, 2018, J CLIN INVEST, V128, P3129, DOI 10.1172/JCI96060; Swaidani S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01293; Wang XC, 2013, J BIOL CHEM, V288, DOI 10.1074/jbc.M113.472704; Wilken JA, 2010, ANN NY ACAD SCI, V1210, P53, DOI 10.1111/j.1749-6632.2010.05782.x; Xu YX, 2002, J BIOL CHEM, V277, P28051, DOI 10.1074/jbc.M202665200; Zazo S, 2016, AM J CANCER RES, V6, P2661; Zepp JA, 2015, J IMMUNOL, V194, P2826, DOI 10.4049/jimmunol.1402647; Zhang L, 2013, MOL CELL, V51, P559, DOI 10.1016/j.molcel.2013.07.014; Zhou J, 2020, ANTI-CANCER DRUG, V31, P558, DOI 10.1097/CAD.0000000000000943	52	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2022	41	35					4119	4129		10.1038/s41388-022-02415-6	http://dx.doi.org/10.1038/s41388-022-02415-6		JUL 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4A3US	35864174	Green Published, hybrid			2022-12-28	WOS:000828442600001
J	Bian, TF; Wang, YZ; Botello, JF; Hu, Q; Jiang, YH; Zingone, A; Ding, HC; Wu, YG; Aly, FZ; Salloum, RG; Warren, G; Huo, ZG; Ryan, BM; Jin, LT; Xing, CG				Bian, Tengfei; Wang, Yuzhi; Botello, Jordy F.; Hu, Qi; Jiang, Yunhan; Zingone, Adriana; Ding, Haocheng; Wu, Yougen; Aly, F. Zahra; Salloum, Ramzi G.; Warren, Graham; Huo, Zhiguang; Ryan, Brid M.; Jin, Lingtao; Xing, Chengguo			LKB1 phosphorylation and deactivation in lung cancer by NNAL, a metabolite of tobacco-specific carcinogen, in an isomer-dependent manner	ONCOGENE			English	Article							PROTEIN-KINASE; SMOKING STATUS; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; NITROSAMINE; BIOMARKER; MOUSE; GENE; PHARMACOKINETICS; GLUCURONIDATION; ADENOCARCINOMA	LKB1 loss of function is one key oncogenic event in lung cancer. Clinical data suggest that LKB1 loss of function is associated with patients' smoking status. The responsible ingredients and molecular mechanisms in tobacco for LKB1 loss of function, however, are not defined. In this study, we reported that NNAL, a major metabolite of a tobacco-specific carcinogen NNK, induces LKB1 phosphorylation and its loss of function via the beta-AR/PKA signaling pathway in an isomer-dependent manner in human lung cancer cells. NNAL exposure also resulted in enhanced lung cancer cell migration and chemoresistance in an LKB1-dependent manner. A 120-day NNAL exposure in lung cancer cells, mimicking its chronic exposure among smokers, resulted in more prominent LKB1 phosphorylation, cell migration, and chemoresistance even in the absence of NNAL, indicating the long-lasting LKB1 loss of function although such an effect eventually disappeared after NNAL was removed for two months. These observations were confirmed in a lung cancer xenograft model. More importantly, human lung cancer tissues revealed elevated LKB1 phosphorylation in comparison to the paired normal lung tissues. These results suggest that LKB1 loss of function in human lung cancer could be extended to its phosphorylation, which may be mediated by NNAL from tobacco smoke in an isomer-dependent manner via the beta-AR/PKA signaling pathway.	[Bian, Tengfei; Wang, Yuzhi; Botello, Jordy F.; Hu, Qi; Wu, Yougen; Xing, Chengguo] Univ Florida, Dept Med Chem, Ctr Nat Prod Drug Discovery & Dev CNPD3, Gainesville, FL 32610 USA; [Jiang, Yunhan; Jin, Lingtao] UT Hlth San Antonio, Dept Mol Med, San Antonio, TX 78229 USA; [Zingone, Adriana; Ryan, Brid M.] NCI, Lab Human Carcinogenesis, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Ding, Haocheng; Huo, Zhiguang] Univ Florida, Coll Publ Hlth & Hlth Profess, Coll Med, Dept Biostat, Gainesville, FL 32610 USA; [Wu, Yougen] Hainan Univ, Coll Trop Agr & Forestry, 58 Renmin Ave, Haikou 570228, Hainan, Peoples R China; [Aly, F. Zahra] Univ Florida, Dept Pathol Immunol & Lab Med, 1345 Ctr Dr, Gainesville, FL 32610 USA; [Salloum, Ramzi G.] Univ Florida, Coll Med, Dept Hlth Outcome & Biomed Informat, Gainesville, FL 32610 USA; [Warren, Graham] Med Univ South Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA	State University System of Florida; University of Florida; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of Florida; Hainan University; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Medical University of South Carolina	Xing, CG (corresponding author), Univ Florida, Dept Med Chem, Ctr Nat Prod Drug Discovery & Dev CNPD3, Gainesville, FL 32610 USA.	chengguoxing@cop.ufl.edu			National Institute of Health [R01CA193286]; Harry T. Mangurian Jr.; College of Pharmacy Frank Duckworth Endowment; University of Florida Health Cancer Center Startup fund; University of Florida Medicinal Chemistry Mass Spectrometry Support; National Science Foundation of China	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harry T. Mangurian Jr.; College of Pharmacy Frank Duckworth Endowment; University of Florida Health Cancer Center Startup fund; University of Florida Medicinal Chemistry Mass Spectrometry Support; National Science Foundation of China(National Natural Science Foundation of China (NSFC))	The work was partly supported by grants from the National Institute of Health (R01CA193286) to CX, the Harry T. Mangurian Jr. Foundation to CX, College of Pharmacy Frank Duckworth Endowment to CX, University of Florida Health Cancer Center Startup fund to CX, and University of Florida Medicinal Chemistry Mass Spectrometry Support to CX. Y Wu was supported by a scholarship from the National Science Foundation of China. The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication. We also acknowledge the National Cancer Institute for providing PLCO information used in this manuscript. We would like to thank Sreekanth C. Narayanapillai, Santanu Hati, and Pedro Corral for the assistance with sample collection and characterization. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.	ADAMS JD, 1985, CARCINOGENESIS, V6, P509, DOI 10.1093/carcin/6.4.509; Amin RMS, 2008, PATHOL INT, V58, P84, DOI 10.1111/j.1440-1827.2007.02194.x; Baser S, 2006, CHEST, V130, P1784, DOI 10.1016/S0012-3692(15)50902-1; Borzi C, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13110385; Calles A, 2015, CLIN CANCER RES, V21, P2851, DOI 10.1158/1078-0432.CCR-14-3112; Carmella SG, 2005, CANCER EPIDEM BIOMAR, V14, P2669, DOI 10.1158/1055-9965.EPI-05-0129; Carmella SG, 1999, CANCER RES, V59, P3602; Carmella SG, 2006, CANCER EPIDEM BIOMAR, V15, P1490, DOI 10.1158/1055-9965.EPI-06-0199; Chen G, 2016, CANCER EPIDEM BIOMAR, V25, P1175, DOI 10.1158/1055-9965.EPI-15-1245; Church TR, 2009, CANCER EPIDEM BIOMAR, V18, P260, DOI 10.1158/1055-9965.EPI-08-0718; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Erickson P, 2018, CANCER EPIDEM BIOMAR, V27, P1518, DOI [10.1158/1055-9965.EPI-18-0366, 10.1158/1055-9965.epi-18-0366]; Ferketich AK, 2013, CANCER-AM CANCER SOC, V119, P847, DOI 10.1002/cncr.27824; Gemine RE, 2019, LUNG CANCER, V129, P1, DOI 10.1016/j.lungcan.2018.12.028; Gill RK, 2011, ONCOGENE, V30, P3784, DOI 10.1038/onc.2011.98; Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225; Hasegawa T, 2020, IN VIVO, V34, P2997, DOI 10.21873/invivo.12131; HECHT SS, 1993, CARCINOGENESIS, V14, P229, DOI 10.1093/carcin/14.2.229; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; Hecht SS, 1999, CANCER RES, V59, P590; HHS, 2014, HLTH CONS SMOK 50 YE; Jalas JR, 2003, CHEM RES TOXICOL, V16, P782, DOI 10.1021/tx034021t; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jin LT, 2018, CANCER CELL, V34, P315, DOI 10.1016/j.ccell.2018.06.012; Jin LT, 2018, MOL CELL, V69, P87, DOI 10.1016/j.molcel.2017.11.025; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Kozlovich S, 2015, CHEM RES TOXICOL, V28, P2112, DOI 10.1021/acs.chemrestox.5b00278; Lee SJ, 2014, THORAC CANCER, V5, P43, DOI 10.1111/1759-7714.12051; Lin CX, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000027841; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Meaney CL, 2019, J THORAC ONCOL, V14, P1192, DOI 10.1016/j.jtho.2019.03.014; Mitchell KG, 2020, ANN THORAC SURG, V110, P1131, DOI 10.1016/j.athoracsur.2020.03.114; Modesto JL, 2015, MOL CARCINOGEN, V54, pE94, DOI 10.1002/mc.22187; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Murphy SE, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0057-y; Narayanapillai SC, 2016, DRUG METAB DISPOS, V44, P422, DOI 10.1124/dmd.115.068387; Nia PS, 2005, LUNG CANCER-J IASLC, V47, P351, DOI 10.1016/j.lungcan.2004.08.011; PLCO Datasets, 2020, US; Pore N, 2021, CANCER DISCOV, V11, P2828, DOI 10.1158/2159-8290.CD-20-1543; Richter E, 2009, CHEM RES TOXICOL, V22, P1008, DOI 10.1021/tx800461d; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Schuller HM, 1999, CANCER RES, V59, P4510; Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x; Shen J, 2012, CANCER LETT, V318, P106, DOI 10.1016/j.canlet.2011.12.008; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Siegel RL, 2018, CA-CANCER J CLIN, V68, P329, DOI 10.3322/caac.21460; Smoking Cessation, 2020, REP SURG GEN; Stepanov I, 2008, CANCER EPIDEM BIOMAR, V17, P1764, DOI 10.1158/1055-9965.EPI-07-2844; Upadhyaya P, 1999, CARCINOGENESIS, V20, P1577, DOI 10.1093/carcin/20.8.1577; Wang Y, 2020, CANCER PREV RES, V13, P483, DOI 10.1158/1940-6207.CAPR-19-0501; Wang Y, 2019, TOXICOL LETT, V311, P11, DOI 10.1016/j.toxlet.2019.04.020; Wang Y, 2018, CHEM RES TOXICOL, V31, P836, DOI 10.1021/acs.chemrestox.8b00155; Wei BN, 2016, J EXPO SCI ENV EPID, V26, P249, DOI 10.1038/jes.2014.88; Xia Y, 2011, BIOMARKERS, V16, P112, DOI 10.3109/1354750X.2010.533288; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Yang CC, 2019, J NURS RES, V27, DOI 10.1097/jnr.0000000000000293	56	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					4042	4054		10.1038/s41388-022-02410-x	http://dx.doi.org/10.1038/s41388-022-02410-x		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35835853				2022-12-28	WOS:000825171000001
J	Meng, Q; Lu, YX; Wei, C; Wang, ZX; Lin, JF; Liao, K; Luo, XJ; Yu, K; Han, Y; Li, JJ; Tan, YT; Li, H; Zeng, ZL; Li, B; Xu, RH; Ju, HQ				Meng, Qi; Lu, Yun-Xin; Wei, Chen; Wang, Zi-Xian; Lin, Jin-Fei; Liao, Kun; Luo, Xiao-Jing; Yu, Kai; Han, Yi; Li, Jia-Jun; Tan, Yue-Tao; Li, Hao; Zeng, Zhao-Lei; Li, Bo; Xu, Rui-Hua; Ju, Huai-Qiang			Arginine methylation of MTHFD1 by PRMT5 enhances anoikis resistance and cancer metastasis	ONCOGENE			English	Article							PHOSPHORYLATION; DETACHMENT; METABOLISM; SURVIVAL; TARGET	Metastasis accounts for the major cause of cancer-related mortality. How disseminated tumor cells survive under suspension conditions and avoid anoikis is largely unknown. Here, using a metabolic enzyme-centered CRISPR-Cas9 genetic screen, we identified methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1 (MTHFD1) as a novel suppressor of anoikis. MTHFD1 depletion obviously restrained the capacity of cellular antioxidant defense and inhibited tumor distant metastasis. Mechanistically, MTHFD1 was found to bind the protein arginine methyltransferase 5 (PRMT5) and then undergo symmetric dimethylation on R173 by PRMT5. Under suspension conditions, the interaction between MTHFD1 and PRMT5 was strengthened, which increased the symmetric dimethylation of MTHFD1. The elevated methylation of MTHFD1 largely augmented its metabolic activity to generate NADPH, therefore leading to anoikis resistance and distant organ metastasis. Therapeutically, genetic depletion or pharmacological inhibition of PRMT5 declined tumor distant metastasis. And R173 symmetric dimethylation status was associated with metastasis and prognosis of ESCC patients. In conclusion, our study uncovered a novel regulatory role and therapeutic implications of PRMT5/MTHFD1 axis in facilitating anoikis resistance and cancer metastasis.	[Meng, Qi; Lu, Yun-Xin; Wei, Chen; Wang, Zi-Xian; Lin, Jin-Fei; Liao, Kun; Luo, Xiao-Jing; Yu, Kai; Han, Yi; Li, Jia-Jun; Tan, Yue-Tao; Li, Hao; Zeng, Zhao-Lei; Xu, Rui-Hua; Ju, Huai-Qiang] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, State Key Lab Oncol,South China Collaborat Innova, Guangzhou 510060, Peoples R China; [Meng, Qi; Lu, Yun-Xin; Wei, Chen; Wang, Zi-Xian; Lin, Jin-Fei; Luo, Xiao-Jing; Yu, Kai; Han, Yi; Li, Jia-Jun; Tan, Yue-Tao; Zeng, Zhao-Lei; Xu, Rui-Hua; Ju, Huai-Qiang] Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou 510060, Peoples R China; [Liao, Kun; Li, Bo] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem & Mol Biol, Guangzhou 510080, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Sun Yat Sen University	Xu, RH; Ju, HQ (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, State Key Lab Oncol,South China Collaborat Innova, Guangzhou 510060, Peoples R China.; Xu, RH; Ju, HQ (corresponding author), Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou 510060, Peoples R China.	xurh@sysucc.org.cn; juhq@sysucc.org.cn	xu, rui/GRX-5734-2022		National Natural Science Foundation of China [81802452, 82002465]; Natural Science Foundation of Guangdong Province [2019A1515010233]; Science and Technology Program of Guangdong [2019B020227002]; Guangdong Esophageal Cancer Institute Science and Technology Program [M202003]; Bureau of Education of Guangzhou Municipality [202032801]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-I2M-5-036]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Program of Guangdong; Guangdong Esophageal Cancer Institute Science and Technology Program; Bureau of Education of Guangzhou Municipality; CAMS Innovation Fund for Medical Sciences (CIFMS)	This research was supported by the National Natural Science Foundation of China (82022052, 82073112 and 81930065), Natural Science Foundation of Guangdong Province (2019A1515010233), Science and Technology Program of Guangdong (2019B020227002), Guangdong Esophageal Cancer Institute Science and Technology Program (M202003), National Natural Science Foundation of China (81802452, 82002465), Bureau of Education of Guangzhou Municipality (202032801) and CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-I2M-5-036).	Antonysamy S, 2017, SUBCELL BIOCHEM, V83, P185, DOI 10.1007/978-3-319-46503-6_7; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Cai CC, 2021, ADV SCI, V8, DOI 10.1002/advs.202003047; Cai Z, 2020, MOL CELL, V80, P263, DOI 10.1016/j.molcel.2020.09.018; Chen H, 2006, NUCLEIC ACIDS RES, V34, pW249, DOI 10.1093/nar/gkl233; Cheng TY, 2018, ONCOGENE, V37, P1730, DOI 10.1038/s41388-017-0086-y; Deng WK, 2017, BRIEF BIOINFORM, V18, P647, DOI 10.1093/bib/bbw041; Du SC, 2021, ONCOGENE, V40, P5764, DOI 10.1038/s41388-021-01988-y; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Guccione E, 2019, NAT REV MOL CELL BIO, V20, P642, DOI 10.1038/s41580-019-0155-x; Gustafsson R, 2017, CANCER RES, V77, P937, DOI 10.1158/0008-5472.CAN-16-1476; Hitosugi T, 2014, ONCOGENE, V33, P4279, DOI 10.1038/onc.2013.406; Hoxhaj G, 2019, SCIENCE, V363, P1088, DOI 10.1126/science.aau3903; Hu D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9419; Hwang JW, 2021, EXP MOL MED, V53, P788, DOI 10.1038/s12276-021-00613-y; Jarrold J, 2019, TRENDS MOL MED, V25, P993, DOI 10.1016/j.molmed.2019.05.007; Ju HQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00326-0; Ju HQ, 2019, JNCI-J NATL CANCER I, V111, P584, DOI 10.1093/jnci/djy160; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Li G, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2019822118; Li W, 2021, NAT METAB, V3, P75, DOI 10.1038/s42255-020-00330-2; Li W, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0843-6; Liang C, 2020, GUT, V69, P888, DOI 10.1136/gutjnl-2018-317163; Lu YX, 2018, CANCER RES, V78, P1972, DOI 10.1158/0008-5472.CAN-17-3155; Mason JA, 2017, TRENDS CANCER, V3, P475, DOI 10.1016/j.trecan.2017.04.009; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Rao XJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9468; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; TheUniProtConsortium, 2017, Nucleic Acids Res, V45, pD158, DOI 10.1093/nar/gkw1099; Wang B, 2020, EMBO REP, V21, DOI 10.15252/embr.201948183; Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556-018-0266-1; Wang XY, 2021, CELL DEATH DIFFER, V28, P2931, DOI 10.1038/s41418-021-00793-0; Wang YN, 2018, ONCOGENE, V37, P6025, DOI 10.1038/s41388-018-0384-z; Wang YQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02951-4; Wei QY, 2020, ONCOGENE, V39, P6139, DOI 10.1038/s41388-020-01432-7; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Yu H, 2019, FUTURE ONCOL, V15, P1771, DOI 10.2217/fon-2018-0606; Zhang HF, 2021, CANCER DISCOV, V11, P2884, DOI 10.1158/2159-8290.CD-20-1690; Zhang J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13732; Zhou LS, 2016, EMBO REP, V17, P811, DOI 10.15252/embr.201541643; Zhu YH, 2020, MOL CELL, V77, P138, DOI 10.1016/j.molcel.2019.10.015	43	1	1	12	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3912	3924		10.1038/s41388-022-02387-7	http://dx.doi.org/10.1038/s41388-022-02387-7		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35798877				2022-12-28	WOS:000821721300005
J	Hang, XH; Zhao, L; Wu, BH; Li, SJ; Liu, PP; Xu, J; Wang, XY; Chi, PL; Chen, C; Niu, T; Dai, LZ; Liu, Y				Hang, Xiaohang; Zhao, Lei; Wu, Baohong; Li, Shujun; Liu, Pengpeng; Xu, Jing; Wang, Xinyuan; Chi, Pengliang; Chen, Chong; Niu, Ting; Dai, Lunzhi; Liu, Yu			BCL-2 isoform beta promotes angiogenesis by TRiC-mediated upregulation of VEGF-A in lymphoma	ONCOGENE			English	Article							EXPRESSION; INHIBITION; CELLS; OVEREXPRESSION; DISCOVERIES; INDUCTION; VEGF(165); SURVIVAL	Bcl-2 (B-cell lymphoma 2), the first identified anti-apoptosis factor, encodes two transcripts, the long isoform alpha and the short isoform beta. The current understanding of the Bcl-2 function mainly focuses on Bcl-2 alpha, while little is known about the function of Bcl-2 beta, which lacks the transmembrane domain and contains 10 unique amino acids at the C-terminus instead. Here, we analyzed the expressions of BCL-2 two isoforms in diffused large B-cell lymphoma (DLBCL) and found a significant positive correlation between them. Then, with the CRISPR/Cas9-based transcriptional activator (CRISPRa), we generated mouse B-cell lymphomas with Bcl-2 upregulation from the endogenous locus, in which both Bcl-2 alpha and Bcl-2 beta levels were increased. Bcl-2 beta itself promoted angiogenesis both in vitro and in vivo through increased vascular endothelial growth factor A (VEGF-A). Inhibiting VEGF receptors with Axitinib reduced angiogenesis induced by Bcl-2 beta overexpression. Co-immunoprecipitation and mass spectrometry analysis revealed that Bcl-2 beta interacted with the T-complex protein ring complex (TRiC). Disruption of TRiC significantly impaired the angiogenesis-promoting activity of Bcl-2 beta, indicated by reduced VEGF-A protein level and HUVEC tube formation. Thus, our study suggests that Bcl-2 isoform beta plays a role in promoting tumor angiogenesis through the Bcl-2 beta-TRiC-VEGF-A axis.	[Hang, Xiaohang; Zhao, Lei; Wu, Baohong; Li, Shujun; Liu, Pengpeng; Xu, Jing; Chi, Pengliang; Chen, Chong; Niu, Ting; Liu, Yu] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Hematol, Chengdu, Sichuan, Peoples R China; [Hang, Xiaohang; Zhao, Lei; Wu, Baohong; Li, Shujun; Liu, Pengpeng; Xu, Jing; Chi, Pengliang; Chen, Chong; Niu, Ting; Liu, Yu] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Sichuan, Peoples R China; [Wang, Xinyuan; Dai, Lunzhi] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Gen Practice, Chengdu, Sichuan, Peoples R China; [Wang, Xinyuan; Dai, Lunzhi] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Natl Clin Res Ctr Geriatr, Chengdu, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University	Liu, Y (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Hematol, Chengdu, Sichuan, Peoples R China.; Liu, Y (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Sichuan, Peoples R China.; Dai, LZ (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Gen Practice, Chengdu, Sichuan, Peoples R China.; Dai, LZ (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Natl Clin Res Ctr Geriatr, Chengdu, Sichuan, Peoples R China.	lunzhi.dai@scu.edu.cn; yuliuscu@scu.edu.cn	wang, xinyuan/HHM-2418-2022	Chen, Chong/0000-0002-6787-0495; Dai, Lunzhi/0000-0002-3003-8910	National Natural Science Foundation of China [82130007, 81670182, 82073221]; National Key R&D Program of China [2017YFA0505600, 2018YFC2000305]; Sichuan Science and Technology Program [2018JZ0077]; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYJC21009, ZYYC20007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Sichuan Science and Technology Program; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University	We thank Dr. Yuquan Wei for his generous support. We thank Dr. Ruizhan Tong and Dr. Yinglan Zhao for their technical assistance. We thank Dr. Jianjun Li for his clinical assistance. We thank all the lab members in the Chen and Liu laboratory for their insightful advice and kindly support. The results published here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.This work was supported by the National Natural Science Foundation of China (grants 82130007, 81670182, and 82073221), the National Key R&D Program of China (grants 2017YFA0505600 and 2018YFC2000305), the Sichuan Science and Technology Program (grants 2018JZ0077), and the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (grants ZYJC21009 and ZYYC20007).	Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Bohonowych JE, 2010, J ONCOL, V2010, DOI 10.1155/2010/412985; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Chavez A, 2015, NAT METHODS, V12, P326, DOI [10.1038/NMETH.3312, 10.1038/nmeth.3312]; Chen M, 2021, CANCER DISCOV, V11, P194, DOI 10.1158/2159-8290.CD-20-0336; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; DeCicco-Skinner KL, 2014, JOVE-J VIS EXP, DOI 10.3791/51312; Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; FUKUHARA S, 1978, INT J CANCER, V22, P14, DOI 10.1002/ijc.2910220105; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Guillem V, 2015, LEUKEMIA RES, V39, P1278, DOI 10.1016/j.leukres.2015.08.014; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095; Kawatani M, 2003, EXP CELL RES, V286, P57, DOI 10.1016/S0014-4827(03)00098-3; Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; Massaad CA, 2004, J BIOL CHEM, V279, P54470, DOI 10.1074/jbc.M407659200; Merino D, 2018, CANCER CELL, V34, P879, DOI 10.1016/j.ccell.2018.11.004; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Ozawa K, 2001, J CLIN INVEST, V108, P41, DOI 10.1172/JCI11772; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; Riedell PA, 2018, CANCER-AM CANCER SOC, V124, P4622, DOI 10.1002/cncr.31646; Singh R, 2019, NAT REV MOL CELL BIO, V20, P175, DOI 10.1038/s41580-018-0089-8; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Warren CFA, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1407-6; Wei T, 2021, CORRPLOT VISUALIZATI; Zhang Q, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.153768	36	2	2	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3655	3663		10.1038/s41388-022-02372-0	http://dx.doi.org/10.1038/s41388-022-02372-0		JUN 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35701534				2022-12-28	WOS:000810849500003
J	Alfaro-Arnedo, E; Lopez, IP; Pineiro-Hermida, S; Canalejo, M; Gotera, C; Sola, JJ; Roncero, A; Peces-Barba, G; Ruiz-Martinez, C; Pichel, JG				Alfaro-Arnedo, Elvira; Lopez, Iciar P.; Pineiro-Hermida, Sergio; Canalejo, Marta; Gotera, Carolina; Javier Sola, Jesus; Roncero, Alejandra; Peces-Barba, German; Ruiz-Martinez, Carlos; Pichel, Jose G.			IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression	ONCOGENE			English	Article							FACTOR 1 RECEPTOR; PROGNOSTIC-FACTOR; DENDRITIC CELLS; GROWTH-FACTORS; UP-REGULATION; T-CELLS; EXPRESSION; ACTIVATION; BLOCKADE; PATHWAY	Given the long-term ineffectiveness of current therapies and late-stage diagnoses, lung cancer is a leading cause of malignant diseases. Tumor progression is influenced by cancer cell interactions with the tumor microenvironment (TME). Insulin-like growth factor 1 receptor (IGF1R) was reported to affect the TME; however, the role of IGF1R in lung TME has not been investigated. First, we assessed IGF1R genomic alterations and expression in NSCLC patient tissue samples, as well as IGF1R serum levels. Next, we performed tumor heterotopic transplantation and pulmonary metastases in IGF1R-deficient mice using melanoma and Lewis lung carcinoma (LLC) cells. Herein we report increased amplification and mRNA expression, as well as increased protein expression (IGF1R/p-IGF1R) and IGF1R levels in tumor samples and serum from NSCLC patients, respectively. Moreover, IGF1R deficiency in mice reduced tumor growth, proliferation, inflammation and vascularization, and increased apoptosis after tumor heterotopic transplantation. Following induction of lung metastasis, IGF1R-deficient lungs also demonstrated a reduced tumor burden, and decreased expression of tumor progression markers, p-IGF1R and p-ERK1/2. Additionally, IGF1R-deficient lungs showed increased apoptosis and diminished proliferation, vascularization, EMT and fibrosis, along with attenuated inflammation and immunosuppression. Accordingly, IGF1R deficiency decreased expression of p-IGF1R in blood vessels, fibroblasts, tumor-associated macrophages and FOXP3(+) tumor-infiltrating lymphocytes. Our results demonstrate that IGF1R promotes( )metastatic tumor initiation and progression in lung TME. Furthermore, our research indicates that IGF1R could be a potential biomarker for early prediction of drug response and clinical evolution in NSCLC patients.	[Alfaro-Arnedo, Elvira; Lopez, Iciar P.; Canalejo, Marta; Pichel, Jose G.] Fdn Rioja Salud, Ctr Biomed Res La Rioja CIBIR, Lung Canc & Resp Dis Unit, Logrono, Spain; [Pineiro-Hermida, Sergio] Spanish Natl Canc Ctr CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, Madrid, Spain; [Gotera, Carolina; Peces-Barba, German] IIS Fdn Jimenez Diaz, Madrid, Spain; [Gotera, Carolina; Peces-Barba, German; Pichel, Jose G.] CIBERES, Spanish Biomed Res Networking Ctr, Madrid, Spain; [Javier Sola, Jesus] Rioja Salud, Pathol Anat Serv, Hosp Univ San Pedro, Logrono, Spain; [Roncero, Alejandra; Ruiz-Martinez, Carlos] Rioja Salud, Hosp Univ San Pedro, Pneumol Serv, Logrono, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Fundacion Jimenez Diaz; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Pichel, JG (corresponding author), Fdn Rioja Salud, Ctr Biomed Res La Rioja CIBIR, Lung Canc & Resp Dis Unit, Logrono, Spain.; Pichel, JG (corresponding author), CIBERES, Spanish Biomed Res Networking Ctr, Madrid, Spain.	jgpichel@riojasalud.es	Pichel, Jose G/AAF-2255-2019; Sola Gallego, Jesus Javier/Q-3991-2017	Pichel, Jose G/0000-0001-8580-0952; Sola Gallego, Jesus Javier/0000-0002-3177-168X	Spanish MCIN/AEI [PGC2018-097397-B-I00]; Fundacion Rioja Salud (Gobierno de La Rioja, Spain) [6.FRS-ABC.006]; European Regional Development and European Social Funds; European Union	Spanish MCIN/AEI; Fundacion Rioja Salud (Gobierno de La Rioja, Spain); European Regional Development and European Social Funds; European Union(European Commission)	This work was supported by the Spanish MCIN/AEI/https://doi.org/10.13039/501100011033 (Project PGC2018-097397-B-I00), the Fundacion Rioja Salud (Gobierno de La Rioja, Spain) (Project 6.FRS-ABC.006), and the European Regional Development and European Social Funds (ERDF/ESF by the European Union) to JGP.	Ahamed K, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-31; Ajona D, 2020, NAT CANCER, V1, P75, DOI 10.1038/s43018-019-0007-9; Alami N, 2008, GROWTH HORM IGF RES, V18, P487, DOI 10.1016/j.ghir.2008.04.002; Alfaro-Arnedo E, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9080912; Bacic I, 2018, ONCOL LETT, V15, P2335, DOI 10.3892/ol.2017.7576; Baxter RC, 2014, NAT REV CANCER, V14, P329, DOI 10.1038/nrc3720; Bertrand F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02358-7; Bertrand F, 2015, CANCER RES, V75, P2619, DOI 10.1158/0008-5472.CAN-14-2524; Bilbao D, 2014, EMBO MOL MED, V6, P1423, DOI 10.15252/emmm.201303376; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008; Chen B, 2013, CANCER INVEST, V31, P454, DOI 10.3109/07357907.2013.820315; Chen YB, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0568-z; Chou CH, 2012, ONCOGENE, V31, P458, DOI 10.1038/onc.2011.240; Cox G, 2000, CLIN CANCER RES, V6, P2349; DiToro D, 2020, IMMUNITY, V52, P650, DOI 10.1016/j.immuni.2020.03.013; El-Badrawy MK, 2014, J BRONCHOL INTERN PU, V21, P327, DOI 10.1097/LBR.0000000000000094; Fraser Douglas D, 2020, Crit Care Explor, V2, pe0189, DOI 10.1097/CCE.0000000000000189; Gerull WD, 2021, J THORAC DIS, V13, P2585, DOI 10.21037/jtd.2020.04.28; Girnita L, 2014, CELL MOL LIFE SCI, V71, P2403, DOI 10.1007/s00018-013-1514-y; Goc J, 2014, CANCER RES, V74, P705, DOI 10.1158/0008-5472.CAN-13-1342; Griffiths CD, 2020, NATURE, V583, P615, DOI 10.1038/s41586-020-2369-7; Han SW, 2006, CANCER RES, V66, P315, DOI 10.1158/0008-5472.CAN-05-2367; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He M, 2014, LAB CHIP, V14, P3773, DOI 10.1039/c4lc00662c; Hiraoka K, 2006, BRIT J CANCER, V94, P275, DOI 10.1038/sj.bjc.6602934; Hou PF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173048; Huang JQ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1895-2; Iams WT, 2015, CLIN CANCER RES, V21, P4270, DOI 10.1158/1078-0432.CCR-14-2518; Ireland L, 2018, ONCOGENE, V37, P2022, DOI 10.1038/s41388-017-0115-x; Ireland L, 2016, CANCER RES, V76, P6851, DOI 10.1158/0008-5472.CAN-16-1201; Jackson HW, 2017, NAT REV CANCER, V17, P38, DOI 10.1038/nrc.2016.115; Kasi, 2021, LUNG METASTASIS; Kellar A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/621324; Kim BN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67325-7; Le HT, 2021, CANCERS, V13, DOI 10.3390/cancers13051041; Li Z, 2018, LUNG CANCER, V123, P127, DOI 10.1016/j.lungcan.2018.07.015; Lin HH, 2015, CANCER SCI, V106, P299, DOI 10.1111/cas.12604; Lopez IP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166388; Maru Y, 2015, J MOL MED, V93, P1185, DOI 10.1007/s00109-015-1355-2; Mojic M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010089; Moody G, 2014, J ENDOCRINOL, V221, P145, DOI 10.1530/JOE-13-0306; Neeve SC, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1076; Nurwidya F, 2016, MALAYS J MED SCI, V23, P9; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orlow I, 2008, J CLIN ONCOL, V26, P3560, DOI 10.1200/JCO.2007.13.2654; Osher E, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080895; Passlick B, 2000, CLIN CANCER RES, V6, P3944; Lopez IP, 2015, TRANSGENIC RES, V24, P279, DOI 10.1007/s11248-014-9837-5; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Perrot I, 2007, J IMMUNOL, V178, P2763, DOI 10.4049/jimmunol.178.5.2763; Pineiro-Hermida S, 2017, ALLERGY, V72, P1317, DOI 10.1111/all.13142; Pineiro-Hermida S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190159; Pineiro-Hermida S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04561-4; Rangachari D, 2013, CURR TREAT OPTION ON, V14, P580, DOI 10.1007/s11864-013-0250-8; Schulze AB, 2020, THORAC CANCER, V11, P120, DOI 10.1111/1759-7714.13248; Shang GS, 2017, ONCOL LETT, V13, P4657, DOI 10.3892/ol.2017.6048; Siegel RL., CANC STAT CA CANC J, V2021, P7; Spadaro O, 2017, CELL REP, V19, P225, DOI 10.1016/j.celrep.2017.03.046; Sumitomo R, 2019, EXP THER MED, V18, P4490, DOI 10.3892/etm.2019.8068; Sung WW, 2013, CLIN CANCER RES, V19, P4092, DOI 10.1158/1078-0432.CCR-12-3439; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Tsai Jong-Rung, 2012, Cell Oncol (Dordr), V35, P461, DOI 10.1007/s13402-012-0105-5; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644; Lopez-Malpartida AV, 2009, LUNG CANCER, V65, P25, DOI 10.1016/j.lungcan.2008.10.009; Wang JY, 2015, ONCOTARGET, V6, P20636, DOI 10.18632/oncotarget.4114; Wang YA, 2017, MOL CANCER RES, V15, P896, DOI 10.1158/1541-7786.MCR-16-0390; Wang Z, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6057589; Xiao Y, 2017, ONCOL LETT, V14, P6876, DOI 10.3892/ol.2017.7014; Yamaguchi T, 2015, INT J CARDIOL, V178, P239, DOI 10.1016/j.ijcard.2014.10.144; Yang CH, 2015, BBA-MOL BASIS DIS, V1852, P1540, DOI 10.1016/j.bbadis.2015.04.020; Yang SC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0700-1; Yang YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099763; Yao MJ, 2020, CELL, V180, P502, DOI 10.1016/j.cell.2019.12.024; Yohena T, 2009, J THORAC ONCOL, V4, P284, DOI 10.1097/JTO.0b013e31819852d5; Yuan JS, 2018, ONCOL LETT, V15, P41, DOI 10.3892/ol.2017.7276; Zaidi MR, 2019, J INTERF CYTOK RES, V39, P30, DOI 10.1089/jir.2018.0087; Zhao YY, 2012, J THORAC ONCOL, V7, P71, DOI 10.1097/JTO.0b013e31823085f4; Zheng X, 2020, CANCER RES, V80, P4414, DOI 10.1158/0008-5472.CAN-20-0069; Zuazo M, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910293	81	2	2	4	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3625	3639		10.1038/s41388-022-02376-w	http://dx.doi.org/10.1038/s41388-022-02376-w		JUN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35688943	hybrid, Green Published			2022-12-28	WOS:000809307500002
J	Ji, DL; Shang, GL; Wei, EW; Jia, YJ; Wang, CY; Zhang, Q; Zeng, L				Ji, Donglei; Shang, Guanglei; Wei, Enwei; Jia, Yanjie; Wang, Chunyu; Zhang, Qiang; Zeng, Lei			Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; ANDROGEN DEPRIVATION THERAPY; BET BROMODOMAIN PROTEINS; CUB-DOMAIN; PROGNOSTIC MARKER; MECHANISMS; IDENTIFICATION; INHIBITION; SURVIVAL; GROWTH	CUB domain-containing protein 1 (CDCP1), a transmembrane protein with tumor pro-metastatic activity, is highly expressed in late-stage and castrate-resistant prostate cancer (CRPC). However, the molecular mechanism driving CDCP1 overexpression in CRPC progress remains elusive. Here we report that transcription cofactors BRD4 and CBP/p300 co-regulate transcriptional expression of CDCP1 in CRPC tumorigenesis. In contrast to androgen receptor (AR) in CRPC, increased expression of BRD4 and CBP/p300 is strongly correlated with CDCP1 gene amplification. Combined knockdown or dual-inhibition of BRD4 and CBP/p300 down-regulated CDCP1 transcription and downstream PI3K/AKT and/or SRC/MAPK signaling pathways in CRPC cells much more so than single-protein perturbation. Our biochemical and structural analyses further showed that NEO2734, a dual-inhibitor targeting BRD4 and p300 bromodomains exhibits greater efficacy than single inhibitors for BRD4 or CBP/p300 in suppressing CDCP1 transcriptional expression and its downstream signaling pathways in CRPC cell proliferation and metastasis. Our study illustrates that targeting CDCP1 through dual-inhibition of BRD4 and CBP/p300 represents a synergistic therapeutic strategy for new treatment of CRPC.	[Ji, Donglei; Shang, Guanglei; Wei, Enwei; Jia, Yanjie; Zhang, Qiang; Zeng, Lei] Jilin Univ, Hosp 1, Bethune Inst Epigenet Med, Changchun 130021, Jilin, Peoples R China; [Ji, Donglei; Shang, Guanglei; Wei, Enwei; Zeng, Lei] Jilin Univ, Int Ctr Future Sci, Changchun 130012, Peoples R China; [Wang, Chunyu] Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Jilin, Peoples R China	Jilin University; Jilin University; Jilin University	Zeng, L (corresponding author), Jilin Univ, Hosp 1, Bethune Inst Epigenet Med, Changchun 130021, Jilin, Peoples R China.; Zeng, L (corresponding author), Jilin Univ, Int Ctr Future Sci, Changchun 130012, Peoples R China.	leizeng@jlu.edu.cn		Zeng, Lei/0000-0002-4236-6735	First Hospital of Jilin University (Changchun, China); Open Project of State Key Laboratory for Supramolecular Structure and Materials, JLU [SKLSSM201602]; JLU Science and Technology Innovative Research Team (JLUSTIRT) [2017TD-25]; International Center of Future Science, JLU; National Natural Science Foundation of China [31770780]	First Hospital of Jilin University (Changchun, China); Open Project of State Key Laboratory for Supramolecular Structure and Materials, JLU; JLU Science and Technology Innovative Research Team (JLUSTIRT); International Center of Future Science, JLU; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported in part by the research fund from the First Hospital of Jilin University (Changchun, China), the Open Project of State Key Laboratory for Supramolecular Structure and Materials, JLU (SKLSSM201602), JLU Science and Technology Innovative Research Team (JLUSTIRT, 2017TD-25), International Center of Future Science, JLU, and National Natural Science Foundation of China (31770780; L.Z.).	Alajati A, 2020, J CLIN INVEST, V130, P2435, DOI 10.1172/JCI131133; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai L, 2018, MOL CELL, V72, P341, DOI 10.1016/j.molcel.2018.08.029; Cao MQ, 2016, TUMOR BIOL, V37, P1651, DOI 10.1007/s13277-015-3527-7; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Devaiah BN, 2020, P NATL ACAD SCI USA, V117, P13457, DOI 10.1073/pnas.1919507117; Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0915-9; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Garcia-Carpizo V, 2019, MOL CANCER RES, V17, P720, DOI 10.1158/1541-7786.MCR-18-0719; Gioia R, 2011, BLOOD, V118, P2211, DOI 10.1182/blood-2010-10-313692; Gusenbauer S, 2013, ONCOGENE, V32, P3846, DOI 10.1038/onc.2012.396; Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Hay DA, 2014, J AM CHEM SOC, V136, P9308, DOI 10.1021/ja412434f; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Heitmann JS, 2020, ANN HEMATOL, V99, P477, DOI 10.1007/s00277-020-03907-9; Holmes L, 2007, PROSTATE CANCER P D, V10, P388, DOI 10.1038/sj.pcan.4500973; Huang YQ, 2018, ONCOL LETT, V15, P6063, DOI 10.3892/ol.2018.8123; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jin LY, 2017, CANCER RES, V77, P5564, DOI 10.1158/0008-5472.CAN-17-0314; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Khan T, 2021, CANCER RES, V81, P2259, DOI 10.1158/0008-5472.CAN-20-2978; Kryza T, 2020, THERANOSTICS, V10, P4116, DOI 10.7150/thno.43589; Leroy C, 2015, ONCOGENE, V34, P5593, DOI 10.1038/onc.2015.19; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Ren CY, 2018, P NATL ACAD SCI USA, V115, P7949, DOI 10.1073/pnas.1720000115; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Shorstova T, 2021, BRIT J CANCER, V124, P1478, DOI 10.1038/s41416-021-01321-0; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Spriano F, 2020, BLOOD ADV, V4, P4124, DOI 10.1182/bloodadvances.2020001879; Uekita T, 2011, CANCER SCI, V102, P1943, DOI 10.1111/j.1349-7006.2011.02052.x; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Welti J, 2021, CANCER DISCOV, V11, P1118, DOI 10.1158/2159-8290.CD-20-0751; Wright HJ, 2016, ONCOGENE, V35, P4762, DOI 10.1038/onc.2016.7; Wu D, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108744; Wyce A, 2013, ONCOTARGET, V4, P2419, DOI 10.18632/oncotarget.1572; Yang CH, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-21; Zaware N, 2019, NAT STRUCT MOL BIOL, V26, P870, DOI 10.1038/s41594-019-0309-8; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang JW, 2017, APOPTOSIS, V22, P877, DOI 10.1007/s10495-017-1368-0; Zucconi BE, 2019, BIOCHEMISTRY-US, V58, P2133, DOI 10.1021/acs.biochem.9b00160	50	0	0	5	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3251	3262		10.1038/s41388-022-02327-5	http://dx.doi.org/10.1038/s41388-022-02327-5		MAY 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35513563				2022-12-28	WOS:000791081400002
J	Zhang, Y; Xu, ZF; Wen, W; Liu, ZC; Zhang, C; Li, M; Hu, FP; Wei, S; Bae, SH; Zhou, JB; Liu, RH; Wang, LZ				Zhang, Yue; Xu, Zhifang; Wen, Wen; Liu, Zhichao; Zhang, Chao; Li, Ming; Hu, Fengping; Wei, Shi; Bae, Sejong; Zhou, Jiangbing; Liu, Runhua; Wang, Lizhong			The microRNA-3622 family at the 8p21 locus exerts oncogenic effects by regulating the p53-downstream gene network in prostate cancer progression	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; FOXP3; EXPRESSION; REPRESSION; APOPTOSIS; SITES; MYC; P53	For human prostate cancer, the chromosome 8p21 locus, which contains NKX3.1 and the microRNA (miR)-3622 family (miR-3622a/b), is a frequently deleted region. Thus, miR-3622 is proposed as a suppressor for prostate cancer, but its role remains debatable. In the present study, we found that expression of miR-3622a was lower, whereas expression of miR-3622b-3p was higher in human prostate cancer tissues than in normal prostate tissues. miR-3622a-3p inhibited cell migration and invasion of human prostate cancer cells, whereas miR-3622b-3p facilitated cell proliferation, migration, and invasion. To address the opposing roles of miR-3622 family members in various human prostate cancer cell lines, we knocked out (KO) endogenous miR-3622, including both miR-3622a/b. Our results showed that miR-3622 KO reduced cell proliferation, migration, and invasion in vitro and tumor growth and metastasis in vivo. Functional analyses revealed that miR-3622 regulated the p53-downstream gene network, including AIFM2, c-MYC, and p21, to control apoptosis and the cell cycle. Furthermore, using CRISPR interference, miRNA/mRNA immunoprecipitation assays, and dual-luciferase assays, we established that AIFM2, a direct target of miR-3622b-3p, is responsible for miR-3622 KO-induced apoptosis. We identified an miR-3622-AIFM2 axis that contributes to oncogenic function during tumor progression. In addition, miR-3622 KO inhibited the epithelial-mesenchymal transition involved in prostate cancer metastasis via upregulation of vimentin. The results show that miR-3622b-3p is upregulated in human prostate cancers and has an oncogenic function in tumor progression and metastasis via repression of p53 signaling, especially through an miR-3622-AIFM2 axis. In contrast, for human prostate cancer, deletion of the miR-3622 locus at 8p21 reduced the oncogenic effects on tumor progression and metastasis.	[Zhang, Yue; Xu, Zhifang; Wen, Wen; Liu, Zhichao; Zhang, Chao; Li, Ming; Hu, Fengping; Liu, Runhua; Wang, Lizhong] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA; [Wei, Shi; Bae, Sejong; Liu, Runhua; Wang, Lizhong] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA; [Wei, Shi] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Wei, Shi] Univ Kansas, Dept Pathol & Lab Med, Sch Med, Kansas City, KS USA; [Bae, Sejong] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA; [Zhou, Jiangbing] Yale Univ, Dept Neurosurg, New Haven, CT USA; [Zhou, Jiangbing] Yale Univ, Dept Biomed Engn, New Haven, CT USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Kansas; University of Kansas Medical Center; University of Alabama System; University of Alabama Birmingham; Yale University; Yale University	Liu, RH; Wang, LZ (corresponding author), Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.; Liu, RH; Wang, LZ (corresponding author), Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA.	runhua@uab.edu; lwang12@uab.edu		bae, sejong/0000-0001-9982-3223; Zhang, Yue/0000-0003-3817-8253	National Cancer Institute [CA118948]; Department of Defense [W81XWH-21-1-0100, W81XWH-15-1-0323, W81XWH-20-1-0426]; Mike Slive Foundation for Prostate Cancer Research	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); Mike Slive Foundation for Prostate Cancer Research	We thank Dr. Donald Hill for editorial assistance in preparing this paper. This work was supported by grants from the National Cancer Institute (CA118948 for LW), the Department of Defense (W81XWH-21-1-0100 for LW and W81XWH-15-1-0323 and W81XWH-20-1-0426 for RL) and the Mike Slive Foundation for Prostate Cancer Research (RL). Results are based, in part, upon data generated by TargetScan (http://www.targetscan.org/), the UALCAN portal (http://ualcan.path.uab.edu/), and the cBioPortal (http://www.cbioportal.org).	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048; Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2; Bhagirath D, 2019, CARCINOGENESIS, V40, P633, DOI 10.1093/carcin/bgz058; Bucay N, 2017, CELL DEATH DIFFER, V24, P1263, DOI 10.1038/cdd.2017.69; Bucay N, 2016, ONCOTARGET, V7, P70388, DOI 10.18632/oncotarget.11865; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chang SC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02789-z; Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fabris L, 2016, EUR UROL, V70, P312, DOI 10.1016/j.eururo.2015.12.054; Fu S, 2019, GENE, V701, P23, DOI 10.1016/j.gene.2019.02.083; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; KAGAN J, 1995, ONCOGENE, V11, P2121; Liu RH, 2015, CANCER RES, V75, P1714, DOI 10.1158/0008-5472.CAN-14-2109; Liu RH, 2015, CANCER RES, V75, P1703, DOI 10.1158/0008-5472.CAN-14-2108; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; Lu J, 2016, TOXICOL LETT, V258, P227, DOI 10.1016/j.toxlet.2016.07.002; Lu MJ, 2017, ONCOTARGET, V8, P23008, DOI 10.18632/oncotarget.14968; Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016; Rebello RJ, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00243-0; Schoenborn JR, 2013, CLIN CANCER RES, V19, P4058, DOI 10.1158/1078-0432.CCR-12-3606; Shenoy A, 2014, NAT REV MOL CELL BIO, V15, P565, DOI 10.1038/nrm3854; Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359; Tao YF, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-014-0118-1; Theodore S, 2010, INT J ONCOL, V37, P1477, DOI 10.3892/ijo_00000800; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Vernon M, 2020, MOL CANCER THER, V19, P1506, DOI 10.1158/1535-7163.MCT-19-0510; Wallis Christopher J D, 2015, EJIFCC, V26, P79; Wang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6909; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Wang M, 2020, MOL CANCER RES, V18, P943, DOI 10.1158/1541-7786.MCR-19-1033; Wang YC, 2019, ONCOGENE, V38, P4820, DOI 10.1038/s41388-019-0760-3; Wu M, 2004, ONCOGENE, V23, P6815, DOI 10.1038/sj.onc.1207909; Zhang W, 2016, CLIN CANCER RES, V22, P2545, DOI 10.1158/1078-0432.CCR-15-1927	37	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3186	3196		10.1038/s41388-022-02289-8	http://dx.doi.org/10.1038/s41388-022-02289-8		MAY 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35501464	Green Accepted			2022-12-28	WOS:000789736500001
J	Wu, JQ; Shen, S; Liu, TQ; Ren, XF; Zhu, C; Liang, QY; Cui, X; Chen, L; Cheng, P; Cheng, W; Wu, AH				Wu, Jianqi; Shen, Shuai; Liu, Tianqi; Ren, Xiufang; Zhu, Chen; Liang, Qingyu; Cui, Xiao; Chen, Ling; Cheng, Peng; Cheng, Wen; Wu, Anhua			Chemerin enhances mesenchymal features of glioblastoma by establishing autocrine and paracrine networks in a CMKLR1-dependent manner	ONCOGENE			English	Article							KAPPA-B; MICROARRAY DATA; RECEPTOR CCRL2; RNA-SEQ; CANCER; CELLS; EXPRESSION; GPR1; MACROPHAGES; PROGRESSION	Glioblastoma multiforme (GBM) with mesenchymal features exhibits enhanced chemotherapeutic resistance and results in reduced overall survival. Recent studies have suggested that there is a positive correlation between the GBM mesenchymal status and immune cell infiltration. However, the mechanisms by which GBM acquires its mesenchymal features in a tumor immune microenvironment-dependent manner remains unknown. Here, we uncovered a chemerin-mediated autocrine and paracrine network by which the mesenchymal phenotype of GBM cells is strengthened. We identified chemerin as a prognostic secretory protein mediating the mesenchymal phenotype-promoting network between tumor-associated macrophages (TAMs) and tumor cells in GBM. Mechanistically, chemerin promoted the mesenchymal features of GBM by suppressing the ubiquitin-proteasomal degradation of CMKLR1, a chemerin receptor predominantly expressed on TAMs and partially expressed on GBM cells, thereby enhancing NF-kappa B pathway activation. Moreover, chemerin was found to be involved in the recruitment of TAMs in the GBM tumor microenvironment. We revealed that chemerin also enhances the mesenchymal phenotype-promoting ability of TAMs and promotes their M2 polarization via a CMKLR1/NF-kappa B axis, which further exacerbates the mesenchymal features of GBM. Blocking the chemerin/CMKLR1 axis with 2-(alpha-naphthoyl) ethyltrimethylammonium iodide disrupted the mesenchymal network and suppressed tumor growth in GBM. These results suggest the therapeutic potential of targeting the chemerin/CMKLR1 axis to block the mesenchymal network in GBM.	[Wu, Jianqi; Shen, Shuai; Liu, Tianqi; Zhu, Chen; Liang, Qingyu; Cui, Xiao; Cheng, Peng; Cheng, Wen; Wu, Anhua] China Med Univ, Hosp 1, Dept Neurosurg, Shenyang, Peoples R China; [Ren, Xiufang] China Med Univ, Hosp 1, Dept Pathol, Shenyang, Peoples R China; [Chen, Ling] Chinese Peoples Liberat Army China PLA, Gen Hosp, Inst Neurosurg Chinese PLA, Med Sch Chinese PLA,Dept Neurosurg, Beijing, Peoples R China	China Medical University; China Medical University	Cheng, W; Wu, AH (corresponding author), China Med Univ, Hosp 1, Dept Neurosurg, Shenyang, Peoples R China.	cmu071207@163.com; ahwu@cmu.edu.cn						Achyut BR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14079-4; Al Delbany D, 2021, CANCERS, V13, DOI 10.3390/cancers13195000; Baj T, 2018, RECENT PATENTS INFLA, V12, P69, DOI [10.2174/1872213X12666180703163824, 10.2174/1872213x12666180703163824]; Bao ZS, 2014, GENOME RES, V24, P1765, DOI 10.1101/gr.165126.113; Barberi T, 2018, CANCER IMMUNOL IMMUN, V67, P1491, DOI 10.1007/s00262-018-2184-2; Baumert BG, 2016, LANCET ONCOL, V17, P1521, DOI 10.1016/S1470-2045(16)30313-8; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Cahill KE, 2016, NEURO-ONCOLOGY, V18, P329, DOI 10.1093/neuonc/nov265; Chen ZH, 2017, CANCER RES, V77, P2266, DOI 10.1158/0008-5472.CAN-16-2310; Cheng W, 2017, J NEUROSURG, V126, P249, DOI 10.3171/2015.11.JNS15432; Cheng W, 2016, NEUROLOGY, V86, P2226, DOI 10.1212/WNL.0000000000002770; Darmanis S, 2017, CELL REP, V21, P1399, DOI 10.1016/j.celrep.2017.10.030; Del Prete A, 2017, BLOOD, V130, P1223, DOI 10.1182/blood-2017-04-777680; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Dimitriadis Georgios K, 2018, Oncotarget, V9, P16678, DOI 10.18632/oncotarget.24659; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Dubois-Vedrenne Ingrid, 2021, Oncotarget, V12, P1903, DOI 10.18632/oncotarget.28056; El-Sagheer G, 2018, BREAST CANCER-TARGET, V10, P169, DOI 10.2147/BCTT.S178181; Engler JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043339; Fedele M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112746; Goralski KB, 2007, J BIOL CHEM, V282, P28175, DOI 10.1074/jbc.M700793200; Goralski KB, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194778; Graham KL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112925; Guo Deliang, 2013, CNS Oncol, V2, P289; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Hoffmann M, 2018, TOXICOL LETT, V291, P61, DOI 10.1016/j.toxlet.2018.04.004; Huang C, 2020, MOL THER-ONCOLYTICS, V18, P602, DOI 10.1016/j.omto.2020.08.013; Huang JF, 2010, BMB REP, V43, P491, DOI 10.5483/BMBRep.2010.43.7.491; Jacenik D, 2020, CLIN CHIM ACTA, V504, P146, DOI 10.1016/j.cca.2020.02.008; Ji ZS, 2022, CELL BIOL TOXICOL, V38, P611, DOI 10.1007/s10565-021-09636-7; Jia QZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07767-w; Kiczmer P, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2020.104377; Kumar JD, 2016, BRIT J CANCER, V114, P1152, DOI 10.1038/bjc.2016.93; Kumar JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104877; Kumar V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43428-8; Kusne Y, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005196; Li JJ, 2018, BRIT J CANCER, V118, P1337, DOI 10.1038/s41416-018-0077-y; Li M, 2021, ARCH PHARM RES, V44, P194, DOI 10.1007/s12272-021-01311-z; Liang QY, 2021, THERANOSTICS, V11, P9884, DOI 10.7150/thno.63202; Lin Y, 2017, ONCOGENE, V36, P3599, DOI 10.1038/onc.2016.516; Long PM, 2015, J CELL PHYSIOL, V230, P1929, DOI 10.1002/jcp.24927; Lu YB, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820948053; Man JH, 2018, CELL STEM CELL, V22, P104, DOI 10.1016/j.stem.2017.10.005; Muller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1362-4; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Pachynski RK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00983; Pachynski RK, 2012, J EXP MED, V209, P1427, DOI 10.1084/jem.20112124; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pozniak PD, 2014, J NEUROIMMUNE PHARM, V9, P133, DOI 10.1007/s11481-013-9517-x; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Regan-Komito D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01621; Rennier K, 2020, CLIN CANCER RES, V26, P5019, DOI 10.1158/1078-0432.CCR-19-4245; Rourke JL, 2015, MOL CELL ENDOCRINOL, V417, P36, DOI 10.1016/j.mce.2015.09.002; Rourke JL, 2014, J ENDOCRINOL, V222, P201, DOI 10.1530/JOE-14-0069; Schioppa T, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.615031; Schmitt MJ, 2021, CANCER DISCOV, V11, P754, DOI 10.1158/2159-8290.CD-20-0219; Segerman A, 2016, CELL REP, V17, P2994, DOI 10.1016/j.celrep.2016.11.056; Sielska M, 2013, J PATHOL, V230, P310, DOI 10.1002/path.4192; Su X, 2021, CLIN CHIM ACTA, V517, P41, DOI 10.1016/j.cca.2021.02.010; Tong N, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.706286; Treeck O, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153750; Tummler C, 2017, ONCOTARGET, V8, P95135, DOI 10.18632/oncotarget.19619; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang CH, 2014, PEPTIDES, V51, P131, DOI 10.1016/j.peptides.2013.10.009; Wang GY, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.798837; Wang QH, 2018, CANCER CELL, V33, P152, DOI 10.1016/j.ccell.2017.12.012; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Wang SC, 2012, LAB INVEST, V92, P151, DOI 10.1038/labinvest.2011.128; Wang Y, 2019, J CELL BIOCHEM, V120, P6459, DOI 10.1002/jcb.27936; Wei J, 2020, NEURO-ONCOLOGY, V22, P180, DOI 10.1093/neuonc/noz212; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Woroniecka KI, 2018, CLIN CANCER RES, V24, P3792, DOI 10.1158/1078-0432.CCR-18-0047; Xu CH, 2017, ONCOTARGET, V8, P22483, DOI 10.18632/oncotarget.14956; Xue GD, 2012, CANCER DISCOV, V2, P248, DOI 10.1158/2159-8290.CD-11-0270; Yamini B, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7090125; Yang YL, 2018, REPROD BIOL ENDOCRIN, V16, P1, DOI 10.1186/s12958-018-0363-9; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Ye YS, 2021, J PERIODONTOL, V92, P1470, DOI 10.1002/JPER.20-0675; Zabel BA, 2008, J EXP MED, V205, P2207, DOI 10.1084/jem.20080300; Zhang CB, 2017, CLIN CANCER RES, V23, P6279, DOI 10.1158/1078-0432.CCR-16-2598; Zhang RL, 2020, INT J MED MICROBIOL, V310, DOI 10.1016/j.ijmm.2020.151416; Zhang ZP, 2020, CANCER IMMUNOL RES, V8, P966, DOI 10.1158/2326-6066.CIR-19-0759; Zhu L, 2021, LIFE SCI, V278, DOI 10.1016/j.lfs.2021.119530	87	0	0	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					3024	3036		10.1038/s41388-022-02295-w	http://dx.doi.org/10.1038/s41388-022-02295-w		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35459783	hybrid, Green Published			2022-12-28	WOS:000787474100001
J	Magrin, L; Fanale, D; Brando, C; Corsini, LR; Randazzo, U; Di Piazza, M; Gurrera, V; Pedone, E; Russo, TDB; Vieni, S; Pantuso, G; Russo, A; Bazan, V				Magrin, Luigi; Fanale, Daniele; Brando, Chiara; Corsini, Lidia Rita; Randazzo, Ugo; Di Piazza, Marianna; Gurrera, Vittorio; Pedone, Erika; Bazan Russo, Tancredi Didier; Vieni, Salvatore; Pantuso, Gianni; Russo, Antonio; Bazan, Viviana			MUTYH-associated tumor syndrome: The other face of MAP	ONCOGENE			English	Review							BASE-EXCISION-REPAIR; FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE COLORECTAL ADENOMA; GERMLINE MUTATIONS; MYH GENE; FUNCTIONAL CONSEQUENCES; INHERITED VARIANTS; DUODENAL ADENOMAS; THYROID-CANCER; BREAST-CANCER	MUTYH gene is involved in the base excision repair (BER) mechanism and its pathogenic alterations are associated with colorectal polyposis and cancer. MUTYH-associated polyposis (MAP) is a condition which is inherited in an autosomal recessive manner. MAP patients, beyond colorectal cancer (CRC), may develop other types of tumors, including duodenal, breast, ovarian, pancreatic, bladder and skin cancers. Carriers of biallelic MUTYH likely pathogenic/pathogenic variants exhibit a high lifetime risk of CRC, though cancer risk evidence becomes less clear when monoallelic carriers and extraintestinal tumors are considered. However, several studies recently reported an increased genetic susceptibility to cancer also for carriers of germline monoallelic MUTYH mutations. Moreover, experimental evidence highlighted the MUTYH involvement in many other biological functions. In future, MUTYH mutation carriers might benefit from new target therapies involving the use of PD-1 or KRAS inhibitors. Therefore, "MUTYH-associated tumor syndrome" might be the most appropriate term, due to the multiplicity of tumors observed in MAP patients and different biological contexts in which MUTYH acts as a "playmaker". In this Review, we will investigate the impact of germline mono- and biallelic MUTYH mutations on cancer risk, providing a proposal for clinical surveillance of mutation carriers.	[Magrin, Luigi; Fanale, Daniele; Brando, Chiara; Corsini, Lidia Rita; Randazzo, Ugo; Di Piazza, Marianna; Gurrera, Vittorio; Pedone, Erika; Russo, Antonio] Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, I-90127 Palermo, Italy; [Bazan Russo, Tancredi Didier] Univ Palermo, Med & Surg Sch, I-90127 Palermo, Italy; [Vieni, Salvatore; Pantuso, Gianni] Univ Palermo, Div Gen & Oncol Surg, Dept Surg Oncol & Oral Sci, I-90127 Palermo, Italy; [Bazan, Viviana] Univ Palermo, Dept Biomed Neurosci & Adv Diagno, I-90127 Palermo, Italy	University of Palermo; University of Palermo; University of Palermo; University of Palermo	Russo, A (corresponding author), Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, I-90127 Palermo, Italy.	antonio.russo@usa.net						Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Aretz S, 2014, EUR J HUM GENET, V22, P923, DOI 10.1038/ejhg.2012.309; Balaguer F, 2007, CLIN GASTROENTEROL H, V5, P379, DOI 10.1016/j.cgh.2006.12.025; Blair HA, 2021, DRUGS, V81, P1573, DOI 10.1007/s40265-021-01574-2; Bono M, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100235; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bulow S, 2004, GUT, V53, P381, DOI 10.1136/gut.2003.027771; Castillejo A, 2014, EUR J CANCER, V50, P2241, DOI 10.1016/j.ejca.2014.05.022; Caswell-Jin JL, 2018, GENET MED, V20, P234, DOI 10.1038/gim.2017.96; Chen JW, 2019, FREE RADICAL BIO MED, V143, P482, DOI 10.1016/j.freeradbiomed.2019.09.005; Chmiel NH, 2003, J MOL BIOL, V327, P431, DOI 10.1016/S0022-2836(03)00124-4; Colas C, 2020, EUR J MED GENET, V63, DOI 10.1016/j.ejmg.2020.104078; Croitoru ME, 2004, JNCI-J NATL CANCER I, V96, P1631, DOI 10.1093/jnci/djh288; Curia MC, 2020, WORLD J CLIN ONCOL, V11, P428, DOI 10.5306/wjco.v11.i7.428; Daans CG, 2020, FAM CANCER, V19, P183, DOI 10.1007/s10689-020-00162-9; El Hachem N, 2019, DIS COLON RECTUM, V62, P470, DOI 10.1097/DCR.0000000000001323; Fanale D, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.827822; Fanale D, 2020, CANCERS, V12, DOI 10.3390/cancers12092415; Farrington SM, 2005, AM J HUM GENET, V77, P112, DOI 10.1086/431213; Filipe B, 2009, CLIN GENET, V76, P242, DOI 10.1111/j.1399-0004.2009.01241.x; Fulk K, 2019, FAM CANCER, V18, P197, DOI 10.1007/s10689-018-00114-4; Grasel RS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.571330; Grolleman JE, 2019, CANCER CELL, V35, P256, DOI 10.1016/j.ccell.2018.12.011; Grover S, 2012, JAMA-J AM MED ASSOC, V308, P485, DOI 10.1001/jama.2012.8780; Gupta S, 2019, J NATL COMPR CANC NE, V17, P1033, DOI 10.6004/jnccn.2019.0044; Halford SER, 2003, AM J PATHOL, V162, P1545, DOI 10.1016/S0002-9440(10)64288-5; Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239; Hong DS., 2021, J CLIN ONCOL, V39, DOI [10.1200/JCO.2021.39.15_suppl.TPS2669, DOI 10.1200/JCO.2021.39.15_SUPPL.TPS2669, 10.1200/jco.2021.39.15_suppl.tps2669]; Hutchcraft ML, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11010084; Ishida H, 2022, CRIT REV ONCOL HEMAT, V172, DOI 10.1016/j.critrevonc.2022.103648; Jenkins MA, 2006, CANCER EPIDEM BIOMAR, V15, P312, DOI 10.1158/1055-9965.EPI-05-0793; Jones N, 2009, GASTROENTEROLOGY, V137, P489, DOI 10.1053/j.gastro.2009.04.047; Jones S, 2002, HUM MOL GENET, V11, P2961, DOI 10.1093/hmg/11.23.2961; Kacerovska D, 2016, AM J DERMATOPATH, V38, P915, DOI 10.1097/DAD.0000000000000649; Kasahara M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-49; Kdissa A, 2020, CANCER GENET-NY, V240, P45, DOI 10.1016/j.cancergen.2019.10.007; Kim CJ, 2004, ONCOGENE, V23, P6820, DOI 10.1038/sj.onc.1207574; Krokan HE, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012583; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lipton L, 2003, CANCER RES, V63, P7595; Lipton L, 2004, CLIN GASTROENTEROL H, V2, P633, DOI 10.1016/S1542-3565(04)00286-1; Lubbe SJ, 2009, J CLIN ONCOL, V27, P3975, DOI 10.1200/JCO.2008.21.6853; Ma XY, 2014, GUT, V63, P326, DOI 10.1136/gutjnl-2012-304121; Magrin L, 2021, ONCOGENE, V40, P5893, DOI 10.1038/s41388-021-01984-2; Maguire S, 2021, JNCI-J NATL CANCER I, V113, P453, DOI 10.1093/jnci/djaa101; Mazzei F, 2013, MUTAT RES-FUND MOL M, V743, P33, DOI 10.1016/j.mrfmmm.2013.03.003; Miyaishi A, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-10; Monahan KJ, 2020, GUT, V69, P411, DOI 10.1136/gutjnl-2019-319915; Moscatello C, 2021, MOL CLIN ONCOL, V14, DOI 10.3892/mco.2020.2177; Nielsen M, 2007, CLIN GENET, V71, P427, DOI 10.1111/j.1399-0004.2007.00766.x; Nielsen M, 2009, GASTROENTEROLOGY, V136, P471, DOI 10.1053/j.gastro.2008.10.056; Nieuwenhuis MH, 2012, GUT, V61, P734, DOI 10.1136/gut.2010.229104; Nones K, 2019, ANN ONCOL, V30, P1071, DOI 10.1093/annonc/mdz132; Out AA, 2010, HUM MUTAT, V31, P1205, DOI 10.1002/humu.21343; Patel R, 2020, COLORECTAL DIS, V22, P1271, DOI 10.1111/codi.15078; Pervaiz MA, 2010, FAM CANCER, V9, P595, DOI 10.1007/s10689-010-9366-1; Picelli S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072091; Picelli S, 2010, EUR J CANCER, V46, P1041, DOI 10.1016/j.ejca.2010.01.013; Pilati C, 2017, J PATHOL, V242, P10, DOI 10.1002/path.4880; Ponti G, 2005, CLIN GENET, V68, P442, DOI 10.1111/j.1399-0004.2005.00519.x; Pope MA, 2005, DNA REPAIR, V4, P315, DOI 10.1016/j.dnarep.2004.10.003; Raetz AG, 2019, DNA REPAIR, V80, P16, DOI 10.1016/j.dnarep.2019.05.005; Rennert G, 2012, CANCER-AM CANCER SOC, V118, P1989, DOI 10.1002/cncr.26506; Rizzolo P, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00583; Ruggieri V, 2013, ONCOGENE, V32, P4500, DOI 10.1038/onc.2012.479; Saha T, 2010, CELL CYCLE, V9, P2471, DOI 10.4161/cc.9.13.12084; Samadder NJ, 2021, JAMA ONCOL, V7, P230, DOI 10.1001/jamaoncol.2020.6252; Santos LS, 2012, ONCOL REP, V28, P1859, DOI 10.3892/or.2012.1975; Scarpa A, 2017, NATURE, V543, P65, DOI 10.1038/nature21063; Schubert SA, 2020, GENE CHROMOSOME CANC, V59, P697, DOI 10.1002/gcc.22883; Schubert SA, 2020, MUTAGENESIS, V35, P221, DOI 10.1093/mutage/gez027; Barreiro RAS, 2022, J PATHOL, V256, P214, DOI 10.1002/path.5829; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Silva SN, 2021, BREAST CANCER RES TR, V188, P295, DOI 10.1007/s10549-021-06159-x; Singh A, 2019, PATHOL ONCOL RES, V25, P1327, DOI 10.1007/s12253-017-0372-6; Skates SJ, 2017, CLIN CANCER RES, V23, P3628, DOI 10.1158/1078-0432.CCR-15-2750; Stjepanovic N, 2019, ANN ONCOL, V30, P1558, DOI 10.1093/annonc/mdz233; Sutcliffe EG, 2019, FAM CANCER, V18, P203, DOI 10.1007/s10689-018-00116-2; Syngal S, 2015, AM J GASTROENTEROL, V110, P223, DOI 10.1038/ajg.2014.435; Takao M, 2018, INT J CLIN ONCOL, V23, P497, DOI 10.1007/s10147-017-1234-7; Tenesa A, 2006, BRIT J CANCER, V95, P239, DOI 10.1038/sj.bjc.6603239; Theodoratou E, 2010, BRIT J CANCER, V103, P1875, DOI 10.1038/sj.bjc.6605966; Thibodeau ML, 2019, CSH MOL CASE STUD, V5, DOI 10.1101/mcs.a003681; Thomas LE, 2021, GASTROENTEROLOGY, V160, P952, DOI 10.1053/j.gastro.2020.10.038; Thomas LE, 2017, CLIN CANCER RES, V23, P6721, DOI 10.1158/1078-0432.CCR-17-1269; Thompson, FAM CANCER, V2022; Ukaegbu C, 2021, FAM CANCER, V20, P111, DOI 10.1007/s10689-020-00198-x; Urso EDL, 2021, DIGEST LIVER DIS, V53, P409, DOI 10.1016/j.dld.2020.11.018; van Leerdam ME, 2019, ENDOSCOPY, V51, P877, DOI 10.1055/a-0965-0605; Vasen HFA, 2008, GUT, V57, DOI 10.1136/gut.2007.136127; Vidal AF, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08089-9; Viel A, 2017, EBIOMEDICINE, V20, P39, DOI 10.1016/j.ebiom.2017.04.022; Vogt S, 2009, GASTROENTEROLOGY, V137, P1976, DOI 10.1053/j.gastro.2009.08.052; Volkov NM, 2020, INVEST NEW DRUG, V38, P894, DOI 10.1007/s10637-019-00842-z; Wallace SS, 2012, CANCER LETT, V327, P73, DOI 10.1016/j.canlet.2011.12.038; Walton SJ, 2016, CLIN GASTROENTEROL H, V14, P986, DOI 10.1016/j.cgh.2016.02.020; Wang MB, 2021, ORAL ONCOL, V112, DOI 10.1016/j.oraloncology.2020.104987; Wasielewski M, 2010, BREAST CANCER RES TR, V124, P635, DOI 10.1007/s10549-010-0801-7; Win AK, 2016, INT J CANCER, V139, P1557, DOI 10.1002/ijc.30197; Win AK, 2014, GASTROENTEROLOGY, V146, P1208, DOI 10.1053/j.gastro.2014.01.022; Win AK, 2011, INT J CANCER, V129, P2256, DOI 10.1002/ijc.25870; Yanus GA, 2018, CLIN GENET, V93, P1015, DOI 10.1111/cge.13228; Zhang YW, 2006, CANCER EPIDEM BIOMAR, V15, P353, DOI 10.1158/1055-9965.EPI-05-0653	103	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2531	2539		10.1038/s41388-022-02304-y	http://dx.doi.org/10.1038/s41388-022-02304-y		APR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35422474				2022-12-28	WOS:000782543300003
J	Shi, CX; Tao, SS; Ren, GW; Yang, EJ; Shu, XD; Mou, PK; Liu, YF; Dang, YJ; Xu, XL; Shim, JS				Shi, Changxiang; Tao, Shishi; Ren, Guowen; Yang, Eun Ju; Shu, Xiaodong; Mou, Pui Kei; Liu, Yifan; Dang, Yongjun; Xu, Xiaoling; Shim, Joong Sup			Aurora kinase A inhibition induces synthetic lethality in SMAD4-deficient colorectal cancer cells via spindle assembly checkpoint activation	ONCOGENE			English	Article							TGF-BETA; CHROMOSOMAL INSTABILITY; A KINASE; CENP-E; SMAD4; PHOSPHORYLATION; IDENTIFICATION; AMPLIFICATION; SEGREGATION; EXPRESSION	SMAD4 loss-of-function mutations have been frequently observed in colorectal cancer (CRC) and are recognized as a drug target for therapeutic exploitation. In this study, we performed a synthetic lethal drug screening with SMAD4-isogenic CRC cells and found that aurora kinase A (AURKA) inhibition is synthetic lethal with SMAD4 loss. Inhibition of AURKA selectively inhibited the growth of SMAD4(-/-) CRC in vitro and in vivo. Mechanistically, SMAD4 negatively regulated AURKA level, resulting in the significant elevation of AURKA in SMAD4(-/-) CRC cells. Inhibition of AURKA induced G(2)/M cell cycle delay in SMAD4(+/+) CRC cells, but induced apoptosis in SMAD4(-/-) CRC cells. We further observed that a high level of AURKA in SMAD4(-/-) CRC cells led to abnormal mitotic spindles, leading to cellular aneuploidy. Moreover, SMAD4(-/-) CRC cells expressed high levels of spindle assembly checkpoint (SAC) proteins, suggesting the hyperactivation of SAC. The silencing of key SAC proteins significantly rescued the AURKA inhibition-induced cell death in SMAD4(-/-) cells, suggesting that SMAD4(-/-) CRC cells are hyper-dependent on AURKA activity for mitotic exit and survival during SAC hyperactivation. This study presents a unique synthetic lethal interaction between SMAD4 and AURKA and suggests that AURKA could be a potential drug target in SMAD4-deficient CRC.	[Shi, Changxiang; Tao, Shishi; Ren, Guowen; Yang, Eun Ju; Shu, Xiaodong; Mou, Pui Kei; Liu, Yifan; Xu, Xiaoling; Shim, Joong Sup] Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Macau, Peoples R China; [Shi, Changxiang; Tao, Shishi; Ren, Guowen; Yang, Eun Ju; Shu, Xiaodong; Mou, Pui Kei; Liu, Yifan; Xu, Xiaoling; Shim, Joong Sup] Univ Macau, MOE Frontiers Sci Ctr Precis Oncol, Taipa, Macau, Peoples R China; [Shi, Changxiang] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Womens Hosp, Nanjing Matern & Child Hlth Care Inst, Nanjing, Peoples R China; [Dang, Yongjun] Chongqing Med Univ, Inst Life Sci, Ctr Novel Target & Therapeut Intervent, Chongqing, Peoples R China	University of Macau; University of Macau; Nanjing Medical University; Chongqing Medical University	Shim, JS (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Macau, Peoples R China.; Shim, JS (corresponding author), Univ Macau, MOE Frontiers Sci Ctr Precis Oncol, Taipa, Macau, Peoples R China.	jsshim@um.edu.mo	Shim, Joong Sup/G-8383-2011	Shim, Joong Sup/0000-0003-0167-7307	Science and Technology Development Fund, Macau SAR [FDCT/0107/2020/A, FDCT/0030/2020/A]; Multi-Year Research Grant, University of Macau [MYRG2019-00116-FHS, MYRG2020-00229-FHS]	Science and Technology Development Fund, Macau SAR; Multi-Year Research Grant, University of Macau	This study was supported by Science and Technology Development Fund, Macau SAR (FDCT/0107/2020/A and FDCT/0030/2020/A to JSS), and the Multi-Year Research Grant, University of Macau (MYRG2019-00116-FHS and MYRG2020-00229-FHS to JSS).	Alfieri C, 2016, NATURE, V536, P431, DOI 10.1038/nature19083; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Boult JKR, 2012, BRIT J CANCER, V106, P1960, DOI 10.1038/bjc.2012.208; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheerambathur DK, 2013, SCIENCE, V342, P1239, DOI 10.1126/science.1246232; Davies RJ, 2005, NAT REV CANCER, V5, P199, DOI 10.1038/nrc1569; Ertych N, 2014, NAT CELL BIOL, V16, P779, DOI 10.1038/ncb2994; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gong XQ, 2019, CANCER DISCOV, V9, P248, DOI 10.1158/2159-8290.CD-18-0469; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Jia L, 2014, MOL CANCER RES, V12, P1779, DOI 10.1158/1541-7786.MCR-14-0191; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kawaguchi Y, 2019, CLIN CANCER RES, V25, P5843, DOI 10.1158/1078-0432.CCR-19-0863; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lara-Gonzalez P, 2012, CURR BIOL, V22, pR966, DOI 10.1016/j.cub.2012.10.006; Lee JW, 2019, CLIN CANCER RES, V25, P3430, DOI 10.1158/1078-0432.CCR-18-0440; Lee S, 2011, CANCER RES, V71, P3225, DOI 10.1158/0008-5472.CAN-10-2167; Lheureux S, 2018, CLIN CANCER RES, V24, P6168, DOI 10.1158/1078-0432.CCR-18-1244; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Lyu J., 2020, NAT COMMUN, V11; Maia ARR, 2014, NAT CELL BIOL, V16, P739, DOI 10.1038/ncb3018; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Montal R, 2020, J HEPATOL, V73, P315, DOI 10.1016/j.jhep.2020.03.008; Mou PK, 2021, EXP MOL MED, V53, P835, DOI 10.1038/s12276-021-00635-6; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Musacchio A, 2015, CURR BIOL, V25, pR1002, DOI 10.1016/j.cub.2015.08.051; O'Connor OA, 2019, J CLIN ONCOL, V37, P613, DOI 10.1200/JCO.18.00899; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Shepperd LA, 2012, CURR BIOL, V22, P891, DOI 10.1016/j.cub.2012.03.051; Shi CX, 2021, ONCOGENE, V40, P937, DOI 10.1038/s41388-020-01580-w; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tagal V, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14098; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wang H, 2006, CANCER RES, V66, P9722, DOI 10.1158/0008-5472.CAN-05-4602; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Wu CJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05694-4; Yamagishi Y, 2012, NAT CELL BIOL, V14, P746, DOI 10.1038/ncb2515; Yan M, 2016, MED RES REV, V36, P1036, DOI 10.1002/med.21399; Yan P, 2016, CLIN CANCER RES, V22, P3037, DOI 10.1158/1078-0432.CCR-15-0939; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903; Zhang C, 2010, ACTA BIOCH BIOPH SIN, V42, P834, DOI 10.1093/abbs/gmq088; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhu JW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58051-1; 2014, BRIT J CANCER, V110, P946	63	0	0	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2734	2748		10.1038/s41388-022-02293-y	http://dx.doi.org/10.1038/s41388-022-02293-y		APR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35393542				2022-12-28	WOS:000779227700002
J	Wang, C; Leavenworth, J; Zhang, C; Liu, ZC; Yuan, KY; Wang, YC; Zhang, GX; Wang, SB; Cui, XL; Zhang, Y; Bae, S; Zhou, JB; Wang, LZ; Liu, RH				Wang, Chao; Leavenworth, Jonathan; Zhang, Chao; Liu, Zhichao; Yuan, Katherine Y.; Wang, Yicun; Zhang, Guangxin; Wang, Shuaibin; Cui, Xuelian; Zhang, Yue; Bae, Sejong; Zhou, Jiangbing; Wang, Lizhong; Liu, Runhua			Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer	ONCOGENE			English	Article							TRANSLATION INITIATION; GENE-EXPRESSION	In prostate cancers, elongation initiation factor 4A1 (eIF4A1) supports an oncogenic translation program and is highly expressed, but its role remains elusive. By the use of human specimens and cell models, we addressed the role of eIF4A1 in prostate cancer in vitro and in vivo. EIF4A1 expression, as determined by mRNA and protein levels, was higher in primary prostate cancers relative to normal prostate tissue. Also, for primary prostate cancers, elevated mRNA levels of EIF4A1 correlated with DNA hypomethylation levels in the CpG-rich island of EIF4A1. Using a DNMT3a CRISPR-Cas9-based tool for specific targeting of DNA methylation, we characterized, in human prostate cancer cells, the epigenetic regulation of EIF4A1 transcripts through DNA methylation in the CpG-rich island of EIF4A1. Next, we investigated the oncogenic effect of EIF4A1 on cancer cell proliferation in vitro and tumor growth in vivo. For prostate cancer cells, EIF4A1 heterozygous knockout or knockdown inhibited protein translation and tumor growth. In addition, using RNA immunoprecipitation with RNA sequencing, we discovered the eIF4A1-mediated translational regulation of the oncogene BRD2, which contains the most enriched eIF4A1-binding motifs in its 5 ' untranslated region, establishing an eIF4A1-BRD2 axis for oncogenic translation. Finally, we found a positive correlation between expression levels of eIF4A1 and BRD2 in primary prostate cancers. Our results demonstrate, for prostate cancer cells, epigenetic regulation of EIF4A1 transcripts through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling.	[Wang, Chao; Leavenworth, Jonathan; Zhang, Chao; Liu, Zhichao; Yuan, Katherine Y.; Wang, Yicun; Zhang, Guangxin; Wang, Shuaibin; Cui, Xuelian; Zhang, Yue; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35487 USA; [Bae, Sejong; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35487 USA; [Bae, Sejong] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Zhou, Jiangbing] Yale Univ, Dept Neurosurg, New Haven, CT USA; [Zhou, Jiangbing] Yale Univ, Dept Biomed Engn, New Haven, CT USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Yale University; Yale University	Wang, LZ; Liu, RH (corresponding author), Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35487 USA.; Wang, LZ; Liu, RH (corresponding author), Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35487 USA.	lwang12@uab.edu; runhua@uab.edu		Leavenworth, Jonathan/0000-0002-6120-8185; bae, sejong/0000-0001-9982-3223; Zhang, Yue/0000-0003-3817-8253	Department of Defense [W81XWH-15-1-0323, W81XWH-20-1-0426, W81XWH-21-1-0100]; National Cancer Institute [CA118948]; Mike Slive Foundation for Prostate Cancer Research	Department of Defense(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Mike Slive Foundation for Prostate Cancer Research	We thank Dr Donald Hill for editorial assistance in preparing this paper. This work was supported by grants from the Department of Defense (W81XWH-15-1-0323 and W81XWH-20-1-0426 for RL and W81XWH-21-1-0100 for LW), the National Cancer Institute (CA118948 for LW), and the Mike Slive Foundation for Prostate Cancer Research (RL).	Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Chan K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13086-5; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 1999, MOL CELL BIOL, V19, P1; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; de la Parra C, 2018, CURR OPIN GENET DEV, V48, P82, DOI 10.1016/j.gde.2017.11.001; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Faivre EJ, 2020, NATURE, V578, P306, DOI 10.1038/s41586-020-1930-8; Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101; Gao CC, 2020, ACTA BIOCH BIOPH SIN, V52, P310, DOI 10.1093/abbs/gmz168; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jin C, 2013, ONCOGENE, V32, P2179, DOI 10.1038/onc.2012.236; Kregel S, 2019, CLIN CANCER RES, V25, P4038, DOI 10.1158/1078-0432.CCR-18-3776; Kumar A, 2021, ELIFE, V10, DOI [10.7554/eLife.72873, 10.7554/eLife.72873.sa1, 10.7554/eLife.72873.sa2]; Leppek K, 2018, NAT REV MOL CELL BIO, V19, P158, DOI 10.1038/nrm.2017.103; Liu XS, 2016, CELL, V167, P233, DOI 10.1016/j.cell.2016.08.056; Malina A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012377; Malka-Mahieu H, 2017, CLIN CANCER RES, V23, P21, DOI 10.1158/1078-0432.CCR-14-2362; Modelska A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.542; Muhar M, 2018, SCIENCE, V360, P800, DOI 10.1126/science.aao2793; Quinn CM, 1999, GENOMICS, V62, P468, DOI 10.1006/geno.1999.6031; Ramamurthy VP, 2017, CURR OPIN ONCOL, V29, P210, DOI 10.1097/CCO.0000000000000367; Raman D, 2020, CANCER REP-US, DOI 10.1002/cnr2.1299; Remondini D, 2005, P NATL ACAD SCI USA, V102, P6902, DOI 10.1073/pnas.0502081102; Rubio CA, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0476-1; Schrecengost R, 2013, SEMIN ONCOL, V40, P244, DOI 10.1053/j.seminoncol.2013.04.001; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Sridharan S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01311; Urbanucci A, 2017, CELL REP, V19, P2045, DOI 10.1016/j.celrep.2017.05.049; Waldron JA, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1901-2; Waldron JA, 2018, NUCLEIC ACIDS RES, V46, P3075, DOI 10.1093/nar/gky108; Wolfe AL, 2014, NATURE, V513, P65, DOI 10.1038/nature13485; Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	35	1	1	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2778	2785		10.1038/s41388-022-02272-3	http://dx.doi.org/10.1038/s41388-022-02272-3		MAR 2022	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35361883	Green Accepted			2022-12-28	WOS:000777357500001
J	Yu, S; Liu, CA; Hou, YT; Li, J; Guo, ZM; Chen, XW; Zhang, LY; Peng, S; Hong, SB; Xu, LX; Li, XX; Liu, RY; Chen, SW; Li, B; Weng, ZP; Li, YB; Lv, WM; Yu, J; Xiao, HP				Yu, Shuang; Liu, Changan; Hou, Yingtong; Li, Jie; Guo, Zhuming; Chen, Xinwen; Zhang, Luyao; Peng, Sui; Hong, Shubin; Xu, Lixia; Li, Xiaoxing; Liu, Rengyun; Chen, Shuwei; Li, Bin; Weng, Zongpeng; Li, Yanbing; Lv, Weiming; Yu, Jun; Xiao, Haipeng			Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer	ONCOGENE			English	Article							NEEDLE-ASPIRATION-CYTOLOGY; INCREASING INCIDENCE; LARGE-SCALE; SERUM; MICROCARCINOMA; ASSOCIATION; LIMITATIONS; ULTRASOUND; BIOMARKERS; BLOOD	Discrimination of malignancy from thyroid nodules poses challenges in clinical practice. We aimed to identify the plasma metabolomic biomarkers in discriminating papillary thyroid cancer (PTC) from benign thyroid nodule (BTN). Metabolomics profiling of plasma was performed in two independent cohorts of 651 subjects of PTC (n = 215), BTN (n = 230), and healthy controls (n = 206). In addition, 132 patients with thyroid micronodules (<1 cm) and 44 patients with BTN suspected malignancy by ultrasound were used for biomarker validation. Recursive feature elimination algorithm was used for metabolic biomarkers selecting. Significant differential metabolites were demonstrated in patients with thyroid nodules (PTC and BTN) from healthy controls (P = 0.0001). A metabolic biomarker panel (17 differential metabolites) was identified to discriminate PTC from BTN with an AUC of 97.03% (95% CI: 95.28-98.79%), 91.89% sensitivity, and 92.63% specificity in discovery cohort. The panel had an AUC of 92.72% (95% CI: 87.46-97.99%), 86.57% sensitivity, and 92.50% specificity in validation cohort. The metabolic biomarker signature could correctly identify 84.09% patients whose nodules were suspected malignant by ultrasonography but finally histological benign. Moreover, high accuracy of 87.88% for diagnosis of papillary thyroid microcarcinoma was displayed by this panel and showed significant improvement in accuracy, AUC and specificity when compared with ultrasound. We identified a novel metabolic biomarker signature to discriminate PTC from BTN. The clinical use of this biomarker panel would have improved diagnosis stratification of thyroid microcarcinoma in comparison to ultrasound.	[Yu, Shuang; Hou, Yingtong; Chen, Xinwen; Zhang, Luyao; Hong, Shubin; Li, Yanbing; Xiao, Haipeng] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Peoples R China; [Liu, Changan; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Liu, Changan; Yu, Jun] Chinese Univ Hong Kong, State Key Lab Digest Dis, Dept Med & Therapeut, Hong Kong, Peoples R China; [Li, Jie; Lv, Weiming] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast & Thyroid Surg, Guangzhou, Peoples R China; [Guo, Zhuming; Chen, Shuwei] Sun Yat Sen Univ, Canc Ctr, Dept Head & Neck Surg, Guangzhou, Peoples R China; [Peng, Sui; Li, Bin; Weng, Zongpeng] Sun Yat Sen Univ, Affiliated Hosp 1, Clin Trials Unit, Guangzhou, Peoples R China; [Peng, Sui; Xu, Lixia; Li, Xiaoxing; Liu, Rengyun] Sun Yat Sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou, Peoples R China; [Xu, Lixia] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Peoples R China	Sun Yat Sen University; Chinese University of Hong Kong; Chinese University of Hong Kong; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Xiao, HP (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Dept Med & Therapeut, Hong Kong, Peoples R China.; Lv, WM (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast & Thyroid Surg, Guangzhou, Peoples R China.	lvwm@mail.sysu.edu.cn; junyu@cuhk.edu.hk; xiaohp@mail.sysu.edu.cn	li, yan/GTI-4638-2022; Liu, Rengyun/O-4039-2018; Li, Xiao-xing/B-9114-2008	Liu, Rengyun/0000-0002-1408-2372; Li, Xiao-xing/0000-0001-8791-7505; Li, Jie/0000-0003-1232-3248				Abooshahab R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00385; Abraham A, 2019, CRIT REV FOOD SCI, V59, P2831, DOI 10.1080/10408398.2018.1474169; Banales JM, 2019, HEPATOLOGY, V70, P547, DOI 10.1002/hep.30319; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brito JP, 2014, J CLIN ENDOCR METAB, V99, P1253, DOI 10.1210/jc.2013-2928; Burman KD, 2015, NEW ENGL J MED, V373, P2347, DOI 10.1056/NEJMcp1415786; Cabanillas ME, 2016, LANCET, V388, P2783, DOI 10.1016/S0140-6736(16)30172-6; Cao ST, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-4544; Chen J, 2019, ENDOCR-RELAT CANCER, V26, P829, DOI 10.1530/ERC-19-0344; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng YR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20877-8; Chong Jasmine, 2019, Curr Protoc Bioinformatics, V68, pe86, DOI 10.1002/cpbi.86; Chong J, 2019, METABOLITES, V9, DOI 10.3390/metabo9030057; Cibas ES, 2013, ANN INTERN MED, V159, P325, DOI 10.7326/0003-4819-159-5-201309030-00006; Cradic KW, 2009, J CLIN ENDOCR METAB, V94, P5001, DOI 10.1210/jc.2009-1349; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Davies L, 2015, ENDOCR PRACT, V21, P686, DOI 10.4158/EP14466.DSCR; de Meer SGA, 2012, DIAGN CYTOPATHOL, V40, pE21, DOI 10.1002/dc.21521; Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335; Fussey JM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00132; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Hofland J, 2018, NAT REV ENDOCRINOL, V14, P656, DOI 10.1038/s41574-018-0082-5; Howlader NR, 2020, BREAST CANCER RES TR, V182, P739, DOI 10.1007/s10549-020-05738-8; Hu SY, 2006, J CLIN ENDOCR METAB, V91, P98, DOI 10.1210/jc.2005-1810; Huang FQ, 2019, INT J CANCER, V144, P868, DOI 10.1002/ijc.31925; Kitahara CM, 2016, NAT REV ENDOCRINOL, V12, P646, DOI 10.1038/nrendo.2016.110; Klubo-Gwiezdzinska J, 2018, J CLIN ENDOCR METAB, V103, P3507, DOI 10.1210/jc.2018-01081; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; Lamartina L, 2020, LANCET DIABETES ENDO, V8, P81, DOI 10.1016/S2213-8587(19)30324-9; Leboulleux S, 2016, LANCET DIABETES ENDO, V4, P933, DOI 10.1016/S2213-8587(16)30180-2; Lee JC, 2013, CANCER-AM CANCER SOC, V119, P4358, DOI 10.1002/cncr.28254; Li JK, 2019, GASTROENTEROLOGY, V157, P257, DOI 10.1053/j.gastro.2019.03.020; Luo P, 2018, HEPATOLOGY, V67, P662, DOI 10.1002/hep.29561; Ma HJ, 2017, ACTA RADIOL, V58, P1303, DOI 10.1177/0284185117692167; Manning AM, 2017, OTOLARYNG HEAD NECK, V156, P611, DOI 10.1177/0194599816688190; Mayerle J, 2018, GUT, V67, P128, DOI 10.1136/gutjnl-2016-312432; Mazeh H, 2011, NAT REV ENDOCRINOL, V7, P581, DOI 10.1038/nrendo.2011.140; Nikiforova MN, 2018, CANCER-AM CANCER SOC, V124, P1682, DOI 10.1002/cncr.31245; Nishino M, 2018, ARCH PATHOL LAB MED, V142, P446, DOI 10.5858/arpa.2017-0174-RA; Nixon AM, 2017, CLIN ENDOCRINOL, V87, P117, DOI 10.1111/cen.13369; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y; Stevens VL, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-018-1393-1; Steward DL, 2019, JAMA ONCOL, V5, P204, DOI 10.1001/jamaoncol.2018.4616; Tessler FN, 2017, J AM COLL RADIOL, V14, P587, DOI 10.1016/j.jacr.2017.01.046; Valvo V, 2021, THYROID, V31, P1335, DOI 10.1089/thy.2020.0311; Wada N, 2003, ANN SURG, V237, P399, DOI 10.1097/00000658-200303000-00015; Wagner K, 2005, J CLIN ENDOCR METAB, V90, P1921, DOI 10.1210/jc.2004-1793; Xu SL, 2020, CLIN ENDOCRINOL, V93, P489, DOI 10.1111/cen.14217; Yang RN, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.598225; Yekta RF, 2018, IRAN J BASIC MED SCI, V21, P1140, DOI 10.22038/IJBMS.2018.30375.7323; Yu XM, 2011, ANN SURG, V254, P653, DOI 10.1097/SLA.0b013e318230036d	55	2	2	8	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2422	2430		10.1038/s41388-022-02254-5	http://dx.doi.org/10.1038/s41388-022-02254-5		MAR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35279704				2022-12-28	WOS:000767909000001
J	Rammohan, M; Harris, E; Bhansali, RS; Zhao, E; Li, LS; Crispino, JD				Rammohan, Malini; Harris, Ethan; Bhansali, Rahul S.; Zhao, Emily; Li, Loretta S.; Crispino, John D.			The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target	ONCOGENE			English	Review							TAU EXON 10; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; DOWN-SYNDROME; INCREASED DOSAGE; ONCOGENIC TRANSFORMATION; TRANSCRIPTION FACTORS; MARINE-INVERTEBRATES; SELECTIVE INHIBITOR; COGNITIVE DEFICITS	Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) is a serine/threonine kinase that belongs to the DYRK family of proteins, a subgroup of the evolutionarily conserved CMGC protein kinase superfamily. Due to its localization on chromosome 21, the biological significance of DYRK1A was initially characterized in the pathogenesis of Down syndrome (DS) and related neurodegenerative diseases. However, increasing evidence has demonstrated a prominent role in cancer through its ability to regulate biologic processes including cell cycle progression, DNA damage repair, transcription, ubiquitination, tyrosine kinase activity, and cancer stem cell maintenance. DYRK1A has been identified as both an oncogene and tumor suppressor in different models, underscoring the importance of cellular context in its function. Here, we review mechanistic contributions of DYRK1A to cancer biology and its role as a potential therapeutic target.	[Rammohan, Malini] Northwestern Univ, Driskill Grad Program Life Sci, Chicago, IL 60611 USA; [Harris, Ethan] Univ Illinois, Coll Med, Chicago, IL USA; [Harris, Ethan; Crispino, John D.] St Jude Childrens Res Hosp, Dept Hematol, Div Expt Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Bhansali, Rahul S.] Hosp Univ Penn, Div Hematol Oncol, Dept Med, 3400 Spruce St, Philadelphia, PA 19104 USA; [Zhao, Emily] Northwestern Univ, Weinberg Coll Arts & Sci, Chicago, IL 60611 USA; [Li, Loretta S.] Ann & Robert H Lurie Childrens Hosp Chicago, Stanley Manne Childrens Res Inst, Mol & Translat Canc Biol Program, Chicago, IL 60611 USA; [Li, Loretta S.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol & Stem Cell Transplantat, Dept Pediat, Chicago, IL 60611 USA	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; St Jude Children's Research Hospital; University of Pennsylvania; Pennsylvania Medicine; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Crispino, JD (corresponding author), St Jude Childrens Res Hosp, Dept Hematol, Div Expt Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.crispino@stjude.org		Bhansali, Rahul/0000-0002-3616-7393; Harris, Ethan/0000-0002-8735-1959	NIH [R35 CA253096]; St. Jude/ALSAC; American Society of Hematology's Medical Student PhysicianScientist Award	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St. Jude/ALSAC; American Society of Hematology's Medical Student PhysicianScientist Award	This review was supported in part by the NIH (R35 CA253096). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Additional support was provided St. Jude/ALSAC. EH is supported by the American Society of Hematology's Medical Student PhysicianScientist Award.	Almatroodi SA, 2020, MOLECULES, V25, DOI 10.3390/molecules25143146; Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Alvarez M, 2003, J CELL SCI, V116, P3099, DOI 10.1242/jcs.00618; An LW, 2018, P NATL ACAD SCI USA, V115, pEB286, DOI 10.1073/pnas.1804823115; Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678; Aznar S, 2001, MOL BIOL CELL, V12, P3282, DOI 10.1091/mbc.12.10.3282; Baek KH, 2009, NATURE, V459, P1126, DOI 10.1038/nature08062; Balint B, 2017, CHEMMEDCHEM, V12, P932, DOI 10.1002/cmdc.201600539; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 2018, FEBS J, V285, P1203, DOI 10.1111/febs.14347; Bhansali RS, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI135937; Borad MJ, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.312; Buontempo F, 2014, LEUKEMIA, V28, P543, DOI 10.1038/leu.2013.349; Canzonetta C, 2008, AM J HUM GENET, V83, P388, DOI 10.1016/j.ajhg.2008.08.012; Chan KS, 2008, ONCOGENE, V27, P1087, DOI 10.1038/sj.onc.1210726; Chen B, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084011; Chen JY, 2013, MOL CELL, V52, P87, DOI 10.1016/j.molcel.2013.09.009; Cho HJ, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.037044; Coombs TC, 2013, BIOORG MED CHEM LETT, V23, P3654, DOI 10.1016/j.bmcl.2013.02.096; Couly F, 2018, MOLECULES, V23, DOI 10.3390/molecules23092181; Coutadeur S, 2015, J NEUROCHEM, V133, P440, DOI 10.1111/jnc.13018; de Graaf Katrin, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-7; Delabar Jean-Maurice, 1993, European Journal of Human Genetics, V1, P114; Deng Xiaobing, 2014, Genes Cancer, V5, P337; Di Vona C, 2015, MOL CELL, V57, P506, DOI 10.1016/j.molcel.2014.12.026; Ding SH, 2012, NEUROBIOL AGING, V33, P1389, DOI 10.1016/j.neurobiolaging.2010.11.021; Djamshidian A, 2016, MOV DISORD CLIN PRAC, V3, P19, DOI 10.1002/mdc3.12242; Fan H, 2008, CHEM REV, V108, P264, DOI 10.1021/cr078199m; Feki A, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8100187; Ferron SR, 2010, CELL STEM CELL, V7, P367, DOI 10.1016/j.stem.2010.06.021; Fruit C, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12040185; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Galceran J, 2003, J NEURAL TRANSM-SUPP, P139; Guard SE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42990-5; Guo XM, 2010, J BIOL CHEM, V285, P13223, DOI 10.1074/jbc.M110.102574; Henderson SH, 2021, J MED CHEM, V64, P11709, DOI 10.1021/acs.jmedchem.1c01115; Henderson SH, 2020, ACS MED CHEM LETT, V11, P1620, DOI 10.1021/acsmedchemlett.0c00279; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Hurtz C, 2020, BLOOD, V136, DOI 10.1182/blood-2020-141258; Imperatore C, 2014, MOLECULES, V19, P20391, DOI 10.3390/molecules191220391; Iness AN, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00223; Jarry M, 2014, NEURO-ONCOLOGY, V16, P1484, DOI 10.1093/neuonc/nou102; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Ji JL, 2015, EUR J HUM GENET, V23, P1473, DOI 10.1038/ejhg.2015.71; Jin J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6930; Jin NN, 2015, J BIOL CHEM, V290, P15219, DOI 10.1074/jbc.M115.645507; Jiramongkol Y, 2020, CANCER METAST REV, V39, P681, DOI 10.1007/s10555-020-09883-w; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Kamal MM, 2012, STEM CELLS, V30, P405, DOI 10.1002/stem.1020; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim H, 1997, ARCH BIOCHEM BIOPHYS, V337, P137, DOI 10.1006/abbi.1996.9771; Kim HM, 2018, ANTICANCER RES, V38, P6171, DOI 10.21873/anticanres.12970; Kinstrie R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000579; Kottakis F, 2011, MOL CELL, V43, P285, DOI 10.1016/j.molcel.2011.06.020; Kumar Nagi B, 2018, Oncotarget, V9, P37798, DOI 10.18632/oncotarget.26519; Kurabayashi N, 2015, EMBO REP, V16, P1548, DOI 10.15252/embr.201540374; Lamoral-Theys D, 2010, CURR MED CHEM, V17, P812, DOI 10.2174/092986710790712183; Lee SB, 2016, NATURE, V529, P172, DOI 10.1038/nature16475; Leontovich AA, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1020-0; Lepagnol-Bestel AM, 2009, HUM MOL GENET, V18, P1405, DOI 10.1093/hmg/ddp047; Li D, 2010, J BIOL CHEM, V285, P35374, DOI 10.1074/jbc.M110.148445; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Li YC, 2021, BLOOD, V138, P2360, DOI 10.1182/blood.2021011247; Li YL, 2019, J CELL MOL MED, V23, P7427, DOI 10.1111/jcmm.14609; Li YL, 2020, CANCER BIOL MED, V17, P387, DOI 10.20892/j.issn.2095-3941.2019.0380; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Liu N, 2014, P NATL ACAD SCI USA, V111, P4109, DOI 10.1073/pnas.1401732111; Liu Q, 2016, J BIOL CHEM, V291, P26399, DOI 10.1074/jbc.M116.717553; Liu Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097974; Lu HS, 2018, NATURE, V558, P318, DOI 10.1038/s41586-018-0174-3; Lu M, 2011, J BIOL CHEM, V286, P10755, DOI 10.1074/jbc.M110.174540; Luna J, 2019, GUT, V68, P1465, DOI 10.1136/gutjnl-2018-316128; MacDonald J, 2017, MOL CANCER RES, V15, P371, DOI 10.1158/1541-7786.MCR-16-0323-T; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Malinge S, 2012, J CLIN INVEST, V122, P948, DOI 10.1172/JCI60455; Martin CE, 2021, EXP CELL RES, V405, DOI 10.1016/j.yexcr.2021.112656; Martins LR, 2014, LEUKEMIA, V28, P179, DOI 10.1038/leu.2013.232; Menon VR, 2019, CELL CYCLE, V18, P531, DOI 10.1080/15384101.2019.1577525; Miyata Y, 2011, BBA-MOL CELL RES, V1813, P1728, DOI 10.1016/j.bbamcr.2011.06.023; Naert G, 2015, EUR NEUROPSYCHOPHARM, V25, P2170, DOI 10.1016/j.euroneuro.2015.03.018; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Negrini S, 2013, TRENDS CELL BIOL, V23, P289, DOI 10.1016/j.tcb.2013.01.006; Okada Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20234-2; Papadopoulos C, 2011, J BIOL CHEM, V286, P5494, DOI 10.1074/jbc.M110.157909; Park J, 2010, J BIOL CHEM, V285, P31895, DOI 10.1074/jbc.M110.147520; Park NS, 2018, J CELL MOL MED, V22, P5833, DOI 10.1111/jcmm.13854; Pozo N, 2013, J CLIN INVEST, V123, P2475, DOI 10.1172/JCI63623; Prins RC, 2013, LEUKEMIA, V27, P2094, DOI 10.1038/leu.2013.228; Qian W, 2011, NUCLEIC ACIDS RES, V39, P6161, DOI 10.1093/nar/gkr195; Quang CT, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.14; Quesada AR, 1996, BRIT J CANCER, V74, P677, DOI 10.1038/bjc.1996.421; Radhakrishnan A, 2016, SCI REP-UK, V6, DOI 10.1038/srep36132; Recasens A, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00456-6; Roewenstrunk J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42445-x; Rossignol E, 2008, ANTI-CANCER DRUG, V19, P789, DOI 10.1097/CAD.0b013e32830ce4d8; Rozen EJ, 2018, CELL REP, V23, P1867, DOI 10.1016/j.celrep.2018.04.008; Ruben K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132453; Sakaguchi M, 2012, J INVEST DERMATOL, V132, P1877, DOI 10.1038/jid.2012.45; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; Shi JH, 2008, J BIOL CHEM, V283, P28660, DOI 10.1074/jbc.M802645200; Shin CM, 2018, CLIN NUTR, V37, P452, DOI 10.1016/j.clnu.2017.01.014; Siddiqui-Jain A, 2010, CANCER RES, V70, P10288, DOI 10.1158/0008-5472.CAN-10-1893; Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; Soppa U, 2014, CELL CYCLE, V13, P2084, DOI 10.4161/cc.29104; Soundararajan M, 2013, STRUCTURE, V21, P986, DOI 10.1016/j.str.2013.03.012; Taira N, 2010, J BIOL CHEM, V285, P4909, DOI 10.1074/jbc.M109.042341; Tazarki H, 2019, EUR J MED CHEM, V166, P304, DOI 10.1016/j.ejmech.2019.01.052; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Thompson BJ, 2015, J EXP MED, V212, P723, DOI 10.1084/jem.20150002; Tubi LQ, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-78; Walmsley DL, 2021, J MED CHEM, V64, P8971, DOI 10.1021/acs.jmedchem.1c00024; Wang E., 2021, BLOOD, V138, P507; Wang PF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12893-4; Wang P, 2021, J CELL MOL MED, V25, P6082, DOI 10.1111/jcmm.16505; Weber C, 2021, J MED CHEM, V64, P6745, DOI 10.1021/acs.jmedchem.1c00023; Wegiel J, 2011, J NEUROPATH EXP NEUR, V70, P36, DOI 10.1097/NEN.0b013e318202bfa1; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Westbrook TF, 2008, NATURE, V452, P370, DOI 10.1038/nature06780; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Wu P, 2016, ONCOTARGET, V7, P19863, DOI 10.18632/oncotarget.7887; Wurzlbauer A, 2020, MOLECULES, V25, DOI 10.3390/molecules25245962; Xu XY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1253-y; Yin WH, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-15; Yin XM, 2012, J BIOL CHEM, V287, P30497, DOI 10.1074/jbc.M112.355412; Yoon HR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186826; Yousefelahiyeh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207779; Yu D, 2019, NUCLEIC ACIDS RES, V47, P4462, DOI 10.1093/nar/gkz162; Zhang L, 2020, ARCH PHARM RES, V43, P1259, DOI 10.1007/s12272-020-01283-6; Zhang P., 2021, CELL DEATH DIS, V12; Zhang YJ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00486-7; Zhao C, 2020, CHEM-BIOL INTERACT, V316, DOI 10.1016/j.cbi.2019.108913; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	134	3	3	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2003	2011		10.1038/s41388-022-02245-6	http://dx.doi.org/10.1038/s41388-022-02245-6		FEB 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35220406	Green Accepted			2022-12-28	WOS:000761854700001
J	Yoshida, A; Phillips-Mason, P; Tarallo, V; Avril, S; Koivisto, C; Leone, G; Diehl, JA				Yoshida, Akihiro; Phillips-Mason, Polly; Tarallo, Vincenzo; Avril, Stefanie; Koivisto, Christopher; Leone, Gustavo; Diehl, J. Alan			Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss	ONCOGENE			English	Article							KAPPA-B; PROTEOLYSIS; CANCER; PRMT5; EXPRESSION; SUBUNIT; MTOR	Cyclin D1 is a regulatory subunit of -Cyclin Dependent Kinases 4 and 6 (CDK4/6) and regulates progression from G1 to S phase of the cell cycle. Dysregulated cyclin D1-CDK4/6 contributes to abnormal cell proliferation and tumor development. Phosphorylation of threonine 286 of cyclin D1 is necessary for ubiquitin-dependent degradation. Non-phosphorylatable cyclin D1 mutants are stabilized and concentrated in the nucleus, contributing to genomic instability and tumor development. Studies investigating the tumor-promoting functions of cyclin D1 mutants have focused on the use of artificial promoters to drive the expression which unfortunately may not accurately reflect tumorigenic functions of mutant cyclin D1 in cancer development. We have generated a conditional knock-in mouse model where cyclin D1T286A is expressed under the control of its endogenous promoter following Cre-dependent excision of a lox-stop-lox sequence. Acute expression of cyclin D1T286A following tamoxifen-inducible Cre recombinase triggers inflammation, lymphocyte abnormality and ultimately mesenteric tumors in the intestine. Tissue-specific expression of cyclin D1T286A in the uterus and endometrium cooperates with Pten loss to drive endometrial hyperplasia and cancer. Mechanistically, cyclin D1T286A mutant activates NF-kappa B signaling, augments inflammation, and contributes to tumor development. These results indicate that mutation of cyclin D1 at threonine 286 has a critical role in regulating inflammation and tumor development.	[Yoshida, Akihiro] Univ Hosp Cleveland, Dept Dermatol, Med Ctr, Cleveland, OH 44106 USA; [Yoshida, Akihiro; Avril, Stefanie] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Yoshida, Akihiro; Phillips-Mason, Polly; Tarallo, Vincenzo; Diehl, J. Alan] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; [Yoshida, Akihiro; Avril, Stefanie; Diehl, J. Alan] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Avril, Stefanie] Univ Hosp Cleveland, Dept Pathol, Med Ctr, Cleveland, OH 44106 USA; [Koivisto, Christopher] Med Univ South Carolina, Dept Biochem, Charleston, SC 29425 USA; [Leone, Gustavo] Med Coll Wisconsin, Canc Ctr, Dept Biochem, Wauwatosa, WI 53226 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Medical University of South Carolina; Medical College of Wisconsin	Yoshida, A (corresponding author), Univ Hosp Cleveland, Dept Dermatol, Med Ctr, Cleveland, OH 44106 USA.; Yoshida, A (corresponding author), Case Western Reserve Univ, Cleveland, OH 44106 USA.; Yoshida, A; Diehl, JA (corresponding author), Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.; Yoshida, A; Diehl, JA (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.	axy234@case.edu; jad283@case.edu		Tarallo, Vincenzo/0000-0001-8158-1326; , J. Alan/0000-0001-9854-5049; Yoshida, Akihiro/0000-0002-9785-9035	National Cancer Institute [R01 CA093237, P01 CA098101, R01 CA121275]; Advancing a Healthier Wisconsin Endowment Award	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Advancing a Healthier Wisconsin Endowment Award	This work was supported by grants from National Cancer Institute: R01 CA093237 and P01 CA098101 (JAD); R01 CA121275 and Advancing a Healthier Wisconsin Endowment Award (GL).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Caserta E, 2015, GENE DEV, V29, P1707, DOI 10.1101/gad.262568.115; Contreras CM, 2010, DIS MODEL MECH, V3, P181, DOI 10.1242/dmm.004440; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; GU L, 2004, BLOOD, V104, P4438, DOI DOI 10.1182/BLOOD.V104.11.4438.4438; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Kwon HJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11686; Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Masclef L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00106; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Pontano LL, 2008, MOL CELL BIOL, V28, P7245, DOI 10.1128/MCB.01085-08; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Tian YQ, 2019, AGING CELL, V18, DOI 10.1111/acel.12858; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Wei H, 2013, P NATL ACAD SCI USA, V110, P13516, DOI 10.1073/pnas.1311784110; Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105	30	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2187	2195		10.1038/s41388-022-02243-8	http://dx.doi.org/10.1038/s41388-022-02243-8		FEB 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35210557				2022-12-28	WOS:000761270800001
J	Humbert, PO; Pryjda, TZ; Pranjic, B; Farrell, A; Fujikura, K; Simoes, RD; Karim, R; Kozieradzki, I; Cronin, SJF; Neely, GG; Meyer, TF; Hagelkruys, A; Richardson, HE; Penninger, JM				Humbert, Patrick O.; Pryjda, Tamara Zoranovic; Pranjic, Blanka; Farrell, Andrew; Fujikura, Kohei; de Matos Simoes, Ricardo; Karim, Rezaul; Kozieradzki, Ivona; Cronin, Shane J. F.; Neely, G. Gregory; Meyer, Thomas F.; Hagelkruys, Astrid; Richardson, Helena E.; Penninger, Josef M.			TSPAN6 is a suppressor of Ras-driven cancer	ONCOGENE			English	Article							CELL POLARITY; EXPRESSION; TETRASPANINS; ACTIVATION; MUTATIONS; JUNCTIONS; RESPONSES; INVASION; MODULE; GROWTH	Oncogenic mutations in the small GTPase RAS contribute to similar to 30% of human cancers. In a Drosophila genetic screen, we identified novel and evolutionary conserved cancer genes that affect Ras-driven tumorigenesis and metastasis in Drosophila including confirmation of the tetraspanin Tsp29Fb. However, it was not known whether the mammalian Tsp29Fb orthologue, TSPAN6, has any role in RAS-driven human epithelial tumors. Here we show that TSPAN6 suppressed tumor growth and metastatic dissemination of human RAS activating mutant pancreatic cancer xenografts. Whole-body knockout as well as tumor cell autonomous inactivation using floxed alleles of Tspan6 in mice enhanced Kras(G12D)-driven lung tumor initiation and malignant progression. Mechanistically, TSPAN6 binds to the EGFR and blocks EGFR-induced RAS activation. Moreover, we show that inactivation of TSPAN6 induces an epithelial-to-mesenchymal transition and inhibits cell migration in vitro and in vivo. Finally, low TSPAN6 expression correlates with poor prognosis of patients with lung and pancreatic cancers with mesenchymal morphology. Our results uncover TSPAN6 as a novel tumor suppressor receptor that controls epithelial cell identify and restrains RAS-driven epithelial cancer.	[Humbert, Patrick O.; Farrell, Andrew; Richardson, Helena E.] La Trobe Univ, Sch Mol Sci, Dept Biochem Genet, Bundoora, Vic 3086, Australia; [Humbert, Patrick O.; Pryjda, Tamara Zoranovic; Pranjic, Blanka; Karim, Rezaul; Kozieradzki, Ivona; Cronin, Shane J. F.; Neely, G. Gregory; Hagelkruys, Astrid; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohrgasse 3, A-1030 Vienna, Austria; [Pryjda, Tamara Zoranovic; Meyer, Thomas F.] Max Planck Inst Infect Biol, Charite Pl 1, D-10117 Berlin, Germany; [Fujikura, Kohei; Kozieradzki, Ivona; Penninger, Josef M.] Univ British Columbia, Inst Life Sci, Dept Med Genet, Vancouver, BC, Canada; [de Matos Simoes, Ricardo] Ctr Integrat Bioinformat Vienna, Max F Perusetz Labs, Dr Bohr Gasse 9-6, A-1030 Vienna, Austria; [Neely, G. Gregory] Univ Sydney, Sch Life & Environm Sci, Dr John & Anne Chong Lab Funct Genom, Charles Perkins Ctr, Sydney, NSW 2006, Australia; [Meyer, Thomas F.] Christian Albrechts Univ Kiel, Inst Clin Mol Biol, Lab Infect Oncol, Kiel, Germany; [Pryjda, Tamara Zoranovic; Pranjic, Blanka] Univ Hosp Schleswig Holstein Campus Kiel, Kiel, Germany	La Trobe University; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Max Planck Society; University of British Columbia; University of Sydney; University of Kiel; University of Kiel; Schleswig Holstein University Hospital	Humbert, PO; Richardson, HE (corresponding author), La Trobe Univ, Sch Mol Sci, Dept Biochem Genet, Bundoora, Vic 3086, Australia.; Humbert, PO; Penninger, JM (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohrgasse 3, A-1030 Vienna, Austria.; Penninger, JM (corresponding author), Univ British Columbia, Inst Life Sci, Dept Med Genet, Vancouver, BC, Canada.	P.Humbert@latrobe.edu.au; H.Richardson@latrobe.edu.au; josef.penninger@ubc.ca	; Humbert, Patrick/L-4264-2016; Penninger, Josef/I-6860-2013	zoranovic, tamara/0000-0002-5369-6385; Humbert, Patrick/0000-0002-1366-6691; Penninger, Josef/0000-0002-8194-3777	IMBA; ERC Advanced Investigator grant; Era of Hope; T. von Zastrow foundation; Canada 150 Chair in Functional Genetics; Marie Curie Excellence grant; Infla-Care grant; Infect-ERA grant; Invest [RD0412515]; Cancer Council Victoria (Australia); National Health & Medical Research Council (NHMRC), Australia; La Trobe University	IMBA; ERC Advanced Investigator grant; Era of Hope; T. von Zastrow foundation; Canada 150 Chair in Functional Genetics; Marie Curie Excellence grant(European Commission); Infla-Care grant; Infect-ERA grant; Invest; Cancer Council Victoria (Australia)(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); National Health & Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); La Trobe University	We thank all members of our laboratories for helpful discussions as well as VDRC and IMP/IMBA core facilities for excellent technical support. We also acknowledge Life Science Editors for editorial support (www.lifescienceeditors.com).JMP was supported by IMBA, ERC Advanced Investigator grant, an Innovator Award from Era of Hope, the T. von Zastrow foundation, and a Canada 150 Chair in Functional Genetics. TZP was supported by a Marie Curie Excellence grant. RK was supported by Infla-Care and Infect-ERA grants. RdMS was supported by a grant from Invest NI RD0412515. AF was supported from funds from the Cancer Council Victoria (Australia) to HER, POH, and JMP. HER and POH were supported by fellowships from the National Health & Medical Research Council (NHMRC), Australia, and by funds from La Trobe University.	Andrijes R, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2011411118; Aubrey BJ, 2018, CELL DEATH DIFFER, V25, P104, DOI 10.1038/cdd.2017.169; Balagurunathan Y, 2008, MOL CANCER THER, V7, P3071, DOI 10.1158/1535-7163.MCT-08-0402; Bar-Sagi D, 1992, Semin Cell Biol, V3, P93; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Caddy J, 2010, DEV CELL, V19, P138, DOI 10.1016/j.devcel.2010.06.008; Charrin S, 2014, J CELL SCI, V127, P3641, DOI 10.1242/jcs.154906; Chen JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026104; Chen SJ, 2019, CURR PHARM DESIGN, V25, P1105, DOI 10.2174/1381612825666190506122228; Cho JH, 2020, CELL DEATH DIFFER, V27, P2681, DOI 10.1038/s41418-020-0537-9; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; DeNicola Gina M, 2009, Eur J Cancer, V45 Suppl 1, P211, DOI 10.1016/S0959-8049(09)70036-X; DiMauro T, 2010, CURR CANCER DRUG TAR, V10, P869, DOI 10.2174/156800910793357998; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Elsum I, 2012, ESSAYS BIOCHEM, V53, P141, DOI [10.1042/bse0530141, 10.1042/BSE0530141]; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Fox RM, 2015, BIOL OPEN, V4, P317, DOI 10.1242/bio.201411205; Garcia-Espana A, 2008, GENOMICS, V91, P326, DOI 10.1016/j.ygeno.2007.12.005; Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640; Hobbs GA, 2016, J CELL SCI, V129, P1287, DOI 10.1242/jcs.182873; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Kummer D, 2020, MED MICROBIOL IMMUN, V209, P397, DOI 10.1007/s00430-020-00673-3; Kuner R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033; La Marca JE, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00042; Lang T, 2020, CURR BIOL, V30, pR204, DOI 10.1016/j.cub.2020.01.007; Leong GR, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-62; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Rizzotto D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910883; Rubinstein E, 2011, BIOCHEM SOC T, V39, P501, DOI 10.1042/BST0390501; Sacco E, 2012, EXPERT OPIN THER PAT, V22, P1263, DOI 10.1517/13543776.2012.728586; Schramek D, 2011, TRENDS ENDOCRIN MET, V22, P188, DOI 10.1016/j.tem.2011.02.007; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Stephens R, 2018, J MOL BIOL, V430, P3585, DOI 10.1016/j.jmb.2018.01.011; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Tepass U, 2012, ANNU REV CELL DEV BI, V28, P655, DOI 10.1146/annurev-cellbio-092910-154033; Termini CM, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00034; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Xu CW, 2019, CELL REP, V26, P670, DOI 10.1016/j.celrep.2018.12.079; Yamamoto M, 2017, NATURE, V542, P246, DOI 10.1038/nature21033; Yanez-Mo M, 2009, TRENDS CELL BIOL, V19, P434, DOI 10.1016/j.tcb.2009.06.004; Young A, 2009, ADV CANCER RES, V102, P1, DOI 10.1016/S0065-230X(09)02001-6; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543; Zoranovic T, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007688	51	1	1	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2095	2105		10.1038/s41388-022-02223-y	http://dx.doi.org/10.1038/s41388-022-02223-y		FEB 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35184157	Green Published, hybrid			2022-12-28	WOS:000757918900001
J	Zeng, Z; Zhang, X; Jiang, CQ; Zhang, YG; Wu, X; Li, J; Tang, S; Li, L; Gu, LJ; Xie, XY; Jiang, YA				Zeng, Zhi; Zhang, Xu; Jiang, Cong-Qing; Zhang, Yong-Gang; Wu, Xue; Li, Jin; Tang, Shan; Li, Lang; Gu, Li-Juan; Xie, Xiao-Yu; Jiang, Ying-An			Identifying novel therapeutic targets in gastric cancer using genome-wide CRISPR-Cas9 screening	ONCOGENE			English	Article							CRISPR/CAS9 LIBRARY; GENETIC SCREENS; PROMOTES; CARCINOMA	Genome-scale CRISPR-Cas9 screening technology is a powerful tool to systematically identify genes essential for cancer cell survival. Herein, TKOv3, a genome-scale CRISPR-Cas9 knock-out library, was screened in the gastric cancer (GC) cells, and relevant validation experiments were performed. We obtained 854 essential genes for the AGS cell line, and 184 were novel essential genes. After knocking down essential genes: SPC25, DHX37, ABCE1, SNRPB, TOP3A, RUVBL1, CIT, TACC3 and MTBP, cell viability and proliferation were significantly decreased. Then, we analysed the detected essential genes at different time points and proved more characteristic genes might appear with the extension of selection. After progressive selection using a series of open datasets, 41 essential genes were identified as potential drug targets. Among them, methyltransferase 1 (METTL1) was over expressed in GC tissues. High METTL1 expression was associated with poor prognosis among 3 of 6 GC cohorts. Furthermore, GC cells growth was significantly inhibited after the down-regulation of METTL1 in vitro and in vivo. Function analysis revealed that METTL1 might play a role in the cell cycle through AKT/STAT3 pathways. In conclusion, compared with existing genome-scale screenings, we obtained 184 novel essential genes. Among them, METTL1 was validated as a potential therapeutic target of GC.	[Zeng, Zhi] Wuhan Univ, Dept Pathol, Renmin Hosp, Wuhan, Hubei, Peoples R China; [Zhang, Xu; Zhang, Yong-Gang; Gu, Li-Juan] Wuhan Univ, Cent Lab, Renmin Hosp, Wuhan, Hubei, Peoples R China; [Jiang, Cong-Qing; Xie, Xiao-Yu] Wuhan Univ, Dept Colorectal & Anal Surg, Zhongnan Hosp, Wuhan, Hubei, Peoples R China; [Wu, Xue; Li, Jin; Tang, Shan; Li, Lang] Ohio State Univ, Dept Biomed Informat, Columbus, OH USA; [Jiang, Ying-An] Wuhan Univ, Dept Infect Dis, Renmin Hosp, Wuhan, Hubei, Peoples R China	Wuhan University; Wuhan University; Wuhan University; University System of Ohio; Ohio State University; Wuhan University	Xie, XY (corresponding author), Wuhan Univ, Dept Colorectal & Anal Surg, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.; Jiang, YA (corresponding author), Wuhan Univ, Dept Infect Dis, Renmin Hosp, Wuhan, Hubei, Peoples R China.	ZN004356@whu.edu.cn; jiangya_cn@aliyun.com		Tang, Shan/0000-0002-8224-2809; Zeng, Zhi/0000-0003-4131-050X				Balusamy SR, 2018, BIOMED PHARMACOTHER, V108, P1835, DOI 10.1016/j.biopha.2018.10.028; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen ZY, 2018, BIOCHEM BIOPH RES CO, V498, P579, DOI 10.1016/j.bbrc.2018.03.022; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Costa R, 2016, ONCOTARGET, V7, P55924, DOI 10.18632/oncotarget.10482; Evers B, 2016, NAT BIOTECHNOL, V34, P631, DOI 10.1038/nbt.3536; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Hart T, 2017, G3-GENES GENOM GENET, V7, P2719, DOI 10.1534/g3.117.041277; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Ho SWT, 2019, CANCER SCI, V110, P3405, DOI 10.1111/cas.14191; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Kurata M, 2018, J HUM GENET, V63, P179, DOI 10.1038/s10038-017-0376-9; Li CS, 2016, GENE, V587, P42, DOI 10.1016/j.gene.2016.04.029; Lin SB, 2018, MOL CELL, V71, P244, DOI 10.1016/j.molcel.2018.06.001; Liu Y, 2020, LIFE SCI, V249, DOI 10.1016/j.lfs.2020.117480; Lu X, 2019, ONCOTARGETS THER, V12, P7489, DOI 10.2147/OTT.S208848; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Marcotte R, 2012, CANCER DISCOV, V2, P172, DOI 10.1158/2159-8290.CD-11-0224; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Morgens DW, 2016, NAT BIOTECHNOL, V34, P634, DOI 10.1038/nbt.3567; Okamoto M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004639; Orellana EA, 2021, MOL CELL, V81, P3323, DOI 10.1016/j.molcel.2021.06.031; Pandolfini L, 2019, MOL CELL, V74, P1278, DOI 10.1016/j.molcel.2019.03.040; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shang WJ, 2021, J PATHOL, V253, P148, DOI 10.1002/path.5568; Sheng Y, 2018, CANCER MANAG RES, V10, P6205, DOI 10.2147/CMAR.S176147; Tao JQ, 2014, TUMOR BIOL, V35, P4389, DOI 10.1007/s13277-013-1578-1; Tian QH, 2019, J MOL MED, V97, P1535, DOI 10.1007/s00109-019-01830-9; Tsai MM, 2012, CANCER SCI, V103, P1136, DOI 10.1111/j.1349-7006.2012.02243.x; Tzelepis K, 2016, CELL REP, V17, P1193, DOI 10.1016/j.celrep.2016.09.079; Venerito M, 2019, HELICOBACTER, V24, DOI 10.1111/hel.12643; Wang BB, 2019, NAT PROTOC, V14, P756, DOI 10.1038/s41596-018-0113-7; Wang C, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12591; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Yuan L, 2021, WORLD J GASTROENTERO, V27, P1785, DOI 10.3748/wjg.v27.i16.1785; Zhou YX, 2014, NATURE, V509, P487, DOI 10.1038/nature13166	38	1	1	8	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2069	2078		10.1038/s41388-022-02177-1	http://dx.doi.org/10.1038/s41388-022-02177-1		FEB 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35177812				2022-12-28	WOS:000757138900002
J	Mota, A; Oltra, SS; Selenica, P; Moiola, CP; Casas-Arozamena, C; Lopez-Gil, C; Diaz, E; Gatius, S; Ruiz-Miro, M; Calvo, A; Rojo-Sebastian, A; Hurtado, P; Pineiro, R; Colas, E; Gil-Moreno, A; Reis-Filho, JS; Muinelo-Romay, L; Abal, M; Matias-Guiu, X; Weigelt, B; Moreno-Bueno, G				Mota, Alba; Oltra, Sara S.; Selenica, Pier; Moiola, Cristian P.; Casas-Arozamena, Carlos; Lopez-Gil, Carlos; Diaz, Eva; Gatius, Sonia; Ruiz-Miro, Maria; Calvo, Ana; Rojo-Sebastian, Alejandro; Hurtado, Pablo; Pineiro, Roberto; Colas, Eva; Gil-Moreno, Antonio; Reis-Filho, Jorge S.; Muinelo-Romay, Laura; Abal, Miguel; Matias-Guiu, Xavier; Weigelt, Britta; Moreno-Bueno, Gema			Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression	ONCOGENE			English	Article							SYNCHRONOUS PRIMARY CANCERS; GENOMIC CHARACTERIZATION; INTERNATIONAL SOCIETY; MUTATIONAL PROCESSES; TUMOR HETEROGENEITY; OVARIAN CANCERS; CELL CARCINOMAS; BREAST; RECOMMENDATIONS; CHEMOTHERAPY	Analyzing different tumor regions by next generation sequencing allows the assessment of intratumor genetic heterogeneity (ITGH), a phenomenon that has been studied widely in some tumor types but has been less well explored in endometrial carcinoma (EC). In this study, we sought to characterize the spatial and temporal heterogeneity of 9 different ECs using whole-exome sequencing, and by performing targeted sequencing validation of the 42 primary tumor regions and 30 metastatic samples analyzed. In addition, copy number alterations of serous carcinomas were assessed by comparative genomic hybridization arrays. From the somatic mutations, identified by whole-exome sequencing, 532 were validated by targeted sequencing. Based on these data, the phylogenetic tree reconstructed for each case allowed us to establish the tumors' evolution and correlate this to tumor progression, prognosis, and the presence of recurrent disease. Moreover, we studied the genetic landscape of an ambiguous EC and the molecular profile obtained was used to guide the selection of a potential personalized therapy for this patient, which was subsequently validated by preclinical testing in patient-derived xenograft models. Overall, our study reveals the impact of analyzing different tumor regions to decipher the ITGH in ECs, which could help make the best treatment decision.	[Mota, Alba; Oltra, Sara S.; Diaz, Eva; Moreno-Bueno, Gema] MD Anderson Int Fdn, Madrid 28033, Spain; [Mota, Alba; Oltra, Sara S.; Moreno-Bueno, Gema] Univ Autonoma Madrid UAM, Inst Invest Biomed Alberto Sols CSIC UAM, Biochem Dept, IdiPaz, Madrid 28029, Spain; [Oltra, Sara S.; Moiola, Cristian P.; Rojo-Sebastian, Alejandro; Colas, Eva; Gil-Moreno, Antonio; Muinelo-Romay, Laura; Abal, Miguel; Matias-Guiu, Xavier; Moreno-Bueno, Gema] Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain; [Selenica, Pier; Reis-Filho, Jorge S.; Weigelt, Britta] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Moiola, Cristian P.; Lopez-Gil, Carlos; Rojo-Sebastian, Alejandro; Colas, Eva; Gil-Moreno, Antonio] Univ Autonoma Barcelona, Vall Hebron Inst Res, Biomed Res Grp Gynecol, Barcelona 08035, Spain; [Casas-Arozamena, Carlos; Muinelo-Romay, Laura; Abal, Miguel] Univ Hosp Santiago de Compostela SERGAS, Hlth Res Inst Santiago de Compostela IDIS, Translat Med Oncol Grp Oncomet, Trav Choupana S-N, Santiago De Compostela 15706, Spain; [Gatius, Sonia; Matias-Guiu, Xavier] Univ Lleida, Hosp U Arnau de Vilanova, Dept Pathol, Lleida, Spain; [Ruiz-Miro, Maria] IRBLLEIDA, Biobank, Lleida, Spain; [Calvo, Ana] Hosp U Arnau de Vilanova, Dept Gynecol, IRBLLEIDA, Lleida, Spain; [Rojo-Sebastian, Alejandro] MD Anderson Canc Ctr, Madrid, Spain; [Hurtado, Pablo; Pineiro, Roberto] Hlth Res Inst Santiago de Compostela IDIS, Roche Chus Joint Unit, Translat Med Oncol Grp Oncomet, Travesia Da Choupana S-N, Santiago De Compostela 15706, Spain; [Gil-Moreno, Antonio] Vall Hebron Univ Hosp, Gynaecol Dept, Barcelona 08035, Spain; [Matias-Guiu, Xavier] Univ Lleida, Hosp U Bellvitge, Dept Pathol, Lleida, Spain; [Matias-Guiu, Xavier] Univ Barcelona, Hosp U Bellvitge, Dept Pathol, Barcelona, Spain; [Matias-Guiu, Xavier] IDIBELL Lleida & Barcelona, Barcelona, Spain	University of Texas System; UTMD Anderson Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Memorial Sloan Kettering Cancer Center; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Complexo Hospitalario Universitario de Santiago de Compostela; Universitat de Lleida; University of Texas System; UTMD Anderson Cancer Center; Complexo Hospitalario Universitario de Santiago de Compostela; Hospital Universitari Vall d'Hebron; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Universitat de Lleida; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona	Moreno-Bueno, G (corresponding author), MD Anderson Int Fdn, Madrid 28033, Spain.; Moreno-Bueno, G (corresponding author), Univ Autonoma Madrid UAM, Inst Invest Biomed Alberto Sols CSIC UAM, Biochem Dept, IdiPaz, Madrid 28029, Spain.; Moreno-Bueno, G (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain.	gmoreno@iib.uam.es	Oltra, Sara/Y-4002-2019; Moreno-Bueno, Gema/K-9354-2016; Piñeiro, Roberto/AAN-5561-2020; Selenica, Pier/GQY-8678-2022	Moreno-Bueno, Gema/0000-0002-5030-6687; Piñeiro, Roberto/0000-0001-9479-139X; Casas-Arozamena, Carlos/0000-0002-3279-2482	MD Anderson Foundation Biobank [B.0000745]; "Plataforma de Biobancos" ISCIII [PT13/0010/0014, B.000609]; Spanish Ministry of Economy and Innovation [PID2019-104644RB-I00]; Instituto de Salud Carlos III (ISCIII, CIBERONC) [FEDER funds] [CB16/12/00295 - GMB, CB16/12/00328 -EC, CB16/12/00231 -XMG]; AECC Scientific Foundation [FC_AECC PROYE19036MOR -GMB]; AECC; Breast Cancer Research Foundation; NIH/NCI [P50 CA247749 01, P30CA008748]	MD Anderson Foundation Biobank; "Plataforma de Biobancos" ISCIII; Spanish Ministry of Economy and Innovation(Spanish Government); Instituto de Salud Carlos III (ISCIII, CIBERONC) [FEDER funds]; AECC Scientific Foundation; AECC; Breast Cancer Research Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all those at the Translational Research Laboratory of the MD Anderson Cancer Center Madrid for their invaluable help with this study. Tissue samples were obtained with the support of the MD Anderson Foundation Biobank (record number B.0000745, ISCIII National Biobank Record), the "Xarxa Catalana de Bancs de Tumors" and "Plataforma de Biobancos" ISCIII (PT13/0010/0014, B.000609). This study has been supported by the Spanish Ministry of Economy and Innovation (PID2019-104644RB-I00 (GMB), the Instituto de Salud Carlos III (ISCIII, CIBERONC, CB16/12/00295 - GMB-, CB16/12/00328 -EC, AGM- and CB16/12/00231 -XMG- [all partly supported by FEDER funds]) and by the AECC Scientific Foundation (FC_AECC PROYE19036MOR -GMB- and Coordinated groups 2018 -XMG, AGM, GMB-). SO is funded by an AECC-postdoctoral grant (2020). JSR-F and BW are funded in part by the Breast Cancer Research Foundation and in part by the NIH/NCI P50 CA247749 01 grant. Research reported in this publication was supported in part by a Cancer Center Support Grant of the NIH/NCI (Grant No. P30CA008748; MSK). We thank the Eurofins Megalab laboratory for helping us to perform the analysis of DNA HPV detection.	Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Anglesio MS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv428; Ashley CW, 2019, GYNECOL ONCOL, V152, P11, DOI 10.1016/j.ygyno.2018.10.032; Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230; Beck-Engeser GB, 2015, EUR J IMMUNOL, V45, P695, DOI 10.1002/eji.201445218; Belhadj H, 2014, INT J GYNECOL OBSTET, V125, P97, DOI 10.1016/j.ijgo.2014.02.003; Bell DW, 2019, ANNU REV PATHOL-MECH, V14, P339, DOI 10.1146/annurev-pathol-020117-043609; Bestvina CM, 2016, ONCOLOGIST, V21, P1250, DOI 10.1634/theoncologist.2016-0062; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Budczies J, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1526613; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cannataro VL, 2019, ONCOGENE, V38, P3475, DOI 10.1038/s41388-018-0657-6; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Casas-Arozamena C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020585; Chao A, 2016, GYNECOL ONCOL, V143, P60, DOI 10.1016/j.ygyno.2016.07.114; Chiang YC, 2008, INT J GYNECOL CANCER, V18, P159, DOI 10.1111/j.1525-1438.2007.00975.x; Choi M, 2016, MOL CANCER THER, V15, P1781, DOI 10.1158/1535-7163.MCT-15-0945; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Connell PP, 1999, GYNECOL ONCOL, V74, P74, DOI 10.1006/gyno.1999.5415; Davis AP, 2019, NUCLEIC ACIDS RES, V47, pD948, DOI 10.1093/nar/gky868; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Demeulemeester J, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1109-7; Dessources K, 2020, JCO PRECIS ONCOL, V4, P1217, DOI 10.1200/PO.20.00044; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Eritja N, 2017, ADV EXP MED BIOL, V943, P149, DOI 10.1007/978-3-319-43139-0_6; Espinosa I, 2016, AM J SURG PATHOL, V40, P972, DOI 10.1097/PAS.0000000000000640; Evans T, 2016, J NATL COMPR CANC NE, V14, P1165, DOI 10.6004/jnccn.2016.0123; GALL JG, 1986, SCIENCE, V233, P1367, DOI 10.1126/science.233.4771.1367-e; Garg K, 2010, MODERN PATHOL, V23, P80, DOI 10.1038/modpathol.2009.153; Gatius S, 2018, PATHOBIOLOGY, V85, P35, DOI 10.1159/000475529; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gibson WJ, 2016, NAT GENET, V48, P848, DOI 10.1038/ng.3602; Grondin CJ, 2016, ENVIRON HEALTH PERSP, V124, P1592, DOI 10.1289/EHP174; Guerini-Rocco E, 2015, J PATHOL, V237, P166, DOI 10.1002/path.4566; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Heitz F, 2014, INT J GYNECOL CANCER, V24, P54, DOI 10.1097/IGC.0000000000000019; HEPPNER GH, 1984, CANCER RES, V44, P2259; Hiley C, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0453-8; Irving JA, 2005, HUM PATHOL, V36, P605, DOI 10.1016/j.humpath.2005.03.005; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jette NR, 2020, CANCERS, V12, DOI 10.3390/cancers12030687; Jiang TT, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-876; Kiess AP, 2012, GYNECOL ONCOL, V127, P321, DOI 10.1016/j.ygyno.2012.07.112; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kommoss S, 2018, ANN ONCOL, V29, P1180, DOI 10.1093/annonc/mdy058; Kuhn E, 2012, JNCI-J NATL CANCER I, V104, P1503, DOI 10.1093/jnci/djs345; Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Kurman RJ, 2014, WORLD HLTH ORG CLASS; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; Lax S F, 1997, Verh Dtsch Ges Pathol, V81, P228; Le Gallo M, 2014, CLIN CHEM, V60, P98, DOI 10.1373/clinchem.2013.205740; Lee JY, 2019, CLIN CANCER RES, V25, P674, DOI 10.1158/1078-0432.CCR-18-1103; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Marquard AM, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0130-0; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; McPherson A, 2016, NAT GENET, V48, P758, DOI 10.1038/ng.3573; Mota A, 2017, MODERN PATHOL, V30, P134, DOI 10.1038/modpathol.2016.143; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; NIKZAINAL S, 2012, CELL, V149; Norman JM, 2011, NAT IMMUNOL, V12, P975, DOI 10.1038/ni.2087; Peterson LE, 2019, MOLECULES, V24, DOI 10.3390/molecules24030645; Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y; Rabban JT, 2019, INT J GYNECOL PATHOL, V38, pS25, DOI 10.1097/PGP.0000000000000512; Reijnen C, 2020, INT J CANCER, V147, P478, DOI 10.1002/ijc.32907; Reiter JG, 2019, NAT REV CANCER, V19, P639, DOI 10.1038/s41568-019-0185-x; Roberts NJ, 2016, CANCER DISCOV, V6, P166, DOI 10.1158/2159-8290.CD-15-0402; Robertson AG, 2018, CELL, V174, P1033, DOI 10.1016/j.cell.2018.07.036; Rosa-Rosa JM, 2016, MODERN PATHOL, V29, P1594, DOI 10.1038/modpathol.2016.184; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/nmeth.2883, 10.1038/NMETH.2883]; Rye IH, 2018, MOL ONCOL, V12, P1838, DOI 10.1002/1878-0261.12375; Ryu D, 2016, HUM GENET, V135, P635, DOI 10.1007/s00439-016-1670-x; Saber A, 2017, CARCINOGENESIS, V38, P144, DOI 10.1093/carcin/bgw128; Santacana M, 2014, HUM PATHOL, V45, P2394, DOI 10.1016/j.humpath.2014.06.031; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schliep KP, 2011, BIOINFORMATICS, V27, P592, DOI 10.1093/bioinformatics/btq706; Schmitt A, 2017, CANCER RES, V77, P3040, DOI 10.1158/0008-5472.CAN-16-3398; Schultheis AM, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv427; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Shi WW, 2018, CELL REP, V25, P1446, DOI 10.1016/j.celrep.2018.10.046; Siegel RL., 2020, CA-CANCER J CLIN, V70; Soliman PT, 2004, GYNECOL ONCOL, V94, P456, DOI 10.1016/j.ygyno.2004.05.006; Soslow RA, 2019, INT J GYNECOL PATHOL, V38, pS64, DOI 10.1097/PGP.0000000000000518; Soslow RA, 2010, SEMIN DIAGN PATHOL, V27, P261, DOI 10.1053/j.semdp.2010.09.003; Talhouk A, 2017, CANCER-AM CANCER SOC, V123, P802, DOI 10.1002/cncr.30496; Tang Wan, 2015, Shanghai Arch Psychiatry, V27, P62, DOI 10.11919/j.issn.1002-0829.215010; Taylor BJM, 2013, ELIFE, V2, DOI 10.7554/eLife.00534; Uchi R, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005778; Vermij L, 2020, HISTOPATHOLOGY, V76, P52, DOI 10.1111/his.14015; Weigelt B, 2018, JNCI-J NATL CANCER I, V110, P1030, DOI 10.1093/jnci/djy028; Weinreb I, 2014, NAT GENET, V46, P1166, DOI 10.1038/ng.3096; Wilkerson MD, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku489; Wu H, 2017, ONCOGENE, V36, P2857, DOI 10.1038/onc.2016.438; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Yi K, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0112-3; Zapatka M, 2020, NAT GENET, V52, P320, DOI 10.1038/s41588-019-0558-9; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zhang W, 2020, ONCOLOGIST, V25, P375, DOI 10.1634/theoncologist.2019-0498	104	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1835	1850		10.1038/s41388-022-02221-0	http://dx.doi.org/10.1038/s41388-022-02221-0		FEB 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35145232	hybrid, Green Published			2022-12-28	WOS:000754012300003
J	Xu, QC; Tien, YC; Shi, YH; Chen, S; Zhu, YQ; Huang, XT; Huang, CS; Zhao, W; Yin, XY				Xu, Qiong-Cong; Tien, Yi-Chih; Shi, Yin-Hao; Chen, Siyun; Zhu, Ying-Qin; Huang, Xi-Tai; Huang, Chen-Song; Zhao, Wei; Yin, Xiao-Yu			METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m(6)A-YTHDF2-dependent manner	ONCOGENE			English	Article							CANCER; RNA	N6-methyladenosine (m(6)A) RNA methylation has recently been found involving in regulatory mechanism of the tumor progression. Our aim was to explore the biological function and clinical significance of the m(6)A methyltransferase METTL3 in intrahepatic cholangiocarcinoma (ICC). In this study, we revealed that METTL3 was upregulated and predicted poor prognosis of patients with ICC. Multivariate regression analysis demonstrated that METTL3 expression was an independent predictor for overall survival in patients with ICC. Moreover, METTL3 knockdown inhibited ICC progression, while METTL3 overexpression showed the opposite effect. METTL3 inhibitor STM2457 also showed anti-tumor effect in ICC. Mechanistically, METTL3 transcription was driven by H3K4me3 activation. Upregulation of METTL3 mediated m(6)A modification of IFIT2 mRNA and accelerated IFIT2 mRNA decay in a YTHDF2-dependent manner, which promoted the development of ICC and lead to poorer prognosis. In summary, our findings revealed that H3K4me3 activation-driven METTL3 transcription promotes ICC progression by YTHDF2-mediated IFIT2 mRNA degradation, suggesting that METTL3 may serve as a potential target for human ICC therapy.	[Xu, Qiong-Cong; Tien, Yi-Chih; Shi, Yin-Hao; Zhu, Ying-Qin; Huang, Xi-Tai; Huang, Chen-Song; Yin, Xiao-Yu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pancreatobiliary Surg, Guangzhou 510080, Peoples R China; [Chen, Siyun; Zhao, Wei] Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Guangzhou 510080, Peoples R China; [Zhao, Wei] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangzhou 510080, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital	Yin, XY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pancreatobiliary Surg, Guangzhou 510080, Peoples R China.; Zhao, W (corresponding author), Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Guangzhou 510080, Peoples R China.; Zhao, W (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangzhou 510080, Peoples R China.	zhaowei23@mail.sysu.edu.cn; yinxy@mail.sysu.edu.cn			National Natural Science Foundation of China [81772522, 82002501, 82072644, 81972651, 31771630]; Guangdong Basic and Applied Basic Research Foundation [2021A1515010123, 2019A1515010096, 2019A1515010686]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation	The authors greatly acknowledge the financial support from National Natural Science Foundation of China (81772522, 82002501, 82072644, 81972651, and 31771630), the Guangdong Basic and Applied Basic Research Foundation (2021A1515010123, 2019A1515010096 and 2019A1515010686).	Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Cheng MS, 2019, ONCOGENE, V38, P3667, DOI 10.1038/s41388-019-0683-z; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9; Huang CS, 2018, CANCER LETT, V421, P63, DOI 10.1016/j.canlet.2018.02.020; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Jusakul A, 2017, CANCER DISCOV, V7, P1116, DOI 10.1158/2159-8290.CD-17-0368; Koh SY, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030624; Lai KC, 2013, ONCOGENE, V32, P3686, DOI 10.1038/onc.2012.384; Lai KC, 2016, CANCER LETT, V370, P207, DOI 10.1016/j.canlet.2015.10.016; Li JF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01267-6; Mavros MN, 2014, JAMA SURG, V149, P565, DOI 10.1001/jamasurg.2013.5137; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Moore MJ, 2014, NAT PROTOC, V9, P263, DOI 10.1038/nprot.2014.012; Nepal C, 2018, HEPATOLOGY, V68, P949, DOI 10.1002/hep.29764; Pidugu VK, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00148; Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0; Rizvi S, 2018, NAT REV CLIN ONCOL, V15, P95, DOI 10.1038/nrclinonc.2017.157; Shen H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0107-3; Shroff RT, 2019, JAMA ONCOL, V5, P824, DOI 10.1001/jamaoncol.2019.0270; Su WY, 2019, ONCOTARGETS THER, V12, P8139, DOI 10.2147/OTT.S220698; Valle Juan, 2010, N Engl J Med, V362, P1273, DOI 10.1056/NEJMoa0908721; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang HS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1108-x; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wardell CP, 2018, J HEPATOL, V68, P959, DOI 10.1016/j.jhep.2018.01.009; Yang C, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03143-z; Yankova E, 2021, NATURE, V593, P597, DOI 10.1038/s41586-021-03536-w; Zeng CW, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00951-w	31	9	9	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1622	1633		10.1038/s41388-022-02185-1	http://dx.doi.org/10.1038/s41388-022-02185-1		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35094011	hybrid, Green Published			2022-12-28	WOS:000750486500004
J	Saliba, J; Coutaud, B; Makhani, K; Roth, NE; Jackson, J; Park, JY; Gagnon, N; Costa, P; Jeyakumar, T; Bury, M; Beauchemin, N; Mann, KK; Blank, V				Saliba, James; Coutaud, Baptiste; Makhani, Kiran; Roth, Noam Epstein; Jackson, Jennie; Park, Joo Yeoun; Gagnon, Natascha; Costa, Paolo; Jeyakumar, Thiviya; Bury, Marina; Beauchemin, Nicole; Mann, Koren K.; Blank, Volker			Loss of NFE2L3 protects against inflammation-induced colorectal cancer through modulation of the tumor microenvironment	ONCOGENE			English	Article							ERYTHROID 2-LIKE 3; MAST-CELLS; NUCLEAR FACTOR; COLON-CANCER; METASTASIS; EXPRESSION; CARCINOMA; IL-33; ACTIVATION; CONTRIBUTE	We investigated the role of the NFE2L3 transcription factor in inflammation-induced colorectal cancer. Our studies revealed that Nfe2l3(-/-) mice exhibit significantly less inflammation in the colon, reduced tumor size and numbers, and skewed localization of tumors with a more pronounced decrease of tumors in the distal colon. CIBERSORT analysis of RNA-seq data from normal and tumor tissue predicted a reduction in mast cells in Nfe2l3(-/-) animals, which was confirmed by toluidine blue staining. Concomitantly, the transcript levels of Il33 and Rab27a, both important regulators of mast cells, were reduced and increased, respectively, in the colorectal tumors of Nfe2l3(-/-) mice. Furthermore, we validated NFE2L3 binding to the regulatory sequences of the IL33 and RAB27A loci in human colorectal carcinoma cells. Using digital spatial profiling, we found that Nfe2l3(-/-) mice presented elevated FOXP3 and immune checkpoint markers CTLA4, TIM3, and LAG3, suggesting an increase in Treg counts. Staining for CD3 and FOXP3 confirmed a significant increase in immunosuppressive Tregs in the colon of Nfe2l3(-/-) animals. Also, Human Microbiome Project (HMP2) data showed that NFE2L3 transcript levels are higher in the rectum of ulcerative colitis patients. The observed changes in the tumor microenvironment provide new insights into the molecular differences regarding colon cancer sidedness. This may be exploited for the treatment of early-onset colorectal cancer as this emerging subtype primarily displays distal/left-sided tumors.	[Saliba, James; Coutaud, Baptiste; Makhani, Kiran; Roth, Noam Epstein; Jackson, Jennie; Park, Joo Yeoun; Gagnon, Natascha; Costa, Paolo; Bury, Marina; Mann, Koren K.; Blank, Volker] Lady Davis Inst Med Res, Montreal, PQ, Canada; [Saliba, James; Makhani, Kiran; Roth, Noam Epstein; Jeyakumar, Thiviya; Beauchemin, Nicole; Blank, Volker] McGill Univ, Dept Med, Montreal, PQ, Canada; [Jeyakumar, Thiviya; Beauchemin, Nicole] McGill Univ, Goodman Canc Inst, Montreal, PQ, Canada; [Jeyakumar, Thiviya; Beauchemin, Nicole] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Jeyakumar, Thiviya; Beauchemin, Nicole] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Mann, Koren K.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada; [Blank, Volker] McGill Univ, Dept Physiol, Montreal, PQ, Canada; [Jackson, Jennie] Univ British Columbia, Life Sci Inst, Vancouver, BC, Canada; [Jackson, Jennie] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC, Canada; [Bury, Marina] UCLouvain, De Duve Inst, Brussels, Belgium	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; University of British Columbia; University of British Columbia; Universite Catholique Louvain	Blank, V (corresponding author), Lady Davis Inst Med Res, Montreal, PQ, Canada.; Blank, V (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Blank, V (corresponding author), McGill Univ, Dept Physiol, Montreal, PQ, Canada.	volker.blank@mcgill.ca		Jackson, Jennie/0000-0003-2890-4047	SEG (Lebanon) studentship; McGill Integrated Cancer Research Training Program (MICRTP) studentship; LDI/TD bank fellowship; Gordon Phillip Studentship; Division of Experimental Medicine, McGilll University; Lady Davis Institute/TB bank studentship; Biotalent Canada; MICRTP studentship; Donner Canada Foundation; MICRTP; FRQS; Cole Foundation fellowship; Canadian Institutes of Health Research (CIHR) [MOP-97932, PJT-152937]	SEG (Lebanon) studentship; McGill Integrated Cancer Research Training Program (MICRTP) studentship; LDI/TD bank fellowship; Gordon Phillip Studentship; Division of Experimental Medicine, McGilll University; Lady Davis Institute/TB bank studentship; Biotalent Canada; MICRTP studentship; Donner Canada Foundation; MICRTP(Canadian Institutes of Health Research (CIHR)); FRQS; Cole Foundation fellowship; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We would like to thank Steven Hebert and Claudia Kleinman for bioinformatics analyses and expertise, and Ulrich Blank for advice on mast cells. JS was supported by SEG (Lebanon) and McGill Integrated Cancer Research Training Program (MICRTP) studentships. KM obtained a studentship from LDI/TD bank fellowship and Gordon Phillip Studentship, NER was supported by a recruitment award (Division of Experimental Medicine, McGilll University) and a Lady Davis Institute/TB bank studentship, JJ received support from Biotalent Canada, JYP was supported by a MICRTP studentship and TJ from Donner Canada Foundation, MB was supported by MICRTP, FRQS and a Cole Foundation fellowship. The study was supported by the Canadian Institutes of Health Research (CIHR) MOP-97932 and PJT-152937 grants to VB.	Akimoto N, 2021, NAT REV CLIN ONCOL, V18, P230, DOI 10.1038/s41571-020-00445-1; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Aono S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133344; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Baran B, 2018, GASTROENTEROL RES, V11, P264, DOI 10.14740/gr1062w; Blank V, 2008, J MOL BIOL, V376, P913, DOI 10.1016/j.jmb.2007.11.074; Blatner NR, 2010, P NATL ACAD SCI USA, V107, P6430, DOI 10.1073/pnas.0913683107; Bleeker JS, 2020, J CLIN ONCOL, V38; Bury M, 2019, CELL REP, V29, P1469, DOI 10.1016/j.celrep.2019.09.087; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Chen LB, 2019, GENE, V692, P119, DOI 10.1016/j.gene.2019.01.001; Chenais B, 2005, MOL ENDOCRINOL, V19, P125, DOI 10.1210/me.2003-0379; Cheon EC, 2011, CANCER RES, V71, P1627, DOI 10.1158/0008-5472.CAN-10-1923; Chevillard G, 2011, CELL MOL LIFE SCI, V68, P3337, DOI 10.1007/s00018-011-0747-x; Chevillard G, 2011, BLOOD, V117, P2005, DOI 10.1182/blood-2010-02-271460; Chowdhury A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42725; Cui GL, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00561; Danelli L, 2015, CANCER IMMUNOL RES, V3, P85, DOI 10.1158/2326-6066.CIR-14-0102; De Oliveira T, 2019, ONCOGENE, V38, P1787, DOI 10.1038/s41388-018-0551-2; Dong WW, 2015, DISCOV MED, V20, P357; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Fodil N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01381-y; Fukuda M, 2013, TRAFFIC, V14, P949, DOI 10.1111/tra.12083; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Gounaris E, 2007, P NATL ACAD SCI USA, V104, P19977, DOI 10.1073/pnas.0704620104; Gulubova MV, 2012, INT J COLORECTAL DIS, V27, P159, DOI 10.1007/s00384-011-1334-1; Heijmans J, 2012, BBA-MOL BASIS DIS, V1822, P9, DOI 10.1016/j.bbadis.2010.12.001; Hodzic Z, 2017, CYTOKINE, V100, P1, DOI 10.1016/j.cyto.2017.06.017; Johnson CM, 2013, CANCER CAUSE CONTROL, V24, P1207, DOI 10.1007/s10552-013-0201-5; Joulia R, 2017, J ALLERGY CLIN IMMUN, V140, P497, DOI 10.1016/j.jaci.2016.09.049; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kannan MB, 2015, J BIOL CHEM, V290, P26292, DOI 10.1074/jbc.M115.666446; Keller DS, 2019, TECH COLOPROCTOL, V23, P3, DOI 10.1007/s10151-019-1926-2; Kitaya K, 2007, INT J MOL MED, V20, P689; Kolde Raivo, 2019, CRAN; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li YK, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0839-7; Li ZY, 2015, CELL MOL IMMUNOL, V12, P558, DOI 10.1038/cmi.2015.10; Liu XJ, 2014, BIOCHEM BIOPH RES CO, V453, P486, DOI 10.1016/j.bbrc.2014.09.106; Loomans-Kropp HA, 2019, J CANCER EPIDEMIOL, V2019, DOI 10.1155/2019/9841295; Low EE, 2020, GASTROENTEROLOGY, V159, P492, DOI 10.1053/j.gastro.2020.01.004; Lunderius-Andersson C, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00082; Mauri G, 2019, MOL ONCOL, V13, P109, DOI 10.1002/1878-0261.12417; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26; Proctor LM, 2019, NATURE, V569, P641, DOI 10.1038/s41586-019-1238-8; Ren YG, 2020, J CANCER, V11, P6939, DOI 10.7150/jca.48100; Ribatti D, 2018, INT ARCH ALLERGY IMM, V176, P55, DOI 10.1159/000487538; Rigoni A, 2015, CANCER RES, V75, P3760, DOI 10.1158/0008-5472.CAN-14-3767; Saluja R, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0076-5; Shi CB, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0303-3; Singh RK, 2013, FEBS J, V280, P892, DOI 10.1111/febs.12081; Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064; Sun JG, 2019, ONCOTARGETS THER, V12, P3019, DOI 10.2147/OTT.S197409; Suzuki R, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-84; Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x; Thaker Ameet I, 2012, J Vis Exp, DOI 10.3791/4100; Van Der Kraak L, 2010, ONCOTARGET, V1, P436; Vuik FER, 2019, GUT, V68, P1820, DOI 10.1136/gutjnl-2018-317592; Vukman KV., 2014, BIOPROTOC, V4, pe1053; Wang CJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90651; Wang H, 2018, CELL CYCLE, V17, P2164, DOI 10.1080/15384101.2018.1520558; Wang J, 2019, J CANCER, V10, P6726, DOI 10.7150/jca.35641; Ward-Hartstonge KA, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.43; Weller CL, 2005, J EXP MED, V201, P1961, DOI 10.1084/jem.20042407; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu MM, 2019, WORLD J GASTROENTERO, V25, P1210, DOI 10.3748/wjg.v25.i10.1210; Yu YX, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1504729; Zhang LH, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/2829798; Zhang Z, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00017	78	1	1	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1563	1575		10.1038/s41388-022-02192-2	http://dx.doi.org/10.1038/s41388-022-02192-2		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35091681	hybrid, Green Published			2022-12-28	WOS:000749073300003
J	He, DD; Shang, XY; Wang, N; Wang, GX; He, KY; Wang, L; Han, ZG				He, Dan-Dan; Shang, Xue-Ying; Wang, Na; Wang, Guang-Xing; He, Kun-Yan; Wang, Lan; Han, Ze-Guang			BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage	ONCOGENE			English	Article							INACTIVATING MUTATIONS; SWI/SNF COMPLEXES; REPAIR; ARID2; CANCER; CELLS; VULNERABILITIES; RESISTANCE; BREAKS; ROLES	Hepatocellular carcinoma (HCC) has emerged as the third cause of cancer-related death owing to lacking effective systemic therapies. Genomic DNA sequencing revealed the high frequency of loss-of-function mutations in ARID2, which encodes a subunit of SWI/SNF chromatin remodeling complex, however, the therapeutic strategy for the HCC patients with ARID2 mutations is still completely unclear. In this study, we first performed a high-throughput screening approach using a compound library consisting of 2 180 FDA-approved drugs and other compounds, to elicit the potential drugs for synthetic lethality to target ARID2-deficient HCC cells. Interestingly, JQ1, a selective inhibitor of bromodomain protein BRD4, uniquely suppressed the growth of ARID2- deficient HCC cells. Next JQ1 is further confirmed to predominantly induce cell lethality upon ARID2 depletion through exacerbating DNA damage, especially double strand breaks (DSBs). Functional assays demonstrated that both BRD4 inhibition and ARID2 deficiency synergistically impede two main DNA damage repair pathways, homologous recombination (HR) and non-homologous end-joining (NHEJ), through attenuating the transcription of BRCA1, RAD51, and 53BP1, which encode the core molecules responsible for DSB repair. Mechanistically, both ARID2 and BRD4 exert a synergistic effect for maintaining transcriptional enhancer-promoter loops of these genes within chromatin conformation. However, as both ARID2 and BRD4 are disrupted, the expression of these DNA repair-related genes in response to DNA damage are hindered, resulting in DSB accumulation and cell apoptosis. Taken together, this study discloses that BRD4 inhibition may induce synthetic lethality in ARID2-deficient HCC cells, which might provide a potential therapeutic strategy for HCC patients with ARID2 mutations.	[He, Dan-Dan; Shang, Xue-Ying; Wang, Na; Wang, Guang-Xing; He, Kun-Yan; Wang, Lan; Han, Ze-Guang] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, Shanghai 200240, Peoples R China; [Han, Ze-Guang] Hangzhou Innovat Inst Syst Oncol HIISCO, 3F Bldg 1,2636 Yuhangtang Rd, Hangzhou 311121, Zhejiang, Peoples R China	Shanghai Jiao Tong University	Han, ZG (corresponding author), Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, Shanghai 200240, Peoples R China.; Han, ZG (corresponding author), Hangzhou Innovat Inst Syst Oncol HIISCO, 3F Bldg 1,2636 Yuhangtang Rd, Hangzhou 311121, Zhejiang, Peoples R China.	hanzg@sjtu.edu.cn		Han, Ze-Guang/0000-0002-1018-1752	National Natural Science Foundation of China [82073116, 81672772]; National Key Research and Development Program of China [2020YFC2002705]; Natural Science Foundation of Shanghai [19140902500]; National Science and Technology Major Project [2017ZX10203207]; Shanghai Jiao Tong University Scientific and Technological Innovation Funds [2019TPA09, ZH2018ZDA33]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); National Science and Technology Major Project; Shanghai Jiao Tong University Scientific and Technological Innovation Funds	We thank all members of Han Lab for helpful discussions on the project. This work was supported by Grants from the National Natural Science Foundation of China (82073116 and 81672772 to ZH), National Key Research and Development Program of China (2020YFC2002705 to ZH), Natural Science Foundation of Shanghai (19140902500 to ZH), National Science and Technology Major Project (2017ZX10203207 to ZH) and Shanghai Jiao Tong University Scientific and Technological Innovation Funds (2019TPA09 and ZH2018ZDA33 to ZH).	Arnoult N, 2017, NATURE, V549, P548, DOI 10.1038/nature24023; Berns K, 2018, ONCOGENE, V37, P4611, DOI 10.1038/s41388-018-0300-6; Bhagwat AS, 2016, CELL REP, V15, P519, DOI 10.1016/j.celrep.2016.03.054; Bitler BG, 2017, NAT CELL BIOL, V19, P962, DOI 10.1038/ncb3582; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cajuso T, 2014, INT J CANCER, V135, P611, DOI 10.1002/ijc.28705; Caruso S, 2019, GASTROENTEROLOGY, V157, P760, DOI 10.1053/j.gastro.2019.05.001; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Centore RC, 2020, TRENDS GENET, V36, P936, DOI 10.1016/j.tig.2020.07.011; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; COLOMBO M, 1992, J HEPATOL, V15, P225, DOI 10.1016/0168-8278(92)90041-M; de Castro RO, 2017, J BIOL CHEM, V292, P8459, DOI 10.1074/jbc.M117.778183; de la Cruz FF, 2015, ANNU REV PHARMACOL, V55, P513, DOI 10.1146/annurev-pharmtox-010814-124511; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Deribe YL, 2018, NAT MED, V24, P1627, DOI 10.1038/s41591-018-0173-9; Devaiah BN, 2016, NAT STRUCT MOL BIOL, V23, P540, DOI 10.1038/nsmb.3228; Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0915-9; Doroshow DB, 2017, ANN ONCOL, V28, P1776, DOI 10.1093/annonc/mdx157; Euskirchen GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002008; Eustermann S, 2015, MOL CELL, V60, P742, DOI 10.1016/j.molcel.2015.10.032; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Friend SH, 1998, NEW ENGL J MED, V338, P125, DOI 10.1056/NEJM199801083380211; Fujisawa T, 2017, NAT REV MOL CELL BIO, V18, P246, DOI 10.1038/nrm.2016.143; Gao QZ, 2017, CANCER SCI, V108, P1328, DOI 10.1111/cas.13277; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; He S, 2020, SCIENCE, V367, P875, DOI 10.1126/science.aaz9761; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Huang A, 2020, NAT REV DRUG DISCOV, V19, P23, DOI 10.1038/s41573-019-0046-z; Jiang H, 2020, P NATL ACAD SCI USA, V117, P4770, DOI 10.1073/pnas.1914937117; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kakarougkas A, 2014, MOL CELL, V55, P723, DOI 10.1016/j.molcel.2014.06.028; Kurimchak AM, 2016, CELL REP, V16, P1273, DOI 10.1016/j.celrep.2016.06.091; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Li SJ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00358-6; Li XY, 2018, CELL REP, V22, P796, DOI 10.1016/j.celrep.2017.12.078; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Loesch R, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102152; Mashtalir N, 2018, CELL, V175, P1272, DOI 10.1016/j.cell.2018.09.032; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Michel BC, 2018, NAT CELL BIOL, V20, P1410, DOI 10.1038/s41556-018-0221-1; Mittal P, 2020, NAT REV CLIN ONCOL, V17, P435, DOI 10.1038/s41571-020-0357-3; Nagarajan S, 2020, NAT GENET, V52, P187, DOI 10.1038/s41588-019-0541-5; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Oba A, 2017, J HEPATOL, V66, P942, DOI 10.1016/j.jhep.2016.12.026; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Schulze K, 2016, J HEPATOL, V65, P1031, DOI 10.1016/j.jhep.2016.05.035; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Shu SK, 2020, MOL CELL, V78, P1096, DOI 10.1016/j.molcel.2020.04.027; Slaughter MJ, 2018, J BIOL CHEM, V293, P13592, DOI 10.1074/jbc.RA118.003381; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Tai Y, 2018, INT J CLIN EXP PATHO, V11, P2931; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004; Yang L, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1645	65	5	5	4	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1397	1409		10.1038/s41388-022-02176-2	http://dx.doi.org/10.1038/s41388-022-02176-2		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35017665				2022-12-28	WOS:000741240600001
J	Alzial, G; Renoult, O; Paris, F; Gratas, C; Clavreul, A; Pecqueur, C				Alzial, Gabriel; Renoult, Ophelie; Paris, Francois; Gratas, Catherine; Clavreul, Anne; Pecqueur, Claire			Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma	ONCOGENE			English	Review							HYPOXIA-INDUCIBLE FACTORS; MUTANT IDH1; REDUCTIVE CARBOXYLATION; ALPHA-KETOGLUTARATE; PROMOTES DIFFERENTIATION; ADJUVANT TEMOZOLOMIDE; SUPPORTS GROWTH; DNA-REPAIR; GLIOMA; CELLS	Brain tumors actively reprogram their cellular metabolism to survive and proliferate, thus offering potential therapeutic opportunities. Over the past decade, extensive research has been done on mutant IDH enzymes as markers of good prognosis in glioblastoma, a highly aggressive brain tumor in adults with dismal prognosis. Yet, 95% of glioblastoma are IDH wild-type. Here, we review current knowledge about IDH wild-type enzymes and their putative role in mechanisms driving tumor progression. After a brief overview on tumor metabolic adaptation, we present the diverse metabolic function of IDH enzymes and their roles in glioblastoma initiation, progression and response to treatments. Finally, we will discuss wild-type IDH targeting in primary glioblastoma.	[Alzial, Gabriel; Renoult, Ophelie; Paris, Francois; Pecqueur, Claire] Univ Nantes, CNRS, INSERM, CRCINA, F-44000 Nantes, France; [Paris, Francois] Inst Cancerol Ouest, St Herblain, France; [Gratas, Catherine] Univ Nantes, CRCINA, INSERM, CHU Nantes, F-44000 Nantes, France; [Clavreul, Anne] Univ Angers, CRCINA, CHU Angers, F-49000 Angers, France; [Clavreul, Anne] CHU Angers, Dept Neurochirurg, Angers, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Pecqueur, C (corresponding author), Univ Nantes, CNRS, INSERM, CRCINA, F-44000 Nantes, France.	claire.pecqueur@univ-nantes.fr	; Paris, francois/L-4915-2015	Renoult, Ophelie/0000-0003-0916-8611; Paris, francois/0000-0002-0176-7348; Alzial, Gabriel/0000-0001-6619-5179	ARC foundation; Ligue Contre le Cancer	ARC foundation(Australian Research Council); Ligue Contre le Cancer(Ligue nationale contre le cancer)	This work was supported by funding from ARC foundation and Ligue Contre le Cancer.	Anderson DD, 2012, J BIOL CHEM, V287, P7051, DOI 10.1074/jbc.M111.333120; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Behnan J, 2019, BRAIN, V142, P847, DOI 10.1093/brain/awz044; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Blazek ER, 2007, INT J RADIAT ONCOL, V67, P1, DOI 10.1016/j.ijrobp.2006.09.037; Bleeker FE, 2010, ACTA NEUROPATHOL, V119, P487, DOI 10.1007/s00401-010-0645-6; Bogdanovic E, 2014, NEUROSCI LETT, V582, P87, DOI 10.1016/j.neulet.2014.09.015; Borodovsky A, 2013, ONCOTARGET, V4, P1737, DOI 10.18632/oncotarget.1408; Calvert AE, 2017, CELL REP, V19, P1858, DOI 10.1016/j.celrep.2017.05.014; Caravella JA, 2020, J MED CHEM, V63, P1612, DOI 10.1021/acs.jmedchem.9b01423; Carey BW, 2015, NATURE, V518, P413, DOI 10.1038/nature13981; Cho YS, 2017, ACS MED CHEM LETT, V8, P1116, DOI 10.1021/acsmedchemlett.7b00342; Comte B, 2002, AM J PHYSIOL-HEART C, V283, pH1505, DOI 10.1152/ajpheart.00287.2002; Cooper LAD, 2012, AM J PATHOL, V180, P2108, DOI 10.1016/j.ajpath.2012.01.040; DADAMO AF, 1965, J BIOL CHEM, V240, P613; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; DiNardo CD, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1073.1073; Du JH, 2016, P NATL ACAD SCI USA, V113, P14710, DOI 10.1073/pnas.1604572113; Fack F, 2017, EMBO MOL MED, V9, P1681, DOI 10.15252/emmm.201707729; Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473; Fendt SM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3236; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Francisco A, 2022, ANTIOXID REDOX SIGN, V36, P864, DOI 10.1089/ars.2021.0111; Garofano L, 2021, NAT CANCER, V2, DOI 10.1038/s43018-020-00159-4; Gaude E, 2018, MOL CELL, V69, P581, DOI 10.1016/j.molcel.2018.01.034; Golub D, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00417; Grassian AR, 2014, CANCER RES, V74, P3317, DOI 10.1158/0008-5472.CAN-14-0772-T; Heddleston JM, 2010, BRIT J CANCER, V102, P789, DOI 10.1038/sj.bjc.6605551; Inoue S, 2016, CANCER CELL, V30, P337, DOI 10.1016/j.ccell.2016.05.018; Jiang L, 2016, NATURE, V532, P255, DOI 10.1038/nature17393; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Koh HJ, 2004, J BIOL CHEM, V279, P39968, DOI 10.1074/jbc.M402260200; Konteatis Z, 2020, ACS MED CHEM LETT, V11, P101, DOI 10.1021/acsmedchemlett.9b00509; Lee P, 2002, ARCH BIOCHEM BIOPHYS, V401, P81, DOI 10.1016/S0003-9861(02)00041-3; Lee W, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07967-4; Lemons JMS, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000514; Leonardi R, 2012, J BIOL CHEM, V287, P14615, DOI 10.1074/jbc.C112.353946; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lu YX, 2017, CANCER RES, V77, P1709, DOI 10.1158/0008-5472.CAN-16-2773; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Ma R, 2018, BIOCHEM BIOPH RES CO, V503, P2912, DOI 10.1016/j.bbrc.2018.08.068; Mailloux RJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000690; Maus A, 2017, AMINO ACIDS, V49, P21, DOI 10.1007/s00726-016-2342-9; May JL, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aat0456; McGregor GH, 2020, CANCER RES, V80, P175, DOI 10.1158/0008-5472.CAN-19-0644; Mellinghoff IK, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.03327; Mergenthaler P, 2013, TRENDS NEUROSCI, V36, P587, DOI 10.1016/j.tins.2013.07.001; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Molinaro AM, 2019, NAT REV NEUROL, V15, P405, DOI 10.1038/s41582-019-0220-2; Mullen AR, 2014, CELL REP, V7, P1679, DOI 10.1016/j.celrep.2014.04.037; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Nam WS, 2012, BBA-MOL BASIS DIS, V1822, P1181, DOI 10.1016/j.bbadis.2012.04.003; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Nunez FJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaq1427; Ohka F, 2014, TUMOR BIOL, V35, P5911, DOI 10.1007/s13277-014-1784-5; Oizel K, 2020, CANCER METAB, V8, DOI 10.1186/s40170-020-00215-8; Oizel K, 2017, CLIN CANCER RES, V23, P6292, DOI 10.1158/1078-0432.CCR-16-3102; Okoye-Okafor UC, 2015, NAT CHEM BIOL, V11, P878, DOI 10.1038/nchembio.1930; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pellegatta S, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-014-0180-0; Platten M, 2021, NATURE, V592, P463, DOI 10.1038/s41586-021-03363-z; Polewski MD, 2016, MOL CANCER RES, V14, P1229, DOI 10.1158/1541-7786.MCR-16-0028; Poon MTC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68011-4; Popovici-Muller J, 2018, ACS MED CHEM LETT, V9, P300, DOI 10.1021/acsmedchemlett.7b00421; Popovici-Muller J, 2012, ACS MED CHEM LETT, V3, P850, DOI 10.1021/ml300225h; Pusch S, 2017, ACTA NEUROPATHOL, V133, P629, DOI 10.1007/s00401-017-1677-y; Qi F, 2008, BBA-PROTEINS PROTEOM, V1784, P1641, DOI 10.1016/j.bbapap.2008.07.001; Reitman ZJ, 2014, J BIOL CHEM, V289, P23318, DOI 10.1074/jbc.M114.575183; Reitman ZJ, 2010, JNCI-J NATL CANCER I, V102, P932, DOI 10.1093/jnci/djq187; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Semenza GL, 2019, ANNU REV PHARMACOL, V59, P379, DOI 10.1146/annurev-pharmtox-010818-021637; Seyfried TN, 2010, LANCET ONCOL, V11, P811, DOI 10.1016/S1470-2045(10)70166-2; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tardito S, 2015, NAT CELL BIOL, V17, P1556, DOI 10.1038/ncb3272; Tennant DA, 2009, ONCOGENE, V28, P4009, DOI 10.1038/onc.2009.250; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Turcan S, 2013, ONCOTARGET, V4, P1729, DOI 10.18632/oncotarget.1412; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; van Noorden CJF, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030705; Venneti S, 2017, ANNU REV PATHOL-MECH, V12, P515, DOI 10.1146/annurev-pathol-012615-044329; Wahl DR, 2017, CANCER RES, V77, P960, DOI 10.1158/0008-5472.CAN-16-2008; Wang D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05955-0; Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769; Wang P, 2015, CELL REP, V13, P2353, DOI 10.1016/j.celrep.2015.11.029; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Yamashita AS, 2019, NEURO-ONCOLOGY, V21, P189, DOI 10.1093/neuonc/noy146; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang LQ, 2012, EXP CELL RES, V318, P2417, DOI 10.1016/j.yexcr.2012.07.017; Yoo H, 2008, J BIOL CHEM, V283, P20621, DOI 10.1074/jbc.M706494200; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	98	10	10	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					613	621		10.1038/s41388-021-02056-1	http://dx.doi.org/10.1038/s41388-021-02056-1		NOV 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34764443	Green Published, hybrid			2022-12-28	WOS:000717402200001
J	Boudhraa, Z; Zaoui, K; Fleury, H; Cahuzac, M; Gilbert, S; Tchakarska, G; Kendall-Dupont, J; Carmona, E; Provencher, D; Mes-Masson, AM				Boudhraa, Zied; Zaoui, Kossay; Fleury, Hubert; Cahuzac, Maxime; Gilbert, Sophie; Tchakarska, Guergana; Kendall-Dupont, Jennifer; Carmona, Euridice; Provencher, Diane; Mes-Masson, Anne-Marie			NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer	ONCOGENE			English	Article							DNA-DAMAGE; CELL-CYCLE; ACTIVATION; METABOLISM; EXPRESSION; SURVIVIN; GRADE	While aneuploidy is a main enabling characteristic of cancers, it also creates specific vulnerabilities. Here we demonstrate that Ran inhibition targets epithelial ovarian cancer (EOC) survival through its characteristic aneuploidy. We show that induction of aneuploidy in rare diploid EOC cell lines or normal cells renders them highly dependent on Ran. We also establish an inverse correlation between Ran and the tumor suppressor NR1D1 and reveal the critical role of Ran/NR1D1 axis in aneuploidy-associated endogenous DNA damage repair. Mechanistically, we show that Ran, through the maturation of miR4472, destabilizes the mRNA of NR1D1 impacting several DNA repair pathways. We showed that NR1D1 interacts with both PARP1 and BRCA1 leading to the inhibition of DNA repair. Concordantly, loss of Ran was associated with NR1D1 induction, accumulation of DNA damages, and lethality of aneuploid EOC cells. Our findings suggest a synthetic lethal strategy targeting aneuploid cells based on their dependency to Ran.	[Boudhraa, Zied; Zaoui, Kossay; Fleury, Hubert; Cahuzac, Maxime; Gilbert, Sophie; Tchakarska, Guergana; Kendall-Dupont, Jennifer; Carmona, Euridice; Provencher, Diane; Mes-Masson, Anne-Marie] Univ Montreal CRCHUM, Ctr Hosp, Ctr Rech, Montreal, PQ, Canada; [Boudhraa, Zied; Zaoui, Kossay; Fleury, Hubert; Cahuzac, Maxime; Gilbert, Sophie; Tchakarska, Guergana; Kendall-Dupont, Jennifer; Carmona, Euridice; Provencher, Diane; Mes-Masson, Anne-Marie] Inst Canc Montreal ICM, Montreal, PQ, Canada; [Provencher, Diane] Univ Montreal, Div Gynecol Oncol, Montreal, PQ, Canada; [Mes-Masson, Anne-Marie] Univ Montreal, Dept Med, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Mes-Masson, AM (corresponding author), Univ Montreal CRCHUM, Ctr Hosp, Ctr Rech, Montreal, PQ, Canada.; Mes-Masson, AM (corresponding author), Inst Canc Montreal ICM, Montreal, PQ, Canada.; Mes-Masson, AM (corresponding author), Univ Montreal, Dept Med, Montreal, PQ, Canada.	anne-marie.mes-masson@umontreal.ca			Canadian Institute for Health Research (CIHR) [MOP142724, PJT148642]; ICM (Fonds Defi Spyder and Anne-Marie Chagnon); Ovarian Cancer Canada (OCC); Banque de tissus et de donnees of the Reseau de recherche sur le cancer of the FRQS; Canadian Tumor Repository Network (CTRNet)	Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); ICM (Fonds Defi Spyder and Anne-Marie Chagnon); Ovarian Cancer Canada (OCC); Banque de tissus et de donnees of the Reseau de recherche sur le cancer of the FRQS; Canadian Tumor Repository Network (CTRNet)	This work was supported by the Canadian Institute for Health Research (CIHR MOP142724 and PJT148642) and the ICM (Fonds Defi Spyder and Anne-Marie Chagnon). Cell lines used in this study were provided by the CRCHUM ovarian tumor bank, which is supported by Ovarian Cancer Canada (OCC) and by the Banque de tissus et de donnees of the Reseau de recherche sur le cancer of the FRQS affiliated with the Canadian Tumor Repository Network (CTRNet).	Altman BJ, 2015, CELL METAB, V22, P1009, DOI 10.1016/j.cmet.2015.09.003; Barres V, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-272; Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230; Boudhraa Z, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00345; Brodeur MN, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-97434-w; Bugge A, 2012, GENE DEV, V26, P657, DOI 10.1101/gad.186858.112; Caceres-Gorriti KY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091000; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cekan P, 2016, MOL BIOL CELL, V27, P1346, DOI 10.1091/mbc.E16-01-0025; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Deng L, 2013, BIOCHEM BIOPH RES CO, V440, P322, DOI 10.1016/j.bbrc.2013.09.079; Fleury H, 2017, ONCOTARGET, V8, P40152, DOI 10.18632/oncotarget.10308; Fleury Hubert, 2015, Genes Cancer, V6, P378; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hasegawa K, 2013, J CELL BIOL, V200, P151, DOI 10.1083/jcb.201206142; Ka NL, 2017, MOL CELL ENDOCRINOL, V454, P87, DOI 10.1016/j.mce.2017.06.004; Ka NL, 2017, CANCER RES, V77, P2453, DOI 10.1158/0008-5472.CAN-16-2099; Kim G, 2015, CLIN CANCER RES, V21, P4257, DOI 10.1158/1078-0432.CCR-15-0887; Krietsch J, 2012, NUCLEIC ACIDS RES, V40, P10287, DOI 10.1093/nar/gks798; Letourneau IJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-379; Levine MS, 2017, DEV CELL, V40, P313, DOI 10.1016/j.devcel.2016.12.022; Mocellin S, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1010-1; Ouellet V, 2005, ONCOGENE, V24, P4672, DOI 10.1038/sj.onc.1208214; Ouellet V, 2006, INT J CANCER, V119, P599, DOI 10.1002/ijc.21902; Ouellet V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-152; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030; Sulli G, 2018, NATURE, V553, P351, DOI 10.1038/nature25170; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Wang YJ, 2015, BIOCHEM PHARMACOL, V96, P315, DOI 10.1016/j.bcp.2015.06.010; Woldt E, 2013, NAT MED, V19, P1039, DOI 10.1038/nm.3213; Xia F, 2008, MOL CELL BIOL, V28, P5299, DOI 10.1128/MCB.02039-07; Zhu J, 2018, DEV CELL, V44, P420, DOI 10.1016/j.devcel.2018.02.002	38	2	2	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					309	320		10.1038/s41388-021-02082-z	http://dx.doi.org/10.1038/s41388-021-02082-z		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34743206	Green Published, hybrid			2022-12-28	WOS:000715015000003
J	Jiang, XJ; Deng, XY; Wang, J; Mo, YZ; Shi, L; Wei, F; Zhang, SS; Gong, ZJ; He, Y; Xiong, F; Wang, YM; Guo, C; Xiang, B; Zhou, M; Liao, QJ; Li, XL; Li, Y; Li, GY; Xiong, W; Zeng, ZY				Jiang, Xianjie; Deng, Xiangying; Wang, Jie; Mo, Yongzhen; Shi, Lei; Wei, Fang; Zhang, Shanshan; Gong, Zhaojian; He, Yi; Xiong, Fang; Wang, Yumin; Guo, Can; Xiang, Bo; Zhou, Ming; Liao, Qianjin; Li, Xiaoling; Li, Yong; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang			BPIFB1 inhibits vasculogenic mimicry via downregulation of GLUT1-mediated H3K27 acetylation in nasopharyngeal carcinoma	ONCOGENE			English	Article							VIRUS-ENCODED MICRORNAS; TUMOR ANGIOGENESIS; HISTONE ACETYLATION; CELL-PROLIFERATION; EXPRESSION; METABOLISM; LPLUNC1; DIFFERENTIATION; SUPPRESSES; MECHANISMS	Nasopharyngeal carcinoma (NPC) demonstrates significant regional differences and a high incidence in Southeast Asia and Southern China. Bactericidal/permeability-increasing-fold- containing family B member 1 (BPIFB1) is a relatively specific and highly expressed protein in the nasopharyngeal epithelium. BPIFB1 expression is substantially downregulated in NPC and is significantly associated with poor prognosis in patients with NPC. However, the specific molecular mechanism by which BPIFB1 regulates NPC is not well understood. In this study, we found that BPIFB1 inhibits vasculogenic mimicry by regulating the metabolic reprogramming of NPC. BPIFB1 decreases GLUT1 transcription by downregulating the JNK/AP1 signaling pathway. Altered glycolysis reduces the acetylation level of histone and decreases the expression of vasculogenic mimicry-related genes, VEGFA, VE-cadherin, and MMP2, ultimately leading to the inhibition of vasculogenic mimicry. To our knowledge, this is the first report on the role and specific mechanism of BPIFB1 as a tumor suppressor gene involved in regulating glycolysis and vasculogenic mimicry in NPC. Overall, these results provide a new therapeutic target for NPC diagnosis and treatment.	[Jiang, Xianjie; He, Yi; Xiang, Bo; Zhou, Ming; Liao, Qianjin; Li, Xiaoling; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang] Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China; [Jiang, Xianjie; He, Yi; Xiang, Bo; Zhou, Ming; Liao, Qianjin; Li, Xiaoling; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang] Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Hunan Key Lab Canc Metab, Changsha, Hunan, Peoples R China; [Jiang, Xianjie; He, Yi; Xiang, Bo; Zhou, Ming; Liao, Qianjin; Li, Xiaoling; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang] Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Affiliated Canc Hosp, Changsha, Hunan, Peoples R China; [Jiang, Xianjie; Deng, Xiangying; Wang, Jie; Mo, Yongzhen; Shi, Lei; Wei, Fang; Wang, Yumin; Guo, Can; Xiang, Bo; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang] Cent South Univ, Canc Res Inst, Chinese Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China; [Shi, Lei; Gong, Zhaojian] Cent South Univ, Xiangya Hosp 2, Dept Oral & Maxillofacial Surg, Changsha, Hunan, Peoples R China; [Zhang, Shanshan; Xiong, Fang] Cent South Univ, Xiangya Hosp, Dept Stomatol, Changsha, Hunan, Peoples R China; [Li, Yong] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Dept Med, Houston, TX 77030 USA	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Baylor College of Medicine	Zeng, ZY (corresponding author), Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Hunan Key Lab Canc Metab, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Affiliated Canc Hosp, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Canc Res Inst, Chinese Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China.	zengzhaoyang@csu.edu.cn	li, xiaofeng/GXF-9442-2022; li, xiao/GSN-6181-2022		National Natural Science Foundation of China [81903138, 81972776, U20A20367]; Overseas Expertize Introduction Project for Discipline Innovation (111 Project) [111-2-12]; Natural Science Foundation of Hunan Province [2019JJ50778, 2019JJ50872, 2020JJ4766]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Overseas Expertize Introduction Project for Discipline Innovation (111 Project); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province)	This study was supported by grants from the National Natural Science Foundation of China (81903138, 81972776, U20A20367), the Overseas Expertize Introduction Project for Discipline Innovation (111 Project, No. 111-2-12), the Natural Science Foundation of Hunan Province (2019JJ50778, 2019JJ50872, 2020JJ4766).	Audia JE, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019521; Bao LL, 2018, ONCOGENE, V37, P2873, DOI 10.1038/s41388-018-0183-6; Barnes CE, 2019, ESSAYS BIOCHEM, V63, P97, DOI 10.1042/EBC20180061; Bo H, 2015, ONCOTARGET, V6, P20404, DOI 10.18632/oncotarget.4057; Chen Q, 2019, CANCER LETT, V463, P37, DOI 10.1016/j.canlet.2019.07.019; Chen SQ, 2020, J CELL PHYSIOL, V235, P7757, DOI 10.1002/jcp.29382; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Dong HY, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0931-9; Fan CM, 2021, CANCER LETT, V496, P41, DOI 10.1016/j.canlet.2020.09.006; Fan CM, 2018, J CANCER, V9, P2852, DOI 10.7150/jca.25460; FOLKMAN J, 1974, CANCER RES, V34, P2109; Ge JS, 2021, CANCER RES, V81, P5074, DOI 10.1158/0008-5472.CAN-20-4321; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jiang XJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01709-5; Ju SW, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01285-4; Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004; Krug B, 2019, CANCER CELL, V35, P782, DOI [10.1016/j.ccell.2019.08.012, 10.1016/j.ccell.2019.04.004]; Liao Q, 2014, ONCOGENE, V33, P2098, DOI 10.1038/onc.2013.161; Liu DS, 2020, J CELL BIOCHEM, V121, P1923, DOI 10.1002/jcb.29427; Loges Sonja, 2010, Genes Cancer, V1, P12, DOI 10.1177/1947601909356574; Lu JC, 2016, CANCER LETT, V380, P191, DOI 10.1016/j.canlet.2016.05.032; Lugano R, 2020, CELL MOL LIFE SCI, V77, P1745, DOI 10.1007/s00018-019-03351-7; Lyu XM, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007484; Ma WL, 2018, CANCER SCI, V109, P1710, DOI 10.1111/cas.13584; Mahfouz N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179202; Moussaieff A, 2015, CELL METAB, V21, P392, DOI 10.1016/j.cmet.2015.02.002; Peleg S, 2016, TRENDS BIOCHEM SCI, V41, P700, DOI 10.1016/j.tibs.2016.05.008; Peng M, 2016, SCIENCE, V354, P481, DOI 10.1126/science.aaf6284; Priya SK, 2016, INT J CANCER, V139, P729, DOI 10.1002/ijc.30067; Rosenbloom KR, 2010, NUCLEIC ACIDS RES, V38, pD620, DOI 10.1093/nar/gkp961; Sabari BR, 2017, NAT REV MOL CELL BIO, V18, P90, DOI 10.1038/nrm.2016.140; Shi L, 2015, CURR OPIN CELL BIOL, V33, P125, DOI 10.1016/j.ceb.2015.02.003; Tang L, 2021, ONCOGENE, V40, P307, DOI 10.1038/s41388-020-01531-5; Tang L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0758-7; Tu CF, 2018, CARCINOGENESIS, V39, P1517, DOI 10.1093/carcin/bgy108; Wang HF, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12600; Wang HR, 2019, ONCOGENE, V38, P5062, DOI 10.1038/s41388-019-0778-6; Wei F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0409-0; Wei F, 2018, BRIT J CANCER, V118, P233, DOI 10.1038/bjc.2017.385; Wei F, 2017, SCI CHINA LIFE SCI, V60, P1271, DOI 10.1007/s11427-017-9172-6; Wei XX, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01288-1; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wu CC, 2019, SCI CHINA LIFE SCI, V62, P640, DOI 10.1007/s11427-018-9461-5; Wu YF, 2020, FASEB J, V34, P16205, DOI 10.1096/fj.202001508R; Xiang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07308-5; Xiong F, 2019, CHINESE MED J-PEKING, V132, P749, DOI 10.1097/CM9.0000000000000132; Xu S, 2018, ONCOL REP, V40, P377, DOI 10.3892/or.2018.6414; Zarrin B, 2017, J RES MED SCI, V22, DOI 10.4103/jrms.JRMS_182_17; Zeng ZY, 2014, SCI CHINA LIFE SCI, V57, P315, DOI 10.1007/s11427-013-4577-y; Zeng ZY, 2011, SCI CHINA LIFE SCI, V54, P966, DOI 10.1007/s11427-011-4223-5; Zhang BC, 2003, GENE CHROMOSOME CANC, V38, P80, DOI 10.1002/gcc.10247; Zhang EB, 2017, NUCLEIC ACIDS RES, V45, P3086, DOI 10.1093/nar/gkw1247; Zhao J, 2020, CANCER LETT, V477, P131, DOI 10.1016/j.canlet.2020.02.010; Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388-018-0250-z; Zhou YJ, 2016, J CANCER, V7, P367, DOI 10.7150/jca.13695; Zhu YJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00025	58	2	2	7	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					233	245		10.1038/s41388-021-02079-8	http://dx.doi.org/10.1038/s41388-021-02079-8		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34725462	Green Submitted			2022-12-28	WOS:000713567000002
J	Gao, SS; Soares, F; Wang, SY; Wong, CC; Chen, HR; Yang, ZJ; Liu, WX; Go, MYY; Ahmed, M; Zeng, Y; O'Brien, CA; Sung, JJY; He, HH; Yu, J				Gao, Shanshan; Soares, Fraser; Wang, Shiyan; Wong, Chi Chun; Chen, Huarong; Yang, Zhenjie; Liu, Weixin; Go, Minnie Y. Y.; Ahmed, Musaddeque; Zeng, Yong; O'Brien, Catherine Adell; Sung, Joseph J. Y.; He, Housheng Hansen; Yu, Jun			CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer	ONCOGENE			English	Article							COLORECTAL-CANCER; TGF-BETA; INITIATING CELLS; SELF-RENEWAL; ENDOCRINE THERAPY; ZOLEDRONIC ACID; BREAST; ID1; IDENTIFICATION; INHIBITORS	Cancer stem cells (CSCs) are responsible for tumor progression, recurrence, and drug resistance. To identify genetic vulnerabilities of colon cancer, we performed targeted CRISPR dropout screens comprising 657 Drugbank targets and 317 epigenetic regulators on two patient-derived colon CSC-enriched spheroids. Next-generation sequencing of pooled genomic DNAs isolated from surviving cells yielded therapeutic candidates. We unraveled 44 essential genes for colon CSC-enriched spheroids propagation, including key cholesterol biosynthetic genes (HMGCR, FDPS, and GGPS1). Cholesterol biosynthesis was induced in colon cancer tissues, especially CSC-enriched spheroids. The genetic and pharmacological inhibition of HMGCR/FDPS impaired self-renewal capacity and tumorigenic potential of the spheroid models in vitro and in vivo. Mechanistically, HMGCR or FDPS depletion impaired cancer stemness characteristics by activating TGF-beta signaling, which in turn downregulated expression of inhibitors of differentiation (ID) proteins, key regulators of cancer stemness. Cholesterol and geranylgeranyl diphosphate (GGPP) rescued the growth inhibitory and signaling effect of HMGCR/FDPS blockade, implying a direct role of these metabolites in modulating stemness. Finally, cholesterol biosynthesis inhibitors and 5-FU demonstrated antitumor synergy in colon CSC-enriched spheroids, tumor organoids, and xenografts. Taken together, our study unravels novel genetic vulnerabilities of colon CSC-enriched spheroids and suggests cholesterol biosynthesis as a potential target in conjunction with traditional chemotherapy for colon cancer treatment.	[Gao, Shanshan; Wong, Chi Chun; Chen, Huarong; Yang, Zhenjie; Liu, Weixin; Go, Minnie Y. Y.; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Gao, Shanshan; Wong, Chi Chun; Chen, Huarong; Yang, Zhenjie; Liu, Weixin; Go, Minnie Y. Y.; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China; [Gao, Shanshan; Soares, Fraser; Wang, Shiyan; Ahmed, Musaddeque; Zeng, Yong; O'Brien, Catherine Adell; He, Housheng Hansen] Univ Hlth Network, Princess Margaret Canc Ctr, Ontario, ON, Canada; [He, Housheng Hansen] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China.; He, HH (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Ontario, ON, Canada.; He, HH (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.	hansenhe@uhnresearch.ca; junyu@cuhk.edu.hk	Chen, Huarong/ABZ-5810-2022; chen, huarong/ABH-8561-2020	chen, huarong/0000-0003-2192-1864; Wong, Chi Chun/0000-0003-1362-3541; Soares, Fraser/0000-0002-3977-7939; Zeng, Yong/0000-0001-5719-1272	National Natural Science Foundation of China (NSFC) [81972576]; RGC-CRF Hong Kong [C4039-19G, C7065-18G]; RGC-GRF Hong Kong [14110819, 14163817, 14108718, 24100520]; HMRF Hong Kong [06170686]; Princess Margaret Cancer Foundation [886012001223]; NSERC discovery Grants [498706]; CIHR operating Grants [142246, 152863, 152864, 159567]; Terry Fox New Frontiers Program Project Grant [1090 P3]; TFRI New Investigator Awards; CIHR New Investigator Awards; OMIR Early Researcher Award; Vice-Chancellor's Discretionary Fund CUHK	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); RGC-CRF Hong Kong; RGC-GRF Hong Kong(Hong Kong Research Grants Council); HMRF Hong Kong; Princess Margaret Cancer Foundation(University of Toronto); NSERC discovery Grants(Natural Sciences and Engineering Research Council of Canada (NSERC)); CIHR operating Grants(Canadian Institutes of Health Research (CIHR)); Terry Fox New Frontiers Program Project Grant; TFRI New Investigator Awards; CIHR New Investigator Awards(Canadian Institutes of Health Research (CIHR)); OMIR Early Researcher Award; Vice-Chancellor's Discretionary Fund CUHK	This project was supported by National Natural Science Foundation of China (NSFC; 81972576), RGC-CRF Hong Kong (C4039-19G, C7065-18G), RGC-GRF Hong Kong (14110819, 14163817, 14108718, 24100520), HMRF Hong Kong (06170686), the Princess Margaret Cancer Foundation (886012001223 to HHH), NSERC discovery Grants (498706 to HHH), CIHR operating Grants (142246, 152863, 152864, and 159567 to HHH), Terry Fox New Frontiers Program Project Grant (1090 P3 to HHH). HHH was supported by TFRI New Investigator Awards and CIHR New Investigator Awards. HHH holds an OMIR Early Researcher Award, Vice-Chancellor's Discretionary Fund CUHK.	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Carpentino JE, 2009, CANCER RES, V69, P8208, DOI 10.1158/0008-5472.CAN-09-1132; Chen CL, 2008, J CELL PHYSIOL, V215, P223, DOI 10.1002/jcp.21303; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031864; Cheung KS, 2019, GUT, V68, P1979, DOI 10.1136/gutjnl-2018-317714; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Ehmsen S, 2019, CELL REP, V27, P3927, DOI 10.1016/j.celrep.2019.05.104; Gabitova-Cornell L, 2020, CANCER CELL, V38, P567, DOI 10.1016/j.ccell.2020.08.015; Ginestier C, 2012, STEM CELLS, V30, P1327, DOI 10.1002/stem.1122; Gnant M, 2015, ANN ONCOL, V26, P313, DOI 10.1093/annonc/mdu544; Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285; Griffith M, 2013, NAT METHODS, V10, P1209, DOI [10.1038/NMETH.2689, 10.1038/nmeth.2689]; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Haynes J, 2018, CLIN CANCER RES, V24, P2116, DOI 10.1158/1078-0432.CCR-17-1715; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Katsuno Y, 2012, J PATHOL, V228, P391, DOI 10.1002/path.4020; Kloudova A, 2017, TRENDS ENDOCRIN MET, V28, P485, DOI 10.1016/j.tem.2017.03.002; Kodach LL, 2007, GASTROENTEROLOGY, V133, P1272, DOI 10.1053/j.gastro.2007.08.021; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Kurata M, 2018, J HUM GENET, V63, P179, DOI 10.1038/s10038-017-0376-9; Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638; Li HY, 2003, BLOOD, V101, P3628, DOI 10.1182/blood-2002-07-2283; Liang YY, 2009, CELL RES, V19, P140, DOI 10.1038/cr.2008.321; Liu CG, 2013, CANCER LETT, V339, P60, DOI 10.1016/j.canlet.2013.07.022; MacLeod G, 2019, CELL REP, V27, P971, DOI 10.1016/j.celrep.2019.03.047; Meng DL, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.152595; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Mishra L, 2005, ONCOGENE, V24, P5775, DOI 10.1038/sj.onc.1208924; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; O'Brien CA, 2012, CANCER CELL, V21, P777, DOI 10.1016/j.ccr.2012.04.036; Park HJ, 1999, P NATL ACAD SCI USA, V96, P11525, DOI 10.1073/pnas.96.20.11525; Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rodriguez-Vita J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003959; Shen Y, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw023; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Teng CF, 2018, CELL TRANSPLANT, V27, P1313, DOI 10.1177/0963689718779777; Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078-0432.CCR-12-0489; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Voorneveld PW, 2017, GASTROENTEROLOGY, V153, P470, DOI 10.1053/j.gastro.2017.05.011; Wang B, 2018, CELL STEM CELL, V22, P206, DOI 10.1016/j.stem.2017.12.017; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041; Wang XX, 2017, CANCER RES, V77, P4947, DOI 10.1158/0008-5472.CAN-17-0114; Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098; Xia Y, 2018, CELL, V175, P1059, DOI 10.1016/j.cell.2018.08.070; Zhao ZQ, 2019, ONCOGENE, V38, P2076, DOI 10.1038/s41388-018-0570-z	52	7	7	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6601	6613		10.1038/s41388-021-01882-7	http://dx.doi.org/10.1038/s41388-021-01882-7		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34621019	hybrid, Green Published			2022-12-28	WOS:000705775200001
J	Chen, XY; Xu, RS; He, D; Zhang, Y; Chen, HT; Zhu, YX; Cheng, YX; Liu, R; Zhu, RR; Gong, L; Xiao, MQ; Wang, ZW; Deng, LP; Cao, K				Chen, Xingyu; Xu, Runshi; He, Dong; Zhang, Yao; Chen, Haotian; Zhu, Yuxing; Cheng, YaXin; Liu, Rui; Zhu, Rongrong; Gong, Lian; Xiao, Mengqing; Wang, Zhanwang; Deng, Liping; Cao, Ke			CD8(+) T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer	ONCOGENE			English	Article							MORTALITY; CXCL13	Immune-checkpoint blockade (ICB) has been routinely implemented to treat bladder cancer; however, most patients have little or no clinical benefit. In this study, 348 pretreated metastatic urothelial cancer samples from the IMvigor210 cohort were used to identify important genes significantly associated with CD8+ T effector and immune checkpoint signatures. The immune checkpoint inhibitor score (IMS) scoring system was constructed to predict the immunotherapy responsiveness. Transcriptome analysis confirmed that the high IMS score group had significant immune activation with better prognosis and higher immunotherapy responsiveness, which was a powerful biomarker for predicting the prognosis and responsiveness of ICB. Tumor immune dysfunction and exclusion (TIDE) scores were calculated using 2031 external bladder cancer samples for further validation. We selected the important Hub genes as potential therapeutic targets, and validated the genes using genomic, transcriptomic, immunomic, and other multi-omics methods. In addition, we construct a risk prediction model which could stratify patients with bladder cancer and predict patient prognosis and ICB treatment responsiveness. In conclusion, this study identified effective biomarkers for the prediction of immune checkpoint inhibitor treatment responsiveness in bladder cancer patients and provided new immunotherapeutic targets.	[Chen, Xingyu; Zhang, Yao; Chen, Haotian; Zhu, Yuxing; Cheng, YaXin; Liu, Rui; Zhu, Rongrong; Gong, Lian; Xiao, Mengqing; Wang, Zhanwang; Deng, Liping; Cao, Ke] Cent South Univ, Xiangya Hosp 3, Dept Oncol, 283 Tongzipo Rd, Changsha 410013, Peoples R China; [Xu, Runshi] Hunan Univ Chinese Med, Med Sch, 300 Xueshi Rd,Hanpu Kejiao Pk, Changsha 410208, Peoples R China; [He, Dong] Hunan Univ Chinese Med, Peoples Hosp Hunan Prov 2, Dept Resp, Changsha 410000, Peoples R China	Central South University; Hunan University of Chinese Medicine; Hunan University of Chinese Medicine	Cao, K (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Oncol, 283 Tongzipo Rd, Changsha 410013, Peoples R China.	csucaoke@163.com	Xu, Runshi/AEI-9782-2022		National Natural Science Foundation of China [81874137]; science and technology innovation Program of Hunan Province [2020RC4011]; Outstanding Youth Foundation of Hunan Province [2018JJ1047]; Hunan Province Science and Technology Talent Promotion Project [2019TJ-Q10]; Young Scholars of "Furong Scholar Program" in Hunan Province [206030106]; Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University [BJ202001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); science and technology innovation Program of Hunan Province; Outstanding Youth Foundation of Hunan Province; Hunan Province Science and Technology Talent Promotion Project; Young Scholars of "Furong Scholar Program" in Hunan Province; Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University	We would like to thank the TCGA, GEO, and TIMER databases for the availability of the data. We would like to thank TissueGnostics Aisa Pacific limited for their technical support, And the help of hongzhe Sun and Xiaojing Liu, the technical engineer. This work was supported by the National Natural Science Foundation of China (81874137), the science and technology innovation Program of Hunan Province (2020RC4011), the Outstanding Youth Foundation of Hunan Province (2018JJ1047), the Hunan Province Science and Technology Talent Promotion Project (2019TJ-Q10), Young Scholars of "Furong Scholar Program" in Hunan Province(206030106), and the Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University (BJ202001).	Ai LY, 2020, ADV EXP MED BIOL, V1248, P33, DOI 10.1007/978-981-15-3266-5_3; Ammirante M, 2014, P NATL ACAD SCI USA, V111, P14776, DOI 10.1073/pnas.1416498111; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Biswas S, 2014, BREAST CANCER RES TR, V143, P265, DOI 10.1007/s10549-013-2811-8; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011; Chen XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672158; Choucair K, 2020, CANCER GENE THER, V27, P841, DOI 10.1038/s41417-020-0174-y; Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1; Das M, 2017, IMMUNOL REV, V276, P97, DOI 10.1111/imr.12520; Diskin B, 2020, NAT IMMUNOL, V21, P442, DOI 10.1038/s41590-020-0620-x; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Groeneveld CS, 2021, EUR J CANCER, V148, P181, DOI 10.1016/j.ejca.2021.01.036; Hasan S, 2020, ANN SURG, V271, P716, DOI 10.1097/SLA.0000000000003051; Hu J, 2021, THERANOSTICS, V11, P3089, DOI 10.7150/thno.53649; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Jimenez-Sanchez A, 2020, NAT GENET, V52, P582, DOI 10.1038/s41588-020-0630-5; Joseph A, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00761-w; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lees JR, 2020, CELL IMMUNOL, V357, DOI 10.1016/j.cellimm.2020.104212; Lino AC, 2018, IMMUNITY, V49, P120, DOI 10.1016/j.immuni.2018.06.007; Marin-Acevedo JA, 2019, MAYO CLIN PROC, V94, P1321, DOI 10.1016/j.mayocp.2019.03.012; Middha S, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00321; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Prokunina L, 2002, NAT GENET, V32, P666, DOI 10.1038/ng1020; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Saginala Kalyan, 2020, Med Sci (Basel), V8, DOI 10.3390/medsci8010015; Sell V, 2020, WORLD J UROL, V38, P1001, DOI 10.1007/s00345-019-02841-4; Spangler JB, 2015, ANNU REV IMMUNOL, V33, P139, DOI 10.1146/annurev-immunol-032713-120211; Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011	33	17	17	10	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6223	6234		10.1038/s41388-021-02019-6	http://dx.doi.org/10.1038/s41388-021-02019-6		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34552192				2022-12-28	WOS:000698327300001
J	Lin, M; Ku, AT; Dong, J; Yue, F; Jiang, WY; Ibrahim, AA; Peng, FL; Creighton, CJ; Nagi, C; Gutierrez, C; Rosen, JM; Zhang, XHF; Hilsenbeck, SG; Chen, X; Du, YCN; Huang, SX; Shi, AP; Fan, ZM; Li, Y				Lin, Meng; Ku, Amy T.; Dong, Jie; Yue, Fei; Jiang, Weiyu; Ibrahim, Ahmed Atef; Peng, Fanglue; Creighton, Chad J.; Nagi, Chandandeep; Gutierrez, Carolina; Rosen, Jeffrey M.; Zhang, Xiang H-F; Hilsenbeck, Susan G.; Chen, Xi; Du, Yi-Chieh Nancy; Huang, Shixia; Shi, Aiping; Fan, Zhimin; Li, Yi			STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; SIGNAL TRANSDUCER; MESENCHYMAL TRANSITION; TRANSCRIPTION FACTORS; BONE METASTASIS; TRANSGENIC MICE; CANCER CELLS; IN-VIVO; ACTIVATION; EXPRESSION	Signal transducer and activator of transcription 5 (STAT5) promotes cell survival and instigates breast tumor formation, and in the normal breast it also drives alveolar differentiation and lactogenesis. However, whether STAT5 drives a differentiated phenotype in breast tumorigenesis and therefore impacts cancer spread and metastasis is unclear. We found in two genetically engineered mouse models of breast cancer that constitutively activated Stat5a (Stat5a(ca)) caused precancerous mammary epithelial cells to become lactogenic and evolve into tumors with diminished potential to metastasize. We also showed that STAT5a(ca) reduced the migratory and invasive ability of human breast cancer cell lines in vitro. Furthermore, we demonstrated that STAT5a(ca) overexpression in human breast cancer cells lowered their metastatic burden in xenografted mice. Moreover, RPPA, Western blotting, and studies of ChIPseq data identified several EMT drivers regulated by STAT5. In addition, bioinformatic studies detected a correlation between STAT5 activity and better prognosis of breast cancer patients. Together, we conclude that STAT5 activation during mammary tumorigenesis specifies a tumor phenotype of lactogenic differentiation, suppresses EMT, and diminishes potential for subsequent metastasis.	[Lin, Meng; Ku, Amy T.; Dong, Jie; Yue, Fei; Jiang, Weiyu; Ibrahim, Ahmed Atef; Gutierrez, Carolina; Zhang, Xiang H-F; Hilsenbeck, Susan G.; Li, Yi] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Lin, Meng; Shi, Aiping; Fan, Zhimin] First Hosp Jilin Univ, Gen Surg Ctr, Dept Breast Surg, Changchun, Jilin, Peoples R China; [Yue, Fei; Creighton, Chad J.; Rosen, Jeffrey M.; Hilsenbeck, Susan G.; Huang, Shixia] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Peng, Fanglue; Rosen, Jeffrey M.; Zhang, Xiang H-F; Chen, Xi; Huang, Shixia; Li, Yi] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Creighton, Chad J.; Rosen, Jeffrey M.; Zhang, Xiang H-F; Hilsenbeck, Susan G.; Chen, Xi; Huang, Shixia; Li, Yi] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Nagi, Chandandeep] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Du, Yi-Chieh Nancy] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA; [Huang, Shixia] Dept Educ Innovat & Technol, Houston, TX USA	Baylor College of Medicine; Jilin University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Cornell University	Li, Y (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.; Li, Y (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Li, Y (corresponding author), Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA.	liyi@bcm.edu	Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X; Lin, Meng/0000-0001-8154-5720	DOD CDMRP [BC191649, BC191646]; SPORE-funded [P50CA186784]; CPRIT Core Facility Support Award [CPRIT-RP180672, RP210227]; NIH [P30 CA125123, S10 RR024574, CA125123]; expert assistance of Joel M. Sederstrom; P30 Cancer Center Support Grant [NCI-CA125123]; NIH S10 instrument award [S10OD028648-01]; Chinese Scholarship Council (CSC);  [T32-CA203690];  [NIH016303]	DOD CDMRP(United States Department of Defense); SPORE-funded; CPRIT Core Facility Support Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); expert assistance of Joel M. Sederstrom; P30 Cancer Center Support Grant; NIH S10 instrument award; Chinese Scholarship Council (CSC)(China Scholarship Council); ; 	This work was supported by DOD CDMRP BC191649 & BC191646 (to YL). The authors thank the SPORE-funded (P50CA186784) Pathology Core Facility at the Breast Center for tissue processing and Dr. Gary Chamness for helpful comments on the manuscript; the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the CPRIT Core Facility Support Award (CPRIT-RP180672), the NIH (P30 CA125123 and S10 RR024574) and the expert assistance of Joel M. Sederstrom; the Antibody-Based Proteomics Core (RPPA core) at Baylor College of Medicine funded by CPRIT Core Facility Award (RP210227) and P30 Cancer Center Support Grant (NCI-CA125123), NIH S10 instrument award (S10OD028648-01), and the expert help of Dr. Xuan Wang. The authors thank Le Ma for gifting reagents and Dr. Wen Bu for intellectual input. ML is supported by the Chinese Scholarship Council (CSC), AK was supported by T32-CA203690. JMR is supported by NIH016303. CJC is supported by NIH CA125123.	Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Bu W, 2020, J MAMMARY GLAND BIOL, V25, P389, DOI 10.1007/s10911-020-09469-w; Bu W, 2009, J MAMMARY GLAND BIOL, V14, P401, DOI 10.1007/s10911-009-9154-4; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Creighton CJ, 2015, DRUG DES DEV THER, V9, P3519, DOI 10.2147/DDDT.S38375; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dong J, 2010, DEV BIOL, V346, P196, DOI 10.1016/j.ydbio.2010.07.027; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Eilon T, 2007, INT J CANCER, V121, P1892, DOI 10.1002/ijc.22954; Gu L, 2010, ENDOCR-RELAT CANCER, V17, P481, DOI 10.1677/ERC-09-0328; Haricharan S, 2014, MOL CELL ENDOCRINOL, V382, P560, DOI 10.1016/j.mce.2013.03.014; Haricharan S, 2013, ELIFE, V2, DOI 10.7554/eLife.00996; Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708; Iavnilovitch E, 2004, INT J CANCER, V112, P607, DOI 10.1002/ijc.20484; Iavnilovitch E, 2006, MOL REPROD DEV, V73, P841, DOI 10.1002/mrd.20479; Johnston AN, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0969-z; Kinslechner K, 2018, MOL CANCER RES, V16, P135, DOI 10.1158/1541-7786.MCR-17-0292; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koppikar P, 2008, CLIN CANCER RES, V14, P7682, DOI 10.1158/1078-0432.CCR-08-1328; Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092; Li HZ, 2005, CLIN CANCER RES, V11, P5863, DOI 10.1158/1078-0432.CCR-05-0562; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Matulka LA, 2007, DEV BIOL, V303, P29, DOI 10.1016/j.ydbio.2006.12.017; Metser G, 2016, NUCLEIC ACIDS RES, V44, P1052, DOI 10.1093/nar/gkv999; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Minieri V, 2018, CANCER RES, V78, P5793, DOI 10.1158/0008-5472.CAN-18-0195; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nouhi Z, 2006, CANCER RES, V66, P1824, DOI 10.1158/0008-5472.CAN-05-2292; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Peck AR, 2011, J CLIN ONCOL, V29, P2448, DOI 10.1200/JCO.2010.30.3552; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Reddy JP, 2009, J MAMMARY GLAND BIOL, V14, P405, DOI 10.1007/s10911-009-9157-1; Salas A, 2020, NAT REV GASTRO HEPAT, V17, P323, DOI 10.1038/s41575-020-0273-0; Schorr K, 2000, CANCER RES, V60, P5950; Shi AP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132214; Strauss BL, 2006, HUM PATHOL, V37, P586, DOI 10.1016/j.humpath.2006.01.009; Sultan AS, 2008, CANCER SCI, V99, P272, DOI 10.1111/j.1349-7006.2007.00685.x; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Talati PG, 2015, AM J PATHOL, V185, P2505, DOI 10.1016/j.ajpath.2015.04.026; Vasaikar SV, 2021, BRIT J CANCER, V124, P259, DOI 10.1038/s41416-020-01178-9; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Wagner KU, 2008, J MAMMARY GLAND BIOL, V13, P93, DOI 10.1007/s10911-008-9062-z; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wang J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad3210; Watson CJ, 2008, SEMIN CELL DEV BIOL, V19, P401, DOI 10.1016/j.semcdb.2008.07.021; Yamaji D, 2013, NUCLEIC ACIDS RES, V41, P1622, DOI 10.1093/nar/gks1310; Yamashita H, 2006, ENDOCR-RELAT CANCER, V13, P885, DOI 10.1677/erc.1.01095; Young A, 2022, CANCER PREV RES, V15, P3, DOI 10.1158/1940-6207.CAPR-21-0031; Yue F, 2021, CANCER RES, V81, P4441, DOI 10.1158/0008-5472.CAN-21-1112; Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	57	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5214	5222		10.1038/s41388-022-02500-w	http://dx.doi.org/10.1038/s41388-022-02500-w		OCT 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36261627				2022-12-28	WOS:000870094500001
J	Wang, YY; Zhang, Y; Mi, JQ; Jiang, CC; Wang, Q; Li, XW; Zhao, ML; Geng, ZJ; Song, X; Li, J; Zuo, LG; Ge, ST; Zhang, ZN; Wen, HX; Wang, ZS; Su, F				Wang, Yanyan; Zhang, Yue; Mi, Jiaqi; Jiang, Chenchen; Wang, Qiang; Li, Xinwei; Zhao, Menglin; Geng, Zhijun; Song, Xue; Li, Jing; Zuo, Lugen; Ge, Sitang; Zhang, Zining; Wen, Hexin; Wang, Zishu; Su, Fang			ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma	ONCOGENE			English	Article							ANKYRIN REPEAT; CANCER; PATHWAYS; GENE; ARCHITECTURE; ACTIVATION; THERAPY; KINASES	Ankyrin repeat and fibronectin type III domain containing 1 (ANKFN1) is reported to be involved in human height and developmental abnormalities, but the expression profile and molecular function of ANKFN1 in hepatocellular carcinoma (HCC) remain unknown. This study aimed to evaluate the clinical significance and biological function of ANKFN1 in HCC and investigate whether ANKFN1 can be used for differential diagnosis in HCC. Here, we showed that ANKFN1 was upregulated in 126 tumor tissues compared with adjacent nontumorous tissues in HCC patients. The upregulation of ANKFN1 in HCC was associated with cirrhosis, alpha-fetoprotein (AFP) levels and poor prognosis. Moreover, silencing ANKFN1 expression suppressed HCC cell proliferation, migration, invasion, and metastasis in vitro and subcutaneous tumorigenesis in vivo. However, ANKFN1 overexpression promoted HCC proliferation and metastasis in an orthotopic liver transplantation model and attenuated the above biological effects in HCC cells. ANKFN1 significantly affected HCC cell proliferation by inducing G1/S transition and cell apoptosis. Mechanistically, we demonstrated that ANKFN1 promoted cell proliferation, migration, and invasion via activation of the cyclin D1/Cdk4/Cdk6 pathway by stimulating the MEK1/2-ERK1/2 pathway. Moreover, ANKFN1-induced cell proliferation, migration, and invasion were partially reversed by ERK1/2 inhibitors. Taken together, our results indicate that ANKFN1 promotes HCC cell proliferation and metastasis by activating the MEK1/2-ERK1/2 signaling pathway. Our work also suggests that ANKFN1 is a potential therapeutic target for HCC.	[Wang, Yanyan; Zhang, Yue; Mi, Jiaqi; Li, Xinwei; Zhao, Menglin; Geng, Zhijun; Song, Xue; Li, Jing; Zuo, Lugen; Ge, Sitang; Zhang, Zining; Wen, Hexin; Wang, Zishu; Su, Fang] Bengbu Med Coll, Affiliated Hosp 1, Bengbu 233004, Anhui, Peoples R China; [Jiang, Chenchen] Univ Newcastle, Canc Neurobiol Grp, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia; [Jiang, Chenchen] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Wang, Qiang] Bengbu Med Coll, Bengbu 233004, Anhui, Peoples R China	Bengbu Medical College; University of Newcastle; University of Newcastle; Bengbu Medical College	Wang, ZS; Su, F (corresponding author), Bengbu Med Coll, Affiliated Hosp 1, Bengbu 233004, Anhui, Peoples R China.	wzshahbb@163.com; sufang2899@163.com	Wen, He/GZL-8825-2022		College Student Innovation Training Program of Bengbu Medical College [Byycx20045]; Support Program for Outstanding Young Talents in Colleges and Universities of Anhui Province [gxyq2018038]; 512 Talent Cultivation Plan of Bengbu Medical College [51201319, 51201107]; Science and Technology Development Fund Project of Bengbu Medical College [BYKF1846]; Research and Innovation Team of Bengbu Medical College [BYKC201908, BYKC201909]	College Student Innovation Training Program of Bengbu Medical College; Support Program for Outstanding Young Talents in Colleges and Universities of Anhui Province; 512 Talent Cultivation Plan of Bengbu Medical College; Science and Technology Development Fund Project of Bengbu Medical College; Research and Innovation Team of Bengbu Medical College	The present study was supported by the 2019 College Student Innovation Training Program of Bengbu Medical College (grant no. Byycx20045), Support Program for Outstanding Young Talents in Colleges and Universities of Anhui Province (grant no. gxyq2018038), 512 Talent Cultivation Plan of Bengbu Medical College (grant numbers by51201319, by 51201107), Science and Technology Development Fund Project of Bengbu Medical College (grant no. BYKF1846) and Research and Innovation Team of Bengbu Medical College (grant no. BYKC201908, grant no. BYKC201909).	Agrawal A, 2011, ADDICT BIOL, V16, P514, DOI 10.1111/j.1369-1600.2010.00255.x; Alvarez-Fernandez M, 2020, CANCER CELL, V37, P514, DOI 10.1016/j.ccell.2020.03.010; Asl ER, 2021, LIFE SCI, V278, DOI 10.1016/j.lfs.2021.119499; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Braicu C, 2019, CANCERS, V11, DOI 10.3390/cancers11101618; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; Chandler PG, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030610; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Drosten M, 2020, CANCER CELL, V37, P543, DOI 10.1016/j.ccell.2020.03.013; Fu J, 2018, CANCER LETT, V412, P283, DOI 10.1016/j.canlet.2017.10.008; Gao XL, 2020, ADV CANCER RES, V148, P147, DOI 10.1016/bs.acr.2020.02.002; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Ingham M, 2017, J CLIN ONCOL, V35, P2949, DOI 10.1200/JCO.2016.69.0032; Iyer M, 2021, EUR J PHARMACOL, V894, DOI 10.1016/j.ejphar.2020.173815; Kane EI, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020609; Kulik L, 2019, GASTROENTEROLOGY, V156, P477, DOI 10.1053/j.gastro.2018.08.065; Kwon JH, 2021, J GASTROINTEST SURG, V25, P941, DOI 10.1007/s11605-020-04555-0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lavoie H, 2020, NAT REV MOL CELL BIO, V21, P607, DOI 10.1038/s41580-020-0255-7; LITTLE E, 1994, J MOL EVOL, V39, P631, DOI 10.1007/BF00160409; Lu WZ, 2021, METAB BRAIN DIS, V36, P1101, DOI 10.1007/s11011-021-00709-4; Martinez-Fernandez ML, 2015, AM J MED GENET A, V167, P2034, DOI 10.1002/ajmg.a.37117; Mishra S, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.601929; Moon H, 2021, CANCERS, V13, DOI 10.3390/cancers13123026; Mosaddeghzadeh N, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071831; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Mosavi LK, 2002, P NATL ACAD SCI USA, V99, P16029, DOI 10.1073/pnas.252537899; Muhammad RN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71531-8; Petrick JL, 2020, INT J CANCER, V147, P317, DOI 10.1002/ijc.32723; Petroni G, 2020, NAT REV IMMUNOL, V20, P669, DOI 10.1038/s41577-020-0300-y; Qi YQ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1415-5; Ren M, 2019, ARTIF CELL NANOMED B, V47, P1014, DOI 10.1080/21691401.2019.1584566; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; Semenov MV, 2007, CELL, V131, DOI 10.1016/j.cell.2007.12.011; Serper M, 2017, GASTROENTEROLOGY, V152, P1954, DOI 10.1053/j.gastro.2017.02.040; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Sucandy I, 2016, HPB, V18, P756, DOI 10.1016/j.hpb.2016.06.010; Sun YH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1350-6; Syed AS, 2010, NUCLEIC ACIDS RES, V38, pD670, DOI 10.1093/nar/gkp957; Tarhouni-Jabberi S, 2017, MAR DRUGS, V15, DOI 10.3390/md15070221; Tian T, 2020, INT J CANCER, V147, P3075, DOI 10.1002/ijc.33130; Unal EB, 2017, FEBS LETT, V591, P2607, DOI 10.1002/1873-3468.12740; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Wang YY, 2018, J OVARIAN RES, V11, DOI 10.1186/s13048-018-0397-9; Wood AR, 2014, NAT GENET, V46, P1173, DOI 10.1038/ng.3097; Wu QH, 2020, J ENZYM INHIB MED CH, V35, P574, DOI 10.1080/14756366.2020.1720013; Ye LB, 2017, DRUG DISCOV TODAY, V22, P1092, DOI 10.1016/j.drudis.2017.04.011; Ye ZD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3803; Zhou X, 2013, J BIOL CHEM, V288, P36179, DOI 10.1074/jbc.R113.515486	52	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2022	41	29					3680	3693		10.1038/s41388-022-02380-0	http://dx.doi.org/10.1038/s41388-022-02380-0		JUN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y6YE	35725908	hybrid, Green Published			2022-12-28	WOS:000813707500001
J	Liu, YT; Ouyang, LL; Mao, C; Chen, YB; Li, TS; Liu, N; Wang, ZL; Lai, WW; Zhou, YL; Cao, Y; Liu, S; Liang, YM; Wang, M; Liu, SP; Chen, L; Shi, Y; Xiao, DS; Tao, YG				Liu, Yating; Ouyang, Lianlian; Mao, Chao; Chen, Yuanbing; Li, Tiansheng; Liu, Na; Wang, Zuli; Lai, Weiwei; Zhou, Yanling; Cao, Ya; Liu, Shuang; Liang, Yinming; Wang, Min; Liu, Shouping; Chen, Ling; Shi, Ying; Xiao, Desheng; Tao, Yongguang			PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma	ONCOGENE			English	Article							METHYLATION	Liver cancer, a result of multifactorial interplay between heredity and the environment, is one of the leading causes of cancer-related death worldwide. Hepatocellular carcinoma (HCC) is the most common histologic type of primary liver cancer. Here, we reported that deficiency in PCDHB14, a member of the cadherin superfamily, participates in the progression of HCC. We found that PCDHB14 is inactivated by aberrant methylation of its promoter in HCC patients and that PCDHB14 functions as a tumor suppressor to promote cell cycle arrest, inhibit cell proliferation, and induce ferroptosis. Furthermore, PCDHB14 ablation dramatically enhanced diethylenenitrite-induced HCC development. Mechanistically, PCDHB14 is induced by p53, and increased PCDHB14 downregulates the expression of SLC7A11, which is critical for ferroptosis. This effect is mediated by accelerated p65 protein degradation resulting from PCDHB14 promoting E3 ubiquitin ligase RNF182-mediated ubiquitination of p65 to block p65 binding to the promoter of SLC7A11. This study reports the new discovery that PCDHB14 serves as a potential prognostic marker for HCC.	[Liu, Yating] Cent South Univ, Xiangya Hosp 3, Postdoctoral Res Stn Clin Med, Changsha 410000, Peoples R China; [Liu, Yating] Cent South Univ, Xiangya Hosp 3, Dept Hematol & Crit Care Med, Changsha 410000, Peoples R China; [Liu, Yating; Ouyang, Lianlian; Mao, Chao; Chen, Yuanbing; Li, Tiansheng; Liu, Na; Wang, Zuli; Lai, Weiwei; Zhou, Yanling; Cao, Ya; Wang, Min; Liu, Shouping; Chen, Ling; Shi, Ying; Xiao, Desheng; Tao, Yongguang] Cent South Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Dept Pathol,Xiangya Hosp, Changsha 410078, Hunan, Peoples R China; [Liu, Yating; Ouyang, Lianlian; Mao, Chao; Chen, Yuanbing; Li, Tiansheng; Liu, Na; Wang, Zuli; Lai, Weiwei; Zhou, Yanling; Wang, Min; Liu, Shouping; Chen, Ling; Shi, Ying; Xiao, Desheng; Tao, Yongguang] Cent South Univ, NHC Key Lab Carcinogenesis, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Liu, Yating; Ouyang, Lianlian; Mao, Chao; Chen, Yuanbing; Li, Tiansheng; Liu, Na; Wang, Zuli; Lai, Weiwei; Zhou, Yanling; Wang, Min; Liu, Shouping; Chen, Ling; Shi, Ying; Xiao, Desheng; Tao, Yongguang] Cent South Univ, Sch Basic Med, Changsha 410078, Hunan, Peoples R China; [Liu, Shuang] Cent South Univ, Xiangya Hosp, Ctr Geriatr Disorders, Inst Med Sci,Dept Oncol,Natl Clin Res, Changsha 410008, Hunan, Peoples R China; [Liang, Yinming] Xinxiang Med Univ, Sch Lab Med, Xinxiang 453003, Henan, Peoples R China; [Tao, Yongguang] Cent South Univ, Xiangya Hosp 2, Hunan Key Lab Early Diag & Precis Therapy Lung Ca, Changsha 410011, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Xinxiang Medical University; Central South University	Shi, Y; Xiao, DS; Tao, YG (corresponding author), Cent South Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Dept Pathol,Xiangya Hosp, Changsha 410078, Hunan, Peoples R China.; Shi, Y; Xiao, DS; Tao, YG (corresponding author), Cent South Univ, NHC Key Lab Carcinogenesis, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.; Shi, Y; Xiao, DS; Tao, YG (corresponding author), Cent South Univ, Sch Basic Med, Changsha 410078, Hunan, Peoples R China.; Tao, YG (corresponding author), Cent South Univ, Xiangya Hosp 2, Hunan Key Lab Early Diag & Precis Therapy Lung Ca, Changsha 410011, Peoples R China.	yingshi@csu.edu.cn; xdsh96@csu.edu.cn; taoyong@csu.edu.cn			National Natural Science Foundation of China [81872285, 81874139, 82073097, 82072594, 82073136]; Natural Science Foundation of Hunan Province [2021JJ30907, 2020JJ5790, 2021JJ40937]; China Postdoctoral Science Foundation [2021M700173]; Hunan Provincial Key Area RD Program [2021SK2013]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Hunan Provincial Key Area RD Program	This work is supported by National Natural Science Foundation of China [81872285 (YS), 81874139 and 82073097 (SL), 82072594 (YT), 82073136 (DX)], Natural Science Foundation of Hunan Province [2021JJ30907 (YS)], [2020JJ5790 (CM)], [2021JJ40937 (YLiu)], China Postdoctoral Science Foundation [2021M700173 (YLiu)] and the Hunan Provincial Key Area R&D Program [2021SK2013 (YT)].	Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055; Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2; Cao LYL, 2016, NATURE, V539, P575, DOI 10.1038/nature20170; Cao Y, 2019, FEBS LETT, V593, P3210, DOI 10.1002/1873-3468.13583; Chen L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0196-9; Chen L, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0302-9; Chen XY, 2022, BRIT J CANCER, V126, P165, DOI 10.1038/s41416-021-01543-2; Danese E, 2013, BRIT J CANCER, V109, P807, DOI 10.1038/bjc.2013.351; Fujiwara N, 2018, J HEPATOL, V68, P526, DOI 10.1016/j.jhep.2017.09.016; Gao RZ, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202114351; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Jiang YQ, 2017, THERANOSTICS, V7, P3293, DOI 10.7150/thno.19988; Koppula P, 2021, PROTEIN CELL, V12, P599, DOI 10.1007/s13238-020-00789-5; Li SJ, 2020, MEDCOMM, V1, P178, DOI 10.1002/mco2.15; Liang C, 2019, ADV MATER, V31, DOI 10.1002/adma.201904197; Liu QY, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-4; Liu YT, 2020, ONCOGENE, V39, P2358, DOI 10.1038/s41388-019-1151-5; Mao C, 2018, CANCER RES, V78, P3484, DOI 10.1158/0008-5472.CAN-17-3454; Mazzaferro V, 2020, LANCET ONCOL, V21, P947, DOI 10.1016/S1470-2045(20)30224-2; Morris LGT, 2013, NAT GENET, V45, P253, DOI 10.1038/ng.2538; Pastushenko I, 2021, NATURE, V589, P448, DOI 10.1038/s41586-020-03046-1; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; Voisinne G, 2019, NAT IMMUNOL, V20, P1530, DOI 10.1038/s41590-019-0489-8; Wang LQ, 2018, CELL, V173, P1413, DOI 10.1016/j.cell.2018.04.012; Wang M, 2019, CELL DEATH DIFFER, V26, P2329, DOI 10.1038/s41418-019-0304-y; Wang ZL, 2021, MOL THER, V29, P263, DOI 10.1016/j.ymthe.2020.09.024; Ye W, 2018, J PATHOL, V245, P222, DOI 10.1002/path.5073; Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zhang T, 2021, MEDCOMM, V2, P618, DOI 10.1002/mco2.104; Zhang YL, 2018, NAT CELL BIOL, V20, P1181, DOI 10.1038/s41556-018-0178-0; Zhang YC, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0610-5; Zhao Y, 2014, CANCER RES, V74, P5103, DOI 10.1158/0008-5472.CAN-14-0427; Zhou XR, 2017, CANCER RES, V77, P187, DOI 10.1158/0008-5472.CAN-16-1267-T	34	2	2	10	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3570	3583		10.1038/s41388-022-02370-2	http://dx.doi.org/10.1038/s41388-022-02370-2		JUN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35688944				2022-12-28	WOS:000809307500001
J	Morimoto, Y; Fushimi, A; Yamashita, N; Hagiwara, M; Bhattacharya, A; Cheng, JW; Frost, TC; Ahmad, R; Daimon, T; Huang, L; Hata, T; Takahashi, H; Yamamoto, M; Suzuki, Y; DeCaprio, JA; Kufe, D				Morimoto, Yoshihiro; Fushimi, Atsushi; Yamashita, Nami; Hagiwara, Masayuki; Bhattacharya, Atrayee; Cheng, Jingwei; Frost, Thomas C.; Ahmad, Rehan; Daimon, Tatsuaki; Huang, Lei; Hata, Tsuyoshi; Takahashi, Hidekazu; Yamamoto, Masaaki; Suzuki, Yozo; DeCaprio, James A.; Kufe, Donald			Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment	ONCOGENE			English	Article							GENE-EXPRESSION; TRANSCRIPTION; ONCOPROTEIN; GROWTH; MYC	Merkel cell carcinoma (MCC) is an aggressive malignancy with neuroendocrine (NE) features, limited treatment options, and a lack of druggable targets. There is no reported involvement of the MUC1-C oncogenic protein in MCC progression. We show here that MUC1-C is broadly expressed in MCCs and at higher levels in Merkel cell polyomavirus (MCPyV)-positive (MCCP) relative to MCPyV-negative (MCCN) tumors. Our results further demonstrate that MUC1-C is expressed in MCCP, as well as MCCN, cell lines and regulates common sets of signaling pathways related to RNA synthesis, processing, and transport in both subtypes. Mechanistically, MUC1-C (i) interacts with MYCL, which drives MCC progression, (ii) is necessary for expression of the OCT4, SOX2, KLF4, MYC, and NANOG pluripotency factors, and (iii) induces the NEUROD1, BRN2 and ATOH1 NE lineage dictating transcription factors. We show that MUC1-C is also necessary for MCCP and MCCN cell survival by suppressing DNA replication stress, the p53 pathway, and apoptosis. In concert with these results, targeting MUC1-C genetically and pharmacologically inhibits MCC self-renewal capacity and tumorigenicity. These findings demonstrate that MCCP and MCCN cells are addicted to MUC1-C and identify MUC1-C as a potential target for MCC treatment.	[Morimoto, Yoshihiro; Fushimi, Atsushi; Yamashita, Nami; Hagiwara, Masayuki; Bhattacharya, Atrayee; Cheng, Jingwei; Frost, Thomas C.; Ahmad, Rehan; Daimon, Tatsuaki; Hata, Tsuyoshi; Takahashi, Hidekazu; Yamamoto, Masaaki; Suzuki, Yozo; DeCaprio, James A.; Kufe, Donald] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Cheng, Jingwei] Univ New Hampshire, Dept Mol Cellular & Biomed Sci, Durham, NH 03824 USA; [Huang, Lei] Shanghai Jiao Tong Univ, Shanghai Key Lab Reprod Med, Chinese Minist Educ,Sch Med, Dept Histoembryol Genet & Dev Biol,Key Lab Cell D, Shanghai, Peoples R China; [Hagiwara, Masayuki] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; [Hata, Tsuyoshi; Takahashi, Hidekazu; Yamamoto, Masaaki; Suzuki, Yozo] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka 5650871, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University System Of New Hampshire; University of New Hampshire; Shanghai Jiao Tong University; Keio University; Osaka University	Kufe, D (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu	Rather, R A/J-3509-2019	Frost, Thomas/0000-0002-7855-1000	National Cancer Institute of the National Institutes of Health [CA97098, CA166480, CA233084]; US Public Health Service [R35CA232128, P01CA203655]	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service)	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under grant numbers CA97098, CA166480, and CA233084 awarded to DK and also in part by US Public Health Service grants R35CA232128 and P01CA203655 awarded to JAD.	Angeles CV, 2021, J SURG ONCOL, V123, P775, DOI 10.1002/jso.26319; Becker JC, 2018, CANCER IMMUNOL IMMUN, V67, P341, DOI 10.1007/s00262-017-2099-3; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhattacharya A, 2022, MOL CANCER RES, V20, P556, DOI 10.1158/1541-7786.MCR-21-0672; Bian X, 2019, CANCERS, V11, DOI 10.3390/cancers11091289; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Cheng JW, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006668; Chteinberg E, 2018, NEOPLASIA, V20, P1227, DOI 10.1016/j.neo.2018.10.003; Daily K, 2015, J INVEST DERMATOL, V135, P1138, DOI 10.1038/jid.2014.518; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; DeCaprio JA, 2021, ANNU REV PATHOL-MECH, V16, P69, DOI 10.1146/annurev-pathmechdis-012419-032817; Fan KJ, 2020, J INVEST DERMATOL, V140, P56, DOI 10.1016/j.jid.2019.06.135; Fernandez-Flores A, 2016, APPL IMMUNOHISTO M M, V24, pE9, DOI 10.1097/PAI.0000000000000148; Hagiwara M, 2021, ONCOGENE, V40, P4930, DOI 10.1038/s41388-021-01899-y; Hagiwara M, 2021, CANCER RES, V81, P1111, DOI 10.1158/0008-5472.CAN-20-2588; Harold A, 2019, P NATL ACAD SCI USA, V116, P20104, DOI 10.1073/pnas.1907154116; Hata T, 2019, CANCER RES, V79, P5711, DOI 10.1158/0008-5472.CAN-19-1034; Hata T, 2019, MOL CANCER THER, V18, P1744, DOI 10.1158/1535-7163.MCT-19-0156; Hiraki M, 2017, ONCOGENE, V36, P2791, DOI 10.1038/onc.2016.439; Huang Lei, 2010, Genes Cancer, V1, P239; Jiang LY, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005895; Kreis NN, 2019, CANCERS, V11, DOI 10.3390/cancers11070989; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2020, CARCINOGENESIS, V41, P1173, DOI 10.1093/carcin/bgaa082; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Li W, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137112; Maricich SM, 2009, SCIENCE, V324, P1580, DOI 10.1126/science.1172890; McCubrey James A., 2017, Advances in Biological Regulation, V63, P32, DOI 10.1016/j.jbior.2016.10.001; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Park DE, 2020, NAT CELL BIOL, V22, P603, DOI 10.1038/s41556-020-0503-2; Park DE, 2019, P NATL ACAD SCI USA, V116, P1027, DOI 10.1073/pnas.1818798116; Petroni G, 2022, NAT REV DRUG DISCOV, V21, P440, DOI 10.1038/s41573-022-00415-5; Rajabi H, 2018, ONCOGENE, V37, P2079, DOI 10.1038/s41388-017-0096-9; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Shamloo B, 2019, CANCERS, V11, DOI 10.3390/cancers11081178; Shao Q, 2014, CANCER RES, V74, P7090, DOI 10.1158/0008-5472.CAN-14-0305; Starrett GJ, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00727-4; Stewart CA, 2020, NAT CANCER, V1, P423, DOI 10.1038/s43018-019-0020-z; Takahashi K, 2016, NAT REV MOL CELL BIO, V17, P183, DOI 10.1038/nrm.2016.8; Thomas A, 2021, CANCER CELL, V39, P566, DOI 10.1016/j.ccell.2021.02.014; Thomas A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6282; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wong SQ, 2015, CANCER RES, V75, P5228, DOI 10.1158/0008-5472.CAN-15-1877; Xiong J, 2022, ONCOL LETT, V23, DOI 10.3892/ol.2021.13139; Yamamoto M, 2019, CANCER RES, V79, P2031, DOI 10.1158/0008-5472.CAN-18-3259; Yasumizu Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14219-6; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Zhang W, 2016, INT J BIOL SCI, V12, P1372, DOI 10.7150/ijbs.16349; Zheng X, 2020, INT J BIOL SCI, V16, P2442, DOI 10.7150/ijbs.46751	50	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3511	3523		10.1038/s41388-022-02361-3	http://dx.doi.org/10.1038/s41388-022-02361-3		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35688945	hybrid, Green Published			2022-12-28	WOS:000809307500003
J	Huang, D; Wang, XS; Huang, ZH; Liu, YZ; Liu, XD; Gin, T; Wong, SH; Yu, J; Zhang, L; Chan, MTV; Chen, HR; Wu, WKK				Huang, Dan; Wang, Xiansong; Huang, Ziheng; Liu, Yingzhi; Liu, Xiaodong; Gin, Tony; Wong, Sunny Hei; Yu, Jun; Zhang, Lin; Chan, Matthew Tak Vai; Chen, Huarong; Wu, William Ka Kei			3 ' untranslated regions of tumor suppressor genes evolved specific features to favor cancer resistance	ONCOGENE			English	Article							POSTTRANSCRIPTIONAL REGULATION; RNA METHYLATION; 3' UTRS; EXPRESSION; SELECTION; PROTEINS; IMPACT	Cancer-related genes have evolved specific genetic and genomic features to favor tumor suppression. Previously we reported that tumor suppressor genes (TSGs) acquired high promoter CpG dinucleotide frequencies during evolution to maintain high expression in normal tissues and resist cancer-specific downregulation. In this study, we investigated whether 3 ' untranslated regions (3 ' UTRs) of TSGs have evolved specific features to carry out similar functions. We found that 3 ' UTRs of TSGs, especially those involved in multiple histological types and pediatric cancers, are longer than those of non-cancer genes. 3 ' UTRs of TSGs also exhibit higher density of binding sites for RNA-binding proteins (RBPs), particularly those having high affinities to C-rich motifs. Both longer 3 ' UTR length and RBP binding sites enrichment are correlated with higher gene expression in normal tissues across tissue types. Moreover, both features together with the correlated N-6-methyladenosine modification and the extent of protein-protein interactions are positively associated with the ability of TSGs to resist cancer-specific downregulation. These results were successfully validated with independent datasets. Collectively, these findings indicate that TSGs have evolved longer 3 ' UTR with increased propensity to RBP binding, N-6-methyladenosine modification and protein-protein interactions for optimizing their tumor-suppressing functions.	[Huang, Dan; Wang, Xiansong; Huang, Ziheng; Liu, Yingzhi; Liu, Xiaodong; Gin, Tony; Zhang, Lin; Chan, Matthew Tak Vai; Chen, Huarong; Wu, William Ka Kei] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Peoples R China; [Huang, Dan; Wang, Xiansong; Huang, Ziheng; Liu, Yingzhi; Liu, Xiaodong; Gin, Tony; Zhang, Lin; Chan, Matthew Tak Vai; Chen, Huarong; Wu, William Ka Kei] Chinese Univ Hong Kong, Peter Hung Pain Res Inst, Hong Kong, Peoples R China; [Huang, Dan; Wang, Xiansong; Huang, Ziheng; Liu, Yingzhi; Liu, Xiaodong; Wong, Sunny Hei; Yu, Jun; Zhang, Lin; Chan, Matthew Tak Vai; Chen, Huarong; Wu, William Ka Kei] CUHK Shenzhen Res Inst, Shenzhen, Guangdong, Peoples R China; [Wong, Sunny Hei; Yu, Jun; Zhang, Lin] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China; [Wong, Sunny Hei; Yu, Jun; Zhang, Lin; Chan, Matthew Tak Vai; Chen, Huarong; Wu, William Ka Kei] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Wong, Sunny Hei; Yu, Jun; Zhang, Lin; Chen, Huarong; Wu, William Ka Kei] Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Wong, Sunny Hei] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Chan, MTV; Chen, HR; Wu, WKK (corresponding author), Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Peoples R China.; Chan, MTV; Chen, HR; Wu, WKK (corresponding author), Chinese Univ Hong Kong, Peter Hung Pain Res Inst, Hong Kong, Peoples R China.; Chan, MTV; Chen, HR; Wu, WKK (corresponding author), CUHK Shenzhen Res Inst, Shenzhen, Guangdong, Peoples R China.; Chan, MTV; Chen, HR; Wu, WKK (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.; Chen, HR; Wu, WKK (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Peoples R China.	mtvchan@cuhk.edu.hk; hchen2@cuhk.edu.hk; wukakei@cuhk.edu.hk	wu, william/HII-5817-2022; chen, huarong/ABH-8561-2020; GIN, Tony/J-2521-2013; Wu, William K.K./A-3277-2009; Chan, Matthew/J-2884-2013; Jun, Yu/D-8569-2015	chen, huarong/0000-0003-2192-1864; GIN, Tony/0000-0001-7283-6761; Wu, William K.K./0000-0002-5662-5240; dan, huang/0000-0003-3022-5772; Chan, Matthew/0000-0002-3574-7855; Jun, Yu/0000-0001-5008-2153; Wang, Xiansong/0000-0001-7308-0978	Shenzhen Science and Technology Programme [JCYJ20180508161604382]; Shenzhen Science and Technology Innovation Commission; National Natural Science Foundation of China (NSFC) [82103245]	Shenzhen Science and Technology Programme; Shenzhen Science and Technology Innovation Commission; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by the Shenzhen Science and Technology Programme (JCYJ20180508161604382 awarded to WKKW), Shenzhen Science and Technology Innovation Commission, and National Natural Science Foundation of China (NSFC; 82103245).	Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; Alba MM, 2005, MOL BIOL EVOL, V22, P598, DOI 10.1093/molbev/msi045; Alkan SA, 2006, BIOCHEM J, V393, P361, DOI 10.1042/BJ20050538; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brouwer-Visser J, 2018, CANCER EPIDEM BIOMAR, V27, P103, DOI 10.1158/1055-9965.EPI-17-0461; Chen CL, 2010, GENOME RES, V20, P447, DOI 10.1101/gr.098947.109; Dolnik A, 2012, BLOOD, V120, pE83, DOI 10.1182/blood-2011-12-401471; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Gealy C, 2005, J VIROL, V79, P472, DOI 10.1128/JVI.79.1.472-485.2005; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Guo MZ, 2017, EMBO MOL MED, V9, P462, DOI 10.15252/emmm.201606711; Gupta S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r24; Huang D, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab040; Huang HL, 2020, ANNU REV CANC BIOL, V4, P221, DOI 10.1146/annurev-cancerbio-030419-033357; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Hubley R., 2013, REPEATMASKER OPEN 40; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lever J, 2019, NAT METHODS, V16, P505, DOI 10.1038/s41592-019-0422-y; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Linker K, 2005, NUCLEIC ACIDS RES, V33, P4813, DOI 10.1093/nar/gki797; Liu S, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02012-4; Matoulkova E, 2012, RNA BIOL, V9, P563, DOI 10.4161/rna.20231; Mayr C, 2017, ANNU REV GENET, V51, P171, DOI 10.1146/annurev-genet-120116-024704; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Ren GX, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01276; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Thomas MA, 2003, MOL BIOL EVOL, V20, P964, DOI 10.1093/molbev/msg110; Vishnoi A, 2010, GENOME RES, V20, P1574, DOI 10.1101/gr.109595.110; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005; Wang X, 2018, ANN ONCOL, V29, P2254, DOI 10.1093/annonc/mdy397; Warnefors M, 2011, GENOME BIOL EVOL, V3, P667, DOI 10.1093/gbe/evr019; Wu L, 2006, MICRORNAS DIRECT RAP, V103, P40349; Wu WKK, 2017, MOL BIOL EVOL, V34, P903, DOI 10.1093/molbev/msw295; Xiao S, 2019, NAT CELL BIOL, V21, P651, DOI 10.1038/s41556-019-0315-4; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yabe-Wada T, 2020, FEBS OPEN BIO, V10, P407, DOI 10.1002/2211-5463.12794; Yin HY, 2019, BRIEF BIOINFORM, V20, P2141, DOI 10.1093/bib/bby074; Yin HY, 2016, GENOME BIOL EVOL, V8, P3083, DOI 10.1093/gbe/evw216; Yu H, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gky1294; Zhang CY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00922; Zhang Z, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax0250; Zhao M, 2016, NUCLEIC ACIDS RES, V44, pD1023, DOI 10.1093/nar/gkv1268; Zhao YC, 2021, THERANOSTICS, V11, P4549, DOI 10.7150/thno.54967; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006	52	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3278	3288		10.1038/s41388-022-02343-5	http://dx.doi.org/10.1038/s41388-022-02343-5		MAY 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35523946				2022-12-28	WOS:000791643000002
J	Georgiou, M; Ntavelou, P; Stokes, W; Roy, R; Maher, GJ; Stoilova, T; Rakhit, CP; Martins, M; Ajuh, P; Horowitz, N; Berkowitz, RS; Elias, K; Seckl, MJ; Pardo, OE				Georgiou, Marina; Ntavelou, Panagiota; Stokes, William; Roy, Rajat; Maher, Geoffrey J.; Stoilova, Tsvetana; Rakhit, Callum P.; Martins, Miguel; Ajuh, Paul; Horowitz, Neil; Berkowitz, Ross S.; Elias, Kevin; Seckl, Michael J.; Pardo, Olivier E.			ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma	ONCOGENE			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; DIHYDROFOLATE-REDUCTASE; WEE1 KINASE; TROPHOBLASTIC-DISEASE; MOLECULAR-MECHANISMS; BREAST-CANCER; DNA; EXPRESSION; THERAPY; P53	Low-risk gestational trophoblastic neoplasia including choriocarcinoma is often effectively treated with Methotrexate (MTX) as a first line therapy. However, MTX resistance (MTX-R) occurs in at least approximate to 33% of cases. This can sometimes be salvaged with actinomycin-D but often requires more toxic combination chemotherapy. Moreover, additional therapy may be needed and, for high-risk patients, 5% still die from the multidrug-resistant disease. Consequently, new treatments that are less toxic and could reverse MTX-R are needed. Here, we compared the proteome/phosphoproteome of MTX-resistant and sensitive choriocarcinoma cells using quantitative mass-spectrometry to identify therapeutically actionable molecular changes associated with MTX-R. Bioinformatics analysis of the proteomic data identified cell cycle and DNA damage repair as major pathways associated with MTX-R. MTX-R choriocarcinoma cells undergo cell cycle delay in G1 phase that enables them to repair DNA damage more efficiently through non-homologous end joining in an ATR-dependent manner. Increased expression of cyclin-dependent kinase 4 (CDK4) and loss of p16(Ink4a) in resistant cells suggested that CDK4 inhibition may be a strategy to treat MTX-R choriocarcinoma. Indeed, inhibition of CDK4/6 using genetic silencing or the clinically relevant inhibitor, Palbociclib, induced growth inhibition both in vitro and in an orthotopic in vivo mouse model. Finally, targeting the ATR pathway, genetically or pharmacologically, re-sensitised resistant cells to MTX in vitro and potently prevented the growth of MTX-R tumours in vivo. In short, we identified two novel therapeutic strategies to tackle MTX-R choriocarcinoma that could rapidly be translated into the clinic.	[Georgiou, Marina; Ntavelou, Panagiota; Stokes, William; Roy, Rajat; Maher, Geoffrey J.; Stoilova, Tsvetana; Seckl, Michael J.; Pardo, Olivier E.] Imperial Coll, Dept Surg & Canc, Div Canc, London, England; [Rakhit, Callum P.; Martins, Miguel] Univ Cambridge, MRC Toxicol Unit, Cambridge, England; [Ajuh, Paul] Gemini Biosci, Liverpool, Merseyside, England; [Horowitz, Neil; Berkowitz, Ross S.; Elias, Kevin] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Obstet & Gynecol,Div Gynecol Oncol, Boston, MA USA	Imperial College London; University of Cambridge; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Seckl, MJ; Pardo, OE (corresponding author), Imperial Coll, Dept Surg & Canc, Div Canc, London, England.	m.seckl@imperial.ac.uk; o.pardo@imperial.ac.uk	Pardo, Oliver/AEM-2071-2022	Pardo, Oliver/0000-0003-2223-1435	MRC [MR/K016776/1]; Cancer Treatment and Research Trust; UK Medical Research Council [MC_UU_00025/3 (RG94521)]	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Treatment and Research Trust; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the MRC for funding the work of MG (MR/K016776/1), The Cancer Treatment and Research Trust for funding WS and RR. The authors gratefully acknowledge infrastructure support from the Cancer Research UK Imperial Centre, the Imperial Experimental Cancer Medicine Centre and the National Institute for Health Research Imperial Biomedical Research Centre. We also acknowledge the Donald P Goldstein, MD Trophoblastic Tumour Registry Endowment and the Dyett Family Trophoblastic Disease Research and Registry Endowment. LMM and CR are funded by the UK Medical Research Council, intramural project MC_UU_00025/3 (RG94521). In addition, we would like to acknowledge the kind help of Drs Lorenzo Ferrando and Gabriele Zoppoli from the Universita di Genova in reformatting our Ion Torrent sequencing data prior to deposition.	Alifrangis C, 2010, FUTURE ONCOL, V6, P1915, DOI 10.2217/FON.10.153; Araki T, 2016, ENDOCR-RELAT CANCER, V23, P857, DOI 10.1530/ERC-16-0206; Assaraf YG, 2006, DRUG RESIST UPDATE, V9, P227, DOI 10.1016/j.drup.2006.09.001; Banerjee D, 1995, ACTA BIOCHIM POL, V42, P457; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; Bertino JR, 2009, BEST PRACT RES CL HA, V22, P577, DOI 10.1016/j.beha.2009.09.004; Bolze PA, 2020, GYNECOL ONCOL, V158, P785, DOI 10.1016/j.ygyno.2020.05.042; Caretti V, 2013, MOL CANCER THER, V12, P141, DOI 10.1158/1535-7163.MCT-12-0735; Castrogiovanni C, 2018, CELL DEATH DIFFER, V25, P190, DOI 10.1038/cdd.2017.143; Chu J, 2012, MOL BIOL CELL, V23, P59, DOI 10.1091/mbc.E11-06-0487; Corrales L, 2017, CELL RES, V27, P96, DOI 10.1038/cr.2016.149; Do K, 2015, J CLIN ONCOL, V33, P3409, DOI 10.1200/JCO.2014.60.4009; Elias KM, 2017, AM J REPROD IMMUNOL, V77, DOI 10.1111/aji.12666; Engelke CG, 2013, CLIN CANCER RES, V19, P4412, DOI 10.1158/1078-0432.CCR-12-3748; Feng X, 2020, EMBO J, V39, DOI 10.15252/embj.2019104036; Fokas E, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.181; Froeling FE., 2014, CURR ONCOL REP, V16; Galletti G, 2017, CANCER TREAT REV, V57, P16, DOI 10.1016/j.ctrv.2017.04.008; Ghorani E, 2017, LANCET, V390, P2343, DOI 10.1016/S0140-6736(17)32894-5; Goldstein M, 2015, ANNU REV MED, V66, P129, DOI 10.1146/annurev-med-081313-121208; Gu GW, 2016, CURR OPIN PHARMACOL, V31, P97, DOI 10.1016/j.coph.2016.11.005; Hamilton E, 2016, CANCER TREAT REV, V45, P129, DOI 10.1016/j.ctrv.2016.03.002; Han B, 2010, INT J GYNECOL CANCER, V20, P1259, DOI 10.1111/IGC.0b013e3181f05128; Hilton BA, 2015, MOL CELL, V60, P35, DOI 10.1016/j.molcel.2015.08.008; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Hochhaus A, 2007, SEMIN HEMATOL, V44, pS15, DOI 10.1053/j.seminhematol.2006.12.002; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; Joukov V, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar4195; Kapke Jonathan T, 2019, Hematol Oncol Stem Cell Ther, V12, P189, DOI 10.1016/j.hemonc.2019.08.008; King C, 2014, INVEST NEW DRUG, V32, P213, DOI 10.1007/s10637-013-0036-7; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; Kori S, 2020, J MOL BIOL, V432, P4061, DOI 10.1016/j.jmb.2020.05.006; Krajewska M, 2015, ONCOGENE, V34, P3474, DOI 10.1038/onc.2014.276; Kuhne C, 2003, NUCLEIC ACIDS RES, V31, P7227, DOI 10.1093/nar/gkg937; LaPak KM, 2014, MOL CANCER RES, V12, P167, DOI 10.1158/1541-7786.MCR-13-0350; Laquente B, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3131-x; Lecona E, 2014, EXP CELL RES, V329, P26, DOI 10.1016/j.yexcr.2014.09.019; Lee EK, 2019, TRENDS CANCER, V5, P524, DOI 10.1016/j.trecan.2019.06.004; Li HD, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.31; Li QY, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-474; Lin LH, 2021, AM J OBSTET GYNECOL, V224, DOI 10.1016/j.ajog.2020.09.048; Liskovykh M, 2019, GENOME RES, V29, P1719, DOI 10.1101/gr.254276.119; Liu MH, 2018, ONCOL REP, V39, P901, DOI 10.3892/or.2018.6221; Liu WJ, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107438; Lurain JR, 2010, AM J OBSTET GYNECOL, V203, P531, DOI 10.1016/j.ajog.2010.06.073; Ma HH, 2012, P NATL ACAD SCI USA, V109, P4828, DOI 10.1073/pnas.1116349109; Mangili G, 2014, INT J GYNECOL CANCER, V24, pS109, DOI 10.1097/IGC.0000000000000294; Meazza C, 2021, EXPERT OPIN PHARMACO, V22, P1995, DOI 10.1080/14656566.2021.1936499; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Meng XN, 2015, J MED GENET, V52, P135, DOI 10.1136/jmedgenet-2014-102703; Menolfi D, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-0376-x; Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104; Mishra SK, 2004, ONCOGENE, V23, P4422, DOI 10.1038/sj.onc.1207569; Muller IB, 2021, RHEUMATOLOGY, V60, P1273, DOI 10.1093/rheumatology/keaa428; Nagel ZD, 2014, P NATL ACAD SCI USA, V111, pE1823, DOI 10.1073/pnas.1401182111; Olsen JV, 2004, P NATL ACAD SCI USA, V101, P13417, DOI 10.1073/pnas.0405549101; Ovejero S, 2012, MOL BIOL CELL, V23, P4515, DOI 10.1091/mbc.E12-04-0260; Pereira AL, 2006, MOL BIOL CELL, V17, P4526, DOI 10.1091/mbc.E06-07-0579; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Roskoski R, 2019, PHARMACOL RES, V139, P471, DOI 10.1016/j.phrs.2018.11.035; Rots MG, 2000, LEUKEMIA, V14, P2166, DOI 10.1038/sj.leu.2401943; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Schnittger A, 2018, TRENDS PLANT SCI, V23, P475, DOI 10.1016/j.tplants.2018.03.015; Seckl MJ, 2010, LANCET, V376, P717, DOI 10.1016/S0140-6736(10)60280-2; Serra M, 2004, ANN ONCOL, V15, P151, DOI 10.1093/annonc/mdh004; Shah MA, 2001, CLIN CANCER RES, V7, P2168; Shamash J, 2020, BJU INT, V125, P843, DOI 10.1111/bju.14947; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422; Spring LM, 2020, LANCET, V395, P817, DOI 10.1016/S0140-6736(20)30165-3; SRIMATKANDADA S, 1983, BIOCHEMISTRY-US, V22, P5774, DOI 10.1021/bi00294a015; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Thingholm TE, 2006, NAT PROTOC, V1, P1929, DOI 10.1038/nprot.2006.185; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Wang BD, 2018, CANCERS, V10, DOI 10.3390/cancers10110458; Whittle JR, 2020, CLIN CANCER RES, V26, P4120, DOI 10.1158/1078-0432.CCR-19-1872; Wisniewski JR, 2009, J PROTEOME RES, V8, P5674, DOI 10.1021/pr900748n; Wojtuszkiewicz A, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0158-9; Wolf J, 2005, ANN RHEUM DIS, V64, P564, DOI 10.1136/ard.2003.014985; Wu Guanming, 2014, F1000Res, V3, P146, DOI 10.12688/f1000research.4431.1; Yap TA, 2020, J CLIN ONCOL, V38, P3195, DOI 10.1200/JCO.19.02404; Zhang W., 2017, J MED CASE REP, V11; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60	87	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2540	2554		10.1038/s41388-022-02251-8	http://dx.doi.org/10.1038/s41388-022-02251-8		MAR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35301407	Green Published, hybrid			2022-12-28	WOS:000770216400001
J	Xia, Q; Jia, J; Hu, CP; Lu, JY; Li, JJ; Xu, HY; Fang, JC; Feng, DJ; Wang, LW; Chen, Y				Xia, Qing; Jia, Jing; Hu, Chupeng; Lu, Jinying; Li, Jiajin; Xu, Haiyan; Fang, Jianchen; Feng, Dongju; Wang, Liwei; Chen, Yun			Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							PYRUVATE-KINASE M2; CANCER-IMMUNOTHERAPY; CARCINOMA CELLS; PATHWAY; METABOLISM	In many types of cancer, tumor cells prefer to use glycolysis as a major energy acquisition method. Here, we found that the (18)fluoro-deoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT)-based markers were positively associated with the expression of programmed cell death ligand 1 (PD-L1), pyruvate kinase M2 (PKM2), both of which indicate poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). However, the regulatory mechanism of PD-L1 remains elusive. In this study, we confirmed that transforming growth factor-beta1 (TGF-beta 1) secreted by tumor-associated macrophages (TAMs) was a key factor contributing to the expression of PD-L1 in PDAC cells by inducing the nuclear translocation of PKM2. Using co-immunoprecipitation and chromatin immunoprecipitation assays, we demonstrated that the interaction between PKM2 and signal transducer and activator of transcription 1 (STAT1) was enhanced by TGF-beta 1 stimulation, which facilitated the transactivation of PD-L1 by the binding of PKM2 and STAT1 to its promoter. In vivo, PKM2 knockdown decreased PD-L1 expression in PDAC cells and inhibited tumor growth partly by promoting natural killer cell activation and function, and the combination of PD-1/PD-L1 blockade with PKM2 knockdown limited tumor growth. In conclusion, PKM2 significantly contributes to TAM-induced PD-L1 overexpression and immunosuppression, providing a novel target for immunotherapies for PDAC.	[Xia, Qing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Oncol, Shanghai 200127, Peoples R China; [Jia, Jing] Nanjing Med Univ, Med Ctr Digest Dis, Affiliated Hosp 2, Nanjing 210011, Jiangsu, Peoples R China; [Hu, Chupeng; Lu, Jinying; Chen, Yun] Nanjing Med Univ, Jiangsu Canc Hosp, Res Ctr Clin Oncol, Jiangsu Inst Canc Res,Affiliated Canc Hosp, Nanjing 210018, Jiangsu, Peoples R China; [Hu, Chupeng; Lu, Jinying; Feng, Dongju; Chen, Yun] Nanjing Med Univ, Dept Immunol, Key Lab Human Funct Genom Jiangsu Prov, Nanjing 211166, Jiangsu, Peoples R China; [Hu, Chupeng; Lu, Jinying; Chen, Yun] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China; [Li, Jiajin] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Nucl Med, Shanghai 200127, Peoples R China; [Xu, Haiyan; Wang, Liwei] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, Shanghai 200127, Peoples R China; [Fang, Jianchen] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Pathol, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Chen, Y (corresponding author), Nanjing Med Univ, Jiangsu Canc Hosp, Res Ctr Clin Oncol, Jiangsu Inst Canc Res,Affiliated Canc Hosp, Nanjing 210018, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Dept Immunol, Key Lab Human Funct Genom Jiangsu Prov, Nanjing 211166, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.; Wang, LW (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, Shanghai 200127, Peoples R China.	liweiwang@shsmu.edu.cn; chenyun@njmu.edu.cn		chen, yun/0000-0002-4118-362X; Li, Jiajin/0000-0003-1300-6025	National Natural Science Foundation of China [82071767, 81772602, 91742105, 91942309, 82073195, 8210102291, 81874048]; Jiangsu Provincial key research development program of China [BE2018750]; Key Laboratory of Emergency and Trauma, Ministry of Education [KLET-201913]; Innovation Group Project of Shanghai Municipal Health Commission [2019CXJQ03]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial key research development program of China; Key Laboratory of Emergency and Trauma, Ministry of Education; Innovation Group Project of Shanghai Municipal Health Commission	This work was supported by project grants from The National Natural Science Foundation of China (82071767, 81772602, 91742105, and 91942309 to Y.C.; 82073195 to Q.X.; 8210102291 to C.P.H., and 81874048 to L.W.W.), Jiangsu Provincial key research development program of China (BE2018750 to Y.C.), Key Laboratory of Emergency and Trauma, Ministry of Education (KLET-201913 to Y.C.), and Innovation Group Project of Shanghai Municipal Health Commission (2019CXJQ03 to L.W.W.).	Adamska A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071338; Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561; Balachandran VP, 2019, GASTROENTEROLOGY, V156, P2056, DOI 10.1053/j.gastro.2018.12.038; Brooks J, 2018, CANCER RES, V78, P475, DOI 10.1158/0008-5472.CAN-17-2415; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Chen BF, 2020, BIOMATERIALS, V255, DOI 10.1016/j.biomaterials.2020.120187; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Cortese N, 2020, CANCER IMMUNOL RES, V8, P493, DOI 10.1158/2326-6066.CIR-19-0403; David JM, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1349589; Deng WJ, 2018, CELL REP, V24, P366, DOI 10.1016/j.celrep.2018.06.026; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Feng MY, 2017, CANCER LETT, V407, P57, DOI 10.1016/j.canlet.2017.08.006; Gao XL, 2013, J BIOL CHEM, V288, P15971, DOI 10.1074/jbc.M112.448753; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Garrido F, 2001, ADV CANCER RES, V83, P117, DOI 10.1016/S0065-230X(01)83005-0; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Gong J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0316-z; Hsu J, 2018, J CLIN INVEST, V128, P4654, DOI 10.1172/JCI99317; Hussain SM, 2021, CELL ONCOL, V44, P673, DOI 10.1007/s13402-021-00594-0; Ijichi H, 2004, ONCOGENE, V23, P1043, DOI 10.1038/sj.onc.1207222; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Joergensen MT, 2010, PANCREAS, V39, P243, DOI 10.1097/MPA.0b013e3181bae8ab; Kumar Y, 2007, PANCREAS, V35, P114, DOI 10.1097/mpa.0b013e3180537237; Li TE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589997; Long L, 2020, J CANCER, V11, P4442, DOI 10.7150/jca.42610; Mohammad GH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151635; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Ohaegbulam KC, 2015, TRENDS MOL MED, V21, P24, DOI 10.1016/j.molmed.2014.10.009; Palsson-McDermott EM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01300; Pan Y, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1581529; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Roemer MGM, 2016, CANCER IMMUNOL RES, V4, P910, DOI 10.1158/2326-6066.CIR-16-0201; Ruscetti M, 2020, CELL, V181, P424, DOI 10.1016/j.cell.2020.03.008; Shifrin N, 2014, SEMIN IMMUNOL, V26, P138, DOI 10.1016/j.smim.2014.02.007; Smahel M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061331; Subramanian G, 2004, CANCER RES, V64, P5200, DOI 10.1158/0008-5472.CAN-04-0018; Van Audenaerde JRM, 2018, PHARMACOL THERAPEUT, V189, P31, DOI 10.1016/j.pharmthera.2018.04.003; Wartenberg M, 2018, CLIN CANCER RES, V24, P4444, DOI 10.1158/1078-0432.CCR-17-3401; Wong N, 2015, CANCER LETT, V356, P184, DOI 10.1016/j.canlet.2014.01.031; Yan L, 2019, CANCERS, V11, DOI 10.3390/cancers11101460; Yang S, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.607209; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zhang C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01295; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-00321-0, 10.1038/s41467-017-01968-5]; Zhang Z, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0317-8	47	11	12	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					865	877		10.1038/s41388-021-02133-5	http://dx.doi.org/10.1038/s41388-021-02133-5		DEC 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34862460	Green Published, hybrid			2022-12-28	WOS:000725939000001
J	Yu, L; Lang, Y; Hsu, CC; Chen, WM; Chiang, JC; Hsieh, JT; Story, MD; Shang, ZF; Chen, BPC; Saha, D				Yu, Lan; Lang, Yue; Hsu, Ching-Cheng; Chen, Wei-Min; Chiang, Jui-Chung; Hsieh, Jer-Tsong; Story, Michael D.; Shang, Zeng-Fu; Chen, Benjamin P. C.; Saha, Debabrata			Mitotic phosphorylation of tumor suppressor DAB2IP maintains spindle assembly checkpoint and chromosomal stability through activating PLK1-Mps1 signal pathway and stabilizing mitotic checkpoint complex	ONCOGENE			English	Article							PROSTATE-CANCER; ANAPHASE; CDC20; MPS1; DRIVES; CELLS; UBIQUITINATION; LOCALIZATION; INACTIVATION; INSTABILITY	Chromosomal instability (CIN) is a driving force for cancer development. The most common causes of CIN include the dysregulation of the spindle assembly checkpoint (SAC), which is a surveillance mechanism that prevents premature chromosome separation during mitosis by targeting anaphase-promoting complex/cyclosome (APC/C). DAB2IP is frequently silenced in advanced prostate cancer (PCa) and is associated with aggressive phenotypes of PCa. Our previous study showed that DAB2IP activates PLK1 and functions in mitotic regulation. Here, we report the novel mitotic phosphorylation of DAB2IP by Cdks, which mediates DAB2IP's interaction with PLK1 and the activation of the PLK1-Mps1 pathway. DAB2IP interacts with Cdc20 in a phosphorylation-independent manner. However, the phosphorylation of DAB2IP inhibits the ubiquitylation of Cdc20 in response to SAC, and blocks the premature release of the APC/C-MCC. The PLK1-Mps1 pathway plays an important role in mitotic checkpoint complex (MCC) assembly. It is likely that DAB2IP acts as a scaffold to aid PLK1-Mps1 in targeting Cdc20. Depletion or loss of the Cdks-mediated phosphorylation of DAB2IP destabilizes the MCC, impairs the SAC, and increases chromosome missegregation and subsequent CIN, thus contributing to tumorigenesis. Collectively, these results demonstrate the mechanism of DAB2IP in SAC regulation and provide a rationale for targeting the SAC to cause lethal CIN against DAB2IP-deficient aggressive PCa, which exhibits a weak SAC.	[Yu, Lan; Hsu, Ching-Cheng; Chen, Wei-Min; Chiang, Jui-Chung; Story, Michael D.; Shang, Zeng-Fu; Chen, Benjamin P. C.; Saha, Debabrata] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA; [Yu, Lan] Nanjing Med Univ, Suzhou Digest Dis & Nutr Res Ctr, Affiliated Suzhou Hosp, Suzhou 215008, Peoples R China; [Lang, Yue; Shang, Zeng-Fu] Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Med Coll, State Key Lab Radiat Med & Protect,Sch Radiat Med, Suzhou 215123, Peoples R China; [Hsieh, Jer-Tsong] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Hsieh, Jer-Tsong; Story, Michael D.; Chen, Benjamin P. C.; Saha, Debabrata] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Hsieh, Jer-Tsong] Natl Taiwan Univ, Dept Oncol, Natl Taiwan Univ Hosp, Coll Med, Taipei 10048, Taiwan	University of Texas System; University of Texas Southwestern Medical Center Dallas; Nanjing Medical University; Soochow University - China; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Taiwan University; National Taiwan University Hospital	Shang, ZF; Chen, BPC; Saha, D (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA.; Shang, ZF (corresponding author), Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Med Coll, State Key Lab Radiat Med & Protect,Sch Radiat Med, Suzhou 215123, Peoples R China.; Chen, BPC; Saha, D (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.	zengfu.shang@utsouthwestern.edu; benjamin.chen@utsouthwestern.edu; debabrata.saha@utsouthwestern.edu		Shang, Zeng-Fu/0000-0002-2396-1416; Saha, Debabrata/0000-0003-3477-4111; Chen, Wei-min/0000-0002-5247-7826; Chiang, Jui-Chung/0000-0001-9979-8347; HSU, CHING-CHENG/0000-0002-8804-6171; Chen, Benjamin/0000-0001-6958-8816	National Institutes of Health [CA233594, CA175879]; National Natural Science Foundation of China [81872546]; Natural Science Foundation of Jiangsu Province [BK20181180]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province)	The authors are grateful to Jonathan Feinberg and John Squire for editing the manuscript. National Institutes of Health [CA175879] to DS; National Institutes of Health [CA233594] to BPC; National Natural Science Foundation of China [#81872546] and Natural Science Foundation of Jiangsu Province [BK20181180] to LY.	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Combes G, 2017, ONCOGENE, V36, P4819, DOI 10.1038/onc.2017.113; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; de Carcer G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05429-5; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Eytan E, 2014, P NATL ACAD SCI USA, V111, P12019, DOI 10.1073/pnas.1412901111; Faesen AC, 2017, NATURE, V542, P498, DOI 10.1038/nature21384; Foster SA, 2012, MOL CELL, V47, P921, DOI 10.1016/j.molcel.2012.07.031; Gao YF, 2011, NAT CELL BIOL, V13, P924, DOI 10.1038/ncb2287; Giam M, 2015, CELL DIV, V10, DOI 10.1186/s13008-015-0009-7; Guo ZY, 2021, ONCOGENE, V40, P1821, DOI 10.1038/s41388-020-01601-8; Ji ZJ, 2017, ELIFE, V6, DOI 10.7554/eLife.22513; Jia LY, 2013, TRENDS BIOCHEM SCI, V38, P302, DOI 10.1016/j.tibs.2013.03.004; Kang JS, 2007, P NATL ACAD SCI USA, V104, P20232, DOI 10.1073/pnas.0710519105; Kong ZL, 2010, CANCER RES, V70, P2829, DOI 10.1158/0008-5472.CAN-09-2919; London N, 2012, CURR BIOL, V22, P900, DOI 10.1016/j.cub.2012.03.052; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; Mansfeld J, 2011, NAT CELL BIOL, V13, P1234, DOI 10.1038/ncb2347; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Miniowitz-Shemtov S, 2012, P NATL ACAD SCI USA, V109, P8056, DOI 10.1073/pnas.1204081109; Moura M, 2017, ELIFE, V6, DOI 10.7554/eLife.25366; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Musacchio A, 2012, NAT STRUCT MOL BIOL, V19, P1059, DOI 10.1038/nsmb.2429; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Orr B, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00164; Palframan WJ, 2006, SCIENCE, V313, P680, DOI 10.1126/science.1127205; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Plumb LA, 2004, METH MOLEC MED, V88, P165; Reddy SK, 2007, NATURE, V446, P921, DOI 10.1038/nature05734; Shepperd LA, 2012, CURR BIOL, V22, P891, DOI 10.1016/j.cub.2012.03.051; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Teichner A, 2011, P NATL ACAD SCI USA, V108, P3187, DOI 10.1073/pnas.1100023108; Uzunova K, 2012, NAT STRUCT MOL BIOL, V19, P1116, DOI 10.1038/nsmb.2412; Vanoosthuyse V, 2009, CURR BIOL, V19, P1176, DOI 10.1016/j.cub.2009.05.060; Varetti G, 2011, MOL CELL, V44, P710, DOI 10.1016/j.molcel.2011.11.014; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; von Schubert C, 2015, CELL REP, V12, P66, DOI 10.1016/j.celrep.2015.06.007; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; Westhorpe FG, 2011, J CELL SCI, V124, P3905, DOI 10.1242/jcs.093286; Wu KJ, 2013, CLIN CANCER RES, V19, P4740, DOI 10.1158/1078-0432.CCR-13-0954; Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107; Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106; Yamagishi Y, 2012, NAT CELL BIOL, V14, P746, DOI 10.1038/ncb2515; Yu L, 2016, NUCLEIC ACIDS RES, V44, P8842, DOI 10.1093/nar/gkw746; Yu L, 2012, NEOPLASIA, V14, P1203, DOI 10.1593/neo.121310; Yun EJ, 2015, ONCOGENE, V34, P2741, DOI 10.1038/onc.2014.215; Yun EJ, 2019, CLIN CANCER RES, V25, P4542, DOI 10.1158/1078-0432.CCR-18-3004	51	1	1	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					489	501		10.1038/s41388-021-02106-8	http://dx.doi.org/10.1038/s41388-021-02106-8		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34775484	Green Published, hybrid			2022-12-28	WOS:000718063600001
J	Gill, T; Wang, HC; Bandaru, R; Lawlor, M; Lu, CY; Nieman, LT; Tao, JN; Zhang, YX; Anderson, DG; Ting, DVT; Chen, X; Bradner, JE; Ott, CJ				Gill, Taylor; Wang, Haichuan; Bandaru, Raj; Lawlor, Matthew; Lu, Chenyue; Nieman, Linda T.; Tao, Junyan; Zhang, Yixian; Anderson, Daniel G.; Ting, David T.; Chen, Xin; Bradner, James E.; Ott, Christopher J.			Selective targeting of MYC mRNA by stabilized antisense oligonucleotides	ONCOGENE			English	Article							LOCKED NUCLEIC-ACIDS; C-MYC; CELL-CYCLE; IN-VITRO; EXPRESSION; INHIBITION; ACTIVATION; GROWTH; OLIGODEOXYNUCLEOTIDE; PROLIFERATION	MYC is a prolific proto-oncogene driving the malignant behaviors of numerous common cancers, yet potent and selective cell-permeable inhibitors of MYC remain elusive. In order to ultimately realize the goal of therapeutic MYC inhibition in cancer, we have initiated discovery chemistry efforts aimed at inhibiting MYC translation. Here we describe a series of conformationally stabilized synthetic antisense oligonucleotides designed to target MYC mRNA (MYCASOs). To support bioactivity, we designed and synthesized this focused library of MYCASOs incorporating locked nucleic acid (LNA) bases at the 5MODIFIER LETTER PRIME- and 3MODIFIER LETTER PRIME-ends, a phosphorothioate backbone, and internal DNA bases. Treatment of MYC-expressing cancer cells with MYCASOs leads to a potent decrease in MYC mRNA and protein levels. Cleaved MYC mRNA in MYCASO-treated cells is detected with a sensitive 5MODIFIER LETTER PRIME Rapid Amplification of cDNA Ends (RACE) assay. MYCASO treatment of cancer cell lines leads to significant inhibition of cellular proliferation while specifically perturbing MYC-driven gene expression signatures. In a MYC-induced model of hepatocellular carcinoma, MYCASO treatment decreases MYC protein levels within tumors, decreases tumor burden, and improves overall survival. MYCASOs represent a new chemical tool for in vitro and in vivo modulation of MYC activity, and promising therapeutic agents for MYC-addicted tumors.	[Gill, Taylor; Anderson, Daniel G.] MIT, Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Gill, Taylor; Bradner, James E.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Gill, Taylor; Ott, Christopher J.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Wang, Haichuan; Tao, Junyan; Chen, Xin] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Bandaru, Raj; Zhang, Yixian] ENZON Pharmaceut, Cranford, NJ 07016 USA; [Lawlor, Matthew; Lu, Chenyue; Nieman, Linda T.; Ting, David T.; Ott, Christopher J.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA; [Anderson, Daniel G.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02142 USA; [Anderson, Daniel G.] MIT, Dept Chem Engn, Cambridge, MA 02142 USA; [Anderson, Daniel G.] MIT, Inst Med Engn & Sci, Cambridge, MA 02142 USA; [Ting, David T.; Bradner, James E.; Ott, Christopher J.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Bradner, James E.] Novartis Inst BioMed Res, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Novartis	Bradner, JE (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; Ott, CJ (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Ott, CJ (corresponding author), Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.; Bradner, JE; Ott, CJ (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.; Bradner, JE (corresponding author), Novartis Inst BioMed Res, Cambridge, MA 02139 USA.	james.bradner@novartis.com; christopher.ott@mgh.harvard.edu	Wang, Haichuan/AAA-3997-2019; Ting, David/F-4389-2017	Wang, Haichuan/0000-0002-6886-5698; Gill, Taylor/0000-0002-7400-2354; Ting, David/0000-0002-3261-2322; Lawlor, Matthew/0000-0003-0700-5763	US National Cancer Institute (NCI) Pathway to Independence Award [K99/R00CA190861]; DFCI; MGH; Broad Institute; Koch Institute Support (core) Grant from the National Cancer Institute [P30-CA14051]	US National Cancer Institute (NCI) Pathway to Independence Award; DFCI; MGH; Broad Institute; Koch Institute Support (core) Grant from the National Cancer Institute	We thank M. Gabay and D. Felsher (Stanford University), S. He, T. Look, E. Dhimolea, C. Mitsiades, and members of the Lurie Family Imaging Center (Dana-Farber Cancer Institute) for assistance with animal studies. This work was supported by a US National Cancer Institute (NCI) Pathway to Independence Award (K99/R00CA190861) (C.J.O), and institutional funding from DFCI, MGH, and the Broad Institute (J.E.B, C.J.O, T.G.), and the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute (D.G.A.).	Adey A, 2013, NATURE, V500, P207, DOI 10.1038/nature12064; Beaulieu ME, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar5012; Bennett CF, 2010, ANNU REV PHARMACOL, V50, P259, DOI 10.1146/annurev.pharmtox.010909.105654; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Browne EP, 2001, J VIROL, V75, P12319, DOI 10.1128/JVI.75.24.12319-12330.2001; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Casey SC, 2017, TRENDS IMMUNOL, V38, P298, DOI 10.1016/j.it.2017.01.002; Castanotto D, 2015, NUCLEIC ACIDS RES, V43, P9350, DOI 10.1093/nar/gkv964; Chan JHP, 2006, CLIN EXP PHARMACOL P, V33, P533, DOI 10.1111/j.1440-1681.2006.04403.x; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Chery J, 2018, NUCLEIC ACID THER, V28, P273, DOI 10.1089/nat.2018.0722; Chow EKH, 2012, HEPATOLOGY, V56, P1331, DOI 10.1002/hep.25776; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Clausen DM, 2010, J PHARMACOL EXP THER, V335, P715, DOI 10.1124/jpet.110.170555; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; Coulis CM, 2000, MOL PHARMACOL, V57, P485, DOI 10.1124/mol.57.3.485; Cowley GS, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.35; Croce C M, 1986, Adv Immunol, V38, P245, DOI 10.1016/S0065-2776(08)60008-5; Crooke S.T., 2007, ANTISENSE DRUG TECHN, VSecond, P519; Crooke ST, 2017, NAT BIOTECHNOL, V35, P230, DOI 10.1038/nbt.3779; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dowling JJ, 2016, NAT REV NEUROL, V12, P675, DOI 10.1038/nrneurol.2016.180; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Han HY, 2019, CANCER CELL, V36, P483, DOI 10.1016/j.ccell.2019.10.001; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; Hong D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5272; Hoy SM, 2017, DRUGS, V77, P473, DOI 10.1007/s40265-017-0711-7; Iwamoto N, 2017, NAT BIOTECHNOL, V35, P845, DOI 10.1038/nbt.3948; Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151; Khvorova A, 2017, NAT BIOTECHNOL, V35, P238, DOI 10.1038/nbt.3765; Kiessling A, 2007, CHEMMEDCHEM, V2, P627, DOI 10.1002/cmdc.200600294; Klar R, 2020, CANCER IMMUNOL IMMUN, V69, P57, DOI 10.1007/s00262-019-02438-1; Koehler AN, 2010, CURR OPIN CHEM BIOL, V14, P331, DOI 10.1016/j.cbpa.2010.03.022; Koshkin AA, 1998, TETRAHEDRON, V54, P3607, DOI 10.1016/S0040-4020(98)00094-5; Le BT, 2017, MOL THER-NUCL ACIDS, V9, P155, DOI 10.1016/j.omtn.2017.09.002; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Mondala PK, 2021, CELL STEM CELL, V28, P623, DOI 10.1016/j.stem.2020.12.017; Mui B, 2001, J PHARMACOL EXP THER, V298, P1185; Palomero T, 2006, LEUKEMIA, V20, P1279, DOI 10.1038/sj.leu.2404258; Parham JS, 2019, EXPERT OPIN PHARMACO, V20, P127, DOI 10.1080/14656566.2018.1550071; Ross SJ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5253; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Schlee M, 2007, ADV CANCER RES, V97, P167, DOI 10.1016/S0065-230X(06)97007-9; Schlee M, 2007, INT J CANCER, V120, P1387, DOI 10.1002/ijc.22372; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Shang RZ, 2021, GUT, V70, P1746, DOI 10.1136/gutjnl-2020-320716; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Singh SK, 1998, CHEM COMMUN, P455, DOI 10.1039/a708608c; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Struntz NB, 2019, CELL CHEM BIOL, V26, P711, DOI 10.1016/j.chembiol.2019.02.009; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wang HB, 2007, MOL CANCER THER, V6, P2399, DOI 10.1158/1535-7163.MCT-07-0005; Wang HB, 2013, ONCOTARGET, V4, P936, DOI 10.18632/oncotarget.1108; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; Wu HJ, 2004, J BIOL CHEM, V279, P17181, DOI 10.1074/jbc.M311683200; Xu Y, 2006, BIOORGAN MED CHEM, V14, P2660, DOI 10.1016/j.bmc.2005.11.052; Yashiro-Ohtani Y, 2014, P NATL ACAD SCI USA, V111, pE4946, DOI 10.1073/pnas.1407079111; Zhang WD, 2005, NAT MED, V11, P56, DOI 10.1038/nm1174; Zhang Y, 2011, GENE THER, V18, P326, DOI 10.1038/gt.2010.133; Zhang YX, 2011, MOL CANCER THER, V10, P2309, DOI 10.1158/1535-7163.MCT-11-0329	68	2	2	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6527	6539		10.1038/s41388-021-02053-4	http://dx.doi.org/10.1038/s41388-021-02053-4		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34650218	Green Accepted, Green Submitted			2022-12-28	WOS:000707295500002
J	Guo, J; Lv, YY; Wang, S; Peng, ZY; Xie, Y; Wang, YX; Jiang, HM; Li, X; Wang, MQ; Hu, ML; Mu, JP; Wang, JY; Xie, YY; Cheng, XK; Zhao, ZG; Liu, ZQ				Guo, Jing; Lv, Yangyang; Wang, Sheng; Peng, Ziyi; Xie, Ying; Wang, Yixuan; Jiang, Hongmei; Li, Xin; Wang, Mengqi; Hu, Meilin; Mu, Jiangpeng; Wang, Jingya; Xie, Yangyang; Cheng, Xiankui; Zhao, Zhigang; Liu, Zhiqiang			Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myeloma	ONCOGENE			English	Article							BORTEZOMIB-RESISTANCE; RECEPTOR; DRUG; INVASION; SUMO	The bone marrow microenvironment in multiple myeloma (MM) is hypoxic and provides multi-advantages for the initiation of chemoresistance, but the underlying mechanisms and key regulators are still indistinct. In the current study, we found that hypoxia stimulus easily induced chemoresistance to proteasome inhibitors (PIs), and the steroid receptor coactivator 3 (SRC-3) expression was remarkably augmented at posttranslational level. Protein interactome analysis identified SENP1 as a key modifier of SRC-3 stability, as SENP1-mediated deSUMOylation attenuated the K11-linked polyubiquitination of SRC-3. SENP1 depletion in the SENP1(fl/fl)CD19(Cre/+) B cells showed impaired SRC3 stability, and knockdown of SENP1 in MM cells by CRISPR/cas9 sgRNA accelerated the degradation of SRC-3 and remarkably overcame the resistance to PIs. In the Vk*Myc and 5TGM1 mouse models as well as patient-derived xenograft (PDX) of myeloma, SENP1 inhibitor Momordin Iota c (Mc) increased the sensitivity to PIs in MM cells. Importantly, SENP1 level was positively correlated with SRC-3 level in the tissues from refractory/relapsed MM, as well as in xenograft tissues from mice treated with bortezomib and Mc. Taken together, our findings suggest that hypoxia-induced SENP1 is a crucial regulator of chemoresistance to PIs, and shed light on developing therapeutic strategies to overcome chemoresistance by using small molecules targeting SENP1 or SRC-3.	[Guo, Jing; Lv, Yangyang; Zhao, Zhigang; Liu, Zhiqiang] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Hematol,Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China; [Wang, Sheng; Peng, Ziyi; Xie, Ying; Wang, Yixuan; Jiang, Hongmei; Li, Xin; Wang, Mengqi; Wang, Jingya; Xie, Yangyang; Liu, Zhiqiang] Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Sch Basic Med Sci, Tianjin 300070, Peoples R China; [Wang, Sheng; Peng, Ziyi; Xie, Ying; Wang, Yixuan; Jiang, Hongmei; Li, Xin; Wang, Mengqi; Wang, Jingya; Xie, Yangyang; Liu, Zhiqiang] Tianjin Med Univ, Tianjin Key Lab Cellular Homeostasis & Human Dis, Sch Basic Med Sci, Tianjin 300070, Peoples R China; [Wang, Sheng; Peng, Ziyi; Xie, Ying; Wang, Yixuan; Jiang, Hongmei; Li, Xin; Wang, Mengqi; Wang, Jingya; Xie, Yangyang; Liu, Zhiqiang] Tianjin Med Univ, Dept Physiol & Pathophysiol, Sch Basic Med Sci, Tianjin 300070, Peoples R China; [Hu, Meilin] Tianjin Med Univ, Tianjin Med Univ Sch Stomatol, Tianjin 300070, Peoples R China; [Mu, Jiangpeng] Tianjin Med Univ, Undergarduate Sch Basic Med Sci, Tianjin 300070, Peoples R China; [Cheng, Xiankui] Shandong Univ, Dept Pathol, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China; [Zhao, Zhigang] Nankai Univ, Tianjin Cent Hosp 1, Sch Med, Dept Med Oncol, Tianjin 300192, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Nankai University	Zhao, ZG; Liu, ZQ (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Hematol,Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.; Liu, ZQ (corresponding author), Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Sch Basic Med Sci, Tianjin 300070, Peoples R China.; Liu, ZQ (corresponding author), Tianjin Med Univ, Tianjin Key Lab Cellular Homeostasis & Human Dis, Sch Basic Med Sci, Tianjin 300070, Peoples R China.; Liu, ZQ (corresponding author), Tianjin Med Univ, Dept Physiol & Pathophysiol, Sch Basic Med Sci, Tianjin 300070, Peoples R China.; Zhao, ZG (corresponding author), Nankai Univ, Tianjin Cent Hosp 1, Sch Med, Dept Med Oncol, Tianjin 300192, Peoples R China.	zzhao01@tmu.edu.cn; zhigiangliu@tmu.edu.cn			Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital; Beijing Natural Science Foundation of China [Z200020]; National Natural Science Foundation of China [81870161, 82070221, 81900215, 81870150]; Tianjin Research Innovation Project for Postgraduate Students [2020YJSB162]; Tianjin Key Medical Discipline (Specialty) Construction Project [TJYXZDXK-009A]	Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital; Beijing Natural Science Foundation of China(Beijing Natural Science Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Research Innovation Project for Postgraduate Students; Tianjin Key Medical Discipline (Specialty) Construction Project	This work was supported by Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital. We thank Dr. Leif Bergsagel at the Mayo Clinic for kindly providing the Vk*Myc mouse spleen cells. This work was supported by the Beijing Natural Science Foundation of China (Z200020, ZQL), the National Natural Science Foundation of China (81870161, 82070221, ZQL; 81900215, JYW; 81870150, ZGZ), the Tianjin Research Innovation Project for Postgraduate Students (2020YJSB162, YX), and Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-009A).	Chang HM, 2020, PHYSIOL REV, V100, P1599, DOI 10.1152/physrev.00025.2019; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; Chesi M, 2012, BLOOD, V120, P376, DOI 10.1182/blood-2012-02-412783; Danet GH, 2003, J CLIN INVEST, V112, P126, DOI 10.1172/JCI200317669; de Heer EC, 2020, J CLIN INVEST, V130, P5074, DOI 10.1172/JCI137552; Geng C, 2014, CANCER RES, V74, P5631, DOI 10.1158/0008-5472.CAN-14-0476; Hu JS, 2010, BLOOD, V116, P1524, DOI 10.1182/blood-2010-02-269126; Ikeda S, 2021, CANCER SCI, V112, P3995, DOI 10.1111/cas.15087; Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233; Kumar R, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201900185; Kunz K, 2018, J CELL SCI, V131, DOI 10.1242/jcs.211904; Lanz RB, 2010, MOL ENDOCRINOL, V24, P859, DOI 10.1210/me.2009-0499; Li LC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094760; Liu J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21386-y; Lothrop AP, 2013, FEBS LETT, V587, P1247, DOI 10.1016/j.febslet.2013.01.047; Ma CC, 2014, TUMOR BIOL, V35, P12729, DOI 10.1007/s13277-014-2598-1; Mani DR, 2022, NAT REV CANCER, V22, P298, DOI 10.1038/s41568-022-00446-5; Martin SK, 2011, LEUKEMIA, V25, P1533, DOI 10.1038/leu.2011.122; Moser-Katz T, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.625199; Mougenot P, 2006, ANTICANCER RES, V26, P2197; Murray MY, 2015, CELL CYCLE, V14, P2367, DOI 10.1080/15384101.2014.998067; PENNATHURDAS R, 1987, BLOOD, V69, P899; Rajkumar SV, 2009, CURR PROB CANCER, V33, P7, DOI 10.1016/j.currproblcancer.2009.01.001; Raninga PV, 2016, CELL CYCLE, V15, P559, DOI 10.1080/15384101.2015.1136038; Ria R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020613; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Sacks D, 2018, J VASC INTERV RADIOL, V29, P441, DOI [10.1016/j.jvir.2017.11.026, 10.1177/1747493018778713]; Scanlon SE, 2015, DNA REPAIR, V32, P180, DOI 10.1016/j.dnarep.2015.04.030; Song XZ, 2016, P NATL ACAD SCI USA, V113, P4970, DOI 10.1073/pnas.1604274113; van de Donk NWCJ, 2021, LANCET, V397, P410, DOI 10.1016/S0140-6736(21)00135-5; Wang JJ, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI149526; Wirth M, 2020, CANCERS, V12, DOI 10.3390/cancers12123764; Wu HJ, 2006, J BIOL CHEM, V281, P21848, DOI 10.1074/jbc.M603772200; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Xu YY, 2021, ONCOGENE, V40, P1231, DOI 10.1038/s41388-020-01590-8; Yan XM, 2016, BIOTECHNOL APPL BIOC, V63, P435, DOI 10.1002/bab.1375; Yen CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113503; Yuen VWH, 2020, J CLIN INVEST, V130, P5052, DOI 10.1172/JCI137553	38	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4971	4979		10.1038/s41388-022-02494-5	http://dx.doi.org/10.1038/s41388-022-02494-5		OCT 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36209257	Green Submitted			2022-12-28	WOS:000865164100001
J	Green, YS; dos Santos, MCF; Fuja, D; Reichert, E; Campos, AR; Cowman, SJ; Pilarte, KA; Kohan, J; Tripp, SR; Leibold, EA; Sirohi, D; Agarwal, N; Liu, XH; Koh, MY				Green, Yangsook Song; dos Santos, Maria C. Ferreira; Fuja, Daniel; Reichert, Ethan; Campos, Alexandre R.; Cowman, Sophie J.; Pilarte, Karen Acuna; Kohan, Jessica; Tripp, Sheryl R.; Leibold, Elizabeth A.; Sirohi, Deepika; Agarwal, Neeraj; Liu, Xiaohui; Koh, Mei Yee			ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma	ONCOGENE			English	Article							OXIDATIVE-PHOSPHORYLATION; TUMOR ANGIOGENESIS; HYPOXIA; HIF-2-ALPHA; PROTEIN; HIF2-ALPHA; LIGASE; DEGRADATION; HIF-1-ALPHA; BIOGENESIS	Clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, is typically initiated by inactivation of the von Hippel Lindau (VHL) gene, which results in the constitutive activation of the hypoxia inducible factors, HIF-1 alpha and HIF-2 alpha. Using a high throughput screen, we identify novel compounds that decrease HIF-1/2 alpha levels and induce ferroptosis by targeting Iron Sulfur Cluster Assembly 2 (ISCA2), a component of the late mitochondrial Iron Sulfur Cluster (L-ISC) assembly complex. ISCA2 inhibition either pharmacologically or using siRNA decreases HIF-2 alpha protein levels by blocking iron-responsive element (IRE)-dependent translation, and at higher concentrations, also decreases HIF-1 alpha translation through unknown mechanisms. Additionally, ISCA2 inhibition triggers the iron starvation response, resulting in iron/metals overload and death via ferroptosis. ISCA2 levels are decreased in ccRCC compared to normal kidney, and decreased ISCA2 levels are associated with pVHL loss and with sensitivity to ferroptosis induced by ISCA2 inhibition. Strikingly, pharmacological inhibition of ISCA2 using an orally available ISCA2 inhibitor significantly reduced ccRCC xenograft growth in vivo, decreased HIF-alpha levels and increased lipid peroxidation, suggesting increased ferroptosis in vivo. Thus, the targeting of ISCA2 may be a promising therapeutic strategy to inhibit HIF-1/2 alpha and to induce ferroptosis in pVHL deficient cells.	[Green, Yangsook Song; Fuja, Daniel; Reichert, Ethan; Cowman, Sophie J.; Pilarte, Karen Acuna; Leibold, Elizabeth A.; Koh, Mei Yee] Univ Utah, Salt Lake City, UT 84112 USA; [dos Santos, Maria C. Ferreira; Liu, Xiaohui; Koh, Mei Yee] Kuda Therapeut Inc, Salt Lake City, UT 84103 USA; [Campos, Alexandre R.] Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA 92037 USA; [Kohan, Jessica; Tripp, Sheryl R.; Sirohi, Deepika] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT 84108 USA; [Sirohi, Deepika; Agarwal, Neeraj; Koh, Mei Yee] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Sanford Burnham Prebys Medical Discovery Institute; Utah System of Higher Education; University of Utah; ARUP Laboratories; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Koh, MY (corresponding author), Univ Utah, Salt Lake City, UT 84112 USA.; Koh, MY (corresponding author), Kuda Therapeut Inc, Salt Lake City, UT 84103 USA.; Koh, MY (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.	mei.koh@utah.edu	M, Y/HHS-8019-2022	Green, Yangsook/0000-0003-3620-0971	NIH [R03DA033980, CA181106, CA217905, R43 CA217385-A1]; Dod KCRP grant [KC190022]; NIH Hematology Training Program Grant [T32DK007115]; Huntsman Cancer Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dod KCRP grant; NIH Hematology Training Program Grant; Huntsman Cancer Foundation	This work was supported by NIH grants R03DA033980, CA181106 and CA217905 and Dod KCRP grant KC190022 to MYK, NIH grant R43 CA217385-A1 to XL, and NIH Hematology Training Program Grant T32DK007115 to DF. We acknowledge financial support by the Huntsman Cancer Foundation. Research reported in this publication utilized the Preclinical Research Shared Resource at Huntsman Cancer Institute at the University of Utah. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; [Anonymous], ONCOGENE; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Beilschmidt LK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15124; Bertout JA, 2009, P NATL ACAD SCI USA, V106, P14391, DOI 10.1073/pnas.0907357106; Biederbick A, 2006, MOL CELL BIOL, V26, P5675, DOI 10.1128/MCB.00112-06; Brancaccio D, 2014, J AM CHEM SOC, V136, P16240, DOI 10.1021/ja507822j; Briston T, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00388; Bussolati B, 2013, CANCER LETT, V338, P141, DOI 10.1016/j.canlet.2012.05.007; Chen X, 2021, NAT REV CLIN ONCOL, V18, P280, DOI 10.1038/s41571-020-00462-0; Choi H, 2010, CANCER RES, V70, P10101, DOI 10.1158/0008-5472.CAN-10-0505; Choueiri TK, 2021, NAT MED, V27, P802, DOI 10.1038/s41591-021-01324-7; Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Cowman SJ, 2022, TRENDS CANCER, V8, P28, DOI 10.1016/j.trecan.2021.10.004; Cowman SJ, 2020, CLIN CANCER RES, V26, P4970, DOI 10.1158/1078-0432.CCR-19-3890; De Leon JAD, 2020, JOVE-J VIS EXP, DOI 10.3791/61122; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dowd AA, 2014, AFR J UROL, V20, P25, DOI 10.1016/j.afju.2013.11.001; Du WN, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01965-8; Gelling C, 2008, MOL CELL BIOL, V28, P1851, DOI 10.1128/MCB.01963-07; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gourdoupis S, 2018, J AM CHEM SOC, V140, P14401, DOI 10.1021/jacs.8b09061; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104; Gudas LJ, 2014, J MOL MED, V92, P825, DOI 10.1007/s00109-014-1180-z; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hervouet E, 2005, CARCINOGENESIS, V26, P531, DOI 10.1093/carcin/bgi001; Hervouet E, 2008, CARCINOGENESIS, V29, P1528, DOI 10.1093/carcin/bgn125; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; Hoefflin R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17873-3; Hu CL, 2019, J NEUROCHEM, V148, P426, DOI 10.1111/jnc.14604; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Kapitsinou PP, 2010, BLOOD, V116, P3039, DOI 10.1182/blood-2010-02-270322; Koh MY, 2008, MOL CELL BIOL, V28, P7081, DOI 10.1128/MCB.00773-08; Koh MY, 2015, CANCER RES, V75, P316, DOI 10.1158/0008-5472.CAN-13-2190; Koh MY, 2012, TRENDS BIOCHEM SCI, V37, P364, DOI 10.1016/j.tibs.2012.06.004; Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Kumar T, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00227; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lill R, 2020, ANNU REV BIOCHEM, V89, P471, DOI 10.1146/annurev-biochem-013118-111540; Lomenick Brett, 2011, Curr Protoc Chem Biol, V3, P163; Mastrogiannaki M, 2013, BLOOD, V122, P885, DOI 10.1182/blood-2012-11-427765; Micucci C, 2015, BRIT J CANCER, V113, P1178, DOI 10.1038/bjc.2015.338; Miess H, 2018, ONCOGENE, V37, P5435, DOI 10.1038/s41388-018-0315-z; Moore LE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002312; Mou YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0720-y; Muhlenhoff U, 2011, J BIOL CHEM, V286, P41205, DOI 10.1074/jbc.M111.296152; Nasta V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55313-5; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PaineMurrieta GD, 1997, CANCER CHEMOTH PHARM, V40, P209, DOI 10.1007/s002800050648; Pap EHW, 1999, FEBS LETT, V453, P278, DOI 10.1016/S0014-5793(99)00696-1; Paul VD, 2015, BBA-MOL CELL RES, V1853, P1528, DOI 10.1016/j.bbamcr.2014.12.018; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ravi R, 2000, GENE DEV, V14, P34; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Sanchez M, 2007, NAT STRUCT MOL BIOL, V14, P420, DOI 10.1038/nsmb1222; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Schneider M, 2010, NEOPLASIA, V12, P254, DOI 10.1593/neo.91782; Schonauer MS, 2009, J BIOL CHEM, V284, P23234, DOI 10.1074/jbc.M109.015594; Sheftel AD, 2012, MOL BIOL CELL, V23, P1157, DOI 10.1091/mbc.E11-09-0772; Society AC, SURV RAT KIDN CANC; Terzi EM, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg4302; Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029; Wada K, 2005, FEBS LETT, V579, P6543, DOI 10.1016/j.febslet.2005.10.046; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang J, 2005, BBA-MOL CELL RES, V1743, P79, DOI 10.1016/j.bbamcr.2004.08.011; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Yang D, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030275; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Zanello P, 2019, J STRUCT BIOL, V205, P103, DOI 10.1016/j.jsb.2019.01.003; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhang Y, 2019, CELL CHEM BIOL, V26, P623, DOI 10.1016/j.chembiol.2019.01.008; Zilka O, 2017, ACS CENTRAL SCI, V3, P232, DOI 10.1021/acscentsci.7b00028; Zimmer M, 2008, MOL CELL, V32, P838, DOI 10.1016/j.molcel.2008.12.004; Zou Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09277-9	80	0	0	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4709	4723		10.1038/s41388-022-02460-1	http://dx.doi.org/10.1038/s41388-022-02460-1		SEP 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36097192	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000852927100002
J	Chen, J; Li, L; Liu, TY; Fu, HF; Lai, YH; Lei, X; Xu, JF; Yu, JS; Xia, YJ; Zhang, TH; Yang, DJ; He, YL				Chen, Jian; Li, Lu; Liu, Tian-Yu; Fu, Hua-Feng; Lai, Yuan-Hui; Lei, Xiong; Xu, Jun-Fa; Yu, Ji-Shang; Xia, Yu-Jian; Zhang, Tian-Hao; Yang, Dong-Jie; He, Yu-Long			CPEB3 suppresses gastric cancer progression by inhibiting ADAR1-mediated RNA editing via localizing ADAR1 mRNA to P bodies	ONCOGENE			English	Article							BINDING PROTEINS; GENE-THERAPY; GROWTH; GW182	Deciphering the crosstalk between RNA-binding proteins and corresponding RNAs will provide a better understanding of gastric cancer (GC) progression. The comprehensive bioinformatics study identified cytoplasmic polyadenylation element-binding protein 3 (CPEB3) might play a vital role in GC progression. Then we found CPEB3 was downregulated in GC and correlated with prognosis. In addition, CPEB3 suppressed GC cell proliferation, invasion and migration in vitro, as well as tumor growth and metastasis in vivo. Mechanistic study demonstrated CPEB3 interacted with 3 '-UTR of ADAR1 mRNA through binding to CPEC nucleotide element, and then inhibited its translation by localizing it to processing bodies (P bodies), eventually leading to the suppression of ADAR1-mediated RNA editing. Microscale thermophoresis assay further revealed that the direct interaction between CPEB3 and GW182, the P-body's major component, was through the 440-698AA region of CPEB3 binding to the 403-860AA region of GW182. Finally, AAV9-CPEB3 was developed and administrated in mouse models to assess its potential value in gene therapy. We found AAV9-CPEB3 inhibited GC growth and metastasis. Besides, AAV9-CPEB3 induced hydropic degeneration in mouse liver, but did not cause kidney damage. These findings concluded that CPEB3 suppresses GC progression by inhibiting ADAR1-mediated RNA editing via localizing ADAR1 mRNA to P bodies.	[Chen, Jian; Fu, Hua-Feng; Yu, Ji-Shang; Xia, Yu-Jian; Zhang, Tian-Hao; Yang, Dong-Jie; He, Yu-Long] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Gastrointestinal Surg, Guangzhou, Guangdong, Peoples R China; [Li, Lu] Guangdong Med Univ, Sch Med Technol, Guangdong Prov Key Lab Med Mol Diagnost, Inst Lab Med,Dept Clin Microbiol Lab, Dongguan, Guangdong, Peoples R China; [Liu, Tian-Yu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Guangzhou, Guangdong, Peoples R China; [Lai, Yuan-Hui] Sun Yat Sen Univ, Affiliated Hosp 1, Eastern Div, Dept Thyroid & Breast Surg, Guangzhou, Guangdong, Peoples R China; [Lei, Xiong] Nanchang Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Nanchang, Jiangxi, Peoples R China; [Xu, Jun-Fa] Guangdong Med Univ, Sch Med Technol, Guangdong Prov Key Lab Med Mol Diagnost, Dept Clin Immunol,Inst Lab Med, Dongguan, Guangdong, Peoples R China; [He, Yu-Long] Sun Yat Sen Univ, Affiliated Hosp 7, Digest Med Ctr, Shenzhen, Guangdong, Peoples R China	Sun Yat Sen University; Guangdong Medical University; Sun Yat Sen University; Sun Yat Sen University; Nanchang University; Guangdong Medical University; Sun Yat Sen University	Yang, DJ; He, YL (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Gastrointestinal Surg, Guangzhou, Guangdong, Peoples R China.; He, YL (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Digest Med Ctr, Shenzhen, Guangdong, Peoples R China.	ydongj@mail.sysu.edu.cn; heyulong@mail.sysu.edu.cn		Chen, Jian/0000-0002-8515-1179	National Natural Science Foundation of China [81802599, 81772579]; Center for Gastrointestinal Surgery; First Affiliated Hospital of Sun Yat-sen University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Center for Gastrointestinal Surgery; First Affiliated Hospital of Sun Yat-sen University	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81802599, 81772579). We thank Prof. Zun-Fu Ke (Department of Pathology, the First Affiliated Hospital of Sun Yat-sen University) and his colleagues for the help of pathological diagnoses and guidance. We appreciate Department of Laboratory Medicine, the First Affiliated Hospital of Sun Yat-sen University for the help of urine and serum detection. We appreciate all supports from Center for Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat-sen University.	Brannan KW, 2021, NAT METHODS, V18, P507, DOI 10.1038/s41592-021-01128-0; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chan THM, 2016, GASTROENTEROLOGY, V151, P637, DOI 10.1053/j.gastro.2016.06.043; Chan THM, 2014, GUT, V63, P832, DOI 10.1136/gutjnl-2012-304037; Chen LL, 2013, NAT MED, V19, P209, DOI 10.1038/nm.3043; Chowdhury EA, 2021, ADV DRUG DELIVER REV, V170, P214, DOI 10.1016/j.addr.2021.01.017; Crews LA, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0370-3; Ballesteros-Briones MC, 2019, MOL THER, V27, P1892, DOI 10.1016/j.ymthe.2019.09.016; D'Ambrogio A, 2013, NAT REV CANCER, V13, P283, DOI 10.1038/nrc3485; Eulalio A, 2007, NAT REV MOL CELL BIO, V8, P9, DOI 10.1038/nrm2080; Ford L, 2019, P NATL ACAD SCI USA, V116, P18078, DOI 10.1073/pnas.1815275116; Fritzell K, 2018, SEMIN CELL DEV BIOL, V79, P123, DOI 10.1016/j.semcdb.2017.11.018; Gebauer F, 2021, NAT REV GENET, V22, P185, DOI 10.1038/s41576-020-00302-y; Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813; Han L, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.013; Han SW, 2014, J EXP MED, V211, P613, DOI 10.1084/jem.20132209; Hentze MW, 2018, NAT REV MOL CELL BIO, V19, P327, DOI 10.1038/nrm.2017.130; Joshi Smita S, 2021, CA Cancer J Clin, V71, P264, DOI 10.3322/caac.21657; Kamiya A, 2019, NAT NEUROSCI, V22, P1289, DOI 10.1038/s41593-019-0430-3; Lee JE, 2020, SCIENCE, V367, P527, DOI 10.1126/science.aay7108; Li CW, 2020, NAT REV GENET, V21, P255, DOI 10.1038/s41576-019-0205-4; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Luo NC, 2020, J BUON, V25, P2097; Mori Takuji, 2003, Gastric Cancer, V6 Suppl 1, P13, DOI 10.1007/s10120-003-0226-7; Okugawa Y, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1740-z; Paz-Yaacov N, 2015, CELL REP, V13, P267, DOI 10.1016/j.celrep.2015.08.080; Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003; Qin YR, 2014, CANCER RES, V74, P840, DOI 10.1158/0008-5472.CAN-13-2545; Ramirez-Moya J, 2020, ONCOGENE, V39, P3738, DOI 10.1038/s41388-020-1248-x; Rehwinkel J, 2005, RNA, V11, P1640, DOI 10.1261/rna.2191905; Richter JD, 2007, TRENDS BIOCHEM SCI, V32, P279, DOI 10.1016/j.tibs.2007.04.004; Shiromoto Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21921-x; Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059; Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573-019-0012-9; Wang E, 2019, CANCER CELL, V35, P369, DOI 10.1016/j.ccell.2019.01.010; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Watanabe M, 2005, HUM GENE THER, V16, P699, DOI 10.1089/hum.2005.16.699; Wienken CJ, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1093; Wu XW, 2020, CELL DEATH DIFFER, V27, P55, DOI 10.1038/s41418-019-0339-0; Yang Z, 2004, J CELL SCI, V117, P5567, DOI 10.1242/jcs.01477; Yao F, 2015, CELL REP, V12, P272, DOI 10.1016/j.celrep.2015.06.020; Youn JY, 2019, MOL CELL, V76, P286, DOI 10.1016/j.molcel.2019.09.014; Zhang H, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02984-y; Zhang Y, 2008, LIFE SCI, V82, P1154, DOI 10.1016/j.lfs.2008.03.023; Zhao WC, 2019, CELL RES, V29, P895, DOI 10.1038/s41422-019-0229-5; Zhong Q, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01637-4; Zipeto MA, 2016, CELL STEM CELL, V19, P177, DOI 10.1016/j.stem.2016.05.004	47	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4591	4605		10.1038/s41388-022-02454-z	http://dx.doi.org/10.1038/s41388-022-02454-z		SEP 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36068334				2022-12-28	WOS:000850425100002
J	Zhang, WY; Chen, SY; Du, Q; Bian, PP; Chen, YT; Liu, ZX; Zheng, J; Sai, K; Mou, YG; Chen, ZP; Fan, X; Jiang, XB				Zhang, Weiyu; Chen, Siyu; Du, Qiu; Bian, Piaopiao; Chen, Yutong; Liu, Zexian; Zheng, Jian; Sai, Ke; Mou, Yonggao; Chen, Zhongping; Fan, Xiang; Jiang, Xiaobing			CircVPS13C promotes pituitary adenoma growth by decreasing the stability of IFITM1 mRNA via interacting with RRBP1	ONCOGENE			English	Article							RIBOSOME-BINDING PROTEIN-1; CIRCULAR RNA; COLORECTAL-CANCER; TRANSLOCATION; EPIDEMIOLOGY; EXPRESSION; INDUCTION; APOPTOSIS; PATHWAY	CircRNAs play important roles in a variety of biological processes by acting as microRNA sponges and protein scaffolds or by encoding functional proteins. However, their functions and underlying mechanisms remain largely unknown. Distinctive circRNA patterns were explored by comparing nonfunctioning pituitary adenomas (NFPAs) and normal pituitary tissues with a circRNA array. The biological functions of selected circRNAs were determined in vitro and in vivo. RNA-seq and circRNA pulldown assays were applied to investigate the underlying mechanisms. The circRNA profile of NFPAs is tremendously different from that of normal pituitary tissues. CircVPS13C is significantly upregulated in NFPA samples and cell lines. Gain- and loss-of-function experiments demonstrate that silencing circVPS13C inhibits the proliferation of pituitary tumor cells in vitro and in vivo. Mechanistically, circVPS13C silencing increases the expression of IFITM1 and subsequently activates its downstream genes involved in MAPK- and apoptosis-associated signaling pathways. Rescue experiments show that IFITM1 overexpression partly reverses the biological effects of circVPS13C. Further studies reveal that circVPS13C inhibits IFITM1 expression through a novel mechanism mainly by competitively interacting with RRBP1, a ribosome-binding protein of the endoplasmic reticulum membrane, and thereby alleviating the stability of IFITM1 mRNA. Clinically, circVPS13C expression is markedly higher in high-risk NFPA samples and is downregulated in patient serum 7 days post-transsphenoidal adenoma resection. Our findings suggest that circVPS13C is a critical regulator in the proliferation and development of NFPAs through a novel mechanism, whereby regulating mRNA stability via interacting with ribosome-binding proteins on the endoplasmic reticulum membrane.	[Zhang, Weiyu; Chen, Siyu; Du, Qiu; Bian, Piaopiao; Sai, Ke; Mou, Yonggao; Chen, Zhongping; Jiang, Xiaobing] Sun Yat Sen Univ, Dept Neurosurg Neurooncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China; [Zhang, Weiyu; Fan, Xiang] Sun Yat Sen Univ, Dept Neurosurg, Affiliated Hosp 5, Zhuhai, Peoples R China; [Du, Qiu] Yangzhou Univ, Dept Neurosurg, Affiliated Hosp, Yangzhou, Jiangsu, Peoples R China; [Bian, Piaopiao] Guangzhou Med Univ, Dept Pathol, Affiliated Hosp 3, Guangzhou, Peoples R China; [Chen, Yutong] Sun Yat Sen Univ, Affiliated Hosp 5, Canc Ctr, Dept Abdominal Oncol, Zhuhai, Peoples R China; [Liu, Zexian; Zheng, Jian] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Jiang, Xiaobing] Jiangmen Cent Hosp, Dept Neurosurg, Jiangmen, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Yangzhou University; Guangzhou Medical University; Sun Yat Sen University; State Key Lab Oncology South China	Jiang, XB (corresponding author), Sun Yat Sen Univ, Dept Neurosurg Neurooncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China.; Fan, X (corresponding author), Sun Yat Sen Univ, Dept Neurosurg, Affiliated Hosp 5, Zhuhai, Peoples R China.; Jiang, XB (corresponding author), Jiangmen Cent Hosp, Dept Neurosurg, Jiangmen, Peoples R China.	xiangfan@msn.com; jiangxiaob1@sysucc.org.cn	CHEN, SI/GZL-4800-2022	Liu, Ze-Xian/0000-0001-9698-0610; zhang, weiyu/0000-0002-8928-6636; Zheng, Jian/0000-0001-9831-7038; chen, zhongping/0000-0002-6226-5771	National Natural Science Foundation of China for Young Scholars [81702479]; Guangdong Basic and Applied Basic Research Foundation [2020A151501281]; Science and Technology Program of Jiangmen, China [2018630100110019805]; Natural Science Foundation of Jiangsu Province [BK20200936]	National Natural Science Foundation of China for Young Scholars(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Science and Technology Program of Jiangmen, China; Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province)	This research was supported by the National Natural Science Foundation of China for Young Scholars (grant number 81702479 to XJ), Guangdong Basic and Applied Basic Research Foundation (grant number 2020A151501281 to XJ), Science and Technology Program of Jiangmen, China (grant number 2018630100110019805 to YM), and the Natural Science Foundation of Jiangsu Province (grant number BK20200936 to QD).	Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Abe N, 2015, SCI REP-UK, V5, DOI 10.1038/srep16435; Aflorei ED, 2014, J NEURO-ONCOL, V117, P379, DOI 10.1007/s11060-013-1354-5; Agustsson TT, 2015, EUR J ENDOCRINOL, V173, P655, DOI 10.1530/EJE-15-0189; Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017; Chen NF, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1594-y; Cui XYA, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001336; Danila DC, 2000, J CLIN ENDOCR METAB, V85, P1180, DOI 10.1210/jc.85.3.1180; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Du Q, 2019, J CLIN ENDOCR METAB, V104, P2419, DOI 10.1210/jc.2018-01851; Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133; Escher TE, 2019, MOL CANCER RES, V17, P1180, DOI 10.1158/1541-7786.MCR-18-0916; Esposito D, 2019, PITUITARY, V22, P422, DOI 10.1007/s11102-019-00960-0; Grow EJ, 2015, NATURE, V522, P221, DOI 10.1038/nature14308; Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hatano H, 2008, CLIN CANCER RES, V14, P6097, DOI 10.1158/1078-0432.CCR-07-4761; Huang AQ, 2020, THERANOSTICS, V10, P3503, DOI 10.7150/thno.42174; Hyde M, 2002, J CELL BIOL, V156, P993, DOI 10.1083/jcb.200112008; Jagannathan S, 2014, J BIOL CHEM, V289, P25907, DOI 10.1074/jbc.M114.580688; Jasim S, 2017, ENDOCRINE, V56, P33, DOI 10.1007/s12020-016-1159-3; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Lei M, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1135-7; Liang XS, 2015, CANCER SCI, V106, P740, DOI 10.1111/cas.12666; Melmed S, 2020, NEW ENGL J MED, V382, P937, DOI 10.1056/NEJMra1810772; Mete O, 2017, ENDOCR PATHOL, V28, P228, DOI 10.1007/s12022-017-9498-z; Ng WL, 2018, RNA BIOL, V15, P995, DOI 10.1080/15476286.2018.1486659; Pan Y, 2015, BRIT J CANCER, V113, P763, DOI 10.1038/bjc.2015.260; Piovesan D, 2016, NUCLEIC ACIDS RES, V44, pW367, DOI 10.1093/nar/gkw315; SAVITZ AJ, 1993, J CELL BIOL, V120, P853, DOI 10.1083/jcb.120.4.853; Song ZJ, 2016, CELL RES, V26, P1255, DOI 10.1038/cr.2016.114; Tsai HY, 2013, ONCOGENE, V32, P4921, DOI 10.1038/onc.2012.514; Yacqub-Usman K, 2012, NAT REV ENDOCRINOL, V8, P486, DOI 10.1038/nrendo.2012.54; Yanez DC, 2020, IMMUNOLOGY, V159, P365, DOI 10.1111/imm.13163; Yang G, 2007, ONCOGENE, V26, P594, DOI 10.1038/sj.onc.1209807; Yang J, 2018, CANCER SCI, V109, P3115, DOI 10.1111/cas.13640; Yang Yibing, 2018, J Natl Cancer Inst, V110, DOI 10.1093/jnci/djx166; Yang ZG, 2017, MOL THER, V25, P2062, DOI 10.1016/j.ymthe.2017.05.022; Yu F, 2015, CANCER LETT, V368, P135, DOI 10.1016/j.canlet.2015.07.034; Zhang LL, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01224-3; Zhang SJ, 2012, EUR J CANCER, V48, P389, DOI 10.1016/j.ejca.2011.11.002	43	3	3	10	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1550	1562		10.1038/s41388-022-02186-0	http://dx.doi.org/10.1038/s41388-022-02186-0		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35091683				2022-12-28	WOS:000749073300005
J	Xu, H; Wong, CC; Li, WL; Zhou, YF; Li, Y; Wang, LF; Liu, L; Yu, J				Xu, Hui; Wong, Chi Chun; Li, Weilin; Zhou, Yunfei; Li, Yan; Wang, Lifu; Liu, Lei; Yu, Jun			RING-finger protein 6 promotes colorectal tumorigenesis by transcriptionally activating SF3B2	ONCOGENE			English	Article							SOMATIC MUTATIONS; PHASE-I; CANCER; GENE; RNF6; TARGET; E7107	RNF6 is a RING finger protein with oncogenic potential. In this study, we established colon-specific RNF6 transgenic (tg) mice, and demonstrated that RNF6 overexpression accelerated colorectal carcinogenesis compared to wild-type littermates in a chemically induced colorectal cancer (CRC) model. To understand whether transcriptional activity of RNF6 underlies its oncogenic effect, we performed integrated chromatin immunoprecipitation (ChIP)-sequencing and RNA-sequencing analysis to identify splicing factor 3b subunit 2 (SF3B2) as a potential downstream target of RNF6. RNF6 binds to the SF3B2 promoter and the overexpression of RNF6 activates SF3B2 expression in CRC cells, primary CRC organoids, and RNF6 tg mice. SF3B2 knockout abrogated the tumor promoting effect of RNF6 overexpression, whereas the reexpression of SF3B2 recused cell growth and migration/invasion in RNF6 knockout cells, indicating that SF3B2 is a functional downstream target of RNF6 in CRC. Targeting of RNF6-SF3B2 axis with SF3B2 inhibitor with pladienolide B suppressed the growth of CRC cells with RNF6 overexpression in vitro and in vivo. Moreover, the combination of 5-fluorouracil (5-FU) plus pladienolide B exerted synergistic effects in CRC with high RNF6 expression, leading to tumor regression in xenograft models. These findings indicate that tumor promoting effect of RNF6 is achieved mainly via transcriptional upregulation of SF3B2, and that RNF6-SF3B2 axis is a promising target for CRC therapy.	[Xu, Hui; Wang, Lifu; Liu, Lei] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China; [Xu, Hui; Wong, Chi Chun; Zhou, Yunfei; Li, Yan; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Xu, Hui; Wong, Chi Chun; Zhou, Yunfei; Li, Yan; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Li, Weilin] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Genet, Boston, MA 02115 USA	Shanghai Jiao Tong University; Chinese University of Hong Kong; Chinese University of Hong Kong; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Wang, LF; Liu, L (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China.	lifuwang@sjtu.edu.cn; ll11860@rjh.com.cn; junyu@cuhk.edu.hk	Li, Weilin/ABG-9032-2021; Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153; Wong, Chi Chun/0000-0003-1362-3541	Natural Science Foundation of China [81802331]; National Key R&D Program of China [2018YFC1315000, 2018YFC1315004, 2017YFE0190700]; National Natural Science Foundation of China (NSFC) [81972576]; Science and Technology Program Grant Shenzhen [JCYJ20170413161534162, JCYJ20180307151253271]; RGC-GRF Hong Kong [14111216, 14163817, 14101917, 14108718, 24100520]; RGC-CRF [C4039-19G]; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Science and Technology Program Grant Shenzhen; RGC-GRF Hong Kong(Hong Kong Research Grants Council); RGC-CRF; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme	This project was supported by Natural Science Foundation of China (81802331), National Key R&D Program of China (No. 2018YFC1315000, 2018YFC1315004, and 2017YFE0190700), National Natural Science Foundation of China (NSFC; 81972576), Science and Technology Program Grant Shenzhen (JCYJ20170413161534162 and JCYJ20180307151253271), RGC-GRF Hong Kong (14111216, 14163817, 14101917, and 14108718, 24100520), RGC-CRF (C4039-19G), Vice-Chancellor's Discretionary Fund CUHK, Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	Cai J, 2019, EXP CELL RES, V374, P152, DOI 10.1016/j.yexcr.2018.11.019; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cretu C, 2016, MOL CELL, V64, P307, DOI 10.1016/j.molcel.2016.08.036; Dehm SM, 2013, CLIN CANCER RES, V19, P6064, DOI 10.1158/1078-0432.CCR-13-2461; Dong YJ, 2019, THERANOSTICS, V9, P6517, DOI 10.7150/thno.34989; Eskens FALM, 2013, CLIN CANCER RES, V19, P6296, DOI 10.1158/1078-0432.CCR-13-0485; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Hong DS, 2014, INVEST NEW DRUG, V32, P436, DOI 10.1007/s10637-013-0046-5; Kawamura N, 2019, CANCER RES, V79, P5204, DOI 10.1158/0008-5472.CAN-18-3965; Kotake Y, 2007, NAT CHEM BIOL, V3, P570, DOI 10.1038/nchembio.2007.16; Liang Q, 2018, CLIN CANCER RES, V24, P1473, DOI 10.1158/1078-0432.CCR-17-2133; Liu L, 2018, CANCER RES, V78, P1958, DOI 10.1158/0008-5472.CAN-17-2683; Lo HS, 2002, CANCER RES, V62, P4191; Lopez P, 2002, MOL CELL BIOL, V22, P3488, DOI 10.1128/MCB.22.10.3488-3496.2002; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Rai K, 2015, CANCER DISCOV, V5, P1314, DOI 10.1158/2159-8290.CD-15-0493; Ren Y, 2020, ACTA PHARMACOL SIN, V41, P394, DOI 10.1038/s41401-019-0309-6; Sato M, 2014, CANCER SCI, V105, P110, DOI 10.1111/cas.12317; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Xu LX, 2016, GUT, V65, P635, DOI 10.1136/gutjnl-2014-308257; Xu X, 2016, J BIOL CHEM, V291, P9617, DOI 10.1074/jbc.M115.701979	24	2	2	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6513	6526		10.1038/s41388-021-01872-9	http://dx.doi.org/10.1038/s41388-021-01872-9		OCT 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34611311	hybrid, Green Published			2022-12-28	WOS:000703836100001
J	Tu, RF; Kang, WQ; Yang, MJ; Wang, LY; Bao, Q; Chen, Z; Dong, Y; Wang, JC; Jiang, J; Liu, HD; Qing, GL				Tu, Rongfu; Kang, Wenqian; Yang, Mengjie; Wang, Liyuan; Bao, Qing; Chen, Zhi; Dong, Yang; Wang, Jingchao; Jiang, Jue; Liu, Hudan; Qing, Guoliang			USP29 coordinates MYC and HIF1 alpha stabilization to promote tumor metabolism and progression	ONCOGENE			English	Article							CANCER METABOLISM; GLUTAMINE-METABOLISM; ONCOGENIC MYC; HIF-ALPHA; EXPRESSION; HYPOXIA; MUTATIONS; PHOSPHORYLATION; PROLIFERATION; KINASE-3	Tumor cells must rewire cellular metabolism to satisfy the demands of unbridled growth and proliferation. How these metabolic processes are integrated to fuel cancer cell growth remains largely unknown. Deciphering the regulatory mechanisms is vital to develop targeted strategies for tumor-selective therapies. We herein performed an unbiased and functional siRNA screen against 96 deubiquitinases, which play indispensable roles in cancer and are emerging as therapeutic targets, and identified USP29 as a top candidate essential for metabolic reprogramming that support biosynthesis and survival in tumor cells. Integrated metabolic flux analysis and molecular investigation reveal that USP29 directly deubiquitinates and stabilizes MYC and HIF1 alpha, two master regulators of metabolic reprogramming, enabling adaptive response of tumor cells in both normoxia and hypoxia. Systemic knockout of Usp29 depleted MYC and HIF1 alpha in MYC-driven neuroblastoma and B cell lymphoma, inhibited critical metabolic targets and significantly prolonged survival of tumor-bearing mice. Strikingly, mice homozygous null for the Usp29 gene are viable, fertile, and display no gross phenotypic abnormalities. Altogether, these results demonstrate that USP29 selectively coordinates MYC and HIF1 alpha to integrate metabolic processes critical for cancer cell growth, and therapeutic targeting of USP29, a potentially targetable enzyme, could create a unique vulnerability given deregulation of MYC and HIF1 alpha frequently occurs in human cancers.	[Tu, Rongfu; Kang, Wenqian; Qing, Guoliang] Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan 430071, Peoples R China; [Tu, Rongfu; Kang, Wenqian; Yang, Mengjie; Wang, Liyuan; Bao, Qing; Chen, Zhi; Dong, Yang; Wang, Jingchao; Jiang, Jue; Liu, Hudan; Qing, Guoliang] Wuhan Univ, Frontier Sci Ctr Immunol & Metab, Med Res Inst, Wuhan 430071, Peoples R China	Wuhan University; Wuhan University	Qing, GL (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan 430071, Peoples R China.; Qing, GL (corresponding author), Wuhan Univ, Frontier Sci Ctr Immunol & Metab, Med Res Inst, Wuhan 430071, Peoples R China.	qingguoliang@whu.edu.cn			National Key R&D Program of China [2017YFA0505600]; National Natural Science Foundation of China [81970152, 81770177, 81830084]; National Science Foundation for Distinguished Young Scholar [81725013, 82025003]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation for Distinguished Young Scholar(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars)	We thank all members of the Qing lab for helpful suggestions, the Core Facility of Medical Research Institute at Wuhan University for providing hypoxia workstations and histology platform. We also thank Dr William A. Weiss (University of California, San Francisco) for providing transgenic TH-MYCN mice, Dr Wuhan Xiao (Institute of Hydrobiology, Chinese Academy of Sciences) for providing transgenic E mu-Myc mice. This study was supported by grants from National Key R&D Program of China (2017YFA0505600 to G.Q.), National Natural Science Foundation of China (81970152, 81770177 to H.L., 81830084 to G.Q.), National Science Foundation for Distinguished Young Scholar (81725013 to G.Q., 82025003 to H.L.).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Cairns RA, 2013, CANCER DISCOV, V3, P730, DOI 10.1158/2159-8290.CD-13-0083; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Chandrasekaran AP, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115766; Cheng J, 2019, BBA-REV CANCER, V1872, DOI 10.1016/j.bbcan.2019.188312; Dang CV, 2016, COLD SH Q B, V81, P79, DOI 10.1101/sqb.2016.81.031153; Dang Chi Van, 2018, Biochim Biophys Acta Rev Cancer, V1870, P1, DOI 10.1016/j.bbcan.2018.07.006; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dong Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00235-2; Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Harrigan JA, 2018, NAT REV DRUG DISCOV, V17, P57, DOI 10.1038/nrd.2017.152; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang J, 2020, CANCER CELL, V37, P200, DOI 10.1016/j.ccell.2020.01.001; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kloor M, 2002, BBA-GENE STRUCT EXPR, V1579, P219, DOI 10.1016/S0167-4781(02)00543-2; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lane AN, 2015, NUCLEIC ACIDS RES, V43, P2466, DOI 10.1093/nar/gkv047; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Liu JH, 2011, EMBO J, V30, P846, DOI 10.1038/emboj.2011.11; Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Su HX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06523-4; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun RC, 2014, CELL METAB, V19, P285, DOI 10.1016/j.cmet.2013.11.022; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; WARBURG O, 1956, SCIENCE, V124, P269; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yuan M, 2012, NAT PROTOC, V7, P872, DOI 10.1038/nprot.2012.024; Yue M, 2017, CELL REP, V21, P3819, DOI 10.1016/j.celrep.2017.12.002; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang Q, 2020, CELL RES, V30, P821, DOI 10.1038/s41422-020-0368-8; Zhu JJ, 2019, NAT REV MOL CELL BIO, V20, P436, DOI 10.1038/s41580-019-0123-5	50	3	3	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6417	6429		10.1038/s41388-021-02031-w	http://dx.doi.org/10.1038/s41388-021-02031-w		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34601505				2022-12-28	WOS:000702807100001
J	Sullivan, DK; Deutzmann, A; Yarbrough, J; Krishnan, MS; Gouw, AM; Bellovin, DI; Adam, SJ; Liefwalker, DF; Dhanasekaran, R; Felsher, DW				Sullivan, Delaney K.; Deutzmann, Anja; Yarbrough, Josiah; Krishnan, Maya S.; Gouw, Arvin M.; Bellovin, David, I; Adam, Stacey J.; Liefwalker, Daniel F.; Dhanasekaran, Renumathy; Felsher, Dean W.			MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes	ONCOGENE			English	Article							SET ENRICHMENT ANALYSIS; C-MYC; SWI/SNF COMPLEX; WEB SERVER; CANCER; INACTIVATION; CELLS; MOUSE; DIFFERENTIATION; ANGIOGENESIS	MYC is a transcription factor frequently overexpressed in cancer. To determine how MYC drives the neoplastic phenotype, we performed transcriptomic analysis using a panel of MYC-driven autochthonous transgenic mouse models. We found that MYC elicited gene expression changes mostly in a tissue- and lineage-specific manner across B-cell lymphoma, T-cell acute lymphoblastic lymphoma, hepatocellular carcinoma, renal cell carcinoma, and lung adenocarcinoma. However, despite these gene expression changes being mostly tissue-specific, we uncovered a convergence on a common pattern of upregulation of embryonic stem cell gene programs and downregulation of tissue-of-origin gene programs across MYC-driven cancers. These changes are representative of lineage dedifferentiation, that may be facilitated by epigenetic alterations that occur during tumorigenesis. Moreover, while several cellular processes are represented among embryonic stem cell genes, ribosome biogenesis is most specifically associated with MYC expression in human primary cancers. Altogether, MYC's capability to drive tumorigenesis in diverse tissue types appears to be related to its ability to both drive a core signature of embryonic genes that includes ribosomal biogenesis genes as well as promote tissue and lineage specific dedifferentiation.	[Sullivan, Delaney K.; Deutzmann, Anja; Yarbrough, Josiah; Krishnan, Maya S.; Gouw, Arvin M.; Bellovin, David, I; Adam, Stacey J.; Dhanasekaran, Renumathy; Felsher, Dean W.] Stanford Univ, Dept Med, Div Oncol, Sch Med, Stanford, CA 94305 USA; [Sullivan, Delaney K.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Caltech Med Scientist Training Program, Los Angeles, CA 90095 USA; [Liefwalker, Daniel F.] Oregon Hlth & Sci Univ, Sch Med, Dept Mol & Med Genet, Portland, OR 97239 USA; [Dhanasekaran, Renumathy] Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Sch Med, Stanford, CA 94305 USA	Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Oregon Health & Science University; Stanford University	Felsher, DW (corresponding author), Stanford Univ, Dept Med, Div Oncol, Sch Med, Stanford, CA 94305 USA.	dfelsher@stanford.edu		felsher, dean/0000-0003-2496-523X; Yarbrough, Josiah/0000-0002-4521-0656; Deutzmann, Anja/0000-0002-3271-1427; Gouw, Arvin/0000-0002-9552-635X	National Institutes of Health (NIH) [R35 CA253180, R01 CA089305, R01 CA170378, U01 CA188383]; UCLA-Caltech Medical Scientist Training Program (NIH NIGMS) [T32 GM008042]; Lymphoma Research Foundation; NIH from the National Cancer Institute (NCI), American College of Gastroenterology Junior Faculty Career Development Grant [CA222676]; Stanford Cancer Translational Nanotechnology Training T32 Training Grant (NCI) [CA196585]; Tumor Biology Training Grant [NIH 5T32CA009151-38]; Stanford University (NCI); Burroughs Wellcome Fund Postdoctoral Enrichment Award; NCI [3U01CA188383-03S1, (K01) CA234453]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UCLA-Caltech Medical Scientist Training Program (NIH NIGMS); Lymphoma Research Foundation; NIH from the National Cancer Institute (NCI), American College of Gastroenterology Junior Faculty Career Development Grant; Stanford Cancer Translational Nanotechnology Training T32 Training Grant (NCI); Tumor Biology Training Grant; Stanford University (NCI); Burroughs Wellcome Fund Postdoctoral Enrichment Award(Burroughs Wellcome Fund); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by National Institutes of Health (NIH) grants: R35 CA253180, R01 CA089305, R01 CA170378, and U01 CA188383, with additional support as follows. DKS -UCLA-Caltech Medical Scientist Training Program (NIH NIGMS training grant T32 GM008042). AD -Lymphoma Research Foundation. RD -NIH grant CA222676 from the National Cancer Institute (NCI), American College of Gastroenterology Junior Faculty Career Development Grant. AMG -Stanford Cancer Translational Nanotechnology Training T32 Training Grant CA196585 (NCI). DFL Tumor Biology Training Grant (NIH 5T32CA009151-38), Stanford University (NCI), Burroughs Wellcome Fund Postdoctoral Enrichment Award, Research Supplement Award (NCI), 3U01CA188383-03S1, and (K01) CA234453 (NCI).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Beer S, 2004, PLOS BIOL, V2, P1785, DOI 10.1371/journal.pbio.0020332; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Brombin A, 2015, CURR OPIN GENET DEV, V34, P61, DOI 10.1016/j.gde.2015.07.006; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Ciribilli Y, 2017, ONCOTARGET, V8, P101808, DOI 10.18632/oncotarget.21981; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dhanasekaran R, 2021, NAT REV CLIN ONCOL, DOI 10.1038/s41571-021-00549-2; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Farrell AS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01967-6; Felsher Dean W, 2010, Genes Cancer, V1, P597, DOI 10.1177/1947601910377798; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gouw AM, 2019, CELL METAB, V30, P556, DOI 10.1016/j.cmet.2019.07.012; Hartl M, 2010, P NATL ACAD SCI USA, V107, P4051, DOI 10.1073/pnas.0911060107; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Ji HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026057; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Jung M, 2017, CANCER RES, V77, P971, DOI 10.1158/0008-5472.CAN-15-2906; Khan A, 2016, NUCLEIC ACIDS RES, V44, pD164, DOI 10.1093/nar/gkv1002; Kieffer-Kwon KR, 2017, MOL CELL, V67, P566, DOI 10.1016/j.molcel.2017.07.013; Kolde R, 2012, BIOINFORMATICS, V28, P573, DOI 10.1093/bioinformatics/btr709; Korotkevich G., 2016, BIORXIV, DOI [10.1101/060012v3, DOI 10.1101/060012, 10.1101/060012]; Kress TR, 2016, CANCER RES, V76, P3463, DOI 10.1158/0008-5472.CAN-16-0316; Krishnan MS, 2021, HEPATOLOGY, V73, P2342, DOI 10.1002/hep.31614; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li Y, 2014, J INTERN MED, V276, P52, DOI 10.1111/joim.12237; Li YL, 2014, CANCER CELL, V26, P262, DOI 10.1016/j.ccr.2014.06.014; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Muhar M, 2018, SCIENCE, V360, P800, DOI 10.1126/science.aao2793; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Perez-Riverol Y, 2022, NUCLEIC ACIDS RES, V50, pD543, DOI 10.1093/nar/gkab1038; Pimentel H, 2017, NAT METHODS, V14, P687, DOI 10.1038/nmeth.4324; Poli V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03264-2; Poole CJ, 2017, ONCOTARGET, V8, P76898, DOI 10.18632/oncotarget.20176; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Sabo A, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014191; Schaub FX, 2018, CELL SYST, V6, P282, DOI 10.1016/j.cels.2018.03.003; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shroff EH, 2015, P NATL ACAD SCI USA, V112, P6539, DOI 10.1073/pnas.1507228112; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Soshnikova NV, 2021, ONCOGENE, V40, P6071, DOI 10.1038/s41388-021-01994-0; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Stojanova A, 2016, CELL CYCLE, V15, P1693, DOI 10.1080/15384101.2016.1146836; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swaminathan S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16447-7; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tesi A, 2019, EMBO REP, V20, DOI 10.15252/embr.201947987; Tran PT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002125; Turi Z, 2019, AGING-US, V11, P2512, DOI 10.18632/aging.101922; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Varlakhanova NV, 2010, DIFFERENTIATION, V80, P9, DOI 10.1016/j.diff.2010.05.001; Vivian J, 2017, NAT BIOTECHNOL, V35, P314, DOI 10.1038/nbt.3772; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Watanabe-Susaki K, 2014, STEM CELLS, V32, P3099, DOI 10.1002/stem.1825; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Wu CH, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000090; Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r130; Yeh Elizabeth S, 2014, Cold Spring Harb Protoc, V2014, DOI 10.1101/pdb.top069823; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	82	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4960	4970		10.1038/s41388-022-02458-9	http://dx.doi.org/10.1038/s41388-022-02458-9		OCT 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36207533				2022-12-28	WOS:000864993400001
J	Tang, WM; Pei, MM; Li, JY; Xu, NZ; Xiao, WS; Yu, Z; Zhang, JM; Hong, LJ; Guo, Z; Lin, JJ; Dai, WY; Xiao, YZ; Wu, XS; Liu, GN; Zhi, FC; Li, GX; Xiong, J; Chen, Y; Zhang, H; Xiang, L; Li, AM; Liu, SD; Wang, JD				Tang, Weimei; Pei, Miaomiao; Li, Jiaying; Xu, Nanzhu; Xiao, Wushuang; Yu, Zhen; Zhang, Jieming; Hong, Linjie; Guo, Zheng; Lin, Jianjiao; Dai, Weiyu; Xiao, Yizhi; Wu, Xiaosheng; Liu, Guangnan; Zhi, Fachao; Li, Guoxin; Xiong, Jing; Chen, Ye; Zhang, Hui; Xiang, Li; Li, Aimin; Liu, Side; Wang, Jide			The miR-3648/FRAT1-FRAT2/c-Myc negative feedback loop modulates the metastasis and invasion of gastric cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; WNT SIGNALING PATHWAY; MOLECULAR-CLONING; TUMOR-METASTASIS; IN-VITRO; C-MYC; PROLIFERATION; FRAT1; EXPRESSION; REGULATOR	Although the abnormal expression of miRNAs in cancer cells is a widely accepted phenomenon, the molecular mechanisms underlying miR-3648 progression and metastasis in gastric cancer (GC) remain unclear. miR-3648 expression is downregulated and its ectopic expression in GC cells significantly suppressed cell proliferation and metastasis. Mechanistic analyses indicated that miR-3648 directly targets FRAT1 or FRAT2 and inhibits FRAT1- or FRAT2-mediated invasion and motility in vitro and in vivo. Moreover, FRAT1 physically interacted with FRAT2. Furthermore, FRAT1 overexpression promoted GC cell invasion, whereas siRNA-mediated repression of FRAT2 in FRAT1-overexpressing GC cells reversed its invasive potential. Besides, miR-3648 inactivated the Wnt/beta-catenin signalling pathway by downregulating FRAT1 and FRAT2 in GC. Interestingly, c-Myc, a downstream effector of Wnt/beta-catenin signalling, was also downregulated by miR-3648 overexpression. In turn, c-Myc negatively regulated miR-3648 expression by binding to the miR-3648 promoter. In addition, miR-3648 expression levels were negatively correlated with c-Myc, FRAT1, and FRAT2 expression in fresh gastric samples. Our studies suggest that miR-3648 acts as a tumour-suppressive miRNA and that the miR-3648/FRAT1-FRAT2/c-Myc negative feedback loop could be a critical regulator of GC progression.	[Tang, Weimei; Pei, Miaomiao; Li, Jiaying; Xu, Nanzhu; Xiao, Wushuang; Yu, Zhen; Zhang, Jieming; Hong, Linjie; Dai, Weiyu; Xiao, Yizhi; Wu, Xiaosheng; Liu, Guangnan; Zhi, Fachao; Xiong, Jing; Li, Aimin; Liu, Side; Wang, Jide] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Peoples R China; [Guo, Zheng] Shenzhen Univ, Gen Hosp, Int Canc Ctr, Dept Hematol & Oncol, Xueyuan AVE 1098, Shenzhen 518000, Guangdong, Peoples R China; [Lin, Jianjiao; Zhi, Fachao; Xiang, Li; Liu, Side; Wang, Jide] Longgang Dist Peoples Hosp, Dept Gastroenterol, Shenzhen 518172, Peoples R China; [Li, Guoxin] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou 510515, Peoples R China; [Chen, Ye] Southern Med Univ, Shenzhen Hosp, Clin Microecol Ctr, Shenzhen 518000, Peoples R China; [Zhang, Hui] Southern Med Univ, Hexian Mem Affiliated Hosp, Dept Gastroenterol, Guangzhou 511400, Peoples R China	Southern Medical University - China; Shenzhen University; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Li, AM; Liu, SD; Wang, JD (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Peoples R China.; Xiang, L; Liu, SD; Wang, JD (corresponding author), Longgang Dist Peoples Hosp, Dept Gastroenterol, Shenzhen 518172, Peoples R China.	shellyxiangli@163.com; lam0725@163.com; liuside2011@163.com; jidewang55@163.com			Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University; National Natural Science Foundation of China [81974448, 81772964, 82073066, 82103152]; GuangDong Basic and Applied Basic Research Foundation [2020A1515110059]; Guangdong Gastrointestinal Disease Research Center [2017B020209003]; Guangdong Medical Research Foundation [B2019126]; Shenzhen Science and Technology Innovation Commission [JCYJ20180306170328854]; Shenzhen Science and Technology Innovation Commission Fund [JCYJ20210324135005013]; Shenzhen Longgang District Science and Technology Innovation commission fund [LGKCYLWS 2021000012]	Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); GuangDong Basic and Applied Basic Research Foundation; Guangdong Gastrointestinal Disease Research Center; Guangdong Medical Research Foundation; Shenzhen Science and Technology Innovation Commission; Shenzhen Science and Technology Innovation Commission Fund; Shenzhen Longgang District Science and Technology Innovation commission fund	We acknowledge the generous support of the Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University. This study was supported by grants from the National Natural Science Foundation of China (Nos. 81974448, 81772964, 82073066 and 82103152), GuangDong Basic and Applied Basic Research Foundation (No. 2020A1515110059), Guangdong Gastrointestinal Disease Research Center (No. 2017B020209003), Guangdong Medical Research Foundation (No. B2019126), Shenzhen Science and Technology Innovation Commission (No. JCYJ20180306170328854), Shenzhen Science and Technology Innovation Commission Fund (No. JCYJ20210324135005013) and Shenzhen Longgang District Science and Technology Innovation commission fund (No. LGKCYLWS 2021000012).	Ahadi A, 2020, IUBMB LIFE, V72, P884, DOI 10.1002/iub.2259; Codolo G, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02923; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Doumpas N, 2019, EMBO J, V38, DOI 10.15252/embj.201798873; Fan HY, 2018, BIOCHEM BIOPH RES CO, V503, P3100, DOI 10.1016/j.bbrc.2018.08.099; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Freemantle SJ, 2002, GENE, V291, P17, DOI 10.1016/S0378-1119(02)00594-2; Gu XF, 2014, NEURO-ONCOLOGY, V16, P217, DOI 10.1093/neuonc/not194; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ibrahim HM, 2019, J GASTROINTEST CANC, V50, P370, DOI 10.1007/s12029-018-0079-2; Jiang JX, 2015, ONCOTARGET, V6, P2767, DOI 10.18632/oncotarget.3089; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Katoh M, 2009, INT J ONCOL, V34, P1411, DOI 10.3892/ijo_00000269; Kirikoshi H, 2001, INT J ONCOL, V19, P111; Li QW, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5683-4; Lin J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2474-4; Liu JJ, 2014, CANCER LETT, V347, P98, DOI 10.1016/j.canlet.2014.01.024; Liu LY, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109865; Liu Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1370-1; Lu J, 2020, J CELL PHYSIOL, V235, P6287, DOI 10.1002/jcp.29556; Lv YF, 2016, CANCER LETT, V373, P164, DOI 10.1016/j.canlet.2016.01.046; Lv ZB, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1357-7; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; Paclikova P, 2021, CELL SIGNAL, V85, DOI 10.1016/j.cellsig.2021.110058; Pang YM, 2018, J CELL MOL MED, V22, P6262, DOI 10.1111/jcmm.13916; Peng Y, 2017, CANCER LETT, V385, P117, DOI 10.1016/j.canlet.2016.10.035; Peng YP, 2019, ONCOL RES, V27, P65, DOI 10.3727/096504018X15191223015016; Ren LL, 2019, THERANOSTICS, V9, P449, DOI 10.7150/thno.29055; Ruan ZY, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106003; Saitoh T, 2002, INT J ONCOL, V20, P785; Saitoh T, 2001, INT J ONCOL, V19, P311; Saitoh T, 2001, BIOCHEM BIOPH RES CO, V281, P815, DOI 10.1006/bbrc.2001.4421; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sun WR, 2019, MOL THER-NUCL ACIDS, V16, P519, DOI 10.1016/j.omtn.2019.04.006; Takahata M, 2009, J BIOL CHEM, V284, P3334, DOI 10.1074/jbc.M808989200; Tang WM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08225-3; Tian WJ, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1139-9; van Amerongen R, 2010, ONCOGENE, V29, P93, DOI 10.1038/onc.2009.310; van der Wal T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227435; Wang B, 2014, HEPATOLOGY, V59, P555, DOI 10.1002/hep.26712; Werner TV, 2017, AGING-US, V9, P932, DOI 10.18632/aging.101201; Xing RW, 2019, J NANOSCI NANOTECHNO, V19, P7526, DOI 10.1166/jnn.2019.16413; Xu K, 2019, MOL THER, V27, P1810, DOI 10.1016/j.ymthe.2019.05.017; Yan GQ, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118726; Yang C, 2016, SCI REP-UK, V6, DOI 10.1038/srep33078; Yang XZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0874-1; Yang ZC, 2018, EXP CELL RES, V368, P194, DOI 10.1016/j.yexcr.2018.04.030; Ye GT, 2017, THERANOSTICS, V7, P3338, DOI 10.7150/thno.20512; Zhang M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1815-7; Zhang P, 2017, BRIT J CANCER, V117, P525, DOI 10.1038/bjc.2017.181; Zhang WJ, 2010, CARCINOGENESIS, V31, P1220, DOI 10.1093/carcin/bgq094; Zhang Y, 2019, J GASTRIC CANCER, V19, P315, DOI 10.5230/jgc.2019.19.e28; Zhao CC, 2017, ONCOL REP, V38, P352, DOI 10.3892/or.2017.5673; Zhao MY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0103-7; Zheng KH, 2016, CANCER LETT, V376, P178, DOI 10.1016/j.canlet.2016.03.024; Zhou DH, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10230; Zhou Y, 2020, J THORAC DIS, V12, P3478, DOI 10.21037/jtd-20-1557A	58	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2022	41	43					4823	4838		10.1038/s41388-022-02451-2	http://dx.doi.org/10.1038/s41388-022-02451-2		SEP 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M4RI	36153370	Green Published, hybrid			2022-12-28	WOS:000857812100002
J	Ying, C; Jin, CM; Zeng, SY; Chao, M; Hu, X				Ying, Chang; Jin, Chengmeng; Zeng, Siying; Chao, Ming; Hu, Xun			Alkalization of cellular pH leads to cancer cell death by disrupting autophagy and mitochondrial function	ONCOGENE			English	Article							PERMEABILITY TRANSITION PORE; ACTIVATED PROTEIN-KINASE; HEPATOCELLULAR-CARCINOMA; TRANSARTERIAL CHEMOEMBOLIZATION; INHIBITION; AMPK; MODULATION; MACHINERY; APOPTOSIS; EFFICACY	We previously found that lactic acidosis in the tumor environment was permissive to cancer cell surviving under glucose deprivation and demonstrated that neutralizing lactic acidosis restored cancer cell susceptibility to glucose deprivation. We then reported that alternate infusion of bicarbonate and anticancer agent into tumors via tumor feeding artery markedly enhanced the efficacy of transarterial chemoembolization (TACE) in the local control of hepatocellular carcinoma (HCC). Here we sought to further investigate the mechanism by which bicarbonate enhances the anticancer activity of TACE. We propose that interfering cellular pH by bicarbonate could induce a cascade of molecular events leading to cancer cell death. Alkalizing cellular pH by bicarbonate decreased pH gradient (Delta pH), membrane potential (Delta psi(m)), and proton motive force (Delta p) across the inner membrane of mitochondria; disruption of oxidative phosphorylation (OXPHOS) due to collapsed Delta p led to a significant increase in adenosine monophosphate (AMP), which activated the classical AMPK-mediated autophagy. Meanwhile, the autophagic flux was ultimately blocked by increased cellular pH, reduced OXPHOS, and inhibition of lysosomal proton pump in alkalized lysosome. Bicarbonate also induced persistent mitochondrial permeability (MPT) and damaged mitochondria. Collectively, this study reveals that interfering cellular pH may provide a valuable approach to treat cancer.	[Ying, Chang; Jin, Chengmeng; Zeng, Siying; Hu, Xun] Zhejiang Univ, Affiliated Hosp 2, Canc Inst,Key Lab Canc Intervent & Prevent, Sch Med,China Natl Minist Educ,Zhejiang Prov Key, Hangzhou, Peoples R China; [Chao, Ming] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Intervent Radiol,Dept Radiol, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Hu, X (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Canc Inst,Key Lab Canc Intervent & Prevent, Sch Med,China Natl Minist Educ,Zhejiang Prov Key, Hangzhou, Peoples R China.; Chao, M (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Intervent Radiol,Dept Radiol, Hangzhou, Peoples R China.	chaoming@zju.edu.cn; huxun@zju.edu.cn	Zeng, Siying/HDO-3064-2022		China Natural Sciences Foundation [82073038, 81772947]; Zhejiang Provincial Department of Sciences and Technologies [2018C03009]; Fundamental Research Funds for the Central Universities [2017XZZX001-01, 2019FZJD009]; National Ministry of Education, China	China Natural Sciences Foundation(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Department of Sciences and Technologies; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Ministry of Education, China(Ministry of Education, China)	This work has been supported in part by China Natural Sciences Foundation projects (82073038, 81772947 to XH), a key project (2018C03009) funded by Zhejiang Provincial Department of Sciences and Technologies (to XH & MC), and the Fundamental Research Funds for the Central Universities (2017XZZX001-01, 2019FZJD009, to XH), National Ministry of Education, China. We thank Dr. Guo-Hua Fong (University of Connecticut School of Medicine, USA) for critical readings of our manuscript and constructive comments, Dr. Wei Liu (Zhejiang University) for the kind gift of plasmids GFP-LC3, Cherry-GFP-LC3, and Dr. Shanrong Cai for the statistical assistance (Zhejiang University).	Ahmad F, 2019, J LIPID RES, V60, P98, DOI 10.1194/jlr.M088245; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bartel K, 2019, J BIOL CHEM, V294, P17239, DOI 10.1074/jbc.RA119.010243; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Beyenbach KW, 2006, J EXP BIOL, V209, P577, DOI 10.1242/jeb.02014; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; Caricato R, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00319; Chao M, 2016, ELIFE, V5, DOI [10.7754/eLife.15691, 10.7554/eLife.15691]; Chen JC, 2019, J BIOL CHEM, V294, P11994, DOI 10.1074/jbc.RA118.007161; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; de Vasconcelos NM, 2019, CELL DEATH DIFFER, V26, P146, DOI 10.1038/s41418-018-0106-7; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, 2019, J Hepatol, V70, P817, DOI 10.1016/j.jhep.2019.01.020; Gong YN, 2017, CELL, V169, P286, DOI 10.1016/j.cell.2017.03.020; Goodall ML, 2016, DEV CELL, V37, P337, DOI 10.1016/j.devcel.2016.04.018; Gowans GJ, 2013, CELL METAB, V18, P556, DOI 10.1016/j.cmet.2013.08.019; Hawley SA, 2016, DIABETES, V65, P2784, DOI 10.2337/db16-0058; Hu X, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.47; Ibrahim-Hashim A, 2012, J UROLOGY, V188, P624, DOI 10.1016/j.juro.2012.03.113; Jansen MC, 2005, EJSO-EUR J SURG ONC, V31, P331, DOI 10.1016/j.ejso.2004.10.011; Jin CM, 2020, J BIOL CHEM, V295, P6425, DOI 10.1074/jbc.RA119.012312; Ju JS, 2010, AUTOPHAGY, V6, P929, DOI 10.4161/auto.6.7.12785; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kloditz K, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0146-x; Lencioni R, 2016, HEPATOLOGY, V64, P106, DOI 10.1002/hep.28453; Liu B, 2014, AUTOPHAGY, V10, P416, DOI 10.4161/auto.27286; Liu J, 2020, CELL CHEM BIOL, V27, P420, DOI 10.1016/j.chembiol.2020.02.005; Liu YE, 2020, MEDCOMM, V1, P129, DOI 10.1002/mco2.16; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Malhi H, 2006, HEPATOLOGY, V43, pS31, DOI 10.1002/hep.21062; Martin NK, 2012, BRIT J CANCER, V106, P1280, DOI 10.1038/bjc.2012.58; Martin NK, 2011, MATH BIOSCI, V230, P1, DOI 10.1016/j.mbs.2010.12.002; Mauvezin C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8007; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Pasquier A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11170-4; Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587; Perry SW, 2011, BIOTECHNIQUES, V50, P98, DOI 10.2144/000113610; Piscaglia F, 2018, LIVER CANCER, V7, P104, DOI 10.1159/000485471; Piscaglia F, 2010, DIGEST LIVER DIS, V42, pS258, DOI 10.1016/S1590-8658(10)60514-2; Poburko D, 2011, J BIOL CHEM, V286, P11672, DOI 10.1074/jbc.M110.159962; Raoul JL, 2011, CANCER TREAT REV, V37, P212, DOI 10.1016/j.ctrv.2010.07.006; Rasola A, 2010, P NATL ACAD SCI USA, V107, P726, DOI 10.1073/pnas.0912742107; Russo M, 2018, BIOCHEM PHARMACOL, V153, P51, DOI 10.1016/j.bcp.2018.02.007; Shlomovitz I, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0437-0; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Wu H, 2012, J PATHOL, V227, P189, DOI 10.1002/path.3978; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Xie JS, 2014, SCI REP-UK, V4, DOI 10.1038/srep04927; Yang KX, 2016, NANOMEDICINE-UK, V11, DOI 10.2217/nnm-2016-0289; Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865; Yue W, 2013, AUTOPHAGY, V9, P714, DOI 10.4161/auto.23997; Zargarian S, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2002711; Zois CE, 2009, AUTOPHAGY, V5, P442, DOI 10.4161/auto.5.4.7667	58	0	0	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3886	3897		10.1038/s41388-022-02396-6	http://dx.doi.org/10.1038/s41388-022-02396-6		JUL 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35780182				2022-12-28	WOS:000819907600001
J	Chen, SY; Chen, KL; Ding, LY; Yu, CH; Wu, HY; Chou, YY; Chang, CJ; Chang, CH; Wu, YN; Wu, SR; Hou, YC; Lee, CT; Chen, PC; Shan, YS; Huang, PH				Chen, Szu-Ying; Chen, Kuan-Lin; Ding, Li-Yun; Yu, Chien-Hung; Wu, Hsin-Yi; Chou, Ya-Yi; Chang, Chia-Jung; Chang, Chih-Han; Wu, Ya-Na; Wu, Shang-Rung; Hou, Ya-Chin; Lee, Chung-Ta; Chen, Peng-Chieh; Shan, Yan-Shen; Huang, Po-Hsien			RNA bisulfite sequencing reveals NSUN2-mediated suppression of epithelial differentiation in pancreatic cancer	ONCOGENE			English	Article							NSUN2; 5-METHYLCYTOSINE; METHYLATION; PROGRESSION; METHYLTRANSFERASE; TRANSCRIPTOME; EXPRESSION; GROWTH; DNMT2; M(5)C	Posttranscriptional modifications in RNA have been considered to contribute to disease pathogenesis and tumor progression. NOL1/NOP2/Sun domain family member 2 (NSUN2) is an RNA methyltransferase that promotes tumor progression in several cancers. Pancreatic cancer relapse inevitably occurs even in cases where primary tumors have been successfully treated. Associations of cancer progression due to reprogramming of the cancer methyl-metabolome and the cancer genome have been noted, but the effect of base modifications, namely 5-methylcytosine (m(5)C), in the transcriptome remains unclear. Aberrant regulation of 5-methylcytosine turnover in cancer may affect posttranscriptional modifications in coding and noncoding RNAs in disease pathogenesis. Mutations in NSUN2 have been reported as drivers of neurodevelopmental disorders in mice, and upregulated expression of NSUN2 in tumors of the breast, bladder, and pancreas has been reported. In this study, we conducted mRNA whole transcriptomic bisulfite sequencing to categorize NSUN2 target sites in the mRNA of human pancreatic cancer cells. We identified a total of 2829 frequent m(5)C sites in mRNA from pancreatic cancer cells. A total of 90.9% (2572/2829) of these m(5)C sites were mapped to annotated genes in autosomes and sex chromosomes X and Y. Immunohistochemistry staining confirmed that the NSUN2 expression was significantly upregulated in cancer lesions in the LSL-Kras(G12D/+);Trp53(fl/fl);Pdx1-Cre (KPC) spontaneous pancreatic cancer mouse model induced by Pdx1-driven Cre/lox system expressing mutant Kras(G12D) and p53 deletion. The in vitro phenotypic analysis of NSUN2 knockdown showed mild effects on pancreatic cancer cell 2D/3D growth, morphology and gemcitabine sensitivity in the early phase of tumorigenesis, but cumulative changes after multiple cell doubling passages over time were required for these mutations to accumulate. Syngeneic transplantation of NSUN2-knockdown KPC cells via subcutaneous injection showed decreased stromal fibrosis and restored differentiation of ductal epithelium in vivo. Significance Transcriptome-wide mRNA bisulfite sequencing identified candidate m5C sites of mRNAs in human pancreatic cancer cells. NSUN2-mediated m5C mRNA metabolism was observed in a mouse model of pancreatic cancer. NSUN2 regulates cancer progression and epithelial differentiation via mRNA methylation.	[Chen, Szu-Ying; Chen, Kuan-Lin; Yu, Chien-Hung; Chou, Ya-Yi; Huang, Po-Hsien] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan; [Chen, Szu-Ying; Ding, Li-Yun; Yu, Chien-Hung; Huang, Po-Hsien] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan; [Wu, Hsin-Yi] Natl Taiwan Univ, Coll Sci, Instrumentat Ctr, Tainan, Taiwan; [Chang, Chia-Jung; Chang, Chih-Han] Natl Cheng Kung Univ, Dept Biomed Engn, Tainan, Taiwan; [Chang, Chih-Han] Natl Cheng Kung Univ, Med Device Innovat Ctr, Tainan, Taiwan; [Chang, Chih-Han] Natl Cheng Kung Univ, Ctr Corp Relat & Technol Transfer, Tainan, Taiwan; [Wu, Ya-Na; Wu, Shang-Rung] Int Inst Macromol Anal & Nanomed Innovat, Tainan, Taiwan; [Wu, Shang-Rung] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan, Taiwan; [Hou, Ya-Chin; Chen, Peng-Chieh; Shan, Yan-Shen] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan; [Hou, Ya-Chin; Shan, Yan-Shen] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg,Div Gen Surg, Tainan, Taiwan; [Lee, Chung-Ta] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Taiwan University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital	Huang, PH (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan.; Huang, PH (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan.; Shan, YS (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan.; Shan, YS (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg,Div Gen Surg, Tainan, Taiwan.	ysshan@mail.ncku.edu.tw; phhuang@mail.ncku.edu.tw		Chen, SzuYing/0000-0002-3998-5922; Chen, Peng-Chieh ( Jessica )/0000-0002-2060-1765; CHANG, CHIA-JUNG/0000-0003-0977-8743; Chen, Kuan-Lin/0000-0003-1387-1596	Ministry of Science and Technology, Taiwan; MOST [110-2320-B-006-038-, 110-2314-B-006-107-]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); MOST	The authors acknowledge technical services from core facilities: Research Center of Clinical Medicine, Center of Cell Therapy, and the Human Biobank and the Cancer Data Bank of National Cheng Kung University Hospital. The authors thank the Core Research Laboratory and the Laboratory Animal Center, College of Medicine, National Cheng Kung University; and Taiwan Animal Consortium. We thank the technical services provided by the following National Core Facilities: Bioimaging Core Facility; and the International Institute for Macromolecular Analysis and Nanomedicine Innovations, National Core Facility for Biopharmaceuticals, Ministry of Science and Technology, Taiwan. Sequencing run, computational analyses and data mining were performed using the system provided by the Center for Bioinformatics and Digital Health at the National Cheng Kung University, supported by Ministry of Science and Technology, Taiwan. The authors acknowledge the mass spectrometry technical research services from NTU Consortia of Key Technologies and NTU Instrumentation Center. We thank the National RNAi Core Facility at Academia Sinica in Taiwan for providing shRNA reagents and related services. This work is supported by grant support from the MOST (110-2320-B-006-038-and 110-2314-B-006-107-) to PHH.	Aldaz P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57047-w; Amort T, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1139-1; Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Chen X, 2019, NAT CELL BIOL, V21, P978, DOI 10.1038/s41556-019-0361-y; Courtney DG, 2019, CELL HOST MICROBE, V26, P217, DOI 10.1016/j.chom.2019.07.005; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Ding LY, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00878-6; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027; Gao Y, 2019, CANCER SCI, V110, P3510, DOI 10.1111/cas.14190; Gigova A, 2014, RNA, V20, P1632, DOI 10.1261/rna.043398.113; Huang T, 2019, NAT STRUCT MOL BIOL, V26, P380, DOI 10.1038/s41594-019-0218-x; Kang M, 2008, J ATHL TRAINING, V43, P215, DOI 10.4085/1062-6050-43.2.215; Kapil S, 2017, ONCOTARGET, V8, P26515, DOI 10.18632/oncotarget.15713; Legrand C, 2017, GENOME RES, V27, P1589, DOI 10.1101/gr.210666.116; Li Q, 2017, J CELL BIOCHEM, V118, P2587, DOI 10.1002/jcb.25957; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Liu N, 2015, NATURE, V518, P560, DOI 10.1038/nature14234; Martinez NM, 2018, QUANT BIOL, V6, P210, DOI 10.1007/s40484-018-0147-4; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Motorin Y, 2010, NUCLEIC ACIDS RES, V38, P1415, DOI 10.1093/nar/gkp1117; Okamoto M, 2012, DNA CELL BIOL, V31, P660, DOI 10.1089/dna.2011.1446; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Rieder D, 2016, BIOINFORMATICS, V32, P782, DOI 10.1093/bioinformatics/btv647; SALDITTGEORGIEFF M, 1976, CELL, V7, P227, DOI 10.1016/0092-8674(76)90022-2; Schaefer M, 2010, GENE DEV, V24, P1590, DOI 10.1101/gad.586710; Schaefer M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn954; Schosserer M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7158; Schumann U, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00769-5; Selmi T, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkaa1193; Squires JE, 2012, NUCLEIC ACIDS RES, V40, P5023, DOI 10.1093/nar/gks144; Sun Z, 2019, EPIGENOMICS-UK, V11, P439, DOI 10.2217/epi-2018-0169; Tang H, 2015, AGING-US, V7, P1143, DOI 10.18632/aging.100860; Taoka M, 2018, NUCLEIC ACIDS RES, V46, P9289, DOI 10.1093/nar/gky811; Tinder TL, 2008, J IMMUNOL, V181, P3116, DOI 10.4049/jimmunol.181.5.3116; Tuorto F, 2012, NAT STRUCT MOL BIOL, V19, P900, DOI 10.1038/nsmb.2357; Xing JY, 2015, MOL CELL BIOL, V35, P4043, DOI 10.1128/MCB.00742-15; Yang X, 2017, CELL RES, V27, P606, DOI 10.1038/cr.2017.55; Yang Y, 2019, MOL CELL, V75, P1188, DOI 10.1016/j.molcel.2019.06.033; Yi J, 2017, ONCOTARGET, V8, P20751, DOI 10.18632/oncotarget.10612; Zhao X, 2014, CELL RES, V24, P1403, DOI 10.1038/cr.2014.151	42	0	0	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3162	3176		10.1038/s41388-022-02325-7	http://dx.doi.org/10.1038/s41388-022-02325-7		MAY 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35501460				2022-12-28	WOS:000789736500003
J	Zhu, S; Zhang, CL; Cao, DY; Bai, J; Yu, SN; Chen, J; Wang, J; Ren, T; Yang, JX; Yu, M; Xiao, X; Gong, YH; Guan, YF; Li, PL; Yue, Y; Yin, RT; Wang, YJ; An, RF; Lou, G; Yuan, JL; Zhang, GN; Xia, XF; Yang, L; Xiang, Y				Zhu, Shan; Zhang, Chunliu; Cao, Dongyan; Bai, Jing; Yu, Shuangni; Chen, Jie; Wang, Jing; Ren, Tong; Yang, Jiaxin; Yu, Mei; Xiao, Xiao; Gong, Yuhua; Guan, Yanfang; Li, Peiling; Yue, Ying; Yin, Rutie; Wang, Yongjun; An, Ruifang; Lou, Ge; Yuan, Jianlin; Zhang, Guonan; Xia, Xuefeng; Yang, Ling; Xiang, Yang			Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes	ONCOGENE			English	Article							MICROSATELLITE INSTABILITY; ANTITUMOR-ACTIVITY; DNA-REPAIR; CHEMOTHERAPY; MUTATIONS; RESISTANT; BLOCKADE; SAFETY; CELLS	Epithelial ovarian cancer (EOC) is classified into five major histotypes: high-grade serous (HGSOC), low-grade serous (LGSOC), clear cell (CCOC), endometrioid (ENOC), and mucinous (MOC). However, the landscape of molecular and immunological alterations in these histotypes, especially LGSOC, CCOC, ENOC, and MOC, is largely uncharacterized. We collected 101 treatment-naive EOC patients. The resected tumor tissues and paired preoperative peripheral blood samples were collected and subjected to target sequencing of 1021 cancer-associated genes and T cell repertoire sequencing. Distinct characteristics of mutations were identified among the five histotypes. Furthermore, tumor mutation burden (TMB) was found to be higher in CCOC and ENOC, but lower in LGSOC and HGSOC. Alterations associated with DNA damage repair (DDR) pathways and homologous recombination deficiencies (HRD) were prevalent in five histotypes. CCOC demonstrated increased level of T cell clonality compared with HSGOC. Interestingly, the proportion of the 100 most common T cell clones was associated with TMB and tumor neoantigen burden in CCOC, highlighting more sensitive anti-tumor responses in this histotype, which was also evidenced by the enhanced convergent recombination of T cell clones. These findings shed light on the molecular traits of genomic alteration and T cell repertoire in the five major EOC histotypes and may help optimize clinical management of EOC with different histotypes.	[Zhu, Shan; Cao, Dongyan; Ren, Tong; Yang, Jiaxin; Yu, Mei; Xiang, Yang] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Natl Clin Res Ctr Obstetr & Gynecol Dis, Dept Obstet & Gynecol,State Key Lab Complex Sever, Beijing, Peoples R China; [Zhang, Chunliu; Bai, Jing; Gong, Yuhua; Guan, Yanfang; Xia, Xuefeng; Yang, Ling] Geneplus Inst, Beijing, Peoples R China; [Yu, Shuangni; Chen, Jie] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Pathol, Beijing, Peoples R China; [Wang, Jing] Cent South Univ, Hunan Canc Hosp, Dept Gynecol Oncol, Changsha, Peoples R China; [Wang, Jing] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China; [Xiao, Xiao] Geneplus Shenzhen, Shenzhen, Peoples R China; [Li, Peiling] Harbin Med Univ, Dept Obstet & Gynecolgoy, Affiliated Hosp 2, Harbin, Peoples R China; [Yue, Ying] First Hosp Jilin Univ, Dept Gynecol Oncol, Changchun, Peoples R China; [Yin, Rutie] Sichuan Univ, Dept Obstet & Gynecol, West China Hosp 2, Chengdu, Peoples R China; [Wang, Yongjun] Peking Univ Int Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China; [An, Ruifang] Xi An Jiao Tong Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China; [Lou, Ge] Harbin Med Univ Canc Hosp, Dept Gynecol Oncol, Harbin, Peoples R China; [Yuan, Jianlin] Xinjiang Med Univ, Dept Gynecol, Affiliated Tumor Hosp, Urumqi, Peoples R China; [Zhang, Guonan] Sichuan Canc Hosp, Dept Gynecol Oncol, Chengdu, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Central South University; Central South University; Harbin Medical University; Jilin University; Sichuan University; Peking University; Xi'an Jiaotong University; Xinjiang Medical University	Xiang, Y (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Natl Clin Res Ctr Obstetr & Gynecol Dis, Dept Obstet & Gynecol,State Key Lab Complex Sever, Beijing, Peoples R China.; Yang, L (corresponding author), Geneplus Inst, Beijing, Peoples R China.	yangl@geneplus.org.cn; xiangy@pumch.cn			National Natural Science Foundation of China [81772783, 81971475]; Chinese Academy of Medical Sciences Initiative for Innovative Medicine [CAMS-2017-I2M-1-002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Medical Sciences Initiative for Innovative Medicine	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81772783 and 81971475) and the Chinese Academy of Medical Sciences Initiative for Innovative Medicine (Nos. CAMS-2017-I2M-1-002).	Abbosh C, 2018, NAT REV CLIN ONCOL, V15, P577, DOI 10.1038/s41571-018-0058-3; Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Alexandros Karatzoglou AS, 2004, J STAT SOFTW, V011, pI09; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Assasi N, 2016, DNA MISMATCH REPAIR; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Banerjee S, 2021, LANCET ONCOL, V22, P1721, DOI 10.1016/S1470-2045(21)00531-3; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown JS, 2017, CANCER DISCOV, V7, P20, DOI 10.1158/2159-8290.CD-16-0860; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cheasley D, 2021, J PATHOL, V253, P41, DOI 10.1002/path.5545; Chui MH, 2019, CANCER RES, V79, P5536, DOI 10.1158/0008-5472.CAN-18-3029; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Csardi G., 2006, INTERJOURNALCOMPLEX, V1695, P1, DOI DOI 10.3724/SP.J.1087.2009.02191; Dash P, 2017, NATURE, V547, P89, DOI 10.1038/nature22383; Dejima H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22890-x; Disis ML, 2019, JAMA ONCOL, V5, P393, DOI 10.1001/jamaoncol.2018.6258; Elsherif SB, 2021, ABDOM RADIOL, V46, P2264, DOI 10.1007/s00261-021-03081-0; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Gorringe KL, 2020, GYNECOL ONCOL, V156, P552, DOI 10.1016/j.ygyno.2019.12.015; GRIFFITHS CT, 1978, SURG CLIN N AM, V58, P131, DOI 10.1016/s0039-6109(16)41440-4; Gulhan DC, 2019, NAT GENET, V51, P912, DOI 10.1038/s41588-019-0390-2; Hamanishi J, 2015, J CLIN ONCOL, V33, P4015, DOI 10.1200/JCO.2015.62.3397; Han C, 2018, GYNECOL ONCOL REP, V25, P41, DOI 10.1016/j.gore.2018.05.011; Han JF, 2020, CANCER IMMUNOL RES, V8, P146, DOI 10.1158/2326-6066.CIR-19-0398; Hess V, 2004, J CLIN ONCOL, V22, P1040, DOI 10.1200/JCO.2004.08.078; Hoffmann K, 2020, EMBO J, V39, DOI 10.15252/embj.2019104013; Hogan SA, 2019, CANCER IMMUNOL RES, V7, P77, DOI 10.1158/2326-6066.CIR-18-0136; Hollis RL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18819-5; Jessen E, 2021, BMC MED GENOMICS, V14, DOI 10.1186/s12920-021-00898-y; Jia QZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07767-w; Joshi K, 2019, NAT MED, V25, P1549, DOI 10.1038/s41591-019-0592-2; Kuo KT, 2009, AM J PATHOL, V174, P1597, DOI 10.2353/ajpath.2009.081000; Lan AH, 2019, FUTURE ONCOL, V15, P2029, DOI 10.2217/fon-2018-0886; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lheureux S, 2019, CA-CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559; Lheureux S, 2019, LANCET, V393, P1240, DOI 10.1016/S0140-6736(18)32552-2; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li J, 2012, BIOINFORMATICS, V28, P1307, DOI 10.1093/bioinformatics/bts146; Mabuchi S, 2016, J GYNECOL ONCOL, V27, DOI 10.3802/jgo.2016.27.e31; Macintyre G, 2018, NAT GENET, V50, P1262, DOI 10.1038/s41588-018-0179-8; Matulonis UA, 2019, ANN ONCOL, V30, P1080, DOI 10.1093/annonc/mdz135; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mendivil AA, 2018, GYNECOL ONCOL REP, V26, P41, DOI 10.1016/j.gore.2018.09.002; Moioli M, 2019, EXPERT OPIN INV DRUG, V28, P1025, DOI 10.1080/13543784.2019.1693999; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755; O'Donnell T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3825-0; Oliveira DVNP, 2021, CANCERS, V13, DOI 10.3390/cancers13205242; Pisano C, 2005, ANTICANCER RES, V25, P3501; Prat J, 2012, VIRCHOWS ARCH, V460, P237, DOI 10.1007/s00428-012-1203-5; Previs RA, 2016, EXPERT REV MOL DIAGN, V16, P1337, DOI 10.1080/14737159.2016.1259069; Pujade-Lauraine E, 2017, ANN ONCOL, V28, P57, DOI 10.1093/annonc/mdx442; Radovich M, 2020, JAMA ONCOL, V6, P1410, DOI 10.1001/jamaoncol.2020.2295; Reuben A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14273-0; Reuben A, 2017, CANCER DISCOV, V7, P1088, DOI 10.1158/2159-8290.CD-17-0256; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Sato N, 2012, ONCOL REP, V27, P1336, DOI 10.3892/or.2012.1626; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Sun YX, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00430; Takekuma Munetaka, 2016, Gynecol Oncol Res Pract, V3, P5, DOI 10.1186/s40661-016-0026-5; Tarazona N, 2019, ANN ONCOL, V30, P1804, DOI 10.1093/annonc/mdz390; Tholander B, 2020, UPSALA J MED SCI, V125, P325, DOI 10.1080/03009734.2020.1826612; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Wang ZJ, 2018, CANCER RES, V78, P6486, DOI 10.1158/0008-5472.CAN-18-1814; Xu W, 2016, CRIT REV ONCOL HEMAT, V102, P26, DOI 10.1016/j.critrevonc.2016.03.015; Yamamoto H, 2015, ARCH TOXICOL, V89, P899, DOI 10.1007/s00204-015-1474-0; Zamarin D, 2020, J CLIN ONCOL, V38, P1814, DOI 10.1200/JCO.19.02059; Zhang AW, 2018, CELL, V173, P1755, DOI 10.1016/j.cell.2018.03.073; Zhang L, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1544-9	76	0	0	5	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3093	3103		10.1038/s41388-022-02277-y	http://dx.doi.org/10.1038/s41388-022-02277-y		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35468938				2022-12-28	WOS:000787133900001
J	Pang, Z; Dong, XR; Deng, HY; Wang, CZ; Liao, XD; Liao, CH; Liao, YH; Tian, WD; Cheng, JK; Chen, GQ; Yi, HY; Huang, L				Pang, Zhi; Dong, Xinran; Deng, Huayun; Wang, Chengzhi; Liao, Xiaodong; Liao, Chunhua; Liao, Yahui; Tian, Weidong; Cheng, Jinke; Chen, Guoqiang; Yi, Haiying; Huang, Lei			MUC1 triggers lineage plasticity of Her2 positive mammary tumors	ONCOGENE			English	Article							SIGNALING PATHWAYS; BREAST; ONCOPROTEIN; ACTIVATION; OVEREXPRESSION; AMPLIFICATION; TUMORIGENESIS; EXPRESSION; RESISTANCE; MUTATIONS	Aberrant overexpression of mucin 1 (MUC1) and human epidermal growth factor receptor 2 (HER2) are often observed in breast cancer. However, the role of concomitant MUC1/HER2 in the development of breast cancer has not been fully illustrated. Following analysis of public microarray datasets that revealed a correlation between double MUC1 and HER2 positivity and a worse clinical outcome, we generated a mouse model overexpressing both Her2 and MUC1 cytoplasmic domain (MUC1-CD) to investigate their interaction in mammary carcinogenesis. Coexpression of Her2 and MUC1-CD conferred a growth advantage and promoted the development of spontaneous mammary tumors. Genomic analysis revealed that enforced expression of MUC1-CD and Her2 induces mammary tumor lineage plasticity, which is supported by gene reprogramming and mammary stem cell enrichment. Through gain- and loss-of-function strategies, we show that coexpression of Her2 and MUC1-CD is associated with downregulation of tricarboxylic acid (TCA) cycle genes in tumors. Importantly, the reduction in TCA cycle genes induced by MUC1-CD was found to be significantly connected to poor prognosis in HER2(+) breast cancer patients. In addition, MUC1 augments the Her2 signaling pathway by inducing Her2/Egfr dimerization. These findings collectively demonstrate the vital role of MUC1-CD/Her2 collaboration in shaping the mammary tumor landscape and highlight the prognostic and therapeutic implications of MUC1 in patients with HER2(+) breast cancer.	[Pang, Zhi; Deng, Huayun; Wang, Chengzhi; Liao, Xiaodong; Liao, Chunhua; Cheng, Jinke; Chen, Guoqiang; Huang, Lei] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Reprod Med,Dept Histoembryol Gen, Chinese Minist Educ,Key Lab Cell Differentiat & A, Shanghai, Peoples R China; [Pang, Zhi] Fudan Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Liver Canc Inst,Zhongshan Hosp, Shanghai, Peoples R China; [Dong, Xinran; Tian, Weidong] Fudan Univ, Ctr Mol Med, Childrens Hosp, Shanghai, Peoples R China; [Liao, Yahui] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Pharm,Huangpu Branch, Shanghai, Peoples R China; [Tian, Weidong] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, Dept Computat Biol,State Key Lab Genet Engn, Shanghai, Peoples R China; [Yi, Haiying] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Breast Surg,Huangpu Branch, Shanghai, Peoples R China	Shanghai Jiao Tong University; Fudan University; Fudan University; Shanghai Jiao Tong University; Fudan University; Shanghai Jiao Tong University	Huang, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Reprod Med,Dept Histoembryol Gen, Chinese Minist Educ,Key Lab Cell Differentiat & A, Shanghai, Peoples R China.; Yi, HY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Breast Surg,Huangpu Branch, Shanghai, Peoples R China.	yihaiying@163.com; leihuang@shsmu.edu.cn		Cheng, Jinke/0000-0002-4344-5363; Liao, Xiaodong/0000-0001-9230-5220; chen, guo qiang/0000-0003-4936-2363; Pang, Zhi/0000-0001-8677-9008	National Natural Science Foundation of China [81874197, 82073111]; Science and Technology Commission of Shanghai Municipality [21S11901600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by the National Natural Science Foundation of China (grant numbers 81874197 and 82073111), Science and Technology Commission of Shanghai Municipality (grant number 21S11901600) to Huang L. The authors appreciate Dr. Shuhai Lin for constructive suggestions.	Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Arkhipov A, 2013, ELIFE, V2, DOI 10.7554/eLife.00708; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Barberan S, 2019, SEMIN CELL DEV BIOL, V87, P45, DOI 10.1016/j.semcdb.2018.05.011; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; [程布凯 Cheng Bukai], 2014, [中国科学. 生命科学, Scientia Sinica Vitae], V44, P143; Cho HJ, 2018, ONCOGENE, V37, P861, DOI 10.1038/onc.2017.386; Chung SS, 2014, INT J ONCOL, V44, P403, DOI 10.3892/ijo.2013.2195; D'Amato V, 2015, CANCER TREAT REV, V41, P877, DOI 10.1016/j.ctrv.2015.08.001; El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017; Fishbein L, 2017, CANCER CELL, V31, P181, DOI 10.1016/j.ccell.2017.01.001; Garcia-Heredia JM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071693; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gimm O, 2000, CANCER RES, V60, P6822; Guo JX, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.644857; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Gyorffy B, 2021, COMPUT STRUCT BIOTEC, V19, P4101, DOI 10.1016/j.csbj.2021.07.014; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549-011-1619-7; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Hynes NE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003186; Janiszewska M, 2015, NAT GENET, V47, P1212, DOI 10.1038/ng.3391; Johnson S., 2013, BIOPROTOC, V3, pe326; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2020, CARCINOGENESIS, V41, P1173, DOI 10.1093/carcin/bgaa082; Lacunza E, 2010, CANCER GENET CYTOGEN, V201, P102, DOI 10.1016/j.cancergencyto.2010.05.015; Li Y, 2018, ONCOTARGET, V9, P3446, DOI 10.18632/oncotarget.23316; Li Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019102; Marquez J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122161; Mehla K, 2014, BBA-REV CANCER, V1845, P126, DOI 10.1016/j.bbcan.2014.01.001; Meier-Abt F, 2014, TRENDS MOL MED, V20, P143, DOI 10.1016/j.molmed.2013.11.002; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Nassar A, 2014, INT J CLIN EXP PATHO, V7, P6254; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Raimundo N, 2011, TRENDS MOL MED, V17, P641, DOI 10.1016/j.molmed.2011.06.001; Raina D, 2014, ONCOGENE, V33, P3422, DOI 10.1038/onc.2013.308; Rajabi H, 2018, ONCOGENE, V37, P2079, DOI 10.1038/s41388-017-0096-9; Sawai Y, 2003, J HEPATOL, V39, P991, DOI 10.1016/S0168-8278(03)00498-7; Schneider MR, 2016, ONCOGENE, V35, P2949, DOI 10.1038/onc.2015.372; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Tanaka H, 2013, J NEURO-ONCOL, V111, P273, DOI 10.1007/s11060-012-1027-9; Vermeer PD, 2013, CANCER RES, V73, P5787, DOI 10.1158/0008-5472.CAN-13-0760; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Wang DS, 2019, CELL RES, V29, P832, DOI 10.1038/s41422-019-0225-9; Weerts MJA, 2016, ONCOTARGET, V7, P29166, DOI 10.18632/oncotarget.8688; Wei T, 2017, J ROY STAT SOC D-STA, V56, P24; Wu BW, 2020, CELL METAB, V32, DOI 10.1016/j.cmet.2020.10.025; Yasumizu Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14219-6; Zhou ZQ, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010016	58	1	1	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3064	3078		10.1038/s41388-022-02320-y	http://dx.doi.org/10.1038/s41388-022-02320-y		APR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35461328				2022-12-28	WOS:000785962300002
J	Chadet, S; Allard, J; Brisson, L; Lopez-Charcas, O; Lemoine, R; Heraud, A; Lerondel, S; Guibon, R; Fromont, G; Le Pape, A; Angoulvant, D; Jiang, LH; Murrell-Lagnado, R; Roger, S				Chadet, Stephanie; Allard, Jordan; Brisson, Lucie; Lopez-Charcas, Osbaldo; Lemoine, Roxane; Heraud, Audrey; Lerondel, Stephanie; Guibon, Roseline; Fromont, Gaelle; Le Pape, Alain; Angoulvant, Denis; Jiang, Lin-Hua; Murrell-Lagnado, Ruth; Roger, Sebastien			P2x4 receptor promotes mammary cancer progression by sustaining autophagy and associated mesenchymal transition	ONCOGENE			English	Article							P2X(4) RECEPTORS; CELLS; RELEASE; INHIBITION; LYSOSOMES; CHANNELS; ROLES; EMT	Metastatic progression is a major burden for breast cancer patients and is associated with the ability of cancer cells to overcome stressful conditions, such as nutrients deprivation and hypoxia, and to gain invasive properties. Autophagy and epithelial-to-mesenchymal transition are critical contributors to these processes. Here, we show that the P2X4 purinergic receptor is upregulated in breast cancer biopsies from patients and it is primarily localised in endolysosomes. We demonstrate that P2X4 enhanced invasion in vitro, as well as mammary tumour growth and metastasis in vivo. The pro-malignant role of P2X4 was mediated by the regulation of lysosome acidity, the promotion of autophagy and cell survival. Furthermore, the autophagic activity was associated with epithelial-to-mesenchymal transition (EMT), and this role of P2X4 was even more pronounced under metabolic challenges. Pharmacological and gene silencing of P2X4 inhibited both autophagy and EMT, whereas its rescue in knocked-down cells led to the restoration of the aggressive phenotype. Together, our results demonstrate a previously unappreciated role for P2X4 in regulating lysosomal functions and fate, promoting breast cancer progression and aggressiveness.	[Chadet, Stephanie; Allard, Jordan; Lopez-Charcas, Osbaldo; Lemoine, Roxane; Heraud, Audrey; Angoulvant, Denis; Roger, Sebastien] Univ Tours, EA4245 Transplantat Immunol Inflammat, Tours, France; [Brisson, Lucie; Guibon, Roseline; Fromont, Gaelle] Univ Tours, Nutr Growth & Canc, Inserm UMR1069, Tours, France; [Lerondel, Stephanie; Le Pape, Alain] Ctr Imagerie Petit Anim, CNRS UPS44 TAAM, Orleans, France; [Jiang, Lin-Hua] Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; [Jiang, Lin-Hua] Xinxiang Med Univ, Sino UK Joint Lab Brain Funct & Injury, Xinxiang 453003, Henan, Peoples R China; [Jiang, Lin-Hua] Xinxiang Med Univ, Dept Physiol & Pathophysiol, Xinxiang 453003, Henan, Peoples R China; [Murrell-Lagnado, Ruth] Univ Sussex, Sch Life Sci, Brighton, E Sussex, England; [Roger, Sebastien] Inst Univ France, Paris, France	Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; University of Leeds; Xinxiang Medical University; Xinxiang Medical University; University of Sussex; Institut Universitaire de France	Chadet, S (corresponding author), Univ Tours, EA4245 Transplantat Immunol Inflammat, Tours, France.	stephanie.chadet@univ-tours.fr	Brisson, Lucie/R-1179-2016	Brisson, Lucie/0000-0001-7811-1382; Murrell-Lagnado, Ruth/0000-0003-2743-7977	Ministere de la Recherche et des Technologies; Region Centre-Val de Loire (grant "CanalEx"); Institut National du Cancer [INCA_16110]; School of Life Science, University of Sussex (UK); AURCIL Association in Tours (France); Ligue Nationale Contre le Cancer -Interregion Grand-Ouest	Ministere de la Recherche et des Technologies; Region Centre-Val de Loire (grant "CanalEx"); Institut National du Cancer(Institut National du Cancer (INCA) France); School of Life Science, University of Sussex (UK); AURCIL Association in Tours (France); Ligue Nationale Contre le Cancer -Interregion Grand-Ouest	This work was supported by the "Ministere de la Recherche et des Technologies", the "Ligue Nationale Contre le Cancer -Interregion Grand-Ouest" to SR, the Region CentreVal de Loire (grant "CanalEx" to SR), the Institut National du Cancer (grant INCA_16110 "PURIN4EXO" to SR). SR was recipient of a prize "Prix Ruban Rose Avenir 2017" from the Charity "le Cancer du sein: parlons-en!". SC was recipient of a post-doctoral grant from the School of Life Science, University of Sussex (UK) and from the AURCIL Association in Tours (France). We thank Mrs Carole Desplanches for secretary and administrative assistance. We thank Mrs Stephanie Retif, Mrs Marilyne Le Mee and M. Julien Sobilo for the assistance with in vivo experiments performed at CNRS UPS44 CIPA, Orleans. Our microscopy data were obtained with the assistance of the IBiSA Electron Microscopy Facility of the University of Tours, and we are grateful to M. Julien Burlaud-Gaillard for his help with electronic and confocal microscopy. We thank Dr Vinh Ta Phuoc for the insightful discussions on lysosomal distribution analyses. This work was supported by the "Ministere de la Recherche et des Technologies", the "Ligue Nationale Contre le Cancer -Interregion Grand-Ouest" to SR, the Region Centre-Val de Loire (grant "CanalEx" to SR), the Institut National du Cancer (grant INCA_16110 "PURIN4EXO" to SR). SR was recipient of a prize "Prix Ruban Rose Avenir 2017" from the Charity "le Cancer du sein: parlons-en!". SC was recipient of a post-doctoral grant from the School of Life Science, University of Sussex (UK) and from the AURCIL Association in Tours (France).	Adinolfi E, 2015, CURR MED CHEM, V22, P878, DOI 10.2174/0929867321666141012172913; Biskou O, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209665; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Brisson L, 2016, CANCER CELL, V30, P418, DOI 10.1016/j.ccell.2016.08.005; Brix DM, 2019, ONCOGENE, V38, P3170, DOI 10.1038/s41388-018-0653-x; Burnstock G, 2013, PURINERG SIGNAL, V9, P541, DOI 10.1007/s11302-013-9381-4; Cao Q, 2015, J CELL BIOL, V209, P879, DOI 10.1083/jcb.201409071; Carnero Corrales MA, 2021, CELL CHEM BIOL; Caviston JP, 2011, MOL BIOL CELL, V22, P478, DOI 10.1091/mbc.E10-03-0233; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen HT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1030-2; Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060; Cogli L, 2013, BBA-MOL CELL RES, V1833, P1283, DOI 10.1016/j.bbamcr.2013.02.024; Di Virgilio F, 2009, PURINERG SIGNAL, V5, P251, DOI 10.1007/s11302-009-9145-3; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Gouirand V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00117; Groth-Pedersen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045381; Gugnoni M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.415; Hamalisto S, 2016, CURR OPIN CELL BIOL, V39, P69, DOI 10.1016/j.ceb.2016.02.009; Huang P, 2014, J BIOL CHEM, V289, P17658, DOI 10.1074/jbc.M114.552158; Ivaska Johanna, 2011, Small GTPases, V2, P51; Izuishi K, 2000, CANCER RES, V60, P6201; Janda E, 2006, ONCOGENE, V25, P7117, DOI 10.1038/sj.onc.1209701; Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Ketterer S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18935-2; Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004; Kundu ST, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05013-x; Lahiri V, 2019, CELL METAB, V29, P803, DOI 10.1016/j.cmet.2019.03.003; Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Li S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09634-8; Liang DH, 2016, CANCER LETT, V376, P249, DOI 10.1016/j.canlet.2016.04.002; Majora M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7510; Martin FT, 2010, BREAST CANCER RES TR, V124, P317, DOI 10.1007/s10549-010-0734-1; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019; Miklavc P, 2011, P NATL ACAD SCI USA, V108, P14503, DOI 10.1073/pnas.1101039108; Morgan MJ, 2018, P NATL ACAD SCI USA, V115, pE8479, DOI 10.1073/pnas.1706526115; Murrell-Lagnado RD, 2019, CURR OPIN PHARMACOL, V47, P126, DOI 10.1016/j.coph.2019.03.002; Murrell-Lagnado RD, 2018, J GEN PHYSIOL, V150, P185, DOI 10.1085/jgp.201711963; Olson OC, 2015, NAT REV CANCER, V15, P712, DOI 10.1038/nrc4027; Roger S, 2015, BBA-BIOMEMBRANES, V1848, P2584, DOI 10.1016/j.bbamem.2014.10.029; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Tan SL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910492; Toulme E, 2010, J GEN PHYSIOL, V135, P333, DOI 10.1085/jgp.200910336; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Westley BR, 1996, EUR J CANCER, V32A, P15, DOI 10.1016/0959-8049(95)00530-7; Zhitomirsky B, 2017, ONCOTARGET, V8, P45117, DOI 10.18632/oncotarget.15155	51	2	2	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2920	2931		10.1038/s41388-022-02297-8	http://dx.doi.org/10.1038/s41388-022-02297-8		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35411034				2022-12-28	WOS:000780668900002
J	Hiwatari, M; Seki, M; Matsuno, R; Yoshida, K; Nagasawa, T; Sato-Otsubo, A; Yamamoto, S; Kato, M; Watanabe, K; Sekiguchi, M; Miyano, S; Ogawa, S; Takita, J				Hiwatari, Mitsuteru; Seki, Masafumi; Matsuno, Ryosuke; Yoshida, Kenichi; Nagasawa, Takeshi; Sato-Otsubo, Aiko; Yamamoto, Shohei; Kato, Motohiro; Watanabe, Kentaro; Sekiguchi, Masahiro; Miyano, Satoru; Ogawa, Seishi; Takita, Junko			Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma	ONCOGENE			English	Article							ANAPLASTIC LYMPHOMA KINASE; YOUNG-ADULTS; EML4-ALK; PROTEIN; GENE; MUTATIONS; INHIBITOR; FAMILY; NPM; TRANSLOCATIONS	The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease. In this study, a translocation within chromosome 2p and 4q was found to bring about the formation of an in-frame fusion gene that was composed of portions of the teneurin transmembrane protein 3 (TENM3, also known as ODZ3) gene and the anaplastic lymphoma kinase (ALK) gene in tumor cells from patients with neuroblastoma. Expression of the full length TENM3-ALK cDNA in NIH-3T3 cells led to the formation of a fusion protein that: (1) possesses constitutive tyrosine kinase activity, (2) induces strong activation of the downstream targets of extracellular signal-regulated kinase (ERK), protein kinase B (a.k.a. AKT), and signal transducer and activator of transcription 3 (STAT3), (3) provokes oncogenic transformation in NOD.Cg-Prkdc(scid)Il2rg(tm1Sug)/ShiJic mice, and (4) possesses sensitivity to ALK inhibitors in vitro and in vivo. Our findings demonstrated that patients with neuroblastoma may express a transforming fusion kinase, which is a promising candidate for a therapeutic target and a diagnostic molecular marker for neuroblastoma. The in-frame 5 ' partner gene that fuses with ALK has not been reported previously in neuroblastoma. Our data provide novel biological insights into the mechanism of ALK activation due to translocation, with implications for neuroblastoma tumorigenesis, and could be useful as a vital marker for the accurate diagnosis of this type of neuroblastoma.	[Hiwatari, Mitsuteru; Seki, Masafumi; Nagasawa, Takeshi; Sato-Otsubo, Aiko; Kato, Motohiro; Watanabe, Kentaro; Sekiguchi, Masahiro] Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan; [Hiwatari, Mitsuteru] Univ Tokyo Hosp, Dept Cell Therapy & Transplantat Med, Tokyo, Japan; [Hiwatari, Mitsuteru] Teikyo Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Matsuno, Ryosuke] Kansai Med Univ, Dept Pediat, Osaka, Japan; [Yoshida, Kenichi; Ogawa, Seishi] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Yoshidakonoecho, Kyoto, Japan; [Yamamoto, Shohei] Tokai Univ, Dept Pediat, Sch Med, Isehara, Kanagawa, Japan; [Miyano, Satoru] Tokyo Med & Dent Univ, Med & Dent Data Sci Ctr, Tokyo, Japan; [Ogawa, Seishi] Kyoto Univ, Inst Adv Study Human Biol WPI ASHBi, Sakyo Ku, Yoshidakonoecho, Kyoto, Japan; [Ogawa, Seishi] Karolinska Inst, Dept Med, Ctr Hematol & Regenerat Med, Stockholm, Sweden; [Takita, Junko] Kyoto Univ, Dept Pediat, Sakyo Ku, Yoshidakonoecho, Kyoto, Japan	University of Tokyo; University of Tokyo; Teikyo University; Kansai Medical University; Kyoto University; Tokai University; Tokyo Medical & Dental University (TMDU); Kyoto University; Karolinska Institutet; Kyoto University	Hiwatari, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan.; Hiwatari, M (corresponding author), Univ Tokyo Hosp, Dept Cell Therapy & Transplantat Med, Tokyo, Japan.; Hiwatari, M (corresponding author), Teikyo Univ, Sch Med, Dept Pediat, Tokyo, Japan.	mhiwatari-tky@umin.ac.jp	HIWATARI, Mitsuteru/HDM-0869-2022; Seki, Masafumi/AAN-1025-2021	Seki, Masafumi/0000-0003-4671-7026; Matsuno, Ryosuke/0000-0003-3231-4760; Yoshida, Kenichi/0000-0003-4612-2778; Sekiguchi, Masahiro/0000-0002-7941-9319; Nagasawa, Takeshi/0000-0002-1552-3619; Yamamoto, Shohei/0000-0003-1582-7062	JSPS KAKENHI [JP19J11112, JP17H04224, JP18K19467, JP20H00528]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) [JP19cm0106509h9904]; Japan Agency for Medical Research and Development (AMED) [JP19ck0106468h001]; Princess Takamatsu Cancer Research Fund; RIKEN Advanced Institute for Computational Science through the HPCI System Research project [hp140230, hp160219, hp150232]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Project for Cancer Research and Therapeutic Evolution (P-CREATE); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Princess Takamatsu Cancer Research Fund; RIKEN Advanced Institute for Computational Science through the HPCI System Research project	The authors would like to thank M. Matsumura, K. Yin, and F. Saito for their excellent technical assistance, Dr. T. Kitamura (Division of Cellular Therapy/Division of Stem Cell Signaling, The Institute of Medical Sciences, The University of Tokyo, Japan) for the kind gift of expression vector pMYs-IRES-Neo. The authors also wish to express their appreciation to K. Chiba and H. Tanaka (The University of Tokyo) for the supercomputer. This work was supported by JSPS KAKENHI Grant Numbers JP19J11112, JP17H04224, JP18K19467, and JP20H00528; Project for Cancer Research and Therapeutic Evolution (P-CREATE; grant no. JP19cm0106509h9904), and Practical Research for Innovative Cancer Control (grant no. JP19ck0106468h001) from the Japan Agency for Medical Research and Development (AMED); Princess Takamatsu Cancer Research Fund. This research also used the computational resources of the K computer provided by the RIKEN Advanced Institute for Computational Science through the HPCI System Research project (hp140230, hp160219, and hp150232) (SM and SO).	Amano Y, 2015, BIOCHEM BIOPH RES CO, V457, P457, DOI 10.1016/j.bbrc.2015.01.014; Arregui CO, 2000, NEUROCHEM RES, V25, P95, DOI 10.1023/A:1007595617447; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Camidge DR, 2018, NEW ENGL J MED, V379, P2027, DOI 10.1056/NEJMoa1810171; Caren H, 2008, BIOCHEM J, V416, P153, DOI 10.1042/BJ20081834; Cazes A, 2013, CANCER RES, V73, P195, DOI 10.1158/0008-5472.CAN-12-1242; Ceccon M, 2016, ONCOGENE, V35, P3854, DOI 10.1038/onc.2015.456; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Choi YL, 2014, J THORAC ONCOL, V9, P563, DOI 10.1097/JTO.0000000000000093; Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365; Della Corte CM, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0776-2; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Feng K, 2002, J BIOL CHEM, V277, P26128, DOI 10.1074/jbc.M203722200; Fransson S, 2015, GENE CHROMOSOME CANC, V54, P99, DOI 10.1002/gcc.22223; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Grande E, 2011, MOL CANCER THER, V10, P569, DOI 10.1158/1535-7163.MCT-10-0615; Hiwatari M, 2003, ONCOGENE, V22, P2851, DOI 10.1038/sj.onc.1206389; Infarinato NR, 2016, CANCER DISCOV, V6, P96, DOI 10.1158/2159-8290.CD-15-1056; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Johnson TW, 2014, J MED CHEM, V57, P4720, DOI 10.1021/jm500261q; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Li ZB, 2014, AM J CLIN PATHOL, V141, P420, DOI 10.1309/AJCPHF51LSPCAXTA; Mano H, 2008, CANCER SCI, V99, P2349, DOI 10.1111/j.1349-7006.2008.00972.x; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Martelli MP, 2009, AM J PATHOL, V174, P661, DOI 10.2353/ajpath.2009.080755; Mason DY, 1998, CANCER RES, V58, P1057; Matsuno R, 2020, PEDIATR INT, V62, P507, DOI 10.1111/ped.14117; Mazzocco K, 2015, PEDIATR BLOOD CANCER, V62, P1725, DOI 10.1002/pbc.25552; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2014, PEDIATR BLOOD CANCER, V61, P627, DOI 10.1002/pbc.24777; Okubo J, 2012, ONCOGENE, V31, P4667, DOI 10.1038/onc.2011.616; Oohashi T, 1999, J CELL BIOL, V145, P563, DOI 10.1083/jcb.145.3.563; Passoni L, 2009, CANCER RES, V69, P7338, DOI 10.1158/0008-5472.CAN-08-4419; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Pulford K, 2004, J CELL PHYSIOL, V199, P330, DOI 10.1002/jcp.10472; Richards MW, 2015, BIOCHEM J, V467, P529, DOI 10.1042/BJ20150039; Richards MW, 2014, P NATL ACAD SCI USA, V111, P5195, DOI 10.1073/pnas.1322892111; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Roskoski R, 2013, PHARMACOL RES, V68, P68, DOI 10.1016/j.phrs.2012.11.007; Seki M, 2017, NAT GENET, V49, P1274, DOI 10.1038/ng.3900; Seki M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8557; SHIOTA M, 1994, ONCOGENE, V9, P1567; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Stein H, 2000, BLOOD, V96, P3681; Tabbo F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00041; Takeuchi K, 2008, CLIN CANCER RES, V14, P6618, DOI 10.1158/1078-0432.CCR-08-1018; Takita J, 2017, CANCER SCI, V108, P1913, DOI 10.1111/cas.13333; Tang ZY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163939; Young TR, 2009, INT J BIOCHEM CELL B, V41, P990, DOI 10.1016/j.biocel.2008.06.014; Ziegler A, 2012, CANCER LETT, V326, P1, DOI 10.1016/j.canlet.2012.07.021	55	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2789	2797		10.1038/s41388-022-02301-1	http://dx.doi.org/10.1038/s41388-022-02301-1		APR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35411036				2022-12-28	WOS:000780668900003
J	Lane, R; Cilibrasi, C; Chen, JN; Shah, KL; Messuti, E; Mazarakis, NK; Stebbing, J; Critchley, G; Song, ER; Simon, T; Giamas, G				Lane, Rosemary; Cilibrasi, Chiara; Chen, Jianing; Shah, Kalpit; Messuti, Eleonora; Mazarakis, Nektarios K.; Stebbing, Justin; Critchley, Giles; Song, Erwei; Simon, Thomas; Giamas, Georgios			PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38(MAPK) signalling	ONCOGENE			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR RECEPTOR; TUMOR-CELLS; ANTITUMOR-ACTIVITY; STEM-CELL; KINASE; PHOSPHORYLATION; THERAPY; CLASSIFICATION; IDENTIFICATION	Glioblastoma (GBM) is the most common and fatal primary brain tumour in adults. Considering that resistance to current therapies leads to limited response in patients, new therapeutic options are urgently needed. In recent years, differentiation therapy has been proposed as an alternative for GBM treatment, with the aim of bringing cancer cells into a post-mitotic/differentiated state, ultimately limiting tumour growth. As an integral component of cancer development and regulation of differentiation processes, kinases are potential targets of differentiation therapies. The present study describes how the screening of a panel of kinase inhibitors (KIs) identified PDGF-R alpha/beta inhibitor CP-673451 as a potential differentiation agent in GBM. We show that targeting PDGF-R alpha/beta with CP-673451 in vitro triggers outgrowth of neurite-like processes in GBM cell lines and GBM stem cells (GSCs), suggesting differentiation into neural-like cells, while reducing proliferation and invasion in 3D hyaluronic acid hydrogels. In addition, we report that treatment with CP-673451 improves the anti-tumour effects of temozolomide in vivo using a subcutaneous xenograft mouse model. RNA sequencing and follow-up proteomic analysis revealed that upregulation of phosphatase DUSP1 and consecutive downregulation of phosphorylated-p38(MAPK) can underlie the pro-differentiation effect of CP-673451 on GBM cells. Overall, the present study identifies a potential novel therapeutic option that could benefit GBM patients in the future, through differentiation of residual GSCs post-surgery, with the aim to limit recurrence and improve quality of life.	[Lane, Rosemary; Cilibrasi, Chiara; Messuti, Eleonora; Simon, Thomas; Giamas, Georgios] Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England; [Chen, Jianing; Song, Erwei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou, Peoples R China; [Shah, Kalpit] Genentech Inc, San Francisco, CA 94080 USA; [Mazarakis, Nektarios K.] Royal Coll Surgeons Ireland, Dublin D02 YN77, Ireland; [Mazarakis, Nektarios K.] Beaumont Hosp, Dept Neurosurg, Dublin D09 V2N0, Ireland; [Stebbing, Justin] Imperial Coll London, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus, London, England; [Critchley, Giles] Univ Hosp Sussex, Dept Neurosurg, Brighton BN2 5BE, E Sussex, England; [Simon, Thomas] Univ Southern Calif, Keck Sch Med, Dept Translat Genom, Los Angeles, CA 90033 USA	University of Sussex; Sun Yat Sen University; Roche Holding; Genentech; Royal College of Surgeons - Ireland; Imperial College London; University of Southern California	Giamas, G (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England.	g.giamas@sussex.ac.uk		Simon, Thomas/0000-0002-3280-2716; Stebbing, Justin/0000-0002-1117-6947; Lane, Rosemary/0000-0002-9463-8034; Messuti, Eleonora/0000-0002-5613-4337	Action Against Cancer [ID6758/G1867]	Action Against Cancer	This research was funded by Action Against Cancer, grant number ID6758/G1867.	Albini A, 2015, CONNECT TISSUE RES, V56, P414, DOI 10.3109/03008207.2015.1066780; Ardito F, 2017, INT J MOL MED, V40, P271, DOI 10.3892/ijmm.2017.3036; Arrizabalaga O, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0003-9; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bates A, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k2924; Bonnin DAA, 2017, MOL CANCER THER, V16, P705, DOI 10.1158/1535-7163.MCT-16-0616; Chao CC, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.414; Cohen MH, 2005, CLIN CANCER RES, V11, P6767, DOI 10.1158/1078-0432.CCR-05-0722; Collins LM, 2013, NEUROMOL MED, V15, P435, DOI 10.1007/s12017-013-8230-5; Corona SP, 2018, DRUG DES DEV THER, V12, P321, DOI 10.2147/DDDT.S137783; Demuth T, 2004, J NEURO-ONCOL, V70, P217, DOI 10.1007/s11060-004-2751-6; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Dolma S, 2016, CANCER CELL, V29, P859, DOI 10.1016/j.ccell.2016.05.002; Erlichman C, 2006, J CLIN ONCOL, V24, P2252, DOI 10.1200/JCO.2005.01.8960; Floryk D, 2004, CANCER RES, V64, P9049, DOI 10.1158/0008-5472.CAN-04-1553; Garcia-Romero N, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01610-0; Ghosh D, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169-018-0211-8; Giamas G, 2007, BIOCHEM J, V406, P389, DOI 10.1042/BJ20070091; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; Gupta A, 2017, J NEUROSCI RURAL PRA, V8, P629, DOI 10.4103/jnrp.jnrp_168_17; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hart S, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.43; Hoppstadter J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01446; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ishay-Ronen D, 2019, CANCER CELL, V35, P17, DOI 10.1016/j.ccell.2018.12.002; Jeanneteau F, 2010, NAT NEUROSCI, V13, P1373, DOI 10.1038/nn.2655; Kong Ling-Ling, 2017, Chronic Dis Transl Med, V3, P221, DOI 10.1016/j.cdtm.2017.11.001; Lane R, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0560-x; Laser-Azogui A, 2015, CURR OPIN CELL BIOL, V32, P92, DOI 10.1016/j.ceb.2015.01.003; Lehman NL, 2012, CELL CYCLE, V11, P489, DOI 10.4161/cc.11.3.18996; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mei X, 2017, NEURO-ONCOLOGY, V19, P1109, DOI 10.1093/neuonc/nox016; Mikitsh JL, 2014, PERSPECT MED CHEM, V6, P11, DOI 10.4137/PMC.S13384; Nunes M, 2004, MOL CANCER THER, V3, P21; Peinado-Ramon P, 1998, MOL BRAIN RES, V56, P256, DOI 10.1016/S0169-328X(98)00047-3; Perez-Sen R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081999; Raub TJ, 2015, DRUG METAB DISPOS, V43, P1360, DOI 10.1124/dmd.114.062745; Roberts WG, 2005, CANCER RES, V65, P957; Sestito S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00874; Simon T, 2020, ONCOGENE, V39, P4477, DOI 10.1038/s41388-020-1308-2; Simon T, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0878-x; Simon T, 2017, TRENDS MOL MED, V23, P282, DOI 10.1016/j.molmed.2017.01.002; Simon T, 2014, NEUROMOL MED, V16, P752, DOI 10.1007/s12017-014-8324-8; Singh SK, 2003, CANCER RES, V63, P5821; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Song K, 2018, AM J CANCER RES, V8, P792; Stebbing J, 2018, ONCOGENE, V37, P3113, DOI 10.1038/s41388-018-0197-0; Taylor OG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00963; Van Brocklyn JR, 2014, CANCER RES, V74, P5364, DOI 10.1158/0008-5472.CAN-14-0386; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; William AD, 2011, J MED CHEM, V54, P4638, DOI 10.1021/jm200326p; Xing F, 2017, CELL REP, V18, P468, DOI 10.1016/j.celrep.2016.12.037; Xu WP, 2014, J DIGEST DIS, V15, P159, DOI 10.1111/1751-2980.12122; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	56	0	0	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2749	2763		10.1038/s41388-022-02294-x	http://dx.doi.org/10.1038/s41388-022-02294-x		APR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35393545	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000779227700001
J	Lv, DM; Ding, SR; Zhong, L; Tu, J; Li, HB; Yao, H; Zou, YT; Zeng, ZL; Liao, Y; Wan, XS; Wen, LL; Xie, XB				Lv, Dongming; Ding, Shirong; Zhong, Li; Tu, Jian; Li, Hongbo; Yao, Hao; Zou, Yutong; Zeng, Ziliang; Liao, Yan; Wan, Xuesi; Wen, Lili; Xie, Xianbiao			M(6)A demethylase FTO-mediated downregulation of DACT1 mRNA stability promotes Wnt signaling to facilitate osteosarcoma progression	ONCOGENE			English	Article							GENE; SUPPRESSES; PROTEIN	Despite advances in clinical diagnosis and treatment, the prognosis of patients with osteosarcoma (OS) remains poor, and the treatment efficacy has plateaued. Therefore, it is important to identify new therapeutic targets for OS. N-6-methyladenosine (m(6)A) modification has been reported to participate in tumor malignancy. In this study, functional screening showed that the m(6)A demethylase FTO could be a candidate therapeutic target for OS. Upregulated FTO in OS could predict a poorer prognosis. FTO promoted the growth and metastasis of OS in vitro and in vivo. Methylated RNA immunoprecipitation sequencing (MeRIP-seq) and RNA sequencing (RNA-seq) were performed to identify DACT1 as a potential target of FTO. In vitro assays demonstrated that FTO could reduce the mRNA stability of DACT1 via m(6)A demethylation, which decreased DACT1 expression and further activated the Wnt signaling pathway. The oncogenic effect of FTO on OS was dependent on DACT1. In addition, the m(6)A reader IGF2BP1 was validated to participate in the regulation of DACT1. Entacapone, a conventional drug for Parkinson's disease, was confirmed to suppress OS via m(6)A-mediated regulation through the FTO/DACT1 axis. Our findings demonstrate that FTO may be a novel therapeutic target and that entacapone has preclinical value to be repurposed for OS.	[Lv, Dongming; Tu, Jian; Li, Hongbo; Yao, Hao; Zou, Yutong; Zeng, Ziliang; Liao, Yan; Xie, Xianbiao] Sun Yat Sen Univ, Dept Musculoskeletal Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China; [Lv, Dongming; Tu, Jian; Li, Hongbo; Yao, Hao; Zou, Yutong; Zeng, Ziliang; Liao, Yan; Xie, Xianbiao] Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou, Peoples R China; [Ding, Shirong] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, Guangzhou, Peoples R China; [Zhong, Li] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Zhong, Li] Sun Yat Sen Univ, Affiliated Hosp 7, Sci Res Ctr, Shenzhen, Peoples R China; [Wan, Xuesi] Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Peoples R China; [Wan, Xuesi] Sun Yat Sen Univ, Diabet Ctr, Affiliated Hosp 1, Guangzhou, Peoples R China; [Wen, Lili] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Anesthesiol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Xie, XB (corresponding author), Sun Yat Sen Univ, Dept Musculoskeletal Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China.; Xie, XB (corresponding author), Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou, Peoples R China.; Wen, LL (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Anesthesiol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.	wenll@sysucc.org.cn; xiexbiao@mail.sysu.edu.cn		Zeng, Ziliang/0000-0002-0095-8396; DONGMING, LV/0000-0001-9642-0410	National Natural Science Foundation of China [81972510, 81772864, 81572638]; Natural Science Foundation of Guangdong Province [2016A030313239]; Medical Scientific Research Foundation of Guangdong Province [A2020483]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Medical Scientific Research Foundation of Guangdong Province	This study was supported by National Natural Science Foundation of China (Grants 81972510, 81772864 and 81572638), Natural Science Foundation of Guangdong Province (No.2016A030313239), and Medical Scientific Research Foundation of Guangdong Province (A2020483).	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P1; Barbieri I, 2020, NAT REV CANCER, V20, P303, DOI 10.1038/s41568-020-0253-2; Berulava T, 2020, EUR J HEART FAIL, V22, P54, DOI 10.1002/ejhf.1672; Cacabelos R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030551; Chen CYA, 2008, METHOD ENZYMOL, V448, P335, DOI 10.1016/S0076-6879(08)02617-7; Chen HR, 2021, GASTROENTEROLOGY, V160, P1284, DOI 10.1053/j.gastro.2020.11.013; Chen SJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02847-6; Chen XX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01220-7; Chen YB, 2021, AUTOPHAGY, V17, P457, DOI 10.1080/15548627.2020.1720431; Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626; Eaton BR, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28352; Esposito M, 2021, NAT CELL BIOL, V23, P257, DOI 10.1038/s41556-021-00641-w; Fischer J, 2009, NATURE, V458, P894, DOI 10.1038/nature07848; Fisher DA, 2006, DEV DYNAM, V235, P2620, DOI 10.1002/dvdy.20917; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; Gao X, 2008, J BIOL CHEM, V283, P35679, DOI 10.1074/jbc.M804088200; Gilbert WV, 2016, SCIENCE, V352, P1408, DOI 10.1126/science.aad8711; Gordin A, 2004, J NEURAL TRANSM, V111, P1343, DOI 10.1007/s00702-004-0190-3; Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939; Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Li HY, 2020, THERANOSTICS, V10, P9477, DOI 10.7150/thno.45763; Li JH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00769; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Liao D, 2015, CLIN CANCER RES, V21, P5349, DOI 10.1158/1078-0432.CCR-15-0198; Lin ZY, 2020, EMBO J, V39, DOI 10.15252/embj.2019103181; Liu H, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018-021-02422-5; Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006; Lv DM, 2020, METABOLOMICS, V16, DOI 10.1007/s11306-020-01745-4; Matsuoka K, 2020, CELL RES, V30, P885, DOI 10.1038/s41422-020-0370-1; Niu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1004-4; Okerlund ND, 2010, J NEUROSCI, V30, P4362, DOI 10.1523/JNEUROSCI.0354-10.2010; Peng SM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau7116; Simpson E, 2018, JAAPA-J AM ACAD PHYS, V31, P15, DOI 10.1097/01.JAA.0000541477.24116.8d; Stojic L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14978-7; Su R, 2020, CANCER CELL, V38, P79, DOI 10.1016/j.ccell.2020.04.017; Sun T, 2020, ONCOGENE, V39, P5358, DOI 10.1038/s41388-020-1338-9; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang XR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15304-x; Wang YJ, 2019, EPIGENOMICS-UK, V11, P1693, DOI 10.2217/epi-2019-0262; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Xiao YR, 2020, P NATL ACAD SCI USA, V117, P21441, DOI 10.1073/pnas.2000516117; Yang CF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21196985; Yang JH, 2019, BIOL RES, V52, DOI 10.1186/s40659-019-0238-3; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Yin XD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3399; Zhang CZ, 2020, ONCOGENE, V39, P4507, DOI 10.1038/s41388-020-1303-7; Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200; Zhao BXS, 2017, NAT REV MOL CELL BIO, V18, P31, DOI 10.1038/nrm.2016.132; Zhong L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00414-1; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006; Zhou B, 2021, HEPATOLOGY, V73, P91, DOI 10.1002/hep.31220; Zhou L, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109964; Zhou ZJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01216-3; Zhu ST, 2020, MOL THER-NUCL ACIDS, V22, P957, DOI 10.1016/j.omtn.2020.10.010; Zhuang CS, 2019, J CELL MOL MED, V23, P2163, DOI 10.1111/jcmm.14128	58	7	7	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1727	1741		10.1038/s41388-022-02214-z	http://dx.doi.org/10.1038/s41388-022-02214-z		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35121825				2022-12-28	WOS:000751251500003
J	Xu, LF; Zhao, B; Butler, W; Xu, H; Song, N; Chen, XF; Hauck, JS; Gao, X; Zhang, H; Groth, J; Yang, Q; Zhao, Y; Moon, D; George, D; Zhou, YL; He, YP; Huang, JT				Xu, Lingfan; Zhao, Bing; Butler, William; Xu, Huan; Song, Nan; Chen, Xufeng; Hauck, J. Spencer; Gao, Xia; Zhang, Hong; Groth, Jeff; Yang, Qing; Zhao, Yue; Moon, David; George, Daniel; Zhou, Yinglu; He, Yiping; Huang, Jiaoti			Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer	ONCOGENE			English	Article							CELL; PTEN	Advanced and aggressive prostate cancer (PCa) depends on glutamine for survival and proliferation. We have previously shown that inhibition of glutaminase 1, which catalyzes the rate-limiting step of glutamine catabolism, achieves significant therapeutic effect; however, therapy resistance is inevitable. Here we report that while the glutamine carbon is critical to PCa survival, a parallel pathway of glutamine nitrogen catabolism that actively contributes to pyrimidine assembly is equally important for PCa cells. Importantly, we demonstrate a reciprocal feedback mechanism between glutamine carbon and nitrogen pathways which leads to therapy resistance when one of the two pathways is inhibited. Combination treatment to inhibit both pathways simultaneously yields better clinical outcome for advanced PCa patients.	[Xu, Lingfan; Zhao, Bing; Butler, William; Xu, Huan; Song, Nan; Chen, Xufeng; Hauck, J. Spencer; Zhang, Hong; Groth, Jeff; Zhao, Yue; Moon, David; He, Yiping; Huang, Jiaoti] Duke Univ, Dept Pathol, Sch Med, Durham, NC 27710 USA; [Gao, Xia; Huang, Jiaoti] Duke Univ, Dept Pharmacol & Canc Biol, Sch Med, Durham, NC 27710 USA; [Gao, Xia] Duke Univ, Duke Mol Physiol Inst, Sch Med, Durham, NC USA; [Yang, Qing] Duke Univ, Duke Sch Nursing, Durham, NC USA; [Zhao, Yue] China Med Univ, Coll Basic Med Sci, Dept Pathol, Shenyang, Peoples R China; [Zhao, Yue] China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China; [George, Daniel] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; [George, Daniel; Huang, Jiaoti] Duke Univ, Duke Canc Inst, Sch Med, Durham, NC 27710 USA; [Zhou, Yinglu] Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA; [Xu, Huan] Shanghai Ninth Peoples Hosp, Dept Urol, Shanghai, Peoples R China; [Song, Nan] Capital Med Univ, Beijing Shijitan Hosp, Dept Urol, Beijing, Peoples R China	Duke University; Duke University; Duke University; Duke University; China Medical University; China Medical University; Duke University; Duke University; Harvard University; Dana-Farber Cancer Institute; Shanghai Jiao Tong University; Capital Medical University	Huang, JT (corresponding author), Duke Univ, Dept Pathol, Sch Med, Durham, NC 27710 USA.; Huang, JT (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, Sch Med, Durham, NC 27710 USA.; Huang, JT (corresponding author), Duke Univ, Duke Canc Inst, Sch Med, Durham, NC 27710 USA.	jiaoti.huang@duke.edu	Zhao, Yue/AGZ-4412-2022	Zhao, Yue/0000-0002-0110-0359; Gao, Xia/0000-0003-0979-9990; Hauck, J. Spencer/0000-0003-1722-8709; xu, lingfan/0000-0003-2465-241X; Zhao, Bing/0000-0001-5423-971X; Butler, William/0000-0001-7274-6352; Yang, Qing/0000-0003-4844-4690	Prostate Cancer Foundation Movember Valor Challenge Award (2018);  [DOD-W81XWH-19-1-0411];  [DOD-W81XWH2110034];  [K99-K99CA237618]	Prostate Cancer Foundation Movember Valor Challenge Award (2018); ; ; 	This work was supported by DOD-W81XWH-19-1-0411 (JH), DOD-W81XWH2110034 (LX), K99-K99CA237618 (XG), Prostate Cancer Foundation Movember Valor Challenge Award (2018).	Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Ben-Sahra I, 2013, SCIENCE, V339, P1323, DOI 10.1126/science.1228792; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Biancur DE, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15965; Bott AJ, 2019, CANCERS, V11, DOI 10.3390/cancers11060770; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chen M, 2018, NAT GENET, V50, P206, DOI 10.1038/s41588-017-0027-2; Cluntun AA, 2017, TRENDS CANCER, V3, P169, DOI 10.1016/j.trecan.2017.01.005; Crumbaker M, 2017, CANCERS, V9, DOI 10.3390/cancers9040034; Davidson SM, 2016, CELL METAB, V23, P517, DOI 10.1016/j.cmet.2016.01.007; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Kodama M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15136-9; Lane AN, 2015, NUCLEIC ACIDS RES, V43, P2466, DOI 10.1093/nar/gkv047; Li YJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax0428; Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Oizel K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2523-z; Park JH, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102308; Park JW, 2016, P NATL ACAD SCI USA, V113, P4482, DOI 10.1073/pnas.1603645113; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Rawla P, 2019, WORLD J ONCOL, V10, P63, DOI 10.14740/wjon1191; Robitaille AM, 2013, SCIENCE, V339, P1320, DOI 10.1126/science.1228771; Spetsieris N, 2020, CANCERS, V12, DOI 10.3390/cancers12123792; Swami U, 2020, TRENDS CANCER, V6, P702, DOI 10.1016/j.trecan.2020.04.010; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wang XX, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau4972; Wang YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08033-9; Wang ZF, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.589508; Xu LF, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2012748118; Yang LF, 2016, CELL METAB, V24, P685, DOI 10.1016/j.cmet.2016.10.011; Yin Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0941-2; Yoo HC, 2020, EXP MOL MED, V52, P1496, DOI 10.1038/s12276-020-00504-8; Yu X, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00394; Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151	38	1	1	5	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1140	1154		10.1038/s41388-021-02155-z	http://dx.doi.org/10.1038/s41388-021-02155-z		JAN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35046532				2022-12-28	WOS:000744388700001
J	Byun, JY; Huang, K; Lee, JS; Huang, WJ; Hu, L; Zheng, XY; Tang, X; Li, FZ; Jo, DG; Song, XM; Huang, C				Byun, Joo-Yun; Huang, Kun; Lee, Jong Suk; Huang, Wenjie; Hu, Li; Zheng, Xuyu; Tang, Xin; Li, Fengzeng; Jo, Dong-Gyu; Song, Xinmao; Huang, Chuang			Targeting HIF-1 alpha/NOTCH1 pathway eliminates CD44(+) cancer stem-like cell phenotypes, malignancy, and resistance to therapy in head and neck squamous cell carcinoma	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTORS; EPITHELIAL-MESENCHYMAL TRANSITION; FACTOR 1-ALPHA; CHEMOTHERAPY RESISTANCE; BREAST-CANCER; EXPRESSION; PROGNOSIS; GROWTH; NOTCH; TH-302	Poor prognosis of head and neck squamous cell carcinomas (HNSCCs) results from resistance to chemotherapy and radiotherapy. To uncover the drivers of HNSCC resistance, including stemness and hypoxia, in this study, we compared the gene expression between CD44(+) and CD44(-) HNSCC cells and assessed the correlation of CD44 and hypoxia-inducible factor 1 alpha (HIF-1 alpha) expression with mouse features and outcomes of patients with HNSCC. We combined the knockdown or activation of HIF-1 alpha with in vitro and in vivo assays to evaluate effects on stemness and resistance of HNSCC cells. Analysis of clinical data showed that activation of HIF-1 alpha in CD44(+) patients with HNSCC was correlated with worse prognosis. Functional assays showed that HIF-1 alpha promoted stemness, resistance, and epithelial-mesenchymal transition in HNSCC CD44(+) cells. HIF-1 alpha activated NOTCH1 signaling in HNSCC stem-like cells characterized by CD44 expression. Moreover, inhibition of these signaling proteins using shRNA or Evofosfamide (Evo) development for cancer treatment, reversed chemoresistance in vitro and in vivo. Taken together, our results indicated that targeting HIF-1 alpha attenuated NOTCH1-induced stemness, which regulates responses to chemotherapy or radiotherapy and malignancy in CD44(+) HNSCCs. HIF-1 alpha/NOTCH1 signaling may represent a target for HNSCC treatment.	[Byun, Joo-Yun; Lee, Jong Suk; Jo, Dong-Gyu] Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea; [Huang, Kun; Hu, Li; Zheng, Xuyu; Tang, Xin; Li, Fengzeng] Chongqing Med Univ, Dept Dermatol, Affiliated Hosp 1, Chongqing, Peoples R China; [Huang, Wenjie] Chongqing Med Univ, Key Lab Diagnost Med, Minist Educ, Chongqing, Peoples R China; [Song, Xinmao] Fudan Univ, Dept Radiat Oncol, Eye Ear Nose & Throat Hosp, Shanghai, Peoples R China; [Huang, Chuang] Chongqing Univ, Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis &, Chongqing, Peoples R China; [Huang, Chuang] Chongqing Canc Inst, Chongqing, Peoples R China; [Huang, Chuang] Chongqing Canc Hosp, Chongqing, Peoples R China	Sungkyunkwan University (SKKU); Chongqing Medical University; Chongqing Medical University; Fudan University; Chongqing University	Jo, DG (corresponding author), Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea.; Song, XM (corresponding author), Fudan Univ, Dept Radiat Oncol, Eye Ear Nose & Throat Hosp, Shanghai, Peoples R China.; Huang, C (corresponding author), Chongqing Univ, Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis &, Chongqing, Peoples R China.; Huang, C (corresponding author), Chongqing Canc Inst, Chongqing, Peoples R China.; Huang, C (corresponding author), Chongqing Canc Hosp, Chongqing, Peoples R China.	jodg@skku.edu; muqinger@sina.com; huangchuang@126.com	Jo, Dong-Gyu/AAN-9278-2021; Song, Xinmao/AAP-9859-2021	Jo, Dong-Gyu/0000-0003-2271-1076; Song, Xinmao/0000-0002-4265-1851	MSKCC Senior Research Scientist Changhwan Yoon; National Natural Science Foundation grants of China [81972942]; Chongqing Science and Health Joint Medical Research Project [2020FYYX017]; Chongqing Innovative Support Program for Returned Overseas Chinese Scholars [cx2020103]; Natural Science Foundation grants of Chongqing [cstc2021jcyj-msxmX0009]; High-level Medical Reserved Personnel Training Project of Chongqing	MSKCC Senior Research Scientist Changhwan Yoon; National Natural Science Foundation grants of China(National Natural Science Foundation of China (NSFC)); Chongqing Science and Health Joint Medical Research Project; Chongqing Innovative Support Program for Returned Overseas Chinese Scholars; Natural Science Foundation grants of Chongqing; High-level Medical Reserved Personnel Training Project of Chongqing	We thank MSKCC Senior Research Scientist Changhwan Yoon for supporting Data and reviewing this manuscript. This study was supported by the National Natural Science Foundation grants of China (grant no. 81972942), the Chongqing Science and Health Joint Medical Research Project (grant no. 2020FYYX017), Chongqing Innovative Support Program for Returned Overseas Chinese Scholars (grant no. cx2020103), and the Natural Science Foundation grants of Chongqing (grant no. cstc2021jcyj-msxmX0009), and High-level Medical Reserved Personnel Training Project of Chongqing.	Acker T, 2005, CANCER CELL, V8, P131, DOI 10.1016/j.ccr.2005.07.003; Aebersold DM, 2001, CANCER RES, V61, P2911; Alison MR, 2012, CANCER TREAT REV, V38, P589, DOI 10.1016/j.ctrv.2012.03.003; Arumugam TV, 2018, PROG NEUROBIOL, V165, P103, DOI 10.1016/j.pneurobio.2018.03.002; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Birner P, 2000, CANCER RES, V60, P4693; Birner P, 2001, CLIN CANCER RES, V7, P1661; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Cheng YL, 2015, PHARMACOL THERAPEUT, V147, P80, DOI 10.1016/j.pharmthera.2014.11.005; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Crowder Spencer W, 2014, Curr Pathobiol Rep, V2, P33; Duan JX, 2008, J MED CHEM, V51, P2412, DOI 10.1021/jm701028q; Fabbro D, 2020, CHIMIA, V74, P779, DOI 10.2533/chimia.2020.779; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Favier J, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-139; Foster JG, 2014, FUTURE ONCOL, V10, P2659, DOI 10.2217/fon.14.201; Gammon L, 2016, J ORAL PATHOL MED, V45, P77, DOI 10.1111/jop.12327; Gao T, 2016, BIOMED PHARMACOTHER, V80, P393, DOI 10.1016/j.biopha.2016.02.044; Ghattass K, 2013, CURR CANCER DRUG TAR, V13, P670, DOI 10.2174/15680096113139990004; Guo M, 2006, APOPTOSIS, V11, P67, DOI 10.1007/s10495-005-3085-3; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hashimoto O, 2011, PATHOBIOLOGY, V78, P181, DOI 10.1159/000325538; Huang C, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2448-6; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kim NS, 2011, PATHOL ONCOL RES, V17, P493, DOI 10.1007/s12253-010-9327-x; Koukourakis MI, 2002, INT J RADIAT ONCOL, V53, P1192, DOI 10.1016/S0360-3016(02)02848-1; Krishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lee KE, 2012, CURR OPIN CELL BIOL, V24, P232, DOI 10.1016/j.ceb.2012.01.005; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Mendez O, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-133; Mimeault M, 2013, J CELL MOL MED, V17, P30, DOI 10.1111/jcmm.12004; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Putra AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134496; Rawluszko-Wieczorek AA, 2014, MOL CANCER RES, V12, P1112, DOI 10.1158/1541-7786.MCR-14-0054; Rocco A, 2012, WORLD J GASTRO ONCOL, V4, P54, DOI 10.4251/wjgo.v4.i3.54; Saggar JK, 2014, INT J CANCER, V134, P2726, DOI 10.1002/ijc.28595; Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Sena JA, 2014, MOL CANCER RES, V12, P1233, DOI 10.1158/1541-7786.MCR-14-0149; Sindhu SK, 2019, ORAL MAXIL SURG CLIN, V31, P145, DOI 10.1016/j.coms.2018.09.003; Sivridis E, 2002, CANCER-AM CANCER SOC, V95, P1055, DOI 10.1002/cncr.10774; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sun JD, 2012, CLIN CANCER RES, V18, P758, DOI 10.1158/1078-0432.CCR-11-1980; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Welander J, 2014, ENDOCR-RELAT CANCER, V21, P495, DOI 10.1530/ERC-13-0384; Yang CF, 2014, CANCER LETT, V344, P260, DOI 10.1016/j.canlet.2013.11.006; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yoon C, 2015, BRIT J CANCER, V113, P46, DOI 10.1038/bjc.2015.186; Yoon C, 2016, CLIN CANCER RES, V22, P971, DOI 10.1158/1078-0432.CCR-15-1356; Zhong H, 1999, CANCER RES, V59, P5830	55	4	5	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1352	1363		10.1038/s41388-021-02166-w	http://dx.doi.org/10.1038/s41388-021-02166-w		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35013621				2022-12-28	WOS:000741571100001
J	Li, H; Roy, M; Liang, L; Cao, WJ; Hu, B; Li, YA; Xiao, XJ; Wang, HQ; Ye, M; Sun, SM; Zhang, B; Liu, J				Li, Hui; Roy, Mridul; Liang, Long; Cao, Wenjie; Hu, Bin; Li, Yanan; Xiao, Xiaojuan; Wang, Haiqin; Ye, Mao; Sun, Shuming; Zhang, Bin; Liu, Jing			Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; APOPTOSIS; DISEASE; CELLS	Despite the establishment of novel therapeutic interventions, multiple myeloma (MM) remains invariably incurable due to development of drug resistance and subsequent relapse, which are attributed to activation of oncogenic pathways such as autophagy. Deubiquitinating enzymes (DUBs) are promising targets to overcome resistance to proteasome inhibitor-based treatment. Ubiquitin-specific protease-12 (USP12) is a DUB with a known prognostic value in several cancers. We found that USP12 protein levels were significantly higher in myeloma patient samples than in non-cancerous human samples. Depletion of USP12 suppressed cell growth and clonogenicity and inhibited autophagy. Mechanistic studies showed that USP12 interacted with, deubiquitylated and stabilized the critical autophagy mediator HMGB1 (high mobility group box-1) protein. Knockdown of USP12 decreased the level of HMGB1 and suppressed HMGB1-mediated autophagy in MM. Furthermore, basal autophagy activity associated with USP12/HMGB1 was elevated in bortezomib (BTZ)-resistant MM cell lines. USP12 depletion, concomitant with a reduced expression of HMGB1, suppressed autophagy and increased the sensitivity of resistant cells to BTZ. Collectively, our findings have identified an important role of the deubiquitylase USP12 in pro-survival autophagy and resultant BTZ resistance in MM by stabilizing HMGB1, suggesting that the USP12/HMGB1 axis might be pursued as a potential diagnostic and therapeutic target in human MM.	[Li, Hui; Roy, Mridul; Ye, Mao] Hunan Univ, Coll Biol, Coll Chem & Chem Engn,State Key Lab Chemo Biosens, Collaborat Innovat Ctr Chem & Mol Med,Mol Sci & B, Changsha 410082, Hunan, Peoples R China; [Li, Hui; Roy, Mridul; Hu, Bin; Li, Yanan; Xiao, Xiaojuan; Wang, Haiqin; Sun, Shuming; Liu, Jing] Cent South Univ, Ctr Med Genet, Sch Life Sci,Mol Biol Res Ctr, Hunan Prov Key Lab Basic & Appl Hematol, Changsha 410078, Peoples R China; [Li, Hui; Liang, Long] Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha 410008, Hunan, Peoples R China; [Cao, Wenjie; Zhang, Bin] Cent South Univ, Xiangya Sch Med, Dept Histol & Embryol, Changsha 410013, Peoples R China	Hunan University; Central South University; Central South University; Central South University	Ye, M (corresponding author), Hunan Univ, Coll Biol, Coll Chem & Chem Engn,State Key Lab Chemo Biosens, Collaborat Innovat Ctr Chem & Mol Med,Mol Sci & B, Changsha 410082, Hunan, Peoples R China.; Sun, SM; Liu, J (corresponding author), Cent South Univ, Ctr Med Genet, Sch Life Sci,Mol Biol Res Ctr, Hunan Prov Key Lab Basic & Appl Hematol, Changsha 410078, Peoples R China.; Zhang, B (corresponding author), Cent South Univ, Xiangya Sch Med, Dept Histol & Embryol, Changsha 410013, Peoples R China.	goldleaf@hnu.edu.cn; sunshuming203@163.com; coolzhangbin22@163.com; jingliucsu@hotmail.com		Ye, Mao/0000-0002-4798-1825; Li, Hui/0000-0003-1086-0402; Cao, Wenjie/0000-0002-7877-4079	National Key Research and Development Program of China [2018YFA0107800]; National Natural Science Foundation of China [21890744, 81672760, 82003286, 81970195, 81920108004, 81772496, 82073099]; Natural Science Foundation of Hunan Province [2021JJ40054, 2019JJ40391]; China Postdoctoral Science Foundation [2020M672474, 2021T140195, 2018M630896]; Hunan Provincial Key Research and Development Plan [2018SK2128]; Changsha Municipal Natural Science Foundation [kq2014041, kq2014042, kq2001012]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Hunan Provincial Key Research and Development Plan; Changsha Municipal Natural Science Foundation	This study was supported by grants from the National Key Research and Development Program of China (2018YFA0107800), the National Natural Science Foundation of China (Nos. 21890744, 81672760, 82003286, 81970195, 81920108004, 81772496 and 82073099), the Natural Science Foundation of Hunan Province (No. 2021JJ40054, 2019JJ40391), the China Postdoctoral Science Foundation (2020M672474, 2021T140195 and 2018M630896), the Hunan Provincial Key Research and Development Plan (2018SK2128), the Changsha Municipal Natural Science Foundation (kq2014041, kq2014042 and kq2001012).	Arnold J, 2016, CELL DEATH DIFFER, V23, P853, DOI 10.1038/cdd.2015.149; Aron R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05653-z; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Boutouja F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122541; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; D'Eliseo Donatella, 2017, Genes Cancer, V8, P426, DOI 10.18632/genesandcancer.131; Gao D, 2017, J CELL BIOCHEM, V118, P3341, DOI 10.1002/jcb.25987; Guo X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0883-3; Hanna J, 2006, CELL, V127, P99, DOI 10.1016/j.cell.2006.07.038; Hussain S, 2015, ONCOTARGET, V6, P40704, DOI 10.18632/oncotarget.5727; Inoue Y, 2013, THROMB RES, V132, P493, DOI 10.1016/j.thromres.2013.08.020; Jacomin AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143078; Jahan AS, 2016, P NATL ACAD SCI USA, V113, pE705, DOI 10.1073/pnas.1521763113; Jarauta V, 2016, CANCER LETT, V382, P1, DOI 10.1016/j.canlet.2016.08.019; Joo HY, 2011, J BIOL CHEM, V286, P7190, DOI 10.1074/jbc.M110.158311; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kumar SK, 2014, LEUKEMIA, V28, P1122, DOI 10.1038/leu.2013.313; Kumar SK, 2016, CLIN CANCER RES, V22, P5453, DOI 10.1158/1078-0432.CCR-16-0868; Liu J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008215; Lu YC, 2018, CANCER SCI, V109, P2706, DOI 10.1111/cas.13711; Mah Li Yen, 2012, Cold Spring Harb Perspect Biol, V4, pa008821, DOI 10.1101/cshperspect.a008821; McClurg UL, 2018, ONCOGENE, V37, P4679, DOI 10.1038/s41388-018-0283-3; Milan E, 2016, J CLIN IMMUNOL, V36, pS18, DOI 10.1007/s10875-016-0254-9; Moretti J, 2012, J BIOL CHEM, V287, P29429, DOI 10.1074/jbc.M112.366807; Nakada S, 2010, NATURE, V466, P941, DOI 10.1038/nature09297; Nayak TKS, 2017, BIOCHEM BIOPH RES CO, V483, P69, DOI 10.1016/j.bbrc.2017.01.004; Nomura S, 2018, J BLOOD MED, V9, P1, DOI 10.2147/JBM.S147743; Pengo N, 2013, NAT IMMUNOL, V14, P298, DOI 10.1038/ni.2524; Pinto V, 2020, CANCERS, V12, DOI 10.3390/cancers12020407; Rajkumar SV, 2009, CURR PROB CANCER, V33, P7, DOI 10.1016/j.currproblcancer.2009.01.001; Roy M, 2016, THERANOSTICS, V6, P2209, DOI 10.7150/thno.15584; Salminen A, 2013, PROG NEUROBIOL, V106, P33, DOI 10.1016/j.pneurobio.2013.06.002; Sridhar S, 2012, J PATHOL, V226, P255, DOI 10.1002/path.3025; Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078; Tian Z, 2014, BLOOD, V123, P706, DOI 10.1182/blood-2013-05-500033; Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264; Xia JL, 2020, MOL ONCOL, V14, P763, DOI 10.1002/1878-0261.12641; Yuan SL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00920-3; Zhang HM, 2018, ONCOL RES, V26, P421, DOI 10.3727/096504017X15049221237147; Zhang MJ, 2015, ONCOTARGET, V6, P8567, DOI 10.18632/oncotarget.3251; Zhang XD, 2014, MOL CELL BIOCHEM, V385, P265, DOI 10.1007/s11010-013-1835-z; Zhuang Y, 2017, LEUKEMIA RES, V59, P97, DOI 10.1016/j.leukres.2017.06.002	43	1	1	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1298	1308		10.1038/s41388-021-02167-9	http://dx.doi.org/10.1038/s41388-021-02167-9		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	34997217				2022-12-28	WOS:000740148500001
J	Desi, N; Teh, V; Tong, QY; Lim, CY; Tabatabaeian, H; Chew, XH; Sanchez-Mejias, A; Chan, JJ; Zhang, B; Pitcheshwar, P; Siew, BE; Wang, S; Lee, KC; Chong, CS; Cheong, WK; Lieske, B; Tan, IJW; Tan, KK; Tay, Y				Desi, Ng; Teh, Velda; Tong, Qing Yun; Lim, Chun You; Tabatabaeian, Hossein; Chew, Xiao Hong; Sanchez-Mejias, Avencia; Chan, Jia Jia; Zhang, Bin; Pitcheshwar, Priyankaa; Siew, Bei-En; Wang, Shi; Lee, Kuok-Chung; Chong, Choon-Seng; Cheong, Wai-Kit; Lieske, Bettina; Tan, Ian Jse-Wei; Tan, Ker-Kan; Tay, Yvonne			MiR-138 is a potent regulator of the heterogenous MYC transcript population in cancers	ONCOGENE			English	Article							C-MYC; CELL-PROLIFERATION; EXPRESSION; INHIBITION; DELIVERY; TARGET; GENE; OVEREXPRESSION; IDENTIFICATION; AMPLIFICATION	3 ' UTR shortening in cancer has been shown to activate oncogenes, partly through the loss of microRNA-mediated repression. This suggests that many reported microRNA-oncogene target interactions may not be present in cancer cells. One of the most well-studied oncogenes is the transcription factor MYC, which is overexpressed in more than half of all cancers. MYC overexpression is not always accompanied by underlying genetic aberrations. In this study, we demonstrate that the MYC 3 ' UTR is shortened in colorectal cancer (CRC). Using unbiased computational and experimental approaches, we identify and validate microRNAs that target the MYC coding region. In particular, we show that miR-138 inhibits MYC expression and suppresses tumor growth of CRC and hepatocellular carcinoma (HCC) cell lines. Critically, the intravenous administration of miR-138 significantly impedes MYC-driven tumor growth in vivo. Taken together, our results highlight the previously uncharacterized shortening of the MYC 3 ' UTR in cancer, and identify miR-138 as a potent regulator of the heterogenous MYC transcript population.	[Desi, Ng; Teh, Velda; Tong, Qing Yun; Lim, Chun You; Tabatabaeian, Hossein; Chew, Xiao Hong; Sanchez-Mejias, Avencia; Chan, Jia Jia; Zhang, Bin; Pitcheshwar, Priyankaa; Chong, Choon-Seng; Tay, Yvonne] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore; [Desi, Ng; Tay, Yvonne] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117597, Singapore; [Siew, Bei-En; Chong, Choon-Seng; Lieske, Bettina; Tan, Ker-Kan] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore, Singapore; [Wang, Shi] Natl Univ Hlth Syst, Dept Pathol, Singapore, Singapore; [Lee, Kuok-Chung; Chong, Choon-Seng; Cheong, Wai-Kit; Lieske, Bettina; Tan, Ian Jse-Wei; Tan, Ker-Kan] Univ Surg Cluster, Natl Univ Hlth Syst, Div Colorectal Surg, Singapore, Singapore; [Sanchez-Mejias, Avencia] Pompeu Fabra Univ, Dept Expt & Hlth Sci, Barcelona 08003, Spain	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; Pompeu Fabra University	Tay, Y (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore.; Tay, Y (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117597, Singapore.	yvonnetay@nus.edu.sg		zhang, bin/0000-0001-8835-8370; Ng, Desi/0000-0001-8167-3925	Singapore National Research Foundation Fellowship; National University of Singapore; NMRC OF-IRG; NUS Research Scholarship; National Research Foundation Singapore; Singapore Ministry of Education under its Research Centres of Excellence initiative; RNA Biology Center at the Cancer Science Institute of Singapore, NUS, Singapore Ministry of Education's AcRF Tier 3 grant [MOE2014-T3-1-006]; NCIS; NUS Cancer Programme Seed Grant	Singapore National Research Foundation Fellowship(National Research Foundation, Singapore); National University of Singapore(National University of Singapore); NMRC OF-IRG; NUS Research Scholarship(National University of Singapore); National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centres of Excellence initiative(Ministry of Education, Singapore); RNA Biology Center at the Cancer Science Institute of Singapore, NUS, Singapore Ministry of Education's AcRF Tier 3 grant; NCIS; NUS Cancer Programme Seed Grant	We thank all past and present YT lab members for their constructive feedback on this project. We also thank MiRXES for the high-throughput qPCR analysis. We apologize to all colleagues whose work could not be cited due to space constraints. YT is funded by a Singapore National Research Foundation Fellowship, a National University of Singapore President's Assistant Professorship, a NMRC OF-IRG, and a Joint NCIS and NUS Cancer Programme Seed Grant. ND is supported by the NUS Research Scholarship. This research is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative, as well as the RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of funding under the Singapore Ministry of Education's AcRF Tier 3 grants, Grant number MOE2014-T3-1-006.	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Akman BH, 2012, NUCLEIC ACIDS RES, V40, P10679, DOI 10.1093/nar/gks855; Avci CB, 2013, CELL BIOL INT, V37, P1205, DOI 10.1002/cbin.10157; Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y; Berkovits BD, 2015, NATURE, V522, P363, DOI 10.1038/nature14321; Chan KL, 2004, HUM PATHOL, V35, P1324, DOI 10.1016/j.humpath.2004.06.012; Chan XHD, 2012, CELL REP, V2, P591, DOI 10.1016/j.celrep.2012.07.012; Chu-Tan JA, 2020, MOL VIS, V26, P48; Conde J, 2016, NAT MATER, V15, P353, DOI [10.1038/nmat4497, 10.1038/NMAT4497]; Cui JK, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1448330; Dell Ralph B, 2002, ILAR J, V43, P207; Desi N, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121634; Endo-Takahashi Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep03883; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fu Y., 2019, EXRNA, V1, P24, DOI [DOI 10.1186/S41544-019-0024-Y, 10.1186/S41544-019-0024-Y,20191:1.1]; FUJIWARA Y, 1993, CANCER RES, V53, P857; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Gao SQ, 2015, ACTA BIOMATER, V25, P184, DOI 10.1016/j.actbio.2015.07.020; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Huang Z, 2014, GUT, V63, P1247, DOI 10.1136/gutjnl-2012-304213; Jackstadt R, 2015, BBA-GENE REGUL MECH, V1849, P544, DOI 10.1016/j.bbagrm.2014.04.003; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KOZMA L, 1994, CANCER LETT, V81, P165, DOI 10.1016/0304-3835(94)90198-8; Lal A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002363; Li DF, 2017, RSC ADV, V7, P52030, DOI 10.1039/c7ra09042k; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Lin F, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-58; Long LM, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-275; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Migliore C, 2012, CLIN CANCER RES, V18, P737, DOI 10.1158/1078-0432.CCR-11-1699; Mihailovich M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9725; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Misiewicz-Krzeminska I, 2016, CLIN CANCER RES, V22, P207, DOI 10.1158/1078-0432.CCR-14-2796; Miyazaki Y, 2012, NAT MED, V18, P1136, DOI 10.1038/nm.2791; Mohammed A, 2019, ONCOL REP, V41, P973, DOI 10.3892/or.2018.6857; Nama S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49155-4; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ouyang M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1151-y; Park HJ, 2018, NAT GENET, V50, P783, DOI 10.1038/s41588-018-0118-8; Qiu SW, 2013, BBA-MOL BASIS DIS, V1832, P1697, DOI 10.1016/j.bbadis.2013.05.015; Ramanujam D, 2016, MOL THER, V24, P1939, DOI 10.1038/mt.2016.166; Reid G, 2013, ANN ONCOL, V24, P3128, DOI 10.1093/annonc/mdt412; Rochlitz CF, 1996, ONCOLOGY, V53, P448; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Seto AG, 2018, BRIT J HAEMATOL, V183, P428, DOI 10.1111/bjh.15547; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shams R, 2020, CANCER MANAG RES, V12, P2393, DOI 10.2147/CMAR.S245872; SMITH DR, 1993, BRIT J CANCER, V68, P407, DOI 10.1038/bjc.1993.350; Wang YY, 2017, THERANOSTICS, V7, P1360, DOI 10.7150/thno.16532; Wang YB, 2018, J CELL BIOCHEM, V119, P1702, DOI 10.1002/jcb.26330; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xie F, 2017, ONCOTARGETS THER, V10, P885, DOI 10.2147/OTT.S122992; Xu XS, 2015, ONCOTARGET, V6, P3988, DOI 10.18632/oncotarget.2905; Xu Y, 2018, EUR REV MED PHARMACO, V22, P8664, DOI 10.26355/eurrev_201812_16631; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Yoon JH, 2012, METHODS, V58, P81, DOI 10.1016/j.ymeth.2012.07.004; You CX, 2019, ONCOL LETT, V17, P2271, DOI 10.3892/ol.2018.9864; Zhang QY, 2015, J CONTROL RELEASE, V197, P208, DOI 10.1016/j.jconrel.2014.11.010; Zhang S, 2021, DRUG DES DEV THER, V15, P721, DOI 10.2147/DDDT.S288859; Zhao L, 2016, ONCOTARGET, V7, P45370, DOI 10.18632/oncotarget.9659	62	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1178	1189		10.1038/s41388-021-02084-x	http://dx.doi.org/10.1038/s41388-021-02084-x		DEC 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	34937878	hybrid, Green Published			2022-12-28	WOS:000733868400001
J	Coronel, L; Hackes, D; Schwab, K; Riege, K; Hoffmann, S; Fischer, M				Coronel, Luis; Haeckes, David; Schwab, Katjana; Riege, Konstantin; Hoffmann, Steve; Fischer, Martin			p53-mediated AKT and mTOR inhibition requires RFX7 and DDIT4 and depends on nutrient abundance	ONCOGENE			English	Article							P53; KINASE; CELL; TARGET; AMPK; TRANSCRIPTION; METABOLISM; ACTIVATION; NETWORK; PATHWAY	In recent years the tumor suppressor p53 has been increasingly recognized as a potent regulator of the cell metabolism and for its ability to inhibit the critical pro-survival kinases AKT and mTOR. The mechanisms through which p53 controls AKT and mTOR, however, are largely unclear. Here, we demonstrate that p53 activates the metabolic regulator DDIT4 indirectly through the regulatory factor X 7 (RFX7). We provide evidence that DDIT4 is required for p53 to inhibit mTOR complex 2 (mTORC2)-dependent AKT activation. Most strikingly, we also find that the DDIT4 regulator RFX7 is required for p53-mediated inhibition of mTORC1 and AKT. Our results suggest that AMPK activation plays no role and p53-mediated AKT inhibition is not critical for p53-mediated mTORC1 inhibition. Moreover, using recently developed physiological cell culture media we uncover that basal p53 and RFX7 activity can play a critical role in restricting mTORC1 activity under physiological nutrient conditions, and we propose a nutrient-dependent model for p53-RFX7-mediated mTORC1 inhibition. These results establish RFX7 and its downstream target DDIT4 as essential effectors in metabolic control elicited by p53.	[Coronel, Luis; Haeckes, David; Schwab, Katjana; Riege, Konstantin; Hoffmann, Steve; Fischer, Martin] Fritz Lipmann Inst FLI, Leibniz Inst Aging, Computat Biol Grp, Beutenbergstr 11, D-07745 Jena, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Hoffmann, S; Fischer, M (corresponding author), Fritz Lipmann Inst FLI, Leibniz Inst Aging, Computat Biol Grp, Beutenbergstr 11, D-07745 Jena, Germany.	Steve.Hoffmann@leibniz-fli.de; Martin.Fischer@leibniz-fli.de	Fischer, Martin/I-4825-2014	Fischer, Martin/0000-0002-3429-1876; Hackes, David/0000-0002-2177-5206; Luis Eduardo, Coronel Carrion/0000-0001-7906-0732; Schwab, Katjana/0000-0002-6916-2900	German Research Foundation (DFG) [FI 1993/2-1]; German Federal Ministry for Education and Research (BMBF) [031L016D]; Federal Government of Germany; State of Thuringia; Projekt DEAL	German Research Foundation (DFG)(German Research Foundation (DFG)); German Federal Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Federal Government of Germany; State of Thuringia; Projekt DEAL	This work was supported by the German Research Foundation (DFG) [research grant FI 1993/2-1 to MF] and the German Federal Ministry for Education and Research (BMBF) [031L016D to SH]. The FLI is a member of the Leibniz Association and is financially supported by the Federal Government of Germany and the State of Thuringia. Open Access funding enabled and organized by Projekt DEAL.	Agarwal S, 2016, MOL CANCER RES, V14, P66, DOI 10.1158/1541-7786.MCR-15-0159; Akeno N, 2015, ONCOGENE, V34, P589, DOI 10.1038/onc.2013.589; Andrysik Z, 2017, GENOME RES, V27, P1645, DOI 10.1101/gr.220533.117; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Baum N, 2009, ONCOGENE, V28, P3915, DOI 10.1038/onc.2009.248; Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769; Bowling S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04167-y; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Cantor JR, 2017, CELL, V169, P258, DOI 10.1016/j.cell.2017.03.023; Castro W, 2018, NAT IMMUNOL, V19, P809, DOI 10.1038/s41590-018-0144-9; Coronel L, 2021, NUCLEIC ACIDS RES, V49, P7437, DOI 10.1093/nar/gkab575; Cui DR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03185-3; Dennis MD, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005103; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Duan L, 2018, J MOL CELL BIOL, V10, P331, DOI 10.1093/jmcb/mjx051; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Fischer BA, 2020, TRENDS CANCER, V6, P6, DOI 10.1016/j.trecan.2019.11.001; Fischer M, 2021, TRENDS CANCER, V7, P12, DOI 10.1016/j.trecan.2020.08.007; Fischer M, 2019, ONCOGENE, V38, P4095, DOI 10.1038/s41388-019-0706-9; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Grande BM, 2019, BLOOD, V133, P1313, DOI 10.1182/blood-2018-09-871418; Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Kawase T, 2009, CELL, V136, P535, DOI 10.1016/j.cell.2008.12.002; Kon N, 2021, GENE DEV, V35, P59, DOI 10.1101/gad.340919.120; Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y; Lopez C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08578-3; Luo YD, 2021, J HEPATOL, V74, P96, DOI 10.1016/j.jhep.2020.07.036; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Menendez D, 2013, NUCLEIC ACIDS RES, V41, P7286, DOI 10.1093/nar/gkt504; Miyamoto T, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1603204; Nicolay BN, 2015, GENE DEV, V29, P1875, DOI 10.1101/gad.264127.115; Parmigiani A, 2014, CELL REP, V9, P1281, DOI 10.1016/j.celrep.2014.10.019; Peng M, 2014, CELL, V159, P122, DOI 10.1016/j.cell.2014.08.038; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275; Zheng RB, 2019, NUCLEIC ACIDS RES, V47, pD729, DOI 10.1093/nar/gky1094	40	3	3	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1063	1069		10.1038/s41388-021-02147-z	http://dx.doi.org/10.1038/s41388-021-02147-z		DEC 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34907345	hybrid, Green Published			2022-12-28	WOS:000730070200001
J	Song, DW; Cismas, S; Crudden, C; Trocme, E; Worrall, C; Suleymanova, N; Lin, TT; Zheng, HY; Seregard, S; Girnita, A; Girnita, L				Song, Dawei; Cismas, Sonia; Crudden, Caitrin; Trocme, Eric; Worrall, Claire; Suleymanova, Naida; Lin, Tingting; Zheng, Huiyuan; Seregard, Stefan; Girnita, Ada; Girnita, Leonard			IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma	ONCOGENE			English	Article							FACTOR-I RECEPTOR; DOWN-REGULATION; BETA-ARRESTIN; MALIGNANT-MELANOMA; UVEAL MELANOMA; GROWTH; EXPRESSION; MDM2; UBIQUITINATION; ACTIVATION	As the p53 tumor suppressor is rarely mutated in conjunctival melanoma (CM), we investigated its activation as a potential therapeutic strategy. Preventing p53/Mdm2 interaction by Nutlin-3, the prototypical Mdm2 antagonist, or via direct siRNA Mdm2 depletion, increased p53 and inhibited viability in CM cell lines. The sensitivity to Nutlin-3 p53 reactivation with concomitant Mdm2 stabilization was higher than that achieved by siRNA, indicative of effects on alternative Mdm2 targets, identified as the cancer-protective IGF-1R. Nutlin-3 treatment increased the association between IGF-1R and beta-arrestin1, the adaptor protein that brings Mdm2 to the IGF-1R, initiating receptor degradation in a ligand-dependent manner. Controlled expression of beta-arrestin1 augmented inhibitory Nutlin-3 effects on CM survival through enhanced IGF-1R degradation. Yet, the effect of IGF-1R downregulation on cell proliferation is balanced by beta-arrestin1-induced p53 inhibition. As mitomycin (MMC) is a well-established adjuvant treatment for CM, and it triggers p53 activation through genotoxic stress, we evaluated how these alternative p53-targeting strategies alter the cancer-relevant bioactivities of CM. In 2D and 3D in vitro models, Nutlin-3 or MMC alone, or in combination, reduces the overall cell tumor growth similar to 30%, with double treatment inhibition rate only marginally higher than single-drug regimens. However, histopathological evaluation of the 3D models revealed that Nutlin-3 was the most effective, causing necrotic areas inside spheroids and complete loss of nuclear staining for the proliferative marker Ki67. These findings were further validated in vivo; zebrafish xenografts demonstrate that Nutlin-3 alone has higher efficacy in restraining CM tumor cell growth and preventing metastasis. Combined, these results reveal that beta-arrestin1 directs Mdm2 toward different substrates, thus balancing IGF-1R pro-tumorigenic and p53-tumor suppressive signals. This study defines a potent dual-hit strategy: simultaneous control of a tumor-promoter (IGF-1R) and tumor-suppressor (p53), which ultimately mitigates recurrent and metastatic potential, thus opening up targeted therapy to CM.	[Song, Dawei; Cismas, Sonia; Crudden, Caitrin; Trocme, Eric; Worrall, Claire; Suleymanova, Naida; Lin, Tingting; Zheng, Huiyuan; Girnita, Ada; Girnita, Leonard] Karolinska Inst, Dept Oncol & Pathol, BioClinicum, Stockholm, Sweden; [Song, Dawei; Cismas, Sonia; Crudden, Caitrin; Trocme, Eric; Worrall, Claire; Suleymanova, Naida; Lin, Tingting; Zheng, Huiyuan; Girnita, Ada; Girnita, Leonard] Karolinska Univ Hosp, Stockholm, Sweden; [Crudden, Caitrin] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Amsterdam UMC, De Boelelaan 1117, Amsterdam, Netherlands; [Trocme, Eric; Seregard, Stefan; Girnita, Leonard] St Erik Eye Hosp, Ophthalm Pathol & Oncol Serv, Stockholm, Sweden; [Lin, Tingting] Tianjin Med Univ Eye Hosp, Tianjin Int Joint Res & Dev Ctr Ophthalmol & Vis, Eye Inst, Tianjin, Peoples R China; [Lin, Tingting] Tianjin Med Univ Eye Hosp, Sch Optometry, Tianjin, Peoples R China; [Zheng, Huiyuan] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Seregard, Stefan] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Girnita, Ada] Karolinska Univ Hosp, Skin Canc Ctr, Theme Canc, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Vrije Universiteit Amsterdam; Tianjin Medical University; Tianjin Medical University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Girnita, L (corresponding author), Karolinska Inst, Dept Oncol & Pathol, BioClinicum, Stockholm, Sweden.; Girnita, L (corresponding author), Karolinska Univ Hosp, Stockholm, Sweden.; Girnita, L (corresponding author), St Erik Eye Hosp, Ophthalm Pathol & Oncol Serv, Stockholm, Sweden.	leonard.girnita@ki.se	Song, Dawei/HGC-7852-2022; Crudden, Caitrin/Q-5172-2018	Crudden, Caitrin/0000-0002-7786-112X; Song, Dawei/0000-0001-7707-7207	Swedish Research Council; Swedish Cancer Society; Swedish Childhood Cancer Foundation; Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; China Scholarship Council [201700260284]; Stockholm Cancer Society; Karolinska Institute	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Childhood Cancer Foundation(European Commission); Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; China Scholarship Council(China Scholarship Council); Stockholm Cancer Society; Karolinska Institute(Karolinska Institutet)	We gratefully acknowledge Prof. Robert J Lefkowitz, Prof. Gerasimos Anastassiou, Prof. Rob J W de Keizer, Prof. Rolf Kiessling, and Prof. A. Ciechanover for providing cell lines and reagents. We thank Anna Malmerfelt at the histology core facility, Karolinska Institutet, for technical assistance. Research support was received from the Swedish Research Council, Swedish Cancer Society, The Swedish Childhood Cancer Foundation, Crown Princess Margareta's Foundation for the Visually Impaired, Welander Finsen Foundation, King Gustaf V Jubilee Foundation, China Scholarship Council (Grant no. 201700260284), Stockholm Cancer Society, Stockholm County and Karolinska Institute. Schematics were partially created with BioRender.com.	All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Brenner M, 2008, PHOTOCHEM PHOTOBIOL, V84, P539, DOI 10.1111/j.1751-1097.2007.00226.x; Burkhart CG, 2005, INT J DERMATOL, V44, P340, DOI 10.1111/j.1365-4632.2004.02556.x; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Cisarova K, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009201; Crudden C, 2021, CANCER RES, V81, P501, DOI 10.1158/0008-5472.CAN-20-1662; Crudden C, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.abb7887; Crudden C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101223; Crudden C, 2018, INT REV CEL MOL BIO, V339, P1, DOI 10.1016/bs.ircmb.2018.02.006; Crudden C, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00064; Crudden C, 2015, GROWTH HORM IGF RES, V25, P2, DOI 10.1016/j.ghir.2014.10.002; de Waard NE, 2015, INVEST OPHTH VIS SCI, V56, P2325, DOI 10.1167/iovs.14-15239; Dziadziuszko R, 2010, J CLIN ONCOL, V28, P2174, DOI 10.1200/JCO.2009.24.6611; Economou MA, 2005, INVEST OPHTH VIS SCI, V46, P4372, DOI 10.1167/iovs.05-0322; Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2337, DOI 10.1167/iovs.07-0819; Fiorentzis M, 2019, ACTA OPHTHALMOL, V97, pE632, DOI 10.1111/aos.13993; Froment P, 2008, CELL CYCLE, V7, P3098, DOI 10.4161/cc.7.19.6807; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gardrat S, 2021, CANCERS, V13, DOI 10.3390/cancers13153836; Gaudy-Marqueste C, 2022, J AM ACAD DERMATOL, V86, P312, DOI 10.1016/j.jaad.2021.07.011; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2016, PROG MOL BIOL TRANSL, V141, P277, DOI 10.1016/bs.pmbts.2016.04.001; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Girnita L, 2014, CELL MOL LIFE SCI, V71, P2403, DOI 10.1007/s00018-013-1514-y; Hara MR, 2011, NATURE, V477, P349, DOI 10.1038/nature10368; Jain P, 2021, BRIT J OPHTHALMOL, V105, P1358, DOI 10.1136/bjophthalmol-2020-316293; Jay V, 1996, ARCH PATHOL LAB MED, V120, P378; JRC, 2020, 2020 CANC INC MORT E; Kanter-Lewensohn L, 1998, MELANOMA RES, V8, P389, DOI 10.1097/00008390-199810000-00002; Keijser S, 2007, BRIT J OPHTHALMOL, V91, P1566, DOI 10.1136/bjo.2006.110841; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Maures T, 2002, ENDOCRINOLOGY, V143, P1858, DOI 10.1210/en.143.5.1858; Mihajlovic M, 2012, INT J CLIN EXP PATHO, V5, P739; Mikkelsen LH, 2020, ACTA OPHTHALMOL, V98, P1, DOI 10.1111/aos.14536; Moll UM, 2003, MOL CANCER RES, V1, P1001; Mundra PA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20432-5; Nareyeck G, 2005, EXP EYE RES, V81, P361, DOI 10.1016/j.exer.2005.04.018; Newel F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11107-x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pacheco RR, 2022, EYE, V36, P603, DOI 10.1038/s41433-021-01508-y; Plonka PM, 2009, EXP DERMATOL, V18, P799, DOI 10.1111/j.1600-0625.2009.00912.x; Ren J, 2017, JOVE-J VIS EXP, DOI 10.3791/55459; Rivolta C, 2016, J HUM GENET, V61, P361, DOI 10.1038/jhg.2015.152; Sehat B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364; Sekulic A, 2008, MAYO CLIN PROC, V83, P825, DOI 10.4065/83.7.825; Seregard S, 1998, SURV OPHTHALMOL, V42, P321, DOI 10.1016/S0039-6257(97)00122-7; Seregard S, 1996, J CLIN PATHOL, V49, P338, DOI 10.1136/jcp.49.4.338; Shields CL, 2021, ASIA-PAC J OPHTHALMO, V10, P146, DOI 10.1097/APO.0000000000000343; Shields CL, 2020, JAMA OPHTHALMOL, V138, P608, DOI 10.1001/jamaophthalmol.2020.0522; Shields CL, 2000, ARCH OPHTHALMOL-CHIC, V118, P1497; Suleymanova N, 2017, ONCOGENE, V36, P5734, DOI 10.1038/onc.2017.179; Suleymanova N, 2017, ONCOTARGET, V8, P82256, DOI 10.18632/oncotarget.19286; Triay E, 2009, BRIT J OPHTHALMOL, V93, P1524, DOI 10.1136/bjo.2009.157933; Tuomaala S, 2002, INVEST OPHTH VIS SCI, V43, P3399; Vasilcanu D, 2006, ONCOGENE, V25, P3186, DOI 10.1038/sj.onc.1209339; Vasilcanu R, 2008, ONCOGENE, V27, P1629, DOI 10.1038/sj.onc.1210797; Vasilcanu R, 2008, MOL PHARMACOL, V73, P930, DOI 10.1124/mol.107.040014; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Virgili G, 2020, JAMA OPHTHALMOL, V138, P601, DOI 10.1001/jamaophthalmol.2020.0531; Wood JM, 1999, EXP DERMATOL, V8, P153, DOI 10.1111/j.1600-0625.1999.tb00365.x; Worrall C, 2017, ONCOGENE, V36, P3274, DOI 10.1038/onc.2016.472; Yang G, 2006, J INVEST DERMATOL, V126, P2490, DOI 10.1038/sj.jid.5700470; Yoshihara H, 2012, BIOCHEM BIOPH RES CO, V423, P122, DOI 10.1016/j.bbrc.2012.05.093	67	4	4	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					600	611		10.1038/s41388-021-02111-x	http://dx.doi.org/10.1038/s41388-021-02111-x		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785779				2022-12-28	WOS:000719276900001
J	Chen, J; Guanizo, A; Luong, Q; Jayasekara, WSN; Jayasinghe, D; Inampudi, C; Szczepny, A; Garama, DJ; Russell, PA; Ganju, V; Cain, JE; Watkins, DN; Gough, DJ				Chen, Jasmine; Guanizo, Aleks; Luong, Quinton; Jayasekara, W. Samantha N.; Jayasinghe, Dhilshan; Inampudi, Chaitanya; Szczepny, Anette; Garama, Daniel J.; Russell, Prudence A.; Ganju, Vinod; Cain, Jason E.; Watkins, D. Neil; Gough, Daniel J.			Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium	ONCOGENE			English	Article							C-MYC; CLARA CELLS; MICE; AMPLIFICATION; PROGRESSION; NUMBER; NFIB	Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer characterized by loss of function TP53 and RB1 mutations in addition to mutations in other oncogenes including MYC. Overexpression of MYC together with Trp53 and Rb1 loss in pulmonary neuroendocrine cells of the mouse lung drives an aggressive neuroendocrine low variant subtype of SCLC. However, the transforming potential of MYC amplification alone on airway epithelium is unclear. Therefore, we selectively and conditionally overexpressed MYC stochastically throughout the airway or specifically in neuroendocrine, club, or alveolar type II cells in the adult mouse lung. We observed that MYC overexpression induced carcinoma in situ which did not progress to invasive disease. The formation of adenoma or SCLC carcinoma in situ was dependent on the cell of origin. In contrast, MYC overexpression combined with conditional deletion of both Trp53 and Rb1 exclusively gave rise to SCLC, irrespective of the cell lineage of origin. However, cell of origin influenced disease latency, metastatic potential, and the transcriptional profile of the SCLC phenotype. Together this reveals that MYC overexpression alone provides a proliferative advantage but when combined with deletion of Trp53 and Rb1 it facilitates the formation of aggressive SCLC from multiple cell lineages.	[Chen, Jasmine; Guanizo, Aleks; Luong, Quinton; Jayasekara, W. Samantha N.; Jayasinghe, Dhilshan; Inampudi, Chaitanya; Szczepny, Anette; Garama, Daniel J.; Ganju, Vinod; Cain, Jason E.; Gough, Daniel J.] Hudson Inst Med Res, Ctr Canc Res, 27-31 Wright St, Clayton, Vic 3168, Australia; [Chen, Jasmine; Guanizo, Aleks; Luong, Quinton; Jayasekara, W. Samantha N.; Jayasinghe, Dhilshan; Inampudi, Chaitanya; Szczepny, Anette; Garama, Daniel J.; Ganju, Vinod; Cain, Jason E.; Gough, Daniel J.] Monash Univ, Dept Mol & Translat Sci, 27-31 Wright St, Clayton, Vic 3168, Australia; [Russell, Prudence A.] St Vincents Hosp, Dept Anat Pathol, Melbourne, Vic, Australia; [Watkins, D. Neil] Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB R3E 0V9, Canada; [Watkins, D. Neil] Univ Manitoba, Rady Fac Hlth Sci, Dept Internal Med, Winnipeg, MB R3T 2N2, Canada	Hudson Institute of Medical Research; Monash University; St Vincent's Hospital Melbourne; University of Manitoba	Gough, DJ (corresponding author), Hudson Inst Med Res, Ctr Canc Res, 27-31 Wright St, Clayton, Vic 3168, Australia.; Gough, DJ (corresponding author), Monash Univ, Dept Mol & Translat Sci, 27-31 Wright St, Clayton, Vic 3168, Australia.	Daniel.gough@hudson.org.au		Gough, Daniel/0000-0001-6479-1735	Operational Infrastructure Support Program by the Victorian Government of Australia; Victorian Cancer Agency Mid-Career Fellowship [MCRF19033]; Cancer Council of Victoria [GNT1140528]	Operational Infrastructure Support Program by the Victorian Government of Australia; Victorian Cancer Agency Mid-Career Fellowship; Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	This work was supported by the Operational Infrastructure Support Program by the Victorian Government of Australia. D.J. Gough is supported by a Victorian Cancer Agency Mid-Career Fellowship (MCRF19033) and a grant in aid from the Cancer Council of Victoria (GNT1140528).	Alves RDS, 2014, J CANCER RES CLIN, V140, P2021, DOI 10.1007/s00432-014-1769-1; Boers JE, 1999, AM J RESP CRIT CARE, V159, P1585, DOI 10.1164/ajrccm.159.5.9806044; Burr ML, 2019, CANCER CELL, V36, P385, DOI 10.1016/j.ccell.2019.08.008; Calado DP, 2012, NAT IMMUNOL, V13, P1092, DOI 10.1038/ni.2418; Denny SK, 2016, CELL, V166, P328, DOI 10.1016/j.cell.2016.05.052; Ehrhardt A, 2001, BRIT J CANCER, V84, P813, DOI 10.1054/bjoc.2000.1676; Farago AF, 2018, TRANSL LUNG CANCER R, V7, P69, DOI 10.21037/tlcr.2018.01.16; Foroutan M, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2435-4; Geick A, 2001, TRANSGENIC RES, V10, P501, DOI 10.1023/A:1013085228119; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Grunblatt E, 2020, GENE DEV, V34, P1210, DOI 10.1101/gad.340133.120; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Huang YH, 2018, GENE DEV, V32, P915, DOI 10.1101/gad.314815.118; Ireland AS, 2020, CANCER CELL, V38, P60, DOI 10.1016/j.ccell.2020.05.001; Johnson BE, 1996, J CELL BIOCHEM, P210; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005; Morton JP, 2013, MOL ONCOL, V7, P248, DOI 10.1016/j.molonc.2013.02.015; Olsen RR, 2021, GENE DEV, V35, P847, DOI 10.1101/gad.348295.121; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Plasschaert LW, 2018, NATURE, V560, P377, DOI 10.1038/s41586-018-0394-6; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Semenova EA, 2016, CELL REP, V16, P631, DOI 10.1016/j.celrep.2016.06.020; Simpson DS, 2009, CANCER RES, V69, P8733, DOI 10.1158/0008-5472.CAN-09-1359; Sutherland KD, 2011, CANCER CELL, V19, P754, DOI 10.1016/j.ccr.2011.04.019; Voortman J, 2010, P NATL ACAD SCI USA, V107, P13040, DOI 10.1073/pnas.1008132107; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Yang D, 2018, CANCER DISCOV, V8, P1316, DOI 10.1158/2159-8290.CD-17-0987; Zhang W, 2018, TRANSL LUNG CANCER R, V7, P32, DOI 10.21037/tlcr.2018.02.02	32	2	2	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					138	145		10.1038/s41388-021-02070-3	http://dx.doi.org/10.1038/s41388-021-02070-3		OCT 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34675406				2022-12-28	WOS:000709687900004
J	Yu, L; Cao, C; Li, X; Zhang, ML; Gu, QS; Gao, H; Balic, JJ; Xu, DG; Zhang, L; Ying, L; Xu, DK; Yang, YQ; Wu, D; He, BK; Jenkins, BJ; Liu, YD; Li, JK				Yu, Liang; Cao, Can; Li, Xu; Zhang, Mili; Gu, Qisheng; Gao, Hugh; Balic, Jesse J.; Xu, Duogang; Zhang, Lei; Ying, Le; Xu, Dakang; Yang, Yuqin; Wu, Di; He, Baokun; Jenkins, Brendan J.; Liu, Youdong; Li, Jikun			Complete loss of miR-200 family induces EMT associated cellular senescence in gastric cancer	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; TARGETING ZEB1; TUMORIGENESIS; EXPRESSION; INHIBITORS	The EMT (epithelial-to-mesenchymal-transition) subtype of gastric cancer (GC) is associated with poor treatment responses and unfavorable clinical outcomes. Despite the broad physiological roles of the micro-RNA (miR)-200 family, they largely serve to maintain the overall epithelial phenotype. However, during late-stage gastric tumorigenesis, members of the miR-200 family are markedly suppressed, resulting in the transition to the mesenchymal state and the acquisition of invasive properties. As such, the miR-200 family represents a robust molecular marker of EMT, and subsequently, disease severity and prognosis. Most reports have studied the effect of single miR-200 family member knockdown. Here, we employ a multiplex CRISPR/Cas9 system to generate a complete miR-200 family knockout (FKO) to investigate their collective and summative role in regulating key cellular processes during GC pathogenesis. Genetic deletion of all miR-200s in the human GC cell lines induced potent morphological alterations, G1/S cell cycle arrest, increased senescence-associated beta-galactosidase (SA-beta-Gal) activity, and aberrant metabolism, collectively resembling the senescent phenotype. Coupling RNA-seq data with publicly available datasets, we revealed a clear separation of senescent and non-senescent states amongst FKO cells and control cells, respectively. Further analysis identified key senescence-associated secretory phenotype (SASP) components in FKO cells and a positive feedback loop for maintenance of the senescent state controlled by activation of TGF-beta and TNF-alpha pathways. Finally, we showed that miR-200 FKO associated senescence in cancer epithelial cells significantly recruited stromal cells in the tumor microenvironment. Our work has identified a new role of miR-200 family members which function as an integrated unit serving to link senescence with EMT, two major conserved biological processes.	[Yu, Liang; Cao, Can; Li, Xu; Zhang, Mili; Xu, Duogang; Liu, Youdong; Li, Jikun] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gen Surg, Sch Med, Shanghai 200080, Peoples R China; [Gu, Qisheng] Chinese Acad Sci, Inst Pasteur Shanghai, Shanghai 200031, Peoples R China; [Gao, Hugh] Univ Melbourne, Dept Clin Pathol, Melbourne, Vic 3133, Australia; [Gao, Hugh] Monash Hlth, Dept Upper Gastrointestinal & Hepatobiliary Surg, Clayton, Vic 3168, Australia; [Balic, Jesse J.; Ying, Le; Jenkins, Brendan J.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia; [Balic, Jesse J.; Ying, Le; Jenkins, Brendan J.] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Mol Translat Sci, Clayton, Vic 3800, Australia; [Zhang, Lei; He, Baokun] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Shanghai Key Lab Pancreat Dis, Sch Med, Shanghai 201620, Peoples R China; [Xu, Dakang] Shanghai Jiao Tong Univ, Ruijin Hosp, Fac Med Lab Sci, Sch Med, Shanghai, Peoples R China; [Yang, Yuqin] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Lab Anim Ctr, Sch Med, Shanghai 201620, Peoples R China; [Wu, Di] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Le Reseau International des Instituts Pasteur (RIIP); University of Melbourne; Hudson Institute of Medical Research; Monash University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of North Carolina; University of North Carolina Chapel Hill	Liu, YD; Li, JK (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gen Surg, Sch Med, Shanghai 200080, Peoples R China.	liuyddoc@163.com; jkli65975@163.com		cao, can/0000-0001-7011-9435; liu, youdong/0000-0001-7788-1916	National Natural Science Foundation of China (NSFC) [81673034, 82072643]; Shanghai Natural Science Foundation [19ZR1441000, 21ZR1452100]; National Health and Medical Research Council (NHMRC) of Australia [APP1139371, APP1154279]; Australian Postgraduate Award from the Australian Government	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award from the Australian Government(Australian Research CouncilAustralian Government)	This work was supported by grants from the National Natural Science Foundation of China (NSFC) (81673034 and 82072643) as well as the Shanghai Natural Science Foundation (19ZR1441000 and 21ZR1452100). This work was also funded by the National Health and Medical Research Council (NHMRC) of Australia (B.J. Jenkins; APP1139371 and APP1154279). J.J. Balic was supported by an Australian Postgraduate Award from the Australian Government.	Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Basisty N, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000599; Battram AM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124346; Breen DM, 2020, CELL METAB, V32, DOI 10.1016/j.cmet.2020.10.023; Casella G, 2019, NUCLEIC ACIDS RES, V47, P11476, DOI 10.1093/nar/gkz879; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; de Barrios O, 2017, GUT, V66, P666, DOI 10.1136/gutjnl-2015-310838; Enache OM, 2020, NAT GENET, V52, P662, DOI 10.1038/s41588-020-0623-4; Furuya S, 2017, FEBS OPEN BIO, V7, P1586, DOI 10.1002/2211-5463.12300; Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846; Ishimoto T, 2017, GASTROENTEROLOGY, V153, P191, DOI 10.1053/j.gastro.2017.03.046; Jiang YN, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00081; Kabadi AM, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku749; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kosicki M, 2018, NAT BIOTECHNOL, V36, P765, DOI 10.1038/nbt.4192; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; Oh SC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04179-8; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Pu MF, 2019, CELL MOL LIFE SCI, V76, P441, DOI 10.1007/s00018-018-2940-7; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; Seok H, 2016, MOL CELLS, V39, P375, DOI 10.14348/molcells.2016.0013; Song FJ, 2014, CLIN CANCER RES, V20, P878, DOI 10.1158/1078-0432.CCR-13-1844; Stavast CJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111465; Stramucci L, 2018, CANCERS, V10, DOI 10.3390/cancers10050131; Tang HL, 2013, CLIN CANCER RES, V19, P5602, DOI 10.1158/1078-0432.CCR-13-1326; Yu L, 2018, CLIN CANCER RES, V24, P1459, DOI 10.1158/1078-0432.CCR-17-2485; Zeng DQ, 2019, CANCER IMMUNOL RES, V7, P737, DOI 10.1158/2326-6066.CIR-18-0436; Zhao T, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00303-7	36	6	6	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					26	36		10.1038/s41388-021-02067-y	http://dx.doi.org/10.1038/s41388-021-02067-y		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34667277	hybrid, Green Published			2022-12-28	WOS:000708806900003
J	Zhang, WY; Pan, RL; Lu, M; Zhang, Q; Lin, ZQ; Qin, Y; Wang, ZY; Gong, SQ; Lin, H; Chong, SY; Lu, LT; Liao, WQ; Lu, XC				Zhang, Wenyi; Pan, Rulu; Lu, Mei; Zhang, Qian; Lin, Ziqi; Qin, Yuan; Wang, Zhanyu; Gong, Siqing; Lin, Huan; Chong, Shuyi; Lu, Liting; Liao, Wanqin; Lu, Xincheng			Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin beta 3/SRC pathway	ONCOGENE			English	Article							THYMIDYLATE SYNTHASE; DRUG-RESISTANCE; SRC ACTIVATION; C-SRC; CELLS; PROGRESSION; SUPPRESSES; MECHANISM; BCL-X(L); PROTEIN	The therapeutic efficacy of 5-fluorouracil (5-FU) is often reduced by the development of drug resistance. We observed significant upregulation of lipocalin 2 (LCN2) expression in a newly established 5-FU-resistant colorectal cancer (CRC) cell line. In this study, we demonstrated that 5-FU-treated CRC cells developed resistance through LCN2 upregulation caused by LCN2 promoter demethylation and that feedback between LCN2 and NF-kappa B further amplified LCN2 expression. High LCN2 expression was associated with poor prognosis in CRC patients. LCN2 attenuated the cytotoxicity of 5-FU by activating the SRC/AKT/ERK-mediated antiapoptotic program. Mechanistically, the LCN2-integrin beta 3 interaction enhanced integrin beta 3 stability, thus recruiting SRC to the cytomembrane for autoactivation, leading to downstream AKT/ERK cascade activation. Targeting LCN2 or SRC compromised the growth of CRC cells with LCN2-induced 5-FU resistance. Our findings demonstrate a novel mechanism of acquired resistance to 5-FU, suggesting that LCN2 can be used as a biomarker and/or therapeutic target for advanced CRC.	[Zhang, Wenyi; Pan, Rulu; Lu, Mei; Zhang, Qian; Lin, Ziqi; Qin, Yuan; Wang, Zhanyu; Gong, Siqing; Lin, Huan; Chong, Shuyi; Lu, Liting; Lu, Xincheng] Wenzhou Med Univ, Sch Basic Med Sci, Wenzhou 325035, Peoples R China; [Zhang, Wenyi] Wenzhou Med Univ, Dept Radiotherapy, Affiliated Hosp 1, Wenzhou, Peoples R China; [Liao, Wanqin] Foshan Univ, Dept Basic Med & Biomed Engn, Foshan 528200, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Foshan University	Lu, XC (corresponding author), Wenzhou Med Univ, Sch Basic Med Sci, Wenzhou 325035, Peoples R China.	xinchenglu@yahoo.com		Lin, Ziqi/0000-0001-7949-2092	National Natural Science Foundation of China [81972765, 81772966]; Zhejiang Provincial Natural Science Foundation [LZ21H160007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation(Natural Science Foundation of Zhejiang Province)	This work was supported by National Natural Science Foundation of China (Grant Nos. 81972765 and 81772966) and Zhejiang Provincial Natural Science Foundation (No. LZ21H160007). The Superbiotek Inc. (Shanghai, China) provided CRC tissue microarray analysis. The authors also thank the Laboratory Animal Research Center in Wenzhou Medical University for technical assistance.	Abella V, 2015, BIOMARKERS, V20, P565, DOI 10.3109/1354750X.2015.1123354; Arachiche A, 2008, J BIOL CHEM, V283, P24406, DOI 10.1074/jbc.M709217200; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Belli S, 2020, CANCERS, V12, DOI 10.3390/cancers12061489; Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532; Borkham-Kamphorst E, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00426; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown R, 2014, NAT REV CANCER, V14, P747, DOI 10.1038/nrc3819; Chen LJ, 2015, NANOSCALE, V7, P14080, DOI 10.1039/c5nr03527a; Chen TK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03030-7; Chi Y, 2020, SCIENCE, V369, P276, DOI 10.1126/science.aaz2193; Conde J, 2016, J PHYSIOL-LONDON, V594, P6133, DOI 10.1113/JP272240; de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321; Desgrosellier JS, 2009, NAT MED, V15, P1163, DOI 10.1038/nm.2009; Dong XM, 2017, CANCER LETT, V402, P153, DOI 10.1016/j.canlet.2017.05.024; Dunn EF, 2011, ONCOGENE, V30, P561, DOI 10.1038/onc.2010.430; Gomez-Chou SB, 2017, CANCER RES, V77, P2647, DOI 10.1158/0008-5472.CAN-16-1986; Griffiths GJ, 2004, J BIOL CHEM, V279, P46113, DOI 10.1074/jbc.M408550200; Guo X, 2018, RECENT PAT ANTI-CANC, V13, P248, DOI 10.2174/1574892813666171221120504; Huang ZX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2177-x; Jin W, 2020, CANCERS, V12, DOI 10.3390/cancers12051339; Kim SL, 2018, INT J ONCOL, V53, P2789, DOI 10.3892/ijo.2018.4562; Leung L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046677; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Martinez-Perez J, 2017, HUM PATHOL, V67, P119, DOI 10.1016/j.humpath.2017.05.025; Meka Phanni bhushann, 2015, Asian Pac J Cancer Prev, V16, P4965; Miao Q, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5088; Ong KL, 2020, DIABETES RES CLIN PR, V169, DOI 10.1016/j.diabres.2020.108450; Perez M, 2016, ONCOTARGET, V7, P33111, DOI 10.18632/oncotarget.8880; Pothuraju R, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01156-y; Reinecke JB, 2014, J CELL SCI, V127, P1684, DOI 10.1242/jcs.133892; Rosenzweig SA, 2018, ADV CANCER RES, V138, P71, DOI 10.1016/bs.acr.2018.02.003; Roskoski R, 2015, PHARMACOL RES, V94, P9, DOI 10.1016/j.phrs.2015.01.003; Salonga D, 2000, CLIN CANCER RES, V6, P1322; Santiago-Sanchez GS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124365; Sun Y, 2011, CLIN CANCER RES, V17, P4331, DOI 10.1158/1078-0432.CCR-11-0226; Tominaga T, 2010, INT J CANCER, V126, P1691, DOI 10.1002/ijc.24929; Tung MC, 2013, PROSTATE, V73, P1281, DOI 10.1002/pros.22670; Viau A, 2010, J CLIN INVEST, V120, P4065, DOI 10.1172/JCI42004; Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146; Wang H, 2020, CANCER SCI, V111, P84, DOI 10.1111/cas.14253; Wang QQ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02594; Wang TL, 2004, P NATL ACAD SCI USA, V101, P3089, DOI 10.1073/pnas.0308716101; Wang ZX, 2018, INT J ONCOL, V53, P2102, DOI 10.3892/ijo.2018.4521; Wilson BJ, 2011, CANCER RES, V71, P5307, DOI 10.1158/0008-5472.CAN-11-0221; Wu CJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4149; Xiao R, 2013, BLOOD, V121, P700, DOI 10.1182/blood-2012-07-440644; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Zhang X, 2016, CANCER LETT, V381, P305, DOI 10.1016/j.canlet.2016.08.004; Zou ZW, 2016, MOL MED REP, V14, P4893, DOI 10.3892/mmr.2016.5812	50	5	5	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6369	6380		10.1038/s41388-021-02029-4	http://dx.doi.org/10.1038/s41388-021-02029-4		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34588619				2022-12-28	WOS:000701380400002
J	Li, CH; Liu, JP; He, DH; Mao, FY; Rao, XJ; Zhao, Y; Lanman, NA; Kazemian, M; Farah, E; Liu, JH; Ngule, CM; Zhang, ZZ; Zhang, YQ; Kong, YF; Li, L; Wang, C; Liu, XQ				Li, Chaohao; Liu, Jinpeng; He, Daheng; Mao, Fengyi; Rao, Xiongjian; Zhao, Yue; Lanman, Nadia A.; Kazemian, Majid; Farah, Elia; Liu, Jinghui; Ngule, Chrispus M.; Zhang, Zhuangzhuang; Zhang, Yanquan; Kong, Yifan; Li, Lang; Wang, Chi; Liu, Xiaoqi			GSTM2 is a key molecular determinant of resistance to SG-ARIs	ONCOGENE			English	Article							PROSTATE-CANCER; OXIDATIVE STRESS; ENZALUTAMIDE; METASTASIS; SURVIVAL	Prostate cancer (PCa) continues to threaten men's health, and treatment targeting the androgen receptor (AR) pathway is the major therapy for PCa patients. Several second-generation androgen receptor inhibitors (SG-ARIs), including enzalutamide (ENZ), apalutamide (APA) and darolutamide (DARO), have been developed to better block the activity of AR. Unavoidably, emergence of resistance to these novel drugs still persists. Herein, we identified glutathione S-transferase Mu 2 (GSTM2) as an important determinant in the acquisition of resistance to SG-ARIs. Elevated GSTM2 was detected in enzalutamide-resistant (ENZ-R) PCa, and overexpression of GSTM2 in naive enzalutamide-sensitive (ENZ-S) cells effectively transformed them to ENZ-R PCa. Aryl hydrocarbon receptor (AhR), the upstream transcription factor, was implicated in the overexpression of GSTM2 in ENZ-R cells. Mechanistically, GSTM2 antagonized the effect of ENZ by rescuing cells from oxidative stress-associated damage and activation of p38 MAPK pathway. Surprisingly, high GSTM2 levels also associated with cross-resistance to APA and DARO. Taking together, these results provide new insight to ameliorate resistance to SG-ARIs and improve treatment outcome.	[Li, Chaohao; Mao, Fengyi; Rao, Xiongjian; Liu, Jinghui; Ngule, Chrispus M.; Zhang, Zhuangzhuang; Zhang, Yanquan; Kong, Yifan; Liu, Xiaoqi] Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA; [Liu, Jinpeng; He, Daheng; Wang, Chi] Univ Kentucky, Dept Biostat, Lexington, KY 40536 USA; [Liu, Jinpeng; He, Daheng; Wang, Chi; Liu, Xiaoqi] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; [Zhao, Yue; Li, Lang] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; [Lanman, Nadia A.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA; [Lanman, Nadia A.] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA; [Kazemian, Majid; Farah, Elia] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; [Kazemian, Majid] Purdue Univ, Dept Comp Sci, W Lafayette, IN 47907 USA	University of Kentucky; University of Kentucky; University of Kentucky; University System of Ohio; Ohio State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Liu, XQ (corresponding author), Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA.; Liu, XQ (corresponding author), Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA.	xiaoqi.liu@uky.edu	; Kazemian, Majid/C-7917-2018	Atallah, Nadia/0000-0002-1819-7070; Kazemian, Majid/0000-0001-7080-8820; Zhang, Zhuangzhuang/0000-0003-2578-7375	NIH [R01 CA157429, R01 CA196634, R01 CA264652, R01 CA256893]; University of Kentucky Markey Cancer Center [P30CA177558]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Kentucky Markey Cancer Center	The research is generously supported by NIH R01 CA157429 (XL), R01 CA196634 (XL), R01 CA264652 (XL), R01 CA256893 (XL). This research is also supported by the Biospecimen Procurement & Translational Pathology, Biostatistics and Bioinformatics, Redox Metabolism, and Flow Cytometry and Immune Monitoring Shared Resources of the University of Kentucky Markey Cancer Center (P30CA177558). We thanks Dr. Alumkal Joshi for the generous sharing of the RNA-seq raw data, and Eleanor Erikson for the critical reading and editing of the manuscript.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Allocati N, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0025-3; Alumkal JJ, 2020, P NATL ACAD SCI USA, V117, P12315, DOI 10.1073/pnas.1922207117; Andonova IE, 2010, BREAST CANCER RES TR, V121, P497, DOI 10.1007/s10549-009-0589-5; Bhattacharjee P, 2013, SCI REP-UK, V3, DOI 10.1038/srep02704; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; Canovas B, 2021, NAT REV MOL CELL BIO, V22, P346, DOI 10.1038/s41580-020-00322-w; Clegg NJ, 2012, CANCER RES, V72, P1494, DOI 10.1158/0008-5472.CAN-11-3948; Coutinho I, 2016, ENDOCR-RELAT CANCER, V23, pT179, DOI 10.1530/ERC-16-0422; Davies A, 2021, NAT CELL BIOL, V23, P1023, DOI 10.1038/s41556-021-00743-5; de Vries R, 2019, DRUG METAB DISPOS, V47, P453, DOI 10.1124/dmd.118.084517; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671; Gibbons JA, 2015, CLIN PHARMACOKINET, V54, P1043, DOI 10.1007/s40262-015-0271-5; Guo EN, 2020, BMC MED GENET, V21, DOI 10.1186/s12881-020-01066-2; Hamdy FC, 2016, NEW ENGL J MED, V375, P1415, DOI 10.1056/NEJMoa1606220; Han I, 2011, PROTEOMICS, V11, P352, DOI 10.1002/pmic.201000475; Hayer A, 2016, NAT CELL BIOL, V18, P1311, DOI 10.1038/ncb3438; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Hayes JD, 2009, TOXICOL SCI, V111, P199, DOI 10.1093/toxsci/kfp168; He YD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21860-7; Higano C, 2019, NAT REV UROL, V16, P335, DOI 10.1038/s41585-019-0186-2; Ji CH, 2020, CHEM RES TOXICOL, V33, P211, DOI 10.1021/acs.chemrestox.9b00247; Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259; Li CH, 2020, J BIOL CHEM, V295, P5470, DOI 10.1074/jbc.RA119.011385; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu CF, 2015, CANCER RES, V75, P1413, DOI 10.1158/0008-5472.CAN-14-3080; Moilanen AM, 2015, SCI REP-UK, V5, DOI 10.1038/srep12007; Neha K, 2019, EUR J MED CHEM, V178, P687, DOI 10.1016/j.ejmech.2019.06.010; Peng LS, 2021, PANCREATOLOGY, V21, P115, DOI 10.1016/j.pan.2020.12.008; Ricci G, 2005, J BIOL CHEM, V280, P26397, DOI 10.1074/jbc.M503295200; Rothhammer V, 2019, NAT REV IMMUNOL, V19, P184, DOI 10.1038/s41577-019-0125-8; Sagar, 2016, DOES GLUTATHIONE TRA; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shiota M, 2010, ONCOGENE, V29, P237, DOI 10.1038/onc.2009.322; Shiota M, 2011, FREE RADICAL BIO MED, V51, P1320, DOI 10.1016/j.freeradbiomed.2011.07.011; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037; Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546; Tang SC, 2013, MOL CANCER RES, V11, P518, DOI 10.1158/1541-7786.MCR-12-0488; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teo MY, 2019, ANNU REV MED, V70, P479, DOI 10.1146/annurev-med-051517-011947; Zhang ZD, 2020, CANCER CELL, V37, P584, DOI 10.1016/j.ccell.2020.03.001; Zhao JG, 2020, MOL CANCER THER, V19, P1708, DOI 10.1158/1535-7163.MCT-20-0015; Zhao Liang, 2010, Front Biosci (Elite Ed), V2, P241, DOI 10.2741/e86; Zhao SG, 2020, NAT GENET, V52, P778, DOI 10.1038/s41588-020-0648-8; Zhou SG, 2008, MOL CELL BIOCHEM, V309, P99, DOI 10.1007/s11010-007-9647-7	49	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4498	4511		10.1038/s41388-022-02444-1	http://dx.doi.org/10.1038/s41388-022-02444-1		AUG 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36038661				2022-12-28	WOS:000847262000002
J	Bell, ES; Shah, P; Zuela-Sopilniak, N; Kim, D; Varlet, AA; Morival, JLP; McGregor, AL; Isermann, P; Davidson, PM; Elacqua, JJ; Lakins, JN; Vahdat, L; Weaver, VM; Smolka, MB; Span, PN; Lammerding, J				Bell, Emily S.; Shah, Pragya; Zuela-Sopilniak, Noam; Kim, Dongsung; Varlet, Alice-Anais; Morival, Julien L. P.; McGregor, Alexandra L.; Isermann, Philipp; Davidson, Patricia M.; Elacqua, Joshua J.; Lakins, Jonathan N.; Vahdat, Linda; Weaver, Valerie M.; Smolka, Marcus B.; Span, Paul N.; Lammerding, Jan			Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer	ONCOGENE			English	Article							A-TYPE LAMINS; NUCLEAR-ENVELOPE; DNA-DAMAGE; RETINOBLASTOMA PROTEIN; CHROMATIN ORGANIZATION; MECHANICAL-PROPERTIES; AKT PHOSPHORYLATION; MESSENGER-RNA; TUMOR-CELLS; EXPRESSION	Aberrations in nuclear size and shape are commonly used to identify cancerous tissue. However, it remains unclear whether the disturbed nuclear structure directly contributes to the cancer pathology or is merely a consequence of other events occurring during tumorigenesis. Here, we show that highly invasive and proliferative breast cancer cells frequently exhibit Akt-driven lower expression of the nuclear envelope proteins lamin A/C, leading to increased nuclear deformability that permits enhanced cell migration through confined environments that mimic interstitial spaces encountered during metastasis. Importantly, increasing lamin A/C expression in highly invasive breast cancer cells reflected gene expression changes characteristic of human breast tumors with higher LMNA expression, and specifically affected pathways related to cell-ECM interactions, cell metabolism, and PI3K/Akt signaling. Further supporting an important role of lamins in breast cancer metastasis, analysis of lamin levels in human breast tumors revealed a significant association between lower lamin A levels, Akt signaling, and decreased disease-free survival. These findings suggest that downregulation of lamin A/C in breast cancer cells may influence both cellular physical properties and biochemical signaling to promote metastatic progression.	[Bell, Emily S.; Shah, Pragya; Zuela-Sopilniak, Noam; Kim, Dongsung; Varlet, Alice-Anais; Morival, Julien L. P.; McGregor, Alexandra L.; Isermann, Philipp; Davidson, Patricia M.; Elacqua, Joshua J.; Smolka, Marcus B.; Lammerding, Jan] Cornell Univ, Weill Inst Cell & Mol Biol, Ithaca, NY 14850 USA; [McGregor, Alexandra L.; Lammerding, Jan] Cornell Univ, Nancy E & Peter C Meinig Sch Biomed Engn, Ithaca, NY 14850 USA; [Lakins, Jonathan N.; Weaver, Valerie M.] Univ Calif San Francisco, Dept Surg, Ctr Bioengn & Tissue Regenerat, San Francisco, CA USA; [Vahdat, Linda] Weill Cornell Med, Dept Med, New York, NY USA; [Weaver, Valerie M.] Univ Calif San Francisco, Helen Diller Canc Ctr, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Weaver, Valerie M.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA; [Span, Paul N.] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol Radiotherapy & Oncolmmunol Lab, Nijmegen, Netherlands; [Bell, Emily S.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Cornell University; Cornell University; University of California System; University of California San Francisco; Cornell University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; Radboud University Nijmegen; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Lammerding, J (corresponding author), Cornell Univ, Weill Inst Cell & Mol Biol, Ithaca, NY 14850 USA.; Lammerding, J (corresponding author), Cornell Univ, Nancy E & Peter C Meinig Sch Biomed Engn, Ithaca, NY 14850 USA.	jan.lammerding@cornell.edu	Span, Paul/G-4710-2012	Span, Paul/0000-0002-1930-6638; Morival, Julien/0000-0003-1252-025X; Varlet, Alice-Anais/0000-0002-1670-4884	National Institutes of Health [R01 HL082792, R01 GM137605, U54 CA210184, U54 CA193461, R35 GM141159, R01 GM123018]; Department of Defense Breast Cancer Research Program [BC150580]; National Science Foundation [CBET-1254846, DGE-1144153, NNCI-2025233]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program(United States Department of Defense); National Science Foundation(National Science Foundation (NSF))	This work was supported by funding from the National Institutes of Health (R01 HL082792, R01 GM137605, U54 CA210184, and U54 CA193461 to JL, R35 GM141159 and R01 GM123018 to MBS), the Department of Defense Breast Cancer Research Program (Breakthrough Award BC150580 to JL), and the National Science Foundation (CAREER Award CBET-1254846 to JL and Graduate Research Fellowship DGE-1144153 to ALM). This work was performed in part at the Cornell NanoScale Science & Technology Facility (CNF), a member of the National Nanotechnology Coordinated Infrastructure NNCI), which is supported by the National Science Foundation (Grant NNCI-2025233).	Agrelo R, 2005, J CLIN ONCOL, V23, P3940, DOI 10.1200/JCO.2005.11.650; Alhudiri IM, 2019, BREAST CANCER RES TR, V174, P661, DOI 10.1007/s10549-018-05092-w; Ali R, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.42; Aljada A, 2016, CELL ONCOL, V39, P161, DOI 10.1007/s13402-015-0265-1; Andres V, 2009, J CELL BIOL, V187, P945, DOI 10.1083/jcb.200904124; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Barati MT, 2006, J PROTEOME RES, V5, P1636, DOI 10.1021/pr0502469; de Oliveira FMB, 2018, METHODS MOL BIOL, V1672, P645, DOI 10.1007/978-1-4939-7306-4_42; Batulan Z, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00285; Bell ES, 2016, EUR J CELL BIOL, V95, P449, DOI 10.1016/j.ejcb.2016.06.007; Belt EJT, 2011, EUR J CANCER, V47, P1837, DOI 10.1016/j.ejca.2011.04.025; Bertacchini J, 2013, FASEB J, V27, P2145, DOI 10.1096/fj.12-218214; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Brady CA, 2010, J CELL SCI, V123, P2527, DOI 10.1242/jcs.064501; Broers JLV, 1997, HISTOCHEM CELL BIOL, V107, P505, DOI 10.1007/s004180050138; Bussolati G, 2014, ADV EXP MED BIOL, V773, P101, DOI 10.1007/978-1-4899-8032-8_5; Bustin M, 2016, SCIENCE, V352, DOI 10.1126/science.aad6933; Buxboim A, 2014, CURR BIOL, V24, P1909, DOI 10.1016/j.cub.2014.07.001; Caille N, 2002, J BIOMECH, V35, P177, DOI 10.1016/S0021-9290(01)00201-9; Capo-chichi Callinice D, 2011, Chin J Cancer, V30, P415; Cenni V, 2008, J PROTEOME RES, V7, P4727, DOI 10.1021/pr800262g; Cho S, 2019, DEV CELL, V49, P920, DOI 10.1016/j.devcel.2019.04.020; Cho S, 2017, J CELL BIOL, V216, P305, DOI 10.1083/jcb.201610042; Collas P, 1999, J CELL SCI, V112, P977; Concin N, 2003, BREAST CANCER RES TR, V79, P37, DOI 10.1023/A:1023351717408; Condor M, 2019, BIOPHYS J, V116, P1305, DOI 10.1016/j.bpj.2019.02.029; Coradeghini R, 2006, ONCOL REP, V15, P609; Davidson PM, 2019, LAB CHIP, V19, P3652, DOI 10.1039/c9lc00444k; Davidson PM, 2015, INTEGR BIOL-UK, V7, P1534, DOI 10.1039/c5ib00200a; Davidson PM, 2014, CELL MOL BIOENG, V7, P293, DOI 10.1007/s12195-014-0342-y; de las Heras JI, 2014, ADV EXP MED BIOL, V773, P5, DOI 10.1007/978-1-4899-8032-8_1; de Leeuw R, 2018, TRENDS CELL BIOL, V28, P34, DOI 10.1016/j.tcb.2017.08.004; de Oliveira FMB, 2015, MOL CELL, V57, P1124, DOI 10.1016/j.molcel.2015.01.043; Denais C, 2014, ADV EXP MED BIOL, V773, P435, DOI 10.1007/978-1-4899-8032-8_20; Denais CM, 2016, SCIENCE, V352, P353, DOI 10.1126/science.aad7297; DEXTER DL, 1978, CANCER RES, V38, P3174; DOERSCHUK CM, 1993, J APPL PHYSIOL, V74, P3040, DOI 10.1152/jappl.1993.74.6.3040; Dubik N, 2020, CANCERS, V12, DOI 10.3390/cancers12123688; Earle AJ, 2020, NAT MATER, V19, P464, DOI 10.1038/s41563-019-0563-5; Fong LG, 2006, J CLIN INVEST, V116, P743, DOI 10.1172/JCI27125; Frock RL, 2006, GENE DEV, V20, P486, DOI 10.1101/gad.1364906; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gong GH, 2015, PATHOL RES PRACT, V211, P175, DOI 10.1016/j.prp.2014.11.008; Gonzalez-Cruz RD, 2018, CELL MOL BIOENG, V11, P131, DOI 10.1007/s12195-018-0518-y; Gonzalo S, 2014, ADV EXP MED BIOL, V773, P377, DOI 10.1007/978-1-4899-8032-8_17; Gruenbaum Y, 2015, ANNU REV BIOCHEM, V84, P131, DOI 10.1146/annurev-biochem-060614-034115; Guilak F, 2000, BIOCHEM BIOPH RES CO, V269, P781, DOI 10.1006/bbrc.2000.2360; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Guz N, 2014, BIOPHYS J, V107, P564, DOI 10.1016/j.bpj.2014.06.033; Han EKH, 2007, ONCOGENE, V26, P5655, DOI 10.1038/sj.onc.1210343; Hanson PI, 2008, J CELL BIOL, V180, P389, DOI 10.1083/jcb.200707031; Harada T, 2014, J CELL BIOL, V204, P669, DOI 10.1083/jcb.201308029; Hetzer MW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000539; Hoxhaj G, 2020, NAT REV CANCER, V20, P74, DOI 10.1038/s41568-019-0216-7; Irianto J, 2016, MOL BIOL CELL, V27, P4011, DOI 10.1091/mbc.E16-06-0428; Irianto J, 2016, CELL MOL BIOENG, V9, P258, DOI 10.1007/s12195-016-0437-8; Isermann P, 2013, CURR BIOL, V23, pR1113, DOI 10.1016/j.cub.2013.11.009; Ivorra' C, 2006, GENE DEV, V20, P307, DOI 10.1101/gad.349506; Johnson BR, 2004, P NATL ACAD SCI USA, V101, P9677, DOI 10.1073/pnas.0403250101; Kennedy BK, 2014, ADV EXP MED BIOL, V773, P127, DOI 10.1007/978-1-4899-8032-8_6; Kim D, 2018, NUCLEIC ACIDS RES, V46, P8311, DOI 10.1093/nar/gky625; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670; Lammerding J, 2006, J BIOL CHEM, V281, P25768, DOI 10.1074/jbc.M513511200; Lautscham LA, 2015, BIOPHYS J, V109, P900, DOI 10.1016/j.bpj.2015.07.025; Lee H, 2015, EXP BIOL MED, V240, P1543, DOI 10.1177/1535370215583799; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Lloyd DJ, 2002, HUM MOL GENET, V11, P769, DOI 10.1093/hmg/11.7.769; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474; Marmiroli S, 2009, J CELL PHYSIOL, V220, P553, DOI 10.1002/jcp.21807; Matsumoto A, 2015, CANCER MED-US, V4, P1547, DOI 10.1002/cam4.495; Maurer M, 2019, ANNU REV BIOMED ENG, V21, P443, DOI 10.1146/annurev-bioeng-060418-052139; Maynard S, 2019, NUCLEIC ACIDS RES, V47, P11709, DOI 10.1093/nar/gkz912; McGregor AL, 2016, CURR OPIN CELL BIOL, V40, P32, DOI 10.1016/j.ceb.2016.01.011; Mekhdjian AH, 2017, MOL BIOL CELL, V28, P1467, DOI 10.1091/mbc.E16-09-0654; Miroshnikova YA, 2016, NAT CELL BIOL, V18, P1336, DOI 10.1038/ncb3429; Mitchell MJ, 2015, AM J PHYSIOL-CELL PH, V309, pC736, DOI 10.1152/ajpcell.00050.2015; Mukherjee A, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008300; Mymrikov EV, 2011, PHYSIOL REV, V91, P1123, DOI 10.1152/physrev.00023.2010; Naeem AS, 2015, CELL DEATH DIFFER, V22, P2123, DOI 10.1038/cdd.2015.62; Nagelkerke A, 2011, RADIOTHER ONCOL, V101, P39, DOI 10.1016/j.radonc.2011.07.009; Nitta RT, 2006, MOL CELL BIOL, V26, P5360, DOI 10.1128/MCB.02464-05; Okumura K, 2004, BIOCHEM BIOPH RES CO, V320, P487, DOI 10.1016/j.bbrc.2004.05.191; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Ortega MA, 2020, J ONCOL, V2020, DOI 10.1155/2020/9258396; Pajerowski JD, 2007, P NATL ACAD SCI USA, V104, P15619, DOI 10.1073/pnas.0702576104; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Pickup MW, 2013, CANCER RES, V73, P5336, DOI 10.1158/0008-5472.CAN-13-0012; Pombo A, 2015, NAT REV MOL CELL BIO, V16, P245, DOI 10.1038/nrm3965; R Core Team, 2015, R LANGUAGE ENV STAT; Raab M, 2016, SCIENCE, V352, P359, DOI 10.1126/science.aad7611; Reddy KL, 2013, SEMIN CANCER BIOL, V23, P109, DOI 10.1016/j.semcancer.2012.12.001; Redwood AB, 2011, CELL CYCLE, V10, P2549, DOI 10.4161/cc.10.15.16531; Rhodes N, 2008, CANCER RES, V68, P2366, DOI 10.1158/0008-5472.CAN-07-5783; Roncato F, 2021, CANCERS, V13, DOI 10.3390/cancers13102383; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Saleh T, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12030609; Schape J, 2009, BIOPHYS J, V96, P4319, DOI 10.1016/j.bpj.2009.02.048; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schreiber KH, 2013, CELL, V152, P1365, DOI 10.1016/j.cell.2013.02.015; Shah P, 2021, CURR BIOL, V31, P753, DOI 10.1016/j.cub.2020.11.037; Shimi T, 2008, GENE DEV, V22, P3409, DOI 10.1101/gad.1735208; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stephens AD, 2018, MOL BIOL CELL, V29, P220, DOI 10.1091/mbc.E17-06-0410; Stephens AD, 2017, MOL BIOL CELL, V28, P1984, DOI 10.1091/mbc.E16-09-0653; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; Stoitzner P, 2002, J INVEST DERMATOL, V118, P117, DOI 10.1046/j.0022-202x.2001.01631.x; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Swift J, 2013, SCIENCE, V341, DOI 10.1126/science.1240104; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tseng Y, 2004, J CELL SCI, V117, P2159, DOI 10.1242/jcs.01073; Van Berlo JH, 2005, HUM MOL GENET, V14, P2839, DOI 10.1093/hmg/ddi316; Vargas JD, 2012, NUCLEUS-PHILA, V3, P88, DOI 10.4161/nucl.18954; Venables RS, 2001, BRIT J CANCER, V84, P512, DOI 10.1054/bjoc.2000.1632; Wang X, 2018, J CELL SCI, V131, DOI 10.1242/jcs.209627; Wazir U, 2013, CELL MOL BIOL LETT, V18, P595, DOI 10.2478/s11658-013-0109-9; Weigelin Bettina, 2012, Intravital, V1, P32, DOI 10.4161/intv.21223; Wennemers M, 2013, INT J BIOL MARKER, V28, P151, DOI [10.5301/JBM.5000008, 10.5301/jbm.5000008]; Willis ND, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002988; Wolf K, 2013, J CELL BIOL, V201, P1069, DOI 10.1083/jcb.201210152; Wong XR, 2020, ANNU REV GENOM HUM G, V21, P263, DOI 10.1146/annurev-genom-121219-083616; Wu ZR, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-8; Zwerger M, 2013, HUM MOL GENET, V22, P2335, DOI 10.1093/hmg/ddt079	125	0	0	12	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2022	41	36					4211	4230		10.1038/s41388-022-02420-9	http://dx.doi.org/10.1038/s41388-022-02420-9		JUL 2022	20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4G5OH	35896617	Green Submitted			2022-12-28	WOS:000830954900001
J	Cheng, Y; Sun, FM; Thornton, K; Jing, XF; Dong, J; Yun, G; Pisano, M; Zhan, FH; Kim, SH; Katzenellenbogen, JA; Katzenellenbogen, BS; Hari, P; Janz, S				Cheng, Yan; Sun, Fumou; Thornton, Krista; Jing, Xuefang; Dong, Jing; Yun, Grant; Pisano, Michael; Zhan, Fenghuang; Kim, Sung Hoon; Katzenellenbogen, John A.; Katzenellenbogen, Benita S.; Hari, Parameswaran; Janz, Siegfried			FOXM1 regulates glycolysis and energy production in multiple myeloma	ONCOGENE			English	Article							TRANSCRIPTION FACTOR FOXM1; CONNECTIVITY MAP; PROGRESSION; PROMOTES; TARGET; PLASTICITY; HSP90; CELLS	The transcription factor, forkhead box M1 (FOXM1), has been implicated in the natural history and outcome of newly diagnosed high-risk myeloma (HRMM) and relapsed/refractory myeloma (RRMM), but the mechanism with which FOXM1 promotes the growth of neoplastic plasma cells is poorly understood. Here we show that FOXM1 is a positive regulator of myeloma metabolism that greatly impacts the bioenergetic pathways of glycolysis and oxidative phosphorylation (OxPhos). Using FOXM1-deficient myeloma cells as principal experimental model system, we find that FOXM1 increases glucose uptake, lactate output, and oxygen consumption in myeloma. We demonstrate that the novel 1,1-diarylethylene small-compound FOXM1 inhibitor, NB73, suppresses myeloma in cell culture and human-in-mouse xenografts using a mechanism that includes enhanced proteasomal FOXM1 degradation. Consistent with the FOXM1-stabilizing chaperone function of heat shock protein 90 (HSP90), the HSP90 inhibitor, geldanamycin, collaborates with NB73 in slowing down myeloma. These findings define FOXM1 as a key driver of myeloma metabolism and underscore the feasibility of targeting FOXM1 for new approaches to myeloma therapy and prevention.	[Cheng, Yan; Dong, Jing; Yun, Grant; Pisano, Michael; Hari, Parameswaran; Janz, Siegfried] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA; [Thornton, Krista] Univ Iowa, Dept Pathol, Master Sci Grad Program, Iowa City, IA 52242 USA; [Jing, Xuefang] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Pisano, Michael] Univ Iowa, Interdisciplinary Grad Program Immunol, Iowa City, IA USA; [Zhan, Fenghuang] Univ Arkansas Med Sci, Myeloma Ctr, Div Hematol & Oncol, Dept Med, Little Rock, AR 72205 USA; [Zhan, Fenghuang] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, Little Rock, AR 72205 USA; [Kim, Sung Hoon; Katzenellenbogen, John A.] Univ Illinois, Dept Chem, Urbana, IL 61801 USA; [Katzenellenbogen, Benita S.] Univ Illinois, Mol & Integrat Physiol & Canc Ctr, Urbana, IL 61801 USA; [Hari, Parameswaran; Janz, Siegfried] Med Coll Wisconsin, Ctr Canc, Milwaukee, WI 53226 USA	Medical College of Wisconsin; University of Iowa; University of Iowa; University of Iowa; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Medical College of Wisconsin	Janz, S (corresponding author), Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA.; Janz, S (corresponding author), Med Coll Wisconsin, Ctr Canc, Milwaukee, WI 53226 USA.	sjanz@mcw.edu		Zhan, Fenghuang/0000-0001-5417-2973; Jing, Xuefang/0000-0002-8670-4505; Dong, Jing/0000-0001-9856-5963; Sun, Fumou/0000-0003-2034-3492	Breast Cancer Research Foundation [083, 084]; NCI [R01CA151354, R01CA236814]; DoD [CA180190]; Riney Family Multiple Myeloma Research Program award; MCW Milwaukee William G. Schuett, Jr., Multiple Myeloma Research Endowment; Myeloma Crowd Research Initiative award	Breast Cancer Research Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DoD(United States Department of Defense); Riney Family Multiple Myeloma Research Program award; MCW Milwaukee William G. Schuett, Jr., Multiple Myeloma Research Endowment; Myeloma Crowd Research Initiative award	We wish to acknowledge expert technical assistance from MCW Cancer Center core facility staff, especially Monika Zielonka, Redox and Bioenergetics Shared Resource (CCRBSR); Galina Petrova, Flow Cytometry Shared Resource; and Donna McAllister, Biomedical Imaging Shared Resource. This work was supported by Breast Cancer Research Foundation grants 083 (to BSK) and 084 (to JAK); by NCI R01CA236814, DoD CA180190, Myeloma Crowd Research Initiative and Riney Family Multiple Myeloma Research Program awards (to FZ); and by NCI R01CA151354 (to SJ). Additional support was provided by the MCW Milwaukee William G. Schuett, Jr., Multiple Myeloma Research Endowment.	Abdollahi P, 2021, FASEB J, V35, DOI 10.1096/fj.202001920RR; Bajpai R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15051-z; Barger CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11020251; Bergamaschi A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0436-4; Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005592; Black M, 2020, MOL BIOL CELL, V31, P1411, DOI 10.1091/mbc.E19-07-0413; Bloedjes TA, 2021, CANCERS, V13, DOI 10.3390/cancers13030396; Boreel DF, 2021, CLIN CANCER RES, V27, P2970, DOI 10.1158/1078-0432.CCR-20-3913; Borhani S, 2020, EXPERT OPIN THER TAR, V24, P205, DOI 10.1080/14728222.2020.1727888; Buchner M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7471; Caillot M, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00253-3; Cui JJ, 2014, CLIN CANCER RES, V20, P2595, DOI 10.1158/1078-0432.CCR-13-2407; Dalva-Aydemir S, 2015, CLIN CANCER RES, V21, P1161, DOI 10.1158/1078-0432.CCR-14-1088; Deribe YL, 2018, NAT MED, V24, P1047, DOI 10.1038/s41591-018-0019-5; Dey P, 2020, CANCERS, V12, DOI 10.3390/cancers12092677; Duncan K, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.61; El Arfani C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041200; Fujiwara S, 2015, EXP HEMATOL ONCOL, V4, DOI 10.1186/s40164-015-0008-z; Gormally MV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6165; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Gu C, 2016, LEUKEMIA, V30, P873, DOI 10.1038/leu.2015.334; Gu CY, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5015-0; Gu CY, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0060-0; Gu ZM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0392-4; Hajek R, 2013, BRIT J HAEMATOL, V163, P551, DOI 10.1111/bjh.12563; Halasi M, 2016, J BIOL CHEM, V291, P142, DOI 10.1074/jbc.M115.678227; Hassanzadeh A, 2019, ANTI-CANCER AGENT ME, V19, P1523, DOI 10.2174/1871520619666190729150442; He YH, 2015, LEUKEMIA RES, V39, P1428, DOI 10.1016/j.leukres.2015.09.019; Hegde NS, 2011, NAT CHEM, V3, P725, DOI [10.1038/NCHEM.1114, 10.1038/nchem.1114]; Hoang PH, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0315-4; Hou Y, 2015, NAT IMMUNOL, V16, P810, DOI 10.1038/ni.3204; Jang JS, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-018-0160-x; Kalathil D, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.626836; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Lagana A, 2018, LEUKEMIA, V32, P120, DOI 10.1038/leu.2017.197; Lam WY, 2016, IMMUNITY, V45, P60, DOI 10.1016/j.immuni.2016.06.011; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lis P, 2016, MOLECULES, V21, DOI 10.3390/molecules21121730; Maiso P, 2015, CANCER RES, V75, P2071, DOI 10.1158/0008-5472.CAN-14-3400; Marlein CR, 2019, CANCER RES, V79, P2285, DOI 10.1158/0008-5472.CAN-18-0773; Misund K, 2020, LEUKEMIA, V34, P322, DOI 10.1038/s41375-019-0543-4; Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood-2005-03-1158; Nakano A, 2012, J BIOENERG BIOMEMBR, V44, P31, DOI 10.1007/s10863-012-9412-9; Pracht K, 2021, EUR J IMMUNOL, V51, P1089, DOI 10.1002/eji.202048993; Qin XD, 2017, SCI REP-UK, V7, DOI 10.1038/srep45305; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Ray A, 2020, ONCOGENE, V39, P2786, DOI 10.1038/s41388-020-1172-0; Ryu D, 2020, CLIN CANCER RES, V26, P935, DOI 10.1158/1078-0432.CCR-19-0694; Sanchez J, 2020, CURR CANCER DRUG TAR, V20, P253, DOI 10.2174/1568009619666191202101330; Sanchez WY, 2013, BRIT J CANCER, V108, P1624, DOI 10.1038/bjc.2013.120; Shukla S, 2019, MOL CANCER THER, V18, P1217, DOI 10.1158/1535-7163.MCT-18-0709; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Trasanidis N, 2022, BLOOD, V139, P1939, DOI 10.1182/blood.2021014391; Waldschmidt JM, 2021, CLIN CANCER RES, V27, P6432, DOI 10.1158/1078-0432.CCR-21-2040; Wang HS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18028-z; Wang Y, 2016, ONCOTARGET, V7, P47985, DOI 10.18632/oncotarget.10103; Xiang Y, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117971; Xu SL, 2019, CANCER RES, V79, P2748, DOI 10.1158/0008-5472.CAN-18-2799; Zhan X, 2017, ONCOTARGET, V8, P111213, DOI 10.18632/oncotarget.22740; Zhang HY, 2018, MOL ONCOL, V12, P1579, DOI 10.1002/1878-0261.12363; Zhang W, 2021, MOL ONCOL, V15, P1466, DOI 10.1002/1878-0261.12879; Ziegler Y, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523-019-0141-7	62	2	2	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3899	3911		10.1038/s41388-022-02398-4	http://dx.doi.org/10.1038/s41388-022-02398-4		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35794249	Green Published, hybrid			2022-12-28	WOS:000823188300001
J	Huang, C; Lv, XM; Chen, PC; Liu, JY; He, CB; Chen, L; Wang, HB; Moness, ML; Dong, JX; Rueda, BR; Davis, JS; Wang, C				Huang, Cong; Lv, Xiangmin; Chen, Peichao; Liu, Jiyuan; He, Chunbo; Chen, Li; Wang, Hongbo; Moness, Madelyn L.; Dong, Jixin; Rueda, Bo R.; Davis, John S.; Wang, Cheng			Human papillomavirus targets the YAP1-LATS2 feedback loop to drive cervical cancer development	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; HIPPO SIGNALING PATHWAY; CELLULAR SENESCENCE; NATURAL-HISTORY; HPV INFECTION; EXPRESSION; WORLDWIDE; ESTROGEN; YAP/TAZ; P53	Human papillomavirus (HPV) infection is very common in sexually active women, but cervical cancer only develops in a small fraction of HPV-infected women, suggesting that unknown intrinsic factors associated with the unique genetic/genomic background of the high-risk population play a critical role in cervical carcinogenesis. Although our previous studies have identified the hyperactivated YAP1 oncogene as a critical contributor to cervical cancer, the molecular mechanism by which YAP1 drives cervical cancer is unknown. In the present study, we found that although the hyperactivated YAP1 caused a malignant transformation of immortalized cervical epithelial cells, it induced cellular senescence in cultures of primary human cervical epithelial cells (HCvECs). However, the hyperactivated YAP1 induced malignant transformation of HCvECs in the presence of high-risk HPV E6/E7 proteins, suggesting that the hyperactivated YAP1 synergizes with HPV to initiate cervical cancer development. Our mechanistic studies demonstrate that YAP1, via up-regulating LATS2, formed a YAP1-LATS2 negative feedback loop in cervical epithelial cells to maintain homeostasis of cervical tissue. Intriguingly, we found that high-risk HPV targets LATS2 to disrupt the feedback loop leading to the malignant transformation of cervical epithelial cells. Finally, we report that mitomycin C, an FDA-approved drug that could upregulate LATS2 and drive cellular senescence in vitro and in vivo, induced a regression of cervical cancer in a pre-clinial animal model. Thus, high-risk HPV targeting the YAP1-LATS2 feedback loop represents a new mechanism of cervical cancer development.	[Huang, Cong; Lv, Xiangmin; Chen, Peichao; Liu, Jiyuan; He, Chunbo; Chen, Li; Wang, Hongbo; Moness, Madelyn L.; Rueda, Bo R.; Wang, Cheng] Harvard Med Sch, Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Vincent Ctr Reprod Biol, Boston, MA 02114 USA; [Chen, Peichao] Wenzhou Univ, Coll Life & Environm Sci, Wenzhou 325035, Zhejiang, Peoples R China; [He, Chunbo; Dong, Jixin; Davis, John S.] Univ Nebraska Med Ctr, Fred & Pamela Canc Ctr, Omaha, NE 68198 USA; [Chen, Li] Chinese Acad Sci, Key Lab Anim Ecol & Conservat Biol, Beijing 100101, Peoples R China; [Davis, John S.] Univ Nebraska Med Ctr, Dept Obstet & Gynecol, Olson Ctr Womens Hlth, Omaha, NE 68198 USA; [Davis, John S.] Vet Adm Nebraska Western Iowa Healthcare Syst, Omaha, NE 68105 USA; [Huang, Cong] Peking Univ Shenzhen Hosp, Shenzhen Peking Univ Hong Kong Univ Sci & Technol, Dept Dermatol, Shenzhen 518036, Peoples R China	Harvard University; Harvard Medical School; Massachusetts General Hospital; Wenzhou University; University of Nebraska System; University of Nebraska Medical Center; Chinese Academy of Sciences; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; Hong Kong University of Science & Technology; Peking University	Wang, C (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Vincent Ctr Reprod Biol, Boston, MA 02114 USA.	cwang34@mgh.harvard.edu		Rueda, Bo/0000-0001-9489-8699	National Cancer Institute/National Institute of Health [1R01CA197976, 1R01CA201500]; Vincent Memorial Hospital Foundation/Vincent Center for Reproductive Biology, Colleen's Dream Foundation; Ruggles Family Foundation; Veterans Administration Senior Research Career Scientist Award; Nile Albright Research Foundation	National Cancer Institute/National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vincent Memorial Hospital Foundation/Vincent Center for Reproductive Biology, Colleen's Dream Foundation; Ruggles Family Foundation; Veterans Administration Senior Research Career Scientist Award; Nile Albright Research Foundation	This work was supported by the National Cancer Institute/National Institute of Health (1R01CA197976, 1R01CA201500), the Vincent Memorial Hospital Foundation/Vincent Center for Reproductive Biology, Colleen's Dream Foundation (no number), and the Ruggles Family Foundation. JSD is the recipient of a Veterans Administration Senior Research Career Scientist Award. BR was supported by the Nile Albright Research Foundation.	Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6; Billman GE, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00200; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Boyer SN, 1996, CANCER RES, V56, P4620; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Brandman O, 2008, SCIENCE, V322, P390, DOI 10.1126/science.1160617; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Castellsague X, 2006, JNCI-J NATL CANCER I, V98, P303, DOI 10.1093/jnci/djj067; Castellsague X, 2008, GYNECOL ONCOL, V110, pS4, DOI 10.1016/j.ygyno.2008.07.045; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000; Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005; Chung SH, 2008, CANCER RES, V68, P9928, DOI 10.1158/0008-5472.CAN-08-2051; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Dai XM, 2015, CELL RES, V25, P1175, DOI 10.1038/cr.2015.101; Dey A, 2020, NAT REV DRUG DISCOV, V19, P480, DOI 10.1038/s41573-020-0070-z; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ferrell JE, 2013, CURR OPIN CELL BIOL, V25, P676, DOI 10.1016/j.ceb.2013.07.007; Fu D, 2014, ENDOCR-RELAT CANCER, V21, P297, DOI 10.1530/ERC-13-0339; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; HARVEY M, 1995, CANCER RES, V55, P1146; He CB, 2019, CELL REP, V26, P2636, DOI 10.1016/j.celrep.2019.02.004; He CB, 2019, EMBO REP, V20, DOI 10.15252/embr.201744948; He CB, 2015, EMBO MOL MED, V7, P1426, DOI 10.15252/emmm.201404976; Howlader N, 2012, SEER CANC STAT REV 1; Hua G, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.207; Korotkevich G., 2016, BIORXIV; Koutsky Laura, 1997, American Journal of Medicine, V102, P3; Kulasingam SL, 2002, JAMA-J AM MED ASSOC, V288, P1749, DOI 10.1001/jama.288.14.1749; Lee S, 2019, NAT CELL BIOL, V21, P94, DOI 10.1038/s41556-018-0249-2; Li XM, 2013, INT J MOL SCI, V14, P2431, DOI 10.3390/ijms14022431; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu XL, 2018, ACTA PHARMACOL SIN, V39, P1553, DOI 10.1038/aps.2017.198; Lv XM, 2017, MOL CANCER THER, V16, P1080, DOI 10.1158/1535-7163.MCT-16-0626; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Modell H, 2015, ADV PHYSIOL EDUC, V39, P259, DOI 10.1152/advan.00107.2015; Molano M, 2003, AM J EPIDEMIOL, V158, P486, DOI 10.1093/aje/kwg171; Moroishi T, 2015, GENE DEV, V29, P1271, DOI 10.1101/gad.262816.115; Moya IM, 2019, NAT REV MOL CELL BIO, V20, P211, DOI 10.1038/s41580-018-0086-y; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Perez-Plasencia C., 2008, INT ARCH MED, V1; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Riley RR, 2003, CANCER RES, V63, P4862; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosty C, 2005, ONCOGENE, V24, P7094, DOI 10.1038/sj.onc.1208854; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schiffman Mark H, 2003, J Natl Cancer Inst, V95, pE2; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Shah R, 2020, J WOMENS HEALTH, V29, P799, DOI 10.1089/jwh.2019.7858; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Stelzle D, 2021, LANCET GLOB HEALTH, V9, pE161, DOI 10.1016/S2214-109X(20)30459-9; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Turrigiano G, 2007, CURR OPIN NEUROBIOL, V17, P318, DOI 10.1016/j.conb.2007.04.004; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.397; Wang C, 2019, MOL CELL ONCOL, V6, DOI 10.1080/23723556.2019.1612677; Wang C, 2010, ENDOCRINOLOGY, V151, P2319, DOI 10.1210/en.2009-1489; Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050; Wyld L, 2020, CANCERS, V12, DOI 10.3390/cancers12082134; Xing BY, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.606335; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang Y, 2021, GENOME RES, V31, DOI 10.1101/gr.275193.120	71	1	1	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3761	3777		10.1038/s41388-022-02390-y	http://dx.doi.org/10.1038/s41388-022-02390-y		JUN 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35761037				2022-12-28	WOS:000817034400001
J	Chen, ZY; Zhang, XG; Xing, Z; Lv, SJ; Huang, LX; Liu, JP; Ye, SBA; Li, XY; Chen, MQ; Zuo, SW; Tao, YX; He, YM				Chen, Ziyang; Zhang, Xiaogang; Xing, Zhe; Lv, Shuaijun; Huang, Linxuan; Liu, Jingping; Ye, Shubiao; Li, Xinyao; Chen, Meiqi; Zuo, Shaowen; Tao, Yingxu; He, Yumei			OLFM4 deficiency delays the progression of colitis to colorectal cancer by abrogating PMN-MDSCs recruitment	ONCOGENE			English	Article							SUPPRESSOR-CELLS; INNATE IMMUNITY; COLON-CANCER; OLFACTOMEDIN-4; IMMUNOTHERAPY; INFLAMMATION; EFFICACY; MARKER; STEM	Chronic inflammatory bowel disease (IBD) is strongly associated with the development of colitis-associated tumorigenesis (CAT). Despite recent advances in the understanding of polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) responses in cancer, the mechanisms of these cells during this process remain largely uncharacterized. Here, we discovered a glycoprotein, olfactomedin-4 (OLFM4), was highly expressed in PMN-MDSCs from colitis to colorectal cancer (CRC), and its expression level and PMN-MDSC population positively correlated with the progression of IBD to CRC. Moreover, mice lacking OLFM4 in myeloid cells showed poor recruitment of PMN-MDSCs, impaired intestinal homeostasis, and delayed development from IBD to CRC, and increased response to anti-PD1 therapy. The main mechanism of OLFM4-mediated PMN-MDSC activity involved the NF-kappa B/PTGS2 pathway, through the binding of LGALS3, a galactoside-binding protein expressed on PMN-MDSCs. Our results showed that the OLFM4/NF-kappa B/PTGS2 pathway promoted PMN-MDSC recruitment, which played an essential role in the maintenance of intestinal homeostasis, but showed resistance to anti-PD1 therapy in CRC.	[Chen, Ziyang; He, Yumei] Southern Med Univ, Dongguan Peoples Hosp, Dept Neurosurg, Affiliated Dongguan Hosp, Dongguan, Peoples R China; [Chen, Ziyang; Zhang, Xiaogang; Xing, Zhe; Lv, Shuaijun; Li, Xinyao; Chen, Meiqi; Zuo, Shaowen; Tao, Yingxu; He, Yumei] Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangzhou, Peoples R China; [Huang, Linxuan] Southern Med Univ, Affiliated Dongguan Hosp, Dongguan Inst Clin Canc Res, Dept Med Oncol,Dongguan Peoples Hosp, Dongguan, Peoples R China; [Liu, Jingping; He, Yumei] Southern Med Univ, Affiliated Hosp 3, Dept Clin Lab, Guangzhou, Peoples R China; [Ye, Shubiao] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Gastroenterol, Guangzhou, Peoples R China; [He, Yumei] Southern Med Univ, Guangdong Prov Key Lab Single Cell Technol & Appl, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Sun Yat Sen University; Southern Medical University - China	He, YM (corresponding author), Southern Med Univ, Dongguan Peoples Hosp, Dept Neurosurg, Affiliated Dongguan Hosp, Dongguan, Peoples R China.; He, YM (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangzhou, Peoples R China.; He, YM (corresponding author), Southern Med Univ, Affiliated Hosp 3, Dept Clin Lab, Guangzhou, Peoples R China.; He, YM (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Single Cell Technol & Appl, Guangzhou, Peoples R China.	hym0909@smu.edu.cn	ye, shubiao/GZM-4506-2022	Huang, Linxuan/0000-0001-6035-495X; Li, Xinyao/0000-0003-1407-8450	Department of Immunology at the School of Basic Medical Sciences; Southern Medical University; High level Talent Start-up Funding of Southern Medical University; National Natural Science Foundation of China [82171706, 81971420, 81991511]; Guangdong Special Support Program for Youth Science and Technology Innovation Talents [2019TQ05Y585]; National Natural Science Foundation of Guangdong [2019A1515011435]; College Students' Innovative Entrepreneurial Training Plan Program [S202012121102]; post-doctoral research project start-up funding of Affiliated Dongguan Hospital [294526]; Dongguan Science and Technology of Social Development Program [2019507163147]	Department of Immunology at the School of Basic Medical Sciences; Southern Medical University; High level Talent Start-up Funding of Southern Medical University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Special Support Program for Youth Science and Technology Innovation Talents; National Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); College Students' Innovative Entrepreneurial Training Plan Program; post-doctoral research project start-up funding of Affiliated Dongguan Hospital; Dongguan Science and Technology of Social Development Program	We thank XL and YZ from Southern Medical University for their technical assistance. We thank ZXL from South China University of Technology, ZPZ and LZ from Southern Medical University for their mice resource support. We thank XD. Wu from Tianjin Medical University for providing murine myeloid cell line 32D. We also thank YXZ and LD from Yangzhou University for providing the BiFC vector. Flow cytometry used in this work was supported by the Department of Immunology at the School of Basic Medical Sciences, the Southern Medical University, and Department of Developmental Biology at the School of Basic Medical Sciences, the Southern Medical University. This work was supported by the following grants to YMH: the High level Talent Start-up Funding of Southern Medical University, the National Natural Science Foundation of China (grants 82171706, 81971420, and 81991511), the Guangdong Special Support Program for Youth Science and Technology Innovation Talents (grant 2019TQ05Y585), the National Natural Science Foundation of Guangdong (grant 2019A1515011435), the College Students' Innovative Entrepreneurial Training Plan Program (grant S202012121102), and the post-doctoral research project start-up funding of Affiliated Dongguan Hospital (grant 294526 to ZYC). It was also supported by the Dongguan Science and Technology of Social Development Program (grant 2019507163147 to LXH).	Alder MN, 2019, INNATE IMMUN-LONDON, V25, P22, DOI 10.1177/1753425918817611; Alder MN, 2017, CRIT CARE MED, V45, pE426, DOI 10.1097/CCM.0000000000002102; Amirbeagi F, 2015, J LEUKOCYTE BIOL, V97, P181, DOI 10.1189/jlb.5A0614-311R; Angell HK, 2020, CLIN CANCER RES, V26, P332, DOI 10.1158/1078-0432.CCR-18-1851; Benson AB, 2018, J NATL COMPR CANC NE, V16, P359, DOI 10.6004/jnccn.2018.0021; Berg KCG, 2019, ONCOGENE, V38, P6109, DOI 10.1038/s41388-019-0868-5; Block AS, 2011, PROSTATE, V71, P711, DOI 10.1002/pros.21287; Cao L, 2020, J MOL CELL BIOL, V12, P688, DOI 10.1093/jmcb/mjaa011; Chen BQ, 2020, GASTROENTEROLOGY, V159, P2146, DOI 10.1053/j.gastro.2020.08.018; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen L, 2021, ONCOGENE, V40, P5925, DOI 10.1038/s41388-021-01965-5; Chen ZY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641874; Clemmensen SN, 2015, J CELL MOL MED, V19, P2865, DOI 10.1111/jcmm.12679; Condamine T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8943; d'Aldebert E, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00363; Davis RJ, 2017, CANCER RES, V77, P2607, DOI 10.1158/0008-5472.CAN-16-2534; Ding L, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02057-8; Dong X, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1590; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Galluzzi L, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat7807; Gao XZ, 2019, J CELL PHYSIOL, V234, P15035, DOI 10.1002/jcp.28144; Gersemann M, 2012, J CROHNS COLITIS, V6, P425, DOI 10.1016/j.crohns.2011.09.013; Glassner KL, 2020, J ALLERGY CLIN IMMUN, V145, P16, DOI 10.1016/j.jaci.2019.11.003; He YM, 2018, NAT MED, V24, P224, DOI 10.1038/nm.4467; He YM, 2017, NUCLEIC ACIDS RES, V45, P106, DOI 10.1093/nar/gkw818; Hirata N, 2018, ONCOGENE, V37, P5367, DOI 10.1038/s41388-018-0330-0; Kajino-Sakamoto R, 2021, ONCOGENE, V40, P408, DOI 10.1038/s41388-020-01541-3; Kan GY, 2021, ADV SCI, V8, DOI 10.1002/advs.202004344; Keenan TE, 2020, J NATL COMPR CANC NE, V18, P479, DOI 10.6004/jnccn.2020.7554; Kim HJ, 2020, TRENDS IMMUNOL, V41, P948, DOI 10.1016/j.it.2020.08.010; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Krishnamoorthy M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051170; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Li T, 2020, NAT CANCER, V1, DOI 10.1038/s43018-020-0061-3; Li ZW, 2019, GASTROENTEROLOGY, V156, P2297, DOI 10.1053/j.gastro.2019.02.040; Liang J, 2019, PHARMACOL RES, V148, DOI 10.1016/j.phrs.2019.104417; Liao WT, 2019, CANCER CELL, V35, P559, DOI 10.1016/j.ccell.2019.02.008; Liu W, 2016, ONCOGENE, V35, P5237, DOI 10.1038/onc.2016.58; Liu WL, 2022, ONCOGENE, V41, P72, DOI 10.1038/s41388-021-02072-1; Liu WL, 2016, CANCER METAST REV, V35, P201, DOI 10.1007/s10555-016-9624-2; Liu WL, 2010, P NATL ACAD SCI USA, V107, P11056, DOI 10.1073/pnas.1001269107; Liu YF, 2019, J CLIN INVEST, V129, P4261, DOI 10.1172/JCI128164; Lv J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1638-6; Messersmith WA, 2019, J NATL COMPR CANC NE, V17, P599, DOI 10.6004/jnccn.2019.5014; Nan G, 2022, ONCOGENE, V41, P983, DOI 10.1038/s41388-021-02143-3; Nan J, 2018, IMMUNOLOGY, V154, P144, DOI 10.1111/imm.12876; Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Pilzecker B, 2017, P NATL ACAD SCI USA, V114, pE6875, DOI 10.1073/pnas.1706508114; Piovani D, 2019, GASTROENTEROLOGY, V157, P647, DOI 10.1053/j.gastro.2019.04.016; Proietti M, 2014, IMMUNITY, V41, P789, DOI 10.1016/j.immuni.2014.10.010; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Schuijers J, 2014, STEM CELL REP, V3, P234, DOI 10.1016/j.stemcr.2014.05.018; Segal AW, 2019, J INTERN MED, V286, P373, DOI 10.1111/joim.12945; Seko N, 2010, EXP THER MED, V1, P73, DOI 10.3892/etm_00000013; Sharma D, 2018, GASTROENTEROLOGY, V154, P948, DOI 10.1053/j.gastro.2017.11.276; Shi MY, 2021, CELL MOL IMMUNOL, V18, P1692, DOI 10.1038/s41423-021-00704-w; Tao Y, 2018, ONCOGENE, V37, P5887, DOI 10.1038/s41388-018-0363-4; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Vuik FER, 2019, GUT, V68, P1820, DOI 10.1136/gutjnl-2018-317592; Wang LL, 2020, EMBO J, V39, DOI 10.15252/embj.2020104514; Wang Shi, 2016, Int J Biol Sci, V12, P746, DOI 10.7150/ijbs.13988; Wang SJ, 2019, ACS APPL MATER INTER, V11, P41829, DOI 10.1021/acsami.9b09560; Wang XY, 2018, WORLD J GASTROENTERO, V24, P1881, DOI 10.3748/wjg.v24.i17.1881; Wang YG, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000609; Wang YG, 2019, ADV SCI, V6, DOI 10.1002/advs.201901278; Yan GF, 2018, CANCER RES, V78, P5586, DOI 10.1158/0008-5472.CAN-17-3962; Yan YP, 2009, BRAIN RES, V1288, P116, DOI 10.1016/j.brainres.2009.06.073; Yassin M, 2019, IMMUNOLOGY, V158, P35, DOI 10.1111/imm.13093; Ye LT, 2020, CLIN TRANSL GASTROEN, V11, DOI 10.14309/ctg.0000000000000124; Yip PK, 2017, SCI REP-UK, V7, DOI 10.1038/srep41689; Zhang JN, 2021, ONCOGENE, V40, P5829, DOI 10.1038/s41388-021-01877-4; Zhang T, 2017, ONCOGENE, V36, P6627, DOI 10.1038/onc.2017.270; Zhao S, 2017, P NATL ACAD SCI USA, V114, pE7245, DOI 10.1073/pnas.1704155114	75	0	0	7	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3131	3150		10.1038/s41388-022-02324-8	http://dx.doi.org/10.1038/s41388-022-02324-8		APR 2022	20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35487976				2022-12-28	WOS:000788990000001
J	Peng, L; Zhou, N; Zhang, CY; Li, GC; Yuan, XQ				Peng, Li; Zhou, Nan; Zhang, Chao-Yang; Li, Guan-Cheng; Yuan, Xiao-Qing			eccDNAdb: a database of extrachromosomal circular DNA profiles in human cancers	ONCOGENE			English	Article							REPEATED GENOMIC SEQUENCES; CHROMATIN; STATISTICS; CIRCLES; ATLAS	Extrachromosomal circular DNA (eccDNA) elements are circular DNA molecules that are derived from but are independent of chromosomal DNA. EccDNA is emerging as a rising star because of its ubiquitous existence in cancers and its crucial role in oncogene amplification and tumor progression. In the present study, whole-genome sequencing (WGS) data of cancer samples were downloaded from public repositories. Afterwards, eccDNAs were identified from WGS data via bioinformatic analyses. To leverage database coverage, eccDNAs were also collected by manual curation of literatures. Gene expression and clinical data were downloaded from TCGA and CCLE and then used to investigate the roles of eccDNAs in cancers. Finally, the first integrated database of eccDNAs, eccDNAdb, was developed. eccDNAdb currently includes 1270 eccDNAs, which were identified in 480 samples (of 42 cancers) after analyzing a total number of 3395 tumor samples (of 57 cancers) including patient tissues, patient-derived xenografts, and cancer cell lines. A total number of 54,901 eccDNA genes were annotated and included in the database as well. With the integration of gene expression, clinical information and chromatin accessibility data, eccDNAdb enables users to easily determine the biological function and clinical relevance of eccDNAs in human cancers. In conclusion, eccDNAdb is freely accessible at http://www.eccdnadb.org. To our knowledge, eccDNAdb is the first database in the eccDNA research field. It is expected to provide insight for novel cancer therapies.	[Peng, Li; Yuan, Xiao-Qing] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangdong Hong Kong Joint Lab RNA Med, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China; [Peng, Li] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangzhou, Peoples R China; [Zhou, Nan] Guangzhou Med Univ, Dept Res, Affiliated Brain Hosp, Guangzhou, Peoples R China; [Zhou, Nan] Guangdong Engn Technol Res Ctr Translat Med Menta, Guangzhou, Peoples R China; [Zhang, Chao-Yang] German Canc Res Ctr, Div Funct Genome Anal, Heidelberg, Germany; [Li, Guan-Cheng] Cent South Univ, Key Lab Carcinogenesis, Chinese Minist Hlth, Changsha, Peoples R China; [Li, Guan-Cheng] Cent South Univ, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Canc Res Inst, Changsha, Peoples R China; [Yuan, Xiao-Qing] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; Helmholtz Association; German Cancer Research Center (DKFZ); Central South University; Central South University; Sun Yat Sen University	Peng, L; Yuan, XQ (corresponding author), Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangdong Hong Kong Joint Lab RNA Med, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China.; Peng, L (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangzhou, Peoples R China.; Yuan, XQ (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Peoples R China.	pengli9@mail.sysu.edu.cn; yuanxq7@mail.sysu.edu.cn		Peng, Li/0000-0001-5358-6736; Zhou, Nan/0000-0002-0393-316X; Zhang, Chaoyang/0000-0001-6816-3840	National Natural Science Foundation of China [81972658, 81802812, 81803636]; Guangdong Basic and Applied Basic Research Foundation [2019A1515012114, 2018A030313129, 2018A0303130329]; National Postdoctoral Program for Innovation Talents [BX20190395]; China Postdoctoral Science Foundation [2019M663254]; Fundamental Research Funds for the Central Universities [20ykpy105]; Basic and Applied Basic Research of Guangzhou Municipal Basic Research Plan [202102020742]; Science and Technology Plan Project of Guangdong Province [2019B030316001]; Guangzhou Municipal Key Discipline in Medicine	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; National Postdoctoral Program for Innovation Talents; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Basic and Applied Basic Research of Guangzhou Municipal Basic Research Plan; Science and Technology Plan Project of Guangdong Province; Guangzhou Municipal Key Discipline in Medicine	This work was supported in part by the National Natural Science Foundation of China (grant no. 81972658 and 81802812 to LP, grant no. 81803636 to XQY), Guangdong Basic and Applied Basic Research Foundation (grant no. 2019A1515012114 and 2018A030313129 to LP, grant no. 2018A0303130329 to XQY), National Postdoctoral Program for Innovation Talents (grant no. BX20190395 to LP), China Postdoctoral Science Foundation (grant no. 2019M663254 to LP), and the Fundamental Research Funds for the Central Universities (grant no. 20ykpy105 to LP). Also, this work was supported in part by Basic and Applied Basic Research of Guangzhou Municipal Basic Research Plan (No. 202102020742); Science and Technology Plan Project of Guangdong Province (No. 2019B030316001); Guangzhou Municipal Key Discipline in Medicine (2021-2023).	Adam RC, 2020, NAT CELL BIOL, V22, P640, DOI 10.1038/s41556-020-0513-0; Alsford NS, 2003, MOL MICROBIOL, V47, P277, DOI 10.1046/j.1365-2958.2003.03266.x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cohen S, 2003, GENOME RES, V13, P1133, DOI 10.1101/gr.907603; Cohen S, 2002, EMBO REP, V3, P1168, DOI 10.1093/embo-reports/kvf240; Cohen S, 1999, MOL CELL BIOL, V19, P6682; Cohen S, 2008, PLANT J, V53, P1027, DOI 10.1111/j.1365-313X.2007.03394.x; Corces MR, 2018, SCIENCE, V362, P420, DOI 10.1126/science.aav1898; COX D, 1965, LANCET, V2, P55; Deshpande V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08200-y; Ding YY, 2021, BLOOD, V137, P190, DOI 10.1182/blood.2020005219; Gorkin DU, 2020, NATURE, V583, P744, DOI 10.1038/s41586-020-2093-3; HOTTA Y, 1965, P NATL ACAD SCI USA, V53, P356, DOI 10.1073/pnas.53.2.356; Hull RM, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000471; Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055; Kim H, 2020, NAT GENET, V52, P891, DOI 10.1038/s41588-020-0678-2; Koche RP, 2020, NAT GENET, V52, P29, DOI 10.1038/s41588-019-0547-z; Kumar P, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba2489; Lanciano S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006630; Lazzarotto CR, 2018, NAT PROTOC, V13, P2615, DOI 10.1038/s41596-018-0055-0; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Link JC, 2020, J CLIN INVEST, V130, P5688, DOI 10.1172/JCI140223; Markenscoff-Papadimitriou E, 2020, CELL, V182, P754, DOI 10.1016/j.cell.2020.06.002; Mehta D, 2020, NAT PROTOC, V15, P1673, DOI 10.1038/s41596-020-0301-0; Miller CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016327; Moller Henrik D, 2015, G3 (Bethesda), V6, P453, DOI 10.1534/g3.115.025858; Moller HD, 2015, P NATL ACAD SCI USA, V112, pE3114, DOI 10.1073/pnas.1508825112; Morton AR, 2019, CELL, V179, P1330, DOI 10.1016/j.cell.2019.10.039; Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328; Navratilova A, 2008, BMC PLANT BIOL, V8, DOI 10.1186/1471-2229-8-90; Prada-Luengo I, 2020, NUCLEIC ACIDS RES, V48, P7883, DOI 10.1093/nar/gkaa545; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tsai SQ, 2017, NAT METHODS, V14, P607, DOI [10.1038/NMETH.4278, 10.1038/nmeth.4278]; TSUDA T, 1983, PLASMID, V10, P235, DOI 10.1016/0147-619X(83)90037-9; Turner KM, 2017, NATURE, V543, P122, DOI 10.1038/nature21356; Verhaak RGW, 2019, NAT REV CANCER, V19, P283, DOI 10.1038/s41568-019-0128-6; Wu SH, 2019, NATURE, V575, P699, DOI 10.1038/s41586-019-1763-5; Yerlici VT, 2019, NUCLEIC ACIDS RES, V47, P9741, DOI 10.1093/nar/gkz725; Zhu J, 2018, MOL DIAGN THER, V22, P515, DOI 10.1007/s40291-018-0348-6	42	2	2	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2696	2705		10.1038/s41388-022-02286-x	http://dx.doi.org/10.1038/s41388-022-02286-x		APR 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35388171	Green Published, hybrid			2022-12-28	WOS:000779712500001
J	Ikeuchi, H; Hirose, T; Ikegami, M; Takamochi, K; Suzuki, K; Mano, H; Kohsaka, S				Ikeuchi, Hiroshi; Hirose, Takeshi; Ikegami, Masachika; Takamochi, Kazuya; Suzuki, Kenji; Mano, Hiroyuki; Kohsaka, Shinji			Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model	ONCOGENE			English	Article							CELL LUNG-CANCER; OPEN-LABEL; 1ST-LINE TREATMENT; OSIMERTINIB; MUTATIONS; AFATINIB; T790M; ADENOCARCINOMA; GEFITINIB; MULTICENTER	The development of tyrosine kinase inhibitors (TKIs) has improved the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The current research priority is to provide viable treatments for patients who have drug-resistant EGFR mutations. We evaluated the drug sensitivity of various EGFR mutants to monotherapies and combination therapies of EGFR-TKIs. In vitro, the transforming potential and drug sensitivity of 357 EGFR variants were assessed. In vivo, we tested the sensitivity of EGFR variants to different regimens of EGFR-TKIs by examining changes in the proportion of each variant within the tumor. Out of 357 variants thoroughly examined for transforming activities, 144 (40.3%) and 282 (79.0%) transformed 3T3 and Ba/F3 cells, respectively. Among the latter variants, 50 (17.7%) were found to be resistant or only partly resistant to osimertinib or afatinib. Four of 25 afatinib-resistant variants (16%) were sensitive to osimertinib, whereas 25 of 46 osimertinib-resistant variants (54.3%) were sensitive to afatinib. Despite the lack of a synergistic impact, TKI combination treatment effectively reduced in vivo the heterogeneous tumors composed of 3T3 cells with different EGFR variants. Regimens starting with afatinib and subsequently switched to osimertinib suppressed tumor development more efficiently than the opposite combination. Combination EGFR-TKI treatment may decrease tumor growth and prevent the development of resistant variants. This work created an experimental model of a heterogeneous tumor to find the best combination therapy regimen and proposes a basic notion of EGFR-TKI combination therapy to enhance the prognosis of NSCLC patients.	[Ikeuchi, Hiroshi; Hirose, Takeshi; Ikegami, Masachika; Mano, Hiroyuki; Kohsaka, Shinji] Natl Canc Ctr, Div Cellular Signaling, Res Inst, Tokyo 1040045, Japan; [Ikeuchi, Hiroshi; Takamochi, Kazuya; Suzuki, Kenji] Juntendo Univ, Dept Gen Thorac Surg, Sch Med, Tokyo 1138431, Japan; [Ikegami, Masachika] Komagome Hosp, Dept Musculoskeletal Oncol, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo 1138677, Japan	National Cancer Center - Japan; Juntendo University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital	Kohsaka, S (corresponding author), Natl Canc Ctr, Div Cellular Signaling, Res Inst, Tokyo 1040045, Japan.	skohsaka@ncc.go.jp		Hirose, Takeshi/0000-0003-1588-9757	Practical Research for Innovative Cancer Control [JP20ck0106536]; Japan Agency for Medical Research and Development (AMED); Boehringer Ingelheim	Practical Research for Innovative Cancer Control; Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Boehringer Ingelheim(Boehringer Ingelheim)	This study was financially supported in part through grants from the Practical Research for Innovative Cancer Control under Grant Number JP20ck0106536 from the Japan Agency for Medical Research and Development (AMED). This work was also supported in part by a grant from Boehringer Ingelheim.	Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Alvarez A, 2014, JOVE-J VIS EXP, DOI 10.3791/51742; Arulananda S, 2017, J THORAC ONCOL, V12, P1728, DOI 10.1016/j.jtho.2017.08.006; Beau-Faller M, 2014, ANN ONCOL, V25, P126, DOI 10.1093/annonc/mdt418; Berger AH, 2016, CANCER CELL, V30, P214, DOI 10.1016/j.ccell.2016.06.022; Blasi M, 2021, CASE REP ONCOL, V14, P477, DOI 10.1159/000513904; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Castellano GM, 2019, J THORAC ONCOL, V14, P1982, DOI 10.1016/j.jtho.2019.06.015; Cho JH, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.00931; Neto JMF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16952-9; Gu JJ, 2020, CANCER-AM CANCER SOC, V126, P3788, DOI 10.1002/cncr.32996; He LY, 2018, METHODS MOL BIOL, V1711, P351, DOI 10.1007/978-1-4939-7493-1_17; Hirose T, 2021, LUNG CANCER, V152, P135, DOI 10.1016/j.lungcan.2020.12.023; Ho CC, 2017, J THORAC ONCOL, V12, P567, DOI 10.1016/j.jtho.2016.11.2231; Kohno T, 2015, TRANSL LUNG CANCER R, V4, P156, DOI 10.3978/j.issn.2218-6751.2014.11.11; Kohsaka S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan6566; La Monica S, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0653-7; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Li TH, 2013, J CLIN ONCOL, V31, P1039, DOI 10.1200/JCO.2012.45.3753; Li X, 2018, CANCER LETT, V418, P1, DOI 10.1016/j.canlet.2018.01.005; Liu YT, 2018, LUNG CANCER, V118, P1, DOI 10.1016/j.lungcan.2018.01.015; Masuda T, 2020, THORAC CANCER, V11, P2351, DOI 10.1111/1759-7714.13532; Murtuza A, 2019, CANCER RES, V79, P689, DOI 10.1158/0008-5472.CAN-18-1281; Nasu S, 2018, INTERNAL MED, V57, P3643, DOI 10.2169/internalmedicine.0923-18; Ou SHI, 2019, LUNG CANCER, V138, P141, DOI 10.1016/j.lungcan.2019.08.013; Park K, 2016, LANCET ONCOL, V17, P577, DOI 10.1016/S1470-2045(16)30033-X; Passaro A, 2021, J THORAC ONCOL, V16, P764, DOI 10.1016/j.jtho.2020.12.002; Piper-Vallillo AJ, 2020, J CLIN ONCOL, V38, P2926, DOI 10.1200/JCO.19.03123; Qin Q, 2020, THORAC CANCER, V11, P2389, DOI 10.1111/1759-7714.13521; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Robichaux JP, 2021, NATURE, V597, P732, DOI 10.1038/s41586-021-03898-1; Sequist LV, 2020, LANCET ONCOL, V21, P373, DOI 10.1016/S1470-2045(19)30785-5; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Starrett JH, 2020, CANCER RES, V80, P2017, DOI 10.1158/0008-5472.CAN-19-3819; Subbiah V, 2020, TRENDS CANCER, V6, P797, DOI 10.1016/j.trecan.2020.05.009; Tian YQ, 2016, ONCOL RES, V24, P295, DOI 10.3727/096504016X14648701447814; Tu HY, 2017, LUNG CANCER, V114, P96, DOI 10.1016/j.lungcan.2017.11.005; Uchibori K, 2018, J THORAC ONCOL, V13, P915, DOI 10.1016/j.jtho.2018.04.005; Wang Z, 2017, J THORAC ONCOL, V12, P1723, DOI 10.1016/j.jtho.2017.06.017; Watanabe H, 2021, CANCER SCI, V112, P1853, DOI 10.1111/cas.14801; Watanabe-Smith K, 2017, ONCOTARGET, V8, P12596, DOI 10.18632/oncotarget.15392; Wu YL, 2017, LANCET ONCOL, V18, P1454, DOI 10.1016/S1470-2045(17)30608-3; Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1; Xu L, 2012, CANCER RES, V72, P3302, DOI 10.1158/0008-5472.CAN-11-3720; Yang JCH, 2020, J THORAC ONCOL, V15, P803, DOI 10.1016/j.jtho.2019.12.126; Zhang TL, 2019, TRANSL LUNG CANCER R, V8, P302, DOI 10.21037/tlcr.2019.04.12	47	4	4	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2470	2479		10.1038/s41388-022-02263-4	http://dx.doi.org/10.1038/s41388-022-02263-4		MAR 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35304574	hybrid, Green Published			2022-12-28	WOS:000770512400001
J	Hochnadel, I; Hoenicke, L; Petriv, N; Neubert, L; Reinhard, E; Hirsch, T; Alfonso, JCL; Suo, HZ; Longerich, T; Geffers, R; Lichtinghagen, R; Guzman, CA; Wedemeyer, H; Lenzen, H; Manns, MP; Bruder, D; Yevsa, T				Hochnadel, Inga; Hoenicke, Lisa; Petriv, Nataliia; Neubert, Lavinia; Reinhard, Elena; Hirsch, Tatjana; Alfonso, Juan Carlos Lopez; Suo, Huizhen; Longerich, Thomas; Geffers, Robert; Lichtinghagen, Ralf; Guzman, Carlos Alberto; Wedemeyer, Heiner; Lenzen, Henrike; Manns, Michael Peter; Bruder, Dunja; Yevsa, Tetyana			Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers	ONCOGENE			English	Article							IMMUNE-RESPONSES; SURVEILLANCE; CELLS; MANAGEMENT; SORAFENIB; FIBROSIS	Primary liver cancer (PLC) comprising hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) represents the third deadliest cancer worldwide with still insufficient treatment options. We have previously found that CD4 T helper 1 (Th1) response is indispensable for the protection against PLC. In the present research, we aimed to test the potent inducers of Th1 responses, live-attenuated Listeria monocytogenes Delta actA/Delta inlB strain as preventive/therapeutic vaccine candidate in liver fibrosis, HCC, and CCA. Studies were performed using autochthonous models of HCC and CCA, highly reflecting human disease. L monocytogenes Delta actA/Delta inlB demonstrated strong safety/efficacy in premalignant and malignant liver diseases. The protective mechanism relied on the induction of strong tumor-specific immune responses that keep the development of hepatobiliary cancers under control. Combination therapy, comprising Listeria vaccination and a checkpoint inhibitor blockade significantly extended the survival of HCC-bearing mice even at the advanced stages of the disease. This is the first report on the safety and efficacy of Listeria-based vaccine in liver fibrosis, as well as the first proof of principle study on Listeria-based vaccines in CCA. Our study paves the way for the use of live-attenuated Listeria as safe and efficient vaccine and a potent inducer of protective immune responses in liver fibrosis and hepatobiliary malignancies.	[Hochnadel, Inga; Hoenicke, Lisa; Petriv, Nataliia; Suo, Huizhen; Wedemeyer, Heiner; Lenzen, Henrike; Manns, Michael Peter; Yevsa, Tetyana] Hannover Med Sch MHH, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany; [Neubert, Lavinia] MHH, Inst Pathol, Hannover, Germany; [Reinhard, Elena; Guzman, Carlos Alberto] Helmholtz Ctr Infect Res HZI, Dept Vaccinol & Appl Microbiol, Braunschweig, Germany; [Hirsch, Tatjana; Bruder, Dunja] HZI, Immune Regulat Grp, Braunschweig, Germany; [Hirsch, Tatjana; Bruder, Dunja] Otto von Guericke Univ, Inst Med Microbiol & Hosp Hyg, Infect Immunol Grp, Magdeburg, Germany; [Alfonso, Juan Carlos Lopez] Tech Univ Carolo Wilhelmina Braunschweig, Dept Syst Immunol, Braunschweig, Germany; [Alfonso, Juan Carlos Lopez] HZI, Braunschweig, Germany; [Longerich, Thomas] Heidelberg Univ Hosp, Inst Pathol, Heidelberg, Germany; [Geffers, Robert] HZI, Genome Analyt, Braunschweig, Germany; [Lichtinghagen, Ralf] MHH, Dept Clin Chem, Hannover, Germany	Hannover Medical School; Hannover Medical School; Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; Otto von Guericke University; Braunschweig University of Technology; Helmholtz Association; Helmholtz-Center for Infection Research; Ruprecht Karls University Heidelberg; Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School	Yevsa, T (corresponding author), Hannover Med Sch MHH, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany.	Yevsa.Tetyana@mh-hannover.de		Hoenicke, Lisa/0000-0003-0613-8337	German Research Foundation (DFG) [YE 151/21, AOBJ: 618426]; Young Academy MHH; Ellen Schmidt Program MHH; Niedersachsische Krebsgesellschaft e.V.; DFG [LO-1676/4-1, SFB/TR209]; German Academic Exchange Service (DAAD) [91736778]; Fritz Thyssen Foundation [REF.10.16.1.031MN]; Wilhelm-Sander Foundation [2013.107.1]; Gilead Sciences International Research Scholars Program in Liver Disease; Projekt DEAL; HiLFII MHH	German Research Foundation (DFG)(German Research Foundation (DFG)); Young Academy MHH; Ellen Schmidt Program MHH; Niedersachsische Krebsgesellschaft e.V.; DFG(German Research Foundation (DFG)); German Academic Exchange Service (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); Fritz Thyssen Foundation; Wilhelm-Sander Foundation; Gilead Sciences International Research Scholars Program in Liver Disease; Projekt DEAL; HiLFII MHH	This work was supported by the German Research Foundation (DFG) (grant YE 151/21, AOBJ: 618426) (TY), Young Academy MHH (TY), HiLFII MHH (TY), Ellen Schmidt Program MHH (TY) and by a grant support of Niedersachsische Krebsgesellschaft e.V. TL acknowledges the support by the DFG (LO-1676/4-1 and SFB/TR209 project B08). NP acknowledges the funding of the German Academic Exchange Service (DAAD) in the scope of the Doctoral Program in Germany (Project-ID 91736778). This work was supported in part by: Fritz Thyssen Foundation (grant REF.10.16.1.031MN) (TY), Wilhelm-Sander Foundation (grant 2013.107.1) (TY, MPM), Gilead Sciences International Research Scholars Program in Liver Disease (Research Award to TY). Open Access funding enabled and organized by Projekt DEAL.	Brockstedt DG, 2004, P NATL ACAD SCI USA, V101, P13832, DOI 10.1073/pnas.0406035101; Buonaguro L, 2019, ANN HEPATOL, V18, P291, DOI 10.1016/j.aohep.2019.04.003; Chen Y, 2012, ONCOGENE, V31, P2140, DOI 10.1038/onc.2011.395; Crowther MD, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071588; Cui M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.613530; Dauch D, 2016, NAT MED, V22, P744, DOI 10.1038/nm.4107; Deng WW, 2018, P NATL ACAD SCI USA, V115, P8179, DOI 10.1073/pnas.1801910115; DiLillo DJ, 2008, J IMMUNOL, V180, P361, DOI 10.4049/jimmunol.180.1.361; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Flickinger JC, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030048; Garaud S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02660; Gilley Ryan P, 2020, Oncotarget, V11, P740, DOI 10.18632/oncotarget.27490; Gu Y, 2019, NAT MED, V25, P312, DOI 10.1038/s41591-018-0309-y; Hochnadel I, 2017, HUM VACC IMMUNOTHER, V13, P2931, DOI 10.1080/21645515.2017.1359362; Hoenicke L, 2012, CARCINOGENESIS, V33, P1123, DOI 10.1093/carcin/bgs124; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kim VM, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0601-5; Kramer ES, 2009, DIGEST DIS SCI, V54, P2016, DOI 10.1007/s10620-009-0867-4; Le DT, 2019, CLIN CANCER RES, V25, P5493, DOI 10.1158/1078-0432.CCR-18-2992; Le DT, 2015, J CLIN ONCOL, V33, P1325, DOI 10.1200/JCO.2014.57.4244; Lee HW, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e11; Ley C., 2019, ONKOL HEUTE, V11, P51; Liau LM, 2002, CANCER RES, V62, P2287; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213; Nault JC, 2020, J HEPATOL, V72, P209, DOI 10.1016/j.jhep.2019.11.006; O'Rourke JM, 2018, WORLD J GASTROENTERO, V24, P4436, DOI 10.3748/wjg.v24.i39.4436; Petriv N, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1874159; Roni DA, 2013, ADV VIROL, V2013, DOI 10.1155/2013/196704; Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Seavey MM, 2009, J IMMUNOL, V182, P5537, DOI 10.4049/jimmunol.0803742; Seehawer M, 2018, NATURE, V562, P69, DOI 10.1038/s41586-018-0519-y; Shalapour S, 2017, NATURE, V551, P340, DOI 10.1038/nature24302; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Valle JW, 2016, ANN ONCOL, V27, pv28, DOI 10.1093/annonc/mdw324; Walcher L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01280; Wallecha A, 2009, CLIN VACCINE IMMUNOL, V16, P96, DOI 10.1128/CVI.00274-08; Wang J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.227; WHO, 2021, CANC; Xu GL, 2020, ONCOGENE, V39, P1429, DOI 10.1038/s41388-019-1072-3; Yang Y, 2014, CELL MOL IMMUNOL, V11, P184, DOI 10.1038/cmi.2013.64; Yevsa T, 2012, ONCOIMMUNOLOGY, V1, P397, DOI 10.4161/onci.19128; Zenewicz LA, 2007, MICROBES INFECT, V9, P1208, DOI 10.1016/j.micinf.2007.05.008	48	1	2	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2039	2053		10.1038/s41388-022-02222-z	http://dx.doi.org/10.1038/s41388-022-02222-z		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35173308	hybrid, Green Published			2022-12-28	WOS:000756457400004
J	Lin, LF; Shi, KX; Zhou, SQ; Cai, MC; Zhang, CY; Sun, YH; Zang, JY; Cheng, L; Ye, KY; Ma, PF; Shen, PY; Zhang, MY; Cheng, Y; Qi, CT; Li, Y; Yin, X; Zheng, YY; Tan, L; Zhuang, GL; Zang, RY				Lin, Lifeng; Shi, Kaixuan; Zhou, Shaoqing; Mei-Chun Cai; Zhang, Caiyan; Sun, Yunheng; Zang, Jingyu; Cheng, Lin; Ye, Kaiyan; Ma, Pengfei; Shen, Peiye; Zhang, Meiying; Cheng, Yan; Qi, Chunting; Li, Ying; Yin, Xia; Zheng, Yiyan; Tan, Li; Zhuang, Guanglei; Zang, Rongyu			SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer	ONCOGENE			English	Article							CELL; REGULATORS; ADDICTION; SPECIFICATION; DEPENDENCIES; BINDING	Mu''llerian tissue-specific oncogenes, prototyped by PAX8, underlie ovarian tumorigenesis and represent unique molecular vulnerabilities. Further delineating such lineage-dependency factors and associated therapeutic implications would provide valuable insights into ovarian cancer biology and treatment. In this study, we identified SOX17 as a new lineage-survival master transcription factor, which shared co-expression pattern with PAX8 in epithelial ovarian carcinoma. Genetic disruption of SOX17 or PAX8 analogously inhibited neoplastic cell viability and downregulated a spectrum of lineage-related transcripts. Mechanistically, we showed that SOX17 physically interacted with PAX8 in cultured cell lines and clinical tumor specimens. The two nuclear proteins bound to overlapping genomic regions and regulated a common set of downstream genes, including those involved in cell cycle and tissue morphogenesis. In addition, we revealed that small-molecule inhibitors of transcriptional cyclin-dependent kinases (CDKs) effectively reduced SOX17 and PAX8 expression. ZSQ1722, a novel orally bioavailable CDK12/13 covalent antagonist, exerted potent anti-tumor activity in xenograft models. These findings shed light on an actionable lineage-survival transcriptional complex in ovarian cancer, and facilitated drug discovery by generating a serial of candidate compounds to pharmacologically target this difficult-to-treat malignancy.	[Lin, Lifeng; Zheng, Yiyan; Zang, Rongyu] Fudan Univ, Zhongshan Hosp, Dept Gynecol Oncol, Ovarian Canc Program, Shanghai, Peoples R China; [Shi, Kaixuan; Sun, Yunheng; Zang, Jingyu; Cheng, Lin; Ye, Kaiyan; Ma, Pengfei; Shen, Peiye; Zhang, Meiying; Yin, Xia; Zhuang, Guanglei] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Dept Obstet & Gynecol,Ren Ji Hosp, Shanghai, Peoples R China; [Shi, Kaixuan; Sun, Yunheng; Zang, Jingyu; Cheng, Lin; Ye, Kaiyan; Ma, Pengfei; Shen, Peiye; Zhang, Meiying; Yin, Xia; Zhuang, Guanglei] Shanghai Jiao Tong Univ, Ren Ji Hosp, Shanghai Key Lab Gynecol Oncol, Sch Med, Shanghai, Peoples R China; [Zhou, Shaoqing; Cheng, Yan; Qi, Chunting; Li, Ying; Tan, Li] Chinese Acad Sci, Interdisciplinary Res Ctr Biol & Chem, Shanghai Inst Organ Chem, Shanghai, Peoples R China; [Zhou, Shaoqing; Tan, Li] Univ Chinese Acad Sci, Beijing, Peoples R China; [Mei-Chun Cai; Zhang, Caiyan] Shanghai Jiao Tong Univ, Ren Ji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China	Fudan University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Shanghai Jiao Tong University	Zang, RY (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Gynecol Oncol, Ovarian Canc Program, Shanghai, Peoples R China.; Zhuang, GL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Dept Obstet & Gynecol,Ren Ji Hosp, Shanghai, Peoples R China.; Zhuang, GL (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Shanghai Key Lab Gynecol Oncol, Sch Med, Shanghai, Peoples R China.; Tan, L (corresponding author), Chinese Acad Sci, Interdisciplinary Res Ctr Biol & Chem, Shanghai Inst Organ Chem, Shanghai, Peoples R China.; Tan, L (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.	tanli@sioc.ac.cn; zhuangguanglei@gmail.com; zang.rongyu@zs-hospital.sh.cn	张, 梅莹/GPC-5265-2022	lin, lifeng/0000-0002-5160-9145	National Natural Science Foundation of China [81972429, 81922047, 82172596, 82173077, 82173111]; Science and Technology Commission of Shanghai Municipality [18140902300, 18JC1420500]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20161313]; Shanghai Municipal Science and Technology Major Project [2019SHZDZX02]; Shanghai Natural Science Foundation [20ZR1433100]; Shanghai Shenkang Hospital Development Center [SHDC2020CR3057B]; Shanghai Collaborative Innovation Center for Translational Medicine [TM202004]; Beijing Kuanghua foundation for the development of Chinese and Western Medicine (BKF) [KH-2021-LLZX-018]; Shanghai Jiao Tong University School of Medicine [YG2021GD02, TMSK-2021-207]; Shanghai Key Laboratory of Gynecologic Oncology [FKZL-2018-02]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Shanghai Municipal Science and Technology Major Project; Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); Shanghai Shenkang Hospital Development Center; Shanghai Collaborative Innovation Center for Translational Medicine; Beijing Kuanghua foundation for the development of Chinese and Western Medicine (BKF); Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Gynecologic Oncology	This work was supported by the National Natural Science Foundation of China (81972429 to RZ; 81922047 and 82172596 to GZ; 82173077 to XY; 82173111 to MZ), the Science and Technology Commission of Shanghai Municipality (18140902300 to RZ; 18JC1420500 to LT), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20161313 to GZ), Shanghai Municipal Science and Technology Major Project (Grant No. 2019SHZDZX02 to LT), Shanghai Natural Science Foundation (20ZR1433100 to XY), Shanghai Shenkang Hospital Development Center (SHDC2020CR3057B to XY), Shanghai Collaborative Innovation Center for Translational Medicine (TM202004 to XY), Beijing Kuanghua foundation for the development of Chinese and Western Medicine (BKF) (KH-2021-LLZX-018 to XY), Shanghai Jiao Tong University School of Medicine (YG2021GD02 and TMSK-2021-207 to XY), the grants from Shanghai Key Laboratory of Gynecologic Oncology (FKZL-2018-02 to PM).	Ashrafizadeh M, 2020, PHARMACOL RES, V161, DOI 10.1016/j.phrs.2020.105159; Augert A, 2014, CANCER CELL, V26, P783, DOI 10.1016/j.ccell.2014.11.012; Blake JA, 2014, DEVELOPMENT, V141, P737, DOI 10.1242/dev.091785; Bleu M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22708-w; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Brien GL, 2016, CANCER CELL, V29, P464, DOI 10.1016/j.ccell.2016.03.007; Cai MC, 2020, J PATHOL, V251, P147, DOI 10.1002/path.5435; Cai MC, 2019, INT J CANCER, V144, P788, DOI 10.1002/ijc.31975; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chaves-Moreira D, 2020, BIORXIV, DOI [10.1101/2020.09.09.290387, DOI 10.1101/2020.09.09.290387]; Chaves-Moreira D, 2021, CANCER RES, V81, P806, DOI 10.1158/0008-5472.CAN-20-3173; Chen Y, 2020, ONCOGENE, V39, P6633, DOI 10.1038/s41388-020-01459-w; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Ding L, 2018, CELL, V173, P305, DOI 10.1016/j.cell.2018.03.033; Dinh HQ, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108978; Durbin AD, 2018, NAT GENET, V50, P1240, DOI 10.1038/s41588-018-0191-z; Elias KM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87988; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Ghannam-Shahbari D, 2018, ONCOGENE, V37, P2213, DOI 10.1038/s41388-017-0040-z; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Gryder BE, 2019, NAT GENET, V51, P1714, DOI 10.1038/s41588-019-0534-4; Gryder BE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11046-7; Huang HT, 2018, CELL CHEM BIOL, V25, P88, DOI 10.1016/j.chembiol.2017.10.005; Jolma A, 2015, NATURE, V527, P384, DOI 10.1038/nature15518; Kamachi Y, 2013, DEVELOPMENT, V140, P4129, DOI 10.1242/dev.091793; Kaya-Okur HS, 2020, NAT PROTOC, V15, P3264, DOI 10.1038/s41596-020-0373-x; Kaya-Okur HS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09982-5; Kuroki L, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3773; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Lheureux S, 2019, LANCET, V393, P1240, DOI 10.1016/S0140-6736(18)32552-2; Lv L, 2020, ELIFE, V9, DOI 10.7554/eLife.59994; Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61; Mills Kathryn, 2017, F1000Res, V6, P84, DOI 10.12688/f1000research.9977.1; Parua PK, 2020, NAT CHEM BIOL, V16, P716, DOI 10.1038/s41589-020-0563-4; Quereda V, 2019, CANCER CELL, V36, P545, DOI 10.1016/j.ccell.2019.09.004; Reddy J, 2019, PREDICTING MASTER TR, DOI [10.1101/839142, DOI 10.1101/839142]; Richters A, 2021, CELL CHEM BIOL, V28, P134, DOI 10.1016/j.chembiol.2020.10.001; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Sharifnia T, 2019, NAT MED, V25, P292, DOI 10.1038/s41591-018-0312-3; Shi KX, 2019, ELIFE, V8, DOI 10.7554/eLife.44306; Slabicki M, 2020, NATURE, V585, P293, DOI 10.1038/s41586-020-2374-x; Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207; Tan DS, 2020, SEMIN CANCER BIOL, V67, P65, DOI 10.1016/j.semcancer.2019.08.008; Wei W, 2013, J CLIN INVEST, V123, P4435, DOI 10.1172/JCI70625; Zaret KS, 2020, ANNU REV GENET, V54, P367, DOI 10.1146/annurev-genet-030220-015007; Zhang TH, 2016, NAT CHEM BIOL, V12, P876, DOI 10.1038/nchembio.2166; Zhang ZF, 2017, MOL CANCER THER, V16, P1739, DOI 10.1158/1535-7163.MCT-17-0078	49	3	3	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1767	1779		10.1038/s41388-022-02210-3	http://dx.doi.org/10.1038/s41388-022-02210-3		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35124696				2022-12-28	WOS:000751581600001
J	Flum, M; Dicks, S; Teng, YH; Schrempp, M; Nystrom, A; Boerries, M; Hecht, A				Flum, Marion; Dicks, Severin; Teng, Yu-Hsiang; Schrempp, Monika; Nystroem, Alexander; Boerries, Melanie; Hecht, Andreas			Canonical TGF beta signaling induces collective invasion in colorectal carcinogenesis through a Snail1-and Zeb1-independent partial EMT	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CONSENSUS MOLECULAR SUBTYPES; COMPETITIVE DISPLACEMENT; CANCER PROGRESSION; DRIVES METASTASIS; TUMOR-SUPPRESSOR; MOUSE MODELS; CELL; EXPRESSION; TRANSPLANTATION	Local invasion is the initial step towards metastasis, the main cause of cancer mortality. In human colorectal cancer (CRC), malignant cells predominantly invade as cohesive collectives and may undergo partial epithelial-mesenchymal transition (pEMT) at the invasive front. How this particular mode of stromal infiltration is generated is unknown. Here we investigated the impact of oncogenic transformation and the microenvironment on tumor cell invasion using genetically engineered organoids as CRC models. We found that inactivation of the Apc tumor suppressor combined with expression of oncogenic Kras(G12D) and dominant-negative Trp53(R172H) did not cell-autonomously induce invasion in vitro. However, oncogenic transformation primed organoids for activation of a collective invasion program upon exposure to the prototypical microenvironmental factor TGF beta 1. Execution of this program co-depended on a permissive extracellular matrix which was further actively remodeled by invading organoids. Although organoids shed some epithelial properties particularly at the invasive edge, TGF beta 1-stimulated organoids largely maintained epithelial gene expression while additionally implementing a mesenchymal transcription pattern, resulting in a pEMT phenotype that did not progress to a fully mesenchymal state. Notably, while TGF beta 1 induced pEMT and promoted collective invasion, it abrogated self-renewal capacity of TKA organoids which correlated with the downregulation of intestinal stem cell (ISC) marker genes. Mechanistically, induction of the non-progressive pEMT required canonical TGF beta signaling mediated by Smad transcription factors (TFs), whereas the EMT master regulators Snail1 and Zeb1 were dispensable. Gene expression profiling provided further evidence for pEMT of TGF beta 1-treated organoids and showed that their transcriptomes resemble those of human poor prognosis CMS4 cancers which likewise exhibit pEMT features. We propose that collective invasion in colorectal carcinogenesis is triggered by microenvironmental stimuli through activation of a novel, transcription-mediated form of non-progressive pEMT independently of classical EMT regulators.	[Flum, Marion; Teng, Yu-Hsiang; Schrempp, Monika; Hecht, Andreas] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; [Flum, Marion] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, D-79104 Freiburg, Germany; [Flum, Marion; Dicks, Severin; Teng, Yu-Hsiang; Hecht, Andreas] Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; [Dicks, Severin; Boerries, Melanie] Univ Freiburg, Med Ctr Univ Freiburg, Fac Med, Inst Med Bioinformat & Syst Med, D-79110 Freiburg, Germany; [Nystroem, Alexander] Univ Freiburg, Med Ctr Univ Freiburg, Fac Med, Dept Dermatol, D-79104 Freiburg, Germany; [Nystroem, Alexander] Univ Freiburg, Freiburg Inst Adv Studies FRIAS, D-79104 Freiburg, Germany; [Boerries, Melanie] Univ Freiburg, German Canc Consortium DKTK, D-79104 Freiburg, Germany; [Boerries, Melanie] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Hecht, Andreas] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Hecht, A (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79104 Freiburg, Germany.	andreas.hecht@mol-med.uni-freiburg.de		Nystrom, Alexander/0000-0002-4666-2240	Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School); Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [322977937/GRK2344, CRC-850, CRC-1479, 441891347-S1, CRC-1160, CRC-1453, 431984000 -S1, TRR167]; German Federal Ministry of Education and Research (BMBF) [FKZ 01ZZ1801B]	Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School); Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	We are grateful to the team of the Genomics and Proteomics Core Facility, German Cancer Research Center/DKFZ, Heidelberg, Germany, for NGS services, and to the staff of the Life Imaging Center (LIC) at the Center for Biological Systems Analysis (ZBSA) of the Albert-Ludwigs-University Freiburg for help with confocal microscopy. We especially appreciate the excellent support in image recording and analysis. We thank Hecht lab members for critical reading of the manuscript and Vivien Freihen for her invaluable advice and initial introduction to the handling of intestinal organoids. This study was supported in part by the Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School) and in part by the Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg. Additional financial support was obtained from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (Grant number 322977937/GRK2344 to AH; CRC-850 subprojects B5 to AH, B11 to AN, and Z1 to MB; CRC-1479 project ID: 441891347-S1 to MB, CRC-1160 project Z02 to MB, CRC-1453 project ID 431984000 -S1 to MB, and TRR167 project Z01 to MB), and from the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept CoNfirm (FKZ 01ZZ1801B to MB).	Aiello NM, 2018, DEV CELL, V45, P681, DOI 10.1016/j.devcel.2018.05.027; Balwierz PJ, 2014, GENOME RES, V24, P869, DOI 10.1101/gr.169508.113; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bays JL, 2017, CELL MOL LIFE SCI, V74, P2999, DOI 10.1007/s00018-017-2511-3; Beyes S, 2019, ONCOGENE, V38, P6647, DOI 10.1038/s41388-019-0905-4; Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; Brown KA, 2007, J CELL BIOCHEM, V101, P9, DOI 10.1002/jcb.21255; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Caravagna G, 2018, NAT METHODS, V15, P707, DOI 10.1038/s41592-018-0108-x; Carstens JL, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108990; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Dekkers JF, 2013, NAT MED, V19, P939, DOI 10.1038/nm.3201; Derynck R, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav5183; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; Eide PW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16747-x; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Feng Gang, 2010, BMC Res Notes, V3, P10, DOI 10.1186/1756-0500-3-10; Fessler E, 2016, EMBO MOL MED, V8, P745, DOI 10.15252/emmm.201606184; Fox J., 2019, R COMPANION APPL REG, V.; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Fumagalli A, 2020, CELL STEM CELL, V26, P569, DOI 10.1016/j.stem.2020.02.008; Fumagalli A, 2017, P NATL ACAD SCI USA, V114, pE2357, DOI 10.1073/pnas.1701219114; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; Groger CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051136; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Isella C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15107; Izumi D, 2015, J CANC METASTASIS TR, V1, P156, DOI DOI 10.4103/2394-4722.165532; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kariya Y, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02003-6; Kroger C, 2019, P NATL ACAD SCI USA, V116, P7353, DOI 10.1073/pnas.1812876116; Kuonen F, 2018, J INVEST DERMATOL, V138, P2432, DOI 10.1016/j.jid.2018.04.029; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li XN, 2014, NAT MED, V20, P769, DOI 10.1038/nm.3585; Linnekamp JF, 2018, CELL DEATH DIFFER, V25, P616, DOI 10.1038/s41418-017-0011-5; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; McFaline-Figueroa JL, 2019, NAT GENET, V51, P1389, DOI 10.1038/s41588-019-0489-5; Mise N, 2012, J BIOL CHEM, V287, P31393, DOI 10.1074/jbc.M112.357624; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Nissen NI, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1110-6; Nystrom A, 2015, EMBO MOL MED, V7, P1211, DOI 10.15252/emmm.201505061; O'Rourke KP, 2017, NAT BIOTECHNOL, V35, P577, DOI 10.1038/nbt.3837; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Pape J, 2020, BRIT J CANCER, V123, P1178, DOI 10.1038/s41416-020-0973-9; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Ronsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016; Roper J, 2017, NAT BIOTECHNOL, V35, P569, DOI 10.1038/nbt.3836; RStudio, 2021, RSTUDIO INT DEV ENV; Sakai E, 2018, CANCER RES, V78, P1334, DOI 10.1158/0008-5472.CAN-17-3303; Schnappauf O, 2016, BBA-GENE REGUL MECH, V1859, P1353, DOI 10.1016/j.bbagrm.2016.08.002; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Simeonov KP, 2021, CANCER CELL, V39, P1150, DOI 10.1016/j.ccell.2021.05.005; Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev-cellbio-100109-104020; Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Tauriello DVF, 2017, MOL ONCOL, V11, P97, DOI 10.1002/1878-0261.12018; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wenzel J, 2020, ONCOGENE, V39, P3893, DOI 10.1038/s41388-020-1259-7; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wiener Z, 2014, P NATL ACAD SCI USA, V111, pE2229, DOI 10.1073/pnas.1406444111; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou Yujuan, 2018, Oncotarget, V9, P33403, DOI 10.18632/oncotarget.23607	83	3	3	5	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1492	1506		10.1038/s41388-022-02190-4	http://dx.doi.org/10.1038/s41388-022-02190-4		JAN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35075245	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000746328800001
J	He, XS; Ye, WL; Zhang, YJ; Yang, XQ; Liu, F; Wang, JR; Ding, XL; Yang, Y; Zhang, RN; Zhao, YY; Bi, HX; Guo, LC; Gan, WJ; Wu, H				He, Xiao-Shun; Ye, Wen-Long; Zhang, Yu-Juan; Yang, Xiao-Qin; Liu, Feng; Wang, Jing-Ru; Ding, Xiao-Lu; Yang, Yun; Zhang, Ruo-Nan; Zhao, Yuan-Yuan; Bi, Hai-Xia; Guo, Ling-Chuan; Gan, Wen-Juan; Wu, Hua			Oncogenic potential of BEST4 in colorectal cancer via activation of PI3K/Akt signaling	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; PIK3CA GENE; HIGH-FREQUENCY; HUMAN COLON; EXPRESSION; PTEN; MUTATIONS; PATHWAY; FAMILY; STABILIZATION	BEST4 is a member of the bestrophin protein family that plays a critical role in human intestinal epithelial cells. However, its role and mechanism in colorectal cancer (CRC) remain largely elusive. Here, we investigated the role and clinical significance of BEST4 in CRC. Our results demonstrate that BEST4 expression is upregulated in clinical CRC samples and its high-level expression correlates with advanced TNM (tumor, lymph nodes, distant metastasis) stage, LNM (lymph node metastasis), and poor survival. Functional studies revealed that ectopic expression of BEST4 promoted CRC cell proliferation and metastasis, whereas the depletion of BEST4 had the opposite effect both in vitro and in vivo. Mechanistically, BEST4 binds to the p85 alpha regulatory subunit of phosphatidylinositol-3-kinase (PI3K) and promotes p110 kinase activity; this leads to activation of Akt signaling and expression of MYC and CCND1, which are critical regulators of cell proliferation and metastasis. In clinical samples, the expression of BEST4 is positively associated with the expression of phosphorylated Akt, MYC and CCND1. Pharmacological inhibition of Akt activity markedly repressed BEST4-mediated Akt signaling and proliferation and metastasis of CRC cells. Importantly, the interaction between BEST4 and p85 alpha was also enhanced by epidermal growth factor (EGF) in CRC cells. Therapeutically, BEST4 suppression effectively sensitized CRC cells to gefitinib treatment in vivo. Taken together, our findings indicate the oncogenic potential of BEST4 in colorectal carcinogenesis and metastasis by modulating BEST4/PI3K/Akt signaling, highlighting a potential strategy for CRC therapy.	[He, Xiao-Shun; Ye, Wen-Long; Zhang, Yu-Juan; Wang, Jing-Ru; Ding, Xiao-Lu; Yang, Yun; Zhang, Ruo-Nan; Zhao, Yuan-Yuan; Bi, Hai-Xia; Guo, Ling-Chuan; Wu, Hua] Soochow Univ, Med Coll, Dept Pathol, Suzhou 215123, Peoples R China; [He, Xiao-Shun; Ye, Wen-Long; Zhang, Yu-Juan; Wang, Jing-Ru; Ding, Xiao-Lu; Yang, Yun; Zhang, Ruo-Nan; Zhao, Yuan-Yuan; Bi, Hai-Xia; Guo, Ling-Chuan; Wu, Hua] Soochow Univ, Affiliated Hosp 1, Suzhou 215123, Peoples R China; [Yang, Xiao-Qin] Soochow Univ, Med Coll, Dept Bioinformat, Suzhou 215123, Peoples R China; [Liu, Feng] Canglang Hosp Suzhou, Dept Gen Surg, Suzhou 215009, Peoples R China; [Gan, Wen-Juan; Wu, Hua] Soochow Univ, Dept Pathol, Dushu Lake Hosp, Suzhou 215124, Peoples R China; [Gan, Wen-Juan] Soochow Univ, Med Ctr, Dept Pathol, Suzhou 215124, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China	Guo, LC; Wu, H (corresponding author), Soochow Univ, Med Coll, Dept Pathol, Suzhou 215123, Peoples R China.; Guo, LC; Wu, H (corresponding author), Soochow Univ, Affiliated Hosp 1, Suzhou 215123, Peoples R China.; Gan, WJ; Wu, H (corresponding author), Soochow Univ, Dept Pathol, Dushu Lake Hosp, Suzhou 215124, Peoples R China.; Gan, WJ (corresponding author), Soochow Univ, Med Ctr, Dept Pathol, Suzhou 215124, Peoples R China.	szglc@hotmail.com; ganwenjuan@suda.edu.cn; wuhua@suda.edu.cn	wang, jing/GVT-8700-2022; ZHAO, YUAN/HCI-5831-2022; Wu, Jing/GZK-5063-2022; Wang, Jin/GYA-2019-2022		Natural Science Foundation of Jiangsu Province [BK20190042, BK20181434, BK20190182]; National Natural Science Foundation of China [82022050, 81972601, 81772541]; Science and Technology Foundation of Suzhou [SYS2019034, SKJY2021070]; Fujian Provincial Key Laboratory of Innovative Drug Target Research; Tang Scholar Funds; Priority Academic Program Development of Jiangsu Higher Education Institutions	Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Foundation of Suzhou; Fujian Provincial Key Laboratory of Innovative Drug Target Research; Tang Scholar Funds; Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported by the Natural Science Foundation of Jiangsu Province (BK20190042, BK20181434, and BK20190182), National Natural Science Foundation of China (82022050, 81972601, and 81772541), and the Science and Technology Foundation of Suzhou (SYS2019034, SKJY2021070). This work was also supported by the Fujian Provincial Key Laboratory of Innovative Drug Target Research, the Tang Scholar Funds, and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Dieterle AM, 2014, ONCOGENE, V33, P3043, DOI 10.1038/onc.2013.266; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Guo PD, 2016, CANCER RES, V76, P3813, DOI 10.1158/0008-5472.CAN-15-2882; He XS, 2017, ONCOTARGET, V8, P68696, DOI 10.18632/oncotarget.19827; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Ito G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079693; Jacobsen K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00450-6; Ji CY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54892-7; Kaneko T, 2008, FRONT BIOSCI-LANDMRK, V13, P4938, DOI 10.2741/3053; Kramer F, 2004, CYTOGENET GENOME RES, V105, P107, DOI 10.1159/000078016; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Liu YN, 2021, ACTA PHARM SIN B, V11, P1412, DOI 10.1016/j.apsb.2020.12.003; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Noorolyai S, 2019, GENE, V698, P120, DOI 10.1016/j.gene.2019.02.076; Papa A, 2014, CELL, V157, P595, DOI 10.1016/j.cell.2014.03.027; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; RAJAGOPAL S, 1995, INT J CANCER, V62, P661, DOI 10.1002/ijc.2910620603; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Stohr H, 2002, EUR J HUM GENET, V10, P281, DOI 10.1038/sj.ejhg.5200796; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Thorpe LM, 2017, P NATL ACAD SCI USA, V114, P7095, DOI 10.1073/pnas.1704706114; Triscott J, 2018, CANCER DISCOV, V8, P682, DOI 10.1158/2159-8290.CD-18-0369; Tsunenari T, 2003, J BIOL CHEM, V278, P41114, DOI 10.1074/jbc.M306150200; Tsunenari T, 2006, J GEN PHYSIOL, V127, P749, DOI 10.1085/jgp.200609527; Wang JR, 2014, CARCINOGENESIS, V35, P2474, DOI 10.1093/carcin/bgu157; Wu H, 2016, J PATHOL, V238, P457, DOI 10.1002/path.4670; Wu L., 2016, SCI REP-UK, V6; Xing C, 2016, CANCER RES, V76, P83, DOI 10.1158/0008-5472.CAN-14-3595; Yan TD, 2010, CANCER RES, V70, P2285, DOI 10.1158/0008-5472.CAN-09-2968; Yang J, 2019, MOL THER-NUCL ACIDS, V18, P1, DOI 10.1016/j.omtn.2019.08.003; Yang JL, 2004, GUT, V53, P123, DOI 10.1136/gut.53.1.123; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu K, 2010, J CLIN INVEST, V120, P1722, DOI 10.1172/JCI41129; Zhou H, 2010, CANCER CELL, V17, P560, DOI 10.1016/j.ccr.2010.04.023	43	2	2	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1166	1177		10.1038/s41388-021-02160-2	http://dx.doi.org/10.1038/s41388-021-02160-2		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35058597				2022-12-28	WOS:000744835400001
J	Avalle, L; Raggi, L; Monteleone, E; Savino, A; Viavattene, D; Statello, L; Camperi, A; Stabile, SA; Salemme, V; De Marzo, N; Marino, F; Guglielmi, C; Lobascio, A; Zanini, C; Forni, M; Incarnato, D; Defilippi, P; Oliviero, S; Poli, V				Avalle, Lidia; Raggi, Laura; Monteleone, Emanuele; Savino, Aurora; Viavattene, Daniele; Statello, Luisa; Camperi, Andrea; Stabile, Simona Aversano; Salemme, Vincenzo; De Marzo, Niccolo; Marino, Francesca; Guglielmi, Chiara; Lobascio, Andrea; Zanini, Cristina; Forni, Marco; Incarnato, Danny; Defilippi, Paola; Oliviero, Salvatore; Poli, Valeria			STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; STROMAL FIBROBLASTS; MONOCLONAL-ANTIBODY; TUMORS REVEALS; UP-REGULATION; METASTASIS; EXPRESSION; TRANSFORMATION; PROMOTES	In the tumor microenvironment, Cancer Associated Fibroblasts (CAFs) become activated by cancer cells and increase their secretory activity to produce soluble factors that contribute to tumor cells proliferation, invasion and dissemination to distant organs. The pro-tumorigenic transcription factor STAT3 and its canonical inducer, the pro-inflammatory cytokine IL-6, act conjunctly in a positive feedback loop that maintains high levels of IL-6 secretion and STAT3 activation in both tumor and stromal cells. Here, we demonstrate that STAT3 is essential for the pro-tumorigenic functions of murine breast cancer CAFs both in vitro and in vivo, and identify a STAT3 signature significantly enriched for genes encoding for secreted proteins. Among these, ANGPTL4, MMP13 and STC-1 were functionally validated as STAT3-dependent mediators of CAF pro-tumorigenic functions by different approaches. Both in vitro and in vivo CAFs activities were moreover impaired by MMP13 inhibition, supporting the feasibility of a therapeutic approach based on inhibiting STAT3-induced CAF-secreted proteins. The clinical potential of such an approach is supported by the observation that an equivalent CAF-STAT3 signature in humans is expressed at high levels in breast cancer stromal cells and characterizes patients with a shorter disease specific survival, including those with basal-like disease.	[Avalle, Lidia; Raggi, Laura; Monteleone, Emanuele; Savino, Aurora; Viavattene, Daniele; Statello, Luisa; Camperi, Andrea; Stabile, Simona Aversano; Salemme, Vincenzo; De Marzo, Niccolo; Marino, Francesca; Guglielmi, Chiara; Lobascio, Andrea; Defilippi, Paola; Poli, Valeria] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Via Nizza 52, I-10126 Turin, Italy; [Zanini, Cristina; Forni, Marco] BioAir SPA Sci Dept, Via Nizza 52, I-10126 Turin, Italy; [Incarnato, Danny; Oliviero, Salvatore] Univ Torino, Dept Life Sci & Syst Biol, Via Nizza 52, I-10126 Turin, Italy; [Raggi, Laura] San Raffaele Telethon Inst Gene Therapy SR TIGET, Milan, Italy; [Monteleone, Emanuele] Univ Vita Salute San Raffaele, Milan, Italy; [Statello, Luisa] Univ Navarra, Ctr Appl Med Res, Pio XII 55 Ave, Pamplona 31008, Spain; [Guglielmi, Chiara] Univ Hosp Pisa, Dept Lab Med, Sect Mol Genet, Pisa, Italy; [Incarnato, Danny] Univ Groningen, Dept Mol Genet, Groningen Biomol Sci & Biotechnol Inst GBB, NL-9747 AG Groningen, Netherlands	University of Turin; University of Turin; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; University of Navarra; University of Pisa; Azienda Ospedaliero Universitaria Pisana; University of Groningen	Avalle, L; Poli, V (corresponding author), Univ Torino, Dept Mol Biotechnol & Hlth Sci, Via Nizza 52, I-10126 Turin, Italy.	lidia.avalle@unito.it; valeria.poli@unito.it	Monteleone, Emanuele/AAC-4847-2022; AVALLE, Lidia/AAX-8735-2020	Monteleone, Emanuele/0000-0001-7440-900X; AVALLE, Lidia/0000-0002-5060-633X; Viavattene, Daniele/0000-0002-6216-3986; Aversano Stabile, Simona/0000-0003-0775-1774; Salemme, Vincenzo/0000-0001-9431-9693; Zanini, Cristina/0000-0002-6554-2113	Italian Cancer Research Association (AIRC) [IG16930, IG 20240]; Italian Ministry of University and Research (MIUR PRIN); Truus and Gerrit van Riemsdijk Foundation, Liechtenstein, donation; Piedmont Region (Deflect); Fondazione Umberto Veronesi	Italian Cancer Research Association (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research (MIUR PRIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Truus and Gerrit van Riemsdijk Foundation, Liechtenstein, donation; Piedmont Region (Deflect); Fondazione Umberto Veronesi(Fondazione Umberto Veronesi)	The authors wish to thank D. Taverna, C. Ambrogio, E. Calautti, M. Mazzone for critically reading the manuscript. This work was supported by the Italian Cancer Research Association (AIRC, IG16930 to V.P.; IG 20240 to S.O.); the Italian Ministry of University and Research (MIUR PRIN 2017 to V.P.); the Truus and Gerrit van Riemsdijk Foundation, Liechtenstein, donation to V.P.; Piedmont Region (Deflect). L. Avalle was supported by Fondazione Umberto Veronesi.	Albrengues J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10204; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Avalle L, 2020, MOL THER-METH CLIN D, V18, P62, DOI 10.1016/j.omtm.2020.05.023; Avalle L, 2017, CELL DEATH DIFFER, V24, P1750, DOI 10.1038/cdd.2017.103; Avalle L, 2017, CYTOKINE, V98, P42, DOI 10.1016/j.cyto.2017.03.018; Avalle Lidia, 2012, JAKSTAT, V1, P65, DOI 10.4161/jkst.20045; Folgueira MAAK, 2013, BIOSCIENCE REP, V33, P921, DOI 10.1042/BSR20130060; Barbieri I, 2010, CANCER RES, V70, P2558, DOI 10.1158/0008-5472.CAN-09-2840; Barbieri I, 2010, MOL CARCINOGEN, V49, P114, DOI 10.1002/mc.20605; Boye K, 2010, AM J PATHOL, V176, P528, DOI 10.2353/ajpath.2010.090526; Chang ACM, 2015, CLIN EXP METASTAS, V32, P15, DOI 10.1007/s10585-014-9687-9; Chong HC, 2014, MOL THER, V22, P1593, DOI 10.1038/mt.2014.102; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Demaria M, 2012, CELL DEATH DIFFER, V19, P1390, DOI 10.1038/cdd.2012.20; Demaria M, 2010, AGING-US, V2, P823, DOI 10.18632/aging.100232; Dijkgraaf EM, 2015, ANN ONCOL, V26, P2141, DOI 10.1093/annonc/mdv309; Dumortier M, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0992-0; Fan YC, 2015, ONCOTARGET, V6, P16120, DOI 10.18632/oncotarget.3878; Garner JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125838; Gendoo DMA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45165-4; Gong XH, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0094-1; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hendrayani SF, 2014, J BIOL CHEM, V289, P30962, DOI 10.1074/jbc.M114.594044; Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karaayvaz M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06052-0; Laklai H, 2016, NAT MED, V22, P497, DOI 10.1038/nm.4082; Li L, 2015, CELL REP, V10, P654, DOI 10.1016/j.celrep.2015.01.011; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; NANNI P, 1983, CLIN EXP METASTAS, V1, P373, DOI 10.1007/BF00121199; Nielsen BS, 2001, CANCER RES, V61, P7091; Paek AR, 2017, BMB REP, V50, P621, DOI 10.5483/BMBRep.2017.50.12.177; Pena C, 2013, CANCER RES, V73, P1287, DOI 10.1158/0008-5472.CAN-12-1875; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Quillard T, 2011, ARTERIOSCL THROM VAS, V31, P2464, DOI 10.1161/ATVBAHA.111.231563; Rossi JF, 2010, BRIT J CANCER, V103, P1154, DOI 10.1038/sj.bjc.6605872; Rovero S, 2000, J IMMUNOL, V165, P5133, DOI 10.4049/jimmunol.165.9.5133; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Savino A, 2021, CANCERS, V13, DOI 10.3390/cancers13133371; Schrors B, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01195; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Tell RW, 2014, P NATL ACAD SCI USA, V111, P12787, DOI 10.1073/pnas.1404881111; Teo Z, 2017, ONCOGENE, V36, P6408, DOI 10.1038/onc.2017.244; Vallania F, 2009, P NATL ACAD SCI USA, V106, P5117, DOI 10.1073/pnas.0900473106; Wang SW, 2014, INT J ONCOL, V44, P1032, DOI 10.3892/ijo.2014.2259; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu HX, 2018, ARTERIOSCL THROM VAS, V38, P555, DOI 10.1161/ATVBAHA.117.310502; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; ZHANG B, 2008, BMC CANCER, V8; Zhao FY, 2020, J CELL MOL MED, V24, P7686, DOI 10.1111/jcmm.15348; Zheng X, 2016, CELL SIGNAL, V28, P1314, DOI 10.1016/j.cellsig.2016.06.009	55	4	4	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1456	1467		10.1038/s41388-021-02172-y	http://dx.doi.org/10.1038/s41388-021-02172-y		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35042959	Green Published			2022-12-28	WOS:000744825500001
J	Shu, L; Chen, A; Li, LR; Yao, L; He, YD; Xu, JB; Gu, W; Li, Q; Wang, K; Zhang, TC; Liu, GQ				Shu, Le; Chen, Ao; Li, Linrui; Yao, Lun; He, Yiduo; Xu, Jianbo; Gu, Wei; Li, Qiang; Wang, Kun; Zhang, Tongcun; Liu, Guoquan			NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; INVASIVENESS; EXPRESSION; HEREGULIN; MICROENVIRONMENT; PROTOONCOGENE; DEGRADATION; INDUCTION; MOTILITY; RNA	Neuregulin 1 (NRG1), an EGF family member, is expressed in most breast cancers. It promotes breast cancer growth and metastasis in HER2 receptor expressing breast cancer. However, its role in triple-negative breast cancer (TNBC) has not been extensively investigated. In this study, we observed that NRG1 knockdown resulted in the suppression of TNBC cells (MDA-MB-231 cell and MDA-MB-468 cell) metastasis and downregulation of Fra-1 (FOS-like 1, AP-1 transcription factor subunit, which is an overexpressed transcription factor in TNBC and acts as a coordinator of metastasis). In addition, the transcriptional regulation of Fra-1 by NRG1 was mediated by ERK1/2-induced recruitment of c-Myc (MYC proto-oncogene, transcription factor) to the promoter of Fra-1. Furthermore, c-Myc was targeted by an E3 ligase Fbxw7 and its ubiquitination and degradation by Fbxw7 was regulated by NRG1 expression and ERK1/2-mediated Fbxw7 phosphorylation that results in the dissociation and nuclear import of c-Myc. Taken together, the results of our study demonstrated that NRG1 regulates the Fra-1 expression to coordinate the TNBC metastasis via the novel ERK1/2-Fbxw7-c-Myc pathway and targeting NRG1 expression could be a potential therapeutic strategy for TNBC.	[Shu, Le; Gu, Wei; Li, Qiang; Liu, Guoquan] Bengbu Med Coll, Anhui Prov Key Lab Translat Canc Res, Bengbu 233030, Anhui, Peoples R China; [Chen, Ao; Zhang, Tongcun] Wuhan Univ Sci & Technol, Coll Life Sci & Hlth, Inst Biol & Med, Wuhan 430070, Hubei, Peoples R China; [Li, Linrui; Yao, Lun] Huazhong Agr Univ, Coll Anim Sci & Vet Med, Wuhan 430070, Hubei, Peoples R China; [He, Yiduo; Xu, Jianbo] Huazhong Agr Univ, Coll Life Sci & Technol, Wuhan 430070, Hubei, Peoples R China; [Gu, Wei; Liu, Guoquan] Bengbu Med Coll, Sch Lab Med, Dept Biochem & Mol Biol, Bengbu 233030, Anhui, Peoples R China; [Li, Qiang] Bengbu Med Coll, Sch Biol Sci, Dept Cell Biol, Bengbu 233030, Anhui, Peoples R China; [Wang, Kun] Hubei Univ Med, Coll Biomed Engn, Shiyan 442000, Hubei, Peoples R China; [Zhang, Tongcun] Tianjin Univ Sci & Technol, Coll Biotechnol, Key Lab Ind Fermentat Microbiol, Minist Educ & Tianjin, Tianjin 300457, Peoples R China	Bengbu Medical College; Wuhan University of Science & Technology; Huazhong Agricultural University; Huazhong Agricultural University; Bengbu Medical College; Bengbu Medical College; Hubei University of Medicine; Tianjin University Science & Technology	Shu, L; Liu, GQ (corresponding author), Bengbu Med Coll, Anhui Prov Key Lab Translat Canc Res, Bengbu 233030, Anhui, Peoples R China.; Liu, GQ (corresponding author), Bengbu Med Coll, Sch Lab Med, Dept Biochem & Mol Biol, Bengbu 233030, Anhui, Peoples R China.	Leshu0101@163.com; guoquanliu@bbmc.edu.cn	Zhang, Tong/HGC-1090-2022	Chen, Ao/0000-0002-2330-0650	National Natural Science Foundation of China [31372418]; Bengbu Medical College Scientific and Technology Self-Innovation Foundation Program [BYKC2003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Bengbu Medical College Scientific and Technology Self-Innovation Foundation Program	This study was partially supported financially by the National Natural Science Foundation of China (31372418, GL) and Bengbu Medical College Scientific and Technology Self-Innovation Foundation Program (No. BYKC2003, GL).	Adiseshaiah P, 2005, ONCOGENE, V24, P4193, DOI 10.1038/sj.onc.1208583; Adiseshaiah P, 2008, J CELL PHYSIOL, V216, P405, DOI 10.1002/jcp.21410; Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Bakiri L, 2015, CELL DEATH DIFFER, V22, P336, DOI 10.1038/cdd.2014.157; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Breuleux M, 2007, CELL MOL LIFE SCI, V64, P2358, DOI 10.1007/s00018-007-7120-0; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Cheng FF, 2016, CANCER LETT, V375, P274, DOI 10.1016/j.canlet.2016.03.010; Cheng LS, 2009, CANCER LETT, V280, P50, DOI 10.1016/j.canlet.2009.02.007; Cizmecioglu O, 2012, J CELL SCI, V125, P981, DOI 10.1242/jcs.095075; Debinski W, 2005, MOL CANCER RES, V3, P237; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Finigan JH, 2011, J BIOL CHEM, V286, P10660, DOI 10.1074/jbc.M110.208041; Hardy KM, 2010, J MAMMARY GLAND BIOL, V15, P191, DOI 10.1007/s10911-010-9172-2; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Leconet W, 2017, CLIN CANCER RES, V23, P2806, DOI 10.1158/1078-0432.CCR-16-1316; Liu GQ, 2012, BLOOD, V120, P1942, DOI 10.1182/blood-2011-12-397430; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; Marino N, 2013, AM J PATHOL, V183, P1084, DOI 10.1016/j.ajpath.2013.06.012; Mizejewski G.J., 2019, J CANC METASTASIS TR, V5, P35, DOI [10.20517/2394-4722.2018.70, DOI 10.20517/2394-4722.2018.70]; Momeny M, 2015, ONCOTARGET, V6, P3932, DOI 10.18632/oncotarget.2846; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Rattanasinchai C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.44; Rothschild E, 2015, BREAST CANCER-BASIC, V9, P7, DOI 10.4137/BCBCR.S29423; Sundqvist A, 2020, ONCOGENE, V39, P4436, DOI 10.1038/s41388-020-1299-z; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Zhang PF, 2016, EMBO REP, V17, P1204, DOI 10.15252/embr.201642067; Zhao CY, 2014, CANCER RES, V74, P3983, DOI 10.1158/0008-5472.CAN-13-3396	34	3	3	5	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					907	919		10.1038/s41388-021-02142-4	http://dx.doi.org/10.1038/s41388-021-02142-4		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34992218				2022-12-28	WOS:000739823800002
J	Williams, R; Jobling, S; Sims, AH; Mou, CY; Wilkinson, L; Collu, GM; Streuli, CH; Gilmore, AP; Headon, DJ; Brennan, K				Williams, Rebecca; Jobling, Stephanie; Sims, Andrew H.; Mou, Chunyan; Wilkinson, Lorna; Collu, Giovanna M.; Streuli, Charles H.; Gilmore, Andrew P.; Headon, Denis J.; Brennan, Keith			Elevated EDAR signalling promotes mammary gland tumourigenesis with squamous metaplasia	ONCOGENE			English	Article							HYPOHIDROTIC ECTODERMAL DYSPLASIA; BREAST-CANCER; KAPPA-B; ANTI-ECTODYSPLASIN; BILATERAL AMASTIA; TRANSGENIC MICE; HAIR; ACTIVATION; GENE; DIFFERENTIATION	Ectodysplasin A receptor (EDAR) is a death receptor in the Tumour Necrosis Factor Receptor (TNFR) superfamily with roles in the development of hair follicles, teeth and cutaneous glands. Here we report that human Oestrogen Receptor (ER) negative breast carcinomas which display squamous differentiation express EDAR strongly. Using a mouse model with a high Edar copy number, we show that elevated EDAR signalling results in a high incidence of mammary tumours in breeding female mice. These tumours resemble the EDAR-high human tumours in that they are characterised by a lack of oestrogen receptor expression, contain extensive squamous metaplasia, and display strong beta-catenin transcriptional activity. In the mouse model, all of the tumours carry somatic deletions of the third exon of the CTNNB1 gene that encodes beta-catenin. Deletion of this exon yields unconstrained beta-catenin signalling activity. We also demonstrate that beta-catenin activity is required for transformed cell growth, showing that increased EDAR signalling creates an environment in which beta-catenin activity can readily promote tumourigenesis. Together, this work identifies a novel death receptor oncogene in breast cancer, whose mechanism of transformation is based on the interaction between the WNT and Ectodysplasin A (EDA) pathways.	[Williams, Rebecca; Jobling, Stephanie; Wilkinson, Lorna; Collu, Giovanna M.; Streuli, Charles H.; Gilmore, Andrew P.; Brennan, Keith] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Manchester, Lancs, England; [Sims, Andrew H.] Edinburgh Canc Res Ctr, Inst Genet & Mol Med, Edinburgh Breakthrough Unit, Appl Bioinformat Canc, Edinburgh, Midlothian, Scotland; [Mou, Chunyan; Headon, Denis J.] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland; [Mou, Chunyan; Headon, Denis J.] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland	University of Manchester; University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Edinburgh	Brennan, K (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Manchester, Lancs, England.; Headon, DJ (corresponding author), Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.; Headon, DJ (corresponding author), Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.	denis.headon@roslin.ed.ac.uk; keith.brennan@manchester.ac.uk	Collu, Giovanna/AAS-5593-2020; Sims, Andrew/E-4819-2012	Collu, Giovanna/0000-0002-7437-4000; Brennan, Keith/0000-0002-9384-125X; Sims, Andrew/0000-0001-9082-3665	Breast Cancer Campaign [2010NovPR63, 2011MayPR33]; Wellcome Trust [085073]; Breakthrough Breast Cancer; BBSRC	Breast Cancer Campaign; Wellcome Trust(Wellcome TrustEuropean Commission); Breakthrough Breast Cancer; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We would like to thank Rebecca Rock for her help establishing the qRT-PCR assays, and Julia Cheung for training SJ in histology techniques. The work was supported by a BBSRC Ph.D. studentship to SJ and RW, and by grants from the Breast Cancer Campaign (KB, grant numbers 2010NovPR63 and 2011MayPR33), Wellcome Trust (KB, grant number 085073), Breakthrough Breast Cancer (AHS) and BBSRC (DJH).	Al Marzouqi F, 2014, BRIT J DERMATOL, V171, P671, DOI 10.1111/bjd.13023; Ashkenazi A, 2014, ANNU REV CELL DEV BI, V30, P337, DOI 10.1146/annurev-cellbio-100913-013226; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33; Brisken C, 2002, DEV CELL, V3, P877, DOI 10.1016/S1534-5807(02)00365-9; Bryk J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002209; Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936; Calza S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1517; Chang SH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007591; CLARKE A, 1987, ARCH DIS CHILD, V62, P989, DOI 10.1136/adc.62.10.989; Collu GM, 2012, DEVELOPMENT, V139, P4405, DOI 10.1242/dev.081885; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fernandez-Valdivia R, 2009, DEV BIOL, V328, P127, DOI 10.1016/j.ydbio.2009.01.019; Fliniaux I, 2008, DEV BIOL, V320, P60, DOI 10.1016/j.ydbio.2008.04.023; Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495; Haghighi A, 2013, BRIT J DERMATOL, V168, P1353, DOI 10.1111/bjd.12151; Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Headon DJ, 2001, NATURE, V414, P913, DOI 10.1038/414913a; Huttner K, 2014, AM J MED GENET A, V164, P2433, DOI 10.1002/ajmg.a.36499; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Kendellen MF, 2014, ONCOGENE, V33, P1297, DOI 10.1038/onc.2013.64; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Kowalczyk C, 2011, J BIOL CHEM, V286, P30769, DOI 10.1074/jbc.M111.267997; Kowalczyk-Quintas C, 2014, J BIOL CHEM, V289, P4273, DOI 10.1074/jbc.M113.535740; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Majumder K, 1998, MAMM GENOME, V9, P863, DOI 10.1007/s003359900884; Meurette O, 2009, CANCER RES, V69, P5015, DOI 10.1158/0008-5472.CAN-08-3478; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Mikkola ML, 2007, SEMIN CELL DEV BIOL, V18, P225, DOI 10.1016/j.semcdb.2007.01.007; Mikkola ML, 2011, ADV EXP MED BIOL, V691, P23, DOI 10.1007/978-1-4419-6612-4_3; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Mou C, 2006, P NATL ACAD SCI USA, V103, P9075, DOI 10.1073/pnas.0600825103; Mou C, 2008, HUM MUTAT, V29, P1405, DOI 10.1002/humu.20795; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pummila M, 2007, DEVELOPMENT, V134, P117, DOI 10.1242/dev.02708; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; Schmidt-Ullrich R, 2006, DEVELOPMENT, V133, P1045, DOI 10.1242/dev.02278; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Shehata M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3334; Shostak K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2886; Sims AH, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-42; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Voutilainen M, 2012, P NATL ACAD SCI USA, V109, P5744, DOI 10.1073/pnas.1110627109; Weigelt B, 2008, J PATHOL, V216, P141, DOI 10.1002/path.2407; Weigelt B, 2010, MOL ONCOL, V4, P192, DOI 10.1016/j.molonc.2010.04.004; Weigelt B, 2009, BREAST CANCER RES TR, V117, P273, DOI 10.1007/s10549-008-0197-9; Zhang YH, 2009, DEV CELL, V17, P49, DOI 10.1016/j.devcel.2009.05.011	52	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1040	1049		10.1038/s41388-021-01902-6	http://dx.doi.org/10.1038/s41388-021-01902-6		DEC 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34916592	Green Published, hybrid			2022-12-28	WOS:000730901200001
J	Demetriadou, C; Raoukka, A; Charidemou, E; Mylonas, C; Michael, C; Parekh, S; Koufaris, C; Skourides, P; Papageorgis, P; Tessarz, P; Kirmizis, A				Demetriadou, Christina; Raoukka, Anastasia; Charidemou, Evelina; Mylonas, Constantine; Michael, Christina; Parekh, Swati; Koufaris, Costas; Skourides, Paris; Papageorgis, Panagiotis; Tessarz, Peter; Kirmizis, Antonis			Histone N-terminal acetyltransferase NAA40 links one-carbon metabolism to chemoresistance	ONCOGENE			English	Article							CANCER; EPIGENETICS; TRANSCRIPTION; GUIDELINES; MECHANISMS	Aberrant function of epigenetic modifiers plays an important role not only in the progression of cancer but also the development of drug resistance. N-alpha-acetyltransferase 40 (NAA40) is a highly specific epigenetic enzyme catalyzing the transfer of an acetyl moiety at the N-terminal end of histones H4 and H2A. Recent studies have illustrated the essential oncogenic role of NAA40 in various cancer types but its role in chemoresistance remains unclear. Here, using transcriptomic followed by metabolomic analysis in colorectal cancer (CRC) cells, we demonstrate that NAA40 controls key one-carbon metabolic genes and corresponding metabolites. In particular, through its acetyltransferase activity NAA40 regulates the methionine cycle thereby affecting global histone methylation and CRC cell survival. Importantly, NAA40-mediated metabolic rewiring promotes resistance of CRC cells to antimetabolite chemotherapy in vitro and in xenograft models. Specifically, NAA40 stimulates transcription of the one-carbon metabolic gene thymidylate synthase (TYMS), whose product is targeted by 5-fluorouracil (5-FU) and accordingly in primary CRC tumours NAA40 expression associates with TYMS levels and poorer 5-FU response. Mechanistically, NAA40 activates TYMS by preventing enrichment of repressive H2A/H4S1ph at the nuclear periphery. Overall, these findings define a novel regulatory link between epigenetics and cellular metabolism mediated by NAA40, which is harnessed by cancer cells to evade chemotherapy.	[Demetriadou, Christina; Raoukka, Anastasia; Charidemou, Evelina; Koufaris, Costas; Skourides, Paris; Kirmizis, Antonis] Univ Cyprus, Dept Biol Sci, CY-2109 Nicosia, Cyprus; [Mylonas, Constantine; Parekh, Swati; Tessarz, Peter] Max Planck Inst Biol Ageing, Cologne, Germany; [Michael, Christina; Papageorgis, Panagiotis] European Univ Cyprus, Dept Life Sci, CY-2404 Nicosia, Cyprus; [Tessarz, Peter] Cologne Excellence Cluster Stress Responses Agein, Joseph Stelzmann Str 26, D-50931 Cologne, Germany	University of Cyprus; Max Planck Society; European University Cyprus	Kirmizis, A (corresponding author), Univ Cyprus, Dept Biol Sci, CY-2109 Nicosia, Cyprus.	kirmizis@ucy.ac.cy	Koufaris, Costas/ABW-5036-2022; Tessarz, Peter/I-9035-2014	Koufaris, Costas/0000-0002-1222-5130; CHARIDEMOU, EVELINA/0000-0002-2299-9471; Tessarz, Peter/0000-0002-6953-9835				Benson A, 2018, J NATL COMPR CANC NE, V16, P874, DOI 10.6004/jnccn.2018.0061; Buchwalter A, 2019, NAT REV GENET, V20, P39, DOI 10.1038/s41576-018-0063-5; Campbell SL, 2018, MOL CELL, V71, P398, DOI 10.1016/j.molcel.2018.07.015; Carrer A, 2015, CURR OPIN BIOTECH, V34, P23, DOI 10.1016/j.copbio.2014.11.012; Dai ZW, 2020, NAT REV GENET, V21, P737, DOI 10.1038/s41576-020-0270-8; Dai ZW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04426-y; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Demetriadou C, 2020, EPIGENET CHROMATIN, V13, DOI 10.1186/s13072-020-00352-w; Demetriadou C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1487-3; Deng Y, 2021, NOVEL BISUBSTRATE IN, DOI 10.1101/2021.01.24.427995; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Farria A, 2015, ONCOGENE, V34, P4901, DOI 10.1038/onc.2014.453; Finlan LE, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000039; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Hole K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024713; Ju JY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00988-5; Karoutas A, 2021, NAT CELL BIOL, V23, P116, DOI 10.1038/s41556-020-00630-5; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Koufaris C, 2020, CANCERS, V12, DOI 10.3390/cancers12092631; Lee S, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1936-4; Liu Z, 2009, INT J BIOCHEM CELL B, V41, P2528, DOI 10.1016/j.biocel.2009.08.009; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lund E, 2013, GENOME RES, V23, P1580, DOI 10.1101/gr.159400.113; Magin RS, 2015, STRUCTURE, V23, P332, DOI 10.1016/j.str.2014.10.025; Marine JC, 2020, NAT REV CANCER, V20, P743, DOI 10.1038/s41568-020-00302-4; Mary Goldman B. C., 2019, BIORXIV, DOI [DOI 10.1101/326470, 10.1101/326470]; Mentch SJ, 2015, CELL METAB, V22, P861, DOI 10.1016/j.cmet.2015.08.024; Nacev BA, 2019, NATURE, V567, P473, DOI 10.1038/s41586-019-1038-1; Shyh-Chang N, 2013, SCIENCE, V339, P222, DOI 10.1126/science.1226603; Reddy KL, 2008, NATURE, V452, P243, DOI 10.1038/nature06727; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Roy DG, 2020, CELL METAB, V31, P250, DOI 10.1016/j.cmet.2020.01.006; Salvarani N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09929-w; Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236; Serefidou M, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00764; Shiraki N, 2014, CELL METAB, V19, P780, DOI 10.1016/j.cmet.2014.03.017; Shuvalov O, 2017, ONCOTARGET, V8, P23955, DOI 10.18632/oncotarget.15053; Suh EJ, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-12-r121; Ulanovskaya OA, 2013, NAT CHEM BIOL, V9, P300, DOI [10.1038/NCHEMBIO.1204, 10.1038/nchembio.1204]; Varghese V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38017-0; Wakasa K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123076; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Ye CQ, 2018, TRENDS ENDOCRIN MET, V29, P626, DOI 10.1016/j.tem.2018.06.002; Ye CQ, 2017, MOL CELL, V66, P180, DOI 10.1016/j.molcel.2017.02.026; Zhang Y, 2004, J BIOL CHEM, V279, P21866, DOI 10.1074/jbc.M400099200	48	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					571	585		10.1038/s41388-021-02113-9	http://dx.doi.org/10.1038/s41388-021-02113-9		NOV 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785778	hybrid, Green Published			2022-12-28	WOS:000719277200004
J	Hao, XH; Bu, WQ; Lv, GS; Xu, LM; Hou, D; Wang, J; Liu, XJ; Yang, TT; Zhang, XY; Liu, Q; Gong, YQ; Shao, CS				Hao, Xiaohe; Bu, Wenqing; Lv, Guosheng; Xu, Limei; Hou, Dong; Wang, Jing; Liu, Xiaojie; Yang, Tingting; Zhang, Xiyu; Liu, Qiao; Gong, Yaoqin; Shao, Changshun			Disrupted mitochondrial homeostasis coupled with mitotic arrest generates antineoplastic oxidative stress	ONCOGENE			English	Article							CHECKPOINT KINASE 1; DNA-DAMAGE; CELL-CYCLE; CANCER-CELLS; CHK1; RESPIRATION; BIOGENESIS; METABOLISM; RESISTANCE; INHIBITION	Reactive oxygen species (ROS) serve as critical signals in various cellular processes. Excessive ROS cause cell death or senescence and mediates the therapeutic effect of many cancer drugs. Recent studies showed that ROS increasingly accumulate during G2/M arrest, the underlying mechanism, however, has not been fully elucidated. Here, we show that in cancer cells treated with anticancer agent TH287 or paclitaxel that causes M arrest, mitochondria accumulate robustly and produce excessive mitochondrial superoxide, which causes oxidative DNA damage and undermines cell survival and proliferation. While mitochondrial mass is greatly increased in cells arrested at M phase, the mitochondrial function is compromised, as reflected by reduced mitochondrial membrane potential, increased SUMOylation and acetylation of mitochondrial proteins, as well as an increased metabolic reliance on glycolysis. CHK1 functional disruption decelerates cell cycle, spares the M arrest and attenuates mitochondrial oxidative stress. Induction of mitophagy and blockade of mitochondrial biogenesis, measures that reduce mitochondrial accumulation, also decelerate cell cycle and abrogate M arrest-coupled mitochondrial oxidative stress. These results suggest that cell cycle progression and mitochondrial homeostasis are interdependent and coordinated, and that impairment of mitochondrial homeostasis and the associated redox signaling may mediate the antineoplastic effect of the M arrest-inducing chemotherapeutics. Our findings provide insights into the fate of cells arrested at M phase and have implications in cancer therapy.	[Hao, Xiaohe; Lv, Guosheng; Xu, Limei; Hou, Dong; Wang, Jing; Zhang, Xiyu; Liu, Qiao; Gong, Yaoqin; Shao, Changshun] Shandong Univ, Sch Basic Med Sci, Dept Genet, MOE Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China; [Bu, Wenqing; Liu, Xiaojie; Yang, Tingting; Shao, Changshun] Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China	Shandong University; Soochow University - China	Shao, CS (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Genet, MOE Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China.; Shao, CS (corresponding author), Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China.	shaoc@suda.edu.cn	Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342	National Natural Science Foundation of China [31771260, 81572785, 81372241]; State Key Laboratory of Radiation Medicine and Protection, Soochow University [GZN1201804]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Radiation Medicine and Protection, Soochow University	We thank Dr. Weihang Chai for critically reading and commenting on the manuscript. This study was supported by National Natural Science Foundation of China (31771260, 81572785 and 81372241), and the State Key Laboratory of Radiation Medicine and Protection, Soochow University (GZN1201804).	Busby EC, 2000, CANCER RES, V60, P2108; Carrassa L, 2009, J CELL MOL MED, V13, P1565, DOI [10.1111/j.1582-4934.2008.00362.x, 10.1111/j.1582-4934.2009.00362.x]; Chen C, 2008, J EXP MED, V205, P2397, DOI 10.1084/jem.20081297; Correia-Melo C, 2016, EMBO J, V35, P724, DOI 10.15252/embj.201592862; Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029; Daud AI, 2015, J CLIN ONCOL, V33, P1060, DOI 10.1200/JCO.2014.57.5027; Dhimolea E, 2021, CANCER CELL, V39, P240, DOI 10.1016/j.ccell.2020.12.002; Fishler T, 2010, ONCOGENE, V29, P4007, DOI 10.1038/onc.2010.163; Fu XA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002009; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; Funakoshi T, 2019, NEUROTOXICOLOGY, V75, P70, DOI 10.1016/j.neuro.2019.09.001; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gad H, 2014, NATURE, V508, P215, DOI 10.1038/nature13181; Glasauer A, 2014, BIOCHEM PHARMACOL, V92, P90, DOI 10.1016/j.bcp.2014.07.017; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gul N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51205-w; Harbauer AB, 2014, SCIENCE, V346, P1109, DOI 10.1126/science.1261253; Havens CG, 2006, MOL CELL BIOL, V26, P4701, DOI 10.1128/MCB.00303-06; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Hou D, 2018, REDOX BIOL, V17, P99, DOI 10.1016/j.redox.2018.03.016; Kawamura T, 2016, SCI REP-UK, V6, DOI 10.1038/srep26521; Leach JK, 2001, CANCER RES, V61, P3894; Liu EY, 2015, P NATL ACAD SCI USA, V112, P773, DOI 10.1073/pnas.1409563112; Liu QH, 2000, GENE DEV, V14, P1448; Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765; Macip S, 2006, ONCOGENE, V25, P6037, DOI 10.1038/sj.onc.1209629; Manic G, 2018, GUT, V67, P903, DOI 10.1136/gutjnl-2016-312623; Marcar L, 2019, CELL REP, V27, P3422, DOI 10.1016/j.celrep.2019.05.058; Matassa DS, 2016, CELL DEATH DIFFER, V23, P1542, DOI 10.1038/cdd.2016.39; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Parmar K, 2019, CLIN CANCER RES, V25, P6127, DOI 10.1158/1078-0432.CCR-19-0448; Patterson JC, 2019, CELL SYST, V9, P74, DOI 10.1016/j.cels.2019.05.009; Patterson JC, 2019, CELL SYST, V8, P163, DOI 10.1016/j.cels.2019.01.005; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pfanner N, 2019, NAT REV MOL CELL BIO, V20, P267, DOI 10.1038/s41580-018-0092-0; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; Qian X, 2019, MOL CELL, V76, P885, DOI 10.1016/j.molcel.2019.09.019; Rehman SK, 2021, CELL, V184, P226, DOI 10.1016/j.cell.2020.11.018; Rudd SG, 2020, CANCER RES, V80, P3530, DOI 10.1158/0008-5472.CAN-19-0883; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Schwer B, 2009, AGING CELL, V8, P604, DOI 10.1111/j.1474-9726.2009.00503.x; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Summer R, 2019, AM J PHYSIOL-LUNG C, V316, pL1049, DOI 10.1152/ajplung.00244.2018; Takai H, 2000, GENE DEV, V14, P1439; Tong LY, 2015, CANCER LETT, V367, P18, DOI 10.1016/j.canlet.2015.07.008; Tsai WB, 2008, NAT CELL BIOL, V10, P460, DOI 10.1038/ncb1709; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Wang TS, 2019, MOL CELL, V75, P823, DOI 10.1016/j.molcel.2019.06.008; Wang ZQ, 2014, DEV CELL, V29, P217, DOI 10.1016/j.devcel.2014.03.012; Willis J, 2013, P NATL ACAD SCI USA, V110, P10592, DOI 10.1073/pnas.1301445110; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu B, 2014, MUTAT RES-FUND MOL M, V770, P1, DOI 10.1016/j.mrfmmm.2014.08.004; Xu LM, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101604; Yamamori T, 2012, FREE RADICAL BIO MED, V53, P260, DOI 10.1016/j.freeradbiomed.2012.04.033; Yu D, 2020, P NATL ACAD SCI USA, V117, P9964, DOI 10.1073/pnas.1913633117; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003; Zasadil LM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007965; Zhang YW, 2014, INT J CANCER, V134, P1013, DOI 10.1002/ijc.28226; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689	63	4	4	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					427	443		10.1038/s41388-021-02105-9	http://dx.doi.org/10.1038/s41388-021-02105-9		NOV 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34773075	Green Published, hybrid			2022-12-28	WOS:000717915200002
J	Findlay, IJ; De Iuliis, GN; Duchatel, RJ; Jackson, ER; Vitanza, NA; Cain, JE; Waszak, SM; Dun, MD				Findlay, Izac J.; De Iuliis, Geoffry N.; Duchatel, Ryan J.; Jackson, Evangeline R.; Vitanza, Nicholas A.; Cain, Jason E.; Waszak, Sebastian M.; Dun, Matthew D.			Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies	ONCOGENE			English	Review							INTRINSIC PONTINE GLIOMA; HIGH-GRADE; THERAPEUTIC TARGETS; MUTATIONS; INHIBITION; ACVR1; PREDISPOSITION; SUBGROUPS; RADIATION; BREAST	Diffuse midline glioma (DMG) is a deadly pediatric and adolescent central nervous system (CNS) tumor localized along the midline structures of the brain atop the spinal cord. With a median overall survival (OS) of just 9-11-months, DMG is characterized by global hypomethylation of histone H3 at lysine 27 (H3K27me3), driven by recurring somatic mutations in H3 genes including, HIST1H3B/C (H3.1K27M) or H3F3A (H3.3K27M), or through overexpression of EZHIP in patients harboring wildtype H3. The recent World Health Organization's 5th Classification of CNS Tumors now designates DMG as, 'H3 K27-altered', suggesting that global H3K27me3 hypomethylation is a ubiquitous feature of DMG and drives devastating transcriptional programs for which there are no treatments. H3-alterations co-segregate with various other somatic driver mutations, highlighting the high-level of intertumoral heterogeneity of DMG. Furthermore, DMG is also characterized by very high-level intratumoral diversity with tumors harboring multiple subclones within each primary tumor. Each subclone contains their own combinations of driver and passenger lesions that continually evolve, making precision-based medicine challenging to successful execute. Whilst the intertumoral heterogeneity of DMG has been extensively investigated, this is yet to translate to an increase in patient survival. Conversely, our understanding of the non-genomic factors that drive the rapid growth and fatal nature of DMG, including endogenous and exogenous microenvironmental influences, neurological cues, and the posttranscriptional and posttranslational architecture of DMG remains enigmatic or at best, immature. However, these factors are likely to play a significant role in the complex biological sequelae that drives the disease. Here we summarize the heterogeneity of DMG and emphasize how analysis of the posttranslational architecture may improve treatment paradigms. We describe factors that contribute to treatment response and disease progression, as well as highlight the potential for pharmaco-proteogenomics (i.e., the integration of genomics, proteomics and pharmacology) in the management of this uniformly fatal cancer.	[Findlay, Izac J.; Duchatel, Ryan J.; Jackson, Evangeline R.; Dun, Matthew D.] Univ Newcastle, Sch Biomed Sci & Pharm, Coll Hlth Med & Wellbeing, Canc Signalling Res Grp, Callaghan, NSW, Australia; [Findlay, Izac J.; Duchatel, Ryan J.; Jackson, Evangeline R.; Dun, Matthew D.] Hunter Med Res Inst, Canc Res Program, New Lambton Hts, NSW, Australia; [De Iuliis, Geoffry N.] Univ Newcastle, Sch Environm & Life Sci, Coll Engn Sci & Environm, Reprod Sci Grp, Callaghan, NSW, Australia; [Vitanza, Nicholas A.] Seattle Childrens Res Inst, Ben Towne Ctr Childhood Canc Res, Seattle, WA USA; [Vitanza, Nicholas A.] Seattle Childrens Hosp, Dept Pediat, Div Pediat Hematol Oncol, Seattle, WA USA; [Cain, Jason E.] Hudson Inst Med Res, Clayton, Vic, Australia; [Cain, Jason E.] Monash Univ, Dept Paediat, Clayton, Vic, Australia; [Waszak, Sebastian M.] Univ Oslo, Nord EMBL Partnership, Ctr Mol Med Norway NCMM, Oslo, Norway; [Waszak, Sebastian M.] Oslo Univ Hosp, Oslo, Norway; [Waszak, Sebastian M.] Oslo Univ Hosp, Rikshosp, Div Pediat & Adolescent Med, Dept Pediat Res, Oslo, Norway	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; Seattle Children's Hospital; Seattle Children's Hospital; Hudson Institute of Medical Research; Monash University; University of Oslo; University of Oslo; University of Oslo; National Hospital Norway	Dun, MD (corresponding author), Univ Newcastle, Sch Biomed Sci & Pharm, Coll Hlth Med & Wellbeing, Canc Signalling Res Grp, Callaghan, NSW, Australia.; Dun, MD (corresponding author), Hunter Med Res Inst, Canc Res Program, New Lambton Hts, NSW, Australia.	matt.dun@newcastle.edu.au	De Iuliis, Geoffry N./G-7042-2013	De Iuliis, Geoffry N./0000-0002-6978-6123; Dun, Matthew/0000-0002-9063-5370; Findlay, Izac/0000-0002-3192-5888; Duchatel, Ryan/0000-0002-3651-7672	Defeat DIPG ChadTough New Investigator Fellowship; NHMRC [GNT1173892]; DIPG Collaborative; RUN DIPG Ltd.; Strategic Group; McDonald Jones Foundation; Vinva Foundation; PNOC Foundation; Yuvaan Tiwari Foundation; Kiriwina Investments, Kids Cancer Project; Hunter Medical Research Institute; Isabella and Marcus Foundation Scholarship; Australian Communities Foundation	Defeat DIPG ChadTough New Investigator Fellowship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); DIPG Collaborative; RUN DIPG Ltd.; Strategic Group; McDonald Jones Foundation; Vinva Foundation; PNOC Foundation; Yuvaan Tiwari Foundation; Kiriwina Investments, Kids Cancer Project; Hunter Medical Research Institute; Isabella and Marcus Foundation Scholarship; Australian Communities Foundation	MDD is supported by a Defeat DIPG ChadTough New Investigator Fellowship and an NHMRC Investigator Grant -GNT1173892. The contents of the published material are solely the responsibility of the research institutions involved or individual authors and do not reflect the views of NHMRC. This project was supported by the DIPG Collaborative, RUN DIPG Ltd, Strategic Group, McDonald Jones Foundation, Vinva Foundation, PNOC Foundation, Yuvaan Tiwari Foundation, Kiriwina Investments, Kids Cancer Project, and the Hunter Medical Research Institute. ERJ is supported via the Josephine Dun Scholarship from the Isabella and Marcus Foundation Scholarship, a sub fund of Australian Communities Foundation.	Akamandisa MP, 2019, NEURO-ONCOLOGY, V21, P786, DOI 10.1093/neuonc/noz053; Ali NA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0437-3; Antin C, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01056-8; Baker SJ, 2016, GLIA, V64, P879, DOI 10.1002/glia.22945; Brown ZZ, 2014, J AM CHEM SOC, V136, P13498, DOI 10.1021/ja5060934; Bruce DL, 2012, FEBS LETT, V586, P1897, DOI 10.1016/j.febslet.2012.02.001; Buczkowicz P, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00147; Buczkowicz P, 2014, NAT GENET, V46, P451, DOI 10.1038/ng.2936; Castel D, 2020, ACTA NEUROPATHOL, V139, P1109, DOI 10.1007/s00401-020-02142-w; Castel D, 2015, ACTA NEUROPATHOL, V130, P815, DOI 10.1007/s00401-015-1478-0; Chambliss AB, 2016, CLIN PROTEOM, V13, DOI 10.1186/s12014-016-9127-8; Chan KM, 2013, GENE DEV, V27, P985, DOI 10.1101/gad.217778.113; Chen ZH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01004; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; Corsello SM, 2020, NAT CANCER, V1, P235, DOI 10.1038/s43018-019-0018-6; de Leeuw R, 2018, CLIN CANCER RES, V24, P4201, DOI 10.1158/1078-0432.CCR-18-0410; Demma MJ, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00248-19; Duchatel RJ, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800479; Dun MD, 2015, MOL CELL PROTEOMICS, V14, P2316, DOI 10.1074/mcp.M114.046110; Fontebasso AM, 2014, NAT GENET, V46, P462, DOI 10.1038/ng.2950; Garner EF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25263-5; Georgescu MM, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-00992-9; Gillis NK, 2014, CLIN PHARMACOL THER, V95, P269, DOI 10.1038/clpt.2013.214; Grasso CS, 2015, NAT MED, V21, P555, DOI 10.1038/nm.3855; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Hanna C, 2020, NEURO-ONCOLOGY, V22, P1840, DOI 10.1093/neuonc/noaa104; Hart LS, 2017, CLIN CANCER RES, V23, P1785, DOI 10.1158/1078-0432.CCR-16-1131; Harutyunyan AS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09140-x; He B, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00830-3; HIRATA E, 2017, CSH PERSPECT MED, V7, DOI [10.1101/cshperspect.a026781, DOI 10.1101/CSHPERSPECT.A026781]; Hoeman CM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08823-9; Hoffman LM, 2018, J CLIN ONCOL, V36, P1963, DOI 10.1200/JCO.2017.75.9308; Hoffman LM, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-015-0269-0; Hong Semie, 2005, Cancer Res Treat, V37, P109, DOI 10.4143/crt.2005.37.2.109; Hopkins BD, 2018, NATURE, V560, P499, DOI 10.1038/s41586-018-0343-4; Jain SU, 2020, MOL CELL, V80, P726, DOI 10.1016/j.molcel.2020.09.028; Kluiver TA, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00092; Koschmann C, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0033-y; Kostaras X, 2014, CURR ONCOL, V21, pE493, DOI 10.3747/co.21.1769; Lapin DH, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00057; Larson JD, 2019, CANCER CELL, V35, P140, DOI 10.1016/j.ccell.2018.11.015; Lee CH, 2019, GENE DEV, V33, P1428, DOI 10.1101/gad.328773.119; Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245; Lin GL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw0064; Lobbous M, 2020, CANCERS, V12, DOI 10.3390/cancers12010114; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Ma XT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7604; Mackay A, 2017, CANCER CELL, V32, P520, DOI 10.1016/j.ccell.2017.08.017; Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268; Martin DDO, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25903-w; Marzluff WF, 2002, GENOMICS, V80, P487, DOI 10.1006/geno.2002.6850; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Menden MP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05811-3; Mu MD, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03105-5; Mueller S, 2019, INT J CANCER, V145, P1889, DOI 10.1002/ijc.32258; Murray HC, 2021, LEUKEMIA, V35, P1782, DOI 10.1038/s41375-020-01050-y; Nagaraja S, 2017, CANCER CELL, V31, P635, DOI 10.1016/j.ccell.2017.03.011; Nandal S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020448; Nikbakht H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11185; Nikolaev A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020490; Oh S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17139-y; Oliver MD, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160258; Omar SI, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200769; Pajovic S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19972-7; Pal S, 2018, CANCER RES, V78, P4007, DOI 10.1158/0008-5472.CAN-17-3691; Paugh BS, 2013, CANCER RES, V73, P6219, DOI 10.1158/0008-5472.CAN-13-1491; Petralia F, 2020, CELL, V183, P1962, DOI 10.1016/j.cell.2020.10.044; Pfaff E, 2019, EUR J CANCER, V114, P27, DOI 10.1016/j.ejca.2019.03.019; Riba A, 2019, P NATL ACAD SCI USA, V116, P15023, DOI 10.1073/pnas.1817299116; Roden DM, 2006, ANN INTERN MED, V145, P749, DOI 10.7326/0003-4819-145-10-200611210-00007; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Rushing EJ, 2021, MEMO-MAG EUR MED ONC, V14, P188, DOI 10.1007/s12254-021-00680-x; Schettini F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00608; Sheppard KE, 2013, CLIN CANCER RES, V19, P5320, DOI 10.1158/1078-0432.CCR-13-0259; Sievers P, 2021, NEURO-ONCOLOGY, V23, P34, DOI 10.1093/neuonc/noaa251; Sillar JR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236003; Silveira AB, 2019, ACTA NEUROPATHOL, V137, P637, DOI 10.1007/s00401-019-01975-4; Sulman EP, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.659800; Szenker E, 2011, CELL RES, V21, P421, DOI 10.1038/cr.2011.14; Taylor IC, 2015, J NEUROPATH EXP NEUR, V74, P778, DOI 10.1097/NEN.0000000000000216; Taylor KR, 2014, NAT GENET, V46, P457, DOI 10.1038/ng.2925; Velpula KK, 2012, TRANSL ONCOL, V5, P379, DOI 10.1593/tlo.12235; Venkatesh HS, 2019, NATURE, V573, P539, DOI 10.1038/s41586-019-1563-y; Vinci M, 2018, NAT MED, V24, P1204, DOI 10.1038/s41591-018-0086-7; Vitanza NA, 2021, J APPL LAB MED, V6, P550, DOI 10.1093/jalm/jfaa086; Vitanza NA, 2021, NEURO-ONCOLOGY, V23, P376, DOI 10.1093/neuonc/noaa249; Walker JA, 2018, EXPERT OPIN THER TAR, V22, P419, DOI 10.1080/14728222.2018.1465931; Wang HW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10299-6; Wang L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161859; Wen PY, 2020, CLIN CANCER RES, V26, P1820, DOI 10.1158/1078-0432.CCR-19-2808; Werbrouck C, 2019, CLIN CANCER RES, V25, P6788, DOI 10.1158/1078-0432.CCR-19-0126; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Wiese M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02800-7; Wong M, 2020, NAT MED, V26, P1742, DOI 10.1038/s41591-020-1072-4; Wu G, 2014, NAT GENET, V46, P444, DOI 10.1038/ng.2938; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; YU JR, 2021, SCI ADV, P7; Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054; Zhang Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0463-7; Zhu XT, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-020-01107-0	100	8	8	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					461	475		10.1038/s41388-021-02102-y	http://dx.doi.org/10.1038/s41388-021-02102-y		NOV 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34759345	hybrid, Green Published			2022-12-28	WOS:000716867900003
J	Cherif, C; Nguyen, DT; Paris, C; Le, TK; Sefiane, T; Carbuccia, N; Finetti, P; Chaffanet, M; El Kaoutari, A; Vernerey, J; Fazli, L; Gleave, M; Manai, M; Barthelemy, P; Birnbaum, D; Bertucci, F; Taieb, D; Rocchi, P				Cherif, Chaima; Nguyen, Dang Tan; Paris, Clement; Le, Thi Khanh; Sefiane, Thibaud; Carbuccia, Nadine; Finetti, Pascal; Chaffanet, Max; El Kaoutari, Abdessamad; Vernerey, Julien; Fazli, Ladan; Gleave, Martin; Manai, Mohamed; Barthelemy, Philippe; Birnbaum, Daniel; Bertucci, Francois; Taieb, David; Rocchi, Palma			Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; ANDROGEN ABLATION; PROTEIN; GENE; APOPTOSIS; SIGNAL; CELLS; HSP27; OPPORTUNITIES; CHEMOTHERAPY	Disease progression and therapeutic resistance of prostate cancer (PC) are linked to multiple molecular events that promote survival and plasticity. We previously showed that heat shock protein 27 (HSP27) acted as a driver of castration-resistant phenotype (CRPC) and developed an oligonucleotides antisense (ASO) against HSP27 with evidence of anti-cancer activity in men with CRPC. Here, we show that the tumor suppressor Menin (MEN1) is highly regulated by HSP27. Menin is overexpressed in high-grade PC and CRPC. High MEN1 mRNA expression is associated with decreased biochemical relapse-free and overall survival. Silencing Menin with ASO technology inhibits CRPC cell proliferation, tumor growth, and restores chemotherapeutic sensitivity. ChIP-seq analysis revealed differential DNA binding sites of Menin in various prostatic cells, suggesting a switch from tumor suppressor to oncogenic functions in CRPC. These data support the evaluation of ASO against Menin for CRPC.	[Cherif, Chaima; Nguyen, Dang Tan; Paris, Clement; Le, Thi Khanh; Sefiane, Thibaud; Carbuccia, Nadine; Finetti, Pascal; Chaffanet, Max; El Kaoutari, Abdessamad; Vernerey, Julien; Birnbaum, Daniel; Bertucci, Francois; Taieb, David; Rocchi, Palma] Aix Marseille Univ, Inst Paoli Calmettes, CNRS UMR 7258, Inserm UMR 1068,Ctr Rech Cancerol Marseille,Predi, 27 Bd Lei Roure, F-13009 Marseille, France; [Cherif, Chaima; Manai, Mohamed] Sci Univ Tunis, Lab Biochem & Mol Biol, Tunis 2092, Tunisia; [Fazli, Ladan; Gleave, Martin] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Barthelemy, Philippe] Univ Bordeaux, ARNA Lab, INSERM U1212, CNRS UMR 5320, F-33076 Bordeaux, France; [Taieb, David] Aix Marseille Univ, La Timone Univ Hosp, European Ctr Res Med Imaging, Biophys & Nucl Med Dept, F-13005 Marseille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Universite de Tunis-El-Manar; University of British Columbia; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Rocchi, P (corresponding author), Aix Marseille Univ, Inst Paoli Calmettes, CNRS UMR 7258, Inserm UMR 1068,Ctr Rech Cancerol Marseille,Predi, 27 Bd Lei Roure, F-13009 Marseille, France.	palma.rocchi@inserm.fr	EL KAOUTARI, Abdessamad/AAR-8318-2021; Taieb, Pr. David/M-5219-2017; CHAFFANET, Max/AAU-5743-2020; Finetti, Pascal/O-8669-2017; Rocchi, Palma/P-5455-2014	EL KAOUTARI, Abdessamad/0000-0003-2334-3121; Bertucci, Francois/0000-0002-0157-0959; Finetti, Pascal/0000-0002-2674-3123; vernerey, Julien/0000-0002-5413-4210; CHAFFANET, Max/0000-0002-2344-1488; Rocchi, Palma/0000-0002-4383-4684; Le, Thi Khanh/0000-0003-1883-0371; CHERIF, Chaima/0000-0002-5689-0327	Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	We would like to thank Jose Adelaide (IPC) for his help with PCR experiments, the platform ICEP for help for Ki67 experiment, Daniel Islardon (CRCM) for his help in confocal microscopy, Sebastien Benizri for antisense oligonucleotides synthesis, Estelle Duprez team and Eddy Pasquier for their help in ChIP-seq experiment, Stephane Audebert for his help with Mass spectrometry analysis for Menin interactome and Association pour la Recherche sur les Tumeurs de la Prostate (ARTP) for CC funding.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Andrieu C, 2010, ONCOGENE, V29, P1883, DOI 10.1038/onc.2009.479; Baylot V, 2012, MOL THER, V20, P2244, DOI 10.1038/mt.2012.155; Bazzi W, 2008, GASTROENTEROLOGY, V135, P1698, DOI 10.1053/j.gastro.2008.07.031; Bello-DeOcampo D, 2003, CURR DRUG TARGETS, V4, P197, DOI 10.2174/1389450033491118; Bonnavion R, 2017, J PATHOL, V242, P90, DOI 10.1002/path.4885; Borkin D, 2018, J MED CHEM, V61, P4832, DOI 10.1021/acs.jmedchem.8b00071; Borkin D, 2016, J MED CHEM, V59, P892, DOI 10.1021/acs.jmedchem.5b01305; Borkin D, 2015, CANCER CELL, V27, P589, DOI 10.1016/j.ccell.2015.02.016; Boukarabila H, 2009, GENE DEV, V23, P1195, DOI 10.1101/gad.512009; Cao YA, 2009, MOL CELL BIOL, V29, P5477, DOI 10.1128/MCB.00335-09; Cao Z, 2015, ASIAN J UROL, V2, P11, DOI 10.1016/j.ajur.2015.04.011; Cierpicki T, 2014, FUTURE MED CHEM, V6, P447, DOI 10.4155/fmc.13.214; Crumbaker M, 2017, CANCERS, V9, DOI 10.3390/cancers9040034; Nguyen DT, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070795; Dong QC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010147; Dreijerink KMA, 2017, ENDOCR-RELAT CANCER, V24, pT135, DOI 10.1530/ERC-17-0281; Falchetti A., 2017, F1000RESEARCH, V6, pF1000 Faculty R, DOI [10.12688/f1000research.7230.1, DOI 10.12688/F1000RESEARCH.7230.1]; Fusi A, 2004, TUMORI J, V90, P535, DOI 10.1177/030089160409000601; Gherardi S, 2017, BBA-GENE REGUL MECH, V1860, P427, DOI 10.1016/j.bbagrm.2017.02.003; Grembecka J, 2012, NAT CHEM BIOL, V8, P277, DOI [10.1038/NCHEMBIO.773, 10.1038/nchembio.773]; Gumulec J, 2014, INT J ONCOL, V44, P923, DOI 10.3892/ijo.2013.2223; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Kao CJ, 2014, ONCOGENE, V33, P2495, DOI 10.1038/onc.2013.200; Katsogiannou M, 2014, MOL CELL PROTEOMICS, V13, P3585, DOI 10.1074/mcp.M114.041228; Kim H, 2003, CANCER RES, V63, P6135; Ko B, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.09; Kosaka T, 2011, J UROLOGY, V185, P2376, DOI 10.1016/j.juro.2011.02.016; Kuhn MWM, 2016, CANCER DISCOV, V6, P1166, DOI 10.1158/2159-8290.CD-16-0237; La P, 2006, ONCOGENE, V25, P3537, DOI 10.1038/sj.onc.1209400; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lemos MC, 2008, HUM MUTAT, V29, P22, DOI 10.1002/humu.20605; Lu J, 2012, ONCOGENE, V31, P3647, DOI 10.1038/onc.2011.538; Malik R, 2015, NAT MED, V21, P344, DOI 10.1038/nm.3830; Matkar S, 2013, TRENDS BIOCHEM SCI, V38, P394, DOI [10.1016/j.tibs.2013.0S.005, 10.1016/j.tibs.2013.05.005]; Menin-ASO, 2017, [No title captured], Patent No. 2017134252; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Pang K, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5423-9; Peng DJ, 2010, BIOCHEM BIOPH RES CO, V394, P600, DOI 10.1016/j.bbrc.2010.03.029; Qian DZ, 2010, PROSTATE, V70, P433, DOI 10.1002/pros.21077; Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Sehrawat A, 2018, P NATL ACAD SCI USA, V115, pE4179, DOI 10.1073/pnas.1719168115; Stein CA, 2017, MOL THER, V25, P1069, DOI 10.1016/j.ymthe.2017.03.023; Wu GW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15278; Xiong HY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073295; Yu EY, 2018, INVEST NEW DRUG, V36, P278, DOI 10.1007/s10637-017-0553-x	50	2	2	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					125	137		10.1038/s41388-021-02039-2	http://dx.doi.org/10.1038/s41388-021-02039-2		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34711954	hybrid, Green Published			2022-12-28	WOS:000712340800001
J	Kyjacova, L; Saup, R; Ronsch, K; Wallbaum, S; Dukowic-Schulze, S; Foss, A; Scherer, SD; Rothley, M; Neeb, A; Grau, N; Thiele, W; Thaler, S; Cremers, N; Sticht, C; Gretz, N; Garvalov, BK; Utikal, J; Sleeman, JP				Kyjacova, Lenka; Saup, Rafael; Roensch, Kerstin; Wallbaum, Sabine; Dukowic-Schulze, Stefanie; Foss, Amelia; Scherer, Sandra D.; Rothley, Melanie; Neeb, Antje; Grau, Nicole; Thiele, Wilko; Thaler, Sonja; Cremers, Natascha; Sticht, Carsten; Gretz, Norbert; Garvalov, Boyan K.; Utikal, Jochen; Sleeman, Jonathan P.			IER2-induced senescence drives melanoma invasion through osteopontin	ONCOGENE			English	Article							IMMEDIATE-EARLY GENE; ONCOGENE-INDUCED SENESCENCE; EARLY RESPONSE PROTEIN-2; CELLULAR SENESCENCE; ECDYSONE RECEPTOR; PREMATURE SENESCENCE; SECRETORY PHENOTYPE; POOR SURVIVAL; TUMOR-GROWTH; HUMAN-CELLS	Expression of the immediate-early response gene IER2 has been associated with the progression of several types of cancer, but its functional role is poorly understood. We found that increased IER2 expression in human melanoma is associated with shorter overall survival, and subsequently investigated the mechanisms through which IER2 exerts this effect. In experimental melanoma models, sustained expression of IER2 induced senescence in a subset of melanoma cells in a p53/MAPK/AKT-dependent manner. The senescent cells produced a characteristic secretome that included high levels of the extracellular phosphoglycoprotein osteopontin. Nuclear localization of the IER2 protein was critical for both the induction of senescence and osteopontin secretion. Osteopontin secreted by IER2-expressing senescent cells strongly stimulated the migration and invasion of non-senescent melanoma cells. Consistently, we observed coordinate expression of IER2, p53/p21, and osteopontin in primary human melanomas and metastases, highlighting the pathophysiological relevance of IER2-mediated senescence in melanoma progression. Together, our study reveals that sustained IER2 expression drives melanoma invasion and progression through stimulating osteopontin secretion via the stochastic induction of senescence.	[Kyjacova, Lenka; Saup, Rafael; Roensch, Kerstin; Dukowic-Schulze, Stefanie; Foss, Amelia; Scherer, Sandra D.; Thiele, Wilko; Thaler, Sonja; Garvalov, Boyan K.; Sleeman, Jonathan P.] Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci ECAS, Dept Microvasc Biol & Pathobiol, Mannheim, Germany; [Roensch, Kerstin; Wallbaum, Sabine; Dukowic-Schulze, Stefanie; Scherer, Sandra D.; Rothley, Melanie; Neeb, Antje; Grau, Nicole; Thiele, Wilko; Cremers, Natascha; Sleeman, Jonathan P.] Karlsruhe Inst Technol KIT, Inst Biol & Chem Syst Biol Informat Proc IBCS BIP, Campus Nord, Karlsruhe, Germany; [Sticht, Carsten; Gretz, Norbert] Heidelberg Univ, Med Fac Mannheim, Med Res Ctr, Mannheim, Germany; [Utikal, Jochen] German Canc Res Ctr, Skin Canc Unit, Heidelberg, Germany; [Utikal, Jochen] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol Venereol & Allergol, Mannheim, Germany; [Roensch, Kerstin] Eurofins GATC Biotech GmbH, Constance, Germany; [Grau, Nicole] Heidelberg Univ Hosp, Dept Radiat Oncol, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; Karlsruhe Institute of Technology; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Sleeman, JP (corresponding author), Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci ECAS, Dept Microvasc Biol & Pathobiol, Mannheim, Germany.; Sleeman, JP (corresponding author), Karlsruhe Inst Technol KIT, Inst Biol & Chem Syst Biol Informat Proc IBCS BIP, Campus Nord, Karlsruhe, Germany.	jonathan.sleeman@medma.uni-heidelberg.de	Thaler, Sonja/AAC-4784-2020		Projekt DEAL	Projekt DEAL	Open Access funding enabled and organized by Projekt DEAL.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Astle MV, 2012, ONCOGENE, V31, P1949, DOI 10.1038/onc.2011.394; Bahrami Shahram, 2016, Advances in Biological Regulation, V62, P37, DOI 10.1016/j.jbior.2016.05.001; Bandopadhyay M, 2014, EXPERT OPIN THER TAR, V18, P883, DOI 10.1517/14728222.2014.925447; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Budczies J, 2015, ONCOTARGET, V6, P570, DOI 10.18632/oncotarget.2677; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Celton-Morizur S, 2009, J CLIN INVEST, V119, P1880, DOI 10.1172/JCI38677; CHARLES CH, 1990, MOL CELL BIOL, V10, P6769, DOI 10.1128/MCB.10.12.6769; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Damsky William E, 2010, Cancers (Basel), V3, P126, DOI 10.3390/cancers3010126; Dang JJ, 2002, CANCER RES, V62, P1222; Angelini PD, 2013, CANCER RES, V73, P450, DOI 10.1158/0008-5472.CAN-12-2301; Davie JR, 2010, ADV ENZYME REGUL, V50, P135, DOI 10.1016/j.advenzreg.2009.10.008; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dunn KL, 2005, ONCOGENE, V24, P3492, DOI 10.1038/sj.onc.1208521; Ebert R, 2015, STEM CELL RES, V15, P231, DOI 10.1016/j.scr.2015.06.008; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Fava LL, 2017, GENE DEV, V31, P34, DOI 10.1101/gad.289728.116; Flanagan KC, 2018, ONCOTARGET, V9, P21, DOI 10.18632/oncotarget.22940; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Haapajarvi T, 1999, CELL GROWTH DIFFER, V10, P163; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015; Healy S, 2013, PHARMACOL THERAPEUT, V137, P64, DOI 10.1016/j.pharmthera.2012.09.001; Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148; Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225; Hoare M, 2016, NAT CELL BIOL, V18, P979, DOI 10.1038/ncb3397; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hong SK, 2009, P NATL ACAD SCI USA, V106, P2230, DOI 10.1073/pnas.0812880106; Hsu CH, 2019, CELL, V178, P361, DOI 10.1016/j.cell.2019.05.041; Huun J, 2017, BMC CELL BIOL, V18, DOI 10.1186/s12860-017-0134-z; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jager K, 2019, CANCERS, V11, DOI 10.3390/cancers11010076; Karzenowski D, 2005, BIOTECHNIQUES, V39, P191, DOI 10.2144/05392ST01; Kato M, 1998, ONCOGENE, V17, P1885, DOI 10.1038/sj.onc.1202077; Kauko O, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1093; Kim EK, 2014, CANCER RES, V74, P6705, DOI 10.1158/0008-5472.CAN-14-1482; Knappe N, 2016, STEM CELLS, V34, P832, DOI 10.1002/stem.2284; Kolesnichenko M, 2012, CELL CYCLE, V11, P2391, DOI 10.4161/cc.20683; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lens SMA, 2019, NAT REV CANCER, V19, P32, DOI 10.1038/s41568-018-0084-6; Levine MS, 2018, GENE DEV, V32, P620, DOI 10.1101/gad.314351.118; Li JH, 2019, J CELL MOL MED, V23, P3867, DOI 10.1111/jcmm.14234; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Loaiza N, 2016, BBA-REV CANCER, V1865, P155, DOI 10.1016/j.bbcan.2016.01.007; Mannava S, 2012, ONCOGENE, V31, P1484, DOI 10.1038/onc.2011.339; McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045; Milanovic M, 2018, TRENDS CELL BIOL, V28, P1049, DOI 10.1016/j.tcb.2018.09.001; Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167; MILLER FR, 1983, INVAS METAST, V3, P22; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Neeb A, 2012, ONCOGENE, V31, P3796, DOI 10.1038/onc.2011.535; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Palli SR, 2003, EUR J BIOCHEM, V270, P1308, DOI 10.1046/j.1432-1033.2003.03501.x; Paluncic J, 2016, BBA-MOL CELL RES, V1863, P770, DOI 10.1016/j.bbamcr.2016.01.025; Panopoulos A, 2014, MOL BIOL CELL, V25, P3105, DOI 10.1091/mbc.E14-03-0844; Pazolli E, 2012, CANCER RES, V72, P2251, DOI 10.1158/0008-5472.CAN-11-3386; Pazolli E, 2009, CANCER RES, V69, P1230, DOI 10.1158/0008-5472.CAN-08-2970; Prasad R, 2014, ONCOTARGET, V5, P10636, DOI 10.18632/oncotarget.2527; Purvis JE, 2012, SCIENCE, V336, P1440, DOI 10.1126/science.1218351; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Sadaie M, 2015, MOL BIOL CELL, V26, P2971, DOI 10.1091/mbc.E15-01-0003; Saker M, 2016, ARTERIOSCL THROM VAS, V36, P1879, DOI 10.1161/ATVBAHA.116.307839; Saleh T, 2019, BIOCHEM PHARMACOL, V162, P202, DOI 10.1016/j.bcp.2018.12.013; Sangaletti S, 2014, CANCER RES, V74, P4706, DOI 10.1158/0008-5472.CAN-13-3334; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; SCOTT JL, 1994, J CELL BIOCHEM, V54, P135, DOI 10.1002/jcb.240540202; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharon Y, 2015, CANCER RES, V75, P963, DOI 10.1158/0008-5472.CAN-14-1990; SHIMIZU N, 1991, J BIOL CHEM, V266, P12157; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takaya T, 2009, BIOSCI BIOTECH BIOCH, V73, P1653, DOI 10.1271/bbb.90162; Ueda T, 2019, CELL SIGNAL, V55, P81, DOI 10.1016/j.cellsig.2018.12.012; van Deursen JM, 2019, SCIENCE, V364, P636, DOI 10.1126/science.aaw1299; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wagner NB, 2015, INT J CANCER, V137, P2607, DOI 10.1002/ijc.29619; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wallbaum H, 2009, BAUINGENIEUR-GERMANY, V84, P291; Wallbaum S, 2009, BIOTECHNIQUES, V46, P433, DOI 10.2144/000113121; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011; Wu WJ, 2015, INT J MOL MED, V36, P1104, DOI 10.3892/ijmm.2015.2310; Wu WJ, 2015, AM J CANCER RES, V5, P1435; Xu X, 2020, NEOPLASMA, V67, P614, DOI 10.4149/neo_2020_190818N781; Xu YX, 2014, TRENDS BIOCHEM SCI, V39, P268, DOI 10.1016/j.tibs.2014.04.004; Xu ZX, 2017, ONCOL REP, V37, P259, DOI 10.3892/or.2016.5215; Yang LX, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.49; Zhao HL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0391-6; Zhou YW, 2005, J INVEST DERMATOL, V124, P1044, DOI 10.1111/j.0022-202X.2005.23680.x; Zlobec I, 2006, MODERN PATHOL, V19, P1236, DOI 10.1038/modpathol.3800642	106	1	1	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6494	6512		10.1038/s41388-021-02027-6	http://dx.doi.org/10.1038/s41388-021-02027-6		OCT 2021	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34611309	hybrid, Green Published			2022-12-28	WOS:000703836100002
J	Wenta, T; Schmidt, A; Zhang, Q; Devarajan, R; Singh, P; Yang, XY; Ahtikoski, A; Vaarala, M; Wei, GH; Manninen, A				Wenta, Tomasz; Schmidt, Anette; Zhang, Qin; Devarajan, Raman; Singh, Prateek; Yang, Xiayun; Ahtikoski, Anne; Vaarala, Markku; Wei, Gong-Hong; Manninen, Aki			Disassembly of alpha 6 beta 4-mediated hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin to focal adhesions	ONCOGENE			English	Article							EXPRESSION; INTEGRIN; INHIBITION; LANDSCAPE; CARCINOMA; EVOLUTION; HALLMARKS; INVASION; TUMORS; CELLS	Loss of alpha 6 beta 4-dependent hemidesmosomal adhesions has been observed during prostate cancer progression. However, the significance and underlying mechanisms by which aberrant hemidesmosome assembly may modulate tumorigenesis remain elusive. Using an extensive CRISPR/Cas9-mediated genetic engineering approaches in different prostate cancer cell lines combined with in vivo tumorigenesis studies in mice, bone marrow-on-chip assays and bioinformatics, as well as histological analysis of prostate cancer patient cohorts, we demonstrated that simultaneous loss of PTEN and hemidesmosomal adhesions induced several tumorigenic properties including proliferation, migration, resistance to anoikis, apoptosis, and drug treatment in vitro, and increased metastatic capacity in vivo. These effects were plectin-depended and plectin was associated with actin-rich adhesions upon hemidesmosome disruption in PTEN-negative prostate cancer cells leading to activation of EGFR/PI3K/Akt- and FAK/Src-pathways. These results suggest that analysis of PTEN and hemidesmosomal proteins may have diagnostic value helping to stratify prostate cancer patients with high risk for development of aggressive disease and highlight actin-associated plectin as a potential therapeutic target specifically in PTEN/hemidesmosome dual-negative prostate cancer.	[Wenta, Tomasz; Schmidt, Anette; Zhang, Qin; Devarajan, Raman; Yang, Xiayun; Wei, Gong-Hong; Manninen, Aki] Univ Oulu, Fac Biochem & Mol Med, Dis Networks Res Unit, Oulu, Finland; [Singh, Prateek] Finnadvance, Oulu, Finland; [Ahtikoski, Anne; Vaarala, Markku] Oulu Univ Hosp, Dept Urol, Oulu, Finland; [Ahtikoski, Anne; Vaarala, Markku] Oulu Univ Hosp, Dept Pathol, Oulu, Finland; [Ahtikoski, Anne; Vaarala, Markku] Oulu Univ Hosp, Dept Radiol, Oulu, Finland; [Ahtikoski, Anne; Vaarala, Markku] Oulu Univ Hosp, Med Res Ctr, Oulu, Finland; [Ahtikoski, Anne; Vaarala, Markku] Univ Oulu, Oulu, Finland; [Wei, Gong-Hong] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Wei, Gong-Hong] Fudan Univ, Dept Biochem & Mol Biol, Sch Basic Med Sci, Shanghai, Peoples R China; [Wei, Gong-Hong] Fudan Univ, Key Lab Metab & Mol Med, Minist Educ, Sch Basic Med Sci, Shanghai, Peoples R China	University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; Fudan University; Fudan University; Fudan University	Manninen, A (corresponding author), Univ Oulu, Fac Biochem & Mol Med, Dis Networks Res Unit, Oulu, Finland.	aki.manninen@oulu.fi	Devarajan, Raman/GOH-0098-2022; Manninen, Aki/AAC-8067-2019; Ahtikoski, Anne/GQH-8901-2022; Vaarala, Markku/B-4116-2013	Manninen, Aki/0000-0002-6263-8101; Ahtikoski, Anne/0000-0003-4100-5900; Wenta, Tomasz/0000-0002-1927-9959; Vaarala, Markku/0000-0003-4735-815X	University of Oulu including Oulu University Hospital	University of Oulu including Oulu University Hospital	Open Access funding provided by University of Oulu including Oulu University Hospital.	Alix-Panabieres C, 2021, CANCER DISCOV, V11, P858, DOI 10.1158/2159-8290.CD-20-1311; Allen MV, 1998, HUM PATHOL, V29, P311, DOI 10.1016/S0046-8177(98)90109-5; Andrews S., 2010, FASTQC QUALITY CONTR; Armenia J, 2018, NAT GENET, V50, P645, DOI 10.1038/s41588-018-0078-z; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Bausch D, 2011, CLIN CANCER RES, V17, P302, DOI 10.1158/1078-0432.CCR-10-0999; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Buckup M, 2021, ONCOGENE, V40, P663, DOI 10.1038/s41388-020-01557-9; Burch TC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065005; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaudhari PR, 2017, EXP CELL RES, V360, P125, DOI 10.1016/j.yexcr.2017.08.034; Cooperberg MR, 2009, JNCI-J NATL CANCER I, V101, P878, DOI 10.1093/jnci/djp122; COX DR, 1972, J R STAT SOC B, V34, P187; Dasari A, 2020, NAT REV CLIN ONCOL, V17, P757, DOI 10.1038/s41571-020-0392-0; Davis TL, 2001, PROSTATE, V46, P240; Demetriou MC, 2004, J CELL BIOCHEM, V91, P26, DOI 10.1002/jcb.10675; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geerts D, 1999, J CELL BIOL, V147, P417, DOI 10.1083/jcb.147.2.417; Gerhauser C, 2018, CANCER CELL, V34, P996, DOI 10.1016/j.ccell.2018.10.016; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Kang HM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180251; Kassambara A., 2021, RSTATIX PIPE FRIENDL; Katada K, 2012, J PROTEOMICS, V75, P1803, DOI 10.1016/j.jprot.2011.12.018; KNOX JD, 1994, AM J PATHOL, V145, P167; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Latonen L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03573-6; Litjens SHM, 2006, TRENDS CELL BIOL, V16, P376, DOI 10.1016/j.tcb.2006.05.004; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Martini V, 2019, CANCERS, V11, DOI 10.3390/cancers11111659; Myllymaki S-M, 2019, MATTERS, DOI [10.19185/matters.201902000007, DOI 10.19185/MATTERS.201902000007]; Myllymaki SM, 2019, MOL CELL PROTEOMICS, V18, P277, DOI 10.1074/mcp.RA118.001095; Nakagawa T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002318; Dalton GN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1535-z; Okubo K, 2017, EJSO-EUR J SURG ONC, V43, P1050, DOI 10.1016/j.ejso.2017.01.241; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; R Core Team, 2015, R LANGUAGE ENV STAT; R Studio Team, 2019, R STUDIO INTEGRATED; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sandhofer N, 2015, LEUKEMIA, V29, P828, DOI 10.1038/leu.2014.305; Sartor AO, 2008, UROLOGY, V72, P12, DOI 10.1016/j.urology.2008.10.004; Schlomm T, 2016, EUR UROL, V69, P1157, DOI 10.1016/j.eururo.2016.02.024; SEIFERT GJ, 1992, EUR J CELL BIOL, V59, P138; Setlur SR, 2008, JNCI-J NATL CANCER I, V100, P815, DOI 10.1093/jnci/djn150; Sinha A, 2019, CANCER CELL, V35, P414, DOI 10.1016/j.ccell.2019.02.005; Song BG, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.616440; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swift S, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1017cs31; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Therneau T., **DATA OBJECT**; TM Therneau., 2000, MODELING SURVIVAL DA, DOI DOI 10.1007/978; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Turnham DJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112342; van den Dries K, 2013, MOL BIOL CELL, V24, P2112, DOI 10.1091/mbc.E12-12-0856; van den Dries K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2402; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Walko G, 2015, CELL TISSUE RES, V360, P529, DOI 10.1007/s00441-015-2216-6; Wang W, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201904137; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Whitington T, 2016, NAT GENET, V48, P387, DOI 10.1038/ng.3523; Witkowski CM, 2000, CARCINOGENESIS, V21, P325, DOI 10.1093/carcin/21.2.325; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhang K, 2017, ONCOGENE, V36, P5681, DOI 10.1038/onc.2017.177	72	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3804	3820		10.1038/s41388-022-02389-5	http://dx.doi.org/10.1038/s41388-022-02389-5		JUL 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35773413	Green Published, hybrid			2022-12-28	WOS:000819316400001
J	Chen, YQ; Zhou, S; Wan, KR; Yu, L; Zhao, CC; Deng, HT; Ou, QJ; Qin, JY; Hu, JB; Hou, ZL				Chen, Yaqi; Zhou, Sha; Wan, Kairui; Yu, Long; Zhao, Chongchong; Deng, Haiteng; Ou, Qingjian; Qin, Jiayi; Hu, Junbo; Hou, Zhenlin			RIOK1 mediates p53 degradation and radioresistance in colorectal cancer through phosphorylation of G3BP2	ONCOGENE			English	Article							ENDORIBONUCLEASE G3BP; MDM2; RADIOTHERAPY; BIOGENESIS; RESISTANCE; PROMOTES; KINASES; CELLS	RIO Kinase 1 (RIOK1) is involved in various pathologies, including cancer. However, the role of RIOK1 in radioresistance of colorectal cancer (CRC) remains largely unknown. In this study, we reported that RIOK1 was overexpressed in rectal cancer tissue with weaker tumor regression after neoadjuvant chemoradiotherapy (neoCRT). Moreover, higher RIOK1 expression predicted a poor prognosis in patients with rectal cancer. Blockade of RIOK1 using Toyocamycin, a pharmacological inhibitor of RIOK1, or by knocking down its expression, decreased the resistance of CRC cells to radiotherapy in vitro and in vivo. A mechanistic study revealed that RIOK1 regulates radioresistance by suppressing the p53 signaling pathway. Furthermore, we found that RIOK1 and Ras-GAP SH3 domain binding protein 2 (G3BP2) interact with each other. RIOK1 phosphorylates G3BP2 at Thr226, which increases the activity of G3BP2. RIOK1-mediated phosphorylation of G3BP2 facilitated ubiquitination of p53 by murine double minute 2 protein (MDM2). Altogether, our study revealed the clinical significance of RIOK1 in CRC, and therapies targeting RIOK1 might alleviate the CRC tumor burden in patients.	[Chen, Yaqi; Wan, Kairui; Hu, Junbo] Huazhong Univ Sci & Technol, Tongji Hosp, GI Canc Res Inst, Wuhan 430030, Peoples R China; [Zhou, Sha] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Anesthesiol, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Peoples R China; [Yu, Long; Ou, Qingjian; Qin, Jiayi; Hou, Zhenlin] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Colorectal Surg, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Peoples R China; [Zhao, Chongchong; Deng, Haiteng] Tsinghua Univ, Prot Chem & Prote Facil, Technol Ctr Prot Res, Beijing 100084, Peoples R China	Huazhong University of Science & Technology; State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Tsinghua University	Hou, ZL (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Colorectal Surg, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Peoples R China.	houzl@sysucc.org.cn		Yu, Long/0000-0003-1045-5407; Deng, Haiteng/0000-0001-9496-1280; Wan, Kairui/0000-0001-5991-5334	China Postdoctoral Science Foundation [2019M663289]; Natural Science Foundation of Guangdong Province [2019A1515110144, 2021A1515111014]; National Natural Science Foundation of China [81572725]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by China Postdoctoral Science Foundation (No. 2019M663289), Natural Science Foundation of Guangdong Province (Nos. 2019A1515110144 and 2021A1515111014) and National Natural Science Foundation of China (No. 81572725).	Angermayr M, 2002, FEBS LETT, V524, P31, DOI 10.1016/S0014-5793(02)02993-9; Angermayr M, 2002, MOL MICROBIOL, V44, P309, DOI 10.1046/j.1365-2958.2002.02881.x; Baker B, 2012, SURG ONCOL, V21, pE103, DOI 10.1016/j.suronc.2012.03.004; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990; Ferreira-Cerca S, 2014, NUCLEIC ACIDS RES, V42, P8635, DOI 10.1093/nar/gku542; Gal J, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00052-19; Gu XY, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0308-x; Guderian G, 2011, J BIOL CHEM, V286, P1976, DOI 10.1074/jbc.M110.148486; Hinata N, 2003, UROL RES, V31, P387, DOI 10.1007/s00240-003-0355-9; Hong HQ, 2018, ACTA PHARMACOL SIN, V39, P184, DOI 10.1038/aps.2017.58; Hong XH, 2018, ELIFE, V7, DOI 10.7554/eLife.29511; Hu S, 2015, AM J CANCER RES, V5, P651; Huang QH, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.586025; Huang QH, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01214; Iacovella MG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7643; Kim BM, 2015, INT J MOL SCI, V16, P26880, DOI 10.3390/ijms161125991; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Kong XH, 2021, ONCOL LETT, V22, DOI 10.3892/ol.2021.12922; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; LaRonde-LeBlanc N, 2005, J BIOL CHEM, V280, P37297, DOI 10.1074/jbc.R500013200; LaRonde-LeBlanc N, 2005, BBA-PROTEINS PROTEOM, V1754, P14, DOI 10.1016/j.bbapap.2005.07.037; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; Li JQ, 2015, J CELL PHYSIOL, V230, P2318, DOI 10.1002/jcp.24994; Line A, 2002, CANCER IMMUNOL IMMUN, V51, P574, DOI 10.1007/s00262-002-0322-2; Lu C, 2009, APOPTOSIS, V14, P597, DOI 10.1007/s10495-009-0330-1; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Prentzell MT, 2021, CELL, V184, P655, DOI 10.1016/j.cell.2020.12.024; Read RD, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003253; Singleton DC, 2015, ONCOGENE, V34, P4713, DOI 10.1038/onc.2014.396; Sun Y, 2019, ONCOGENE, V38, P4856, DOI 10.1038/s41388-019-0762-1; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Tsai WC, 2017, J BIOL CHEM, V292, P18886, DOI 10.1074/jbc.M117.800706; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Weinberg F, 2017, EBIOMEDICINE, V20, P79, DOI 10.1016/j.ebiom.2017.04.015; Williams AB, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026070; Williams E, 2007, EXTREMOPHILES, V11, P19, DOI 10.1007/s00792-006-0002-9; Xie J, 2018, THERANOSTICS, V8, P650, DOI 10.7150/thno.21963; Yang PX, 2017, J GASTROEN HEPATOL, V32, P837, DOI 10.1111/jgh.13606	43	1	1	7	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3433	3444		10.1038/s41388-022-02352-4	http://dx.doi.org/10.1038/s41388-022-02352-4		MAY 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35589951				2022-12-28	WOS:000799459800002
J	Liu, Y; Luo, YW; Yan, SM; Lian, YF; Wu, SY; Xu, M; Feng, L; Zhang, X; Li, R; Zhang, XT; Feng, QS; Zeng, YX; Zhang, H				Liu, Yang; Luo, Yuewen; Yan, Shumei; Lian, Yi-Fan; Wu, Shiyu; Xu, Miao; Feng, Lin; Zhang, Xu; Li, Rong; Zhang, Xiantao; Feng, Qi-Sheng; Zeng, Yi-Xin; Zhang, Hui			CRL2(KLHDC3) mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression	ONCOGENE			English	Article							UBIQUITIN LIGASE; CANCER; MUTATIONS; RESISTANCE; PROTEIN; DICHLOROACETATE; EXPRESSION; GEFITINIB; MDM2	Kelch superfamily involves a variety of proteins containing multiple kelch motif and is well characterized as substrate adaptors for CUL3 E3 ligases, which play critical roles in carcinogenesis. However, the role of kelch proteins in lung cancer remains largely unknown. In this study, the non-small cell lung cancer (NSCLC) patients with higher expression of a kelch protein, kelch domain containing 3 (KLHDC3), showed worse overall survival. KLHDC3 deficiency affected NSCLC cell lines proliferation in vitro and in vivo. Further study indicated that KLHDC3 mediated CUL2 E3 ligase and tumor suppressor p14ARF interaction, facilitating the N-terminal ubiquitylation and subsequent degradation of p14ARF. Interestingly, Gefitinib-resistant NSCLC cell lines displayed higher KLHDC3 protein levels. Gefitinib and Osimertinib medications were capable of upregulating KLHDC3 expression to promote p14ARF degradation in the NSCLC cell lines. KLHDC3 shortage significantly increased the sensitivity of lung cancer cells to epidermal growth factor receptor (EGFR)-targeted drugs, providing an alternative explanation for the development of Gefitinib and Osimertinib resistance in NSCLC therapy. Our works suggest that CRL2(KLHDC3) could be a valuable target to regulate the abundance of p14ARF and postpone the occurrence of EGFR-targeted drugs resistance.	[Liu, Yang; Xu, Miao; Feng, Lin; Feng, Qi-Sheng; Zeng, Yi-Xin] Sun Yat Sen Univ Canc Ctr, Dept Expt Res, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Luo, Yuewen; Wu, Shiyu; Zhang, Xu; Li, Rong; Zhang, Xiantao; Zhang, Hui] Sun Yat Sen Univ, Guangdong Engn Res Ctr Antimicrobial Agent & Immu, Zhongshan Sch Med, Inst Human Virol,Key Lab Trop Dis Control,Minist, Guangzhou, Guangdong, Peoples R China; [Luo, Yuewen] Sun Yat Sen Univ, Sch Med, Guangzhou 510080, Peoples R China; [Yan, Shumei] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Pathol, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Lian, Yi-Fan] Sun Yat Sen Univ, Guangdong Prov Key Lab Liver Dis Res, Affiliated Hosp 3, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Zeng, YX (corresponding author), Sun Yat Sen Univ Canc Ctr, Dept Expt Res, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Zhang, H (corresponding author), Sun Yat Sen Univ, Guangdong Engn Res Ctr Antimicrobial Agent & Immu, Zhongshan Sch Med, Inst Human Virol,Key Lab Trop Dis Control,Minist, Guangzhou, Guangdong, Peoples R China.	zengyx@sysucc.org.cn; zhangh92@mail.sysu.edu.cn		Feng, Lin/0000-0001-6461-5838	Special Reserach Program of Sun Yat-sen University Cancer Center; National Special Research Program of China for Important Infectious Diseases [2018ZX10302103, 2017ZX10202102]; Important Key Program of NSFC [81730060]; Joint-Innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou [201803040002]; Natural Science Foundation of Guangdong, China (Excellent Youth Foundation); Fundamental Research Funds for the Central Universities	Special Reserach Program of Sun Yat-sen University Cancer Center; National Special Research Program of China for Important Infectious Diseases; Important Key Program of NSFC; Joint-Innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou; Natural Science Foundation of Guangdong, China (Excellent Youth Foundation); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank Dr Li Zhang for kindly providing lung cancer cell lines. This work was supported by the Special Reserach Program of Sun Yat-sen University Cancer Center to Y-XZ; the National Special Research Program of China for Important Infectious Diseases (2018ZX10302103 and 2017ZX10202102), the Important Key Program of NSFC (81730060), and the Joint-Innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou (201803040002) to HZ; the Natural Science Foundation of Guangdong, China (Excellent Youth Foundation) and the Fundamental Research Funds for the Central Universities to MX.	Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; Chen J, 2018, NATURE, V557, P585, DOI 10.1038/s41586-018-0128-9; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Dhanoa BS, 2013, HUM GENOMICS, V7, DOI 10.1186/1479-7364-7-13; Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050; Garon EB, 2014, J CANCER RES CLIN, V140, P443, DOI 10.1007/s00432-014-1583-9; Guo Y, 2015, FREE RADICAL BIO MED, V88, P337, DOI 10.1016/j.freeradbiomed.2015.06.013; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; Juan O, 2017, THER ADV MED ONCOL, V9, P201, DOI 10.1177/1758834016687262; Kamijo T, 1999, CANCER RES, V59, P2217; Khazaei Z, 2019, ADV HUM BIOL, V9, P245, DOI 10.4103/2321-8568.262891; Ko A, 2012, JNCI-J NATL CANCER I, V104, P1660, DOI 10.1093/jnci/djs424; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002; Lian YF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152820; Luo YW, 2019, J IMMUNOL, V203, P269, DOI 10.4049/jimmunol.1900125; Mahrour N, 2008, J BIOL CHEM, V283, P8005, DOI 10.1074/jbc.M706987200; Maione P, 2015, THER ADV MED ONCOL, V7, P263, DOI 10.1177/1758834015595048; Nacak TG, 2007, CIRC RES, V100, P1155, DOI 10.1161/01.RES.0000265844.56493.ac; Ohinata Y, 2003, FEBS LETT, V537, P1, DOI 10.1016/S0014-5793(03)00036-X; Olszewski U, 2010, CLIN PHARMACOL-ADV A, V2, P177, DOI 10.2147/CPAA.S11795; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Recondo G, 2018, NAT REV CLIN ONCOL, V15, P694, DOI 10.1038/s41571-018-0081-4; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Schwaederle M, 2015, CANCER RES, V75, P1187, DOI 10.1158/0008-5472.CAN-14-2305; Senga SS, 2021, OPEN BIOL, V11, DOI 10.1098/rsob.200358; Shibata S, 2013, P NATL ACAD SCI USA, V110, P7838, DOI 10.1073/pnas.1304592110; Stogios PJ, 2004, TRENDS BIOCHEM SCI, V29, P634, DOI 10.1016/j.tibs.2004.10.003; Strutt H, 2013, DEVELOPMENT, V140, P1693, DOI 10.1242/dev.089656; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Wang D, 2017, CANCER METAST REV, V36, P683, DOI 10.1007/s10555-017-9703-z; Wang XW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2533; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Yan SM, 2016, J CANCER, V7, P618, DOI 10.7150/jca.14030; Yu WS, 2008, MOL CELLS, V26, P443; Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589; Zhong WZ, 2018, ANN ONCOL, V29, P738	50	0	0	4	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3104	3117		10.1038/s41388-022-02318-6	http://dx.doi.org/10.1038/s41388-022-02318-6		APR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35468939				2022-12-28	WOS:000787133900002
J	Gao, P; Hao, JL; Xie, QW; Han, GQ; Xu, BB; Hu, H; Sa, NE; Du, XW; Tang, HL; Yan, J; Dong, XM				Gao, Ping; Hao, Jing-Lan; Xie, Qian-Wen; Han, Gui-Qin; Xu, Bin-Bing; Hu, Hang; Sa, Na-Er; Du, Xiao-Wen; Tang, Hai-Long; Yan, Jian; Dong, Xiao-Ming			PELO facilitates PLK1-induced the ubiquitination and degradation of Smad4 and promotes the progression of prostate cancer	ONCOGENE			English	Article							INHIBITORS	PLK1 and Smad4 are two important factors in prostate cancer initiation and progression. They have been reported to play the opposite role in Pten-deleted mice, one is an oncogene, the other is a tumor suppressor. Moreover, they could reversely regulate the PI3K/AKT/mTOR pathway and the activation of MYC. However, the connections between PLK1 and Smad4 have never been studied. Here, we showed that PLK1 could interact with Smad4 and promote the ubiquitination and degradation of Smad4 in PCa cells. PLK1 and PELO could bind to different domains of Smad4 and formed a protein complex. PELO facilitated the degradation of Smad4 through cooperating with PLK1, thereby resulting in proliferation and metastasis of prostate cancer cell. Changes in protein levels of Smad4 led to the alteration of biological function that caused by PLK1 in prostate cancer cells. Further studies showed that PELO upregulation was positively associated with high grade PCa and knockdown of PELO expression significantly decreased PCa cell proliferation and metastasis in vitro and vivo. PELO knockdown in PCa cells could enhance the tumor suppressive role of PLK1 inhibitor. In addition, blocking the interaction between PELO and Smad4 by using specific peptide could effectively inhibit PCa cell metastasis ability in vitro and vivo. Overall, these findings identified a novel regulatory relationship among PLK1, Smad4 and PELO, and provided a potential therapeutic strategy for advanced PCa therapy by co-targeting PLK1 and PELO.	[Gao, Ping; Hao, Jing-Lan; Xie, Qian-Wen; Han, Gui-Qin; Xu, Bin-Bing; Hu, Hang; Sa, Na-Er; Du, Xiao-Wen; Dong, Xiao-Ming] Shaanxi Normal Univ, Coll Life Sci, Xian 710119, Peoples R China; [Tang, Hai-Long] Fourth Mil Med Univ, Xijing Hosp, Dept Hematol, Xian 710032, Peoples R China; [Yan, Jian] Northwest Univ, Sch Med, Xian 710069, Peoples R China; [Yan, Jian] City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China	Shaanxi Normal University; Air Force Military Medical University; Northwest University Xi'an; City University of Hong Kong	Gao, P; Dong, XM (corresponding author), Shaanxi Normal Univ, Coll Life Sci, Xian 710119, Peoples R China.	ping.gao2016@outlook.com; xiaomingdong@snnu.edu.cn	; Yan, Jian/B-2631-2018	Dong, xiao-ming/0000-0003-2413-8541; Yan, Jian/0000-0002-1267-2870; gao, ping/0000-0003-1383-3290	College of Life Sciences at Shaanxi Normal University - National Natural Science Foundation of China [81972417]; "1000 Young Scholars" Program of Shaanxi Province; Natural Science Foundation of Shaanxi Province [2020JM-292, 2020JQ-430]; Fundamental Research Funds for the Central Universities [GK201902002, GK201903061]; College Students' Innovative Entrepreneurial Training Plan Program [S202110718036]	College of Life Sciences at Shaanxi Normal University - National Natural Science Foundation of China; "1000 Young Scholars" Program of Shaanxi Province; Natural Science Foundation of Shaanxi Province(Natural Science Foundation of Shaanxi Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); College Students' Innovative Entrepreneurial Training Plan Program	We thank the College of Life Sciences at Shaanxi Normal University for the sharing platform of laboratory apparatus. This work was funded by the National Natural Science Foundation of China (81972417), The "1000 Young Scholars" Program of Shaanxi Province, Natural Science Foundation of Shaanxi Province (2020JM-292, 2020JQ-430), Fundamental Research Funds for the Central Universities (GK201902002, GK201903061) and College Students' Innovative Entrepreneurial Training Plan Program (S202110718036).	Adham IM, 2003, MOL CELL BIOL, V23, P1470, DOI 10.1128/MCB.23.4.1470-1476.2003; Garcia IA, 2020, MUTAT RES-FUND MOL M, V821, DOI 10.1016/j.mrfmmm.2020.111693; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen SQ, 2012, BIOORG MED CHEM LETT, V22, P1247, DOI 10.1016/j.bmcl.2011.11.052; Davis L, 1998, GENETICS, V149, P45; Demagny H, 2014, CELL REP, V9, P688, DOI 10.1016/j.celrep.2014.09.020; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Dong XM, 2020, FASEB J, V34, P8416, DOI 10.1096/fj.201902946R; Drucker DJ, 2020, NAT REV DRUG DISCOV, V19, P277, DOI 10.1038/s41573-019-0053-0; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gheghiani L, 2021, CANCER RES, V81, P1293, DOI 10.1158/0008-5472.CAN-20-1377; Goroshchuk O, 2019, ONCOGENE, V38, P1, DOI 10.1038/s41388-018-0443-5; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; KUMAR S, 2015, BIOMED RES INT, V2015, DOI DOI 10.1155/2015/705745; Liakath-Ali K, 2018, NATURE, V556, P376, DOI 10.1038/s41586-018-0032-3; Liu XS, 2011, J BIOL CHEM, V286, P35795, DOI 10.1074/jbc.C111.269050; Ogawa R, 2019, CLIN CANCER RES, V25, P2887, DOI 10.1158/1078-0432.CCR-18-3684; Olmos D, 2011, CLIN CANCER RES, V17, P3420, DOI 10.1158/1078-0432.CCR-10-2946; Pedersen K, 2014, ONCOGENE, V33, P1190, DOI 10.1038/onc.2013.35; Roelen BAJ, 2003, AM J PHYSIOL-CELL PH, V285, pC823, DOI 10.1152/ajpcell.00053.2003; Shi CX, 2021, ONCOGENE, V40, P937, DOI 10.1038/s41388-020-01580-w; Song B, 2019, J CLIN INVEST, V129, P569, DOI 10.1172/JCI122367; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595; van der Toom EE, 2019, NAT REV UROL, V16, P7, DOI 10.1038/s41585-018-0119-5; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; Whittaker SR, 2017, PHARMACOL THERAPEUT, V173, P83, DOI 10.1016/j.pharmthera.2017.02.008; Yao YS, 2020, EXP BIOL MED, V245, P777, DOI 10.1177/1535370220916709; Zhang M, 2017, CANCER LETT, V392, P71, DOI 10.1016/j.canlet.2017.01.024; Zhang Z, 2014, CANCER RES, V74, P6635, DOI 10.1158/0008-5472.CAN-14-1916	33	1	1	5	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2945	2957		10.1038/s41388-022-02316-8	http://dx.doi.org/10.1038/s41388-022-02316-8		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35437307	Green Submitted			2022-12-28	WOS:000784068300001
J	Somatilaka, BN; Sadek, A; McKay, RM; Le, LQ				Somatilaka, Bandarigoda N.; Sadek, Ali; McKay, Renee M.; Le, Lu Q.			Malignant peripheral nerve sheath tumor: models, biology, and translation	ONCOGENE			English	Review							SOFT-TISSUE SARCOMA; FARNESYLTRANSFERASE INHIBITOR TIPIFARNIB; RECEPTOR TYROSINE KINASES; NEUROFIBROMATOSIS TYPE-I; CANCER STEM-CELL; SCHWANN-CELLS; MOUSE MODELS; PHASE-II; MOLECULAR CHARACTERIZATION; PLEXIFORM NEUROFIBROMAS	Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, invasive cancer that comprise around 10% of all soft tissue sarcomas and develop in about 8-13% of patients with Neurofibromatosis Type 1. They are associated with poor prognosis and are the leading cause of mortality in NF1 patients. MPNSTs can also develop sporadically or following exposure to radiation. There is currently no effective targeted therapy to treat MPNSTs and surgical removal remains the mainstay treatment. Unfortunately, surgery is not always possible due to the size and location of the tumor, thus, a better understanding of MPNST initiation and development is required to design novel therapeutics. Here, we provide an overview of MPNST biology and genetics, discuss findings regarding the developmental origin of MPNST, and summarize the various model systems employed to study MPNST. Finally, we discuss current management strategies for MPNST, as well as recent developments in translating basic research findings into potential therapies.	[Somatilaka, Bandarigoda N.; Sadek, Ali; McKay, Renee M.; Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, ODonnell Brain Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, ODonnell Brain Inst, Dallas, TX 75390 USA.	lu.le@utsouthwestern.edu		Somatilaka, Bandarigoda Nipunika/0000-0003-4366-9153; McKay, Renee/0000-0001-5976-1996; Le, Lu/0000-0003-2817-5382	Burroughs Wellcome Fund; US Department of Defense [NF210010]; National Cancer Institute of the NIH [R01 CA166593]; Developmental and Hyperactive RAS Tumor SPORE [U54 CA196519]; Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	Burroughs Wellcome Fund(Burroughs Wellcome Fund); US Department of Defense(United States Department of Defense); National Cancer Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Developmental and Hyperactive RAS Tumor SPORE; Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	LQL held a Career Award for Medical Scientists from the Burroughs Wellcome Fund and is the Thomas L. Shield, M.D. endowed Professor in Dermatology. He is supported by funding from the US Department of Defense (NF210010), the National Cancer Institute of the NIH (R01 CA166593), and the Developmental and Hyperactive RAS Tumor SPORE (U54 CA196519); the Neurofibromatosis Therapeutic Acceleration Program; the NF1 Research Consortium Fund; and the Giorgio Foundation.	Ahlawat S, 2020, SKELETAL RADIOL, V49, P199, DOI 10.1007/s00256-019-03290-1; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Albers AC, 2009, EXPERT REV NEUROTHER, V9, P535, DOI [10.1586/ern.09.4, 10.1586/ERN.09.4]; Albritton KH, 2006, J CLIN ONCOL, V24, p524S; Ambrosini G, 2008, MOL CANCER THER, V7, P890, DOI 10.1158/1535-7163.MCT-07-0518; Anastasaki C, 2020, STEM CELL REP, V14, P541, DOI 10.1016/j.stemcr.2020.03.007; Arshi A, 2015, ORAL ONCOL, V51, P1088, DOI 10.1016/j.oraloncology.2015.08.012; Astone M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145178; Badache A, 1998, J CELL PHYSIOL, V177, P334, DOI 10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9; Bates JE, 2014, PEDIATR BLOOD CANCER, V61, P1955, DOI 10.1002/pbc.25149; Beert E, 2011, GENE CHROMOSOME CANC, V50, P1021, DOI 10.1002/gcc.20921; Berner JM, 1999, GENE CHROMOSOME CANC, V26, P151, DOI 10.1002/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.0.CO;2-A; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhatia S, 2019, J CLIN ONCOL, V37, P3050, DOI 10.1200/JCO.19.00114; Bhola P, 2010, INT J CANCER, V126, P563, DOI 10.1002/ijc.24783; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Bottillo I, 2009, J PATHOL, V217, P693, DOI 10.1002/path.2494; Boyd KP, 2009, J AM ACAD DERMATOL, V61, P1, DOI 10.1016/j.jaad.2008.12.051; Bradtmoller M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047595; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Brohl AS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15183-1; Brosseau JP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07452-y; Buchanan ME, 2010, J NEUROSCI, V30, P10135, DOI 10.1523/JNEUROSCI.0283-10.2010; Butti R, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0797-x; Byer SJ, 2011, NEURO-ONCOLOGY, V13, P28, DOI 10.1093/neuonc/noq146; Carli M, 2005, J CLIN ONCOL, V23, P8422, DOI 10.1200/JCO.2005.01.4886; Carrio M, 2019, STEM CELL REP, V12, P411, DOI 10.1016/j.stemcr.2019.01.001; Carroll SL, 2016, AM J PATHOL, V186, P464, DOI 10.1016/j.ajpath.2015.10.023; Carroll SL, 2012, ACTA NEUROPATHOL, V123, P321, DOI 10.1007/s00401-011-0928-6; Castells-Roca L, 2021, CANCERS, V13, DOI 10.3390/cancers13071591; Castellsague J, 2015, EMBO MOL MED, V7, P608, DOI 10.15252/emmm.201404430; Chamseddin BH., 2020, NEUROONCOL ADV, V2, pi107; Chaney KE, 2020, CANCER RES, V80, P4720, DOI 10.1158/0008-5472.CAN-19-1429; Chau V, 2014, CANCER RES, V74, P586, DOI 10.1158/0008-5472.CAN-13-1934; Chen ZG, 2014, CANCER CELL, V26, P695, DOI 10.1016/j.ccell.2014.09.009; Chou D, 2017, J NEUROSURG-SPINE, V26, P291, DOI 10.3171/2016.8.SPINE151548; Chugh R, 2009, J CLIN ONCOL, V27, P3148, DOI 10.1200/JCO.2008.20.5054; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Cleven AHG, 2016, MODERN PATHOL, V29, P582, DOI 10.1038/modpathol.2016.45; Cooper JM, 2019, CLIN CANCER RES, V25, P3404, DOI 10.1158/1078-0432.CCR-18-2437; Cox Adrienne D, 2010, Small GTPases, V1, P2; DAHLBERG WK, 1993, INT J RADIAT BIOL, V63, P191, DOI 10.1080/09553009314550251; Dang I, 2005, J NEUROSCI RES, V79, P318, DOI 10.1002/jnr.20334; Dasgupta B, 2005, CANCER RES, V65, P2755, DOI 10.1158/0008-5472.CAN-04-4058; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; De Raedt T, 2011, CANCER CELL, V20, P400, DOI 10.1016/j.ccr.2011.08.014; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DeClue JE, 2000, J CLIN INVEST, V105, P1233, DOI 10.1172/JCI7610; Dehner C, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.146351; Demestre M, 2013, J NEURO-ONCOL, V115, P391, DOI 10.1007/s11060-013-1252-x; Deyle DR, 2015, GENE, V565, P140, DOI 10.1016/j.gene.2015.04.001; Dodd RD, 2017, CANCER RES, V77, P4486, DOI 10.1158/0008-5472.CAN-16-2643; Dodd RD, 2013, MOL CANCER THER, V12, P1906, DOI 10.1158/1535-7163.MCT-13-0189; Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943; Dunn GP, 2013, J NEUROSURG, V118, P142, DOI 10.3171/2012.9.JNS101610; Ebben JD, 2010, EXPERT OPIN THER TAR, V14, P621, DOI 10.1517/14712598.2010.485186; Eckert JM, 2009, GLIA, V57, P1501, DOI 10.1002/glia.20866; Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Fang YQ, 2009, ANTICANCER RES, V29, P1255; Farid M, 2014, ONCOLOGIST, V19, P193, DOI 10.1634/theoncologist.2013-0328; Ferner RE, 2008, ANN ONCOL, V19, P390, DOI 10.1093/annonc/mdm450; Ferner RE, 2000, J NEUROL NEUROSUR PS, V68, P353, DOI 10.1136/jnnp.68.3.353; Ferner RE, 2002, CANCER RES, V62, P1573; Ferner RE, 2007, LANCET NEUROL, V6, P340, DOI 10.1016/S1474-4422(07)70075-3; Ferrari A, 2011, EUR J CANCER, V47, P724, DOI 10.1016/j.ejca.2010.11.013; Fisher MJ, 2012, NEURO-ONCOLOGY, V14, P790, DOI 10.1093/neuonc/nos076; Fuchs Bruno, 2005, J Surg Orthop Adv, V14, P168; Gachiani John, 2007, Neurosurg Focus, V22, pE13; Garozzo D, 2019, NEUROL INDIA, V67, pS38, DOI 10.4103/0028-3886.250697; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; Gouzi JY, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002281; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gregorian C, 2009, P NATL ACAD SCI USA, V106, P19479, DOI 10.1073/pnas.0910398106; Gross AM, 2020, NEW ENGL J MED, V382, P1430, DOI 10.1056/NEJMoa1912735; Guo HF, 2000, NATURE, V403, P895, DOI 10.1038/35002593; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; Guo JM, 2020, AM J CANCER RES, V10, P856; Guo JM, 2017, AM J CANCER RES, V7, P923; Gupta G, 2008, NEUROSURG CLIN N AM, V19, P533, DOI 10.1016/j.nec.2008.07.004; Gutmann DH, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.4; Hakozaki M, 2009, VIRCHOWS ARCH, V455, P517, DOI 10.1007/s00428-009-0848-1; Harachi M, 2021, METABOLITES, V11, DOI 10.3390/metabo11040216; Higham Christine S., 2017, Sarcoma, V2017, P8685638, DOI 10.1155/2017/8685638; Hirbe AC, 2016, ONCOTARGET, V7, P7403, DOI 10.18632/oncotarget.7232; Hirbe AC, 2014, NEURO-ONCOLOGY, V16, P466, DOI 10.1093/neuonc/not248; Hirokowa Y, 2005, CANCER BIOL THER, V4, P379; Ho IS, 2007, J NEUROSCI, V27, P6852, DOI 10.1523/JNEUROSCI.0933-07.2007; HOLT GR, 1987, OTOLARYNG CLIN N AM, V20, P179; Holtkamp N, 2006, CARCINOGENESIS, V27, P664, DOI 10.1093/carcin/bgi273; Holtkamp N, 2008, NEURO-ONCOLOGY, V10, P946, DOI 10.1215/15228517-2008-053; Hubbard SR, 2007, CURR OPIN CELL BIOL, V19, P117, DOI 10.1016/j.ceb.2007.02.010; Huijbregts RPH, 2003, J NEUROSCI, V23, P7269; Imaizumi S, 1998, VIRCHOWS ARCH, V433, P435, DOI 10.1007/s004280050271; Inoue A, 2019, CANCERS, V11, DOI 10.3390/cancers11091321; Isfort I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56247-8; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Johannessen CM, 2008, CURR BIOL, V18, P56, DOI 10.1016/j.cub.2007.11.066; Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335; Joseph NM, 2008, CANCER CELL, V13, P129, DOI 10.1016/j.ccr.2008.01.003; Jouhilahti EM, 2011, AM J PATHOL, V178, P1932, DOI 10.1016/j.ajpath.2010.12.056; Kahen Elliot John, 2018, Oncotarget, V9, P22571, DOI 10.18632/oncotarget.25181; Kahn J, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00324; Kaplan HG, 2018, J NATL COMPR CANC NE, V16, P967, DOI 10.6004/jnccn.2018.7033; Kar Madhabananda, 2006, World J Surg Oncol, V4, P55, DOI 10.1186/1477-7819-4-55; Katoh M, 2017, INT J ONCOL, V51, P1357, DOI 10.3892/ijo.2017.4129; Kazmi SJ, 2013, AM J PATHOL, V182, P646, DOI 10.1016/j.ajpath.2012.11.017; Keng Vincent W., 2012, Sarcoma, V2012, P620834, DOI 10.1155/2012/620834; Keng VW, 2012, CANCER RES, V72, P3405, DOI 10.1158/0008-5472.CAN-11-4092; Ki DH, 2017, ONCOGENE, V36, P1058, DOI 10.1038/onc.2016.269; Ki DH, 2019, ONCOGENE, V38, P6585, DOI 10.1038/s41388-019-0965-5; Kim AeRang, 2020, Sarcoma, V2020, P5784876, DOI 10.1155/2020/5784876; Kim AeRang, 2017, Sarcoma, V2017, P7429697, DOI 10.1155/2017/7429697; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; King LB, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008920; King LB, 2016, G3-GENES GENOM GENET, V6, P1083, DOI 10.1534/g3.115.026484; Koelsche C, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-33; Kohlmeyer JL, 2020, CLIN CANCER RES, V26, P2997, DOI 10.1158/1078-0432.CCR-19-2706; Kolberg M, 2017, MOL ONCOL, V11, P1156, DOI 10.1002/1878-0261.12086; Kolberg M, 2013, NEURO-ONCOLOGY, V15, P135, DOI 10.1093/neuonc/nos287; Kraniak JM, 2018, EXP NEUROL, V299, P289, DOI 10.1016/j.expneurol.2017.10.012; Kumari Rashmi, 2018, Oncotarget, V9, P23494, DOI 10.18632/oncotarget.25236; LaFemina J, 2013, ANN SURG ONCOL, V20, P66, DOI 10.1245/s10434-012-2573-2; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Laycock-van Spyk Sebastian, 2011, Human Genomics, V5, P623; Lee PR, 2004, NEURON GLIA BIOL, V1, P135, DOI 10.1017/S1740925X04000274; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; LEGIUS E, 1994, GENE CHROMOSOME CANC, V10, P250, DOI 10.1002/gcc.2870100405; Lemberg KM, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060691; Levi AD, 2010, NEUROSURGERY, V66, P833, DOI 10.1227/01.NEU.0000367636.91555.70; Li H, 2016, LAB INVEST, V96, P1105, DOI 10.1038/labinvest.2016.88; Li HZ, 2002, CANCER RES, V62, P4507; Li YW, 2004, ONCOGENE, V23, P1146, DOI 10.1038/sj.onc.1207068; Lock R, 2016, J CLIN INVEST, V126, P2181, DOI 10.1172/JCI85183; Longo JF, 2018, ADV ANAT PATHOL, V25, P353, DOI 10.1097/PAP.0000000000000197; Longo JF, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85055-2; Lopez G, 2011, CANCER RES, V71, P185, DOI 10.1158/0008-5472.CAN-10-2799; Luscan A, 2014, CLIN CANCER RES, V20, P358, DOI 10.1158/1078-0432.CCR-13-0780; MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105; Mahller YY, 2008, CANCER RES, V68, P1170, DOI 10.1158/0008-5472.CAN-07-2734; Mak IWY, 2014, AM J TRANSL RES, V6, P114; Maki RG, 2009, J CLIN ONCOL, V27, P3133, DOI 10.1200/JCO.2008.20.4495; Maldonado AR, 2010, J GENE MED, V12, P613, DOI 10.1002/jgm.1479; Malone CF, 2017, CANCER DISCOV, V7, P1450, DOI 10.1158/2159-8290.CD-17-0177; Malone CF, 2014, CANCER DISCOV, V4, P1062, DOI 10.1158/2159-8290.CD-14-0159; Mantripragada KK, 2008, CLIN CANCER RES, V14, P1015, DOI 10.1158/1078-0432.CCR-07-1305; Markham A, 2020, DRUGS, V80, P931, DOI 10.1007/s40265-020-01331-x; Martin E, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28138; Mashour GA, 2005, ONCOGENE, V24, P2367, DOI 10.1038/sj.onc.1208425; Mattingly RR, 2006, J PHARMACOL EXP THER, V316, P456, DOI 10.1124/jpet.105.091454; Mautner VF, 2003, NEURORADIOLOGY, V45, P618, DOI 10.1007/s00234-003-0964-6; MERTENS F, 1995, INT J CANCER, V61, P793, DOI 10.1002/ijc.2910610609; Miettinen MM, 2017, HUM PATHOL, V67, P1, DOI 10.1016/j.humpath.2017.05.010; Miller DT, 2020, GENES-BASEL, V11, DOI 10.3390/genes11040387; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Misra JR, 2018, ANNU REV GENET, V52, P65, DOI 10.1146/annurev-genet-120417-031621; Mo J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139807; Mo W, 2013, CELL, V152, P1077, DOI 10.1016/j.cell.2013.01.053; Moll C, 2013, JOVE-J VIS EXP, DOI 10.3791/50460; Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009; Morrison Deborah K, 2012, Cold Spring Harb Perspect Biol, V4, DOI 10.1101/cshperspect.a011254; Muir D, 2001, AM J PATHOL, V158, P501, DOI 10.1016/S0002-9440(10)63992-2; Nagabushan S, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00145-8; NAGASHIMA Y, 1990, VIRCHOWS ARCH B, V59, P321, DOI 10.1007/BF02899420; Nakamura JL, 2011, CANCER RES, V71, P106, DOI 10.1158/0008-5472.CAN-10-2732; O'Sullivan B, 2002, LANCET, V359, P2235, DOI 10.1016/S0140-6736(02)09292-9; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohishi J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-224; Oppel F, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008039; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Patel AJ, 2014, CELL REP, V6, P81, DOI 10.1016/j.celrep.2013.12.001; Patwardhan PP, 2014, CLIN CANCER RES, V20, P3146, DOI 10.1158/1078-0432.CCR-13-2576; Peacock JD, 2018, CANCER RES, V78, P3672, DOI 10.1158/0008-5472.CAN-17-3167; Pekmezci M, 2015, MODERN PATHOL, V28, P187, DOI 10.1038/modpathol.2014.109; Pemov Alexander, 2020, Neurooncol Adv, V2, pi50, DOI 10.1093/noajnl/vdz049; Pemov A, 2019, NEURO-ONCOLOGY, V21, P981, DOI 10.1093/neuonc/noz028; Perrin GQ, 2007, LAB INVEST, V87, P1092, DOI 10.1038/labinvest.3700675; Pollard K, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-0508-5; Rad E, 2016, SEMIN CELL DEV BIOL, V52, P39, DOI 10.1016/j.semcdb.2016.02.007; Rahrmann EP, 2014, AM J PATHOL, V184, P2082, DOI 10.1016/j.ajpath.2014.04.006; Rahrmann EP, 2013, NAT GENET, V45, P756, DOI 10.1038/ng.2641; Ratner N, 2015, NAT REV CANCER, V15, P290, DOI 10.1038/nrc3911; Regad T, 2015, CANCERS, V7, P1758, DOI 10.3390/cancers7030860; Reilly KM, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx124; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; Reuss DE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057152; Rhodes SD, 2019, HUM MOL GENET, V28, P2752, DOI 10.1093/hmg/ddz095; Rosenbaum T, 2014, KLIN PADIATR, V226, P309, DOI 10.1055/s-0034-1382021; RYAN JJ, 1994, J NEUROSCI RES, V37, P415, DOI 10.1002/jnr.490370314; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Scaife Courtney L, 2003, Surg Oncol Clin N Am, V12, P355, DOI 10.1016/S1055-3207(03)00003-6; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidt H, 2001, CANCER GENET CYTOGEN, V128, P14, DOI 10.1016/S0165-4608(01)00393-4; Schuetze SM, 2016, CANCER-AM CANCER SOC, V122, P868, DOI 10.1002/cncr.29858; Semenova G, 2017, BIOCHIMIE, V135, P1, DOI 10.1016/j.biochi.2017.01.001; Shin J, 2012, DIS MODEL MECH, V5, P881, DOI 10.1242/dmm.009779; Singh SK, 2003, CANCER RES, V63, P5821; Sonobe H, 2000, INT J ONCOL, V17, P347; Spyra M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021099; Stalnecker CA, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay6013; Subramanian S, 2010, J PATHOL, V220, P58, DOI 10.1002/path.2633; Sun DC, 2021, CELL STEM CELL, V28, P1397, DOI 10.1016/j.stem.2021.04.029; Sun Daochun, 2012, Transl Oncogenomics, V5, P1, DOI 10.4137/TOG.S8830; Suratwala SJ, 2020, SPINE DEFORM, V8, P333, DOI 10.1007/s43390-019-00013-3; Szymanski JJ, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003734; Tabone-Eglinger Severine, 2008, Sarcoma, V2008, P1, DOI 10.1155/2008/849156; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TAKAMIYA Y, 1993, J NEUROSURG, V78, P470, DOI 10.3171/jns.1993.78.3.0470; Teicher BA, 2015, MOL CANCER THER, V14, P2452, DOI 10.1158/1535-7163.MCT-15-0074; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; Theos A, 2006, ANN INTERN MED, V144, P842, DOI 10.7326/0003-4819-144-11-200606060-00010; Thomson CS, 2021, ONCOGENE, V40, P4229, DOI 10.1038/s41388-021-01773-x; Tierney JF, 1997, LANCET, V350, P1647; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; Torres KE, 2011, CLIN CANCER RES, V17, P3943, DOI 10.1158/1078-0432.CCR-11-0193; Tovmassian D, 2016, INT J SURG ONCOL, V2016, DOI 10.1155/2016/6162182; van der Voet M, 2016, MOL PSYCHIATR, V21, P565, DOI 10.1038/mp.2015.55; Varin J, 2016, ONCOTARGET, V7, P35753, DOI 10.18632/oncotarget.7099; Verdijk RM, 2010, J NEUROPATH EXP NEUR, V69, P16, DOI 10.1097/NEN.0b013e3181c55d55; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Walker JA, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003958; Wang W, 2012, J INT MED RES, V40, P2284, DOI 10.1177/030006051204000626; Watson AL, 2014, ONCOTARGET, V5, P1502, DOI 10.18632/oncotarget.1609; Watson AL, 2013, CANCER DISCOV, V3, P674, DOI 10.1158/2159-8290.CD-13-0081; Wegscheid ML, 2018, EXP NEUROL, V299, P270, DOI 10.1016/j.expneurol.2017.04.001; Weiss B, 2015, NEURO-ONCOLOGY, V17, P596, DOI 10.1093/neuonc/nou235; Widemann BC, 2006, J CLIN ONCOL, V24, P507, DOI 10.1200/JCO.2005.03.8638; Widemann Brigitte C., 2019, Sarcoma, V2019, P7656747, DOI 10.1155/2019/7656747; Widemann BC, 2018, J CLIN ONCOL, V36, P160, DOI 10.1200/JCO.2017.75.3467; Widemann BC, 2014, NEURO-ONCOLOGY, V16, P707, DOI 10.1093/neuonc/nou004; Williams JA, 2001, SCIENCE, V293, P2251, DOI 10.1126/science.1063097; Williams KB, 2020, GENES-BASEL, V11, DOI 10.3390/genes11050477; Williams KB, 2017, MOL CANCER THER, V16; Wojtkowiak JW, 2008, J PHARMACOL EXP THER, V326, P1, DOI 10.1124/jpet.107.135830; Wood M, 2011, MOL CANCER THER, V10, P1740, DOI 10.1158/1535-7163.MCT-11-0309; Wu J, 2014, ONCOGENE, V33, P173, DOI 10.1038/onc.2012.579; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Wu LMN, 2018, CANCER CELL, V33, P292, DOI 10.1016/j.ccell.2018.01.005; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; YAN N, 1995, CANCER RES, V55, P3569; Yang FC, 2008, CELL, V135, P437, DOI 10.1016/j.cell.2008.08.041; Yang JC, 1998, J CLIN ONCOL, V16, P197, DOI 10.1200/JCO.1998.16.1.197; Yang JL, 2011, CLIN CANCER RES, V17, P7563, DOI 10.1158/1078-0432.CCR-11-1707; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yoshida GJ, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0829-z; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452; Zou CY, 2009, ANN SURG, V249, P1014, DOI 10.1097/SLA.0b013e3181a77e9a	254	5	5	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2405	2421		10.1038/s41388-022-02290-1	http://dx.doi.org/10.1038/s41388-022-02290-1		APR 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35393544	Green Accepted			2022-12-28	WOS:000779227700003
J	Wang, CH; Zhang, SS; Ma, BY; Fu, Y; Luo, YZ				Wang, Caihong; Zhang, Shaosen; Ma, Boyuan; Fu, Yan; Luo, Yongzhang			TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression	ONCOGENE			English	Article							RAB-COUPLING PROTEIN; MUTANT P53; CELL; GAIN; INVASION; GENE; ACTIVATION; INTEGRIN	Mutant p53 (mtp53) can exert cancer-promoting activities via "gain-of-function", which has become a popular research target. Although lots of researchers focus on the tumor-suppressor role for p53, the regulation of mutant p53 remains unknown. Here, we report a mechanism by which mtp53 regulate the transcription of Rab coupling protein (RCP) to influence lung cancer behavior. First, we show that RCP is specifically expressed at high levels in lung cancer tissues and cells, and RCP knockout suppresses tumor growth and metastasis. Further mass spectrometry and functional analysis identify that Sp1, Sp3 and Stat3 are the transcriptional activators of RCP. Moreover, p53 is involved in modulating RCP expression in an Sp1/3 dependent manner. Mechanistically, in contrast to wild-type p53 suppression of RCP transcription by decreasing Sp1/3 proteins, TP53 mutations have changed on Sp1/3 expression via "loss-of-function". Surprisingly, the DNA contact mutants of p53 further robustly enhance their binding ability with Sp1/3 to drive RCP expression through the "gain-of-function" activity. Collectively, we reveal a mechanism by which p53 regulating the transcription of RCP to influence lung cancer progression, which provides new insights for treating p53 mutant lung cancer.	[Wang, Caihong] Capital Med Univ, Beijing Friendship Hosp, Beijing Inst Trop Med, Beijing 100050, Peoples R China; [Wang, Caihong; Zhang, Shaosen; Ma, Boyuan; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China; [Wang, Caihong; Zhang, Shaosen; Ma, Boyuan; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Natl Engn Res Ctr Prot Technol, Beijing 100084, Peoples R China; [Wang, Caihong; Zhang, Shaosen; Ma, Boyuan; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Beijing Key Lab Prot Therapeut, Beijing 100084, Peoples R China; [Zhang, Shaosen] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Etiol & Carcinogenesis, Beijing 100021, Peoples R China	Capital Medical University; Tsinghua University; Tsinghua University; Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Luo, YZ (corresponding author), Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China.; Luo, YZ (corresponding author), Tsinghua Univ, Natl Engn Res Ctr Prot Technol, Beijing 100084, Peoples R China.; Luo, YZ (corresponding author), Tsinghua Univ, Beijing Key Lab Prot Therapeut, Beijing 100084, Peoples R China.	yluo@tsinghua.edu.cn		Zhang, Shaosen/0000-0003-0010-1445	National Natural Science Foundation of China [82103071]; National Major Scientific and Technological Special Project for "Significant New Drugs Development" [20181821569]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Major Scientific and Technological Special Project for "Significant New Drugs Development"	This work was supported by the National Natural Science Foundation of China (No. 82103071 to CW) and the National Major Scientific and Technological Special Project for "Significant New Drugs Development" (No. 20181821569 to YL).	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Balsara BR, 1997, CANCER RES, V57, P2116; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Cho KH, 2019, ARCH PHARM RES, V42, P101, DOI 10.1007/s12272-019-01129-w; Choe SR, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0078-1; Dai YZ, 2012, ONCOL LETT, V3, P1231, DOI 10.3892/ol.2012.652; Donehower LA, 2019, CELL REP, V28, P1370, DOI 10.1016/j.celrep.2019.07.001; Escoll M, 2017, ONCOGENE, V36, P3515, DOI 10.1038/onc.2016.518; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gettinger SN, 2012, J CLIN ONCOL, V30; Ghosh M, 2021, CANCER CELL, V39, P494, DOI 10.1016/j.ccell.2021.01.003; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gundry C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14646; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hwang CI, 2011, P NATL ACAD SCI USA, V108, P14240, DOI 10.1073/pnas.1017536108; Hwang MH, 2017, ONCOGENE, V36, P1102, DOI 10.1038/onc.2016.277; Jacquemet G, 2013, J CELL BIOL, V202, P917, DOI 10.1083/jcb.201302041; Kim JY, 2020, EXP MOL MED, V52, P1152, DOI 10.1038/s12276-020-0474-1; Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Kurppa KJ, 2020, CANCER CELL, V37, P104, DOI 10.1016/j.ccell.2019.12.006; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Lindsay AJ, 2017, ONCOTARGET, V8, P104717, DOI 10.18632/oncotarget.10513; Lozano G, 2007, CURR OPIN GENET DEV, V17, P66, DOI 10.1016/j.gde.2006.12.003; Mills GB, 2009, J CLIN INVEST, V119, P2123, DOI 10.1172/JCI40256; Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005; Monteleone E, 2019, CANCERS, V11, DOI 10.3390/cancers11010101; Morello V, 2011, ONCOGENE, V30, P4087, DOI 10.1038/onc.2011.107; Muller PAJ, 2013, ONCOGENE, V32, P1252, DOI 10.1038/onc.2012.148; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Novo D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07339-y; Oduah EI, 2020, CANCER BIOL THER, V21, P293, DOI 10.1080/15384047.2019.1702403; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Phatak V, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03497-y; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Schuette W, 2005, J CLIN ONCOL, V23, P8389, DOI 10.1200/JCO.2005.02.3739; Su HW, 2009, AM J PHYSIOL-CELL PH, V296, pC13, DOI 10.1152/ajpcell.00263.2008; Suske G, 2005, GENOMICS, V85, P551, DOI 10.1016/j.ygeno.2005.01.005; Tang QS, 2021, EMBO REP, V22, DOI 10.15252/embr.201948351; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; van 't Veer LJ, 2008, NATURE, V452, P564, DOI 10.1038/nature06915; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Xu SR, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1442-3; Zhang J, 2019, P NATL ACAD SCI USA, V116, P24259, DOI 10.1073/pnas.1913919116; Zhang JQ, 2009, J CLIN INVEST, V119, P2171, DOI 10.1172/JCI37622; Zhang L, 2010, J BIOL CHEM, V285, P38463, DOI 10.1074/jbc.M110.153999; Zhang SS, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107879; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	54	1	1	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2357	2371		10.1038/s41388-022-02260-7	http://dx.doi.org/10.1038/s41388-022-02260-7		MAR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35256783				2022-12-28	WOS:000765674100001
J	Turdo, A; Gaggianesi, M; Di Franco, S; Veschi, V; D'Accardo, C; Porcelli, G; Lo Iacono, M; Pillitteri, I; Verona, F; Militello, G; Zippo, A; Poli, V; Fagnocchi, L; Beyes, S; Stella, S; Lattanzio, R; Faldetta, N; Lentini, VL; Porcasi, R; Pistone, G; Bongiorno, MR; Stassi, G; De Maria, R; Todaro, M				Turdo, Alice; Gaggianesi, Miriam; Di Franco, Simone; Veschi, Veronica; D'Accardo, Caterina; Porcelli, Gaetana; Lo Iacono, Melania; Pillitteri, Irene; Verona, Francesco; Militello, Gabriella; Zippo, Alessio; Poli, Vittoria; Fagnocchi, Luca; Beyes, Sven; Stella, Stefania; Lattanzio, Rossano; Faldetta, Naida; Lentini, Vincenzo L.; Porcasi, Rossana; Pistone, Giuseppe; Bongiorno, Maria Rita; Stassi, Giorgio; De Maria, Ruggero; Todaro, Matilde			Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51	ONCOGENE			English	Article							RESISTANCE; COMBINATION; PROGNOSIS; DYNAMICS; MARKER; GENES	Breast cancer (BC) is the second cause of cancer-related deceases in the worldwide female population. Despite the successful treatment advances, 25% of BC develops resistance to current therapeutic regimens, thereby remaining a major hurdle for patient management. Current therapies, targeting the molecular events underpinning the adaptive resistance, still require effort to improve BC treatment. Using BC sphere cells (BCSphCs) as a model, here we showed that BC stem-like cells express high levels of Myc, which requires the presence of the multifunctional DNA/RNA binding protein Sam68 for the DNA-damage repair. Analysis of a cohort of BC patients displayed that Sam68 is an independent negative factor correlated with the progression of the disease. Genetic inhibition of Sam68 caused a defect in PARP-induced PAR chain synthesis upon DNA-damaging insults, resulting in cell death of TNBC cells. In contrast, BC stem-like cells were able to survive due to an upregulation of Rad51. Importantly, the inhibition of Rad51 showed synthetic lethal effect with the silencing of Sam68, hampering the cell viability of patient-derived BCSphCs and stabilizing the growth of tumor xenografts, including those TNBC carrying BRCA mutation. Moreover, the analysis of Myc, Sam68 and Rad51 expression demarcated a signature of a poor outcome in a large cohort of BC patients. Thus, our findings suggest the importance of targeting Sam68-PARP1 axis and Rad51 as potential therapeutic candidates to counteract the expansion of BC cells with an aggressive phenotype.	[Turdo, Alice; D'Accardo, Caterina; Porcelli, Gaetana; Lo Iacono, Melania; Pillitteri, Irene; Verona, Francesco; Porcasi, Rossana; Pistone, Giuseppe; Bongiorno, Maria Rita; Todaro, Matilde] Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties PROMISE, Palermo, Italy; [Gaggianesi, Miriam; Di Franco, Simone; Veschi, Veronica; Militello, Gabriella; Stassi, Giorgio] Univ Palermo, Dept Surg Oncol & Stomatol Sci DICHIRONS, Palermo, Italy; [Zippo, Alessio; Poli, Vittoria; Fagnocchi, Luca; Beyes, Sven] Univ Trento, Dept Cellular Computat & Integrat Biol, Trento, Italy; [Stella, Stefania] Univ Catania, Ctr Expt Oncol & Hematol, Dept Clin & Expt Med, AOU Policlin Vittorio Emanuele, Catania, Italy; [Lattanzio, Rossano] G dAnnunzio Univ Chieti Pescara, Ctr Adv Studies & Technol Cast, Dept Innovat Technol Med & Dent, Chieti, Italy; [Faldetta, Naida; Lentini, Vincenzo L.] Villa Sofia Cervello Hosp, Palermo, Italy; [De Maria, Ruggero] Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Dipartimento Med & Chirurg Traslaz, Rome, Italy; [De Maria, Ruggero] Fdn Policlin A Gemelli IRCCS, Rome, Lazio, Italy	University of Palermo; University of Palermo; University of Trento; Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Presidio Ferraotto; University of Catania; G d'Annunzio University of Chieti-Pescara; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Todaro, M (corresponding author), Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties PROMISE, Palermo, Italy.; De Maria, R (corresponding author), Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Dipartimento Med & Chirurg Traslaz, Rome, Italy.; De Maria, R (corresponding author), Fdn Policlin A Gemelli IRCCS, Rome, Lazio, Italy.	ruggero.demaria@unicatt.it; matilde.todaro@unipa.it	di franco, simone/M-3714-2019; Turdo, Alice/ABB-8063-2022; Fagnocchi, Luca/M-2715-2017; Turdo, Alice/AIA-6591-2022	di franco, simone/0000-0002-6217-2161; Turdo, Alice/0000-0002-6152-4903; Fagnocchi, Luca/0000-0002-9551-5474; Turdo, Alice/0000-0002-6152-4903; Veschi, Veronica/0000-0002-6379-7366; GAGGIANESI, Miriam/0000-0002-7810-856X	European Union-FESR FSE, PON Ricerca e Innovazione 2014-2020 (AIM line 1); AIRC fellowship; AIRC [2018-ID. 22911, 2018-ID. 21492]; PSN2015, 6.2 project [CUP176J17000470001]	European Union-FESR FSE, PON Ricerca e Innovazione 2014-2020 (AIM line 1); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); PSN2015, 6.2 project	The authors thank Giorgia Scalici and Antonella Loggia for their contribution to patient data management, and Francesco Cal and Dario Cricchio for statistical analysis and image editing. AT and VV are research fellows funded by European Union-FESR FSE, PON Ricerca e Innovazione 2014-2020 (AIM line 1). G.P., C.D. and F.V. are PhD students in the Molecular and Clinical Medicine program. VP is recipient of an AIRC fellowship. AZ received funding from AIRC under IG 2018-ID. 22911 project. MT received funding from AIRC under IG 2018-ID. 21492 project and from PSN2015, 6.2, CUP176J17000470001 project.	Akashi-Tanaka S, 2015, CLIN BREAST CANCER, V15, P80, DOI 10.1016/j.clbc.2014.08.003; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Benoit YD, 2017, CELL CHEM BIOL, V24, P833, DOI 10.1016/j.chembiol.2017.05.026; Bielli P, 2011, ENDOCR-RELAT CANCER, V18, pR91, DOI 10.1530/ERC-11-0041; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Busa R, 2010, NUCLEIC ACIDS RES, V38, P3005, DOI 10.1093/nar/gkq004; Byrum AK, 2019, TRENDS CELL BIOL, V29, P740, DOI 10.1016/j.tcb.2019.06.005; Caggiano C, 2019, NUCLEIC ACIDS RES, V47, P6160, DOI 10.1093/nar/gkz344; Carey JPW, 2018, CANCER RES, V78, P742, DOI 10.1158/0008-5472.CAN-17-1494; Cerrato A, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0456-2; Cheng CH, 2006, GENE DEV, V20, P1715, DOI 10.1101/gad.1430906; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cruz C, 2018, ANN ONCOL, V29, P1203, DOI 10.1093/annonc/mdy099; Di Franco S, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102664; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Fagnocchi L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11903; Fu K, 2016, ELIFE, V5, DOI 10.7554/eLife.21957; Fu K, 2016, ELIFE, V5, DOI 10.7554/eLife.15018; Gaggianesi M, 2017, CANCER RES, V77, P3268, DOI 10.1158/0008-5472.CAN-16-3126; Gaytan-Cervantes J, 2017, J BIOL CHEM, V292, P13745, DOI 10.1074/jbc.M117.800318; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Golan H, 2018, STEM CELL REP, V11, P795, DOI 10.1016/j.stemcr.2018.07.010; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; Heijink AM, 2019, CELL REP, V28, P2345, DOI 10.1016/j.celrep.2019.07.070; Huang RX, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0150-x; Johnson SF, 2016, CELL REP, V17, P2367, DOI 10.1016/j.celrep.2016.10.077; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kollareddy M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8389; Lee JH, 2020, BLOOD ADV, V4, P2032, DOI 10.1182/bloodadvances.2019000757; Leroy B, 2014, HUM MUTAT, V35, P756, DOI 10.1002/humu.22556; Liston DR, 2017, CLIN CANCER RES, V23, P3489, DOI 10.1158/1078-0432.CCR-16-3083; Liu YJ, 2017, CLIN CANCER RES, V23, P514, DOI 10.1158/1078-0432.CCR-15-1348; Mangiapane LR, 2022, GUT, V71, P119, DOI 10.1136/gutjnl-2020-323553; Manic G, 2018, GUT, V67, P903, DOI 10.1136/gutjnl-2016-312623; McGill G, 1999, J CLIN INVEST, V104, P223, DOI 10.1172/JCI7861; Misenko SM, 2018, CELL CYCLE, V17, P881, DOI 10.1080/15384101.2018.1456295; Mitri Z, 2015, INVEST NEW DRUG, V33, P890, DOI 10.1007/s10637-015-0244-4; Pak S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1342-5; Paronetto MP, 2010, CANCER RES, V70, P229, DOI 10.1158/0008-5472.CAN-09-2788; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Piggott L, 2018, CLIN CANCER RES, V24, P2452, DOI 10.1158/1078-0432.CCR-17-1381; Poli V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03264-2; Polyak Kornelia, 2012, Cancer Cell, V22, P562, DOI 10.1016/j.ccr.2012.06.021; Rottenberg S, 2007, P NATL ACAD SCI USA, V104, P12117, DOI 10.1073/pnas.0702955104; Sachs N, 2018, CELL, V172, P373, DOI 10.1016/j.cell.2017.11.010; Schnitt SJ, 2010, MODERN PATHOL, V23, pS60, DOI 10.1038/modpathol.2010.33; Siegel RL., 2020, CA-CANCER J CLIN, V70; Sniadecki M, 2020, GENES-BASEL, V11, DOI 10.3390/genes11111251; Song LB, 2010, J PATHOL, V222, P227, DOI 10.1002/path.2751; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Turdo A, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00016; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Wu M, 2019, INT J CLIN EXP PATHO, V12, P1; Zhang JF, 2020, BREAST CANCER RES TR, V182, P719, DOI 10.1007/s10549-020-05730-2; Zhang SP, 2019, P NATL ACAD SCI USA, V116, P1370, DOI 10.1073/pnas.1816262116; Zhu YH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03951-0	59	2	2	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2196	2209		10.1038/s41388-022-02239-4	http://dx.doi.org/10.1038/s41388-022-02239-4		FEB 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35217791	Green Published, hybrid			2022-12-28	WOS:000761867900001
J	Ciraku, L; Bacigalupa, ZA; Ju, J; Moeller, RA; Minh, GL; Lee, RH; Smith, MD; Ferrer, CM; Trefely, S; Izzo, LT; Doan, MT; Gocal, WA; D'Agostino, L; Shi, WY; Jackson, JG; Katsetos, CD; Wellen, KE; Snyder, NW; Reginato, MJ				Ciraku, Lorela; Bacigalupa, Zachary A.; Ju, Jing; Moeller, Rebecca A.; Giang Le Minh; Lee, Rusia H.; Smith, Michael D.; Ferrer, Christina M.; Trefely, Sophie; Izzo, Luke T.; Doan, Mary T.; Gocal, Wiktoria A.; D'Agostino, Luca; Shi, Wenyin; Jackson, Joshua G.; Katsetos, Christos D.; Wellen, Kathryn E.; Snyder, Nathaniel W.; Reginato, Mauricio J.			O-GlcNAc transferase regulates glioblastoma acetate metabolism via regulation of CDK5-dependent ACSS2 phosphorylation	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASE-5; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; CYTOSOLIC PROTEINS; EXPRESSION; INHIBITOR; CDK5; DINACICLIB; SURVIVAL; NUCLEAR	Glioblastomas (GBMs) preferentially generate acetyl-CoA from acetate as a fuel source to promote tumor growth. O-GlcNAcylation has been shown to be elevated by increasing O-GlcNAc transferase (OGT) in many cancers and reduced O-GlcNAcylation can block cancer growth. Here, we identify a novel mechanism whereby OGT regulates acetate-dependent acetyl-CoA and lipid production by regulating phosphorylation of acetyl-CoA synthetase 2 (ACSS2) by cyclin-dependent kinase 5 (CDK5). OGT is required and sufficient for GBM cell growth and regulates acetate conversion to acetyl-CoA and lipids. Elevating O-GlcNAcylation in GBM cells increases phosphorylation of ACSS2 on Ser-267 in a CDK5-dependent manner. Importantly, we show that ACSS2 Ser-267 phosphorylation regulates its stability by reducing polyubiquitination and degradation. ACSS2 Ser-267 is critical for OGT-mediated GBM growth as overexpression of ACSS2 Ser-267 phospho-mimetic rescues growth in vitro and in vivo. Importantly, we show that pharmacologically targeting OGT and CDK5 reduces GBM growth ex vivo. Thus, the OGT/CDK5/ACSS2 pathway may be a way to target altered metabolic dependencies in brain tumors.	[Ciraku, Lorela; Bacigalupa, Zachary A.; Ju, Jing; Moeller, Rebecca A.; Giang Le Minh; Lee, Rusia H.; Smith, Michael D.; Ferrer, Christina M.; Gocal, Wiktoria A.; Reginato, Mauricio J.] Drexel Univ, Dept Biochem & Mol Biol, Coll Med, Philadelphia, PA 19102 USA; [Trefely, Sophie; Doan, Mary T.; Snyder, Nathaniel W.] Temple Univ, Ctr Metab Dis Res, Dept Microbiol & Immunol, Lewis Katz Sch Med, Philadelphia, PA 19140 USA; [Izzo, Luke T.; Wellen, Kathryn E.] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; [Izzo, Luke T.; Wellen, Kathryn E.] Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [D'Agostino, Luca; Katsetos, Christos D.] Drexel Univ, Dept Pathol & Lab Med, Coll Med, Philadelphia, PA 19102 USA; [Shi, Wenyin] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA; [Jackson, Joshua G.] Drexel Univ, Dept Pharmacol & Physiol, Coll Med, Philadelphia, PA 19102 USA; [Reginato, Mauricio J.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Translat Cellular Oncol Program, Philadelphia, PA 19107 USA	Drexel University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Drexel University; Jefferson University; Drexel University; Jefferson University	Reginato, MJ (corresponding author), Drexel Univ, Dept Biochem & Mol Biol, Coll Med, Philadelphia, PA 19102 USA.; Reginato, MJ (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Translat Cellular Oncol Program, Philadelphia, PA 19107 USA.	mjr53@drexel.edu		Izzo, Luke/0000-0002-6217-9240; , Jing/0000-0002-1901-6980; Gocal, Wiktoria/0000-0001-8894-8047; Jackson, Joshua/0000-0003-4166-9213; Doan, Mary/0000-0001-6295-4895	PA CURE grant [UO1CA244303]; Drexel University Dean's Fellowship award;  [R01CA228339];  [2-T32-CA-115299-14]	PA CURE grant; Drexel University Dean's Fellowship award; ; 	This work was supported by PA CURE grant (to MJR, NWS and JGJ), UO1CA244303 (to MJR), Drexel University Dean's Fellowship award (to ZAB and LC). KEW acknowledges R01CA228339. LTI is supported by 2-T32-CA-115299-14. The authors thank Chaitali Bhadiadra for technical assistance, Dr. Valerie Sodi and Dr. Edward Hartsough for helpful discussions. In memoriam Christos D. Katsetos.	Antoniou X, 2011, BRAIN RES, V1381, P1, DOI 10.1016/j.brainres.2010.10.071; Bond MR, 2015, J CELL BIOL, V208, P869, DOI 10.1083/jcb.201501101; Bulusu V, 2017, CELL REP, V18, P647, DOI 10.1016/j.celrep.2016.12.055; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Catania A, 2001, NEURO-ONCOLOGY, V3, P89, DOI 10.1093/neuonc/3.2.89; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen XX, 2015, ONCOTARGET, V6, P14926, DOI 10.18632/oncotarget.3717; Ciraku L, J VIS EXP, V2021, P175; Comerford SA, 2014, CELL, V159, P1591, DOI 10.1016/j.cell.2014.11.020; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Feldmann G, 2011, CANCER BIOL THER, V12, P598, DOI 10.4161/cbt.12.7.16475; Ferraro GB, 2021, NAT CANCER, V2, P414, DOI 10.1038/s43018-021-00183-y; Ferrer CM, 2016, J MOL BIOL, V428, P3282, DOI 10.1016/j.jmb.2016.05.028; Ferrer CM, 2014, MOL CELL, V54, P820, DOI 10.1016/j.molcel.2014.04.026; Fu AKY, 2004, P NATL ACAD SCI USA, V101, P6728, DOI 10.1073/pnas.0307606100; Futatsugi A, 2012, CELL CYCLE, V11, P1603, DOI 10.4161/cc.20009; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Gloster TM, 2011, NAT CHEM BIOL, V7, P174, DOI 10.1038/NCHEMBIO.520; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Hothi P, 2012, ONCOTARGET, V3, P1124; Jackson JG, 2014, J NEUROSCI, V34, P1613, DOI 10.1523/JNEUROSCI.3510-13.2014; Jin X, 2020, NATURE, V588, P331, DOI 10.1038/s41586-020-2969-2; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Kumar SK, 2015, BLOOD, V125, P443, DOI 10.1182/blood-2014-05-573741; Lenjisa JL, 2017, FUTURE MED CHEM, V9, P1939, DOI 10.4155/fmc-2017-0097; Lewis CA, 2015, ONCOGENE, V34, P5128, DOI 10.1038/onc.2014.439; Li XJ, 2017, MOL CELL, V66, P684, DOI 10.1016/j.molcel.2017.04.026; Lin H, 2007, J BIOL CHEM, V282, P2776, DOI 10.1074/jbc.M607234200; Lindqvist J, 2015, MOL BIOL CELL, V26, P1971, DOI 10.1091/mbc.E14-12-1634; Liu R, 2008, P NATL ACAD SCI USA, V105, P7570, DOI 10.1073/pnas.0712306105; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; Magistretti PJ, 2015, NEURON, V86, P883, DOI 10.1016/j.neuron.2015.03.035; Mashimo T, 2014, CELL, V159, P1603, DOI 10.1016/j.cell.2014.11.025; Ning XJ, 2017, CELL MOL NEUROBIOL, V37, P527, DOI 10.1007/s10571-016-0391-y; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Parry D, 2010, MOL CANCER THER, V9, P2344, DOI 10.1158/1535-7163.MCT-10-0324; Piedrahita D, 2010, J NEUROSCI, V30, P13966, DOI 10.1523/JNEUROSCI.3637-10.2010; Pozo K, 2016, TRENDS CANCER, V2, P606, DOI 10.1016/j.trecan.2016.09.001; Schild T, 2018, CANCER CELL, V33, P347, DOI 10.1016/j.ccell.2018.02.001; Schug ZT, 2016, NAT REV CANCER, V16, P708, DOI 10.1038/nrc.2016.87; Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002; Sharma S, 2020, P NATL ACAD SCI USA, V117, P8001, DOI 10.1073/pnas.1912617117; Sodi VL, 2018, ONCOGENE, V37, P924, DOI 10.1038/onc.2017.395; Sodi VL, 2015, MOL CANCER RES, V13, P923, DOI 10.1158/1541-7786.MCR-14-0536; Thompson JW, 2018, METHOD ENZYMOL, V598, P101, DOI 10.1016/bs.mie.2017.06.009; Trefely S, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1360-7; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; Yoshii Y, 2009, CANCER SCI, V100, P821, DOI 10.1111/j.1349-7006.2009.01099.x; Yushan R., 2015, WORLD J SURG ONCOL, V13; Zachara NE, 2004, TRENDS CELL BIOL, V14, P218, DOI 10.1016/j.tcb.2004.03.005; Zhao S, 2016, CELL REP, V17, P1037, DOI 10.1016/j.celrep.2016.09.069	53	6	6	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2122	2136		10.1038/s41388-022-02237-6	http://dx.doi.org/10.1038/s41388-022-02237-6		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35190642	Green Accepted, Green Submitted			2022-12-28	WOS:000758961200001
J	Fu, LC; Fan, J; Maity, S; McFadden, G; Shi, YX; Kong, W				Fu, Lingchen; Fan, Jia; Maity, Sudipa; McFadden, Grant; Shi, Yixin; Kong, Wei			PD-L1 interacts with Frizzled 6 to activate beta-catenin and form a positive feedback loop to promote cancer stem cell expansion	ONCOGENE			English	Article							COLON-CANCER; WNT/BETA-CATENIN; EXPRESSION; DIFFERENTIATION; MICE; APC; IDENTIFICATION; PROGENITORS; PROGRESSION; CLONING	Cancer stem cells (CSCs) drive tumor initiation, progression, metastasis, and drug resistance. We report here that programmed cell death ligand 1 (PD-L1) is constitutively expressed in cancer cells to maintain and expand CSC through a novel mechanism in addition to promoting cancer cell immune evasion. We discovered that PD-L1 interacts with receptor Frizzled 6 to activate beta-catenin signaling and increase beta-catenin-targeted gene expression, such as a putative stem cell marker leucine-rich-repeat-containing G-protein-coupled receptor 5. Blockage of PD-L1 function, using a specific small hairpin RNA or a specific antibody, inhibits disease progression by reducing the CSC population in both colorectal and breast tumors. Moreover, beta-catenin conversely regulates PD-L1 expression through a beta-catenin complex binding site in the PD-L1 promoter. Our discoveries reveal that besides assistant tumor cell immune escaping, PD-L1 and beta-catenin signaling form a positive feedback loop to promote cancer progression through CSC maintenance and expansion.	[Fu, Lingchen; McFadden, Grant; Shi, Yixin; Kong, Wei] Arizona State Univ, Biodesign Ctr Immunotherapy Vaccines & Virotherap, Tempe, AZ 85281 USA; [Fan, Jia; Maity, Sudipa] Tulane Univ, Sch Med, Ctr Cellular & Mol Diagnost, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Fan, Jia; Maity, Sudipa] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA; [McFadden, Grant; Shi, Yixin] Arizona State Univ, Sch Life Sci, Tempe, AZ 85281 USA	Arizona State University; Arizona State University-Tempe; Tulane University; Tulane University; Arizona State University; Arizona State University-Tempe	Shi, YX; Kong, W (corresponding author), Arizona State Univ, Biodesign Ctr Immunotherapy Vaccines & Virotherap, Tempe, AZ 85281 USA.; Shi, YX (corresponding author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85281 USA.	yixin.shi@asu.edu; wei.kong@asu.edu			National Institutes of Health/National Cancer Institute [CA249517]; Arizona State University [5300]; National Institutes of Health National/Institute of Dental and Craniofacial [DE024607]	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Arizona State University; National Institutes of Health National/Institute of Dental and Craniofacial	This work was supported by grants National Institutes of Health/National Cancer Institute (CA249517 to WK); Arizona State University (Startup fund 5300 to WK); National Institutes of Health National/Institute of Dental and Craniofacial (DE024607 to YS and WK).	Adams S, 2010, BREAST CANCER RES TR, V124, P723, DOI 10.1007/s10549-010-1181-8; American Cancer Society, 2021, KEY STAT CHILDH CANC; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Beyaz S, 2016, NATURE, V531, P53, DOI 10.1038/nature17173; Birnbaum DJ, 2016, ONCOTARGET, V7, P71198, DOI 10.18632/oncotarget.11685; Cantilena S, 2011, ONCOTARGET, V2, P976, DOI 10.18632/oncotarget.410; Castagnoli L, 2019, ONCOGENE, V38, P4047, DOI 10.1038/s41388-019-0700-2; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Corda G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.69; Corda G, 2017, J PATHOL, V241, P350, DOI 10.1002/path.4841; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Dong PX, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00386; Du LY, 2020, J EXP MED, V217, DOI 10.1084/jem.20191115; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Finkbeiner SR, 2013, DIGEST DIS SCI, V58, P1176, DOI 10.1007/s10620-013-2620-2; FZD6, 2021, HUM PROT ATL; Garcia MI, 2009, DEV BIOL, V331, P58, DOI 10.1016/j.ydbio.2009.04.020; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; HASHIMOTO Y, 1993, AM J HEMATOL, V43, P319, DOI 10.1002/ajh.2830430420; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Kanwar SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-212; Kawai T, 2016, SCI REP-UK, V6, DOI 10.1038/srep30489; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lee Y, 2016, CLIN CANCER RES, V22, P3571, DOI 10.1158/1078-0432.CCR-15-2665; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Lin YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116711; Litviakov Nikolai, 2020, Oncotarget, V11, P1988, DOI 10.18632/oncotarget.27608; Liu Z, 2014, NEOPLASMA, V61, P177, DOI 10.4149/neo_2014_016; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Mansour FA, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1729299; Pearce DJ, 2005, STEM CELLS, V23, P752, DOI 10.1634/stemcells.2004-0292; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Shenoy AK, 2012, CANCER RES, V72, P5091, DOI 10.1158/0008-5472.CAN-12-1806; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Singh SK, 2003, CANCER RES, V63, P5821; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Tokuhara M, 1998, BIOCHEM BIOPH RES CO, V243, P622, DOI 10.1006/bbrc.1998.8143; Tong GL, 2019, CANCER MED-US, V8, P7044, DOI 10.1002/cam4.2542; Van Raay TJ, 2005, NEURON, V46, P23, DOI 10.1016/j.neuron.2005.02.023; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Wei F, 2019, CANCER LETT, V450, P1, DOI 10.1016/j.canlet.2019.02.022; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yang L, 2015, STEM CELLS, V33, P2913, DOI 10.1002/stem.2083; Yanheng W., 2017, CLIN EXP PHARM PHYSL, V44, P3; Yu WD, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2701-z; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Zheng AY, 2019, ONCOL REP, V41, P2833, DOI 10.3892/or.2019.7053	53	6	6	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1100	1113		10.1038/s41388-021-02144-2	http://dx.doi.org/10.1038/s41388-021-02144-2		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35034965				2022-12-28	WOS:000743007800001
J	Huang, WC; Yen, JH; Sung, YW; Tung, SL; Chen, PM; Chu, PY; Shih, YC; Chi, HC; Huang, YC; Huang, SJ; Wang, LH				Huang, Wei-Chieh; Yen, Jia-Hau; Sung, Yu-Wen; Tung, Shiao-Lin; Chen, Po-Ming; Chu, Pei-Yi; Shih, Ya-Chi; Chi, Hsiang-Cheng; Huang, Yi-Ching; Huang, Shih-Jei; Wang, Lu-Hai			Novel function of THEMIS2 in the enhancement of cancer stemness and chemoresistance by releasing PTP1B from MET	ONCOGENE			English	Article							PROTEIN-TYROSINE PHOSPHATASES; C-MET; CELLS; EXPRESSION; RECEPTOR; OVARIAN; ICB-1; ONCOGENE; PATHWAYS; TARGETS	Triple negative breast cancer (TNBC) possesses poor prognosis mainly due to lack of effective endocrine or targeted therapies, aggressive nature and high rate of chemoresistance. Cancer stem cells (CSCs) are considered to play critical roles in cancer recurrence and chemoresistance. THEMIS2 was identified as the sole common elevated gene in three triple negative breast cancer (TNBC) and two ovarian CSC lines. We discovered an intrinsic signaling scaffold function of THEMIS2, which acts as a novel regulator of cancer stemness in promoting multiple cancer stemness properties including sphere formation, stemness markers expression, chemoresistance and tumorigenicity with low numbers of cancer cells implantation. For the first time, we demonstrated that THEMIS2 specifically enhanced MET activating phosphorylation by suppressing the association of protein-tyrosine phosphatases 1B (PTP1B) with p-MET and MET, which accounted mainly for THEMIS2-mediated effect on cancer stemness and chemoresistance. Increased THEMIS2 expression was associated with poor survival in TNBC patients and in patients from our breast cancer cohort. We found that non-cytotoxic dosages of cryptotanshinone (CPT) could potently inhibit cancer stemness, chemoresistance and tumorigenicity by suppressing expression of THEMIS2. Notably, stable overexpression of THEMIS2 is associated with enhanced sensitivity toward Capmatinib and CPT treatment. Expression levels of THEMIS2 and p-MET protein were positively correlated in the 465 breast cancer specimens. Our study revealed the novel oncogenic role of THEMIS2 and its underlying mechanism via suppressing PTP1B association with MET and thus leading to its activation. Our findings suggest that THEMIS2 could be a biomarker for MET targeted therapy and also provide a potential clinical application using low dosages of CPT for treatment of THEMIS2 positive TNBC.	[Huang, Wei-Chieh; Chen, Po-Ming; Shih, Ya-Chi; Chi, Hsiang-Cheng; Huang, Yi-Ching; Huang, Shih-Jei; Wang, Lu-Hai] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Huang, Wei-Chieh; Shih, Ya-Chi; Chi, Hsiang-Cheng; Huang, Shih-Jei; Wang, Lu-Hai] China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan; [Yen, Jia-Hau] China Med Univ Hosp, Res Canc Ctr Tradit Chinese Med, Dept Med Res, Taichung, Taiwan; [Sung, Yu-Wen] China Med Univ Hosp, Dept Obstet & Gynecol, Taichung, Taiwan; [Tung, Shiao-Lin] Ton Yen Gen Hosp, Dept Hematol & Oncol, Zhubei City, Hsinchu County, Taiwan; [Tung, Shiao-Lin] Hsin Sheng Jr Coll Med Care & Management, Dept Nursing, Taoyuan, Taiwan; [Chu, Pei-Yi] Show Chwan Mem Hosp, Dept Pathol, Chung Shang Rd, Changhua, Changhua County, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Show Chwan Memorial Hospital	Wang, LH (corresponding author), China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.; Wang, LH (corresponding author), China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan.	luhaiwang@mail.cmu.edu.tw		Tung, Shiao-Lin/0000-0002-6241-6293	Ministry of Science and Technology, Taiwan [MOST 107-2320-B-039-059-MY3, MOST 107-2320-B-039-065, MOST 109-2320-B-039 -067, MOST 110-2320-B-039 -061]; China Medical University, Taiwan [CMU107-TU-11, CMU110-Z-06, CMU110-MF-26, CMU110-N-02]; "Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program within Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan [CMRC-CENTER-0]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); China Medical University, Taiwan(China Medical University); "Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program within Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan	This work were supported by the Ministry of Science and Technology, Taiwan (MOST 107-2320-B-039-059-MY3, MOST 107-2320-B-039-065, MOST 109-2320-B-039 -067, MOST 110-2320-B-039 -061), and China Medical University, Taiwan (CMU107-TU-11, CMU110-Z-06, CMU110-MF-26 and CMU110-N-02), and the "Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (CMRC-CENTER-0).	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Al Moustafa AE, 2013, CELL ADHES MIGR, V7, P424, DOI 10.4161/cam.26728; Bollmann J, 2008, J STEROID BIOCHEM, V109, P16, DOI 10.1016/j.jsbmb.2007.12.007; Chan SH, 2014, ONCOGENE, V33, P4496, DOI 10.1038/onc.2014.10; Cheng D, 2017, NAT IMMUNOL, V18, P205, DOI 10.1038/ni.3642; Cortazar P, 2019, LANCET, V393, P986; El Darsa Haidar, 2020, J Exp Pharmacol, V12, P349, DOI 10.2147/JEP.S242958; Firuzi O, 2019, CANCERS, V11, DOI 10.3390/cancers11050638; Garajova Ingrid, 2015, Transl Oncogenomics, V7, P13, DOI 10.4137/TOG.S30534; Hage C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.158; Hodgkinson CL, 2014, NAT MED, V20, P897, DOI 10.1038/nm.3600; Huang WC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1091-5; Huang X, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00152; Kakazu A, 2008, INVEST OPHTH VIS SCI, V49, P2927, DOI 10.1167/iovs.07-0709; Karamboulas C, 2013, BBA-GEN SUBJECTS, V1830, P2481, DOI 10.1016/j.bbagen.2012.11.008; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Konwisorz A, 2010, ENDOCR-RELAT CANCER, V17, P147, DOI 10.1677/ERC-09-0095; Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923; Lee GD, 2017, J THORAC ONCOL, V12, P1233, DOI 10.1016/j.jtho.2017.04.031; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Liang H, 2020, ONCOTARGETS THER, V13, P2491, DOI 10.2147/OTT.S231257; Liu XD, 2011, CLIN CANCER RES, V17, P7127, DOI 10.1158/1078-0432.CCR-11-1157; Luo Susan Y, 2013, Transl Respir Med, V1, P6, DOI 10.1186/2213-0802-1-6; Luvero D, 2014, THER ADV MED ONCOL, V6, P229, DOI 10.1177/1758834014544121; Matsumura A, 2013, INT J ONCOL, V42, P535, DOI 10.3892/ijo.2012.1728; Ng YP, 2006, J BIOL CHEM, V281, P15636, DOI 10.1074/jbc.M601863200; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; O'Conor CJ, 2018, BIOMARK MED, V12, P813, DOI 10.2217/bmm-2017-0398; O'Reilly EA, 2015, BBA CLIN, V3, P257, DOI 10.1016/j.bbacli.2015.03.003; Peirce MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011465; Riedmeier M, 2021, ARCH GYNECOL OBSTET, V304, P203, DOI 10.1007/s00404-020-05902-x; Sangwan V, 2011, J BIOL CHEM, V286, P45000, DOI 10.1074/jbc.M111.270934; Sangwan V, 2008, J BIOL CHEM, V283, P34374, DOI 10.1074/jbc.M805916200; Shin DS, 2009, CANCER RES, V69, P193, DOI 10.1158/0008-5472.CAN-08-2575; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Stoker AW, 2005, J ENDOCRINOL, V185, P19, DOI 10.1677/joe.1.06069; Treeck O, 2012, J CELL BIOCHEM, V113, P2979, DOI 10.1002/jcb.24175; Tung SL, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.25; Verma N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7064; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Wang H, 2017, ONCOL LETT, V14, P5890, DOI 10.3892/ol.2017.6959; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wolf J, 2020, NEW ENGL J MED, V383, P944, DOI 10.1056/NEJMoa2002787; Wu YL, 2021, CANCER TREAT REV, V95, DOI 10.1016/j.ctrv.2021.102173; Zagouri F, 2013, BRIT J CANCER, V108, P1100, DOI 10.1038/bjc.2013.31; Zhang Y, 2016, ONCOL LETT, V11, P3803, DOI 10.3892/ol.2016.4444	46	1	1	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					997	1010		10.1038/s41388-021-02136-2	http://dx.doi.org/10.1038/s41388-021-02136-2		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34974522	hybrid, Green Published			2022-12-28	WOS:000736941300001
J	Klimovich, B; Merle, N; Neumann, M; Elmshauser, S; Nist, A; Mernberger, M; Kazdal, D; Stenzinger, A; Timofeev, O; Stiewe, T				Klimovich, Boris; Merle, Nastasja; Neumann, Michelle; Elmshaeuser, Sabrina; Nist, Andrea; Mernberger, Marco; Kazdal, Daniel; Stenzinger, Albrecht; Timofeev, Oleg; Stiewe, Thorsten			p53 partial loss-of-function mutations sensitize to chemotherapy	ONCOGENE			English	Article							CELL-CYCLE ARREST; DNA-BINDING COOPERATIVITY; MUTANT P53; TUMOR SUPPRESSION; APOPTOTIC RESPONSE; CANCER; TUMORIGENESIS; ACTIVATION; MDM2; RECOGNITION	The tumor suppressive transcription factor p53 is frequently inactivated in cancer cells by missense mutations that cluster in the DNA binding domain. 30% hit mutational hotspot residues, resulting in a complete loss of transcriptional activity and mutant p53-driven chemotherapy resistance. Of the remaining 70% of non-hotspot mutants, many are partial loss-of-function (partial-LOF) mutants with residual transcriptional activity. The therapeutic consequences of a partial-LOF have remained largely elusive. Using a p53 mutation engineered to reduce DNA binding, we demonstrate that partial-LOF is sufficient to enhance oncogene-driven tumorigenesis in mouse models of lung and pancreatic ductal adenocarcinoma and acute myeloid leukemia. Interestingly, mouse and human tumors with partial-LOF mutations showed mutant p53 protein accumulation similar as known for hotspot mutants. Different from the chemotherapy resistance caused by p53-loss, the partial-LOF mutant sensitized to an apoptotic chemotherapy response and led to a survival benefit. Mechanistically, the pro-apoptotic transcriptional activity of mouse and human partial-LOF mutants was rescued at high mutant protein levels, suggesting that accumulation of partial-LOF mutants enables the observed apoptotic chemotherapy response. p53 non-hotspot mutants with partial-LOF, therefore, represent tumorigenic p53 mutations that need to be distinguished from other mutations because of their beneficial impact on survival in a therapy context.	[Klimovich, Boris; Merle, Nastasja; Neumann, Michelle; Elmshaeuser, Sabrina; Mernberger, Marco; Timofeev, Oleg; Stiewe, Thorsten] Univ Giessen & Marburg Lung Ctr UGMLC, Inst Mol Oncol, Marburg, Germany; [Klimovich, Boris; Merle, Nastasja; Neumann, Michelle; Elmshaeuser, Sabrina; Mernberger, Marco; Timofeev, Oleg; Stiewe, Thorsten] Philipps Univ, German Ctr Lung Res DZL, Marburg, Germany; [Nist, Andrea; Stiewe, Thorsten] Philipps Univ, Genom Core Facil, Marburg, Germany; [Kazdal, Daniel; Stenzinger, Albrecht] Heidelberg Univ Hosp, Translat Lung Res Ctr Heidelberg TLRC H, Inst Pathol, Heidelberg, Germany; [Kazdal, Daniel; Stenzinger, Albrecht] German Ctr Lung Res DZL, Heidelberg, Germany	Philipps University Marburg; Philipps University Marburg; Ruprecht Karls University Heidelberg	Timofeev, O; Stiewe, T (corresponding author), Univ Giessen & Marburg Lung Ctr UGMLC, Inst Mol Oncol, Marburg, Germany.; Timofeev, O; Stiewe, T (corresponding author), Philipps Univ, German Ctr Lung Res DZL, Marburg, Germany.; Stiewe, T (corresponding author), Philipps Univ, Genom Core Facil, Marburg, Germany.		Kazdal, Daniel/ABG-7629-2020	Kazdal, Daniel/0000-0001-8187-3281; Merle, Nastasja/0000-0003-4957-8463; Timofeev, Oleg/0000-0002-3114-6403; Stiewe, Thorsten/0000-0003-0134-7826	Projekt DEAL	Projekt DEAL	Open Access funding enabled and organized by Projekt DEAL.	Abbas HA, 2010, CELL STEM CELL, V7, P606, DOI 10.1016/j.stem.2010.09.013; Andreeff M, 2016, CLIN CANCER RES, V22, P868, DOI 10.1158/1078-0432.CCR-15-0481; Blanden AR, 2020, ELIFE, V9, DOI [10.7554/eLife.61487, 10.7594/eLife.61487]; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dehner A, 2005, ANGEW CHEM INT EDIT, V44, P5247, DOI 10.1002/anie.200501887; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 2019, CELL REP, V28, P1370, DOI 10.1016/j.celrep.2019.07.001; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Giacomelli AO, 2018, NAT GENET, V50, P1381, DOI 10.1038/s41588-018-0204-y; Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027; Joerger AC, 2008, ANNU REV BIOCHEM, V77, P557, DOI 10.1146/annurev.biochem.77.060806.091238; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Kitayner M, 2010, NAT STRUCT MOL BIOL, V17, P423, DOI 10.1038/nsmb.1800; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Klimovich B, 2020, CELL CYCLE, V19, P109, DOI 10.1080/15384101.2019.1693748; Kotler E, 2018, MOL CELL, V71, P178, DOI 10.1016/j.molcel.2018.06.012; Kracikova M, 2013, CELL DEATH DIFFER, V20, P576, DOI 10.1038/cdd.2012.155; Leroy B, 2014, HUM MUTAT, V35, P672, DOI 10.1002/humu.22552; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Mellert H, 2013, CELL REP, V3, P1335, DOI 10.1016/j.celrep.2013.05.011; Mello SS, 2018, CURR OPIN CELL BIOL, V51, P65, DOI 10.1016/j.ceb.2017.11.005; Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506; Menendez D, 2006, MOL CELL BIOL, V26, P2297, DOI 10.1128/MCB.26.6.2297-2308.2006; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Paek AL, 2016, CELL, V165, P631, DOI 10.1016/j.cell.2016.03.025; Post SM, 2010, ONCOGENE, V29, P1260, DOI 10.1038/onc.2009.423; Purvis JE, 2012, SCIENCE, V336, P1440, DOI 10.1126/science.1218351; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010; Robles AI, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026294; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sabapathy K, 2018, NAT REV CLIN ONCOL, V15, P13, DOI 10.1038/nrclinonc.2017.151; Schlereth K, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003726; Schlereth K, 2010, MOL CELL, V38, P356, DOI 10.1016/j.molcel.2010.02.037; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Stiewe T, 2018, DRUG RESIST UPDATE, V38, P27, DOI 10.1016/j.drup.2018.05.001; Terzian T, 2007, MOL CELL BIOL, V27, P5479, DOI 10.1128/MCB.00555-06; Timofeev O, 2021, CANCERS, V13, DOI 10.3390/cancers13102422; Timofeev O, 2020, CANCER RES, V80, P5231, DOI 10.1158/0008-5472.CAN-20-2002; Timofeev O, 2019, EMBO J, V38, DOI 10.15252/embj.2019102096; Timofeev O, 2013, CELL REP, V3, P1512, DOI 10.1016/j.celrep.2013.04.008; Tiwari B, 2020, GENE DEV, V34, P1439, DOI 10.1101/gad.343186.120; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Zuber J, 2009, GENE DEV, V23, P877, DOI 10.1101/gad.1771409	56	10	10	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1011	1023		10.1038/s41388-021-02141-5	http://dx.doi.org/10.1038/s41388-021-02141-5		DEC 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34907344	hybrid, Green Published			2022-12-28	WOS:000730070200002
J	Seo, SU; Woo, SM; Kim, S; Park, JW; Lee, HS; Bae, YS; Kim, SH; Im, SS; Seo, JH; Min, KJ; Kwon, TK				Seo, Seung Un; Woo, Seon Min; Kim, Shin; Park, Jong-Wook; Lee, Hyun-Shik; Bae, Young-Seuk; Kim, Sang Hyun; Im, Seung-Soon; Seo, Ji Hae; Min, Kyoung-Jin; Kwon, Taeg Kyu			Inhibition of cathepsin K sensitizes oxaliplatin-induced apoptotic cell death by Bax upregulation through OTUB1-mediated p53 stabilization in vitro and in vivo	ONCOGENE			English	Article							TUMOR-SUPPRESSOR P53; MEMBRANE PERMEABILIZATION; EXPRESSION; BCL-2	Cathepsin K is highly expressed in various types of cancers. However, the effect of cathepsin K inhibition in cancer cells is not well characterized. Here, cathepsin K inhibitor (odanacatib; ODN) and knockdown of cathepsin K (siRNA) enhanced oxaliplatin-induced apoptosis in multiple cancer cells through Bax upregulation. Bax knockdown significantly inhibited the combined ODN and oxaliplatin treatment-induced apoptotic cell death. Stabilization of p53 by ODN played a critical role in upregulating Bax expression at the transcriptional level. Casein kinase 2 (CK2)-dependent phosphorylation of OTUB1 at Ser16 played a critical role in ODN- and cathepsin K siRNA-mediated p53 stabilization. Interestingly, ODN-induced p53 and Bax upregulation were modulated by the production of mitochondrial reactive oxygen species (ROS). Mitochondrial ROS scavengers prevented OTUB1-mediated p53 stabilization and Bax upregulation by ODN. These in vitro results were confirmed by in mouse xenograft model, combined treatment with ODN and oxaliplatin significantly reduced tumor size and induced Bax upregulation. Furthermore, human renal clear carcinoma (RCC) tissues revealed a strong correlation between phosphorylation of OTUB1(Ser16) and p53/Bax expression. Our results demonstrate that cathepsin K inhibition enhances oxaliplatin-induced apoptosis by increasing OTUB1 phosphorylation via CK2 activation, thereby promoting p53 stabilization, and hence upregulating Bax.	[Seo, Seung Un; Woo, Seon Min; Kim, Shin; Park, Jong-Wook; Kwon, Taeg Kyu] Keimyung Univ, Sch Med, Dept Immunol, Daegu 42601, South Korea; [Lee, Hyun-Shik; Bae, Young-Seuk] Kyungpook Natl Univ, Coll Nat Sci, Sch Life Sci, BK21 Plus KNU Creat BioRes Grp, Daegu 41566, South Korea; [Kim, Sang Hyun] Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Daegu 41944, South Korea; [Im, Seung-Soon] Keimyung Univ, Sch Med, Dept Physiol, Daegu 42601, South Korea; [Seo, Ji Hae] Keimyung Univ, Sch Med, Dept Biochem, Daegu 42601, South Korea; [Min, Kyoung-Jin] Daegu Gyeongbuk Med Innovat Fdn DGMIF, New Drug Dev Ctr, Daegu 41061, South Korea; [Kwon, Taeg Kyu] Keimyung Univ, Ctr Forens Pharmaceut Sci, Daegu 42601, South Korea	Keimyung University; Kyungpook National University; Kyungpook National University; Keimyung University; Keimyung University; Keimyung University	Kwon, TK (corresponding author), Keimyung Univ, Sch Med, Dept Immunol, Daegu 42601, South Korea.; Kwon, TK (corresponding author), Keimyung Univ, Ctr Forens Pharmaceut Sci, Daegu 42601, South Korea.	kwontk@dsmc.or.kr						Ashton TM, 2018, CLIN CANCER RES, V24, P2482, DOI 10.1158/1078-0432.CCR-17-3070; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Brooks CL, 2004, CELL CYCLE, V3, P895; Dai R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00433; Grabowska UB, 2005, CURR OPIN DRUG DISC, V8, P619; Gu XY, 2019, EUR J PHARMACOL, V858, DOI 10.1016/j.ejphar.2019.05.011; Herhaus L, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa0441; Hock AK, 2014, BBA-MOL CELL RES, V1843, P137, DOI 10.1016/j.bbamcr.2013.05.022; Kim S, 2019, CANCERS, V11, DOI 10.3390/cancers11030344; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Leusink FK, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4315-8; Liang WP, 2019, J CANCER RES CLIN, V145, P1999, DOI 10.1007/s00432-019-02950-y; Mauri G, 2020, CANCER TREAT REV, V91, DOI 10.1016/j.ctrv.2020.102112; Min KJ, 2020, TOXICOL RES-GER, V36, P167, DOI 10.1007/s43188-019-00025-1; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Petermann I, 2006, FASEB J, V20, P1266, DOI 10.1096/fj.05-5517fje; Saldana M, 2019, ENDOCR-RELAT CANCER, V26, pR1, DOI 10.1530/ERC-18-0264; Seo BR, 2017, ANTIOXID REDOX SIGN, V27, P215, DOI 10.1089/ars.2016.6749; Seo J, 2018, ONCOGENE, V37, P4994, DOI 10.1038/s41388-018-0323-z; Seo SU, 2020, REDOX BIOL, V30, DOI 10.1016/j.redox.2019.101422; Seo SU, 2018, ONCOGENE, V37, P5205, DOI 10.1038/s41388-018-0345-6; Simpson D, 2003, DRUGS, V63, P2127, DOI 10.2165/00003495-200363190-00013; Sun XX, 2012, EMBO J, V31, P576, DOI 10.1038/emboj.2011.434; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Tsukuba T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082415; Verbovsek U, 2015, SEMIN CANCER BIOL, V35, P71, DOI 10.1016/j.semcancer.2015.08.010; Wiener R, 2013, NAT STRUCT MOL BIOL, V20, P1033, DOI 10.1038/nsmb.2655; Wiener R, 2012, NATURE, V483, P618, DOI 10.1038/nature10911; Yang H, 2020, MOLECULES, V25, DOI 10.3390/molecules25184136; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; ZHAN QM, 1994, ONCOGENE, V9, P3743	32	2	2	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					550	559		10.1038/s41388-021-02088-7	http://dx.doi.org/10.1038/s41388-021-02088-7		NOV 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785775	Green Published, hybrid			2022-12-28	WOS:000719277200002
J	Cicek, E; Circir, A; Oyken, M; Caliskan, OA; Dioken, DN; Ergun, SG; Cetin-Atalay, R; Sapmaz, A; Ovaa, H; Sahin, O; Erson-Bensan, AE				Cicek, Esra; Circir, Ayca; Oyken, Merve; Caliskan, Ozge Akbulut; Dioken, Didem Naz; Ergun, Sezen Guntekin; Cetin-Atalay, Rengul; Sapmaz, Aysegul; Ovaa, Huib; Sahin, Ozgur; Erson-Bensan, Ayse Elif			EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; UP-REGULATION; RETROGRADE TRANSPORT; DEGRADATION; RETROMER; EGFR; TRAFFICKING; EXPRESSION; INHIBITOR; EFFICACY	Epidermal growth factor receptor (EGFR) has critical roles in epithelial cell physiology. Over-expression and over-activation of EGFR have been implicated in diverse cancers, including triple-negative breast cancers (TNBCs), prompting anti-EGFR therapies. Therefore, developing potent therapies and addressing the inevitable drug resistance mechanisms necessitates deciphering of EGFR related networks. Here, we describe Sorting Nexin 3 (SNX3), a member of the recycling retromer complex, as a critical player in the epidermal growth factor (EGF) stimulated EGFR network in TNBCs. We show that SNX3 is an immediate and sustained target of EGF stimulation initially at the protein level and later at the transcriptional level, causing increased SNX3 abundance. Using a proximity labeling approach, we observed increased interaction of SNX3 and EGFR upon EGF stimulation. We also detected colocalization of SNX3 with early endosomes and endocytosed EGF. Moreover, we show that EGFR protein levels are sensitive to SNX3 loss. Transient RNAi models of SNX3 downregulation have a temporary reduction in EGFR levels. In contrast, long-term silencing forces cells to recover and overexpress EGFR mRNA and protein, resulting in increased proliferation, colony formation, migration, invasion in TNBC cells, and increased tumor growth and metastasis in syngeneic models. Consistent with these results, low SNX3 and high EGFR mRNA levels correlate with poor relapse-free survival in breast cancer patients. Overall, our results suggest that SNX3 is a critical player in the EGFR network in TNBCs with implications for other cancers dependent on EGFR activity.	[Cicek, Esra; Circir, Ayca; Oyken, Merve; Dioken, Didem Naz; Erson-Bensan, Ayse Elif] Middle East Tech Univ METU, Dept Biol Sci, Dumlupinar Blv 1,Universiteler Mah, TR-06800 Ankara, Turkey; [Oyken, Merve; Sapmaz, Aysegul; Ovaa, Huib] Leiden Univ, Oncode Inst, Med Ctr, Einthovenweg 20, NL-2333 ZC Leiden, Netherlands; [Oyken, Merve; Sapmaz, Aysegul; Ovaa, Huib] Leiden Univ, Dept Cell & Chem Biol, Med Ctr, Einthovenweg 20, NL-2333 ZC Leiden, Netherlands; [Caliskan, Ozge Akbulut] Bilkent Univ, Dept Mol Biol & Genet, TR-06800 Ankara, Turkey; [Ergun, Sezen Guntekin; Cetin-Atalay, Rengul; Erson-Bensan, Ayse Elif] Middle East Tech Univ, Grad Sch Informat, Canc Syst Biol Lab, CanSyL, TR-06800 Ankara, Turkey; [Sahin, Ozgur] Univ South Carolina, Coll Pharm, Drug Discovery & Biomed Sci, Columbia, SC 29208 USA	Middle East Technical University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ihsan Dogramaci Bilkent University; Middle East Technical University; University of South Carolina System; University of South Carolina Columbia	Erson-Bensan, AE (corresponding author), Middle East Tech Univ METU, Dept Biol Sci, Dumlupinar Blv 1,Universiteler Mah, TR-06800 Ankara, Turkey.	erson@metu.edu.tr	Akbulut Çalışkan, Özge/Q-8134-2018; Erson-Bensan, AYSE ELIF/L-7229-2018; DIOKEN, Didem Naz/AAE-7962-2022; Sahin, Ozgur/F-4403-2014	Akbulut Çalışkan, Özge/0000-0002-3647-1969; Erson-Bensan, AYSE ELIF/0000-0001-7398-9313; Sahin, Ozgur/0000-0002-8033-7089; Sapmaz, Aysegul/0000-0003-3942-7602; DIOKEN, Didem Naz/0000-0001-8285-8147	TUBITAK [116Z257, 119Z672]; EMBO short term fellowship; National Institutes of Health [2P20GM109091-06, 1R01CA251374-01A1]; Turkish Ministry of Development project [KanSil 2016K121540]	TUBITAK(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); EMBO short term fellowship(European Molecular Biology Organization (EMBO)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Turkish Ministry of Development project	We thank current and past members of the laboratory for critical reading of the manuscript and discussions. We thank METABRIC Consortium for sharing the breast cancer data. TUBITAK 116Z257 (AEEB), and 119Z672 (EC). EMBO short term fellowship (MO). National Institutes of Health Grant 2P20GM109091-06 (OS), 1R01CA251374-01A1 (OS). The Turkish Ministry of Development project #KanSil 2016K121540 (CanSyL).	Akhavantabasi S, 2012, CELL STRUCT FUNCT, V37, P27; Akman BH, 2012, NUCLEIC ACIDS RES, V40, P10679, DOI 10.1093/nar/gks855; Akman HB, 2015, HUM MOL GENET, V24, P6910, DOI 10.1093/hmg/ddv391; Ali R, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.42; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Arighi CN, 2004, J CELL BIOL, V165, P123, DOI 10.1083/jcb.200312055; Bag N, 2015, BIOPHYS J, V109, P1925, DOI 10.1016/j.bpj.2015.09.007; Bakker J, 2017, J CELL SCI, V130, P4087, DOI 10.1242/jcs.209197; Brzozowska B, 2019, RADIAT ENVIRON BIOPH, V58, P109, DOI 10.1007/s00411-018-00772-z; Burd C, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016774; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Cavet ME, 2008, FASEB J, V22, P3607, DOI 10.1096/fj.07-094086; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307; Chiow KH, 2012, CELL MOL LIFE SCI, V69, P1505, DOI 10.1007/s00018-011-0887-z; Choi JH, 2004, J CELL SCI, V117, P4209, DOI 10.1242/jcs.01233; Ciuffreda L, 2009, NEOPLASIA, V11, P720, DOI 10.1593/neo.09398; Crowley Lisa C, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087171; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dickler MN, 2009, BREAST CANCER RES TR, V115, P115, DOI 10.1007/s10549-008-0055-9; Erfani P, 2015, EPIGENETICS-US, V10, P496, DOI 10.1080/15592294.2015.1042645; Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003; Franovic A, 2007, P NATL ACAD SCI USA, V104, P13092, DOI 10.1073/pnas.0702387104; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Golan-Lavi R, 2017, CELL REP, V18, P3129, DOI 10.1016/j.celrep.2017.03.014; Gullapalli A, 2004, MOL BIOL CELL, V15, P2143, DOI 10.1091/mbc.E03-09-0711; Harterink M, 2011, NAT CELL BIOL, V13, P914, DOI 10.1038/ncb2281; Heesom, 2013, NAT CELL BIOL, V15, P821; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Horibe T, 2014, LUMINESCENCE, V29, P96, DOI 10.1002/bio.2508; Huang YL, 2018, CANCER MANAG RES, V10, P545, DOI 10.2147/CMAR.S142650; Hwang SG, 2005, J BIOL CHEM, V280, P12758, DOI 10.1074/jbc.M413367200; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01854-0; Liu H, 2006, BIOCHEM BIOPH RES CO, V342, P537, DOI 10.1016/j.bbrc.2006.01.179; Lu J, 2021, CELL DEATH DIFFER, V28, P2871, DOI 10.1038/s41418-021-00789-w; Lucas M, 2016, CELL, V167, P1623, DOI 10.1016/j.cell.2016.10.056; Lurje G, 2009, ONCOLOGY-BASEL, V77, P400, DOI 10.1159/000279388; Masuda Hiroko, 2012, Breast Cancer Res Treat, V136, P331, DOI 10.1007/s10549-012-2289-9; McGough IJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06114-3; Miller HE, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007005; Nishi H, 2002, CANCER RES, V62, P827; Pan BR, 2019, ONCOL LETT, V18, P5332, DOI 10.3892/ol.2019.10860; Park HS, 2014, MODERN PATHOL, V27, P1212, DOI 10.1038/modpathol.2013.251; Pons V, 2008, PLOS BIOL, V6, P1942, DOI 10.1371/journal.pbio.0060214; Priya A, 2017, J CELL SCI, V130, P2707, DOI 10.1242/jcs.201905; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Rimawi MF, 2010, CANCER-AM CANCER SOC, V116, P1234, DOI 10.1002/cncr.24816; SAINSBURY JRC, 1987, LANCET, V1, P1398; Sapmaz A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09437-x; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Shinde SR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10689; Singh Bhuminder, 2016, F1000Res, V5, DOI 10.12688/f1000research.9025.1; Strochlic TI, 2007, J CELL BIOL, V177, P115, DOI 10.1083/jcb.200609161; Temkin P, 2011, NAT CELL BIOL, V13, P715, DOI 10.1038/ncb2252; van Weering JRT, 2012, EMBO J, V31, P4466, DOI 10.1038/emboj.2012.283; Vardarajan BN, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2012.04.020; Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zeisel A, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.62; Zhang P, 2011, CELL RES, V21, P1677, DOI 10.1038/cr.2011.167	65	2	2	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					220	232		10.1038/s41388-021-02086-9	http://dx.doi.org/10.1038/s41388-021-02086-9		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34718348	Green Published, Green Accepted			2022-12-28	WOS:000712941800003
J	Liu, WX; Gou, HY; Wang, XH; Li, XM; Hu, XX; Su, H; Li, SM; Yu, J				Liu, Wenxiu; Gou, Hongyan; Wang, Xiaohong; Li, Xiaoming; Hu, Xiaoxu; Su, Hao; Li, Shengmian; Yu, Jun			TTPAL promotes gastric tumorigenesis by directly targeting NNMT to activate PI3K/AKT signaling	ONCOGENE			English	Article							CANCER	Copy number alterations are crucial for gastric cancer (GC) development. In this study, Tocopherol alpha transfer protein-like (TTPAL) was identified to be highly amplified in our primary GC cohort (30/86). Multivariate analysis showed that high TTPAL expression was correlated with the poor prognosis of GC patients. Ectopic expression of TTPAL promoted GC cell proliferation, migration, and invasion in vitro and promoted murine xenograft tumor growth and lung metastasis in vivo. Conversely, silencing of TTPAL exerted significantly opposite effects in vitro. Moreover, RNA-sequencing and co-immunoprecipitation (Co-IP) followed by liquid chromatograph-mass spectrometry (LC-MS) identified that TTPAL exerted oncogenic functions via the interaction of Nicotinamide-N-methyl transferase (NNMT) and activated PI3K/AKT signaling pathway. Collectively, TTPAL plays a pivotal oncogenic role in gastric carcinogenesis through promoting PI3K/AKT pathway via cooperating with NNMT. TTPAL may serve as a prognostic biomarker of patients with GC.	[Liu, Wenxiu; Gou, Hongyan; Wang, Xiaohong; Hu, Xiaoxu; Su, Hao; Yu, Jun] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Liu, Wenxiu; Li, Xiaoming; Li, Shengmian] Hebei Med Univ, Dept Gastroenterol & Hepatol, Hosp 4, Shijiazhuang, Hebei, Peoples R China; [Gou, Hongyan; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China; [Gou, Hongyan; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China	Chinese University of Hong Kong, Shenzhen; Hebei Medical University; Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.; Li, SM (corresponding author), Hebei Med Univ, Dept Gastroenterol & Hepatol, Hosp 4, Shijiazhuang, Hebei, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China.	shengmianli2013@163.com; junyu@cuhk.edu.hk	Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153	Science and Technology Program Grant Shenzhen [JCYJ20 180307151253271, JCY20190814170401660]; RGC Collaborative Research Fund [C4039-19GF, C7065-18GF]; Hebei province's special fund for introducing intelligence project [2527005]; RGC-GRF Hong Kong [14163817]; Natural Science Foundation of Guangdong Province [2019A1515011218]; Vice-Chancellor's Discretionary Fund Chinese University of Hong Kong	Science and Technology Program Grant Shenzhen; RGC Collaborative Research Fund(Hong Kong Research Grants Council); Hebei province's special fund for introducing intelligence project; RGC-GRF Hong Kong(Hong Kong Research Grants Council); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Vice-Chancellor's Discretionary Fund Chinese University of Hong Kong	Science and Technology Program Grant Shenzhen (JCYJ20 180307151253271 and JCY20190814170401660); RGC Collaborative Research Fund (C4039-19GF, C7065-18GF), Hebei province's special fund for introducing intelligence project (2527005); RGC-GRF Hong Kong (14163817); Natural Science Foundation of Guangdong Province (2019A1515011218). Vice-Chancellor's Discretionary Fund Chinese University of Hong Kong.	Akar S, 2019, TURK J MED SCI, V49, P1547, DOI 10.3906/sag-1907-166; Asplund J, 2018, ANN SURG ONCOL, V25, P2693, DOI 10.1245/s10434-018-6627-y; Belletti B, 2015, AGING-US, V7, P529, DOI 10.18632/aging.100786; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Calderwood SK, 2016, TRENDS BIOCHEM SCI, V41, P311, DOI 10.1016/j.tibs.2016.01.003; Cao HY, 2020, EUR REV MED PHARMACO, V24, P11468, DOI [10.26355/eurrev_202011_23761, 10.26355/eurrev_202011_23759]; Chen HR, 2019, THERANOSTICS, V9, P5246, DOI 10.7150/thno.34713; Chivu-Economescu M, 2018, WORLD J GASTROENTERO, V24, P1942, DOI 10.3748/wjg.v24.i18.1942; Della Peruta M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-61; Fatima V, 2020, CANCERS, V12, P880; Fu QF, 2017, CLIN CANCER RES, V23, P6336, DOI 10.1158/1078-0432.CCR-16-2813; Gou HY, 2019, CANCER RES, V79, P3332, DOI 10.1158/0008-5472.CAN-18-2986; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Kimura Y, 2004, MODERN PATHOL, V17, P1328, DOI 10.1038/modpathol.3800180; Palanichamy K, 2017, CLIN CANCER RES, V23, P2325, DOI 10.1158/1078-0432.CCR-16-1323; Pentimalli F, 2018, ONCOGENE, V37, P3657, DOI 10.1038/s41388-018-0214-3; Qiao JL, 2016, ONCOTARGET, V7, P46088, DOI 10.18632/oncotarget.10024; Qin J, 2012, CURR OPIN CELL BIOL, V24, P607, DOI 10.1016/j.ceb.2012.06.003; Tang JT, 2018, ONCOGENE, V37, P3006, DOI 10.1038/s41388-018-0196-1; Zhang L, 2019, ONCOGENE, V38, P4590, DOI 10.1038/s41388-019-0743-4	21	5	5	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6666	6679		10.1038/s41388-021-01838-x	http://dx.doi.org/10.1038/s41388-021-01838-x		OCT 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34642500	Green Published, hybrid			2022-12-28	WOS:000706593200002
J	Zhang, JW; Zhai, JN; Wong, CC; Chen, HR; Wang, XH; Ji, JF; Yu, J				Zhang, Jingwan; Zhai, Jianning; Wong, Chi Chun; Chen, Huarong; Wang, Xiaohong; Ji, Jiafu; Yu, Jun			A novel amplification gene PCI domain containing 2 (PCID2) promotes colorectal cancer through directly degrading a tumor suppressor promyelocytic leukemia (PML)	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CADHERIN EXPRESSION; CELL; ONCOGENE; CLEAVAGE; PATHWAY; DAMAGE	Using whole genome sequencing, PCI Domain Containing 2 (PCID2) was identified to be amplified in colorectal cancer (CRC). In this study, we investigated the expression, biological function, molecular mechanism, and clinical implication of PCID2 in CRC. PCID2 mRNA and protein expression were higher in CRC cells and tumor tissues compared to healthy colonic tissues. The copy number of PCID2 was positively correlated with its mRNA expression. Multivariate analysis revealed that PCID2 is an independent prognostic factor for CRC recurrence. Functional studies showed that PCID2 promoted cell growth, cell cycle progression, and cell migration/invasion, while apoptosis was suppressed. Moreover, PCID2 promoted xenograft growth and lung metastasis in nude mice. Using co-immunoprecipitation and mass spectroscopy, we showed that PCID2 binds to promyelocytic leukemia (PML), a tumor suppressor involved in non-canonical beta-catenin signaling. PCID2 promoted the degradation of PML via poly-ubiquitination, which in turn, induced Wnt/beta-catenin signaling while simultaneously repressing ARF-p53 pathway. Thus, these results demonstrated that PCID2 functions as an oncogene in CRC by enhancing canonical Wnt/beta-catenin signaling and inhibition of CTNNB1-ARF-p53 axis. PCID2 promoted canonical Wnt/beta-catenin signaling in CRC via degradation of PML. PCID2 may serve as an independent prediction marker for CRC recurrence.	[Zhang, Jingwan; Zhai, Jianning; Wong, Chi Chun; Chen, Huarong; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst, Hong Kong, Peoples R China; [Zhang, Jingwan; Zhai, Jianning; Wong, Chi Chun; Chen, Huarong; Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst, Hong Kong, Peoples R China; [Wang, Xiaohong; Ji, Jiafu] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Chen, Huarong/ABZ-5810-2022; zhai, jianning/GSD-4306-2022; ZHANG, Jingwan/AIC-2560-2022; chen, huarong/ABH-8561-2020; Jun, Yu/D-8569-2015	zhai, jianning/0000-0002-8780-492X; chen, huarong/0000-0003-2192-1864; Jun, Yu/0000-0001-5008-2153; JI, JIAFU/0000-0001-6878-5543; Wong, Chi Chun/0000-0003-1362-3541; ZHANG, Jingwan/0000-0002-0344-3398	National Natural Science Foundation of China [81972576]; RGC-CRF Hong Kong [C4039-19GF, C7065-18GF]; RGC-GRF Hong Kong [14163817, 14110819]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); RGC-CRF Hong Kong; RGC-GRF Hong Kong(Hong Kong Research Grants Council)	This project was supported by National Natural Science Foundation of China (81972576), RGC-CRF Hong Kong (C4039-19GF, C7065-18GF), RGC-GRF Hong Kong (14163817, 14110819), Vice-Chancellor's Discretionary Fund CUHK.	ABULAFI AM, 1994, BRIT J SURG, V81, P7, DOI 10.1002/bjs.1800810106; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Calcagno DQ, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-141; Cancer Genome Atlas N., 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Erdem JS, 2016, J CANCER, V7, P512, DOI 10.7150/jca.13651; Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Harada K, 2000, ORAL ONCOL, V36, P3, DOI 10.1016/S1368-8375(99)00049-4; Kachnic LA, 1999, J BIOL CHEM, V274, P13111, DOI 10.1074/jbc.274.19.13111; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Loser T, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110157; Melchor L, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2456; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Norton N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153411; Salari K, 2012, P NATL ACAD SCI USA, V109, pE3196, DOI 10.1073/pnas.1206004109; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; Sasaki H, 2011, J THORAC ONCOL, V6, P15, DOI 10.1097/JTO.0b013e31820594f0; Schmidt H, 2005, MODERN PATHOL, V18, P638, DOI 10.1038/modpathol.3800326; Shtutman Michael, 2002, Cancer Research, V62, P5947; Stella A, 2007, CLIN GENET, V71, P130, DOI 10.1111/j.1399-0004.2007.00745.x; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wang YT, 2017, J CLIN INVEST, V127, P2982, DOI 10.1172/JCI89957; Xie T, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0042001, 10.1371/journal.pone.0047577]; Yang YM, 2015, ONCOGENE, V34, P2910, DOI 10.1038/onc.2014.218; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008	29	0	0	5	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6641	6652		10.1038/s41388-021-01941-z	http://dx.doi.org/10.1038/s41388-021-01941-z		OCT 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34625711	hybrid, Green Published			2022-12-28	WOS:000705760400003
J	Dunn, S; Eberlein, C; Yu, J; Gris-Oliver, A; Ong, SH; Yelland, U; Cureton, N; Staniszewska, A; McEwen, R; Fox, M; Pilling, J; Hopcroft, P; Coker, EA; Jaaks, P; Garnett, MJ; Isherwood, B; Serra, V; Davies, BR; Barry, ST; Lynch, JT; Yusa, K				Dunn, Shanade; Eberlein, Cath; Yu, Jason; Gris-Oliver, Albert; Ong, Swee Hoe; Yelland, Urs; Cureton, Natalie; Staniszewska, Anna; McEwen, Robert; Fox, Millie; Pilling, James; Hopcroft, Philip; Coker, Elizabeth A.; Jaaks, Patricia; Garnett, Mathew J.; Isherwood, Beverley; Serra, Violeta; Davies, Barry R.; Barry, Simon T.; Lynch, James T.; Yusa, Kosuke			AKT-mTORC1 reactivation is the dominant resistance driver for PI3K beta/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors	ONCOGENE			English	Article							AKT INHIBITOR; TUMORS; PI3K-ALPHA; COMBINATION; DISCOVERY; PATHWAY; MTORC1; CAPIVASERTIB; MULTICENTER; FULVESTRANT	The PI3K pathway is commonly activated in breast cancer, with PI3K-AKT pathway inhibitors used clinically. However, mechanisms that limit or enhance the therapeutic effects of PI3K-AKT inhibitors are poorly understood at a genome-wide level. Parallel CRISPR screens in 3 PTEN-null breast cancer cell lines identified genes mediating resistance to capivasertib (AKT inhibitor) and AZD8186 (PI3K beta inhibitor). The dominant mechanism causing resistance is reactivated PI3K-AKT-mTOR signalling, but not other canonical signalling pathways. Deletion of TSC1/2 conferred resistance to PI3K beta i and AKTi through mTORC1. However, deletion of PIK3R2 and INPPL1 drove specific PI3K beta i resistance through AKT. Conversely deletion of PIK3CA, ERBB2, ERBB3 increased PI3K beta i sensitivity while modulation of RRAGC, LAMTOR1, LAMTOR4 increased AKTi sensitivity. Significantly, we found that Mcl-1 loss enhanced response through rapid apoptosis induction with AKTi and PI3K beta i in both sensitive and drug resistant TSC1/2 null cells. The combination effect was BAK but not BAX dependent. The Mcl-1i + PI3K beta/AKTi combination was effective across a panel of breast cancer cell lines with PIK3CA and PTEN mutations, and delivered increased anti-tumor benefit in vivo. This study demonstrates that different resistance drivers to PI3K beta i and AKTi converge to reactivate PI3K-AKT or mTOR signalling and combined inhibition of Mcl-1 and PI3K-AKT has potential as a treatment strategy for PI3K beta i/AKTi sensitive and resistant breast tumours.	[Dunn, Shanade; Yu, Jason; Ong, Swee Hoe; Coker, Elizabeth A.; Jaaks, Patricia; Garnett, Mathew J.; Yusa, Kosuke] Wellcome Sanger Inst, Cambridge, England; [Dunn, Shanade; Staniszewska, Anna; McEwen, Robert; Fox, Millie; Davies, Barry R.; Barry, Simon T.; Lynch, James T.] AstraZeneca, Early Oncol, Biosci, Cambridge, England; [Eberlein, Cath; Yelland, Urs; Cureton, Natalie] AstraZeneca, Early Oncol, Biosci, Alderley Pk, England; [Gris-Oliver, Albert; Serra, Violeta] Vall dHebron Inst Oncol, Barcelona, Spain; [Pilling, James; Hopcroft, Philip; Isherwood, Beverley] AstraZeneca, Discovery Sci, Cambridge, England; [Yusa, Kosuke] Kyoto Univ, Inst Frontier Life & Med Sci, Kyoto, Japan; [Yu, Jason] Francis Crick Inst, Mol Biol Metab Lab, London, England	Wellcome Trust Sanger Institute; AstraZeneca; AstraZeneca; Vall d'Hebron Institut d'Oncologia (VHIO); AstraZeneca; Kyoto University; Francis Crick Institute	Yusa, K (corresponding author), Wellcome Sanger Inst, Cambridge, England.; Barry, ST (corresponding author), AstraZeneca, Early Oncol, Biosci, Cambridge, England.; Yusa, K (corresponding author), Kyoto Univ, Inst Frontier Life & Med Sci, Kyoto, Japan.	Simon.T.Barry@astrazeneca.com; k.yusa@infront.kyoto-u.ac.jp	Gris Oliver, Albert/AAL-6783-2021	Gris Oliver, Albert/0000-0003-1802-9541; Yu, Jason/0000-0001-5203-3603	Wellcome Trust [WT206194]; AstraZeneca	Wellcome Trust(Wellcome Trust); AstraZeneca(AstraZeneca)	This work was funded by the Wellcome Trust (WT206194) to KY and MJG and by AstraZeneca to KY, BRD, STB and JTL.	Balachander SB, 2020, CLIN CANCER RES, V26, P6535, DOI 10.1158/1078-0432.CCR-20-0863; Banerji U, 2018, CLIN CANCER RES, V24, P2050, DOI 10.1158/1078-0432.CCR-17-2260; Barlaam B, 2015, BIOORG MED CHEM LETT, V25, P5155, DOI 10.1016/j.bmcl.2015.10.002; Barlaam B, 2013, ACS MED CHEM LETT, V4, P742, DOI 10.1021/ml400146c; Bertucci F, 2019, NATURE, V569, P560, DOI 10.1038/s41586-019-1056-z; Cai YY, 2021, CANCER RES, V81, P2470, DOI 10.1158/0008-5472.CAN-20-3232; Cardoso F, 2020, ANN ONCOL, V31, P1623, DOI 10.1016/j.annonc.2020.09.010; Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Cortes I, 2012, P NATL ACAD SCI USA, V109, P11318, DOI 10.1073/pnas.1118138109; Cosentino K, 2022, MOL CELL, V82, P933, DOI 10.1016/j.molcel.2022.01.008; Costa C, 2020, CANCER DISCOV, V10, P72, DOI 10.1158/2159-8290.CD-18-0830; Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007; Crafter C, 2015, INT J ONCOL, V47, P446, DOI 10.3892/ijo.2015.3062; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies BR, 2015, MOL CANCER THER, V14, P2441, DOI 10.1158/1535-7163.MCT-15-0230; Davies BR, 2012, MOL CANCER THER, V11, P873, DOI 10.1158/1535-7163.MCT-11-0824-T; Elkabets M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005747; Faber AC, 2014, CANCER DISCOV, V4, P42, DOI 10.1158/2159-8290.CD-13-0315; Fizazi K, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.TPS178; Gris-Oliver A, 2020, CLIN CANCER RES, V26, P3720, DOI 10.1158/1078-0432.CCR-19-3324; Guichard SM, 2015, MOL CANCER THER, V14, P2508, DOI 10.1158/1535-7163.MCT-15-0365; Hancox U, 2015, MOL CANCER THER, V14, P48, DOI 10.1158/1535-7163.MCT-14-0406; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Hyman DM, 2017, J CLIN ONCOL, V35, P2251, DOI 10.1200/JCO.2017.73.0143; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jones RH, 2020, LANCET ONCOL, V21, P345, DOI 10.1016/S1470-2045(19)30817-4; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Kale J, 2018, EMBO REP, V19, DOI 10.15252/embr.201745235; Kim SB, 2017, LANCET ONCOL, V18, P1360, DOI 10.1016/S1470-2045(17)30450-3; Kingston Belinda, 2019, JCO Precis Oncol, V3, DOI 10.1200/PO.19.00130; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koike-Yusa H, 2014, NAT BIOTECHNOL, V32, P267, DOI 10.1038/nbt.2800; Lebok P, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1770-3; Lehar J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100116; Li M, 2018, CELL REP, V24, P489, DOI 10.1016/j.celrep.2018.06.027; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lin J, 2013, CLIN CANCER RES, V19, P1760, DOI 10.1158/1078-0432.CCR-12-3072; Lynch JT, 2018, MOL CANCER THER, V17, P2309, DOI 10.1158/1535-7163.MCT-18-0183; Millis SZ, 2016, JAMA ONCOL, V2, P1565, DOI 10.1001/jamaoncol.2016.0891; Millis SZ, 2015, CLIN BREAST CANCER, V15, P473, DOI 10.1016/j.clbc.2015.04.008; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Milton CK, 2020, MOL CANCER THER, V19, P1423, DOI 10.1158/1535-7163.MCT-19-1131; Mukherjee R, 2021, MOL CELL, V81, P708, DOI 10.1016/j.molcel.2021.01.033; Oliveira M, 2019, ANN ONCOL, V30, P1289, DOI 10.1093/annonc/mdz177; Pascual J, 2019, ANN ONCOL, V30, P1051, DOI 10.1093/annonc/mdz133; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Rahmani M, 2018, CANCER RES, V78, P3075, DOI 10.1158/0008-5472.CAN-17-3024; Rao L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16061-7; Ros S, 2020, CANCER CELL, V38, P516, DOI 10.1016/j.ccell.2020.08.016; Schmid P, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.00368; Schwartz S, 2015, CANCER CELL, V27, P109, DOI 10.1016/j.ccell.2014.11.008; Smyth LM, 2020, CLIN CANCER RES, V26, P3947, DOI 10.1158/1078-0432.CCR-19-3953; Sun L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0943-9; Tron AE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07551-w; Tzelepis K, 2016, CELL REP, V17, P1193, DOI 10.1016/j.celrep.2016.09.079; Verret B, 2019, ANN ONCOL, V30, P12, DOI 10.1093/annonc/mdz381; Vis DJ, 2016, PHARMACOGENOMICS, V17, P691, DOI 10.2217/pgs.16.15; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Weir HM, 2016, CANCER RES, V76, P3307, DOI 10.1158/0008-5472.CAN-15-2357; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111	61	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					5046	5060		10.1038/s41388-022-02482-9	http://dx.doi.org/10.1038/s41388-022-02482-9		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36241868	Green Published, hybrid			2022-12-28	WOS:000873991500002
J	Li, YH; Deng, YR; Zhao, YN; Zhang, W; Zhang, S; Zhang, L; Wang, BY; Xu, YY; Chen, S				Li, Yaohua; Deng, Yiran; Zhao, Yannan; Zhang, Wei; Zhang, Si; Zhang, Li; Wang, Biyun; Xu, Yingying; Chen, She			Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK	ONCOGENE			English	Article							FOCAL-ADHESION KINASE; GENE-EXPRESSION; TUMOR-SUPPRESSOR; MUTANT P53; MUTATIONS; STATISTICS; SURVIVAL; MOLECULES; PROTEINS; GROWTH	Metastasis of breast cancer represents the major reason for its poor prognosis, leading to high mortality. In breast cancer, a tumor suppressor gene TP53 is commonly mutated. TP53 mutation leads to an altered expression of various genes, an event that is associated with aggressive tumor and is a strong independent marker for survival. In this study, we identified a novel p53 target gene, immunoglobulin superfamily 9 (IGSF9). IGSF9 is generally down-regulated in breast cancer tissues. Loss of IGSF9 is associated with frequent metastasis and poor prognosis of breast cancer patients. Wild-type p53, but not R175H mutant, trans-activates the transcription of IGSF9 via binding to its promoter (-137 to -131 bp), inhibits epithelial-mesenchymal transition (EMT), consequently the inhibition of breast cancer cells migration and invasion. IGSF9 interacts with focal adhesion kinase (FAK) and inhibits FAK/AKT signaling activity. PND1186, FAK inhibitor, inhibits breast cancer metastasis induced by IGSF9 knockdown in vitro and in vivo. Taken together, IGSF9 is trans-activated by p53 and inhibits breast cancer metastasis by modulating FAK/AKT signaling pathway. IGSF9 could serve as a prognostic marker and potential therapeutic target for breast cancer.	[Li, Yaohua; Deng, Yiran; Zhao, Yannan; Zhang, Wei; Zhang, Si; Zhang, Li; Xu, Yingying; Chen, She] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, NHC Key Lab Glycoconjugate Res, 130 Dongan Rd, Shanghai 200032, Peoples R China; [Li, Yaohua; Zhao, Yannan; Wang, Biyun] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Med Oncol, 270 Dongan Rd, Shanghai 200032, Peoples R China; [Li, Yaohua] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Lab Med, Sch Med, Shanghai 200080, Peoples R China	Fudan University; Fudan University; Shanghai Jiao Tong University	Xu, YY; Chen, S (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, NHC Key Lab Glycoconjugate Res, 130 Dongan Rd, Shanghai 200032, Peoples R China.	yingyingxu@fudan.edu.cn; shechen@fudan.edu.cn		zhang, Si/0000-0002-5682-4995	National Natural Science Foundation of China (NSFC) [81772615, 81972294, 81772968]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	We thank Dr. Wenjiao Zeng from the Department of Pathology, School of Basic Medical Sciences, Fudan University, for technical assistance. This work was supported by the National Natural Science Foundation of China (NSFC) (81772615, 81972294, 81772968).	Bowden NA, 2007, HERED CANCER CLIN PR, V5, P79, DOI 10.1186/1897-4287-5-2-79; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Chang JW, 2018, ONCOGENE, V37, P4137, DOI 10.1038/s41388-018-0253-9; DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134; Dong PP, 2020, J HEPATOL, V73, P1446, DOI 10.1016/j.jhep.2020.06.027; Doudney K, 2002, GENOMICS, V79, P663, DOI 10.1006/geno.2002.6757; Duffy MJ, 2018, BREAST CANCER RES TR, V170, P213, DOI 10.1007/s10549-018-4753-7; Golubovskaya VM, 2007, INT REV CYTOL, V263, P103, DOI 10.1016/S0074-7696(07)63003-4; Hansen M, 2013, NEUROCHEM RES, V38, P1236, DOI 10.1007/s11064-013-0999-y; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kelkar MG, 2017, BREAST CANCER RES TR, V164, P603, DOI 10.1007/s10549-017-4297-2; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kim JH, 2008, TUMOR BIOL, V29, P41, DOI 10.1159/000132570; Lee BY, 2015, PHARMACOL THERAPEUT, V146, P132, DOI 10.1016/j.pharmthera.2014.10.001; Lee G, 2012, CANCER IMMUNOL IMMUN, V61, P89, DOI 10.1007/s00262-011-1088-1; Li DM, 2011, BREAST CANCER RES TR, V128, P7, DOI 10.1007/s10549-011-1499-x; Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Makrilia N, 2009, CANCER INVEST, V27, P1023, DOI 10.3109/07357900902769749; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Perrone C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228422; Press DJ, 2017, CLIN EXP METASTAS, V34, P457, DOI 10.1007/s10585-017-9871-9; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Schneider Christoph, 2003, Archives of Gynecology and Obstetrics, V269, P9, DOI 10.1007/s00404-002-0445-x; Shapira I, 2013, CRIT REV ONCOL HEMAT, V88, P284, DOI 10.1016/j.critrevonc.2013.05.003; Shi ZG, 2018, J ONCOL, V2018, DOI 10.1155/2018/2439527; Siegel Rebecca L, 2019, CA Cancer J Clin, V69, P7, DOI 10.3322/caac.21551; Sigal A, 2000, CANCER RES, V60, P6788; Silwal-Pandit L, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026252; Smith AP, 2005, CANCER BIOL THER, V4, P1018, DOI 10.4161/cbt.4.9.2165; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walsh C, 2010, CANCER BIOL THER, V9, P778, DOI 10.4161/cbt.9.10.11433; Wang XX, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100730; Watermann DO, 2005, BRIT J CANCER, V93, P694, DOI 10.1038/sj.bjc.6602744; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wu HJ, 2020, ONCOGENE, V39, P2539, DOI 10.1038/s41388-020-1162-2; Ye M, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01273-0; Zouq NK, 2009, J CELL SCI, V122, P357, DOI 10.1242/jcs.030478	49	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4658	4672		10.1038/s41388-022-02459-8	http://dx.doi.org/10.1038/s41388-022-02459-8		SEP 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36088502	hybrid, Green Published			2022-12-28	WOS:000852343800001
J	Zhang, T; Li, JJ; Yang, MK; Ma, XL; Wang, ZY; Ma, XJ; Sun, MX; Sun, W; Xu, J; Hua, YQ; Cal, ZD				Zhang, Tao; Li, Jingjie; Yang, Mengkai; Ma, Xinglong; Wang, Zhuoying; Ma, Xiaojun; Sun, Mengxiong; Sun, Wei; Xu, Jing; Hua, Yingqi; Cal, Zhengdong			CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma	ONCOGENE			English	Article							CANCER GROWTH; ER CHAPERONE; CDK7; PROTEIN; GRP78; KINASE; TRANSCRIPTION; CHEMOTHERAPY; INDUCTION; PATHWAY	Osteosarcoma derives from primitive bone-forming mesenchymal cells and is the most common primary bone malignancy. Therapeutic targeting of osteosarcoma has been unsuccessful; therefore, identifying novel osteosarcoma pathogenesis could offer new therapeutic options. CDK7 is a subunit within the general transcription factor TFIIH. We aim to explore the new mechanism by which CDK7 regulates osteosarcoma and our studies may provide new theoretical support for the use of CDK7 inhibitors in the treatment of osteosarcoma. Here, we investigate the molecular mechanism underlying the association between CDK7 and GRP78 in osteosarcoma. Specifically, we find that an E3 ubiquitin ligase TRIM21 binds and targets GRP78 for ubiquitination and degradation, whereas CDK7 phosphorylates GRP78 at T69 to inhibit TRIM21 recruitment, leading to GRP78 stabilization. Notably, a CDK7-specific inhibitor, THZ1, blunts osteosarcoma growth and metastasis. Combination treatment with CDK7 and GRP78 inhibitors yield additive effects on osteosarcoma growth and progression inhibition. Thus, simultaneous suppression of CDK7 and GRP78 activity represents a potential new approach for the treatment of osteosarcoma. In conclusion, the discovery of this previously unknown CDK7/GRP78 signaling axis provides the molecular basis and the rationale to target human osteosarcoma.	[Zhang, Tao; Yang, Mengkai; Ma, Xinglong; Wang, Zhuoying; Ma, Xiaojun; Sun, Mengxiong; Sun, Wei; Xu, Jing; Hua, Yingqi; Cal, Zhengdong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai Bone Tumor Inst,Dept Orthoped, Shanghai 200080, Peoples R China; [Li, Jingjie] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Precis Res Ctr Refractory Dis, Sch Med, Shanghai 200080, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, T; Hua, YQ; Cal, ZD (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai Bone Tumor Inst,Dept Orthoped, Shanghai 200080, Peoples R China.	zhangtaoabc@2008.sina.com; yhua@shsmu.edu.cn; caizhengdong@sjtu.edu.cn			NSFC [81874124]; Shanghai Science and Technology Committee Rising-Star Program [19QA1407200]	NSFC(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee Rising-Star Program	This work was supported by NSFC (81874124); Shanghai Science and Technology Committee Rising-Star Program (19QA1407200).	Bensimon A, 2011, FEBS LETT, V585, P1625, DOI 10.1016/j.febslet.2011.05.013; Cerezo M, 2016, CANCER CELL, V30, P183, DOI 10.1016/j.ccell.2016.06.007; Chang YW, 2016, ONCOGENE, V35, P1517, DOI 10.1038/onc.2015.214; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Cho YS, 2020, GENE DEV, V34, P53, DOI 10.1101/gad.333146.119; Du TD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10824-7; Ferrari S, 2015, EXPERT OPIN PHARMACO, V16, P2727, DOI 10.1517/14656566.2015.1102226; Gonzalez-Gronow M, 2006, CANCER RES, V66, P11424, DOI 10.1158/0008-5472.CAN-06-1721; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; Hu SH, 2019, CANCER RES, V79, P3479, DOI 10.1158/0008-5472.CAN-19-0119; Itou J, 2018, J BIOL CHEM, V293, P6556, DOI 10.1074/jbc.RA117.000245; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660; Lee JH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00906-9; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Lolli G, 2007, PROTEINS, V67, P1048, DOI 10.1002/prot.21370; Lolli G, 2009, NUCLEIC ACIDS RES, V37, P1260, DOI 10.1093/nar/gkn1061; Lu HS, 2018, NATURE, V558, P318, DOI 10.1038/s41586-018-0174-3; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Pan JA, 2016, MOL CELL, V62, P149, DOI 10.1016/j.molcel.2016.03.015; Patel H, 2018, MOL CANCER THER, V17, P1156, DOI 10.1158/1535-7163.MCT-16-0847; Qian Y, 2017, CANCER RES, V77, P1968, DOI 10.1158/0008-5472.CAN-16-1595; Rasool RU, 2019, CANCER DISCOV, V9, P1538, DOI 10.1158/2159-8290.CD-19-0189; Rosales JL, 2003, CELL PHYSIOL BIOCHEM, V13, P285, DOI 10.1159/000074543; Sava GP, 2020, CANCER METAST REV, V39, P805, DOI 10.1007/s10555-020-09885-8; Sava GP, 2020, ONCOGENE, V39, P651, DOI 10.1038/s41388-019-1008-y; Schachter MM, 2013, MOL CELL, V50, P250, DOI 10.1016/j.molcel.2013.04.003; Serra M, 2017, PHARMACOGENOMICS J, V17, P11, DOI 10.1038/tpj.2016.45; Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585-009-9259-6; Wang JQ, 2014, BREAST CANCER RES TR, V148, P279, DOI 10.1007/s10549-014-3165-6; Wang YC, 2013, J BIOL CHEM, V288, P9028, DOI 10.1074/jbc.M112.432005; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Wu ZC, 2016, SCI REP-UK, V6, DOI 10.1038/srep24611; Yang X, 2017, CANCER RES, V77, P1142, DOI 10.1158/0008-5472.CAN-16-1378; Yoo SA, 2012, J EXP MED, V209, P871, DOI 10.1084/jem.20111783; Yoshimi R, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/718237; Yuan J, 2017, CANCER RES, V77, P6614, DOI 10.1158/0008-5472.CAN-17-1143; Zhang HY, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3640; Zhang JJ, 2020, CLIN CANCER RES, V26, P2681, DOI 10.1158/1078-0432.CCR-19-1418; Zhang T, 2017, ONCOGENE, V36, P6627, DOI 10.1038/onc.2017.270; Zhang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06179-0; Zhang T, 2015, ELIFE, V4, DOI 10.7554/eLife.06734; Zhang Y, 2019, CLIN CANCER RES, V25, P6195, DOI 10.1158/1078-0432.CCR-18-3788	48	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4524	4536		10.1038/s41388-022-02446-z	http://dx.doi.org/10.1038/s41388-022-02446-z		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36042349				2022-12-28	WOS:000847653000001
J	Peng, HY; Nerreter, T; Mestermann, K; Wachter, J; Chang, J; Hudecek, M; Rader, C				Peng, Haiyong; Nerreter, Thomas; Mestermann, Katrin; Wachter, Jakob; Chang, Jing; Hudecek, Michael; Rader, Christoph			ROR1-targeting switchable CAR-T cells for cancer therapy	ONCOGENE			English	Article; Early Access							ANTIBODY-LIKE IMMUNORECEPTORS; CHIMERIC ANTIGEN RECEPTORS; AFFINITY; ROR1; TARGET; ACTIVATION; EXPRESSION; DESIGN; DOMAIN; RECRUITMENT	The success of chimeric antigen receptor T cell (CAR-T) therapy in the treatment of hematologic malignancies has prompted the development of numerous CAR-T technologies, including switchable CAR-T (sCAR-T) systems that combine a universal CAR-T with bispecific adapter proteins. Owing to their controllability and versatility, sCAR-Ts have received considerable attention. To explore the therapeutic utility of sCAR-Ts targeting the receptor tyrosine kinase ROR1, which is expressed in hematologic and solid malignancies, and to identify bispecific adaptor proteins that efficiently mediate universal CAR-T engagement, a panel of switches based on ROR1-targeting Fabs with different epitopes and affinities was compared in in vitro and in vivo models of ROR1-expressing cancers. For switches targeting overlapping or identical epitopes, potency correlated with affinity. Surprisingly, however, we identified a switch targeting a unique epitope with low affinity but mediating potent and selective antitumor activity in vitro and in vivo. Converted to a conventional CAR-T, the same anti-ROR1 mAb (324) outperformed a clinically investigated conventional CAR-T that is based on an anti-ROR1 mAb (R12) with similar to 200-fold higher affinity. Thus, demonstrating therapeutic utility on their own, sCAR-Ts also facilitate higher throughput screening for the identification of conventional CAR-T candidates for preclinical and clinical studies.	[Peng, Haiyong; Chang, Jing; Rader, Christoph] Univ Florida, Dept Immunol & Microbiol, Scripps Biomed Res, Jupiter, FL 33458 USA; [Nerreter, Thomas; Mestermann, Katrin; Wachter, Jakob; Hudecek, Michael] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany	State University System of Florida; University of Florida; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg	Peng, HY; Rader, C (corresponding author), Univ Florida, Dept Immunol & Microbiol, Scripps Biomed Res, Jupiter, FL 33458 USA.	h.peng@ufl.edu; c.rader@ufl.edu		peng, haiyong/0000-0003-0312-1337; Rader, Christoph/0000-0001-9955-3454	National Institutes of Health (NIH) [R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961, R21 CA263240]; Klorfine Foundation	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Klorfine Foundation	CR acknowledges support by National Institutes of Health (NIH) grants R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961, and R21 CA263240, and by the Klorfine Foundation.	Acevedo-Rocha CG, 2015, SCI REP-UK, V5, DOI 10.1038/srep10654; Arndt C, 2020, CANCERS, V12, DOI 10.3390/cancers12051302; Balakrishnan A, 2017, CLIN CANCER RES, V23, P3061, DOI 10.1158/1078-0432.CCR-16-2083; Baskar S, 2008, CLIN CANCER RES, V14, P396, DOI 10.1158/1078-0432.CCR-07-1823; Benmebarek MR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061283; Berger C, 2015, CANCER IMMUNOL RES, V3, P206, DOI 10.1158/2326-6066.CIR-14-0163; Cao Y, 2016, ANGEW CHEM INT EDIT, V55, P7520, DOI 10.1002/anie.201601902; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chmielewski M, 2004, J IMMUNOL, V173, P7647, DOI 10.4049/jimmunol.173.12.7647; Cho JH, 2018, CELL, V173, P1426, DOI 10.1016/j.cell.2018.03.038; Choi MY, 2018, CELL STEM CELL, V22, P951, DOI 10.1016/j.stem.2018.05.018; Dana H, 2021, ACTA PHARM SIN B, V11, P1129, DOI 10.1016/j.apsb.2020.10.020; Darowski D, 2019, MABS-AUSTIN, V11, P621, DOI 10.1080/19420862.2019.1596511; Dave H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052655; Depil S, 2020, NAT REV DRUG DISCOV, V19, P185, DOI 10.1038/s41573-019-0051-2; Feins S, 2019, AM J HEMATOL, V94, pS3, DOI 10.1002/ajh.25418; Ghorashian S, 2019, NAT MED, V25, P1408, DOI 10.1038/s41591-019-0549-5; Goydel RS, 2020, J BIOL CHEM, V295, P5995, DOI 10.1074/jbc.RA120.012791; Greenman R, 2021, MOL CANCER THER, V20, P872, DOI 10.1158/1535-7163.MCT-19-1109; Hojjat-Farsangi M, 2014, SEMIN CANCER BIOL, V29, P21, DOI 10.1016/j.semcancer.2014.07.005; Hombach AA, 2007, J IMMUNOL, V178, P4650, DOI 10.4049/jimmunol.178.7.4650; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Hoyos V, 2010, LEUKEMIA, V24, P1160, DOI 10.1038/leu.2010.75; Hudecek M, 2015, CANCER IMMUNOL RES, V3, P125, DOI 10.1158/2326-6066.CIR-14-0127; Hudecek M, 2013, CLIN CANCER RES, V19, P3153, DOI 10.1158/1078-0432.CCR-13-0330; Hudecek M, 2010, BLOOD, V116, P4532, DOI 10.1182/blood-2010-05-283309; Jayaraman J, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102931; Jensen MC, 2015, CURR OPIN IMMUNOL, V33, P9, DOI 10.1016/j.coi.2015.01.002; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kamrani A, 2019, EXPERT OPIN THER TAR, V23, P447, DOI 10.1080/14728222.2019.1602608; Labanieh L, 2022, CELL, V185, P1745, DOI 10.1016/j.cell.2022.03.041; Larson RC, 2021, NAT REV CANCER, V21, P145, DOI 10.1038/s41568-020-00323-z; Lee YG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10565-7; Lindner SE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz3223; Liu XJ, 2015, CANCER RES, V75, P3596, DOI 10.1158/0008-5472.CAN-15-0159; Menck K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010142; Minutolo NG, 2020, J AM CHEM SOC, V142, P6554, DOI 10.1021/jacs.9b11622; Minutolo NG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00176; Moreno-Cortes E, 2021, CRIT REV ONCOL HEMAT, V159, DOI 10.1016/j.critrevonc.2021.103239; Nerreter T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10948-w; Peng Haiyong, 2021, Antib Ther, V4, P222, DOI 10.1093/abt/tbab023; Peng H, 2017, J MOL BIOL, V429, P2954, DOI 10.1016/j.jmb.2017.08.003; Picanco-Castro V, 2020, METHODS MOL BIOL, V2086, P1, DOI 10.1007/978-1-0716-0146-4_1; Qi JP, 2020, ANGEW CHEM INT EDIT, V59, P12178, DOI 10.1002/anie.202005432; Qi JP, 2018, P NATL ACAD SCI USA, V115, pE5467, DOI 10.1073/pnas.1719905115; Raj D, 2019, GUT, V68, P1052, DOI 10.1136/gutjnl-2018-316595; Rennert P, 2019, BLOOD, V134, DOI 10.1182/blood-2019-130654; Rodgers DT, 2016, P NATL ACAD SCI USA, V113, pE459, DOI 10.1073/pnas.1524155113; Rydzek J, 2019, MOL THER, V27, P287, DOI 10.1016/j.ymthe.2018.11.015; Sahillioglu AC, 2022, CURR OPIN IMMUNOL, V74, P190, DOI 10.1016/j.coi.2021.07.002; Schmid DA, 2010, J IMMUNOL, V184, P4936, DOI 10.4049/jimmunol.1000173; Shabani M, 2015, EXPERT OPIN THER TAR, V19, P941, DOI 10.1517/14728222.2015.1025753; Srivastava S, 2021, CANCER CELL, V39, P193, DOI 10.1016/j.ccell.2020.11.005; Srivastava S, 2019, CANCER CELL, V35, P489, DOI 10.1016/j.ccell.2019.02.003; Townsend MH, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0817-0; Viaud S, 2018, P NATL ACAD SCI USA, V115, pE10898, DOI 10.1073/pnas.1810060115; Wang M.L., 2022, NEJM EVID, V1, pEVIDoa2100001, DOI [10.1056/EVIDoa2100001, DOI 10.1056/EVIDOA2100001]; Wang XL, 2011, BLOOD, V118, P1255, DOI 10.1182/blood-2011-02-337360; Wu CY, 2015, SCIENCE, V350, DOI 10.1126/science.aab4077; Yam PY, 2002, MOL THER, V5, P479, DOI 10.1006/mthe.2002.0558; Yang JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021018; Zahnd C, 2004, J BIOL CHEM, V279, P18870, DOI 10.1074/jbc.M309169200; Zhao YM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.680834	63	1	1	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/541388-022-02416-5	http://dx.doi.org/10.1038/541388-022-02416-5		JUL 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D9PU	35859167				2022-12-28	WOS:000829626500001
J	Quek, LE; van Geldermalsen, M; Guan, YF; Wahi, K; Mayoh, C; Balaban, S; Pang, A; Wang, Q; Cowley, MJ; Brown, KK; Turner, N; Hoy, AJ; Holst, J				Quek, Lake-Ee; van Geldermalsen, Michelle; Guan, Yi Fang; Wahi, Kanu; Mayoh, Chelsea; Balaban, Seher; Pang, Angel; Wang, Qian; Cowley, Mark J.; Brown, Kristin K.; Turner, Nigel; Hoy, Andrew J.; Holst, Jeff			Glutamine addiction promotes glucose oxidation in triple-negative breast cancer	ONCOGENE			English	Article							METABOLISM; CELLS; GROWTH; INHIBITOR; PROTEINS; STRESS; ACID	Glutamine is a conditionally essential nutrient for many cancer cells, but it remains unclear how consuming glutamine in excess of growth requirements confers greater fitness to glutamine-addicted cancers. By contrasting two breast cancer subtypes with distinct glutamine dependencies, we show that glutamine-indispensable triple-negative breast cancer (TNBC) cells rely on a non-canonical glutamine-to-glutamate overflow, with glutamine carbon routed once through the TCA cycle. Importantly, this single-pass glutaminolysis increases TCA cycle fluxes and replenishes TCA cycle intermediates in TNBC cells, a process that achieves net oxidation of glucose but not glutamine. The coupling of glucose and glutamine catabolism appears hard-wired via a distinct TNBC gene expression profile biased to strip and then sequester glutamine nitrogen, but hampers the ability of TNBC cells to oxidise glucose when glutamine is limiting. Our results provide a new understanding of how metabolically rigid TNBC cells are sensitive to glutamine deprivation and a way to select vulnerable TNBC subtypes that may be responsive to metabolic-targeted therapies.	[Quek, Lake-Ee] Univ Sydney, Sch Math & Stat, Camperdown, NSW, Australia; [van Geldermalsen, Michelle] Univ Sydney, Centenary Inst, Origins Canc Program, Camperdown, NSW, Australia; [van Geldermalsen, Michelle] Univ Sydney, Sydney Med Sch, Camperdown, NSW, Australia; [Guan, Yi Fang; Wahi, Kanu; Pang, Angel; Wang, Qian; Holst, Jeff] UNSW Sydney, Sch Med Sci, Kensington, NSW, Australia; [Guan, Yi Fang; Wahi, Kanu; Pang, Angel; Wang, Qian; Holst, Jeff] UNSW Sydney, Sch Clin Med, Kensington, NSW, Australia; [Mayoh, Chelsea; Cowley, Mark J.] UNSW Sydney, Childrens Canc Inst, Lowy Canc Ctr, Kensington, NSW, Australia; [Mayoh, Chelsea; Cowley, Mark J.] UNSW Sydney, Sch Womens & Childrens Hlth, Kensington, NSW, Australia; [Balaban, Seher; Hoy, Andrew J.] Univ Sydney, Charles Perkins Ctr, Sch Med Sci, Camperdown, NSW, Australia; [Brown, Kristin K.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Brown, Kristin K.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Brown, Kristin K.] Univ Melbourne, Dept Biochem & Pharmacol, Melbourne, Vic, Australia; [Turner, Nigel] UNSW Sydney, Dept Pharmacol, Sch Med Sci, Kensington, NSW, Australia	University of Sydney; University of Sydney; Centenary Institute; University of Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of Sydney; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; University of New South Wales Sydney	Quek, LE (corresponding author), Univ Sydney, Sch Math & Stat, Camperdown, NSW, Australia.; Holst, J (corresponding author), UNSW Sydney, Sch Med Sci, Kensington, NSW, Australia.; Holst, J (corresponding author), UNSW Sydney, Sch Clin Med, Kensington, NSW, Australia.	lake-ee.quek@sydney.edu.au; j.holst@unsw.edu.au	; Hoy, Andrew/J-2289-2017	Cowley, Mark/0000-0002-9519-5714; BROWN, KRISTIN/0000-0002-4991-8870; Hoy, Andrew/0000-0003-3922-1137; Pang, Angel/0000-0003-1001-5102	National Breast Cancer Foundation [ECF-12-05]; Cancer Council NSW [RG18-06]; Cancer Institute NSW; Australian Cancer Research Foundation (Tumour Metabolism Laboratory); Robinson Fellowship; University of Sydney; Luminesce Alliance: Innovation for Children's Health; Victorian Cancer Agency; Susan G. Komen; Sydney Catalyst	National Breast Cancer Foundation; Cancer Council NSW(Cancer Council New South Wales); Cancer Institute NSW; Australian Cancer Research Foundation (Tumour Metabolism Laboratory); Robinson Fellowship; University of Sydney(University of Sydney); Luminesce Alliance: Innovation for Children's Health; Victorian Cancer Agency; Susan G. Komen(Susan G. Komen Breast Cancer Foundation); Sydney Catalyst	This work was supported by grants from the National Breast Cancer Foundation (ECF-12-05 to JH); Cancer Council NSW (RG18-06 to JH); Cancer Institute NSW and Sydney Catalyst (MvG, LEQ and JH); and the Australian Cancer Research Foundation (Tumour Metabolism Laboratory to JH). AJH is supported by a Robinson Fellowship and funding from The University of Sydney. MJC is supported by Luminesce Alliance: Innovation for Children's Health. KKB is supported by grants from The Victorian Cancer Agency and Susan G. Komen. Metabolomics was facilitated by access to Sydney Mass Spectrometry, a core research facility at the University of Sydney and the Bioanalytical Mass Spectrometry Facility within the Mark Wainwright Analytical Centre of the University of New South Wales.	Ahn WS, 2013, METAB ENG, V15, P34, DOI 10.1016/j.ymben.2012.10.001; Brown KK, 2017, CANCER DISCOV, V7, P391, DOI 10.1158/2159-8290.CD-16-0611; Brunk E, 2018, NAT BIOTECHNOL, V36, P272, DOI 10.1038/nbt.4072; Budczies J, 2015, INT J CANCER, V136, P1619, DOI 10.1002/ijc.29152; Cantor JR, 2017, CELL, V169, P258, DOI 10.1016/j.cell.2017.03.023; Cao MD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-941; Centenera MM, 2013, NAT REV UROL, V10, P483, DOI 10.1038/nrurol.2013.126; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Craze ML, 2019, BREAST CANCER RES TR, V174, P79, DOI 10.1007/s10549-018-5060-z; Davidson SM, 2016, CELL METAB, V23, P517, DOI 10.1016/j.cmet.2016.01.007; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; dos Reis LM, 2019, J BIOL CHEM, V294, P9342, DOI 10.1074/jbc.RA119.008180; Fan J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.65; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Hosios AM, 2016, DEV CELL, V36, P540, DOI 10.1016/j.devcel.2016.02.012; Hui S, 2017, NATURE, V551, P115, DOI 10.1038/nature24057; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Jeon YJ, 2015, CANCER CELL, V27, P354, DOI 10.1016/j.ccell.2015.02.006; Kim S, 2013, TUMOR BIOL, V34, P2683, DOI 10.1007/s13277-013-0819-7; Knott SRV, 2018, NATURE, V554, P378, DOI 10.1038/nature25465; Kung HN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002229; Lampa M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185092; Lanning NJ, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0168-x; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Lee P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14374-1; Li HX, 2019, NAT MED, V25, P850, DOI 10.1038/s41591-019-0404-8; Li XX, 2022, NAT METAB, V4, P141, DOI 10.1038/s42255-021-00517-1; Liao CH, 2022, CANCER RES, V82, P665, DOI 10.1158/0008-5472.CAN-21-2745; Martin SD, 2019, CANCER METAB, V7, DOI 10.1186/s40170-019-0207-x; Martinez-Reyes I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13668-3; Mendez-Lucas A, 2020, NAT METAB, V2, P335, DOI 10.1038/s42255-020-0195-8; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Osanai-Sasakawa A, 2018, AM J CANCER RES, V8, P1499; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Quek Lake-Ee, 2014, Methods Mol Biol, V1191, P209, DOI 10.1007/978-1-4939-1170-7_13; Shin CS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15074; Simoes RV, 2015, NEOPLASIA, V17, P671, DOI 10.1016/j.neo.2015.08.005; Smith B, 2016, CELL REP, V17, P821, DOI 10.1016/j.celrep.2016.09.045; Spinelli JB, 2017, SCIENCE, V358, P941, DOI 10.1126/science.aam9305; Tardito S, 2015, NAT CELL BIOL, V17, P1556, DOI 10.1038/ncb3272; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; van Geldermalsen M, 2016, ONCOGENE, V35, P3201, DOI 10.1038/onc.2015.381; van Geldermalsen M, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4599-8; Vatrinet R, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0165-0; Vettore L, 2020, BRIT J CANCER, V122, P150, DOI 10.1038/s41416-019-0620-5; Voorde JV, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau7314; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wu Q, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18020-8; Yang CS, 2018, EMBO REP, V19, DOI 10.15252/embr.201643577; Zhang J, 2012, NAT PROTOC, V7, P1068, DOI 10.1038/nprot.2012.048	50	1	1	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2022	41	34					4066	4078		10.1038/s41388-022-02408-5	http://dx.doi.org/10.1038/s41388-022-02408-5		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3W0LE	35851845	Green Published, hybrid			2022-12-28	WOS:000826844200003
J	Dutta, S; Polavaram, NS; Islam, R; Bhattacharya, S; Bodas, S; Mayr, T; Roy, S; Albala, SAY; Toma, MI; Darehshouri, A; Borkowetz, A; Conrad, S; Fuessel, S; Wirth, M; Baretton, GB; Hofbauer, LC; Ghosh, P; Pienta, KJ; Klinkebiel, DL; Batra, SK; Muders, MH; Datta, K				Dutta, Samikshan; Polavaram, Navatha Shree; Islam, Ridwan; Bhattacharya, Sreyashi; Bodas, Sanika; Mayr, Thomas; Roy, Sohini; Albala, Sophie Alvarez Y.; Toma, Marieta, I; Darehshouri, Anza; Borkowetz, Angelika; Conrad, Stefanie; Fuessel, Susanne; Wirth, Manfred; Baretton, Gustavo B.; Hofbauer, Lorenz C.; Ghosh, Paramita; Pienta, Kenneth J.; Klinkebiel, David L.; Batra, Surinder K.; Muders, Michael H.; Datta, Kaustubh			Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer	ONCOGENE			English	Article							NUCLEAR-PORE COMPLEXES; PROTEINS; NUP98	Aberrant transcriptional activity of androgen receptor (AR) is one of the dominant mechanisms for developing of castration-resistant prostate cancer (CRPC). Analyzing AR-transcriptional complex related to CRPC is therefore important towards understanding the mechanism of therapy resistance. While studying its mechanism, we observed that a transmembrane protein called neuropilin-2 (NRP2) plays a contributory role in forming a novel AR-transcriptional complex containing nuclear pore proteins. Using immunogold electron microscopy, high-resolution confocal microscopy, chromatin immunoprecipitation, proteomics, and other biochemical techniques, we delineated the molecular mechanism of how a specific splice variant of NRP2 becomes sumoylated upon ligand stimulation and translocates to the inner nuclear membrane. This splice variant of NRP2 then stabilizes the complex between AR and nuclear pore proteins to promote CRPC specific gene expression. Both full-length and splice variants of AR have been identified in this specific transcriptional complex. In vitro cell line-based assays indicated that depletion of NRP2 not only destabilizes the AR-nuclear pore protein interaction but also inhibits the transcriptional activities of AR. Using an in vivo bone metastasis model, we showed that the inhibition of NRP2 led to the sensitization of CRPC cells toward established anti-AR therapies such as enzalutamide. Overall, our finding emphasize the importance of combinatorial inhibition of NRP2 and AR as an effective therapeutic strategy against treatment refractory prostate cancer.	[Dutta, Samikshan; Polavaram, Navatha Shree; Islam, Ridwan; Bhattacharya, Sreyashi; Bodas, Sanika; Roy, Sohini; Klinkebiel, David L.; Batra, Surinder K.; Datta, Kaustubh] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Mayr, Thomas; Muders, Michael H.] Univ Bonn, Med Fac, Rudolf Becker Lab Prostate Canc Res, Bonn, Germany; [Mayr, Thomas; Toma, Marieta, I; Muders, Michael H.] Univ Bonn, Med Fac, Inst Pathol, Bonn, Germany; [Mayr, Thomas; Toma, Marieta, I; Baretton, Gustavo B.; Muders, Michael H.] Tech Univ Dresden, Inst Pathol, Dresden, Germany; [Albala, Sophie Alvarez Y.] Univ Nebraska, Dept Agron & Hort, Lincoln, NE USA; [Darehshouri, Anza] UT Southwestern Med Ctr, Dept Cell Biol, Dallas, TX USA; [Borkowetz, Angelika; Fuessel, Susanne; Wirth, Manfred] Tech Univ Dresden, Dept Urol, Dresden, Germany; [Conrad, Stefanie; Hofbauer, Lorenz C.] Tech Univ Dresden, Dept Med 3, Div Endocrinol & Metab Bone Dis, Dresden, Germany; [Conrad, Stefanie; Hofbauer, Lorenz C.] Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany; [Baretton, Gustavo B.; Hofbauer, Lorenz C.] German Res Ctr DKFZ, German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany; [Baretton, Gustavo B.] Univ Hosp, Univ Canc Ctr UCC, Tumor & Normal Tissue Bank, Dresden, Germany; [Baretton, Gustavo B.] Tech Univ Dresden, Fac Med, Dresden, Germany; [Ghosh, Paramita] Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA; [Pienta, Kenneth J.] Johns Hopkins Univ, Sch Med, Brady Urol Inst, Baltimore, MD USA	University of Nebraska System; University of Nebraska Medical Center; University of Bonn; University of Bonn; Technische Universitat Dresden; University of Nebraska System; University of Nebraska Lincoln; University of Texas System; University of Texas Southwestern Medical Center Dallas; Technische Universitat Dresden; Technische Universitat Dresden; Technische Universitat Dresden; Helmholtz Association; German Cancer Research Center (DKFZ); Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; University of California System; University of California Davis; Johns Hopkins University	Dutta, S; Datta, K (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	samikshan.dutta@unmc.edu; kaustubh.datta@unmc.edu		Dutta, samikshan/0000-0002-4160-1422	Lageschulte Fund [1R21CA241234-01, NE-LB506]; DoD [W81XWH2110628]; DFG [273676790, 416001651]; Rudolf-Becker-Foundation; DFG;  [R01CA182435];  [R01CA239343]	Lageschulte Fund; DoD(United States Department of Defense); DFG(German Research Foundation (DFG)); Rudolf-Becker-Foundation; DFG(German Research Foundation (DFG)); ; 	This work was supported by grants for SD (1R21CA241234-01, NE-LB506, Lageschulte Fund), KD (R01CA182435, R01CA239343, DoD W81XWH2110628), MHM and LHH (DFG project number 273676790), and MHM (DFG project number 416001651). MM is funded by the Rudolf-Becker-Foundation for his professorship. The construction of the prostate cancer tissue microarray was funded by the DFG Forschergruppe-1586 SKELMET to LCH and SF.	Ark AV, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00180; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Borkowetz A, 2020, INT J CANCER, V146, P2619, DOI 10.1002/ijc.32679; Coleman DJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40518-5; Coutinho I, 2016, ENDOCR-RELAT CANCER, V23, pT179, DOI 10.1530/ERC-16-0422; D'Angelo MA, 2018, NUCLEUS-PHILA, V9, P142, DOI 10.1080/19491034.2017.1395542; Dieppois G, 2010, J CELL SCI, V123, P1989, DOI 10.1242/jcs.053694; Drozdz MM, 2017, NUCLEUS-PHILA, V8, P34, DOI 10.1080/19491034.2016.1252893; Dutta S, 2016, SCI REP-UK, V6, DOI 10.1038/srep23588; Franks TM, 2013, TRENDS CELL BIOL, V23, P112, DOI 10.1016/j.tcb.2012.10.013; Fricker M, 1997, J CELL BIOL, V136, P531, DOI 10.1083/jcb.136.3.531; Garcia-Oliver E, 2012, BBA-GENE REGUL MECH, V1819, P555, DOI 10.1016/j.bbagrm.2011.11.011; Gemmill RM, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aag0528; Giacinti S, 2018, ANTICANCER RES, V38, P6029, DOI 10.21873/anticanres.12953; Gomez-Cavazos JS, 2015, J CELL BIOL, V208, P671, DOI 10.1083/jcb.201410047; He YD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21860-7; Holzer K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10133-z; Ibarra A, 2016, GENE DEV, V30, P2253, DOI 10.1101/gad.287417.116; Ibarra A, 2015, GENE DEV, V29, P337, DOI 10.1101/gad.256495.114; Imamura Y, 2016, INT J UROL, V23, P654, DOI 10.1111/iju.13137; Kersemans V, 2013, J MAGN RESON IMAGING, V37, P1499, DOI 10.1002/jmri.23829; Kitazawa T, 2017, NEURON, V96, P259, DOI 10.1016/j.neuron.2017.09.059; Kuhn TM, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111414; Kuhn TM, 2019, J CELL BIOL, V218, P2945, DOI 10.1083/jcb.201807139; Labade AS, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0106-0; Liang Y, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003308; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Palancade B, 2007, MOL BIOL CELL, V18, P2912, DOI 10.1091/mbc.E07-02-0123; Parker MW, 2015, STRUCTURE, V23, P677, DOI 10.1016/j.str.2015.01.018; Polavaram NS, 2021, BONE RES, V9, DOI 10.1038/s41413-021-00136-2; Powers E, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00978-z; Ptak C, 2014, CURR OPIN CELL BIOL, V28, P46, DOI 10.1016/j.ceb.2014.02.001; Raices M, 2017, DEV CELL, V41, P540, DOI 10.1016/j.devcel.2017.05.007; Raices M, 2017, CURR OPIN CELL BIOL, V46, P26, DOI 10.1016/j.ceb.2016.12.006; Rodriguez-Bravo V, 2018, CELL, V174, P1200, DOI 10.1016/j.cell.2018.07.015; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Rossignol M, 2000, GENOMICS, V70, P211, DOI 10.1006/geno.2000.6381; Roumiguie M, 2021, FUTURE ONCOL, V17, P1811, DOI 10.2217/fon-2020-1104; Ruben GJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021923; Savoy RM, 2015, ENDOCR-RELAT CANCER, V22, P369, DOI 10.1530/ERC-15-0021; Schmidt KT, 2021, NAT REV UROL, V18, P209, DOI 10.1038/s41585-021-00438-4; Schweizer MT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198389; Shafran JS, 2019, MOL CANCER RES, V17, P1627, DOI 10.1158/1541-7786.MCR-18-1279; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Stanton MJ, 2013, CANCER RES, V73, P160, DOI 10.1158/0008-5472.CAN-11-3635; Su YL, 2018, GENE DEV, V32, P1398, DOI 10.1101/gad.314377.118; Sulpice E, 2008, BLOOD, V111, P2036, DOI 10.1182/blood-2007-04-084269; Sump B, 2017, GENE DEV, V31, P2201, DOI 10.1101/gad.310359.117; Tan KN, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186622; Tucci M, 2018, ONCOTARGETS THER, V11, P7353, DOI 10.2147/OTT.S153764; Tucci M, 2018, MINERVA UROL NEFROL, V70, P144, DOI 10.23736/S0393-2249.17.03066-1; Wang LM, 2020, J CLIN INVEST, V130, P1782, DOI 10.1172/JCI126327	52	3	3	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3747	3760		10.1038/s41388-022-02382-y	http://dx.doi.org/10.1038/s41388-022-02382-y		JUN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35754042				2022-12-28	WOS:000815742800001
J	Puccini, A; Poorman, K; Catalano, F; Seeber, A; Goldberg, RM; Salem, ME; Shields, AF; Berger, MD; Battaglin, F; Tokunaga, R; Naseem, M; Zhang, W; Philip, PA; Marshall, JL; Korn, WM; Lenz, HJ				Puccini, Alberto; Poorman, Kelsey; Catalano, Fabio; Seeber, Andreas; Goldberg, Richard M.; Salem, Mohamed E.; Shields, Anthony F.; Berger, Martin D.; Battaglin, Francesca; Tokunaga, Ryuma; Naseem, Madiha; Zhang, Wu; Philip, Philip A.; Marshall, John L.; Korn, W. Michael; Lenz, Heinz-Josef			Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets	ONCOGENE			English	Article							PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CANCER; HISTOLOGY; FEATURES; OUTCOMES	Signet ring cell carcinoma (SRCC) is rare: about 10% of gastric cancer (GC) and 1% of colorectal cancer (CRC). SRCC is associated with poor prognosis, however the underlying molecular characteristics are unknown. SRCCs were analyzed using NGS, immunohistochemistry, and in situ hybridization. Tumor mutational burden (TMB) was calculated based on somatic nonsynonymous missense mutations, and microsatellite instability (MSI) was evaluated by NGS of known MSI loci. A total of 8500 CRC and 1100 GC were screened. Seventy-six SRCC were identified from the CRC cohort (<1%) and 98 from the GC cohort (9%). The most frequently mutated genes in CRC-SRCC were TP53 (47%), ARID1A (26%), APC (25%); in GC-SRCC were TP53 (42%), ARID1A (27%), CDH1 (11%). When compared to non-SRCC histology (N = 3522), CRC-SRCC (N = 37) more frequently had mutations in BRCA1 (11% vs 1%, P < 0.001) and less frequently mutations in APC (19% vs 78%, P < 0.001), KRAS (22% vs 51%, P = 0.001) and TP53 (47% vs 73%, P = 0.001). Among the GC cohort, SRCC (N = 54) had a higher frequency of mutations in CDH1, BAP1, and ERBB2, compared to non-SRCC (N = 540). Our data suggest that SRCCs harbor a similar molecular profile, regardless of the tumor location. Tailored therapy may become available for these patients.	[Puccini, Alberto; Berger, Martin D.; Battaglin, Francesca; Tokunaga, Ryuma; Naseem, Madiha; Zhang, Wu; Lenz, Heinz-Josef] Univ Southern Calif, Norris Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90007 USA; [Puccini, Alberto; Catalano, Fabio] Univ Genoa, Osped Policlin San Martino IRCCS, Genoa, Italy; [Poorman, Kelsey; Korn, W. Michael] Caris Life Sci, Phoenix, AZ USA; [Seeber, Andreas] Innsbruck Med Univ, Comprehens Canc Ctr Innsbruck, Dept Hematol & Oncol, Innsbruck, Austria; [Goldberg, Richard M.] West Virginia Univ, Canc Inst, Morgantown, WV 26506 USA; [Salem, Mohamed E.] Levine Canc Inst, Charlotte, NC USA; [Shields, Anthony F.; Philip, Philip A.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA; [Marshall, John L.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Med Ctr, Washington, DC USA	University of Southern California; University of Genoa; Medical University of Innsbruck; West Virginia University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Georgetown University	Lenz, HJ (corresponding author), Univ Southern Calif, Norris Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90007 USA.	lenz@med.usc.edu	Battaglin, Francesca/C-2746-2017	Battaglin, Francesca/0000-0002-9869-0163; Puccini, Alberto/0000-0002-2492-4043	National Cancer Institute [P30CA014089]; Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Gene Gregg Pancreas Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; Victoria and Philip Wilson Research Fund; Fong research project; Ming Hsieh research fund	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Gene Gregg Pancreas Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; Victoria and Philip Wilson Research Fund; Fong research project; Ming Hsieh research fund	This work was partly supported by National Cancer Institute (grant number P30CA014089), Gloria Borges WunderGlo Foundation, Dhont Family Foundation, Gene Gregg Pancreas Research Fund, San Pedro Peninsula Cancer Guild, Daniel Butler Research Fund, Victoria and Philip Wilson Research Fund, Fong research project and Ming Hsieh research fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute of the National Institutes of Health.	Alvi MA, 2017, BRIT J CANCER, V117, P203, DOI 10.1038/bjc.2017.168; Andre T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699; Bamboat ZM, 2014, ANN SURG ONCOL, V21, P1678, DOI 10.1245/s10434-013-3466-8; Barresi V, 2020, FUTURE ONCOL, V16, P1161, DOI 10.2217/fon-2020-0242; Benesch MGK, 2020, CANCERS, V12, DOI 10.3390/cancers12061544; Bosman F., 2010, WHO CLASSIFICATION T, V4th; Bosman F. T., 2010, WHO CLASSIFICATION T; Caravagna G, 2018, NAT METHODS, V15, P707, DOI 10.1038/s41592-018-0108-x; Catalano F, 2022, CANCERS, V14, DOI 10.3390/cancers14061388; Chen L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176637; Chon HJ, 2017, ANN SURG, V265, P946, DOI 10.1097/SLA.0000000000001793; Gong HY, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820960746; Henson DE, 2004, ARCH PATHOL LAB MED, V128, P765; Hugen N, 2015, INT J CANCER, V136, P333, DOI 10.1002/ijc.28981; Hyngstrom JR, 2012, ANN SURG ONCOL, V19, P2814, DOI 10.1245/s10434-012-2321-7; Inamura K, 2015, ANN SURG ONCOL, V22, P1226, DOI 10.1245/s10434-014-4159-7; Jin SY, 2017, ONCOTARGET, V8, P38850, DOI 10.18632/oncotarget.16407; Kim S, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0148-y; Kong PF, 2016, SCI REP-UK, V6, DOI 10.1038/srep26313; Korphaisarn K, 2019, BRIT J CANCER, V121, P505, DOI 10.1038/s41416-019-0548-9; Kwon KJ, 2014, GASTRIC CANCER, V17, P43, DOI 10.1007/s10120-013-0234-1; Lee WS, 2007, AM J SURG, V194, P294, DOI 10.1016/j.amjsurg.2006.12.041; Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105; Mariette C, 2019, GASTRIC CANCER, V22, P1, DOI 10.1007/s10120-018-0868-0; Mauri G, 2020, ANN ONCOL, V31, P1135, DOI 10.1016/j.annonc.2020.05.027; Mengardo V, 2018, UPDATES SURG, V70, P167, DOI 10.1007/s13304-018-0550-4; Nagtegaal ID, 2020, HISTOPATHOLOGY, V76, P182, DOI 10.1111/his.13975; Nitsche U, 2016, J CANCER RES CLIN, V142, P2357, DOI 10.1007/s00432-016-2224-2; Nitsche U, 2013, ANN SURG, V258, P775, DOI 10.1097/SLA.0b013e3182a69f7e; Noh MG, 2021, EXP MOL MED, V53, P223, DOI 10.1038/s12276-021-00559-1; Pande R, 2008, DIS COLON RECTUM, V51, P50, DOI 10.1007/s10350-007-9073-7; Pernot S, 2015, WORLD J GASTROENTERO, V21, P11428, DOI 10.3748/wjg.v21.i40.11428; Piessen G, 2009, ANN SURG, V250, P878, DOI 10.1097/SLA.0b013e3181b21c7b; Puccini A, 2019, ONCOLOGIST, V24, P319, DOI 10.1634/theoncologist.2018-0117; Taghavi S, 2012, J CLIN ONCOL, V30, P3493, DOI 10.1200/JCO.2012.42.6635; Tajiri K, 2017, ANTICANCER RES, V37, P3817, DOI 10.21873/anticanres.11760; Tung SY, 1996, AM J GASTROENTEROL, V91, P2195; Warner JN, 2010, MAYO CLIN PROC, V85, P1130, DOI 10.4065/mcp.2010.0463; World Health Organization, 2019, DIG SYST TUM, V5th, DOI DOI 10.1111/HIS.13975; Wu XF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162088; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Zhao Z, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70985-0; Zimmer K, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.662055	43	2	2	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3455	3460		10.1038/s41388-022-02350-6	http://dx.doi.org/10.1038/s41388-022-02350-6		MAY 2022	6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35618879	Green Accepted			2022-12-28	WOS:000805545200001
J	Lv, Y; Tang, WT; Zhang, ZY; Lin, Q; Luo, YX; Zheng, P; Li, K; Jia, XN; Pang, YZ; Ji, ML; Feng, QY; He, GD; Wang, YX; Xu, JM				Lv Yang; Tang WenTao; Zhang ZhiYuan; Lin Qi; Luo YuXiang; Zheng Peng; Li Ke; Jia XiaoNa; Pang YuZhi; Ji MeiLing; Feng QingYang; He GuoDong; Wang YueXiang; Xu JianMin			Cullin-9/p53 mediates HNRNPC degradation to inhibit erastin-induced ferroptosis and is blocked by MDM2 inhibition in colorectal cancer	ONCOGENE			English	Article							CELL-DEATH; VULNERABILITY; STATISTICS; SUBTYPES; COMPLEX; PARC; KRAS	Colorectal cancer (CRC) is the leading cause of cancer associated death worldwide. Ferroptosis is a newly defined form of regulated cell death characterized by the accumulation of lipid hydroperoxides and exerts an increased attention for cancer treatment. However, little is known about ferroptosis in CRC. In this study, through whole genome sequencing and external differential differentiated expression analysis, we identify CUL9 as a novel important modulator for ferroptosis in CRC. Here we demonstrated that CUL9 can binds p53 to ubiquitylate heterogeneous nuclear ribonucleoprotein C for degradation. Overexpression of CUL9 increases resistance to erastin-induced ferroptosis. Then, we discovered this resistance was mediated by CUL9-HNRNPC-MATE1 negative loop, which can provide us with a novel target to overcome drug resistance to ferroptosis activators. Finally, we found that targeting MDM2 was developed as an effective strategy to destroy precious drug-resistant CRC cells.	[Lv Yang; Tang WenTao; Zhang ZhiYuan; Lin Qi; Zheng Peng; Ji MeiLing; Feng QingYang; He GuoDong; Xu JianMin] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Lv Yang; Tang WenTao; Zhang ZhiYuan; Lin Qi; Zheng Peng; Ji MeiLing; Feng QingYang; He GuoDong; Xu JianMin] Fudan Univ, Zhongshan Hosp, Canc Ctr, Shanghai, Peoples R China; [Tang WenTao; Zhang ZhiYuan; Lin Qi; Zheng Peng; Ji MeiLing; Feng QingYang; He GuoDong; Xu JianMin] Shanghai Engn Res Ctr Colorectal Canc Minimally I, Shanghai, Peoples R China; [Luo YuXiang; Li Ke; Jia XiaoNa; Pang YuZhi; Wang YueXiang] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai, Peoples R China	Fudan University; Fudan University; Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; University of Chinese Academy of Sciences, CAS	Xu, JM (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China.; Xu, JM (corresponding author), Fudan Univ, Zhongshan Hosp, Canc Ctr, Shanghai, Peoples R China.; Xu, JM (corresponding author), Shanghai Engn Res Ctr Colorectal Canc Minimally I, Shanghai, Peoples R China.; Wang, YX (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai, Peoples R China.	yxwang76@sibs.ac.cn; xujmin@aliyun.com	Wang, Yuexiang/GNH-5248-2022; zhang, zhiyuan/GRS-2141-2022	Zhang, Zhiyuan/0000-0003-0336-7783	National Natural Science Foundation of China [81602040, 81903067, 82072678, 81402341]; Clinical science and technology innovation project of Shanghai [SHDC12016104]; Shanghai Science and Technology Committee Project [17411951300, 18140903200, 19511121300]; Youth fund of Zhongshan Hospital [2019ZSQN28]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Clinical science and technology innovation project of Shanghai; Shanghai Science and Technology Committee Project(Shanghai Science & Technology Committee); Youth fund of Zhongshan Hospital	This work was supported by National Natural Science Foundation of China (Grant No. 81602040, 81903067, 82072678 and 81402341), Clinical science and technology innovation project of Shanghai (SHDC12016104), Shanghai Science and Technology Committee Project (17411951300, 18140903200 and 19511121300) and Youth fund of Zhongshan Hospital (2019ZSQN28). The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in the writing of the paper.	Aldrovandi M, 2020, CELL RES, V30, P1061, DOI 10.1038/s41422-020-00434-0; AMOR B, 1984, ANN INTERN MED, V101, P878, DOI 10.7326/0003-4819-101-6-878_1; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen Y, 2019, CELL SIGNAL, V63, DOI 10.1016/j.cellsig.2019.109384; Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; Fang XX, 2019, P NATL ACAD SCI USA, V116, P2672, DOI 10.1073/pnas.1821022116; Gama V, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005309; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Giordano G, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1019-5; Guo JP, 2018, CANCER RES TREAT, V50, P445, DOI 10.4143/crt.2016.572; Hassannia B, 2019, CANCER CELL, V35, P830, DOI 10.1016/j.ccell.2019.04.002; Hattori K, 2017, EMBO REP, V18, P2067, DOI 10.15252/embr.201744228; Ishizawa J, 2019, CANCER CELL, V35, P721, DOI 10.1016/j.ccell.2019.03.014; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580-020-00324-8; Khan OM, 2018, J CLIN INVEST, V128, P1326, DOI 10.1172/JCI97325; Kunii A, 2018, CRISPR J, V1, P337, DOI 10.1089/crispr.2018.0009; Lal N, 2018, CLIN CANCER RES, V24, P224, DOI 10.1158/1078-0432.CCR-17-1090; Li ZJ, 2014, MOL CELL, V54, P805, DOI 10.1016/j.molcel.2014.03.046; Liu Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.596679; Liu YH, 2015, NATURE, V520, P697, DOI 10.1038/nature14418; Lopez J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005619; Loree JM, 2018, JNCI-J NATL CANCER I, V110, P1409, DOI 10.1093/jnci/djy067; Louandre C, 2013, INT J CANCER, V133, P1732, DOI 10.1002/ijc.28159; Lu B, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00992; Maldonado EN, 2013, J BIOL CHEM, V288, P11920, DOI 10.1074/jbc.M112.433847; Mou YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0720-y; Nagpal A, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1177-1; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Oliphant R, 2013, BRIT J SURG, V100, P1388, DOI 10.1002/bjs.9227; Rink Jonathan S, 2020, J Biol Chem, V296, P100100, DOI 10.1074/jbc.RA120.014888; Santos C, 2018, ANN ONCOL, V29, P1340, DOI 10.1093/annonc/mdy132; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Toyokuni S, 2020, CANCER SCI, V111, P2665, DOI 10.1111/cas.14496; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Xie YC, 2017, CELL REP, V20, P1692, DOI 10.1016/j.celrep.2017.07.055; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yang YT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15883-9; Yu Y, 2015, MOL CELL ONCOL, V2, DOI 10.1080/23723556.2015.1054549; Zhang X, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101211; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045; Zheng P, 2018, J ONCOL, V2018, DOI 10.1155/2018/5072987; Zheng YY, 2018, NUCLEIC ACIDS RES, V46, pD139, DOI 10.1093/nar/gkx895	44	4	4	7	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3210	3221		10.1038/s41388-022-02284-z	http://dx.doi.org/10.1038/s41388-022-02284-z		MAY 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35505093				2022-12-28	WOS:000790289600002
J	Segeren, HA; van Liere, EA; Riemers, FM; de Bruin, A; Westendorp, B				Segeren, Hendrika A.; van Liere, Elsbeth A.; Riemers, Frank M.; de Bruin, Alain; Westendorp, Bart			Oncogenic RAS sensitizes cells to drug-induced replication stress via transcriptional silencing of P53	ONCOGENE			English	Article							DNA-DAMAGE; GENOMIC INSTABILITY; SIGNALING PATHWAYS; TGF-BETA; CANCER; EXPRESSION; CYCLE; ATR; ACTIVATION; DYNAMICS	Cancer cells often experience high basal levels of DNA replication stress (RS), for example due to hyperactivation of oncoproteins like MYC or RAS. Therefore, cancer cells are considered to be sensitive to drugs that exacerbate the level of RS or block the intra S-phase checkpoint. Consequently, RS-inducing drugs including ATR and CHK1 inhibitors are used or evaluated as anti-cancer therapies. However, drug resistance and lack of biomarkers predicting therapeutic efficacy limit efficient use. This raises the question what determines sensitivity of individual cancer cells to RS. Here, we report that oncogenic RAS does not only enhance the sensitivity to ATR/CHK1 inhibitors by directly causing RS. Instead, we observed that HRAS(G12V) dampens the activation of the P53-dependent transcriptional response to drug-induced RS, which in turn confers sensitivity to RS. We demonstrate that inducible expression of HRAS(G12V) sensitized cells to ATR and CHK1 inhibitors. Using RNA-sequencing of FACS-sorted cells we discovered that P53 signaling is the sole transcriptional response to RS. However, oncogenic RAS attenuates the transcription of P53 and TGF-beta pathway components which consequently dampens P53 target gene expression. Accordingly, live cell imaging showed that HRAS(G12V) exacerbates RS in S/G2-phase, which could be rescued by stabilization of P53. Thus, our results demonstrate that transcriptional control of P53 target genes is the prime determinant in the response to ATR/CHK1 inhibitors and show that hyperactivation of the MAPK pathway impedes this response. Our findings suggest that the level of oncogenic MAPK signaling could predict sensitivity to intra-S-phase checkpoint inhibition in cancers with intact P53.	[Segeren, Hendrika A.; van Liere, Elsbeth A.; Riemers, Frank M.; de Bruin, Alain; Westendorp, Bart] Univ Utrecht, Fac Vet Med, Dept Biomol Hlth Sci, Utrecht, Netherlands; [Riemers, Frank M.] Univ Utrecht, Fac Vet Med, Dept Clin Sci, Utrecht, Netherlands; [de Bruin, Alain] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands	Utrecht University; Utrecht University; University of Groningen	Westendorp, B (corresponding author), Univ Utrecht, Fac Vet Med, Dept Biomol Hlth Sci, Utrecht, Netherlands.	b.westendorp@uu.nl		Westendorp, Bart/0000-0003-1043-3638; Riemers, Frank/0000-0003-4732-9447	KWF Kankerbestrijding (Dutch Cancer Society) [11941-2018-II]; ZonMW [91116011]; Utrecht Life Sciences; University Medical Center Utrecht, Hubrecht Institute, Utrecht University; Netherlands X-omics Initiative (NWO) [184.034.019]	KWF Kankerbestrijding (Dutch Cancer Society); ZonMW(Netherlands Organization for Health Research and Development); Utrecht Life Sciences; University Medical Center Utrecht, Hubrecht Institute, Utrecht University; Netherlands X-omics Initiative (NWO)	This work is financially supported by the KWF Kankerbestrijding (Dutch Cancer Society, project grant 11941-2018-II) and ZonMW (grant 91116011). Further financial support was provided by research infrastructure grants from Utrecht Life Sciences to the Single Cell Analysis Center and the Center for Cell Imaging. Utrecht Sequencing Facility is subsidized by the University Medical Center Utrecht, Hubrecht Institute, Utrecht University and The Netherlands X-omics Initiative (NWO project 184.034.019).	Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Andrews S., 2010, FASTQC QUALITY CONTR; Arora M, 2017, CELL REP, V19, P1351, DOI 10.1016/j.celrep.2017.04.055; Bacevic K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12868-5; Bajar BT, 2016, NAT METHODS, V13, P993, DOI [10.1038/NMETH.4045, 10.1038/nmeth.4045]; Barnes RP, 2018, CANCER RES, V78, P6549, DOI 10.1158/0008-5472.CAN-17-3931; Beck H, 2010, J CELL BIOL, V188, P629, DOI 10.1083/jcb.200905059; Buisson R, 2015, MOL CELL, V59, P1011, DOI 10.1016/j.molcel.2015.07.029; Chao HX, 2017, CELL SYST, V5, P445, DOI 10.1016/j.cels.2017.09.015; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; Daigh LH, 2018, CELL SYST, V7, P17, DOI 10.1016/j.cels.2018.05.011; Daly AC, 2010, J BIOL CHEM, V285, P6489, DOI 10.1074/jbc.M109.043877; David L, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac9704; De S, 2020, CELL REP, V30, P2083, DOI 10.1016/j.celrep.2020.01.074; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dietlein F, 2015, CELL, V162, P146, DOI 10.1016/j.cell.2015.05.053; Dillon MT, 2017, MOL CANCER THER, V16, P25, DOI 10.1158/1535-7163.MCT-16-0239; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feringa FM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06308-9; FILMUS J, 1994, ONCOGENE, V9, P3627; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Galanos P, 2016, NAT CELL BIOL, V18, P777, DOI 10.1038/ncb3378; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Hamer PCD, 2011, CLIN CANCER RES, V17, P4200, DOI 10.1158/1078-0432.CCR-10-2537; Hamppa S, 2016, P NATL ACAD SCI USA, V113, pE4311, DOI 10.1073/pnas.1605828113; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Her J, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00472-17; Hong DS, 2018, CLIN CANCER RES, V24, P3263, DOI 10.1158/1078-0432.CCR-17-3347; Hornsveld M, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108675; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hsu CH, 2019, CELL, V178, P361, DOI 10.1016/j.cell.2019.05.041; Italiano A, 2018, ANN ONCOL, V29, P1304, DOI 10.1093/annonc/mdy076; Kawarada Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep35483; Klusmann I, 2016, CELL REP, V17, P1845, DOI 10.1016/j.celrep.2016.10.036; Kotsantis P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13087; Koundrioukoff S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003643; Kranz D, 2006, CANCER RES, V66, P10274, DOI 10.1158/0008-5472.CAN-06-1527; Krenning L, 2014, MOL CELL, V55, P59, DOI 10.1016/j.molcel.2014.05.007; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lerner LK, 2017, NUCLEIC ACIDS RES, V45, P1270, DOI 10.1093/nar/gkw1196; Liu HS, 2009, BIOCHEM J, V422, P543, DOI 10.1042/BJ20090342; Lloyd RL, 2021, NUCLEIC ACIDS RES, V49, P8665, DOI 10.1093/nar/gkab628; Lopez-Contreras AJ, 2012, J EXP MED, V209, P455, DOI 10.1084/jem.20112147; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Macheret M, 2018, NATURE, V555, P112, DOI 10.1038/nature25507; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Masamsetti VP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12255-w; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Moreno E, 2021, HEPATOLOGY, V73, P303, DOI 10.1002/hep.31259; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Oo ZY, 2018, CLIN CANCER RES, V24, P2901, DOI 10.1158/1078-0432.CCR-17-2701; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Patel PL, 2016, P NATL ACAD SCI USA, V113, pE5024, DOI 10.1073/pnas.1602379113; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Purvis JE, 2012, SCIENCE, V336, P1440, DOI 10.1126/science.1218351; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Reyes J, 2018, MOL CELL, V71, P581, DOI 10.1016/j.molcel.2018.06.031; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roy S, 2018, ELIFE, V7, DOI 10.7554/eLife.31723; Sa G, 2004, EXP CELL RES, V300, P427, DOI 10.1016/j.yexcr.2004.07.032; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Scagliotti G, 2016, INVEST NEW DRUG, V34, P625, DOI 10.1007/s10637-016-0368-1; Schoppy DW, 2012, J CLIN INVEST, V122, P241, DOI 10.1172/JCI58928; Segeren HA, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108449; Su J, 2020, NATURE, V577, P566, DOI 10.1038/s41586-019-1897-5; Suram A, 2012, EMBO J, V31, P2839, DOI 10.1038/emboj.2012.132; Tarasov A, 2015, BIOINFORMATICS, V31, P2032, DOI 10.1093/bioinformatics/btv098; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Techer H, 2017, NAT REV GENET, V18, P535, DOI 10.1038/nrg.2017.46; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Wang C, 2019, NATURE, V574, P268, DOI 10.1038/s41586-019-1607-3; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Wilhelm T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11584-0; Xu YX, 2017, ELIFE, V6, DOI 10.7554/eLife.30523; Yang HW, 2017, NATURE, V549, P404, DOI 10.1038/nature23880	83	3	3	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2719	2733		10.1038/s41388-022-02291-0	http://dx.doi.org/10.1038/s41388-022-02291-0		APR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35393546	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000779227700005
J	Cui, YM; Jiao, HL; Ye, YP; Chen, CM; Wang, JX; Tang, N; Li, TT; Lin, J; Qi, L; Wu, P; Wang, SY; He, MR; Liang, L; Bian, XW; Liao, WT; Ding, YQ				Cui, Y-M; Jiao, H-L; Ye, Y-P; Chen, C-M; Wang, J-X; Tang, N.; Li, T-T; Lin, J.; Qi, L.; Wu, P.; Wang, S-Y; He, M-R; Liang, L.; Bian, X-W; Liao, W-T; Ding, Y-Q			RETRACTION: FOXC2 promotes colorectal cancer metastasis by directly targeting MET (Retraction of Vol 34, Pg 4379, 2015)	ONCOGENE			English	Retraction												liaowt2002@gmail.com; dyqgz@126.com						Cui YM, 2015, ONCOGENE, V34, P4379, DOI 10.1038/onc.2014.368; Cui YM, 2014, CANCER LETT, V353, P87, DOI 10.1016/j.canlet.2014.07.008	2	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2529	2529		10.1038/s41388-022-02287-w	http://dx.doi.org/10.1038/s41388-022-02287-w		APR 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35365752	Bronze			2022-12-28	WOS:000777275200002
J	Landras, A; de Moura, CR; Villoutreix, BO; Battistella, M; Sadoux, A; Dumaz, N; Menashi, S; Fernandez-Recio, J; Lebbe, C; Mourah, S				Landras, Alexandra; de Moura, Coralie Reger; Villoutreix, Bruno O.; Battistella, Maxime; Sadoux, Aurelie; Dumaz, Nicolas; Menashi, Suzanne; Fernandez-Recio, Juan; Lebbe, Celeste; Mourah, Samia			Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction	ONCOGENE			English	Article							METASTATIC MELANOMA; GROWTH-FACTOR; OPEN-LABEL; PHASE-II; MEK INHIBITORS; BRAF; STAT3; MULTICENTER; BIOMARKER; SURVIVAL	More than 70% of human NRAS(mut) melanomas are resistant to MEK inhibitors highlighting the crucial need for efficient therapeutic strategies for these tumors. CD147, a membrane receptor, is overexpressed in most cancers including melanoma and is associated with poor prognosis. We show here that CD147i, a specific inhibitor of CD147/VEGFR-2 interaction represents a potential therapeutic strategy for NRAS(mut) melanoma cells. It significantly inhibited the malignant properties of NRAS(mut) melanomas ex vivo and in vivo. Importantly, NRAS(mut) patient's-derived xenografts, which were resistant to MEKi, became sensitive when combined with CD147i leading to decreased proliferation ex vivo and tumor regression in vivo. Mechanistic studies revealed that CD147i effects were mediated through STAT3 pathway. These data bring a proof of concept on the impact of the inhibition of CD147/VEGFR-2 interaction on melanoma progression and represents a new therapeutic opportunity for NRAS(mut) melanoma when combined with MEKi.	[Landras, Alexandra; de Moura, Coralie Reger; Battistella, Maxime; Dumaz, Nicolas; Lebbe, Celeste; Mourah, Samia] Univ Paris, UMR S976, INSERM, F-75010 Paris, France; [de Moura, Coralie Reger; Sadoux, Aurelie; Menashi, Suzanne; Mourah, Samia] Hop St Louis, AP HP, Pharmacogen Dept, F-75010 Paris, France; [Villoutreix, Bruno O.] Hop Robert Debre, UMR S1141, INSERM, F-75019 Paris, France; [Battistella, Maxime] Hop St Louis, AP HP, Pathol Dept, F-75010 Paris, France; [Fernandez-Recio, Juan] Univ La Rioja, Inst Ciencias & Vino ICVV, CSIC, Gobierno La Rioja, Logrono, Spain; [Lebbe, Celeste] Hop St Louis, AP HP, Dermatol Dept, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de La Rioja; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Mourah, S (corresponding author), Univ Paris, UMR S976, INSERM, F-75010 Paris, France.; Mourah, S (corresponding author), Hop St Louis, AP HP, Pharmacogen Dept, F-75010 Paris, France.	samia.mourah@aphp.fr	Battistella, Maxime/K-2949-2012; Landras, Alexandra/GNP-5158-2022; Dumaz, Nicolas/B-5907-2008	Battistella, Maxime/0000-0002-7053-7431; Reger de Moura, Coralie/0000-0002-3728-6722; Villoutreix, Bruno/0000-0002-6456-7730; Mourah, Samia/0000-0002-9283-1068; Dumaz, Nicolas/0000-0003-3511-2160	La Ligue Nationale contre le Cancer; Institut National de la Sante et de la Recherche Medicale (INSERM); La Societe Francaise de Dermatologie; Spanish Ministry of Science and Innovation [PID2019-110167RB-I00]; Ligue Nationale contre le Cancer	La Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); La Societe Francaise de Dermatologie; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This work was supported by La Ligue Nationale contre le Cancer, the Institut National de la Sante et de la Recherche Medicale (INSERM) and La Societe Francaise de Dermatologie. AL was supported by a PhD funding from La Ligue Nationale contre le Cancer and the Spanish Ministry of Science and Innovation (PID2019-110167RB-I00). We thank technological platform of the Institut Recherche Saint-Louis (IRSL) for confocal microscopy analyses and Dr Benoit Souquet for technical support.	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Ascierto PA, 2013, LANCET ONCOL, V14, P249, DOI 10.1016/S1470-2045(13)70024-X; Boespflug A, 2017, THER ADV MED ONCOL, V9, P481, DOI 10.1177/1758834017708160; Bougatef F, 2009, BLOOD, V114, P5547, DOI 10.1182/blood-2009-04-217380; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Caudron A, 2016, EXP DERMATOL, V25, P618, DOI 10.1111/exd.13022; Chapman PB, 2017, ANN ONCOL, V28, P2581, DOI 10.1093/annonc/mdx339; Chen SH, 2008, CANCER BIOL THER, V7, P1994, DOI 10.4161/cbt.7.12.6967; Davis EJ, 2018, CANCER-AM CANCER SOC, V124, P3490, DOI 10.1002/cncr.31345; de Moura CR, 2020, TRANSL ONCOL, V13, P275, DOI 10.1016/j.tranon.2019.10.003; Decoster L, 2015, ANTICANCER RES, V35, P6893; Delord JP, 2017, CLIN CANCER RES, V23, P5339, DOI 10.1158/1078-0432.CCR-16-2923; Delyon J, 2018, J INVEST DERMATOL, V138, P58, DOI 10.1016/j.jid.2017.07.839; Delyon J, 2016, ONCOTARGET, V7, P13069, DOI 10.18632/oncotarget.7541; Dummer R, 2017, LANCET ONCOL, V18, P435, DOI 10.1016/S1470-2045(17)30180-8; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Echevarria-Vargas IM, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708446; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Favier B, 2006, BLOOD, V108, P1243, DOI 10.1182/blood-2005-11-4447; Fedorenko IV, 2013, ONCOGENE, V32, P3009, DOI 10.1038/onc.2012.453; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Fu ZG, 2016, ONCOTARGET, V7, P9430, DOI 10.18632/oncotarget.6990; Graells J, 2004, J INVEST DERMATOL, V123, P1151, DOI 10.1111/j.0022-202X.2004.23460.x; Grass GD, 2013, J BIOL CHEM, V288, P26089, DOI 10.1074/jbc.M113.497685; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hayes TK, 2019, CANCER RES, V79, P2352, DOI 10.1158/0008-5472.CAN-18-2711; Hillion J, 2008, CANCER RES, V68, P10121, DOI 10.1158/0008-5472.CAN-08-2121; Ivy SP, 2009, NAT REV CLIN ONCOL, V6, P569, DOI 10.1038/nrclinonc.2009.130; Jiang TX, 2012, BLOOD, V120, P2330, DOI 10.1182/blood-2012-01-406108; Jouve N, 2015, INT J CANCER, V137, P50, DOI 10.1002/ijc.29370; Khayati F, 2015, ONCOTARGET, V6, P9766, DOI 10.18632/oncotarget.2870; Kim J, 2020, CANCERS, V12, DOI 10.3390/cancers12010119; Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9; Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502; Landras A, 2019, CANCERS, V11, DOI 10.3390/cancers11111803; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Lebbe C, 2020, CANCERS, V12, DOI 10.3390/cancers12071727; LOCKSHIN A, 1985, CANCER RES, V45, P345; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Mahapatra DK, 2017, EXPERT OPIN THER PAT, V27, P887, DOI 10.1080/13543776.2017.1339688; Mandala M, 2014, CRIT REV ONCOL HEMAT, V92, P107, DOI 10.1016/j.critrevonc.2014.05.005; Munoz-Couselo E, 2017, ONCOTARGETS THER, V10, P3941, DOI 10.2147/OTT.S117121; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Oladipupo SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33037-2; Posch C, 2013, P NATL ACAD SCI USA, V110, P4015, DOI 10.1073/pnas.1216013110; Robinson JP, 2017, MELANOMA RES, V27, P545, DOI 10.1097/CMR.0000000000000403; Sarkisian S, 2018, DRUG DES DEV THER, V12, P2553, DOI 10.2147/DDDT.S131721; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Tang Y, 2005, CANCER RES, V65, P3193, DOI 10.1158/0008-5472.CAN-04-3605; Tremmel M, 2009, BLOOD, V114, P5236, DOI 10.1182/blood-2009-04-219204; Trojaniello C, 2019, EXPERT REV CLIN PHAR, V12, P259, DOI 10.1080/17512433.2019.1570847; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wu PK, 2015, SEMIN ONCOL, V42, P849, DOI 10.1053/j.seminoncol.2015.09.023; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818	54	1	1	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2254	2264		10.1038/s41388-022-02244-7	http://dx.doi.org/10.1038/s41388-022-02244-7		FEB 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35217792				2022-12-28	WOS:000761868000002
J	Rao, VS; Gu, QY; Tzschentke, S; Lin, KL; Ganig, N; Thepkaysone, ML; Wong, FC; Polster, H; Seifert, L; Seifert, AM; Buck, N; Riediger, C; Weisse, J; Gutschner, T; Michen, S; Temme, A; Schneider, M; Baenke, F; Weitz, J; Kahlert, C				Rao, Venkatesh Sadananda; Gu, Qianyu; Tzschentke, Sandra; Lin, Kuailu; Ganig, Nicole; Thepkaysone, May-Linn; Wong, Fang Cheng; Polster, Heike; Seifert, Lena; Seifert, Adrian M.; Buck, Nathalie; Riediger, Carina; Weisse, Jonas; Gutschner, Tony; Michen, Susanne; Temme, Achim; Schneider, Martin; Baenke, Franziska; Weitz, Juergen; Kahlert, Christoph			Extravesicular TIMP-1 is a non-invasive independent prognostic marker and potential therapeutic target in colorectal liver metastases	ONCOGENE			English	Article							TISSUE INHIBITOR; EXTRACELLULAR VESICLES; CANCER; MATRIX; METALLOPROTEINASES-1; PLASMA; NICHE	Molecular reprogramming of stromal microarchitecture by tumour-derived extracellular vesicles (EVs) is proposed to favour pre-metastatic niche formation. We elucidated the role of extravesicular tissue inhibitor of matrix metalloproteinase-1 (TIMP1(EV)) in pro-invasive extracellular matrix (ECM) remodelling of the liver microenvironment to aid tumour progression in colorectal cancer (CRC). Immunohistochemistry analysis revealed a high expression of stromal TIMP1 in the invasion front that was associated with poor progression-free survival in patients with colorectal liver metastases. Molecular analysis identified TIMP1(EV) enrichment in CRC-EVs as a major factor in the induction of TIMP1 upregulation in recipient fibroblasts. Mechanistically, we proved that EV-mediated TIMP1 upregulation in recipient fibroblasts induced ECM remodelling. This effect was recapitulated by human serum-derived EVs providing strong evidence that CRC release active EVs into the blood circulation of patients for the horizontal transfer of malignant traits to recipient cells. Moreover, EV-associated TIMP1 binds to HSP90AA, a heat-shock protein, and the inhibition of HSP90AA on human-derived serum EVs attenuates TIMP1(EV)-mediated ECM remodelling, rendering EV-associated TIMP1 a potential therapeutic target. Eventually, in accordance with REMARK guidelines, we demonstrated in three independent cohorts that EV-bound TIMP1 is a robust circulating biomarker for a non-invasive, preoperative risk stratification in patients with colorectal liver metastases.	[Rao, Venkatesh Sadananda; Gu, Qianyu; Lin, Kuailu; Ganig, Nicole; Thepkaysone, May-Linn; Wong, Fang Cheng; Polster, Heike; Seifert, Lena; Seifert, Adrian M.; Buck, Nathalie; Riediger, Carina; Baenke, Franziska; Weitz, Juergen; Kahlert, Christoph] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, Dresden, Germany; [Tzschentke, Sandra] Goethe Univ, Univ Hosp Frankfurt, Dept Med Haematol Oncol, Frankfurt, Germany; [Seifert, Lena; Seifert, Adrian M.; Weitz, Juergen; Kahlert, Christoph] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Seifert, Lena; Seifert, Adrian M.; Weitz, Juergen; Kahlert, Christoph] Natl Ctr Tumor Dis, Partner Site Dresden, Heidelberg, Germany; [Weisse, Jonas; Gutschner, Tony] Martin Luther Univ Halle Wittenberg, Med Fac, Jr Res Grp RNA Biol & Pathogenesis, Halle An Der Saale, Germany; [Michen, Susanne; Temme, Achim] Tech Univ Dresden, Dept Neurosurg, Sect Expt Neurosurg & Tumour Immunol, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Schneider, Martin] Univ Hosp Heidelberg, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Martin Luther University Halle Wittenberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Ruprecht Karls University Heidelberg	Kahlert, C (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, Dresden, Germany.; Kahlert, C (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.	Christoph.Kahlert@uniklinikum-dresden.de	Seifert, Adrian M./AAL-3453-2021	Seifert, Adrian M./0000-0002-5329-3164	Roland-Ernst-Foundation, Dresden [5/15]; Deutsche Forschungsgemeinschaft (DFG) [KA 3511/3-1]	Roland-Ernst-Foundation, Dresden; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank all the patients and their families for agreeing to the use of their samples. We also thank the surgeons of the VTG department who performed the surgeries. Special thanks to Falk Zakrewski for his assistance with the digital slide scanner. This work was funded by the Roland-Ernst-Foundation, Dresden (project no. 5/15) and Deutsche Forschungsgemeinschaft (DFG) (KA 3511/3-1).	Aaberg-Jessen C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4179-y; Abdouh M, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0587-0; Angioni R, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1757900; Atai NA, 2013, J NEURO-ONCOL, V115, P343, DOI 10.1007/s11060-013-1235-y; Baker-Williams AJ, 2019, CELL REP, V28, P1894, DOI 10.1016/j.celrep.2019.07.045; Bockelman C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4589-x; Dechene A, 2010, HEPATOLOGY, V52, P1008, DOI 10.1002/hep.23754; Engstrand J, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3925-x; Forte D, 2017, ONCOTARGET, V8, P2261, DOI 10.18632/oncotarget.13664; Franzen CA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/619829; Galindo-Hernandez O, 2013, ARCH MED RES, V44, P208, DOI 10.1016/j.arcmed.2013.03.002; Gong YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077366; Han L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0980-8; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; Holten-Andersen MN, 2005, INT J CANCER, V113, P198, DOI 10.1002/ijc.20566; Huang T, 2019, INT J BIOL SCI, V15, P1, DOI 10.7150/ijbs.27796; Kahlert C, 2008, ANTICANCER RES, V28, P1459; Kaushik S, 2016, CANCER METAST REV, V35, P655, DOI 10.1007/s10555-016-9650-0; Kim H, 2019, PROTEOME SCI, V17, DOI 10.1186/s12953-019-0154-z; Kopitz C, 2007, CANCER RES, V67, P8615, DOI 10.1158/0008-5472.CAN-07-0232; Kur P, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082620; Lachowski D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43759-6; Lee JH, 2011, J GASTROINTEST LIVER, V20, P287; Liu LX, 2003, WORLD J GASTROENTERO, V9, P193, DOI 10.3748/wjg.v9.i2.193; McShane LM, 2005, BRIT J CANCER, V93, P387, DOI 10.1038/sj.bjc.6602678; Park HK, 2020, EXP MOL MED, V52, P79, DOI 10.1038/s12276-019-0360-x; Pretzsch E, 2019, J ONCOL, V2019, DOI 10.1155/2019/7407190; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ries C, 2014, CELL MOL LIFE SCI, V71, P659, DOI 10.1007/s00018-013-1457-3; Robinson BK, 2016, BIOL OPEN, V5, P875, DOI 10.1242/bio.017632; Seubert B, 2015, HEPATOLOGY, V61, P238, DOI 10.1002/hep.27378; Sontake V, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91454; Takawale A, 2017, HYPERTENSION, V69, P1092, DOI 10.1161/HYPERTENSIONAHA.117.09045; Terpos E, 2010, LEUKEMIA RES, V34, P399, DOI 10.1016/j.leukres.2009.08.035; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Tommelein J, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00063; Vong Sylvia, 2011, Genes Cancer, V2, P1139, DOI 10.1177/1947601911423940; Weidle UH, 2017, CANCER GENOM PROTEOM, V14, P1, DOI 10.21873/cgp.20015; Wendler F, 2017, ONCOGENE, V36, P877, DOI 10.1038/onc.2016.253; Wurtz SO, 2008, MOL CELL PROTEOMICS, V7, P424, DOI 10.1074/mcp.M700305-MCP200; Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9	42	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1809	1820		10.1038/s41388-022-02218-9	http://dx.doi.org/10.1038/s41388-022-02218-9		FEB 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35140332	Green Published, hybrid			2022-12-28	WOS:000753256900002
J	Fan, M; Sun, WK; Gu, XF; Lu, SS; Shen, Q; Liu, X; Zhang, XW				Fan, Meng; Sun, Weikuan; Gu, Xiaofan; Lu, Shanshan; Shen, Qiang; Liu, Xuan; Zhang, Xiongwen			The critical role of STAT3 in biogenesis of tumor-derived exosomes with potency of inducing cancer cachexia in vitro and in vivo	ONCOGENE			English	Article							SNARE COMPLEXES; IL-6; INHIBITION; GLYCOLYSIS; ACTIVATION; PATHWAY; PKM2; MICROENVIRONMENT; PROLIFERATION; TRANSCRIPTION	Tumor-derived exosomes are emerging mediators of cancer cachexia. Clarifying the regulation of exosome biogenesis and finding possible targets for cancer cachexia therapy are important and necessary. In the present study, systemic analysis of the roles of STAT3 in controlling exosome biogenesis of murine C26 colon tumor cells and its contribution to the development of cancer cachexia is conducted. The genetic manipulation of STAT3 expression, STAT3 knockout (KO) or overexpression (OE), significantly affected the exosome biogenesis and also the potency of C26 conditioned medium (CM) in inducing muscle atrophy and lipolysis in vitro. The genetic manipulation of STAT3 expression caused change in phosphorylation of PKM2 and glycolysis. PKM2/SNAP23 pathway was involved in regulation of exosome biogenesis by STAT3 genetic manipulation as well as by STAT3 inhibitors in C26 cells. Mice inoculated with STAT3 knockout or overexpression C26 cells exhibited ameliorated or aggravated cancer cachexia symptoms, with a positive correlation with the serum exosome and IL-6 levels. The STAT3/PKM2/SNAP23 pathway was affected in C26 tumor tissues with genetic manipulation of STAT3 expression. The capacity of exosome biogenesis of different human cancer cells also exhibited a positive correlation with the activation of STAT3/PKM2/SNAP23 pathway. The research presented here confirms that STAT3 plays a critical role in regulating biogenesis of tumor-derived exosomes which could contribute to cancer cachexia development.	[Fan, Meng; Sun, Weikuan; Gu, Xiaofan; Lu, Shanshan; Zhang, Xiongwen] East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai, Peoples R China; [Shen, Qiang; Liu, Xuan] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China	East China Normal University; Shanghai University of Traditional Chinese Medicine	Zhang, XW (corresponding author), East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai, Peoples R China.; Liu, X (corresponding author), Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China.	xuanliu@shutcm.edu.cn; xwzhang@sat.ecnu.edu.cn		Liu, Xuan/0000-0002-7356-7898; Gu, Xiaofan/0000-0002-2441-3489; Fan, Meng/0000-0002-3761-4431	National Nature Science Foundation of China [81872496, 81873056]; Science and Technology Commission of Shanghai Municipality [20S11902200, 16DZ2280100]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by National Nature Science Foundation of China (No. 81872496 and 81873056), and the Science and Technology Commission of Shanghai Municipality (20S11902200 and 16DZ2280100).	Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Damasceno LEA, 2020, J EXP MED, V217, DOI 10.1084/jem.20190613; Arora Gurpreet, 2020, JCSM Rapid Commun, V3, P115, DOI 10.1002/rco2.24; Baracos VE, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.105; Bi YH, 2019, WORLD J GASTROENTERO, V25, P1936, DOI 10.3748/wjg.v25.i16.1936; Bian ZH, 2018, CLIN CANCER RES, V24, P4808, DOI 10.1158/1078-0432.CCR-17-2967; Bonetto A, 2012, AM J PHYSIOL-ENDOC M, V303, pE410, DOI 10.1152/ajpendo.00039.2012; Chai EZP, 2016, PHARMACOL THERAPEUT, V162, P86, DOI 10.1016/j.pharmthera.2015.10.004; Chaneton B, 2012, TRENDS BIOCHEM SCI, V37, P309, DOI 10.1016/j.tibs.2012.04.003; Chen LL, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.113066; Chen LL, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104871; Chitti SV, 2018, BIOCHEM SOC T, V46, P1129, DOI 10.1042/BST20180213; D'Souza-Schorey C, 2012, GENE DEV, V26, P1287, DOI 10.1101/gad.192351.112; Demaria Marco, 2012, JAKSTAT, V1, P194, DOI 10.4161/jkst.20662; Dorayappan KDP, 2018, ONCOGENE, V37, P3806, DOI 10.1038/s41388-018-0189-0; Eskiler GG, 2019, BRATISL MED J, V120, P819, DOI 10.4149/BLL_2019_136; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011; Fu XQ, 2018, EXP DERMATOL, V27, P201, DOI 10.1111/exd.13454; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Gao SM, 2019, J CELL BIOCHEM, V120, P1193, DOI 10.1002/jcb.26915; Gao XH, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12060; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Harada Y, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108261; Hu WJ, 2018, BIOCHEM BIOPH RES CO, V506, P122, DOI 10.1016/j.bbrc.2018.09.139; Jaskiewicz A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218261; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kalra H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020170; Kim NH, 2020, BIOCHEM BIOPH RES CO, V533, P1378, DOI 10.1016/j.bbrc.2020.10.025; Kosgodage US, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00889; Kroon P, 2013, CANCER RES, V73, P5288, DOI 10.1158/0008-5472.CAN-13-0874; Kunou S, 2021, ONCOGENE, V40, P3989, DOI 10.1038/s41388-021-01829-y; Li M, 2017, ONCOTARGET, V8, P24777, DOI 10.18632/oncotarget.15801; Li YX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00273; Liu Y, 2008, EVID-BASED COMPL ALT, V5, P337, DOI 10.1093/ecam/nem031; Lu SS, 2021, J CACHEXIA SARCOPENI, V12, P779, DOI 10.1002/jcsm.12710; Marinho R, 2018, FRONT NUTR, V4, DOI 10.3389/fnut.2017.00069; Marrocco I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091048; McAndrews KM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0963-9; Miao CX, 2021, MOL THER-NUCL ACIDS, V24, P923, DOI 10.1016/j.omtn.2021.04.015; Miller A, 2017, ONCOGENE, V36, P3059, DOI 10.1038/onc.2016.437; Ou BC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1418-2; Palsson-McDermott EM, 2013, BIOESSAYS, V35, P965, DOI 10.1002/bies.201300084; Pawlus MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072358; Prado BL, 2019, ANN PALLIAT MED, V8, P67, DOI 10.21037/apm.2018.07.06; Puckett DL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031171; Puri N, 2006, TRAFFIC, V7, P1482, DOI 10.1111/j.1600-0854.2006.00490.x; Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123; Ren RX, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0325-8; Rice GE, 2015, J CLIN ENDOCR METAB, V100, pE1280, DOI 10.1210/jc.2015-2270; Rodriguez-Barrueco R, 2015, GENE DEV, V29, P1631, DOI 10.1101/gad.262642.115; Silva KAS, 2015, J BIOL CHEM, V290, P11177, DOI 10.1074/jbc.M115.641514; Seto DN, 2015, J BIOL CHEM, V290, P19976, DOI 10.1074/jbc.M115.638411; Shin MK, 2021, BIOL PHARM BULL, V44, P686, DOI 10.1248/bpb.b20-01032; Shirai T, 2016, J EXP MED, V213, P337, DOI 10.1084/jem.20150900; Shouda T, 2006, CANCER LETT, V231, P176, DOI 10.1016/j.canlet.2005.01.042; Simon T, 2020, ONCOGENE, V39, P4477, DOI 10.1038/s41388-020-1308-2; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; Sun L, 2015, NUTR CANCER, V67, P1056, DOI 10.1080/01635581.2015.1073753; Suzuki T, 2020, EXPERT OPIN DRUG DIS, V15, P627, DOI 10.1080/17460441.2020.1724954; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Valle-Mendiola A, 2020, CANCERS, V12, DOI 10.3390/cancers12010124; Vallee A, 2018, REV NEUROSCIENCE, V29, P71, DOI 10.1515/revneuro-2017-0032; Vaupel P, 2021, J PHYSIOL-LONDON, V599, P1745, DOI 10.1113/JP278810; Wei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14041; Wendler F, 2017, ONCOGENE, V36, P877, DOI 10.1038/onc.2016.253; Wu Q, 2019, ADIPOCYTE, V8, P31, DOI 10.1080/21623945.2018.1551688; Wu Q, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0899-5; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Yang M, 2017, CELL PHYSIOL BIOCHEM, V44, P293, DOI 10.1159/000484885; Yang X, 2021, ONCOGENE, V40, P4307, DOI 10.1038/s41388-021-01837-y; Yoon YJ, 2018, CANCER LETT, V434, P42, DOI 10.1016/j.canlet.2018.07.015; Zahra K, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00159; Zhang GH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00726-x; Zhang QQ, 2021, J CANCER, V12, P4830, DOI 10.7150/jca.58494; Zhang WL, 2020, ACTA PHARMACOL SIN, V41, P237, DOI 10.1038/s41401-019-0275-z; Zhao WN, 2013, INT J MOL SCI, V14, P13577, DOI 10.3390/ijms140713577; Zhou L, 2021, SKELET MUSCLE, V11, DOI 10.1186/s13395-021-00274-5; Zhu B, 2018, J ETHNOPHARMACOL, V226, P143, DOI 10.1016/j.jep.2018.08.023; Zimmers TA, 2016, SEMIN CELL DEV BIOL, V54, P28, DOI 10.1016/j.semcdb.2016.02.009	80	5	5	7	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1050	1062		10.1038/s41388-021-02151-3	http://dx.doi.org/10.1038/s41388-021-02151-3		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	35034093				2022-12-28	WOS:000742810100001
J	Lee, YC; Lin, SC; Yu, GY; Zhu, M; Song, JH; Rivera, K; Pappin, D; Logothetis, CJ; Panaretakis, T; Wang, GC; Yu-Lee, LY; Lin, SH				Lee, Yu-Chen; Lin, Song-Chang; Yu, Guoyu; Zhu, Ming; Song, Jian H.; Rivera, Keith; Pappin, Darryl; Logothetis, Christopher J.; Panaretakis, Theocharis; Wang, Guocan; Yu-Lee, Li-Yuan; Lin, Sue-Hwa			Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition	ONCOGENE			English	Article							BONE; CELLS; EXPRESSION; GROWTH; PROGRESSION; RECEPTOR; INTEGRIN; LNCAP; PHOSPHORYLATION; ACTIVATION	Metastatic prostate cancer (PCa) in bone induces bone-forming lesions that enhance PCa progression. How tumor-induced bone formation enhances PCa progression is not known. We have previously shown that PCa-induced bone originates from endothelial cells (ECs) that have undergone endothelial-to-osteoblast (EC-to-OSB) transition by tumor-secreted bone morphogenetic protein 4 (BMP4). Here, we show that EC-to-OSB transition leads to changes in the tumor microenvironment that increases the metastatic potential of PCa cells. We found that conditioned medium (CM) from EC-OSB hybrid cells increases the migration, invasion, and survival of PC3-mm2 and C4-2B4 PCa cells. Quantitative mass spectrometry (Isobaric Tags for Relative and Absolute Quantitation) identified Tenascin C (TNC) as one of the major proteins secreted from EC-OSB hybrid cells. TNC expression in tumor-induced OSBs was confirmed by immunohistochemistry of MDA PCa-118b xenograft and human bone metastasis specimens. Mechanistically, BMP4 increases TNC expression in EC-OSB cells through the Smad1-Notch/Hey1 pathway. How TNC promotes PCa metastasis was next interrogated by in vitro and in vivo studies. In vitro studies showed that a TNC-neutralizing antibody inhibits EC-OSB-CM-mediated PCa cell migration and survival. TNC knockdown decreased, while the addition of recombinant TNC or TNC overexpression increased migration and anchorage-independent growth of PC3 or C4-2b cells. When injected orthotopically, PC3-mm2-shTNC clones decreased metastasis to bone, while C4-2b-TNC-overexpressing cells increased metastasis to lymph nodes. TNC enhances PCa cell migration through alpha 5 beta 1 integrin-mediated YAP/TAZ inhibition. These studies elucidate that tumor-induced stromal reprogramming generates TNC that enhances PCa metastasis and suggest that TNC may be a target for PCa therapy.	[Lee, Yu-Chen; Lin, Song-Chang; Yu, Guoyu; Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Zhu, Ming; Song, Jian H.; Logothetis, Christopher J.; Panaretakis, Theocharis; Wang, Guocan; Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Rivera, Keith; Pappin, Darryl] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Yu-Lee, Li-Yuan] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Yu-Lee, Li-Yuan] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Cold Spring Harbor Laboratory; Baylor College of Medicine; Baylor College of Medicine	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.; Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.	slin@mdanderson.org			NIH [R01CA174798, 5P50CA140388, P30CA16672]; Cancer Prevention Research Institute of Texas grants [RP150179, RP190252]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas grants	This work was supported by grants from the NIH R01CA174798 (to S-HL, L-YY-L), NIH 5P50CA140388 (to CJL, S-HL), NIH P30CA16672 Core grant to MD Anderson Cancer Center, and Cancer Prevention Research Institute of Texas grants RP150179 and RP190252 (to S-HL and L-YY-L).	Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Carey WA, 2010, AM J PHYSIOL-LUNG C, V299, pL785, DOI 10.1152/ajplung.00385.2009; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; Conklin MW, 2012, CELL ADHES MIGR, V6, P249, DOI 10.4161/cam.20567; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Fischer A, 2005, MOL CELL BIOL, V25, P8960, DOI 10.1128/MCB.25.20.8960-8970.2005; Grahovac J, 2013, J INVEST DERMATOL, V133, P210, DOI 10.1038/jid.2012.263; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Heindryckx F, 2015, WORLD J HEPATOL, V7, P165, DOI 10.4254/wjh.v7.i2.165; Herold-Mende C, 2002, INT J CANCER, V98, P362, DOI 10.1002/ijc.10233; Hong CC, 2009, CYTOKINE GROWTH F R, V20, P409, DOI 10.1016/j.cytogfr.2009.10.021; Hosein AN, 2020, NAT REV GASTRO HEPAT, V17, P487, DOI 10.1038/s41575-020-0300-1; Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008-5472.CAN-09-3016; Jachetti E, 2015, CANCER RES, V75, P2095, DOI 10.1158/0008-5472.CAN-14-2346; Jiao SP, 2019, CELL, V179, P1177, DOI 10.1016/j.cell.2019.10.029; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Katoh D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.27; Lee YC, 2018, J PROTEOME RES, V17, P348, DOI 10.1021/acs.jproteome.7b00599; Lee YC, 2015, CANCER RES, V75, P4949, DOI 10.1158/0008-5472.CAN-15-1215; Lee YC, 2013, MOL CANCER RES, V11, P1401, DOI 10.1158/1541-7786.MCR-13-0108; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008-5472.CAN-10-4374; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Martin RS, 2017, CANCER RES, V77, P5977, DOI 10.1158/0008-5472.CAN-17-0064; Midwood KS, 2016, J CELL SCI, V129, P4321, DOI 10.1242/jcs.190546; Miroshnikova YA, 2016, NAT CELL BIOL, V18, P1336, DOI 10.1038/ncb3429; Morrissey C, 2010, NEOPLASIA, V12, P192, DOI 10.1593/neo.91836; Mutvei AP, 2018, ONCOGENE, V37, P6083, DOI 10.1038/s41388-018-0400-3; Nagaharu K, 2011, AM J PATHOL, V178, P754, DOI 10.1016/j.ajpath.2010.10.015; Ni WD, 2017, BIOCHEM BIOPH RES CO, V486, P607, DOI 10.1016/j.bbrc.2017.03.021; Nordstrand A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041223; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95; Riedel A, 2016, NAT IMMUNOL, V17, P1118, DOI 10.1038/ni.3492; Sarkar S, 2017, CANCER RES, V77, P3231, DOI 10.1158/0008-5472.CAN-16-2171; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Sun Z, 2018, CANCER RES, V78, P950, DOI 10.1158/0008-5472.CAN-17-1597; Sung SY, 2008, CANCER RES, V68, P9996, DOI 10.1158/0008-5472.CAN-08-2492; Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; Totaro A, 2018, NAT CELL BIOL, V20, P888, DOI 10.1038/s41556-018-0142-z; Tu Shi-Ming, 2004, Cancer Treat Res, V118, P23; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; Ye XC, 2012, PROSTATE, V72, P291, DOI 10.1002/pros.21431; Yu G, 2021, ISCIENCE, V24; Yu G, 2015, MOL CANCER RES, V13, P348, DOI 10.1158/1541-7786.MCR-14-0384-T; Yu-Lee LY, 2018, CANCER RES, V78, P2911, DOI 10.1158/0008-5472.CAN-17-1051; Zhu M, 2021, ONCOGENE, V40, P6049, DOI 10.1038/s41388-021-02000-3	55	5	6	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					757	769		10.1038/s41388-021-02131-7	http://dx.doi.org/10.1038/s41388-021-02131-7		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34845375	Green Submitted, Green Accepted			2022-12-28	WOS:000723571700003
J	Lu, YW; Wu, FY; Cao, QY; Sun, Y; Huang, ML; Xiao, J; Zhou, B; Zhang, L				Lu, Youwei; Wu, Fengying; Cao, Qiuyi; Sun, Yu; Huang, Moli; Xiao, Jing; Zhou, Bin; Zhang, Liang			B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression	ONCOGENE			English	Article							IMMUNE MICROENVIRONMENT; CHECKPOINT INHIBITORS; PD-1 BLOCKADE; SOLID TUMORS; CANCER; PEMBROLIZUMAB; EXPRESSION; NIVOLUMAB; SENSITIVITY; DOCETAXEL	PD-1/PD-L1 inhibitors have shown clinical benefit in lung adenocarcinoma (LUAD). However, the immunotherapy strategy is less effective in patients with EGFR-activating mutations (EGFR MT). Studies showed that besides low expression of PD-L1, the absence of TILs and distinct expression profile of immune checkpoint molecules might be associated with low response of the patient subset. In this study, we first compared CD8A, GZMB and PRF1 mRNA levels in different LUAD subtypes harboring different driver mutations by dataset analyses and investigated the association between 15 well-defined B7-CD28 family members and driver mutations. The results showed that the decreases in the density and function of CD8(+) TILs, CD274 (PD-L1 gene), and CD86 and increases in VTCN1 (B7-H4 gene) and HHLA2 were associated with LUAD with EGFR-activating mutations. Immunohistochemical staining studies further supported that PD-L1 was downregulated and B7-H4 was upregulated in the subtype. Furthermore, PD-L1 expression was positively associated with levels of CD8A and granzyme B, while B7-H4 expression was negatively associated with granzyme B levels. In lung cancer cell lines, EGFR-activating mutations effectively upregulated B7-H4 and downregulated PD-L1. MEK/ERK-pathway activation upregulated B7-H4, and PI3K/Akt activation upregulated PD-L1. EGFR 19Del mutation was associated with inhibition of CD8(+) T-cell function, while knocking down B7-H4 could reverse the inhibition, and further showed tumor-growth inhibition and longer survival in vivo. Taken together, this study shed light on that B7-H4 might be an alternative immune-checkpoint molecule and a potential therapeutic target for LUAD with EGFR MT.	[Lu, Youwei; Cao, Qiuyi; Sun, Yu; Zhang, Liang] Soochow Univ, Coll Pharmaceut Sci, Suzhou, Jiangsu, Peoples R China; [Wu, Fengying] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China; [Huang, Moli] Soochow Univ, Sch Biol & Basic Med Sci, Dept Bioinformat, Suzhou, Peoples R China; [Xiao, Jing] Songgang Peoples Hosp Shenzhen Baoan Dist, Cent Lab, Shenzhen, Guangdong, Peoples R China; [Zhou, Bin; Zhang, Liang] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Clin Immunol, Suzhou, Jiangsu, Peoples R China; [Zhou, Bin; Zhang, Liang] Soochow Univ, Jiangsu Key Lab Clin Immunol, Suzhou, Jiangsu, Peoples R China; [Zhou, Bin; Zhang, Liang] Soochow Univ, Jiangsu Key Lab Gastrointestinal Tumor Immunol, Suzhou, Jiangsu, Peoples R China	Soochow University - China; Tongji University; Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China	Zhang, L (corresponding author), Soochow Univ, Coll Pharmaceut Sci, Suzhou, Jiangsu, Peoples R China.; Zhou, B; Zhang, L (corresponding author), Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Clin Immunol, Suzhou, Jiangsu, Peoples R China.; Zhou, B; Zhang, L (corresponding author), Soochow Univ, Jiangsu Key Lab Clin Immunol, Suzhou, Jiangsu, Peoples R China.; Zhou, B; Zhang, L (corresponding author), Soochow Univ, Jiangsu Key Lab Gastrointestinal Tumor Immunol, Suzhou, Jiangsu, Peoples R China.	karichou@163.com; zliang@suda.edu.cn		Zhang, Liang/0000-0002-5041-8005	National Nature Science Foundation of China [31370872, 81402381, 81502454]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Nature Science Foundation of China (Grant No. 31370872, No. 81402381, and No. 81502454).	Altan M, 2017, CLIN CANCER RES, V23, P5202, DOI 10.1158/1078-0432.CCR-16-3107; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Buder-Bakhaya K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01474; Chen JA, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864-020-00750-y; Chen Q, 2018, ONCOTARGETS THER, V11, P4673, DOI 10.2147/OTT.S168313; Chen Y, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.153134; Cheng HY, 2018, CLIN CANCER RES, V24, P1954, DOI 10.1158/1078-0432.CCR-17-2924; D'Incecco A, 2015, BRIT J CANCER, V112, P95, DOI 10.1038/bjc.2014.555; Dong ZY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356145; Du HW, 2019, CANCER CELL, V35, P221, DOI 10.1016/j.ccell.2019.01.002; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gruosso T, 2019, J CLIN INVEST, V129, P1785, DOI 10.1172/JCI96313; Hamid O, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-204; Haratani K, 2017, ANN ONCOL, V28, P1532, DOI 10.1093/annonc/mdx183; Harris-Bookman S, 2018, INT J CANCER, V143, P3201, DOI 10.1002/ijc.31661; Hatogai K, 2020, BRIT J CANCER, V122, P413, DOI 10.1038/s41416-019-0622-3; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Iizuka A, 2019, CLIN CANCER RES, V25, P2925, DOI 10.1158/1078-0432.CCR-17-3123; Janakiram M, 2017, IMMUNOL REV, V276, P26, DOI 10.1111/imr.12521; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; John P, 2019, TRENDS PHARMACOL SCI, V40, P883, DOI 10.1016/j.tips.2019.09.008; Jung KH, 2019, CLIN CANCER RES, V25, P3220, DOI 10.1158/1078-0432.CCR-18-2740; Kasten BB, 2020, CURR MED CHEM, V27, P4016, DOI 10.2174/0929867326666190228120908; Krawczyk P, 2016, ANN ONCOL, V27, P358, DOI 10.1093/annonc/mdv553; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007; Leprieur EG, 2017, EUR J CANCER, V78, P16, DOI 10.1016/j.ejca.2016.12.041; Li J, 2018, IMMUNITY, V48, P773, DOI 10.1016/j.immuni.2018.03.018; Mazzaschi G, 2018, CLIN CANCER RES, V24, P407, DOI 10.1158/1078-0432.CCR-17-2156; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Ni L, 2017, MOL CANCER THER, V16, P1203, DOI 10.1158/1535-7163.MCT-16-0761; Oble Darryl A, 2009, Cancer Immun, V9, P3; Pai-Scherf L, 2017, ONCOLOGIST, V22, P1392, DOI 10.1634/theoncologist.2017-0078; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Rousalova I, 2010, INT J ONCOL, V37, P1361, DOI 10.3892/ijo_00000788; Schliekelman MJ, 2015, CANCER RES, V75, P1789, DOI 10.1158/0008-5472.CAN-14-2535; Sul J, 2016, ONCOLOGIST, V21, P643, DOI 10.1634/theoncologist.2015-0498; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Toki MI, 2018, J THORAC ONCOL, V13, P1884, DOI 10.1016/j.jtho.2018.09.012; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Westover D, 2018, ANN ONCOL, V29, pI10, DOI 10.1093/annonc/mdx703; Xing XF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1356144; Yagi T, 2019, ANN SURG, V269, P471, DOI 10.1097/SLA.0000000000002616; Yoshida H, 2018, ANN ONCOL, V29, P777, DOI 10.1093/annonc/mdx745; Yu SR, 2020, ONCOGENE, V39, P2643, DOI 10.1038/s41388-020-1182-y; Zhao ZM, 2020, CANCER LETT, V485, P14, DOI 10.1016/j.canlet.2020.04.013	54	4	4	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					704	717		10.1038/s41388-021-02124-6	http://dx.doi.org/10.1038/s41388-021-02124-6		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34839353				2022-12-28	WOS:000722970800001
J	Mazziotta, C; Rotondo, JC; Lanzillotti, C; Campione, G; Martini, F; Tognon, M				Mazziotta, Chiara; Rotondo, John Charles; Lanzillotti, Carmen; Campione, Giulia; Martini, Fernanda; Tognon, Mauro			Cancer biology and molecular genetics of A(3) adenosine receptor	ONCOGENE			English	Review							CELL-CYCLE ARREST; CL-IB-MECA; PROMOTER HYPERMETHYLATION; SEMEN SAMPLES; AGONIST; PROLIFERATION; EXPRESSION; TARGET; GROWTH; PHOSPHORYLATION	A(3) adenosine receptor (A(3)AR) is a cell membrane protein, which has been found to be overexpressed in a large number of cancer types. This receptor plays an important role in cancer by interacting with adenosine. Specifically, A(3)AR has a dual nature in different pathophysiological conditions, as it is expressed according to tissue type and stimulated by an adenosine dose-dependent manner. A(3)AR activation leads to tumor growth, cell proliferation and survival in some cases, while triggering cytostatic and apoptotic pathways in others. This review aims to describe the most relevant aspects of A(3)AR activation and its ligands whereas it summarizes A(3)AR activities in cancer. Progress in the field of A(3)AR modulators, with a potential therapeutic role in cancer treatment are reported, as well.	[Mazziotta, Chiara; Rotondo, John Charles; Lanzillotti, Carmen; Campione, Giulia; Martini, Fernanda; Tognon, Mauro] Univ Ferrara, Sch Med, Dept Med Sci, Labs Cell Biol & Mol Genet,Sect Expt Med, 64-B Fossato Mortara St, I-44121 Ferrara, Italy; [Mazziotta, Chiara; Rotondo, John Charles; Lanzillotti, Carmen] Univ Ferrara, Ctr Studies Gender Med, Dept Med Sci, 64-B Fossato Mortara St, I-44121 Ferrara, Italy; [Martini, Fernanda] Univ Ferrara, Lab Technol Adv Therapies LTTA, I-44121 Ferrara, Italy	University of Ferrara; University of Ferrara; University of Ferrara	Martini, F; Tognon, M (corresponding author), Univ Ferrara, Sch Med, Dept Med Sci, Labs Cell Biol & Mol Genet,Sect Expt Med, 64-B Fossato Mortara St, I-44121 Ferrara, Italy.; Martini, F (corresponding author), Univ Ferrara, Lab Technol Adv Therapies LTTA, I-44121 Ferrara, Italy.	mrf@unife.it; tgm@unife.it		Tognon, Mauro/0000-0001-8269-7937; Mazziotta, Chiara/0000-0002-5091-0497	Associazione Italiana per la Ricerca sul Cancro (AIRC) [MFAG 21956, IG 21617]; International Association for the Study of Lung Cancer (IASLC)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); International Association for the Study of Lung Cancer (IASLC)	The works of JCR and MT have been supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), grants MFAG 21956 and IG 21617, respectively. JCR was also supported by The International Association for the Study of Lung Cancer (IASLC).	Abedi H, 2014, TUMOR BIOL, V35, P11027, DOI 10.1007/s13277-014-2396-9; Aghaei M, 2011, J CANCER RES CLIN, V137, P1511, DOI 10.1007/s00432-011-1031-z; Ahmad A, 2010, EXTRACELLULAR ATP AND ADENOSINE AS REGULATORS OF ENDOTHELIAL CELL FUNCTION, P113, DOI 10.1007/978-90-481-3435-9_7; Allard B, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1601481; Bar-Yehuda S, 2008, INT J ONCOL, V33, P287, DOI 10.3892/ijo_00000008; Bar-Yehuda S, 2007, EXPERT OPIN INV DRUG, V16, P1601, DOI 10.1517/13543784.16.10.1601; Borea PA, 2018, PHYSIOL REV, V98, P1591, DOI 10.1152/physrev.00049.2017; Borea PA, 2015, PHARMACOL REV, V67, P74, DOI 10.1124/pr.113.008540; Borea PA, 2016, TRENDS PHARMACOL SCI, V37, P419, DOI 10.1016/j.tips.2016.02.006; Cohen S, 2011, J CELL PHYSIOL, V226, P2438, DOI 10.1002/jcp.22593; Contini C, 2019, J CELL PHYSIOL, V234, P100, DOI 10.1002/jcp.26952; Di Bonaventura MVM, 2019, J PSYCHOPHARMACOL, V33, P1550, DOI 10.1177/0269881119845798; Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206; Effendi WI, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030785; Ezeamuzie CI, 1999, BRIT J PHARMACOL, V127, P188, DOI 10.1038/sj.bjp.0702476; Fishman, 2007, J RHEUMATOL; Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355; Fishman P, 2009, Handb Exp Pharmacol, P399, DOI 10.1007/978-3-540-89615-9_14; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Fishman P, 2000, EUR J CANCER, V36, P1452, DOI 10.1016/S0959-8049(00)00130-1; Fishman P, 2016, CLIN RHEUMATOL, V35, P2359, DOI 10.1007/s10067-016-3202-4; Fishman P, 2012, DRUG DISCOV TODAY, V17, P359, DOI 10.1016/j.drudis.2011.10.007; Gessi S, 2004, CLIN CANCER RES, V10, P5895, DOI 10.1158/1078-0432.CCR-1134-03; Gessi S, 2008, PHARMACOL THERAPEUT, V117, P123, DOI 10.1016/j.pharmthera.2007.09.002; Gessi S, 2007, J CELL PHYSIOL, V211, P826, DOI 10.1002/jcp.20994; Gessi S, 2011, BBA-BIOMEMBRANES, V1808, P1400, DOI 10.1016/j.bbamem.2010.09.020; Gessi S, 2010, BIOCHEM PHARMACOL, V79, P1483, DOI 10.1016/j.bcp.2010.01.009; Gorain B, 2019, CURR PHARM DESIGN, V25, P2828, DOI 10.2174/1381612825666190716102037; Gorlach A, 2005, CIRC RES, V97, P1, DOI 10.1161/01.RES.0000174112.36064.77; Gorzalczany Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102603; Hajizadeh F, 2020, INT IMMUNOPHARMACOL, V87, DOI 10.1016/j.intimp.2020.106853; Hammarberg C, 2003, J NEUROCHEM, V86, P1051, DOI 10.1046/j.1471-4159.2003.01919.x; HERSHFIELD MS, 1976, J BIOL CHEM, V251, P7348; Jacobson KA, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00124; Jacobson KA, 2018, MED RES REV, V38, P1031, DOI 10.1002/med.21456; Jajoo S, 2009, NEOPLASIA, V11, P1132, DOI 10.1593/neo.09744; Joshaghani HR, 2017, J CANCER RES THER, V13, P107, DOI 10.4103/0973-1482.199381; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Karakashev SV, 2015, CANCER MANAG RES, V7, P253, DOI 10.2147/CMAR.S58285; Kazemi MH, 2018, J CELL PHYSIOL, V233, P2032, DOI 10.1002/jcp.25873; Kim SJ, 2008, CANCER LETT, V264, P309, DOI 10.1016/j.canlet.2008.01.037; Kim TH, 2012, NEUROCHEM RES, V37, P2667, DOI 10.1007/s11064-012-0855-5; Klaasse EC, 2008, PURINERG SIGNAL, V4, P21, DOI 10.1007/s11302-007-9086-7; Koscso B, 2011, EXPERT OPIN INV DRUG, V20, P757, DOI 10.1517/13543784.2011.573785; Koszalka P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151420; Lanzillotti C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.646032; Ledderose C, 2016, PURINERG SIGNAL, V12, P673, DOI 10.1007/s11302-016-9531-6; Lee HS, 2011, IMMUNOBIOLOGY, V216, P997, DOI 10.1016/j.imbio.2011.03.008; Lee JY, 2006, NEUROSCI LETT, V396, P1, DOI 10.1016/j.neulet.2005.11.004; Liu Z., 2020, CANCER CELL INT, V24, DOI [DOI 10.1186/S12935-019-1086-5, 10.1186/s12935-019-1086-5]; Lofgren L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205707; Mailavaram RP, 2019, CURR PHARM DESIGN, V25, P2772, DOI 10.2174/1381612825666190716114056; Marwein S, 2019, CURR PHARM DESIGN, V25, P2842, DOI 10.2174/1381612825666190716141851; Maugeri G, 2019, J MOL NEUROSCI, V69, P166, DOI 10.1007/s12031-019-01346-4; Mazziotta C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.676627; Mazzoni E, 2020, J INFECTION, V80, P563, DOI 10.1016/j.jinf.2020.02.006; Merighi S, 2005, NEOPLASIA, V7, P894, DOI 10.1593/neo.05334; Merighi S, 2005, J BIOL CHEM, V280, P19516, DOI 10.1074/jbc.M413772200; Merighi S, 2002, J INVEST DERMATOL, V119, P923, DOI 10.1046/j.1523-1747.2002.00111.x; Merighi S, 2007, MOL PHARMACOL, V72, P162, DOI 10.1124/mol.106.031849; Merighi S, 2006, BIOCHEM PHARMACOL, V72, P19, DOI 10.1016/j.bcp.2006.03.020; Merighi Stefania, 2006, Purinergic Signal, V2, P627, DOI 10.1007/s11302-006-9020-4; Mlejnek P, 2013, J PHYSIOL BIOCHEM, V69, P405, DOI 10.1007/s13105-012-0222-7; Montinaro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045401; Morello S, 2008, CANCER BIOL THER, V7, P278, DOI 10.4161/cbt.7.2.5301; Nigim F, 2015, J NEUROPATH EXP NEUR, V74, P710, DOI 10.1097/NEN.0000000000000210; Pastor-Anglada M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00627; PHILLIS JW, 1992, LIFE SCI, V51, pPL149, DOI 10.1016/0024-3205(92)90363-T; Preti M, 2020, INFECT AGENTS CANCER, V15, DOI 10.1186/s13027-020-00286-8; Przybyla T, 2018, ACTA BIOCHIM POL, V65, P1, DOI 10.18388/abp.2017_1588; Ren TH, 2015, SCI REP-UK, V5, DOI 10.1038/srep09047; Ren TH, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/818251; ROSE FR, 1988, J EXP MED, V167, P1186, DOI 10.1084/jem.167.3.1186; Roth S, 2019, EBIOMEDICINE, V48, P20, DOI 10.1016/j.ebiom.2019.09.030; Rotondo JC, 2012, HUM REPROD, V27, P3632, DOI 10.1093/humrep/des319; Rotondo JC, 2013, EPIGENETICS-US, V8, P990, DOI 10.4161/epi.25798; Rotondo JC, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.689624; Rotondo JC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.591452; Rotondo JC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.550543; Rotondo JC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00670; Rotondo JC, 2018, ENVIRON TOXICOL CHEM, V37, P942, DOI 10.1002/etc.4029; Rotondo JC, 2016, JAMA DERMATOL, V152, P928, DOI 10.1001/jamadermatol.2016.1336; Salvatore CA, 2000, J BIOL CHEM, V275, P4429, DOI 10.1074/jbc.275.6.4429; Santos, 2014, PHARMACOL THERAPEUT, DOI [10.5772/57206, DOI 10.5772/57206]; Schulte G, 2000, MOL PHARMACOL, V58, P477, DOI 10.1124/mol.58.3.477; Stemmer SM, 2012, J HEPATOL, V56, pS555, DOI 10.1016/S0168-8278(12)61422-6; Stomper J, 2021, LEUKEMIA, V35, P1873, DOI 10.1038/s41375-021-01218-0; Suresh RR, 2020, PURINERG SIGNAL, V16, P367, DOI 10.1007/s11302-020-09715-0; Taliani S, 2010, J MED CHEM, V53, P3954, DOI 10.1021/jm901785w; Tognon M, 2015, CANCER-AM CANCER SOC, V121, P2618, DOI 10.1002/cncr.29404; Tsuchiya A, 2015, WORLD J GASTROENTERO, V21, P10931, DOI 10.3748/wjg.v21.i39.10931; Vaisitti T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041167; Varani K, 2010, BRIT J PHARMACOL, V160, P101, DOI 10.1111/j.1476-5381.2010.00667.x; Varani K, 2013, EUR J CANCER, V49, P482, DOI 10.1016/j.ejca.2012.06.005; Varani K, 2011, AM J RESP CRIT CARE, V183, P522, DOI 10.1164/rccm.201006-0980OC; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	96	15	15	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					301	308		10.1038/s41388-021-02090-z	http://dx.doi.org/10.1038/s41388-021-02090-z		NOV 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34750517	hybrid, Green Published			2022-12-28	WOS:000715670800002
J	Tang, SC; Lion, Q; Peulen, O; Chariot, P; Lavergne, A; Mayer, A; Fuster, PA; Close, P; Klein, S; Florin, A; Buttner, R; Nemazanyy, I; Shostak, K; Chariot, A				Tang, Seng Chuan; Lion, Quentin; Peulen, Olivier; Chariot, Philippe; Lavergne, Arnaud; Mayer, Alice; Fuster, Paula Allepuz; Close, Pierre; Klein, Sebastian; Florin, Alexandra; Buettner, Reinhard; Nemazanyy, Ivan; Shostak, Kateryna; Chariot, Alain			The E3 ligase COP1 promotes ER alpha signaling and suppresses EMT in breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; REGULATES C-JUN; TUMOR-SUPPRESSOR; CELLS; EXPRESSION; TRANSCRIPTION; MECHANISMS; RESISTANCE; STABILITY; PHOSPHORYLATION	ER alpha signaling drives proliferation, survival and cancer initiation in the mammary gland. Therefore, it is critical to elucidate mechanisms by which ER alpha expression is regulated. We show that the tumor suppressor E3 ligase COP1 promotes the degradative polyubiquitination of the microtubule-associated protein HPIP. As such, COP1 negatively regulates estrogen-dependent AKT activation in breast cancer cells. However, COP1 also induces ER alpha expression and ER alpha-dependent gene transcription, at least through c-Jun degradation. COP1 and ER alpha levels are positively correlated in clinical cases of breast cancer. COP1 also supports the metabolic reprogramming by estrogens, including glycolysis. On the other hand, COP1 suppresses EMT in breast cancer cells. COP1 deficiency also contributes to Tamoxifen resistance, at least through protective autophagy. Therefore, COP1 acts as an oncogenic E3 ligase by promoting ER alpha signaling but also acts as a tumor suppressor candidate by preventing EMT, which reflects a dual role of COP1 in breast cancer.	[Tang, Seng Chuan; Lion, Quentin; Peulen, Olivier; Chariot, Philippe; Lavergne, Arnaud; Mayer, Alice; Fuster, Paula Allepuz; Close, Pierre; Shostak, Kateryna; Chariot, Alain] Univ Liege, Interdisciplinary Cluster Appl Genoprote, CHU, Liege, Belgium; [Tang, Seng Chuan; Lion, Quentin; Chariot, Philippe; Fuster, Paula Allepuz; Shostak, Kateryna; Chariot, Alain] Univ Liege, Lab Med Chem, GIGA Stem Cells, CHU, Liege, Belgium; [Peulen, Olivier] Univ Liege, Metastasis Res Lab, GIGA Canc, CHU, Liege, Belgium; [Lavergne, Arnaud; Mayer, Alice] Univ Liege, GIGA Genom Platform, CHU, Liege, Belgium; [Close, Pierre] Univ Liege, Lab Canc Signaling, GIGA Stem Cells, CHU, B-4000 Liege, Belgium; [Close, Pierre; Chariot, Alain] Walloon Excellence Life Sci & Biotechnol WELBIO, Wavres, Belgium; [Klein, Sebastian; Florin, Alexandra; Buettner, Reinhard] Univ Hosp Cologne, Inst Pathol, Cologne, Germany; [Nemazanyy, Ivan] INSERM, Platform Metab Anal, Struct Federat Rech Necker, US24 CNRS UMS 3633, Paris, France	University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; WELBIO; University of Cologne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Chariot, A (corresponding author), Univ Liege, Interdisciplinary Cluster Appl Genoprote, CHU, Liege, Belgium.; Chariot, A (corresponding author), Univ Liege, Lab Med Chem, GIGA Stem Cells, CHU, Liege, Belgium.; Chariot, A (corresponding author), Walloon Excellence Life Sci & Biotechnol WELBIO, Wavres, Belgium.	Alain.chariot@uliege.ac.be	Peulen, Olivier/C-1250-2018	Peulen, Olivier/0000-0002-6933-0134; Tang, Seng Chuan/0000-0002-8709-3531; LION, Quentin/0000-0002-9662-9318	Belgian National Funds for Scientific Research (FNRS); Special Research Funds (FSR) at the University of Liege; Belgian foundation against Cancer [FAF-F/2016/794]; Walloon Excellence in Life Sciences and Biotechnology [WELBIO-CR-2015A-02]; "Fondation Leon Fredericq" of the CHU Liege	Belgian National Funds for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS); Special Research Funds (FSR) at the University of Liege; Belgian foundation against Cancer; Walloon Excellence in Life Sciences and Biotechnology; "Fondation Leon Fredericq" of the CHU Liege	The authors thank Arnaud Blomme (Laboratory of Cancer Signaling, University of Liege, Liege, Belgium) for the gift of PyMT cells. The authors also thank the GIGA Imaging and Flow Cytometry Facility as well as the GIGA Genomics Platform for RNA-Sequencing analyses. This study was supported by Grants from the Belgian National Funds for Scientific Research (FNRS) and from Special Research Funds (FSR) at the University of Liege, the Belgian foundation against Cancer (FAF-F/2016/794), as well as from the Walloon Excellence in Life Sciences and Biotechnology (WELBIO-CR-2015A-02). We are also grateful to the "Fondation Leon Fredericq" of the CHU Liege for its financial support. A. Chariot and P. Close are Research Director and Senior Research Associate at the FNRS, respectively. The authors declare no conflict of interest.	Allred DC, 2004, BREAST CANCER RES, V6, P240, DOI 10.1186/bcr938; Baert JL, 2010, ONCOGENE, V29, P1810, DOI 10.1038/onc.2009.471; Chan EYW, 2007, J BIOL CHEM, V282, P25464, DOI 10.1074/jbc.M703663200; Cook KL, 2012, CANCER RES, V72, P3337, DOI 10.1158/0008-5472.CAN-12-0269; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ewels PA, 2020, NAT BIOTECHNOL, V38, P276, DOI 10.1038/s41587-020-0439-x; Folkerd EJ, 2010, J CLIN ONCOL, V28, P4038, DOI 10.1200/JCO.2009.27.4290; Gatot JS, 2007, J BIOL CHEM, V282, P31131, DOI 10.1074/jbc.M701690200; Grabinski N, 2014, CELL SIGNAL, V26, P1021, DOI 10.1016/j.cellsig.2014.01.018; Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001; Hendriks MMWB, 2007, PROTEOMICS, V7, P3672, DOI 10.1002/pmic.200700046; Ikeda K, 2015, ACTA PHARMACOL SIN, V36, P24, DOI 10.1038/aps.2014.123; Jia M, 2016, CANCER RES, V76, P5634, DOI 10.1158/0008-5472.CAN-15-2910; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; Lorent J, 2019, EMBO J, V38, DOI 10.15252/embj.2018101323; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luque-Bolivar A, 2020, BREAST CANCER-TARGET, V12, P211, DOI 10.2147/BCTT.S270799; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; Manavathi B, 2006, P NATL ACAD SCI USA, V103, P15981, DOI 10.1073/pnas.0607445103; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marine JC, 2012, NAT REV CANCER, V12, P455, DOI 10.1038/nrc3271; Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200; Migliorini D, 2011, J CLIN INVEST, V121, P1329, DOI 10.1172/JCI45784; NEEMAN M, 1989, P NATL ACAD SCI USA, V86, P5585, DOI 10.1073/pnas.86.14.5585; NEEMAN M, 1989, CANCER RES, V49, P589; O'Mahony F, 2012, MOL ENDOCRINOL, V26, P2058, DOI 10.1210/me.2012-1191; Ouyang M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1151-y; Rademaker G, 2018, ONCOGENE, V37, P4398, DOI 10.1038/s41388-018-0287-z; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447; Shostak K, 2014, CELL DEATH DIFFER, V21, P811, DOI 10.1038/cdd.2014.2; Shostak K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15003-7; Shostak K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6232; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Tecalco-Cruz AC, 2017, CLIN BREAST CANCER, V17, P1, DOI 10.1016/j.clbc.2016.07.015; Turner BC, 1998, CANCER RES, V58, P5466; van Gastel N, 2020, NATURE, V579, P111, DOI 10.1038/s41586-020-2050-1; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vitari AC, 2011, NATURE, V474, P403, DOI 10.1038/nature10005; Wang SC, 2015, BIOMED PHARMACOTHER, V75, P33, DOI 10.1016/j.biopha.2015.08.027; Welboren WJ, 2009, ENDOCR-RELAT CANCER, V16, P1073, DOI 10.1677/ERC-09-0086; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380; Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193; Zou SS, 2017, MOL NEUROBIOL, V54, P5008, DOI 10.1007/s12035-016-0033-x	50	3	3	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					173	190		10.1038/s41388-021-02038-3	http://dx.doi.org/10.1038/s41388-021-02038-3		OCT 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34716429				2022-12-28	WOS:000712720900001
J	Bischoff, P; Trinks, A; Obermayer, B; Pett, JP; Wiederspahn, J; Uhlitz, F; Liang, XZ; Lehmann, A; Jurmeister, P; Elsner, A; Dziodzio, T; Ruckert, JC; Neudecker, J; Falk, C; Beule, D; Sers, C; Morkel, M; Horst, D; Bluthgen, N; Klauschen, F				Bischoff, Philip; Trinks, Alexandra; Obermayer, Benedikt; Pett, Jan Patrick; Wiederspahn, Jennifer; Uhlitz, Florian; Liang, Xizi; Lehmann, Annika; Jurmeister, Philipp; Elsner, Aron; Dziodzio, Tomasz; Rueckert, Jens-Carsten; Neudecker, Jens; Falk, Christine; Beule, Dieter; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils; Klauschen, Frederick			Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma	ONCOGENE			English	Article							TO-MACROPHAGE DIFFERENTIATION; INTERNATIONAL ASSOCIATION; GENE-EXPRESSION; CLASSIFICATION; SIGNATURES; DENSITY	Recent developments in immuno-oncology demonstrate that not only cancer cells, but also the tumor microenvironment can guide precision medicine. A comprehensive and in-depth characterization of the tumor microenvironment is challenging since its cell populations are diverse and can be important even if scarce. To identify clinically relevant microenvironmental and cancer features, we applied single-cell RNA sequencing to ten human lung adenocarcinomas and ten normal control tissues. Our analyses revealed heterogeneous carcinoma cell transcriptomes reflecting histological grade and oncogenic pathway activities, and two distinct microenvironmental patterns. The immune-activated (CPE)-E-2 microenvironment was composed of cancer-associated myofibroblasts, proinflammatory monocyte-derived macrophages, plasmacytoid dendritic cells and exhausted CD8+ T cells, and was prognostically unfavorable. In contrast, the inert (NMC)-M-3 microenvironment was characterized by normal-like myofibroblasts, non-inflammatory monocyte-derived macrophages, NK cells, myeloid dendritic cells and conventional T cells, and was associated with a favorable prognosis. Microenvironmental marker genes and signatures identified in single-cell profiles had progonostic value in bulk tumor profiles. In summary, single-cell RNA profiling of lung adenocarcinoma provides additional prognostic information based on the microenvironment, and may help to predict therapy response and to reveal possible target cell populations for future therapeutic approaches.	[Bischoff, Philip; Trinks, Alexandra; Wiederspahn, Jennifer; Liang, Xizi; Lehmann, Annika; Jurmeister, Philipp; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils; Klauschen, Frederick] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany; [Bischoff, Philip; Trinks, Alexandra; Wiederspahn, Jennifer; Liang, Xizi; Lehmann, Annika; Jurmeister, Philipp; Elsner, Aron; Dziodzio, Tomasz; Rueckert, Jens-Carsten; Neudecker, Jens; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils; Klauschen, Frederick] Free Univ Berlin, Berlin, Germany; [Bischoff, Philip; Trinks, Alexandra; Wiederspahn, Jennifer; Liang, Xizi; Lehmann, Annika; Jurmeister, Philipp; Elsner, Aron; Dziodzio, Tomasz; Rueckert, Jens-Carsten; Neudecker, Jens; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils; Klauschen, Frederick] Humboldt Univ, Berlin, Germany; [Bischoff, Philip; Trinks, Alexandra; Jurmeister, Philipp; Dziodzio, Tomasz; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany; [Obermayer, Benedikt; Pett, Jan Patrick; Beule, Dieter] Charite Univ Med Berlin, Core Unit Bioinformat CUBI, Berlin Inst Hlth, Berlin, Germany; [Wiederspahn, Jennifer; Uhlitz, Florian; Bluethgen, Nils] Humboldt Univ, IRI Life Sci, Berlin, Germany; [Uhlitz, Florian; Jurmeister, Philipp; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils; Klauschen, Frederick] German Canc Res Ctr, German Canc Consortium DKTK Partner Site Berlin, Heidelberg, Germany; [Elsner, Aron; Dziodzio, Tomasz; Rueckert, Jens-Carsten; Neudecker, Jens] Charite Univ Med Berlin, Dept Surg, Campus Charite Mitte, Berlin, Germany; [Elsner, Aron; Dziodzio, Tomasz; Rueckert, Jens-Carsten; Neudecker, Jens] Charite Univ Med Berlin, Dept Surg, Campus Virchow Klinikum, Berlin, Germany; [Falk, Christine] Hannover Med Sch, Inst Transplant Immunol, Hannover, Germany; [Falk, Christine] German Ctr Infect Dis DZIF, TTU IICH Hannover Braunschweig Site, Braunschweig, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School; German Center for Infection Research	Bischoff, P (corresponding author), Charite Univ Med Berlin, Inst Pathol, Berlin, Germany.; Bischoff, P (corresponding author), Free Univ Berlin, Berlin, Germany.; Bischoff, P (corresponding author), Humboldt Univ, Berlin, Germany.; Bischoff, P (corresponding author), Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany.	philip.bischoff@charite.de	Klauschen, Frederick/C-5637-2015; Bischoff, Philip/HHC-2955-2022; Sers, Christine/B-5438-2010	Klauschen, Frederick/0000-0002-9131-2389; Bischoff, Philip/0000-0002-4442-7116; Dziodzio, Tomasz/0000-0002-3337-4573; Beule, Dieter/0000-0002-3284-0632; Obermayer, Benedikt/0000-0002-9116-630X; Trinks, Alexandra/0000-0001-9983-1506; Sers, christine/0000-0002-6219-1514; Lehmann, Annika/0000-0001-9424-5882; von Schlichting, Jennifer/0000-0003-0117-9754; Morkel, Markus/0000-0002-2553-9999	Berlin Institute of Health; German Cancer Consortium DKTK; German Research Foundation DFG [RTG2424 CompCancer]; Einstein Foundation/Stiftung Charite; Charite-Universitatsmedizin Berlin; Projekt DEAL	Berlin Institute of Health; German Cancer Consortium DKTK; German Research Foundation DFG(German Research Foundation (DFG)); Einstein Foundation/Stiftung Charite; Charite-Universitatsmedizin Berlin; Projekt DEAL	The work was in part funded by the Berlin Institute of Health (to PB, PJ, DH, MM, CS, and NB), the German Cancer Consortium DKTK (to MM and NB), the German Research Foundation DFG (RTG2424 CompCancer to NB) and the Einstein Foundation/Stiftung Charite (to NB). PB is participant in the BIH-Charite Junior Clinician Scientist Program funded by the Charite-Universitatsmedizin Berlin and the Berlin Institute of Health. PJ is participant in the BIH-Charite Digital Clinician Scientist Program funded by the Charite-Universitatsmedizin Berlin and the Berlin Institute of Health and the German Research Foundation (DFG). Open Access funding enabled and organized by Projekt DEAL.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Altorki NK, 2019, NAT REV CANCER, V19, P9, DOI 10.1038/s41568-018-0081-9; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Braga FAV, 2019, NAT MED, V25, P1153, DOI 10.1038/s41591-019-0468-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buenostro JD, 2015, NATURE, V523, P486, DOI 10.1038/nature14590; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Conway EM, 2016, AM J RESP CRIT CARE, V193, P116, DOI 10.1164/rccm.201508-1545CI; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596-020-0292-x; Franklin RA, 2016, TRENDS CANCER, V2, P20, DOI 10.1016/j.trecan.2015.11.004; Gao Y, 2018, INT J CANCER, V143, P931, DOI 10.1002/ijc.31357; Geng YT, 2015, CELL PHYSIOL BIOCHEM, V37, P1560, DOI 10.1159/000438523; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Habermann AC, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1972; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hafemeister C, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1874-1; Hao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112767; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Holland CH, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1949-z; House IG, 2020, CLIN CANCER RES, V26, P487, DOI 10.1158/1078-0432.CCR-19-1868; Huang JB, 2020, CANCER SCI, V111, P1876, DOI 10.1111/cas.14390; Inoue C, 2019, VIRCHOWS ARCH, V475, P181, DOI 10.1007/s00428-019-02587-9; Ito M, 2012, CHEST, V142, P151, DOI 10.1378/chest.11-2458; Jiang WQ, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.622509; Jiang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.162; Kim N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16164-1; Koucky V, 2019, CANCERS, V11, DOI 10.3390/cancers11040470; Kubouchi Y, 2018, HISTOPATHOLOGY, V72, P490, DOI 10.1111/his.13390; Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591-018-0096-5; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Lee HO, 2020, NAT GENET, V52, P594, DOI 10.1038/s41588-020-0636-z; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657; Lin ZY, 2019, J CANCER, V10, P211, DOI 10.7150/jca.26444; Liu YY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10992; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Memon H, 2019, LIFE SCI, V233, DOI 10.1016/j.lfs.2019.116713; Mohrherr J, 2019, INT J CANCER, V145, P3376, DOI 10.1002/ijc.32624; Molina-Romero C, 2017, HUM PATHOL, V66, P188, DOI 10.1016/j.humpath.2017.06.002; Moreira AL, 2020, J THORAC ONCOL, V15, P1599, DOI 10.1016/j.jtho.2020.06.001; Niemira M, 2020, CANCERS, V12, DOI 10.3390/cancers12010037; Ojlert AK, 2019, MOL ONCOL, V13, P1166, DOI 10.1002/1878-0261.12475; Okazaki T, 2018, J THORAC ONCOL, V13, pS523, DOI 10.1016/j.jtho.2018.08.712; Parra ER, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0368-0; Patel AJ, 2020, CANCER IMMUNOL IMMUN, V69, P325, DOI 10.1007/s00262-019-02461-2; Peng H, PROFILING TUMOR IMMU, V2021, DOI 10.1101/2021.05.28.446005; Petrova V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0011-9; Qu Y, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107873; Rajewsky N, 2020, NATURE, V587, P377, DOI 10.1038/s41586-020-2715-9; Schalper KA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju435; Schubert M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02391-6; Shi JL, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.01.82; Sholl LM, 2020, J THORAC ONCOL, V15, P1409, DOI 10.1016/j.jtho.2020.05.019; Solberg R, 2015, BIOL CHEM, V396, P71, DOI 10.1515/hsz-2014-0172; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Stahl PL, 2016, SCIENCE, V353, P78, DOI 10.1126/science.aaf2403; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/nmeth.4380, 10.1038/NMETH.4380]; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Tam SY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00486; Tan AC, 2020, THORAC CANCER, V11, P511, DOI 10.1111/1759-7714.13328; Tao Y, 2020, FUTURE ONCOL, V16, P1825, DOI 10.2217/fon-2019-0829; Tata PR, 2017, DEVELOPMENT, V144, P755, DOI 10.1242/dev.143784; Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255; Travaglini KJ, 2020, NATURE, V587, DOI 10.1038/s41586-020-2922-4; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Wakelee HA, 2007, J CLIN ONCOL, V25, P472, DOI 10.1200/JCO.2006.07.2983; Wrangle JM, 2018, LANCET ONCOL, V19, P694, DOI 10.1016/S1470-2045(18)30148-7; Xu NZ, 2019, J HISTOCHEM CYTOCHEM, V67, P453, DOI 10.1369/0022155419829050; Yang HR, 2019, MOL THER-ONCOLYTICS, V14, P82, DOI 10.1016/j.omto.2019.03.012; Yoshida GJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01611-0; Zhang S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01242	76	12	12	6	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6748	6758		10.1038/s41388-021-02054-3	http://dx.doi.org/10.1038/s41388-021-02054-3		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34663877	Green Accepted, Green Submitted, hybrid, Green Published			2022-12-28	WOS:000708355700001
J	Singh, SK; Kumar, S; Viswakarma, N; Principe, DR; Das, S; Sondarva, G; Nair, RS; Srivastava, P; Sinha, SC; Grippo, PJ; Thatcher, GRJ; Rana, B; Rana, A				Singh, Sunil Kumar; Kumar, Sandeep; Viswakarma, Navin; Principe, Daniel R.; Das, Subhasis; Sondarva, Gautam; Nair, Rakesh Sathish; Srivastava, Piush; Sinha, Subhash C.; Grippo, Paul J.; Thatcher, Gregory R. J.; Rana, Basabi; Rana, Ajay			MAP4K4 promotes pancreatic tumorigenesis via phosphorylation and activation of mixed lineage kinase 3	ONCOGENE			English	Article							PROTEIN-KINASE; SCAFFOLD PROTEINS; FAMILY KINASES; STE20 KINASE; STRESS; CELLS; ADENOCARCINOMA; INHIBITOR; REGULATOR; APOPTOSIS	MAP4K4 is a Ste20 member and reported to play important roles in various pathologies, including in cancer. However, the mechanism by which MAP4K4 promotes pancreatic cancer is not fully understood. It is suggested that MAP4K4 might function as a cancer promoter via specific downstream target(s) in an organ-specific manner. Here we identified MLK3 as a direct downstream target of MAP4K4. The MAP4K4 and MLK3 associates with each other, and MAP4K4 phosphorylates MLK3 on Thr738 and increases MLK3 kinase activity and downstream signaling. The phosphorylation of MLK3 by MAP4K4 promotes pancreatic cancer cell proliferation, migration, and colony formation. Moreover, MAP4K4 is overexpressed in human pancreatic tumors and directly correlates with the disease progression. The MAP4K4-specific pharmacological inhibitor, GNE-495, impedes pancreatic cancer cell growth, migration, induces cell death, and arrests cell cycle progression. Additionally, the GNE-495 reduced the tumor burden and extended survival of the KPC mice with pancreatic cancer. The MAP4K4 inhibitor also reduced MAP4K4 protein expression, tumor stroma, and induced cell death in murine pancreatic tumors. These findings collectively suggest that MLK3 phosphorylation by MAP4K4 promotes pancreatic cancer, and therefore therapies targeting MAP4K4 might alleviate the pancreatic cancer tumor burden in patients.	[Singh, Sunil Kumar; Kumar, Sandeep; Viswakarma, Navin; Principe, Daniel R.; Das, Subhasis; Sondarva, Gautam; Nair, Rakesh Sathish; Srivastava, Piush; Rana, Basabi; Rana, Ajay] Univ Illinois, Dept Surg, Div Surg Oncol, Chicago, IL 60612 USA; [Sinha, Subhash C.] Weill Cornell Med, New York, NY 10021 USA; [Grippo, Paul J.] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Thatcher, Gregory R. J.] Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; [Rana, Basabi; Rana, Ajay] Univ Illinois, Univ Illinois Hosp, Chicago, IL 60612 USA; [Rana, Basabi; Rana, Ajay] Univ Illinois, Hlth Sci Syst Canc Ctr, Chicago, IL 60612 USA; [Rana, Basabi; Rana, Ajay] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cornell University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Arizona; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Rana, A (corresponding author), Univ Illinois, Dept Surg, Div Surg Oncol, Chicago, IL 60612 USA.; Rana, A (corresponding author), Univ Illinois, Univ Illinois Hosp, Chicago, IL 60612 USA.; Rana, A (corresponding author), Univ Illinois, Hlth Sci Syst Canc Ctr, Chicago, IL 60612 USA.; Rana, A (corresponding author), Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.	arana@uic.edu	Singh, Sunil/AAA-1630-2022; Das, Subhasis/O-8421-2017	Singh, Sunil/0000-0001-7639-9212; Principe, Daniel/0000-0003-4355-6597; Srivastava, Piush/0000-0003-4646-9392; Sinha, Subhash/0000-0001-8916-5677; Das, Subhasis/0000-0003-1032-4407	Veterans Affairs Merit Award [BX004903]; Career Scientist Award [BX004855]; VA-Merit [BX003296]; National Cancer Institute [CA216410, CA176846, CA178063, CA219764]; UIC-Cancer Center pilot grant; NIH shared instrument grant [S100D018445]	Veterans Affairs Merit Award(US Department of Veterans Affairs); Career Scientist Award; VA-Merit; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UIC-Cancer Center pilot grant; NIH shared instrument grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We acknowledge funding support from Veterans Affairs Merit Award (BX004903) and Career Scientist Award (BX004855) to A.R., and VA-Merit to B.R. (BX003296). This work is partly supported through grants from the National Cancer Institute to A.R. (CA216410 and CA176846), and B.R. (CA178063 and CA219764), and UIC-Cancer Center pilot grant award to BR. We also acknowledge the NIH shared instrument grant # S100D018445, awarded to U.A.M.S. Proteomics Core Lab, Little Rock, Arkansas, USA. Per the funding policy of the Department of Veterans Affairs, we are required to state that these contents do not represent the views of the Department of Veterans Affairs or the United States Government.	Aouadi M, 2009, NATURE, V458, P1180, DOI 10.1038/nature07774; Bos PH, 2019, CELL CHEM BIOL, V26, P1703, DOI 10.1016/j.chembiol.2019.10.005; Chuang HC, 2016, ADV IMMUNOL, V129, P277, DOI 10.1016/bs.ai.2015.09.006; Chuang HC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5602; Collins CS, 2006, P NATL ACAD SCI USA, V103, P3775, DOI 10.1073/pnas.0600040103; Das S, 2020, ONCOGENE, V39, P722, DOI 10.1038/s41388-019-1011-3; Das S, 2015, J BIOL CHEM, V290, P21705, DOI 10.1074/jbc.M115.655563; Delpire E, 2009, PFLUG ARCH EUR J PHY, V458, P953, DOI 10.1007/s00424-009-0674-y; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Egberts JH, 2008, CANCER RES, V68, P1443, DOI 10.1158/0008-5472.CAN-07-5704; Farrow B, 2002, SURG ONCOL, V10, P153, DOI 10.1016/S0960-7404(02)00015-4; Flach RJR, 2016, MOL CELL BIOL, V36, P1740, DOI 10.1128/MCB.01121-15; Flach RJR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9995; Gao X, 2017, MOL ONCOL, V11, P628, DOI 10.1002/1878-0261.12055; Gao X, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0121-7; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Jin M, 2016, ENVIRON TOXICOL PHAR, V46, P246, DOI 10.1016/j.etap.2016.08.006; Kumar S, 2016, MOL ONCOL, V10, P949, DOI 10.1016/j.molonc.2016.03.007; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Larhammar M, 2017, J NEUROSCI, V37, P11074, DOI 10.1523/JNEUROSCI.0905-17.2017; Liang JJ, 2008, CLIN CANCER RES, V14, P7043, DOI 10.1158/1078-0432.CCR-08-0381; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Ndubaku CO, 2015, ACS MED CHEM LETT, V6, P913, DOI 10.1021/acsmedchemlett.5b00174; Prolo LM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50160-w; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Rana Ajay, 2013, Genes Cancer, V4, P334, DOI 10.1177/1947601913485415; Rangasamy V, 2012, P NATL ACAD SCI USA, V109, P8149, DOI 10.1073/pnas.1200804109; Rangasamy V, 2010, CANCER RES, V70, P1731, DOI 10.1158/0008-5472.CAN-09-3492; Rattanasinchai C, 2016, CANCERS, V8, DOI 10.3390/cancers8050051; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Schroder P, 2015, ANGEW CHEM INT EDIT, V54, P12398, DOI 10.1002/anie.201501515; Schwaid AG, 2015, ACS CHEM BIOL, V10, P2667, DOI 10.1021/acschembio.5b00679; Tang XQ, 2006, P NATL ACAD SCI USA, V103, P2087, DOI 10.1073/pnas.0507660103; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Vitorino P, 2015, NATURE, V519, P425, DOI 10.1038/nature14323; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Wright JH, 2003, MOL CELL BIOL, V23, P2068, DOI 10.1128/MCB.23.6.2068-2082.2003; Xue YZ, 2001, DEVELOPMENT, V128, P1559; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yue JP, 2014, DEV CELL, V31, P572, DOI 10.1016/j.devcel.2014.10.025; Zhao XD, 2016, ONCOTARGET, V7, P81110, DOI 10.18632/oncotarget.13212	43	4	4	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6153	6165		10.1038/s41388-021-02007-w	http://dx.doi.org/10.1038/s41388-021-02007-w		SEP 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34511598	hybrid, Green Published			2022-12-28	WOS:000695127400001
J	Huang, TT; Burkett, SS; Tandon, M; Yamamoto, TM; Gupta, N; Bitler, BG; Lee, JM; Nair, JR				Huang, Tzu-Ting; Burkett, Sandra Sczerba; Tandon, Mayank; Yamamoto, Tomomi M.; Gupta, Nitasha; Bitler, Benjamin G.; Lee, Jung-Min; Nair, Jayakumar R.			Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer	ONCOGENE			English	Article							MESENCHYMAL TRANSITION EMT; MUTATIONS; PROTEIN; CELLS; DEGRADATION; RESECTION; PATHWAYS; DAMAGE; CHK1	Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a major advance in ovarian cancer, now as a treatment and as a maintenance therapy in the upfront and recurrent settings. However, patients often develop resistance to PARPis, underlining the importance of dissecting resistance mechanisms. Here, we report different dosing/timing schemes of PARPi treatment in BRCA2-mutant PEO1 cells, resulting in the simultaneous development of distinct resistance mechanisms. PARPi-resistant variants PEO1/OlaJR, established by higher initial doses and short-term PARPi treatment, develops PARPi resistance by rapidly restoring functional BRCA2 and promoting drug efflux activity. In contrast, PEO1/OlaR, developed by lower initial doses with long-term PARPi exposure, shows no regained BRCA2 function but a mesenchymal-like phenotype with greater invasion ability, and exhibits activated ATR/CHK1 and suppressed EZH2/MUS81 signaling cascades to regain HR repair and fork stabilization, respectively. Our study suggests that PARPi resistance mechanisms can be governed by treatment strategies and have a molecular basis on BRCA2 functionality. Further, we define different mechanisms that may serve as useful biomarkers to assess subsequent treatment strategies in PARPi-resistant ovarian cancer.	[Huang, Tzu-Ting; Gupta, Nitasha; Lee, Jung-Min; Nair, Jayakumar R.] NCI, Womens Malignancies Branch WMB, Ctr Canc Res CCR, NIH, Bethesda, MD 20892 USA; [Burkett, Sandra Sczerba] NCI, Mol Cytogenet Core Facil, MCGP, CCR,NIH, Frederick, MD 20892 USA; [Tandon, Mayank] NCI, Ctr Canc Res Collaborat Bioinformat Resource, CCR, NIH, Bethesda, MD 20892 USA; [Yamamoto, Tomomi M.; Bitler, Benjamin G.] Univ Colorado, Dept OB GYN, Div Reprod Sci, Aurora, CO USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Colorado System; University of Colorado Anschutz Medical Campus	Lee, JM (corresponding author), NCI, Womens Malignancies Branch WMB, Ctr Canc Res CCR, NIH, Bethesda, MD 20892 USA.	leej6@mail.nih.gov		Burkett, Sandra/0000-0002-5476-4028; Bitler, Benjamin/0000-0002-5809-5271; Gupta, Nitasha/0000-0003-4337-2368	intramural research program of the CCR, NCI, NIH [ZIA BC011525]; NIH/NCI grant [R37CA261987-01]	intramural research program of the CCR, NCI, NIH; NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was funded by the intramural research program of the CCR, NCI, NIH (ZIA BC011525 awarded to JL). This study was partly supported by an NIH/NCI grant (R37CA261987-01 awarded to BB).	Baribeau S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086987; Bhat KP, 2018, NAT STRUCT MOL BIOL, V25, P446, DOI 10.1038/s41594-018-0075-z; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Clairmont CS, 2020, NAT CELL BIOL, V22, P87, DOI 10.1038/s41556-019-0442-y; Clements KE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19961-w; Cong K, 2021, MOL CELL, V81, P3227, DOI 10.1016/j.molcel.2021.07.015; D'Andrea AD, 2018, DNA REPAIR, V71, P172, DOI 10.1016/j.dnarep.2018.08.021; Dias MP, 2021, NAT REV CLIN ONCOL, V18, P773, DOI 10.1038/s41571-021-00532-x; Do KT, 2021, CLIN CANCER RES, V27, P4710, DOI 10.1158/1078-0432.CCR-21-1279; Drean A, 2017, MOL CANCER THER, V16, P2022, DOI 10.1158/1535-7163.MCT-17-0098; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Gomez MK, 2020, CANCERS, V12, DOI 10.3390/cancers12061503; Gupta N, 2022, PHARMACOL RES, V178, DOI 10.1016/j.phrs.2022.106162; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; Haynes B, 2018, CANCER TREAT REV, V71, P1, DOI 10.1016/j.ctrv.2018.09.003; Howlader N., 2021, SEER CANC STAT REV, P1975; Huang RYJ, 2012, CURR DRUG TARGETS, V13, P1649; Jaspers JE, 2015, CANCER RES, V75, P732, DOI 10.1158/0008-5472.CAN-14-0839; Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049; Kim H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17127-2; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kolinjivadi AM, 2017, MOL CELL, V67, P867, DOI 10.1016/j.molcel.2017.07.001; Kondrashova O, 2017, CANCER DISCOV, V7, P984, DOI 10.1158/2159-8290.CD-17-0419; Lee JM, 2014, ANN ONCOL, V25, P32, DOI 10.1093/annonc/mdt384; Lee JM, 2017, ONCOTARGET, V8, P95036, DOI 10.18632/oncotarget.20852; Lee JM, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0604-z; Li H, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01227-0; Lin KK, 2019, CANCER DISCOV, V9, P210, DOI 10.1158/2159-8290.CD-18-0715; McMullen M, 2020, CANCERS, V12, DOI 10.3390/cancers12061607; Mijic S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01164-5; Nair J, 2020, ONCOGENE, V39, P5520, DOI 10.1038/s41388-020-1383-4; Noordermeer SM, 2019, TRENDS CELL BIOL, V29, P820, DOI 10.1016/j.tcb.2019.07.008; Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980; Ordonez Liliana D, 2019, Oncotarget, V10, P2586, DOI 10.18632/oncotarget.26830; Peng J, 2011, PROTEINS, V79, P161, DOI 10.1002/prot.23175; Pettitt SJ, 2020, CANCER DISCOV, V10, P1475, DOI 10.1158/2159-8290.CD-19-1485; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Rondinelli B, 2017, NAT CELL BIOL, V19, P1371, DOI 10.1038/ncb3626; Sakai W, 2009, CANCER RES, V69, P6381, DOI 10.1158/0008-5472.CAN-09-1178; Saldivar JC, 2017, NAT REV MOL CELL BIO, V18, P622, DOI 10.1038/nrm.2017.67; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Stewart CA, 2017, ONCOTARGET, V8, P28575, DOI 10.18632/oncotarget.15338; Taglialatela A, 2017, MOL CELL, V68, P414, DOI 10.1016/j.molcel.2017.09.036; Tew WP, 2020, J CLIN ONCOL, V38, P3468, DOI 10.1200/JCO.20.01924; Toledo L, 2017, MOL CELL, V66, P735, DOI 10.1016/j.molcel.2017.05.001; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Watson ZL, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0758-2; Xu GT, 2015, NATURE, V521, P541, DOI 10.1038/nature14328; Yamamoto TM, 2019, MOL CARCINOGEN, V58, P1770, DOI 10.1002/mc.23064; Yang QY, 2017, P NATL ACAD SCI USA, V114, pE6054, DOI 10.1073/pnas.1700694114; Yazinski SA, 2017, GENE DEV, V31, P318, DOI 10.1101/gad.290957.116; Yuan SSF, 1999, CANCER RES, V59, P3547	56	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					5020	5031		10.1038/s41388-022-02491-8	http://dx.doi.org/10.1038/s41388-022-02491-8		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36224341				2022-12-28	WOS:000866316700001
J	Battaglin, F; Jayachandran, P; Strelez, C; Lenz, A; Algaze, S; Soni, S; Lo, JH; Yang, Y; Millstein, J; Zhang, W; Torres, ETR; Shih, JC; Mumenthaler, SM; Neman, J; Lenz, HJ				Battaglin, Francesca; Jayachandran, Priya; Strelez, Carly; Lenz, Annika; Algaze, Sandra; Soni, Shivani; Lo, Jae Ho; Yang, Yan; Millstein, Joshua; Zhang, Wu; Roussos Torres, Evanthia T.; Shih, Jean C.; Mumenthaler, Shannon M.; Neman, Josh; Lenz, Heinz-Josef			Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment	ONCOGENE			English	Review							ALPHA-7-NICOTINIC ACETYLCHOLINE-RECEPTOR; GAMMA-AMINOBUTYRIC-ACID; CELL-PROLIFERATION; GENE-EXPRESSION; NERVOUS-SYSTEM; TUMOR-GROWTH; MCRC DATA; COLON; PATHWAY; GABA	The brain-gut axis, a bidirectional network between the central and enteric nervous system, plays a critical role in modulating the gastrointestinal tract function and homeostasis. Recently, increasing evidence suggests that neuronal signaling molecules can promote gastrointestinal cancers, however, the mechanisms remain unclear. Aberrant expression of neurotransmitter signaling genes in colorectal cancer supports the role of neurotransmitters to stimulate tumor growth and metastatic spread by promoting cell proliferation, migration, invasion, and angiogenesis. In addition, neurotransmitters can interact with immune and endothelial cells in the tumor microenvironment to promote inflammation and tumor progression. As such, pharmacological targeting of neurotransmitter signaling represent a promising novel anticancer approach. Here, we present an overview of the current evidence supporting the role of neurotransmitters in colorectal cancer biology and treatment.	[Battaglin, Francesca; Jayachandran, Priya; Lenz, Annika; Algaze, Sandra; Soni, Shivani; Lo, Jae Ho; Zhang, Wu; Roussos Torres, Evanthia T.; Mumenthaler, Shannon M.; Lenz, Heinz-Josef] Univ Southern Calif, Keck Sch Med, Div Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA; [Strelez, Carly; Mumenthaler, Shannon M.] Lawrence J Ellison Inst Transformat Med, Los Angeles, CA USA; [Yang, Yan; Millstein, Joshua] Univ Southern Calif, Keck Sch Med, Dept Populat & Publ Hlth Sci, Los Angeles, CA 90007 USA; [Shih, Jean C.] Univ Southern Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90007 USA; [Mumenthaler, Shannon M.] Univ Southern Calif, Viterbi Sch Engn, Dept Biomed Engn, Los Angeles, CA 90007 USA; [Neman, Josh] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, USC Brain Tumor Ctr,Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Lenz, HJ (corresponding author), Univ Southern Calif, Keck Sch Med, Div Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA.	lenz@med.usc.edu	Battaglin, Francesca/C-2746-2017	Battaglin, Francesca/0000-0002-9869-0163	National Cancer Institute [P30CA014089, R01CA241137]; Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Gene Gregg Pancreas Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; V foundation for cancer research; Victoria and Philip Wilson Research Fund; Fong research project; Ming Hsieh research fund; Boyd and Elsie Welin Professorship; USC Trustee Tsai family fund	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Gene Gregg Pancreas Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; V foundation for cancer research; Victoria and Philip Wilson Research Fund; Fong research project; Ming Hsieh research fund; Boyd and Elsie Welin Professorship; USC Trustee Tsai family fund	This work was partly supported by National Cancer Institute (grant numbers P30CA014089 and R01CA241137), Gloria Borges WunderGlo Foundation, Dhont Family Foundation, Gene Gregg Pancreas Research Fund, San Pedro Peninsula Cancer Guild, Daniel Butler Research Fund, V foundation for cancer research, Victoria and Philip Wilson Research Fund, Fong research project, Ming Hsieh research fund, Boyd and Elsie Welin Professorship to JCS and USC Trustee Tsai family fund to JCS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute of the National Institutes of Health.	Agirman G, 2021, SCIENCE, V374, P1087, DOI 10.1126/science.abi6087; Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008; Alizadeh M, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.857563; Aljanabi R, 2021, MOLECULES, V26, DOI 10.3390/molecules26196019; An J, 2021, J MICROBIOL, V59, P202, DOI 10.1007/s12275-021-0562-5; Ataee R, 2010, J CANCER RES CLIN, V136, P1461, DOI 10.1007/s00432-010-0801-3; Auteri M, 2015, PHARMACOL RES, V93, P11, DOI 10.1016/j.phrs.2014.12.001; Battaglin F, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3048; Battaglin F, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3595; Beaulieu JM, 2015, BRIT J PHARMACOL, V172, P1, DOI 10.1111/bph.12906; Beaulieu JM, 2011, PHARMACOL REV, V63, P182, DOI 10.1124/pr.110.002642; Bortolato M, 2008, ADV DRUG DELIVER REV, V60, P1527, DOI 10.1016/j.addr.2008.06.002; Carvajal AE, 2017, BBA-MOL BASIS DIS, V1863, P2126, DOI 10.1016/j.bbadis.2017.05.026; Castellano E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11245; Catala-Lopez F, 2014, PSYCHOTHER PSYCHOSOM, V83, P89, DOI 10.1159/000356498; Chan YL, 2020, CANCERS, V12, DOI 10.3390/cancers12071844; Cheng KR, 2005, BIOCHEM PHARMACOL, V70, P1035, DOI 10.1016/j.bcp.2005.07.023; Cheng KR, 2008, AM J PHYSIOL-GASTR L, V295, pG591, DOI 10.1152/ajpgi.00055.2008; Cheng KR, 2017, ONCOTARGET, V8, P21106, DOI 10.18632/oncotarget.15500; Cheng KR, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-77; Ngo DH, 2019, MOLECULES, V24, DOI 10.3390/molecules24152678; de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9; Deng H, 2018, AGEING RES REV, V42, P72, DOI 10.1016/j.arr.2017.12.007; Di YZ, 2019, WORLD J CLIN CASES, V7, P1554, DOI 10.12998/wjcc.v7.i13.1554; Dohi O, 2010, INT J ONCOL, V36, P85, DOI 10.3892/ijo_00000478; Drilon A, 2019, ANN ONCOL, V30, pVIII23, DOI 10.1093/annonc/mdz282; Eglen R. M., 2006, Autonomic & Autacoid Pharmacology, V26, P219, DOI 10.1111/j.1474-8673.2006.00368.x; Ejma M, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8100416; Fang CK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038886; Fang HS, 2021, BMC GERIATR, V21, DOI 10.1186/s12877-021-02497-z; Farhana L, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0439-4; Fatemi SH, 2001, MOL PSYCHIATR, V6, P129, DOI 10.1038/sj.mp.4000129; Feng DD, 2015, TRANSL NEURODEGENER, V4, DOI 10.1186/s40035-015-0043-z; Fujikawa H, 2012, J GASTROENTEROL, V47, P775, DOI 10.1007/s00535-012-0532-0; Furness JB, 2012, NAT REV GASTRO HEPAT, V9, P286, DOI 10.1038/nrgastro.2012.32; Gemignani F, 2005, CANCER EPIDEM BIOMAR, V14, P1633, DOI 10.1158/1055-9965.EPI-05-0057; Grant CE, 2022, CARCINOGENESIS, V43, P517, DOI 10.1093/carcin/bgac045; Hajiasgharzadeh K, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03611; Hayakawa Y, 2017, CANCER CELL, V31, P21, DOI 10.1016/j.ccell.2016.11.005; Hayashi S, 2014, AM J PHYSIOL-GASTR L, V307, pG968, DOI 10.1152/ajpgi.00346.2013; Hering NA, 2021, CANCERS, V13, DOI 10.3390/cancers13133220; Huang D, 2022, NAT CELL BIOL, V24, P230, DOI 10.1038/s41556-021-00820-9; Huang SM, 2015, ENDOCR-RELAT CANCER, V22, P455, DOI 10.1530/ERC-15-0007; Jiang SH, 2020, ONCOGENE, V39, P503, DOI 10.1038/s41388-019-1006-0; Joseph J, 2002, CANCER RES, V62, P6467; Kannen V, 2020, TRENDS ENDOCRIN MET, V31, P611, DOI 10.1016/j.tem.2020.04.008; Kannen V, 2015, CELL SIGNAL, V27, P1781, DOI 10.1016/j.cellsig.2015.05.008; Kawai H, 2001, J NEUROCHEM, V78, P1367, DOI 10.1046/j.1471-4159.2001.00526.x; Killinger BA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar5280; Kojadinovic A, 2021, CRIT REV ONCOL HEMAT, V165, DOI 10.1016/j.critrevonc.2021.103451; Kontos CK, 2010, BRIT J CANCER, V102, P1384, DOI 10.1038/sj.bjc.6605654; Kwon YH, 2022, AM J PHYSIOL-CELL PH, V323, pC550, DOI 10.1152/ajpcell.00433.2021; Lee GH, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00122; Lee H, 2021, CANCER SCI, V112, P3732, DOI 10.1111/cas.15026; Lee JYS, 2022, AGING-US, V14, P2148, DOI 10.18632/aging.203932; Leng ZG, 2017, AUTOPHAGY, V13, P1404, DOI 10.1080/15548627.2017.1328347; Li T, 2021, CANCER IMMUNOL RES, V9, P1008, DOI 10.1158/2326-6066.CIR-20-1043; Li WH, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/657570; Liu SM, 2018, NEUROGASTROENT MOTIL, V30, DOI 10.1111/nmo.13446; Liu T, 2021, COMPUT MATH METHOD M, V2021, DOI 10.1155/2021/5544182; Lutgendorf SK, 2011, PSYCHOSOM MED, V73, P724, DOI 10.1097/PSY.0b013e318235be76; Margolis KG, 2021, GASTROENTEROLOGY, V160, P1486, DOI 10.1053/j.gastro.2020.10.066; Mawe GM, 2013, NAT REV GASTRO HEPAT, V10, P473, DOI 10.1038/nrgastro.2013.105; Meldolesi J, 2018, REV PHYSIOL BIOCH P, V174, P67, DOI 10.1007/112_2017_6; Miao YF, 2010, BIOMED PHARMACOTHER, V64, P583, DOI 10.1016/j.biopha.2010.03.006; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Mittal R, 2017, J CELL PHYSIOL, V232, P2359, DOI 10.1002/jcp.25518; Molloy Niamh H, 2011, Cancers (Basel), V3, P510, DOI 10.3390/cancers3010510; Nocito A, 2008, CANCER RES, V68, P5152, DOI 10.1158/0008-5472.CAN-08-0202; Parrish WR, 2008, MOL MED, V14, P567, DOI 10.2119/2008-00079.Parrish; Pavlov VA, 2003, MOL MED, V9, P125, DOI 10.1007/BF03402177; Pavlov VA, 2015, IMMUNOL RES, V63, P38, DOI 10.1007/s12026-015-8718-1; Penedo MA., 2021, BRAIN BEHAV IMMUN HL, V12, P100199, DOI [10.1016/j.bbih.2021.100199, DOI 10.1016/J.BBIH.2021.100199]; Peng ZS, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-204; Qiu YP, 2014, CLIN CANCER RES, V20, P2136, DOI 10.1158/1078-0432.CCR-13-1939; Radin DP, 2017, ANTICANCER RES, V37, P3983, DOI 10.21873/anticanres.11783; Raufman JP, 2008, CANCER RES, V68, P3573, DOI 10.1158/0008-5472.CAN-07-6810; Raufman JP, 2015, CARCINOGENESIS, V36, P1193, DOI 10.1093/carcin/bgv107; Ren YG, 2018, LIFE SCI, V209, P267, DOI 10.1016/j.lfs.2018.08.027; Sadighparvar S, 2021, EUR J PHARMACOL, V913, DOI 10.1016/j.ejphar.2021.174626; Said AH, 2017, BIOCHEM J, V474, P647, DOI 10.1042/BCJ20160704; Sakita JY, 2019, J PATHOL, V249, P102, DOI 10.1002/path.5285; Sarkar C, 2008, CLIN CANCER RES, V14, P2502, DOI 10.1158/1078-0432.CCR-07-1778; Sarrouilhe D, 2019, BIOCHIMIE, V161, P46, DOI 10.1016/j.biochi.2018.06.016; Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008; Schledwitz A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143776; Schuller HM, 2009, NAT REV CANCER, V9, P195, DOI 10.1038/nrc2590; Shu Q, 2016, CANCER MED-US, V5, P1259, DOI 10.1002/cam4.686; Song LH, 2016, TUMOR BIOL, V37, P14885, DOI 10.1007/s13277-016-5367-5; Stein T, 2008, BREAST CANCER RES, V10, pS15, DOI 10.1186/bcr1909; Sui H, 2015, ONCOTARGET, V6, P25975, DOI 10.18632/oncotarget.4543; Tait C, 2021, EUR J INTERN MED, V84, P1, DOI 10.1016/j.ejim.2020.12.023; TATSUTA M, 1992, INT J CANCER, V50, P298, DOI 10.1002/ijc.2910500221; Tolaymat M, 2019, CANCERS, V11, DOI 10.3390/cancers11030308; Vignot S, 2015, EUR J CANCER, V51, P791, DOI 10.1016/j.ejca.2015.02.012; Von Rosenvinge Erik C, 2011, Cancers (Basel), V3, P971, DOI 10.3390/cancers3010971; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang HH, 2021, INT J BIOL SCI, V17, P1953, DOI 10.7150/ijbs.58135; Wang X, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abh2383; Wang YC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23164-2; Wei PL, 2011, ANN SURG ONCOL, V18, P1782, DOI 10.1245/s10434-010-1504-3; Wong HPS, 2007, TOXICOL SCI, V97, P279, DOI 10.1093/toxsci/kfm060; Wong HPS, 2007, TOXICOL APPL PHARM, V221, P261, DOI 10.1016/j.taap.2007.04.002; Xia Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01029; Xiang T, 2016, ONCOL REP, V35, P205, DOI 10.3892/or.2015.4363; Yan H, 2016, ONCOGENE, V35, P3995, DOI 10.1038/onc.2015.423; Yan L, 2020, ONCOL LETT, V20, P275, DOI 10.3892/ol.2020.11573; Yang XM, 2013, EXP THER MED, V6, P1475, DOI 10.3892/etm.2013.1330; Yang YC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082813; Ye YN, 2004, J PHARMACOL EXP THER, V311, P123, DOI 10.1124/jpet.104.068031; Zhang BH, 2021, NATURE, V599, P471, DOI 10.1038/s41586-021-04082-1; Zhang HY, 2020, EXP HEMATOL ONCOL, V9, DOI 10.1186/s40164-020-00191-1; Zhang NQ, 2021, AM J GASTROENTEROL, V116, P2310, DOI 10.14309/ajg.0000000000001520; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569; Zhu PP, 2022, NEURON, V110, P2268, DOI 10.1016/j.neuron.2022.04.024	115	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2022	41	43					4769	4778		10.1038/s41388-022-02479-4	http://dx.doi.org/10.1038/s41388-022-02479-4		OCT 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M4RI	36182970				2022-12-28	WOS:000862526800001
J	Chen, PW; Dey, P				Chen, Peiwen; Dey, Prasenjit			Co-dependencies in the tumor immune microenvironment	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; BETA-CATENIN; LUNG ADENOCARCINOMA; T-CELLS; PD-L1 EXPRESSION; DENDRITIC CELLS; CANCER; PTEN; PROMOTES; IMMUNOTHERAPY	Activated oncogenes and disrupted tumor suppressor genes (TSGs) not only endow aspiring cancer cells with new biological capabilities but also influence the composition and function of host cells in the tumor microenvironment (TME). These non-cancer host cells can in turn provide cancer cells with growth support and protection from the anti-tumor immune response. In this ecosystem, geospatially heterogenous "subTME" adds to the complexity of the "global" TME which bestows tumors with increased tumorigenic ability and resistance to therapy. This review highlights how specific genetic alterations in cancer cells establish various symbiotic co-dependencies with surrounding host cells and details the cooperative role of the host cells in tumor biology. These essential interactions expand the repertoire of targets for the development of precision cancer treatments.	[Chen, Peiwen] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA; [Dey, Prasenjit] Roswell Park Comprehens Canc Ctr, Dept Immunol, Buffalo, NY 14263 USA	Northwestern University; Feinberg School of Medicine	Dey, P (corresponding author), Roswell Park Comprehens Canc Ctr, Dept Immunol, Buffalo, NY 14263 USA.	prasenjit.dey@roswellpark.org		dey, prasenjit/0000-0001-6678-503X	Roswell Park Alliance Foundation [62-2839-01]; NCI Cancer Center Support Grant [P30CA016056]; NIH [R00 CA240896]; DoD Career Development Award [W81XWH-21-1-0380]; Cancer Research Foundation Young Investigator Award; Lynn Sage Scholar Award; American Cancer Society Institutional Research Grant [IRG-21-144-27]; Bill Bass Foundation;  [5R00CA218891-04];  [1R01CA262822-01]	Roswell Park Alliance Foundation; NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD Career Development Award; Cancer Research Foundation Young Investigator Award; Lynn Sage Scholar Award; American Cancer Society Institutional Research Grant(American Cancer Society); Bill Bass Foundation; ; 	This study was supported in part by 5R00CA218891-04 (PD); 1R01CA262822-01 (PD), The Roswell Park Alliance Foundation-62-2839-01 (PD); NCI Cancer Center Support Grant P30CA016056 (PD); NIH R00 CA240896 (PC), DoD Career Development Award W81XWH-21-1-0380 (PC), Cancer Research Foundation Young Investigator Award (PC), Lynn Sage Scholar Award (PC), American Cancer Society Institutional Research Grant IRG-21-144-27 (PC), philanthropic donation from Mindy Jacobson and the Bill Bass Foundation (PC). Figures created with BioRender.com.	AbdulJabbar K, 2020, NAT MED, V26, P1054, DOI 10.1038/s41591-020-0900-x; Aguirre AJ, 2004, P NATL ACAD SCI USA, V101, P9067, DOI 10.1073/pnas.0402932101; Ahn MJ, 2017, EXPERT OPIN DRUG SAF, V16, P465, DOI 10.1080/14740338.2017.1300656; Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Alam A, 2022, CANCER CELL, V40, P153, DOI 10.1016/j.ccell.2022.01.003; An ZY, 2018, CANCER RES, V78, P6785, DOI 10.1158/0008-5472.CAN-17-3551; Anson M, 2012, J CLIN INVEST, V122, P586, DOI 10.1172/JCI43937; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; Armstrong CWD, 2016, ONCOTARGET, V7, P7885, DOI 10.18632/oncotarget.6955; Atkins D, 2004, INT J CANCER, V109, P265, DOI 10.1002/ijc.11681; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Balli D, 2017, CLIN CANCER RES, V23, P3129, DOI 10.1158/1078-0432.CCR-16-2128; Bassanelli M, 2018, ANTICANCER RES, V38, P3789, DOI 10.21873/anticanres.12662; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Beck AH, 2009, CLIN CANCER RES, V15, P778, DOI 10.1158/1078-0432.CCR-08-1283; Bezzi M, 2018, NAT MED, V24, P165, DOI 10.1038/nm.4463; Bister K, 2015, P NATL ACAD SCI USA, V112, P15259, DOI 10.1073/pnas.1521145112; Blagih J, 2020, CELL REP, V30, P481, DOI 10.1016/j.celrep.2019.12.028; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Brandetti E, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1316439; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Burnet F M, 1971, Transplant Rev, V7, P3; Busch SE, 2016, J IMMUNOL, V197, P4493, DOI 10.4049/jimmunol.1600576; Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500; Chen PW, 2019, CANCER CELL, V35, P868, DOI 10.1016/j.ccell.2019.05.003; Cheng Y, 2019, BBA-REV CANCER, V1871, P289, DOI 10.1016/j.bbcan.2019.01.005; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi M, 2017, ANN ONCOL, V28, P83, DOI 10.1093/annonc/mdw437; Chun E, 2015, CELL REP, V12, P244, DOI 10.1016/j.celrep.2015.06.024; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Coley W B, 1910, Proc R Soc Med, V3, P1; Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Dart Anna, 2016, Nat Rev Cancer, V16, P411, DOI 10.1038/nrc.2016.67; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Dey P, 2020, CANCER DISCOV, V10, P608, DOI 10.1158/2159-8290.CD-19-0297; Di Mitri D, 2019, CELL REP, V28, P2156, DOI 10.1016/j.celrep.2019.07.068; DUESBERG PH, 1970, P NATL ACAD SCI USA, V67, P1673, DOI 10.1073/pnas.67.4.1673; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Ehrlich P., 1960, COLLECTED PAPERS P E; Eng CHL, 2019, NATURE, V568, P235, DOI 10.1038/s41586-019-1049-y; Faget J, 2017, CELL REP, V21, P3190, DOI 10.1016/j.celrep.2017.11.052; Falk AT, 2018, LUNG CANCER, V121, P70, DOI 10.1016/j.lungcan.2018.05.009; Fu CM, 2015, P NATL ACAD SCI USA, V112, P2823, DOI 10.1073/pnas.1414167112; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Garcia AJ, 2014, MOL CELL BIOL, V34, P2017, DOI 10.1128/MCB.00090-14; Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982; George S, 2017, IMMUNITY, V46, P197, DOI 10.1016/j.immuni.2017.02.001; Grunwald BT, 2021, CELL, V184, P5577, DOI 10.1016/j.cell.2021.09.022; Guerriero JL, 2017, NATURE, V543, P428, DOI 10.1038/nature21409; Ham SW, 2019, CELL DEATH DIFFER, V26, P409, DOI 10.1038/s41418-018-0126-3; Highfill SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007974; Hlaing AM, 2018, BIOCHEM BIOPH RES CO, V503, P2764, DOI 10.1016/j.bbrc.2018.08.037; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Hong Y, 2015, CANCER RES, V75, P656, DOI 10.1158/0008-5472.CAN-14-2377; Horton BL, 2019, TRENDS CANCER, V5, P593, DOI 10.1016/j.trecan.2019.07.006; Hurwitz H, 2018, INVEST NEW DRUG, V36, P683, DOI 10.1007/s10637-018-0580-2; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jaspers JE, 2017, PHARMACOL THERAPEUT, V178, P83, DOI 10.1016/j.pharmthera.2017.03.012; Kadara H, 2017, ANN ONCOL, V28, P75, DOI 10.1093/annonc/mdw436; Kargl J, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130850; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kerr KM, 2019, LUNG CANCER, V131, P95, DOI 10.1016/j.lungcan.2019.03.012; Kim SH, 2017, J INVEST DERMATOL, V137, P1740, DOI 10.1016/j.jid.2017.03.033; Kitapma S, 2019, CANCER DISCOV, V9, P34, DOI 10.1158/2159-8290.CD-18-0689; Knox T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42237-3; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Koyama S, 2016, CANCER RES, V76, P999, DOI 10.1158/0008-5472.CAN-15-1439; Layer JP, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1320626; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lee R, 2022, CANCER DISCOV, V12, P1702, DOI 10.1158/2159-8290.CD-21-0680; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li YJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax0428; Liao WT, 2019, CANCER CELL, V35, P559, DOI 10.1016/j.ccell.2019.02.008; Ligorio M, 2019, CELL, V178, P160, DOI 10.1016/j.cell.2019.05.012; Liu CM, 2020, CANCER LETT, V470, P95, DOI 10.1016/j.canlet.2019.10.027; Liu HS, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00534-2; Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676; Lubeck E, 2014, NAT METHODS, V11, P360, DOI 10.1038/nmeth.2892; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Luke JJ, 2019, CLIN CANCER RES, V25, P3074, DOI 10.1158/1078-0432.CCR-18-1942; Maddalena M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2025631118; Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x; Nakamura K, 2020, CELL MOL IMMUNOL, V17, P1, DOI 10.1038/s41423-019-0306-1; Neubert NJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan3311; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Pang L, 2022, TRENDS CANCER; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Pathria P, 2019, TRENDS IMMUNOL, V40, P310, DOI 10.1016/j.it.2019.02.003; Pena CG, 2015, J CLIN INVEST, V125, P4063, DOI 10.1172/JCI82152; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Raedler Lisa A, 2015, Am Health Drug Benefits, V8, P75; Rodriques SG, 2019, SCIENCE, V363, P1463, DOI 10.1126/science.aaw1219; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Sainz B, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9012369; Salgia R, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2020.100186; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Siolas D, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109578; Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Spranger S, 2018, NAT REV CANCER, V18, P139, DOI 10.1038/nrc.2017.117; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Spranger S, 2016, P NATL ACAD SCI USA, V113, pE7759, DOI 10.1073/pnas.1609376113; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Stromnes IM, 2014, GUT, V63, P1769, DOI 10.1136/gutjnl-2013-306271; Sugiyama E, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aav3937; Sumimoto H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166626; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Theivanthiran B, 2020, J CLIN INVEST, V130, P2570, DOI 10.1172/JCI133055; Torphy RJ, 2018, ANN GASTROENT SURG, V2, P274, DOI 10.1002/ags3.12176; Umansky V, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040036; Wang DH, 2017, CLIN CANCER RES, V23, P778, DOI 10.1158/1078-0432.CCR-15-2597; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Wellenstein MD, 2019, NATURE, V572, P538, DOI 10.1038/s41586-019-1450-6; Werb Z, 2015, CANCER J, V21, P250, DOI 10.1097/PPO.0000000000000127; White MC, 2014, AM J PREV MED, V46, pS7, DOI 10.1016/j.amepre.2013.10.029; Wormann SM, 2016, GASTROENTEROLOGY, V151, P180, DOI 10.1053/j.gastro.2016.03.010; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6; Yetil A, 2015, ONCOTARGET, V6, P3563, DOI 10.18632/oncotarget.2969; Ying HQ, 2016, GENE DEV, V30, P355, DOI 10.1101/gad.275776.115; Zdanov S, 2016, CANCER IMMUNOL RES, V4, P354, DOI 10.1158/2326-6066.CIR-15-0241; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhao D, 2020, CANCER DISCOV, V10, P1374, DOI 10.1158/2159-8290.CD-19-1352; Zhao D, 2017, NATURE, V542, P484, DOI 10.1038/nature21357; Zhao J, 2019, NAT MED, V25, P462, DOI 10.1038/s41591-019-0349-y; Zhao Y, 2020, PHARMACOL THERAPEUT, V212, DOI 10.1016/j.pharmthera.2020.107556; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9; Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723; Zucman D, 2018, NEW ENGL J MED, V378, P2144, DOI 10.1056/NEJMc1804812	144	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3821	3829		10.1038/s41388-022-02406-7	http://dx.doi.org/10.1038/s41388-022-02406-7		JUL 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35817840				2022-12-28	WOS:000825078900001
J	Zhang, XC; Hu, YB; Pan, YL; Xiong, YX; Zhang, YX; Han, MZ; Dong, KS; Song, J; Liang, HF; Ding, ZY; Zhang, XW; Zhu, H; Liu, QM; Lu, X; Feng, YD; Chen, XP; Zhang, ZG; Zhang, BX				Zhang, Xiaochao; Hu, Yabing; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Feng, Yongdong; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang			DDR1 promotes hepatocellular carcinoma metastasis through recruiting PSD4 to ARF6	ONCOGENE			English	Article							DOMAIN RECEPTOR 1; TYROSINE KINASES; GROWTH-FACTOR; DISCOIDIN; EXPRESSION; INHIBITION; OVEREXPRESSION; ACTIVATION; SURVIVAL; ROLES	Discoidin domain receptor 1 (DDR1) is a member of the receptor tyrosine kinase family, and its ligand is collagen. Previous studies demonstrated that DDR1 is highly expressed in many tumors. However, its role in hepatocellular carcinoma (HCC) remains obscure. In this study, we found that DDR1 was upregulated in HCC tissues, and the expression of DDR1 in TNM stage II-IV was higher than that in TNM stage I in HCC tissues, and high DDR1 expression was associated with poor prognosis. Gene expression analysis showed that DDR1 target genes were functionally involved in HCC metastasis. DDR1 positively regulated the migration and invasion of HCC cells and promoted lung metastasis. Human Phospho-Kinase Array showed that DDR1 activated ERK/MAPK signaling pathway. Mechanically, DDR1 interacted with ARF6 and activated ARF6 through recruiting PSD4. The kinase activity of DDR1 was required for ARF6 activation and its role in metastasis. High expression of PSD4 was associated with poor prognosis in HCC. In summary, our findings indicate that DDR1 promotes HCC metastasis through collagen induced DDR1 signaling mediated PSD4/ARF6 signaling, suggesting that DDR1 and ARF6 may serve as novel prognostic biomarkers and therapeutic targets for metastatic HCC.	[Zhang, Xiaochao; Hu, Yabing; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China; [Zhang, Xiaochao; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang] ChinaClin Med Res Ctr Hepat Surg Hubei Prov, Wuhan, Peoples R China; [Zhang, Xiaochao; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang] Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Zhang, Xiaochao; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang] Natl Hlth Commiss, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Zhang, Xiaochao; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang] Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Zhang, Xiaochao] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dermatol, Wuhan, Peoples R China; [Hu, Yabing] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Biochem & Mol Biol, Wuhan, Hubei, Peoples R China; [Feng, Yongdong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Canc Res Inst, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zhang, ZG; Zhang, BX (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China.; Zhang, ZG; Zhang, BX (corresponding author), ChinaClin Med Res Ctr Hepat Surg Hubei Prov, Wuhan, Peoples R China.; Zhang, ZG; Zhang, BX (corresponding author), Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China.; Zhang, ZG; Zhang, BX (corresponding author), Natl Hlth Commiss, Key Lab Organ Transplantat, Wuhan, Peoples R China.; Zhang, ZG; Zhang, BX (corresponding author), Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan, Peoples R China.	zhanguo_tjh@hust.edu.cn; bixiangzhang@163.com	Ding, Ze-yang/HHC-6329-2022; yuxin, Zhang/GNH-2283-2022	Ding, Ze-yang/0000-0001-5826-0970; Liang, Huifang/0000-0001-6874-3634	National Natural Science Foundation of China [81372327, 81874149, 81874189, 81572855, 81572427, 81874065]; State Key Project on Infection Disease of China [2018ZX10723204-003]; National Key Research and Development Program of China [2018YFA0208904]; Hepato-BiliaryPancreatic Investigation Fund of Chen Xiaoping Foundation for the Development of Science and Technology of Hubei Province [CXPJJH11800001-2018356]; HCP project of Huazhong University of Science and Technology [5001540059, 5001540006]; Major Technological Innovation Projects of Hubei Province [2018ACA137]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Project on Infection Disease of China; National Key Research and Development Program of China; Hepato-BiliaryPancreatic Investigation Fund of Chen Xiaoping Foundation for the Development of Science and Technology of Hubei Province; HCP project of Huazhong University of Science and Technology; Major Technological Innovation Projects of Hubei Province	This research was supported by grants from the National Natural Science Foundation of China (No.81372327, 81874149, 81874189, 81572855, 81572427, 81874065), the State Key Project on Infection Disease of China (No. 2018ZX10723204-003), the National Key Research and Development Program of China (2018YFA0208904), the Hepato-BiliaryPancreatic Investigation Fund of Chen Xiaoping Foundation for the Development of Science and Technology of Hubei Province (CXPJJH11800001-2018356), the HCP project of Huazhong University of Science and Technology (No. 5001540059, 5001540006), Major Technological Innovation Projects of Hubei Province (2018ACA137).	Agarwal G, 2007, J MOL BIOL, V367, P443, DOI 10.1016/j.jmb.2006.12.073; Aguilera KY, 2017, MOL CANCER THER, V16, P2473, DOI 10.1158/1535-7163.MCT-16-0834; ALVES F, 1995, ONCOGENE, V10, P609; Ambrogio C, 2016, NAT MED, V22, P270, DOI 10.1038/nm.4041; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Cox R, 2004, MOL BIOL CELL, V15, P1487, DOI 10.1091/mbc.E03-06-0443; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Dai W, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00563-x; Ding ZY, 2014, HEPATOLOGY, V60, P1620, DOI 10.1002/hep.27273; Ding ZY, 2013, CELL SIGNAL, V25, P1981, DOI 10.1016/j.cellsig.2013.05.027; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Gao H, 2016, CELL, V166, P47, DOI 10.1016/j.cell.2016.06.009; Grossmann AH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003398; Hashimoto S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10656; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Hongu T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8925; Hu B, 2009, CANCER RES, V69, P794, DOI 10.1158/0008-5472.CAN-08-2110; Hunzicker-Dunn M, 2002, FEBS LETT, V521, P3, DOI 10.1016/S0014-5793(02)02822-3; Jeitany M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201707918; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P10891, DOI 10.1073/pnas.90.22.10891; Juin A, 2014, J CELL BIOL, V207, P517, DOI 10.1083/jcb.201404079; Leitinger B, 2014, INT REV CEL MOL BIO, V310, P39, DOI 10.1016/B978-0-12-800180-6.00002-5; Meng ZP, 2010, HEPATOLOGY, V52, P2148, DOI 10.1002/hep.23915; Morishige M, 2008, NAT CELL BIOL, V10, P85, DOI 10.1038/ncb1672; Muralidharan-Chari V, 2009, CANCER RES, V69, P2201, DOI 10.1158/0008-5472.CAN-08-1301; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Romayor I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75395-w; Tsochatzis EA, 2012, NEW ENGL J MED, V366, P92, DOI 10.1056/NEJMc1112501; Valencia K, 2012, CLIN CANCER RES, V18, P969, DOI 10.1158/1078-0432.CCR-11-1686; Vehlow A, 2019, CELL REP, V26, P3672, DOI 10.1016/j.celrep.2019.02.096; Villalba M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51066-3; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Wei S, 2012, CARCINOGENESIS, V33, P538, DOI 10.1093/carcin/bgr319; Weiner HL, 2000, NEUROSURGERY, V47, P1400, DOI 10.1097/00006123-200012000-00028; Yang J, 2017, SCI REP-UK, V7, DOI 10.1038/srep40358; Yang J, 2019, THERANOSTICS, V9, P5810, DOI 10.7150/thno.34973; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yoo JH, 2016, CANCER CELL, V29, P889, DOI 10.1016/j.ccell.2016.04.015; Zangari J, 2014, CANCER RES, V74, P5493, DOI 10.1158/0008-5472.CAN-14-0298; Zhavoronkov A, 2019, NAT BIOTECHNOL, V37, P1038, DOI 10.1038/s41587-019-0224-x; Zhou L, 2008, WORLD J SURG, V32, P1748, DOI 10.1007/s00268-008-9615-8	44	1	1	10	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1821	1834		10.1038/s41388-022-02212-1	http://dx.doi.org/10.1038/s41388-022-02212-1		FEB 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35140331	Green Published, hybrid			2022-12-28	WOS:000753256900001
J	Xu, YF; He, XY; Wang, SZ; Sun, BF; Jia, RB; Chai, PW; Li, F; Yang, Y; Ge, SF; Jia, RB; Yang, YG; Fan, XQ				Xu, Yangfan; He, Xiaoyu; Wang, Shanzheng; Sun, Baofa; Jia, Ruobing; Chai, Peiwei; Li, Fang; Yang, Ying; Ge, Shengfang; Jia, Renbing; Yang, Yun-Gui; Fan, Xianqun			The m(6)A reading protein YTHDF3 potentiates tumorigenicity of cancer stem-like cells in ocular melanoma through facilitating CTNNB1 translation	ONCOGENE			English	Article							CONJUNCTIVAL MELANOMA; MALIGNANT-MELANOMA; HITS-CLIP; RNA; EXPRESSION; PROMOTES; DIFFERENTIATION; ACTIVATION; TISSUE; MODEL	N-6-methyladenosine (m(6)A) is the most universal internal RNA modification on messenger RNAs and regulates the fate and functions of m(6)A-modified transcripts through m(6)A-specific binding proteins. Nevertheless, the functional role and potential mechanism of the m(6)A reading proteins in ocular melanoma tumorigenicity, especially cancer stem-like cell (CSC) properties, remain to be elucidated. Herein, we demonstrated that the m(6)A reading protein YTHDF3 promotes the translation of the target transcript CTNNB1, contributing to ocular melanoma propagation and migration through m(6)A methylation. YTHDF3 is highly expressed in ocular melanoma stem-like cells and abundantly enriched in ocular melanoma tissues, which is related to poor clinical prognosis. Moreover, YTHDF3 is required for the maintenance of CSC properties and tumor initiation capacity in ocular melanoma both in vitro and in vivo. Ocular melanoma cells with targeted YTHDF3 knockdown exhibited inhibitory tumor proliferation and migration abilities. Transcriptome-wide mapping of m(6)A peaks and YTHDF3 binding peaks on mRNAs revealed a key target gene candidate, CTNNB1. Mechanistically, YTHDF3 enhances CTNNB1 translation through recognizing and binding the m(6)A peaks on CTNNB1 mRNA.	[Xu, Yangfan; He, Xiaoyu; Jia, Ruobing; Chai, Peiwei; Li, Fang; Ge, Shengfang; Jia, Renbing; Fan, Xianqun] Shanghai Jiao Tong Univ, Ninth Peoples Hosp, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China; [Xu, Yangfan; He, Xiaoyu; Jia, Ruobing; Chai, Peiwei; Li, Fang; Ge, Shengfang; Jia, Renbing; Fan, Xianqun] Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai, Peoples R China; [Wang, Shanzheng; Sun, Baofa; Yang, Ying; Yang, Yun-Gui] Chinese Acad Sci, Collaborat Innovat Ctr Genet & Dev, Beijing Inst Genom, Key Lab Genom & Precis Med, Beijing, Peoples R China; [Wang, Shanzheng; Sun, Baofa; Yang, Ying; Yang, Yun-Gui] China Natl Ctr Bioinformat, Beijing, Peoples R China; [Wang, Shanzheng; Sun, Baofa; Yang, Ying; Yang, Yun-Gui] Univ Chinese Acad Sci, Sino Danish Coll, Beijing, Peoples R China; [Sun, Baofa; Yang, Ying; Yang, Yun-Gui] Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences	Fan, XQ (corresponding author), Shanghai Jiao Tong Univ, Ninth Peoples Hosp, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China.; Fan, XQ (corresponding author), Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai, Peoples R China.; Yang, YG (corresponding author), Chinese Acad Sci, Collaborat Innovat Ctr Genet & Dev, Beijing Inst Genom, Key Lab Genom & Precis Med, Beijing, Peoples R China.; Yang, YG (corresponding author), China Natl Ctr Bioinformat, Beijing, Peoples R China.; Yang, YG (corresponding author), Univ Chinese Acad Sci, Sino Danish Coll, Beijing, Peoples R China.; Yang, YG (corresponding author), Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing, Peoples R China.	ygyang@big.ac.cn; fanxq@sjtu.edu.cn	Yang, Ying/GRO-4537-2022	Yang, Ying/0000-0002-8104-5985	National Key Research and Development Plan [2017YFE0196300]; National Natural Science Foundation of China [81772875, U1932135, 82073889]; Science and Technology Commission of Shanghai [20DZ2270800, 19JC1410200]; Clinical Research Plan of SHDC [SHDC2020CR1009A]	National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai(Science & Technology Commission of Shanghai Municipality (STCSM)); Clinical Research Plan of SHDC	We express our sincere thanks for all the patients participated in our study and wish them good health. This work was supported by the National Key Research and Development Plan (2017YFE0196300), the National Natural Science Foundation of China (81772875, U1932135, 82073889), the Clinical Research Plan of SHDC (SHDC2020CR1009A), the Science and Technology Commission of Shanghai (20DZ2270800 and 19JC1410200).	Angeloni V, 2015, SEMIN CANCER BIOL, V31, P43, DOI 10.1016/j.semcancer.2014.08.004; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Braun KM, 2008, CELL STEM CELL, V2, P406, DOI 10.1016/j.stem.2008.04.011; Chang GQ, 2020, CANCER CELL, V38, P857, DOI 10.1016/j.ccell.2020.10.004; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; de Waard NE, 2015, OCUL ONCOL PATHOL, V1, P182, DOI 10.1159/000371555; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Gao YF, 2019, CELL RES, V29, P767, DOI 10.1038/s41422-019-0210-3; Giraud J, 2016, CANCER RES, V76, P3618, DOI 10.1158/0008-5472.CAN-15-1497; Han B, 2020, EMBO REP, V21, DOI 10.15252/embr.201949229; Hsu PJ, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1336-6; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jia RB, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1088-x; Jin B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01173-x; Kalirai H, 2011, INVEST OPHTH VIS SCI, V52, P8458, DOI 10.1167/iovs.11-7379; Katoh M, 2017, INT J ONCOL, V51, P1357, DOI 10.3892/ijo.2017.4129; Lai CY, 2012, CANCER RES, V72, P5111, DOI 10.1158/0008-5472.CAN-12-0624; Larsen AC, 2016, ACTA OPHTHALMOL, V94, P1, DOI 10.1111/aos.13100; Li A, 2017, CELL RES, V27, P444, DOI 10.1038/cr.2017.10; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li P, 2020, AUTOPHAGY, V16, P1186, DOI 10.1080/15548627.2019.1659614; Li ZR, 2018, CELL RES, V28, P904, DOI 10.1038/s41422-018-0072-0; Linder B, 2015, NAT METHODS, V12, P767, DOI [10.1038/nmeth.3453, 10.1038/NMETH.3453]; Liu L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1119-7; Liu LW, 2019, J CANCER, V10, P5447, DOI 10.7150/jca.35053; Mackiewicz J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0456-1; Meyer KD, 2019, NAT METHODS, V16, P1275, DOI 10.1038/s41592-019-0570-0; Missotten GS, 2005, INVEST OPHTH VIS SCI, V46, P75, DOI 10.1167/iovs.04-0344; Moore AR, 2018, CELL REP, V22, P2455, DOI 10.1016/j.celrep.2018.01.081; Moore MJ, 2014, NAT PROTOC, V9, P263, DOI 10.1038/nprot.2014.012; Murphy GF, 2014, MOL ASPECTS MED, V39, P33, DOI 10.1016/j.mam.2013.10.003; Newel F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11107-x; Ni W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1079-y; Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Rappa G, 2013, EXP CELL RES, V319, P810, DOI 10.1016/j.yexcr.2013.01.003; Shah A, 2017, BIOINFORMATICS, V33, P566, DOI 10.1093/bioinformatics/btw653; Shang QF, 2019, EPIGENOMICS-UK, V11, P787, DOI 10.2217/epi-2019-0029; Shi HL, 2018, NATURE, V563, P249, DOI 10.1038/s41586-018-0666-1; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Shidal C, 2019, CANCER RES, V79, P3622, DOI 10.1158/0008-5472.CAN-18-2659; Shields CL, 2000, ARCH OPHTHALMOL-CHIC, V118, P1497; Smit KN, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100800; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Sun Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12733-1; Terai K, 2018, STEM CELLS, V36, P1154, DOI 10.1002/stem.2835; Tuomaala S, 2002, INVEST OPHTH VIS SCI, V43, P3399; Vu LP, 2019, CANCER DISCOV, V9, P25, DOI 10.1158/2159-8290.CD-18-0959; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016; Weyn-Vanhentenryck SM, 2014, CELL REP, V6, P1139, DOI 10.1016/j.celrep.2014.02.005; Yang J, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758834018757175; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8; Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yue YN, 2015, GENE DEV, V29, P1343, DOI 10.1101/gad.262766.115; Zhang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1070-7; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang Sisi, 2018, Yichuan, V40, P1044, DOI 10.16288/j.yczz.18-178; Zhang Y, 2019, P NATL ACAD SCI USA, V116, P976, DOI 10.1073/pnas.1812536116; Zhang Z, 2017, NUCLEIC ACIDS RES, V45, pD18, DOI 10.1093/nar/gkw1060; Zhao L, 2020, J CELL MOL MED, V24, P511, DOI 10.1111/jcmm.14758; Zhou JF, 2017, THERANOSTICS, V7, P1447, DOI 10.7150/thno.17451	66	9	9	4	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1281	1297		10.1038/s41388-021-02146-0	http://dx.doi.org/10.1038/s41388-021-02146-0		FEB 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35110680				2022-12-28	WOS:000749991400001
J	Han, FY; Zhang, L; Liao, SX; Zhang, YM; Qian, LL; Hou, FJ; Gong, JW; Lai, MD; Zhang, HH				Han, Fengyan; Zhang, Lei; Liao, Shaoxia; Zhang, Yanmin; Qian, Lili; Hou, Feijun; Gong, Jingwen; Lai, Maode; Zhang, Honghe			The interaction between S100A2 and KPNA2 mediates NFYA nuclear import and is a novel therapeutic target for colorectal cancer metastasis	ONCOGENE			English	Article							ALPHA-2 KPNA2; PROTEIN; TRANSPORT; MARKER; EXPRESSION; MECHANISM; SUBUNIT; P53	Nucleocytoplasmic transport of proteins is disrupted and dysregulated in cancer cells. Nuclear pore complexes and cargo proteins are two main transportation regulators. However, the mechanism regulating nucleocytoplasmic transport in cancer remains elusive. Here, we identified a S100A2/KPNA2 cotransport complex that transports the tumor-associated transcription factor NFYA in colorectal cancer (CRC). Through the S100A2/KNPA2 complex, depending on its interaction with S100A2, NFYA is transported to the nucleus and inhibits the transcriptional activity of E-cadherin, which in turn promotes CRC metastasis. Targeting the S100A2/KPNA2 binding sites with the specific inhibitor delanzomib is a potential therapeutic approach for CRC.	[Han, Fengyan; Liao, Shaoxia; Qian, Lili; Hou, Feijun; Zhang, Honghe] Zhejiang Univ, Dept Pathol, Chinese Acad Med Sci,Sch Med, Res Unit Intelligence Classificat Tumor Pathol &, 2019RU042, Hangzhou 310058, Zhejiang, Peoples R China; [Han, Fengyan; Liao, Shaoxia; Qian, Lili; Hou, Feijun; Zhang, Honghe] Zhejiang Univ, Womens Hosp, Chinese Acad Med Sci,Sch Med, Res Unit Intelligence Classificat Tumor Pathol &, 2019RU042, Hangzhou 310058, Zhejiang, Peoples R China; [Zhang, Lei; Gong, Jingwen; Lai, Maode; Zhang, Honghe] Key Lab Dis Prote Zhejiang Prov, Hangzhou 310058, Zhejiang, Peoples R China; [Zhang, Lei; Gong, Jingwen; Lai, Maode; Zhang, Honghe] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China; [Zhang, Lei; Lai, Maode] China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Peoples R China; [Zhang, Yanmin] China Pharmaceut Univ, Sch Sci, Lab Mol Design & Drug Discovery, 639 Longmian Ave, Nanjing 211198, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Zhejiang University; Chinese Academy of Medical Sciences - Peking Union Medical College; Zhejiang University; Zhejiang University; China Pharmaceutical University; China Pharmaceutical University	Zhang, HH (corresponding author), Zhejiang Univ, Dept Pathol, Chinese Acad Med Sci,Sch Med, Res Unit Intelligence Classificat Tumor Pathol &, 2019RU042, Hangzhou 310058, Zhejiang, Peoples R China.; Zhang, HH (corresponding author), Zhejiang Univ, Womens Hosp, Chinese Acad Med Sci,Sch Med, Res Unit Intelligence Classificat Tumor Pathol &, 2019RU042, Hangzhou 310058, Zhejiang, Peoples R China.; Lai, MD; Zhang, HH (corresponding author), Key Lab Dis Prote Zhejiang Prov, Hangzhou 310058, Zhejiang, Peoples R China.; Lai, MD; Zhang, HH (corresponding author), Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China.; Lai, MD (corresponding author), China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Peoples R China.	lmp@zju.edu.cn; honghezhang@zju.edu.cn	钱, 钱丽丽/GWV-8162-2022		National Natural Science Foundation of China [81871937, 82001586, 91859204, 82072629, 82072811]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-I2M-5-044]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS)	This work is supported by the National Natural Science Foundation of China (81871937, 82001586, 91859204, 82072629, 82072811) and CAMS Innovation Fund for Medical Sciences (CIFMS, 2019-I2M-5-044).	Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Bulk E, 2009, CLIN CANCER RES, V15, P22, DOI 10.1158/1078-0432.CCR-08-0953; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Christiansen A, 2013, CANCER LETT, V331, P18, DOI 10.1016/j.canlet.2012.12.013; Dummer R, 1997, DERMATOLOGY, V194, P208, DOI 10.1159/000246103; Gravina GL, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0085-1; Jamieson C, 2014, SEMIN CANCER BIOL, V27, P20, DOI 10.1016/j.semcancer.2014.04.012; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Kelley JB, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-63; Kirschner RD, 2008, NUCLEIC ACIDS RES, V36, P2969, DOI 10.1093/nar/gkn132; Kumar M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0369-9; Li C, 2020, FASEB J, V34, P13333, DOI 10.1096/fj.202000555R; Li J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0861-9; Li XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-232; Masuda T, 2016, INT J ONCOL, V48, P975, DOI 10.3892/ijo.2016.3329; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mueller A, 2005, J BIOL CHEM, V280, P29186, DOI 10.1074/jbc.M505000200; Narayanan S, 2020, DRUG RESIST UPDATE, V48, DOI 10.1016/j.drup.2019.100663; Naz S, 2014, CARCINOGENESIS, V35, P14, DOI 10.1093/carcin/bgt287; Ohuchida K, 2007, J PATHOL, V213, P275, DOI 10.1002/path.2250; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Sato Y, 2013, J GASTROEN HEPATOL, V28, P1422, DOI 10.1111/jgh.12247; Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114; Strom AC, 2001, GENOME BIOL, V2; Takata M, 2010, FEBS LETT, V584, P4517, DOI 10.1016/j.febslet.2010.09.052; van Bon L, 2014, ANN RHEUM DIS, V73, P1585, DOI 10.1136/annrheumdis-2013-205013; van Dieck J, 2010, ONCOGENE, V29, P2024, DOI 10.1038/onc.2009.490; Wang CI, 2012, MOL CELL PROTEOMICS, V11, P1105, DOI 10.1074/mcp.M111.016592; Wang HJ, 2005, INT J CANCER, V116, P285, DOI 10.1002/ijc.21035; Xiang SS, 2019, ONCOGENE, V38, P1269, DOI 10.1038/s41388-018-0494-7	31	2	2	7	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					657	670		10.1038/s41388-021-02116-6	http://dx.doi.org/10.1038/s41388-021-02116-6		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34802034				2022-12-28	WOS:000720700200002
J	Li, Y; Liu, HT; Chen, X; Wang, YW; Tian, YR; Ma, RR; Song, L; Zou, YX; Gao, P				Li, Yan; Liu, Hai-Ting; Chen, Xu; Wang, Ya-Wen; Tian, Ya-Ru; Ma, Ran-ran; Song, Lin; Zou, Yong-Xin; Gao, Peng			Aberrant promoter hypermethylation inhibits RGMA expression and contributes to tumor progression in breast cancer	ONCOGENE			English	Article							REPULSIVE GUIDANCE MOLECULE; DNA METHYLATION; APOPTOSIS; SURVIVAL; PROLIFERATION; INACTIVATION; RECEPTORS; ADHESION; GROWTH; CELLS	Breast cancer (BC) is the most common cancer in women worldwide, and the exploration of aberrantly expressed genes might clarify tumorigenesis and help uncover new therapeutic strategies for BC. Although RGMA was recently recognized as a tumor suppressor gene, its detailed biological function and regulation in BC remain unclear. Herein, we found that RGMA was downregulated in BC tissues compared with non-tumorous breast tissues, particularly in metastatic BC samples, and that patients with low RGMA expression manifested a poorer prognosis. Furthermore, DNMT1 and DNMT3A were found to be recruited to the RGMA promoter and induced aberrant hypermethylation, resulting in downregulation of RGMA expression in BC. In contrast, RGMA overexpression suppressed BC cell proliferation and colony-formation capabilities and increased BC cell apoptosis. Furthermore, RGMA knockdown accelerated BC cell proliferation and suppressed cellular apoptosis in vitro and in vivo. Reversal of RGMA promoter methylation with 5-Aza-CdR restored RGMA expression and blocked tumor growth. Overall, DNMT1- and DNMT3A-mediated RGMA promoter hypermethylation led to downregulation of RGMA expression, and low RGMA expression contributed to BC growth via activation of the FAK/Src/PI3K/AKT-signaling pathway. Our data thus suggested that RGMA might be a promising therapeutic target in BC.	[Li, Yan; Liu, Hai-Ting; Chen, Xu; Wang, Ya-Wen; Tian, Ya-Ru; Ma, Ran-ran; Song, Lin; Gao, Peng] Shandong Univ, Dept Pathol, Qilu Hosp, Jinan 250012, Shandong, Peoples R China; [Li, Yan; Liu, Hai-Ting; Chen, Xu; Wang, Ya-Wen; Tian, Ya-Ru; Ma, Ran-ran; Song, Lin; Zou, Yong-Xin; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ,Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Li, Yan] Shandong Univ, Qilu Hosp Qingdao, Dept Gastroenterol, Qingdao 266035, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University	Gao, P (corresponding author), Shandong Univ, Dept Pathol, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.; Zou, YX; Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ,Dept Pathol, Jinan 250012, Shandong, Peoples R China.	zouyongxin@sdu.edu.cn; gaopeng@sdu.edu.cn			National Natural Science Foundation of China [81872362, 82072665]; Taishan Scholars Program of Shandong Province [ts201511096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province	We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this paper. This study was supported by the National Natural Science Foundation of China (Grant No. 81872362 and 82072665) and the Taishan Scholars Program of Shandong Province (Grant No. ts201511096).	Abdel-Hafiz HA, 2015, EPIGENOMICS-UK, V7, P847, DOI 10.2217/epi.15.10; Bao RK, 2017, ENVIRON SCI POLLUT R, V24, P20342, DOI 10.1007/s11356-017-9422-6; Borges S, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3460; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Endo M, 2009, J NEUROSCI, V29, P6649, DOI 10.1523/JNEUROSCI.0927-09.2009; Feng FB, 2018, BIOMED PHARMACOTHER, V102, P1209, DOI 10.1016/j.biopha.2018.03.142; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Jia XQ, 2019, J BUON, V24, P1985; Klutstein M, 2016, CANCER RES, V76, P3446, DOI 10.1158/0008-5472.CAN-15-3278; Korecka JA, 2017, J NEUROSCI, V37, P9361, DOI 10.1523/JNEUROSCI.0084-17.2017; Ku JL, 2011, METHODS MOL BIOL, V791, P23, DOI 10.1007/978-1-61779-316-5_3; Li J, 2012, INT J ONCOL, V40, P544, DOI 10.3892/ijo.2011.1251; Li VSW, 2009, GASTROENTEROLOGY, V137, P176, DOI 10.1053/j.gastro.2009.03.005; Li Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.559486; Li Y, 2020, CLIN BREAST CANCER, V20, pE113, DOI 10.1016/j.clbc.2019.08.010; Liu H, 2020, CELL DEATH DIFFER, V27, P966, DOI 10.1038/s41418-019-0389-3; Lu YJ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108608; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y; Niit Maximilian, 2015, BioMolecular Concepts, V6, P383, DOI 10.1515/bmc-2015-0022; O'Leary C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081711; Pathania R, 2016, CANCER RES, V76, P3224, DOI 10.1158/0008-5472.CAN-15-2249; Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Schoeps A, 2014, GENET EPIDEMIOL, V38, P84, DOI 10.1002/gepi.21771; Siebold C, 2017, TRENDS CELL BIOL, V27, P365, DOI 10.1016/j.tcb.2016.11.009; Specht E, 2015, HISTOPATHOLOGY, V67, P368, DOI 10.1111/his.12662; Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080; Xiao B, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4314-9; Zhang G, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00504; Zhang Y, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00138; Zhao ZW, 2012, ONCOL REP, V27, P1653, DOI 10.3892/or.2012.1693	33	5	5	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					361	371		10.1038/s41388-021-02083-y	http://dx.doi.org/10.1038/s41388-021-02083-y		NOV 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34754080				2022-12-28	WOS:000716255200001
J	Boice, AG; Lopez, KE; Pandita, RK; Parsons, MJ; Charendoff, CI; Charaka, V; Carisey, AF; Pandita, TK; Bouchier-Hayes, L				Boice, Ashley G.; Lopez, Karla E.; Pandita, Raj K.; Parsons, Melissa J.; Charendoff, Chloe, I; Charaka, Vijay; Carisey, Alexandre F.; Pandita, Tej K.; Bouchier-Hayes, Lisa			Caspase-2 regulates S-phase cell cycle events to protect from DNA damage accumulation independent of apoptosis	ONCOGENE			English	Article							GENOMIC INSTABILITY; REPLICATION FORKS; LICENSING FACTOR; ATM; CHECKPOINT; ACTIVATION; PHOSPHORYLATION; PIDDOSOME; KINASE; CHK2	In addition to its classical role in apoptosis, accumulating evidence suggests that caspase-2 has non-apoptotic functions, including regulation of cell division. Loss of caspase-2 is known to increase proliferation rates but how caspase-2 is regulating this process is currently unclear. We show that caspase-2 is activated in dividing cells in G1-phase of the cell cycle. In the absence of caspase-2, cells exhibit numerous S-phase defects including delayed exit from S-phase, defects in repair of chromosomal aberrations during S-phase, and increased DNA damage following S-phase arrest. In addition, caspase-2-deficient cells have a higher frequency of stalled replication forks, decreased DNA fiber length, and impeded progression of DNA replication tracts. This indicates that caspase-2 protects from replication stress and promotes replication fork protection to maintain genomic stability. These functions are independent of the pro-apoptotic function of caspase-2 because blocking caspase-2-induced cell death had no effect on cell division, DNA damage-induced cell cycle arrest, or DNA damage. Thus, our data supports a model where caspase-2 regulates cell cycle and DNA repair events to protect from the accumulation of DNA damage independently of its pro-apoptotic function.	[Boice, Ashley G.; Lopez, Karla E.; Parsons, Melissa J.; Charendoff, Chloe, I; Bouchier-Hayes, Lisa] Baylor Coll Med, Dept Pediat, Sect Hematol Oncol, Houston, TX 77030 USA; [Boice, Ashley G.; Lopez, Karla E.; Charendoff, Chloe, I; Carisey, Alexandre F.; Bouchier-Hayes, Lisa] Texas Childrens Hosp William T Shearer Ctr Human, Houston, TX 77030 USA; [Boice, Ashley G.; Lopez, Karla E.; Pandita, Raj K.; Pandita, Tej K.; Bouchier-Hayes, Lisa] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Pandita, Raj K.; Pandita, Tej K.] Texas A&M Inst Biosci & Technol, Houston, TX 77030 USA; [Charaka, Vijay; Pandita, Tej K.] Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX 77030 USA; [Carisey, Alexandre F.] Baylor Coll Med, Dept Pediat, Sect Allergy & Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine	Bouchier-Hayes, L (corresponding author), Baylor Coll Med, Dept Pediat, Sect Hematol Oncol, Houston, TX 77030 USA.; Bouchier-Hayes, L (corresponding author), Texas Childrens Hosp William T Shearer Ctr Human, Houston, TX 77030 USA.; Bouchier-Hayes, L (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	bouchier@bcm.edu	Carisey, Alexandre F/A-5026-2015	Carisey, Alexandre F/0000-0003-1326-2205; Lopez, Karla/0000-0001-7301-5260; Bouchier-Hayes, Lisa/0000-0003-3886-5977	NIH/NIGMS [R01GM121389, T32GM008231]; NIH/NCI [R21CA256606]; Cytometry and Cell Sorting Core at Baylor College of Medicine; NIH [P30 AI036211, P30 CA125123, S10 RR024574]; Texas Children's Hospital William T. Shearer Center for Human Immunobiology	NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cytometry and Cell Sorting Core at Baylor College of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Texas Children's Hospital William T. Shearer Center for Human Immunobiology	We would like to thank Jennifer Martinez (NIEHS) for careful reading of this paper. Funding for this project includes NIH/NIGMS R01GM121389 (LBH), NIH/NCI R21CA256606 (LBH) and NIH/NIGMS T32GM008231 (KEL). This project was supported by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (P30 AI036211, P30 CA125123, and S10 RR024574) and the expert assistance of J. M. Sederstrom. We would like to acknowledge the Texas Children's Hospital William T. Shearer Center for Human Immunobiology for their generous support for this research and the expert assistance of Rebecca Kairis.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Andersen JL, 2009, EMBO J, V28, P3216, DOI 10.1038/emboj.2009.253; Ando K, 2017, J CELL BIOL, V216, P1795, DOI 10.1083/jcb.201608095; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Baptiste-Okoh N, 2008, P NATL ACAD SCI USA, V105, P1937, DOI 10.1073/pnas.0711800105; Beck H, 2012, MOL CELL BIOL, V32, P4226, DOI 10.1128/MCB.00412-12; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Boice A, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118688; Bonzon C, 2006, MOL BIOL CELL, V17, P2150, DOI 10.1091/mbc.E05-12-1107; Bouchier-Hayes L, 2012, CELL DEATH DIFFER, V19, P51, DOI 10.1038/cdd.2011.157; Bouchier-Hayes L, 2010, J CELL MOL MED, V14, P1212, DOI 10.1111/j.1582-4934.2010.01037.x; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Ceccaldi R, 2016, NAT REV MOL CELL BIO, V17, P337, DOI 10.1038/nrm.2016.48; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Couch FB, 2013, GENE DEV, V27, P1610, DOI 10.1101/gad.214080.113; Dawar S, 2017, ONCOGENE, V36, P2704, DOI 10.1038/onc.2016.423; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Fava LL, 2017, GENE DEV, V31, P34, DOI 10.1101/gad.289728.116; Gao ZH, 2005, J BIOL CHEM, V280, P38271, DOI 10.1074/jbc.M506488200; Gatei M, 2000, CANCER RES, V60, P3299; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goldwasser F, 1996, CANCER RES, V56, P4430; Gundry MC, 2016, CELL REP, V17, P1453, DOI 10.1016/j.celrep.2016.09.092; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Henry CM, 2017, MOL CELL, V65, P715, DOI 10.1016/j.molcel.2017.01.022; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; HOWARD A, 1986, INT J RADIAT BIOL, V49, P207, DOI 10.1080/09553008514552501; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Ismail IH, 2005, J BIOL CHEM, V280, P4649, DOI 10.1074/jbc.M411588200; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Krull A, 2019, PROC CVPR IEEE, P2124, DOI 10.1109/CVPR.2019.00223; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; Lapytsko A, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0816-5; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lim Y, 2021, CELL DEATH DIFFER, V28, P349, DOI 10.1038/s41418-020-00604-y; Lin YF, 2018, NUCLEIC ACIDS RES, V46, P1847, DOI 10.1093/nar/gkx1298; Liu SZ, 2011, MOL CELL, V43, P192, DOI 10.1016/j.molcel.2011.06.019; Lopez-Garcia C, 2017, CANCER CELL, V31, P79, DOI 10.1016/j.ccell.2016.11.001; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Manzl C, 2009, J CELL BIOL, V185, P291, DOI 10.1083/jcb.200811105; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mattoo AR, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00535-16; Moreno-Mateos MA, 2015, NAT METHODS, V12, P982, DOI [10.1038/NMETH.3543, 10.1038/nmeth.3543]; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nishitani H, 2004, J BIOL CHEM, V279, P30807, DOI 10.1074/jbc.M312644200; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Oliver TG, 2011, MOL CELL, V43, P57, DOI 10.1016/j.molcel.2011.06.012; Pan Y, 2009, CANCER BIOL THER, V8, P1559, DOI 10.4161/cbt.8.16.8955; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Ren KQ, 2012, J BIOL CHEM, V287, P14792, DOI 10.1074/jbc.M112.347625; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robeson AC, 2018, EMBO J, V37, DOI 10.15252/embj.201797072; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Saldivar JC, 2017, NAT REV MOL CELL BIO, V18, P622, DOI 10.1038/nrm.2017.67; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sharma GG, 2003, MOL CELL BIOL, V23, P8363, DOI 10.1128/MCB.23.22.8363-8376.2003; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Singh DK, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00484-17; Singh M, 2013, MOL CELL BIOL, V33, P1210, DOI 10.1128/MCB.01676-12; Stringer C, 2021, NAT METHODS, V18, P100, DOI 10.1038/s41592-020-01018-x; Terry MR, 2015, CELL DEATH DIFFER, V22, P719, DOI 10.1038/cdd.2014.159; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; von Chamier L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22518-0; Wang HY, 2004, CANCER RES, V64, P7139, DOI 10.1158/0008-5472.CAN-04-1289; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhong Y, 2013, J CELL BIOL, V201, P373, DOI 10.1083/jcb.201208060; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	80	1	1	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					204	219		10.1038/s41388-021-02085-w	http://dx.doi.org/10.1038/s41388-021-02085-w		OCT 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34718349	Green Accepted, Green Submitted			2022-12-28	WOS:000712941800001
J	Huang, DQ; Savage, SR; Calinawan, AP; Lin, CW; Zhang, B; Wang, P; Starr, TK; Birrer, MJ; Paulovich, AG				Huang, Dongqing; Savage, Sara R.; Calinawan, Anna P.; Lin, Chenwei; Zhang, Bing; Wang, Pei; Starr, Timothy K.; Birrer, Michael J.; Paulovich, Amanda G.			A highly annotated database of genes associated with platinum resistance in cancer	ONCOGENE			English	Review							ACQUIRED CISPLATIN RESISTANCE; NUCLEOTIDE EXCISION-REPAIR; C-MYC; DNA-REPAIR; CELL-DEATH; MODULATES CHEMOSENSITIVITY; MEDIATED CHEMORESISTANCE; OXIDATIVE-METABOLISM; DRUG-RESISTANCE; CARCINOMA-CELLS	Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, is prescribed to 10-20% of all cancer patients. Unfortunately, platinum resistance develops in a significant number of patients and is a determinant of clinical outcome. Extensive research has been conducted to understand and overcome platinum resistance, and mechanisms of resistance can be categorized into several broad biological processes, including (1) regulation of drug entry, exit, accumulation, sequestration, and detoxification, (2) enhanced repair and tolerance of platinum-induced DNA damage, (3) alterations in cell survival pathways, (4) alterations in pleiotropic processes and pathways, and (5) changes in the tumor microenvironment. As a resource to the cancer research community, we provide a comprehensive overview accompanied by a manually curated database of the >900 genes/proteins that have been associated with platinum resistance over the last 30 years of literature. The database is annotated with possible pathways through which the curated genes are related to platinum resistance, types of evidence, and hyperlinks to literature sources. The searchable, downloadable database is available online at .	[Huang, Dongqing; Lin, Chenwei; Paulovich, Amanda G.] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA; [Savage, Sara R.; Zhang, Bing] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Calinawan, Anna P.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Starr, Timothy K.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Starr, Timothy K.] Univ Minnesota, Dept Obstet Gynecol & Womens Hlth, Minneapolis, MN USA; [Birrer, Michael J.] Univ Arkansas Med Sci, Little Rock, AR USA	Fred Hutchinson Cancer Center; Baylor College of Medicine; Icahn School of Medicine at Mount Sinai; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Arkansas System; University of Arkansas Medical Sciences	Paulovich, AG (corresponding author), Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA.	apaulovi@fredhutch.org	Lin, Chen/GRR-2799-2022	Starr, Timothy/0000-0002-6308-3451; Paulovich, Amanda/0000-0001-6532-6499	U.S. National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC); DOD [W81XWH-16-2-0038, U24CA210993]; University of Minnesota Grand Challenges grant; Randy Shaver Cancer Research and Community Fund; NIH NCI [R21CA216652]; Scientific Computing Infrastructure at Fred Hutch - ORIP grant [S10OD028685];  [U01CA214114]	U.S. National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); University of Minnesota Grand Challenges grant; Randy Shaver Cancer Research and Community Fund; NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Scientific Computing Infrastructure at Fred Hutch - ORIP grant; 	This work was done in collaboration with the U.S. National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) and supported by grants U01CA214114 (AGP, MJB), DOD W81XWH-16-2-0038 (MJB), U24CA210993 (PW), University of Minnesota Grand Challenges grant, Randy Shaver Cancer Research and Community Fund Grant and NIH NCI R21CA216652 (TKS), and Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685.	Adam-Zahir S, 2014, CHEMOTHERAPY, V60, P310, DOI 10.1159/000430086; Ai ZH, 2016, CANCER LETT, V373, P36, DOI 10.1016/j.canlet.2016.01.009; Alkema NG, 2014, GYNECOL ONCOL, V133, P591, DOI 10.1016/j.ygyno.2014.03.557; Altan B, 2016, ANTICANCER RES, V36, P5237, DOI 10.21873/anticanres.11094; Annunziata CM, 2010, CANCER-AM CANCER SOC, V116, P3276, DOI 10.1002/cncr.25190; Ashrafizadeh M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114002; Baiceanu E, 2015, FUTURE MED CHEM, V7, P2041, DOI 10.4155/fmc.15.131; Balamurugan K, 2016, INT J CANCER, V138, P1058, DOI 10.1002/ijc.29519; Bell EH, 2016, CLIN CANCER RES, V22, P2396, DOI 10.1158/1078-0432.CCR-15-1468; Beretta GL, 2010, BIOCHEM PHARMACOL, V79, P1108, DOI 10.1016/j.bcp.2009.12.002; Biyanee Abhiruchi, 2015, Oncoscience, V2, P731; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Bousova I, 2012, DRUG METAB REV, V44, P267, DOI 10.3109/03602532.2012.713969; Brozovic A, 2004, INT J CANCER, V112, P974, DOI 10.1002/ijc.20522; Burkitt K, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-24; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chakraborty PK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14634; Chaney SG, 2005, CRIT REV ONCOL HEMAT, V53, P3, DOI 10.1016/j.critrevonc.2004.08.008; Chaudhuri AR, 2016, NATURE, V535, P382, DOI 10.1038/nature18325; Chauhan SS, 2003, BRIT J CANCER, V88, P1327, DOI 10.1038/sj.bjc.6600861; Chen R, 2020, INT J ONCOL, V56, P932, DOI 10.3892/ijo.2020.4987; Ciarimboli G, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/473829; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Cooke SL, 2010, ONCOGENE, V29, P4905, DOI 10.1038/onc.2010.245; Cruz JJ, 2007, ANN ONCOL, V18, P421, DOI 10.1093/annonc/mdl175; Cruz-Bermudez A, 2019, FREE RADICAL BIO MED, V135, P167, DOI 10.1016/j.freeradbiomed.2019.03.009; Dai Y, 2017, ONCOTARGET, V8, P1354, DOI 10.18632/oncotarget.13817; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dar S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09206-0; Davidson Jean, 2018, Oncotarget, V9, P9608, DOI 10.18632/oncotarget.20033; Dempke W, 2000, ANTI-CANCER DRUG, V11, P225, DOI 10.1097/00001813-200004000-00001; Deramaudt BMJM, 1999, J CELL BIOCHEM, V72, P311, DOI 10.1002/(SICI)1097-4644(19990301)72:3<311::AID-JCB1>3.3.CO;2-7; Dev H, 2018, NAT CELL BIOL, V20, P954, DOI 10.1038/s41556-018-0140-1; Dhillon KK, 2011, CANCER SCI, V102, P663, DOI 10.1111/j.1349-7006.2010.01840.x; Diaz Osterman CJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47327; Dubbury SJ, 2018, NATURE, V564, P141, DOI 10.1038/s41586-018-0758-y; Dungrawala H, 2017, MOL CELL, V67, P374, DOI 10.1016/j.molcel.2017.06.023; FAN SJ, 1995, CANCER RES, V55, P1649; Fan TJ, 2019, CANCERS, V11, DOI 10.3390/cancers11030317; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gaustad JV, 2020, CANCERS, V12, DOI 10.3390/cancers12071979; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732; Godwin P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00120; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Gregorc V, 2011, CLIN CANCER RES, V17, P1964, DOI 10.1158/1078-0432.CCR-10-1376; Guillemette S, 2015, GENE DEV, V29, P489, DOI 10.1101/gad.256214.114; Han JY, 2003, MED ONCOL, V20, P355, DOI 10.1385/MO:20:4:355; Hayakawa J, 2000, CANCER RES, V60, P5988; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hill SJ, 2018, CANCER DISCOV, V8, P1404, DOI 10.1158/2159-8290.CD-18-0474; Hong Soon-Sun, 2004, Cancer Res Treat, V36, P343, DOI 10.4143/crt.2004.36.6.343; Hsieh AL, 2015, SEMIN CELL DEV BIOL, V43, P11, DOI 10.1016/j.semcdb.2015.08.003; Hustedt N, 2019, GENE DEV, V33, P1397, DOI 10.1101/gad.329508.119; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Izquierdo MA, 1998, CYTOTECHNOLOGY, V27, P137, DOI 10.1023/A:1008004502861; Jego G, 2013, CANCER LETT, V332, P275, DOI 10.1016/j.canlet.2010.10.014; Jones VS, 2016, BBA-REV CANCER, V1865, P255, DOI 10.1016/j.bbcan.2016.03.005; Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012; Kang BW, 2012, CANCER CHEMOTH PHARM, V70, P735, DOI 10.1007/s00280-012-1964-1; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Kirschner K, 2010, ANTICANCER RES, V30, P3223; Kleih M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2081-4; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Lagunas Vilma Maldonado, 2008, Metal-Based Drugs, P576104, DOI 10.1155/2008/576104; Lawrence Toby, 2009, Cold Spring Harb Perspect Biol, V1, pa001651, DOI 10.1101/cshperspect.a001651; Lee S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031102; Legrier ME, 2016, BRIT J CANCER, V114, P177, DOI 10.1038/bjc.2015.398; Li ZQ, 2019, CLIN CANCER RES, V25, P5947, DOI 10.1158/1078-0432.CCR-18-4145; Liang Xiaobing, 2011, Chemother Res Pract, V2011, P715469, DOI 10.1155/2011/715469; Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Liu H, 2003, KIDNEY INT, V63, P1687, DOI 10.1046/j.1523-1755.2003.00908.x; Liu Q, 2018, CLIN CANCER RES, V24, P6001, DOI 10.1158/1078-0432.CCR-18-1346; Liu RY, 2011, ONCOGENE, V30, P4814, DOI 10.1038/onc.2011.189; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Liu T, 2016, ONCOTARGET, V7, P66851, DOI 10.18632/oncotarget.11694; Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008; Ma LS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00005; Madamanchi NR, 2001, ARTERIOSCL THROM VAS, V21, P321, DOI 10.1161/01.ATV.21.3.321; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Marchini S, 2013, EUR J CANCER, V49, P520, DOI 10.1016/j.ejca.2012.06.026; Marquard FE, 2020, BIOCHEM PHARMACOL, V172, DOI 10.1016/j.bcp.2019.113729; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matassa DS, 2016, CELL DEATH DIFFER, V23, P1542, DOI 10.1038/cdd.2016.39; Meng J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2327-1; Miyamoto M, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e33; Musa F, 2016, MOL CANCER THER, V15, P1557, DOI 10.1158/1535-7163.MCT-15-0926; Nallanthighal S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2442-z; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Obrist F, 2018, EMBO J, V37, DOI 10.15252/embj.201798597; Pan JS, 2009, WORLD J GASTROENTERO, V15, P1702, DOI 10.3748/wjg.15.1702; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Penzvalto Z, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-837; Prathapam T, 2010, J BIOL CHEM, V285, P32529, DOI 10.1074/jbc.M110.151902; Pujade-Lauraine E, 2019, J CLIN ONCOL, V37, P2437, DOI 10.1200/JCO.19.00194; Quereda V, 2019, CANCER CELL, V36, P545, DOI 10.1016/j.ccell.2019.09.004; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Rocha CRR, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e478s; Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701; Reyes-Gonzalez JM, 2015, MOL CANCER THER, V14, P2260, DOI 10.1158/1535-7163.MCT-14-0801; Rezvani HR, 2010, NUCLEIC ACIDS RES, V38, P797, DOI 10.1093/nar/gkp1072; Rohwer N, 2013, ONCOGENE, V32, P3569, DOI 10.1038/onc.2012.510; ROSENBERG B, 1965, NATURE, V205, P698, DOI 10.1038/205698a0; Rottenberg S, 2021, NAT REV CANCER, V21, P37, DOI 10.1038/s41568-020-00308-y; Roy S, 2020, EXP BIOL MED, V245, P1073, DOI 10.1177/1535370220934038; Sakai W, 2009, CANCER RES, V69, P6381, DOI 10.1158/0008-5472.CAN-09-1178; Santamaria G, 2006, CARCINOGENESIS, V27, P925, DOI 10.1093/carcin/bgi315; Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230; Sarbia M, 2007, BRIT J CANCER, V97, P1404, DOI 10.1038/sj.bjc.6604037; Sawant A, 2017, DNA REPAIR, V51, P46, DOI 10.1016/j.dnarep.2017.01.002; Schmidtova S, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0730-x; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Stronach EA, 2011, CANCER RES, V71, P4412, DOI 10.1158/0008-5472.CAN-10-4111; Su YW, 2020, CANCER LETT, V483, P127, DOI 10.1016/j.canlet.2020.02.015; Sun J, 2019, ONCOGENE, V38, P564, DOI 10.1038/s41388-018-0459-x; Sung CY, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109135; Tajeddine N, 2008, ONCOGENE, V27, P4221, DOI 10.1038/onc.2008.63; Tramonti A, 2018, BIOCHEMISTRY-US, V57, P6984, DOI 10.1021/acs.biochem.8b01074; Trop-Steinberg S, 2017, AM J MED SCI, V353, P474, DOI 10.1016/j.amjms.2017.01.019; Valencia T, 2014, CANCER CELL, V26, P121, DOI 10.1016/j.ccr.2014.05.004; Varghese E, 2020, CANCERS, V12, DOI 10.3390/cancers12082252; Varoni EM, 2016, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00008; Vomund S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122772; Wang HF, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-1536-x; Wang J, 2018, ARTIF CELL NANOMED B, V46, P1505, DOI 10.1080/21691401.2017.1374285; Wang WM, 2016, CELL, V165, P1092, DOI 10.1016/j.cell.2016.04.009; Wangpaichitr M, 2012, MOL CANCER THER, V11, P604, DOI 10.1158/1535-7163.MCT-11-0599; Wu CJ, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-25; Wu W J, 2016, Zhonghua Fu Chan Ke Za Zhi, V51, P515, DOI 10.3760/cma.j.issn.0529-567X.2016.07.007; Wysham WZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030042; Yamada M, 1996, CLIN CANCER RES, V2, P427; Yao CJ, 2013, PHARMAZIE, V68, P5, DOI 10.1691/ph.2013.2674; YOKOMIZO A, 1995, CANCER RES, V55, P4293; Yoshihara M, 2020, INT J CANCER, V146, P2268, DOI 10.1002/ijc.32854; Yuan YG, 2015, CELL PHYSIOL BIOCHEM, V37, P1240, DOI 10.1159/000430247; Yung MMH, 2016, ACTA BIOCH BIOPH SIN, V48, P301, DOI 10.1093/abbs/gmv128; Zeller C, 2012, ONCOGENE, V31, P4567, DOI 10.1038/onc.2011.611; Zhang D, 2015, CANCER BIOL THER, V16, P1005, DOI 10.1080/15384047.2015.1046022; Zhang HF, 2017, MOL CARCINOGEN, V56, P1150, DOI 10.1002/mc.22581; Zhang HD, 2020, CRIT REV BIOCHEM MOL, V55, P219, DOI 10.1080/10409238.2020.1768205; Zhang X, 2010, CANCER SCI, V101, P2163, DOI 10.1111/j.1349-7006.2010.01664.x	149	10	10	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6395	6405		10.1038/s41388-021-02055-2	http://dx.doi.org/10.1038/s41388-021-02055-2		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34645978	Green Published, hybrid			2022-12-28	WOS:000706949900001
J	Chen, Z; Yu, DL; Owonikoko, TK; Ramalingam, SS; Sun, SY				Chen, Zhen; Yu, Danlei; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Sun, Shi-Yong			Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib	ONCOGENE			English	Article							FATTY-ACID SYNTHESIS; THERAPEUTIC-EFFICACY; ACQUIRED-RESISTANCE; LIPID-METABOLISM; INHIBITION; AZD9291; GROWTH; BIM	Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. Fully understanding the biology underlying the response of EGFR mutant non-small cell lung cancer (NSCLC) to osimertinib is the foundation for development of mechanism-driven strategies to overcome acquired resistance to osimertinib or other third-generation EGFR inhibitors. This study focused on tackling this important issue by elucidating the critical role of sterol regulatory element-binding protein 1 (SREBP1) degradation in conferring the response of EGFR mutant NSCLC cells to osimertinib and by validating the strategy via directly targeting SREBP1 for overcoming osimertinib acquired resistance. Osimertinib facilitated degradation of the mature form of SREBP1 (mSREBP1) in a GSK3/FBXW7-dependent manner and reduced protein levels of its regulated genes in EGFR-mutant NSCLC cells/tumors accompanied with suppression of lipogenesis. Once resistant, EGFR-mutant NSCLC cell lines possessed elevated levels of mSREBP1, which were resistant to osimertinib modulation. Both genetic and pharmacological inhibition of SREBP1 sensitized osimertinib-resistant cells and tumors to osimertinib primarily through enhancing Bim-dependent induction of apoptosis, whereas enforced expression of ectopic SREBP1 in sensitive EGFR-mutant NSCLC cells compromised osimertinib's cell-killing effects. Collectively, we have demonstrated a novel connection between osimertinib and SREBP1 degradation and its impact on the response of EGFR mutant NSCLC cells to osimertinib and suggested an effective strategy for overcoming acquired resistance to osimertinib, and possibly other EGFR inhibitors, via targeting SREBP1.	[Chen, Zhen; Yu, Danlei; Ramalingam, Suresh S.; Sun, Shi-Yong] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Chen, Zhen; Yu, Danlei; Ramalingam, Suresh S.; Sun, Shi-Yong] Winship Canc Inst, Atlanta, GA 30322 USA; [Owonikoko, Taofeek K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; [Owonikoko, Taofeek K.] Hillman Canc Ctr, Pittsburgh, PA USA	Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sun, SY (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.; Sun, SY (corresponding author), Winship Canc Inst, Atlanta, GA 30322 USA.	ssun@emory.edu	; Owonikoko, Taofeek/C-3012-2011	Sun, Shi-Yong/0000-0002-0117-8826; Owonikoko, Taofeek/0000-0002-7724-7728	NIH/NCI [R01 CA223220, R01 CA245386, UG1 CA233259, P50 CA217691]; Emory University Winship Cancer Institute lung cancer pilot funds	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Emory University Winship Cancer Institute lung cancer pilot funds	We are thankful to Dr. Dongsheng Wang and Mr. Guojing Zhang in our department for helping us with animal experiments, to Dr. Teng Wang and Dr. Dong Hua (Affiliated Hospital of Jiangnan University) for providing us with clinical samples, to Dr. Peng Zhang (Longgang E.N.T. Hospital & Shenzhen Key Laboratory of E.N.T.) for staining the patients' samples, and to Drs. Deliang Guo and Wenyi Wei for providing some shRNAs. We are also grateful to Dr. Anthea Hammond in our department for editing the manuscript. This work was supported by the NIH/NCI R01 CA223220 (to S-YS), R01 CA245386 (to S-YS), UG1 CA233259 (to SSR) and lung cancer SPORE P50 CA217691 DRP award (to S-YS) and Emory University Winship Cancer Institute lung cancer pilot funds (to S-YS). DY is a visiting medical student participating in the Xiangya-Emory Visiting Medical Student Program. SSR, TKO, and S-YS are Georgia Research Alliance Distinguished Cancer Scientists.	Ali A, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708313; Cheng X, 2018, CURR TOP MED CHEM, V18, P484, DOI 10.2174/1568026618666180523104541; Geng F, 2016, CLIN CANCER RES, V22, P5337, DOI 10.1158/1078-0432.CCR-15-2973; Guo DL, 2014, CURR PHARM DESIGN, V20, P2619, DOI 10.2174/13816128113199990486; Guo DL, 2011, CANCER DISCOV, V1, P442, DOI 10.1158/2159-8290.CD-11-0102; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Li JJ, 2016, ONCOTARGET, V7, P52392, DOI 10.18632/oncotarget.10721; Li S, 2016, ONCOGENE, V35, P642, DOI 10.1038/onc.2015.123; Li YT, 2020, CANCER-AM CANCER SOC, V126, P1339, DOI 10.1002/cncr.32655; Malvezzi M, 2017, ANN ONCOL, V28, P1117, DOI 10.1093/annonc/mdx033; Salvador MM, 2017, CRIT REV ONCOL HEMAT, V112, P31, DOI 10.1016/j.critrevonc.2017.02.001; Oh WJ, 2011, CELL CYCLE, V10, P2305, DOI 10.4161/cc.10.14.16586; Polonio-Alcala E, 2020, CANCERS, V12, DOI 10.3390/cancers12051283; Recondo G, 2018, NAT REV CLIN ONCOL, V15, P694, DOI 10.1038/s41571-018-0081-4; Rohrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89; Shi PY, 2017, CLIN CANCER RES, V23, P6567, DOI 10.1158/1078-0432.CCR-17-1574; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Sun SY, 1997, CANCER RES, V57, P4931; Takada M, 2017, CANCER RES, V77, P4881, DOI 10.1158/0008-5472.CAN-17-1240; Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052; Yao WL, 2015, CANCER LETT, V364, P70, DOI 10.1016/j.canlet.2015.04.028; Yu DL, 2020, AM J CANCER RES, V10, P3316; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019; Zang HJ, 2020, MOL ONCOL, V14, P882, DOI 10.1002/1878-0261.12645; Zhao W, 2021, CANCER LETT, V519, P141, DOI 10.1016/j.canlet.2021.07.007; Zhou J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1057-7	29	11	11	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6653	6665		10.1038/s41388-021-02057-0	http://dx.doi.org/10.1038/s41388-021-02057-0		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34635799	Green Accepted			2022-12-28	WOS:000706082100001
J	Cheradame, L; Guerrera, IC; Gaston, J; Schmitt, A; Jung, V; Goudin, N; Pouillard, M; Radosevic-Robin, N; Modesti, M; Judde, JG; Cairo, S; Goffin, V				Cheradame, Laura; Guerrera, Ida Chiara; Gaston, Julie; Schmitt, Alain; Jung, Vincent; Goudin, Nicolas; Pouillard, Marion; Radosevic-Robin, Nina; Modesti, Mauro; Judde, Jean-Gabriel; Cairo, Stefano; Goffin, Vincent			STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway	ONCOGENE			English	Article							DOUBLE-STRAND BREAK; I INTERFERON; HOMOLOGOUS RECOMBINATION; CHROMOSOMAL INSTABILITY; NUCLEAR-DNA; DAMAGE; ACTIVATION; REPAIR; CGAS; METASTASIS	STING (Stimulator of Interferon Genes) is an endoplasmic reticulum-anchored adaptor of the innate immunity best known to trigger pro-inflammatory cytokine expression in response to pathogen infection. In cancer, this canonical pathway can be activated by intrinsic or drug-induced genomic instability, potentiating antitumor immune responses. Here we report that STING downregulation decreases cell survival and increases sensitivity to genotoxic treatment in a panel of breast cancer cell lines in a cell-autonomous manner. STING silencing impaired DNA Damage Response (53BP1) foci formation and increased DNA break accumulation. These newly identified properties were found to be independent of STING partner cGAS and of its canonical pro-inflammatory pathway. STING was shown to partially localize at the inner nuclear membrane in a variety of breast cancer cell models and clinical tumor samples. Interactomics analysis of nuclear STING identified several proteins of the DNA Damage Response, including the three proteins of the DNA-PK complex, further supporting a role of STING in the regulation of genomic stability. In breast and ovarian cancer patients that received adjuvant chemotherapy, high STING expression is associated with increased risk of relapse. In summary, this study highlights an alternative, non-canonical tumor-promoting role of STING that opposes its well-documented function in tumor immunosurveillance.	[Cheradame, Laura; Gaston, Julie; Pouillard, Marion; Goffin, Vincent] Univ Paris, CNRS, Inst Necker Enfants Malades INEM, INSERM,U1151,UMR8253, F-75015 Paris, France; [Cheradame, Laura; Gaston, Julie; Judde, Jean-Gabriel; Cairo, Stefano] XenTech, F-91000 Evry, France; [Guerrera, Ida Chiara; Jung, Vincent] Univ Paris Struct Federat Rech Necker, CNRS, Prote Platform Necker, INSERM,US24,UMS3633, F-75015 Paris, France; [Schmitt, Alain] Univ Paris, CNRS, Inst Cochin, INSERM, F-75014 Paris, France; [Goudin, Nicolas] CNRS, Necker Bioimage Anal, INSERM, US24,UMS 3633, F-75015 Paris, France; [Radosevic-Robin, Nina] Univ Clermont Auvergne, INSERM, Ctr Jean Perrin, Dept Pathol,U1240, F-63011 Clermont Ferrand, France; [Modesti, Mauro] Aix Marseille Univ, CNRS, Canc Res Ctr Marseille, INSERM,Inst Paoli Calmettes,U1068,UMR7258, F-13009 Marseille, France; [Gaston, Julie] Yubsis, 4 Rue Pierre Fontaine, F-91000 Evry, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Goffin, V (corresponding author), Univ Paris, CNRS, Inst Necker Enfants Malades INEM, INSERM,U1151,UMR8253, F-75015 Paris, France.	vincent.goffin@inserm.fr	GUERRERA, Ida Chiara/GOJ-9151-2022; GOFFIN, Vincent/G-3322-2013; Modesti, Mauro/D-6258-2017	GUERRERA, Ida Chiara/0000-0002-4832-6793; GOFFIN, Vincent/0000-0002-8021-3086; Modesti, Mauro/0000-0002-4964-331X; gaston, julie/0000-0002-2660-1651; Jung, Vincent/0000-0003-0530-1737; Cheradame, Laura/0000-0002-8369-9923	XenTech; Inserm; University Paris Descartes; ECLER; CIFRE fellowship from the Association Nationale de la Recherche et de la Technologie (ANRT); Ligue Nationale contre le Cancer	XenTech; Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University Paris Descartes; ECLER; CIFRE fellowship from the Association Nationale de la Recherche et de la Technologie (ANRT)(French National Research Agency (ANR)); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This study was funded by XenTech, annual funding from Inserm and the University Paris Descartes, and ECLER non-profit association. JG and LC were recipient of a CIFRE fellowship from the Association Nationale de la Recherche et de la Technologie (ANRT). MM is supported by the Ligue Nationale contre le Cancer. We are grateful to Patrice Codogno, Etienne Morel, Ganna Panasyuk, Thierry Dubois and Frederic Rieux-Laucat for helpful discussions, to Dr Orgunc and Pr S. Fillatreau for providing biological materials, and to Katheryn Meek for critical reading of the manuscript.	Abe T, 2014, J VIROL, V88, P5328, DOI 10.1128/JVI.00037-14; Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306; Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6166; Baghirova S, 2015, METHODSX, V2, P440, DOI 10.1016/j.mex.2015.11.001; Baird JR, 2016, CANCER RES, V76, P50, DOI 10.1158/0008-5472.CAN-14-3619; Bakhoum SF, 2018, CELL, V174, P1347, DOI 10.1016/j.cell.2018.08.027; Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; Barber GN, 2014, TRENDS IMMUNOL, V35, P88, DOI 10.1016/j.it.2013.10.010; Basit A, 2020, EXP MOL MED, V52, P643, DOI 10.1038/s12276-020-0416-y; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Britton S, 2013, J CELL BIOL, V202, P579, DOI 10.1083/jcb.201303073; Brown JS, 2018, BRIT J CANCER, V118, P312, DOI 10.1038/bjc.2017.376; Bu Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165681; Burleigh K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba4219; Chen H, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8941; Chen HH, 2014, J IMMUNOL, V192, P1162, DOI 10.4049/jimmunol.1300798; Chen HH, 2011, CELL, V147, P436, DOI 10.1016/j.cell.2011.09.022; Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268; Chen YF, 2017, J EXP MED, V214, P991, DOI 10.1084/jem.20161387; Chung DKC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8742; Clarke TL, 2017, MOL CELL, V65, P900, DOI 10.1016/j.molcel.2017.01.019; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Ding L, 2015, BBA-MOL BASIS DIS, V1852, P2494, DOI 10.1016/j.bbadis.2015.08.011; Dobrzynska A, 2016, NUCLEUS-PHILA, V7, P233, DOI 10.1080/19491034.2016.1183848; Dunphy G, 2018, MOL CELL, V71, P745, DOI 10.1016/j.molcel.2018.07.034; Erdal E, 2017, GENE DEV, V31, P353, DOI 10.1101/gad.289769.116; Ferguson BJ, 2012, ELIFE, V1, DOI 10.7554/eLife.00047; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gaston Julie, 2019, Oncotarget, V10, P4249, DOI 10.18632/oncotarget.27042; Gaston J, 2016, ONCOTARGET, V7, P77205, DOI 10.18632/oncotarget.12858; Gonugunta VK, 2017, CELL REP, V21, P3234, DOI 10.1016/j.celrep.2017.11.061; Goodwin JF, 2014, CANCER DISCOV, V4, P1126, DOI 10.1158/2159-8290.CD-14-0358; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Harding SM, 2017, NATURE, V548, P466, DOI 10.1038/nature23470; Hartlova A, 2015, IMMUNITY, V42, P332, DOI 10.1016/j.immuni.2015.01.012; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Jiang H, 2019, EMBO J, V38, DOI 10.15252/embj.2019102718; Katta SS, 2014, TRENDS CELL BIOL, V24, P221, DOI 10.1016/j.tcb.2013.10.006; Kondo T, 2013, P NATL ACAD SCI USA, V110, P2969, DOI 10.1073/pnas.1222694110; Konno H, 2018, ONCOGENE, V37, P2037, DOI 10.1038/s41388-017-0120-0; Lan YY, 2014, CELL REP, V9, P180, DOI 10.1016/j.celrep.2014.08.074; Lans H, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-4; Legrier ME, 2016, BRIT J CANCER, V114, P177, DOI 10.1038/bjc.2015.398; Lemaitre C, 2014, GENE DEV, V28, P2450, DOI 10.1101/gad.248369.114; Li T, 2018, J EXP MED, V215, P1287, DOI 10.1084/jem.20180139; Linsley PS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109760; Litvin O, 2015, MOL CELL, V57, P784, DOI 10.1016/j.molcel.2014.12.030; Liu HP, 2018, NATURE, V563, P131, DOI 10.1038/s41586-018-0629-6; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Mackenzie KJ, 2017, NATURE, V548, P461, DOI 10.1038/nature23449; Malik P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111851; Malik P, 2010, CELL MOL LIFE SCI, V67, P1353, DOI 10.1007/s00018-010-0257-2; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Marnef A, 2017, CURR OPIN CELL BIOL, V46, P1, DOI 10.1016/j.ceb.2016.12.003; Mazur L, 2012, ANTICANCER RES, V32, P2783; Mohiuddin IS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00635; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Neal JA, 2011, MUTAT RES-FUND MOL M, V711, P73, DOI 10.1016/j.mrfmmm.2011.02.010; Ochi T, 2015, SCIENCE, V347, P185, DOI 10.1126/science.1261971; Oliveira DV, 2014, J CELL SCI, V127, P763, DOI 10.1242/jcs.135855; Oza P, 2009, GENE DEV, V23, P912, DOI 10.1101/gad.1782209; Parkes EE, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw199; Potts PR, 2006, EMBO J, V25, P3377, DOI 10.1038/sj.emboj.7601218; Ranoa DRE, 2019, CANCER RES, V79, P1465, DOI 10.1158/0008-5472.CAN-18-1972; Ryu T, 2015, NAT CELL BIOL, V17, P1401, DOI 10.1038/ncb3258; Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106; Sawasdichai Anyaporn, 2010, J Vis Exp, DOI 10.3791/1958; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Schmidt U, 2018, LECT NOTES COMPUT SC, V11071, P265, DOI 10.1007/978-3-030-00934-2_30; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shang GJ, 2019, NATURE, V567, P389, DOI 10.1038/s41586-019-0998-5; Shin YJ, 2013, CANCER BIOL THER, V14, P213, DOI 10.4161/cbt.23292; Smeenk G, 2013, J CELL SCI, V126, P889, DOI 10.1242/jcs.109413; Song SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep39858; Sui HY, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah5054; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618; Wang H, 2017, P NATL ACAD SCI USA, V114, P1637, DOI 10.1073/pnas.1621363114; Wu Z, 2019, NAT METAB, V1, P1209, DOI 10.1038/s42255-019-0150-8; Xia TL, 2016, CANCER RES, V76, P6747, DOI 10.1158/0008-5472.CAN-16-1404; Xia TL, 2016, CELL REP, V14, P282, DOI 10.1016/j.celrep.2015.12.029	85	9	9	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6627	6640		10.1038/s41388-021-02037-4	http://dx.doi.org/10.1038/s41388-021-02037-4		OCT 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34625708				2022-12-28	WOS:000705760400001
J	Hong, SB; Xie, YB; Cheng, Z; Li, J; He, WM; Guo, ZM; Zhang, Q; Peng, S; He, MH; Yu, S; Xu, LX; Liu, RY; Xu, TY; Zhang, YJ; Li, YB; Wang, JG; Lv, WM; Yu, J; Xiao, HP				Hong, Shubin; Xie, Yubin; Cheng, Zhen; Li, Jie; He, Weiman; Guo, Zhuming; Zhang, Quan; Peng, Sui; He, Minghui; Yu, Shuang; Xu, Lixia; Liu, Rengyun; Xu, Tianyi; Zhang, Yunjian; Li, Yanbing; Wang, Jiguang; Lv, Weiming; Yu, Jun; Xiao, Haipeng			Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability	ONCOGENE			English	Article							NODE-METASTASIS; BRAF MUTATION; CANCER; ASSOCIATION; EXPRESSION; IDENTIFICATION; MANAGEMENT; PATHWAY	Papillary thyroid carcinoma (PTC) is heterogeneous and its molecular characteristics remain elusive. We integrated transcriptomic sequencing, genomic analysis and clinicopathologic information from 582 tissue samples of 216 PTC and 75 benign thyroid nodule (BTN) patients. We discovered four subtypes of PTC including Immune-enriched Subtype, BRAF-enriched Subtype, Stromal Subtype and CNV-enriched Subtype. Molecular subtypes were validated in an external cohort of 497 PTC cases from the TCGA. Tumors in the Immune-enriched Subtype showed higher immune infiltration and overexpression of immune checkpoints, whilst BRAF-enriched Subtype showed a higher tendency for extrathyroidal extension and more advanced TNM stage. Key oncogenes including LRRK2, SLC34A2, MUC1, FOXQ1 and KRT19 were overexpressed and enriched in oncogenic MAPK and PI3K/AKT signaling pathways in BRAF-enriched subtype. Further analysis of BRAF-enriched Subtype identified three subclasses with different degrees of malignancies. We also uncovered the molecular link of the initiation and progression from BTN to subtypes of PTC using trajectory analysis. Moreover, a 20-gene expression signature was generated for differential diagnosis of PTC from BTN patients. Together, our work identified previously unreported molecular subtypes of PTC, offering opportunities to stratify patients into optimal treatment plans based on molecular subtyping.	[Hong, Shubin; Cheng, Zhen; He, Weiman; Yu, Shuang; Xu, Tianyi; Li, Yanbing; Xiao, Haipeng] Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Peoples R China; [Xie, Yubin; Peng, Sui; Liu, Rengyun; Yu, Jun] Sun Yat Sen Univ, Inst Precis Med, Affiliated Hosp 1, Guangzhou, Peoples R China; [Li, Jie; Zhang, Yunjian; Lv, Weiming] Sun Yat Sen Univ, Dept Breast & Thyroid Surg, Affiliated Hosp 1, Guangzhou, Peoples R China; [Guo, Zhuming; Zhang, Quan] Sun Yat Sen Univ, Dept Head & Neck Surg, Canc Ctr, Guangzhou, Peoples R China; [Peng, Sui; He, Minghui] Sun Yat Sen Univ, Clin Trials Unit, Affiliated Hosp 1, Guangzhou, Peoples R China; [Xu, Lixia] Sun Yat Sen Univ, Dept Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China; [Wang, Jiguang] Hong Kong Univ Sci & Technol, Div Life Sci, Dept Chem & Biol Engn, State Key Lab Mol Neurosci, Hong Kong, Peoples R China; [Wang, Jiguang] Hong Kong Univ Sci & Technol, Hong Kong Ctr Neurodegenerat Dis, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis & Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Chinese University of Hong Kong	Xiao, HP (corresponding author), Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Peoples R China.; Yu, J (corresponding author), Sun Yat Sen Univ, Inst Precis Med, Affiliated Hosp 1, Guangzhou, Peoples R China.; Lv, WM (corresponding author), Sun Yat Sen Univ, Dept Breast & Thyroid Surg, Affiliated Hosp 1, Guangzhou, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis & Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China.	lvwm@mail.sysu.edu.cn; junyu@cuhk.edu.hk; xiaohp@mail.sysu.edu.cn	Liu, Rengyun/O-4039-2018; zhang, yunjian/T-2564-2019	Liu, Rengyun/0000-0002-1408-2372; zhang, yunjian/0000-0001-8457-8421; Li, Jie/0000-0003-1232-3248	National Natural Science Foundation of China [81772850, 82072956]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Yingtong Hou and Xuejie Wang for help with the sample collection. We thank Huanjing Hu for assistance with bioinformatics analysis, and thank Yijia Sun and Jiawei Ge for help with the fluorescent multiplexed immunohistochemistry (mIHC) and functional studies. This work was supported by the grants from National Natural Science Foundation of China (grant number 81772850 to H.X. and 82072956 to S.H.).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Alexander EK, 2022, LANCET DIABETES ENDO, V10, P533, DOI 10.1016/S2213-8587(22)00101-2; Altmann A, 2010, BIOINFORMATICS, V26, P1340, DOI 10.1093/bioinformatics/btq134; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Breuer K, 2013, NUCLEIC ACIDS RES, V41, pD1228, DOI 10.1093/nar/gks1147; Brown RL, 2011, J CANCER, V2, P193, DOI 10.7150/jca.2.193; Caronia LM, 2011, CLIN CANCER RES, V17, P7511, DOI 10.1158/1078-0432.CCR-11-1155; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Chmielik E, 2018, PATHOBIOLOGY, V85, P117, DOI 10.1159/000486422; Durante C, 2015, JAMA-J AM MED ASSOC, V313, P926, DOI 10.1001/jama.2015.0956; Elisei R, 2008, J CLIN ENDOCR METAB, V93, P3943, DOI 10.1210/jc.2008-0607; Fagin JA, 2016, NEW ENGL J MED, V375, P1054, DOI 10.1056/NEJMra1501993; Ferrari SM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184413; Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735; Han YL, 2021, J CANCER, V12, P1779, DOI 10.7150/jca.51551; Harmanci AS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13779-x; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; He J, 2020, ONCOGENE, V39, P2658, DOI 10.1038/s41388-020-1181-z; Howlader N., 2020, SEER CANC STAT REV 1; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Kimura ET, 2003, CANCER RES, V63, P1454; Liang JL, 2018, J PATHOL, V244, P215, DOI 10.1002/path.5005; Mimura K, 2018, CANCER SCI, V109, P43, DOI 10.1111/cas.13424; Noureldine SI, 2015, CURR OPIN ONCOL, V27, P21, DOI 10.1097/CCO.0000000000000150; Oler G, 2008, CLIN CANCER RES, V14, P4735, DOI 10.1158/1078-0432.CCR-07-4372; Pei XB, 2014, IEEE T CYBERNETICS, V44, P1821, DOI 10.1109/TCYB.2013.2296117; Pu WL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26343-3; Renaud F, 2014, THYROID, V24, P1375, DOI 10.1089/thy.2013.0594; Salem A, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2020.188499; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shin JH, 2016, IMMUNE NETW, V16, P134, DOI 10.4110/in.2016.16.2.134; Sia D, 2017, GASTROENTEROLOGY, V153, P812, DOI 10.1053/j.gastro.2017.06.007; Song YS, 2019, ENDOCR-RELAT CANCER, V26, P629, DOI 10.1530/ERC-17-0562; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Tuttle RM, 2017, THYROID, V27, P751, DOI 10.1089/thy.2017.0102; Wang XH, 2019, ONCOL LETT, V18, P927, DOI 10.3892/ol.2019.10360; Xing MZ, 2013, JAMA-J AM MED ASSOC, V309, P1493, DOI 10.1001/jama.2013.3190; Xing MZ, 2005, J CLIN ENDOCR METAB, V90, P6373, DOI 10.1210/jc.2005-0987; Ye L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15533; Yoo SK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10680-5; Zeng QW, 2021, CANCER BIOMARK, V30, P105, DOI 10.3233/CBM-200006; Zhang JW, 2020, DNA CELL BIOL, V39, P1545, DOI 10.1089/dna.2020.5596; Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900	46	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5121	5132		10.1038/s41388-022-02499-0	http://dx.doi.org/10.1038/s41388-022-02499-0		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36253446	hybrid, Green Published			2022-12-28	WOS:000868969900001
J	Saha, G; Sarkar, S; Mohanta, PS; Kumar, K; Chakrabarti, S; Basu, M; Ghosh, MK				Saha, Gouranga; Sarkar, Sibani; Mohanta, Partha S.; Kumar, Krishna; Chakrabarti, Saikat; Basu, Malini; Ghosh, Mrinal K.			USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITORS; APOPTOSIS PROTEIN XIAP; X-LINKED INHIBITOR; CELL-DEATH; EXPRESSION; RESISTANCE; FAMILY; HAUSP; OVEREXPRESSION; CARCINOMA	Ubiquitin specific peptidase 7 (USP7) is a deubiquitinating enzyme (DUB) that removes ubiquitin tags from specific target protein substrates in order to alter their degradation rate, sub-cellular localization, interaction, and activity. The induction of apoptosis upon USP7 inhibition is well established in cancer containing wild type p53, which operates through the 'USP7-Mdm2-p53' axis. However, in cancers without functional p53, USP7-dependent apoptosis is induced through many other alternative pathways. Here, we have identified another critical p53 independent path active under USP7 to regulate apoptosis. Proteomics analysis identifies XIAP as a potential target of USP7-dependent deubiquitination. GSEA analysis revealed up-regulation of apoptosis signalling upon USP7 inhibition associated with XIAP down-regulation. Modulation of USP7 expression and activity in multiple cancer cell lines showed that USP7 deubiquitinates XIAP to inhibit apoptosis in a caspase-dependent pathway, and the combinatorial inhibition of USP7 and XIAP induces apoptosis in vitro and in vivo. Immunohistochemical staining revealed that grade-wise accumulation of USP7 correlated with an elevated level of XIAP in glioma tissue. This is the first report on the identification and validation of XIAP as a novel substrate of USP7 and together, they involve in the empowerment of the tumorigenic potential of cancer cells by inhibiting apoptosis.	[Saha, Gouranga; Sarkar, Sibani; Mohanta, Partha S.; Ghosh, Mrinal K.] Council Sci & Ind Res Indian Inst Chem Biol CSIR, Canc Biol & Inflammatory Disorder Div, TRUE Campus,CN-6,Sect 5, Kolkata 700091, India; [Saha, Gouranga; Sarkar, Sibani; Mohanta, Partha S.; Ghosh, Mrinal K.] Council Sci & Ind Res Indian Inst Chem Biol CSIR, Canc Biol & Inflammatory Disorder Div, 4 Raja SC Mullick Rd, Kolkata 700032, India; [Kumar, Krishna; Chakrabarti, Saikat] CSIR IICB, Struct Biol & Bioinformat Div, TRUE Campus,CN-6,Sect 5, Kolkata 700091, India; [Basu, Malini] Dhruba Chand Halder Coll, Dept Microbiol, South 24 Paraganas, Dakshin Barasat 743372, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Ghosh, MK (corresponding author), Council Sci & Ind Res Indian Inst Chem Biol CSIR, Canc Biol & Inflammatory Disorder Div, TRUE Campus,CN-6,Sect 5, Kolkata 700091, India.; Ghosh, MK (corresponding author), Council Sci & Ind Res Indian Inst Chem Biol CSIR, Canc Biol & Inflammatory Disorder Div, 4 Raja SC Mullick Rd, Kolkata 700032, India.	mrinal.res@gmail.com			Department of Science and Technology [DST/NM/NT/2018/105(G), EMR/2017/000992]; Focused Basic Research, CSIR, Govt. of India [FBR #31-2(274)2020-21/Bud-II]	Department of Science and Technology(Department of Science & Technology (India)); Focused Basic Research, CSIR, Govt. of India	This work is jointly supported by the Department of Science and Technology (NanoMission: DST/NM/NT/2018/105(G); SERB: EMR/2017/000992) and Focused Basic Research (FBR #31-2(274)2020-21/Bud-II), HCT & HCP-40, CSIR, Govt. of India.	Agathanggelou A, 2017, BLOOD, V130, P156, DOI 10.1182/blood-2016-12-758219; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bhattacharya S, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0012-y; Bhattacharya S, 2014, FEBS J, V281, P3061, DOI 10.1111/febs.12843; Bhowmik A, ANTISSTR2 PEPTIDE BA; Bijnsdorp IV, 2011, METHODS MOL BIOL, V731, P421, DOI 10.1007/978-1-61779-080-5_34; Carra G, 2017, ONCOTARGET, V8, P35508, DOI 10.18632/oncotarget.16348; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Cheng CD, 2013, ONCOL REP, V29, P1730, DOI 10.3892/or.2013.2342; Choi H, 2011, NAT METHODS, V8, P70, DOI 10.1038/NMETH.1541; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Clague MJ, 2013, PHYSIOL REV, V93, P1289, DOI 10.1152/physrev.00002.2013; Dar A, 2013, MOL CELL BIOL, V33, P3309, DOI 10.1128/MCB.00358-13; Datta N, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1889-2; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Emery IF, 2017, J NEURO-ONCOL, V133, P47, DOI 10.1007/s11060-017-2422-z; Engel K, 2016, EMBO MOL MED, V8, P851, DOI 10.15252/emmm.201506047; Fan YH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.400; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; HE J, 1994, GENE CHROMOSOME CANC, V11, P91, DOI 10.1002/gcc.2870110205; Huang X, 2013, EMBO J, V32, P2204, DOI 10.1038/emboj.2013.133; Kategaya L, 2017, NATURE, V550, P534, DOI 10.1038/nature24006; Khare V, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1304-y; Kojima K, 2006, BLOOD, V108, P993, DOI 10.1182/blood-2005-12-5148; Krepela E, 2009, INT J ONCOL, V35, P1449, DOI 10.3892/ijo_00000464; Lee G, 2016, BIOCHEM BIOPH RES CO, V470, P181, DOI 10.1016/j.bbrc.2016.01.021; Lee YJ, 2017, ENVIRON TOXICOL, V32, P2371, DOI 10.1002/tox.22450; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Lopes RB, 2007, INT J CANCER, V120, P2344, DOI 10.1002/ijc.22554; Mansouri A, 2003, ONCOL RES, V13, P399; Mellacheruvu D, 2013, NAT METHODS, V10, P730, DOI 10.1038/nmeth.2557; Min DJ, 2019, CANCER CHEMOTH PHARM, V84, P771, DOI 10.1007/s00280-019-03898-z; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Oberoi-Khanuja TK, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.311; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Qi SM, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00233; Sampath D, 2017, BLOOD, V130, P100, DOI 10.1182/blood-2017-06-786236; Sarkar M, 2017, ONCOGENE, V36, P3080, DOI 10.1038/onc.2016.449; Sarkar M, 2015, ONCOGENE, V34, P5843, DOI 10.1038/onc.2015.42; Schauer NJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62076-x; Skaar JR, 2014, NAT REV DRUG DISCOV, V13, P889, DOI 10.1038/nrd4432; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Su DX, 2018, J CLIN INVEST, V128, P4280, DOI 10.1172/JCI120518; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sung KW, 2009, J KOREAN MED SCI, V24, P605, DOI 10.3346/jkms.2009.24.4.605; Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200; Tamm I, 2004, HEMATOL J, V5, P489, DOI 10.1038/sj.thj.6200549; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; WANG LB, 2021, CANCER RES, V81; Wang Q, 2016, J CLIN INVEST, V126, P2205, DOI 10.1172/JCI85747; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhang Y, 2018, CANCERS, V10, DOI 10.3390/cancers10090297; Zhou Z, 2017, EBIOMEDICINE, V15, P48, DOI 10.1016/j.ebiom.2016.12.014	57	1	1	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5061	5075		10.1038/s41388-022-02486-5	http://dx.doi.org/10.1038/s41388-022-02486-5		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36243803				2022-12-28	WOS:000869205700002
J	Yousefi, H; Khosla, M; Lauterboeck, L; Okpechi, SC; Worthylake, D; Garai, J; Zabaleta, J; Guidry, J; Zarandi, MA; Wyczechowska, D; Jayawickramarajah, J; Yang, QL; Kissil, J; Alahari, SK				Yousefi, Hassan; Khosla, Maninder; Lauterboeck, Lothar; Okpechi, Samuel C.; Worthylake, David; Garai, Jone; Zabaleta, Jovanny; Guidry, Jessie; Zarandi, Mohammad Amin; Wyczechowska, Dorota; Jayawickramarajah, Janarthanan; Yang, Qinglin; Kissil, Joseph; Alahari, Suresh K.			A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN; CELL-PROLIFERATION; CARCINOMA INVASION; STEM-CELLS; MECHANISMS; EXPRESSION; METASTASIS; RESISTANCE; PROTEIN	Treatment of patients with triple-negative breast cancer (TNBC) has been challenging due to the absence of well-defined molecular targets and the highly invasive and proliferative nature of TNBC cells. Current treatments against TNBC have shown little promise due to high recurrence rate in patients. Consequently, there is a pressing need for novel and efficacious therapies against TNBC. Here, we report the discovery of a novel small molecule inhibitor (NSC33353) with potent anti-tumor activity against TNBC cells. The anti-proliferative effects of this small molecule inhibitor were determined using 2D and 3D cell proliferation assays. We found that NSC33353 significantly reduces the proliferation of TNBC cells in these assays. Using proteomics, next generation sequencing (NGS), and gene enrichment analysis, we investigated global regulatory pathways affected by this compound in TNBC cells. Proteomics data indicate a significant metabolic reprograming affecting both glycolytic enzymes and energy generation through oxidative phosphorylation. Subsequently, using metabolic (Seahorse) and enzymatic assays, we validated our proteomics and NGS analysis findings. Finally, we showed the inhibitory and anti-tumor effects of this small molecule in vitro and confirmed its inhibitory activity in vivo. Doxorubicin is one of the most effective agents in the treatment of TNBC and resistance to this drug has been a major problem. We show that the combination of NSC33353 and doxorubicin suppresses the growth of TNBC cells synergistically, suggesting that NSC33353 enhances TNBC sensitivity to doxorubicin. In summary, our data indicate that the small molecule inhibitor, NSC33353, exhibits anti-tumor activity in TNBC cells, and works in a synergistic fashion with a well-known chemotherapeutic agent.	[Yousefi, Hassan; Khosla, Maninder; Okpechi, Samuel C.; Worthylake, David; Alahari, Suresh K.] Louisiana State Univ, Hlth Sci Ctr LSUHSC, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Lauterboeck, Lothar; Yang, Qinglin] Louisiana State Univ, Hlth Sci Ctr LSUHSC, Sch Med, Dept Pharmacol & Expt Therapeut,Cardiovasc Ctr Ex, New Orleans, LA 70112 USA; [Garai, Jone; Zabaleta, Jovanny; Wyczechowska, Dorota] LSUHSC, Stanley S Scott Canc Ctr, New Orleans, LA USA; [Zabaleta, Jovanny] LSUHSC, Dept Interdisciplinary Oncol, New Orleans, LA USA; [Guidry, Jessie] Louisiana State Univ, Hlth Sci Ctr LSUHSC, Prote Core Facil, New Orleans, LA USA; [Zarandi, Mohammad Amin; Jayawickramarajah, Janarthanan] Tulane Univ, Dept Chem, New Orleans, LA 70118 USA; [Kissil, Joseph] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL USA	Louisiana State University System; Louisiana State University System; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Tulane University; H Lee Moffitt Cancer Center & Research Institute	Alahari, SK (corresponding author), Louisiana State Univ, Hlth Sci Ctr LSUHSC, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.	salaha@lsuhsc.edu			LSUHSC School of Medicine, Fred G. Brazda foundation; NIH [P20CA202922, P20GM121288-01, P30GM114732]	LSUHSC School of Medicine, Fred G. Brazda foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work is supported by funds from LSUHSC School of Medicine, Fred G. Brazda foundation, and from NIH grants P20CA202922, P20GM121288-01, P30GM114732 to JZ.	Adams S, 2019, JAMA ONCOL, V5, P334, DOI 10.1001/jamaoncol.2018.5152; Alvarez-Fernandez M, 2020, CANCER CELL, V37, P514, DOI 10.1016/j.ccell.2020.03.010; Andre F, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mds195; Androic I, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-391; Andrzejewski S, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00372; Andrzejewski S, 2017, CELL METAB, V26, P778, DOI 10.1016/j.cmet.2017.09.006; Arumugam A, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-018-0197-8; Avagliano A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050401; Avanzato D, 2018, CANCER RES, V78, P3432, DOI 10.1158/0008-5472.CAN-17-3018; Barrett-Lee PJ, 2009, ANN ONCOL, V20, P816, DOI 10.1093/annonc/mdn728; Bianchini G, 2022, NAT REV CLIN ONCOL, V19, P91, DOI 10.1038/s41571-021-00565-2; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Bonnomet A, 2012, ONCOGENE, V31, P3741, DOI 10.1038/onc.2011.540; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Christowitz C, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5939-z; Clara JA, 2020, NAT REV CLIN ONCOL, V17, P204, DOI 10.1038/s41571-019-0293-2; Clark AS, 2016, JAMA ONCOL, V2, P253, DOI 10.1001/jamaoncol.2015.4701; Coller HA, 2014, AM J PATHOL, V184, P4, DOI 10.1016/j.ajpath.2013.07.035; Coradini D, 2015, BREAST, V24, P294, DOI 10.1016/j.breast.2015.01.007; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; de Moraes GN, 2015, CELL SIGNAL, V27, P2496, DOI 10.1016/j.cellsig.2015.09.013; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Ferrari-Amorotti G, 2014, NEOPLASIA, V16, P1047, DOI 10.1016/j.neo.2014.10.006; Flygare JA, 2012, J MED CHEM, V55, P4101, DOI 10.1021/jm300060k; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; GILLETT C, 1994, CANCER RES, V54, P1812; Goodwin CM, 2015, CELL DEATH DIFFER, V22, P2098, DOI 10.1038/cdd.2015.73; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guestini F, 2019, BREAST CANCER RES TR, V173, P275, DOI 10.1007/s10549-018-4985-6; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hajra KM, 2002, CANCER RES, V62, P1613; Hakimi AA, 2016, CANCER CELL, V29, P104, DOI 10.1016/j.ccell.2015.12.004; Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; He JC, 2019, BREAST CANCER RES TR, V178, P263, DOI 10.1007/s10549-019-05380-z; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HENNIG G, 1995, ONCOGENE, V11, P475; Huang XJ, 2016, BREAST, V30, P39, DOI 10.1016/j.breast.2016.08.014; Hussein YR, 2011, TRANSL ONCOL, V4, P321, DOI 10.1593/tlo.11256; Ji MJ, 2011, DIAGN PATHOL, V6, DOI [10.1186/1746-1596-6-48, 10.1186/1746-1596-6-49]; Jin XJ, 2019, J CELL PHYSIOL, V234, P6624, DOI 10.1002/jcp.27403; Karihtala P, 2013, BREAST CANCER RES TR, V138, P81, DOI 10.1007/s10549-013-2442-0; Keung MY, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040940; Kim JY, 2016, SCI REP-UK, V6, DOI 10.1038/srep31804; Kim J, 2019, CELL METAB, V30, P434, DOI 10.1016/j.cmet.2019.08.013; Kim S, 2013, TUMOR BIOL, V34, P1699, DOI 10.1007/s13277-013-0707-1; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kota S, 2018, ONCOGENE, V37, P4372, DOI 10.1038/s41388-018-0257-5; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lane AN, 2015, NUCLEIC ACIDS RES, V43, P2466, DOI 10.1093/nar/gkv047; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lee CK, 2019, SCIENCE, V363, P644, DOI 10.1126/science.aav0173; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Lev S, 2020, BIOCHEM SOC T, V48, P657, DOI 10.1042/BST20191055; Lin NU, 2008, CANCER-AM CANCER SOC, V113, P2638, DOI 10.1002/cncr.23930; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Lopez J, 2015, BRIT J CANCER, V112, P957, DOI 10.1038/bjc.2015.85; Lunetti P, 2019, FEBS J, V286, P688, DOI 10.1111/febs.14756; Ma F, 2014, CANCER LETT, V353, P153, DOI 10.1016/j.canlet.2014.06.022; Marinello PC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42357-w; Marra A, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-00197-2; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Masson N, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-3; Momeny M, 2018, INT J BIOCHEM CELL B, V99, P1, DOI 10.1016/j.biocel.2018.03.015; Moriai R, 2009, BREAST CANCER RES TR, V117, P261, DOI 10.1007/s10549-008-0164-5; O'Neill S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39789-9; Oh S, 2017, BMB REP, V50, P132, DOI 10.5483/BMBRep.2017.50.3.189; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Paredes J, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01498; Pascale CL, 2020, J CEREBR BLOOD F MET, V40, P1077, DOI 10.1177/0271678X19858888; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pinheiro C, 2010, HISTOPATHOLOGY, V56, P860, DOI 10.1111/j.1365-2559.2010.03560.x; Prasad CP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-325; Reznik E, 2018, CELL SYST, V6, P301, DOI 10.1016/j.cels.2017.12.014; Ribatti D, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100773; Rugo HS, 2019, ANN ONCOL, V30, P858; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Sher I, 2009, INT J CANCER, V124, P553, DOI 10.1002/ijc.23963; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193; Simoes RV, 2015, NEOPLASIA, V17, P671, DOI 10.1016/j.neo.2015.08.005; Span PN, 2004, CLIN CHEM, V50, P1986, DOI 10.1373/clinchem.2004.039149; Spinazzi M, 2012, NAT PROTOC, V7, P1235, DOI 10.1038/nprot.2012.058; Stover DG, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523-018-0060-z; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Sun XY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00428; Syn NL, 2017, LANCET ONCOL, V18, pE731, DOI 10.1016/S1470-2045(17)30607-1; Tadesse S, 2019, J MED CHEM, V62, P4233, DOI 10.1021/acs.jmedchem.8b01469; Tajbakhsh A, 2019, CRIT REV ONCOL HEMAT, V140, P17, DOI 10.1016/j.critrevonc.2019.05.009; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tan EY, 2009, BRIT J CANCER, V100, P405, DOI 10.1038/sj.bjc.6604844; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tolaney SM, 2021, CLIN CANCER RES, V27, P3061, DOI 10.1158/1078-0432.CCR-20-4726; Urra FA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31367-9; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang Liang, 2016, Front Pharmacol, V7, P249, DOI 10.3389/fphar.2016.00249; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Won KA, 2020, INT J ONCOL, V57, P1245, DOI 10.3892/ijo.2020.5135; Wright HJ, 2017, P NATL ACAD SCI USA, V114, pE6556, DOI 10.1073/pnas.1703791114; Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691; Yamada A, 2013, BREAST CANCER RES TR, V137, P773, DOI 10.1007/s10549-012-2398-5; Yin L, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01296-5; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Zhao H, 2018, ONCOL REP, V40, P3223, DOI 10.3892/or.2018.6716; Zhou M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-33	125	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5076	5091		10.1038/s41388-022-02497-2	http://dx.doi.org/10.1038/s41388-022-02497-2		OCT 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36243802				2022-12-28	WOS:000869205700001
J	Ahn, S; Saha, A; Clark, R; Kolonin, MG; DiGiovanni, J				Ahn, Songyeon; Saha, Achinto; Clark, Rachel; Kolonin, Mikhail G.; DiGiovanni, John			CXCR4 and CXCR7 signaling promotes tumor progression and obesity-associated epithelial-mesenchymal transition in prostate cancer cells	ONCOGENE			English	Article							ADIPOSE-TISSUE; CHEMOKINE RECEPTOR-4; FACTOR-I; GROWTH; METASTASIS; EXPRESSION; PATHWAYS; AXIS; DIFFERENTIATION; COMBINATION	Obesity is associated with increased prostate cancer (PCa) progression and higher mortality, however, the mechanism(s) remain still unclear. Here, we investigated signaling by the ASC-secreted chemokine CXCL12 in a mouse allograft model of PCa and in HiMyc mice in the context of diet-induced obesity. Treatment of mice with CXCR4 antagonist inhibited CXCL12-induced signaling pathways, tumor growth and EMT in HMVP2 allograft tumors. Similar results were obtained following prostate epithelium-specific deletion of CXCR4 in HiMyc mice. We also show that CXCR4 signaling regulates expression of JMJD2A histone demethylase and histone methylation which is modulated by AMD3100. Importantly, treatment with a CXCR7 antagonist also inhibited allograft tumor growth and EMT. The current results demonstrate that both CXCR4 and CXCR7 play an important role in cancer progression and establish CXCL12 signaling pathways, activated in obesity, as potential targets for PCa intervention. In addition, other factors secreted by ASCs, may also contribute to cancer aggressiveness in obesity.	[Ahn, Songyeon; Saha, Achinto; Clark, Rachel; DiGiovanni, John] Univ Texas Austin, Div Pharmacol & Toxicol, Austin, TX 78723 USA; [Ahn, Songyeon; Saha, Achinto; Clark, Rachel; DiGiovanni, John] Univ Texas Austin, Dell Pediat Res Inst, Austin, TX 78723 USA; [Saha, Achinto; DiGiovanni, John] Univ Texas Austin, Ctr Mol Carcinogenesis & Toxicol, Austin, TX 78723 USA; [Saha, Achinto; DiGiovanni, John] Univ Texas Austin, Dell Med Sch, Livestrong Canc Inst, Austin, TX 78723 USA; [Kolonin, Mikhail G.] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med Prevent Dis, Houston, TX 77030 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Health Science Center Houston	DiGiovanni, J (corresponding author), Univ Texas Austin, Div Pharmacol & Toxicol, Austin, TX 78723 USA.; DiGiovanni, J (corresponding author), Univ Texas Austin, Dell Pediat Res Inst, Austin, TX 78723 USA.; DiGiovanni, J (corresponding author), Univ Texas Austin, Ctr Mol Carcinogenesis & Toxicol, Austin, TX 78723 USA.; DiGiovanni, J (corresponding author), Univ Texas Austin, Dell Med Sch, Livestrong Canc Inst, Austin, TX 78723 USA.	john.digiovanni@austin.utexas.edu		Kolonin, Mikhail/0000-0002-3743-7869; DiGiovanni, John/0000-0003-4233-6728	NIH [R01 CA196259]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank Steve Carbajal for his significant and extensive assistance to various aspects of this study. This study was supported by NIH grant R01 CA196259 (to JD and MGK).	Ablett MP, 2014, ONCOTARGET, V5, P599, DOI 10.18632/oncotarget.1169; Balic A, 2014, MOL CANCER THER, V13, P1758, DOI 10.1158/1535-7163.MCT-13-0948; Bellows CF, 2011, CANCER EPIDEM BIOMAR, V20, P2461, DOI 10.1158/1055-9965.EPI-11-0556; Bhurosy Trishnee, 2014, ScientificWorldJournal, V2014, P964236, DOI 10.1155/2014/964236; Blando J, 2011, CANCER PREV RES, V4, P2002, DOI 10.1158/1940-6207.CAPR-11-0182; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Couture JF, 2007, NAT STRUCT MOL BIOL, V14, P689, DOI 10.1038/nsmb1273; Cui K, 2011, J SURG RES, V171, P143, DOI 10.1016/j.jss.2010.03.001; Daquinag AC, 2015, CELL DEATH DIFFER, V22, P351, DOI 10.1038/cdd.2014.148; Daquinag AC, 2017, MOL THER-ONCOLYTICS, V6, P1, DOI 10.1016/j.omto.2017.05.003; Daquinag AC, 2011, CELL STEM CELL, V9, P74, DOI 10.1016/j.stem.2011.05.017; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; De Clercq Erik, 2019, Antiviral Chemistry & Chemotherapy, V27, p2040206619829382, DOI 10.1177/2040206619829382; Dickerman BA, 2019, CANCER-AM CANCER SOC, V125, P2877, DOI 10.1002/cncr.32167; Dubrovska A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031226; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Fryar CD, 2018, NCHS HLTH E STATS; Gong ZH, 2007, CANCER-AM CANCER SOC, V109, P1192, DOI 10.1002/cncr.22534; Hales Craig M, 2020, NCHS Data Brief, P1; Hernandez L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3074; Himbert C, 2017, CANCER PREV RES, V10, P494, DOI 10.1158/1940-6207.CAPR-16-0322; Kim D, 2014, DIABETOLOGIA, V57, P1456, DOI 10.1007/s00125-014-3237-5; Kim TD, 2016, J CLIN INVEST, V126, P706, DOI 10.1172/JCI78132; Kolonin MG, 2019, TRANSL ANDROL UROL, V8, pS348, DOI 10.21037/tau.2019.04.07; Kshattry S, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0088-z; Laurent V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10230; Lawrence M, 2016, TRENDS GENET, V32, P42, DOI 10.1016/j.tig.2015.10.007; Lengyel E, 2018, TRENDS CANCER, V4, P374, DOI 10.1016/j.trecan.2018.03.004; Li M, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01177-z; Li Y, 2019, MOL MED REP, V19, P2489, DOI 10.3892/mmr.2019.9916; Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Mimeault M, 2011, MOL MED, V17, P949, DOI 10.2119/molmed.2011.00115; Mochizuki H, 2004, BIOCHEM BIOPH RES CO, V320, P656, DOI 10.1016/j.bbrc.2004.06.013; Moore T, 2008, CANCER PREV RES, V1, P65, DOI 10.1158/1940-6207.CAPR-08-0022; Nunez NP, 2008, NUTR CANCER, V60, P534, DOI 10.1080/01635580801966195; Nunez NP, 2007, OBESITY, V15, P1980, DOI 10.1038/oby.2007.236; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Saglam K, 2003, J UROLOGY, V169, P1308, DOI 10.1097/01.ju.0000055903.18400.25; Saha A, 2017, CANCER RES, V77, P5158, DOI [10.1158/0008-5472.CAN-17-0284, 10.1158/0008-5472.can-17-0284]; Saha A, 2016, ONCOTARGET, V7, P25194, DOI 10.18632/oncotarget.7535; Saha A, 2015, CANCER PREV RES, V8, P597, DOI 10.1158/1940-6207.CAPR-15-0014; Scala S, 2015, CLIN CANCER RES, V21, P4278, DOI 10.1158/1078-0432.CCR-14-0914; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Shi Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.574667; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Silva KR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174115; Singh AK, 2013, CYTOKINE GROWTH F R, V24, P41, DOI 10.1016/j.cytogfr.2012.08.007; Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181; Song ZY, 2019, ONCOGENE, V38, P1560, DOI 10.1038/s41388-018-0519-2; Stillman B, 2018, CELL, V175, P6, DOI 10.1016/j.cell.2018.08.032; Su F, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00160-9; Su F, 2020, MOL THER-ONCOLYTICS, V18, P579, DOI 10.1016/j.omto.2020.08.012; Su F, 2019, ONCOGENE, V38, P1979, DOI 10.1038/s41388-018-0558-8; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Tian Y, 2017, ONCOL LETT, V13, P2253, DOI 10.3892/ol.2017.5694; Trautmann F, 2014, INT J RADIAT BIOL, V90, P687, DOI 10.3109/09553002.2014.906766; Wang FY, 2019, ONCOL REP, V42, P1431, DOI 10.3892/or.2019.7246; Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200; Wang XW, 2017, ONCOTARGET, V8, P36149, DOI 10.18632/oncotarget.15254; Wright ME, 2007, CANCER-AM CANCER SOC, V109, P675, DOI 10.1002/cncr.22443; Yang JH, 2018, MED SCI MONITOR, V24, P5185, DOI 10.12659/MSM.906180; Yang N, 2020, THERANOSTICS, V10, P5790, DOI 10.7150/thno.44789; Yasumoto K, 2006, CANCER RES, V66, P2181, DOI 10.1158/0008-5472.CAN-05-3393; Zabel BA, 2009, J IMMUNOL, V183, P3204, DOI 10.4049/jimmunol.0900269; Zhang Y, 2009, CANCER RES, V69, P5259, DOI 10.1158/0008-5472.CAN-08-3444; Zhao HL, 2015, ONCOTARGET, V6, P5022, DOI 10.18632/oncotarget.3217; Zhao W, 2014, J BIOMOL SCREEN, V19, P817, DOI 10.1177/1087057114521867	73	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4633	4644		10.1038/s41388-022-02466-9	http://dx.doi.org/10.1038/s41388-022-02466-9		SEP 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36088505				2022-12-28	WOS:000852343800002
J	Wang, C; Li, WC; Hu, Q; Feng, NH; Liu, CH; Shi, NP; Chen, SQ; Chen, M; Guan, H; You, ZH; Xu, B				Wang, Can; Li, Wenchao; Hu, Qiang; Feng, Ninghan; Liu, Chunhui; Shi, Naipeng; Chen, Shuqiu; Chen, Ming; Guan, Han; You, Zonghao; Xu, Bin			Transgenic construction and functional miRNA analysis identify the role of miR-7 in prostate cancer suppression	ONCOGENE			English	Article							STEM-LIKE CELLS; GENE-EXPRESSION; IN-VITRO; MICRORNA; METASTASIS; TRANSITION; RESISTANCE; TARGETS	Although miR-7 suppresses the initiation and progression in cancers, little is known about its role in prostate cancer, especially in transgenic mouse models. In present study, we found that expression of miR-7, regulated by p53, was lower in prostate cancer tissues, and miR-7 overexpression significantly mitigated prostate cancer cells growth both in vitro, in organoids and in vivo regardless of p53 status. After we generated miR-7 overexpression transgenic mice and miR-7(+)/TRAMP mice, we found that transgenic overexpression of miR-7 in mice is safe and miR-7(+)/TRAMP mice have a preferred overall survival. Moreover, in vivo treatment of miR-7 inhibited subcutaneous tumour growth in mice and prolonged the survival of mice harboring prostate cancer lung metastasis when co-injection with PD-1 antibody. In addition, miR-7 downregulated glycolysis of prostate cancer cells by inhibiting several key pathways including HIF-1 alpha, and subsequently remodeled acidic tumour microenvironment, PanKLa level and T cell infiltration. In summary, our findings highlighted a promising target for development of miRNA-based therapeutics for prostate cancer patients regardless of p53 status.	[Wang, Can; Li, Wenchao; Hu, Qiang; Liu, Chunhui; Shi, Naipeng; Chen, Shuqiu; Chen, Ming; You, Zonghao; Xu, Bin] Southeast Univ, Dept Urol, Affiliated Zhongda Hosp, Nanjing 210009, Peoples R China; [Wang, Can; Li, Wenchao; Hu, Qiang; Liu, Chunhui; Shi, Naipeng; Chen, Shuqiu; Chen, Ming; You, Zonghao; Xu, Bin] Southeast Univ, Surg Res Ctr, Inst Urol, Med Sch, Nanjing 210009, Peoples R China; [Feng, Ninghan] Nanjing Med Univ, Wuxi 2 Hosp, Dept Urol, Wuxi 214002, Jiangsu, Peoples R China; [Guan, Han] Bengbu Med Coll, Dept Urol, Affiliated Hosp 1, Bengbu 233004, Peoples R China; [Xu, Bin] Southeast Univ, Affiliated Zhongda Hosp, Inst Med Phen Res, Nanjing 210009, Peoples R China	Southeast University - China; Southeast University - China; Nanjing Medical University; Bengbu Medical College; Southeast University - China	Chen, M; You, ZH; Xu, B (corresponding author), Southeast Univ, Dept Urol, Affiliated Zhongda Hosp, Nanjing 210009, Peoples R China.; Chen, M; You, ZH; Xu, B (corresponding author), Southeast Univ, Surg Res Ctr, Inst Urol, Med Sch, Nanjing 210009, Peoples R China.; Guan, H (corresponding author), Bengbu Med Coll, Dept Urol, Affiliated Hosp 1, Bengbu 233004, Peoples R China.; Xu, B (corresponding author), Southeast Univ, Affiliated Zhongda Hosp, Inst Med Phen Res, Nanjing 210009, Peoples R China.	mingchen0712@seu.edu.cn; gh668689@126.com; 101012899@seu.edu.cn; njxbseu@seu.edu.cn		, Zonghao/0000-0003-4807-9750; Guan, Han/0000-0002-7043-6307	National Natural Science Foundation of China [81872089, 81672551, 82102799]; Natural Science Foundation of Jiangsu Province [BK20210230]; Key Research and Development Program of Jiangsu Province [BE2019751]; Jiangsu Provincial Medical Talent [ZDRCA2016080]; Jiangsu Provincial Medical Innovation Team [CXTDA2017025]; Doctor of Entrepreneurship and Innovation in Jiangsu Province [JSSCBS20210138, JSSCBS20210088]; General Project of Medical Research of Jiangsu Health and Wellness Committee [M2020049]; Key R&D (Social Development) Projects of Jiangsu Province [BE2018629]; Wuxi "Taihu Talents Program" Medical and Health High-level Talents Project, First Affiliated Hospital of Bengbu Medical College Science Fund for Outstanding Young Scholars [2019BYYFYYQ09]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Key Research and Development Program of Jiangsu Province; Jiangsu Provincial Medical Talent; Jiangsu Provincial Medical Innovation Team; Doctor of Entrepreneurship and Innovation in Jiangsu Province; General Project of Medical Research of Jiangsu Health and Wellness Committee; Key R&D (Social Development) Projects of Jiangsu Province; Wuxi "Taihu Talents Program" Medical and Health High-level Talents Project, First Affiliated Hospital of Bengbu Medical College Science Fund for Outstanding Young Scholars	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (grant numbers 81872089, 81672551 and 82102799), Natural Science Foundation of Jiangsu Province (grant number BK20210230), Key Research and Development Program of Jiangsu Province (grant number BE2019751), Jiangsu Provincial Medical Talent (grant number ZDRCA2016080), The Jiangsu Provincial Medical Innovation Team (grant number CXTDA2017025), Doctor of Entrepreneurship and Innovation in Jiangsu Province (grant number JSSCBS20210138, JSSCBS20210088), The General Project of Medical Research of Jiangsu Health and Wellness Committee (grant number M2020049), Key R&D (Social Development) Projects of Jiangsu Province (BE2018629) Wuxi "Taihu Talents Program" Medical and Health High-level Talents Project, First Affiliated Hospital of Bengbu Medical College Science Fund for Outstanding Young Scholars (No. 2019BYYFYYQ09).	Bayraktar R, 2018, CLIN CANCER RES, V24, P4225, DOI 10.1158/1078-0432.CCR-17-1959; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Cardozo V, 2021, NEUROCHEM INT, V147, DOI 10.1016/j.neuint.2021.105064; Chang YL, 2015, ONCOTARGET, V6, P24017, DOI 10.18632/oncotarget.4447; Cheteh EH, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0272-5; Culp MB, 2020, EUR UROL, V77, P38, DOI 10.1016/j.eururo.2019.08.005; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Fang YX, 2012, HEPATOLOGY, V55, P1852, DOI 10.1002/hep.25576; Gao YS, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01421-6; George AL, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-80; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hu JH, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01169-0; Irizarry-Caro RA, 2020, P NATL ACAD SCI USA, V117, P30628, DOI 10.1073/pnas.2009778117; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Lee KS, 2008, AM J RESP CRIT CARE, V178, P787, DOI 10.1164/rccm.200801-008OC; Lequeux A, 2021, ONCOGENE, V40, P4725, DOI 10.1038/s41388-021-01846-x; Li M, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01264-z; Li ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16306-5; Lin CL, 2020, MOL THER-NUCL ACIDS, V20, P699, DOI 10.1016/j.omtn.2020.04.009; Lin RW, 2018, CELL CYCLE, V17, P2175, DOI 10.1080/15384101.2018.1520565; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Okuda H, 2013, CANCER RES, V73, P1434, DOI 10.1158/0008-5472.CAN-12-2037; Ottosen S, 2015, ANTIMICROB AGENTS CH, V59, P599, DOI 10.1128/AAC.04220-14; Pan CM, 2020, CANCER LETT, V493, P133, DOI 10.1016/j.canlet.2020.08.024; Qi Z., 2022, NAT COMMUN, V13, DOI 10.1038/s41467-021-27833-0; Reid MA, 2017, NAT CELL BIOL, V19, P1298, DOI 10.1038/ncb3629; Ren RY, 2020, J CELL PHYSIOL, V235, P6204, DOI 10.1002/jcp.29549; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Riganti C, 2009, BRIT J PHARMACOL, V156, P1054, DOI 10.1111/j.1476-5381.2009.00117.x; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sahraei M, 2019, J CLIN INVEST, V129, P5518, DOI 10.1172/JCI127125; Sehrawat A, 2018, P NATL ACAD SCI USA, V115, pE4179, DOI 10.1073/pnas.1719168115; Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sun YF, 2016, AM J CANCER RES, V6, P114; Thapa D, 2014, CANCER RES, V74, P5644, DOI 10.1158/0008-5472.CAN-14-0562; van Zandwijk N, 2017, LANCET ONCOL, V18, P1386, DOI 10.1016/S1470-2045(17)30621-6; Wang CQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16966-3; Wang J, 2016, J CELL PHYSIOL, V231, P25, DOI 10.1002/jcp.25056; Ward C, 2013, CANCER TREAT REV, V39, P171, DOI 10.1016/j.ctrv.2012.08.004; Westra J, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-61; Wu ZC, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.517637; Xiong Le, 2021, Nanotheranostics, V5, P143, DOI 10.7150/ntno.53844; Yang Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08759-0; Zhang D, 2019, NATURE, V574, P575, DOI 10.1038/s41586-019-1678-1; Zhang T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080544; Zhu HT, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1159-2	47	0	0	22	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4645	4657		10.1038/s41388-022-02461-0	http://dx.doi.org/10.1038/s41388-022-02461-0		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36088503	Green Submitted			2022-12-28	WOS:000852343800003
J	He, WT; Lin, SY; Guo, Y; Wu, YZ; Zhang, LL; Deng, QL; Du, ZM; Wei, MB; Zhu, WJ; Chen, WJ; Shao, JY; Xu, GL				He, Wenting; Lin, Shiyong; Guo, Yi; Wu, Yuanzhong; Zhang, Lu-Lu; Deng, Qiling; Du, Zi-Ming; Wei, Mingbiao; Zhu, Weijie; Chen, Wan-Juan; Shao, Jian-Yong; Xu, Guo-Liang			Targeted demethylation at ZNF154 promotor upregulates ZNF154 expression and inhibits the proliferation and migration of Esophageal Squamous Carcinoma cells	ONCOGENE			English	Article							TET PROTEINS; DNA METHYLATION; CANCER; GENES; 5-METHYLCYTOSINE; CONVERSION; DISEASE; LOCUS	Zinc finger protein 154 (ZNF154) is hypermethylated at the promoter in many epithelial-derived solid tumors. However, its methylation status and function in esophageal squamous carcinoma (ESCC) are poorly understood. We found that the ZNF154 promoter is hypermethylated in ESCC and portends poor prognosis. In addition, ZNF154 functions as a tumor suppressor gene (TSG) in ESCC, and is downregulated by promoter hypermethylation. We established a targeted demethylation strategy based on CRISPR/dCas9 technology and found that the hypermethylation of ZNF154 promoter repressed ZNF154 induction, which in turn promoted the proliferation and migration of ESCC cells in vitro and in vivo. Finally, high-throughput CUT&Tag analysis, GEPIA software and qPCR were used to revealed the role of ZNF154 as a transcription factor to upregulate the expression of ESCC-associated tumor suppressor genes. Taken together, hypermethylation of the ZNF154 promoter plays an important role in the development of ESCC, and epigenetic editing is a promising tool for inhibiting ESCC cells with aberrant DNA methylation.	[He, Wenting; Zhang, Lu-Lu; Deng, Qiling; Du, Zi-Ming; Wei, Mingbiao; Zhu, Weijie; Shao, Jian-Yong] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Lin, Shiyong; Xu, Guo-Liang] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Endoscopy & Laser, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Guo, Yi] Shantou Univ, Dept Endoscopy, Canc Hosp, Shantou, Peoples R China; [Wu, Yuanzhong] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Chen, Wan-Juan] Anhui Targene Med Technol Co Ltd, Res & Dev Dept, Wuhu, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Shantou University; State Key Lab Oncology South China; Sun Yat Sen University	Shao, JY (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.; Xu, GL (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Endoscopy & Laser, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.; Chen, WJ (corresponding author), Anhui Targene Med Technol Co Ltd, Res & Dev Dept, Wuhu, Peoples R China.	chenwanjuan@targene.cn; shaojy@sysucc.org.cn; xugl@sysucc.org.cn	he, wenting/GYD-5727-2022	Wu, Yuanzhong/0000-0002-3577-7069	National Natural Science Foundation of China [82002220]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grant No. 82002220 from the National Natural Science Foundation of China. The sponsors or funding organizations had no role in the design or conduct of this research.	Aparicio Ana, 2002, Curr Opin Investig Drugs, V3, P627; Bender CM, 1998, CANCER RES, V58, P95; Chen FF, 2019, MOL MED REP, V20, P3649, DOI 10.3892/mmr.2019.10608; Chen NP, 2016, P NATL ACAD SCI USA, V113, P990, DOI 10.1073/pnas.1515605113; Cheng AW, 2013, CELL RES, V23, P1163, DOI 10.1038/cr.2013.122; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Falahi F, 2013, MOL CANCER RES, V11, P1029, DOI 10.1158/1541-7786.MCR-12-0567; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Hamilton JP, 2006, CLIN GASTROENTEROL H, V4, P701, DOI 10.1016/j.cgh.2006.03.007; Han SC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02859-2; He WW, 2018, J THORAC DIS, V10, P5714, DOI 10.21037/jtd.2018.09.55; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Heller EA, 2014, NAT NEUROSCI, V17, P1720, DOI 10.1038/nn.3871; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Huntley S, 2006, GENOME RES, V16, P669, DOI 10.1101/gr.4842106; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaya-Okur HS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09982-5; Kaz AM, 2014, CANCER LETT, V342, P193, DOI 10.1016/j.canlet.2012.02.036; Lao-Sirieix P, 2012, NAT REV CLIN ONCOL, V9, P278, DOI 10.1038/nrclinonc.2012.35; Li JS, 2013, CHIN J CANCER, V32, P3, DOI 10.5732/cjc.011.10381; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Margolin G, 2016, J MOL DIAGN, V18, P283, DOI 10.1016/j.jmoldx.2015.11.004; Masoumi KC, 2017, MOL BIOL CELL, V28, P346, DOI 10.1091/mbc.E16-07-0547; Mehdipour P, 2020, PHARMACOL THERAPEUT, V205, DOI 10.1016/j.pharmthera.2019.107416; Mocciaro A, 2010, J CELL BIOL, V189, P631, DOI 10.1083/jcb.200910057; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Pennathur A, 2009, ANN THORAC SURG, V87, P1048, DOI 10.1016/j.athoracsur.2008.12.060; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; Rodriguez C, 2010, BIOCHEM BIOPH RES CO, V392, P129, DOI 10.1016/j.bbrc.2009.12.159; Sarbia M, 2007, BRIT J CANCER, V97, P1404, DOI 10.1038/sj.bjc.6604037; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Vaquerizas JM, 2009, NAT REV GENET, V10, P252, DOI 10.1038/nrg2538; Verma N, 2018, NAT GENET, V50, P83, DOI 10.1038/s41588-017-0002-y; Xu XX, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.9; Yang YM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00323-3	42	0	0	8	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4537	4546		10.1038/s41388-022-02366-y	http://dx.doi.org/10.1038/s41388-022-02366-y		SEP 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36064578	Green Published, hybrid			2022-12-28	WOS:000849997400002
J	Tan, Z; Shi, S; Xu, J; Liu, XM; Lei, YB; Zhang, B; Hua, J; Meng, QC; Wang, W; Yu, XJ; Liang, C				Tan, Zhen; Shi, Si; Xu, Jin; Liu, Xiaomeng; Lei, Yubin; Zhang, Bo; Hua, Jie; Meng, Qingcai; Wang, Wei; Yu, Xianjun; Liang, Chen			RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m(6)A-YTHDF2-dependent manner	ONCOGENE			English	Article							GROWTH-FACTOR-C; OBESITY	RNA N6-methyladenosine (m(6)A) is an emerging regulator of mRNA modifications and represents a novel player in tumorigenesis. Although it has functional significance in both pathological and physiological processes, the role of m(6)A modification in pancreatic ductal cancer (PDAC) remains elusive. Here, we showed that high fat mass and obesity-associated gene (FTO) expression was associated with a poor prognosis in PDAC patients and that suppression of FTO expression inhibited cell proliferation. Here, m(6)A sequencing (m(6)A-seq) was performed to screen genes targeted by FTO. The effects of FTO stimulation on the biological characteristics of pancreatic cancer cells, including proliferation and colony formation, were investigated in vitro and in vivo. The results indicate that FTO directly targets platelet-derived growth factor C (PDGFC) and stabilizes its mRNA expression in an m(6)A-YTHDF2-dependent manner. m(6)A-methylated RNA immunoprecipitation-qPCR (MeRIP-qPCR), RNA immunoprecipitation (RIP), and luciferase reporter assays were employed to validate the specific binding of FTO to PDGFC. PDGFC upregulation led to reactivation of the Akt signaling pathway, promoting cell growth. Overall, our study reveals that FTO downregulation leads to increased m(6)A modifications in the 3MODIFIER LETTER PRIME UTR of PDGFC and then modulates the degradation of its transcriptional level in an m(6)A-YTHDF2-dependent manner, highlighting a potential therapeutic target for PDAC treatment and prognostic prediction.	[Tan, Zhen; Shi, Si; Xu, Jin; Liu, Xiaomeng; Lei, Yubin; Zhang, Bo; Hua, Jie; Meng, Qingcai; Wang, Wei; Yu, Xianjun; Liang, Chen] Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Tan, Zhen; Shi, Si; Xu, Jin; Liu, Xiaomeng; Lei, Yubin; Zhang, Bo; Hua, Jie; Meng, Qingcai; Wang, Wei; Yu, Xianjun; Liang, Chen] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Tan, Zhen; Shi, Si; Xu, Jin; Liu, Xiaomeng; Lei, Yubin; Zhang, Bo; Hua, Jie; Meng, Qingcai; Wang, Wei; Yu, Xianjun; Liang, Chen] Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China; [Tan, Zhen; Shi, Si; Xu, Jin; Liu, Xiaomeng; Lei, Yubin; Zhang, Bo; Hua, Jie; Meng, Qingcai; Wang, Wei; Yu, Xianjun; Liang, Chen] Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Wang, W; Yu, XJ; Liang, C (corresponding author), Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Wang, W; Yu, XJ; Liang, C (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Wang, W; Yu, XJ; Liang, C (corresponding author), Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China.; Wang, W; Yu, XJ; Liang, C (corresponding author), Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China.	wangwei@fudanpci.org; yuxianjun@fudanpci.org; liangchen@fudanpci.org			National Natural Science Foundation of China [81802352, 81902428, 82002541, U21A20374]; Shanghai Municipal Science and Technology Major Project [21JC1401500]; Scientific Innovation Project of Shanghai Education Committee [2019-01-07-00-07-E00057]; Clinical Research Plan of Shanghai Hospital Development Center [SHDC2020CR1006A]; Shanghai Sailing Program [19YF1409400]; Xuhui District Artificial Intelligence Medical Hospital Cooperation Project [2021-011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Science and Technology Major Project; Scientific Innovation Project of Shanghai Education Committee; Clinical Research Plan of Shanghai Hospital Development Center; Shanghai Sailing Program; Xuhui District Artificial Intelligence Medical Hospital Cooperation Project	This study was jointly funded by the National Natural Science Foundation of China (No. 81802352, 81902428, 82002541 and U21A20374), Shanghai Municipal Science and Technology Major Project (21JC1401500), Scientific Innovation Project of Shanghai Education Committee (2019-01-07-00-07-E00057), Clinical Research Plan of Shanghai Hospital Development Center (SHDC2020CR1006A), and Xuhui District Artificial Intelligence Medical Hospital Cooperation Project (2021-011), the Shanghai Sailing Program (No. 19YF1409400).	Anderson AC, 2011, DRUG DISCOV TODAY, V16, P755, DOI 10.1016/j.drudis.2011.07.001; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Cao YH, 2013, TRENDS MOL MED, V19, P460, DOI 10.1016/j.molmed.2013.05.002; Chen JL, 2019, J CANCER RES CLIN, V145, P19, DOI 10.1007/s00432-018-2796-0; Cho YS, 2009, NAT GENET, V41, P527, DOI 10.1038/ng.357; Christenson ES, 2020, LANCET ONCOL, V21, pE135, DOI 10.1016/S1470-2045(19)30795-8; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Deng XL, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00396; Dina C, 2007, NAT GENET, V39, P724, DOI 10.1038/ng2048; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Grossberg AJ, 2020, CA-CANCER J CLIN, V70, P375, DOI 10.3322/caac.21626; He CA, 2010, NAT CHEM BIOL, V6, P863, DOI 10.1038/nchembio.482; He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9; Hirayama M, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.028; Huang XY, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12464; Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Kramer F, 2020, HAEMATOLOGICA, V105, P2083, DOI 10.3324/haematol.2019.226332; Lei H, 2008, EXP EYE RES, V86, P711, DOI 10.1016/j.exer.2007.08.007; Li Q, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00453-8; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Liang C, 2020, GUT, V69, P888, DOI 10.1136/gutjnl-2018-317163; Liu J, 2018, NAT CELL BIOL, V20, P1074, DOI 10.1038/s41556-018-0174-4; Liu T, 2020, J CELL PHYSIOL, V235, P548, DOI 10.1002/jcp.28994; Lurie G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016756; Mizrahi JD, 2020, LANCET, V395, P2008, DOI 10.1016/S0140-6736(20)30974-0; Niu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1004-4; Pietras K, 2002, CANCER RES, V62, P5476; Reigstad LJ, 2003, J BIOL CHEM, V278, P17114, DOI 10.1074/jbc.M301728200; Salgado-Montilla Jeannette L, 2017, Arch Cancer Res, V5, DOI 10.21767/2254-6081.1000148; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Son D, 2014, J BIOL CHEM, V289, P6225, DOI 10.1074/jbc.M113.508994; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Tang XD, 2019, ONCOL LETT, V17, P2473, DOI 10.3892/ol.2018.9873; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang TY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01204-7; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580-019-0168-5; Zhao BXS, 2017, NAT REV MOL CELL BIO, V18, P31, DOI 10.1038/nrm.2016.132; Zhao X, 2014, CELL RES, V24, P1403, DOI 10.1038/cr.2014.151; Zhou ZJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01216-3	44	5	5	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2860	2872		10.1038/s41388-022-02306-w	http://dx.doi.org/10.1038/s41388-022-02306-w		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35422475	Green Published, hybrid			2022-12-28	WOS:000782543300001
J	Chen, BB; Jiang, W; Huang, Y; Zhang, J; Yu, P; Wu, LR; Peng, H				Chen, Binbin; Jiang, Wei; Huang, Ying; Zhang, Jian; Yu, Peng; Wu, Lirong; Peng, Hao			N-7-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT/beta-catenin pathway in nasopharyngeal carcinoma	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; STAGING SYSTEM; CANCER; TRANSLATION; METHYLATION; METASTASIS; EXPRESSION; WNT; WDR4	Treatment selections are very limited for patients with advanced nasopharyngeal carcinoma (NPC) experiencing disease progression. Uncovering mechanisms underlying NPC progression is crucial for the development of novel treatments. Here we show that N-7-methylguanosine (m(7)G) tRNA modification enzyme METTL1 and its partner WDR4 are significantly elevated in NPC and are associated with poor prognosis. Loss-of-function and gain-of-function assays demonstrated that METTL1/WDR4 promotes NPC growth and metastasis in vitro and in vivo. Mechanistically, ARNT was identified as an upstream transcription factor regulating METTL1 expression in NPC. METTL1 depletion resulted in decreased m(7)G tRNA modification and expression, which led to impaired codon recognition during mRNA translation, therefore reducing the translation efficiencies of mRNAs with higher m(7)G codons. METTL1 upregulated the WNT/beta-catenin signaling pathway and promoted NPC cell epithelial-mesenchymal transition (EMT) and chemoresistance to cisplatin and docetaxel in vitro and in vivo. Overexpression of WNT3A bypassed the requirement of METTL1 for EMT and chemoresistance. This work uncovers novel insights into tRNA modification-mediated mRNA translation regulation and highlights the critical function of tRNA modification in cancer progression.	[Chen, Binbin; Peng, Hao] Sun Yat Sen Univ, Affiliated Hosp 1, Precis Med Inst, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China; [Chen, Binbin] Sun Yat Sen Univ, Dept Clin Nutr, Canc Ctr, State Key Lab Oncol South China,Collaborat Innova, Guangzhou 510060, Peoples R China; [Jiang, Wei] Guilin Med Univ, Affiliated Hosp, Dept Radiat Oncol, Guilin 541001, Peoples R China; [Huang, Ying] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, State Key Lab Oncol South China,Collaborat Innova, Guangzhou 510060, Peoples R China; [Zhang, Jian; Yu, Peng] Guangzhou Inst Resp Dis, Dept Radiat Oncol, Affiliated Canc Hosp, Guangzhou 510095, Peoples R China; [Zhang, Jian; Yu, Peng] Inst Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou Inst Resp Dis, Guangzhou 510095, Peoples R China; [Wu, Lirong] Nanjing Med Univ, Dept Radiat Oncol, Jiangsu Canc Hosp, Nanjing 210009, Peoples R China; [Wu, Lirong] Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 210009, Peoples R China; [Wu, Lirong] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 210009, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Guilin Medical University; State Key Lab Oncology South China; Sun Yat Sen University; State Key Laboratory of Respiratory Disease; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Peng, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Precis Med Inst, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China.; Wu, LR (corresponding author), Nanjing Med Univ, Dept Radiat Oncol, Jiangsu Canc Hosp, Nanjing 210009, Peoples R China.; Wu, LR (corresponding author), Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 210009, Peoples R China.; Wu, LR (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 210009, Peoples R China.	wulirong126@126.com; pengh67@mail.sysu.edu.cn			National Natural Science Foundation of China [82002981, 82003232, 82003212]; China Postdoctoral Science Foundation [2020M673003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We sincerely thank professor Jun Ma (Department of Radiation Oncology, Sun Yat-sen University Cancer Center) for kindly donate the NPC cell lines and nasopharyngeal normal cell lines. We sincerely thank Drs. Weidong Ji and Shuibin Lin for kindly sharing us with the plasmids for METTL1 overexpression and depletion. We thank all the patients who generously donate the tissues. The work was funded by National Natural Science Foundation of China (82002981, 82003232 and 82003212) and China Postdoctoral Science Foundation (2020M673003).	Alexandrov A, 2002, RNA, V8, P1253, DOI 10.1017/S1355838202024019; Bernaudo S, 2016, ONCOGENE, V35, P4828, DOI 10.1038/onc.2016.65; Blanco S, 2014, EMBO J, V33, P2020, DOI 10.15252/embj.201489282; Boccaletto P, 2018, NUCLEIC ACIDS RES, V46, pD202, DOI 10.1093/nar/gkx966; Boccaletto P, 2018, NUCLEIC ACIDS RES, V46, pD303, DOI 10.1093/nar/gkx1030; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chang GQ, 2020, CANCER CELL, V38, P857, DOI 10.1016/j.ccell.2020.10.004; Chen G, 2020, MOL CARCINOGEN, V59, P897, DOI 10.1002/mc.23201; Chen X, 2018, EUR J MED GENET, V61, P468, DOI 10.1016/j.ejmg.2018.03.007; Chen XY, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1033-z; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Chou HJ, 2017, MOL CELL, V68, P978, DOI 10.1016/j.molcel.2017.11.002; Dai ZH, 2021, MOL CELL, V81, P3339, DOI 10.1016/j.molcel.2021.07.003; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Frye M, 2018, SCIENCE, V361, P1346, DOI 10.1126/science.aau1646; Torres AG, 2014, TRENDS MOL MED, V20, P306, DOI 10.1016/j.molmed.2014.01.008; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Guy MP, 2015, HUM MUTAT, V36, P1176, DOI 10.1002/humu.22897; Han X, 2021, SEMIN CANCER BIOL, V75, P97, DOI 10.1016/j.semcancer.2020.11.007; Hong XH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01149-x; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huo FC, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12921; Kim SW, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1235; Kirchner S, 2015, NAT REV GENET, V16, P98, DOI 10.1038/nrg3861; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Leick KM, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1665978; Lin S., 2009, NAT PROTOC, V4, P44; Lin SB, 2018, MOL CELL, V71, P244, DOI 10.1016/j.molcel.2018.06.001; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Liu FG, 2016, CELL, V167, P816, DOI 10.1016/j.cell.2016.09.038; Liu J, 2019, TRENDS CELL BIOL, V29, P487, DOI 10.1016/j.tcb.2019.02.008; Liu L, 2020, MOL THER, V28, P2177, DOI 10.1016/j.ymthe.2020.06.024; Liu Y, 2020, LIFE SCI, V249, DOI 10.1016/j.lfs.2020.117480; Ma JY, 2021, MOL THER, V29, P3422, DOI 10.1016/j.ymthe.2021.08.005; Mao YP, 2008, CLIN CANCER RES, V14, P7497, DOI 10.1158/1078-0432.CCR-08-0271; Mao YP, 2009, INT J RADIAT ONCOL, V73, P1326, DOI 10.1016/j.ijrobp.2008.07.062; Michaud J, 2000, GENOMICS, V68, P71, DOI 10.1006/geno.2000.6258; Najmabadi H, 2011, NATURE, V478, P57, DOI 10.1038/nature10423; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Okamoto M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004639; Orellana EA, 2021, MOL CELL, V81, P3323, DOI 10.1016/j.molcel.2021.06.031; Pan JJ, 2016, CANCER-AM CANCER SOC, V122, P546, DOI 10.1002/cncr.29795; Pan T, 2018, CELL RES, V28, P395, DOI 10.1038/s41422-018-0013-y; Peng H, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0997-7; Persson CU, 2020, EXP CELL RES, V388, DOI 10.1016/j.yexcr.2020.111845; Pinello N, 2018, CANCER BIOL MED, V15, P323, DOI 10.20892/j.issn.2095-3941.2018.0365; Polakis P, 2000, GENE DEV, V14, P1837; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ren XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14053; Schimmel P, 2018, NAT REV MOL CELL BIO, V19, P45, DOI 10.1038/nrm.2017.77; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Shaheen R, 2016, HUM GENET, V135, P707, DOI 10.1007/s00439-016-1665-7; Shaheen R, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0779-x; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Song P, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01244-z; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Terashima J, 2016, CELL BIOL INT, V40, P1187, DOI 10.1002/cbin.10656; Tian QH, 2019, J MOL MED, V97, P1535, DOI 10.1007/s00109-019-01830-9; Trimouille A, 2018, CLIN GENET, V93, P374, DOI 10.1111/cge.13074; Wu LR, 2017, ORAL ONCOL, V69, P26, DOI 10.1016/j.oraloncology.2017.03.015; Zhang J, 2020, AGING-US, V12, P5423, DOI 10.18632/aging.102968; Zhang PP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1224-3; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	64	11	11	5	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2239	2253		10.1038/s41388-022-02250-9	http://dx.doi.org/10.1038/s41388-022-02250-9		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35217794				2022-12-28	WOS:000761868000003
J	Baker, SC; Mason, AS; Slip, RG; Skinner, KT; Macdonald, A; Masood, O; Harris, RS; Fenton, TR; Periyasamy, M; Ali, S; Southgate, J				Baker, Simon C.; Mason, Andrew S.; Slip, Raphael G.; Skinner, Katie T.; Macdonald, Andrew; Masood, Omar; Harris, Reuben S.; Fenton, Tim R.; Periyasamy, Manikandan; Ali, Simak; Southgate, Jennifer			Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a hit-and-run driver for bladder cancer	ONCOGENE			English	Article							TRANSPLANT RECIPIENTS; MUTATIONAL SIGNATURES; DEAMINASE APOBEC3B; GENE-EXPRESSION; JC VIRUS; RISK; PROLIFERATION; INFECTION; CELLS; REPLICATION	Limited understanding of bladder cancer aetiopathology hampers progress in reducing incidence. Mutational signatures show the anti-viral apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) enzymes are responsible for the preponderance of mutations in bladder tumour genomes, but no causative viral agent has been identified. BK polyomavirus (BKPyV) is a common childhood infection that remains latent in the adult kidney, where reactivation leads to viruria. This study provides missing mechanistic evidence linking reactivated BKPyV-infection to bladder cancer risk. We used a mitotically-quiescent, functionally-differentiated model of normal human urothelium to examine BKPyV-infection. BKPyV-infection led to significantly elevated APOBEC3A and APOBEC3B protein, increased deaminase activity and greater numbers of apurinic/apyrimidinic sites in the host urothelial genome. BKPyV Large T antigen (LT-Ag) stimulated re-entry from G0 into the cell cycle through inhibition of retinoblastoma protein and activation of EZH2, E2F1 and FOXM1, with cells arresting in G2. The single-stranded DNA displacement loops formed in urothelial cells during BKPyV-infection interacted with LT-Ag to provide a substrate for APOBEC3-activity. Addition of interferon gamma (IFN gamma) to infected urothelium suppressed expression of the viral genome. These results support reactivated BKPyV infections in adults as a risk factor for bladder cancer in immune-insufficient populations.	[Baker, Simon C.; Mason, Andrew S.; Slip, Raphael G.; Skinner, Katie T.; Southgate, Jennifer] Univ York, Dept Biol, Jack Birch Unit Mol Carcinogenesis, York YO10 5DD, N Yorkshire, England; [Baker, Simon C.; Mason, Andrew S.; Slip, Raphael G.; Skinner, Katie T.; Southgate, Jennifer] Univ York, York Biomed Res Inst, York YO10 5DD, N Yorkshire, England; [Macdonald, Andrew] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Pathol, Leeds, W Yorkshire, England; [Masood, Omar] St James Univ Hosp, Leeds Kidney Unit, Leeds, W Yorkshire, England; [Harris, Reuben S.] Univ Minnesota, Coll Biol Sci, Minneapolis, MN 55455 USA; [Fenton, Tim R.] Univ Kent, Sch Biosci, Canterbury CT2 7NJ, Kent, England; [Periyasamy, Manikandan; Ali, Simak] Imperial Coll London, Fac Med, Dept Surg & Canc, London, England; [Fenton, Tim R.] Univ Southampton, Fac Med, Sch Canc Sci, Canc Res UK Ctr, Southampton SO16 6YD, Hants, England; [Periyasamy, Manikandan] Inst Mol & Cell Biol IMCB, Dis Intervent Technol Lab DITL, Neuros Immunos, 8A Biomedical Grove,Neuros Immunos 06-04-05, Singapore 060405, Singapore	University of York - UK; University of York - UK; University of Leeds; Saint James's University Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Kent; Imperial College London; Cancer Research UK; University of Southampton; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Baker, SC (corresponding author), Univ York, Dept Biol, Jack Birch Unit Mol Carcinogenesis, York YO10 5DD, N Yorkshire, England.; Baker, SC (corresponding author), Univ York, York Biomed Res Inst, York YO10 5DD, N Yorkshire, England.	simon.baker@york.ac.uk	Southgate, Jennifer/AAJ-9089-2021; Ali, Simak/M-6912-2018	Southgate, Jennifer/0000-0002-0135-480X; Fenton, Tim/0000-0002-4737-8233; Ali, Simak/0000-0002-1320-0816; Baker, Simon/0000-0002-2755-6012; Slip, Raphael Grettir/0000-0002-5218-2251; Harris, Reuben/0000-0002-9034-9112; Macdonald, Andrew/0000-0002-5978-4693	York Against Cancer	York Against Cancer	This study was funded by York Against Cancer.	Abend JR, 2007, J VIROL, V81, P272, DOI 10.1128/JVI.01571-06; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Baker SC, 2020, EUR UROL, V78, P143, DOI 10.1016/j.eururo.2020.03.049; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Caller LG, 2019, J VIROL, V93, DOI 10.1128/JVI.00595-19; Chen X, 2013, MOL CELL BIOL, V33, P227, DOI 10.1128/MCB.00881-12; CHESTERS PM, 1983, J INFECT DIS, V147, P676, DOI 10.1093/infdis/147.4.676; Cortez LM, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008545; Cross WR, 2005, AM J PHYSIOL-RENAL, V289, pF459, DOI 10.1152/ajprenal.00040.2005; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; Engels EA, 2011, JAMA-J AM MED ASSOC, V306, P1891, DOI 10.1001/jama.2011.1592; Erickson KD, 2019, VIROLOGY, V528, P198, DOI 10.1016/j.virol.2018.12.014; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fulciniti M, 2018, CELL REP, V25, P3693, DOI 10.1016/j.celrep.2018.12.016; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Gupta G, 2018, AM J TRANSPLANT, V18, P245, DOI 10.1111/ajt.14530; Jalili P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16802-8; KATAJA V, 1993, AM J EPIDEMIOL, V138, P735, DOI 10.1093/oxfordjournals.aje.a116911; Kean JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000363; Kesherwani V, 2019, VACCINE, V37, P3457, DOI 10.1016/j.vaccine.2019.04.096; Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587-019-0201-4; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Lawson ARJ, 2020, SCIENCE, V370, P75, DOI 10.1126/science.aba8347; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li RM, 2013, VIROLOGY, V440, P41, DOI 10.1016/j.virol.2013.01.024; Linke SP, 2003, CANCER RES, V63, P2596; Llewellyn MA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29438-y; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Middlebrooks CD, 2016, NAT GENET, V48, P1330, DOI 10.1038/ng.3670; Mohammadi MH, 2021, VIROL J, V18, DOI 10.1186/s12985-021-01582-4; Nickeleit V, 1999, J AM SOC NEPHROL, V10, P1080; Panou MM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030902; Periyasamy M, 2017, NUCLEIC ACIDS RES, V45, P11056, DOI 10.1093/nar/gkx721; Pimentel H, 2017, NAT METHODS, V14, P687, DOI 10.1038/nmeth.4324; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Roelofs PA, 2020, ELIFE, V9, DOI 10.7554/eLife.61287; Solovjeva L, 2015, BMC MOL BIOL, V16, DOI 10.1186/s12867-015-0046-4; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Starrett GJ, 2019, MBIO, V10, DOI 10.1128/mBio.02690-18; Thielen BK, 2010, J BIOL CHEM, V285, P27753, DOI 10.1074/jbc.M110.102822; Tokunaga R, 2018, CANCER TREAT REV, V63, P40, DOI 10.1016/j.ctrv.2017.11.007; Tylden GD, 2015, ANTIMICROB AGENTS CH, V59, P3306, DOI 10.1128/AAC.00238-15; Varley C, 2005, EXP CELL RES, V306, P216, DOI 10.1016/j.yexcr.2005.02.004; Verhalen B, 2016, J VIROL, V90, P6379, DOI 10.1128/JVI.00771-16; Weinreb DB, 2006, DIAGN CYTOPATHOL, V34, P201, DOI 10.1002/dc.20429; Xiao YF, 2014, BIOINFORMATICS, V30, P801, DOI 10.1093/bioinformatics/btr671; Yu J, 2019, CANCER MANAG RES, V11, P157, DOI 10.2147/CMAR.S185796; Zapatka M, 2020, NAT GENET, V52, P320, DOI 10.1038/s41588-019-0558-9; Zareei N, 2019, MICROB PATHOGENESIS, V129, P187, DOI 10.1016/j.micpath.2019.02.015	51	3	3	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2139	2151		10.1038/s41388-022-02235-8	http://dx.doi.org/10.1038/s41388-022-02235-8		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35194151	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000759404700002
J	de Wet, L; Williams, A; Gillard, M; Kregel, S; Lamperis, S; Gutgesell, LC; Vellky, JE; Brown, R; Conger, K; Paner, GP; Wang, H; Platz, EE; De Marzo, AM; Mu, P; Coloff, JL; Szmulewitz, RZ; Vander Griend, DJ				de Wet, Larischa; Williams, Anthony; Gillard, Marc; Kregel, Steven; Lamperis, Sophia; Gutgesell, Lisa C.; Vellky, Jordan E.; Brown, Ryan; Conger, Kelly; Paner, Gladell P.; Wang, Heng; Platz, Elizabeth E.; De Marzo, Angelo M.; Mu, Ping; Coloff, Jonathan L.; Szmulewitz, Russell Z.; Vander Griend, Donald J.			SOX2 mediates metabolic reprogramming of prostate cancer cells	ONCOGENE			English	Article							LINEAGE PLASTICITY; SIGNALING PATHWAY; STEM; EXPRESSION; RESISTANCE; ADULT; AMPLIFICATION; ABIRATERONE; METASTASIS; MARKERS	New strategies are needed to predict and overcome metastatic progression and therapy resistance in prostate cancer. One potential clinical target is the stem cell transcription factor SOX2, which has a critical role in prostate development and cancer. We thus investigated the impact of SOX2 expression on patient outcomes and its function within prostate cancer cells. Analyses of SOX2 expression among a case-control cohort of 1028 annotated tumor specimens demonstrated that SOX2 expression confers a more rapid time to metastasis and decreased patient survival after biochemical recurrence. SOX2 ChIP-Seq analyses revealed SOX2-binding sites within prostate cancer cells which differ significantly from canonical embryonic SOX2 gene targets, and prostate-specific SOX2 gene targets are associated with multiple oncogenic pathways. Interestingly, phenotypic and gene expression analyses after CRISPR-mediated deletion of SOX2 in castration-resistant prostate cancer cells, as well as ectopic SOX2 expression in androgen-sensitive prostate cancer cells, demonstrated that SOX2 promotes changes in multiple metabolic pathways and metabolites. SOX2 expression in prostate cancer cell lines confers increased glycolysis and glycolytic capacity, as well as increased basal and maximal oxidative respiration and increased spare respiratory capacity. Further, SOX2 expression was associated with increased quantities of mitochondria, and metabolomic analyses revealed SOX2-associated changes in the metabolism of purines, pyrimidines, amino acids and sugars, and the pentose phosphate pathway. Analyses of SOX2 gene targets with central functions metabolism (CERK, ECHS1, HS6SDT1, LPCAT4, PFKP, SLC16A3, SLC46A1, and TST) document significant expression correlation with SOX2 among RNA-Seq datasets derived from patient tumors and metastases. These data support a key role for SOX2 in metabolic reprogramming of prostate cancer cells and reveal new mechanisms to understand how SOX2 enables metastatic progression, lineage plasticity, and therapy resistance. Further, our data suggest clinical opportunities to exploit SOX2 as a biomarker for staging and imaging, as well as a potential pharmacologic target.	[de Wet, Larischa; Kregel, Steven] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; [Williams, Anthony; Gillard, Marc; Szmulewitz, Russell Z.] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA; [Lamperis, Sophia; Gutgesell, Lisa C.; Vellky, Jordan E.; Brown, Ryan; Vander Griend, Donald J.] Univ Illinois, Dept Pathol, Chicago, IL 60637 USA; [Conger, Kelly; Coloff, Jonathan L.] Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60637 USA; [Paner, Gladell P.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Wang, Heng] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL 60607 USA; [Platz, Elizabeth E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [De Marzo, Angelo M.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21218 USA; [De Marzo, Angelo M.] Johns Hopkins Univ, Dept Urol, Baltimore, MD 21218 USA; [De Marzo, Angelo M.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21218 USA; [De Marzo, Angelo M.] Johns Hopkins Univ, Brady Urol Res Inst, Baltimore, MD 21218 USA; [De Marzo, Angelo M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21218 USA; [Mu, Ping] Univ Texas Southwestern Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Southwestern Medical Center Dallas	Vander Griend, DJ (corresponding author), Univ Illinois, Dept Pathol, Chicago, IL 60637 USA.	dvanderg@uic.edu		Lamperis, Sophia/0000-0001-9346-1639	University of Chicago Comprehensive Cancer Center Support Grant [P30CA014599]; The Brinson Foundation; Alvin Baum Family Fund; The Pierce Foundation; National Center for Advancing Translational Sciences [UL1TR002003]; Department of Defense Prostate Cancer Research Program [W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH14-2-0186, W81XWH-15-2-0062, W81XWH-18-1-0411]; Goldblatt Foundation Fellowship; Cancer Biology Training Grant [T32 CA 009594]; CPRIT [RR170050]; Welch Foundation [I-2005-20190330]; Prostate Cancer Foundation [17YOUN12];  [R01CA178431];  [R00CA218885-04]	University of Chicago Comprehensive Cancer Center Support Grant; The Brinson Foundation; Alvin Baum Family Fund; The Pierce Foundation; National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Department of Defense Prostate Cancer Research Program(United States Department of Defense); Goldblatt Foundation Fellowship; Cancer Biology Training Grant; CPRIT; Welch Foundation(The Welch Foundation); Prostate Cancer Foundation; ; 	R01CA178431 (DJ Vander Griend), R00CA218885-04 (P.M.); University of Chicago Comprehensive Cancer Center Support Grant (P30CA014599); The Brinson Foundation; Alvin Baum Family Fund; The Pierce Foundation; and National Center for Advancing Translational Sciences (UL1TR002003). The Prostate Cancer Biorepository Network is funded by the Department of Defense Prostate Cancer Research Program Award No. W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH14-2-0186, and W81XWH-15-2-0062, and W81XWH-18-1-0411 (P.M.). L. de Wet was supported by the Goldblatt Foundation Fellowship; S. Kregel was supported by a Cancer Biology Training Grant (T32 CA 009594). P.M. is also supported by CPRIT (RR170050), Welch Foundation (I-2005-20190330) and Prostate Cancer Foundation (17YOUN12).	Alonso MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026740; Annovazzi L, 2011, CANCER GENOM PROTEOM, V8, P139; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Bhanvadia RR, 2018, CLIN CANCER RES, V24, P3668, DOI 10.1158/1078-0432.CCR-17-3673; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chen S, 2014, CARCINOGENESIS, V35, P613, DOI 10.1093/carcin/bgt371; Chen SS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0050456, 10.1371/journal.pone.0036784, 10.1371/journal.pone.0049275, 10.1371/journal.pone.0045763]; Cutruzzola F, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00097; Dracopoli NC, 1994, CURRENT PROTOCOLS HU; Elia I, 2018, TRENDS CELL BIOL, V28, P673, DOI 10.1016/j.tcb.2018.04.002; Fraum TJ, 2018, CAN J UROL, V25, P9371; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Griend DJV, 2008, CANCER RES, V68, P9703, DOI 10.1158/0008-5472.CAN-08-3084; Han X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041335; Hempel HA, 2017, PROSTATE, V77, P412, DOI 10.1002/pros.23280; Herreros-Villanueva M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.23; Hutz K, 2014, CARCINOGENESIS, V35, P942, DOI 10.1093/carcin/bgt410; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Jadvar H, 2016, SEMIN NUCL MED, V46, P502, DOI 10.1053/j.semnuclmed.2016.07.004; Ji J, 2010, HUM PATHOL, V41, P1438, DOI 10.1016/j.humpath.2009.11.021; Jia XP, 2011, J MOL CELL BIOL, V3, P230, DOI 10.1093/jmcb/mjr002; Kar S, 2017, BBA-MOL BASIS DIS, V1863, P253, DOI 10.1016/j.bbadis.2016.11.001; Kregel S, 2016, ONCOTARGET, V7, P26259, DOI 10.18632/oncotarget.8456; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kwon OJ, 2020, ONCOGENE, V39, P7142, DOI 10.1038/s41388-020-01487-6; Li HY, 2020, LAB INVEST, V100, P570, DOI 10.1038/s41374-019-0343-5; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu P, 2016, GENOME RES, V26, P1124, DOI 10.1101/gr.199174.115; Lou XY, 2013, OMICS, V17, P510, DOI 10.1089/omi.2013.0058; Lowrance WT, 2021, J UROLOGY, V205, P22, DOI 10.1097/JU.0000000000001376; Maier S, 2011, HUM PATHOL, V42, P1078, DOI 10.1016/j.humpath.2010.11.010; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Matsika A, 2015, PATHOLOGY, V47, P622, DOI 10.1097/PAT.0000000000000325; McAuley E, 2019, STEM CELLS, V37, P690, DOI 10.1002/stem.2987; Metz EP, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07370-7; Metz EP, 2020, J CELL PHYSIOL, V235, P3731, DOI 10.1002/jcp.29267; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Pflueger D, 2011, GENOME RES, V21, P56, DOI 10.1101/gr.110684.110; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Russo MV, 2016, ONCOTARGET, V7, P12372, DOI 10.18632/oncotarget.6029; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Schlomm T, 2016, EUR UROL, V69, P1157, DOI 10.1016/j.eururo.2016.02.024; Sedelaar JPM, 2013, PROSTATE, V73, P1316, DOI 10.1002/pros.22677; Stolzenburg S, 2012, TARGETED SILENCING O; Sun C, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0503-1; Toubaji A, 2011, MODERN PATHOL, V24, P1511, DOI 10.1038/modpathol.2011.111; Ugolkov AV, 2011, PROSTATE, V71, P18, DOI 10.1002/pros.21217; Van den Broeck T, 2019, EUR UROL, V75, P967, DOI 10.1016/j.eururo.2018.10.011; Varum S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020914; Vazquez-Martin A, 2013, CELL CYCLE, V12, P3471, DOI 10.4161/cc.26692; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wang MH, 2009, CANCER EPIDEM BIOMAR, V18, P706, DOI 10.1158/1055-9965.EPI-08-0839; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wegner M, 2010, INT J BIOCHEM CELL B, V42, P381, DOI 10.1016/j.biocel.2009.07.006; Whitburn J, 2021, CURR OSTEOPOROS REP, V19, P494, DOI 10.1007/s11914-021-00695-7; Wuebben EL, 2017, ONCOTARGET, V8, P44917, DOI 10.18632/oncotarget.16570; Yoo YA, 2019, JNCI-J NATL CANCER I, V111, P311, DOI 10.1093/jnci/djy142; Yu X, 2014, PROSTATE CANCER P D, V17, P301, DOI 10.1038/pcan.2014.29; Zhang Shuchen, 2014, World J Stem Cells, V6, P305, DOI 10.4252/wjsc.v6.i3.305; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhang ZD, 2020, CANCER CELL, V37, P584, DOI 10.1016/j.ccell.2020.03.001; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	68	9	9	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1190	1202		10.1038/s41388-021-02157-x	http://dx.doi.org/10.1038/s41388-021-02157-x		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35067686	Green Accepted			2022-12-28	WOS:000745771900001
J	Very, N; Hardiville, S; Decourcelle, A; Thevenet, J; Djouina, M; Page, A; Vergoten, G; Schulz, C; Kerr-Conte, J; Lefebvre, T; Dehennaut, V; El Yazidi-Belkoura, I				Very, Ninon; Hardiville, Stephan; Decourcelle, Amelie; Thevenet, Julien; Djouina, Madjid; Page, Adeline; Vergoten, Gerard; Schulz, Celine; Kerr-Conte, Julie; Lefebvre, Tony; Dehennaut, Vanessa; El Yazidi-Belkoura, Ikram			Thymidylate synthase O-GlcNAcylation: a molecular mechanism of 5-FU sensitization in colorectal cancer	ONCOGENE			English	Article							STRUCTURAL DETERMINANTS; FORCE-FIELD; 5-FLUOROURACIL; DEGRADATION; PHOSPHORYLATION; RESISTANCE; PURIFICATION; EXPRESSION; CISPLATIN; GLCNACASE	Alteration of O-GlcNAcylation, a dynamic posttranslational modification, is associated with tumorigenesis and tumor progression. Its role in chemotherapy response is poorly investigated. Standard treatment for colorectal cancer (CRC), 5-fluorouracil (5-FU), mainly targets Thymidylate Synthase (TS). TS O-GlcNAcylation was reported but not investigated yet. We hypothesize that O-GlcNAcylation interferes with 5-FU CRC sensitivity by regulating TS. In vivo, we observed that combined 5-FU with Thiamet-G (O-GlcNAcase (OGA) inhibitor) treatment had a synergistic inhibitory effect on grade and tumor progression. 5-FU decreased O-GlcNAcylation and, reciprocally, elevation of O-GlcNAcylation was associated with TS increase. In vitro in non-cancerous and cancerous colon cells, we showed that 5-FU impacts O-GlcNAcylation by decreasing O-GlcNAc Transferase (OGT) expression both at mRNA and protein levels. Reciprocally, OGT knockdown decreased 5-FU-induced cancer cell apoptosis by reducing TS protein level and activity. Mass spectrometry, mutagenesis and structural studies mapped O-GlcNAcylated sites on T251 and T306 residues and deciphered their role in TS proteasomal degradation. We reveal a crosstalk between O-GlcNAcylation and 5-FU metabolism in vitro and in vivo that converges to 5-FU CRC sensitization by stabilizing TS. Overall, our data propose that combining 5-FU-based chemotherapy with Thiamet-G could be a new way to enhance CRC response to 5-FU.	[Very, Ninon; Hardiville, Stephan; Schulz, Celine; Lefebvre, Tony; El Yazidi-Belkoura, Ikram] Univ Lille, CNRS, UMR 8576, UGSF,Unite Glycobiol Struct & Fonct, F-59000 Lille, France; [Decourcelle, Amelie; Dehennaut, Vanessa] Univ Lille, CNRS, INSERM, CHU Lille,UMR9020 U1277 CANTHER Canc Heterogene P, F-59000 Lille, France; [Thevenet, Julien; Kerr-Conte, Julie] Univ Lille, INSERM, CHU Lille, Inst Pasteur Lille,U1190,EGID, F-59000 Lille, France; [Djouina, Madjid; Vergoten, Gerard] Univ Lille, INSERM, CHU Lille, U1286,Inst Translat Res Inflammat,INFINITE, F-59000 Lille, France; [Page, Adeline] UCBL, SFR BioSci, Prot Sci Facil, CNRS UMS3444,INSERM US8,ENS Lyon, Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	El Yazidi-Belkoura, I (corresponding author), Univ Lille, CNRS, UMR 8576, UGSF,Unite Glycobiol Struct & Fonct, F-59000 Lille, France.	ikram.el-yazidi@univ-lille.fr	DJOUINA, MADJID/GYV-1455-2022; El Yazidi-Belkoura, Ikram/AAE-8805-2022	DJOUINA, MADJID/0000-0003-3557-4103; Hardiville, Stephan/0000-0002-3554-277X; page, adeline/0000-0001-7885-1014; EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509	Ligue Contre le Cancer/Comite du Nord/Comite de la Somme; "Region Hauts-de-France" (Cancer Regional Program); University of Lille; Center National de la Recherche Scientifique; Ministere de l'Enseignement Superieur et de la Recherche; ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante, National Alliance for Life Sciences and Health)	Ligue Contre le Cancer/Comite du Nord/Comite de la Somme; "Region Hauts-de-France" (Cancer Regional Program); University of Lille; Center National de la Recherche Scientifique; Ministere de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission); ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante, National Alliance for Life Sciences and Health)	This work was supported by the "Ligue Contre le Cancer/Comite du Nord/Comite de la Somme", the "Region Hauts-de-France" (Cancer Regional Program), the University of Lille and the "Center National de la Recherche Scientifique". NV is the recipient of a fellowship from the "Ministere de l'Enseignement Superieur et de la Recherche". The authors acknowledge the financial support from ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante, National Alliance for Life Sciences and Health) within the framework of the cancer plan for Orbitrap mass spectrometer funding. We thank Dr. Guillemette Huet (CANTHER UMR9020 UMR1277, Lille, France) for HT-29 5F31 cell line [26], Dr. Matthew G. Alteen (Department of Chemistry, Simon Fraser University, Canada) for Thiamet-G and Dr. Cyril Couturier (UMR8090 IBL, Lille, France) for pcDNA3.1-Ub-HA plasmid gifts.	Almog R, 2001, PROTEIN SCI, V10, P988, DOI 10.1110/ps.47601; Anderson DD, 2007, CLIN CHEM LAB MED, V45, P1760, DOI 10.1515/CCLM.2007.355; Bai WQ, 2015, INT J CLIN EXP PATHO, V8, P12333; Barbour KW, 2013, BIOSCIENCE REP, V33, P165, DOI 10.1042/BSR20120112; Becker C, 2005, GUT, V54, P950, DOI 10.1136/gut.2004.061283; Chanama S, 2017, SE ASIAN J TROP MED, V48, P722; de Queiroz RM, 2016, J BIOL CHEM, V291, P18897, DOI 10.1074/jbc.M116.734533; Decourcelle A, 2020, CANCERS, V12, DOI 10.3390/cancers12113168; Decourcelle A, 2020, BIOCHEM BIOPH RES CO, V521, P125, DOI 10.1016/j.bbrc.2019.10.090; Etienne MC, 2004, BRIT J CANCER, V90, P526, DOI 10.1038/sj.bjc.6601523; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Forsthoefel AM, 2004, BIOCHEMISTRY-US, V43, P1972, DOI 10.1021/bi035894p; Fraczyk T, 2015, BBA-PROTEINS PROTEOM, V1854, P1922, DOI 10.1016/j.bbapap.2015.08.007; Fraczyk T, 2010, BIOORG CHEM, V38, P124, DOI 10.1016/j.bioorg.2010.02.001; Gajjar, 2021, INFL THYM SYNTH EXPR; Hahne H, 2013, J PROTEOME RES, V12, P927, DOI 10.1021/pr300967y; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hanover JA, 2018, J BIOENERG BIOMEMBR, V50, P155, DOI 10.1007/s10863-018-9751-2; Hardiville S, 2020, MOL CELL, V77, P1143, DOI 10.1016/j.molcel.2019.11.022; Ishikawa M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-188; Jorgensen WL, 2005, J COMPUT CHEM, V26, P1689, DOI 10.1002/jcc.20297; Kang KA, 2016, ONCOTARGET, V7, P40594, DOI 10.18632/oncotarget.9745; Kanwal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069150; Kristensen MH, 2010, J INT MED RES, V38, P484, DOI 10.1177/147323001003800212; Lagant P, 2004, J PHYS CHEM A, V108, P4019, DOI [10.1021/jp031178l, 10.1021/jp0311781]; Lam C, 2021, CANCER LETT, V503, P11, DOI 10.1016/j.canlet.2021.01.010; Lee H, 2019, CANCER RES, V79, P2839, DOI 10.1158/0008-5472.CAN-18-1991; LESUFFLEUR T, 1991, INT J CANCER, V49, P721, DOI 10.1002/ijc.2910490516; Luanpitpong S, 2018, MOL CANCER THER, V17, P484, DOI 10.1158/1535-7163.MCT-17-0390; Luanpitpong S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10886-x; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; Nishiyama M, 1999, CLIN CANCER RES, V5, P2620; Olivier-Van Stichelen S, 2014, FASEB J, V28, P3325, DOI 10.1096/fj.13-243535; Palmirotta Raffaele, 2018, Oncotarget, V9, P25355, DOI 10.18632/oncotarget.25256; PEDERSON NV, 1994, MAGN RESON MED, V31, P224, DOI 10.1002/mrm.1910310217; Pena MMO, 2009, J BIOL CHEM, V284, P31597, DOI 10.1074/jbc.M109.038455; Pena MMO, 2006, BIOCHEM J, V394, P355, DOI 10.1042/BJ20051479; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; PETERS GJ, 1995, EUR J CANCER, V31A, P1299, DOI 10.1016/0959-8049(95)00172-F; Pozzi C, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9040134; Raab S, 2021, CELL MOL LIFE SCI, V78, P5397, DOI 10.1007/s00018-021-03857-z; Rahman L, 2004, CANCER CELL, V5, P341, DOI 10.1016/S1535-6108(04)00080-7; Ruan HB, 2013, MOL CELL PROTEOMICS, V12, P3489, DOI 10.1074/mcp.R113.029751; Samsonoff WA, 1997, J BIOL CHEM, V272, P13281, DOI 10.1074/jbc.272.20.13281; Sekine H, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00252-18; Singh JP, 2020, ONCOGENE, V39, P560, DOI 10.1038/s41388-019-0975-3; Sprung R, 2005, J PROTEOME RES, V4, P950, DOI 10.1021/pr050033j; Stastna M, 2019, GENES-BASEL, V10, DOI 10.3390/genes10100788; Steenackers A, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00046; SWAIN SM, 1989, J CLIN ONCOL, V7, P890, DOI 10.1200/JCO.1989.7.7.890; Vergoten G, 2003, BIOCHIMIE, V85, P65, DOI 10.1016/S0300-9084(03)00052-X; Very N, 2018, ONCOTARGET, V9, P1380, DOI 10.18632/oncotarget.22377; Wakasa K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123076; Xi YG, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-68; Xie X, O GLCNAC REGULATES M, V2021, DOI 10.1101/2021.02.08.430201; Yang SZ, 2020, LAB INVEST, V100, P777, DOI 10.1038/s41374-019-0365-z; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22; Yang YR, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.24; Yang YR, 2012, AGING CELL, V11, P439, DOI 10.1111/j.1474-9726.2012.00801.x; Yu M, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.009; Yuzwa SA, 2008, NAT CHEM BIOL, V4, P483, DOI 10.1038/nchembio.96; Zhou FX, 2018, THERANOSTICS, V8, P5200, DOI 10.7150/thno.27806	62	4	4	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					745	756		10.1038/s41388-021-02121-9	http://dx.doi.org/10.1038/s41388-021-02121-9		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34845374	Green Submitted			2022-12-28	WOS:000723571700002
J	Chen, Y; Zhao, H; Liang, WL; Jiang, E; Zhou, XC; Shao, Z; Liu, K; Shang, ZJ				Chen, Yang; Zhao, Hui; Liang, Weilian; Jiang, Erhui; Zhou, Xiaocheng; Shao, Zhe; Liu, Ke; Shang, Zhengjun			Autophagy regulates the cancer stem cell phenotype of head and neck squamous cell carcinoma through the noncanonical FOXO3/SOX2 axis	ONCOGENE			English	Article							EXPRESSION; TUMOR; BMI1	Autophagy is an essential catabolic process that orchestrates cellular homeostasis and plays dual roles in tumor promotion and suppression. However, the mechanism by which autophagy affects the self-renewal of cancer stem cells (CSCs) remains unclear. In this study, we investigated whether autophagy activation contributes to CSC properties of head and neck squamous cell carcinoma (HNSCC). The results showed that the autophagy level and CSC properties of HNSCC cells were elevated in response to several adverse conditions, including treatment with cisplatin, starvation, and hypoxia. Pretreatment with autophagy inhibitors, such as 3-MA and chloroquine, diminished the CSC properties acquired under adverse conditions. In addition, the isolated CSCs were endowed with stronger autophagic activity than non-CSCs, and the CSC properties were dampened when autophagy was inhibited either by 3-MA, chloroquine, or Beclin1 knockdown. Notably, the tumor-initiating activity of CSCs was decreased upon knocking down Beclin1. Further study revealed that FOXO3, a substrate for autophagy, was enriched in the nucleus of cells with lower autophagy levels. Nuclear FOXO3 directly bound to the promoter region of SOX2 and negatively regulated its transcriptional activity. Overexpression of FOXO3 decreased the expression of SOX2 and thereby impaired the CSC phenotype both in vitro and in vivo. Taken together, our findings suggest that the activation of autophagy is essential for the acquisition of CSC properties in adverse conditions and the self-renewal of CSCs. We clarify the role of autophagy in regulating the CSC phenotype and demonstrate that the noncanonical FOXO3/SOX2 axis is the intrinsic regulatory mechanism.	[Chen, Yang; Zhao, Hui; Liang, Weilian; Jiang, Erhui; Zhou, Xiaocheng; Shao, Zhe; Liu, Ke; Shang, Zhengjun] Wuhan Univ, Hubei Prov & Key Lab Oral Biomed, State Key Lab Breeding Base Basic Sci Stomatol, Hubei MOST KLOS & KLOBM, Wuhan, Peoples R China; [Jiang, Erhui; Zhou, Xiaocheng; Shao, Zhe; Liu, Ke; Shang, Zhengjun] Wuhan Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Head & Neck Oncol, Wuhan, Peoples R China	Wuhan University; Wuhan University	Shang, ZJ (corresponding author), Wuhan Univ, Hubei Prov & Key Lab Oral Biomed, State Key Lab Breeding Base Basic Sci Stomatol, Hubei MOST KLOS & KLOBM, Wuhan, Peoples R China.	shangzhengjun@whu.edu.cn		Chen, Yang/0000-0002-9838-0843; shang, zhengjun/0000-0002-4884-8129	National Natural Science Foundation of China [81972547]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (Grant no. 81972547 to Z Shang). In addition, YC wants to thank, in particular, Ying Tang (Wuhan University) for her invaluable support over the past years.	Abbaszadegan MR, 2017, J CELL PHYSIOL, V232, P2008, DOI 10.1002/jcp.25759; Agro L, 2015, Bio Protoc, V5, P1; Alemohammad H, 2020, LIFE SCI, V260, DOI 10.1016/j.lfs.2020.118337; An YF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2308-4; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Buccarelli M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0864-7; Camuzard O, 2020, CANCER LETT, V490, P143, DOI 10.1016/j.canlet.2020.06.015; Chaurasia M, 2019, AUTOPHAGY, V15, P1391, DOI 10.1080/15548627.2019.1582973; Chen Y, 2020, J CELL PHYSIOL, V235, P5995, DOI 10.1002/jcp.29525; Chow LQM, 2020, NEW ENGL J MED, V382, P60, DOI 10.1056/NEJMra1715715; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; Fitzwalter BE, 2018, DEV CELL, V44, P555, DOI 10.1016/j.devcel.2018.02.014; Folkerts H, 2019, MED RES REV, V39, P517, DOI 10.1002/med.21531; Gasch C, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0601-3; Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252; Hao CC, 2019, THER ADV RESPIR DIS, V13, DOI 10.1177/1753466619866097; Hornsveld M, 2018, SEMIN CANCER BIOL, V50, P90, DOI 10.1016/j.semcancer.2017.11.017; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jia LF, 2020, CELL STEM CELL, V27, P238, DOI 10.1016/j.stem.2020.06.022; Jiramongkol Y, 2020, CANCER METAST REV, V39, P681, DOI 10.1007/s10555-020-09883-w; Khammanivong A, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-260; Kumazoe M, 2017, ONCOGENE, V36, P2643, DOI 10.1038/onc.2016.426; Kumazoe M, 2017, J BIOL CHEM, V292, P10813, DOI 10.1074/jbc.M116.772111; Li K, 2019, EBIOMEDICINE, V48, P70, DOI 10.1016/j.ebiom.2019.09.027; Liu H, 2020, CELL DEATH DIFFER, V27, P966, DOI 10.1038/s41418-019-0389-3; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Liu YQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0751-3; Marie-Egyptienne DT, 2013, CANCER LETT, V341, P63, DOI 10.1016/j.canlet.2012.11.019; Muhammad N, 2017, CLIN CANCER RES, V23, P3120, DOI 10.1158/1078-0432.CCR-16-2811; Nakano T, 2021, J DENT RES, V100, P377, DOI 10.1177/0022034520965141; Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y; Peng QH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0644-8; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Siegel RL., 2020, CA-CANCER J CLIN, V70; Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6; Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222; Sun XY, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110623; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Yang LQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0110-5; Yang MC, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0449-3; Yang WY, 2019, CANCER LETT, V451, P34, DOI 10.1016/j.canlet.2019.02.052; Yeo SK, 2016, CANCER RES, V76, P3397, DOI 10.1158/0008-5472.CAN-15-2946; Yu SS, 2020, J CELL PHYSIOL, V235, P65, DOI 10.1002/jcp.28963	46	2	2	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					634	646		10.1038/s41388-021-02115-7	http://dx.doi.org/10.1038/s41388-021-02115-7		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34795388	Green Published, hybrid			2022-12-28	WOS:000720257200001
J	Ren, SW; Zhang, N; Shen, LP; Lu, YY; Chang, YX; Lin, ZN; Sun, N; Zhang, YM; Xu, JH; Huang, HS; Jin, HL				Ren, Shuwei; Zhang, Ning; Shen, Liping; Lu, Yongyong; Chang, Yixin; Lin, Zhenni; Sun, Ning; Zhang, Yuanmei; Xu, Jiheng; Huang, Haishan; Jin, Honglei			Lnc00892 competes with c-Jun to block NCL transcription, reducing the stability of RhoA/RhoC mRNA and impairing bladder cancer invasion	ONCOGENE			English	Article							LONG NONCODING RNA; RHO-GTPASES; LNCRNA; EXPRESSION; LOCALIZATION	Metastasis of bladder cancer is a complex process and has been associated with poor clinical outcomes. However, the mechanisms of bladder cancer metastasis remain largely unknown. The present study found that the long noncoding RNA lnc00892 was significantly downregulated in bladder cancer tissues, with low lnc00892 expression associated with poor prognosis of bladder cancer patients. Lnc00892 significantly inhibited the migration, invasion, and metastasis of bladder cancer cells in vitro and in vivo. In-depth analysis showed that RhoA/C acted downstream of lnc00892 to inhibit bladder cancer metastasis. Mechanistically, lnc00892 reduces nucleolin gene transcription by competitively binding the promoter of nucleolin with c-Jun, thereby inhibiting nucleolin-mediated stabilization of RhoA/RhoC mRNA. Taken together, these findings provide novel insights into understanding the mechanisms of bladder cancer metastasis and suggest that lnc00892 can serve as a potential therapeutic target in patients with invasive bladder cancer.	[Ren, Shuwei; Zhang, Ning; Shen, Liping; Chang, Yixin; Lin, Zhenni; Sun, Ning; Zhang, Yuanmei; Xu, Jiheng; Huang, Haishan; Jin, Honglei] Wenzhou Med Univ, Sch Lab Med & Life Sci, Minist Educ, Zhejiang Prov Key Lab Med Genet,Key Lab Lab Med, Wenzhou, Zhejiang, Peoples R China; [Ren, Shuwei] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Clin Lab, Guangzhou, Guangdong, Peoples R China; [Lu, Yongyong] Wenzhou Med Univ, Affiliated Hosp 1, Dept Urol, Wenzhou, Zhejiang, Peoples R China	Wenzhou Medical University; Sun Yat Sen University; Wenzhou Medical University	Jin, HL (corresponding author), Wenzhou Med Univ, Sch Lab Med & Life Sci, Minist Educ, Zhejiang Prov Key Lab Med Genet,Key Lab Lab Med, Wenzhou, Zhejiang, Peoples R China.	jinhonglei@wmu.edu.cn	Xu, Jiheng/AAV-5732-2020	Xu, Jiheng/0000-0002-3538-3174	Natural Science Foundation of China [NSFC81702530]; Wenzhou Science and Technology Bureau [Y20190065]; Key Discipline of Zhejiang Province in Medical Technology	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wenzhou Science and Technology Bureau; Key Discipline of Zhejiang Province in Medical Technology	This work was partially supported by the Natural Science Foundation of China NSFC81702530, and Wenzhou Science and Technology Bureau (Y20190065), Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A).	Abdelmohsen K, 2010, WIRES RNA, V1, P214, DOI 10.1002/wrna.4; Amodio N, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0606-4; Berger CM, 2015, BIOCHIMIE, V113, P78, DOI 10.1016/j.biochi.2015.03.023; Caswell PT, 2009, NAT REV MOL CELL BIO, V10, P843, DOI 10.1038/nrm2799; Chen CH, 2020, J CLIN INVEST, V130, P404, DOI 10.1172/JCI130892; Chen CH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06152-x; Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Diring J, 2019, NAT CELL BIOL, V21, P845, DOI 10.1038/s41556-019-0337-y; Evans JR, 2016, J CLIN INVEST, V126, P2775, DOI 10.1172/JCI84421; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gongadze E, 2011, INT J NANOMED, V6, P1801, DOI [10.2147/IJN.S21755, 10.2147/IJN.S16982]; He W, 2018, J CLIN INVEST, V128, P861, DOI 10.1172/JCI96218; Hua XH, 2020, CELL DEATH DIFFER, V27, P632, DOI 10.1038/s41418-019-0377-7; Huang JG, 2016, NUCLEIC ACIDS RES, V44, P3059, DOI 10.1093/nar/gkv1353; Jia WY, 2017, LIFE SCI, V186, P1, DOI 10.1016/j.lfs.2017.07.025; Jin HL, 2021, AUTOPHAGY, V17, P840, DOI 10.1080/15548627.2020.1733262; Jordan B, 2019, NAT REV UROL, V16, P23, DOI 10.1038/s41585-018-0105-y; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim JG, 2018, J CELL PHYSIOL, V233, P6381, DOI 10.1002/jcp.26487; Kim J, 2016, NUCLEIC ACIDS RES, V44, P2378, DOI 10.1093/nar/gkw017; Kim J, 2018, NAT GENET, V50, P1705, DOI 10.1038/s41588-018-0252-3; Kramer S, 2011, TRENDS PARASITOL, V27, P23, DOI 10.1016/j.pt.2010.06.011; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Li Y, 2020, CANCER LETT, V485, P38, DOI 10.1016/j.canlet.2020.04.023; Lin GT, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.567200; Liu GH, 2017, AM J CANCER RES, V7, P2515; Liu H, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0950-9; Marin-Bejar O, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1331-y; Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003; Meeks JJ, 2012, EUR UROL, V62, P523, DOI 10.1016/j.eururo.2012.05.048; Ni W, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0449-4; Nomikou E, 2018, CELL MOL LIFE SCI, V75, P2111, DOI 10.1007/s00018-018-2787-y; Peng MG, 2019, AUTOPHAGY, V15, P1523, DOI 10.1080/15548627.2019.1586254; Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184; Pittayapruek P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060868; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Salviano-Silva Amanda, 2018, Non-Coding RNA, V4, P3, DOI 10.3390/ncrna4010003; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Soundararajan S, 2008, CANCER RES, V68, P2358, DOI 10.1158/0008-5472.CAN-07-5723; Sun J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000110; Sun TT, 2016, CANCER DISCOV, V6, P784, DOI 10.1158/2159-8290.CD-15-0921; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tan X, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03413-4; Tang Y, 2008, FRONT BIOSCI-LANDMRK, V13, P759, DOI 10.2741/2718; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Wang X, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0860-7; Wu YC, 2020, AGING-US, V12, P23306, DOI 10.18632/aging.104115; Yan C, 2014, NATURE, V515, P443, DOI 10.1038/nature13713; Yoon JH, 2013, J MOL BIOL, V425, P3723, DOI 10.1016/j.jmb.2012.11.024; Yoshino H, 2013, NAT REV UROL, V10, P396, DOI 10.1038/nrurol.2013.113; Yu YH, 2018, INT J CANCER, V142, P2040, DOI 10.1002/ijc.31223; Zhan Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0893-y; Zhan YH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1143-7; Zhang XN, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0182-7; Zuiverloon TCM, 2018, BLADDER CANCER, V4, P169, DOI 10.3233/BLC-180167	60	2	2	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6579	6589		10.1038/s41388-021-02033-8	http://dx.doi.org/10.1038/s41388-021-02033-8		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34615995				2022-12-28	WOS:000705759400001
J	Twafra, S; Sokolik, CG; Sneh, T; Srikanth, KD; Meirson, T; Genna, A; Chill, JH; Gil-Henn, H				Twafra, Shams; Sokolik, Chana G.; Sneh, Tal; Srikanth, Kolluru D.; Meirson, Tomer; Genna, Alessandro; Chill, Jordan H.; Gil-Henn, Hava			A novel Pyk2-derived peptide inhibits invadopodia-mediated breast cancer metastasis	ONCOGENE			English	Article; Early Access							FOCAL ADHESION KINASE; SH3 DOMAIN; MATRIX-METALLOPROTEINASE; STRUCTURAL BASIS; CORTACTIN; PROLINE; BINDING; SRC; PROTEIN; MEMBRANE	Dissemination of cancer cells from the primary tumor into distant body tissues and organs is the leading cause of death in cancer patients. While most clinical strategies aim to reduce or impede the growth of the primary tumor, no treatment to eradicate metastatic cancer exists at present. Metastasis is mediated by feet-like cytoskeletal structures called invadopodia which allow cells to penetrate through the basement membrane and intravasate into blood vessels during their spread to distant tissues and organs. The non-receptor tyrosine kinase Pyk2 is highly expressed in breast cancer, where it mediates invadopodia formation and function via interaction with the actin-nucleation-promoting factor cortactin. Here, we designed a cell-permeable peptide inhibitor that contains the second proline-rich region (PRR2) sequence of Pyk2, which binds to the SH3 domain of cortactin and inhibits the interaction between Pyk2 and cortactin in invadopodia. The Pyk2-PRR2 peptide blocks spontaneous lung metastasis in immune-competent mice by inhibiting cortactin tyrosine phosphorylation and actin polymerization-mediated maturation and activation of invadopodia, leading to reduced MMP-dependent tumor cell invasiveness. The native structure of the Pyk2-PRR2:cortactin-SH3 complex was determined using nuclear magnetic resonance (NMR), revealing an extended class II interaction surface spanning the canonical binding groove and a second hydrophobic surface which significantly contributes to ligand affinity. Using structure-guided design, we created a mutant peptide lacking critical residues involved in binding that failed to inhibit invadopodia maturation and function and consequent metastatic dissemination in mice. Our findings shed light on the specific molecular interactions between Pyk2 and cortactin and may lead to the development of novel strategies for preventing dissemination of primary breast tumors predicted at the time of diagnosis to be highly metastatic, and of secondary tumors that have already spread to other parts of the body.	[Twafra, Shams; Sneh, Tal; Srikanth, Kolluru D.; Meirson, Tomer; Genna, Alessandro; Gil-Henn, Hava] Bar Ilan Univ, Azrieli Fac Med, Cell Migrat & Invas Lab, IL-1311502 Safed, Israel; [Sokolik, Chana G.; Chill, Jordan H.] Bar Ilan Univ, Dept Chem, BioNMR Lab, IL-52900 Ramat Gan, Israel	Bar Ilan University; Bar Ilan University	Gil-Henn, H (corresponding author), Bar Ilan Univ, Azrieli Fac Med, Cell Migrat & Invas Lab, IL-1311502 Safed, Israel.; Chill, JH (corresponding author), Bar Ilan Univ, Dept Chem, BioNMR Lab, IL-52900 Ramat Gan, Israel.	Jordan.Chill@biu.ac.il; Hava.Henn@biu.ac.il		Meirson, Tomer/0000-0002-5011-5477	Israel Cancer Research Fund [20-101-PG]; Israel Cancer Association [20210071]; Israel Science Foundation [964/19]	Israel Cancer Research Fund; Israel Cancer Association; Israel Science Foundation(Israel Science Foundation)	This paper is dedicated to the memory of Mr. Abd Elhaleem Abu Salah, who sadly passed away before completion of this work. We wish to thank Dr. Avraham Samson, Dr. Moshe Dessau, and Ms. Trishna Saha for technical assistance and advice, Mr. Jonathan Solomon and Ms. Michal Gendler for critical reading of the manuscript, and Ms. Natalia Saleev and Ms. Michal Gendler for technical assistance during revisions. This work was funded by the Israel Cancer Research Fund (grant number 20-101-PG), the Israel Cancer Association (grant number 20210071) and the Israel Science Foundation (grant number 2142/21) (to HG-H), and the Israel Science Foundation (grant number 964/19) (to JC).	Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Cosen-Binker LI, 2006, PHYSIOLOGY, V21, P352, DOI 10.1152/physiol.00012.2006; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Genna A, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1449584; Genna A, 2018, J CELL BIOL, V217, P375, DOI 10.1083/jcb.201702184; Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284; Gligorijevic B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001995; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hashimoto A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023359; Hashimoto S, 2006, P NATL ACAD SCI USA, V103, P7036, DOI 10.1073/pnas.0509166103; Hayes KE, 2013, ONCOGENE, V32, P4766, DOI 10.1038/onc.2012.513; Hou P, 2003, HUM MOL GENET, V12, P1981, DOI 10.1093/hmg/ddg209; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim JM, 2008, J MOL BIOL, V377, P889, DOI 10.1016/j.jmb.2008.01.063; Kurochkina Natalya, 2013, Biophys Rev, V5, P29, DOI 10.1007/s12551-012-0081-z; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lipinski CA, 2010, EXPERT OPIN THER TAR, V14, P95, DOI 10.1517/14728220903473194; Liu WZ, 2012, ACTA CRYSTALLOGR F, V68, P154, DOI 10.1107/S1744309111056132; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Mayer BJ, 2001, J CELL SCI, V114, P1253; Meirson T, 2020, BIOINFORMATICS, V36, P154, DOI 10.1093/bioinformatics/btz527; Meirson Tomer, 2018, Oncotarget, V9, P22158, DOI 10.18632/oncotarget.25243; MONSKY WL, 1994, CANCER RES, V54, P5702; Morken JP, 1998, J AM CHEM SOC, V120, P30, DOI 10.1021/ja972729m; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Oser M, 2010, J CELL SCI, V123, P3662, DOI 10.1242/jcs.068163; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Saksela K, 2012, FEBS LETT, V586, P2609, DOI 10.1016/j.febslet.2012.04.042; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Sinha S, 2016, J CELL BIOL, V214, P197, DOI 10.1083/jcb.201601025; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Stylli SS, 2008, J CLIN NEUROSCI, V15, P725, DOI 10.1016/j.jocn.2008.03.003; Sutoh M, 2010, ONCOL RES, V19, P85, DOI 10.3727/096504010X12875107808008; Teyra J, 2017, STRUCTURE, V25, P1598, DOI 10.1016/j.str.2017.07.017; Tomar A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044041; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Yamamoto H, 2011, J UROLOGY, V185, P1930, DOI 10.1016/j.juro.2010.12.027; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zondlo NJ, 2013, ACCOUNTS CHEM RES, V46, P1039, DOI 10.1021/ar300087y	56	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02481-w	http://dx.doi.org/10.1038/s41388-022-02481-w		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5K2WQ	36258022	Green Submitted			2022-12-28	WOS:000869591700001
J	Chand, V; Liao, XB; Guzman, G; Benevolenskaya, E; Raychaudhuri, P				Chand, Vaibhav; Liao, Xiubei; Guzman, Grace; Benevolenskaya, Elizaveta; Raychaudhuri, Pradip			Hepatocellular carcinoma evades RB1-induced senescence by activating the FOXM1-FOXO1 axis	ONCOGENE			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; TRANSCRIPTIONAL PROGRAM; FOXM1; PHOSPHORYLATION; PROTEIN; GENES; RB; PROGRESSION; BINDING; PRB	Hepatocellular carcinoma (HCC) is one of the deadliest cancers. The retinoblastoma protein (RB1), a regulator of cell proliferation, is functionally inactivated in HCC by CYCLIN D/E-mediated phosphorylation. However, the mechanism of RB1-inactivation is unclear because only small percentages of HCCs exhibit amplification of CYCLIN D/E or mutations in the CDK-inhibitory genes. We show that FOXM1, which is overexpressed and critical for HCC, plays essential roles in inactivating RB1 and suppressing RB1-induced senescence of the HCC cells. Mechanistically, FOXM1 binds RB1 and DNMT3B to repress the expression of FOXO1, leading to a decrease in the levels of the CDK-inhibitors, creating an environment for phosphorylation and inactivation of RB1. Consistent with that, inhibition of FOXM1 causes increased expression of FOXO1 with consequent activation of RB1, leading to senescence of the HCC cells, in vitro and in vivo. Also, repression-deficient mutants of FOXM1 induce senescence that is blocked by depletion of RB1 or FOXO1. We provide evidence that human HCCs rely upon this FOXM1-FOXO1 axis for phosphorylation and inactivation of RB1. The observations demonstrate the existence of a new autoregulatory loop of RB1-inactivation in HCC involving a FOXM1-FOXO1 axis that is required for phosphorylation of RB1 and for aggressive progression of HCC.	[Chand, Vaibhav; Liao, Xiubei; Benevolenskaya, Elizaveta; Raychaudhuri, Pradip] Univ Illinois, Coll Med, Dept Biochem & Mol Genet MC 669, 900S Ashland Ave, Chicago, IL 60607 USA; [Guzman, Grace] Univ Illinois, Coll Med, Dept Pathol, Chicago, IL 60612 USA; [Raychaudhuri, Pradip] Jesse Brown VA Med Ctr, 820S Damen Ave, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Raychaudhuri, P (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet MC 669, 900S Ashland Ave, Chicago, IL 60607 USA.; Raychaudhuri, P (corresponding author), Jesse Brown VA Med Ctr, 820S Damen Ave, Chicago, IL 60612 USA.	pradip@uic.edu		Benevolenskaya, Elizaveta/0000-0003-3573-1754; raychaudhuri, pradip/0000-0003-2968-4701	Department of Veterans Affair (Biomedical Laboratory Research Development Service) [I01 BX000131]; NIH [5 RO1 CA243247, RO1 CA211095]	Department of Veterans Affair (Biomedical Laboratory Research Development Service); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a grant (I01 BX000131) from the Department of Veterans Affair (Biomedical Laboratory Research Development Service), and a grant from the NIH (5 RO1 CA243247) to PR. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. EB acknowledges support from NIH grant (RO1 CA211095).	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055; Baker GL, 2005, CELL CYCLE, V4, P330; Barsotti AM, 2009, ONCOGENE, V28, P4295, DOI 10.1038/onc.2009.282; Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012; Berman SD, 2008, MOL CANCER RES, V6, P1440, DOI 10.1158/1541-7786.MCR-08-0176; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Carr JR, 2012, CELL REP, V1, P715, DOI 10.1016/j.celrep.2012.05.005; Chand V, 2019, MOL CANCER RES, V17, P1063, DOI 10.1158/1541-7786.MCR-18-0968; Chen YJ, 2009, J BIOL CHEM, V284, P30695, DOI 10.1074/jbc.M109.007997; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Diep CH, 2013, CELL CYCLE, V12, P1433, DOI 10.4161/cc.24550; Dimri GP, 1996, BIOL SIGNAL, V5, P154; Dimri GP, 1996, MOL BIOL CELL, V7, P3102; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Jiao W, 2006, J BIOL CHEM, V281, P38098, DOI 10.1074/jbc.M605271200; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Knudsen ES, 2019, TRENDS CANCER, V5, P308, DOI 10.1016/j.trecan.2019.03.005; Kopanja D, 2015, J HEPATOL, V63, P429, DOI 10.1016/j.jhep.2015.03.023; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Liu JK, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12660; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Marceau AH, 2019, ELIFE, V8, DOI 10.7554/eLife.46131; Midorikawa Y, 2020, CANCER RES, V80, P3810, DOI 10.1158/0008-5472.CAN-20-0225; Mukhopadhyay NK, 2017, SCI REP-UK, V7, DOI 10.1038/srep46017; Narasimha AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02872; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nowak K, 2007, BBA-GENE STRUCT EXPR, V1769, P244, DOI 10.1016/j.bbaexp.2007.04.001; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Park HJ, 2011, EMBO MOL MED, V3, P21, DOI 10.1002/emmm.201000107; Park JW, 2019, J HEPATOL, V70, P684, DOI 10.1016/j.jhep.2018.11.029; Pozo OJ, 2007, ANAL BIOANAL CHEM, V389, P1765, DOI 10.1007/s00216-007-1407-8; Reed CA, 2009, ONCOGENE, V28, P4434, DOI 10.1038/onc.2009.303; Rubin SM, 2020, MOL CELL, V80, P183, DOI 10.1016/j.molcel.2020.08.020; Ruscetti M, 2020, CELL, V181, P424, DOI 10.1016/j.cell.2020.03.008; Shang YK, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010892; Siegel R., 2015, CA-CANCER J CLIN, V65, P29, DOI [10.3322/caac.21254, DOI 10.3322/CAAC.21254, DOI 10.3322/caac.21208]; Song BN, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.159; Topacio BR, 2019, MOL CELL, V74, P758, DOI 10.1016/j.molcel.2019.03.020; Viatour P, 2011, J EXP MED, V208, P1963, DOI 10.1084/jem.20110198; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Zappia MP, 2019, CELL REP, V26, P702, DOI 10.1016/j.celrep.2018.12.080; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	46	2	2	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3778	3790		10.1038/s41388-022-02394-8	http://dx.doi.org/10.1038/s41388-022-02394-8		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35761036				2022-12-28	WOS:000817034400002
J	Datta, J; Bianchi, A; Silva, ID; Deshpande, NU; Cao, LL; Mehra, S; Singh, S; Rafie, C; Sun, XD; Chen, X; Dai, XZ; Colaprico, A; Sharma, P; Dosch, AR; Pillai, A; Hosein, PJ; Nagathihalli, NS; Komanduri, KV; Wilson, JM; Ban, YG; Merchant, NB				Datta, Jashodeep; Bianchi, Anna; Silva, Iago De Castro; Deshpande, Nilesh U.; Cao, Long Long; Mehra, Siddharth; Singh, Samara; Rafie, Christine; Sun, Xiaodian; Chen, Xi; Dai, Xizi; Colaprico, Antonio; Sharma, Prateek; Dosch, Austin R.; Pillai, Asha; Hosein, Peter J.; Nagathihalli, Nagaraj S.; Komanduri, Krishna, V; Wilson, Julie M.; Ban, Yuguang; Merchant, Nipun B.			Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer	ONCOGENE			English	Article							GENOMIC CHARACTERIZATION; ONCOGENIC KRAS; ADENOCARCINOMA; COOPERATE; PATHWAY; HETEROGENEITY; KRAS(G12D)	Co-occurrent KRAS and TP53 mutations define a majority of patients with pancreatic ductal adenocarcinoma (PDAC) and define its pro-metastatic proclivity. Here, we demonstrate that KRAS-TP53 co-alteration is associated with worse survival compared with either KRAS-alone or TP53-alone altered PDAC in 245 patients with metastatic disease treated at a tertiary referral cancer center, and validate this observation in two independent molecularly annotated datasets. Compared with non-TP53 mutated KRAS-altered tumors, KRAS-TP53 co-alteration engenders disproportionately innate immune-enriched and CD8(+) T-cell-excluded immune signatures. Leveraging in silico, in vitro, and in vivo models of human and murine PDAC, we discover a novel intersection between KRAS-TP53 co-altered transcriptomes, TP63-defined squamous trans-differentiation, and myeloid-cell migration into the tumor microenvironment. Comparison of single-cell transcriptomes between KRAS-TP53 co-altered and KRAS-altered/TP53(WT) tumors revealed cancer cell-autonomous transcriptional programs that orchestrate innate immune trafficking and function. Moreover, we uncover granulocyte-derived inflammasome activation and TNF signaling as putative paracrine mediators of innate immunoregulatory transcriptional programs in KRAS-TP53 co-altered PDAC. Immune subtyping of KRAS-TP53 co-altered PDAC reveals conflation of intratumor heterogeneity with progenitor-like stemness properties. Coalescing these distinct molecular characteristics into a KRAS-TP53 co-altered "immunoregulatory program" predicts chemoresistance in metastatic PDAC patients enrolled in the COMPASS trial, as well as worse overall survival.	[Datta, Jashodeep; Bianchi, Anna; Silva, Iago De Castro; Deshpande, Nilesh U.; Cao, Long Long; Mehra, Siddharth; Singh, Samara; Rafie, Christine; Dai, Xizi; Dosch, Austin R.; Nagathihalli, Nagaraj S.; Merchant, Nipun B.] Univ Miami, Miller Sch Med, Div Surg Oncol, Dept Surg, Miami, FL 33136 USA; [Datta, Jashodeep; Pillai, Asha; Hosein, Peter J.; Nagathihalli, Nagaraj S.; Komanduri, Krishna, V; Merchant, Nipun B.] Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Sun, Xiaodian; Chen, Xi; Colaprico, Antonio; Ban, Yuguang] Univ Miami, Miller Sch Med, Biostat & Bioinformat Shared Resource, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Sharma, Prateek] Univ Nebraska, Dept Surg, Omaha, NE USA; [Pillai, Asha] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA; [Pillai, Asha] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Hosein, Peter J.; Komanduri, Krishna, V] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Wilson, Julie M.] Ontario Inst Canc Res, PanCuRx Translat Res Initiat, Toronto, ON, Canada	University of Miami; University of Miami; University of Nebraska System; University of Miami; University of Miami; University of Miami; Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates	Datta, J (corresponding author), Univ Miami, Miller Sch Med, Div Surg Oncol, Dept Surg, Miami, FL 33136 USA.; Datta, J (corresponding author), Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.	jash.datta@med.miami.edu		Datta, Jashodeep/0000-0003-2869-1571	Miami CTSI under NIH Award [UL1TR002736]; Stanley Glaser Foundation; American College of Surgeons Franklin Martin Career Development Award; Association for Academic Surgery Joel J. Roslyn Faculty Award; NIH [R01 CA161976]; NCI/NIH Award [P30CA240139]	Miami CTSI under NIH Award; Stanley Glaser Foundation; American College of Surgeons Franklin Martin Career Development Award; Association for Academic Surgery Joel J. Roslyn Faculty Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI/NIH Award	This work was supported by KL2 career development grant from Miami CTSI under NIH Award UL1TR002736, Stanley Glaser Foundation, American College of Surgeons Franklin Martin Career Development Award, and Association for Academic Surgery Joel J. Roslyn Faculty Award (to JD); NIH R01 CA161976 (to NBM); and NCI/NIH Award P30CA240139 (to JD and NBM).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Aung KL, 2018, CLIN CANCER RES, V24, P1344, DOI 10.1158/1078-0432.CCR-17-2994; Bailey JM, 2016, ONCOGENE, V35, P4282, DOI 10.1038/onc.2015.441; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Balachandran VP, 2019, GASTROENTEROLOGY, V156, P2056, DOI 10.1053/j.gastro.2018.12.038; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Blagih J, 2020, CELL REP, V30, P481, DOI 10.1016/j.celrep.2019.12.028; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Chakravarty D, 2017, JCO PRECIS ONCOL, V1; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Cui Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111942; Datta J, 2022, ANN SURG, V276, pE474, DOI 10.1097/SLA.0000000000004613; Datta J, 2020, CLIN CANCER RES, V26, P1077, DOI 10.1158/1078-0432.CCR-19-2390; Dosch Austin R, 2021, Oncotarget, V12, P2104, DOI 10.18632/oncotarget.27983; Dosch Austin R, 2020, Oncoscience, V7, P26, DOI 10.18632/oncoscience.503; Fan J, 2016, NAT METHODS, V13, P241, DOI [10.1038/NMETH.3734, 10.1038/nmeth.3734]; Gillet JP, 2012, CLIN CANCER RES, V18, P3197, DOI 10.1158/1078-0432.CCR-12-0056; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393; Hamarsheh S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19288-6; Hamarsheh S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01444; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hosein AN, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129212; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; KATO H, 1979, JPN CIRC J, V43, P343, DOI 10.1253/jcj.43.343; Kim MP, 2021, CANCER DISCOV, V11, P2094, DOI 10.1158/2159-8290.CD-20-1228; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kuhn DJ, 2005, FRONT BIOSCI-LANDMRK, V10, P1462, DOI 10.2741/1631; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Li JY, 2018, IMMUNITY, V49, P178, DOI 10.1016/j.immuni.2018.06.006; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Maddalena M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2025631118; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Miao YR, 2020, ADV SCI, V7, DOI 10.1002/advs.201902880; Mukherjee A, 2019, CANCER RES, V79, P3185, DOI 10.1158/0008-5472.CAN-19-0542; Nirmal AJ, 2018, CANCER IMMUNOL RES, V6, P1388, DOI 10.1158/2326-6066.CIR-18-0342; O'Kane GM, 2020, CLIN CANCER RES, V26, P4901, DOI 10.1158/1078-0432.CCR-19-3724; Oh JY, 2010, POULTRY SCI, V89, P2116, DOI 10.3382/ps.2010-00918; Pan Y, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0822-6; Rogan PK, 2019, MOL GENET METAB, V128, P45, DOI 10.1016/j.ymgme.2019.08.005; Rose Dianne, 2002, South Med J, V95, P621; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sharif PM, 2020, CYTOKINE, V130, DOI 10.1016/j.cyto.2020.155066; Smith JJ, 2019, CANCER MED-US, V8, P6538, DOI 10.1002/cam4.2415; Tavassoly I, 2019, MOL ONCOL, V13, P1725, DOI 10.1002/1878-0261.12521; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Tomkiewicz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047170; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; ZHOU YY, 2019, NAT COMMUN, V10, DOI [10.1038/S41467-019-09234-6, DOI 10.1038/s41587-020-0546-8, DOI 10.1038/S41467-019-09234-6]	59	1	1	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3640	3654		10.1038/s41388-022-02368-w	http://dx.doi.org/10.1038/s41388-022-02368-w		JUN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35701533	Green Submitted			2022-12-28	WOS:000810849500002
J	Tyagi, A; Wu, SY; Sharma, S; Wu, KR; Zhao, D; Deshpande, R; Singh, R; Li, WC; Topaloglu, U; Ruiz, J; Watabe, K				Tyagi, Abhishek; Wu, Shih-Ying; Sharma, Sambad; Wu, Kerui; Zhao, Dan; Deshpande, Ravindra; Singh, Ravi; Li, Wencheng; Topaloglu, Umit; Ruiz, Jimmy; Watabe, Kounosuke			Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis	ONCOGENE			English	Article							CIGARETTE-SMOKING; LYMPHOCYTE RATIO; BRAIN METASTASES; SERUM COTININE; SURVIVAL; PROTEIN; GLIOBLASTOMA; PROLIFERATION; COLONIZATION; INFLAMMATION	Smoking is associated with lung cancer and has a profound impact on tumor immunity. Nicotine, the addictive and non-carcinogenic smoke component, influences various brain cells and the immune system. However, how long-term use of nicotine affects brain metastases is poorly understood. We, therefore, examined the mechanism by which nicotine promotes lung cancer brain metastasis. In this study, we conducted a retrospective analysis of 810 lung cancer patients with smoking history and assessed brain metastasis. We found that current smoker's lung cancer patients have significantly higher brain metastatic incidence compared to the never smokers. We also found that chronic nicotine exposure recruited STAT3-activated N2-neutrophils within the brain pre-metastatic niche and secreted exosomal miR-4466 which promoted stemness and metabolic switching via SKI/SOX2/CPT1A axis in the tumor cells in the brain thereby enabling metastasis. Importantly, exosomal miR-4466 levels were found to be elevated in serum/urine of cancer-free subjects with a smoking history and promote tumor growth in vivo, suggesting that exosomal miR-4466 may serve as a promising prognostic biomarker for predicting increased risk of metastatic disease among smoker(s). Our findings suggest a novel pro-metastatic role of nicotine-induced N2-neutrophils in the progression of brain metastasis. We also demonstrated that inhibiting nicotine-induced STAT3-mediated neutrophil polarization effectively abrogated brain metastasis in vivo. Our results revealed a novel mechanistic insight on how chronic nicotine exposure contributes to worse clinical outcome of metastatic lung cancer and implicated the risk of using nicotine gateway for smoking cessation in cancer patients.	[Tyagi, Abhishek; Wu, Shih-Ying; Sharma, Sambad; Wu, Kerui; Zhao, Dan; Deshpande, Ravindra; Singh, Ravi; Li, Wencheng; Topaloglu, Umit; Ruiz, Jimmy; Watabe, Kounosuke] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Watabe, K (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	kwatabe@wakehealth.edu	Zhao, Dan/Y-8065-2019; Tyagi, Abhishek/AFZ-6213-2022; Tyagi, Abhishek/CAF-1274-2022; Singh, Ravi/A-5740-2011	Zhao, Dan/0000-0002-5120-6725; Tyagi, Abhishek/0000-0002-0155-2099; Tyagi, Abhishek/0000-0002-0155-2099; Singh, Ravi/0000-0003-0750-1804	NIH [R01CA173499, R01CA185650, R01CA205067]; Comprehensive Cancer Center of Wake Forest University, National Institutes of Health [P30CA012197]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Comprehensive Cancer Center of Wake Forest University, National Institutes of Health	This work was supported by NIH grant R01CA173499, R01CA185650 and R01CA205067 (to KW). This study used various Shared Resources including Tumor Tissue and Pathology, Cancer Genomics, Flow Cytometry, Biostatistics and Cell Engineering that are supported by the Comprehensive Cancer Center of Wake Forest University, National Institutes of Health Grant (P30CA012197).	Ali A, 2013, CURR ONCOL, V20, pE300, DOI 10.3747/co.20.1481; Aoshiba K, 1996, J LAB CLIN MED, V127, P186, DOI 10.1016/S0022-2143(96)90077-3; Asakura K, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0863-y; Bambury RM, 2013, J NEURO-ONCOL, V114, P149, DOI 10.1007/s11060-013-1164-9; Benhammou K, 2000, NEUROPHARMACOLOGY, V39, P2818, DOI 10.1016/S0028-3908(00)00153-2; Bleesing JJH, 2003, CYTOM PART B-CLIN CY, V51B, P1, DOI 10.1002/cyto.b.10007; Boire A, 2017, CELL, V168, P1101, DOI 10.1016/j.cell.2017.02.025; Caraballo RS, 1998, JAMA-J AM MED ASSOC, V280, P135, DOI 10.1001/jama.280.2.135; Caraballo RS, 2004, NICOTINE TOB RES, V6, P19, DOI 10.1080/14622200310001656821; Souto JC, 2011, MED RES REV, V31, P311, DOI 10.1002/med.20185; Ceccarelli SM, 2011, J MED CHEM, V54, P3109, DOI 10.1021/jm100809g; Chawla K, 2013, BIOINFORMATICS, V29, P2519, DOI 10.1093/bioinformatics/btt432; Cheng L, 2019, IMMUNOBIOLOGY, V224, P388, DOI 10.1016/j.imbio.2019.02.009; Chou YT, 2013, STEM CELLS, V31, P2607, DOI 10.1002/stem.1518; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Cui P, 2020, CELL SIGNAL, V71, DOI 10.1016/j.cellsig.2020.109598; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; DeJarnette JB, 1998, P NATL ACAD SCI USA, V95, P14909, DOI 10.1073/pnas.95.25.14909; Deng C, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016875; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Doi H, 2019, IN VIVO, V33, P195, DOI 10.21873/invivo.11459; Dong Y, 2018, ANN NEUROL, V83, P387, DOI 10.1002/ana.25159; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fuchs J, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253601; Gong JN, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00941; Haftchenary S, 2013, ACS MED CHEM LETT, V4, P1102, DOI 10.1021/ml4003138; Han SJ, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01201; Hawkins BT, 2004, BRAIN RES, V1027, P48, DOI 10.1016/j.brainres.2004.08.043; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Hsiao SH, 2013, LUNG CANCER, V82, P319, DOI 10.1016/j.lungcan.2013.08.004; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karachaliou N, 2013, TRANSL LUNG CANCER R, V2, P172, DOI 10.3978/j.issn.2218-6751.2013.01.01; Kazuyori TTN., 2017, J CANC SCI RES, V3, P1; Kim S, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121236; Kobayashi H, 2018, ONCOL LETT, V16, P4243, DOI 10.3892/ol.2018.9225; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kudo Y, 2019, ANN ONCOL, V30, P1521, DOI 10.1093/annonc/mdz207; Laughney AM, 2020, NAT MED, V26, P259, DOI 10.1038/s41591-019-0750-6; Lauterstein DE, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13040417; Lee W, 2019, J EXP MED, V216, P176, DOI 10.1084/jem.20181170; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Li YPD, 2019, J NEURO-ONCOL, V143, P337, DOI 10.1007/s11060-019-03169-0; Lin H, 2017, NEURO-ONCOLOGY, V19, P43, DOI 10.1093/neuonc/now128; Liu Y, 2013, NEURO-ONCOLOGY, V15, P891, DOI 10.1093/neuonc/not031; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Loeffler JS, 2020, EPIDEMIOLOGY CLIN MA; Luke Florian, 2018, Oncotarget, V9, P18844, DOI 10.18632/oncotarget.24787; Mansouri Sheila, 2016, CNS Oncol, V5, P159, DOI 10.2217/cns-2016-0001; Maru Y, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a036897; Mashimo T, 2014, CELL, V159, P1603, DOI 10.1016/j.cell.2014.11.025; Mitsuya K, 2017, J NEUROSURG, V127, P433, DOI 10.3171/2016.8.JNS16899; Morad G, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1627164; O'Keeffe LM, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021611; O'Loughlin J, 2008, NICOTINE TOB RES, V10, P525, DOI 10.1080/14622200801901997; Ohsawa K, 2004, J NEUROCHEM, V88, P844, DOI 10.1046/j.1471-4159.2003.02213.x; Panopoulos AD, 2006, BLOOD, V108, P3682, DOI 10.1182/blood-2006-02-003012; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Piccard H, 2012, CRIT REV ONCOL HEMAT, V82, P296, DOI 10.1016/j.critrevonc.2011.06.004; Rodrigues G, 2019, NAT CELL BIOL, V21, P1403, DOI 10.1038/s41556-019-0404-4; Rottiers V, 2012, NAT REV MOL CELL BIO, V13, P239, DOI 10.1038/nrm3313; Sacks P, 2020, NEUROSURG CLIN N AM, V31, P481, DOI 10.1016/j.nec.2020.06.001; Schaal CM, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0901-2; Shaul ME, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1232221; Shenker RF, 2017, CANCER MED-US, V6, P944, DOI 10.1002/cam4.1058; Shigdar S, 2014, CANCER LETT, V345, P271, DOI 10.1016/j.canlet.2013.07.031; Sifat AE, 2018, J NEUROCHEM, V147, P204, DOI 10.1111/jnc.14561; Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73; Singh SP, 2000, TOXICOL APPL PHARM, V164, P65, DOI 10.1006/taap.2000.8897; Sodja E, 2016, RADIOL ONCOL, V50, P188, DOI 10.1515/raon-2015-0027; Stapleton JM, 2003, NEUROPSYCHOPHARMACOL, V28, P765, DOI 10.1038/sj.npp.1300106; Szczerba BM, 2019, NATURE, V566, P553, DOI 10.1038/s41586-019-0915-y; TOTTI N, 1984, SCIENCE, V223, P169, DOI 10.1126/science.6318317; Tyagi A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20733-9; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang TY, 2018, CELL METAB, V27, P1357, DOI 10.1016/j.cmet.2018.04.018; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wingrove E, 2019, CELL REP, V27, P1277, DOI 10.1016/j.celrep.2019.03.085; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; Zhang HY, 2010, BLOOD, V116, P2462, DOI 10.1182/blood-2009-12-259630; Zhang L, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz5387	82	2	2	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3079	3092		10.1038/s41388-022-02322-w	http://dx.doi.org/10.1038/s41388-022-02322-w		APR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35461327	Green Published, hybrid			2022-12-28	WOS:000785962300001
J	Gu, YH; Guo, YY; Gao, N; Fang, Y; Xu, C; Hu, GM; Guo, MX; Ma, YX; Zhang, YF; Zhou, J; Luo, YL; Zhang, HF; Wen, Q; Qiao, HL				Gu, Yuhan; Guo, Yuanyuan; Gao, Na; Fang, Yan; Xu, Chen; Hu, Guiming; Guo, Mengxue; Ma, Yaxing; Zhang, Yunfei; Zhou, Jun; Luo, Yanlin; Zhang, Haifeng; Wen, Qiang; Qiao, Hailing			The proteomic characterization of the peritumor microenvironment in human hepatocellular carcinoma	ONCOGENE			English	Article							THYMIDINE PHOSPHORYLASE EXPRESSION; PROTEOGENOMIC CHARACTERIZATION; CANCER; HETEROGENEITY; PROGRESSION; PROGNOSIS; DATABASE; DENSITY; EVASION; TARGET	The tumor microenvironment (TME) was usually studied in tumor tissue and in relation to only tumor progression, with little involved in occurrence, recurrence and metastasis of tumor. Thus, a new concept "peritumor microenvironment (PME)" was proposed in the proteomic characterization of peritumor liver tissues in human hepatocellular carcinoma (HCC). The PME for occurrence (PME-O) and progression (PME-P) were almost totally different at proteome composition and function. Proteins for occurrence and progression rarely overlapped and crossed. Immunity played a central role in PME-O, whereas inflammation, angiogenesis and metabolism were critical in PME-P. Proteome profiling identified three PME subtypes with different features of HCC. Thymidine phosphorylase (TYMP) was validated as an antiangiogenic target in an orthotopic HCC mouse model. Overall, the proteomic characterization of the PME revealed that the entire processes of HCC occurrence and progression differ substantially. These findings could enable advances in cancer biology, diagnostics and therapeutics.	[Gu, Yuhan; Guo, Yuanyuan; Gao, Na; Fang, Yan; Xu, Chen; Hu, Guiming; Guo, Mengxue; Ma, Yaxing; Zhang, Haifeng; Wen, Qiang; Qiao, Hailing] Zhengzhou Univ, Inst Clin Pharmacol, Zhengzhou, Peoples R China; [Guo, Yuanyuan] Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Zhang, Yunfei; Luo, Yanlin] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China; [Zhou, Jun] Zhengzhou Univ, Affiliated Peoples Hosp, Zhengzhou, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University; Zhengzhou University	Qiao, HL (corresponding author), Zhengzhou Univ, Inst Clin Pharmacol, Zhengzhou, Peoples R China.	qiaohl@zzu.edu.cn		Gu, yuhan/0000-0002-6021-7215	National Natural Science Foundation of China (NSFC) [81473279, 81673507, 81872931, 82073930]; Zhengzhou Major Scientific and Technological Innovation Projects [2020CXZX0076]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Zhengzhou Major Scientific and Technological Innovation Projects	This work was supported by National Natural Science Foundation of China (NSFC) (Nos. 81473279, 81673507, 81872931 and 82073930), Zhengzhou Major Scientific and Technological Innovation Projects (No.2020CXZX0076). We thank Prof. Xiaohong Qian and Yangjun Zhang (State Key Laboratory of Proteomics) for technical support of mass spectrometry detection and suggestions for data processing.	Affo S, 2017, ANNU REV PATHOL-MECH, V12, P153, DOI 10.1146/annurev-pathol-052016-100322; Archer TC, 2018, CANCER CELL, V34, P396, DOI 10.1016/j.ccell.2018.08.004; Billan S, 2020, LANCET ONCOL, V21, pE463, DOI 10.1016/S1470-2045(20)30328-4; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Casanova E, 2006, J MED CHEM, V49, P5562, DOI 10.1021/jm0605379; Chakrabarti S, 2021, PHARMACOL THERAPEUT, V224, DOI 10.1016/j.pharmthera.2021.107823; Chapouly C, 2015, BRAIN, V138, P1548, DOI 10.1093/brain/awv077; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; De Clercq E, 2011, MED RES REV, V31, P118, DOI 10.1002/med.20179; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Forget A, 2019, ADV MATER, V31, DOI 10.1002/adma.201808050; FURUKAWA T, 1992, NATURE, V356, P668, DOI 10.1038/356668a0; Furukawa T, 2018, PHARMACOL RES, V132, P15, DOI 10.1016/j.phrs.2018.03.019; Gao J, 2018, MOL CARCINOGEN, V57, P1371, DOI 10.1002/mc.22851; Gao J, 2018, J PHARMACOL EXP THER, V365, P398, DOI 10.1124/jpet.117.245555; Gao N, 2016, EUR J PHARM SCI, V92, P86, DOI 10.1016/j.ejps.2016.06.015; Gao Q, 2019, CELL, V179, P561, DOI 10.1016/j.cell.2019.08.052; Ge S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03121-2; Goliwas KF, 2021, PHYSIOL REV, V101, P417, DOI 10.1152/physrev.00008.2020; Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962; Imazono Y, 1997, J CLIN ONCOL, V15, P2570, DOI 10.1200/JCO.1997.15.7.2570; Javaid S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225056; Jiang LH, 2020, CELL, V183, P269, DOI 10.1016/j.cell.2020.08.036; Jiang Y, 2019, NATURE, V567, P257, DOI 10.1038/s41586-019-0987-8; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Lawson KA, 2020, NATURE, V586, P120, DOI 10.1038/s41586-020-2746-2; Li W, 2018, TRENDS CARDIOVAS MED, V28, P157, DOI 10.1016/j.tcm.2017.10.003; Li W, 2014, CIRC RES, V115, P997, DOI 10.1161/CIRCRESAHA.115.304591; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liekens S, 2004, J BIOL CHEM, V279, P29598, DOI 10.1074/jbc.M402602200; Liekens S, 2006, MOL PHARMACOL, V70, P501, DOI 10.1124/mol.105.021188; Lin C, 2019, GUT, V68, P1764, DOI 10.1136/gutjnl-2018-316324; Mascaux C, 2019, NATURE, V571, P570, DOI 10.1038/s41586-019-1330-0; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; McLaughlin M, 2020, NAT REV CANCER, V20, P203, DOI 10.1038/s41568-020-0246-1; Ortmayr K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09695-9; PAGET S, 1989, CANCER METAST REV, V8, P98; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Toi M, 1999, CLIN CANCER RES, V5, P1131; Toi M, 2005, LANCET ONCOL, V6, P158, DOI 10.1016/S1470-2045(05)01766-3; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958; Yao YX, 2001, CLIN CANCER RES, V7, P4021; Yoshihama S, 2016, P NATL ACAD SCI USA, V113, P5999, DOI 10.1073/pnas.1602069113; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zhang HF, 2016, J PHARMACOL EXP THER, V358, P83, DOI 10.1124/jpet.116.233635; Zhang HF, 2015, SCI REP-UK, V5, DOI 10.1038/srep17671; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	59	1	1	8	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2480	2491		10.1038/s41388-022-02264-3	http://dx.doi.org/10.1038/s41388-022-02264-3		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35314790	Green Published, hybrid			2022-12-28	WOS:000771325000001
J	Qiao, GL; Kone, LB; Phillips, EH; Lee, SSY; Brown, GE; Khetani, SR; Thakur, A; Lum, LG; Prabhakar, BS; Maker, AV				Qiao, Guilin; Kone, Lyonell B.; Phillips, Evan H.; Lee, Steve Seung-Young; Brown, Grace E.; Khetani, Salman R.; Thakur, Archana; Lum, Lawrence G.; Prabhakar, Bellur S.; Maker, Ajay, V			LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer	ONCOGENE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; COLORECTAL-CANCER; PROGNOSTIC-FACTOR; CYTOLYTIC ACTIVITY; IMMUNE CELLS; HIGH-RISK; SURVIVAL; ERADICATION; METASTASIS; BLOCKADE	Increased tumor infiltrating lymphocytes (TIL) are associated with improved patient responses to immunotherapy. As a result, there is interest in enhancing lymphocyte trafficking particularly to colon cancers since the majority are checkpoint blockade-resistant and microsatellite stable. Here, we demonstrate that activated T-cells (ATC) armed with anti-CD3 x anti-EGFR bispecific antibody increases TIL and mediate anti-tumor cytotoxicity while decreasing tumor cell viability. Furthermore, treatment induces endogenous anti-tumor immunity that resisted tumor rechallenge and increased memory T-cell subsets in the tumor. When combined with targeted tumor expression of the tumor necrosis factor superfamily member LIGHT, activated T-cell proliferation and infiltration were further enhanced, and human colorectal tumor regressions were observed. Our data indicate that tumor-targeted armed bispecific antibody increases TIL trafficking and is a potentially potent strategy that can be paired with combination immunotherapy to battle microsatellite stable colon cancer. Significance Enhancing trafficking of tumor infiltrating lymphocytes (TILs) to solid tumors has been shown to improve outcomes. Unfortunately, few strategies have been successful in the clinical setting for solid tumors, particularly for "cold" microsatellite stable colon cancers. In order to address this gap in knowledge, this study combined TNFSF14/LIGHT immunomodulation with a bispecific antibody armed with activated T-cells targeted to the tumor. This unique T-cell trafficking strategy successfully generated anti-tumor immunity in a microsatellite stable colon cancer model, stimulated T-cell infiltration, and holds promise as a combination immunotherapy for treating advanced and metastatic colorectal cancer.	[Qiao, Guilin; Maker, Ajay, V] Univ Calif San Francisco, Dept Surg, Div Surg Oncol, San Francisco, CA 94143 USA; [Kone, Lyonell B.; Maker, Ajay, V] Univ Illinois, Coll Med, Dept Surg, Div Surg Oncol, Chicago, IL 60612 USA; [Phillips, Evan H.; Lee, Steve Seung-Young] Univ Illinois, Coll Pharm, Dept Pharmaceut Sci, Chicago, IL 60612 USA; [Brown, Grace E.; Khetani, Salman R.] Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA; [Thakur, Archana; Lum, Lawrence G.] Univ Virginia, Dept Med, Div Hematol Oncol, Canc Ctr, Charlottesville, VA USA; [Prabhakar, Bellur S.; Maker, Ajay, V] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of California System; University of California San Francisco; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Virginia; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Maker, AV (corresponding author), Univ Calif San Francisco, Dept Surg, Div Surg Oncol, San Francisco, CA 94143 USA.; Maker, AV (corresponding author), Univ Illinois, Coll Med, Dept Surg, Div Surg Oncol, Chicago, IL 60612 USA.; Maker, AV (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA.	Ajay.Maker@ucsf.edu		Prabhakar, Bellur S./0000-0001-9815-9850	 [R37CA238435];  [K08CA190855];  [R00EB022636];  [R01CA140314];  [R01CA092344];  [P30CA044579]	; ; ; ; ; 	R37CA238435 (AVM), K08CA190855 (AVM); R00EB022636 (SSYL); R01CA140314, R01CA092344, P30CA044579 (LGL).	Bhutani D, 2015, CURR OPIN HEMATOL, V22, P476, DOI 10.1097/MOH.0000000000000176; Bibeau F, 2006, VIRCHOWS ARCH, V449, P281, DOI 10.1007/s00428-006-0247-9; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654; Chiba T, 2004, BRIT J CANCER, V91, P1711, DOI 10.1038/sj.bjc.6602201; Chung KY, 2010, J CLIN ONCOL, V28, P3485, DOI 10.1200/JCO.2010.28.3994; Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003; Correale P, 2012, CLIN CANCER RES, V18, P850, DOI 10.1158/1078-0432.CCR-10-3186; Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760; Flaherty DC, 2016, J AM COLL SURGEONS, V223, P134, DOI 10.1016/j.jamcollsurg.2016.03.003; Gajewski TF, 2013, CURR OPIN IMMUNOL, V25, P268, DOI 10.1016/j.coi.2013.02.009; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Giordano G, 2019, CANCERS, V11, DOI 10.3390/cancers11081089; Grabert RC, 2006, CLIN CANCER RES, V12, P569, DOI 10.1158/1078-0432.CCR-05-2005; Halama N, 2011, CANCER RES, V71, P5670, DOI 10.1158/0008-5472.CAN-11-0268; Huang CW, 2017, ONCOTARGET, V8, P114663, DOI 10.18632/oncotarget.23072; Katz SC, 2013, ANN SURG ONCOL, V20, P946, DOI 10.1245/s10434-012-2668-9; Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lee SSY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16987-x; Lee WS, 2010, CANCER-AM CANCER SOC, V116, P5188, DOI 10.1002/cncr.25293; Lin Christine, 2017, Curr Protoc Toxicol, V72, DOI 10.1002/cptx.23; Lum LG, 2014, BONE MARROW TRANSPL, V49, P73, DOI 10.1038/bmt.2013.133; Lum LG, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.4108; Lum LG, 2016, BIOL BLOOD MARROW TR, V22, P869, DOI 10.1016/j.bbmt.2015.12.030; Lum Lawrence G, 2003, Clin Breast Cancer, V4, P212, DOI 10.3816/CBC.2003.n.028; Lum LG, 2013, BIOL BLOOD MARROW TR, V19, P925, DOI 10.1016/j.bbmt.2013.03.010; Lum LG, 2011, BIODRUGS, V25, P365, DOI 10.2165/11595950-000000000-00000; Maker AV, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1069937; Maker AV, 2015, CANCER IMMUNOL RES, V3, P380, DOI 10.1158/2326-6066.CIR-14-0212; Maker AV, 2005, ANN SURG ONCOL, V12, P1005, DOI 10.1245/ASO.2005.03.536; Naito Y, 1998, CANCER RES, V58, P3491; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; Prall F, 2004, HUM PATHOL, V35, P808, DOI 10.1016/j.humpath.2004.01.022; Qiao GL, 2017, CANCER RES, V77, P1880, DOI 10.1158/0008-5472.CAN-16-1655; Qin JZ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-70; Qin JZ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.473; Reusch U, 2006, CLIN CANCER RES, V12, P183, DOI 10.1158/1078-0432.CCR-05-1855; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Sen M, 2001, J HEMATOTH STEM CELL, V10, P247, DOI 10.1089/15258160151134944; Shibutani M, 2018, IN VIVO, V32, P151, DOI 10.21873/invivo.11218; Siegel RL, 2017, JAMA-J AM MED ASSOC, V318, P572, DOI 10.1001/jama.2017.7630; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun ZC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11782-w; Thakur A, 2018, BLOOD REV, V32, P339, DOI 10.1016/j.blre.2018.02.004; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Vasu C, 2003, INT IMMUNOL, V15, P641, DOI 10.1093/intimm/dxg061; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Yankelevich M, 2012, PEDIATR BLOOD CANCER, V59, P1198, DOI 10.1002/pbc.24237; Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029; Yu P, 2008, CYTOKINE GROWTH F R, V19, P285, DOI 10.1016/j.cytogfr.2008.04.004; Zboralski D, 2017, CANCER IMMUNOL RES, V5, P950, DOI 10.1158/2326-6066.CIR-16-0303; Zitron IM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-83; Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180	56	1	1	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2054	2068		10.1038/s41388-022-02209-w	http://dx.doi.org/10.1038/s41388-022-02209-w		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35177811	hybrid, Green Published			2022-12-28	WOS:000757138900001
J	Park, YL; Kim, HP; Ock, CY; Min, DW; Kang, JK; Lim, YJ; Song, SH; Han, SW; Kim, TY				Park, Ye-Lim; Kim, Hwang-Phill; Ock, Chan-Young; Min, Dong-Wook; Kang, Jun Kyu; Lim, Yoo Joo; Song, Sang-Hyun; Han, Sae-Won; Kim, Tae-You			EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer	ONCOGENE			English	Article							NF-KAPPA-B; CETUXIMAB RESISTANCE; TUMOR HETEROGENEITY; MUTATIONS; ACTIVATION; EXPRESSION; CYTOKINES; GROWTH; TRANSACTIVATION; CHEMOTHERAPY	The emergence of RAS/RAF mutant clone is the main feature of EGFR inhibitor resistance in KRAS wild-type colon cancer. However, its molecular mechanism is thought to be multifactorial, mainly due to cellular heterogeneity. In order to better understand the resistance mechanism in a single clone level, we successfully isolated nine cells with cetuximab-resistant (CR) clonality from in vitro system. All CR cells harbored either KRAS or BRAF mutations. Characteristically, these cells showed a higher EMT (Epithelial to mesenchymal transition) signature, showing increased EMT markers such as SNAI2. Moreover, the expression level of CXCL1/5, a secreted protein, was significantly higher in CR cells compared to the parental cells. In these CR cells, CXCL1/5 expression was coordinately regulated by SNAI2/NFKB and transactivated EGFR through CXCR/MMPI/EGF axis via autocrine singling. We also observed that combined cetuximab/MEK inhibitor not only showed growth inhibition but also reduced the secreted amounts of CXCL1/5. We further found that serum CXCL1/5 level was positively correlated with the presence of RAS/RAF mutation in colon cancer patients during cetuximab therapy, suggesting its role as a biomarker. These data indicated that the application of serum CXCL1/5 could be a potential serologic biomarker for predicting resistance to EGFR therapy in colorectal cancer.	[Park, Ye-Lim; Kim, Hwang-Phill; Kang, Jun Kyu; Kim, Tae-You] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea; [Park, Ye-Lim; Kim, Hwang-Phill; Min, Dong-Wook; Kang, Jun Kyu; Song, Sang-Hyun; Han, Sae-Won; Kim, Tae-You] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea; [Kim, Hwang-Phill] IMBDx Inc, Seoul, South Korea; [Ock, Chan-Young; Lim, Yoo Joo; Han, Sae-Won; Kim, Tae-You] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Park, YL; Kim, TY (corresponding author), Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea.; Park, YL; Kim, TY (corresponding author), Seoul Natl Univ, Canc Res Inst, Seoul, South Korea.; Kim, TY (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea.	yelim_park@snu.ac.kr; kimty@snu.ac.kr		Lim, Yoojoo/0000-0002-4181-2916; PARK, YE-LIM/0000-0002-3043-9984	Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health Welfare [HI14C1277, HI13C2096]; Ministry of Science, ICT & Future Planning [2016M3A9B6026918, 2018R1C1B6005264]; National Research Foundation of Korea [2017M3C9A5029978]; Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science ICT [NRF-2017M3A9A7050610]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health Welfare; Ministry of Science, ICT & Future Planning(Ministry of Science, ICT & Future Planning, Republic of Korea); National Research Foundation of Korea(National Research Foundation of Korea); Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science ICT(National Research Foundation of KoreaMinistry of Science, ICT & Future Planning, Republic of Korea)	We thank H. Nikki March, Ph.D., from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. The authors are grateful to all members of our group for their helpful advice. This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare (HI14C1277, HI13C2096), by the Ministry of Science, ICT & Future Planning (2016M3A9B6026918, 2018R1C1B6005264), and by the National Research Foundation of Korea (2017M3C9A5029978), and by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT (NRF-2017M3A9A7050610).	Arena S, 2015, CLIN CANCER RES, V21, P2157, DOI 10.1158/1078-0432.CCR-14-2821; Bolitho C, 2010, ENDOCR-RELAT CANCER, V17, P929, DOI 10.1677/ERC-10-0107; Bommarito A, 2011, ENDOCR-RELAT CANCER, V18, P669, DOI 10.1530/ERC-11-0076; Burke SJ, 2014, AM J PHYSIOL-ENDOC M, V306, pE131, DOI 10.1152/ajpendo.00347.2013; Chen C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1431-6; Choi YH, 2019, MOL CELLS, V42, P189, DOI 10.14348/molcells.2019.2446; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Cremolini C, 2015, NAT REV CLIN ONCOL, V12, P607, DOI 10.1038/nrclinonc.2015.129; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Girbl T, 2018, IMMUNITY, V49, P1062, DOI 10.1016/j.immuni.2018.09.018; Goldman SL, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00008; Grepin R, 2014, CANCER RES, V74, P873, DOI 10.1158/0008-5472.CAN-13-1267; Grisanti LA, 2017, J CARDIOVASC PHARM, V70, P3, DOI 10.1097/FJC.0000000000000462; Hensley CT, 2016, CELL, V164, P681, DOI 10.1016/j.cell.2015.12.034; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Hsu HC, 2016, ONCOTARGET, V7, P22257, DOI 10.18632/oncotarget.8076; Hu BW, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0562-7; Jones VS, 2016, BBA-REV CANCER, V1865, P255, DOI 10.1016/j.bbcan.2016.03.005; Kogan-Sakin I, 2009, CARCINOGENESIS, V30, P698, DOI 10.1093/carcin/bgp043; Kuo PL, 2012, CARCINOGENESIS, V33, P2477, DOI 10.1093/carcin/bgs299; Lawson DA, 2018, NAT CELL BIOL, V20, P1349, DOI 10.1038/s41556-018-0236-7; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Mangahas CR, 2005, J INVEST DERMATOL, V125, P307, DOI 10.1111/j.0022-202X.2005.23820.x; MILNE GWA, 1994, J CHEM INF COMP SCI, V34, P1219, DOI 10.1021/ci00021a032; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Mishra J, 2013, CRIT REV ONCOL HEMAT, V86, P232, DOI 10.1016/j.critrevonc.2012.09.014; Mizumoto Y, 2011, CLIN CANCER RES, V17, P1341, DOI 10.1158/1078-0432.CCR-10-2291; Nolen BM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2096; Park MH, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020015; Park YL, 2019, INT J CANCER, V144, P389, DOI 10.1002/ijc.31662; Pommier AJC, 2014, BRIT J CANCER, V111, P1590, DOI 10.1038/bjc.2014.436; Ramesh G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/480739; Saunders NA, 2012, EMBO MOL MED, V4, P675, DOI 10.1002/emmm.201101131; Shaw VE, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-114; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303; Song SH, 2007, MOL CELL, V28, P810, DOI 10.1016/j.molcel.2007.09.025; Spaks A, 2017, J THORAC DIS, V9, pS164, DOI 10.21037/jtd.2017.03.61; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Susek KH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02159; Taylor SC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02217-x; Turner MD, 2014, BBA-MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014; van Brummelen EMJ, 2017, ONCOLOGIST, V22, P864, DOI 10.1634/theoncologist.2017-0031; Wang ZX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010095; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Xu JM, 2017, CLIN CANCER RES, V23, P4602, DOI 10.1158/1078-0432.CCR-16-2738; Yako YY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154016; Yamazaki N, 2017, CANCER SCI, V108, P1022, DOI 10.1111/cas.13226; Yuan M, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6530410; Yun J, 2016, NUCLEIC ACIDS RES, V44, P558, DOI 10.1093/nar/gkv933; Zhao B, 2017, ONCOTARGET, V8, P3980, DOI 10.18632/oncotarget.14012	55	4	4	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2026	2038		10.1038/s41388-021-01920-4	http://dx.doi.org/10.1038/s41388-021-01920-4		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35173310				2022-12-28	WOS:000756457400003
J	Li, BS; Kang, HY; Xiao, YF; Du, YX; Xiao, YH; Song, GJ; Zhang, Y; Guo, Y; Yang, F; He, FT; Yang, SM				Li, Bosheng; Kang, Houyi; Xiao, Yufeng; Du, Yexiang; Xiao, Yunhua; Song, Guojing; Zhang, Yan; Guo, Yu; Yang, Fan; He, Fengtian; Yang, Shiming			LncRNA GAL promotes colorectal cancer liver metastasis through stabilizing GLUT1	ONCOGENE			English	Article							GLUCOSE; SUMOYLATION; INTERACTS	Colorectal cancer liver metastasis (CRLM) is the leading cause of colorectal cancer-related deaths and remains a clinical challenge. Enhancement of glucose uptake is involved in CRLM; however, whether long noncoding RNAs (lncRNAs) participate in these molecular events remains largely unclear. Here, we report an lncRNA, GAL (glucose transporter 1 (GLUT1) associated lncRNA), that was upregulated in CRLM tissues compared with primary colorectal cancer (CRC) tissues or matched normal tissues and was associated with the overall survival rates of CRLM patients. Functionally, GAL served as an oncogene because it promoted CRC cell migration and invasion in vitro and enhanced the ability of CRC cells to metastasize from the intestine to the liver in vivo. Mechanistically, GAL interacted with the GLUT1 protein to increase GLUT1 SUMOylation, inhibiting the effect of the ubiquitin-proteasome system on the GLUT1 protein. GLUT1-knockout (-/+) repressed the GAL-mediated increase in CRC cell uptake of glucose, migrate, and invade in vitro, as well as metastasis from the intestine to the liver in vivo, and enforced expression of GLUT1 rescued GAL knockout-induced biological functions in CRC cells. Taken together, our findings demonstrated that GAL promotes CRLM by stabilizing GLUT1, suggesting that the GAL-GLUT1 complex may act as a potential therapeutic target for CRLM.	[Li, Bosheng; Zhang, Yan; Yang, Fan; He, Fengtian] Army Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China; [Li, Bosheng; Xiao, Yufeng; Du, Yexiang; Yang, Shiming] Army Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing 400037, Peoples R China; [Kang, Houyi; Guo, Yu] Army Med Univ, Daping Hosp, Dept Radiol, Chongqing 400042, Peoples R China; [Xiao, Yunhua] Army Med Univ, Southwest Hosp, Dept Radiol, Chongqing 400038, Peoples R China; [Song, Guojing] Army Med Univ, Southwest Hosp, Dept Urol, Chongqing 400038, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Army Medical University; Army Medical University	He, FT (corresponding author), Army Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China.; Yang, SM (corresponding author), Army Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing 400037, Peoples R China.	hefengtian06@aliyun.com; yangshiming@tmmu.edu.cn	He, Feng/HHS-6457-2022	He, Feng/0000-0002-1996-0744; Xiao, Yu-Feng/0000-0002-4410-4448; Xiao, Yunhua/0000-0002-2898-7180	Natural Science Foundation of China [81773037]; Chongqing Science and Technology Commission Fund [cstc2019jcyj-msxmX0378, cstc2019jcyj-bshX0040]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chongqing Science and Technology Commission Fund	This work was supported by grants from the Natural Science Foundation of China (81773037) and the Chongqing Science and Technology Commission Fund (cstc2019jcyj-msxmX0378 and cstc2019jcyj-bshX0040).	Actis Dato V, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84090-3; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; Bu PC, 2018, CELL METAB, V27, P1249, DOI 10.1016/j.cmet.2018.04.003; Bu PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7879; Burger AM, 2004, EUR J CANCER, V40, P2217, DOI 10.1016/j.ejca.2004.07.006; Chen HR, 2021, GASTROENTEROLOGY, V160, P1284, DOI 10.1053/j.gastro.2020.11.013; Deng D, 2014, NATURE, V510, P121, DOI 10.1038/nature13306; Fang YW, 2016, GENOM PROTEOM BIOINF, V14, P42, DOI 10.1016/j.gpb.2015.09.006; Fernandes R, 2004, MOL VIS, V10, P618; Ferre F, 2016, BRIEF BIOINFORM, V17, P106, DOI 10.1093/bib/bbv031; Gil N, 2020, NAT REV GENET, V21, P102, DOI 10.1038/s41576-019-0184-5; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Gras D, 2014, REV NEUROL-FRANCE, V170, P91, DOI 10.1016/j.neurol.2013.09.005; Graziano F, 2017, PHARMACOGENOMICS J, V17, P258, DOI 10.1038/tpj.2016.13; Gu J, 2006, DIGEST DIS SCI, V51, P2198, DOI 10.1007/s10620-006-9428-2; Haber RS, 1998, CANCER, V83, P34, DOI 10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E; Han X, 2015, GRAEF ARCH CLIN EXP, V253, P1279, DOI 10.1007/s00417-015-2999-x; Huang HJ, 2015, AM J CANCER RES, V5, P309; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Lee MH, 2006, NAT CELL BIOL, V8, P1424, DOI 10.1038/ncb1512; Li SJ, 2020, CELL SIGNAL, V73, DOI 10.1016/j.cellsig.2020.109686; Liao ZM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.641343; McHugh CA, 2015, NATURE, V521, P232, DOI 10.1038/nature14443; Mueckler M, 2013, MOL ASPECTS MED, V34, P121, DOI 10.1016/j.mam.2012.07.001; Nickels KC, 2016, NAT REV NEUROL, V12, P465, DOI 10.1038/nrneurol.2016.98; Salvi AM, 2021, NAT CELL BIOL, V23, P457, DOI 10.1038/s41556-021-00677-y; Sarropoulos I, 2019, NATURE, V571, P510, DOI 10.1038/s41586-019-1341-x; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Tang JY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11447-8; Tsoi LC, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0570-4; Zambrano A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133374; Zhang MY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36238-x; Zhang YC, 2020, ACTA PHARMACOL SIN B, V10, P79, DOI 10.1016/j.apsb.2019.12.005	34	2	2	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1882	1894		10.1038/s41388-022-02230-z	http://dx.doi.org/10.1038/s41388-022-02230-z		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35149838				2022-12-28	WOS:000754149100001
J	Jeong, HS; Lee, DH; Kim, SH; Lee, CH; Shin, HM; Kim, HR; Cho, CH				Jeong, Han-Seok; Lee, Da-Hye; Kim, Seung-Hoon; Lee, Chang-Han; Shin, Hyun Mu; Kim, Hang-Rae; Cho, Chung-Hyun			Hyperglycemia-induced oxidative stress promotes tumor metastasis by upregulating vWF expression in endothelial cells through the transcription factor GATA1	ONCOGENE			English	Article							VON-WILLEBRAND-FACTOR; TIGHT JUNCTION PROTEINS; VASCULAR-PERMEABILITY; STAT3 ACTIVATION; PLASMA-LEVELS; CANCER; SECRETION; INFLAMMATION; PLATELETS; INSIGHTS	Diabetes mellitus (DM) characterized by hyperglycemia is a chronic metabolic disorder that leads to many symptoms and vascular complications. Despite the close association between DM and cancer progression, the response and role of endothelial cells (ECs) under diabetic conditions in tumor metastasis remain to be elucidated. In this study, we sought to determine whether and how ECs under diabetic conditions contribute to tumor metastasis. We have taken advantage of syngeneic mouse tumor models of Lewis lung carcinoma (LLC) and melanoma (B16F10) cells and a streptozotocin (STZ)-induced hyperglycemia model. We demonstrated that hyperglycemia increased the metastasis of LLC and B16F10 cells in an experimental metastasis model with an intravenous injection of the tumor cells. We also found that hyperglycemia promoted lung metastasis of tumor cells by increasing the adhesiveness of ECs to facilitate the adhesion of tumor cells to ECs rather than affecting the metastatic behavior of tumor cells themselves. From the analysis of gene expression in primary lung ECs from STZ-treated mice, we identified that vWF promoted the adhesion of tumor cells to ECs and the transendothelial migration of tumor cells. Mechanistically, hyperglycemia-induced oxidative stress in ECs, and increased oxidative stress enhanced vWF expression in ECs through an increase in the transcription factor GATA1. These results provide evidence for the role of vWF in ECs in promoting hyperglycemia-induced tumor metastasis and potential therapeutic targets for the regulation of vWF expression in ECs and hyperglycemia-induced tumor metastasis.	[Jeong, Han-Seok; Lee, Da-Hye; Kim, Seung-Hoon; Lee, Chang-Han; Shin, Hyun Mu; Kim, Hang-Rae; Cho, Chung-Hyun] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 03080, South Korea; [Jeong, Han-Seok; Lee, Da-Hye; Kim, Seung-Hoon; Lee, Chang-Han; Cho, Chung-Hyun] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 03080, South Korea; [Shin, Hyun Mu] Seoul Natl Univ, Coll Med, Wide River Inst Immunol, Hongcheon 25159, South Korea; [Kim, Hang-Rae] Seoul Natl Univ, Dept Anat & Cell Biol, Seoul 03080, South Korea; [Cho, Chung-Hyun] Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul 03080, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Cho, CH (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 03080, South Korea.; Cho, CH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 03080, South Korea.; Cho, CH (corresponding author), Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul 03080, South Korea.	iamhyun@snu.ac.kr		Kim, Hang-Rae/0000-0002-3983-6193	National Research Foundation of Korea - Korea government [2020R1A2C1008008]; SNUH Research Fund [0420210290]	National Research Foundation of Korea - Korea government(National Research Foundation of KoreaKorean Government); SNUH Research Fund	We appreciate Dr. Kyong Soo Park for technical assistance in insulin supplementation experiments. This work is supported by funding from the National Research Foundation of Korea grant funded by the Korea government (2020R1A2C1008008 to CHC) and the SNUH Research Fund (0420210290 to CHC).	Aghajanian A, 2008, J THROMB HAEMOST, V6, P1453, DOI 10.1111/j.1538-7836.2008.03087.x; Avdonin PV, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020196; Basta G, 2004, CARDIOVASC RES, V63, P582, DOI 10.1016/j.cardiores.2004.05.001; Blann AD, 2011, PROSTATE, V71, P1047, DOI 10.1002/pros.21319; Carstensen B, 2016, DIABETOLOGIA, V59, P980, DOI 10.1007/s00125-016-3884-9; Chan Norman N, 2003, Med Sci Monit, V9, pCR297; Chan SHH, 2009, CIRC RES, V105, P886, DOI 10.1161/CIRCRESAHA.109.199018; Coller BS, 2008, BLOOD, V112, P3011, DOI 10.1182/blood-2008-06-077891; De Ceunynck K, 2013, BLOOD, V121, P270, DOI 10.1182/blood-2012-07-442285; Dmitrieva NI, 2014, P NATL ACAD SCI USA, V111, P6485, DOI 10.1073/pnas.1404809111; Drummond GR, 2014, TRENDS ENDOCRIN MET, V25, P452, DOI 10.1016/j.tem.2014.06.012; Dymkowska D, 2014, ARCH BIOCHEM BIOPHYS, V542, P7, DOI 10.1016/j.abb.2013.11.008; Fainsod-Levi T, 2017, CELL REP, V21, P2384, DOI 10.1016/j.celrep.2017.11.010; Fan C, 2009, J BIOL CHEM, V284, P23331, DOI 10.1074/jbc.M109.036079; Foda HD, 2001, DRUG DISCOV TODAY, V6, P478, DOI 10.1016/S1359-6446(01)01752-4; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Franchini M, 2013, THROMB RES, V131, P290, DOI 10.1016/j.thromres.2013.01.015; Franses JW, 2013, INT J CANCER, V133, P1334, DOI 10.1002/ijc.28146; GADDUCCI A, 1994, GYNECOL ONCOL, V53, P352, DOI 10.1006/gyno.1994.1146; Garcia-Roman J, 2013, CANCER LETT, V335, P259, DOI 10.1016/j.canlet.2013.03.005; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; Gorin Y, 2013, CLIN SCI, V125, P361, DOI 10.1042/CS20130065; He H, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01531; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Ikemura M, 2017, ANTICANCER RES, V37, P5463, DOI 10.21873/anticanres.11975; Ikemura M, 2013, J CONTROL RELEASE, V170, P191, DOI 10.1016/j.jconrel.2013.05.028; Jafar N, 2016, AM J MED SCI, V351, P201, DOI 10.1016/j.amjms.2015.11.011; Jeon HY, 2019, FASEB J, V33, P750, DOI 10.1096/fj.201800723R; KARPATKIN S, 1988, J CLIN INVEST, V81, P1012, DOI 10.1172/JCI113411; Kim KJ, 2017, ONCOGENE, V36, P5445, DOI 10.1038/onc.2017.148; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Li NL, 2016, INT J CANCER, V138, P2078, DOI 10.1002/ijc.29847; Li WJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1309-6; Liu J, 2009, J THROMB HAEMOST, V7, P1384, DOI 10.1111/j.1538-7836.2009.03501.x; Lou ZK, 2018, MOL MED REP, V17, P2479, DOI 10.3892/mmr.2017.8124; Marini A, 2018, P NATL ACAD SCI USA, V115, P6219, DOI 10.1073/pnas.1718531115; MORDES DB, 1983, DIABETES, V32, P876, DOI 10.2337/diabetes.32.9.876; Morganti M, 2000, BIOMED PHARMACOTHER, V54, P431, DOI 10.1016/S0753-3322(00)00006-8; NICHOLS TC, 1995, P NATL ACAD SCI USA, V92, P2455, DOI 10.1073/pnas.92.7.2455; Noh Y, 2019, INT J CANCER, V144, P1530, DOI 10.1002/ijc.31870; O'Sullivan JM, 2018, SEMIN THROMB HEMOST, V44, P159, DOI 10.1055/s-0037-1607352; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Pilch J, 2002, J BIOL CHEM, V277, P21930, DOI 10.1074/jbc.M201630200; Rohsig LM, 2001, BRAZ J MED BIOL RES, V34, P1125; Sadler JE, 2013, BLOOD, V121, P2583, DOI 10.1182/blood-2013-02-482000; Scappaticcio L, 2017, ENDOCRINE, V56, P231, DOI 10.1007/s12020-016-1216-y; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; Seligman BGS, 2000, DIABETES CARE, V23, P1395, DOI 10.2337/diacare.23.9.1395; Spratt DE, 2016, INT J RADIAT ONCOL, V94, P523, DOI 10.1016/j.ijrobp.2015.11.007; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Takano M, 2002, AM J PHYSIOL-HEART C, V283, pH2054, DOI 10.1152/ajpheart.01001.2001; Terraube V, 2006, J THROMB HAEMOST, V4, P519, DOI 10.1111/j.1538-7836.2005.01770.x; Terraube V, 2007, THROMB RES, V120, pS64, DOI 10.1016/S0049-3848(07)70132-9; Umetani M, 2001, ARTERIOSCL THROM VAS, V21, P917, DOI 10.1161/01.ATV.21.6.917; VISCHER UM, 1995, BLOOD, V85, P3164, DOI 10.1182/blood.V85.11.3164.bloodjournal85113164; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Wang JP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37130-4; Wang WS, 2005, WORLD J GASTROENTERO, V11, P2166, DOI 10.3748/wjg.v11.i14.2166; Xiang YZ, 2015, BLOOD, V125, P3377, DOI 10.1182/blood-2015-01-620278; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yun JH, 2021, J CELL PHYSIOL, V236, P7058, DOI 10.1002/jcp.30373; Yun JH, 2017, J CELL PHYSIOL, V232, P1123, DOI 10.1002/jcp.25575; Zheng Y, 2016, AM J PATHOL, V186, P1081, DOI 10.1016/j.ajpath.2015.12.020	64	1	1	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1634	1646		10.1038/s41388-022-02207-y	http://dx.doi.org/10.1038/s41388-022-02207-y		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35094008				2022-12-28	WOS:000750486500003
J	Okpechi, SC; Yousefi, H; Nguyen, K; Cheng, T; Alahari, NV; Collins-Burow, B; Burow, ME; Alahari, SK				Okpechi, Samuel C.; Yousefi, Hassan; Nguyen, Khoa; Cheng, Thomas; Alahari, Nikhilesh, V; Collins-Burow, Bridgette; Burow, Matthew E.; Alahari, Suresh K.			Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer	ONCOGENE			English	Review							BINDING PROTEIN NISCHARIN; IMIDAZOLINE RECEPTOR; DOWN-REGULATION; EXPRESSION; KINASE; IRAS; INHIBITION; MODULATION; ACTIVATION; SECRETION	Nischarin has been demonstrated to have tumor suppressor functions. In this review, we comprehensively discuss up to date information about Nischarin. In addition, this paper aims to report the prognostic value, clinical relevance, and biological significance of the Nischarin gene (NISCH) in breast cancer (BCa) patients using the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas (TCGA) datasets. We evaluated NISCH gene expression and its correlation to patient survival, baseline expression, and expression variation based on age groups, tumor stage, tumor size, tumor grade, and lymph node status in different subtypes of BCa. Since NISCH has been extensively reported to inhibit EMT and cancer cell migration, we also checked for the correlation between NISCH and EMT genes in addition to the correlation between NISCH and cell migration genes. Our results indicate that NISCH is a tumor suppressor that plays a critical role in BCa initiation, progression, and tumor development. We find that there is a higher level of NISCH expression in normal breast tissues compared to breast cancer tissues. Also, aggressive subtypes of breast cancers, such as the triple negative/basal category, have decreased levels of NISCH as the disease progresses. Finally, we report that NISCH is inversely correlated with many EMT and cancer cell migration genes in BCa. Interestingly, we identified a significant negative correlation between NISCH expression and its methylation in breast cancer patients. Overall, the goal of this report is to establish a strong clinical basis for further investigation into the cellular, molecular, and physiological roles of NISCH in BCa. Ultimately, NISCH gene expression might be clinically harnessed as a biomarker or predictor of invasiveness and metastasis in BCa.	[Okpechi, Samuel C.; Yousefi, Hassan; Alahari, Suresh K.] Louisiana State Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Okpechi, Samuel C.; Yousefi, Hassan; Alahari, Suresh K.] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA; [Okpechi, Samuel C.; Yousefi, Hassan; Alahari, Suresh K.] Louisiana State Univ, Sch Med, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; [Nguyen, Khoa; Cheng, Thomas; Collins-Burow, Bridgette; Burow, Matthew E.] Tulane Univ, Sch Med, Sect Hematol & Med Oncol, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Alahari, Nikhilesh, V] Louisiana State Univ Biol Sci, Baton Rouge, LA USA	Louisiana State University System; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Tulane University; Louisiana State University System; Louisiana State University	Alahari, SK (corresponding author), Louisiana State Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.; Alahari, SK (corresponding author), Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA.; Alahari, SK (corresponding author), Louisiana State Univ, Sch Med, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA.	salaha@lsuhsc.edu			Fred G. Brazda Foundation; Department of Biochemistry and Molecular Biology, Louisiana State University School of Medicine and Health Sciences Center, New Orleans	Fred G. Brazda Foundation; Department of Biochemistry and Molecular Biology, Louisiana State University School of Medicine and Health Sciences Center, New Orleans	We wish to thank the Fred G. Brazda Foundation and the Department of Biochemistry and Molecular Biology, Louisiana State University School of Medicine and Health Sciences Center, New Orleans, for their financial support.	Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Amisten S, 2018, J DIABETES COMPLICAT, V32, P813, DOI 10.1016/j.jdiacomp.2018.06.010; Baranwal S, 2011, J NATL CANCER I, V103, P1513, DOI 10.1093/jnci/djr350; Cai YJ, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12154; Chang C, 2017, BIOCHEM BIOPH RES CO, V484, P536, DOI 10.1016/j.bbrc.2017.01.109; Chen J, 2015, MOL MED REP, V12, P77, DOI 10.3892/mmr.2015.3373; Chen MJ, 2003, ANN NY ACAD SCI, V1009, P427, DOI 10.1196/annals.1304.057; Crompton M, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006969; Ding YM, 2017, NEURAL REGEN RES, V12, P1687, DOI 10.4103/1673-5374.217348; Ding YM, 2008, MOL CELL BIOL, V28, P3742, DOI 10.1128/MCB.01832-07; Ding YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144948; Ding YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054563; Dong SL, 2020, INT J CANCER, V146, P2576, DOI 10.1002/ijc.32690; Dong SL, 2019, INT J OBESITY, V43, P1046, DOI 10.1038/s41366-018-0241-8; Dong SL, 2017, J BIOL CHEM, V292, P16833, DOI 10.1074/jbc.M117.784256; Eastlack SC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198945; Geng RS, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01395; Guo ZP, 2020, NEUROREPORT, V31, P1199, DOI 10.1097/WNR.0000000000001536; Guo ZP, 2019, EXP THER MED, V17, P663, DOI 10.3892/etm.2018.7017; Heid IM, 2010, NAT GENET, V42, P949, DOI 10.1038/ng.685; Hotta K, 2013, J ATHEROSCLER THROMB, V20, P336, DOI 10.5551/jat.14589; Jain P, 2013, J BIOL CHEM, V288, P15495, DOI 10.1074/jbc.M112.418103; Jemal A., 2021, J CLIN, V71, P33, DOI [10.3322/caac.21654, DOI 10.3322/CAAC.21654]; Jin LJ, 2013, CANCER RES, V73, P2884, DOI 10.1158/0008-5472.CAN-12-2162; Keller B, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00258; Keller B, 2017, NEUROCHEM INT, V108, P169, DOI 10.1016/j.neuint.2017.03.012; Keller B, 2017, J AFFECT DISORDERS, V208, P646, DOI 10.1016/j.jad.2016.10.007; Kuijl C, 2013, EMBO J, V32, P713, DOI 10.1038/emboj.2013.10; Li F, 2006, J CELL BIOCHEM, V98, P1615, DOI 10.1002/jcb.20806; Li F, 2016, MOL NEUROBIOL, V53, P4918, DOI 10.1007/s12035-015-9417-6; Li F, 2012, ADDICT BIOL, V17, P392, DOI 10.1111/j.1369-1600.2011.00373.x; Li J, 2015, MOL CANCER THER, V14, P1202, DOI 10.1158/1535-7163.MCT-14-0911; Li S, 2019, BIOCHEM BIOPH RES CO, V512, P460, DOI 10.1016/j.bbrc.2019.03.055; Lim KP, 2004, J BIOL CHEM, V279, P54770, DOI 10.1074/jbc.M411315200; Lin MH, 2017, CLIN EXP PHARMACOL P, V44, P1254, DOI 10.1111/1440-1681.12815; Maziveyi M, 2019, CANCER RES, V79, P2152, DOI 10.1158/0008-5472.CAN-18-0842; Maziveyi M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0764-6; Maziveyi M, 2015, CANCER RES, V75, P4252, DOI 10.1158/0008-5472.CAN-15-1395; McAndrews KM, 2019, CANCER RES, V79, P2099, DOI 10.1158/0008-5472.CAN-19-0387; McGuire A, 2015, CANCERS, V7, P908, DOI 10.3390/cancers7020815; Nagakura Y, 2021, NEUROSCI LETT, V761, DOI 10.1016/j.neulet.2021.136113; Nagini S, 2017, ANTI-CANCER AGENT ME, V17, P152, DOI 10.2174/1871520616666160502122724; Ostrow KL, 2010, CLIN CANCER RES, V16, P3463, DOI 10.1158/1078-0432.CCR-09-3304; Piletz JE, 1999, ANN NY ACAD SCI, V881, P1, DOI 10.1111/j.1749-6632.1999.tb09335.x; Rathnam C, 2017, ARTIF INTELL MED, V75, P1, DOI 10.1016/j.artmed.2016.10.003; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Tsang JYS, 2020, ADV ANAT PATHOL, V27, P27, DOI 10.1097/PAP.0000000000000232; Uren C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174738; Wiatrak B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040958; Wu N, 2006, EUR J PHARMACOL, V548, P21, DOI 10.1016/j.ejphar.2006.07.013; Wu XH, 2013, INFLAMM RES, V62, P929, DOI 10.1007/s00011-013-0631-2; Zhang J, 2008, J PHARMACOL EXP THER, V324, P72, DOI 10.1124/jpet.107.129049; Zhang L, 2013, CNS NEUROSCI THER, V19, P978, DOI 10.1111/cns.12192; Zhao Y, 2018, NEUROSCI BIOBEHAV R, V95, P347, DOI 10.1016/j.neubiorev.2018.10.005	54	0	0	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1079	1086		10.1038/s41388-021-02150-4	http://dx.doi.org/10.1038/s41388-021-02150-4		JAN 2022	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35064214				2022-12-28	WOS:000745402900002
J	Guo, F; Cheng, X; Jing, BP; Wu, HS; Jin, X				Guo, Feng; Cheng, Xiang; Jing, Boping; Wu, Heshui; Jin, Xin			FGD3 binds with HSF4 to suppress p65 expression and inhibit pancreatic cancer progression	ONCOGENE			English	Article							FACTOR-KAPPA-B; HEAT-SHOCK FACTORS; MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR; R PACKAGE; GENE; GEMCITABINE; GROWTH; CELLS	Pancreatic cancer is regarded as the most lethal solid tumor worldwide. Deregulated and constitutively activated NF-kappa B signaling is one of the major characteristics of pancreatic cancer. The total expression level and subcellular localization of RelA/p65 have been shown to determine the activation of canonical NF-kappa B signaling in pancreatic cancer. FGD3, which is involved in regulating the actin cytoskeleton and cell shape, has been reported to inhibit cancer cell migration and predict a favorable prognosis in multiple types of cancer. However, the specific role of FGD3 in pancreatic cancer is still unknown. In this study, we conducted a systematic investigation of the cancer-related role of FGD3 in pancreatic cancer. We demonstrated that FGD3 was abnormally downregulated in pancreatic cancer tissues and that low expression of FGD3 was associated with unfavorable prognosis in patients with pancreatic cancer. Then, we showed that FGD3 inhibited pancreatic cancer cell proliferation, invasion and metastasis in vivo and in vitro. Moreover, we revealed that FGD3 silencing activated the NF-kappa B signaling pathway by promoting HSF4 nuclear translocation and increasing p65 expression in pancreatic cancer cells. Therefore, our results identified a novel and targetable FGD3/HSF4/p65 signaling axis in pancreatic cancer cells.	[Guo, Feng; Wu, Heshui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pancreat Surg, Wuhan 430022, Peoples R China; [Guo, Feng; Wu, Heshui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Sino German Lab Personalized Med Pancreat Canc, Wuhan 430022, Peoples R China; [Cheng, Xiang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China; [Jing, Boping] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Ultrasound, Wuhan 430022, Hubei, Peoples R China; [Jin, Xin] Cent South Univ, Xiangya Hosp 2, Dept Urol, Changsha 410011, Hunan, Peoples R China; [Jin, Xin] Cent South Univ, Urooncol Inst, Changsha 410011, Hunan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Central South University; Central South University	Wu, HS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pancreat Surg, Wuhan 430022, Peoples R China.; Wu, HS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Sino German Lab Personalized Med Pancreat Canc, Wuhan 430022, Peoples R China.; Jin, X (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Urol, Changsha 410011, Hunan, Peoples R China.; Jin, X (corresponding author), Cent South Univ, Urooncol Inst, Changsha 410011, Hunan, Peoples R China.	Heshuiwu@hust.edu.cn; jinxinxy2@csu.edu.cn		Jin, Xin/0000-0001-6461-6005; Guo, Feng/0000-0003-0882-5296; jing, boping/0000-0001-8664-201X	National Natural Science Foundation of China [82073178, 82073321]; Science Foundation of Ministry of Education of China [2172019kfyRCPY069]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Foundation of Ministry of Education of China(Ministry of Education, China)	This work was supported by grants from the National Natural Science Foundation of China (Grant No. 82073178 (H.W.), Grant No. 82073321 (X.J.)) and Science Foundation of Ministry of Education of China (Grant No. 2172019kfyRCPY069 (X.J.)).	Abane R, 2010, FEBS J, V277, P4150, DOI 10.1111/j.1742-4658.2010.07830.x; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Azoitei N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-015-0490-2; Cable J, 2021, ANN NY ACAD SCI, V1489, P30, DOI 10.1111/nyas.14526; Chen R, 2011, ONCOGENE, V30, P2570, DOI 10.1038/onc.2010.623; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Cui XK, 2012, BBA-MOL BASIS DIS, V1822, P1308, DOI 10.1016/j.bbadis.2012.05.005; Dougan SK, 2017, CANCER J, V23, P321, DOI 10.1097/PPO.0000000000000288; Fan P, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1044-z; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fujimoto M, 2004, EMBO J, V23, P4297, DOI 10.1038/sj.emboj.7600435; Hanson JL, 2004, CANCER RES, V64, P7248, DOI 10.1158/0008-5472.CAN-03-3898; Jin X, 2019, MOL CELL, V73, P22, DOI 10.1016/j.molcel.2018.10.034; Jin XJ, 2012, MOL CANCER RES, V10, P523, DOI 10.1158/1541-7786.MCR-11-0530; Jing BP, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-020-00746-8; Kabacaoglu D, 2019, CANCERS, V11, DOI 10.3390/cancers11070937; Khalaf N, 2021, CLIN GASTROENTEROL H, V19, P876, DOI 10.1016/j.cgh.2020.02.054; Kong R, 2010, CANCER LETT, V291, P90, DOI 10.1016/j.canlet.2009.10.001; Liao SJ, 2018, GENE, V655, P30, DOI 10.1016/j.gene.2018.02.033; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Ma C, 2019, BIOMARK MED, V13, P1399, DOI 10.2217/bmm-2019-0273; Ma P, 2020, LIVER INT, V40, P1211, DOI 10.1111/liv.14410; Makieva S, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.02.009; Matsuo Y, 2004, PANCREAS, V28, P344, DOI 10.1097/00006676-200404000-00025; Meng QC, 2020, THERANOSTICS, V10, P3967, DOI 10.7150/thno.40566; Nakanishi H, 2008, J CELL MOL MED, V12, P1169, DOI 10.1111/j.1582-4934.2008.00345.x; Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev; Oshima T, 2010, BIOL PHARM BULL, V33, P35, DOI 10.1248/bpb.33.35; Pan X, 2008, CLIN CANCER RES, V14, P8143, DOI 10.1158/1078-0432.CCR-08-1539; Pasteris NG, 2000, GENE, V242, P237, DOI 10.1016/S0378-1119(99)00518-1; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Renda I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51766-w; Shi XH, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-10; Susini T, 2020, ANTICANCER RES, V40, P3645, DOI 10.21873/anticanres.14353; Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300; Wang L, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0627-6; Wang LL, 2017, CANCER LETT, V398, P24, DOI 10.1016/j.canlet.2017.04.001; Wang WX, 1999, CLIN CANCER RES, V5, P119; Willis S, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00009; Wu J, 2021, DIGEST DIS SCI, V66, P359, DOI 10.1007/s10620-020-06183-9; Wu JM, 2017, TRENDS PHARMACOL SCI, V38, P226, DOI 10.1016/j.tips.2016.11.009; Wu W, 2020, THERANOSTICS, V10, P2859, DOI 10.7150/thno.41279; Yan J, 2013, CELL, V154, P801, DOI 10.1016/j.cell.2013.07.034; Yang YC, 2017, IUBMB LIFE, V69, P956, DOI 10.1002/iub.1692; Yang YP, 2015, J CLIN INVEST, V125, P3335, DOI 10.1172/JCI83871; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118	46	0	0	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					838	851		10.1038/s41388-021-02140-6	http://dx.doi.org/10.1038/s41388-021-02140-6		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34975151				2022-12-28	WOS:000737109100002
J	Pehkonen, H; de Curtis, I; Monni, O				Pehkonen, Henna; de Curtis, Ivan; Monni, Outi			Liprins in oncogenic signaling and cancer cell adhesion	ONCOGENE			English	Review							PROTEIN-TYROSINE-PHOSPHATASE; RESOLUTION COPY NUMBER; EXTRACELLULAR-MATRIX; ACTIVE ZONE; NEUROTRANSMITTER RELEASE; 11Q13 AMPLIFICATION; INTEGRIN ADHESOME; POOR-PROGNOSIS; ALPHA FAMILY; ORAL-CANCER	Liprins are a multifunctional family of scaffold proteins, identified by their involvement in several important neuronal functions related to signaling and organization of synaptic structures. More recently, the knowledge on the liprin family has expanded from neuronal functions to processes relevant to cancer progression, including cell adhesion, cell motility, cancer cell invasion, and signaling. These proteins consist of regions, which by prediction are intrinsically disordered, and may be involved in the assembly of supramolecular structures relevant for their functions. This review summarizes the current understanding of the functions of liprins in different cellular processes, with special emphasis on liprins in tumor progression. The available data indicate that liprins may be potential biomarkers for cancer progression and may have therapeutic importance.	[Pehkonen, Henna; Monni, Outi] Univ Helsinki, Fac Med, Appl Tumor Genom Res Program, Helsinki, Finland; [Pehkonen, Henna; Monni, Outi] Univ Helsinki, Fac Med, Dept Oncol, Helsinki, Finland; [de Curtis, Ivan] San Raffaele Vita Salute Univ, IRCSS, San Raffaele Sci Inst, Cell Adhes Unit,Div Neurosci, Milan, Italy; [Monni, Outi] iCAN Digital Precis Canc Med Flagship, Helsinki, Finland	University of Helsinki; University of Helsinki; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Monni, O (corresponding author), Univ Helsinki, Fac Med, Appl Tumor Genom Res Program, Helsinki, Finland.; Monni, O (corresponding author), Univ Helsinki, Fac Med, Dept Oncol, Helsinki, Finland.; Monni, O (corresponding author), iCAN Digital Precis Canc Med Flagship, Helsinki, Finland.	outi.monni@helsinki.fi		Monni, Outi/0000-0002-2319-8799	University of Helsinki including Helsinki University Central Hospital	University of Helsinki including Helsinki University Central Hospital	Open access funding provided by University of Helsinki including Helsinki University Central Hospital.	AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6; Alfarsi LH, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06939-6; Asperti C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020757; Asperti C, 2010, EXP CELL RES, V316, P915, DOI 10.1016/j.yexcr.2010.01.017; Asperti C, 2009, J CELL SCI, V122, P3225, DOI 10.1242/jcs.054155; Astigarraga S, 2010, J NEUROSCI, V30, P15358, DOI 10.1523/JNEUROSCI.1862-10.2010; Astro V, 2011, ONCOGENE, V30, P1841, DOI 10.1038/onc.2010.562; Astro V, 2016, SCI REP-UK, V6, DOI 10.1038/srep33653; Astro V, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa3312; Astro V, 2014, J CELL SCI, V127, P3862, DOI 10.1242/jcs.155663; Banani SF, 2017, NAT REV MOL CELL BIO, V18, P285, DOI 10.1038/nrm.2017.7; Bari R, 2009, AM J PATHOL, V174, P647, DOI 10.2353/ajpath.2009.080685; Barros MC, 2018, ORAL ONCOL, V83, P81, DOI 10.1016/j.oraloncology.2018.06.010; Bera R, 2014, HEPATOLOGY, V59, P2238, DOI 10.1002/hep.27030; Bernadzki KM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09590-7; Boija A, 2021, CANCER CELL, V39, P174, DOI 10.1016/j.ccell.2020.12.003; Bomkamp C, 2019, FRONT SYNAPTIC NEURO, V11, DOI 10.3389/fnsyn.2019.00017; Branch KM, 2012, BIOL OPEN, V1, P711, DOI 10.1242/bio.20121867; Brenig J, 2015, J BIOL CHEM, V290, P14314, DOI 10.1074/jbc.M114.621946; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Buraschi S, 2020, MATRIX BIOL, V93, P10, DOI 10.1016/j.matbio.2020.03.009; Cai DF, 2021, TRENDS BIOCHEM SCI, V46, P535, DOI 10.1016/j.tibs.2021.01.002; Carneiro A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-98; Chia PH, 2013, MOL CELL NEUROSCI, V56, P76, DOI 10.1016/j.mcn.2013.03.004; Chiaretti S, 2016, BIOL CELL, V108, P65, DOI 10.1111/boc.201500063; Chiaretti S, 2016, CURR CANCER DRUG TAR, V16, P238, DOI 10.2174/156800961603160206124103; Choe KM, 2006, P NATL ACAD SCI USA, V103, P11601, DOI 10.1073/pnas.0601185103; Colas E, 2011, INT J CANCER, V129, P2435, DOI 10.1002/ijc.25901; Dai Y, 2006, NAT NEUROSCI, V9, P1479, DOI 10.1038/nn1808; de Curtis I, 2021, TRENDS CELL BIOL, V31, P145, DOI 10.1016/j.tcb.2020.12.002; de Curtis I, 2011, EXP CELL RES, V317, P1, DOI 10.1016/j.yexcr.2010.09.014; Di Martino J, 2016, J CELL SCI, V129, P1759, DOI 10.1242/jcs.182329; Dickinson ME, 2016, NATURE, V537, P508, DOI 10.1038/nature19356; Emperador-Melero J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23116-w; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Gligorijevic B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001995; Gu CM, 2019, MOL THER-NUCL ACIDS, V16, P1, DOI 10.1016/j.omtn.2019.01.015; Hallam SJ, 2002, NAT NEUROSCI, V5, P1137, DOI 10.1038/nn959; Head BP, 2014, BBA-BIOMEMBRANES, V1838, P532, DOI 10.1016/j.bbamem.2013.07.018; Hoogenraad CC, 2007, DEV CELL, V12, P587, DOI 10.1016/j.devcel.2007.02.006; Horton ER, 2015, NAT CELL BIOL, V17, P1577, DOI 10.1038/ncb3257; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Huang X, 2006, GENE CHROMOSOME CANC, V45, P1058, DOI 10.1002/gcc.20371; Innocenti M, 2018, CELL ADHES MIGR, V12, P401, DOI 10.1080/19336918.2018.1448352; Iyama K, 2017, THYROID, V27, P811, DOI 10.1089/thy.2016.0673; Jakobsen Kristine Raaby, 2013, J Mol Signal, V8, P9, DOI 10.1186/1750-2187-8-9; Jarvinen AK, 2006, ONCOGENE, V25, P6997, DOI 10.1038/sj.onc.1209690; Jarvinen AK, 2008, GENE CHROMOSOME CANC, V47, P500, DOI 10.1002/gcc.20551; Johnson KG, 2003, PHYSIOL REV, V83, P1, DOI 10.1152/physrev.00016.2002; Kaufmann N, 2002, NEURON, V34, P27, DOI 10.1016/S0896-6273(02)00643-8; Kim S, 2003, J BIOL CHEM, V278, P6291, DOI 10.1074/jbc.M212287200; Kittelmann M, 2013, J CELL BIOL, V203, P849, DOI 10.1083/jcb.201302022; Ko J, 2003, J BIOL CHEM, V278, P42377, DOI 10.1074/jbc.M307561200; Ko J, 2003, J NEUROSCI, V23, P1667; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; Laude AJ, 2004, MOL MEMBR BIOL, V21, P193, DOI 10.1080/09687680410001700517; LeVea CM, 2000, BREAST CANCER RES TR, V64, P221, DOI 10.1023/A:1006410509740; Linder S, 2005, J CELL SCI, V118, P2079, DOI 10.1242/jcs.02390; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Linder S, 2009, J CELL SCI, V122, P3009, DOI 10.1242/jcs.032631; Linding R, 2003, STRUCTURE, V11, P1453, DOI 10.1016/j.str.2003.10.002; Liu WM, 2006, CANCER LETT, V240, P183, DOI 10.1016/j.canlet.2005.08.018; Liu YLC, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005608; Luo M, 2016, EXP DERMATOL, V25, P321, DOI 10.1111/exd.12933; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mana G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13546; Mattauch S, 2010, EXP CELL RES, V316, P2883, DOI 10.1016/j.yexcr.2010.06.022; Maturi V, 2018, MOL ONCOL, V12, P1153, DOI 10.1002/1878-0261.12317; McDonald NA, 2020, NATURE, V588, P454, DOI 10.1038/s41586-020-2942-0; Menzies AM, 2015, PIGM CELL MELANOMA R, V28, P607, DOI 10.1111/pcmr.12388; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; Miller KE, 2005, CURR BIOL, V15, P684, DOI 10.1016/j.cub.2005.02.061; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nachat R, 2009, J CELL SCI, V122, P4035, DOI 10.1242/jcs.047266; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Norrmen C, 2010, BLOOD, V115, P906, DOI 10.1182/blood-2009-03-212274; Oates ME, 2013, NUCLEIC ACIDS RES, V41, pD508, DOI 10.1093/nar/gks1226; Olsen O, 2006, CURR OPIN CELL BIOL, V18, P223, DOI 10.1016/j.ceb.2006.02.010; Olsen O, 2005, J CELL BIOL, V170, P1127, DOI 10.1083/jcb.200503011; Ono M, 1999, CANCER RES, V59, P2335; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Owald D, 2010, J CELL BIOL, V188, P565, DOI 10.1083/jcb.200908055; Patel MR, 2006, NAT NEUROSCI, V9, P1488, DOI 10.1038/nn1806; Patel MR, 2009, SCIENCE, V323, P1500, DOI 10.1126/science.1169025; Pehkonen H, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0253-y; Pehkonen H, 2016, SCI REP-UK, V6, DOI 10.1038/srep24486; Petrie RJ, 2009, NAT REV MOL CELL BIO, V10, P538, DOI 10.1038/nrm2729; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; Ramos-Garcia P, 2017, ORAL ONCOL, V72, P7, DOI 10.1016/j.oraloncology.2017.04.016; Robertson J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7265; Sakamoto S, 2012, J CELL SCI, V125, P108, DOI 10.1242/jcs.087411; Sala K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49630-y; Sala K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19447-2; Sarhan AR, 2016, MOL CELL PROTEOMICS, V15, P1823, DOI 10.1074/mcp.M115.053652; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; SCHUURING E, 1992, CANCER RES, V52, P5229; Serra-Pages C, 2005, BIOCHEMISTRY-US, V44, P15715, DOI 10.1021/bi051434f; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shen JC, 2007, CANCER RES, V67, P2552, DOI 10.1158/0008-5472.CAN-06-3870; Shin H, 2003, J BIOL CHEM, V278, P11393, DOI 10.1074/jbc.M211874200; Song JL, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1642-0; Spangler SA, 2007, BIOCHEM SOC T, V35, P1278, DOI 10.1042/BST0351278; Spangler SA, 2013, J CELL BIOL, V201, P915, DOI 10.1083/jcb.201301011; Spangler SA, 2011, J COMP NEUROL, V519, P3040, DOI 10.1002/cne.22665; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; Stryker E, 2007, J CELL SCI, V120, P3723, DOI 10.1242/jcs.03491; Stylli SS, 2008, J CLIN NEUROSCI, V15, P725, DOI 10.1016/j.jocn.2008.03.003; Sun ZQ, 2016, NAT CELL BIOL, V18, P941, DOI 10.1038/ncb3402; Takeuchi K, 2011, CLIN CANCER RES, V17, P3341, DOI 10.1158/1078-0432.CCR-11-0063; Takkunen M, 2010, J CELL MOL MED, V14, P1569, DOI 10.1111/j.1582-4934.2009.00868.x; Tan KD, 2008, GENE CHROMOSOME CANC, V47, P353, DOI 10.1002/gcc.20539; Taru H, 2011, J NEUROSCI, V31, P16261, DOI 10.1523/JNEUROSCI.0002-11.2011; van der Vaart B, 2013, DEV CELL, V27, P145, DOI 10.1016/j.devcel.2013.09.010; von Thun A, 2012, J CELL SCI, V125, P1465, DOI 10.1242/jcs.092916; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Wei ZY, 2011, MOL CELL, V43, P586, DOI 10.1016/j.molcel.2011.07.021; Whitmore TE, 2012, J PROTEOME RES, V11, P2653, DOI 10.1021/pr201200n; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Wilkerson PM, 2013, GENE CHROMOSOME CANC, V52, P333, DOI 10.1002/gcc.22037; Winograd-Katz SE, 2014, NAT REV MOL CELL BIO, V15, P273, DOI 10.1038/nrm3769; Wong MY, 2018, P NATL ACAD SCI USA, V115, P2234, DOI 10.1073/pnas.1719012115; Wu YS, 2018, PROSTATE, V78, P1222, DOI 10.1002/pros.23697; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Xie XQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13949-x; Xu C, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-143; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; YANG J, 2017, TUMOR BIOL, V39; Yeh I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8174; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886; Zhou B, 2004, CANCER RES, V64, P7455, DOI 10.1158/0008-5472.CAN-04-1574; Zurner M, 2011, J COMP NEUROL, V519, P3019, DOI 10.1002/cne.22664; Zurner M, 2009, GENOMICS, V93, P243, DOI 10.1016/j.ygeno.2008.10.007	135	3	3	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6406	6416		10.1038/s41388-021-02048-1	http://dx.doi.org/10.1038/s41388-021-02048-1		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34654889	Green Published, hybrid			2022-12-28	WOS:000707986000001
J	Block, CJ; Mitchell, AV; Wu, L; Glassbrook, J; Craig, D; Chen, W; Dyson, G; DeGracia, D; Polin, L; Ratnam, M; Gibson, H; Wu, GJ				Block, C. James; Mitchell, Allison, V; Wu, Ling; Glassbrook, James; Craig, Douglas; Chen, Wei; Dyson, Gregory; DeGracia, Donald; Polin, Lisa; Ratnam, Manohar; Gibson, Heather; Wu, Guojun			RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; POOR-PROGNOSIS; DOWN-REGULATION; EXPRESSION; METASTASIS; INDUCER; ROLES; CELLS	The epithelial-to-mesenchymal transition (EMT) has been recognized as a driving force for tumor progression in breast cancer. Recently, our group identified the RNA Binding Motif Single Stranded Interacting Protein 3 (RBMS3) to be significantly associated with an EMT transcriptional program in breast cancer. Additional expression profiling demonstrated that RBMS3 was consistently upregulated by multiple EMT transcription factors and correlated with mesenchymal gene expression in breast cancer cell lines. Functionally, RBMS3 was sufficient to induce EMT in two immortalized mammary epithelial cell lines. In triple-negative breast cancer (TNBC) models, RBMS3 was necessary for maintaining the mesenchymal phenotype and invasion and migration in vitro. Loss of RBMS3 significantly impaired both tumor progression and spontaneous metastasis in vivo. Using a genome-wide approach to interrogate mRNA stability, we found that ectopic expression of RBMS3 upregulates many genes that are resistant to degradation following transcriptional blockade by actinomycin D (ACTD). Specifically, RBMS3 was shown to interact with the mRNA of EMT transcription factor PRRX1 and promote PRRX1 mRNA stability. PRRX1 is required for RBMS3-mediated EMT and is partially sufficient to rescue the effect of RBMS3 knockdown in TNBC cell lines. Together, this study identifies RBMS3 as a novel and common effector of EMT, which could be a promising therapeutic target for TNBC treatment.	[Block, C. James; Mitchell, Allison, V; Wu, Ling; Glassbrook, James; Craig, Douglas; Chen, Wei; Dyson, Gregory; Polin, Lisa; Ratnam, Manohar; Gibson, Heather; Wu, Guojun] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Oncol, Sch Med, 4100 John R, Detroit, MI 48201 USA; [Wu, Ling] Baylor Coll Med, McNair Med Inst, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA; [DeGracia, Donald] Wayne State Univ, Dept Physiol, Sch Med, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Baylor College of Medicine; Wayne State University	Wu, GJ (corresponding author), Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Oncol, Sch Med, 4100 John R, Detroit, MI 48201 USA.	wugu@karmanos.org	Gibson, Heather/GLV-4595-2022	Gibson, Heather/0000-0003-2652-8252; Wu, Ling/0000-0002-5786-4315	Wayne State University; KCI strategic plan cancer immunology and immunotherapy award;  [P30-CA022453-38]	Wayne State University; KCI strategic plan cancer immunology and immunotherapy award; 	This work is supported by Grant boost from Wayne State University (GW) and KCI strategic plan cancer immunology and immunotherapy award (GW and HG). The Biostatistics Core, AMTEC and the Biobanking and Correlative Sciences Core of KCI are supported by grant number P30-CA022453-38.	Addison JB, 2021, MOL CANCER RES, V19, P784, DOI 10.1158/1541-7786.MCR-20-0532; Aiello NM, 2019, J EXP MED, V216, P1016, DOI 10.1084/jem.20181827; Bagati A, 2017, CELL REP, V20, P2820, DOI 10.1016/j.celrep.2017.08.057; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Block CJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54282-z; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Chen J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044636; Corley SM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55434-x; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Davis FM, 2014, TRENDS PHARMACOL SCI, V35, P479, DOI 10.1016/j.tips.2014.06.006; Fritz D, 2007, J MOL BIOL, V371, P585, DOI 10.1016/j.jmb.2007.06.006; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Iorns E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047995; Jayasena CS, 2012, J CELL BIOL, V199, P453, DOI 10.1083/jcb.201204138; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Li Y, 2011, CANCER RES, V71, P6106, DOI 10.1158/0008-5472.CAN-10-4291; Li Y, 2016, INT J ONCOL, V49, P51, DOI 10.3892/ijo.2016.3517; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu CK, 2012, DNA CELL BIOL, V31, P1245, DOI 10.1089/dna.2012.1619; Lv ZD, 2016, J CELL MOL MED, V20, P864, DOI 10.1111/jcmm.12770; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13; McDowell IC, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1005896; Meng FY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13034-3; Meng FY, 2015, CANCER RES, V75, P584, DOI 10.1158/0008-5472.CAN-13-3029; Morel AP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002723; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Orellana Esteban A, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1984; Park SY, 2015, ONCOTARGET, V6, P37535, DOI 10.18632/oncotarget.6063; Pasquier J, 2015, J ONCOL, V2015, DOI 10.1155/2015/792182; Penkov D, 2000, GENE, V243, P27, DOI 10.1016/S0378-1119(99)00515-6; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Puchalapalli M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163521; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y; Takahashi Y, 2013, BRIT J CANCER, V109, P307, DOI 10.1038/bjc.2013.339; Takano S, 2016, GENE DEV, V30, P233, DOI 10.1101/gad.263327.115; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wang J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02243-3; Wu GY, 2019, CLIN CANCER RES, V25, P1022, DOI 10.1158/1078-0432.CCR-18-2554; Wu YL, 2020, ONCOL REP, V44, P55, DOI 10.3892/or.2020.7594; Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017; Zhang HJ, 2011, CANCER RES, V71, P4846, DOI 10.1158/0008-5472.CAN-11-0414; Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825; Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048; Zhang T, 2016, AM J CANCER RES, V6, P2679; Zhu L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1111-5	51	5	5	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6430	6442		10.1038/s41388-021-02030-x	http://dx.doi.org/10.1038/s41388-021-02030-x		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34608266	Green Accepted			2022-12-28	WOS:000703526900003
J	Li, MY; Li, XY; Goldsmith, JR; Shi, SL; Zhang, L; Zamani, A; Wan, L; Sun, HH; Li, T; Yu, JY; Etwebi, Z; Bou-Dargham, MJ; Chen, YHH				Li, Mingyue; Li, Xinyuan; Goldsmith, Jason R.; Shi, Songlin; Zhang, Li; Zamani, Ali; Wan, Lin; Sun, Honghong; Li, Ting; Yu, Jiyeon; Etwebi, Zienab; Bou-Dargham, Mayassa J.; Chen, Youhai H.			Decoupling tumor cell metastasis from growth by cellular pilot protein TNFAIP8	ONCOGENE			English	Article							HIPPO-YAP PATHWAY; ORGAN SIZE; COMPENSATORY PROLIFERATION; NEGATIVE REGULATOR; CANCER; OVEREXPRESSION; TUMORIGENESIS; INFLAMMATION; MIGRATION; MOLECULE	Cancer metastasis accounts for nearly 90% of all cancer deaths. Metastatic cancer progression requires both cancer cell migration to the site of the metastasis and subsequent proliferation after colonization. However, it has long been recognized that cancer cell migration and proliferation can be uncoupled; but the mechanism underlying this paradox is not well understood. Here we report that TNFAIP8 (tumor necrosis factor-alpha-induced protein 8), a "professional" transfer protein of phosphoinositide second messengers, promotes cancer cell migration or metastasis but inhibits its proliferation or cancer growth. TNFAIP8-deficient mice developed larger tumors, but TNFAIP8-deficient tumor cells completely lost their ability to migrate toward chemoattractants and were defective in colonizing lung tissues as compared to wild-type counterparts. Mechanistically, TNFAIP8 served as a cellular "pilot" of tumor cell migration by locally amplifying PI3K-AKT and Rac signals on the cell membrane facing chemoattractant; at the same time, TNFAIP8 also acted as a global inhibitor of tumor cell growth and proliferation by regulating Hippo signaling pathway. These findings help explain the migration-proliferation paradox of cancer cells that characterizes many cancers.	[Li, Mingyue; Li, Xinyuan; Goldsmith, Jason R.; Shi, Songlin; Zhang, Li; Zamani, Ali; Wan, Lin; Sun, Honghong; Li, Ting; Yu, Jiyeon; Etwebi, Zienab; Bou-Dargham, Mayassa J.; Chen, Youhai H.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Chen, Youhai H.] CAS Shenzhen Inst Adv Technol, Fac Pharmaceut Sci, Shenzhen, Peoples R China; [Zhang, Li] Shandong First Med Univ, Dept Clin Lab Med, Affiliated Hosp 1, Jinan, Shandong, Peoples R China; [Zhang, Li] Shandong Prov Qianfoshan Hosp, Jinan, Shandong, Peoples R China	University of Pennsylvania; Pennsylvania Medicine; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences	Li, MY; Chen, YHH (corresponding author), Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA.; Chen, YHH (corresponding author), CAS Shenzhen Inst Adv Technol, Fac Pharmaceut Sci, Shenzhen, Peoples R China.	Mingyue.Li@pennmedicine.upenn.edu; yhc@pennmedicine.upenn.edu		Bou-Dargham, Mayassa/0000-0002-1551-8887; Shi, Song-Lin/0000-0003-1213-0550	National Institutes of Health (NIH), USA [R01AI143676, R01AI1136945]	National Institutes of Health (NIH), USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by grants from the National Institutes of Health (NIH), USA (R01AI143676 and R01AI1136945).	Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Briata P, 2012, CELL DEATH DIFFER, V19, P478, DOI 10.1038/cdd.2011.117; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Day TF, 2019, MOL CANCER RES, V17, P1207, DOI 10.1158/1541-7786.MCR-18-0731; Devalaraja S, 2020, CELL, V180, P1098, DOI 10.1016/j.cell.2020.02.042; Fayngerts SA, 2017, NAT IMMUNOL, V18, P1353, DOI 10.1038/ni.3866; Goldsmith JR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16379-2; Goldsmith JR, 2017, CELL MOL IMMUNOL, V14, P482, DOI 10.1038/cmi.2017.4; Hadisaputri YE, 2012, ANN SURG ONCOL, V19, pS589, DOI 10.1245/s10434-011-2097-1; Han Y, 2018, MOL CARCINOGEN, V57, P159, DOI 10.1002/mc.22740; Haugh JM, 2018, LYSOPHOSPHATIDIC ACI, V2019, DOI [10.1101/355610, DOI 10.1101/355610]; Kango-Singh M, 2009, DEV DYNAM, V238, P1627, DOI 10.1002/dvdy.21996; Kohrman AQ, 2017, TRENDS CELL BIOL, V27, P12, DOI 10.1016/j.tcb.2016.08.003; Kumar D, 2004, ONCOGENE, V23, P612, DOI 10.1038/sj.onc.1207123; Laliberte B, 2010, J CELL PHYSIOL, V225, P865, DOI 10.1002/jcp.22297; Leung HW, 2015, BBA-MOL CELL RES, V1853, P1827, DOI 10.1016/j.bbamcr.2015.04.020; Li T, 2020, NAT CANCER, V1, DOI 10.1038/s43018-020-0061-3; Liu T, 2013, BRIT J CANCER, V109, P1685, DOI 10.1038/bjc.2013.501; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Miller E, 2012, CHEM BIOL, V19, P955, DOI 10.1016/j.chembiol.2012.07.005; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Niture S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010009; Padmavathi G, 2018, CANCER LETT, V432, P260, DOI 10.1016/j.canlet.2018.06.017; Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016; Schreiber TH, 2009, BRIT J CANCER, V101, P381, DOI 10.1038/sj.bjc.6605198; Sun HH, 2008, CELL, V133, P415, DOI 10.1016/j.cell.2008.03.026; Sun HH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63629-w; Sun HH, 2015, J IMMUNOL, V194, P5736, DOI 10.4049/jimmunol.1401986; Svensson S, 2003, CANCER RES, V63, P1737; Swann JB, 2008, P NATL ACAD SCI USA, V105, P652, DOI 10.1073/pnas.0708594105; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Wang ZJ, 2012, P NATL ACAD SCI USA, V109, P15413, DOI 10.1073/pnas.1204525109; Watt KI, 2010, BIOCHEM BIOPH RES CO, V393, P619, DOI 10.1016/j.bbrc.2010.02.034; Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005; Xie Y, 2018, EXP THER MED, V16, P4975, DOI 10.3892/etm.2018.6819; Xing Y, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0254-x; Yang M, 2014, HISTOPATHOLOGY, V65, P517, DOI 10.1111/his.12413; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037846; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001; Zhong MY, 2020, J CANCER, V11, P3061, DOI 10.7150/jca.40191	43	1	1	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6456	6468		10.1038/s41388-021-02035-6	http://dx.doi.org/10.1038/s41388-021-02035-6		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34608264	Green Accepted			2022-12-28	WOS:000703526900001
J	Zimmerman, SM; Nixon, SJ; Chen, PY; Raj, L; Smith, SR; Paolini, RL; Lin, PN; Souroullas, GP				Zimmerman, Sarah M.; Nixon, Samantha J.; Chen, Pei Yu; Raj, Leela; Smith, Sofia R.; Paolini, Rachel L.; Lin, Phyo Nay; Souroullas, George P.			EZh2(Y641F) mutations co-operate with Stat3 to regulate MHC class I antigen processing and alter the tumor immune response in melanoma	ONCOGENE			English	Article							CHROMATIN IMMUNOPRECIPITATION; TARGET GENES; EZH2; TRANSCRIPTION; EXPRESSION; GENOME; PLURIPOTENCY; METHYLATION; PROSTATE; ESBAF	Enhancer of Zeste Homolog 2 (EZH2) is the catalytic component of the Polycomb Repressive Complex 2, a chromatin modifying complex, which mediates methylation of lysine 27 on histone 3 (H3K27me3), a repressive chromatin mark. Genetic alterations in EZH2 in melanoma include amplifications and activating point mutations at tyrosine 641 (Y641) whose underlying oncogenic mechanisms remain largely unknown. Here, we found that expression of Ezh2(Y641F) causes upregulation of a subset of interferon-regulated genes in melanoma cells. Upregulation of these genes was not a direct effect of changes in H3K27me3, but via a non-canonical interaction between Ezh2 and Signal Transducer and Activator of Transcription 3 (Stat3). Ezh2 and Stat3 together function as transcriptional activators to mediate gene activation of numerous genes, including MHC Class 1b antigen processing genes. Furthermore, expression of Stat3 is required to maintain an anti-tumor immune response in Ezh2(Y641F) melanomas and to prevent melanoma progression and recurrence.	[Zimmerman, Sarah M.; Nixon, Samantha J.; Chen, Pei Yu; Raj, Leela; Smith, Sofia R.; Paolini, Rachel L.; Lin, Phyo Nay; Souroullas, George P.] Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA; [Zimmerman, Sarah M.; Nixon, Samantha J.; Chen, Pei Yu; Raj, Leela; Smith, Sofia R.; Paolini, Rachel L.; Lin, Phyo Nay; Souroullas, George P.] Washington Univ, Sch Med, Div Oncol, Mol Oncol Sect, St Louis, MO 63110 USA; [Souroullas, George P.] Washington Univ, Sch Med, Siteman Comprehens Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Souroullas, GP (corresponding author), Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA.; Souroullas, GP (corresponding author), Washington Univ, Sch Med, Div Oncol, Mol Oncol Sect, St Louis, MO 63110 USA.; Souroullas, GP (corresponding author), Washington Univ, Sch Med, Siteman Comprehens Canc Ctr, St Louis, MO 63110 USA.	george.souroullas@wustl.edu		Smith, Sofia/0000-0003-3454-6207; Zimmerman, Sarah/0000-0003-3923-3963; Souroullas, George P./0000-0003-2196-8662	US National Cancer Institute [K22-CA229612-01, T32 CA113275-10]; Cancer Research Foundation, Chicago IL, (GPS); Harry J. Lloyd Charitable Trust	US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research Foundation, Chicago IL, (GPS); Harry J. Lloyd Charitable Trust	This work was supported by the US National Cancer Institute K22-CA229612-01(GPS) and T32 CA113275-10 (SZ), the Cancer Research Foundation, Chicago IL, (GPS), The Harry J. Lloyd Charitable Trust (GPS).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Asangani IA, 2012, ONCOTARGET, V3, P1011, DOI 10.18632/oncotarget.622; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Ballotti R, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01290-7; Burr ML, 2019, CANCER CELL, V36, P385, DOI 10.1016/j.ccell.2019.08.008; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Dasgupta M, 2015, P NATL ACAD SCI USA, V112, P3985, DOI 10.1073/pnas.1503152112; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Furlan-Magaril M, 2009, METHODS MOL BIOL, V543, P253, DOI 10.1007/978-1-60327-015-1_17; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Ho L, 2011, NAT CELL BIOL, V13, P903, DOI 10.1038/ncb2285; Ho LN, 2009, P NATL ACAD SCI USA, V106, P5187, DOI 10.1073/pnas.0812888106; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kumar SM, 2014, ONCOGENE, V33, P832, DOI 10.1038/onc.2012.642; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Lerner L, 2003, GENE DEV, V17, P2564, DOI 10.1101/gad.1135003; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Marine JC, 2020, NAT REV CANCER, V20, P743, DOI 10.1038/s41568-020-00302-4; McHugh JB, 2007, J CUTAN PATHOL, V34, P597, DOI 10.1111/j.1600-0560.2006.00678.x; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Schell TD, 2002, INT IMMUNOL, V14, P775, DOI 10.1093/intimm/dxf041; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Snyder M, 2008, J BIOL CHEM, V283, P3791, DOI 10.1074/jbc.M706976200; Souroullas GP, 2016, NAT MED, V22, P632, DOI 10.1038/nm.4092; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun W, 2006, FEBS LETT, V580, P5880, DOI 10.1016/j.febslet.2006.09.054; Tiffen J, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12280; Tripathi SK, 2017, CELL REP, V19, P1888, DOI 10.1016/j.celrep.2017.05.013; Wang J, 2022, NAT CELL BIOL, V24, P384, DOI 10.1038/s41556-022-00850-x; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Zhang HK, 2016, CANCER DISCOV, V6, P1006, DOI 10.1158/2159-8290.CD-16-0164; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051	46	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					4983	4993		10.1038/s41388-022-02492-7	http://dx.doi.org/10.1038/s41388-022-02492-7		OCT 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36220978				2022-12-28	WOS:000865904600001
J	Guo, YM; He, JF; Zhang, HL; Chen, R; Li, L; Liu, XJ; Huang, CH; Qiang, Z; Zhou, ZH; Wang, YL; Huang, J; Zhao, X; Zheng, JK; Chen, GQ; Yu, JX				Guo, Yanmin; He, Jianfeng; Zhang, Hailong; Chen, Ran; Li, Lian; Liu, Xiaojia; Huang, Caihu; Qiang, Zhe; Zhou, Zihan; Wang, Yanli; Huang, Jian; Zhao, Xian; Zheng, Junke; Chen, Guo-Qiang; Yu, Jianxiu			Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; TUMOR-SUPPRESSOR; COWDEN DISEASE; NUCLEAR PTEN; LIGASE; BREAST; LUBAC; STABILITY; OTULIN; NEMO	PTEN is frequently mutated in human cancers, which leads to the excessive activation of PI3K/AKT signaling and thus promotes tumorigenesis and drug resistance. Met(1)-linked ubiquitination (M1-Ubi) is also involved in cancer progression, but the mechanism is poorly defined. Here we find that HOIP, one important component of linear ubiquitin chain assembly complex (LUBAC), promotes prostate cancer (PCa) progression by enhancing AKT signaling in a PTEN-dependent manner. Mechanistically, PTEN is modified by M1-Ubi at two sites K144 and K197, which significantly inhibits PTEN phosphatase activity and thus accelerates PCa progression. More importantly, we identify that the high-frequency mutants PTENR173H and PTENR173C in PCa patients showed the enhanced level of M1-Ubi, which impairs PTEN function in inhibition of AKT phosphorylation and cell growth. We also find that HOIP depletion sensitizes PCa cells to therapeutic agents BKM120 and Enzalutamide. Furthermore, the clinical data analyses confirm that HOIP is upregulated and positively correlated with AKT activation in PCa patient specimen, which may promote PCa progression and increase the risk of PCa biochemical relapse. Together, our study reveals a key role of PTEN M1-Ubi in regulation of AKT activation and PCa progression, which may propose a new strategy for PCa therapy.	[Guo, Yanmin; He, Jianfeng; Zhang, Hailong; Chen, Ran; Li, Lian; Liu, Xiaojia; Huang, Caihu; Qiang, Zhe; Zhou, Zihan; Wang, Yanli; Huang, Jian; Zhao, Xian; Yu, Jianxiu] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China; [Zheng, Junke] Shanghai Jiao Tong Univ, Sch Med, Chinese Minist Educ, Dept Pathophysiol,Key Lab Cell Differentiat & Apo, Shanghai 200025, Peoples R China; [Chen, Guo-Qiang] Shanghai Jiao Tong Univ, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes, Sch Med, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yu, JX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China.	Jianxiu.Yu@gmail.com			China's National Key R&D Programmes (NKP) [2019YFE0110600]; National Natural Science Foundation of China [81630075, 82103082, 81721004, 81902866, 82002712, 81972585]; Shanghai Science and Technology Commission [20JC1410100]	China's National Key R&D Programmes (NKP); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Commission(Shanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by grants from China's National Key R&D Programmes (NKP) (No. 2019YFE0110600), the National Natural Science Foundation of China (81630075, 82103082, 81721004, 81902866, 82002712, 81972585) and Shanghai Science and Technology Commission (20JC1410100).	Armstrong AJ, 2017, EUR J CANCER, V81, P228, DOI 10.1016/j.ejca.2017.02.030; Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Chen Chang-fu, 2015, China Journal of Highway and Transport, V28, P1; Damgaard RB, 2012, MOL CELL, V46, P746, DOI 10.1016/j.molcel.2012.04.014; de Almagro MC, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.158; Deng R, 2021, MOL ONCOL, V15, P279, DOI 10.1002/1878-0261.12844; Dittmar G, 2020, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00915; Dou JZ, 2020, MOL ONCOL, V14, P2288, DOI 10.1002/1878-0261.12694; Fiil BK, 2013, MOL CELL, V50, P818, DOI 10.1016/j.molcel.2013.06.004; Fu YS, 2021, MOL CELL, V81, P3187, DOI 10.1016/j.molcel.2021.05.031; Ge MK, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15578-1; Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816; Goto E, 2017, BIOCHEM BIOPH RES CO, V485, P152, DOI [10.1016/J.bbrc.2017.02.040, 10.1016/j.bbrc.2017.02.040]; Gu TT, 2011, CANCER RES, V71, P2821, DOI 10.1158/0008-5472.CAN-10-3399; Guo J, 2015, BIOCHEM BIOPH RES CO, V464, P1302, DOI 10.1016/j.bbrc.2015.07.127; He LZ, 2010, J CLIN INVEST, V120, P2094, DOI 10.1172/JCI40778; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Ikeda F, 2011, NATURE, V471, P637, DOI 10.1038/nature09814; Inn KS, 2011, MOL CELL, V41, P354, DOI 10.1016/j.molcel.2010.12.029; Iwai K, 2014, NAT REV MOL CELL BIO, V15, P503, DOI 10.1038/nrm3836; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Kharman-Biz A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197183; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Kliza K, 2017, NAT METHODS, V14, P504, DOI [10.1038/NMETH.4228, 10.1038/nmeth.4228]; Lee YR, 2018, NAT REV MOL CELL BIO, V19, P547, DOI 10.1038/s41580-018-0015-0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474; Marsh DJ, 1998, GENE CHROMOSOME CANC, V21, P61, DOI 10.1002/(SICI)1098-2264(199801)21:1<61::AID-GCC8>3.0.CO;2-6; Noad J, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.63; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Peltzer N, 2014, CELL REP, V9, P153, DOI 10.1016/j.celrep.2014.08.066; Qiu P, 2018, ONCOL LETT, V15, P789, DOI 10.3892/ol.2017.7431; Rahighi S, 2009, CELL, V136, P1098, DOI 10.1016/j.cell.2009.03.007; Rivkin E, 2013, NATURE, V498, P318, DOI 10.1038/nature12296; Sakamoto H, 2015, ACS CHEM BIOL, V10, P675, DOI 10.1021/cb500653y; Sasaki Y, 2013, EMBO J, V32, P2463, DOI 10.1038/emboj.2013.184; Schaeffer V, 2014, MOL CELL, V54, P349, DOI 10.1016/j.molcel.2014.03.016; Serebriiskii IG, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-29227-2; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shi YJ, 2014, NAT STRUCT MOL BIOL, V21, P522, DOI 10.1038/nsmb.2828; Singh G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-490; Smith IN, 2016, PROTEINS, V84, P1625, DOI 10.1002/prot.25105; Takiuchi T, 2014, GENES CELLS, V19, P254, DOI 10.1111/gtc.12128; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Thompson HGR, 2004, EXP CELL RES, V295, P448, DOI 10.1016/j.yexcr.2004.01.019; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; van Well EM, 2019, EMBO J, V38, DOI 10.15252/embj.2018100730; Vanhaesebroeck B, 2021, NAT REV DRUG DISCOV, V20, P741, DOI 10.1038/s41573-021-00209-1; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17770-9; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wong CW, 2018, AUTISM RES, V11, P1098, DOI 10.1002/aur.1950; Wu PJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641469; Xie P, 2021, CELL RES, V31, P291, DOI 10.1038/s41422-020-00443-z; Yang M, 2017, ONCOGENE, V36, P3673, DOI 10.1038/onc.2016.493; Yu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-y; Zhang HL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25739-5; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhu J, 2016, ONCOGENE, V35, P1955, DOI 10.1038/onc.2015.260; Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573; Zuo YB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14948-z	65	0	0	10	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4877	4892		10.1038/s41388-022-02485-6	http://dx.doi.org/10.1038/s41388-022-02485-6		OCT 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36192478				2022-12-28	WOS:000865226400002
J	Du, QY; Huo, FC; Du, WQ; Sun, XL; Jiang, X; Zhang, LS; Pei, DS				Du, Qiu-Ying; Huo, Fu-Chun; Du, Wen-Qi; Sun, Xiao-Lin; Jiang, Xin; Zhang, Lan-Sheng; Pei, Dong-Sheng			METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; DISULFIDE-ISOMERASE; LUNG-CANCER; EXPRESSION; APOPTOSIS; PROTEIN; CARCINOMA; ETS-1; TRANSCRIPTION; INVOLVEMENT	N6-methyladenosine (m6A) is the most abundant chemical modification on mRNA and plays significant roles in many bioprocesses. However, the functions of m6A on cervical cancer (CC) tumorigenesis remain unclear. Here we found methyltransferase-like 3 (METTL3), a core member of the m6A methyltransferase family, was greatly upregulated as an independent prognostic factor in CC. Mechanistically, the transcription factor ETS1 recruited P300 and WDR5 which separately mediated H3K27ac and H3K4me3 histone modification in the promoter of METTL3 and induced METTL3 transcription activation. Furthermore, we identified TXNDC5 as a target of METTL3-mediated m6A modification through MeRIP-seq, and revealed that METTL3-mediated TXNDC5 expression relied on the m6A reader-dependent manner. Functionally, we verified that METTL3 promoted proliferation and metastasis of CC cells by regulating of TXNDC5 expression through in vitro and in vivo experiments. In addition, our study verified the effect of METTL3/TXNDC5 axis on ER stress. Taken together, METTL3 facilitates the malignant progression of CC, suggesting that METTL3 might be a potential prognostic biomarker and therapeutic target for CC.	[Du, Qiu-Ying; Huo, Fu-Chun; Du, Wen-Qi; Sun, Xiao-Lin; Jiang, Xin; Pei, Dong-Sheng] Xuzhou Med Univ, Dept Pathol, 209 Tong Shan Rd, Xuzhou 221004, Jiangsu, Peoples R China; [Zhang, Lan-Sheng] Xuzhou Med Univ, Affiliated Hosp 2, Dept Oncol Radiotherapy, Xuzhou, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University	Pei, DS (corresponding author), Xuzhou Med Univ, Dept Pathol, 209 Tong Shan Rd, Xuzhou 221004, Jiangsu, Peoples R China.; Zhang, LS (corresponding author), Xuzhou Med Univ, Affiliated Hosp 2, Dept Oncol Radiotherapy, Xuzhou, Jiangsu, Peoples R China.	lanshengyan@163.com; dspei@xzhmu.edu.cn			National Natural Science Foundation of China [81872080]; Jiangsu Provincial Medical Talent [ZDRCA2016055]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Medical Talent	This work was supported by the National Natural Science Foundation of China (No.81872080), Jiangsu Provincial Medical Talent (ZDRCA2016055).	Beacon TH, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01126-1; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Biancotto C, 2010, ADV GENET, V70, P341, DOI [10.1016/B978-0-12-380866-0.60013-7, 10.1016/S0065-2660(10)70013-4]; Chawsheen HA, 2019, J BIOL CHEM, V294, P8991, DOI 10.1074/jbc.RA118.005804; Chen X, 2021, INT IMMUNOPHARMACOL, V95, DOI 10.1016/j.intimp.2021.107519; Datan E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.409; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Du QY, 2021, INVEST NEW DRUG, V39, P1682, DOI 10.1007/s10637-021-01148-9; Froimchuk E, 2017, GENE, V627, P337, DOI 10.1016/j.gene.2017.06.056; Funkner A, 2013, J MOL BIOL, V425, P1340, DOI 10.1016/j.jmb.2013.01.029; Hasanain M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.219; Horna-Terron E, 2014, INT J MOL SCI, V15, P23501, DOI 10.3390/ijms151223501; Jorgensen MM, 2003, APMIS, V111, P86; Kojima R, 2014, STRUCTURE, V22, P431, DOI 10.1016/j.str.2013.12.013; Kumar P, 2009, HYPERTENSION, V54, P172, DOI 10.1161/HYPERTENSIONAHA.109.133033; Lee CG, 2012, J IMMUNOL, V188, P2244, DOI 10.4049/jimmunol.1101614; Li Jian, 2017, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V34, P448, DOI 10.3760/cma.j.issn.1003-9406.2017.03.031; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Li X, 2017, ONCOTARGET, V8, P96103, DOI 10.18632/oncotarget.21726; Lin Y, 2020, CANCER MED-US, V9, P2859, DOI 10.1002/cam4.2918; Liu JY, 2020, ONCOTARGETS THER, V13, P11957, DOI 10.2147/OTT.S276559; Liu K, 2016, CURR PROTEIN PEPT SC, V17, P306, DOI 10.2174/1389203716666150901113553; Liu SP, 2020, AM J CANCER RES, V10, P1631; Liu SP, 2020, AM J CANCER RES, V10, P1068; Lu MJ, 2020, NAT MICROBIOL, V5, P584, DOI 10.1038/s41564-019-0653-9; Luo GY, 2020, J CELL PHYSIOL, V235, P7107, DOI 10.1002/jcp.29608; Lopez AM, 2021, GENES-BASEL, V12, DOI 10.3390/genes12071019; Matsusaki M, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2019.04.003; Park MS, 2013, ANTICANCER RES, V33, P3983; Pecoraro A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197334; Peng FS, 2018, MOL MED REP, V17, P4767, DOI 10.3892/mmr.2018.8376; Ren Tao-wen, 2009, Zhonghua Zhong Liu Za Zhi, V31, P674; Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Song SL, 2017, J CELL PHYSIOL, V232, P2977, DOI 10.1002/jcp.25785; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Sun T, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108613; Tan FB, 2018, INT J MOL MED, V42, P935, DOI 10.3892/ijmm.2018.3664; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Tong JY, 2018, FRONT MED-PRC, V12, P481, DOI 10.1007/s11684-018-0654-8; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang L, 2015, ONCOGENE, V34, P4735, DOI 10.1038/onc.2014.401; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang QQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03071-y; Wang TY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01204-7; Wang XL, 2017, ONCOTARGET, V8, P98918, DOI 10.18632/oncotarget.22041; Wei WW, 2019, CANCER MANAG RES, V11, P1177, DOI 10.2147/CMAR.S181058; Xu B, 2017, ONCOTARGET, V8, P91009, DOI 10.18632/oncotarget.18857; Xu J, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009530; Xu Y, 2015, MOL MED REP, V11, P189, DOI 10.3892/mmr.2014.2683; Yan JJ, 2020, BIOCHEM BIOPH RES CO, V521, P887, DOI 10.1016/j.bbrc.2019.11.016; Yang YX, 2020, J CELL MOL MED, V24, P2772, DOI 10.1111/jcmm.15030; Yue B, 2021, MOL THER-NUCL ACIDS, V26, P458, DOI 10.1016/j.omtn.2021.08.019; Zeng CW, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00951-w; Zhao W, 2020, MOL THER-NUCL ACIDS, V20, P1, DOI 10.1016/j.omtn.2020.01.033; Zhu LY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1585-2; Zou DL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1045-1	58	1	1	13	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4420	4432		10.1038/s41388-022-02435-2	http://dx.doi.org/10.1038/s41388-022-02435-2		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	35987795				2022-12-28	WOS:000843263800001
J	Yi, YM; Li, P; Huang, YF; Chen, DY; Fan, SW; Wang, J; Yang, MQ; Zeng, SS; Deng, J; Lv, XW; Luo, K; He, ZW; Liu, H				Yi, Yanmei; Li, Pan; Huang, Yuanfeng; Chen, Danyang; Fan, Siwen; Wang, Jun; Yang, Minqiang; Zeng, Shanshan; Deng, Jin; Lv, Xinwu; Luo, Kai; He, Zhiwei; Liu, Hao			P21-activated kinase 2-mediated beta-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer	ONCOGENE			English	Article							ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; UP-REGULATION; OPEN-LABEL; INHIBITORS; MUTATION; TKI; CHEMOTHERAPY; CONTRIBUTES; ACTIVATION	Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), used for treating patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-activating mutations or the resistant T790M mutation. However, acquired resistance to osimertinib is inevitable in EGFR-mutant NSCLC. By employing a global mass spectrometry-based phosphoproteomics approach, we identified that the activated p21-activated kinase 2 (PAK2)/beta-catenin axis acts as a driver of osimertinib resistance. We found that PAK2 directly phosphorylates beta-catenin and increases the nuclear localization of beta-catenin, leading to the increased expression and transcriptional activity of beta-catenin, which in turn enhances cancer stem-like properties and osimertinib resistance. Moreover, we revealed that HER3 as an upstream regulator of PAK2, drives the activation of PAK2/beta-catenin pathways in osimertinib-resistant cells. The clinical relevance of these findings was further confirmed by examining tissue specimens from patients with EGFR-mutant NSCLC. The results demonstrated that the levels of HER3, phospho-PAK2 (p-PAK2) and beta-catenin in the tissues from patients with EGFR-mutant NSCLC, that had relapsed after treatment with osimertinib, were elevated compared to those of the corresponding untreated tissues. Additionally, the high levels of HER3, p-PAK2 and beta-catenin correlated with shorter progression-free survival (PFS) in patients with EGFR-TKI-treated NSCLC. We additionally observed that the suppression of PAK2 via knockdown or pharmacological targeting with PAK inhibitors markedly restored the response of osimertinib-resistant NSCLC cells to osimertinib both in vitro and in vivo. In conclusion, these results indicated that the PAK2-mediated activation of beta-catenin is important for osimertinib resistance and targeting the HER3/PAK2/beta-catenin pathway has potential therapeutic value in NSCLCs with acquired resistance to osimertinib.	[Yi, Yanmei; Fan, Siwen; Lv, Xinwu; He, Zhiwei] Guangdong Med Univ, Sch Basic Med Sci, Zhanjiang, Guangdong, Peoples R China; [Li, Pan; Huang, Yuanfeng; Chen, Danyang; Wang, Jun; Yang, Minqiang; Zeng, Shanshan; Deng, Jin; Luo, Kai; Liu, Hao] Guangzhou Med Univ, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Affiliated Canc Hosp & Inst, Guangzhou, Guangdong, Peoples R China; [He, Zhiwei] Guangdong Med Univ, China Amer Canc Res Inst, Guangzhou, Guangdong, Peoples R China	Guangdong Medical University; Guangzhou Medical University; Guangdong Medical University	He, ZW (corresponding author), Guangdong Med Univ, Sch Basic Med Sci, Zhanjiang, Guangdong, Peoples R China.; Luo, K; Liu, H (corresponding author), Guangzhou Med Univ, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Affiliated Canc Hosp & Inst, Guangzhou, Guangdong, Peoples R China.; He, ZW (corresponding author), Guangdong Med Univ, China Amer Canc Res Inst, Guangzhou, Guangdong, Peoples R China.	luokainan@126.com; 467853605@qq.com; liuhao@gzhmu.edu.cn		Chen, Danyang/0000-0002-7894-9457	National Natural Science Foundation of China [81972194, 82172810, 81772825]; Guangdong Natural Science Funds [2019A1515010113]; Science and Technology Program of Guangzhou [202201010839]; Medical Scientific Research Foundation of Guangdong [B2020165]; Discipline construction project of Guangdong Medical University [4SG22005G]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Funds; Science and Technology Program of Guangzhou; Medical Scientific Research Foundation of Guangdong; Discipline construction project of Guangdong Medical University	This work was supported by the National Natural Science Foundation of China (81972194, 82172810, 81772825); Guangdong Natural Science Funds (2019A1515010113); The Science and Technology Program of Guangzhou (202201010839); Medical Scientific Research Foundation of Guangdong (B2020165); Discipline construction project of Guangdong Medical University (4SG22005G).	Araiza-Olivera D, 2018, ONCOGENE, V37, P944, DOI 10.1038/onc.2017.400; Arasada RR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05626-2; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Chiu CF, 2016, P NATL ACAD SCI USA, V113, pE2526, DOI 10.1073/pnas.1522612113; Coniglio SJ, 2008, MOL CELL BIOL, V28, P4162, DOI 10.1128/MCB.01532-07; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Del Re M, 2018, STEM CELLS, V36, P633, DOI 10.1002/stem.2787; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Eberlein CA, 2015, CANCER RES, V75, P2489, DOI 10.1158/0008-5472.CAN-14-3167; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Gupta A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0887-0; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Huynh N, 2016, CANCER BIOL THER, V17, P813, DOI 10.1080/15384047.2016.1195045; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kumar R, 2016, ADV CANCER RES, V130, P137, DOI 10.1016/bs.acr.2016.01.002; Kumar R, 2017, GENE, V605, P20, DOI 10.1016/j.gene.2016.12.014; Kuo MH, 2020, CANCER RES, V80, P4426, DOI 10.1158/0008-5472.CAN-19-3228; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Licciulli S, 2013, J BIOL CHEM, V288, P29105, DOI 10.1074/jbc.M113.510933; Lopez-Haber C, 2016, MOL CELL BIOL, V36, P2011, DOI 10.1128/MCB.00180-16; Lu HZ, 2017, NATURE, V550, P133, DOI 10.1038/nature24040; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mok Tony S, 2017, N Engl J Med, V376, P629, DOI 10.1056/NEJMoa1612674; Nakayama S, 2014, CANCER RES, V74, P5891, DOI 10.1158/0008-5472.CAN-14-0184; Ortiz-Cuaran S, 2016, CLIN CANCER RES, V22, P4837, DOI 10.1158/1078-0432.CCR-15-1915; Papadimitrakopoulou VA, 2020, ANN ONCOL, V31, P1536, DOI 10.1016/j.annonc.2020.08.2100; Park K, 2016, LANCET ONCOL, V17, P577, DOI 10.1016/S1470-2045(16)30033-X; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Ramalingam SS, 2018, J CLIN ONCOL, V36, P841, DOI 10.1200/JCO.2017.74.7576; Rane CK, 2019, SEMIN CANCER BIOL, V54, P40, DOI 10.1016/j.semcancer.2018.01.006; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rudolph J, 2016, J MED CHEM, V59, P5520, DOI 10.1021/acs.jmedchem.6b00638; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shah KN, 2019, NAT MED, V25, P111, DOI 10.1038/s41591-018-0264-7; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Sun J, 2009, ONCOGENE, V28, P3132, DOI 10.1038/onc.2009.167; Taniguchi H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08074-0; Togashi Y, 2015, J THORAC ONCOL, V10, P93, DOI 10.1097/JTO.0000000000000353; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang K, 2019, AM J TRANSL RES, V11, P3353; Yeo D, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2057-z; Yonesaka K, 2022, CLIN CANCER RES, V28, P390, DOI 10.1158/1078-0432.CCR-21-3359; Yu HA, 2015, JAMA ONCOL, V1, P981, DOI 10.1001/jamaoncol.2015.1066; Zeng Y, 2022, CURR OPIN ONCOL, V34, P54, DOI 10.1097/CCO.0000000000000805; Zhang F, 2021, ONCOGENE, V40, P5854, DOI 10.1038/s41388-021-01986-0; Zhang X, 2021, CANCER RES, V81, P3051, DOI 10.1158/0008-5472.CAN-20-2435; Zhang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00990-3; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060	53	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4318	4329		10.1038/s41388-022-02438-z	http://dx.doi.org/10.1038/s41388-022-02438-z		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35986102				2022-12-28	WOS:000843252700002
J	Mouillet-Richard, S; Martin-Lanneree, S; Le Corre, D; Hirsch, TZ; Ghazi, A; Sroussi, M; Pilati, C; de Reynies, A; Djouadi, F; Vodovar, N; Launay, JM; Laurent-Puig, P				Mouillet-Richard, Sophie; Martin-Lanneree, Severine; Le Corre, Delphine; Hirsch, Theo Z.; Ghazi, Alexandre; Sroussi, Marine; Pilati, Camilla; de Reynies, Aurelien; Djouadi, Fatima; Vodovar, Nicolas; Launay, Jean-Marie; Laurent-Puig, Pierre			A proof of concept for targeting the PrPC-Amyloid beta peptide interaction in basal prostate cancer and mesenchymal colon cancer	ONCOGENE			English	Article							CELLULAR PRION PROTEIN; CLEAVAGE	The cellular prion protein PrPC partners with caveolin-1 (CAV1) in neurodegenerative diseases but whether this interplay occurs in cancer has never been investigated. By leveraging patient and cell line datasets, we uncover a molecular link between PrPC and CAV1 across cancer. Using cell-based assays, we show that PrPC regulates the expression of and interacts with CAV1. PrPC additionally controls the expression of the amyloid precursor protein APP and of the A beta generating enzyme BACE1, and regulates the levels of A beta, whose accumulation is a central event in Alzheimer's disease. We further identify DKK1 and DKK3, involved in both Alzheimer's disease and cancer progression, as targets of the PrPC-dependent axis. Finally, we establish that antibody-mediated blocking of the A beta-PrPC interaction delays the growth of prostate cancer cell line-derived xenografts and prevents the development of metastases. Our data additionally support an enrichment of the A beta-PrPC-dependent pathway in the basal subtype of prostate cancer, associated with anti-hormonal therapy resistance, and in mesenchymal colon cancer, associated with poor prognosis. Thus, based on a parallel with neurodegenerative diseases, our results bring to light an A beta-PrPC axis and support the potential of targeting this pathway in patients with selected subtypes of prostate and colon cancer.	[Mouillet-Richard, Sophie; Martin-Lanneree, Severine; Le Corre, Delphine; Hirsch, Theo Z.; Ghazi, Alexandre; Sroussi, Marine; Pilati, Camilla; de Reynies, Aurelien; Djouadi, Fatima; Laurent-Puig, Pierre] Univ Paris, Sorbonne Univ, INSERM, Ctr Rech Cordeliers, F-75006 Paris, France; [Sroussi, Marine] Ecole Super Phys & Chim Ind Ville Paris, Lab Biochim, F-75005 Paris, France; [Vodovar, Nicolas; Launay, Jean-Marie] Univ Paris Cite, Paris, France; [Vodovar, Nicolas; Launay, Jean-Marie] Inserm UMR S942 MASCOT, Paris, France; [Launay, Jean-Marie] F Hoffmann La Roche Ltd, Pharma Res Dept, CH-4070 Basel, Switzerland; [Laurent-Puig, Pierre] Hop Europeen Georges Pompidou, AP HP, Inst Canc Paris CARPEM, Dept Biol, F-75015 Paris, France; [Martin-Lanneree, Severine] IntegraGen SA, Genopole Campus 1,Rue Henri Desbrueres, F-91000 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Roche Holding; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Genopole	Mouillet-Richard, S (corresponding author), Univ Paris, Sorbonne Univ, INSERM, Ctr Rech Cordeliers, F-75006 Paris, France.	sophie.mouillet-richard@parisdescartes.fr	Mouillet, Sophie/E-4960-2017; laurent-puig, pierre/B-2226-2013	Mouillet, Sophie/0000-0002-8950-1949; laurent-puig, pierre/0000-0001-8475-5459; Hirsch, Theo/0000-0003-4428-2997	Canceropole Ile de France [2016-1-EMERG-36-UP 5-1]; Association pour la Recherche sur le Cancer [PJA 20171206220]; SIRIC CARPEM (CAncer Research for PErsonalized Medicine) [INCaDGOS Inserm_12561]; Labex Immuno-oncology, SATT Ile de France [415]; INSERM; Groupement des Entreprises Francaises dans la Lutte contre le Cancer (GEFLUC); Fondation pour la Recherche Medicale [FDM202006011237]	Canceropole Ile de France(Region Ile-de-France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); SIRIC CARPEM (CAncer Research for PErsonalized Medicine); Labex Immuno-oncology, SATT Ile de France; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Groupement des Entreprises Francaises dans la Lutte contre le Cancer (GEFLUC); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	Grant support was provided by the following: Canceropole Ile de France (grant number 2016-1-EMERG-36-UP 5-1), Association pour la Recherche sur le Cancer (grant number PJA 20171206220), SIRIC CARPEM (CAncer Research for PErsonalized Medicine, INCaDGOS Inserm_12561), Labex Immuno-oncology, SATT Ile de France (grant number 415) as well as INSERM and Groupement des Entreprises Francaises dans la Lutte contre le Cancer (GEFLUC). M. Sroussi was supported by a fellowship from Fondation pour la Recherche Medicale (FRM grant FDM202006011237). The authors acknowledge N. Pierron and F. d'Agostini for expert methodological assistance.	Aguzzi A, 2009, PHYSIOL REV, V89, P1105, DOI 10.1152/physrev.00006.2009; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bruggink KA, 2015, J NEUROCHEM, V134, P1152, DOI 10.1111/jnc.13216; D'Amico L, 2016, J EXP MED, V213, P827, DOI 10.1084/jem.20150950; Ferrari N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07987-0; Ghazi A, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1940674; Griffiths HH, 2011, J BIOL CHEM, V286, P33489, DOI 10.1074/jbc.M111.278556; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hampel H, 2021, BIOL PSYCHIAT, V89, P745, DOI 10.1016/j.biopsych.2020.02.001; Hirsch TZ, 2017, PROG MOL BIOL TRANSL, V150, P1, DOI 10.1016/bs.pmbts.2017.06.001; Kamoun A, 2018, ANN ONCOL, V29, P1814, DOI 10.1093/annonc/mdy224; Karran E, 2022, NAT REV DRUG DISCOV, V21, P306, DOI 10.1038/s41573-022-00391-w; Killick R, 2014, MOL PSYCHIATR, V19, P88, DOI 10.1038/mp.2012.163; Kleffman K, 2022, CANCER DISCOV, V12, P1314, DOI 10.1158/2159-8290.CD-21-1006; Kralovicova S, 2009, MOL CELL NEUROSCI, V41, P135, DOI 10.1016/j.mcn.2009.02.002; Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761; Le Corre D, 2019, EBIOMEDICINE, V46, P94, DOI 10.1016/j.ebiom.2019.07.036; Li J, 2017, CANCER CELL, V31, P225, DOI 10.1016/j.ccell.2017.01.005; Linsenmeier L, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abj1826; McHugh PC, 2012, NEUROCHEM INT, V61, P672, DOI 10.1016/j.neuint.2012.07.002; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Mouillet-Richard S, 2021, CANCERS, V13, DOI 10.3390/cancers13195032; Pankiewicz JE, 2019, MOL NEUROBIOL, V56, P2073, DOI 10.1007/s12035-018-1208-4; Parkin ET, 2007, P NATL ACAD SCI USA, V104, P11062, DOI 10.1073/pnas.0609621104; Qin KF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44317-w; Rajan P, 2014, EUR UROL, P66; Rajan P, 2014, EUR UROL, V66, P32, DOI 10.1016/j.eururo.2013.08.011; Smith BA, 2015, P NATL ACAD SCI USA, V112, pE6544, DOI 10.1073/pnas.1518007112; Whitehouse IJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159119; Whitehouse IJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059554; Zhang DX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10798; Zhao SG, 2017, JAMA ONCOL, V3, P1663, DOI 10.1001/jamaoncol.2017.0751	32	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4397	4404		10.1038/s41388-022-02430-7	http://dx.doi.org/10.1038/s41388-022-02430-7		AUG 2022	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35962130	hybrid, Green Published			2022-12-28	WOS:000840000600002
J	Shen, ZJ; Gu, LK; Liu, YW; Wang, LF; Zhu, JW; Tang, SS; Wei, XY; Wang, JY; Zhang, SF; Wang, XY; Cheng, XD; Xie, X; Lu, WG				Shen, Zhangjin; Gu, Lingkai; Liu, Yuwan; Wang, Lingfang; Zhu, Jiawei; Tang, Sangsang; Wei, Xinyi; Wang, Jiaying; Zhang, Songfa; Wang, Xinyu; Cheng, Xiaodong; Xie, Xing; Lu, Weiguo			PLAA suppresses ovarian cancer metastasis via METTL3-mediated m(6)A modification of TRPC3 mRNA	ONCOGENE			English	Article							ACTIVATING PROTEIN; CALCIUM; N6-METHYLADENOSINE; PROGRESSION; METABOLISM	Wide metastasis contributes to a high death rate in ovarian cancer, and understanding of the molecular mechanism helps to find effective targets for metastatic ovarian cancer therapy. It has been found that phospholipase A2-activating protein (PLAA) is inactivated in some cancers, but its role in cancer metastasis remains unknown. Here, we found that PLAA was significantly downregulated in ovarian cancer highly metastatic cell lines and patients, and the low expression of PLAA was associated with poorer prognosis and high-risk clinicopathological features of patients. PLAA inhibited the migration and invasion of ovarian cancer cells and metastasis of transplanted tumor in the orthotopic xenograft mouse model. Meanwhile, PLAA inhibited metastasis of ovarian cancer by inhibiting transient receptor potential channel canonical 3 (TRPC3)-mediated the intracellular Ca2+ level. Mechanistically, PLAA inhibited methyltransferase-like 3 (METTL3) expression through the ubiquitin-mediated degradation, and METTL3 stabilized TRPC3 mRNA expression via N6-methyladenosine (m(6)A) modification. Our study verified the function and mechanism of the PLAA-METTL3-TRPC3 axis involved in ovarian cancer metastasis, with a view to providing a potential therapeutic approach for ovarian cancer.	[Shen, Zhangjin; Gu, Lingkai; Liu, Yuwan; Wang, Lingfang; Tang, Sangsang; Wei, Xinyi] Zhejiang Univ, Sch Med, Womens Hosp, Womens Reprod Hlth Lab Zhejiang Prov, Hangzhou 310006, Zhejiang, Peoples R China; [Zhu, Jiawei; Zhang, Songfa; Wang, Xinyu; Cheng, Xiaodong; Xie, Xing; Lu, Weiguo] Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, Hangzhou 310006, Zhejiang, Peoples R China; [Wang, Jiaying] Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Obstet & Gynecol, Beijing 100853, Peoples R China; [Wang, Xinyu; Cheng, Xiaodong; Lu, Weiguo] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China; [Wang, Xinyu] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Obstet & Gynecol, Hangzhou 310003, Zhejiang, Peoples R China; [Cheng, Xiaodong] Zhejiang Univ, Sch Med, Womens Hosp, Zhejiang Prov Key Lab Precis Diag & Therapy Major, Hangzhou 310006, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Chinese People's Liberation Army General Hospital; Zhejiang University; Zhejiang University; Zhejiang University	Lu, WG (corresponding author), Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, Hangzhou 310006, Zhejiang, Peoples R China.; Lu, WG (corresponding author), Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China.	lbwg@zju.edu.cn	Lu, Wei/AAE-2921-2022	Lu, Wei/0000-0002-4150-8674	National Natural Science Foundation of China [82072856]; Key Research and Development Program of Zhejiang Province, China [2019C03010]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Program of Zhejiang Province, China	We thank our laboratory members and teachers for critical discussions. Thanks for the technical support by the core facilities, Zhejiang University School of Medicine. This work was supported by National Natural Science Foundation of China (Grant number: 82072856) and the Key Research and Development Program of Zhejiang Province, China (Grant number: 2019C03010).	Baljinnyam E, 2010, CANCER RES, V70, P5607, DOI 10.1158/0008-5472.CAN-10-0056; Beatty BG, 1999, GENOMICS, V62, P529, DOI 10.1006/geno.1999.5999; Bi XH, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00600-2; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Cortes-Guiral D, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00326-6; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Goddard DH, 1998, DRUG NEWS PERSPECT, V11, P104, DOI 10.1358/dnp.1998.11.2.863682; Grasset EM, 2018, CANCER RES, V78, P5229, DOI 10.1158/0008-5472.CAN-18-0601; Han J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1036-9; Hsu KF, 2015, BRIT J CANCER, V113, P414, DOI 10.1038/bjc.2015.254; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Jiang HN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067637; Jiang RB, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3972534; Jiang XL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00450-x; Jin D, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01048-8; Kim JM, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.40; Koivisto AP, 2022, NAT REV DRUG DISCOV, V21, P41, DOI 10.1038/s41573-021-00268-4; Lee Y, 2020, TRENDS GENET, V36, P177, DOI 10.1016/j.tig.2019.12.007; Lin DC, 2021, CANCER LETT, V519, P211, DOI 10.1016/j.canlet.2021.07.038; Liu T, 2020, NUCLEIC ACIDS RES, V48, P3816, DOI 10.1093/nar/gkaa048; Moccia F, 2018, J CELL PHYSIOL, V233, P3901, DOI 10.1002/jcp.26152; Monteith GR, 2017, NAT REV CANCER, V17, P367, DOI 10.1038/nrc.2017.18; Muller S, 2018, NUCLEIC ACIDS RES, V46, P6285, DOI 10.1093/nar/gky229; Mullally JE, 2006, MOL CELL BIOL, V26, P822, DOI 10.1128/MCB.26.3.822-830.2006; Numaga-Tomita T, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00056; Papadopoulos C, 2017, EMBO J, V36, P135, DOI 10.15252/embj.201695148; Pashkova N, 2010, MOL CELL, V40, P433, DOI 10.1016/j.molcel.2010.10.018; Peer E, 2017, CURR OPIN CHEM BIOL, V41, P93, DOI 10.1016/j.cbpa.2017.10.008; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Roberts JZ, 2022, CELL DEATH DIFFER, V29, P272, DOI 10.1038/s41418-021-00922-9; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Shen XM, 2021, J OVARIAN RES, V14, DOI 10.1186/s13048-021-00776-2; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Sommerfeld L, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.633; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Wang HB, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107497; Wang X, 2016, NATURE, V534, P575, DOI 10.1038/nature18298; Yang SL, 2009, ONCOGENE, V28, P1320, DOI 10.1038/onc.2008.475; Yue B, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1065-4; Zaccai TCF, 2017, BRAIN, V140, P370, DOI 10.1093/brain/aww295; Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580-019-0168-5; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015	44	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2022	41	35					4145	4158		10.1038/s41388-022-02411-w	http://dx.doi.org/10.1038/s41388-022-02411-w		JUL 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4A3US	35869392	Green Published, hybrid			2022-12-28	WOS:000828959400001
J	Yu, HG; Bijian, K; da Silva, SD; Su, J; Morand, G; Spatz, A; Alaoui-Jamali, MA				Yu, Henry G.; Bijian, Krikor; da Silva, Sabrina D.; Su, Jie; Morand, Gregoire; Spatz, Alan; Alaoui-Jamali, Moulay A.			NEDD9 links anaplastic thyroid cancer stemness to chromosomal instability through integrated centrosome asymmetry and DNA sensing regulation	ONCOGENE			English	Article							PROGNOSTIC IMPLICATIONS; METASTASIS; CELLS; ACTIVATION; CARCINOMA; EVOLUTION; HETEROGENEITY; AMPLIFICATION; ASSOCIATION; MECHANISMS	Stemness and chromosomal instability (CIN) are two common contributors to intratumor heterogeneity and therapy relapse in advanced cancer, but their interplays are poorly defined. Here, in anaplastic thyroid cancer (ATC), we show that ALDH+ stem-like cancer cells possess increased CIN-tolerance owing to transcriptional upregulation of the scaffolding protein NEDD9. Thyroid patient tissues and transcriptomic data reveals NEDD9/ALDH1A3 to be co-expressed and co-upregulated in ATC. Compared to bulk ALDH- cells, ALDH+ cells were highly efficient at propagating CIN due to their intrinsic tolerance of both centrosome amplification and micronuclei. ALDH+ cells mitigated the fitness-impairing effects of centrosome amplification by partially inactivating supernumerary centrosomes. Meanwhile, ALDH+ cells also mitigated cell death caused by micronuclei-mediated type 1 interferon secretion by suppressing the expression of the DNA-sensor protein STING. Both mechanisms of CIN-tolerance were lost upon RNAi-mediated NEDD9 silencing. Both in vitro and in vivo, NEDD9-depletion attenuated stemness, CIN, cell/tumor growth, while enhancing paclitaxel effectiveness. Collectively, these findings reveal that ATC progression can involve an ALDH1A3/NEDD9-regulated program linking their stemness to CIN-tolerance that could be leveraged for ATC treatment.	[Yu, Henry G.; Bijian, Krikor; da Silva, Sabrina D.; Su, Jie; Morand, Gregoire; Spatz, Alan; Alaoui-Jamali, Moulay A.] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ, Canada; [Yu, Henry G.; Bijian, Krikor; da Silva, Sabrina D.; Su, Jie; Morand, Gregoire; Spatz, Alan; Alaoui-Jamali, Moulay A.] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ, Canada; [da Silva, Sabrina D.; Morand, Gregoire] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Otolaryngol Head & Neck Surg, Montreal, PQ, Canada; [Spatz, Alan] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Pathol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Alaoui-Jamali, MA (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ, Canada.; Alaoui-Jamali, MA (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ, Canada.	moulay.alaoui-jamali@mcgill.ca		Spatz, Alan/0000-0003-3020-1420; Morand, Gregoire/0000-0002-6150-6772	Canadian Institutes of Health Research [178116]; McGill Interdisciplinary Initiative in Infection and Immunity (MI4); Swiss Cancer League [BIL KFS-3002-082012]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); McGill Interdisciplinary Initiative in Infection and Immunity (MI4); Swiss Cancer League	This study was supported by the Canadian Institutes of Health Research (Grant#178116) and in part by McGill Interdisciplinary Initiative in Infection and Immunity (MI4); GB Morand was supported by the Swiss Cancer League (BIL KFS-3002-082012).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Ahn J, 2012, J CELL SCI, V125, P1814, DOI 10.1242/jcs.101444; Bajar BT, 2016, NAT METHODS, V13, P993, DOI [10.1038/NMETH.4045, 10.1038/nmeth.4045]; Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; Bakhoum SF, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a029611; Bible KC, 2021, THYROID, V31, P337, DOI 10.1089/thy.2020.0944; Binder JX, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau012; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan JY, 2011, INT J BIOL SCI, V7, P1122, DOI 10.7150/ijbs.7.1122; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chen H, 2016, MOL BIOL EVOL, V33, P4, DOI 10.1093/molbev/msv212; Cosenza MR, 2017, CELL REP, V20, P1906, DOI 10.1016/j.celrep.2017.08.005; Feng Y, 2012, CANCER RES, V72, P6502, DOI 10.1158/0008-5472.CAN-12-1909; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Gabbasov R, 2018, ONCOGENE, V37, P4854, DOI 10.1038/s41388-018-0296-y; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Ganly I, 2014, THYROID, V24, P662, DOI 10.1089/thy.2013.0503; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gentili M, 2019, CELL REP, V26, P2377, DOI 10.1016/j.celrep.2019.01.105; Hatch EM, 2013, CELL, V154, P47, DOI 10.1016/j.cell.2013.06.007; Heiden KB, 2014, J CLIN ENDOCR METAB, V99, pE2178, DOI 10.1210/jc.2014-1844; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Hopfner KP, 2020, NAT REV MOL CELL BIO, V21, P501, DOI 10.1038/s41580-020-0244-x; Isham CR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004358; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Jin YJ, 2014, INT J CANCER, V134, P2294, DOI 10.1002/ijc.28568; JOHNSON TL, 1988, AM J SURG PATHOL, V12, P22, DOI 10.1097/00000478-198801000-00003; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Knutson DC, 2008, ARCH BIOCHEM BIOPHYS, V477, P163, DOI 10.1016/j.abb.2008.06.005; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Li W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065095; Lin RY, 2011, NAT REV ENDOCRINOL, V7, P609, DOI 10.1038/nrendo.2011.127; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lohard S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13689-y; Mackenzie KJ, 2017, NATURE, V548, P461, DOI 10.1038/nature23449; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Mariappan A, 2019, EMBO J, V38, DOI 10.15252/embj.201899876; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Miao YX, 2019, CELL, V177, P1172, DOI 10.1016/j.cell.2019.03.025; Milunovic-Jevtic A, 2016, CURR OPIN BIOTECH, V40, P113, DOI 10.1016/j.copbio.2016.03.011; Miranda A, 2019, P NATL ACAD SCI USA, V116, P9020, DOI 10.1073/pnas.1818210116; Molinaro E, 2017, NAT REV ENDOCRINOL, V13, P644, DOI 10.1038/nrendo.2017.76; Morel AP, 2017, NAT MED, V23, P568, DOI 10.1038/nm.4323; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Nagayama Y, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00020; Nigg EA, 2011, NAT CELL BIOL, V13, P1154, DOI 10.1038/ncb2345; Paludan SR, 2019, NAT REV IMMUNOL, V19, P141, DOI 10.1038/s41577-018-0117-0; Pillai S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10072; Prabakaran T, 2018, EMBO J, V37, DOI 10.15252/embj.201797858; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Ranjan R, 2019, CELL STEM CELL, V25, P666, DOI 10.1016/j.stem.2019.08.014; Reeb N., 2015, J THYROID DISORD THE, V4, P2, DOI [10.4172/2167-7948.1000e179, DOI 10.4172/2167-7948.1000E179]; Shagisultanova E, 2015, GENE, V567, P1, DOI 10.1016/j.gene.2015.04.086; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shimamura M, 2014, ENDOCR J, V61, P481, DOI 10.1507/endocrj.EJ13-0526; Shiraiwa K, 2019, THYROID, V29, P674, DOI 10.1089/thy.2018.0212; Singh MK, 2007, CELL BIOCHEM BIOPHYS, V48, P54, DOI 10.1007/s12013-007-0036-3; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Todaro M, 2010, CANCER RES, V70, P8874, DOI 10.1158/0008-5472.CAN-10-1994; Visciano C, 2015, ONCOGENE, V34, P5175, DOI 10.1038/onc.2014.441; Wang ZP, 2017, ONCOTARGET, V8, P1714, DOI 10.18632/oncotarget.13852; Wilkens L, 2004, P NATL ACAD SCI USA, V101, P1309, DOI 10.1073/pnas.0305817101; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Yamashita YM, 2008, J CELL BIOL, V180, P261, DOI 10.1083/jcb.200707083; Yamashita YM, 2007, SCIENCE, V315, P518, DOI 10.1126/science.1134910; Zhou W, 2014, LEUKEMIA, V28, P1155, DOI 10.1038/leu.2013.383; Zhu XG, 2019, ENDOCR-RELAT CANCER, V26, P739, DOI 10.1530/ERC-19-0107; Zierhut C, 2019, CELL, V178, P302, DOI 10.1016/j.cell.2019.05.035	74	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2984	2999		10.1038/s41388-022-02317-7	http://dx.doi.org/10.1038/s41388-022-02317-7		APR 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35449243				2022-12-28	WOS:000784606800001
J	He, RS; Xhabija, B; Gopi, LK; Kurup, JT; Xu, ZS; Liu, Z; Kidder, BL				He, Runsheng; Xhabija, Besa; Gopi, Lijin K.; Kurup, Jiji T.; Xu, Zhishan; Liu, Zhe; Kidder, Benjamin L.			H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity	ONCOGENE			English	Article							GENE-EXPRESSION; STEM-CELLS; DRUG-RESISTANCE; MESSENGER-RNA; BREAST-CANCER; SELF-RENEWAL; JARID1B; METHYLATION; PATTERNS; PROLIFERATION	The H3K4 demethylase KDM5B is overexpressed in multiple cancer types, and elevated expression levels of KDM5B is associated with decreased survival. However, the underlying mechanistic contribution of dysregulated expression of KDM5B and H3K4 demethylation in cancer is poorly understood. Our results show that loss of KDM5B in multiple types of cancer cells leads to increased proliferation and elevated expression of cancer stem cell markers. In addition, we observed enhanced tumor formation following KDM5B depletion in a subset of representative cancer cell lines. Our findings also support a role for KDM5B in regulating epigenetic plasticity, where loss of KDM5B in cancer cells with elevated KDM5B expression leads to alterations in activity of chromatin states, which facilitate activation or repression of alternative transcriptional programs. In addition, we define KDM5B-centric epigenetic and transcriptional patterns that support cancer cell plasticity, where KDM5B depleted cancer cells exhibit altered epigenetic and transcriptional profiles resembling a more primitive cellular state. This study also provides a resource for evaluating associations between alterations in epigenetic patterning upon depletion of KDM5B and gene expression in a diverse set of cancer cells.	[He, Runsheng; Xhabija, Besa; Gopi, Lijin K.; Kurup, Jiji T.; Xu, Zhishan; Kidder, Benjamin L.] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48202 USA; [He, Runsheng; Xhabija, Besa; Gopi, Lijin K.; Kurup, Jiji T.; Xu, Zhishan; Kidder, Benjamin L.] Wayne State Univ, Karmanos Canc Inst, Sch Med, Detroit, MI 48202 USA; [Xu, Zhishan] Xinxiang Med Univ, Inst Precis Med, Xinxiang 453000, Henan, Peoples R China; [Xu, Zhishan] Shandong Normal Univ, Coll Chem Chem Engn & Mat Sci, Jinan 250014, Shandong, Peoples R China; [Liu, Zhe] Qufu Normal Univ, Dept Chem & Chem Engn, Qufu 273165, Shandong, Peoples R China; [Xhabija, Besa] Univ Michigan, Dept Chem & Biochem, Flint, MI 48503 USA; [Kurup, Jiji T.] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Xinxiang Medical University; Shandong Normal University; Qufu Normal University; University of Michigan System; University of Michigan; University of Michigan Flint; Columbia University	Kidder, BL (corresponding author), Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48202 USA.; Kidder, BL (corresponding author), Wayne State Univ, Karmanos Canc Inst, Sch Med, Detroit, MI 48202 USA.	benjamin.kidder@wayne.edu	LIU, zhe/HGD-6875-2022; Xhabija, Besa/GOP-2447-2022	Xhabija, Besa/0000-0002-4784-2454	Wayne State University, Karmanos Cancer Institute; Elsa U. Pardee Foundation	Wayne State University, Karmanos Cancer Institute; Elsa U. Pardee Foundation	This work was supported by Wayne State University, Karmanos Cancer Institute, and a grant from the Elsa U. Pardee Foundation awarded to BLK.	Abaan OD, 2013, CANCER RES, V73, P4372, DOI 10.1158/0008-5472.CAN-12-3342; Albert M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003461; Badea L, 2008, HEPATO-GASTROENTEROL, V55, P2016; Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Benayoun BA, 2014, CELL, V158, P673, DOI 10.1016/j.cell.2014.06.027; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Catchpole S, 2011, INT J ONCOL, V38, P1267, DOI 10.3892/ijo.2011.956; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chen KF, 2015, NAT GENET, V47, P1149, DOI 10.1038/ng.3385; Cheng CJ, 2009, CANCER RES, V69, P3634, DOI 10.1158/0008-5472.CAN-08-3615; Cutcliffe C, 2005, CLIN CANCER RES, V11, P7986, DOI 10.1158/1078-0432.CCR-05-1354; Dai B, 2014, BIOCHEM BIOPH RES CO, V454, P221, DOI 10.1016/j.bbrc.2014.10.078; Davoli T, 2013, CELL, V155, P948, DOI 10.1016/j.cell.2013.10.011; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dey BK, 2008, MOL CELL BIOL, V28, P5312, DOI 10.1128/MCB.00128-08; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Eisenberg E, 2013, TRENDS GENET, V29, P569, DOI 10.1016/j.tig.2013.05.010; Evertts AG, 2013, MOL BIOL CELL, V24, P3025, DOI 10.1091/mbc.E12-07-0529; Facompre ND, 2016, CANCER RES, V76, P5538, DOI 10.1158/0008-5472.CAN-15-3377; Frankenberg S, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-8; Gopi LK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21707-1; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Hayami S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-59; He RS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29074-6; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hinohara K, 2018, CANCER CELL, V34, P939, DOI 10.1016/j.ccell.2018.10.014; Hu GQ, 2014, METHODS MOL BIOL, V1150, P175, DOI 10.1007/978-1-4939-0512-6_11; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Khan A, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1708-7; Kidder BL, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0115-7; Kidder BL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r32; Kidder BL, 2013, MOL CELL BIOL, V33, P4793, DOI 10.1128/MCB.00692-13; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Li X, 2013, INT J MOL SCI, V14, P7866, DOI 10.3390/ijms14047866; Liu HF, 2010, MOL CANCER THER, V9, P1080, DOI 10.1158/1535-7163.MCT-09-0965; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Min MW, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000178; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Muntean AG, 2009, AM J PATHOL, V175, P1353, DOI 10.2353/ajpath.2009.081142; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Ohta K, 2013, INT J ONCOL, V42, P1212, DOI 10.3892/ijo.2013.1799; Oshimori N, 2015, CELL, V160, P963, DOI 10.1016/j.cell.2015.01.043; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Reinhold WC, 2019, CANCER RES, V79, P3514, DOI 10.1158/0008-5472.CAN-18-2047; Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roesch A, 2006, J INVEST DERMATOL, V126, P1850, DOI 10.1038/sj.jid.5700324; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schmitz SU, 2011, EMBO J, V30, P4586, DOI 10.1038/emboj.2011.383; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shigekawa Yoshinobu, 2018, Oncotarget, V9, P34320, DOI 10.18632/oncotarget.26144; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; STINSON SF, 1992, ANTICANCER RES, V12, P1035; Stuelten CH, 2010, STEM CELLS, V28, P649, DOI 10.1002/stem.324; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Taylor-Papadimitriou J, 2017, EXPERT OPIN THER TAR, V21, P5, DOI 10.1080/14728222.2017.1263616; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Vinogradova M, 2016, NAT CHEM BIOL, V12, P531, DOI 10.1038/nchembio.2085; Wang LS, 2015, TUMOR BIOL, V36, P2465, DOI 10.1007/s13277-014-2859-z; Wang ZR, 2015, AM J CANCER RES, V5, P87; Xhabija B, 2019, SEMIN CANCER BIOL, V57, P79, DOI 10.1016/j.semcancer.2018.11.001; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Xie LQ, 2011, EMBO J, V30, P1473, DOI 10.1038/emboj.2011.91; Xu J, 2018, BIOL OPEN, V7, DOI 10.1242/bio.031245; Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024; Yu GC, 2010, BIOINFORMATICS, V26, P976, DOI 10.1093/bioinformatics/btq064; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340	84	0	0	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2958	2972		10.1038/s41388-022-02311-z	http://dx.doi.org/10.1038/s41388-022-02311-z		APR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35440714	Green Accepted			2022-12-28	WOS:000784875000001
J	Fujita, H; Ikeda, M; Ui, A; Ouchi, Y; Mikami, Y; Kanno, S; Yasui, A; Tanaka, K				Fujita, Hiroki; Ikeda, Masanori; Ui, Ayako; Ouchi, Yunosuke; Mikami, Yoshiko; Kanno, Shin-ichiro; Yasui, Akira; Tanaka, Kozo			CHAMP1-POGZ counteracts the inhibitory effect of 53BP1 on homologous recombination and affects PARP inhibitor resistance	ONCOGENE			English	Article							STRAND BREAK REPAIR; DNA-END RESECTION; EPIGENETIC HISTONE MARKS; INTELLECTUAL DISABILITY; PATHWAY CHOICE; DAMAGE; PROTEIN; POGZ; MAD2L2; BRCA1	DNA double-strand break (DSB) repair-pathway choice regulated by 53BP1 and BRCA1 contributes to genome stability. 53BP1 cooperates with the REV7-Shieldin complex and inhibits DNA end resection to block homologous recombination (HR) and affects the sensitivity to inhibitors for poly (ADP-ribose) polymerases (PARPs) in BRCA1-deficient cells. Here, we show that a REV7 binding protein, CHAMP1 (chromosome alignment-maintaining phosphoprotein 1), has an opposite function of REV7 in DSB repair and promotes HR through DNA end resection together with POGZ (POGO transposable element with ZNF domain). CHAMP1 was recruited to laser-micro-irradiation-induced DSB sites and promotes HR, but not NHEJ. CHAMP1 depletion suppressed the recruitment of BRCA1, but not the recruitment of 53BP1, suggesting that CHAMP1 regulates DSB repair pathway in favor of HR. Depletion of either CHAMP1 or POGZ impaired the recruitment of phosphorylated RPA2 and CtIP (CtBP-interacting protein) at DSB sites, implying that CHAMP1, in complex with POGZ, promotes DNA end resection for HR. Furthermore, loss of CHAMP1 and POGZ restored the sensitivity to a PARP inhibitor in cells depleted of 53BP1 together with BRCA1. These data suggest that CHAMP1and POGZ counteract the inhibitory effect of 53BP1 on HR by promoting DNA end resection and affect the resistance to PARP inhibitors.	[Fujita, Hiroki; Ikeda, Masanori; Ui, Ayako; Ouchi, Yunosuke; Mikami, Yoshiko; Tanaka, Kozo] Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Oncol, 4-1 Seiryo Machi,Aoba Ku, Sendai, Miyagi 9808575, Japan; [Ui, Ayako; Kanno, Shin-ichiro; Yasui, Akira] Tohoku Univ, Inst Dev Aging & Canc, IDAC Lab, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University	Tanaka, K (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Oncol, 4-1 Seiryo Machi,Aoba Ku, Sendai, Miyagi 9808575, Japan.	kozo.tanaka.d2@tohoku.ac.jp	Ui, Ayako/GON-4666-2022; Tanaka, Kozo/Y-6566-2018	Ui, Ayako/0000-0001-6698-7168; Tanaka, Kozo/0000-0001-6086-2858	JSPS KAKENHI [24370078, 24650616, 15H04368, 18H02434, 17K19615]; MEXT KAKENHI [26116501, 16H01296, 18H04896]; Takeda Science Foundation; Princess Takamatsu Cancer Research Fund [10-24210]; Naito Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Princess Takamatsu Cancer Research Fund; Naito Foundation(Naito Memorial Foundation)	The authors thank Dr. H. Kurumizaka (The University of Tokyo) for an antibody against Rad51, Dr. M. Takata (Kyoto University) for U2OS cells stably expressing GFP-tagged CtIP, and Dr. T. Hirota (The Cancer Institute of Japanese Foundation for Cancer Research) for HeLa Kyoto cells. The authors also thank members of the K.T. laboratory for discussions, Y. Yoshizaki for his critical reading of the manuscript, and A. Harata for technical assistance. This work was supported by JSPS KAKENHI Grant Numbers 24370078, 24650616, 15H04368, 18H02434 and 17K19615; MEXT KAKENHI Grant Numbers 26116501, 16H01296, and 18H04896; and grants from the Takeda Science Foundation, Princess Takamatsu Cancer Research Fund (10-24210), and the Naito Foundation to K.T.	Abe Y, 2016, DEV CELL, V36, P487, DOI 10.1016/j.devcel.2016.02.008; Adachi N, 2004, J BIOL CHEM, V279, P37343, DOI 10.1074/jbc.M313910200; Baude A, 2016, NUCLEIC ACIDS RES, V44, P2214, DOI 10.1093/nar/gkv1526; Bluhm A, 2016, PROTEOMICS, V16, P427, DOI 10.1002/pmic.201500217; Bochum Sylvia, 2018, Recent Results Cancer Res, V211, P217, DOI 10.1007/978-3-319-91442-8_15; Boersma V, 2015, NATURE, V521, P537, DOI 10.1038/nature14216; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Caron MC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10741-9; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Chen H, 2013, MOL CELL, V50, P589, DOI 10.1016/j.molcel.2013.04.032; Chen J, 2001, GENE DEV, V15, P1765, DOI 10.1101/gad.898701; Clairmont CS, 2020, NAT CELL BIOL, V22, P87, DOI 10.1038/s41556-019-0442-y; Cruz-Garcia A, 2014, CELL REP, V9, P451, DOI 10.1016/j.celrep.2014.08.076; Daugaard M, 2012, NAT STRUCT MOL BIOL, V19, P803, DOI 10.1038/nsmb.2314; Dev H, 2018, NAT CELL BIOL, V20, P954, DOI 10.1038/s41556-018-0140-1; Escribano-Diaz C, 2013, MOL CELL, V49, P872, DOI 10.1016/j.molcel.2013.01.001; Fanti L, 2008, CURR OPIN GENET DEV, V18, P169, DOI 10.1016/j.gde.2008.01.009; Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318; Garrity M, 2021, CSH MOL CASE STUD, V7, DOI 10.1101/mcs.a006092; Ghezraoui H, 2018, NATURE, V560, P122, DOI 10.1038/s41586-018-0362-1; Gudmundsdottir B, 2018, CELL REP, V23, P3236, DOI 10.1016/j.celrep.2018.05.043; Gupta R, 2018, CELL, V173, P972, DOI 10.1016/j.cell.2018.03.050; Hara K, 2017, J BIOL CHEM, V292, P17658, DOI 10.1074/jbc.M117.804237; Hein MY, 2015, CELL, V163, P712, DOI 10.1016/j.cell.2015.09.053; Hempel M, 2015, AM J HUM GENET, V97, P493, DOI 10.1016/j.ajhg.2015.08.003; Hino M, 2021, CANCER SCI, V112, P3711, DOI 10.1111/cas.15018; Ikeda M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09114-3; Isidor B, 2016, HUM MUTAT, V37, P354, DOI 10.1002/humu.22952; Itoh G, 2011, EMBO J, V30, P130, DOI 10.1038/emboj.2010.276; Kowalczykowski SC, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016410; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lan L, 2010, MOL CELL, V40, P976, DOI 10.1016/j.molcel.2010.12.003; Lee YJ, 2006, CARCINOGENESIS, V27, P446, DOI 10.1093/carcin/bgi254; Marechal A, 2015, CELL RES, V25, P9, DOI 10.1038/cr.2014.147; Mcrae JF, 2017, NATURE, V542, P433, DOI 10.1038/nature21062; Mirman Z, 2018, NATURE, V560, P112, DOI 10.1038/s41586-018-0324-7; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Nakajima S, 2006, J BIOL CHEM, V281, P34687, DOI 10.1074/jbc.M605545200; Noordermeer SM, 2018, NATURE, V560, P117, DOI 10.1038/s41586-018-0340-7; Nozawa RS, 2010, NAT CELL BIOL, V12, P719, DOI 10.1038/ncb2075; Ogiwara H, 2011, ONCOGENE, V30, P2135, DOI [10.1038/onc.2010.592, 10.1038/onc.2010.592;]; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rose M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.564601; Rulten SL, 2013, DNA REPAIR, V12, P558, DOI 10.1016/j.dnarep.2013.04.008; Sack LM, 2018, CELL, V173, P499, DOI 10.1016/j.cell.2018.02.037; Sale JE, 2015, EMBO J, V34, P1609, DOI 10.15252/embj.201591697; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Sharma S, 2012, NUCLEIC ACIDS RES, V40, P682, DOI 10.1093/nar/gkr769; Silverman J, 2004, GENE DEV, V18, P2108, DOI 10.1101/gad.1216004; Simonetta M, 2018, CELL CYCLE, V17, P124, DOI 10.1080/15384101.2017.1404210; Stessman HAF, 2016, AM J HUM GENET, V98, P541, DOI 10.1016/j.ajhg.2016.02.004; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Tan B, 2016, J HUM GENET, V61, P357, DOI 10.1038/jhg.2015.156; Tanaka AJ, 2016, CSH MOL CASE STUD, V2, DOI 10.1101/mcs.a000661; Tomida J, 2018, EMBO J, V37, DOI 10.15252/embj.201899543; Unno J, 2014, CELL REP, V7, P1039, DOI 10.1016/j.celrep.2014.04.005; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; White J, 2016, GENOME MED, V8, DOI 10.1186/s13073-015-0253-0; Willmore E, 2004, BLOOD, V103, P4659, DOI 10.1182/blood-2003-07-2527; Xu GT, 2015, NATURE, V521, P541, DOI 10.1038/nature14328; Ye Y, 2015, CSH MOL CASE STUD, V1, DOI 10.1101/mcs.a000455; Yearim A, 2015, CELL REP, V10, P1122, DOI 10.1016/j.celrep.2015.01.038; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; You ZS, 2009, MOL CELL, V36, P954, DOI 10.1016/j.molcel.2009.12.002; Zeng W, 2010, EPIGENETICS-US, V5, P287, DOI 10.4161/epi.5.4.11683; Zhu Z, 2008, CELL, V134, P981, DOI 10.1016/j.cell.2008.08.037	69	2	2	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2706	2718		10.1038/s41388-022-02299-6	http://dx.doi.org/10.1038/s41388-022-02299-6		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35393543				2022-12-28	WOS:000779227700004
J	Wang, L; Wang, JY; Yin, XL; Guan, X; Li, Y; Xin, CQ; Liu, J				Wang, Liang; Wang, Jiayi; Yin, Xiaolin; Guan, Xin; Li, Ying; Xin, Chenqi; Liu, Jing			GIPC2 interacts with Fzd7 to promote prostate cancer metastasis by activating WNT signaling	ONCOGENE			English	Article							INHIBITION; STATISTICS; EXOSOMES; PROTEIN; CELLS	Prostate cancer (PCa) causes significant mortality and morbidity, with advanced metastasis. WNT signaling is a promising therapeutic target for metastatic PCa. GIPC2 is a GIPC1 paralog involved in WNT signaling pathways associated with tumor progression, but its role in PCa metastasis remains unclear. Herein, we demonstrated that high GIPC2 expression in PCa tissues was significantly associated with distant metastasis and poor prognosis. Functional studies demonstrated that high GIPC2 expression due to CpG-island demethylation promoted increased metastatic capabilities of PCa cells. Conversely, silencing GIPC2 expression significantly inhibited PCa metastasis in vitro and in vivo. Furthermore, GIPC2 directly bound the WNT co-receptor Fzd7 through its PDZ domain, which enabled activation of WNT-beta-catenin cascades, thereby stimulating PCa metastasis. Interestingly, GIPC2 protein was also identified as a component of exosomes and that it robustly stimulated PCa adhesion, invasion, and migration. The presence of GIPC2 in tumor-derived exosomes and ability to impact the behavior of tumor cells suggest that GIPC2 is a novel epigenetic oncogene involved in PCa metastasis. Our findings identified GIPC2 as a novel exosomal molecule associated with WNT signaling and may represent a potential therapeutic target and biomarker for metastatic PCa.	[Wang, Liang; Wang, Jiayi; Yin, Xiaolin; Guan, Xin; Li, Ying; Xin, Chenqi; Liu, Jing] Dalian Med Univ, Affiliated Hosp 1, Regenerat Med Ctr, Stem Cell Clin Res Ctr,Natl Joint Engn Lab, 193 Lianhe Rd, Dalian 116011, Liaoning, Peoples R China; [Wang, Liang; Wang, Jiayi; Yin, Xiaolin; Guan, Xin; Li, Ying; Xin, Chenqi; Liu, Jing] Dalian Innovat Inst Stem Cell & Precis Med, 57 Xinda St,Dalian High Tech Pk, Dalian 116023, Liaoning, Peoples R China	Dalian Medical University	Liu, J (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Regenerat Med Ctr, Stem Cell Clin Res Ctr,Natl Joint Engn Lab, 193 Lianhe Rd, Dalian 116011, Liaoning, Peoples R China.; Liu, J (corresponding author), Dalian Innovat Inst Stem Cell & Precis Med, 57 Xinda St,Dalian High Tech Pk, Dalian 116023, Liaoning, Peoples R China.	liujing@dmu.edu.cn		Wang, Liang/0000-0003-2244-7535	National Nature Science Foundation of China [31600614, 82072953]; Innovative leading talents of Liaoning Province [XLYC1902031]; Young top talents of Liaoning Province [XLYC1907009]; Dalian outstanding young scientific and technological talents [2021RJ12]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovative leading talents of Liaoning Province; Young top talents of Liaoning Province; Dalian outstanding young scientific and technological talents	We would like to acknowledge the patients for the tissue samples. This work was supported by the National Nature Science Foundation of China (Grant Nos. 31600614, 82072953), the Innovative leading talents of Liaoning Province (Grant No. XLYC1902031), Young top talents of Liaoning Province (Grant No. XLYC1907009), and Dalian outstanding young scientific and technological talents (Grant No. 2021RJ12).	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Atala Anthony, 2017, J Urol, V197, P701, DOI 10.1016/j.juro.2016.12.032; Bersini S, 2014, BIOMATERIALS, V35, P2454, DOI 10.1016/j.biomaterials.2013.11.050; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Cooperberg MR, 2015, EUR UROL, V67, P326, DOI 10.1016/j.eururo.2014.05.039; Culp MB, 2020, EUR UROL, V77, P38, DOI 10.1016/j.eururo.2019.08.005; Dong Y., CELL DEATH DIS, V2021; Francis JC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003180; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; Ito K, 2014, NAT REV UROL, V11, P197, DOI 10.1038/nrurol.2014.42; Katoh M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.49; Kirikoshi H, 2002, INT J ONCOL, V20, P571; Kong J, 2016, ONCOTARGET, V7, P78421, DOI 10.18632/oncotarget.9382; Kuang SQ, 2008, LEUKEMIA, V22, P1529, DOI 10.1038/leu.2008.130; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Kypta RM, 2012, NAT REV UROL, V9, P418, DOI 10.1038/nrurol.2012.116; Li J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150247; Li Y, 2017, ONCOGENE, V36, P6293, DOI 10.1038/onc.2017.223; Liu TJ, 2009, ELECTROPHORESIS, V30, P4285, DOI 10.1002/elps.200900289; Ma F, 2016, J CLIN INVEST, V126, P1745, DOI 10.1172/JCI78815; Mao XY, 2010, CANCER RES, V70, P5207, DOI 10.1158/0008-5472.CAN-09-4074; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151; Muders MH, 2009, CLIN CANCER RES, V15, P4095, DOI 10.1158/1078-0432.CCR-08-2837; Murillo-Garzon V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Nilsson J, 2009, BRIT J CANCER, V100, P1603, DOI 10.1038/sj.bjc.6605058; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Pernar CH, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a030361; Phesse T, 2016, CANCERS, V8, DOI 10.3390/cancers8050050; Shang GJ, 2017, ELIFE, V6, P1, DOI 10.7554/eLife.27322; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Song JW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005756; Tan C, 2001, DEVELOPMENT, V128, P3665; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thiele S, 2011, J CELL BIOCHEM, V112, P1593, DOI 10.1002/jcb.23070; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; van Amerongen R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007914; Yang YH, 2013, MOL BIOL REP, V40, P4241, DOI 10.1007/s11033-013-2506-6; Yavelsky V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-247; You SY, 2016, CANCER RES, V76, P4948, DOI 10.1158/0008-5472.CAN-16-0902; Zong Y, 2012, P NATL ACAD SCI USA, V109, pE3395, DOI 10.1073/pnas.1217982109	45	2	2	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2609	2623		10.1038/s41388-022-02255-4	http://dx.doi.org/10.1038/s41388-022-02255-4		MAR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35347223	hybrid, Green Published			2022-12-28	WOS:000773837500001
J	Chen, XX; Wang, ZY; Zhao, XG; Zhang, LL; Zhou, L; Li, XX; Ge, C; Zhao, FY; Chen, TY; Xie, HY; Cui, Y; Tian, H; Li, H; Yao, M; Li, JJ				Chen, Xiaoxia; Wang, Zhenyu; Zhao, Xinge; Zhang, Lili; Zhou, Lianer; Li, Xianxian; Ge, Chao; Zhao, Fangyu; Chen, Taoyang; Xie, Haiyang; Cui, Ying; Tian, Hua; Li, Hong; Yao, Ming; Li, Jinjun			STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1	ONCOGENE			English	Article							CDYL; CANCER; TRIMETHYLATION; ACTIVATION; EXPRESSION; PROMOTES	Chromodomain Y-like 2 (CDYL2), as a member of CDY family known to be involved in spermatogenesis, has been reported to participate in breast cancer development recently, but its exact biological role in hepatocellular carcinoma (HCC) remains unclear. Here, we observed that CDYL2 was down-regulated in human primary HCC tissues and the low levels of CDYL2 expression were correlated with poor survival. Gain- and loss-of-function experiments showed that CDYL2 inhibited the proliferation and metastasis of HCC cells in vitro and in vivo. Mechanistically, CDYL2 down-regulates solute carrier family 7 member 6 (SLC7A6) by decreasing the enrichment of H3K4me3 on the promoter region of SLC7A6. Additionally, we also found that signal transducer and activator of transcription 5A (STAT5A) could directly and positively regulate the expression of CDYL2. Thus, CDYL2 was regulated by STAT5A, and suppressed the amino acid transportation through down-regulation of SLC7A6, and then inhibits the mTORC1/S6K pathway, a master regulator of cell growth. Consistently, CDYL2 expression correlated significantly with STAT5A and SLC7A6 expression in HCC. Collectively, we propose a model for a STAT5A/CDYL2/SLC7A6 axis that provides novel insight into CDYL2, which may serve as a potential factor for predicting prognosis and a therapeutic target for HCC patients.	[Chen, Xiaoxia; Li, Jinjun] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Biomed Engn, Shanghai 200032, Peoples R China; [Chen, Xiaoxia; Wang, Zhenyu; Zhao, Xinge; Zhou, Lianer; Li, Xianxian; Ge, Chao; Zhao, Fangyu; Tian, Hua; Li, Hong; Yao, Ming; Li, Jinjun] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, Sch Med, Shanghai 200032, Peoples R China; [Zhang, Lili] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Oncol, Sch Med, Shanghai 200080, Peoples R China; [Chen, Taoyang] Qi Dong Liver Canc Inst, Qi Dong 226200, Peoples R China; [Xie, Haiyang] Zhejiang Univ, Dept Gen Surg, Affiliated Hosp 1, Sch Med, Hangzhou 310000, Peoples R China; [Cui, Ying] Canc Inst Guangxi, Nanning 530027, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Zhejiang University	Li, JJ (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Biomed Engn, Shanghai 200032, Peoples R China.; Li, JJ (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, Sch Med, Shanghai 200032, Peoples R China.	jjli@shsci.org			National Natural Science Foundation of China [82173331, 81972580, 81773152]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors are grateful to Dr. Daqiang Li for donating pLVX-CDYL2 vector. This work was supported by the National Natural Science Foundation of China [Grant number 82173331, 81972580, 81773152].	Abu-Zhayia ER, 2018, J MOL CELL BIOL, V10, P341, DOI 10.1093/jmcb/mjx050; Audia JE, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019521; Bernaciak TM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2341; Dorus S, 2003, HUM MOL GENET, V12, P1643, DOI 10.1093/hmg/ddg185; Escamilla-Del-Arenal M, 2013, MOL CELL BIOL, V33, P5005, DOI 10.1128/MCB.00866-13; Gunasekaran G, 2021, HEPATOLOGY, V73, P128, DOI 10.1002/hep.31325; Jewell JL, 2013, NAT REV MOL CELL BIO, V14, P133, DOI 10.1038/nrm3522; Jiang YB, 2021, MOL ONCOL, V15, P710, DOI 10.1002/1878-0261.12846; Kandasamy P, 2018, TRENDS BIOCHEM SCI, V43, P752, DOI 10.1016/j.tibs.2018.05.003; Kollmann S, 2019, LEUKEMIA, V33, P1583, DOI 10.1038/s41375-018-0369-5; Lahn BT, 2002, P NATL ACAD SCI USA, V99, P8707, DOI 10.1073/pnas.082248899; Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092; Liu P, 2017, HEPATOLOGY, V66, P167, DOI 10.1002/hep.29183; Liu SM, 2017, MOL CELL, V67, P853, DOI 10.1016/j.molcel.2017.07.011; McGlynn KA, 2021, HEPATOLOGY, V73, P4, DOI 10.1002/hep.31288; Menezes ME, 2016, ADV CANCER RES, V132, P1, DOI 10.1016/bs.acr.2016.07.001; Milewski K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112308; Mulligan P, 2008, MOL CELL, V32, P718, DOI 10.1016/j.molcel.2008.10.025; Qiu ZG, 2019, THERANOSTICS, V9, P4717, DOI 10.7150/thno.33680; Rask-Andersen M, 2013, MOL ASPECTS MED, V34, P702, DOI 10.1016/j.mam.2012.07.015; Rotoli BM, 2020, J CELL MOL MED, V24, P921, DOI 10.1111/jcmm.14801; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shen E, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0514; Siouda M, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101141; Tang JZ, 2010, ENDOCRINOLOGY, V151, P43, DOI 10.1210/en.2009-0651; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Wang A, 2008, ANIM GENET, V39, P207, DOI 10.1111/j.1365-2052.2008.01706.x; Wang Q, 2015, AM J CANCER RES, V5, P1281; Wu H, 2013, GENE CHROMOSOME CANC, V52, P644, DOI 10.1002/gcc.22060; Xia XY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1455-y; Yang J, 2019, THERANOSTICS, V9, P5810, DOI 10.7150/thno.34973; Yang LF, 2020, THERANOSTICS, V10, P5242, DOI 10.7150/thno.43744; Yu JH, 2012, HEPATOLOGY, V56, P2375, DOI 10.1002/hep.25900; Yu JH, 2010, HEPATOLOGY, V52, P1808, DOI 10.1002/hep.23882; Yue M, 2017, CELL REP, V21, P3819, DOI 10.1016/j.celrep.2017.12.002; Zhang LL, 2020, CANCER RES, V80, P2599, DOI 10.1158/0008-5472.CAN-19-3226; Zhang Y, 2011, J BIOL CHEM, V286, P42414, DOI 10.1074/jbc.M111.271064	37	1	1	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2492	2504		10.1038/s41388-022-02273-2	http://dx.doi.org/10.1038/s41388-022-02273-2		MAR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35314791				2022-12-28	WOS:000771325000002
J	Wang, H; Zhang, DY; Cui, XX; Dai, YB; Wang, CC; Feng, WL; Lv, XQ; Li, YF; Wang, LN; Ru, YX; Zhang, YC; Ren, Q; Zheng, GG				Wang, Hao; Zhang, Dongyue; Cui, Xiaoxi; Dai, Yibo; Wang, Chenchen; Feng, Wenli; Lv, Xiaoqian; Li, Yifei; Wang, Lina; Ru, Yongxin; Zhang, Yingchi; Ren, Qian; Zheng, Guoguang			Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion	ONCOGENE			English	Article							BLOOD-BRAIN-BARRIER; STEM-CELLS; TRANSCRIPTION FACTORS; BONE METASTASIS; CANCER CELLS; MODEL; ESTABLISHMENT; CHALLENGES; REGULATOR; FAMILY	Interferon regulatory factor 7 (IRF7) is widely studied in inflammatory models. Its effects on malignant progression have been documented mainly from the perspective of the microenvironment. However, its role in leukemia has not been established. Here we used MLL-AF9-induced acute myeloid leukemia (AML) mouse models with IRF7 knockout or overexpression and xenograft mouse models to explore the intrinsic effects of IRF7 in AML. AML-IRF7(-/-) mice exhibited accelerated disease progression with intracerebral invasion of AML cells. AML-IRF7(-/-) cells showed increased proliferation and elevated leukemia stem cell (LSC) levels. Overexpression of IRF7 in AML cells decreased cell proliferation and LSC levels. Furthermore, overexpression of transforming growth-interacting factor 1 (TGIF1) rescued the enhanced proliferation and high LSC levels caused by IRF7 deficiency. Moreover, upregulation of vascular cell adhesion molecule 1 (VCAM1), which correlated with high LSC levels, was detected in AML-IRF7(-/-) cells. In addition, blocking VCAM1-very late antigen 4 (VLA-4) axis delayed disease progression and attenuated intracerebral invasion of AML cells. Therefore, our findings uncover the intrinsic effects of IRF7 in AML and provide a potential strategy to control central nervous system myeloid leukemia.	[Wang, Hao; Zhang, Dongyue; Cui, Xiaoxi; Dai, Yibo; Wang, Chenchen; Feng, Wenli; Lv, Xiaoqian; Li, Yifei; Wang, Lina; Ru, Yongxin; Zhang, Yingchi; Ren, Qian; Zheng, Guoguang] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp,Haihe Lab Cell Ecos, 288 Nanjing Rd, Tianjin 300020, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Peking Union Medical College	Zheng, GG (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp,Haihe Lab Cell Ecos, 288 Nanjing Rd, Tianjin 300020, Peoples R China.	zhengggtjchn@aliyun.com		Wang, Chenchen/0000-0003-3329-0756	National Natural Science Foundation of China (NSFC) [81970155, 82170174, 81770183]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2021-I<INF>2</INF>M-1-041]; Graduate Student Innovation Fund of Peking Union Medical College [2018-0710-08]; New Century Excellent Talents in University [NCET-08-0329]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS); Graduate Student Innovation Fund of Peking Union Medical College; New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET))	This work was supported by grants 81970155, 82170174, and 81770183 from the National Natural Science Foundation of China (NSFC); program 2021-I<INF>2</INF>M-1-041 from the CAMS Innovation Fund for Medical Sciences (CIFMS); and the grant 2018-0710-08 from the Graduate Student Innovation Fund of Peking Union Medical College. Z.GG. is a recipient of the New Century Excellent Talents in University (NCET-08-0329).	Bakst RL, 2011, BLOOD, V118, P3785, DOI 10.1182/blood-2011-04-347229; Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830; Chen XM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12850-x; Chen YY, 2021, STEM CELLS, V39, P183, DOI 10.1002/stem.3308; Chen Z, 2021, ONCOGENE, V40, P3786, DOI 10.1038/s41388-021-01818-1; Chu YJ, 2020, ONCOGENE, V39, P7239, DOI 10.1038/s41388-020-01495-6; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Felix A, 2018, J PEDIAT HEMATOL ONC, V40, P43, DOI 10.1097/MPH.0000000000001034; Feng WL, 2021, HAEMATOLOGICA, V106, P1278, DOI 10.3324/haematol.2019.243360; Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004; Greenwood J, 2011, NEUROPATH APPL NEURO, V37, P24, DOI 10.1111/j.1365-2990.2010.01140.x; Grove RA, 2013, EUR J NEUROL, V20, P1032, DOI 10.1111/ene.12097; Guca E, 2018, NUCLEIC ACIDS RES, V46, P9220, DOI 10.1093/nar/gky680; Hamid R, 2009, MOL ONCOL, V3, P451, DOI 10.1016/j.molonc.2009.07.004; Hayakawa Y, 2015, CANCER CELL, V28, P800, DOI 10.1016/j.ccell.2015.10.003; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hu GH, 2020, CL LYMPH MYELOM LEUK, V20, pE813, DOI 10.1016/j.clml.2020.06.009; Kim TH, 2020, GENES-BASEL, V11, DOI 10.3390/genes11040385; Kinstrie R, 2020, LEUKEMIA, V34, P1613, DOI 10.1038/s41375-019-0684-5; Lan Q, 2019, ONCOGENE, V38, P2814, DOI 10.1038/s41388-018-0624-2; Li DF, 2014, ONCOL REP, V32, P684, DOI 10.3892/or.2014.3254; Li YP, 2015, CELL PROLIFERAT, V48, P643, DOI 10.1111/cpr.12223; Li ZJ, 2006, EUR J HAEMATOL, V77, P128, DOI 10.1111/j.1600-0609.2006.00686.x; Li ZZ, 2017, J CANCER, V8, P207, DOI 10.7150/jca.16415; Litzow MR, 2015, BLOOD, V126, P833, DOI 10.1182/blood-2014-10-551895; Liu YX, 2021, INT J ONCOL, V58, P371, DOI 10.3892/ijo.2021.5180; LYNCH RG, 1975, J NATL CANCER I, V55, P611, DOI 10.1093/jnci/55.3.611; Negishi H, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028423; Parajuli P, 2019, EMBO J, V38, DOI 10.15252/embj.2018101067; Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925; Puhalla S, 2015, NEURO-ONCOLOGY, V17, P639, DOI 10.1093/neuonc/nov023; Pui CH, 2008, LANCET ONCOL, V9, P257, DOI 10.1016/S1470-2045(08)70070-6; Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Si MY, 2018, CANCER MANAG RES, V10, P305, DOI 10.2147/CMAR.S152419; Soto MS, 2014, NEURO-ONCOLOGY, V16, P541, DOI 10.1093/neuonc/not222; Takeshita Y, 2012, IMMUNOL REV, V248, P228, DOI 10.1111/j.1600-065X.2012.01127.x; Tamura T, 2008, ANNU REV IMMUNOL, V26, P535, DOI 10.1146/annurev.immunol.26.021607.090400; Wang DY, 2020, STEM CELL REP, V14, P1093, DOI 10.1016/j.stemcr.2020.05.012; Wang R, 2020, CANCER LETT, V469, P151, DOI 10.1016/j.canlet.2019.10.032; Willer A, 2015, LEUKEMIA, V29, P1018, DOI 10.1038/leu.2014.307; Wu MH, 2019, ANN RHEUM DIS, V78, P1583, DOI 10.1136/annrheumdis-2019-215208; Yan L, 2020, J CELL MOL MED, V24, P13472, DOI 10.1111/jcmm.15977; Yan L, 2013, MOL CELL BIOL, V33, P4824, DOI 10.1128/MCB.01076-13; Yanai H, 2012, ONCOIMMUNOLOGY, V1, P1376, DOI 10.4161/onci.22475; Yang Q, 2017, ONCOGENE, V36, P2969, DOI 10.1038/onc.2016.448; Yang X, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412910; Yu X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07384-7; Zhao Y, 2017, ONCOL RES, V25, P511, DOI 10.3727/096504016X14756226781802; Zhou XX, 2015, BLOOD, V126, P1433, DOI 10.1182/blood-2015-01-624833; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	51	1	1	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2303	2314		10.1038/s41388-022-02233-w	http://dx.doi.org/10.1038/s41388-022-02233-w		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35256780	hybrid, Green Published			2022-12-28	WOS:000765674100002
J	Han, L; Lin, X; Yan, Q; Gu, CC; Li, MS; Pan, L; Meng, Y; Zhao, XM; Liu, SD; Li, AM				Han, Lu; Lin, Xin; Yan, Qun; Gu, Chuncai; Li, Mengshu; Pan, Lei; Meng, Yan; Zhao, Xinmei; Liu, Side; Li, Aimin			PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; SORAFENIB; PROTEIN; VEGF; EXPRESSION; MIGRATION; PATHWAY; DISEASE; GROWTH	Sustained anti-angiogenesis therapy increases the level of tumor hypoxia, leading to increased expression of HIF-1a, thereby contributing to the resistance to anti-angiogenesis therapy in hepatocellular carcinoma (HCC). Here, we report that phenazine biosynthesis-like domain-containing protein (PBLD) inhibits hypoxia-induced angiogenesis via ERK/HIF-1a/VEGF axis in HCC cells. Bioinformatic analysis of the TCGA database and clinical samples validation also identify a negative correlation between PBLD and angiogenesis-related genes expression including HIF-1a. Apart from the downregulation of HIF-1a/VEGF expression in HCC cells, PBLD also blocks VEGF receptor 2 (VEGFR2) on endothelial cells via HCC-derived exosomal miR-940. PBLD also activates TCF4 transcriptional promotion effects on miR-940 by directly interacting with it. Together, PBLD exerts an inhibitory effect on angiogenesis not only via blocking the VEGFR2 expression in endothelial cells, but also through downregulating HIF-1a-induced VEGF expression and secretion in HCC cells. These explorations may provide a theoretical basis for exploring new targets and strategies to overcome resistance to anti-angiogenesis therapy.	[Han, Lu; Lin, Xin; Yan, Qun; Gu, Chuncai; Li, Mengshu; Pan, Lei; Meng, Yan; Zhao, Xinmei; Liu, Side; Li, Aimin] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China; [Han, Lu] Guangzhou Univ Tradit Chinese Med, Affiliated Hosp 2, Dept Gastroenterol, Guangzhou 510120, Guangdong, Peoples R China	Southern Medical University - China; Guangzhou University of Chinese Medicine	Zhao, XM; Liu, SD; Li, AM (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China.	xmzhao914@163.com; liuside2011@163.com; lam0725@163.com	Meng, Yan/HGC-0394-2022	zhao, Xinmei/0000-0003-3940-788X	National Natural Science Foundation of China [81402028, 82072758, 12026605]; Guangdong Science and Technology Project [2017A020215046]; Guangdong Gastrointestinal Disease Research Center [2017B020209003, 2017B030314037]; Major National Science and Technology Special Fund Projects [2020ZX09201017]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Science and Technology Project; Guangdong Gastrointestinal Disease Research Center; Major National Science and Technology Special Fund Projects	This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81402028, 82072758, 12026605), Guangdong Science and Technology Project (grant numbers 2017A020215046), Guangdong Gastrointestinal Disease Research Center (grant numbers 2017B020209003 and 2017B030314037), and the Major National Science and Technology Special Fund Projects (grant numbers 2020ZX09201017).	Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021; Arderiu G, 2019, CIRC RES, V125, P74, DOI 10.1161/CIRCRESAHA.118.314290; Bayly R, 2004, J BIOL CHEM, V279, P55362, DOI 10.1074/jbc.M408654200; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Caunt CJ, 2013, FEBS J, V280, P489, DOI 10.1111/j.1742-4658.2012.08716.x; Chappell JC, 2019, J CLIN INVEST, V129, P442, DOI 10.1172/JCI120855; Chen HF, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112668; Chen X, 2017, ONCOL REP, V38, P522, DOI 10.3892/or.2017.5697; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Choudhry H, 2018, CELL METAB, V27, P281, DOI 10.1016/j.cmet.2017.10.005; Conigliaro A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0426-x; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Dittmer J, 2015, SEMIN CANCER BIOL, V35, P20, DOI 10.1016/j.semcancer.2015.09.010; Forrest MP, 2014, TRENDS MOL MED, V20, P322, DOI 10.1016/j.molmed.2014.01.010; Gu CC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1962-x; Hannafon BN, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0400-7; Huang AX, 2015, INT J BIOL SCI, V11, P961, DOI 10.7150/ijbs.11943; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kaelin WG, 2010, NATURE, V465, P562, DOI 10.1038/465562a; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Kurokawa Y, 2004, J EXP CLIN CANC RES, V23, P135; Li AM, 2016, ONCOTARGET, V7, P524, DOI 10.18632/oncotarget.6358; Li P, 2019, J CELL MOL MED, V23, P2475, DOI 10.1111/jcmm.14121; Li QY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1330-9; Liang YJ, 2013, HEPATOLOGY, V57, P1847, DOI 10.1002/hep.26224; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Long JA, 2010, HEPATOB PANCREAT DIS, V9, P296; Lonne GK, 2009, J BIOL CHEM, V284, P33456, DOI 10.1074/jbc.M109.036186; Martin MJ, 2012, CANCER DISCOV, V2, P344, DOI 10.1158/2159-8290.CD-11-0280; Mashouri L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0991-5; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Meurette O, 2018, CANCER CELL, V34, P536, DOI 10.1016/j.ccell.2018.07.009; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87; Tang WM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08225-3; Wirgenes KV, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.39; Yen C, 2017, LIVER CANCER, V6, P313, DOI 10.1159/000480441; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937; Zhao J, 2020, ONCOGENE, V39, P1724, DOI 10.1038/s41388-019-1093-y; Zhao Shaorong, 2019, Cell Physiol Biochem, V53, P19, DOI 10.33594/000000118	43	2	2	7	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1851	1865		10.1038/s41388-022-02197-x	http://dx.doi.org/10.1038/s41388-022-02197-x		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35140333	Green Published, hybrid			2022-12-28	WOS:000753256400001
J	Li, J; Zheng, CM; Wang, MS; Umano, AD; Dai, QY; Zhang, CY; Huang, H; Yang, Q; Yang, XZ; Lu, JY; Pan, WF; Li, B; Yao, SZ; Pan, CY				Li, Jie; Zheng, Cuimiao; Wang, Mingshuo; Umano, Anna D.; Dai, Qingyuan; Zhang, Chunyu; Huang, Hua; Yang, Qing; Yang, Xianzhi; Lu, Jingyi; Pan, Wenfeng; Li, Bo; Yao, Shuzhong; Pan, Chaoyun			ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer	ONCOGENE			English	Article							KINASE-II; ACTIVATION; PROTEIN	Platinum resistance accounts for much of the high mortality and morbidity associated with ovarian cancer. Identification of targets with significant clinical translational potential remains an unmet challenge. Through a high-throughput synthetical lethal screening for clinically relevant targets using 290 kinase inhibitors, we identify calcium/calmodulin-dependent protein kinase II gamma (CAMK2G) as a critical vulnerability in cisplatin-resistant ovarian cancer cells. Pharmacologic inhibition of CAMK2G significantly sensitizes ovarian cancer cells to cisplatin treatment in vitro and in vivo. Mechanistically, CAMK2G directly senses ROS, both basal and cisplatin-induced, to control the phosphorylation of ITPKB at serine 174, which directly regulates ITPKB activity to modulate cisplatin-induced ROS stress. Thereby, CAMK2G facilitates the adaptive redox homeostasis upon cisplatin treatment and drives cisplatin resistance. Clinically, upregulation of CAMK2G activity and ITPKB pS174 correlates with cisplatin resistance in human ovarian cancers. This study reveals a key kinase network consisting of CAMK2G and ITPKB for ROS sense and scavenging in ovarian cancer cells to maintain redox homeostasis, offering a potential strategy for cisplatin resistance treatment.	[Li, Jie; Zhang, Chunyu; Huang, Hua; Yao, Shuzhong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Guangzhou 510080, Peoples R China; [Zheng, Cuimiao; Wang, Mingshuo; Dai, Qingyuan; Yang, Qing; Yang, Xianzhi; Lu, Jingyi; Pan, Wenfeng; Li, Bo; Pan, Chaoyun] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem & Mol Biol, Guangzhou 510080, Peoples R China; [Zheng, Cuimiao; Li, Bo; Pan, Chaoyun] Sun Yat Sen Univ, Affiliated Hosp 1, Adv Med Technol Ctr, Zhongshan Sch Med, Guangzhou 510080, Peoples R China; [Umano, Anna D.] Duke Univ, Dept Microbiol & Mol Genet, Sch Med, Durham, NC 27708 USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Duke University	Pan, CY (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem & Mol Biol, Guangzhou 510080, Peoples R China.; Pan, CY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Adv Med Technol Ctr, Zhongshan Sch Med, Guangzhou 510080, Peoples R China.	panchy27@mail.sysu.edu.cn	Zhang, Chun-yu/HDP-5776-2022; Yang, Xian/GVU-9087-2022	Yao, Shuzhong/0000-0002-5145-5705; Zheng, Cuimiao/0000-0002-1177-0575	National Natural Science Foundation of China [82003194, 82073074]; Guangdong Basic and Applied Basic Research Foundation [2021A1515012446]; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation [2020B1212060018]; 2019 AACR Anna D. Barker Basic Cancer Research Fellowship	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation; 2019 AACR Anna D. Barker Basic Cancer Research Fellowship	This work was supported by the grants from the National Natural Science Foundation of China 82003194 (CP) and 82073074 (BL), Guangdong Basic and Applied Basic Research Foundation 2021A1515012446 (CP), Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation 2020B1212060018 (CP), and 2019 AACR Anna D. Barker Basic Cancer Research Fellowship (CP).	[Anonymous], 2019, CA-CANCER J CLIN, DOI [DOI 10.3322/CAAC.21551, DOI 10.3322/caac.21551]; Bhullar KS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0804-2; Chen D, 2019, CANCER DISCOV, V9, P756, DOI 10.1158/2159-8290.CD-18-1040; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gu Y, 2017, CANCER CELL, V32, P115, DOI 10.1016/j.ccell.2017.06.001; He YJ, 2018, NATURE, V563, P522, DOI 10.1038/s41586-018-0670-5; Hegyi B, 2021, CIRC RES, V129, P98, DOI 10.1161/CIRCRESAHA.120.318402; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Holmes D, 2015, NATURE, V527, pS217, DOI 10.1038/527S217a; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Ishida S, 2010, CANCER CELL, V17, P574, DOI 10.1016/j.ccr.2010.04.011; Jin LT, 2018, CANCER CELL, V34, P315, DOI 10.1016/j.ccell.2018.06.012; Li J, 2020, CLIN CANCER RES, V26, P3843, DOI 10.1158/1078-0432.CCR-19-3790; Liu D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03590-5; Liu XJ, 2021, CIRCULATION, V143, P1894, DOI 10.1161/CIRCULATIONAHA.120.048698; Marechal Y, 2011, IMMUNOBIOLOGY, V216, P103, DOI 10.1016/j.imbio.2010.03.012; Miller AT, 2009, J IMMUNOL, V182, P4696, DOI 10.4049/jimmunol.0802850; Nassal D, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00035; Pan CY, 2019, J CLIN INVEST, V129, P2431, DOI 10.1172/JCI124550; Pellicena P, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00021; Pouillon V, 2003, NAT IMMUNOL, V4, P1136, DOI 10.1038/ni980; Sanij E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16393-4; Schroyer AL, 2018, ONCOGENE, V37, P1031, DOI 10.1038/onc.2017.396; Wen CY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2035-x; Wojtaszek JL, 2019, CELL, V178, P152, DOI 10.1016/j.cell.2019.05.028; Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013	28	2	2	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1114	1128		10.1038/s41388-021-02149-x	http://dx.doi.org/10.1038/s41388-021-02149-x		JAN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35039634				2022-12-28	WOS:000743422300001
J	King, RJ; Shukla, SK; He, CB; Vernucci, E; Thakur, R; Attri, KS; Dasgupta, A; Chaika, NV; Mulder, SE; Abrego, J; Murthy, D; Gunda, V; Pacheco, CG; Grandgenett, PM; Lazenby, AJ; Hollingsworth, MA; Yu, F; Mehla, K; Singh, PK				King, Ryan J.; Shukla, Surendra K.; He, Chunbo; Vernucci, Enza; Thakur, Ravi; Attri, Kuldeep S.; Dasgupta, Aneesha; Chaika, Nina V.; Mulder, Scott E.; Abrego, Jaime; Murthy, Divya; Gunda, Venugopal; Pacheco, Camila G.; Grandgenett, Paul M.; Lazenby, Audrey J.; Hollingsworth, Michael A.; Yu, Fang; Mehla, Kamiya; Singh, Pankaj K.			CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis	ONCOGENE			English	Article							TUMOR-GROWTH; TGF-BETA; ADENOSINE; PROMOTES; GEMCITABINE; GENERATION; TOLERANCE; ANTIBODY; IMMUNITY; BURDEN	Metabolic alterations regulate cancer aggressiveness and immune responses. Given the poor response of pancreatic ductal adenocarcinoma (PDAC) to conventional immunotherapies, we investigated the link between metabolic alterations and immunosuppression. Our metabolic enzyme screen indicated that elevated expression of CD73, an ecto-5'-nucleotidase that generates adenosine, correlates with increased aggressiveness. Correspondingly, we observed increased interstitial adenosine levels in tumors from spontaneous PDAC mouse models. Diminishing CD73 by genetic manipulations ablated in vivo tumor growth, and decreased myeloid-derived suppressor cells (MDSC) in orthotopic mouse models of PDAC. A high-throughput cytokine profiling demonstrated decreased GM-CSF in mice implanted with CD73 knockdowns. Furthermore, we noted increased IFN-gamma expression by intratumoral CD4(+) and CD8(+) T cells in pancreatic tumors with CD73 knockdowns. Depletion of CD4(+) T cells, but not CD8(+) T cells abrogated the beneficial effects of decreased CD73. We also observed that splenic MDSCs from Nt5e knockdown tumor-bearing mice were incompetent in suppressing T cell activation in the ex vivo assays. Replenishing GM-CSF restored tumor growth in Nt5e knockout tumors, which was reverted by MDSC depletion. Finally, anti-CD73 antibody treatment significantly improved gemcitabine efficacy in orthotopic models. Thus, targeting the adenosine axis presents a novel therapeutic opportunity for improving the anti-tumoral immune response against PDAC.	[King, Ryan J.; Shukla, Surendra K.; He, Chunbo; Vernucci, Enza; Thakur, Ravi; Attri, Kuldeep S.; Dasgupta, Aneesha; Chaika, Nina V.; Mulder, Scott E.; Abrego, Jaime; Murthy, Divya; Gunda, Venugopal; Pacheco, Camila G.; Grandgenett, Paul M.; Hollingsworth, Michael A.; Mehla, Kamiya; Singh, Pankaj K.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Mulder, Scott E.; Hollingsworth, Michael A.; Singh, Pankaj K.] Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Lazenby, Audrey J.; Hollingsworth, Michael A.; Singh, Pankaj K.] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Yu, Fang] Univ Nebraska, Med Ctr, Dept Biostat, Omaha, NE 68198 USA; [Singh, Pankaj K.] Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Mehla, K; Singh, PK (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.	kamiya.mehla@unmc.edu; pankaj.singh@unmc.edu	Thakur, Ravi/AGH-8433-2022	Thakur, Ravi/0000-0003-2505-9757; Singh, Pankaj/0000-0001-8903-0131; Shukla, Surendra K/0000-0003-4490-8013	National Institutes of Health [R01CA163649, R01CA210439, R01CA216853]; Specialized Programs of Research Excellence (SPORE) [2P50 CA127297]; PCDC [U01CA210240]; NCI Research Specialist award [5R50CA211462]; Fred & Pamela Buffett Cancer Center Support Grant [P30CA036727]; SPORE Career Development Award (NCI) [2P50 CA127297]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Specialized Programs of Research Excellence (SPORE); PCDC; NCI Research Specialist award; Fred & Pamela Buffett Cancer Center Support Grant; SPORE Career Development Award (NCI)	This work was supported in part by funding from the National Institutes of Health grant (R01CA163649, R01CA210439, and R01CA216853, NCI) to PKS; the Specialized Programs of Research Excellence (SPORE, 2P50 CA127297, NCI) to PKS and MAH; SPORE Career Development Award (2P50 CA127297, NCI) to KM; the PCDC U01CA210240 to MAH; NCI Research Specialist award (5R50CA211462) to PMG. We would also like to acknowledge the Fred & Pamela Buffett Cancer Center Support Grant (P30CA036727, NCI) for supporting shared resources.	Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528; Andersson J, 2008, J EXP MED, V205, P1975, DOI 10.1084/jem.20080308; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Bhat P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.67; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Condamine T, 2015, J LEUKOCYTE BIOL, V98, P913, DOI 10.1189/jlb.4RI0515-204R; Daniel SK, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0226-9; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Dosch M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041222; Foley K, 2016, CANCER LETT, V381, P244, DOI 10.1016/j.canlet.2015.12.020; Gravett AM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1438107; Gunda V, 2017, CLIN CANCER RES, V23, P5881, DOI 10.1158/1078-0432.CCR-17-1151; Gupta S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00068; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jackaman C, 2012, CANCER IMMUNOL IMMUN, V61, P2343, DOI 10.1007/s00262-012-1307-4; Jiang T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4073-7; Johnson BA, 2017, CLIN CANCER RES, V23, P1656, DOI 10.1158/1078-0432.CCR-16-2318; Junger WG, 2011, NAT REV IMMUNOL, V11, P201, DOI 10.1038/nri2938; Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; King RJ, 2017, ONCOTARGET, V8, P67152, DOI 10.18632/oncotarget.17934; Lee CR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030869; Li CX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01234-1; Linden J, 2012, ARTERIOSCL THROM VAS, V32, P2097, DOI 10.1161/ATVBAHA.111.226837; Looi CK, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1153-8; Lytle NK, 2019, CELL, V177, P572, DOI 10.1016/j.cell.2019.03.010; Ma N, 2017, INT J IMMUNOPATH PH, V30, P152, DOI 10.1177/0394632017711055; Masuda K, 2016, J EXP MED, V213, P605, DOI 10.1084/jem.20151289; Mauti LA, 2011, J CLIN INVEST, V121, P2794, DOI 10.1172/JCI41936; Molinier-Frenkel V, 2017, FEBS LETT, V591, P3135, DOI 10.1002/1873-3468.12784; MOSER GH, 1989, AM J PHYSIOL, V256, pC799, DOI 10.1152/ajpcell.1989.256.4.C799; O'Reilly EM, 2019, JAMA ONCOL, V5, P1431, DOI 10.1001/jamaoncol.2019.1588; O'Sullivan T, 2014, CELL REP, V7, P989, DOI 10.1016/j.celrep.2014.03.073; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Ostrand-Rosenberg S, 2018, J IMMUNOL, V200, P422, DOI 10.4049/jimmunol.1701019; Plate JMD, 2005, CANCER IMMUNOL IMMUN, V54, P915, DOI 10.1007/s00262-004-0638-1; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rivadeneira DB, 2018, CLIN CANCER RES, V24, P2473, DOI 10.1158/1078-0432.CCR-17-0894; Salminen A, 2019, CELL MOL LIFE SCI, V76, P1901, DOI 10.1007/s00018-019-03048-x; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Srivastava MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040677; Stagg J, 2011, CANCER RES, V71, P2892, DOI 10.1158/0008-5472.CAN-10-4246; Stagg J, 2010, P NATL ACAD SCI USA, V107, P1547, DOI 10.1073/pnas.0908801107; Sugiura A, 2018, J IMMUNOL, V200, P400, DOI 10.4049/jimmunol.1701041; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Szomolay B, 2012, J THEOR BIOL, V303, P141, DOI 10.1016/j.jtbi.2012.03.024; Tran DQ, 2012, J MOL CELL BIOL, V4, P29, DOI 10.1093/jmcb/mjr033; Vigano S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00925; Vijayan D, 2017, NAT REV CANCER, V17, P709, DOI 10.1038/nrc.2017.86; Wang L, 2011, J CLIN INVEST, V121, P2371, DOI 10.1172/JCI45559; Wang R, 2017, ONCOTARGET, V8, P57327, DOI 10.18632/oncotarget.16905; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zarek PE, 2008, BLOOD, V111, P251, DOI 10.1182/blood-2007-03-081646; Zarek PE, 2007, AUTOIMMUNITY, V40, P425, DOI 10.1080/08916930701464939; Zhang B, 2012, ONCOIMMUNOLOGY, V1, P67, DOI 10.4161/onci.1.1.18068; Zhao H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01578; Zhou LJ, 2019, J MOL MED, V97, P803, DOI 10.1007/s00109-018-01742-0	63	6	6	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					971	982		10.1038/s41388-021-02132-6	http://dx.doi.org/10.1038/s41388-021-02132-6		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	35001076	Green Accepted			2022-12-28	WOS:000740643000001
J	McCann, JJ; Vasilevskaya, IA; McNair, C; Gallagher, P; Neupane, NP; de Leeuw, R; Shafi, AA; Dylgjeri, E; Mandigo, AC; Schiewer, MJ; Knudsen, KE				McCann, Jennifer J.; Vasilevskaya, Irina A.; McNair, Christopher; Gallagher, Peter; Neupane, Neermala Poudel; de Leeuw, Renee; Shafi, Ayesha A.; Dylgjeri, Emanuela; Mandigo, Amy C.; Schiewer, Matthew J.; Knudsen, Karen E.			Mutant p53 elicits context-dependent pro-tumorigenic phenotypes	ONCOGENE			English	Article							GAIN-OF-FUNCTION; MUTATIONAL LANDSCAPE; DRIVE CANCER; DNA-BINDING; COMBINATIONS; ANTAGONISTS; CHROMATIN; EVOLUTION; PATHWAYS; GENOMICS	The tumor suppressor gene TP53 is the most frequently mutated gene in numerous cancer types, including prostate cancer (PCa). Specifically, missense mutations in TP53 are selectively enriched in PCa, and cluster to particular "hot spots" in the p53 DNA binding domain with mutation at the R273 residue occurring most frequently. While this residue is similarly mutated to R273C-p53 or R273H-p53 in all cancer types examined, in PCa selective enrichment of R273C-p53 is observed. Importantly, examination of clinical datasets indicated that TP53 heterozygosity can either be maintained or loss of heterozygosity (LOH) occurs. Thus, to mimic tumor-associated mutant p53, R273C-p53 and R273H-p53 isogenic PCa models were developed in the presence or absence of wild-type p53. In the absence of wild-type p53, both R273C-p53 and R273H-p53 exhibited similar loss of DNA binding, transcriptional profiles, and loss of canonical tumor suppressor functions associated with wild-type p53. In the presence of wild-type p53 expression, both R273C-p53 and R273H-p53 supported canonical p53 target gene expression yet elicited distinct cistromic and transcriptional profiles when compared to each other. Moreover, heterozygous modeling of R273C-p53 or R273H-p53 expression resulted in distinct phenotypic outcomes in vitro and in vivo. Thus, mutant p53 acts in a context-dependent manner to elicit pro-tumorigenic transcriptional profiles, providing critical insight into mutant p53-mediated prostate cancer progression.	[McCann, Jennifer J.; Vasilevskaya, Irina A.; McNair, Christopher; Gallagher, Peter; Neupane, Neermala Poudel; de Leeuw, Renee; Shafi, Ayesha A.; Dylgjeri, Emanuela; Mandigo, Amy C.; Schiewer, Matthew J.; Knudsen, Karen E.] Sidney Kimmel Med Coll, Dept Canc Biol, Philadelphia, PA 19107 USA	Jefferson University	Knudsen, KE (corresponding author), Sidney Kimmel Med Coll, Dept Canc Biol, Philadelphia, PA 19107 USA.	karen.knudsen@jefferson.edu		Shafi, Ayesha/0000-0003-0335-638X; Dylgjeri, Emanuela/0000-0002-1784-634X	National Cancer Institute [F99CA212225, 5R01CA17640105, 5R01CA18256905, 5R01CA21732903]; Sidney Kimmel Cancer Center [5P30CA056036-17]; Laboratory Animals, MetaOmics, Translational Pathology shared resources; Prostate Cancer Foundation	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Sidney Kimmel Cancer Center; Laboratory Animals, MetaOmics, Translational Pathology shared resources; Prostate Cancer Foundation	We gratefully thank all members of the Knudsen laboratory for their invaluable input and support. We also thank the institutions that supported this work: The National Cancer Institute (F99CA212225 JJM, 5R01CA17640105 KEK, 5R01CA18256905 KEK, 5R01CA21732903 KEK), the Sidney Kimmel Cancer Center (Support Grant 5P30CA056036-17), the Laboratory Animals, MetaOmics, Translational Pathology shared resources, as well as awards from the Prostate Cancer Foundation.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Abida W, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00029; Armenia J, 2018, NAT GENET, V50, P645, DOI 10.1038/s41588-018-0078-z; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Boettcher S, 2019, SCIENCE, V365, P599, DOI 10.1126/science.aax3649; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chicas A, 2000, BIOCHEM BIOPH RES CO, V279, P383, DOI 10.1006/bbrc.2000.3965; Comel A, 2014, FEBS LETT, V588, P2600, DOI 10.1016/j.febslet.2014.04.015; De Laere B, 2019, CLIN CANCER RES, V25, P1766, DOI 10.1158/1078-0432.CCR-18-1943; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Agostino S, 2016, EMBO REP, V17, P188, DOI 10.15252/embr.201540488; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hainaut P, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026179; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Henrich IC, 2021, CANCER RES, V81, P2171, DOI 10.1158/0008-5472.CAN-20-1458; Hieronymus H, 2014, P NATL ACAD SCI USA, V111, P11139, DOI 10.1073/pnas.1411446111; Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710; Junk DJ, 2008, NEOPLASIA, V10, P450, DOI 10.1593/neo.08120; Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lehen'kyi V, 2007, ONCOGENE, V26, P7380, DOI 10.1038/sj.onc.1210545; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Liu Y, 2016, NATURE, V531, P471, DOI 10.1038/nature17157; Mantovani F, 2019, CELL DEATH DIFFER, V26, P199, DOI 10.1038/s41418-018-0246-9; McCann JJ, 2020, CANCER RES, V80, P430, DOI 10.1158/0008-5472.CAN-19-1033; McNair C, 2017, ONCOGENE, V36, P1655, DOI 10.1038/onc.2016.334; McNair C, 2018, J CLIN INVEST, V128, P341, DOI 10.1172/JCI93566; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirosevich J, 2006, PROSTATE, V66, P1013, DOI 10.1002/pros.20299; Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; NGUYEN B, 2020, EUR UROL; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Polotskaia A, 2015, P NATL ACAD SCI USA, V112, pE1220, DOI 10.1073/pnas.1416318112; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Reich NC, 2013, J INTERF CYTOK RES, V33, P199, DOI 10.1089/jir.2012.0159; Ren SC, 2018, EUR UROL, V73, P322, DOI 10.1016/j.eururo.2017.08.027; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Sandy Z, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111557; Schrecengost RS, 2014, CANCER RES, V74, P272, DOI 10.1158/0008-5472.CAN-13-1954; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Shiota M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060602; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Stopsack KH, 2020, CLIN CANCER RES, V26, P3230, DOI 10.1158/1078-0432.CCR-20-0168; Tang QS, 2020, TRENDS CANCER, V6, P62, DOI 10.1016/j.trecan.2019.11.004; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Yamamoto S, 2019, CANCERS, V11, DOI 10.3390/cancers11010004; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	75	5	5	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					444	458		10.1038/s41388-021-01903-5	http://dx.doi.org/10.1038/s41388-021-01903-5		NOV 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34773073	Green Published, hybrid			2022-12-28	WOS:000717915200004
J	ter Steege, EJ; Bakker, ERM				ter Steege, Eline J.; Bakker, Elvira R. M.			The role of R-spondin proteins in cancer biology	ONCOGENE			English	Review							MAMMARY STEM-CELLS; APICAL ECTODERMAL RIDGE; WNT SIGNALING PATHWAY; BETA-CATENIN; WNT/BETA-CATENIN; COLORECTAL-CANCER; BREAST-CANCER; R-SPONDIN-4 RSPO4; EPIGENETIC INACTIVATION; PROGENITOR CELLS	R-spondin (RSPO) proteins constitute a family of four secreted glycoproteins (RSPO1-4) that have appeared as multipotent signaling ligands. The best-known molecular function of RSPOs lie within their capacity to agonize the Wnt/beta-catenin signaling pathway. As RSPOs act upon cognate receptors LGR4/5/6 that are typically expressed by stem cells and progenitor cells, RSPO proteins importantly potentiate Wnt/beta-catenin signaling especially within these proliferative stem cell compartments. Since multiple organs express LGR4/5/6 receptors and RSPO ligands within their stem cell niches, RSPOs can exert an influential role in stem cell regulation throughout the body. Inherently, over the last decade a multitude of reports implicated the deregulation of RSPOs in cancer development. First, RSPO2 and RSPO3 gene fusions with concomitant enhanced expression have been identified in colon cancer patients, and proposed as an alternative driver of Wnt/beta-catenin hyperactivation that earmarks cancer in the colorectal tract. Moreover, the causal oncogenic capacity of RSPO3 overactivation has been demonstrated in the mouse intestine. As a paradigm organ in this field, most of current knowledge about RSPOs in cancer is derived from studies in the intestinal tract. However, RSPO gene fusions as well as enhanced RSPO expression have been reported in multiple additional cancer types, affecting different organs that involve divergent stem cell hierarchies. Importantly, the emerging oncogenic role of RSPO and its potential clinical utility as a therapeutic target have been recognized and investigated in preclinical and clinical settings. This review provides a survey of current knowledge on the role of RSPOs in cancer biology, addressing the different organs implicated, and of efforts made to explore intervention opportunities in cancer cases with RSPO overrepresentation, including the potential utilization of RSPO as novel therapeutic target itself.	[ter Steege, Eline J.; Bakker, Elvira R. M.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Bakker, ERM (corresponding author), Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands.	e.r.m.bakker-8@umcutrecht.nl			Netherlands Organization for Scientific Research [NWO/ZonMW VENI 016.186.138]; Dutch Cancer Society [10957]	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding)	This work was financially supported by the Netherlands Organization for Scientific Research (NWO/ZonMW VENI 016.186.138) and the Dutch Cancer Society (KWF Young Investigator Grant 10957).	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379; Alexander CM, 2018, PROG MOL BIOL TRANSL, V153, P271, DOI 10.1016/bs.pmbts.2017.11.020; Aoki M, 2008, DEV GROWTH DIFFER, V50, P85, DOI 10.1111/j.1440-169x.2007.00978.x; Aoki M, 2007, DEV BIOL, V301, P218, DOI 10.1016/j.ydbio.2006.08.018; Badders NM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006594; Bakker ERM, 2013, ONCOGENE, V32, P4579, DOI 10.1038/onc.2012.449; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bell SM, 2008, DEVELOPMENT, V135, P1049, DOI 10.1242/dev.013359; Bendell J, 2016, EUR J CANCER, V69, pS29, DOI 10.1016/S0959-8049(16)32668-5; Bergmann C, 2006, AM J HUM GENET, V79, P1105, DOI 10.1086/509789; Blaas L, 2016, NAT CELL BIOL, V18, P1346, DOI 10.1038/ncb3434; Blagodatski Artem, 2014, Mol Cell Ther, V2, P28, DOI 10.1186/2052-8426-2-28; Blaydon DC, 2006, NAT GENET, V38, P1245, DOI 10.1038/ng1883; Bruchle NO, 2008, J INVEST DERMATOL, V128, P791, DOI 10.1038/sj.jid.5701088; Cai CG, 2014, GENE DEV, V28, P2205, DOI 10.1101/gad.245142.114; Callahan R, 2012, ONCOTARGET, V3, P1320, DOI 10.18632/oncotarget.682; Carmon KS, 2014, P NATL ACAD SCI USA, V111, pE1221, DOI 10.1073/pnas.1323106111; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Castillo-Azofeifa D, 2019, EMBO J, V38, DOI 10.15252/embj.201899984; Chadi S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162566; Chadi S, 2009, BIOCHEM BIOPH RES CO, V390, P1040, DOI 10.1016/j.bbrc.2009.10.104; Chartier C, 2016, CANCER RES, V76, P713, DOI 10.1158/0008-5472.CAN-15-0561; Chassot AA, 2008, HUM MOL GENET, V17, P1264, DOI 10.1093/hmg/ddn016; Chassot AA, 2012, DEVELOPMENT, V139, P4461, DOI 10.1242/dev.078972; Chassot AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025641; Chen JZ, 2002, MOL BIOL REP, V29, P287, DOI 10.1023/A:1020479301379; Chen PH, 2013, GENE DEV, V27, P1345, DOI 10.1101/gad.219915.113; Chen ZH, 2019, CARCINOGENESIS, V40, P360, DOI 10.1093/carcin/bgy140; Clements WM, 2002, CANCER RES, V62, P3503; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Colacino JA, 2018, STEM CELL REP, V10, P1596, DOI 10.1016/j.stemcr.2018.03.001; Conboy CB, 2019, HEPATOL COMMUN, V3, P1496, DOI 10.1002/hep4.1422; Coussy F, 2017, BRIT J CANCER, V116, P1595, DOI 10.1038/bjc.2017.131; De Cian MC, 2017, ONCOGENE, V36, P208, DOI 10.1038/onc.2016.191; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; de Visser KE, 2012, J PATHOL, V228, P300, DOI 10.1002/path.4096; Dong XM, 2017, CANCER LETT, V402, P153, DOI 10.1016/j.canlet.2017.05.024; Dubey R, 2020, ELIFE, V9, DOI 10.7554/eLife.54469; Fischer AS, 2019, BIOMEDICINES, V7, DOI 10.3390/biomedicines7020044; Fischer M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02831-9; Francis JC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003180; Gaspar C, 2004, INT J DEV BIOL, V48, P377, DOI 10.1387/ijdb.041807cg; Gaspar C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000547; Gattelli A, 2006, J VIROL, V80, P11409, DOI 10.1128/JVI.00234-06; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175; Gong X, 2015, ONCOGENE, V34, P4692, DOI 10.1038/onc.2014.417; Greicius G, 2018, P NATL ACAD SCI USA, V115, pE3173, DOI 10.1073/pnas.1713510115; Han T, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms15945; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Harnack C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12349-5; Hashimoto T, 2019, HISTOPATHOLOGY, V75, P266, DOI 10.1111/his.13867; He YJ, 2014, MOL MED REP, V9, P137, DOI 10.3892/mmr.2013.1774; Hilkens J, 2017, GUT, V66, P1095, DOI 10.1136/gutjnl-2016-311606; Ilmer M, 2015, CANCER RES, V75, P1883, DOI 10.1158/0008-5472.CAN-14-1327; Ishii Y, 2008, J INVEST DERMATOL, V128, P867, DOI 10.1038/sj.jid.5701078; Jonsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2; Joshi PA, 2015, STEM CELL REP, V5, P31, DOI 10.1016/j.stemcr.2015.05.012; Kamata T, 2004, BBA-GENE STRUCT EXPR, V1676, P51, DOI 10.1016/j.bbaexp.2003.10.009; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Kang E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152859; Karayiannakis AJ, 2001, EUR J SURG ONCOL, V27, P31, DOI 10.1053/ejso.1999.1017; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kazanskaya O, 2008, DEVELOPMENT, V135, P3655, DOI 10.1242/dev.027284; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim KA, 2006, CELL CYCLE, V5, P23, DOI 10.4161/cc.5.1.2305; Klauzinska M, 2012, J CELL PHYSIOL, V227, P1960, DOI 10.1002/jcp.22924; Kleeman SO, 2020, CANCERS, V12, DOI 10.3390/cancers12113355; Kleeman SO, 2020, GUT, V69, P1092, DOI 10.1136/gutjnl-2019-319126; Klijn C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062113; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Koushyar S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113927; Kuchenbaecker KB, 2015, NAT GENET, V47, P164, DOI 10.1038/ng.3185; Lebensohn AM, 2018, ELIFE, V7, DOI 10.7554/eLife.33126; Lee H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19373-w; Li CL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22731-w; Li SG, 2014, TUMOR BIOL, V35, P7693, DOI 10.1007/s13277-014-1975-0; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Longerich T, 2019, GUT, V68, P1287, DOI 10.1136/gutjnl-2018-317632; Lopez-Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055-9965.EPI-09-0741; Lorenzi MV., PROC AACR IASLC JT C; Luo WJ, 2013, STEM CELLS, V31, P2492, DOI 10.1002/stem.1484; Maatouk DM, 2013, DEV BIOL, V383, P295, DOI 10.1016/j.ydbio.2013.08.026; Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280; Mehta V, 2011, DEV DYNAM, V240, P2548, DOI 10.1002/dvdy.22741; Mesci A, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1878-3; Mizuguchi Y, 2019, VIRCHOWS ARCH, V475, P659, DOI 10.1007/s00428-019-02604-x; Morgan RG, 2018, BRIT J CANCER, V118, P1410, DOI 10.1038/s41416-018-0118-6; Murillo-Garzon V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144; Mustata RC, 2011, EMBO REP, V12, P558, DOI 10.1038/embor.2011.52; Nam JS, 2006, J BIOL CHEM, V281, P13247, DOI 10.1074/jbc.M508324200; Nam JS, 2007, DEV BIOL, V311, P124, DOI 10.1016/j.ydbio.2007.08.023; Ohkawara B, 2011, DEV CELL, V20, P303, DOI 10.1016/j.devcel.2011.01.006; Ozaki S, 2005, ONCOL REP, V14, P1437; Park S, 2018, J BIOL CHEM, V293, P9759, DOI 10.1074/jbc.RA118.002743; Parma P, 2006, NAT GENET, V38, P1304, DOI 10.1038/ng1907; Peng WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083110; Picco G, 2017, EMBO MOL MED, V9, P293, DOI 10.15252/emmm.201606773; Plaks V, 2013, CELL REP, V3, P70, DOI 10.1016/j.celrep.2012.12.017; Planas-Paz L, 2016, NAT CELL BIOL, V18, P467, DOI 10.1038/ncb3337; Planche A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018640; Prasad CP, 2007, ONCOLOGY-BASEL, V73, P112, DOI 10.1159/000120999; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rocha AS, 2015, CELL REP, V13, P1757, DOI 10.1016/j.celrep.2015.10.049; Salik B, 2020, CANCER CELL, V38, P263, DOI 10.1016/j.ccell.2020.05.014; Santos AJM, 2018, TRENDS CELL BIOL, V28, P1062, DOI 10.1016/j.tcb.2018.08.001; Scheele CLGJ, 2017, NATURE, V542, P313, DOI 10.1038/nature21046; Schindler AJ, 2018, ONCOTARGET, V9, P1346, DOI 10.18632/oncotarget.20178; Sekine S, 2017, HISTOPATHOLOGY, V71, P601, DOI 10.1111/his.13265; Sekine S, 2016, J PATHOL, V239, P133, DOI 10.1002/path.4709; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shinmura K, 2014, MOL BIOL REP, V41, P5375, DOI 10.1007/s11033-014-3409-x; Sigal M, 2019, NAT CELL BIOL, V21, P812, DOI 10.1038/s41556-019-0339-9; Sigal M, 2017, NATURE, V548, P451, DOI 10.1038/nature23642; Simons BW, 2012, DEV BIOL, V371, P246, DOI 10.1016/j.ydbio.2012.08.016; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Storm EE, 2016, NATURE, V529, P97, DOI 10.1038/nature16466; Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259; Szenker-Ravi E, 2018, NATURE, V557, P564, DOI 10.1038/s41586-018-0118-y; Teeuwssen M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101658; Tharmapalan P, 2019, EMBO J, V38, DOI 10.15252/embj.2018100852; Theodorou V, 2007, NAT GENET, V39, P759, DOI 10.1038/ng2034; Tocci JM, 2020, IUBMB LIFE, V72, P1546, DOI 10.1002/iub.2278; Tocci JM, 2018, CANCER RES, V78, P4497, DOI 10.1158/0008-5472.CAN-17-2676; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Tomizuka K, 2008, HUM MOL GENET, V17, P1278, DOI 10.1093/hmg/ddn036; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; van Schie EH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00025; Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076; Veeck J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-217; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Wang DS, 2015, NATURE, V517, P81, DOI 10.1038/nature13851; Wang DL, 2013, GENE DEV, V27, P1339, DOI 10.1101/gad.219360.113; Wu CJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4149; Wuidart A, 2016, GENE DEV, V30, P1261, DOI 10.1101/gad.280057.116; Xie Y, 2013, EMBO REP, V14, P1120, DOI 10.1038/embor.2013.167; Xu K, 2013, STRUCTURE, V21, P1683, DOI 10.1016/j.str.2013.07.001; Yamada W, 2009, BIOCHEM BIOPH RES CO, V381, P453, DOI 10.1016/j.bbrc.2009.02.066; Yan KS, 2017, NATURE, V545, P238, DOI 10.1038/nature22313; Zebisch M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3787; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020	150	5	5	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6469	6478		10.1038/s41388-021-02059-y	http://dx.doi.org/10.1038/s41388-021-02059-y		OCT 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34663878	hybrid, Green Published			2022-12-28	WOS:000708355700003
J	Li, BW; Xia, YW; Lv, JL; Wang, WZ; Xuan, Z; Chen, C; Jiang, TL; Fang, L; Wang, LJ; Li, Z; He, ZY; Li, QY; Xie, L; Qiu, SK; Zhang, L; Zhang, DC; Xu, H; Xu, ZK				Li, Bowen; Xia, Yiwen; Lv, Jialun; Wang, Weizhi; Xuan, Zhe; Chen, Cen; Jiang, Tianlu; Fang, Lang; Wang, Linjun; Li, Zheng; He, Zhongyuan; Li, Qingya; Xie, Li; Qiu, Shengkui; Zhang, Lu; Zhang, Diancai; Xu, Hao; Xu, Zekuan			miR-151a-3p-rich small extracellular vesicles derived from gastric cancer accelerate liver metastasis via initiating a hepatic stemness-enhancing niche	ONCOGENE			English	Article							PREMETASTATIC NICHE; PROSTATE-CANCER; KUPFFER CELLS; MICROENVIRONMENT; EXOSOMES; BONE; TRANSLATION; ACTIVATION; INHIBITOR; PHENOTYPE	Liver metastasis (LM) severely affects gastric cancer (GC) patients' prognosis. Small extracellular vesicles (sEVs) play key roles in intercellular communication. Specific sEV-miRNAs from several types of cancer were found to induce a premetastatic niche in target organs before tumor cell arrive. However, whether the primary GC affects hepatic microenvironment or the role of sEV-miRNAs in GC-LM is yet unclear. We report that GC-derived sEVs are primarily absorbed by Kupffer cells (KCs). sEV-miR-151a-3p is highly expressed in GC-LM patients' plasma and presents poor prognosis. Treating mice with sEVs-enriched in miR-151a-3p promotes GC-LM, whereas has no influence on the proliferation of GC cells in situ. Mechanistically, sEV-miR-151a-3p inhibits SP3 in KCs. Simultaneously, sEV-miR-151a-3p targets YTHDF3 to decrease the transcriptional inhibitory activity of SP3 by reducing SUMO1 translation in a N6-methyladenosine-dependent manner. These factors contribute to TGF-beta 1 transactivation in KCs, subsequently activating the SMAD2/3 pathway and enhancing the stem cell-like properties of incoming GC cells. Furthermore, sEV-miR-151a-3p induces miR-151a-3p transcription in KCs to form a positive feedback loop. In summary, our results reveal a previously unidentified regulatory axis initiated by sEV-miR-151a-3p that establishes a hepatic stemness-permissive niche to support GC-LM. sEV-miR-151a-3p could be a promising diagnostic biomarker and preventive treatment candidate for GC-LM.	[Li, Bowen; Xia, Yiwen; Lv, Jialun; Wang, Weizhi; Xuan, Zhe; Jiang, Tianlu; Fang, Lang; Wang, Linjun; Li, Zheng; He, Zhongyuan; Li, Qingya; Xie, Li; Qiu, Shengkui; Zhang, Lu; Zhang, Diancai; Xu, Hao; Xu, Zekuan] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China; [Chen, Cen] Southern Med Univ, Sch Clin Med 1, Jinling Hosp, Dept Resp & Crit Care Med, Nanjing 210002, Jiangsu, Peoples R China; [Qiu, Shengkui] Nantong Univ, Affiliated Hosp 2, Dept Gen Surg, Nantong 226001, Jiangsu, Peoples R China; [Xu, Zekuan] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China	Nanjing Medical University; Southern Medical University - China; Nantong University; Nanjing Medical University	Xu, ZK (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China.; Xu, ZK (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.	xuzekuan@njmu.edu.cn	wang, lin/GSE-3040-2022; wang, lili/HDL-7210-2022	xu, zekuan/0000-0001-5179-4128	National Natural Science Foundation of China [81871946, 82002558, 82072708]; Special Foundation for National Science and Technology Basic Research Program of China [2019FY101104]; Primary Research & Development Plan of Jiangsu Province [BE2016786]; Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) [JX10231801]; Jiangsu Key Medical Discipline (General Surgery) [ZDXKA2016005]; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Special Foundation for National Science and Technology Basic Research Program of China; Primary Research & Development Plan of Jiangsu Province; Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Key Medical Discipline (General Surgery); Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University	This work was partially supported by the National Natural Science Foundation of China (81871946, 82002558, 82072708); Special Foundation for National Science and Technology Basic Research Program of China (2019FY101104); the Primary Research & Development Plan of Jiangsu Province (BE2016786); the Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX10231801); Jiangsu Key Medical Discipline (General Surgery) (ZDXKA2016005); Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University. We would like to express our gratitude to Dr Xiaofei Zhi and Dr Zheng Chen for their valuable advice on our study. We also thank Prof. Xinyu Xu for her help on FACS experiments.	Badiola I, 2012, GUT, V61, P1465, DOI 10.1136/gutjnl-2011-300810; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460; Celia-Terrassa T, 2017, NAT CELL BIOL, V19, P711, DOI 10.1038/ncb3533; Chang GQ, 2020, CANCER CELL, V38, P857, DOI 10.1016/j.ccell.2020.10.004; Chen J, 2013, EJSO-EUR J SURG ONC, V39, P701, DOI 10.1016/j.ejso.2013.03.023; Chen L, 2012, BIOMATERIALS, V33, P1437, DOI 10.1016/j.biomaterials.2011.10.056; Colletti M, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1774144; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Cui X, 2018, BIOMATERIALS, V161, P164, DOI 10.1016/j.biomaterials.2018.01.053; Dou CW, 2018, GASTROENTEROLOGY, V154, P2209, DOI 10.1053/j.gastro.2018.02.015; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Gonzalez-Ramos M, 2013, INT J BIOCHEM CELL B, V45, P232, DOI 10.1016/j.biocel.2012.10.001; Grillet F, 2017, GUT, V66, P1802, DOI 10.1136/gutjnl-2016-311447; Grunwald B, 2016, GASTROENTEROLOGY, V151, P1011, DOI 10.1053/j.gastro.2016.07.043; Hashimoto K, 2018, P NATL ACAD SCI USA, V115, P2204, DOI 10.1073/pnas.1717363115; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hsu KW, 2016, ONCOTARGET, V7, P38036, DOI 10.18632/oncotarget.9342; Huang XY, 2015, EUR UROL, V67, P33, DOI 10.1016/j.eururo.2014.07.035; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; KAN ZX, 1995, HEPATOLOGY, V21, P487, DOI 10.1002/hep.1840210233; Kasar S, 2014, ONCOGENE, V33, P3307, DOI 10.1038/onc.2013.291; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Lee D, 2015, HEPATOLOGY, V61, P1978, DOI 10.1002/hep.27721; Leek RD, 1999, BRIT J CANCER, V79, P991, DOI 10.1038/sj.bjc.6690158; Li A, 2017, CELL RES, V27, P444, DOI 10.1038/cr.2017.10; Li X, 2020, AGING-US, V12, P14157, DOI 10.18632/aging.103423; Lima CR, 2017, MOL CELL ENDOCRINOL, V456, P62, DOI 10.1016/j.mce.2017.03.015; Lissbrant IF, 2000, INT J ONCOL, V17, P445; Little AC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00456; Liu BH, 2019, BRIEF FUNCT GENOMICS, V18, P255, DOI 10.1093/bfgp/elz002; Liu C, 2017, ACS NANO, V11, P6968, DOI 10.1021/acsnano.7b02277; Liu HB, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20191357; Liu TR, 2018, CANCER RES, V78, P6632, DOI 10.1158/0008-5472.CAN-18-0650; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Luo Z, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01353; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Ma G, 2019, CANCER BIOMARK, V26, P491, DOI 10.3233/CBM-190256; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Matsumura H, 2014, INT J ONCOL, V45, P2303, DOI 10.3892/ijo.2014.2662; O'Dea KP, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1706708; PAGET S, 1989, CANCER METAST REV, V8, P98; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Qiu XL, 2019, THERANOSTICS, V9, P2618, DOI 10.7150/thno.32363; Rosonina E, 2017, TRANSCR-AUSTIN, V8, P220, DOI 10.1080/21541264.2017.1311829; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Stielow B, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001203; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Wang YG, 2019, HEPATOLOGY, V70, P1409, DOI 10.1002/hep.30668; Wen SW, 2013, CANCER BIOL THER, V14, P606, DOI 10.4161/cbt.24593; Yeh HW, 2018, NAT CELL BIOL, V20, P479, DOI 10.1038/s41556-018-0062-y; Yeh TC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168171; Yue CC, 2020, J BIOMED NANOTECHNOL, V16, P876, DOI 10.1166/jbn.2020.2941; Zhang HY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15016; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhang XP, 2019, ONCOGENE, V38, P699, DOI 10.1038/s41388-018-0447-1; Zhang Y, 2019, P NATL ACAD SCI USA, V116, P976, DOI 10.1073/pnas.1812536116; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030; Zhang ZR, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1139-6	64	7	7	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6180	6194		10.1038/s41388-021-02011-0	http://dx.doi.org/10.1038/s41388-021-02011-0		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34535770				2022-12-28	WOS:000696766300002
J	Jia, XM; Liu, HJ; Ren, XN; Li, P; Song, RJ; Li, XR; Guo, YD; Li, XD				Jia, Xiaomeng; Liu, Huijiao; Ren, Xinmin; Li, Peng; Song, Runjie; Li, Xiru; Guo, Yangdong; Li, Xiangdong			Nucleolar protein NOC4L inhibits tumorigenesis and progression by attenuating SIRT1-mediated p53 deacetylation	ONCOGENE			English	Article							PROMOTES CELL-SURVIVAL; HEPATOCELLULAR-CARCINOMA; SIRT1 INTERACTS; POOR-PROGNOSIS; EXPRESSION; CANCER; TRANSCRIPTION; LOCALIZATION; COLON	SIRT1 is an NAD(+)-dependent deacetylase and plays an important role in the deacetylation of both histone and non-histone proteins. Many studies revealed that SIRT1 is upregulated in a variety of tumors and tightly associated with tumorigenesis and cancer progression, but the detailed underlying mechanism of the biological processes remains unclarified. In the present study, we found a nucleolar protein NOC4L, human ortholog of yeast Noc4p, which is essential for the nuclear export of the ribosomal 40S subunit and could bind to SIRT1 to inhibit SIRT1 mediated deacetylation of p53. NOC4L interacts with SIRT1 in variety of cells under nucleolar stress and directly interacts with SIRT1 in vitro. Furthermore, we determined the C-terminal of NOC4L and the catalytic domain of SIRT1 were required for their interaction. Overexpression of NOC4L did not change the protein levels of SIRT1 or p53, but increased the acetylation of p53 and promoted cell apoptosis. Additionally, NOC4L inhibited tumor cell proliferation in a p53-dependent manner and restrained tumor growth in a nude mice xenograft model. Clinically, colorectal cancer patients with the high expression of NOC4L had a better prognosis as TP53 was normally expressed, but no significant difference was observed in survival with mutant TP53. Taken together, our results identified a novel SIRT1 regulatory protein and broaden our understanding of the molecular mechanism of how nucleolar protein NOC4L regulates p53 under nucleolar stress. This research provides an insight into tumorigenesis and cell self-protection in the early stage of DNA damage.	[Jia, Xiaomeng; Liu, Huijiao; Ren, Xinmin; Li, Peng; Song, Runjie; Li, Xiangdong] China Agr Univ, Coll Biol Sci, State Key Lab Agro Biotechnol, Beijing 100193, Peoples R China; [Liu, Huijiao; Guo, Yangdong] China Agr Univ, Coll Hort Sci, Beijing 100193, Peoples R China; [Liu, Huijiao; Li, Xiangdong] China Agr Univ, Dept Nutr & Human Hlth, Beijing, Peoples R China; [Li, Xiru] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China; [Li, Xiangdong] Med Univ Bialystok, Dept Reprod & Gynecol Endocrinol, Bialystok, Poland	China Agricultural University; China Agricultural University; China Agricultural University; Chinese People's Liberation Army General Hospital; Medical University of Bialystok	Li, XD (corresponding author), China Agr Univ, Coll Biol Sci, State Key Lab Agro Biotechnol, Beijing 100193, Peoples R China.; Li, XD (corresponding author), China Agr Univ, Dept Nutr & Human Hlth, Beijing, Peoples R China.; Li, XD (corresponding author), Med Univ Bialystok, Dept Reprod & Gynecol Endocrinol, Bialystok, Poland.	xiangdongli@cau.edu.cn		Li, Xiangdong/0000-0003-2261-2393	National Natural Science Foundation of China [82171854, 31970802]; Beijing Municipal Natural Science Foundation [7202099]; Open Project of the State Key Laboratory of Agrobiotechnology [2022SKLAB6-05]; Science & Technology Innovation Program for National Defense [19-163-15-ZD-009-001-03]; Ji Nan Science & Technology Bureau [2021GXRC060]; Medical University of Bialystok, Poland [SUB/1/DN/21/002/1104]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Natural Science Foundation(Beijing Natural Science Foundation); Open Project of the State Key Laboratory of Agrobiotechnology; Science & Technology Innovation Program for National Defense; Ji Nan Science & Technology Bureau; Medical University of Bialystok, Poland	This study was supported by grants from National Natural Science Foundation of China (31970802); National Natural Science Foundation of China (82171854); Beijing Municipal Natural Science Foundation (7202099); Open Project of the State Key Laboratory of Agrobiotechnology (2022SKLAB6-05); Science & Technology Innovation Program for National Defense (19-163-15-ZD-009-001-03); Ji Nan Science & Technology Bureau (2021GXRC060); Medical University of Bialystok, Poland (SUB/1/DN/21/002/1104). We are grateful to Prof. Xiaojuan Du and Prof. Jianyuan Luo for advising this research. We thank YunLiu for flow cytometry assistance. We thank Xin Ren for the revision of the manuscript language.	Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Byles V, 2010, INT J BIOL SCI, V6, P599; Cao WX, 2017, BIOCHEM BIOPH RES CO, V483, P638, DOI 10.1016/j.bbrc.2016.12.090; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; CHAN PK, 1985, EXP CELL RES, V161, P101, DOI 10.1016/0014-4827(85)90494-X; Chen HC, 2012, ANN SURG ONCOL, V19, P2011, DOI 10.1245/s10434-011-2159-4; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Feng AN, 2011, INT J SURG PATHOL, V19, P743, DOI 10.1177/1066896911412181; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jang KY, 2009, PATHOLOGY, V41, P366, DOI 10.1080/00313020902884451; Jang SH, 2012, J CLIN PATHOL, V65, P735, DOI 10.1136/jclinpath-2012-200685; Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kerr LE, 2007, ONCOGENE, V26, P2554, DOI 10.1038/sj.onc.1210044; Kim JK, 2013, HEPATOLOGY, V57, P1055, DOI 10.1002/hep.26101; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Lee S, 2012, CELL DEATH DIFFER, V19, P1613, DOI 10.1038/cdd.2012.40; Li K, 2008, J BIOL CHEM, V283, P7590, DOI 10.1074/jbc.M709707200; Liang XJ, 2008, MOL CANCER RES, V6, P1499, DOI 10.1158/1541-7786.MCR-07-2130; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Milkereit P, 2003, J BIOL CHEM, V278, P4072, DOI 10.1074/jbc.M208898200; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Qin YL, 2017, PROTEIN CELL, V8, P230, DOI 10.1007/s13238-016-0335-9; Takemura M, 1999, J BIOCHEM-TOKYO, V125, P904, DOI 10.1093/oxfordjournals.jbchem.a022367; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang HN, 2012, ONCOL REP, V28, P311, DOI 10.3892/or.2012.1788; Wang L, 2012, J BIOL CHEM, V287, P30157, DOI 10.1074/jbc.M112.376640; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Warda AS, 2016, HUM MOL GENET, V25, P5353, DOI 10.1093/hmg/ddw351; Wild T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000522; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; Wu MQ, 2012, MED ONCOL, V29, P3240, DOI 10.1007/s12032-012-0260-6; Yang K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13599; Yao Z, 2010, ONCOGENE, V29, P1821, DOI 10.1038/onc.2009.473; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; Zhang R, 2010, J BIOL CHEM, V285, P7097, DOI 10.1074/jbc.M109.038604; Zhao J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1246-4; Zhu XP, 2019, CELL REP, V27, P1205, DOI 10.1016/j.celrep.2019.03.083	56	0	0	12	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4474	4484		10.1038/s41388-022-02447-y	http://dx.doi.org/10.1038/s41388-022-02447-y		AUG 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	36030331				2022-12-28	WOS:000846097500001
J	Tian, LS; Xie, XF; Das, U; Chen, YL; Sun, YL; Liu, F; Lu, HZ; Nan, P; Zhu, Y; Gu, XL; Deng, HT; Xie, JY; Zhao, XH				Tian, Lusong; Xie, Xiufeng; Das, Urmi; Chen, Yuling; Sun, Yulin; Liu, Fang; Lu, Haizhen; Nan, Peng; Zhu, Ying; Gu, Xinglu; Deng, Haiteng; Xie, Jiuyong; Zhao, Xiaohang			Forming cytoplasmic stress granules PUR alpha suppresses mRNA translation initiation of IGFBP3 to promote esophageal squamous cell carcinoma progression	ONCOGENE			English	Article							POSTNATAL BRAIN-DEVELOPMENT; FACTOR-BINDING-PROTEINS; SINGLE-STRANDED-DNA; GROWTH; CANCER; TRANSCRIPTION; ASSOCIATION; ACTIVATION; GENE; IDENTIFICATION	Esophageal squamous cell carcinoma (ESCC) is one of the most fatal malignancies worldwide. Recently, our group identified purine-rich element binding protein alpha (PUR alpha), a single-stranded DNA/RNA-binding protein, to be significantly associated with the progression of ESCC. Additional immunofluorescence staining demonstrated that PUR alpha forms cytoplasmic stress granules to suppress mRNA translation initiation. The expression level of cytoplasmic PUR alpha in ESCC tumor tissues was significantly higher than that in adjacent epithelia and correlated with a worse patient survival rate by immunohistochemistry. Functionally, PUR alpha strongly preferred to bind to UG-/U-rich motifs and mRNA 3 ' UTR by CLIP-seq analysis. Moreover, PUR alpha knockout significantly increased the protein level of insulin-like growth factor binding protein 3 (IGFBP3). In addition, it was further demonstrated that PUR alpha-interacting proteins are remarkably associated with translation initiation factors and ribosome-related proteins and that PUR alpha regulates protein expression by interacting with translation initiation factors, such as PABPC1, eIF3B and eIF3F, in an RNA-independent manner, while the interaction with ribosome-related proteins is significantly dependent on RNA. Specifically, PUR alpha was shown to interact with the mRNA 3 ' UTR of IGFBP3 and inhibit its expression by suppressing mRNA translation initiation. Together, this study identifies cytoplasmic PUR alpha as a modulator of IGFBP3, which could be a promising therapeutic target for ESCC treatment.	[Tian, Lusong; Xie, Xiufeng; Sun, Yulin; Liu, Fang; Nan, Peng; Zhu, Ying; Gu, Xinglu; Zhao, Xiaohang] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China; [Das, Urmi; Xie, Jiuyong] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Physiol & Pathophysiol, Winnipeg, MB, Canada; [Chen, Yuling; Deng, Haiteng] Tsinghua Univ, Ctr Synthet & Systemat Biol, Sch Life Sci, MOE Key Lab Bioinformat, Beijing, Peoples R China; [Lu, Haizhen] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Pathol, Canc Hosp, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; University of Manitoba; Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Zhao, XH (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.; Xie, JY (corresponding author), Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Physiol & Pathophysiol, Winnipeg, MB, Canada.; Deng, HT (corresponding author), Tsinghua Univ, Ctr Synthet & Systemat Biol, Sch Life Sci, MOE Key Lab Bioinformat, Beijing, Peoples R China.	dht@mail.tsinghua.edu.cn; xiej@umanitoba.ca; zhaoxh@cicams.ac.cn	; Xie, Jiuyong/D-2899-2013	Das, Urmi/0000-0001-7639-6521; Xie, Jiuyong/0000-0003-2909-1033	National Natural Science Foundation of China [81872033, 81572365, 82073327]; National Key R&D Program of China [2018YFC1313101, 2016YFC0901403]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-001, 2019-I2M-1-003, 2021-I2M-1-066]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; CAMS Innovation Fund for Medical Sciences	This work was partly supported by the National Natural Science Foundation of China (81872033 and 81572365 to XZ; 82073327 to YS), the National Key R&D Program of China (2018YFC1313101 and 2016YFC0901403 to XZ) and the CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001, 2019-I2M-1-003 and 2021-I2M-1-066 to XZ and YS) of China.	Asadi MR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.745394; Bassler J, 2019, ANNU REV BIOCHEM, V88, P281, DOI 10.1146/annurev-biochem-013118-110817; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; Bratkovic T, 2020, NUCLEIC ACIDS RES, V48, P1627, DOI 10.1093/nar/gkz1140; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai Q, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051261; Chen BB, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-1-r18; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; Clemmons DR, 1998, MOL CELL ENDOCRINOL, V140, P19, DOI 10.1016/S0303-7207(98)00024-0; Daigle JG, 2016, ACTA NEUROPATHOL, V131, P605, DOI 10.1007/s00401-015-1530-0; Daniel DC, 2018, GENE, V643, P133, DOI 10.1016/j.gene.2017.12.004; Darbinian N, 2004, ANTICANCER RES, V24, P2585; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; Di Salvio M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.295; Gallia GL, 1999, P NATL ACAD SCI USA, V96, P11572, DOI 10.1073/pnas.96.20.11572; Gao JJ, 2021, CANCER LETT, V498, P98, DOI 10.1016/j.canlet.2020.10.030; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; Han JF, 2011, CANCER LETT, V307, P200, DOI 10.1016/j.canlet.2011.04.004; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hinnebusch AG, 2014, ANNU REV BIOCHEM, V83, P779, DOI 10.1146/annurev-biochem-060713-035802; Hirano H, 2019, JPN J CLIN ONCOL, V49, P412, DOI 10.1093/jjco/hyz034; Hokkanen S, 2012, HUM MOL GENET, V21, P473, DOI 10.1093/hmg/ddr476; Hunt D, 2014, J MED GENET, V51, P806, DOI 10.1136/jmedgenet-2014-102798; Ivanov P, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a032813; Jain S, 2016, CELL, V164, P487, DOI 10.1016/j.cell.2015.12.038; Johnson EM, 2006, J NEUROSCI RES, V83, P929, DOI 10.1002/jnr.20806; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Johnson MA, 2014, GROWTH HORM IGF RES, V24, P164, DOI 10.1016/j.ghir.2014.04.007; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; Khalili K, 2003, MOL CELL BIOL, V23, P6857, DOI 10.1128/MCB.23.19.6857-6875.2003; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim JH, 2011, BLOOD, V118, P2622, DOI 10.1182/blood-2010-08-299784; Lee HY, 2002, CANCER RES, V62, P3530; Lezon-Geyda K, 2001, LEUKEMIA, V15, P954, DOI 10.1038/sj.leu.2402108; Lin DC, 2018, GASTROENTEROLOGY, V154, P374, DOI 10.1053/j.gastro.2017.06.066; Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014; Martincorena I, 2018, SCIENCE, V362, P911, DOI 10.1126/science.aau3879; Merrick WC, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a033092; Mitsumori K, 2017, MOL BIOL CELL, V28, P1412, DOI 10.1091/mbc.E16-07-0497; Natsuizaka M, 2014, AM J CANCER RES, V4, P29; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Ojha S, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050783; Pandey PR, 2020, NUCLEIC ACIDS RES, V48, P3789, DOI 10.1093/nar/gkaa035; Protter DSW, 2016, TRENDS CELL BIOL, V26, P668, DOI 10.1016/j.tcb.2016.05.004; Rossi S, 2015, J CELL SCI, V128, P1787, DOI 10.1242/jcs.165332; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Sariyer IK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156819; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Tanaka AJ, 2015, CSH MOL CASE STUD, V1, DOI 10.1101/mcs.a000356; Trau SP, 2020, PEDIATR NEUROL, V104, P62, DOI 10.1016/j.pediatrneurol.2019.09.008; Turriziani Benedetta, 2014, Biology (Basel), V3, P320, DOI 10.3390/biology3020320; Van Nostrand EL, 2016, NAT METHODS, V13, P508, DOI [10.1038/NMETH.3810, 10.1038/nmeth.3810]; Wang LG, 2008, CANCER RES, V68, P2678, DOI 10.1158/0008-5472.CAN-07-6017; White MK, 2009, CELL CYCLE, V8, P414, DOI 10.4161/cc.8.3.7585; Wolozin B, 2019, NAT REV NEUROSCI, V20, P649, DOI 10.1038/s41583-019-0222-5; Xia H, 2017, BBA-GENE REGUL MECH, V1860, P911, DOI 10.1016/j.bbagrm.2017.07.004; Xu ZH, 2013, P NATL ACAD SCI USA, V110, P7778, DOI 10.1073/pnas.1219643110; Yang PG, 2020, CELL, V181, P325, DOI 10.1016/j.cell.2020.03.046; Yokoyama A, 2019, NATURE, V565, P312, DOI 10.1038/s41586-018-0811-x; Youn JY, 2019, MOL CELL, V76, P286, DOI 10.1016/j.molcel.2019.09.014	62	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4336	4348		10.1038/s41388-022-02426-3	http://dx.doi.org/10.1038/s41388-022-02426-3		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35945453	hybrid, Green Published			2022-12-28	WOS:000837926900001
J	Zheng, QW; Ni, QZ; Zhu, B; Liang, X; Ma, N; Wang, YK; Xu, S; Cao, HJ; Xia, J; Zhang, FK; Zhang, EB; Qiu, XS; Ding, XF; Qiu, L; Zhang, XL; Dong, ZH; Li, ZG; Zhang, XL; Xie, D; Li, JJ				Zheng, Qian-Wen; Ni, Qian-Zhi; Zhu, Bing; Liang, Xin; Ma, Ning; Wang, Yi-Kang; Xu, Sheng; Cao, Hui-Jun; Xia, Ji; Zhang, Feng-Kun; Zhang, Er-Bin; Qiu, Xiao-Song; Ding, Xu-Fen; Qiu, Lin; Zhang, Xi-Lin; Dong, Zhao-Hui; Li, Zhi-Gang; Zhang, Xue-Li; Xie, Dong; Li, Jing-Jing			PPDPF promotes lung adenocarcinoma progression via inhibiting apoptosis and NK cell-mediated cytotoxicity through STAT3	ONCOGENE			English	Article							MUTATIONS; PHENOTYPE; RECEPTOR; BMPR2	Lung cancer is the most common malignancy and the leading cause of cancer death worldwide, and lung adenocarcinoma (LUAD) is the most prevalent subtype. Considering the emergence of resistance to therapies, it is urgent to develop more effective therapies to improve the prognosis. Here we reported that pancreatic progenitor cell differentiation and proliferation factor (PPDPF) deficiency inhibited LUAD development both in vitro and in vivo. Mechanistically, PPDPF induces hyperactive STAT3 by interfering STAT3-PTPN1 interaction. Activated STAT3 promoted BMPR2 transcription, which further inhibited apoptosis. Moreover, PPDPF reduced NK cell infiltration and activation to develop an immunosuppressive microenvironment, which was also mediated by STAT3. Furthermore, we identified that the expression of PPDPF was positively correlated with the malignant features of LUAD, as well as BMPR2 and p-STAT3 level in clinical samples. Therefore, our study suggests that PPDPF positively regulates BMPR2 expression and facilitates immune escape via regulating STAT3 activity, providing a potential therapy target for LUAD.	[Zheng, Qian-Wen; Ni, Qian-Zhi; Zhu, Bing; Liang, Xin; Wang, Yi-Kang; Xu, Sheng; Cao, Hui-Jun; Xia, Ji; Zhang, Feng-Kun; Zhang, Er-Bin; Qiu, Xiao-Song; Ding, Xu-Fen; Qiu, Lin; Xie, Dong; Li, Jing-Jing] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China; [Zheng, Qian-Wen; Qiu, Xiao-Song; Xie, Dong] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China; [Ma, Ning; Li, Zhi-Gang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Sect Esophageal Surg, Shanghai 200030, Peoples R China; [Zhang, Xi-Lin] Huzhou Univ, Affiliated Hosp 1, Dept Cent Lab, Huzhou 313000, Zhejiang, Peoples R China; [Dong, Zhao-Hui] Huzhou Univ, Affiliated Hosp 1, Dept Crit Care Med, Huzhou 313000, Zhejiang, Peoples R China; [Zhang, Xue-Li] Shanghai Fengxian Cent Hosp, Dept Gen Surg, Shanghai 201499, Peoples R China; [Xie, Dong] China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; University of Chinese Academy of Sciences, CAS; ShanghaiTech University; Shanghai Jiao Tong University; Huzhou University; Huzhou University	Xie, D; Li, JJ (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China.; Xie, D (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.; Zhang, XL (corresponding author), Shanghai Fengxian Cent Hosp, Dept Gen Surg, Shanghai 201499, Peoples R China.; Xie, D (corresponding author), China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China.	tide7@163.com; dxie@sibs.ac.cn; lejing_1996@163.com	Cao, Huijun/HDM-1523-2022	, Ning/0000-0003-1825-8854	National Natural Science Foundation of China [82172950, 81972757, 81730083, 82030084]; Youth Innovation Promotion Association of Chinese Academy of Sciences [2017324]; Sanofi-SIBS 2018 Young Faculty Award	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association of Chinese Academy of Sciences; Sanofi-SIBS 2018 Young Faculty Award	This work was supported by the National Natural Science Foundation of China (82172950, 81972757), Youth Innovation Promotion Association of Chinese Academy of Sciences grant (2017324) and Sanofi-SIBS 2018 Young Faculty Award to J-JL; and the National Natural Science Foundation of China (81730083 and 82030084) to DX.	Aktas E, 2009, CELL IMMUNOL, V254, P149, DOI 10.1016/j.cellimm.2008.08.007; Augeri DJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0511-9; Bedel R, 2011, CANCER RES, V71, P1615, DOI 10.1158/0008-5472.CAN-09-4540; Beppu H, 2008, ONCOGENE, V27, P1063, DOI 10.1038/sj.onc.1210720; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bruno A, 2013, NEOPLASIA, V15, P133, DOI 10.1593/neo.121758; Cacalano NA, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00128; Degos C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00877; Galon J, 2020, IMMUNITY, V52, P55, DOI 10.1016/j.immuni.2019.12.018; Ihara S, 2012, CANCER RES, V72, P2990, DOI 10.1158/0008-5472.CAN-11-4062; Jiang Z, 2008, PLOS BIOL, V6, P2450, DOI 10.1371/journal.pbio.0060293; Jiao G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.540; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Liu GH, 2019, BIOCHEM BIOPH RES CO, V513, P207, DOI 10.1016/j.bbrc.2019.03.213; Liu MY, 2014, SCI REP-UK, V4, DOI 10.1038/srep05095; Liu ZP, 2009, BBA-MOL CELL RES, V1793, P1819, DOI 10.1016/j.bbamcr.2009.09.012; Lund IK, 2005, J MOL ENDOCRINOL, V34, P339, DOI 10.1677/jme.1.01694; Ma N, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23285-8; Mao ZF, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014552; Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7; Nakamura T, 2010, MOL CELL, V39, P184, DOI 10.1016/j.molcel.2010.07.002; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; Peng CW, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1060-2; Peters S, 2019, ANN ONCOL, V30, P884, DOI 10.1093/annonc/mdz109; Pickup MW, 2015, MOL ONCOL, V9, P179, DOI 10.1016/j.molonc.2014.08.004; Platonova S, 2011, CANCER RES, V71, P5412, DOI 10.1158/0008-5472.CAN-10-4179; Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604; Remark R, 2015, AM J RESP CRIT CARE, V191, P377, DOI 10.1164/rccm.201409-1671PP; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Schuijs MJ, 2020, NAT IMMUNOL, V21, P998, DOI 10.1038/s41590-020-0745-y; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Soon E, 2015, AM J RESP CRIT CARE, V192, P859, DOI 10.1164/rccm.201408-1509OC; Sui QJ, 2014, J IMMUNOL, V193, P2016, DOI 10.4049/jimmunol.1302389; Sun XX, 2013, MOL CANCER THER, V12, P2885, DOI 10.1158/1535-7163.MCT-12-1087; Tkach M, 2012, J IMMUNOL, V189, P1162, DOI 10.4049/jimmunol.1102538; Tulotta C, 2019, CLIN CANCER RES, V25, P2769, DOI 10.1158/1078-0432.CCR-18-2202; Wang ZD, 2021, LEUKEMIA LYMPHOMA, V62, P937, DOI 10.1080/10428194.2020.1849680; Wellenstein MD, 2018, IMMUNITY, V48, P399, DOI 10.1016/j.immuni.2018.03.004; Xiao YJ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.669603; Zeng FW, 2012, HYBRIDOMA, V31, P209, DOI 10.1089/hyb.2011.0115	41	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2022	41	36					4244	4256		10.1038/s41388-022-02418-3	http://dx.doi.org/10.1038/s41388-022-02418-3		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4G5OH	35906391				2022-12-28	WOS:000832824600002
J	Shen, J; Huang, QW; Jia, WY; Feng, SJ; Liu, L; Li, XL; Tao, DD; Xie, DX				Shen, Jie; Huang, Qingwen; Jia, Weiyi; Feng, Shengjie; Liu, Liang; Li, Xiaolan; Tao, Deding; Xie, Daxing			YAP1 induces invadopodia formation by transcriptionally activating TIAM1 through enhancer in breast cancer	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HIPPO SIGNALING PATHWAY; METASTASIS; CORTACTIN; BINDING; ASSOCIATION; PODOSOMES; MOLECULE; INVASION; COMPLEX	Yes-associated protein 1 (YAP1), a central component of the Hippo pathway, plays an important role in tumor metastasis; however, the underlying mechanism remains to be elucidated. Invadopodia are actin-rich protrusions containing multiple proteases and have been widely reported to promote cell invasiveness by degrading the extracellular matrix. In the present study, we report that YAP1 induces invadopodia formation and promotes tumor metastasis in breast cancer cells. We also identify TIAM1, a guanine nucleotide exchange factor, as a target of the YAP1-TEAD4 complex. Our results demonstrate that YAP1 could promote TEAD4 binding to the enhancer region of TIAM1, which activates TIAM1 expression, subsequently increasing RAC1 activity and inducing invadopodia formation. These findings reveal the functional role of Hippo signaling in the regulation of invadopodia and provide potential molecular targets for preventing tumor metastasis in breast cancer.	[Shen, Jie; Huang, Qingwen; Jia, Weiyi; Feng, Shengjie; Liu, Liang; Li, Xiaolan; Tao, Deding; Xie, Daxing] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Mol Med Ctr, Wuhan, Peoples R China; [Shen, Jie; Huang, Qingwen; Jia, Weiyi; Feng, Shengjie; Liu, Liang; Xie, Daxing] Huazhong Univ Sci & Technol, Tongji Hosp, Dept GI Surg, Tongji Med Coll, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Xie, DX (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Mol Med Ctr, Wuhan, Peoples R China.; Xie, DX (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept GI Surg, Tongji Med Coll, Wuhan, Peoples R China.	dxxie@tjh.tjmu.edu.cn		Shen, Jie/0000-0002-8442-7268	National Natural Science Foundation of China [81572861, 81773053]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (Grant numbers: 81572861, 81773053).	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Alonso DF, 2011, CURR PHARM BIOTECHNO, V12, P1974; Baik M, 2019, METHODSX, V6, P718, DOI 10.1016/j.mex.2019.03.024; Benjamin DC, 2020, CANCER RES, V80, P3867, DOI 10.1158/0008-5472.CAN-20-0212; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Boissier P, 2014, CELL SIGNAL, V26, P483, DOI 10.1016/j.cellsig.2013.11.034; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Caldon CE, 2012, MOL CANCER THER, V11, P1488, DOI 10.1158/1535-7163.MCT-11-0963; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Diamantopoulou Z, 2017, CANCER CELL, V31, P621, DOI 10.1016/j.ccell.2017.03.007; Diaz B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000368; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; Feldker N, 2020, EMBO J, V39, DOI 10.15252/embj.2019103209; Feng SJ, 2022, CANCER LETT, V532, DOI 10.1016/j.canlet.2022.215588; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Galouzis CC, 2022, CURR OPIN CELL BIOL, V75, DOI 10.1016/j.ceb.2022.01.010; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Harper K, 2010, CANCER RES, V70, P4634, DOI 10.1158/0008-5472.CAN-09-3813; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Khan A, 2018, NUCLEIC ACIDS RES, V46, pD260, DOI 10.1093/nar/gkx1126; Kudlik G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218117; Lin KC, 2017, TRENDS BIOCHEM SCI, V42, P862, DOI 10.1016/j.tibs.2017.09.003; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lohmer LL, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005786; Lohmer LL, 2014, CELL ADHES MIGR, V8, P246, DOI 10.4161/cam.28406; Maugeri-Sacca M, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.12; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Pocaterra A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.230425; Qadir MI, 2015, CHEM BIOL DRUG DES, V86, P432, DOI 10.1111/cbdd.12556; Qiao YT, 2017, CELL REP, V19, P1495, DOI 10.1016/j.celrep.2017.04.075; Revach OY, 2016, EXP CELL RES, V343, P82, DOI 10.1016/j.yexcr.2016.02.003; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rosenberg BJ, 2017, MOL BIOL CELL, V28, P1347, DOI 10.1091/mbc.E16-12-0885; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sabatier R, 2011, BREAST CANCER RES TR, V126, P407, DOI 10.1007/s10549-010-0897-9; Seano G, 2015, CELL CYCLE, V14, P1370, DOI 10.1080/15384101.2015.1026523; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Shen J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0850-z; Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun X, 2020, NUCLEIC ACIDS RES, V48, P7182, DOI 10.1093/nar/gkaa482; Surviladze Z., 2010, PROBE REPORTS NIH MO; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tong M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02240-6; Vinci M, 2015, JOVE-J VIS EXP, DOI 10.3791/52686; Wang ZY, 2014, P NATL ACAD SCI USA, V111, pE89, DOI 10.1073/pnas.1319190110; Wang ZQ, 2016, METHODS MOL BIOL, V1406, P203, DOI 10.1007/978-1-4939-3444-7_18; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Yang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109980; Yu HX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051239; Zagryazhskaya-Masson A, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201910132; Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591-018-0158-8; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhu C, 2019, MOL CELL, V75, P791, DOI 10.1016/j.molcel.2019.06.010	67	1	1	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3830	3845		10.1038/s41388-022-02344-4	http://dx.doi.org/10.1038/s41388-022-02344-4		JUN 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35773411	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000819316500002
J	Liu, ZL; Liu, JL; Chen, TL; Wang, Y; Shi, AD; Li, KS; Li, XY; Qiu, B; Zheng, LJ; Zhao, LM; Shu, LZ; Lian, S; Huang, SH; Zhang, ZL; Xu, YF				Liu, Zengli; Liu, Jialiang; Chen, Tianli; Wang, Yue; Shi, Anda; Li, Kangshuai; Li, Xingyong; Qiu, Bo; Zheng, Lijie; Zhao, Liming; Shu, Lizhuang; Lian, Shuo; Huang, Shaohui; Zhang, Zongli; Xu, Yunfei			Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway	ONCOGENE			English	Article							BETA-CATENIN; INVASION; TARGETS; GROWTH; CANCER; SOX9	Cholangiocarcinoma (CCA) is a type of highly malignant tumor originating from bile ducts. The prognosis of CCA is poor and the treatment options are limited. The biomarker study of CCA has made little progresses in recent years because of the difficulty to obtain CCA specimens. SOX9 is an important regulator of cholangiocyte proliferation and differentiation. We performed mRNA sequencing of CCA, retrieved TCGA data, and detected SOX9 expression in a large CCA cohort. With WNT3A stimulation, SOX9 expression and transcription was elevated by TCF7. Moreover, SOX9 was substantially up-regulated in CCA tissues and was identified as a prognostic biomarker of CCA. With mRNA sequencing and in vitro/vivo validation, we demonstrated that SOX9 enhanced the transcription and expression of FGF7 and FGFR2. FGF7 was significantly up-regulated in the bile and serum of CCA patients, and may promote CCA proliferation by activating FGFR2 in an autocrine pathway. co-expression of FGF7 and FGFR2 was a more sensitive marker for poor prognosis. SOX9-induced overexpression of FGF7 and FGFR2 was the key reason of SOX9-involved pemigatinib resistance. In conclusion, SOX9 and FGF7 were prognostic biomarkers of CCA. WNT3A-TCF7-SOX9 axis could induce pemigatinib resistance in two independent pathways: (1)SOX9 directly promotes FGFR2 transcription and expression; (2)SOX9 elevates FGF7 expression, which could be secreted from CCA cells and activates FGFR2 phosphorylation in an autocrine pathway.	[Liu, Zengli; Liu, Jialiang; Chen, Tianli; Wang, Yue; Shi, Anda; Li, Kangshuai; Qiu, Bo; Zheng, Lijie; Zhao, Liming; Shu, Lizhuang; Lian, Shuo; Huang, Shaohui; Zhang, Zongli; Xu, Yunfei] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Gen Surg, Jinan 250012, Shandong, Peoples R China; [Li, Xingyong] Shandong Univ, Shandong Prov Hosp 3, Cheeloo Coll Med, Dept Hepatobiliary Surg, Jinan 250012, Shandong, Peoples R China	Shandong University; Shandong University	Zhang, ZL; Xu, YF (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Gen Surg, Jinan 250012, Shandong, Peoples R China.	zzlzzl1900@163.com; xuyunfei1988@126.com			Shandong University Multidisciplinary Research and Innovation Team of Young Scholars [2020QNQT002]; Shandong Province Key RD Program [,2021CXGC011105]; National Natural Science Foundation of China [82072676, 82172791]; China Postdoctoral Science Foundation [2020M682190, 2020M682195]; Clinical Research Foundation of Shandong University [2020SDUCRCA018]; Natural Science Foundation of Shandong Province [ZR2019MH008]; Jinan City Science and Technology Development Program [201805017, 201805013]; Clinical Research Innovation Fund Project [CXPJJH11800001-2018240]; Hengrui Hepatobiliary and Pancreatic Foundation; Key Research and Development Program of Shandong Province [2019GSF108254]; Beijing Medical Award Foundation [YXJL-2020-0785-0967, YXJL-2020-0785-0968]	Shandong University Multidisciplinary Research and Innovation Team of Young Scholars; Shandong Province Key RD Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Clinical Research Foundation of Shandong University; Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Jinan City Science and Technology Development Program; Clinical Research Innovation Fund Project; Hengrui Hepatobiliary and Pancreatic Foundation; Key Research and Development Program of Shandong Province; Beijing Medical Award Foundation	Our study was supported by Shandong University Multidisciplinary Research and Innovation Team of Young Scholars (Grant No. 2020QNQT002), Shandong Province Key R&D Program(Major Scientific Innovation Projects,2021CXGC011105), National Natural Science Foundation of China (Grant No. 82072676, 82172791), China Postdoctoral Science Foundation (Grant No. 2020M682190, 2020M682195), Clinical Research Foundation of Shandong University (Grant No. 2020SDUCRCA018), Natural Science Foundation of Shandong Province (ZR2019MH008), Jinan City Science and Technology Development Program (Grant No. 201805017, 201805013), Clinical Research Innovation Fund Project(CXPJJH11800001-2018240), Hengrui Hepatobiliary and Pancreatic Foundation (Grant No.Y-2017-144), Key Research and Development Program of Shandong Province (Grant No. 2019GSF108254), Beijing Medical Award Foundation (YXJL-2020-0785-0967, YXJL-2020-0785-0968).	Abou-Alfa GK, 2020, LANCET ONCOL, V21, P671, DOI 10.1016/S1470-2045(20)30109-1; Andersen JB, 2012, GASTROENTEROLOGY, V142, P1021, DOI 10.1053/j.gastro.2011.12.005; Antoniou A, 2009, GASTROENTEROLOGY, V136, P2325, DOI 10.1053/j.gastro.2009.02.051; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Chen TL, 2021, ONCOGENE, V40, P4941, DOI 10.1038/s41388-021-01850-1; Chen TL, 2021, MOL THER, V29, P2134, DOI 10.1016/j.ymthe.2021.02.017; Davis K, 1990, Int J Technol Assess Health Care, V6, P203; Fan EW, 2015, J UROLOGY, V194, P223, DOI 10.1016/j.juro.2015.01.073; Goyal L, 2021, CANCER TREAT REV, V95, DOI 10.1016/j.ctrv.2021.102170; Hoy SM, 2020, DRUGS, V80, P923, DOI 10.1007/s40265-020-01330-y; Huang TT, 2017, INT J ONCOL, V50, P1501, DOI 10.3892/ijo.2017.3927; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Kawaguchi Y, 2013, J CLIN INVEST, V123, P1881, DOI 10.1172/JCI66022; Lau WM, 2018, MOL CANCER THER, V17, P232, DOI 10.1158/1535-7163.MCT-17-0367; Li ZP, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01890-1; Liu PCC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231877; Liu ZL, 2019, EBIOMEDICINE, V45, P181, DOI 10.1016/j.ebiom.2019.06.023; Pai R, 2008, CANCER RES, V68, P5086, DOI 10.1158/0008-5472.CAN-07-2325; Poncy A, 2015, DEV BIOL, V404, P136, DOI 10.1016/j.ydbio.2015.05.012; Qiu B, 2019, EBIOMEDICINE, V50, P166, DOI 10.1016/j.ebiom.2019.11.021; Rizvi S, 2018, NAT REV CLIN ONCOL, V15, P95, DOI 10.1038/nrclinonc.2017.157; Ropiquet F, 1999, INT J CANCER, V82, P237, DOI 10.1002/(SICI)1097-0215(19990719)82:2<237::AID-IJC14>3.0.CO;2-Q; Sarabipour S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10262; Shimokawa T, 2003, CANCER RES, V63, P6116; Silverman IM, 2021, CANCER DISCOV, V11, P326, DOI 10.1158/2159-8290.CD-20-0766; Sun RQ, 2019, EBIOMEDICINE, V47, P142, DOI 10.1016/j.ebiom.2019.08.062; Valle JW, 2021, LANCET, V397, P428, DOI 10.1016/S0140-6736(21)00153-7; Xie YL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00222-7; Xu YF, 2019, ONCOGENE, V38, P868, DOI 10.1038/s41388-018-0485-8; Xu YF, 2014, BIOCHEM BIOPH RES CO, V446, P54, DOI 10.1016/j.bbrc.2014.02.050; Yuan XD, 2018, BRIT J CANCER, V119, P1358, DOI 10.1038/s41416-018-0338-9	31	5	5	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2885	2896		10.1038/s41388-022-02313-x	http://dx.doi.org/10.1038/s41388-022-02313-x		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35428876				2022-12-28	WOS:000782705700001
J	Chen, S; Cheng, JH; Zhong, YH; Liu, RM; Lu, ZX; Luo, XY				Chen, Shuai; Cheng, Jianghong; Zhong, Yanhong; Liu, Ruimin; Lu, Zhongxian; Luo, Xianyang			Liver-specific overexpression of Gab2 accelerates hepatocellular carcinoma progression by activating immunosuppression of myeloid-derived suppressor cells	ONCOGENE			English	Article							CANCER; AMPLIFICATION; CARCINOGENESIS; TARGET	GRB2-associated-binding protein 2 (Gab2) deletion has a preventive effect of on chronic liver inflammation and hepatocellular carcinoma. This study was aimed to elaborate Gab2-initiated immunoregulation during hepatocarcinogenesis. Compared to wild-type group, liver-specific overexpression of Gab2 mice (L-Gab2) displayed early hepatocarcinogenesis after 5-month diethylnitrosamine (DEN) induction, and accelerated tumor growth after 9-month DEN challenge. More myeloid-derived suppressor cells (MDSCs) were observed in DEN-challenged L-Gab2 mice than that in DEN-treated wild-type mice. Additionally, MDSCs activation-induced tumor angiogenesis capability and immunosuppression function were exceedingly activated in DEN-exposed L-Gab2 mice, which reflected in the increased platelet endothelial cell adhesion molecule (PECAM) and vascular endothelial growth factor (VEGF), and the decreased cytotoxic T lymphocytes. Mechanistically, DEN-challenged L-Gab2 mice produced more IL-6, and IL-6 depletion significantly deprived Gab2-overexpression-mediated tumor-promotion phenomena, accompanied by the impairment of MDSCs-initiated immunosuppression function. MDSCs isolated from IL-6-depleted L-Gab2 mice or inactivating MDSCs partly restored the immune function of cytotoxic T cells. Of note, MDSCs gene signatures had a significant association with the increased Gab2 or IL6 in hepatoma specimens. Collectively, L-Gab2 mice accelerated hepatoma progression possibly through activating IL-6-initiated the activation of MDSCs. This study provides a novel insights for exploring the role of Gab2 in autoimmune tolerance during hepatocarcinogenesis.	[Chen, Shuai; Luo, Xianyang] Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Otolaryngol Head & Neck Surg, Xiamen 361003, Peoples R China; [Cheng, Jianghong] Xian Med Univ, Xian Key Lab Pathogen Microorganism & Tumor Immun, Xian 710021, Peoples R China; [Zhong, Yanhong; Liu, Ruimin; Lu, Zhongxian] Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Pharmaceut Sci, Xiamen 361005, Fujian, Peoples R China; [Luo, Xianyang] Xiamen Key Lab Otolaryngol Head & Neck Surg, Xiamen 361003, Peoples R China	Xiamen University; Xi'an Medical University; Xiamen University	Luo, XY (corresponding author), Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Otolaryngol Head & Neck Surg, Xiamen 361003, Peoples R China.; Lu, ZX (corresponding author), Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Pharmaceut Sci, Xiamen 361005, Fujian, Peoples R China.; Luo, XY (corresponding author), Xiamen Key Lab Otolaryngol Head & Neck Surg, Xiamen 361003, Peoples R China.	zhongxian@xmu.edu.cn; luoxianyang126@126.com		Lu, zhongxian/0000-0002-1682-7147	Natural Science Foundation of China [81802332, 8210115473]; Natural Science Foundation of Fujian Province [2020J05302, 2021J011358]; Science Foundation of the Fujian provincial Commission of Health and Family Planning [2021GGB026]; Natural Science Basic Research Program of Shaanxi Province [2021JQ-780]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); Science Foundation of the Fujian provincial Commission of Health and Family Planning; Natural Science Basic Research Program of Shaanxi Province	We thank the Gene Expression Profiling Interactive Analysis 2.0 online database (GEPIA2). This work was supported by the grants from Natural Science Foundation of China (81802332 and 8210115473), Natural Science Foundation of Fujian Province (2020J05302 and 2021J011358), Science Foundation of the Fujian provincial Commission of Health and Family Planning (2021GGB026) and Natural Science Basic Research Program of Shaanxi Province (2021JQ-780).	Arihara F, 2013, CANCER IMMUNOL IMMUN, V62, P1421, DOI 10.1007/s00262-013-1447-1; Atretkhany KSN, 2016, BIOCHEMISTRY-MOSCOW+, V81, P1274, DOI 10.1134/S0006297916110055; Beury DW, 2014, J LEUKOCYTE BIOL, V96, P1109, DOI 10.1189/jlb.3A0414-210R; Bocanegra M, 2010, ONCOGENE, V29, P774, DOI 10.1038/onc.2009.364; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brodaczewska KK, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12704; Chang Wen-Chi L, 2017, World J Gastrointest Pharmacol Ther, V8, P47, DOI 10.4292/wjgpt.v8.i1.47; Chen S, 2016, J MOL CELL BIOL, V8, P492, DOI 10.1093/jmcb/mjw028; Chen ZQ, 2020, AM J CANCER RES, V10, P2993; Cheng JH, 2017, FASEB J, V31, P5530, DOI 10.1096/fj.201700120RR; Chernoff KA, 2009, CLIN CANCER RES, V15, P4288, DOI 10.1158/1078-0432.CCR-09-0280; Choo YW, 2018, ACS NANO, V12, P8977, DOI 10.1021/acsnano.8b02446; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; De Cicco P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01680; Deng Y, 2017, ONCOGENE, V36, P1090, DOI 10.1038/onc.2016.273; Ding CB, 2015, MOL MED REP, V12, P4007, DOI 10.3892/mmr.2015.3951; Ding CB, 2015, INT J CLIN EXP PATHO, V8, P2779; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Groth C, 2019, BRIT J CANCER, V120, P16, DOI 10.1038/s41416-018-0333-1; Guo XH, 2017, J BIOL CHEM, V292, P14003, DOI 10.1074/jbc.M117.802066; Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002; Herr R, 2018, ONCOGENE, V37, P1576, DOI 10.1038/s41388-017-0063-5; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; Kapanadze T, 2013, J HEPATOL, V59, P1007, DOI 10.1016/j.jhep.2013.06.010; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Lee AW, 2011, MOL CELL BIOL, V31, P4563, DOI 10.1128/MCB.05706-11; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Lu LC, 2019, J HEPATOCELL CARCINO, V6, P71, DOI 10.2147/JHC.S159693; Park YR, 2017, J KOREAN MED SCI, V32, P1784, DOI 10.3346/jkms.2017.32.11.1784; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Ribechini E, 2010, MED MICROBIOL IMMUN, V199, P273, DOI 10.1007/s00430-010-0151-4; Saviano A, 2019, MOL TRANSL MED, P317, DOI 10.1007/978-3-030-21540-8_15; Schrader J, 2013, J HEPATOL, V59, P921, DOI 10.1016/j.jhep.2013.08.003; Triantafyllou E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02948; Urakawa S, 2019, CANCER IMMUNOL IMMUN, V68, P1341, DOI 10.1007/s00262-019-02366-0; Waldron TJ, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24117; Yang Y, 2013, ONCOGENE, V32, P3627, DOI 10.1038/onc.2012.367; Zanconato F, 2019, NAT REV CANCER, V19, P454, DOI 10.1038/s41568-019-0168-y; Zatkova A, 2006, GENE CHROMOSOME CANC, V45, P798, DOI 10.1002/gcc.20344; Zhang YS, 2018, CANCER BIOL THER, V19, P735, DOI 10.1080/15384047.2018.1453971; Zhao F, 2012, IMMUNOLOGY, V136, P176, DOI 10.1111/j.1365-2567.2012.03566.x	43	2	2	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3316	3327		10.1038/s41388-022-02298-7	http://dx.doi.org/10.1038/s41388-022-02298-7		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35411035				2022-12-28	WOS:000780668900001
J	Ma, Y; Zhang, HB; Chen, C; Liu, LX; Ding, T; Wang, Y; Ma, DC; Ling, XL; Chen, XH; Li, JP; Zhong, GS; Ru, GQ; Zhang, L; Tang, JM				Ma, Yan; Zhang, Haibo; Chen, Cheng; Liu, Lixin; Ding, Ting; Wang, Ying; Ma, Dachang; Ling, Xiaoling; Chen, Xiaohua; Li, Jianping; Zhong, Guansheng; Ru, Guoqing; Zhang, Lei; Tang, Jianming			TRIM32 promotes radioresistance by disrupting TC45-STAT3 interaction in triple-negative breast cancer	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; UBIQUITIN LIGASE TRIM32; STAT3; PHOSPHORYLATION; PROLIFERATION; RADIOTHERAPY; DEGRADATION; ACTIVATION; PROGNOSIS; ENZYME	Radioresistance is common in the treatment of triple-negative breast cancer (TNBC), but the molecular mechanisms involved remain unclear. Herein, we reveal that tripartite motif-containing protein 32 (TRIM32) is upregulated in TNBC and is negatively associated with survival of TNBC patients. Radiotherapy resulted in enhanced expression of TRIM32, whereas TRIM32 depletion reduced TNBC radioresistance in vitro and in vivo. Mechanistically, radiotherapy promoted the association between TRIM32 and nuclear STAT3, which suppressed TC45-induced dephosphorylation of STAT3, resulting in increased STAT3 transcriptional activation and TNBC radioresistance. Finally, we demonstrated that TRIM32 and STAT3 phosphorylation are co-expressed in TNBC tissues. Moreover, high expression of TRIM32 and STAT3 phosphorylation is positively linked to poor prognosis of TNBC patients. Our study demonstrates that TRIM32 is a novel target for predicting radioresistance in TNBC patients.	[Ma, Yan; Chen, Xiaohua; Tang, Jianming] Lanzhou Univ, Hosp 1, Dept Radiat Oncol, Lanzhou 730000, Gansu, Peoples R China; [Zhang, Haibo; Wang, Ying] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Oncol Ctr,Dept Radiat Oncol, Hangzhou 310014, Zhejiang, Peoples R China; [Chen, Cheng; Ma, Dachang] Lanzhou Univ, Hosp 1, Dept Breast Surg, Lanzhou 730000, Gansu, Peoples R China; [Liu, Lixin] Lanzhou Univ, Hosp 1, Dept Thorac Surg, Lanzhou 730000, Gansu, Peoples R China; [Ding, Ting] Yiyang Cent Hosp, Dept Endocrinol, Yiyang 413000, Hunan, Peoples R China; [Ling, Xiaoling] Lanzhou Univ, Hosp 1, Dept Oncol, Lanzhou 730000, Gansu, Peoples R China; [Li, Jianping] Shanghai Bioegene Co Ltd, Shanghai 200003, Peoples R China; [Zhong, Guansheng] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Breast Surg, Hangzhou 310003, Zhejiang, Peoples R China; [Ru, Guoqing] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Dept Pathol, Hangzhou 310014, Zhejiang, Peoples R China; [Zhang, Lei] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Radiat Oncol, Shanghai 200127, Peoples R China	Lanzhou University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Lanzhou University; Lanzhou University; Lanzhou University; Zhejiang University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Shanghai Jiao Tong University	Tang, JM (corresponding author), Lanzhou Univ, Hosp 1, Dept Radiat Oncol, Lanzhou 730000, Gansu, Peoples R China.; Zhang, L (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Radiat Oncol, Shanghai 200127, Peoples R China.	hrbmuzl@126.com; 15900792812@163.com	Li, Jing/GYU-5036-2022; LI, JIAN/GRY-2197-2022; li, jian/GSE-0245-2022	Zhang, Haibo/0000-0002-5134-4167	National Natural Science Foundation of China [82003236]; Zhejiang Provincial Nature Science Foundation of China [LY20H160044]; Gansu Provincial National Science Foundation for Distinguished Young Scholars [21JR7RA389]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Nature Science Foundation of China; Gansu Provincial National Science Foundation for Distinguished Young Scholars	This study was supported, in part, by grants from the National Natural Science Foundation of China (Grant number: 82003236 to Haibo Zhang), Zhejiang Provincial Nature Science Foundation of China (Grant number: LQ20H160063 to Jianming Tang), Gansu Provincial National Science Foundation for Distinguished Young Scholars (Grant number: 21JR7RA389 to Jianming Tang), Zhejiang Provincial Nature Science Foundation of China (Grant number: LY20H160044 to Ying Wang).	Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; Bi ZF, 2020, ADV SCI, V7, DOI 10.1002/advs.202000915; Brett-Morris A, 2014, CANCER RES, V74, P6925, DOI 10.1158/0008-5472.CAN-14-1249; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Cui XP, 2016, MOL CELL BIOCHEM, V421, P127, DOI 10.1007/s11010-016-2793-z; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Gillison ML, 2019, LANCET, V393, P40, DOI 10.1016/S0140-6736(18)32779-X; Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002; He KY, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003900; He L, 2019, CANCER MANAG RES, V11, P5765, DOI 10.2147/CMAR.S213663; He MY, 2018, CRIT REV ONCOL HEMAT, V131, P96, DOI 10.1016/j.critrevonc.2018.09.004; Horn EJ, 2004, CARCINOGENESIS, V25, P157, DOI 10.1093/carcin/bgh003; Ikeda O, 2009, BIOCHEM BIOPH RES CO, V384, P71, DOI 10.1016/j.bbrc.2009.04.076; Kano S, 2008, CANCER RES, V68, P5572, DOI 10.1158/0008-5472.CAN-07-6231; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kudryashova E, 2009, HUM MOL GENET, V18, P1353, DOI 10.1093/hmg/ddp036; Lazzari E, 2016, INT J BIOCHEM CELL B, V79, P469, DOI 10.1016/j.biocel.2016.07.023; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu J, 2014, CELL DEATH DIFFER, V21, P1792, DOI 10.1038/cdd.2014.121; Lu L, 2018, ONCOGENE, V37, P5292, DOI 10.1038/s41388-018-0340-y; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Okawa T, 1999, Gan To Kagaku Ryoho, V26 Suppl 1, P15; Park SY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1405-7; Qiu LY, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-03021-y; Sang YZ, 2018, CANCER RES, V78, P1792, DOI 10.1158/0008-5472.CAN-17-2774; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Wang J, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7297631; Wang ML, 2020, CELL DEATH DIFFER, V27, P1286, DOI 10.1038/s41418-019-0415-5; Wang XH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01120; Wang YM, 2014, MOL CELL, V53, P752, DOI 10.1016/j.molcel.2014.01.020; Wang Y, 2020, CELL DEATH DIFFER, V27, P695, DOI 10.1038/s41418-019-0381-y; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yin HM, 2019, J CELL BIOCHEM, V120, P5232, DOI 10.1002/jcb.27798; Zhao TT, 2018, J CANCER, V9, P1349, DOI 10.7150/jca.22390; Zhou ZC, 2014, GASTROENTEROLOGY, V147, P1043, DOI 10.1053/j.gastro.2014.07.021	36	1	1	6	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1589	1599		10.1038/s41388-022-02204-1	http://dx.doi.org/10.1038/s41388-022-02204-1		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35091679				2022-12-28	WOS:000749073300004
J	Qu, JW; Hou, YF; Chen, QX; Chen, J; Li, Y; Zhang, EF; Gu, HY; Xu, RY; Liu, Y; Cao, W; Zhang, JN; Cao, LQ; He, JS; Cai, Z				Qu, Jianwei; Hou, Yifan; Chen, Qingxiao; Chen, Jing; Li, Yi; Zhang, Enfan; Gu, Huiyao; Xu, Ruyi; Liu, Yang; Cao, Wen; Zhang, Jinna; Cao, Liqin; He, Jingsong; Cai, Zhen			RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-kappa B and MAPK signaling pathways	ONCOGENE			English	Article							LARGE-CELL LYMPHOMA; GENE-EXPRESSION; MOLECULAR CLASSIFICATION; NUCLEAR-RNA; STEM-CELLS; LEUKEMIA; N6-METHYLADENOSINE; HYPERDIPLOIDY; METHYLATION; PROGRESSION	N-6-methyladenosine (m(6)A), an internal modification in mRNA, plays a critical role in regulating gene expression. Dysregulation of m(6)A modifiers promotes oncogenesis through enzymatic functions that disrupt the balance between the deposition and removal of m(6)A modification on critical transcripts. However, the roles of mRNA m(6)A in multiple myeloma (MM) are poorly understood. The present study showed that RNA demethylase ALKBH5 was overexpressed in MM and associated with a poor prognosis in MM patients. Knocking down ALKBH5 induced apoptosis and inhibited the growth of MM cells in vitro. Xenograft models and gene set enrichment analysis with patient transcriptome datasets also supported the oncogenic role of ALKBH5 in MM. Mechanistic studies showed that ALKBH5 exerted tumorigenic effects in myeloma in an m(6)A-dependent manner, and TNF receptor-associated factor 1 (TRAF1) was a critical target of ALKBH5. Specifically, ALKBH5 regulated TRAF1 expression via decreasing m(6)A abundance in the 3'-untranslated region (3'-UTR) of TRAF1 transcripts and enhancing TRAF1 mRNA stability. As a result, ALKBH5 promoted MM cell growth and survival through TRAF1-mediated activation of NF-kappa B and MAPK signaling pathways. Collectively, our data demonstrated that ALKBH5 played a critical role in MM tumorigenesis and suggested that ALKBH5 could be a novel therapeutic target in MM.	[Qu, Jianwei; Hou, Yifan; Chen, Qingxiao; Chen, Jing; Li, Yi; Zhang, Enfan; Gu, Huiyao; Xu, Ruyi; Liu, Yang; Cao, Wen; Zhang, Jinna; Cao, Liqin; He, Jingsong; Cai, Zhen] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Bone Marrow Transplantat Ctr, Hangzhou, Zhejiang, Peoples R China; [Cai, Zhen] Zhejiang Univ, Inst Hematol, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Cai, Z (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Sch Med, Bone Marrow Transplantat Ctr, Hangzhou, Zhejiang, Peoples R China.; Cai, Z (corresponding author), Zhejiang Univ, Inst Hematol, Hangzhou, Zhejiang, Peoples R China.	caiz@zju.edu.cn			National Natural Science Foundation of China [81800201, 81800202, 81872322]; Zhejiang Key Research and Development Project [2020C03014]; National Major Scientific and Technological Special Project for Significant New Drug Development [2018ZX09733-003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Key Research and Development Project; National Major Scientific and Technological Special Project for Significant New Drug Development	We thank the members of our laboratory for helpful discussions and assistance. This study was supported by grants from the National Natural Science Foundation of China (81800201, 81800202, and 81872322), the Zhejiang Key Research and Development Project (2020C03014), and the National Major Scientific and Technological Special Project for Significant New Drug Development (2018ZX09733-003).	Abate F, 2015, LEUKEMIA, V29, P1390, DOI 10.1038/leu.2014.347; Aik W, 2014, NUCLEIC ACIDS RES, V42, P4741, DOI 10.1093/nar/gku085; Alzrigat M, 2018, SEMIN CANCER BIOL, V51, P101, DOI 10.1016/j.semcancer.2017.09.007; Avet-Loiseau H, 2007, BLOOD, V109, P3489, DOI 10.1182/blood-2006-08-040410; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood-2009-12-261032; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chen Y, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01207-4; Chng W, 2006, LEUKEMIA, V20, P807, DOI 10.1038/sj.leu.2404172; Chretien ML, 2015, BLOOD, V126, P2713, DOI 10.1182/blood-2015-06-650242; Dixit D, 2021, CANCER DISCOV, V11, P480, DOI 10.1158/2159-8290.CD-20-0331; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626; Durkop H, 2003, J PATHOL, V200, P229, DOI 10.1002/path.1351; Edilova MI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02969; Feldman AL, 2013, GENE CHROMOSOME CANC, V52, P1097, DOI 10.1002/gcc.22104; Hao LL, 2021, AGING-US, V13, P4045, DOI 10.18632/aging.202371; Heuck CJ, 2014, LEUKEMIA, V28, P2410, DOI 10.1038/leu.2014.232; Hideshima T, 2021, CANCERS, V13, DOI 10.3390/cancers13020216; Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Jiang FJ, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01066-6; Kumar SK, 2018, NAT REV CLIN ONCOL, V15, P409, DOI 10.1038/s41571-018-0018-y; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; Li J, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01259-6; Li Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03763-z; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Mao SW, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04192-8; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Meyer KD, 2015, CELL, V163, P999, DOI 10.1016/j.cell.2015.10.012; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Mitchell JS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12050; Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood-2006-09-044974; Munzert G, 2002, BLOOD, V100, P3749, DOI 10.1182/blood.V100.10.3749; Pan YT, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0590-8; Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021; Pawlyn C, 2015, BLOOD, V125, P831, DOI 10.1182/blood-2014-07-584268; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Pinto V, 2020, CANCERS, V12, DOI 10.3390/cancers12020407; Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566; Ren ZH, 2019, BLOOD, V134, P1176, DOI 10.1182/blood.2019000578; Shen C, 2020, CELL STEM CELL, V27, P64, DOI 10.1016/j.stem.2020.04.009; Shen XD, 2021, FRONT GENET, V11, DOI 10.3389/fgene.2020.592042; Tarte K, 2003, BLOOD, V102, P592, DOI 10.1182/blood-2002-10-3161; Thalhammer A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016210; Todoerti K, 2013, CLIN CANCER RES, V19, P3247, DOI 10.1158/1078-0432.CCR-12-3461; van de Donk NWCJ, 2021, LANCET, V397, P410, DOI 10.1016/S0140-6736(21)00135-5; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang JZ, 2020, CELL STEM CELL, V27, P81, DOI 10.1016/j.stem.2020.04.001; Wang JY, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01807-0; Wang QS, 2018, CANCER RES, V78, P3982, DOI 10.1158/0008-5472.CAN-18-0429; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Weinhold N, 2016, BLOOD, V128, P1735, DOI 10.1182/blood-2016-06-723007; Wen XX, 2018, CLIN RESPIR J, V12, P2197, DOI 10.1111/crj.12789; Wu TF, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695930; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Yang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00980-5; Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580-019-0168-5; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zapata Juan M, 2002, Sci STKE, V2002, ppe27; Zhan FH, 2007, BLOOD, V109, P1692, DOI 10.1182/blood-2006-07-037077; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006; Zhu SN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02111	68	6	6	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					400	413		10.1038/s41388-021-02095-8	http://dx.doi.org/10.1038/s41388-021-02095-8		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34759347	Green Published, hybrid			2022-12-28	WOS:000716867900004
J	Arai, H; Elliott, A; Millstein, J; Xiu, J; Ou, FS; Innocenti, F; Wang, JY; Battaglin, F; Jayachandran, P; Kawanishi, N; Soni, S; Zhang, W; Sohal, D; Goldberg, RM; Hall, MJ; Scott, AJ; Khushman, M; Hwang, JJ; Lou, E; Weinberg, BA; Lockhart, AC; Shields, AF; Abraham, JP; Magee, D; Stafford, P; Zhang, J; Venook, AP; Korn, WM; Lenz, HJ				Arai, Hiroyuki; Elliott, Andrew; Millstein, Joshua; Xiu, Joanne; Ou, Fang-Shu; Innocenti, Federico; Wang, Jingyuan; Battaglin, Francesca; Jayachandran, Priya; Kawanishi, Natsuko; Soni, Shivani; Zhang, Wu; Sohal, Davendra; Goldberg, Richard M.; Hall, Michael J.; Scott, Aaron J.; Khushman, Mohd; Hwang, Jimmy J.; Lou, Emil; Weinberg, Benjamin A.; Lockhart, Albert Craig; Shields, Anthony Frank; Abraham, Jim P.; Magee, Daniel; Stafford, Phillip; Zhang, Jian; Venook, Alan P.; Korn, W. Michael; Lenz, Heinz-Josef			Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer	ONCOGENE			English	Article							EGFR INHIBITION; RESISTANCE; ACTIVATION; LANDSCAPE; CETUXIMAB; PATHWAY	Loss-of-function alterations of Neurofibromin 1 (NF1) activate RAS, a driver of colorectal cancer. However, the clinical implications of NF1 alterations are largely unknown. We performed a comprehensive molecular profiling of NF1-mutant colorectal cancer using data from 8150 patients included in a dataset of commercial CLIA-certified laboratory (Caris Life Sciences). In addition, NF1 expression levels were tested for associations with clinical outcomes using data from 431 patients in the CALGB/SWOG 80405 trial. In the Caris dataset, 2.2% of patients had pathogenic or presumed pathogenic NF1 mutations. NF1-mutant tumors more frequently harbored PIK3CA (25.0% vs. 16.7%) and PTEN mutations (24.0% vs. 4.2%) than wild type tumors. Gene set enrichment analysis revealed that MAPK and PI3K pathway signatures were enriched in NF1-mutant tumors. In the CALGB/SWOG 80405 cohort, low NF1 expression was associated with poor prognosis, and high NF1 expression was associated with better efficacy of cetuximab than bevacizumab. Together, we revealed concurrent genetic alterations in the PI3K pathways in NF1-mutant tumors, suggesting the need to simultaneously block MAPK and PI3K pathways in treatment. The potential of NF1 alteration as a novel biomarker for targeted therapy was highlighted, warranting further investigations in clinical settings.	[Arai, Hiroyuki; Wang, Jingyuan; Battaglin, Francesca; Jayachandran, Priya; Kawanishi, Natsuko; Soni, Shivani; Zhang, Wu; Lenz, Heinz-Josef] Univ Southern Calif, Div Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA; [Elliott, Andrew; Xiu, Joanne; Abraham, Jim P.; Magee, Daniel; Stafford, Phillip; Zhang, Jian; Korn, W. Michael] Caris Life Sci, Med Affairs, Clin & Translat Res, Phoenix, AZ USA; [Millstein, Joshua] Univ Southern Calif, Dept Prevent Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA; [Ou, Fang-Shu] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; [Innocenti, Federico] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA; [Sohal, Davendra] Univ Cincinnati, Div Hematol Oncol, Cincinnati, OH USA; [Goldberg, Richard M.] West Virginia Univ, Canc Inst, Morgantown, WV 26506 USA; [Hall, Michael J.] Fox Chase Canc Ctr, Dept Clin Genet, Philadelphia, PA 19111 USA; [Scott, Aaron J.] Banner Univ Arizona, Dept Med, Div Hematol & Oncol, Tucson, AZ USA; [Khushman, Mohd] Univ S Alabama, Mitchell Canc Inst, Med Oncol, Mobile, AL 36688 USA; [Hwang, Jimmy J.] Levine Canc Inst, GI Med Oncol, Dept Solid Tumor Oncol, Charlotte, NC USA; [Lou, Emil] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA; [Weinberg, Benjamin A.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC USA; [Lockhart, Albert Craig] Univ Miami, Miller Sch Med, Dept Med, Div Oncol, Miami, FL 33136 USA; [Shields, Anthony Frank] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA; [Venook, Alan P.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA	University of Southern California; University of Southern California; Mayo Clinic; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; University of Cincinnati; West Virginia University; Fox Chase Cancer Center; University of Arizona; University of South Alabama; University of Minnesota System; University of Minnesota Twin Cities; Georgetown University; University of Miami; Barbara Ann Karmanos Cancer Institute; Wayne State University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Lenz, HJ (corresponding author), Univ Southern Calif, Div Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA.	lenz@usc.edu	Battaglin, Francesca/C-2746-2017	Battaglin, Francesca/0000-0002-9869-0163; Arai, Hiroyuki/0000-0002-1886-7070	National Cancer Institute of the National Institutes of Health [U10CA180821, U10CA180882, UG1CA233163, P30CA 014089]; Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Victoria and Philip Wilson Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; Bristol-Myers Squibb; Genentech; Pfizer	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Victoria and Philip Wilson Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; Bristol-Myers Squibb(Bristol-Myers Squibb); Genentech(Roche HoldingGenentech); Pfizer(Pfizer)	We thank all patients who contributed to this study. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), UG1CA233163, P30CA 014089 [to H-JL], Gloria Borges WunderGlo Foundation, Dhont Family Foundation, Victoria and Philip Wilson Research Fund, San Pedro Peninsula Cancer Guild, and Daniel Butler Research Fund. Also supported in part by funds from Bristol-Myers Squibb, Genentech, and Pfizer. tThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Arai H, 2021, CLIN CANCER RES, V27, P3234, DOI 10.1158/1078-0432.CCR-20-3635; Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969; Campbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; Diez D, 2011, NUCLEIC ACIDS RES, V39, P5526, DOI 10.1093/nar/gkr154; Georgiou A, 2020, MOL CANCER RES, V18, P835, DOI 10.1158/1541-7786.MCR-19-1201; Kumagai Shogo, 2021, Nat Rev Cancer, V21, P181, DOI 10.1038/s41568-020-00322-0; Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125; Maertens O, 2014, CANCER DISCOV, V4, P519, DOI 10.1158/2159-8290.CD-14-0286; Magnuson AM, 2018, P NATL ACAD SCI USA, V115, pE10672, DOI 10.1073/pnas.1810580115; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mauri G, 2020, ANN ONCOL, V31, P1135, DOI 10.1016/j.annonc.2020.05.027; Moore AR, 2020, NAT REV DRUG DISCOV, V19, P533, DOI 10.1038/s41573-020-0068-6; Post Jasmin B, 2019, Oncotarget, V10, P1440, DOI 10.18632/oncotarget.26677; Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4; Rad E, 2016, SEMIN CELL DEV BIOL, V52, P39, DOI 10.1016/j.semcdb.2016.02.007; Riaz N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00921-w; Sepulveda AR, 2017, J CLIN ONCOL, V35, P1453, DOI 10.1200/JCO.2016.71.9807; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Vanderwalde A, 2018, CANCER MED-US, V7, P746, DOI 10.1002/cam4.1372; Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105; Vidotto T, 2020, BRIT J CANCER, V122, P1732, DOI 10.1038/s41416-020-0834-6; Wagle MC, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0051-4; Woolston A, 2019, CANCER CELL, V36, P35, DOI 10.1016/j.ccell.2019.05.013	25	4	4	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					260	267		10.1038/s41388-021-02074-z	http://dx.doi.org/10.1038/s41388-021-02074-z		NOV 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34728807	Green Accepted			2022-12-28	WOS:000713936100002
J	Hua, QL; Zhang, BY; Xu, GJ; Wang, LQ; Wang, HH; Lin, ZY; Yu, DD; Ren, JH; Zhang, DJ; Zhao, L; Zhang, T				Hua, Qingling; Zhang, Biying; Xu, Guojie; Wang, Lanqing; Wang, Haihong; Lin, Zhenyu; Yu, Dandan; Ren, Jinghua; Zhang, Dejun; Zhao, Lei; Zhang, Tao			CEMIP, a novel adaptor protein of OGT, promotes colorectal cancer metastasis through glutamine metabolic reprogramming via reciprocal regulation of beta-catenin	ONCOGENE			English	Article							O-GLCNACYLATION; COLON-CANCER; EXPRESSION; KIAA1199; LOCALIZATION; TRANSDUCTION; TRANSPORTER; REVEALS; SLC1A5; GENE	Metastasis is the leading cause of colorectal cancer (CRC)-induced death. However, the underlying molecular mechanisms of CRC metastasis are poorly understood. Metabolic reprogramming is an intrinsic feature of cancer, which have complicated effects on cancer metastasis. Here, we find that a novel metastasis-related protein, cell migration-inducing and hyaluronan-binding protein (CEMIP), can act as a novel adaptor protein of O-GlcNAc transferase (OGT) to promote CRC metastasis through glutamine metabolic reprogramming. Mechanistically, CEMIP interacts with OGT and beta-catenin, which leads to elevated O-GlcNAcylation of beta-catenin and enhanced beta-catenin nuclear translocation from cytomembrane. Furthermore, accumulated beta-catenin in nucleus enhances the transcription of CEMIP to reciprocally regulate beta-catenin and contributes to over-expression of glutaminase 1 and glutamine transporters (SLC1A5 and SLC38A2). Combinational inhibition of CEMIP and glutamine metabolism could dramatically attenuate the metastasis of CRC in vivo. Collectively, this study reveals the importance of glutamine metabolic reprogramming in CEMIP-induced CRC metastasis, indicating the great potential of CEMIP and glutamine metabolism for CRC metastasis prevention.	[Hua, Qingling; Zhang, Biying; Xu, Guojie; Wang, Lanqing; Wang, Haihong; Lin, Zhenyu; Yu, Dandan; Ren, Jinghua; Zhang, Dejun; Zhao, Lei; Zhang, Tao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China	Huazhong University of Science & Technology	Zhao, L; Zhang, T (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China.	zhaolei8704@126.com; taozhangxh@hust.edu.cn		Hua, Qingling/0000-0002-4708-987X	National Natural Science Foundation of China [81874061, 81702392, 81903103]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work is supported by the National Natural Science Foundation of China (81874061 to TZ, 81702392 to LZ, and 81903103 to DZ).	Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Birkenkamp-Demtroder K, 2011, BRIT J CANCER, V105, P552, DOI 10.1038/bjc.2011.268; Broer A, 2016, J BIOL CHEM, V291, P13194, DOI 10.1074/jbc.M115.700534; Chen C, 2014, INT J CLIN EXP MED, V7, P4253; Cheung WD, 2008, J BIOL CHEM, V283, P13009, DOI 10.1074/jbc.M801222200; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Ding MC, 2020, INT J BIOL SCI, V16, P3100, DOI 10.7150/ijbs.48066; Evensen NA, 2013, JNCI-J NATL CANCER I, V105, P1402, DOI 10.1093/jnci/djt224; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gao SC, 2019, DNA CELL BIOL, V38, P286, DOI 10.1089/dna.2018.4447; Ha JR, 2014, EXP CELL RES, V321, P153, DOI 10.1016/j.yexcr.2013.11.021; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Duong HQ, 2018, CANCER RES, V78, P4533, DOI 10.1158/0008-5472.CAN-17-3149; Kasprowicz A, 2020, MOLECULES, V25, DOI 10.3390/molecules25194501; Liang GD, 2018, ACTA HISTOCHEM, V120, P56, DOI 10.1016/j.acthis.2017.11.002; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Mafra ACP, 2019, CANCER RES, V79, P1302, DOI 10.1158/0008-5472.CAN-19-0313; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morotti M, 2021, BRIT J CANCER, V124, P494, DOI 10.1038/s41416-020-01113-y; Naka Y, 2020, ONCOL LETT, V20, P1171, DOI 10.3892/ol.2020.11665; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Sayat R, 2008, EXP CELL RES, V314, P2774, DOI 10.1016/j.yexcr.2008.05.017; Schild T, 2018, CANCER CELL, V33, P347, DOI 10.1016/j.ccell.2018.02.001; Schulte ML, 2018, NAT MED, V24, P194, DOI 10.1038/nm.4464; Sharma NS, 2020, J CLIN INVEST, V130, P451, DOI 10.1172/JCI127515; Shen YA, 2020, CANCER RES, V80, P4514, DOI 10.1158/0008-5472.CAN-19-3971; Shostak K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6232; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stichelen SOV, 2012, AM J PHYSIOL-ENDOC M, V302, pE417, DOI 10.1152/ajpendo.00390.2011; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tiwari A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069473; Wei QY, 2020, ONCOGENE, V39, P6139, DOI 10.1038/s41388-020-01432-7; Yoo HC, 2020, CELL METAB, V31, P267, DOI 10.1016/j.cmet.2019.11.020; Yoshida H, 2013, P NATL ACAD SCI USA, V110, P5612, DOI 10.1073/pnas.1215432110; Zhang DJ, 2017, INT J CANCER, V140, P2298, DOI 10.1002/ijc.30656; Zhang P, 2018, FASEB J, V32, P3924, DOI 10.1096/fj.201701078R; Zhang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00990-3; Zhao L, 2019, ONCOGENE, V38, P935, DOI 10.1038/s41388-018-0493-8; Zhou L, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152681	45	7	7	5	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6443	6455		10.1038/s41388-021-02023-w	http://dx.doi.org/10.1038/s41388-021-02023-w		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34608265				2022-12-28	WOS:000703526900002
J	Ling, H; Cao, CH; Han, K; Lv, YR; Ma, XD; Cao, JH; Chen, JW; Li, S; Lin, JL; Fang, YJ; Pan, ZZ; Xie, D; Wang, FW				Ling, Han; Cao, Chen-Hui; Han, Kai; Lv, Yong-Rui; Ma, Xiao-Dan; Cao, Jing-Hua; Chen, Jie-Wei; Li, Si; Lin, Jin-Long; Fang, Yu-Jing; Pan, Zhi-Zhong; Xie, Dan; Wang, Feng-Wei			CEP63 upregulates YAP1 to promote colorectal cancer progression through stabilizing RNA binding protein FXR1	ONCOGENE			English	Article							MESSENGER-RNA; CHROMOSOME SEGREGATION; CENTROSOME; TRANSLATION; COMPLEX	Abnormal regulation of centrosome components can induce chromosome instability and tumorigenesis. Centrosomal protein 63 (CEP63) is a vital member for assembling centrosome. Yet, the involvement of CEP63 in cancer pathogenesis remains unclear. Here we identify CEP63 as an important mediator for RNA-binding proteins (RBPs) to facilitate regulation on their RNA targets in colorectal cancer (CRC). We demonstrate that CEP63 protein is upregulated in a large cohort of colorectal cancer tissues and predicts poor prognosis, and USP36 is identified for stabilizing CEP63 by enhancing its K48-dependent deubiquitination. CEP63 overexpression promotes the proliferation and tumor growth of CRC cells in vitro and in vivo. Furthermore, we find that CEP63 can promote cancer stem-like cell properties by enhancing YAP1 expression through binding with and inhibiting the K63-ubiquitylation degradation of RBP FXR1 in CRC cells. Importantly, we further verify that the KH domain of FXR1 is necessary for the interaction between CEP63 and FXR1. Moreover, microtube motor proteins can form a complex with CEP63 and FXR1 to mediate the regulation of FXR1 on RNA targets. Additionally, we also confirm that CEP63 can bind and regulate multiple RBPs. In conclusion, our findings unveil an unrecognized CEP63/RBPs/RNA axis that CEP63 may perform as an adapter facilitating the formation of RBPs complex to regulate RNA progression and discover the role of CEP63 involved in signal transduction and RNA regulation, providing potential therapeutic target for CRC patients.	[Ling, Han; Cao, Chen-Hui; Han, Kai; Lv, Yong-Rui; Ma, Xiao-Dan; Cao, Jing-Hua; Chen, Jie-Wei; Li, Si; Lin, Jin-Long; Fang, Yu-Jing; Pan, Zhi-Zhong; Xie, Dan; Wang, Feng-Wei] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Cao, Chen-Hui] Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Sichuan Canc Hosp & Inst,Integrat Canc Ctr, Chengdu 610041, Peoples R China; [Cao, Chen-Hui] Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Sichuan Canc Hosp & Inst,Canc Clin Res Ctr, Chengdu 610041, Peoples R China; [Han, Kai; Fang, Yu-Jing; Pan, Zhi-Zhong] Sun Yat Sen Univ, Canc Ctr, Dept Colorectal Surg, Guangzhou 510060, Peoples R China; [Chen, Jie-Wei; Xie, Dan] Sun Yat Sen Univ, Canc Ctr, Dept Pathol, Guangzhou 510060, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; University of Electronic Science & Technology of China; University of Electronic Science & Technology of China; Sun Yat Sen University; Sun Yat Sen University	Xie, D; Wang, FW (corresponding author), Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ, Canc Ctr, Dept Pathol, Guangzhou 510060, Peoples R China.	xiedan@sysucc.org.cn; wangfengw@sysucc.org.cn			National Key R&D Program of China [2021YFA1300201]; National Natural Science Foundation of China [81972227, 81730072, 82072608, 81872001, 81903007, 82002467]; Guangzhou Science and Technology Plan Projects [201904020044]; China Postdoctoral Science Foundation [2020M672999]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Plan Projects; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from the National Key R&D Program of China (grant number 2021YFA1300201); the National Natural Science Foundation of China (grant numbers 81972227, 81730072, 82072608, 81872001, 81903007 and 82002467); the Guangzhou Science and Technology Plan Projects (grant number 201904020044) and the China Postdoctoral Science Foundation (2020M672999).	Agote-Aran A, 2020, EMBO J, V39, DOI 10.15252/embj.2020104467; Auslander D, 2018, NAT METHODS, V15, P57, DOI [10.1038/NMETH.4505, 10.1038/nmeth.4505]; Boo SH, 2020, EXP MOL MED, V52, P400, DOI 10.1038/s12276-020-0407-z; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown NJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069986; Cai Z, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.674933; Conduit PT, 2015, NAT REV MOL CELL BIO, V16, P611, DOI 10.1038/nrm4062; De Simone A, 2016, CELL REP, V14, P2250, DOI 10.1016/j.celrep.2016.01.077; Denes LT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26383-9; Dockendorff TC, 2019, MOL NEUROBIOL, V56, P711, DOI 10.1007/s12035-018-1122-9; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Dumont J, 2012, TRENDS CELL BIOL, V22, P241, DOI 10.1016/j.tcb.2012.02.007; Eliscovich C, 2013, J BIOL CHEM, V288, P20361, DOI 10.1074/jbc.R113.452094; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Fallmann J, 2016, NUCLEIC ACIDS RES, V44, pD90, DOI 10.1093/nar/gkv1238; Farina F, 2016, NAT CELL BIOL, V18, P65, DOI 10.1038/ncb3285; Frederick MI, 2021, BIOL CHEM, V402, P425, DOI 10.1515/hsz-2020-0325; Giampetruzzi A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11837-y; Gurkaslar HK, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107630; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; Herman AB, 2018, CELL REP, V24, P1176, DOI 10.1016/j.celrep.2018.07.002; Hirokawa N, 2006, J NEUROSCI, V26, P7139, DOI 10.1523/JNEUROSCI.1821-06.2006; Honda S, 2017, ONCOTARGET, V8, P14277, DOI 10.18632/oncotarget.15362; Hong AW, 2016, NAT REV GASTRO HEPAT, V13, P324, DOI 10.1038/nrgastro.2016.59; Jayaraman D, 2016, NEURON, V92, P813, DOI 10.1016/j.neuron.2016.09.056; Ke WL, 2022, BIOENGINEERED, V13, P5443, DOI 10.1080/21655979.2022.2030572; Kim TS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08838-2; Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Liu Q, 2019, BIOCHEM BIOPH RES CO, V513, P502, DOI 10.1016/j.bbrc.2019.03.043; Loffler H, 2011, CANCER RES, V71, P2129, DOI 10.1158/0008-5472.CAN-10-2684; Lukinaviclus G, 2013, CURR BIOL, V23, P265, DOI 10.1016/j.cub.2012.12.030; Madiraju C, 2022, TRENDS IMMUNOL, V43, P148, DOI 10.1016/j.it.2021.12.005; Marjanovic M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8676; Mondal T, 2018, CANCER CELL, V33, P417, DOI 10.1016/j.ccell.2018.01.020; Ohtake F, 2018, P NATL ACAD SCI USA, V115, pE1401, DOI 10.1073/pnas.1716673115; Peng F, 2021, CELL RES, V31, P345, DOI 10.1038/s41422-020-00397-2; Richards J, 2021, MOL MICROBIOL, V116, P361, DOI 10.1111/mmi.14723; Rowinsky EK, 2020, INVEST NEW DRUG, V38, P1448, DOI 10.1007/s10637-020-00915-4; SANTIAGO TC, 1987, NUCLEIC ACIDS RES, V15, P2417, DOI 10.1093/nar/15.6.2417; Say E, 2010, MOL CELL, V38, P236, DOI 10.1016/j.molcel.2010.04.004; Schaeffer C, 2003, BIOL CELL, V95, P221, DOI 10.1016/S0248-4900(03)00037-6; Sir JH, 2011, NAT GENET, V43, P1147, DOI 10.1038/ng.971; Turner-Bridger B, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200177; Uchida Y, 2019, J BIOCHEM, V166, P375, DOI 10.1093/jb/mvz067; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; Vasudevan S, 2007, CELL, V128, P1105, DOI 10.1016/j.cell.2007.01.038; Watanabe Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13508; Wei Z, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00535-19; Xia WL, 2018, J CELL BIOL, V217, P3464, DOI 10.1083/jcb.201801143; Xu N, 2020, CIRC RES, V126, P907, DOI 10.1161/CIRCRESAHA.119.316444; Yan YL, 2020, NUCLEIC ACIDS RES, V48, P12711, DOI 10.1093/nar/gkaa1090; Zhang JY, 2019, CANCER LETT, V440, P106, DOI 10.1016/j.canlet.2018.10.010	53	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4433	4445		10.1038/s41388-022-02439-y	http://dx.doi.org/10.1038/s41388-022-02439-y		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	35989368				2022-12-28	WOS:000842428900001
J	Diskin, B; Adam, S; Soto, GS; Liria, M; Aykut, B; Sundberg, B; Li, E; Leinwand, J; Chen, R; Kim, M; Salas, RD; Cassini, MF; Buttar, C; Wang, W; Farooq, MS; Shadaloey, SAA; Werba, G; Fnu, A; Yang, F; Hirsch, C; Glinski, J; Panjwani, A; Weitzner, Y; Cohen, D; Miller, G				Diskin, Brian; Adam, Salma; Soto, Gustavo Sanchez; Liria, Miguel; Aykut, Berk; Sundberg, Belen; Li, Eric; Leinwand, Joshua; Chen, Ruonan; Kim, Mirhee; Salas, Ruben D.; Cassini, Marcelo F.; Buttar, Chandan; Wang, Wei; Farooq, Mohammad Saad; Shadaloey, Sorin A. A.; Werba, Gregor; Fnu, Amreek; Yang, Fan; Hirsch, Carolina; Glinski, John; Panjwani, Angilee; Weitzner, Yael; Cohen, Deirdre; Miller, George			BTLA(+)CD200(+) B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer	ONCOGENE			English	Article							LIVER; ONCOGENESIS; RESPONSES; NICHE	Response to cancer immunotherapy in primary versus metastatic disease has not been well-studied. We found primary pancreatic ductal adenocarcinoma (PDA) is responsive to diverse immunotherapies whereas liver metastases are resistant. We discovered divergent immune landscapes in each compartment. Compared to primary tumor, liver metastases in both mice and humans are infiltrated by highly anergic T cells and MHCII(lo)IL10(+) macrophages that are unable to present tumor-antigen. Moreover, a distinctive population of CD24(+)CD44(-)CD40(-) B cells dominate liver metastases. These B cells are recruited to the metastatic milieu by Muc1(hi)IL18(hi) tumor cells, which are enriched >10-fold in liver metastases. Recruited B cells drive macrophage-mediated adaptive immune-tolerance via CD200 and BTLA. Depleting B cells or targeting CD200/BTLA enhanced macrophage and T-cell immunogenicity and enabled immunotherapeutic efficacy of liver metastases. Our data detail the mechanistic underpinnings for compartment-specific immunotherapy-responsiveness and suggest that primary PDA models are poor surrogates for evaluating immunity in advanced disease.	[Diskin, Brian; Adam, Salma; Soto, Gustavo Sanchez; Liria, Miguel; Aykut, Berk; Sundberg, Belen; Li, Eric; Leinwand, Joshua; Chen, Ruonan; Kim, Mirhee; Salas, Ruben D.; Cassini, Marcelo F.; Buttar, Chandan; Wang, Wei; Farooq, Mohammad Saad; Shadaloey, Sorin A. A.; Werba, Gregor; Fnu, Amreek; Yang, Fan; Hirsch, Carolina; Glinski, John; Panjwani, Angilee; Weitzner, Yael; Miller, George] NYU, Dept Surg, SA Localio Lab, Sch Med, New York, NY 10016 USA; [Cohen, Deirdre] NYU, Sch Med, Dept Med, New York, NY USA; [Miller, George] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; [Miller, George] Trinity Hlth New England, Waterbury, CT 06706 USA	New York University; New York University; New York University	Miller, G (corresponding author), NYU, Dept Surg, SA Localio Lab, Sch Med, New York, NY 10016 USA.; Miller, G (corresponding author), NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.; Miller, G (corresponding author), Trinity Hlth New England, Waterbury, CT 06706 USA.	gedalyamil@gmail.com		Aykut, Berk/0000-0001-8343-4258; Salas Parra, Ruben Dario/0000-0002-8960-266X	American College of Surgeons Resident Research Fellowship; Deutsche Forschungsgemeinschaft [AY 126/1-1]; NIH [CA168611, CA203105, CA215471, CA19311, DK106025]	American College of Surgeons Resident Research Fellowship; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the American College of Surgeons Resident Research Fellowship (BD), Deutsche Forschungsgemeinschaft grant AY 126/1-1 (BA), and NIH grants CA168611 (DC, GM), CA203105 (GM), CA215471 (GM), CA19311 (GM), and DK106025 (GM).	Bodogai M, 2015, CANCER RES, V75, P3456, DOI 10.1158/0008-5472.CAN-14-3077; Canning C, 2006, IMMUNOL LETT, V107, P83, DOI 10.1016/j.imlet.2006.07.002; Chen J, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/8282391; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Daley D, 2017, J EXP MED, V214, P1711, DOI 10.1084/jem.20161707; Daley D, 2017, NAT MED, V23, P556, DOI 10.1038/nm.4314; Daley D, 2016, CELL, V166, P1485, DOI 10.1016/j.cell.2016.07.046; Disibio G, 2008, ARCH PATHOL LAB MED, V132, P931, DOI 10.1043/1543-2165(2008)132[931:MPOCRF]2.0.CO;2; Enoksson SL, 2011, P NATL ACAD SCI USA, V108, pE1399, DOI 10.1073/pnas.1107830108; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Grunwald B, 2016, GASTROENTEROLOGY, V151, P1011, DOI 10.1053/j.gastro.2016.07.043; Gunderson AJ, 2016, CANCER DISCOV, V6, P270, DOI 10.1158/2159-8290.CD-15-0827; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Liu Y, 2016, J MOL MED, V94, P509, DOI 10.1007/s00109-015-1376-x; Mieli-Vergani G, 2018, NAT REV DIS PRIMERS, V4, DOI [10.1038/nrdp.2018.17, 10.1038/nrdp.2018.18]; Moini M, 2015, WORLD J HEPATOL, V7, P1355, DOI 10.4254/wjh.v7.i10.1355; Nielsen SR, 2016, NAT CELL BIOL, V18, P549, DOI 10.1038/ncb3340; Pylayeva-Gupta Y, 2016, CANCER DISCOV, V6, P247, DOI 10.1158/2159-8290.CD-15-0843; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Seifert L, 2016, NATURE, V532, P245, DOI 10.1038/nature17403; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Wang Wei, 2018, Cancer Cell, V34, P757, DOI 10.1016/j.ccell.2018.10.006; Wrenshall LE, 2001, TRANSPLANTATION, V71, P841, DOI 10.1097/00007890-200104150-00004; Yachida S, 2009, ARCH PATHOL LAB MED, V133, P413, DOI 10.1043/1543-2165-133.3.413; Zhao Y., 2018, ONCOTARGET, V9, P14803, DOI [10.18632/oncotarget.22976, DOI 10.18632/ONCOTARGET.22976]; Zhu Y, 2017, IMMUNITY, V47, P323, DOI 10.1016/j.immuni.2017.07.014	28	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4349	4360		10.1038/s41388-022-02425-4	http://dx.doi.org/10.1038/s41388-022-02425-4		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35948648				2022-12-28	WOS:000838482900002
J	Zheng, XC; Liu, ZF; Zhong, JL; Zhou, LW; Chen, JW; Zheng, LS; Li, ZY; Zhang, RH; Pan, JX; Wu, YZ; Liu, ZW; Kang, TB				Zheng, Xianchong; Liu, Zefu; Zhong, Jianliang; Zhou, Liwen; Chen, Jiawei; Zheng, Lisi; Li, Zhiyong; Zhang, Ruhua; Pan, Jingxuan; Wu, Yuanzhong; Liu, Zhuowei; Kang, Tiebang			Downregulation of HINFP induces senescence-associated secretory phenotype to promote metastasis in a non-cell-autonomous manner in bladder cancer	ONCOGENE			English	Article							C-MYC; EXPRESSION; IDENTIFICATION; CISPLATIN	Transcription dysregulation is a salient characteristic of bladder cancer (BC), but no appropriate therapeutic target for it has been established. Here, we found that heterogeneous downregulation of histone H4 transcription factor (HINFP) was associated with senescence in BC tissues and that lower HINFP expression could predict an unfavorable outcome in BC patients. Knockout of HINFP transcriptionally inhibited H1F0 and H1FX to trigger DNA damage, consequently inducing cell senescence to repress the proliferation and growth of BC cells. However, the senescence-associated secretory phenotype, characterized by increases in MMP1/3, enhances the invasion and metastasis of non-senescent BC cells. Histone deacetylase inhibitors (HDACis) could efficiently eliminate the senescent cells induced by HINFP knockout to suppress the invasion and metastasis of BC cells. Our study suggests that HDACis, widely used in multiple cancer types in a clinical context, may also benefit BC patients with metastases induced by cell senescence.	[Zheng, Xianchong; Liu, Zefu; Zhong, Jianliang; Zhou, Liwen; Chen, Jiawei; Zheng, Lisi; Zhang, Ruhua; Wu, Yuanzhong; Liu, Zhuowei; Kang, Tiebang] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Zheng, Xianchong; Liu, Zefu; Chen, Jiawei; Li, Zhiyong; Liu, Zhuowei] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Peoples R China; [Pan, Jingxuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Wu, YZ; Liu, ZW; Kang, TB (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China.; Liu, ZW (corresponding author), Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Peoples R China.	wuyzh@sysucc.org.cn; liuzhw@sysucc.org.cn; kangtb@sysucc.org.cn		Wu, Yuanzhong/0000-0002-3577-7069; Kang, Tiebang/0000-0001-8805-4174	National Key Research and Development Program of China [2021YFA1300601, 2020YFA0509400]; National Nature Science Foundation of China (NSFC) [82030090, 82073103, 82103264, 82172939, 82002917]; Science and Technology Program of Guangzhou [202002020092]	National Key Research and Development Program of China; National Nature Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangzhou	We thank Dr. Meisongzhu Yang from SYSUCC for her help in constructing the animal models and Dr. Jietian Jin from SYSUCC for help with pathological diagnosis. This work was supported by grants from the National Key Research and Development Program of China (2021YFA1300601 to TK, 2020YFA0509400 to JP), the National Nature Science Foundation of China (NSFC) (82030090 to TK, 82073103 to ZWL, 82103264 to XCZ, 82172939 to YW, 82002917 to LWZ), and the Science and Technology Program of Guangzhou (202002020092).	Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Brooks TA, 2009, NAT REV CANCER, V9, P849, DOI 10.1038/nrc2733; Cai YS, 2020, CELL RES, V30, P574, DOI 10.1038/s41422-020-0314-9; Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Faget DV, 2019, NAT REV CANCER, V19, P439, DOI 10.1038/s41568-019-0156-2; Fane M, 2020, NAT REV CANCER, V20, P89, DOI 10.1038/s41568-019-0222-9; Funayama R, 2006, J CELL BIOL, V175, P869, DOI 10.1083/jcb.200604005; Ghule PN, 2016, DEV BIOL, V419, P311, DOI 10.1016/j.ydbio.2016.09.003; Guccini I, 2021, CANCER CELL, V39, P68, DOI 10.1016/j.ccell.2020.10.012; Guo YX, 2020, CELL DEATH DIFFER, V27, P1862, DOI 10.1038/s41418-019-0466-7; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hayden A, 2014, UROL ONCOL-SEMIN ORI, V32, P806, DOI 10.1016/j.urolonc.2014.02.006; Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8; Kim YH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15208; Koike-Yusa H, 2014, NAT BIOTECHNOL, V32, P267, DOI 10.1038/nbt.2800; Li C, 2002, J AM COLL CARDIOL, V39, P1852, DOI 10.1016/S0735-1097(02)01873-9; Liu LJ, 2011, GENE, V483, P1, DOI 10.1016/j.gene.2011.05.002; Milanovic M, 2018, TRENDS CELL BIOL, V28, P1049, DOI 10.1016/j.tcb.2018.09.001; Sardi I, 1998, EUR UROL, V33, P424, DOI 10.1159/000019629; SchmitzDrager BJ, 1997, UROL RES, V25, pS45, DOI 10.1007/BF00942047; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Sieben CJ, 2018, TRENDS CELL BIOL, V28, P723, DOI 10.1016/j.tcb.2018.04.006; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stein JP, 2006, WORLD J UROL, V24, P296, DOI 10.1007/s00345-006-0061-7; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Sun Y, 2018, TRENDS MOL MED, V24, P871, DOI 10.1016/j.molmed.2018.08.002; Valencia AM, 2019, NAT CELL BIOL, V21, P152, DOI 10.1038/s41556-018-0258-1; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Wang LQ, 2018, CELL, V173, P1413, DOI 10.1016/j.cell.2018.04.012; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Watanabe S, 2017, CANCER SCI, V108, P563, DOI 10.1111/cas.13184; Xie RL, 2009, P NATL ACAD SCI USA, V106, P12359, DOI 10.1073/pnas.0905651106; Xu Y, 2017, DRUG TODAY, V53, P167, DOI 10.1358/dot.2017.53.3.2595452; Zhang Z, 2007, HUM PATHOL, V38, P598, DOI 10.1016/j.humpath.2006.10.004; Zhou YX, 2014, NATURE, V509, P487, DOI 10.1038/nature13166	38	2	2	5	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3587	3598		10.1038/s41388-022-02371-1	http://dx.doi.org/10.1038/s41388-022-02371-1		JUN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35668172				2022-12-28	WOS:000806674700001
J	Lorenzo-Martin, LF; Menacho-Marquez, M; Fernandez-Parejo, N; Rodriguez-Fdez, S; Pascual, G; Abad, A; Crespo, P; Dosil, M; Benitah, SA; Bustelo, XR				Francisco Lorenzo-Martin, L.; Menacho-Marquez, Mauricio; Fernandez-Parejo, Natalia; Rodriguez-Fdez, Sonia; Pascual, Gloria; Abad, Antonio; Crespo, Piero; Dosil, Mercedes; Benitah, Salvador A.; Bustelo, Xose R.			The Rho guanosine nucleotide exchange factors Vav2 and Vav3 modulate epidermal stem cell function	ONCOGENE			English	Article							HAIR FOLLICLE; ENRICHMENT ANALYSIS; IN-VIVO; RAC1; DIFFERENTIATION; TRANSCRIPTION; PROTEINS; DELETION; TURNOVER; PROGRAM	It is known that Rho GTPases control different aspects of the biology of skin stem cells (SSCs). However, little information is available on the role of their upstream regulators under normal and tumorigenic conditions in this process. To address this issue, we have used here mouse models in which the activity of guanosine nucleotide exchange factors of the Vav subfamily has been manipulated using both gain- and loss-of-function strategies. These experiments indicate that Vav2 and Vav3 regulate the number, functional status, and responsiveness of hair follicle bulge stem cells. This is linked to gene expression programs related to the reinforcement of the identity and the quiescent state of normal SSCs. By contrast, in the case of cancer stem cells, they promote transcriptomal programs associated with the identity, activation state, and cytoskeletal remodeling. These results underscore the role of these Rho exchange factors in the regulation of normal and tumor epidermal stem cells.	[Francisco Lorenzo-Martin, L.; Menacho-Marquez, Mauricio; Fernandez-Parejo, Natalia; Rodriguez-Fdez, Sonia; Abad, Antonio; Dosil, Mercedes; Bustelo, Xose R.] Univ Salamanca, Ctr Invest Canc, CSIC, Mol Mech Canc Program, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Menacho-Marquez, Mauricio; Fernandez-Parejo, Natalia; Rodriguez-Fdez, Sonia; Abad, Antonio; Dosil, Mercedes; Bustelo, Xose R.] Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Menacho-Marquez, Mauricio; Abad, Antonio; Crespo, Piero; Dosil, Mercedes; Bustelo, Xose R.] Ctr Invest Biomed Red Canc CIBERONC, Salamanca 37007, Spain; [Pascual, Gloria; Benitah, Salvador A.] Inst Reserca Biomed, Barcelona 08028, Spain; [Crespo, Piero] Univ Cantabria, Inst Biomed & Biotecnol Cantabria, CSIC, Santander 39011, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC)	Bustelo, XR (corresponding author), Univ Salamanca, Ctr Invest Canc, CSIC, Mol Mech Canc Program, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Salamanca 37007, Spain.	xbustelo@usal.es	; Bustelo, Xose R./A-9526-2010; Dosil, Mercedes/A-9536-2016; Aznar Benitah, Salvador/F-4761-2016; Crespo, Piero/M-3273-2014	Rodriguez-Fdez, Sonia/0000-0001-5369-2969; Lorenzo-Martin, L. Francisco/0000-0003-4717-9338; Bustelo, Xose R./0000-0001-9398-6072; Abad de Blas, Antonio Luis/0000-0001-8019-2775; Dosil, Mercedes/0000-0001-8119-8263; Aznar Benitah, Salvador/0000-0002-9059-5049; Crespo, Piero/0000-0003-2825-7783	Worldwide Cancer Research [14-1248, RTI2018-096481-B-100, MCIN/AEI/10.13039/501100011033]; European Research Development Fund "A way of making Europe" of the European Union; Spanish Association against Cancer [GC16173472GARC]; Castilla-Leon autonomous government [CSI252P18, CSI145P20, CLC-2017-01]; "la Caixa" Banking Foundation [HR20-00164]; Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government [CLC-2017-01]; Spanish Ministry of Education, Culture and Sports [MCIN/AEI/10.13039/501100011033, CLC-2017-01, FPU13/02923, BES-2013-063573]; European Social Fund "Investing in your future" of the European Union; European Regional Development Fund	Worldwide Cancer Research; European Research Development Fund "A way of making Europe" of the European Union; Spanish Association against Cancer; Castilla-Leon autonomous government; "la Caixa" Banking Foundation(La Caixa Foundation); Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government; Spanish Ministry of Education, Culture and Sports(Spanish Government); European Social Fund "Investing in your future" of the European Union; European Regional Development Fund(European Commission)	We thank M. Blazquez and the personnel of the CIC Flow Cytometry, Microscopy, Pathology and Genomics Units for expert technical work. The X.R.B.'s project leading to these results has received funding from Worldwide Cancer Research (14-1248), the RTI2018-096481-B-100 grant cofunded by MCIN/AEI/10.13039/501100011033 and the European Research Development Fund "A way of making Europe" of the European Union, the Spanish Association against Cancer (GC16173472GARC), the Castilla-Leon autonomous government (CSI252P18, CSI145P20, CLC-2017-01), and "la Caixa" Banking Foundation (HR20-00164). X.R.B.'s institution is supported by the Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government (CLC-2017-01) L.F.L.-M. contract has been mostly supported by funding from the Spanish Ministry of Education, Culture and Sports (FPU13/02923) and, subsequently, by the CLC-2017-01 grant. S.R.-F. contracts was supported by the grant BES-2013-063573 funded by both the MCIN/AEI/10.13039/501100011033 and the European Social Fund "Investing in your future" of the European Union. The funding from the Castilla-Leon governments has been also partially supported by the European Regional Development Fund.	Artegiani B, 2015, EMBO J, V34, P896, DOI 10.15252/embj.201490061; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Borrelli S, 2010, CELL DEATH DIFFER, V17, P1896, DOI 10.1038/cdd.2010.59; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Bustelo Xose R, 2014, Small GTPases, V5, P9, DOI 10.4161/21541248.2014.973757; Cangkrama M, 2013, INT J MOL SCI, V14, P13670, DOI 10.3390/ijms140713670; Castilho RM, 2007, ONCOGENE, V26, P5078, DOI 10.1038/sj.onc.1210322; Chai LL, 2010, INT J MOL MED, V25, P723, DOI 10.3892/ijmm_00000397; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; Cook DR, 2014, ONCOGENE, V33, P4021, DOI 10.1038/onc.2013.362; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; Doles J, 2012, GENE DEV, V26, P2144, DOI 10.1101/gad.192294.112; Doody GM, 2000, EMBO J, V19, P6173, DOI 10.1093/emboj/19.22.6173; Dotto GP, 2016, CANCER CELL, V29, P622, DOI 10.1016/j.ccell.2016.04.004; Eckert RL, 2013, J SKIN CANCER, V2013, DOI 10.1155/2013/537028; Eigentler TK, 2017, J INVEST DERMATOL, V137, P2309, DOI 10.1016/j.jid.2017.06.025; Fabbiano S, 2014, MOL CELL BIOL, V34, P4404, DOI 10.1128/MCB.01066-14; Lorenzo-Martin LF, 2020, ONCOGENE, V39, P5098, DOI 10.1038/s41388-020-1353-x; Lorenzo-Martin LF, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010165; Lorenzo-Martin LF, 2020, CANCERS, V12, DOI 10.3390/cancers12092498; Fuchs E, 2008, J CELL BIOL, V180, P273, DOI 10.1083/jcb.200708185; HALPRIN KM, 1972, BRIT J DERMATOL, V86, P14, DOI 10.1111/j.1365-2133.1972.tb01886.x; Heath J, 2009, J INVEST DERMATOL, V129, P2358, DOI 10.1038/jid.2009.102; Hsu YC, 2014, CELL, V157, P935, DOI 10.1016/j.cell.2014.02.057; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ito M, 2008, J INVEST DERMATOL, V128, P1059, DOI 10.1038/jid.2008.86; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Langton AK, 2008, J INVEST DERMATOL, V128, P1311, DOI 10.1038/sj.jid.5701178; Lapouge G, 2011, P NATL ACAD SCI USA, V108, P7431, DOI 10.1073/pnas.1012720108; Leishman E, 2013, DEVELOPMENT, V140, P3809, DOI 10.1242/dev.097477; Lien WH, 2011, CELL STEM CELL, V9, P219, DOI 10.1016/j.stem.2011.07.015; Lorenzo-Martin LF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18524-3; Mair B, 2019, CELL REP, V27, P599, DOI 10.1016/j.celrep.2019.02.041; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Menacho-Marquez M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001615; Mignone JL, 2007, CELL CYCLE, V6, P2161, DOI 10.4161/cc.6.17.4593; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodriguez-Fdez S, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10090857; Rodriguez-Fdez S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19489-z; Rodriguez-Fdez S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050465; Salgado G, 2017, DIFFERENTIATION, V98, P14, DOI 10.1016/j.diff.2017.09.004; Sauzeau V, 2006, NAT MED, V12, P841, DOI 10.1038/nm1426; Sauzeau V, 2007, MOL BIOL CELL, V18, P943, DOI 10.1091/mbc.E06-09-0877; Sauzeau V, 2010, J CLIN INVEST, V120, P315, DOI 10.1172/JCI38356; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tscharntke M, 2007, J CELL SCI, V120, P1480, DOI 10.1242/jcs.03426; Vanheer L, 2019, J CELL SCI, V132, DOI 10.1242/jcs.232223; Wang F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172613; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu XW, 2006, GENE DEV, V20, P571, DOI 10.1101/gad.361406; Zhan RX, 2016, SCI REP-UK, V6, DOI 10.1038/srep30687; Zhao SL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/986048	63	0	0	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3341	3354		10.1038/s41388-022-02341-7	http://dx.doi.org/10.1038/s41388-022-02341-7		MAY 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35534539	Green Published, hybrid			2022-12-28	WOS:000792558400001
J	Li, K; Niu, Y; Yuan, YC; Qiu, JL; Shi, YX; Zhong, CR; Qiu, ZY; Li, KR; Lin, Z; Huang, ZK; Zhang, C; Zuo, DL; He, W; Yuan, YF; Li, BK				Li, Kai; Niu, Yi; Yuan, Yichuan; Qiu, Jiliang; Shi, Yunxing; Zhong, Chengrui; Qiu, Zhiyu; Li, Keren; Lin, Zhu; Huang, Zhenkun; Zhang, Chao; Zuo, Dinglan; He, Wei; Yuan, Yunfei; Li, Binkui			Insufficient ablation induces E3-ligase Nedd4 to promote hepatocellular carcinoma progression by tuning TGF-beta signaling	ONCOGENE			English	Article							E3 UBIQUITIN LIGASE; RADIOFREQUENCY ABLATION; CANCER STATISTICS; PROLIFERATION; MECHANISMS; RECEPTOR; BINDING; PROTEIN; WEB	Thermal ablation is a main curative therapy for early-stage hepatocellular carcinoma (HCC). However, insufficient ablation has been shown to promote HCC progression. E3 ligases have been approved to play important roles in malignant tumors. Whether E3 ligases are involved in HCC progression caused by insufficient ablation remains unclear. Herein, using RNA-sequencing coupled with an in vitro loss-of-function screen, we found that the E3 ligase Neuronal Precursor cell-expressed Developmentally Downregulated 4 (Nedd4) was upregulated in HCC insufficient ablation tissues and promoted HCC cells migration. The upregulation of Nedd4 was induced by METTL14-mediated N-6-methyladenosine modification after sublethal heat treatment. Knockdown of Nedd4 inhibited HCC metastasis and growth in vitro and in vivo. Mechanistically, Nedd4 enhanced TGF-beta signal transduction mediated tumor progression by directly binding to TGF-beta type I receptor (TGFBR1) and forming K27-linked ubiquitin at Lysine 391. Additionally, the adverse effect on HCC of sublethal heat treatment was mediated by Nedd4. Clinically, high Nedd4 expression was positively correlated with aggressive tumor phenotypes and poor prognosis in HCC patients. Patient-derived xenograft (PDX) model confirmed this conclusion. Collectively, this study demonstrated that Nedd4 induced by insufficient ablation plays a crucial role in promoting HCC progression and provides a novel therapeutic target for HCC.	[Li, Kai; Niu, Yi; Yuan, Yichuan; Qiu, Jiliang; Shi, Yunxing; Zhong, Chengrui; Qiu, Zhiyu; Li, Keren; Lin, Zhu; Huang, Zhenkun; Zhang, Chao; Zuo, Dinglan; He, Wei; Yuan, Yunfei; Li, Binkui] Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Li, Kai; Niu, Yi; Yuan, Yichuan; Qiu, Jiliang; Shi, Yunxing; Zhong, Chengrui; Qiu, Zhiyu; Li, Keren; Lin, Zhu; Huang, Zhenkun; Zhang, Chao; Zuo, Dinglan; He, Wei; Yuan, Yunfei; Li, Binkui] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China; [Li, Kai; Yuan, Yichuan; Qiu, Jiliang; Shi, Yunxing; Zhong, Chengrui; Qiu, Zhiyu; Li, Keren; Lin, Zhu; Huang, Zhenkun; He, Wei; Yuan, Yunfei; Li, Binkui] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China; [Zhang, Chao] Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Yuan, YF; Li, BK (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China.; Yuan, YF; Li, BK (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China.; Yuan, YF; Li, BK (corresponding author), Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China.	yuanyf@mail.sysu.edu.cn; libk@sysucc.org.cn		Yuan, Yunfei/0000-0003-2467-3683; Li, Binkui/0000-0003-3201-2914	National Natural Science Foundation of China [81772625, 81972301, 81802421]; Guangzhou Science and Technology Program of China [201804020093]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Program of China	National Natural Science Foundation of China (No. 81772625, No. 81972301 and No. 81802421). Guangzhou Science and Technology Program of China (No. 201804020093).	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen Y, 2021, CANCER LETT, V518, P23, DOI 10.1016/j.canlet.2021.06.001; Chesarino NM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005095; Chu KF, 2014, NAT REV CANCER, V14, P199, DOI 10.1038/nrc3672; Damgaard RB, 2021, CELL DEATH DIFFER, V28, P423, DOI 10.1038/s41418-020-00703-w; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2021, NAT REV CLIN ONCOL, V18, P9, DOI 10.1038/s41571-020-0403-1; Gatti M, 2015, CELL REP, V10, P226, DOI 10.1016/j.celrep.2014.12.021; Grice GL, 2016, CELL MOL LIFE SCI, V73, P3497, DOI 10.1007/s00018-016-2255-5; Han ZY, 2014, J VIROL, V88, P7294, DOI 10.1128/JVI.00591-14; Hang XF, 2016, CELL PHYSIOL BIOCHEM, V39, P768, DOI 10.1159/000445667; Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086; Huang Z, 2015, ONCOGENE, V34, P1105, DOI 10.1038/onc.2014.56; Huang ZJ, 2017, ONCOL LETT, V14, P2649, DOI 10.3892/ol.2017.6532; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lee DH, 2014, RADIOLOGY, V270, P900, DOI 10.1148/radiol.13130940; Li JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep38550; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00299-9; Li YY, 2015, CELL PROLIFERAT, V48, P338, DOI 10.1111/cpr.12184; Lian QY, 2018, GENOM PROTEOM BIOINF, V16, P269, DOI 10.1016/j.gpb.2018.07.003; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Liu WW, 2018, ALIMENT PHARM THER, V48, P671, DOI 10.1111/apt.14929; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Narita T, 2019, NAT REV MOL CELL BIO, V20, P156, DOI 10.1038/s41580-018-0081-3; Niu Y, 2021, HEPATOLOGY, V74, P1461, DOI 10.1002/hep.31846; Ohtake F, 2016, MOL CELL, V64, P251, DOI 10.1016/j.molcel.2016.09.014; Popovic D, 2014, NAT MED, V20, P1242, DOI 10.1038/nm.3739; Rape M, 2018, NAT REV MOL CELL BIO, V19, P59, DOI 10.1038/nrm.2017.83; Shao GB, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0784-2; Shi LR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13204-3; Su TH, 2021, HEPATOLOGY, V74, P1339, DOI 10.1002/hep.31766; Su TH, 2018, ONCOGENE, V37, P3514, DOI 10.1038/s41388-018-0169-4; Sun AQ, 2017, AUTOPHAGY, V13, P522, DOI 10.1080/15548627.2016.1268301; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Wan T, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.625169; Wang L, 2017, ONCOL REP, V37, P2565, DOI 10.3892/or.2017.5572; Wang Z, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11224-7; Xu C, 2015, ONCOGENE, V34, P342, DOI 10.1038/onc.2013.557; Xu JJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01281-8; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22; Yang YF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14324-x; Zhang L, 2013, MOL CELL, V51, P559, DOI 10.1016/j.molcel.2013.07.014; Zhang ZK, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02029-7; Zhao ZZ, 2018, CANCER LETT, V421, P73, DOI 10.1016/j.canlet.2018.02.024; Zhou WH, 2014, ONCOTARGET, V5, P6746, DOI 10.18632/oncotarget.2246	50	1	1	5	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3197	3209		10.1038/s41388-022-02334-6	http://dx.doi.org/10.1038/s41388-022-02334-6		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35501461				2022-12-28	WOS:000789736600001
J	Tu, YM; Xu, L; Xu, J; Bao, ZY; Tian, W; Ye, YF; Sun, GC; Miao, Z; Chao, HL; You, YP; Liu, N; Ji, J				Tu, Yiming; Xu, Lei; Xu, Jia; Bao, Zhongyuan; Tian, Wei; Ye, Yangfan; Sun, Guangchi; Miao, Zong; Chao, Honglu; You, Yongping; Liu, Ning; Ji, Jing			Loss of deubiquitylase USP2 triggers development of glioblastoma via TGF-beta signaling	ONCOGENE			English	Article							CELL-PROLIFERATION; SMAD7; UBIQUITINATION; DEGRADATION; METHYLATION; SIGNATURE; PROTEIN	Glioblastoma (GBM) is the most aggressive primary brain tumor as one of the deadliest cancers. The TGF-beta signaling acts as an oncogenic factor in GBM, and plays vital roles in development of GBM. SMAD7 is a major inhibitor of TGF-beta signaling, while the deubiquitination of SMAD7 has been poorly studied in GBM. Here, we found USP2 as a new prominent candidate that could regulate SMAD7 stability. USP2 was lost in GBM, leading to the poor prognosis in patients. Moreover, aberrant DNA methylation mediated by DNMT3A induced the low expression of USP2 in GBM. USP2 depletion induced TGF-beta signaling and progression of GBM. In contrast, overexpressed USP2 suppressed TGF-beta signaling and GBM development. Specifically, USP2 interacted with SMAD7 and prevented SMAD7 ubiquitination. USP2 directly cleaved Lys27- and Lys48-linked poly-ubiquitin chains of SMAD7, and Lys27-linked poly-ubiquitin chains of SMAD7 K185 mediated the recruitment of SMAD7 to HERC3, which regulated Lys63-linked poly-ubiquitination of SMAD7. Moreover, we demonstrated that the DNMT3A inhibitor SGI-1027 induced USP2, suppressed TGF-beta signaling and GBM development. Thus, USP2 repressed development of GBM by inhibition TGF-beta signaling pathway via the deubiquitination of SMAD7.	[Tu, Yiming; Xu, Lei; Xu, Jia; Bao, Zhongyuan; Tian, Wei; Ye, Yangfan; Sun, Guangchi; Miao, Zong; Chao, Honglu; You, Yongping; Liu, Ning; Ji, Jing] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China; [You, Yongping; Ji, Jing] Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Inst Brain Tumors, Nanjing, Jiangsu, Peoples R China; [Ji, Jing] Nanjing Med Univ, Gusu Sch, Suzhou, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Ji, J (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China.; Ji, J (corresponding author), Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Inst Brain Tumors, Nanjing, Jiangsu, Peoples R China.; Ji, J (corresponding author), Nanjing Med Univ, Gusu Sch, Suzhou, Peoples R China.	jijing@njmu.edu.cn			National Natural Science Foundation of China [82120108018, 81972153]; China Postdoctoral Science Foundation [2021M701495]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) [JX10231803]; Gusu School, Nanjing Medical University [GSKY202201010]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Gusu School, Nanjing Medical University	This study was supported by grants from the National Natural Science Foundation of China (82120108018 and 81972153), China Postdoctoral Science Foundation (2021M701495), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, Grant No. JX10231803), and Gusu School, Nanjing Medical University (GSKY202201010).	Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Behnan J, 2019, BRAIN, V142, P847, DOI 10.1093/brain/awz044; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Chai RC, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01124-z; De Boeck M, 2012, UPSALA J MED SCI, V117, P153, DOI 10.3109/03009734.2012.654858; Dixit D, 2021, CANCER DISCOV, V11, P480, DOI 10.1158/2159-8290.CD-20-0331; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Gu XH, 2018, AM J TRANSL RES, V10, P2834; He JB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1512-6; Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270; Imamura T, 2013, J BIOCHEM, V154, P481, DOI 10.1093/jb/mvt097; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jiang T, 2021, CANCER LETT, V499, P60, DOI 10.1016/j.canlet.2020.10.050; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; Li H, 2019, CLIN CANCER RES, V25, P3602, DOI 10.1158/1078-0432.CCR-18-3791; Lui SKL, 2017, EMBO REP, V18, P797, DOI 10.15252/embr.201643270; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Niederlander C, 2001, NATURE, V410, P830, DOI 10.1038/35071103; Park SH, 2015, MOL CELLS, V38, P20, DOI 10.14348/molcells.2015.2120; Qu Q, 2015, TUMOR BIOL, V36, P5415, DOI 10.1007/s13277-015-3207-7; Sanai N, 2018, CLIN CANCER RES, V24, P3820, DOI 10.1158/1078-0432.CCR-17-3348; Song B, 2019, J CLIN INVEST, V129, P569, DOI 10.1172/JCI122367; Song YF, 2020, NEURO-ONCOLOGY, V22, P46, DOI 10.1093/neuonc/noz136; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tang YL, 2019, GASTROENTEROLOGY, V156, P692, DOI 10.1053/j.gastro.2018.10.023; Tong L, 2020, CELL DEATH DIFFER, V27, P1795, DOI 10.1038/s41418-019-0459-6; Tu YM, 2020, CLIN CANCER RES, V26, P1749, DOI 10.1158/1078-0432.CCR-19-1515; Wang QH, 2018, CANCER CELL, V33, P152, DOI 10.1016/j.ccell.2017.12.012; Wang QX, 2018, THERANOSTICS, V8, P4733, DOI 10.7150/thno.26550; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Wu X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12145-1; Xu TH, 2020, NATURE, V586, P151, DOI 10.1038/s41586-020-2747-1; Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018; Yin Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09844-0; Zhang JR, 2020, CELL DEATH DIFFER, V27, P2710, DOI 10.1038/s41418-020-0538-8; Zhang QT, 2019, NAT CELL BIOL, V21, P179, DOI 10.1038/s41556-018-0264-3; Zhang SP, 2007, MOL CELL BIOL, V27, P4488, DOI 10.1128/MCB.01636-06; Zhang ZK, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02029-7; Zhao YG, 2011, J BIOL CHEM, V286, P40520, DOI 10.1074/jbc.M111.292961	41	1	1	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2597	2608		10.1038/s41388-022-02275-0	http://dx.doi.org/10.1038/s41388-022-02275-0		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35332268				2022-12-28	WOS:000772732900001
J	Guo, XY; Liu, TT; Zhu, WJ; Liu, HT; Zhang, GH; Song, L; Zhao, RN; Chen, X; Gao, P				Guo, Xiang-Yu; Liu, Tian-Tian; Zhu, Wen-Jie; Liu, Hai-Ting; Zhang, Guo-Hao; Song, Lin; Zhao, Rui-Nan; Chen, Xu; Gao, Peng			CircKDM4B suppresses breast cancer progression via the miR-675/NEDD4L axis	ONCOGENE			English	Article							CIRCULAR RNAS; ANGIOGENESIS; PROMOTES; INVASION; VEGFA; PROLIFERATION; CELLS	Increasing studies have indicated that circular RNAs (circRNAs) play pivotal roles in various cancers. Here, we aimed to explore the roles of circRNAs in breast cancer. We identified a novel circRNA circKDM4B (hsa_circ_0002926) by whole-transcriptome sequencing and validated this by Real-time quantitative polymerase chain reaction (RT-qPCR) and Sanger sequencing. It was significantly decreased in breast cancer tissues compared with adjacent non-tumor tissues. Furthermore, circKDM4B, which is mainly localized in the cytoplasm, was more resistant to actinomycin D or ribonuclease R than its linear transcript KDM4B. In addition, the overexpression of circKDM4B inhibited cell migration and invasion in vitro, while knockdown of circKDM4B induced the opposite effects. In vivo, circKDM4B suppressed tumor growth and metastasis. Additionally, circKDM4B inhibited migration and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro and angiogenesis in vivo. Mechanically, circKDM4B sponged miR-675 to upregulate the expression of NEDD4-like E3 ubiquitin protein ligase (NEDD4L), which catalyzes ubiquitination of PI3KCA, thereby inhibiting PI3K/AKT and VEGFA secretion. Collectively, these findings uncovered the tumor-suppressor role of circKDM4B in breast cancer, especially in angiogenesis and tumor metastasis, indicating that circKDM4B could be a potential therapeutic target for breast cancer progression.	[Guo, Xiang-Yu; Liu, Tian-Tian; Zhu, Wen-Jie; Liu, Hai-Ting; Zhang, Guo-Hao; Zhao, Rui-Nan; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan, Peoples R China; [Guo, Xiang-Yu; Liu, Tian-Tian; Zhu, Wen-Jie; Liu, Hai-Ting; Zhang, Guo-Hao; Zhao, Rui-Nan; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Pathol, Jinan, Peoples R China; [Guo, Xiang-Yu; Liu, Tian-Tian; Zhu, Wen-Jie; Liu, Hai-Ting; Zhang, Guo-Hao; Song, Lin; Zhao, Rui-Nan; Chen, Xu; Gao, Peng] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pathol, Jinan, Peoples R China; [Song, Lin] Shandong First Med Univ, Dept Pathol, Shandong Prov Hosp, Jinan, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences	Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Pathol, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pathol, Jinan, Peoples R China.	gaopeng@sdu.edu.cn			National Natural Science Foundation of China [81872362, 82072665]; Taishan Scholars Program of Shandong Province [ts201511096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province	This study was supported by the National Natural Science Foundation of China (Grant nos. 81872362 and 82072665), the Taishan Scholars Program of Shandong Province (Grant no. ts201511096).	Barbagallo D, 2019, CANCERS, V11, DOI 10.3390/cancers11020194; Chen B, 2018, THERANOSTICS, V8, P4003, DOI 10.7150/thno.24106; Chen NF, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1594-y; Cheng J, 2019, CLIN CANCER RES, V25, P3732, DOI 10.1158/1078-0432.CCR-18-3001; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; DeSantis CE, 2019, CA-CANCER J CLIN, V69, P438, DOI 10.3322/caac.21583; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Goel P, 2015, GENE, V557, P1, DOI 10.1016/j.gene.2014.11.051; Guarnieri AL, 2018, ONCOGENE, V37, P3879, DOI 10.1038/s41388-018-0239-7; Guo JP, 2021, ADV SCI, V8, DOI 10.1002/advs.202004303; Gyparaki MT, 2014, CANCER LETT, V354, P1, DOI 10.1016/j.canlet.2014.07.036; Hanniford D, 2020, CANCER CELL, V37, P55, DOI 10.1016/j.ccell.2019.12.007; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; He QR, 2018, MOL THER-NUCL ACIDS, V10, P331, DOI 10.1016/j.omtn.2017.12.014; Karedath T, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5723-0; Kovacevic Z, 2013, ANTIOXID REDOX SIGN, V18, P874, DOI 10.1089/ars.2011.4273; Li QD, 2019, CELL METAB, V30, P157, DOI 10.1016/j.cmet.2019.05.009; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liang YR, 2019, ONCOGENE, V38, P6850, DOI 10.1038/s41388-019-0926-z; Liu G, 2016, ONCOL RES, V23, P99, DOI 10.3727/096504015X14496932933575; Lu J, 2020, CANCER LETT, V471, P38, DOI 10.1016/j.canlet.2019.11.038; Luo Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01203-8; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Morland C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15557; Protopsaltis NJ, 2019, ANGIOGENESIS, V22, P311, DOI 10.1007/s10456-018-9658-x; Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Suhasini AN, 2016, LEUKEMIA, V30, P617, DOI 10.1038/leu.2015.302; Szabo L, 2016, NAT REV GENET, V17, P679, DOI 10.1038/nrg.2016.114; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456-017-9562-9; Wang LQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0889-7; Wang ZX, 2016, J BIOL CHEM, V291, P17467, DOI 10.1074/jbc.M116.726083; Xiao MS, 2020, TRENDS CELL BIOL, V30, P226, DOI 10.1016/j.tcb.2019.12.004; Xu JZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1382-y; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Zhang HY, 2019, ONCOGENE, V38, P2844, DOI 10.1038/s41388-018-0619-z; Zheng J, 2019, ONCOGENE, V38, P7073, DOI 10.1038/s41388-019-0934-z; Zhong ZY, 2017, CANCER LETT, V403, P305, DOI 10.1016/j.canlet.2017.06.027; Zhuang M, 2014, BIOCHEM BIOPH RES CO, V448, P315, DOI 10.1016/j.bbrc.2013.12.126	41	7	7	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1895	1906		10.1038/s41388-022-02232-x	http://dx.doi.org/10.1038/s41388-022-02232-x		FEB 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35145234				2022-12-28	WOS:000754011900001
J	Ma, GZ; Deng, YF; Qian, LX; Vallega, KA; Zhang, GJ; Deng, XM; Owonikoko, TK; Ramalingam, SS; Fang, DD; Zhai, YF; Sun, SY				Ma, Guangzhi; Deng, Yunfu; Qian, Luxi; Vallega, Karin A.; Zhang, Guojing; Deng, Xingming; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Fang, Douglas D.; Zhai, Yifan; Sun, Shi-Yong			Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both	ONCOGENE			English	Article							LUNG-CANCER; MODULATION	Treatment of EGFR-mutant non-small cell lung cancer (NSCLC) with mutation-selective third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib has achieved remarkable success in the clinic. However, the immediate challenge is the emergence of acquired resistance, limiting the long-term remission of patients. This study suggests a novel strategy to overcome acquired resistance to osimertinib and other third-generation EGFR-TKIs through directly targeting the intrinsic apoptotic pathway. We found that osimertinib, when combined with Mcl-1 inhibition or Bax activation, synergistically decreased the survival of different osimertinib-resistant cell lines, enhanced the induction of intrinsic apoptosis, and inhibited the growth of osimertinib-resistant tumor in vivo. Interestingly, the triple-combination of osimertinib with Mcl-1 inhibition and Bax activation exhibited the most potent activity in decreasing the survival and inducing apoptosis of osimertinib-resistant cells and in suppressing the growth of osimertinib-resistant tumors. These effects were associated with increased activation of the intrinsic apoptotic pathway evidenced by augmented mitochondrial cytochrome C and Smac release. Hence, this study convincingly demonstrates a novel strategy for overcoming acquired resistance to osimertinib and other 3rd generation EGFR-TKIs by targeting activation of the intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation or both, warranting further clinical validation of this strategy.	[Ma, Guangzhi] Sichuan Univ, West China Hosp, Dept Thorac Surg, Chengdu, Sichuan, Peoples R China; [Ma, Guangzhi; Deng, Yunfu; Qian, Luxi; Vallega, Karin A.; Zhang, Guojing; Ramalingam, Suresh S.; Sun, Shi-Yong] Emory Univ, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA; [Ma, Guangzhi; Deng, Yunfu; Qian, Luxi; Vallega, Karin A.; Zhang, Guojing; Deng, Xingming; Ramalingam, Suresh S.; Sun, Shi-Yong] Winship Canc Inst, Atlanta, GA 30322 USA; [Deng, Yunfu] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China; [Qian, Luxi] Nanjing Med Univ, Dept Radiat Oncol, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China; [Qian, Luxi] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China; [Deng, Xingming] Emory Univ, Dept Radiat Oncol, Sch Med, Atlanta, GA 30322 USA; [Owonikoko, Taofeek K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; [Owonikoko, Taofeek K.] Hillman Canc Ctr, Pittsburgh, PA USA; [Fang, Douglas D.; Zhai, Yifan] Ascentage Pharma Suzhou Co Ltd, Suzhou, Jiangsu, Peoples R China	Sichuan University; Emory University; Sichuan University; Nanjing Medical University; Nanjing Medical University; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sun, SY (corresponding author), Emory Univ, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA.; Sun, SY (corresponding author), Winship Canc Inst, Atlanta, GA 30322 USA.	ssun@emory.edu	Owonikoko, Taofeek/C-3012-2011	Owonikoko, Taofeek/0000-0002-7724-7728	Emory University Winship Cancer Institute lung cancer pilot fund; NIH/NCI [SPORE P50 CA217691]; Ascentage Pharma	Emory University Winship Cancer Institute lung cancer pilot fund; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ascentage Pharma(Dexcel Pharma)	We thank Dr. A. Hammond in our department for editing the manuscript. This work was supported by Emory University Winship Cancer Institute lung cancer pilot fund (to SYS), NIH/NCI SPORE P50 CA217691 (to XD) and a research fund from Ascentage Pharma (to SYS). TKO, SSR and SYS are Georgia Research Alliance Distinguished Cancer Scientists.	Carlisle JW, 2019, FUTURE ONCOL, V15, P805, DOI 10.2217/fon-2018-0626; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Fulda S, 2009, J CELL MOL MED, V13, P1221, DOI 10.1111/j.1582-4934.2009.00748.x; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Li R, 2017, CANCER RES, V77, P3001, DOI 10.1158/0008-5472.CAN-16-2356; Negi A, 2021, EUR J MED CHEM, V210, DOI 10.1016/j.ejmech.2020.113038; Penn L Z, 2001, Curr Opin Investig Drugs, V2, P684; Piper-Vallillo AJ, 2020, J CLIN ONCOL, V38, P2926, DOI 10.1200/JCO.19.03123; Pogmore JP, 2021, J MED CHEM, V64, P5276, DOI 10.1021/acs.jmedchem.0c02200; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Rowinsky EK, 2005, J CLIN ONCOL, V23, P9394, DOI 10.1200/JCO.2005.02.2889; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Shah R, 2020, CLIN LUNG CANCER, V21, pE216, DOI 10.1016/j.cllc.2019.12.003; Shi PY, 2017, CLIN CANCER RES, V23, P6567, DOI 10.1158/1078-0432.CCR-17-1574; Shi PY, 2016, CANCER LETT, V380, P494, DOI 10.1016/j.canlet.2016.07.021; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Sun SY, 2004, JNCI-J NATL CANCER I, V96, P662, DOI 10.1093/jnci/djh123; Sun SY, 1997, CANCER RES, V57, P4931; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Walensky LD, 2019, NAT CHEM BIOL, V15, P657, DOI 10.1038/s41589-019-0306-6; Wang HL, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01079-1; Xin MG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5935; Zang HJ, 2020, CANCER-AM CANCER SOC, V126, P2024, DOI 10.1002/cncr.32744; Zhang LL, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188569; Zimmermann KC, 2001, J ALLERGY CLIN IMMUN, V108, pS99, DOI 10.1067/mai.2001.117819; Zong D, 2020, CANCER RES, V80, P2380, DOI 10.1158/0008-5472.CAN-19-3674	28	2	2	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1691	1700		10.1038/s41388-022-02200-5	http://dx.doi.org/10.1038/s41388-022-02200-5		JAN 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35102249				2022-12-28	WOS:000750409400002
J	Frank, DN; Qiu, Y; Cao, Y; Zhang, SG; Lu, L; Kofonow, JM; Robertson, CE; Liu, YQ; Wang, HB; Levens, CL; Kuhn, KA; Song, J; Ramakrishnan, VR; Lu, SL				Frank, Daniel N.; Qiu, Yue; Cao, Yu; Zhang, Shuguang; Lu, Ling; Kofonow, Jennifer M.; Robertson, Charles E.; Liu, Yanqiu; Wang, Haibo; Levens, Cassandra L.; Kuhn, Kristine A.; Song, John; Ramakrishnan, Vijay R.; Lu, Shi-Long			A dysbiotic microbiome promotes head and neck squamous cell carcinoma	ONCOGENE			English	Article							ARYL-HYDROCARBON RECEPTOR; GUT MICROBIOTA; ORAL-CANCER; TRYPTOPHAN; ASSOCIATION; METABOLITES; ACTIVATION; DIVERSITY; EFFICACY; MODELS	Recent studies have reported dysbiotic oral microbiota and tumor-resident bacteria in human head and neck squamous cell carcinoma (HNSCC). We aimed to identify and validate oral microbial signatures in treatment-naive HNSCC patients compared with healthy control subjects. We confirm earlier reports that the relative abundances of Lactobacillus spp. and Neisseria spp. are elevated and diminished, respectively, in human HNSCC. In parallel, we examined the disease-modifying effects of microbiota in HNSCC, through both antibiotic depletion of microbiota in an induced HNSCC mouse model (4-Nitroquinoline 1-oxide, 4NQO) and reconstitution of tumor-associated microbiota in a germ-free orthotopic mouse model. We demonstrate that depletion of microbiota delays oral tumorigenesis, while microbiota transfer from mice with oral cancer accelerates tumorigenesis. Enrichment of Lactobacillus spp. was also observed in murine HNSCC, and activation of the aryl-hydrocarbon receptor was documented in both murine and human tumors. Together, our findings support the hypothesis that dysbiosis promotes HNSCC development.	[Frank, Daniel N.; Kofonow, Jennifer M.; Robertson, Charles E.] Univ Colorado, Dept Med, Div Infect Dis, Anschutz Med Ctr, Aurora, CO 80045 USA; [Qiu, Yue; Cao, Yu; Zhang, Shuguang; Lu, Ling; Liu, Yanqiu; Wang, Haibo; Song, John; Ramakrishnan, Vijay R.; Lu, Shi-Long] Univ Colorado, Dept Otolaryngol Head & Neck Surg, Anschutz Med Ctr, Aurora, CO 80045 USA; [Qiu, Yue] China Med Univ, Coll Basic Med Sci, Dept Immunol, Shenyang 110122, Peoples R China; [Cao, Yu] China Med Univ, Univ Hosp 1, Dept Surg Oncol, Shenyang 110122, Peoples R China; [Levens, Cassandra L.; Kuhn, Kristine A.] Univ Colorado, Dept Med, Div Rheumatol, Anschutz Med Ctr, Aurora, CO USA; [Levens, Cassandra L.; Kuhn, Kristine A.] Univ Colorado, Dept Med, Mucosal Inflammat Program, Anschutz Med Ctr, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; China Medical University; China Medical University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Frank, DN (corresponding author), Univ Colorado, Dept Med, Div Infect Dis, Anschutz Med Ctr, Aurora, CO 80045 USA.; Lu, SL (corresponding author), Univ Colorado, Dept Otolaryngol Head & Neck Surg, Anschutz Med Ctr, Aurora, CO 80045 USA.	daniel.frank@cuanschutz.edu; shi-long.lu@cuanschutz.edu			NIH-NIDCR [R56 DE028959]; NIH-NIAMS [R01 AR075033]; Cancer League of Colorado; Golfers Against Cancer; University of Colorado Cancer Center; University of Colorado GI and Liver Innate Immunity Program; NIH-NIDCD [K23 DC014747]	NIH-NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH-NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Cancer League of Colorado; Golfers Against Cancer; University of Colorado Cancer Center; University of Colorado GI and Liver Innate Immunity Program; NIH-NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was funded by grants from NIH-NIDCR (R56 DE028959; SLL & DNF), NIH-NIAMS (R01 AR075033; KAK), the Cancer League of Colorado (SLL & DNF), Golfers Against Cancer (SLL & DNF), and the University of Colorado Cancer Center (SLL & DNF). DNF, CER, and JMK were supported in part by the University of Colorado GI and Liver Innate Immunity Program. VRR was supported in part by a Career Development Grant from the University of Colorado Cancer Center and NIH-NIDCD K23 DC014747 (VRR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding organizations.	Al-hebshi NN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02079-3; Alexeev EE, 2018, AM J PATHOL, V188, P1183, DOI 10.1016/j.ajpath.2018.01.011; Alfano M, 2016, NAT REV UROL, V13, P77, DOI 10.1038/nrurol.2015.292; Anderson MJ, 2011, ECOL LETT, V14, P19, DOI 10.1111/j.1461-0248.2010.01552.x; Andreeva NV, 2020, CURR OPIN MICROBIOL, V56, P118, DOI 10.1016/j.mib.2020.09.001; Bebek G, 2012, HUM MOL GENET, V21, P1557, DOI 10.1093/hmg/ddr593; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blaser MJ, 2008, CANCER PREV RES, V1, P15, DOI 10.1158/1940-6207.CAPR-08-0024; Brennan CA, 2016, ANNU REV MICROBIOL, V70, P395, DOI 10.1146/annurev-micro-102215-095513; BUCKLAND ST, 1993, J APPL ECOL, V30, P478, DOI 10.2307/2404188; Bultman SJ, 2014, CARCINOGENESIS, V35, P249, DOI 10.1093/carcin/bgt392; Cao KAL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-253; Cervantes-Barragan L, 2017, SCIENCE, V357, P806, DOI 10.1126/science.aah5825; Chang H, 2006, TOXICOL SCI, V89, P205, DOI 10.1093/toxsci/kfj025; Chen X, 2020, MOL ONCOL, V14, P139, DOI 10.1002/1878-0261.12584; Chow LQM, 2020, NEW ENGL J MED, V382, P60, DOI 10.1056/NEJMra1715715; Cullin N, 2021, CANCER CELL, V39, P1317, DOI 10.1016/j.ccell.2021.08.006; Daniel CR, 2019, TRENDS CANCER, V5, P521, DOI 10.1016/j.trecan.2019.07.003; Du L, 2016, ONCOGENE, V35, P4641, DOI 10.1038/onc.2016.1; Elinav E, 2019, NAT REV CANCER, V19, P371, DOI 10.1038/s41568-019-0155-3; Fan XZ, 2018, GUT, V67, P120, DOI 10.1136/gutjnl-2016-312580; Fernandes AD, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-15; Fernandes AD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067019; Fox J., 2019, R COMPANION APPL REG, V.; Frank DN, 2021, J MED GENET, V58, P442, DOI 10.1136/jmedgenet-2020-106844; Frank DN, 2012, JAIDS-J ACQ IMM DEF, V60, P299, DOI 10.1097/QAI.0b013e31824e4bdb; Frank JA, 2008, APPL ENVIRON MICROB, V74, P2461, DOI 10.1128/AEM.02272-07; Frankel AE, 2017, NEOPLASIA, V19, P848, DOI 10.1016/j.neo.2017.08.004; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Ganly I, 2019, INT J CANCER, V145, P775, DOI 10.1002/ijc.32152; Gholizadeh P, 2016, BIOMED PHARMACOTHER, V84, P552, DOI 10.1016/j.biopha.2016.09.082; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gopalakrishnan V, 2018, CANCER CELL, V33, P570, DOI 10.1016/j.ccell.2018.03.015; Guerrero-Preston R, 2017, ONCOTARGET, V8, P110931, DOI 10.18632/oncotarget.20677; Guerrero-Preston R, 2016, ONCOTARGET, V7, P51320, DOI 10.18632/oncotarget.9710; Hayes RB, 2018, JAMA ONCOL, V4, P358, DOI 10.1001/jamaoncol.2017.4777; Healy CM, 2019, ORAL ONCOL, V89, P30, DOI 10.1016/j.oraloncology.2018.12.003; Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7; Hold GL, 2015, NAT REV GASTRO HEPAT, V12, P128, DOI 10.1038/nrgastro.2015.25; Hooper SJ, 2006, J CLIN MICROBIOL, V44, P1719, DOI 10.1128/JCM.44.5.1719-1725.2006; Hooper SJ, 2009, HEAD NECK-J SCI SPEC, V31, P1228, DOI 10.1002/hed.21140; Jenkinson HF, 2005, TRENDS MICROBIOL, V13, P589, DOI 10.1016/j.tim.2005.09.006; Jin UH, 2014, MOL PHARMACOL, V85, P777, DOI 10.1124/mol.113.091165; Lamas B, 2016, NAT MED, V22, P598, DOI 10.1038/nm.4102; Lanis JM, 2017, MUCOSAL IMMUNOL, V10, P1133, DOI 10.1038/mi.2016.133; Liu YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15207; Mager DL, 2003, J CLIN PERIODONTOL, V30, P644, DOI 10.1034/j.1600-051X.2003.00376.x; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Nadkarni MA, 2002, MICROBIOL-SGM, V148, P257, DOI 10.1099/00221287-148-1-257; Neville BW, 2002, CA-CANCER J CLIN, V52, P195, DOI 10.3322/canjclin.52.4.195; Ohtani N, 2015, SEMIN IMMUNOPATHOL, V37, P65, DOI 10.1007/s00281-014-0457-1; Oksanen J., 2016, VEGAN COMMUNITY ECOL; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Pfister DG, 2020, J NATL COMPR CANC NE, V18, P873, DOI 10.6004/jnccn.2020.0031; Plottel CS, 2011, CELL HOST MICROBE, V10, P324, DOI 10.1016/j.chom.2011.10.003; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Pruesse E, 2012, BIOINFORMATICS, V28, P1823, DOI 10.1093/bioinformatics/bts252; Pushalkar S, 2011, FEMS IMMUNOL MED MIC, V61, P269, DOI 10.1111/j.1574-695X.2010.00773.x; Quast Christian, 2013, Nucleic Acids Res, V41, pD590, DOI 10.1093/nar/gks1219; Quintana FJ, 2013, PHARMACOL REV, V65, P1148, DOI 10.1124/pr.113.007823; Quintana FJ, 2013, IMMUNOLOGY, V138, P183, DOI 10.1111/imm.12046; R Development Core Team, 2009, R LANG ENV STAT COMP; Roager HM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05470-4; Robertson CE, 2013, BIOINFORMATICS, V29, P3100, DOI 10.1093/bioinformatics/btt526; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Rothhammer V, 2016, NAT MED, V22, P586, DOI 10.1038/nm.4106; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Schwabe RF, 2013, NAT REV CANCER, V13, P800, DOI 10.1038/nrc3610; Sfanos KS, 2018, NAT REV UROL, V15, P11, DOI 10.1038/nrurol.2017.167; Shay Elizabeth, 2020, Oncotarget, V11, P2375, DOI 10.18632/oncotarget.27629; Stanford EA, 2016, MOL CANCER RES, V14, P696, DOI 10.1158/1541-7786.MCR-16-0069; Stange J, 2013, SEMIN IMMUNOPATHOL, V35, P645, DOI 10.1007/s00281-013-0389-1; Statnikov A, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-11; Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245; Stockinger B, 2011, SEMIN IMMUNOL, V23, P99, DOI 10.1016/j.smim.2011.01.008; Vickery TW., 2020, PROSTAGLANDINS LEUKO, V164; Vitale-Cross L, 2009, CANCER PREV RES, V2, P419, DOI 10.1158/1940-6207.CAPR-09-0058; Wie SM, 2017, MOL CANCER THER, V16, P1989, DOI 10.1158/1535-7163.MCT-17-0267; Wolf A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06361-2; Yu GQ, 2014, CANCER EPIDEM BIOMAR, V23, P735, DOI 10.1158/1055-9965.EPI-13-0855; Yu LX, 2017, NAT REV GASTRO HEPAT, V14, P527, DOI 10.1038/nrgastro.2017.72; Zelante T, 2013, IMMUNITY, V39, P372, DOI 10.1016/j.immuni.2013.08.003; Zhang L, 2007, ORAL ONCOL, V43, P693, DOI 10.1016/j.oraloncology.2006.08.008; Zitvogel L, 2018, SCIENCE, V359, P1366, DOI 10.1126/science.aar6918	84	4	4	9	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1269	1280		10.1038/s41388-021-02137-1	http://dx.doi.org/10.1038/s41388-021-02137-1		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35087236	Green Accepted			2022-12-28	WOS:000749068000001
J	Gravemeyer, J; Spassova, I; Verhaegen, ME; Dlugosz, AA; Hoffmann, D; Lange, A; Becker, JC				Gravemeyer, Jan; Spassova, Ivelina; Verhaegen, Monique E.; Dlugosz, Andrzej A.; Hoffmann, Daniel; Lange, Anja; Becker, Juergen C.			DNA-methylation patterns imply a common cellular origin of virus- and UV-associated Merkel cell carcinoma	ONCOGENE			English	Article							NEUROENDOCRINE CARCINOMA; EXPRESSION; EZH2; CANCER; CLASSIFICATION; MECHANISMS; SELECTION; TARGETS	Merkel cell carcinoma (MCC) is a neuroendocrine tumor either induced by integration of the Merkel cell polyomavirus into the cell genome or by accumulation of UV-light-associated mutations (VP-MCC and UV-MCC). Whether VP- and UV-MCC have the same or different cellular origins is unclear; with mesenchymal or epidermal origins discussed. DNA-methylation patterns have a proven utility in determining cellular origins of cancers. Therefore, we used this approach to uncover evidence regarding the cell of origin of classical VP- and UV-MCC cell lines, i.e., cell lines with a neuroendocrine growth pattern (n = 9 and n = 4, respectively). Surprisingly, we observed high global similarities in the DNA-methylation of UV- and VP-MCC cell lines. CpGs of lower methylation in VP-MCC cell lines were associated with neuroendocrine marker genes such as SOX2 and INSM1, or linked to binding sites of EZH2 and SUZ12 of the polycomb repressive complex 2, i.e., genes with an impact on carcinogenesis and differentiation of neuroendocrine cancers. Thus, the observed differences appear to be rooted in viral compared to mutation-driven carcinogenesis rather than distinct cells of origin. To test this hypothesis, we used principal component analysis, to compare DNA-methylation data from different epithelial and non-epithelial neuroendocrine cancers and established a scoring model for epithelial and neuroendocrine characteristics. Subsequently, we applied this scoring model to the DNA-methylation data of the VP- and UV-MCC cell lines, revealing that both clearly scored as epithelial cancers. In summary, our comprehensive analysis of DNA-methylation suggests a common epithelial origin of UV- and VP-MCC cell lines.	[Gravemeyer, Jan; Spassova, Ivelina; Becker, Juergen C.] Univ Duisburg Essen, Translat Skin Canc Res TSCR, Essen, Germany; [Gravemeyer, Jan; Becker, Juergen C.] German Canc Consortium DKTK, Heidelberg, Germany; [Gravemeyer, Jan; Becker, Juergen C.] German Canc Res Ctr, Heidelberg, Germany; [Spassova, Ivelina; Becker, Juergen C.] Univ Hosp Essen, Dept Dermatol, Essen, Germany; [Verhaegen, Monique E.; Dlugosz, Andrzej A.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; [Dlugosz, Andrzej A.] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; [Hoffmann, Daniel; Lange, Anja] Univ Duisburg Essen, Bioinformat & Computat Biophys, Essen, Germany	University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Duisburg Essen	Becker, JC (corresponding author), Univ Duisburg Essen, Translat Skin Canc Res TSCR, Essen, Germany.; Becker, JC (corresponding author), German Canc Consortium DKTK, Heidelberg, Germany.; Becker, JC (corresponding author), German Canc Res Ctr, Heidelberg, Germany.; Becker, JC (corresponding author), Univ Hosp Essen, Dept Dermatol, Essen, Germany.	j.becker@dkfz.de	Hoffmann, Daniel/P-5624-2019	Hoffmann, Daniel/0000-0003-2973-7869; Becker, Jurgen/0000-0001-9183-653X; Spassova, Ivelina/0000-0003-4663-7966; Verhaegen, Monique/0000-0003-0229-5917	German Cancer Consortium (DKTK) [ED003]	German Cancer Consortium (DKTK)	The project was funded by the German Cancer Consortium (DKTK) ED003. We thank the microarray unit of the DKFZ Genomics and Proteomics Core Facility for providing the Illumina Human Methylation arrays and related services.	Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; Augsburger D, 2017, ONCOTARGET, V8, P104638, DOI 10.18632/oncotarget.20136; Balanis NG, 2019, CANCER CELL, V36, P17, DOI 10.1016/j.ccell.2019.06.005; Battafarano RJ, 2005, J THORAC CARDIOV SUR, V130, P166, DOI 10.1016/j.jtcvs.2005.02.064; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Esposti DD, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0419-z; Fan KJ, 2020, J INVEST DERMATOL, V140, P56, DOI 10.1016/j.jid.2019.06.135; Faviana P, 2019, APPL IMMUNOHISTO M M, V27, P689, DOI 10.1097/PAI.0000000000000647; Fehrmann RSN, 2015, NAT GENET, V47, P115, DOI 10.1038/ng.3173; Ferone G, 2020, GENE DEV, V34, P1017, DOI 10.1101/gad.338228.120; Fisseler-Eckhoff Annette, 2012, Cancers (Basel), V4, P777, DOI 10.3390/cancers4030777; Gravemeyer J, 2021, J INVEST DERMATOL, V141, P1675, DOI 10.1016/j.jid.2021.01.012; Gujar H, 2021, GENOME MED, V13, DOI 10.1186/s13073-021-00946-3; Guo HY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08133-6; Harms KL, 2017, HUM PATHOL, V67, P78, DOI 10.1016/j.humpath.2017.07.009; Harms PW, 2022, J INVEST DERMATOL, V142, P641, DOI 10.1016/j.jid.2021.07.173; Harms PW, 2015, CANCER RES, V75, P3720, DOI 10.1158/0008-5472.CAN-15-0702; Harold A, 2019, P NATL ACAD SCI USA, V116, P20104, DOI 10.1073/pnas.1907154116; Heinz S, 2015, NAT REV MOL CELL BIO, V16, P144, DOI 10.1038/nrm3949; Hesbacher S, 2016, ONCOTARGET, V7, P32956, DOI 10.18632/oncotarget.8793; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hon GC, 2013, NAT GENET, V45, P1198, DOI 10.1038/ng.2746; Horny K, 2021, CANCERS, V13, DOI 10.3390/cancers13040649; Kervarrec T, 2022, J INVEST DERMATOL, V142, P516, DOI 10.1016/j.jid.2021.07.175; Kervarrec T, 2020, CANCERS, V12, DOI 10.3390/cancers12071989; Kervarrec T, 2020, J INVEST DERMATOL, V140, P976, DOI 10.1016/j.jid.2019.09.026; Kervarrec T, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00451; Khan SN, 2013, LEUKEMIA, V27, P1301, DOI 10.1038/leu.2013.80; Kim M, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.10; Knepper TC, 2019, CLIN CANCER RES, V25, P5961, DOI 10.1158/1078-0432.CCR-18-4159; Laga AC, 2010, AM J PATHOL, V176, P903, DOI 10.2353/ajpath.2010.090495; Lilo MT, 2018, AM J SURG PATHOL, V42, P1541, DOI 10.1097/PAS.0000000000001136; Liu W, 2016, CELL HOST MICROBE, V19, P775, DOI 10.1016/j.chom.2016.04.024; Llaguno SRA, 2016, BRIT J CANCER, V115, P1445, DOI 10.1038/bjc.2016.354; Maksimovic Jovana, 2016, F1000Res, V5, P1281, DOI 10.12688/f1000research.8839.3; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Moran S, 2016, LANCET ONCOL, V17, P1386, DOI 10.1016/S1470-2045(16)30297-2; Nirenberg A, 2020, J EUR ACAD DERMATOL, V34, P1425, DOI 10.1111/jdv.16158; Ostrowski SM, 2015, DEVELOPMENT, V142, P2533, DOI 10.1242/dev.123141; Park DE, 2020, NAT CELL BIOL, V22, P603, DOI 10.1038/s41556-020-0503-2; Park JW, 2018, SCIENCE, V362, P91, DOI 10.1126/science.aat5749; Phipson B, 2016, BIOINFORMATICS, V32, P286, DOI 10.1093/bioinformatics/btv560; Pulitzer MP, 2015, MODERN PATHOL, V28, P1023, DOI 10.1038/modpathol.2015.60; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodriguez-Paredes M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03025-1; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sheffield NC, 2016, BIOINFORMATICS, V32, P587, DOI 10.1093/bioinformatics/btv612; Sunshine JC, 2018, ONCOGENE, V37, P1409, DOI 10.1038/s41388-017-0073-3; Tei S, 2009, J CELL SCI, V122, P3190, DOI 10.1242/jcs.049627; Tenjin Y, 2020, LAB INVEST, V100, P1575, DOI 10.1038/s41374-020-00479-0; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Town J, 2016, P NATL ACAD SCI USA, V113, P3603, DOI 10.1073/pnas.1521251113; Tu Jian, 2017, Cancer Rep Rev, V1, DOI 10.15761/CRR.1000111; Verhaegen ME, 2014, J INVEST DERMATOL, V134, P2241, DOI 10.1038/jid.2014.138; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Yan W, 2011, AM J CANCER RES, V1, P275; Zhang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06177-2	62	3	3	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					37	45		10.1038/s41388-021-02064-1	http://dx.doi.org/10.1038/s41388-021-02064-1		OCT 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34667274	Green Published, hybrid			2022-12-28	WOS:000708806900001
J	Vaziri, C; Rogozin, IB; Gu, QS; Wu, D; Day, TA				Vaziri, Cyrus; Rogozin, Igor B.; Gu, Qisheng; Wu, Di; Day, Tovah A.			Unravelling roles of error-prone DNA polymerases in shaping cancer genomes	ONCOGENE			English	Review							FRAGILE SITE STABILITY; MUTATIONAL SIGNATURES; SOMATIC HYPERMUTATION; GERMLINE MUTATIONS; COLORECTAL ADENOMAS; EXCISION-REPAIR; POLE MUTATIONS; A-T; ETA; REPLICATION	Mutagenesis is a key hallmark and enabling characteristic of cancer cells, yet the diverse underlying mutagenic mechanisms that shape cancer genomes are not understood. This review will consider the emerging challenge of determining how DNA damage response pathways-both tolerance and repair-act upon specific forms of DNA damage to generate mutations characteristic of tumors. DNA polymerases are typically the ultimate mutagenic effectors of DNA repair pathways. Therefore, understanding the contributions of DNA polymerases is critical to develop a more comprehensive picture of mutagenic mechanisms in tumors. Selection of an appropriate DNA polymerase-whether error-free or error-prone-for a particular DNA template is critical to the maintenance of genome stability. We review different modes of DNA polymerase dysregulation including mutation, polymorphism, and over-expression of the polymerases themselves or their associated activators. Based upon recent findings connecting DNA polymerases with specific mechanisms of mutagenesis, we propose that compensation for DNA repair defects by error-prone polymerases may be a general paradigm molding the mutational landscape of cancer cells. Notably, we demonstrate that correlation of error-prone polymerase expression with mutation burden in a subset of patient tumors from The Cancer Genome Atlas can identify mechanistic hypotheses for further testing. We contrast experimental approaches from broad, genome-wide strategies to approaches with a narrower focus on a few hundred base pairs of DNA. In addition, we consider recent developments in computational annotation of patient tumor data to identify patterns of mutagenesis. Finally, we discuss the innovations and future experiments that will develop a more comprehensive portrait of mutagenic mechanisms in human tumors.	[Vaziri, Cyrus] Univ N Carolina, Dept Pathol & Lab Med, 614 Brinkhous Bullitt Bldg, Chapel Hill, NC 27599 USA; [Rogozin, Igor B.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; [Gu, Qisheng; Wu, Di] Univ N Carolina, Dept Biostat, 135 Dauer Dr,3101 McGavran Greenberg Hall, Chapel Hill, NC 27599 USA; [Day, Tovah A.] Northeastern Univ, Dept Biol, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); University of North Carolina; University of North Carolina Chapel Hill; Northeastern University	Day, TA (corresponding author), Northeastern Univ, Dept Biol, Boston, MA 02115 USA.	t.day@northeastern.edu		Gu, Qisheng/0000-0001-7294-042X; Day, Tovah/0000-0003-3894-1407	Intramural Research Program of the National Library of Medicine at the National Institutes of Health; National Institute of Health [R01CA215347, R01ES029079, R01CA229530, K01AG056554]	Intramural Research Program of the National Library of Medicine at the National Institutes of Health; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the Intramural Research Program of the National Library of Medicine at the National Institutes of Health (IBR), and National Institute of Health grants R01CA215347, R01ES029079, R01CA229530 (CV), and K01AG056554 (TAD).	Adar S, 2016, P NATL ACAD SCI USA, V113, pE2124, DOI 10.1073/pnas.1603388113; Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Allen F, 2019, NAT BIOTECHNOL, V37, P64, DOI 10.1038/nbt.4317; Aoude LG, 2015, FAM CANCER, V14, P621, DOI 10.1007/s10689-015-9826-8; Arana ME, 2008, NUCLEIC ACIDS RES, V36, P3847, DOI 10.1093/nar/gkn310; Bacolla A, 2021, NUCLEIC ACIDS RES, V49, P221, DOI 10.1093/nar/gkaa1120; Barnes RP, 2017, DNA REPAIR, V57, P1, DOI 10.1016/j.dnarep.2017.05.006; Bavoux C, 2005, CANCER RES, V65, P325; Bellido F, 2016, GENET MED, V18, P325, DOI 10.1038/gim.2015.75; Bergoglio V, 2013, J CELL BIOL, V201, P395, DOI 10.1083/jcb.201207066; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Bhattacharya P, 2008, EUR J IMMUNOL, V38, P227, DOI 10.1002/eji.200737664; Brinkman EK, 2018, MOL CELL, V70, P801, DOI 10.1016/j.molcel.2018.04.016; Brown AJ, 2018, METHOD ENZYMOL, V601, P111, DOI 10.1016/bs.mie.2017.11.028; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Carvajal-Garcia J, 2020, P NATL ACAD SCI USA, V117, P8476, DOI 10.1073/pnas.1921791117; Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184; Chakrabarti AM, 2019, MOL CELL, V73, P699, DOI 10.1016/j.molcel.2018.11.031; Chan K, 2015, NAT GENET, V47, P1067, DOI 10.1038/ng.3378; Charpentier M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03475-7; Chroma K, 2017, ONCOGENE, V36, P2405, DOI 10.1038/onc.2016.392; Church DN, 2013, HUM MOL GENET, V22, P2820, DOI 10.1093/hmg/ddt131; Cipolla L, 2019, NUCLEIC ACIDS RES, V47, P11268, DOI 10.1093/nar/gkz824; Clarke R, 2018, MOL CELL, V71, P42, DOI 10.1016/j.molcel.2018.06.005; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Dai ZM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002826; Durando M, 2013, NUCLEIC ACIDS RES, V41, P3079, DOI 10.1093/nar/gkt016; Erson-Omay EZ, 2015, NEURO-ONCOLOGY, V17, P1356, DOI 10.1093/neuonc/nov027; Feng WJ, 2021, NUCLEIC ACIDS RES, V49, P5095, DOI 10.1093/nar/gkab299; Fouquerel E, 2019, MOL CELL, V75, P117, DOI 10.1016/j.molcel.2019.04.024; Gadgil RY, 2020, J BIOL CHEM, V295, P15378, DOI 10.1074/jbc.RA120.013495; Gao YZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12105; Ghezraoui H, 2014, MOL CELL, V55, P829, DOI 10.1016/j.molcel.2014.08.002; Gisler S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09551-w; Goncearenco A, 2017, NUCLEIC ACIDS RES, V45, pW514, DOI 10.1093/nar/gkx367; Hansen MF, 2015, FAM CANCER, V14, P437, DOI 10.1007/s10689-015-9803-2; Heng YJ, 2020, CANCER EPIDEM BIOMAR, V29, P599, DOI 10.1158/1055-9965.EPI-19-1087; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hile SE, 2008, NUCLEIC ACIDS RES, V36, P688, DOI 10.1093/nar/gkm1089; Hino H, 2019, CANCER MED-US, V8, P4587, DOI 10.1002/cam4.2344; Hollstein M, 2017, ONCOGENE, V36, P158, DOI 10.1038/onc.2016.192; House NCM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237759; Hu JC, 2016, P NATL ACAD SCI USA, V113, P11507, DOI 10.1073/pnas.1614430113; Hu JC, 2015, GENE DEV, V29, P948, DOI 10.1101/gad.261271.115; Hu X., 2020, NAR CANC, V2, pZCAA026; Hwang Taejoo, 2020, NAR Cancer, V2, pzcaa017, DOI 10.1093/narcan/zcaa017; Ingram SP, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008476; Jung YS, 2012, DNA REPAIR, V11, P177, DOI 10.1016/j.dnarep.2011.10.017; Khodaverdian VY, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx1056; Koole W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4216; Kosicki M, 2018, NAT BIOTECHNOL, V36, P765, DOI 10.1038/nbt.4192; Kryklyva V, 2020, PANCREAS, V49, P999, DOI 10.1097/MPA.0000000000001588; Kumari N, 2019, ISCIENCE, V21, P288, DOI 10.1016/j.isci.2019.10.033; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Kurashima K, 2018, J CELL SCI, V131, DOI 10.1242/jcs.212183; Layer JV, 2020, P NATL ACAD SCI USA, V117, P27566, DOI 10.1073/pnas.2014176117; Lee DH, 2003, J BIOL CHEM, V278, P10314, DOI 10.1074/jbc.M212696200; Lemmens B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9909; Lemos BR, 2018, P NATL ACAD SCI USA, V115, pE2040, DOI 10.1073/pnas.1716855115; Li HD, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138829; Li HD, 2018, J CLIN INVEST, V128, P4179, DOI 10.1172/JCI122095; Lin JR, 2011, MOL CELL, V42, P237, DOI 10.1016/j.molcel.2011.02.026; Lindsay H, 2019, CSH MOL CASE STUD, V5, DOI 10.1101/mcs.a004499; Listovsky T, 2013, J CELL BIOL, V203, P87, DOI 10.1083/jcb.201302060; Loeillet S, 2020, P NATL ACAD SCI USA, V117, P24947, DOI 10.1073/pnas.2011332117; Lou, 2021, NAR CANC, V3, pZCAA037; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; Martomo SA, 2008, DNA REPAIR, V7, P1603, DOI 10.1016/j.dnarep.2008.04.002; Masuda K, 2005, P NATL ACAD SCI USA, V102, P13986, DOI 10.1073/pnas.0505636102; McCulloch SD, 2008, CELL RES, V18, P148, DOI 10.1038/cr.2008.4; McVey M, 2016, ANNU REV GENET, V50, P393, DOI 10.1146/annurev-genet-120215-035243; MILLER JH, 1983, ANNU REV GENET, V17, P215, DOI 10.1146/annurev.ge.17.120183.001243; Moreno NC, 2020, NUCLEIC ACIDS RES, V48, P1941, DOI 10.1093/nar/gkz1182; Mosbach V, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008924; Nayak S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7808; Nguyen L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19406-4; Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503; Park J, 2017, BIOINFORMATICS, V33, P286, DOI 10.1093/bioinformatics/btw561; Pinello L, 2016, NAT BIOTECHNOL, V34, P695, DOI 10.1038/nbt.3583; Prodhomme MK, 2021, CANCER RES, V81, P1595, DOI 10.1158/0008-5472.CAN-20-2626; Ray S, 2018, NUCLEIC ACIDS RES, V46, P242, DOI 10.1093/nar/gkx1147; Rey L, 2009, MOL CELL BIOL, V29, P3344, DOI 10.1128/MCB.00115-09; Richardson CD, 2016, NAT BIOTECHNOL, V34, P339, DOI 10.1038/nbt.3481; Richardson RR, 2020, CAS9 FUSIONS PRECISI, DOI 10.1101/2020.07.15.199620; Roerink SF, 2014, GENOME RES, V24, P954, DOI 10.1101/gr.170431.113; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Rogozin IB, 2003, MUTAT RES-REV MUTAT, V544, P65, DOI 10.1016/S1383-5742(03)00032-2; Rogozin IB, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.671866; Rogozin IB, 2019, CANCERS, V11, DOI 10.3390/cancers11020211; Rogozin IB, 2018, CELL CYCLE, V17, P348, DOI 10.1080/15384101.2017.1404208; Rogozin IB, 2018, BRIEF BIOINFORM, V19, P1085, DOI 10.1093/bib/bbx049; Rohlin A, 2014, INT J ONCOL, V45, P77, DOI 10.3892/ijo.2014.2410; Rosner G, 2018, DIS COLON RECTUM, V61, P1073, DOI 10.1097/DCR.0000000000001150; Sakiyama T, 2005, INT J CANCER, V114, P730, DOI 10.1002/ijc.20790; Sasatani M, 2017, CARCINOGENESIS, V38, P570, DOI 10.1093/carcin/bgw208; Schep R, 2021, MOL CELL, V81, P2216, DOI 10.1016/j.molcel.2021.03.032; Schimmel J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25154-w; Shachar S, 2009, EMBO J, V28, P383, DOI 10.1038/emboj.2008.281; Shen MW, 2018, NATURE, V563, P646, DOI 10.1038/s41586-018-0686-x; Shou J, 2018, MOL CELL, V71, P498, DOI 10.1016/j.molcel.2018.06.021; Siraj AK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1058-9; Soong CP, 2015, DNA REPAIR, V26, P44, DOI 10.1016/j.dnarep.2014.12.002; Spier I, 2015, INT J CANCER, V137, P320, DOI 10.1002/ijc.29396; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; Stewart GS, 2009, CELL CYCLE, V8, P1532, DOI 10.4161/cc.8.10.8351; Supek F, 2017, CELL, V170, P534, DOI 10.1016/j.cell.2017.07.003; Taheri-Ghahfarokhi A, 2018, NUCLEIC ACIDS RES, V46, P8417, DOI 10.1093/nar/gky653; Temiz NA, 2015, HUM GENET, V134, P851, DOI 10.1007/s00439-015-1566-1; Temko D, 2018, J PATHOL, V245, P283, DOI 10.1002/path.5081; Tonzi P, 2018, ELIFE, V7, DOI 10.7554/eLife.41426; Tsao WC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103255; Tubbs A, 2018, CELL, V174, P1127, DOI 10.1016/j.cell.2018.07.011; Valle L, 2014, HUM MOL GENET, V23, P3506, DOI 10.1093/hmg/ddu058; van Bostelen I, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008759; van Overbeek M, 2016, MOL CELL, V63, P633, DOI 10.1016/j.molcel.2016.06.037; van Schendel R, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006368; van Schendel R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8394; Volkova NV, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15912-7; Walsh E, 2013, J MOL BIOL, V425, P232, DOI 10.1016/j.jmb.2012.11.016; Wang AS, 2020, MOL CELL, V79, P221, DOI 10.1016/j.molcel.2020.06.014; Wang HB, 2010, NEURO-ONCOLOGY, V12, P679, DOI 10.1093/neuonc/nop074; Wang R, 2020, P NATL ACAD SCI USA, V117, P33436, DOI 10.1073/pnas.2008821117; Wang Y, 2007, CANCER RES, V67, P3018, DOI 10.1158/0008-5472.CAN-06-3073; Willis NA, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007486; Wimmer K, 2017, FAM CANCER, V16, P67, DOI 10.1007/s10689-016-9925-1; Wong A, 2016, GYNECOL ONCOL, V141, P113, DOI 10.1016/j.ygyno.2015.12.031; Wyatt DW, 2016, MOL CELL, V63, P662, DOI 10.1016/j.molcel.2016.06.020; Xu HL, 2013, CANCER EPIDEMIOL, V37, P917, DOI 10.1016/j.canep.2013.08.003; Yang J, 2004, CANCER RES, V64, P5597, DOI 10.1158/0008-5472.CAN-04-0603; Yang Y, 2017, J CELL BIOL, V216, P3097, DOI 10.1083/jcb.201702006; Yeom M, 2016, CHEM RES TOXICOL, V29, P367, DOI 10.1021/acs.chemrestox.5b00513; Yuan F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069317; Zammataro L, 2019, P NATL ACAD SCI USA, V116, P22730, DOI 10.1073/pnas.1911385116; Zan H, 2005, EMBO J, V24, P3757, DOI 10.1038/sj.emboj.7600833; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740; Zhang JJ, 2019, NAT BIOTECHNOL, V37, P367, DOI 10.1038/s41587-019-0055-9; ZHANG Y, 2021, PLOS GENET, V17; Ziv O, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6437; Ziv O, 2009, P NATL ACAD SCI USA, V106, P11552, DOI 10.1073/pnas.0812548106; Zou XQ, 2021, NAT CANCER, V2, DOI 10.1038/s43018-021-00200-0	144	2	2	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6549	6565		10.1038/s41388-021-02032-9	http://dx.doi.org/10.1038/s41388-021-02032-9		OCT 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34663880	hybrid, Green Published			2022-12-28	WOS:000708355700002
J	Dewaele, S; Delhaye, L; De Paepe, B; de Bony, EJ; De Wilde, J; Vanderheyden, K; Anckaert, J; Yigit, N; Nuytens, J; Vanden Eynde, E; Smet, J; Verschoore, M; Nemati, F; Decaudin, D; Rodrigues, M; Zhao, PH; Jochemsen, A; Leucci, E; Vandesompele, J; Van Dorpe, J; Marine, JC; Van Coster, R; Eyckerman, S; Mestdagh, P				Dewaele, Shanna; Delhaye, Louis; De Paepe, Boel; de Bony, Eric James; De Wilde, Jilke; Vanderheyden, Katrien; Anckaert, Jasper; Yigit, Nurten; Nuytens, Justine; Vanden Eynde, Eveline; Smet, Joel; Verschoore, Maxime; Nemati, Fariba; Decaudin, Didier; Rodrigues, Manuel; Zhao, Peihua; Jochemsen, Aart; Leucci, Eleonora; Vandesompele, Jo; Van Dorpe, Jo; Marine, Jean-Christophe; Van Coster, Rudy; Eyckerman, Sven; Mestdagh, Pieter			The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival	ONCOGENE			English	Article							ESTABLISHMENT; GLYCYLCYCLINE; TIGECYCLINE; KI-67	Long non-coding RNAs (lncRNAs) can exhibit cell-type and cancer-type specific expression profiles, making them highly attractive as therapeutic targets. Pan-cancer RNA sequencing data revealed broad expression of the SAMMSON lncRNA in uveal melanoma (UM), the most common primary intraocular malignancy in adults. Currently, there are no effective treatments for UM patients with metastatic disease, resulting in a median survival time of 6-12 months. We aimed to investigate the therapeutic potential of SAMMSON inhibition in UM. Antisense oligonucleotide (ASO)-mediated SAMMSON inhibition impaired the growth and viability of a genetically diverse panel of uveal melanoma cell lines. These effects were accompanied by an induction of apoptosis and were recapitulated in two uveal melanoma patient derived xenograft (PDX) models through subcutaneous ASO delivery. SAMMSON pulldown revealed several candidate interaction partners, including various proteins involved in mitochondrial translation. Consequently, inhibition of SAMMSON impaired global, mitochondrial and cytosolic protein translation levels and mitochondrial function in uveal melanoma cells. The present study demonstrates that SAMMSON expression is essential for uveal melanoma cell survival. ASO-mediated silencing of SAMMSON may provide an effective treatment strategy to treat primary and metastatic uveal melanoma patients.	[Dewaele, Shanna; Delhaye, Louis; de Bony, Eric James; De Wilde, Jilke; Vanderheyden, Katrien; Anckaert, Jasper; Yigit, Nurten; Nuytens, Justine; Vanden Eynde, Eveline; Vandesompele, Jo; Mestdagh, Pieter] Univ Ghent, Ctr Med Genet CMGG, OncoRNALab, Ghent, Belgium; [Dewaele, Shanna; Delhaye, Louis; de Bony, Eric James; De Wilde, Jilke; Vanderheyden, Katrien; Anckaert, Jasper; Yigit, Nurten; Nuytens, Justine; Vanden Eynde, Eveline; Vandesompele, Jo; Van Dorpe, Jo; Eyckerman, Sven; Mestdagh, Pieter] Canc Res Inst Ghent CRIG, Ghent, Belgium; [Dewaele, Shanna; Delhaye, Louis; de Bony, Eric James; De Wilde, Jilke; Vanderheyden, Katrien; Anckaert, Jasper; Yigit, Nurten; Nuytens, Justine; Vanden Eynde, Eveline; Vandesompele, Jo; Eyckerman, Sven; Mestdagh, Pieter] Univ Ghent, Dept Biomol Med, Ghent, Belgium; [Delhaye, Louis; Eyckerman, Sven] VIB Ghent Univ, Ctr Med Biotechnol, Ghent, Belgium; [De Paepe, Boel; Smet, Joel; Verschoore, Maxime; Van Coster, Rudy] Ghent Univ Hosp, Dept Pediat, Div Pediat Neurol & Metab, Ghent, Belgium; [De Wilde, Jilke; Van Dorpe, Jo] Ghent Univ Hosp, Dept Pathol, Ghent, Belgium; [Nemati, Fariba; Decaudin, Didier] PSL Res Univ, Inst Curie, Lab Preclin Invest, Translat Res Dept, Paris, France; [Decaudin, Didier; Rodrigues, Manuel] PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France; [Rodrigues, Manuel] PSL Res Univ, Inserm U830, DNA Repair & Uveal Melanoma DRUM, Equipe Labellisee Ligue Natl Canc,Inst Curie, F-75005 Paris, France; [Zhao, Peihua] VIB KU Leuven Ctr Canc Biol, Ctr Med Biotechnol, Leuven, Belgium; [Zhao, Peihua; Leucci, Eleonora; Marine, Jean-Christophe] Katholieke Univ Leuven, Lab RNA Canc Biol, Dept Oncol, Leuven, Belgium; [Jochemsen, Aart] Leiden Univ, Dept Cell & Chem Biol, Med Ctr, Leiden, Netherlands; [Leucci, Eleonora] LKI Leuven Canc Inst, TRACE, Leuven, Belgium	Ghent University; Ghent University; Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Flanders Institute for Biotechnology (VIB); KU Leuven; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Mestdagh, P (corresponding author), Univ Ghent, Ctr Med Genet CMGG, OncoRNALab, Ghent, Belgium.; Mestdagh, P (corresponding author), Canc Res Inst Ghent CRIG, Ghent, Belgium.; Mestdagh, P (corresponding author), Univ Ghent, Dept Biomol Med, Ghent, Belgium.	pieter.mestdagh@ugent.be	Rodrigues, Manuel/C-8506-2018; Vandesompele, Jo/W-3411-2018; Leucci, Eleonora/G-4938-2011; De Paepe, Boel/B-7548-2013; Marine, Jean-Christophe/K-3292-2016	Rodrigues, Manuel/0000-0002-5443-0802; Vandesompele, Jo/0000-0001-6274-0184; Leucci, Eleonora/0000-0002-2898-748X; Nuytens, Justine/0000-0002-4878-1200; de Bony, Eric James/0000-0002-1289-7199; De Paepe, Boel/0000-0001-9403-4401; Mestdagh, Pieter/0000-0001-7821-9684; Delhaye, Louis/0000-0001-8876-7385; Yigit, Nurten/0000-0003-1183-8688; De Wilde, Jilke/0000-0003-0392-7162; Vanden Eynde, Eveline/0000-0003-0454-4171; ANCKAERT, JASPER/0000-0001-8144-4639; Marine, Jean-Christophe/0000-0003-2433-9837; Dewaele, Shanna/0000-0002-2219-8930	Foundation Against Cancer grant (Stichting tegen Kanker); Standup Against Cancer grant (Kom op tegen Kanker); Ghent University Industrial Research Fund (IOF); Ghent University GOA research grant; Fund for Scientific Research Flanders (FWO Vlaanderen); Melanoma Research Alliance (MRA) Amanda; Jonathan Eilian young investigator award; Fund of Scientific Research Flanders (FWO Vlaanderen)	Foundation Against Cancer grant (Stichting tegen Kanker); Standup Against Cancer grant (Kom op tegen Kanker); Ghent University Industrial Research Fund (IOF); Ghent University GOA research grant; Fund for Scientific Research Flanders (FWO Vlaanderen)(FWO); Melanoma Research Alliance (MRA) Amanda; Jonathan Eilian young investigator award; Fund of Scientific Research Flanders (FWO Vlaanderen)(FWO)	We would like to thank the VIB proteomics core for performing LC-MS/MS analysis and Prof. Olivier De Wever for providing the CT5.3hTERT cell line. The authors would also like to thank the Animal PlatformCRP2-UMS 3612 CNRS-US25 Inserm-IRD (Faculty of Pharmacy, Paris University, Paris), and the Animal Platform of Institut Curie. They also thank Justine Fleury for her technical assistance (Laboratory of preclinical Investigation, Institut Curie). This work was supported by a Foundation Against Cancer grant (Stichting tegen Kanker), a Standup Against Cancer grant (Kom op tegen Kanker), a Ghent University Industrial Research Fund (IOF), a Ghent University GOA research grant and Fund for Scientific Research Flanders (FWO Vlaanderen). EL is the recipient of the Melanoma Research Alliance (MRA) Amanda and Jonathan Eilian young investigator award. SD, LD and JDW are recipients of a grant from the Fund of Scientific Research Flanders (FWO Vlaanderen).	Amirouchene-Angelozzi N, 2014, MOL ONCOL, V8, P1508, DOI 10.1016/j.molonc.2014.06.004; Bakalian S, 2008, CLIN CANCER RES, V14, P951, DOI 10.1158/1078-0432.CCR-06-2630; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Cheng Z, 2019, NUCLEIC ACIDS RES, V47, P5061, DOI 10.1093/nar/gkz231; Coyne LP, 2018, FEBS LETT, V592, P759, DOI 10.1002/1873-3468.12894; De Paepe B, 2012, PEDIATR RES, V72, P232, DOI 10.1038/pr.2012.84; DEWAARDSIEBINGA I, 1995, INT J CANCER, V62, P155, DOI 10.1002/ijc.2910620208; Doan TL, 2006, CLIN THER, V28, P1079, DOI 10.1016/j.clinthera.2006.08.011; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Helgadottir H, 2016, APPL CLIN GENET, V9, P147, DOI 10.2147/TACG.S69210; Hong D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5272; Khan MS, 2013, BRIT J CANCER, V108, P1838, DOI 10.1038/bjc.2013.156; Koripella RK, 2019, P NATL ACAD SCI USA, V116, P8283, DOI 10.1073/pnas.1815675116; Krantz BA, 2017, CLIN OPHTHALMOL, V11, P279, DOI 10.2147/OPTH.S89591; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Li XP, 2017, ONCOTARGET, V8, P103785, DOI 10.18632/oncotarget.21792; Lindahl L, 2020, BIORXIV2020202010153; Luyten GPM, 1996, INT J CANCER, V66, P380, DOI 10.1002/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F; Matatall KA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-371; MOOY CM, 1990, OPHTHALMOLOGY, V97, P1275; Nareyeck G, 2005, EXP EYE RES, V81, P361, DOI 10.1016/j.exer.2005.04.018; Ni HZ, 2021, CELL MOL NEUROBIOL, V41, P79, DOI 10.1007/s10571-020-00833-2; Nicholas D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170975; Noskin GA, 2005, CLIN INFECT DIS, V41, pS303, DOI 10.1086/431672; OBRIEN TW, 1990, BIOCHIM BIOPHYS ACTA, V1050, P174, DOI 10.1016/0167-4781(90)90162-U; Papastefanou VP, 2011, J SKIN CANCER, V2011, DOI 10.1155/2011/573974; Park JJ, 2018, PIGM CELL MELANOMA R, V31, P661, DOI 10.1111/pcmr.12708; Richards JR, 2020, PIGM CELL MELANOMA R, V33, P264, DOI 10.1111/pcmr.12853; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Rodrigues M, 2020, JAMA OPHTHALMOL, V138, P182, DOI 10.1001/jamaophthalmol.2019.5403; Rodriguez A, 2016, MOL CLIN ONCOL, V5, P675, DOI 10.3892/mco.2016.1037; Roger AJ, 2017, CURR BIOL, V27, pR1177, DOI 10.1016/j.cub.2017.09.015; Rossi L, 2015, BRIT J CANCER, V113, P996, DOI 10.1038/bjc.2015.239; Saw PE, 2020, SCI CHINA LIFE SCI, V63, P485, DOI 10.1007/s11427-018-9438-y; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Shao L, 2020, IUBMB LIFE, V72, P237, DOI 10.1002/iub.2158; Sharma A, 2018, CLIN GENET, V93, P952, DOI 10.1111/cge.13136; Sugase T, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02377-x; Van Maerken T, 2009, JNCI-J NATL CANCER I, V101, P1562, DOI 10.1093/jnci/djp355; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Vendramin R, 2018, NAT STRUCT MOL BIOL, V25, P1035, DOI 10.1038/s41594-018-0143-4; Verma, 2018, ASTROCYTE, V5, P81, DOI [10.4103/astrocyte.astrocyte_55_18, DOI 10.4103/ASTROCYTE.ASTROCYTE_55_18]; Wang A, 2016, J CLIN PATHOL, V69, P750, DOI 10.1136/jclinpath-2016-203866; Wang YH, 2019, CLIN EXP PHARMACOL P, V46, P890, DOI 10.1111/1440-1681.13126; Xie JW, 2019, NEUROREPORT, V30, P817, DOI 10.1097/WNR.0000000000001278; Yang H, 2008, MELANOMA RES, V18, P95, DOI 10.1097/CMR.0b013e3282f628df; Yang SZ, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190615; Yang X, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0005-2; Zhou X, 2015, J MOL CELL BIOL, V7, P92, DOI 10.1093/jmcb/mjv014	49	5	5	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					15	25		10.1038/s41388-021-02006-x	http://dx.doi.org/10.1038/s41388-021-02006-x		SEP 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34508176	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000694774500001
J	Liu, CA; Ng, SK; Ding, YQ; Lin, YF; Liu, WX; Wong, SH; Sung, JJY; Yu, J				Liu, Changan; Ng, Siu-Kin; Ding, Yanqiang; Lin, Yufeng; Liu, Weixin; Wong, Sunny Hei; Sung, Joseph Jao-Yiu; Yu, Jun			Meta-analysis of mucosal microbiota reveals universal microbial signatures and dysbiosis in gastric carcinogenesis	ONCOGENE			English	Article							HELICOBACTER-PYLORI; INTESTINAL METAPLASIA; CANCER; ERADICATION; DISCOVERY; INFECTION; DISEASE; RISK	The consistency of the associations between gastric mucosal microbiome and gastric cancer across studies remained unexamined. We aimed to identify universal microbial signatures in gastric carcinogenesis through a meta-analysis of gastric microbiome from multiple studies. Compositional and ecological profiles of gastric microbes across stages of gastric carcinogenesis were significantly altered. Meta-analysis revealed that opportunistic pathobionts Fusobacterium, Parvimonas, Veillonella, Prevotella and Peptostreptococcus were enriched in GC, while commensals Bifidobacterium, Bacillus and Blautia were depleted in comparison to SG. The co-occurring correlation strengths of GC-enriched bacteria were increased along disease progression while those of GC-depleted bacteria were decreased. Eight bacterial taxa, including Veillonella, Dialister, Granulicatella, Herbaspirillum, Comamonas, Chryseobacterium, Shewanella and Helicobacter, were newly identified by this study as universal biomarkers for robustly discriminating GC from SG, with an area under the curve (AUC) of 0.85. Moreover, H. pylori-positive samples exhibited reduced microbial diversity, altered microbiota community and weaker interactions among gastric microbes. Our meta-analysis demonstrated comprehensive and generalizable gastric mucosa microbial features associated with histological stages of gastric carcinogenesis, including GC associated bacteria, diagnostic biomarkers, bacterial network alteration and H. pylori influence.	[Liu, Changan; Ng, Siu-Kin; Ding, Yanqiang; Lin, Yufeng; Liu, Weixin; Wong, Sunny Hei; Sung, Joseph Jao-Yiu; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China; [Liu, Changan; Ng, Siu-Kin; Ding, Yanqiang; Lin, Yufeng; Liu, Weixin; Wong, Sunny Hei; Sung, Joseph Jao-Yiu; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China; [Wong, Sunny Hei; Sung, Joseph Jao-Yiu] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore	Chinese University of Hong Kong; Chinese University of Hong Kong; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153; LIN, Yufeng/0000-0001-5705-0787	RGC Theme-based Res Scheme Hong Kong [T21-705/20-N]; National Key R&D Program of China [2020YFA0509200/2020YFA0509203]; RGC Collaborative Research Fund [C4039-19GF, C7065-18GF]; RGC-GRF Hong Kong [14163817]	RGC Theme-based Res Scheme Hong Kong; National Key R&D Program of China; RGC Collaborative Research Fund(Hong Kong Research Grants Council); RGC-GRF Hong Kong(Hong Kong Research Grants Council)	This study was supported by RGC Theme-based Res Scheme Hong Kong (T21-705/20-N), National Key R&D Program of China (No. 2020YFA0509200/2020YFA0509203), RGC Collaborative Research Fund (C4039-19GF, C7065-18GF), RGC-GRF Hong Kong (14163817), Vice-Chancellor's Discretionary Fund CUHK.	Ahn J, 2013, JNCI-J NATL CANCER I, V105, P1907, DOI 10.1093/jnci/djt300; Aviles-Jimenez F, 2014, SCI REP-UK, V4, DOI 10.1038/srep04202; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carding Simon, 2015, Microbial Ecology in Health and Disease, V26, P26191, DOI 10.3402/mehd.v26.26191; Castano-Rodriguez N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16289-2; Coker OO, 2018, GUT, V67, P1024, DOI 10.1136/gutjnl-2017-314281; CORREA P, 1992, CANCER RES, V52, P6735; Correa P, 2013, GASTROENTEROL CLIN N, V42, P211, DOI 10.1016/j.gtc.2013.01.002; Delgado S, 2013, MICROB ECOL, V65, P763, DOI 10.1007/s00248-013-0192-5; Devi TB, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.631140; Douglas GM, 2020, NAT BIOTECHNOL, V38, P685, DOI 10.1038/s41587-020-0548-6; ElOmar EM, 1997, GASTROENTEROLOGY, V113, P15, DOI 10.1016/S0016-5085(97)70075-1; Elshaghabee FMF, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01490; Eun CS, 2014, HELICOBACTER, V19, P407, DOI 10.1111/hel.12145; Feng X, 2020, EMBO J, V39, DOI 10.15252/embj.2019104036; Ferreira RM, 2018, GUT, V67, P226, DOI 10.1136/gutjnl-2017-314205; Fukase K, 2008, LANCET, V372, P392, DOI 10.1016/S0140-6736(08)61159-9; Geng JW, 2014, GUT PATHOG, V6, DOI 10.1186/1757-4749-6-26; Gevers D, 2014, CELL HOST MICROBE, V15, P382, DOI 10.1016/j.chom.2014.02.005; Guerrero-Preston R, 2016, ONCOTARGET, V7, P51320, DOI 10.18632/oncotarget.9710; Huang N, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2708-5; Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007; Larsen JM, 2017, IMMUNOLOGY, V151, P363, DOI 10.1111/imm.12760; Li P, 2020, CARCINOGENESIS, V41, P397, DOI 10.1093/carcin/bgaa013; Li TH, 2017, SCI REP-UK, V7, DOI 10.1038/srep44935; Liu XM, 2021, GUT MICROBES, V13, DOI 10.1080/19490976.2021.1875796; Lofgren JL, 2011, GASTROENTEROLOGY, V140, P210, DOI 10.1053/j.gastro.2010.09.048; Morita E, 2003, CANCER SCI, V94, P492, DOI 10.1111/j.1349-7006.2003.tb01471.x; Nada HG, 2020, PHARMANUTRITION, V14, DOI 10.1016/j.phanu.2020.100219; Naffouje R, 2019, CANCERS, V11, DOI 10.3390/cancers11091346; Nakatsu G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9727; Nwizu N, 2020, PERIODONTOL 2000, V83, P213, DOI 10.1111/prd.12329; Plottel CS, 2011, CELL HOST MICROBE, V10, P324, DOI 10.1016/j.chom.2011.10.003; Sasaki H, 1998, CANCER RES, V58, P2991; Schulz C, 2018, GUT, V67, P216, DOI 10.1136/gutjnl-2016-312904; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Sheh A, 2013, GUT MICROBES, V4, P505, DOI 10.4161/gmic.26205; Suarez G, 2015, CANCER RES, V75, P1749, DOI 10.1158/0008-5472.CAN-14-2291; Sung JJY, 2020, GUT, V69, P1572, DOI 10.1136/gutjnl-2019-319826; Tang B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165701; Wen J, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111680; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Yan XM, 2015, AM J CANCER RES, V5, P3111; Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018; Yin XH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149653; Yoneda M, 2016, J GASTROINTEST DIG S, V6; Yu GQ, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00302; Yu J, 2017, GUT, V66, P70, DOI 10.1136/gutjnl-2015-309800	50	1	1	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3599	3610		10.1038/s41388-022-02377-9	http://dx.doi.org/10.1038/s41388-022-02377-9		JUN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35680985	Green Published, hybrid			2022-12-28	WOS:000808419000001
J	Liu, CG; Ng, SK; Ding, YQ; Lin, YF; Liu, WX; Wong, SH; Sung, JJY; Yu, J				Liu, Changan; Ng, Siu-Kin; Ding, Yanqiang; Lin, Yufeng; Liu, Weixin; Wong, Sunny H.; Sung, Joseph J. Y.; Yu, Jun			META-ANALYSIS OF MUCOSAL MICROBIOTA REVEALS UNIVERSAL MICROBIAL SIGNATURES AND DYSBIOSIS IN GASTRIC CARCINOGENESIS	GASTROENTEROLOGY			English	Meeting Abstract	Digestive Disease Week (DDW)	MAY 21-24, 2022	San Diego, CA										Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153; LIN, Yufeng/0000-0001-5705-0787					0	1	1	6	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085	1528-0012		GASTROENTEROLOGY	Gastroenterology	MAY	2022	162	7		SUPPL		283	S66	S66						1	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Gastroenterology & Hepatology	2Z2XI	35680985	hybrid, Green Published			2022-12-28	WOS:000826446200164
J	Wu, WZ; Wang, LP; Dong, N; Wang, K				Wu, Weizhen; Wang, Luping; Dong, Ning; Wang, Kang			Primary Sjogren's syndrome-related Choroiditis in a Newly Diagnosed Older Adult	OCULAR IMMUNOLOGY AND INFLAMMATION			English	Article; Early Access						Choroidal thickening; multiple focal subretinal fluids; serous retinal detachment; choroiditis; Primary Sjogren's syndrome	RETINAL VASCULITIS; AMERICAN-COLLEGE; CLASSIFICATION; CRITERIA	PurposeTo report a case of secondary bilateral choroiditis in a patient with primary Sjogren's syndrome(pSS).Study DesignCase report.ResultsA 69-year-old woman visited our hospital for consultation due to decreased visual acuity in both eyes for 1 month. At the first visit, best corrected visual acuity (BCVA) was 0.2 and 0.3 in her right and left eyes, respectively. Intraocular pressure values were 15 mmHg and 16 mmHg in her right and left eyes, respectively. Examination revealed edema of the eyelids and conjunctiva,and corneal fluorescence staining was positive. No inflammation in the anterior chamber or vitreous opacities were observed. Bilateral multiple retinal detachments were observed on the posterior fundus, and optical coherence tomography revealed bilateral multiple areas of retinal neuroepithelial detachment, choroidal thickening, and choroidal folds. No abnormal fluorescence leakage was observed on fundus fluorescein angiography or indocyanine green angiography. In addition, systematic manifestations included recurrent bilateral parotid gland enlargement. Labial gland biopsy revealed dilated glandular ducts, scattered interstitial glands, and lymphocytic foci. Salivary gland scintigraphy revealed severe impairment of glandular excretory function. Moreover, blood tests for anti-Ro/SSA and anti-La/SSBantibodies were positive. The patient was diagnosed with primary Sjogren's syndrome. After 2 months treatment with oral prednisolone acetate combined with hydroxychloroquine, her BCVAimproved to 0.8 and 1.0 in the right and left eyes, respectively. The fundus also recovered to normal, and no recurrence was observed during the 1-year follow-up period.ConclusionsThe current case highlights that pSS, which usually manifests with dry eye and keratoconjunctivitis, may manifest with chronic choroiditis in both eyes as well. Based on our experience with this case, patients with clinically suspected bilateral choroiditis should be evaluated for pSS.	[Wu, Weizhen; Wang, Luping; Dong, Ning; Wang, Kang] Capital Med Univ, Beijing Friendship Hosp, Dept Ophthalmol, Beijing, Peoples R China	Capital Medical University	Wu, WZ (corresponding author), Capital Med Univ, Beijing Friendship Hosp, Dept Ophthalmol, Beijing, Peoples R China.	wangkang@ccmu.edu.cn		He, Shun-peng/0000-0001-6307-9690; Wong, Ping Pui/0000-0003-1592-4823	National Natural Science Foundation of China;  [82000899]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 	National Natural Science Foundation of China (82000899).	Agarwal A, 2019, EYE, V33, P50, DOI 10.1038/s41433-018-0224-y; Akpek EK, 2019, CORNEA, V38, P658, DOI 10.1097/ICO.0000000000001865; Babu K, 2018, OCUL IMMUNOL INFLAMM, V26, P130, DOI 10.1080/09273948.2016.1199711; Baumann SL, 2018, KLIN MONATSBL AUGENH, V235, P480, DOI 10.1055/s-0043-123641; Bjordal O, 2020, SURV OPHTHALMOL, V65, P119, DOI 10.1016/j.survophthal.2019.10.004; Chen XY, 2018, CLIN RHEUMATOL, V37, P1743, DOI 10.1007/s10067-018-4153-8; Feist E, 2009, Z RHEUMATOL, V68, P305, DOI 10.1007/s00393-008-0400-8; Fox RI, 2006, CLIN DERMATOL, V24, P393, DOI 10.1016/j.clindermatol.2006.07.005; Furukawa Yudai, 2020, Am J Ophthalmol Case Rep, V19, P100829, DOI 10.1016/j.ajoc.2020.100829; Hobsley M, 1970, Ann R Coll Surg Engl, V46, P224; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Joye A, 2021, CURR OPIN OPHTHALMOL, V32, P574, DOI 10.1097/ICU.0000000000000809; Lim BS, 2016, CLIN EXP OPTOM, V99, P87, DOI 10.1111/cxo.12307; Manoussakis MN, 2004, ARTHRITIS RHEUM-US, V50, P882, DOI 10.1002/art.20093; Maslinska M, 2021, RHEUMATOL INT, V41, P643, DOI 10.1007/s00296-020-04782-3; Mavragani CP, 2014, ANNU REV PATHOL-MECH, V9, P273, DOI 10.1146/annurev-pathol-012513-104728; Ramos-Casals M, 2004, MEDICINE, V83, P96, DOI 10.1097/01.md.0000119465.24818.98; Ramos-Casals M, 2020, ANN RHEUM DIS, V79, P3, DOI 10.1136/annrheumdis-2019-216114; Roszkowska AM, 2021, GENES-BASEL, V12, DOI 10.3390/genes12030365; Scofield RH, 2011, CURR RHEUMATOL REP, V13, P482, DOI 10.1007/s11926-011-0207-5; Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI [10.1002/art.39859, 10.1136/annrheumdis-2016-210571]; TSOKOS M, 1987, AM J CLIN PATHOL, V88, P26, DOI 10.1093/ajcp/88.1.26; Watanabe T, 2019, RHEUMATOLOGY, V58, P1244, DOI 10.1093/rheumatology/key405; Witte T, 2010, Z RHEUMATOL, V69, P50, DOI 10.1007/s00393-009-0519-2; Yang PZ, 2018, OCUL IMMUNOL INFLAMM, V26, P387, DOI 10.1080/09273948.2016.1241282; Zandbelt M, 2009, CLIN EXP RHEUMATOL, V27, P536; Zappi Daniela C., 2015, Rodriguésia, V66, P1085, DOI 10.1590/2175-7860201566411	27	4	4	5	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0927-3948	1744-5078		OCUL IMMUNOL INFLAMM	Ocul. Immunol. Inflamm.												10.1080/09273948.2022.2109490	http://dx.doi.org/10.1080/09273948.2022.2109490		DEC 2022	5	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	6W6SB	35256782				2022-12-28	WOS:000895856700001
J	Wu, WR; Shi, XD; Zhang, FP; Zhu, K; Zhang, R; Yu, XH; Qin, YF; He, SP; Fu, HW; Zhang, L; Zeng, H; Zhu, MS; Xu, LB; Wong, PP; Liu, C				Wu, Wen-Rui; Shi, Xiang-De; Zhang, Fa-Peng; Zhu, Ke; Zhang, Rui; Yu, Xian-Huan; Qin, Yu-Fei; He, Shun-Peng; Fu, Hou-Wei; Zhang, Lei; Zeng, Hong; Zhu, Man-Sheng; Xu, Lei-Bo; Wong, Ping-Pui; Liu, Chao			Activation of the Notch1-c-myc-VCAM1 signalling axis initiates liver progenitor cell-driven hepatocarcinogenesis and pulmonary metastasis	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; POTENTIAL THERAPEUTIC TARGET; NEOPLASTIC TRANSFORMATION; BREAST-CANCER; STEM-CELLS; VCAM-1; NOTCH1; MACROPHAGES; HEPATOCYTES; EXPRESSION	The cellular origin of hepatocellular carcinomas (HCC) and the role of Notch1 signalling in HCC initiation are controversial. Herein, we establish Notch1 as a regulator of HCC development and progression. Clinically, high Notch1 expression correlates with enhanced cancer progression, elevated lung metastasis, increased cancer stem cell (CSC)-like cells' gene signature expression, and poor overall survival in HCC patients. Notch1 intracellular domain (N1ICD) overexpression spontaneously transforms rat liver progenitor cells (LPC) into CSC-like cells (WBN1ICD C5) under a selective growth environment, while orthotopic injection of these cells generates liver tumors and spontaneous pulmonary metastasis in an isogenic rat model. Mechanistically, the elevated Notch1 activity increases c-myc expression, which then transcriptionally upregulates VCAM1 expression to activate macrophage dependent HCC transendothelial migration. In vivo, silencing c-myc prohibits the tumorigenicity of WBN1ICD C5 cells, while depletion of VCAM1 reduces spontaneous lung metastasis without affecting primary WBN1ICD C5 orthotopic liver tumor growth. Importantly, depletion of macrophage or blockade of macrophage VCAM1 binding receptor alpha 4 beta 1-integrin reduces the number of WBN1ICD C5 lung nodules in an experimental metastasis model. Overall, our work discovers that the Notch1-c-myc-VCAM1 signaling axis initiates LPC-driven hepatocarcinogenesis and metastasis, providing a preclinical model for HCC study and therapeutic targets for an improved HCC treatment.	[Wu, Wen-Rui; Shi, Xiang-De; Zhang, Fa-Peng; Zhu, Ke; Zhang, Rui; Yu, Xian-Huan; Qin, Yu-Fei; He, Shun-Peng; Fu, Hou-Wei; Zhang, Lei; Zeng, Hong; Zhu, Man-Sheng; Xu, Lei-Bo; Liu, Chao] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Biliary Pancreat Surg, Guangzhou 510120, Peoples R China; [Wu, Wen-Rui; Shi, Xiang-De; Zhang, Fa-Peng; Zhu, Ke; Zhang, Rui; Yu, Xian-Huan; Qin, Yu-Fei; He, Shun-Peng; Fu, Hou-Wei; Zhang, Lei; Zeng, Hong; Zhu, Man-Sheng; Xu, Lei-Bo; Wong, Ping-Pui; Liu, Chao] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangdong Hong Kong Joint Lab RNA Med, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China; [Wong, Ping-Pui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangzhou 510120, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Xu, LB; Liu, C (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Biliary Pancreat Surg, Guangzhou 510120, Peoples R China.; Xu, LB; Wong, PP; Liu, C (corresponding author), Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangdong Hong Kong Joint Lab RNA Med, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China.; Wong, PP (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangzhou 510120, Peoples R China.	xuleibo3@mail.sysu.edu.cn; huangbp3@mail.sysu.edu.cn; liuchao3@mail.sysu.edu.cn		He, Shun-peng/0000-0001-6307-9690; Wong, Ping Pui/0000-0003-1592-4823	National Natural Science Foundation of China [81972255, 82173195, 81920108028, 81872142, 81772597, 82173229, 81702904, 81972262]; Guangdong Natural Science Foundation [2021A1515010095, 712055485047]; Guangzhou Science and Technology Program Key Project [201904020008]; Sun Yat-sen University Clinical Research 5010 Program [2018008]; Science and Technology Program of Guangzhou [202102010326]; Sun Yat-sen University Fundamental Research Funds [19ykpy113]; Key Training Program for Young Scholars of Sun Yat-sen University [18ykzd07]; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology [[2013]163]; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes [KLB09001]; Guangdong Science and Technology Department [2020A0505100029, 2020B1212060018, 2020B1212030004]; Guangdong Translational Medicine Public Platform of Guangdong Province [4202037]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Program Key Project; Sun Yat-sen University Clinical Research 5010 Program; Science and Technology Program of Guangzhou; Sun Yat-sen University Fundamental Research Funds; Key Training Program for Young Scholars of Sun Yat-sen University; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes; Guangdong Science and Technology Department; Guangdong Translational Medicine Public Platform of Guangdong Province	Some of the illustrations were created using Biorender.com. This work was supported by grants from the National Natural Science Foundation of China (81972255, 82173195, 81920108028, 81872142, 81772597, 82173229, 81702904, 81972262), Guangdong Natural Science Foundation (2021A1515010095, 712055485047), Guangzhou Science and Technology Program Key Project (201904020008), Sun Yat-sen University Clinical Research 5010 Program (2018008), Science and Technology Program of Guangzhou (202102010326), Sun Yat-sen University Fundamental Research Funds (19ykpy113), the Key Training Program for Young Scholars of Sun Yat-sen University (18ykzd07), grant from the Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology ([2013]163), the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes (KLB09001), Guangdong Science and Technology Department (2020A0505100029, 2020B1212060018, 2020B1212030004), the Guangdong Translational Medicine Public Platform of Guangdong Province (4202037).	Ahn S, 2013, HEPATOB PANCREAT DIS, V12, P286, DOI 10.1016/S1499-3872(13)60046-6; Benhamouche S, 2010, GENE DEV, V24, P1718, DOI 10.1101/gad.1938710; Byrne GJ, 2000, J NATL CANCER I, V92, P1329, DOI 10.1093/jnci/92.16.1329; Cardoso AP, 2014, ONCOGENE, V33, P2123, DOI 10.1038/onc.2013.154; Chan LH, 2015, MOL CELLS, V38, P202, DOI 10.14348/molcells.2015.2356; Chen Q, 2012, CLIN CANCER RES, V18, P5520, DOI 10.1158/1078-0432.CCR-11-2904; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Cook J, 2013, CURR OPIN PHARMACOL, V13, P595, DOI 10.1016/j.coph.2013.05.017; Ding L, 2014, EXP TOXICOL PATHOL, V66, P139, DOI 10.1016/j.etp.2013.11.007; Fan B, 2012, J CLIN INVEST, V122, P2911, DOI 10.1172/JCI63212; Font-Burgada J, 2015, CELL, V162, P766, DOI 10.1016/j.cell.2015.07.026; Gurzu S, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2962580; Harney AS, 2015, CANCER DISCOV, V5, P932, DOI 10.1158/2159-8290.CD-15-0012; Hooth MJ, 1998, AM J PATHOL, V153, P1913, DOI 10.1016/S0002-9440(10)65705-7; Hussain SP, 2007, ONCOGENE, V26, P2166, DOI 10.1038/sj.onc.1210279; Jin H, 2006, CANCER RES, V66, P2146, DOI 10.1158/0008-5472.CAN-05-2704; Kim MJ, 2018, DEV CELL, V44, P582, DOI 10.1016/j.devcel.2018.02.010; Lai GH, 2005, GASTROENTEROLOGY, V129, P2047, DOI 10.1053/j.gastro.2005.10.010; Lai YS, 2019, J CELL MOL MED, V23, P1257, DOI 10.1111/jcmm.14027; Li XF, 2010, CANCER SCI, V101, P1099, DOI 10.1111/j.1349-7006.2010.01513.x; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Luo ZY, 2020, J MOL CELL BIOL, V12, P345, DOI 10.1093/jmcb/mjz088; Mishra A, 2016, J IMMUNOL, V197, P2828, DOI 10.4049/jimmunol.1501041; Mishra L, 2009, HEPATOLOGY, V49, P318, DOI 10.1002/hep.22704; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Ntziachristos P, 2014, CANCER CELL, V25, P318, DOI 10.1016/j.ccr.2014.02.018; Padilla-Nash HM, 2012, GENE CHROMOSOME CANC, V51, P353, DOI 10.1002/gcc.21921; Qi RZ, 2003, CANCER RES, V63, P8323; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Sell S, 2008, J CLIN ONCOL, V26, P2800, DOI 10.1200/JCO.2007.15.5945; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Strazzabosco M, 2012, GASTROENTEROLOGY, V143, P1430, DOI 10.1053/j.gastro.2012.10.025; Sun Q, 2014, ONCOL REP, V31, P933, DOI 10.3892/or.2013.2917; Vandereyken M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185786; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Verginelli F, 2015, ONCOTARGET, V6, P43216, DOI 10.18632/oncotarget.6456; Viatour P, 2011, J EXP MED, V208, P1963, DOI 10.1084/jem.20110198; Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002; Wei C, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0976-4; Wieland E, 2017, CANCER CELL, V31, P355, DOI 10.1016/j.ccell.2017.01.007; Wu K, 2012, HEPATOLOGY, V56, P2255, DOI 10.1002/hep.26007; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Zhang HL, 2019, ONCOL LETT, V17, P4487, DOI 10.3892/ol.2019.10081; Zhang R, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.6; Zhang RL, 2013, NATURE, V498, P497, DOI 10.1038/nature12322; Zhang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08863-5; Zhu WJ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2005-1	48	4	4	5	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2340	2356		10.1038/s41388-022-02246-5	http://dx.doi.org/10.1038/s41388-022-02246-5		MAR 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35256782				2022-12-28	WOS:000765674100003
